Famotidine	NOUN	O	O	1
-	PUNCT	O	O	1
associated	VERB	O	O	1
delirium	NOUN	O	Disease	1
.	PUNCT	O	O	1
Famotidine	NOUN	O	O	2
is	AUX	O	O	2
a	PRON	O	O	2
histamine	NOUN	O	Chemical	2
H2-receptor	NOUN	O	O	2
antagonist	NOUN	O	O	2
used	VERB	O	O	2
in	ADP	O	O	2
inpatient	ADJ	O	O	2
settings	NOUN	O	O	2
for	ADP	O	O	2
prevention	NOUN	O	O	2
of	ADP	O	O	2
stress	NOUN	O	O	2
ulcers	NOUN	O	O	2
and	CCONJ	O	O	2
is	AUX	O	O	2
showing	VERB	O	O	2
increasing	VERB	O	O	2
popularity	NOUN	O	O	2
because	SCONJ	O	O	2
of	ADP	O	O	2
its	PRON	O	O	2
low	ADJ	O	O	2
cost	NOUN	O	O	2
.	PUNCT	O	O	2
Although	SCONJ	O	O	3
all	PRON	O	O	3
of	ADP	O	O	3
the	PRON	O	O	3
currently	ADV	O	O	3
available	ADJ	O	O	3
H2-receptor	NOUN	O	O	3
antagonists	NOUN	O	O	3
have	VERB	O	O	3
shown	VERB	O	O	3
the	PRON	O	O	3
propensity	NOUN	O	O	3
to	PART	O	O	3
cause	VERB	O	O	3
delirium	NOUN	O	Disease	3
,	PUNCT	O	O	3
only	ADV	O	O	3
two	NUM	O	O	3
previously	ADV	O	O	3
reported	VERB	O	O	3
cases	NOUN	O	O	3
have	VERB	O	O	3
been	AUX	O	O	3
associated	VERB	O	O	3
with	ADP	O	O	3
famotidine	NOUN	O	O	3
.	PUNCT	O	O	3
The	PRON	O	O	4
authors	NOUN	O	O	4
report	VERB	O	O	4
on	ADP	O	O	4
six	NUM	O	O	4
cases	NOUN	O	O	4
of	ADP	O	O	4
famotidine	NOUN	O	O	4
-	PUNCT	O	O	4
associated	VERB	O	O	4
delirium	NOUN	O	Disease	4
in	ADP	O	O	4
hospitalized	VERB	O	O	4
patients	NOUN	O	O	4
who	PRON	O	O	4
cleared	VERB	O	O	4
completely	ADV	O	O	4
upon	SCONJ	O	O	4
removal	NOUN	O	O	4
of	ADP	O	O	4
famotidine	NOUN	O	O	4
.	PUNCT	O	O	4
The	PRON	O	O	5
pharmacokinetics	NOUN	O	O	5
of	ADP	O	O	5
famotidine	NOUN	O	O	5
are	AUX	O	O	5
reviewed	VERB	O	O	5
,	PUNCT	O	O	5
with	ADP	O	O	5
no	PRON	O	O	5
change	VERB	O	O	5
in	ADP	O	O	5
its	PRON	O	O	5
metabolism	NOUN	O	O	5
in	ADP	O	O	5
the	PRON	O	O	5
elderly	ADJ	O	O	5
population	NOUN	O	O	5
seen	VERB	O	O	5
.	PUNCT	O	O	5
The	PRON	O	O	6
implications	NOUN	O	O	6
of	ADP	O	O	6
using	VERB	O	O	6
famotidine	NOUN	O	O	6
in	ADP	O	O	6
elderly	ADJ	O	O	6
persons	NOUN	O	O	6
are	AUX	O	O	6
discussed	VERB	O	O	6
.	PUNCT	O	O	6
Indomethacin	PROPN	O	Chemical	9
induced	VERB	O	O	9
hypotension	NOUN	O	Disease	9
in	ADP	O	O	9
sodium	NOUN	O	Chemical	9
and	CCONJ	O	O	9
volume	PROPN	O	O	9
depleted	VERB	O	O	9
rats	NOUN	O	O	9
.	PUNCT	O	O	9
After	ADP	O	O	10
a	PRON	O	O	10
single	ADJ	O	O	10
oral	ADJ	O	O	10
dose	NOUN	O	O	10
of	ADP	O	O	10
4	NUM	O	O	10
mg	VERB	O	O	10
/	PUNCT	O	O	10
kg	VERB	O	O	10
indomethacin	VERB	O	Chemical	10
(	PUNCT	O	O	10
IDM	NOUN	O	O	10
)	PUNCT	O	O	10
to	PART	O	O	10
sodium	NOUN	O	Chemical	10
and	CCONJ	O	O	10
volume	PROPN	O	O	10
depleted	VERB	O	O	10
rats	NOUN	O	O	10
plasma	NOUN	O	O	10
renin	PROPN	O	O	10
activity	NOUN	O	O	10
(	PUNCT	O	O	10
PRA	PROPN	O	O	10
)	PUNCT	O	O	10
and	CCONJ	O	O	10
systolic	ADV	O	O	10
blood	NOUN	O	O	10
pressure	NOUN	O	O	10
fell	VERB	O	O	10
significantly	ADV	O	O	10
within	ADP	O	O	10
four	NUM	O	O	10
hours	NOUN	O	O	10
.	PUNCT	O	O	10
In	ADP	O	O	11
sodium	NOUN	O	Chemical	11
repleted	VERB	O	O	11
animals	NOUN	O	O	11
indomethacin	VERB	O	Chemical	11
did	VERB	O	O	11
not	PART	O	O	11
change	VERB	O	O	11
systolic	ADV	O	O	11
blood	NOUN	O	O	11
pressure	NOUN	O	O	11
(	PUNCT	O	O	11
BP	PROPN	O	O	11
)	PUNCT	O	O	11
although	SCONJ	O	O	11
plasma	NOUN	O	O	11
renin	PROPN	O	O	11
activity	NOUN	O	O	11
was	AUX	O	O	11
decreased	VERB	O	O	11
.	PUNCT	O	O	11
Thus	ADV	O	O	12
,	PUNCT	O	O	12
indomethacin	VERB	O	Chemical	12
by	ADP	O	O	12
inhibition	NOUN	O	O	12
of	ADP	O	O	12
prostaglandin	NOUN	O	Chemical	12
synthesis	NOUN	O	O	12
may	AUX	O	O	12
diminish	VERB	O	O	12
the	PRON	O	O	12
blood	NOUN	O	O	12
pressure	NOUN	O	O	12
maintaining	VERB	O	O	12
effect	VERB	O	O	12
of	ADP	O	O	12
the	PRON	O	O	12
stimulated	VERB	O	O	12
renin	PROPN	O	O	12
-	PUNCT	O	O	12
angiotensin	NOUN	O	Chemical	12
system	NOUN	O	O	12
in	ADP	O	O	12
sodium	NOUN	O	Chemical	12
and	CCONJ	O	O	12
volume	PROPN	O	O	12
depletion	NOUN	O	O	12
.	PUNCT	O	O	12
Late	ADV	O	O	15
-	PUNCT	O	O	15
onset	VERB	O	O	15
scleroderma	PROPN	O	O	15
renal	ADJ	O	O	15
crisis	NOUN	O	O	15
induced	VERB	O	O	15
by	ADP	O	O	15
tacrolimus	NOUN	O	Chemical	15
and	CCONJ	O	O	15
prednisolone	NOUN	O	Chemical	15
:	PUNCT	O	O	15
a	PRON	O	O	15
case	NOUN	O	O	15
report	VERB	O	O	15
.	PUNCT	O	O	15
Scleroderma	PROPN	O	O	16
renal	ADJ	O	O	16
crisis	NOUN	O	O	16
(	PUNCT	O	O	16
SRC	PROPN	O	O	16
)	PUNCT	O	O	16
is	AUX	O	O	16
a	PRON	O	O	16
rare	ADJ	O	O	16
complication	NOUN	O	O	16
of	ADP	O	O	16
systemic sclerosis	NOUN	O	Disease	16
(	PUNCT	O	O	16
SSc	PROPN	O	O	16
)	PUNCT	O	O	16
but	CCONJ	O	O	16
can	AUX	O	O	16
be	AUX	O	O	16
severe	ADJ	O	O	16
enough	ADV	O	O	16
to	PART	O	O	16
require	VERB	O	O	16
temporary	ADJ	O	O	16
or	CCONJ	O	O	16
permanent	ADJ	O	O	16
renal	ADJ	O	O	16
replacement	NOUN	O	O	16
therapy	NOUN	O	O	16
.	PUNCT	O	O	16
Moderate	ADJ	O	O	17
to	PART	O	O	17
high	ADJ	O	O	17
dose	NOUN	O	O	17
corticosteroid	NOUN	O	Chemical	17
use	VERB	O	O	17
is	AUX	O	O	17
recognized	VERB	O	O	17
as	ADP	O	O	17
a	PRON	O	O	17
major	ADJ	O	O	17
risk	NOUN	O	O	17
factor	NOUN	O	O	17
for	ADP	O	O	17
SRC	PROPN	O	O	17
.	PUNCT	O	O	17
Furthermore	ADV	O	O	18
,	PUNCT	O	O	18
there	ADV	O	O	18
have	VERB	O	O	18
been	AUX	O	O	18
reports	VERB	O	O	18
of	ADP	O	O	18
thrombotic	ADJ	O	Disease	18
microangiopathy	VERB	O	Disease	18
precipitated	VERB	O	O	18
by	ADP	O	O	18
cyclosporine	NOUN	O	Chemical	18
in	ADP	O	O	18
patients	NOUN	O	O	18
with	ADP	O	O	18
SSc	PROPN	O	O	18
.	PUNCT	O	O	18
In	ADP	O	O	19
this	PRON	O	O	19
article	NOUN	O	O	19
,	PUNCT	O	O	19
we	PRON	O	O	19
report	VERB	O	O	19
a	PRON	O	O	19
patient	NOUN	O	O	19
with	ADP	O	O	19
SRC	PROPN	O	O	19
induced	VERB	O	O	19
by	ADP	O	O	19
tacrolimus	NOUN	O	Chemical	19
and	CCONJ	O	O	19
corticosteroids	NOUN	O	Chemical	19
.	PUNCT	O	O	19
The	PRON	O	O	20
aim	VERB	O	O	20
of	ADP	O	O	20
this	PRON	O	O	20
work	NOUN	O	O	20
is	AUX	O	O	20
to	PART	O	O	20
call	VERB	O	O	20
attention	NOUN	O	O	20
to	PART	O	O	20
the	PRON	O	O	20
risk	NOUN	O	O	20
of	ADP	O	O	20
tacrolimus	NOUN	O	Chemical	20
use	VERB	O	O	20
in	ADP	O	O	20
patients	NOUN	O	O	20
with	ADP	O	O	20
SSc	PROPN	O	O	20
.	PUNCT	O	O	20
The	PRON	O	O	23
risk	NOUN	O	O	23
and	CCONJ	O	O	23
associated	VERB	O	O	23
factors	NOUN	O	O	23
of	ADP	O	O	23
methamphetamine	NOUN	O	Chemical	23
psychosis	VERB	O	Disease	23
in	ADP	O	O	23
methamphetamine	NOUN	O	Chemical	23
-	PUNCT	O	O	23
dependent	ADJ	O	O	23
patients	NOUN	O	O	23
in	ADP	O	O	23
Malaysia	PROPN	O	O	23
.	PUNCT	O	O	23
The	PRON	O	O	24
objective	VERB	O	O	24
of	ADP	O	O	24
this	PRON	O	O	24
study	VERB	O	O	24
was	AUX	O	O	24
to	PART	O	O	24
determine	VERB	O	O	24
the	PRON	O	O	24
risk	NOUN	O	O	24
of	ADP	O	O	24
lifetime	NOUN	O	O	24
and	CCONJ	O	O	24
current	ADJ	O	O	24
methamphetamine	NOUN	O	Chemical	24
-	PUNCT	O	O	24
induced	VERB	O	O	24
psychosis	VERB	O	Disease	24
in	ADP	O	O	24
patients	NOUN	O	O	24
with	ADP	O	O	24
methamphetamine	NOUN	O	Chemical	24
dependence	NOUN	O	O	24
.	PUNCT	O	O	24
The	PRON	O	O	25
association	PROPN	O	O	25
between	ADP	O	O	25
psychiatric	ADJ	O	Disease	25
co	NOUN	O	O	25
-	PUNCT	O	O	25
morbidity	NOUN	O	O	25
and	CCONJ	O	O	25
methamphetamine	NOUN	O	Chemical	25
-	PUNCT	O	O	25
induced	VERB	O	O	25
psychosis	VERB	O	Disease	25
was	AUX	O	O	25
also	ADV	O	O	25
studied	VERB	O	O	25
.	PUNCT	O	O	25
Patients	NOUN	O	O	26
with	ADP	O	O	26
the	PRON	O	O	26
diagnosis	NOUN	O	O	26
of	ADP	O	O	26
methamphetamine	NOUN	O	Chemical	26
based	VERB	O	O	26
on	ADP	O	O	26
DSM	PROPN	O	O	26
-	PUNCT	O	O	26
IV	NUM	O	O	26
were	AUX	O	O	26
interviewed	VERB	O	O	26
using	VERB	O	O	26
the	PRON	O	O	26
Mini	NOUN	O	O	26
International	PROPN	O	O	26
Neuropsychiatric	ADJ	O	O	26
Interview	NOUN	O	O	26
(	PUNCT	O	O	26
M.I.N.I.	PROPN	O	O	26
)	PUNCT	O	O	26
for	ADP	O	O	26
methamphetamine	NOUN	O	Chemical	26
-	PUNCT	O	O	26
induced	VERB	O	O	26
psychosis	VERB	O	Disease	26
and	CCONJ	O	O	26
other	ADJ	O	O	26
Axis	NOUN	O	O	26
I	PRON	O	O	26
psychiatric disorders	NOUN	O	Disease	26
.	PUNCT	O	O	26
Of	ADV	O	O	27
292	NUM	O	O	27
subjects	NOUN	O	O	27
,	PUNCT	O	O	27
47.9%	NOUN	O	O	27
of	ADP	O	O	27
the	PRON	O	O	27
subjects	NOUN	O	O	27
had	VERB	O	O	27
a	PRON	O	O	27
past	ADP	O	O	27
history	NOUN	O	O	27
of	ADP	O	O	27
psychotic symptoms	NOUN	O	Disease	27
and	CCONJ	O	O	27
13.0%	NOUN	O	O	27
of	ADP	O	O	27
the	PRON	O	O	27
patients	NOUN	O	O	27
were	AUX	O	O	27
having	VERB	O	O	27
current	ADJ	O	O	27
psychotic symptoms	NOUN	O	Disease	27
.	PUNCT	O	O	27
Co	PROPN	O	O	28
-	PUNCT	O	O	28
morbid	ADJ	O	O	28
major	ADJ	O	O	28
depressive	ADJ	O	Disease	28
disorder	NOUN	O	O	28
(	PUNCT	O	O	28
OR=7.18	NUM	O	O	28
,	PUNCT	O	O	28
95	NUM	O	O	28
CI=2.612	NOUN	O	O	28
-	PUNCT	O	O	28
19.708	NUM	O	O	28
)	PUNCT	O	O	28
,	PUNCT	O	O	28
bipolar disorder	NOUN	O	Disease	28
(	PUNCT	O	O	28
OR=13.807	PROPN	O	O	28
,	PUNCT	O	O	28
95	NUM	O	O	28
CI=5.194	NUM	O	O	28
-	PUNCT	O	O	28
36.706	NUM	O	O	28
)	PUNCT	O	O	28
,	PUNCT	O	O	28
antisocial	ADJ	O	O	28
personality	NOUN	O	O	28
disorder	NOUN	O	O	28
(	PUNCT	O	O	28
OR=12.619	PROPN	O	O	28
,	PUNCT	O	O	28
95	NUM	O	O	28
CI=6.702	NUM	O	O	28
-	PUNCT	O	O	28
23.759	NUM	O	O	28
)	PUNCT	O	O	28
and	CCONJ	O	O	28
heavy	ADJ	O	O	29
methamphetamine	NOUN	O	Chemical	29
uses	VERB	O	O	29
were	AUX	O	O	29
significantly	ADV	O	O	29
associated	VERB	O	O	29
with	ADP	O	O	29
lifetime	NOUN	O	O	29
methamphetamine	NOUN	O	Chemical	29
-	PUNCT	O	O	29
induced	VERB	O	O	29
psychosis	VERB	O	Disease	29
after	ADP	O	O	29
adjusted	VERB	O	O	29
for	ADP	O	O	29
other	ADJ	O	O	29
factors	NOUN	O	O	29
.	PUNCT	O	O	29
Major	ADJ	O	O	30
depressive	ADJ	O	Disease	30
disorder	NOUN	O	O	30
(	PUNCT	O	O	30
OR=2.870	NUM	O	O	30
,	PUNCT	O	O	30
CI=1.154	NUM	O	O	30
-	PUNCT	O	O	30
7.142	NUM	O	O	30
)	PUNCT	O	O	30
and	CCONJ	O	O	30
antisocial	ADJ	O	O	30
personality	NOUN	O	O	30
disorder	NOUN	O	O	30
(	PUNCT	O	O	30
OR=3.299	X	O	O	30
,	PUNCT	O	O	30
95	NUM	O	O	30
CI=1.375	NUM	O	O	30
-	PUNCT	O	O	30
7.914	NUM	O	O	30
)	PUNCT	O	O	30
were	AUX	O	O	30
the	PRON	O	O	30
only	ADV	O	O	30
factors	NOUN	O	O	30
associated	VERB	O	O	30
with	ADP	O	O	30
current	ADJ	O	O	30
psychosis	VERB	O	Disease	30
.	PUNCT	O	O	30
CONCLUSION	PROPN	O	O	31
:	PUNCT	O	O	31
There	ADV	O	O	31
was	AUX	O	O	31
a	PRON	O	O	31
high	ADJ	O	O	31
risk	NOUN	O	O	31
of	ADP	O	O	31
psychosis	VERB	O	Disease	31
in	ADP	O	O	31
patients	NOUN	O	O	31
with	ADP	O	O	31
methamphetamine	NOUN	O	Chemical	31
dependence	NOUN	O	O	31
.	PUNCT	O	O	31
It	PRON	O	O	32
was	AUX	O	O	32
associated	VERB	O	O	32
with	ADP	O	O	32
co	NOUN	O	O	32
-	PUNCT	O	O	32
morbid	ADJ	O	O	32
affective	ADJ	O	O	32
disorder	NOUN	O	O	32
,	PUNCT	O	O	32
antisocial	ADJ	O	O	32
personality	NOUN	O	O	32
,	PUNCT	O	O	32
and	CCONJ	O	O	32
heavy	ADJ	O	O	32
methamphetamine	NOUN	O	Chemical	32
use	VERB	O	O	32
.	PUNCT	O	O	32
It	PRON	O	O	33
is	AUX	O	O	33
recommended	VERB	O	O	33
that	SCONJ	O	O	33
all	PRON	O	O	33
cases	NOUN	O	O	33
of	ADP	O	O	33
methamphetamine	NOUN	O	Chemical	33
dependence	NOUN	O	O	33
should	AUX	O	O	33
be	AUX	O	O	33
screened	VERB	O	O	33
for	ADP	O	O	33
psychotic symptoms	NOUN	O	Disease	33
.	PUNCT	O	O	33
motor	NOUN	O	O	36
cortical	ADJ	O	O	36
plasticity	NOUN	O	O	36
in	ADP	O	O	36
Parkinson	NOUN	O	O	36
's	AUX	O	O	36
disease	PROPN	O	O	36
:	PUNCT	O	O	36
clues	NOUN	O	O	37
from	ADP	O	O	37
dyskinetic	VERB	O	Disease	37
patients	NOUN	O	O	37
.	PUNCT	O	O	37
The	PRON	O	O	38
plasticity	NOUN	O	O	38
of	ADP	O	O	38
primary	NOUN	O	O	38
motor	NOUN	O	O	38
cortex	VERB	O	O	38
(	PUNCT	O	O	38
M1	PROPN	O	O	38
)	PUNCT	O	O	38
in	ADP	O	O	38
patients	NOUN	O	O	38
with	ADP	O	O	38
Parkinson	NOUN	O	O	38
's	AUX	O	O	38
disease	PROPN	O	O	38
(	PUNCT	O	O	38
PD	PROPN	O	Disease	38
)	PUNCT	O	O	38
and	CCONJ	O	O	38
levodopa	NOUN	O	Chemical	38
-	PUNCT	O	O	38
induced	VERB	O	O	38
dyskinesias	PROPN	O	Disease	38
(	PUNCT	O	O	38
LIDs	NOUN	O	O	38
)	PUNCT	O	O	38
is	AUX	O	O	38
severely	ADV	O	O	38
impaired	VERB	O	O	38
.	PUNCT	O	O	38
This	PRON	O	O	39
study	VERB	O	O	39
demonstrates	VERB	O	O	39
that	SCONJ	O	O	39
the	PRON	O	O	39
deficient	ADJ	O	O	39
sensorimotor	PROPN	O	O	39
M1	PROPN	O	O	39
plasticity	NOUN	O	O	39
in	ADP	O	O	39
16	NUM	O	O	39
patients	NOUN	O	O	39
with	ADP	O	O	39
LIDs	NOUN	O	O	39
could	AUX	O	O	39
be	AUX	O	O	39
reinstated	VERB	O	O	39
by	ADP	O	O	39
a	PRON	O	O	39
single	ADJ	O	O	39
session	NOUN	O	O	39
of	ADP	O	O	39
real	ADV	O	O	39
inhibitory	ADJ	O	O	39
cerebellar	ADJ	O	O	39
stimulation	NOUN	O	O	39
but	CCONJ	O	O	39
not	PART	O	O	39
sham	NOUN	O	O	39
stimulation	NOUN	O	O	39
.	PUNCT	O	O	39
The	PRON	O	O	40
benefit	VERB	O	O	40
of	ADP	O	O	40
inhibitory	ADJ	O	O	40
cerebellar	ADJ	O	O	40
stimulation	NOUN	O	O	40
on	ADP	O	O	40
LIDs	NOUN	O	O	40
is	AUX	O	O	40
known	VERB	O	O	40
.	PUNCT	O	O	40
To	PART	O	O	41
explore	VERB	O	O	41
whether	SCONJ	O	O	41
this	PRON	O	O	41
benefit	VERB	O	O	41
is	AUX	O	O	41
linked	VERB	O	O	41
to	PART	O	O	41
the	PRON	O	O	41
restoration	NOUN	O	O	41
of	ADP	O	O	41
sensorimotor	PROPN	O	O	41
plasticity	NOUN	O	O	41
of	ADP	O	O	41
M1	PROPN	O	O	41
,	PUNCT	O	O	41
we	PRON	O	O	41
conducted	VERB	O	O	41
an	PRON	O	O	41
additional	ADJ	O	O	41
study	VERB	O	O	41
looking	VERB	O	O	41
at	ADP	O	O	41
changes	VERB	O	O	41
in	ADP	O	O	41
LIDs	NOUN	O	O	41
and	CCONJ	O	O	41
PAS	PROPN	O	O	41
-	PUNCT	O	O	41
induced	VERB	O	O	41
plasticity	NOUN	O	O	41
after	ADP	O	O	41
10	NUM	O	O	41
sessions	NOUN	O	O	41
of	ADP	O	O	41
either	ADV	O	O	41
bilateral	ADJ	O	O	41
,	PUNCT	O	O	41
real	ADV	O	O	41
inhibitory	ADJ	O	O	41
cerebellar	ADJ	O	O	41
stimulation	NOUN	O	O	41
or	CCONJ	O	O	41
sham	NOUN	O	O	41
stimulation	NOUN	O	O	41
.	PUNCT	O	O	41
These	PRON	O	O	42
results	VERB	O	O	42
suggest	VERB	O	O	42
that	SCONJ	O	O	42
alterations	NOUN	O	O	42
in	ADP	O	O	42
cerebellar	ADJ	O	O	42
sensory	ADJ	O	O	42
processing	NOUN	O	O	42
function	NOUN	O	O	42
,	PUNCT	O	O	42
occurring	VERB	O	O	42
secondary	ADJ	O	O	42
to	PART	O	O	42
abnormal	ADJ	O	O	42
basal	PROPN	O	O	42
ganglia	NOUN	O	O	42
signals	VERB	O	O	42
reaching	VERB	O	O	42
it	PRON	O	O	42
,	PUNCT	O	O	42
may	AUX	O	O	42
be	AUX	O	O	42
an	PRON	O	O	42
important	ADJ	O	O	42
element	NOUN	O	O	42
contributing	VERB	O	O	42
to	PART	O	O	42
the	PRON	O	O	42
maladaptive	ADJ	O	O	42
sensorimotor	PROPN	O	O	42
plasticity	NOUN	O	O	42
of	ADP	O	O	42
M1	PROPN	O	O	42
and	CCONJ	O	O	42
the	PRON	O	O	42
emergence	NOUN	O	O	42
of	ADP	O	O	42
abnormal	ADJ	O	O	42
involuntary movements	NOUN	O	Disease	42
.	PUNCT	O	O	42
The	PRON	O	O	45
function	NOUN	O	O	45
of	ADP	O	O	45
P2X3	PROPN	O	O	45
receptor	NOUN	O	O	45
and	CCONJ	O	O	45
NK1	NOUN	O	O	45
receptor	NOUN	O	O	45
antagonists	NOUN	O	O	45
on	ADP	O	O	45
cyclophosphamide	VERB	O	Chemical	45
-	PUNCT	O	O	45
induced	VERB	O	O	45
cystitis	NOUN	O	Disease	45
in	ADP	O	O	45
rats	NOUN	O	O	45
.	PUNCT	O	O	45
The	PRON	O	O	46
purpose	NOUN	O	O	46
of	ADP	O	O	46
the	PRON	O	O	46
study	VERB	O	O	46
is	AUX	O	O	46
to	PART	O	O	46
explore	VERB	O	O	46
the	PRON	O	O	46
function	NOUN	O	O	46
of	ADP	O	O	46
P2X3	PROPN	O	O	46
and	CCONJ	O	O	46
NK1	NOUN	O	O	46
receptors	NOUN	O	O	46
antagonists	NOUN	O	O	46
on	ADP	O	O	46
cyclophosphamide	VERB	O	Chemical	46
(	PUNCT	O	O	46
CYP)-induced	VERB	O	O	46
cystitis	NOUN	O	Disease	46
in	ADP	O	O	46
rats	NOUN	O	O	46
.	PUNCT	O	O	46
injected	VERB	O	O	47
with	ADP	O	O	47
CYP	PROPN	O	Chemical	47
(	PUNCT	O	O	47
150	NUM	O	O	47
mg	VERB	O	O	47
/	PUNCT	O	O	47
kg	VERB	O	O	47
)	PUNCT	O	O	47
;	PUNCT	O	O	47
and	CCONJ	O	O	47
the	PRON	O	O	47
rats	NOUN	O	O	47
in	ADP	O	O	47
the	PRON	O	O	47
intervention	NOUN	O	O	47
group	NOUN	O	O	47
were	AUX	O	O	47
i.p	NOUN	O	O	47
.	PUNCT	O	O	47
injected	VERB	O	O	48
with	ADP	O	O	48
CYP	PROPN	O	Chemical	48
with	ADP	O	O	48
subsequently	ADV	O	O	48
perfusion	NOUN	O	O	48
of	ADP	O	O	48
bladder	NOUN	O	O	48
with	ADP	O	O	48
P2X3	PROPN	O	O	48
and	CCONJ	O	O	48
NK1	NOUN	O	O	48
receptors	NOUN	O	O	48
'	PUNCT	O	O	48
antagonists	NOUN	O	O	48
,	PUNCT	O	O	48
Suramin	NOUN	O	O	48
and	CCONJ	O	O	48
GR	PROPN	O	O	48
82334	NUM	O	O	48
.	PUNCT	O	O	48
Spontaneous	ADJ	O	O	49
pain	NOUN	O	Disease	49
behaviors	NOUN	O	O	49
following	VERB	O	O	49
the	PRON	O	O	49
administration	NOUN	O	O	49
of	ADP	O	O	49
CYP	PROPN	O	Chemical	49
were	AUX	O	O	49
observed	VERB	O	O	49
.	PUNCT	O	O	49
RESULTS	VERB	O	O	50
:	PUNCT	O	O	50
Cyclophosphamide	PROPN	O	Chemical	50
treatment	NOUN	O	O	50
increased	VERB	O	O	50
the	PRON	O	O	50
spontaneous	ADJ	O	O	50
pain	NOUN	O	Disease	50
behaviors	NOUN	O	O	50
scores	NOUN	O	O	50
.	PUNCT	O	O	50
Histological	NOUN	O	O	51
changes	VERB	O	O	51
evident	ADJ	O	O	51
in	ADP	O	O	51
model	NOUN	O	O	51
and	CCONJ	O	O	51
intervention	NOUN	O	O	51
groups	NOUN	O	O	51
rats	NOUN	O	O	51
'	PUNCT	O	O	51
bladder	NOUN	O	O	51
included	VERB	O	O	51
edema	NOUN	O	Disease	51
,	PUNCT	O	O	51
vasodilation	NOUN	O	O	51
,	PUNCT	O	O	51
and	CCONJ	O	O	51
infiltration	NOUN	O	O	51
of	ADP	O	O	51
inflammatory	ADJ	O	O	51
cells	NOUN	O	O	51
.	PUNCT	O	O	51
In	ADP	O	O	52
CYP	PROPN	O	Chemical	52
-	PUNCT	O	O	52
induced	VERB	O	O	52
cystitis	NOUN	O	Disease	52
,	PUNCT	O	O	52
the	PRON	O	O	52
expression	NOUN	O	O	52
of	ADP	O	O	52
P2X3	PROPN	O	O	52
and	CCONJ	O	O	52
NK1	NOUN	O	O	52
receptors	NOUN	O	O	52
increased	VERB	O	O	52
in	ADP	O	O	52
urothelium	NOUN	O	O	52
and/or	CCONJ	O	O	52
suburothelium	NOUN	O	O	52
.	PUNCT	O	O	52
Acute	PROPN	O	O	55
hepatitis	NOUN	O	Disease	55
associated	VERB	O	O	55
with	ADP	O	O	55
clopidogrel	NOUN	O	O	55
:	PUNCT	O	O	55
a	PRON	O	O	55
case	NOUN	O	O	55
report	VERB	O	O	55
and	CCONJ	O	O	55
review	VERB	O	O	55
of	ADP	O	O	55
the	PRON	O	O	55
literature	NOUN	O	O	55
.	PUNCT	O	O	55
Drug	NOUN	O	O	56
-	PUNCT	O	O	56
induced	VERB	O	O	56
hepatotoxicity	NOUN	O	Disease	56
is	AUX	O	O	56
a	PRON	O	O	56
common	ADJ	O	O	56
cause	VERB	O	O	56
of	ADP	O	O	56
acute	ADJ	O	O	56
hepatitis	NOUN	O	Disease	56
,	PUNCT	O	O	56
and	CCONJ	O	O	56
the	PRON	O	O	56
recognition	NOUN	O	O	56
of	ADP	O	O	56
the	PRON	O	O	56
responsible	ADJ	O	O	56
drug	NOUN	O	O	56
may	AUX	O	O	56
be	AUX	O	O	56
difficult	ADJ	O	O	56
.	PUNCT	O	O	56
We	PRON	O	O	57
describe	VERB	O	O	57
a	PRON	O	O	57
case	NOUN	O	O	57
of	ADP	O	O	57
clopidogrel	NOUN	O	O	57
-	PUNCT	O	O	57
related	ADJ	O	O	57
acute	ADJ	O	O	57
hepatitis	NOUN	O	Disease	57
.	PUNCT	O	O	57
Reports	NOUN	O	O	58
about	ADP	O	O	58
cases	NOUN	O	O	58
of	ADP	O	O	58
hepatotoxicity	NOUN	O	Disease	58
due	ADJ	O	O	58
to	PART	O	O	58
clopidogrel	NOUN	O	O	58
are	AUX	O	O	58
increasing	VERB	O	O	58
in	ADP	O	O	58
the	PRON	O	O	58
last	VERB	O	O	58
few	ADJ	O	O	58
years	NOUN	O	O	58
,	PUNCT	O	O	58
after	ADP	O	O	58
the	PRON	O	O	58
increased	VERB	O	O	58
use	VERB	O	O	58
of	ADP	O	O	58
this	PRON	O	O	58
drug	NOUN	O	O	58
.	PUNCT	O	O	58
In	ADP	O	O	59
conclusion	NOUN	O	O	59
,	PUNCT	O	O	59
we	PRON	O	O	59
believe	VERB	O	O	59
that	SCONJ	O	O	59
physicians	NOUN	O	O	59
should	AUX	O	O	59
carefully	ADV	O	O	59
consider	VERB	O	O	59
the	PRON	O	O	59
risk	NOUN	O	O	59
of	ADP	O	O	59
drug	NOUN	O	O	59
-	PUNCT	O	O	59
induced	VERB	O	O	59
hepatic injury	NOUN	O	Disease	59
when	SCONJ	O	O	59
clopidogrel	NOUN	O	O	59
is	AUX	O	O	59
prescribed	VERB	O	O	59
.	PUNCT	O	O	59
Bortezomib	PROPN	O	O	62
and	CCONJ	O	O	62
dexamethasone	NOUN	O	Chemical	62
as	ADP	O	O	62
salvage	NOUN	O	O	62
therapy	NOUN	O	O	62
in	ADP	O	O	62
patients	NOUN	O	O	62
with	ADP	O	O	62
relapsed	VERB	O	O	62
/	PUNCT	O	O	62
refractory	ADJ	O	O	63
multiple myeloma	NOUN	O	Disease	63
:	PUNCT	O	O	63
analysis	NOUN	O	O	63
of	ADP	O	O	63
long	ADV	O	O	63
-	PUNCT	O	O	63
term	NOUN	O	O	63
clinical	ADJ	O	O	63
outcomes	NOUN	O	O	63
.	PUNCT	O	O	63
Bortezomib	PROPN	O	O	64
(	PUNCT	O	O	65
bort)-dexamethasone	NOUN	O	O	65
(	PUNCT	O	O	65
dex	PROPN	O	Chemical	65
)	PUNCT	O	O	65
is	AUX	O	O	65
an	PRON	O	O	65
effective	ADJ	O	O	65
therapy	NOUN	O	O	65
for	ADP	O	O	65
relapsed	VERB	O	O	65
/	PUNCT	O	O	65
refractory	ADJ	O	O	65
(	PUNCT	O	O	65
R	NOUN	O	O	65
/	PUNCT	O	O	65
R	NOUN	O	O	65
)	PUNCT	O	O	65
multiple myeloma	NOUN	O	Disease	65
(	PUNCT	O	O	65
MM	PROPN	O	Disease	65
)	PUNCT	O	O	65
.	PUNCT	O	O	65
This	PRON	O	O	66
retrospective	ADJ	O	O	66
study	VERB	O	O	66
investigated	VERB	O	O	66
the	PRON	O	O	66
combination	NOUN	O	O	66
of	ADP	O	O	66
bort	X	O	O	66
(	PUNCT	O	O	66
1.3	NUM	O	O	66
mg	VERB	O	O	66
/	PUNCT	O	O	66
m(2	NUM	O	O	66
)	PUNCT	O	O	66
on	ADP	O	O	66
days	NOUN	O	O	66
1	X	O	O	66
,	PUNCT	O	O	66
4	NUM	O	O	66
,	PUNCT	O	O	66
8	NUM	O	O	66
,	PUNCT	O	O	66
and	CCONJ	O	O	66
11	NUM	O	O	66
every	PRON	O	O	66
3	X	O	O	66
weeks	NOUN	O	O	66
)	PUNCT	O	O	66
and	CCONJ	O	O	66
dex	PROPN	O	Chemical	66
(	PUNCT	O	O	66
20	NUM	O	O	66
mg	VERB	O	O	66
on	ADP	O	O	66
the	PRON	O	O	66
day	NOUN	O	O	66
of	ADP	O	O	66
and	CCONJ	O	O	66
the	PRON	O	O	66
day	NOUN	O	O	66
after	ADP	O	O	66
bort	X	O	O	66
)	PUNCT	O	O	66
as	ADP	O	O	66
salvage	NOUN	O	O	66
treatment	NOUN	O	O	66
in	ADP	O	O	66
85	NUM	O	O	66
patients	NOUN	O	O	66
with	ADP	O	O	66
R	NOUN	O	O	66
/	PUNCT	O	O	66
R	NOUN	O	O	66
MM	PROPN	O	Disease	66
after	ADP	O	O	66
prior	ADV	O	O	66
autologous	ADJ	O	O	66
stem	VERB	O	O	66
cell	NOUN	O	O	66
transplantation	NOUN	O	O	66
or	CCONJ	O	O	66
conventional	ADJ	O	O	66
chemotherapy	NOUN	O	O	66
.	PUNCT	O	O	66
Eighty	NUM	O	O	67
-	PUNCT	O	O	67
seven	NUM	O	O	67
percent	NOUN	O	O	67
of	ADP	O	O	67
the	PRON	O	O	67
patients	NOUN	O	O	67
had	VERB	O	O	67
received	VERB	O	O	67
immunomodulatory	NOUN	O	O	67
drugs	NOUN	O	O	67
included	VERB	O	O	67
in	ADP	O	O	67
some	PRON	O	O	67
line	NOUN	O	O	67
of	ADP	O	O	67
therapy	NOUN	O	O	67
before	ADP	O	O	67
bort	X	O	O	67
-	PUNCT	O	O	67
dex	PROPN	O	Chemical	67
.	PUNCT	O	O	67
The	PRON	O	O	68
median	ADJ	O	O	68
number	NOUN	O	O	68
of	ADP	O	O	68
bort	X	O	O	68
-	PUNCT	O	O	68
dex	PROPN	O	Chemical	68
cycles	NOUN	O	O	68
was	AUX	O	O	68
6	NUM	O	O	68
,	PUNCT	O	O	68
up	ADP	O	O	68
to	PART	O	O	68
a	PRON	O	O	68
maximum	ADV	O	O	68
of	ADP	O	O	68
12	NUM	O	O	68
cycles	NOUN	O	O	68
.	PUNCT	O	O	68
The	PRON	O	O	69
most	ADV	O	O	69
relevant	ADJ	O	O	69
adverse	ADJ	O	O	69
event	NOUN	O	O	69
was	AUX	O	O	69
peripheral neuropathy	NOUN	O	Disease	69
,	PUNCT	O	O	69
which	PRON	O	O	69
occurred	VERB	O	O	69
in	ADP	O	O	69
78	NUM	O	O	69
%	INTJ	O	O	69
of	ADP	O	O	69
the	PRON	O	O	69
patients	NOUN	O	O	69
(	PUNCT	O	O	69
grade	NOUN	O	O	69
II	NUM	O	O	69
,	PUNCT	O	O	69
38	NUM	O	O	69
%	INTJ	O	O	69
;	PUNCT	O	O	69
grade	NOUN	O	O	69
III	NUM	O	O	69
,	PUNCT	O	O	69
21	NUM	O	O	69
%	INTJ	O	O	69
)	PUNCT	O	O	69
and	CCONJ	O	O	69
led	VERB	O	O	69
to	PART	O	O	69
treatment	NOUN	O	O	69
discontinuation	NOUN	O	O	69
in	ADP	O	O	69
6	NUM	O	O	69
%	INTJ	O	O	69
.	PUNCT	O	O	69
Prolonged	VERB	O	O	70
PFS	PROPN	O	O	70
and	CCONJ	O	O	70
OS	NOUN	O	O	70
were	AUX	O	O	70
observed	VERB	O	O	70
in	ADP	O	O	70
patients	NOUN	O	O	70
achieving	VERB	O	O	70
CR	NOUN	O	O	70
and	CCONJ	O	O	70
receiving	VERB	O	O	70
bort	X	O	O	70
-	PUNCT	O	O	70
dex	PROPN	O	Chemical	70
a	PRON	O	O	70
single	ADJ	O	O	70
line	NOUN	O	O	70
of	ADP	O	O	70
prior	ADV	O	O	70
therapy	NOUN	O	O	70
.	PUNCT	O	O	70
Bort	PROPN	O	O	71
-	PUNCT	O	O	71
dex	PROPN	O	Chemical	71
was	AUX	O	O	71
an	PRON	O	O	71
effective	ADJ	O	O	71
salvage	NOUN	O	O	71
treatment	NOUN	O	O	71
for	ADP	O	O	71
MM	PROPN	O	Disease	71
patients	NOUN	O	O	71
,	PUNCT	O	O	71
particularly	ADV	O	O	71
for	ADP	O	O	71
those	PRON	O	O	71
in	ADP	O	O	71
first	ADV	O	O	71
relapse	VERB	O	O	71
.	PUNCT	O	O	71
Pubertal	NOUN	O	O	74
exposure	NOUN	O	O	74
to	PART	O	O	74
Bisphenol	NOUN	O	O	74
A	PRON	O	O	74
increases	VERB	O	O	74
anxiety	NOUN	O	Disease	74
-	PUNCT	O	O	74
like	INTJ	O	O	74
behavior	NOUN	O	O	74
and	CCONJ	O	O	74
decreases	VERB	O	O	74
acetylcholinesterase	NOUN	O	O	74
activity	NOUN	O	O	74
of	ADP	O	O	74
hippocampus	NOUN	O	O	74
in	ADP	O	O	74
adult	NOUN	O	O	74
male	NOUN	O	O	74
mice	NOUN	O	O	74
.	PUNCT	O	O	74
The	PRON	O	O	75
negative	ADJ	O	O	75
effects	NOUN	O	O	75
of	ADP	O	O	75
Bisphenol	NOUN	O	O	75
A	PRON	O	O	75
(	PUNCT	O	O	75
BPA	NOUN	O	O	75
)	PUNCT	O	O	75
on	ADP	O	O	75
neurodevelopment	NOUN	O	O	75
and	CCONJ	O	O	75
behaviors	NOUN	O	O	75
have	VERB	O	O	75
been	AUX	O	O	75
well	ADV	O	O	75
established	VERB	O	O	75
.	PUNCT	O	O	75
Acetylcholinesterase	PROPN	O	O	76
(	PUNCT	O	O	76
AChE	PROPN	O	O	76
)	PUNCT	O	O	76
is	AUX	O	O	76
a	PRON	O	O	76
regulatory	ADJ	O	O	76
enzyme	NOUN	O	O	76
which	PRON	O	O	76
is	AUX	O	O	76
involved	VERB	O	O	76
in	ADP	O	O	76
anxiety	NOUN	O	Disease	76
-	PUNCT	O	O	76
like	INTJ	O	O	76
behavior	NOUN	O	O	76
.	PUNCT	O	O	76
This	PRON	O	O	77
study	VERB	O	O	77
investigated	VERB	O	O	77
behavioral	ADJ	O	O	77
phenotypes	NOUN	O	O	77
and	CCONJ	O	O	77
AChE	PROPN	O	O	77
activity	NOUN	O	O	77
in	ADP	O	O	77
male	NOUN	O	O	77
mice	NOUN	O	O	77
following	VERB	O	O	77
BPA	NOUN	O	O	77
exposure	NOUN	O	O	77
during	ADP	O	O	77
puberty	VERB	O	O	77
.	PUNCT	O	O	77
On	ADP	O	O	78
postnatal	ADJ	O	O	78
day	NOUN	O	O	78
(	PUNCT	O	O	78
PND	PROPN	O	O	78
)	PUNCT	O	O	78
35	NUM	O	O	78
,	PUNCT	O	O	78
male	NOUN	O	O	78
mice	NOUN	O	O	78
were	AUX	O	O	78
exposed	VERB	O	O	78
to	PART	O	O	78
50	NUM	O	O	78
mg	VERB	O	O	78
BPA	NOUN	O	O	78
/	PUNCT	O	O	78
kg	VERB	O	O	78
diet	PROPN	O	O	78
per	ADP	O	O	78
day	NOUN	O	O	78
for	ADP	O	O	78
a	PRON	O	O	78
period	NOUN	O	O	78
of	ADP	O	O	78
35	NUM	O	O	78
days	NOUN	O	O	78
.	PUNCT	O	O	78
Results	NOUN	O	O	79
from	ADP	O	O	79
our	PRON	O	O	79
behavioral	ADJ	O	O	79
phenotyping	NOUN	O	O	79
indicated	VERB	O	O	79
that	SCONJ	O	O	79
anxiety	NOUN	O	Disease	79
-	PUNCT	O	O	79
like	INTJ	O	O	79
behavior	NOUN	O	O	79
was	AUX	O	O	79
increased	VERB	O	O	79
in	ADP	O	O	79
mice	NOUN	O	O	79
exposed	VERB	O	O	79
to	PART	O	O	79
BPA	NOUN	O	O	79
.	PUNCT	O	O	79
AChE	PROPN	O	O	80
activity	NOUN	O	O	80
was	AUX	O	O	80
significantly	ADV	O	O	80
decreased	VERB	O	O	80
in	ADP	O	O	80
the	PRON	O	O	80
hippocampus	NOUN	O	O	80
of	ADP	O	O	80
mice	NOUN	O	O	80
with	ADP	O	O	80
BPA	NOUN	O	O	80
compared	VERB	O	O	80
to	PART	O	O	80
control	VERB	O	O	80
mice	NOUN	O	O	80
,	PUNCT	O	O	80
whereas	SCONJ	O	O	80
no	PRON	O	O	80
difference	NOUN	O	O	80
was	AUX	O	O	80
found	VERB	O	O	80
in	ADP	O	O	80
the	PRON	O	O	80
prefrontal	ADJ	O	O	80
cortex	VERB	O	O	80
,	PUNCT	O	O	80
hypothalamus	PROPN	O	O	80
and	CCONJ	O	O	80
cerebellum	NOUN	O	O	80
.	PUNCT	O	O	80
Our	PRON	O	O	81
findings	NOUN	O	O	81
showed	VERB	O	O	81
that	SCONJ	O	O	81
pubertal	ADJ	O	O	81
BPA	NOUN	O	O	81
exposure	NOUN	O	O	81
increased	VERB	O	O	81
anxiety	NOUN	O	Disease	81
-	PUNCT	O	O	81
like	INTJ	O	O	81
behavior	NOUN	O	O	81
,	PUNCT	O	O	81
which	PRON	O	O	81
may	AUX	O	O	81
be	AUX	O	O	81
associated	VERB	O	O	81
with	ADP	O	O	81
decreased	VERB	O	O	81
AChE	PROPN	O	O	81
activity	NOUN	O	O	81
of	ADP	O	O	81
the	PRON	O	O	81
hippocampus	NOUN	O	O	81
in	ADP	O	O	81
adult	NOUN	O	O	81
male	NOUN	O	O	81
mice	NOUN	O	O	81
.	PUNCT	O	O	81
Further	ADV	O	O	82
studies	NOUN	O	O	82
are	AUX	O	O	82
necessary	ADJ	O	O	82
to	PART	O	O	82
investigate	VERB	O	O	82
the	PRON	O	O	82
cholinergic	ADJ	O	O	82
signaling	VERB	O	O	82
of	ADP	O	O	82
the	PRON	O	O	82
hippocampus	NOUN	O	O	82
in	ADP	O	O	82
PBE	PROPN	O	O	82
induced	VERB	O	O	82
anxiety	NOUN	O	Disease	82
-	PUNCT	O	O	82
like	INTJ	O	O	82
behaviors	NOUN	O	O	82
.	PUNCT	O	O	82
Biochemical	ADJ	O	O	85
effects	NOUN	O	O	85
of	ADP	O	O	85
Solidago	PROPN	O	O	85
virgaurea	ADV	O	O	85
extract	VERB	O	O	85
on	ADP	O	O	85
experimental	ADJ	O	O	85
cardiotoxicity	NOUN	O	Disease	85
.	PUNCT	O	O	85
Cardiovascular	NOUN	O	O	86
diseases	NOUN	O	O	86
(	PUNCT	O	O	86
CVDs	NOUN	O	O	86
)	PUNCT	O	O	86
are	AUX	O	O	86
the	PRON	O	O	86
major	ADJ	O	O	86
health	NOUN	O	O	86
problem	NOUN	O	O	86
of	ADP	O	O	86
advanced	ADJ	O	O	86
as	ADP	O	O	86
well	ADV	O	O	86
as	ADP	O	O	86
developing	VERB	O	O	86
countries	NOUN	O	O	86
of	ADP	O	O	86
the	PRON	O	O	86
world	NOUN	O	O	86
.	PUNCT	O	O	86
The	PRON	O	O	87
aim	VERB	O	O	87
of	ADP	O	O	87
the	PRON	O	O	87
present	NOUN	O	O	87
study	VERB	O	O	87
was	AUX	O	O	87
to	PART	O	O	87
investigate	VERB	O	O	87
the	PRON	O	O	87
protective	ADJ	O	O	87
effect	VERB	O	O	87
of	ADP	O	O	87
the	PRON	O	O	87
Solidago	PROPN	O	O	87
virgaurea	ADV	O	O	87
extract	VERB	O	O	87
on	ADP	O	O	87
isoproterenol	NOUN	O	Chemical	87
-	PUNCT	O	O	87
induced	VERB	O	O	87
cardiotoxicity	NOUN	O	Disease	87
in	ADP	O	O	87
rats	NOUN	O	O	87
.	PUNCT	O	O	87
The	PRON	O	O	88
subcutaneous	ADJ	O	O	88
injection	NOUN	O	O	88
of	ADP	O	O	88
isoproterenol	NOUN	O	Chemical	88
(	PUNCT	O	O	88
30	NUM	O	O	88
mg	VERB	O	O	88
/	PUNCT	O	O	88
kg	VERB	O	O	88
)	PUNCT	O	O	88
into	ADP	O	O	88
rats	NOUN	O	O	88
twice	ADV	O	O	88
at	ADP	O	O	88
an	PRON	O	O	88
interval	NOUN	O	O	88
of	ADP	O	O	88
24	NUM	O	O	88
h	X	O	O	88
,	PUNCT	O	O	88
for	ADP	O	O	88
two	NUM	O	O	88
consecutive	ADJ	O	O	88
days	NOUN	O	O	88
,	PUNCT	O	O	88
led	VERB	O	O	88
to	PART	O	O	88
a	PRON	O	O	88
significant	ADJ	O	O	88
increase	VERB	O	O	88
in	ADP	O	O	88
serum	NOUN	O	O	88
lactate	NOUN	O	Chemical	88
dehydrogenase	NOUN	O	O	88
,	PUNCT	O	O	88
creatine	PROPN	O	Chemical	88
phosphokinase	NOUN	O	O	88
,	PUNCT	O	O	88
alanine	NOUN	O	Chemical	88
transaminase	X	O	O	88
,	PUNCT	O	O	88
aspartate	NOUN	O	Chemical	88
transaminase	X	O	O	88
,	PUNCT	O	O	88
and	CCONJ	O	O	88
angiotensin	NOUN	O	Chemical	88
-	PUNCT	O	O	88
converting	VERB	O	O	88
enzyme	NOUN	O	O	88
activities	NOUN	O	O	88
,	PUNCT	O	O	88
total	ADJ	O	O	88
cholesterol	NOUN	O	Chemical	88
,	PUNCT	O	O	88
triglycerides	NOUN	O	Chemical	88
,	PUNCT	O	O	88
free	ADJ	O	O	88
serum	NOUN	O	O	88
fatty	ADJ	O	O	88
acid	PROPN	O	O	88
,	PUNCT	O	O	88
cardiac	ADJ	O	O	88
tissue	NOUN	O	O	88
malondialdehyde	PROPN	O	Chemical	88
(	PUNCT	O	O	88
MDA	PROPN	O	Chemical	88
)	PUNCT	O	O	88
,	PUNCT	O	O	88
and	CCONJ	O	O	88
nitric oxide	NOUN	O	Chemical	88
levels	NOUN	O	O	88
and	CCONJ	O	O	88
a	PRON	O	O	88
significant	ADJ	O	O	88
decrease	VERB	O	O	88
in	ADP	O	O	88
levels	NOUN	O	O	88
of	ADP	O	O	88
glutathione	NOUN	O	Chemical	88
and	CCONJ	O	O	88
superoxide	NOUN	O	Chemical	88
dismutase	ADP	O	O	88
in	ADP	O	O	88
cardiac	ADJ	O	O	88
tissue	NOUN	O	O	88
as	ADP	O	O	88
compared	VERB	O	O	88
to	PART	O	O	88
the	PRON	O	O	88
normal	ADJ	O	O	88
control	VERB	O	O	88
group	NOUN	O	O	88
(	PUNCT	O	O	88
P	NOUN	O	Chemical	88
<	X	O	O	88
0.05	NUM	O	O	88
)	PUNCT	O	O	88
.	PUNCT	O	O	88
Pretreatment	NOUN	O	O	89
with	ADP	O	O	89
S.	PROPN	O	O	89
virgaurea	ADV	O	O	89
extract	VERB	O	O	89
for	ADP	O	O	89
5	NUM	O	O	89
weeks	NOUN	O	O	89
at	ADP	O	O	89
a	PRON	O	O	89
dose	NOUN	O	O	89
of	ADP	O	O	89
250	NUM	O	O	89
mg	VERB	O	O	89
/	PUNCT	O	O	89
kg	VERB	O	O	89
followed	VERB	O	O	89
by	ADP	O	O	89
isoproterenol	NOUN	O	Chemical	89
injection	NOUN	O	O	89
significantly	ADV	O	O	89
prevented	VERB	O	O	89
the	PRON	O	O	89
observed	VERB	O	O	89
alterations	NOUN	O	O	89
.	PUNCT	O	O	89
Captopril	PROPN	O	Chemical	90
(	PUNCT	O	O	90
50	NUM	O	O	90
mg	VERB	O	O	90
/	PUNCT	O	O	90
kg	VERB	O	O	90
/	PUNCT	O	O	90
day	NOUN	O	O	90
,	PUNCT	O	O	90
given	VERB	O	O	90
orally	ADV	O	O	90
)	PUNCT	O	O	90
,	PUNCT	O	O	90
an	PRON	O	O	90
inhibitor	NOUN	O	O	90
of	ADP	O	O	90
angiotensin	NOUN	O	Chemical	90
-	PUNCT	O	O	90
converting	VERB	O	O	90
enzyme	NOUN	O	O	90
used	VERB	O	O	90
as	ADP	O	O	90
a	PRON	O	O	90
standard	PROPN	O	O	90
cardioprotective	ADJ	O	O	90
drug	NOUN	O	O	90
,	PUNCT	O	O	90
was	AUX	O	O	90
used	VERB	O	O	90
as	ADP	O	O	90
a	PRON	O	O	90
positive	ADJ	O	O	90
control	VERB	O	O	90
in	ADP	O	O	90
this	PRON	O	O	90
study	VERB	O	O	90
.	PUNCT	O	O	90
The	PRON	O	O	91
data	NOUN	O	O	91
of	ADP	O	O	91
the	PRON	O	O	91
present	NOUN	O	O	91
study	VERB	O	O	91
suggest	VERB	O	O	91
that	SCONJ	O	O	91
S.	PROPN	O	O	91
virgaurea	ADV	O	O	91
extract	VERB	O	O	91
exerts	VERB	O	O	91
its	PRON	O	O	91
protective	ADJ	O	O	91
effect	VERB	O	O	91
by	ADP	O	O	91
decreasing	VERB	O	O	91
MDA	PROPN	O	Chemical	91
level	VERB	O	O	91
and	CCONJ	O	O	91
increasing	VERB	O	O	91
the	PRON	O	O	91
antioxidant	ADJ	O	O	91
status	NOUN	O	O	91
in	ADP	O	O	91
isoproterenol	NOUN	O	Chemical	91
-	PUNCT	O	O	91
treated	VERB	O	O	91
rats	NOUN	O	O	91
.	PUNCT	O	O	91
""""	PUNCT	O	O	94
Real	ADJ	O	O	94
-	PUNCT	O	O	94
world	NOUN	O	O	94
""""	PUNCT	O	O	94
data	NOUN	O	O	94
on	ADP	O	O	94
the	PRON	O	O	94
efficacy	NOUN	O	O	94
and	CCONJ	O	O	94
safety	NOUN	O	O	94
of	ADP	O	O	94
lenalidomide	PROPN	O	O	94
and	CCONJ	O	O	94
dexamethasone	NOUN	O	Chemical	94
in	ADP	O	O	94
patients	NOUN	O	O	94
with	ADP	O	O	94
relapsed	VERB	O	O	94
/	PUNCT	O	O	94
refractory	ADJ	O	O	94
multiple myeloma	NOUN	O	Disease	94
who	PRON	O	O	94
were	AUX	O	O	94
treated	VERB	O	O	94
according	VERB	O	O	94
to	PART	O	O	94
the	PRON	O	O	94
standard	PROPN	O	O	94
clinical	ADJ	O	O	94
practice	VERB	O	O	94
:	PUNCT	O	O	94
a	PRON	O	O	94
study	VERB	O	O	94
of	ADP	O	O	94
the	PRON	O	O	94
Greek	PROPN	O	O	94
Myeloma	NOUN	O	O	94
Study	NOUN	O	O	94
Group	PROPN	O	O	94
.	PUNCT	O	O	94
Lenalidomide	NOUN	O	O	95
and	CCONJ	O	O	95
dexamethasone	NOUN	O	Chemical	95
(	PUNCT	O	O	95
RD	PROPN	O	O	95
)	PUNCT	O	O	95
is	AUX	O	O	95
a	PRON	O	O	95
standard	PROPN	O	O	95
of	ADP	O	O	95
care	VERB	O	O	95
for	ADP	O	O	95
relapsed	VERB	O	O	95
/	PUNCT	O	O	95
refractory	ADJ	O	O	95
multiple myeloma	NOUN	O	Disease	95
(	PUNCT	O	O	95
RRMM	NOUN	O	O	95
)	PUNCT	O	O	95
,	PUNCT	O	O	95
but	CCONJ	O	O	95
there	ADV	O	O	95
is	AUX	O	O	95
limited	VERB	O	O	95
published	VERB	O	O	95
data	NOUN	O	O	95
on	ADP	O	O	95
its	PRON	O	O	95
efficacy	NOUN	O	O	95
and	CCONJ	O	O	95
safety	NOUN	O	O	95
in	ADP	O	O	95
the	PRON	O	O	95
""""	PUNCT	O	O	95
real	ADV	O	O	95
world	NOUN	O	O	95
""""	PUNCT	O	O	95
(	PUNCT	O	O	95
RW	NOUN	O	O	95
)	PUNCT	O	O	95
,	PUNCT	O	O	95
according	VERB	O	O	95
to	PART	O	O	95
the	PRON	O	O	95
International	PROPN	O	O	95
Society	NOUN	O	O	95
of	ADP	O	O	95
Pharmacoeconomics	NOUN	O	O	95
and	CCONJ	O	O	95
Outcomes	NOUN	O	O	95
Research	NOUN	O	O	95
definition	NOUN	O	O	95
.	PUNCT	O	O	95
We	PRON	O	O	96
studied	VERB	O	O	96
212	NUM	O	O	96
RRMM	NOUN	O	O	96
patients	NOUN	O	O	96
who	PRON	O	O	96
received	VERB	O	O	96
RD	PROPN	O	O	96
in	ADP	O	O	96
RW	NOUN	O	O	96
.	PUNCT	O	O	96
Median	ADJ	O	O	97
time	NOUN	O	O	97
to	PART	O	O	97
CR	NOUN	O	O	97
when	SCONJ	O	O	97
RD	PROPN	O	O	97
was	AUX	O	O	97
given	VERB	O	O	97
as	ADP	O	O	97
2nd	NOUN	O	O	97
or	CCONJ	O	O	97
>	PUNCT	O	O	97
2(nd)-line	NUM	O	O	97
treatment	NOUN	O	O	97
at	ADP	O	O	97
4	NUM	O	O	97
and	CCONJ	O	O	97
11	NUM	O	O	97
months	NOUN	O	O	97
,	PUNCT	O	O	97
respectively	ADV	O	O	97
.	PUNCT	O	O	97
Quality	NOUN	O	O	98
of	ADP	O	O	98
response	NOUN	O	O	98
was	AUX	O	O	98
independent	ADJ	O	O	98
of	ADP	O	O	98
previous	ADJ	O	O	98
lines	NOUN	O	O	98
of	ADP	O	O	98
therapies	NOUN	O	O	98
or	CCONJ	O	O	98
previous	ADJ	O	O	98
exposure	NOUN	O	O	98
to	PART	O	O	98
thalidomide	NOUN	O	Chemical	98
or	CCONJ	O	O	98
bortezomib	VERB	O	Chemical	98
.	PUNCT	O	O	98
Median	ADJ	O	O	99
duration	NOUN	O	O	99
of	ADP	O	O	99
response	NOUN	O	O	99
was	AUX	O	O	99
34.4	NUM	O	O	99
months	NOUN	O	O	99
,	PUNCT	O	O	99
and	CCONJ	O	O	99
it	PRON	O	O	99
was	AUX	O	O	99
higher	ADJ	O	O	99
in	ADP	O	O	99
patients	NOUN	O	O	99
who	PRON	O	O	99
received	VERB	O	O	99
RD	PROPN	O	O	99
until	ADP	O	O	99
progression	NOUN	O	O	99
(	PUNCT	O	O	99
not	PART	O	O	99
reached	VERB	O	O	99
versus	ADP	O	O	99
19	NUM	O	O	99
months	NOUN	O	O	99
,	PUNCT	O	O	99
p	NOUN	O	O	99
<	X	O	O	99
0.001	NUM	O	O	99
)	PUNCT	O	O	99
.	PUNCT	O	O	99
Adverse	ADJ	O	O	100
events	NOUN	O	O	100
were	AUX	O	O	100
reported	VERB	O	O	100
in	ADP	O	O	100
68.9	NUM	O	O	100
%	INTJ	O	O	100
of	ADP	O	O	100
patients	NOUN	O	O	100
(	PUNCT	O	O	100
myelosuppression	NOUN	O	Disease	100
in	ADP	O	O	100
49.4	NUM	O	O	100
%	INTJ	O	O	100
)	PUNCT	O	O	100
and	CCONJ	O	O	100
12.7	NUM	O	O	100
%	INTJ	O	O	100
of	ADP	O	O	100
patients	NOUN	O	O	100
needed	VERB	O	O	100
hospitalization	NOUN	O	O	100
.	PUNCT	O	O	100
Peripheral neuropathy	NOUN	O	Disease	101
was	AUX	O	O	101
observed	VERB	O	O	101
only	ADV	O	O	101
in	ADP	O	O	101
2.5	NUM	O	O	101
%	INTJ	O	O	101
of	ADP	O	O	101
patients	NOUN	O	O	101
and	CCONJ	O	O	101
deep	ADJ	O	O	101
vein thrombosis	NOUN	O	Disease	101
in	ADP	O	O	101
5.7	NUM	O	O	101
%	INTJ	O	O	101
.	PUNCT	O	O	101
Performance	NOUN	O	O	102
status	NOUN	O	O	102
(	PUNCT	O	O	102
PS	PROPN	O	O	102
)	PUNCT	O	O	102
and	CCONJ	O	O	102
initial	ADJ	O	O	102
lenalidomide	PROPN	O	O	102
dose	NOUN	O	O	102
predicted	VERB	O	O	102
for	ADP	O	O	102
treatment	NOUN	O	O	102
discontinuation	NOUN	O	O	102
.	PUNCT	O	O	102
Our	PRON	O	O	103
study	VERB	O	O	103
confirms	VERB	O	O	103
that	SCONJ	O	O	103
RD	PROPN	O	O	103
is	AUX	O	O	103
effective	ADJ	O	O	103
and	CCONJ	O	O	103
safe	ADJ	O	O	103
in	ADP	O	O	103
RRMM	NOUN	O	O	103
in	ADP	O	O	103
the	PRON	O	O	103
RW	NOUN	O	O	103
;	PUNCT	O	O	103
it	PRON	O	O	103
produces	VERB	O	O	103
durable	ADJ	O	O	103
responses	NOUN	O	O	103
especially	ADV	O	O	103
in	ADP	O	O	103
patients	NOUN	O	O	103
who	PRON	O	O	103
continue	VERB	O	O	103
on	ADP	O	O	103
treatment	NOUN	O	O	103
till	SCONJ	O	O	103
progression	NOUN	O	O	103
and	CCONJ	O	O	103
improves	VERB	O	O	103
humoral	ADJ	O	O	103
immunity	NOUN	O	O	103
even	ADV	O	O	103
in	ADP	O	O	103
patients	NOUN	O	O	103
with	ADP	O	O	103
stable	ADJ	O	O	103
disease	PROPN	O	O	103
.	PUNCT	O	O	103
The	PRON	O	O	106
cytogenetic	ADJ	O	O	106
action	NOUN	O	O	106
of	ADP	O	O	106
ifosfamide	ADP	O	Chemical	106
,	PUNCT	O	O	106
mesna	NOUN	O	Chemical	106
,	PUNCT	O	O	106
and	CCONJ	O	O	106
their	PRON	O	O	106
combination	NOUN	O	O	106
on	ADP	O	O	106
peripheral	ADJ	O	O	106
rabbit	NOUN	O	O	106
lymphocytes	VERB	O	O	106
:	PUNCT	O	O	106
an	PRON	O	O	106
in	ADP	O	O	106
vivo	VERB	O	O	106
/	PUNCT	O	O	106
in	ADP	O	O	106
vitro	X	O	O	106
cytogenetic	ADJ	O	O	106
study	VERB	O	O	106
.	PUNCT	O	O	106
Ifosfamide	PROPN	O	Chemical	107
(	PUNCT	O	O	107
IFO	PROPN	O	O	107
)	PUNCT	O	O	107
is	AUX	O	O	107
an	PRON	O	O	107
alkylating	VERB	O	O	107
nitrogen	NOUN	O	O	107
mustard	NOUN	O	O	107
,	PUNCT	O	O	107
administrated	VERB	O	O	107
as	ADP	O	O	107
an	PRON	O	O	107
antineoplasmic	NOUN	O	O	107
agent	NOUN	O	O	107
.	PUNCT	O	O	107
It	PRON	O	O	108
is	AUX	O	O	108
characterized	VERB	O	O	108
by	ADP	O	O	108
its	PRON	O	O	108
intense	ADJ	O	O	108
urotoxic	PROPN	O	O	108
action	NOUN	O	O	108
,	PUNCT	O	O	108
leading	VERB	O	O	108
to	PART	O	O	108
hemorrhagic cystitis	NOUN	O	Disease	108
.	PUNCT	O	O	108
This	PRON	O	O	109
side	NOUN	O	O	109
effect	VERB	O	O	109
of	ADP	O	O	109
IFO	PROPN	O	O	109
raises	VERB	O	O	109
the	PRON	O	O	109
requirement	NOUN	O	O	109
for	ADP	O	O	109
the	PRON	O	O	109
co	NOUN	O	O	109
-	PUNCT	O	O	109
administration	NOUN	O	O	109
with	ADP	O	O	109
sodium	NOUN	O	Chemical	109
2-sulfanylethanesulfonate	NOUN	O	O	109
(	PUNCT	O	O	109
Mesna	NOUN	O	Chemical	109
)	PUNCT	O	O	109
aiming	VERB	O	O	109
to	PART	O	O	109
avoid	VERB	O	O	109
or	CCONJ	O	O	109
minimize	VERB	O	O	109
this	PRON	O	O	109
effect	VERB	O	O	109
.	PUNCT	O	O	109
IFO	PROPN	O	O	110
and	CCONJ	O	O	110
Mesna	NOUN	O	Chemical	110
were	AUX	O	O	110
administrated	VERB	O	O	110
separately	ADV	O	O	110
on	ADP	O	O	110
rabbit	NOUN	O	O	110
's	AUX	O	O	110
lymphocytes	VERB	O	O	110
in	ADP	O	O	110
vivo	VERB	O	O	110
,	PUNCT	O	O	110
which	PRON	O	O	110
were	AUX	O	O	110
later	ADV	O	O	110
developed	VERB	O	O	110
in	ADP	O	O	110
vitro	X	O	O	110
.	PUNCT	O	O	110
Mesna	NOUN	O	Chemical	111
's	AUX	O	O	111
action	NOUN	O	O	111
,	PUNCT	O	O	111
in	ADP	O	O	111
conjunction	NOUN	O	O	111
with	ADP	O	O	111
IFO	PROPN	O	O	111
reduces	VERB	O	O	111
the	PRON	O	O	111
frequency	NOUN	O	O	111
of	ADP	O	O	111
SCEs	VERB	O	O	111
,	PUNCT	O	O	111
in	ADP	O	O	111
comparison	NOUN	O	O	111
with	ADP	O	O	111
the	PRON	O	O	111
SCEs	VERB	O	O	111
recordings	NOUN	O	O	111
obtained	VERB	O	O	111
when	SCONJ	O	O	111
IFO	PROPN	O	O	111
is	AUX	O	O	111
administered	VERB	O	O	111
alone	ADV	O	O	111
.	PUNCT	O	O	111
In	ADP	O	O	112
addition	NOUN	O	O	112
to	PART	O	O	112
this	PRON	O	O	112
,	PUNCT	O	O	112
when	SCONJ	O	O	112
high	ADJ	O	O	112
concentrations	NOUN	O	O	112
of	ADP	O	O	112
Mesna	NOUN	O	Chemical	112
were	AUX	O	O	112
administered	VERB	O	O	112
alone	ADV	O	O	112
significant	ADJ	O	O	112
reductions	NOUN	O	O	112
of	ADP	O	O	112
the	PRON	O	O	112
PRI	PROPN	O	O	112
were	AUX	O	O	112
noted	VERB	O	O	112
,	PUNCT	O	O	112
than	ADP	O	O	112
with	ADP	O	O	112
IFO	PROPN	O	O	112
acting	VERB	O	O	112
at	ADP	O	O	112
the	PRON	O	O	112
same	ADJ	O	O	112
concentration	NOUN	O	O	112
on	ADP	O	O	112
the	PRON	O	O	112
lymphocytes	VERB	O	O	112
.	PUNCT	O	O	112
Mesna	NOUN	O	Chemical	113
significantly	ADV	O	O	113
reduces	VERB	O	O	113
IFO	PROPN	O	O	113
's	AUX	O	O	113
genotoxicity	NOUN	O	O	113
,	PUNCT	O	O	113
while	SCONJ	O	O	113
when	SCONJ	O	O	113
administered	VERB	O	O	113
in	ADP	O	O	113
high	ADJ	O	O	113
concentrations	NOUN	O	O	113
it	PRON	O	O	113
acts	VERB	O	O	113
in	ADP	O	O	113
an	PRON	O	O	113
inhibitory	ADJ	O	O	113
fashion	NOUN	O	O	113
on	ADP	O	O	113
the	PRON	O	O	113
cytostatic	ADJ	O	O	113
action	NOUN	O	O	113
of	ADP	O	O	113
the	PRON	O	O	113
drug	NOUN	O	O	113
.	PUNCT	O	O	113
Risk	NOUN	O	O	116
factors	NOUN	O	O	116
and	CCONJ	O	O	116
predictors	NOUN	O	O	116
of	ADP	O	O	116
levodopa	NOUN	O	Chemical	116
-	PUNCT	O	O	116
induced	VERB	O	O	116
dyskinesia	NOUN	O	Disease	116
among	ADP	O	O	116
multiethnic	ADJ	O	O	116
Malaysians	PROPN	O	O	116
with	ADP	O	O	116
Parkinson	NOUN	O	O	116
's	AUX	O	O	116
disease	PROPN	O	O	116
.	PUNCT	O	O	116
Chronic	NOUN	O	O	117
pulsatile	ADJ	O	O	117
levodopa	NOUN	O	Chemical	117
therapy	NOUN	O	O	117
for	ADP	O	O	117
Parkinson	NOUN	O	O	117
's	AUX	O	O	117
disease	PROPN	O	O	117
(	PUNCT	O	O	117
PD	PROPN	O	Disease	117
)	PUNCT	O	O	117
leads	VERB	O	O	117
to	PART	O	O	117
the	PRON	O	O	117
development	NOUN	O	O	117
of	ADP	O	O	117
motor	NOUN	O	O	117
fluctuations	NOUN	O	O	117
and	CCONJ	O	O	117
dyskinesia	NOUN	O	Disease	117
.	PUNCT	O	O	117
We	PRON	O	O	118
studied	VERB	O	O	118
the	PRON	O	O	118
prevalence	NOUN	O	O	118
and	CCONJ	O	O	118
predictors	NOUN	O	O	118
of	ADP	O	O	118
levodopa	NOUN	O	Chemical	118
-	PUNCT	O	O	118
induced	VERB	O	O	118
dyskinesia	NOUN	O	Disease	118
among	ADP	O	O	118
multiethnic	ADJ	O	O	118
Malaysian	ADJ	O	O	118
patients	NOUN	O	O	118
with	ADP	O	O	118
PD	PROPN	O	Disease	118
.	PUNCT	O	O	118
This	PRON	O	O	119
is	AUX	O	O	119
a	PRON	O	O	119
cross	VERB	O	O	119
-	PUNCT	O	O	119
sectional	ADJ	O	O	119
study	VERB	O	O	119
involving	VERB	O	O	119
95	NUM	O	O	119
patients	NOUN	O	O	119
with	ADP	O	O	119
PD	PROPN	O	Disease	119
on	ADP	O	O	119
uninterrupted	ADJ	O	O	119
levodopa	NOUN	O	Chemical	119
therapy	NOUN	O	O	119
for	ADP	O	O	119
at	ADP	O	O	119
least	ADJ	O	O	119
6	NUM	O	O	119
months	NOUN	O	O	119
.	PUNCT	O	O	119
The	PRON	O	O	120
predictors	NOUN	O	O	120
of	ADP	O	O	120
dyskinesia	NOUN	O	Disease	120
were	AUX	O	O	120
determined	VERB	O	O	120
using	VERB	O	O	120
multivariate	ADJ	O	O	120
logistic	ADJ	O	O	120
regression	NOUN	O	O	120
analysis	NOUN	O	O	120
.	PUNCT	O	O	120
Dyskinesia	NOUN	O	O	121
was	AUX	O	O	121
present	NOUN	O	O	121
in	ADP	O	O	121
44%	NOUN	O	O	121
(	PUNCT	O	O	121
n	CCONJ	O	O	121
=	PUNCT	O	O	121
42	NUM	O	O	121
)	PUNCT	O	O	121
with	ADP	O	O	121
median	ADJ	O	O	121
levodopa	NOUN	O	Chemical	121
therapy	NOUN	O	O	121
of	ADP	O	O	121
3	X	O	O	121
years	NOUN	O	O	121
.	PUNCT	O	O	121
Eighty	NUM	O	O	122
-	PUNCT	O	O	122
one	NUM	O	O	122
percent	NOUN	O	O	122
of	ADP	O	O	122
patients	NOUN	O	O	122
with	ADP	O	O	122
dyskinesia	NOUN	O	Disease	122
had	VERB	O	O	122
clinical	ADJ	O	O	122
fluctuations	NOUN	O	O	122
.	PUNCT	O	O	122
Patients	NOUN	O	O	123
with	ADP	O	O	123
dyskinesia	NOUN	O	Disease	123
had	VERB	O	O	123
lower	ADJ	O	O	123
onset	VERB	O	O	123
age	NOUN	O	O	123
(	PUNCT	O	O	123
p	NOUN	O	O	123
<	X	O	O	124
0.001	NUM	O	O	124
)	PUNCT	O	O	124
,	PUNCT	O	O	124
longer	ADV	O	O	124
duration	NOUN	O	O	124
of	ADP	O	O	124
levodopa	NOUN	O	Chemical	124
therapy	NOUN	O	O	124
(	PUNCT	O	O	124
p	NOUN	O	O	124
<	X	O	O	125
0.001	NUM	O	O	125
)	PUNCT	O	O	125
,	PUNCT	O	O	125
higher	ADJ	O	O	125
total	ADJ	O	O	125
daily	ADV	O	O	125
levodopa	NOUN	O	Chemical	125
dose	NOUN	O	O	125
(	PUNCT	O	O	125
p	NOUN	O	O	125
<	X	O	O	126
0.001	NUM	O	O	126
)	PUNCT	O	O	126
,	PUNCT	O	O	126
and	CCONJ	O	O	126
higher	ADJ	O	O	126
total	ADJ	O	O	126
UPDRS	PROPN	O	O	126
scores	NOUN	O	O	126
(	PUNCT	O	O	126
p	NOUN	O	O	126
=	PUNCT	O	O	126
0.005	NUM	O	O	126
)	PUNCT	O	O	126
than	ADP	O	O	126
patients	NOUN	O	O	126
without	ADP	O	O	126
dyskinesia	NOUN	O	Disease	126
.	PUNCT	O	O	126
The	PRON	O	O	127
three	NUM	O	O	127
significant	ADJ	O	O	127
predictors	NOUN	O	O	127
of	ADP	O	O	127
dyskinesia	NOUN	O	Disease	127
were	AUX	O	O	127
duration	NOUN	O	O	127
of	ADP	O	O	127
levodopa	NOUN	O	Chemical	127
therapy	NOUN	O	O	127
,	PUNCT	O	O	127
onset	VERB	O	O	127
age	NOUN	O	O	127
,	PUNCT	O	O	127
and	CCONJ	O	O	127
total	ADJ	O	O	127
daily	ADV	O	O	127
levodopa	NOUN	O	Chemical	127
dose	NOUN	O	O	127
.	PUNCT	O	O	127
The	PRON	O	O	128
prevalence	NOUN	O	O	128
of	ADP	O	O	128
levodopa	NOUN	O	Chemical	128
-	PUNCT	O	O	128
induced	VERB	O	O	128
dyskinesia	NOUN	O	Disease	128
in	ADP	O	O	128
our	PRON	O	O	128
patients	NOUN	O	O	128
was	AUX	O	O	128
44%	NOUN	O	O	128
.	PUNCT	O	O	128
The	PRON	O	O	129
most	ADV	O	O	129
significant	ADJ	O	O	129
predictors	NOUN	O	O	129
were	AUX	O	O	129
duration	NOUN	O	O	129
of	ADP	O	O	129
levodopa	NOUN	O	Chemical	129
therapy	NOUN	O	O	129
,	PUNCT	O	O	129
total	ADJ	O	O	129
daily	ADV	O	O	129
levodopa	NOUN	O	Chemical	129
dose	NOUN	O	O	129
,	PUNCT	O	O	129
and	CCONJ	O	O	129
onset	VERB	O	O	129
age	NOUN	O	O	129
.	PUNCT	O	O	129
An	PRON	O	O	132
unexpected	ADJ	O	O	132
diagnosis	NOUN	O	O	132
in	ADP	O	O	132
a	PRON	O	O	132
renal	ADJ	O	O	132
-	PUNCT	O	O	132
transplant	NOUN	O	O	132
patient	NOUN	O	O	132
with	ADP	O	O	132
proteinuria	X	O	Disease	132
treated	VERB	O	O	132
with	ADP	O	O	132
everolimus	ADJ	O	Chemical	132
:	PUNCT	O	O	132
AL	PROPN	O	O	132
amyloidosis	NOUN	O	O	132
.	PUNCT	O	O	132
Proteinuria	PROPN	O	Disease	133
is	AUX	O	O	133
an	PRON	O	O	133
expected	VERB	O	O	133
complication	NOUN	O	O	133
in	ADP	O	O	133
transplant	NOUN	O	O	133
patients	NOUN	O	O	133
treated	VERB	O	O	133
with	ADP	O	O	133
mammalian	ADJ	O	O	133
target	NOUN	O	O	133
of	ADP	O	O	133
rapamycin	NOUN	O	Chemical	133
inhibitors	NOUN	O	O	133
(	PUNCT	O	O	133
mTOR	PROPN	O	O	133
-	PUNCT	O	O	133
i	PRON	O	O	133
)	PUNCT	O	O	133
.	PUNCT	O	O	133
However	ADV	O	O	134
,	PUNCT	O	O	134
clinical	ADJ	O	O	134
suspicion	NOUN	O	O	134
should	AUX	O	O	134
always	ADV	O	O	134
be	AUX	O	O	134
supported	VERB	O	O	134
by	ADP	O	O	134
histological	ADJ	O	O	134
evidence	NOUN	O	O	134
in	ADP	O	O	134
order	NOUN	O	O	134
to	PART	O	O	134
investigate	VERB	O	O	134
potential	ADJ	O	O	134
alternate	ADJ	O	O	134
diagnoses	NOUN	O	O	134
such	ADJ	O	O	134
as	ADP	O	O	134
acute	ADJ	O	O	134
or	CCONJ	O	O	134
chronic	ADJ	O	O	134
rejection	NOUN	O	O	134
,	PUNCT	O	O	134
interstitial	ADJ	O	O	134
fibrosis	NOUN	O	Disease	134
and	CCONJ	O	O	134
tubular	ADJ	O	O	134
atrophy	NOUN	O	Disease	134
,	PUNCT	O	O	134
or	CCONJ	O	O	134
recurrent	ADJ	O	O	134
or	CCONJ	O	O	134
de	VERB	O	O	134
novo	PROPN	O	O	134
glomerulopathy	ADJ	O	O	134
.	PUNCT	O	O	134
In	ADP	O	O	135
this	PRON	O	O	135
case	NOUN	O	O	135
we	PRON	O	O	135
report	VERB	O	O	135
the	PRON	O	O	135
unexpected	ADJ	O	O	135
diagnosis	NOUN	O	O	135
of	ADP	O	O	135
amyloidosis	NOUN	O	O	135
in	ADP	O	O	135
a	PRON	O	O	135
renal	ADJ	O	O	135
-	PUNCT	O	O	135
transplant	NOUN	O	O	135
patient	NOUN	O	O	135
with	ADP	O	O	135
pre	VERB	O	O	135
-	PUNCT	O	O	135
transplant	NOUN	O	O	135
monoclonal	NOUN	O	O	135
gammapathy	NOUN	O	O	135
of	ADP	O	O	135
undetermined	ADJ	O	O	135
significance	NOUN	O	O	135
who	PRON	O	O	135
developed	VERB	O	O	135
proteinuria	X	O	Disease	135
after	ADP	O	O	135
conversion	NOUN	O	O	135
from	ADP	O	O	135
tacrolimus	NOUN	O	Chemical	135
to	PART	O	O	135
everolimus	ADJ	O	Chemical	135
.	PUNCT	O	O	135
An	PRON	O	O	138
investigation	NOUN	O	O	138
of	ADP	O	O	138
the	PRON	O	O	138
pattern	NOUN	O	O	138
of	ADP	O	O	138
kidney	NOUN	O	O	138
injury	NOUN	O	O	138
in	ADP	O	O	138
HIV	PROPN	O	O	138
-	PUNCT	O	O	138
positive	ADJ	O	O	138
persons	NOUN	O	O	138
exposed	VERB	O	O	138
to	PART	O	O	138
tenofovir disoproxil fumarate	NOUN	O	Chemical	138
:	PUNCT	O	O	138
an	PRON	O	O	138
examination	NOUN	O	O	138
of	ADP	O	O	138
a	PRON	O	O	138
large	ADJ	O	O	138
population	NOUN	O	O	138
database	NOUN	O	O	138
(	PUNCT	O	O	138
MHRA	PROPN	O	O	138
database	NOUN	O	O	138
)	PUNCT	O	O	138
.	PUNCT	O	O	138
The	PRON	O	O	139
potential	ADJ	O	O	139
for	ADP	O	O	139
tenofovir	NOUN	O	Chemical	139
to	PART	O	O	139
cause	VERB	O	O	139
a	PRON	O	O	139
range	VERB	O	O	139
of	ADP	O	O	139
kidney	NOUN	O	O	139
syndromes	NOUN	O	O	139
has	VERB	O	O	139
been	AUX	O	O	139
established	VERB	O	O	139
from	ADP	O	O	139
mechanistic	ADJ	O	O	139
and	CCONJ	O	O	139
randomised	VERB	O	O	139
clinical	ADJ	O	O	139
trials	NOUN	O	O	139
.	PUNCT	O	O	139
We	PRON	O	O	140
undertook	VERB	O	O	140
a	PRON	O	O	140
descriptive	ADJ	O	O	140
analysis	NOUN	O	O	140
of	ADP	O	O	140
Yellow	NOUN	O	O	140
Card	NOUN	O	O	140
records	NOUN	O	O	140
of	ADP	O	O	140
407	NUM	O	O	140
HIV	PROPN	O	O	140
-	PUNCT	O	O	140
positive	ADJ	O	O	140
persons	NOUN	O	O	140
taking	VERB	O	O	140
tenofovir disoproxil fumarate	NOUN	O	Chemical	140
(	PUNCT	O	O	140
TDF	PROPN	O	O	140
)	PUNCT	O	O	140
as	ADP	O	O	140
part	NOUN	O	O	140
of	ADP	O	O	140
their	PRON	O	O	140
antiretroviral	ADJ	O	O	140
therapy	NOUN	O	O	140
regimen	NOUN	O	O	140
and	CCONJ	O	O	140
submitted	VERB	O	O	140
to	PART	O	O	140
the	PRON	O	O	140
Medicines	NOUN	O	O	140
and	CCONJ	O	O	140
Healthcare	PROPN	O	O	140
Products	NOUN	O	O	140
Regulatory	ADJ	O	O	140
Agency	PROPN	O	O	140
(	PUNCT	O	O	140
MHRA	PROPN	O	O	140
)	PUNCT	O	O	140
with	ADP	O	O	140
suspected	VERB	O	O	140
kidney	NOUN	O	O	140
adverse	ADJ	O	O	140
effects	NOUN	O	O	140
.	PUNCT	O	O	140
Reports	NOUN	O	O	141
that	SCONJ	O	O	141
satisfy	VERB	O	O	141
defined	VERB	O	O	141
criteria	NOUN	O	O	141
were	AUX	O	O	141
classified	VERB	O	O	141
as	ADP	O	O	141
acute	ADJ	O	O	141
kidney	NOUN	O	O	141
injury	NOUN	O	O	141
,	PUNCT	O	O	141
kidney	NOUN	O	O	141
tubular	ADJ	O	O	141
dysfunction	NOUN	O	O	141
and	CCONJ	O	O	141
Fanconi syndrome	NOUN	O	Disease	141
.	PUNCT	O	O	141
Of	ADV	O	O	142
the	PRON	O	O	142
407	NUM	O	O	142
Yellow	NOUN	O	O	142
Card	NOUN	O	O	142
records	NOUN	O	O	142
analysed	VERB	O	O	142
,	PUNCT	O	O	142
106	NUM	O	O	142
satisfied	ADJ	O	O	142
criteria	NOUN	O	O	142
for	ADP	O	O	142
TDF	PROPN	O	O	142
-	PUNCT	O	O	142
related	ADJ	O	O	142
kidney	NOUN	O	O	142
disease	PROPN	O	O	142
,	PUNCT	O	O	142
of	ADP	O	O	142
which	PRON	O	O	142
53	NUM	O	O	142
(	PUNCT	O	O	142
50%	NOUN	O	O	142
)	PUNCT	O	O	142
had	VERB	O	O	142
features	VERB	O	O	142
of	ADP	O	O	142
kidney	NOUN	O	O	142
tubular	ADJ	O	O	142
dysfunction	NOUN	O	O	142
,	PUNCT	O	O	142
35	NUM	O	O	142
(	PUNCT	O	O	142
33%	NOUN	O	O	142
)	PUNCT	O	O	142
were	AUX	O	O	142
found	VERB	O	O	142
to	PART	O	O	142
have	VERB	O	O	142
features	VERB	O	O	142
of	ADP	O	O	142
glomerular	ADJ	O	O	142
dysfunction	NOUN	O	O	142
and	CCONJ	O	O	142
18	NUM	O	O	142
(	PUNCT	O	O	142
17%	NOUN	O	O	142
)	PUNCT	O	O	142
had	VERB	O	O	142
Fanconi syndrome	NOUN	O	Disease	142
.	PUNCT	O	O	142
The	PRON	O	O	143
median	ADJ	O	O	143
TDF	PROPN	O	O	143
exposure	NOUN	O	O	143
was	AUX	O	O	143
316	NUM	O	O	143
days	NOUN	O	O	143
(	PUNCT	O	O	143
interquartile	PROPN	O	O	143
range	VERB	O	O	143
120	NUM	O	O	143
-	PUNCT	O	O	143
740	NUM	O	O	143
)	PUNCT	O	O	143
.	PUNCT	O	O	143
The	PRON	O	O	144
incidence	NOUN	O	O	144
of	ADP	O	O	144
hospitalisation	NOUN	O	O	144
for	ADP	O	O	144
TDF	PROPN	O	O	144
kidney	NOUN	O	O	144
adverse	ADJ	O	O	144
effects	NOUN	O	O	144
was	AUX	O	O	144
high	ADJ	O	O	144
,	PUNCT	O	O	144
particularly	ADV	O	O	144
amongst	ADV	O	O	144
patients	NOUN	O	O	144
with	ADP	O	O	144
features	VERB	O	O	144
of	ADP	O	O	144
Fanconi syndrome	NOUN	O	Disease	144
.	PUNCT	O	O	144
Cessation	NOUN	O	O	145
of	ADP	O	O	145
TDF	PROPN	O	O	145
was	AUX	O	O	145
associated	VERB	O	O	145
with	ADP	O	O	145
complete	VERB	O	O	145
restoration	NOUN	O	O	145
of	ADP	O	O	145
kidney	NOUN	O	O	145
function	NOUN	O	O	145
in	ADP	O	O	145
up	ADP	O	O	145
half	NOUN	O	O	145
of	ADP	O	O	145
the	PRON	O	O	145
patients	NOUN	O	O	145
in	ADP	O	O	145
this	PRON	O	O	145
report	VERB	O	O	145
.	PUNCT	O	O	145
Incidence	NOUN	O	O	148
of	ADP	O	O	148
postoperative delirium	NOUN	O	Disease	148
is	AUX	O	O	148
high	ADJ	O	O	148
even	ADV	O	O	148
in	ADP	O	O	148
a	PRON	O	O	148
population	NOUN	O	O	148
without	ADP	O	O	148
known	VERB	O	O	148
risk	NOUN	O	O	148
factors	NOUN	O	O	148
.	PUNCT	O	O	148
Postoperative delirium	NOUN	O	Disease	149
is	AUX	O	O	149
a	PRON	O	O	149
recognized	VERB	O	O	149
complication	NOUN	O	O	149
in	ADP	O	O	149
populations	NOUN	O	O	149
at	ADP	O	O	149
risk	NOUN	O	O	149
.	PUNCT	O	O	149
The	PRON	O	O	150
aim	VERB	O	O	150
of	ADP	O	O	150
this	PRON	O	O	150
study	VERB	O	O	150
is	AUX	O	O	150
to	PART	O	O	150
assess	VERB	O	O	150
the	PRON	O	O	150
prevalence	NOUN	O	O	150
of	ADP	O	O	150
early	ADV	O	O	150
postoperative delirium	NOUN	O	Disease	150
in	ADP	O	O	150
a	PRON	O	O	150
population	NOUN	O	O	150
without	ADP	O	O	150
known	VERB	O	O	150
risk	NOUN	O	O	150
factors	NOUN	O	O	150
admitted	VERB	O	O	150
to	PART	O	O	150
the	PRON	O	O	150
ICU	PROPN	O	O	150
for	ADP	O	O	150
postoperative	ADJ	O	O	150
monitoring	NOUN	O	O	150
after	ADP	O	O	150
elective	PROPN	O	O	150
major	ADJ	O	O	150
surgery	NOUN	O	O	150
.	PUNCT	O	O	150
Exclusion	NOUN	O	O	151
criteria	NOUN	O	O	151
were	AUX	O	O	151
any	PRON	O	O	151
preexisting	VERB	O	O	151
predisposing	VERB	O	O	151
factor	NOUN	O	O	151
for	ADP	O	O	151
delirium	NOUN	O	Disease	151
or	CCONJ	O	O	151
other	ADJ	O	O	151
potentially	ADV	O	O	151
confounding	VERB	O	O	151
neurological dysfunctions	NOUN	O	Disease	151
.	PUNCT	O	O	151
Patients	NOUN	O	O	152
were	AUX	O	O	152
assessed	VERB	O	O	152
daily	ADV	O	O	152
using	VERB	O	O	152
the	PRON	O	O	152
confusion	NOUN	O	Disease	152
assessment	NOUN	O	O	152
method	NOUN	O	O	152
for	ADP	O	O	152
the	PRON	O	O	152
ICU	PROPN	O	O	152
scale	NOUN	O	O	152
for	ADP	O	O	152
3	X	O	O	152
days	NOUN	O	O	152
after	ADP	O	O	152
the	PRON	O	O	152
surgical	ADJ	O	O	152
procedure	NOUN	O	O	152
.	PUNCT	O	O	152
Early	ADJ	O	O	153
postoperative delirium	NOUN	O	Disease	153
incidence	NOUN	O	O	153
risk	NOUN	O	O	153
factors	NOUN	O	O	153
were	AUX	O	O	153
then	ADV	O	O	153
assessed	VERB	O	O	153
through	ADP	O	O	153
three	NUM	O	O	153
different	ADJ	O	O	153
multiple	ADJ	O	O	153
regression	NOUN	O	O	153
models	NOUN	O	O	153
.	PUNCT	O	O	153
According	VERB	O	O	154
to	PART	O	O	154
the	PRON	O	O	154
confusion	NOUN	O	Disease	154
assessment	NOUN	O	O	154
method	NOUN	O	O	154
for	ADP	O	O	154
the	PRON	O	O	154
ICU	PROPN	O	O	154
scale	NOUN	O	O	154
,	PUNCT	O	O	154
28	NUM	O	O	154
%	INTJ	O	O	154
of	ADP	O	O	154
patients	NOUN	O	O	154
were	AUX	O	O	154
diagnosed	VERB	O	O	154
with	ADP	O	O	154
early	ADV	O	O	154
postoperative delirium	NOUN	O	Disease	154
.	PUNCT	O	O	154
The	PRON	O	O	155
use	VERB	O	O	155
of	ADP	O	O	155
thiopentone	NOUN	O	Chemical	155
was	AUX	O	O	155
significantly	ADV	O	O	155
associated	VERB	O	O	155
with	ADP	O	O	155
an	PRON	O	O	155
eight	NUM	O	O	155
-	PUNCT	O	O	155
fold	VERB	O	O	155
-	PUNCT	O	O	155
higher	ADJ	O	O	155
risk	NOUN	O	O	155
for	ADP	O	O	155
delirium	NOUN	O	Disease	155
compared	VERB	O	O	155
to	PART	O	O	155
propofol	VERB	O	Chemical	155
(	PUNCT	O	O	155
57.1%	NOUN	O	O	155
CONCLUSION	PROPN	O	O	156
:	PUNCT	O	O	156
In	ADP	O	O	156
this	PRON	O	O	156
study	VERB	O	O	156
early	ADV	O	O	156
postoperative delirium	NOUN	O	Disease	156
was	AUX	O	O	156
found	VERB	O	O	156
to	PART	O	O	156
be	AUX	O	O	156
a	PRON	O	O	156
very	ADV	O	O	156
common	ADJ	O	O	156
complication	NOUN	O	O	156
after	ADP	O	O	156
major	ADJ	O	O	156
surgery	NOUN	O	O	156
,	PUNCT	O	O	156
even	ADV	O	O	156
in	ADP	O	O	156
a	PRON	O	O	156
population	NOUN	O	O	156
without	ADP	O	O	156
known	VERB	O	O	156
risk	NOUN	O	O	156
factors	NOUN	O	O	156
.	PUNCT	O	O	156
Thiopentone	NOUN	O	O	157
was	AUX	O	O	157
independently	ADV	O	O	157
associated	VERB	O	O	157
with	ADP	O	O	157
an	PRON	O	O	157
increase	VERB	O	O	157
in	ADP	O	O	157
its	PRON	O	O	157
relative	ADJ	O	O	157
risk	NOUN	O	O	157
.	PUNCT	O	O	157
A	PRON	O	O	160
single	ADJ	O	O	160
neurotoxic	ADJ	O	Disease	160
dose	NOUN	O	O	160
of	ADP	O	O	160
methamphetamine	NOUN	O	Chemical	160
induces	VERB	O	O	160
a	PRON	O	O	160
long	ADV	O	O	160
-	PUNCT	O	O	160
lasting	VERB	O	O	160
depressive	ADJ	O	Disease	160
-	PUNCT	O	O	160
like	INTJ	O	O	160
behaviour	NOUN	O	O	160
in	ADP	O	O	160
mice	NOUN	O	O	160
.	PUNCT	O	O	160
Methamphetamine	NOUN	O	Chemical	161
(	PUNCT	O	O	161
METH	NOUN	O	Chemical	161
)	PUNCT	O	O	161
triggers	VERB	O	O	161
a	PRON	O	O	161
disruption	NOUN	O	O	161
of	ADP	O	O	161
the	PRON	O	O	161
monoaminergic	ADJ	O	O	161
system	NOUN	O	O	161
and	CCONJ	O	O	161
METH	NOUN	O	Chemical	161
abuse	VERB	O	O	161
leads	VERB	O	O	161
to	PART	O	O	161
negative	ADJ	O	O	161
emotional	ADJ	O	O	161
states	VERB	O	O	161
including	VERB	O	O	161
depressive symptoms	NOUN	O	Disease	161
during	ADP	O	O	161
drug	NOUN	O	O	161
withdrawal	NOUN	O	O	161
.	PUNCT	O	O	161
However	ADV	O	O	162
,	PUNCT	O	O	162
it	PRON	O	O	162
is	AUX	O	O	162
currently	ADV	O	O	162
unknown	ADJ	O	O	162
if	SCONJ	O	O	162
the	PRON	O	O	162
acute	ADJ	O	O	162
toxic	ADJ	O	O	162
dosage	NOUN	O	O	162
of	ADP	O	O	162
METH	NOUN	O	Chemical	162
also	ADV	O	O	162
causes	VERB	O	O	162
a	PRON	O	O	162
long	ADV	O	O	162
-	PUNCT	O	O	162
lasting	VERB	O	O	162
depressive	ADJ	O	Disease	162
phenotype	NOUN	O	O	162
and	CCONJ	O	O	162
persistent	ADJ	O	O	162
monoaminergic	ADJ	O	O	162
deficits	NOUN	O	O	162
.	PUNCT	O	O	162
Thus	ADV	O	O	163
,	PUNCT	O	O	163
we	PRON	O	O	163
now	ADV	O	O	163
assessed	VERB	O	O	163
the	PRON	O	O	163
depressive	ADJ	O	Disease	163
-	PUNCT	O	O	163
like	INTJ	O	O	163
behaviour	NOUN	O	O	163
in	ADP	O	O	163
mice	NOUN	O	O	163
at	ADP	O	O	163
early	ADV	O	O	163
and	CCONJ	O	O	163
long	ADV	O	O	163
-	PUNCT	O	O	163
term	NOUN	O	O	163
periods	NOUN	O	O	163
following	VERB	O	O	163
a	PRON	O	O	163
single	ADJ	O	O	163
high	ADJ	O	O	163
METH	NOUN	O	Chemical	163
dose	NOUN	O	O	163
(	PUNCT	O	O	163
30	NUM	O	O	163
mg	VERB	O	O	163
/	PUNCT	O	O	163
kg	VERB	O	O	163
,	PUNCT	O	O	163
i.p	NOUN	O	O	163
.	PUNCT	O	O	163
)	PUNCT	O	O	163
.	PUNCT	O	O	163
METH	NOUN	O	Chemical	164
did	VERB	O	O	164
not	PART	O	O	164
alter	VERB	O	O	164
the	PRON	O	O	164
motor	NOUN	O	O	164
function	NOUN	O	O	164
and	CCONJ	O	O	164
procedural	ADJ	O	O	164
memory	NOUN	O	O	164
of	ADP	O	O	164
mice	NOUN	O	O	164
as	ADP	O	O	164
assessed	VERB	O	O	164
by	ADP	O	O	164
swimming	VERB	O	O	164
speed	NOUN	O	O	164
and	CCONJ	O	O	164
escape	VERB	O	O	164
latency	VERB	O	O	164
to	PART	O	O	164
find	VERB	O	O	164
the	PRON	O	O	164
platform	NOUN	O	O	164
in	ADP	O	O	164
a	PRON	O	O	164
cued	VERB	O	O	164
version	NOUN	O	O	164
of	ADP	O	O	164
the	PRON	O	O	164
water	PROPN	O	O	164
maze	NOUN	O	O	164
task	NOUN	O	O	164
.	PUNCT	O	O	164
However	ADV	O	O	165
,	PUNCT	O	O	165
METH	NOUN	O	Chemical	165
significantly	ADV	O	O	165
increased	VERB	O	O	165
the	PRON	O	O	165
immobility	NOUN	O	O	165
time	NOUN	O	O	165
in	ADP	O	O	165
the	PRON	O	O	165
tail	NOUN	O	O	165
suspension	NOUN	O	O	165
test	NOUN	O	O	165
at	ADP	O	O	165
3	X	O	O	165
and	CCONJ	O	O	165
49	NUM	O	O	165
days	NOUN	O	O	165
post	VERB	O	O	165
-	PUNCT	O	O	165
administration	NOUN	O	O	165
.	PUNCT	O	O	165
This	PRON	O	O	166
depressive	ADJ	O	Disease	166
-	PUNCT	O	O	166
like	INTJ	O	O	166
profile	NOUN	O	O	166
induced	VERB	O	O	166
by	ADP	O	O	166
METH	NOUN	O	Chemical	166
was	AUX	O	O	166
accompanied	VERB	O	O	166
by	ADP	O	O	166
a	PRON	O	O	166
marked	VERB	O	O	166
depletion	NOUN	O	O	166
of	ADP	O	O	166
frontostriatal	NOUN	O	O	166
dopaminergic	ADJ	O	O	166
and	CCONJ	O	O	166
serotonergic	ADJ	O	O	166
neurotransmission	NOUN	O	O	166
,	PUNCT	O	O	166
indicated	VERB	O	O	166
by	ADP	O	O	166
a	PRON	O	O	166
reduction	NOUN	O	O	166
in	ADP	O	O	166
the	PRON	O	O	166
levels	NOUN	O	O	166
of	ADP	O	O	166
dopamine	NOUN	O	Chemical	166
,	PUNCT	O	O	166
DOPAC	PROPN	O	Chemical	166
and	CCONJ	O	O	166
HVA	PROPN	O	O	166
,	PUNCT	O	O	166
tyrosine	NOUN	O	Chemical	166
hydroxylase	NOUN	O	O	166
and	CCONJ	O	O	166
serotonin	PROPN	O	Chemical	166
,	PUNCT	O	O	166
observed	VERB	O	O	166
at	ADP	O	O	166
both	PRON	O	O	166
3	X	O	O	166
and	CCONJ	O	O	166
49	NUM	O	O	166
days	NOUN	O	O	166
post	VERB	O	O	166
-	PUNCT	O	O	166
administration	NOUN	O	O	166
.	PUNCT	O	O	166
In	ADP	O	O	167
parallel	ADJ	O	O	167
,	PUNCT	O	O	167
another	PRON	O	O	167
neurochemical	ADJ	O	O	167
feature	VERB	O	O	167
of	ADP	O	O	167
depression	PROPN	O	Disease	167
--	PUNCT	O	O	167
astroglial	ADV	O	O	167
dysfunction	NOUN	O	O	167
--	PUNCT	O	O	167
was	AUX	O	O	167
unaffected	ADJ	O	O	167
in	ADP	O	O	167
the	PRON	O	O	167
cortex	VERB	O	O	167
and	CCONJ	O	O	167
the	PRON	O	O	167
striatal	ADJ	O	O	167
levels	NOUN	O	O	167
of	ADP	O	O	167
the	PRON	O	O	167
astrocytic	ADJ	O	O	167
protein	NOUN	O	O	167
marker	NOUN	O	O	167
,	PUNCT	O	O	167
glial	ADJ	O	O	167
fibrillary	NOUN	O	O	167
acidic	ADJ	O	O	167
protein	NOUN	O	O	167
,	PUNCT	O	O	167
were	AUX	O	O	167
only	ADV	O	O	167
transiently	ADV	O	O	167
increased	VERB	O	O	167
at	ADP	O	O	167
3	X	O	O	167
days	NOUN	O	O	167
.	PUNCT	O	O	167
These	PRON	O	O	168
findings	NOUN	O	O	168
demonstrate	VERB	O	O	168
for	ADP	O	O	168
the	PRON	O	O	168
first	ADV	O	O	168
time	NOUN	O	O	168
that	SCONJ	O	O	168
a	PRON	O	O	168
single	ADJ	O	O	168
high	ADJ	O	O	168
dose	NOUN	O	O	168
of	ADP	O	O	168
METH	NOUN	O	Chemical	168
induces	VERB	O	O	168
long	ADV	O	O	168
-	PUNCT	O	O	168
lasting	VERB	O	O	168
depressive	ADJ	O	Disease	168
-	PUNCT	O	O	168
like	INTJ	O	O	168
behaviour	NOUN	O	O	168
in	ADP	O	O	168
mice	NOUN	O	O	168
associated	VERB	O	O	168
with	ADP	O	O	168
a	PRON	O	O	168
persistent	ADJ	O	O	168
disruption	NOUN	O	O	168
of	ADP	O	O	168
frontostriatal	NOUN	O	O	168
dopaminergic	ADJ	O	O	168
and	CCONJ	O	O	168
serotonergic	ADJ	O	O	168
homoeostasis	NOUN	O	O	168
.	PUNCT	O	O	168
Linezolid	NOUN	O	O	171
-	PUNCT	O	O	171
induced	VERB	O	O	171
optic neuropathy	NOUN	O	Disease	171
.	PUNCT	O	O	171
We	PRON	O	O	172
describe	VERB	O	O	172
a	PRON	O	O	172
case	NOUN	O	O	172
of	ADP	O	O	172
progressive	ADJ	O	O	172
loss of vision	NOUN	O	Disease	172
associated	VERB	O	O	172
with	ADP	O	O	172
linezolid	PROPN	O	O	172
therapy	NOUN	O	O	172
.	PUNCT	O	O	172
A	PRON	O	O	173
45-year	NOUN	O	O	173
-	PUNCT	O	O	173
old	ADJ	O	O	173
male	NOUN	O	O	173
patient	NOUN	O	O	173
who	PRON	O	O	173
was	AUX	O	O	173
on	ADP	O	O	173
treatment	NOUN	O	O	173
with	ADP	O	O	173
multiple	ADJ	O	O	173
second	ADV	O	O	173
-	PUNCT	O	O	173
line	NOUN	O	O	173
anti	ADJ	O	O	173
-	PUNCT	O	O	173
tuberculous	ADJ	O	Disease	173
drugs	NOUN	O	O	173
including	VERB	O	O	173
linezolid	PROPN	O	O	173
and	CCONJ	O	O	173
ethambutol	PROPN	O	Chemical	173
for	ADP	O	O	173
extensively	ADV	O	O	173
drug	NOUN	O	O	173
-	PUNCT	O	O	173
resistant	ADJ	O	O	173
tuberculosis	NOUN	O	Disease	173
(	PUNCT	O	O	173
XDR	PROPN	O	O	173
-	PUNCT	O	O	173
TB	PROPN	O	O	173
)	PUNCT	O	O	173
presented	VERB	O	O	173
to	PART	O	O	173
us	PRON	O	O	173
with	ADP	O	O	173
painless	ADJ	O	O	173
progressive	ADJ	O	O	173
loss of vision	NOUN	O	Disease	173
in	ADP	O	O	173
both	PRON	O	O	173
eyes	NOUN	O	O	173
.	PUNCT	O	O	173
Color	NOUN	O	O	174
vision	PROPN	O	O	174
was	AUX	O	O	174
defective	ADJ	O	O	174
and	CCONJ	O	O	174
fundus	NOUN	O	O	174
examination	NOUN	O	O	174
revealed	VERB	O	O	174
optic	NOUN	O	O	174
disc	NOUN	O	O	174
edema	NOUN	O	Disease	174
in	ADP	O	O	174
both	PRON	O	O	174
eyes	NOUN	O	O	174
.	PUNCT	O	O	174
Ethambutol	PROPN	O	Chemical	175
-	PUNCT	O	O	175
induced	VERB	O	O	175
toxic optic neuropathy	NOUN	O	Disease	175
was	AUX	O	O	175
suspected	VERB	O	O	175
and	CCONJ	O	O	175
tablet	PROPN	O	O	175
ethambutol	PROPN	O	Chemical	175
was	AUX	O	O	175
withdrawn	VERB	O	O	175
.	PUNCT	O	O	175
Deterioration	NOUN	O	O	176
of	ADP	O	O	176
vision	PROPN	O	O	176
occurred	VERB	O	O	176
despite	SCONJ	O	O	176
withdrawal	NOUN	O	O	176
of	ADP	O	O	176
ethambutol	PROPN	O	Chemical	176
.	PUNCT	O	O	176
Discontinuation	NOUN	O	O	177
of	ADP	O	O	177
linezolid	PROPN	O	O	177
resulted	VERB	O	O	177
in	ADP	O	O	177
marked	VERB	O	O	177
improvement	NOUN	O	O	177
of	ADP	O	O	177
vision	PROPN	O	O	177
.	PUNCT	O	O	177
Our	PRON	O	O	178
report	VERB	O	O	178
emphasizes	VERB	O	O	178
the	PRON	O	O	178
need	VERB	O	O	178
for	ADP	O	O	178
monitoring	NOUN	O	O	178
of	ADP	O	O	178
visual	ADJ	O	O	178
function	NOUN	O	O	178
in	ADP	O	O	178
patients	NOUN	O	O	178
on	ADP	O	O	178
long	ADV	O	O	178
-	PUNCT	O	O	178
term	NOUN	O	O	178
linezolid	PROPN	O	O	178
treatment	NOUN	O	O	178
.	PUNCT	O	O	178
Resuscitation	NOUN	O	O	181
with	ADP	O	O	181
lipid	NOUN	O	O	181
,	PUNCT	O	O	181
epinephrine	NOUN	O	Chemical	181
,	PUNCT	O	O	181
or	CCONJ	O	O	181
both	PRON	O	O	181
in	ADP	O	O	181
levobupivacaine	PROPN	O	Chemical	181
-	PUNCT	O	O	181
induced	VERB	O	O	181
cardiac toxicity	NOUN	O	Disease	181
in	ADP	O	O	181
newborn	ADJ	O	O	181
piglets	NOUN	O	O	181
.	PUNCT	O	O	181
The	PRON	O	O	182
optimal	ADJ	O	O	182
dosing	VERB	O	O	182
regimens	NOUN	O	O	182
of	ADP	O	O	182
lipid	NOUN	O	O	182
emulsion	NOUN	O	O	182
,	PUNCT	O	O	182
epinephrine	NOUN	O	Chemical	182
,	PUNCT	O	O	182
or	CCONJ	O	O	182
both	PRON	O	O	182
are	AUX	O	O	182
not	PART	O	O	182
yet	ADV	O	O	182
determined	VERB	O	O	182
in	ADP	O	O	182
neonates	NOUN	O	O	182
in	ADP	O	O	182
cases	NOUN	O	O	182
of	ADP	O	O	182
local	ADJ	O	O	182
anaesthetic	NOUN	O	O	182
systemic	ADJ	O	O	182
toxicity	NOUN	O	Disease	182
(	PUNCT	O	O	182
LAST	ADJ	O	O	182
)	PUNCT	O	O	182
.	PUNCT	O	O	182
Newborn	ADJ	O	O	183
piglets	NOUN	O	O	183
received	VERB	O	O	183
levobupivacaine	PROPN	O	Chemical	183
until	ADP	O	O	183
cardiovascular	ADJ	O	O	183
collapse	VERB	O	O	183
occurred	VERB	O	O	183
.	PUNCT	O	O	183
Standard	PROPN	O	O	184
cardiopulmonary	VERB	O	O	184
resuscitation	NOUN	O	O	184
was	AUX	O	O	184
started	VERB	O	O	184
and	CCONJ	O	O	184
electrocardiogram	PROPN	O	O	184
(	PUNCT	O	O	184
ECG	PROPN	O	O	184
)	PUNCT	O	O	184
was	AUX	O	O	184
monitored	VERB	O	O	184
for	ADP	O	O	184
ventricular tachycardia	NOUN	O	Disease	184
,	PUNCT	O	O	184
fibrillation	NOUN	O	O	184
,	PUNCT	O	O	184
or	CCONJ	O	O	184
QRS	PROPN	O	O	184
prolongation	NOUN	O	O	184
.	PUNCT	O	O	184
Piglets	NOUN	O	O	185
were	AUX	O	O	185
then	ADV	O	O	185
randomly	ADV	O	O	185
allocated	VERB	O	O	185
to	PART	O	O	185
four	NUM	O	O	185
groups	NOUN	O	O	185
:	PUNCT	O	O	185
control	VERB	O	O	185
(	PUNCT	O	O	185
saline	NOUN	O	O	185
)	PUNCT	O	O	185
,	PUNCT	O	O	185
Intralipid	NOUN	O	O	185
(	PUNCT	O	O	185
)	PUNCT	O	O	185
alone	ADV	O	O	185
,	PUNCT	O	O	185
epinephrine	NOUN	O	Chemical	185
alone	ADV	O	O	185
,	PUNCT	O	O	185
or	CCONJ	O	O	185
a	PRON	O	O	185
combination	NOUN	O	O	185
of	ADP	O	O	185
Intralipd	PROPN	O	O	185
plus	CCONJ	O	O	185
epinephrine	NOUN	O	Chemical	185
.	PUNCT	O	O	185
The	PRON	O	O	186
number	NOUN	O	O	186
of	ADP	O	O	186
ECG	PROPN	O	O	186
abnormalities	NOUN	O	O	186
was	AUX	O	O	186
zero	NUM	O	O	186
in	ADP	O	O	186
the	PRON	O	O	186
Intralipid	NOUN	O	O	186
only	ADV	O	O	186
group	NOUN	O	O	186
,	PUNCT	O	O	186
but	CCONJ	O	O	186
14	NUM	O	O	186
and	CCONJ	O	O	186
17	NUM	O	O	186
,	PUNCT	O	O	186
respectively	ADV	O	O	186
,	PUNCT	O	O	186
in	ADP	O	O	186
the	PRON	O	O	186
epinephrine	NOUN	O	Chemical	186
and	CCONJ	O	O	186
epinephrine	NOUN	O	Chemical	186
plus	CCONJ	O	O	186
lipid	NOUN	O	O	186
groups	NOUN	O	O	186
(	PUNCT	O	O	186
P<0.05	NOUN	O	O	186
)	PUNCT	O	O	186
.	PUNCT	O	O	186
Lipid	NOUN	O	O	187
emulsion	NOUN	O	O	187
with	ADP	O	O	187
or	CCONJ	O	O	187
without	ADP	O	O	187
epinephrine	NOUN	O	Chemical	187
,	PUNCT	O	O	187
or	CCONJ	O	O	187
epinephrine	NOUN	O	Chemical	187
alone	ADV	O	O	187
were	AUX	O	O	187
equally	ADV	O	O	187
effective	ADJ	O	O	187
in	ADP	O	O	187
achieving	VERB	O	O	187
a	PRON	O	O	187
return	VERB	O	O	187
to	PART	O	O	187
spontaneous	ADJ	O	O	187
circulation	NOUN	O	O	187
in	ADP	O	O	187
this	PRON	O	O	187
model	NOUN	O	O	187
of	ADP	O	O	187
LAST	ADJ	O	O	187
.	PUNCT	O	O	187
Epinephrine	NOUN	O	Chemical	188
alone	ADV	O	O	188
or	CCONJ	O	O	188
in	ADP	O	O	188
combination	NOUN	O	O	188
with	ADP	O	O	188
lipid	NOUN	O	O	188
was	AUX	O	O	188
associated	VERB	O	O	188
with	ADP	O	O	188
an	PRON	O	O	188
increased	VERB	O	O	188
number	NOUN	O	O	188
of	ADP	O	O	188
ECG	PROPN	O	O	188
abnormalities	NOUN	O	O	188
compared	VERB	O	O	188
with	ADP	O	O	188
lipid	NOUN	O	O	188
emulsion	NOUN	O	O	188
alone	ADV	O	O	188
.	PUNCT	O	O	188
Incidence	NOUN	O	O	191
of	ADP	O	O	191
heparin	NOUN	O	Chemical	191
-	PUNCT	O	O	191
induced	VERB	O	O	191
thrombocytopenia	PROPN	O	Disease	191
type	NOUN	O	O	191
II	NUM	O	O	191
and	CCONJ	O	O	191
postoperative	ADJ	O	O	191
recovery	NOUN	O	O	191
of	ADP	O	O	191
platelet	NOUN	O	O	191
count	VERB	O	O	191
in	ADP	O	O	191
liver	NOUN	O	O	191
graft	NOUN	O	O	191
recipients	NOUN	O	O	191
:	PUNCT	O	O	191
a	PRON	O	O	191
retrospective	ADJ	O	O	191
cohort	NOUN	O	O	191
analysis	NOUN	O	O	191
.	PUNCT	O	O	191
Thrombocytopenia	PROPN	O	Disease	192
in	ADP	O	O	192
patients	NOUN	O	O	192
with	ADP	O	O	192
end	VERB	O	O	192
-	PUNCT	O	O	192
stage	NOUN	O	O	192
liver disease	NOUN	O	Disease	192
is	AUX	O	O	192
a	PRON	O	O	192
common	ADJ	O	O	192
disorder	NOUN	O	O	192
caused	VERB	O	O	192
mainly	ADV	O	O	192
by	ADP	O	O	192
portal	PROPN	O	O	192
hypertension	NOUN	O	Disease	192
,	PUNCT	O	O	192
low	ADJ	O	O	192
levels	NOUN	O	O	192
of	ADP	O	O	192
thrombopoetin	PROPN	O	O	192
,	PUNCT	O	O	192
and	CCONJ	O	O	192
endotoxemia	NOUN	O	O	192
.	PUNCT	O	O	192
The	PRON	O	O	193
impact	NOUN	O	O	193
of	ADP	O	O	193
immune	NOUN	O	O	193
-	PUNCT	O	O	193
mediated	VERB	O	O	193
heparin	NOUN	O	Chemical	193
-	PUNCT	O	O	193
induced	VERB	O	O	193
thrombocytopenia	PROPN	O	Disease	193
type	NOUN	O	O	193
II	NUM	O	O	193
(	PUNCT	O	O	193
HIT	VERB	O	Disease	193
type	NOUN	O	O	193
II	NUM	O	O	193
)	PUNCT	O	O	193
as	ADP	O	O	193
a	PRON	O	O	193
cause	VERB	O	O	193
of	ADP	O	O	193
thrombocytopenia	PROPN	O	Disease	193
after	ADP	O	O	193
liver	NOUN	O	O	193
transplantation	NOUN	O	O	193
is	AUX	O	O	193
not	PART	O	O	193
yet	ADV	O	O	193
understood	VERB	O	O	193
,	PUNCT	O	O	193
with	ADP	O	O	193
few	ADJ	O	O	193
literature	NOUN	O	O	193
citations	NOUN	O	O	193
reporting	VERB	O	O	193
contradictory	ADJ	O	O	193
results	VERB	O	O	193
.	PUNCT	O	O	193
The	PRON	O	O	194
aim	VERB	O	O	194
of	ADP	O	O	194
our	PRON	O	O	194
study	VERB	O	O	194
was	AUX	O	O	194
to	PART	O	O	194
demonstrate	VERB	O	O	194
the	PRON	O	O	194
perioperative	ADJ	O	O	194
course	NOUN	O	O	194
of	ADP	O	O	194
thrombocytopenia	PROPN	O	Disease	194
after	ADP	O	O	194
liver	NOUN	O	O	194
transplantation	NOUN	O	O	194
and	CCONJ	O	O	194
determine	VERB	O	O	194
the	PRON	O	O	194
occurrence	NOUN	O	O	194
of	ADP	O	O	194
clinical	ADJ	O	O	194
HIT	VERB	O	Disease	194
type	NOUN	O	O	194
II	NUM	O	O	194
.	PUNCT	O	O	194
We	PRON	O	O	195
retrospectively	ADV	O	O	195
evaluated	VERB	O	O	195
the	PRON	O	O	195
medical	ADJ	O	O	195
records	NOUN	O	O	195
of	ADP	O	O	195
205	NUM	O	O	195
consecutive	ADJ	O	O	195
adult	NOUN	O	O	195
patients	NOUN	O	O	195
who	PRON	O	O	195
underwent	VERB	O	O	195
full	ADJ	O	O	195
-	PUNCT	O	O	195
size	NOUN	O	O	195
liver	NOUN	O	O	195
transplantation	NOUN	O	O	195
between	ADP	O	O	195
January	PROPN	O	O	195
2006	NUM	O	O	195
and	CCONJ	O	O	195
December	PROPN	O	O	195
2010	NUM	O	O	195
due	ADJ	O	O	195
to	PART	O	O	195
end	VERB	O	O	195
-	PUNCT	O	O	195
stage	NOUN	O	O	195
or	CCONJ	O	O	195
malignant	ADJ	O	O	195
liver disease	NOUN	O	Disease	195
.	PUNCT	O	O	195
Preoperative	PROPN	O	O	196
platelet	NOUN	O	O	196
count	VERB	O	O	196
,	PUNCT	O	O	196
postoperative	ADJ	O	O	196
course	NOUN	O	O	196
of	ADP	O	O	196
platelets	VERB	O	O	196
,	PUNCT	O	O	196
and	CCONJ	O	O	196
clinical	ADJ	O	O	196
signs	NOUN	O	O	196
of	ADP	O	O	196
HIT	VERB	O	Disease	196
type	NOUN	O	O	196
II	NUM	O	O	196
were	AUX	O	O	196
analyzed	VERB	O	O	196
.	PUNCT	O	O	196
A	PRON	O	O	197
total	ADJ	O	O	197
of	ADP	O	O	197
155	NUM	O	O	197
(	PUNCT	O	O	197
75.6%	NOUN	O	O	197
)	PUNCT	O	O	197
of	ADP	O	O	197
205	NUM	O	O	197
patients	NOUN	O	O	197
had	VERB	O	O	197
thrombocytopenia	PROPN	O	Disease	197
before	ADP	O	O	197
transplantation	NOUN	O	O	197
,	PUNCT	O	O	197
significantly	ADV	O	O	197
influenced	VERB	O	O	197
by	ADP	O	O	197
Model	NOUN	O	O	197
of	ADP	O	O	197
End	NOUN	O	O	197
-	PUNCT	O	O	197
Stage	NOUN	O	O	197
Liver	NOUN	O	O	197
Disease	NOUN	O	O	197
score	VERB	O	O	197
and	CCONJ	O	O	197
liver cirrhosis	NOUN	O	Disease	197
.	PUNCT	O	O	197
The	PRON	O	O	198
platelet	NOUN	O	O	198
count	VERB	O	O	198
exceeded	VERB	O	O	198
100,000/uL	ADJ	O	O	198
in	ADP	O	O	198
most	ADV	O	O	198
of	ADP	O	O	198
the	PRON	O	O	198
patients	NOUN	O	O	198
(	PUNCT	O	O	198
n	CCONJ	O	O	198
=	PUNCT	O	O	198
193	NUM	O	O	198
)	PUNCT	O	O	198
at	ADP	O	O	198
a	PRON	O	O	198
medium	ADJ	O	O	198
of	ADP	O	O	198
7	NUM	O	O	198
d.	PROPN	O	O	198
Regarding	VERB	O	O	198
HIT	VERB	O	Disease	198
II	NUM	O	O	198
,	PUNCT	O	O	198
there	ADV	O	O	198
were	AUX	O	O	198
four	NUM	O	O	198
(	PUNCT	O	O	198
1.95%	NOUN	O	O	198
)	PUNCT	O	O	198
patients	NOUN	O	O	199
with	ADP	O	O	199
a	PRON	O	O	199
background	NOUN	O	O	199
of	ADP	O	O	199
HIT	VERB	O	Disease	199
type	NOUN	O	O	199
II	NUM	O	O	199
.	PUNCT	O	O	199
The	PRON	O	O	200
incidence	NOUN	O	O	200
of	ADP	O	O	200
HIT	VERB	O	Disease	200
in	ADP	O	O	200
patients	NOUN	O	O	200
with	ADP	O	O	200
end	VERB	O	O	200
-	PUNCT	O	O	200
stage	NOUN	O	O	200
hepatic failure	NOUN	O	Disease	200
is	AUX	O	O	200
,	PUNCT	O	O	200
with	ADP	O	O	200
about	ADP	O	O	200
1.95%	NOUN	O	O	200
,	PUNCT	O	O	200
rare	ADJ	O	O	200
.	PUNCT	O	O	200
For	ADP	O	O	201
further	ADV	O	O	201
reduction	NOUN	O	O	201
of	ADP	O	O	201
HIT	VERB	O	Disease	201
type	NOUN	O	O	201
II	NUM	O	O	201
,	PUNCT	O	O	201
the	PRON	O	O	201
use	VERB	O	O	201
of	ADP	O	O	201
intravenous	ADJ	O	O	201
heparin	NOUN	O	Chemical	201
should	AUX	O	O	201
be	AUX	O	O	201
avoided	VERB	O	O	201
and	CCONJ	O	O	201
the	PRON	O	O	201
prophylactic	ADJ	O	O	201
anticoagulation	NOUN	O	O	201
should	AUX	O	O	201
be	AUX	O	O	201
performed	VERB	O	O	201
with	ADP	O	O	201
low	ADJ	O	O	201
-	PUNCT	O	O	201
molecular	ADJ	O	O	201
-	PUNCT	O	O	201
weight	NOUN	O	O	201
heparin	NOUN	O	Chemical	201
after	ADP	O	O	201
normalization	NOUN	O	O	201
of	ADP	O	O	201
platelet	NOUN	O	O	201
count	VERB	O	O	201
.	PUNCT	O	O	201
Takotsubo	NOUN	O	O	204
syndrome	NOUN	O	O	204
(	PUNCT	O	O	204
or	CCONJ	O	O	204
apical ballooning	NOUN	O	Disease	204
syndrome	NOUN	O	O	204
)	PUNCT	O	O	204
secondary	ADJ	O	O	204
to	PART	O	O	204
Zolmitriptan	PROPN	O	O	204
.	PUNCT	O	O	204
Takotsubo	NOUN	O	O	205
syndrome	NOUN	O	O	205
(	PUNCT	O	O	205
TS	NOUN	O	O	205
)	PUNCT	O	O	205
,	PUNCT	O	O	205
also	ADV	O	O	205
known	VERB	O	O	205
as	ADP	O	O	205
broken	VERB	O	O	205
heart	NOUN	O	O	205
syndrome	NOUN	O	O	205
,	PUNCT	O	O	205
is	AUX	O	O	205
characterized	VERB	O	O	205
by	ADP	O	O	205
left	VERB	O	O	205
ventricle	NOUN	O	O	205
apical ballooning	NOUN	O	Disease	205
with	ADP	O	O	205
elevated	ADJ	O	O	205
cardiac	ADJ	O	O	205
biomarkers	NOUN	O	O	205
and	CCONJ	O	O	205
electrocardiographic	NOUN	O	O	205
changes	VERB	O	O	205
suggestive	ADJ	O	O	205
of	ADP	O	O	205
an	PRON	O	O	205
acute	ADJ	O	O	205
coronary	ADJ	O	O	205
syndrome	NOUN	O	O	205
(	PUNCT	O	O	205
ie	ADV	O	O	205
,	PUNCT	O	O	205
ST	PROPN	O	O	205
-	PUNCT	O	O	205
segment	NOUN	O	O	205
elevation	NOUN	O	O	205
,	PUNCT	O	O	205
T	NOUN	O	Chemical	205
wave	NOUN	O	O	205
inversions	NOUN	O	O	205
,	PUNCT	O	O	205
and	CCONJ	O	O	205
pathologic	ADJ	O	O	205
Q	NOUN	O	O	205
waves	NOUN	O	O	205
)	PUNCT	O	O	205
.	PUNCT	O	O	205
We	PRON	O	O	206
report	VERB	O	O	206
a	PRON	O	O	206
case	NOUN	O	O	206
of	ADP	O	O	206
54-year	NOUN	O	O	206
-	PUNCT	O	O	206
old	ADJ	O	O	206
woman	NOUN	O	O	206
with	ADP	O	O	206
medical	ADJ	O	O	206
history	NOUN	O	O	206
of	ADP	O	O	206
mitral	ADJ	O	O	206
valve	PROPN	O	O	206
prolapse	NOUN	O	O	206
and	CCONJ	O	O	206
migraines	NOUN	O	O	206
,	PUNCT	O	O	206
who	PRON	O	O	206
was	AUX	O	O	206
admitted	VERB	O	O	206
to	PART	O	O	206
the	PRON	O	O	206
hospital	PROPN	O	O	206
for	ADP	O	O	206
substernal	ADJ	O	O	206
chest pain	NOUN	O	Disease	206
and	CCONJ	O	O	206
electrocardiogram	PROPN	O	O	206
demonstrated	VERB	O	O	206
1/2	NUM	O	O	206
mm	INTJ	O	O	206
ST	PROPN	O	O	206
-	PUNCT	O	O	206
segment	NOUN	O	O	206
elevation	NOUN	O	O	206
in	ADP	O	O	206
leads	VERB	O	O	206
II	NUM	O	O	206
,	PUNCT	O	O	206
III	NUM	O	O	206
,	PUNCT	O	O	206
aVF	VERB	O	O	206
,	PUNCT	O	O	206
V5	VERB	O	O	206
,	PUNCT	O	O	206
and	CCONJ	O	O	206
V6	ADJ	O	O	206
and	CCONJ	O	O	206
positive	ADJ	O	O	206
troponin	PROPN	O	O	206
I.	NOUN	O	O	206
Emergent	ADJ	O	O	206
coronary	ADJ	O	O	206
angiogram	PROPN	O	O	206
revealed	VERB	O	O	206
normal	ADJ	O	O	206
coronary	ADJ	O	O	206
arteries	NOUN	O	O	206
with	ADP	O	O	206
moderately	ADV	O	O	206
reduced	VERB	O	O	206
left	VERB	O	O	206
ventricular	ADJ	O	O	206
ejection	NOUN	O	O	206
fraction	NOUN	O	O	206
with	ADP	O	O	206
wall	PROPN	O	O	206
motion	NOUN	O	O	206
abnormalities	NOUN	O	O	206
consistent	ADJ	O	O	206
with	ADP	O	O	206
TS	NOUN	O	O	206
.	PUNCT	O	O	206
Detailed	VERB	O	O	207
history	NOUN	O	O	207
obtained	VERB	O	O	207
retrospectively	ADV	O	O	207
revealed	VERB	O	O	207
that	SCONJ	O	O	207
the	PRON	O	O	207
patient	NOUN	O	O	207
took	VERB	O	O	207
zolmitriptan	NOUN	O	O	207
sparingly	ADV	O	O	207
only	ADV	O	O	207
when	SCONJ	O	O	207
she	PRON	O	O	207
had	VERB	O	O	207
migraines	NOUN	O	O	207
.	PUNCT	O	O	207
But	CCONJ	O	O	208
before	ADP	O	O	208
this	PRON	O	O	208
event	NOUN	O	O	208
,	PUNCT	O	O	208
she	PRON	O	O	208
was	AUX	O	O	208
taking	VERB	O	O	208
zolmitriptan	NOUN	O	O	208
2	X	O	O	208
-	PUNCT	O	O	208
3	X	O	O	208
times	NOUN	O	O	208
daily	ADV	O	O	208
for	ADP	O	O	208
several	ADJ	O	O	208
days	NOUN	O	O	208
because	SCONJ	O	O	208
of	ADP	O	O	208
a	PRON	O	O	208
persistent	ADJ	O	O	208
migraine headache	PROPN	O	Disease	208
.	PUNCT	O	O	208
There	ADV	O	O	209
was	AUX	O	O	209
no	PRON	O	O	209
evidence	NOUN	O	O	209
of	ADP	O	O	209
any	PRON	O	O	209
recent	ADJ	O	O	209
stress	NOUN	O	O	209
or	CCONJ	O	O	209
status	NOUN	O	O	209
migrainosus	PROPN	O	O	209
.	PUNCT	O	O	209
Extensive	PROPN	O	O	210
literature	NOUN	O	O	210
search	NOUN	O	O	210
revealed	VERB	O	O	210
multiple	ADJ	O	O	210
cases	NOUN	O	O	210
of	ADP	O	O	210
coronary	ADJ	O	O	210
artery	NOUN	O	O	210
vasospasm	NOUN	O	Disease	210
secondary	ADJ	O	O	210
to	PART	O	O	210
zolmitriptan	NOUN	O	O	210
,	PUNCT	O	O	210
but	CCONJ	O	O	210
none	NOUN	O	O	210
of	ADP	O	O	210
the	PRON	O	O	210
cases	NOUN	O	O	210
were	AUX	O	O	210
associated	VERB	O	O	210
with	ADP	O	O	210
TS	NOUN	O	O	210
.	PUNCT	O	O	210
Depression	NOUN	O	O	213
,	PUNCT	O	O	213
impulsiveness	NOUN	O	O	213
,	PUNCT	O	O	213
sleep	VERB	O	O	213
,	PUNCT	O	O	213
and	CCONJ	O	O	213
memory	NOUN	O	O	213
in	ADP	O	O	213
past	ADP	O	O	213
and	CCONJ	O	O	213
present	NOUN	O	O	213
polydrug	NOUN	O	O	213
users	NOUN	O	O	213
of	ADP	O	O	213
3,4-methylenedioxymethamphetamine	NOUN	O	Chemical	213
(	PUNCT	O	O	213
MDMA	PROPN	O	Chemical	213
,	PUNCT	O	O	213
ecstasy	NOUN	O	Chemical	213
)	PUNCT	O	O	213
.	PUNCT	O	O	213
RATIONALE	PROPN	O	O	214
:	PUNCT	O	O	214
Ecstasy	NOUN	O	O	214
(	PUNCT	O	O	214
3,4-methylenedioxymethamphetamine	NOUN	O	Chemical	214
,	PUNCT	O	O	214
MDMA	PROPN	O	Chemical	214
)	PUNCT	O	O	214
is	AUX	O	O	214
a	PRON	O	O	214
worldwide	ADV	O	O	214
recreational	ADJ	O	O	214
drug	NOUN	O	O	214
of	ADP	O	O	214
abuse	VERB	O	O	214
.	PUNCT	O	O	214
The	PRON	O	O	215
present	NOUN	O	O	215
study	VERB	O	O	215
aimed	VERB	O	O	215
to	PART	O	O	215
be	AUX	O	O	215
the	PRON	O	O	215
largest	ADJ	O	O	215
to	PART	O	O	215
date	PROPN	O	O	215
in	ADP	O	O	215
sample	NOUN	O	O	215
size	NOUN	O	O	215
and	CCONJ	O	O	215
5HT	PROPN	O	O	215
-	PUNCT	O	O	215
related	ADJ	O	O	215
behaviors	NOUN	O	O	215
;	PUNCT	O	O	215
the	PRON	O	O	215
first	ADV	O	O	215
to	PART	O	O	215
compare	VERB	O	O	215
present	NOUN	O	O	215
ecstasy	NOUN	O	Chemical	215
users	NOUN	O	O	215
with	ADP	O	O	215
past	ADP	O	O	215
users	NOUN	O	O	215
after	ADP	O	O	215
an	PRON	O	O	215
abstinence	NOUN	O	O	215
of	ADP	O	O	215
4	NUM	O	O	215
or	CCONJ	O	O	215
more	ADJ	O	O	215
years	NOUN	O	O	215
,	PUNCT	O	O	215
and	CCONJ	O	O	215
the	PRON	O	O	215
first	ADV	O	O	215
to	PART	O	O	215
include	VERB	O	O	215
robust	ADJ	O	O	215
controls	VERB	O	O	215
for	ADP	O	O	215
other	ADJ	O	O	215
recreational	ADJ	O	O	215
substances	NOUN	O	O	215
.	PUNCT	O	O	215
A	PRON	O	O	216
sample	NOUN	O	O	216
of	ADP	O	O	216
997	NUM	O	O	216
participants	NOUN	O	O	216
(	PUNCT	O	O	216
52	NUM	O	O	216
%	INTJ	O	O	216
male	NOUN	O	O	216
)	PUNCT	O	O	216
was	AUX	O	O	216
recruited	VERB	O	O	216
to	PART	O	O	216
four	NUM	O	O	216
control	VERB	O	O	216
groups	NOUN	O	O	216
(	PUNCT	O	O	216
non	ADJ	O	O	216
-	PUNCT	O	O	216
drug	NOUN	O	O	216
(	PUNCT	O	O	216
ND	PROPN	O	O	216
)	PUNCT	O	O	216
,	PUNCT	O	O	216
alcohol	NOUN	O	Chemical	216
/	PUNCT	O	O	216
nicotine	NOUN	O	Chemical	216
(	PUNCT	O	O	216
AN	PRON	O	O	216
)	PUNCT	O	O	216
,	PUNCT	O	O	216
cannabis	NOUN	O	O	216
/	PUNCT	O	O	216
alcohol	NOUN	O	Chemical	216
/	PUNCT	O	O	216
nicotine	NOUN	O	Chemical	216
(	PUNCT	O	O	216
CAN	AUX	O	O	216
)	PUNCT	O	O	216
,	PUNCT	O	O	216
non	ADJ	O	O	216
-	PUNCT	O	O	216
ecstasy	NOUN	O	Chemical	216
polydrug	NOUN	O	O	216
(	PUNCT	O	O	216
PD	PROPN	O	Disease	216
)	PUNCT	O	O	216
)	PUNCT	O	O	216
,	PUNCT	O	O	216
and	CCONJ	O	O	216
two	NUM	O	O	216
ecstasy	NOUN	O	Chemical	216
polydrug	NOUN	O	O	216
groups	NOUN	O	O	216
(	PUNCT	O	O	216
present	NOUN	O	O	216
(	PUNCT	O	O	216
MDMA	PROPN	O	Chemical	216
)	PUNCT	O	O	216
and	CCONJ	O	O	216
past	ADP	O	O	216
users	NOUN	O	O	216
(	PUNCT	O	O	216
EX	NOUN	O	O	216
-	PUNCT	O	O	216
MDMA	PROPN	O	Chemical	216
)	PUNCT	O	O	216
.	PUNCT	O	O	216
Participants	NOUN	O	O	217
completed	VERB	O	O	217
a	PRON	O	O	217
drug	NOUN	O	O	217
history	NOUN	O	O	217
questionnaire	NOUN	O	O	217
,	PUNCT	O	O	217
Beck	PROPN	O	O	217
Depression	NOUN	O	O	217
Inventory	NOUN	O	O	217
,	PUNCT	O	O	217
Barratt	PROPN	O	O	217
Impulsiveness	NOUN	O	O	217
Scale	NOUN	O	O	217
,	PUNCT	O	O	217
Pittsburgh	PROPN	O	O	217
Sleep	VERB	O	O	217
Quality	NOUN	O	O	217
Index	NOUN	O	O	217
,	PUNCT	O	O	217
and	CCONJ	O	O	217
Wechsler	NOUN	O	O	217
Memory	NOUN	O	O	217
Scale	NOUN	O	O	217
-	PUNCT	O	O	217
Revised	VERB	O	O	217
which	PRON	O	O	217
,	PUNCT	O	O	217
in	ADP	O	O	217
total	ADJ	O	O	217
,	PUNCT	O	O	217
provided	VERB	O	O	217
13	NUM	O	O	217
psychometric	ADJ	O	O	217
measures	NOUN	O	O	217
.	PUNCT	O	O	217
While	SCONJ	O	O	218
the	PRON	O	O	218
CAN	AUX	O	O	218
and	CCONJ	O	O	218
PD	PROPN	O	Disease	218
groups	NOUN	O	O	218
tended	VERB	O	O	218
to	PART	O	O	218
record	NOUN	O	O	218
greater	ADJ	O	O	218
deficits	NOUN	O	O	218
than	ADP	O	O	218
the	PRON	O	O	218
non	ADJ	O	O	218
-	PUNCT	O	O	218
drug	NOUN	O	O	218
controls	VERB	O	O	218
,	PUNCT	O	O	218
the	PRON	O	O	218
MDMA	PROPN	O	Chemical	218
and	CCONJ	O	O	218
EX	NOUN	O	O	218
-	PUNCT	O	O	218
MDMA	PROPN	O	Chemical	218
groups	NOUN	O	O	218
recorded	VERB	O	O	218
greater	ADJ	O	O	218
deficits	NOUN	O	O	218
than	ADP	O	O	218
all	PRON	O	O	218
the	PRON	O	O	218
control	VERB	O	O	218
groups	NOUN	O	O	218
on	ADP	O	O	218
ten	NUM	O	O	218
of	ADP	O	O	218
the	PRON	O	O	218
13	NUM	O	O	218
psychometric	ADJ	O	O	218
measures	NOUN	O	O	218
.	PUNCT	O	O	218
Strikingly	ADV	O	O	219
,	PUNCT	O	O	219
despite	SCONJ	O	O	219
prolonged	VERB	O	O	219
abstinence	NOUN	O	O	219
(	PUNCT	O	O	219
mean	VERB	O	O	219
,	PUNCT	O	O	219
4.98	NUM	O	O	219
;	PUNCT	O	O	219
range	VERB	O	O	219
,	PUNCT	O	O	219
4	NUM	O	O	219
-	PUNCT	O	O	219
9	NUM	O	O	219
years	NOUN	O	O	219
)	PUNCT	O	O	219
,	PUNCT	O	O	219
past	ADP	O	O	219
ecstasy	NOUN	O	Chemical	219
users	NOUN	O	O	219
showed	VERB	O	O	219
few	ADJ	O	O	219
signs	NOUN	O	O	219
of	ADP	O	O	219
recovery	NOUN	O	O	219
.	PUNCT	O	O	219
Compared	VERB	O	O	220
with	ADP	O	O	220
present	NOUN	O	O	220
ecstasy	NOUN	O	Chemical	220
users	NOUN	O	O	220
,	PUNCT	O	O	220
the	PRON	O	O	220
past	ADP	O	O	220
users	NOUN	O	O	220
showed	VERB	O	O	220
no	PRON	O	O	220
change	VERB	O	O	220
for	ADP	O	O	220
ten	NUM	O	O	220
measures	NOUN	O	O	220
,	PUNCT	O	O	220
increased	VERB	O	O	220
impairment	NOUN	O	O	220
for	ADP	O	O	220
two	NUM	O	O	220
measures	NOUN	O	O	220
,	PUNCT	O	O	220
and	CCONJ	O	O	220
improvement	NOUN	O	O	220
on	ADP	O	O	220
just	ADV	O	O	220
one	NUM	O	O	220
measure	VERB	O	O	220
.	PUNCT	O	O	220
Given	VERB	O	O	221
this	PRON	O	O	221
record	NOUN	O	O	221
of	ADP	O	O	221
impaired memory	NOUN	O	Disease	221
and	CCONJ	O	O	221
clinically	ADV	O	O	221
significant	ADJ	O	O	221
levels	NOUN	O	O	221
of	ADP	O	O	221
depression	PROPN	O	Disease	221
,	PUNCT	O	O	221
impulsiveness	NOUN	O	O	221
,	PUNCT	O	O	221
and	CCONJ	O	O	221
sleep	VERB	O	O	221
disturbance	NOUN	O	O	221
,	PUNCT	O	O	221
the	PRON	O	O	221
prognosis	VERB	O	O	221
for	ADP	O	O	221
the	PRON	O	O	221
current	ADJ	O	O	221
generation	NOUN	O	O	221
of	ADP	O	O	221
ecstasy	NOUN	O	Chemical	221
users	NOUN	O	O	221
is	AUX	O	O	221
a	PRON	O	O	221
major	ADJ	O	O	221
cause	VERB	O	O	221
for	ADP	O	O	221
concern	NOUN	O	O	221
.	PUNCT	O	O	221
Association	PROPN	O	O	224
of	ADP	O	O	224
common	ADJ	O	O	224
genetic	ADJ	O	O	224
variants	NOUN	O	O	224
of	ADP	O	O	224
HOMER1	NOUN	O	O	224
gene	NOUN	O	O	224
with	ADP	O	O	224
levodopa	NOUN	O	Chemical	224
adverse	ADJ	O	O	224
effects	NOUN	O	O	224
in	ADP	O	O	224
Parkinson	NOUN	O	O	224
's	AUX	O	O	224
disease	PROPN	O	O	224
patients	NOUN	O	O	224
.	PUNCT	O	O	224
Levodopa	NOUN	O	Chemical	225
is	AUX	O	O	225
the	PRON	O	O	225
most	ADV	O	O	225
effective	ADJ	O	O	225
symptomatic	ADJ	O	O	225
therapy	NOUN	O	O	225
for	ADP	O	O	225
Parkinson	NOUN	O	O	225
's	AUX	O	O	225
disease	PROPN	O	O	225
,	PUNCT	O	O	225
but	CCONJ	O	O	225
its	PRON	O	O	225
chronic	ADJ	O	O	225
use	VERB	O	O	225
could	AUX	O	O	225
lead	VERB	O	Chemical	225
to	PART	O	O	225
chronic	ADJ	O	O	225
adverse	ADJ	O	O	225
outcomes	NOUN	O	O	225
,	PUNCT	O	O	225
such	ADJ	O	O	225
as	ADP	O	O	225
motor	NOUN	O	O	225
fluctuations	NOUN	O	O	225
,	PUNCT	O	O	225
dyskinesia	NOUN	O	Disease	225
and	CCONJ	O	O	225
visual hallucinations	NOUN	O	Disease	225
.	PUNCT	O	O	225
HOMER1	NOUN	O	O	226
is	AUX	O	O	226
a	PRON	O	O	226
protein	NOUN	O	O	226
with	ADP	O	O	226
pivotal	ADJ	O	O	226
function	NOUN	O	O	226
in	ADP	O	O	226
glutamate	NOUN	O	Chemical	226
transmission	NOUN	O	O	226
,	PUNCT	O	O	226
which	PRON	O	O	226
has	VERB	O	O	226
been	AUX	O	O	226
related	ADJ	O	O	226
to	PART	O	O	226
the	PRON	O	O	226
pathogenesis	NOUN	O	O	226
of	ADP	O	O	226
these	PRON	O	O	226
complications	NOUN	O	O	226
.	PUNCT	O	O	226
This	PRON	O	O	227
study	VERB	O	O	227
investigates	VERB	O	O	227
whether	SCONJ	O	O	227
polymorphisms	NOUN	O	O	227
in	ADP	O	O	227
the	PRON	O	O	227
HOMER1	NOUN	O	O	227
gene	NOUN	O	O	227
promoter	NOUN	O	O	227
region	NOUN	O	O	227
are	AUX	O	O	227
associated	VERB	O	O	227
with	ADP	O	O	227
the	PRON	O	O	227
occurrence	NOUN	O	O	227
of	ADP	O	O	227
the	PRON	O	O	227
chronic	ADJ	O	O	227
complications	NOUN	O	O	227
of	ADP	O	O	227
levodopa	NOUN	O	Chemical	227
therapy	NOUN	O	O	227
.	PUNCT	O	O	227
A	PRON	O	O	228
total	ADJ	O	O	228
of	ADP	O	O	228
205	NUM	O	O	228
patients	NOUN	O	O	228
with	ADP	O	O	228
idiopathic	ADJ	O	O	228
Parkinson	NOUN	O	O	228
's	AUX	O	O	228
disease	PROPN	O	O	228
were	AUX	O	O	228
investigated	VERB	O	O	228
.	PUNCT	O	O	228
The	PRON	O	O	229
rs4704559	PROPN	O	O	229
G	NOUN	O	O	229
allele	PROPN	O	O	229
was	AUX	O	O	229
associated	VERB	O	O	229
with	ADP	O	O	229
a	PRON	O	O	229
lower	ADJ	O	O	229
prevalence	NOUN	O	O	229
of	ADP	O	O	229
dyskinesia	NOUN	O	Disease	229
(	PUNCT	O	O	229
prevalence	NOUN	O	O	229
ratio	NOUN	O	O	229
(	PUNCT	O	O	229
PR)=0.615	PROPN	O	O	229
,	PUNCT	O	O	229
95%	NOUN	O	O	229
confidence	NOUN	O	O	229
interval	NOUN	O	O	229
(	PUNCT	O	O	229
CI	NOUN	O	O	229
)	PUNCT	O	O	229
0.426	NUM	O	O	229
-	PUNCT	O	O	229
0.887	NUM	O	O	229
,	PUNCT	O	O	229
P=0.009	NOUN	O	O	229
)	PUNCT	O	O	229
and	CCONJ	O	O	229
visual hallucinations	NOUN	O	Disease	229
(	PUNCT	O	O	229
PR=0.515	NOUN	O	O	229
,	PUNCT	O	O	229
95%	NOUN	O	O	229
CI	NOUN	O	O	229
0.295	NUM	O	O	229
-	PUNCT	O	O	229
0.899	NUM	O	O	229
,	PUNCT	O	O	229
P=0.020	X	O	O	229
)	PUNCT	O	O	229
.	PUNCT	O	O	229
Our	PRON	O	O	230
data	NOUN	O	O	230
suggest	VERB	O	O	230
that	SCONJ	O	O	230
HOMER1	NOUN	O	O	230
rs4704559	PROPN	O	O	230
G	NOUN	O	O	230
allele	PROPN	O	O	230
has	VERB	O	O	230
a	PRON	O	O	230
protective	ADJ	O	O	230
role	NOUN	O	O	230
for	ADP	O	O	230
the	PRON	O	O	230
development	NOUN	O	O	230
of	ADP	O	O	230
levodopa	NOUN	O	Chemical	230
adverse	ADJ	O	O	230
effects	NOUN	O	O	230
.	PUNCT	O	O	230
Crocin	PROPN	O	O	233
improves	VERB	O	O	233
lipid	NOUN	O	O	233
dysregulation	NOUN	O	O	233
in	ADP	O	O	233
subacute	VERB	O	O	233
diazinon	NOUN	O	O	233
exposure	NOUN	O	O	233
through	ADP	O	O	233
ERK1/2	VERB	O	O	233
pathway	NOUN	O	O	233
in	ADP	O	O	233
rat	NOUN	O	O	233
liver	NOUN	O	O	233
.	PUNCT	O	O	233
Diazinon	NOUN	O	O	234
Yis	PROPN	O	O	234
one	NUM	O	O	234
of	ADP	O	O	234
the	PRON	O	O	234
most	ADV	O	O	234
broadly	ADV	O	O	234
used	VERB	O	O	234
organophosphorus	PROPN	O	Chemical	234
insecticides	NOUN	O	O	234
in	ADP	O	O	234
agriculture	NOUN	O	O	234
.	PUNCT	O	O	234
It	PRON	O	O	235
has	VERB	O	O	235
been	AUX	O	O	235
shown	VERB	O	O	235
that	SCONJ	O	O	235
exposure	NOUN	O	O	235
to	PART	O	O	235
diazinon	NOUN	O	O	235
may	AUX	O	O	235
interfere	VERB	O	O	235
with	ADP	O	O	235
lipid	NOUN	O	O	235
metabolism	NOUN	O	O	235
.	PUNCT	O	O	235
Moreover	ADV	O	O	236
,	PUNCT	O	O	236
the	PRON	O	O	236
hypolipidemic	PROPN	O	O	236
effect	VERB	O	O	236
of	ADP	O	O	236
crocin	PROPN	O	Chemical	236
has	VERB	O	O	236
been	AUX	O	O	236
established	VERB	O	O	236
.	PUNCT	O	O	236
The	PRON	O	O	237
aim	VERB	O	O	237
of	ADP	O	O	237
this	PRON	O	O	237
study	VERB	O	O	237
was	AUX	O	O	237
to	PART	O	O	237
evaluate	VERB	O	O	237
changes	VERB	O	O	237
in	ADP	O	O	237
the	PRON	O	O	237
regulation	NOUN	O	O	237
of	ADP	O	O	237
lipid	NOUN	O	O	237
metabolism	NOUN	O	O	237
,	PUNCT	O	O	237
ERK	PROPN	O	O	237
and	CCONJ	O	O	237
LDLr	NOUN	O	O	237
expression	NOUN	O	O	237
in	ADP	O	O	237
the	PRON	O	O	237
liver	NOUN	O	O	237
of	ADP	O	O	237
rats	NOUN	O	O	237
exposed	VERB	O	O	237
to	PART	O	O	237
subacute	VERB	O	O	237
diazinon	NOUN	O	O	237
.	PUNCT	O	O	237
Furthermore	ADV	O	O	238
ameliorating	VERB	O	O	238
effect	VERB	O	O	238
of	ADP	O	O	238
crocin	PROPN	O	Chemical	238
on	ADP	O	O	238
diazinon	NOUN	O	O	238
induced	VERB	O	O	238
disturbed	ADJ	O	O	238
cholesterol	NOUN	O	Chemical	238
homeostasis	NOUN	O	O	238
was	AUX	O	O	238
studied	VERB	O	O	238
.	PUNCT	O	O	238
24	NUM	O	O	239
Rats	NOUN	O	O	239
were	AUX	O	O	239
divided	VERB	O	O	239
into	ADP	O	O	239
4	NUM	O	O	239
groups	NOUN	O	O	239
and	CCONJ	O	O	239
received	VERB	O	O	239
following	VERB	O	O	239
treatments	NOUN	O	O	239
for	ADP	O	O	239
4	NUM	O	O	239
weeks	NOUN	O	O	239
;	PUNCT	O	O	239
Corn	NOUN	O	O	239
oil	NOUN	O	O	239
(	PUNCT	O	O	239
control	VERB	O	O	239
)	PUNCT	O	O	239
,	PUNCT	O	O	239
diazinon	NOUN	O	O	239
(	PUNCT	O	O	239
15mg	NOUN	O	O	239
/	PUNCT	O	O	239
kg	VERB	O	O	239
per	ADP	O	O	239
day	NOUN	O	O	239
,	PUNCT	O	O	239
orally	ADV	O	O	239
)	PUNCT	O	O	239
and	CCONJ	O	O	239
crocin	PROPN	O	Chemical	239
(	PUNCT	O	O	239
12.5	NUM	O	O	239
and	CCONJ	O	O	239
25mg	NOUN	O	O	239
/	PUNCT	O	O	239
kg	VERB	O	O	240
per	ADP	O	O	240
day	NOUN	O	O	240
,	PUNCT	O	O	240
intraperitoneally	ADV	O	O	240
)	PUNCT	O	O	240
in	ADP	O	O	240
combination	NOUN	O	O	240
with	ADP	O	O	240
diazinon	NOUN	O	O	240
(	PUNCT	O	O	240
15	NUM	O	O	240
mg	VERB	O	O	240
/	PUNCT	O	O	240
kg	VERB	O	O	240
)	PUNCT	O	O	240
.	PUNCT	O	O	240
The	PRON	O	O	241
levels	NOUN	O	O	241
of	ADP	O	O	241
cholesterol	NOUN	O	Chemical	241
,	PUNCT	O	O	241
triglyceride	PROPN	O	O	241
and	CCONJ	O	O	241
LDL	NOUN	O	O	241
in	ADP	O	O	241
blood	NOUN	O	O	241
of	ADP	O	O	241
rats	NOUN	O	O	241
were	AUX	O	O	241
analyzed	VERB	O	O	241
.	PUNCT	O	O	241
RESULTS	VERB	O	O	242
:	PUNCT	O	O	242
Our	PRON	O	O	242
data	NOUN	O	O	242
showed	VERB	O	O	242
that	SCONJ	O	O	242
subacute	VERB	O	O	242
exposure	NOUN	O	O	242
to	PART	O	O	242
diazinon	NOUN	O	O	242
significantly	ADV	O	O	242
increased	VERB	O	O	242
concentrations	NOUN	O	O	242
of	ADP	O	O	242
cholesterol	NOUN	O	Chemical	242
,	PUNCT	O	O	242
triglyceride	PROPN	O	O	242
and	CCONJ	O	O	242
LDL	NOUN	O	O	242
.	PUNCT	O	O	242
Moreover	ADV	O	O	243
diazinon	NOUN	O	O	243
decreased	VERB	O	O	243
ERK1/2	VERB	O	O	243
protein	NOUN	O	O	243
phosphorylation	NOUN	O	O	243
and	CCONJ	O	O	243
LDLr	NOUN	O	O	243
transcript	PROPN	O	O	243
.	PUNCT	O	O	243
Crocin	PROPN	O	O	244
reduced	VERB	O	O	244
inhibition	NOUN	O	O	244
of	ADP	O	O	244
ERK	PROPN	O	O	244
activation	NOUN	O	O	244
and	CCONJ	O	O	244
diazinon	NOUN	O	O	244
-	PUNCT	O	O	244
induced	VERB	O	O	244
hyperlipemia	NOUN	O	O	244
and	CCONJ	O	O	244
increased	VERB	O	O	244
levels	NOUN	O	O	244
of	ADP	O	O	244
LDLr	NOUN	O	O	244
transcript	PROPN	O	O	244
.	PUNCT	O	O	244
Crocin	PROPN	O	O	245
may	AUX	O	O	245
be	AUX	O	O	245
considered	VERB	O	O	245
as	ADP	O	O	245
a	PRON	O	O	245
novel	NOUN	O	O	245
protective	ADJ	O	O	245
agent	NOUN	O	O	245
in	ADP	O	O	245
diazinon	NOUN	O	O	245
-	PUNCT	O	O	245
induced	VERB	O	O	245
hyperlipemia	NOUN	O	O	245
through	ADP	O	O	245
modulating	VERB	O	O	245
of	ADP	O	O	245
ERK	PROPN	O	O	245
pathway	NOUN	O	O	245
and	CCONJ	O	O	245
increase	VERB	O	O	245
of	ADP	O	O	245
LDLr	NOUN	O	O	245
expression	NOUN	O	O	245
.	PUNCT	O	O	245
GEM	NOUN	O	O	248
-	PUNCT	O	O	248
P	NOUN	O	Chemical	248
chemotherapy	NOUN	O	O	248
is	AUX	O	O	248
active	ADJ	O	O	248
in	ADP	O	O	248
the	PRON	O	O	248
treatment	NOUN	O	O	248
of	ADP	O	O	248
relapsed	VERB	O	O	248
Hodgkin	PROPN	O	O	248
lymphoma	PROPN	O	Disease	248
.	PUNCT	O	O	248
Hodgkin	PROPN	O	O	249
lymphoma	PROPN	O	Disease	249
(	PUNCT	O	O	249
HL	PROPN	O	O	249
)	PUNCT	O	O	249
is	AUX	O	O	249
a	PRON	O	O	249
relatively	ADV	O	O	249
chemosensitive	NOUN	O	O	249
malignancy	NOUN	O	Disease	249
.	PUNCT	O	O	249
Regimens	NOUN	O	O	250
commonly	ADV	O	O	250
used	VERB	O	O	250
often	ADV	O	O	250
require	VERB	O	O	250
inpatient	ADJ	O	O	250
administration	NOUN	O	O	250
and	CCONJ	O	O	250
can	AUX	O	O	250
be	AUX	O	O	250
difficult	ADJ	O	O	250
to	PART	O	O	250
deliver	VERB	O	O	250
due	ADJ	O	O	250
to	PART	O	O	250
toxicity	NOUN	O	Disease	250
.	PUNCT	O	O	250
Gemcitabine	NOUN	O	O	251
and	CCONJ	O	O	251
cisplatin	NOUN	O	Chemical	251
have	VERB	O	O	251
activity	NOUN	O	O	251
in	ADP	O	O	251
HL	PROPN	O	O	251
,	PUNCT	O	O	251
non	ADJ	O	O	251
-	PUNCT	O	O	251
overlapping	VERB	O	O	251
toxicity	NOUN	O	Disease	251
with	ADP	O	O	251
first	ADV	O	O	251
-	PUNCT	O	O	251
line	NOUN	O	O	251
chemotherapeutics	NOUN	O	O	251
,	PUNCT	O	O	251
and	CCONJ	O	O	251
may	AUX	O	O	251
be	AUX	O	O	251
delivered	VERB	O	O	251
in	ADP	O	O	251
an	PRON	O	O	251
outpatient	NOUN	O	O	251
setting	VERB	O	O	251
.	PUNCT	O	O	251
In	ADP	O	O	252
this	PRON	O	O	252
retrospective	ADJ	O	O	252
single	ADJ	O	O	252
-	PUNCT	O	O	252
centre	PROPN	O	O	252
analysis	NOUN	O	O	252
,	PUNCT	O	O	252
patients	NOUN	O	O	252
with	ADP	O	O	252
relapsed	VERB	O	O	252
or	CCONJ	O	O	252
refractory	ADJ	O	O	252
HL	PROPN	O	O	252
treated	VERB	O	O	252
with	ADP	O	O	252
gemcitabine	NOUN	O	O	252
1,000	NUM	O	O	252
mg	VERB	O	O	252
/	PUNCT	O	O	252
m(2	NUM	O	O	252
)	PUNCT	O	O	252
day	NOUN	O	O	252
(	PUNCT	O	O	252
D)1	NOUN	O	O	252
,	PUNCT	O	O	252
D8	NOUN	O	O	252
and	CCONJ	O	O	252
D15	NOUN	O	O	252
;	PUNCT	O	O	252
methylprednisolone	NOUN	O	Chemical	252
1,000	NUM	O	O	252
mg	VERB	O	O	252
D1	PROPN	O	O	252
-	PUNCT	O	O	252
5	NUM	O	O	252
;	PUNCT	O	O	252
and	CCONJ	O	O	252
cisplatin	NOUN	O	Chemical	252
100	NUM	O	O	252
mg	VERB	O	O	252
/	PUNCT	O	O	252
m(2	NUM	O	O	252
)	PUNCT	O	O	252
D15	NOUN	O	O	252
,	PUNCT	O	O	252
every	PRON	O	O	252
28	NUM	O	O	252
days	NOUN	O	O	252
(	PUNCT	O	O	252
GEM	NOUN	O	O	252
-	PUNCT	O	O	252
P	NOUN	O	Chemical	252
)	PUNCT	O	O	252
were	AUX	O	O	252
included	VERB	O	O	252
.	PUNCT	O	O	252
Demographic	ADJ	O	O	253
,	PUNCT	O	O	253
survival	NOUN	O	O	253
,	PUNCT	O	O	253
response	NOUN	O	O	253
and	CCONJ	O	O	253
toxicity	NOUN	O	Disease	253
data	NOUN	O	O	253
were	AUX	O	O	253
recorded	VERB	O	O	253
.	PUNCT	O	O	253
One	NUM	O	O	254
hundred	NUM	O	O	254
and	CCONJ	O	O	254
twenty	NUM	O	O	254
-	PUNCT	O	O	254
two	NUM	O	O	254
cycles	NOUN	O	O	254
of	ADP	O	O	254
GEM	NOUN	O	O	254
-	PUNCT	O	O	254
P	NOUN	O	Chemical	254
were	AUX	O	O	254
administered	VERB	O	O	254
in	ADP	O	O	254
total	ADJ	O	O	254
(	PUNCT	O	O	254
median	ADJ	O	O	254
3	X	O	O	254
cycles	NOUN	O	O	254
;	PUNCT	O	O	254
range	VERB	O	O	254
1	X	O	O	254
-	PUNCT	O	O	254
6	NUM	O	O	254
)	PUNCT	O	O	254
.	PUNCT	O	O	254
patients	NOUN	O	O	255
received	VERB	O	O	255
GEM	NOUN	O	O	255
-	PUNCT	O	O	255
P	NOUN	O	Chemical	255
as	ADP	O	O	255
second	ADV	O	O	255
-	PUNCT	O	O	255
line	NOUN	O	O	255
treatment	NOUN	O	O	255
and	CCONJ	O	O	255
11/41	NUM	O	O	255
(	PUNCT	O	O	255
27	NUM	O	O	255
%	INTJ	O	O	255
)	PUNCT	O	O	255
as	ADP	O	O	255
third	ADV	O	O	255
-	PUNCT	O	O	255
line	NOUN	O	O	255
therapy	NOUN	O	O	255
.	PUNCT	O	O	255
Overall	ADV	O	O	256
response	NOUN	O	O	256
rate	NOUN	O	O	256
(	PUNCT	O	O	256
ORR	PROPN	O	O	256
)	PUNCT	O	O	256
to	PART	O	O	256
GEM	NOUN	O	O	256
-	PUNCT	O	O	256
P	NOUN	O	Chemical	256
in	ADP	O	O	256
the	PRON	O	O	256
entire	ADJ	O	O	256
cohort	NOUN	O	O	256
was	AUX	O	O	256
80	NUM	O	O	256
%	INTJ	O	O	256
(	PUNCT	O	O	256
complete	VERB	O	O	256
response	NOUN	O	O	256
(	PUNCT	O	O	256
CR	NOUN	O	O	256
)	PUNCT	O	O	256
37	NUM	O	O	256
%	INTJ	O	O	256
,	PUNCT	O	O	256
partial	ADJ	O	O	256
response	NOUN	O	O	256
44	NUM	O	O	256
%	INTJ	O	O	256
)	PUNCT	O	O	256
with	ADP	O	O	256
14/15	NUM	O	O	256
CR	NOUN	O	O	256
confirmed	VERB	O	O	256
as	ADP	O	O	256
a	PRON	O	O	256
metabolic	ADJ	O	O	256
CR	NOUN	O	O	256
on	ADP	O	O	256
PET	NOUN	O	O	256
and	CCONJ	O	O	256
ORR	PROPN	O	O	256
of	ADP	O	O	256
85	NUM	O	O	256
%	INTJ	O	O	256
in	ADP	O	O	256
the	PRON	O	O	256
20	NUM	O	O	256
second	ADV	O	O	256
-	PUNCT	O	O	256
line	NOUN	O	O	256
patients	NOUN	O	O	256
.	PUNCT	O	O	256
3/4	NUM	O	O	257
toxicities	NOUN	O	Disease	257
were	AUX	O	O	257
haematological	NOUN	O	O	257
:	PUNCT	O	O	257
neutropenia	ADJ	O	Disease	257
54	NUM	O	O	257
%	INTJ	O	O	257
and	CCONJ	O	O	257
thrombocytopenia	PROPN	O	Disease	257
51	NUM	O	O	257
%	INTJ	O	O	257
.	PUNCT	O	O	257
Median	ADJ	O	O	258
follow	VERB	O	O	258
-	PUNCT	O	O	258
up	ADP	O	O	258
from	ADP	O	O	258
the	PRON	O	O	258
start	VERB	O	O	258
of	ADP	O	O	258
GEM	NOUN	O	O	258
-	PUNCT	O	O	258
P	NOUN	O	Chemical	258
was	AUX	O	O	258
4.5	NUM	O	O	258
years	NOUN	O	O	258
.	PUNCT	O	O	258
Following	VERB	O	O	259
GEM	NOUN	O	O	259
-	PUNCT	O	O	259
P	NOUN	O	Chemical	259
,	PUNCT	O	O	259
5-year	NOUN	O	O	259
progression	NOUN	O	O	259
-	PUNCT	O	O	259
free	ADJ	O	O	259
survival	NOUN	O	O	259
was	AUX	O	O	259
46	NUM	O	O	259
%	INTJ	O	O	259
(	PUNCT	O	O	259
95	NUM	O	O	259
%	INTJ	O	O	259
confidence	NOUN	O	O	259
interval	NOUN	O	O	259
(	PUNCT	O	O	259
CI	NOUN	O	O	259
)	PUNCT	O	O	259
,	PUNCT	O	O	259
30	NUM	O	O	259
-	PUNCT	O	O	259
62	NUM	O	O	259
%	INTJ	O	O	259
)	PUNCT	O	O	259
and	CCONJ	O	O	259
5-year	NOUN	O	O	259
overall	ADV	O	O	259
survival	NOUN	O	O	259
was	AUX	O	O	259
59	NUM	O	O	259
%	INTJ	O	O	259
(	PUNCT	O	O	259
95	NUM	O	O	259
%	INTJ	O	O	259
CI	NOUN	O	O	259
,	PUNCT	O	O	259
43	NUM	O	O	259
-	PUNCT	O	O	259
74	NUM	O	O	259
%	INTJ	O	O	259
)	PUNCT	O	O	259
.	PUNCT	O	O	259
GEM	NOUN	O	O	260
-	PUNCT	O	O	260
P	NOUN	O	Chemical	260
is	AUX	O	O	260
a	PRON	O	O	260
salvage	NOUN	O	O	260
chemotherapy	NOUN	O	O	260
with	ADP	O	O	260
relatively	ADV	O	O	260
high	ADJ	O	O	260
response	NOUN	O	O	260
rates	NOUN	O	O	260
,	PUNCT	O	O	260
leading	VERB	O	O	260
to	PART	O	O	260
successful	ADJ	O	O	260
transplantation	NOUN	O	O	260
in	ADP	O	O	260
appropriate	ADJ	O	O	260
patients	NOUN	O	O	260
,	PUNCT	O	O	260
in	ADP	O	O	260
the	PRON	O	O	260
treatment	NOUN	O	O	260
of	ADP	O	O	260
relapsed	VERB	O	O	260
or	CCONJ	O	O	260
refractory	ADJ	O	O	260
HL	PROPN	O	O	260
.	PUNCT	O	O	260
Basal	PROPN	O	O	263
functioning	VERB	O	O	263
of	ADP	O	O	263
the	PRON	O	O	263
hypothalamic	ADJ	O	O	263
-	PUNCT	O	O	263
pituitary	NOUN	O	O	263
-	PUNCT	O	O	263
adrenal	ADJ	O	O	263
(	PUNCT	O	O	263
HPA	PROPN	O	O	263
)	PUNCT	O	O	263
axis	NOUN	O	O	263
and	CCONJ	O	O	263
psychological	ADJ	O	O	263
distress	NOUN	O	O	263
in	ADP	O	O	263
recreational	ADJ	O	O	263
ecstasy	NOUN	O	Chemical	263
polydrug	NOUN	O	O	263
users	NOUN	O	O	263
.	PUNCT	O	O	263
RATIONALE	PROPN	O	O	264
:	PUNCT	O	O	264
Ecstasy	NOUN	O	O	264
(	PUNCT	O	O	264
MDMA	PROPN	O	Chemical	264
)	PUNCT	O	O	264
is	AUX	O	O	264
a	PRON	O	O	264
psychostimulant	NOUN	O	O	264
drug	NOUN	O	O	264
which	PRON	O	O	264
is	AUX	O	O	264
increasingly	ADV	O	O	264
associated	VERB	O	O	264
with	ADP	O	O	264
psychobiological	ADJ	O	O	264
dysfunction	NOUN	O	O	264
.	PUNCT	O	O	264
The	PRON	O	O	265
current	ADJ	O	O	265
study	VERB	O	O	265
is	AUX	O	O	265
the	PRON	O	O	265
first	ADV	O	O	265
to	PART	O	O	265
explore	VERB	O	O	265
the	PRON	O	O	265
effects	NOUN	O	O	265
of	ADP	O	O	265
ecstasy	NOUN	O	Chemical	265
-	PUNCT	O	O	265
polydrug	NOUN	O	O	265
use	VERB	O	O	265
on	ADP	O	O	265
psychological	ADJ	O	O	265
distress	NOUN	O	O	265
and	CCONJ	O	O	265
basal	PROPN	O	O	265
functioning	VERB	O	O	265
of	ADP	O	O	265
the	PRON	O	O	265
HPA	PROPN	O	O	265
axis	NOUN	O	O	265
through	ADP	O	O	265
assessing	VERB	O	O	265
the	PRON	O	O	265
secretion	NOUN	O	O	265
of	ADP	O	O	265
cortisol	NOUN	O	O	265
across	ADP	O	O	265
the	PRON	O	O	265
diurnal	ADJ	O	O	265
period	NOUN	O	O	265
.	PUNCT	O	O	265
METHOD	NOUN	O	O	266
:	PUNCT	O	O	266
Seventy	NUM	O	O	266
-	PUNCT	O	O	266
six	NUM	O	O	266
participants	NOUN	O	O	266
(	PUNCT	O	O	266
21	NUM	O	O	266
nonusers	NOUN	O	O	266
,	PUNCT	O	O	266
29	NUM	O	O	266
light	ADJ	O	O	266
ecstasy	NOUN	O	Chemical	266
-	PUNCT	O	O	266
polydrug	NOUN	O	O	266
users	NOUN	O	O	266
,	PUNCT	O	O	266
26	NUM	O	O	266
heavy	ADJ	O	O	266
ecstasy	NOUN	O	Chemical	266
-	PUNCT	O	O	266
polydrug	NOUN	O	O	266
users	NOUN	O	O	266
)	PUNCT	O	O	266
completed	VERB	O	O	266
a	PRON	O	O	266
substance	NOUN	O	O	266
use	VERB	O	O	266
inventory	NOUN	O	O	266
and	CCONJ	O	O	266
measures	NOUN	O	O	266
of	ADP	O	O	266
psychological	ADJ	O	O	266
distress	NOUN	O	O	266
at	ADP	O	O	266
baseline	VERB	O	O	266
,	PUNCT	O	O	266
then	ADV	O	O	266
two	NUM	O	O	266
consecutive	ADJ	O	O	266
days	NOUN	O	O	266
of	ADP	O	O	266
cortisol	NOUN	O	O	266
sampling	NOUN	O	O	266
(	PUNCT	O	O	266
on	ADP	O	O	266
awakening	VERB	O	O	266
,	PUNCT	O	O	266
30	NUM	O	O	266
min	NOUN	O	O	266
post	VERB	O	O	266
awakening	VERB	O	O	266
,	PUNCT	O	O	266
between	ADP	O	O	266
1400	NUM	O	O	266
and	CCONJ	O	O	266
1600	NUM	O	O	266
hours	NOUN	O	O	266
and	CCONJ	O	O	266
pre	VERB	O	O	266
bedtime	NOUN	O	O	266
)	PUNCT	O	O	266
.	PUNCT	O	O	266
Both	PRON	O	O	267
user	NOUN	O	O	267
groups	NOUN	O	O	267
exhibited	VERB	O	O	267
significantly	ADV	O	O	267
greater	ADJ	O	O	267
levels	NOUN	O	O	267
of	ADP	O	O	267
anxiety	NOUN	O	Disease	267
and	CCONJ	O	O	267
depression	PROPN	O	Disease	267
than	ADP	O	O	267
nonusers	NOUN	O	O	267
.	PUNCT	O	O	267
On	ADP	O	O	268
day	NOUN	O	O	268
1	X	O	O	268
,	PUNCT	O	O	268
all	PRON	O	O	268
participants	NOUN	O	O	268
exhibited	VERB	O	O	268
a	PRON	O	O	268
typical	ADJ	O	O	268
cortisol	NOUN	O	O	268
profile	NOUN	O	O	268
,	PUNCT	O	O	268
though	SCONJ	O	O	268
light	ADJ	O	O	268
users	NOUN	O	O	268
had	VERB	O	O	268
significantly	ADV	O	O	268
elevated	ADJ	O	O	268
levels	NOUN	O	O	268
pre	VERB	O	O	268
-	PUNCT	O	O	268
bed	NOUN	O	O	268
.	PUNCT	O	O	268
On	ADP	O	O	269
day	NOUN	O	O	269
2	X	O	O	269
,	PUNCT	O	O	269
heavy	ADJ	O	O	269
users	NOUN	O	O	269
demonstrated	VERB	O	O	269
elevated	ADJ	O	O	269
levels	NOUN	O	O	269
upon	SCONJ	O	O	269
awakening	VERB	O	O	269
and	CCONJ	O	O	269
all	PRON	O	O	269
ecstasy	NOUN	O	Chemical	269
-	PUNCT	O	O	269
polydrug	NOUN	O	O	269
users	NOUN	O	O	269
demonstrated	VERB	O	O	269
elevated	ADJ	O	O	269
pre	VERB	O	O	269
-	PUNCT	O	O	269
bed	NOUN	O	O	269
levels	NOUN	O	O	269
compared	VERB	O	O	269
to	PART	O	O	269
non	ADJ	O	O	269
-	PUNCT	O	O	269
users	NOUN	O	O	269
.	PUNCT	O	O	269
Significant	ADJ	O	O	270
between	ADP	O	O	270
group	NOUN	O	O	270
differences	NOUN	O	O	270
were	AUX	O	O	270
also	ADV	O	O	270
observed	VERB	O	O	270
in	ADP	O	O	270
afternoon	NOUN	O	O	270
cortisol	NOUN	O	O	270
levels	NOUN	O	O	270
and	CCONJ	O	O	270
in	ADP	O	O	270
overall	ADV	O	O	270
cortisol	NOUN	O	O	270
secretion	NOUN	O	O	270
across	ADP	O	O	270
the	PRON	O	O	270
day	NOUN	O	O	270
.	PUNCT	O	O	270
The	PRON	O	O	271
increases	VERB	O	O	271
in	ADP	O	O	271
anxiety	NOUN	O	Disease	271
and	CCONJ	O	O	271
depression	PROPN	O	Disease	271
are	AUX	O	O	271
in	ADP	O	O	271
line	NOUN	O	O	271
with	ADP	O	O	271
previous	ADJ	O	O	271
observations	NOUN	O	O	271
in	ADP	O	O	271
recreational	ADJ	O	O	271
ecstasy	NOUN	O	Chemical	271
-	PUNCT	O	O	271
polydrug	NOUN	O	O	271
users	NOUN	O	O	271
.	PUNCT	O	O	271
Dysregulated	VERB	O	O	272
diurnal	ADJ	O	O	272
cortisol	NOUN	O	O	272
may	AUX	O	O	272
be	AUX	O	O	272
indicative	ADJ	O	O	272
of	ADP	O	O	272
inappropriate	ADJ	O	O	272
anticipation	NOUN	O	O	272
of	ADP	O	O	272
forthcoming	ADJ	O	O	272
demands	VERB	O	O	272
and	CCONJ	O	O	272
hypersecretion	PROPN	O	O	272
may	AUX	O	O	272
lead	VERB	O	Chemical	272
to	PART	O	O	272
the	PRON	O	O	272
increased	VERB	O	O	272
psychological	ADJ	O	O	272
and	CCONJ	O	O	272
physical	ADJ	O	O	272
morbidity	NOUN	O	O	272
associated	VERB	O	O	272
with	ADP	O	O	272
heavy	ADJ	O	O	272
recreational	ADJ	O	O	272
use	VERB	O	O	272
of	ADP	O	O	272
ecstasy	NOUN	O	Chemical	272
.	PUNCT	O	O	272
Ifosfamide	PROPN	O	Chemical	275
related	ADJ	O	O	275
encephalopathy	NOUN	O	Disease	275
:	PUNCT	O	O	275
the	PRON	O	O	275
need	VERB	O	O	275
for	ADP	O	O	275
a	PRON	O	O	275
timely	ADV	O	O	275
EEG	NOUN	O	O	275
evaluation	NOUN	O	O	275
.	PUNCT	O	O	275
Ifosfamide	PROPN	O	Chemical	276
is	AUX	O	O	276
an	PRON	O	O	276
alkylating	VERB	O	O	276
agent	NOUN	O	O	276
useful	ADJ	O	O	276
in	ADP	O	O	276
the	PRON	O	O	276
treatment	NOUN	O	O	276
of	ADP	O	O	276
a	PRON	O	O	276
wide	ADV	O	O	276
range	VERB	O	O	276
of	ADP	O	O	276
cancers	NOUN	O	Disease	276
including	VERB	O	O	276
sarcomas	NOUN	O	O	276
,	PUNCT	O	O	276
lymphoma	PROPN	O	Disease	276
,	PUNCT	O	O	276
gynecologic	ADJ	O	O	276
and	CCONJ	O	O	276
testicular	ADJ	O	O	276
cancers	NOUN	O	Disease	276
.	PUNCT	O	O	276
Encephalopathy	NOUN	O	O	277
has	VERB	O	O	277
been	AUX	O	O	277
reported	VERB	O	O	277
in	ADP	O	O	277
10	NUM	O	O	277
-	PUNCT	O	O	277
40%	NOUN	O	O	277
of	ADP	O	O	277
patients	NOUN	O	O	277
receiving	VERB	O	O	277
high	ADJ	O	O	277
-	PUNCT	O	O	277
dose	NOUN	O	O	277
IV	NUM	O	O	277
ifosfamide	ADP	O	Chemical	277
.	PUNCT	O	O	277
OBJECTIVE	VERB	O	O	278
:	PUNCT	O	O	278
To	PART	O	O	278
highlight	VERB	O	O	278
the	PRON	O	O	278
role	NOUN	O	O	278
of	ADP	O	O	278
electroencephalogram	PROPN	O	O	278
(	PUNCT	O	O	278
EEG	NOUN	O	O	278
)	PUNCT	O	O	278
in	ADP	O	O	278
the	PRON	O	O	278
early	ADV	O	O	278
detection	NOUN	O	O	278
and	CCONJ	O	O	278
management	NOUN	O	O	278
of	ADP	O	O	278
ifosfamide	ADP	O	Chemical	278
related	ADJ	O	O	278
encephalopathy	NOUN	O	Disease	278
.	PUNCT	O	O	278
Retrospective	ADJ	O	O	279
chart	NOUN	O	O	279
review	VERB	O	O	279
including	VERB	O	O	279
clinical	ADJ	O	O	279
data	NOUN	O	O	279
and	CCONJ	O	O	279
EEG	NOUN	O	O	279
recordings	NOUN	O	O	279
was	AUX	O	O	279
done	VERB	O	O	279
on	ADP	O	O	279
five	NUM	O	O	279
patients	NOUN	O	O	279
,	PUNCT	O	O	279
admitted	VERB	O	O	279
to	PART	O	O	279
MD	PROPN	O	Disease	279
Anderson	PROPN	O	O	279
Cancer	NOUN	O	O	279
Center	NOUN	O	O	279
between	ADP	O	O	279
years	NOUN	O	O	279
2009	NUM	O	O	279
and	CCONJ	O	O	279
2012	NUM	O	O	279
,	PUNCT	O	O	279
who	PRON	O	O	279
developed	VERB	O	O	279
ifosfamide	ADP	O	Chemical	279
related	ADJ	O	O	279
acute	ADJ	O	O	279
encephalopathy	NOUN	O	Disease	279
.	PUNCT	O	O	279
All	PRON	O	O	280
five	NUM	O	O	280
patients	NOUN	O	O	280
experienced	ADJ	O	O	280
symptoms	NOUN	O	O	280
of	ADP	O	O	280
encephalopathy	NOUN	O	Disease	280
soon	ADV	O	O	280
after	ADP	O	O	280
(	PUNCT	O	O	280
within	ADP	O	O	280
12	NUM	O	O	280
h-2	VERB	O	O	280
days	NOUN	O	O	280
)	PUNCT	O	O	280
receiving	VERB	O	O	280
ifosfamide	ADP	O	Chemical	280
.	PUNCT	O	O	280
Two	NUM	O	O	281
patients	NOUN	O	O	281
developed	VERB	O	O	281
generalized	VERB	O	O	281
convulsions	NOUN	O	Disease	281
while	SCONJ	O	O	281
one	NUM	O	O	281
patient	NOUN	O	O	281
developed	VERB	O	O	281
continuous	ADJ	O	O	281
non	ADJ	O	O	281
-	PUNCT	O	O	281
convulsive	ADJ	O	Disease	281
status epilepticus	VERB	O	Disease	281
(	PUNCT	O	O	281
NCSE	NOUN	O	O	281
)	PUNCT	O	O	281
that	SCONJ	O	O	281
required	VERB	O	O	281
ICU	PROPN	O	O	281
admission	NOUN	O	O	281
and	CCONJ	O	O	281
intubation	NOUN	O	O	281
.	PUNCT	O	O	281
CONCLUSIONS	NOUN	O	O	282
:	PUNCT	O	O	282
Severity	NOUN	O	O	282
of	ADP	O	O	282
ifosfamide	ADP	O	Chemical	282
related	ADJ	O	O	282
encephalopathy	NOUN	O	Disease	282
correlates	VERB	O	O	282
with	ADP	O	O	282
EEG	NOUN	O	O	282
changes	VERB	O	O	282
.	PUNCT	O	O	282
We	PRON	O	O	283
suggest	VERB	O	O	283
a	PRON	O	O	283
timely	ADV	O	O	283
EEG	NOUN	O	O	283
evaluation	NOUN	O	O	283
for	ADP	O	O	283
patients	NOUN	O	O	283
receiving	VERB	O	O	283
ifosfamide	ADP	O	Chemical	283
who	PRON	O	O	283
develop	VERB	O	O	283
features	VERB	O	O	283
of	ADP	O	O	283
encephalopathy	NOUN	O	Disease	283
.	PUNCT	O	O	283
Incidence	NOUN	O	O	286
of	ADP	O	O	286
contrast	NOUN	O	O	286
-	PUNCT	O	O	286
induced	VERB	O	O	286
nephropathy	NOUN	O	Disease	286
in	ADP	O	O	286
hospitalised	VERB	O	O	286
patients	NOUN	O	O	286
with	ADP	O	O	286
cancer	NOUN	O	Disease	286
.	PUNCT	O	O	286
OBJECTIVES	NOUN	O	O	287
:	PUNCT	O	O	287
To	PART	O	O	287
determine	VERB	O	O	287
the	PRON	O	O	287
frequency	NOUN	O	O	287
of	ADP	O	O	287
and	CCONJ	O	O	287
possible	ADJ	O	O	287
factors	NOUN	O	O	287
related	ADJ	O	O	287
to	PART	O	O	287
contrast	NOUN	O	O	287
-	PUNCT	O	O	287
induced	VERB	O	O	287
nephropathy	NOUN	O	Disease	287
(	PUNCT	O	O	287
CIN	PROPN	O	Disease	287
)	PUNCT	O	O	287
in	ADP	O	O	287
hospitalised	VERB	O	O	287
patients	NOUN	O	O	287
with	ADP	O	O	287
cancer	NOUN	O	Disease	287
.	PUNCT	O	O	287
Patients	NOUN	O	O	288
with	ADP	O	O	288
risk	NOUN	O	O	288
factors	NOUN	O	O	288
for	ADP	O	O	288
acute	ADJ	O	O	288
renal failure	NOUN	O	Disease	288
were	AUX	O	O	288
excluded	VERB	O	O	288
.	PUNCT	O	O	288
Blood	NOUN	O	O	289
samples	NOUN	O	O	289
were	AUX	O	O	289
examined	VERB	O	O	289
the	PRON	O	O	289
day	NOUN	O	O	289
before	ADP	O	O	289
contrast	NOUN	O	O	289
-	PUNCT	O	O	289
enhanced	VERB	O	O	289
computed	VERB	O	O	289
tomography	NOUN	O	O	289
(	PUNCT	O	O	289
CT	PROPN	O	O	289
)	PUNCT	O	O	289
and	CCONJ	O	O	289
serially	ADV	O	O	289
for	ADP	O	O	289
3	X	O	O	289
days	NOUN	O	O	289
thereafter	ADV	O	O	289
.	PUNCT	O	O	289
CIN	PROPN	O	Disease	290
was	AUX	O	O	290
defined	VERB	O	O	290
as	ADP	O	O	290
an	PRON	O	O	290
increase	VERB	O	O	290
in	ADP	O	O	290
serum	NOUN	O	O	290
creatinine	PROPN	O	Chemical	290
(	PUNCT	O	O	290
Cr	NOUN	O	Chemical	290
)	PUNCT	O	O	290
of	ADP	O	O	290
0.5	NUM	O	O	290
mg	VERB	O	O	290
/	PUNCT	O	O	290
dl	X	O	O	290
or	CCONJ	O	O	290
more	ADJ	O	O	290
,	PUNCT	O	O	290
or	CCONJ	O	O	290
elevation	NOUN	O	O	290
of	ADP	O	O	290
Cr	NOUN	O	Chemical	290
to	PART	O	O	290
25	NUM	O	O	290
%	INTJ	O	O	290
over	ADP	O	O	290
baseline	VERB	O	O	290
.	PUNCT	O	O	290
CIN	PROPN	O	Disease	291
was	AUX	O	O	291
significantly	ADV	O	O	291
more	ADJ	O	O	291
after	ADP	O	O	291
treatment	NOUN	O	O	291
with	ADP	O	O	291
bevacizumab	PROPN	O	O	291
/	PUNCT	O	O	291
irinotecan	VERB	O	O	291
(	PUNCT	O	O	291
P	NOUN	O	Chemical	291
=	PUNCT	O	O	291
0.021	NUM	O	O	291
)	PUNCT	O	O	291
and	CCONJ	O	O	291
in	ADP	O	O	291
patients	NOUN	O	O	291
with	ADP	O	O	291
hypertension	NOUN	O	Disease	291
(	PUNCT	O	O	291
P	NOUN	O	Chemical	291
=	PUNCT	O	O	291
0.044	NUM	O	O	291
)	PUNCT	O	O	291
.	PUNCT	O	O	291
CIN	PROPN	O	Disease	292
developed	VERB	O	O	292
4.5-times	NOUN	O	O	292
more	ADJ	O	O	292
frequently	ADV	O	O	292
in	ADP	O	O	292
patients	NOUN	O	O	292
with	ADP	O	O	292
cancer	NOUN	O	Disease	292
who	PRON	O	O	292
had	VERB	O	O	292
undergone	VERB	O	O	292
recent	ADJ	O	O	292
chemotherapy	NOUN	O	O	292
.	PUNCT	O	O	292
Hypertension	NOUN	O	Disease	293
and	CCONJ	O	O	293
the	PRON	O	O	293
combination	NOUN	O	O	293
of	ADP	O	O	293
bevacizumab	PROPN	O	O	293
/	PUNCT	O	O	293
irinotecan	VERB	O	O	293
may	AUX	O	O	293
be	AUX	O	O	293
additional	ADJ	O	O	293
risk	NOUN	O	O	293
factors	NOUN	O	O	293
for	ADP	O	O	293
CIN	PROPN	O	Disease	293
development	NOUN	O	O	293
.	PUNCT	O	O	293
Contrast	NOUN	O	O	294
-	PUNCT	O	O	294
induced	VERB	O	O	294
nephropathy	NOUN	O	Disease	294
(	PUNCT	O	O	294
CIN	PROPN	O	Disease	294
)	PUNCT	O	O	294
is	AUX	O	O	294
a	PRON	O	O	294
concern	NOUN	O	O	294
for	ADP	O	O	294
oncological	ADJ	O	O	294
patients	NOUN	O	O	294
undergoing	VERB	O	O	294
CT	PROPN	O	O	294
.	PUNCT	O	O	294
.	PUNCT	O	O	294
Hypertension	NOUN	O	Disease	295
and	CCONJ	O	O	295
treatment	NOUN	O	O	295
with	ADP	O	O	295
bevacizumab	PROPN	O	O	295
appear	VERB	O	O	295
to	PART	O	O	295
be	AUX	O	O	295
additional	ADJ	O	O	295
risk	NOUN	O	O	295
factors	NOUN	O	O	295
.	PUNCT	O	O	295
Syndrome	NOUN	O	O	298
of	ADP	O	O	298
inappropriate	ADJ	O	O	298
antidiuretic	ADJ	O	O	298
hormone	NOUN	O	O	298
secretion	NOUN	O	O	298
associated	VERB	O	O	298
with	ADP	O	O	298
desvenlafaxine	NOUN	O	O	298
.	PUNCT	O	O	298
OBJECTIVE	VERB	O	O	299
:	PUNCT	O	O	299
To	PART	O	O	299
report	VERB	O	O	299
a	PRON	O	O	299
case	NOUN	O	O	299
of	ADP	O	O	299
syndrome	NOUN	O	O	299
of	ADP	O	O	299
inappropriate	ADJ	O	O	299
anti	ADJ	O	O	299
-	PUNCT	O	O	299
diuretic	ADJ	O	Chemical	299
hormone	NOUN	O	O	299
(	PUNCT	O	O	299
SIADH	PROPN	O	Disease	299
)	PUNCT	O	O	299
secretion	NOUN	O	O	299
associated	VERB	O	O	299
with	ADP	O	O	299
desvenlafaxine	NOUN	O	O	299
.	PUNCT	O	O	299
A	PRON	O	O	300
57-year	NOUN	O	O	300
old	ADJ	O	O	300
female	ADJ	O	O	300
with	ADP	O	O	300
hyponatraemia	NOUN	O	O	300
.	PUNCT	O	O	300
Her	PRON	O	O	301
medications	NOUN	O	O	301
included	VERB	O	O	301
desvenlafaxine	NOUN	O	O	301
,	PUNCT	O	O	301
and	CCONJ	O	O	301
symptoms	NOUN	O	O	301
included	VERB	O	O	301
nausea	NOUN	O	Disease	301
,	PUNCT	O	O	301
anxiety	NOUN	O	Disease	301
and	CCONJ	O	O	301
confusion	NOUN	O	Disease	301
.	PUNCT	O	O	301
The	PRON	O	O	302
serum	NOUN	O	O	302
sodium	NOUN	O	Chemical	302
at	ADP	O	O	302
this	PRON	O	O	302
time	NOUN	O	O	302
was	AUX	O	O	302
120	NUM	O	O	302
mmol	NOUN	O	O	302
/	PUNCT	O	O	302
L	NOUN	O	O	302
,	PUNCT	O	O	302
serum	NOUN	O	O	302
osmolality	NOUN	O	O	302
was	AUX	O	O	302
263	NUM	O	O	302
mosmol	PROPN	O	O	302
/	PUNCT	O	O	302
kg	VERB	O	O	302
,	PUNCT	O	O	302
urine	NOUN	O	O	302
osmolality	NOUN	O	O	302
410	NUM	O	O	303
mosmol	PROPN	O	O	303
/	PUNCT	O	O	303
kg	VERB	O	O	303
and	CCONJ	O	O	303
urine	NOUN	O	O	303
sodium	NOUN	O	Chemical	303
63	NUM	O	O	303
mmol	NOUN	O	O	303
/	PUNCT	O	O	303
L	NOUN	O	O	303
,	PUNCT	O	O	303
consistent	ADJ	O	O	303
with	ADP	O	O	303
a	PRON	O	O	303
diagnosis	NOUN	O	O	303
of	ADP	O	O	303
SIADH	PROPN	O	Disease	303
.	PUNCT	O	O	303
Desvenlafaxine	NOUN	O	O	304
was	AUX	O	O	304
ceased	VERB	O	O	304
and	CCONJ	O	O	304
fluid	NOUN	O	O	304
restriction	NOUN	O	O	304
implemented	VERB	O	O	304
.	PUNCT	O	O	304
After	ADP	O	O	305
4	NUM	O	O	305
days	NOUN	O	O	305
the	PRON	O	O	305
sodium	NOUN	O	Chemical	305
increased	VERB	O	O	305
to	PART	O	O	305
128	NUM	O	O	305
mmol	NOUN	O	O	305
/	PUNCT	O	O	305
L	NOUN	O	O	305
and	CCONJ	O	O	305
fluid	NOUN	O	O	305
restriction	NOUN	O	O	305
was	AUX	O	O	305
relaxed	ADJ	O	O	305
.	PUNCT	O	O	305
During	ADP	O	O	306
her	PRON	O	O	306
further	ADV	O	O	306
3	X	O	O	306
weeks	NOUN	O	O	306
inpatient	ADJ	O	O	306
admission	NOUN	O	O	306
the	PRON	O	O	306
serum	NOUN	O	O	306
sodium	NOUN	O	Chemical	306
ranged	VERB	O	O	306
from	ADP	O	O	306
134	NUM	O	O	306
to	PART	O	O	306
137	NUM	O	O	306
mmol	NOUN	O	O	306
/	PUNCT	O	O	306
L	NOUN	O	O	306
during	ADP	O	O	306
treatment	NOUN	O	O	306
with	ADP	O	O	306
mirtazapine	NOUN	O	O	306
.	PUNCT	O	O	306
SIADH	PROPN	O	Disease	307
has	VERB	O	O	307
been	AUX	O	O	307
widely	ADV	O	O	307
reported	VERB	O	O	307
with	ADP	O	O	307
a	PRON	O	O	307
range	VERB	O	O	307
of	ADP	O	O	307
antidepressants	NOUN	O	O	307
.	PUNCT	O	O	307
This	PRON	O	O	308
case	NOUN	O	O	308
report	VERB	O	O	308
suggests	VERB	O	O	308
that	SCONJ	O	O	308
desvenlafaxine	NOUN	O	O	308
might	AUX	O	O	308
cause	VERB	O	O	308
clinically	ADV	O	O	308
significant	ADJ	O	O	308
hyponatremia	NOUN	O	O	308
.	PUNCT	O	O	308
Clinicians	NOUN	O	O	309
should	AUX	O	O	309
be	AUX	O	O	309
aware	ADJ	O	O	309
of	ADP	O	O	309
the	PRON	O	O	309
potential	ADJ	O	O	309
for	ADP	O	O	309
antidepressants	NOUN	O	O	309
to	PART	O	O	309
cause	VERB	O	O	309
hyponatremia	NOUN	O	O	309
,	PUNCT	O	O	309
and	CCONJ	O	O	309
take	VERB	O	O	309
appropriate	ADJ	O	O	309
corrective	ADJ	O	O	309
action	NOUN	O	O	309
where	SCONJ	O	O	309
necessary	ADJ	O	O	309
.	PUNCT	O	O	309
Oxidative	NOUN	O	O	312
stress	NOUN	O	O	312
on	ADP	O	O	312
cardiotoxicity	NOUN	O	Disease	312
after	ADP	O	O	312
treatment	NOUN	O	O	312
with	ADP	O	O	312
single	ADJ	O	O	312
and	CCONJ	O	O	312
multiple	ADJ	O	O	312
doses	NOUN	O	O	312
of	ADP	O	O	312
doxorubicin	VERB	O	Chemical	312
.	PUNCT	O	O	312
The	PRON	O	O	313
mechanism	NOUN	O	O	313
of	ADP	O	O	313
doxorubicin	VERB	O	Chemical	313
(	PUNCT	O	O	313
DOX)-induced	PROPN	O	O	313
cardiotoxicity	NOUN	O	Disease	313
remains	VERB	O	O	313
controversial	ADJ	O	O	313
.	PUNCT	O	O	313
Wistar	PROPN	O	O	314
rats	NOUN	O	O	314
(	PUNCT	O	O	314
n	CCONJ	O	O	314
=	PUNCT	O	O	314
66	NUM	O	O	314
)	PUNCT	O	O	314
received	VERB	O	O	314
DOX	PROPN	O	Chemical	314
injections	NOUN	O	O	314
intraperitoneally	ADV	O	O	314
and	CCONJ	O	O	314
were	AUX	O	O	314
randomly	ADV	O	O	314
assigned	VERB	O	O	314
to	PART	O	O	314
2	X	O	O	314
experimental	ADJ	O	O	314
protocols	NOUN	O	O	314
:	PUNCT	O	O	314
(	PUNCT	O	O	314
1	X	O	O	314
)	PUNCT	O	O	314
rats	NOUN	O	O	314
were	AUX	O	O	314
killed	VERB	O	O	314
before	ADP	O	O	314
(	PUNCT	O	O	314
-24	NOUN	O	O	314
h	X	O	O	314
,	PUNCT	O	O	314
n	CCONJ	O	O	314
=	PUNCT	O	O	314
8)	NUM	O	O	314
and	CCONJ	O	O	314
24	NUM	O	O	314
h	X	O	O	314
after	ADP	O	O	314
(	PUNCT	O	O	314
+	ADP	O	O	314
24	NUM	O	O	314
h	X	O	O	314
,	PUNCT	O	O	314
n	CCONJ	O	O	314
=	PUNCT	O	O	314
8)	NUM	O	O	314
a	PRON	O	O	314
single	ADJ	O	O	314
dose	NOUN	O	O	314
of	ADP	O	O	314
DOX	PROPN	O	Chemical	314
(	PUNCT	O	O	314
4	NUM	O	O	314
mg	VERB	O	O	314
/	PUNCT	O	O	314
kg	VERB	O	O	314
body	NOUN	O	O	314
weight	NOUN	O	O	314
)	PUNCT	O	O	314
to	PART	O	O	314
determine	VERB	O	O	314
the	PRON	O	O	314
DOX	PROPN	O	Chemical	314
acute	ADJ	O	O	314
effect	VERB	O	O	314
and	CCONJ	O	O	314
(	PUNCT	O	O	314
2	X	O	O	314
)	PUNCT	O	O	314
rats	NOUN	O	O	314
(	PUNCT	O	O	314
n	CCONJ	O	O	314
=	PUNCT	O	O	314
58	NUM	O	O	314
)	PUNCT	O	O	314
received	VERB	O	O	314
4	NUM	O	O	314
injections	NOUN	O	O	314
of	ADP	O	O	314
DOX	PROPN	O	Chemical	314
(	PUNCT	O	O	314
4	NUM	O	O	314
mg	VERB	O	O	314
/	PUNCT	O	O	314
kg	VERB	O	O	314
body	NOUN	O	O	314
weight	NOUN	O	O	314
/	PUNCT	O	O	314
week	NOUN	O	O	314
)	PUNCT	O	O	314
and	CCONJ	O	O	314
were	AUX	O	O	314
killed	VERB	O	O	314
before	ADP	O	O	314
the	PRON	O	O	314
first	ADV	O	O	314
injection	NOUN	O	O	314
(	PUNCT	O	O	314
M0	NOUN	O	O	314
)	PUNCT	O	O	314
and	CCONJ	O	O	314
1	X	O	O	314
week	NOUN	O	O	314
after	ADP	O	O	314
each	PRON	O	O	314
injection	NOUN	O	O	314
(	PUNCT	O	O	314
M1	PROPN	O	O	314
,	PUNCT	O	O	314
M2	PROPN	O	O	314
,	PUNCT	O	O	314
M3	PROPN	O	O	314
,	PUNCT	O	O	314
and	CCONJ	O	O	314
M4	PROPN	O	O	314
)	PUNCT	O	O	314
to	PART	O	O	314
determine	VERB	O	O	314
the	PRON	O	O	314
chronological	ADJ	O	O	314
effects	NOUN	O	O	314
.	PUNCT	O	O	314
Single	ADJ	O	O	315
dose	NOUN	O	O	315
of	ADP	O	O	315
DOX	PROPN	O	Chemical	315
was	AUX	O	O	315
associated	VERB	O	O	315
with	ADP	O	O	315
increased	VERB	O	O	315
cardiac	ADJ	O	O	315
disarrangement	NOUN	O	O	315
,	PUNCT	O	O	315
necrosis	NOUN	O	Disease	315
,	PUNCT	O	O	315
and	CCONJ	O	O	315
DNA	NOUN	O	O	315
damage	NOUN	O	O	315
(	PUNCT	O	O	315
strand	NOUN	O	O	315
breaks	VERB	O	O	315
(	PUNCT	O	O	315
SBs	NOUN	O	O	315
)	PUNCT	O	O	315
and	CCONJ	O	O	315
oxidized	VERB	O	O	315
pyrimidines	NOUN	O	O	315
)	PUNCT	O	O	315
and	CCONJ	O	O	315
decreased	VERB	O	O	315
TAP	VERB	O	O	315
.	PUNCT	O	O	315
The	PRON	O	O	316
chronological	ADJ	O	O	316
study	VERB	O	O	316
showed	VERB	O	O	316
an	PRON	O	O	316
effect	VERB	O	O	316
of	ADP	O	O	316
a	PRON	O	O	316
cumulative	ADJ	O	O	316
dose	NOUN	O	O	316
on	ADP	O	O	316
body	NOUN	O	O	316
weight	NOUN	O	O	316
(	PUNCT	O	O	316
R	NOUN	O	O	316
=	PUNCT	O	O	316
-0.99	PUNCT	O	O	316
,	PUNCT	O	O	316
p	NOUN	O	O	316
=	PUNCT	O	O	316
0.011	NUM	O	O	316
)	PUNCT	O	O	316
,	PUNCT	O	O	316
necrosis	NOUN	O	Disease	316
(	PUNCT	O	O	316
R	NOUN	O	O	316
=	PUNCT	O	O	316
1.00	NUM	O	O	316
,	PUNCT	O	O	316
p	NOUN	O	O	316
=	PUNCT	O	O	316
0.004	NUM	O	O	316
)	PUNCT	O	O	316
,	PUNCT	O	O	316
TAP	VERB	O	O	316
(	PUNCT	O	O	316
DNA	NOUN	O	O	317
SBs	NOUN	O	O	317
damage	NOUN	O	O	317
was	AUX	O	O	317
negatively	ADV	O	O	317
associated	VERB	O	O	317
with	ADP	O	O	317
TAP	VERB	O	O	317
(	PUNCT	O	O	317
R	NOUN	O	O	317
=	PUNCT	O	O	317
-0.98	NUM	O	O	317
,	PUNCT	O	O	317
p	NOUN	O	O	317
=	PUNCT	O	O	317
0.018	NUM	O	O	317
)	PUNCT	O	O	317
,	PUNCT	O	O	317
and	CCONJ	O	O	317
necrosis	NOUN	O	Disease	317
Our	PRON	O	O	318
results	VERB	O	O	318
suggest	VERB	O	O	318
that	SCONJ	O	O	318
oxidative	NOUN	O	O	318
damage	NOUN	O	O	318
is	AUX	O	O	318
associated	VERB	O	O	318
with	ADP	O	O	318
acute	ADJ	O	O	318
cardiotoxicity	NOUN	O	Disease	318
induced	VERB	O	O	318
by	ADP	O	O	318
a	PRON	O	O	318
single	ADJ	O	O	318
dose	NOUN	O	O	318
of	ADP	O	O	318
DOX	PROPN	O	Chemical	318
only	ADV	O	O	318
.	PUNCT	O	O	318
Increased	VERB	O	O	319
resistance	NOUN	O	O	319
to	PART	O	O	319
the	PRON	O	O	319
oxidative	NOUN	O	O	319
stress	NOUN	O	O	319
is	AUX	O	O	319
plausible	ADJ	O	O	319
for	ADP	O	O	319
the	PRON	O	O	319
multiple	ADJ	O	O	319
dose	NOUN	O	O	319
of	ADP	O	O	319
DOX	PROPN	O	Chemical	319
.	PUNCT	O	O	319
Thus	ADV	O	O	320
,	PUNCT	O	O	320
different	ADJ	O	O	320
mechanisms	NOUN	O	O	320
may	AUX	O	O	320
be	AUX	O	O	320
involved	VERB	O	O	320
in	ADP	O	O	320
acute	ADJ	O	O	320
toxicity	NOUN	O	Disease	320
versus	ADP	O	O	320
chronic	ADJ	O	O	320
toxicity	NOUN	O	Disease	320
.	PUNCT	O	O	320
Tacrolimus	PROPN	O	Chemical	323
-	PUNCT	O	O	323
related	ADJ	O	O	323
seizure	NOUN	O	Disease	323
after	ADP	O	O	323
pediatric	ADJ	O	O	323
liver	NOUN	O	O	323
transplantation	NOUN	O	O	323
--	PUNCT	O	O	323
a	PRON	O	O	323
single	ADJ	O	O	323
-	PUNCT	O	O	323
center	PROPN	O	O	323
experience	NOUN	O	O	323
.	PUNCT	O	O	323
To	PART	O	O	324
identify	VERB	O	O	324
the	PRON	O	O	324
risk	NOUN	O	O	324
factors	NOUN	O	O	324
for	ADP	O	O	324
new	ADJ	O	O	324
-	PUNCT	O	O	324
onset	VERB	O	O	324
seizures	NOUN	O	Disease	324
after	ADP	O	O	324
pediatric	ADJ	O	O	324
LT	PROPN	O	O	324
and	CCONJ	O	O	324
to	PART	O	O	324
assess	VERB	O	O	324
their	PRON	O	O	324
clinical	ADJ	O	O	324
implications	NOUN	O	O	324
and	CCONJ	O	O	324
long	ADV	O	O	324
-	PUNCT	O	O	324
term	NOUN	O	O	324
prognosis	VERB	O	O	324
.	PUNCT	O	O	324
Patients	NOUN	O	O	325
were	AUX	O	O	325
divided	VERB	O	O	325
into	ADP	O	O	325
seizures	NOUN	O	Disease	325
group	NOUN	O	O	325
and	CCONJ	O	O	325
a	PRON	O	O	325
non	ADJ	O	O	325
-	PUNCT	O	O	325
seizures	NOUN	O	Disease	325
group	NOUN	O	O	325
.	PUNCT	O	O	325
Seizures	NOUN	O	Disease	326
occurred	VERB	O	O	326
in	ADP	O	O	326
four	NUM	O	O	326
children	NOUN	O	O	326
,	PUNCT	O	O	326
an	PRON	O	O	326
incidence	NOUN	O	O	326
of	ADP	O	O	326
14.8%	NOUN	O	O	326
.	PUNCT	O	O	326
All	PRON	O	O	327
exhibited	VERB	O	O	327
generalized	VERB	O	O	327
tonic	PROPN	O	O	327
-	PUNCT	O	O	327
clonic	ADJ	O	O	327
seizures	NOUN	O	Disease	327
within	ADP	O	O	327
the	PRON	O	O	327
first	ADV	O	O	327
two	NUM	O	O	327
wk	X	O	O	327
after	ADP	O	O	327
LT	PROPN	O	O	327
.	PUNCT	O	O	327
Univariate	NOUN	O	O	328
analysis	NOUN	O	O	328
showed	VERB	O	O	328
that	SCONJ	O	O	328
the	PRON	O	O	328
risk	NOUN	O	O	328
factors	NOUN	O	O	328
associated	VERB	O	O	328
with	ADP	O	O	328
seizures	NOUN	O	Disease	328
after	ADP	O	O	328
pediatric	ADJ	O	O	328
LT	PROPN	O	O	328
included	VERB	O	O	328
gender	NOUN	O	O	328
,	PUNCT	O	O	328
pediatric	ADJ	O	O	328
end	VERB	O	O	328
-	PUNCT	O	O	328
stage	NOUN	O	O	328
liver disease	NOUN	O	Disease	328
score	VERB	O	O	328
before	ADP	O	O	328
surgery	NOUN	O	O	328
,	PUNCT	O	O	328
Child	NOUN	O	O	328
-	PUNCT	O	O	328
Pugh	PROPN	O	O	328
score	VERB	O	O	328
before	ADP	O	O	328
surgery	NOUN	O	O	328
,	PUNCT	O	O	328
serum	NOUN	O	O	328
total	ADJ	O	O	328
bilirubin	ADJ	O	Chemical	328
after	ADP	O	O	328
surgery	NOUN	O	O	328
,	PUNCT	O	O	328
and	CCONJ	O	O	328
trough	NOUN	O	O	328
TAC	PROPN	O	O	328
level	VERB	O	O	328
.	PUNCT	O	O	328
Multivariate	NOUN	O	O	329
analysis	NOUN	O	O	329
showed	VERB	O	O	329
that	SCONJ	O	O	329
trough	NOUN	O	O	329
TAC	PROPN	O	O	329
level	VERB	O	O	329
was	AUX	O	O	329
the	PRON	O	O	329
only	ADV	O	O	329
independent	ADJ	O	O	329
risk	NOUN	O	O	329
factor	NOUN	O	O	329
associated	VERB	O	O	329
with	ADP	O	O	329
the	PRON	O	O	329
seizures	NOUN	O	Disease	329
.	PUNCT	O	O	329
All	PRON	O	O	330
children	NOUN	O	O	330
who	PRON	O	O	330
experienced	ADJ	O	O	330
seizures	NOUN	O	Disease	330
survived	VERB	O	O	330
with	ADP	O	O	330
good	ADJ	O	O	330
graft	NOUN	O	O	330
function	NOUN	O	O	330
and	CCONJ	O	O	330
remained	VERB	O	O	330
seizure	NOUN	O	Disease	330
-	PUNCT	O	O	330
free	ADJ	O	O	330
without	ADP	O	O	330
anti	ADJ	O	O	330
-	PUNCT	O	O	330
epileptic	ADJ	O	Disease	330
drugs	NOUN	O	O	330
over	ADP	O	O	330
a	PRON	O	O	330
mean	VERB	O	O	330
follow	VERB	O	O	330
-	PUNCT	O	O	330
up	ADP	O	O	330
period	NOUN	O	O	330
of	ADP	O	O	330
33.7	NUM	O	O	330
+	ADP	O	O	330
14.6	NUM	O	O	330
months	NOUN	O	O	330
.	PUNCT	O	O	330
High	ADJ	O	O	331
trough	NOUN	O	O	331
TAC	PROPN	O	O	331
level	VERB	O	O	331
was	AUX	O	O	331
the	PRON	O	O	331
predominant	ADJ	O	O	331
factor	NOUN	O	O	331
that	SCONJ	O	O	331
contributed	VERB	O	O	331
to	PART	O	O	331
seizures	NOUN	O	Disease	331
in	ADP	O	O	331
the	PRON	O	O	331
early	ADV	O	O	331
post	VERB	O	O	331
-	PUNCT	O	O	331
operative	NOUN	O	O	331
period	NOUN	O	O	331
after	ADP	O	O	331
pediatric	ADJ	O	O	331
LT	PROPN	O	O	331
.	PUNCT	O	O	331
High	ADJ	O	O	332
PELD	PROPN	O	O	332
and	CCONJ	O	O	332
Child	NOUN	O	O	332
-	PUNCT	O	O	332
Pugh	PROPN	O	O	332
scores	NOUN	O	O	332
before	ADP	O	O	332
LT	PROPN	O	O	332
and	CCONJ	O	O	332
high	ADJ	O	O	332
post	VERB	O	O	332
-	PUNCT	O	O	332
operative	NOUN	O	O	332
serum	NOUN	O	O	332
Tbil	NOUN	O	O	332
may	AUX	O	O	332
be	AUX	O	O	332
contributory	ADJ	O	O	332
risk	NOUN	O	O	332
factors	NOUN	O	O	332
for	ADP	O	O	332
TAC	PROPN	O	O	332
-	PUNCT	O	O	332
related	ADJ	O	O	332
seizures	NOUN	O	Disease	332
.	PUNCT	O	O	332
The	PRON	O	O	335
flavonoid	NOUN	O	O	335
apigenin	NOUN	O	O	335
delays	VERB	O	O	335
forgetting	VERB	O	O	335
of	ADP	O	O	335
passive	ADJ	O	O	335
avoidance	NOUN	O	O	335
conditioning	NOUN	O	O	335
in	ADP	O	O	335
rats	NOUN	O	O	335
.	PUNCT	O	O	335
The	PRON	O	O	336
present	NOUN	O	O	336
experiments	NOUN	O	O	336
were	AUX	O	O	336
performed	VERB	O	O	336
to	PART	O	O	336
study	VERB	O	O	336
the	PRON	O	O	336
effect	VERB	O	O	336
of	ADP	O	O	336
the	PRON	O	O	336
flavonoid	NOUN	O	O	336
apigenin	NOUN	O	O	336
(	PUNCT	O	O	336
20	NUM	O	O	336
mg	VERB	O	O	336
/	PUNCT	O	O	336
kg	VERB	O	O	336
intraperitoneally	ADV	O	O	336
(	PUNCT	O	O	336
i.p	NOUN	O	O	336
.	PUNCT	O	O	336
)	PUNCT	O	O	336
,	PUNCT	O	O	336
1	X	O	O	336
h	X	O	O	336
before	ADP	O	O	336
acquisition	NOUN	O	O	336
)	PUNCT	O	O	336
,	PUNCT	O	O	336
on	ADP	O	O	336
24	NUM	O	O	336
h	X	O	O	336
retention	NOUN	O	O	336
performance	NOUN	O	O	336
and	CCONJ	O	O	336
forgetting	VERB	O	O	336
of	ADP	O	O	336
a	PRON	O	O	336
step	VERB	O	O	336
-	PUNCT	O	O	336
through	ADP	O	O	336
passive	ADJ	O	O	336
avoidance	NOUN	O	O	336
task	NOUN	O	O	336
,	PUNCT	O	O	336
in	ADP	O	O	336
young	ADJ	O	O	336
male	NOUN	O	O	336
Wistar	PROPN	O	O	336
rats	NOUN	O	O	336
.	PUNCT	O	O	336
There	ADV	O	O	337
were	AUX	O	O	337
no	PRON	O	O	337
differences	NOUN	O	O	337
between	ADP	O	O	337
saline-	ADP	O	O	337
and	CCONJ	O	O	337
apigenin	NOUN	O	O	337
-	PUNCT	O	O	337
treated	VERB	O	O	337
groups	NOUN	O	O	337
in	ADP	O	O	337
the	PRON	O	O	337
24	NUM	O	O	337
h	X	O	O	337
retention	NOUN	O	O	337
trial	NOUN	O	O	337
.	PUNCT	O	O	337
Furthermore	ADV	O	O	338
,	PUNCT	O	O	338
apigenin	NOUN	O	O	338
did	VERB	O	O	338
not	PART	O	O	338
prevent	VERB	O	O	338
the	PRON	O	O	338
amnesia	NOUN	O	Disease	338
induced	VERB	O	O	338
by	ADP	O	O	338
scopolamine	NOUN	O	Chemical	338
(	PUNCT	O	O	338
1mg	NOUN	O	O	338
/	PUNCT	O	O	338
kg	VERB	O	O	338
,	PUNCT	O	O	338
i.p	NOUN	O	O	338
.	PUNCT	O	O	338
The	PRON	O	O	339
saline-	ADP	O	O	339
and	CCONJ	O	O	339
apigenin	NOUN	O	O	339
-	PUNCT	O	O	339
treated	VERB	O	O	339
rats	NOUN	O	O	339
that	SCONJ	O	O	339
did	VERB	O	O	339
not	PART	O	O	339
step	VERB	O	O	339
through	ADP	O	O	339
into	ADP	O	O	339
the	PRON	O	O	339
dark	ADJ	O	O	339
compartment	NOUN	O	O	339
during	ADP	O	O	339
the	PRON	O	O	339
cut	VERB	O	O	339
-	PUNCT	O	O	339
off	ADP	O	O	339
time	NOUN	O	O	339
(	PUNCT	O	O	339
540	NUM	O	O	339
s	X	O	O	339
)	PUNCT	O	O	339
were	AUX	O	O	339
retested	VERB	O	O	339
weekly	ADV	O	O	339
for	ADP	O	O	339
up	ADP	O	O	339
to	PART	O	O	339
eight	NUM	O	O	339
weeks	NOUN	O	O	339
.	PUNCT	O	O	339
In	ADP	O	O	340
the	PRON	O	O	340
saline	NOUN	O	O	340
treated	VERB	O	O	340
group	NOUN	O	O	340
,	PUNCT	O	O	340
the	PRON	O	O	340
first	ADV	O	O	340
significant	ADJ	O	O	340
decline	VERB	O	O	340
in	ADP	O	O	340
passive	ADJ	O	O	340
avoidance	NOUN	O	O	340
response	NOUN	O	O	340
was	AUX	O	O	340
observed	VERB	O	O	340
at	ADP	O	O	340
four	NUM	O	O	340
weeks	NOUN	O	O	340
,	PUNCT	O	O	340
and	CCONJ	O	O	340
complete	VERB	O	O	340
memory	NOUN	O	O	340
loss	NOUN	O	O	340
was	AUX	O	O	340
found	VERB	O	O	340
five	NUM	O	O	340
weeks	NOUN	O	O	340
after	ADP	O	O	340
the	PRON	O	O	340
acquisition	NOUN	O	O	340
of	ADP	O	O	340
the	PRON	O	O	340
passive	ADJ	O	O	340
avoidance	NOUN	O	O	340
task	NOUN	O	O	340
.	PUNCT	O	O	340
At	ADP	O	O	341
the	PRON	O	O	341
end	VERB	O	O	341
of	ADP	O	O	341
the	PRON	O	O	341
experimental	ADJ	O	O	341
period	NOUN	O	O	341
,	PUNCT	O	O	341
60%	NOUN	O	O	341
of	ADP	O	O	341
the	PRON	O	O	341
animals	NOUN	O	O	341
treated	VERB	O	O	341
with	ADP	O	O	341
apigenin	NOUN	O	O	341
still	ADV	O	O	341
did	VERB	O	O	341
not	PART	O	O	341
step	VERB	O	O	341
through	ADP	O	O	341
.	PUNCT	O	O	341
These	PRON	O	O	342
data	NOUN	O	O	342
suggest	VERB	O	O	342
that	SCONJ	O	O	342
1	X	O	O	342
)	PUNCT	O	O	342
apigenin	NOUN	O	O	342
delays	VERB	O	O	342
the	PRON	O	O	342
long	ADV	O	O	342
-	PUNCT	O	O	342
term	NOUN	O	O	342
forgetting	VERB	O	O	342
but	CCONJ	O	O	342
did	VERB	O	O	342
not	PART	O	O	342
modulate	VERB	O	O	342
the	PRON	O	O	342
24	NUM	O	O	342
h	X	O	O	342
retention	NOUN	O	O	342
of	ADP	O	O	342
fear	VERB	O	O	342
memory	NOUN	O	O	342
and	CCONJ	O	O	342
2	X	O	O	342
)	PUNCT	O	O	342
the	PRON	O	O	342
obtained	VERB	O	O	342
beneficial	ADJ	O	O	342
effect	VERB	O	O	342
of	ADP	O	O	342
apigenin	NOUN	O	O	342
on	ADP	O	O	342
the	PRON	O	O	342
passive	ADJ	O	O	342
avoidance	NOUN	O	O	342
conditioning	NOUN	O	O	342
is	AUX	O	O	342
mediated	VERB	O	O	342
by	ADP	O	O	342
mechanisms	NOUN	O	O	342
that	SCONJ	O	O	342
do	VERB	O	O	342
not	PART	O	O	342
implicate	VERB	O	O	342
its	PRON	O	O	342
action	NOUN	O	O	342
on	ADP	O	O	342
the	PRON	O	O	342
muscarinic	PROPN	O	O	342
cholinergic	ADJ	O	O	342
system	NOUN	O	O	342
.	PUNCT	O	O	342
Cholecystokinin	NOUN	O	O	345
-	PUNCT	O	O	345
octapeptide	NOUN	O	O	345
restored	VERB	O	O	345
morphine	NOUN	O	Chemical	345
-	PUNCT	O	O	345
induced	VERB	O	O	345
hippocampal	NOUN	O	O	345
long	ADV	O	O	345
-	PUNCT	O	O	345
term	NOUN	O	O	345
potentiation	NOUN	O	O	345
impairment	NOUN	O	O	345
in	ADP	O	O	345
rats	NOUN	O	O	345
.	PUNCT	O	O	345
Cholecystokinin	NOUN	O	O	346
-	PUNCT	O	O	346
octapeptide	NOUN	O	O	346
(	PUNCT	O	O	346
CCK-8	PROPN	O	O	346
)	PUNCT	O	O	346
,	PUNCT	O	O	346
which	PRON	O	O	346
is	AUX	O	O	346
a	PRON	O	O	346
typical	ADJ	O	O	346
brain	NOUN	O	O	346
-	PUNCT	O	O	346
gut	VERB	O	O	346
peptide	NOUN	O	O	346
,	PUNCT	O	O	346
exerts	VERB	O	O	346
a	PRON	O	O	346
wide	ADV	O	O	346
range	VERB	O	O	346
of	ADP	O	O	346
biological	ADJ	O	O	346
activities	NOUN	O	O	346
on	ADP	O	O	346
the	PRON	O	O	346
central	ADJ	O	O	346
nervous	ADJ	O	O	346
system	NOUN	O	O	346
.	PUNCT	O	O	346
We	PRON	O	O	347
have	VERB	O	O	347
previously	ADV	O	O	347
reported	VERB	O	O	347
that	SCONJ	O	O	347
CCK-8	PROPN	O	O	347
significantly	ADV	O	O	347
alleviated	VERB	O	O	347
morphine	NOUN	O	Chemical	347
-	PUNCT	O	O	347
induced	VERB	O	O	347
amnesia	NOUN	O	Disease	347
and	CCONJ	O	O	347
reversed	VERB	O	O	347
spine	NOUN	O	O	347
density	NOUN	O	O	347
decreases	VERB	O	O	347
in	ADP	O	O	347
the	PRON	O	O	347
CA1	PROPN	O	O	347
region	NOUN	O	O	347
of	ADP	O	O	347
the	PRON	O	O	347
hippocampus	NOUN	O	O	347
in	ADP	O	O	347
morphine	NOUN	O	Chemical	347
-	PUNCT	O	O	347
treated	VERB	O	O	347
animals	NOUN	O	O	347
.	PUNCT	O	O	347
Here	ADV	O	O	348
,	PUNCT	O	O	348
we	PRON	O	O	348
investigated	VERB	O	O	348
the	PRON	O	O	348
effects	NOUN	O	O	348
of	ADP	O	O	348
CCK-8	PROPN	O	O	348
on	ADP	O	O	348
long	ADV	O	O	348
-	PUNCT	O	O	348
term	NOUN	O	O	348
potentiation	NOUN	O	O	348
(	PUNCT	O	O	348
LTP	PROPN	O	O	348
)	PUNCT	O	O	348
in	ADP	O	O	348
the	PRON	O	O	348
lateral	PROPN	O	O	348
perforant	ADJ	O	O	348
path	NOUN	O	O	348
(	PUNCT	O	O	348
LPP)-granule	NOUN	O	O	348
cell	NOUN	O	O	348
synapse	NOUN	O	O	348
of	ADP	O	O	348
rat	NOUN	O	O	348
dentate	ADJ	O	O	348
gyrus	PROPN	O	O	348
(	PUNCT	O	O	348
DG	PROPN	O	O	348
)	PUNCT	O	O	348
in	ADP	O	O	348
acute	ADJ	O	O	348
saline	NOUN	O	O	348
or	CCONJ	O	O	348
morphine	NOUN	O	Chemical	348
-	PUNCT	O	O	348
treated	VERB	O	O	348
rats	NOUN	O	O	348
.	PUNCT	O	O	348
Acute	PROPN	O	O	349
morphine	NOUN	O	Chemical	349
treatment	NOUN	O	O	350
significantly	ADV	O	O	350
attenuated	VERB	O	O	350
hippocampal	NOUN	O	O	350
LTP	PROPN	O	O	350
and	CCONJ	O	O	350
CCK-8	PROPN	O	O	350
(	PUNCT	O	O	350
1ug	VERB	O	O	350
,	PUNCT	O	O	350
i.c.v	NOUN	O	O	350
.	PUNCT	O	O	350
)	PUNCT	O	O	350
restored	VERB	O	O	350
the	PRON	O	O	350
amplitude	VERB	O	O	350
of	ADP	O	O	350
PS	PROPN	O	O	350
that	SCONJ	O	O	350
was	AUX	O	O	350
attenuated	VERB	O	O	350
by	ADP	O	O	350
morphine	NOUN	O	Chemical	350
injection	NOUN	O	O	350
.	PUNCT	O	O	350
Furthermore	ADV	O	O	351
,	PUNCT	O	O	351
microinjection	NOUN	O	O	351
of	ADP	O	O	351
CCK-8	PROPN	O	O	351
(	PUNCT	O	O	351
0.1	NUM	O	O	351
and	CCONJ	O	O	351
1ug	VERB	O	O	351
,	PUNCT	O	O	351
i.c.v	NOUN	O	O	351
.	PUNCT	O	O	351
)	PUNCT	O	O	351
also	ADV	O	O	351
significantly	ADV	O	O	351
augmented	VERB	O	O	351
hippocampal	NOUN	O	O	351
LTP	PROPN	O	O	351
in	ADP	O	O	351
saline	NOUN	O	O	351
-	PUNCT	O	O	351
treated	VERB	O	O	351
(	PUNCT	O	O	351
1ml	NOUN	O	O	351
/	PUNCT	O	O	351
kg	VERB	O	O	351
,	PUNCT	O	O	351
s.c	PROPN	O	O	351
.	PUNCT	O	O	351
)	PUNCT	O	O	351
rats	NOUN	O	O	351
.	PUNCT	O	O	351
Pre	ADJ	O	O	352
-	PUNCT	O	O	352
treatment	NOUN	O	O	352
of	ADP	O	O	352
the	PRON	O	O	352
CCK2	PROPN	O	O	352
receptor	NOUN	O	O	352
antagonist	NOUN	O	O	352
L-365,260	NOUN	O	O	352
(	PUNCT	O	O	352
10ug	NOUN	O	O	352
,	PUNCT	O	O	352
i.c.v	NOUN	O	O	352
)	PUNCT	O	O	352
reversed	VERB	O	O	352
the	PRON	O	O	352
effects	NOUN	O	O	352
of	ADP	O	O	352
CCK-8	PROPN	O	O	352
,	PUNCT	O	O	352
but	CCONJ	O	O	352
the	PRON	O	O	352
CCK1	PROPN	O	O	352
receptor	NOUN	O	O	352
antagonist	NOUN	O	O	352
L-364,718	ADV	O	O	352
(	PUNCT	O	O	352
10ug	NOUN	O	O	352
,	PUNCT	O	O	352
The	PRON	O	O	353
present	NOUN	O	O	353
results	VERB	O	O	353
demonstrate	VERB	O	O	353
that	SCONJ	O	O	353
CCK-8	PROPN	O	O	353
attenuates	VERB	O	O	353
the	PRON	O	O	353
effect	VERB	O	O	353
of	ADP	O	O	353
morphine	NOUN	O	Chemical	353
on	ADP	O	O	353
hippocampal	NOUN	O	O	353
LTP	PROPN	O	O	353
through	ADP	O	O	353
CCK2	PROPN	O	O	353
receptors	NOUN	O	O	353
and	CCONJ	O	O	353
suggest	VERB	O	O	353
an	PRON	O	O	353
ameliorative	ADJ	O	O	353
function	NOUN	O	O	353
of	ADP	O	O	353
CCK-8	PROPN	O	O	353
on	ADP	O	O	353
morphine	NOUN	O	Chemical	353
-	PUNCT	O	O	353
induced	VERB	O	O	353
memory impairment	NOUN	O	Disease	353
.	PUNCT	O	O	353
Glial	NOUN	O	O	356
activation	NOUN	O	O	356
and	CCONJ	O	O	356
post	VERB	O	O	356
-	PUNCT	O	O	356
synaptic	ADJ	O	O	356
neurotoxicity	NOUN	O	Disease	356
:	PUNCT	O	O	356
the	PRON	O	O	356
key	NOUN	O	O	356
events	NOUN	O	O	356
in	ADP	O	O	356
Streptozotocin	PROPN	O	O	356
(	PUNCT	O	O	356
ICV	PROPN	O	O	356
)	PUNCT	O	O	356
induced	VERB	O	O	356
memory impairment	NOUN	O	Disease	356
in	ADP	O	O	356
rats	NOUN	O	O	356
.	PUNCT	O	O	356
In	ADP	O	O	357
the	PRON	O	O	357
present	NOUN	O	O	357
study	VERB	O	O	357
the	PRON	O	O	357
role	NOUN	O	O	357
of	ADP	O	O	357
glial	ADJ	O	O	357
activation	NOUN	O	O	357
and	CCONJ	O	O	357
post	VERB	O	O	357
synaptic	ADJ	O	O	357
toxicity	NOUN	O	Disease	357
in	ADP	O	O	357
ICV	PROPN	O	O	357
Streptozotocin	PROPN	O	O	357
(	PUNCT	O	O	357
STZ	PROPN	O	Chemical	357
)	PUNCT	O	O	357
induced	VERB	O	O	357
memory	NOUN	O	O	357
impaired	VERB	O	O	357
rats	NOUN	O	O	357
was	AUX	O	O	357
explored	VERB	O	O	357
.	PUNCT	O	O	357
In	ADP	O	O	358
experiment	NOUN	O	O	358
set	VERB	O	O	358
up	ADP	O	O	358
1	X	O	O	358
:	PUNCT	O	O	358
Memory	NOUN	O	O	358
deficit	NOUN	O	O	358
was	AUX	O	O	358
found	VERB	O	O	358
in	ADP	O	O	358
Morris	PROPN	O	O	358
water	PROPN	O	O	358
maze	NOUN	O	O	358
test	NOUN	O	O	358
on	ADP	O	O	358
14	NUM	O	O	358
-	PUNCT	O	O	358
16	NUM	O	O	358
days	NOUN	O	O	358
after	ADP	O	O	358
STZ	PROPN	O	Chemical	358
(	PUNCT	O	O	358
ICV	PROPN	O	O	358
;	PUNCT	O	O	358
3mg	NOUN	O	O	358
/	PUNCT	O	O	358
Kg	NOUN	O	O	358
)	PUNCT	O	O	358
administration	NOUN	O	O	358
.	PUNCT	O	O	358
STZ	PROPN	O	Chemical	359
causes	VERB	O	O	359
increased	VERB	O	O	359
expression	NOUN	O	O	359
of	ADP	O	O	359
GFAP	VERB	O	O	359
,	PUNCT	O	O	359
CD11b	NOUN	O	O	359
and	CCONJ	O	O	359
TNF	PROPN	O	O	359
-	PUNCT	O	O	359
a	PRON	O	O	359
indicating	VERB	O	O	359
glial	ADJ	O	O	359
activation	NOUN	O	O	359
and	CCONJ	O	O	359
neuroinflammation	NOUN	O	O	359
.	PUNCT	O	O	359
STZ	PROPN	O	Chemical	360
also	ADV	O	O	360
significantly	ADV	O	O	360
increased	VERB	O	O	360
the	PRON	O	O	360
level	VERB	O	O	360
of	ADP	O	O	360
ROS	PROPN	O	O	360
,	PUNCT	O	O	360
nitrite	PROPN	O	Chemical	360
,	PUNCT	O	O	360
Ca(2	PROPN	O	O	360
+	ADP	O	O	360
)	PUNCT	O	O	360
and	CCONJ	O	O	360
reduced	VERB	O	O	360
the	PRON	O	O	360
mitochondrial	ADJ	O	O	360
activity	NOUN	O	O	360
in	ADP	O	O	360
synaptosomal	PROPN	O	O	360
preparation	NOUN	O	O	360
illustrating	VERB	O	O	360
free	ADJ	O	O	360
radical	ADJ	O	O	360
generation	NOUN	O	O	360
and	CCONJ	O	O	360
excitotoxicity	NOUN	O	O	360
.	PUNCT	O	O	360
Increased	VERB	O	O	361
expression	NOUN	O	O	361
and	CCONJ	O	O	361
activity	NOUN	O	O	361
of	ADP	O	O	361
Caspase-3	PROPN	O	O	361
was	AUX	O	O	361
also	ADV	O	O	361
observed	VERB	O	O	361
in	ADP	O	O	361
STZ	PROPN	O	Chemical	361
treated	VERB	O	O	361
rat	NOUN	O	O	361
which	PRON	O	O	361
specify	VERB	O	O	361
apoptotic	ADJ	O	O	361
cell	NOUN	O	O	361
death	NOUN	O	O	361
in	ADP	O	O	361
hippocampus	NOUN	O	O	361
and	CCONJ	O	O	361
cortex	VERB	O	O	361
.	PUNCT	O	O	361
STZ	PROPN	O	Chemical	362
treatment	NOUN	O	O	362
showed	VERB	O	O	362
decrease	VERB	O	O	362
expression	NOUN	O	O	362
of	ADP	O	O	362
post	VERB	O	O	362
synaptic	ADJ	O	O	362
markers	NOUN	O	O	362
CaMKIIa	PROPN	O	O	362
and	CCONJ	O	O	362
PSD-95	NUM	O	O	362
,	PUNCT	O	O	362
while	SCONJ	O	O	362
,	PUNCT	O	O	362
expression	NOUN	O	O	362
of	ADP	O	O	362
pre	VERB	O	O	362
synaptic	ADJ	O	O	362
markers	NOUN	O	O	362
(	PUNCT	O	O	362
synaptophysin	NOUN	O	O	362
and	CCONJ	O	O	362
SNAP-25	NOUN	O	O	362
)	PUNCT	O	O	362
remains	VERB	O	O	362
unaltered	ADJ	O	O	362
indicating	VERB	O	O	362
selective	ADJ	O	O	362
post	VERB	O	O	362
synaptic	ADJ	O	O	362
neurotoxicity	NOUN	O	Disease	362
.	PUNCT	O	O	362
Oral	NOUN	O	O	363
treatment	NOUN	O	O	363
with	ADP	O	O	363
Memantine	NOUN	O	O	363
(	PUNCT	O	O	363
10mg	NOUN	O	O	363
/	PUNCT	O	O	363
kg	VERB	O	O	363
)	PUNCT	O	O	363
and	CCONJ	O	O	363
Ibuprofen	NOUN	O	Chemical	363
(	PUNCT	O	O	363
50	NUM	O	O	363
mg	VERB	O	O	363
/	PUNCT	O	O	363
kg	VERB	O	O	363
)	PUNCT	O	O	363
daily	ADV	O	O	363
for	ADP	O	O	363
13	NUM	O	O	363
days	NOUN	O	O	363
attenuated	VERB	O	O	363
STZ	PROPN	O	Chemical	364
induced	VERB	O	O	364
glial	ADJ	O	O	364
activation	NOUN	O	O	364
,	PUNCT	O	O	364
apoptotic	ADJ	O	O	364
cell	NOUN	O	O	364
death	NOUN	O	O	364
and	CCONJ	O	O	364
post	VERB	O	O	364
synaptic	ADJ	O	O	364
neurotoxicity	NOUN	O	Disease	364
in	ADP	O	O	364
rat	NOUN	O	O	364
brain	NOUN	O	O	364
.	PUNCT	O	O	364
Further	ADV	O	O	365
,	PUNCT	O	O	365
in	ADP	O	O	365
experiment	NOUN	O	O	365
set	VERB	O	O	365
up	ADP	O	O	365
2	X	O	O	365
:	PUNCT	O	O	365
where	SCONJ	O	O	365
memory	NOUN	O	O	365
function	NOUN	O	O	365
was	AUX	O	O	365
not	PART	O	O	365
affected	VERB	O	O	365
i.e.	X	O	O	365
7	NUM	O	O	365
-	PUNCT	O	O	365
9	NUM	O	O	365
days	NOUN	O	O	365
after	ADP	O	O	365
STZ	PROPN	O	Chemical	365
treatment	NOUN	O	O	365
.	PUNCT	O	O	365
The	PRON	O	O	366
level	VERB	O	O	366
of	ADP	O	O	366
GFAP	VERB	O	O	366
,	PUNCT	O	O	366
CD11b	NOUN	O	O	366
,	PUNCT	O	O	366
TNF	PROPN	O	O	366
-	PUNCT	O	O	366
a	PRON	O	O	366
,	PUNCT	O	O	366
ROS	PROPN	O	O	366
and	CCONJ	O	O	366
nitrite	PROPN	O	Chemical	366
levels	NOUN	O	O	366
were	AUX	O	O	366
increased	VERB	O	O	366
.	PUNCT	O	O	366
On	ADP	O	O	367
the	PRON	O	O	367
other	ADJ	O	O	367
hand	NOUN	O	O	367
,	PUNCT	O	O	367
apoptotic	ADJ	O	O	367
marker	NOUN	O	O	367
,	PUNCT	O	O	367
synaptic	ADJ	O	O	367
markers	NOUN	O	O	367
,	PUNCT	O	O	367
mitochondrial	ADJ	O	O	367
activity	NOUN	O	O	367
and	CCONJ	O	O	367
Ca(2	PROPN	O	O	367
+	ADP	O	O	367
)	PUNCT	O	O	367
levels	NOUN	O	O	367
remained	VERB	O	O	367
unaffected	ADJ	O	O	367
.	PUNCT	O	O	367
Collective	PROPN	O	O	368
data	NOUN	O	O	368
indicates	VERB	O	O	368
that	SCONJ	O	O	368
neuroinflammatory	NOUN	O	O	368
process	NOUN	O	O	368
and	CCONJ	O	O	368
oxidative	NOUN	O	O	368
stress	NOUN	O	O	368
occurs	VERB	O	O	368
earlier	ADV	O	O	368
to	PART	O	O	368
apoptosis	NOUN	O	O	368
and	CCONJ	O	O	368
does	VERB	O	O	368
not	PART	O	O	368
affect	VERB	O	O	368
memory	NOUN	O	O	368
function	NOUN	O	O	368
.	PUNCT	O	O	368
Present	PROPN	O	O	369
study	VERB	O	O	369
clearly	ADV	O	O	369
suggests	VERB	O	O	369
that	SCONJ	O	O	369
glial	ADJ	O	O	369
activation	NOUN	O	O	369
and	CCONJ	O	O	369
post	VERB	O	O	369
synaptic	ADJ	O	O	369
neurotoxicity	NOUN	O	Disease	369
are	AUX	O	O	369
the	PRON	O	O	369
key	NOUN	O	O	369
factors	NOUN	O	O	369
in	ADP	O	O	369
STZ	PROPN	O	Chemical	369
induced	VERB	O	O	369
memory impairment	NOUN	O	Disease	369
and	CCONJ	O	O	369
neuronal	ADJ	O	O	369
cell	NOUN	O	O	369
death	NOUN	O	O	369
.	PUNCT	O	O	369
Comparison	NOUN	O	O	372
of	ADP	O	O	372
effects	NOUN	O	O	372
of	ADP	O	O	372
isotonic	ADJ	O	O	372
sodium chloride	NOUN	O	Chemical	372
with	ADP	O	O	372
diltiazem	VERB	O	Chemical	372
in	ADP	O	O	372
prevention	NOUN	O	O	372
of	ADP	O	O	372
contrast	NOUN	O	O	372
-	PUNCT	O	O	372
induced	VERB	O	O	372
nephropathy	NOUN	O	Disease	372
.	PUNCT	O	O	372
INTRODUCTION	NOUN	O	O	373
AND	CCONJ	O	O	373
OBJECTIVE	VERB	O	O	373
:	PUNCT	O	O	373
Contrast	NOUN	O	O	373
-	PUNCT	O	O	373
induced	VERB	O	O	373
nephropathy	NOUN	O	Disease	373
(	PUNCT	O	O	373
CIN	PROPN	O	Disease	373
)	PUNCT	O	O	373
significantly	ADV	O	O	373
increases	VERB	O	O	373
the	PRON	O	O	373
morbidity	NOUN	O	O	373
and	CCONJ	O	O	373
mortality	NOUN	O	O	373
of	ADP	O	O	373
patients	NOUN	O	O	373
.	PUNCT	O	O	373
The	PRON	O	O	374
aim	VERB	O	O	374
of	ADP	O	O	374
this	PRON	O	O	374
study	VERB	O	O	374
is	AUX	O	O	374
to	PART	O	O	374
investigate	VERB	O	O	374
and	CCONJ	O	O	374
compare	VERB	O	O	374
the	PRON	O	O	374
protective	ADJ	O	O	374
effects	NOUN	O	O	374
of	ADP	O	O	374
isotonic	ADJ	O	O	374
sodium chloride	NOUN	O	Chemical	374
with	ADP	O	O	374
sodium bicarbonate	NOUN	O	Chemical	374
infusion	NOUN	O	O	374
and	CCONJ	O	O	374
isotonic	ADJ	O	O	374
sodium chloride	NOUN	O	Chemical	374
infusion	NOUN	O	O	374
with	ADP	O	O	374
diltiazem	VERB	O	Chemical	374
,	PUNCT	O	O	374
a	PRON	O	O	374
calcium	NOUN	O	Chemical	374
channel	PROPN	O	O	374
blocker	NOUN	O	O	374
,	PUNCT	O	O	374
in	ADP	O	O	374
preventing	VERB	O	O	374
CIN	PROPN	O	Disease	374
.	PUNCT	O	O	374
MATERIALS	NOUN	O	O	375
AND	CCONJ	O	O	375
METHODS	NOUN	O	O	375
:	PUNCT	O	O	375
Our	PRON	O	O	375
study	VERB	O	O	375
included	VERB	O	O	375
patients	NOUN	O	O	375
who	PRON	O	O	375
were	AUX	O	O	375
administered	VERB	O	O	375
30	NUM	O	O	375
-	PUNCT	O	O	375
60	NUM	O	O	375
mL	PROPN	O	O	375
of	ADP	O	O	375
iodinated	VERB	O	O	375
contrast	NOUN	O	O	375
agent	NOUN	O	O	375
for	ADP	O	O	375
percutaneous	ADJ	O	O	375
coronary	ADJ	O	O	375
angiography	NOUN	O	O	375
(	PUNCT	O	O	375
PCAG	NOUN	O	O	375
)	PUNCT	O	O	375
,	PUNCT	O	O	375
all	PRON	O	O	375
with	ADP	O	O	375
creatinine	PROPN	O	Chemical	375
values	NOUN	O	O	375
between	ADP	O	O	375
1.1	NUM	O	O	375
and	CCONJ	O	O	375
3.1	NUM	O	O	375
mg	VERB	O	O	375
/	PUNCT	O	O	375
dL.	PROPN	O	O	375
Patients	NOUN	O	O	375
were	AUX	O	O	375
divided	VERB	O	O	375
into	ADP	O	O	375
three	NUM	O	O	375
groups	NOUN	O	O	375
and	CCONJ	O	O	375
each	PRON	O	O	375
group	NOUN	O	O	375
had	VERB	O	O	375
20	NUM	O	O	375
patients	NOUN	O	O	375
.	PUNCT	O	O	375
The	PRON	O	O	376
first	ADV	O	O	376
group	NOUN	O	O	376
of	ADP	O	O	376
patients	NOUN	O	O	376
was	AUX	O	O	376
administered	VERB	O	O	376
isotonic	ADJ	O	O	376
sodium chloride	NOUN	O	Chemical	376
;	PUNCT	O	O	376
the	PRON	O	O	376
second	ADV	O	O	376
group	NOUN	O	O	376
was	AUX	O	O	376
administered	VERB	O	O	376
a	PRON	O	O	376
solution	NOUN	O	O	376
that	SCONJ	O	O	376
of	ADP	O	O	376
5%	NOUN	O	O	376
dextrose	ADJ	O	Chemical	376
and	CCONJ	O	O	376
sodium bicarbonate	NOUN	O	Chemical	376
,	PUNCT	O	O	376
while	SCONJ	O	O	376
the	PRON	O	O	376
third	ADV	O	O	376
group	NOUN	O	O	376
was	AUX	O	O	376
administered	VERB	O	O	376
isotonic	ADJ	O	O	376
sodium chloride	NOUN	O	Chemical	376
before	ADP	O	O	376
and	CCONJ	O	O	376
after	ADP	O	O	376
the	PRON	O	O	376
contrast	NOUN	O	O	376
injection	NOUN	O	O	376
.	PUNCT	O	O	376
The	PRON	O	O	377
third	ADV	O	O	377
group	NOUN	O	O	377
received	VERB	O	O	377
an	PRON	O	O	377
additional	ADJ	O	O	377
injection	NOUN	O	O	377
of	ADP	O	O	377
diltiazem	VERB	O	Chemical	377
the	PRON	O	O	377
day	NOUN	O	O	377
before	ADP	O	O	377
and	CCONJ	O	O	377
first	ADV	O	O	377
2	X	O	O	377
days	NOUN	O	O	377
after	ADP	O	O	377
the	PRON	O	O	377
contrast	NOUN	O	O	377
injection	NOUN	O	O	377
.	PUNCT	O	O	377
All	PRON	O	O	378
of	ADP	O	O	378
the	PRON	O	O	378
patients	NOUN	O	O	378
'	PUNCT	O	O	378
plasma	NOUN	O	O	378
blood	NOUN	O	O	378
urea nitrogen	NOUN	O	Chemical	378
(	PUNCT	O	O	378
BUN	PROPN	O	Chemical	378
)	PUNCT	O	O	378
and	CCONJ	O	O	378
creatinine	PROPN	O	Chemical	378
levels	NOUN	O	O	378
were	AUX	O	O	378
measured	VERB	O	O	378
on	ADP	O	O	378
the	PRON	O	O	378
second	ADV	O	O	378
and	CCONJ	O	O	378
seventh	ADJ	O	O	378
day	NOUN	O	O	378
after	ADP	O	O	378
the	PRON	O	O	378
administration	NOUN	O	O	378
of	ADP	O	O	378
intravenous	ADJ	O	O	378
contrast	NOUN	O	O	378
material	ADJ	O	O	378
.	PUNCT	O	O	378
The	PRON	O	O	379
basal	PROPN	O	O	379
creatinine	PROPN	O	Chemical	379
levels	NOUN	O	O	379
were	AUX	O	O	379
similar	ADJ	O	O	379
for	ADP	O	O	379
all	PRON	O	O	379
three	NUM	O	O	379
groups	NOUN	O	O	379
(	PUNCT	O	O	379
p	NOUN	O	O	379
>	PUNCT	O	O	379
0.05	NUM	O	O	379
)	PUNCT	O	O	379
.	PUNCT	O	O	379
Among	ADP	O	O	380
a	PRON	O	O	380
total	ADJ	O	O	380
of	ADP	O	O	380
60	NUM	O	O	380
patients	NOUN	O	O	380
included	VERB	O	O	380
in	ADP	O	O	380
the	PRON	O	O	380
study	VERB	O	O	380
,	PUNCT	O	O	380
16	NUM	O	O	380
patients	NOUN	O	O	380
developed	VERB	O	O	380
acute	ADJ	O	O	380
renal failure	NOUN	O	Disease	380
(	PUNCT	O	O	380
ARF	PROPN	O	Disease	380
)	PUNCT	O	O	380
on	ADP	O	O	380
the	PRON	O	O	380
second	ADV	O	O	380
day	NOUN	O	O	380
after	ADP	O	O	380
contrast	NOUN	O	O	380
material	ADJ	O	O	380
was	AUX	O	O	380
injected	VERB	O	O	380
(	PUNCT	O	O	380
26.6%	NOUN	O	O	380
)	PUNCT	O	O	380
.	PUNCT	O	O	380
The	PRON	O	O	381
number	NOUN	O	O	381
of	ADP	O	O	381
patients	NOUN	O	O	381
who	PRON	O	O	381
developed	VERB	O	O	381
ARF	PROPN	O	Disease	381
on	ADP	O	O	381
the	PRON	O	O	381
second	ADV	O	O	381
day	NOUN	O	O	381
after	ADP	O	O	381
the	PRON	O	O	381
injection	NOUN	O	O	381
in	ADP	O	O	381
the	PRON	O	O	381
first	ADV	O	O	381
group	NOUN	O	O	381
was	AUX	O	O	381
five	NUM	O	O	381
(	PUNCT	O	O	381
25%	NOUN	O	O	381
)	PUNCT	O	O	381
,	PUNCT	O	O	381
in	ADP	O	O	381
the	PRON	O	O	381
second	ADV	O	O	381
group	NOUN	O	O	381
was	AUX	O	O	381
six	NUM	O	O	381
(	PUNCT	O	O	381
30%	NOUN	O	O	381
)	PUNCT	O	O	381
and	CCONJ	O	O	381
the	PRON	O	O	381
third	ADV	O	O	381
group	NOUN	O	O	381
was	AUX	O	O	381
five	NUM	O	O	381
(	PUNCT	O	O	381
25%	NOUN	O	O	381
)	PUNCT	O	O	381
(	PUNCT	O	O	381
p	NOUN	O	O	381
>	PUNCT	O	O	381
0.05	NUM	O	O	381
)	PUNCT	O	O	381
.	PUNCT	O	O	381
CONCLUSION	PROPN	O	O	382
:	PUNCT	O	O	382
There	ADV	O	O	382
was	AUX	O	O	382
no	PRON	O	O	382
significant	ADJ	O	O	382
difference	NOUN	O	O	382
between	ADP	O	O	382
isotonic	ADJ	O	O	382
sodium chloride	NOUN	O	Chemical	382
,	PUNCT	O	O	382
sodium bicarbonate	NOUN	O	Chemical	382
and	CCONJ	O	O	382
isotonic	ADJ	O	O	382
sodium chloride	NOUN	O	Chemical	382
with	ADP	O	O	382
diltiazem	VERB	O	Chemical	382
application	NOUN	O	O	382
in	ADP	O	O	382
prevention	NOUN	O	O	382
of	ADP	O	O	382
CIN	PROPN	O	Disease	382
.	PUNCT	O	O	382
Neurocognitive	PROPN	O	O	385
and	CCONJ	O	O	385
neuroradiologic	PROPN	O	O	385
central	ADJ	O	O	385
nervous	ADJ	O	O	385
system	NOUN	O	O	385
late	ADV	O	O	385
effects	NOUN	O	O	385
in	ADP	O	O	385
children	NOUN	O	O	385
treated	VERB	O	O	385
on	ADP	O	O	385
Pediatric	ADJ	O	O	385
Oncology	NOUN	O	O	385
Group	PROPN	O	O	385
(	PUNCT	O	O	385
POG	PROPN	O	O	385
)	PUNCT	O	O	385
P9605	NOUN	O	O	385
(	PUNCT	O	O	385
standard	PROPN	O	O	385
risk	NOUN	O	O	385
)	PUNCT	O	O	385
and	CCONJ	O	O	385
P9201	VERB	O	O	385
(	PUNCT	O	O	385
lesser	ADJ	O	O	385
risk	NOUN	O	O	385
)	PUNCT	O	O	385
acute	ADJ	O	O	385
lymphoblastic	NOUN	O	O	385
leukemia	NOUN	O	Disease	385
protocols	NOUN	O	O	385
(	PUNCT	O	O	385
ACCL0131	VERB	O	O	385
)	PUNCT	O	O	385
:	PUNCT	O	O	385
a	PRON	O	O	385
methotrexate	CCONJ	O	Chemical	385
consequence	NOUN	O	O	385
?	PUNCT	O	O	385
Concerns	NOUN	O	O	386
about	ADP	O	O	386
long	ADV	O	O	386
-	PUNCT	O	O	386
term	NOUN	O	O	386
methotrexate	CCONJ	O	Chemical	386
(	PUNCT	O	O	386
MTX	PROPN	O	O	386
)	PUNCT	O	O	386
neurotoxicity	NOUN	O	Disease	387
in	ADP	O	O	387
the	PRON	O	O	387
1990s	NUM	O	O	387
led	VERB	O	O	387
to	PART	O	O	387
modifications	NOUN	O	O	387
in	ADP	O	O	387
intrathecal	ADJ	O	O	387
(	PUNCT	O	O	387
IT	PRON	O	O	387
)	PUNCT	O	O	387
therapy	NOUN	O	O	387
,	PUNCT	O	O	387
leucovorin	NOUN	O	O	387
rescue	NOUN	O	O	387
,	PUNCT	O	O	387
and	CCONJ	O	O	387
frequency	NOUN	O	O	387
of	ADP	O	O	387
systemic	ADJ	O	O	387
MTX	PROPN	O	O	387
administration	NOUN	O	O	387
in	ADP	O	O	387
children	NOUN	O	O	387
with	ADP	O	O	387
acute	ADJ	O	O	387
lymphoblastic	NOUN	O	O	387
leukemia	NOUN	O	Disease	387
.	PUNCT	O	O	387
In	ADP	O	O	388
this	PRON	O	O	388
study	VERB	O	O	388
,	PUNCT	O	O	388
neurocognitive	PROPN	O	O	388
outcomes	NOUN	O	O	388
and	CCONJ	O	O	388
neuroradiologic	PROPN	O	O	388
evidence	NOUN	O	O	388
of	ADP	O	O	388
leukoencephalopathy	ADJ	O	Disease	388
were	AUX	O	O	388
compared	VERB	O	O	388
in	ADP	O	O	388
children	NOUN	O	O	388
treated	VERB	O	O	388
with	ADP	O	O	388
intense	ADJ	O	O	388
central	ADJ	O	O	388
nervous	ADJ	O	O	388
system	NOUN	O	O	388
(	PUNCT	O	O	388
CNS)-directed	VERB	O	O	388
therapy	NOUN	O	O	388
(	PUNCT	O	O	388
P9605	NOUN	O	O	388
)	PUNCT	O	O	388
versus	ADP	O	O	388
those	PRON	O	O	388
receiving	VERB	O	O	388
fewer	ADJ	O	O	388
CNS	PROPN	O	O	388
-	PUNCT	O	O	388
directed	VERB	O	O	388
treatment	NOUN	O	O	388
days	NOUN	O	O	388
during	ADP	O	O	388
intensive	ADJ	O	O	388
consolidation	NOUN	O	O	388
(	PUNCT	O	O	388
P9201	VERB	O	O	388
)	PUNCT	O	O	388
.	PUNCT	O	O	388
A	PRON	O	O	389
total	ADJ	O	O	389
of	ADP	O	O	389
66	NUM	O	O	389
children	NOUN	O	O	389
from	ADP	O	O	389
16	NUM	O	O	389
Pediatric	ADJ	O	O	389
Oncology	NOUN	O	O	389
Group	PROPN	O	O	389
institutions	NOUN	O	O	389
with	ADP	O	O	389
""""	PUNCT	O	O	389
standard	PROPN	O	O	389
-	PUNCT	O	O	389
risk	NOUN	O	O	389
""""	PUNCT	O	O	389
acute	ADJ	O	O	389
lymphoblastic	NOUN	O	O	389
leukemia	NOUN	O	Disease	389
,	PUNCT	O	O	389
1.00	NUM	O	O	389
to	PART	O	O	389
9.99	NUM	O	O	389
years	NOUN	O	O	389
at	ADP	O	O	389
diagnosis	NOUN	O	O	389
,	PUNCT	O	O	389
without	ADP	O	O	389
evidence	NOUN	O	O	389
of	ADP	O	O	389
CNS	PROPN	O	O	389
leukemia	NOUN	O	Disease	389
at	ADP	O	O	389
diagnosis	NOUN	O	O	389
were	AUX	O	O	389
enrolled	VERB	O	O	389
on	ADP	O	O	389
ACCL0131	VERB	O	O	389
:	PUNCT	O	O	389
28	NUM	O	O	389
from	ADP	O	O	389
P9201	VERB	O	O	389
and	CCONJ	O	O	389
38	NUM	O	O	389
from	ADP	O	O	389
P9605	NOUN	O	O	389
.	PUNCT	O	O	389
Significantly	ADV	O	O	390
more	ADJ	O	O	390
P9605	NOUN	O	O	390
patients	NOUN	O	O	390
developed	VERB	O	O	390
leukoencephalopathy	ADJ	O	Disease	390
compared	VERB	O	O	390
with	ADP	O	O	390
P9201	VERB	O	O	390
patients	NOUN	O	O	390
(	PUNCT	O	O	390
68%	NOUN	O	O	390
,	PUNCT	O	O	390
95%	NOUN	O	O	390
confidence	NOUN	O	O	390
interval	NOUN	O	O	390
49%-83%	NOUN	O	O	390
vs.	CCONJ	O	O	390
22%	NOUN	O	O	390
,	PUNCT	O	O	390
95%	NOUN	O	O	390
confidence	NOUN	O	O	390
interval	NOUN	O	O	390
5%-44%	NOUN	O	O	390
;	PUNCT	O	O	390
P=0.001	NUM	O	O	390
)	PUNCT	O	O	390
identified	VERB	O	O	390
as	ADP	O	O	390
late	ADV	O	O	390
as	ADP	O	O	390
7.7	NUM	O	O	390
years	NOUN	O	O	390
after	ADP	O	O	390
the	PRON	O	O	390
end	VERB	O	O	390
of	ADP	O	O	390
treatment	NOUN	O	O	390
.	PUNCT	O	O	390
Children	NOUN	O	O	391
on	ADP	O	O	391
both	PRON	O	O	391
studies	NOUN	O	O	391
had	VERB	O	O	391
significant	ADJ	O	O	391
attention	NOUN	O	O	391
problems	NOUN	O	O	391
,	PUNCT	O	O	391
but	CCONJ	O	O	391
P9605	NOUN	O	O	391
children	NOUN	O	O	391
scored	VERB	O	O	391
below	ADP	O	O	391
average	ADJ	O	O	391
on	ADP	O	O	391
more	ADJ	O	O	391
neurocognitive	PROPN	O	O	391
measures	NOUN	O	O	391
than	ADP	O	O	391
those	PRON	O	O	391
treated	VERB	O	O	391
on	ADP	O	O	391
P9201	VERB	O	O	391
(	PUNCT	O	O	391
82%	NOUN	O	O	391
,	PUNCT	O	O	391
14/17	NUM	O	O	391
measures	NOUN	O	O	391
vs.	CCONJ	O	O	391
24%	NOUN	O	O	391
,	PUNCT	O	O	391
4/17	NUM	O	O	391
measures	NOUN	O	O	391
)	PUNCT	O	O	391
.	PUNCT	O	O	391
This	PRON	O	O	392
supports	VERB	O	O	392
ongoing	ADJ	O	O	392
concerns	NOUN	O	O	392
about	ADP	O	O	392
intensive	ADJ	O	O	392
MTX	PROPN	O	O	392
exposure	NOUN	O	O	392
as	ADP	O	O	392
a	PRON	O	O	392
major	ADJ	O	O	392
contributor	NOUN	O	O	392
to	PART	O	O	392
CNS	PROPN	O	O	392
late	ADV	O	O	392
effects	NOUN	O	O	392
.	PUNCT	O	O	392
Tranexamic	NOUN	O	O	395
acid	PROPN	O	O	395
overdosage	NOUN	O	O	395
-	PUNCT	O	O	395
induced	VERB	O	O	395
generalized	VERB	O	O	395
seizure	NOUN	O	Disease	395
in	ADP	O	O	395
renal failure	NOUN	O	Disease	395
.	PUNCT	O	O	395
We	PRON	O	O	396
report	VERB	O	O	396
a	PRON	O	O	396
45-year	NOUN	O	O	396
-	PUNCT	O	O	396
old	ADJ	O	O	396
lady	PROPN	O	O	396
with	ADP	O	O	396
chronic	ADJ	O	O	396
kidney	NOUN	O	O	396
disease	PROPN	O	O	396
stage	NOUN	O	O	396
4	NUM	O	O	396
due	ADJ	O	O	396
to	PART	O	O	396
chronic	ADJ	O	O	396
tubulointerstial	ADJ	O	O	396
disease	PROPN	O	O	396
.	PUNCT	O	O	396
She	PRON	O	O	397
was	AUX	O	O	397
admitted	VERB	O	O	397
to	PART	O	O	397
our	PRON	O	O	397
center	PROPN	O	O	397
for	ADP	O	O	397
severe	ADJ	O	O	397
anemia	NOUN	O	Disease	397
due	ADJ	O	O	397
to	PART	O	O	397
menorrhagia	NOUN	O	Disease	397
and	CCONJ	O	O	397
deterioration	NOUN	O	O	397
of	ADP	O	O	397
renal	ADJ	O	O	397
function	NOUN	O	O	397
.	PUNCT	O	O	397
Tranexamic	NOUN	O	O	398
acid	PROPN	O	O	398
(	PUNCT	O	O	398
TNA	PROPN	O	O	398
)	PUNCT	O	O	398
1	X	O	O	399
g	X	O	O	399
8-hourly	NOUN	O	O	399
was	AUX	O	O	399
administered	VERB	O	O	399
to	PART	O	O	399
her	PRON	O	O	399
to	PART	O	O	399
control	VERB	O	O	399
bleeding	VERB	O	Disease	399
per	ADP	O	O	399
vaginum	PROPN	O	O	399
.	PUNCT	O	O	399
Two	NUM	O	O	400
hours	NOUN	O	O	400
after	ADP	O	O	400
the	PRON	O	O	400
sixth	ADV	O	O	400
dose	NOUN	O	O	400
of	ADP	O	O	400
TNA	PROPN	O	O	400
,	PUNCT	O	O	400
she	PRON	O	O	400
had	VERB	O	O	400
an	PRON	O	O	400
episode	PROPN	O	O	400
of	ADP	O	O	400
generalized	VERB	O	O	400
tonic	PROPN	O	O	400
clonic	ADJ	O	O	400
convulsions	NOUN	O	Disease	400
.	PUNCT	O	O	400
TNA	PROPN	O	O	401
was	AUX	O	O	401
discontinued	VERB	O	O	401
.	PUNCT	O	O	401
Investigations	NOUN	O	O	402
of	ADP	O	O	402
the	PRON	O	O	402
patient	NOUN	O	O	402
revealed	VERB	O	O	402
no	PRON	O	O	402
biochemical	ADJ	O	O	402
or	CCONJ	O	O	402
structural	ADJ	O	O	402
central	ADJ	O	O	402
nervous	ADJ	O	O	402
system	NOUN	O	O	402
abnormalities	NOUN	O	O	402
that	SCONJ	O	O	402
could	AUX	O	O	402
have	VERB	O	O	402
provoked	VERB	O	O	402
the	PRON	O	O	402
convulsions	NOUN	O	Disease	402
.	PUNCT	O	O	402
She	PRON	O	O	403
had	VERB	O	O	403
no	PRON	O	O	403
further	ADV	O	O	403
episodes	NOUN	O	O	403
of	ADP	O	O	403
convulsion	NOUN	O	Disease	403
till	SCONJ	O	O	403
dis	VERB	O	O	403
-	PUNCT	O	O	403
charge	NOUN	O	O	403
and	CCONJ	O	O	403
during	ADP	O	O	403
the	PRON	O	O	403
two	NUM	O	O	403
months	NOUN	O	O	403
of	ADP	O	O	403
follow	VERB	O	O	403
-	PUNCT	O	O	403
up	ADP	O	O	403
.	PUNCT	O	O	403
Thus	ADV	O	O	404
,	PUNCT	O	O	404
the	PRON	O	O	404
precipitating	VERB	O	O	404
cause	VERB	O	O	404
of	ADP	O	O	404
convulsions	NOUN	O	Disease	404
was	AUX	O	O	404
believed	VERB	O	O	404
to	PART	O	O	404
be	AUX	O	O	404
an	PRON	O	O	404
overdose	NOUN	O	Disease	404
of	ADP	O	O	404
TNA	PROPN	O	O	404
.	PUNCT	O	O	404
Pre	ADJ	O	O	407
-	PUNCT	O	O	407
treatment	NOUN	O	O	407
of	ADP	O	O	407
bupivacaine	NOUN	O	Chemical	407
-	PUNCT	O	O	407
induced	VERB	O	O	407
cardiovascular depression	NOUN	O	Disease	407
using	VERB	O	O	407
different	ADJ	O	O	407
lipid	NOUN	O	O	407
formulations	NOUN	O	O	407
of	ADP	O	O	407
propofol	VERB	O	Chemical	407
.	PUNCT	O	O	407
Pre	ADJ	O	O	408
-	PUNCT	O	O	408
treatment	NOUN	O	O	408
with	ADP	O	O	408
lipid	NOUN	O	O	408
emulsions	NOUN	O	O	408
has	VERB	O	O	408
been	AUX	O	O	408
shown	VERB	O	O	408
to	PART	O	O	408
increase	VERB	O	O	408
lethal	ADJ	O	O	408
doses	NOUN	O	O	408
of	ADP	O	O	408
bupivacaine	NOUN	O	Chemical	408
,	PUNCT	O	O	408
and	CCONJ	O	O	408
the	PRON	O	O	408
lipid	NOUN	O	O	408
content	NOUN	O	O	408
of	ADP	O	O	408
propofol	VERB	O	Chemical	408
may	AUX	O	O	408
alleviate	VERB	O	O	408
bupivacaine	NOUN	O	Chemical	408
-	PUNCT	O	O	408
induced	VERB	O	O	408
cardiotoxicity	NOUN	O	Disease	408
.	PUNCT	O	O	408
The	PRON	O	O	409
aim	VERB	O	O	409
of	ADP	O	O	409
this	PRON	O	O	409
study	VERB	O	O	409
is	AUX	O	O	409
to	PART	O	O	409
investigate	VERB	O	O	409
the	PRON	O	O	409
effects	NOUN	O	O	409
of	ADP	O	O	409
propofol	VERB	O	Chemical	409
in	ADP	O	O	409
intralipid	NOUN	O	O	409
or	CCONJ	O	O	409
medialipid	PROPN	O	O	409
emulsions	NOUN	O	O	409
on	ADP	O	O	409
bupivacaine	NOUN	O	Chemical	409
-	PUNCT	O	O	409
induced	VERB	O	O	409
cardiotoxicity	NOUN	O	Disease	409
.	PUNCT	O	O	409
Rats	NOUN	O	O	410
were	AUX	O	O	410
anaesthetised	VERB	O	O	410
with	ADP	O	O	410
ketamine	VERB	O	Chemical	410
and	CCONJ	O	O	410
were	AUX	O	O	410
given	VERB	O	O	410
0.5	NUM	O	O	410
mg	VERB	O	O	410
/	PUNCT	O	O	410
kg	VERB	O	O	410
/	PUNCT	O	O	410
min	NOUN	O	O	410
propofol	VERB	O	Chemical	410
in	ADP	O	O	410
intralipid	NOUN	O	O	410
(	PUNCT	O	O	410
Group	PROPN	O	O	410
P	NOUN	O	Chemical	410
)	PUNCT	O	O	410
,	PUNCT	O	O	410
propofol	VERB	O	Chemical	410
in	ADP	O	O	410
medialipid	PROPN	O	O	410
(	PUNCT	O	O	410
Group	PROPN	O	O	410
L	NOUN	O	O	410
)	PUNCT	O	O	410
,	PUNCT	O	O	410
or	CCONJ	O	O	410
saline	NOUN	O	O	410
(	PUNCT	O	O	410
Group	PROPN	O	O	410
C	NOUN	O	O	410
)	PUNCT	O	O	410
over	ADP	O	O	410
20	NUM	O	O	410
min	NOUN	O	O	410
.	PUNCT	O	O	410
bupivacaine	NOUN	O	Chemical	411
0.5%	NOUN	O	O	411
was	AUX	O	O	411
infused	VERB	O	O	411
.	PUNCT	O	O	411
We	PRON	O	O	412
recorded	VERB	O	O	412
time	NOUN	O	O	412
to	PART	O	O	412
first	ADV	O	O	412
dysrhythmia	NOUN	O	O	412
occurrence	NOUN	O	O	412
,	PUNCT	O	O	412
respective	ADJ	O	O	412
times	NOUN	O	O	412
to	PART	O	O	412
25%	NOUN	O	O	412
and	CCONJ	O	O	412
50%	NOUN	O	O	412
reduction	NOUN	O	O	412
of	ADP	O	O	412
the	PRON	O	O	412
heart	NOUN	O	O	412
rate	NOUN	O	O	412
(	PUNCT	O	O	412
HR	NOUN	O	O	412
)	PUNCT	O	O	412
and	CCONJ	O	O	412
mean	VERB	O	O	412
arterial	ADJ	O	O	412
pressure	NOUN	O	O	412
,	PUNCT	O	O	412
and	CCONJ	O	O	412
time	NOUN	O	O	412
to	PART	O	O	412
asystole	NOUN	O	Disease	412
and	CCONJ	O	O	412
total	ADJ	O	O	412
amount	NOUN	O	O	412
of	ADP	O	O	412
bupivacaine	NOUN	O	Chemical	412
consumption	NOUN	O	O	412
.	PUNCT	O	O	412
Blood	NOUN	O	O	413
and	CCONJ	O	O	413
tissue	NOUN	O	O	413
samples	NOUN	O	O	413
were	AUX	O	O	413
collected	VERB	O	O	413
following	VERB	O	O	413
asystole	NOUN	O	Disease	413
.	PUNCT	O	O	413
The	PRON	O	O	414
time	NOUN	O	O	414
to	PART	O	O	414
first	ADV	O	O	414
dysrhythmia	NOUN	O	O	414
occurrence	NOUN	O	O	414
,	PUNCT	O	O	414
time	NOUN	O	O	414
to	PART	O	O	414
25%	NOUN	O	O	414
and	CCONJ	O	O	414
50%	NOUN	O	O	414
reductions	NOUN	O	O	414
in	ADP	O	O	414
HR	NOUN	O	O	414
,	PUNCT	O	O	414
and	CCONJ	O	O	414
time	NOUN	O	O	414
to	PART	O	O	414
asystole	NOUN	O	Disease	414
were	AUX	O	O	414
longer	ADV	O	O	414
in	ADP	O	O	414
Group	PROPN	O	O	414
P	NOUN	O	Chemical	414
than	ADP	O	O	414
the	PRON	O	O	414
other	ADJ	O	O	414
groups	NOUN	O	O	414
.	PUNCT	O	O	414
The	PRON	O	O	415
cumulative	ADJ	O	O	415
bupivacaine	NOUN	O	Chemical	415
dose	NOUN	O	O	415
given	VERB	O	O	415
at	ADP	O	O	415
those	PRON	O	O	415
time	NOUN	O	O	415
points	VERB	O	O	415
was	AUX	O	O	415
higher	ADJ	O	O	415
in	ADP	O	O	415
Group	PROPN	O	O	415
P.	PROPN	O	O	415
Plasma	NOUN	O	O	415
bupivacaine	NOUN	O	Chemical	415
levels	NOUN	O	O	415
were	AUX	O	O	415
significantly	ADV	O	O	415
lower	ADJ	O	O	415
in	ADP	O	O	415
Group	PROPN	O	O	415
P	NOUN	O	Chemical	415
than	ADP	O	O	415
in	ADP	O	O	415
Group	PROPN	O	O	415
C.	PROPN	O	O	415
Bupivacaine	NOUN	O	Chemical	415
levels	NOUN	O	O	415
in	ADP	O	O	415
the	PRON	O	O	415
brain	NOUN	O	O	415
and	CCONJ	O	O	415
heart	NOUN	O	O	415
were	AUX	O	O	415
significantly	ADV	O	O	415
lower	ADJ	O	O	415
in	ADP	O	O	415
Group	PROPN	O	O	415
P	NOUN	O	Chemical	415
and	CCONJ	O	O	415
Group	PROPN	O	O	415
L	NOUN	O	O	415
than	ADP	O	O	415
in	ADP	O	O	415
Group	PROPN	O	O	415
C.	PROPN	O	O	415
CONCLUSION	PROPN	O	O	415
:	PUNCT	O	O	415
We	PRON	O	O	415
conclude	VERB	O	O	415
that	SCONJ	O	O	415
pre	VERB	O	O	415
-	PUNCT	O	O	415
treatment	NOUN	O	O	415
with	ADP	O	O	415
propofol	VERB	O	Chemical	415
in	ADP	O	O	415
intralipid	NOUN	O	O	415
,	PUNCT	O	O	415
compared	VERB	O	O	415
with	ADP	O	O	415
propofol	VERB	O	Chemical	415
in	ADP	O	O	415
medialipid	PROPN	O	O	415
or	CCONJ	O	O	415
saline	NOUN	O	O	415
,	PUNCT	O	O	415
delayed	VERB	O	O	415
the	PRON	O	O	415
onset	VERB	O	O	415
of	ADP	O	O	415
bupivacaine	NOUN	O	Chemical	415
-	PUNCT	O	O	415
induced	VERB	O	O	415
cardiotoxic	ADJ	O	Disease	415
effects	NOUN	O	O	415
as	ADP	O	O	415
well	ADV	O	O	415
as	ADP	O	O	415
reduced	VERB	O	O	415
plasma	NOUN	O	O	415
bupivacaine	NOUN	O	Chemical	415
levels	NOUN	O	O	415
.	PUNCT	O	O	415
Further	ADV	O	O	416
studies	NOUN	O	O	416
are	AUX	O	O	416
needed	VERB	O	O	416
to	PART	O	O	416
explore	VERB	O	O	416
tissue	NOUN	O	O	416
bupivacaine	NOUN	O	Chemical	416
levels	NOUN	O	O	416
of	ADP	O	O	416
propofol	VERB	O	Chemical	416
in	ADP	O	O	416
medialipid	PROPN	O	O	416
and	CCONJ	O	O	416
adapt	VERB	O	O	416
these	PRON	O	O	416
results	VERB	O	O	416
to	PART	O	O	416
clinical	ADJ	O	O	416
practice	VERB	O	O	416
.	PUNCT	O	O	416
Drug	NOUN	O	O	419
-	PUNCT	O	O	419
Induced	VERB	O	O	419
Acute	PROPN	O	O	419
Liver	NOUN	O	O	419
Injury	NOUN	O	O	419
Within	ADP	O	O	420
12	NUM	O	O	420
Hours	NOUN	O	O	420
After	ADP	O	O	420
Fluvastatin	PROPN	O	O	420
Therapy	NOUN	O	O	420
.	PUNCT	O	O	420
Although	SCONJ	O	O	421
statins	NOUN	O	O	421
are	AUX	O	O	421
generally	ADV	O	O	421
well	ADV	O	O	421
-	PUNCT	O	O	421
tolerated	VERB	O	O	421
drugs	NOUN	O	O	421
,	PUNCT	O	O	421
recent	ADJ	O	O	421
cases	NOUN	O	O	421
of	ADP	O	O	421
drug	NOUN	O	O	421
-	PUNCT	O	O	421
induced	VERB	O	O	421
liver injury	NOUN	O	Disease	421
associated	VERB	O	O	421
with	ADP	O	O	421
their	PRON	O	O	421
use	VERB	O	O	421
have	VERB	O	O	421
been	AUX	O	O	421
reported	VERB	O	O	421
.	PUNCT	O	O	421
A	PRON	O	O	422
52-year	NOUN	O	O	422
-	PUNCT	O	O	422
old	ADJ	O	O	422
Chinese	PROPN	O	O	422
man	NOUN	O	O	422
reported	VERB	O	O	422
with	ADP	O	O	422
liver damage	NOUN	O	Disease	422
,	PUNCT	O	O	422
which	PRON	O	O	422
appeared	VERB	O	O	422
12	NUM	O	O	422
hours	NOUN	O	O	422
after	ADP	O	O	422
beginning	VERB	O	O	422
treatment	NOUN	O	O	422
with	ADP	O	O	422
fluvastatin	NOUN	O	O	422
.	PUNCT	O	O	422
Patient	NOUN	O	O	423
presented	VERB	O	O	423
with	ADP	O	O	423
complaints	NOUN	O	O	423
of	ADP	O	O	423
increasing	VERB	O	O	423
nausea	NOUN	O	Disease	423
,	PUNCT	O	O	423
anorexia	X	O	Disease	423
,	PUNCT	O	O	423
and	CCONJ	O	O	423
upper	ADJ	O	O	423
abdominal pain	NOUN	O	Disease	423
.	PUNCT	O	O	423
His	PRON	O	O	424
laboratory	NOUN	O	O	424
values	NOUN	O	O	424
showed	VERB	O	O	424
elevated	ADJ	O	O	424
creatine	PROPN	O	Chemical	424
kinase	VERB	O	O	424
and	CCONJ	O	O	424
transaminases	NOUN	O	O	424
.	PUNCT	O	O	424
The	PRON	O	O	425
liver	NOUN	O	O	425
biochemistries	NOUN	O	O	425
eventually	ADV	O	O	425
normalized	VERB	O	O	425
within	ADP	O	O	425
3	X	O	O	425
weeks	NOUN	O	O	425
of	ADP	O	O	425
stopping	VERB	O	O	425
the	PRON	O	O	425
fluvastatin	NOUN	O	O	425
.	PUNCT	O	O	425
Therefore	ADV	O	O	426
,	PUNCT	O	O	426
when	SCONJ	O	O	426
prescribing	VERB	O	O	426
statins	NOUN	O	O	426
,	PUNCT	O	O	426
the	PRON	O	O	426
possibility	NOUN	O	O	426
of	ADP	O	O	426
hepatic damage	NOUN	O	Disease	426
should	AUX	O	O	426
be	AUX	O	O	426
taken	VERB	O	O	426
into	ADP	O	O	426
account	VERB	O	O	426
.	PUNCT	O	O	426
Fluconazole	PROPN	O	Chemical	429
associated	VERB	O	O	429
agranulocytosis	ADJ	O	O	429
and	CCONJ	O	O	429
thrombocytopenia	PROPN	O	Disease	429
.	PUNCT	O	O	429
CASE	NOUN	O	O	430
:	PUNCT	O	O	430
We	PRON	O	O	430
describe	VERB	O	O	430
a	PRON	O	O	430
second	ADV	O	O	430
case	NOUN	O	O	430
of	ADP	O	O	430
fluconazole	CCONJ	O	Chemical	430
associated	VERB	O	O	430
agranulocytosis	ADJ	O	O	430
with	ADP	O	O	430
thrombocytopenia	PROPN	O	Disease	430
and	CCONJ	O	O	430
recovery	NOUN	O	O	430
upon	SCONJ	O	O	430
discontinuation	NOUN	O	O	430
of	ADP	O	O	430
therapy	NOUN	O	O	430
.	PUNCT	O	O	430
The	PRON	O	O	431
patient	NOUN	O	O	431
began	VERB	O	O	431
to	PART	O	O	431
have	VERB	O	O	431
changes	VERB	O	O	431
in	ADP	O	O	431
white	ADJ	O	O	431
blood	NOUN	O	O	431
cells	NOUN	O	O	431
and	CCONJ	O	O	431
platelets	VERB	O	O	431
within	ADP	O	O	431
48	NUM	O	O	431
h	X	O	O	431
of	ADP	O	O	431
administration	NOUN	O	O	431
of	ADP	O	O	431
fluconazole	CCONJ	O	Chemical	431
and	CCONJ	O	O	431
began	VERB	O	O	431
to	PART	O	O	431
recover	VERB	O	O	431
with	ADP	O	O	431
48	NUM	O	O	431
h	X	O	O	431
of	ADP	O	O	431
discontinuation	NOUN	O	O	431
.	PUNCT	O	O	431
This	PRON	O	O	432
case	NOUN	O	O	432
highlights	VERB	O	O	432
that	SCONJ	O	O	432
drug	NOUN	O	O	432
-	PUNCT	O	O	432
induced	VERB	O	O	432
blood	NOUN	O	O	432
dyscrasias	PROPN	O	O	432
can	AUX	O	O	432
occur	VERB	O	O	432
unexpectedly	ADV	O	O	432
as	ADP	O	O	432
a	PRON	O	O	432
result	VERB	O	O	432
of	ADP	O	O	432
treatment	NOUN	O	O	432
with	ADP	O	O	432
a	PRON	O	O	432
commonly	ADV	O	O	432
used	VERB	O	O	432
drug	NOUN	O	O	432
thought	VERB	O	O	432
to	PART	O	O	432
be	AUX	O	O	432
""""	PUNCT	O	O	432
safe	ADJ	O	O	432
""""	PUNCT	O	O	432
.	PUNCT	O	O	432
According	VERB	O	O	433
to	PART	O	O	433
Naranjo	PROPN	O	O	433
's	AUX	O	O	433
algorithm	VERB	O	O	433
the	PRON	O	O	433
likelihood	NOUN	O	O	433
that	SCONJ	O	O	433
our	PRON	O	O	433
patient	NOUN	O	O	433
's	AUX	O	O	433
agranulocytosis	ADJ	O	O	433
and	CCONJ	O	O	433
thrombocytopenia	PROPN	O	Disease	433
occurred	VERB	O	O	433
as	ADP	O	O	433
a	PRON	O	O	433
result	VERB	O	O	433
of	ADP	O	O	433
therapy	NOUN	O	O	433
with	ADP	O	O	433
fluconazole	CCONJ	O	Chemical	433
is	AUX	O	O	433
probable	ADJ	O	O	433
,	PUNCT	O	O	433
with	ADP	O	O	433
a	PRON	O	O	433
total	ADJ	O	O	433
of	ADP	O	O	433
six	NUM	O	O	433
points	VERB	O	O	433
.	PUNCT	O	O	433
In	ADP	O	O	434
particular	ADJ	O	O	434
the	PRON	O	O	434
temporal	ADJ	O	O	434
relationship	NOUN	O	O	434
of	ADP	O	O	434
bone	NOUN	O	O	434
marrow suppression	NOUN	O	Disease	434
to	PART	O	O	434
the	PRON	O	O	434
initiation	NOUN	O	O	434
of	ADP	O	O	434
fluconazole	CCONJ	O	Chemical	434
and	CCONJ	O	O	434
the	PRON	O	O	434
abatement	NOUN	O	O	434
of	ADP	O	O	434
symptoms	NOUN	O	O	434
that	SCONJ	O	O	434
rapidly	ADV	O	O	434
reversed	VERB	O	O	434
immediately	ADV	O	O	434
following	VERB	O	O	434
discontinuation	NOUN	O	O	434
.	PUNCT	O	O	434
Two	NUM	O	O	437
-	PUNCT	O	O	437
dimensional	ADJ	O	O	437
speckle	NOUN	O	O	437
tracking	NOUN	O	O	437
echocardiography	NOUN	O	O	437
combined	VERB	O	O	437
with	ADP	O	O	437
high	ADJ	O	O	437
-	PUNCT	O	O	437
sensitive	ADJ	O	O	437
cardiac	ADJ	O	O	437
troponin	PROPN	O	O	437
T	NOUN	O	Chemical	437
in	ADP	O	O	437
early	ADV	O	O	437
detection	NOUN	O	O	437
and	CCONJ	O	O	437
prediction	NOUN	O	O	437
of	ADP	O	O	437
cardiotoxicity	NOUN	O	Disease	437
during	ADP	O	O	437
epirubicine	NOUN	O	O	437
-	PUNCT	O	O	437
based	VERB	O	O	437
chemotherapy	NOUN	O	O	437
.	PUNCT	O	O	437
To	PART	O	O	438
investigate	VERB	O	O	438
whether	SCONJ	O	O	438
alterations	NOUN	O	O	438
of	ADP	O	O	438
myocardial	ADJ	O	O	438
strain	VERB	O	O	438
and	CCONJ	O	O	438
high	ADJ	O	O	438
-	PUNCT	O	O	438
sensitive	ADJ	O	O	438
cardiac	ADJ	O	O	438
troponin	PROPN	O	O	438
T	NOUN	O	Chemical	438
(	PUNCT	O	O	438
cTnT	VERB	O	O	438
)	PUNCT	O	O	438
could	AUX	O	O	438
predict	VERB	O	O	438
future	NOUN	O	O	438
cardiac dysfunction	NOUN	O	Disease	438
in	ADP	O	O	438
patients	NOUN	O	O	438
after	ADP	O	O	438
epirubicin	VERB	O	O	438
exposure	NOUN	O	O	438
.	PUNCT	O	O	438
METHODS	NOUN	O	O	439
:	PUNCT	O	O	439
Seventy	NUM	O	O	439
-	PUNCT	O	O	439
five	NUM	O	O	439
patients	NOUN	O	O	439
with	ADP	O	O	439
non	ADJ	O	O	439
-	PUNCT	O	O	439
Hodgkin	PROPN	O	O	439
lymphoma	PROPN	O	Disease	439
treated	VERB	O	O	439
with	ADP	O	O	439
epirubicin	VERB	O	O	439
were	AUX	O	O	439
studied	VERB	O	O	439
.	PUNCT	O	O	439
Cardiotoxicity	NOUN	O	Disease	440
was	AUX	O	O	440
defined	VERB	O	O	440
as	ADP	O	O	440
a	PRON	O	O	440
reduction	NOUN	O	O	440
of	ADP	O	O	440
the	PRON	O	O	440
LVEF	PROPN	O	O	440
of	ADP	O	O	440
>	PUNCT	O	O	440
5%	NOUN	O	O	441
to	PART	O	O	441
<	X	O	O	441
55%	NOUN	O	O	441
with	ADP	O	O	441
symptoms	NOUN	O	O	441
of	ADP	O	O	441
heart failure	NOUN	O	Disease	441
or	CCONJ	O	O	441
an	PRON	O	O	441
asymptomatic	ADJ	O	O	441
reduction	NOUN	O	O	441
of	ADP	O	O	441
the	PRON	O	O	441
LVEF	PROPN	O	O	441
of	ADP	O	O	441
>	PUNCT	O	O	441
RESULTS	VERB	O	O	442
:	PUNCT	O	O	442
Fourteen	NUM	O	O	442
patients	NOUN	O	O	442
(	PUNCT	O	O	442
18.67%	NOUN	O	O	442
)	PUNCT	O	O	442
developed	VERB	O	O	442
cardiotoxicity	NOUN	O	Disease	442
after	ADP	O	O	442
treatment	NOUN	O	O	442
.	PUNCT	O	O	442
AUC	NOUN	O	O	443
=	PUNCT	O	O	443
0.757	NUM	O	O	443
;	PUNCT	O	O	443
P	NOUN	O	Chemical	443
=	PUNCT	O	O	443
0.005	NUM	O	O	443
)	PUNCT	O	O	443
from	ADP	O	O	443
baseline	VERB	O	O	443
to	PART	O	O	443
the	PRON	O	O	443
third	ADV	O	O	443
cycle	PROPN	O	O	443
of	ADP	O	O	443
chemotherapy	NOUN	O	O	443
predicted	VERB	O	O	443
later	ADV	O	O	443
cardiotoxicity	NOUN	O	Disease	443
.	PUNCT	O	O	443
The	PRON	O	O	444
decrease	VERB	O	O	444
in	ADP	O	O	444
GLS	PROPN	O	O	444
remained	VERB	O	O	444
the	PRON	O	O	444
only	ADV	O	O	444
independent	ADJ	O	O	444
predictor	NOUN	O	O	444
of	ADP	O	O	444
cardiotoxicity	NOUN	O	Disease	444
(	PUNCT	O	O	444
P	NOUN	O	Chemical	444
=	PUNCT	O	O	444
0.000	NUM	O	O	444
)	PUNCT	O	O	444
.	PUNCT	O	O	444
GLS	PROPN	O	O	445
combined	VERB	O	O	445
with	ADP	O	O	445
cTnT	VERB	O	O	445
may	AUX	O	O	445
provide	VERB	O	O	445
a	PRON	O	O	445
reliable	ADJ	O	O	445
and	CCONJ	O	O	445
non	ADJ	O	O	445
-	PUNCT	O	O	445
invasive	ADJ	O	O	445
method	NOUN	O	O	445
to	PART	O	O	445
predict	VERB	O	O	445
cardiac dysfunction	NOUN	O	Disease	445
in	ADP	O	O	445
patients	NOUN	O	O	445
receiving	VERB	O	O	445
anthracycline	NOUN	O	Chemical	445
-	PUNCT	O	O	445
based	VERB	O	O	445
chemotherapy	NOUN	O	O	445
.	PUNCT	O	O	445
Prevention	NOUN	O	O	448
of	ADP	O	O	448
etomidate	VERB	O	Chemical	448
-	PUNCT	O	O	448
induced	VERB	O	O	448
myoclonus	NOUN	O	Disease	448
:	PUNCT	O	O	448
which	PRON	O	O	448
is	AUX	O	O	448
superior	PROPN	O	O	448
:	PUNCT	O	O	448
Fentanyl	NOUN	O	O	449
,	PUNCT	O	O	449
midazolam	PROPN	O	Chemical	449
,	PUNCT	O	O	449
or	CCONJ	O	O	449
a	PRON	O	O	449
combination	NOUN	O	O	449
?	PUNCT	O	O	449
In	ADP	O	O	450
this	PRON	O	O	450
retrospective	ADJ	O	O	450
comparative	ADJ	O	O	450
study	VERB	O	O	450
,	PUNCT	O	O	450
we	PRON	O	O	450
aimed	VERB	O	O	450
to	PART	O	O	450
compare	VERB	O	O	450
the	PRON	O	O	450
effectiveness	NOUN	O	O	450
of	ADP	O	O	450
fentanyl	ADJ	O	Chemical	450
,	PUNCT	O	O	450
midazolam	PROPN	O	Chemical	450
,	PUNCT	O	O	450
and	CCONJ	O	O	450
a	PRON	O	O	450
combination	NOUN	O	O	450
of	ADP	O	O	450
fentanyl	ADJ	O	Chemical	450
and	CCONJ	O	O	450
midazolam	PROPN	O	Chemical	450
to	PART	O	O	450
prevent	VERB	O	O	450
etomidate	VERB	O	Chemical	450
-	PUNCT	O	O	450
induced	VERB	O	O	450
myoclonus	NOUN	O	Disease	450
.	PUNCT	O	O	450
Depending	VERB	O	O	451
on	ADP	O	O	451
the	PRON	O	O	451
drugs	NOUN	O	O	451
that	SCONJ	O	O	451
would	AUX	O	O	451
be	AUX	O	O	451
given	VERB	O	O	451
before	ADP	O	O	451
the	PRON	O	O	451
induction	NOUN	O	O	451
of	ADP	O	O	451
anesthesia	NOUN	O	O	451
with	ADP	O	O	451
etomidate	VERB	O	Chemical	451
,	PUNCT	O	O	451
the	PRON	O	O	451
patients	NOUN	O	O	451
were	AUX	O	O	451
separated	VERB	O	O	451
into	ADP	O	O	451
4	NUM	O	O	451
groups	NOUN	O	O	451
:	PUNCT	O	O	451
no	PRON	O	O	451
pretreatment	NOUN	O	O	451
(	PUNCT	O	O	451
Group	PROPN	O	O	451
NP	PROPN	O	O	451
)	PUNCT	O	O	451
,	PUNCT	O	O	451
fentanyl	ADJ	O	Chemical	451
1	X	O	O	451
ug.kg-1	NOUN	O	O	451
(	PUNCT	O	O	451
Group	PROPN	O	O	451
F	NOUN	O	O	451
)	PUNCT	O	O	451
,	PUNCT	O	O	451
midazolam	PROPN	O	Chemical	451
0.03	NUM	O	O	451
mg.kg-1	NOUN	O	O	451
(	PUNCT	O	O	451
Group	PROPN	O	O	451
M	NOUN	O	Chemical	451
)	PUNCT	O	O	451
,	PUNCT	O	O	451
and	CCONJ	O	O	451
midazolam	PROPN	O	Chemical	451
0.015	NUM	O	O	451
mg.kg-1	NOUN	O	O	451
+	ADP	O	O	451
fentanyl	ADJ	O	Chemical	451
Patients	NOUN	O	O	452
who	PRON	O	O	452
received	VERB	O	O	452
the	PRON	O	O	452
same	ADJ	O	O	452
anesthetic	NOUN	O	O	452
procedure	NOUN	O	O	452
were	AUX	O	O	452
selected	VERB	O	O	452
:	PUNCT	O	O	452
2	X	O	O	452
minutes	NOUN	O	O	452
after	ADP	O	O	452
intravenous	ADJ	O	O	452
injections	NOUN	O	O	452
of	ADP	O	O	452
the	PRON	O	O	452
pretreatment	NOUN	O	O	452
drugs	NOUN	O	O	452
,	PUNCT	O	O	452
anesthesia	NOUN	O	O	452
is	AUX	O	O	452
induced	VERB	O	O	452
with	ADP	O	O	452
0.3	NUM	O	O	452
mg.kg-1	NOUN	O	O	452
etomidate	VERB	O	Chemical	452
injected	VERB	O	O	452
intravenously	ADV	O	O	452
over	ADP	O	O	452
a	PRON	O	O	452
period	NOUN	O	O	452
of	ADP	O	O	452
20	NUM	O	O	452
-	PUNCT	O	O	452
30	NUM	O	O	452
seconds	NOUN	O	O	452
.	PUNCT	O	O	452
Myoclonic	PROPN	O	O	453
movements	NOUN	O	O	453
are	AUX	O	O	453
evaluated	VERB	O	O	453
,	PUNCT	O	O	453
which	PRON	O	O	453
were	AUX	O	O	453
observed	VERB	O	O	453
and	CCONJ	O	O	453
graded	VERB	O	O	453
according	VERB	O	O	453
to	PART	O	O	453
clinical	ADJ	O	O	453
severity	NOUN	O	O	453
during	ADP	O	O	453
the	PRON	O	O	453
2	X	O	O	453
minutes	NOUN	O	O	453
after	ADP	O	O	453
etomidate	VERB	O	Chemical	453
injection	NOUN	O	O	453
.	PUNCT	O	O	453
The	PRON	O	O	454
severity	NOUN	O	O	454
of	ADP	O	O	454
pain	NOUN	O	Disease	454
due	ADJ	O	O	454
to	PART	O	O	454
etomidate	VERB	O	Chemical	454
injection	NOUN	O	O	454
,	PUNCT	O	O	454
mean	VERB	O	O	454
arterial	ADJ	O	O	454
pressure	NOUN	O	O	454
,	PUNCT	O	O	454
heart	NOUN	O	O	454
rate	NOUN	O	O	454
,	PUNCT	O	O	454
and	CCONJ	O	O	454
adverse	ADJ	O	O	454
effects	NOUN	O	O	454
were	AUX	O	O	454
also	ADV	O	O	454
evaluated	VERB	O	O	454
.	PUNCT	O	O	454
Study	NOUN	O	O	455
results	VERB	O	O	455
showed	VERB	O	O	455
that	SCONJ	O	O	455
myoclonus	NOUN	O	Disease	455
incidence	NOUN	O	O	455
was	AUX	O	O	455
85%	NOUN	O	O	455
,	PUNCT	O	O	455
40%	NOUN	O	O	455
,	PUNCT	O	O	455
70%	NOUN	O	O	455
,	PUNCT	O	O	455
and	CCONJ	O	O	455
25%	NOUN	O	O	455
in	ADP	O	O	455
Group	PROPN	O	O	455
NP	PROPN	O	O	455
,	PUNCT	O	O	455
Group	PROPN	O	O	455
F	NOUN	O	O	455
,	PUNCT	O	O	455
Group	PROPN	O	O	455
M	NOUN	O	Chemical	455
,	PUNCT	O	O	455
and	CCONJ	O	O	455
Group	PROPN	O	O	455
FM	PROPN	O	O	455
,	PUNCT	O	O	455
respectively	ADV	O	O	455
,	PUNCT	O	O	455
and	CCONJ	O	O	455
were	AUX	O	O	455
significantly	ADV	O	O	455
lower	ADJ	O	O	455
in	ADP	O	O	455
Group	PROPN	O	O	455
F	NOUN	O	O	455
and	CCONJ	O	O	455
Group	PROPN	O	O	455
FM	PROPN	O	O	455
.	PUNCT	O	O	455
CONCLUSIONS	NOUN	O	O	456
:	PUNCT	O	O	456
We	PRON	O	O	456
conclude	VERB	O	O	456
that	SCONJ	O	O	456
pretreatment	NOUN	O	O	456
with	ADP	O	O	456
fentanyl	ADJ	O	Chemical	456
or	CCONJ	O	O	456
combination	NOUN	O	O	456
of	ADP	O	O	456
fentanyl	ADJ	O	Chemical	456
and	CCONJ	O	O	456
midazolam	PROPN	O	Chemical	456
was	AUX	O	O	456
effective	ADJ	O	O	456
in	ADP	O	O	456
preventing	VERB	O	O	456
etomidate	VERB	O	Chemical	456
-	PUNCT	O	O	456
induced	VERB	O	O	456
myoclonus	NOUN	O	Disease	456
.	PUNCT	O	O	456
Cholestatic	NOUN	O	O	459
presentation	NOUN	O	O	459
of	ADP	O	O	459
yellow	ADJ	O	O	459
phosphorus	NOUN	O	O	459
poisoning	VERB	O	O	459
.	PUNCT	O	O	459
Yellow	NOUN	O	O	460
phosphorus	NOUN	O	O	460
,	PUNCT	O	O	460
a	PRON	O	O	460
component	NOUN	O	O	460
of	ADP	O	O	460
certain	ADJ	O	O	460
pesticide	NOUN	O	O	460
pastes	NOUN	O	O	460
and	CCONJ	O	O	460
fireworks	NOUN	O	O	460
,	PUNCT	O	O	460
is	AUX	O	O	460
well	ADV	O	O	460
known	VERB	O	O	460
to	PART	O	O	460
cause	VERB	O	O	460
hepatotoxicity	NOUN	O	Disease	460
.	PUNCT	O	O	460
Poisoning	NOUN	O	O	461
with	ADP	O	O	461
yellow	ADJ	O	O	461
phosphorus	NOUN	O	O	461
classically	ADV	O	O	461
manifests	VERB	O	O	461
with	ADP	O	O	461
acute	ADJ	O	O	461
hepatitis	NOUN	O	Disease	461
leading	VERB	O	O	461
to	PART	O	O	461
acute liver failure	NOUN	O	Disease	461
which	PRON	O	O	461
may	AUX	O	O	461
need	VERB	O	O	461
liver	NOUN	O	O	461
transplantation	NOUN	O	O	461
.	PUNCT	O	O	461
We	PRON	O	O	462
present	NOUN	O	O	462
a	PRON	O	O	462
case	NOUN	O	O	462
of	ADP	O	O	462
yellow	ADJ	O	O	462
phosphorus	NOUN	O	O	462
poisoning	VERB	O	O	462
in	ADP	O	O	462
which	PRON	O	O	462
a	PRON	O	O	462
patient	NOUN	O	O	462
presented	VERB	O	O	462
with	ADP	O	O	462
florid	ADJ	O	O	462
clinical	ADJ	O	O	462
features	VERB	O	O	462
of	ADP	O	O	462
cholestasis	NOUN	O	Disease	462
highlighting	VERB	O	O	462
the	PRON	O	O	462
fact	NOUN	O	O	462
that	SCONJ	O	O	462
cholestasis	NOUN	O	Disease	462
can	AUX	O	O	462
rarely	ADV	O	O	462
be	AUX	O	O	462
a	PRON	O	O	462
presenting	VERB	O	O	462
feature	VERB	O	O	462
of	ADP	O	O	462
yellow	ADJ	O	O	462
phosphorus	NOUN	O	O	462
hepatotoxicity	NOUN	O	Disease	462
.	PUNCT	O	O	462
Vasovagal	NOUN	O	O	465
syncope	VERB	O	Disease	465
and	CCONJ	O	O	465
severe	ADJ	O	O	465
bradycardia	NOUN	O	Disease	465
following	VERB	O	O	465
intranasal	NOUN	O	O	465
dexmedetomidine	PROPN	O	Chemical	465
for	ADP	O	O	465
pediatric	ADJ	O	O	465
procedural	ADJ	O	O	465
sedation	NOUN	O	O	465
.	PUNCT	O	O	465
We	PRON	O	O	466
report	VERB	O	O	466
syncope	VERB	O	Disease	466
and	CCONJ	O	O	466
bradycardia	NOUN	O	Disease	466
in	ADP	O	O	466
an	PRON	O	O	466
11-year	NOUN	O	O	466
-	PUNCT	O	O	466
old	ADJ	O	O	466
girl	NOUN	O	O	466
following	VERB	O	O	466
administration	NOUN	O	O	466
of	ADP	O	O	466
intranasal	NOUN	O	O	466
dexmedetomidine	PROPN	O	Chemical	466
for	ADP	O	O	466
sedation	NOUN	O	O	466
for	ADP	O	O	466
a	PRON	O	O	466
voiding	VERB	O	O	466
cystourethrogram	NOUN	O	O	466
.	PUNCT	O	O	466
The	PRON	O	O	467
primary	NOUN	O	O	467
abnormality	NOUN	O	O	467
found	VERB	O	O	467
was	AUX	O	O	467
persistent	ADJ	O	O	467
bradycardia	NOUN	O	Disease	467
,	PUNCT	O	O	467
and	CCONJ	O	O	467
she	PRON	O	O	467
was	AUX	O	O	467
admitted	VERB	O	O	467
to	PART	O	O	467
the	PRON	O	O	467
hospital	PROPN	O	O	467
for	ADP	O	O	467
telemetric	ADJ	O	O	467
observation	NOUN	O	O	467
.	PUNCT	O	O	467
The	PRON	O	O	468
bradycardia	NOUN	O	Disease	468
lasted	VERB	O	O	468
~2	PROPN	O	O	468
h	X	O	O	468
,	PUNCT	O	O	468
and	CCONJ	O	O	468
further	ADV	O	O	468
cardiac	ADJ	O	O	468
workup	VERB	O	O	468
revealed	VERB	O	O	468
no	PRON	O	O	468
underlying	VERB	O	O	468
abnormality	NOUN	O	O	468
.	PUNCT	O	O	468
Paradoxical	PROPN	O	O	471
severe	ADJ	O	O	471
agitation	NOUN	O	Disease	471
induced	VERB	O	O	471
by	ADP	O	O	471
add	VERB	O	O	471
-	PUNCT	O	O	471
on	ADP	O	O	471
high	ADJ	O	O	471
-	PUNCT	O	O	471
doses	NOUN	O	O	471
quetiapine	ADV	O	Chemical	471
in	ADP	O	O	471
schizo	PROPN	O	O	471
-	PUNCT	O	O	471
affective	ADJ	O	O	471
disorder	NOUN	O	O	471
.	PUNCT	O	O	471
We	PRON	O	O	472
report	VERB	O	O	472
the	PRON	O	O	472
case	NOUN	O	O	472
of	ADP	O	O	472
a	PRON	O	O	472
35-year	NOUN	O	O	472
-	PUNCT	O	O	472
old	ADJ	O	O	472
patient	NOUN	O	O	472
suffering	VERB	O	O	472
from	ADP	O	O	472
schizo	PROPN	O	O	472
-	PUNCT	O	O	472
affective	ADJ	O	O	472
disorder	NOUN	O	O	472
since	SCONJ	O	O	472
the	PRON	O	O	472
age	NOUN	O	O	472
of	ADP	O	O	472
19	NUM	O	O	472
years	NOUN	O	O	472
,	PUNCT	O	O	472
treated	VERB	O	O	472
by	ADP	O	O	472
a	PRON	O	O	472
combination	NOUN	O	O	472
of	ADP	O	O	472
first	ADV	O	O	472
-	PUNCT	O	O	472
generation	NOUN	O	O	472
antipsychotics	NOUN	O	O	472
,	PUNCT	O	O	472
zuclopenthixol	PROPN	O	O	472
(	PUNCT	O	O	472
100	NUM	O	O	472
mg	VERB	O	O	472
/	PUNCT	O	O	472
day	NOUN	O	O	472
)	PUNCT	O	O	472
and	CCONJ	O	O	472
lithium	NOUN	O	Chemical	472
(	PUNCT	O	O	472
1200	NUM	O	O	472
mg	VERB	O	O	472
/	PUNCT	O	O	472
day	NOUN	O	O	472
)	PUNCT	O	O	472
(	PUNCT	O	O	472
serum	NOUN	O	O	472
lithium=0.85	NOUN	O	O	472
mEq	VERB	O	O	472
/	PUNCT	O	O	472
l	X	O	O	472
)	PUNCT	O	O	472
.	PUNCT	O	O	472
This	PRON	O	O	473
patient	NOUN	O	O	473
had	VERB	O	O	473
no	PRON	O	O	473
associated	VERB	O	O	473
personality	NOUN	O	O	473
disorder	NOUN	O	O	473
(	PUNCT	O	O	473
particularly	ADV	O	O	473
no	PRON	O	O	473
antisocial	ADJ	O	O	473
disorder	NOUN	O	O	473
)	PUNCT	O	O	473
and	CCONJ	O	O	473
no	PRON	O	O	473
substance abuse	NOUN	O	Disease	473
disorder	NOUN	O	O	473
.	PUNCT	O	O	473
Within	ADP	O	O	474
the	PRON	O	O	474
48	NUM	O	O	474
h	X	O	O	474
following	VERB	O	O	474
the	PRON	O	O	474
gradual	ADJ	O	O	474
introduction	NOUN	O	O	474
of	ADP	O	O	474
quetiapine	ADV	O	Chemical	474
(	PUNCT	O	O	474
up	ADP	O	O	474
to	PART	O	O	474
600	NUM	O	O	474
mg	VERB	O	O	474
/	PUNCT	O	O	474
day	NOUN	O	O	474
)	PUNCT	O	O	474
,	PUNCT	O	O	474
the	PRON	O	O	474
patient	NOUN	O	O	474
presented	VERB	O	O	474
severe	ADJ	O	O	474
agitation	NOUN	O	Disease	474
without	ADP	O	O	474
an	PRON	O	O	474
environmental	ADJ	O	O	474
explanation	NOUN	O	O	474
,	PUNCT	O	O	474
contrasting	VERB	O	O	474
with	ADP	O	O	474
the	PRON	O	O	474
absence	NOUN	O	O	474
of	ADP	O	O	474
a	PRON	O	O	474
history	NOUN	O	O	474
of	ADP	O	O	474
aggressiveness	NOUN	O	Disease	474
or	CCONJ	O	O	474
personality	NOUN	O	O	474
disorder	NOUN	O	O	474
.	PUNCT	O	O	474
The	PRON	O	O	475
diagnoses	NOUN	O	O	475
of	ADP	O	O	475
manic	ADJ	O	O	475
shift	NOUN	O	O	475
and	CCONJ	O	O	475
akathisia	PROPN	O	Disease	475
were	AUX	O	O	475
dismissed	VERB	O	O	475
.	PUNCT	O	O	475
The	PRON	O	O	476
withdrawal	NOUN	O	O	476
and	CCONJ	O	O	476
the	PRON	O	O	476
gradual	ADJ	O	O	476
reintroduction	NOUN	O	O	476
of	ADP	O	O	476
quetiapine	ADV	O	Chemical	476
2	X	O	O	476
weeks	NOUN	O	O	476
later	ADV	O	O	476
,	PUNCT	O	O	476
which	PRON	O	O	476
led	VERB	O	O	476
to	PART	O	O	476
another	PRON	O	O	476
severe	ADJ	O	O	476
agitation	NOUN	O	Disease	476
,	PUNCT	O	O	476
enabled	VERB	O	O	476
us	PRON	O	O	476
to	PART	O	O	476
attribute	NOUN	O	O	476
the	PRON	O	O	476
agitation	NOUN	O	Disease	476
specifically	ADV	O	O	476
to	PART	O	O	476
quetiapine	ADV	O	Chemical	476
.	PUNCT	O	O	476
Antioxidant	NOUN	O	O	479
effects	NOUN	O	O	479
of	ADP	O	O	479
bovine	NOUN	O	O	479
lactoferrin	PROPN	O	O	479
on	ADP	O	O	479
dexamethasone	NOUN	O	Chemical	479
-	PUNCT	O	O	479
induced	VERB	O	O	479
hypertension	NOUN	O	Disease	479
in	ADP	O	O	479
rat	NOUN	O	O	479
.	PUNCT	O	O	479
Dexamethasone-	PROPN	O	O	480
(	PUNCT	O	O	480
Dex-	VERB	O	O	480
)	PUNCT	O	O	480
induced	VERB	O	O	480
hypertension	NOUN	O	Disease	480
is	AUX	O	O	480
associated	VERB	O	O	480
with	ADP	O	O	480
enhanced	VERB	O	O	480
oxidative	NOUN	O	O	480
stress	NOUN	O	O	480
.	PUNCT	O	O	480
Lactoferrin	PROPN	O	O	481
(	PUNCT	O	O	481
LF	NOUN	O	O	481
)	PUNCT	O	O	481
is	AUX	O	O	481
an	PRON	O	O	481
iron	NOUN	O	Chemical	481
-	PUNCT	O	O	481
binding	VERB	O	O	481
glycoprotein	NOUN	O	O	481
with	ADP	O	O	481
antihypertensive	ADV	O	O	481
properties	NOUN	O	O	481
.	PUNCT	O	O	481
In	ADP	O	O	482
this	PRON	O	O	482
study	VERB	O	O	482
,	PUNCT	O	O	482
we	PRON	O	O	482
investigated	VERB	O	O	482
the	PRON	O	O	482
effect	VERB	O	O	482
of	ADP	O	O	482
chronic	ADJ	O	O	482
administration	NOUN	O	O	482
of	ADP	O	O	482
LF	NOUN	O	O	482
on	ADP	O	O	482
oxidative	NOUN	O	O	482
stress	NOUN	O	O	482
and	CCONJ	O	O	482
hypertension	NOUN	O	Disease	482
upon	SCONJ	O	O	482
Dex	PROPN	O	Chemical	482
administration	NOUN	O	O	482
.	PUNCT	O	O	482
Male	NOUN	O	O	483
Wistar	PROPN	O	O	483
rats	NOUN	O	O	483
were	AUX	O	O	483
treated	VERB	O	O	483
by	ADP	O	O	483
Dex	PROPN	O	Chemical	483
(	PUNCT	O	O	483
30	NUM	O	O	483
u	X	O	O	483
In	ADP	O	O	484
a	PRON	O	O	484
prevention	NOUN	O	O	484
study	VERB	O	O	484
,	PUNCT	O	O	484
rats	NOUN	O	O	484
received	VERB	O	O	484
4	NUM	O	O	484
days	NOUN	O	O	484
of	ADP	O	O	484
LF	NOUN	O	O	484
treatment	NOUN	O	O	484
followed	VERB	O	O	484
by	ADP	O	O	484
Dex	PROPN	O	Chemical	484
and	CCONJ	O	O	484
continued	VERB	O	O	484
during	ADP	O	O	484
the	PRON	O	O	484
test	NOUN	O	O	484
period	NOUN	O	O	484
.	PUNCT	O	O	484
Plasma	NOUN	O	O	485
hydrogen peroxide	NOUN	O	Chemical	485
(	PUNCT	O	O	485
H2O2	NOUN	O	O	485
)	PUNCT	O	O	485
concentration	NOUN	O	O	485
and	CCONJ	O	O	485
ferric	ADJ	O	O	485
reducing	VERB	O	O	485
antioxidant	ADJ	O	O	485
power	NOUN	O	O	485
(	PUNCT	O	O	485
FRAP	PROPN	O	O	485
)	PUNCT	O	O	485
value	NOUN	O	O	485
were	AUX	O	O	485
determined	VERB	O	O	485
.	PUNCT	O	O	485
Dexamethasone	NOUN	O	Chemical	486
significantly	ADV	O	O	486
increased	VERB	O	O	486
SBP	NOUN	O	O	486
and	CCONJ	O	O	486
plasma	NOUN	O	O	486
H2O2	NOUN	O	O	486
level	VERB	O	O	486
and	CCONJ	O	O	486
decreased	VERB	O	O	486
thymus	NOUN	O	O	486
and	CCONJ	O	O	486
body	NOUN	O	O	486
weights	NOUN	O	O	486
.	PUNCT	O	O	486
LF	NOUN	O	O	487
lowered	VERB	O	O	487
(	PUNCT	O	O	487
P	NOUN	O	Chemical	487
<	X	O	O	487
0.01	NUM	O	O	487
)	PUNCT	O	O	487
and	CCONJ	O	O	487
dose	NOUN	O	O	487
dependently	ADV	O	O	487
prevented	VERB	O	O	487
(	PUNCT	O	O	487
P	NOUN	O	Chemical	487
<	X	O	O	487
0.001	NUM	O	O	487
)	PUNCT	O	O	487
Dex	PROPN	O	Chemical	487
-	PUNCT	O	O	487
induced	VERB	O	O	487
hypertension	NOUN	O	Disease	487
.	PUNCT	O	O	487
LF	NOUN	O	O	488
prevented	VERB	O	O	488
body	NOUN	O	O	488
weight loss	NOUN	O	Disease	488
and	CCONJ	O	O	488
significantly	ADV	O	O	488
reduced	VERB	O	O	488
the	PRON	O	O	488
elevated	ADJ	O	O	488
plasma	NOUN	O	O	488
H2O2	NOUN	O	O	488
and	CCONJ	O	O	488
increased	VERB	O	O	488
FRAP	PROPN	O	O	488
values	NOUN	O	O	488
.	PUNCT	O	O	488
Chronic	NOUN	O	O	489
administration	NOUN	O	O	489
of	ADP	O	O	489
LF	NOUN	O	O	489
strongly	ADV	O	O	489
reduced	VERB	O	O	489
the	PRON	O	O	489
blood	NOUN	O	O	489
pressure	NOUN	O	O	489
and	CCONJ	O	O	489
production	NOUN	O	O	489
of	ADP	O	O	489
ROS	PROPN	O	O	489
and	CCONJ	O	O	489
improved	VERB	O	O	489
antioxidant	ADJ	O	O	489
capacity	NOUN	O	O	489
in	ADP	O	O	489
Dex	PROPN	O	Chemical	489
-	PUNCT	O	O	489
induced	VERB	O	O	489
hypertension	NOUN	O	Disease	489
,	PUNCT	O	O	489
suggesting	VERB	O	O	489
the	PRON	O	O	489
role	NOUN	O	O	489
of	ADP	O	O	489
inhibition	NOUN	O	O	489
of	ADP	O	O	489
oxidative	NOUN	O	O	489
stress	NOUN	O	O	489
as	ADP	O	O	489
another	PRON	O	O	489
mechanism	NOUN	O	O	489
of	ADP	O	O	489
antihypertensive	ADV	O	O	489
action	NOUN	O	O	489
of	ADP	O	O	489
LF	NOUN	O	O	489
.	PUNCT	O	O	489
The	PRON	O	O	492
association	PROPN	O	O	492
between	ADP	O	O	492
tranexamic acid	PROPN	O	Chemical	492
and	CCONJ	O	O	492
convulsive	ADJ	O	Disease	492
seizures	NOUN	O	Disease	492
after	ADP	O	O	492
cardiac	ADJ	O	O	492
surgery	NOUN	O	O	492
:	PUNCT	O	O	492
a	PRON	O	O	492
multivariate	ADJ	O	O	492
analysis	NOUN	O	O	492
in	ADP	O	O	492
11	NUM	O	O	492
529	NUM	O	O	492
patients	NOUN	O	O	492
.	PUNCT	O	O	492
Because	SCONJ	O	O	493
of	ADP	O	O	493
a	PRON	O	O	493
lack	VERB	O	O	493
of	ADP	O	O	493
contemporary	ADJ	O	O	493
data	NOUN	O	O	493
regarding	VERB	O	O	493
seizures	NOUN	O	Disease	493
after	ADP	O	O	493
cardiac	ADJ	O	O	493
surgery	NOUN	O	O	493
,	PUNCT	O	O	493
we	PRON	O	O	493
undertook	VERB	O	O	493
a	PRON	O	O	493
retrospective	ADJ	O	O	493
analysis	NOUN	O	O	493
of	ADP	O	O	493
prospectively	ADV	O	O	493
collected	VERB	O	O	493
data	NOUN	O	O	493
from	ADP	O	O	493
11	NUM	O	O	493
529	NUM	O	O	493
patients	NOUN	O	O	493
in	ADP	O	O	493
whom	PRON	O	O	493
cardiopulmonary	VERB	O	O	493
bypass	NOUN	O	O	493
was	AUX	O	O	493
used	VERB	O	O	493
from	ADP	O	O	493
January	PROPN	O	O	493
2004	NUM	O	O	493
to	PART	O	O	493
December	PROPN	O	O	493
2010	NUM	O	O	493
.	PUNCT	O	O	493
A	PRON	O	O	494
convulsive	ADJ	O	Disease	494
seizure	NOUN	O	Disease	494
was	AUX	O	O	494
defined	VERB	O	O	494
as	ADP	O	O	494
a	PRON	O	O	494
transient	ADJ	O	O	494
episode	PROPN	O	O	494
of	ADP	O	O	494
disturbed	ADJ	O	O	494
brain	NOUN	O	O	494
function	NOUN	O	O	494
characterised	VERB	O	O	494
by	ADP	O	O	494
abnormal	ADJ	O	O	494
involuntary	ADJ	O	O	494
motor	NOUN	O	O	494
movements	NOUN	O	O	494
.	PUNCT	O	O	494
Multivariate	NOUN	O	O	495
regression	NOUN	O	O	495
analysis	NOUN	O	O	495
was	AUX	O	O	495
performed	VERB	O	O	495
to	PART	O	O	495
identify	VERB	O	O	495
independent	ADJ	O	O	495
predictors	NOUN	O	O	495
of	ADP	O	O	495
postoperative	ADJ	O	O	495
seizures	NOUN	O	Disease	495
.	PUNCT	O	O	495
A	PRON	O	O	496
total	ADJ	O	O	496
of	ADP	O	O	496
100	NUM	O	O	496
(	PUNCT	O	O	496
0.9%	NOUN	O	O	496
)	PUNCT	O	O	496
patients	NOUN	O	O	496
developed	VERB	O	O	496
postoperative	ADJ	O	O	496
convulsive	ADJ	O	Disease	496
seizures	NOUN	O	Disease	496
.	PUNCT	O	O	496
Generalised	VERB	O	O	497
and	CCONJ	O	O	497
focal	ADJ	O	O	497
seizures	NOUN	O	Disease	497
were	AUX	O	O	497
identified	VERB	O	O	497
in	ADP	O	O	497
68	NUM	O	O	497
and	CCONJ	O	O	497
32	NUM	O	O	497
patients	NOUN	O	O	497
,	PUNCT	O	O	497
respectively	ADV	O	O	497
.	PUNCT	O	O	497
)	PUNCT	O	O	498
time	NOUN	O	O	498
after	ADP	O	O	498
surgery	NOUN	O	O	498
when	SCONJ	O	O	498
the	PRON	O	O	498
seizure	NOUN	O	Disease	498
occurred	VERB	O	O	498
was	AUX	O	O	498
7	NUM	O	O	498
(	PUNCT	O	O	498
6	NUM	O	O	498
-	PUNCT	O	O	498
12	NUM	O	O	498
[	X	O	O	498
1	X	O	O	498
-	PUNCT	O	O	498
216	NUM	O	O	498
]	PUNCT	O	O	498
)	PUNCT	O	O	498
Independent	ADJ	O	O	499
predictors	NOUN	O	O	499
of	ADP	O	O	499
postoperative	ADJ	O	O	499
seizures	NOUN	O	Disease	499
included	VERB	O	O	499
age	NOUN	O	O	499
,	PUNCT	O	O	499
female	ADJ	O	O	499
sex	NOUN	O	O	499
,	PUNCT	O	O	499
redo	VERB	O	O	499
cardiac	ADJ	O	O	499
surgery	NOUN	O	O	499
,	PUNCT	O	O	499
calcification	NOUN	O	O	499
of	ADP	O	O	499
ascending	VERB	O	O	499
aorta	NOUN	O	O	499
,	PUNCT	O	O	499
congestive	ADJ	O	O	499
heart failure	NOUN	O	Disease	499
,	PUNCT	O	O	499
deep	ADJ	O	O	499
hypothermic	ADJ	O	Disease	499
circulatory	ADJ	O	O	499
arrest	VERB	O	O	499
,	PUNCT	O	O	499
duration	NOUN	O	O	499
of	ADP	O	O	499
aortic	ADJ	O	O	499
cross	VERB	O	O	499
-	PUNCT	O	O	499
clamp	VERB	O	O	499
and	CCONJ	O	O	499
tranexamic acid	PROPN	O	Chemical	499
.	PUNCT	O	O	499
When	SCONJ	O	O	500
tested	VERB	O	O	500
in	ADP	O	O	500
a	PRON	O	O	500
multivariate	ADJ	O	O	500
regression	NOUN	O	O	500
analysis	NOUN	O	O	500
,	PUNCT	O	O	500
tranexamic acid	PROPN	O	Chemical	500
was	AUX	O	O	500
a	PRON	O	O	500
strong	ADJ	O	O	500
independent	ADJ	O	O	500
predictor	NOUN	O	O	500
of	ADP	O	O	500
seizures	NOUN	O	Disease	500
(	PUNCT	O	O	500
OR	CCONJ	O	O	500
14.3	NUM	O	O	500
,	PUNCT	O	O	500
95%	NOUN	O	O	500
Patients	NOUN	O	O	501
with	ADP	O	O	501
convulsive	ADJ	O	Disease	501
seizures	NOUN	O	Disease	501
had	VERB	O	O	501
2.5	NUM	O	O	501
times	NOUN	O	O	501
higher	ADJ	O	O	501
in	ADP	O	O	501
-	PUNCT	O	O	501
hospital	PROPN	O	O	501
mortality	NOUN	O	O	501
rates	NOUN	O	O	501
and	CCONJ	O	O	501
twice	ADV	O	O	501
the	PRON	O	O	501
length	NOUN	O	O	501
of	ADP	O	O	501
hospital	PROPN	O	O	501
stay	VERB	O	O	501
compared	VERB	O	O	501
with	ADP	O	O	501
patients	NOUN	O	O	501
without	ADP	O	O	501
convulsive	ADJ	O	Disease	501
seizures	NOUN	O	Disease	501
.	PUNCT	O	O	501
h	X	O	O	502
in	ADP	O	O	502
patients	NOUN	O	O	502
with	ADP	O	O	502
convulsive	ADJ	O	Disease	502
seizures	NOUN	O	Disease	502
compared	VERB	O	O	502
with	ADP	O	O	502
26	NUM	O	O	502
(	PUNCT	O	O	502
22	NUM	O	O	502
-	PUNCT	O	O	502
69	NUM	O	O	502
[	X	O	O	502
14	NUM	O	O	502
-	PUNCT	O	O	502
1080	NUM	O	O	502
]	PUNCT	O	O	502
)	PUNCT	O	O	502
h	X	O	O	503
in	ADP	O	O	503
patients	NOUN	O	O	503
without	ADP	O	O	503
seizures	NOUN	O	Disease	503
(	PUNCT	O	O	503
p	NOUN	O	O	503
<	X	O	O	503
0.001	NUM	O	O	503
)	PUNCT	O	O	503
.	PUNCT	O	O	503
Convulsive	ADJ	O	O	504
seizures	NOUN	O	Disease	504
are	AUX	O	O	504
a	PRON	O	O	504
serious	ADJ	O	O	504
postoperative	ADJ	O	O	504
complication	NOUN	O	O	504
after	ADP	O	O	504
cardiac	ADJ	O	O	504
surgery	NOUN	O	O	504
.	PUNCT	O	O	504
As	ADP	O	O	505
tranexamic acid	PROPN	O	Chemical	505
is	AUX	O	O	505
the	PRON	O	O	505
only	ADV	O	O	505
modifiable	ADJ	O	O	505
factor	NOUN	O	O	505
,	PUNCT	O	O	505
its	PRON	O	O	505
administration	NOUN	O	O	505
,	PUNCT	O	O	505
particularly	ADV	O	O	505
in	ADP	O	O	505
doses	NOUN	O	O	505
exceeding	VERB	O	O	505
80	NUM	O	O	505
mg.kg(-1	VERB	O	O	505
)	PUNCT	O	O	505
,	PUNCT	O	O	505
should	AUX	O	O	505
be	AUX	O	O	505
weighed	VERB	O	O	505
against	ADP	O	O	505
the	PRON	O	O	505
risk	NOUN	O	O	505
of	ADP	O	O	505
postoperative	ADJ	O	O	505
seizures	NOUN	O	Disease	505
.	PUNCT	O	O	505
Dysfunctional	ADJ	O	O	508
overnight	ADV	O	O	508
memory	NOUN	O	O	508
consolidation	NOUN	O	O	508
in	ADP	O	O	508
ecstasy	NOUN	O	Chemical	508
users	NOUN	O	O	508
.	PUNCT	O	O	508
Previous	ADJ	O	O	509
studies	NOUN	O	O	509
indicate	VERB	O	O	509
that	SCONJ	O	O	509
ecstasy	NOUN	O	Chemical	509
users	NOUN	O	O	509
have	VERB	O	O	509
marked	VERB	O	O	509
and	CCONJ	O	O	509
persistent	ADJ	O	O	509
neurocognitive	PROPN	O	O	509
and	CCONJ	O	O	509
sleep	VERB	O	O	509
-	PUNCT	O	O	509
related	ADJ	O	O	509
impairments	VERB	O	O	509
.	PUNCT	O	O	509
We	PRON	O	O	510
extend	VERB	O	O	510
past	ADP	O	O	510
research	NOUN	O	O	510
by	ADP	O	O	510
examining	VERB	O	O	510
overnight	ADV	O	O	510
memory	NOUN	O	O	510
consolidation	NOUN	O	O	510
among	ADP	O	O	510
regular	ADJ	O	O	510
ecstasy	NOUN	O	Chemical	510
users	NOUN	O	O	510
(	PUNCT	O	O	510
n=12	ADV	O	O	510
)	PUNCT	O	O	510
and	CCONJ	O	O	510
drug	NOUN	O	O	510
naive	ADJ	O	O	510
healthy	ADJ	O	O	510
controls	VERB	O	O	510
(	PUNCT	O	O	510
n=26	VERB	O	O	510
)	PUNCT	O	O	510
.	PUNCT	O	O	510
Ecstasy	NOUN	O	O	511
users	NOUN	O	O	511
demonstrated	VERB	O	O	511
impaired	VERB	O	O	511
overnight	ADV	O	O	511
memory	NOUN	O	O	511
consolidation	NOUN	O	O	511
,	PUNCT	O	O	511
a	PRON	O	O	511
finding	VERB	O	O	511
that	SCONJ	O	O	511
was	AUX	O	O	511
more	ADJ	O	O	511
pronounced	VERB	O	O	511
following	VERB	O	O	511
associative	ADJ	O	O	511
interference	NOUN	O	O	511
.	PUNCT	O	O	511
Additionally	ADV	O	O	512
,	PUNCT	O	O	512
ecstasy	NOUN	O	Chemical	512
users	NOUN	O	O	512
demonstrated	VERB	O	O	512
impairments	VERB	O	O	512
on	ADP	O	O	512
tasks	NOUN	O	O	512
recruiting	VERB	O	O	512
frontostriatal	NOUN	O	O	512
and	CCONJ	O	O	512
hippocampal	NOUN	O	O	512
neural	NOUN	O	O	512
circuitry	NOUN	O	O	512
,	PUNCT	O	O	512
in	ADP	O	O	512
the	PRON	O	O	512
domains	NOUN	O	O	512
of	ADP	O	O	512
proactive	PROPN	O	O	512
interference	NOUN	O	O	512
memory	NOUN	O	O	512
,	PUNCT	O	O	512
long	ADV	O	O	512
-	PUNCT	O	O	512
term	NOUN	O	O	512
memory	NOUN	O	O	512
,	PUNCT	O	O	512
encoding	VERB	O	O	512
,	PUNCT	O	O	512
working	VERB	O	O	512
memory	NOUN	O	O	512
and	CCONJ	O	O	512
complex	ADJ	O	O	512
planning	VERB	O	O	512
.	PUNCT	O	O	512
We	PRON	O	O	513
suggest	VERB	O	O	513
that	SCONJ	O	O	513
ecstasy	NOUN	O	Chemical	513
-	PUNCT	O	O	513
associated	VERB	O	O	513
dysfunction	NOUN	O	O	513
in	ADP	O	O	513
fronto	NOUN	O	O	513
-	PUNCT	O	O	513
temporal	ADJ	O	O	513
circuitry	NOUN	O	O	513
may	AUX	O	O	513
underlie	VERB	O	O	513
overnight	ADV	O	O	513
consolidation	NOUN	O	O	513
memory impairments	NOUN	O	Disease	513
in	ADP	O	O	513
regular	ADJ	O	O	513
ecstasy	NOUN	O	Chemical	513
users	NOUN	O	O	513
.	PUNCT	O	O	513
Normoammonemic	PROPN	O	O	516
encephalopathy	NOUN	O	Disease	516
:	PUNCT	O	O	516
solely	ADV	O	O	516
valproate	VERB	O	Chemical	516
induced	VERB	O	O	516
or	CCONJ	O	O	516
multiple	ADJ	O	O	516
mechanisms	NOUN	O	O	516
?	PUNCT	O	O	516
A	PRON	O	O	517
77-year	NOUN	O	O	517
-	PUNCT	O	O	517
old	ADJ	O	O	517
woman	NOUN	O	O	517
presented	VERB	O	O	517
with	ADP	O	O	517
subacute	VERB	O	O	517
onset	VERB	O	O	517
progressive	ADJ	O	O	517
confusion	NOUN	O	Disease	517
,	PUNCT	O	O	517
aggression	NOUN	O	Disease	517
,	PUNCT	O	O	517
auditory	NOUN	O	O	517
hallucinations	NOUN	O	Disease	517
and	CCONJ	O	O	517
delusions	NOUN	O	O	517
.	PUNCT	O	O	517
In	ADP	O	O	518
the	PRON	O	O	518
preceding	VERB	O	O	518
months	NOUN	O	O	518
,	PUNCT	O	O	518
the	PRON	O	O	518
patient	NOUN	O	O	518
had	VERB	O	O	518
a	PRON	O	O	518
number	NOUN	O	O	518
of	ADP	O	O	518
admissions	NOUN	O	O	518
with	ADP	O	O	518
transient	ADJ	O	O	518
unilateral	ADJ	O	O	518
hemiparesis	PROPN	O	Disease	518
with	ADP	O	O	518
facial	ADJ	O	O	518
droop	NOUN	O	O	518
,	PUNCT	O	O	518
and	CCONJ	O	O	518
had	VERB	O	O	518
been	AUX	O	O	518
started	VERB	O	O	518
on	ADP	O	O	518
valproate	VERB	O	Chemical	518
for	ADP	O	O	518
presumed	VERB	O	O	518
hemiplegic	ADJ	O	O	518
migraine	NOUN	O	Disease	518
.	PUNCT	O	O	518
Valproate	VERB	O	Chemical	519
was	AUX	O	O	519
withdrawn	VERB	O	O	519
soon	ADV	O	O	519
after	ADP	O	O	519
admission	NOUN	O	O	519
and	CCONJ	O	O	519
her	PRON	O	O	519
cognitive	ADJ	O	O	519
abilities	NOUN	O	O	519
have	VERB	O	O	519
gradually	ADV	O	O	519
improved	VERB	O	O	519
over	ADP	O	O	519
3	X	O	O	519
months	NOUN	O	O	519
of	ADP	O	O	519
follow	VERB	O	O	519
-	PUNCT	O	O	519
up	ADP	O	O	519
.	PUNCT	O	O	519
Valproate	VERB	O	Chemical	520
levels	NOUN	O	O	520
taken	VERB	O	O	520
prior	ADV	O	O	520
to	PART	O	O	520
withdrawal	NOUN	O	O	520
were	AUX	O	O	520
subtherapeutic	ADJ	O	O	520
and	CCONJ	O	O	520
the	PRON	O	O	520
patient	NOUN	O	O	520
was	AUX	O	O	520
normoammonaemic	PROPN	O	O	520
.	PUNCT	O	O	520
EEG	NOUN	O	O	521
undertaken	VERB	O	O	521
during	ADP	O	O	521
inpatient	ADJ	O	O	521
stay	VERB	O	O	521
showed	VERB	O	O	521
changes	VERB	O	O	521
consistent	ADJ	O	O	521
with	ADP	O	O	521
encephalopathy	NOUN	O	Disease	521
,	PUNCT	O	O	521
and	CCONJ	O	O	521
low	ADJ	O	O	521
titre	PROPN	O	O	521
N	NUM	O	O	522
-	PUNCT	O	O	522
methyl	NOUN	O	O	522
-	PUNCT	O	O	522
D	NOUN	O	O	522
-	PUNCT	O	O	522
aspartate	NOUN	O	Chemical	522
(	PUNCT	O	O	522
NMDA	PROPN	O	Chemical	522
)	PUNCT	O	O	522
receptor	NOUN	O	O	522
antibodies	NOUN	O	O	522
were	AUX	O	O	522
present	NOUN	O	O	522
in	ADP	O	O	522
this	PRON	O	O	522
patient	NOUN	O	O	522
.	PUNCT	O	O	522
The	PRON	O	O	523
possible	ADJ	O	O	523
aetiologies	NOUN	O	O	523
of	ADP	O	O	523
valproate	VERB	O	Chemical	523
-	PUNCT	O	O	523
induced	VERB	O	O	523
encephalopathy	NOUN	O	Disease	523
and	CCONJ	O	O	523
NMDA	PROPN	O	Chemical	523
receptor	NOUN	O	O	523
-	PUNCT	O	O	523
associated	VERB	O	O	523
encephalitis	NOUN	O	O	523
present	NOUN	O	O	523
a	PRON	O	O	523
diagnostic	ADJ	O	O	523
dilemma	NOUN	O	O	523
.	PUNCT	O	O	523
Cerebellar	ADJ	O	O	526
and	CCONJ	O	O	526
oculomotor	NOUN	O	O	526
dysfunction	NOUN	O	O	526
induced	VERB	O	O	526
by	ADP	O	O	526
rapid	ADJ	O	O	526
infusion	NOUN	O	O	526
of	ADP	O	O	526
pethidine	NOUN	O	O	526
.	PUNCT	O	O	526
Pethidine	NOUN	O	O	527
is	AUX	O	O	527
an	PRON	O	O	527
opioid	NOUN	O	O	527
that	SCONJ	O	O	527
gains	VERB	O	O	527
its	PRON	O	O	527
popularity	NOUN	O	O	527
for	ADP	O	O	527
the	PRON	O	O	527
effective	ADJ	O	O	527
pain	NOUN	O	Disease	527
control	VERB	O	O	527
through	ADP	O	O	527
acting	VERB	O	O	527
on	ADP	O	O	527
the	PRON	O	O	527
opioid	NOUN	O	O	527
-	PUNCT	O	O	527
receptors	NOUN	O	O	527
.	PUNCT	O	O	527
However	ADV	O	O	528
,	PUNCT	O	O	528
rapid	ADJ	O	O	528
pain	NOUN	O	Disease	528
relief	NOUN	O	O	528
sometimes	ADV	O	O	528
brings	VERB	O	O	528
about	ADP	O	O	528
unfavourable	ADJ	O	O	528
side	NOUN	O	O	528
effects	NOUN	O	O	528
that	SCONJ	O	O	528
largely	ADV	O	O	528
limit	NOUN	O	O	528
its	PRON	O	O	528
clinical	ADJ	O	O	528
utility	NOUN	O	O	528
.	PUNCT	O	O	528
Common	ADJ	O	O	529
side	NOUN	O	O	529
effects	NOUN	O	O	529
include	VERB	O	O	529
nausea	NOUN	O	Disease	529
,	PUNCT	O	O	529
vomiting	VERB	O	Disease	529
and	CCONJ	O	O	529
hypotension	NOUN	O	Disease	529
.	PUNCT	O	O	529
In	ADP	O	O	530
patients	NOUN	O	O	530
with	ADP	O	O	530
impaired	VERB	O	O	530
renal	ADJ	O	O	530
and	CCONJ	O	O	530
liver	NOUN	O	O	530
function	NOUN	O	O	530
,	PUNCT	O	O	530
and	CCONJ	O	O	530
those	PRON	O	O	530
who	PRON	O	O	530
need	VERB	O	O	530
long	ADV	O	O	530
-	PUNCT	O	O	530
term	NOUN	O	O	530
pain	NOUN	O	Disease	530
control	VERB	O	O	530
,	PUNCT	O	O	530
pethidine	NOUN	O	O	530
may	AUX	O	O	530
cause	VERB	O	O	530
excitatory	ADJ	O	O	530
central	ADJ	O	O	530
nervous	ADJ	O	O	530
system	NOUN	O	O	530
(	PUNCT	O	O	530
CNS	PROPN	O	O	530
)	PUNCT	O	O	530
effects	NOUN	O	O	530
through	ADP	O	O	530
its	PRON	O	O	530
neurotoxic	ADJ	O	Disease	530
metabolite	NOUN	O	O	530
,	PUNCT	O	O	530
norpethidine	NOUN	O	O	530
,	PUNCT	O	O	530
resulting	VERB	O	O	530
in	ADP	O	O	530
irritability	NOUN	O	Disease	530
and	CCONJ	O	O	530
seizure	NOUN	O	Disease	530
attack	VERB	O	O	530
.	PUNCT	O	O	530
On	ADP	O	O	531
the	PRON	O	O	531
contrary	ADV	O	O	531
,	PUNCT	O	O	531
though	SCONJ	O	O	531
not	PART	O	O	531
clinically	ADV	O	O	531
apparent	ADJ	O	O	531
,	PUNCT	O	O	531
pethidine	NOUN	O	O	531
potentially	ADV	O	O	531
causes	VERB	O	O	531
inhibitory	ADJ	O	O	531
impacts	NOUN	O	O	531
on	ADP	O	O	531
the	PRON	O	O	531
CNS	PROPN	O	O	531
and	CCONJ	O	O	531
impairs	VERB	O	O	531
normal	ADJ	O	O	531
cerebellar	ADJ	O	O	531
and	CCONJ	O	O	531
oculomotor	NOUN	O	O	531
function	NOUN	O	O	531
in	ADP	O	O	531
the	PRON	O	O	531
short	ADJ	O	O	531
term	NOUN	O	O	531
.	PUNCT	O	O	531
In	ADP	O	O	532
this	PRON	O	O	532
case	NOUN	O	O	532
report	VERB	O	O	532
,	PUNCT	O	O	532
we	PRON	O	O	532
highlight	VERB	O	O	532
opioid	NOUN	O	O	532
's	AUX	O	O	532
inhibitory	ADJ	O	O	532
side	NOUN	O	O	532
effects	NOUN	O	O	532
on	ADP	O	O	532
the	PRON	O	O	532
cerebellar	ADJ	O	O	532
structure	NOUN	O	O	532
that	SCONJ	O	O	532
causes	VERB	O	O	532
dysmetria	PROPN	O	O	532
,	PUNCT	O	O	532
dysarthria	NOUN	O	O	532
,	PUNCT	O	O	532
reduced	VERB	O	O	532
smooth	VERB	O	O	532
pursuit	NOUN	O	O	532
gain	VERB	O	O	532
and	CCONJ	O	O	532
decreased	VERB	O	O	532
saccadic	ADJ	O	O	532
velocity	NOUN	O	O	532
.	PUNCT	O	O	532
Baboon	PROPN	O	O	535
syndrome	NOUN	O	O	535
induced	VERB	O	O	535
by	ADP	O	O	535
ketoconazole	PROPN	O	Chemical	535
.	PUNCT	O	O	535
A	PRON	O	O	536
27-year	NOUN	O	O	536
-	PUNCT	O	O	536
old	ADJ	O	O	536
male	NOUN	O	O	536
patient	NOUN	O	O	536
presented	VERB	O	O	536
with	ADP	O	O	536
a	PRON	O	O	536
maculopapular	ADJ	O	O	536
eruption	NOUN	O	O	536
on	ADP	O	O	536
the	PRON	O	O	536
flexural	ADV	O	O	536
areas	NOUN	O	O	536
and	CCONJ	O	O	536
buttocks	NOUN	O	O	536
after	ADP	O	O	536
using	VERB	O	O	536
oral	ADJ	O	O	536
ketoconazole	PROPN	O	Chemical	536
.	PUNCT	O	O	536
The	PRON	O	O	537
patient	NOUN	O	O	537
was	AUX	O	O	537
diagnosed	VERB	O	O	537
with	ADP	O	O	537
drug	NOUN	O	O	537
-	PUNCT	O	O	537
induced	VERB	O	O	537
baboon	NOUN	O	O	537
syndrome	NOUN	O	O	537
based	VERB	O	O	537
on	ADP	O	O	537
his	PRON	O	O	537
history	NOUN	O	O	537
,	PUNCT	O	O	537
which	PRON	O	O	537
included	VERB	O	O	537
prior	ADV	O	O	537
sensitivity	NOUN	O	O	537
to	PART	O	O	537
topical	ADJ	O	O	537
ketoconazole	PROPN	O	Chemical	537
,	PUNCT	O	O	537
a	PRON	O	O	537
physical	ADJ	O	O	537
examination	NOUN	O	O	537
,	PUNCT	O	O	537
and	CCONJ	O	O	537
histopathological	ADJ	O	O	537
findings	NOUN	O	O	537
.	PUNCT	O	O	537
Baboon	PROPN	O	O	538
syndrome	NOUN	O	O	538
is	AUX	O	O	538
a	PRON	O	O	538
drug-	PROPN	O	O	538
or	CCONJ	O	O	538
contact	NOUN	O	O	538
allergen	NOUN	O	O	538
-	PUNCT	O	O	538
related	ADJ	O	O	538
maculopapular	ADJ	O	O	538
eruption	NOUN	O	O	538
that	SCONJ	O	O	538
typically	ADV	O	O	538
involves	VERB	O	O	538
the	PRON	O	O	538
flexural	ADV	O	O	538
and	CCONJ	O	O	538
gluteal	PROPN	O	O	538
areas	NOUN	O	O	538
.	PUNCT	O	O	538
To	PART	O	O	539
the	PRON	O	O	539
best	ADV	O	O	539
of	ADP	O	O	539
our	PRON	O	O	539
knowledge	NOUN	O	O	539
,	PUNCT	O	O	539
this	PRON	O	O	539
is	AUX	O	O	539
the	PRON	O	O	539
first	ADV	O	O	539
reported	VERB	O	O	539
case	NOUN	O	O	539
of	ADP	O	O	539
ketoconazole	PROPN	O	Chemical	539
-	PUNCT	O	O	539
induced	VERB	O	O	539
baboon	NOUN	O	O	539
syndrome	NOUN	O	O	539
in	ADP	O	O	539
the	PRON	O	O	539
English	PROPN	O	O	539
literature	NOUN	O	O	539
.	PUNCT	O	O	539
A	PRON	O	O	542
Case	NOUN	O	O	542
of	ADP	O	O	542
Sudden	PROPN	O	O	542
Cardiac	ADJ	O	O	542
Death	NOUN	O	O	542
due	ADJ	O	O	542
to	PART	O	O	542
Pilsicainide	NOUN	O	O	542
-	PUNCT	O	O	542
Induced	VERB	O	O	542
Torsades	NOUN	O	O	542
de	VERB	O	O	542
Pointes	NOUN	O	O	542
.	PUNCT	O	O	542
An	PRON	O	O	543
84-year	NOUN	O	O	543
-	PUNCT	O	O	543
old	ADJ	O	O	543
male	NOUN	O	O	543
received	VERB	O	O	543
oral	ADJ	O	O	543
pilsicainide	ADJ	O	O	543
,	PUNCT	O	O	543
a	PRON	O	O	543
pure	ADJ	O	O	543
sodium	NOUN	O	Chemical	543
channel	PROPN	O	O	543
blocker	NOUN	O	O	543
with	ADP	O	O	543
slow	VERB	O	O	543
recovery	NOUN	O	O	543
kinetics	NOUN	O	O	543
,	PUNCT	O	O	543
to	PART	O	O	543
convert	VERB	O	O	543
his	PRON	O	O	543
paroxysmal	ADJ	O	O	543
atrial fibrillation	NOUN	O	Disease	543
to	PART	O	O	543
a	PRON	O	O	543
sinus	NOUN	O	O	543
rhythm	VERB	O	O	543
;	PUNCT	O	O	543
the	PRON	O	O	543
patient	NOUN	O	O	543
developed	VERB	O	O	543
sudden cardiac death	NOUN	O	Disease	543
two	NUM	O	O	543
days	NOUN	O	O	543
later	ADV	O	O	543
.	PUNCT	O	O	543
The	PRON	O	O	544
Holter	PROPN	O	O	544
electrocardiogram	PROPN	O	O	544
,	PUNCT	O	O	544
which	PRON	O	O	544
was	AUX	O	O	544
worn	VERB	O	O	544
by	ADP	O	O	544
chance	NOUN	O	O	544
,	PUNCT	O	O	544
revealed	VERB	O	O	544
torsade de pointes	NOUN	O	Disease	544
with	ADP	O	O	544
gradually	ADV	O	O	544
prolonged	VERB	O	O	544
QT	NOUN	O	O	544
intervals	NOUN	O	O	544
.	PUNCT	O	O	544
Although	SCONJ	O	O	545
the	PRON	O	O	545
patient	NOUN	O	O	545
's	AUX	O	O	545
renal	ADJ	O	O	545
function	NOUN	O	O	545
was	AUX	O	O	545
not	PART	O	O	545
highly	ADV	O	O	545
impaired	VERB	O	O	545
and	CCONJ	O	O	545
the	PRON	O	O	545
dose	NOUN	O	O	545
of	ADP	O	O	545
pilsicainide	ADJ	O	O	545
was	AUX	O	O	545
low	ADJ	O	O	545
,	PUNCT	O	O	545
the	PRON	O	O	545
plasma	NOUN	O	O	545
concentration	NOUN	O	O	545
of	ADP	O	O	545
pilsicainide	ADJ	O	O	545
may	AUX	O	O	545
have	VERB	O	O	545
been	AUX	O	O	545
high	ADJ	O	O	545
,	PUNCT	O	O	545
which	PRON	O	O	545
can	AUX	O	O	545
produce	VERB	O	O	545
torsades de pointes	NOUN	O	Disease	545
in	ADP	O	O	545
the	PRON	O	O	545
octogenarian	NOUN	O	O	545
.	PUNCT	O	O	545
Although	SCONJ	O	O	546
the	PRON	O	O	546
oral	ADJ	O	O	546
administration	NOUN	O	O	546
of	ADP	O	O	546
class	NOUN	O	O	546
IC	PROPN	O	O	546
drugs	NOUN	O	O	546
,	PUNCT	O	O	546
including	VERB	O	O	546
pilsicainide	ADJ	O	O	546
,	PUNCT	O	O	546
is	AUX	O	O	546
effective	ADJ	O	O	546
to	PART	O	O	546
terminate	VERB	O	O	546
atrial fibrillation	NOUN	O	Disease	546
,	PUNCT	O	O	546
careful	ADJ	O	O	546
consideration	NOUN	O	O	546
must	AUX	O	O	546
be	AUX	O	O	546
taken	VERB	O	O	546
before	ADP	O	O	546
giving	VERB	O	O	546
these	PRON	O	O	546
drugs	NOUN	O	O	546
to	PART	O	O	546
octogenarians	NOUN	O	O	546
.	PUNCT	O	O	546
All	PRON	O	O	549
-	PUNCT	O	O	549
trans	PROPN	O	O	549
retinoic	NOUN	O	O	549
acid	PROPN	O	O	549
-	PUNCT	O	O	549
induced	VERB	O	O	549
inflammatory	ADJ	O	O	549
myositis	PROPN	O	Disease	549
in	ADP	O	O	549
a	PRON	O	O	549
patient	NOUN	O	O	549
with	ADP	O	O	549
acute promyelocytic leukemia	NOUN	O	Disease	549
.	PUNCT	O	O	549
All	PRON	O	O	550
-	PUNCT	O	O	550
trans	PROPN	O	O	550
retinoic	NOUN	O	O	550
acid	PROPN	O	O	550
(	PUNCT	O	O	550
ATRA	NOUN	O	Chemical	550
)	PUNCT	O	O	550
,	PUNCT	O	O	550
a	PRON	O	O	550
component	NOUN	O	O	550
of	ADP	O	O	550
standard	PROPN	O	O	550
therapy	NOUN	O	O	550
for	ADP	O	O	550
acute promyelocytic leukemia	NOUN	O	Disease	550
(	PUNCT	O	O	550
APL	PROPN	O	Disease	550
)	PUNCT	O	O	550
,	PUNCT	O	O	550
is	AUX	O	O	550
associated	VERB	O	O	550
with	ADP	O	O	550
potentially	ADV	O	O	550
serious	ADJ	O	O	550
but	CCONJ	O	O	550
treatable	ADJ	O	O	550
adverse	ADJ	O	O	550
effects	NOUN	O	O	550
involving	VERB	O	O	550
numerous	ADJ	O	O	550
organ	NOUN	O	O	550
systems	NOUN	O	O	550
,	PUNCT	O	O	550
including	VERB	O	O	550
rare	ADJ	O	O	550
skeletal	ADJ	O	O	550
muscle	NOUN	O	O	550
involvement	NOUN	O	O	550
.	PUNCT	O	O	550
Only	ADV	O	O	551
a	PRON	O	O	551
handful	NOUN	O	O	551
of	ADP	O	O	551
cases	NOUN	O	O	551
of	ADP	O	O	551
ATRA	NOUN	O	Chemical	551
-	PUNCT	O	O	551
induced	VERB	O	O	551
myositis	PROPN	O	Disease	551
in	ADP	O	O	551
children	NOUN	O	O	551
have	VERB	O	O	551
been	AUX	O	O	551
reported	VERB	O	O	551
,	PUNCT	O	O	551
and	CCONJ	O	O	551
none	NOUN	O	O	551
in	ADP	O	O	551
the	PRON	O	O	551
radiology	NOUN	O	O	551
literature	NOUN	O	O	551
.	PUNCT	O	O	551
We	PRON	O	O	552
present	NOUN	O	O	552
such	ADJ	O	O	552
a	PRON	O	O	552
case	NOUN	O	O	552
in	ADP	O	O	552
a	PRON	O	O	552
15-year	NOUN	O	O	552
-	PUNCT	O	O	552
old	ADJ	O	O	552
boy	NOUN	O	O	552
with	ADP	O	O	552
APL	PROPN	O	Disease	552
,	PUNCT	O	O	552
where	SCONJ	O	O	552
recognition	NOUN	O	O	552
of	ADP	O	O	552
imaging	VERB	O	O	552
findings	NOUN	O	O	552
played	VERB	O	O	552
a	PRON	O	O	552
crucial	ADJ	O	O	552
role	NOUN	O	O	552
in	ADP	O	O	552
making	VERB	O	O	552
the	PRON	O	O	552
diagnosis	NOUN	O	O	552
and	CCONJ	O	O	552
facilitated	VERB	O	O	552
prompt	PROPN	O	O	552
,	PUNCT	O	O	552
effective	ADJ	O	O	552
treatment	NOUN	O	O	552
.	PUNCT	O	O	552
Tolerability	NOUN	O	O	555
of	ADP	O	O	555
lomustine	PROPN	O	Chemical	555
in	ADP	O	O	555
combination	NOUN	O	O	555
with	ADP	O	O	555
cyclophosphamide	VERB	O	Chemical	555
in	ADP	O	O	555
dogs	NOUN	O	O	555
with	ADP	O	O	555
lymphoma	PROPN	O	Disease	555
.	PUNCT	O	O	555
This	PRON	O	O	556
retrospective	ADJ	O	O	556
study	VERB	O	O	556
describes	VERB	O	O	556
toxicity	NOUN	O	Disease	556
associated	VERB	O	O	556
with	ADP	O	O	556
a	PRON	O	O	556
protocol	PROPN	O	O	556
of	ADP	O	O	556
lomustine	PROPN	O	Chemical	556
(	PUNCT	O	O	556
CCNU	NOUN	O	Chemical	556
)	PUNCT	O	O	556
and	CCONJ	O	O	556
cyclophosphamide	VERB	O	Chemical	556
(	PUNCT	O	O	556
CTX	PROPN	O	O	556
)	PUNCT	O	O	556
in	ADP	O	O	556
dogs	NOUN	O	O	556
with	ADP	O	O	556
lymphoma	PROPN	O	Disease	556
.	PUNCT	O	O	556
CCNU	NOUN	O	Chemical	557
was	AUX	O	O	557
administered	VERB	O	O	557
per	ADP	O	O	557
os	INTJ	O	O	557
(	PUNCT	O	O	557
PO	NOUN	O	O	557
)	PUNCT	O	O	557
at	ADP	O	O	557
a	PRON	O	O	557
targeted	VERB	O	O	557
dosage	NOUN	O	O	557
of	ADP	O	O	557
60	NUM	O	O	557
mg	VERB	O	O	557
/	PUNCT	O	O	557
m(2	NUM	O	O	557
)	PUNCT	O	O	557
body	NOUN	O	O	557
surface	NOUN	O	O	557
area	NOUN	O	O	557
on	ADP	O	O	557
day	NOUN	O	O	557
0	NUM	O	O	557
,	PUNCT	O	O	557
CTX	PROPN	O	O	557
was	AUX	O	O	557
administered	VERB	O	O	557
PO	NOUN	O	O	557
at	ADP	O	O	557
a	PRON	O	O	557
targeted	VERB	O	O	557
dosage	NOUN	O	O	557
of	ADP	O	O	557
250	NUM	O	O	557
mg	VERB	O	O	557
/	PUNCT	O	O	557
m(2	NUM	O	O	557
)	PUNCT	O	O	557
divided	VERB	O	O	557
over	ADP	O	O	557
days	NOUN	O	O	557
0	NUM	O	O	557
through	ADP	O	O	557
4	NUM	O	O	557
,	PUNCT	O	O	557
and	CCONJ	O	O	557
all	PRON	O	O	557
dogs	NOUN	O	O	557
received	VERB	O	O	557
prophylactic	ADJ	O	O	557
antibiotics	VERB	O	O	557
.	PUNCT	O	O	557
Neutropenia	NOUN	O	O	558
was	AUX	O	O	558
the	PRON	O	O	558
principal	NOUN	O	O	558
toxic	ADJ	O	O	558
effect	VERB	O	O	558
,	PUNCT	O	O	558
and	CCONJ	O	O	558
the	PRON	O	O	558
overall	ADV	O	O	558
frequency	NOUN	O	O	558
of	ADP	O	O	558
grade	NOUN	O	O	558
4	NUM	O	O	558
neutropenia	ADJ	O	Disease	558
after	ADP	O	O	558
the	PRON	O	O	558
first	ADV	O	O	558
treatment	NOUN	O	O	558
of	ADP	O	O	558
CCNU	NOUN	O	Chemical	558
/	PUNCT	O	O	558
CTX	PROPN	O	O	558
was	AUX	O	O	558
30%	NOUN	O	O	558
(	PUNCT	O	O	558
95%	NOUN	O	O	558
confidence	NOUN	O	O	558
interval	NOUN	O	O	558
,	PUNCT	O	O	558
19	NUM	O	O	558
-	PUNCT	O	O	558
43%	NOUN	O	O	558
)	PUNCT	O	O	558
.	PUNCT	O	O	558
The	PRON	O	O	559
mean	VERB	O	O	559
body	NOUN	O	O	559
weight	NOUN	O	O	559
of	ADP	O	O	559
dogs	NOUN	O	O	559
with	ADP	O	O	559
grade	NOUN	O	O	559
4	NUM	O	O	559
neutropenia	ADJ	O	Disease	559
(	PUNCT	O	O	559
19.7	NUM	O	O	559
kg	VERB	O	O	559
+	ADP	O	O	559
13.4	NUM	O	O	559
kg	VERB	O	O	559
)	PUNCT	O	O	559
was	AUX	O	O	559
significantly	ADV	O	O	559
less	ADV	O	O	559
than	ADP	O	O	559
the	PRON	O	O	559
mean	VERB	O	O	559
body	NOUN	O	O	559
weight	NOUN	O	O	559
of	ADP	O	O	559
dogs	NOUN	O	O	559
that	SCONJ	O	O	559
did	VERB	O	O	559
not	PART	O	O	559
develop	VERB	O	O	559
grade	NOUN	O	O	559
4	NUM	O	O	559
neutropenia	ADJ	O	Disease	559
(	PUNCT	O	O	559
31.7	NUM	O	O	559
kg	VERB	O	O	559
+	ADP	O	O	559
12.4	NUM	O	O	559
kg	VERB	O	O	559
;	PUNCT	O	O	559
P	NOUN	O	Chemical	559
=	PUNCT	O	O	559
.005	NUM	O	O	559
)	PUNCT	O	O	559
.	PUNCT	O	O	559
One	NUM	O	O	560
dog	NOUN	O	O	560
(	PUNCT	O	O	560
3%	NOUN	O	O	560
)	PUNCT	O	O	560
developed	VERB	O	O	560
hematologic	ADJ	O	O	560
changes	VERB	O	O	560
suggestive	ADJ	O	O	560
of	ADP	O	O	560
hepatotoxicity	NOUN	O	Disease	560
.	PUNCT	O	O	560
No	PRON	O	O	561
dogs	NOUN	O	O	561
had	VERB	O	O	561
evidence	NOUN	O	O	561
of	ADP	O	O	561
either	ADV	O	O	561
renal toxicity	NOUN	O	Disease	561
or	CCONJ	O	O	561
hemorrhagic cystitis	NOUN	O	Disease	561
.	PUNCT	O	O	561
On	ADP	O	O	562
the	PRON	O	O	562
basis	NOUN	O	O	562
of	ADP	O	O	562
the	PRON	O	O	562
findings	NOUN	O	O	562
reported	VERB	O	O	562
herein	VERB	O	O	562
,	PUNCT	O	O	562
a	PRON	O	O	562
dose	NOUN	O	O	562
of	ADP	O	O	562
60	NUM	O	O	562
mg	VERB	O	O	562
/	PUNCT	O	O	562
m(2	NUM	O	O	562
)	PUNCT	O	O	562
of	ADP	O	O	562
CCNU	NOUN	O	Chemical	562
combined	VERB	O	O	562
with	ADP	O	O	562
250	NUM	O	O	562
mg	VERB	O	O	562
/	PUNCT	O	O	562
m(2	NUM	O	O	562
)	PUNCT	O	O	562
of	ADP	O	O	562
CTX	PROPN	O	O	562
(	PUNCT	O	O	562
divided	VERB	O	O	562
over	ADP	O	O	562
5	NUM	O	O	562
days	NOUN	O	O	562
)	PUNCT	O	O	562
4	NUM	O	O	563
wk	X	O	O	563
is	AUX	O	O	563
tolerable	ADJ	O	O	563
in	ADP	O	O	563
tumor	NOUN	O	Disease	563
-	PUNCT	O	O	563
bearing	VERB	O	O	563
dogs	NOUN	O	O	563
.	PUNCT	O	O	563
Nelarabine	NOUN	O	O	566
neurotoxicity	NOUN	O	Disease	566
with	ADP	O	O	566
concurrent	ADJ	O	O	566
intrathecal	ADJ	O	O	566
chemotherapy	NOUN	O	O	566
:	PUNCT	O	O	566
Severe	ADJ	O	O	567
nelarabine	NOUN	O	O	567
neurotoxicity	NOUN	O	Disease	567
in	ADP	O	O	567
a	PRON	O	O	567
patient	NOUN	O	O	567
who	PRON	O	O	567
received	VERB	O	O	567
concurrent	ADJ	O	O	567
intrathecal	ADJ	O	O	567
A	PRON	O	O	568
37-year	NOUN	O	O	568
-	PUNCT	O	O	568
old	ADJ	O	O	568
Caucasian	ADJ	O	O	568
woman	NOUN	O	O	568
with	ADP	O	O	568
a	PRON	O	O	568
history	NOUN	O	O	568
of	ADP	O	O	568
T	NOUN	O	Chemical	568
-	PUNCT	O	O	568
cell	NOUN	O	O	568
lymphoblastic	NOUN	O	O	568
lymphoma	PROPN	O	Disease	568
was	AUX	O	O	568
admitted	VERB	O	O	568
for	ADP	O	O	568
relapsed	VERB	O	O	568
disease	PROPN	O	O	568
.	PUNCT	O	O	568
She	PRON	O	O	569
developed	VERB	O	O	569
relapsed	VERB	O	O	569
disease	PROPN	O	O	569
10	NUM	O	O	569
months	NOUN	O	O	569
later	ADV	O	O	569
with	ADP	O	O	569
leukemic	ADJ	O	O	569
involvement	NOUN	O	O	569
.	PUNCT	O	O	569
She	PRON	O	O	570
was	AUX	O	O	570
re	ADP	O	O	570
-	PUNCT	O	O	570
induced	VERB	O	O	570
with	ADP	O	O	570
nelarabine	NOUN	O	O	570
1500	NUM	O	O	570
mg	VERB	O	O	570
/	PUNCT	O	O	570
m(2	NUM	O	O	570
)	PUNCT	O	O	570
on	ADP	O	O	570
days	NOUN	O	O	570
1	X	O	O	570
,	PUNCT	O	O	570
3	X	O	O	570
,	PUNCT	O	O	570
and	CCONJ	O	O	570
5	NUM	O	O	570
with	ADP	O	O	570
1	X	O	O	570
dose	NOUN	O	O	570
of	ADP	O	O	570
IT	PRON	O	O	570
cytarabine	NOUN	O	O	570
100	NUM	O	O	570
mg	VERB	O	O	570
on	ADP	O	O	570
day	NOUN	O	O	570
2	X	O	O	570
as	ADP	O	O	570
central	ADJ	O	O	570
nervous	ADJ	O	O	570
system	NOUN	O	O	570
(	PUNCT	O	O	570
CNS	PROPN	O	O	570
)	PUNCT	O	O	570
prophylaxis	NOUN	O	O	570
.	PUNCT	O	O	570
At	ADP	O	O	571
the	PRON	O	O	571
time	NOUN	O	O	571
of	ADP	O	O	571
treatment	NOUN	O	O	571
,	PUNCT	O	O	571
she	PRON	O	O	571
was	AUX	O	O	571
on	ADP	O	O	571
continuous	ADJ	O	O	571
renal	ADJ	O	O	571
replacement	NOUN	O	O	571
therapy	NOUN	O	O	571
due	ADJ	O	O	571
to	PART	O	O	571
sequelae	ADJ	O	O	571
of	ADP	O	O	571
tumor	NOUN	O	Disease	571
lysis	NOUN	O	O	571
syndrome	NOUN	O	O	571
(	PUNCT	O	O	571
TLS	PROPN	O	O	571
)	PUNCT	O	O	571
.	PUNCT	O	O	571
She	PRON	O	O	572
received	VERB	O	O	572
a	PRON	O	O	572
second	ADV	O	O	572
cycle	PROPN	O	O	572
of	ADP	O	O	572
nelarabine	NOUN	O	O	572
without	ADP	O	O	572
additional	ADJ	O	O	572
IT	PRON	O	O	572
prophylaxis	NOUN	O	O	572
one	NUM	O	O	572
month	NOUN	O	O	572
later	ADV	O	O	572
.	PUNCT	O	O	572
Predominantly	ADV	O	O	573
sensory	ADJ	O	O	573
,	PUNCT	O	O	573
though	SCONJ	O	O	573
also	ADV	O	O	573
motor	NOUN	O	O	573
and	CCONJ	O	O	573
autonomic	ADJ	O	O	573
,	PUNCT	O	O	573
peripheral neuropathy	NOUN	O	Disease	573
started	VERB	O	O	573
in	ADP	O	O	573
her	PRON	O	O	573
feet	NOUN	O	O	573
,	PUNCT	O	O	573
ascended	VERB	O	O	573
proximally	ADV	O	O	573
to	PART	O	O	573
the	PRON	O	O	573
mid	PROPN	O	O	573
-	PUNCT	O	O	573
thoracic	ADJ	O	O	573
region	NOUN	O	O	573
,	PUNCT	O	O	573
and	CCONJ	O	O	573
eventually	ADV	O	O	573
included	VERB	O	O	573
her	PRON	O	O	573
distal	NOUN	O	O	573
upper	ADJ	O	O	573
extremities	NOUN	O	O	573
.	PUNCT	O	O	573
Nelarabine	NOUN	O	O	574
was	AUX	O	O	574
felt	VERB	O	O	574
to	PART	O	O	574
be	AUX	O	O	574
the	PRON	O	O	574
cause	VERB	O	O	574
of	ADP	O	O	574
her	PRON	O	O	574
symptoms	NOUN	O	O	574
.	PUNCT	O	O	574
Her	PRON	O	O	575
neuropathy	NOUN	O	Disease	575
stabilized	VERB	O	O	575
and	CCONJ	O	O	575
showed	VERB	O	O	575
slight	ADJ	O	O	575
improvement	NOUN	O	O	575
and	CCONJ	O	O	575
ultimately	ADV	O	O	575
received	VERB	O	O	575
an	PRON	O	O	575
unrelated	ADJ	O	O	575
,	PUNCT	O	O	575
reduced	VERB	O	O	575
-	PUNCT	O	O	575
intensity	NOUN	O	O	575
allogeneic	ADJ	O	O	575
transplant	NOUN	O	O	575
while	SCONJ	O	O	575
in	ADP	O	O	575
complete	VERB	O	O	575
remission	NOUN	O	O	575
,	PUNCT	O	O	575
but	CCONJ	O	O	575
relapsed	VERB	O	O	575
disease	PROPN	O	O	575
10	NUM	O	O	575
weeks	NOUN	O	O	575
later	ADV	O	O	575
.	PUNCT	O	O	575
To	PART	O	O	576
our	PRON	O	O	576
knowledge	NOUN	O	O	576
,	PUNCT	O	O	576
this	PRON	O	O	576
is	AUX	O	O	576
the	PRON	O	O	576
first	ADV	O	O	576
published	VERB	O	O	576
case	NOUN	O	O	576
report	VERB	O	O	576
of	ADP	O	O	576
severe	ADJ	O	O	576
neurotoxicity	NOUN	O	Disease	576
caused	VERB	O	O	576
by	ADP	O	O	576
nelarabine	NOUN	O	O	576
in	ADP	O	O	576
a	PRON	O	O	576
patient	NOUN	O	O	576
who	PRON	O	O	576
received	VERB	O	O	576
concurrent	ADJ	O	O	576
IT	PRON	O	O	576
chemotherapy	NOUN	O	O	576
.	PUNCT	O	O	576
Valproate	VERB	O	Chemical	579
-	PUNCT	O	O	579
induced	VERB	O	O	579
hyperammonemic	VERB	O	O	579
encephalopathy	NOUN	O	Disease	579
in	ADP	O	O	579
a	PRON	O	O	579
renal	ADJ	O	O	579
transplanted	VERB	O	O	579
patient	NOUN	O	O	579
.	PUNCT	O	O	579
Neurological	ADJ	O	O	580
complications	NOUN	O	O	580
after	ADP	O	O	580
renal	ADJ	O	O	580
transplantation	NOUN	O	O	580
constitute	VERB	O	O	580
an	PRON	O	O	580
important	ADJ	O	O	580
cause	VERB	O	O	580
of	ADP	O	O	580
morbidity	NOUN	O	O	580
and	CCONJ	O	O	580
mortality	NOUN	O	O	580
.	PUNCT	O	O	580
Valproate	VERB	O	Chemical	581
-	PUNCT	O	O	581
induced	VERB	O	O	581
hyperammonemic	VERB	O	O	581
encephalopathy	NOUN	O	Disease	581
is	AUX	O	O	581
an	PRON	O	O	581
uncommon	ADJ	O	O	581
but	CCONJ	O	O	581
serious	ADJ	O	O	581
effect	VERB	O	O	581
of	ADP	O	O	581
valproate	VERB	O	Chemical	581
treatment	NOUN	O	O	581
.	PUNCT	O	O	581
Here	ADV	O	O	582
,	PUNCT	O	O	582
we	PRON	O	O	582
describe	VERB	O	O	582
the	PRON	O	O	582
case	NOUN	O	O	582
of	ADP	O	O	582
a	PRON	O	O	582
15-year	NOUN	O	O	582
-	PUNCT	O	O	582
old	ADJ	O	O	582
girl	NOUN	O	O	582
who	PRON	O	O	582
was	AUX	O	O	582
on	ADP	O	O	582
a	PRON	O	O	582
long	ADV	O	O	582
-	PUNCT	O	O	582
term	NOUN	O	O	582
therapy	NOUN	O	O	582
with	ADP	O	O	582
valproate	VERB	O	Chemical	582
due	ADJ	O	O	582
to	PART	O	O	582
epilepsy	NOUN	O	Disease	582
and	CCONJ	O	O	582
revealed	VERB	O	O	582
impaired	VERB	O	O	582
consciousness	NOUN	O	O	582
with	ADP	O	O	582
hyperammonemia	PROPN	O	Disease	582
12	NUM	O	O	582
days	NOUN	O	O	582
after	ADP	O	O	582
renal	ADJ	O	O	582
transplantation	NOUN	O	O	582
.	PUNCT	O	O	582
After	ADP	O	O	583
withdraw	VERB	O	O	583
of	ADP	O	O	583
valproate	VERB	O	Chemical	583
,	PUNCT	O	O	583
patients	NOUN	O	O	583
'	PUNCT	O	O	583
symptoms	NOUN	O	O	583
resolved	VERB	O	O	583
within	ADP	O	O	583
24	NUM	O	O	583
h.	PROPN	O	O	583
Clinicians	NOUN	O	O	583
should	AUX	O	O	583
increase	VERB	O	O	583
their	PRON	O	O	583
awareness	NOUN	O	O	583
for	ADP	O	O	583
potential	ADJ	O	O	583
complication	NOUN	O	O	583
of	ADP	O	O	583
valproate	VERB	O	Chemical	583
,	PUNCT	O	O	583
especially	ADV	O	O	583
in	ADP	O	O	583
transplanted	VERB	O	O	583
patients	NOUN	O	O	583
.	PUNCT	O	O	583
Necrotising	NOUN	O	O	586
fasciitis	NOUN	O	O	586
after	ADP	O	O	586
bortezomib	VERB	O	Chemical	586
and	CCONJ	O	O	586
dexamethasone	NOUN	O	Chemical	586
-	PUNCT	O	O	586
containing	VERB	O	O	586
regimen	NOUN	O	O	586
in	ADP	O	O	586
an	PRON	O	O	586
elderly	ADJ	O	O	586
patient	NOUN	O	O	586
of	ADP	O	O	586
Waldenstrom	PROPN	O	O	586
macroglobulinaemia	VERB	O	O	586
.	PUNCT	O	O	586
Bortezomib	PROPN	O	O	587
and	CCONJ	O	O	587
high	ADJ	O	O	587
-	PUNCT	O	O	587
dose	NOUN	O	O	587
dexamethasone	NOUN	O	Chemical	587
-	PUNCT	O	O	587
containing	VERB	O	O	587
regimens	NOUN	O	O	587
are	AUX	O	O	587
considered	VERB	O	O	587
to	PART	O	O	587
be	AUX	O	O	587
generally	ADV	O	O	587
tolerable	ADJ	O	O	587
with	ADP	O	O	587
few	ADJ	O	O	587
severe	ADJ	O	O	587
bacterial infections	NOUN	O	Disease	587
in	ADP	O	O	587
patients	NOUN	O	O	587
with	ADP	O	O	587
B	NOUN	O	O	587
-	PUNCT	O	O	587
cell	NOUN	O	O	587
malignancies	NOUN	O	O	587
.	PUNCT	O	O	587
We	PRON	O	O	588
report	VERB	O	O	588
a	PRON	O	O	588
case	NOUN	O	O	588
of	ADP	O	O	588
a	PRON	O	O	588
76-year	NOUN	O	O	588
-	PUNCT	O	O	588
old	ADJ	O	O	588
man	NOUN	O	O	588
with	ADP	O	O	588
Waldenstrom	PROPN	O	O	588
macroglobulinaemia	VERB	O	O	588
who	PRON	O	O	588
suffered	VERB	O	O	588
necrotising	VERB	O	O	588
fasciitis	NOUN	O	O	588
without	ADP	O	O	588
neutropenia	ADJ	O	Disease	588
after	ADP	O	O	588
the	PRON	O	O	588
combination	NOUN	O	O	588
treatment	NOUN	O	O	588
with	ADP	O	O	588
bortezomib	VERB	O	Chemical	588
,	PUNCT	O	O	588
high	ADJ	O	O	588
-	PUNCT	O	O	588
dose	NOUN	O	O	588
dexamethasone	NOUN	O	Chemical	588
and	CCONJ	O	O	588
rituximab	VERB	O	O	588
.	PUNCT	O	O	588
Physicians	NOUN	O	O	589
should	AUX	O	O	589
recognise	VERB	O	O	589
the	PRON	O	O	589
possibility	NOUN	O	O	589
of	ADP	O	O	589
fatal	ADJ	O	O	589
bacterial infections	NOUN	O	Disease	589
related	ADJ	O	O	589
to	PART	O	O	589
bortezomib	VERB	O	Chemical	589
plus	CCONJ	O	O	589
high	ADJ	O	O	589
-	PUNCT	O	O	589
dose	NOUN	O	O	589
dexamethasone	NOUN	O	Chemical	589
in	ADP	O	O	589
elderly	ADJ	O	O	589
patients	NOUN	O	O	589
,	PUNCT	O	O	589
and	CCONJ	O	O	589
we	PRON	O	O	589
believe	VERB	O	O	589
this	PRON	O	O	589
case	NOUN	O	O	589
warrants	NOUN	O	O	589
further	ADV	O	O	589
investigation	NOUN	O	O	589
.	PUNCT	O	O	589
An	PRON	O	O	592
integrated	VERB	O	O	592
characterization	NOUN	O	O	592
of	ADP	O	O	592
serological	ADJ	O	O	592
,	PUNCT	O	O	592
pathological	ADJ	O	O	592
,	PUNCT	O	O	592
and	CCONJ	O	O	592
functional	ADJ	O	O	592
events	NOUN	O	O	592
in	ADP	O	O	592
doxorubicin	VERB	O	Chemical	592
-	PUNCT	O	O	592
induced	VERB	O	O	592
cardiotoxicity	NOUN	O	Disease	592
.	PUNCT	O	O	592
Many	ADJ	O	O	593
efficacious	ADJ	O	O	593
cancer	NOUN	O	Disease	593
treatments	NOUN	O	O	593
cause	VERB	O	O	593
significant	ADJ	O	O	593
cardiac	ADJ	O	O	593
morbidity	NOUN	O	O	593
,	PUNCT	O	O	593
yet	ADV	O	O	593
biomarkers	NOUN	O	O	593
or	CCONJ	O	O	593
functional	ADJ	O	O	593
indices	NOUN	O	O	593
of	ADP	O	O	593
early	ADV	O	O	593
damage	NOUN	O	O	593
,	PUNCT	O	O	593
which	PRON	O	O	593
would	AUX	O	O	593
allow	VERB	O	O	593
monitoring	NOUN	O	O	593
and	CCONJ	O	O	593
intervention	NOUN	O	O	593
,	PUNCT	O	O	593
are	AUX	O	O	593
lacking	VERB	O	O	593
.	PUNCT	O	O	593
In	ADP	O	O	594
this	PRON	O	O	594
study	VERB	O	O	594
,	PUNCT	O	O	594
we	PRON	O	O	594
have	VERB	O	O	594
utilized	VERB	O	O	594
a	PRON	O	O	594
rat	NOUN	O	O	594
model	NOUN	O	O	594
of	ADP	O	O	594
progressive	ADJ	O	O	594
doxorubicin	VERB	O	Chemical	594
(	PUNCT	O	O	594
DOX)-induced	PROPN	O	O	594
cardiomyopathy	ADJ	O	Disease	594
,	PUNCT	O	O	594
applying	VERB	O	O	594
multiple	ADJ	O	O	594
approaches	VERB	O	O	594
,	PUNCT	O	O	594
including	VERB	O	O	594
cardiac	ADJ	O	O	594
magnetic	ADJ	O	O	594
resonance	NOUN	O	O	594
imaging	VERB	O	O	594
(	PUNCT	O	O	594
MRI	PROPN	O	O	594
)	PUNCT	O	O	594
,	PUNCT	O	O	594
to	PART	O	O	594
provide	VERB	O	O	594
the	PRON	O	O	594
most	ADV	O	O	594
comprehensive	ADJ	O	O	594
characterization	NOUN	O	O	594
to	PART	O	O	594
date	PROPN	O	O	594
of	ADP	O	O	594
the	PRON	O	O	594
timecourse	NOUN	O	O	594
of	ADP	O	O	594
serological	ADJ	O	O	594
,	PUNCT	O	O	594
pathological	ADJ	O	O	594
,	PUNCT	O	O	594
and	CCONJ	O	O	594
functional	ADJ	O	O	594
events	NOUN	O	O	594
underlying	VERB	O	O	594
this	PRON	O	O	594
toxicity	NOUN	O	Disease	594
.	PUNCT	O	O	594
Hannover	PROPN	O	O	595
Wistar	PROPN	O	O	595
rats	NOUN	O	O	595
were	AUX	O	O	595
dosed	VERB	O	O	595
with	ADP	O	O	595
1.25	NUM	O	O	595
mg	VERB	O	O	595
/	PUNCT	O	O	595
kg	VERB	O	O	595
DOX	PROPN	O	Chemical	595
weekly	ADV	O	O	595
for	ADP	O	O	595
8	NUM	O	O	595
weeks	NOUN	O	O	595
followed	VERB	O	O	595
by	ADP	O	O	595
a	PRON	O	O	595
4	NUM	O	O	595
week	NOUN	O	O	595
off	ADP	O	O	595
-	PUNCT	O	O	595
dosing	VERB	O	O	595
""""	PUNCT	O	O	595
recovery	NOUN	O	O	595
""""	PUNCT	O	O	595
period	NOUN	O	O	595
.	PUNCT	O	O	595
Electron	NOUN	O	O	596
microscopy	NOUN	O	O	596
of	ADP	O	O	596
the	PRON	O	O	596
myocardium	NOUN	O	O	596
revealed	VERB	O	O	596
subcellular	ADJ	O	O	596
degeneration	NOUN	O	O	596
and	CCONJ	O	O	596
marked	VERB	O	O	596
mitochondrial	ADJ	O	O	596
changes	VERB	O	O	596
after	ADP	O	O	596
a	PRON	O	O	596
single	ADJ	O	O	596
dose	NOUN	O	O	596
.	PUNCT	O	O	596
Histopathological	PROPN	O	O	597
analysis	NOUN	O	O	597
revealed	VERB	O	O	597
progressive	ADJ	O	O	597
cardiomyocyte	NOUN	O	O	597
degeneration	NOUN	O	O	597
,	PUNCT	O	O	597
hypertrophy	VERB	O	Disease	597
/	PUNCT	O	O	597
cytomegaly	NOUN	O	O	597
,	PUNCT	O	O	597
and	CCONJ	O	O	597
extensive	ADJ	O	O	597
vacuolation	NOUN	O	O	597
after	ADP	O	O	597
two	NUM	O	O	597
doses	NOUN	O	O	597
.	PUNCT	O	O	597
Extensive	PROPN	O	O	598
replacement	NOUN	O	O	598
fibrosis	NOUN	O	Disease	598
(	PUNCT	O	O	598
quantified	VERB	O	O	598
by	ADP	O	O	598
Sirius	PROPN	O	O	598
red	ADJ	O	O	598
staining	VERB	O	O	598
)	PUNCT	O	O	598
developed	VERB	O	O	598
during	ADP	O	O	598
the	PRON	O	O	598
off	ADP	O	O	598
-	PUNCT	O	O	598
dosing	VERB	O	O	598
period	NOUN	O	O	598
.	PUNCT	O	O	598
Functional	ADJ	O	O	599
indices	NOUN	O	O	599
assessed	VERB	O	O	599
by	ADP	O	O	599
cardiac	ADJ	O	O	599
MRI	PROPN	O	O	599
(	PUNCT	O	O	599
including	VERB	O	O	599
left	VERB	O	O	599
ventricular	ADJ	O	O	599
ejection	NOUN	O	O	599
fraction	NOUN	O	O	599
(	PUNCT	O	O	599
LVEF	PROPN	O	O	599
)	PUNCT	O	O	599
,	PUNCT	O	O	599
cardiac	ADJ	O	O	599
output	NOUN	O	O	599
,	PUNCT	O	O	599
and	CCONJ	O	O	599
E	NOUN	O	Chemical	599
/	PUNCT	O	O	599
A	PRON	O	O	599
ratio	NOUN	O	O	599
)	PUNCT	O	O	599
declined	VERB	O	O	599
progressively	ADV	O	O	599
,	PUNCT	O	O	599
reaching	VERB	O	O	599
statistical	ADJ	O	O	599
significance	NOUN	O	O	599
after	ADP	O	O	599
two	NUM	O	O	599
doses	NOUN	O	O	599
and	CCONJ	O	O	599
culminating	VERB	O	O	599
in	ADP	O	O	599
""""	PUNCT	O	O	599
clinical	ADJ	O	O	599
""""	PUNCT	O	O	599
LV	PROPN	O	Disease	599
dysfunction	NOUN	O	O	599
by	ADP	O	O	599
12	NUM	O	O	599
weeks	NOUN	O	O	599
.	PUNCT	O	O	599
Troponin	PROPN	O	O	600
I	PRON	O	O	600
levels	NOUN	O	O	600
positively	ADV	O	O	600
correlated	VERB	O	O	600
with	ADP	O	O	600
delayed	VERB	O	O	600
and	CCONJ	O	O	600
peak	PROPN	O	O	600
gadolinium	NOUN	O	O	600
contrast	NOUN	O	O	600
enhancement	NOUN	O	O	600
,	PUNCT	O	O	600
histopathological	ADJ	O	O	600
grading	NOUN	O	O	600
,	PUNCT	O	O	600
and	CCONJ	O	O	600
diastolic	ADV	O	O	600
dysfunction	NOUN	O	O	600
.	PUNCT	O	O	600
In	ADP	O	O	601
summary	NOUN	O	O	601
,	PUNCT	O	O	601
subcellular	ADJ	O	O	601
cardiomyocyte	NOUN	O	O	601
degeneration	NOUN	O	O	601
was	AUX	O	O	601
the	PRON	O	O	601
earliest	ADJ	O	O	601
marker	NOUN	O	O	601
,	PUNCT	O	O	601
followed	VERB	O	O	601
by	ADP	O	O	601
progressive	ADJ	O	O	601
functional	ADJ	O	O	601
decline	VERB	O	O	601
and	CCONJ	O	O	601
histopathological	ADJ	O	O	601
manifestations	NOUN	O	O	601
.	PUNCT	O	O	601
However	ADV	O	O	602
,	PUNCT	O	O	602
all	PRON	O	O	602
indices	NOUN	O	O	602
predated	VERB	O	O	602
""""	PUNCT	O	O	602
clinical	ADJ	O	O	602
""""	PUNCT	O	O	602
LV	PROPN	O	Disease	602
dysfunction	NOUN	O	O	602
and	CCONJ	O	O	602
thus	ADV	O	O	602
warrant	NOUN	O	O	602
further	ADV	O	O	602
evaluation	NOUN	O	O	602
as	ADP	O	O	602
predictive	ADJ	O	O	602
biomarkers	NOUN	O	O	602
.	PUNCT	O	O	602
Intradermal	INTJ	O	O	605
glutamate	NOUN	O	Chemical	605
and	CCONJ	O	O	605
capsaicin	NOUN	O	Chemical	605
injections	NOUN	O	O	605
:	PUNCT	O	O	605
intra-	ADJ	O	O	605
and	CCONJ	O	O	605
interindividual	VERB	O	O	605
variability	NOUN	O	O	605
of	ADP	O	O	605
provoked	VERB	O	O	605
hyperalgesia	NOUN	O	Disease	605
and	CCONJ	O	O	605
allodynia	NOUN	O	Disease	605
.	PUNCT	O	O	605
Intradermal	INTJ	O	O	606
injections	NOUN	O	O	606
of	ADP	O	O	606
glutamate	NOUN	O	Chemical	606
and	CCONJ	O	O	606
capsaicin	NOUN	O	Chemical	606
are	AUX	O	O	606
attractive	ADJ	O	O	606
to	PART	O	O	606
use	VERB	O	O	606
in	ADP	O	O	606
human	PROPN	O	O	606
experimental	ADJ	O	O	606
pain	NOUN	O	Disease	606
models	NOUN	O	O	606
because	SCONJ	O	O	606
hyperalgesia	NOUN	O	Disease	606
and	CCONJ	O	O	606
allodynia	NOUN	O	Disease	606
mimic	VERB	O	O	606
isolated	VERB	O	O	606
aspects	NOUN	O	O	606
of	ADP	O	O	606
clinical	ADJ	O	O	606
pain	NOUN	O	Disease	606
disorders	NOUN	O	O	606
.	PUNCT	O	O	606
Twenty	NUM	O	O	607
healthy	ADJ	O	O	607
male	NOUN	O	O	607
volunteers	NOUN	O	O	607
(	PUNCT	O	O	607
mean	VERB	O	O	607
age	NOUN	O	O	607
24	NUM	O	O	607
years	NOUN	O	O	607
;	PUNCT	O	O	607
range	VERB	O	O	607
18	NUM	O	O	607
-	PUNCT	O	O	607
38	NUM	O	O	607
years	NOUN	O	O	607
)	PUNCT	O	O	607
received	VERB	O	O	607
intradermal	ADJ	O	O	607
injections	NOUN	O	O	607
of	ADP	O	O	607
glutamate	NOUN	O	Chemical	607
and	CCONJ	O	O	607
capsaicin	NOUN	O	Chemical	607
in	ADP	O	O	607
the	PRON	O	O	607
volar	ADJ	O	O	607
forearm	NOUN	O	O	607
.	PUNCT	O	O	607
Magnitudes	PROPN	O	O	608
of	ADP	O	O	608
secondary	ADJ	O	O	608
pinprick	PROPN	O	O	608
hyperalgesia	NOUN	O	Disease	608
and	CCONJ	O	O	608
brush	NOUN	O	O	608
-	PUNCT	O	O	608
evoked	VERB	O	O	608
allodynia	NOUN	O	Disease	608
were	AUX	O	O	608
investigated	VERB	O	O	608
using	VERB	O	O	608
von	PROPN	O	O	608
Frey	PROPN	O	O	608
filaments	NOUN	O	O	608
(	PUNCT	O	O	608
gauges	NOUN	O	O	608
10	NUM	O	O	608
,	PUNCT	O	O	608
15	NUM	O	O	608
,	PUNCT	O	O	608
60	NUM	O	O	608
and	CCONJ	O	O	608
100	NUM	O	O	608
g	X	O	O	608
)	PUNCT	O	O	608
and	CCONJ	O	O	608
brush	NOUN	O	O	608
strokes	NOUN	O	Disease	608
.	PUNCT	O	O	608
Areas	NOUN	O	O	609
of	ADP	O	O	609
secondary	ADJ	O	O	609
hyperalgesia	NOUN	O	Disease	609
and	CCONJ	O	O	609
allodynia	NOUN	O	Disease	609
were	AUX	O	O	609
quantified	VERB	O	O	609
immediately	ADV	O	O	609
after	ADP	O	O	609
injection	NOUN	O	O	609
and	CCONJ	O	O	609
after	ADP	O	O	609
15	NUM	O	O	609
,	PUNCT	O	O	609
30	NUM	O	O	609
and	CCONJ	O	O	609
60	NUM	O	O	609
min	NOUN	O	O	609
.	PUNCT	O	O	609
Secondary	ADJ	O	O	610
pinprick	PROPN	O	O	610
hyperalgesia	NOUN	O	Disease	610
was	AUX	O	O	610
observed	VERB	O	O	610
as	ADP	O	O	610
a	PRON	O	O	610
marked	VERB	O	O	610
increase	VERB	O	O	610
in	ADP	O	O	610
the	PRON	O	O	610
visual	ADJ	O	O	610
analogue	NOUN	O	O	610
scale	NOUN	O	O	610
(	PUNCT	O	O	610
VAS	PROPN	O	O	610
)	PUNCT	O	O	610
response	NOUN	O	O	610
to	PART	O	O	610
von	PROPN	O	O	610
Frey	PROPN	O	O	610
gauges	NOUN	O	O	610
60	NUM	O	O	610
and	CCONJ	O	O	610
100	NUM	O	O	610
g	X	O	O	610
<	X	O	O	611
0.001	NUM	O	O	611
)	PUNCT	O	O	611
after	ADP	O	O	611
glutamate	NOUN	O	Chemical	611
injection	NOUN	O	O	611
.	PUNCT	O	O	611
For	ADP	O	O	612
capsaicin	NOUN	O	Chemical	612
,	PUNCT	O	O	612
secondary	ADJ	O	O	612
pinprick	PROPN	O	O	612
hyperalgesia	NOUN	O	Disease	612
was	AUX	O	O	612
detected	VERB	O	O	612
with	ADP	O	O	612
all	PRON	O	O	612
von	PROPN	O	O	612
Frey	PROPN	O	O	612
gauges	NOUN	O	O	612
(	PUNCT	O	O	612
P	NOUN	O	Chemical	612
<	X	O	O	612
0.001	NUM	O	O	612
)	PUNCT	O	O	612
.	PUNCT	O	O	612
Glutamate	NOUN	O	O	613
evoked	VERB	O	O	613
reproducible	ADJ	O	O	613
VAS	PROPN	O	O	613
response	NOUN	O	O	613
to	PART	O	O	613
all	PRON	O	O	613
von	PROPN	O	O	613
Frey	PROPN	O	O	613
gauges	NOUN	O	O	613
(	PUNCT	O	O	613
ICC	PROPN	O	O	613
>	PUNCT	O	O	613
0.60	NUM	O	O	613
)	PUNCT	O	O	613
and	CCONJ	O	O	613
brush	NOUN	O	O	613
strokes	NOUN	O	Disease	613
(	PUNCT	O	O	613
ICC	PROPN	O	O	613
>	PUNCT	O	O	613
0.83	NUM	O	O	613
)	PUNCT	O	O	613
.	PUNCT	O	O	613
Capsaicin	PROPN	O	O	614
injection	NOUN	O	O	614
was	AUX	O	O	614
reproducible	ADJ	O	O	614
for	ADP	O	O	614
secondary	ADJ	O	O	614
hyperalgesia	NOUN	O	Disease	614
(	PUNCT	O	O	614
ICC	PROPN	O	O	614
>	PUNCT	O	O	614
0.70	NUM	O	O	614
)	PUNCT	O	O	614
and	CCONJ	O	O	614
allodynia	NOUN	O	Disease	614
Intra	PROPN	O	O	615
-	PUNCT	O	O	615
individual	ADJ	O	O	615
variability	NOUN	O	O	615
was	AUX	O	O	615
generally	ADV	O	O	615
lower	ADJ	O	O	615
for	ADP	O	O	615
the	PRON	O	O	615
VAS	PROPN	O	O	615
response	NOUN	O	O	615
to	PART	O	O	615
von	PROPN	O	O	615
Frey	PROPN	O	O	615
and	CCONJ	O	O	615
brush	NOUN	O	O	615
compared	VERB	O	O	615
with	ADP	O	O	615
areas	NOUN	O	O	615
of	ADP	O	O	615
secondary	ADJ	O	O	615
hyperalgesia	NOUN	O	Disease	615
and	CCONJ	O	O	615
allodynia	NOUN	O	Disease	615
.	PUNCT	O	O	615
In	ADP	O	O	616
conclusion	NOUN	O	O	616
,	PUNCT	O	O	616
glutamate	NOUN	O	Chemical	616
and	CCONJ	O	O	616
capsaicin	NOUN	O	Chemical	616
yield	VERB	O	O	616
reproducible	ADJ	O	O	616
hyperalgesic	PROPN	O	Disease	616
and	CCONJ	O	O	616
allodynic	PROPN	O	O	616
responses	NOUN	O	O	616
,	PUNCT	O	O	616
and	CCONJ	O	O	616
the	PRON	O	O	616
present	NOUN	O	O	616
model	NOUN	O	O	616
is	AUX	O	O	616
well	ADV	O	O	616
suited	VERB	O	O	616
for	ADP	O	O	616
basic	ADJ	O	O	616
research	NOUN	O	O	616
,	PUNCT	O	O	616
as	ADP	O	O	616
well	ADV	O	O	616
as	ADP	O	O	616
for	ADP	O	O	616
assessing	VERB	O	O	616
the	PRON	O	O	616
modulation	NOUN	O	O	616
of	ADP	O	O	616
central	ADJ	O	O	616
phenomena	VERB	O	O	616
.	PUNCT	O	O	616
Ocular	ADJ	O	O	619
-	PUNCT	O	O	619
specific	ADJ	O	O	619
ER	INTJ	O	O	619
stress	NOUN	O	O	619
reduction	NOUN	O	O	619
rescues	VERB	O	O	619
glaucoma	NOUN	O	Disease	619
in	ADP	O	O	619
murine	ADJ	O	O	619
glucocorticoid	NOUN	O	O	619
-	PUNCT	O	O	619
induced	VERB	O	O	619
glaucoma	NOUN	O	Disease	619
.	PUNCT	O	O	619
Administration	NOUN	O	O	620
of	ADP	O	O	620
glucocorticoids	NOUN	O	O	620
induces	VERB	O	O	620
ocular hypertension	NOUN	O	Disease	620
in	ADP	O	O	620
some	PRON	O	O	620
patients	NOUN	O	O	620
.	PUNCT	O	O	620
If	SCONJ	O	O	621
untreated	ADJ	O	O	621
,	PUNCT	O	O	621
these	PRON	O	O	621
patients	NOUN	O	O	621
can	AUX	O	O	621
develop	VERB	O	O	621
a	PRON	O	O	621
secondary	ADJ	O	O	621
glaucoma	NOUN	O	Disease	621
that	SCONJ	O	O	621
resembles	VERB	O	O	621
primary	NOUN	O	O	621
open	VERB	O	O	621
-	PUNCT	O	O	621
angle	NOUN	O	O	621
glaucoma	NOUN	O	Disease	621
(	PUNCT	O	O	621
POAG	PROPN	O	O	621
)	PUNCT	O	O	621
.	PUNCT	O	O	621
The	PRON	O	O	622
underlying	VERB	O	O	622
pathology	NOUN	O	O	622
of	ADP	O	O	622
glucocorticoid	NOUN	O	O	622
-	PUNCT	O	O	622
induced	VERB	O	O	622
glaucoma	NOUN	O	Disease	622
is	AUX	O	O	622
not	PART	O	O	622
fully	ADV	O	O	622
understood	VERB	O	O	622
,	PUNCT	O	O	622
due	ADJ	O	O	622
in	ADP	O	O	622
part	NOUN	O	O	622
to	PART	O	O	622
lack	VERB	O	O	622
of	ADP	O	O	622
an	PRON	O	O	622
appropriate	ADJ	O	O	622
animal	NOUN	O	O	622
model	NOUN	O	O	622
.	PUNCT	O	O	622
Here	ADV	O	O	623
,	PUNCT	O	O	623
we	PRON	O	O	623
developed	VERB	O	O	623
a	PRON	O	O	623
murine	ADJ	O	O	623
model	NOUN	O	O	623
of	ADP	O	O	623
glucocorticoid	NOUN	O	O	623
-	PUNCT	O	O	623
induced	VERB	O	O	623
glaucoma	NOUN	O	Disease	623
that	SCONJ	O	O	623
exhibits	VERB	O	O	623
glaucoma	NOUN	O	Disease	623
features	VERB	O	O	623
that	SCONJ	O	O	623
are	AUX	O	O	623
observed	VERB	O	O	623
in	ADP	O	O	623
patients	NOUN	O	O	623
.	PUNCT	O	O	623
Treatment	NOUN	O	O	624
of	ADP	O	O	624
WT	NOUN	O	O	624
mice	NOUN	O	O	624
with	ADP	O	O	624
topical	ADJ	O	O	624
ocular	ADJ	O	O	624
0.1%	NOUN	O	O	624
dexamethasone	NOUN	O	Chemical	624
led	VERB	O	O	624
to	PART	O	O	624
elevation	NOUN	O	O	624
of	ADP	O	O	624
intraocular	ADJ	O	O	624
pressure	NOUN	O	O	624
(	PUNCT	O	O	624
IOP	PROPN	O	O	624
)	PUNCT	O	O	624
,	PUNCT	O	O	624
functional	ADJ	O	O	624
and	CCONJ	O	O	624
structural	ADJ	O	O	624
loss	NOUN	O	O	624
of	ADP	O	O	624
retinal	ADJ	O	O	624
ganglion	NOUN	O	O	624
cells	NOUN	O	O	624
,	PUNCT	O	O	624
and	CCONJ	O	O	624
axonal degeneration	NOUN	O	Disease	624
,	PUNCT	O	O	624
resembling	VERB	O	O	624
glucocorticoid	NOUN	O	O	624
-	PUNCT	O	O	624
induced	VERB	O	O	624
glaucoma	NOUN	O	Disease	624
in	ADP	O	O	624
human	PROPN	O	O	624
patients	NOUN	O	O	624
.	PUNCT	O	O	624
Furthermore	ADV	O	O	625
,	PUNCT	O	O	625
dexamethasone	NOUN	O	Chemical	625
-	PUNCT	O	O	625
induced	VERB	O	O	625
ocular hypertension	NOUN	O	Disease	625
was	AUX	O	O	625
associated	VERB	O	O	625
with	ADP	O	O	625
chronic	ADJ	O	O	625
ER	INTJ	O	O	625
stress	NOUN	O	O	625
of	ADP	O	O	625
the	PRON	O	O	625
trabecular	NOUN	O	O	625
meshwork	NOUN	O	O	625
(	PUNCT	O	O	625
TM	NOUN	O	O	625
)	PUNCT	O	O	625
.	PUNCT	O	O	625
Similar	ADJ	O	O	626
to	PART	O	O	626
patients	NOUN	O	O	626
,	PUNCT	O	O	626
withdrawal	NOUN	O	O	626
of	ADP	O	O	626
dexamethasone	NOUN	O	Chemical	626
treatment	NOUN	O	O	626
reduced	VERB	O	O	626
elevated	ADJ	O	O	626
IOP	PROPN	O	O	626
and	CCONJ	O	O	626
ER	INTJ	O	O	626
stress	NOUN	O	O	626
in	ADP	O	O	626
this	PRON	O	O	626
animal	NOUN	O	O	626
model	NOUN	O	O	626
.	PUNCT	O	O	626
Dexamethasone	NOUN	O	Chemical	627
induced	VERB	O	O	627
the	PRON	O	O	627
transcriptional	ADJ	O	O	627
factor	NOUN	O	O	627
CHOP	VERB	O	O	627
,	PUNCT	O	O	627
a	PRON	O	O	627
marker	NOUN	O	O	627
for	ADP	O	O	627
chronic	ADJ	O	O	627
ER	INTJ	O	O	627
stress	NOUN	O	O	627
,	PUNCT	O	O	627
in	ADP	O	O	627
the	PRON	O	O	627
anterior	PROPN	O	O	627
segment	NOUN	O	O	627
tissues	NOUN	O	O	627
,	PUNCT	O	O	627
and	CCONJ	O	O	627
Chop	VERB	O	O	627
deletion	NOUN	O	O	627
reduced	VERB	O	O	627
ER	INTJ	O	O	627
stress	NOUN	O	O	627
in	ADP	O	O	627
these	PRON	O	O	627
tissues	NOUN	O	O	627
and	CCONJ	O	O	627
prevented	VERB	O	O	627
dexamethasone	NOUN	O	Chemical	627
-	PUNCT	O	O	627
induced	VERB	O	O	627
ocular hypertension	NOUN	O	Disease	627
.	PUNCT	O	O	627
Furthermore	ADV	O	O	628
,	PUNCT	O	O	628
reduction	NOUN	O	O	628
of	ADP	O	O	628
ER	INTJ	O	O	628
stress	NOUN	O	O	628
in	ADP	O	O	628
the	PRON	O	O	628
TM	NOUN	O	O	628
with	ADP	O	O	628
sodium	NOUN	O	Chemical	628
4-phenylbutyrate	ADJ	O	O	628
prevented	VERB	O	O	628
dexamethasone	NOUN	O	Chemical	628
-	PUNCT	O	O	628
induced	VERB	O	O	628
ocular hypertension	NOUN	O	Disease	628
in	ADP	O	O	628
WT	NOUN	O	O	628
mice	NOUN	O	O	628
.	PUNCT	O	O	628
Our	PRON	O	O	629
data	NOUN	O	O	629
indicate	VERB	O	O	629
that	SCONJ	O	O	629
ER	INTJ	O	O	629
stress	NOUN	O	O	629
contributes	VERB	O	O	629
to	PART	O	O	629
glucocorticoid	NOUN	O	O	629
-	PUNCT	O	O	629
induced	VERB	O	O	629
ocular hypertension	NOUN	O	Disease	629
and	CCONJ	O	O	629
suggest	VERB	O	O	629
that	SCONJ	O	O	629
reducing	VERB	O	O	629
ER	INTJ	O	O	629
stress	NOUN	O	O	629
has	VERB	O	O	629
potential	ADJ	O	O	629
as	ADP	O	O	629
a	PRON	O	O	629
therapeutic	ADJ	O	O	629
strategy	NOUN	O	O	629
for	ADP	O	O	629
treating	VERB	O	O	629
glucocorticoid	NOUN	O	O	629
-	PUNCT	O	O	629
induced	VERB	O	O	629
glaucoma	NOUN	O	Disease	629
.	PUNCT	O	O	629
Effects	NOUN	O	O	632
of	ADP	O	O	632
ginsenosides	NOUN	O	O	632
on	ADP	O	O	632
opioid	NOUN	O	O	632
-	PUNCT	O	O	632
induced	VERB	O	O	632
hyperalgesia	NOUN	O	Disease	632
in	ADP	O	O	632
mice	NOUN	O	O	632
.	PUNCT	O	O	632
Opioid	NOUN	O	O	633
-	PUNCT	O	O	633
induced	VERB	O	O	633
hyperalgesia	NOUN	O	Disease	633
(	PUNCT	O	O	633
OIH	PRON	O	O	633
)	PUNCT	O	O	633
is	AUX	O	O	633
characterized	VERB	O	O	633
by	ADP	O	O	633
nociceptive	ADJ	O	O	633
sensitization	NOUN	O	O	633
caused	VERB	O	O	633
by	ADP	O	O	633
the	PRON	O	O	633
cessation	NOUN	O	O	633
of	ADP	O	O	633
chronic	ADJ	O	O	633
opioid	NOUN	O	O	633
use	VERB	O	O	633
.	PUNCT	O	O	633
OIH	PRON	O	O	634
can	AUX	O	O	634
limit	NOUN	O	O	634
the	PRON	O	O	634
clinical	ADJ	O	O	634
use	VERB	O	O	634
of	ADP	O	O	634
opioid	NOUN	O	O	634
analgesics	NOUN	O	O	634
and	CCONJ	O	O	634
complicate	VERB	O	O	634
withdrawal	NOUN	O	O	634
from	ADP	O	O	634
opioid	NOUN	O	O	634
addiction	NOUN	O	O	634
.	PUNCT	O	O	634
In	ADP	O	O	635
this	PRON	O	O	635
study	VERB	O	O	635
,	PUNCT	O	O	635
we	PRON	O	O	635
investigated	VERB	O	O	635
the	PRON	O	O	635
effects	NOUN	O	O	635
of	ADP	O	O	635
Re	ADP	O	O	635
,	PUNCT	O	O	635
Rg1	NOUN	O	O	635
,	PUNCT	O	O	635
and	CCONJ	O	O	635
Rb1	PROPN	O	O	635
ginsenosides	NOUN	O	O	635
,	PUNCT	O	O	635
the	PRON	O	O	635
bioactive	ADJ	O	O	635
components	NOUN	O	O	635
of	ADP	O	O	635
ginseng	PROPN	O	O	635
,	PUNCT	O	O	635
on	ADP	O	O	635
OIH	PRON	O	O	635
.	PUNCT	O	O	635
OIH	PRON	O	O	636
was	AUX	O	O	636
achieved	VERB	O	O	636
in	ADP	O	O	636
mice	NOUN	O	O	636
after	ADP	O	O	636
subcutaneous	ADJ	O	O	636
administration	NOUN	O	O	636
of	ADP	O	O	636
morphine	NOUN	O	Chemical	636
for	ADP	O	O	636
7	NUM	O	O	636
consecutive	ADJ	O	O	636
days	NOUN	O	O	636
three	NUM	O	O	636
times	NOUN	O	O	636
per	ADP	O	O	636
day	NOUN	O	O	636
.	PUNCT	O	O	636
During	ADP	O	O	637
withdrawal	NOUN	O	O	637
(	PUNCT	O	O	637
days	NOUN	O	O	637
8	NUM	O	O	637
and	CCONJ	O	O	637
9	NUM	O	O	637
)	PUNCT	O	O	637
,	PUNCT	O	O	637
these	PRON	O	O	637
mice	NOUN	O	O	637
were	AUX	O	O	637
administered	VERB	O	O	637
Re	ADP	O	O	637
,	PUNCT	O	O	637
Rg1	NOUN	O	O	637
,	PUNCT	O	O	637
or	CCONJ	O	O	637
Rb1	PROPN	O	O	637
intragastrically	ADV	O	O	637
two	NUM	O	O	637
times	NOUN	O	O	637
per	ADP	O	O	637
day	NOUN	O	O	637
.	PUNCT	O	O	637
On	ADP	O	O	638
the	PRON	O	O	638
test	NOUN	O	O	638
day	NOUN	O	O	638
(	PUNCT	O	O	638
day	NOUN	O	O	638
10	NUM	O	O	638
)	PUNCT	O	O	638
,	PUNCT	O	O	638
mice	NOUN	O	O	638
were	AUX	O	O	638
subjected	VERB	O	O	638
to	PART	O	O	638
the	PRON	O	O	638
thermal	PROPN	O	O	638
sensitivity	NOUN	O	O	638
test	NOUN	O	O	638
and	CCONJ	O	O	638
the	PRON	O	O	638
acetic acid	NOUN	O	Chemical	638
-	PUNCT	O	O	638
induced	VERB	O	O	638
writhing	VERB	O	Disease	638
test	NOUN	O	O	638
.	PUNCT	O	O	638
Re	ADP	O	O	639
(	PUNCT	O	O	639
300	NUM	O	O	639
mg	VERB	O	O	639
/	PUNCT	O	O	639
kg	VERB	O	O	639
)	PUNCT	O	O	639
inhibited	VERB	O	O	639
OIH	PRON	O	O	639
in	ADP	O	O	639
both	PRON	O	O	639
the	PRON	O	O	639
thermal	PROPN	O	O	639
sensitivity	NOUN	O	O	639
test	NOUN	O	O	639
and	CCONJ	O	O	639
the	PRON	O	O	639
acetic acid	NOUN	O	Chemical	639
-	PUNCT	O	O	639
induced	VERB	O	O	639
writhing	VERB	O	Disease	639
test	NOUN	O	O	639
.	PUNCT	O	O	639
However	ADV	O	O	640
,	PUNCT	O	O	640
the	PRON	O	O	640
Rg1	NOUN	O	O	640
and	CCONJ	O	O	640
Rb1	PROPN	O	O	640
ginsenosides	NOUN	O	O	640
failed	VERB	O	O	640
to	PART	O	O	640
prevent	VERB	O	O	640
OIH	PRON	O	O	640
in	ADP	O	O	640
either	ADV	O	O	640
test	NOUN	O	O	640
.	PUNCT	O	O	640
Furthermore	ADV	O	O	641
,	PUNCT	O	O	641
Rg1	NOUN	O	O	641
showed	VERB	O	O	641
a	PRON	O	O	641
tendency	NOUN	O	O	641
to	PART	O	O	641
aggravate	VERB	O	O	641
OIH	PRON	O	O	641
in	ADP	O	O	641
the	PRON	O	O	641
acetic acid	NOUN	O	Chemical	641
-	PUNCT	O	O	641
induced	VERB	O	O	641
writhing	VERB	O	Disease	641
test	NOUN	O	O	641
.	PUNCT	O	O	641
Our	PRON	O	O	642
data	NOUN	O	O	642
suggested	VERB	O	O	642
that	SCONJ	O	O	642
the	PRON	O	O	642
ginsenoside	NOUN	O	O	642
Re	ADP	O	O	642
,	PUNCT	O	O	642
but	CCONJ	O	O	642
not	PART	O	O	642
Rg1	NOUN	O	O	642
or	CCONJ	O	O	642
Rb1	PROPN	O	O	642
,	PUNCT	O	O	642
may	AUX	O	O	642
contribute	VERB	O	O	642
toward	ADP	O	O	642
reversal	NOUN	O	O	642
of	ADP	O	O	642
OIH	PRON	O	O	642
.	PUNCT	O	O	642
A	PRON	O	O	645
comparison	NOUN	O	O	645
of	ADP	O	O	645
severe	ADJ	O	O	645
hemodynamic	ADJ	O	O	645
disturbances	NOUN	O	O	645
between	ADP	O	O	645
dexmedetomidine	PROPN	O	Chemical	645
and	CCONJ	O	O	645
propofol	VERB	O	Chemical	645
for	ADP	O	O	645
sedation	NOUN	O	O	645
in	ADP	O	O	645
neurocritical	ADJ	O	O	645
care	VERB	O	O	645
patients	NOUN	O	O	645
.	PUNCT	O	O	645
Dexmedetomidine	PROPN	O	Chemical	646
and	CCONJ	O	O	646
propofol	VERB	O	Chemical	646
are	AUX	O	O	646
commonly	ADV	O	O	646
used	VERB	O	O	646
sedatives	NOUN	O	O	646
in	ADP	O	O	646
neurocritical	ADJ	O	O	646
care	VERB	O	O	646
as	ADP	O	O	646
they	PRON	O	O	646
allow	VERB	O	O	646
for	ADP	O	O	646
frequent	ADJ	O	O	646
neurologic	ADJ	O	O	646
examinations	NOUN	O	O	646
.	PUNCT	O	O	646
The	PRON	O	O	647
primary	NOUN	O	O	647
objective	VERB	O	O	647
of	ADP	O	O	647
this	PRON	O	O	647
study	VERB	O	O	647
is	AUX	O	O	647
to	PART	O	O	647
compare	VERB	O	O	647
the	PRON	O	O	647
prevalence	NOUN	O	O	647
of	ADP	O	O	647
severe	ADJ	O	O	647
hemodynamic	ADJ	O	O	647
effects	NOUN	O	O	647
in	ADP	O	O	647
neurocritical	ADJ	O	O	647
care	VERB	O	O	647
patients	NOUN	O	O	647
receiving	VERB	O	O	647
dexmedetomidine	PROPN	O	Chemical	647
and	CCONJ	O	O	647
propofol	VERB	O	Chemical	647
.	PUNCT	O	O	647
INTERVENTIONS	NOUN	O	O	648
:	PUNCT	O	O	648
Continuous	ADJ	O	O	648
sedation	NOUN	O	O	648
with	ADP	O	O	648
dexmedetomidine	PROPN	O	Chemical	648
or	CCONJ	O	O	648
propofol	VERB	O	Chemical	648
.	PUNCT	O	O	648
A	PRON	O	O	649
total	ADJ	O	O	649
of	ADP	O	O	649
342	NUM	O	O	649
patients	NOUN	O	O	649
(	PUNCT	O	O	649
105	NUM	O	O	649
dexmedetomidine	PROPN	O	Chemical	649
and	CCONJ	O	O	649
237	NUM	O	O	649
propofol	VERB	O	Chemical	649
)	PUNCT	O	O	649
were	AUX	O	O	649
included	VERB	O	O	649
in	ADP	O	O	649
the	PRON	O	O	649
analysis	NOUN	O	O	649
,	PUNCT	O	O	649
with	ADP	O	O	649
190	NUM	O	O	649
matched	VERB	O	O	649
(	PUNCT	O	O	649
95	NUM	O	O	649
in	ADP	O	O	649
each	PRON	O	O	649
group	NOUN	O	O	649
)	PUNCT	O	O	649
by	ADP	O	O	649
propensity	NOUN	O	O	649
score	VERB	O	O	649
.	PUNCT	O	O	649
The	PRON	O	O	650
primary	NOUN	O	O	650
outcome	NOUN	O	O	650
of	ADP	O	O	650
this	PRON	O	O	650
study	VERB	O	O	650
was	AUX	O	O	650
a	PRON	O	O	650
composite	ADJ	O	O	650
of	ADP	O	O	650
severe	ADJ	O	O	650
hypotension	NOUN	O	Disease	650
(	PUNCT	O	O	650
mean	VERB	O	O	650
arterial	ADJ	O	O	650
pressure	NOUN	O	O	650
<	X	O	O	650
60	NUM	O	O	650
mm	INTJ	O	O	650
Hg	PROPN	O	O	650
)	PUNCT	O	O	650
and	CCONJ	O	O	650
bradycardia	NOUN	O	Disease	650
(	PUNCT	O	O	650
heart	NOUN	O	O	650
rate	NOUN	O	O	650
<	X	O	O	650
50	NUM	O	O	650
beats	NOUN	O	O	650
/	PUNCT	O	O	650
min	NOUN	O	O	650
)	PUNCT	O	O	650
during	ADP	O	O	650
sedative	NOUN	O	O	650
infusion	NOUN	O	O	650
.	PUNCT	O	O	650
When	SCONJ	O	O	651
analyzed	VERB	O	O	651
separately	ADV	O	O	651
,	PUNCT	O	O	651
no	PRON	O	O	651
differences	NOUN	O	O	651
could	AUX	O	O	651
be	AUX	O	O	651
found	VERB	O	O	651
in	ADP	O	O	651
the	PRON	O	O	651
prevalence	NOUN	O	O	651
of	ADP	O	O	651
severe	ADJ	O	O	651
hypotension	NOUN	O	Disease	651
or	CCONJ	O	O	651
bradycardia	NOUN	O	Disease	651
in	ADP	O	O	651
either	ADV	O	O	651
the	PRON	O	O	651
unmatched	NOUN	O	O	651
or	CCONJ	O	O	651
matched	VERB	O	O	651
cohorts	NOUN	O	O	651
.	PUNCT	O	O	651
Severe	ADJ	O	O	652
hypotension	NOUN	O	Disease	652
and	CCONJ	O	O	652
bradycardia	NOUN	O	Disease	652
occur	VERB	O	O	652
at	ADP	O	O	652
similar	ADJ	O	O	652
prevalence	NOUN	O	O	652
in	ADP	O	O	652
neurocritical	ADJ	O	O	652
care	VERB	O	O	652
patients	NOUN	O	O	652
who	PRON	O	O	652
receive	VERB	O	O	652
dexmedetomidine	PROPN	O	Chemical	652
or	CCONJ	O	O	652
propofol	VERB	O	Chemical	652
.	PUNCT	O	O	652
Providers	NOUN	O	O	653
should	AUX	O	O	653
similarly	ADV	O	O	653
consider	VERB	O	O	653
the	PRON	O	O	653
likelihood	NOUN	O	O	653
of	ADP	O	O	653
hypotension	NOUN	O	Disease	653
or	CCONJ	O	O	653
bradycardia	NOUN	O	Disease	653
before	ADP	O	O	653
starting	VERB	O	O	653
either	ADV	O	O	653
sedative	NOUN	O	O	653
.	PUNCT	O	O	653
Hydroxytyrosol	PROPN	O	O	656
ameliorates	VERB	O	O	656
oxidative	NOUN	O	O	656
stress	NOUN	O	O	656
and	CCONJ	O	O	656
mitochondrial	ADJ	O	O	656
dysfunction	NOUN	O	O	656
in	ADP	O	O	656
doxorubicin	VERB	O	Chemical	656
-	PUNCT	O	O	656
induced	VERB	O	O	656
cardiotoxicity	NOUN	O	Disease	656
in	ADP	O	O	656
rats	NOUN	O	O	656
with	ADP	O	O	656
breast cancer	NOUN	O	Disease	656
.	PUNCT	O	O	656
Oxidative	NOUN	O	O	657
stress	NOUN	O	O	657
is	AUX	O	O	657
involved	VERB	O	O	657
in	ADP	O	O	657
several	ADJ	O	O	657
processes	NOUN	O	O	657
including	VERB	O	O	657
cancer	NOUN	O	Disease	657
,	PUNCT	O	O	657
aging	VERB	O	O	657
and	CCONJ	O	O	657
cardiovascular disease	NOUN	O	Disease	657
,	PUNCT	O	O	657
and	CCONJ	O	O	657
has	VERB	O	O	657
been	AUX	O	O	657
shown	VERB	O	O	657
to	PART	O	O	657
potentiate	VERB	O	O	657
the	PRON	O	O	657
therapeutic	ADJ	O	O	657
effect	VERB	O	O	657
of	ADP	O	O	657
drugs	NOUN	O	O	657
such	ADJ	O	O	657
as	ADP	O	O	657
doxorubicin	VERB	O	Chemical	657
.	PUNCT	O	O	657
Doxorubicin	PROPN	O	Chemical	658
causes	VERB	O	O	658
significant	ADJ	O	O	658
cardiotoxicity	NOUN	O	Disease	658
characterized	VERB	O	O	658
by	ADP	O	O	658
marked	VERB	O	O	658
increases	VERB	O	O	658
in	ADP	O	O	658
oxidative	NOUN	O	O	658
stress	NOUN	O	O	658
and	CCONJ	O	O	658
mitochondrial	ADJ	O	O	658
dysfunction	NOUN	O	O	658
.	PUNCT	O	O	658
Herein	ADV	O	O	659
,	PUNCT	O	O	659
we	PRON	O	O	659
investigate	VERB	O	O	659
whether	SCONJ	O	O	659
doxorubicin	VERB	O	Chemical	659
-	PUNCT	O	O	659
associated	VERB	O	O	659
chronic	ADJ	O	O	659
cardiac toxicity	NOUN	O	Disease	659
can	AUX	O	O	659
be	AUX	O	O	659
ameliorated	VERB	O	O	659
with	ADP	O	O	659
the	PRON	O	O	659
antioxidant	ADJ	O	O	659
hydroxytyrosol	PROPN	O	O	659
in	ADP	O	O	659
rats	NOUN	O	O	659
with	ADP	O	O	659
breast cancer	NOUN	O	Disease	659
.	PUNCT	O	O	659
Thirty	NUM	O	O	660
-	PUNCT	O	O	660
six	NUM	O	O	660
rats	NOUN	O	O	660
bearing	VERB	O	O	660
breast	NOUN	O	O	660
tumors	NOUN	O	Disease	660
induced	VERB	O	O	660
chemically	ADV	O	O	660
were	AUX	O	O	660
divided	VERB	O	O	660
into	ADP	O	O	660
4	NUM	O	O	660
groups	NOUN	O	O	660
:	PUNCT	O	O	660
control	VERB	O	O	660
,	PUNCT	O	O	660
hydroxytyrosol	PROPN	O	O	660
(	PUNCT	O	O	660
0.5mg	NOUN	O	O	660
/	PUNCT	O	O	660
kg	VERB	O	O	660
,	PUNCT	O	O	660
5days	NUM	O	O	660
/	PUNCT	O	O	660
week	NOUN	O	O	660
)	PUNCT	O	O	660
,	PUNCT	O	O	660
doxorubicin	VERB	O	Chemical	660
(	PUNCT	O	O	660
1mg	NOUN	O	O	660
/	PUNCT	O	O	660
kg	VERB	O	O	660
/	PUNCT	O	O	660
week	NOUN	O	O	660
)	PUNCT	O	O	660
,	PUNCT	O	O	660
and	CCONJ	O	O	660
doxorubicin	VERB	O	Chemical	660
plus	CCONJ	O	O	660
hydroxytyrosol	PROPN	O	O	660
.	PUNCT	O	O	660
Cardiac	ADJ	O	O	661
disturbances	NOUN	O	O	661
at	ADP	O	O	661
the	PRON	O	O	661
cellular	NOUN	O	O	661
and	CCONJ	O	O	661
mitochondrial	ADJ	O	O	661
level	VERB	O	O	661
,	PUNCT	O	O	661
mitochondrial	ADJ	O	O	661
electron	NOUN	O	O	661
transport	NOUN	O	O	661
chain	NOUN	O	O	661
complexes	NOUN	O	O	661
I	PRON	O	O	661
-	PUNCT	O	O	661
IV	NUM	O	O	661
and	CCONJ	O	O	661
apoptosis	NOUN	O	O	661
-	PUNCT	O	O	661
inducing	VERB	O	O	661
factor	NOUN	O	O	661
,	PUNCT	O	O	661
and	CCONJ	O	O	661
oxidative	NOUN	O	O	661
stress	NOUN	O	O	661
markers	NOUN	O	O	661
have	VERB	O	O	661
been	AUX	O	O	661
analyzed	VERB	O	O	661
.	PUNCT	O	O	661
Hydroxytyrosol	PROPN	O	O	662
improved	VERB	O	O	662
the	PRON	O	O	662
cardiac	ADJ	O	O	662
disturbances	NOUN	O	O	662
enhanced	VERB	O	O	662
by	ADP	O	O	662
doxorubicin	VERB	O	Chemical	662
by	ADP	O	O	662
significantly	ADV	O	O	662
reducing	VERB	O	O	662
the	PRON	O	O	662
percentage	NOUN	O	O	662
of	ADP	O	O	662
altered	VERB	O	O	662
mitochondria	PROPN	O	O	662
and	CCONJ	O	O	662
oxidative	NOUN	O	O	662
damage	NOUN	O	O	662
.	PUNCT	O	O	662
These	PRON	O	O	663
results	VERB	O	O	663
suggest	VERB	O	O	663
that	SCONJ	O	O	663
hydroxytyrosol	PROPN	O	O	663
improve	VERB	O	O	663
the	PRON	O	O	663
mitochondrial	ADJ	O	O	663
electron	NOUN	O	O	663
transport	NOUN	O	O	663
chain	NOUN	O	O	663
.	PUNCT	O	O	663
This	PRON	O	O	664
study	VERB	O	O	664
demonstrates	VERB	O	O	664
that	SCONJ	O	O	664
hydroxytyrosol	PROPN	O	O	664
protect	VERB	O	O	664
rat	NOUN	O	O	664
heart damage	NOUN	O	Disease	664
provoked	VERB	O	O	664
by	ADP	O	O	664
doxorubicin	VERB	O	Chemical	664
decreasing	VERB	O	O	664
oxidative	NOUN	O	O	664
damage	NOUN	O	O	664
and	CCONJ	O	O	664
mitochondrial	ADJ	O	O	664
alterations	NOUN	O	O	664
.	PUNCT	O	O	664
Amiodarone	NOUN	O	Chemical	667
-	PUNCT	O	O	667
induced	VERB	O	O	667
myxoedema	PROPN	O	O	667
coma	NOUN	O	Disease	667
.	PUNCT	O	O	667
A	PRON	O	O	668
62-year	NOUN	O	O	668
-	PUNCT	O	O	668
old	ADJ	O	O	668
man	NOUN	O	O	668
was	AUX	O	O	668
found	VERB	O	O	668
to	PART	O	O	668
have	VERB	O	O	668
bradycardia	NOUN	O	Disease	668
,	PUNCT	O	O	668
hypothermia	VERB	O	Disease	668
and	CCONJ	O	O	668
respiratory failure	NOUN	O	Disease	668
3	X	O	O	668
weeks	NOUN	O	O	668
after	ADP	O	O	668
initiation	NOUN	O	O	668
of	ADP	O	O	668
amiodarone	NOUN	O	Chemical	668
therapy	NOUN	O	O	668
for	ADP	O	O	668
atrial fibrillation	NOUN	O	Disease	668
.	PUNCT	O	O	668
0.3	NUM	O	O	669
-	PUNCT	O	O	669
5	NUM	O	O	669
uIU	ADJ	O	O	669
/	PUNCT	O	O	669
mL	PROPN	O	O	669
)	PUNCT	O	O	669
and	CCONJ	O	O	669
free	ADJ	O	O	669
thyroxine	NOUN	O	Chemical	669
(	PUNCT	O	O	669
FT4	NOUN	O	O	669
)	PUNCT	O	O	669
was	AUX	O	O	669
<	X	O	O	669
0.2	NUM	O	O	669
ng	PROPN	O	O	669
/	PUNCT	O	O	669
dL	VERB	O	O	669
(	PUNCT	O	O	669
nl	PROPN	O	O	669
.	PUNCT	O	O	669
He	PRON	O	O	670
received	VERB	O	O	670
intravenous	ADJ	O	O	670
fluids	NOUN	O	O	670
,	PUNCT	O	O	670
vasopressor	NOUN	O	O	670
therapy	NOUN	O	O	670
and	CCONJ	O	O	670
stress	NOUN	O	O	670
dose	NOUN	O	O	670
steroids	NOUN	O	Chemical	670
;	PUNCT	O	O	670
he	PRON	O	O	670
was	AUX	O	O	670
intubated	VERB	O	O	670
and	CCONJ	O	O	670
admitted	VERB	O	O	670
to	PART	O	O	670
the	PRON	O	O	670
intensive	ADJ	O	O	670
care	VERB	O	O	670
unit	NOUN	O	O	670
.	PUNCT	O	O	670
He	PRON	O	O	671
received	VERB	O	O	671
500	NUM	O	O	671
ug	NOUN	O	O	671
of	ADP	O	O	671
intravenous	ADJ	O	O	671
levothyroxine	VERB	O	O	671
in	ADP	O	O	671
the	PRON	O	O	671
first	ADV	O	O	671
18	NUM	O	O	671
h	X	O	O	671
of	ADP	O	O	671
therapy	NOUN	O	O	671
,	PUNCT	O	O	671
and	CCONJ	O	O	671
150	NUM	O	O	671
ug	NOUN	O	O	671
intravenous	ADJ	O	O	671
daily	ADV	O	O	671
thereafter	ADV	O	O	671
.	PUNCT	O	O	671
The	PRON	O	O	672
patient	NOUN	O	O	672
was	AUX	O	O	672
maintained	VERB	O	O	672
on	ADP	O	O	672
levothyroxine	VERB	O	O	672
175	NUM	O	O	672
(	PUNCT	O	O	672
g	X	O	O	672
POorally	NOUN	O	O	672
daily	ADV	O	O	672
.	PUNCT	O	O	672
The	PRON	O	O	673
24	NUM	O	O	673
hour	NOUN	O	O	673
excretion	NOUN	O	O	673
of	ADP	O	O	673
iodine	PROPN	O	O	673
was	AUX	O	O	673
3657	NUM	O	O	673
(	PUNCT	O	O	673
mcg	PROPN	O	O	673
(	PUNCT	O	O	673
25	NUM	O	O	673
-	PUNCT	O	O	673
756	NUM	O	O	673
(	PUNCT	O	O	673
mcg	PROPN	O	O	673
)	PUNCT	O	O	673
.	PUNCT	O	O	673
The	PRON	O	O	674
only	ADV	O	O	674
two	NUM	O	O	674
cases	NOUN	O	O	674
of	ADP	O	O	674
amiodarone	NOUN	O	Chemical	674
-	PUNCT	O	O	674
induced	VERB	O	O	674
myxoedema	PROPN	O	O	674
coma	NOUN	O	Disease	674
in	ADP	O	O	674
the	PRON	O	O	674
literature	NOUN	O	O	674
report	VERB	O	O	674
patient	NOUN	O	O	674
death	NOUN	O	O	674
despite	SCONJ	O	O	674
supportive	ADJ	O	O	674
therapy	NOUN	O	O	674
and	CCONJ	O	O	674
thyroid	NOUN	O	O	674
hormone	NOUN	O	O	674
replacement	NOUN	O	O	674
.	PUNCT	O	O	674
This	PRON	O	O	675
case	NOUN	O	O	675
represents	VERB	O	O	675
the	PRON	O	O	675
most	ADV	O	O	675
thoroughly	ADV	O	O	675
investigated	VERB	O	O	675
case	NOUN	O	O	675
of	ADP	O	O	675
amiodarone	NOUN	O	Chemical	675
-	PUNCT	O	O	675
induced	VERB	O	O	675
myxoedema	PROPN	O	O	675
coma	NOUN	O	Disease	675
with	ADP	O	O	675
a	PRON	O	O	675
history	NOUN	O	O	675
significant	ADJ	O	O	675
for	ADP	O	O	675
subclinical	ADJ	O	O	675
thyroid disease	NOUN	O	Disease	675
.	PUNCT	O	O	675
Use	VERB	O	O	678
of	ADP	O	O	678
argatroban	NOUN	O	O	678
and	CCONJ	O	O	678
catheter	VERB	O	O	678
-	PUNCT	O	O	678
directed	VERB	O	O	678
thrombolysis	NOUN	O	O	678
with	ADP	O	O	678
alteplase	NOUN	O	O	678
in	ADP	O	O	678
an	PRON	O	O	678
oncology	NOUN	O	O	678
patient	NOUN	O	O	678
with	ADP	O	O	678
heparin	NOUN	O	Chemical	678
-	PUNCT	O	O	678
induced	VERB	O	O	678
thrombocytopenia	PROPN	O	Disease	678
with	ADP	O	O	678
thrombosis	NOUN	O	Disease	678
.	PUNCT	O	O	678
The	PRON	O	O	679
case	NOUN	O	O	679
of	ADP	O	O	679
an	PRON	O	O	679
oncology	NOUN	O	O	679
patient	NOUN	O	O	679
who	PRON	O	O	679
developed	VERB	O	O	679
heparin	NOUN	O	Chemical	679
-	PUNCT	O	O	679
induced	VERB	O	O	679
thrombocytopenia	PROPN	O	Disease	679
with	ADP	O	O	679
thrombosis	NOUN	O	Disease	679
(	PUNCT	O	O	679
HITT	PROPN	O	O	679
)	PUNCT	O	O	679
and	CCONJ	O	O	679
was	AUX	O	O	679
treated	VERB	O	O	679
with	ADP	O	O	679
argatroban	NOUN	O	O	679
plus	CCONJ	O	O	679
catheter	VERB	O	O	679
-	PUNCT	O	O	679
directed	VERB	O	O	679
thrombolysis	NOUN	O	O	679
(	PUNCT	O	O	679
CDT	PROPN	O	O	679
)	PUNCT	O	O	679
with	ADP	O	O	679
alteplase	NOUN	O	O	679
is	AUX	O	O	679
presented	VERB	O	O	679
.	PUNCT	O	O	679
A	PRON	O	O	680
63-year	NOUN	O	O	680
-	PUNCT	O	O	680
old	ADJ	O	O	680
Caucasian	ADJ	O	O	680
man	NOUN	O	O	680
with	ADP	O	O	680
renal	ADJ	O	O	680
amyloidosis	NOUN	O	O	680
undergoing	VERB	O	O	680
peripheral	ADJ	O	O	680
blood	NOUN	O	O	680
stem	VERB	O	O	680
cell	NOUN	O	O	680
collection	NOUN	O	O	680
for	ADP	O	O	680
an	PRON	O	O	680
autologous	ADJ	O	O	680
stem	VERB	O	O	680
cell	NOUN	O	O	680
transplant	NOUN	O	O	680
developed	VERB	O	O	680
extensive	ADJ	O	O	680
bilateral	ADJ	O	O	680
upper	ADJ	O	O	680
-	PUNCT	O	O	680
extremity	NOUN	O	O	680
deep	ADJ	O	O	680
venous thrombosis	NOUN	O	Disease	680
(	PUNCT	O	O	680
DVT	PROPN	O	O	680
)	PUNCT	O	O	680
and	CCONJ	O	O	680
pulmonary embolism	NOUN	O	O	680
secondary	ADJ	O	O	680
to	PART	O	O	680
heparin	NOUN	O	Chemical	680
-	PUNCT	O	O	680
induced	VERB	O	O	680
thrombocytopenia	PROPN	O	Disease	680
.	PUNCT	O	O	680
infusion	NOUN	O	O	681
of	ADP	O	O	681
argatroban	NOUN	O	O	681
was	AUX	O	O	681
initiated	VERB	O	O	681
,	PUNCT	O	O	681
and	CCONJ	O	O	681
the	PRON	O	O	681
patient	NOUN	O	O	681
was	AUX	O	O	681
managed	VERB	O	O	681
on	ADP	O	O	681
the	PRON	O	O	681
general	ADJ	O	O	681
medical	ADJ	O	O	681
floor	NOUN	O	O	681
.	PUNCT	O	O	681
After	ADP	O	O	682
one	NUM	O	O	682
week	NOUN	O	O	682
of	ADP	O	O	682
therapy	NOUN	O	O	682
,	PUNCT	O	O	682
he	PRON	O	O	682
was	AUX	O	O	682
transferred	VERB	O	O	682
to	PART	O	O	682
the	PRON	O	O	682
intensive	ADJ	O	O	682
care	VERB	O	O	682
unit	NOUN	O	O	682
with	ADP	O	O	682
cardiopulmonary	VERB	O	O	682
compromise	NOUN	O	O	682
related	ADJ	O	O	682
to	PART	O	O	682
superior	PROPN	O	O	682
vena	PROPN	O	O	682
cava	NOUN	O	O	682
(	PUNCT	O	O	682
SVC	NOUN	O	O	682
)	PUNCT	O	O	682
syndrome	NOUN	O	O	682
.	PUNCT	O	O	682
A	PRON	O	O	683
percutaneous	ADJ	O	O	683
mechanical	ADJ	O	O	683
thrombectomy	ADV	O	O	683
and	CCONJ	O	O	683
CDT	PROPN	O	O	683
with	ADP	O	O	683
alteplase	NOUN	O	O	683
were	AUX	O	O	683
attempted	VERB	O	O	683
,	PUNCT	O	O	683
but	CCONJ	O	O	683
the	PRON	O	O	683
procedure	NOUN	O	O	683
was	AUX	O	O	683
aborted	VERB	O	O	683
due	ADJ	O	O	683
to	PART	O	O	683
epistaxis	PROPN	O	O	683
.	PUNCT	O	O	683
The	PRON	O	O	684
epistaxis	PROPN	O	O	684
resolved	VERB	O	O	684
the	PRON	O	O	684
next	ADV	O	O	684
day	NOUN	O	O	684
,	PUNCT	O	O	684
and	CCONJ	O	O	684
the	PRON	O	O	684
patient	NOUN	O	O	684
was	AUX	O	O	684
restarted	VERB	O	O	684
on	ADP	O	O	684
argatroban	NOUN	O	O	684
.	PUNCT	O	O	684
Postthrombectomy	NOUN	O	O	685
continuous	ADJ	O	O	685
CDT	PROPN	O	O	685
with	ADP	O	O	685
alteplase	NOUN	O	O	685
was	AUX	O	O	685
commenced	VERB	O	O	685
while	SCONJ	O	O	685
argatroban	NOUN	O	O	685
was	AUX	O	O	685
withheld	VERB	O	O	685
,	PUNCT	O	O	685
and	CCONJ	O	O	685
complete	VERB	O	O	685
patency	NOUN	O	O	685
of	ADP	O	O	685
the	PRON	O	O	685
SVC	NOUN	O	O	685
and	CCONJ	O	O	685
central	ADJ	O	O	685
veins	NOUN	O	O	685
was	AUX	O	O	685
achieved	VERB	O	O	685
after	ADP	O	O	685
three	NUM	O	O	685
days	NOUN	O	O	685
of	ADP	O	O	685
therapy	NOUN	O	O	685
.	PUNCT	O	O	685
Alteplase	PROPN	O	O	686
was	AUX	O	O	686
discontinued	VERB	O	O	686
,	PUNCT	O	O	686
and	CCONJ	O	O	686
the	PRON	O	O	686
patient	NOUN	O	O	686
was	AUX	O	O	686
reinitiated	VERB	O	O	686
on	ADP	O	O	686
argatroban	NOUN	O	O	686
;	PUNCT	O	O	686
ultimately	ADV	O	O	686
,	PUNCT	O	O	686
he	PRON	O	O	686
was	AUX	O	O	686
transitioned	VERB	O	O	686
to	PART	O	O	686
warfarin	VERB	O	Chemical	686
for	ADP	O	O	686
long	ADV	O	O	686
-	PUNCT	O	O	686
term	NOUN	O	O	686
anticoagulation	NOUN	O	O	686
.	PUNCT	O	O	686
Although	SCONJ	O	O	687
the	PRON	O	O	687
patient	NOUN	O	O	687
recovered	VERB	O	O	687
,	PUNCT	O	O	687
he	PRON	O	O	687
experienced	ADJ	O	O	687
permanent	ADJ	O	O	687
vision	PROPN	O	O	687
and	CCONJ	O	O	687
hearing loss	NOUN	O	Disease	687
,	PUNCT	O	O	687
as	ADP	O	O	687
well	ADV	O	O	687
as	ADP	O	O	687
end	VERB	O	O	687
-	PUNCT	O	O	687
stage	NOUN	O	O	687
renal disease	NOUN	O	Disease	687
.	PUNCT	O	O	687
A	PRON	O	O	688
63-year	NOUN	O	O	688
-	PUNCT	O	O	688
old	ADJ	O	O	688
man	NOUN	O	O	688
with	ADP	O	O	688
renal	ADJ	O	O	688
amyloidosis	NOUN	O	O	688
and	CCONJ	O	O	688
SVC	NOUN	O	O	688
syndrome	NOUN	O	O	688
secondary	ADJ	O	O	688
to	PART	O	O	688
HITT	PROPN	O	O	688
was	AUX	O	O	688
successfully	ADV	O	O	688
treated	VERB	O	O	688
with	ADP	O	O	688
argatroban	NOUN	O	O	688
and	CCONJ	O	O	688
CDT	PROPN	O	O	688
with	ADP	O	O	688
alteplase	NOUN	O	O	688
.	PUNCT	O	O	688
Effects	NOUN	O	O	691
of	ADP	O	O	691
dehydroepiandrosterone	NOUN	O	O	691
in	ADP	O	O	691
amphetamine	NOUN	O	Chemical	691
-	PUNCT	O	O	691
induced	VERB	O	O	691
schizophrenia	PROPN	O	Disease	691
models	NOUN	O	O	691
in	ADP	O	O	691
mice	NOUN	O	O	691
.	PUNCT	O	O	691
OBJECTIVE	VERB	O	O	692
:	PUNCT	O	O	692
To	PART	O	O	692
examine	VERB	O	O	692
the	PRON	O	O	692
effects	NOUN	O	O	692
of	ADP	O	O	692
dehydroepiandrosterone	NOUN	O	O	692
(	PUNCT	O	O	692
DHEA	PROPN	O	O	692
)	PUNCT	O	O	692
on	ADP	O	O	692
animal	NOUN	O	O	692
models	NOUN	O	O	692
of	ADP	O	O	692
schizophrenia	PROPN	O	Disease	692
.	PUNCT	O	O	692
METHODS	NOUN	O	O	693
:	PUNCT	O	O	693
Seventy	NUM	O	O	693
Swiss	PROPN	O	O	693
albino	PROPN	O	O	693
female	ADJ	O	O	693
mice	NOUN	O	O	693
(	PUNCT	O	O	693
25	NUM	O	O	693
-	PUNCT	O	O	693
35	NUM	O	O	693
g	X	O	O	693
)	PUNCT	O	O	693
were	AUX	O	O	693
divided	VERB	O	O	693
into	ADP	O	O	693
4	NUM	O	O	693
groups	NOUN	O	O	693
:	PUNCT	O	O	693
amphetamine	NOUN	O	Chemical	693
-	PUNCT	O	O	693
free	ADJ	O	O	693
(	PUNCT	O	O	693
control	VERB	O	O	693
)	PUNCT	O	O	693
,	PUNCT	O	O	693
amphetamine	NOUN	O	Chemical	693
,	PUNCT	O	O	693
50	NUM	O	O	693
,	PUNCT	O	O	693
and	CCONJ	O	O	693
100	NUM	O	O	693
mg	VERB	O	O	693
/	PUNCT	O	O	693
kg	VERB	O	O	693
DHEA	PROPN	O	O	693
.	PUNCT	O	O	693
The	PRON	O	O	694
DHEA	PROPN	O	O	694
was	AUX	O	O	694
administered	VERB	O	O	694
intraperitoneally	ADV	O	O	694
(	PUNCT	O	O	694
ip	X	O	O	694
)	PUNCT	O	O	694
for	ADP	O	O	694
5	NUM	O	O	694
days	NOUN	O	O	694
.	PUNCT	O	O	694
Amphetamine	NOUN	O	Chemical	695
(	PUNCT	O	O	695
3	X	O	O	695
mg	VERB	O	O	695
/	PUNCT	O	O	695
kg	VERB	O	O	695
ip	X	O	O	695
)	PUNCT	O	O	695
induced	VERB	O	O	695
hyper	ADJ	O	O	695
locomotion	NOUN	O	O	695
,	PUNCT	O	O	695
apomorphine	PROPN	O	Chemical	695
(	PUNCT	O	O	695
1.5	NUM	O	O	695
mg	VERB	O	O	695
/	PUNCT	O	O	695
kg	VERB	O	O	695
subcutaneously	ADV	O	O	696
[	X	O	O	696
sc	PROPN	O	O	696
]	PUNCT	O	O	696
)	PUNCT	O	O	696
induced	VERB	O	O	696
climbing	VERB	O	O	696
,	PUNCT	O	O	696
and	CCONJ	O	O	696
haloperidol	NOUN	O	Chemical	696
(	PUNCT	O	O	696
1.5	NUM	O	O	696
mg	VERB	O	O	696
/	PUNCT	O	O	696
kg	VERB	O	O	696
sc	PROPN	O	O	696
)	PUNCT	O	O	696
induced	VERB	O	O	696
catalepsy	VERB	O	Disease	696
tests	VERB	O	O	696
were	AUX	O	O	696
used	VERB	O	O	696
as	ADP	O	O	696
animal	NOUN	O	O	696
models	NOUN	O	O	696
of	ADP	O	O	696
schizophrenia	PROPN	O	Disease	696
.	PUNCT	O	O	696
Statistical	ADJ	O	O	697
analysis	NOUN	O	O	697
was	AUX	O	O	697
carried	VERB	O	O	697
out	ADP	O	O	697
using	VERB	O	O	697
Kruskal	PROPN	O	O	697
-	PUNCT	O	O	697
Wallis	PROPN	O	O	697
test	NOUN	O	O	697
for	ADP	O	O	697
hyper	ADJ	O	O	697
locomotion	NOUN	O	O	697
,	PUNCT	O	O	697
and	CCONJ	O	O	697
one	NUM	O	O	697
-	PUNCT	O	O	697
way	NOUN	O	O	697
ANOVA	PROPN	O	O	697
for	ADP	O	O	697
climbing	VERB	O	O	697
and	CCONJ	O	O	697
catalepsy	VERB	O	Disease	697
tests	VERB	O	O	697
.	PUNCT	O	O	697
In	ADP	O	O	698
the	PRON	O	O	698
amphetamine	NOUN	O	Chemical	698
-	PUNCT	O	O	698
induced	VERB	O	O	698
locomotion	NOUN	O	O	698
test	NOUN	O	O	698
,	PUNCT	O	O	698
there	ADV	O	O	698
were	AUX	O	O	698
significant	ADJ	O	O	698
increases	VERB	O	O	698
in	ADP	O	O	698
all	PRON	O	O	698
movements	NOUN	O	O	698
compared	VERB	O	O	698
with	ADP	O	O	698
the	PRON	O	O	698
amphetamine	NOUN	O	Chemical	698
-	PUNCT	O	O	698
free	ADJ	O	O	698
group	NOUN	O	O	698
.	PUNCT	O	O	698
Both	PRON	O	O	699
DHEA	PROPN	O	O	699
50	NUM	O	O	699
mg	VERB	O	O	699
/	PUNCT	O	O	699
kg	VERB	O	O	699
(	PUNCT	O	O	699
p<0.05	NOUN	O	O	699
)	PUNCT	O	O	699
,	PUNCT	O	O	699
and	CCONJ	O	O	699
100	NUM	O	O	699
mg	VERB	O	O	699
/	PUNCT	O	O	699
kg	VERB	O	O	699
(	PUNCT	O	O	699
p<0.01	ADV	O	O	699
)	PUNCT	O	O	699
significantly	ADV	O	O	699
decreased	VERB	O	O	699
all	PRON	O	O	699
movements	NOUN	O	O	699
compared	VERB	O	O	699
with	ADP	O	O	699
the	PRON	O	O	699
amphetamine	NOUN	O	Chemical	699
-	PUNCT	O	O	699
induced	VERB	O	O	699
locomotion	NOUN	O	O	699
group	NOUN	O	O	699
.	PUNCT	O	O	699
There	ADV	O	O	700
was	AUX	O	O	700
a	PRON	O	O	700
significant	ADJ	O	O	700
difference	NOUN	O	O	700
between	ADP	O	O	700
groups	NOUN	O	O	700
in	ADP	O	O	700
the	PRON	O	O	700
haloperidol	NOUN	O	Chemical	700
-	PUNCT	O	O	700
induced	VERB	O	O	700
catalepsy	VERB	O	Disease	700
test	NOUN	O	O	700
(	PUNCT	O	O	700
p<0.05	NOUN	O	O	700
)	PUNCT	O	O	700
.	PUNCT	O	O	700
There	ADV	O	O	701
was	AUX	O	O	701
no	PRON	O	O	701
significant	ADJ	O	O	701
difference	NOUN	O	O	701
between	ADP	O	O	701
groups	NOUN	O	O	701
in	ADP	O	O	701
terms	NOUN	O	O	701
of	ADP	O	O	701
total	ADJ	O	O	701
climbing	VERB	O	O	701
time	NOUN	O	O	701
in	ADP	O	O	701
the	PRON	O	O	701
apomorphine	PROPN	O	Chemical	701
-	PUNCT	O	O	701
induced	VERB	O	O	701
climbing	VERB	O	O	701
test	NOUN	O	O	701
(	PUNCT	O	O	701
p>0.05	PROPN	O	O	701
)	PUNCT	O	O	701
.	PUNCT	O	O	701
We	PRON	O	O	702
observed	VERB	O	O	702
that	SCONJ	O	O	702
DHEA	PROPN	O	O	702
reduced	VERB	O	O	702
locomotor	PROPN	O	O	702
activity	NOUN	O	O	702
and	CCONJ	O	O	702
increased	VERB	O	O	702
catalepsy	VERB	O	Disease	702
at	ADP	O	O	702
both	PRON	O	O	702
doses	NOUN	O	O	702
,	PUNCT	O	O	702
while	SCONJ	O	O	702
it	PRON	O	O	702
had	VERB	O	O	702
no	PRON	O	O	702
effect	VERB	O	O	702
on	ADP	O	O	702
climbing	VERB	O	O	702
behavior	NOUN	O	O	702
.	PUNCT	O	O	702
We	PRON	O	O	703
suggest	VERB	O	O	703
that	SCONJ	O	O	703
DHEA	PROPN	O	O	703
displays	VERB	O	O	703
typical	ADJ	O	O	703
neuroleptic	NOUN	O	O	703
-	PUNCT	O	O	703
like	INTJ	O	O	703
effects	NOUN	O	O	703
,	PUNCT	O	O	703
and	CCONJ	O	O	703
may	AUX	O	O	703
be	AUX	O	O	703
used	VERB	O	O	703
in	ADP	O	O	703
the	PRON	O	O	703
treatment	NOUN	O	O	703
of	ADP	O	O	703
schizophrenia	PROPN	O	Disease	703
.	PUNCT	O	O	703
Availability	NOUN	O	O	706
of	ADP	O	O	706
human	PROPN	O	O	706
induced	VERB	O	O	706
pluripotent	VERB	O	O	706
stem	VERB	O	O	706
cell	NOUN	O	O	706
-	PUNCT	O	O	706
derived	VERB	O	O	706
cardiomyocytes	NOUN	O	O	706
in	ADP	O	O	706
assessment	NOUN	O	O	706
of	ADP	O	O	706
drug	NOUN	O	O	706
potential	ADJ	O	O	706
for	ADP	O	O	706
QT prolongation	NOUN	O	Disease	706
.	PUNCT	O	O	706
Field	NOUN	O	O	707
potential	ADJ	O	O	707
duration	NOUN	O	O	707
(	PUNCT	O	O	707
FPD	PROPN	O	O	707
)	PUNCT	O	O	707
in	ADP	O	O	707
human	PROPN	O	O	707
-	PUNCT	O	O	707
induced	VERB	O	O	707
pluripotent	VERB	O	O	707
stem	VERB	O	O	707
cell	NOUN	O	O	707
-	PUNCT	O	O	707
derived	VERB	O	O	707
cardiomyocytes	NOUN	O	O	707
(	PUNCT	O	O	707
hiPS	PUNCT	O	O	707
-	PUNCT	O	O	707
CMs	PROPN	O	O	707
)	PUNCT	O	O	707
,	PUNCT	O	O	707
which	PRON	O	O	707
can	AUX	O	O	707
express	VERB	O	O	707
QT	NOUN	O	O	707
interval	NOUN	O	O	707
in	ADP	O	O	707
an	PRON	O	O	707
electrocardiogram	PROPN	O	O	707
,	PUNCT	O	O	707
is	AUX	O	O	707
reported	VERB	O	O	707
to	PART	O	O	707
be	AUX	O	O	707
a	PRON	O	O	707
useful	ADJ	O	O	707
tool	NOUN	O	O	707
to	PART	O	O	707
predict	VERB	O	O	707
K(+	NOUN	O	O	707
)	PUNCT	O	O	707
channel	PROPN	O	O	707
and	CCONJ	O	O	707
Ca(2	PROPN	O	O	707
+	ADP	O	O	707
)	PUNCT	O	O	707
channel	PROPN	O	O	707
blocker	NOUN	O	O	707
effects	NOUN	O	O	707
on	ADP	O	O	707
QT	NOUN	O	O	707
interval	NOUN	O	O	707
.	PUNCT	O	O	707
However	ADV	O	O	708
,	PUNCT	O	O	708
there	ADV	O	O	708
is	AUX	O	O	708
no	PRON	O	O	708
report	VERB	O	O	708
showing	VERB	O	O	708
that	SCONJ	O	O	708
this	PRON	O	O	708
technique	NOUN	O	O	708
can	AUX	O	O	708
be	AUX	O	O	708
used	VERB	O	O	708
to	PART	O	O	708
predict	VERB	O	O	708
multichannel	PROPN	O	O	708
blocker	NOUN	O	O	708
potential	ADJ	O	O	708
for	ADP	O	O	708
QT prolongation	NOUN	O	Disease	708
.	PUNCT	O	O	708
The	PRON	O	O	709
aim	VERB	O	O	709
of	ADP	O	O	709
this	PRON	O	O	709
study	VERB	O	O	709
is	AUX	O	O	709
to	PART	O	O	709
show	VERB	O	O	709
that	SCONJ	O	O	709
FPD	PROPN	O	O	709
from	ADP	O	O	709
MEA	PROPN	O	O	709
(	PUNCT	O	O	709
Multielectrode	NOUN	O	O	709
array	NOUN	O	O	709
)	PUNCT	O	O	709
of	ADP	O	O	709
hiPS	PUNCT	O	O	709
-	PUNCT	O	O	709
CMs	PROPN	O	O	709
can	AUX	O	O	709
detect	VERB	O	O	709
QT prolongation	NOUN	O	Disease	709
induced	VERB	O	O	709
by	ADP	O	O	709
multichannel	PROPN	O	O	709
blockers	NOUN	O	O	709
.	PUNCT	O	O	709
IKr	NOUN	O	O	710
and	CCONJ	O	O	710
IKs	NOUN	O	O	710
blockers	NOUN	O	O	710
concentration	NOUN	O	O	710
-	PUNCT	O	O	710
dependently	ADV	O	O	710
prolonged	VERB	O	O	710
corrected	VERB	O	O	710
FPD	PROPN	O	O	710
(	PUNCT	O	O	710
FPDc	NOUN	O	O	710
)	PUNCT	O	O	710
,	PUNCT	O	O	710
whereas	SCONJ	O	O	710
Ca(2	PROPN	O	O	710
+	ADP	O	O	710
)	PUNCT	O	O	710
channel	PROPN	O	O	710
blockers	NOUN	O	O	710
concentration	NOUN	O	O	710
-	PUNCT	O	O	710
dependently	ADV	O	O	710
shortened	VERB	O	O	710
FPDc	NOUN	O	O	710
.	PUNCT	O	O	710
Also	ADV	O	O	711
,	PUNCT	O	O	711
the	PRON	O	O	711
multichannel	PROPN	O	O	711
blockers	NOUN	O	O	711
Amiodarone	NOUN	O	Chemical	711
,	PUNCT	O	O	711
Paroxetine	NOUN	O	O	711
,	PUNCT	O	O	711
Terfenadine	PROPN	O	O	711
and	CCONJ	O	O	711
Citalopram	PROPN	O	O	711
prolonged	VERB	O	O	711
FPDc	NOUN	O	O	711
in	ADP	O	O	711
a	PRON	O	O	711
concentration	NOUN	O	O	711
dependent	ADJ	O	O	711
manner	VERB	O	O	711
.	PUNCT	O	O	711
Finally	ADV	O	O	712
,	PUNCT	O	O	712
the	PRON	O	O	712
IKr	NOUN	O	O	712
blockers	NOUN	O	O	712
,	PUNCT	O	O	712
Terfenadine	PROPN	O	O	712
and	CCONJ	O	O	712
Citalopram	PROPN	O	O	712
,	PUNCT	O	O	712
which	PRON	O	O	712
are	AUX	O	O	712
reported	VERB	O	O	712
to	PART	O	O	712
cause	VERB	O	O	712
Torsade	NOUN	O	O	712
de	VERB	O	O	712
Pointes	NOUN	O	O	712
(	PUNCT	O	O	712
TdP	NOUN	O	Disease	712
)	PUNCT	O	O	712
in	ADP	O	O	712
clinical	ADJ	O	O	712
practice	VERB	O	O	712
,	PUNCT	O	O	712
produced	VERB	O	O	712
early	ADV	O	O	712
afterdepolarization	NOUN	O	O	712
(	PUNCT	O	O	712
EAD	PROPN	O	O	712
)	PUNCT	O	O	712
.	PUNCT	O	O	712
This	PRON	O	O	713
study	VERB	O	O	713
also	ADV	O	O	713
shows	VERB	O	O	713
that	SCONJ	O	O	713
this	PRON	O	O	713
assay	NOUN	O	O	713
can	AUX	O	O	713
help	VERB	O	O	713
detect	VERB	O	O	713
EAD	PROPN	O	O	713
for	ADP	O	O	713
drugs	NOUN	O	O	713
with	ADP	O	O	713
TdP	NOUN	O	Disease	713
potential	ADJ	O	O	713
.	PUNCT	O	O	713
Dermal	PROPN	O	O	716
developmental	ADJ	O	O	716
toxicity	NOUN	O	Disease	716
of	ADP	O	O	716
N	NUM	O	O	716
-	PUNCT	O	O	716
phenylimide	ADV	O	O	716
herbicides	NOUN	O	O	716
in	ADP	O	O	716
rats	NOUN	O	O	716
.	PUNCT	O	O	716
BACKGROUND	NOUN	O	O	717
:	PUNCT	O	O	717
S-53482	VERB	O	O	717
and	CCONJ	O	O	717
S-23121	NOUN	O	O	717
are	AUX	O	O	717
N	NUM	O	O	717
-	PUNCT	O	O	717
phenylimide	ADV	O	O	717
herbicides	NOUN	O	O	717
and	CCONJ	O	O	717
produced	VERB	O	O	717
embryolethality	NOUN	O	O	717
,	PUNCT	O	O	717
teratogenicity	NOUN	O	O	717
(	PUNCT	O	O	717
mainly	ADV	O	O	717
ventricular septal defects	NOUN	O	Disease	717
and	CCONJ	O	O	717
wavy	ADJ	O	O	717
ribs	NOUN	O	O	717
)	PUNCT	O	O	717
,	PUNCT	O	O	717
and	CCONJ	O	O	717
growth	NOUN	O	O	717
retardation	NOUN	O	O	717
in	ADP	O	O	717
rats	NOUN	O	O	717
in	ADP	O	O	717
conventional	ADJ	O	O	717
oral	ADJ	O	O	717
developmental	ADJ	O	O	717
toxicity	NOUN	O	Disease	717
studies	NOUN	O	O	717
.	PUNCT	O	O	717
Our	PRON	O	O	718
objective	VERB	O	O	718
in	ADP	O	O	718
this	PRON	O	O	718
study	VERB	O	O	718
was	AUX	O	O	718
to	PART	O	O	718
investigate	VERB	O	O	718
whether	SCONJ	O	O	718
the	PRON	O	O	718
compounds	NOUN	O	O	718
induce	VERB	O	O	718
developmental	ADJ	O	O	718
toxicity	NOUN	O	Disease	718
via	ADP	O	O	718
the	PRON	O	O	718
dermal	NOUN	O	O	718
route	VERB	O	O	718
,	PUNCT	O	O	718
which	PRON	O	O	718
is	AUX	O	O	718
more	ADJ	O	O	718
relevant	ADJ	O	O	718
to	PART	O	O	718
occupational	ADJ	O	O	718
exposure	NOUN	O	O	718
,	PUNCT	O	O	718
hence	ADV	O	O	718
better	ADV	O	O	718
addressing	VERB	O	O	718
human	PROPN	O	O	718
health	NOUN	O	O	718
risks	NOUN	O	O	718
.	PUNCT	O	O	718
S-53482	VERB	O	O	719
was	AUX	O	O	719
administered	VERB	O	O	719
dermally	ADV	O	O	719
to	PART	O	O	719
rats	NOUN	O	O	719
at	ADP	O	O	719
30	NUM	O	O	719
,	PUNCT	O	O	719
100	NUM	O	O	719
,	PUNCT	O	O	719
and	CCONJ	O	O	719
300	NUM	O	O	719
mg	VERB	O	O	719
/	PUNCT	O	O	719
kg	VERB	O	O	719
during	ADP	O	O	719
organogenesis	NOUN	O	O	719
,	PUNCT	O	O	719
and	CCONJ	O	O	719
S-23121	NOUN	O	O	719
was	AUX	O	O	719
administered	VERB	O	O	719
at	ADP	O	O	719
200	NUM	O	O	719
,	PUNCT	O	O	719
400	NUM	O	O	719
,	PUNCT	O	O	719
and	CCONJ	O	O	719
800	NUM	O	O	719
mg	VERB	O	O	719
/	PUNCT	O	O	719
kg	VERB	O	O	719
(	PUNCT	O	O	719
the	PRON	O	O	719
maximum	ADV	O	O	719
applicable	ADJ	O	O	719
dose	NOUN	O	O	719
level	VERB	O	O	719
)	PUNCT	O	O	719
.	PUNCT	O	O	719
RESULTS	VERB	O	O	720
:	PUNCT	O	O	720
Dermal	PROPN	O	O	720
exposure	NOUN	O	O	720
of	ADP	O	O	720
rats	NOUN	O	O	720
to	PART	O	O	720
S-53482	VERB	O	O	720
at	ADP	O	O	720
300	NUM	O	O	720
mg	VERB	O	O	720
/	PUNCT	O	O	720
kg	VERB	O	O	720
produced	VERB	O	O	720
patterns	NOUN	O	O	720
of	ADP	O	O	720
developmental	ADJ	O	O	720
toxicity	NOUN	O	Disease	720
similar	ADJ	O	O	720
to	PART	O	O	720
those	PRON	O	O	720
resulting	VERB	O	O	720
from	ADP	O	O	720
oral	ADJ	O	O	720
exposure	NOUN	O	O	720
.	PUNCT	O	O	720
Toxicity	NOUN	O	Disease	721
included	VERB	O	O	721
embryolethality	NOUN	O	O	721
,	PUNCT	O	O	721
teratogenicity	NOUN	O	O	721
,	PUNCT	O	O	721
and	CCONJ	O	O	721
growth	NOUN	O	O	721
retardation	NOUN	O	O	721
.	PUNCT	O	O	721
Dermal	PROPN	O	O	722
administration	NOUN	O	O	722
of	ADP	O	O	722
S-23121	NOUN	O	O	722
at	ADP	O	O	722
800	NUM	O	O	722
mg	VERB	O	O	722
/	PUNCT	O	O	722
kg	VERB	O	O	722
resulted	VERB	O	O	722
in	ADP	O	O	722
an	PRON	O	O	722
increased	VERB	O	O	722
incidence	NOUN	O	O	722
of	ADP	O	O	722
embryonic	ADJ	O	O	722
death	NOUN	O	O	722
and	CCONJ	O	O	722
ventricular septal defect	NOUN	O	Disease	722
,	PUNCT	O	O	722
but	CCONJ	O	O	722
retarded	ADJ	O	O	722
fetal	ADJ	O	O	722
growth	NOUN	O	O	722
was	AUX	O	O	722
not	PART	O	O	722
observed	VERB	O	O	722
as	ADP	O	O	722
it	PRON	O	O	722
was	AUX	O	O	722
following	VERB	O	O	722
oral	ADJ	O	O	722
exposure	NOUN	O	O	722
to	PART	O	O	722
S-23121	NOUN	O	O	722
.	PUNCT	O	O	722
CONCLUSIONS	NOUN	O	O	723
:	PUNCT	O	O	723
Based	VERB	O	O	723
on	ADP	O	O	723
the	PRON	O	O	723
results	VERB	O	O	723
,	PUNCT	O	O	723
S-53482	VERB	O	O	723
and	CCONJ	O	O	723
S-23121	NOUN	O	O	723
were	AUX	O	O	723
teratogenic	ADJ	O	O	723
when	SCONJ	O	O	723
administered	VERB	O	O	723
dermally	ADV	O	O	723
to	PART	O	O	723
pregnant	ADJ	O	O	723
rats	NOUN	O	O	723
as	ADP	O	O	723
were	AUX	O	O	723
the	PRON	O	O	723
compounds	NOUN	O	O	723
administered	VERB	O	O	723
orally	ADV	O	O	723
.	PUNCT	O	O	723
Rates	NOUN	O	O	726
of	ADP	O	O	726
Renal	NOUN	O	O	726
Toxicity	NOUN	O	Disease	726
in	ADP	O	O	726
Cancer	NOUN	O	O	726
Patients	NOUN	O	O	726
Receiving	VERB	O	O	727
Cisplatin	PROPN	O	O	727
With	ADP	O	O	728
and	CCONJ	O	O	728
Without	ADP	O	O	728
Mannitol	PROPN	O	Chemical	728
.	PUNCT	O	O	728
Cisplatin	PROPN	O	O	729
is	AUX	O	O	729
a	PRON	O	O	729
widely	ADV	O	O	729
used	VERB	O	O	729
antineoplastic	ADJ	O	O	729
.	PUNCT	O	O	729
One	NUM	O	O	730
of	ADP	O	O	730
the	PRON	O	O	730
major	ADJ	O	O	730
complications	NOUN	O	O	730
of	ADP	O	O	730
cisplatin	NOUN	O	Chemical	730
use	VERB	O	O	730
is	AUX	O	O	730
dose	NOUN	O	O	730
-	PUNCT	O	O	730
limiting	VERB	O	O	730
nephrotoxicity	NOUN	O	Disease	730
.	PUNCT	O	O	730
There	ADV	O	O	731
are	AUX	O	O	731
many	ADJ	O	O	731
strategies	NOUN	O	O	731
to	PART	O	O	731
prevent	VERB	O	O	731
this	PRON	O	O	731
toxicity	NOUN	O	Disease	731
,	PUNCT	O	O	731
including	VERB	O	O	731
the	PRON	O	O	731
use	VERB	O	O	731
of	ADP	O	O	731
mannitol	PROPN	O	Chemical	731
as	ADP	O	O	731
a	PRON	O	O	731
nephroprotectant	NOUN	O	O	731
in	ADP	O	O	731
combination	NOUN	O	O	731
with	ADP	O	O	731
hydration	NOUN	O	O	731
.	PUNCT	O	O	731
OBJECTIVE	VERB	O	O	732
:	PUNCT	O	O	732
We	PRON	O	O	732
aimed	VERB	O	O	732
to	PART	O	O	732
evaluate	VERB	O	O	732
the	PRON	O	O	732
rates	NOUN	O	O	732
of	ADP	O	O	732
cisplatin	NOUN	O	Chemical	732
-	PUNCT	O	O	732
induced	VERB	O	O	732
nephrotoxicity	NOUN	O	Disease	732
in	ADP	O	O	732
cancer	NOUN	O	Disease	732
patients	NOUN	O	O	732
receiving	VERB	O	O	732
single	ADJ	O	O	732
-	PUNCT	O	O	732
agent	NOUN	O	O	732
cisplatin	NOUN	O	Chemical	732
with	ADP	O	O	732
and	CCONJ	O	O	732
without	ADP	O	O	732
mannitol	PROPN	O	Chemical	732
.	PUNCT	O	O	732
This	PRON	O	O	733
single	ADJ	O	O	733
-	PUNCT	O	O	733
center	PROPN	O	O	733
retrospective	ADJ	O	O	733
analysis	NOUN	O	O	733
was	AUX	O	O	733
a	PRON	O	O	733
quasi	ADJ	O	O	733
experiment	NOUN	O	O	733
created	VERB	O	O	733
by	ADP	O	O	733
the	PRON	O	O	733
national	ADJ	O	O	733
mannitol	PROPN	O	Chemical	733
shortage	NOUN	O	O	733
.	PUNCT	O	O	733
Data	NOUN	O	O	734
were	AUX	O	O	734
collected	VERB	O	O	734
on	ADP	O	O	734
adult	NOUN	O	O	734
cancer	NOUN	O	Disease	734
patients	NOUN	O	O	734
receiving	VERB	O	O	734
single	ADJ	O	O	734
-	PUNCT	O	O	734
agent	NOUN	O	O	734
cisplatin	NOUN	O	Chemical	734
as	ADP	O	O	734
an	PRON	O	O	734
outpatient	NOUN	O	O	734
from	ADP	O	O	734
January	PROPN	O	O	734
2011	NUM	O	O	734
to	PART	O	O	734
September	PROPN	O	O	734
2012	NUM	O	O	734
.	PUNCT	O	O	734
The	PRON	O	O	735
primary	NOUN	O	O	735
outcome	NOUN	O	O	735
was	AUX	O	O	735
acute	ADJ	O	O	735
kidney	NOUN	O	O	735
injury	NOUN	O	O	735
(	PUNCT	O	O	735
AKI	PROPN	O	O	735
)	PUNCT	O	O	735
.	PUNCT	O	O	735
We	PRON	O	O	736
evaluated	VERB	O	O	736
143	NUM	O	O	736
patients	NOUN	O	O	736
who	PRON	O	O	736
received	VERB	O	O	736
single	ADJ	O	O	736
-	PUNCT	O	O	736
agent	NOUN	O	O	736
cisplatin	NOUN	O	Chemical	736
;	PUNCT	O	O	736
97.2%	NOUN	O	O	736
of	ADP	O	O	736
patients	NOUN	O	O	736
had	VERB	O	O	736
head	NOUN	O	O	736
and	CCONJ	O	O	736
neck	NOUN	O	O	736
cancer	NOUN	O	Disease	736
as	ADP	O	O	736
their	PRON	O	O	736
primary	NOUN	O	O	736
malignancy	NOUN	O	Disease	736
.	PUNCT	O	O	736
Patients	NOUN	O	O	737
who	PRON	O	O	737
did	VERB	O	O	737
not	PART	O	O	737
receive	VERB	O	O	737
mannitol	PROPN	O	Chemical	737
were	AUX	O	O	737
more	ADJ	O	O	737
likely	ADV	O	O	737
to	PART	O	O	737
develop	VERB	O	O	737
nephrotoxicity	NOUN	O	Disease	737
:	PUNCT	O	O	737
odds	NOUN	O	O	737
ratio	NOUN	O	O	737
[	X	O	O	737
OR	CCONJ	O	O	737
]	PUNCT	O	O	737
=	PUNCT	O	O	737
2.646	NUM	O	O	737
(	PUNCT	O	O	737
95%	NOUN	O	O	737
CI	NOUN	O	O	737
=	PUNCT	O	O	737
1.008	NUM	O	O	737
,	PUNCT	O	O	737
6.944	NUM	O	O	737
;	PUNCT	O	O	737
P	NOUN	O	Chemical	737
=	PUNCT	O	O	737
0.048	NUM	O	O	737
)	PUNCT	O	O	737
.	PUNCT	O	O	737
Patients	NOUN	O	O	738
who	PRON	O	O	738
received	VERB	O	O	738
the	PRON	O	O	738
100	NUM	O	O	738
mg	VERB	O	O	738
/	PUNCT	O	O	738
m(2	NUM	O	O	738
)	PUNCT	O	O	738
dosing	VERB	O	O	738
and	CCONJ	O	O	738
patients	NOUN	O	O	738
who	PRON	O	O	738
had	VERB	O	O	738
a	PRON	O	O	738
history	NOUN	O	O	738
of	ADP	O	O	738
hypertension	NOUN	O	Disease	738
also	ADV	O	O	738
had	VERB	O	O	738
a	PRON	O	O	738
higher	ADJ	O	O	738
likelihood	NOUN	O	O	738
of	ADP	O	O	738
developing	VERB	O	O	738
nephrotoxicity	NOUN	O	Disease	738
:	PUNCT	O	O	738
OR	CCONJ	O	O	738
=	PUNCT	O	O	738
11.494	NUM	O	O	738
(	PUNCT	O	O	738
95%	NOUN	O	O	738
CI	NOUN	O	O	738
=	PUNCT	O	O	738
4.149	NUM	O	O	738
,	PUNCT	O	O	738
32.258	NUM	O	O	738
;	PUNCT	O	O	738
CONCLUSIONS	NOUN	O	O	739
:	PUNCT	O	O	739
When	SCONJ	O	O	739
limited	VERB	O	O	739
quantities	NOUN	O	O	739
of	ADP	O	O	739
mannitol	PROPN	O	Chemical	739
are	AUX	O	O	739
available	ADJ	O	O	739
,	PUNCT	O	O	739
it	PRON	O	O	739
should	AUX	O	O	739
preferentially	ADV	O	O	739
be	AUX	O	O	739
given	VERB	O	O	739
to	PART	O	O	739
patients	NOUN	O	O	739
at	ADP	O	O	739
particularly	ADV	O	O	739
high	ADJ	O	O	739
risk	NOUN	O	O	739
of	ADP	O	O	739
nephrotoxicity	NOUN	O	Disease	739
.	PUNCT	O	O	739
Our	PRON	O	O	740
analysis	NOUN	O	O	740
suggests	VERB	O	O	740
that	SCONJ	O	O	740
those	PRON	O	O	740
patients	NOUN	O	O	740
receiving	VERB	O	O	740
the	PRON	O	O	740
dosing	VERB	O	O	740
schedule	NOUN	O	O	740
of	ADP	O	O	740
100	NUM	O	O	740
mg	VERB	O	O	740
/	PUNCT	O	O	740
m(2	NUM	O	O	740
)	PUNCT	O	O	740
cisplatin	NOUN	O	Chemical	740
every	PRON	O	O	740
3	X	O	O	740
weeks	NOUN	O	O	740
and	CCONJ	O	O	740
those	PRON	O	O	740
with	ADP	O	O	740
hypertension	NOUN	O	Disease	740
are	AUX	O	O	740
at	ADP	O	O	740
the	PRON	O	O	740
greatest	ADJ	O	O	740
risk	NOUN	O	O	740
of	ADP	O	O	740
nephrotoxicity	NOUN	O	Disease	740
and	CCONJ	O	O	740
would	AUX	O	O	740
benefit	VERB	O	O	740
from	ADP	O	O	740
the	PRON	O	O	740
addition	NOUN	O	O	740
of	ADP	O	O	740
mannitol	PROPN	O	Chemical	740
.	PUNCT	O	O	740
Metformin	NOUN	O	Chemical	743
protects	VERB	O	O	743
against	ADP	O	O	743
seizures	NOUN	O	Disease	743
,	PUNCT	O	O	743
learning	VERB	O	O	743
and	CCONJ	O	O	743
memory impairments	NOUN	O	Disease	743
and	CCONJ	O	O	743
oxidative	NOUN	O	O	743
damage	NOUN	O	O	743
induced	VERB	O	O	743
by	ADP	O	O	743
pentylenetetrazole	NOUN	O	Chemical	743
-	PUNCT	O	O	743
induced	VERB	O	O	743
kindling	VERB	O	O	743
in	ADP	O	O	743
mice	NOUN	O	O	743
.	PUNCT	O	O	743
Cognitive	NOUN	O	O	744
impairment	NOUN	O	O	744
,	PUNCT	O	O	744
the	PRON	O	O	744
most	ADV	O	O	744
common	ADJ	O	O	744
and	CCONJ	O	O	744
severe	ADJ	O	O	744
comorbidity	NOUN	O	O	744
of	ADP	O	O	744
epilepsy	NOUN	O	Disease	744
,	PUNCT	O	O	744
greatly	ADV	O	O	744
diminishes	VERB	O	O	744
the	PRON	O	O	744
quality	NOUN	O	O	744
of	ADP	O	O	744
life	NOUN	O	O	744
.	PUNCT	O	O	744
However	ADV	O	O	745
,	PUNCT	O	O	745
current	ADJ	O	O	745
therapeutic	ADJ	O	O	745
interventions	NOUN	O	O	745
for	ADP	O	O	745
epilepsy	NOUN	O	Disease	745
can	AUX	O	O	745
also	ADV	O	O	745
cause	VERB	O	O	745
untoward	ADJ	O	O	745
cognitive	ADJ	O	O	745
effects	NOUN	O	O	745
.	PUNCT	O	O	745
Thus	ADV	O	O	746
,	PUNCT	O	O	746
there	ADV	O	O	746
is	AUX	O	O	746
an	PRON	O	O	746
urgent	ADJ	O	O	746
need	VERB	O	O	746
for	ADP	O	O	746
new	ADJ	O	O	746
kinds	NOUN	O	O	746
of	ADP	O	O	746
agents	NOUN	O	O	746
targeting	VERB	O	O	746
both	PRON	O	O	746
seizures	NOUN	O	Disease	746
and	CCONJ	O	O	746
cognition	NOUN	O	O	746
deficits	NOUN	O	O	746
.	PUNCT	O	O	746
Oxidative	NOUN	O	O	747
stress	NOUN	O	O	747
is	AUX	O	O	747
considered	VERB	O	O	747
to	PART	O	O	747
play	VERB	O	O	747
an	PRON	O	O	747
important	ADJ	O	O	747
role	NOUN	O	O	747
in	ADP	O	O	747
epileptogenesis	NOUN	O	O	747
and	CCONJ	O	O	747
cognitive deficits	NOUN	O	Disease	747
,	PUNCT	O	O	747
and	CCONJ	O	O	747
antioxidants	NOUN	O	O	747
have	VERB	O	O	747
a	PRON	O	O	747
putative	ADJ	O	O	747
antiepileptic	ADJ	O	O	747
potential	ADJ	O	O	747
.	PUNCT	O	O	747
Metformin	NOUN	O	Chemical	748
,	PUNCT	O	O	748
the	PRON	O	O	748
most	ADV	O	O	748
commonly	ADV	O	O	748
prescribed	VERB	O	O	748
antidiabetic	NOUN	O	O	748
oral	ADJ	O	O	748
drug	NOUN	O	O	748
,	PUNCT	O	O	748
has	VERB	O	O	748
antioxidant	ADJ	O	O	748
properties	NOUN	O	O	748
.	PUNCT	O	O	748
This	PRON	O	O	749
study	VERB	O	O	749
was	AUX	O	O	749
designed	VERB	O	O	749
to	PART	O	O	749
evaluate	VERB	O	O	749
the	PRON	O	O	749
ameliorative	ADJ	O	O	749
effects	NOUN	O	O	749
of	ADP	O	O	749
metformin	PROPN	O	Chemical	749
on	ADP	O	O	749
seizures	NOUN	O	Disease	749
,	PUNCT	O	O	749
cognitive impairment	NOUN	O	Disease	749
and	CCONJ	O	O	749
brain	NOUN	O	O	749
oxidative	NOUN	O	O	749
stress	NOUN	O	O	749
markers	NOUN	O	O	749
observed	VERB	O	O	749
in	ADP	O	O	749
pentylenetetrazole	NOUN	O	Chemical	749
-	PUNCT	O	O	749
induced	VERB	O	O	749
kindling	VERB	O	O	749
animals	NOUN	O	O	749
.	PUNCT	O	O	749
Male	NOUN	O	O	750
C57BL/6	NOUN	O	O	750
mice	NOUN	O	O	750
were	AUX	O	O	750
administered	VERB	O	O	750
with	ADP	O	O	750
subconvulsive	ADJ	O	O	750
dose	NOUN	O	O	750
of	ADP	O	O	750
pentylenetetrazole	NOUN	O	Chemical	750
(	PUNCT	O	O	750
37	NUM	O	O	750
mg	VERB	O	O	750
/	PUNCT	O	O	750
kg	VERB	O	O	750
,	PUNCT	O	O	750
i.p	NOUN	O	O	750
.	PUNCT	O	O	750
)	PUNCT	O	O	750
every	PRON	O	O	750
other	ADJ	O	O	750
day	NOUN	O	O	750
for	ADP	O	O	750
14	NUM	O	O	750
injections	NOUN	O	O	750
.	PUNCT	O	O	750
Metformin	NOUN	O	Chemical	751
was	AUX	O	O	751
injected	VERB	O	O	751
intraperitoneally	ADV	O	O	751
in	ADP	O	O	751
dose	NOUN	O	O	751
of	ADP	O	O	751
200mg	ADV	O	O	751
/	PUNCT	O	O	751
kg	VERB	O	O	752
along	ADV	O	O	752
with	ADP	O	O	752
alternate	ADJ	O	O	752
-	PUNCT	O	O	752
day	NOUN	O	O	752
PTZ	PROPN	O	Chemical	752
.	PUNCT	O	O	752
We	PRON	O	O	753
found	VERB	O	O	753
that	SCONJ	O	O	753
metformin	PROPN	O	Chemical	753
suppressed	VERB	O	O	753
the	PRON	O	O	753
progression	NOUN	O	O	753
of	ADP	O	O	753
kindling	VERB	O	O	753
,	PUNCT	O	O	753
ameliorated	VERB	O	O	753
the	PRON	O	O	753
cognitive impairment	NOUN	O	Disease	753
and	CCONJ	O	O	753
decreased	VERB	O	O	753
brain	NOUN	O	O	753
oxidative	NOUN	O	O	753
stress	NOUN	O	O	753
.	PUNCT	O	O	753
Thus	ADV	O	O	754
the	PRON	O	O	754
present	NOUN	O	O	754
study	VERB	O	O	754
concluded	VERB	O	O	754
that	SCONJ	O	O	754
metformin	PROPN	O	Chemical	754
may	AUX	O	O	754
be	AUX	O	O	754
a	PRON	O	O	754
potential	ADJ	O	O	754
agent	NOUN	O	O	754
for	ADP	O	O	754
the	PRON	O	O	754
treatment	NOUN	O	O	754
of	ADP	O	O	754
epilepsy	NOUN	O	Disease	754
as	ADP	O	O	754
well	ADV	O	O	754
as	ADP	O	O	754
a	PRON	O	O	754
protective	ADJ	O	O	754
medicine	NOUN	O	O	754
against	ADP	O	O	754
cognitive impairment	NOUN	O	Disease	754
induced	VERB	O	O	754
by	ADP	O	O	754
seizures	NOUN	O	Disease	754
.	PUNCT	O	O	754
P53	NUM	O	O	757
inhibition	NOUN	O	O	757
exacerbates	VERB	O	O	757
late	ADV	O	O	757
-	PUNCT	O	O	757
stage	NOUN	O	O	757
anthracycline	NOUN	O	Chemical	757
cardiotoxicity	NOUN	O	Disease	757
.	PUNCT	O	O	757
AIMS	VERB	O	O	758
:	PUNCT	O	O	758
Doxorubicin	PROPN	O	Chemical	758
(	PUNCT	O	O	758
DOX	PROPN	O	Chemical	758
)	PUNCT	O	O	758
is	AUX	O	O	758
an	PRON	O	O	758
effective	ADJ	O	O	758
anti	ADJ	O	O	758
-	PUNCT	O	O	758
cancer	NOUN	O	Disease	758
therapeutic	ADJ	O	O	758
,	PUNCT	O	O	758
but	CCONJ	O	O	758
is	AUX	O	O	758
associated	VERB	O	O	758
with	ADP	O	O	758
both	PRON	O	O	758
acute	ADJ	O	O	758
and	CCONJ	O	O	758
late	ADV	O	O	758
-	PUNCT	O	O	758
stage	NOUN	O	O	758
cardiotoxicity	NOUN	O	Disease	758
.	PUNCT	O	O	758
Children	NOUN	O	O	759
are	AUX	O	O	759
particularly	ADV	O	O	759
sensitive	ADJ	O	O	759
to	PART	O	O	759
DOX	PROPN	O	Chemical	759
-	PUNCT	O	O	759
induced	VERB	O	O	759
heart failure	NOUN	O	Disease	759
.	PUNCT	O	O	759
Here	ADV	O	O	760
,	PUNCT	O	O	760
the	PRON	O	O	760
impact	NOUN	O	O	760
of	ADP	O	O	760
p53	NOUN	O	O	760
inhibition	NOUN	O	O	760
on	ADP	O	O	760
acute	ADJ	O	O	760
vs.	CCONJ	O	O	760
late	ADV	O	O	760
-	PUNCT	O	O	760
stage	NOUN	O	O	760
DOX	PROPN	O	Chemical	760
cardiotoxicity	NOUN	O	Disease	760
was	AUX	O	O	760
examined	VERB	O	O	760
in	ADP	O	O	760
a	PRON	O	O	760
juvenile	NOUN	O	O	760
model	NOUN	O	O	760
.	PUNCT	O	O	760
littermates	NOUN	O	O	761
received	VERB	O	O	761
weekly	ADV	O	O	761
DOX	PROPN	O	Chemical	761
injections	NOUN	O	O	761
for	ADP	O	O	761
5	NUM	O	O	761
weeks	NOUN	O	O	761
(	PUNCT	O	O	761
25	NUM	O	O	761
mg	VERB	O	O	761
/	PUNCT	O	O	761
kg	VERB	O	O	761
cumulative	ADJ	O	O	761
dose	NOUN	O	O	761
)	PUNCT	O	O	761
.	PUNCT	O	O	761
One	NUM	O	O	762
week	NOUN	O	O	762
after	ADP	O	O	762
the	PRON	O	O	762
last	VERB	O	O	762
DOX	PROPN	O	Chemical	762
treatment	NOUN	O	O	762
(	PUNCT	O	O	762
acute	ADJ	O	O	762
stage	NOUN	O	O	762
)	PUNCT	O	O	762
,	PUNCT	O	O	762
MHC	PROPN	O	O	762
-	PUNCT	O	O	762
CB7	PROPN	O	O	762
mice	NOUN	O	O	762
exhibited	VERB	O	O	762
improved	VERB	O	O	762
cardiac	ADJ	O	O	762
function	NOUN	O	O	762
and	CCONJ	O	O	762
lower	ADJ	O	O	762
levels	NOUN	O	O	762
of	ADP	O	O	762
cardiomyocyte	NOUN	O	O	762
apoptosis	NOUN	O	O	762
when	SCONJ	O	O	762
compared	VERB	O	O	762
with	ADP	O	O	762
the	PRON	O	O	762
NON	ADJ	O	O	762
-	PUNCT	O	O	762
TXG	NOUN	O	O	762
mice	NOUN	O	O	762
.	PUNCT	O	O	762
Surprisingly	ADV	O	O	763
,	PUNCT	O	O	763
by	ADP	O	O	763
13	NUM	O	O	763
weeks	NOUN	O	O	763
following	VERB	O	O	763
the	PRON	O	O	763
last	VERB	O	O	763
DOX	PROPN	O	Chemical	763
treatment	NOUN	O	O	763
(	PUNCT	O	O	763
late	ADV	O	O	763
stage	NOUN	O	O	763
)	PUNCT	O	O	763
,	PUNCT	O	O	763
MHC	PROPN	O	O	763
-	PUNCT	O	O	763
CB7	PROPN	O	O	763
exhibited	VERB	O	O	763
a	PRON	O	O	763
progressive	ADJ	O	O	763
decrease	VERB	O	O	763
in	ADP	O	O	763
cardiac	ADJ	O	O	763
function	NOUN	O	O	763
and	CCONJ	O	O	763
higher	ADJ	O	O	763
rates	NOUN	O	O	763
of	ADP	O	O	763
cardiomyocyte	NOUN	O	O	763
apoptosis	NOUN	O	O	763
when	SCONJ	O	O	763
compared	VERB	O	O	763
with	ADP	O	O	763
NON	ADJ	O	O	763
-	PUNCT	O	O	763
TXG	NOUN	O	O	763
mice	NOUN	O	O	763
.	PUNCT	O	O	763
p53	NOUN	O	O	764
inhibition	NOUN	O	O	764
blocked	VERB	O	O	764
transient	ADJ	O	O	764
DOX	PROPN	O	Chemical	764
-	PUNCT	O	O	764
induced	VERB	O	O	764
STAT3	NOUN	O	O	764
activation	NOUN	O	O	764
in	ADP	O	O	764
MHC	PROPN	O	O	764
-	PUNCT	O	O	764
CB7	PROPN	O	O	764
mice	NOUN	O	O	764
,	PUNCT	O	O	764
which	PRON	O	O	764
was	AUX	O	O	764
associated	VERB	O	O	764
with	ADP	O	O	764
enhanced	VERB	O	O	764
induction	NOUN	O	O	764
of	ADP	O	O	764
the	PRON	O	O	764
DNA	NOUN	O	O	764
repair	PROPN	O	O	764
proteins	NOUN	O	O	764
Ku70	PROPN	O	O	764
and	CCONJ	O	O	764
Ku80	NOUN	O	O	764
.	PUNCT	O	O	764
Mice	NOUN	O	O	765
with	ADP	O	O	765
cardiomyocyte	NOUN	O	O	765
-	PUNCT	O	O	765
restricted	VERB	O	O	765
deletion	NOUN	O	O	765
of	ADP	O	O	765
STAT3	NOUN	O	O	765
exhibited	VERB	O	O	765
worse	ADJ	O	O	765
cardiac	ADJ	O	O	765
function	NOUN	O	O	765
,	PUNCT	O	O	765
higher	ADJ	O	O	765
levels	NOUN	O	O	765
of	ADP	O	O	765
cardiomyocyte	NOUN	O	O	765
apoptosis	NOUN	O	O	765
,	PUNCT	O	O	765
and	CCONJ	O	O	765
a	PRON	O	O	765
greater	ADJ	O	O	765
induction	NOUN	O	O	765
of	ADP	O	O	765
Ku70	PROPN	O	O	765
and	CCONJ	O	O	765
Ku80	NOUN	O	O	765
in	ADP	O	O	765
response	NOUN	O	O	765
to	PART	O	O	765
DOX	PROPN	O	Chemical	765
treatment	NOUN	O	O	765
during	ADP	O	O	765
the	PRON	O	O	765
acute	ADJ	O	O	765
stage	NOUN	O	O	765
when	SCONJ	O	O	765
compared	VERB	O	O	765
with	ADP	O	O	765
control	VERB	O	O	765
animals	NOUN	O	O	765
.	PUNCT	O	O	765
CONCLUSION	PROPN	O	O	766
:	PUNCT	O	O	766
These	PRON	O	O	766
data	NOUN	O	O	766
support	NOUN	O	O	766
a	PRON	O	O	766
model	NOUN	O	O	766
wherein	ADV	O	O	766
a	PRON	O	O	766
p53-dependent	ADJ	O	O	766
cardioprotective	ADJ	O	O	766
pathway	NOUN	O	O	766
,	PUNCT	O	O	766
mediated	VERB	O	O	766
via	ADP	O	O	766
STAT3	NOUN	O	O	766
activation	NOUN	O	O	766
,	PUNCT	O	O	766
mitigates	VERB	O	O	766
DOX	PROPN	O	Chemical	766
-	PUNCT	O	O	766
induced	VERB	O	O	766
myocardial	ADJ	O	O	766
stress	NOUN	O	O	766
during	ADP	O	O	766
drug	NOUN	O	O	766
delivery	NOUN	O	O	766
.	PUNCT	O	O	766
Furthermore	ADV	O	O	767
,	PUNCT	O	O	767
these	PRON	O	O	767
data	NOUN	O	O	767
suggest	VERB	O	O	767
an	PRON	O	O	767
explanation	NOUN	O	O	767
as	ADP	O	O	767
to	PART	O	O	767
how	SCONJ	O	O	767
p53	NOUN	O	O	767
inhibition	NOUN	O	O	767
can	AUX	O	O	767
result	VERB	O	O	767
in	ADP	O	O	767
cardioprotection	NOUN	O	O	767
during	ADP	O	O	767
drug	NOUN	O	O	767
treatment	NOUN	O	O	767
and	CCONJ	O	O	767
,	PUNCT	O	O	767
paradoxically	ADV	O	O	767
,	PUNCT	O	O	767
enhanced	VERB	O	O	767
cardiotoxicity	NOUN	O	Disease	767
long	ADV	O	O	767
after	ADP	O	O	767
the	PRON	O	O	767
cessation	NOUN	O	O	767
of	ADP	O	O	767
drug	NOUN	O	O	767
treatment	NOUN	O	O	767
.	PUNCT	O	O	767
Metronidazole	NOUN	O	O	770
-	PUNCT	O	O	770
induced	VERB	O	O	770
encephalopathy	NOUN	O	Disease	770
:	PUNCT	O	O	770
an	PRON	O	O	770
uncommon	ADJ	O	O	770
scenario	NOUN	O	O	770
.	PUNCT	O	O	770
Metronidazole	NOUN	O	O	771
can	AUX	O	O	771
produce	VERB	O	O	771
neurological	ADJ	O	O	771
complications	NOUN	O	O	771
although	SCONJ	O	O	771
it	PRON	O	O	771
is	AUX	O	O	771
not	PART	O	O	771
a	PRON	O	O	771
common	ADJ	O	O	771
scenario	NOUN	O	O	771
.	PUNCT	O	O	771
We	PRON	O	O	772
present	NOUN	O	O	772
a	PRON	O	O	772
case	NOUN	O	O	772
where	SCONJ	O	O	772
a	PRON	O	O	772
patient	NOUN	O	O	772
developed	VERB	O	O	772
features	VERB	O	O	772
of	ADP	O	O	772
encephalopathy	NOUN	O	Disease	772
following	VERB	O	O	772
prolonged	VERB	O	O	772
metronidazole	VERB	O	O	772
intake	PROPN	O	O	772
.	PUNCT	O	O	772
The	PRON	O	O	773
diagnosis	NOUN	O	O	773
of	ADP	O	O	773
metronidazole	VERB	O	O	773
toxicity	NOUN	O	Disease	773
was	AUX	O	O	773
made	VERB	O	O	773
by	ADP	O	O	773
the	PRON	O	O	773
MRI	PROPN	O	O	773
findings	NOUN	O	O	773
and	CCONJ	O	O	773
supported	VERB	O	O	773
clinically	ADV	O	O	773
.	PUNCT	O	O	773
Aconitine	PROPN	O	O	776
-	PUNCT	O	O	776
induced	VERB	O	O	776
Ca2	VERB	O	O	776
+	ADP	O	O	776
overload	NOUN	O	O	776
causes	VERB	O	O	776
arrhythmia	NOUN	O	Disease	776
and	CCONJ	O	O	776
triggers	VERB	O	O	776
apoptosis	NOUN	O	O	776
through	ADP	O	O	776
p38	NUM	O	O	776
MAPK	NOUN	O	O	776
signaling	VERB	O	O	776
pathway	NOUN	O	O	776
in	ADP	O	O	776
rats	NOUN	O	O	776
.	PUNCT	O	O	776
Aconitine	PROPN	O	O	777
is	AUX	O	O	777
a	PRON	O	O	777
major	ADJ	O	O	777
bioactive	ADJ	O	O	777
diterpenoid	PROPN	O	O	777
alkaloid	NOUN	O	O	777
with	ADP	O	O	777
high	ADJ	O	O	777
content	NOUN	O	O	777
derived	VERB	O	O	777
from	ADP	O	O	777
herbal	ADJ	O	O	777
aconitum	ADV	O	O	777
plants	NOUN	O	O	777
.	PUNCT	O	O	777
Emerging	VERB	O	O	778
evidence	NOUN	O	O	778
indicates	VERB	O	O	778
that	SCONJ	O	O	778
voltage	NOUN	O	O	778
-	PUNCT	O	O	778
dependent	ADJ	O	O	778
Na(+	NUM	O	O	778
)	PUNCT	O	O	778
channels	NOUN	O	O	778
have	VERB	O	O	778
pivotal	ADJ	O	O	778
roles	NOUN	O	O	778
in	ADP	O	O	778
the	PRON	O	O	778
cardiotoxicity	NOUN	O	Disease	778
of	ADP	O	O	778
aconitine	PROPN	O	Chemical	778
.	PUNCT	O	O	778
However	ADV	O	O	779
,	PUNCT	O	O	779
no	PRON	O	O	779
reports	VERB	O	O	779
are	AUX	O	O	779
available	ADJ	O	O	779
on	ADP	O	O	779
the	PRON	O	O	779
role	NOUN	O	O	779
of	ADP	O	O	779
Ca(2	PROPN	O	O	779
+	ADP	O	O	779
)	PUNCT	O	O	779
in	ADP	O	O	779
aconitine	PROPN	O	Chemical	779
poisoning	VERB	O	O	779
.	PUNCT	O	O	779
In	ADP	O	O	780
this	PRON	O	O	780
study	VERB	O	O	780
,	PUNCT	O	O	780
we	PRON	O	O	780
explored	VERB	O	O	780
the	PRON	O	O	780
importance	NOUN	O	O	780
of	ADP	O	O	780
pathological	ADJ	O	O	780
Ca(2	PROPN	O	O	780
+	ADP	O	O	780
)	PUNCT	O	O	780
signaling	VERB	O	O	780
in	ADP	O	O	780
aconitine	PROPN	O	Chemical	780
poisoning	VERB	O	O	780
in	ADP	O	O	780
vitro	X	O	O	780
and	CCONJ	O	O	780
in	ADP	O	O	780
vivo	VERB	O	O	780
.	PUNCT	O	O	780
We	PRON	O	O	781
found	VERB	O	O	781
that	SCONJ	O	O	781
Ca(2	PROPN	O	O	781
+	ADP	O	O	781
)	PUNCT	O	O	781
overload	NOUN	O	O	781
lead	VERB	O	Chemical	781
to	PART	O	O	781
accelerated	VERB	O	O	781
beating	VERB	O	O	781
rhythm	VERB	O	O	781
in	ADP	O	O	781
adult	NOUN	O	O	781
rat	NOUN	O	O	781
ventricular	ADJ	O	O	781
myocytes	NOUN	O	O	781
and	CCONJ	O	O	781
caused	VERB	O	O	781
arrhythmia	NOUN	O	Disease	781
in	ADP	O	O	781
conscious	ADJ	O	O	781
freely	ADV	O	O	781
moving	VERB	O	O	781
rats	NOUN	O	O	781
.	PUNCT	O	O	781
To	PART	O	O	782
investigate	VERB	O	O	782
effects	NOUN	O	O	782
of	ADP	O	O	782
aconitine	PROPN	O	Chemical	782
on	ADP	O	O	782
myocardial injury	NOUN	O	Disease	782
,	PUNCT	O	O	782
we	PRON	O	O	782
performed	VERB	O	O	782
cytotoxicity	NOUN	O	Disease	782
assay	NOUN	O	O	782
in	ADP	O	O	782
neonatal	NOUN	O	O	782
rat	NOUN	O	O	782
ventricular	ADJ	O	O	782
myocytes	NOUN	O	O	782
(	PUNCT	O	O	782
NRVMs	NOUN	O	O	782
)	PUNCT	O	O	782
,	PUNCT	O	O	782
as	ADP	O	O	782
well	ADV	O	O	782
as	ADP	O	O	782
measured	VERB	O	O	782
lactate	NOUN	O	Chemical	782
dehydrogenase	NOUN	O	O	782
level	VERB	O	O	782
in	ADP	O	O	782
the	PRON	O	O	782
culture	NOUN	O	O	782
medium	ADJ	O	O	782
of	ADP	O	O	782
NRVMs	NOUN	O	O	782
and	CCONJ	O	O	782
activities	NOUN	O	O	782
of	ADP	O	O	782
serum	NOUN	O	O	782
cardiac	ADJ	O	O	782
enzymes	NOUN	O	O	782
in	ADP	O	O	782
rats	NOUN	O	O	782
.	PUNCT	O	O	782
The	PRON	O	O	783
results	VERB	O	O	783
showed	VERB	O	O	783
that	SCONJ	O	O	783
aconitine	PROPN	O	Chemical	783
resulted	VERB	O	O	783
in	ADP	O	O	783
myocardial injury	NOUN	O	Disease	783
and	CCONJ	O	O	783
reduced	VERB	O	O	783
NRVMs	NOUN	O	O	783
viability	NOUN	O	O	783
dose	NOUN	O	O	783
-	PUNCT	O	O	783
dependently	ADV	O	O	783
.	PUNCT	O	O	783
transferase	PROPN	O	O	784
-	PUNCT	O	O	784
mediated	VERB	O	O	784
dUTP	PROPN	O	O	784
-	PUNCT	O	O	784
biotin	PROPN	O	O	784
nick	PROPN	O	O	784
end	VERB	O	O	784
labeling	NOUN	O	O	784
assay	NOUN	O	O	784
.	PUNCT	O	O	784
The	PRON	O	O	785
results	VERB	O	O	785
showed	VERB	O	O	785
that	SCONJ	O	O	785
aconitine	PROPN	O	Chemical	785
stimulated	VERB	O	O	785
apoptosis	NOUN	O	O	785
time	NOUN	O	O	785
-	PUNCT	O	O	785
dependently	ADV	O	O	785
.	PUNCT	O	O	785
The	PRON	O	O	786
expression	NOUN	O	O	786
analysis	NOUN	O	O	786
of	ADP	O	O	786
Ca(2	PROPN	O	O	786
+	ADP	O	O	786
)	PUNCT	O	O	786
handling	VERB	O	O	787
proteins	NOUN	O	O	787
demonstrated	VERB	O	O	787
that	SCONJ	O	O	787
aconitine	PROPN	O	Chemical	787
promoted	VERB	O	O	787
Ca(2	PROPN	O	O	787
+	ADP	O	O	787
)	PUNCT	O	O	787
overload	NOUN	O	O	787
through	ADP	O	O	787
the	PRON	O	O	787
expression	NOUN	O	O	787
regulation	NOUN	O	O	787
of	ADP	O	O	787
Ca(2	PROPN	O	O	787
+	ADP	O	O	787
)	PUNCT	O	O	787
handling	VERB	O	O	787
proteins	NOUN	O	O	787
.	PUNCT	O	O	787
Hence	ADV	O	O	788
,	PUNCT	O	O	788
our	PRON	O	O	788
results	VERB	O	O	788
suggest	VERB	O	O	788
that	SCONJ	O	O	788
aconitine	PROPN	O	Chemical	788
significantly	ADV	O	O	788
aggravates	VERB	O	O	788
Ca(2	PROPN	O	O	788
+	ADP	O	O	788
)	PUNCT	O	O	788
overload	NOUN	O	O	788
and	CCONJ	O	O	788
causes	VERB	O	O	788
arrhythmia	NOUN	O	Disease	788
and	CCONJ	O	O	788
finally	ADV	O	O	788
promotes	VERB	O	O	788
apoptotic	ADJ	O	O	788
development	NOUN	O	O	788
via	ADP	O	O	788
phosphorylation	NOUN	O	O	788
of	ADP	O	O	788
P38	NUM	O	O	788
mitogen	NOUN	O	O	788
-	PUNCT	O	O	788
activated	VERB	O	O	788
protein	NOUN	O	O	788
kinase	VERB	O	O	788
.	PUNCT	O	O	788
Chronic	NOUN	O	O	791
treatment	NOUN	O	O	791
with	ADP	O	O	791
metformin	PROPN	O	Chemical	791
suppresses	VERB	O	O	791
toll	NOUN	O	O	791
-	PUNCT	O	O	791
like	INTJ	O	O	791
receptor	NOUN	O	O	791
4	NUM	O	O	791
signaling	VERB	O	O	791
and	CCONJ	O	O	791
attenuates	VERB	O	O	791
left ventricular dysfunction	NOUN	O	Disease	791
following	VERB	O	O	791
myocardial infarction	NOUN	O	Disease	791
.	PUNCT	O	O	791
Acute	PROPN	O	O	792
treatment	NOUN	O	O	792
with	ADP	O	O	792
metformin	PROPN	O	Chemical	792
has	VERB	O	O	792
a	PRON	O	O	792
protective	ADJ	O	O	792
effect	VERB	O	O	792
in	ADP	O	O	792
myocardial infarction	NOUN	O	Disease	792
by	ADP	O	O	792
suppression	NOUN	O	O	792
of	ADP	O	O	792
inflammatory	ADJ	O	O	792
responses	NOUN	O	O	792
due	ADJ	O	O	792
to	PART	O	O	792
activation	NOUN	O	O	792
of	ADP	O	O	792
AMP	NOUN	O	Chemical	792
-	PUNCT	O	O	792
activated	VERB	O	O	792
protein	NOUN	O	O	792
kinase	VERB	O	O	792
(	PUNCT	O	O	792
AMPK	PROPN	O	O	792
)	PUNCT	O	O	792
.	PUNCT	O	O	792
In	ADP	O	O	793
the	PRON	O	O	793
present	NOUN	O	O	793
study	VERB	O	O	793
,	PUNCT	O	O	793
the	PRON	O	O	793
effect	VERB	O	O	793
of	ADP	O	O	793
chronic	ADJ	O	O	793
pre	VERB	O	O	793
-	PUNCT	O	O	793
treatment	NOUN	O	O	793
with	ADP	O	O	793
metformin	PROPN	O	Chemical	793
on	ADP	O	O	793
cardiac dysfunction	NOUN	O	Disease	793
and	CCONJ	O	O	793
toll	NOUN	O	O	793
-	PUNCT	O	O	793
like	INTJ	O	O	793
receptor	NOUN	O	O	793
4	NUM	O	O	793
(	PUNCT	O	O	793
TLR4	PROPN	O	O	793
)	PUNCT	O	O	793
activities	NOUN	O	O	793
following	VERB	O	O	793
myocardial infarction	NOUN	O	Disease	793
and	CCONJ	O	O	793
their	PRON	O	O	793
relation	NOUN	O	O	793
with	ADP	O	O	793
AMPK	PROPN	O	O	793
were	AUX	O	O	793
assessed	VERB	O	O	793
.	PUNCT	O	O	793
Male	NOUN	O	O	794
Wistar	PROPN	O	O	794
rats	NOUN	O	O	794
were	AUX	O	O	794
randomly	ADV	O	O	794
assigned	VERB	O	O	794
to	PART	O	O	794
one	NUM	O	O	794
of	ADP	O	O	794
5	NUM	O	O	794
groups	NOUN	O	O	794
(	PUNCT	O	O	794
n=6	NOUN	O	O	794
)	PUNCT	O	O	794
:	PUNCT	O	O	794
normal	ADJ	O	O	794
control	VERB	O	O	794
and	CCONJ	O	O	794
groups	NOUN	O	O	794
were	AUX	O	O	794
injected	VERB	O	O	794
isoproterenol	NOUN	O	Chemical	794
after	ADP	O	O	794
chronic	ADJ	O	O	794
pre	VERB	O	O	794
-	PUNCT	O	O	794
treatment	NOUN	O	O	794
with	ADP	O	O	794
0	NUM	O	O	794
,	PUNCT	O	O	794
25	NUM	O	O	794
,	PUNCT	O	O	794
50	NUM	O	O	794
,	PUNCT	O	O	794
or	CCONJ	O	O	794
100mg	ADV	O	O	794
/	PUNCT	O	O	794
kg	VERB	O	O	795
of	ADP	O	O	795
metformin	PROPN	O	Chemical	795
twice	ADV	O	O	795
daily	ADV	O	O	795
for	ADP	O	O	795
14	NUM	O	O	795
days	NOUN	O	O	795
.	PUNCT	O	O	795
Isoproterenol	NOUN	O	Chemical	796
(	PUNCT	O	O	796
100mg	ADV	O	O	796
/	PUNCT	O	O	796
kg	VERB	O	O	796
)	PUNCT	O	O	796
was	AUX	O	O	796
injected	VERB	O	O	796
subcutaneously	ADV	O	O	796
on	ADP	O	O	796
the	PRON	O	O	796
13th	PROPN	O	O	796
and	CCONJ	O	O	796
14th	ADJ	O	O	796
days	NOUN	O	O	796
to	PART	O	O	796
induce	VERB	O	O	796
acute	ADJ	O	O	796
myocardial infarction	NOUN	O	Disease	796
.	PUNCT	O	O	796
Isoproterenol	NOUN	O	Chemical	797
alone	ADV	O	O	797
decreased	VERB	O	O	797
left	VERB	O	O	797
ventricular	ADJ	O	O	797
systolic	ADV	O	O	797
pressure	NOUN	O	O	797
and	CCONJ	O	O	797
myocardial	ADJ	O	O	797
contractility	NOUN	O	O	797
indexed	VERB	O	O	797
as	ADP	O	O	797
LVdp	NOUN	O	O	797
/	PUNCT	O	O	797
dtmax	NOUN	O	O	797
and	CCONJ	O	O	797
LVdp	NOUN	O	O	797
/	PUNCT	O	O	797
dtmin	PROPN	O	O	797
.	PUNCT	O	O	797
The	PRON	O	O	798
left ventricular dysfunction	NOUN	O	Disease	798
was	AUX	O	O	798
significantly	ADV	O	O	798
lower	ADJ	O	O	798
in	ADP	O	O	798
the	PRON	O	O	798
groups	NOUN	O	O	798
treated	VERB	O	O	798
with	ADP	O	O	798
25	NUM	O	O	798
and	CCONJ	O	O	798
50mg	NUM	O	O	798
/	PUNCT	O	O	798
kg	VERB	O	O	799
of	ADP	O	O	799
metformin	PROPN	O	Chemical	799
.	PUNCT	O	O	799
Metfromin	NOUN	O	O	800
markedly	ADV	O	O	800
lowered	VERB	O	O	800
isoproterenol	NOUN	O	Chemical	800
-	PUNCT	O	O	800
induced	VERB	O	O	800
elevation	NOUN	O	O	800
in	ADP	O	O	800
the	PRON	O	O	800
levels	NOUN	O	O	800
of	ADP	O	O	800
TLR4	PROPN	O	O	800
mRNA	PROPN	O	O	800
,	PUNCT	O	O	800
myeloid	NOUN	O	O	800
differentiation	NOUN	O	O	800
protein	NOUN	O	O	800
88	NUM	O	O	800
(	PUNCT	O	O	800
MyD88	PROPN	O	O	800
)	PUNCT	O	O	800
,	PUNCT	O	O	800
tumor	NOUN	O	Disease	800
necrosis	NOUN	O	Disease	800
factor	NOUN	O	O	800
-	PUNCT	O	O	800
alpha	PROPN	O	O	800
(	PUNCT	O	O	800
TNF	PROPN	O	O	800
-	PUNCT	O	O	800
a	PRON	O	O	800
)	PUNCT	O	O	800
,	PUNCT	O	O	800
and	CCONJ	O	O	800
interleukin	ADJ	O	O	800
6	NUM	O	O	800
(	PUNCT	O	O	800
IL-6	NUM	O	O	800
)	PUNCT	O	O	800
in	ADP	O	O	800
the	PRON	O	O	800
heart	NOUN	O	O	800
tissues	NOUN	O	O	800
.	PUNCT	O	O	800
kg	VERB	O	O	801
of	ADP	O	O	801
metformin	PROPN	O	Chemical	801
,	PUNCT	O	O	801
slightly	ADV	O	O	801
by	ADP	O	O	801
50mg	NUM	O	O	801
/	PUNCT	O	O	801
kg	VERB	O	O	801
,	PUNCT	O	O	801
but	CCONJ	O	O	801
not	PART	O	O	801
by	ADP	O	O	801
100mg	ADV	O	O	801
Chronic	NOUN	O	O	802
pre	VERB	O	O	802
-	PUNCT	O	O	802
treatment	NOUN	O	O	802
with	ADP	O	O	802
metformin	PROPN	O	Chemical	802
reduces	VERB	O	O	802
post	VERB	O	O	802
-	PUNCT	O	O	802
myocardial infarction	NOUN	O	Disease	802
cardiac dysfunction	NOUN	O	Disease	802
and	CCONJ	O	O	802
suppresses	VERB	O	O	802
inflammatory	ADJ	O	O	802
responses	NOUN	O	O	802
,	PUNCT	O	O	802
possibly	ADV	O	O	802
through	ADP	O	O	802
inhibition	NOUN	O	O	802
of	ADP	O	O	802
TLR4	PROPN	O	O	802
activities	NOUN	O	O	802
.	PUNCT	O	O	802
Neuroleptic malignant syndrome	NOUN	O	Disease	805
induced	VERB	O	O	805
by	ADP	O	O	805
combination	NOUN	O	O	805
therapy	NOUN	O	O	805
with	ADP	O	O	805
tetrabenazine	PROPN	O	O	805
and	CCONJ	O	O	805
tiapride	ADV	O	Chemical	805
in	ADP	O	O	805
a	PRON	O	O	805
Japanese	NOUN	O	O	805
patient	NOUN	O	O	805
with	ADP	O	O	805
Huntington	PROPN	O	O	805
's	AUX	O	O	805
disease	PROPN	O	O	805
at	ADP	O	O	805
the	PRON	O	O	805
terminal	PROPN	O	O	805
stage	NOUN	O	O	805
of	ADP	O	O	805
recurrent	ADJ	O	O	805
breast cancer	NOUN	O	Disease	805
.	PUNCT	O	O	805
We	PRON	O	O	806
herein	VERB	O	O	806
describe	VERB	O	O	806
the	PRON	O	O	806
case	NOUN	O	O	806
of	ADP	O	O	806
an	PRON	O	O	806
81-year	NOUN	O	O	806
-	PUNCT	O	O	806
old	ADJ	O	O	806
Japanese	NOUN	O	O	806
woman	NOUN	O	O	806
with	ADP	O	O	806
neuroleptic malignant syndrome	NOUN	O	Disease	806
that	SCONJ	O	O	806
occurred	VERB	O	O	806
36	NUM	O	O	806
days	NOUN	O	O	806
after	ADP	O	O	806
the	PRON	O	O	806
initiation	NOUN	O	O	806
of	ADP	O	O	806
combination	NOUN	O	O	806
therapy	NOUN	O	O	806
with	ADP	O	O	806
tiapride	ADV	O	Chemical	806
(	PUNCT	O	O	806
75	NUM	O	O	806
mg	VERB	O	O	806
/	PUNCT	O	O	806
day	NOUN	O	O	806
)	PUNCT	O	O	806
and	CCONJ	O	O	806
tetrabenazine	PROPN	O	O	806
(	PUNCT	O	O	806
12.5	NUM	O	O	806
mg	VERB	O	O	806
/	PUNCT	O	O	806
day	NOUN	O	O	806
)	PUNCT	O	O	806
for	ADP	O	O	806
Huntington	PROPN	O	O	806
's	AUX	O	O	806
disease	PROPN	O	O	806
.	PUNCT	O	O	806
The	PRON	O	O	807
patient	NOUN	O	O	807
had	VERB	O	O	807
been	AUX	O	O	807
treated	VERB	O	O	807
with	ADP	O	O	807
tiapride	ADV	O	Chemical	807
or	CCONJ	O	O	807
tetrabenazine	PROPN	O	O	807
alone	ADV	O	O	807
without	ADP	O	O	807
any	PRON	O	O	807
adverse	ADJ	O	O	807
effects	NOUN	O	O	807
before	ADP	O	O	807
the	PRON	O	O	807
administration	NOUN	O	O	807
of	ADP	O	O	807
the	PRON	O	O	807
combination	NOUN	O	O	807
therapy	NOUN	O	O	807
.	PUNCT	O	O	807
She	PRON	O	O	808
also	ADV	O	O	808
had	VERB	O	O	808
advanced	ADJ	O	O	808
breast cancer	NOUN	O	Disease	808
when	SCONJ	O	O	808
the	PRON	O	O	808
combination	NOUN	O	O	808
therapy	NOUN	O	O	808
was	AUX	O	O	808
initiated	VERB	O	O	808
.	PUNCT	O	O	808
To	PART	O	O	809
the	PRON	O	O	809
best	ADV	O	O	809
of	ADP	O	O	809
our	PRON	O	O	809
knowledge	NOUN	O	O	809
,	PUNCT	O	O	809
the	PRON	O	O	809
occurrence	NOUN	O	O	809
of	ADP	O	O	809
neuroleptic malignant syndrome	NOUN	O	Disease	809
due	ADJ	O	O	809
to	PART	O	O	809
combination	NOUN	O	O	809
therapy	NOUN	O	O	809
with	ADP	O	O	809
tetrabenazine	PROPN	O	O	809
and	CCONJ	O	O	809
tiapride	ADV	O	Chemical	809
has	VERB	O	O	809
not	PART	O	O	809
been	AUX	O	O	809
previously	ADV	O	O	809
reported	VERB	O	O	809
.	PUNCT	O	O	809
Tetrabenazine	PROPN	O	O	810
should	AUX	O	O	810
be	AUX	O	O	810
administered	VERB	O	O	810
very	ADV	O	O	810
carefully	ADV	O	O	810
in	ADP	O	O	810
combination	NOUN	O	O	810
with	ADP	O	O	810
other	ADJ	O	O	810
neuroleptic	NOUN	O	O	810
drugs	NOUN	O	O	810
,	PUNCT	O	O	810
particularly	ADV	O	O	810
in	ADP	O	O	810
patients	NOUN	O	O	810
with	ADP	O	O	810
a	PRON	O	O	810
worsening	VERB	O	O	810
general	ADJ	O	O	810
condition	NOUN	O	O	810
.	PUNCT	O	O	810
A	PRON	O	O	813
metoprolol	NOUN	O	Chemical	813
-	PUNCT	O	O	813
terbinafine	NOUN	O	O	813
combination	NOUN	O	O	813
induced	VERB	O	O	813
bradycardia	NOUN	O	Disease	813
.	PUNCT	O	O	813
To	PART	O	O	814
report	VERB	O	O	814
a	PRON	O	O	814
sinus	NOUN	O	O	814
bradycardia	NOUN	O	Disease	814
induced	VERB	O	O	814
by	ADP	O	O	814
metoprolol	NOUN	O	Chemical	814
and	CCONJ	O	O	814
terbinafine	NOUN	O	O	814
drug	NOUN	O	O	814
-	PUNCT	O	O	814
drug	NOUN	O	O	814
interaction	NOUN	O	O	814
and	CCONJ	O	O	814
its	PRON	O	O	814
management	NOUN	O	O	814
.	PUNCT	O	O	814
A	PRON	O	O	815
63	NUM	O	O	815
year	NOUN	O	O	815
-	PUNCT	O	O	815
old	ADJ	O	O	815
Caucasian	ADJ	O	O	815
man	NOUN	O	O	815
on	ADP	O	O	815
metoprolol	NOUN	O	Chemical	815
200	NUM	O	O	815
mg	VERB	O	O	815
/	PUNCT	O	O	815
day	NOUN	O	O	815
for	ADP	O	O	815
stable	ADJ	O	O	815
coronary artery disease	NOUN	O	Disease	815
was	AUX	O	O	815
prescribed	VERB	O	O	815
a	PRON	O	O	815
90-day	NOUN	O	O	815
course	NOUN	O	O	815
of	ADP	O	O	815
oral	ADJ	O	O	815
terbinafine	NOUN	O	O	815
250	NUM	O	O	815
mg	VERB	O	O	815
/	PUNCT	O	O	815
day	NOUN	O	O	815
for	ADP	O	O	815
onychomycosis	NOUN	O	O	815
.	PUNCT	O	O	815
On	ADP	O	O	816
the	PRON	O	O	816
49th	ADJ	O	O	816
day	NOUN	O	O	816
of	ADP	O	O	816
terbinafine	NOUN	O	O	816
therapy	NOUN	O	O	816
,	PUNCT	O	O	816
he	PRON	O	O	816
was	AUX	O	O	816
brought	VERB	O	O	816
to	PART	O	O	816
the	PRON	O	O	816
emergency	NOUN	O	O	816
room	NOUN	O	O	816
for	ADP	O	O	816
a	PRON	O	O	816
decrease	VERB	O	O	816
of	ADP	O	O	816
his	PRON	O	O	816
global	ADJ	O	O	816
health	NOUN	O	O	816
status	NOUN	O	O	816
,	PUNCT	O	O	816
confusion	NOUN	O	Disease	816
and	CCONJ	O	O	816
falls	VERB	O	O	816
.	PUNCT	O	O	816
The	PRON	O	O	817
electrocardiogram	PROPN	O	O	817
revealed	VERB	O	O	817
a	PRON	O	O	817
37	NUM	O	O	817
beats	NOUN	O	O	817
/	PUNCT	O	O	817
min	NOUN	O	O	817
sinus	NOUN	O	O	817
bradycardia	NOUN	O	Disease	817
.	PUNCT	O	O	817
A	PRON	O	O	818
score	VERB	O	O	818
of	ADP	O	O	818
7	NUM	O	O	818
on	ADP	O	O	818
the	PRON	O	O	818
Naranjo	PROPN	O	O	818
adverse	ADJ	O	O	818
drug	NOUN	O	O	818
reaction	NOUN	O	O	818
probability	NOUN	O	O	818
scale	NOUN	O	O	818
indicates	VERB	O	O	818
a	PRON	O	O	818
probable	ADJ	O	O	818
relationship	NOUN	O	O	818
between	ADP	O	O	818
the	PRON	O	O	818
patient	NOUN	O	O	818
's	AUX	O	O	818
sinus	NOUN	O	O	818
bradycardia	NOUN	O	Disease	818
and	CCONJ	O	O	818
the	PRON	O	O	818
drug	NOUN	O	O	818
interaction	NOUN	O	O	818
between	ADP	O	O	818
metoprolol	NOUN	O	Chemical	818
and	CCONJ	O	O	818
terbinafine	NOUN	O	O	818
.	PUNCT	O	O	818
The	PRON	O	O	819
heart	NOUN	O	O	819
rate	NOUN	O	O	819
ameliorated	VERB	O	O	819
first	ADV	O	O	819
with	ADP	O	O	819
a	PRON	O	O	819
decrease	VERB	O	O	819
in	ADP	O	O	819
the	PRON	O	O	819
dose	NOUN	O	O	819
of	ADP	O	O	819
metoprolol	NOUN	O	Chemical	819
.	PUNCT	O	O	819
It	PRON	O	O	820
was	AUX	O	O	820
subsequently	ADV	O	O	820
changed	VERB	O	O	820
to	PART	O	O	820
bisoprolol	VERB	O	O	820
and	CCONJ	O	O	820
the	PRON	O	O	820
heart	NOUN	O	O	820
rate	NOUN	O	O	820
remained	VERB	O	O	820
normal	ADJ	O	O	820
.	PUNCT	O	O	820
By	ADP	O	O	821
inhibiting	VERB	O	O	821
the	PRON	O	O	821
cytochrome	ADP	O	O	821
P450	VERB	O	O	821
2D6	X	O	O	821
,	PUNCT	O	O	821
terbinafine	NOUN	O	O	821
had	VERB	O	O	821
decreased	VERB	O	O	821
metoprolol	NOUN	O	Chemical	821
's	AUX	O	O	821
clearance	NOUN	O	O	821
,	PUNCT	O	O	821
leading	VERB	O	O	821
in	ADP	O	O	821
metoprolol	NOUN	O	Chemical	821
accumulation	NOUN	O	O	821
which	PRON	O	O	821
has	VERB	O	O	821
resulted	VERB	O	O	821
in	ADP	O	O	821
clinically	ADV	O	O	821
significant	ADJ	O	O	821
sinus	NOUN	O	O	821
bradycardia	NOUN	O	Disease	821
.	PUNCT	O	O	821
Optochiasmatic	NOUN	O	O	824
and	CCONJ	O	O	824
peripheral neuropathy	NOUN	O	Disease	824
due	ADJ	O	O	824
to	PART	O	O	824
ethambutol	PROPN	O	Chemical	824
overtreatment	NOUN	O	O	824
.	PUNCT	O	O	824
Ethambutol	PROPN	O	Chemical	825
is	AUX	O	O	825
known	VERB	O	O	825
to	PART	O	O	825
cause	VERB	O	O	825
optic neuropathy	NOUN	O	Disease	825
and	CCONJ	O	O	825
,	PUNCT	O	O	825
more	ADJ	O	O	825
rarely	ADV	O	O	825
,	PUNCT	O	O	825
axonal	ADJ	O	O	825
polyneuropathy	ADJ	O	Disease	825
.	PUNCT	O	O	825
We	PRON	O	O	826
characterize	VERB	O	O	826
the	PRON	O	O	826
clinical	ADJ	O	O	826
,	PUNCT	O	O	826
neurophysiological	ADJ	O	O	826
,	PUNCT	O	O	826
and	CCONJ	O	O	826
neuroimaging	VERB	O	O	826
findings	NOUN	O	O	826
in	ADP	O	O	826
a	PRON	O	O	826
72-year	NOUN	O	O	826
-	PUNCT	O	O	826
old	ADJ	O	O	826
man	NOUN	O	O	826
who	PRON	O	O	826
developed	VERB	O	O	826
visual loss	NOUN	O	Disease	826
and	CCONJ	O	O	826
paresthesias	PROPN	O	O	826
after	ADP	O	O	826
11	NUM	O	O	826
weeks	NOUN	O	O	826
of	ADP	O	O	826
exposure	NOUN	O	O	826
to	PART	O	O	826
a	PRON	O	O	826
supratherapeutic	ADJ	O	O	826
dose	NOUN	O	O	826
of	ADP	O	O	826
ethambutol	PROPN	O	Chemical	826
.	PUNCT	O	O	826
This	PRON	O	O	827
case	NOUN	O	O	827
demonstrates	VERB	O	O	827
the	PRON	O	O	827
selective	ADJ	O	O	827
vulnerability	NOUN	O	O	827
of	ADP	O	O	827
the	PRON	O	O	827
anterior	PROPN	O	O	827
visual	ADJ	O	O	827
pathways	NOUN	O	O	827
and	CCONJ	O	O	827
peripheral	ADJ	O	O	827
nerves	NOUN	O	O	827
to	PART	O	O	827
ethambutol	PROPN	O	Chemical	827
toxicity	NOUN	O	Disease	827
.	PUNCT	O	O	827
Testosterone	PROPN	O	O	830
ameliorates	VERB	O	O	830
streptozotocin	PROPN	O	Chemical	830
-	PUNCT	O	O	830
induced	VERB	O	O	830
memory impairment	NOUN	O	Disease	830
in	ADP	O	O	830
male	NOUN	O	O	830
rats	NOUN	O	O	830
.	PUNCT	O	O	830
AIM	VERB	O	O	831
:	PUNCT	O	O	831
To	PART	O	O	831
study	VERB	O	O	831
the	PRON	O	O	831
effects	NOUN	O	O	831
of	ADP	O	O	831
testosterone	PROPN	O	Chemical	831
on	ADP	O	O	831
streptozotocin	PROPN	O	Chemical	831
(	PUNCT	O	O	831
STZ)-induced	VERB	O	O	831
memory impairment	NOUN	O	Disease	831
in	ADP	O	O	831
male	NOUN	O	O	831
rats	NOUN	O	O	831
.	PUNCT	O	O	831
Adult	NOUN	O	O	832
male	NOUN	O	O	832
Wistar	PROPN	O	O	832
rats	NOUN	O	O	832
were	AUX	O	O	832
intracerebroventricularly	ADV	O	O	832
(	PUNCT	O	O	832
icv	VERB	O	O	832
)	PUNCT	O	O	832
infused	VERB	O	O	832
with	ADP	O	O	832
STZ	PROPN	O	Chemical	832
(	PUNCT	O	O	832
750	NUM	O	O	832
ug	NOUN	O	O	832
)	PUNCT	O	O	832
on	ADP	O	O	832
d	X	O	O	832
1	X	O	O	832
and	CCONJ	O	O	832
d	X	O	O	832
3	X	O	O	832
,	PUNCT	O	O	832
and	CCONJ	O	O	832
a	PRON	O	O	832
passive	ADJ	O	O	832
avoidance	NOUN	O	O	832
task	NOUN	O	O	832
was	AUX	O	O	832
assessed	VERB	O	O	832
2	X	O	O	832
weeks	NOUN	O	O	832
after	ADP	O	O	832
the	PRON	O	O	832
first	ADV	O	O	832
injection	NOUN	O	O	832
of	ADP	O	O	832
STZ	PROPN	O	Chemical	832
.	PUNCT	O	O	832
Testosterone	PROPN	O	O	833
(	PUNCT	O	O	833
1	X	O	O	833
mg.kg(-1).d(-1	X	O	O	833
)	PUNCT	O	O	833
,	PUNCT	O	O	833
sc	PROPN	O	O	833
)	PUNCT	O	O	833
,	PUNCT	O	O	833
the	PRON	O	O	833
androgen	PROPN	O	Chemical	833
receptor	NOUN	O	O	833
antagonist	NOUN	O	O	833
flutamide	NOUN	O	O	833
(	PUNCT	O	O	833
10	NUM	O	O	833
mg.kg(-1).d(-1	X	O	O	833
)	PUNCT	O	O	833
,	PUNCT	O	O	833
ip	X	O	O	833
)	PUNCT	O	O	833
,	PUNCT	O	O	833
the	PRON	O	O	833
estrogen	PROPN	O	Chemical	833
receptor	NOUN	O	O	833
antagonist	NOUN	O	O	833
tamoxifen	PROPN	O	Chemical	833
(	PUNCT	O	O	833
1	X	O	O	833
mg.kg(-1).d(-1	X	O	O	833
)	PUNCT	O	O	833
,	PUNCT	O	O	833
ip	X	O	O	833
)	PUNCT	O	O	833
or	CCONJ	O	O	833
the	PRON	O	O	833
aromatase	PROPN	O	O	833
inhibitor	NOUN	O	O	833
letrozole	NOUN	O	O	833
(	PUNCT	O	O	833
4	NUM	O	O	833
mg.kg(-1).d(-1	X	O	O	833
)	PUNCT	O	O	833
,	PUNCT	O	O	833
ip	X	O	O	833
)	PUNCT	O	O	833
were	AUX	O	O	833
administered	VERB	O	O	833
for	ADP	O	O	833
6	NUM	O	O	833
d	X	O	O	833
after	ADP	O	O	833
the	PRON	O	O	833
first	ADV	O	O	833
injection	NOUN	O	O	833
of	ADP	O	O	833
STZ	PROPN	O	Chemical	833
.	PUNCT	O	O	833
STZ	PROPN	O	Chemical	834
administration	NOUN	O	O	834
and	CCONJ	O	O	834
castration	NOUN	O	O	834
markedly	ADV	O	O	834
decreased	VERB	O	O	834
both	PRON	O	O	834
STL1	PROPN	O	O	834
(	PUNCT	O	O	834
the	PRON	O	O	834
short	ADJ	O	O	834
memory	NOUN	O	O	834
)	PUNCT	O	O	834
and	CCONJ	O	O	834
STL2	PROPN	O	O	834
(	PUNCT	O	O	834
the	PRON	O	O	834
long	ADV	O	O	834
memory	NOUN	O	O	834
)	PUNCT	O	O	834
in	ADP	O	O	834
passive	ADJ	O	O	834
avoidance	NOUN	O	O	834
tests	VERB	O	O	834
.	PUNCT	O	O	834
Testosterone	PROPN	O	O	835
replacement	NOUN	O	O	835
almost	ADV	O	O	835
restored	VERB	O	O	835
the	PRON	O	O	835
STL1	PROPN	O	O	835
and	CCONJ	O	O	835
STL2	PROPN	O	O	835
in	ADP	O	O	835
castrated	VERB	O	O	835
rats	NOUN	O	O	835
,	PUNCT	O	O	835
and	CCONJ	O	O	835
significantly	ADV	O	O	835
prolonged	VERB	O	O	835
the	PRON	O	O	835
STL1	PROPN	O	O	835
and	CCONJ	O	O	835
STL2	PROPN	O	O	835
in	ADP	O	O	835
STZ	PROPN	O	Chemical	835
-	PUNCT	O	O	835
treated	VERB	O	O	835
rats	NOUN	O	O	835
.	PUNCT	O	O	835
Administration	NOUN	O	O	836
of	ADP	O	O	836
flutamide	NOUN	O	O	836
,	PUNCT	O	O	836
letrozole	NOUN	O	O	836
or	CCONJ	O	O	836
tamoxifen	PROPN	O	Chemical	836
significantly	ADV	O	O	836
impaired	VERB	O	O	836
the	PRON	O	O	836
memory	NOUN	O	O	836
in	ADP	O	O	836
intact	ADJ	O	O	836
rats	NOUN	O	O	836
,	PUNCT	O	O	836
and	CCONJ	O	O	836
significantly	ADV	O	O	836
attenuated	VERB	O	O	836
the	PRON	O	O	836
testosterone	PROPN	O	Chemical	836
replacement	NOUN	O	O	836
in	ADP	O	O	836
improving	VERB	O	O	836
STZ-	NUM	O	O	836
and	CCONJ	O	O	836
castration	NOUN	O	O	836
-	PUNCT	O	O	836
induced	VERB	O	O	836
memory impairment	NOUN	O	Disease	836
.	PUNCT	O	O	836
Testosterone	PROPN	O	O	837
administration	NOUN	O	O	837
ameliorates	VERB	O	O	837
STZ-	NUM	O	O	837
and	CCONJ	O	O	837
castration	NOUN	O	O	837
-	PUNCT	O	O	837
induced	VERB	O	O	837
memory impairment	NOUN	O	Disease	837
in	ADP	O	O	837
male	NOUN	O	O	837
Wistar	PROPN	O	O	837
rats	NOUN	O	O	837
.	PUNCT	O	O	837
Behavioral	NOUN	O	O	840
and	CCONJ	O	O	840
neurochemical	ADJ	O	O	840
studies	NOUN	O	O	840
in	ADP	O	O	840
mice	NOUN	O	O	840
pretreated	VERB	O	O	840
with	ADP	O	O	840
garcinielliptone	NOUN	O	O	840
FC	NOUN	O	O	840
in	ADP	O	O	840
pilocarpine	NOUN	O	Chemical	840
-	PUNCT	O	O	840
induced	VERB	O	O	840
seizures	NOUN	O	Disease	840
.	PUNCT	O	O	840
Garcinielliptone	PROPN	O	O	841
FC	NOUN	O	O	841
(	PUNCT	O	O	841
GFC	PROPN	O	O	841
)	PUNCT	O	O	841
isolated	VERB	O	O	841
from	ADP	O	O	841
hexanic	VERB	O	O	841
fraction	NOUN	O	O	841
seed	NOUN	O	O	841
extract	VERB	O	O	841
of	ADP	O	O	841
species	NOUN	O	O	841
Platonia	PROPN	O	O	841
insignis	PROPN	O	O	841
Mart	PROPN	O	O	841
.	PUNCT	O	O	841
It	PRON	O	O	842
is	AUX	O	O	842
widely	ADV	O	O	842
used	VERB	O	O	842
in	ADP	O	O	842
folk	NOUN	O	O	842
medicine	NOUN	O	O	842
to	PART	O	O	842
treat	VERB	O	O	842
skin	NOUN	O	O	842
diseases	NOUN	O	O	842
in	ADP	O	O	842
both	PRON	O	O	842
humans	NOUN	O	O	842
and	CCONJ	O	O	842
animals	NOUN	O	O	842
as	ADP	O	O	842
well	ADV	O	O	842
as	ADP	O	O	842
the	PRON	O	O	842
seed	NOUN	O	O	842
decoction	PROPN	O	O	842
has	VERB	O	O	842
been	AUX	O	O	842
used	VERB	O	O	842
to	PART	O	O	842
treat	VERB	O	O	842
diarrheas	NOUN	O	O	842
and	CCONJ	O	O	842
inflammatory diseases	NOUN	O	Disease	842
.	PUNCT	O	O	842
However	ADV	O	O	843
,	PUNCT	O	O	843
there	ADV	O	O	843
is	AUX	O	O	843
no	PRON	O	O	843
research	NOUN	O	O	843
on	ADP	O	O	843
GFC	PROPN	O	O	843
effects	NOUN	O	O	843
in	ADP	O	O	843
the	PRON	O	O	843
central	ADJ	O	O	843
nervous	ADJ	O	O	843
system	NOUN	O	O	843
of	ADP	O	O	843
rodents	NOUN	O	O	843
.	PUNCT	O	O	843
The	PRON	O	O	844
present	NOUN	O	O	844
study	VERB	O	O	844
aimed	VERB	O	O	844
to	PART	O	O	844
evaluate	VERB	O	O	844
the	PRON	O	O	844
GFC	PROPN	O	O	844
effects	NOUN	O	O	844
at	ADP	O	O	844
doses	NOUN	O	O	844
of	ADP	O	O	844
25	NUM	O	O	844
,	PUNCT	O	O	844
50	NUM	O	O	844
or	CCONJ	O	O	844
75	NUM	O	O	844
mg	VERB	O	O	844
/	PUNCT	O	O	844
kg	VERB	O	O	844
on	ADP	O	O	844
seizure	NOUN	O	Disease	844
parameters	NOUN	O	O	844
to	PART	O	O	844
determine	VERB	O	O	844
their	PRON	O	O	844
anticonvulsant	ADJ	O	O	844
activity	NOUN	O	O	844
and	CCONJ	O	O	844
its	PRON	O	O	844
effects	NOUN	O	O	844
on	ADP	O	O	844
amino acid	NOUN	O	Chemical	844
(	PUNCT	O	O	844
r	X	O	O	844
-	PUNCT	O	O	844
aminobutyric	PROPN	O	O	844
acid	PROPN	O	O	844
(	PUNCT	O	O	844
GABA	PROPN	O	Chemical	844
)	PUNCT	O	O	844
,	PUNCT	O	O	844
glutamine	PROPN	O	O	844
,	PUNCT	O	O	844
aspartate	NOUN	O	Chemical	844
and	CCONJ	O	O	844
glutathione	NOUN	O	Chemical	844
)	PUNCT	O	O	844
levels	NOUN	O	O	844
as	ADP	O	O	844
well	ADV	O	O	844
as	ADP	O	O	844
on	ADP	O	O	844
acetylcholinesterase	NOUN	O	O	844
(	PUNCT	O	O	844
AChE	PROPN	O	O	844
)	PUNCT	O	O	844
activity	NOUN	O	O	844
in	ADP	O	O	844
mice	NOUN	O	O	844
hippocampus	NOUN	O	O	844
after	ADP	O	O	844
seizures	NOUN	O	Disease	844
.	PUNCT	O	O	844
GFC	PROPN	O	O	845
produced	VERB	O	O	845
an	PRON	O	O	845
increased	VERB	O	O	845
latency	VERB	O	O	845
to	PART	O	O	845
first	ADV	O	O	845
seizure	NOUN	O	Disease	845
,	PUNCT	O	O	845
at	ADP	O	O	845
doses	NOUN	O	O	845
25mg	NOUN	O	O	845
/	PUNCT	O	O	845
kg	VERB	O	O	845
(	PUNCT	O	O	845
20.12	NUM	O	O	845
+	ADP	O	O	845
2.20	NUM	O	O	845
min	NOUN	O	O	845
)	PUNCT	O	O	845
,	PUNCT	O	O	845
50mg	NUM	O	O	845
/	PUNCT	O	O	845
kg	VERB	O	O	845
(	PUNCT	O	O	845
20.95	NUM	O	O	845
+	ADP	O	O	845
2.21	NUM	O	O	845
min	NOUN	O	O	845
)	PUNCT	O	O	845
or	CCONJ	O	O	845
75	NUM	O	O	845
mg	VERB	O	O	845
/	PUNCT	O	O	845
kg	VERB	O	O	845
(	PUNCT	O	O	845
23.43	NUM	O	O	845
+	ADP	O	O	845
1.99	NUM	O	O	845
min	NOUN	O	O	845
)	PUNCT	O	O	845
when	SCONJ	O	O	845
compared	VERB	O	O	845
with	ADP	O	O	845
seized	VERB	O	O	845
mice	NOUN	O	O	845
.	PUNCT	O	O	845
In	ADP	O	O	846
addition	NOUN	O	O	846
,	PUNCT	O	O	846
GABA	PROPN	O	Chemical	846
content	NOUN	O	O	846
of	ADP	O	O	846
mice	NOUN	O	O	846
hippocampus	NOUN	O	O	846
treated	VERB	O	O	846
with	ADP	O	O	846
GFC75	NOUN	O	O	846
plus	CCONJ	O	O	846
P400	NOUN	O	O	846
showed	VERB	O	O	846
an	PRON	O	O	846
increase	VERB	O	O	846
of	ADP	O	O	846
46.90%	NOUN	O	O	846
when	SCONJ	O	O	846
compared	VERB	O	O	846
with	ADP	O	O	846
seized	VERB	O	O	846
mice	NOUN	O	O	846
.	PUNCT	O	O	846
In	ADP	O	O	847
aspartate	NOUN	O	Chemical	847
,	PUNCT	O	O	847
glutamine	PROPN	O	O	847
and	CCONJ	O	O	847
glutamate	NOUN	O	Chemical	847
levels	NOUN	O	O	847
detected	VERB	O	O	847
a	PRON	O	O	847
decrease	VERB	O	O	847
of	ADP	O	O	847
5.21%	NOUN	O	O	847
,	PUNCT	O	O	847
13.55%	NOUN	O	O	847
and	CCONJ	O	O	847
21.80%	NOUN	O	O	847
,	PUNCT	O	O	847
respectively	ADV	O	O	847
in	ADP	O	O	847
mice	NOUN	O	O	847
hippocampus	NOUN	O	O	847
treated	VERB	O	O	847
with	ADP	O	O	847
GFC75	NOUN	O	O	847
plus	CCONJ	O	O	847
P400	NOUN	O	O	847
when	SCONJ	O	O	847
compared	VERB	O	O	847
with	ADP	O	O	847
seized	VERB	O	O	847
mice	NOUN	O	O	847
.	PUNCT	O	O	847
The	PRON	O	O	848
results	VERB	O	O	848
indicate	VERB	O	O	848
that	SCONJ	O	O	848
GFC	PROPN	O	O	848
can	AUX	O	O	848
exert	VERB	O	O	848
anticonvulsant	ADJ	O	O	848
activity	NOUN	O	O	848
and	CCONJ	O	O	848
reduce	VERB	O	O	848
the	PRON	O	O	848
frequency	NOUN	O	O	848
of	ADP	O	O	848
installation	NOUN	O	O	848
of	ADP	O	O	848
pilocarpine	NOUN	O	Chemical	848
-	PUNCT	O	O	848
induced	VERB	O	O	848
status epilepticus	VERB	O	Disease	848
,	PUNCT	O	O	848
as	ADP	O	O	848
demonstrated	VERB	O	O	848
by	ADP	O	O	848
increase	VERB	O	O	848
in	ADP	O	O	848
latency	VERB	O	O	848
to	PART	O	O	848
first	ADV	O	O	848
seizure	NOUN	O	Disease	848
and	CCONJ	O	O	848
decrease	VERB	O	O	848
in	ADP	O	O	848
mortality	NOUN	O	O	848
rate	NOUN	O	O	848
of	ADP	O	O	848
animals	NOUN	O	O	848
.	PUNCT	O	O	848
In	ADP	O	O	849
conclusion	NOUN	O	O	849
,	PUNCT	O	O	849
our	PRON	O	O	849
data	NOUN	O	O	849
suggest	VERB	O	O	849
that	SCONJ	O	O	849
GFC	PROPN	O	O	849
may	AUX	O	O	849
influence	NOUN	O	O	849
in	ADP	O	O	849
epileptogenesis	NOUN	O	O	849
and	CCONJ	O	O	849
promote	VERB	O	O	849
anticonvulsant	ADJ	O	O	849
actions	NOUN	O	O	849
in	ADP	O	O	849
pilocarpine	NOUN	O	Chemical	849
model	NOUN	O	O	849
by	ADP	O	O	849
modulating	VERB	O	O	849
the	PRON	O	O	849
GABA	PROPN	O	Chemical	849
and	CCONJ	O	O	849
glutamate	NOUN	O	Chemical	849
contents	NOUN	O	O	849
and	CCONJ	O	O	849
of	ADP	O	O	849
AChE	PROPN	O	O	849
activity	NOUN	O	O	849
in	ADP	O	O	849
seized	VERB	O	O	849
mice	NOUN	O	O	849
hippocampus	NOUN	O	O	849
.	PUNCT	O	O	849
Standard	PROPN	O	O	852
operating	VERB	O	O	852
procedures	NOUN	O	O	852
for	ADP	O	O	852
antibiotic	ADJ	O	O	852
therapy	NOUN	O	O	852
and	CCONJ	O	O	852
the	PRON	O	O	852
occurrence	NOUN	O	O	852
of	ADP	O	O	852
acute	ADJ	O	O	852
kidney	NOUN	O	O	852
injury	NOUN	O	O	852
:	PUNCT	O	O	852
a	PRON	O	O	852
prospective	ADJ	O	O	852
,	PUNCT	O	O	852
clinical	ADJ	O	O	852
,	PUNCT	O	O	852
non	ADJ	O	O	852
-	PUNCT	O	O	852
interventional	ADJ	O	O	852
,	PUNCT	O	O	852
observational	ADJ	O	O	852
study	VERB	O	O	852
.	PUNCT	O	O	852
Acute	PROPN	O	O	853
kidney	NOUN	O	O	853
injury	NOUN	O	O	853
(	PUNCT	O	O	853
AKI	PROPN	O	O	853
)	PUNCT	O	O	853
occurs	VERB	O	O	853
in	ADP	O	O	853
7%	NOUN	O	O	853
of	ADP	O	O	853
hospitalized	VERB	O	O	853
and	CCONJ	O	O	853
66%	NOUN	O	O	853
of	ADP	O	O	853
Intensive	PROPN	O	O	853
Care	VERB	O	O	853
Unit	NOUN	O	O	853
(	PUNCT	O	O	853
ICU	PROPN	O	O	853
)	PUNCT	O	O	853
The	PRON	O	O	854
aim	VERB	O	O	854
of	ADP	O	O	854
this	PRON	O	O	854
study	VERB	O	O	854
was	AUX	O	O	854
to	PART	O	O	854
investigate	VERB	O	O	854
,	PUNCT	O	O	854
whether	SCONJ	O	O	854
there	ADV	O	O	854
is	AUX	O	O	854
an	PRON	O	O	854
association	PROPN	O	O	854
between	ADP	O	O	854
adherence	PROPN	O	O	854
to	PART	O	O	854
guidelines	NOUN	O	O	854
(	PUNCT	O	O	854
standard	PROPN	O	O	854
operating	VERB	O	O	854
procedures	NOUN	O	O	854
(	PUNCT	O	O	854
SOP	PROPN	O	O	854
)	PUNCT	O	O	854
)	PUNCT	O	O	854
for	ADP	O	O	854
potentially	ADV	O	O	854
nephrotoxic	NOUN	O	Disease	854
antibiotics	VERB	O	O	854
and	CCONJ	O	O	854
the	PRON	O	O	854
occurrence	NOUN	O	O	854
of	ADP	O	O	854
AKI	PROPN	O	O	854
.	PUNCT	O	O	854
163	NUM	O	O	855
of	ADP	O	O	855
these	PRON	O	O	855
had	VERB	O	O	855
therapy	NOUN	O	O	855
with	ADP	O	O	855
vancomycin	VERB	O	Chemical	855
,	PUNCT	O	O	855
gentamicin	VERB	O	Chemical	855
,	PUNCT	O	O	855
or	CCONJ	O	O	855
tobramycin	NOUN	O	Chemical	855
;	PUNCT	O	O	855
were	AUX	O	O	855
>	PUNCT	O	O	855
18	NUM	O	O	855
years	NOUN	O	O	855
;	PUNCT	O	O	855
and	CCONJ	O	O	855
treated	VERB	O	O	855
in	ADP	O	O	855
the	PRON	O	O	855
ICU	PROPN	O	O	855
for	ADP	O	O	855
>	PUNCT	O	O	855
24	NUM	O	O	855
hours	NOUN	O	O	855
.	PUNCT	O	O	855
AKI	PROPN	O	O	856
was	AUX	O	O	856
defined	VERB	O	O	856
according	VERB	O	O	856
to	PART	O	O	856
RIFLE	PROPN	O	O	856
criteria	NOUN	O	O	856
.	PUNCT	O	O	856
Development	NOUN	O	O	857
of	ADP	O	O	857
AKI	PROPN	O	O	857
was	AUX	O	O	857
compared	VERB	O	O	857
between	ADP	O	O	857
groups	NOUN	O	O	857
with	ADP	O	O	857
exact	VERB	O	O	857
Chi2-test	NOUN	O	O	857
and	CCONJ	O	O	857
multivariate	ADJ	O	O	857
logistic	ADJ	O	O	857
regression	NOUN	O	O	857
analysis	NOUN	O	O	857
(	PUNCT	O	O	857
two	NUM	O	O	857
-	PUNCT	O	O	857
sided	VERB	O	O	857
P	NOUN	O	Chemical	857
<	X	O	O	857
0.05	NUM	O	O	857
)	PUNCT	O	O	857
.	PUNCT	O	O	857
AKI	PROPN	O	O	858
occurred	VERB	O	O	858
significantly	ADV	O	O	858
more	ADJ	O	O	858
often	ADV	O	O	858
in	ADP	O	O	858
LAG	PROPN	O	O	858
with	ADP	O	O	858
36%	NOUN	O	O	858
versus	ADP	O	O	858
21%	NOUN	O	O	858
in	ADP	O	O	858
HAG	NOUN	O	O	858
(	PUNCT	O	O	858
P	NOUN	O	Chemical	858
=	PUNCT	O	O	858
0.035	NUM	O	O	858
)	PUNCT	O	O	858
.	PUNCT	O	O	858
Basic	PROPN	O	O	859
characteristics	NOUN	O	O	859
were	AUX	O	O	859
comparable	ADJ	O	O	859
,	PUNCT	O	O	859
except	SCONJ	O	O	859
an	PRON	O	O	859
increased	VERB	O	O	859
rate	NOUN	O	O	859
of	ADP	O	O	859
soft	ADJ	O	O	859
tissue	NOUN	O	O	859
infections	NOUN	O	Disease	859
in	ADP	O	O	859
LAG	PROPN	O	O	859
.	PUNCT	O	O	859
Multivariate	NOUN	O	O	860
analysis	NOUN	O	O	860
revealed	VERB	O	O	860
an	PRON	O	O	860
odds	NOUN	O	O	860
ratio	NOUN	O	O	860
of	ADP	O	O	860
2.5-fold	ADV	O	O	860
for	ADP	O	O	860
LAG	PROPN	O	O	860
to	PART	O	O	860
develop	VERB	O	O	860
AKI	PROPN	O	O	860
compared	VERB	O	O	860
with	ADP	O	O	860
HAG	NOUN	O	O	860
(	PUNCT	O	O	860
95%	NOUN	O	O	860
confidence	NOUN	O	O	860
interval	NOUN	O	O	860
1.195	NUM	O	O	860
to	PART	O	O	860
5.124	NUM	O	O	860
,	PUNCT	O	O	860
P	NOUN	O	Chemical	860
=	PUNCT	O	O	860
0.039	NUM	O	O	860
)	PUNCT	O	O	860
.	PUNCT	O	O	860
CONCLUSION	PROPN	O	O	861
:	PUNCT	O	O	861
Low	ADJ	O	O	861
adherence	PROPN	O	O	861
to	PART	O	O	861
SOPs	NOUN	O	O	861
for	ADP	O	O	861
potentially	ADV	O	O	861
nephrotoxic	NOUN	O	Disease	861
antibiotics	VERB	O	O	861
was	AUX	O	O	861
associated	VERB	O	O	861
with	ADP	O	O	861
a	PRON	O	O	861
higher	ADJ	O	O	861
occurrence	NOUN	O	O	861
of	ADP	O	O	861
AKI	PROPN	O	O	861
.	PUNCT	O	O	861
Rhabdomyolysis	NOUN	O	O	864
in	ADP	O	O	864
a	PRON	O	O	864
hepatitis C	PROPN	O	Disease	864
virus	NOUN	O	O	864
infected	VERB	O	O	864
patient	NOUN	O	O	864
treated	VERB	O	O	864
with	ADP	O	O	864
telaprevir	NOUN	O	O	864
and	CCONJ	O	O	864
simvastatin	PROPN	O	Chemical	864
.	PUNCT	O	O	864
A	PRON	O	O	865
46-year	NOUN	O	O	865
old	ADJ	O	O	865
man	NOUN	O	O	865
with	ADP	O	O	865
a	PRON	O	O	865
chronic hepatitis C	NOUN	O	Disease	865
virus	NOUN	O	O	865
infection	NOUN	O	Disease	865
received	VERB	O	O	865
triple	ADV	O	O	865
therapy	NOUN	O	O	865
with	ADP	O	O	865
ribavirin	NOUN	O	Chemical	865
,	PUNCT	O	O	865
pegylated	VERB	O	O	865
interferon	PROPN	O	Chemical	865
and	CCONJ	O	O	865
telaprevir	NOUN	O	O	865
.	PUNCT	O	O	865
The	PRON	O	O	866
patient	NOUN	O	O	866
also	ADV	O	O	866
received	VERB	O	O	866
simvastatin	PROPN	O	Chemical	866
.	PUNCT	O	O	866
One	NUM	O	O	867
month	NOUN	O	O	867
after	ADP	O	O	867
starting	VERB	O	O	867
the	PRON	O	O	867
antiviral	ADJ	O	O	867
therapy	NOUN	O	O	867
,	PUNCT	O	O	867
the	PRON	O	O	867
patient	NOUN	O	O	867
was	AUX	O	O	867
admitted	VERB	O	O	867
to	PART	O	O	867
the	PRON	O	O	867
hospital	PROPN	O	O	867
because	SCONJ	O	O	867
he	PRON	O	O	867
developed	VERB	O	O	867
rhabdomyolysis	NOUN	O	Disease	867
.	PUNCT	O	O	867
At	ADP	O	O	868
admission	NOUN	O	O	868
simvastatin	PROPN	O	Chemical	868
and	CCONJ	O	O	868
all	PRON	O	O	868
antiviral	ADJ	O	O	868
drugs	NOUN	O	O	868
were	AUX	O	O	868
discontinued	VERB	O	O	868
because	SCONJ	O	O	868
toxicity	NOUN	O	Disease	868
due	ADJ	O	O	868
to	PART	O	O	868
a	PRON	O	O	868
drug	NOUN	O	O	868
-	PUNCT	O	O	868
drug	NOUN	O	O	868
interaction	NOUN	O	O	868
was	AUX	O	O	868
suspected	VERB	O	O	868
.	PUNCT	O	O	868
The	PRON	O	O	869
creatine	PROPN	O	Chemical	869
kinase	VERB	O	O	869
peaked	VERB	O	O	869
at	ADP	O	O	869
62,246	NUM	O	O	869
IU	PROPN	O	O	869
/	PUNCT	O	O	869
L	NOUN	O	O	869
and	CCONJ	O	O	869
the	PRON	O	O	869
patient	NOUN	O	O	869
was	AUX	O	O	869
treated	VERB	O	O	869
with	ADP	O	O	869
intravenous	ADJ	O	O	869
normal	ADJ	O	O	869
saline	NOUN	O	O	869
.	PUNCT	O	O	869
Fourteen	NUM	O	O	870
days	NOUN	O	O	870
after	ADP	O	O	870
hospitalization	NOUN	O	O	870
,	PUNCT	O	O	870
creatine	PROPN	O	Chemical	870
kinase	VERB	O	O	870
level	VERB	O	O	870
had	VERB	O	O	870
returned	VERB	O	O	870
to	PART	O	O	870
230	NUM	O	O	870
IU	PROPN	O	O	870
/	PUNCT	O	O	870
L	NOUN	O	O	870
and	CCONJ	O	O	870
the	PRON	O	O	870
patient	NOUN	O	O	870
was	AUX	O	O	870
discharged	VERB	O	O	870
.	PUNCT	O	O	870
Telaprevir	PROPN	O	O	871
was	AUX	O	O	871
considered	VERB	O	O	871
the	PRON	O	O	871
probable	ADJ	O	O	871
causative	ADJ	O	O	871
agent	NOUN	O	O	871
of	ADP	O	O	871
an	PRON	O	O	871
interaction	NOUN	O	O	871
with	ADP	O	O	871
simvastatin	PROPN	O	Chemical	871
according	VERB	O	O	871
to	PART	O	O	871
the	PRON	O	O	871
Drug	NOUN	O	O	871
Interaction	NOUN	O	O	871
Probability	NOUN	O	O	871
Scale	NOUN	O	O	871
.	PUNCT	O	O	871
The	PRON	O	O	872
interaction	NOUN	O	O	872
is	AUX	O	O	872
due	ADJ	O	O	872
to	PART	O	O	872
inhibition	NOUN	O	O	872
of	ADP	O	O	872
CYP3A4-mediated	VERB	O	O	872
simvastatin	PROPN	O	Chemical	872
clearance	NOUN	O	O	872
.	PUNCT	O	O	872
Simvastatin	PROPN	O	O	873
plasma	NOUN	O	O	873
concentration	NOUN	O	O	873
increased	VERB	O	O	873
30	NUM	O	O	873
times	NOUN	O	O	873
in	ADP	O	O	873
this	PRON	O	O	873
patient	NOUN	O	O	873
and	CCONJ	O	O	873
statin	PROPN	O	O	873
induced	VERB	O	O	873
muscle	NOUN	O	O	873
toxicity	NOUN	O	Disease	873
is	AUX	O	O	873
related	ADJ	O	O	873
to	PART	O	O	873
the	PRON	O	O	873
concentration	NOUN	O	O	873
of	ADP	O	O	873
the	PRON	O	O	873
statin	PROPN	O	O	873
in	ADP	O	O	873
blood	NOUN	O	O	873
.	PUNCT	O	O	873
In	ADP	O	O	874
conclusion	NOUN	O	O	874
,	PUNCT	O	O	874
with	ADP	O	O	874
this	PRON	O	O	874
case	NOUN	O	O	874
we	PRON	O	O	874
illustrate	VERB	O	O	874
that	SCONJ	O	O	874
telaprevir	NOUN	O	O	874
as	ADP	O	O	874
well	ADV	O	O	874
as	ADP	O	O	874
statins	NOUN	O	O	874
are	AUX	O	O	874
susceptible	ADJ	O	O	874
to	PART	O	O	874
clinical	ADJ	O	O	874
relevant	ADJ	O	O	874
drug	NOUN	O	O	874
-	PUNCT	O	O	874
drug	NOUN	O	O	874
interactions	NOUN	O	O	874
.	PUNCT	O	O	874
Combination	NOUN	O	O	877
of	ADP	O	O	877
bortezomib	VERB	O	Chemical	877
,	PUNCT	O	O	877
thalidomide	NOUN	O	Chemical	877
,	PUNCT	O	O	877
and	CCONJ	O	O	877
dexamethasone	NOUN	O	Chemical	877
(	PUNCT	O	O	877
VTD	PROPN	O	O	877
)	PUNCT	O	O	877
as	ADP	O	O	877
a	PRON	O	O	877
consolidation	NOUN	O	O	877
therapy	NOUN	O	O	877
after	ADP	O	O	877
autologous	ADJ	O	O	877
stem	VERB	O	O	877
cell	NOUN	O	O	877
transplantation	NOUN	O	O	877
for	ADP	O	O	877
symptomatic	ADJ	O	O	877
multiple myeloma	NOUN	O	Disease	877
in	ADP	O	O	877
Japanese	NOUN	O	O	877
patients	NOUN	O	O	877
.	PUNCT	O	O	877
Consolidation	NOUN	O	O	878
therapy	NOUN	O	O	878
for	ADP	O	O	878
patients	NOUN	O	O	878
with	ADP	O	O	878
multiple myeloma	NOUN	O	Disease	878
(	PUNCT	O	O	878
MM	PROPN	O	Disease	878
)	PUNCT	O	O	878
has	VERB	O	O	878
been	AUX	O	O	878
widely	ADV	O	O	878
adopted	VERB	O	O	878
to	PART	O	O	878
improve	VERB	O	O	878
treatment	NOUN	O	O	878
response	NOUN	O	O	878
following	VERB	O	O	878
autologous	ADJ	O	O	878
stem	VERB	O	O	878
cell	NOUN	O	O	878
transplantation	NOUN	O	O	878
.	PUNCT	O	O	878
In	ADP	O	O	879
this	PRON	O	O	879
study	VERB	O	O	879
,	PUNCT	O	O	879
we	PRON	O	O	879
retrospectively	ADV	O	O	879
analyzed	VERB	O	O	879
the	PRON	O	O	879
safety	NOUN	O	O	879
and	CCONJ	O	O	879
efficacy	NOUN	O	O	879
of	ADP	O	O	879
combination	NOUN	O	O	879
regimen	NOUN	O	O	879
of	ADP	O	O	879
bortezomib	VERB	O	Chemical	879
,	PUNCT	O	O	879
thalidomide	NOUN	O	Chemical	879
,	PUNCT	O	O	879
and	CCONJ	O	O	879
dexamethasone	NOUN	O	Chemical	879
(	PUNCT	O	O	879
VTD	PROPN	O	O	879
)	PUNCT	O	O	879
as	ADP	O	O	879
consolidation	NOUN	O	O	879
therapy	NOUN	O	O	879
in	ADP	O	O	879
24	NUM	O	O	879
Japanese	NOUN	O	O	879
patients	NOUN	O	O	879
with	ADP	O	O	879
newly	ADV	O	O	879
diagnosed	VERB	O	O	879
MM	PROPN	O	Disease	879
.	PUNCT	O	O	879
VTD	PROPN	O	O	880
consisted	VERB	O	O	880
of	ADP	O	O	880
bortezomib	VERB	O	Chemical	880
at	ADP	O	O	880
a	PRON	O	O	880
dose	NOUN	O	O	880
of	ADP	O	O	880
1.3	NUM	O	O	880
mg	VERB	O	O	880
/	PUNCT	O	O	880
m(2	NUM	O	O	880
)	PUNCT	O	O	880
and	CCONJ	O	O	880
dexamethasone	NOUN	O	Chemical	880
at	ADP	O	O	880
a	PRON	O	O	880
dose	NOUN	O	O	880
of	ADP	O	O	880
40	NUM	O	O	880
mg	VERB	O	O	880
/	PUNCT	O	O	880
day	NOUN	O	O	880
on	ADP	O	O	880
days	NOUN	O	O	880
1	X	O	O	880
,	PUNCT	O	O	880
8	NUM	O	O	880
,	PUNCT	O	O	880
15	NUM	O	O	880
,	PUNCT	O	O	880
and	CCONJ	O	O	880
22	NUM	O	O	880
of	ADP	O	O	880
a	PRON	O	O	880
35-day	NOUN	O	O	880
cycle	PROPN	O	O	880
,	PUNCT	O	O	880
with	ADP	O	O	880
daily	ADV	O	O	880
oral	ADJ	O	O	880
thalidomide	NOUN	O	Chemical	880
at	ADP	O	O	880
a	PRON	O	O	880
dose	NOUN	O	O	880
of	ADP	O	O	880
100	NUM	O	O	880
mg	VERB	O	O	880
/	PUNCT	O	O	880
day	NOUN	O	O	880
.	PUNCT	O	O	880
Grade	NOUN	O	O	881
3	X	O	O	881
-	PUNCT	O	O	881
4	NUM	O	O	881
neutropenia	ADJ	O	Disease	881
and	CCONJ	O	O	881
thrombocytopenia	PROPN	O	Disease	881
were	AUX	O	O	881
documented	VERB	O	O	881
in	ADP	O	O	881
four	NUM	O	O	881
and	CCONJ	O	O	881
three	NUM	O	O	881
patients	NOUN	O	O	881
(	PUNCT	O	O	881
17	NUM	O	O	881
and	CCONJ	O	O	881
13	NUM	O	O	881
%	INTJ	O	O	881
)	PUNCT	O	O	881
,	PUNCT	O	O	881
respectively	ADV	O	O	881
,	PUNCT	O	O	881
but	CCONJ	O	O	881
drug	NOUN	O	O	881
dose	NOUN	O	O	881
reduction	NOUN	O	O	881
due	ADJ	O	O	881
to	PART	O	O	881
cytopenia	NOUN	O	O	881
was	AUX	O	O	881
not	PART	O	O	881
required	VERB	O	O	881
in	ADP	O	O	881
any	PRON	O	O	881
case	NOUN	O	O	881
.	PUNCT	O	O	881
Peripheral neuropathy	NOUN	O	Disease	882
was	AUX	O	O	882
common	ADJ	O	O	882
(	PUNCT	O	O	882
63	NUM	O	O	882
%	INTJ	O	O	882
)	PUNCT	O	O	882
,	PUNCT	O	O	882
but	CCONJ	O	O	882
severe	ADJ	O	O	882
grade	NOUN	O	O	882
3	X	O	O	882
-	PUNCT	O	O	882
4	NUM	O	O	882
peripheral neuropathy	NOUN	O	Disease	882
was	AUX	O	O	882
not	PART	O	O	882
observed	VERB	O	O	882
.	PUNCT	O	O	882
Conversion	NOUN	O	O	885
to	PART	O	O	885
sirolimus	NOUN	O	Chemical	885
ameliorates	VERB	O	O	885
cyclosporine	NOUN	O	Chemical	885
-	PUNCT	O	O	885
induced	VERB	O	O	885
nephropathy	NOUN	O	Disease	885
in	ADP	O	O	885
the	PRON	O	O	885
rat	NOUN	O	O	885
:	PUNCT	O	O	885
focus	NOUN	O	O	885
on	ADP	O	O	885
serum	NOUN	O	O	885
,	PUNCT	O	O	885
urine	NOUN	O	O	885
,	PUNCT	O	O	885
gene	NOUN	O	O	885
,	PUNCT	O	O	885
and	CCONJ	O	O	885
protein	NOUN	O	O	885
renal	ADJ	O	O	885
expression	NOUN	O	O	885
biomarkers	NOUN	O	O	885
.	PUNCT	O	O	885
Protocols	NOUN	O	O	886
of	ADP	O	O	886
conversion	NOUN	O	O	886
from	ADP	O	O	886
cyclosporin A	PRON	O	Chemical	886
(	PUNCT	O	O	886
CsA	PROPN	O	Chemical	886
)	PUNCT	O	O	886
to	PART	O	O	886
sirolimus	NOUN	O	Chemical	886
(	PUNCT	O	O	886
SRL	PROPN	O	O	886
)	PUNCT	O	O	886
have	VERB	O	O	886
been	AUX	O	O	886
widely	ADV	O	O	886
used	VERB	O	O	886
in	ADP	O	O	886
immunotherapy	NOUN	O	O	886
after	ADP	O	O	886
transplantation	NOUN	O	O	886
to	PART	O	O	886
prevent	VERB	O	O	886
CsA	PROPN	O	Chemical	886
-	PUNCT	O	O	886
induced	VERB	O	O	886
nephropathy	NOUN	O	Disease	886
,	PUNCT	O	O	886
but	CCONJ	O	O	886
the	PRON	O	O	886
molecular	ADJ	O	O	886
mechanisms	NOUN	O	O	886
underlying	VERB	O	O	886
these	PRON	O	O	886
protocols	NOUN	O	O	886
remain	VERB	O	O	886
nuclear	ADJ	O	O	886
.	PUNCT	O	O	886
This	PRON	O	O	887
study	VERB	O	O	887
aimed	VERB	O	O	887
to	PART	O	O	887
identify	VERB	O	O	887
the	PRON	O	O	887
molecular	ADJ	O	O	887
pathways	NOUN	O	O	887
and	CCONJ	O	O	887
putative	ADJ	O	O	887
biomarkers	NOUN	O	O	887
of	ADP	O	O	887
CsA	PROPN	O	Chemical	887
-	PUNCT	O	O	887
to	PART	O	O	887
-	PUNCT	O	O	887
SRL	PROPN	O	O	887
conversion	NOUN	O	O	887
in	ADP	O	O	887
a	PRON	O	O	887
rat	NOUN	O	O	887
model	NOUN	O	O	887
.	PUNCT	O	O	887
Four	NUM	O	O	888
animal	NOUN	O	O	888
groups	NOUN	O	O	888
(	PUNCT	O	O	888
n	CCONJ	O	O	888
=	PUNCT	O	O	888
6	NUM	O	O	888
)	PUNCT	O	O	888
were	AUX	O	O	888
tested	VERB	O	O	888
during	ADP	O	O	888
9	NUM	O	O	888
weeks	NOUN	O	O	888
:	PUNCT	O	O	888
control	VERB	O	O	888
,	PUNCT	O	O	888
CsA	PROPN	O	Chemical	888
,	PUNCT	O	O	888
SRL	PROPN	O	O	888
,	PUNCT	O	O	888
and	CCONJ	O	O	888
conversion	NOUN	O	O	888
(	PUNCT	O	O	888
CsA	PROPN	O	Chemical	888
for	ADP	O	O	888
3	X	O	O	888
weeks	NOUN	O	O	888
followed	VERB	O	O	888
by	ADP	O	O	888
SRL	PROPN	O	O	888
for	ADP	O	O	888
6	NUM	O	O	888
weeks	NOUN	O	O	888
)	PUNCT	O	O	888
.	PUNCT	O	O	888
Renal lesions	NOUN	O	Disease	889
were	AUX	O	O	889
analyzed	VERB	O	O	889
in	ADP	O	O	889
hematoxylin	VERB	O	O	889
and	CCONJ	O	O	889
eosin	NOUN	O	O	889
,	PUNCT	O	O	889
periodic acid	NOUN	O	Chemical	889
-	PUNCT	O	O	889
Schiff	PROPN	O	O	889
,	PUNCT	O	O	889
and	CCONJ	O	O	889
Masson	PROPN	O	O	889
's	AUX	O	O	889
trichrome	VERB	O	O	889
stains	NOUN	O	O	889
.	PUNCT	O	O	889
SRL	PROPN	O	O	890
-	PUNCT	O	O	890
treated	VERB	O	O	890
rats	NOUN	O	O	890
presented	VERB	O	O	890
proteinuria	X	O	Disease	890
and	CCONJ	O	O	890
NGAL	PROPN	O	O	890
(	PUNCT	O	O	890
serum	NOUN	O	O	890
and	CCONJ	O	O	890
urinary	ADJ	O	O	890
)	PUNCT	O	O	890
as	ADP	O	O	890
the	PRON	O	O	890
best	ADV	O	O	890
markers	NOUN	O	O	890
of	ADP	O	O	890
renal impairment	NOUN	O	Disease	890
.	PUNCT	O	O	890
Short	ADJ	O	O	891
CsA	PROPN	O	Chemical	891
treatment	NOUN	O	O	891
presented	VERB	O	O	891
slight	ADJ	O	O	891
or	CCONJ	O	O	891
even	ADV	O	O	891
absent	ADJ	O	O	891
kidney	NOUN	O	O	891
lesions	NOUN	O	O	891
and	CCONJ	O	O	891
TGF	PROPN	O	O	891
-	PUNCT	O	O	891
b	X	O	O	891
,	PUNCT	O	O	891
NF-	NOUN	O	O	891
kb	PROPN	O	O	891
,	PUNCT	O	O	891
mTOR	PROPN	O	O	891
,	PUNCT	O	O	891
PCNA	PROPN	O	O	891
,	PUNCT	O	O	891
TP53	PROPN	O	O	891
,	PUNCT	O	O	891
KIM-1	NOUN	O	O	891
,	PUNCT	O	O	891
and	CCONJ	O	O	891
CTGF	ADV	O	O	891
as	ADP	O	O	891
relevant	ADJ	O	O	891
gene	NOUN	O	O	891
and	CCONJ	O	O	891
protein	NOUN	O	O	891
changes	VERB	O	O	891
.	PUNCT	O	O	891
Prolonged	VERB	O	O	892
CsA	PROPN	O	Chemical	892
exposure	NOUN	O	O	892
aggravated	VERB	O	O	892
renal damage	NOUN	O	Disease	892
,	PUNCT	O	O	892
without	ADP	O	O	892
clear	ADJ	O	O	892
changes	VERB	O	O	892
on	ADP	O	O	892
the	PRON	O	O	892
traditional	ADJ	O	O	892
markers	NOUN	O	O	892
,	PUNCT	O	O	892
but	CCONJ	O	O	892
with	ADP	O	O	892
changes	VERB	O	O	892
in	ADP	O	O	892
serums	NOUN	O	O	892
TGF-	NUM	O	O	892
b	X	O	O	892
and	CCONJ	O	O	892
IL-7	PROPN	O	O	892
,	PUNCT	O	O	892
TBARs	NOUN	O	Chemical	892
clearance	NOUN	O	O	892
,	PUNCT	O	O	892
and	CCONJ	O	O	892
kidney	NOUN	O	O	892
TGF	PROPN	O	O	892
-	PUNCT	O	O	892
b	X	O	O	892
and	CCONJ	O	O	892
mTOR	PROPN	O	O	892
.	PUNCT	O	O	892
Conversion	NOUN	O	O	893
to	PART	O	O	893
SRL	PROPN	O	O	893
prevented	VERB	O	O	893
CsA	PROPN	O	Chemical	893
-	PUNCT	O	O	893
induced	VERB	O	O	893
renal damage	NOUN	O	Disease	893
evolution	NOUN	O	O	893
(	PUNCT	O	O	893
absent	ADJ	O	O	893
/	PUNCT	O	O	893
mild	ADJ	O	O	893
grade	NOUN	O	O	893
lesions	NOUN	O	O	893
)	PUNCT	O	O	893
,	PUNCT	O	O	893
while	SCONJ	O	O	893
NGAL	PROPN	O	O	893
(	PUNCT	O	O	893
serum	NOUN	O	O	893
versus	ADP	O	O	893
urine	NOUN	O	O	893
)	PUNCT	O	O	893
seems	VERB	O	O	893
to	PART	O	O	893
be	AUX	O	O	893
a	PRON	O	O	893
feasible	ADJ	O	O	893
biomarker	NOUN	O	O	893
of	ADP	O	O	893
CsA	PROPN	O	Chemical	893
replacement	NOUN	O	O	893
to	PART	O	O	893
SRL	PROPN	O	O	893
.	PUNCT	O	O	893
cisplatin	NOUN	O	Chemical	896
-	PUNCT	O	O	896
induced	VERB	O	O	896
acute	ADJ	O	O	896
renal injury	NOUN	O	Disease	896
.	PUNCT	O	O	896
Cisplatin	PROPN	O	O	897
treatment	NOUN	O	O	897
has	VERB	O	O	897
been	AUX	O	O	897
adopted	VERB	O	O	897
in	ADP	O	O	897
some	PRON	O	O	897
chemotherapies	NOUN	O	O	897
;	PUNCT	O	O	897
however	ADV	O	O	897
,	PUNCT	O	O	897
this	PRON	O	O	897
drug	NOUN	O	O	897
can	AUX	O	O	897
induce	VERB	O	O	897
acute	ADJ	O	O	897
kidney	NOUN	O	O	897
injury	NOUN	O	O	897
due	ADJ	O	O	897
its	PRON	O	O	897
ability	NOUN	O	O	897
to	PART	O	O	897
negatively	ADV	O	O	897
affect	VERB	O	O	897
renal	ADJ	O	O	897
function	NOUN	O	O	897
,	PUNCT	O	O	897
augment	VERB	O	O	897
serum	NOUN	O	O	897
levels	NOUN	O	O	897
of	ADP	O	O	897
creatinine	PROPN	O	Chemical	897
and	CCONJ	O	O	897
urea	PROPN	O	Chemical	897
,	PUNCT	O	O	897
increase	VERB	O	O	897
the	PRON	O	O	897
acute	ADJ	O	O	897
tubular necrosis	NOUN	O	Disease	897
score	VERB	O	O	897
and	CCONJ	O	O	897
up	ADP	O	O	897
-	PUNCT	O	O	897
regulate	VERB	O	O	897
cytokines	NOUN	O	O	897
(	PUNCT	O	O	897
e.g.	ADV	O	O	897
,	PUNCT	O	O	897
IL-1b	PROPN	O	O	897
and	CCONJ	O	O	897
TNF	PROPN	O	O	897
-	PUNCT	O	O	897
a	PRON	O	O	897
)	PUNCT	O	O	897
.	PUNCT	O	O	897
The	PRON	O	O	898
kinin	PROPN	O	O	898
B2	NOUN	O	O	898
receptor	NOUN	O	O	898
has	VERB	O	O	898
been	AUX	O	O	898
associated	VERB	O	O	898
with	ADP	O	O	898
the	PRON	O	O	898
inflammation	NOUN	O	Disease	898
process	NOUN	O	O	898
,	PUNCT	O	O	898
as	ADP	O	O	898
well	ADV	O	O	898
as	ADP	O	O	898
the	PRON	O	O	898
regulation	NOUN	O	O	898
of	ADP	O	O	898
cytokine	NOUN	O	O	898
expression	NOUN	O	O	898
,	PUNCT	O	O	898
and	CCONJ	O	O	898
its	PRON	O	O	898
deletion	NOUN	O	O	898
resulted	VERB	O	O	898
in	ADP	O	O	898
an	PRON	O	O	898
improvement	NOUN	O	O	898
in	ADP	O	O	898
the	PRON	O	O	898
diabetic nephropathy	NOUN	O	Disease	898
status	NOUN	O	O	898
.	PUNCT	O	O	898
To	PART	O	O	899
examine	VERB	O	O	899
the	PRON	O	O	899
role	NOUN	O	O	899
of	ADP	O	O	899
the	PRON	O	O	899
kinin	PROPN	O	O	899
B2	NOUN	O	O	899
receptor	NOUN	O	O	899
in	ADP	O	O	899
cisplatin	NOUN	O	Chemical	899
-	PUNCT	O	O	899
induced	VERB	O	O	899
acute	ADJ	O	O	899
kidney	NOUN	O	O	899
injury	NOUN	O	O	899
,	PUNCT	O	O	899
kinin	PROPN	O	O	899
B2	NOUN	O	O	899
receptor	NOUN	O	O	899
knockout	NOUN	O	O	899
mice	NOUN	O	O	899
were	AUX	O	O	899
challenged	VERB	O	O	899
with	ADP	O	O	899
cisplatin	NOUN	O	Chemical	899
.	PUNCT	O	O	899
Additionally	ADV	O	O	900
,	PUNCT	O	O	900
WT	NOUN	O	O	900
mice	NOUN	O	O	900
were	AUX	O	O	900
treated	VERB	O	O	900
with	ADP	O	O	900
a	PRON	O	O	900
B2	NOUN	O	O	900
receptor	NOUN	O	O	900
antagonist	NOUN	O	O	900
after	ADP	O	O	900
cisplatin	NOUN	O	Chemical	900
administration	NOUN	O	O	900
.	PUNCT	O	O	900
B2	NOUN	O	O	901
receptor	NOUN	O	O	901
-	PUNCT	O	O	901
deficient	ADJ	O	O	901
mice	NOUN	O	O	901
were	AUX	O	O	901
less	ADV	O	O	901
sensitive	ADJ	O	O	901
to	PART	O	O	901
this	PRON	O	O	901
drug	NOUN	O	O	901
than	ADP	O	O	901
the	PRON	O	O	901
WT	NOUN	O	O	901
mice	NOUN	O	O	901
,	PUNCT	O	O	901
as	ADP	O	O	901
shown	VERB	O	O	901
by	ADP	O	O	901
reduced	VERB	O	O	901
weight loss	NOUN	O	Disease	901
,	PUNCT	O	O	901
better	ADV	O	O	901
preservation	NOUN	O	O	901
of	ADP	O	O	901
kidney	NOUN	O	O	901
function	NOUN	O	O	901
,	PUNCT	O	O	901
down	ADP	O	O	901
regulation	NOUN	O	O	901
of	ADP	O	O	901
inflammatory	ADJ	O	O	901
cytokines	NOUN	O	O	901
and	CCONJ	O	O	901
less	ADV	O	O	901
acute	ADJ	O	O	901
tubular necrosis	NOUN	O	Disease	901
.	PUNCT	O	O	901
Moreover	ADV	O	O	902
,	PUNCT	O	O	902
treatment	NOUN	O	O	902
with	ADP	O	O	902
the	PRON	O	O	902
kinin	PROPN	O	O	902
B2	NOUN	O	O	902
receptor	NOUN	O	O	902
antagonist	NOUN	O	O	902
effectively	ADV	O	O	902
reduced	VERB	O	O	902
the	PRON	O	O	902
levels	NOUN	O	O	902
of	ADP	O	O	902
serum	NOUN	O	O	902
creatinine	PROPN	O	Chemical	902
and	CCONJ	O	O	902
blood	NOUN	O	O	902
urea	PROPN	O	Chemical	902
after	ADP	O	O	902
cisplatin	NOUN	O	Chemical	902
administration	NOUN	O	O	902
.	PUNCT	O	O	902
Thus	ADV	O	O	903
,	PUNCT	O	O	903
our	PRON	O	O	903
data	NOUN	O	O	903
suggest	VERB	O	O	903
that	SCONJ	O	O	903
the	PRON	O	O	903
kinin	PROPN	O	O	903
B2	NOUN	O	O	903
receptor	NOUN	O	O	903
is	AUX	O	O	903
involved	VERB	O	O	903
in	ADP	O	O	903
cisplatin	NOUN	O	Chemical	903
-	PUNCT	O	O	903
induced	VERB	O	O	903
acute	ADJ	O	O	903
kidney	NOUN	O	O	903
injury	NOUN	O	O	903
by	ADP	O	O	903
mediating	VERB	O	O	903
the	PRON	O	O	903
necrotic	ADJ	O	O	903
process	NOUN	O	O	903
and	CCONJ	O	O	903
the	PRON	O	O	903
expression	NOUN	O	O	903
of	ADP	O	O	903
inflammatory	ADJ	O	O	903
cytokines	NOUN	O	O	903
,	PUNCT	O	O	903
thus	ADV	O	O	903
resulting	VERB	O	O	903
in	ADP	O	O	903
declined	VERB	O	O	903
renal	ADJ	O	O	903
function	NOUN	O	O	903
.	PUNCT	O	O	903
These	PRON	O	O	904
results	VERB	O	O	904
highlight	VERB	O	O	904
the	PRON	O	O	904
kinin	PROPN	O	O	904
B2	NOUN	O	O	904
receptor	NOUN	O	O	904
antagonist	NOUN	O	O	904
treatment	NOUN	O	O	904
in	ADP	O	O	904
amelioration	NOUN	O	O	904
of	ADP	O	O	904
nephrotoxicity	NOUN	O	Disease	904
induced	VERB	O	O	904
by	ADP	O	O	904
cisplatin	NOUN	O	Chemical	904
therapy	NOUN	O	O	904
.	PUNCT	O	O	904
Safety	NOUN	O	O	907
and	CCONJ	O	O	907
efficacy	NOUN	O	O	907
of	ADP	O	O	907
fluocinolone acetonide	NOUN	O	Chemical	907
intravitreal	NOUN	O	O	907
implant	NOUN	O	O	907
(	PUNCT	O	O	907
0.59	NUM	O	O	907
mg	VERB	O	O	907
)	PUNCT	O	O	907
in	ADP	O	O	907
birdshot	VERB	O	O	907
retinochoroidopathy	ADJ	O	O	907
.	PUNCT	O	O	907
PURPOSE	NOUN	O	O	908
:	PUNCT	O	O	908
To	PART	O	O	908
report	VERB	O	O	908
the	PRON	O	O	908
treatment	NOUN	O	O	908
outcomes	NOUN	O	O	908
of	ADP	O	O	908
the	PRON	O	O	908
fluocinolone acetonide	NOUN	O	Chemical	908
intravitreal	NOUN	O	O	908
implant	NOUN	O	O	908
(	PUNCT	O	O	908
0.59	NUM	O	O	908
mg	VERB	O	O	908
)	PUNCT	O	O	908
in	ADP	O	O	908
patients	NOUN	O	O	908
with	ADP	O	O	908
birdshot	VERB	O	O	908
retinochoroidopathy	ADJ	O	O	908
whose	DET	O	O	908
disease	PROPN	O	O	908
is	AUX	O	O	908
refractory	ADJ	O	O	908
or	CCONJ	O	O	908
intolerant	ADJ	O	O	908
to	PART	O	O	908
conventional	ADJ	O	O	908
immunomodulatory	NOUN	O	O	908
therapy	NOUN	O	O	908
.	PUNCT	O	O	908
A	PRON	O	O	909
retrospective	ADJ	O	O	909
case	NOUN	O	O	909
series	PROPN	O	O	909
involving	VERB	O	O	909
11	NUM	O	O	909
birdshot	VERB	O	O	909
retinochoroidopathy	ADJ	O	O	909
patients	NOUN	O	O	909
(	PUNCT	O	O	909
11	NUM	O	O	909
eyes	NOUN	O	O	909
)	PUNCT	O	O	909
.	PUNCT	O	O	909
Eleven	NUM	O	O	910
patients	NOUN	O	O	910
(	PUNCT	O	O	910
11	NUM	O	O	910
eyes	NOUN	O	O	910
)	PUNCT	O	O	910
underwent	VERB	O	O	910
surgery	NOUN	O	O	910
for	ADP	O	O	910
fluocinolone acetonide	NOUN	O	Chemical	910
implant	NOUN	O	O	910
(	PUNCT	O	O	910
0.59	NUM	O	O	910
mg	VERB	O	O	910
)	PUNCT	O	O	910
.	PUNCT	O	O	910
Treatment	NOUN	O	O	911
outcomes	NOUN	O	O	911
of	ADP	O	O	911
interest	NOUN	O	O	911
were	AUX	O	O	911
noted	VERB	O	O	911
at	ADP	O	O	911
baseline	VERB	O	O	911
,	PUNCT	O	O	911
before	ADP	O	O	911
fluocinolone acetonide	NOUN	O	Chemical	911
implant	NOUN	O	O	911
,	PUNCT	O	O	911
and	CCONJ	O	O	911
then	ADV	O	O	911
at	ADP	O	O	911
6	NUM	O	O	911
months	NOUN	O	O	911
,	PUNCT	O	O	911
1	X	O	O	911
year	NOUN	O	O	911
,	PUNCT	O	O	911
2	X	O	O	911
years	NOUN	O	O	911
,	PUNCT	O	O	911
3	X	O	O	911
years	NOUN	O	O	911
,	PUNCT	O	O	911
and	CCONJ	O	O	911
beyond	ADP	O	O	911
3	X	O	O	911
years	NOUN	O	O	911
.	PUNCT	O	O	911
Disease	NOUN	O	O	912
activity	NOUN	O	O	912
markers	NOUN	O	O	912
,	PUNCT	O	O	912
including	VERB	O	O	912
signs	NOUN	O	O	912
of	ADP	O	O	912
ocular	ADJ	O	O	912
inflammation	NOUN	O	Disease	912
,	PUNCT	O	O	912
evidence	NOUN	O	O	912
of	ADP	O	O	912
retinal	ADJ	O	O	912
vasculitis	NOUN	O	Disease	912
,	PUNCT	O	O	912
Swedish	ADJ	O	O	912
interactive	ADJ	O	O	912
threshold	NOUN	O	O	912
algorithm	VERB	O	O	912
-	PUNCT	O	O	912
short	ADJ	O	O	912
wavelength	NOUN	O	O	912
automated	VERB	O	O	912
perimetry	NOUN	O	O	912
Humphrey	PROPN	O	O	912
visual	ADJ	O	O	912
field	NOUN	O	O	912
analysis	NOUN	O	O	912
,	PUNCT	O	O	912
electroretinographic	NOUN	O	O	912
parameters	NOUN	O	O	912
,	PUNCT	O	O	912
and	CCONJ	O	O	912
optical	PROPN	O	O	912
coherence	VERB	O	O	912
tomography	NOUN	O	O	912
were	AUX	O	O	912
recorded	VERB	O	O	912
.	PUNCT	O	O	912
Data	NOUN	O	O	913
on	ADP	O	O	913
occurrence	NOUN	O	O	913
of	ADP	O	O	913
cataract	NOUN	O	Disease	913
and	CCONJ	O	O	913
raised	VERB	O	O	913
intraocular	ADJ	O	O	913
pressure	NOUN	O	O	913
were	AUX	O	O	913
collected	VERB	O	O	913
in	ADP	O	O	913
all	PRON	O	O	913
eyes	NOUN	O	O	913
.	PUNCT	O	O	913
RESULTS	VERB	O	O	914
:	PUNCT	O	O	914
Intraocular	NOUN	O	O	914
inflammation	NOUN	O	Disease	914
was	AUX	O	O	914
present	NOUN	O	O	914
in	ADP	O	O	914
54.5	NUM	O	O	914
,	PUNCT	O	O	914
9.9	NUM	O	O	914
,	PUNCT	O	O	914
11.1	NUM	O	O	914
,	PUNCT	O	O	914
and	CCONJ	O	O	914
0%	NOUN	O	O	914
of	ADP	O	O	914
patients	NOUN	O	O	914
at	ADP	O	O	914
baseline	VERB	O	O	914
,	PUNCT	O	O	914
6	NUM	O	O	914
months	NOUN	O	O	914
,	PUNCT	O	O	914
1	X	O	O	914
year	NOUN	O	O	914
,	PUNCT	O	O	914
2	X	O	O	914
years	NOUN	O	O	914
,	PUNCT	O	O	914
3	X	O	O	914
years	NOUN	O	O	914
,	PUNCT	O	O	914
and	CCONJ	O	O	914
beyond	ADP	O	O	914
3	X	O	O	914
years	NOUN	O	O	914
after	ADP	O	O	914
receiving	VERB	O	O	914
the	PRON	O	O	914
implant	NOUN	O	O	914
,	PUNCT	O	O	914
respectively	ADV	O	O	914
.	PUNCT	O	O	914
Active	ADJ	O	O	915
vasculitis	NOUN	O	Disease	915
was	AUX	O	O	915
noted	VERB	O	O	915
in	ADP	O	O	915
36.3%	NOUN	O	O	915
patients	NOUN	O	O	915
at	ADP	O	O	915
baseline	VERB	O	O	915
and	CCONJ	O	O	915
0%	NOUN	O	O	915
at	ADP	O	O	915
3	X	O	O	915
years	NOUN	O	O	915
of	ADP	O	O	915
follow	VERB	O	O	915
-	PUNCT	O	O	915
up	ADP	O	O	915
.	PUNCT	O	O	915
More	ADJ	O	O	916
than	ADP	O	O	916
20%	NOUN	O	O	916
(	PUNCT	O	O	916
47.61	NUM	O	O	916
-	PUNCT	O	O	916
67.2%	NOUN	O	O	916
)	PUNCT	O	O	916
reduction	NOUN	O	O	916
in	ADP	O	O	916
central	ADJ	O	O	916
retinal	ADJ	O	O	916
thickness	NOUN	O	O	916
was	AUX	O	O	916
noted	VERB	O	O	916
in	ADP	O	O	916
all	PRON	O	O	916
patients	NOUN	O	O	916
with	ADP	O	O	916
cystoid	PROPN	O	O	916
macular	ADJ	O	O	916
edema	NOUN	O	Disease	916
at	ADP	O	O	916
6	NUM	O	O	916
months	NOUN	O	O	916
,	PUNCT	O	O	916
1	X	O	O	916
year	NOUN	O	O	916
,	PUNCT	O	O	916
2	X	O	O	916
years	NOUN	O	O	916
,	PUNCT	O	O	916
and	CCONJ	O	O	916
3	X	O	O	916
years	NOUN	O	O	916
postimplant	PROPN	O	O	916
.	PUNCT	O	O	916
Adverse	ADJ	O	O	917
events	NOUN	O	O	917
included	VERB	O	O	917
increased	VERB	O	O	917
intraocular	ADJ	O	O	917
pressure	NOUN	O	O	917
(	PUNCT	O	O	917
54.5%	NOUN	O	O	917
)	PUNCT	O	O	917
and	CCONJ	O	O	917
cataract	NOUN	O	Disease	917
formation	NOUN	O	O	917
(	PUNCT	O	O	917
100%	NOUN	O	O	917
)	PUNCT	O	O	917
.	PUNCT	O	O	917
The	PRON	O	O	918
data	NOUN	O	O	918
suggest	VERB	O	O	918
that	SCONJ	O	O	918
fluocinolone acetonide	NOUN	O	Chemical	918
implant	NOUN	O	O	918
(	PUNCT	O	O	918
0.59	NUM	O	O	918
mg	VERB	O	O	918
)	PUNCT	O	O	918
helps	VERB	O	O	918
to	PART	O	O	918
control	VERB	O	O	918
inflammation	NOUN	O	Disease	918
in	ADP	O	O	918
otherwise	ADV	O	O	918
treatment	NOUN	O	O	918
-	PUNCT	O	O	918
refractory	ADJ	O	O	918
cases	NOUN	O	O	918
of	ADP	O	O	918
birdshot	VERB	O	O	918
retinochoroidopathy	ADJ	O	O	918
.	PUNCT	O	O	918
It	PRON	O	O	919
is	AUX	O	O	919
associated	VERB	O	O	919
with	ADP	O	O	919
significant	ADJ	O	O	919
side	NOUN	O	O	919
effects	NOUN	O	O	919
of	ADP	O	O	919
cataract	NOUN	O	Disease	919
and	CCONJ	O	O	919
ocular hypertension	NOUN	O	Disease	919
requiring	VERB	O	O	919
treatment	NOUN	O	O	919
.	PUNCT	O	O	919
Optimal	ADJ	O	O	922
precurarizing	VERB	O	O	922
dose	NOUN	O	O	922
of	ADP	O	O	922
rocuronium	NOUN	O	Chemical	922
to	PART	O	O	922
decrease	VERB	O	O	922
fasciculation	NOUN	O	Disease	922
and	CCONJ	O	O	922
myalgia	NOUN	O	Disease	922
following	VERB	O	O	922
succinylcholine	NOUN	O	Chemical	922
administration	NOUN	O	O	922
.	PUNCT	O	O	922
Succinylcholine	NOUN	O	Chemical	923
commonly	ADV	O	O	923
produces	VERB	O	O	923
frequent	ADJ	O	O	923
adverse	ADJ	O	O	923
effects	NOUN	O	O	923
,	PUNCT	O	O	923
including	VERB	O	O	923
muscle fasciculation	NOUN	O	Disease	923
and	CCONJ	O	O	923
myalgia	NOUN	O	Disease	923
.	PUNCT	O	O	923
The	PRON	O	O	924
current	ADJ	O	O	924
study	VERB	O	O	924
identified	VERB	O	O	924
the	PRON	O	O	924
optimal	ADJ	O	O	924
dose	NOUN	O	O	924
of	ADP	O	O	924
rocuronium	NOUN	O	Chemical	924
to	PART	O	O	924
prevent	VERB	O	O	924
succinylcholine	NOUN	O	Chemical	924
-	PUNCT	O	O	924
induced	VERB	O	O	924
fasciculation	NOUN	O	Disease	924
and	CCONJ	O	O	924
myalgia	NOUN	O	Disease	924
and	CCONJ	O	O	924
evaluated	VERB	O	O	924
the	PRON	O	O	924
influence	NOUN	O	O	924
of	ADP	O	O	924
rocuronium	NOUN	O	Chemical	924
on	ADP	O	O	924
the	PRON	O	O	924
speed	NOUN	O	O	924
of	ADP	O	O	924
onset	VERB	O	O	924
produced	VERB	O	O	924
by	ADP	O	O	924
succinylcholine	NOUN	O	Chemical	924
.	PUNCT	O	O	924
/	PUNCT	O	O	925
kg	VERB	O	O	925
rocuronium	NOUN	O	Chemical	925
as	ADP	O	O	925
a	PRON	O	O	925
precurarizing	VERB	O	O	925
dose	NOUN	O	O	925
.	PUNCT	O	O	925
All	PRON	O	O	926
patients	NOUN	O	O	926
received	VERB	O	O	926
succinylcholine	NOUN	O	Chemical	926
1.5	NUM	O	O	927
mg	VERB	O	O	927
/	PUNCT	O	O	927
kg	VERB	O	O	927
at	ADP	O	O	927
2	X	O	O	927
minutes	NOUN	O	O	927
after	ADP	O	O	927
the	PRON	O	O	927
precurarization	NOUN	O	O	927
,	PUNCT	O	O	927
and	CCONJ	O	O	927
were	AUX	O	O	927
assessed	VERB	O	O	927
the	PRON	O	O	927
incidence	NOUN	O	O	927
and	CCONJ	O	O	927
severity	NOUN	O	O	927
of	ADP	O	O	927
fasciculations	NOUN	O	O	927
,	PUNCT	O	O	927
while	SCONJ	O	O	927
myalgia	NOUN	O	Disease	927
was	AUX	O	O	927
assessed	VERB	O	O	927
at	ADP	O	O	927
24	NUM	O	O	927
hours	NOUN	O	O	927
after	ADP	O	O	927
surgery	NOUN	O	O	927
.	PUNCT	O	O	927
The	PRON	O	O	928
incidence	NOUN	O	O	928
and	CCONJ	O	O	928
severity	NOUN	O	O	928
of	ADP	O	O	928
visible	ADJ	O	O	928
muscle fasciculation	NOUN	O	Disease	928
was	AUX	O	O	928
significantly	ADV	O	O	928
less	ADV	O	O	928
with	ADP	O	O	928
increasing	VERB	O	O	928
the	PRON	O	O	928
amount	NOUN	O	O	928
of	ADP	O	O	928
precurarizing	VERB	O	O	928
dose	NOUN	O	O	928
of	ADP	O	O	928
rocuronium	NOUN	O	Chemical	928
(	PUNCT	O	O	928
P	NOUN	O	Chemical	928
<	X	O	O	928
0.001	NUM	O	O	928
)	PUNCT	O	O	928
.	PUNCT	O	O	928
Those	PRON	O	O	929
of	ADP	O	O	929
myalgia	NOUN	O	Disease	929
tend	VERB	O	O	929
to	PART	O	O	929
decrease	VERB	O	O	929
according	VERB	O	O	929
to	PART	O	O	929
increasing	VERB	O	O	929
the	PRON	O	O	929
amount	NOUN	O	O	929
of	ADP	O	O	929
precurarizing	VERB	O	O	929
dose	NOUN	O	O	929
of	ADP	O	O	929
rocuronium	NOUN	O	Chemical	929
,	PUNCT	O	O	929
but	CCONJ	O	O	929
there	ADV	O	O	929
was	AUX	O	O	929
no	PRON	O	O	929
significance	NOUN	O	O	929
(	PUNCT	O	O	929
P	NOUN	O	Chemical	929
=	PUNCT	O	O	929
0.072	NUM	O	O	929
)	PUNCT	O	O	929
.	PUNCT	O	O	929
The	PRON	O	O	930
onset	VERB	O	O	930
time	NOUN	O	O	930
of	ADP	O	O	930
succinylcholine	NOUN	O	Chemical	930
was	AUX	O	O	930
significantly	ADV	O	O	930
longer	ADV	O	O	930
with	ADP	O	O	930
increasing	VERB	O	O	930
the	PRON	O	O	930
amount	NOUN	O	O	930
of	ADP	O	O	930
precurarizing	VERB	O	O	930
dose	NOUN	O	O	930
of	ADP	O	O	930
rocuronium	NOUN	O	Chemical	930
(	PUNCT	O	O	930
P	NOUN	O	Chemical	930
<	X	O	O	930
0.001	NUM	O	O	930
)	PUNCT	O	O	930
.	PUNCT	O	O	930
Precurarization	NOUN	O	O	931
with	ADP	O	O	931
0.04	NUM	O	O	931
mg	VERB	O	O	931
/	PUNCT	O	O	931
kg	VERB	O	O	931
rocuronium	NOUN	O	Chemical	931
was	AUX	O	O	931
the	PRON	O	O	931
optimal	ADJ	O	O	931
dose	NOUN	O	O	931
considering	VERB	O	O	931
the	PRON	O	O	931
reduction	NOUN	O	O	931
in	ADP	O	O	931
the	PRON	O	O	931
incidence	NOUN	O	O	931
and	CCONJ	O	O	931
severity	NOUN	O	O	931
of	ADP	O	O	931
fasciculation	NOUN	O	Disease	931
and	CCONJ	O	O	931
myalgia	NOUN	O	Disease	931
with	ADP	O	O	931
acceptable	ADJ	O	O	931
onset	VERB	O	O	931
time	NOUN	O	O	931
,	PUNCT	O	O	931
and	CCONJ	O	O	931
the	PRON	O	O	931
safe	ADJ	O	O	931
and	CCONJ	O	O	931
effective	ADJ	O	O	931
precurarization	NOUN	O	O	931
.	PUNCT	O	O	931
Absence	NOUN	O	O	934
of	ADP	O	O	934
PKC	NOUN	O	O	934
-	PUNCT	O	O	934
alpha	PROPN	O	O	934
attenuates	VERB	O	O	934
lithium	NOUN	O	Chemical	934
-	PUNCT	O	O	934
induced	VERB	O	O	934
nephrogenic	PROPN	O	O	934
diabetes insipidus	NOUN	O	Disease	934
.	PUNCT	O	O	934
Lithium	NOUN	O	Chemical	935
,	PUNCT	O	O	935
an	PRON	O	O	935
effective	ADJ	O	O	935
antipsychotic	ADJ	O	O	935
,	PUNCT	O	O	935
induces	VERB	O	O	935
nephrogenic	PROPN	O	O	935
diabetes insipidus	NOUN	O	Disease	935
(	PUNCT	O	O	935
NDI	PROPN	O	O	935
)	PUNCT	O	O	935
in	ADP	O	O	935
40%	NOUN	O	O	935
of	ADP	O	O	935
patients	NOUN	O	O	935
.	PUNCT	O	O	935
The	PRON	O	O	936
decreased	VERB	O	O	936
capacity	NOUN	O	O	936
to	PART	O	O	936
concentrate	VERB	O	O	936
urine	NOUN	O	O	936
is	AUX	O	O	936
likely	ADV	O	O	936
due	ADJ	O	O	936
to	PART	O	O	936
lithium	NOUN	O	Chemical	936
acutely	ADV	O	O	936
disrupting	VERB	O	O	936
the	PRON	O	O	936
cAMP	NOUN	O	Chemical	936
pathway	NOUN	O	O	936
and	CCONJ	O	O	936
chronically	ADV	O	O	936
reducing	VERB	O	O	936
urea	PROPN	O	Chemical	936
transporter	NOUN	O	O	936
(	PUNCT	O	O	936
UT	PROPN	O	O	936
-	PUNCT	O	O	936
A1	PROPN	O	O	936
)	PUNCT	O	O	936
and	CCONJ	O	O	936
water	PROPN	O	O	936
channel	PROPN	O	O	936
(	PUNCT	O	O	936
AQP2	PROPN	O	O	936
)	PUNCT	O	O	936
expression	NOUN	O	O	936
in	ADP	O	O	936
the	PRON	O	O	936
inner	ADJ	O	O	936
medulla	NOUN	O	O	936
.	PUNCT	O	O	936
Targeting	VERB	O	O	937
an	PRON	O	O	937
alternative	ADV	O	O	937
signaling	VERB	O	O	937
pathway	NOUN	O	O	937
,	PUNCT	O	O	937
such	ADJ	O	O	937
as	ADP	O	O	937
PKC	NOUN	O	O	937
-	PUNCT	O	O	937
mediated	VERB	O	O	937
signaling	VERB	O	O	937
,	PUNCT	O	O	937
may	AUX	O	O	937
be	AUX	O	O	937
an	PRON	O	O	937
effective	ADJ	O	O	937
method	NOUN	O	O	937
of	ADP	O	O	937
treating	VERB	O	O	937
lithium	NOUN	O	Chemical	937
-	PUNCT	O	O	937
induced	VERB	O	O	937
polyuria	PROPN	O	Disease	937
.	PUNCT	O	O	937
)	PUNCT	O	O	938
controls	VERB	O	O	938
were	AUX	O	O	938
treated	VERB	O	O	938
with	ADP	O	O	938
lithium	NOUN	O	Chemical	938
for	ADP	O	O	938
0	NUM	O	O	938
,	PUNCT	O	O	938
3	X	O	O	938
or	CCONJ	O	O	938
5	NUM	O	O	938
days	NOUN	O	O	938
.	PUNCT	O	O	938
Animals	NOUN	O	O	939
were	AUX	O	O	939
also	ADV	O	O	939
treated	VERB	O	O	939
with	ADP	O	O	939
lithium	NOUN	O	Chemical	939
for	ADP	O	O	939
6	NUM	O	O	939
weeks	NOUN	O	O	939
.	PUNCT	O	O	939
Lithium	NOUN	O	Chemical	940
-	PUNCT	O	O	940
treated	VERB	O	O	940
WT	NOUN	O	O	940
mice	NOUN	O	O	940
had	VERB	O	O	940
19-fold	ADV	O	O	940
increased	VERB	O	O	940
urine	NOUN	O	O	940
output	NOUN	O	O	940
whereas	SCONJ	O	O	940
treated	VERB	O	O	940
PKCa	NOUN	O	O	940
KO	PROPN	O	O	940
animals	NOUN	O	O	940
had	VERB	O	O	940
a	PRON	O	O	940
4-fold	ADV	O	O	940
increase	VERB	O	O	940
in	ADP	O	O	940
output	NOUN	O	O	940
.	PUNCT	O	O	940
AQP2	PROPN	O	O	941
and	CCONJ	O	O	941
UT	PROPN	O	O	941
-	PUNCT	O	O	941
A1	PROPN	O	O	941
expression	NOUN	O	O	941
was	AUX	O	O	941
lowered	VERB	O	O	941
in	ADP	O	O	941
6	NUM	O	O	941
week	NOUN	O	O	941
lithium	NOUN	O	Chemical	941
-	PUNCT	O	O	941
treated	VERB	O	O	941
WT	NOUN	O	O	941
animals	NOUN	O	O	941
whereas	SCONJ	O	O	941
in	ADP	O	O	941
treated	VERB	O	O	941
PKCa	NOUN	O	O	941
KO	PROPN	O	O	941
mice	NOUN	O	O	941
,	PUNCT	O	O	941
AQP2	PROPN	O	O	941
was	AUX	O	O	941
only	ADV	O	O	941
reduced	VERB	O	O	941
by	ADP	O	O	941
2-fold	VERB	O	O	941
and	CCONJ	O	O	941
UT	PROPN	O	O	941
-	PUNCT	O	O	941
A1	PROPN	O	O	941
expression	NOUN	O	O	941
was	AUX	O	O	941
unaffected	ADJ	O	O	941
.	PUNCT	O	O	941
Urinary	NOUN	O	O	942
sodium	NOUN	O	Chemical	942
,	PUNCT	O	O	942
potassium	NOUN	O	Chemical	942
and	CCONJ	O	O	942
calcium	NOUN	O	Chemical	942
were	AUX	O	O	942
elevated	ADJ	O	O	942
in	ADP	O	O	942
lithium	NOUN	O	Chemical	942
-	PUNCT	O	O	942
fed	VERB	O	O	942
WT	NOUN	O	O	942
but	CCONJ	O	O	942
not	PART	O	O	942
in	ADP	O	O	942
lithium	NOUN	O	Chemical	942
-	PUNCT	O	O	942
fed	VERB	O	O	942
PKCa	NOUN	O	O	942
KO	PROPN	O	O	942
mice	NOUN	O	O	942
.	PUNCT	O	O	942
Our	PRON	O	O	943
data	NOUN	O	O	943
show	VERB	O	O	943
that	SCONJ	O	O	943
ablation	NOUN	O	O	943
of	ADP	O	O	943
PKCa	NOUN	O	O	943
preserves	VERB	O	O	943
AQP2	PROPN	O	O	943
and	CCONJ	O	O	943
UT	PROPN	O	O	943
-	PUNCT	O	O	943
A1	PROPN	O	O	943
protein	NOUN	O	O	943
expression	NOUN	O	O	943
and	CCONJ	O	O	943
localization	NOUN	O	O	943
in	ADP	O	O	943
lithium	NOUN	O	Chemical	943
-	PUNCT	O	O	943
induced	VERB	O	O	943
NDI	PROPN	O	O	943
,	PUNCT	O	O	943
and	CCONJ	O	O	943
prevents	VERB	O	O	943
the	PRON	O	O	943
development	NOUN	O	O	943
of	ADP	O	O	943
the	PRON	O	O	943
severe	ADJ	O	O	943
polyuria	PROPN	O	Disease	943
associated	VERB	O	O	943
with	ADP	O	O	943
lithium	NOUN	O	Chemical	943
therapy	NOUN	O	O	943
.	PUNCT	O	O	943
Is	AUX	O	O	946
Dysguesia	NOUN	O	O	946
Going	VERB	O	O	946
to	PART	O	O	946
be	AUX	O	O	946
a	PRON	O	O	946
Rare	ADJ	O	O	946
or	CCONJ	O	O	946
a	PRON	O	O	946
Common	ADJ	O	O	946
Side	NOUN	O	O	946
-	PUNCT	O	O	946
effect	VERB	O	O	946
of	ADP	O	O	946
Amlodipine	NOUN	O	O	946
?	PUNCT	O	O	946
A	PRON	O	O	947
very	ADV	O	O	947
rare	ADJ	O	O	947
side	NOUN	O	O	947
-	PUNCT	O	O	947
effect	VERB	O	O	947
of	ADP	O	O	947
amlodipine	NOUN	O	Chemical	947
is	AUX	O	O	947
dysguesia	NOUN	O	O	947
.	PUNCT	O	O	947
We	PRON	O	O	948
report	VERB	O	O	948
a	PRON	O	O	948
case	NOUN	O	O	948
about	ADP	O	O	948
a	PRON	O	O	948
female	ADJ	O	O	948
with	ADP	O	O	948
essential	ADJ	O	O	948
hypertension	NOUN	O	Disease	948
on	ADP	O	O	948
drug	NOUN	O	O	948
treatment	NOUN	O	O	948
with	ADP	O	O	948
amlodipine	NOUN	O	Chemical	948
developed	VERB	O	O	948
loss	NOUN	O	O	948
of	ADP	O	O	948
taste	NOUN	O	O	948
sensation	NOUN	O	O	948
.	PUNCT	O	O	948
We	PRON	O	O	949
conclude	VERB	O	O	949
that	SCONJ	O	O	949
amlodipine	NOUN	O	Chemical	949
can	AUX	O	O	949
cause	VERB	O	O	949
dysguesia	NOUN	O	O	949
.	PUNCT	O	O	949
Here	ADV	O	O	950
,	PUNCT	O	O	950
we	PRON	O	O	950
describe	VERB	O	O	950
the	PRON	O	O	950
clinical	ADJ	O	O	950
presentation	NOUN	O	O	950
and	CCONJ	O	O	950
review	VERB	O	O	950
the	PRON	O	O	950
relevant	ADJ	O	O	950
literature	NOUN	O	O	950
on	ADP	O	O	950
amlodipine	NOUN	O	Chemical	950
and	CCONJ	O	O	950
dysguesia	NOUN	O	O	950
.	PUNCT	O	O	950
Rhabdomyolysis	NOUN	O	O	953
in	ADP	O	O	953
association	PROPN	O	O	953
with	ADP	O	O	953
simvastatin	PROPN	O	Chemical	953
and	CCONJ	O	O	953
dosage	NOUN	O	O	953
increment	NOUN	O	O	953
in	ADP	O	O	953
clarithromycin	PROPN	O	Chemical	953
.	PUNCT	O	O	953
Clarithromycin	NOUN	O	Chemical	954
is	AUX	O	O	954
the	PRON	O	O	954
most	ADV	O	O	954
documented	VERB	O	O	954
cytochrome	ADP	O	O	954
P450	VERB	O	O	954
3A4	X	O	O	954
(	PUNCT	O	O	954
CYP3A4	PROPN	O	O	954
)	PUNCT	O	O	954
inhibitor	NOUN	O	O	954
to	PART	O	O	954
cause	VERB	O	O	954
an	PRON	O	O	954
adverse	ADJ	O	O	954
interaction	NOUN	O	O	954
with	ADP	O	O	954
simvastatin	PROPN	O	Chemical	954
.	PUNCT	O	O	954
This	PRON	O	O	955
particular	ADJ	O	O	955
case	NOUN	O	O	955
is	AUX	O	O	955
of	ADP	O	O	955
interest	NOUN	O	O	955
as	ADP	O	O	955
rhabdomyolysis	NOUN	O	Disease	955
only	ADV	O	O	955
occurred	VERB	O	O	955
after	ADP	O	O	955
an	PRON	O	O	955
increase	VERB	O	O	955
in	ADP	O	O	955
the	PRON	O	O	955
dose	NOUN	O	O	955
of	ADP	O	O	955
clarithromycin	PROPN	O	Chemical	955
.	PUNCT	O	O	955
The	PRON	O	O	956
patient	NOUN	O	O	956
developed	VERB	O	O	956
raised	VERB	O	O	956
cardiac	ADJ	O	O	956
biomarkers	NOUN	O	O	956
without	ADP	O	O	956
any	PRON	O	O	956
obvious	ADJ	O	O	956
cardiac	ADJ	O	O	956
issues	NOUN	O	O	956
,	PUNCT	O	O	956
a	PRON	O	O	956
phenomenon	NOUN	O	O	956
that	SCONJ	O	O	956
has	VERB	O	O	956
been	AUX	O	O	956
linked	VERB	O	O	956
to	PART	O	O	956
rhabdomyolysis	NOUN	O	Disease	956
previously	ADV	O	O	956
.	PUNCT	O	O	956
To	PART	O	O	957
date	PROPN	O	O	957
,	PUNCT	O	O	957
there	ADV	O	O	957
has	VERB	O	O	957
been	AUX	O	O	957
no	PRON	O	O	957
reported	VERB	O	O	957
effect	VERB	O	O	957
of	ADP	O	O	957
rhabdomyolysis	NOUN	O	Disease	957
on	ADP	O	O	957
the	PRON	O	O	957
structure	NOUN	O	O	957
and	CCONJ	O	O	957
function	NOUN	O	O	957
of	ADP	O	O	957
cardiac	ADJ	O	O	957
muscle	NOUN	O	O	957
.	PUNCT	O	O	957
Clinicians	NOUN	O	O	958
need	VERB	O	O	958
to	PART	O	O	958
be	AUX	O	O	958
aware	ADJ	O	O	958
of	ADP	O	O	958
prescribing	VERB	O	O	958
concomitant	ADJ	O	O	958
medications	NOUN	O	O	958
that	SCONJ	O	O	958
increase	VERB	O	O	958
the	PRON	O	O	958
risk	NOUN	O	O	958
of	ADP	O	O	958
myopathy	PROPN	O	Disease	958
or	CCONJ	O	O	958
inhibit	VERB	O	O	958
the	PRON	O	O	958
CYP3A4	PROPN	O	O	958
enzyme	NOUN	O	O	958
.	PUNCT	O	O	958
Our	PRON	O	O	959
case	NOUN	O	O	959
suggests	VERB	O	O	959
that	SCONJ	O	O	959
troponin	PROPN	O	O	959
elevation	NOUN	O	O	959
could	AUX	O	O	959
be	AUX	O	O	959
associated	VERB	O	O	959
with	ADP	O	O	959
statin	PROPN	O	O	959
induced	VERB	O	O	959
rhabdomyolysis	NOUN	O	Disease	959
,	PUNCT	O	O	959
which	PRON	O	O	959
may	AUX	O	O	959
warrant	NOUN	O	O	959
further	ADV	O	O	959
studies	NOUN	O	O	959
.	PUNCT	O	O	959
Val204Asp	NOUN	O	O	962
)	PUNCT	O	O	962
causes	VERB	O	O	962
loss	NOUN	O	O	962
of	ADP	O	O	962
activity	NOUN	O	O	962
and	CCONJ	O	O	962
prolonged	VERB	O	O	962
apnea	PROPN	O	Disease	962
with	ADP	O	O	962
suxamethonium	NOUN	O	O	962
.	PUNCT	O	O	962
Butyrylcholinesterase	NOUN	O	O	963
deficiency	NOUN	O	O	963
is	AUX	O	O	963
characterized	VERB	O	O	963
by	ADP	O	O	963
prolonged	VERB	O	O	963
apnea	PROPN	O	Disease	963
after	ADP	O	O	963
the	PRON	O	O	963
use	VERB	O	O	963
of	ADP	O	O	963
muscle	NOUN	O	O	963
relaxants	NOUN	O	O	963
(	PUNCT	O	O	963
suxamethonium	NOUN	O	O	963
or	CCONJ	O	O	963
mivacurium	NOUN	O	O	963
)	PUNCT	O	O	963
in	ADP	O	O	963
patients	NOUN	O	O	963
who	PRON	O	O	963
have	VERB	O	O	963
mutations	NOUN	O	O	963
in	ADP	O	O	963
the	PRON	O	O	963
BCHE	PROPN	O	O	963
gene	NOUN	O	O	963
.	PUNCT	O	O	963
Here	ADV	O	O	964
,	PUNCT	O	O	964
we	PRON	O	O	964
report	VERB	O	O	964
a	PRON	O	O	964
case	NOUN	O	O	964
of	ADP	O	O	964
prolonged	VERB	O	O	964
neuromuscular	ADJ	O	O	964
block	NOUN	O	O	964
after	ADP	O	O	964
administration	NOUN	O	O	964
of	ADP	O	O	964
suxamethonium	NOUN	O	O	964
leading	VERB	O	O	964
to	PART	O	O	964
the	PRON	O	O	964
discovery	NOUN	O	O	964
of	ADP	O	O	964
a	PRON	O	O	964
novel	NOUN	O	O	964
BCHE	PROPN	O	O	964
variant	NOUN	O	O	964
(	PUNCT	O	O	964
c.695T	NOUN	O	O	964
>	PUNCT	O	O	964
A	PRON	O	O	964
,	PUNCT	O	O	964
p	NOUN	O	O	964
.	PUNCT	O	O	964
Low	ADJ	O	O	965
activity	NOUN	O	O	965
of	ADP	O	O	965
patient	NOUN	O	O	965
plasma	NOUN	O	O	965
butyrylcholinesterase	NOUN	O	O	965
with	ADP	O	O	965
butyrylthiocholine	NOUN	O	O	965
(	PUNCT	O	O	965
BTC	NOUN	O	O	965
)	PUNCT	O	O	965
and	CCONJ	O	O	965
benzoylcholine	NOUN	O	O	965
,	PUNCT	O	O	965
and	CCONJ	O	O	965
values	NOUN	O	O	965
of	ADP	O	O	965
dibucaine	PROPN	O	O	965
and	CCONJ	O	O	965
fluoride	NOUN	O	O	965
numbers	NOUN	O	O	965
fit	ADJ	O	O	965
with	ADP	O	O	965
heterozygous	ADJ	O	O	965
atypical	ADJ	O	O	965
silent	ADJ	O	O	965
genotype	NOUN	O	O	965
.	PUNCT	O	O	965
BChE	PROPN	O	O	966
displays	VERB	O	O	966
a	PRON	O	O	966
pure	ADJ	O	O	966
Michaelian	ADJ	O	O	966
behavior	NOUN	O	O	966
with	ADP	O	O	966
BTC	NOUN	O	O	966
as	ADP	O	O	966
the	PRON	O	O	966
substrate	NOUN	O	O	966
.	PUNCT	O	O	966
Both	PRON	O	O	967
catalytic	ADJ	O	O	967
parameters	NOUN	O	O	967
Km	PROPN	O	O	967
=	PUNCT	O	O	967
265	NUM	O	O	967
uM	INTJ	O	O	967
for	ADP	O	O	967
BTC	NOUN	O	O	967
,	PUNCT	O	O	967
two	NUM	O	O	967
times	NOUN	O	O	967
higher	ADJ	O	O	967
than	ADP	O	O	967
that	SCONJ	O	O	967
of	ADP	O	O	967
the	PRON	O	O	967
atypical	ADJ	O	O	967
enzyme	NOUN	O	O	967
,	PUNCT	O	O	967
and	CCONJ	O	O	967
a	PRON	O	O	967
low	ADJ	O	O	967
Vmax	PROPN	O	O	967
are	AUX	O	O	967
consistent	ADJ	O	O	967
with	ADP	O	O	967
the	PRON	O	O	967
absence	NOUN	O	O	967
of	ADP	O	O	967
activity	NOUN	O	O	967
against	ADP	O	O	967
suxamethonium	NOUN	O	O	967
.	PUNCT	O	O	967
Val204Asp	NOUN	O	O	968
is	AUX	O	O	968
disruption	NOUN	O	O	968
of	ADP	O	O	968
hydrogen	PROPN	O	O	968
bonding	NOUN	O	O	968
between	ADP	O	O	968
Gln223	PROPN	O	O	968
and	CCONJ	O	O	968
Glu441	PROPN	O	O	968
,	PUNCT	O	O	968
leading	VERB	O	O	968
Ser198	NOUN	O	O	968
and	CCONJ	O	O	968
His438	PROPN	O	O	968
to	PART	O	O	968
move	VERB	O	O	968
away	ADV	O	O	968
from	ADP	O	O	968
each	PRON	O	O	968
other	ADJ	O	O	968
with	ADP	O	O	968
subsequent	ADJ	O	O	968
disruption	NOUN	O	O	968
of	ADP	O	O	968
the	PRON	O	O	968
catalytic	ADJ	O	O	968
triad	PROPN	O	O	968
functionality	NOUN	O	O	968
regardless	ADV	O	O	968
of	ADP	O	O	968
the	PRON	O	O	968
type	NOUN	O	O	968
of	ADP	O	O	968
substrate	NOUN	O	O	968
.	PUNCT	O	O	968
Delayed	VERB	O	O	971
anemia	NOUN	O	Disease	971
after	ADP	O	O	971
treatment	NOUN	O	O	971
with	ADP	O	O	971
injectable	ADJ	O	O	971
artesunate	PROPN	O	O	971
in	ADP	O	O	971
the	PRON	O	O	971
Democratic	ADJ	O	O	971
Republic	NOUN	O	O	971
of	ADP	O	O	971
the	PRON	O	O	971
Congo	PROPN	O	O	971
:	PUNCT	O	O	971
a	PRON	O	O	971
manageable	ADJ	O	O	971
issue	NOUN	O	O	971
.	PUNCT	O	O	971
Cases	NOUN	O	O	972
of	ADP	O	O	972
delayed	VERB	O	O	972
hemolytic anemia	NOUN	O	Disease	972
have	VERB	O	O	972
been	AUX	O	O	972
described	VERB	O	O	972
after	ADP	O	O	972
treatment	NOUN	O	O	972
with	ADP	O	O	972
injectable	ADJ	O	O	972
artesunate	PROPN	O	O	972
,	PUNCT	O	O	972
the	PRON	O	O	972
current	ADJ	O	O	972
World	NOUN	O	O	972
Health	NOUN	O	O	972
Organization	PROPN	O	O	972
(	PUNCT	O	O	972
WHO)-recommended	VERB	O	O	972
first	ADV	O	O	972
-	PUNCT	O	O	972
line	NOUN	O	O	972
drug	NOUN	O	O	972
for	ADP	O	O	972
the	PRON	O	O	972
treatment	NOUN	O	O	972
of	ADP	O	O	972
severe	ADJ	O	O	972
malaria	NOUN	O	O	972
.	PUNCT	O	O	972
>	PUNCT	O	O	973
5	NUM	O	O	973
years	NOUN	O	O	973
of	ADP	O	O	973
age	NOUN	O	O	973
)	PUNCT	O	O	973
were	AUX	O	O	973
followed	VERB	O	O	973
-	PUNCT	O	O	973
up	ADP	O	O	973
after	ADP	O	O	973
treatment	NOUN	O	O	973
with	ADP	O	O	973
injectable	ADJ	O	O	973
artesunate	PROPN	O	O	973
for	ADP	O	O	973
severe	ADJ	O	O	973
malaria	NOUN	O	O	973
in	ADP	O	O	973
hospitals	NOUN	O	O	973
and	CCONJ	O	O	973
health	NOUN	O	O	973
centers	NOUN	O	O	973
of	ADP	O	O	973
the	PRON	O	O	973
Democratic	ADJ	O	O	973
Republic	NOUN	O	O	973
of	ADP	O	O	973
the	PRON	O	O	973
Congo	PROPN	O	O	973
.	PUNCT	O	O	973
All	PRON	O	O	974
cases	NOUN	O	O	974
of	ADP	O	O	974
delayed	VERB	O	O	974
anemia	NOUN	O	Disease	974
were	AUX	O	O	974
clinically	ADV	O	O	974
manageable	ADJ	O	O	974
and	CCONJ	O	O	974
resolved	VERB	O	O	974
within	ADP	O	O	974
one	NUM	O	O	974
month	NOUN	O	O	974
.	PUNCT	O	O	974
Regulation	NOUN	O	O	977
of	ADP	O	O	977
signal	VERB	O	O	977
transducer	NOUN	O	O	977
and	CCONJ	O	O	977
activator	NOUN	O	O	977
of	ADP	O	O	977
transcription	PROPN	O	O	977
3	X	O	O	977
and	CCONJ	O	O	977
apoptotic	ADJ	O	O	977
pathways	NOUN	O	O	977
by	ADP	O	O	977
betaine	PROPN	O	O	977
attenuates	VERB	O	O	977
isoproterenol	NOUN	O	Chemical	977
-	PUNCT	O	O	977
induced	VERB	O	O	977
acute	ADJ	O	O	977
myocardial injury	NOUN	O	Disease	977
in	ADP	O	O	977
rats	NOUN	O	O	977
.	PUNCT	O	O	977
The	PRON	O	O	978
present	NOUN	O	O	978
study	VERB	O	O	978
was	AUX	O	O	978
designed	VERB	O	O	978
to	PART	O	O	978
investigate	VERB	O	O	978
the	PRON	O	O	978
cardioprotective	ADJ	O	O	978
effects	NOUN	O	O	978
of	ADP	O	O	978
betaine	PROPN	O	O	978
on	ADP	O	O	978
acute	ADJ	O	O	978
myocardial ischemia	NOUN	O	Disease	978
induced	VERB	O	O	978
experimentally	ADV	O	O	978
in	ADP	O	O	978
rats	NOUN	O	O	978
focusing	VERB	O	O	978
on	ADP	O	O	978
regulation	NOUN	O	O	978
of	ADP	O	O	978
signal	VERB	O	O	978
transducer	NOUN	O	O	978
and	CCONJ	O	O	978
activator	NOUN	O	O	978
of	ADP	O	O	978
transcription	PROPN	O	O	978
3	X	O	O	978
(	PUNCT	O	O	978
STAT3	NOUN	O	O	978
)	PUNCT	O	O	978
and	CCONJ	O	O	978
apoptotic	ADJ	O	O	978
pathways	NOUN	O	O	978
as	ADP	O	O	978
the	PRON	O	O	978
potential	ADJ	O	O	978
mechanism	NOUN	O	O	978
underlying	VERB	O	O	978
the	PRON	O	O	978
drug	NOUN	O	O	978
effect	VERB	O	O	978
.	PUNCT	O	O	978
Male	NOUN	O	O	979
Sprague	PROPN	O	O	979
Dawley	NOUN	O	O	979
rats	NOUN	O	O	979
were	AUX	O	O	979
treated	VERB	O	O	979
with	ADP	O	O	979
betaine	PROPN	O	O	979
(	PUNCT	O	O	979
100	NUM	O	O	979
,	PUNCT	O	O	979
200	NUM	O	O	979
,	PUNCT	O	O	979
and	CCONJ	O	O	979
400	NUM	O	O	979
mg	VERB	O	O	979
/	PUNCT	O	O	979
kg	VERB	O	O	979
)	PUNCT	O	O	979
orally	ADV	O	O	979
for	ADP	O	O	979
40	NUM	O	O	979
days	NOUN	O	O	979
.	PUNCT	O	O	979
Acute	PROPN	O	O	980
myocardial	ADJ	O	O	980
ischemic	VERB	O	Disease	980
injury	NOUN	O	O	980
was	AUX	O	O	980
induced	VERB	O	O	980
in	ADP	O	O	980
rats	NOUN	O	O	980
by	ADP	O	O	980
subcutaneous	ADJ	O	O	980
injection	NOUN	O	O	980
of	ADP	O	O	980
isoproterenol	NOUN	O	Chemical	980
(	PUNCT	O	O	980
85	NUM	O	O	980
mg	VERB	O	O	980
/	PUNCT	O	O	980
kg	VERB	O	O	980
)	PUNCT	O	O	980
,	PUNCT	O	O	980
for	ADP	O	O	980
two	NUM	O	O	980
consecutive	ADJ	O	O	980
days	NOUN	O	O	980
.	PUNCT	O	O	980
Oral	NOUN	O	O	981
administration	NOUN	O	O	981
of	ADP	O	O	981
betaine	PROPN	O	O	981
(	PUNCT	O	O	981
200	NUM	O	O	981
and	CCONJ	O	O	981
400	NUM	O	O	981
mg	VERB	O	O	981
/	PUNCT	O	O	981
kg	VERB	O	O	981
)	PUNCT	O	O	981
significantly	ADV	O	O	981
reduced	VERB	O	O	981
the	PRON	O	O	981
level	VERB	O	O	981
of	ADP	O	O	981
cardiac	ADJ	O	O	981
marker	NOUN	O	O	981
enzyme	NOUN	O	O	981
in	ADP	O	O	981
the	PRON	O	O	981
serum	NOUN	O	O	981
and	CCONJ	O	O	981
prevented	VERB	O	O	981
left	VERB	O	O	981
ventricular	ADJ	O	O	981
remodeling	VERB	O	O	981
.	PUNCT	O	O	981
Western	ADJ	O	O	982
blot	NOUN	O	O	982
analysis	NOUN	O	O	982
showed	VERB	O	O	982
that	SCONJ	O	O	982
isoproterenol	NOUN	O	Chemical	982
-	PUNCT	O	O	982
induced	VERB	O	O	982
phosphorylation	NOUN	O	O	982
of	ADP	O	O	982
STAT3	NOUN	O	O	982
was	AUX	O	O	982
maintained	VERB	O	O	982
or	CCONJ	O	O	982
further	ADV	O	O	982
enhanced	VERB	O	O	982
by	ADP	O	O	982
betaine	PROPN	O	O	982
treatment	NOUN	O	O	982
in	ADP	O	O	982
myocardium	NOUN	O	O	982
.	PUNCT	O	O	982
Furthermore	ADV	O	O	983
,	PUNCT	O	O	983
betaine	PROPN	O	O	983
(	PUNCT	O	O	983
200	NUM	O	O	983
and	CCONJ	O	O	983
400	NUM	O	O	983
mg	VERB	O	O	983
/	PUNCT	O	O	983
kg	VERB	O	O	983
)	PUNCT	O	O	983
treatment	NOUN	O	O	983
increased	VERB	O	O	983
the	PRON	O	O	983
ventricular	ADJ	O	O	983
expression	NOUN	O	O	983
of	ADP	O	O	983
Bcl-2	VERB	O	O	983
and	CCONJ	O	O	983
reduced	VERB	O	O	983
the	PRON	O	O	983
level	VERB	O	O	983
of	ADP	O	O	983
Bax	NOUN	O	O	983
,	PUNCT	O	O	983
therefore	ADV	O	O	983
causing	VERB	O	O	983
a	PRON	O	O	983
significant	ADJ	O	O	983
increase	VERB	O	O	983
in	ADP	O	O	983
the	PRON	O	O	983
ratio	NOUN	O	O	983
of	ADP	O	O	983
Bcl-2/Bax	NOUN	O	O	983
.	PUNCT	O	O	983
The	PRON	O	O	984
protective	ADJ	O	O	984
role	NOUN	O	O	984
of	ADP	O	O	984
betaine	PROPN	O	O	984
on	ADP	O	O	984
myocardial damage	NOUN	O	Disease	984
was	AUX	O	O	984
further	ADV	O	O	984
confirmed	VERB	O	O	984
by	ADP	O	O	984
histopathological	ADJ	O	O	984
examination	NOUN	O	O	984
.	PUNCT	O	O	984
In	ADP	O	O	985
summary	NOUN	O	O	985
,	PUNCT	O	O	985
our	PRON	O	O	985
results	VERB	O	O	985
showed	VERB	O	O	985
that	SCONJ	O	O	985
betaine	PROPN	O	O	985
pretreatment	NOUN	O	O	985
attenuated	VERB	O	O	985
isoproterenol	NOUN	O	Chemical	985
-	PUNCT	O	O	985
induced	VERB	O	O	985
acute	ADJ	O	O	985
myocardial ischemia	NOUN	O	Disease	985
via	ADP	O	O	985
the	PRON	O	O	985
regulation	NOUN	O	O	985
of	ADP	O	O	985
STAT3	NOUN	O	O	985
and	CCONJ	O	O	985
apoptotic	ADJ	O	O	985
pathways	NOUN	O	O	985
.	PUNCT	O	O	985
Quetiapine	PROPN	O	O	988
-	PUNCT	O	O	988
induced	VERB	O	O	988
neutropenia	ADJ	O	Disease	988
in	ADP	O	O	988
a	PRON	O	O	988
bipolar	ADJ	O	O	988
patient	NOUN	O	O	988
with	ADP	O	O	988
hepatocellular carcinoma	NOUN	O	Disease	988
.	PUNCT	O	O	988
OBJECTIVE	VERB	O	O	989
:	PUNCT	O	O	989
Quetiapine	PROPN	O	O	989
is	AUX	O	O	989
a	PRON	O	O	989
dibenzothiazepine	ADJ	O	O	989
derivative	ADJ	O	O	989
,	PUNCT	O	O	989
similar	ADJ	O	O	989
to	PART	O	O	989
clozapine	PROPN	O	Chemical	989
,	PUNCT	O	O	989
which	PRON	O	O	989
has	VERB	O	O	989
the	PRON	O	O	989
highest	ADJ	O	O	989
risk	NOUN	O	O	989
of	ADP	O	O	989
causing	VERB	O	O	989
blood	NOUN	O	O	989
dyscrasias	PROPN	O	O	989
,	PUNCT	O	O	989
especially	ADV	O	O	989
neutropenia	ADJ	O	Disease	989
.	PUNCT	O	O	989
There	ADV	O	O	990
are	AUX	O	O	990
some	PRON	O	O	990
case	NOUN	O	O	990
reports	VERB	O	O	990
about	ADP	O	O	990
this	PRON	O	O	990
side	NOUN	O	O	990
effect	VERB	O	O	990
of	ADP	O	O	990
quetiapine	ADV	O	Chemical	990
,	PUNCT	O	O	990
but	CCONJ	O	O	990
possible	ADJ	O	O	990
risk	NOUN	O	O	990
factors	NOUN	O	O	990
are	AUX	O	O	990
seldom	ADV	O	O	990
discussed	VERB	O	O	990
and	CCONJ	O	O	990
identified	VERB	O	O	990
.	PUNCT	O	O	990
A	PRON	O	O	991
case	NOUN	O	O	991
of	ADP	O	O	991
a	PRON	O	O	991
patient	NOUN	O	O	991
with	ADP	O	O	991
hepatocellular carcinoma	NOUN	O	Disease	991
that	SCONJ	O	O	991
developed	VERB	O	O	991
neutropenia	ADJ	O	Disease	991
after	ADP	O	O	991
treatment	NOUN	O	O	991
with	ADP	O	O	991
quetiapine	ADV	O	Chemical	991
is	AUX	O	O	991
described	VERB	O	O	991
here	ADV	O	O	991
.	PUNCT	O	O	991
CASE	NOUN	O	O	992
REPORT	VERB	O	O	992
:	PUNCT	O	O	992
A	PRON	O	O	992
62-year	NOUN	O	O	992
-	PUNCT	O	O	992
old	ADJ	O	O	992
Taiwanese	PROPN	O	O	992
widow	NOUN	O	O	992
with	ADP	O	O	992
bipolar disorder	NOUN	O	Disease	992
was	AUX	O	O	992
diagnosed	VERB	O	O	992
with	ADP	O	O	992
hepatocellular carcinoma	NOUN	O	Disease	992
at	ADP	O	O	992
age	NOUN	O	O	992
60	NUM	O	O	992
.	PUNCT	O	O	992
She	PRON	O	O	993
developed	VERB	O	O	993
leucopenia	PROPN	O	O	993
after	ADP	O	O	993
being	AUX	O	O	993
treated	VERB	O	O	993
with	ADP	O	O	993
quetiapine	ADV	O	Chemical	993
.	PUNCT	O	O	993
After	ADP	O	O	994
quetiapine	ADV	O	Chemical	994
was	AUX	O	O	994
discontinued	VERB	O	O	994
,	PUNCT	O	O	994
her	PRON	O	O	994
white	ADJ	O	O	994
blood	NOUN	O	O	994
cell	NOUN	O	O	994
count	VERB	O	O	994
returned	VERB	O	O	994
to	PART	O	O	994
normal	ADJ	O	O	994
.	PUNCT	O	O	994
CONCLUSIONS	NOUN	O	O	995
:	PUNCT	O	O	995
Although	SCONJ	O	O	995
neutropenia	ADJ	O	Disease	995
is	AUX	O	O	995
not	PART	O	O	995
a	PRON	O	O	995
common	ADJ	O	O	995
side	NOUN	O	O	995
effect	VERB	O	O	995
of	ADP	O	O	995
quetiapine	ADV	O	Chemical	995
,	PUNCT	O	O	995
physicians	NOUN	O	O	995
should	AUX	O	O	995
be	AUX	O	O	995
cautious	ADJ	O	O	995
about	ADP	O	O	995
its	PRON	O	O	995
presentation	NOUN	O	O	995
and	CCONJ	O	O	995
associated	VERB	O	O	995
risk	NOUN	O	O	995
factors	NOUN	O	O	995
.	PUNCT	O	O	995
Hepatic dysfunction	NOUN	O	Disease	996
may	AUX	O	O	996
be	AUX	O	O	996
one	NUM	O	O	996
of	ADP	O	O	996
the	PRON	O	O	996
possible	ADJ	O	O	996
risk	NOUN	O	O	996
factors	NOUN	O	O	996
,	PUNCT	O	O	996
and	CCONJ	O	O	996
concomitant	ADJ	O	O	996
fever	NOUN	O	Disease	996
may	AUX	O	O	996
be	AUX	O	O	996
a	PRON	O	O	996
diagnostic	ADJ	O	O	996
marker	NOUN	O	O	996
for	ADP	O	O	996
adverse	ADJ	O	O	996
reaction	NOUN	O	O	996
to	PART	O	O	996
quetiapine	ADV	O	Chemical	996
.	PUNCT	O	O	996
Lateral	ADJ	O	O	999
antebrachial	ADJ	O	O	999
cutaneous	ADJ	O	O	999
neuropathy	NOUN	O	Disease	999
after	ADP	O	O	999
steroid	NOUN	O	Chemical	999
injection	NOUN	O	O	999
at	ADP	O	O	999
lateral	PROPN	O	O	999
epicondyle	NOUN	O	O	999
.	PUNCT	O	O	999
This	PRON	O	O	1000
report	VERB	O	O	1000
aimed	VERB	O	O	1000
to	PART	O	O	1000
present	NOUN	O	O	1000
a	PRON	O	O	1000
case	NOUN	O	O	1000
of	ADP	O	O	1000
lateral	PROPN	O	O	1000
antebrachial	ADJ	O	O	1000
cutaneous	ADJ	O	O	1000
neuropathy	NOUN	O	Disease	1000
(	PUNCT	O	O	1000
LACNP	VERB	O	O	1000
)	PUNCT	O	O	1000
that	SCONJ	O	O	1000
occurred	VERB	O	O	1000
after	ADP	O	O	1000
a	PRON	O	O	1000
steroid	NOUN	O	Chemical	1000
injection	NOUN	O	O	1000
in	ADP	O	O	1000
the	PRON	O	O	1000
lateral	PROPN	O	O	1000
epicondyle	NOUN	O	O	1000
to	PART	O	O	1000
treat	VERB	O	O	1000
lateral	PROPN	O	O	1000
epicondylitis	NOUN	O	O	1000
in	ADP	O	O	1000
a	PRON	O	O	1000
40-year	NOUN	O	O	1000
-	PUNCT	O	O	1000
old	ADJ	O	O	1000
woman	NOUN	O	O	1000
.	PUNCT	O	O	1000
A	PRON	O	O	1001
40-year	NOUN	O	O	1001
-	PUNCT	O	O	1001
old	ADJ	O	O	1001
woman	NOUN	O	O	1001
presented	VERB	O	O	1001
with	ADP	O	O	1001
decreased	VERB	O	O	1001
sensation	NOUN	O	O	1001
and	CCONJ	O	O	1001
paresthesia	NOUN	O	O	1001
over	ADP	O	O	1001
her	PRON	O	O	1001
right	ADV	O	O	1001
lateral	PROPN	O	O	1001
forearm	NOUN	O	O	1001
;	PUNCT	O	O	1001
the	PRON	O	O	1001
paresthesia	NOUN	O	O	1001
had	VERB	O	O	1001
occurred	VERB	O	O	1001
after	ADP	O	O	1001
a	PRON	O	O	1001
steroid	NOUN	O	Chemical	1001
injection	NOUN	O	O	1001
in	ADP	O	O	1001
the	PRON	O	O	1001
right	ADV	O	O	1001
lateral	PROPN	O	O	1001
epicondyle	NOUN	O	O	1001
3	X	O	O	1001
months	NOUN	O	O	1001
before	ADP	O	O	1001
.	PUNCT	O	O	1001
Her	PRON	O	O	1002
sensation	NOUN	O	O	1002
of	ADP	O	O	1002
light	ADJ	O	O	1002
touch	VERB	O	O	1002
and	CCONJ	O	O	1002
pain	NOUN	O	Disease	1002
was	AUX	O	O	1002
diminished	VERB	O	O	1002
over	ADP	O	O	1002
the	PRON	O	O	1002
lateral	PROPN	O	O	1002
side	NOUN	O	O	1002
of	ADP	O	O	1002
the	PRON	O	O	1002
right	ADV	O	O	1002
forearm	NOUN	O	O	1002
and	CCONJ	O	O	1002
wrist	NOUN	O	O	1002
area	NOUN	O	O	1002
.	PUNCT	O	O	1002
This	PRON	O	O	1003
report	VERB	O	O	1003
describes	VERB	O	O	1003
the	PRON	O	O	1003
case	NOUN	O	O	1003
of	ADP	O	O	1003
a	PRON	O	O	1003
woman	NOUN	O	O	1003
with	ADP	O	O	1003
LACNP	VERB	O	O	1003
that	SCONJ	O	O	1003
developed	VERB	O	O	1003
after	ADP	O	O	1003
a	PRON	O	O	1003
steroid	NOUN	O	Chemical	1003
injection	NOUN	O	O	1003
for	ADP	O	O	1003
the	PRON	O	O	1003
treatment	NOUN	O	O	1003
of	ADP	O	O	1003
lateral	PROPN	O	O	1003
epicondylitis	NOUN	O	O	1003
.	PUNCT	O	O	1003
Curcumin	NOUN	O	O	1006
prevents	VERB	O	O	1006
maleate	NOUN	O	O	1006
-	PUNCT	O	O	1006
induced	VERB	O	O	1006
nephrotoxicity	NOUN	O	Disease	1006
:	PUNCT	O	O	1006
relation	NOUN	O	O	1006
to	PART	O	O	1006
hemodynamic	ADJ	O	O	1006
alterations	NOUN	O	O	1006
,	PUNCT	O	O	1006
oxidative	NOUN	O	O	1006
stress	NOUN	O	O	1006
,	PUNCT	O	O	1006
mitochondrial	ADJ	O	O	1006
oxygen	NOUN	O	Chemical	1006
consumption	NOUN	O	O	1006
and	CCONJ	O	O	1006
activity	NOUN	O	O	1006
of	ADP	O	O	1006
respiratory	NOUN	O	O	1006
complex	ADJ	O	O	1006
I.	NOUN	O	O	1006
The	PRON	O	O	1006
potential	ADJ	O	O	1006
protective	ADJ	O	O	1006
effect	VERB	O	O	1006
of	ADP	O	O	1006
the	PRON	O	O	1006
dietary	ADJ	O	O	1006
antioxidant	ADJ	O	O	1006
curcumin	PROPN	O	O	1006
(	PUNCT	O	O	1006
120	NUM	O	O	1006
mg	VERB	O	O	1006
/	PUNCT	O	O	1006
Kg	NOUN	O	O	1006
/	PUNCT	O	O	1006
day	NOUN	O	O	1006
for	ADP	O	O	1006
6	NUM	O	O	1006
days	NOUN	O	O	1006
)	PUNCT	O	O	1006
against	ADP	O	O	1006
the	PRON	O	O	1006
renal injury	NOUN	O	Disease	1006
induced	VERB	O	O	1006
by	ADP	O	O	1006
maleate	NOUN	O	O	1006
was	AUX	O	O	1006
evaluated	VERB	O	O	1006
.	PUNCT	O	O	1006
Tubular	ADJ	O	O	1007
proteinuria	X	O	Disease	1007
and	CCONJ	O	O	1007
oxidative	NOUN	O	O	1007
stress	NOUN	O	O	1007
were	AUX	O	O	1007
induced	VERB	O	O	1007
by	ADP	O	O	1007
a	PRON	O	O	1007
single	ADJ	O	O	1007
injection	NOUN	O	O	1007
of	ADP	O	O	1007
maleate	NOUN	O	O	1007
(	PUNCT	O	O	1007
400	NUM	O	O	1007
mg	VERB	O	O	1007
/	PUNCT	O	O	1007
kg	VERB	O	O	1007
)	PUNCT	O	O	1007
in	ADP	O	O	1007
rats	NOUN	O	O	1007
.	PUNCT	O	O	1007
Maleate	PROPN	O	O	1008
-	PUNCT	O	O	1008
induced	VERB	O	O	1008
renal injury	NOUN	O	Disease	1008
included	VERB	O	O	1008
increase	VERB	O	O	1008
in	ADP	O	O	1008
renal	ADJ	O	O	1008
vascular	ADJ	O	O	1008
resistance	NOUN	O	O	1008
and	CCONJ	O	O	1008
in	ADP	O	O	1008
the	PRON	O	O	1008
urinary	ADJ	O	O	1008
excretion	NOUN	O	O	1008
of	ADP	O	O	1008
total	ADJ	O	O	1008
protein	NOUN	O	O	1008
,	PUNCT	O	O	1008
glucose	NOUN	O	Chemical	1008
,	PUNCT	O	O	1008
sodium	NOUN	O	Chemical	1008
,	PUNCT	O	O	1008
neutrophil	ADJ	O	O	1008
gelatinase	NOUN	O	O	1008
-	PUNCT	O	O	1008
associated	VERB	O	O	1008
lipocalin	PROPN	O	O	1008
(	PUNCT	O	O	1008
NGAL	PROPN	O	O	1008
)	PUNCT	O	O	1008
and	CCONJ	O	O	1008
N	NUM	O	O	1008
-	PUNCT	O	O	1008
acetyl	PROPN	O	O	1008
b	X	O	O	1008
-	PUNCT	O	O	1008
D	NOUN	O	O	1008
-	PUNCT	O	O	1008
glucosaminidase	PROPN	O	O	1008
(	PUNCT	O	O	1008
NAG	PROPN	O	O	1008
)	PUNCT	O	O	1008
,	PUNCT	O	O	1008
upregulation	NOUN	O	O	1008
of	ADP	O	O	1008
kidney	NOUN	O	O	1008
injury	NOUN	O	O	1008
molecule	PROPN	O	O	1008
(	PUNCT	O	O	1008
KIM)-1	PROPN	O	O	1008
,	PUNCT	O	O	1008
decrease	VERB	O	O	1008
in	ADP	O	O	1008
renal	ADJ	O	O	1008
blood	NOUN	O	O	1008
flow	NOUN	O	O	1008
and	CCONJ	O	O	1008
claudin-2	NUM	O	O	1008
expression	NOUN	O	O	1008
besides	ADV	O	O	1008
of	ADP	O	O	1008
necrosis	NOUN	O	Disease	1008
and	CCONJ	O	O	1008
apoptosis	NOUN	O	O	1008
of	ADP	O	O	1008
tubular	ADJ	O	O	1008
cells	NOUN	O	O	1008
on	ADP	O	O	1008
24	NUM	O	O	1008
h.	PROPN	O	O	1008
Oxidative	NOUN	O	O	1008
stress	NOUN	O	O	1008
was	AUX	O	O	1008
determined	VERB	O	O	1008
by	ADP	O	O	1008
measuring	VERB	O	O	1008
the	PRON	O	O	1008
oxidation	ADV	O	O	1008
of	ADP	O	O	1008
lipids	NOUN	O	O	1008
and	CCONJ	O	O	1008
proteins	NOUN	O	O	1008
and	CCONJ	O	O	1008
diminution	NOUN	O	O	1008
in	ADP	O	O	1008
renal	ADJ	O	O	1008
Nrf2	NUM	O	O	1008
levels	NOUN	O	O	1008
.	PUNCT	O	O	1008
Maleate	PROPN	O	O	1009
induced	VERB	O	O	1009
cell	NOUN	O	O	1009
damage	NOUN	O	O	1009
and	CCONJ	O	O	1009
reactive	ADJ	O	O	1009
oxygen	NOUN	O	Chemical	1009
species	NOUN	O	O	1009
(	PUNCT	O	O	1009
ROS	PROPN	O	O	1009
)	PUNCT	O	O	1009
production	NOUN	O	O	1009
in	ADP	O	O	1009
LLC	PROPN	O	O	1009
-	PUNCT	O	O	1009
PK1	NOUN	O	O	1009
cells	NOUN	O	O	1009
in	ADP	O	O	1009
culture	NOUN	O	O	1009
.	PUNCT	O	O	1009
In	ADP	O	O	1010
addition	NOUN	O	O	1010
,	PUNCT	O	O	1010
maleate	NOUN	O	O	1010
treatment	NOUN	O	O	1010
reduced	VERB	O	O	1010
oxygen	NOUN	O	Chemical	1010
consumption	NOUN	O	O	1010
in	ADP	O	O	1010
ADP	PROPN	O	Chemical	1010
-	PUNCT	O	O	1010
stimulated	VERB	O	O	1010
mitochondria	PROPN	O	O	1010
and	CCONJ	O	O	1010
diminished	VERB	O	O	1010
respiratory	NOUN	O	O	1010
control	VERB	O	O	1010
index	NOUN	O	O	1010
when	SCONJ	O	O	1010
using	VERB	O	O	1010
malate	PROPN	O	O	1010
/	PUNCT	O	O	1010
glutamate	NOUN	O	Chemical	1010
as	ADP	O	O	1010
substrate	NOUN	O	O	1010
.	PUNCT	O	O	1010
All	PRON	O	O	1011
the	PRON	O	O	1011
above	ADP	O	O	1011
-	PUNCT	O	O	1011
described	VERB	O	O	1011
alterations	NOUN	O	O	1011
were	AUX	O	O	1011
prevented	VERB	O	O	1011
by	ADP	O	O	1011
curcumin	PROPN	O	O	1011
.	PUNCT	O	O	1011
It	PRON	O	O	1012
is	AUX	O	O	1012
concluded	VERB	O	O	1012
that	SCONJ	O	O	1012
curcumin	PROPN	O	O	1012
is	AUX	O	O	1012
able	ADJ	O	O	1012
to	PART	O	O	1012
attenuate	VERB	O	O	1012
in	ADP	O	O	1012
vivo	VERB	O	O	1012
maleate	NOUN	O	O	1012
-	PUNCT	O	O	1012
induced	VERB	O	O	1012
nephropathy	NOUN	O	Disease	1012
and	CCONJ	O	O	1012
in	ADP	O	O	1012
vitro	X	O	O	1012
cell	NOUN	O	O	1012
damage	NOUN	O	O	1012
.	PUNCT	O	O	1012
The	PRON	O	O	1013
in	ADP	O	O	1013
vivo	VERB	O	O	1013
protection	NOUN	O	O	1013
was	AUX	O	O	1013
associated	VERB	O	O	1013
to	PART	O	O	1013
the	PRON	O	O	1013
prevention	NOUN	O	O	1013
of	ADP	O	O	1013
oxidative	NOUN	O	O	1013
stress	NOUN	O	O	1013
and	CCONJ	O	O	1013
preservation	NOUN	O	O	1013
of	ADP	O	O	1013
mitochondrial	ADJ	O	O	1013
oxygen	NOUN	O	Chemical	1013
consumption	NOUN	O	O	1013
and	CCONJ	O	O	1013
activity	NOUN	O	O	1013
of	ADP	O	O	1013
respiratory	NOUN	O	O	1013
complex	ADJ	O	O	1013
I	PRON	O	O	1013
,	PUNCT	O	O	1013
and	CCONJ	O	O	1013
the	PRON	O	O	1013
in	ADP	O	O	1013
vitro	X	O	O	1013
protection	NOUN	O	O	1013
was	AUX	O	O	1013
associated	VERB	O	O	1013
to	PART	O	O	1013
the	PRON	O	O	1013
prevention	NOUN	O	O	1013
of	ADP	O	O	1013
ROS	PROPN	O	O	1013
production	NOUN	O	O	1013
.	PUNCT	O	O	1013
Incidence	NOUN	O	O	1016
of	ADP	O	O	1016
solid	ADJ	O	O	1016
tumours	NOUN	O	Disease	1016
among	ADP	O	O	1016
pesticide	NOUN	O	O	1016
applicators	NOUN	O	O	1016
exposed	VERB	O	O	1016
to	PART	O	O	1016
the	PRON	O	O	1016
organophosphate	NOUN	O	O	1016
insecticide	NOUN	O	O	1016
diazinon	NOUN	O	O	1016
in	ADP	O	O	1016
the	PRON	O	O	1016
Agricultural	ADJ	O	O	1016
Health	NOUN	O	O	1016
Study	NOUN	O	O	1016
:	PUNCT	O	O	1016
an	PRON	O	O	1016
updated	VERB	O	O	1016
analysis	NOUN	O	O	1016
.	PUNCT	O	O	1016
OBJECTIVE	VERB	O	O	1017
:	PUNCT	O	O	1017
Diazinon	NOUN	O	O	1017
,	PUNCT	O	O	1017
a	PRON	O	O	1017
common	ADJ	O	O	1017
organophosphate	NOUN	O	O	1017
insecticide	NOUN	O	O	1017
with	ADP	O	O	1017
genotoxic	ADJ	O	O	1017
properties	NOUN	O	O	1017
,	PUNCT	O	O	1017
was	AUX	O	O	1017
previously	ADV	O	O	1017
associated	VERB	O	O	1017
with	ADP	O	O	1017
lung cancer	NOUN	O	Disease	1017
in	ADP	O	O	1017
the	PRON	O	O	1017
Agricultural	ADJ	O	O	1017
Health	NOUN	O	O	1017
Study	NOUN	O	O	1017
(	PUNCT	O	O	1017
AHS	PROPN	O	O	1017
)	PUNCT	O	O	1017
cohort	NOUN	O	O	1017
,	PUNCT	O	O	1017
but	CCONJ	O	O	1017
few	ADJ	O	O	1017
other	ADJ	O	O	1017
epidemiological	ADJ	O	O	1017
studies	NOUN	O	O	1017
have	VERB	O	O	1017
examined	VERB	O	O	1017
diazinon	NOUN	O	O	1017
-	PUNCT	O	O	1017
associated	VERB	O	O	1017
cancer	NOUN	O	Disease	1017
risk	NOUN	O	O	1017
.	PUNCT	O	O	1017
We	PRON	O	O	1018
used	VERB	O	O	1018
updated	VERB	O	O	1018
diazinon	NOUN	O	O	1018
exposure	NOUN	O	O	1018
and	CCONJ	O	O	1018
cancer	NOUN	O	Disease	1018
incidence	NOUN	O	O	1018
information	NOUN	O	O	1018
to	PART	O	O	1018
evaluate	VERB	O	O	1018
solid	ADJ	O	O	1018
tumour	NOUN	O	O	1018
risk	NOUN	O	O	1018
in	ADP	O	O	1018
the	PRON	O	O	1018
AHS	PROPN	O	O	1018
.	PUNCT	O	O	1018
Male	NOUN	O	O	1019
pesticide	NOUN	O	O	1019
applicators	NOUN	O	O	1019
in	ADP	O	O	1019
Iowa	PROPN	O	O	1019
and	CCONJ	O	O	1019
North	NOUN	O	O	1019
Carolina	PROPN	O	O	1019
reported	VERB	O	O	1019
lifetime	NOUN	O	O	1019
diazinon	NOUN	O	O	1019
use	VERB	O	O	1019
at	ADP	O	O	1019
enrolment	NOUN	O	O	1019
(	PUNCT	O	O	1019
1993	NUM	O	O	1019
-	PUNCT	O	O	1019
1997	NUM	O	O	1019
)	PUNCT	O	O	1019
and	CCONJ	O	O	1019
follow	VERB	O	O	1019
-	PUNCT	O	O	1019
up	ADP	O	O	1019
(	PUNCT	O	O	1019
1998	NUM	O	O	1019
-	PUNCT	O	O	1019
2005	NUM	O	O	1019
)	PUNCT	O	O	1019
;	PUNCT	O	O	1019
cancer	NOUN	O	Disease	1019
incidence	NOUN	O	O	1019
was	AUX	O	O	1019
assessed	VERB	O	O	1019
through	ADP	O	O	1019
2010(North	NUM	O	O	1019
Carolina)/2011(Iowa	NUM	O	O	1019
)	PUNCT	O	O	1019
.	PUNCT	O	O	1019
Among	ADP	O	O	1020
applicators	NOUN	O	O	1020
with	ADP	O	O	1020
usage	NOUN	O	O	1020
information	NOUN	O	O	1020
sufficient	ADJ	O	O	1020
to	PART	O	O	1020
evaluate	VERB	O	O	1020
exposure	NOUN	O	O	1020
-	PUNCT	O	O	1020
response	NOUN	O	O	1020
patterns	NOUN	O	O	1020
,	PUNCT	O	O	1020
we	PRON	O	O	1020
used	VERB	O	O	1020
Poisson	NOUN	O	O	1020
regression	NOUN	O	O	1020
to	PART	O	O	1020
estimate	VERB	O	O	1020
adjusted	VERB	O	O	1020
rate	NOUN	O	O	1020
ratios	VERB	O	O	1020
(	PUNCT	O	O	1020
RRs	PROPN	O	O	1020
)	PUNCT	O	O	1020
and	CCONJ	O	O	1020
95%	NOUN	O	O	1020
CI	NOUN	O	O	1020
for	ADP	O	O	1020
cancer	NOUN	O	Disease	1020
sites	NOUN	O	O	1020
with	ADP	O	O	1020
>	PUNCT	O	O	1020
10	NUM	O	O	1020
exposed	VERB	O	O	1020
cases	NOUN	O	O	1020
for	ADP	O	O	1020
both	PRON	O	O	1020
lifetime	NOUN	O	O	1020
(	PUNCT	O	O	1020
LT	PROPN	O	O	1020
)	PUNCT	O	O	1020
exposure	NOUN	O	O	1020
days	NOUN	O	O	1020
and	CCONJ	O	O	1020
intensity	NOUN	O	O	1020
-	PUNCT	O	O	1020
weighted	VERB	O	O	1020
(	PUNCT	O	O	1020
IW	PROPN	O	O	1020
)	PUNCT	O	O	1020
lifetime	NOUN	O	O	1020
exposure	NOUN	O	O	1020
days	NOUN	O	O	1020
(	PUNCT	O	O	1020
accounting	VERB	O	O	1020
for	ADP	O	O	1020
factors	NOUN	O	O	1020
impacting	VERB	O	O	1020
exposure	NOUN	O	O	1020
)	PUNCT	O	O	1020
.	PUNCT	O	O	1020
We	PRON	O	O	1021
observed	VERB	O	O	1021
elevated	ADJ	O	O	1021
lung cancer	NOUN	O	Disease	1021
risks	NOUN	O	O	1021
(	PUNCT	O	O	1021
N=283	NUM	O	O	1021
)	PUNCT	O	O	1021
among	ADP	O	O	1021
applicators	NOUN	O	O	1021
with	ADP	O	O	1021
the	PRON	O	O	1021
greatest	ADJ	O	O	1021
number	NOUN	O	O	1021
of	ADP	O	O	1021
LT	PROPN	O	O	1021
(	PUNCT	O	O	1021
RR=1.60	PROPN	O	O	1021
;	PUNCT	O	O	1021
95%	NOUN	O	O	1021
CI	NOUN	O	O	1021
1.11	NUM	O	O	1021
to	PART	O	O	1021
2.31	NUM	O	O	1021
;	PUNCT	O	O	1021
Ptrend=0.02	NOUN	O	O	1021
)	PUNCT	O	O	1021
and	CCONJ	O	O	1021
IW	PROPN	O	O	1021
days	NOUN	O	O	1021
of	ADP	O	O	1021
diazinon	NOUN	O	O	1021
use	VERB	O	O	1021
(	PUNCT	O	O	1021
RR=1.41	NUM	O	O	1021
;	PUNCT	O	O	1021
95%	NOUN	O	O	1021
CI	NOUN	O	O	1021
0.98	NUM	O	O	1021
to	PART	O	O	1021
2.04	NUM	O	O	1021
;	PUNCT	O	O	1021
Ptrend=0.08	NOUN	O	O	1021
)	PUNCT	O	O	1021
.	PUNCT	O	O	1021
Kidney	NOUN	O	O	1022
cancer	NOUN	O	Disease	1022
(	PUNCT	O	O	1022
N=94	PROPN	O	O	1022
)	PUNCT	O	O	1022
risks	NOUN	O	O	1023
were	AUX	O	O	1023
non	ADJ	O	O	1023
-	PUNCT	O	O	1023
significantly	ADV	O	O	1023
elevated	ADJ	O	O	1023
(	PUNCT	O	O	1023
RRLT	NOUN	O	O	1023
days=1.77	NOUN	O	O	1023
;	PUNCT	O	O	1023
95%	NOUN	O	O	1023
CI	NOUN	O	O	1023
0.90	NUM	O	O	1023
to	PART	O	O	1023
3.51	NUM	O	O	1023
;	PUNCT	O	O	1023
Ptrend=0.09	VERB	O	O	1023
;	PUNCT	O	O	1023
RRIW	PROPN	O	O	1023
days	NOUN	O	O	1023
1.37	NUM	O	O	1023
;	PUNCT	O	O	1023
95%	NOUN	O	O	1023
CI	NOUN	O	O	1023
0.64	NUM	O	O	1023
to	PART	O	O	1023
2.92	NUM	O	O	1023
;	PUNCT	O	O	1023
Ptrend=0.50	NOUN	O	O	1023
)	PUNCT	O	O	1023
,	PUNCT	O	O	1023
as	ADP	O	O	1023
were	AUX	O	O	1023
risks	NOUN	O	O	1023
for	ADP	O	O	1023
aggressive	ADJ	O	O	1023
prostate cancer	NOUN	O	Disease	1023
(	PUNCT	O	O	1023
N=656	NUM	O	O	1023
)	PUNCT	O	O	1023
.	PUNCT	O	O	1023
Our	PRON	O	O	1024
updated	VERB	O	O	1024
evaluation	NOUN	O	O	1024
of	ADP	O	O	1024
diazinon	NOUN	O	O	1024
provides	VERB	O	O	1024
additional	ADJ	O	O	1024
evidence	NOUN	O	O	1024
of	ADP	O	O	1024
an	PRON	O	O	1024
association	PROPN	O	O	1024
with	ADP	O	O	1024
lung cancer	NOUN	O	Disease	1024
risk	NOUN	O	O	1024
.	PUNCT	O	O	1024
Newly	PROPN	O	O	1025
identified	VERB	O	O	1025
links	NOUN	O	O	1025
to	PART	O	O	1025
kidney	NOUN	O	O	1025
cancer	NOUN	O	Disease	1025
and	CCONJ	O	O	1025
associations	NOUN	O	O	1025
with	ADP	O	O	1025
aggressive	ADJ	O	O	1025
prostate cancer	NOUN	O	Disease	1025
require	VERB	O	O	1025
further	ADV	O	O	1025
evaluation	NOUN	O	O	1025
.	PUNCT	O	O	1025
Associations	NOUN	O	O	1028
of	ADP	O	O	1028
Ozone	NOUN	O	O	1028
and	CCONJ	O	O	1028
PM2.5	NOUN	O	O	1028
Concentrations	NOUN	O	O	1028
With	ADP	O	O	1028
Parkinson	NOUN	O	O	1028
's	AUX	O	O	1028
Disease	NOUN	O	O	1028
Among	ADP	O	O	1028
Participants	NOUN	O	O	1028
in	ADP	O	O	1028
the	PRON	O	O	1028
Agricultural	ADJ	O	O	1028
Health	NOUN	O	O	1028
Study	NOUN	O	O	1028
.	PUNCT	O	O	1028
This	PRON	O	O	1029
study	VERB	O	O	1029
describes	VERB	O	O	1029
associations	NOUN	O	O	1029
of	ADP	O	O	1029
ozone	NOUN	O	O	1029
and	CCONJ	O	O	1029
fine	ADJ	O	O	1029
particulate	NOUN	O	O	1029
matter	VERB	O	O	1029
with	ADP	O	O	1029
Parkinson	NOUN	O	O	1029
's	AUX	O	O	1029
disease	PROPN	O	O	1029
observed	VERB	O	O	1029
among	ADP	O	O	1029
farmers	NOUN	O	O	1029
in	ADP	O	O	1029
North	NOUN	O	O	1029
Carolina	PROPN	O	O	1029
and	CCONJ	O	O	1029
Iowa	PROPN	O	O	1029
.	PUNCT	O	O	1029
:	PUNCT	O	O	1030
We	PRON	O	O	1030
used	VERB	O	O	1030
logistic	ADJ	O	O	1030
regression	NOUN	O	O	1030
to	PART	O	O	1030
determine	VERB	O	O	1030
the	PRON	O	O	1030
associations	NOUN	O	O	1030
of	ADP	O	O	1030
these	PRON	O	O	1030
pollutants	NOUN	O	O	1030
with	ADP	O	O	1030
self	VERB	O	O	1030
-	PUNCT	O	O	1030
reported	VERB	O	O	1030
,	PUNCT	O	O	1030
doctor	NOUN	O	O	1030
-	PUNCT	O	O	1030
diagnosed	VERB	O	O	1030
Parkinson	NOUN	O	O	1030
's	AUX	O	O	1030
disease	PROPN	O	O	1030
.	PUNCT	O	O	1030
We	PRON	O	O	1031
observed	VERB	O	O	1031
positive	ADJ	O	O	1031
associations	NOUN	O	O	1031
of	ADP	O	O	1031
Parkinson	NOUN	O	O	1031
's	AUX	O	O	1031
disease	PROPN	O	O	1031
with	ADP	O	O	1031
ozone	NOUN	O	O	1031
(	PUNCT	O	O	1031
odds	NOUN	O	O	1031
ratio	NOUN	O	O	1031
=	PUNCT	O	O	1031
1.39	NUM	O	O	1031
;	PUNCT	O	O	1031
95%	NOUN	O	O	1031
CI	NOUN	O	O	1031
:	PUNCT	O	O	1031
0.98	NUM	O	O	1031
to	PART	O	O	1031
1.98	NUM	O	O	1031
)	PUNCT	O	O	1031
and	CCONJ	O	O	1031
fine	ADJ	O	O	1031
particulate	NOUN	O	O	1031
matter	VERB	O	O	1031
(	PUNCT	O	O	1031
odds	NOUN	O	O	1031
ratio	NOUN	O	O	1031
=	PUNCT	O	O	1031
1.34	NUM	O	O	1031
;	PUNCT	O	O	1031
95%	NOUN	O	O	1031
CI	NOUN	O	O	1031
:	PUNCT	O	O	1031
0.93	NUM	O	O	1031
to	PART	O	O	1031
1.93	NUM	O	O	1031
)	PUNCT	O	O	1031
in	ADP	O	O	1031
North	NOUN	O	O	1031
Carolina	PROPN	O	O	1031
but	CCONJ	O	O	1031
not	PART	O	O	1031
in	ADP	O	O	1031
Iowa	PROPN	O	O	1031
.	PUNCT	O	O	1031
The	PRON	O	O	1032
plausibility	NOUN	O	O	1032
of	ADP	O	O	1032
an	PRON	O	O	1032
effect	VERB	O	O	1032
of	ADP	O	O	1032
ambient	NOUN	O	O	1032
concentrations	NOUN	O	O	1032
of	ADP	O	O	1032
these	PRON	O	O	1032
pollutants	NOUN	O	O	1032
on	ADP	O	O	1032
Parkinson	NOUN	O	O	1032
's	AUX	O	O	1032
disease	PROPN	O	O	1032
risk	NOUN	O	O	1032
is	AUX	O	O	1032
supported	VERB	O	O	1032
by	ADP	O	O	1032
experimental	ADJ	O	O	1032
data	NOUN	O	O	1032
demonstrating	VERB	O	O	1032
damage	NOUN	O	O	1032
to	PART	O	O	1032
dopaminergic	ADJ	O	O	1032
neurons	NOUN	O	O	1032
at	ADP	O	O	1032
relevant	ADJ	O	O	1032
concentrations	NOUN	O	O	1032
.	PUNCT	O	O	1032
Low	ADJ	O	O	1035
functional	ADJ	O	O	1035
programming	NOUN	O	O	1035
of	ADP	O	O	1035
renal	ADJ	O	O	1035
AT2R	ADJ	O	O	1035
mediates	VERB	O	O	1035
the	PRON	O	O	1035
developmental	ADJ	O	O	1035
origin	NOUN	O	O	1035
of	ADP	O	O	1035
glomerulosclerosis	PROPN	O	O	1035
in	ADP	O	O	1035
adult	NOUN	O	O	1035
offspring	VERB	O	O	1035
induced	VERB	O	O	1035
by	ADP	O	O	1035
prenatal	ADJ	O	O	1035
caffeine	NOUN	O	Chemical	1035
exposure	NOUN	O	O	1035
.	PUNCT	O	O	1035
UNASSIGNED	PROPN	O	O	1036
:	PUNCT	O	O	1036
Our	PRON	O	O	1036
previous	ADJ	O	O	1036
study	VERB	O	O	1036
has	VERB	O	O	1036
indicated	VERB	O	O	1036
that	SCONJ	O	O	1036
prenatal	ADJ	O	O	1036
caffeine	NOUN	O	Chemical	1036
exposure	NOUN	O	O	1036
(	PUNCT	O	O	1036
PCE	NOUN	O	O	1036
)	PUNCT	O	O	1036
could	AUX	O	O	1036
induce	VERB	O	O	1036
intrauterine	ADJ	O	O	1036
growth	NOUN	O	O	1036
retardation	NOUN	O	O	1036
(	PUNCT	O	O	1036
IUGR	NOUN	O	O	1036
)	PUNCT	O	O	1036
of	ADP	O	O	1036
offspring	VERB	O	O	1036
.	PUNCT	O	O	1036
Recent	ADJ	O	O	1037
research	NOUN	O	O	1037
suggested	VERB	O	O	1037
that	SCONJ	O	O	1037
IUGR	NOUN	O	O	1037
is	AUX	O	O	1037
a	PRON	O	O	1037
risk	NOUN	O	O	1037
factor	NOUN	O	O	1037
for	ADP	O	O	1037
glomerulosclerosis	PROPN	O	O	1037
.	PUNCT	O	O	1037
However	ADV	O	O	1038
,	PUNCT	O	O	1038
whether	SCONJ	O	O	1038
PCE	NOUN	O	O	1038
could	AUX	O	O	1038
induce	VERB	O	O	1038
glomerulosclerosis	PROPN	O	O	1038
and	CCONJ	O	O	1038
its	PRON	O	O	1038
underlying	VERB	O	O	1038
mechanisms	NOUN	O	O	1038
remain	VERB	O	O	1038
unknown	ADJ	O	O	1038
.	PUNCT	O	O	1038
This	PRON	O	O	1039
study	VERB	O	O	1039
aimed	VERB	O	O	1039
to	PART	O	O	1039
demonstrate	VERB	O	O	1039
the	PRON	O	O	1039
induction	NOUN	O	O	1039
to	PART	O	O	1039
glomerulosclerosis	PROPN	O	O	1039
in	ADP	O	O	1039
adult	NOUN	O	O	1039
offspring	VERB	O	O	1039
by	ADP	O	O	1039
PCE	NOUN	O	O	1039
and	CCONJ	O	O	1039
its	PRON	O	O	1039
intrauterine	ADJ	O	O	1039
programming	NOUN	O	O	1039
mechanisms	NOUN	O	O	1039
.	PUNCT	O	O	1039
A	PRON	O	O	1040
rat	NOUN	O	O	1040
model	NOUN	O	O	1040
of	ADP	O	O	1040
IUGR	NOUN	O	O	1040
was	AUX	O	O	1040
established	VERB	O	O	1040
by	ADP	O	O	1040
PCE	NOUN	O	O	1040
,	PUNCT	O	O	1040
male	NOUN	O	O	1040
fetuses	NOUN	O	O	1040
and	CCONJ	O	O	1040
adult	NOUN	O	O	1040
offspring	VERB	O	O	1040
at	ADP	O	O	1040
the	PRON	O	O	1040
age	NOUN	O	O	1040
of	ADP	O	O	1040
postnatal	ADJ	O	O	1040
week	NOUN	O	O	1040
24	NUM	O	O	1040
were	AUX	O	O	1040
euthanized	VERB	O	O	1040
.	PUNCT	O	O	1040
The	PRON	O	O	1041
results	VERB	O	O	1041
revealed	VERB	O	O	1041
that	SCONJ	O	O	1041
the	PRON	O	O	1041
adult	NOUN	O	O	1041
offspring	VERB	O	O	1041
kidneys	NOUN	O	O	1041
in	ADP	O	O	1041
the	PRON	O	O	1041
PCE	NOUN	O	O	1041
group	NOUN	O	O	1041
exhibited	VERB	O	O	1041
glomerulosclerosis	PROPN	O	O	1041
as	ADP	O	O	1041
well	ADV	O	O	1041
as	ADP	O	O	1041
interstitial	ADJ	O	O	1041
fibrosis	NOUN	O	Disease	1041
,	PUNCT	O	O	1041
accompanied	VERB	O	O	1041
by	ADP	O	O	1041
elevated	ADJ	O	O	1041
levels	NOUN	O	O	1041
of	ADP	O	O	1041
serum	NOUN	O	O	1041
creatinine	PROPN	O	Chemical	1041
and	CCONJ	O	O	1041
urine	NOUN	O	O	1041
protein	NOUN	O	O	1041
.	PUNCT	O	O	1041
Renal	NOUN	O	O	1042
angiotensin II	PROPN	O	Chemical	1042
receptor	NOUN	O	O	1042
type	NOUN	O	O	1042
2	X	O	O	1042
(	PUNCT	O	O	1042
AT2R	ADJ	O	O	1042
)	PUNCT	O	O	1042
gene	NOUN	O	O	1042
expression	NOUN	O	O	1042
in	ADP	O	O	1042
adult	NOUN	O	O	1042
offspring	VERB	O	O	1042
was	AUX	O	O	1042
reduced	VERB	O	O	1042
by	ADP	O	O	1042
PCE	NOUN	O	O	1042
,	PUNCT	O	O	1042
whereas	SCONJ	O	O	1042
the	PRON	O	O	1042
renal	ADJ	O	O	1042
angiotensin II	PROPN	O	Chemical	1042
receptor	NOUN	O	O	1042
type	NOUN	O	O	1042
1a	NUM	O	O	1042
(	PUNCT	O	O	1042
AT1aR)/AT2R	VERB	O	O	1042
expression	NOUN	O	O	1042
ratio	NOUN	O	O	1042
was	AUX	O	O	1042
increased	VERB	O	O	1042
.	PUNCT	O	O	1042
Moreover	ADV	O	O	1043
,	PUNCT	O	O	1043
AT2R	ADJ	O	O	1043
gene	NOUN	O	O	1043
and	CCONJ	O	O	1043
protein	NOUN	O	O	1043
expressions	NOUN	O	O	1043
in	ADP	O	O	1043
fetal	ADJ	O	O	1043
kidneys	NOUN	O	O	1043
were	AUX	O	O	1043
inhibited	VERB	O	O	1043
by	ADP	O	O	1043
PCE	NOUN	O	O	1043
,	PUNCT	O	O	1043
associated	VERB	O	O	1043
with	ADP	O	O	1043
the	PRON	O	O	1043
repression	NOUN	O	O	1043
of	ADP	O	O	1043
the	PRON	O	O	1043
gene	NOUN	O	O	1043
expression	NOUN	O	O	1043
of	ADP	O	O	1043
glial	ADJ	O	O	1043
-	PUNCT	O	O	1043
cell	NOUN	O	O	1043
-	PUNCT	O	O	1043
line	NOUN	O	O	1043
-	PUNCT	O	O	1043
derived	VERB	O	O	1043
neurotrophic	PROPN	O	O	1043
factor	NOUN	O	O	1043
(	PUNCT	O	O	1043
GDNF)/tyrosine	VERB	O	O	1043
kinase	VERB	O	O	1043
receptor	NOUN	O	O	1043
(	PUNCT	O	O	1043
c	X	O	O	1043
-	PUNCT	O	O	1043
Ret	PROPN	O	O	1043
)	PUNCT	O	O	1043
signaling	VERB	O	O	1043
pathway	NOUN	O	O	1043
.	PUNCT	O	O	1043
These	PRON	O	O	1044
results	VERB	O	O	1044
demonstrated	VERB	O	O	1044
that	SCONJ	O	O	1044
PCE	NOUN	O	O	1044
could	AUX	O	O	1044
induce	VERB	O	O	1044
dysplasia	NOUN	O	O	1044
of	ADP	O	O	1044
fetal	ADJ	O	O	1044
kidneys	NOUN	O	O	1044
as	ADP	O	O	1044
well	ADV	O	O	1044
as	ADP	O	O	1044
glomerulosclerosis	PROPN	O	O	1044
of	ADP	O	O	1044
adult	NOUN	O	O	1044
offspring	VERB	O	O	1044
,	PUNCT	O	O	1044
and	CCONJ	O	O	1044
the	PRON	O	O	1044
low	ADJ	O	O	1044
functional	ADJ	O	O	1044
programming	NOUN	O	O	1044
of	ADP	O	O	1044
renal	ADJ	O	O	1044
AT2R	ADJ	O	O	1044
might	AUX	O	O	1044
mediate	VERB	O	O	1044
the	PRON	O	O	1044
developmental	ADJ	O	O	1044
origin	NOUN	O	O	1044
of	ADP	O	O	1044
adult	NOUN	O	O	1044
glomerulosclerosis	PROPN	O	O	1044
.	PUNCT	O	O	1044
1,3-Butadiene	PROPN	O	O	1047
,	PUNCT	O	O	1047
CML	PROPN	O	O	1047
and	CCONJ	O	O	1047
the	PRON	O	O	1047
t(9:22	PUNCT	O	O	1047
)	PUNCT	O	O	1047
Epidemiological	ADJ	O	O	1048
studies	NOUN	O	O	1048
of	ADP	O	O	1048
1,3-butadiene	NOUN	O	O	1048
have	VERB	O	O	1048
suggest	VERB	O	O	1048
that	SCONJ	O	O	1048
exposures	NOUN	O	O	1048
to	PART	O	O	1048
humans	NOUN	O	O	1048
are	AUX	O	O	1048
associated	VERB	O	O	1048
with	ADP	O	O	1048
chronic	ADJ	O	O	1048
myeloid	NOUN	O	O	1048
leukemia	NOUN	O	Disease	1048
(	PUNCT	O	O	1048
CML	PROPN	O	O	1048
)	PUNCT	O	O	1048
.	PUNCT	O	O	1048
CML	PROPN	O	O	1049
has	VERB	O	O	1049
a	PRON	O	O	1049
well	ADV	O	O	1049
-	PUNCT	O	O	1049
documented	VERB	O	O	1049
association	PROPN	O	O	1049
with	ADP	O	O	1049
ionizing	VERB	O	O	1049
radiation	NOUN	O	O	1049
,	PUNCT	O	O	1049
but	CCONJ	O	O	1049
reports	VERB	O	O	1049
of	ADP	O	O	1049
associations	NOUN	O	O	1049
with	ADP	O	O	1049
chemical	PROPN	O	O	1049
exposures	NOUN	O	O	1049
have	VERB	O	O	1049
been	AUX	O	O	1049
questioned	VERB	O	O	1049
.	PUNCT	O	O	1049
Ionizing	VERB	O	O	1050
radiation	NOUN	O	O	1050
is	AUX	O	O	1050
capable	ADJ	O	O	1050
of	ADP	O	O	1050
inducing	VERB	O	O	1050
the	PRON	O	O	1050
requisite	ADJ	O	O	1050
CML	PROPN	O	O	1050
-	PUNCT	O	O	1050
associated	VERB	O	O	1050
t(9:22	PUNCT	O	O	1050
)	PUNCT	O	O	1050
translocation	NOUN	O	O	1051
(	PUNCT	O	O	1051
Philadelphia	PROPN	O	O	1051
chromosome	NOUN	O	O	1051
)	PUNCT	O	O	1051
in	ADP	O	O	1051
appropriate	ADJ	O	O	1051
cells	NOUN	O	O	1051
in	ADP	O	O	1051
vitro	X	O	O	1051
We	PRON	O	O	1052
have	VERB	O	O	1052
proposed	VERB	O	O	1052
that	SCONJ	O	O	1052
1,3-butadiene	NOUN	O	O	1052
metabolites	VERB	O	O	1052
be	AUX	O	O	1052
so	ADV	O	O	1052
tested	VERB	O	O	1052
as	ADP	O	O	1052
a	PRON	O	O	1052
reality	NOUN	O	O	1052
check	VERB	O	O	1052
on	ADP	O	O	1052
the	PRON	O	O	1052
epidemiological	ADJ	O	O	1052
reports	VERB	O	O	1052
.	PUNCT	O	O	1052
Conditions	NOUN	O	O	1053
that	SCONJ	O	O	1053
will	AUX	O	O	1053
be	AUX	O	O	1053
required	VERB	O	O	1053
for	ADP	O	O	1053
studies	NOUN	O	O	1053
of	ADP	O	O	1053
1,3-butadiene	NOUN	O	O	1053
are	AUX	O	O	1053
discussed	VERB	O	O	1053
.	PUNCT	O	O	1053
Cancer	NOUN	O	O	1056
incidence	NOUN	O	O	1056
and	CCONJ	O	O	1056
metolachlor	NOUN	O	O	1056
use	VERB	O	O	1056
in	ADP	O	O	1056
the	PRON	O	O	1056
Agricultural	ADJ	O	O	1056
Health	NOUN	O	O	1056
Study	NOUN	O	O	1056
:	PUNCT	O	O	1056
Metolachlor	NOUN	O	O	1057
,	PUNCT	O	O	1057
a	PRON	O	O	1057
widely	ADV	O	O	1057
used	VERB	O	O	1057
herbicide	NOUN	O	O	1057
,	PUNCT	O	O	1057
is	AUX	O	O	1057
classified	VERB	O	O	1057
as	ADP	O	O	1057
a	PRON	O	O	1057
Group	PROPN	O	O	1057
C	NOUN	O	O	1057
carcinogen	PROPN	O	O	1057
by	ADP	O	O	1057
the	PRON	O	O	1057
U.S.	PROPN	O	O	1057
Environmental	ADJ	O	O	1057
Protection	NOUN	O	O	1057
Agency	PROPN	O	O	1057
based	VERB	O	O	1057
on	ADP	O	O	1057
increased	VERB	O	O	1057
liver	NOUN	O	O	1057
neoplasms	NOUN	O	O	1057
in	ADP	O	O	1057
female	ADJ	O	O	1057
rats	NOUN	O	O	1057
.	PUNCT	O	O	1057
Epidemiologic	ADJ	O	O	1058
studies	NOUN	O	O	1058
of	ADP	O	O	1058
the	PRON	O	O	1058
health	NOUN	O	O	1058
effects	NOUN	O	O	1058
of	ADP	O	O	1058
metolachlor	NOUN	O	O	1058
have	VERB	O	O	1058
been	AUX	O	O	1058
limited	VERB	O	O	1058
.	PUNCT	O	O	1058
We	PRON	O	O	1059
evaluated	VERB	O	O	1059
cancer	NOUN	O	Disease	1059
incidence	NOUN	O	O	1059
through	ADP	O	O	1059
2010/2011	NUM	O	O	1059
(	PUNCT	O	O	1059
NC	PROPN	O	O	1059
/	PUNCT	O	O	1059
IA	PROPN	O	O	1059
)	PUNCT	O	O	1059
for	ADP	O	O	1059
49,616	NUM	O	O	1059
applicators	NOUN	O	O	1059
,	PUNCT	O	O	1059
53%	NOUN	O	O	1059
of	ADP	O	O	1059
whom	PRON	O	O	1059
reported	VERB	O	O	1059
ever	ADV	O	O	1059
using	VERB	O	O	1059
metolachlor	NOUN	O	O	1059
.	PUNCT	O	O	1059
We	PRON	O	O	1060
used	VERB	O	O	1060
Poisson	NOUN	O	O	1060
regression	NOUN	O	O	1060
to	PART	O	O	1060
evaluate	VERB	O	O	1060
relations	NOUN	O	O	1060
between	ADP	O	O	1060
two	NUM	O	O	1060
metrics	NOUN	O	O	1060
of	ADP	O	O	1060
metolachlor	NOUN	O	O	1060
use	VERB	O	O	1060
(	PUNCT	O	O	1060
lifetime	NOUN	O	O	1060
days	NOUN	O	O	1060
,	PUNCT	O	O	1060
intensity	NOUN	O	O	1060
-	PUNCT	O	O	1060
weighted	VERB	O	O	1060
lifetime	NOUN	O	O	1060
days	NOUN	O	O	1060
)	PUNCT	O	O	1060
and	CCONJ	O	O	1060
cancer	NOUN	O	Disease	1060
incidence	NOUN	O	O	1060
.	PUNCT	O	O	1060
We	PRON	O	O	1061
saw	VERB	O	O	1061
no	PRON	O	O	1061
association	PROPN	O	O	1061
between	ADP	O	O	1061
metolachlor	NOUN	O	O	1061
use	VERB	O	O	1061
and	CCONJ	O	O	1061
incidence	NOUN	O	O	1061
of	ADP	O	O	1061
all	PRON	O	O	1061
cancers	NOUN	O	Disease	1061
combined	VERB	O	O	1061
(	PUNCT	O	O	1061
n	CCONJ	O	O	1061
=	PUNCT	O	O	1061
5,701	NUM	O	O	1061
with	ADP	O	O	1061
a	PRON	O	O	1061
5-year	NOUN	O	O	1061
lag	VERB	O	O	1061
)	PUNCT	O	O	1061
or	CCONJ	O	O	1061
most	ADV	O	O	1061
site	NOUN	O	O	1061
-	PUNCT	O	O	1061
specific	ADJ	O	O	1061
cancers	NOUN	O	Disease	1061
.	PUNCT	O	O	1061
For	ADP	O	O	1062
liver	NOUN	O	O	1062
cancer	NOUN	O	Disease	1062
,	PUNCT	O	O	1062
in	ADP	O	O	1062
analyses	NOUN	O	O	1062
restricted	VERB	O	O	1062
to	PART	O	O	1062
exposed	VERB	O	O	1062
workers	NOUN	O	O	1062
,	PUNCT	O	O	1062
elevations	NOUN	O	O	1062
observed	VERB	O	O	1062
at	ADP	O	O	1062
higher	ADJ	O	O	1062
categories	NOUN	O	O	1062
of	ADP	O	O	1062
use	VERB	O	O	1062
were	AUX	O	O	1062
not	PART	O	O	1062
statistically	ADV	O	O	1062
significant	ADJ	O	O	1062
.	PUNCT	O	O	1062
However	ADV	O	O	1063
,	PUNCT	O	O	1063
trends	NOUN	O	O	1063
for	ADP	O	O	1063
both	PRON	O	O	1063
lifetime	NOUN	O	O	1063
and	CCONJ	O	O	1063
intensity	NOUN	O	O	1063
-	PUNCT	O	O	1063
weighted	VERB	O	O	1063
lifetime	NOUN	O	O	1063
days	NOUN	O	O	1063
of	ADP	O	O	1063
metolachor	NOUN	O	O	1063
use	VERB	O	O	1063
were	AUX	O	O	1063
positive	ADJ	O	O	1063
and	CCONJ	O	O	1063
statistically	ADV	O	O	1063
significant	ADJ	O	O	1063
with	ADP	O	O	1063
an	PRON	O	O	1063
unexposed	ADJ	O	O	1063
reference	NOUN	O	O	1063
group	NOUN	O	O	1063
.	PUNCT	O	O	1063
A	PRON	O	O	1064
similar	ADJ	O	O	1064
pattern	NOUN	O	O	1064
was	AUX	O	O	1064
observed	VERB	O	O	1064
for	ADP	O	O	1064
follicular	ADJ	O	O	1064
cell	NOUN	O	O	1064
lymphoma	PROPN	O	Disease	1064
,	PUNCT	O	O	1064
but	CCONJ	O	O	1064
no	PRON	O	O	1064
other	ADJ	O	O	1064
lymphoma	PROPN	O	Disease	1064
subtypes	NOUN	O	O	1064
.	PUNCT	O	O	1064
An	PRON	O	O	1065
earlier	ADV	O	O	1065
suggestion	NOUN	O	O	1065
of	ADP	O	O	1065
increased	VERB	O	O	1065
lung cancer	NOUN	O	Disease	1065
risk	NOUN	O	O	1065
at	ADP	O	O	1065
high	ADJ	O	O	1065
levels	NOUN	O	O	1065
of	ADP	O	O	1065
metolachlor	NOUN	O	O	1065
use	VERB	O	O	1065
in	ADP	O	O	1065
this	PRON	O	O	1065
cohort	NOUN	O	O	1065
was	AUX	O	O	1065
not	PART	O	O	1065
confirmed	VERB	O	O	1065
in	ADP	O	O	1065
this	PRON	O	O	1065
update	VERB	O	O	1065
.	PUNCT	O	O	1065
This	PRON	O	O	1066
suggestion	NOUN	O	O	1066
of	ADP	O	O	1066
an	PRON	O	O	1066
association	PROPN	O	O	1066
between	ADP	O	O	1066
metolachlor	NOUN	O	O	1066
and	CCONJ	O	O	1066
liver	NOUN	O	O	1066
cancer	NOUN	O	Disease	1066
among	ADP	O	O	1066
pesticide	NOUN	O	O	1066
applicators	NOUN	O	O	1066
is	AUX	O	O	1066
a	PRON	O	O	1066
novel	NOUN	O	O	1066
finding	VERB	O	O	1066
and	CCONJ	O	O	1066
echoes	VERB	O	O	1066
observation	NOUN	O	O	1066
of	ADP	O	O	1066
increased	VERB	O	O	1066
liver	NOUN	O	O	1066
neoplasms	NOUN	O	O	1066
in	ADP	O	O	1066
some	PRON	O	O	1066
animal	NOUN	O	O	1066
studies	NOUN	O	O	1066
.	PUNCT	O	O	1066
However	ADV	O	O	1067
,	PUNCT	O	O	1067
our	PRON	O	O	1067
findings	NOUN	O	O	1067
for	ADP	O	O	1067
both	PRON	O	O	1067
liver	NOUN	O	O	1067
cancer	NOUN	O	Disease	1067
and	CCONJ	O	O	1067
follicular	ADJ	O	O	1067
cell	NOUN	O	O	1067
lymphoma	PROPN	O	Disease	1067
warrant	NOUN	O	O	1067
follow	VERB	O	O	1067
-	PUNCT	O	O	1067
up	ADP	O	O	1067
to	PART	O	O	1067
better	ADV	O	O	1067
differentiate	VERB	O	O	1067
effects	NOUN	O	O	1067
of	ADP	O	O	1067
metolachlor	NOUN	O	O	1067
use	VERB	O	O	1067
from	ADP	O	O	1067
other	ADJ	O	O	1067
factors	NOUN	O	O	1067
.	PUNCT	O	O	1067
Mechanisms	NOUN	O	O	1070
Underlying	VERB	O	O	1070
Latent	NOUN	O	O	1070
Disease	NOUN	O	O	1070
Risk	NOUN	O	O	1070
Associated	NOUN	O	O	1070
with	ADP	O	O	1070
Early	ADJ	O	O	1070
-	PUNCT	O	O	1070
Life	NOUN	O	O	1070
Arsenic	NOUN	O	O	1070
Millions	NOUN	O	O	1071
of	ADP	O	O	1071
individuals	NOUN	O	O	1071
worldwide	ADV	O	O	1071
,	PUNCT	O	O	1071
particularly	ADV	O	O	1071
those	PRON	O	O	1071
living	VERB	O	O	1071
in	ADP	O	O	1071
rural	ADJ	O	O	1071
and	CCONJ	O	O	1071
developing	VERB	O	O	1071
areas	NOUN	O	O	1071
,	PUNCT	O	O	1071
are	AUX	O	O	1071
exposed	VERB	O	O	1071
to	PART	O	O	1071
harmful	ADJ	O	O	1071
levels	NOUN	O	O	1071
of	ADP	O	O	1071
inorganic	ADJ	O	O	1071
arsenic	NOUN	O	O	1071
(	PUNCT	O	O	1071
iAs	ADJ	O	O	1071
)	PUNCT	O	O	1071
in	ADP	O	O	1071
their	PRON	O	O	1071
drinking	VERB	O	O	1071
water	PROPN	O	O	1071
.	PUNCT	O	O	1071
Inorganic	PROPN	O	O	1072
As	ADP	O	O	1072
exposure	NOUN	O	O	1072
during	ADP	O	O	1072
key	NOUN	O	O	1072
developmental	ADJ	O	O	1072
periods	NOUN	O	O	1072
is	AUX	O	O	1072
associated	VERB	O	O	1072
with	ADP	O	O	1072
a	PRON	O	O	1072
variety	NOUN	O	O	1072
of	ADP	O	O	1072
adverse	ADJ	O	O	1072
health	NOUN	O	O	1072
effects	NOUN	O	O	1072
including	VERB	O	O	1072
those	PRON	O	O	1072
that	SCONJ	O	O	1072
are	AUX	O	O	1072
evident	ADJ	O	O	1072
in	ADP	O	O	1072
adulthood	NOUN	O	O	1072
.	PUNCT	O	O	1072
There	ADV	O	O	1073
is	AUX	O	O	1073
considerable	ADJ	O	O	1073
interest	NOUN	O	O	1073
in	ADP	O	O	1073
identifying	VERB	O	O	1073
the	PRON	O	O	1073
molecular	ADJ	O	O	1073
mechanisms	NOUN	O	O	1073
that	SCONJ	O	O	1073
relate	VERB	O	O	1073
early	ADV	O	O	1073
-	PUNCT	O	O	1073
life	NOUN	O	O	1073
iAs	ADJ	O	O	1073
exposure	NOUN	O	O	1073
to	PART	O	O	1073
the	PRON	O	O	1073
development	NOUN	O	O	1073
of	ADP	O	O	1073
these	PRON	O	O	1073
latent	ADJ	O	O	1073
diseases	NOUN	O	O	1073
,	PUNCT	O	O	1073
particularly	ADV	O	O	1073
in	ADP	O	O	1073
relationship	NOUN	O	O	1073
to	PART	O	O	1073
cancer	NOUN	O	Disease	1073
.	PUNCT	O	O	1073
This	PRON	O	O	1074
work	NOUN	O	O	1074
summarizes	VERB	O	O	1074
research	NOUN	O	O	1074
on	ADP	O	O	1074
the	PRON	O	O	1074
molecular	ADJ	O	O	1074
mechanisms	NOUN	O	O	1074
that	SCONJ	O	O	1074
underlie	VERB	O	O	1074
the	PRON	O	O	1074
increased	VERB	O	O	1074
risk	NOUN	O	O	1074
of	ADP	O	O	1074
cancer	NOUN	O	Disease	1074
development	NOUN	O	O	1074
in	ADP	O	O	1074
adulthood	NOUN	O	O	1074
that	SCONJ	O	O	1074
is	AUX	O	O	1074
associated	VERB	O	O	1074
with	ADP	O	O	1074
early	ADV	O	O	1074
-	PUNCT	O	O	1074
life	NOUN	O	O	1074
iAs	ADJ	O	O	1074
exposure	NOUN	O	O	1074
.	PUNCT	O	O	1074
DISCUSSION	NOUN	O	O	1075
:	PUNCT	O	O	1075
Epigenetic	PROPN	O	O	1075
reprogramming	NOUN	O	O	1075
that	SCONJ	O	O	1075
imparts	VERB	O	O	1075
functional	ADJ	O	O	1075
changes	VERB	O	O	1075
in	ADP	O	O	1075
gene	NOUN	O	O	1075
expression	NOUN	O	O	1075
,	PUNCT	O	O	1075
the	PRON	O	O	1075
development	NOUN	O	O	1075
of	ADP	O	O	1075
cancer	NOUN	O	Disease	1075
stem	VERB	O	O	1075
cells	NOUN	O	O	1075
,	PUNCT	O	O	1075
and	CCONJ	O	O	1075
immunomodulation	PROPN	O	O	1075
are	AUX	O	O	1075
plausible	ADJ	O	O	1075
underlying	VERB	O	O	1075
mechanisms	NOUN	O	O	1075
by	ADP	O	O	1075
which	PRON	O	O	1075
early	ADV	O	O	1075
-	PUNCT	O	O	1075
life	NOUN	O	O	1075
iAs	ADJ	O	O	1075
exposure	NOUN	O	O	1075
elicits	VERB	O	O	1075
latent	ADJ	O	O	1075
carcinogenic	ADJ	O	Disease	1075
effects	NOUN	O	O	1075
.	PUNCT	O	O	1075
Evidence	NOUN	O	O	1076
is	AUX	O	O	1076
mounting	VERB	O	O	1076
that	SCONJ	O	O	1076
relates	VERB	O	O	1076
early	ADV	O	O	1076
-	PUNCT	O	O	1076
life	NOUN	O	O	1076
iAs	ADJ	O	O	1076
exposure	NOUN	O	O	1076
and	CCONJ	O	O	1076
cancer	NOUN	O	Disease	1076
development	NOUN	O	O	1076
later	ADV	O	O	1076
in	ADP	O	O	1076
life	NOUN	O	O	1076
.	PUNCT	O	O	1076
On	ADP	O	O	1079
the	PRON	O	O	1079
antiarrhythmic	PROPN	O	O	1079
activity	NOUN	O	O	1079
of	ADP	O	O	1079
one	NUM	O	O	1079
N	NUM	O	O	1079
-	PUNCT	O	O	1079
substituted	VERB	O	O	1079
piperazine	NOUN	O	O	1079
derivative	ADJ	O	O	1079
of	ADP	O	O	1079
trans-2-amino-3-hydroxy-1	NUM	O	O	1079
,	PUNCT	O	O	1079
2	X	O	O	1079
,	PUNCT	O	O	1079
3	X	O	O	1079
,	PUNCT	O	O	1079
4-tetrahydroanaphthalene	NOUN	O	O	1079
.	PUNCT	O	O	1079
The	PRON	O	O	1080
antiarrhythmic	PROPN	O	O	1080
activity	NOUN	O	O	1080
of	ADP	O	O	1080
the	PRON	O	O	1080
compound	NOUN	O	O	1080
N-(trans-3-hydroxy-1,2,3,4-tetrahydro-2-naphthyl)-N-(3-oxo-3-phenyl-2-methylpropyl)-piperazine	NOUN	O	O	1080
hydrochloride	NOUN	O	O	1080
,	PUNCT	O	O	1080
referred	VERB	O	O	1080
to	PART	O	O	1080
as	ADP	O	O	1080
P11	NOUN	O	O	1080
,	PUNCT	O	O	1080
is	AUX	O	O	1080
studied	VERB	O	O	1080
on	ADP	O	O	1080
anaesthesized	VERB	O	O	1080
cats	NOUN	O	O	1080
and	CCONJ	O	O	1080
Wistar	PROPN	O	O	1080
albino	PROPN	O	O	1080
rats	NOUN	O	O	1080
,	PUNCT	O	O	1080
as	ADP	O	O	1080
well	ADV	O	O	1080
as	ADP	O	O	1080
on	ADP	O	O	1080
non	ADJ	O	O	1080
-	PUNCT	O	O	1080
anaesthesized	VERB	O	O	1080
rabbits	NOUN	O	O	1080
.	PUNCT	O	O	1080
Four	NUM	O	O	1081
types	NOUN	O	O	1081
of	ADP	O	O	1081
experimental	ADJ	O	O	1081
arrhythmia	NOUN	O	Disease	1081
are	AUX	O	O	1081
used	VERB	O	O	1081
--	PUNCT	O	O	1081
with	ADP	O	O	1081
BaCl2	VERB	O	O	1081
,	PUNCT	O	O	1081
with	ADP	O	O	1081
chloroform	NOUN	O	Chemical	1081
-	PUNCT	O	O	1081
adrenaline	NOUN	O	Chemical	1081
,	PUNCT	O	O	1081
with	ADP	O	O	1081
strophantine	PROPN	O	O	1081
G	NOUN	O	O	1081
and	CCONJ	O	O	1081
with	ADP	O	O	1081
aconitine	PROPN	O	Chemical	1081
.	PUNCT	O	O	1081
The	PRON	O	O	1082
compound	NOUN	O	O	1082
P11	NOUN	O	O	1082
is	AUX	O	O	1082
introduced	VERB	O	O	1082
in	ADP	O	O	1082
doses	NOUN	O	O	1082
of	ADP	O	O	1082
0.25	NUM	O	O	1082
and	CCONJ	O	O	1082
0.50	NUM	O	O	1082
mg	VERB	O	O	1082
/	PUNCT	O	O	1082
kg	VERB	O	O	1082
intravenously	ADV	O	O	1082
and	CCONJ	O	O	1082
10	NUM	O	O	1082
mg	VERB	O	O	1082
/	PUNCT	O	O	1082
kg	VERB	O	O	1082
orally	ADV	O	O	1082
.	PUNCT	O	O	1082
The	PRON	O	O	1083
compound	NOUN	O	O	1083
manifests	VERB	O	O	1083
antiarrhythmic	PROPN	O	O	1083
activity	NOUN	O	O	1083
in	ADP	O	O	1083
all	PRON	O	O	1083
models	NOUN	O	O	1083
of	ADP	O	O	1083
experimental	ADJ	O	O	1083
arrhythmia	NOUN	O	Disease	1083
used	VERB	O	O	1083
,	PUNCT	O	O	1083
causing	VERB	O	O	1083
greatest	ADJ	O	O	1083
inhibition	NOUN	O	O	1083
on	ADP	O	O	1083
the	PRON	O	O	1083
arrhythmia	NOUN	O	Disease	1083
induced	VERB	O	O	1083
by	ADP	O	O	1083
chloroform	NOUN	O	Chemical	1083
-	PUNCT	O	O	1083
adrenaline	NOUN	O	Chemical	1083
(	PUNCT	O	O	1083
in	ADP	O	O	1083
90	NUM	O	O	1083
per	ADP	O	O	1083
cent	NOUN	O	O	1083
)	PUNCT	O	O	1083
and	CCONJ	O	O	1083
with	ADP	O	O	1083
BaCl2	VERB	O	O	1083
(	PUNCT	O	O	1083
in	ADP	O	O	1083
84	NUM	O	O	1083
per	ADP	O	O	1083
cent	NOUN	O	O	1083
)	PUNCT	O	O	1083
.	PUNCT	O	O	1083
Experimental	ADJ	O	O	1086
progressive	ADJ	O	O	1086
muscular dystrophy	NOUN	O	Disease	1086
and	CCONJ	O	O	1086
its	PRON	O	O	1086
treatment	NOUN	O	O	1086
with	ADP	O	O	1086
high	ADJ	O	O	1086
doses	NOUN	O	O	1086
anabolizing	VERB	O	O	1086
agents	NOUN	O	O	1086
.	PUNCT	O	O	1086
We	PRON	O	O	1087
are	AUX	O	O	1087
still	ADV	O	O	1087
a	PRON	O	O	1087
long	ADV	O	O	1087
way	NOUN	O	O	1087
from	ADP	O	O	1087
discovering	VERB	O	O	1087
an	PRON	O	O	1087
unequivocal	ADJ	O	O	1087
pathogenetic	NOUN	O	O	1087
interpretation	NOUN	O	O	1087
of	ADP	O	O	1087
progressive	ADJ	O	O	1087
muscular dystrophy	NOUN	O	Disease	1087
in	ADP	O	O	1087
man	NOUN	O	O	1087
.	PUNCT	O	O	1087
Myopathy	PROPN	O	Disease	1088
due	ADJ	O	O	1088
to	PART	O	O	1088
lack	VERB	O	O	1088
of	ADP	O	O	1088
vitamin E	NOUN	O	Chemical	1088
and	CCONJ	O	O	1088
myopathy	PROPN	O	Disease	1088
induced	VERB	O	O	1088
by	ADP	O	O	1088
certain	ADJ	O	O	1088
viruses	NOUN	O	O	1088
have	VERB	O	O	1088
much	ADJ	O	O	1088
in	ADP	O	O	1088
common	ADJ	O	O	1088
anatomically	ADV	O	O	1088
and	CCONJ	O	O	1088
pathologically	ADV	O	O	1088
with	ADP	O	O	1088
the	PRON	O	O	1088
human	PROPN	O	O	1088
form	NOUN	O	O	1088
.	PUNCT	O	O	1088
The	PRON	O	O	1089
authors	NOUN	O	O	1089
induced	VERB	O	O	1089
myodystrophy	NOUN	O	O	1089
in	ADP	O	O	1089
the	PRON	O	O	1089
rat	NOUN	O	O	1089
by	ADP	O	O	1089
giving	VERB	O	O	1089
it	PRON	O	O	1089
a	PRON	O	O	1089
diet	PROPN	O	O	1089
lacking	VERB	O	O	1089
in	ADP	O	O	1089
vitamin E.	PROPN	O	O	1089
The	PRON	O	O	1089
pharmacological	ADJ	O	O	1089
characteristics	NOUN	O	O	1089
of	ADP	O	O	1089
vitamin E	NOUN	O	Chemical	1089
and	CCONJ	O	O	1089
the	PRON	O	O	1089
degenerative	ADJ	O	O	1089
changes	VERB	O	O	1089
brought	VERB	O	O	1089
about	ADP	O	O	1089
by	ADP	O	O	1089
its	PRON	O	O	1089
deficiency	NOUN	O	O	1089
,	PUNCT	O	O	1089
especially	ADV	O	O	1089
in	ADP	O	O	1089
the	PRON	O	O	1089
muscles	NOUN	O	O	1089
,	PUNCT	O	O	1089
are	AUX	O	O	1089
illustrated	VERB	O	O	1089
.	PUNCT	O	O	1089
It	PRON	O	O	1090
is	AUX	O	O	1090
thus	ADV	O	O	1090
confirmed	VERB	O	O	1090
that	SCONJ	O	O	1090
the	PRON	O	O	1090
histological	ADJ	O	O	1090
characteristics	NOUN	O	O	1090
of	ADP	O	O	1090
myopathic	PROPN	O	O	1090
rat	NOUN	O	O	1090
muscle	NOUN	O	O	1090
induced	VERB	O	O	1090
experimentally	ADV	O	O	1090
are	AUX	O	O	1090
extraordinarily	ADV	O	O	1090
similar	ADJ	O	O	1090
to	PART	O	O	1090
those	PRON	O	O	1090
of	ADP	O	O	1090
human	PROPN	O	O	1090
myopathy	PROPN	O	Disease	1090
as	ADP	O	O	1090
confirmed	VERB	O	O	1090
during	ADP	O	O	1090
biopsies	NOUN	O	O	1090
performed	VERB	O	O	1090
at	ADP	O	O	1090
the	PRON	O	O	1090
Orthopaedic	ADJ	O	O	1090
Traumatological	PROPN	O	O	1090
Centre	NOUN	O	O	1090
,	PUNCT	O	O	1090
Florence	PROPN	O	O	1090
.	PUNCT	O	O	1090
The	PRON	O	O	1091
encouraging	VERB	O	O	1091
results	VERB	O	O	1091
obtained	VERB	O	O	1091
in	ADP	O	O	1091
various	ADJ	O	O	1091
authoratative	ADJ	O	O	1091
departments	NOUN	O	O	1091
in	ADP	O	O	1091
myopathic	PROPN	O	O	1091
patients	NOUN	O	O	1091
by	ADP	O	O	1091
using	VERB	O	O	1091
anabolizing	VERB	O	O	1091
steroids	NOUN	O	Chemical	1091
have	VERB	O	O	1091
encouraged	VERB	O	O	1091
the	PRON	O	O	1091
authors	NOUN	O	O	1091
to	PART	O	O	1091
investigate	VERB	O	O	1091
the	PRON	O	O	1091
beneficial	ADJ	O	O	1091
effects	NOUN	O	O	1091
of	ADP	O	O	1091
one	NUM	O	O	1091
anabolizing	VERB	O	O	1091
agent	NOUN	O	O	1091
(	PUNCT	O	O	1091
Dianabol	PROPN	O	O	1091
,	PUNCT	O	O	1091
CIBA	PROPN	O	O	1091
)	PUNCT	O	O	1091
at	ADP	O	O	1091
high	ADJ	O	O	1091
doses	NOUN	O	O	1091
in	ADP	O	O	1091
rats	NOUN	O	O	1091
rendered	VERB	O	O	1091
myopathic	PROPN	O	O	1091
by	ADP	O	O	1091
a	PRON	O	O	1091
diet	PROPN	O	O	1091
deficient	ADJ	O	O	1091
in	ADP	O	O	1091
vitamin E.	PROPN	O	O	1091
In	ADP	O	O	1092
this	PRON	O	O	1092
way	NOUN	O	O	1092
they	PRON	O	O	1092
obtained	VERB	O	O	1092
appreciable	ADJ	O	O	1092
changes	VERB	O	O	1092
in	ADP	O	O	1092
body	NOUN	O	O	1092
weight	NOUN	O	O	1092
(	PUNCT	O	O	1092
increased	VERB	O	O	1092
from	ADP	O	O	1092
50	NUM	O	O	1092
to	PART	O	O	1092
70	NUM	O	O	1092
g	X	O	O	1092
after	ADP	O	O	1092
forty	NUM	O	O	1092
days	NOUN	O	O	1092
at	ADP	O	O	1092
a	PRON	O	O	1092
dose	NOUN	O	O	1092
of	ADP	O	O	1092
5	NUM	O	O	1092
mg	VERB	O	O	1092
per	ADP	O	O	1092
day	NOUN	O	O	1092
of	ADP	O	O	1092
anabolizing	VERB	O	O	1092
agent	NOUN	O	O	1092
)	PUNCT	O	O	1092
,	PUNCT	O	O	1092
but	CCONJ	O	O	1092
most	ADV	O	O	1092
of	ADP	O	O	1092
all	PRON	O	O	1092
they	PRON	O	O	1092
found	VERB	O	O	1092
histological	ADJ	O	O	1092
changes	VERB	O	O	1092
due	ADJ	O	O	1092
to	PART	O	O	1092
""""	PUNCT	O	O	1092
regenerative	ADJ	O	O	1092
""""	PUNCT	O	O	1092
changes	VERB	O	O	1092
in	ADP	O	O	1092
the	PRON	O	O	1092
muscle	NOUN	O	O	1092
tissue	NOUN	O	O	1092
,	PUNCT	O	O	1092
which	PRON	O	O	1092
however	ADV	O	O	1092
maintained	VERB	O	O	1092
its	PRON	O	O	1092
myopathic	PROPN	O	O	1092
characteristics	NOUN	O	O	1092
in	ADP	O	O	1092
the	PRON	O	O	1092
control	VERB	O	O	1092
animals	NOUN	O	O	1092
that	SCONJ	O	O	1092
were	AUX	O	O	1092
not	PART	O	O	1092
treated	VERB	O	O	1092
with	ADP	O	O	1092
the	PRON	O	O	1092
anabolizing	VERB	O	O	1092
agent	NOUN	O	O	1092
.	PUNCT	O	O	1092
The	PRON	O	O	1093
authors	NOUN	O	O	1093
conclude	VERB	O	O	1093
by	ADP	O	O	1093
affirming	VERB	O	O	1093
the	PRON	O	O	1093
undoubted	ADJ	O	O	1093
efficacy	NOUN	O	O	1093
of	ADP	O	O	1093
the	PRON	O	O	1093
anabolizing	VERB	O	O	1093
steroids	NOUN	O	Chemical	1093
in	ADP	O	O	1093
experimental	ADJ	O	O	1093
myopathic	PROPN	O	O	1093
disease	PROPN	O	O	1093
,	PUNCT	O	O	1093
but	CCONJ	O	O	1093
they	PRON	O	O	1093
have	VERB	O	O	1093
reservations	NOUN	O	O	1093
as	ADP	O	O	1093
to	PART	O	O	1093
the	PRON	O	O	1093
transfer	NOUN	O	O	1093
of	ADP	O	O	1093
the	PRON	O	O	1093
results	VERB	O	O	1093
into	ADP	O	O	1093
the	PRON	O	O	1093
human	PROPN	O	O	1093
field	NOUN	O	O	1093
,	PUNCT	O	O	1093
where	SCONJ	O	O	1093
high	ADJ	O	O	1093
dosage	NOUN	O	O	1093
can	AUX	O	O	1093
not	PART	O	O	1093
be	AUX	O	O	1093
carried	VERB	O	O	1093
out	ADP	O	O	1093
continuously	ADV	O	O	1093
because	SCONJ	O	O	1093
of	ADP	O	O	1093
the	PRON	O	O	1093
effects	NOUN	O	O	1093
of	ADP	O	O	1093
the	PRON	O	O	1093
drug	NOUN	O	O	1093
on	ADP	O	O	1093
virility	NOUN	O	O	1093
;	PUNCT	O	O	1093
because	SCONJ	O	O	1093
the	PRON	O	O	1093
tissue	NOUN	O	O	1093
injury	NOUN	O	O	1093
too	ADV	O	O	1093
often	ADV	O	O	1093
occurs	VERB	O	O	1093
at	ADP	O	O	1093
an	PRON	O	O	1093
irreversible	ADJ	O	O	1093
stage	NOUN	O	O	1093
vis	X	O	O	1093
-	PUNCT	O	O	1093
a	PRON	O	O	1093
-	PUNCT	O	O	1093
vis	X	O	O	1093
the	PRON	O	O	1093
""""	PUNCT	O	O	1093
regeneration	NOUN	O	O	1093
""""	PUNCT	O	O	1093
of	ADP	O	O	1093
the	PRON	O	O	1093
muscle	NOUN	O	O	1093
tissue	NOUN	O	O	1093
;	PUNCT	O	O	1093
and	CCONJ	O	O	1093
finally	ADV	O	O	1093
because	SCONJ	O	O	1093
the	PRON	O	O	1093
dystrophic	ADJ	O	O	1093
injurious	ADJ	O	O	1093
agent	NOUN	O	O	1093
is	AUX	O	O	1093
certainly	ADV	O	O	1093
not	PART	O	O	1093
the	PRON	O	O	1093
lack	VERB	O	O	1093
of	ADP	O	O	1093
vitamin E	NOUN	O	Chemical	1093
but	CCONJ	O	O	1093
something	PRON	O	O	1093
as	ADP	O	O	1093
yet	ADV	O	O	1093
unknown	ADJ	O	O	1093
.	PUNCT	O	O	1093
Fetal	ADJ	O	O	1096
risks	NOUN	O	O	1096
due	ADJ	O	O	1096
to	PART	O	O	1096
warfarin	VERB	O	Chemical	1096
therapy	NOUN	O	O	1096
during	ADP	O	O	1096
pregnancy	NOUN	O	O	1096
.	PUNCT	O	O	1096
Two	NUM	O	O	1097
mothers	NOUN	O	O	1097
with	ADP	O	O	1097
heart	NOUN	O	O	1097
valve	PROPN	O	O	1097
prosthesis	NOUN	O	O	1097
were	AUX	O	O	1097
treated	VERB	O	O	1097
with	ADP	O	O	1097
warfarin	VERB	O	Chemical	1097
during	ADP	O	O	1097
pregnancy	NOUN	O	O	1097
.	PUNCT	O	O	1097
In	ADP	O	O	1098
the	PRON	O	O	1098
first	ADV	O	O	1098
case	NOUN	O	O	1098
a	PRON	O	O	1098
caesarean	PROPN	O	O	1098
section	NOUN	O	O	1098
was	AUX	O	O	1098
done	VERB	O	O	1098
one	NUM	O	O	1098
week	NOUN	O	O	1098
after	ADP	O	O	1098
replacement	NOUN	O	O	1098
of	ADP	O	O	1098
warfarin	VERB	O	Chemical	1098
with	ADP	O	O	1098
heparin	NOUN	O	Chemical	1098
.	PUNCT	O	O	1098
The	PRON	O	O	1099
baby	NOUN	O	O	1099
died	VERB	O	O	1099
of	ADP	O	O	1099
cerebral	ADJ	O	O	1099
and	CCONJ	O	O	1099
pulmonary	ADJ	O	O	1099
hemorrhage	NOUN	O	Disease	1099
.	PUNCT	O	O	1099
The	PRON	O	O	1100
baby	NOUN	O	O	1100
showed	VERB	O	O	1100
warfarin	VERB	O	Chemical	1100
-	PUNCT	O	O	1100
induced	VERB	O	O	1100
embryopathy	PROPN	O	O	1100
with	ADP	O	O	1100
nasal	ADJ	O	O	1100
hypoplasia	NOUN	O	O	1100
and	CCONJ	O	O	1100
stippled	VERB	O	O	1100
epiphyses	NOUN	O	O	1100
(	PUNCT	O	O	1100
chondrodysplasia	NOUN	O	O	1100
punctata	PROPN	O	O	1100
)	PUNCT	O	O	1100
.	PUNCT	O	O	1100
Nasal	NOUN	O	O	1101
hypoplasia	NOUN	O	O	1101
with	ADP	O	O	1101
or	CCONJ	O	O	1101
without	ADP	O	O	1101
stippled	VERB	O	O	1101
epiphyses	NOUN	O	O	1101
has	VERB	O	O	1101
now	ADV	O	O	1101
been	AUX	O	O	1101
reported	VERB	O	O	1101
in	ADP	O	O	1101
11	NUM	O	O	1101
infants	NOUN	O	O	1101
born	VERB	O	O	1101
to	PART	O	O	1101
mothers	NOUN	O	O	1101
treated	VERB	O	O	1101
with	ADP	O	O	1101
warfarin	VERB	O	Chemical	1101
during	ADP	O	O	1101
the	PRON	O	O	1101
first	ADV	O	O	1101
trimester	VERB	O	O	1101
,	PUNCT	O	O	1101
and	CCONJ	O	O	1101
a	PRON	O	O	1101
causal	NOUN	O	O	1101
association	PROPN	O	O	1101
is	AUX	O	O	1101
probable	ADJ	O	O	1101
.	PUNCT	O	O	1101
Isradipine	NOUN	O	O	1104
treatment	NOUN	O	O	1104
for	ADP	O	O	1104
hypertension	NOUN	O	Disease	1104
in	ADP	O	O	1104
general	ADJ	O	O	1104
practice	VERB	O	O	1104
in	ADP	O	O	1104
Hong	PROPN	O	O	1104
Kong	PROPN	O	O	1104
.	PUNCT	O	O	1104
A	PRON	O	O	1105
6-week	NOUN	O	O	1105
open	VERB	O	O	1105
study	VERB	O	O	1105
of	ADP	O	O	1105
the	PRON	O	O	1105
introduction	NOUN	O	O	1105
of	ADP	O	O	1105
isradipine	NOUN	O	O	1105
treatment	NOUN	O	O	1105
was	AUX	O	O	1105
conducted	VERB	O	O	1105
in	ADP	O	O	1105
general	ADJ	O	O	1105
practice	VERB	O	O	1105
in	ADP	O	O	1105
Hong	PROPN	O	O	1105
Kong	PROPN	O	O	1105
.	PUNCT	O	O	1105
303	NUM	O	O	1106
Chinese	PROPN	O	O	1106
patients	NOUN	O	O	1106
with	ADP	O	O	1106
mild	ADJ	O	O	1106
to	PART	O	O	1106
moderate	ADJ	O	O	1106
hypertension	NOUN	O	Disease	1106
entered	VERB	O	O	1106
the	PRON	O	O	1106
study	VERB	O	O	1106
.	PUNCT	O	O	1106
The	PRON	O	O	1107
main	ADJ	O	O	1107
side	NOUN	O	O	1107
-	PUNCT	O	O	1107
effects	NOUN	O	O	1107
were	AUX	O	O	1107
headache	PROPN	O	Disease	1107
,	PUNCT	O	O	1107
dizziness	NOUN	O	Disease	1107
,	PUNCT	O	O	1107
palpitation	NOUN	O	O	1107
and	CCONJ	O	O	1107
flushing	VERB	O	Disease	1107
and	CCONJ	O	O	1107
these	PRON	O	O	1107
were	AUX	O	O	1107
not	PART	O	O	1107
more	ADJ	O	O	1107
frequent	ADJ	O	O	1107
than	ADP	O	O	1107
reported	VERB	O	O	1107
in	ADP	O	O	1107
other	ADJ	O	O	1107
studies	NOUN	O	O	1107
with	ADP	O	O	1107
isradipine	NOUN	O	O	1107
or	CCONJ	O	O	1107
with	ADP	O	O	1107
placebo	NOUN	O	O	1107
.	PUNCT	O	O	1107
Similar	ADJ	O	O	1108
reductions	NOUN	O	O	1108
occurred	VERB	O	O	1108
in	ADP	O	O	1108
standing	VERB	O	O	1108
blood	NOUN	O	O	1108
pressure	NOUN	O	O	1108
and	CCONJ	O	O	1108
there	ADV	O	O	1108
was	AUX	O	O	1108
no	PRON	O	O	1108
evidence	NOUN	O	O	1108
of	ADP	O	O	1108
postural	ADJ	O	O	1108
hypotension	NOUN	O	Disease	1108
.	PUNCT	O	O	1108
Tachyphylaxis	ADJ	O	O	1111
to	PART	O	O	1111
systemic	ADJ	O	O	1111
but	CCONJ	O	O	1111
not	PART	O	O	1111
to	PART	O	O	1111
airway	NOUN	O	O	1111
responses	NOUN	O	O	1111
during	ADP	O	O	1111
prolonged	VERB	O	O	1111
therapy	NOUN	O	O	1111
with	ADP	O	O	1111
high	ADJ	O	O	1111
dose	NOUN	O	O	1111
inhaled	VERB	O	O	1111
salbutamol	NOUN	O	Chemical	1111
in	ADP	O	O	1111
asthmatics	NOUN	O	O	1111
.	PUNCT	O	O	1111
High	ADJ	O	O	1112
doses	NOUN	O	O	1112
of	ADP	O	O	1112
inhaled	VERB	O	O	1112
salbutamol	NOUN	O	Chemical	1112
produce	VERB	O	O	1112
substantial	ADJ	O	O	1112
improvements	NOUN	O	O	1112
in	ADP	O	O	1112
airway	NOUN	O	O	1112
response	NOUN	O	O	1112
in	ADP	O	O	1112
patients	NOUN	O	O	1112
with	ADP	O	O	1112
asthma	PROPN	O	Disease	1112
,	PUNCT	O	O	1112
and	CCONJ	O	O	1112
are	AUX	O	O	1112
associated	VERB	O	O	1112
with	ADP	O	O	1112
dose	NOUN	O	O	1112
-	PUNCT	O	O	1112
dependent	ADJ	O	O	1112
systemic	ADJ	O	O	1112
beta	NOUN	O	O	1112
-	PUNCT	O	O	1112
adrenoceptor	NOUN	O	O	1112
responses	NOUN	O	O	1112
.	PUNCT	O	O	1112
The	PRON	O	O	1113
purpose	NOUN	O	O	1113
of	ADP	O	O	1113
the	PRON	O	O	1113
present	NOUN	O	O	1113
study	VERB	O	O	1113
was	AUX	O	O	1113
to	PART	O	O	1113
investigate	VERB	O	O	1113
whether	SCONJ	O	O	1113
tachyphylaxis	ADJ	O	O	1113
occurs	VERB	O	O	1113
during	ADP	O	O	1113
prolonged	VERB	O	O	1113
treatment	NOUN	O	O	1113
with	ADP	O	O	1113
high	ADJ	O	O	1113
dose	NOUN	O	O	1113
inhaled	VERB	O	O	1113
salbutamol	NOUN	O	Chemical	1113
.	PUNCT	O	O	1113
Twelve	NUM	O	O	1114
asthmatic	ADJ	O	O	1114
patients	NOUN	O	O	1114
(	PUNCT	O	O	1114
FEV1	PROPN	O	O	1114
,	PUNCT	O	O	1114
81	NUM	O	O	1114
were	AUX	O	O	1115
given	VERB	O	O	1115
a	PRON	O	O	1115
14-day	NOUN	O	O	1115
treatment	NOUN	O	O	1115
with	ADP	O	O	1115
high	ADJ	O	O	1115
dose	NOUN	O	O	1115
inhaled	VERB	O	O	1115
salbutamol	NOUN	O	Chemical	1115
(	PUNCT	O	O	1115
HDS	PROPN	O	O	1115
)	PUNCT	O	O	1115
,	PUNCT	O	O	1115
4,000	NUM	O	O	1115
micrograms	NOUN	O	O	1115
daily	ADV	O	O	1115
,	PUNCT	O	O	1115
low	ADJ	O	O	1115
dose	NOUN	O	O	1115
inhaled	VERB	O	O	1115
salbutamol	NOUN	O	Chemical	1115
(	PUNCT	O	O	1115
LDS	PROPN	O	O	1115
)	PUNCT	O	O	1115
,	PUNCT	O	O	1115
800	NUM	O	O	1115
micrograms	NOUN	O	O	1115
daily	ADV	O	O	1115
,	PUNCT	O	O	1115
or	CCONJ	O	O	1115
placebo	NOUN	O	O	1115
(	PUNCT	O	O	1115
PI	NOUN	O	O	1115
)	PUNCT	O	O	1115
by	ADP	O	O	1115
metered	VERB	O	O	1115
-	PUNCT	O	O	1115
dose	NOUN	O	O	1115
inhaler	NOUN	O	O	1115
in	ADP	O	O	1115
a	PRON	O	O	1115
double	ADJ	O	O	1115
-	PUNCT	O	O	1115
blind	ADJ	O	Disease	1115
,	PUNCT	O	O	1115
randomized	VERB	O	O	1115
crossover	NOUN	O	O	1115
design	NOUN	O	O	1115
.	PUNCT	O	O	1115
During	ADP	O	O	1116
the	PRON	O	O	1116
14-day	NOUN	O	O	1116
run	VERB	O	O	1116
-	PUNCT	O	O	1116
in	ADP	O	O	1116
and	CCONJ	O	O	1116
during	ADP	O	O	1116
washout	NOUN	O	O	1116
periods	NOUN	O	O	1116
,	PUNCT	O	O	1116
inhaled	VERB	O	O	1116
beta	NOUN	O	O	1116
-	PUNCT	O	O	1116
agonists	NOUN	O	O	1116
were	AUX	O	O	1116
withheld	VERB	O	O	1116
and	CCONJ	O	O	1116
ipratropium	PROPN	O	O	1116
bromide	NOUN	O	O	1116
was	AUX	O	O	1116
substituted	VERB	O	O	1116
for	ADP	O	O	1116
rescue	NOUN	O	O	1116
purposes	NOUN	O	O	1116
.	PUNCT	O	O	1116
chronotropic	NOUN	O	O	1117
(	PUNCT	O	O	1117
HR	NOUN	O	O	1117
)	PUNCT	O	O	1117
,	PUNCT	O	O	1117
tremor	NOUN	O	Disease	1117
,	PUNCT	O	O	1117
and	CCONJ	O	O	1117
metabolic	ADJ	O	O	1117
(	PUNCT	O	O	1117
K	PROPN	O	Chemical	1117
,	PUNCT	O	O	1117
Glu	PROPN	O	O	1117
)	PUNCT	O	O	1117
responses	NOUN	O	O	1117
were	AUX	O	O	1117
measured	VERB	O	O	1117
at	ADP	O	O	1117
each	PRON	O	O	1117
step	VERB	O	O	1117
(	PUNCT	O	O	1117
from	ADP	O	O	1117
100	NUM	O	O	1117
to	PART	O	O	1117
4,000	NUM	O	O	1117
micrograms	NOUN	O	O	1117
)	PUNCT	O	O	1117
.	PUNCT	O	O	1117
DRC	PROPN	O	O	1118
for	ADP	O	O	1118
HR	NOUN	O	O	1118
(	PUNCT	O	O	1118
p	NOUN	O	O	1118
less	ADV	O	O	1118
than	ADP	O	O	1118
0.001	NUM	O	O	1118
)	PUNCT	O	O	1118
,	PUNCT	O	O	1118
K	PROPN	O	Chemical	1118
(	PUNCT	O	O	1118
p	NOUN	O	O	1118
less	ADV	O	O	1118
than	ADP	O	O	1118
0.001	NUM	O	O	1118
)	PUNCT	O	O	1118
,	PUNCT	O	O	1118
and	CCONJ	O	O	1118
Glu	PROPN	O	O	1118
(	PUNCT	O	O	1118
p	NOUN	O	O	1118
less	ADV	O	O	1118
than	ADP	O	O	1118
0.005	NUM	O	O	1118
)	PUNCT	O	O	1118
were	AUX	O	O	1118
attenuated	VERB	O	O	1118
after	ADP	O	O	1118
treatment	NOUN	O	O	1118
with	ADP	O	O	1118
HDS	PROPN	O	O	1118
compared	VERB	O	O	1118
with	ADP	O	O	1118
PI	NOUN	O	O	1118
.	PUNCT	O	O	1118
There	ADV	O	O	1119
were	AUX	O	O	1119
also	ADV	O	O	1119
differences	NOUN	O	O	1119
between	ADP	O	O	1119
HDS	PROPN	O	O	1119
and	CCONJ	O	O	1119
LDS	PROPN	O	O	1119
for	ADP	O	O	1119
HR	NOUN	O	O	1119
(	PUNCT	O	O	1119
p	NOUN	O	O	1119
less	ADV	O	O	1119
than	ADP	O	O	1119
0.001	NUM	O	O	1119
)	PUNCT	O	O	1119
and	CCONJ	O	O	1119
Glu	PROPN	O	O	1119
(	PUNCT	O	O	1119
p	NOUN	O	O	1119
less	ADV	O	O	1119
than	ADP	O	O	1119
0.05	NUM	O	O	1119
)	PUNCT	O	O	1119
responses	NOUN	O	O	1119
.	PUNCT	O	O	1119
Frequency	NOUN	O	O	1120
and	CCONJ	O	O	1120
severity	NOUN	O	O	1120
of	ADP	O	O	1120
subjective	ADJ	O	O	1120
adverse	ADJ	O	O	1120
effects	NOUN	O	O	1120
were	AUX	O	O	1120
also	ADV	O	O	1120
reduced	VERB	O	O	1120
after	ADP	O	O	1120
HDS	PROPN	O	O	1120
:	PUNCT	O	O	1120
tremor	NOUN	O	Disease	1120
(	PUNCT	O	O	1120
p	NOUN	O	O	1120
less	ADV	O	O	1120
than	ADP	O	O	1120
0.001	NUM	O	O	1120
)	PUNCT	O	O	1120
,	PUNCT	O	O	1120
palpitations	NOUN	O	O	1120
(	PUNCT	O	O	1120
p	NOUN	O	O	1120
less	ADV	O	O	1120
than	ADP	O	O	1120
0.001).(ABSTRACT	X	O	O	1120
TRUNCATED	ADJ	O	O	1120
AT	ADP	O	O	1120
250	NUM	O	O	1120
WORDS	NOUN	O	O	1120
)	PUNCT	O	O	1120
Increased	VERB	O	O	1123
anxiogenic	ADJ	O	O	1123
effects	NOUN	O	O	1123
of	ADP	O	O	1123
caffeine	NOUN	O	Chemical	1123
in	ADP	O	O	1123
panic	VERB	O	O	1123
disorders	NOUN	O	O	1123
.	PUNCT	O	O	1123
The	PRON	O	O	1124
effects	NOUN	O	O	1124
of	ADP	O	O	1124
oral	ADJ	O	O	1124
administration	NOUN	O	O	1124
of	ADP	O	O	1124
caffeine	NOUN	O	Chemical	1124
(	PUNCT	O	O	1124
10	NUM	O	O	1124
mg	VERB	O	O	1124
/	PUNCT	O	O	1124
kg	VERB	O	O	1124
)	PUNCT	O	O	1124
on	ADP	O	O	1124
behavioral	ADJ	O	O	1124
ratings	NOUN	O	O	1124
,	PUNCT	O	O	1124
somatic	ADJ	O	O	1124
symptoms	NOUN	O	O	1124
,	PUNCT	O	O	1124
blood	NOUN	O	O	1124
pressure	NOUN	O	O	1124
and	CCONJ	O	O	1124
plasma	NOUN	O	O	1124
levels	NOUN	O	O	1124
of	ADP	O	O	1124
3-methoxy-4-hydroxyphenethyleneglycol	NOUN	O	O	1124
(	PUNCT	O	O	1124
MHPG	VERB	O	O	1124
)	PUNCT	O	O	1124
and	CCONJ	O	O	1124
cortisol	NOUN	O	O	1124
were	AUX	O	O	1124
determined	VERB	O	O	1124
in	ADP	O	O	1124
17	NUM	O	O	1124
healthy	ADJ	O	O	1124
subjects	NOUN	O	O	1124
and	CCONJ	O	O	1124
21	NUM	O	O	1124
patients	NOUN	O	O	1124
meeting	NOUN	O	O	1124
DSM	PROPN	O	O	1124
-	PUNCT	O	O	1124
III	NUM	O	O	1124
criteria	NOUN	O	O	1124
for	ADP	O	O	1124
agoraphobia	VERB	O	O	1124
with	ADP	O	O	1124
panic	VERB	O	O	1124
attacks	NOUN	O	O	1124
or	CCONJ	O	O	1124
panic	VERB	O	O	1124
disorder	NOUN	O	O	1124
.	PUNCT	O	O	1124
Caffeine	NOUN	O	Chemical	1125
produced	VERB	O	O	1125
significantly	ADV	O	O	1125
greater	ADJ	O	O	1125
increases	VERB	O	O	1125
in	ADP	O	O	1125
subject	ADJ	O	O	1125
-	PUNCT	O	O	1125
rated	VERB	O	O	1125
anxiety	NOUN	O	Disease	1125
,	PUNCT	O	O	1125
nervousness	NOUN	O	O	1125
,	PUNCT	O	O	1125
fear	VERB	O	O	1125
,	PUNCT	O	O	1125
nausea	NOUN	O	Disease	1125
,	PUNCT	O	O	1125
palpitations	NOUN	O	O	1125
,	PUNCT	O	O	1125
restlessness	NOUN	O	Disease	1125
,	PUNCT	O	O	1125
and	CCONJ	O	O	1125
tremors	NOUN	O	Disease	1125
in	ADP	O	O	1125
the	PRON	O	O	1125
patients	NOUN	O	O	1125
compared	VERB	O	O	1125
with	ADP	O	O	1125
healthy	ADJ	O	O	1125
subjects	NOUN	O	O	1125
.	PUNCT	O	O	1125
In	ADP	O	O	1126
the	PRON	O	O	1126
patients	NOUN	O	O	1126
,	PUNCT	O	O	1126
but	CCONJ	O	O	1126
not	PART	O	O	1126
the	PRON	O	O	1126
healthy	ADJ	O	O	1126
subjects	NOUN	O	O	1126
,	PUNCT	O	O	1126
these	PRON	O	O	1126
symptoms	NOUN	O	O	1126
were	AUX	O	O	1126
significantly	ADV	O	O	1126
correlated	VERB	O	O	1126
with	ADP	O	O	1126
plasma	NOUN	O	O	1126
caffeine	NOUN	O	Chemical	1126
levels	NOUN	O	O	1126
.	PUNCT	O	O	1126
Seventy	NUM	O	O	1127
-	PUNCT	O	O	1127
one	NUM	O	O	1127
percent	NOUN	O	O	1127
of	ADP	O	O	1127
the	PRON	O	O	1127
patients	NOUN	O	O	1127
reported	VERB	O	O	1127
that	SCONJ	O	O	1127
the	PRON	O	O	1127
behavioral	ADJ	O	O	1127
effects	NOUN	O	O	1127
of	ADP	O	O	1127
caffeine	NOUN	O	Chemical	1127
were	AUX	O	O	1127
similar	ADJ	O	O	1127
to	PART	O	O	1127
those	PRON	O	O	1127
experienced	ADJ	O	O	1127
during	ADP	O	O	1127
panic	VERB	O	O	1127
attacks	NOUN	O	O	1127
.	PUNCT	O	O	1127
Caffeine	NOUN	O	Chemical	1128
did	VERB	O	O	1128
not	PART	O	O	1128
alter	VERB	O	O	1128
plasma	NOUN	O	O	1128
MHPG	VERB	O	O	1128
levels	NOUN	O	O	1128
in	ADP	O	O	1128
either	ADV	O	O	1128
the	PRON	O	O	1128
healthy	ADJ	O	O	1128
subjects	NOUN	O	O	1128
or	CCONJ	O	O	1128
patients	NOUN	O	O	1128
.	PUNCT	O	O	1128
Caffeine	NOUN	O	Chemical	1129
increased	VERB	O	O	1129
plasma	NOUN	O	O	1129
cortisol	NOUN	O	O	1129
levels	NOUN	O	O	1129
equally	ADV	O	O	1129
in	ADP	O	O	1129
the	PRON	O	O	1129
patient	NOUN	O	O	1129
and	CCONJ	O	O	1129
healthy	ADJ	O	O	1129
groups	NOUN	O	O	1129
.	PUNCT	O	O	1129
Because	SCONJ	O	O	1130
caffeine	NOUN	O	Chemical	1130
is	AUX	O	O	1130
an	PRON	O	O	1130
adenosine	PROPN	O	Chemical	1130
receptor	NOUN	O	O	1130
antagonist	NOUN	O	O	1130
,	PUNCT	O	O	1130
these	PRON	O	O	1130
results	VERB	O	O	1130
suggest	VERB	O	O	1130
that	SCONJ	O	O	1130
some	PRON	O	O	1130
panic	VERB	O	O	1130
disorder	NOUN	O	O	1130
patients	NOUN	O	O	1130
may	AUX	O	O	1130
have	VERB	O	O	1130
abnormalities	NOUN	O	O	1130
in	ADP	O	O	1130
neuronal	ADJ	O	O	1130
systems	NOUN	O	O	1130
involving	VERB	O	O	1130
adenosine	PROPN	O	Chemical	1130
.	PUNCT	O	O	1130
Patients	NOUN	O	O	1131
with	ADP	O	O	1131
anxiety	NOUN	O	Disease	1131
disorders	NOUN	O	O	1131
may	AUX	O	O	1131
benefit	VERB	O	O	1131
by	ADP	O	O	1131
avoiding	VERB	O	O	1131
caffeine	NOUN	O	Chemical	1131
-	PUNCT	O	O	1131
containing	VERB	O	O	1131
foods	NOUN	O	O	1131
and	CCONJ	O	O	1131
beverages	NOUN	O	O	1131
.	PUNCT	O	O	1131
intestinal	ADJ	O	Disease	1134
polypeptide	ADP	O	O	1134
:	PUNCT	O	O	1134
decrease	VERB	O	O	1134
with	ADP	O	O	1134
heart failure	NOUN	O	Disease	1134
.	PUNCT	O	O	1134
Myocardial	PROPN	O	O	1135
levels	NOUN	O	O	1135
of	ADP	O	O	1135
VIP	VERB	O	O	1135
were	AUX	O	O	1135
assayed	VERB	O	O	1135
before	ADP	O	O	1135
and	CCONJ	O	O	1135
after	ADP	O	O	1135
the	PRON	O	O	1135
development	NOUN	O	O	1135
of	ADP	O	O	1135
heart failure	NOUN	O	Disease	1135
in	ADP	O	O	1135
two	NUM	O	O	1135
canine	NOUN	O	O	1135
models	NOUN	O	O	1135
.	PUNCT	O	O	1135
In	ADP	O	O	1136
the	PRON	O	O	1136
first	ADV	O	O	1136
,	PUNCT	O	O	1136
cobalt	NOUN	O	O	1136
cardiomyopathy	ADJ	O	Disease	1136
was	AUX	O	O	1136
induced	VERB	O	O	1136
in	ADP	O	O	1136
eight	NUM	O	O	1136
dogs	NOUN	O	O	1136
;	PUNCT	O	O	1136
VIP	VERB	O	O	1136
(	PUNCT	O	O	1136
by	ADP	O	O	1136
radioimmunoassay	PROPN	O	O	1136
)	PUNCT	O	O	1136
decreased	VERB	O	O	1136
from	ADP	O	O	1136
35	NUM	O	O	1136
+	ADP	O	O	1136
/-	PUNCT	O	O	1136
In	ADP	O	O	1137
six	NUM	O	O	1137
dogs	NOUN	O	O	1137
with	ADP	O	O	1137
doxorubicin	VERB	O	Chemical	1137
-	PUNCT	O	O	1137
induced	VERB	O	O	1137
heart failure	NOUN	O	Disease	1137
,	PUNCT	O	O	1137
VIP	VERB	O	O	1137
decreased	VERB	O	O	1137
from	ADP	O	O	1137
31	NUM	O	O	1137
+	ADP	O	O	1137
/-	PUNCT	O	O	1137
In	ADP	O	O	1138
addition	NOUN	O	O	1138
,	PUNCT	O	O	1138
VIP	VERB	O	O	1138
content	NOUN	O	O	1138
of	ADP	O	O	1138
left	VERB	O	O	1138
ventricular	ADJ	O	O	1138
muscle	NOUN	O	O	1138
of	ADP	O	O	1138
resected	VERB	O	O	1138
failing	VERB	O	O	1138
hearts	NOUN	O	O	1138
in	ADP	O	O	1138
10	NUM	O	O	1138
patients	NOUN	O	O	1138
receiving	VERB	O	O	1138
a	PRON	O	O	1138
heart	NOUN	O	O	1138
transplant	NOUN	O	O	1138
was	AUX	O	O	1138
compared	VERB	O	O	1138
with	ADP	O	O	1138
the	PRON	O	O	1138
papillary	ADJ	O	O	1138
muscles	NOUN	O	O	1138
in	ADP	O	O	1138
14	NUM	O	O	1138
patients	NOUN	O	O	1138
(	PUNCT	O	O	1138
five	NUM	O	O	1138
with	ADP	O	O	1138
rheumatic	ADJ	O	O	1138
disease	PROPN	O	O	1138
,	PUNCT	O	O	1138
nine	NUM	O	O	1138
with	ADP	O	O	1138
myxomatous	ADJ	O	O	1138
degeneration	NOUN	O	O	1138
)	PUNCT	O	O	1138
receiving	VERB	O	O	1138
mitral	ADJ	O	O	1138
valve	PROPN	O	O	1138
prostheses	NOUN	O	O	1138
.	PUNCT	O	O	1138
The	PRON	O	O	1139
lowest	ADJ	O	O	1139
myocardial	ADJ	O	O	1139
VIP	VERB	O	O	1139
concentration	NOUN	O	O	1139
was	AUX	O	O	1139
found	VERB	O	O	1139
in	ADP	O	O	1139
the	PRON	O	O	1139
hearts	NOUN	O	O	1139
of	ADP	O	O	1139
patients	NOUN	O	O	1139
with	ADP	O	O	1139
coronary disease	NOUN	O	Disease	1139
(	PUNCT	O	O	1139
one	NUM	O	O	1139
patient	NOUN	O	O	1139
receiving	VERB	O	O	1139
a	PRON	O	O	1139
transplant	NOUN	O	O	1139
and	CCONJ	O	O	1139
three	NUM	O	O	1139
receiving	VERB	O	O	1139
mitral	ADJ	O	O	1139
prostheses	NOUN	O	O	1139
)	PUNCT	O	O	1139
(	PUNCT	O	O	1139
6.3	NUM	O	O	1139
+	ADP	O	O	1139
/-	PUNCT	O	O	1139
The	PRON	O	O	1140
hearts	NOUN	O	O	1140
without	ADP	O	O	1140
coronary artery disease	NOUN	O	Disease	1140
(	PUNCT	O	O	1140
average	ADJ	O	O	1140
ejection	NOUN	O	O	1140
fraction	NOUN	O	O	1140
of	ADP	O	O	1140
this	PRON	O	O	1140
group	NOUN	O	O	1140
62%	NOUN	O	O	1140
+	ADP	O	O	1140
/-	PUNCT	O	O	1140
7.9	NUM	O	O	1141
pg	PROPN	O	Chemical	1141
/	PUNCT	O	O	1141
mg	VERB	O	O	1141
protein	NOUN	O	O	1141
,	PUNCT	O	O	1141
and	CCONJ	O	O	1141
this	PRON	O	O	1141
was	AUX	O	O	1141
greater	ADJ	O	O	1141
than	ADP	O	O	1141
in	ADP	O	O	1141
hearts	NOUN	O	O	1141
of	ADP	O	O	1141
the	PRON	O	O	1141
patients	NOUN	O	O	1141
with	ADP	O	O	1141
coronary disease	NOUN	O	Disease	1141
and	CCONJ	O	O	1141
the	PRON	O	O	1141
hearts	NOUN	O	O	1141
of	ADP	O	O	1141
patients	NOUN	O	O	1141
receiving	VERB	O	O	1141
a	PRON	O	O	1141
transplant	NOUN	O	O	1141
(	PUNCT	O	O	1141
P	NOUN	O	Chemical	1141
less	ADV	O	O	1141
than	ADP	O	O	1141
0.05	NUM	O	O	1141
)	PUNCT	O	O	1141
.	PUNCT	O	O	1141
Myocardial	PROPN	O	O	1142
catecholamines	NOUN	O	Chemical	1142
were	AUX	O	O	1142
also	ADV	O	O	1142
determined	VERB	O	O	1142
in	ADP	O	O	1142
14	NUM	O	O	1142
subjects	NOUN	O	O	1142
;	PUNCT	O	O	1142
a	PRON	O	O	1142
weak	ADJ	O	O	1142
correlation	NOUN	O	O	1142
(	PUNCT	O	O	1142
r	X	O	O	1142
=	PUNCT	O	O	1142
0.57	NUM	O	O	1142
,	PUNCT	O	O	1142
P	NOUN	O	Chemical	1142
less	ADV	O	O	1142
than	ADP	O	O	1142
0.05	NUM	O	O	1142
)	PUNCT	O	O	1142
between	ADP	O	O	1142
the	PRON	O	O	1142
tissue	NOUN	O	O	1142
concentrations	NOUN	O	O	1142
of	ADP	O	O	1142
VIP	VERB	O	O	1142
and	CCONJ	O	O	1142
norepinephrine	NOUN	O	Chemical	1142
was	AUX	O	O	1142
noted.(ABSTRACT	PROPN	O	O	1142
TRUNCATED	ADJ	O	O	1142
AT	ADP	O	O	1142
250	NUM	O	O	1142
WORDS	NOUN	O	O	1142
)	PUNCT	O	O	1142
Interstrain	NOUN	O	O	1145
variation	NOUN	O	O	1145
in	ADP	O	O	1145
acute	ADJ	O	O	1145
toxic	ADJ	O	O	1145
response	NOUN	O	O	1145
to	PART	O	O	1145
caffeine	NOUN	O	Chemical	1145
among	ADP	O	O	1145
inbred	ADJ	O	O	1145
mice	NOUN	O	O	1145
.	PUNCT	O	O	1145
Acute	PROPN	O	O	1146
toxic	ADJ	O	O	1146
dosage	NOUN	O	O	1146
-	PUNCT	O	O	1146
dependent	ADJ	O	O	1146
behavioral	ADJ	O	O	1146
effects	NOUN	O	O	1146
of	ADP	O	O	1146
caffeine	NOUN	O	Chemical	1146
were	AUX	O	O	1146
compared	VERB	O	O	1146
in	ADP	O	O	1146
adult	NOUN	O	O	1146
males	NOUN	O	O	1146
from	ADP	O	O	1146
seven	NUM	O	O	1146
inbred	ADJ	O	O	1146
mouse	PROPN	O	O	1146
strains	VERB	O	O	1146
(	PUNCT	O	O	1146
A	PRON	O	O	1146
/	PUNCT	O	O	1146
J	PROPN	O	O	1146
,	PUNCT	O	O	1146
BALB	PROPN	O	O	1146
/	PUNCT	O	O	1146
cJ	VERB	O	O	1146
,	PUNCT	O	O	1146
CBA	PROPN	O	O	1146
/	PUNCT	O	O	1146
J	PROPN	O	O	1146
,	PUNCT	O	O	1146
C3H	PROPN	O	O	1146
/	PUNCT	O	O	1146
HeJ	PROPN	O	O	1146
,	PUNCT	O	O	1146
C57BL/6J	NOUN	O	O	1146
,	PUNCT	O	O	1146
DBA/2J	NUM	O	O	1146
,	PUNCT	O	O	1146
SWR	PROPN	O	O	1146
/	PUNCT	O	O	1146
J	PROPN	O	O	1146
)	PUNCT	O	O	1146
.	PUNCT	O	O	1146
C57BL/6J	NOUN	O	O	1147
,	PUNCT	O	O	1147
chosen	VERB	O	O	1147
as	ADP	O	O	1147
a	PRON	O	O	1147
""""	PUNCT	O	O	1147
prototypic	NOUN	O	O	1147
""""	PUNCT	O	O	1147
mouse	PROPN	O	O	1147
strain	VERB	O	O	1147
,	PUNCT	O	O	1147
was	AUX	O	O	1147
used	VERB	O	O	1147
to	PART	O	O	1147
determine	VERB	O	O	1147
behavioral	ADJ	O	O	1147
responses	NOUN	O	O	1147
to	PART	O	O	1147
a	PRON	O	O	1147
broad	ADJ	O	O	1147
range	VERB	O	O	1147
(	PUNCT	O	O	1147
5	NUM	O	O	1147
-	PUNCT	O	O	1147
500	NUM	O	O	1147
mg	VERB	O	O	1147
/	PUNCT	O	O	1147
kg	VERB	O	O	1147
)	PUNCT	O	O	1147
of	ADP	O	O	1147
caffeine	NOUN	O	Chemical	1147
doses	NOUN	O	O	1147
.	PUNCT	O	O	1147
Five	NUM	O	O	1148
phenotypic	NOUN	O	O	1148
characteristics	NOUN	O	O	1148
--	PUNCT	O	O	1148
locomotor	PROPN	O	O	1148
activity	NOUN	O	O	1148
,	PUNCT	O	O	1148
righting	VERB	O	O	1148
ability	NOUN	O	O	1148
,	PUNCT	O	O	1148
clonic	ADJ	O	O	1148
seizure	NOUN	O	Disease	1148
induction	NOUN	O	O	1148
,	PUNCT	O	O	1148
stress	NOUN	O	O	1148
-	PUNCT	O	O	1148
induced	VERB	O	O	1148
lethality	NOUN	O	O	1148
,	PUNCT	O	O	1148
death	NOUN	O	O	1148
without	ADP	O	O	1148
external	ADJ	O	O	1148
stress	NOUN	O	O	1148
--	PUNCT	O	O	1148
were	AUX	O	O	1148
scored	VERB	O	O	1148
at	ADP	O	O	1148
various	ADJ	O	O	1148
caffeine	NOUN	O	Chemical	1148
doses	NOUN	O	O	1148
in	ADP	O	O	1148
drug	NOUN	O	O	1148
-	PUNCT	O	O	1148
naive	ADJ	O	O	1148
animals	NOUN	O	O	1148
under	ADP	O	O	1148
empirically	ADV	O	O	1148
optimized	VERB	O	O	1148
,	PUNCT	O	O	1148
rigidly	ADV	O	O	1148
constant	ADJ	O	O	1148
experimental	ADJ	O	O	1148
conditions	NOUN	O	O	1148
.	PUNCT	O	O	1148
Mice	NOUN	O	O	1149
(	PUNCT	O	O	1149
n	CCONJ	O	O	1149
=	PUNCT	O	O	1149
12	NUM	O	O	1149
for	ADP	O	O	1149
each	PRON	O	O	1149
point	VERB	O	O	1149
)	PUNCT	O	O	1149
received	VERB	O	O	1149
single	ADJ	O	O	1149
IP	PROPN	O	O	1149
injections	NOUN	O	O	1149
of	ADP	O	O	1149
a	PRON	O	O	1149
fixed	VERB	O	O	1149
volume	PROPN	O	O	1149
/	PUNCT	O	O	1149
g	X	O	O	1149
body	NOUN	O	O	1149
weight	NOUN	O	O	1149
of	ADP	O	O	1149
physiological	ADJ	O	O	1149
saline	NOUN	O	O	1149
carrier	NOUN	O	O	1149
with	ADP	O	O	1149
or	CCONJ	O	O	1149
without	ADP	O	O	1149
caffeine	NOUN	O	Chemical	1149
in	ADP	O	O	1149
doses	NOUN	O	O	1149
ranging	VERB	O	O	1149
from	ADP	O	O	1149
125	NUM	O	O	1149
-	PUNCT	O	O	1149
500	NUM	O	O	1149
mg	VERB	O	O	1149
/	PUNCT	O	O	1149
kg	VERB	O	O	1149
.	PUNCT	O	O	1149
In	ADP	O	O	1150
the	PRON	O	O	1150
same	ADJ	O	O	1150
animals	NOUN	O	O	1150
the	PRON	O	O	1150
occurrence	NOUN	O	O	1150
of	ADP	O	O	1150
clonic	ADJ	O	O	1150
seizures	NOUN	O	Disease	1150
was	AUX	O	O	1150
scored	VERB	O	O	1150
as	ADP	O	O	1150
to	PART	O	O	1150
time	NOUN	O	O	1150
of	ADP	O	O	1150
onset	VERB	O	O	1150
and	CCONJ	O	O	1150
severity	NOUN	O	O	1150
for	ADP	O	O	1150
20	NUM	O	O	1150
min	NOUN	O	O	1150
after	ADP	O	O	1150
drug	NOUN	O	O	1150
administration	NOUN	O	O	1150
.	PUNCT	O	O	1150
When	SCONJ	O	O	1151
these	PRON	O	O	1151
proceeded	VERB	O	O	1151
to	PART	O	O	1151
tonic	PROPN	O	O	1151
seizures	NOUN	O	Disease	1151
,	PUNCT	O	O	1151
death	NOUN	O	O	1151
occurred	VERB	O	O	1151
in	ADP	O	O	1151
less	ADV	O	O	1151
than	ADP	O	O	1151
20	NUM	O	O	1151
min	NOUN	O	O	1151
.	PUNCT	O	O	1151
Animals	NOUN	O	O	1152
surviving	VERB	O	O	1152
for	ADP	O	O	1152
20	NUM	O	O	1152
min	NOUN	O	O	1152
were	AUX	O	O	1152
immediately	ADV	O	O	1152
stressed	VERB	O	O	1152
by	ADP	O	O	1152
a	PRON	O	O	1152
swim	VERB	O	O	1152
test	NOUN	O	O	1152
in	ADP	O	O	1152
25	NUM	O	O	1152
degrees	NOUN	O	O	1152
C	NOUN	O	O	1152
water	PROPN	O	O	1152
,	PUNCT	O	O	1152
and	CCONJ	O	O	1152
death	NOUN	O	O	1152
-	PUNCT	O	O	1152
producing	VERB	O	O	1152
tonic	PROPN	O	O	1152
seizures	NOUN	O	Disease	1152
were	AUX	O	O	1152
scored	VERB	O	O	1152
for	ADP	O	O	1152
2	X	O	O	1152
min	NOUN	O	O	1152
.	PUNCT	O	O	1152
In	ADP	O	O	1153
other	ADJ	O	O	1153
animals	NOUN	O	O	1153
locomotor	PROPN	O	O	1153
activity	NOUN	O	O	1153
was	AUX	O	O	1153
measured	VERB	O	O	1153
15	NUM	O	O	1153
or	CCONJ	O	O	1153
60	NUM	O	O	1153
min	NOUN	O	O	1153
after	ADP	O	O	1153
caffeine	NOUN	O	Chemical	1153
administration	NOUN	O	O	1153
.	PUNCT	O	O	1153
By	ADP	O	O	1154
any	PRON	O	O	1154
single	ADJ	O	O	1154
behavioral	ADJ	O	O	1154
criterion	NOUN	O	O	1154
or	CCONJ	O	O	1154
a	PRON	O	O	1154
combination	NOUN	O	O	1154
of	ADP	O	O	1154
these	PRON	O	O	1154
criteria	NOUN	O	O	1154
,	PUNCT	O	O	1154
marked	VERB	O	O	1154
differences	NOUN	O	O	1154
in	ADP	O	O	1154
response	NOUN	O	O	1154
to	PART	O	O	1154
toxic	ADJ	O	O	1154
caffeine	NOUN	O	Chemical	1154
doses	NOUN	O	O	1154
were	AUX	O	O	1154
observed	VERB	O	O	1154
between	ADP	O	O	1154
strains	VERB	O	O	1154
.	PUNCT	O	O	1154
These	PRON	O	O	1155
results	VERB	O	O	1155
indicate	VERB	O	O	1155
that	SCONJ	O	O	1155
behavioral	ADJ	O	O	1155
toxicity	NOUN	O	Disease	1155
testing	NOUN	O	O	1155
of	ADP	O	O	1155
alkylxanthines	VERB	O	O	1155
in	ADP	O	O	1155
a	PRON	O	O	1155
single	ADJ	O	O	1155
mouse	PROPN	O	O	1155
strain	VERB	O	O	1155
may	AUX	O	O	1155
be	AUX	O	O	1155
misleading	VERB	O	O	1155
and	CCONJ	O	O	1155
suggest	VERB	O	O	1155
that	SCONJ	O	O	1155
toxic	ADJ	O	O	1155
responses	NOUN	O	O	1155
of	ADP	O	O	1155
the	PRON	O	O	1155
central	ADJ	O	O	1155
nervous	ADJ	O	O	1155
system	NOUN	O	O	1155
to	PART	O	O	1155
this	PRON	O	O	1155
class	NOUN	O	O	1155
of	ADP	O	O	1155
compounds	NOUN	O	O	1155
are	AUX	O	O	1155
genetically	ADV	O	O	1155
influenced	VERB	O	O	1155
in	ADP	O	O	1155
mammals	NOUN	O	O	1155
.	PUNCT	O	O	1155
Invasive	PROPN	O	O	1158
carcinoma	NOUN	O	Disease	1158
of	ADP	O	O	1158
the	PRON	O	O	1158
renal	ADJ	O	O	1158
pelvis	ADJ	O	O	1158
following	VERB	O	O	1158
cyclophosphamide	VERB	O	Chemical	1158
therapy	NOUN	O	O	1158
for	ADP	O	O	1158
nonmalignant	NOUN	O	O	1158
disease	PROPN	O	O	1158
.	PUNCT	O	O	1158
A	PRON	O	O	1159
47-year	NOUN	O	O	1159
-	PUNCT	O	O	1159
old	ADJ	O	O	1159
woman	NOUN	O	O	1159
with	ADP	O	O	1159
right	ADV	O	O	1159
hydroureteronephrosis	VERB	O	O	1159
due	ADJ	O	O	1159
to	PART	O	O	1159
ureterovesical	ADJ	O	O	1159
junction	NOUN	O	O	1159
obstruction	NOUN	O	O	1159
had	VERB	O	O	1159
gross	ADJ	O	O	1159
hematuria	PROPN	O	Disease	1159
after	ADP	O	O	1159
being	AUX	O	O	1159
treated	VERB	O	O	1159
for	ADP	O	O	1159
five	NUM	O	O	1159
years	NOUN	O	O	1159
wtih	PRON	O	O	1159
cyclophosphamide	VERB	O	Chemical	1159
for	ADP	O	O	1159
cerebral	ADJ	O	O	1159
vasculitis	NOUN	O	Disease	1159
.	PUNCT	O	O	1159
A	PRON	O	O	1160
right	ADV	O	O	1160
nephroureterectomy	NOUN	O	O	1160
was	AUX	O	O	1160
required	VERB	O	O	1160
for	ADP	O	O	1160
control	VERB	O	O	1160
of	ADP	O	O	1160
bleeding	VERB	O	Disease	1160
.	PUNCT	O	O	1160
The	PRON	O	O	1161
pathology	NOUN	O	O	1161
specimen	NOUN	O	O	1161
contained	VERB	O	O	1161
clinically	ADV	O	O	1161
occult	NOUN	O	O	1161
invasive	ADJ	O	O	1161
carcinoma	NOUN	O	Disease	1161
of	ADP	O	O	1161
the	PRON	O	O	1161
renal	ADJ	O	O	1161
pelvis	ADJ	O	O	1161
.	PUNCT	O	O	1161
Although	SCONJ	O	O	1162
the	PRON	O	O	1162
ability	NOUN	O	O	1162
of	ADP	O	O	1162
cyclophosphamide	VERB	O	Chemical	1162
to	PART	O	O	1162
cause	VERB	O	O	1162
hemorrhagic cystitis	NOUN	O	Disease	1162
and	CCONJ	O	O	1162
urine	NOUN	O	O	1162
cytologic	PROPN	O	O	1162
abnormalities	NOUN	O	O	1162
indistinguishable	ADJ	O	O	1162
from	ADP	O	O	1162
high	ADJ	O	O	1162
grade	NOUN	O	O	1162
carcinoma	NOUN	O	Disease	1162
is	AUX	O	O	1162
well	ADV	O	O	1162
known	VERB	O	O	1162
,	PUNCT	O	O	1162
it	PRON	O	O	1162
is	AUX	O	O	1162
less	ADV	O	O	1162
widely	ADV	O	O	1162
appreciated	VERB	O	O	1162
that	SCONJ	O	O	1162
it	PRON	O	O	1162
is	AUX	O	O	1162
also	ADV	O	O	1162
associated	VERB	O	O	1162
with	ADP	O	O	1162
carcinoma	NOUN	O	Disease	1162
of	ADP	O	O	1162
the	PRON	O	O	1162
urinary	ADJ	O	O	1162
tract	NOUN	O	O	1162
.	PUNCT	O	O	1162
Twenty	NUM	O	O	1163
carcinomas	VERB	O	O	1163
of	ADP	O	O	1163
the	PRON	O	O	1163
urinary	ADJ	O	O	1163
bladder	NOUN	O	O	1163
and	CCONJ	O	O	1163
one	NUM	O	O	1163
carcinoma	NOUN	O	Disease	1163
of	ADP	O	O	1163
the	PRON	O	O	1163
prostate	NOUN	O	O	1163
have	VERB	O	O	1163
been	AUX	O	O	1163
reported	VERB	O	O	1163
in	ADP	O	O	1163
association	PROPN	O	O	1163
with	ADP	O	O	1163
its	PRON	O	O	1163
use	VERB	O	O	1163
.	PUNCT	O	O	1163
The	PRON	O	O	1164
present	NOUN	O	O	1164
case	NOUN	O	O	1164
is	AUX	O	O	1164
the	PRON	O	O	1164
first	ADV	O	O	1164
carcinoma	NOUN	O	Disease	1164
of	ADP	O	O	1164
the	PRON	O	O	1164
renal	ADJ	O	O	1164
pelvis	ADJ	O	O	1164
reported	VERB	O	O	1164
in	ADP	O	O	1164
association	PROPN	O	O	1164
with	ADP	O	O	1164
cyclophosphamide	VERB	O	Chemical	1164
treatment	NOUN	O	O	1164
.	PUNCT	O	O	1164
It	PRON	O	O	1165
is	AUX	O	O	1165
the	PRON	O	O	1165
third	ADV	O	O	1165
urinary	ADJ	O	O	1165
tract	NOUN	O	O	1165
cancer	NOUN	O	Disease	1165
reported	VERB	O	O	1165
in	ADP	O	O	1165
association	PROPN	O	O	1165
with	ADP	O	O	1165
cyclophosphamide	VERB	O	Chemical	1165
treatment	NOUN	O	O	1165
for	ADP	O	O	1165
nonmalignant	NOUN	O	O	1165
disease	PROPN	O	O	1165
.	PUNCT	O	O	1165
The	PRON	O	O	1166
association	PROPN	O	O	1166
of	ADP	O	O	1166
the	PRON	O	O	1166
tumor	NOUN	O	Disease	1166
with	ADP	O	O	1166
preexisting	VERB	O	O	1166
hydroureteronephrosis	VERB	O	O	1166
suggests	VERB	O	O	1166
that	SCONJ	O	O	1166
stasis	NOUN	O	O	1166
prolonged	VERB	O	O	1166
and	CCONJ	O	O	1166
intensified	VERB	O	O	1166
exposure	NOUN	O	O	1166
of	ADP	O	O	1166
upper	ADJ	O	O	1166
urinary	ADJ	O	O	1166
tract	NOUN	O	O	1166
epithelium	NOUN	O	O	1166
to	PART	O	O	1166
cyclophosphamide	VERB	O	Chemical	1166
.	PUNCT	O	O	1166
Patients	NOUN	O	O	1167
who	PRON	O	O	1167
are	AUX	O	O	1167
candidates	NOUN	O	O	1167
for	ADP	O	O	1167
long	ADV	O	O	1167
-	PUNCT	O	O	1167
term	NOUN	O	O	1167
cyclophosphamide	VERB	O	Chemical	1167
treatment	NOUN	O	O	1167
should	AUX	O	O	1167
be	AUX	O	O	1167
routinely	ADV	O	O	1167
evaluated	VERB	O	O	1167
for	ADP	O	O	1167
obstructive	ADJ	O	O	1167
uropathy	PROPN	O	O	1167
.	PUNCT	O	O	1167
Ascending	VERB	O	O	1170
dose	NOUN	O	O	1170
tolerance	NOUN	O	O	1170
study	VERB	O	O	1170
of	ADP	O	O	1170
intramuscular	ADJ	O	O	1170
carbetocin	NOUN	O	O	1170
administered	VERB	O	O	1170
after	ADP	O	O	1170
normal	ADJ	O	O	1170
vaginal	ADJ	O	O	1170
birth	NOUN	O	O	1170
.	PUNCT	O	O	1170
OBJECTIVE	VERB	O	O	1171
:	PUNCT	O	O	1171
To	PART	O	O	1171
determine	VERB	O	O	1171
the	PRON	O	O	1171
maximum	ADV	O	O	1171
tolerated	VERB	O	O	1171
dose	NOUN	O	O	1171
(	PUNCT	O	O	1171
MTD	PROPN	O	O	1171
)	PUNCT	O	O	1171
of	ADP	O	O	1171
carbetocin	NOUN	O	O	1171
(	PUNCT	O	O	1171
a	PRON	O	O	1171
long	ADV	O	O	1171
-	PUNCT	O	O	1171
acting	VERB	O	O	1171
synthetic	NOUN	O	O	1171
analogue	NOUN	O	O	1171
of	ADP	O	O	1171
oxytocin	PROPN	O	Chemical	1171
)	PUNCT	O	O	1171
,	PUNCT	O	O	1171
when	SCONJ	O	O	1171
administered	VERB	O	O	1171
immediately	ADV	O	O	1171
after	ADP	O	O	1171
vaginal	ADJ	O	O	1171
delivery	NOUN	O	O	1171
at	ADP	O	O	1171
term	NOUN	O	O	1171
.	PUNCT	O	O	1171
Carbetocin	PROPN	O	O	1172
was	AUX	O	O	1172
given	VERB	O	O	1172
as	ADP	O	O	1172
an	PRON	O	O	1172
intramuscular	ADJ	O	O	1172
injection	NOUN	O	O	1172
immediately	ADV	O	O	1172
after	ADP	O	O	1172
the	PRON	O	O	1172
birth	NOUN	O	O	1172
of	ADP	O	O	1172
the	PRON	O	O	1172
infant	NOUN	O	O	1172
in	ADP	O	O	1172
45	NUM	O	O	1172
healthy	ADJ	O	O	1172
women	NOUN	O	O	1172
with	ADP	O	O	1172
normal	ADJ	O	O	1172
singleton	PROPN	O	O	1172
pregnancies	NOUN	O	O	1172
who	PRON	O	O	1172
delivered	VERB	O	O	1172
vaginally	ADV	O	O	1172
at	ADP	O	O	1172
term	NOUN	O	O	1172
.	PUNCT	O	O	1172
Dosage	NOUN	O	O	1173
groups	NOUN	O	O	1173
of	ADP	O	O	1173
15	NUM	O	O	1173
,	PUNCT	O	O	1173
30	NUM	O	O	1173
,	PUNCT	O	O	1173
50	NUM	O	O	1173
,	PUNCT	O	O	1173
75	NUM	O	O	1173
,	PUNCT	O	O	1173
100	NUM	O	O	1173
,	PUNCT	O	O	1173
125	NUM	O	O	1173
,	PUNCT	O	O	1173
150	NUM	O	O	1173
,	PUNCT	O	O	1173
175	NUM	O	O	1173
or	CCONJ	O	O	1173
200	NUM	O	O	1173
microg	PROPN	O	O	1173
carbetocin	NOUN	O	O	1173
were	AUX	O	O	1173
assigned	VERB	O	O	1173
to	PART	O	O	1173
blocks	NOUN	O	O	1173
of	ADP	O	O	1173
three	NUM	O	O	1173
women	NOUN	O	O	1173
according	VERB	O	O	1173
to	PART	O	O	1173
the	PRON	O	O	1173
continual	ADJ	O	O	1173
reassessment	NOUN	O	O	1173
method	NOUN	O	O	1173
(	PUNCT	O	O	1173
CRM	NOUN	O	O	1173
)	PUNCT	O	O	1173
.	PUNCT	O	O	1173
Recorded	VERB	O	O	1174
were	AUX	O	O	1174
dose	NOUN	O	O	1174
-	PUNCT	O	O	1174
limiting	VERB	O	O	1174
adverse	ADJ	O	O	1174
events	NOUN	O	O	1174
:	PUNCT	O	O	1174
hyper-	PUNCT	O	O	1174
or	CCONJ	O	O	1174
hypotension	NOUN	O	Disease	1174
(	PUNCT	O	O	1174
three	NUM	O	O	1174
)	PUNCT	O	O	1174
,	PUNCT	O	O	1174
severe	ADJ	O	O	1174
abdominal pain	NOUN	O	Disease	1174
(	PUNCT	O	O	1174
0	NUM	O	O	1174
)	PUNCT	O	O	1174
,	PUNCT	O	O	1174
vomiting	VERB	O	Disease	1174
(	PUNCT	O	O	1174
0	NUM	O	O	1174
)	PUNCT	O	O	1174
and	CCONJ	O	O	1174
retained	VERB	O	O	1174
placenta	ADJ	O	O	1174
(	PUNCT	O	O	1174
four	NUM	O	O	1174
)	PUNCT	O	O	1174
.	PUNCT	O	O	1174
Serious	ADJ	O	O	1175
adverse	ADJ	O	O	1175
events	NOUN	O	O	1175
occurred	VERB	O	O	1175
in	ADP	O	O	1175
seven	NUM	O	O	1175
women	NOUN	O	O	1175
:	PUNCT	O	O	1175
six	NUM	O	O	1175
cases	NOUN	O	O	1175
with	ADP	O	O	1175
blood loss	NOUN	O	Disease	1175
>	PUNCT	O	O	1175
or	CCONJ	O	O	1175
=	PUNCT	O	O	1175
1000	NUM	O	O	1175
ml	ADP	O	O	1175
,	PUNCT	O	O	1175
four	NUM	O	O	1175
cases	NOUN	O	O	1175
of	ADP	O	O	1175
manual	NOUN	O	O	1175
placenta	ADJ	O	O	1175
removal	NOUN	O	O	1175
,	PUNCT	O	O	1175
five	NUM	O	O	1175
cases	NOUN	O	O	1175
of	ADP	O	O	1175
additional	ADJ	O	O	1175
oxytocics	NOUN	O	O	1175
administration	NOUN	O	O	1175
and	CCONJ	O	O	1175
five	NUM	O	O	1175
cases	NOUN	O	O	1175
of	ADP	O	O	1175
blood	NOUN	O	O	1175
transfusion	NOUN	O	O	1175
.	PUNCT	O	O	1175
Maximum	ADJ	O	O	1176
blood loss	NOUN	O	Disease	1176
was	AUX	O	O	1176
greatest	ADJ	O	O	1176
at	ADP	O	O	1176
the	PRON	O	O	1176
upper	ADJ	O	O	1176
and	CCONJ	O	O	1176
lower	ADJ	O	O	1176
dose	NOUN	O	O	1176
levels	NOUN	O	O	1176
,	PUNCT	O	O	1176
and	CCONJ	O	O	1176
lowest	ADJ	O	O	1176
in	ADP	O	O	1176
the	PRON	O	O	1176
70	NUM	O	O	1176
-	PUNCT	O	O	1176
125	NUM	O	O	1176
microg	PROPN	O	O	1176
dose	NOUN	O	O	1176
range	VERB	O	O	1176
.	PUNCT	O	O	1176
Four	NUM	O	O	1177
out	ADP	O	O	1177
of	ADP	O	O	1177
six	NUM	O	O	1177
cases	NOUN	O	O	1177
with	ADP	O	O	1177
blood loss	NOUN	O	Disease	1177
>	PUNCT	O	O	1177
or	CCONJ	O	O	1177
=	PUNCT	O	O	1177
1000	NUM	O	O	1177
ml	ADP	O	O	1177
occurred	VERB	O	O	1177
in	ADP	O	O	1177
the	PRON	O	O	1177
200	NUM	O	O	1177
microg	PROPN	O	O	1177
group	NOUN	O	O	1177
.	PUNCT	O	O	1177
The	PRON	O	O	1178
MTD	PROPN	O	O	1178
was	AUX	O	O	1178
calculated	VERB	O	O	1178
to	PART	O	O	1178
be	AUX	O	O	1178
at	ADP	O	O	1178
200	NUM	O	O	1178
microg	PROPN	O	O	1178
carbetocin	NOUN	O	O	1178
.	PUNCT	O	O	1178
A	PRON	O	O	1181
pilot	NOUN	O	O	1181
study	VERB	O	O	1181
to	PART	O	O	1181
assess	VERB	O	O	1181
the	PRON	O	O	1181
safety	NOUN	O	O	1181
of	ADP	O	O	1181
dobutamine	NOUN	O	Chemical	1181
stress	NOUN	O	O	1181
echocardiography	NOUN	O	O	1181
in	ADP	O	O	1181
the	PRON	O	O	1181
emergency	NOUN	O	O	1181
department	NOUN	O	O	1181
evaluation	NOUN	O	O	1181
of	ADP	O	O	1181
cocaine	NOUN	O	Chemical	1181
-	PUNCT	O	O	1181
associated	VERB	O	O	1181
chest pain	NOUN	O	Disease	1181
.	PUNCT	O	O	1181
STUDY	NOUN	O	O	1182
OBJECTIVE	VERB	O	O	1182
:	PUNCT	O	O	1182
Chest	NOUN	O	O	1182
pain	NOUN	O	Disease	1182
in	ADP	O	O	1182
the	PRON	O	O	1182
setting	VERB	O	O	1182
of	ADP	O	O	1182
cocaine	NOUN	O	Chemical	1182
use	VERB	O	O	1182
poses	VERB	O	O	1182
a	PRON	O	O	1182
diagnostic	ADJ	O	O	1182
dilemma	NOUN	O	O	1182
.	PUNCT	O	O	1182
Dobutamine	NOUN	O	Chemical	1183
stress	NOUN	O	O	1183
echocardiography	NOUN	O	O	1183
(	PUNCT	O	O	1183
DSE	PROPN	O	O	1183
)	PUNCT	O	O	1183
is	AUX	O	O	1183
a	PRON	O	O	1183
widely	ADV	O	O	1183
available	ADJ	O	O	1183
and	CCONJ	O	O	1183
sensitive	ADJ	O	O	1183
test	NOUN	O	O	1183
for	ADP	O	O	1183
evaluating	VERB	O	O	1183
cardiac	ADJ	O	O	1183
ischemia	NOUN	O	Disease	1183
.	PUNCT	O	O	1183
Because	SCONJ	O	O	1184
of	ADP	O	O	1184
the	PRON	O	O	1184
theoretical	ADJ	O	O	1184
concern	NOUN	O	O	1184
regarding	VERB	O	O	1184
administration	NOUN	O	O	1184
of	ADP	O	O	1184
dobutamine	NOUN	O	Chemical	1184
in	ADP	O	O	1184
the	PRON	O	O	1184
setting	VERB	O	O	1184
of	ADP	O	O	1184
cocaine	NOUN	O	Chemical	1184
use	VERB	O	O	1184
,	PUNCT	O	O	1184
we	PRON	O	O	1184
conducted	VERB	O	O	1184
a	PRON	O	O	1184
pilot	NOUN	O	O	1184
study	VERB	O	O	1184
to	PART	O	O	1184
assess	VERB	O	O	1184
the	PRON	O	O	1184
safety	NOUN	O	O	1184
of	ADP	O	O	1184
DSE	PROPN	O	O	1184
in	ADP	O	O	1184
emergency	NOUN	O	O	1184
department	NOUN	O	O	1184
patients	NOUN	O	O	1184
with	ADP	O	O	1184
cocaine	NOUN	O	Chemical	1184
-	PUNCT	O	O	1184
associated	VERB	O	O	1184
chest pain	NOUN	O	Disease	1184
.	PUNCT	O	O	1184
Patients	NOUN	O	O	1185
were	AUX	O	O	1185
eligible	ADJ	O	O	1185
for	ADP	O	O	1185
DSE	PROPN	O	O	1185
if	SCONJ	O	O	1185
they	PRON	O	O	1185
had	VERB	O	O	1185
used	VERB	O	O	1185
cocaine	NOUN	O	Chemical	1185
within	ADP	O	O	1185
24	NUM	O	O	1185
hours	NOUN	O	O	1185
preceding	VERB	O	O	1185
the	PRON	O	O	1185
onset	VERB	O	O	1185
of	ADP	O	O	1185
chest pain	NOUN	O	Disease	1185
and	CCONJ	O	O	1185
had	VERB	O	O	1185
a	PRON	O	O	1185
normal	ADJ	O	O	1185
ECG	PROPN	O	O	1185
and	CCONJ	O	O	1185
tropinin	PROPN	O	O	1185
I	PRON	O	O	1185
level	VERB	O	O	1185
.	PUNCT	O	O	1185
Patients	NOUN	O	O	1186
exhibiting	VERB	O	O	1186
signs	NOUN	O	O	1186
of	ADP	O	O	1186
continuing	VERB	O	O	1186
cocaine	NOUN	O	Chemical	1186
toxicity	NOUN	O	Disease	1186
were	AUX	O	O	1186
excluded	VERB	O	O	1186
from	ADP	O	O	1186
the	PRON	O	O	1186
study	VERB	O	O	1186
.	PUNCT	O	O	1186
Two	NUM	O	O	1187
patients	NOUN	O	O	1187
had	VERB	O	O	1187
inadequate	ADJ	O	O	1187
resting	VERB	O	O	1187
images	NOUN	O	O	1187
,	PUNCT	O	O	1187
one	NUM	O	O	1187
DSE	PROPN	O	O	1187
was	AUX	O	O	1187
terminated	VERB	O	O	1187
because	SCONJ	O	O	1187
of	ADP	O	O	1187
inferior	ADJ	O	O	1187
hypokinesis	VERB	O	O	1187
,	PUNCT	O	O	1187
another	PRON	O	O	1187
DSE	PROPN	O	O	1187
was	AUX	O	O	1187
terminated	VERB	O	O	1187
because	SCONJ	O	O	1187
of	ADP	O	O	1187
a	PRON	O	O	1187
rate	NOUN	O	O	1187
-	PUNCT	O	O	1187
related	ADJ	O	O	1187
atrial	ADJ	O	O	1187
conduction	NOUN	O	O	1187
deficit	NOUN	O	O	1187
,	PUNCT	O	O	1187
and	CCONJ	O	O	1187
1	X	O	O	1187
patient	NOUN	O	O	1187
did	VERB	O	O	1187
not	PART	O	O	1187
reach	VERB	O	O	1187
the	PRON	O	O	1187
target	NOUN	O	O	1187
heart	NOUN	O	O	1187
rate	NOUN	O	O	1187
.	PUNCT	O	O	1187
None	NOUN	O	O	1188
of	ADP	O	O	1188
the	PRON	O	O	1188
patients	NOUN	O	O	1188
experienced	ADJ	O	O	1188
signs	NOUN	O	O	1188
of	ADP	O	O	1188
exaggerated	ADJ	O	O	1188
adrenergic	NOUN	O	O	1188
response	NOUN	O	O	1188
,	PUNCT	O	O	1188
which	PRON	O	O	1188
was	AUX	O	O	1188
defined	VERB	O	O	1188
as	ADP	O	O	1188
a	PRON	O	O	1188
systolic	ADV	O	O	1188
blood	NOUN	O	O	1188
pressure	NOUN	O	O	1188
of	ADP	O	O	1188
greater	ADJ	O	O	1188
than	ADP	O	O	1188
200	NUM	O	O	1188
mm	INTJ	O	O	1188
Hg	PROPN	O	O	1188
or	CCONJ	O	O	1188
the	PRON	O	O	1188
occurrence	NOUN	O	O	1188
of	ADP	O	O	1188
tachydysrhythmias	PROPN	O	O	1188
(	PUNCT	O	O	1188
excluding	VERB	O	O	1188
sinus	NOUN	O	O	1188
tachycardia	PROPN	O	Disease	1188
)	PUNCT	O	O	1188
.	PUNCT	O	O	1188
Further	ADV	O	O	1189
suggesting	VERB	O	O	1189
lack	VERB	O	O	1189
of	ADP	O	O	1189
exaggerated	ADJ	O	O	1189
adrenergic	NOUN	O	O	1189
response	NOUN	O	O	1189
,	PUNCT	O	O	1189
13	NUM	O	O	1189
(	PUNCT	O	O	1189
65%	NOUN	O	O	1189
)	PUNCT	O	O	1189
of	ADP	O	O	1189
20	NUM	O	O	1189
patients	NOUN	O	O	1189
required	VERB	O	O	1189
supplemental	PROPN	O	O	1189
atropine	NOUN	O	Chemical	1189
to	PART	O	O	1189
reach	VERB	O	O	1189
their	PRON	O	O	1189
target	NOUN	O	O	1189
heart	NOUN	O	O	1189
rates	NOUN	O	O	1189
.	PUNCT	O	O	1189
No	PRON	O	O	1190
exaggerated	ADJ	O	O	1190
adrenergic	NOUN	O	O	1190
response	NOUN	O	O	1190
was	AUX	O	O	1190
detected	VERB	O	O	1190
when	SCONJ	O	O	1190
dobutamine	NOUN	O	Chemical	1190
was	AUX	O	O	1190
administered	VERB	O	O	1190
to	PART	O	O	1190
patients	NOUN	O	O	1190
with	ADP	O	O	1190
cocaine	NOUN	O	Chemical	1190
-	PUNCT	O	O	1190
related	ADJ	O	O	1190
chest pain	NOUN	O	Disease	1190
.	PUNCT	O	O	1190
Amiodarone	NOUN	O	Chemical	1193
-	PUNCT	O	O	1193
induced	VERB	O	O	1193
torsade de pointes	NOUN	O	Disease	1193
during	ADP	O	O	1193
bladder	NOUN	O	O	1193
irrigation	NOUN	O	O	1193
:	PUNCT	O	O	1193
an	PRON	O	O	1193
unusual	ADJ	O	O	1193
presentation	NOUN	O	O	1193
--	PUNCT	O	O	1193
a	PRON	O	O	1193
case	NOUN	O	O	1193
report	VERB	O	O	1193
.	PUNCT	O	O	1193
The	PRON	O	O	1194
authors	NOUN	O	O	1194
present	NOUN	O	O	1194
a	PRON	O	O	1194
case	NOUN	O	O	1194
of	ADP	O	O	1194
early	ADV	O	O	1194
(	PUNCT	O	O	1194
within	ADP	O	O	1194
4	NUM	O	O	1194
days	NOUN	O	O	1194
)	PUNCT	O	O	1194
development	NOUN	O	O	1194
of	ADP	O	O	1194
torsade de pointes	NOUN	O	Disease	1194
(	PUNCT	O	O	1194
TdP	NOUN	O	Disease	1194
)	PUNCT	O	O	1194
associated	VERB	O	O	1194
with	ADP	O	O	1194
oral	ADJ	O	O	1194
amiodarone	NOUN	O	Chemical	1194
therapy	NOUN	O	O	1194
.	PUNCT	O	O	1194
Consistent	ADJ	O	O	1195
with	ADP	O	O	1195
other	ADJ	O	O	1195
reports	VERB	O	O	1195
this	PRON	O	O	1195
case	NOUN	O	O	1195
of	ADP	O	O	1195
TdP	NOUN	O	Disease	1195
occurred	VERB	O	O	1195
in	ADP	O	O	1195
the	PRON	O	O	1195
context	NOUN	O	O	1195
of	ADP	O	O	1195
multiple	ADJ	O	O	1195
exacerbating	VERB	O	O	1195
factors	NOUN	O	O	1195
including	VERB	O	O	1195
hypokalemia	PROPN	O	Disease	1195
and	CCONJ	O	O	1195
digoxin	PROPN	O	Chemical	1195
excess	ADJ	O	O	1195
.	PUNCT	O	O	1195
Transient	ADJ	O	O	1196
prolongation	NOUN	O	O	1196
of	ADP	O	O	1196
the	PRON	O	O	1196
QT	NOUN	O	O	1196
during	ADP	O	O	1196
bladder	NOUN	O	O	1196
irrigation	NOUN	O	O	1196
prompted	VERB	O	O	1196
the	PRON	O	O	1196
episode	PROPN	O	O	1196
of	ADP	O	O	1196
TdP.	NOUN	O	O	1196
It	PRON	O	O	1196
is	AUX	O	O	1196
well	ADV	O	O	1196
known	VERB	O	O	1196
that	SCONJ	O	O	1196
bradycardia	NOUN	O	Disease	1196
exacerbates	VERB	O	O	1196
acquired	VERB	O	O	1196
TdP.	NOUN	O	O	1196
The	PRON	O	O	1197
authors	NOUN	O	O	1197
speculate	VERB	O	O	1197
that	SCONJ	O	O	1197
the	PRON	O	O	1197
increased	VERB	O	O	1197
vagal	ADJ	O	O	1197
tone	NOUN	O	O	1197
during	ADP	O	O	1197
bladder	NOUN	O	O	1197
irrigation	NOUN	O	O	1197
,	PUNCT	O	O	1197
a	PRON	O	O	1197
vagal	ADJ	O	O	1197
maneuver	VERB	O	O	1197
,	PUNCT	O	O	1197
in	ADP	O	O	1197
the	PRON	O	O	1197
context	NOUN	O	O	1197
of	ADP	O	O	1197
amiodarone	NOUN	O	Chemical	1197
therapy	NOUN	O	O	1197
resulted	VERB	O	O	1197
in	ADP	O	O	1197
amiodarone	NOUN	O	Chemical	1197
-	PUNCT	O	O	1197
induced	VERB	O	O	1197
proarrhythmia	NOUN	O	O	1197
.	PUNCT	O	O	1197
In	ADP	O	O	1198
the	PRON	O	O	1198
absence	NOUN	O	O	1198
of	ADP	O	O	1198
amiodarone	NOUN	O	Chemical	1198
therapy	NOUN	O	O	1198
,	PUNCT	O	O	1198
a	PRON	O	O	1198
second	ADV	O	O	1198
bladder	NOUN	O	O	1198
irrigation	NOUN	O	O	1198
did	VERB	O	O	1198
not	PART	O	O	1198
induce	VERB	O	O	1198
TdP	NOUN	O	Disease	1198
despite	SCONJ	O	O	1198
hypokalemia	PROPN	O	Disease	1198
and	CCONJ	O	O	1198
hypomagnesemia	ADV	O	Disease	1198
.	PUNCT	O	O	1198
Acute	PROPN	O	O	1201
renal insufficiency	NOUN	O	Disease	1201
after	ADP	O	O	1201
high	ADJ	O	O	1201
-	PUNCT	O	O	1201
dose	NOUN	O	O	1201
melphalan	NOUN	O	O	1201
in	ADP	O	O	1201
patients	NOUN	O	O	1201
with	ADP	O	O	1201
primary	NOUN	O	O	1201
systemic	ADJ	O	O	1201
amyloidosis	NOUN	O	O	1201
during	ADP	O	O	1201
stem	VERB	O	O	1201
cell	NOUN	O	O	1201
transplantation	NOUN	O	O	1201
.	PUNCT	O	O	1201
Patients	NOUN	O	O	1202
with	ADP	O	O	1202
primary	NOUN	O	O	1202
systemic	ADJ	O	O	1202
amyloidosis	NOUN	O	O	1202
(	PUNCT	O	O	1202
AL	PROPN	O	O	1202
)	PUNCT	O	O	1202
have	VERB	O	O	1202
a	PRON	O	O	1202
poor	ADJ	O	O	1202
prognosis	VERB	O	O	1202
.	PUNCT	O	O	1202
High	ADJ	O	O	1203
-	PUNCT	O	O	1203
dose	NOUN	O	O	1203
intravenous	ADJ	O	O	1203
melphalan	NOUN	O	O	1203
followed	VERB	O	O	1203
by	ADP	O	O	1203
peripheral	ADJ	O	O	1203
blood	NOUN	O	O	1203
stem	VERB	O	O	1203
cell	NOUN	O	O	1203
transplant	NOUN	O	O	1203
(	PUNCT	O	O	1203
PBSCT	PROPN	O	O	1203
)	PUNCT	O	O	1203
appears	VERB	O	O	1203
to	PART	O	O	1203
be	AUX	O	O	1203
the	PRON	O	O	1203
most	ADV	O	O	1203
promising	VERB	O	O	1203
therapy	NOUN	O	O	1203
,	PUNCT	O	O	1203
but	CCONJ	O	O	1203
treatment	NOUN	O	O	1203
mortality	NOUN	O	O	1203
can	AUX	O	O	1203
be	AUX	O	O	1203
high	ADJ	O	O	1203
.	PUNCT	O	O	1203
The	PRON	O	O	1204
authors	NOUN	O	O	1204
have	VERB	O	O	1204
noted	VERB	O	O	1204
the	PRON	O	O	1204
development	NOUN	O	O	1204
of	ADP	O	O	1204
acute	ADJ	O	O	1204
renal insufficiency	NOUN	O	Disease	1204
immediately	ADV	O	O	1204
after	ADP	O	O	1204
melphalan	NOUN	O	O	1204
conditioning	NOUN	O	O	1204
.	PUNCT	O	O	1204
METHODS	NOUN	O	O	1205
:	PUNCT	O	O	1205
Consecutive	ADJ	O	O	1205
AL	PROPN	O	O	1205
patients	NOUN	O	O	1205
who	PRON	O	O	1205
underwent	VERB	O	O	1205
PBSCT	PROPN	O	O	1205
were	AUX	O	O	1205
studied	VERB	O	O	1205
retrospectively	ADV	O	O	1205
.	PUNCT	O	O	1205
Acute	PROPN	O	O	1206
renal insufficiency	NOUN	O	Disease	1206
(	PUNCT	O	O	1206
ARI	PROPN	O	O	1206
)	PUNCT	O	O	1206
after	ADP	O	O	1206
high	ADJ	O	O	1206
-	PUNCT	O	O	1206
dose	NOUN	O	O	1206
melphalan	NOUN	O	O	1206
was	AUX	O	O	1206
defined	VERB	O	O	1206
by	ADP	O	O	1206
a	PRON	O	O	1206
minimum	ADJ	O	O	1206
increase	VERB	O	O	1206
of	ADP	O	O	1206
0.5	NUM	O	O	1206
mg	VERB	O	O	1206
/	PUNCT	O	O	1206
dL	VERB	O	O	1206
(	PUNCT	O	O	1206
44	NUM	O	O	1206
micromol	NOUN	O	O	1206
/	PUNCT	O	O	1206
L	NOUN	O	O	1206
)	PUNCT	O	O	1206
in	ADP	O	O	1206
the	PRON	O	O	1206
serum	NOUN	O	O	1206
creatinine	PROPN	O	Chemical	1206
level	VERB	O	O	1206
that	SCONJ	O	O	1206
is	AUX	O	O	1206
greater	ADJ	O	O	1206
than	ADP	O	O	1206
50%	NOUN	O	O	1206
of	ADP	O	O	1206
baseline	VERB	O	O	1206
immediately	ADV	O	O	1206
after	ADP	O	O	1206
conditioning	NOUN	O	O	1206
.	PUNCT	O	O	1206
Of	ADV	O	O	1207
the	PRON	O	O	1207
80	NUM	O	O	1207
patients	NOUN	O	O	1207
studied	VERB	O	O	1207
,	PUNCT	O	O	1207
ARI	PROPN	O	O	1207
developed	VERB	O	O	1207
in	ADP	O	O	1207
18.8%	NOUN	O	O	1207
of	ADP	O	O	1207
the	PRON	O	O	1207
patients	NOUN	O	O	1207
after	ADP	O	O	1207
high	ADJ	O	O	1207
-	PUNCT	O	O	1207
dose	NOUN	O	O	1207
melphalan	NOUN	O	O	1207
.	PUNCT	O	O	1207
Univariate	NOUN	O	O	1208
analysis	NOUN	O	O	1208
identified	VERB	O	O	1208
age	NOUN	O	O	1208
,	PUNCT	O	O	1208
hypoalbuminemia	ADV	O	Disease	1208
,	PUNCT	O	O	1208
heavy	ADJ	O	O	1208
proteinuria	X	O	Disease	1208
,	PUNCT	O	O	1208
diuretic	ADJ	O	Chemical	1208
use	VERB	O	O	1208
,	PUNCT	O	O	1208
and	CCONJ	O	O	1208
urine	NOUN	O	O	1208
sediment	NOUN	O	O	1208
score	VERB	O	O	1208
(	PUNCT	O	O	1208
>	PUNCT	O	O	1208
3	X	O	O	1208
)	PUNCT	O	O	1208
as	ADP	O	O	1208
risk	NOUN	O	O	1208
factors	NOUN	O	O	1208
.	PUNCT	O	O	1208
Patients	NOUN	O	O	1209
who	PRON	O	O	1209
had	VERB	O	O	1209
ARI	PROPN	O	O	1209
after	ADP	O	O	1209
high	ADJ	O	O	1209
-	PUNCT	O	O	1209
dose	NOUN	O	O	1209
melphalan	NOUN	O	O	1209
underwent	VERB	O	O	1209
dialysis	NOUN	O	O	1209
more	ADJ	O	O	1209
often	ADV	O	O	1209
(	PUNCT	O	O	1209
P	NOUN	O	Chemical	1209
=	PUNCT	O	O	1209
0.007	NUM	O	O	1209
)	PUNCT	O	O	1209
,	PUNCT	O	O	1209
and	CCONJ	O	O	1209
had	VERB	O	O	1209
a	PRON	O	O	1209
worse	ADJ	O	O	1209
1-year	NOUN	O	O	1209
survival	NOUN	O	O	1209
(	PUNCT	O	O	1209
P	NOUN	O	Chemical	1209
=	PUNCT	O	O	1209
0.03	NUM	O	O	1209
)	PUNCT	O	O	1209
.	PUNCT	O	O	1209
The	PRON	O	O	1210
timing	NOUN	O	O	1210
of	ADP	O	O	1210
renal injury	NOUN	O	Disease	1210
strongly	ADV	O	O	1210
suggests	VERB	O	O	1210
melphalan	NOUN	O	O	1210
as	ADP	O	O	1210
the	PRON	O	O	1210
causative	ADJ	O	O	1210
agent	NOUN	O	O	1210
.	PUNCT	O	O	1210
Ongoing	ADJ	O	O	1211
tubular	ADJ	O	O	1211
injury	NOUN	O	O	1211
may	AUX	O	O	1211
be	AUX	O	O	1211
a	PRON	O	O	1211
prerequisite	NOUN	O	O	1211
for	ADP	O	O	1211
renal injury	NOUN	O	Disease	1211
by	ADP	O	O	1211
melphalan	NOUN	O	O	1211
as	ADP	O	O	1211
evidenced	VERB	O	O	1211
by	ADP	O	O	1211
the	PRON	O	O	1211
active	ADJ	O	O	1211
urinary	ADJ	O	O	1211
sediment	NOUN	O	O	1211
.	PUNCT	O	O	1211
Development	NOUN	O	O	1212
of	ADP	O	O	1212
ARI	PROPN	O	O	1212
adversely	ADV	O	O	1212
affected	VERB	O	O	1212
the	PRON	O	O	1212
outcome	NOUN	O	O	1212
after	ADP	O	O	1212
PBSCT	PROPN	O	O	1212
.	PUNCT	O	O	1212
Effective	ADJ	O	O	1213
preventive	ADJ	O	O	1213
measures	NOUN	O	O	1213
may	AUX	O	O	1213
help	VERB	O	O	1213
decrease	VERB	O	O	1213
the	PRON	O	O	1213
treatment	NOUN	O	O	1213
mortality	NOUN	O	O	1213
of	ADP	O	O	1213
PBSCT	PROPN	O	O	1213
in	ADP	O	O	1213
AL	PROPN	O	O	1213
patients	NOUN	O	O	1213
.	PUNCT	O	O	1213
Impaired	ADJ	O	O	1216
fear	VERB	O	O	1216
recognition	NOUN	O	O	1216
in	ADP	O	O	1216
regular	ADJ	O	O	1216
recreational	ADJ	O	O	1216
cocaine	NOUN	O	Chemical	1216
users	NOUN	O	O	1216
.	PUNCT	O	O	1216
The	PRON	O	O	1217
aim	VERB	O	O	1217
of	ADP	O	O	1217
the	PRON	O	O	1217
present	NOUN	O	O	1217
study	VERB	O	O	1217
was	AUX	O	O	1217
to	PART	O	O	1217
conduct	VERB	O	O	1217
the	PRON	O	O	1217
first	ADV	O	O	1217
investigation	NOUN	O	O	1217
of	ADP	O	O	1217
facial	ADJ	O	O	1217
expression	NOUN	O	O	1217
recognition	NOUN	O	O	1217
performance	NOUN	O	O	1217
in	ADP	O	O	1217
recreational	ADJ	O	O	1217
cocaine	NOUN	O	Chemical	1217
users	NOUN	O	O	1217
.	PUNCT	O	O	1217
MATERIALS	NOUN	O	O	1218
AND	CCONJ	O	O	1218
METHODS	NOUN	O	O	1218
:	PUNCT	O	O	1218
Three	NUM	O	O	1218
groups	NOUN	O	O	1218
,	PUNCT	O	O	1218
comprised	VERB	O	O	1218
of	ADP	O	O	1218
21	NUM	O	O	1218
cocaine	NOUN	O	Chemical	1218
naive	ADJ	O	O	1218
participants	NOUN	O	O	1218
(	PUNCT	O	O	1218
CN	PROPN	O	O	1218
)	PUNCT	O	O	1218
,	PUNCT	O	O	1218
30	NUM	O	O	1218
occasional	ADJ	O	O	1218
cocaine	NOUN	O	Chemical	1218
(	PUNCT	O	O	1218
OC	PROPN	O	O	1218
)	PUNCT	O	O	1218
,	PUNCT	O	O	1218
and	CCONJ	O	O	1218
48	NUM	O	O	1218
regular	ADJ	O	O	1218
recreational	ADJ	O	O	1218
cocaine	NOUN	O	Chemical	1218
(	PUNCT	O	O	1218
RC	PROPN	O	O	1218
)	PUNCT	O	O	1218
users	NOUN	O	O	1218
,	PUNCT	O	O	1218
were	AUX	O	O	1218
compared	VERB	O	O	1218
.	PUNCT	O	O	1218
There	ADV	O	O	1219
were	AUX	O	O	1219
no	PRON	O	O	1219
group	NOUN	O	O	1219
differences	NOUN	O	O	1219
in	ADP	O	O	1219
psychopathology	NOUN	O	O	1219
or	CCONJ	O	O	1219
""""	PUNCT	O	O	1219
eyes	NOUN	O	O	1219
task	NOUN	O	O	1219
""""	PUNCT	O	O	1219
performance	NOUN	O	O	1219
,	PUNCT	O	O	1219
but	CCONJ	O	O	1219
the	PRON	O	O	1219
RC	PROPN	O	O	1219
group	NOUN	O	O	1219
,	PUNCT	O	O	1219
who	PRON	O	O	1219
otherwise	ADV	O	O	1219
had	VERB	O	O	1219
similar	ADJ	O	O	1219
illicit	ADJ	O	O	1219
substance	NOUN	O	O	1219
use	VERB	O	O	1219
histories	NOUN	O	O	1219
to	PART	O	O	1219
the	PRON	O	O	1219
OC	PROPN	O	O	1219
group	NOUN	O	O	1219
,	PUNCT	O	O	1219
exhibited	VERB	O	O	1219
impaired	VERB	O	O	1219
fear	VERB	O	O	1219
recognition	NOUN	O	O	1219
accuracy	NOUN	O	O	1219
compared	VERB	O	O	1219
to	PART	O	O	1219
the	PRON	O	O	1219
OC	PROPN	O	O	1219
and	CCONJ	O	O	1219
CN	PROPN	O	O	1219
groups	NOUN	O	O	1219
.	PUNCT	O	O	1219
The	PRON	O	O	1220
selective	ADJ	O	O	1220
deficit	NOUN	O	O	1220
in	ADP	O	O	1220
fear	VERB	O	O	1220
recognition	NOUN	O	O	1220
accuracy	NOUN	O	O	1220
manifested	VERB	O	O	1220
by	ADP	O	O	1220
the	PRON	O	O	1220
RC	PROPN	O	O	1220
group	NOUN	O	O	1220
can	AUX	O	O	1220
not	PART	O	O	1220
be	AUX	O	O	1220
explained	VERB	O	O	1220
by	ADP	O	O	1220
the	PRON	O	O	1220
subacute	VERB	O	O	1220
effects	NOUN	O	O	1220
of	ADP	O	O	1220
cocaine	NOUN	O	Chemical	1220
,	PUNCT	O	O	1220
or	CCONJ	O	O	1220
ecstasy	NOUN	O	Chemical	1220
,	PUNCT	O	O	1220
because	SCONJ	O	O	1220
recent	ADJ	O	O	1220
and	CCONJ	O	O	1220
less	ADV	O	O	1220
recent	ADJ	O	O	1220
users	NOUN	O	O	1220
of	ADP	O	O	1220
these	PRON	O	O	1220
drugs	NOUN	O	O	1220
within	ADP	O	O	1220
this	PRON	O	O	1220
group	NOUN	O	O	1220
were	AUX	O	O	1220
similarly	ADV	O	O	1220
impaired	VERB	O	O	1220
.	PUNCT	O	O	1220
Possible	ADJ	O	O	1221
parallels	VERB	O	O	1221
between	ADP	O	O	1221
RC	PROPN	O	O	1221
users	NOUN	O	O	1221
and	CCONJ	O	O	1221
psychopaths	NOUN	O	O	1221
with	ADP	O	O	1221
respect	VERB	O	O	1221
to	PART	O	O	1221
impaired	VERB	O	O	1221
fear	VERB	O	O	1221
recognition	NOUN	O	O	1221
,	PUNCT	O	O	1221
amygdala	NOUN	O	O	1221
dysfunction	NOUN	O	O	1221
,	PUNCT	O	O	1221
and	CCONJ	O	O	1221
etiology	NOUN	O	O	1221
are	AUX	O	O	1221
discussed	VERB	O	O	1221
.	PUNCT	O	O	1221
Corneal	NOUN	O	O	1224
ulcers	NOUN	O	O	1224
associated	VERB	O	O	1224
with	ADP	O	O	1224
aerosolized	VERB	O	O	1224
crack cocaine	NOUN	O	Chemical	1224
use	VERB	O	O	1224
.	PUNCT	O	O	1224
We	PRON	O	O	1225
report	VERB	O	O	1225
4	NUM	O	O	1225
cases	NOUN	O	O	1225
of	ADP	O	O	1225
corneal	PROPN	O	O	1225
ulcers	NOUN	O	O	1225
associated	VERB	O	O	1225
with	ADP	O	O	1225
drug abuse	NOUN	O	Disease	1225
.	PUNCT	O	O	1225
The	PRON	O	O	1226
pathogenesis	NOUN	O	O	1226
of	ADP	O	O	1226
these	PRON	O	O	1226
ulcers	NOUN	O	O	1226
and	CCONJ	O	O	1226
management	NOUN	O	O	1226
of	ADP	O	O	1226
these	PRON	O	O	1226
patients	NOUN	O	O	1226
are	AUX	O	O	1226
also	ADV	O	O	1226
reviewed	VERB	O	O	1226
.	PUNCT	O	O	1226
METHODS	NOUN	O	O	1227
:	PUNCT	O	O	1227
Review	NOUN	O	O	1227
of	ADP	O	O	1227
all	PRON	O	O	1227
cases	NOUN	O	O	1227
of	ADP	O	O	1227
corneal	PROPN	O	O	1227
ulcers	NOUN	O	O	1227
associated	VERB	O	O	1227
with	ADP	O	O	1227
drug abuse	NOUN	O	Disease	1227
seen	VERB	O	O	1227
at	ADP	O	O	1227
our	PRON	O	O	1227
institution	NOUN	O	O	1227
from	ADP	O	O	1227
July	PROPN	O	O	1227
2006	NUM	O	O	1227
to	PART	O	O	1227
December	PROPN	O	O	1227
2006	NUM	O	O	1227
.	PUNCT	O	O	1227
RESULTS	VERB	O	O	1228
:	PUNCT	O	O	1228
Four	NUM	O	O	1228
patients	NOUN	O	O	1228
with	ADP	O	O	1228
corneal	PROPN	O	O	1228
ulcers	NOUN	O	O	1228
associated	VERB	O	O	1228
with	ADP	O	O	1228
crack cocaine	NOUN	O	Chemical	1228
use	VERB	O	O	1228
were	AUX	O	O	1228
reviewed	VERB	O	O	1228
.	PUNCT	O	O	1228
All	PRON	O	O	1229
corneal	PROPN	O	O	1229
ulcers	NOUN	O	O	1229
were	AUX	O	O	1229
cultured	ADJ	O	O	1229
,	PUNCT	O	O	1229
and	CCONJ	O	O	1229
the	PRON	O	O	1229
patients	NOUN	O	O	1229
were	AUX	O	O	1229
admitted	VERB	O	O	1229
to	PART	O	O	1229
the	PRON	O	O	1229
hospital	PROPN	O	O	1229
for	ADP	O	O	1229
intensive	ADJ	O	O	1229
topical	ADJ	O	O	1229
antibiotic	ADJ	O	O	1229
treatment	NOUN	O	O	1229
.	PUNCT	O	O	1229
Each	PRON	O	O	1230
patient	NOUN	O	O	1230
received	VERB	O	O	1230
comprehensive	ADJ	O	O	1230
health	NOUN	O	O	1230
care	VERB	O	O	1230
,	PUNCT	O	O	1230
including	VERB	O	O	1230
medical	ADJ	O	O	1230
and	CCONJ	O	O	1230
substance abuse	NOUN	O	Disease	1230
consultations	NOUN	O	O	1230
.	PUNCT	O	O	1230
The	PRON	O	O	1231
infections	NOUN	O	Disease	1231
responded	VERB	O	O	1231
to	PART	O	O	1231
antibiotic	ADJ	O	O	1231
treatment	NOUN	O	O	1231
.	PUNCT	O	O	1231
Two	NUM	O	O	1232
patients	NOUN	O	O	1232
needed	VERB	O	O	1232
a	PRON	O	O	1232
lateral	PROPN	O	O	1232
tarsorrhaphy	NOUN	O	O	1232
for	ADP	O	O	1232
persistent	ADJ	O	O	1232
epithelial	ADJ	O	O	1232
defects	NOUN	O	O	1232
.	PUNCT	O	O	1232
CONCLUSIONS	NOUN	O	O	1233
:	PUNCT	O	O	1233
Aerosolized	VERB	O	O	1233
crack cocaine	NOUN	O	Chemical	1233
use	VERB	O	O	1233
can	AUX	O	O	1233
be	AUX	O	O	1233
associated	VERB	O	O	1233
with	ADP	O	O	1233
the	PRON	O	O	1233
development	NOUN	O	O	1233
of	ADP	O	O	1233
corneal	PROPN	O	O	1233
ulcers	NOUN	O	O	1233
.	PUNCT	O	O	1233
Drug	NOUN	O	O	1234
abuse	VERB	O	O	1234
provides	VERB	O	O	1234
additional	ADJ	O	O	1234
challenges	VERB	O	O	1234
for	ADP	O	O	1234
management	NOUN	O	O	1234
.	PUNCT	O	O	1234
Not	PART	O	O	1235
only	ADV	O	O	1235
treatment	NOUN	O	O	1235
of	ADP	O	O	1235
their	PRON	O	O	1235
infections	NOUN	O	Disease	1235
but	CCONJ	O	O	1235
also	ADV	O	O	1235
the	PRON	O	O	1235
overall	ADV	O	O	1235
poor	ADJ	O	O	1235
health	NOUN	O	O	1235
of	ADP	O	O	1235
the	PRON	O	O	1235
patients	NOUN	O	O	1235
and	CCONJ	O	O	1235
increased	VERB	O	O	1235
risk	NOUN	O	O	1235
of	ADP	O	O	1235
noncompliance	NOUN	O	O	1235
need	VERB	O	O	1235
to	PART	O	O	1235
be	AUX	O	O	1235
addressed	VERB	O	O	1235
.	PUNCT	O	O	1235
Comprehensive	ADJ	O	O	1236
care	VERB	O	O	1236
may	AUX	O	O	1236
provide	VERB	O	O	1236
the	PRON	O	O	1236
patient	NOUN	O	O	1236
the	PRON	O	O	1236
opportunity	NOUN	O	O	1236
to	PART	O	O	1236
discontinue	VERB	O	O	1236
their	PRON	O	O	1236
substance abuse	NOUN	O	Disease	1236
,	PUNCT	O	O	1236
improve	VERB	O	O	1236
their	PRON	O	O	1236
overall	ADV	O	O	1236
health	NOUN	O	O	1236
,	PUNCT	O	O	1236
and	CCONJ	O	O	1236
prevent	VERB	O	O	1236
future	NOUN	O	O	1236
corneal	PROPN	O	O	1236
complications	NOUN	O	O	1236
.	PUNCT	O	O	1236
Levetiracetam	NOUN	O	O	1239
as	ADP	O	O	1239
an	PRON	O	O	1239
adjunct	NOUN	O	O	1239
to	PART	O	O	1239
phenobarbital	NOUN	O	Chemical	1239
treatment	NOUN	O	O	1239
in	ADP	O	O	1239
cats	NOUN	O	O	1239
with	ADP	O	O	1239
suspected	VERB	O	O	1239
idiopathic	ADJ	O	O	1239
epilepsy	NOUN	O	Disease	1239
.	PUNCT	O	O	1239
OBJECTIVE	VERB	O	O	1240
:	PUNCT	O	O	1240
To	PART	O	O	1240
assess	VERB	O	O	1240
pharmacokinetics	NOUN	O	O	1240
,	PUNCT	O	O	1240
efficacy	NOUN	O	O	1240
,	PUNCT	O	O	1240
and	CCONJ	O	O	1240
tolerability	NOUN	O	O	1240
of	ADP	O	O	1240
oral	ADJ	O	O	1240
levetiracetam	VERB	O	O	1240
administered	VERB	O	O	1240
as	ADP	O	O	1240
an	PRON	O	O	1240
adjunct	NOUN	O	O	1240
to	PART	O	O	1240
phenobarbital	NOUN	O	Chemical	1240
treatment	NOUN	O	O	1240
in	ADP	O	O	1240
cats	NOUN	O	O	1240
with	ADP	O	O	1240
poorly	ADV	O	O	1240
controlled	VERB	O	O	1240
suspected	VERB	O	O	1240
idiopathic	ADJ	O	O	1240
epilepsy	NOUN	O	Disease	1240
.	PUNCT	O	O	1240
ANIMALS	NOUN	O	O	1241
:	PUNCT	O	O	1241
12	NUM	O	O	1241
cats	NOUN	O	O	1241
suspected	VERB	O	O	1241
to	PART	O	O	1241
have	VERB	O	O	1241
idiopathic	ADJ	O	O	1241
epilepsy	NOUN	O	Disease	1241
that	SCONJ	O	O	1241
was	AUX	O	O	1241
poorly	ADV	O	O	1241
controlled	VERB	O	O	1241
with	ADP	O	O	1241
phenobarbital	NOUN	O	Chemical	1241
or	CCONJ	O	O	1241
that	SCONJ	O	O	1241
had	VERB	O	O	1241
unacceptable	ADJ	O	O	1241
adverse	ADJ	O	O	1241
effects	NOUN	O	O	1241
when	SCONJ	O	O	1241
treated	VERB	O	O	1241
with	ADP	O	O	1241
phenobarbital	NOUN	O	Chemical	1241
.	PUNCT	O	O	1241
Cats	NOUN	O	O	1242
were	AUX	O	O	1242
treated	VERB	O	O	1242
with	ADP	O	O	1242
levetiracetam	VERB	O	O	1242
(	PUNCT	O	O	1242
20	NUM	O	O	1242
mg	VERB	O	O	1242
/	PUNCT	O	O	1242
kg	VERB	O	O	1242
[	X	O	O	1242
9.1	NUM	O	O	1242
mg	VERB	O	O	1242
/	PUNCT	O	O	1242
lb	NUM	O	O	1242
]	PUNCT	O	O	1242
,	PUNCT	O	O	1242
PO	NOUN	O	O	1242
,	PUNCT	O	O	1242
q	X	O	O	1242
8	NUM	O	O	1242
h	X	O	O	1242
)	PUNCT	O	O	1242
.	PUNCT	O	O	1242
After	ADP	O	O	1243
a	PRON	O	O	1243
minimum	ADJ	O	O	1243
of	ADP	O	O	1243
1	X	O	O	1243
week	NOUN	O	O	1243
of	ADP	O	O	1243
treatment	NOUN	O	O	1243
,	PUNCT	O	O	1243
serum	NOUN	O	O	1243
levetiracetam	VERB	O	O	1243
concentrations	NOUN	O	O	1243
were	AUX	O	O	1243
measured	VERB	O	O	1243
before	ADP	O	O	1243
and	CCONJ	O	O	1243
2	X	O	O	1243
,	PUNCT	O	O	1243
4	NUM	O	O	1243
,	PUNCT	O	O	1243
and	CCONJ	O	O	1243
6	NUM	O	O	1243
hours	NOUN	O	O	1243
after	ADP	O	O	1243
drug	NOUN	O	O	1243
administration	NOUN	O	O	1243
,	PUNCT	O	O	1243
and	CCONJ	O	O	1243
maximum	ADV	O	O	1243
and	CCONJ	O	O	1243
minimum	ADJ	O	O	1243
serum	NOUN	O	O	1243
concentrations	NOUN	O	O	1243
and	CCONJ	O	O	1243
elimination	NOUN	O	O	1243
half	NOUN	O	O	1243
-	PUNCT	O	O	1243
life	NOUN	O	O	1243
were	AUX	O	O	1243
calculated	VERB	O	O	1243
.	PUNCT	O	O	1243
Seizure	NOUN	O	Disease	1244
frequencies	NOUN	O	O	1244
before	ADP	O	O	1244
and	CCONJ	O	O	1244
after	ADP	O	O	1244
initiation	NOUN	O	O	1244
of	ADP	O	O	1244
levetiracetam	VERB	O	O	1244
treatment	NOUN	O	O	1244
were	AUX	O	O	1244
compared	VERB	O	O	1244
,	PUNCT	O	O	1244
and	CCONJ	O	O	1244
adverse	ADJ	O	O	1244
effects	NOUN	O	O	1244
were	AUX	O	O	1244
recorded	VERB	O	O	1244
.	PUNCT	O	O	1244
Median	ADJ	O	O	1245
maximum	ADV	O	O	1245
serum	NOUN	O	O	1245
levetiracetam	VERB	O	O	1245
concentration	NOUN	O	O	1245
was	AUX	O	O	1245
25.5	NUM	O	O	1245
microg	PROPN	O	O	1245
/	PUNCT	O	O	1245
mL	PROPN	O	O	1245
,	PUNCT	O	O	1245
median	ADJ	O	O	1245
minimum	ADJ	O	O	1245
serum	NOUN	O	O	1245
levetiracetam	VERB	O	O	1245
concentration	NOUN	O	O	1245
was	AUX	O	O	1245
8.3	NUM	O	O	1245
microg	PROPN	O	O	1245
/	PUNCT	O	O	1245
mL	PROPN	O	O	1245
,	PUNCT	O	O	1245
and	CCONJ	O	O	1245
median	ADJ	O	O	1245
elimination	NOUN	O	O	1245
half	NOUN	O	O	1245
-	PUNCT	O	O	1245
life	NOUN	O	O	1245
was	AUX	O	O	1245
2.9	NUM	O	O	1245
hours	NOUN	O	O	1245
.	PUNCT	O	O	1245
Median	ADJ	O	O	1246
seizure	NOUN	O	Disease	1246
frequency	NOUN	O	O	1246
prior	ADV	O	O	1246
to	PART	O	O	1246
treatment	NOUN	O	O	1246
with	ADP	O	O	1246
levetiracetam	VERB	O	O	1246
(	PUNCT	O	O	1246
2.1	NUM	O	O	1246
seizures	NOUN	O	Disease	1246
/	PUNCT	O	O	1246
mo	PROPN	O	O	1246
)	PUNCT	O	O	1246
was	AUX	O	O	1246
significantly	ADV	O	O	1246
higher	ADJ	O	O	1246
than	ADP	O	O	1246
median	ADJ	O	O	1246
seizure	NOUN	O	Disease	1246
frequency	NOUN	O	O	1246
after	ADP	O	O	1246
initiation	NOUN	O	O	1246
of	ADP	O	O	1246
levetiracetam	VERB	O	O	1246
treatment	NOUN	O	O	1246
(	PUNCT	O	O	1246
0.42	NUM	O	O	1246
seizures	NOUN	O	Disease	1246
/	PUNCT	O	O	1246
mo	PROPN	O	O	1246
)	PUNCT	O	O	1246
,	PUNCT	O	O	1246
and	CCONJ	O	O	1246
7	NUM	O	O	1246
of	ADP	O	O	1246
10	NUM	O	O	1246
cats	NOUN	O	O	1246
were	AUX	O	O	1246
classified	VERB	O	O	1246
as	ADP	O	O	1246
having	VERB	O	O	1246
responded	VERB	O	O	1246
to	PART	O	O	1246
levetiracetam	VERB	O	O	1246
treatment	NOUN	O	O	1246
(	PUNCT	O	O	1246
ie	ADV	O	O	1246
,	PUNCT	O	O	1246
reduction	NOUN	O	O	1246
in	ADP	O	O	1246
seizure	NOUN	O	Disease	1246
frequency	NOUN	O	O	1246
of	ADP	O	O	1246
>	PUNCT	O	O	1246
or=50%	NOUN	O	O	1246
)	PUNCT	O	O	1246
.	PUNCT	O	O	1246
Two	NUM	O	O	1247
cats	NOUN	O	O	1247
had	VERB	O	O	1247
transient	ADJ	O	O	1247
lethargy	NOUN	O	Disease	1247
and	CCONJ	O	O	1247
inappetence	NOUN	O	O	1247
.	PUNCT	O	O	1247
Results	NOUN	O	O	1248
suggested	VERB	O	O	1248
that	SCONJ	O	O	1248
levetiracetam	VERB	O	O	1248
is	AUX	O	O	1248
well	ADV	O	O	1248
tolerated	VERB	O	O	1248
in	ADP	O	O	1248
cats	NOUN	O	O	1248
and	CCONJ	O	O	1248
may	AUX	O	O	1248
be	AUX	O	O	1248
useful	ADJ	O	O	1248
as	ADP	O	O	1248
an	PRON	O	O	1248
adjunct	NOUN	O	O	1248
to	PART	O	O	1248
phenobarbital	NOUN	O	Chemical	1248
treatment	NOUN	O	O	1248
in	ADP	O	O	1248
cats	NOUN	O	O	1248
with	ADP	O	O	1248
idiopathic	ADJ	O	O	1248
epilepsy	NOUN	O	Disease	1248
.	PUNCT	O	O	1248
Bilateral	ADJ	O	O	1251
haemorrhagic	ADJ	O	Disease	1251
infarction	NOUN	O	O	1251
of	ADP	O	O	1251
the	PRON	O	O	1251
globus	PROPN	O	O	1251
pallidus	VERB	O	O	1251
after	ADP	O	O	1251
cocaine	NOUN	O	Chemical	1251
and	CCONJ	O	O	1251
alcohol	NOUN	O	Chemical	1251
intoxication	NOUN	O	O	1251
.	PUNCT	O	O	1251
Cocaine	NOUN	O	Chemical	1252
is	AUX	O	O	1252
a	PRON	O	O	1252
risk	NOUN	O	O	1252
factor	NOUN	O	O	1252
for	ADP	O	O	1252
both	PRON	O	O	1252
ischemic	VERB	O	Disease	1252
and	CCONJ	O	O	1252
haemorrhagic	ADJ	O	Disease	1252
stroke	VERB	O	Disease	1252
.	PUNCT	O	O	1252
We	PRON	O	O	1253
present	NOUN	O	O	1253
the	PRON	O	O	1253
case	NOUN	O	O	1253
of	ADP	O	O	1253
a	PRON	O	O	1253
31-year	NOUN	O	O	1253
-	PUNCT	O	O	1253
old	ADJ	O	O	1253
man	NOUN	O	O	1253
with	ADP	O	O	1253
bilateral	ADJ	O	O	1253
ischemia	NOUN	O	Disease	1253
of	ADP	O	O	1253
the	PRON	O	O	1253
globus	PROPN	O	O	1253
pallidus	VERB	O	O	1253
after	ADP	O	O	1253
excessive	ADJ	O	O	1253
alcohol	NOUN	O	Chemical	1253
and	CCONJ	O	O	1253
intranasal	NOUN	O	O	1253
cocaine	NOUN	O	Chemical	1253
use	VERB	O	O	1253
.	PUNCT	O	O	1253
Drug	NOUN	O	O	1254
-	PUNCT	O	O	1254
related	ADJ	O	O	1254
globus	PROPN	O	O	1254
pallidus	VERB	O	O	1254
infarctions	NOUN	O	O	1254
are	AUX	O	O	1254
most	ADV	O	O	1254
often	ADV	O	O	1254
associated	VERB	O	O	1254
with	ADP	O	O	1254
heroin	NOUN	O	Chemical	1254
.	PUNCT	O	O	1254
Bilateral	ADJ	O	O	1255
basal	PROPN	O	O	1255
ganglia	NOUN	O	O	1255
infarcts	VERB	O	O	1255
after	ADP	O	O	1255
the	PRON	O	O	1255
use	VERB	O	O	1255
of	ADP	O	O	1255
cocaine	NOUN	O	Chemical	1255
,	PUNCT	O	O	1255
without	ADP	O	O	1255
concurrent	ADJ	O	O	1255
heroin	NOUN	O	Chemical	1255
use	VERB	O	O	1255
,	PUNCT	O	O	1255
have	VERB	O	O	1255
never	ADV	O	O	1255
been	AUX	O	O	1255
reported	VERB	O	O	1255
.	PUNCT	O	O	1255
In	ADP	O	O	1256
our	PRON	O	O	1256
patient	NOUN	O	O	1256
,	PUNCT	O	O	1256
transient	ADJ	O	O	1256
cardiac arrhythmia	NOUN	O	Disease	1256
or	CCONJ	O	O	1256
respiratory	NOUN	O	O	1256
dysfunction	NOUN	O	O	1256
related	ADJ	O	O	1256
to	PART	O	O	1256
cocaine	NOUN	O	Chemical	1256
and/or	CCONJ	O	O	1256
ethanol	NOUN	O	Chemical	1256
use	VERB	O	O	1256
were	AUX	O	O	1256
the	PRON	O	O	1256
most	ADV	O	O	1256
likely	ADV	O	O	1256
causes	VERB	O	O	1256
of	ADP	O	O	1256
cerebral	ADJ	O	O	1256
hypoperfusion	NOUN	O	O	1256
.	PUNCT	O	O	1256
Acute	PROPN	O	O	1259
renal failure	NOUN	O	Disease	1259
after	ADP	O	O	1259
high	ADJ	O	O	1259
-	PUNCT	O	O	1259
dose	NOUN	O	O	1259
methotrexate	CCONJ	O	Chemical	1259
therapy	NOUN	O	O	1259
in	ADP	O	O	1259
a	PRON	O	O	1259
patient	NOUN	O	O	1259
with	ADP	O	O	1259
ileostomy	NOUN	O	O	1259
.	PUNCT	O	O	1259
High	ADJ	O	O	1260
-	PUNCT	O	O	1260
dose	NOUN	O	O	1260
methotrexate	CCONJ	O	Chemical	1260
(	PUNCT	O	O	1260
HD	NOUN	O	O	1260
-	PUNCT	O	O	1260
MTX	PROPN	O	O	1260
)	PUNCT	O	O	1260
is	AUX	O	O	1260
an	PRON	O	O	1260
important	ADJ	O	O	1260
treatment	NOUN	O	O	1260
for	ADP	O	O	1260
Burkitt	PROPN	O	O	1260
lymphoma	PROPN	O	Disease	1260
,	PUNCT	O	O	1260
but	CCONJ	O	O	1260
can	AUX	O	O	1260
cause	VERB	O	O	1260
hepatic	ADJ	O	O	1260
and	CCONJ	O	O	1260
renal toxicity	NOUN	O	Disease	1260
when	SCONJ	O	O	1260
its	PRON	O	O	1260
clearance	NOUN	O	O	1260
is	AUX	O	O	1260
delayed	VERB	O	O	1260
.	PUNCT	O	O	1260
We	PRON	O	O	1261
report	VERB	O	O	1261
a	PRON	O	O	1261
case	NOUN	O	O	1261
of	ADP	O	O	1261
acute	ADJ	O	O	1261
renal failure	NOUN	O	Disease	1261
after	ADP	O	O	1261
HD	NOUN	O	O	1261
-	PUNCT	O	O	1261
MTX	PROPN	O	O	1261
therapy	NOUN	O	O	1261
in	ADP	O	O	1261
a	PRON	O	O	1261
patient	NOUN	O	O	1261
with	ADP	O	O	1261
ileostomy	NOUN	O	O	1261
,	PUNCT	O	O	1261
The	PRON	O	O	1261
patient	NOUN	O	O	1261
was	AUX	O	O	1261
a	PRON	O	O	1261
3-year	NOUN	O	O	1261
-	PUNCT	O	O	1261
old	ADJ	O	O	1261
boy	NOUN	O	O	1261
who	PRON	O	O	1261
had	VERB	O	O	1261
received	VERB	O	O	1261
a	PRON	O	O	1261
living	VERB	O	O	1261
-	PUNCT	O	O	1261
related	ADJ	O	O	1261
liver	NOUN	O	O	1261
transplantation	NOUN	O	O	1261
for	ADP	O	O	1261
congenital	NOUN	O	O	1261
biliary	ADJ	O	O	1261
atresia	PRON	O	O	1261
.	PUNCT	O	O	1261
At	ADP	O	O	1262
day	NOUN	O	O	1262
833	NUM	O	O	1262
after	ADP	O	O	1262
the	PRON	O	O	1262
transplantation	NOUN	O	O	1262
,	PUNCT	O	O	1262
he	PRON	O	O	1262
was	AUX	O	O	1262
diagnosed	VERB	O	O	1262
with	ADP	O	O	1262
PTLD	PROPN	O	Disease	1262
(	PUNCT	O	O	1262
post	VERB	O	O	1262
-	PUNCT	O	O	1262
transplantation	NOUN	O	O	1262
lymphoproliferative	VERB	O	O	1262
disorder	NOUN	O	O	1262
,	PUNCT	O	O	1262
Burkitt	PROPN	O	O	1262
-	PUNCT	O	O	1262
type	NOUN	O	O	1262
malignant	ADJ	O	O	1262
lymphoma	PROPN	O	Disease	1262
)	PUNCT	O	O	1262
.	PUNCT	O	O	1262
Subsequent	PROPN	O	O	1263
HD	NOUN	O	O	1263
-	PUNCT	O	O	1263
MTX	PROPN	O	O	1263
therapy	NOUN	O	O	1263
caused	VERB	O	O	1263
acute	ADJ	O	O	1263
renal failure	NOUN	O	Disease	1263
that	SCONJ	O	O	1263
required	VERB	O	O	1263
continuous	ADJ	O	O	1263
hemodialysis	NOUN	O	O	1263
.	PUNCT	O	O	1263
We	PRON	O	O	1264
supposed	VERB	O	O	1264
that	SCONJ	O	O	1264
intravascular	ADJ	O	O	1264
hypovolemia	NOUN	O	O	1264
due	ADJ	O	O	1264
to	PART	O	O	1264
substantial	ADJ	O	O	1264
drainage	NOUN	O	O	1264
from	ADP	O	O	1264
the	PRON	O	O	1264
ileostoma	VERB	O	O	1264
caused	VERB	O	O	1264
acute	ADJ	O	O	1264
prerenal failure	NOUN	O	O	1264
.	PUNCT	O	O	1264
After	ADP	O	O	1265
recovery	NOUN	O	O	1265
of	ADP	O	O	1265
his	PRON	O	O	1265
renal	ADJ	O	O	1265
function	NOUN	O	O	1265
,	PUNCT	O	O	1265
we	PRON	O	O	1265
could	AUX	O	O	1265
safely	ADV	O	O	1265
treat	VERB	O	O	1265
the	PRON	O	O	1265
patient	NOUN	O	O	1265
with	ADP	O	O	1265
HD	NOUN	O	O	1265
-	PUNCT	O	O	1265
MTX	PROPN	O	O	1265
therapy	NOUN	O	O	1265
by	ADP	O	O	1265
controlling	VERB	O	O	1265
drainage	NOUN	O	O	1265
from	ADP	O	O	1265
ileostoma	VERB	O	O	1265
with	ADP	O	O	1265
total	ADJ	O	O	1265
parenteral	ADJ	O	O	1265
nutrition	NOUN	O	O	1265
.	PUNCT	O	O	1265
Antithrombotic	ADJ	O	O	1268
drug	NOUN	O	O	1268
use	VERB	O	O	1268
,	PUNCT	O	O	1268
cerebral	ADJ	O	O	1268
microbleeds	NOUN	O	O	1268
,	PUNCT	O	O	1268
and	CCONJ	O	O	1268
intracerebral hemorrhage	NOUN	O	Disease	1268
:	PUNCT	O	O	1268
a	PRON	O	O	1268
systematic	ADJ	O	O	1268
review	VERB	O	O	1268
of	ADP	O	O	1268
published	VERB	O	O	1268
and	CCONJ	O	O	1268
unpublished	ADJ	O	O	1268
studies	NOUN	O	O	1268
.	PUNCT	O	O	1268
BACKGROUND	NOUN	O	O	1269
AND	CCONJ	O	O	1269
PURPOSE	NOUN	O	O	1269
:	PUNCT	O	O	1269
Cerebral	ADJ	O	O	1269
microbleeds	NOUN	O	O	1269
(	PUNCT	O	O	1269
MB	NOUN	O	O	1269
)	PUNCT	O	O	1269
are	AUX	O	O	1269
potential	ADJ	O	O	1269
risk	NOUN	O	O	1269
factors	NOUN	O	O	1269
for	ADP	O	O	1269
intracerebral hemorrhage	NOUN	O	Disease	1269
(	PUNCT	O	O	1269
ICH	PROPN	O	Disease	1269
)	PUNCT	O	O	1269
,	PUNCT	O	O	1269
but	CCONJ	O	O	1269
it	PRON	O	O	1269
is	AUX	O	O	1269
unclear	ADJ	O	O	1269
if	SCONJ	O	O	1269
they	PRON	O	O	1269
are	AUX	O	O	1269
a	PRON	O	O	1269
contraindication	NOUN	O	O	1269
to	PART	O	O	1269
using	VERB	O	O	1269
antithrombotic	ADJ	O	O	1269
drugs	NOUN	O	O	1269
.	PUNCT	O	O	1269
Insights	NOUN	O	O	1270
could	AUX	O	O	1270
be	AUX	O	O	1270
gained	VERB	O	O	1270
by	ADP	O	O	1270
pooling	VERB	O	O	1270
data	NOUN	O	O	1270
on	ADP	O	O	1270
MB	NOUN	O	O	1270
frequency	NOUN	O	O	1270
stratified	ADJ	O	O	1270
by	ADP	O	O	1270
antithrombotic	ADJ	O	O	1270
use	VERB	O	O	1270
in	ADP	O	O	1270
cohorts	NOUN	O	O	1270
with	ADP	O	O	1270
ICH	PROPN	O	Disease	1270
and	CCONJ	O	O	1270
ischemic	VERB	O	Disease	1270
stroke	VERB	O	Disease	1270
(	PUNCT	O	O	1270
IS)/transient	NOUN	O	O	1270
ischemic	VERB	O	Disease	1270
attack	VERB	O	O	1270
(	PUNCT	O	O	1270
TIA	PROPN	O	O	1270
)	PUNCT	O	O	1270
.	PUNCT	O	O	1270
:	PUNCT	O	O	1271
We	PRON	O	O	1271
performed	VERB	O	O	1271
a	PRON	O	O	1271
systematic	ADJ	O	O	1271
review	VERB	O	O	1271
of	ADP	O	O	1271
published	VERB	O	O	1271
and	CCONJ	O	O	1271
unpublished	ADJ	O	O	1271
data	NOUN	O	O	1271
from	ADP	O	O	1271
cohorts	NOUN	O	O	1271
with	ADP	O	O	1271
stroke	VERB	O	Disease	1271
or	CCONJ	O	O	1271
TIA	PROPN	O	O	1271
to	PART	O	O	1271
compare	VERB	O	O	1271
the	PRON	O	O	1271
presence	NOUN	O	O	1271
of	ADP	O	O	1271
MB	NOUN	O	O	1271
in	ADP	O	O	1271
:	PUNCT	O	O	1271
(	PUNCT	O	O	1271
1	X	O	O	1271
)	PUNCT	O	O	1271
antithrombotic	ADJ	O	O	1271
users	NOUN	O	O	1271
vs	ADP	O	O	1271
nonantithrombotic	ADJ	O	O	1271
users	NOUN	O	O	1271
with	ADP	O	O	1271
ICH	PROPN	O	Disease	1271
;	PUNCT	O	O	1271
(	PUNCT	O	O	1271
2	X	O	O	1271
)	PUNCT	O	O	1271
antithrombotic	ADJ	O	O	1271
users	NOUN	O	O	1271
vs	ADP	O	O	1271
nonusers	NOUN	O	O	1271
with	ADP	O	O	1271
IS	AUX	O	O	1271
/	PUNCT	O	O	1271
TIA	PROPN	O	O	1271
;	PUNCT	O	O	1271
and	CCONJ	O	O	1271
(	PUNCT	O	O	1271
3	X	O	O	1271
)	PUNCT	O	O	1271
ICH	PROPN	O	Disease	1271
vs	ADP	O	O	1271
ischemic	VERB	O	Disease	1271
events	NOUN	O	O	1271
stratified	ADJ	O	O	1271
by	ADP	O	O	1271
antithrombotic	ADJ	O	O	1271
use	VERB	O	O	1271
.	PUNCT	O	O	1271
We	PRON	O	O	1272
also	ADV	O	O	1272
analyzed	VERB	O	O	1272
published	VERB	O	O	1272
and	CCONJ	O	O	1272
unpublished	ADJ	O	O	1272
follow	VERB	O	O	1272
-	PUNCT	O	O	1272
up	ADP	O	O	1272
data	NOUN	O	O	1272
to	PART	O	O	1272
determine	VERB	O	O	1272
the	PRON	O	O	1272
risk	NOUN	O	O	1272
of	ADP	O	O	1272
ICH	PROPN	O	Disease	1272
in	ADP	O	O	1272
antithrombotic	ADJ	O	O	1272
users	NOUN	O	O	1272
with	ADP	O	O	1272
MB	NOUN	O	O	1272
.	PUNCT	O	O	1272
In	ADP	O	O	1273
a	PRON	O	O	1273
pooled	VERB	O	O	1273
analysis	NOUN	O	O	1273
of	ADP	O	O	1273
1460	NUM	O	O	1273
ICH	PROPN	O	Disease	1273
and	CCONJ	O	O	1273
3817	NUM	O	O	1273
IS	AUX	O	O	1273
/	PUNCT	O	O	1273
TIA	PROPN	O	O	1273
,	PUNCT	O	O	1273
MB	NOUN	O	O	1273
were	AUX	O	O	1273
more	ADJ	O	O	1273
frequent	ADJ	O	O	1273
in	ADP	O	O	1273
ICH	PROPN	O	Disease	1273
vs	ADP	O	O	1273
IS	AUX	O	O	1274
/	PUNCT	O	O	1274
TIA	PROPN	O	O	1274
in	ADP	O	O	1274
all	PRON	O	O	1274
treatment	NOUN	O	O	1274
groups	NOUN	O	O	1274
,	PUNCT	O	O	1274
but	CCONJ	O	O	1274
the	PRON	O	O	1274
excess	ADJ	O	O	1274
increased	VERB	O	O	1274
from	ADP	O	O	1274
2.8	NUM	O	O	1274
(	PUNCT	O	O	1274
odds	NOUN	O	O	1274
ratio	NOUN	O	O	1274
;	PUNCT	O	O	1274
range	VERB	O	O	1274
,	PUNCT	O	O	1274
2.3	NUM	O	O	1274
-	PUNCT	O	O	1274
3.5	NUM	O	O	1274
)	PUNCT	O	O	1274
in	ADP	O	O	1274
nonantithrombotic	ADJ	O	O	1274
users	NOUN	O	O	1274
to	PART	O	O	1274
5.7	NUM	O	O	1274
(	PUNCT	O	O	1274
range	VERB	O	O	1274
,	PUNCT	O	O	1274
3.4	NUM	O	O	1274
-	PUNCT	O	O	1274
9.7	NUM	O	O	1274
)	PUNCT	O	O	1274
in	ADP	O	O	1274
antiplatelet	ADV	O	O	1274
users	NOUN	O	O	1274
and	CCONJ	O	O	1274
8.0	NUM	O	O	1274
(	PUNCT	O	O	1274
range	VERB	O	O	1274
,	PUNCT	O	O	1274
3.5	NUM	O	O	1274
-	PUNCT	O	O	1274
17.8	NUM	O	O	1274
)	PUNCT	O	O	1274
in	ADP	O	O	1274
warfarin	VERB	O	Chemical	1274
users	NOUN	O	O	1274
(	PUNCT	O	O	1274
P	NOUN	O	Chemical	1274
difference=0.01	VERB	O	O	1274
)	PUNCT	O	O	1274
.	PUNCT	O	O	1274
There	ADV	O	O	1275
was	AUX	O	O	1275
also	ADV	O	O	1275
an	PRON	O	O	1275
excess	ADJ	O	O	1275
of	ADP	O	O	1275
MB	NOUN	O	O	1275
in	ADP	O	O	1275
warfarin	VERB	O	Chemical	1275
users	NOUN	O	O	1275
vs	ADP	O	O	1275
nonusers	NOUN	O	O	1275
with	ADP	O	O	1275
ICH	PROPN	O	Disease	1275
(	PUNCT	O	O	1275
OR	CCONJ	O	O	1275
,	PUNCT	O	O	1275
2.7	NUM	O	O	1275
;	PUNCT	O	O	1275
95%	NOUN	O	O	1275
CI	NOUN	O	O	1275
,	PUNCT	O	O	1275
1.6	NUM	O	O	1275
-	PUNCT	O	O	1275
4.4	NUM	O	O	1275
;	PUNCT	O	O	1275
P<0.001	ADJ	O	O	1275
)	PUNCT	O	O	1275
but	CCONJ	O	O	1275
none	NOUN	O	O	1275
in	ADP	O	O	1275
warfarin	VERB	O	Chemical	1275
users	NOUN	O	O	1275
with	ADP	O	O	1275
IS	AUX	O	O	1275
/	PUNCT	O	O	1275
TIA	PROPN	O	O	1275
(	PUNCT	O	O	1275
OR	CCONJ	O	O	1275
,	PUNCT	O	O	1275
1.3	NUM	O	O	1275
;	PUNCT	O	O	1275
95%	NOUN	O	O	1275
CI	NOUN	O	O	1275
,	PUNCT	O	O	1275
0.9	NUM	O	O	1275
-	PUNCT	O	O	1275
1.7	NUM	O	O	1275
;	PUNCT	O	O	1275
P=0.33	NOUN	O	O	1275
;	PUNCT	O	O	1275
P	NOUN	O	Chemical	1275
difference=0.01	VERB	O	O	1275
)	PUNCT	O	O	1275
.	PUNCT	O	O	1275
There	ADV	O	O	1276
was	AUX	O	O	1276
a	PRON	O	O	1276
smaller	ADJ	O	O	1276
excess	ADJ	O	O	1276
of	ADP	O	O	1276
MB	NOUN	O	O	1276
in	ADP	O	O	1276
antiplatelet	ADV	O	O	1276
users	NOUN	O	O	1276
vs	ADP	O	O	1276
nonusers	NOUN	O	O	1276
with	ADP	O	O	1276
ICH	PROPN	O	Disease	1276
(	PUNCT	O	O	1276
OR	CCONJ	O	O	1276
,	PUNCT	O	O	1276
1.7	NUM	O	O	1276
;	PUNCT	O	O	1276
95%	NOUN	O	O	1276
CI	NOUN	O	O	1276
,	PUNCT	O	O	1276
1.3	NUM	O	O	1276
-	PUNCT	O	O	1276
2.3	NUM	O	O	1276
;	PUNCT	O	O	1276
P<0.001	ADJ	O	O	1276
)	PUNCT	O	O	1276
,	PUNCT	O	O	1276
but	CCONJ	O	O	1276
findings	NOUN	O	O	1276
were	AUX	O	O	1276
similar	ADJ	O	O	1276
for	ADP	O	O	1276
antiplatelet	ADV	O	O	1276
users	NOUN	O	O	1276
with	ADP	O	O	1276
IS	AUX	O	O	1276
/	PUNCT	O	O	1276
TIA	PROPN	O	O	1276
(	PUNCT	O	O	1276
OR	CCONJ	O	O	1276
,	PUNCT	O	O	1276
1.4	NUM	O	O	1276
;	PUNCT	O	O	1276
95%	NOUN	O	O	1276
CI	NOUN	O	O	1276
,	PUNCT	O	O	1276
1.2	NUM	O	O	1276
-	PUNCT	O	O	1276
1.7	NUM	O	O	1276
;	PUNCT	O	O	1276
P<0.001	ADJ	O	O	1276
;	PUNCT	O	O	1276
P	NOUN	O	Chemical	1276
difference=0.25	ADV	O	O	1276
)	PUNCT	O	O	1276
.	PUNCT	O	O	1276
In	ADP	O	O	1277
pooled	VERB	O	O	1277
follow	VERB	O	O	1277
-	PUNCT	O	O	1277
up	ADP	O	O	1277
data	NOUN	O	O	1277
for	ADP	O	O	1277
768	NUM	O	O	1277
antithrombotic	ADJ	O	O	1277
users	NOUN	O	O	1277
,	PUNCT	O	O	1277
presence	NOUN	O	O	1277
of	ADP	O	O	1277
MB	NOUN	O	O	1277
at	ADP	O	O	1277
baseline	VERB	O	O	1277
was	AUX	O	O	1277
associated	VERB	O	O	1277
with	ADP	O	O	1277
a	PRON	O	O	1277
substantially	ADV	O	O	1277
increased	VERB	O	O	1277
risk	NOUN	O	O	1277
of	ADP	O	O	1277
subsequent	ADJ	O	O	1277
ICH	PROPN	O	Disease	1277
(	PUNCT	O	O	1277
OR	CCONJ	O	O	1277
,	PUNCT	O	O	1277
12.1	NUM	O	O	1277
;	PUNCT	O	O	1277
95%	NOUN	O	O	1277
CI	NOUN	O	O	1277
,	PUNCT	O	O	1277
3.4	NUM	O	O	1277
-	PUNCT	O	O	1277
42.5	NUM	O	O	1277
;	PUNCT	O	O	1277
P<0.001	ADJ	O	O	1277
)	PUNCT	O	O	1277
.	PUNCT	O	O	1277
The	PRON	O	O	1278
excess	ADJ	O	O	1278
of	ADP	O	O	1278
MB	NOUN	O	O	1278
in	ADP	O	O	1278
warfarin	VERB	O	Chemical	1278
users	NOUN	O	O	1278
with	ADP	O	O	1278
ICH	PROPN	O	Disease	1278
compared	VERB	O	O	1278
to	PART	O	O	1278
other	ADJ	O	O	1278
groups	NOUN	O	O	1278
suggests	VERB	O	O	1278
that	SCONJ	O	O	1278
MB	NOUN	O	O	1278
increase	VERB	O	O	1278
the	PRON	O	O	1278
risk	NOUN	O	O	1278
of	ADP	O	O	1278
warfarin	VERB	O	Chemical	1278
-	PUNCT	O	O	1278
associated	VERB	O	O	1278
ICH	PROPN	O	Disease	1278
.	PUNCT	O	O	1278
Verapamil	PROPN	O	Chemical	1281
stimulation	NOUN	O	O	1281
test	NOUN	O	O	1281
in	ADP	O	O	1281
hyperprolactinemia	NOUN	O	Disease	1281
:	PUNCT	O	O	1281
loss	NOUN	O	O	1281
of	ADP	O	O	1281
prolactin	PROPN	O	O	1281
response	NOUN	O	O	1281
in	ADP	O	O	1281
anatomic	ADJ	O	O	1281
or	CCONJ	O	O	1281
functional	ADJ	O	O	1281
stalk	VERB	O	O	1281
effect	VERB	O	O	1281
.	PUNCT	O	O	1281
Verapamil	PROPN	O	Chemical	1282
stimulation	NOUN	O	O	1282
test	NOUN	O	O	1282
was	AUX	O	O	1282
previously	ADV	O	O	1282
investigated	VERB	O	O	1282
as	ADP	O	O	1282
a	PRON	O	O	1282
tool	NOUN	O	O	1282
for	ADP	O	O	1282
differential	ADJ	O	O	1282
diagnosis	NOUN	O	O	1282
of	ADP	O	O	1282
hyperprolactinemia	NOUN	O	Disease	1282
,	PUNCT	O	O	1282
but	CCONJ	O	O	1282
with	ADP	O	O	1282
conflicting	VERB	O	O	1282
results	VERB	O	O	1282
.	PUNCT	O	O	1282
Macroprolactinemia	NOUN	O	O	1283
was	AUX	O	O	1283
never	ADV	O	O	1283
considered	VERB	O	O	1283
in	ADP	O	O	1283
those	PRON	O	O	1283
previous	ADJ	O	O	1283
studies	NOUN	O	O	1283
.	PUNCT	O	O	1283
Here	ADV	O	O	1284
,	PUNCT	O	O	1284
we	PRON	O	O	1284
aimed	VERB	O	O	1284
to	PART	O	O	1284
re	ADP	O	O	1284
-	PUNCT	O	O	1284
investigate	VERB	O	O	1284
the	PRON	O	O	1284
diagnostic	ADJ	O	O	1284
value	NOUN	O	O	1284
of	ADP	O	O	1284
verapamil	PROPN	O	Chemical	1284
in	ADP	O	O	1284
a	PRON	O	O	1284
population	NOUN	O	O	1284
who	PRON	O	O	1284
were	AUX	O	O	1284
all	PRON	O	O	1284
screened	VERB	O	O	1284
for	ADP	O	O	1284
macroprolactinemia	NOUN	O	O	1284
.	PUNCT	O	O	1284
Prolactin	NOUN	O	O	1285
responses	NOUN	O	O	1285
to	PART	O	O	1285
verapamil	PROPN	O	Chemical	1285
in	ADP	O	O	1285
65	NUM	O	O	1285
female	ADJ	O	O	1285
patients	NOUN	O	O	1285
(	PUNCT	O	O	1285
age	NOUN	O	O	1285
:	PUNCT	O	O	1285
29.9	NUM	O	O	1285
+	ADP	O	O	1285
/-	PUNCT	O	O	1285
8.1	NUM	O	O	1286
years	NOUN	O	O	1286
)	PUNCT	O	O	1286
with	ADP	O	O	1286
hyperprolactinemia	NOUN	O	Disease	1286
were	AUX	O	O	1286
tested	VERB	O	O	1286
in	ADP	O	O	1286
a	PRON	O	O	1286
descriptive	ADJ	O	O	1286
,	PUNCT	O	O	1286
matched	VERB	O	O	1286
case	NOUN	O	O	1286
-	PUNCT	O	O	1286
control	VERB	O	O	1286
study	VERB	O	O	1286
.	PUNCT	O	O	1286
METHODS	NOUN	O	O	1287
:	PUNCT	O	O	1287
Verapamil	PROPN	O	Chemical	1287
80	NUM	O	O	1287
mg	VERB	O	O	1287
,	PUNCT	O	O	1287
p.o	PROPN	O	O	1287
.	PUNCT	O	O	1287
Verapamil	PROPN	O	Chemical	1288
responsiveness	NOUN	O	O	1288
was	AUX	O	O	1288
determined	VERB	O	O	1288
by	ADP	O	O	1288
peak	PROPN	O	O	1288
percent	NOUN	O	O	1288
change	VERB	O	O	1288
in	ADP	O	O	1288
basal	PROPN	O	O	1288
prolactin	PROPN	O	O	1288
levels	NOUN	O	O	1288
(	PUNCT	O	O	1288
PRL	NOUN	O	Chemical	1288
)	PUNCT	O	O	1288
.	PUNCT	O	O	1288
Verapamil	PROPN	O	Chemical	1289
significantly	ADV	O	O	1289
increased	VERB	O	O	1289
PRL	NOUN	O	Chemical	1289
levels	NOUN	O	O	1289
in	ADP	O	O	1289
healthy	ADJ	O	O	1289
controls	VERB	O	O	1289
(	PUNCT	O	O	1289
N.	NOUN	O	O	1289
8	NUM	O	O	1289
,	PUNCT	O	O	1289
PRL	NOUN	O	Chemical	1289
:	PUNCT	O	O	1289
183%	NOUN	O	O	1289
)	PUNCT	O	O	1289
,	PUNCT	O	O	1289
macroprolactinoma	VERB	O	O	1289
(	PUNCT	O	O	1289
N.	NOUN	O	O	1289
8	NUM	O	O	1289
,	PUNCT	O	O	1289
PRL	NOUN	O	Chemical	1289
:	PUNCT	O	O	1289
7%	NOUN	O	O	1289
)	PUNCT	O	O	1289
,	PUNCT	O	O	1289
microprolactinoma	NOUN	O	O	1289
(	PUNCT	O	O	1289
N.	NOUN	O	O	1289
19	NUM	O	O	1289
,	PUNCT	O	O	1289
PRL	NOUN	O	Chemical	1289
:	PUNCT	O	O	1289
21%	NOUN	O	O	1289
)	PUNCT	O	O	1289
,	PUNCT	O	O	1289
macroprolactinemia	NOUN	O	O	1289
but	CCONJ	O	O	1290
not	PART	O	O	1290
in	ADP	O	O	1290
pseudoprolactinoma	VERB	O	O	1290
(	PUNCT	O	O	1290
N.	NOUN	O	O	1290
8	NUM	O	O	1290
,	PUNCT	O	O	1290
PRL	NOUN	O	Chemical	1290
:	PUNCT	O	O	1290
0.8%	NOUN	O	O	1290
)	PUNCT	O	O	1290
,	PUNCT	O	O	1290
and	CCONJ	O	O	1290
risperidone	VERB	O	Chemical	1290
-	PUNCT	O	O	1290
induced	VERB	O	O	1290
hyperprolactinemia	NOUN	O	Disease	1290
(	PUNCT	O	O	1290
N.	NOUN	O	O	1290
7	NUM	O	O	1290
,	PUNCT	O	O	1290
ROC	PROPN	O	O	1291
curve	NOUN	O	O	1291
analysis	NOUN	O	O	1291
revealed	VERB	O	O	1291
that	SCONJ	O	O	1291
unresponsiveness	NOUN	O	O	1291
to	PART	O	O	1291
verapamil	PROPN	O	Chemical	1291
defined	VERB	O	O	1291
as	ADP	O	O	1291
PRL	NOUN	O	Chemical	1291
<	X	O	O	1292
0.001	NUM	O	O	1292
,	PUNCT	O	O	1292
CI	NOUN	O	O	1292
:	PUNCT	O	O	1292
0.768	NUM	O	O	1292
-	PUNCT	O	O	1292
0.942	NUM	O	O	1292
)	PUNCT	O	O	1292
associated	VERB	O	O	1292
with	ADP	O	O	1292
pseudoprolactinoma	VERB	O	O	1292
or	CCONJ	O	O	1292
risperidone	VERB	O	Chemical	1292
-	PUNCT	O	O	1292
induced	VERB	O	O	1292
hyperprolactinemia	NOUN	O	Disease	1292
,	PUNCT	O	O	1292
respectively	ADV	O	O	1292
.	PUNCT	O	O	1292
CONCLUSION	PROPN	O	O	1293
:	PUNCT	O	O	1293
Verapamil	PROPN	O	Chemical	1293
responsiveness	NOUN	O	O	1293
is	AUX	O	O	1293
not	PART	O	O	1293
a	PRON	O	O	1293
reliable	ADJ	O	O	1293
finding	VERB	O	O	1293
for	ADP	O	O	1293
the	PRON	O	O	1293
differential	ADJ	O	O	1293
diagnosis	NOUN	O	O	1293
of	ADP	O	O	1293
hyperprolactinemia	NOUN	O	Disease	1293
.	PUNCT	O	O	1293
However	ADV	O	O	1294
,	PUNCT	O	O	1294
verapamil	PROPN	O	Chemical	1294
unresponsiveness	NOUN	O	O	1294
discriminates	VERB	O	O	1294
stalk	VERB	O	O	1294
effect	VERB	O	O	1294
(	PUNCT	O	O	1294
i.e.	X	O	O	1294
,	PUNCT	O	O	1294
anatomically	ADV	O	O	1294
or	CCONJ	O	O	1294
functionally	ADV	O	O	1294
inhibited	VERB	O	O	1294
dopaminergic	ADJ	O	O	1294
tonus	NOUN	O	O	1294
)	PUNCT	O	O	1294
from	ADP	O	O	1294
other	ADJ	O	O	1294
causes	VERB	O	O	1294
of	ADP	O	O	1294
hyperprolactinemia	NOUN	O	Disease	1294
with	ADP	O	O	1294
varying	VERB	O	O	1294
degrees	NOUN	O	O	1294
of	ADP	O	O	1294
responsiveness	NOUN	O	O	1294
.	PUNCT	O	O	1294
The	PRON	O	O	1297
effect	VERB	O	O	1297
of	ADP	O	O	1297
clonidine	NOUN	O	Chemical	1297
,	PUNCT	O	O	1297
naphazoline	NOUN	O	O	1297
and	CCONJ	O	O	1297
xylometazoline	NOUN	O	O	1297
on	ADP	O	O	1297
analgesia	NOUN	O	Disease	1297
induced	VERB	O	O	1297
by	ADP	O	O	1297
morphine	NOUN	O	Chemical	1297
,	PUNCT	O	O	1297
codeine	PROPN	O	O	1297
,	PUNCT	O	O	1297
fentanyl	ADJ	O	Chemical	1297
and	CCONJ	O	O	1297
pentazocine	NOUN	O	O	1297
,	PUNCT	O	O	1297
and	CCONJ	O	O	1297
on	ADP	O	O	1297
cataleptic	NOUN	O	Disease	1297
effect	VERB	O	O	1297
of	ADP	O	O	1297
morphine	NOUN	O	Chemical	1297
,	PUNCT	O	O	1297
codine	PROPN	O	O	1297
and	CCONJ	O	O	1297
fentanyl	ADJ	O	Chemical	1297
was	AUX	O	O	1297
studied	VERB	O	O	1297
in	ADP	O	O	1297
rats	NOUN	O	O	1297
.	PUNCT	O	O	1297
The	PRON	O	O	1298
biochemical	ADJ	O	O	1298
assays	NOUN	O	O	1298
on	ADP	O	O	1298
the	PRON	O	O	1298
influence	NOUN	O	O	1298
of	ADP	O	O	1298
four	NUM	O	O	1298
analgesics	NOUN	O	O	1298
on	ADP	O	O	1298
the	PRON	O	O	1298
brain	NOUN	O	O	1298
concentration	NOUN	O	O	1298
and	CCONJ	O	O	1298
turnover	NOUN	O	O	1298
of	ADP	O	O	1298
noradrenaline	NOUN	O	Chemical	1298
(	PUNCT	O	O	1298
NA	PROPN	O	O	1298
)	PUNCT	O	O	1298
were	AUX	O	O	1298
also	ADV	O	O	1298
performed	VERB	O	O	1298
.	PUNCT	O	O	1298
It	PRON	O	O	1299
was	AUX	O	O	1299
found	VERB	O	O	1299
that	SCONJ	O	O	1299
three	NUM	O	O	1299
drugs	NOUN	O	O	1299
stimulating	VERB	O	O	1299
central	ADJ	O	O	1299
NA	PROPN	O	O	1299
receptors	NOUN	O	O	1299
failed	VERB	O	O	1299
to	PART	O	O	1299
affect	VERB	O	O	1299
the	PRON	O	O	1299
analgesic	PROPN	O	O	1299
ED50	PROPN	O	O	1299
of	ADP	O	O	1299
all	PRON	O	O	1299
antinociceptive	VERB	O	O	1299
agents	NOUN	O	O	1299
and	CCONJ	O	O	1299
they	PRON	O	O	1299
enhanced	VERB	O	O	1299
catalepsy	VERB	O	Disease	1299
induced	VERB	O	O	1299
by	ADP	O	O	1299
morphine	NOUN	O	Chemical	1299
and	CCONJ	O	O	1299
fentanyl	ADJ	O	Chemical	1299
.	PUNCT	O	O	1299
Codeine	NOUN	O	O	1300
catalepsy	VERB	O	Disease	1300
was	AUX	O	O	1300
increased	VERB	O	O	1300
by	ADP	O	O	1300
clonidine	NOUN	O	Chemical	1300
and	CCONJ	O	O	1300
decreased	VERB	O	O	1300
by	ADP	O	O	1300
naphazoline	NOUN	O	O	1300
and	CCONJ	O	O	1300
xylometazoline	NOUN	O	O	1300
.	PUNCT	O	O	1300
The	PRON	O	O	1301
brain	NOUN	O	O	1301
concentration	NOUN	O	O	1301
of	ADP	O	O	1301
NA	PROPN	O	O	1301
was	AUX	O	O	1301
not	PART	O	O	1301
changed	VERB	O	O	1301
by	ADP	O	O	1301
morphine	NOUN	O	Chemical	1301
and	CCONJ	O	O	1301
fentanyl	ADJ	O	Chemical	1301
,	PUNCT	O	O	1301
but	CCONJ	O	O	1301
one	NUM	O	O	1301
of	ADP	O	O	1301
the	PRON	O	O	1301
doses	NOUN	O	O	1301
of	ADP	O	O	1301
codeine	PROPN	O	O	1301
(	PUNCT	O	O	1301
45	NUM	O	O	1301
mg	VERB	O	O	1301
/	PUNCT	O	O	1301
kg	VERB	O	O	1301
)	PUNCT	O	O	1301
slightly	ADV	O	O	1301
enhanced	VERB	O	O	1301
it	PRON	O	O	1301
.	PUNCT	O	O	1301
Pentazocine	NOUN	O	O	1302
dose	NOUN	O	O	1302
-	PUNCT	O	O	1302
dependently	ADV	O	O	1302
decreased	VERB	O	O	1302
the	PRON	O	O	1302
brain	NOUN	O	O	1302
level	VERB	O	O	1302
of	ADP	O	O	1302
NA	PROPN	O	O	1302
.	PUNCT	O	O	1302
The	PRON	O	O	1303
rate	NOUN	O	O	1303
of	ADP	O	O	1303
NA	PROPN	O	O	1303
turnover	NOUN	O	O	1303
was	AUX	O	O	1303
not	PART	O	O	1303
altered	VERB	O	O	1303
by	ADP	O	O	1303
analgesics	NOUN	O	O	1303
except	SCONJ	O	O	1303
for	ADP	O	O	1303
the	PRON	O	O	1303
higher	ADJ	O	O	1303
dose	NOUN	O	O	1303
of	ADP	O	O	1303
fentanyl	ADJ	O	Chemical	1303
(	PUNCT	O	O	1303
0.2	NUM	O	O	1303
mg	VERB	O	O	1303
/	PUNCT	O	O	1303
kg	VERB	O	O	1303
)	PUNCT	O	O	1303
following	VERB	O	O	1303
which	PRON	O	O	1303
the	PRON	O	O	1303
disappearance	NOUN	O	O	1303
of	ADP	O	O	1303
NA	PROPN	O	O	1303
from	ADP	O	O	1303
the	PRON	O	O	1303
brain	NOUN	O	O	1303
was	AUX	O	O	1303
diminished	VERB	O	O	1303
.	PUNCT	O	O	1303
It	PRON	O	O	1304
is	AUX	O	O	1304
suggested	VERB	O	O	1304
that	SCONJ	O	O	1304
in	ADP	O	O	1304
rats	NOUN	O	O	1304
the	PRON	O	O	1304
brain	NOUN	O	O	1304
NA	PROPN	O	O	1304
plays	VERB	O	O	1304
a	PRON	O	O	1304
less	ADV	O	O	1304
important	ADJ	O	O	1304
function	NOUN	O	O	1304
than	ADP	O	O	1304
the	PRON	O	O	1304
other	ADJ	O	O	1304
monoamines	NOUN	O	O	1304
in	ADP	O	O	1304
the	PRON	O	O	1304
behavioural	ADJ	O	O	1304
activity	NOUN	O	O	1304
of	ADP	O	O	1304
potent	ADJ	O	O	1304
analgesics	NOUN	O	O	1304
.	PUNCT	O	O	1304
Modification	NOUN	O	O	1307
by	ADP	O	O	1307
propranolol	NOUN	O	Chemical	1307
of	ADP	O	O	1307
cardiovascular	ADJ	O	O	1307
effects	NOUN	O	O	1307
of	ADP	O	O	1307
induced	VERB	O	O	1307
hypoglycaemia	NOUN	O	O	1307
.	PUNCT	O	O	1307
The	PRON	O	O	1308
cardiovascular	ADJ	O	O	1308
effects	NOUN	O	O	1308
of	ADP	O	O	1308
hypoglycaemia	NOUN	O	O	1308
,	PUNCT	O	O	1308
with	ADP	O	O	1308
and	CCONJ	O	O	1308
without	ADP	O	O	1308
beta	NOUN	O	O	1308
-	PUNCT	O	O	1308
blockade	VERB	O	O	1308
,	PUNCT	O	O	1308
were	AUX	O	O	1308
compared	VERB	O	O	1308
in	ADP	O	O	1308
fourteen	NUM	O	O	1308
healthy	ADJ	O	O	1308
men	NOUN	O	O	1308
.	PUNCT	O	O	1308
Eight	NUM	O	O	1309
received	VERB	O	O	1309
insulin	NOUN	O	O	1309
alone	ADV	O	O	1309
,	PUNCT	O	O	1309
and	CCONJ	O	O	1309
eight	NUM	O	O	1309
,	PUNCT	O	O	1309
including	VERB	O	O	1309
two	NUM	O	O	1309
of	ADP	O	O	1309
the	PRON	O	O	1309
original	ADJ	O	O	1309
insulin	NOUN	O	O	1309
-	PUNCT	O	O	1309
only	ADV	O	O	1309
group	NOUN	O	O	1309
,	PUNCT	O	O	1309
were	AUX	O	O	1309
given	VERB	O	O	1309
propranolol	NOUN	O	Chemical	1309
and	CCONJ	O	O	1309
insulin	NOUN	O	O	1309
.	PUNCT	O	O	1309
In	ADP	O	O	1310
the	PRON	O	O	1310
insulin	NOUN	O	O	1310
-	PUNCT	O	O	1310
group	NOUN	O	O	1310
the	PRON	O	O	1310
period	NOUN	O	O	1310
of	ADP	O	O	1310
hypoglycaemia	NOUN	O	O	1310
was	AUX	O	O	1310
associated	VERB	O	O	1310
with	ADP	O	O	1310
an	PRON	O	O	1310
increase	VERB	O	O	1310
in	ADP	O	O	1310
heart	NOUN	O	O	1310
-	PUNCT	O	O	1310
rate	NOUN	O	O	1310
and	CCONJ	O	O	1310
a	PRON	O	O	1310
fall	VERB	O	O	1310
in	ADP	O	O	1310
diastolic	ADV	O	O	1310
blood	NOUN	O	O	1310
-	PUNCT	O	O	1310
pressure	NOUN	O	O	1310
.	PUNCT	O	O	1310
In	ADP	O	O	1311
the	PRON	O	O	1311
propranolol	NOUN	O	Chemical	1311
-	PUNCT	O	O	1311
insulin	NOUN	O	O	1311
group	NOUN	O	O	1311
there	ADV	O	O	1311
was	AUX	O	O	1311
a	PRON	O	O	1311
significant	ADJ	O	O	1311
fall	VERB	O	O	1311
in	ADP	O	O	1311
heart	NOUN	O	O	1311
-	PUNCT	O	O	1311
rate	NOUN	O	O	1311
in	ADP	O	O	1311
most	ADV	O	O	1311
subjects	NOUN	O	O	1311
and	CCONJ	O	O	1311
an	PRON	O	O	1311
increase	VERB	O	O	1311
in	ADP	O	O	1311
diastolic	ADV	O	O	1311
pressure	NOUN	O	O	1311
.	PUNCT	O	O	1311
/	PUNCT	O	O	1312
T	NOUN	O	Chemical	1312
changes	VERB	O	O	1312
occurred	VERB	O	O	1312
in	ADP	O	O	1312
the	PRON	O	O	1312
insulin	NOUN	O	O	1312
-	PUNCT	O	O	1312
group	NOUN	O	O	1312
but	CCONJ	O	O	1312
in	ADP	O	O	1312
none	NOUN	O	O	1312
of	ADP	O	O	1312
the	PRON	O	O	1312
propranolol	NOUN	O	Chemical	1312
-	PUNCT	O	O	1312
insulin	NOUN	O	O	1312
group	NOUN	O	O	1312
.	PUNCT	O	O	1312
Hypertension	NOUN	O	Disease	1313
in	ADP	O	O	1313
diabetics	NOUN	O	Disease	1313
prone	ADJ	O	O	1313
to	PART	O	O	1313
hypoglycaemia	NOUN	O	O	1313
attacks	NOUN	O	O	1313
should	AUX	O	O	1313
not	PART	O	O	1313
be	AUX	O	O	1313
treated	VERB	O	O	1313
with	ADP	O	O	1313
beta	NOUN	O	O	1313
-	PUNCT	O	O	1313
blockers	NOUN	O	O	1313
because	SCONJ	O	O	1313
these	PRON	O	O	1313
drugs	NOUN	O	O	1313
may	AUX	O	O	1313
cause	VERB	O	O	1313
a	PRON	O	O	1313
sharp	ADJ	O	O	1313
rise	VERB	O	O	1313
in	ADP	O	O	1313
blood	NOUN	O	O	1313
-	PUNCT	O	O	1313
pressure	NOUN	O	O	1313
in	ADP	O	O	1313
such	ADJ	O	O	1313
patients	NOUN	O	O	1313
.	PUNCT	O	O	1313
Prevention	NOUN	O	O	1316
and	CCONJ	O	O	1316
treatment	NOUN	O	O	1316
of	ADP	O	O	1316
endometrial	ADJ	O	O	1316
disease	PROPN	O	O	1316
in	ADP	O	O	1316
climacteric	PROPN	O	O	1316
women	NOUN	O	O	1316
receiving	VERB	O	O	1316
oestrogen	PROPN	O	Chemical	1316
therapy	NOUN	O	O	1316
.	PUNCT	O	O	1316
The	PRON	O	O	1317
treatment	NOUN	O	O	1317
regimens	NOUN	O	O	1317
are	AUX	O	O	1317
described	VERB	O	O	1317
in	ADP	O	O	1317
74	NUM	O	O	1317
patients	NOUN	O	O	1317
with	ADP	O	O	1317
endometrial	ADJ	O	O	1317
disease	PROPN	O	O	1317
among	ADP	O	O	1317
850	NUM	O	O	1317
climacteric	PROPN	O	O	1317
women	NOUN	O	O	1317
receiving	VERB	O	O	1317
oestrogen	PROPN	O	Chemical	1317
therapy	NOUN	O	O	1317
.	PUNCT	O	O	1317
Cystic	PROPN	O	O	1318
hyperplasia	NOUN	O	Disease	1318
was	AUX	O	O	1318
associated	VERB	O	O	1318
with	ADP	O	O	1318
unopposed	ADJ	O	O	1318
oestrogen	PROPN	O	Chemical	1318
therapy	NOUN	O	O	1318
without	ADP	O	O	1318
progestagen	PROPN	O	O	1318
.	PUNCT	O	O	1318
Two	NUM	O	O	1319
courses	NOUN	O	O	1319
of	ADP	O	O	1319
21	NUM	O	O	1319
days	NOUN	O	O	1319
of	ADP	O	O	1319
5	NUM	O	O	1319
mg	VERB	O	O	1319
norethisterone	VERB	O	O	1319
daily	ADV	O	O	1319
caused	VERB	O	O	1319
reversion	NOUN	O	O	1319
to	PART	O	O	1319
normal	ADJ	O	O	1319
in	ADP	O	O	1319
all	PRON	O	O	1319
57	NUM	O	O	1319
cases	NOUN	O	O	1319
of	ADP	O	O	1319
cystic	PROPN	O	O	1319
hyperplasia	NOUN	O	Disease	1319
and	CCONJ	O	O	1319
6	NUM	O	O	1319
of	ADP	O	O	1319
the	PRON	O	O	1319
8	NUM	O	O	1319
cases	NOUN	O	O	1319
of	ADP	O	O	1319
atypical	ADJ	O	O	1319
hyperplasia	NOUN	O	Disease	1319
.	PUNCT	O	O	1319
4	NUM	O	O	1320
cases	NOUN	O	O	1320
of	ADP	O	O	1320
endometrial carcinoma	NOUN	O	Disease	1320
referred	VERB	O	O	1320
from	ADP	O	O	1320
elsewhere	ADV	O	O	1320
demonstrated	VERB	O	O	1320
the	PRON	O	O	1320
problems	NOUN	O	O	1320
of	ADP	O	O	1320
inappropriate	ADJ	O	O	1320
and	CCONJ	O	O	1320
unsupervised	ADJ	O	O	1320
unopposed	ADJ	O	O	1320
oestrogen	PROPN	O	Chemical	1320
therapy	NOUN	O	O	1320
and	CCONJ	O	O	1320
the	PRON	O	O	1320
difficulty	NOUN	O	O	1320
in	ADP	O	O	1320
distinguishing	VERB	O	O	1320
severe	ADJ	O	O	1320
hyperplasia	NOUN	O	Disease	1320
from	ADP	O	O	1320
malignancy	NOUN	O	Disease	1320
.	PUNCT	O	O	1320
Cyclical	ADJ	O	O	1321
low	ADJ	O	O	1321
-	PUNCT	O	O	1321
dose	NOUN	O	O	1321
oestrogen	PROPN	O	Chemical	1321
therapy	NOUN	O	O	1321
with	ADP	O	O	1321
7	NUM	O	O	1321
-	PUNCT	O	O	1321
-13	NUM	O	O	1321
days	NOUN	O	O	1321
of	ADP	O	O	1321
progestagen	PROPN	O	O	1321
does	VERB	O	O	1321
not	PART	O	O	1321
seem	VERB	O	O	1321
to	PART	O	O	1321
increase	VERB	O	O	1321
the	PRON	O	O	1321
risk	NOUN	O	O	1321
of	ADP	O	O	1321
endometrial	ADJ	O	O	1321
hyperplasia	NOUN	O	Disease	1321
or	CCONJ	O	O	1321
carcinoma	NOUN	O	Disease	1321
.	PUNCT	O	O	1321
Pure	ADJ	O	O	1324
red	ADJ	O	O	1324
cell	NOUN	O	O	1324
aplasia	NOUN	O	O	1324
,	PUNCT	O	O	1324
toxic	ADJ	O	O	1324
dermatitis	NOUN	O	Disease	1324
and	CCONJ	O	O	1324
lymphadenopathy	ADJ	O	O	1324
in	ADP	O	O	1324
a	PRON	O	O	1324
patient	NOUN	O	O	1324
taking	VERB	O	O	1324
diphenylhydantoin	ADJ	O	Chemical	1324
.	PUNCT	O	O	1324
A	PRON	O	O	1325
patient	NOUN	O	O	1325
taking	VERB	O	O	1325
diphenylhydantoin	ADJ	O	Chemical	1325
for	ADP	O	O	1325
3	X	O	O	1325
weeks	NOUN	O	O	1325
developed	VERB	O	O	1325
a	PRON	O	O	1325
generalized	VERB	O	O	1325
skin rash	ADJ	O	Disease	1325
,	PUNCT	O	O	1325
lymphadenopathy	ADJ	O	O	1325
and	CCONJ	O	O	1325
pure	ADJ	O	O	1325
red	ADJ	O	O	1325
cell	NOUN	O	O	1325
aplasia	NOUN	O	O	1325
.	PUNCT	O	O	1325
Skin	NOUN	O	O	1326
rash	ADJ	O	Disease	1326
is	AUX	O	O	1326
a	PRON	O	O	1326
well	ADV	O	O	1326
-	PUNCT	O	O	1326
known	VERB	O	O	1326
complication	NOUN	O	O	1326
of	ADP	O	O	1326
diphenylhydantoin	ADJ	O	Chemical	1326
treatment	NOUN	O	O	1326
as	ADP	O	O	1326
is	AUX	O	O	1326
benign	ADJ	O	O	1326
and	CCONJ	O	O	1326
malignant	ADJ	O	O	1326
lymphadenopathy	ADJ	O	O	1326
.	PUNCT	O	O	1326
Pure	ADJ	O	O	1327
red	ADJ	O	O	1327
cell	NOUN	O	O	1327
aplasia	NOUN	O	O	1327
associated	VERB	O	O	1327
with	ADP	O	O	1327
diphenylhydantoin	ADJ	O	Chemical	1327
medication	NOUN	O	O	1327
has	VERB	O	O	1327
been	AUX	O	O	1327
reported	VERB	O	O	1327
in	ADP	O	O	1327
3	X	O	O	1327
patients	NOUN	O	O	1327
.	PUNCT	O	O	1327
The	PRON	O	O	1328
exact	VERB	O	O	1328
mechanism	NOUN	O	O	1328
by	ADP	O	O	1328
which	PRON	O	O	1328
diphenylhydantoin	ADJ	O	Chemical	1328
exerts	VERB	O	O	1328
its	PRON	O	O	1328
toxic	ADJ	O	O	1328
effects	NOUN	O	O	1328
is	AUX	O	O	1328
not	PART	O	O	1328
known	VERB	O	O	1328
.	PUNCT	O	O	1328
In	ADP	O	O	1329
this	PRON	O	O	1329
patient	NOUN	O	O	1329
the	PRON	O	O	1329
time	NOUN	O	O	1329
relation	NOUN	O	O	1329
between	ADP	O	O	1329
the	PRON	O	O	1329
ingestion	NOUN	O	O	1329
of	ADP	O	O	1329
diphenylhydantoin	ADJ	O	Chemical	1329
and	CCONJ	O	O	1329
the	PRON	O	O	1329
occurrence	NOUN	O	O	1329
of	ADP	O	O	1329
the	PRON	O	O	1329
skin rash	ADJ	O	Disease	1329
,	PUNCT	O	O	1329
lymphadenopathy	ADJ	O	O	1329
and	CCONJ	O	O	1329
pure	ADJ	O	O	1329
red	ADJ	O	O	1329
cell	NOUN	O	O	1329
aplasia	NOUN	O	O	1329
is	AUX	O	O	1329
very	ADV	O	O	1329
suggestive	ADJ	O	O	1329
of	ADP	O	O	1329
a	PRON	O	O	1329
direct	ADJ	O	O	1329
connection	NOUN	O	O	1329
.	PUNCT	O	O	1329
Continuous	ADJ	O	O	1332
infusion	NOUN	O	O	1332
tobramycin	NOUN	O	Chemical	1332
combined	VERB	O	O	1332
with	ADP	O	O	1332
carbenicillin	PROPN	O	O	1332
for	ADP	O	O	1332
infections	NOUN	O	Disease	1332
in	ADP	O	O	1332
cancer	NOUN	O	Disease	1332
patients	NOUN	O	O	1332
.	PUNCT	O	O	1332
The	PRON	O	O	1333
cure	VERB	O	O	1333
rate	NOUN	O	O	1333
of	ADP	O	O	1333
infections	NOUN	O	Disease	1333
in	ADP	O	O	1333
cancer	NOUN	O	Disease	1333
patients	NOUN	O	O	1333
is	AUX	O	O	1333
adversely	ADV	O	O	1333
affected	VERB	O	O	1333
by	ADP	O	O	1333
neutropenia	ADJ	O	Disease	1333
(	PUNCT	O	O	1333
less	ADV	O	O	1333
than	ADP	O	O	1333
1,000/mm3	NOUN	O	O	1333
)	PUNCT	O	O	1333
.	PUNCT	O	O	1333
In	ADP	O	O	1334
particular	ADJ	O	O	1334
,	PUNCT	O	O	1334
patients	NOUN	O	O	1334
with	ADP	O	O	1334
severe	ADJ	O	O	1334
neutropenia	ADJ	O	Disease	1334
(	PUNCT	O	O	1334
less	ADV	O	O	1334
than	ADP	O	O	1334
100/mm3	NOUN	O	O	1334
)	PUNCT	O	O	1334
have	VERB	O	O	1334
shown	VERB	O	O	1334
a	PRON	O	O	1334
poor	ADJ	O	O	1334
response	NOUN	O	O	1334
to	PART	O	O	1334
antibiotics	VERB	O	O	1334
.	PUNCT	O	O	1334
To	PART	O	O	1335
overcome	VERB	O	O	1335
the	PRON	O	O	1335
adverse	ADJ	O	O	1335
effects	NOUN	O	O	1335
of	ADP	O	O	1335
neutropenia	ADJ	O	Disease	1335
,	PUNCT	O	O	1335
tobramycin	NOUN	O	Chemical	1335
was	AUX	O	O	1335
given	VERB	O	O	1335
by	ADP	O	O	1335
continuous	ADJ	O	O	1335
infusion	NOUN	O	O	1335
and	CCONJ	O	O	1335
combined	VERB	O	O	1335
with	ADP	O	O	1335
intermittent	ADJ	O	O	1335
carbenicillin	PROPN	O	O	1335
.	PUNCT	O	O	1335
Tobramycin	PROPN	O	Chemical	1336
was	AUX	O	O	1336
given	VERB	O	O	1336
to	PART	O	O	1336
a	PRON	O	O	1336
total	ADJ	O	O	1336
daily	ADV	O	O	1336
dose	NOUN	O	O	1336
of	ADP	O	O	1336
300	NUM	O	O	1336
mg	VERB	O	O	1336
/	PUNCT	O	O	1336
m2	PROPN	O	O	1336
and	CCONJ	O	O	1336
carbenicillin	PROPN	O	O	1336
was	AUX	O	O	1336
given	VERB	O	O	1336
at	ADP	O	O	1336
a	PRON	O	O	1336
dose	NOUN	O	O	1336
of	ADP	O	O	1336
5	NUM	O	O	1336
gm	PROPN	O	O	1336
every	PRON	O	O	1336
four	NUM	O	O	1336
hours	NOUN	O	O	1336
.	PUNCT	O	O	1336
There	ADV	O	O	1337
were	AUX	O	O	1337
125	NUM	O	O	1337
infectious	ADJ	O	O	1337
episodes	NOUN	O	O	1337
in	ADP	O	O	1337
116	NUM	O	O	1337
cancer	NOUN	O	Disease	1337
patients	NOUN	O	O	1337
receiving	VERB	O	O	1337
myelosuppressive	ADJ	O	O	1337
chemotherapy	NOUN	O	O	1337
.	PUNCT	O	O	1337
Pneumonia	NOUN	O	O	1338
was	AUX	O	O	1338
the	PRON	O	O	1338
most	ADV	O	O	1338
common	ADJ	O	O	1338
infection	NOUN	O	Disease	1338
and	CCONJ	O	O	1338
61%	NOUN	O	O	1338
of	ADP	O	O	1338
59	NUM	O	O	1338
episodes	NOUN	O	O	1338
were	AUX	O	O	1338
cured	VERB	O	O	1338
.	PUNCT	O	O	1338
Gram	PROPN	O	O	1339
-	PUNCT	O	O	1339
negative	ADJ	O	O	1339
bacilli	ADJ	O	O	1339
were	AUX	O	O	1339
the	PRON	O	O	1339
most	ADV	O	O	1339
common	ADJ	O	O	1339
causative	ADJ	O	O	1339
organisms	NOUN	O	O	1339
and	CCONJ	O	O	1339
69%	NOUN	O	O	1339
of	ADP	O	O	1339
these	PRON	O	O	1339
infections	NOUN	O	Disease	1339
were	AUX	O	O	1339
cured	VERB	O	O	1339
.	PUNCT	O	O	1339
The	PRON	O	O	1340
most	ADV	O	O	1340
common	ADJ	O	O	1340
pathogen	PROPN	O	O	1340
was	AUX	O	O	1340
Klebsiella	NOUN	O	O	1340
pneumoniae	NOUN	O	O	1340
and	CCONJ	O	O	1340
this	PRON	O	O	1340
,	PUNCT	O	O	1340
together	ADV	O	O	1340
with	ADP	O	O	1340
Escherichia	NOUN	O	O	1340
coli	NOUN	O	O	1340
and	CCONJ	O	O	1340
Pseudomonas	NOUN	O	O	1340
aeruginosa	PROPN	O	O	1340
,	PUNCT	O	O	1340
accounted	VERB	O	O	1340
for	ADP	O	O	1340
74%	NOUN	O	O	1340
of	ADP	O	O	1340
all	PRON	O	O	1340
gram	PROPN	O	O	1340
-	PUNCT	O	O	1340
negative	ADJ	O	O	1340
bacillary	NOUN	O	O	1340
infections	NOUN	O	Disease	1340
.	PUNCT	O	O	1340
Response	NOUN	O	O	1341
was	AUX	O	O	1341
not	PART	O	O	1341
influenced	VERB	O	O	1341
by	ADP	O	O	1341
the	PRON	O	O	1341
initial	ADJ	O	O	1341
neutrophil	ADJ	O	O	1341
count	VERB	O	O	1341
,	PUNCT	O	O	1341
with	ADP	O	O	1341
a	PRON	O	O	1341
62%	NOUN	O	O	1341
cure	VERB	O	O	1341
rate	NOUN	O	O	1341
for	ADP	O	O	1341
39	NUM	O	O	1341
episodes	NOUN	O	O	1341
associated	VERB	O	O	1341
with	ADP	O	O	1341
severe	ADJ	O	O	1341
neutropenia	ADJ	O	Disease	1341
.	PUNCT	O	O	1341
Azotemia	PROPN	O	O	1342
was	AUX	O	O	1342
the	PRON	O	O	1342
major	ADJ	O	O	1342
side	NOUN	O	O	1342
effect	VERB	O	O	1342
recognized	VERB	O	O	1342
,	PUNCT	O	O	1342
and	CCONJ	O	O	1342
it	PRON	O	O	1342
occurred	VERB	O	O	1342
in	ADP	O	O	1342
11%	NOUN	O	O	1342
of	ADP	O	O	1342
episodes	NOUN	O	O	1342
.	PUNCT	O	O	1342
Major	ADJ	O	O	1343
azotemia	NOUN	O	O	1343
(	PUNCT	O	O	1343
serum	NOUN	O	O	1343
creatinine	PROPN	O	Chemical	1343
greater	ADJ	O	O	1343
than	ADP	O	O	1343
2.5	NUM	O	O	1343
mg	VERB	O	O	1343
/	PUNCT	O	O	1343
dl	X	O	O	1343
or	CCONJ	O	O	1343
BUN	PROPN	O	Chemical	1343
greater	ADJ	O	O	1343
than	ADP	O	O	1343
50	NUM	O	O	1343
mg	VERB	O	O	1343
/	PUNCT	O	O	1343
dl	X	O	O	1343
)	PUNCT	O	O	1343
occurred	VERB	O	O	1343
in	ADP	O	O	1343
only	ADV	O	O	1343
2%	NOUN	O	O	1343
.	PUNCT	O	O	1343
Azotemia	PROPN	O	O	1344
was	AUX	O	O	1344
not	PART	O	O	1344
related	ADJ	O	O	1344
to	PART	O	O	1344
duration	NOUN	O	O	1344
of	ADP	O	O	1344
therapy	NOUN	O	O	1344
or	CCONJ	O	O	1344
serum	NOUN	O	O	1344
tobramycin	NOUN	O	Chemical	1344
concentration	NOUN	O	O	1344
.	PUNCT	O	O	1344
This	PRON	O	O	1345
antibiotic	ADJ	O	O	1345
regimen	NOUN	O	O	1345
showed	VERB	O	O	1345
both	PRON	O	O	1345
therapeutic	ADJ	O	O	1345
efficacy	NOUN	O	O	1345
and	CCONJ	O	O	1345
acceptable	ADJ	O	O	1345
renal toxicity	NOUN	O	Disease	1345
for	ADP	O	O	1345
these	PRON	O	O	1345
patients	NOUN	O	O	1345
.	PUNCT	O	O	1345
Recurrent	ADJ	O	O	1348
subarachnoid hemorrhage	NOUN	O	Disease	1348
associated	VERB	O	O	1348
with	ADP	O	O	1348
aminocaproic	VERB	O	O	1348
acid	PROPN	O	O	1348
therapy	NOUN	O	O	1348
and	CCONJ	O	O	1348
acute	ADJ	O	O	1348
renal	ADJ	O	O	1348
artery	NOUN	O	O	1348
thrombosis	NOUN	O	Disease	1348
.	PUNCT	O	O	1348
Epsilon	PROPN	O	O	1349
aminocaproic	VERB	O	O	1349
acid	PROPN	O	O	1349
(	PUNCT	O	O	1349
EACA	VERB	O	Chemical	1349
)	PUNCT	O	O	1349
has	VERB	O	O	1349
been	AUX	O	O	1349
used	VERB	O	O	1349
to	PART	O	O	1349
prevent	VERB	O	O	1349
rebleeding	VERB	O	O	1349
in	ADP	O	O	1349
patients	NOUN	O	O	1349
with	ADP	O	O	1349
subarachnoid hemorrhage	NOUN	O	Disease	1349
(	PUNCT	O	O	1349
SAH	PROPN	O	Disease	1349
)	PUNCT	O	O	1349
.	PUNCT	O	O	1349
Although	SCONJ	O	O	1350
this	PRON	O	O	1350
agent	NOUN	O	O	1350
does	VERB	O	O	1350
decrease	VERB	O	O	1350
the	PRON	O	O	1350
frequency	NOUN	O	O	1350
of	ADP	O	O	1350
rebleeding	VERB	O	O	1350
,	PUNCT	O	O	1350
several	ADJ	O	O	1350
reports	VERB	O	O	1350
have	VERB	O	O	1350
described	VERB	O	O	1350
thrombotic	ADJ	O	Disease	1350
complications	NOUN	O	O	1350
of	ADP	O	O	1350
EACA	VERB	O	Chemical	1350
therapy	NOUN	O	O	1350
.	PUNCT	O	O	1350
These	PRON	O	O	1351
complications	NOUN	O	O	1351
have	VERB	O	O	1351
included	VERB	O	O	1351
clinical	ADJ	O	O	1351
deterioration	NOUN	O	O	1351
and	CCONJ	O	O	1351
intracranial	ADJ	O	O	1351
vascular	ADJ	O	O	1351
thrombosis	NOUN	O	Disease	1351
in	ADP	O	O	1351
patients	NOUN	O	O	1351
with	ADP	O	O	1351
SAH	PROPN	O	Disease	1351
,	PUNCT	O	O	1351
arteriolar	ADJ	O	O	1351
and	CCONJ	O	O	1351
capillary	NOUN	O	O	1351
fibrin	PROPN	O	O	1351
thrombi	NOUN	O	Disease	1352
in	ADP	O	O	1352
patients	NOUN	O	O	1352
with	ADP	O	O	1352
fibrinolytic	NOUN	O	O	1352
syndromes	NOUN	O	O	1352
treated	VERB	O	O	1352
with	ADP	O	O	1352
EACA	VERB	O	Chemical	1352
,	PUNCT	O	O	1352
or	CCONJ	O	O	1352
other	ADJ	O	O	1352
thromboembolic	PROPN	O	Disease	1352
phenomena	VERB	O	O	1352
.	PUNCT	O	O	1352
Since	SCONJ	O	O	1353
intravascular	ADJ	O	O	1353
fibrin	PROPN	O	O	1353
thrombi	NOUN	O	Disease	1353
are	AUX	O	O	1353
often	ADV	O	O	1353
observed	VERB	O	O	1353
in	ADP	O	O	1353
patients	NOUN	O	O	1353
with	ADP	O	O	1353
fibrinolytic	NOUN	O	O	1353
disorders	NOUN	O	O	1353
,	PUNCT	O	O	1353
EACA	VERB	O	Chemical	1353
should	AUX	O	O	1353
not	PART	O	O	1353
be	AUX	O	O	1353
implicated	VERB	O	O	1353
in	ADP	O	O	1353
the	PRON	O	O	1353
pathogenesis	NOUN	O	O	1353
of	ADP	O	O	1353
fibrin	PROPN	O	O	1353
thrombi	NOUN	O	Disease	1353
in	ADP	O	O	1353
patients	NOUN	O	O	1353
with	ADP	O	O	1353
disseminated	VERB	O	O	1353
intravascular	ADJ	O	O	1353
coagulation	NOUN	O	O	1353
or	CCONJ	O	O	1353
other	ADJ	O	O	1353
""""	PUNCT	O	O	1353
consumption	NOUN	O	O	1353
coagulopathies	NOUN	O	O	1353
.	PUNCT	O	O	1353
""""	PUNCT	O	O	1354
This	PRON	O	O	1354
report	VERB	O	O	1354
describes	VERB	O	O	1354
subtotal	PROPN	O	O	1354
infarction	NOUN	O	O	1354
of	ADP	O	O	1354
the	PRON	O	O	1354
kidney	NOUN	O	O	1354
due	ADJ	O	O	1354
to	PART	O	O	1354
thrombosis	NOUN	O	Disease	1354
of	ADP	O	O	1354
a	PRON	O	O	1354
normal	ADJ	O	O	1354
renal	ADJ	O	O	1354
artery	NOUN	O	O	1354
.	PUNCT	O	O	1354
This	PRON	O	O	1355
occlusion	NOUN	O	O	1355
occurred	VERB	O	O	1355
after	ADP	O	O	1355
EACA	VERB	O	Chemical	1355
therapy	NOUN	O	O	1355
in	ADP	O	O	1355
a	PRON	O	O	1355
patient	NOUN	O	O	1355
with	ADP	O	O	1355
SAH	PROPN	O	Disease	1355
and	CCONJ	O	O	1355
histopathological	ADJ	O	O	1355
documentation	NOUN	O	O	1355
of	ADP	O	O	1355
recurrent	ADJ	O	O	1355
SAH	PROPN	O	Disease	1355
.	PUNCT	O	O	1355
The	PRON	O	O	1356
corresponding	VERB	O	O	1356
clinical	ADJ	O	O	1356
event	NOUN	O	O	1356
was	AUX	O	O	1356
characterized	VERB	O	O	1356
by	ADP	O	O	1356
marked	VERB	O	O	1356
hypertension	NOUN	O	Disease	1356
and	CCONJ	O	O	1356
abrupt	ADJ	O	O	1356
neurological	ADJ	O	O	1356
deterioration	NOUN	O	O	1356
.	PUNCT	O	O	1356
Long	ADV	O	O	1359
-	PUNCT	O	O	1359
term	NOUN	O	O	1359
propranolol	NOUN	O	Chemical	1359
therapy	NOUN	O	O	1359
in	ADP	O	O	1359
pregnancy	NOUN	O	O	1359
:	PUNCT	O	O	1359
maternal	ADJ	O	O	1359
and	CCONJ	O	O	1359
fetal	ADJ	O	O	1359
outcome	NOUN	O	O	1359
.	PUNCT	O	O	1359
Propranolol	NOUN	O	Chemical	1360
,	PUNCT	O	O	1360
a	PRON	O	O	1360
beta	NOUN	O	O	1360
-	PUNCT	O	O	1360
adrenergic	NOUN	O	O	1360
blocking	VERB	O	O	1360
agent	NOUN	O	O	1360
,	PUNCT	O	O	1360
has	VERB	O	O	1360
found	VERB	O	O	1360
an	PRON	O	O	1360
important	ADJ	O	O	1360
position	NOUN	O	O	1360
in	ADP	O	O	1360
the	PRON	O	O	1360
practice	VERB	O	O	1360
of	ADP	O	O	1360
medicine	NOUN	O	O	1360
.	PUNCT	O	O	1360
Ten	NUM	O	O	1361
patients	NOUN	O	O	1361
and	CCONJ	O	O	1361
12	NUM	O	O	1361
pregnancies	NOUN	O	O	1361
are	AUX	O	O	1361
reported	VERB	O	O	1361
where	SCONJ	O	O	1361
chronic	ADJ	O	O	1361
propranolol	NOUN	O	Chemical	1361
has	VERB	O	O	1361
been	AUX	O	O	1361
administered	VERB	O	O	1361
.	PUNCT	O	O	1361
Five	NUM	O	O	1362
patients	NOUN	O	O	1362
with	ADP	O	O	1362
serial	ADJ	O	O	1362
pregnancies	NOUN	O	O	1362
with	ADP	O	O	1362
and	CCONJ	O	O	1362
without	ADP	O	O	1362
propranolol	NOUN	O	Chemical	1362
therapy	NOUN	O	O	1362
are	AUX	O	O	1362
also	ADV	O	O	1362
examined	VERB	O	O	1362
.	PUNCT	O	O	1362
We	PRON	O	O	1363
conclude	VERB	O	O	1363
that	SCONJ	O	O	1363
previously	ADV	O	O	1363
reported	VERB	O	O	1363
hypoglycemia	NOUN	O	O	1363
,	PUNCT	O	O	1363
hyperbilirubinemia	PROPN	O	Disease	1363
,	PUNCT	O	O	1363
polycythemia	NOUN	O	O	1363
,	PUNCT	O	O	1363
neonatal	NOUN	O	O	1363
apnea	PROPN	O	Disease	1363
,	PUNCT	O	O	1363
and	CCONJ	O	O	1363
bradycardia	NOUN	O	Disease	1363
are	AUX	O	O	1363
not	PART	O	O	1363
invariable	ADJ	O	O	1363
and	CCONJ	O	O	1363
can	AUX	O	O	1363
not	PART	O	O	1363
be	AUX	O	O	1363
statistically	ADV	O	O	1363
correlated	VERB	O	O	1363
with	ADP	O	O	1363
chronic	ADJ	O	O	1363
propranolol	NOUN	O	Chemical	1363
therapy	NOUN	O	O	1363
.	PUNCT	O	O	1363
Growth	NOUN	O	O	1364
retardation	NOUN	O	O	1364
,	PUNCT	O	O	1364
however	ADV	O	O	1364
,	PUNCT	O	O	1364
appears	VERB	O	O	1364
to	PART	O	O	1364
be	AUX	O	O	1364
significant	ADJ	O	O	1364
in	ADP	O	O	1364
both	PRON	O	O	1364
of	ADP	O	O	1364
our	PRON	O	O	1364
series	PROPN	O	O	1364
.	PUNCT	O	O	1364
Use	VERB	O	O	1367
of	ADP	O	O	1367
propranolol	NOUN	O	Chemical	1367
in	ADP	O	O	1367
the	PRON	O	O	1367
treatment	NOUN	O	O	1367
of	ADP	O	O	1367
idiopathic	ADJ	O	O	1367
orthostatic hypotension	NOUN	O	Disease	1367
.	PUNCT	O	O	1367
Five	NUM	O	O	1368
patients	NOUN	O	O	1368
with	ADP	O	O	1368
idiopathic	ADJ	O	O	1368
orthostatic hypotension	NOUN	O	Disease	1368
who	PRON	O	O	1368
had	VERB	O	O	1368
physiologic	ADJ	O	O	1368
and	CCONJ	O	O	1368
biochemical	ADJ	O	O	1368
evidence	NOUN	O	O	1368
of	ADP	O	O	1368
severe	ADJ	O	O	1368
autonomic	ADJ	O	O	1368
dysfunction	NOUN	O	O	1368
were	AUX	O	O	1368
included	VERB	O	O	1368
in	ADP	O	O	1368
the	PRON	O	O	1368
study	VERB	O	O	1368
.	PUNCT	O	O	1368
They	PRON	O	O	1369
all	PRON	O	O	1369
exhibited	VERB	O	O	1369
markedly	ADV	O	O	1369
reduced	VERB	O	O	1369
plasma	NOUN	O	O	1369
catecholamines	NOUN	O	Chemical	1369
and	CCONJ	O	O	1369
plasma	NOUN	O	O	1369
renin	PROPN	O	O	1369
activity	NOUN	O	O	1369
in	ADP	O	O	1369
both	PRON	O	O	1369
recumbent	ADJ	O	O	1369
and	CCONJ	O	O	1369
upright	ADJ	O	O	1369
positions	NOUN	O	O	1369
and	CCONJ	O	O	1369
had	VERB	O	O	1369
marked	VERB	O	O	1369
hypersensitivity	NOUN	O	Disease	1369
to	PART	O	O	1369
the	PRON	O	O	1369
pressor	ADJ	O	O	1369
effects	NOUN	O	O	1369
of	ADP	O	O	1369
infused	VERB	O	O	1369
norepinephrine	NOUN	O	Chemical	1369
.	PUNCT	O	O	1369
Treatment	NOUN	O	O	1370
with	ADP	O	O	1370
propanolol	NOUN	O	O	1370
administered	VERB	O	O	1370
intravenously	ADV	O	O	1370
(	PUNCT	O	O	1370
1	X	O	O	1370
-	PUNCT	O	O	1370
5	NUM	O	O	1370
mg	VERB	O	O	1370
)	PUNCT	O	O	1370
produced	VERB	O	O	1370
increases	VERB	O	O	1370
in	ADP	O	O	1370
supine	ADJ	O	O	1370
and	CCONJ	O	O	1370
upright	ADJ	O	O	1370
blood	NOUN	O	O	1370
pressure	NOUN	O	O	1370
in	ADP	O	O	1370
4	NUM	O	O	1370
of	ADP	O	O	1370
the	PRON	O	O	1370
5	NUM	O	O	1370
individuals	NOUN	O	O	1370
with	ADP	O	O	1370
rises	VERB	O	O	1370
ranging	VERB	O	O	1370
from	ADP	O	O	1370
11/6	NUM	O	O	1370
to	PART	O	O	1370
22/11	NUM	O	O	1370
mmHg	PROPN	O	O	1370
.	PUNCT	O	O	1370
Chronic	NOUN	O	O	1371
oral	ADJ	O	O	1371
administration	NOUN	O	O	1371
of	ADP	O	O	1371
propranolol	NOUN	O	Chemical	1371
(	PUNCT	O	O	1371
40	NUM	O	O	1371
-	PUNCT	O	O	1371
160	NUM	O	O	1371
mg	VERB	O	O	1371
/	PUNCT	O	O	1371
day	NOUN	O	O	1371
)	PUNCT	O	O	1371
also	ADV	O	O	1371
elevated	ADJ	O	O	1371
the	PRON	O	O	1371
blood	NOUN	O	O	1371
pressures	NOUN	O	O	1371
of	ADP	O	O	1371
these	PRON	O	O	1371
individuals	NOUN	O	O	1371
with	ADP	O	O	1371
increases	VERB	O	O	1371
in	ADP	O	O	1371
the	PRON	O	O	1371
order	NOUN	O	O	1371
of	ADP	O	O	1371
20	NUM	O	O	1371
-	PUNCT	O	O	1371
35/15	NUM	O	O	1371
-	PUNCT	O	O	1371
25	NUM	O	O	1371
mmg	INTJ	O	O	1371
being	AUX	O	O	1371
observed	VERB	O	O	1371
.	PUNCT	O	O	1371
In	ADP	O	O	1372
1	X	O	O	1372
patient	NOUN	O	O	1372
,	PUNCT	O	O	1372
marked	VERB	O	O	1372
hypertension	NOUN	O	Disease	1372
was	AUX	O	O	1372
induced	VERB	O	O	1372
by	ADP	O	O	1372
propranolol	NOUN	O	Chemical	1372
and	CCONJ	O	O	1372
the	PRON	O	O	1372
drug	NOUN	O	O	1372
had	VERB	O	O	1372
to	PART	O	O	1372
be	AUX	O	O	1372
withdrawn	VERB	O	O	1372
.	PUNCT	O	O	1372
Hemodynamic	PROPN	O	O	1373
measurements	NOUN	O	O	1373
in	ADP	O	O	1373
1	X	O	O	1373
of	ADP	O	O	1373
the	PRON	O	O	1373
patients	NOUN	O	O	1373
demonstrated	VERB	O	O	1373
an	PRON	O	O	1373
increase	VERB	O	O	1373
in	ADP	O	O	1373
total	ADJ	O	O	1373
peripheral	ADJ	O	O	1373
resistance	NOUN	O	O	1373
and	CCONJ	O	O	1373
essentially	ADV	O	O	1373
no	PRON	O	O	1373
change	VERB	O	O	1373
in	ADP	O	O	1373
cardiac	ADJ	O	O	1373
output	NOUN	O	O	1373
following	VERB	O	O	1373
propranolol	NOUN	O	Chemical	1373
therapy	NOUN	O	O	1373
.	PUNCT	O	O	1373
The	PRON	O	O	1374
studies	NOUN	O	O	1374
suggest	VERB	O	O	1374
that	SCONJ	O	O	1374
propranolol	NOUN	O	Chemical	1374
is	AUX	O	O	1374
a	PRON	O	O	1374
useful	ADJ	O	O	1374
drug	NOUN	O	O	1374
in	ADP	O	O	1374
selected	VERB	O	O	1374
patients	NOUN	O	O	1374
with	ADP	O	O	1374
severe	ADJ	O	O	1374
idiopathic	ADJ	O	O	1374
orthostatic hypotension	NOUN	O	Disease	1374
.	PUNCT	O	O	1374
Total	ADJ	O	O	1377
intravenous	ADJ	O	O	1377
anesthesia	NOUN	O	O	1377
with	ADP	O	O	1377
etomidate	VERB	O	Chemical	1377
.	PUNCT	O	O	1377
An	PRON	O	O	1378
investigation	NOUN	O	O	1378
was	AUX	O	O	1378
undertaken	VERB	O	O	1378
to	PART	O	O	1378
determine	VERB	O	O	1378
the	PRON	O	O	1378
dosage	NOUN	O	O	1378
of	ADP	O	O	1378
etomidate	VERB	O	Chemical	1378
required	VERB	O	O	1378
to	PART	O	O	1378
maintain	VERB	O	O	1378
sleep	VERB	O	O	1378
in	ADP	O	O	1378
adults	NOUN	O	O	1378
undergoing	VERB	O	O	1378
surgery	NOUN	O	O	1378
under	ADP	O	O	1378
regional	ADJ	O	O	1378
local	ADJ	O	O	1378
anesthesia	NOUN	O	O	1378
.	PUNCT	O	O	1378
Premedication	NOUN	O	O	1379
of	ADP	O	O	1379
diazepam	NOUN	O	Chemical	1379
10	NUM	O	O	1379
mg	VERB	O	O	1379
and	CCONJ	O	O	1379
atropine	NOUN	O	Chemical	1379
0.5	NUM	O	O	1379
mg	VERB	O	O	1379
was	AUX	O	O	1379
given	VERB	O	O	1379
,	PUNCT	O	O	1379
and	CCONJ	O	O	1379
sleep	VERB	O	O	1379
was	AUX	O	O	1379
induced	VERB	O	O	1379
and	CCONJ	O	O	1379
maintained	VERB	O	O	1379
by	ADP	O	O	1379
intermittent	ADJ	O	O	1379
intravenous	ADJ	O	O	1379
injections	NOUN	O	O	1379
of	ADP	O	O	1379
etomidate	VERB	O	Chemical	1379
0.1/mg	VERB	O	O	1379
/	PUNCT	O	O	1379
kg	VERB	O	O	1379
,	PUNCT	O	O	1379
given	VERB	O	O	1379
whenever	SCONJ	O	O	1379
the	PRON	O	O	1379
patient	NOUN	O	O	1379
would	AUX	O	O	1379
open	VERB	O	O	1379
his	PRON	O	O	1379
eyes	NOUN	O	O	1379
on	ADP	O	O	1379
request	NOUN	O	O	1379
.	PUNCT	O	O	1379
A	PRON	O	O	1380
mean	VERB	O	O	1380
overall	ADV	O	O	1380
dose	NOUN	O	O	1380
of	ADP	O	O	1380
etomidate	VERB	O	Chemical	1380
17.4	NUM	O	O	1380
microgram	PROPN	O	O	1380
/	PUNCT	O	O	1380
kg	VERB	O	O	1380
/	PUNCT	O	O	1380
min	NOUN	O	O	1380
.	PUNCT	O	O	1380
The	PRON	O	O	1381
investigation	NOUN	O	O	1381
was	AUX	O	O	1381
discontinued	VERB	O	O	1381
after	ADP	O	O	1381
18	NUM	O	O	1381
patients	NOUN	O	O	1381
because	SCONJ	O	O	1381
of	ADP	O	O	1381
the	PRON	O	O	1381
frequency	NOUN	O	O	1381
and	CCONJ	O	O	1381
intensity	NOUN	O	O	1381
of	ADP	O	O	1381
side	NOUN	O	O	1381
-	PUNCT	O	O	1381
effects	NOUN	O	O	1381
,	PUNCT	O	O	1381
particularly	ADV	O	O	1381
pain	NOUN	O	Disease	1381
and	CCONJ	O	O	1381
myoclonia	NOUN	O	O	1381
,	PUNCT	O	O	1381
which	PRON	O	O	1381
caused	VERB	O	O	1381
the	PRON	O	O	1381
technique	NOUN	O	O	1381
to	PART	O	O	1381
be	AUX	O	O	1381
abandoned	VERB	O	O	1381
in	ADP	O	O	1381
two	NUM	O	O	1381
cases	NOUN	O	O	1381
.	PUNCT	O	O	1381
It	PRON	O	O	1382
is	AUX	O	O	1382
considered	VERB	O	O	1382
unlikely	ADJ	O	O	1382
that	SCONJ	O	O	1382
etomidate	VERB	O	Chemical	1382
will	AUX	O	O	1382
prove	VERB	O	O	1382
to	PART	O	O	1382
be	AUX	O	O	1382
the	PRON	O	O	1382
hypnotic	ADJ	O	O	1382
of	ADP	O	O	1382
choice	NOUN	O	O	1382
for	ADP	O	O	1382
a	PRON	O	O	1382
totally	ADV	O	O	1382
intravenous	ADJ	O	O	1382
anesthetic	NOUN	O	O	1382
technique	NOUN	O	O	1382
in	ADP	O	O	1382
adults	NOUN	O	O	1382
because	SCONJ	O	O	1382
of	ADP	O	O	1382
the	PRON	O	O	1382
high	ADJ	O	O	1382
incidence	NOUN	O	O	1382
of	ADP	O	O	1382
myoclonia	NOUN	O	O	1382
after	ADP	O	O	1382
prolonged	VERB	O	O	1382
administration	NOUN	O	O	1382
.	PUNCT	O	O	1382
A	PRON	O	O	1385
method	NOUN	O	O	1385
for	ADP	O	O	1385
the	PRON	O	O	1385
measurement	NOUN	O	O	1385
of	ADP	O	O	1385
tremor	NOUN	O	Disease	1385
,	PUNCT	O	O	1385
and	CCONJ	O	O	1385
a	PRON	O	O	1385
comparison	NOUN	O	O	1385
of	ADP	O	O	1385
the	PRON	O	O	1385
effects	NOUN	O	O	1385
of	ADP	O	O	1385
tocolytic	ADJ	O	O	1385
beta	NOUN	O	O	1385
-	PUNCT	O	O	1385
mimetics	NOUN	O	O	1385
.	PUNCT	O	O	1385
A	PRON	O	O	1386
method	NOUN	O	O	1386
permitting	VERB	O	O	1386
measurement	NOUN	O	O	1386
of	ADP	O	O	1386
finger	NOUN	O	O	1386
tremor	NOUN	O	Disease	1386
as	ADP	O	O	1386
a	PRON	O	O	1386
displacement	NOUN	O	O	1386
-	PUNCT	O	O	1386
time	NOUN	O	O	1386
curve	NOUN	O	O	1386
is	AUX	O	O	1386
described	VERB	O	O	1386
,	PUNCT	O	O	1386
using	VERB	O	O	1386
a	PRON	O	O	1386
test	NOUN	O	O	1386
system	NOUN	O	O	1386
with	ADP	O	O	1386
simple	ADJ	O	O	1386
amplitude	VERB	O	O	1386
calibration	NOUN	O	O	1386
.	PUNCT	O	O	1386
By	ADP	O	O	1387
means	VERB	O	O	1387
of	ADP	O	O	1387
a	PRON	O	O	1387
computer	NOUN	O	O	1387
program	PROPN	O	O	1387
,	PUNCT	O	O	1387
periods	NOUN	O	O	1387
and	CCONJ	O	O	1387
amplitudes	NOUN	O	O	1387
of	ADP	O	O	1387
tremor	NOUN	O	Disease	1387
oscillations	NOUN	O	O	1387
were	AUX	O	O	1387
calculated	VERB	O	O	1387
and	CCONJ	O	O	1387
classified	VERB	O	O	1387
.	PUNCT	O	O	1387
The	PRON	O	O	1388
actions	NOUN	O	O	1388
of	ADP	O	O	1388
fenoterol	VERB	O	O	1388
-	PUNCT	O	O	1388
hydrobromide	NOUN	O	O	1388
,	PUNCT	O	O	1388
ritodrin	PROPN	O	O	1388
-	PUNCT	O	O	1388
HCl	PROPN	O	O	1388
and	CCONJ	O	O	1388
placebo	NOUN	O	O	1388
given	VERB	O	O	1388
to	PART	O	O	1388
10	NUM	O	O	1388
healthy	ADJ	O	O	1388
subjects	NOUN	O	O	1388
by	ADP	O	O	1388
intravenous	ADJ	O	O	1388
infusion	NOUN	O	O	1388
in	ADP	O	O	1388
a	PRON	O	O	1388
double	ADJ	O	O	1388
-	PUNCT	O	O	1388
blind	ADJ	O	Disease	1388
crossover	NOUN	O	O	1388
study	VERB	O	O	1388
were	AUX	O	O	1388
tested	VERB	O	O	1388
by	ADP	O	O	1388
this	PRON	O	O	1388
method	NOUN	O	O	1388
.	PUNCT	O	O	1388
At	ADP	O	O	1389
therapeutic	ADJ	O	O	1389
doses	NOUN	O	O	1389
both	PRON	O	O	1389
substances	NOUN	O	O	1389
raised	VERB	O	O	1389
the	PRON	O	O	1389
mean	VERB	O	O	1389
tremor	NOUN	O	Disease	1389
amplitude	VERB	O	O	1389
to	PART	O	O	1389
about	ADP	O	O	1389
three	NUM	O	O	1389
times	NOUN	O	O	1389
the	PRON	O	O	1389
control	VERB	O	O	1389
level	VERB	O	O	1389
.	PUNCT	O	O	1389
After	ADP	O	O	1390
the	PRON	O	O	1390
end	VERB	O	O	1390
of	ADP	O	O	1390
fenoterol	VERB	O	O	1390
-	PUNCT	O	O	1390
hydrobromide	NOUN	O	O	1390
infusion	NOUN	O	O	1390
,	PUNCT	O	O	1390
tremor	NOUN	O	Disease	1390
amplitudes	NOUN	O	O	1390
decreased	VERB	O	O	1390
significantly	ADV	O	O	1390
faster	ADV	O	O	1390
than	ADP	O	O	1390
those	PRON	O	O	1390
following	VERB	O	O	1390
ritodrin	PROPN	O	O	1390
-	PUNCT	O	O	1390
HCl	PROPN	O	O	1390
infusion	NOUN	O	O	1390
.	PUNCT	O	O	1390
Bilateral	ADJ	O	O	1393
retinal	ADJ	O	O	1393
artery	NOUN	O	O	1393
and	CCONJ	O	O	1393
choriocapillaris	VERB	O	O	1393
occlusion	NOUN	O	O	1393
following	VERB	O	O	1393
the	PRON	O	O	1393
injection	NOUN	O	O	1393
of	ADP	O	O	1393
long	ADV	O	O	1393
-	PUNCT	O	O	1393
acting	VERB	O	O	1393
corticosteroid	NOUN	O	Chemical	1393
suspensions	NOUN	O	O	1393
in	ADP	O	O	1393
combination	NOUN	O	O	1393
with	ADP	O	O	1393
other	ADJ	O	O	1393
drugs	NOUN	O	O	1393
:	PUNCT	O	O	1393
I.	NOUN	O	O	1393
Clinical	NOUN	O	O	1393
studies	NOUN	O	O	1393
.	PUNCT	O	O	1393
Two	NUM	O	O	1394
well	ADV	O	O	1394
-	PUNCT	O	O	1394
documented	VERB	O	O	1394
cases	NOUN	O	O	1394
of	ADP	O	O	1394
bilateral	ADJ	O	O	1394
retinal	ADJ	O	O	1394
artery	NOUN	O	O	1394
and	CCONJ	O	O	1394
choriocapillaris	VERB	O	O	1394
occlusions	NOUN	O	O	1394
with	ADP	O	O	1394
blindness	NOUN	O	Disease	1394
following	VERB	O	O	1394
head	NOUN	O	O	1394
and	CCONJ	O	O	1394
neck	NOUN	O	O	1394
soft	ADJ	O	O	1394
-	PUNCT	O	O	1394
tissue	NOUN	O	O	1394
injection	NOUN	O	O	1394
with	ADP	O	O	1394
methylprednisolone	NOUN	O	Chemical	1394
acetate	NOUN	O	O	1394
in	ADP	O	O	1394
combination	NOUN	O	O	1394
with	ADP	O	O	1394
lidocaine	NOUN	O	Chemical	1394
,	PUNCT	O	O	1394
epinephrine	NOUN	O	Chemical	1394
,	PUNCT	O	O	1394
or	CCONJ	O	O	1394
penicillin	NOUN	O	Chemical	1394
are	AUX	O	O	1394
reported	VERB	O	O	1394
.	PUNCT	O	O	1394
The	PRON	O	O	1395
acute	ADJ	O	O	1395
observations	NOUN	O	O	1395
included	VERB	O	O	1395
hazy	ADJ	O	O	1395
sensorium	NOUN	O	O	1395
,	PUNCT	O	O	1395
superior	PROPN	O	O	1395
gaze	VERB	O	O	1395
palsy	PROPN	O	O	1395
,	PUNCT	O	O	1395
pupillary	ADJ	O	O	1395
abnormalities	NOUN	O	O	1395
,	PUNCT	O	O	1395
and	CCONJ	O	O	1395
conjunctival	NOUN	O	O	1395
hemorrhages	VERB	O	O	1395
with	ADP	O	O	1395
edema	NOUN	O	Disease	1395
.	PUNCT	O	O	1395
Follow	VERB	O	O	1396
-	PUNCT	O	O	1396
up	ADP	O	O	1396
changes	VERB	O	O	1396
showed	VERB	O	O	1396
marked	VERB	O	O	1396
visual loss	NOUN	O	Disease	1396
,	PUNCT	O	O	1396
constricted	ADJ	O	O	1396
visual	ADJ	O	O	1396
fields	NOUN	O	O	1396
,	PUNCT	O	O	1396
optic	NOUN	O	O	1396
nerve	NOUN	O	O	1396
pallor	NOUN	O	O	1396
,	PUNCT	O	O	1396
vascular	ADJ	O	O	1396
attenuation	NOUN	O	O	1396
,	PUNCT	O	O	1396
and	CCONJ	O	O	1396
chorioretinal	NOUN	O	O	1396
atrophy	NOUN	O	Disease	1396
.	PUNCT	O	O	1396
Cephalothin	PROPN	O	O	1399
-	PUNCT	O	O	1399
induced	VERB	O	O	1399
immune	NOUN	O	O	1399
hemolytic anemia	NOUN	O	Disease	1399
.	PUNCT	O	O	1399
A	PRON	O	O	1400
patient	NOUN	O	O	1400
with	ADP	O	O	1400
renal disease	NOUN	O	Disease	1400
developed	VERB	O	O	1400
Coombs	NOUN	O	O	1400
-	PUNCT	O	O	1400
positive	ADJ	O	O	1400
hemolytic anemia	NOUN	O	Disease	1400
while	SCONJ	O	O	1400
receiving	VERB	O	O	1400
cephalothin	VERB	O	O	1400
therapy	NOUN	O	O	1400
.	PUNCT	O	O	1400
An	PRON	O	O	1401
anti	ADJ	O	O	1401
-	PUNCT	O	O	1401
cephalothin	VERB	O	O	1401
IgG	PROPN	O	O	1401
antibody	NOUN	O	O	1401
was	AUX	O	O	1401
detected	VERB	O	O	1401
in	ADP	O	O	1401
the	PRON	O	O	1401
patient	NOUN	O	O	1401
's	AUX	O	O	1401
serum	NOUN	O	O	1401
and	CCONJ	O	O	1401
in	ADP	O	O	1401
the	PRON	O	O	1401
eluates	VERB	O	O	1401
from	ADP	O	O	1401
her	PRON	O	O	1401
erythrocytes	VERB	O	O	1401
.	PUNCT	O	O	1401
In	ADP	O	O	1402
addition	NOUN	O	O	1402
,	PUNCT	O	O	1402
nonimmunologic	ADJ	O	O	1402
binding	VERB	O	O	1402
of	ADP	O	O	1402
normal	ADJ	O	O	1402
and	CCONJ	O	O	1402
patient	NOUN	O	O	1402
's	AUX	O	O	1402
serum	NOUN	O	O	1402
proteins	NOUN	O	O	1402
to	PART	O	O	1402
her	PRON	O	O	1402
own	ADJ	O	O	1402
and	CCONJ	O	O	1402
cephalothin	VERB	O	O	1402
-	PUNCT	O	O	1402
coated	VERB	O	O	1402
normal	ADJ	O	O	1402
red	ADJ	O	O	1402
cells	NOUN	O	O	1402
was	AUX	O	O	1402
demonstrated	VERB	O	O	1402
.	PUNCT	O	O	1402
Skin	NOUN	O	O	1403
tests	VERB	O	O	1403
and	CCONJ	O	O	1403
in	ADP	O	O	1403
vitro	X	O	O	1403
lymphocyte	NOUN	O	O	1403
stimulation	NOUN	O	O	1403
revealed	VERB	O	O	1403
that	SCONJ	O	O	1403
the	PRON	O	O	1403
patient	NOUN	O	O	1403
was	AUX	O	O	1403
sensitized	VERB	O	O	1403
to	PART	O	O	1403
cephalothin	VERB	O	O	1403
and	CCONJ	O	O	1403
also	ADV	O	O	1403
to	PART	O	O	1403
ampicillin	PROPN	O	O	1403
.	PUNCT	O	O	1403
Careful	ADJ	O	O	1404
investigation	NOUN	O	O	1404
of	ADP	O	O	1404
drug	NOUN	O	O	1404
-	PUNCT	O	O	1404
induced	VERB	O	O	1404
hemolytic anemias	NOUN	O	Disease	1404
reveals	VERB	O	O	1404
the	PRON	O	O	1404
complexity	NOUN	O	O	1404
of	ADP	O	O	1404
the	PRON	O	O	1404
immune	NOUN	O	O	1404
mechanisms	NOUN	O	O	1404
involved	VERB	O	O	1404
.	PUNCT	O	O	1404
Kaliuretic	VERB	O	O	1407
effect	VERB	O	O	1407
of	ADP	O	O	1407
L	NOUN	O	O	1407
-	PUNCT	O	O	1407
dopa	PROPN	O	O	1407
treatment	NOUN	O	O	1407
in	ADP	O	O	1407
parkinsonian	PROPN	O	Disease	1407
patients	NOUN	O	O	1407
.	PUNCT	O	O	1407
Hypokalemia	PROPN	O	Disease	1408
,	PUNCT	O	O	1408
sometimes	ADV	O	O	1408
severe	ADJ	O	O	1408
,	PUNCT	O	O	1408
was	AUX	O	O	1408
observed	VERB	O	O	1408
in	ADP	O	O	1408
some	PRON	O	O	1408
L	NOUN	O	O	1408
-	PUNCT	O	O	1408
dopa	PROPN	O	O	1408
-	PUNCT	O	O	1408
treated	VERB	O	O	1408
parkinsonian	PROPN	O	Disease	1408
patients	NOUN	O	O	1408
.	PUNCT	O	O	1408
The	PRON	O	O	1409
influence	NOUN	O	O	1409
of	ADP	O	O	1409
L	NOUN	O	O	1409
-	PUNCT	O	O	1409
dopa	PROPN	O	O	1409
on	ADP	O	O	1409
the	PRON	O	O	1409
renal	ADJ	O	O	1409
excretion	NOUN	O	O	1409
of	ADP	O	O	1409
potassium	NOUN	O	Chemical	1409
was	AUX	O	O	1409
studied	VERB	O	O	1409
in	ADP	O	O	1409
3	X	O	O	1409
patients	NOUN	O	O	1409
with	ADP	O	O	1409
hypokalemia	PROPN	O	Disease	1409
and	CCONJ	O	O	1409
in	ADP	O	O	1409
5	NUM	O	O	1409
normokalemic	PROPN	O	O	1409
patients	NOUN	O	O	1409
by	ADP	O	O	1409
determination	NOUN	O	O	1409
of	ADP	O	O	1409
renal	ADJ	O	O	1409
plasma	NOUN	O	O	1409
flow	NOUN	O	O	1409
,	PUNCT	O	O	1409
glomerular	ADJ	O	O	1409
filtration	NOUN	O	O	1409
rate	NOUN	O	O	1409
,	PUNCT	O	O	1409
plasma	NOUN	O	O	1409
concentration	NOUN	O	O	1409
of	ADP	O	O	1409
potassium	NOUN	O	Chemical	1409
and	CCONJ	O	O	1409
sodium	NOUN	O	Chemical	1409
as	ADP	O	O	1409
well	ADV	O	O	1409
as	ADP	O	O	1409
urinary	ADJ	O	O	1409
excretion	NOUN	O	O	1409
of	ADP	O	O	1409
potassium	NOUN	O	Chemical	1409
,	PUNCT	O	O	1409
sodium	NOUN	O	Chemical	1409
and	CCONJ	O	O	1409
aldosterone	NOUN	O	Chemical	1409
.	PUNCT	O	O	1409
L	NOUN	O	O	1410
-	PUNCT	O	O	1410
Dopa	NOUN	O	O	1410
intake	PROPN	O	O	1410
was	AUX	O	O	1410
found	VERB	O	O	1410
to	PART	O	O	1410
cause	VERB	O	O	1410
an	PRON	O	O	1410
increased	VERB	O	O	1410
excretion	NOUN	O	O	1410
of	ADP	O	O	1410
potassium	NOUN	O	Chemical	1410
,	PUNCT	O	O	1410
and	CCONJ	O	O	1410
sometimes	ADV	O	O	1410
also	ADV	O	O	1410
of	ADP	O	O	1410
sodium	NOUN	O	Chemical	1410
,	PUNCT	O	O	1410
in	ADP	O	O	1410
the	PRON	O	O	1410
hypokalemic	PROPN	O	O	1410
but	CCONJ	O	O	1410
not	PART	O	O	1410
in	ADP	O	O	1410
the	PRON	O	O	1410
normokalemic	PROPN	O	O	1410
patients	NOUN	O	O	1410
.	PUNCT	O	O	1410
It	PRON	O	O	1411
is	AUX	O	O	1411
not	PART	O	O	1411
known	VERB	O	O	1411
why	SCONJ	O	O	1411
this	PRON	O	O	1411
effect	VERB	O	O	1411
occurred	VERB	O	O	1411
in	ADP	O	O	1411
some	PRON	O	O	1411
individuals	NOUN	O	O	1411
but	CCONJ	O	O	1411
not	PART	O	O	1411
in	ADP	O	O	1411
others	NOUN	O	O	1411
,	PUNCT	O	O	1411
but	CCONJ	O	O	1411
our	PRON	O	O	1411
results	VERB	O	O	1411
indicate	VERB	O	O	1411
a	PRON	O	O	1411
correlation	NOUN	O	O	1411
between	ADP	O	O	1411
aldosterone	NOUN	O	Chemical	1411
production	NOUN	O	O	1411
and	CCONJ	O	O	1411
this	PRON	O	O	1411
renal	ADJ	O	O	1411
effect	VERB	O	O	1411
of	ADP	O	O	1411
L	NOUN	O	O	1411
-	PUNCT	O	O	1411
dopa	PROPN	O	O	1411
.	PUNCT	O	O	1411
Phenytoin	NOUN	O	O	1414
encephalopathy	NOUN	O	Disease	1414
as	ADP	O	O	1414
probable	ADJ	O	O	1414
idiosyncratic	ADJ	O	O	1414
reaction	NOUN	O	O	1414
:	PUNCT	O	O	1414
case	NOUN	O	O	1414
report	VERB	O	O	1414
.	PUNCT	O	O	1414
A	PRON	O	O	1415
case	NOUN	O	O	1415
of	ADP	O	O	1415
phenytoin	NOUN	O	Chemical	1415
(	PUNCT	O	O	1415
DPH	PROPN	O	Chemical	1415
)	PUNCT	O	O	1415
encephalopathy	NOUN	O	Disease	1416
with	ADP	O	O	1416
increasing	VERB	O	O	1416
seizures	NOUN	O	Disease	1416
and	CCONJ	O	O	1416
EEG	NOUN	O	O	1416
and	CCONJ	O	O	1416
mental	ADJ	O	O	1416
changes	VERB	O	O	1416
is	AUX	O	O	1416
described	VERB	O	O	1416
.	PUNCT	O	O	1416
Despite	SCONJ	O	O	1417
adequate	ADJ	O	O	1417
oral	ADJ	O	O	1417
dosage	NOUN	O	O	1417
of	ADP	O	O	1417
DPH	PROPN	O	Chemical	1417
(	PUNCT	O	O	1417
5	NUM	O	O	1417
mg	VERB	O	O	1417
/	PUNCT	O	O	1417
kg	VERB	O	O	1417
/	PUNCT	O	O	1417
daily	ADV	O	O	1417
)	PUNCT	O	O	1417
the	PRON	O	O	1417
plasma	NOUN	O	O	1417
level	VERB	O	O	1417
was	AUX	O	O	1417
very	ADV	O	O	1417
low	ADJ	O	O	1417
(	PUNCT	O	O	1417
2.8	NUM	O	O	1417
microgramg	NOUN	O	O	1417
/	PUNCT	O	O	1417
ml	ADP	O	O	1417
)	PUNCT	O	O	1417
.	PUNCT	O	O	1417
The	PRON	O	O	1418
encephalopathy	NOUN	O	Disease	1418
was	AUX	O	O	1418
probably	ADV	O	O	1418
an	PRON	O	O	1418
idiosyncratic	ADJ	O	O	1418
and	CCONJ	O	O	1418
not	PART	O	O	1418
toxic	ADJ	O	O	1418
or	CCONJ	O	O	1418
allergic	ADJ	O	O	1418
reaction	NOUN	O	O	1418
.	PUNCT	O	O	1418
In	ADP	O	O	1419
fact	NOUN	O	O	1419
the	PRON	O	O	1419
concentration	NOUN	O	O	1419
of	ADP	O	O	1419
free	ADJ	O	O	1419
DPH	PROPN	O	Chemical	1419
was	AUX	O	O	1419
normal	ADJ	O	O	1419
,	PUNCT	O	O	1419
the	PRON	O	O	1419
patient	NOUN	O	O	1419
presented	VERB	O	O	1419
a	PRON	O	O	1419
retarded	ADJ	O	O	1419
morbilliform	NOUN	O	O	1419
rash	ADJ	O	Disease	1419
during	ADP	O	O	1419
DPH	PROPN	O	Chemical	1419
treatment	NOUN	O	O	1419
,	PUNCT	O	O	1419
the	PRON	O	O	1419
protidogram	NOUN	O	O	1419
was	AUX	O	O	1419
normal	ADJ	O	O	1419
,	PUNCT	O	O	1419
and	CCONJ	O	O	1419
an	PRON	O	O	1419
intradermic	PROPN	O	O	1419
DPH	PROPN	O	Chemical	1419
injection	NOUN	O	O	1419
had	VERB	O	O	1419
no	PRON	O	O	1419
local	ADJ	O	O	1419
effect	VERB	O	O	1419
.	PUNCT	O	O	1419
The	PRON	O	O	1420
authors	NOUN	O	O	1420
conclude	VERB	O	O	1420
that	SCONJ	O	O	1420
in	ADP	O	O	1420
a	PRON	O	O	1420
patient	NOUN	O	O	1420
starting	VERB	O	O	1420
DPH	PROPN	O	Chemical	1420
treatment	NOUN	O	O	1420
an	PRON	O	O	1420
unexpected	ADJ	O	O	1420
increase	VERB	O	O	1420
in	ADP	O	O	1420
seizures	NOUN	O	Disease	1420
,	PUNCT	O	O	1420
with	ADP	O	O	1420
EEG	NOUN	O	O	1420
and	CCONJ	O	O	1420
mental	ADJ	O	O	1420
changes	VERB	O	O	1420
occurring	VERB	O	O	1420
simultaneously	ADV	O	O	1420
,	PUNCT	O	O	1420
should	AUX	O	O	1420
alert	ADJ	O	O	1420
the	PRON	O	O	1420
physician	NOUN	O	O	1420
to	PART	O	O	1420
the	PRON	O	O	1420
possible	ADJ	O	O	1420
need	VERB	O	O	1420
for	ADP	O	O	1420
eliminating	VERB	O	O	1420
DPH	PROPN	O	Chemical	1420
from	ADP	O	O	1420
the	PRON	O	O	1420
therapeutic	ADJ	O	O	1420
regimen	NOUN	O	O	1420
,	PUNCT	O	O	1420
even	ADV	O	O	1420
if	SCONJ	O	O	1420
plasma	NOUN	O	O	1420
concentrations	NOUN	O	O	1420
are	AUX	O	O	1420
low	ADJ	O	O	1420
.	PUNCT	O	O	1420
Effects	NOUN	O	O	1423
of	ADP	O	O	1423
exercise	VERB	O	O	1423
on	ADP	O	O	1423
the	PRON	O	O	1423
severity	NOUN	O	O	1423
of	ADP	O	O	1423
isoproterenol	NOUN	O	Chemical	1423
-	PUNCT	O	O	1423
induced	VERB	O	O	1423
myocardial infarction	NOUN	O	Disease	1423
.	PUNCT	O	O	1423
The	PRON	O	O	1424
effect	VERB	O	O	1424
of	ADP	O	O	1424
exercise	VERB	O	O	1424
on	ADP	O	O	1424
the	PRON	O	O	1424
severity	NOUN	O	O	1424
of	ADP	O	O	1424
isoproterenol	NOUN	O	Chemical	1424
-	PUNCT	O	O	1424
induced	VERB	O	O	1424
myocardial infarction	NOUN	O	Disease	1424
was	AUX	O	O	1424
studied	VERB	O	O	1424
in	ADP	O	O	1424
male	NOUN	O	O	1424
rats	NOUN	O	O	1424
.	PUNCT	O	O	1424
The	PRON	O	O	1425
exercise	VERB	O	O	1425
-	PUNCT	O	O	1425
isoproterenol	NOUN	O	Chemical	1425
(	PUNCT	O	O	1425
E-1	NOUN	O	O	1425
)	PUNCT	O	O	1425
and	CCONJ	O	O	1425
exercise	VERB	O	O	1425
control	VERB	O	O	1425
(	PUNCT	O	O	1425
EC	PROPN	O	O	1425
)	PUNCT	O	O	1425
groups	NOUN	O	O	1425
exercised	VERB	O	O	1425
daily	ADV	O	O	1425
for	ADP	O	O	1425
thirty	NUM	O	O	1425
days	NOUN	O	O	1425
on	ADP	O	O	1425
a	PRON	O	O	1425
treadmill	NOUN	O	O	1425
at	ADP	O	O	1425
1	X	O	O	1425
mph	NOUN	O	O	1425
,	PUNCT	O	O	1425
2%	NOUN	O	O	1425
grade	NOUN	O	O	1425
while	SCONJ	O	O	1425
animals	NOUN	O	O	1425
of	ADP	O	O	1425
the	PRON	O	O	1425
sedentary	ADJ	O	O	1425
-	PUNCT	O	O	1425
isoproterenol	NOUN	O	Chemical	1425
(	PUNCT	O	O	1425
S	NOUN	O	O	1425
-	PUNCT	O	O	1425
I	PRON	O	O	1425
)	PUNCT	O	O	1425
group	NOUN	O	O	1425
remained	VERB	O	O	1425
sedentary	ADJ	O	O	1425
.	PUNCT	O	O	1425
Forty	NUM	O	O	1426
-	PUNCT	O	O	1426
eight	NUM	O	O	1426
hours	NOUN	O	O	1426
after	ADP	O	O	1426
the	PRON	O	O	1426
final	ADJ	O	O	1426
exercise	VERB	O	O	1426
period	NOUN	O	O	1426
,	PUNCT	O	O	1426
S	NOUN	O	O	1426
-	PUNCT	O	O	1426
I	PRON	O	O	1426
and	CCONJ	O	O	1426
E	NOUN	O	Chemical	1426
-	PUNCT	O	O	1426
I	PRON	O	O	1426
animals	NOUN	O	O	1426
received	VERB	O	O	1426
a	PRON	O	O	1426
single	ADJ	O	O	1426
subcutaneous	ADJ	O	O	1426
injection	NOUN	O	O	1426
of	ADP	O	O	1426
isoproterenol	NOUN	O	Chemical	1426
(	PUNCT	O	O	1426
250	NUM	O	O	1426
mg	VERB	O	O	1426
/	PUNCT	O	O	1426
kg	VERB	O	O	1426
body	NOUN	O	O	1426
weight	NOUN	O	O	1426
)	PUNCT	O	O	1426
.	PUNCT	O	O	1426
Animals	NOUN	O	O	1427
of	ADP	O	O	1427
the	PRON	O	O	1427
S	NOUN	O	O	1427
-	PUNCT	O	O	1427
I	PRON	O	O	1427
group	NOUN	O	O	1427
exhibited	VERB	O	O	1427
significantly	ADV	O	O	1427
(	PUNCT	O	O	1427
Pp	NOUN	O	O	1427
less	ADV	O	O	1427
than	ADP	O	O	1427
0.05	NUM	O	O	1427
)	PUNCT	O	O	1427
greater	ADJ	O	O	1427
mortality	NOUN	O	O	1427
from	ADP	O	O	1427
the	PRON	O	O	1427
effects	NOUN	O	O	1427
of	ADP	O	O	1427
isoproterenol	NOUN	O	Chemical	1427
than	ADP	O	O	1427
animals	NOUN	O	O	1427
of	ADP	O	O	1427
the	PRON	O	O	1427
E	NOUN	O	Chemical	1427
-	PUNCT	O	O	1427
I	PRON	O	O	1427
group	NOUN	O	O	1427
.	PUNCT	O	O	1427
Serum	NOUN	O	O	1428
CPK	PROPN	O	O	1428
activity	NOUN	O	O	1428
for	ADP	O	O	1428
E	NOUN	O	Chemical	1428
-	PUNCT	O	O	1428
I	PRON	O	O	1428
animals	NOUN	O	O	1428
was	AUX	O	O	1428
significantly	ADV	O	O	1428
(	PUNCT	O	O	1428
p	NOUN	O	O	1428
less	ADV	O	O	1428
than	ADP	O	O	1428
0.05	NUM	O	O	1428
)	PUNCT	O	O	1428
greater	ADJ	O	O	1428
than	ADP	O	O	1428
for	ADP	O	O	1428
animals	NOUN	O	O	1428
in	ADP	O	O	1428
the	PRON	O	O	1428
S	NOUN	O	O	1428
-	PUNCT	O	O	1428
I	PRON	O	O	1428
and	CCONJ	O	O	1428
EC	PROPN	O	O	1428
groups	NOUN	O	O	1428
twenty	NUM	O	O	1428
hours	NOUN	O	O	1428
following	VERB	O	O	1428
isoproterenol	NOUN	O	Chemical	1428
injection	NOUN	O	O	1428
.	PUNCT	O	O	1428
No	PRON	O	O	1429
statistically	ADV	O	O	1429
significant	ADJ	O	O	1429
differences	NOUN	O	O	1429
were	AUX	O	O	1429
observed	VERB	O	O	1429
between	ADP	O	O	1429
the	PRON	O	O	1429
two	NUM	O	O	1429
isoproterenol	NOUN	O	Chemical	1429
treated	VERB	O	O	1429
groups	NOUN	O	O	1429
for	ADP	O	O	1429
severity	NOUN	O	O	1429
of	ADP	O	O	1429
the	PRON	O	O	1429
induced	VERB	O	O	1429
lesions	NOUN	O	O	1429
,	PUNCT	O	O	1429
changes	VERB	O	O	1429
in	ADP	O	O	1429
heart	NOUN	O	O	1429
weight	NOUN	O	O	1429
,	PUNCT	O	O	1429
or	CCONJ	O	O	1429
heart	NOUN	O	O	1429
weight	NOUN	O	O	1429
to	PART	O	O	1429
body	NOUN	O	O	1429
weight	NOUN	O	O	1429
ratios	VERB	O	O	1429
.	PUNCT	O	O	1429
The	PRON	O	O	1430
results	VERB	O	O	1430
indicated	VERB	O	O	1430
that	SCONJ	O	O	1430
exercise	VERB	O	O	1430
reduced	VERB	O	O	1430
the	PRON	O	O	1430
mortality	NOUN	O	O	1430
associated	VERB	O	O	1430
with	ADP	O	O	1430
the	PRON	O	O	1430
effects	NOUN	O	O	1430
of	ADP	O	O	1430
large	ADJ	O	O	1430
dosages	NOUN	O	O	1430
of	ADP	O	O	1430
isoproterenol	NOUN	O	Chemical	1430
but	CCONJ	O	O	1430
had	VERB	O	O	1430
little	ADJ	O	O	1430
on	ADP	O	O	1430
the	PRON	O	O	1430
severity	NOUN	O	O	1430
of	ADP	O	O	1430
the	PRON	O	O	1430
infarction	NOUN	O	O	1430
.	PUNCT	O	O	1430
Effect	VERB	O	O	1433
of	ADP	O	O	1433
D	NOUN	O	O	1433
-	PUNCT	O	O	1433
Glucarates	NOUN	O	O	1433
on	ADP	O	O	1433
basic	ADJ	O	O	1433
antibiotic	ADJ	O	O	1433
-	PUNCT	O	O	1433
induced	VERB	O	O	1433
renal damage	NOUN	O	Disease	1433
in	ADP	O	O	1433
rats	NOUN	O	O	1433
.	PUNCT	O	O	1433
Dehydrated	ADJ	O	O	1434
rats	NOUN	O	O	1434
regularly	ADV	O	O	1434
develop	VERB	O	O	1434
acute	ADJ	O	O	1434
renal failure	NOUN	O	Disease	1434
following	VERB	O	O	1434
single	ADJ	O	O	1434
injection	NOUN	O	O	1434
of	ADP	O	O	1434
aminoglycoside	ADV	O	Chemical	1434
antibiotics	VERB	O	O	1434
combined	VERB	O	O	1434
with	ADP	O	O	1434
dextran	NOUN	O	Chemical	1434
or	CCONJ	O	O	1434
of	ADP	O	O	1434
antibiotics	VERB	O	O	1434
only	ADV	O	O	1434
.	PUNCT	O	O	1434
Oral	NOUN	O	O	1435
administration	NOUN	O	O	1435
of	ADP	O	O	1435
2,5-di	NOUN	O	O	1435
-	PUNCT	O	O	1435
O	INTJ	O	O	1435
-	PUNCT	O	O	1435
acetyl	PROPN	O	O	1435
-	PUNCT	O	O	1435
D	NOUN	O	O	1435
-	PUNCT	O	O	1435
glucaro-1,4	ADV	O	O	1435
-	PUNCT	O	O	1435
6,3-dilactone	NOUN	O	O	1435
protected	VERB	O	O	1435
rats	NOUN	O	O	1435
against	ADP	O	O	1435
renal failure	NOUN	O	Disease	1435
induced	VERB	O	O	1435
by	ADP	O	O	1435
kanamycin	VERB	O	Chemical	1435
-	PUNCT	O	O	1435
dextran	NOUN	O	Chemical	1435
.	PUNCT	O	O	1435
The	PRON	O	O	1436
protective	ADJ	O	O	1436
effect	VERB	O	O	1436
was	AUX	O	O	1436
prevalent	ADJ	O	O	1436
among	ADP	O	O	1436
D	NOUN	O	O	1436
-	PUNCT	O	O	1436
glucarates	VERB	O	O	1436
,	PUNCT	O	O	1436
and	CCONJ	O	O	1436
also	ADV	O	O	1436
to	PART	O	O	1436
other	ADJ	O	O	1436
saccharic	PROPN	O	O	1436
acid	PROPN	O	O	1436
,	PUNCT	O	O	1436
hexauronic	VERB	O	O	1436
acids	NOUN	O	O	1436
and	CCONJ	O	O	1436
hexaaldonic	PROPN	O	O	1436
acids	NOUN	O	O	1436
,	PUNCT	O	O	1436
although	SCONJ	O	O	1436
to	PART	O	O	1436
a	PRON	O	O	1436
lesser	ADJ	O	O	1436
degree	PROPN	O	O	1436
,	PUNCT	O	O	1436
but	CCONJ	O	O	1436
not	PART	O	O	1436
to	PART	O	O	1436
a	PRON	O	O	1436
hexaaldose	NOUN	O	O	1436
,	PUNCT	O	O	1436
sugar	NOUN	O	O	1436
alcohols	NOUN	O	O	1436
,	PUNCT	O	O	1436
substances	NOUN	O	O	1436
inthe	ADV	O	O	1436
TCA	PROPN	O	O	1436
cycle	PROPN	O	O	1436
and	CCONJ	O	O	1436
other	ADJ	O	O	1436
acidic	ADJ	O	O	1436
compounds	NOUN	O	O	1436
.	PUNCT	O	O	1436
D	NOUN	O	O	1437
-	PUNCT	O	O	1437
Glucarates	NOUN	O	O	1437
were	AUX	O	O	1437
effective	ADJ	O	O	1437
against	ADP	O	O	1437
renal damage	NOUN	O	Disease	1437
induced	VERB	O	O	1437
by	ADP	O	O	1437
peptide	NOUN	O	O	1437
antibiotics	VERB	O	O	1437
as	ADP	O	O	1437
well	ADV	O	O	1437
as	ADP	O	O	1437
various	ADJ	O	O	1437
aminoglycoside	ADV	O	Chemical	1437
antibitocis	NOUN	O	O	1437
.	PUNCT	O	O	1437
Dose	NOUN	O	O	1438
-	PUNCT	O	O	1438
responses	NOUN	O	O	1438
were	AUX	O	O	1438
observed	VERB	O	O	1438
in	ADP	O	O	1438
the	PRON	O	O	1438
protective	ADJ	O	O	1438
effect	VERB	O	O	1438
of	ADP	O	O	1438
D	NOUN	O	O	1438
-	PUNCT	O	O	1438
Glucarates	NOUN	O	O	1438
.	PUNCT	O	O	1438
With	ADP	O	O	1439
a	PRON	O	O	1439
D	NOUN	O	O	1439
-	PUNCT	O	O	1439
glucarate	NOUN	O	O	1439
of	ADP	O	O	1439
a	PRON	O	O	1439
fixed	VERB	O	O	1439
size	NOUN	O	O	1439
of	ADP	O	O	1439
dose	NOUN	O	O	1439
,	PUNCT	O	O	1439
approximately	ADV	O	O	1439
the	PRON	O	O	1439
same	ADJ	O	O	1439
degree	PROPN	O	O	1439
of	ADP	O	O	1439
protection	NOUN	O	O	1439
was	AUX	O	O	1439
obtained	VERB	O	O	1439
against	ADP	O	O	1439
renal damages	NOUN	O	O	1439
induced	VERB	O	O	1439
by	ADP	O	O	1439
different	ADJ	O	O	1439
basic	ADJ	O	O	1439
antibiotics	VERB	O	O	1439
despite	SCONJ	O	O	1439
large	ADJ	O	O	1439
disparities	NOUN	O	O	1439
in	ADP	O	O	1439
administration	NOUN	O	O	1439
doses	NOUN	O	O	1439
of	ADP	O	O	1439
different	ADJ	O	O	1439
antibiotics	VERB	O	O	1439
.	PUNCT	O	O	1439
D	NOUN	O	O	1440
-	PUNCT	O	O	1440
Glucarates	NOUN	O	O	1440
had	VERB	O	O	1440
the	PRON	O	O	1440
ability	NOUN	O	O	1440
to	PART	O	O	1440
prevent	VERB	O	O	1440
renal damage	NOUN	O	Disease	1440
but	CCONJ	O	O	1440
not	PART	O	O	1440
to	PART	O	O	1440
cure	VERB	O	O	1440
it	PRON	O	O	1440
.	PUNCT	O	O	1440
Rats	NOUN	O	O	1441
excreted	VERB	O	O	1441
acidic	ADJ	O	O	1441
urine	NOUN	O	O	1441
when	SCONJ	O	O	1441
they	PRON	O	O	1441
were	AUX	O	O	1441
spared	VERB	O	O	1441
from	ADP	O	O	1441
renal lesions	NOUN	O	Disease	1441
by	ADP	O	O	1441
monosaccharides	NOUN	O	O	1441
.	PUNCT	O	O	1441
The	PRON	O	O	1442
reduction	NOUN	O	O	1442
effect	VERB	O	O	1442
of	ADP	O	O	1442
D	NOUN	O	O	1442
-	PUNCT	O	O	1442
glucarates	VERB	O	O	1442
against	ADP	O	O	1442
nephrotoxicity	NOUN	O	Disease	1442
of	ADP	O	O	1442
basic	ADJ	O	O	1442
antibiotics	VERB	O	O	1442
was	AUX	O	O	1442
discussed	VERB	O	O	1442
.	PUNCT	O	O	1442
Paraplegia	NOUN	O	O	1445
following	VERB	O	O	1445
intrathecal	ADJ	O	O	1445
methotrexate	CCONJ	O	Chemical	1445
:	PUNCT	O	O	1445
report	VERB	O	O	1445
of	ADP	O	O	1445
a	PRON	O	O	1445
case	NOUN	O	O	1445
and	CCONJ	O	O	1445
review	VERB	O	O	1445
of	ADP	O	O	1445
the	PRON	O	O	1445
literature	NOUN	O	O	1445
.	PUNCT	O	O	1445
A	PRON	O	O	1446
patient	NOUN	O	O	1446
who	PRON	O	O	1446
developed	VERB	O	O	1446
paraplegia	NOUN	O	O	1446
following	VERB	O	O	1446
the	PRON	O	O	1446
intrathecal	ADJ	O	O	1446
instillation	NOUN	O	O	1446
of	ADP	O	O	1446
methotrexate	CCONJ	O	Chemical	1446
is	AUX	O	O	1446
discribed	VERB	O	O	1446
.	PUNCT	O	O	1446
The	PRON	O	O	1447
following	VERB	O	O	1447
factors	NOUN	O	O	1447
appear	VERB	O	O	1447
to	PART	O	O	1447
predispose	VERB	O	O	1447
to	PART	O	O	1447
the	PRON	O	O	1447
development	NOUN	O	O	1447
of	ADP	O	O	1447
this	PRON	O	O	1447
complication	NOUN	O	O	1447
:	PUNCT	O	O	1447
abnormal	ADJ	O	O	1447
cerebrospinal	ADJ	O	O	1447
dynamics	NOUN	O	O	1447
related	ADJ	O	O	1447
to	PART	O	O	1447
the	PRON	O	O	1447
presence	NOUN	O	O	1447
of	ADP	O	O	1447
central	ADJ	O	O	1447
nervous	ADJ	O	O	1447
system	NOUN	O	O	1447
leukemia	NOUN	O	Disease	1447
,	PUNCT	O	O	1447
and	CCONJ	O	O	1447
epidural	ADV	O	O	1447
cerebrospinal	ADJ	O	O	1447
leakage	NOUN	O	O	1447
;	PUNCT	O	O	1447
elevated	ADJ	O	O	1447
cerebrospinal	ADJ	O	O	1447
fluid	NOUN	O	O	1447
methothexate	NOUN	O	O	1447
concentration	NOUN	O	O	1447
related	ADJ	O	O	1447
to	PART	O	O	1447
abnormal	ADJ	O	O	1447
cerebrospinal	ADJ	O	O	1447
fluid	NOUN	O	O	1447
dynamics	NOUN	O	O	1447
and	CCONJ	O	O	1447
to	PART	O	O	1447
inappropriately	ADV	O	O	1447
high	ADJ	O	O	1447
methotrexate	CCONJ	O	Chemical	1447
doses	NOUN	O	O	1447
based	VERB	O	O	1447
on	ADP	O	O	1447
body	NOUN	O	O	1447
surface	NOUN	O	O	1447
area	NOUN	O	O	1447
calculations	NOUN	O	O	1447
in	ADP	O	O	1447
older	ADJ	O	O	1447
children	NOUN	O	O	1447
and	CCONJ	O	O	1447
adults	NOUN	O	O	1447
;	PUNCT	O	O	1447
the	PRON	O	O	1447
presence	NOUN	O	O	1447
of	ADP	O	O	1447
neurotoxic	ADJ	O	Disease	1447
preservatives	NOUN	O	O	1447
in	ADP	O	O	1447
commercially	ADV	O	O	1447
available	ADJ	O	O	1447
methotrexate	CCONJ	O	Chemical	1447
preparations	NOUN	O	O	1447
and	CCONJ	O	O	1447
diluents	NOUN	O	O	1447
;	PUNCT	O	O	1447
and	CCONJ	O	O	1447
the	PRON	O	O	1447
use	VERB	O	O	1447
of	ADP	O	O	1447
methotrexate	CCONJ	O	Chemical	1447
diluents	NOUN	O	O	1447
of	ADP	O	O	1447
unphysiologic	ADJ	O	O	1447
pH	NOUN	O	O	1447
,	PUNCT	O	O	1447
ionic	NOUN	O	O	1447
content	NOUN	O	O	1447
and	CCONJ	O	O	1447
osmolarity	NOUN	O	O	1447
.	PUNCT	O	O	1447
The	PRON	O	O	1448
role	NOUN	O	O	1448
of	ADP	O	O	1448
methotrexate	CCONJ	O	Chemical	1448
contaminants	NOUN	O	O	1448
,	PUNCT	O	O	1448
local	ADJ	O	O	1448
folate	VERB	O	Chemical	1448
deficiency	NOUN	O	O	1448
,	PUNCT	O	O	1448
and	CCONJ	O	O	1448
cranial	ADJ	O	O	1448
irradiation	NOUN	O	O	1448
in	ADP	O	O	1448
the	PRON	O	O	1448
pathogenesis	NOUN	O	O	1448
of	ADP	O	O	1448
intrathecal	ADJ	O	O	1448
methotrexate	CCONJ	O	Chemical	1448
toxicity	NOUN	O	Disease	1448
is	AUX	O	O	1448
unclear	ADJ	O	O	1448
.	PUNCT	O	O	1448
The	PRON	O	O	1449
incidence	NOUN	O	O	1449
of	ADP	O	O	1449
neurotoxicity	NOUN	O	Disease	1449
may	AUX	O	O	1449
be	AUX	O	O	1449
reduced	VERB	O	O	1449
by	ADP	O	O	1449
employing	VERB	O	O	1449
lower	ADJ	O	O	1449
doses	NOUN	O	O	1449
of	ADP	O	O	1449
methotrexate	CCONJ	O	Chemical	1449
in	ADP	O	O	1449
the	PRON	O	O	1449
presence	NOUN	O	O	1449
of	ADP	O	O	1449
central	ADJ	O	O	1449
nervous	ADJ	O	O	1449
system	NOUN	O	O	1449
leukemia	NOUN	O	Disease	1449
,	PUNCT	O	O	1449
in	ADP	O	O	1449
older	ADJ	O	O	1449
children	NOUN	O	O	1449
and	CCONJ	O	O	1449
adults	NOUN	O	O	1449
,	PUNCT	O	O	1449
and	CCONJ	O	O	1449
in	ADP	O	O	1449
the	PRON	O	O	1449
presence	NOUN	O	O	1449
of	ADP	O	O	1449
epidural	ADV	O	O	1449
leakage	NOUN	O	O	1449
.	PUNCT	O	O	1449
Only	ADV	O	O	1450
preservative	NOUN	O	O	1450
-	PUNCT	O	O	1450
free	ADJ	O	O	1450
methotrexate	CCONJ	O	Chemical	1450
in	ADP	O	O	1450
Elliott	PROPN	O	O	1450
's	AUX	O	O	1450
B	NOUN	O	O	1450
Solution	NOUN	O	O	1450
at	ADP	O	O	1450
a	PRON	O	O	1450
concentration	NOUN	O	O	1450
of	ADP	O	O	1450
not	PART	O	O	1450
more	ADJ	O	O	1450
than	ADP	O	O	1450
1	X	O	O	1450
mg	VERB	O	O	1450
/	PUNCT	O	O	1450
ml	ADP	O	O	1450
should	AUX	O	O	1450
be	AUX	O	O	1450
used	VERB	O	O	1450
for	ADP	O	O	1450
intrathecal	ADJ	O	O	1450
administration	NOUN	O	O	1450
.	PUNCT	O	O	1450
Periodic	ADJ	O	O	1451
monitoring	NOUN	O	O	1451
of	ADP	O	O	1451
cerebruspinal	NOUN	O	O	1451
fluid	NOUN	O	O	1451
methotrexate	CCONJ	O	Chemical	1451
levels	NOUN	O	O	1451
may	AUX	O	O	1451
be	AUX	O	O	1451
predictive	ADJ	O	O	1451
of	ADP	O	O	1451
the	PRON	O	O	1451
development	NOUN	O	O	1451
of	ADP	O	O	1451
serious	ADJ	O	O	1451
neurotoxicity	NOUN	O	Disease	1451
.	PUNCT	O	O	1451
Centrally	ADV	O	O	1454
mediated	VERB	O	O	1454
cardiovascular	ADJ	O	O	1454
effects	NOUN	O	O	1454
of	ADP	O	O	1454
intracisternal	PROPN	O	O	1454
application	NOUN	O	O	1454
of	ADP	O	O	1454
carbachol	NOUN	O	Chemical	1454
in	ADP	O	O	1454
anesthetized	VERB	O	O	1454
rats	NOUN	O	O	1454
.	PUNCT	O	O	1454
injection	NOUN	O	O	1455
of	ADP	O	O	1455
carbachol	NOUN	O	Chemical	1455
(	PUNCT	O	O	1455
1	X	O	O	1455
mug	NOUN	O	O	1455
)	PUNCT	O	O	1455
in	ADP	O	O	1455
anesthetized	VERB	O	O	1455
rats	NOUN	O	O	1455
was	AUX	O	O	1455
analyzed	VERB	O	O	1455
.	PUNCT	O	O	1455
injection	NOUN	O	O	1456
of	ADP	O	O	1456
guanethidine	VERB	O	O	1456
(	PUNCT	O	O	1456
5	NUM	O	O	1456
mg	VERB	O	O	1456
)	PUNCT	O	O	1456
,	PUNCT	O	O	1456
hexamethonium	ADJ	O	Chemical	1456
(	PUNCT	O	O	1456
10	NUM	O	O	1456
mg	VERB	O	O	1456
)	PUNCT	O	O	1456
or	CCONJ	O	O	1456
phentolamine	ADV	O	Chemical	1456
(	PUNCT	O	O	1456
5	NUM	O	O	1456
mg	VERB	O	O	1456
)	PUNCT	O	O	1456
,	PUNCT	O	O	1456
and	CCONJ	O	O	1456
conversely	ADV	O	O	1456
,	PUNCT	O	O	1456
potentiated	VERB	O	O	1456
by	ADP	O	O	1456
i.v	NOUN	O	O	1456
.	PUNCT	O	O	1456
desmethylimipramine	PROPN	O	O	1457
(	PUNCT	O	O	1457
0.3	NUM	O	O	1457
mg	VERB	O	O	1457
)	PUNCT	O	O	1457
,	PUNCT	O	O	1457
while	SCONJ	O	O	1457
propranolol	NOUN	O	Chemical	1457
(	PUNCT	O	O	1457
0.5	NUM	O	O	1457
mg	VERB	O	O	1457
)	PUNCT	O	O	1457
i.v	NOUN	O	O	1457
.	PUNCT	O	O	1457
selectively	ADV	O	O	1458
inhibited	VERB	O	O	1458
the	PRON	O	O	1458
enlargement	NOUN	O	O	1458
of	ADP	O	O	1458
pulse	NOUN	O	O	1458
pressure	NOUN	O	O	1458
and	CCONJ	O	O	1458
the	PRON	O	O	1458
tachycardia	PROPN	O	Disease	1458
following	VERB	O	O	1458
i.c	INTJ	O	O	1458
.	PUNCT	O	O	1458
carbachol	NOUN	O	Chemical	1459
(	PUNCT	O	O	1459
1	X	O	O	1459
mug	NOUN	O	O	1459
)	PUNCT	O	O	1459
.	PUNCT	O	O	1459
carbachol	NOUN	O	Chemical	1460
(	PUNCT	O	O	1460
1	X	O	O	1460
mug	NOUN	O	O	1460
)	PUNCT	O	O	1460
was	AUX	O	O	1460
almost	ADV	O	O	1460
completely	ADV	O	O	1460
blocked	VERB	O	O	1460
by	ADP	O	O	1460
i.c	INTJ	O	O	1460
.	PUNCT	O	O	1460
atropine	NOUN	O	Chemical	1461
(	PUNCT	O	O	1461
3	X	O	O	1461
mug	NOUN	O	O	1461
)	PUNCT	O	O	1461
or	CCONJ	O	O	1461
hexamethonium	ADJ	O	Chemical	1461
(	PUNCT	O	O	1461
500	NUM	O	O	1461
mug	NOUN	O	O	1461
)	PUNCT	O	O	1461
,	PUNCT	O	O	1461
and	CCONJ	O	O	1461
significantly	ADV	O	O	1461
reduced	VERB	O	O	1461
by	ADP	O	O	1461
i.c	INTJ	O	O	1461
.	PUNCT	O	O	1461
chlorpromazine	NOUN	O	Chemical	1462
(	PUNCT	O	O	1462
50	NUM	O	O	1462
mug	NOUN	O	O	1462
)	PUNCT	O	O	1462
but	CCONJ	O	O	1462
desmethylimipramine	PROPN	O	O	1463
(	PUNCT	O	O	1463
30	NUM	O	O	1463
mug	NOUN	O	O	1463
)	PUNCT	O	O	1463
.	PUNCT	O	O	1463
carbachol	NOUN	O	Chemical	1464
(	PUNCT	O	O	1464
1	X	O	O	1464
mug	NOUN	O	O	1464
)	PUNCT	O	O	1464
remained	VERB	O	O	1464
unchanged	ADJ	O	O	1464
after	ADP	O	O	1464
sectioning	NOUN	O	O	1464
of	ADP	O	O	1464
the	PRON	O	O	1464
bilateral	ADJ	O	O	1464
cervical	ADJ	O	O	1464
vagal	ADJ	O	O	1464
nerves	NOUN	O	O	1464
but	CCONJ	O	O	1464
disappeared	VERB	O	O	1464
after	ADP	O	O	1464
sectioning	NOUN	O	O	1464
of	ADP	O	O	1464
the	PRON	O	O	1464
spinal	NOUN	O	O	1464
cord	NOUN	O	O	1464
(	PUNCT	O	O	1464
C7-C8	PROPN	O	O	1464
)	PUNCT	O	O	1464
.	PUNCT	O	O	1464
carbachol	NOUN	O	Chemical	1465
ortral	ADJ	O	O	1465
and	CCONJ	O	O	1465
peripheral	ADJ	O	O	1465
adrenergic	NOUN	O	O	1465
mechanisms	NOUN	O	O	1465
,	PUNCT	O	O	1465
and	CCONJ	O	O	1465
that	SCONJ	O	O	1465
the	PRON	O	O	1465
sympathetic	ADJ	O	O	1465
trunk	NOUN	O	O	1465
is	AUX	O	O	1465
the	PRON	O	O	1465
main	ADJ	O	O	1465
pathway	NOUN	O	O	1465
.	PUNCT	O	O	1465
Hyperglycemic	PROPN	O	Disease	1468
effect	VERB	O	O	1468
of	ADP	O	O	1468
amino	NOUN	O	O	1468
compounds	NOUN	O	O	1468
structurally	ADV	O	O	1468
related	ADJ	O	O	1468
to	PART	O	O	1468
caproate	NOUN	O	O	1468
in	ADP	O	O	1468
rats	NOUN	O	O	1468
.	PUNCT	O	O	1468
The	PRON	O	O	1469
chronic	ADJ	O	O	1469
feeding	VERB	O	O	1469
of	ADP	O	O	1469
small	ADJ	O	O	1469
amounts	VERB	O	O	1469
(	PUNCT	O	O	1469
0.3	NUM	O	O	1469
-	PUNCT	O	O	1469
3%	NOUN	O	O	1469
of	ADP	O	O	1469
diet	PROPN	O	O	1469
weight	NOUN	O	O	1469
)	PUNCT	O	O	1469
of	ADP	O	O	1469
certain	ADJ	O	O	1469
amino	NOUN	O	O	1469
derivatives	NOUN	O	O	1469
of	ADP	O	O	1469
caproate	NOUN	O	O	1469
resulted	VERB	O	O	1469
in	ADP	O	O	1469
hyperglycemia	NOUN	O	Disease	1469
,	PUNCT	O	O	1469
an	PRON	O	O	1469
elevated	ADJ	O	O	1469
glucose	NOUN	O	Chemical	1469
tolerance	NOUN	O	O	1469
curve	NOUN	O	O	1469
and	CCONJ	O	O	1469
,	PUNCT	O	O	1469
occasionally	ADV	O	O	1469
,	PUNCT	O	O	1469
glucosuria	VERB	O	O	1469
.	PUNCT	O	O	1469
Effective	ADJ	O	O	1470
compounds	NOUN	O	O	1470
included	VERB	O	O	1470
norleucine	PROPN	O	O	1470
,	PUNCT	O	O	1470
norvaline	NOUN	O	O	1470
,	PUNCT	O	O	1470
glutamate	NOUN	O	Chemical	1470
,	PUNCT	O	O	1470
epsilon	PROPN	O	O	1470
-	PUNCT	O	O	1470
aminocaproate	PROPN	O	O	1470
,	PUNCT	O	O	1470
methionine	NOUN	O	O	1470
,	PUNCT	O	O	1470
and	CCONJ	O	O	1470
leucine	NOUN	O	O	1470
.	PUNCT	O	O	1470
Fatty	NOUN	O	O	1473
liver	NOUN	O	O	1473
induced	VERB	O	O	1473
by	ADP	O	O	1473
tetracycline	PROPN	O	O	1473
in	ADP	O	O	1473
the	PRON	O	O	1473
rat	NOUN	O	O	1473
.	PUNCT	O	O	1473
Dose	NOUN	O	O	1474
-	PUNCT	O	O	1474
response	NOUN	O	O	1474
relationships	NOUN	O	O	1474
,	PUNCT	O	O	1474
biochemical	ADJ	O	O	1474
mechanisms	NOUN	O	O	1474
,	PUNCT	O	O	1474
and	CCONJ	O	O	1474
sex	NOUN	O	O	1474
differences	NOUN	O	O	1474
in	ADP	O	O	1474
the	PRON	O	O	1474
experimental	ADJ	O	O	1474
fatty	ADJ	O	O	1474
liver	NOUN	O	O	1474
induced	VERB	O	O	1474
by	ADP	O	O	1474
tetracycline	PROPN	O	O	1474
were	AUX	O	O	1474
studied	VERB	O	O	1474
in	ADP	O	O	1474
the	PRON	O	O	1474
intact	ADJ	O	O	1474
rat	NOUN	O	O	1474
and	CCONJ	O	O	1474
with	ADP	O	O	1474
the	PRON	O	O	1474
isolated	VERB	O	O	1474
perfused	VERB	O	O	1474
rat	NOUN	O	O	1474
liver	NOUN	O	O	1474
in	ADP	O	O	1474
vitro	X	O	O	1474
.	PUNCT	O	O	1474
In	ADP	O	O	1475
the	PRON	O	O	1475
intact	ADJ	O	O	1475
male	NOUN	O	O	1475
and	CCONJ	O	O	1475
female	ADJ	O	O	1475
rat	NOUN	O	O	1475
,	PUNCT	O	O	1475
no	PRON	O	O	1475
direct	ADJ	O	O	1475
relationship	NOUN	O	O	1475
was	AUX	O	O	1475
observed	VERB	O	O	1475
between	ADP	O	O	1475
dose	NOUN	O	O	1475
of	ADP	O	O	1475
tetracycline	PROPN	O	O	1475
and	CCONJ	O	O	1475
hepatic	ADJ	O	O	1475
accumulation	NOUN	O	O	1475
of	ADP	O	O	1475
triglyceride	PROPN	O	O	1475
.	PUNCT	O	O	1475
With	ADP	O	O	1476
provision	NOUN	O	O	1476
of	ADP	O	O	1476
adequate	ADJ	O	O	1476
oleic	NOUN	O	O	1476
acid	PROPN	O	O	1476
as	ADP	O	O	1476
a	PRON	O	O	1476
substrate	NOUN	O	O	1476
for	ADP	O	O	1476
the	PRON	O	O	1476
isolated	VERB	O	O	1476
perfused	VERB	O	O	1476
liver	NOUN	O	O	1476
,	PUNCT	O	O	1476
a	PRON	O	O	1476
direct	ADJ	O	O	1476
relationship	NOUN	O	O	1476
was	AUX	O	O	1476
observed	VERB	O	O	1476
between	ADP	O	O	1476
dose	NOUN	O	O	1476
of	ADP	O	O	1476
tetracycline	PROPN	O	O	1476
and	CCONJ	O	O	1476
both	PRON	O	O	1476
accumulation	NOUN	O	O	1476
of	ADP	O	O	1476
triglyceride	PROPN	O	O	1476
in	ADP	O	O	1476
the	PRON	O	O	1476
liver	NOUN	O	O	1476
and	CCONJ	O	O	1476
depression	PROPN	O	Disease	1476
of	ADP	O	O	1476
output	NOUN	O	O	1476
of	ADP	O	O	1476
triglyceride	PROPN	O	O	1476
by	ADP	O	O	1476
livers	NOUN	O	O	1476
from	ADP	O	O	1476
male	NOUN	O	O	1476
and	CCONJ	O	O	1476
female	ADJ	O	O	1476
rats	NOUN	O	O	1476
.	PUNCT	O	O	1476
Marked	VERB	O	O	1477
differences	NOUN	O	O	1477
were	AUX	O	O	1477
observed	VERB	O	O	1477
between	ADP	O	O	1477
female	ADJ	O	O	1477
and	CCONJ	O	O	1477
male	NOUN	O	O	1477
rats	NOUN	O	O	1477
with	ADP	O	O	1477
regard	NOUN	O	O	1477
to	PART	O	O	1477
base	PROPN	O	O	1477
line	NOUN	O	O	1477
(	PUNCT	O	O	1477
control	VERB	O	O	1477
)	PUNCT	O	O	1477
hepatic	ADJ	O	O	1477
concentration	NOUN	O	O	1477
of	ADP	O	O	1477
triglyceride	PROPN	O	O	1477
and	CCONJ	O	O	1477
output	NOUN	O	O	1477
of	ADP	O	O	1477
triglyceride	PROPN	O	O	1477
.	PUNCT	O	O	1477
Accumulation	NOUN	O	O	1478
of	ADP	O	O	1478
hepatic	ADJ	O	O	1478
triglyceride	PROPN	O	O	1478
,	PUNCT	O	O	1478
as	ADP	O	O	1478
a	PRON	O	O	1478
per	ADP	O	O	1478
cent	NOUN	O	O	1478
of	ADP	O	O	1478
control	VERB	O	O	1478
values	NOUN	O	O	1478
,	PUNCT	O	O	1478
in	ADP	O	O	1478
response	NOUN	O	O	1478
to	PART	O	O	1478
graded	VERB	O	O	1478
doses	NOUN	O	O	1478
of	ADP	O	O	1478
tetracycline	PROPN	O	O	1478
,	PUNCT	O	O	1478
did	VERB	O	O	1478
not	PART	O	O	1478
differ	VERB	O	O	1478
significantly	ADV	O	O	1478
between	ADP	O	O	1478
male	NOUN	O	O	1478
,	PUNCT	O	O	1478
female	ADJ	O	O	1478
and	CCONJ	O	O	1478
pregnant	ADJ	O	O	1478
rat	NOUN	O	O	1478
livers	NOUN	O	O	1478
.	PUNCT	O	O	1478
However	ADV	O	O	1479
,	PUNCT	O	O	1479
livers	NOUN	O	O	1479
from	ADP	O	O	1479
female	ADJ	O	O	1479
,	PUNCT	O	O	1479
and	CCONJ	O	O	1479
especially	ADV	O	O	1479
pregnant	ADJ	O	O	1479
female	ADJ	O	O	1479
rats	NOUN	O	O	1479
,	PUNCT	O	O	1479
were	AUX	O	O	1479
strikingly	ADV	O	O	1479
resistant	ADJ	O	O	1479
to	PART	O	O	1479
the	PRON	O	O	1479
effects	NOUN	O	O	1479
of	ADP	O	O	1479
tetracycline	PROPN	O	O	1479
on	ADP	O	O	1479
depression	PROPN	O	Disease	1479
of	ADP	O	O	1479
output	NOUN	O	O	1479
of	ADP	O	O	1479
triglyceride	PROPN	O	O	1479
under	ADP	O	O	1479
these	PRON	O	O	1479
experimental	ADJ	O	O	1479
conditions	NOUN	O	O	1479
.	PUNCT	O	O	1479
These	PRON	O	O	1480
differences	NOUN	O	O	1480
between	ADP	O	O	1480
the	PRON	O	O	1480
sexes	NOUN	O	O	1480
could	AUX	O	O	1480
not	PART	O	O	1480
be	AUX	O	O	1480
related	ADJ	O	O	1480
to	PART	O	O	1480
altered	VERB	O	O	1480
disposition	NOUN	O	O	1480
of	ADP	O	O	1480
tetracycline	PROPN	O	O	1480
or	CCONJ	O	O	1480
altered	VERB	O	O	1480
uptake	NOUN	O	O	1480
of	ADP	O	O	1480
oleic	NOUN	O	O	1480
acid	PROPN	O	O	1480
.	PUNCT	O	O	1480
Depressed	ADJ	O	O	1481
hepatic	ADJ	O	O	1481
secretion	NOUN	O	O	1481
of	ADP	O	O	1481
triglyceride	PROPN	O	O	1481
accounted	VERB	O	O	1481
only	ADV	O	O	1481
for	ADP	O	O	1481
30	NUM	O	O	1481
to	PART	O	O	1481
50%	NOUN	O	O	1481
of	ADP	O	O	1481
accumulated	VERB	O	O	1481
hepatic	ADJ	O	O	1481
triglyceride	PROPN	O	O	1481
,	PUNCT	O	O	1481
indicating	VERB	O	O	1481
that	SCONJ	O	O	1481
additional	ADJ	O	O	1481
mechanisms	NOUN	O	O	1481
must	AUX	O	O	1481
be	AUX	O	O	1481
involved	VERB	O	O	1481
in	ADP	O	O	1481
the	PRON	O	O	1481
production	NOUN	O	O	1481
of	ADP	O	O	1481
the	PRON	O	O	1481
triglyceride	PROPN	O	O	1481
-	PUNCT	O	O	1481
rich	ADJ	O	O	1481
fatty	ADJ	O	O	1481
liver	NOUN	O	O	1481
in	ADP	O	O	1481
response	NOUN	O	O	1481
to	PART	O	O	1481
tetracycline	PROPN	O	O	1481
.	PUNCT	O	O	1481
Fatal	ADJ	O	O	1484
myeloencephalopathy	PROPN	O	O	1484
due	ADJ	O	O	1484
to	PART	O	O	1484
intrathecal	ADJ	O	O	1484
vincristine	NOUN	O	Chemical	1484
administration	NOUN	O	O	1484
.	PUNCT	O	O	1484
Vincristine	NOUN	O	O	1485
was	AUX	O	O	1485
accidentally	ADV	O	O	1485
given	VERB	O	O	1485
intrathecally	ADV	O	O	1485
to	PART	O	O	1485
a	PRON	O	O	1485
child	NOUN	O	O	1485
with	ADP	O	O	1485
leukaemia	NOUN	O	Disease	1485
,	PUNCT	O	O	1485
producing	VERB	O	O	1485
sensory	ADJ	O	O	1485
and	CCONJ	O	O	1485
motor	NOUN	O	O	1485
dysfunction	NOUN	O	O	1485
followed	VERB	O	O	1485
by	ADP	O	O	1485
encephalopathy	NOUN	O	Disease	1485
and	CCONJ	O	O	1485
death	NOUN	O	O	1485
.	PUNCT	O	O	1485
Separate	ADJ	O	O	1486
times	NOUN	O	O	1486
for	ADP	O	O	1486
administering	VERB	O	O	1486
vincristine	NOUN	O	Chemical	1486
and	CCONJ	O	O	1486
intrathecal	ADJ	O	O	1486
therapy	NOUN	O	O	1486
is	AUX	O	O	1486
recommended	VERB	O	O	1486
.	PUNCT	O	O	1486
Progesterone	NOUN	O	O	1489
potentiation	NOUN	O	O	1489
of	ADP	O	O	1489
bupivacaine	NOUN	O	Chemical	1489
arrhythmogenicity	NOUN	O	O	1489
in	ADP	O	O	1489
pentobarbital	NOUN	O	Chemical	1489
-	PUNCT	O	O	1489
anesthetized	VERB	O	O	1489
rats	NOUN	O	O	1489
and	CCONJ	O	O	1489
beating	VERB	O	O	1489
rat	NOUN	O	O	1489
heart	NOUN	O	O	1489
cell	NOUN	O	O	1489
cultures	NOUN	O	O	1489
.	PUNCT	O	O	1489
The	PRON	O	O	1490
effects	NOUN	O	O	1490
of	ADP	O	O	1490
progesterone	NOUN	O	Chemical	1490
treatment	NOUN	O	O	1490
on	ADP	O	O	1490
bupivacaine	NOUN	O	Chemical	1490
arrhythmogenicity	NOUN	O	O	1490
in	ADP	O	O	1490
beating	VERB	O	O	1490
rat	NOUN	O	O	1490
heart	NOUN	O	O	1490
myocyte	PROPN	O	O	1490
cultures	NOUN	O	O	1490
and	CCONJ	O	O	1490
on	ADP	O	O	1490
anesthetized	VERB	O	O	1490
rats	NOUN	O	O	1490
were	AUX	O	O	1490
determined	VERB	O	O	1490
.	PUNCT	O	O	1490
After	ADP	O	O	1491
determining	VERB	O	O	1491
the	PRON	O	O	1491
bupivacaine	NOUN	O	Chemical	1491
AD50	PROPN	O	O	1491
(	PUNCT	O	O	1491
the	PRON	O	O	1491
concentration	NOUN	O	O	1491
of	ADP	O	O	1491
bupivacaine	NOUN	O	Chemical	1491
that	SCONJ	O	O	1491
caused	VERB	O	O	1491
50%	NOUN	O	O	1491
of	ADP	O	O	1491
all	PRON	O	O	1491
beating	VERB	O	O	1491
rat	NOUN	O	O	1491
heart	NOUN	O	O	1491
myocyte	PROPN	O	O	1491
cultures	NOUN	O	O	1491
to	PART	O	O	1491
become	VERB	O	O	1491
arrhythmic	ADJ	O	Disease	1491
)	PUNCT	O	O	1491
,	PUNCT	O	O	1491
we	PRON	O	O	1491
determined	VERB	O	O	1491
the	PRON	O	O	1491
effect	VERB	O	O	1491
of	ADP	O	O	1491
1-hour	NOUN	O	O	1491
progesterone	NOUN	O	Chemical	1491
HCl	PROPN	O	O	1491
exposure	NOUN	O	O	1491
on	ADP	O	O	1491
myocyte	PROPN	O	O	1491
contractile	ADJ	O	O	1491
rhythm	VERB	O	O	1491
.	PUNCT	O	O	1491
Each	PRON	O	O	1492
concentration	NOUN	O	O	1492
of	ADP	O	O	1492
progesterone	NOUN	O	Chemical	1492
(	PUNCT	O	O	1492
6.25	NUM	O	O	1492
,	PUNCT	O	O	1492
12.5	NUM	O	O	1492
,	PUNCT	O	O	1492
25	NUM	O	O	1492
,	PUNCT	O	O	1492
and	CCONJ	O	O	1492
50	NUM	O	O	1492
micrograms	NOUN	O	O	1492
/	PUNCT	O	O	1492
ml	ADP	O	O	1492
)	PUNCT	O	O	1492
caused	VERB	O	O	1492
a	PRON	O	O	1492
significant	ADJ	O	O	1492
and	CCONJ	O	O	1492
concentration	NOUN	O	O	1492
-	PUNCT	O	O	1492
dependent	ADJ	O	O	1492
reduction	NOUN	O	O	1492
in	ADP	O	O	1492
the	PRON	O	O	1492
AD50	PROPN	O	O	1492
for	ADP	O	O	1492
bupivacaine	NOUN	O	Chemical	1492
.	PUNCT	O	O	1492
Estradiol	NOUN	O	O	1493
treatment	NOUN	O	O	1493
also	ADV	O	O	1493
increased	VERB	O	O	1493
the	PRON	O	O	1493
arrhythmogenicity	NOUN	O	O	1493
of	ADP	O	O	1493
bupivacaine	NOUN	O	Chemical	1493
in	ADP	O	O	1493
myocyte	PROPN	O	O	1493
cultures	NOUN	O	O	1493
,	PUNCT	O	O	1493
but	CCONJ	O	O	1493
was	AUX	O	O	1493
only	ADV	O	O	1493
one	NUM	O	O	1493
fourth	ADV	O	O	1493
as	ADP	O	O	1493
potent	ADJ	O	O	1493
as	ADP	O	O	1493
progesterone	NOUN	O	Chemical	1493
.	PUNCT	O	O	1493
Neither	PRON	O	O	1494
progesterone	NOUN	O	Chemical	1494
nor	CCONJ	O	O	1494
estradiol	VERB	O	Chemical	1494
effects	NOUN	O	O	1494
on	ADP	O	O	1494
bupivacaine	NOUN	O	Chemical	1494
arrhythmogenicity	NOUN	O	O	1494
were	AUX	O	O	1494
potentiated	VERB	O	O	1494
by	ADP	O	O	1494
epinephrine	NOUN	O	Chemical	1494
.	PUNCT	O	O	1494
Chronic	NOUN	O	O	1495
progesterone	NOUN	O	Chemical	1495
pretreatment	NOUN	O	O	1495
(	PUNCT	O	O	1496
5	NUM	O	O	1496
mg	VERB	O	O	1496
/	PUNCT	O	O	1496
kg	VERB	O	O	1496
/	PUNCT	O	O	1496
day	NOUN	O	O	1496
for	ADP	O	O	1496
21	NUM	O	O	1496
days	NOUN	O	O	1496
)	PUNCT	O	O	1496
caused	VERB	O	O	1496
a	PRON	O	O	1496
significant	ADJ	O	O	1496
increase	VERB	O	O	1496
in	ADP	O	O	1496
bupivacaine	NOUN	O	Chemical	1496
arrhythmogenicity	NOUN	O	O	1496
in	ADP	O	O	1496
intact	ADJ	O	O	1496
pentobarbital	NOUN	O	Chemical	1496
-	PUNCT	O	O	1496
anesthetized	VERB	O	O	1496
rats	NOUN	O	O	1496
.	PUNCT	O	O	1496
There	ADV	O	O	1497
was	AUX	O	O	1497
a	PRON	O	O	1497
significant	ADJ	O	O	1497
decrease	VERB	O	O	1497
in	ADP	O	O	1497
the	PRON	O	O	1497
time	NOUN	O	O	1497
to	PART	O	O	1497
onset	VERB	O	O	1497
of	ADP	O	O	1497
arrhythmia	NOUN	O	Disease	1497
as	ADP	O	O	1497
compared	VERB	O	O	1497
with	ADP	O	O	1497
control	VERB	O	O	1497
nonprogesterone	NOUN	O	O	1497
-	PUNCT	O	O	1497
treated	VERB	O	O	1497
rats	NOUN	O	O	1497
(	PUNCT	O	O	1497
6.2	NUM	O	O	1497
+	ADP	O	O	1497
/-	PUNCT	O	O	1497
The	PRON	O	O	1498
results	VERB	O	O	1498
of	ADP	O	O	1498
this	PRON	O	O	1498
study	VERB	O	O	1498
indicate	VERB	O	O	1498
that	SCONJ	O	O	1498
progesterone	NOUN	O	Chemical	1498
can	AUX	O	O	1498
potentiate	VERB	O	O	1498
bupivacaine	NOUN	O	Chemical	1498
arrhythmogenicity	NOUN	O	O	1498
both	PRON	O	O	1498
in	ADP	O	O	1498
vivo	VERB	O	O	1498
and	CCONJ	O	O	1498
in	ADP	O	O	1498
vitro	X	O	O	1498
.	PUNCT	O	O	1498
Potentiation	NOUN	O	O	1499
of	ADP	O	O	1499
bupivacaine	NOUN	O	Chemical	1499
arrhythmia	NOUN	O	Disease	1499
in	ADP	O	O	1499
myocyte	PROPN	O	O	1499
cultures	NOUN	O	O	1499
suggests	VERB	O	O	1499
that	SCONJ	O	O	1499
this	PRON	O	O	1499
effect	VERB	O	O	1499
is	AUX	O	O	1499
at	ADP	O	O	1499
least	ADJ	O	O	1499
partly	ADV	O	O	1499
mediated	VERB	O	O	1499
at	ADP	O	O	1499
the	PRON	O	O	1499
myocyte	PROPN	O	O	1499
level	VERB	O	O	1499
.	PUNCT	O	O	1499
Acute	PROPN	O	O	1502
renal failure	NOUN	O	Disease	1502
occurring	VERB	O	O	1502
during	ADP	O	O	1502
intravenous	ADJ	O	O	1502
desferrioxamine	NOUN	O	O	1502
therapy	NOUN	O	O	1502
:	PUNCT	O	O	1502
recovery	NOUN	O	O	1502
after	ADP	O	O	1502
haemodialysis	VERB	O	O	1502
.	PUNCT	O	O	1502
A	PRON	O	O	1503
patient	NOUN	O	O	1503
with	ADP	O	O	1503
transfusion	NOUN	O	O	1503
-	PUNCT	O	O	1503
dependent	ADJ	O	O	1503
thalassemia	NOUN	O	O	1503
was	AUX	O	O	1503
undergoing	VERB	O	O	1503
home	NOUN	O	O	1503
intravenous	ADJ	O	O	1503
desferrioxamine	NOUN	O	O	1503
(	PUNCT	O	O	1503
DFX	PROPN	O	O	1503
)	PUNCT	O	O	1503
treatment	NOUN	O	O	1503
by	ADP	O	O	1503
means	VERB	O	O	1503
of	ADP	O	O	1503
a	PRON	O	O	1503
totally	ADV	O	O	1503
implanted	VERB	O	O	1503
system	NOUN	O	O	1503
because	SCONJ	O	O	1503
of	ADP	O	O	1503
his	PRON	O	O	1503
poor	ADJ	O	O	1503
compliance	NOUN	O	O	1503
with	ADP	O	O	1503
the	PRON	O	O	1503
nightly	ADV	O	O	1503
subcutaneous	ADJ	O	O	1503
therapy	NOUN	O	O	1503
.	PUNCT	O	O	1503
Due	ADP	O	O	1504
to	PART	O	O	1504
an	PRON	O	O	1504
accidental	ADJ	O	O	1504
malfunctioning	VERB	O	O	1504
of	ADP	O	O	1504
the	PRON	O	O	1504
infusion	NOUN	O	O	1504
pump	VERB	O	O	1504
,	PUNCT	O	O	1504
the	PRON	O	O	1504
patient	NOUN	O	O	1504
was	AUX	O	O	1504
inadvertently	ADV	O	O	1504
administered	VERB	O	O	1504
a	PRON	O	O	1504
toxic	ADJ	O	O	1504
dosage	NOUN	O	O	1504
of	ADP	O	O	1504
the	PRON	O	O	1504
drug	NOUN	O	O	1504
which	PRON	O	O	1504
caused	VERB	O	O	1504
renal insufficiency	NOUN	O	Disease	1504
.	PUNCT	O	O	1504
Given	VERB	O	O	1505
the	PRON	O	O	1505
progressive	ADJ	O	O	1505
deterioration	NOUN	O	O	1505
of	ADP	O	O	1505
the	PRON	O	O	1505
symptoms	NOUN	O	O	1505
and	CCONJ	O	O	1505
of	ADP	O	O	1505
the	PRON	O	O	1505
laboratory	NOUN	O	O	1505
values	NOUN	O	O	1505
,	PUNCT	O	O	1505
despite	SCONJ	O	O	1505
adequate	ADJ	O	O	1505
medical	ADJ	O	O	1505
treatment	NOUN	O	O	1505
,	PUNCT	O	O	1505
a	PRON	O	O	1505
decision	NOUN	O	O	1505
was	AUX	O	O	1505
made	VERB	O	O	1505
to	PART	O	O	1505
introduce	VERB	O	O	1505
haemodialytical	NOUN	O	O	1505
therapy	NOUN	O	O	1505
in	ADP	O	O	1505
order	NOUN	O	O	1505
to	PART	O	O	1505
remove	VERB	O	O	1505
the	PRON	O	O	1505
drug	NOUN	O	O	1505
and	CCONJ	O	O	1505
therapy	NOUN	O	O	1505
reduce	VERB	O	O	1505
the	PRON	O	O	1505
nephrotoxicity	NOUN	O	Disease	1505
.	PUNCT	O	O	1505
From	ADP	O	O	1506
the	PRON	O	O	1506
results	VERB	O	O	1506
obtained	VERB	O	O	1506
,	PUNCT	O	O	1506
haemodialysis	VERB	O	O	1506
can	AUX	O	O	1506
therefore	ADV	O	O	1506
be	AUX	O	O	1506
suggested	VERB	O	O	1506
as	ADP	O	O	1506
a	PRON	O	O	1506
useful	ADJ	O	O	1506
therapy	NOUN	O	O	1506
in	ADP	O	O	1506
rare	ADJ	O	O	1506
cases	NOUN	O	O	1506
of	ADP	O	O	1506
progressive	ADJ	O	O	1506
acute	ADJ	O	O	1506
renal failure	NOUN	O	Disease	1506
caused	VERB	O	O	1506
by	ADP	O	O	1506
desferrioxamine	NOUN	O	O	1506
.	PUNCT	O	O	1506
Neuroleptic	NOUN	O	O	1509
-	PUNCT	O	O	1509
associated	VERB	O	O	1509
hyperprolactinemia	NOUN	O	Disease	1509
.	PUNCT	O	O	1509
Can	AUX	O	O	1510
it	PRON	O	O	1510
be	AUX	O	O	1510
treated	VERB	O	O	1510
with	ADP	O	O	1510
bromocriptine	NOUN	O	Chemical	1510
?	PUNCT	O	O	1510
Six	NUM	O	O	1511
stable	ADJ	O	O	1511
psychiatric	ADJ	O	Disease	1511
outpatients	NOUN	O	O	1511
with	ADP	O	O	1511
hyperprolactinemia	NOUN	O	Disease	1511
and	CCONJ	O	O	1511
amenorrhea	PROPN	O	O	1511
/	PUNCT	O	O	1511
oligomenorrhea	NOUN	O	O	1511
associated	VERB	O	O	1511
with	ADP	O	O	1511
their	PRON	O	O	1511
neuroleptic	NOUN	O	O	1511
medications	NOUN	O	O	1511
were	AUX	O	O	1511
treated	VERB	O	O	1511
with	ADP	O	O	1511
bromocriptine	NOUN	O	Chemical	1511
.	PUNCT	O	O	1511
Daily	PROPN	O	O	1512
dosages	NOUN	O	O	1512
of	ADP	O	O	1512
5	NUM	O	O	1512
-	PUNCT	O	O	1512
10	NUM	O	O	1512
mg	VERB	O	O	1512
corrected	VERB	O	O	1512
the	PRON	O	O	1512
hyperprolactinemia	NOUN	O	Disease	1512
and	CCONJ	O	O	1512
restored	VERB	O	O	1512
menstruation	NOUN	O	O	1512
in	ADP	O	O	1512
four	NUM	O	O	1512
of	ADP	O	O	1512
the	PRON	O	O	1512
six	NUM	O	O	1512
patients	NOUN	O	O	1512
.	PUNCT	O	O	1512
One	NUM	O	O	1513
woman	NOUN	O	O	1513
,	PUNCT	O	O	1513
however	ADV	O	O	1513
,	PUNCT	O	O	1513
developed	VERB	O	O	1513
worsened	VERB	O	O	1513
psychiatric	ADJ	O	Disease	1513
symptoms	NOUN	O	O	1513
while	SCONJ	O	O	1513
taking	VERB	O	O	1513
bromocriptine	NOUN	O	Chemical	1513
,	PUNCT	O	O	1513
and	CCONJ	O	O	1513
it	PRON	O	O	1513
was	AUX	O	O	1513
discontinued	VERB	O	O	1513
.	PUNCT	O	O	1513
Thus	ADV	O	O	1514
,	PUNCT	O	O	1514
three	NUM	O	O	1514
of	ADP	O	O	1514
six	NUM	O	O	1514
patients	NOUN	O	O	1514
had	VERB	O	O	1514
their	PRON	O	O	1514
menstrual	ADJ	O	O	1514
irregularity	NOUN	O	O	1514
successfully	ADV	O	O	1514
corrected	VERB	O	O	1514
with	ADP	O	O	1514
bromocriptine	NOUN	O	Chemical	1514
.	PUNCT	O	O	1514
This	PRON	O	O	1515
suggests	VERB	O	O	1515
that	SCONJ	O	O	1515
bromocriptine	NOUN	O	Chemical	1515
should	AUX	O	O	1515
be	AUX	O	O	1515
further	ADV	O	O	1515
evaluated	VERB	O	O	1515
as	ADP	O	O	1515
potential	ADJ	O	O	1515
therapy	NOUN	O	O	1515
for	ADP	O	O	1515
neuroleptic	NOUN	O	O	1515
-	PUNCT	O	O	1515
associated	VERB	O	O	1515
hyperprolactinemia	NOUN	O	Disease	1515
and	CCONJ	O	O	1515
amenorrhea	PROPN	O	O	1515
/	PUNCT	O	O	1515
galactorrhea	PROPN	O	O	1515
.	PUNCT	O	O	1515
Ethacrynic	NOUN	O	O	1518
acid	PROPN	O	O	1518
-	PUNCT	O	O	1518
induced	VERB	O	O	1518
convulsions	NOUN	O	Disease	1518
and	CCONJ	O	O	1518
brain	NOUN	O	O	1518
neurotransmitters	NOUN	O	O	1518
in	ADP	O	O	1518
mice	NOUN	O	O	1518
.	PUNCT	O	O	1518
Intracerebroventricular	PROPN	O	O	1519
injection	NOUN	O	O	1519
of	ADP	O	O	1519
ethacrynic	VERB	O	O	1519
acid	PROPN	O	O	1519
(	PUNCT	O	O	1519
50%	NOUN	O	O	1519
convulsive	ADJ	O	Disease	1519
dose	NOUN	O	O	1519
;	PUNCT	O	O	1520
50	NUM	O	O	1520
micrograms	NOUN	O	O	1520
/	PUNCT	O	O	1520
mouse	PROPN	O	O	1520
)	PUNCT	O	O	1520
accelerated	VERB	O	O	1520
the	PRON	O	O	1520
synthesis	NOUN	O	O	1520
/	PUNCT	O	O	1520
turnover	NOUN	O	O	1520
of	ADP	O	O	1520
5-hydroxytryptamine	NOUN	O	Chemical	1520
(	PUNCT	O	O	1520
5-HT	NOUN	O	Chemical	1520
)	PUNCT	O	O	1520
but	CCONJ	O	O	1520
suppressed	VERB	O	O	1520
the	PRON	O	O	1520
synthesis	NOUN	O	O	1520
of	ADP	O	O	1520
gamma	PROPN	O	O	1520
-	PUNCT	O	O	1520
aminobutyric	PROPN	O	O	1520
acid	PROPN	O	O	1520
and	CCONJ	O	O	1520
acetylcholine	NOUN	O	Chemical	1520
in	ADP	O	O	1520
mouse	PROPN	O	O	1520
brain	NOUN	O	O	1520
.	PUNCT	O	O	1520
These	PRON	O	O	1521
effects	NOUN	O	O	1521
were	AUX	O	O	1521
completely	ADV	O	O	1521
antagonized	VERB	O	O	1521
by	ADP	O	O	1521
pretreatment	NOUN	O	O	1521
with	ADP	O	O	1521
a	PRON	O	O	1521
glutamate	NOUN	O	Chemical	1521
/	PUNCT	O	O	1521
N	NUM	O	O	1521
-	PUNCT	O	O	1521
methyl	NOUN	O	O	1521
-	PUNCT	O	O	1521
D	NOUN	O	O	1521
-	PUNCT	O	O	1521
aspartate	NOUN	O	Chemical	1521
antagonist	NOUN	O	O	1521
,	PUNCT	O	O	1521
aminophosphonovaleric	PROPN	O	O	1521
acid	PROPN	O	O	1521
.	PUNCT	O	O	1521
In	ADP	O	O	1522
ethacrynic	VERB	O	O	1522
acid	PROPN	O	O	1522
-	PUNCT	O	O	1522
induced	VERB	O	O	1522
convulsions	NOUN	O	Disease	1522
,	PUNCT	O	O	1522
these	PRON	O	O	1522
neurotransmitter	NOUN	O	O	1522
systems	NOUN	O	O	1522
may	AUX	O	O	1522
be	AUX	O	O	1522
differentially	ADV	O	O	1522
modulated	VERB	O	O	1522
,	PUNCT	O	O	1522
probably	ADV	O	O	1522
through	ADP	O	O	1522
activation	NOUN	O	O	1522
of	ADP	O	O	1522
glutaminergic	NOUN	O	O	1522
neurons	NOUN	O	O	1522
in	ADP	O	O	1522
the	PRON	O	O	1522
brain	NOUN	O	O	1522
.	PUNCT	O	O	1522
Pharmacology	NOUN	O	O	1525
of	ADP	O	O	1525
gamma	PROPN	O	O	1525
-	PUNCT	O	O	1525
aminobutyric	PROPN	O	O	1525
acidA	ADV	O	O	1525
receptor	NOUN	O	O	1525
complex	ADJ	O	O	1525
after	ADP	O	O	1525
the	PRON	O	O	1525
in	ADP	O	O	1525
vivo	VERB	O	O	1525
administration	NOUN	O	O	1525
of	ADP	O	O	1525
the	PRON	O	O	1525
anxioselective	NOUN	O	O	1525
and	CCONJ	O	O	1525
anticonvulsant	ADJ	O	O	1525
beta	NOUN	O	O	1525
-	PUNCT	O	O	1525
carboline	PROPN	O	O	1525
derivative	ADJ	O	O	1525
abecarnil	NOUN	O	O	1525
.	PUNCT	O	O	1525
In	ADP	O	O	1526
rodents	NOUN	O	O	1526
,	PUNCT	O	O	1526
the	PRON	O	O	1526
effect	VERB	O	O	1526
of	ADP	O	O	1526
the	PRON	O	O	1526
beta	NOUN	O	O	1526
-	PUNCT	O	O	1526
carboline	PROPN	O	O	1526
derivative	ADJ	O	O	1526
isopropyl-6-	PRON	O	O	1526
benzyloxy-4-methoxymethyl	NOUN	O	O	1526
-	PUNCT	O	O	1526
beta	NOUN	O	O	1526
-	PUNCT	O	O	1526
carboline-3-carboxylate	NOUN	O	O	1526
(	PUNCT	O	O	1526
abecarrnil	ADP	O	O	1526
)	PUNCT	O	O	1526
,	PUNCT	O	O	1526
a	PRON	O	O	1526
new	ADJ	O	O	1526
ligand	NOUN	O	O	1526
for	ADP	O	O	1526
benzodiazepine	PROPN	O	Chemical	1526
receptors	NOUN	O	O	1526
possessing	VERB	O	O	1526
anxiolytic	ADJ	O	O	1526
and	CCONJ	O	O	1526
anticonvulsant	ADJ	O	O	1526
properties	NOUN	O	O	1526
,	PUNCT	O	O	1526
was	AUX	O	O	1526
evaluated	VERB	O	O	1526
on	ADP	O	O	1526
the	PRON	O	O	1526
function	NOUN	O	O	1526
of	ADP	O	O	1526
central	ADJ	O	O	1526
gamma	PROPN	O	O	1526
-	PUNCT	O	O	1526
aminobutyric	PROPN	O	O	1526
acid	PROPN	O	O	1526
(	PUNCT	O	O	1526
GABA)A	NOUN	O	O	1526
receptor	NOUN	O	O	1526
complex	ADJ	O	O	1526
,	PUNCT	O	O	1526
both	PRON	O	O	1526
in	ADP	O	O	1526
vitro	X	O	O	1526
and	CCONJ	O	O	1526
in	ADP	O	O	1526
vivo	VERB	O	O	1526
.	PUNCT	O	O	1526
Added	VERB	O	O	1527
in	ADP	O	O	1527
vitro	X	O	O	1527
to	PART	O	O	1527
rat	NOUN	O	O	1527
cortical	ADJ	O	O	1527
membrane	NOUN	O	O	1527
preparation	NOUN	O	O	1527
,	PUNCT	O	O	1527
abecarnil	NOUN	O	O	1527
increased	VERB	O	O	1527
[	X	O	O	1527
3H]GABA	NUM	O	O	1527
binding	VERB	O	O	1527
,	PUNCT	O	O	1527
enhanced	VERB	O	O	1527
muscimol	NOUN	O	Chemical	1527
-	PUNCT	O	O	1527
stimulated	VERB	O	O	1527
36Cl-	NUM	O	O	1527
uptake	NOUN	O	O	1527
and	CCONJ	O	O	1527
reduced	VERB	O	O	1527
the	PRON	O	O	1527
binding	VERB	O	O	1527
of	ADP	O	O	1527
t-[35S]butylbicyclophosphorothionate	VERB	O	O	1527
(	PUNCT	O	O	1527
[	X	O	O	1527
35S]TBPS	NUM	O	O	1527
)	PUNCT	O	O	1527
.	PUNCT	O	O	1527
These	PRON	O	O	1528
effects	NOUN	O	O	1528
were	AUX	O	O	1528
similar	ADJ	O	O	1528
to	PART	O	O	1528
those	PRON	O	O	1528
induced	VERB	O	O	1528
by	ADP	O	O	1528
diazepam	NOUN	O	Chemical	1528
,	PUNCT	O	O	1528
whereas	SCONJ	O	O	1528
the	PRON	O	O	1528
partial	ADJ	O	O	1528
agonist	NOUN	O	O	1528
Ro	INTJ	O	O	1528
16	NUM	O	O	1528
-	PUNCT	O	O	1528
6028	NUM	O	O	1528
(	PUNCT	O	O	1528
tert	NOUN	O	O	1528
-	PUNCT	O	O	1528
butyl-(S)-8-bromo-11,12,13,13a	NOUN	O	O	1528
-	PUNCT	O	O	1528
tetrahydro-9-oxo-9H-	NUM	O	O	1528
imidazo[1,5-a]-pyrrolo-[2,1-c][1,4]benzodiazepine-1-carboxylate	NOUN	O	O	1528
)	PUNCT	O	O	1528
showed	VERB	O	O	1528
very	ADV	O	O	1528
weak	ADJ	O	O	1528
efficacy	NOUN	O	O	1528
in	ADP	O	O	1528
these	PRON	O	O	1528
biochemical	ADJ	O	O	1528
tests	VERB	O	O	1528
.	PUNCT	O	O	1528
injection	NOUN	O	O	1529
to	PART	O	O	1529
rats	NOUN	O	O	1529
,	PUNCT	O	O	1529
abecarnil	NOUN	O	O	1529
and	CCONJ	O	O	1529
diazepam	NOUN	O	Chemical	1529
decreased	VERB	O	O	1529
in	ADP	O	O	1529
a	PRON	O	O	1529
time	NOUN	O	O	1529
-	PUNCT	O	O	1529
dependent	ADJ	O	O	1529
and	CCONJ	O	O	1529
dose	NOUN	O	O	1529
-	PUNCT	O	O	1529
related	ADJ	O	O	1529
(	PUNCT	O	O	1529
0.25	NUM	O	O	1529
-	PUNCT	O	O	1529
20	NUM	O	O	1529
mg	VERB	O	O	1529
/	PUNCT	O	O	1529
kg	VERB	O	O	1529
i.p	NOUN	O	O	1529
.	PUNCT	O	O	1529
)	PUNCT	O	O	1529
manner	VERB	O	O	1530
[	X	O	O	1530
35S]TBPS	NUM	O	O	1530
binding	VERB	O	O	1530
measured	VERB	O	O	1530
ex	PRON	O	O	1530
vivo	VERB	O	O	1530
in	ADP	O	O	1530
the	PRON	O	O	1530
cerebral	ADJ	O	O	1530
cortex	VERB	O	O	1530
.	PUNCT	O	O	1530
Moreover	ADV	O	O	1531
,	PUNCT	O	O	1531
both	PRON	O	O	1531
drugs	NOUN	O	O	1531
at	ADP	O	O	1531
the	PRON	O	O	1531
dose	NOUN	O	O	1531
of	ADP	O	O	1531
0.5	NUM	O	O	1531
mg	VERB	O	O	1531
/	PUNCT	O	O	1531
kg	VERB	O	O	1531
antagonized	VERB	O	O	1531
completely	ADV	O	O	1531
the	PRON	O	O	1531
convulsant	ADJ	O	O	1531
activity	NOUN	O	O	1531
and	CCONJ	O	O	1531
the	PRON	O	O	1531
increase	VERB	O	O	1531
of	ADP	O	O	1531
[	X	O	O	1531
35S]TBPS	NUM	O	O	1531
binding	VERB	O	O	1531
induced	VERB	O	O	1531
by	ADP	O	O	1531
isoniazide	NOUN	O	O	1531
(	PUNCT	O	O	1531
350	NUM	O	O	1531
mg	VERB	O	O	1531
/	PUNCT	O	O	1531
kg	VERB	O	O	1531
s.c	PROPN	O	O	1531
.	PUNCT	O	O	1531
)	PUNCT	O	O	1531
as	ADP	O	O	1532
well	ADV	O	O	1532
as	ADP	O	O	1532
the	PRON	O	O	1532
increase	VERB	O	O	1532
of	ADP	O	O	1532
[	X	O	O	1532
35S]TBPS	NUM	O	O	1532
binding	VERB	O	O	1532
induced	VERB	O	O	1532
by	ADP	O	O	1532
foot	NOUN	O	O	1532
-	PUNCT	O	O	1532
shock	NOUN	O	O	1532
stress	NOUN	O	O	1532
.	PUNCT	O	O	1532
To	PART	O	O	1533
better	ADV	O	O	1533
correlate	VERB	O	O	1533
the	PRON	O	O	1533
biochemical	ADJ	O	O	1533
and	CCONJ	O	O	1533
the	PRON	O	O	1533
pharmacological	ADJ	O	O	1533
effects	NOUN	O	O	1533
,	PUNCT	O	O	1533
we	PRON	O	O	1533
studied	VERB	O	O	1533
the	PRON	O	O	1533
action	NOUN	O	O	1533
of	ADP	O	O	1533
abecarnil	NOUN	O	O	1533
on	ADP	O	O	1533
[	X	O	O	1533
35S]TBPS	NUM	O	O	1533
binding	VERB	O	O	1533
,	PUNCT	O	O	1533
exploratory	ADJ	O	O	1533
motility	NOUN	O	O	1533
and	CCONJ	O	O	1533
on	ADP	O	O	1533
isoniazid	NOUN	O	Chemical	1533
-	PUNCT	O	O	1533
induced	VERB	O	O	1533
biochemical	ADJ	O	O	1533
and	CCONJ	O	O	1533
pharmacological	ADJ	O	O	1533
effects	NOUN	O	O	1533
in	ADP	O	O	1533
mice	NOUN	O	O	1533
.	PUNCT	O	O	1533
In	ADP	O	O	1534
these	PRON	O	O	1534
animals	NOUN	O	O	1534
,	PUNCT	O	O	1534
abecarnil	NOUN	O	O	1534
produced	VERB	O	O	1534
a	PRON	O	O	1534
paralleled	VERB	O	O	1534
dose	NOUN	O	O	1534
-	PUNCT	O	O	1534
dependent	ADJ	O	O	1534
(	PUNCT	O	O	1534
0.05	NUM	O	O	1534
-	PUNCT	O	O	1534
1	X	O	O	1534
mg	VERB	O	O	1534
/	PUNCT	O	O	1534
kg	VERB	O	O	1534
i.p	NOUN	O	O	1534
.	PUNCT	O	O	1534
)	PUNCT	O	O	1534
reduction	NOUN	O	O	1534
of	ADP	O	O	1534
both	PRON	O	O	1534
motor	NOUN	O	O	1534
behavior	NOUN	O	O	1534
and	CCONJ	O	O	1534
cortical	ADJ	O	O	1534
[	X	O	O	1534
35S]TBPS	NUM	O	O	1534
binding	VERB	O	O	1534
.	PUNCT	O	O	1534
kg	VERB	O	O	1535
of	ADP	O	O	1535
this	PRON	O	O	1535
beta	NOUN	O	O	1535
-	PUNCT	O	O	1535
carboline	PROPN	O	O	1535
reduced	VERB	O	O	1535
markedly	ADV	O	O	1535
the	PRON	O	O	1535
increase	VERB	O	O	1535
of	ADP	O	O	1535
[	X	O	O	1535
35S]TBPS	NUM	O	O	1535
binding	VERB	O	O	1535
and	CCONJ	O	O	1535
the	PRON	O	O	1535
convulsions	NOUN	O	Disease	1535
induced	VERB	O	O	1535
by	ADP	O	O	1535
isoniazid	NOUN	O	Chemical	1535
(	PUNCT	O	O	1535
200	NUM	O	O	1535
mg	VERB	O	O	1535
/	PUNCT	O	O	1535
kg	VERB	O	O	1535
s.c.).(ABSTRACT	X	O	O	1535
TRUNCATED	ADJ	O	O	1535
AT	ADP	O	O	1535
250	NUM	O	O	1535
WORDS	NOUN	O	O	1535
)	PUNCT	O	O	1535
Recurrent	ADJ	O	O	1538
myocardial infarction	NOUN	O	Disease	1538
in	ADP	O	O	1538
a	PRON	O	O	1538
postpartum	PROPN	O	O	1538
patient	NOUN	O	O	1538
receiving	VERB	O	O	1538
bromocriptine	NOUN	O	Chemical	1538
.	PUNCT	O	O	1538
Myocardial infarction	NOUN	O	Disease	1539
in	ADP	O	O	1539
puerperium	NOUN	O	O	1539
is	AUX	O	O	1539
infrequently	ADV	O	O	1539
reported	VERB	O	O	1539
.	PUNCT	O	O	1539
Spasm	NOUN	O	O	1540
,	PUNCT	O	O	1540
coronary	ADJ	O	O	1540
dissection	NOUN	O	O	1540
,	PUNCT	O	O	1540
or	CCONJ	O	O	1540
atheromatous	PROPN	O	O	1540
etiology	NOUN	O	O	1540
has	VERB	O	O	1540
been	AUX	O	O	1540
described	VERB	O	O	1540
.	PUNCT	O	O	1540
Bromocriptine	PROPN	O	Chemical	1541
has	VERB	O	O	1541
been	AUX	O	O	1541
implicated	VERB	O	O	1541
in	ADP	O	O	1541
several	ADJ	O	O	1541
previous	ADJ	O	O	1541
case	NOUN	O	O	1541
reports	VERB	O	O	1541
of	ADP	O	O	1541
myocardial infarction	NOUN	O	Disease	1541
in	ADP	O	O	1541
the	PRON	O	O	1541
puerperium	NOUN	O	O	1541
.	PUNCT	O	O	1541
Although	SCONJ	O	O	1542
generally	ADV	O	O	1542
regarded	VERB	O	O	1542
as	ADP	O	O	1542
""""	PUNCT	O	O	1542
safe	ADJ	O	O	1542
,	PUNCT	O	O	1542
""""	PUNCT	O	O	1542
possible	ADJ	O	O	1542
serious	ADJ	O	O	1542
cardiac	ADJ	O	O	1542
effects	NOUN	O	O	1542
of	ADP	O	O	1542
bromocriptine	NOUN	O	Chemical	1542
should	AUX	O	O	1542
be	AUX	O	O	1542
acknowledged	VERB	O	O	1542
.	PUNCT	O	O	1542
Asterixis	PROPN	O	O	1545
induced	VERB	O	O	1545
by	ADP	O	O	1545
carbamazepine	NOUN	O	Chemical	1545
therapy	NOUN	O	O	1545
.	PUNCT	O	O	1545
There	ADV	O	O	1546
are	AUX	O	O	1546
very	ADV	O	O	1546
few	ADJ	O	O	1546
reports	VERB	O	O	1546
about	ADP	O	O	1546
asterixis	PROPN	O	O	1546
as	ADP	O	O	1546
a	PRON	O	O	1546
side	NOUN	O	O	1546
effect	VERB	O	O	1546
of	ADP	O	O	1546
treatment	NOUN	O	O	1546
with	ADP	O	O	1546
psychopharmacologic	ADJ	O	O	1546
agents	NOUN	O	O	1546
.	PUNCT	O	O	1546
In	ADP	O	O	1547
this	PRON	O	O	1547
report	VERB	O	O	1547
we	PRON	O	O	1547
present	NOUN	O	O	1547
four	NUM	O	O	1547
patients	NOUN	O	O	1547
treated	VERB	O	O	1547
with	ADP	O	O	1547
a	PRON	O	O	1547
combination	NOUN	O	O	1547
of	ADP	O	O	1547
different	ADJ	O	O	1547
psychotropic	NOUN	O	O	1547
drugs	NOUN	O	O	1547
,	PUNCT	O	O	1547
in	ADP	O	O	1547
whom	PRON	O	O	1547
asterixis	PROPN	O	O	1547
was	AUX	O	O	1547
triggered	VERB	O	O	1547
either	ADV	O	O	1547
by	ADP	O	O	1547
adding	VERB	O	O	1547
carbamazepine	NOUN	O	Chemical	1547
(	PUNCT	O	O	1547
CBZ	PROPN	O	Chemical	1547
)	PUNCT	O	O	1547
to	PART	O	O	1547
a	PRON	O	O	1547
treatment	NOUN	O	O	1547
regimen	NOUN	O	O	1547
,	PUNCT	O	O	1547
or	CCONJ	O	O	1547
by	ADP	O	O	1547
increasing	VERB	O	O	1547
its	PRON	O	O	1547
dosage	NOUN	O	O	1547
.	PUNCT	O	O	1547
Neither	PRON	O	O	1548
dosage	NOUN	O	O	1548
nor	CCONJ	O	O	1548
serum	NOUN	O	O	1548
levels	NOUN	O	O	1548
of	ADP	O	O	1548
CBZ	PROPN	O	Chemical	1548
were	AUX	O	O	1548
in	ADP	O	O	1548
a	PRON	O	O	1548
higher	ADJ	O	O	1548
range	VERB	O	O	1548
.	PUNCT	O	O	1548
We	PRON	O	O	1549
consider	VERB	O	O	1549
asterixis	PROPN	O	O	1549
to	PART	O	O	1549
be	AUX	O	O	1549
an	PRON	O	O	1549
easily	ADV	O	O	1549
overlooked	VERB	O	O	1549
sign	VERB	O	O	1549
of	ADP	O	O	1549
neurotoxicity	NOUN	O	Disease	1549
,	PUNCT	O	O	1549
which	PRON	O	O	1549
may	AUX	O	O	1549
occur	VERB	O	O	1549
even	ADV	O	O	1549
at	ADP	O	O	1549
low	ADJ	O	O	1549
or	CCONJ	O	O	1549
moderate	ADJ	O	O	1549
dosage	NOUN	O	O	1549
levels	NOUN	O	O	1549
,	PUNCT	O	O	1549
if	SCONJ	O	O	1549
certain	ADJ	O	O	1549
drugs	NOUN	O	O	1549
as	ADP	O	O	1549
lithium	NOUN	O	Chemical	1549
or	CCONJ	O	O	1549
clozapine	PROPN	O	Chemical	1549
are	AUX	O	O	1549
used	VERB	O	O	1549
in	ADP	O	O	1549
combination	NOUN	O	O	1549
with	ADP	O	O	1549
CBZ	PROPN	O	Chemical	1549
.	PUNCT	O	O	1549
Pharmacodynamics	NOUN	O	O	1552
of	ADP	O	O	1552
the	PRON	O	O	1552
hypotensive	ADJ	O	Disease	1552
effect	VERB	O	O	1552
of	ADP	O	O	1552
levodopa	NOUN	O	Chemical	1552
in	ADP	O	O	1552
parkinsonian	PROPN	O	Disease	1552
patients	NOUN	O	O	1552
.	PUNCT	O	O	1552
levodopa	NOUN	O	Chemical	1553
were	AUX	O	O	1553
examined	VERB	O	O	1553
in	ADP	O	O	1553
parkinsonian	PROPN	O	Disease	1553
patients	NOUN	O	O	1553
with	ADP	O	O	1553
stable	ADJ	O	O	1553
and	CCONJ	O	O	1553
fluctuating	VERB	O	O	1553
responses	NOUN	O	O	1553
to	PART	O	O	1553
levodopa	NOUN	O	Chemical	1553
.	PUNCT	O	O	1553
The	PRON	O	O	1554
magnitude	NOUN	O	O	1554
of	ADP	O	O	1554
the	PRON	O	O	1554
hypotensive	ADJ	O	Disease	1554
effect	VERB	O	O	1554
of	ADP	O	O	1554
levodopa	NOUN	O	Chemical	1554
was	AUX	O	O	1554
concentration	NOUN	O	O	1554
dependent	ADJ	O	O	1554
and	CCONJ	O	O	1554
was	AUX	O	O	1554
fit	ADJ	O	O	1554
to	PART	O	O	1554
an	PRON	O	O	1554
Emax	NOUN	O	O	1554
model	NOUN	O	O	1554
in	ADP	O	O	1554
fluctuating	VERB	O	O	1554
responders	NOUN	O	O	1554
.	PUNCT	O	O	1554
Stable	ADJ	O	O	1555
responders	NOUN	O	O	1555
demonstrated	VERB	O	O	1555
a	PRON	O	O	1555
small	ADJ	O	O	1555
hypotensive	ADJ	O	Disease	1555
response	NOUN	O	O	1555
.	PUNCT	O	O	1555
Baseline	PROPN	O	O	1556
blood	NOUN	O	O	1556
pressures	NOUN	O	O	1556
were	AUX	O	O	1556
higher	ADJ	O	O	1556
in	ADP	O	O	1556
fluctuating	VERB	O	O	1556
patients	NOUN	O	O	1556
;	PUNCT	O	O	1556
a	PRON	O	O	1556
higher	ADJ	O	O	1556
baseline	VERB	O	O	1556
blood	NOUN	O	O	1556
pressure	NOUN	O	O	1556
correlated	VERB	O	O	1556
with	ADP	O	O	1556
greater	ADJ	O	O	1556
hypotensive	ADJ	O	Disease	1556
effects	NOUN	O	O	1556
.	PUNCT	O	O	1556
Antiparkinsonian	PROPN	O	O	1557
effects	NOUN	O	O	1557
of	ADP	O	O	1557
levodopa	NOUN	O	Chemical	1557
temporally	ADV	O	O	1557
correlated	VERB	O	O	1557
with	ADP	O	O	1557
blood	NOUN	O	O	1557
pressure	NOUN	O	O	1557
changes	VERB	O	O	1557
.	PUNCT	O	O	1557
Phenylalanine	NOUN	O	O	1558
,	PUNCT	O	O	1558
a	PRON	O	O	1558
large	ADJ	O	O	1558
neutral	ADJ	O	O	1558
amino acid	NOUN	O	Chemical	1558
(	PUNCT	O	O	1558
LNAA	PROPN	O	O	1558
)	PUNCT	O	O	1558
competing	VERB	O	O	1558
with	ADP	O	O	1558
levodopa	NOUN	O	Chemical	1558
for	ADP	O	O	1558
transport	NOUN	O	O	1558
across	ADP	O	O	1558
the	PRON	O	O	1558
blood	NOUN	O	O	1558
-	PUNCT	O	O	1558
brain	NOUN	O	O	1558
barrier	NOUN	O	O	1558
,	PUNCT	O	O	1558
reduced	VERB	O	O	1558
the	PRON	O	O	1558
hypotensive	ADJ	O	Disease	1558
and	CCONJ	O	O	1558
antiparkinsonian	ADJ	O	O	1558
effects	NOUN	O	O	1558
of	ADP	O	O	1558
levodopa	NOUN	O	Chemical	1558
.	PUNCT	O	O	1558
We	PRON	O	O	1559
conclude	VERB	O	O	1559
that	SCONJ	O	O	1559
levodopa	NOUN	O	Chemical	1559
has	VERB	O	O	1559
a	PRON	O	O	1559
central	ADJ	O	O	1559
hypotensive	ADJ	O	Disease	1559
action	NOUN	O	O	1559
that	SCONJ	O	O	1559
parallels	VERB	O	O	1559
the	PRON	O	O	1559
motor	NOUN	O	O	1559
effects	NOUN	O	O	1559
in	ADP	O	O	1559
fluctuating	VERB	O	O	1559
patients	NOUN	O	O	1559
.	PUNCT	O	O	1559
The	PRON	O	O	1560
hypotensive	ADJ	O	Disease	1560
effect	VERB	O	O	1560
appears	VERB	O	O	1560
to	PART	O	O	1560
be	AUX	O	O	1560
related	ADJ	O	O	1560
to	PART	O	O	1560
the	PRON	O	O	1560
higher	ADJ	O	O	1560
baseline	VERB	O	O	1560
blood	NOUN	O	O	1560
pressure	NOUN	O	O	1560
we	PRON	O	O	1560
observed	VERB	O	O	1560
in	ADP	O	O	1560
fluctuating	VERB	O	O	1560
patients	NOUN	O	O	1560
relative	ADJ	O	O	1560
to	PART	O	O	1560
stable	ADJ	O	O	1560
patients	NOUN	O	O	1560
.	PUNCT	O	O	1560
Syndrome	NOUN	O	O	1563
of	ADP	O	O	1563
inappropriate	ADJ	O	O	1563
secretion	NOUN	O	O	1563
of	ADP	O	O	1563
antidiuretic	ADJ	O	O	1563
hormone	NOUN	O	O	1563
after	ADP	O	O	1563
infusional	NOUN	O	O	1563
vincristine	NOUN	O	Chemical	1563
.	PUNCT	O	O	1563
A	PRON	O	O	1564
77-year	NOUN	O	O	1564
-	PUNCT	O	O	1564
old	ADJ	O	O	1564
woman	NOUN	O	O	1564
with	ADP	O	O	1564
refractory	ADJ	O	O	1564
multiple myeloma	NOUN	O	Disease	1564
was	AUX	O	O	1564
treated	VERB	O	O	1564
with	ADP	O	O	1564
a	PRON	O	O	1564
4-day	NOUN	O	O	1564
continuous	ADJ	O	O	1564
intravenous	ADJ	O	O	1564
infusion	NOUN	O	O	1564
of	ADP	O	O	1564
vincristine	NOUN	O	Chemical	1564
and	CCONJ	O	O	1564
doxorubicin	VERB	O	Chemical	1564
and	CCONJ	O	O	1564
4	NUM	O	O	1564
days	NOUN	O	O	1564
of	ADP	O	O	1564
oral	ADJ	O	O	1564
dexamethasone	NOUN	O	Chemical	1564
.	PUNCT	O	O	1564
Nine	NUM	O	O	1565
days	NOUN	O	O	1565
after	ADP	O	O	1565
her	PRON	O	O	1565
second	ADV	O	O	1565
cycle	PROPN	O	O	1565
she	PRON	O	O	1565
presented	VERB	O	O	1565
with	ADP	O	O	1565
lethargy	NOUN	O	Disease	1565
and	CCONJ	O	O	1565
weakness	NOUN	O	Disease	1565
associated	VERB	O	O	1565
with	ADP	O	O	1565
hyponatremia	NOUN	O	O	1565
.	PUNCT	O	O	1565
Evaluation	NOUN	O	O	1566
revealed	VERB	O	O	1566
the	PRON	O	O	1566
syndrome of inappropriate secretion of antidiuretic hormone	NOUN	O	Disease	1566
,	PUNCT	O	O	1566
which	PRON	O	O	1566
was	AUX	O	O	1566
attributed	VERB	O	O	1566
to	PART	O	O	1566
the	PRON	O	O	1566
vincristine	NOUN	O	Chemical	1566
infusion	NOUN	O	O	1566
.	PUNCT	O	O	1566
After	ADP	O	O	1567
normal	ADJ	O	O	1567
serum	NOUN	O	O	1567
sodium	NOUN	O	Chemical	1567
levels	NOUN	O	O	1567
returned	VERB	O	O	1567
,	PUNCT	O	O	1567
further	ADV	O	O	1567
doxorubicin	VERB	O	Chemical	1567
and	CCONJ	O	O	1567
dexamethasone	NOUN	O	Chemical	1567
chemotherapy	NOUN	O	O	1567
without	ADP	O	O	1567
vincristine	NOUN	O	Chemical	1567
did	VERB	O	O	1567
not	PART	O	O	1567
produce	VERB	O	O	1567
this	PRON	O	O	1567
complication	NOUN	O	O	1567
.	PUNCT	O	O	1567
Heart	NOUN	O	O	1570
failure	NOUN	O	O	1570
:	PUNCT	O	O	1570
to	PART	O	O	1570
digitalise	PROPN	O	O	1570
or	CCONJ	O	O	1570
not	PART	O	O	1570
?	PUNCT	O	O	1570
Despite	SCONJ	O	O	1571
extensive	ADJ	O	O	1571
clinical	ADJ	O	O	1571
experience	NOUN	O	O	1571
the	PRON	O	O	1571
role	NOUN	O	O	1571
of	ADP	O	O	1571
digoxin	PROPN	O	Chemical	1571
is	AUX	O	O	1571
still	ADV	O	O	1571
not	PART	O	O	1571
well	ADV	O	O	1571
defined	VERB	O	O	1571
.	PUNCT	O	O	1571
In	ADP	O	O	1572
patients	NOUN	O	O	1572
with	ADP	O	O	1572
atrial fibrillation	NOUN	O	Disease	1572
digoxin	PROPN	O	Chemical	1572
is	AUX	O	O	1572
beneficial	ADJ	O	O	1572
for	ADP	O	O	1572
ventricular	ADJ	O	O	1572
rate	NOUN	O	O	1572
control	VERB	O	O	1572
.	PUNCT	O	O	1572
For	ADP	O	O	1573
patients	NOUN	O	O	1573
in	ADP	O	O	1573
sinus	NOUN	O	O	1573
rhythm	VERB	O	O	1573
and	CCONJ	O	O	1573
heart failure	NOUN	O	Disease	1573
the	PRON	O	O	1573
situation	NOUN	O	O	1573
is	AUX	O	O	1573
less	ADV	O	O	1573
clear	ADJ	O	O	1573
.	PUNCT	O	O	1573
Digoxin	NOUN	O	O	1574
has	VERB	O	O	1574
a	PRON	O	O	1574
narrow	ADJ	O	O	1574
therapeutic	ADJ	O	O	1574
:	PUNCT	O	O	1574
toxic	ADJ	O	O	1574
ratio	NOUN	O	O	1574
and	CCONJ	O	O	1574
concentrations	NOUN	O	O	1574
are	AUX	O	O	1574
affected	VERB	O	O	1574
by	ADP	O	O	1574
a	PRON	O	O	1574
number	NOUN	O	O	1574
of	ADP	O	O	1574
drugs	NOUN	O	O	1574
.	PUNCT	O	O	1574
Also	ADV	O	O	1575
,	PUNCT	O	O	1575
digoxin	PROPN	O	Chemical	1575
has	VERB	O	O	1575
undesirable	ADJ	O	O	1575
effects	NOUN	O	O	1575
such	ADJ	O	O	1575
as	ADP	O	O	1575
increasing	VERB	O	O	1575
peripheral	ADJ	O	O	1575
resistance	NOUN	O	O	1575
and	CCONJ	O	O	1575
myocardial	ADJ	O	O	1575
demands	VERB	O	O	1575
,	PUNCT	O	O	1575
and	CCONJ	O	O	1575
causing	VERB	O	O	1575
arrhythmias	VERB	O	Disease	1575
.	PUNCT	O	O	1575
More	ADJ	O	O	1576
convincing	ADJ	O	O	1576
evidence	NOUN	O	O	1576
is	AUX	O	O	1576
required	VERB	O	O	1576
showing	VERB	O	O	1576
that	SCONJ	O	O	1576
digoxin	PROPN	O	Chemical	1576
improves	VERB	O	O	1576
symptoms	NOUN	O	O	1576
or	CCONJ	O	O	1576
exercise	VERB	O	O	1576
capacity	NOUN	O	O	1576
.	PUNCT	O	O	1576
Pooled	VERB	O	O	1577
analysis	NOUN	O	O	1577
of	ADP	O	O	1577
the	PRON	O	O	1577
effects	NOUN	O	O	1577
of	ADP	O	O	1577
other	ADJ	O	O	1577
inotropic	NOUN	O	O	1577
drugs	NOUN	O	O	1577
shows	VERB	O	O	1577
an	PRON	O	O	1577
excess	ADJ	O	O	1577
mortality	NOUN	O	O	1577
and	CCONJ	O	O	1577
there	ADV	O	O	1577
is	AUX	O	O	1577
a	PRON	O	O	1577
possibility	NOUN	O	O	1577
that	SCONJ	O	O	1577
digoxin	PROPN	O	Chemical	1577
may	AUX	O	O	1577
increase	VERB	O	O	1577
mortality	NOUN	O	O	1577
after	ADP	O	O	1577
myocardial infarction	NOUN	O	Disease	1577
(	PUNCT	O	O	1577
MI	PROPN	O	Disease	1577
)	PUNCT	O	O	1577
.	PUNCT	O	O	1577
Angiotensin	NOUN	O	O	1578
-	PUNCT	O	O	1578
converting	VERB	O	O	1578
enzyme	NOUN	O	O	1578
(	PUNCT	O	O	1578
ACE	PROPN	O	O	1578
)	PUNCT	O	O	1578
inhibitors	NOUN	O	O	1578
should	AUX	O	O	1578
be	AUX	O	O	1578
used	VERB	O	O	1578
first	ADV	O	O	1578
as	ADP	O	O	1578
they	PRON	O	O	1578
are	AUX	O	O	1578
safer	ADJ	O	O	1578
,	PUNCT	O	O	1578
do	VERB	O	O	1578
not	PART	O	O	1578
require	VERB	O	O	1578
blood	NOUN	O	O	1578
level	VERB	O	O	1578
monitoring	NOUN	O	O	1578
,	PUNCT	O	O	1578
modify	VERB	O	O	1578
progression	NOUN	O	O	1578
of	ADP	O	O	1578
disease	PROPN	O	O	1578
,	PUNCT	O	O	1578
relieve	VERB	O	O	1578
symptoms	NOUN	O	O	1578
,	PUNCT	O	O	1578
improve	VERB	O	O	1578
exercise	VERB	O	O	1578
tolerance	NOUN	O	O	1578
and	CCONJ	O	O	1578
reduce	VERB	O	O	1578
mortality	NOUN	O	O	1578
.	PUNCT	O	O	1578
Caution	NOUN	O	O	1579
should	AUX	O	O	1579
be	AUX	O	O	1579
exercised	VERB	O	O	1579
in	ADP	O	O	1579
using	VERB	O	O	1579
digoxin	PROPN	O	Chemical	1579
until	ADP	O	O	1579
large	ADJ	O	O	1579
mortality	NOUN	O	O	1579
trials	NOUN	O	O	1579
are	AUX	O	O	1579
completed	VERB	O	O	1579
showing	VERB	O	O	1579
either	ADV	O	O	1579
benefit	VERB	O	O	1579
or	CCONJ	O	O	1579
harm	NOUN	O	O	1579
.	PUNCT	O	O	1579
Until	ADP	O	O	1580
then	ADV	O	O	1580
digoxin	PROPN	O	Chemical	1580
should	AUX	O	O	1580
be	AUX	O	O	1580
considered	VERB	O	O	1580
a	PRON	O	O	1580
third	ADV	O	O	1580
-	PUNCT	O	O	1580
line	NOUN	O	O	1580
therapy	NOUN	O	O	1580
.	PUNCT	O	O	1580
Intravascular	PROPN	O	O	1583
hemolysis	NOUN	O	Disease	1583
and	CCONJ	O	O	1583
acute	ADJ	O	O	1583
renal failure	NOUN	O	Disease	1583
following	VERB	O	O	1583
intermittent	ADJ	O	O	1583
rifampin	ADV	O	Chemical	1583
therapy	NOUN	O	O	1583
.	PUNCT	O	O	1583
Renal failure	NOUN	O	Disease	1584
is	AUX	O	O	1584
a	PRON	O	O	1584
rare	ADJ	O	O	1584
complication	NOUN	O	O	1584
associated	VERB	O	O	1584
with	ADP	O	O	1584
the	PRON	O	O	1584
use	VERB	O	O	1584
of	ADP	O	O	1584
rifampin	ADV	O	Chemical	1584
.	PUNCT	O	O	1584
Intravascular	PROPN	O	O	1585
hemolysis	NOUN	O	Disease	1585
leading	VERB	O	O	1585
to	PART	O	O	1585
acute	ADJ	O	O	1585
renal failure	NOUN	O	Disease	1585
following	VERB	O	O	1585
rifampin	ADV	O	Chemical	1585
therapy	NOUN	O	O	1585
is	AUX	O	O	1585
extremely	ADV	O	O	1585
rare	ADJ	O	O	1585
.	PUNCT	O	O	1585
Two	NUM	O	O	1586
patients	NOUN	O	O	1586
with	ADP	O	O	1586
leprosy	NOUN	O	O	1586
who	PRON	O	O	1586
developed	VERB	O	O	1586
hemolysis	NOUN	O	Disease	1586
and	CCONJ	O	O	1586
acute	ADJ	O	O	1586
renal failure	NOUN	O	Disease	1586
following	VERB	O	O	1586
rifampin	ADV	O	Chemical	1586
are	AUX	O	O	1586
reported	VERB	O	O	1586
.	PUNCT	O	O	1586
Zidovudine	PROPN	O	O	1589
-	PUNCT	O	O	1589
induced	VERB	O	O	1589
hepatitis	NOUN	O	Disease	1589
.	PUNCT	O	O	1589
A	PRON	O	O	1590
case	NOUN	O	O	1590
of	ADP	O	O	1590
acute	ADJ	O	O	1590
hepatitis	NOUN	O	Disease	1590
induced	VERB	O	O	1590
by	ADP	O	O	1590
zidovudine	NOUN	O	Chemical	1590
in	ADP	O	O	1590
a	PRON	O	O	1590
38-year	NOUN	O	O	1590
-	PUNCT	O	O	1590
old	ADJ	O	O	1590
patient	NOUN	O	O	1590
with	ADP	O	O	1590
AIDS	PROPN	O	Disease	1590
is	AUX	O	O	1590
presented	VERB	O	O	1590
.	PUNCT	O	O	1590
The	PRON	O	O	1591
mechanism	NOUN	O	O	1591
whereby	ADV	O	O	1591
the	PRON	O	O	1591
hepatitis	NOUN	O	Disease	1591
was	AUX	O	O	1591
induced	VERB	O	O	1591
is	AUX	O	O	1591
not	PART	O	O	1591
known	VERB	O	O	1591
.	PUNCT	O	O	1591
However	ADV	O	O	1592
,	PUNCT	O	O	1592
the	PRON	O	O	1592
patient	NOUN	O	O	1592
tolerated	VERB	O	O	1592
well	ADV	O	O	1592
an	PRON	O	O	1592
alternative	ADV	O	O	1592
reverse	VERB	O	O	1592
transcriptase	VERB	O	O	1592
inhibitor	NOUN	O	O	1592
,	PUNCT	O	O	1592
2'3	NUM	O	O	1592
'	PUNCT	O	O	1592
dideoxyinosine	NOUN	O	O	1592
.	PUNCT	O	O	1592
Physicians	NOUN	O	O	1593
caring	VERB	O	O	1593
for	ADP	O	O	1593
patients	NOUN	O	O	1593
with	ADP	O	O	1593
AIDS	PROPN	O	Disease	1593
should	AUX	O	O	1593
be	AUX	O	O	1593
aware	ADJ	O	O	1593
of	ADP	O	O	1593
this	PRON	O	O	1593
hitherto	ADV	O	O	1593
rarely	ADV	O	O	1593
reported	VERB	O	O	1593
complication	NOUN	O	O	1593
.	PUNCT	O	O	1593
Thoracic	NOUN	O	O	1596
hematomyelia	PROPN	O	O	1596
secondary	ADJ	O	O	1596
to	PART	O	O	1596
coumadin	PROPN	O	O	1596
anticoagulant	ADJ	O	O	1596
therapy	NOUN	O	O	1596
:	PUNCT	O	O	1596
a	PRON	O	O	1596
case	NOUN	O	O	1596
report	VERB	O	O	1596
.	PUNCT	O	O	1596
A	PRON	O	O	1597
case	NOUN	O	O	1597
of	ADP	O	O	1597
thoracic	ADJ	O	O	1597
hematomyelia	PROPN	O	O	1597
secondary	ADJ	O	O	1597
to	PART	O	O	1597
anticoagulant	ADJ	O	O	1597
therapy	NOUN	O	O	1597
is	AUX	O	O	1597
presented	VERB	O	O	1597
.	PUNCT	O	O	1597
Mania	NOUN	O	O	1600
associated	VERB	O	O	1600
with	ADP	O	O	1600
fluoxetine	NOUN	O	Chemical	1600
treatment	NOUN	O	O	1600
in	ADP	O	O	1600
adolescents	NOUN	O	O	1600
.	PUNCT	O	O	1600
Fluoxetine	NOUN	O	Chemical	1601
,	PUNCT	O	O	1601
a	PRON	O	O	1601
selective	ADJ	O	O	1601
serotonin	PROPN	O	Chemical	1601
reuptake	PROPN	O	O	1601
inhibitor	NOUN	O	O	1601
,	PUNCT	O	O	1601
is	AUX	O	O	1601
gaining	VERB	O	O	1601
increased	VERB	O	O	1601
acceptance	NOUN	O	O	1601
in	ADP	O	O	1601
the	PRON	O	O	1601
treatment	NOUN	O	O	1601
of	ADP	O	O	1601
adolescent	ADJ	O	O	1601
depression	PROPN	O	Disease	1601
.	PUNCT	O	O	1601
Generally	ADV	O	O	1602
safe	ADJ	O	O	1602
and	CCONJ	O	O	1602
well	ADV	O	O	1602
tolerated	VERB	O	O	1602
by	ADP	O	O	1602
adults	NOUN	O	O	1602
,	PUNCT	O	O	1602
fluoxetine	NOUN	O	Chemical	1602
has	VERB	O	O	1602
been	AUX	O	O	1602
reported	VERB	O	O	1602
to	PART	O	O	1602
induce	VERB	O	O	1602
mania	NOUN	O	O	1602
.	PUNCT	O	O	1602
The	PRON	O	O	1603
cases	NOUN	O	O	1603
of	ADP	O	O	1603
five	NUM	O	O	1603
depressed	ADJ	O	O	1603
adolescents	NOUN	O	O	1603
,	PUNCT	O	O	1603
14	NUM	O	O	1603
-	PUNCT	O	O	1603
16	NUM	O	O	1603
years	NOUN	O	O	1603
of	ADP	O	O	1603
age	NOUN	O	O	1603
,	PUNCT	O	O	1603
who	PRON	O	O	1603
developed	VERB	O	O	1603
mania	NOUN	O	O	1603
during	ADP	O	O	1603
pharmacotherapy	NOUN	O	O	1603
with	ADP	O	O	1603
fluoxetine	NOUN	O	Chemical	1603
,	PUNCT	O	O	1603
are	AUX	O	O	1603
reported	VERB	O	O	1603
here	ADV	O	O	1603
.	PUNCT	O	O	1603
Apparent	ADJ	O	O	1604
risk	NOUN	O	O	1604
factors	NOUN	O	O	1604
for	ADP	O	O	1604
the	PRON	O	O	1604
development	NOUN	O	O	1604
of	ADP	O	O	1604
mania	NOUN	O	O	1604
or	CCONJ	O	O	1604
hypomania	PROPN	O	Disease	1604
during	ADP	O	O	1604
fluoxetine	NOUN	O	Chemical	1604
pharmacotherapy	NOUN	O	O	1604
in	ADP	O	O	1604
this	PRON	O	O	1604
population	NOUN	O	O	1604
were	AUX	O	O	1604
the	PRON	O	O	1604
combination	NOUN	O	O	1604
of	ADP	O	O	1604
attention	NOUN	O	O	1604
-	PUNCT	O	O	1604
deficit	NOUN	O	O	1604
hyperactivity	NOUN	O	Disease	1604
disorder	NOUN	O	O	1604
and	CCONJ	O	O	1604
affective	ADJ	O	O	1604
instability	NOUN	O	O	1604
;	PUNCT	O	O	1604
major	ADJ	O	O	1604
depression	PROPN	O	Disease	1604
with	ADP	O	O	1604
psychotic	ADJ	O	O	1604
features	VERB	O	O	1604
;	PUNCT	O	O	1604
a	PRON	O	O	1604
family	NOUN	O	O	1604
history	NOUN	O	O	1604
of	ADP	O	O	1604
affective	ADJ	O	O	1604
disorder	NOUN	O	O	1604
,	PUNCT	O	O	1604
especially	ADV	O	O	1604
bipolar disorder	NOUN	O	Disease	1604
;	PUNCT	O	O	1604
and	CCONJ	O	O	1604
a	PRON	O	O	1604
diagnosis	NOUN	O	O	1604
of	ADP	O	O	1604
bipolar disorder	NOUN	O	Disease	1604
.	PUNCT	O	O	1604
Further	ADV	O	O	1605
study	VERB	O	O	1605
is	AUX	O	O	1605
needed	VERB	O	O	1605
to	PART	O	O	1605
determine	VERB	O	O	1605
the	PRON	O	O	1605
optimal	ADJ	O	O	1605
dosage	NOUN	O	O	1605
and	CCONJ	O	O	1605
to	PART	O	O	1605
identify	VERB	O	O	1605
risk	NOUN	O	O	1605
factors	NOUN	O	O	1605
that	SCONJ	O	O	1605
increase	VERB	O	O	1605
individual	ADJ	O	O	1605
vulnerability	NOUN	O	O	1605
to	PART	O	O	1605
fluoxetine	NOUN	O	Chemical	1605
induced	VERB	O	O	1605
mania	NOUN	O	O	1605
in	ADP	O	O	1605
adolescents	NOUN	O	O	1605
.	PUNCT	O	O	1605
Gemfibrozil	PROPN	O	O	1608
-	PUNCT	O	O	1608
lovastatin	NOUN	O	Chemical	1608
therapy	NOUN	O	O	1608
for	ADP	O	O	1608
primary	NOUN	O	O	1608
hyperlipoproteinemias	NOUN	O	O	1608
.	PUNCT	O	O	1608
The	PRON	O	O	1609
specific	ADJ	O	O	1609
aim	VERB	O	O	1609
of	ADP	O	O	1609
this	PRON	O	O	1609
retrospective	ADJ	O	O	1609
,	PUNCT	O	O	1609
observational	ADJ	O	O	1609
study	VERB	O	O	1609
was	AUX	O	O	1609
to	PART	O	O	1609
assess	VERB	O	O	1609
safety	NOUN	O	O	1609
and	CCONJ	O	O	1609
efficacy	NOUN	O	O	1609
of	ADP	O	O	1609
long	ADV	O	O	1609
-	PUNCT	O	O	1609
term	NOUN	O	O	1609
(	PUNCT	O	O	1609
21	NUM	O	O	1609
months	NOUN	O	O	1609
/	PUNCT	O	O	1609
patient	NOUN	O	O	1609
)	PUNCT	O	O	1609
,	PUNCT	O	O	1609
open	VERB	O	O	1609
-	PUNCT	O	O	1609
label	PROPN	O	O	1609
,	PUNCT	O	O	1609
gemfibrozil	PROPN	O	O	1609
-	PUNCT	O	O	1609
lovastatin	NOUN	O	Chemical	1609
treatment	NOUN	O	O	1609
in	ADP	O	O	1609
80	NUM	O	O	1609
patients	NOUN	O	O	1609
with	ADP	O	O	1609
primary	NOUN	O	O	1609
mixed	VERB	O	O	1609
hyperlipidemia	NOUN	O	Disease	1609
(	PUNCT	O	O	1609
68%	NOUN	O	O	1609
of	ADP	O	O	1609
whom	PRON	O	O	1609
had	VERB	O	O	1609
atherosclerotic	ADJ	O	O	1609
vascular	ADJ	O	O	1609
disease	PROPN	O	O	1609
)	PUNCT	O	O	1609
.	PUNCT	O	O	1609
Because	SCONJ	O	O	1610
ideal	ADJ	O	O	1610
lipid	NOUN	O	O	1610
targets	VERB	O	O	1610
were	AUX	O	O	1610
not	PART	O	O	1610
reached	VERB	O	O	1610
(	PUNCT	O	O	1610
low	ADJ	O	O	1610
-	PUNCT	O	O	1610
density	NOUN	O	O	1610
lipoprotein	NOUN	O	O	1610
(	PUNCT	O	O	1610
LDL	NOUN	O	O	1610
)	PUNCT	O	O	1610
cholesterol	NOUN	O	Chemical	1610
less	ADV	O	O	1610
than	ADP	O	O	1610
130	NUM	O	O	1610
mg	VERB	O	O	1610
/	PUNCT	O	O	1610
dl	X	O	O	1610
,	PUNCT	O	O	1610
high	ADJ	O	O	1610
-	PUNCT	O	O	1610
density	NOUN	O	O	1610
lipoprotein	NOUN	O	O	1610
(	PUNCT	O	O	1610
HDL	PROPN	O	O	1610
)	PUNCT	O	O	1610
cholesterol	NOUN	O	Chemical	1610
greater	ADJ	O	O	1610
than	ADP	O	O	1610
35	NUM	O	O	1610
mg	VERB	O	O	1610
/	PUNCT	O	O	1610
dl	X	O	O	1610
,	PUNCT	O	O	1610
or	CCONJ	O	O	1610
total	ADJ	O	O	1610
cholesterol	NOUN	O	Chemical	1610
/	PUNCT	O	O	1610
HDL	PROPN	O	O	1610
cholesterol	NOUN	O	Chemical	1610
less	ADV	O	O	1610
than	ADP	O	O	1610
4.5	NUM	O	O	1610
mg	VERB	O	O	1610
/	PUNCT	O	O	1610
dl	X	O	O	1610
)	PUNCT	O	O	1610
with	ADP	O	O	1610
diet	PROPN	O	O	1610
plus	CCONJ	O	O	1610
a	PRON	O	O	1610
single	ADJ	O	O	1610
drug	NOUN	O	O	1610
,	PUNCT	O	O	1610
gemfibrozil	PROPN	O	O	1610
(	PUNCT	O	O	1610
1.2	NUM	O	O	1610
g	X	O	O	1610
/	PUNCT	O	O	1610
day)-lovastatin	NOUN	O	O	1610
(	PUNCT	O	O	1610
primarily	ADV	O	O	1610
20	NUM	O	O	1610
or	CCONJ	O	O	1610
40	NUM	O	O	1610
mg	VERB	O	O	1610
)	PUNCT	O	O	1610
treatment	NOUN	O	O	1610
was	AUX	O	O	1610
given	VERB	O	O	1610
.	PUNCT	O	O	1610
Follow	VERB	O	O	1611
-	PUNCT	O	O	1611
up	ADP	O	O	1611
visits	VERB	O	O	1611
were	AUX	O	O	1611
scheduled	VERB	O	O	1611
with	ADP	O	O	1611
2-drug	NOUN	O	O	1611
therapy	NOUN	O	O	1611
every	PRON	O	O	1611
6	NUM	O	O	1611
to	PART	O	O	1611
8	NUM	O	O	1611
weeks	NOUN	O	O	1611
,	PUNCT	O	O	1611
an	PRON	O	O	1611
average	ADJ	O	O	1611
of	ADP	O	O	1611
10.3	NUM	O	O	1611
visits	VERB	O	O	1611
per	ADP	O	O	1611
patient	NOUN	O	O	1611
,	PUNCT	O	O	1611
with	ADP	O	O	1611
741	NUM	O	O	1611
batteries	NOUN	O	O	1611
of	ADP	O	O	1611
6	NUM	O	O	1611
liver	NOUN	O	O	1611
function	NOUN	O	O	1611
tests	VERB	O	O	1611
and	CCONJ	O	O	1611
714	NUM	O	O	1611
creatine	PROPN	O	Chemical	1611
phosphokinase	NOUN	O	O	1611
levels	NOUN	O	O	1611
measured	VERB	O	O	1611
.	PUNCT	O	O	1611
Of	ADV	O	O	1612
the	PRON	O	O	1612
714	NUM	O	O	1612
creatine	PROPN	O	Chemical	1612
phosphokinase	NOUN	O	O	1612
levels	NOUN	O	O	1612
,	PUNCT	O	O	1612
9%	NOUN	O	O	1612
were	AUX	O	O	1612
high	ADJ	O	O	1612
;	PUNCT	O	O	1612
only	ADV	O	O	1612
1	X	O	O	1612
(	PUNCT	O	O	1612
0.1%	NOUN	O	O	1612
)	PUNCT	O	O	1612
was	AUX	O	O	1612
greater	ADJ	O	O	1612
than	ADP	O	O	1612
or	CCONJ	O	O	1612
equal	ADJ	O	O	1612
to	PART	O	O	1612
3	X	O	O	1612
times	NOUN	O	O	1612
the	PRON	O	O	1612
upper	ADJ	O	O	1612
normal	ADJ	O	O	1612
limit	NOUN	O	O	1612
.	PUNCT	O	O	1612
With	ADP	O	O	1613
2-drug	NOUN	O	O	1613
therapy	NOUN	O	O	1613
,	PUNCT	O	O	1613
mean	VERB	O	O	1613
total	ADJ	O	O	1613
cholesterol	NOUN	O	Chemical	1613
decreased	VERB	O	O	1613
22%	NOUN	O	O	1613
from	ADP	O	O	1613
255	NUM	O	O	1613
to	PART	O	O	1613
200	NUM	O	O	1613
mg	VERB	O	O	1613
/	PUNCT	O	O	1613
dl	X	O	O	1613
,	PUNCT	O	O	1613
triglyceride	PROPN	O	O	1613
levels	NOUN	O	O	1613
decreased	VERB	O	O	1613
35%	NOUN	O	O	1613
from	ADP	O	O	1613
236	NUM	O	O	1613
to	PART	O	O	1613
154	NUM	O	O	1613
mg	VERB	O	O	1613
/	PUNCT	O	O	1613
dl	X	O	O	1613
,	PUNCT	O	O	1613
LDL	NOUN	O	O	1613
cholesterol	NOUN	O	Chemical	1613
decreased	VERB	O	O	1613
26%	NOUN	O	O	1613
from	ADP	O	O	1613
176	NUM	O	O	1613
to	PART	O	O	1613
131	NUM	O	O	1613
mg	VERB	O	O	1613
/	PUNCT	O	O	1613
dl	X	O	O	1613
,	PUNCT	O	O	1613
and	CCONJ	O	O	1613
the	PRON	O	O	1613
total	ADJ	O	O	1613
cholesterol	NOUN	O	Chemical	1613
/	PUNCT	O	O	1613
HDL	PROPN	O	O	1613
cholesterol	NOUN	O	Chemical	1613
ratio	NOUN	O	O	1613
decreased	VERB	O	O	1613
24%	NOUN	O	O	1613
from	ADP	O	O	1613
7.1	NUM	O	O	1613
to	PART	O	O	1613
5.4	NUM	O	O	1613
,	PUNCT	O	O	1613
all	PRON	O	O	1613
p	NOUN	O	O	1613
less	ADV	O	O	1613
than	ADP	O	O	1613
or	CCONJ	O	O	1613
equal	ADJ	O	O	1613
to	PART	O	O	1613
0.0001	NUM	O	O	1613
.	PUNCT	O	O	1613
Myositis	NOUN	O	Disease	1614
,	PUNCT	O	O	1614
attributable	ADJ	O	O	1614
to	PART	O	O	1614
the	PRON	O	O	1614
drug	NOUN	O	O	1614
combination	NOUN	O	O	1614
and	CCONJ	O	O	1614
symptomatic	ADJ	O	O	1614
enough	ADV	O	O	1614
to	PART	O	O	1614
discontinue	VERB	O	O	1614
it	PRON	O	O	1614
,	PUNCT	O	O	1614
occurred	VERB	O	O	1614
in	ADP	O	O	1614
3%	NOUN	O	O	1614
of	ADP	O	O	1614
patients	NOUN	O	O	1614
,	PUNCT	O	O	1614
and	CCONJ	O	O	1614
in	ADP	O	O	1614
1%	NOUN	O	O	1614
with	ADP	O	O	1614
concurrent	ADJ	O	O	1614
high	ADJ	O	O	1614
creatine	PROPN	O	Chemical	1614
phosphokinase	NOUN	O	O	1614
(	PUNCT	O	O	1614
769	NUM	O	O	1614
U	NOUN	O	O	1614
/	PUNCT	O	O	1614
liter	NOUN	O	O	1614
)	PUNCT	O	O	1614
;	PUNCT	O	O	1614
no	PRON	O	O	1614
patients	NOUN	O	O	1614
had	VERB	O	O	1614
rhabdomyolysis	NOUN	O	Disease	1614
or	CCONJ	O	O	1614
myoglobinuria.(ABSTRACT	NOUN	O	O	1614
TRUNCATED	ADJ	O	O	1614
AT	ADP	O	O	1614
250	NUM	O	O	1614
WORDS	NOUN	O	O	1614
)	PUNCT	O	O	1614
Hepatocellular	NOUN	O	O	1617
carcinoma	NOUN	O	Disease	1617
in	ADP	O	O	1617
Fanconi	NOUN	O	O	1617
's	AUX	O	O	1617
anemia	NOUN	O	Disease	1617
treated	VERB	O	O	1617
with	ADP	O	O	1617
androgen	PROPN	O	Chemical	1617
and	CCONJ	O	O	1617
corticosteroid	NOUN	O	Chemical	1617
.	PUNCT	O	O	1617
The	PRON	O	O	1618
case	NOUN	O	O	1618
of	ADP	O	O	1618
an	PRON	O	O	1618
11-year	NOUN	O	O	1618
-	PUNCT	O	O	1618
old	ADJ	O	O	1618
boy	NOUN	O	O	1618
is	AUX	O	O	1618
reported	VERB	O	O	1618
who	PRON	O	O	1618
was	AUX	O	O	1618
known	VERB	O	O	1618
to	PART	O	O	1618
have	VERB	O	O	1618
Fanconi	NOUN	O	O	1618
's	AUX	O	O	1618
anemia	NOUN	O	Disease	1618
for	ADP	O	O	1618
3	X	O	O	1618
years	NOUN	O	O	1618
and	CCONJ	O	O	1618
was	AUX	O	O	1618
treated	VERB	O	O	1618
with	ADP	O	O	1618
androgens	VERB	O	Chemical	1618
,	PUNCT	O	O	1618
corticosteroids	NOUN	O	Chemical	1618
and	CCONJ	O	O	1618
transfusions	NOUN	O	O	1618
.	PUNCT	O	O	1618
Two	NUM	O	O	1619
weeks	NOUN	O	O	1619
before	ADP	O	O	1619
his	PRON	O	O	1619
death	NOUN	O	O	1619
he	PRON	O	O	1619
was	AUX	O	O	1619
readmitted	VERB	O	O	1619
because	SCONJ	O	O	1619
of	ADP	O	O	1619
aplastic	ADJ	O	O	1619
crisis	NOUN	O	O	1619
with	ADP	O	O	1619
septicemia	VERB	O	O	1619
and	CCONJ	O	O	1619
marked	VERB	O	O	1619
abnormalities	NOUN	O	O	1619
in	ADP	O	O	1619
liver	NOUN	O	O	1619
function	NOUN	O	O	1619
and	CCONJ	O	O	1619
died	VERB	O	O	1619
of	ADP	O	O	1619
hemorrhagic	ADJ	O	Disease	1619
bronchopneumonia	NOUN	O	Disease	1619
.	PUNCT	O	O	1619
At	ADP	O	O	1620
autopsy	ADJ	O	O	1620
peliosis	NOUN	O	O	1620
and	CCONJ	O	O	1620
multiple	ADJ	O	O	1620
hepatic	ADJ	O	O	1620
tumors	NOUN	O	Disease	1620
were	AUX	O	O	1620
found	VERB	O	O	1620
which	PRON	O	O	1620
histologically	ADV	O	O	1620
proved	VERB	O	O	1620
to	PART	O	O	1620
be	AUX	O	O	1620
well	ADV	O	O	1620
-	PUNCT	O	O	1620
differentiated	VERB	O	O	1620
hepatocellular carcinoma	NOUN	O	Disease	1620
.	PUNCT	O	O	1620
This	PRON	O	O	1621
case	NOUN	O	O	1621
contributes	VERB	O	O	1621
to	PART	O	O	1621
the	PRON	O	O	1621
previous	ADJ	O	O	1621
observations	NOUN	O	O	1621
that	SCONJ	O	O	1621
non	ADJ	O	O	1621
-	PUNCT	O	O	1621
metastasizing	VERB	O	O	1621
hepatic	ADJ	O	O	1621
neoplasms	NOUN	O	O	1621
and	CCONJ	O	O	1621
peliosis	NOUN	O	O	1621
can	AUX	O	O	1621
develop	VERB	O	O	1621
in	ADP	O	O	1621
patients	NOUN	O	O	1621
with	ADP	O	O	1621
androgen-	ADJ	O	O	1621
and	CCONJ	O	O	1621
corticosteroid	NOUN	O	Chemical	1621
-	PUNCT	O	O	1621
treated	VERB	O	O	1621
Fanconi	NOUN	O	O	1621
's	AUX	O	O	1621
anemia	NOUN	O	Disease	1621
.	PUNCT	O	O	1621
Chronic	NOUN	O	O	1624
lesion	NOUN	O	O	1624
of	ADP	O	O	1624
rostral	ADJ	O	O	1624
ventrolateral	ADJ	O	O	1624
medulla	NOUN	O	O	1624
in	ADP	O	O	1624
spontaneously	ADV	O	O	1624
hypertensive	ADJ	O	Disease	1624
rats	NOUN	O	O	1624
.	PUNCT	O	O	1624
We	PRON	O	O	1625
studied	VERB	O	O	1625
the	PRON	O	O	1625
effects	NOUN	O	O	1625
of	ADP	O	O	1625
chronic	ADJ	O	O	1625
selective	ADJ	O	O	1625
neuronal	ADJ	O	O	1625
lesion	NOUN	O	O	1625
of	ADP	O	O	1625
rostral	ADJ	O	O	1625
ventrolateral	ADJ	O	O	1625
medulla	NOUN	O	O	1625
on	ADP	O	O	1625
mean	VERB	O	O	1625
arterial	ADJ	O	O	1625
pressure	NOUN	O	O	1625
,	PUNCT	O	O	1625
heart	NOUN	O	O	1625
rate	NOUN	O	O	1625
,	PUNCT	O	O	1625
and	CCONJ	O	O	1625
neurogenic	ADJ	O	O	1625
tone	NOUN	O	O	1625
in	ADP	O	O	1625
conscious	ADJ	O	O	1625
,	PUNCT	O	O	1625
unrestrained	ADJ	O	O	1625
spontaneously	ADV	O	O	1625
hypertensive	ADJ	O	Disease	1625
rats	NOUN	O	O	1625
.	PUNCT	O	O	1625
N	NUM	O	O	1626
-	PUNCT	O	O	1626
methyl	NOUN	O	O	1626
-	PUNCT	O	O	1626
D	NOUN	O	O	1626
-	PUNCT	O	O	1626
aspartic	ADJ	O	O	1626
acid	PROPN	O	O	1626
.	PUNCT	O	O	1626
The	PRON	O	O	1627
restimulation	NOUN	O	O	1627
of	ADP	O	O	1627
this	PRON	O	O	1627
area	NOUN	O	O	1627
with	ADP	O	O	1627
N	NUM	O	O	1627
-	PUNCT	O	O	1627
methyl	NOUN	O	O	1627
-	PUNCT	O	O	1627
D	NOUN	O	O	1627
-	PUNCT	O	O	1627
aspartic	ADJ	O	O	1627
acid	PROPN	O	O	1627
15	NUM	O	O	1627
days	NOUN	O	O	1627
postlesion	NOUN	O	O	1627
failed	VERB	O	O	1627
to	PART	O	O	1627
produce	VERB	O	O	1627
a	PRON	O	O	1627
pressor	ADJ	O	O	1627
response	NOUN	O	O	1627
.	PUNCT	O	O	1627
The	PRON	O	O	1628
ganglionic	ADJ	O	O	1628
blocker	NOUN	O	O	1628
trimethaphan	ADP	O	O	1628
(	PUNCT	O	O	1628
5	NUM	O	O	1628
mg	VERB	O	O	1628
/	PUNCT	O	O	1628
kg	VERB	O	O	1628
i.v	NOUN	O	O	1628
.	PUNCT	O	O	1628
)	PUNCT	O	O	1628
The	PRON	O	O	1629
trimethaphan	ADP	O	O	1629
-	PUNCT	O	O	1629
induced	VERB	O	O	1629
hypotension	NOUN	O	Disease	1629
was	AUX	O	O	1629
accompanied	VERB	O	O	1629
by	ADP	O	O	1629
a	PRON	O	O	1629
significant	ADJ	O	O	1629
bradycardia	NOUN	O	Disease	1629
in	ADP	O	O	1629
lesioned	VERB	O	O	1629
rats	NOUN	O	O	1629
(	PUNCT	O	O	1629
-32	PROPN	O	O	1629
13	NUM	O	O	1630
beats	NOUN	O	O	1630
per	ADP	O	O	1630
minute	VERB	O	O	1630
)	PUNCT	O	O	1630
but	CCONJ	O	O	1630
a	PRON	O	O	1630
tachycardia	PROPN	O	Disease	1630
in	ADP	O	O	1630
sham	NOUN	O	O	1630
rats	NOUN	O	O	1630
(	PUNCT	O	O	1630
+	ADP	O	O	1630
33	NUM	O	O	1630
+	ADP	O	O	1630
/-	PUNCT	O	O	1630
Therefore	ADV	O	O	1631
,	PUNCT	O	O	1631
rostral	ADJ	O	O	1631
ventrolateral	ADJ	O	O	1631
medulla	NOUN	O	O	1631
neurons	NOUN	O	O	1631
appear	VERB	O	O	1631
to	PART	O	O	1631
play	VERB	O	O	1631
a	PRON	O	O	1631
significant	ADJ	O	O	1631
role	NOUN	O	O	1631
in	ADP	O	O	1631
maintaining	VERB	O	O	1631
hypertension	NOUN	O	Disease	1631
in	ADP	O	O	1631
conscious	ADJ	O	O	1631
spontaneously	ADV	O	O	1631
hypertensive	ADJ	O	Disease	1631
rats	NOUN	O	O	1631
.	PUNCT	O	O	1631
Spinal	NOUN	O	O	1632
or	CCONJ	O	O	1632
suprabulbar	VERB	O	O	1632
structures	NOUN	O	O	1632
could	AUX	O	O	1632
be	AUX	O	O	1632
responsible	ADJ	O	O	1632
for	ADP	O	O	1632
the	PRON	O	O	1632
gradual	ADJ	O	O	1632
recovery	NOUN	O	O	1632
of	ADP	O	O	1632
the	PRON	O	O	1632
hypertension	NOUN	O	Disease	1632
in	ADP	O	O	1632
the	PRON	O	O	1632
lesioned	VERB	O	O	1632
rats	NOUN	O	O	1632
.	PUNCT	O	O	1632
Damage	NOUN	O	O	1635
of	ADP	O	O	1635
substantia	X	O	O	1635
nigra	NOUN	O	O	1635
pars	NOUN	O	O	1635
reticulata	NOUN	O	O	1635
during	ADP	O	O	1635
pilocarpine	NOUN	O	Chemical	1635
-	PUNCT	O	O	1635
induced	VERB	O	O	1635
status epilepticus	VERB	O	Disease	1635
in	ADP	O	O	1635
the	PRON	O	O	1635
rat	NOUN	O	O	1635
:	PUNCT	O	O	1635
immunohistochemical	ADJ	O	O	1635
study	VERB	O	O	1635
of	ADP	O	O	1635
neurons	NOUN	O	O	1635
,	PUNCT	O	O	1635
astrocytes	VERB	O	O	1635
and	CCONJ	O	O	1635
serum	NOUN	O	O	1635
-	PUNCT	O	O	1635
protein	NOUN	O	O	1635
extravasation	NOUN	O	O	1635
.	PUNCT	O	O	1635
The	PRON	O	O	1636
substantia	X	O	O	1636
nigra	NOUN	O	O	1636
has	VERB	O	O	1636
a	PRON	O	O	1636
gating	NOUN	O	O	1636
function	NOUN	O	O	1636
controlling	VERB	O	O	1636
the	PRON	O	O	1636
spread	VERB	O	O	1636
of	ADP	O	O	1636
epileptic	ADJ	O	Disease	1636
seizure	NOUN	O	Disease	1636
activity	NOUN	O	O	1636
.	PUNCT	O	O	1636
Additionally	ADV	O	O	1637
,	PUNCT	O	O	1637
in	ADP	O	O	1637
models	NOUN	O	O	1637
of	ADP	O	O	1637
prolonged	VERB	O	O	1637
status epilepticus	VERB	O	Disease	1637
the	PRON	O	O	1637
pars	NOUN	O	O	1637
reticulata	NOUN	O	O	1637
of	ADP	O	O	1637
substantia	X	O	O	1637
nigra	NOUN	O	O	1637
(	PUNCT	O	O	1637
SNR	NOUN	O	O	1637
)	PUNCT	O	O	1637
suffers	VERB	O	O	1637
from	ADP	O	O	1637
a	PRON	O	O	1637
massive	ADJ	O	O	1637
lesion	NOUN	O	O	1637
which	PRON	O	O	1637
may	AUX	O	O	1637
arise	VERB	O	O	1637
from	ADP	O	O	1637
a	PRON	O	O	1637
massive	ADJ	O	O	1637
metabolic	ADJ	O	O	1637
derangement	NOUN	O	O	1637
and	CCONJ	O	O	1637
hyperexcitation	NOUN	O	O	1637
developing	VERB	O	O	1637
in	ADP	O	O	1637
the	PRON	O	O	1637
activated	VERB	O	O	1637
SNR	NOUN	O	O	1637
.	PUNCT	O	O	1637
In	ADP	O	O	1638
this	PRON	O	O	1638
study	VERB	O	O	1638
,	PUNCT	O	O	1638
status epilepticus	VERB	O	Disease	1638
was	AUX	O	O	1638
induced	VERB	O	O	1638
by	ADP	O	O	1638
systemic	ADJ	O	O	1638
injection	NOUN	O	O	1638
of	ADP	O	O	1638
pilocarpine	NOUN	O	Chemical	1638
in	ADP	O	O	1638
rats	NOUN	O	O	1638
.	PUNCT	O	O	1638
Animals	NOUN	O	O	1639
surviving	VERB	O	O	1639
20	NUM	O	O	1639
,	PUNCT	O	O	1639
30	NUM	O	O	1639
,	PUNCT	O	O	1639
40	NUM	O	O	1639
,	PUNCT	O	O	1639
60	NUM	O	O	1639
min	NOUN	O	O	1639
,	PUNCT	O	O	1639
2	X	O	O	1639
,	PUNCT	O	O	1639
3	X	O	O	1639
,	PUNCT	O	O	1639
6	NUM	O	O	1639
hours	NOUN	O	O	1639
,	PUNCT	O	O	1639
1	X	O	O	1639
,	PUNCT	O	O	1639
2	X	O	O	1639
,	PUNCT	O	O	1639
and	CCONJ	O	O	1639
3	X	O	O	1639
days	NOUN	O	O	1639
after	ADP	O	O	1639
induction	NOUN	O	O	1639
of	ADP	O	O	1639
status epilepticus	VERB	O	Disease	1639
were	AUX	O	O	1639
perfusion	NOUN	O	O	1639
-	PUNCT	O	O	1639
fixed	VERB	O	O	1639
,	PUNCT	O	O	1639
and	CCONJ	O	O	1639
brains	NOUN	O	O	1639
processed	VERB	O	O	1639
for	ADP	O	O	1639
immunohistochemical	ADJ	O	O	1639
staining	VERB	O	O	1639
of	ADP	O	O	1639
SNR	NOUN	O	O	1639
.	PUNCT	O	O	1639
Nissl	NOUN	O	O	1640
-	PUNCT	O	O	1640
staining	VERB	O	O	1640
and	CCONJ	O	O	1640
antibodies	NOUN	O	O	1640
against	ADP	O	O	1640
the	PRON	O	O	1640
neuron	PROPN	O	O	1640
-	PUNCT	O	O	1640
specific	ADJ	O	O	1640
calcium	NOUN	O	Chemical	1640
-	PUNCT	O	O	1640
binding	VERB	O	O	1640
protein	NOUN	O	O	1640
,	PUNCT	O	O	1640
parvalbumin	NOUN	O	O	1640
,	PUNCT	O	O	1640
served	VERB	O	O	1640
to	PART	O	O	1640
detect	VERB	O	O	1640
neuronal damage	NOUN	O	Disease	1640
in	ADP	O	O	1640
SNR	NOUN	O	O	1640
.	PUNCT	O	O	1640
Antibodies	NOUN	O	O	1641
against	ADP	O	O	1641
the	PRON	O	O	1641
astroglia	PROPN	O	O	1641
-	PUNCT	O	O	1641
specific	ADJ	O	O	1641
cytoskeletal	ADJ	O	O	1641
protein	NOUN	O	O	1641
,	PUNCT	O	O	1641
glial	ADJ	O	O	1641
fibrillary	NOUN	O	O	1641
acidic	ADJ	O	O	1641
protein	NOUN	O	O	1641
(	PUNCT	O	O	1641
GFAP	VERB	O	O	1641
)	PUNCT	O	O	1641
,	PUNCT	O	O	1641
and	CCONJ	O	O	1641
against	ADP	O	O	1641
the	PRON	O	O	1641
glial	ADJ	O	O	1641
calcium	NOUN	O	Chemical	1641
-	PUNCT	O	O	1641
binding	VERB	O	O	1641
protein	NOUN	O	O	1641
,	PUNCT	O	O	1641
S-100	VERB	O	O	1641
protein	NOUN	O	O	1641
,	PUNCT	O	O	1641
were	AUX	O	O	1641
used	VERB	O	O	1641
to	PART	O	O	1641
assess	VERB	O	O	1641
the	PRON	O	O	1641
status	NOUN	O	O	1641
of	ADP	O	O	1641
astrocytes	VERB	O	O	1641
.	PUNCT	O	O	1641
Immunohistochemical	PROPN	O	O	1642
staining	VERB	O	O	1642
for	ADP	O	O	1642
serum	NOUN	O	O	1642
-	PUNCT	O	O	1642
albumin	PROPN	O	O	1642
and	CCONJ	O	O	1642
immunoglobulins	VERB	O	O	1642
in	ADP	O	O	1642
brain	NOUN	O	O	1642
tissue	NOUN	O	O	1642
was	AUX	O	O	1642
taken	VERB	O	O	1642
as	ADP	O	O	1642
indicator	NOUN	O	O	1642
of	ADP	O	O	1642
blood	NOUN	O	O	1642
-	PUNCT	O	O	1642
brain	NOUN	O	O	1642
barrier	NOUN	O	O	1642
disturbances	NOUN	O	O	1642
and	CCONJ	O	O	1642
vasogenic	PROPN	O	O	1642
edema	NOUN	O	Disease	1642
formation	NOUN	O	O	1642
.	PUNCT	O	O	1642
Immunohistochemical	PROPN	O	O	1643
staining	VERB	O	O	1643
indicated	VERB	O	O	1643
loss	NOUN	O	O	1643
of	ADP	O	O	1643
GFAP	VERB	O	O	1643
-	PUNCT	O	O	1643
staining	VERB	O	O	1643
already	ADV	O	O	1643
at	ADP	O	O	1643
30	NUM	O	O	1643
min	NOUN	O	O	1643
after	ADP	O	O	1643
induction	NOUN	O	O	1643
of	ADP	O	O	1643
seizures	NOUN	O	Disease	1643
in	ADP	O	O	1643
an	PRON	O	O	1643
oval	NOUN	O	O	1643
focus	NOUN	O	O	1643
situated	VERB	O	O	1643
in	ADP	O	O	1643
the	PRON	O	O	1643
center	PROPN	O	O	1643
of	ADP	O	O	1643
SNR	NOUN	O	O	1643
while	SCONJ	O	O	1643
sparing	VERB	O	O	1643
medial	ADJ	O	O	1643
and	CCONJ	O	O	1643
lateral	PROPN	O	O	1643
aspects	NOUN	O	O	1643
.	PUNCT	O	O	1643
By	ADP	O	O	1644
2	X	O	O	1644
hours	NOUN	O	O	1644
,	PUNCT	O	O	1644
parvalbumin	NOUN	O	O	1644
-	PUNCT	O	O	1644
staining	VERB	O	O	1644
changed	VERB	O	O	1644
in	ADP	O	O	1644
the	PRON	O	O	1644
central	ADJ	O	O	1644
SNR	NOUN	O	O	1644
indicating	VERB	O	O	1644
neuronal damage	NOUN	O	Disease	1644
,	PUNCT	O	O	1644
and	CCONJ	O	O	1644
Nissl	NOUN	O	O	1644
-	PUNCT	O	O	1644
staining	VERB	O	O	1644
visualized	VERB	O	O	1644
some	PRON	O	O	1644
neuronal	ADJ	O	O	1644
distortion	NOUN	O	O	1644
.	PUNCT	O	O	1644
By	ADP	O	O	1645
6	NUM	O	O	1645
h	X	O	O	1645
,	PUNCT	O	O	1645
vasogenic	PROPN	O	O	1645
edema	NOUN	O	Disease	1645
covered	VERB	O	O	1645
the	PRON	O	O	1645
lesioned	VERB	O	O	1645
SNR	NOUN	O	O	1645
.	PUNCT	O	O	1645
In	ADP	O	O	1646
a	PRON	O	O	1646
further	ADV	O	O	1646
group	NOUN	O	O	1646
of	ADP	O	O	1646
animals	NOUN	O	O	1646
surviving	VERB	O	O	1646
1	X	O	O	1646
to	PART	O	O	1646
5	NUM	O	O	1646
days	NOUN	O	O	1646
,	PUNCT	O	O	1646
conventional	ADJ	O	O	1646
paraffin	NOUN	O	O	1646
-	PUNCT	O	O	1646
sections	NOUN	O	O	1646
confirmed	VERB	O	O	1646
the	PRON	O	O	1646
neuronal	ADJ	O	O	1646
and	CCONJ	O	O	1646
glial	ADJ	O	O	1646
damage	NOUN	O	O	1646
of	ADP	O	O	1646
SNR	NOUN	O	O	1646
.	PUNCT	O	O	1646
Both	PRON	O	O	1647
cell	NOUN	O	O	1647
elements	NOUN	O	O	1647
may	AUX	O	O	1647
suffer	VERB	O	O	1647
in	ADP	O	O	1647
common	ADJ	O	O	1647
from	ADP	O	O	1647
metabolic	ADJ	O	O	1647
disturbance	NOUN	O	O	1647
and	CCONJ	O	O	1647
neurotransmitter	NOUN	O	O	1647
dysfunction	NOUN	O	O	1647
as	ADP	O	O	1647
occur	VERB	O	O	1647
during	ADP	O	O	1647
massive	ADJ	O	O	1647
status epilepticus	VERB	O	Disease	1647
.	PUNCT	O	O	1647
Reduced	VERB	O	O	1650
cardiotoxicity	NOUN	O	Disease	1650
of	ADP	O	O	1650
doxorubicin	VERB	O	Chemical	1650
given	VERB	O	O	1650
in	ADP	O	O	1650
the	PRON	O	O	1650
form	NOUN	O	O	1650
of	ADP	O	O	1650
N-(2-hydroxypropyl)methacrylamide	NOUN	O	O	1650
conjugates	NOUN	O	O	1650
:	PUNCT	O	O	1650
and	CCONJ	O	O	1650
experimental	ADJ	O	O	1650
study	VERB	O	O	1650
in	ADP	O	O	1650
the	PRON	O	O	1650
rat	NOUN	O	O	1650
.	PUNCT	O	O	1650
A	PRON	O	O	1651
rat	NOUN	O	O	1651
model	NOUN	O	O	1651
was	AUX	O	O	1651
used	VERB	O	O	1651
to	PART	O	O	1651
evaluate	VERB	O	O	1651
the	PRON	O	O	1651
general	ADJ	O	O	1651
acute	ADJ	O	O	1651
toxicity	NOUN	O	Disease	1651
and	CCONJ	O	O	1651
the	PRON	O	O	1651
late	ADV	O	O	1651
cardiotoxicity	NOUN	O	Disease	1651
of	ADP	O	O	1651
4	NUM	O	O	1651
mg	VERB	O	O	1651
/	PUNCT	O	O	1651
kg	VERB	O	O	1651
doxorubicin	VERB	O	Chemical	1651
(	PUNCT	O	O	1651
DOX	PROPN	O	Chemical	1651
)	PUNCT	O	O	1651
given	VERB	O	O	1651
either	ADV	O	O	1651
as	ADP	O	O	1651
free	ADJ	O	O	1651
drug	NOUN	O	O	1651
or	CCONJ	O	O	1651
in	ADP	O	O	1651
the	PRON	O	O	1651
form	NOUN	O	O	1651
of	ADP	O	O	1651
three	NUM	O	O	1651
N-(2-hydroxypropyl)methacrylamide	NOUN	O	O	1651
(	PUNCT	O	O	1651
HPMA	PROPN	O	O	1651
)	PUNCT	O	O	1651
In	ADP	O	O	1652
these	PRON	O	O	1652
HPMA	PROPN	O	O	1652
copolymers	NOUN	O	O	1652
,	PUNCT	O	O	1652
DOX	PROPN	O	Chemical	1652
was	AUX	O	O	1652
covalently	ADV	O	O	1652
bound	VERB	O	O	1652
via	ADP	O	O	1652
peptide	NOUN	O	O	1652
linkages	NOUN	O	O	1652
that	SCONJ	O	O	1652
were	AUX	O	O	1652
either	ADV	O	O	1652
non	ADJ	O	O	1652
-	PUNCT	O	O	1652
biodegradable	ADJ	O	O	1652
(	PUNCT	O	O	1652
Gly	PROPN	O	O	1652
-	PUNCT	O	O	1652
Gly	PROPN	O	O	1652
)	PUNCT	O	O	1652
or	CCONJ	O	O	1652
degradable	ADJ	O	O	1652
by	ADP	O	O	1652
lysosomal	NOUN	O	O	1652
proteinases	VERB	O	O	1652
(	PUNCT	O	O	1652
Gly	PROPN	O	O	1652
-	PUNCT	O	O	1652
Phe	PROPN	O	O	1652
-	PUNCT	O	O	1652
Leu	PROPN	O	O	1652
-	PUNCT	O	O	1652
Gly	PROPN	O	O	1652
)	PUNCT	O	O	1652
.	PUNCT	O	O	1652
In	ADP	O	O	1653
addition	NOUN	O	O	1653
,	PUNCT	O	O	1653
one	NUM	O	O	1653
biodegradable	ADJ	O	O	1653
conjugate	NOUN	O	O	1653
containing	VERB	O	O	1653
galactosamine	NOUN	O	Chemical	1653
was	AUX	O	O	1653
used	VERB	O	O	1653
;	PUNCT	O	O	1653
this	PRON	O	O	1653
residue	PROPN	O	O	1653
was	AUX	O	O	1653
targeted	VERB	O	O	1653
to	PART	O	O	1653
the	PRON	O	O	1653
liver	NOUN	O	O	1653
.	PUNCT	O	O	1653
administration	NOUN	O	O	1654
of	ADP	O	O	1654
free	ADJ	O	O	1654
and	CCONJ	O	O	1654
polymer	NOUN	O	O	1654
-	PUNCT	O	O	1654
bound	VERB	O	O	1654
DOX	PROPN	O	Chemical	1654
,	PUNCT	O	O	1654
all	PRON	O	O	1654
animals	NOUN	O	O	1654
showed	VERB	O	O	1654
a	PRON	O	O	1654
transient	ADJ	O	O	1654
reduction	NOUN	O	O	1654
in	ADP	O	O	1654
body	NOUN	O	O	1654
weight	NOUN	O	O	1654
.	PUNCT	O	O	1654
However	ADV	O	O	1655
,	PUNCT	O	O	1655
the	PRON	O	O	1655
maximal	ADJ	O	O	1655
reduction	NOUN	O	O	1655
in	ADP	O	O	1655
body	NOUN	O	O	1655
weight	NOUN	O	O	1655
seen	VERB	O	O	1655
in	ADP	O	O	1655
animals	NOUN	O	O	1655
that	SCONJ	O	O	1655
received	VERB	O	O	1655
polymer	NOUN	O	O	1655
-	PUNCT	O	O	1655
bound	VERB	O	O	1655
DOX	PROPN	O	Chemical	1655
(	PUNCT	O	O	1655
4	NUM	O	O	1655
mg	VERB	O	O	1655
/	PUNCT	O	O	1655
kg	VERB	O	O	1655
)	PUNCT	O	O	1655
was	AUX	O	O	1655
significantly	ADV	O	O	1655
lower	ADJ	O	O	1655
than	ADP	O	O	1655
that	SCONJ	O	O	1655
observed	VERB	O	O	1655
in	ADP	O	O	1655
those	PRON	O	O	1655
that	SCONJ	O	O	1655
received	VERB	O	O	1655
free	ADJ	O	O	1655
DOX	PROPN	O	Chemical	1655
(	PUNCT	O	O	1655
4	NUM	O	O	1655
mg	VERB	O	O	1655
/	PUNCT	O	O	1655
kg	VERB	O	O	1655
)	PUNCT	O	O	1655
or	CCONJ	O	O	1655
a	PRON	O	O	1655
mixture	NOUN	O	O	1655
of	ADP	O	O	1655
the	PRON	O	O	1655
unmodified	ADJ	O	O	1655
parent	NOUN	O	O	1655
HPMA	PROPN	O	O	1655
copolymer	NOUN	O	O	1655
and	CCONJ	O	O	1655
free	ADJ	O	O	1655
DOX	PROPN	O	Chemical	1655
(	PUNCT	O	O	1655
4	NUM	O	O	1655
mg	VERB	O	O	1655
/	PUNCT	O	O	1655
kg	VERB	O	O	1655
;	PUNCT	O	O	1655
P	NOUN	O	Chemical	1655
less	ADV	O	O	1655
than	ADP	O	O	1655
0.01	NUM	O	O	1655
)	PUNCT	O	O	1655
.	PUNCT	O	O	1655
Throughout	ADP	O	O	1656
the	PRON	O	O	1656
study	VERB	O	O	1656
(	PUNCT	O	O	1656
20	NUM	O	O	1656
weeks	NOUN	O	O	1656
)	PUNCT	O	O	1656
,	PUNCT	O	O	1656
deaths	NOUN	O	O	1656
related	ADJ	O	O	1656
to	PART	O	O	1656
cardiotoxicity	NOUN	O	Disease	1656
were	AUX	O	O	1656
observed	VERB	O	O	1656
only	ADV	O	O	1656
in	ADP	O	O	1656
animals	NOUN	O	O	1656
that	SCONJ	O	O	1656
received	VERB	O	O	1656
either	ADV	O	O	1656
free	ADJ	O	O	1656
DOX	PROPN	O	Chemical	1656
or	CCONJ	O	O	1656
the	PRON	O	O	1656
mixture	NOUN	O	O	1656
of	ADP	O	O	1656
HPMA	PROPN	O	O	1656
copolymer	NOUN	O	O	1656
and	CCONJ	O	O	1656
free	ADJ	O	O	1656
DOX	PROPN	O	Chemical	1656
;	PUNCT	O	O	1656
in	ADP	O	O	1656
these	PRON	O	O	1656
cases	NOUN	O	O	1656
,	PUNCT	O	O	1656
histological	ADJ	O	O	1656
investigations	NOUN	O	O	1656
revealed	VERB	O	O	1656
marked	VERB	O	O	1656
changes	VERB	O	O	1656
in	ADP	O	O	1656
the	PRON	O	O	1656
heart	NOUN	O	O	1656
that	SCONJ	O	O	1656
were	AUX	O	O	1656
consistent	ADJ	O	O	1656
with	ADP	O	O	1656
DOX	PROPN	O	Chemical	1656
-	PUNCT	O	O	1656
induced	VERB	O	O	1656
cardiotoxicity	NOUN	O	Disease	1656
.	PUNCT	O	O	1656
Sequential	ADJ	O	O	1657
measurements	NOUN	O	O	1657
of	ADP	O	O	1657
cardiac	ADJ	O	O	1657
output	NOUN	O	O	1657
in	ADP	O	O	1657
surviving	VERB	O	O	1657
animals	NOUN	O	O	1657
that	SCONJ	O	O	1657
received	VERB	O	O	1657
either	ADV	O	O	1657
free	ADJ	O	O	1657
DOX	PROPN	O	Chemical	1657
or	CCONJ	O	O	1657
the	PRON	O	O	1657
mixture	NOUN	O	O	1657
of	ADP	O	O	1657
HPMA	PROPN	O	O	1657
copolymer	NOUN	O	O	1657
and	CCONJ	O	O	1657
free	ADJ	O	O	1657
DOX	PROPN	O	Chemical	1657
showed	VERB	O	O	1657
a	PRON	O	O	1657
reduction	NOUN	O	O	1657
of	ADP	O	O	1657
approximately	ADV	O	O	1657
30%	NOUN	O	O	1657
in	ADP	O	O	1657
function	NOUN	O	O	1657
beginning	VERB	O	O	1657
at	ADP	O	O	1657
the	PRON	O	O	1657
4th	ADJ	O	O	1657
week	NOUN	O	O	1657
after	ADP	O	O	1657
drug	NOUN	O	O	1657
administration	NOUN	O	O	1657
.	PUNCT	O	O	1657
Animals	NOUN	O	O	1658
that	SCONJ	O	O	1658
were	AUX	O	O	1658
given	VERB	O	O	1658
the	PRON	O	O	1658
HPMA	PROPN	O	O	1658
copolymer	NOUN	O	O	1658
conjugates	NOUN	O	O	1658
containing	VERB	O	O	1658
DOX	PROPN	O	Chemical	1658
exhibited	VERB	O	O	1658
no	PRON	O	O	1658
significant	ADJ	O	O	1658
change	VERB	O	O	1658
in	ADP	O	O	1658
cardiac	ADJ	O	O	1658
output	NOUN	O	O	1658
throughout	ADP	O	O	1658
the	PRON	O	O	1658
study	VERB	O	O	1658
(	PUNCT	O	O	1658
P	NOUN	O	Chemical	1658
less	ADV	O	O	1658
than	ADP	O	O	1658
0.05	NUM	O	O	1658
)	PUNCT	O	O	1658
.	PUNCT	O	O	1658
In	ADP	O	O	1659
addition	NOUN	O	O	1659
,	PUNCT	O	O	1659
no	PRON	O	O	1659
significant	ADJ	O	O	1659
histological	ADJ	O	O	1659
change	VERB	O	O	1659
was	AUX	O	O	1659
observed	VERB	O	O	1659
in	ADP	O	O	1659
the	PRON	O	O	1659
heart	NOUN	O	O	1659
of	ADP	O	O	1659
animals	NOUN	O	O	1659
that	SCONJ	O	O	1659
received	VERB	O	O	1659
DOX	PROPN	O	Chemical	1659
in	ADP	O	O	1659
the	PRON	O	O	1659
form	NOUN	O	O	1659
of	ADP	O	O	1659
HPMA	PROPN	O	O	1659
copolymer	NOUN	O	O	1659
conjugates	NOUN	O	O	1659
and	CCONJ	O	O	1659
were	AUX	O	O	1659
killed	VERB	O	O	1659
at	ADP	O	O	1659
the	PRON	O	O	1659
end	VERB	O	O	1659
of	ADP	O	O	1659
the	PRON	O	O	1659
study	VERB	O	O	1659
.	PUNCT	O	O	1659
Topical	PROPN	O	O	1662
0.025%	NOUN	O	O	1662
capsaicin	NOUN	O	Chemical	1662
in	ADP	O	O	1662
chronic	ADJ	O	O	1662
post	VERB	O	O	1662
-	PUNCT	O	O	1662
herpetic	ADJ	O	O	1662
neuralgia	NOUN	O	Disease	1662
:	PUNCT	O	O	1662
efficacy	NOUN	O	O	1662
,	PUNCT	O	O	1662
predictors	NOUN	O	O	1662
of	ADP	O	O	1662
response	NOUN	O	O	1662
and	CCONJ	O	O	1662
long	ADV	O	O	1662
-	PUNCT	O	O	1662
term	NOUN	O	O	1662
course	NOUN	O	O	1662
.	PUNCT	O	O	1662
In	ADP	O	O	1663
order	NOUN	O	O	1663
to	PART	O	O	1663
evaluate	VERB	O	O	1663
the	PRON	O	O	1663
efficacy	NOUN	O	O	1663
,	PUNCT	O	O	1663
time	NOUN	O	O	1663
-	PUNCT	O	O	1663
course	NOUN	O	O	1663
of	ADP	O	O	1663
action	NOUN	O	O	1663
and	CCONJ	O	O	1663
predictors	NOUN	O	O	1663
of	ADP	O	O	1663
response	NOUN	O	O	1663
to	PART	O	O	1663
topical	ADJ	O	O	1663
capsaicin	NOUN	O	Chemical	1663
,	PUNCT	O	O	1663
39	NUM	O	O	1663
patients	NOUN	O	O	1663
with	ADP	O	O	1663
chronic	ADJ	O	O	1663
post	VERB	O	O	1663
-	PUNCT	O	O	1663
herpetic	ADJ	O	O	1663
neuralgia	NOUN	O	Disease	1663
(	PUNCT	O	O	1663
PHN	PROPN	O	O	1663
)	PUNCT	O	O	1663
,	PUNCT	O	O	1663
median	ADJ	O	O	1663
duration	NOUN	O	O	1663
24	NUM	O	O	1663
months	NOUN	O	O	1663
,	PUNCT	O	O	1663
were	AUX	O	O	1663
treated	VERB	O	O	1663
with	ADP	O	O	1663
0.025%	NOUN	O	O	1663
capsaicin	NOUN	O	Chemical	1663
cream	NOUN	O	O	1663
for	ADP	O	O	1663
8	NUM	O	O	1663
weeks	NOUN	O	O	1663
.	PUNCT	O	O	1663
During	ADP	O	O	1664
therapy	NOUN	O	O	1664
the	PRON	O	O	1664
patients	NOUN	O	O	1664
rated	VERB	O	O	1664
their	PRON	O	O	1664
pain	NOUN	O	Disease	1664
on	ADP	O	O	1664
a	PRON	O	O	1664
visual	ADJ	O	O	1664
analogue	NOUN	O	O	1664
scale	NOUN	O	O	1664
(	PUNCT	O	O	1664
VAS	PROPN	O	O	1664
)	PUNCT	O	O	1664
and	CCONJ	O	O	1664
a	PRON	O	O	1664
verbal	ADJ	O	O	1664
outcome	NOUN	O	O	1664
scale	NOUN	O	O	1664
.	PUNCT	O	O	1664
Nineteen	NUM	O	O	1665
patients	NOUN	O	O	1665
(	PUNCT	O	O	1665
48.7%	NOUN	O	O	1665
)	PUNCT	O	O	1665
substantially	ADV	O	O	1665
improved	VERB	O	O	1665
after	ADP	O	O	1665
the	PRON	O	O	1665
8-week	NOUN	O	O	1665
trial	NOUN	O	O	1665
;	PUNCT	O	O	1665
5	NUM	O	O	1665
(	PUNCT	O	O	1665
12.8%	NOUN	O	O	1665
)	PUNCT	O	O	1665
discontinued	VERB	O	O	1665
therapy	NOUN	O	O	1665
due	ADJ	O	O	1665
to	PART	O	O	1665
side	NOUN	O	O	1665
-	PUNCT	O	O	1665
effects	NOUN	O	O	1665
such	ADJ	O	O	1665
as	ADP	O	O	1665
intolerable	ADJ	O	O	1665
capsaicin	NOUN	O	Chemical	1665
-	PUNCT	O	O	1665
induced	VERB	O	O	1665
burning	VERB	O	O	1665
sensations	NOUN	O	O	1665
(	PUNCT	O	O	1665
4	NUM	O	O	1665
)	PUNCT	O	O	1665
or	CCONJ	O	O	1665
mastitis	NOUN	O	O	1665
(	PUNCT	O	O	1665
1	X	O	O	1665
)	PUNCT	O	O	1665
;	PUNCT	O	O	1665
15	NUM	O	O	1665
(	PUNCT	O	O	1665
38.5%	NOUN	O	O	1665
)	PUNCT	O	O	1665
reported	VERB	O	O	1665
no	PRON	O	O	1665
benefit	VERB	O	O	1665
.	PUNCT	O	O	1665
Treatment	NOUN	O	O	1666
effect	VERB	O	O	1666
was	AUX	O	O	1666
not	PART	O	O	1666
dependent	ADJ	O	O	1666
on	ADP	O	O	1666
patient	NOUN	O	O	1666
's	AUX	O	O	1666
age	NOUN	O	O	1666
,	PUNCT	O	O	1666
duration	NOUN	O	O	1666
or	CCONJ	O	O	1666
localization	NOUN	O	O	1666
of	ADP	O	O	1666
PHN	PROPN	O	O	1666
(	PUNCT	O	O	1666
trigeminal	ADJ	O	O	1666
involvement	NOUN	O	O	1666
was	AUX	O	O	1666
excluded	VERB	O	O	1666
)	PUNCT	O	O	1666
,	PUNCT	O	O	1666
sensory	ADJ	O	O	1666
disturbance	NOUN	O	O	1666
or	CCONJ	O	O	1666
pain	NOUN	O	Disease	1666
character	NOUN	O	O	1666
.	PUNCT	O	O	1666
Treatment	NOUN	O	O	1667
response	NOUN	O	O	1667
was	AUX	O	O	1667
not	PART	O	O	1667
correlated	VERB	O	O	1667
with	ADP	O	O	1667
the	PRON	O	O	1667
incidence	NOUN	O	O	1667
,	PUNCT	O	O	1667
time	NOUN	O	O	1667
-	PUNCT	O	O	1667
course	NOUN	O	O	1667
or	CCONJ	O	O	1667
severity	NOUN	O	O	1667
of	ADP	O	O	1667
capsaicin	NOUN	O	Chemical	1667
-	PUNCT	O	O	1667
induced	VERB	O	O	1667
burning	VERB	O	O	1667
.	PUNCT	O	O	1667
If	SCONJ	O	O	1668
confirmed	VERB	O	O	1668
in	ADP	O	O	1668
controlled	VERB	O	O	1668
trials	NOUN	O	O	1668
,	PUNCT	O	O	1668
the	PRON	O	O	1668
long	ADV	O	O	1668
-	PUNCT	O	O	1668
term	NOUN	O	O	1668
results	VERB	O	O	1668
of	ADP	O	O	1668
this	PRON	O	O	1668
open	VERB	O	O	1668
,	PUNCT	O	O	1668
non	ADJ	O	O	1668
-	PUNCT	O	O	1668
randomized	VERB	O	O	1668
study	VERB	O	O	1668
might	AUX	O	O	1668
indicate	VERB	O	O	1668
that	SCONJ	O	O	1668
the	PRON	O	O	1668
analgesic	PROPN	O	O	1668
effect	VERB	O	O	1668
of	ADP	O	O	1668
capsaicin	NOUN	O	Chemical	1668
in	ADP	O	O	1668
PHN	PROPN	O	O	1668
is	AUX	O	O	1668
mediated	VERB	O	O	1668
by	ADP	O	O	1668
both	PRON	O	O	1668
interference	NOUN	O	O	1668
with	ADP	O	O	1668
neuropeptide	NOUN	O	O	1668
metabolism	NOUN	O	O	1668
and	CCONJ	O	O	1668
morphological	ADJ	O	O	1668
changes	VERB	O	O	1668
(	PUNCT	O	O	1668
perhaps	ADV	O	O	1668
degeneration	NOUN	O	O	1668
)	PUNCT	O	O	1668
of	ADP	O	O	1668
nociceptive	ADJ	O	O	1668
afferents	NOUN	O	O	1668
.	PUNCT	O	O	1668
Serotonin	NOUN	O	Chemical	1671
reuptake	PROPN	O	O	1671
inhibitors	NOUN	O	O	1671
,	PUNCT	O	O	1671
paranoia	NOUN	O	Disease	1671
,	PUNCT	O	O	1671
and	CCONJ	O	O	1671
the	PRON	O	O	1671
ventral	ADV	O	O	1671
basal	PROPN	O	O	1671
ganglia	NOUN	O	O	1671
.	PUNCT	O	O	1671
Antidepressants	NOUN	O	O	1672
have	VERB	O	O	1672
previously	ADV	O	O	1672
been	AUX	O	O	1672
associated	VERB	O	O	1672
with	ADP	O	O	1672
paranoid	ADJ	O	O	1672
reactions	NOUN	O	O	1672
in	ADP	O	O	1672
psychiatric	ADJ	O	Disease	1672
patients	NOUN	O	O	1672
.	PUNCT	O	O	1672
Five	NUM	O	O	1673
cases	NOUN	O	O	1673
of	ADP	O	O	1673
paranoid	ADJ	O	O	1673
exacerbation	NOUN	O	O	1673
with	ADP	O	O	1673
the	PRON	O	O	1673
serotonin	PROPN	O	Chemical	1673
reuptake	PROPN	O	O	1673
inhibitors	NOUN	O	O	1673
fluoxetine	NOUN	O	Chemical	1673
and	CCONJ	O	O	1673
amitriptyline	PROPN	O	Chemical	1673
are	AUX	O	O	1673
reported	VERB	O	O	1673
here	ADV	O	O	1673
.	PUNCT	O	O	1673
Elements	NOUN	O	O	1674
common	ADJ	O	O	1674
to	PART	O	O	1674
these	PRON	O	O	1674
cases	NOUN	O	O	1674
included	VERB	O	O	1674
a	PRON	O	O	1674
history	NOUN	O	O	1674
of	ADP	O	O	1674
paranoid	ADJ	O	O	1674
symptomatology	NOUN	O	O	1674
and	CCONJ	O	O	1674
the	PRON	O	O	1674
concomitant	ADJ	O	O	1674
occurrence	NOUN	O	O	1674
of	ADP	O	O	1674
depressive	ADJ	O	Disease	1674
and	CCONJ	O	O	1674
psychotic symptoms	NOUN	O	Disease	1674
.	PUNCT	O	O	1674
Complicated	ADJ	O	O	1675
depressive	ADJ	O	Disease	1675
disorders	NOUN	O	O	1675
(	PUNCT	O	O	1675
including	VERB	O	O	1675
atypicality	NOUN	O	O	1675
of	ADP	O	O	1675
course	NOUN	O	O	1675
and	CCONJ	O	O	1675
symptomatology	NOUN	O	O	1675
,	PUNCT	O	O	1675
chronicity	NOUN	O	O	1675
,	PUNCT	O	O	1675
psychosis	VERB	O	Disease	1675
,	PUNCT	O	O	1675
bipolarity	NOUN	O	O	1675
,	PUNCT	O	O	1675
and	CCONJ	O	O	1675
secondary	ADJ	O	O	1675
onset	VERB	O	O	1675
in	ADP	O	O	1675
the	PRON	O	O	1675
course	NOUN	O	O	1675
of	ADP	O	O	1675
a	PRON	O	O	1675
primary	NOUN	O	O	1675
psychosis	VERB	O	Disease	1675
)	PUNCT	O	O	1675
may	AUX	O	O	1675
present	NOUN	O	O	1675
particular	ADJ	O	O	1675
vulnerability	NOUN	O	O	1675
to	PART	O	O	1675
paranoid	ADJ	O	O	1675
exacerbations	NOUN	O	O	1675
associated	VERB	O	O	1675
with	ADP	O	O	1675
serotonin	PROPN	O	Chemical	1675
reuptake	PROPN	O	O	1675
inhibitors	NOUN	O	O	1675
.	PUNCT	O	O	1675
Although	SCONJ	O	O	1676
the	PRON	O	O	1676
pharmacology	NOUN	O	O	1676
and	CCONJ	O	O	1676
neurobiology	NOUN	O	O	1676
of	ADP	O	O	1676
paranoia	NOUN	O	Disease	1676
remain	VERB	O	O	1676
cryptic	ADJ	O	O	1676
,	PUNCT	O	O	1676
several	ADJ	O	O	1676
mechanisms	NOUN	O	O	1676
,	PUNCT	O	O	1676
including	VERB	O	O	1676
5HT3	NOUN	O	O	1676
receptor	NOUN	O	O	1676
-	PUNCT	O	O	1676
mediated	VERB	O	O	1676
dopamine	NOUN	O	Chemical	1676
release	NOUN	O	O	1676
,	PUNCT	O	O	1676
beta	NOUN	O	O	1676
-	PUNCT	O	O	1676
noradrenergic	ADJ	O	O	1676
receptor	NOUN	O	O	1676
downregulation	NOUN	O	O	1676
,	PUNCT	O	O	1676
or	CCONJ	O	O	1676
GABAB	PROPN	O	O	1676
receptor	NOUN	O	O	1676
upregulation	NOUN	O	O	1676
acting	VERB	O	O	1676
in	ADP	O	O	1676
the	PRON	O	O	1676
vicinity	NOUN	O	O	1676
of	ADP	O	O	1676
the	PRON	O	O	1676
ventral	ADV	O	O	1676
basal	PROPN	O	O	1676
ganglia	NOUN	O	O	1676
(	PUNCT	O	O	1676
possibly	ADV	O	O	1676
in	ADP	O	O	1676
lateral	PROPN	O	O	1676
orbitofrontal	PROPN	O	O	1676
or	CCONJ	O	O	1676
anterior	PROPN	O	O	1676
cingulate	NOUN	O	O	1676
circuits	NOUN	O	O	1676
)	PUNCT	O	O	1676
,	PUNCT	O	O	1676
might	AUX	O	O	1676
apply	VERB	O	O	1676
to	PART	O	O	1676
this	PRON	O	O	1676
phenomenon	NOUN	O	O	1676
.	PUNCT	O	O	1676
These	PRON	O	O	1677
cases	NOUN	O	O	1677
call	VERB	O	O	1677
attention	NOUN	O	O	1677
to	PART	O	O	1677
possible	ADJ	O	O	1677
paranoid	ADJ	O	O	1677
exacerbations	NOUN	O	O	1677
with	ADP	O	O	1677
serotonin	PROPN	O	Chemical	1677
reuptake	PROPN	O	O	1677
blockers	NOUN	O	O	1677
in	ADP	O	O	1677
select	VERB	O	O	1677
patients	NOUN	O	O	1677
and	CCONJ	O	O	1677
raise	VERB	O	O	1677
neurobiological	ADJ	O	O	1677
considerations	NOUN	O	O	1677
regarding	VERB	O	O	1677
paranoia	NOUN	O	Disease	1677
.	PUNCT	O	O	1677
Five	NUM	O	O	1680
cases	NOUN	O	O	1680
of	ADP	O	O	1680
encephalitis	NOUN	O	O	1680
during	ADP	O	O	1680
treatment	NOUN	O	O	1680
of	ADP	O	O	1680
loiasis	NOUN	O	O	1680
with	ADP	O	O	1680
diethylcarbamazine	NOUN	O	O	1680
.	PUNCT	O	O	1680
Five	NUM	O	O	1681
cases	NOUN	O	O	1681
of	ADP	O	O	1681
encephalitis	NOUN	O	O	1681
following	VERB	O	O	1681
treatment	NOUN	O	O	1681
with	ADP	O	O	1681
diethylcarbamazine	NOUN	O	O	1681
(	PUNCT	O	O	1681
DEC	PROPN	O	O	1681
)	PUNCT	O	O	1681
were	AUX	O	O	1681
observed	VERB	O	O	1681
in	ADP	O	O	1681
Congolese	NOUN	O	O	1681
patients	NOUN	O	O	1681
with	ADP	O	O	1681
Loa	NOUN	O	O	1681
loa	NOUN	O	O	1681
filariasis	NOUN	O	O	1681
.	PUNCT	O	O	1681
The	PRON	O	O	1682
notable	ADJ	O	O	1682
fact	NOUN	O	O	1682
was	AUX	O	O	1682
that	SCONJ	O	O	1682
this	PRON	O	O	1682
complication	NOUN	O	O	1682
occurred	VERB	O	O	1682
in	ADP	O	O	1682
three	NUM	O	O	1682
patients	NOUN	O	O	1682
hospitalized	VERB	O	O	1682
before	ADP	O	O	1682
treatment	NOUN	O	O	1682
began	VERB	O	O	1682
,	PUNCT	O	O	1682
with	ADP	O	O	1682
whom	PRON	O	O	1682
particularly	ADV	O	O	1682
strict	ADJ	O	O	1682
therapeutic	ADJ	O	O	1682
precautions	NOUN	O	O	1682
were	AUX	O	O	1682
taken	VERB	O	O	1682
,	PUNCT	O	O	1682
i.e.	X	O	O	1682
,	PUNCT	O	O	1682
initial	ADJ	O	O	1682
dose	NOUN	O	O	1682
less	ADV	O	O	1682
than	ADP	O	O	1682
10	NUM	O	O	1682
mg	VERB	O	O	1682
of	ADP	O	O	1682
DEC	PROPN	O	O	1682
,	PUNCT	O	O	1682
very	ADV	O	O	1682
gradual	ADJ	O	O	1682
dose	NOUN	O	O	1682
increases	VERB	O	O	1682
,	PUNCT	O	O	1682
and	CCONJ	O	O	1682
associated	VERB	O	O	1682
anti	ADJ	O	O	1682
-	PUNCT	O	O	1682
allergic	ADJ	O	O	1682
treatment	NOUN	O	O	1682
.	PUNCT	O	O	1682
The	PRON	O	O	1683
relationship	NOUN	O	O	1683
between	ADP	O	O	1683
the	PRON	O	O	1683
occurrence	NOUN	O	O	1683
of	ADP	O	O	1683
encephalitis	NOUN	O	O	1683
and	CCONJ	O	O	1683
the	PRON	O	O	1683
decrease	VERB	O	O	1683
in	ADP	O	O	1683
microfilaremia	ADP	O	O	1683
is	AUX	O	O	1683
evident	ADJ	O	O	1683
.	PUNCT	O	O	1683
Delirium	NOUN	O	O	1686
in	ADP	O	O	1686
an	PRON	O	O	1686
elderly	ADJ	O	O	1686
woman	NOUN	O	O	1686
possibly	ADV	O	O	1686
associated	VERB	O	O	1686
with	ADP	O	O	1686
administration	NOUN	O	O	1686
of	ADP	O	O	1686
misoprostol	PROPN	O	Chemical	1686
.	PUNCT	O	O	1686
Misoprostol	PROPN	O	O	1687
has	VERB	O	O	1687
been	AUX	O	O	1687
associated	VERB	O	O	1687
with	ADP	O	O	1687
adverse	ADJ	O	O	1687
reactions	NOUN	O	O	1687
,	PUNCT	O	O	1687
including	VERB	O	O	1687
gastrointestinal symptoms	NOUN	O	Disease	1687
,	PUNCT	O	O	1687
gynecologic	ADJ	O	O	1687
problems	NOUN	O	O	1687
,	PUNCT	O	O	1687
and	CCONJ	O	O	1687
headache	PROPN	O	Disease	1687
.	PUNCT	O	O	1687
We	PRON	O	O	1688
present	NOUN	O	O	1688
a	PRON	O	O	1688
case	NOUN	O	O	1688
in	ADP	O	O	1688
which	PRON	O	O	1688
an	PRON	O	O	1688
89-year	NOUN	O	O	1688
-	PUNCT	O	O	1688
old	ADJ	O	O	1688
woman	NOUN	O	O	1688
in	ADP	O	O	1688
a	PRON	O	O	1688
long	ADV	O	O	1688
-	PUNCT	O	O	1688
term	NOUN	O	O	1688
care	VERB	O	O	1688
facility	NOUN	O	O	1688
became	VERB	O	O	1688
confused	ADJ	O	O	1688
after	ADP	O	O	1688
the	PRON	O	O	1688
initiation	NOUN	O	O	1688
of	ADP	O	O	1688
misoprostol	PROPN	O	Chemical	1688
therapy	NOUN	O	O	1688
.	PUNCT	O	O	1688
Her	PRON	O	O	1689
delirium	NOUN	O	Disease	1689
significantly	ADV	O	O	1689
improved	VERB	O	O	1689
after	ADP	O	O	1689
misoprostol	PROPN	O	Chemical	1689
was	AUX	O	O	1689
discontinued	VERB	O	O	1689
and	CCONJ	O	O	1689
her	PRON	O	O	1689
mental	ADJ	O	O	1689
status	NOUN	O	O	1689
returned	VERB	O	O	1689
to	PART	O	O	1689
normal	ADJ	O	O	1689
within	ADP	O	O	1689
a	PRON	O	O	1689
week	NOUN	O	O	1689
.	PUNCT	O	O	1689
Because	SCONJ	O	O	1690
no	PRON	O	O	1690
other	ADJ	O	O	1690
factors	NOUN	O	O	1690
related	ADJ	O	O	1690
to	PART	O	O	1690
this	PRON	O	O	1690
patient	NOUN	O	O	1690
changed	VERB	O	O	1690
significantly	ADV	O	O	1690
,	PUNCT	O	O	1690
the	PRON	O	O	1690
delirium	NOUN	O	Disease	1690
experienced	ADJ	O	O	1690
by	ADP	O	O	1690
this	PRON	O	O	1690
patient	NOUN	O	O	1690
possibly	ADV	O	O	1690
resulted	VERB	O	O	1690
from	ADP	O	O	1690
misoprostol	PROPN	O	Chemical	1690
therapy	NOUN	O	O	1690
.	PUNCT	O	O	1690
Hepatocellular	NOUN	O	O	1693
oxidant	ADJ	O	O	1693
stress	NOUN	O	O	1693
following	VERB	O	O	1693
intestinal	ADJ	O	Disease	1693
ischemia	NOUN	O	Disease	1693
-	PUNCT	O	O	1693
reperfusion	NOUN	O	O	1693
injury	NOUN	O	O	1693
.	PUNCT	O	O	1693
Reperfusion	NOUN	O	O	1694
of	ADP	O	O	1694
ischemic	VERB	O	Disease	1694
intestine	NOUN	O	O	1694
results	VERB	O	O	1694
in	ADP	O	O	1694
acute	ADJ	O	O	1694
liver dysfunction	NOUN	O	Disease	1694
characterized	VERB	O	O	1694
by	ADP	O	O	1694
hepatocellular	NOUN	O	O	1694
enzyme	NOUN	O	O	1694
release	NOUN	O	O	1694
into	ADP	O	O	1694
plasma	NOUN	O	O	1694
,	PUNCT	O	O	1694
reduction	NOUN	O	O	1694
in	ADP	O	O	1694
bile	NOUN	O	O	1694
flow	NOUN	O	O	1694
rate	NOUN	O	O	1694
,	PUNCT	O	O	1694
and	CCONJ	O	O	1694
neutrophil	ADJ	O	O	1694
sequestration	NOUN	O	O	1694
within	ADP	O	O	1694
the	PRON	O	O	1694
liver	NOUN	O	O	1694
.	PUNCT	O	O	1694
The	PRON	O	O	1695
pathophysiology	NOUN	O	O	1695
underlying	VERB	O	O	1695
this	PRON	O	O	1695
acute	ADJ	O	O	1695
hepatic injury	NOUN	O	Disease	1695
is	AUX	O	O	1695
unknown	ADJ	O	O	1695
.	PUNCT	O	O	1695
This	PRON	O	O	1696
study	VERB	O	O	1696
was	AUX	O	O	1696
undertaken	VERB	O	O	1696
to	PART	O	O	1696
determine	VERB	O	O	1696
whether	SCONJ	O	O	1696
oxidants	NOUN	O	O	1696
are	AUX	O	O	1696
associated	VERB	O	O	1696
with	ADP	O	O	1696
the	PRON	O	O	1696
hepatic injury	NOUN	O	Disease	1696
and	CCONJ	O	O	1696
to	PART	O	O	1696
determine	VERB	O	O	1696
the	PRON	O	O	1696
relative	ADJ	O	O	1696
value	NOUN	O	O	1696
of	ADP	O	O	1696
several	ADJ	O	O	1696
indirect	ADJ	O	O	1696
methods	NOUN	O	O	1696
of	ADP	O	O	1696
assessing	VERB	O	O	1696
oxidant	ADJ	O	O	1696
exposure	NOUN	O	O	1696
in	ADP	O	O	1696
vivo	VERB	O	O	1696
.	PUNCT	O	O	1696
Rats	NOUN	O	O	1697
were	AUX	O	O	1697
subjected	VERB	O	O	1697
to	PART	O	O	1697
a	PRON	O	O	1697
standardized	VERB	O	O	1697
intestinal	ADJ	O	Disease	1697
ischemia	NOUN	O	Disease	1697
-	PUNCT	O	O	1697
reperfusion	NOUN	O	O	1697
injury	NOUN	O	O	1697
.	PUNCT	O	O	1697
Hepatic	ADJ	O	O	1698
tissue	NOUN	O	O	1698
was	AUX	O	O	1698
assayed	VERB	O	O	1698
for	ADP	O	O	1698
lipid	NOUN	O	O	1698
peroxidation	NOUN	O	O	1698
products	NOUN	O	O	1698
and	CCONJ	O	O	1698
oxidized	VERB	O	O	1698
and	CCONJ	O	O	1698
reduced glutathione	NOUN	O	Chemical	1698
.	PUNCT	O	O	1698
There	ADV	O	O	1699
was	AUX	O	O	1699
no	PRON	O	O	1699
change	VERB	O	O	1699
in	ADP	O	O	1699
hepatic	ADJ	O	O	1699
tissue	NOUN	O	O	1699
total	ADJ	O	O	1699
glutathione	NOUN	O	Chemical	1699
following	VERB	O	O	1699
intestinal	ADJ	O	Disease	1699
ischemia	NOUN	O	Disease	1699
-	PUNCT	O	O	1699
reperfusion	NOUN	O	O	1699
injury	NOUN	O	O	1699
.	PUNCT	O	O	1699
Oxidized	VERB	O	O	1700
glutathione	NOUN	O	Chemical	1700
(	PUNCT	O	O	1700
GSSG	PROPN	O	O	1700
)	PUNCT	O	O	1700
increased	VERB	O	O	1700
significantly	ADV	O	O	1700
following	VERB	O	O	1700
30	NUM	O	O	1700
and	CCONJ	O	O	1700
60	NUM	O	O	1700
min	NOUN	O	O	1700
of	ADP	O	O	1700
reperfusion	NOUN	O	O	1700
.	PUNCT	O	O	1700
An	PRON	O	O	1701
increase	VERB	O	O	1701
in	ADP	O	O	1701
GSSG	PROPN	O	O	1701
within	ADP	O	O	1701
hepatic	ADJ	O	O	1701
tissue	NOUN	O	O	1701
during	ADP	O	O	1701
intestinal	ADJ	O	Disease	1701
reperfusion	NOUN	O	O	1701
suggests	VERB	O	O	1701
exposure	NOUN	O	O	1701
of	ADP	O	O	1701
hepatocytes	VERB	O	O	1701
to	PART	O	O	1701
an	PRON	O	O	1701
oxidant	ADJ	O	O	1701
stress	NOUN	O	O	1701
.	PUNCT	O	O	1701
These	PRON	O	O	1702
data	NOUN	O	O	1702
also	ADV	O	O	1702
suggest	VERB	O	O	1702
that	SCONJ	O	O	1702
the	PRON	O	O	1702
measurement	NOUN	O	O	1702
of	ADP	O	O	1702
tissue	NOUN	O	O	1702
GSSG	PROPN	O	O	1702
may	AUX	O	O	1702
be	AUX	O	O	1702
a	PRON	O	O	1702
more	ADJ	O	O	1702
sensitive	ADJ	O	O	1702
indicator	NOUN	O	O	1702
of	ADP	O	O	1702
oxidant	ADJ	O	O	1702
stress	NOUN	O	O	1702
than	ADP	O	O	1702
measurement	NOUN	O	O	1702
of	ADP	O	O	1702
products	NOUN	O	O	1702
of	ADP	O	O	1702
lipid	NOUN	O	O	1702
peroxidation	NOUN	O	O	1702
.	PUNCT	O	O	1702
Diphenhydramine	NOUN	O	O	1705
prevents	VERB	O	O	1705
the	PRON	O	O	1705
haemodynamic	ADJ	O	O	1705
changes	VERB	O	O	1705
of	ADP	O	O	1705
cimetidine	NOUN	O	Chemical	1705
in	ADP	O	O	1705
ICU	PROPN	O	O	1705
patients	NOUN	O	O	1705
.	PUNCT	O	O	1705
Cimetidine	PROPN	O	O	1706
,	PUNCT	O	O	1706
a	PRON	O	O	1706
histamine	NOUN	O	Chemical	1706
2	X	O	O	1706
(	PUNCT	O	O	1706
H2	NOUN	O	O	1706
)	PUNCT	O	O	1706
antagonist	NOUN	O	O	1706
,	PUNCT	O	O	1706
produces	VERB	O	O	1706
a	PRON	O	O	1706
decrease	VERB	O	O	1706
in	ADP	O	O	1706
arterial	ADJ	O	O	1706
pressure	NOUN	O	O	1706
due	ADJ	O	O	1706
to	PART	O	O	1706
vasodilatation	NOUN	O	O	1706
,	PUNCT	O	O	1706
especially	ADV	O	O	1706
in	ADP	O	O	1706
critically	ADV	O	O	1706
ill	PROPN	O	O	1706
patients	NOUN	O	O	1706
.	PUNCT	O	O	1706
This	PRON	O	O	1707
may	AUX	O	O	1707
be	AUX	O	O	1707
because	SCONJ	O	O	1707
cimetidine	NOUN	O	Chemical	1707
acts	VERB	O	O	1707
as	ADP	O	O	1707
a	PRON	O	O	1707
histamine	NOUN	O	Chemical	1707
agonist	NOUN	O	O	1707
.	PUNCT	O	O	1707
We	PRON	O	O	1708
,	PUNCT	O	O	1708
therefore	ADV	O	O	1708
,	PUNCT	O	O	1708
investigated	VERB	O	O	1708
the	PRON	O	O	1708
effects	NOUN	O	O	1708
of	ADP	O	O	1708
the	PRON	O	O	1708
histamine	NOUN	O	Chemical	1708
1(H1	NUM	O	O	1708
)	PUNCT	O	O	1708
receptor	NOUN	O	O	1708
antagonist	NOUN	O	O	1708
,	PUNCT	O	O	1708
diphenhydramine	NOUN	O	O	1708
,	PUNCT	O	O	1708
on	ADP	O	O	1708
the	PRON	O	O	1708
haemodynamic	ADJ	O	O	1708
changes	VERB	O	O	1708
observed	VERB	O	O	1708
after	ADP	O	O	1708
cimetidine	NOUN	O	Chemical	1708
in	ADP	O	O	1708
ICU	PROPN	O	O	1708
patients	NOUN	O	O	1708
.	PUNCT	O	O	1708
In	ADP	O	O	1709
a	PRON	O	O	1709
random	ADJ	O	O	1709
fashion	NOUN	O	O	1709
,	PUNCT	O	O	1709
they	PRON	O	O	1709
received	VERB	O	O	1709
cimetidine	NOUN	O	Chemical	1709
200	NUM	O	O	1709
mg	VERB	O	O	1709
iv	X	O	O	1709
on	ADP	O	O	1709
one	NUM	O	O	1709
day	NOUN	O	O	1709
,	PUNCT	O	O	1709
and	CCONJ	O	O	1709
on	ADP	O	O	1709
the	PRON	O	O	1709
other	ADJ	O	O	1709
,	PUNCT	O	O	1709
a	PRON	O	O	1709
pretreatment	NOUN	O	O	1709
of	ADP	O	O	1709
diphenhydramine	NOUN	O	O	1709
40	NUM	O	O	1709
mg	VERB	O	O	1709
iv	X	O	O	1709
with	ADP	O	O	1709
cimetidine	NOUN	O	Chemical	1709
200	NUM	O	O	1709
mg	VERB	O	O	1709
iv	X	O	O	1709
.	PUNCT	O	O	1709
11.4	NUM	O	O	1710
mmHg	PROPN	O	O	1710
(	PUNCT	O	O	1710
P	NOUN	O	Chemical	1710
less	ADV	O	O	1710
than	ADP	O	O	1710
0.01	NUM	O	O	1710
)	PUNCT	O	O	1710
two	NUM	O	O	1710
minutes	NOUN	O	O	1710
after	ADP	O	O	1710
cimetidine	NOUN	O	Chemical	1710
.	PUNCT	O	O	1710
We	PRON	O	O	1711
conclude	VERB	O	O	1711
that	SCONJ	O	O	1711
an	PRON	O	O	1711
H1	NOUN	O	O	1711
antagonist	NOUN	O	O	1711
may	AUX	O	O	1711
be	AUX	O	O	1711
useful	ADJ	O	O	1711
in	ADP	O	O	1711
preventing	VERB	O	O	1711
hypotension	NOUN	O	Disease	1711
caused	VERB	O	O	1711
by	ADP	O	O	1711
iv	X	O	O	1711
cimetidine	NOUN	O	Chemical	1711
,	PUNCT	O	O	1711
since	SCONJ	O	O	1711
the	PRON	O	O	1711
vasodilating	VERB	O	O	1711
activity	NOUN	O	O	1711
of	ADP	O	O	1711
cimetidine	NOUN	O	Chemical	1711
is	AUX	O	O	1711
mediated	VERB	O	O	1711
,	PUNCT	O	O	1711
in	ADP	O	O	1711
part	NOUN	O	O	1711
,	PUNCT	O	O	1711
through	ADP	O	O	1711
the	PRON	O	O	1711
H1	NOUN	O	O	1711
receptor	NOUN	O	O	1711
.	PUNCT	O	O	1711
Acute	PROPN	O	O	1714
renal failure	NOUN	O	Disease	1714
due	ADJ	O	O	1714
to	PART	O	O	1714
rifampicin	VERB	O	Chemical	1714
.	PUNCT	O	O	1714
A	PRON	O	O	1715
23-year	NOUN	O	O	1715
-	PUNCT	O	O	1715
old	ADJ	O	O	1715
male	NOUN	O	O	1715
patient	NOUN	O	O	1715
with	ADP	O	O	1715
bacteriologically	ADV	O	O	1715
proven	VERB	O	O	1715
pulmonary	ADJ	O	O	1715
tuberculosis	NOUN	O	Disease	1715
was	AUX	O	O	1715
treated	VERB	O	O	1715
with	ADP	O	O	1715
the	PRON	O	O	1715
various	ADJ	O	O	1715
regimens	NOUN	O	O	1715
of	ADP	O	O	1715
antituberculosis	NOUN	O	O	1715
drugs	NOUN	O	O	1715
for	ADP	O	O	1715
nearly	ADV	O	O	1715
15	NUM	O	O	1715
months	NOUN	O	O	1715
.	PUNCT	O	O	1715
Rifampicin	PROPN	O	O	1716
was	AUX	O	O	1716
administered	VERB	O	O	1716
thrice	ADV	O	O	1716
as	ADP	O	O	1716
one	NUM	O	O	1716
of	ADP	O	O	1716
the	PRON	O	O	1716
3	X	O	O	1716
-	PUNCT	O	O	1716
4	NUM	O	O	1716
drug	NOUN	O	O	1716
regimen	NOUN	O	O	1716
and	CCONJ	O	O	1716
each	PRON	O	O	1716
time	NOUN	O	O	1716
he	PRON	O	O	1716
developed	VERB	O	O	1716
untoward	ADJ	O	O	1716
side	NOUN	O	O	1716
effects	NOUN	O	O	1716
like	INTJ	O	O	1716
nausea	NOUN	O	Disease	1716
,	PUNCT	O	O	1716
vomiting	VERB	O	Disease	1716
and	CCONJ	O	O	1716
fever	NOUN	O	Disease	1716
with	ADP	O	O	1716
chills	NOUN	O	O	1716
and	CCONJ	O	O	1716
rigors	NOUN	O	O	1716
.	PUNCT	O	O	1716
Severe	ADJ	O	O	1719
polyneuropathy	ADJ	O	Disease	1719
and	CCONJ	O	O	1719
motor	NOUN	O	O	1719
loss	NOUN	O	O	1719
after	ADP	O	O	1719
intrathecal	ADJ	O	O	1719
thiotepa	NOUN	O	O	1720
combination	NOUN	O	O	1720
chemotherapy	NOUN	O	O	1720
:	PUNCT	O	O	1720
Two	NUM	O	O	1721
cases	NOUN	O	O	1721
of	ADP	O	O	1721
severe	ADJ	O	O	1721
delayed	VERB	O	O	1721
neurologic	ADJ	O	O	1721
toxicity	NOUN	O	Disease	1721
related	ADJ	O	O	1721
to	PART	O	O	1721
the	PRON	O	O	1721
administration	NOUN	O	O	1721
of	ADP	O	O	1721
intrathecal	ADJ	O	O	1721
(	PUNCT	O	O	1721
IT	PRON	O	O	1721
)	PUNCT	O	O	1721
combination	NOUN	O	O	1721
chemotherapy	NOUN	O	O	1721
including	VERB	O	O	1721
thiotepa	NOUN	O	O	1721
(	PUNCT	O	O	1721
TSPA	NOUN	O	O	1721
)	PUNCT	O	O	1721
are	AUX	O	O	1721
presented	VERB	O	O	1721
.	PUNCT	O	O	1721
Both	PRON	O	O	1722
cases	NOUN	O	O	1722
developed	VERB	O	O	1722
axonal	ADJ	O	O	1722
neuropathy	NOUN	O	Disease	1722
with	ADP	O	O	1722
motor	NOUN	O	O	1722
predominance	NOUN	O	O	1722
in	ADP	O	O	1722
the	PRON	O	O	1722
lower	ADJ	O	O	1722
extremities	NOUN	O	O	1722
1	X	O	O	1722
and	CCONJ	O	O	1722
6	NUM	O	O	1722
months	NOUN	O	O	1722
after	ADP	O	O	1722
IT	PRON	O	O	1722
chemotherapy	NOUN	O	O	1722
was	AUX	O	O	1722
administered	VERB	O	O	1722
.	PUNCT	O	O	1722
Neurologic	ADJ	O	O	1723
toxicities	NOUN	O	Disease	1723
have	VERB	O	O	1723
been	AUX	O	O	1723
described	VERB	O	O	1723
with	ADP	O	O	1723
IT	PRON	O	O	1723
-	PUNCT	O	O	1723
methotrexate	CCONJ	O	Chemical	1723
,	PUNCT	O	O	1723
IT	PRON	O	O	1723
-	PUNCT	O	O	1723
cytosine arabinoside	NOUN	O	Chemical	1723
and	CCONJ	O	O	1723
IT	PRON	O	O	1723
-	PUNCT	O	O	1723
TSPA	NOUN	O	O	1723
.	PUNCT	O	O	1723
To	PART	O	O	1724
our	PRON	O	O	1724
knowledge	NOUN	O	O	1724
,	PUNCT	O	O	1724
however	ADV	O	O	1724
,	PUNCT	O	O	1724
axonal	ADJ	O	O	1724
neuropathy	NOUN	O	Disease	1724
In	ADP	O	O	1725
spite	NOUN	O	O	1725
of	ADP	O	O	1725
the	PRON	O	O	1725
fact	NOUN	O	O	1725
that	SCONJ	O	O	1725
TSPA	NOUN	O	O	1725
is	AUX	O	O	1725
a	PRON	O	O	1725
useful	ADJ	O	O	1725
IT	PRON	O	O	1725
agent	NOUN	O	O	1725
,	PUNCT	O	O	1725
its	PRON	O	O	1725
combination	NOUN	O	O	1725
with	ADP	O	O	1725
MTX	PROPN	O	O	1725
,	PUNCT	O	O	1725
ara	PROPN	O	O	1725
-	PUNCT	O	O	1725
C	NOUN	O	O	1725
and	CCONJ	O	O	1725
radiotherapy	NOUN	O	O	1725
could	AUX	O	O	1725
cause	VERB	O	O	1725
severe	ADJ	O	O	1725
neurotoxicity	NOUN	O	Disease	1725
.	PUNCT	O	O	1725
This	PRON	O	O	1726
unexpected	ADJ	O	O	1726
complication	NOUN	O	O	1726
indicates	VERB	O	O	1726
the	PRON	O	O	1726
need	VERB	O	O	1726
for	ADP	O	O	1726
further	ADV	O	O	1726
toxicology	NOUN	O	O	1726
research	NOUN	O	O	1726
on	ADP	O	O	1726
IT	PRON	O	O	1726
-	PUNCT	O	O	1726
TSPA	NOUN	O	O	1726
.	PUNCT	O	O	1726
Effects	NOUN	O	O	1729
of	ADP	O	O	1729
cromakalim	NOUN	O	O	1729
and	CCONJ	O	O	1729
pinacidil	NOUN	O	O	1729
on	ADP	O	O	1729
large	ADJ	O	O	1729
epicardial	ADJ	O	O	1729
and	CCONJ	O	O	1729
small	ADJ	O	O	1729
coronary	ADJ	O	O	1729
arteries	NOUN	O	O	1729
in	ADP	O	O	1729
conscious	ADJ	O	O	1729
dogs	NOUN	O	O	1729
.	PUNCT	O	O	1729
bolus	NOUN	O	O	1730
administration	NOUN	O	O	1730
of	ADP	O	O	1730
cromakalim	NOUN	O	O	1730
(	PUNCT	O	O	1730
1	X	O	O	1730
-	PUNCT	O	O	1730
10	NUM	O	O	1730
micrograms	NOUN	O	O	1730
/	PUNCT	O	O	1730
kg	VERB	O	O	1730
)	PUNCT	O	O	1730
and	CCONJ	O	O	1730
pinacidil	NOUN	O	O	1730
(	PUNCT	O	O	1730
3	X	O	O	1730
-	PUNCT	O	O	1730
100	NUM	O	O	1730
micrograms	NOUN	O	O	1730
/	PUNCT	O	O	1730
kg	VERB	O	O	1730
)	PUNCT	O	O	1730
on	ADP	O	O	1730
large	ADJ	O	O	1730
(	PUNCT	O	O	1730
circumflex	NOUN	O	O	1730
artery	NOUN	O	O	1730
)	PUNCT	O	O	1730
and	CCONJ	O	O	1730
small	ADJ	O	O	1730
coronary	ADJ	O	O	1730
arteries	NOUN	O	O	1730
and	CCONJ	O	O	1730
on	ADP	O	O	1730
systemic	ADJ	O	O	1730
hemodynamics	NOUN	O	O	1730
were	AUX	O	O	1730
investigated	VERB	O	O	1730
in	ADP	O	O	1730
chronically	ADV	O	O	1730
instrumented	VERB	O	O	1730
conscious	ADJ	O	O	1730
dogs	NOUN	O	O	1730
and	CCONJ	O	O	1730
compared	VERB	O	O	1730
to	PART	O	O	1730
those	PRON	O	O	1730
of	ADP	O	O	1730
nitroglycerin	PROPN	O	Chemical	1730
(	PUNCT	O	O	1730
0.03	NUM	O	O	1730
-	PUNCT	O	O	1730
10	NUM	O	O	1730
micrograms	NOUN	O	O	1730
/	PUNCT	O	O	1730
kg	VERB	O	O	1730
)	PUNCT	O	O	1730
.	PUNCT	O	O	1730
Nitroglycerin	PROPN	O	O	1731
,	PUNCT	O	O	1731
up	ADP	O	O	1731
to	PART	O	O	1731
0.3	NUM	O	O	1731
micrograms	NOUN	O	O	1731
/	PUNCT	O	O	1731
kg	VERB	O	O	1731
,	PUNCT	O	O	1731
selectively	ADV	O	O	1731
increased	VERB	O	O	1731
circumflex	NOUN	O	O	1731
artery	NOUN	O	O	1731
diameter	NOUN	O	O	1731
(	PUNCT	O	O	1731
CxAD	NOUN	O	O	1731
)	PUNCT	O	O	1731
without	ADP	O	O	1731
simultaneously	ADV	O	O	1731
affecting	VERB	O	O	1731
any	PRON	O	O	1731
other	ADJ	O	O	1731
cardiac	ADJ	O	O	1731
or	CCONJ	O	O	1731
systemic	ADJ	O	O	1731
hemodynamic	ADJ	O	O	1731
parameter	NOUN	O	O	1731
.	PUNCT	O	O	1731
In	ADP	O	O	1732
contrast	NOUN	O	O	1732
,	PUNCT	O	O	1732
cromakalim	NOUN	O	O	1732
and	CCONJ	O	O	1732
pinacidil	NOUN	O	O	1732
at	ADP	O	O	1732
all	PRON	O	O	1732
doses	NOUN	O	O	1732
and	CCONJ	O	O	1732
nitroglycerin	PROPN	O	Chemical	1732
at	ADP	O	O	1732
doses	NOUN	O	O	1732
higher	ADJ	O	O	1732
than	ADP	O	O	1732
0.3	NUM	O	O	1732
micrograms	NOUN	O	O	1732
/	PUNCT	O	O	1732
kg	VERB	O	O	1732
simultaneously	ADV	O	O	1732
and	CCONJ	O	O	1732
dose	NOUN	O	O	1732
-	PUNCT	O	O	1732
dependently	ADV	O	O	1732
increased	VERB	O	O	1732
CxAD	NOUN	O	O	1732
,	PUNCT	O	O	1732
coronary	ADJ	O	O	1732
blood	NOUN	O	O	1732
flow	NOUN	O	O	1732
and	CCONJ	O	O	1732
heart	NOUN	O	O	1732
rate	NOUN	O	O	1732
and	CCONJ	O	O	1732
decreased	VERB	O	O	1732
coronary	ADJ	O	O	1732
vascular	ADJ	O	O	1732
resistance	NOUN	O	O	1732
and	CCONJ	O	O	1732
aortic	ADJ	O	O	1732
pressure	NOUN	O	O	1732
.	PUNCT	O	O	1732
Cromakalim	NOUN	O	O	1733
was	AUX	O	O	1733
approximately	ADV	O	O	1733
8-	X	O	O	1733
to	PART	O	O	1733
9.5-fold	ADV	O	O	1733
more	ADJ	O	O	1733
potent	ADJ	O	O	1733
than	ADP	O	O	1733
pinacidil	NOUN	O	O	1733
in	ADP	O	O	1733
increasing	VERB	O	O	1733
CxAD	NOUN	O	O	1733
.	PUNCT	O	O	1733
Vasodilation	NOUN	O	O	1734
of	ADP	O	O	1734
large	ADJ	O	O	1734
and	CCONJ	O	O	1734
small	ADJ	O	O	1734
coronary	ADJ	O	O	1734
vessels	NOUN	O	O	1734
and	CCONJ	O	O	1734
hypotension	NOUN	O	Disease	1734
induced	VERB	O	O	1734
by	ADP	O	O	1734
cromakalim	NOUN	O	O	1734
and	CCONJ	O	O	1734
pinacidil	NOUN	O	O	1734
were	AUX	O	O	1734
not	PART	O	O	1734
affected	VERB	O	O	1734
by	ADP	O	O	1734
prior	ADV	O	O	1734
combined	VERB	O	O	1734
beta	NOUN	O	O	1734
adrenergic	NOUN	O	O	1734
and	CCONJ	O	O	1734
muscarinic	PROPN	O	O	1734
receptors	NOUN	O	O	1734
blockade	VERB	O	O	1734
but	CCONJ	O	O	1734
drug	NOUN	O	O	1734
-	PUNCT	O	O	1734
induced	VERB	O	O	1734
tachycardia	PROPN	O	Disease	1734
was	AUX	O	O	1734
abolished	VERB	O	O	1734
.	PUNCT	O	O	1734
When	SCONJ	O	O	1735
circumflex	NOUN	O	O	1735
artery	NOUN	O	O	1735
blood	NOUN	O	O	1735
flow	NOUN	O	O	1735
was	AUX	O	O	1735
maintained	VERB	O	O	1735
constant	ADJ	O	O	1735
,	PUNCT	O	O	1735
the	PRON	O	O	1735
increases	VERB	O	O	1735
in	ADP	O	O	1735
CxAD	NOUN	O	O	1735
induced	VERB	O	O	1735
by	ADP	O	O	1735
cromakalim	NOUN	O	O	1735
(	PUNCT	O	O	1735
10	NUM	O	O	1735
micrograms	NOUN	O	O	1735
/	PUNCT	O	O	1735
kg	VERB	O	O	1735
)	PUNCT	O	O	1735
,	PUNCT	O	O	1735
pinacidil	NOUN	O	O	1735
(	PUNCT	O	O	1735
30	NUM	O	O	1735
micrograms	NOUN	O	O	1735
/	PUNCT	O	O	1735
kg	VERB	O	O	1735
)	PUNCT	O	O	1735
and	CCONJ	O	O	1735
nitroglycerin	PROPN	O	Chemical	1735
(	PUNCT	O	O	1735
10	NUM	O	O	1735
micrograms	NOUN	O	O	1735
/	PUNCT	O	O	1735
kg	VERB	O	O	1735
)	PUNCT	O	O	1735
were	AUX	O	O	1735
reduced	VERB	O	O	1735
by	ADP	O	O	1735
68	NUM	O	O	1735
+	ADP	O	O	1735
/-	PUNCT	O	O	1735
Thus	ADV	O	O	1736
,	PUNCT	O	O	1736
whereas	SCONJ	O	O	1736
nitroglycerin	PROPN	O	Chemical	1736
preferentially	ADV	O	O	1736
and	CCONJ	O	O	1736
flow	NOUN	O	O	1736
-	PUNCT	O	O	1736
independently	ADV	O	O	1736
dilates	VERB	O	O	1736
large	ADJ	O	O	1736
coronary	ADJ	O	O	1736
arteries	NOUN	O	O	1736
,	PUNCT	O	O	1736
cromakalim	NOUN	O	O	1736
and	CCONJ	O	O	1736
pinacidil	NOUN	O	O	1736
dilate	VERB	O	O	1736
both	PRON	O	O	1736
large	ADJ	O	O	1736
and	CCONJ	O	O	1736
small	ADJ	O	O	1736
coronary	ADJ	O	O	1736
arteries	NOUN	O	O	1736
and	CCONJ	O	O	1736
this	PRON	O	O	1736
effect	VERB	O	O	1736
is	AUX	O	O	1736
not	PART	O	O	1736
dependent	ADJ	O	O	1736
upon	SCONJ	O	O	1736
the	PRON	O	O	1736
simultaneous	ADJ	O	O	1736
beta	NOUN	O	O	1736
adrenoceptors	VERB	O	O	1736
-	PUNCT	O	O	1736
mediated	VERB	O	O	1736
rise	VERB	O	O	1736
in	ADP	O	O	1736
myocardial	ADJ	O	O	1736
metabolic	ADJ	O	O	1736
demand	NOUN	O	O	1736
.	PUNCT	O	O	1736
Finally	ADV	O	O	1737
,	PUNCT	O	O	1737
two	NUM	O	O	1737
mechanisms	NOUN	O	O	1737
at	ADP	O	O	1737
least	ADJ	O	O	1737
,	PUNCT	O	O	1737
direct	ADJ	O	O	1737
vasodilation	NOUN	O	O	1737
and	CCONJ	O	O	1737
flow	NOUN	O	O	1737
dependency	NOUN	O	O	1737
,	PUNCT	O	O	1737
are	AUX	O	O	1737
involved	VERB	O	O	1737
in	ADP	O	O	1737
the	PRON	O	O	1737
cromakalim-	ADV	O	O	1737
and	CCONJ	O	O	1737
pinacidil	NOUN	O	O	1737
-	PUNCT	O	O	1737
induced	VERB	O	O	1737
increase	VERB	O	O	1737
in	ADP	O	O	1737
CxAD	NOUN	O	O	1737
.	PUNCT	O	O	1737
Mefenamic	PROPN	O	O	1740
acid	PROPN	O	O	1740
-	PUNCT	O	O	1740
induced	VERB	O	O	1740
neutropenia	ADJ	O	Disease	1740
and	CCONJ	O	O	1740
renal failure	NOUN	O	Disease	1740
in	ADP	O	O	1740
elderly	ADJ	O	O	1740
females	NOUN	O	O	1740
with	ADP	O	O	1740
hypothyroidism	PROPN	O	Disease	1740
.	PUNCT	O	O	1740
We	PRON	O	O	1741
report	VERB	O	O	1741
mefenamic acid	NOUN	O	Chemical	1741
-	PUNCT	O	O	1741
induced	VERB	O	O	1741
non	ADJ	O	O	1741
-	PUNCT	O	O	1741
oliguric	PROPN	O	O	1741
renal failure	NOUN	O	Disease	1741
and	CCONJ	O	O	1741
severe	ADJ	O	O	1741
neutropenia	ADJ	O	Disease	1741
occurring	VERB	O	O	1741
simultaneously	ADV	O	O	1741
in	ADP	O	O	1741
two	NUM	O	O	1741
elderly	ADJ	O	O	1741
females	NOUN	O	O	1741
.	PUNCT	O	O	1741
The	PRON	O	O	1742
neutropenia	ADJ	O	Disease	1742
was	AUX	O	O	1742
due	ADJ	O	O	1742
to	PART	O	O	1742
maturation	NOUN	O	O	1742
arrest	VERB	O	O	1742
of	ADP	O	O	1742
the	PRON	O	O	1742
myeloid	NOUN	O	O	1742
series	PROPN	O	O	1742
in	ADP	O	O	1742
one	NUM	O	O	1742
patient	NOUN	O	O	1742
.	PUNCT	O	O	1742
Both	PRON	O	O	1743
patients	NOUN	O	O	1743
were	AUX	O	O	1743
also	ADV	O	O	1743
hypothyroid	PROPN	O	Disease	1743
,	PUNCT	O	O	1743
but	CCONJ	O	O	1743
it	PRON	O	O	1743
is	AUX	O	O	1743
not	PART	O	O	1743
clear	ADJ	O	O	1743
whether	SCONJ	O	O	1743
this	PRON	O	O	1743
was	AUX	O	O	1743
a	PRON	O	O	1743
predisposing	VERB	O	O	1743
factor	NOUN	O	O	1743
to	PART	O	O	1743
the	PRON	O	O	1743
development	NOUN	O	O	1743
of	ADP	O	O	1743
these	PRON	O	O	1743
adverse	ADJ	O	O	1743
reactions	NOUN	O	O	1743
.	PUNCT	O	O	1743
However	ADV	O	O	1744
,	PUNCT	O	O	1744
it	PRON	O	O	1744
would	AUX	O	O	1744
seem	VERB	O	O	1744
prudent	ADJ	O	O	1744
not	PART	O	O	1744
to	PART	O	O	1744
use	VERB	O	O	1744
mefenamic acid	NOUN	O	Chemical	1744
in	ADP	O	O	1744
hypothyroid	PROPN	O	Disease	1744
patients	NOUN	O	O	1744
until	ADP	O	O	1744
the	PRON	O	O	1744
hypothyroidism	PROPN	O	Disease	1744
has	VERB	O	O	1744
been	AUX	O	O	1744
corrected	VERB	O	O	1744
.	PUNCT	O	O	1744
Etiology	NOUN	O	O	1747
of	ADP	O	O	1747
hypercalcemia	NOUN	O	Disease	1747
in	ADP	O	O	1747
hemodialysis	NOUN	O	O	1747
patients	NOUN	O	O	1747
on	ADP	O	O	1747
calcium carbonate	NOUN	O	Chemical	1747
therapy	NOUN	O	O	1747
.	PUNCT	O	O	1747
Fourteen	NUM	O	O	1748
of	ADP	O	O	1748
39	NUM	O	O	1748
dialysis	NOUN	O	O	1748
patients	NOUN	O	O	1748
(	PUNCT	O	O	1748
36%	NOUN	O	O	1748
)	PUNCT	O	O	1748
became	VERB	O	O	1748
hypercalcemic	ADV	O	O	1748
after	ADP	O	O	1748
switching	VERB	O	O	1748
to	PART	O	O	1748
calcium carbonate	NOUN	O	Chemical	1748
as	ADP	O	O	1748
their	PRON	O	O	1748
principal	NOUN	O	O	1748
phosphate	NOUN	O	Chemical	1748
binder	NOUN	O	O	1748
.	PUNCT	O	O	1748
In	ADP	O	O	1749
order	NOUN	O	O	1749
to	PART	O	O	1749
identify	VERB	O	O	1749
risk	NOUN	O	O	1749
factors	NOUN	O	O	1749
associated	VERB	O	O	1749
with	ADP	O	O	1749
the	PRON	O	O	1749
development	NOUN	O	O	1749
of	ADP	O	O	1749
hypercalcemia	NOUN	O	Disease	1749
,	PUNCT	O	O	1749
indirect	ADJ	O	O	1749
parameters	NOUN	O	O	1749
of	ADP	O	O	1749
intestinal	ADJ	O	Disease	1749
calcium	NOUN	O	Chemical	1749
reabsorption	NOUN	O	O	1749
and	CCONJ	O	O	1749
bone	NOUN	O	O	1749
turnover	NOUN	O	O	1749
rate	NOUN	O	O	1749
in	ADP	O	O	1749
these	PRON	O	O	1749
14	NUM	O	O	1749
patients	NOUN	O	O	1749
were	AUX	O	O	1749
compared	VERB	O	O	1749
with	ADP	O	O	1749
results	VERB	O	O	1749
in	ADP	O	O	1749
14	NUM	O	O	1749
eucalcemic	ADJ	O	O	1749
patients	NOUN	O	O	1749
matched	VERB	O	O	1749
for	ADP	O	O	1749
age	NOUN	O	O	1749
,	PUNCT	O	O	1749
sex	NOUN	O	O	1749
,	PUNCT	O	O	1749
length	NOUN	O	O	1749
of	ADP	O	O	1749
time	NOUN	O	O	1749
on	ADP	O	O	1749
dialysis	NOUN	O	O	1749
,	PUNCT	O	O	1749
and	CCONJ	O	O	1749
etiology	NOUN	O	O	1749
of	ADP	O	O	1749
renal disease	NOUN	O	Disease	1749
.	PUNCT	O	O	1749
In	ADP	O	O	1750
addition	NOUN	O	O	1750
to	PART	O	O	1750
experiencing	VERB	O	O	1750
hypercalcemic	ADV	O	O	1750
episodes	NOUN	O	O	1750
with	ADP	O	O	1750
peak	PROPN	O	O	1750
calcium	NOUN	O	Chemical	1750
values	NOUN	O	O	1750
of	ADP	O	O	1750
2.7	NUM	O	O	1750
to	PART	O	O	1750
3.8	NUM	O	O	1750
mmol	NOUN	O	O	1750
/	PUNCT	O	O	1750
L	NOUN	O	O	1750
(	PUNCT	O	O	1750
10.7	NUM	O	O	1750
to	PART	O	O	1750
15.0	NUM	O	O	1750
mg	VERB	O	O	1750
/	PUNCT	O	O	1750
dL	VERB	O	O	1750
)	PUNCT	O	O	1750
,	PUNCT	O	O	1750
patients	NOUN	O	O	1750
in	ADP	O	O	1750
the	PRON	O	O	1750
hypercalcemic	ADV	O	O	1750
group	NOUN	O	O	1750
exhibited	VERB	O	O	1750
a	PRON	O	O	1750
significant	ADJ	O	O	1750
increase	VERB	O	O	1750
in	ADP	O	O	1750
the	PRON	O	O	1750
mean	VERB	O	O	1750
calcium	NOUN	O	Chemical	1750
concentration	NOUN	O	O	1750
obtained	VERB	O	O	1750
during	ADP	O	O	1750
6	NUM	O	O	1750
months	NOUN	O	O	1750
before	ADP	O	O	1750
the	PRON	O	O	1750
switch	VERB	O	O	1750
,	PUNCT	O	O	1750
compared	VERB	O	O	1750
with	ADP	O	O	1750
the	PRON	O	O	1750
mean	VERB	O	O	1750
value	NOUN	O	O	1750
obtained	VERB	O	O	1750
during	ADP	O	O	1750
the	PRON	O	O	1750
7	NUM	O	O	1750
months	NOUN	O	O	1750
of	ADP	O	O	1750
observation	NOUN	O	O	1750
after	ADP	O	O	1750
the	PRON	O	O	1750
switch	VERB	O	O	1750
(	PUNCT	O	O	1750
2.4	NUM	O	O	1750
+	ADP	O	O	1750
/-	PUNCT	O	O	1750
In	ADP	O	O	1751
contrast	NOUN	O	O	1751
,	PUNCT	O	O	1751
eucalcemic	ADJ	O	O	1751
patients	NOUN	O	O	1751
exhibited	VERB	O	O	1751
no	PRON	O	O	1751
change	VERB	O	O	1751
in	ADP	O	O	1751
mean	VERB	O	O	1751
calcium	NOUN	O	Chemical	1751
values	NOUN	O	O	1751
over	ADP	O	O	1751
the	PRON	O	O	1751
same	ADJ	O	O	1751
time	NOUN	O	O	1751
period	NOUN	O	O	1751
(	PUNCT	O	O	1751
2.3	NUM	O	O	1751
+	ADP	O	O	1751
/-	PUNCT	O	O	1751
CaCO3	NOUN	O	O	1752
dosage	NOUN	O	O	1752
,	PUNCT	O	O	1752
calculated	VERB	O	O	1752
dietary	ADJ	O	O	1752
calcium	NOUN	O	Chemical	1752
intake	PROPN	O	O	1752
,	PUNCT	O	O	1752
and	CCONJ	O	O	1752
circulating	VERB	O	O	1752
levels	NOUN	O	O	1752
of	ADP	O	O	1752
vitamin D	NOUN	O	Chemical	1752
metabolites	VERB	O	O	1752
were	AUX	O	O	1752
similar	ADJ	O	O	1752
in	ADP	O	O	1752
both	PRON	O	O	1752
groups	NOUN	O	O	1752
.	PUNCT	O	O	1752
Physical	NOUN	O	O	1753
activity	NOUN	O	O	1753
index	NOUN	O	O	1753
and	CCONJ	O	O	1753
predialysis	VERB	O	O	1753
serum	NOUN	O	O	1753
bicarbonate	NOUN	O	O	1753
levels	NOUN	O	O	1753
also	ADV	O	O	1753
were	AUX	O	O	1753
similar	ADJ	O	O	1753
in	ADP	O	O	1753
both	PRON	O	O	1753
groups	NOUN	O	O	1753
.	PUNCT	O	O	1753
Methyldopa	NOUN	O	O	1756
-	PUNCT	O	O	1756
induced	VERB	O	O	1756
hemolytic anemia	NOUN	O	Disease	1756
in	ADP	O	O	1756
a	PRON	O	O	1756
15	NUM	O	O	1756
year	NOUN	O	O	1756
old	ADJ	O	O	1756
presenting	VERB	O	O	1756
as	ADP	O	O	1756
near	ADP	O	O	1756
-	PUNCT	O	O	1756
syncope	VERB	O	Disease	1756
.	PUNCT	O	O	1756
Methyldopa	NOUN	O	O	1757
is	AUX	O	O	1757
an	PRON	O	O	1757
antihypertensive	ADV	O	O	1757
medication	NOUN	O	O	1757
which	PRON	O	O	1757
is	AUX	O	O	1757
available	ADJ	O	O	1757
generically	ADV	O	O	1757
and	CCONJ	O	O	1757
under	ADP	O	O	1757
the	PRON	O	O	1757
trade	NOUN	O	O	1757
name	NOUN	O	O	1757
Aldomet	NOUN	O	O	1757
that	SCONJ	O	O	1757
is	AUX	O	O	1757
widely	ADV	O	O	1757
prescribed	VERB	O	O	1757
in	ADP	O	O	1757
the	PRON	O	O	1757
adult	NOUN	O	O	1757
population	NOUN	O	O	1757
and	CCONJ	O	O	1757
infrequently	ADV	O	O	1757
used	VERB	O	O	1757
in	ADP	O	O	1757
children	NOUN	O	O	1757
.	PUNCT	O	O	1757
Methyldopa	NOUN	O	O	1758
causes	VERB	O	O	1758
an	PRON	O	O	1758
autoimmune	PROPN	O	O	1758
hemolytic anemia	NOUN	O	Disease	1758
in	ADP	O	O	1758
a	PRON	O	O	1758
small	ADJ	O	O	1758
percentage	NOUN	O	O	1758
of	ADP	O	O	1758
patients	NOUN	O	O	1758
who	PRON	O	O	1758
take	VERB	O	O	1758
the	PRON	O	O	1758
drug	NOUN	O	O	1758
.	PUNCT	O	O	1758
We	PRON	O	O	1759
report	VERB	O	O	1759
a	PRON	O	O	1759
case	NOUN	O	O	1759
of	ADP	O	O	1759
methyldopa	ADJ	O	Chemical	1759
-	PUNCT	O	O	1759
induced	VERB	O	O	1759
hemolytic anemia	NOUN	O	Disease	1759
in	ADP	O	O	1759
a	PRON	O	O	1759
15-year	NOUN	O	O	1759
-	PUNCT	O	O	1759
old	ADJ	O	O	1759
boy	NOUN	O	O	1759
who	PRON	O	O	1759
presented	VERB	O	O	1759
to	PART	O	O	1759
the	PRON	O	O	1759
emergency	NOUN	O	O	1759
department	NOUN	O	O	1759
with	ADP	O	O	1759
near	ADP	O	O	1759
-	PUNCT	O	O	1759
syncope	VERB	O	Disease	1759
.	PUNCT	O	O	1759
The	PRON	O	O	1760
boy	NOUN	O	O	1760
had	VERB	O	O	1760
been	AUX	O	O	1760
treated	VERB	O	O	1760
with	ADP	O	O	1760
intravenous	ADJ	O	O	1760
methyldopa	ADJ	O	Chemical	1760
during	ADP	O	O	1760
a	PRON	O	O	1760
trauma	NOUN	O	O	1760
admission	NOUN	O	O	1760
seven	NUM	O	O	1760
weeks	NOUN	O	O	1760
prior	ADV	O	O	1760
to	PART	O	O	1760
presentation	NOUN	O	O	1760
.	PUNCT	O	O	1760
Transfusion	NOUN	O	O	1761
and	CCONJ	O	O	1761
corticosteroid	NOUN	O	Chemical	1761
therapy	NOUN	O	O	1761
resulted	VERB	O	O	1761
in	ADP	O	O	1761
a	PRON	O	O	1761
complete	VERB	O	O	1761
recovery	NOUN	O	O	1761
of	ADP	O	O	1761
the	PRON	O	O	1761
patient	NOUN	O	O	1761
.	PUNCT	O	O	1761
A	PRON	O	O	1762
brief	PROPN	O	O	1762
review	VERB	O	O	1762
of	ADP	O	O	1762
autoimmune	PROPN	O	O	1762
and	CCONJ	O	O	1762
drug	NOUN	O	O	1762
-	PUNCT	O	O	1762
induced	VERB	O	O	1762
hemolytic anemias	NOUN	O	Disease	1762
is	AUX	O	O	1762
provided	VERB	O	O	1762
.	PUNCT	O	O	1762
The	PRON	O	O	1765
long	ADV	O	O	1765
-	PUNCT	O	O	1765
term	NOUN	O	O	1765
safety	NOUN	O	O	1765
of	ADP	O	O	1765
danazol	PROPN	O	O	1765
in	ADP	O	O	1765
women	NOUN	O	O	1765
with	ADP	O	O	1765
hereditary	ADJ	O	O	1765
angioedema	NOUN	O	Disease	1765
.	PUNCT	O	O	1765
Although	SCONJ	O	O	1766
the	PRON	O	O	1766
short	ADJ	O	O	1766
-	PUNCT	O	O	1766
term	NOUN	O	O	1766
safety	NOUN	O	O	1766
(	PUNCT	O	O	1766
less	ADV	O	O	1766
than	ADP	O	O	1766
or	CCONJ	O	O	1766
equal	ADJ	O	O	1766
to	PART	O	O	1766
6	NUM	O	O	1766
months	NOUN	O	O	1766
)	PUNCT	O	O	1766
of	ADP	O	O	1766
danazol	PROPN	O	O	1766
has	VERB	O	O	1766
been	AUX	O	O	1766
established	VERB	O	O	1766
in	ADP	O	O	1766
a	PRON	O	O	1766
variety	NOUN	O	O	1766
of	ADP	O	O	1766
settings	NOUN	O	O	1766
,	PUNCT	O	O	1766
no	PRON	O	O	1766
information	NOUN	O	O	1766
exists	VERB	O	O	1766
as	ADP	O	O	1766
to	PART	O	O	1766
its	PRON	O	O	1766
long	ADV	O	O	1766
-	PUNCT	O	O	1766
term	NOUN	O	O	1766
safety	NOUN	O	O	1766
.	PUNCT	O	O	1766
We	PRON	O	O	1767
therefore	ADV	O	O	1767
investigated	VERB	O	O	1767
the	PRON	O	O	1767
long	ADV	O	O	1767
-	PUNCT	O	O	1767
term	NOUN	O	O	1767
safety	NOUN	O	O	1767
of	ADP	O	O	1767
danazol	PROPN	O	O	1767
by	ADP	O	O	1767
performing	VERB	O	O	1767
a	PRON	O	O	1767
retrospective	ADJ	O	O	1767
chart	NOUN	O	O	1767
review	VERB	O	O	1767
of	ADP	O	O	1767
60	NUM	O	O	1767
female	ADJ	O	O	1767
patients	NOUN	O	O	1767
with	ADP	O	O	1767
hereditary	ADJ	O	O	1767
angioedema	NOUN	O	Disease	1767
treated	VERB	O	O	1767
with	ADP	O	O	1767
danazol	PROPN	O	O	1767
for	ADP	O	O	1767
a	PRON	O	O	1767
continuous	ADJ	O	O	1767
period	NOUN	O	O	1767
of	ADP	O	O	1767
6	NUM	O	O	1767
months	NOUN	O	O	1767
or	CCONJ	O	O	1767
longer	ADV	O	O	1767
.	PUNCT	O	O	1767
Menstrual	ADJ	O	O	1768
abnormalities	NOUN	O	O	1768
(	PUNCT	O	O	1768
79%	NOUN	O	O	1768
)	PUNCT	O	O	1768
,	PUNCT	O	O	1768
weight	NOUN	O	O	1768
gain	VERB	O	O	1768
(	PUNCT	O	O	1768
60%	NOUN	O	O	1768
)	PUNCT	O	O	1768
,	PUNCT	O	O	1768
muscle	NOUN	O	O	1768
cramps	NOUN	O	O	1768
/	PUNCT	O	O	1768
myalgias	PROPN	O	O	1768
(	PUNCT	O	O	1768
40%	NOUN	O	O	1768
)	PUNCT	O	O	1768
,	PUNCT	O	O	1768
and	CCONJ	O	O	1768
transaminase	X	O	O	1768
elevations	NOUN	O	O	1768
(	PUNCT	O	O	1768
40%	NOUN	O	O	1768
)	PUNCT	O	O	1768
were	AUX	O	O	1768
the	PRON	O	O	1768
most	ADV	O	O	1768
common	ADJ	O	O	1768
adverse	ADJ	O	O	1768
reactions	NOUN	O	O	1768
.	PUNCT	O	O	1768
We	PRON	O	O	1769
conclude	VERB	O	O	1769
that	SCONJ	O	O	1769
,	PUNCT	O	O	1769
despite	SCONJ	O	O	1769
a	PRON	O	O	1769
relatively	ADV	O	O	1769
high	ADJ	O	O	1769
incidence	NOUN	O	O	1769
of	ADP	O	O	1769
adverse	ADJ	O	O	1769
reactions	NOUN	O	O	1769
,	PUNCT	O	O	1769
danazol	PROPN	O	O	1769
has	VERB	O	O	1769
proven	VERB	O	O	1769
to	PART	O	O	1769
be	AUX	O	O	1769
remarkably	ADV	O	O	1769
safe	ADJ	O	O	1769
over	ADP	O	O	1769
the	PRON	O	O	1769
long	ADV	O	O	1769
-	PUNCT	O	O	1769
term	NOUN	O	O	1769
in	ADP	O	O	1769
this	PRON	O	O	1769
group	NOUN	O	O	1769
of	ADP	O	O	1769
patients	NOUN	O	O	1769
.	PUNCT	O	O	1769
Patient	NOUN	O	O	1772
tolerance	NOUN	O	O	1772
study	VERB	O	O	1772
of	ADP	O	O	1772
topical	ADJ	O	O	1772
chlorhexidine	NOUN	O	O	1772
diphosphanilate	PROPN	O	O	1772
:	PUNCT	O	O	1772
a	PRON	O	O	1772
new	ADJ	O	O	1772
topical	ADJ	O	O	1772
agent	NOUN	O	O	1772
for	ADP	O	O	1772
burns	VERB	O	O	1772
.	PUNCT	O	O	1772
Effective	ADJ	O	O	1773
topical	ADJ	O	O	1773
antimicrobial	ADJ	O	O	1773
agents	NOUN	O	O	1773
decrease	VERB	O	O	1773
infection	NOUN	O	Disease	1773
and	CCONJ	O	O	1773
mortality	NOUN	O	O	1773
in	ADP	O	O	1773
burn	VERB	O	O	1773
patients	NOUN	O	O	1773
.	PUNCT	O	O	1773
Chlorhexidine	NOUN	O	O	1774
phosphanilate	PROPN	O	O	1774
(	PUNCT	O	O	1774
CHP	PROPN	O	O	1774
)	PUNCT	O	O	1774
,	PUNCT	O	O	1774
a	PRON	O	O	1774
new	ADJ	O	O	1774
broad	ADJ	O	O	1774
-	PUNCT	O	O	1774
spectrum	NOUN	O	O	1774
antimicrobial	ADJ	O	O	1774
agent	NOUN	O	O	1774
,	PUNCT	O	O	1774
has	VERB	O	O	1774
been	AUX	O	O	1774
evaluated	VERB	O	O	1774
as	ADP	O	O	1774
a	PRON	O	O	1774
topical	ADJ	O	O	1774
burn	VERB	O	O	1774
wound	VERB	O	O	1774
dressing	VERB	O	O	1774
in	ADP	O	O	1774
cream	NOUN	O	O	1774
form	NOUN	O	O	1774
,	PUNCT	O	O	1774
but	CCONJ	O	O	1774
preliminary	ADJ	O	O	1774
clinical	ADJ	O	O	1774
trials	NOUN	O	O	1774
reported	VERB	O	O	1774
that	SCONJ	O	O	1774
it	PRON	O	O	1774
was	AUX	O	O	1774
painful	ADJ	O	Disease	1774
upon	SCONJ	O	O	1774
application	NOUN	O	O	1774
.	PUNCT	O	O	1774
This	PRON	O	O	1775
study	VERB	O	O	1775
compared	VERB	O	O	1775
various	ADJ	O	O	1775
concentrations	NOUN	O	O	1775
of	ADP	O	O	1775
CHP	PROPN	O	O	1775
to	PART	O	O	1775
determine	VERB	O	O	1775
if	SCONJ	O	O	1775
a	PRON	O	O	1775
tolerable	ADJ	O	O	1775
concentration	NOUN	O	O	1775
could	AUX	O	O	1775
be	AUX	O	O	1775
identified	VERB	O	O	1775
with	ADP	O	O	1775
retention	NOUN	O	O	1775
of	ADP	O	O	1775
antimicrobial	ADJ	O	O	1775
efficacy	NOUN	O	O	1775
.	PUNCT	O	O	1775
Twenty	NUM	O	O	1776
-	PUNCT	O	O	1776
nine	NUM	O	O	1776
burn	VERB	O	O	1776
patients	NOUN	O	O	1776
,	PUNCT	O	O	1776
each	PRON	O	O	1776
with	ADP	O	O	1776
two	NUM	O	O	1776
similar	ADJ	O	O	1776
burns	VERB	O	O	1776
which	PRON	O	O	1776
could	AUX	O	O	1776
be	AUX	O	O	1776
separately	ADV	O	O	1776
treated	VERB	O	O	1776
,	PUNCT	O	O	1776
were	AUX	O	O	1776
given	VERB	O	O	1776
pairs	NOUN	O	O	1776
of	ADP	O	O	1776
treatments	NOUN	O	O	1776
at	ADP	O	O	1776
successive	ADV	O	O	1776
12-h	NOUN	O	O	1776
intervals	NOUN	O	O	1776
over	ADP	O	O	1776
a	PRON	O	O	1776
3-day	NOUN	O	O	1776
period	NOUN	O	O	1776
.	PUNCT	O	O	1776
One	NUM	O	O	1777
burn	VERB	O	O	1777
site	NOUN	O	O	1777
was	AUX	O	O	1777
treated	VERB	O	O	1777
with	ADP	O	O	1777
each	PRON	O	O	1777
of	ADP	O	O	1777
four	NUM	O	O	1777
different	ADJ	O	O	1777
CHP	PROPN	O	O	1777
concentrations	NOUN	O	O	1777
,	PUNCT	O	O	1777
from	ADP	O	O	1777
0.25	NUM	O	O	1777
per	ADP	O	O	1777
cent	NOUN	O	O	1777
to	PART	O	O	1777
2	X	O	O	1777
per	ADP	O	O	1777
cent	NOUN	O	O	1777
,	PUNCT	O	O	1777
their	PRON	O	O	1777
vehicle	NOUN	O	O	1777
,	PUNCT	O	O	1777
and	CCONJ	O	O	1777
1	X	O	O	1777
per	ADP	O	O	1777
cent	NOUN	O	O	1777
silver	NOUN	O	O	1777
sulphadiazine	ADJ	O	O	1777
(	PUNCT	O	O	1777
AgSD	VERB	O	O	1777
)	PUNCT	O	O	1777
cream	NOUN	O	O	1777
,	PUNCT	O	O	1777
an	PRON	O	O	1777
antimicrobial	ADJ	O	O	1777
agent	NOUN	O	O	1777
frequently	ADV	O	O	1777
used	VERB	O	O	1777
for	ADP	O	O	1777
topical	ADJ	O	O	1777
treatment	NOUN	O	O	1777
of	ADP	O	O	1777
burn	VERB	O	O	1777
wounds	NOUN	O	O	1777
.	PUNCT	O	O	1777
The	PRON	O	O	1778
other	ADJ	O	O	1778
site	NOUN	O	O	1778
was	AUX	O	O	1778
always	ADV	O	O	1778
treated	VERB	O	O	1778
with	ADP	O	O	1778
AgSD	VERB	O	O	1778
cream	NOUN	O	O	1778
.	PUNCT	O	O	1778
There	ADV	O	O	1779
was	AUX	O	O	1779
a	PRON	O	O	1779
direct	ADJ	O	O	1779
relationship	NOUN	O	O	1779
between	ADP	O	O	1779
CHP	PROPN	O	O	1779
concentration	NOUN	O	O	1779
and	CCONJ	O	O	1779
patients	NOUN	O	O	1779
'	PUNCT	O	O	1779
ratings	NOUN	O	O	1779
of	ADP	O	O	1779
pain	NOUN	O	Disease	1779
on	ADP	O	O	1779
an	PRON	O	O	1779
analogue	NOUN	O	O	1779
scale	NOUN	O	O	1779
.	PUNCT	O	O	1779
The	PRON	O	O	1780
0.25	NUM	O	O	1780
per	ADP	O	O	1780
cent	NOUN	O	O	1780
CHP	PROPN	O	O	1780
cream	NOUN	O	O	1780
was	AUX	O	O	1780
closest	ADJ	O	O	1780
to	PART	O	O	1780
AgSD	VERB	O	O	1780
in	ADP	O	O	1780
pain	NOUN	O	Disease	1780
tolerance	NOUN	O	O	1780
;	PUNCT	O	O	1780
however	ADV	O	O	1780
,	PUNCT	O	O	1780
none	NOUN	O	O	1780
of	ADP	O	O	1780
the	PRON	O	O	1780
treatments	NOUN	O	O	1780
differed	VERB	O	O	1780
statistically	ADV	O	O	1780
from	ADP	O	O	1780
AgSD	VERB	O	O	1780
or	CCONJ	O	O	1780
from	ADP	O	O	1780
each	PRON	O	O	1780
other	ADJ	O	O	1780
.	PUNCT	O	O	1780
In	ADP	O	O	1781
addition	NOUN	O	O	1781
,	PUNCT	O	O	1781
ease	NOUN	O	O	1781
of	ADP	O	O	1781
application	NOUN	O	O	1781
of	ADP	O	O	1781
CHP	PROPN	O	O	1781
creams	NOUN	O	O	1781
was	AUX	O	O	1781
less	ADV	O	O	1781
satisfactory	ADJ	O	O	1781
than	ADP	O	O	1781
that	SCONJ	O	O	1781
of	ADP	O	O	1781
AgSD	VERB	O	O	1781
.	PUNCT	O	O	1781
It	PRON	O	O	1782
was	AUX	O	O	1782
concluded	VERB	O	O	1782
that	SCONJ	O	O	1782
formulations	NOUN	O	O	1782
at	ADP	O	O	1782
or	CCONJ	O	O	1782
below	ADP	O	O	1782
0.5	NUM	O	O	1782
per	ADP	O	O	1782
cent	NOUN	O	O	1782
CHP	PROPN	O	O	1782
may	AUX	O	O	1782
prove	VERB	O	O	1782
acceptable	ADJ	O	O	1782
for	ADP	O	O	1782
wound	VERB	O	O	1782
care	VERB	O	O	1782
,	PUNCT	O	O	1782
but	CCONJ	O	O	1782
the	PRON	O	O	1782
vehicle	NOUN	O	O	1782
system	NOUN	O	O	1782
needs	VERB	O	O	1782
pharmaceutical	NOUN	O	O	1782
improvement	NOUN	O	O	1782
to	PART	O	O	1782
render	VERB	O	O	1782
it	PRON	O	O	1782
more	ADJ	O	O	1782
tolerable	ADJ	O	O	1782
and	CCONJ	O	O	1782
easier	ADJ	O	O	1782
to	PART	O	O	1782
use	VERB	O	O	1782
.	PUNCT	O	O	1782
Dose	NOUN	O	O	1785
-	PUNCT	O	O	1785
dependent	ADJ	O	O	1785
neurotoxicity	NOUN	O	Disease	1785
of	ADP	O	O	1785
high	ADJ	O	O	1785
-	PUNCT	O	O	1785
dose	NOUN	O	O	1785
busulfan	VERB	O	O	1785
in	ADP	O	O	1785
children	NOUN	O	O	1785
:	PUNCT	O	O	1785
a	PRON	O	O	1785
clinical	ADJ	O	O	1785
and	CCONJ	O	O	1785
pharmacological	ADJ	O	O	1785
study	VERB	O	O	1785
.	PUNCT	O	O	1785
Busulfan	PROPN	O	O	1786
is	AUX	O	O	1786
known	VERB	O	O	1786
to	PART	O	O	1786
be	AUX	O	O	1786
neurotoxic	ADJ	O	Disease	1786
in	ADP	O	O	1786
animals	NOUN	O	O	1786
and	CCONJ	O	O	1786
humans	NOUN	O	O	1786
,	PUNCT	O	O	1786
but	CCONJ	O	O	1786
its	PRON	O	O	1786
acute	ADJ	O	O	1786
neurotoxicity	NOUN	O	Disease	1786
remains	VERB	O	O	1786
poorly	ADV	O	O	1786
characterized	VERB	O	O	1786
in	ADP	O	O	1786
children	NOUN	O	O	1786
.	PUNCT	O	O	1786
We	PRON	O	O	1787
report	VERB	O	O	1787
here	ADV	O	O	1787
a	PRON	O	O	1787
retrospective	ADJ	O	O	1787
study	VERB	O	O	1787
of	ADP	O	O	1787
123	NUM	O	O	1787
children	NOUN	O	O	1787
(	PUNCT	O	O	1787
median	ADJ	O	O	1787
age	NOUN	O	O	1787
,	PUNCT	O	O	1787
6.5	NUM	O	O	1787
years	NOUN	O	O	1787
)	PUNCT	O	O	1787
receiving	VERB	O	O	1787
high	ADJ	O	O	1787
-	PUNCT	O	O	1787
dose	NOUN	O	O	1787
busulfan	VERB	O	O	1787
in	ADP	O	O	1787
combined	VERB	O	O	1787
chemotherapy	NOUN	O	O	1787
before	ADP	O	O	1787
bone	NOUN	O	O	1787
marrow	PROPN	O	O	1787
transplantation	NOUN	O	O	1787
for	ADP	O	O	1787
malignant	ADJ	O	O	1787
solid	ADJ	O	O	1787
tumors	NOUN	O	Disease	1787
,	PUNCT	O	O	1787
brain tumors	NOUN	O	Disease	1787
excluded	VERB	O	O	1787
.	PUNCT	O	O	1787
Busulfan	PROPN	O	O	1788
was	AUX	O	O	1788
given	VERB	O	O	1788
p.o	PROPN	O	O	1788
.	PUNCT	O	O	1788
Ninety	NUM	O	O	1789
-	PUNCT	O	O	1789
six	NUM	O	O	1789
patients	NOUN	O	O	1789
were	AUX	O	O	1789
not	PART	O	O	1789
given	VERB	O	O	1789
anticonvulsive	ADJ	O	O	1789
prophylaxis	NOUN	O	O	1789
;	PUNCT	O	O	1789
7	NUM	O	O	1789
(	PUNCT	O	O	1789
7.5%	NOUN	O	O	1789
)	PUNCT	O	O	1789
developed	VERB	O	O	1789
seizures	NOUN	O	Disease	1789
during	ADP	O	O	1789
the	PRON	O	O	1789
4	NUM	O	O	1789
days	NOUN	O	O	1789
of	ADP	O	O	1789
the	PRON	O	O	1789
busulfan	VERB	O	O	1789
course	NOUN	O	O	1789
or	CCONJ	O	O	1789
within	ADP	O	O	1789
24	NUM	O	O	1789
h	X	O	O	1789
after	ADP	O	O	1789
the	PRON	O	O	1789
last	VERB	O	O	1789
dosing	VERB	O	O	1789
.	PUNCT	O	O	1789
When	SCONJ	O	O	1790
the	PRON	O	O	1790
total	ADJ	O	O	1790
busulfan	VERB	O	O	1790
dose	NOUN	O	O	1790
was	AUX	O	O	1790
taken	VERB	O	O	1790
into	ADP	O	O	1790
account	VERB	O	O	1790
,	PUNCT	O	O	1790
there	ADV	O	O	1790
was	AUX	O	O	1790
a	PRON	O	O	1790
significant	ADJ	O	O	1790
difference	NOUN	O	O	1790
in	ADP	O	O	1790
terms	NOUN	O	O	1790
of	ADP	O	O	1790
neurotoxicity	NOUN	O	Disease	1790
incidence	NOUN	O	O	1790
among	ADP	O	O	1790
patients	NOUN	O	O	1790
under	ADP	O	O	1790
16	NUM	O	O	1790
mg	VERB	O	O	1790
/	PUNCT	O	O	1790
kg	VERB	O	O	1790
(	PUNCT	O	O	1790
1	X	O	O	1790
of	ADP	O	O	1790
57	NUM	O	O	1790
,	PUNCT	O	O	1790
1.7%	NOUN	O	O	1790
)	PUNCT	O	O	1790
and	CCONJ	O	O	1790
patients	NOUN	O	O	1790
under	ADP	O	O	1790
600	NUM	O	O	1790
mg	VERB	O	O	1790
/	PUNCT	O	O	1790
m2	PROPN	O	O	1790
(	PUNCT	O	O	1790
6	NUM	O	O	1790
of	ADP	O	O	1790
39	NUM	O	O	1790
,	PUNCT	O	O	1790
15.4%	NOUN	O	O	1790
)	PUNCT	O	O	1790
(	PUNCT	O	O	1790
P	NOUN	O	Chemical	1790
less	ADV	O	O	1790
than	ADP	O	O	1790
0.02	NUM	O	O	1790
)	PUNCT	O	O	1790
.	PUNCT	O	O	1790
Twenty	NUM	O	O	1791
-	PUNCT	O	O	1791
seven	NUM	O	O	1791
patients	NOUN	O	O	1791
were	AUX	O	O	1791
given	VERB	O	O	1791
a	PRON	O	O	1791
600-mg	NOUN	O	O	1791
/	PUNCT	O	O	1791
m2	PROPN	O	O	1791
busulfan	VERB	O	O	1791
total	ADJ	O	O	1791
dose	NOUN	O	O	1791
with	ADP	O	O	1791
continuous	ADJ	O	O	1791
i.v	NOUN	O	O	1791
.	PUNCT	O	O	1791
infusion	NOUN	O	O	1792
of	ADP	O	O	1792
clonazepam	NOUN	O	Chemical	1792
;	PUNCT	O	O	1792
none	NOUN	O	O	1792
had	VERB	O	O	1792
any	PRON	O	O	1792
neurological	ADJ	O	O	1792
symptoms	NOUN	O	O	1792
.	PUNCT	O	O	1792
Busulfan	PROPN	O	O	1793
levels	NOUN	O	O	1793
were	AUX	O	O	1793
measured	VERB	O	O	1793
by	ADP	O	O	1793
a	PRON	O	O	1793
gas	NOUN	O	O	1793
chromatographic	PROPN	O	O	1793
-	PUNCT	O	O	1793
mass	PROPN	O	O	1793
spectrometry	NOUN	O	O	1793
assay	NOUN	O	O	1793
in	ADP	O	O	1793
the	PRON	O	O	1793
plasma	NOUN	O	O	1793
and	CCONJ	O	O	1793
cerebrospinal	ADJ	O	O	1793
fluid	NOUN	O	O	1793
of	ADP	O	O	1793
9	NUM	O	O	1793
children	NOUN	O	O	1793
without	ADP	O	O	1793
central	ADJ	O	O	1793
nervous	ADJ	O	O	1793
system	NOUN	O	O	1793
disease	PROPN	O	O	1793
under	ADP	O	O	1793
600	NUM	O	O	1793
mg	VERB	O	O	1793
/	PUNCT	O	O	1793
m2	PROPN	O	O	1793
busulfan	VERB	O	O	1793
with	ADP	O	O	1793
clonazepam	NOUN	O	Chemical	1793
:	PUNCT	O	O	1793
busulfan	VERB	O	O	1794
cerebrospinal	ADJ	O	O	1794
fluid	NOUN	O	O	1794
:	PUNCT	O	O	1794
plasma	NOUN	O	O	1794
ratio	NOUN	O	O	1794
was	AUX	O	O	1794
1.39	NUM	O	O	1794
.	PUNCT	O	O	1794
This	PRON	O	O	1795
was	AUX	O	O	1795
significantly	ADV	O	O	1795
different	ADJ	O	O	1795
(	PUNCT	O	O	1795
P	NOUN	O	Chemical	1795
less	ADV	O	O	1795
than	ADP	O	O	1795
0.02	NUM	O	O	1795
)	PUNCT	O	O	1795
from	ADP	O	O	1795
the	PRON	O	O	1795
cerebrospinal	ADJ	O	O	1795
fluid	NOUN	O	O	1795
:	PUNCT	O	O	1795
plasma	NOUN	O	O	1795
ratio	NOUN	O	O	1795
previously	ADV	O	O	1795
defined	VERB	O	O	1795
in	ADP	O	O	1795
children	NOUN	O	O	1795
receiving	VERB	O	O	1795
a	PRON	O	O	1795
16-mg	NOUN	O	O	1795
/	PUNCT	O	O	1795
kg	VERB	O	O	1795
total	ADJ	O	O	1795
dose	NOUN	O	O	1795
of	ADP	O	O	1795
busulfan	VERB	O	O	1795
.	PUNCT	O	O	1795
This	PRON	O	O	1796
study	VERB	O	O	1796
shows	VERB	O	O	1796
that	SCONJ	O	O	1796
busulfan	VERB	O	O	1796
neurotoxicity	NOUN	O	Disease	1796
is	AUX	O	O	1796
dose	NOUN	O	O	1796
-	PUNCT	O	O	1796
dependent	ADJ	O	O	1796
in	ADP	O	O	1796
children	NOUN	O	O	1796
and	CCONJ	O	O	1796
efficiently	ADV	O	O	1796
prevented	VERB	O	O	1796
by	ADP	O	O	1796
clonazepam	NOUN	O	Chemical	1796
.	PUNCT	O	O	1796
A	PRON	O	O	1797
busulfan	VERB	O	O	1797
dose	NOUN	O	O	1797
calculated	VERB	O	O	1797
on	ADP	O	O	1797
the	PRON	O	O	1797
basis	NOUN	O	O	1797
of	ADP	O	O	1797
body	NOUN	O	O	1797
surface	NOUN	O	O	1797
area	NOUN	O	O	1797
,	PUNCT	O	O	1797
resulting	VERB	O	O	1797
in	ADP	O	O	1797
higher	ADJ	O	O	1797
doses	NOUN	O	O	1797
in	ADP	O	O	1797
young	ADJ	O	O	1797
children	NOUN	O	O	1797
,	PUNCT	O	O	1797
was	AUX	O	O	1797
followed	VERB	O	O	1797
by	ADP	O	O	1797
increased	VERB	O	O	1797
neurotoxicity	NOUN	O	Disease	1797
,	PUNCT	O	O	1797
close	ADV	O	O	1797
to	PART	O	O	1797
neurotoxicity	NOUN	O	Disease	1797
incidence	NOUN	O	O	1797
observed	VERB	O	O	1797
in	ADP	O	O	1797
adults	NOUN	O	O	1797
.	PUNCT	O	O	1797
Since	SCONJ	O	O	1798
plasma	NOUN	O	O	1798
pharmacokinetic	VERB	O	O	1798
studies	NOUN	O	O	1798
showed	VERB	O	O	1798
a	PRON	O	O	1798
faster	ADV	O	O	1798
busulfan	VERB	O	O	1798
clearance	NOUN	O	O	1798
in	ADP	O	O	1798
children	NOUN	O	O	1798
than	ADP	O	O	1798
in	ADP	O	O	1798
adults	NOUN	O	O	1798
,	PUNCT	O	O	1798
this	PRON	O	O	1798
new	ADJ	O	O	1798
dose	NOUN	O	O	1798
may	AUX	O	O	1798
approximate	VERB	O	O	1798
more	ADJ	O	O	1798
closely	ADV	O	O	1798
the	PRON	O	O	1798
adult	NOUN	O	O	1798
systemic	ADJ	O	O	1798
exposure	NOUN	O	O	1798
obtained	VERB	O	O	1798
after	ADP	O	O	1798
the	PRON	O	O	1798
usual	ADJ	O	O	1798
16-mg	NOUN	O	O	1798
/	PUNCT	O	O	1798
kg	VERB	O	O	1798
total	ADJ	O	O	1798
dose	NOUN	O	O	1798
,	PUNCT	O	O	1798
with	ADP	O	O	1798
potential	ADJ	O	O	1798
inferences	NOUN	O	O	1798
in	ADP	O	O	1798
terms	NOUN	O	O	1798
of	ADP	O	O	1798
anticancer	NOUN	O	O	1798
or	CCONJ	O	O	1798
myeloablative	PROPN	O	O	1798
effects	NOUN	O	O	1798
.	PUNCT	O	O	1798
The	PRON	O	O	1799
busulfan	VERB	O	O	1799
dose	NOUN	O	O	1799
in	ADP	O	O	1799
children	NOUN	O	O	1799
and	CCONJ	O	O	1799
infants	NOUN	O	O	1799
undergoing	VERB	O	O	1799
bone	NOUN	O	O	1799
marrow	PROPN	O	O	1799
transplantation	NOUN	O	O	1799
should	AUX	O	O	1799
be	AUX	O	O	1799
reconsidered	VERB	O	O	1799
on	ADP	O	O	1799
the	PRON	O	O	1799
basis	NOUN	O	O	1799
of	ADP	O	O	1799
pharmacokinetic	VERB	O	O	1799
studies	NOUN	O	O	1799
.	PUNCT	O	O	1799
Histamine	NOUN	O	O	1802
antagonists	NOUN	O	O	1802
and	CCONJ	O	O	1802
d	X	O	O	1802
-	PUNCT	O	O	1802
tubocurarine	NOUN	O	O	1802
-	PUNCT	O	O	1802
induced	VERB	O	O	1802
hypotension	NOUN	O	Disease	1802
in	ADP	O	O	1802
cardiac	ADJ	O	O	1802
surgical	ADJ	O	O	1802
patients	NOUN	O	O	1802
.	PUNCT	O	O	1802
Hemodynamic	PROPN	O	O	1803
effects	NOUN	O	O	1803
and	CCONJ	O	O	1803
histamine	NOUN	O	Chemical	1803
release	NOUN	O	O	1803
by	ADP	O	O	1803
bolus	NOUN	O	O	1803
injection	NOUN	O	O	1803
of	ADP	O	O	1803
0.35	NUM	O	O	1803
mg	VERB	O	O	1803
/	PUNCT	O	O	1803
kg	VERB	O	O	1803
of	ADP	O	O	1803
d	X	O	O	1803
-	PUNCT	O	O	1803
tubocurarine	NOUN	O	O	1803
were	AUX	O	O	1803
studied	VERB	O	O	1803
in	ADP	O	O	1803
24	NUM	O	O	1803
patients	NOUN	O	O	1803
.	PUNCT	O	O	1803
H1-	PROPN	O	O	1804
and	CCONJ	O	O	1804
H2-histamine	NOUN	O	O	1804
antagonists	NOUN	O	O	1804
or	CCONJ	O	O	1804
placebo	NOUN	O	O	1804
were	AUX	O	O	1804
given	VERB	O	O	1804
before	ADP	O	O	1804
dosing	VERB	O	O	1804
with	ADP	O	O	1804
d	X	O	O	1804
-	PUNCT	O	O	1804
tubocurarine	NOUN	O	O	1804
in	ADP	O	O	1804
a	PRON	O	O	1804
randomized	VERB	O	O	1804
double	ADJ	O	O	1804
-	PUNCT	O	O	1804
blind	ADJ	O	Disease	1804
fashion	NOUN	O	O	1804
to	PART	O	O	1804
four	NUM	O	O	1804
groups	NOUN	O	O	1804
:	PUNCT	O	O	1804
group	NOUN	O	O	1804
1	X	O	O	1804
-	PUNCT	O	O	1804
-placebo	NOUN	O	O	1804
;	PUNCT	O	O	1804
group	NOUN	O	O	1804
2	X	O	O	1804
-	PUNCT	O	O	1804
-cimetidine	NOUN	O	O	1804
,	PUNCT	O	O	1804
4	NUM	O	O	1804
mg	VERB	O	O	1804
/	PUNCT	O	O	1804
kg	VERB	O	O	1804
,	PUNCT	O	O	1804
plus	CCONJ	O	O	1804
placebo	NOUN	O	O	1804
;	PUNCT	O	O	1804
group	NOUN	O	O	1804
3	X	O	O	1804
-	PUNCT	O	O	1804
-chlorpheniramine	INTJ	O	O	1804
,	PUNCT	O	O	1804
0.1	NUM	O	O	1804
mg	VERB	O	O	1805
/	PUNCT	O	O	1805
kg	VERB	O	O	1805
,	PUNCT	O	O	1805
plus	CCONJ	O	O	1805
placebo	NOUN	O	O	1805
;	PUNCT	O	O	1805
and	CCONJ	O	O	1805
group	NOUN	O	O	1805
4	NUM	O	O	1805
-	PUNCT	O	O	1805
-cimetidine	NOUN	O	O	1805
plus	CCONJ	O	O	1805
chlorpheniramine	PROPN	O	Chemical	1805
.	PUNCT	O	O	1805
Histamine	NOUN	O	O	1806
release	NOUN	O	O	1806
occurred	VERB	O	O	1806
in	ADP	O	O	1806
most	ADV	O	O	1806
patients	NOUN	O	O	1806
,	PUNCT	O	O	1806
the	PRON	O	O	1806
highest	ADJ	O	O	1806
level	VERB	O	O	1806
2	X	O	O	1806
minutes	NOUN	O	O	1806
after	ADP	O	O	1806
d	X	O	O	1806
-	PUNCT	O	O	1806
tubocurarine	NOUN	O	O	1806
dosing	VERB	O	O	1806
.	PUNCT	O	O	1806
Group	PROPN	O	O	1807
1	X	O	O	1807
had	VERB	O	O	1807
a	PRON	O	O	1807
moderate	ADJ	O	O	1807
negative	ADJ	O	O	1807
correlation	NOUN	O	O	1807
between	ADP	O	O	1807
plasma	NOUN	O	O	1807
histamine	NOUN	O	Chemical	1807
change	VERB	O	O	1807
and	CCONJ	O	O	1807
systemic	ADJ	O	O	1807
vascular	ADJ	O	O	1807
resistance	NOUN	O	O	1807
(	PUNCT	O	O	1807
r	X	O	O	1807
=	PUNCT	O	O	1807
0.58	NUM	O	O	1807
;	PUNCT	O	O	1807
P	NOUN	O	Chemical	1807
less	ADV	O	O	1807
than	ADP	O	O	1807
0.05	NUM	O	O	1807
)	PUNCT	O	O	1807
not	PART	O	O	1807
present	NOUN	O	O	1807
in	ADP	O	O	1807
group	NOUN	O	O	1807
4	NUM	O	O	1807
.	PUNCT	O	O	1807
These	PRON	O	O	1808
data	NOUN	O	O	1808
demonstrate	VERB	O	O	1808
that	SCONJ	O	O	1808
the	PRON	O	O	1808
hemodynamic	ADJ	O	O	1808
changes	VERB	O	O	1808
associated	VERB	O	O	1808
with	ADP	O	O	1808
d	X	O	O	1808
-	PUNCT	O	O	1808
tubocurarine	NOUN	O	O	1808
dosing	VERB	O	O	1808
are	AUX	O	O	1808
only	ADV	O	O	1808
partially	ADV	O	O	1808
explained	VERB	O	O	1808
by	ADP	O	O	1808
histamine	NOUN	O	Chemical	1808
release	NOUN	O	O	1808
.	PUNCT	O	O	1808
Convulsant	NOUN	O	O	1811
effect	VERB	O	O	1811
of	ADP	O	O	1811
lindane	NOUN	O	Chemical	1811
and	CCONJ	O	O	1811
regional	ADJ	O	O	1811
brain	NOUN	O	O	1811
concentration	NOUN	O	O	1811
of	ADP	O	O	1811
GABA	PROPN	O	Chemical	1811
and	CCONJ	O	O	1811
dopamine	NOUN	O	Chemical	1811
.	PUNCT	O	O	1811
Lindane	NOUN	O	O	1812
(	PUNCT	O	O	1812
gamma	PROPN	O	O	1812
-	PUNCT	O	O	1812
hexachlorocyclohexane	VERB	O	O	1812
)	PUNCT	O	O	1812
is	AUX	O	O	1812
an	PRON	O	O	1812
organochlorine	PROPN	O	O	1812
insecticide	NOUN	O	O	1812
with	ADP	O	O	1812
known	VERB	O	O	1812
neurotoxic	ADJ	O	Disease	1812
effects	NOUN	O	O	1812
.	PUNCT	O	O	1812
Its	PRON	O	O	1813
mechanism	NOUN	O	O	1813
of	ADP	O	O	1813
action	NOUN	O	O	1813
is	AUX	O	O	1813
not	PART	O	O	1813
well	ADV	O	O	1813
understood	VERB	O	O	1813
although	SCONJ	O	O	1813
it	PRON	O	O	1813
has	VERB	O	O	1813
been	AUX	O	O	1813
proposed	VERB	O	O	1813
that	SCONJ	O	O	1813
lindane	NOUN	O	Chemical	1813
acts	VERB	O	O	1813
as	ADP	O	O	1813
a	PRON	O	O	1813
non	ADJ	O	O	1813
-	PUNCT	O	O	1813
competitive	ADJ	O	O	1813
antagonist	NOUN	O	O	1813
at	ADP	O	O	1813
the	PRON	O	O	1813
gamma	PROPN	O	O	1813
-	PUNCT	O	O	1813
aminobutyric	PROPN	O	O	1813
acid	PROPN	O	O	1813
(	PUNCT	O	O	1813
GABA)-A	NUM	O	O	1813
receptor	NOUN	O	O	1813
.	PUNCT	O	O	1813
We	PRON	O	O	1814
studied	VERB	O	O	1814
the	PRON	O	O	1814
effect	VERB	O	O	1814
of	ADP	O	O	1814
lindane	NOUN	O	Chemical	1814
(	PUNCT	O	O	1814
150	NUM	O	O	1814
mg	VERB	O	O	1814
/	PUNCT	O	O	1814
kg	VERB	O	O	1814
)	PUNCT	O	O	1814
on	ADP	O	O	1814
the	PRON	O	O	1814
GABAergic	PROPN	O	O	1814
and	CCONJ	O	O	1814
dopaminergic	ADJ	O	O	1814
systems	NOUN	O	O	1814
by	ADP	O	O	1814
measuring	VERB	O	O	1814
the	PRON	O	O	1814
concentration	NOUN	O	O	1814
of	ADP	O	O	1814
GABA	PROPN	O	Chemical	1814
,	PUNCT	O	O	1814
dopamine	NOUN	O	Chemical	1814
and	CCONJ	O	O	1814
its	PRON	O	O	1814
metabolites	VERB	O	O	1814
in	ADP	O	O	1814
7	NUM	O	O	1814
brain	NOUN	O	O	1814
areas	NOUN	O	O	1814
at	ADP	O	O	1814
the	PRON	O	O	1814
onset	VERB	O	O	1814
of	ADP	O	O	1814
seizures	NOUN	O	Disease	1814
.	PUNCT	O	O	1814
All	PRON	O	O	1815
animals	NOUN	O	O	1815
suffered	VERB	O	O	1815
tonic	PROPN	O	O	1815
convulsions	NOUN	O	Disease	1815
at	ADP	O	O	1815
18.3	NUM	O	O	1815
1.4	NUM	O	O	1816
min	NOUN	O	O	1816
after	ADP	O	O	1816
lindane	NOUN	O	Chemical	1816
administration	NOUN	O	O	1816
.	PUNCT	O	O	1816
The	PRON	O	O	1817
concentration	NOUN	O	O	1817
of	ADP	O	O	1817
GABA	PROPN	O	Chemical	1817
was	AUX	O	O	1817
only	ADV	O	O	1817
slightly	ADV	O	O	1817
but	CCONJ	O	O	1817
significantly	ADV	O	O	1817
decreased	VERB	O	O	1817
in	ADP	O	O	1817
the	PRON	O	O	1817
colliculi	NOUN	O	O	1817
without	ADP	O	O	1817
modifications	NOUN	O	O	1817
in	ADP	O	O	1817
the	PRON	O	O	1817
other	ADJ	O	O	1817
areas	NOUN	O	O	1817
.	PUNCT	O	O	1817
The	PRON	O	O	1818
concentration	NOUN	O	O	1818
of	ADP	O	O	1818
dopamine	NOUN	O	Chemical	1818
was	AUX	O	O	1818
increased	VERB	O	O	1818
in	ADP	O	O	1818
the	PRON	O	O	1818
mesencephalon	NOUN	O	O	1818
and	CCONJ	O	O	1818
that	SCONJ	O	O	1818
of	ADP	O	O	1818
its	PRON	O	O	1818
metabolite	NOUN	O	O	1818
DOPAC	PROPN	O	Chemical	1818
was	AUX	O	O	1818
also	ADV	O	O	1818
increased	VERB	O	O	1818
in	ADP	O	O	1818
the	PRON	O	O	1818
mesencephalon	NOUN	O	O	1818
and	CCONJ	O	O	1818
the	PRON	O	O	1818
striatum	NOUN	O	O	1818
.	PUNCT	O	O	1818
Two	NUM	O	O	1821
cases	NOUN	O	O	1821
of	ADP	O	O	1821
propylthiouracil	NOUN	O	Chemical	1821
-	PUNCT	O	O	1821
associated	VERB	O	O	1821
acute	ADJ	O	O	1821
hepatitis	NOUN	O	Disease	1821
,	PUNCT	O	O	1821
one	NUM	O	O	1821
case	NOUN	O	O	1821
of	ADP	O	O	1821
fatal	ADJ	O	O	1821
methimazole	VERB	O	Chemical	1821
-	PUNCT	O	O	1821
associated	VERB	O	O	1821
hepatocellular	NOUN	O	O	1821
necrosis	NOUN	O	Disease	1821
and	CCONJ	O	O	1821
one	NUM	O	O	1821
case	NOUN	O	O	1821
of	ADP	O	O	1821
propylthiouracil	NOUN	O	Chemical	1821
-	PUNCT	O	O	1821
associated	VERB	O	O	1821
lupus	PROPN	O	Disease	1821
-	PUNCT	O	O	1821
like	INTJ	O	O	1821
syndrome	NOUN	O	O	1821
are	AUX	O	O	1821
described	VERB	O	O	1821
.	PUNCT	O	O	1821
It	PRON	O	O	1822
is	AUX	O	O	1822
concluded	VERB	O	O	1822
that	SCONJ	O	O	1822
in	ADP	O	O	1822
most	ADV	O	O	1822
circumstances	NOUN	O	O	1822
131I	NUM	O	O	1822
is	AUX	O	O	1822
the	PRON	O	O	1822
therapy	NOUN	O	O	1822
of	ADP	O	O	1822
choice	NOUN	O	O	1822
for	ADP	O	O	1822
hyperthyroidism	NOUN	O	Disease	1822
.	PUNCT	O	O	1822
Anticonvulsant	NOUN	O	O	1825
actions	NOUN	O	O	1825
of	ADP	O	O	1825
MK-801	PROPN	O	Chemical	1825
on	ADP	O	O	1825
the	PRON	O	O	1825
lithium	NOUN	O	Chemical	1825
-	PUNCT	O	O	1825
pilocarpine	NOUN	O	Chemical	1825
model	NOUN	O	O	1825
of	ADP	O	O	1825
status epilepticus	VERB	O	Disease	1825
in	ADP	O	O	1825
rats	NOUN	O	O	1825
.	PUNCT	O	O	1825
MK-801	PROPN	O	Chemical	1826
,	PUNCT	O	O	1826
a	PRON	O	O	1826
noncompetitive	ADJ	O	O	1826
N	NUM	O	O	1826
-	PUNCT	O	O	1826
methyl	NOUN	O	O	1826
-	PUNCT	O	O	1826
D	NOUN	O	O	1826
-	PUNCT	O	O	1826
aspartate	NOUN	O	Chemical	1826
(	PUNCT	O	O	1826
NMDA	PROPN	O	Chemical	1826
)	PUNCT	O	O	1826
receptor	NOUN	O	O	1826
antagonist	NOUN	O	O	1826
,	PUNCT	O	O	1826
was	AUX	O	O	1826
tested	VERB	O	O	1826
for	ADP	O	O	1826
anticonvulsant	ADJ	O	O	1826
effects	NOUN	O	O	1826
in	ADP	O	O	1826
rats	NOUN	O	O	1826
using	VERB	O	O	1826
two	NUM	O	O	1826
seizure	NOUN	O	Disease	1826
models	NOUN	O	O	1826
,	PUNCT	O	O	1826
coadministration	NOUN	O	O	1826
of	ADP	O	O	1826
lithium	NOUN	O	Chemical	1826
and	CCONJ	O	O	1826
pilocarpine	NOUN	O	Chemical	1826
and	CCONJ	O	O	1826
administration	NOUN	O	O	1826
of	ADP	O	O	1826
a	PRON	O	O	1826
high	ADJ	O	O	1826
dose	NOUN	O	O	1826
of	ADP	O	O	1826
pilocarpine	NOUN	O	Chemical	1826
alone	ADV	O	O	1826
.	PUNCT	O	O	1826
First	ADV	O	O	1827
,	PUNCT	O	O	1827
pretreatment	NOUN	O	O	1827
with	ADP	O	O	1827
MK-801	PROPN	O	Chemical	1827
produced	VERB	O	O	1827
an	PRON	O	O	1827
effective	ADJ	O	O	1827
and	CCONJ	O	O	1827
dose	NOUN	O	O	1827
-	PUNCT	O	O	1827
dependent	ADJ	O	O	1827
anticonvulsant	ADJ	O	O	1827
action	NOUN	O	O	1827
with	ADP	O	O	1827
the	PRON	O	O	1827
lithium	NOUN	O	Chemical	1827
-	PUNCT	O	O	1827
pilocarpine	NOUN	O	Chemical	1827
model	NOUN	O	O	1827
but	CCONJ	O	O	1827
not	PART	O	O	1827
with	ADP	O	O	1827
rats	NOUN	O	O	1827
treated	VERB	O	O	1827
with	ADP	O	O	1827
pilocarpine	NOUN	O	Chemical	1827
alone	ADV	O	O	1827
,	PUNCT	O	O	1827
suggesting	VERB	O	O	1827
that	SCONJ	O	O	1827
different	ADJ	O	O	1827
biochemical	ADJ	O	O	1827
mechanisms	NOUN	O	O	1827
control	VERB	O	O	1827
seizures	NOUN	O	Disease	1827
in	ADP	O	O	1827
these	PRON	O	O	1827
two	NUM	O	O	1827
models	NOUN	O	O	1827
.	PUNCT	O	O	1827
Second	ADJ	O	O	1828
,	PUNCT	O	O	1828
the	PRON	O	O	1828
anticonvulsant	ADJ	O	O	1828
effect	VERB	O	O	1828
of	ADP	O	O	1828
MK-801	PROPN	O	Chemical	1828
in	ADP	O	O	1828
the	PRON	O	O	1828
lithium	NOUN	O	Chemical	1828
-	PUNCT	O	O	1828
pilocarpine	NOUN	O	Chemical	1828
model	NOUN	O	O	1828
only	ADV	O	O	1828
occurred	VERB	O	O	1828
after	ADP	O	O	1828
initial	ADJ	O	O	1828
periods	NOUN	O	O	1828
of	ADP	O	O	1828
seizure	NOUN	O	Disease	1828
activity	NOUN	O	O	1828
.	PUNCT	O	O	1828
This	PRON	O	O	1829
observation	NOUN	O	O	1829
is	AUX	O	O	1829
suggested	VERB	O	O	1829
to	PART	O	O	1829
be	AUX	O	O	1829
an	PRON	O	O	1829
in	ADP	O	O	1829
vivo	VERB	O	O	1829
demonstration	NOUN	O	O	1829
of	ADP	O	O	1829
the	PRON	O	O	1829
conclusion	NOUN	O	O	1829
derived	VERB	O	O	1829
from	ADP	O	O	1829
in	ADP	O	O	1829
vitro	X	O	O	1829
experiments	NOUN	O	O	1829
that	SCONJ	O	O	1829
MK-801	PROPN	O	Chemical	1829
binding	VERB	O	O	1829
requires	VERB	O	O	1829
agonist	NOUN	O	O	1829
-	PUNCT	O	O	1829
induced	VERB	O	O	1829
opening	VERB	O	O	1829
of	ADP	O	O	1829
the	PRON	O	O	1829
channel	PROPN	O	O	1829
sites	NOUN	O	O	1829
of	ADP	O	O	1829
the	PRON	O	O	1829
NMDA	PROPN	O	Chemical	1829
receptor	NOUN	O	O	1829
.	PUNCT	O	O	1829
Third	ADJ	O	O	1830
,	PUNCT	O	O	1830
although	SCONJ	O	O	1830
it	PRON	O	O	1830
is	AUX	O	O	1830
relatively	ADV	O	O	1830
easy	ADV	O	O	1830
to	PART	O	O	1830
block	NOUN	O	O	1830
seizures	NOUN	O	Disease	1830
induced	VERB	O	O	1830
by	ADP	O	O	1830
lithium	NOUN	O	Chemical	1830
and	CCONJ	O	O	1830
pilocarpine	NOUN	O	Chemical	1830
by	ADP	O	O	1830
administration	NOUN	O	O	1830
of	ADP	O	O	1830
anticonvulsants	NOUN	O	O	1830
prior	ADV	O	O	1830
to	PART	O	O	1830
pilocarpine	NOUN	O	Chemical	1830
,	PUNCT	O	O	1830
it	PRON	O	O	1830
is	AUX	O	O	1830
more	ADJ	O	O	1830
difficult	ADJ	O	O	1830
to	PART	O	O	1830
terminate	VERB	O	O	1830
ongoing	ADJ	O	O	1830
status epilepticus	VERB	O	Disease	1830
and	CCONJ	O	O	1830
block	NOUN	O	O	1830
the	PRON	O	O	1830
lethality	NOUN	O	O	1830
of	ADP	O	O	1830
the	PRON	O	O	1830
seizures	NOUN	O	Disease	1830
.	PUNCT	O	O	1830
Administration	NOUN	O	O	1831
of	ADP	O	O	1831
MK-801	PROPN	O	Chemical	1831
30	NUM	O	O	1831
or	CCONJ	O	O	1831
60	NUM	O	O	1831
min	NOUN	O	O	1831
after	ADP	O	O	1831
pilocarpine	NOUN	O	Chemical	1831
,	PUNCT	O	O	1831
i.e.	X	O	O	1831
,	PUNCT	O	O	1831
during	ADP	O	O	1831
status epilepticus	VERB	O	Disease	1831
,	PUNCT	O	O	1831
gradually	ADV	O	O	1831
reduced	VERB	O	O	1831
electrical	ADJ	O	O	1831
and	CCONJ	O	O	1831
behavioral	ADJ	O	O	1831
seizure	NOUN	O	Disease	1831
activity	NOUN	O	O	1831
and	CCONJ	O	O	1831
greatly	ADV	O	O	1831
enhanced	VERB	O	O	1831
the	PRON	O	O	1831
survival	NOUN	O	O	1831
rate	NOUN	O	O	1831
.	PUNCT	O	O	1831
These	PRON	O	O	1832
results	VERB	O	O	1832
suggest	VERB	O	O	1832
that	SCONJ	O	O	1832
activation	NOUN	O	O	1832
of	ADP	O	O	1832
NMDA	PROPN	O	Chemical	1832
receptors	NOUN	O	O	1832
plays	VERB	O	O	1832
an	PRON	O	O	1832
important	ADJ	O	O	1832
role	NOUN	O	O	1832
in	ADP	O	O	1832
status epilepticus	VERB	O	Disease	1832
and	CCONJ	O	O	1832
brain damage	NOUN	O	Disease	1832
in	ADP	O	O	1832
the	PRON	O	O	1832
lithium	NOUN	O	Chemical	1832
-	PUNCT	O	O	1832
pilocarpine	NOUN	O	Chemical	1832
model	NOUN	O	O	1832
.	PUNCT	O	O	1832
This	PRON	O	O	1833
was	AUX	O	O	1833
further	ADV	O	O	1833
supported	VERB	O	O	1833
by	ADP	O	O	1833
results	VERB	O	O	1833
showing	VERB	O	O	1833
that	SCONJ	O	O	1833
nonconvulsive	ADJ	O	O	1833
doses	NOUN	O	O	1833
of	ADP	O	O	1833
NMDA	PROPN	O	Chemical	1833
and	CCONJ	O	O	1833
pilocarpine	NOUN	O	Chemical	1833
were	AUX	O	O	1833
synergistic	ADJ	O	O	1833
,	PUNCT	O	O	1833
resulting	VERB	O	O	1833
in	ADP	O	O	1833
status epilepticus	VERB	O	Disease	1833
and	CCONJ	O	O	1833
subsequent	ADJ	O	O	1833
mortality	NOUN	O	O	1833
.	PUNCT	O	O	1833
Nifedipine	NOUN	O	O	1836
induced	VERB	O	O	1836
bradycardia	NOUN	O	Disease	1836
in	ADP	O	O	1836
a	PRON	O	O	1836
patient	NOUN	O	O	1836
with	ADP	O	O	1836
autonomic	ADJ	O	O	1836
neuropathy	NOUN	O	Disease	1836
.	PUNCT	O	O	1836
An	PRON	O	O	1837
80	NUM	O	O	1837
year	NOUN	O	O	1837
old	ADJ	O	O	1837
diabetic	ADJ	O	Disease	1837
male	NOUN	O	O	1837
with	ADP	O	O	1837
evidence	NOUN	O	O	1837
of	ADP	O	O	1837
peripheral	ADJ	O	O	1837
and	CCONJ	O	O	1837
autonomic	ADJ	O	O	1837
neuropathy	NOUN	O	Disease	1837
was	AUX	O	O	1837
admitted	VERB	O	O	1837
with	ADP	O	O	1837
chest pain	NOUN	O	Disease	1837
.	PUNCT	O	O	1837
He	PRON	O	O	1838
was	AUX	O	O	1838
found	VERB	O	O	1838
to	PART	O	O	1838
have	VERB	O	O	1838
atrial flutter	NOUN	O	Disease	1838
at	ADP	O	O	1838
a	PRON	O	O	1838
ventricular	ADJ	O	O	1838
rate	NOUN	O	O	1838
of	ADP	O	O	1838
70/min	NOUN	O	O	1838
which	PRON	O	O	1838
slowed	VERB	O	O	1838
down	ADP	O	O	1838
to	PART	O	O	1838
30	NUM	O	O	1838
-	PUNCT	O	O	1838
40/min	NOUN	O	O	1838
when	SCONJ	O	O	1838
nifedipine	PROPN	O	Chemical	1838
(	PUNCT	O	O	1838
60	NUM	O	O	1838
mg	VERB	O	O	1838
)	PUNCT	O	O	1838
in	ADP	O	O	1838
3	X	O	O	1838
divided	VERB	O	O	1838
doses	NOUN	O	O	1838
,	PUNCT	O	O	1838
during	ADP	O	O	1838
which	PRON	O	O	1838
he	PRON	O	O	1838
was	AUX	O	O	1838
paced	ADJ	O	O	1838
at	ADP	O	O	1838
a	PRON	O	O	1838
rate	NOUN	O	O	1838
of	ADP	O	O	1838
70/min	NOUN	O	O	1838
.	PUNCT	O	O	1838
This	PRON	O	O	1839
is	AUX	O	O	1839
inconsistent	ADJ	O	O	1839
with	ADP	O	O	1839
the	PRON	O	O	1839
well	ADV	O	O	1839
-	PUNCT	O	O	1839
established	VERB	O	O	1839
finding	VERB	O	O	1839
that	SCONJ	O	O	1839
nifedipine	PROPN	O	Chemical	1839
induces	VERB	O	O	1839
tachycardia	PROPN	O	Disease	1839
in	ADP	O	O	1839
normally	ADV	O	O	1839
innervated	VERB	O	O	1839
hearts	NOUN	O	O	1839
.	PUNCT	O	O	1839
However	ADV	O	O	1840
,	PUNCT	O	O	1840
in	ADP	O	O	1840
hearts	NOUN	O	O	1840
deprived	VERB	O	O	1840
of	ADP	O	O	1840
compensatory	ADJ	O	O	1840
sympathetic	ADJ	O	O	1840
drive	VERB	O	O	1840
,	PUNCT	O	O	1840
it	PRON	O	O	1840
may	AUX	O	O	1840
lead	VERB	O	Chemical	1840
to	PART	O	O	1840
bradycardia	NOUN	O	Disease	1840
.	PUNCT	O	O	1840
The	PRON	O	O	1843
effect	VERB	O	O	1843
of	ADP	O	O	1843
haloperidol	NOUN	O	Chemical	1843
in	ADP	O	O	1843
cocaine	NOUN	O	Chemical	1843
and	CCONJ	O	O	1843
amphetamine	NOUN	O	Chemical	1843
intoxication	NOUN	O	O	1843
.	PUNCT	O	O	1843
The	PRON	O	O	1844
effectiveness	NOUN	O	O	1844
of	ADP	O	O	1844
haloperidol	NOUN	O	Chemical	1844
pretreatment	NOUN	O	O	1844
in	ADP	O	O	1844
preventing	VERB	O	O	1844
the	PRON	O	O	1844
toxic	ADJ	O	O	1844
effects	NOUN	O	O	1844
of	ADP	O	O	1844
high	ADJ	O	O	1844
doses	NOUN	O	O	1844
of	ADP	O	O	1844
amphetamine	NOUN	O	Chemical	1844
and	CCONJ	O	O	1844
cocaine	NOUN	O	Chemical	1844
was	AUX	O	O	1844
studied	VERB	O	O	1844
in	ADP	O	O	1844
rats	NOUN	O	O	1844
.	PUNCT	O	O	1844
injection	NOUN	O	O	1845
of	ADP	O	O	1845
amphetamine	NOUN	O	Chemical	1845
75	NUM	O	O	1845
mg	VERB	O	O	1845
/	PUNCT	O	O	1845
kg	VERB	O	O	1845
(	PUNCT	O	O	1845
100%	NOUN	O	O	1845
death	NOUN	O	O	1845
rate	NOUN	O	O	1845
)	PUNCT	O	O	1845
or	CCONJ	O	O	1845
cocaine	NOUN	O	Chemical	1845
70	NUM	O	O	1845
mg	VERB	O	O	1845
/	PUNCT	O	O	1845
kg	VERB	O	O	1845
(	PUNCT	O	O	1845
82%	NOUN	O	O	1845
death	NOUN	O	O	1845
rate	NOUN	O	O	1845
)	PUNCT	O	O	1845
.	PUNCT	O	O	1845
Haloperidol	NOUN	O	Chemical	1846
failed	VERB	O	O	1846
to	PART	O	O	1846
prevent	VERB	O	O	1846
amphetamine	NOUN	O	Chemical	1846
-	PUNCT	O	O	1846
induced	VERB	O	O	1846
seizures	NOUN	O	Disease	1846
,	PUNCT	O	O	1846
but	CCONJ	O	O	1846
did	VERB	O	O	1846
lower	ADJ	O	O	1846
the	PRON	O	O	1846
mortality	NOUN	O	O	1846
rate	NOUN	O	O	1846
at	ADP	O	O	1846
most	ADV	O	O	1846
doses	NOUN	O	O	1846
tested	VERB	O	O	1846
.	PUNCT	O	O	1846
Haloperidol	NOUN	O	Chemical	1847
decreased	VERB	O	O	1847
the	PRON	O	O	1847
incidence	NOUN	O	O	1847
of	ADP	O	O	1847
cocaine	NOUN	O	Chemical	1847
-	PUNCT	O	O	1847
induced	VERB	O	O	1847
seizures	NOUN	O	Disease	1847
at	ADP	O	O	1847
the	PRON	O	O	1847
two	NUM	O	O	1847
highest	ADJ	O	O	1847
doses	NOUN	O	O	1847
,	PUNCT	O	O	1847
but	CCONJ	O	O	1847
the	PRON	O	O	1847
lowering	VERB	O	O	1847
of	ADP	O	O	1847
the	PRON	O	O	1847
mortality	NOUN	O	O	1847
rate	NOUN	O	O	1847
did	VERB	O	O	1847
not	PART	O	O	1847
reach	VERB	O	O	1847
statistical	ADJ	O	O	1847
significance	NOUN	O	O	1847
at	ADP	O	O	1847
any	PRON	O	O	1847
dose	NOUN	O	O	1847
.	PUNCT	O	O	1847
These	PRON	O	O	1848
data	NOUN	O	O	1848
suggest	VERB	O	O	1848
a	PRON	O	O	1848
protective	ADJ	O	O	1848
role	NOUN	O	O	1848
for	ADP	O	O	1848
the	PRON	O	O	1848
central	ADJ	O	O	1848
dopamine	NOUN	O	Chemical	1848
blocker	NOUN	O	O	1848
haloperidol	NOUN	O	Chemical	1848
against	ADP	O	O	1848
death	NOUN	O	O	1848
from	ADP	O	O	1848
high	ADJ	O	O	1848
-	PUNCT	O	O	1848
dose	NOUN	O	O	1848
amphetamine	NOUN	O	Chemical	1848
exposure	NOUN	O	O	1848
without	ADP	O	O	1848
reducing	VERB	O	O	1848
the	PRON	O	O	1848
incidence	NOUN	O	O	1848
of	ADP	O	O	1848
seizures	NOUN	O	Disease	1848
.	PUNCT	O	O	1848
In	ADP	O	O	1849
contrast	NOUN	O	O	1849
,	PUNCT	O	O	1849
haloperidol	NOUN	O	Chemical	1849
demonstrated	VERB	O	O	1849
an	PRON	O	O	1849
ability	NOUN	O	O	1849
to	PART	O	O	1849
reduce	VERB	O	O	1849
cocaine	NOUN	O	Chemical	1849
-	PUNCT	O	O	1849
induced	VERB	O	O	1849
seizures	NOUN	O	Disease	1849
without	ADP	O	O	1849
significantly	ADV	O	O	1849
reducing	VERB	O	O	1849
mortality	NOUN	O	O	1849
.	PUNCT	O	O	1849
Autoradiographic	PROPN	O	O	1852
evidence	NOUN	O	O	1852
of	ADP	O	O	1852
estrogen	PROPN	O	Chemical	1852
binding	VERB	O	O	1852
sites	NOUN	O	O	1852
in	ADP	O	O	1852
nuclei	NOUN	O	O	1852
of	ADP	O	O	1852
diethylstilbesterol	NOUN	O	O	1852
induced	VERB	O	O	1852
hamster	NOUN	O	O	1852
renal	ADJ	O	O	1852
carcinomas	VERB	O	O	1852
.	PUNCT	O	O	1852
Estrogen	NOUN	O	O	1853
binding	VERB	O	O	1853
sites	NOUN	O	O	1853
were	AUX	O	O	1853
demonstrated	VERB	O	O	1853
by	ADP	O	O	1853
autoradiography	NOUN	O	O	1853
in	ADP	O	O	1853
one	NUM	O	O	1853
transplantable	ADJ	O	O	1853
and	CCONJ	O	O	1853
five	NUM	O	O	1853
primary	NOUN	O	O	1853
diethylstilbesterol	NOUN	O	O	1853
induced	VERB	O	O	1854
renal	ADJ	O	O	1854
carcinomas	VERB	O	O	1854
in	ADP	O	O	1854
three	NUM	O	O	1854
hamsters	NOUN	O	O	1854
.	PUNCT	O	O	1854
Radiolabelling	VERB	O	O	1855
,	PUNCT	O	O	1855
following	VERB	O	O	1855
the	PRON	O	O	1855
in	ADP	O	O	1855
vivo	VERB	O	O	1855
injection	NOUN	O	O	1855
of	ADP	O	O	1855
3H-17	NUM	O	O	1855
beta	NOUN	O	O	1855
estradiol	VERB	O	Chemical	1855
,	PUNCT	O	O	1855
was	AUX	O	O	1855
increased	VERB	O	O	1855
only	ADV	O	O	1855
over	ADP	O	O	1855
the	PRON	O	O	1855
nuclei	NOUN	O	O	1855
of	ADP	O	O	1855
tumor	NOUN	O	Disease	1855
cells	NOUN	O	O	1855
;	PUNCT	O	O	1855
stereologic	ADJ	O	O	1855
analysis	NOUN	O	O	1855
revealed	VERB	O	O	1855
a	PRON	O	O	1855
4.5-	NUM	O	O	1855
to	PART	O	O	1855
6.7-times	NOUN	O	O	1855
higher	ADJ	O	O	1855
concentration	NOUN	O	O	1855
of	ADP	O	O	1855
reduced	VERB	O	O	1855
silver	NOUN	O	O	1855
grains	NOUN	O	O	1855
over	ADP	O	O	1855
nuclei	NOUN	O	O	1855
than	ADP	O	O	1855
cytoplasm	ADJ	O	O	1855
of	ADP	O	O	1855
these	PRON	O	O	1855
cells	NOUN	O	O	1855
.	PUNCT	O	O	1855
Despite	SCONJ	O	O	1856
rapid	ADJ	O	O	1856
tubular	ADJ	O	O	1856
excretion	NOUN	O	O	1856
of	ADP	O	O	1856
estradiol	VERB	O	Chemical	1856
which	PRON	O	O	1856
peaked	VERB	O	O	1856
in	ADP	O	O	1856
less	ADV	O	O	1856
than	ADP	O	O	1856
1	X	O	O	1856
This	PRON	O	O	1857
is	AUX	O	O	1857
the	PRON	O	O	1857
first	ADV	O	O	1857
published	VERB	O	O	1857
report	VERB	O	O	1857
documenting	VERB	O	O	1857
the	PRON	O	O	1857
preferential	ADJ	O	O	1857
in	ADP	O	O	1857
vivo	VERB	O	O	1857
binding	VERB	O	O	1857
of	ADP	O	O	1857
estrogen	PROPN	O	Chemical	1857
to	PART	O	O	1857
nuclei	NOUN	O	O	1857
of	ADP	O	O	1857
cells	NOUN	O	O	1857
in	ADP	O	O	1857
estrogen	PROPN	O	Chemical	1857
induced	VERB	O	O	1857
hamster	NOUN	O	O	1857
renal	ADJ	O	O	1857
carcinomas	VERB	O	O	1857
.	PUNCT	O	O	1857
Bradycardia	PROPN	O	Disease	1860
due	ADJ	O	O	1860
to	PART	O	O	1860
biperiden	VERB	O	Chemical	1860
.	PUNCT	O	O	1860
In	ADP	O	O	1861
a	PRON	O	O	1861
38-year	NOUN	O	O	1861
-	PUNCT	O	O	1861
old	ADJ	O	O	1861
male	NOUN	O	O	1861
patient	NOUN	O	O	1861
suffering	VERB	O	O	1861
from	ADP	O	O	1861
a	PRON	O	O	1861
severe	ADJ	O	O	1861
postzosteric	PROPN	O	O	1861
trigeminal	ADJ	O	O	1861
neuralgia	NOUN	O	Disease	1861
,	PUNCT	O	O	1861
intravenous	ADJ	O	O	1861
application	NOUN	O	O	1861
of	ADP	O	O	1861
10	NUM	O	O	1861
mg	VERB	O	O	1861
biperiden	VERB	O	Chemical	1861
lactate	NOUN	O	Chemical	1861
led	VERB	O	O	1861
to	PART	O	O	1861
a	PRON	O	O	1861
long	ADV	O	O	1861
-	PUNCT	O	O	1861
lasting	VERB	O	O	1861
paradoxical	ADJ	O	O	1861
reaction	NOUN	O	O	1861
characterized	VERB	O	O	1861
by	ADP	O	O	1861
considerable	ADJ	O	O	1861
bradycardia	NOUN	O	Disease	1861
,	PUNCT	O	O	1861
dysarthria	NOUN	O	O	1861
,	PUNCT	O	O	1861
and	CCONJ	O	O	1861
dysphagia	NOUN	O	O	1861
.	PUNCT	O	O	1861
The	PRON	O	O	1862
heart	NOUN	O	O	1862
rate	NOUN	O	O	1862
was	AUX	O	O	1862
back	ADV	O	O	1862
to	PART	O	O	1862
normal	ADJ	O	O	1862
within	ADP	O	O	1862
12	NUM	O	O	1862
hours	NOUN	O	O	1862
upon	SCONJ	O	O	1862
administration	NOUN	O	O	1862
of	ADP	O	O	1862
orciprenaline	NOUN	O	O	1862
under	ADP	O	O	1862
cardiac	ADJ	O	O	1862
monitoring	NOUN	O	O	1862
in	ADP	O	O	1862
an	PRON	O	O	1862
intensive	ADJ	O	O	1862
care	VERB	O	O	1862
unit	NOUN	O	O	1862
.	PUNCT	O	O	1862
Bradycardia	PROPN	O	Disease	1863
induced	VERB	O	O	1863
by	ADP	O	O	1863
biperiden	VERB	O	Chemical	1863
is	AUX	O	O	1863
attributed	VERB	O	O	1863
to	PART	O	O	1863
the	PRON	O	O	1863
speed	NOUN	O	O	1863
of	ADP	O	O	1863
injection	NOUN	O	O	1863
and	CCONJ	O	O	1863
to	PART	O	O	1863
a	PRON	O	O	1863
dose	NOUN	O	O	1863
-	PUNCT	O	O	1863
related	ADJ	O	O	1863
dual	ADJ	O	O	1863
effect	VERB	O	O	1863
of	ADP	O	O	1863
atropine	NOUN	O	Chemical	1863
-	PUNCT	O	O	1863
like	INTJ	O	O	1863
drugs	NOUN	O	O	1863
on	ADP	O	O	1863
muscarine	PROPN	O	O	1863
receptors	NOUN	O	O	1863
.	PUNCT	O	O	1863
Deliberate	VERB	O	O	1866
hypotension	NOUN	O	Disease	1866
induced	VERB	O	O	1866
by	ADP	O	O	1866
labetalol	NOUN	O	Chemical	1866
with	ADP	O	O	1866
halothane	VERB	O	Chemical	1866
,	PUNCT	O	O	1866
enflurane	NOUN	O	Chemical	1866
or	CCONJ	O	O	1866
isoflurane	NOUN	O	Chemical	1866
for	ADP	O	O	1866
middle	ADJ	O	O	1866
-	PUNCT	O	O	1866
ear	NOUN	O	O	1866
surgery	NOUN	O	O	1866
.	PUNCT	O	O	1866
The	PRON	O	O	1867
feasibility	NOUN	O	O	1867
of	ADP	O	O	1867
using	VERB	O	O	1867
labetalol	NOUN	O	Chemical	1867
,	PUNCT	O	O	1867
an	PRON	O	O	1867
alpha-	X	O	O	1867
and	CCONJ	O	O	1867
beta	NOUN	O	O	1867
-	PUNCT	O	O	1867
adrenergic	NOUN	O	O	1867
blocking	VERB	O	O	1867
agent	NOUN	O	O	1867
,	PUNCT	O	O	1867
as	ADP	O	O	1867
a	PRON	O	O	1867
hypotensive	ADJ	O	Disease	1867
agent	NOUN	O	O	1867
in	ADP	O	O	1867
combination	NOUN	O	O	1867
with	ADP	O	O	1867
inhalation	NOUN	O	O	1867
anaesthetics	NOUN	O	O	1867
(	PUNCT	O	O	1867
halothane	VERB	O	Chemical	1867
,	PUNCT	O	O	1867
enflurane	NOUN	O	Chemical	1867
or	CCONJ	O	O	1867
isoflurane	NOUN	O	Chemical	1867
)	PUNCT	O	O	1867
was	AUX	O	O	1867
studied	VERB	O	O	1867
in	ADP	O	O	1867
23	NUM	O	O	1867
adult	NOUN	O	O	1867
patients	NOUN	O	O	1867
undergoing	VERB	O	O	1867
middle	ADJ	O	O	1867
-	PUNCT	O	O	1867
ear	NOUN	O	O	1867
surgery	NOUN	O	O	1867
.	PUNCT	O	O	1867
10	NUM	O	O	1868
min	NOUN	O	O	1868
in	ADP	O	O	1868
the	PRON	O	O	1868
halothane	VERB	O	Chemical	1868
(	PUNCT	O	O	1868
H	NOUN	O	Chemical	1868
)	PUNCT	O	O	1868
group	NOUN	O	O	1868
,	PUNCT	O	O	1868
from	ADP	O	O	1868
79	NUM	O	O	1868
+	ADP	O	O	1868
/-	PUNCT	O	O	1868
11	NUM	O	O	1869
min	NOUN	O	O	1869
in	ADP	O	O	1869
the	PRON	O	O	1869
enflurane	NOUN	O	Chemical	1869
(	PUNCT	O	O	1869
E	NOUN	O	Chemical	1869
)	PUNCT	O	O	1869
group	NOUN	O	O	1869
,	PUNCT	O	O	1869
and	CCONJ	O	O	1869
from	ADP	O	O	1869
80	NUM	O	O	1869
+	ADP	O	O	1869
/-	PUNCT	O	O	1869
15	NUM	O	O	1870
min	NOUN	O	O	1870
in	ADP	O	O	1870
the	PRON	O	O	1870
isoflurane	NOUN	O	Chemical	1870
(	PUNCT	O	O	1870
I	PRON	O	O	1870
)	PUNCT	O	O	1870
group	NOUN	O	O	1870
.	PUNCT	O	O	1870
The	PRON	O	O	1871
mean	VERB	O	O	1871
H	NOUN	O	Chemical	1871
concentration	NOUN	O	O	1871
during	ADP	O	O	1871
hypotension	NOUN	O	Disease	1871
in	ADP	O	O	1871
the	PRON	O	O	1871
inspiratory	NOUN	O	O	1871
gas	NOUN	O	O	1871
was	AUX	O	O	1871
0.7	NUM	O	O	1871
+	ADP	O	O	1871
/-	PUNCT	O	O	1871
0.1	NUM	O	O	1872
vol%	NOUN	O	O	1872
,	PUNCT	O	O	1872
the	PRON	O	O	1872
mean	VERB	O	O	1872
E	NOUN	O	Chemical	1872
concentration	NOUN	O	O	1872
1.6	NUM	O	O	1872
+	ADP	O	O	1872
/-	PUNCT	O	O	1872
I	PRON	O	O	1873
concentration	NOUN	O	O	1873
1.0	NUM	O	O	1873
+	ADP	O	O	1873
/-	PUNCT	O	O	1873
In	ADP	O	O	1874
addition	NOUN	O	O	1874
,	PUNCT	O	O	1874
the	PRON	O	O	1874
patients	NOUN	O	O	1874
received	VERB	O	O	1874
fentanyl	ADJ	O	Chemical	1874
and	CCONJ	O	O	1874
d	X	O	O	1874
-	PUNCT	O	O	1874
tubocurarine	NOUN	O	O	1874
.	PUNCT	O	O	1874
The	PRON	O	O	1875
initial	ADJ	O	O	1875
dose	NOUN	O	O	1875
of	ADP	O	O	1875
labetalol	NOUN	O	Chemical	1875
for	ADP	O	O	1875
lowering	VERB	O	O	1875
blood	NOUN	O	O	1875
pressure	NOUN	O	O	1875
was	AUX	O	O	1875
similar	ADJ	O	O	1875
,	PUNCT	O	O	1875
0.52	NUM	O	O	1875
-	PUNCT	O	O	1875
0.59	NUM	O	O	1875
mg	VERB	O	O	1875
/	PUNCT	O	O	1875
kg	VERB	O	O	1875
,	PUNCT	O	O	1875
in	ADP	O	O	1875
all	PRON	O	O	1875
the	PRON	O	O	1875
groups	NOUN	O	O	1875
.	PUNCT	O	O	1875
During	ADP	O	O	1876
hypotension	NOUN	O	Disease	1876
,	PUNCT	O	O	1876
the	PRON	O	O	1876
heart	NOUN	O	O	1876
rate	NOUN	O	O	1876
was	AUX	O	O	1876
stable	ADJ	O	O	1876
without	ADP	O	O	1876
tachy-	ADJ	O	O	1876
or	CCONJ	O	O	1876
bradycardia	NOUN	O	Disease	1876
.	PUNCT	O	O	1876
The	PRON	O	O	1877
operating	VERB	O	O	1877
conditions	NOUN	O	O	1877
regarding	VERB	O	O	1877
bleeding	VERB	O	Disease	1877
were	AUX	O	O	1877
estimated	VERB	O	O	1877
in	ADP	O	O	1877
a	PRON	O	O	1877
double	ADJ	O	O	1877
-	PUNCT	O	O	1877
blind	ADJ	O	Disease	1877
manner	VERB	O	O	1877
,	PUNCT	O	O	1877
and	CCONJ	O	O	1877
did	VERB	O	O	1877
not	PART	O	O	1877
differ	VERB	O	O	1877
significantly	ADV	O	O	1877
between	ADP	O	O	1877
the	PRON	O	O	1877
groups	NOUN	O	O	1877
.	PUNCT	O	O	1877
During	ADP	O	O	1878
hypotension	NOUN	O	Disease	1878
,	PUNCT	O	O	1878
the	PRON	O	O	1878
serum	NOUN	O	O	1878
creatinine	PROPN	O	Chemical	1878
concentration	NOUN	O	O	1878
rose	VERB	O	O	1878
significantly	ADV	O	O	1878
in	ADP	O	O	1878
all	PRON	O	O	1878
groups	NOUN	O	O	1878
from	ADP	O	O	1878
the	PRON	O	O	1878
values	NOUN	O	O	1878
before	ADP	O	O	1878
hypotension	NOUN	O	Disease	1878
and	CCONJ	O	O	1878
returned	VERB	O	O	1878
postoperatively	PROPN	O	O	1878
to	PART	O	O	1878
the	PRON	O	O	1878
initial	ADJ	O	O	1878
level	VERB	O	O	1878
in	ADP	O	O	1878
the	PRON	O	O	1878
other	ADJ	O	O	1878
groups	NOUN	O	O	1878
,	PUNCT	O	O	1878
except	SCONJ	O	O	1878
the	PRON	O	O	1878
isoflurane	NOUN	O	Chemical	1878
group	NOUN	O	O	1878
.	PUNCT	O	O	1878
After	ADP	O	O	1879
hypotension	NOUN	O	Disease	1879
there	ADV	O	O	1879
was	AUX	O	O	1879
no	PRON	O	O	1879
rebound	VERB	O	O	1879
phenomenon	NOUN	O	O	1879
in	ADP	O	O	1879
either	ADV	O	O	1879
blood	NOUN	O	O	1879
pressure	NOUN	O	O	1879
or	CCONJ	O	O	1879
heart	NOUN	O	O	1879
rate	NOUN	O	O	1879
.	PUNCT	O	O	1879
These	PRON	O	O	1880
results	VERB	O	O	1880
indicate	VERB	O	O	1880
that	SCONJ	O	O	1880
labetalol	NOUN	O	Chemical	1880
induces	VERB	O	O	1880
easily	ADV	O	O	1880
adjustable	ADJ	O	O	1880
hypotension	NOUN	O	Disease	1880
without	ADP	O	O	1880
compensatory	ADJ	O	O	1880
tachycardia	PROPN	O	Disease	1880
and	CCONJ	O	O	1880
rebound	VERB	O	O	1880
hypertension	NOUN	O	Disease	1880
.	PUNCT	O	O	1880
Convulsion	NOUN	O	O	1883
following	VERB	O	O	1883
intravenous	ADJ	O	O	1883
fluorescein	VERB	O	O	1883
angiography	NOUN	O	O	1883
.	PUNCT	O	O	1883
Tonic	NOUN	O	O	1884
-	PUNCT	O	O	1884
clonic	ADJ	O	O	1884
seizures	NOUN	O	Disease	1884
followed	VERB	O	O	1884
intravenous	ADJ	O	O	1884
fluorescein	VERB	O	O	1884
injection	NOUN	O	O	1884
for	ADP	O	O	1884
fundus	NOUN	O	O	1884
angiography	NOUN	O	O	1884
in	ADP	O	O	1884
a	PRON	O	O	1884
47-year	NOUN	O	O	1884
-	PUNCT	O	O	1884
old	ADJ	O	O	1884
male	NOUN	O	O	1884
.	PUNCT	O	O	1884
Despite	SCONJ	O	O	1885
precautions	NOUN	O	O	1885
this	PRON	O	O	1885
adverse	ADJ	O	O	1885
reaction	NOUN	O	O	1885
recurred	VERB	O	O	1885
on	ADP	O	O	1885
re	ADP	O	O	1885
-	PUNCT	O	O	1885
exposure	NOUN	O	O	1885
to	PART	O	O	1885
intravenous	ADJ	O	O	1885
fluorescein	VERB	O	O	1885
.	PUNCT	O	O	1885
Pharmacology	NOUN	O	O	1888
of	ADP	O	O	1888
ACC-9653	PROPN	O	O	1888
(	PUNCT	O	O	1888
phenytoin	NOUN	O	Chemical	1888
prodrug	NOUN	O	O	1888
)	PUNCT	O	O	1888
.	PUNCT	O	O	1888
ACC-9653	PROPN	O	O	1889
,	PUNCT	O	O	1889
the	PRON	O	O	1889
disodium	PROPN	O	O	1889
phosphate	NOUN	O	Chemical	1889
ester	PROPN	O	O	1889
of	ADP	O	O	1889
3-hydroxymethyl-5,5-diphenylhydantoin	NOUN	O	O	1889
,	PUNCT	O	O	1889
is	AUX	O	O	1889
a	PRON	O	O	1889
prodrug	NOUN	O	O	1889
of	ADP	O	O	1889
phenytoin	NOUN	O	Chemical	1889
with	ADP	O	O	1889
advantageous	ADJ	O	O	1889
physicochemical	ADJ	O	O	1889
properties	NOUN	O	O	1889
.	PUNCT	O	O	1889
ACC-9653	PROPN	O	O	1890
is	AUX	O	O	1890
rapidly	ADV	O	O	1890
converted	VERB	O	O	1890
enzymatically	ADV	O	O	1890
to	PART	O	O	1890
phenytoin	NOUN	O	Chemical	1890
in	ADP	O	O	1890
vivo	VERB	O	O	1890
.	PUNCT	O	O	1890
ACC-9653	PROPN	O	O	1891
and	CCONJ	O	O	1891
phenytoin	NOUN	O	Chemical	1891
sodium	NOUN	O	Chemical	1891
have	VERB	O	O	1892
equivalent	ADJ	O	O	1892
anticonvulsant	ADJ	O	O	1892
activity	NOUN	O	O	1892
against	ADP	O	O	1892
seizures	NOUN	O	Disease	1892
induced	VERB	O	O	1892
by	ADP	O	O	1892
maximal	ADJ	O	O	1892
electroshock	NOUN	O	O	1892
(	PUNCT	O	O	1892
MES	PROPN	O	O	1892
)	PUNCT	O	O	1892
in	ADP	O	O	1892
mice	NOUN	O	O	1892
following	VERB	O	O	1892
i.p	NOUN	O	O	1892
.	PUNCT	O	O	1892
ACC-9653	PROPN	O	O	1893
and	CCONJ	O	O	1893
8	NUM	O	O	1893
mg	VERB	O	O	1893
/	PUNCT	O	O	1893
kg	VERB	O	O	1893
for	ADP	O	O	1893
i.v	NOUN	O	O	1893
.	PUNCT	O	O	1893
phenytoin	NOUN	O	Chemical	1894
sodium	NOUN	O	Chemical	1894
.	PUNCT	O	O	1894
ACC-9653	PROPN	O	O	1895
and	CCONJ	O	O	1895
phenytoin	NOUN	O	Chemical	1895
sodium	NOUN	O	Chemical	1895
have	VERB	O	O	1895
similar	ADJ	O	O	1895
antiarrhythmic	PROPN	O	O	1895
activity	NOUN	O	O	1895
against	ADP	O	O	1895
ouabain	PROPN	O	Chemical	1895
-	PUNCT	O	O	1895
induced	VERB	O	O	1895
ventricular tachycardia	NOUN	O	Disease	1895
in	ADP	O	O	1895
anesthetized	VERB	O	O	1895
dogs	NOUN	O	O	1895
.	PUNCT	O	O	1895
The	PRON	O	O	1896
total	ADJ	O	O	1896
doses	NOUN	O	O	1896
of	ADP	O	O	1896
ACC-9653	PROPN	O	O	1896
or	CCONJ	O	O	1896
phenytoin	NOUN	O	Chemical	1896
sodium	NOUN	O	Chemical	1896
necessary	ADJ	O	O	1896
to	PART	O	O	1896
convert	VERB	O	O	1896
the	PRON	O	O	1896
arrhythmia	NOUN	O	Disease	1896
to	PART	O	O	1896
a	PRON	O	O	1896
normal	ADJ	O	O	1896
sinus	NOUN	O	O	1896
rhythm	VERB	O	O	1896
were	AUX	O	O	1896
24	NUM	O	O	1896
+	ADP	O	O	1896
/-	PUNCT	O	O	1896
Only	ADV	O	O	1897
phenytoin	NOUN	O	Chemical	1897
sodium	NOUN	O	Chemical	1897
displayed	VERB	O	O	1897
in	ADP	O	O	1897
vitro	X	O	O	1897
antiarrhythmic	PROPN	O	O	1897
activity	NOUN	O	O	1897
against	ADP	O	O	1897
strophanthidin	VERB	O	O	1897
-	PUNCT	O	O	1897
induced	VERB	O	O	1897
arrhythmias	VERB	O	Disease	1897
in	ADP	O	O	1897
guinea	NOUN	O	O	1897
pig	NOUN	O	O	1897
right	ADV	O	O	1897
atria	ADV	O	O	1897
.	PUNCT	O	O	1897
In	ADP	O	O	1898
anesthetized	VERB	O	O	1898
dogs	NOUN	O	O	1898
,	PUNCT	O	O	1898
a	PRON	O	O	1898
high	ADJ	O	O	1898
dose	NOUN	O	O	1898
of	ADP	O	O	1898
ACC-9653	PROPN	O	O	1898
(	PUNCT	O	O	1898
31	NUM	O	O	1898
mg	VERB	O	O	1898
/	PUNCT	O	O	1898
kg	VERB	O	O	1898
)	PUNCT	O	O	1898
was	AUX	O	O	1898
infused	VERB	O	O	1898
over	ADP	O	O	1898
15	NUM	O	O	1898
,	PUNCT	O	O	1898
20	NUM	O	O	1898
,	PUNCT	O	O	1898
and	CCONJ	O	O	1898
30	NUM	O	O	1898
min	NOUN	O	O	1898
and	CCONJ	O	O	1898
the	PRON	O	O	1898
responses	NOUN	O	O	1898
were	AUX	O	O	1898
compared	VERB	O	O	1898
to	PART	O	O	1898
an	PRON	O	O	1898
equimolar	NOUN	O	O	1898
dose	NOUN	O	O	1898
of	ADP	O	O	1898
phenytoin	NOUN	O	Chemical	1898
sodium	NOUN	O	Chemical	1898
(	PUNCT	O	O	1898
21	NUM	O	O	1898
mg	VERB	O	O	1898
/	PUNCT	O	O	1898
kg	VERB	O	O	1898
)	PUNCT	O	O	1898
.	PUNCT	O	O	1898
The	PRON	O	O	1899
ACC-9653	PROPN	O	O	1899
and	CCONJ	O	O	1899
phenytoin	NOUN	O	Chemical	1899
sodium	NOUN	O	Chemical	1899
treatments	NOUN	O	O	1899
produced	VERB	O	O	1899
similar	ADJ	O	O	1899
marked	VERB	O	O	1899
reductions	NOUN	O	O	1899
in	ADP	O	O	1899
diastolic	ADV	O	O	1899
blood	NOUN	O	O	1899
pressure	NOUN	O	O	1899
and	CCONJ	O	O	1899
contractile	ADJ	O	O	1899
force	NOUN	O	O	1899
(	PUNCT	O	O	1899
LVdP	NOUN	O	O	1899
/	PUNCT	O	O	1899
dt	PROPN	O	O	1899
)	PUNCT	O	O	1899
.	PUNCT	O	O	1899
The	PRON	O	O	1900
maximum	ADV	O	O	1900
effects	NOUN	O	O	1900
of	ADP	O	O	1900
each	PRON	O	O	1900
treatment	NOUN	O	O	1900
occurred	VERB	O	O	1900
at	ADP	O	O	1900
the	PRON	O	O	1900
time	NOUN	O	O	1900
of	ADP	O	O	1900
maximum	ADV	O	O	1900
phenytoin	NOUN	O	Chemical	1900
sodium	NOUN	O	Chemical	1900
levels	NOUN	O	O	1900
.	PUNCT	O	O	1900
Acute	PROPN	O	O	1901
toxicity	NOUN	O	Disease	1901
studies	NOUN	O	O	1901
of	ADP	O	O	1901
ACC-9653	PROPN	O	O	1901
and	CCONJ	O	O	1901
phenytoin	NOUN	O	Chemical	1901
sodium	NOUN	O	Chemical	1901
were	AUX	O	O	1901
carried	VERB	O	O	1901
out	ADP	O	O	1901
in	ADP	O	O	1901
mice	NOUN	O	O	1901
,	PUNCT	O	O	1901
rats	NOUN	O	O	1901
,	PUNCT	O	O	1901
rabbits	NOUN	O	O	1901
,	PUNCT	O	O	1901
and	CCONJ	O	O	1901
dogs	NOUN	O	O	1901
by	ADP	O	O	1901
i.v	NOUN	O	O	1901
.	PUNCT	O	O	1901
Importantly	ADV	O	O	1902
,	PUNCT	O	O	1902
the	PRON	O	O	1902
local	ADJ	O	O	1902
irritation	NOUN	O	O	1902
of	ADP	O	O	1902
ACC-9653	PROPN	O	O	1902
was	AUX	O	O	1902
markedly	ADV	O	O	1902
less	ADV	O	O	1902
than	ADP	O	O	1902
phenytoin	NOUN	O	Chemical	1902
sodium	NOUN	O	Chemical	1902
following	VERB	O	O	1902
i.m	PROPN	O	O	1902
.	PUNCT	O	O	1902
Phenytoin	NOUN	O	O	1905
induced	VERB	O	O	1905
fatal	ADJ	O	O	1905
hepatic injury	NOUN	O	Disease	1905
.	PUNCT	O	O	1905
A	PRON	O	O	1906
61	NUM	O	O	1906
year	NOUN	O	O	1906
old	ADJ	O	O	1906
female	ADJ	O	O	1906
developed	VERB	O	O	1906
fatal	ADJ	O	O	1906
hepatic failure	NOUN	O	Disease	1906
after	ADP	O	O	1906
phenytoin	NOUN	O	Chemical	1906
administration	NOUN	O	O	1906
.	PUNCT	O	O	1906
A	PRON	O	O	1907
typical	ADJ	O	O	1907
multisystem	VERB	O	O	1907
clinical	ADJ	O	O	1907
pattern	NOUN	O	O	1907
precedes	VERB	O	O	1907
the	PRON	O	O	1907
manifestations	NOUN	O	O	1907
of	ADP	O	O	1907
hepatic injury	NOUN	O	Disease	1907
.	PUNCT	O	O	1907
The	PRON	O	O	1908
hematologic	ADJ	O	O	1908
,	PUNCT	O	O	1908
biochemical	ADJ	O	O	1908
and	CCONJ	O	O	1908
pathologic	ADJ	O	O	1908
features	VERB	O	O	1908
indicate	VERB	O	O	1908
a	PRON	O	O	1908
mixed	VERB	O	O	1908
hepatocellular	NOUN	O	O	1908
damage	NOUN	O	O	1908
due	ADJ	O	O	1908
to	PART	O	O	1908
drug	NOUN	O	O	1908
hypersensitivity	NOUN	O	Disease	1908
.	PUNCT	O	O	1908
In	ADP	O	O	1909
a	PRON	O	O	1909
patient	NOUN	O	O	1909
receiving	VERB	O	O	1909
phenytoin	NOUN	O	Chemical	1909
who	PRON	O	O	1909
presents	VERB	O	O	1909
a	PRON	O	O	1909
viral	ADJ	O	O	1909
-	PUNCT	O	O	1909
like	INTJ	O	O	1909
illness	VERB	O	O	1909
,	PUNCT	O	O	1909
early	ADV	O	O	1909
recognition	NOUN	O	O	1909
and	CCONJ	O	O	1909
discontinuation	NOUN	O	O	1909
of	ADP	O	O	1909
the	PRON	O	O	1909
drug	NOUN	O	O	1909
are	AUX	O	O	1909
mandatory	ADJ	O	O	1909
.	PUNCT	O	O	1909
Treatment	NOUN	O	O	1912
of	ADP	O	O	1912
lethal	ADJ	O	O	1912
pertussis	NOUN	O	O	1912
vaccine	NOUN	O	O	1912
reaction	NOUN	O	O	1912
with	ADP	O	O	1912
histamine	NOUN	O	Chemical	1912
H1	NOUN	O	O	1912
antagonists	NOUN	O	O	1912
.	PUNCT	O	O	1912
We	PRON	O	O	1913
studied	VERB	O	O	1913
mortality	NOUN	O	O	1913
after	ADP	O	O	1913
pertussis	NOUN	O	O	1913
immunization	NOUN	O	O	1913
in	ADP	O	O	1913
the	PRON	O	O	1913
mouse	PROPN	O	O	1913
.	PUNCT	O	O	1913
Without	ADP	O	O	1914
treatment	NOUN	O	O	1914
,	PUNCT	O	O	1914
73	NUM	O	O	1914
of	ADP	O	O	1914
92	NUM	O	O	1914
animals	NOUN	O	O	1914
(	PUNCT	O	O	1914
80%	NOUN	O	O	1914
)	PUNCT	O	O	1914
died	VERB	O	O	1914
after	ADP	O	O	1914
injection	NOUN	O	O	1914
of	ADP	O	O	1914
bovine	NOUN	O	O	1914
serum	NOUN	O	O	1914
albumin	PROPN	O	O	1914
(	PUNCT	O	O	1914
BSA	PROPN	O	O	1914
)	PUNCT	O	O	1914
on	ADP	O	O	1914
day	NOUN	O	O	1914
+	ADP	O	O	1914
7	NUM	O	O	1914
of	ADP	O	O	1914
pertussis	NOUN	O	O	1914
immunization	NOUN	O	O	1914
.	PUNCT	O	O	1914
After	ADP	O	O	1915
pretreatment	NOUN	O	O	1915
with	ADP	O	O	1915
3	X	O	O	1915
mg	VERB	O	O	1915
of	ADP	O	O	1915
cyproheptadine	NOUN	O	O	1915
,	PUNCT	O	O	1915
2	X	O	O	1915
mg	VERB	O	O	1915
mianserin	PROPN	O	O	1915
,	PUNCT	O	O	1915
or	CCONJ	O	O	1915
2	X	O	O	1915
mg	VERB	O	O	1915
chlorpheniramine	PROPN	O	Chemical	1915
,	PUNCT	O	O	1915
only	ADV	O	O	1915
5	NUM	O	O	1915
of	ADP	O	O	1915
105	NUM	O	O	1915
animals	NOUN	O	O	1915
(	PUNCT	O	O	1915
5%	NOUN	O	O	1915
)	PUNCT	O	O	1915
died	VERB	O	O	1915
after	ADP	O	O	1915
receiving	VERB	O	O	1915
BSA	PROPN	O	O	1915
on	ADP	O	O	1915
day	NOUN	O	O	1915
+	ADP	O	O	1915
7	NUM	O	O	1915
(	PUNCT	O	O	1915
p	NOUN	O	O	1915
less	ADV	O	O	1915
than	ADP	O	O	1915
0.001	NUM	O	O	1915
)	PUNCT	O	O	1915
.	PUNCT	O	O	1915
Blockade	NOUN	O	O	1916
of	ADP	O	O	1916
histamine	NOUN	O	Chemical	1916
H1	NOUN	O	O	1916
receptors	NOUN	O	O	1916
may	AUX	O	O	1916
reduce	VERB	O	O	1916
mortality	NOUN	O	O	1916
in	ADP	O	O	1916
pertussis	NOUN	O	O	1916
immunization	NOUN	O	O	1916
-	PUNCT	O	O	1916
induced	VERB	O	O	1916
encephalopathy	NOUN	O	Disease	1916
in	ADP	O	O	1916
mice	NOUN	O	O	1916
.	PUNCT	O	O	1916
Support	NOUN	O	O	1919
for	ADP	O	O	1919
adrenaline	NOUN	O	Chemical	1919
-	PUNCT	O	O	1919
hypertension	NOUN	O	Disease	1919
hypothesis	NOUN	O	O	1919
:	PUNCT	O	O	1919
18	NUM	O	O	1919
hour	NOUN	O	O	1919
pressor	ADJ	O	O	1919
effect	VERB	O	O	1919
after	ADP	O	O	1919
6	NUM	O	O	1919
hours	NOUN	O	O	1919
adrenaline	NOUN	O	Chemical	1919
infusion	NOUN	O	O	1919
.	PUNCT	O	O	1919
In	ADP	O	O	1920
a	PRON	O	O	1920
double	ADJ	O	O	1920
blind	ADJ	O	Disease	1920
,	PUNCT	O	O	1920
crossover	NOUN	O	O	1920
study	VERB	O	O	1920
6	NUM	O	O	1920
h	X	O	O	1920
infusions	NOUN	O	O	1920
of	ADP	O	O	1920
adrenaline	NOUN	O	Chemical	1920
(	PUNCT	O	O	1920
15	NUM	O	O	1921
ng	PROPN	O	O	1921
/	PUNCT	O	O	1921
kg	VERB	O	O	1921
/	PUNCT	O	O	1921
min	NOUN	O	O	1921
;	PUNCT	O	O	1921
1	X	O	O	1921
ng	PROPN	O	O	1921
=	PUNCT	O	O	1921
5.458	NUM	O	O	1921
pmol	PROPN	O	O	1921
)	PUNCT	O	O	1921
,	PUNCT	O	O	1921
noradrenaline	NOUN	O	Chemical	1921
(	PUNCT	O	O	1921
30	NUM	O	O	1921
ng	PROPN	O	O	1921
/	PUNCT	O	O	1921
kg	VERB	O	O	1921
/	PUNCT	O	O	1921
min	NOUN	O	O	1921
;	PUNCT	O	O	1921
1	X	O	O	1921
ng	PROPN	O	O	1921
=	PUNCT	O	O	1921
5.911	NUM	O	O	1921
pmol	PROPN	O	O	1921
)	PUNCT	O	O	1921
,	PUNCT	O	O	1921
and	CCONJ	O	O	1921
a	PRON	O	O	1921
5%	NOUN	O	O	1921
dextrose	ADJ	O	Chemical	1921
solution	NOUN	O	O	1921
(	PUNCT	O	O	1921
5.4	NUM	O	O	1921
ml	ADP	O	O	1921
/	PUNCT	O	O	1921
h	X	O	O	1921
)	PUNCT	O	O	1921
,	PUNCT	O	O	1921
were	AUX	O	O	1921
given	VERB	O	O	1921
to	PART	O	O	1921
ten	NUM	O	O	1921
healthy	ADJ	O	O	1921
volunteers	NOUN	O	O	1921
in	ADP	O	O	1921
random	ADJ	O	O	1921
order	NOUN	O	O	1921
2	X	O	O	1921
weeks	NOUN	O	O	1921
apart	ADV	O	O	1921
.	PUNCT	O	O	1921
Adrenaline	NOUN	O	O	1922
,	PUNCT	O	O	1922
but	CCONJ	O	O	1922
not	PART	O	O	1922
noradrenaline	NOUN	O	Chemical	1922
,	PUNCT	O	O	1922
caused	VERB	O	O	1922
a	PRON	O	O	1922
delayed	VERB	O	O	1922
and	CCONJ	O	O	1922
protracted	VERB	O	O	1922
pressor	ADJ	O	O	1922
effect	VERB	O	O	1922
.	PUNCT	O	O	1922
Over	ADP	O	O	1923
the	PRON	O	O	1923
total	ADJ	O	O	1923
postinfusion	NOUN	O	O	1923
period	NOUN	O	O	1923
systolic	ADV	O	O	1923
and	CCONJ	O	O	1923
diastolic	ADV	O	O	1923
arterial	ADJ	O	O	1923
pressure	NOUN	O	O	1923
were	AUX	O	O	1923
6	NUM	O	O	1923
(	PUNCT	O	O	1923
SEM	INTJ	O	O	1923
2)%	NUM	O	O	1923
and	CCONJ	O	O	1923
7	NUM	O	O	1923
(	PUNCT	O	O	1923
2)%	NUM	O	O	1923
,	PUNCT	O	O	1923
respectively	ADV	O	O	1923
,	PUNCT	O	O	1923
higher	ADJ	O	O	1923
than	ADP	O	O	1923
after	ADP	O	O	1923
dextrose	ADJ	O	Chemical	1923
infusion	NOUN	O	O	1923
(	PUNCT	O	O	1923
ANOVA	PROPN	O	O	1923
,	PUNCT	O	O	1923
p	NOUN	O	O	1923
less	ADV	O	O	1923
than	ADP	O	O	1923
0.001	NUM	O	O	1923
)	PUNCT	O	O	1923
.	PUNCT	O	O	1923
Thus	ADV	O	O	1924
,	PUNCT	O	O	1924
""""	PUNCT	O	O	1924
stress	NOUN	O	O	1924
""""	PUNCT	O	O	1924
levels	NOUN	O	O	1924
of	ADP	O	O	1924
adrenaline	NOUN	O	Chemical	1924
(	PUNCT	O	O	1924
230	NUM	O	O	1924
pg	PROPN	O	Chemical	1924
/	PUNCT	O	O	1924
ml	ADP	O	O	1924
)	PUNCT	O	O	1924
for	ADP	O	O	1924
6	NUM	O	O	1924
h	X	O	O	1924
cause	VERB	O	O	1924
a	PRON	O	O	1924
delayed	VERB	O	O	1924
and	CCONJ	O	O	1924
protracted	VERB	O	O	1924
pressor	ADJ	O	O	1924
effect	VERB	O	O	1924
.	PUNCT	O	O	1924
These	PRON	O	O	1925
findings	NOUN	O	O	1925
are	AUX	O	O	1925
strong	ADJ	O	O	1925
support	NOUN	O	O	1925
for	ADP	O	O	1925
the	PRON	O	O	1925
adrenaline	NOUN	O	Chemical	1925
-	PUNCT	O	O	1925
hypertension	NOUN	O	Disease	1925
hypothesis	NOUN	O	O	1925
in	ADP	O	O	1925
man	NOUN	O	O	1925
.	PUNCT	O	O	1925
Effect	VERB	O	O	1928
of	ADP	O	O	1928
alkylxanthines	VERB	O	O	1928
on	ADP	O	O	1928
gentamicin	VERB	O	Chemical	1928
-	PUNCT	O	O	1928
induced	VERB	O	O	1928
acute	ADJ	O	O	1928
renal failure	NOUN	O	Disease	1928
in	ADP	O	O	1928
the	PRON	O	O	1928
rat	NOUN	O	O	1928
.	PUNCT	O	O	1928
Adenosine	NOUN	O	Chemical	1929
antagonists	NOUN	O	O	1929
have	VERB	O	O	1929
been	AUX	O	O	1929
previously	ADV	O	O	1929
shown	VERB	O	O	1929
to	PART	O	O	1929
be	AUX	O	O	1929
of	ADP	O	O	1929
benefit	VERB	O	O	1929
in	ADP	O	O	1929
some	PRON	O	O	1929
ischaemic	ADJ	O	O	1929
and	CCONJ	O	O	1929
nephrotoxic	NOUN	O	Disease	1929
models	NOUN	O	O	1929
of	ADP	O	O	1929
acute	ADJ	O	O	1929
renal failure	NOUN	O	Disease	1929
(	PUNCT	O	O	1929
ARF	PROPN	O	Disease	1929
)	PUNCT	O	O	1929
.	PUNCT	O	O	1929
In	ADP	O	O	1930
the	PRON	O	O	1930
present	NOUN	O	O	1930
study	VERB	O	O	1930
,	PUNCT	O	O	1930
the	PRON	O	O	1930
effects	NOUN	O	O	1930
of	ADP	O	O	1930
three	NUM	O	O	1930
alkylxanthines	VERB	O	O	1930
with	ADP	O	O	1930
different	ADJ	O	O	1930
potencies	NOUN	O	O	1930
as	ADP	O	O	1930
adenosine	PROPN	O	Chemical	1930
antagonists	NOUN	O	O	1930
8-phenyltheophylline	NOUN	O	O	1930
,	PUNCT	O	O	1930
theophylline	ADV	O	Chemical	1930
and	CCONJ	O	O	1930
enprofylline	NOUN	O	O	1930
,	PUNCT	O	O	1930
were	AUX	O	O	1930
examined	VERB	O	O	1930
in	ADP	O	O	1930
rats	NOUN	O	O	1930
developing	VERB	O	O	1930
acute	ADJ	O	O	1930
renal failure	NOUN	O	Disease	1930
after	ADP	O	O	1930
4	NUM	O	O	1930
daily	ADV	O	O	1930
injections	NOUN	O	O	1930
of	ADP	O	O	1930
gentamicin	VERB	O	Chemical	1930
(	PUNCT	O	O	1930
200	NUM	O	O	1930
mg	VERB	O	O	1930
kg-1	VERB	O	O	1930
)	PUNCT	O	O	1930
.	PUNCT	O	O	1930
Renal	NOUN	O	O	1931
function	NOUN	O	O	1931
was	AUX	O	O	1931
assessed	VERB	O	O	1931
by	ADP	O	O	1931
biochemical	ADJ	O	O	1931
(	PUNCT	O	O	1931
plasma	NOUN	O	O	1931
urea	PROPN	O	Chemical	1931
and	CCONJ	O	O	1931
creatinine	PROPN	O	Chemical	1931
)	PUNCT	O	O	1931
,	PUNCT	O	O	1931
functional	ADJ	O	O	1931
(	PUNCT	O	O	1931
urine	NOUN	O	O	1931
analysis	NOUN	O	O	1931
and	CCONJ	O	O	1931
[	X	O	O	1931
3H]inulin	NUM	O	O	1931
and	CCONJ	O	O	1931
[	X	O	O	1931
14C]p	NUM	O	O	1931
-	PUNCT	O	O	1931
aminohippuric acid	PROPN	O	O	1931
clearances	NOUN	O	O	1931
)	PUNCT	O	O	1931
and	CCONJ	O	O	1931
morphological	ADJ	O	O	1931
(	PUNCT	O	O	1931
degree	PROPN	O	O	1931
of	ADP	O	O	1931
necrosis	NOUN	O	Disease	1931
)	PUNCT	O	O	1931
indices	NOUN	O	O	1931
.	PUNCT	O	O	1931
However	ADV	O	O	1932
,	PUNCT	O	O	1932
any	PRON	O	O	1932
improvement	NOUN	O	O	1932
produced	VERB	O	O	1932
by	ADP	O	O	1932
drug	NOUN	O	O	1932
treatment	NOUN	O	O	1932
was	AUX	O	O	1932
largely	ADV	O	O	1932
a	PRON	O	O	1932
result	VERB	O	O	1932
of	ADP	O	O	1932
a	PRON	O	O	1932
beneficial	ADJ	O	O	1932
effect	VERB	O	O	1932
exerted	VERB	O	O	1932
by	ADP	O	O	1932
its	PRON	O	O	1932
vehicle	NOUN	O	O	1932
(	PUNCT	O	O	1932
polyethylene	NOUN	O	O	1932
glycol	NOUN	O	O	1932
and	CCONJ	O	O	1932
NaOH	PROPN	O	O	1932
)	PUNCT	O	O	1932
.	PUNCT	O	O	1932
The	PRON	O	O	1933
lack	VERB	O	O	1933
of	ADP	O	O	1933
any	PRON	O	O	1933
consistent	ADJ	O	O	1933
protective	ADJ	O	O	1933
effect	VERB	O	O	1933
noted	VERB	O	O	1933
with	ADP	O	O	1933
the	PRON	O	O	1933
alkylxanthines	VERB	O	O	1933
tested	VERB	O	O	1933
in	ADP	O	O	1933
the	PRON	O	O	1933
present	NOUN	O	O	1933
study	VERB	O	O	1933
indicates	VERB	O	O	1933
that	SCONJ	O	O	1933
adenosine	PROPN	O	Chemical	1933
plays	VERB	O	O	1933
little	ADJ	O	O	1933
,	PUNCT	O	O	1933
if	SCONJ	O	O	1933
any	PRON	O	O	1933
,	PUNCT	O	O	1933
pathophysiological	ADJ	O	O	1933
role	NOUN	O	O	1933
in	ADP	O	O	1933
gentamicin	VERB	O	Chemical	1933
-	PUNCT	O	O	1933
induced	VERB	O	O	1933
ARF	PROPN	O	Disease	1933
.	PUNCT	O	O	1933
Adverse	ADJ	O	O	1936
ocular	ADJ	O	O	1936
reactions	NOUN	O	O	1936
possibly	ADV	O	O	1936
associated	VERB	O	O	1936
with	ADP	O	O	1936
isotretinoin	PROPN	O	O	1936
.	PUNCT	O	O	1936
A	PRON	O	O	1937
total	ADJ	O	O	1937
of	ADP	O	O	1937
261	NUM	O	O	1937
adverse	ADJ	O	O	1937
ocular	ADJ	O	O	1937
reactions	NOUN	O	O	1937
occurred	VERB	O	O	1937
in	ADP	O	O	1937
237	NUM	O	O	1937
patients	NOUN	O	O	1937
who	PRON	O	O	1937
received	VERB	O	O	1937
isotretinoin	PROPN	O	O	1937
,	PUNCT	O	O	1937
a	PRON	O	O	1937
commonly	ADV	O	O	1937
used	VERB	O	O	1937
drug	NOUN	O	O	1937
in	ADP	O	O	1937
the	PRON	O	O	1937
treatment	NOUN	O	O	1937
of	ADP	O	O	1937
severe	ADJ	O	O	1937
cystic	PROPN	O	O	1937
acne	NOUN	O	O	1937
.	PUNCT	O	O	1937
Blepharoconjunctivitis	NOUN	O	O	1938
,	PUNCT	O	O	1938
subjective	ADJ	O	O	1938
complaints	NOUN	O	O	1938
of	ADP	O	O	1938
dry	VERB	O	O	1938
eyes	NOUN	O	O	1938
,	PUNCT	O	O	1938
blurred	VERB	O	O	1938
vision	PROPN	O	O	1938
,	PUNCT	O	O	1938
contact	NOUN	O	O	1938
lens	NOUN	O	O	1938
intolerance	NOUN	O	O	1938
,	PUNCT	O	O	1938
and	CCONJ	O	O	1938
photodermatitis	NOUN	O	O	1938
are	AUX	O	O	1938
reversible	ADJ	O	O	1938
side	NOUN	O	O	1938
effects	NOUN	O	O	1938
.	PUNCT	O	O	1938
More	ADJ	O	O	1939
serious	ADJ	O	O	1939
ocular	ADJ	O	O	1939
adverse	ADJ	O	O	1939
reactions	NOUN	O	O	1939
include	VERB	O	O	1939
papilledema	NOUN	O	O	1939
,	PUNCT	O	O	1939
pseudotumor	NOUN	O	O	1939
cerebri	NOUN	O	O	1939
,	PUNCT	O	O	1939
and	CCONJ	O	O	1939
white	ADJ	O	O	1939
or	CCONJ	O	O	1939
gray	PROPN	O	O	1939
subepithelial	NOUN	O	O	1939
corneal	PROPN	O	O	1939
opacities	NOUN	O	O	1939
;	PUNCT	O	O	1939
all	PRON	O	O	1939
of	ADP	O	O	1939
these	PRON	O	O	1939
are	AUX	O	O	1939
reversible	ADJ	O	O	1939
if	SCONJ	O	O	1939
the	PRON	O	O	1939
drug	NOUN	O	O	1939
is	AUX	O	O	1939
discontinued	VERB	O	O	1939
.	PUNCT	O	O	1939
Isotretinoin	NOUN	O	O	1940
is	AUX	O	O	1940
contraindicated	VERB	O	O	1940
in	ADP	O	O	1940
pregnancy	NOUN	O	O	1940
because	SCONJ	O	O	1940
of	ADP	O	O	1940
the	PRON	O	O	1940
many	ADJ	O	O	1940
reported	VERB	O	O	1940
congenital	NOUN	O	O	1940
abnormalities	NOUN	O	O	1940
after	ADP	O	O	1940
maternal	ADJ	O	O	1940
use	VERB	O	O	1940
(	PUNCT	O	O	1940
including	VERB	O	O	1940
microphthalmos	ADV	O	O	1940
,	PUNCT	O	O	1940
orbital	ADJ	O	O	1940
hypertelorism	PROPN	O	O	1940
,	PUNCT	O	O	1940
and	CCONJ	O	O	1940
optic	NOUN	O	O	1940
nerve	NOUN	O	O	1940
hypoplasia	NOUN	O	O	1940
)	PUNCT	O	O	1940
.	PUNCT	O	O	1940
Procaterol	PROPN	O	O	1943
and	CCONJ	O	O	1943
terbutaline	NOUN	O	Chemical	1943
in	ADP	O	O	1943
bronchial	ADJ	O	O	1943
asthma	PROPN	O	Disease	1943
.	PUNCT	O	O	1943
Procaterol	PROPN	O	O	1944
,	PUNCT	O	O	1944
a	PRON	O	O	1944
new	ADJ	O	O	1944
beta-2	NUM	O	O	1944
adrenoceptor	NOUN	O	O	1944
stimulant	NOUN	O	O	1944
,	PUNCT	O	O	1944
was	AUX	O	O	1944
studied	VERB	O	O	1944
in	ADP	O	O	1944
a	PRON	O	O	1944
double	ADJ	O	O	1944
-	PUNCT	O	O	1944
blind	ADJ	O	Disease	1944
,	PUNCT	O	O	1944
placebo	NOUN	O	O	1944
-	PUNCT	O	O	1944
controlled	VERB	O	O	1944
,	PUNCT	O	O	1944
cross	VERB	O	O	1944
-	PUNCT	O	O	1944
over	ADP	O	O	1944
trial	NOUN	O	O	1944
in	ADP	O	O	1944
patients	NOUN	O	O	1944
with	ADP	O	O	1944
bronchial	ADJ	O	O	1944
asthma	PROPN	O	Disease	1944
.	PUNCT	O	O	1944
Oral	NOUN	O	O	1945
procaterol	VERB	O	O	1945
50	NUM	O	O	1945
micrograms	NOUN	O	O	1945
b.d	PROPN	O	O	1945
.	PUNCT	O	O	1945
,	PUNCT	O	O	1946
procaterol	VERB	O	O	1946
100	NUM	O	O	1946
micrograms	NOUN	O	O	1946
b.d	PROPN	O	O	1946
.	PUNCT	O	O	1946
terbutaline	NOUN	O	Chemical	1947
5	NUM	O	O	1947
mg	VERB	O	O	1947
t.i.d	ADJ	O	O	1947
.	PUNCT	O	O	1947
The	PRON	O	O	1948
best	ADV	O	O	1948
clinical	ADJ	O	O	1948
effect	VERB	O	O	1948
was	AUX	O	O	1948
found	VERB	O	O	1948
with	ADP	O	O	1948
terbutaline	NOUN	O	Chemical	1948
.	PUNCT	O	O	1948
Both	PRON	O	O	1949
anti	ADJ	O	O	1949
-	PUNCT	O	O	1949
asthmatic	ADJ	O	O	1949
and	CCONJ	O	O	1949
tremorgenic	PROPN	O	O	1949
effects	NOUN	O	O	1949
of	ADP	O	O	1949
procaterol	VERB	O	O	1949
were	AUX	O	O	1949
dose	NOUN	O	O	1949
-	PUNCT	O	O	1949
related	ADJ	O	O	1949
.	PUNCT	O	O	1949
Procaterol	PROPN	O	O	1950
appeared	VERB	O	O	1950
effective	ADJ	O	O	1950
in	ADP	O	O	1950
the	PRON	O	O	1950
doses	NOUN	O	O	1950
tested	VERB	O	O	1950
,	PUNCT	O	O	1950
and	CCONJ	O	O	1950
a	PRON	O	O	1950
twice	ADV	O	O	1950
daily	ADV	O	O	1950
regimen	NOUN	O	O	1950
would	AUX	O	O	1950
appear	VERB	O	O	1950
to	PART	O	O	1950
be	AUX	O	O	1950
suitable	ADJ	O	O	1950
with	ADP	O	O	1950
this	PRON	O	O	1950
drug	NOUN	O	O	1950
.	PUNCT	O	O	1950
Subacute	VERB	O	O	1953
effects	NOUN	O	O	1953
of	ADP	O	O	1953
propranolol	NOUN	O	Chemical	1953
and	CCONJ	O	O	1953
B	NOUN	O	O	1953
24/76	NUM	O	O	1953
on	ADP	O	O	1953
isoproterenol	NOUN	O	Chemical	1953
-	PUNCT	O	O	1953
induced	VERB	O	O	1953
rat	NOUN	O	O	1953
heart	NOUN	O	O	1953
hypertrophy	VERB	O	Disease	1953
in	ADP	O	O	1953
correlation	NOUN	O	O	1953
with	ADP	O	O	1953
blood	NOUN	O	O	1953
pressure	NOUN	O	O	1953
.	PUNCT	O	O	1953
24/76	NUM	O	O	1954
i.e.	X	O	O	1954
1-(2,4-dichlorophenoxy)-3[2	NOUN	O	O	1954
-	PUNCT	O	O	1954
3,4-dimethoxyphenyl)ethanolamino]-prop	NOUN	O	O	1954
an-2-ol	NOUN	O	O	1954
,	PUNCT	O	O	1954
which	PRON	O	O	1954
is	AUX	O	O	1954
characterized	VERB	O	O	1954
by	ADP	O	O	1954
beta	NOUN	O	O	1954
1-adrenoceptor	NOUN	O	O	1954
blocking	VERB	O	O	1954
and	CCONJ	O	O	1954
beta	NOUN	O	O	1954
2-adrenoceptor	NOUN	O	O	1954
stimulating	VERB	O	O	1954
properties	NOUN	O	O	1954
with	ADP	O	O	1954
propranolol	NOUN	O	Chemical	1954
.	PUNCT	O	O	1954
The	PRON	O	O	1955
studies	NOUN	O	O	1955
were	AUX	O	O	1955
performed	VERB	O	O	1955
using	VERB	O	O	1955
an	PRON	O	O	1955
experimental	ADJ	O	O	1955
model	NOUN	O	O	1955
of	ADP	O	O	1955
isoproterenol	NOUN	O	Chemical	1955
-	PUNCT	O	O	1955
induced	VERB	O	O	1955
heart	NOUN	O	O	1955
hypertrophy	VERB	O	Disease	1955
in	ADP	O	O	1955
rats	NOUN	O	O	1955
.	PUNCT	O	O	1955
A	PRON	O	O	1956
correlation	NOUN	O	O	1956
of	ADP	O	O	1956
the	PRON	O	O	1956
blood	NOUN	O	O	1956
pressure	NOUN	O	O	1956
was	AUX	O	O	1956
neither	ADV	O	O	1956
found	VERB	O	O	1956
in	ADP	O	O	1956
the	PRON	O	O	1956
development	NOUN	O	O	1956
nor	CCONJ	O	O	1956
in	ADP	O	O	1956
the	PRON	O	O	1956
attempt	VERB	O	O	1956
to	PART	O	O	1956
suppress	VERB	O	O	1956
the	PRON	O	O	1956
development	NOUN	O	O	1956
of	ADP	O	O	1956
heart	NOUN	O	O	1956
hypertrophy	VERB	O	Disease	1956
with	ADP	O	O	1956
the	PRON	O	O	1956
two	NUM	O	O	1956
beta	NOUN	O	O	1956
-	PUNCT	O	O	1956
receptor	NOUN	O	O	1956
blockers	NOUN	O	O	1956
.	PUNCT	O	O	1956
Both	PRON	O	O	1957
beta	NOUN	O	O	1957
-	PUNCT	O	O	1957
blockers	NOUN	O	O	1957
influenced	VERB	O	O	1957
the	PRON	O	O	1957
development	NOUN	O	O	1957
of	ADP	O	O	1957
hypertrophy	VERB	O	Disease	1957
to	PART	O	O	1957
a	PRON	O	O	1957
different	ADJ	O	O	1957
,	PUNCT	O	O	1957
but	CCONJ	O	O	1957
not	PART	O	O	1957
reproducible	ADJ	O	O	1957
extent	NOUN	O	O	1957
.	PUNCT	O	O	1957
It	PRON	O	O	1958
was	AUX	O	O	1958
possible	ADJ	O	O	1958
to	PART	O	O	1958
suppress	VERB	O	O	1958
the	PRON	O	O	1958
increased	VERB	O	O	1958
ornithine	PROPN	O	O	1958
decarboxylase	PROPN	O	O	1958
activity	NOUN	O	O	1958
with	ADP	O	O	1958
both	PRON	O	O	1958
beta	NOUN	O	O	1958
-	PUNCT	O	O	1958
blockers	NOUN	O	O	1958
in	ADP	O	O	1958
hypertrophied	ADJ	O	O	1958
hearts	NOUN	O	O	1958
,	PUNCT	O	O	1958
but	CCONJ	O	O	1958
there	ADV	O	O	1958
was	AUX	O	O	1958
no	PRON	O	O	1958
effect	VERB	O	O	1958
on	ADP	O	O	1958
the	PRON	O	O	1958
heart	NOUN	O	O	1958
mass	PROPN	O	O	1958
.	PUNCT	O	O	1958
Neither	PRON	O	O	1959
propranolol	NOUN	O	Chemical	1959
nor	CCONJ	O	O	1959
B	NOUN	O	O	1959
24/76	NUM	O	O	1959
could	AUX	O	O	1959
stop	VERB	O	O	1959
the	PRON	O	O	1959
changes	VERB	O	O	1959
in	ADP	O	O	1959
the	PRON	O	O	1959
characteristic	ADJ	O	O	1959
myosin	ADV	O	O	1959
isoenzyme	VERB	O	O	1959
pattern	NOUN	O	O	1959
of	ADP	O	O	1959
the	PRON	O	O	1959
hypertrophied	ADJ	O	O	1959
rat	NOUN	O	O	1959
heart	NOUN	O	O	1959
.	PUNCT	O	O	1959
Thus	ADV	O	O	1960
,	PUNCT	O	O	1960
the	PRON	O	O	1960
investigations	NOUN	O	O	1960
did	VERB	O	O	1960
not	PART	O	O	1960
provide	VERB	O	O	1960
any	PRON	O	O	1960
evidence	NOUN	O	O	1960
that	SCONJ	O	O	1960
the	PRON	O	O	1960
beta	NOUN	O	O	1960
-	PUNCT	O	O	1960
receptor	NOUN	O	O	1960
blockers	NOUN	O	O	1960
propranolol	NOUN	O	Chemical	1960
and	CCONJ	O	O	1960
B	NOUN	O	O	1960
24/76	NUM	O	O	1960
have	VERB	O	O	1960
the	PRON	O	O	1960
potency	NOUN	O	O	1960
to	PART	O	O	1960
prevent	VERB	O	O	1960
isoproterenol	NOUN	O	Chemical	1960
from	ADP	O	O	1960
producing	VERB	O	O	1960
heart	NOUN	O	O	1960
hypertrophy	VERB	O	Disease	1960
.	PUNCT	O	O	1960
Comparison	NOUN	O	O	1963
of	ADP	O	O	1963
the	PRON	O	O	1963
effect	VERB	O	O	1963
of	ADP	O	O	1963
oxitropium	VERB	O	O	1963
bromide	NOUN	O	O	1963
and	CCONJ	O	O	1963
of	ADP	O	O	1963
slow	VERB	O	O	1963
-	PUNCT	O	O	1963
release	NOUN	O	O	1963
theophylline	ADV	O	Chemical	1963
on	ADP	O	O	1963
nocturnal	ADJ	O	O	1963
asthma	PROPN	O	Disease	1963
.	PUNCT	O	O	1963
The	PRON	O	O	1964
effects	NOUN	O	O	1964
of	ADP	O	O	1964
a	PRON	O	O	1964
new	ADJ	O	O	1964
inhaled	VERB	O	O	1964
antimuscarinic	NOUN	O	O	1964
drug	NOUN	O	O	1964
,	PUNCT	O	O	1964
oxitropium	VERB	O	O	1964
bromide	NOUN	O	O	1964
,	PUNCT	O	O	1964
and	CCONJ	O	O	1964
of	ADP	O	O	1964
a	PRON	O	O	1964
slow	VERB	O	O	1964
-	PUNCT	O	O	1964
release	NOUN	O	O	1964
theophylline	ADV	O	Chemical	1964
preparation	NOUN	O	O	1964
upon	SCONJ	O	O	1964
nocturnal	ADJ	O	O	1964
asthma	PROPN	O	Disease	1964
were	AUX	O	O	1964
compared	VERB	O	O	1964
in	ADP	O	O	1964
a	PRON	O	O	1964
placebo	NOUN	O	O	1964
-	PUNCT	O	O	1964
controlled	VERB	O	O	1964
double	ADJ	O	O	1964
-	PUNCT	O	O	1964
blind	ADJ	O	Disease	1964
study	VERB	O	O	1964
.	PUNCT	O	O	1964
Two	NUM	O	O	1965
samples	NOUN	O	O	1965
were	AUX	O	O	1965
studied	VERB	O	O	1965
:	PUNCT	O	O	1965
12	NUM	O	O	1965
patients	NOUN	O	O	1965
received	VERB	O	O	1965
oxitropium	VERB	O	O	1965
at	ADP	O	O	1965
600	NUM	O	O	1965
micrograms	NOUN	O	O	1965
(	PUNCT	O	O	1965
6	NUM	O	O	1965
subjects	NOUN	O	O	1965
)	PUNCT	O	O	1965
or	CCONJ	O	O	1965
at	ADP	O	O	1965
400	NUM	O	O	1965
micrograms	NOUN	O	O	1965
t.i.d	ADJ	O	O	1965
.	PUNCT	O	O	1965
(	PUNCT	O	O	1966
6	NUM	O	O	1966
subjects	NOUN	O	O	1966
)	PUNCT	O	O	1966
whereas	SCONJ	O	O	1966
11	NUM	O	O	1966
received	VERB	O	O	1966
theophylline	ADV	O	Chemical	1966
at	ADP	O	O	1966
300	NUM	O	O	1966
mg	VERB	O	O	1966
b.i.d	PROPN	O	O	1966
.	PUNCT	O	O	1966
No	PRON	O	O	1967
significant	ADJ	O	O	1967
difference	NOUN	O	O	1967
was	AUX	O	O	1967
noticed	VERB	O	O	1967
between	ADP	O	O	1967
results	VERB	O	O	1967
obtained	VERB	O	O	1967
with	ADP	O	O	1967
either	ADV	O	O	1967
active	ADJ	O	O	1967
drug	NOUN	O	O	1967
,	PUNCT	O	O	1967
as	ADP	O	O	1967
well	ADV	O	O	1967
as	ADP	O	O	1967
with	ADP	O	O	1967
either	ADV	O	O	1967
dosage	NOUN	O	O	1967
of	ADP	O	O	1967
oxitropium	VERB	O	O	1967
.	PUNCT	O	O	1967
No	PRON	O	O	1968
subject	ADJ	O	O	1968
reported	VERB	O	O	1968
side	NOUN	O	O	1968
effects	NOUN	O	O	1968
of	ADP	O	O	1968
oxitropium	VERB	O	O	1968
,	PUNCT	O	O	1968
as	ADP	O	O	1968
compared	VERB	O	O	1968
to	PART	O	O	1968
three	NUM	O	O	1968
subjects	NOUN	O	O	1968
reporting	VERB	O	O	1968
nausea	NOUN	O	Disease	1968
,	PUNCT	O	O	1968
vomiting	VERB	O	Disease	1968
and	CCONJ	O	O	1968
tremors	NOUN	O	Disease	1968
after	ADP	O	O	1968
theophylline	ADV	O	Chemical	1968
.	PUNCT	O	O	1968
Oxitropium	NOUN	O	O	1969
proves	VERB	O	O	1969
to	PART	O	O	1969
be	AUX	O	O	1969
a	PRON	O	O	1969
valuable	ADJ	O	O	1969
alternative	ADV	O	O	1969
to	PART	O	O	1969
theophylline	ADV	O	Chemical	1969
in	ADP	O	O	1969
nocturnal	ADJ	O	O	1969
asthma	PROPN	O	Disease	1969
,	PUNCT	O	O	1969
since	SCONJ	O	O	1969
it	PRON	O	O	1969
is	AUX	O	O	1969
equally	ADV	O	O	1969
potent	ADJ	O	O	1969
,	PUNCT	O	O	1969
safer	ADJ	O	O	1969
and	CCONJ	O	O	1969
does	VERB	O	O	1969
not	PART	O	O	1969
require	VERB	O	O	1969
the	PRON	O	O	1969
titration	NOUN	O	O	1969
of	ADP	O	O	1969
dosage	NOUN	O	O	1969
.	PUNCT	O	O	1969
Penicillin	NOUN	O	Chemical	1972
anaphylaxis	NOUN	O	O	1972
.	PUNCT	O	O	1972
A	PRON	O	O	1973
case	NOUN	O	O	1973
of	ADP	O	O	1973
oral	ADJ	O	O	1973
penicillin	NOUN	O	Chemical	1973
anaphylaxis	NOUN	O	O	1973
is	AUX	O	O	1973
described	VERB	O	O	1973
,	PUNCT	O	O	1973
and	CCONJ	O	O	1973
the	PRON	O	O	1973
terminology	NOUN	O	O	1973
,	PUNCT	O	O	1973
occurrence	NOUN	O	O	1973
,	PUNCT	O	O	1973
clinical	ADJ	O	O	1973
manifestations	NOUN	O	O	1973
,	PUNCT	O	O	1973
pathogenesis	NOUN	O	O	1973
,	PUNCT	O	O	1973
prevention	NOUN	O	O	1973
,	PUNCT	O	O	1973
and	CCONJ	O	O	1973
treatment	NOUN	O	O	1973
of	ADP	O	O	1973
anaphylaxis	NOUN	O	O	1973
are	AUX	O	O	1973
reviewed	VERB	O	O	1973
.	PUNCT	O	O	1973
Emergency	NOUN	O	O	1974
physicians	NOUN	O	O	1974
should	AUX	O	O	1974
be	AUX	O	O	1974
aware	ADJ	O	O	1974
of	ADP	O	O	1974
oral	ADJ	O	O	1974
penicillin	NOUN	O	Chemical	1974
anaphylaxis	NOUN	O	O	1974
in	ADP	O	O	1974
order	NOUN	O	O	1974
to	PART	O	O	1974
prevent	VERB	O	O	1974
its	PRON	O	O	1974
occurrence	NOUN	O	O	1974
by	ADP	O	O	1974
prescribing	VERB	O	O	1974
the	PRON	O	O	1974
antibiotic	ADJ	O	O	1974
judiciously	ADV	O	O	1974
and	CCONJ	O	O	1974
knowledgeably	ADV	O	O	1974
and	CCONJ	O	O	1974
to	PART	O	O	1974
offer	VERB	O	O	1974
optimal	ADJ	O	O	1974
medical	ADJ	O	O	1974
therapy	NOUN	O	O	1974
once	ADV	O	O	1974
this	PRON	O	O	1974
life	NOUN	O	O	1974
-	PUNCT	O	O	1974
threatening	VERB	O	O	1974
reaction	NOUN	O	O	1974
has	VERB	O	O	1974
begun	VERB	O	O	1974
.	PUNCT	O	O	1974
Reversible	ADJ	O	O	1977
valproic acid	NOUN	O	Chemical	1977
-	PUNCT	O	O	1977
induced	VERB	O	O	1977
dementia	NOUN	O	Disease	1977
:	PUNCT	O	O	1977
a	PRON	O	O	1977
case	NOUN	O	O	1977
report	VERB	O	O	1977
.	PUNCT	O	O	1977
Reversible	ADJ	O	O	1978
valproic acid	NOUN	O	Chemical	1978
-	PUNCT	O	O	1978
induced	VERB	O	O	1978
dementia	NOUN	O	Disease	1978
was	AUX	O	O	1978
documented	VERB	O	O	1978
in	ADP	O	O	1978
a	PRON	O	O	1978
21-year	NOUN	O	O	1978
-	PUNCT	O	O	1978
old	ADJ	O	O	1978
man	NOUN	O	O	1978
with	ADP	O	O	1978
epilepsy	NOUN	O	Disease	1978
who	PRON	O	O	1978
had	VERB	O	O	1978
a	PRON	O	O	1978
3-year	NOUN	O	O	1978
history	NOUN	O	O	1978
of	ADP	O	O	1978
insidious	ADJ	O	O	1978
progressive	ADJ	O	O	1978
decline	VERB	O	O	1978
in	ADP	O	O	1978
global	ADJ	O	O	1978
cognitive	ADJ	O	O	1978
abilities	NOUN	O	O	1978
documented	VERB	O	O	1978
by	ADP	O	O	1978
serial	ADJ	O	O	1978
neuropsychological	ADJ	O	O	1978
studies	NOUN	O	O	1978
.	PUNCT	O	O	1978
Possible	ADJ	O	O	1979
pathophysiological	ADJ	O	O	1979
mechanisms	NOUN	O	O	1979
which	PRON	O	O	1979
may	AUX	O	O	1979
have	VERB	O	O	1979
been	AUX	O	O	1979
operative	NOUN	O	O	1979
in	ADP	O	O	1979
this	PRON	O	O	1979
case	NOUN	O	O	1979
include	VERB	O	O	1979
:	PUNCT	O	O	1979
a	PRON	O	O	1979
direct	ADJ	O	O	1979
central	ADJ	O	O	1979
nervous	ADJ	O	O	1979
system	NOUN	O	O	1979
(	PUNCT	O	O	1979
CNS	PROPN	O	O	1979
)	PUNCT	O	O	1979
toxic	ADJ	O	O	1979
effect	VERB	O	O	1979
of	ADP	O	O	1979
valproic acid	NOUN	O	Chemical	1979
;	PUNCT	O	O	1979
a	PRON	O	O	1979
paradoxical	ADJ	O	O	1979
epileptogenic	NOUN	O	O	1979
effect	VERB	O	O	1979
secondary	ADJ	O	O	1979
to	PART	O	O	1979
the	PRON	O	O	1979
drug	NOUN	O	O	1979
;	PUNCT	O	O	1979
and	CCONJ	O	O	1979
an	PRON	O	O	1979
indirect	ADJ	O	O	1979
CNS	PROPN	O	O	1979
toxic	ADJ	O	O	1979
effect	VERB	O	O	1979
mediated	VERB	O	O	1979
through	ADP	O	O	1979
valproic acid	NOUN	O	Chemical	1979
-	PUNCT	O	O	1979
induced	VERB	O	O	1979
hyperammonemia	PROPN	O	Disease	1979
.	PUNCT	O	O	1979
Reversal	NOUN	O	O	1982
of	ADP	O	O	1982
scopolamine	NOUN	O	Chemical	1982
-	PUNCT	O	O	1982
induced	VERB	O	O	1982
amnesia	NOUN	O	Disease	1982
of	ADP	O	O	1982
passive	ADJ	O	O	1982
avoidance	NOUN	O	O	1982
by	ADP	O	O	1982
pre-	ADV	O	O	1982
and	CCONJ	O	O	1982
post	VERB	O	O	1982
-	PUNCT	O	O	1982
training	NOUN	O	O	1982
naloxone	NOUN	O	Chemical	1982
.	PUNCT	O	O	1982
In	ADP	O	O	1983
a	PRON	O	O	1983
series	PROPN	O	O	1983
of	ADP	O	O	1983
five	NUM	O	O	1983
experiments	NOUN	O	O	1983
,	PUNCT	O	O	1983
the	PRON	O	O	1983
modulating	VERB	O	O	1983
role	NOUN	O	O	1983
of	ADP	O	O	1983
naloxone	NOUN	O	Chemical	1983
on	ADP	O	O	1983
a	PRON	O	O	1983
scopolamine	NOUN	O	Chemical	1983
-	PUNCT	O	O	1983
induced	VERB	O	O	1983
retention	NOUN	O	O	1983
deficit	NOUN	O	O	1983
in	ADP	O	O	1983
a	PRON	O	O	1983
passive	ADJ	O	O	1983
avoidance	NOUN	O	O	1983
paradigm	NOUN	O	O	1983
was	AUX	O	O	1983
investigated	VERB	O	O	1983
in	ADP	O	O	1983
mice	NOUN	O	O	1983
.	PUNCT	O	O	1983
Scopolamine	NOUN	O	Chemical	1984
,	PUNCT	O	O	1984
but	CCONJ	O	O	1984
not	PART	O	O	1984
methyl	NOUN	O	O	1984
scopolamine	NOUN	O	Chemical	1984
(	PUNCT	O	O	1984
1	X	O	O	1984
and	CCONJ	O	O	1984
3	X	O	O	1984
mg	VERB	O	O	1984
/	PUNCT	O	O	1984
kg	VERB	O	O	1984
)	PUNCT	O	O	1984
,	PUNCT	O	O	1984
induced	VERB	O	O	1984
an	PRON	O	O	1984
amnesia	NOUN	O	Disease	1984
as	ADP	O	O	1984
measured	VERB	O	O	1984
by	ADP	O	O	1984
latency	VERB	O	O	1984
and	CCONJ	O	O	1984
duration	NOUN	O	O	1984
parameters	NOUN	O	O	1984
.	PUNCT	O	O	1984
Naloxone	NOUN	O	Chemical	1985
(	PUNCT	O	O	1985
0.3	NUM	O	O	1985
,	PUNCT	O	O	1985
1	X	O	O	1985
,	PUNCT	O	O	1985
3	X	O	O	1985
,	PUNCT	O	O	1985
and	CCONJ	O	O	1985
10	NUM	O	O	1985
mg	VERB	O	O	1985
/	PUNCT	O	O	1985
kg	VERB	O	O	1985
)	PUNCT	O	O	1985
injected	VERB	O	O	1985
prior	ADV	O	O	1985
to	PART	O	O	1985
training	NOUN	O	O	1985
attenuated	VERB	O	O	1985
the	PRON	O	O	1985
retention	NOUN	O	O	1985
deficit	NOUN	O	O	1985
with	ADP	O	O	1985
a	PRON	O	O	1985
peak	PROPN	O	O	1985
of	ADP	O	O	1985
activity	NOUN	O	O	1985
at	ADP	O	O	1985
3	X	O	O	1985
mg	VERB	O	O	1985
/	PUNCT	O	O	1985
kg	VERB	O	O	1985
.	PUNCT	O	O	1985
The	PRON	O	O	1986
effect	VERB	O	O	1986
of	ADP	O	O	1986
naloxone	NOUN	O	Chemical	1986
could	AUX	O	O	1986
be	AUX	O	O	1986
antagonized	VERB	O	O	1986
with	ADP	O	O	1986
morphine	NOUN	O	Chemical	1986
(	PUNCT	O	O	1986
1	X	O	O	1986
,	PUNCT	O	O	1986
3	X	O	O	1986
,	PUNCT	O	O	1986
and	CCONJ	O	O	1986
10	NUM	O	O	1986
mg	VERB	O	O	1986
/	PUNCT	O	O	1986
kg	VERB	O	O	1986
)	PUNCT	O	O	1986
,	PUNCT	O	O	1986
demonstrating	VERB	O	O	1986
the	PRON	O	O	1986
opioid	NOUN	O	O	1986
specificity	NOUN	O	O	1986
of	ADP	O	O	1986
the	PRON	O	O	1986
naloxone	NOUN	O	Chemical	1986
effect	VERB	O	O	1986
.	PUNCT	O	O	1986
Post	NOUN	O	O	1987
-	PUNCT	O	O	1987
training	NOUN	O	O	1987
administration	NOUN	O	O	1987
of	ADP	O	O	1987
naloxone	NOUN	O	Chemical	1987
(	PUNCT	O	O	1987
3	X	O	O	1987
mg	VERB	O	O	1987
/	PUNCT	O	O	1987
kg	VERB	O	O	1987
)	PUNCT	O	O	1987
as	ADP	O	O	1987
a	PRON	O	O	1987
single	ADJ	O	O	1987
or	CCONJ	O	O	1987
as	ADP	O	O	1987
a	PRON	O	O	1987
split	NOUN	O	O	1987
dose	NOUN	O	O	1987
also	ADV	O	O	1987
attenuated	VERB	O	O	1987
the	PRON	O	O	1987
scopolamine	NOUN	O	Chemical	1987
-	PUNCT	O	O	1987
induced	VERB	O	O	1987
amnesia	NOUN	O	Disease	1987
.	PUNCT	O	O	1987
Control	NOUN	O	O	1988
experiments	NOUN	O	O	1988
indicated	VERB	O	O	1988
that	SCONJ	O	O	1988
neither	ADV	O	O	1988
an	PRON	O	O	1988
increase	VERB	O	O	1988
in	ADP	O	O	1988
pain	NOUN	O	Disease	1988
sensitivity	NOUN	O	O	1988
(	PUNCT	O	O	1988
pre	VERB	O	O	1988
-	PUNCT	O	O	1988
training	NOUN	O	O	1988
naloxone	NOUN	O	Chemical	1988
)	PUNCT	O	O	1988
nor	CCONJ	O	O	1988
an	PRON	O	O	1988
induced	VERB	O	O	1988
aversive	ADJ	O	O	1988
state	NOUN	O	O	1988
(	PUNCT	O	O	1988
post	VERB	O	O	1988
-	PUNCT	O	O	1988
training	NOUN	O	O	1988
naloxone	NOUN	O	Chemical	1988
)	PUNCT	O	O	1988
appear	VERB	O	O	1988
to	PART	O	O	1988
be	AUX	O	O	1988
responsible	ADJ	O	O	1988
for	ADP	O	O	1988
the	PRON	O	O	1988
influence	NOUN	O	O	1988
of	ADP	O	O	1988
naloxone	NOUN	O	Chemical	1988
on	ADP	O	O	1988
the	PRON	O	O	1988
scopolamine	NOUN	O	Chemical	1988
-	PUNCT	O	O	1988
induced	VERB	O	O	1988
retention	NOUN	O	O	1988
deficit	NOUN	O	O	1988
.	PUNCT	O	O	1988
Electron	NOUN	O	O	1991
microscopic	ADJ	O	O	1991
investigations	NOUN	O	O	1991
of	ADP	O	O	1991
the	PRON	O	O	1991
cyclophosphamide	VERB	O	Chemical	1991
-	PUNCT	O	O	1991
induced	VERB	O	O	1991
lesions	NOUN	O	O	1991
of	ADP	O	O	1991
the	PRON	O	O	1991
urinary	ADJ	O	O	1991
bladder	NOUN	O	O	1991
of	ADP	O	O	1991
the	PRON	O	O	1991
rat	NOUN	O	O	1991
and	CCONJ	O	O	1991
their	PRON	O	O	1991
prevention	NOUN	O	O	1991
by	ADP	O	O	1991
mesna	NOUN	O	Chemical	1991
.	PUNCT	O	O	1991
Fully	ADV	O	O	1992
developed	VERB	O	O	1992
cyclophosphamide	VERB	O	Chemical	1992
-	PUNCT	O	O	1992
induced	VERB	O	O	1992
cystitis	NOUN	O	Disease	1992
is	AUX	O	O	1992
characterized	VERB	O	O	1992
by	ADP	O	O	1992
nearly	ADV	O	O	1992
complete	VERB	O	O	1992
detachment	NOUN	O	O	1992
of	ADP	O	O	1992
the	PRON	O	O	1992
urothelium	NOUN	O	O	1992
,	PUNCT	O	O	1992
severe	ADJ	O	O	1992
submucosal	PROPN	O	O	1992
edema	NOUN	O	Disease	1992
owing	VERB	O	O	1992
to	PART	O	O	1992
damage	NOUN	O	O	1992
to	PART	O	O	1992
the	PRON	O	O	1992
microvascular	ADJ	O	O	1992
bed	NOUN	O	O	1992
and	CCONJ	O	O	1992
focal	ADJ	O	O	1992
muscle	NOUN	O	O	1992
necroses	NOUN	O	O	1992
.	PUNCT	O	O	1992
The	PRON	O	O	1993
initial	ADJ	O	O	1993
response	NOUN	O	O	1993
to	PART	O	O	1993
the	PRON	O	O	1993
primary	NOUN	O	O	1993
attack	VERB	O	O	1993
by	ADP	O	O	1993
the	PRON	O	O	1993
cyclophosphamide	VERB	O	Chemical	1993
metabolites	VERB	O	O	1993
seems	VERB	O	O	1993
to	PART	O	O	1993
be	AUX	O	O	1993
fragmentation	NOUN	O	O	1993
of	ADP	O	O	1993
the	PRON	O	O	1993
luminal	ADJ	O	O	1993
membrane	NOUN	O	O	1993
.	PUNCT	O	O	1993
Subsequent	PROPN	O	O	1994
breaks	VERB	O	O	1994
in	ADP	O	O	1994
the	PRON	O	O	1994
lateral	PROPN	O	O	1994
cell	NOUN	O	O	1994
membranes	NOUN	O	O	1994
of	ADP	O	O	1994
the	PRON	O	O	1994
superficial	ADJ	O	O	1994
cells	NOUN	O	O	1994
and	CCONJ	O	O	1994
in	ADP	O	O	1994
all	PRON	O	O	1994
the	PRON	O	O	1994
plasma	NOUN	O	O	1994
membranes	NOUN	O	O	1994
of	ADP	O	O	1994
the	PRON	O	O	1994
intermediate	PROPN	O	O	1994
and	CCONJ	O	O	1994
basal	PROPN	O	O	1994
cells	NOUN	O	O	1994
,	PUNCT	O	O	1994
intercellular	ADJ	O	O	1994
and	CCONJ	O	O	1994
intracellular	ADJ	O	O	1994
edema	NOUN	O	Disease	1994
and	CCONJ	O	O	1994
disintegration	NOUN	O	O	1994
of	ADP	O	O	1994
the	PRON	O	O	1994
desmosomes	NOUN	O	O	1994
and	CCONJ	O	O	1994
hemidesmosomes	NOUN	O	O	1994
lead	VERB	O	Chemical	1994
to	PART	O	O	1994
progressive	ADJ	O	O	1994
degeneration	NOUN	O	O	1994
and	CCONJ	O	O	1994
detachment	NOUN	O	O	1994
of	ADP	O	O	1994
the	PRON	O	O	1994
epithelial	ADJ	O	O	1994
cells	NOUN	O	O	1994
with	ADP	O	O	1994
exposure	NOUN	O	O	1994
and	CCONJ	O	O	1994
splitting	NOUN	O	O	1994
of	ADP	O	O	1994
the	PRON	O	O	1994
basal	PROPN	O	O	1994
membrane	NOUN	O	O	1994
.	PUNCT	O	O	1994
These	PRON	O	O	1995
changes	VERB	O	O	1995
can	AUX	O	O	1995
be	AUX	O	O	1995
effectively	ADV	O	O	1995
prevented	VERB	O	O	1995
by	ADP	O	O	1995
mesna	NOUN	O	Chemical	1995
.	PUNCT	O	O	1995
Increase	VERB	O	O	1998
in	ADP	O	O	1998
intragastric	NOUN	O	O	1998
pressure	NOUN	O	O	1998
during	ADP	O	O	1998
suxamethonium	NOUN	O	O	1998
-	PUNCT	O	O	1998
induced	VERB	O	O	1998
muscle fasciculations	NOUN	O	O	1998
in	ADP	O	O	1998
children	NOUN	O	O	1998
:	PUNCT	O	O	1998
inhibition	NOUN	O	O	1998
by	ADP	O	O	1998
alfentanil	NOUN	O	Chemical	1998
.	PUNCT	O	O	1998
Changes	NOUN	O	O	1999
in	ADP	O	O	1999
intragastric	NOUN	O	O	1999
pressure	NOUN	O	O	1999
after	ADP	O	O	1999
the	PRON	O	O	1999
administration	NOUN	O	O	1999
of	ADP	O	O	1999
suxamethonium	NOUN	O	O	1999
1.5	NUM	O	O	1999
mg	VERB	O	O	1999
kg-1	VERB	O	O	1999
i.v	NOUN	O	O	1999
.	PUNCT	O	O	1999
were	AUX	O	O	1999
studied	VERB	O	O	1999
in	ADP	O	O	1999
32	NUM	O	O	1999
children	NOUN	O	O	1999
(	PUNCT	O	O	1999
mean	VERB	O	O	1999
age	NOUN	O	O	1999
6.9	NUM	O	O	1999
yr	NOUN	O	O	1999
)	PUNCT	O	O	1999
pretreated	VERB	O	O	1999
with	ADP	O	O	1999
either	ADV	O	O	1999
physiological	ADJ	O	O	1999
saline	NOUN	O	O	1999
or	CCONJ	O	O	1999
alfentanil	NOUN	O	Chemical	1999
50	NUM	O	O	1999
micrograms	NOUN	O	O	1999
kg-1	VERB	O	O	1999
.	PUNCT	O	O	1999
Anaesthesia	NOUN	O	O	2000
was	AUX	O	O	2000
induced	VERB	O	O	2000
with	ADP	O	O	2000
thiopentone	NOUN	O	Chemical	2000
5	NUM	O	O	2000
mg	VERB	O	O	2000
kg-1	VERB	O	O	2000
.	PUNCT	O	O	2000
The	PRON	O	O	2001
incidence	NOUN	O	O	2001
and	CCONJ	O	O	2001
intensity	NOUN	O	O	2001
of	ADP	O	O	2001
muscle fasciculations	NOUN	O	O	2001
caused	VERB	O	O	2001
by	ADP	O	O	2001
suxamethonium	NOUN	O	O	2001
were	AUX	O	O	2001
significantly	ADV	O	O	2001
greater	ADJ	O	O	2001
in	ADP	O	O	2001
the	PRON	O	O	2001
control	VERB	O	O	2001
than	ADP	O	O	2001
in	ADP	O	O	2001
the	PRON	O	O	2001
alfentanil	NOUN	O	Chemical	2001
group	NOUN	O	O	2001
.	PUNCT	O	O	2001
The	PRON	O	O	2002
intragastric	NOUN	O	O	2002
pressure	NOUN	O	O	2002
during	ADP	O	O	2002
muscle fasciculations	NOUN	O	O	2002
was	AUX	O	O	2002
significantly	ADV	O	O	2002
higher	ADJ	O	O	2002
in	ADP	O	O	2002
the	PRON	O	O	2002
control	VERB	O	O	2002
group	NOUN	O	O	2002
(	PUNCT	O	O	2002
16	NUM	O	O	2002
+	ADP	O	O	2002
/-	PUNCT	O	O	2002
0.7	NUM	O	O	2003
(	PUNCT	O	O	2003
SEM	INTJ	O	O	2003
)	PUNCT	O	O	2003
cm	NOUN	O	O	2003
H2O	NOUN	O	O	2003
)	PUNCT	O	O	2003
than	ADP	O	O	2003
in	ADP	O	O	2003
the	PRON	O	O	2003
alfentanil	NOUN	O	Chemical	2003
group	NOUN	O	O	2003
(	PUNCT	O	O	2003
7.7	NUM	O	O	2003
+	ADP	O	O	2003
/-	PUNCT	O	O	2003
(	PUNCT	O	O	2004
SEM	INTJ	O	O	2004
)	PUNCT	O	O	2004
cm	NOUN	O	O	2004
H2O	NOUN	O	O	2004
)	PUNCT	O	O	2004
.	PUNCT	O	O	2004
The	PRON	O	O	2005
increase	VERB	O	O	2005
in	ADP	O	O	2005
intragastric	NOUN	O	O	2005
pressure	NOUN	O	O	2005
was	AUX	O	O	2005
directly	ADV	O	O	2005
related	ADJ	O	O	2005
to	PART	O	O	2005
the	PRON	O	O	2005
intensity	NOUN	O	O	2005
of	ADP	O	O	2005
muscle fasciculations	NOUN	O	O	2005
(	PUNCT	O	O	2005
regression	NOUN	O	O	2005
line	NOUN	O	O	2005
:	PUNCT	O	O	2005
y	X	O	O	2005
=	PUNCT	O	O	2005
0.5	NUM	O	O	2005
+	ADP	O	O	2005
4.78x	NUM	O	O	2005
with	ADP	O	O	2005
r	X	O	O	2005
of	ADP	O	O	2005
0.78	NUM	O	O	2005
)	PUNCT	O	O	2005
.	PUNCT	O	O	2005
It	PRON	O	O	2006
is	AUX	O	O	2006
concluded	VERB	O	O	2006
that	SCONJ	O	O	2006
intragastric	NOUN	O	O	2006
pressure	NOUN	O	O	2006
increases	VERB	O	O	2006
significantly	ADV	O	O	2006
during	ADP	O	O	2006
muscle fasciculations	NOUN	O	O	2006
caused	VERB	O	O	2006
by	ADP	O	O	2006
suxamethonium	NOUN	O	O	2006
in	ADP	O	O	2006
healthy	ADJ	O	O	2006
children	NOUN	O	O	2006
.	PUNCT	O	O	2006
Alfentanil	NOUN	O	O	2007
50	NUM	O	O	2007
micrograms	NOUN	O	O	2007
kg-1	VERB	O	O	2007
effectively	ADV	O	O	2007
inhibits	VERB	O	O	2007
the	PRON	O	O	2007
incidence	NOUN	O	O	2007
and	CCONJ	O	O	2007
intensity	NOUN	O	O	2007
of	ADP	O	O	2007
suxamethonium	NOUN	O	O	2007
-	PUNCT	O	O	2007
induced	VERB	O	O	2007
muscle fasciculations	NOUN	O	O	2007
;	PUNCT	O	O	2007
moreover	ADV	O	O	2007
,	PUNCT	O	O	2007
intragastric	NOUN	O	O	2007
pressure	NOUN	O	O	2007
remains	VERB	O	O	2007
at	ADP	O	O	2007
its	PRON	O	O	2007
control	VERB	O	O	2007
value	NOUN	O	O	2007
.	PUNCT	O	O	2007
Acute	PROPN	O	O	2010
insulin	NOUN	O	O	2010
treatment	NOUN	O	O	2010
normalizes	VERB	O	O	2010
the	PRON	O	O	2010
resistance	NOUN	O	O	2010
to	PART	O	O	2010
the	PRON	O	O	2010
cardiotoxic	ADJ	O	Disease	2010
effect	VERB	O	O	2010
of	ADP	O	O	2010
isoproterenol	NOUN	O	Chemical	2010
in	ADP	O	O	2010
streptozotocin	PROPN	O	Chemical	2010
diabetic	ADJ	O	Disease	2010
rats	NOUN	O	O	2010
.	PUNCT	O	O	2010
A	PRON	O	O	2011
morphometric	PROPN	O	O	2011
study	VERB	O	O	2011
of	ADP	O	O	2011
isoproterenol	NOUN	O	Chemical	2011
induced	VERB	O	O	2011
myocardial	ADJ	O	O	2011
fibrosis	NOUN	O	Disease	2011
.	PUNCT	O	O	2011
The	PRON	O	O	2012
acute	ADJ	O	O	2012
effect	VERB	O	O	2012
of	ADP	O	O	2012
insulin	NOUN	O	O	2012
treatment	NOUN	O	O	2012
on	ADP	O	O	2012
the	PRON	O	O	2012
earlier	ADV	O	O	2012
reported	VERB	O	O	2012
protective	ADJ	O	O	2012
effect	VERB	O	O	2012
of	ADP	O	O	2012
streptozotocin	PROPN	O	Chemical	2012
diabetes	NOUN	O	Disease	2012
against	ADP	O	O	2012
the	PRON	O	O	2012
cardiotoxic	ADJ	O	Disease	2012
effect	VERB	O	O	2012
of	ADP	O	O	2012
high	ADJ	O	O	2012
doses	NOUN	O	O	2012
of	ADP	O	O	2012
isoproterenol	NOUN	O	Chemical	2012
(	PUNCT	O	O	2012
ISO	PROPN	O	Chemical	2012
)	PUNCT	O	O	2012
was	AUX	O	O	2012
investigated	VERB	O	O	2012
in	ADP	O	O	2012
rats	NOUN	O	O	2012
.	PUNCT	O	O	2012
Thirty	NUM	O	O	2013
to	PART	O	O	2013
135	NUM	O	O	2013
min	NOUN	O	O	2013
after	ADP	O	O	2013
the	PRON	O	O	2013
injection	NOUN	O	O	2013
of	ADP	O	O	2013
crystalline	ADJ	O	O	2013
insulin	NOUN	O	O	2013
,	PUNCT	O	O	2013
ISO	PROPN	O	Chemical	2013
was	AUX	O	O	2013
given	VERB	O	O	2013
subcutaneously	ADV	O	O	2013
and	CCONJ	O	O	2013
when	SCONJ	O	O	2013
ISO	PROPN	O	Chemical	2013
induced	VERB	O	O	2013
fibrosis	NOUN	O	Disease	2013
in	ADP	O	O	2013
the	PRON	O	O	2013
myocardium	NOUN	O	O	2013
was	AUX	O	O	2013
morphometrically	ADV	O	O	2013
analyzed	VERB	O	O	2013
7	NUM	O	O	2013
days	NOUN	O	O	2013
later	ADV	O	O	2013
,	PUNCT	O	O	2013
a	PRON	O	O	2013
highly	ADV	O	O	2013
significant	ADJ	O	O	2013
correlation	NOUN	O	O	2013
(	PUNCT	O	O	2013
r	X	O	O	2013
=	PUNCT	O	O	2013
0.83	NUM	O	O	2013
,	PUNCT	O	O	2013
2	X	O	O	2013
p	NOUN	O	O	2013
=	PUNCT	O	O	2013
0.006	NUM	O	O	2013
)	PUNCT	O	O	2013
to	PART	O	O	2013
the	PRON	O	O	2013
slope	NOUN	O	O	2013
of	ADP	O	O	2013
the	PRON	O	O	2013
fall	VERB	O	O	2013
in	ADP	O	O	2013
blood	NOUN	O	O	2013
glucose	NOUN	O	Chemical	2013
after	ADP	O	O	2013
insulin	NOUN	O	O	2013
treatment	NOUN	O	O	2013
appeared	VERB	O	O	2013
.	PUNCT	O	O	2013
The	PRON	O	O	2014
myocardial	ADJ	O	O	2014
content	NOUN	O	O	2014
of	ADP	O	O	2014
catecholamines	NOUN	O	Chemical	2014
was	AUX	O	O	2014
estimated	VERB	O	O	2014
in	ADP	O	O	2014
these	PRON	O	O	2014
8	NUM	O	O	2014
day	NOUN	O	O	2014
diabetic	ADJ	O	Disease	2014
rats	NOUN	O	O	2014
.	PUNCT	O	O	2014
The	PRON	O	O	2015
norepinephrine	NOUN	O	Chemical	2015
content	NOUN	O	O	2015
was	AUX	O	O	2015
significantly	ADV	O	O	2015
increased	VERB	O	O	2015
while	SCONJ	O	O	2015
epinephrine	NOUN	O	Chemical	2015
remained	VERB	O	O	2015
unchanged	ADJ	O	O	2015
.	PUNCT	O	O	2015
An	PRON	O	O	2016
enhanced	VERB	O	O	2016
sympathetic	ADJ	O	O	2016
nervous	ADJ	O	O	2016
system	NOUN	O	O	2016
activity	NOUN	O	O	2016
with	ADP	O	O	2016
a	PRON	O	O	2016
consequent	NOUN	O	O	2016
down	ADP	O	O	2016
regulation	NOUN	O	O	2016
of	ADP	O	O	2016
the	PRON	O	O	2016
myocardial	ADJ	O	O	2016
beta	NOUN	O	O	2016
-	PUNCT	O	O	2016
adrenergic	NOUN	O	O	2016
receptors	NOUN	O	O	2016
could	AUX	O	O	2016
,	PUNCT	O	O	2016
therefore	ADV	O	O	2016
,	PUNCT	O	O	2016
explain	VERB	O	O	2016
this	PRON	O	O	2016
catecholamine	ADJ	O	Chemical	2016
resistance	NOUN	O	O	2016
.	PUNCT	O	O	2016
The	PRON	O	O	2017
rapid	ADJ	O	O	2017
reversion	NOUN	O	O	2017
after	ADP	O	O	2017
insulin	NOUN	O	O	2017
treatment	NOUN	O	O	2017
excludes	VERB	O	O	2017
the	PRON	O	O	2017
possibility	NOUN	O	O	2017
that	SCONJ	O	O	2017
streptozotocin	PROPN	O	Chemical	2017
in	ADP	O	O	2017
itself	PRON	O	O	2017
causes	VERB	O	O	2017
the	PRON	O	O	2017
ISO	PROPN	O	Chemical	2017
resistance	NOUN	O	O	2017
and	CCONJ	O	O	2017
points	VERB	O	O	2017
towards	ADP	O	O	2017
a	PRON	O	O	2017
direct	ADJ	O	O	2017
insulin	NOUN	O	O	2017
effect	VERB	O	O	2017
on	ADP	O	O	2017
myocardial	ADJ	O	O	2017
catecholamine	ADJ	O	Chemical	2017
sensitivity	NOUN	O	O	2017
in	ADP	O	O	2017
diabetic	ADJ	O	Disease	2017
rats	NOUN	O	O	2017
.	PUNCT	O	O	2017
The	PRON	O	O	2018
phenomenon	NOUN	O	O	2018
described	VERB	O	O	2018
might	AUX	O	O	2018
elucidate	VERB	O	O	2018
pathogenetic	NOUN	O	O	2018
mechanisms	NOUN	O	O	2018
behind	ADP	O	O	2018
toxic	ADJ	O	O	2018
myocardial	ADJ	O	O	2018
cell	NOUN	O	O	2018
degeneration	NOUN	O	O	2018
and	CCONJ	O	O	2018
may	AUX	O	O	2018
possibly	ADV	O	O	2018
have	VERB	O	O	2018
relevance	NOUN	O	O	2018
for	ADP	O	O	2018
acute	ADJ	O	O	2018
cardiovascular	ADJ	O	O	2018
complications	NOUN	O	O	2018
in	ADP	O	O	2018
diabetic	ADJ	O	Disease	2018
patients	NOUN	O	O	2018
.	PUNCT	O	O	2018
Differential	ADJ	O	O	2021
effects	NOUN	O	O	2021
of	ADP	O	O	2021
non	ADJ	O	O	2021
-	PUNCT	O	O	2021
steroidal	ADJ	O	O	2021
anti	ADJ	O	O	2021
-	PUNCT	O	O	2021
inflammatory	ADJ	O	O	2021
drugs	NOUN	O	O	2021
on	ADP	O	O	2021
seizures	NOUN	O	Disease	2021
produced	VERB	O	O	2021
by	ADP	O	O	2021
pilocarpine	NOUN	O	Chemical	2021
in	ADP	O	O	2021
rats	NOUN	O	O	2021
.	PUNCT	O	O	2021
The	PRON	O	O	2022
muscarinic	PROPN	O	O	2022
cholinergic	ADJ	O	O	2022
agonist	NOUN	O	O	2022
pilocarpine	NOUN	O	Chemical	2022
induces	VERB	O	O	2022
in	ADP	O	O	2022
rats	NOUN	O	O	2022
seizures	NOUN	O	Disease	2022
and	CCONJ	O	O	2022
status epilepticus	VERB	O	Disease	2022
followed	VERB	O	O	2022
by	ADP	O	O	2022
widespread	ADJ	O	O	2022
damage	NOUN	O	O	2022
to	PART	O	O	2022
the	PRON	O	O	2022
forebrain	NOUN	O	O	2022
.	PUNCT	O	O	2022
anti	ADJ	O	O	2023
-	PUNCT	O	O	2023
inflammatory	ADJ	O	O	2023
drugs	NOUN	O	O	2023
,	PUNCT	O	O	2023
sodium	NOUN	O	Chemical	2023
salicylate	NOUN	O	Chemical	2023
,	PUNCT	O	O	2023
phenylbutazone	NOUN	O	O	2023
,	PUNCT	O	O	2023
indomethacin	VERB	O	Chemical	2023
,	PUNCT	O	O	2023
ibuprofen	PROPN	O	Chemical	2023
and	CCONJ	O	O	2023
mefenamic acid	NOUN	O	Chemical	2023
,	PUNCT	O	O	2023
on	ADP	O	O	2023
seizures	NOUN	O	Disease	2023
produced	VERB	O	O	2023
by	ADP	O	O	2023
pilocarpine	NOUN	O	Chemical	2023
.	PUNCT	O	O	2023
Pretreatment	NOUN	O	O	2024
of	ADP	O	O	2024
rats	NOUN	O	O	2024
with	ADP	O	O	2024
sodium	NOUN	O	Chemical	2024
salicylate	NOUN	O	Chemical	2024
,	PUNCT	O	O	2024
ED50	PROPN	O	O	2024
103	NUM	O	O	2024
mg	VERB	O	O	2024
/	PUNCT	O	O	2024
kg	VERB	O	O	2024
(	PUNCT	O	O	2024
60	NUM	O	O	2024
-	PUNCT	O	O	2024
174	NUM	O	O	2024
)	PUNCT	O	O	2024
,	PUNCT	O	O	2024
and	CCONJ	O	O	2024
phenylbutazone	NOUN	O	O	2024
,	PUNCT	O	O	2024
59	NUM	O	O	2024
mg	VERB	O	O	2024
/	PUNCT	O	O	2024
kg	VERB	O	O	2024
(	PUNCT	O	O	2024
50	NUM	O	O	2024
-	PUNCT	O	O	2024
70	NUM	O	O	2024
)	PUNCT	O	O	2024
converted	VERB	O	O	2024
the	PRON	O	O	2024
non	ADJ	O	O	2024
-	PUNCT	O	O	2024
convulsant	ADJ	O	O	2024
dose	NOUN	O	O	2024
of	ADP	O	O	2024
pilocarpine	NOUN	O	Chemical	2024
,	PUNCT	O	O	2024
200	NUM	O	O	2024
mg	VERB	O	O	2024
/	PUNCT	O	O	2024
kg	VERB	O	O	2024
,	PUNCT	O	O	2024
to	PART	O	O	2024
a	PRON	O	O	2024
convulsant	ADJ	O	O	2024
one	NUM	O	O	2024
.	PUNCT	O	O	2024
Indomethacin	PROPN	O	Chemical	2025
,	PUNCT	O	O	2025
1	X	O	O	2025
-	PUNCT	O	O	2025
10	NUM	O	O	2025
mg	VERB	O	O	2025
/	PUNCT	O	O	2025
kg	VERB	O	O	2025
,	PUNCT	O	O	2025
and	CCONJ	O	O	2025
ibuprofen	PROPN	O	Chemical	2025
,	PUNCT	O	O	2025
10	NUM	O	O	2025
-	PUNCT	O	O	2025
100	NUM	O	O	2025
mg	VERB	O	O	2025
/	PUNCT	O	O	2025
kg	VERB	O	O	2025
,	PUNCT	O	O	2025
failed	VERB	O	O	2025
to	PART	O	O	2025
modulate	VERB	O	O	2025
seizures	NOUN	O	Disease	2025
produced	VERB	O	O	2025
by	ADP	O	O	2025
pilocarpine	NOUN	O	Chemical	2025
.	PUNCT	O	O	2025
Mefenamic	PROPN	O	O	2026
acid	PROPN	O	O	2026
,	PUNCT	O	O	2026
26	NUM	O	O	2026
(	PUNCT	O	O	2026
22	NUM	O	O	2026
-	PUNCT	O	O	2026
30	NUM	O	O	2026
)	PUNCT	O	O	2026
mg	VERB	O	O	2026
/	PUNCT	O	O	2026
kg	VERB	O	O	2026
,	PUNCT	O	O	2026
prevented	VERB	O	O	2026
seizures	NOUN	O	Disease	2026
and	CCONJ	O	O	2026
protected	VERB	O	O	2026
rats	NOUN	O	O	2026
from	ADP	O	O	2026
seizure	NOUN	O	Disease	2026
-	PUNCT	O	O	2026
related	ADJ	O	O	2026
brain damage	NOUN	O	Disease	2026
induced	VERB	O	O	2026
by	ADP	O	O	2026
pilocarpine	NOUN	O	Chemical	2026
,	PUNCT	O	O	2026
380	NUM	O	O	2026
mg	VERB	O	O	2026
/	PUNCT	O	O	2026
kg	VERB	O	O	2026
.	PUNCT	O	O	2026
These	PRON	O	O	2027
results	VERB	O	O	2027
indicate	VERB	O	O	2027
that	SCONJ	O	O	2027
non	ADJ	O	O	2027
-	PUNCT	O	O	2027
steroidal	ADJ	O	O	2027
anti	ADJ	O	O	2027
-	PUNCT	O	O	2027
inflammatory	ADJ	O	O	2027
drugs	NOUN	O	O	2027
differentially	ADV	O	O	2027
modulate	VERB	O	O	2027
the	PRON	O	O	2027
threshold	NOUN	O	O	2027
for	ADP	O	O	2027
pilocarpine	NOUN	O	Chemical	2027
-	PUNCT	O	O	2027
induced	VERB	O	O	2027
seizures	NOUN	O	Disease	2027
.	PUNCT	O	O	2027
Acute	PROPN	O	O	2030
neurologic	ADJ	O	O	2030
dysfunction	NOUN	O	O	2030
after	ADP	O	O	2030
high	ADJ	O	O	2030
-	PUNCT	O	O	2030
dose	NOUN	O	O	2030
etoposide	ADV	O	Chemical	2030
therapy	NOUN	O	O	2030
for	ADP	O	O	2030
malignant glioma	NOUN	O	Disease	2030
.	PUNCT	O	O	2030
Etoposide	NOUN	O	Chemical	2031
(	PUNCT	O	O	2031
VP-16	NUM	O	O	2031
-	PUNCT	O	O	2031
213	NUM	O	O	2031
)	PUNCT	O	O	2031
has	VERB	O	O	2031
been	AUX	O	O	2031
used	VERB	O	O	2031
in	ADP	O	O	2031
the	PRON	O	O	2031
treatment	NOUN	O	O	2031
of	ADP	O	O	2031
many	ADJ	O	O	2031
solid	ADJ	O	O	2031
tumors	NOUN	O	Disease	2031
and	CCONJ	O	O	2031
hematologic	ADJ	O	O	2031
malignancies	NOUN	O	O	2031
.	PUNCT	O	O	2031
When	SCONJ	O	O	2032
used	VERB	O	O	2032
in	ADP	O	O	2032
high	ADJ	O	O	2032
doses	NOUN	O	O	2032
and	CCONJ	O	O	2032
in	ADP	O	O	2032
conjunction	NOUN	O	O	2032
with	ADP	O	O	2032
autologous	ADJ	O	O	2032
bone	NOUN	O	O	2032
marrow	PROPN	O	O	2032
transplantation	NOUN	O	O	2032
,	PUNCT	O	O	2032
this	PRON	O	O	2032
agent	NOUN	O	O	2032
has	VERB	O	O	2032
activity	NOUN	O	O	2032
against	ADP	O	O	2032
several	ADJ	O	O	2032
treatment	NOUN	O	O	2032
-	PUNCT	O	O	2032
resistant	ADJ	O	O	2032
cancers	NOUN	O	Disease	2032
including	VERB	O	O	2032
malignant glioma	NOUN	O	Disease	2032
.	PUNCT	O	O	2032
In	ADP	O	O	2033
six	NUM	O	O	2033
of	ADP	O	O	2033
eight	NUM	O	O	2033
patients	NOUN	O	O	2033
(	PUNCT	O	O	2033
75%	NOUN	O	O	2033
)	PUNCT	O	O	2033
who	PRON	O	O	2033
we	PRON	O	O	2033
treated	VERB	O	O	2033
for	ADP	O	O	2033
recurrent	ADJ	O	O	2033
or	CCONJ	O	O	2033
resistant	ADJ	O	O	2033
glioma	NOUN	O	Disease	2033
,	PUNCT	O	O	2033
sudden	ADJ	O	O	2033
severe	ADJ	O	O	2033
neurologic	ADJ	O	O	2033
deterioration	NOUN	O	O	2033
occurred	VERB	O	O	2033
.	PUNCT	O	O	2033
This	PRON	O	O	2034
developed	VERB	O	O	2034
a	PRON	O	O	2034
median	ADJ	O	O	2034
of	ADP	O	O	2034
9	NUM	O	O	2034
days	NOUN	O	O	2034
after	ADP	O	O	2034
initiation	NOUN	O	O	2034
of	ADP	O	O	2034
high	ADJ	O	O	2034
-	PUNCT	O	O	2034
dose	NOUN	O	O	2034
etoposide	ADV	O	Chemical	2034
therapy	NOUN	O	O	2034
.	PUNCT	O	O	2034
Significant	ADJ	O	O	2035
clinical	ADJ	O	O	2035
manifestations	NOUN	O	O	2035
have	VERB	O	O	2035
included	VERB	O	O	2035
confusion	NOUN	O	Disease	2035
,	PUNCT	O	O	2035
papilledema	NOUN	O	O	2035
,	PUNCT	O	O	2035
somnolence	NOUN	O	Disease	2035
,	PUNCT	O	O	2035
exacerbation	NOUN	O	O	2035
of	ADP	O	O	2035
motor	NOUN	O	O	2035
deficits	NOUN	O	O	2035
,	PUNCT	O	O	2035
and	CCONJ	O	O	2035
sharp	ADJ	O	O	2035
increase	VERB	O	O	2035
in	ADP	O	O	2035
seizure	NOUN	O	Disease	2035
activity	NOUN	O	O	2035
.	PUNCT	O	O	2035
These	PRON	O	O	2036
abnormalities	NOUN	O	O	2036
resolved	VERB	O	O	2036
rapidly	ADV	O	O	2036
after	ADP	O	O	2036
initiation	NOUN	O	O	2036
of	ADP	O	O	2036
high	ADJ	O	O	2036
-	PUNCT	O	O	2036
dose	NOUN	O	O	2036
intravenous	ADJ	O	O	2036
dexamethasone	NOUN	O	Chemical	2036
therapy	NOUN	O	O	2036
.	PUNCT	O	O	2036
brain	NOUN	O	O	2037
scans	VERB	O	O	2037
demonstrated	VERB	O	O	2037
stability	PROPN	O	O	2037
in	ADP	O	O	2037
tumor	NOUN	O	Disease	2037
size	NOUN	O	O	2037
and	CCONJ	O	O	2037
peritumor	PROPN	O	O	2037
edema	NOUN	O	Disease	2037
when	SCONJ	O	O	2037
compared	VERB	O	O	2037
with	ADP	O	O	2037
pretransplant	ADJ	O	O	2037
scans	VERB	O	O	2037
.	PUNCT	O	O	2037
This	PRON	O	O	2038
complication	NOUN	O	O	2038
appears	VERB	O	O	2038
to	PART	O	O	2038
represent	VERB	O	O	2038
a	PRON	O	O	2038
significant	ADJ	O	O	2038
new	ADJ	O	O	2038
toxicity	NOUN	O	Disease	2038
of	ADP	O	O	2038
high	ADJ	O	O	2038
-	PUNCT	O	O	2038
dose	NOUN	O	O	2038
etoposide	ADV	O	Chemical	2038
therapy	NOUN	O	O	2038
for	ADP	O	O	2038
malignant glioma	NOUN	O	Disease	2038
.	PUNCT	O	O	2038
Progressive	PROPN	O	O	2041
bile duct injury	NOUN	O	Disease	2041
after	ADP	O	O	2041
thiabendazole	NOUN	O	O	2041
administration	NOUN	O	O	2041
.	PUNCT	O	O	2041
A	PRON	O	O	2042
27-yr	NOUN	O	O	2042
-	PUNCT	O	O	2042
old	ADJ	O	O	2042
man	NOUN	O	O	2042
developed	VERB	O	O	2042
jaundice	NOUN	O	Disease	2042
2	X	O	O	2042
wk	X	O	O	2042
after	ADP	O	O	2042
exposure	NOUN	O	O	2042
to	PART	O	O	2042
thiabendazole	NOUN	O	O	2042
.	PUNCT	O	O	2042
Cholestasis	NOUN	O	O	2043
persisted	VERB	O	O	2043
for	ADP	O	O	2043
3	X	O	O	2043
yr	NOUN	O	O	2043
,	PUNCT	O	O	2043
at	ADP	O	O	2043
which	PRON	O	O	2043
time	NOUN	O	O	2043
a	PRON	O	O	2043
liver	NOUN	O	O	2043
transplant	NOUN	O	O	2043
was	AUX	O	O	2043
performed	VERB	O	O	2043
.	PUNCT	O	O	2043
Prominent	ADJ	O	O	2044
fibrosis	NOUN	O	Disease	2044
and	CCONJ	O	O	2044
hepatocellular	NOUN	O	O	2044
regeneration	NOUN	O	O	2044
were	AUX	O	O	2044
also	ADV	O	O	2044
present	NOUN	O	O	2044
;	PUNCT	O	O	2044
however	ADV	O	O	2044
,	PUNCT	O	O	2044
the	PRON	O	O	2044
lobular	ADJ	O	O	2044
architecture	NOUN	O	O	2044
was	AUX	O	O	2044
preserved	VERB	O	O	2044
.	PUNCT	O	O	2044
This	PRON	O	O	2045
case	NOUN	O	O	2045
represents	VERB	O	O	2045
an	PRON	O	O	2045
example	NOUN	O	O	2045
of	ADP	O	O	2045
""""	PUNCT	O	O	2045
idiosyncratic	ADJ	O	O	2045
""""	PUNCT	O	O	2045
drug	NOUN	O	O	2045
-	PUNCT	O	O	2045
induced	VERB	O	O	2045
liver damage	NOUN	O	Disease	2045
in	ADP	O	O	2045
which	PRON	O	O	2045
the	PRON	O	O	2045
primary	NOUN	O	O	2045
target	NOUN	O	O	2045
of	ADP	O	O	2045
injury	NOUN	O	O	2045
is	AUX	O	O	2045
the	PRON	O	O	2045
bile	NOUN	O	O	2045
duct	NOUN	O	O	2045
.	PUNCT	O	O	2045
An	PRON	O	O	2046
autoimmune	PROPN	O	O	2046
pathogenesis	NOUN	O	O	2046
of	ADP	O	O	2046
the	PRON	O	O	2046
bile	NOUN	O	O	2046
duct	NOUN	O	O	2046
destruction	NOUN	O	O	2046
is	AUX	O	O	2046
suggested	VERB	O	O	2046
.	PUNCT	O	O	2046
Differential	ADJ	O	O	2049
effects	NOUN	O	O	2049
of	ADP	O	O	2049
1,4-dihydropyridine	NOUN	O	O	2049
calcium	NOUN	O	Chemical	2049
channel	PROPN	O	O	2049
blockers	NOUN	O	O	2049
:	PUNCT	O	O	2049
therapeutic	ADJ	O	O	2049
implications	NOUN	O	O	2049
.	PUNCT	O	O	2049
Increasing	VERB	O	O	2050
recognition	NOUN	O	O	2050
of	ADP	O	O	2050
the	PRON	O	O	2050
importance	NOUN	O	O	2050
of	ADP	O	O	2050
calcium	NOUN	O	Chemical	2050
in	ADP	O	O	2050
the	PRON	O	O	2050
pathogenesis	NOUN	O	O	2050
of	ADP	O	O	2050
cardiovascular disease	NOUN	O	Disease	2050
has	VERB	O	O	2050
stimulated	VERB	O	O	2050
research	NOUN	O	O	2050
into	ADP	O	O	2050
the	PRON	O	O	2050
use	VERB	O	O	2050
of	ADP	O	O	2050
calcium	NOUN	O	Chemical	2050
channel	PROPN	O	O	2050
blocking	VERB	O	O	2050
agents	NOUN	O	O	2050
for	ADP	O	O	2050
treatment	NOUN	O	O	2050
of	ADP	O	O	2050
a	PRON	O	O	2050
variety	NOUN	O	O	2050
of	ADP	O	O	2050
cardiovascular diseases	NOUN	O	O	2050
.	PUNCT	O	O	2050
Clinical	NOUN	O	O	2051
applications	NOUN	O	O	2051
of	ADP	O	O	2051
calcium	NOUN	O	Chemical	2051
channel	PROPN	O	O	2051
blockers	NOUN	O	O	2051
parallel	ADJ	O	O	2051
their	PRON	O	O	2051
tissue	NOUN	O	O	2051
selectivity	NOUN	O	O	2051
.	PUNCT	O	O	2051
In	ADP	O	O	2052
contrast	NOUN	O	O	2052
to	PART	O	O	2052
verapamil	PROPN	O	Chemical	2052
and	CCONJ	O	O	2052
diltiazem	VERB	O	Chemical	2052
,	PUNCT	O	O	2052
which	PRON	O	O	2052
are	AUX	O	O	2052
roughly	ADV	O	O	2052
equipotent	ADJ	O	O	2052
in	ADP	O	O	2052
their	PRON	O	O	2052
actions	NOUN	O	O	2052
on	ADP	O	O	2052
the	PRON	O	O	2052
heart	NOUN	O	O	2052
and	CCONJ	O	O	2052
vascular	ADJ	O	O	2052
smooth	VERB	O	O	2052
muscle	NOUN	O	O	2052
,	PUNCT	O	O	2052
the	PRON	O	O	2052
dihydropyridine	NOUN	O	Chemical	2052
calcium	NOUN	O	Chemical	2052
channel	PROPN	O	O	2052
blockers	NOUN	O	O	2052
are	AUX	O	O	2052
a	PRON	O	O	2052
group	NOUN	O	O	2052
of	ADP	O	O	2052
potent	ADJ	O	O	2052
peripheral	ADJ	O	O	2052
vasodilator	NOUN	O	O	2052
agents	NOUN	O	O	2052
that	SCONJ	O	O	2052
exert	VERB	O	O	2052
minimal	ADJ	O	O	2052
electrophysiologic	VERB	O	O	2052
effects	NOUN	O	O	2052
on	ADP	O	O	2052
cardiac	ADJ	O	O	2052
nodal	ADJ	O	O	2052
or	CCONJ	O	O	2052
conduction	NOUN	O	O	2052
tissue	NOUN	O	O	2052
.	PUNCT	O	O	2052
As	ADP	O	O	2053
the	PRON	O	O	2053
first	ADV	O	O	2053
dihydropyridine	NOUN	O	Chemical	2053
available	ADJ	O	O	2053
for	ADP	O	O	2053
use	VERB	O	O	2053
in	ADP	O	O	2053
the	PRON	O	O	2053
United	PROPN	O	O	2053
States	NOUN	O	O	2053
,	PUNCT	O	O	2053
nifedipine	PROPN	O	Chemical	2053
controls	VERB	O	O	2053
angina	NOUN	O	Disease	2053
and	CCONJ	O	O	2053
hypertension	NOUN	O	Disease	2053
with	ADP	O	O	2053
minimal	ADJ	O	O	2053
depression	PROPN	O	Disease	2053
of	ADP	O	O	2053
cardiac	ADJ	O	O	2053
function	NOUN	O	O	2053
.	PUNCT	O	O	2053
Additional	ADJ	O	O	2054
members	NOUN	O	O	2054
of	ADP	O	O	2054
this	PRON	O	O	2054
group	NOUN	O	O	2054
of	ADP	O	O	2054
calcium	NOUN	O	Chemical	2054
channel	PROPN	O	O	2054
blockers	NOUN	O	O	2054
have	VERB	O	O	2054
been	AUX	O	O	2054
studied	VERB	O	O	2054
for	ADP	O	O	2054
a	PRON	O	O	2054
variety	NOUN	O	O	2054
of	ADP	O	O	2054
indications	NOUN	O	O	2054
for	ADP	O	O	2054
which	PRON	O	O	2054
they	PRON	O	O	2054
may	AUX	O	O	2054
offer	VERB	O	O	2054
advantages	NOUN	O	O	2054
over	ADP	O	O	2054
current	ADJ	O	O	2054
therapy	NOUN	O	O	2054
.	PUNCT	O	O	2054
Once	ADV	O	O	2055
or	CCONJ	O	O	2055
twice	ADV	O	O	2055
daily	ADV	O	O	2055
dosage	NOUN	O	O	2055
possible	ADJ	O	O	2055
with	ADP	O	O	2055
nitrendipine	ADJ	O	O	2055
and	CCONJ	O	O	2055
nisoldipine	NOUN	O	O	2055
offers	VERB	O	O	2055
a	PRON	O	O	2055
convenient	ADJ	O	O	2055
administration	NOUN	O	O	2055
schedule	NOUN	O	O	2055
,	PUNCT	O	O	2055
which	PRON	O	O	2055
encourages	VERB	O	O	2055
patient	NOUN	O	O	2055
compliance	NOUN	O	O	2055
in	ADP	O	O	2055
long	ADV	O	O	2055
-	PUNCT	O	O	2055
term	NOUN	O	O	2055
therapy	NOUN	O	O	2055
of	ADP	O	O	2055
hypertension	NOUN	O	Disease	2055
.	PUNCT	O	O	2055
The	PRON	O	O	2056
coronary	ADJ	O	O	2056
vasodilating	VERB	O	O	2056
properties	NOUN	O	O	2056
of	ADP	O	O	2056
nisoldipine	NOUN	O	O	2056
have	VERB	O	O	2056
led	VERB	O	O	2056
to	PART	O	O	2056
the	PRON	O	O	2056
investigation	NOUN	O	O	2056
of	ADP	O	O	2056
this	PRON	O	O	2056
agent	NOUN	O	O	2056
for	ADP	O	O	2056
use	VERB	O	O	2056
in	ADP	O	O	2056
angina	NOUN	O	Disease	2056
.	PUNCT	O	O	2056
Selectivity	NOUN	O	O	2057
for	ADP	O	O	2057
the	PRON	O	O	2057
cerebrovascular	ADJ	O	O	2057
bed	NOUN	O	O	2057
makes	VERB	O	O	2057
nimodipine	NOUN	O	Chemical	2057
potentially	ADV	O	O	2057
useful	ADJ	O	O	2057
in	ADP	O	O	2057
the	PRON	O	O	2057
treatment	NOUN	O	O	2057
of	ADP	O	O	2057
subarachnoid hemorrhage	NOUN	O	Disease	2057
,	PUNCT	O	O	2057
migraine headache	PROPN	O	Disease	2057
,	PUNCT	O	O	2057
dementia	NOUN	O	Disease	2057
,	PUNCT	O	O	2057
and	CCONJ	O	O	2057
stroke	VERB	O	Disease	2057
.	PUNCT	O	O	2057
In	ADP	O	O	2058
general	ADJ	O	O	2058
,	PUNCT	O	O	2058
the	PRON	O	O	2058
dihydropyridine	NOUN	O	Chemical	2058
calcium	NOUN	O	Chemical	2058
channel	PROPN	O	O	2058
blockers	NOUN	O	O	2058
are	AUX	O	O	2058
usually	ADV	O	O	2058
well	ADV	O	O	2058
tolerated	VERB	O	O	2058
,	PUNCT	O	O	2058
with	ADP	O	O	2058
headache	PROPN	O	Disease	2058
,	PUNCT	O	O	2058
facial flushing	NOUN	O	O	2058
,	PUNCT	O	O	2058
palpitations	NOUN	O	O	2058
,	PUNCT	O	O	2058
edema	NOUN	O	Disease	2058
,	PUNCT	O	O	2058
nausea	NOUN	O	Disease	2058
,	PUNCT	O	O	2058
anorexia	X	O	Disease	2058
,	PUNCT	O	O	2058
and	CCONJ	O	O	2058
dizziness	NOUN	O	Disease	2058
being	AUX	O	O	2058
the	PRON	O	O	2058
more	ADJ	O	O	2058
common	ADJ	O	O	2058
adverse	ADJ	O	O	2058
effects	NOUN	O	O	2058
.	PUNCT	O	O	2058
The	PRON	O	O	2061
enhancement	NOUN	O	O	2061
of	ADP	O	O	2061
aminonucleoside	NOUN	O	Chemical	2061
nephrosis	NOUN	O	Disease	2061
by	ADP	O	O	2061
the	PRON	O	O	2061
co	NOUN	O	O	2061
-	PUNCT	O	O	2061
administration	NOUN	O	O	2061
of	ADP	O	O	2061
protamine	PROPN	O	O	2061
.	PUNCT	O	O	2061
An	PRON	O	O	2062
experimental	ADJ	O	O	2062
model	NOUN	O	O	2062
of	ADP	O	O	2062
focal	ADJ	O	O	2062
segmental	ADJ	O	O	2062
glomerular	ADJ	O	O	2062
sclerosis	NOUN	O	O	2062
(	PUNCT	O	O	2062
FSGS	PROPN	O	O	2062
)	PUNCT	O	O	2062
was	AUX	O	O	2062
developed	VERB	O	O	2062
in	ADP	O	O	2062
rats	NOUN	O	O	2062
by	ADP	O	O	2062
the	PRON	O	O	2062
combined	VERB	O	O	2062
administration	NOUN	O	O	2062
of	ADP	O	O	2062
puromycin	PROPN	O	O	2062
-	PUNCT	O	O	2062
aminonucleoside	NOUN	O	Chemical	2062
(	PUNCT	O	O	2062
AMNS	PROPN	O	O	2062
)	PUNCT	O	O	2062
and	CCONJ	O	O	2062
protamine	PROPN	O	O	2062
sulfate	NOUN	O	O	2062
(	PUNCT	O	O	2062
PS	PROPN	O	O	2062
)	PUNCT	O	O	2062
.	PUNCT	O	O	2062
Male	NOUN	O	O	2063
Sprague	PROPN	O	O	2063
-	PUNCT	O	O	2063
Dawley	NOUN	O	O	2063
rats	NOUN	O	O	2063
,	PUNCT	O	O	2063
uninephrectomized	VERB	O	O	2063
three	NUM	O	O	2063
weeks	NOUN	O	O	2063
before	ADP	O	O	2063
,	PUNCT	O	O	2063
received	VERB	O	O	2063
daily	ADV	O	O	2063
injections	NOUN	O	O	2063
of	ADP	O	O	2063
subcutaneous	ADJ	O	O	2063
AMNS	PROPN	O	O	2063
(	PUNCT	O	O	2063
1	X	O	O	2063
mg/100	VERB	O	O	2063
g	X	O	O	2063
body	NOUN	O	O	2063
wt	NOUN	O	O	2064
)	PUNCT	O	O	2064
and	CCONJ	O	O	2064
intravenous	ADJ	O	O	2064
PS	PROPN	O	O	2064
(	PUNCT	O	O	2064
2	X	O	O	2064
separated	VERB	O	O	2064
doses	NOUN	O	O	2064
of	ADP	O	O	2064
2.5	NUM	O	O	2064
mg/100	VERB	O	O	2064
g	X	O	O	2064
body	NOUN	O	O	2064
wt	NOUN	O	O	2064
)	PUNCT	O	O	2064
for	ADP	O	O	2064
four	NUM	O	O	2064
days	NOUN	O	O	2064
.	PUNCT	O	O	2064
They	PRON	O	O	2065
developed	VERB	O	O	2065
nephrotic syndrome	NOUN	O	Disease	2065
and	CCONJ	O	O	2065
finally	ADV	O	O	2065
renal failure	NOUN	O	Disease	2065
.	PUNCT	O	O	2065
The	PRON	O	O	2066
time	NOUN	O	O	2066
-	PUNCT	O	O	2066
course	NOUN	O	O	2066
curve	NOUN	O	O	2066
of	ADP	O	O	2066
creatinine	PROPN	O	Chemical	2066
clearance	NOUN	O	O	2066
dropped	VERB	O	O	2066
and	CCONJ	O	O	2066
showed	VERB	O	O	2066
significant	ADJ	O	O	2066
difference	NOUN	O	O	2066
(	PUNCT	O	O	2066
P	NOUN	O	Chemical	2066
less	ADV	O	O	2066
than	ADP	O	O	2066
0.01	NUM	O	O	2066
)	PUNCT	O	O	2066
from	ADP	O	O	2066
that	SCONJ	O	O	2066
of	ADP	O	O	2066
each	PRON	O	O	2066
control	VERB	O	O	2066
group	NOUN	O	O	2066
,	PUNCT	O	O	2066
such	ADJ	O	O	2066
as	ADP	O	O	2066
,	PUNCT	O	O	2066
AMNS	PROPN	O	O	2066
alone	ADV	O	O	2066
,	PUNCT	O	O	2066
PS	PROPN	O	O	2066
alone	ADV	O	O	2066
or	CCONJ	O	O	2066
saline	NOUN	O	O	2066
injected	VERB	O	O	2066
.	PUNCT	O	O	2066
Their	PRON	O	O	2067
glomeruli	VERB	O	O	2067
showed	VERB	O	O	2067
changes	VERB	O	O	2067
of	ADP	O	O	2067
progressive	ADJ	O	O	2067
FSGS	PROPN	O	O	2067
.	PUNCT	O	O	2067
The	PRON	O	O	2068
ultrastructural	ADJ	O	O	2068
studies	NOUN	O	O	2068
in	ADP	O	O	2068
the	PRON	O	O	2068
initial	ADJ	O	O	2068
stage	NOUN	O	O	2068
revealed	VERB	O	O	2068
significant	ADJ	O	O	2068
lack	VERB	O	O	2068
of	ADP	O	O	2068
particles	NOUN	O	O	2068
of	ADP	O	O	2068
perfused	VERB	O	O	2068
ruthenium	NOUN	O	O	2068
red	ADJ	O	O	2068
on	ADP	O	O	2068
the	PRON	O	O	2068
lamina	ADJ	O	O	2068
rara	PROPN	O	O	2068
externa	VERB	O	O	2068
and	CCONJ	O	O	2068
marked	VERB	O	O	2068
changes	VERB	O	O	2068
in	ADP	O	O	2068
epithelial	ADJ	O	O	2068
cell	NOUN	O	O	2068
cytoplasm	ADJ	O	O	2068
.	PUNCT	O	O	2068
Therefore	ADV	O	O	2069
,	PUNCT	O	O	2069
it	PRON	O	O	2069
is	AUX	O	O	2069
suggested	VERB	O	O	2069
that	SCONJ	O	O	2069
the	PRON	O	O	2069
administration	NOUN	O	O	2069
of	ADP	O	O	2069
PS	PROPN	O	O	2069
enhances	VERB	O	O	2069
the	PRON	O	O	2069
toxicity	NOUN	O	Disease	2069
of	ADP	O	O	2069
AMNS	PROPN	O	O	2069
on	ADP	O	O	2069
the	PRON	O	O	2069
glomerulus	NOUN	O	O	2069
and	CCONJ	O	O	2069
readily	ADV	O	O	2069
produces	VERB	O	O	2069
progressive	ADJ	O	O	2069
FSGS	PROPN	O	O	2069
in	ADP	O	O	2069
rats	NOUN	O	O	2069
resulting	VERB	O	O	2069
in	ADP	O	O	2069
the	PRON	O	O	2069
end	VERB	O	O	2069
-	PUNCT	O	O	2069
stage	NOUN	O	O	2069
renal disease	NOUN	O	Disease	2069
.	PUNCT	O	O	2069
Theophylline	NOUN	O	O	2072
neurotoxicity	NOUN	O	Disease	2072
in	ADP	O	O	2072
pregnant	ADJ	O	O	2072
rats	NOUN	O	O	2072
.	PUNCT	O	O	2072
The	PRON	O	O	2073
purpose	NOUN	O	O	2073
of	ADP	O	O	2073
this	PRON	O	O	2073
investigation	NOUN	O	O	2073
was	AUX	O	O	2073
to	PART	O	O	2073
determine	VERB	O	O	2073
whether	SCONJ	O	O	2073
the	PRON	O	O	2073
neurotoxicity	NOUN	O	Disease	2073
of	ADP	O	O	2073
theophylline	ADV	O	Chemical	2073
is	AUX	O	O	2073
altered	VERB	O	O	2073
in	ADP	O	O	2073
advanced	ADJ	O	O	2073
pregnancy	NOUN	O	O	2073
.	PUNCT	O	O	2073
Sprague	PROPN	O	O	2074
-	PUNCT	O	O	2074
Dawley	NOUN	O	O	2074
rats	NOUN	O	O	2074
that	SCONJ	O	O	2074
were	AUX	O	O	2074
20	NUM	O	O	2074
days	NOUN	O	O	2074
pregnant	ADJ	O	O	2074
and	CCONJ	O	O	2074
nonpregnant	ADJ	O	O	2074
rats	NOUN	O	O	2074
of	ADP	O	O	2074
the	PRON	O	O	2074
same	ADJ	O	O	2074
age	NOUN	O	O	2074
and	CCONJ	O	O	2074
strain	VERB	O	O	2074
received	VERB	O	O	2074
infusions	NOUN	O	O	2074
of	ADP	O	O	2074
aminophylline	VERB	O	Chemical	2074
until	ADP	O	O	2074
onset	VERB	O	O	2074
of	ADP	O	O	2074
maximal	ADJ	O	O	2074
seizures	NOUN	O	Disease	2074
which	PRON	O	O	2074
occurred	VERB	O	O	2074
after	ADP	O	O	2074
28	NUM	O	O	2074
and	CCONJ	O	O	2074
30	NUM	O	O	2074
minutes	NOUN	O	O	2074
respectively	ADV	O	O	2074
.	PUNCT	O	O	2074
Theophylline	NOUN	O	O	2075
concentrations	NOUN	O	O	2075
at	ADP	O	O	2075
this	PRON	O	O	2075
endpoint	NOUN	O	O	2075
in	ADP	O	O	2075
serum	NOUN	O	O	2075
(	PUNCT	O	O	2075
total	ADJ	O	O	2075
)	PUNCT	O	O	2075
and	CCONJ	O	O	2075
CSF	PROPN	O	O	2075
were	AUX	O	O	2075
similar	ADJ	O	O	2075
but	CCONJ	O	O	2075
serum	NOUN	O	O	2075
(	PUNCT	O	O	2075
free	ADJ	O	O	2075
)	PUNCT	O	O	2075
and	CCONJ	O	O	2075
brain	NOUN	O	O	2075
concentrations	NOUN	O	O	2075
were	AUX	O	O	2075
slightly	ADV	O	O	2075
different	ADJ	O	O	2075
in	ADP	O	O	2075
pregnant	ADJ	O	O	2075
rats	NOUN	O	O	2075
.	PUNCT	O	O	2075
Theophylline	NOUN	O	O	2076
serum	NOUN	O	O	2076
protein	NOUN	O	O	2076
binding	VERB	O	O	2076
determined	VERB	O	O	2076
by	ADP	O	O	2076
equilibrium	NOUN	O	O	2076
dialysis	NOUN	O	O	2076
was	AUX	O	O	2076
lower	ADJ	O	O	2076
in	ADP	O	O	2076
pregnant	ADJ	O	O	2076
rats	NOUN	O	O	2076
.	PUNCT	O	O	2076
Fetal	ADJ	O	O	2077
serum	NOUN	O	O	2077
concentrations	NOUN	O	O	2077
at	ADP	O	O	2077
onset	VERB	O	O	2077
of	ADP	O	O	2077
seizures	NOUN	O	Disease	2077
in	ADP	O	O	2077
the	PRON	O	O	2077
mother	NOUN	O	O	2077
were	AUX	O	O	2077
similar	ADJ	O	O	2077
to	PART	O	O	2077
maternal	ADJ	O	O	2077
brain	NOUN	O	O	2077
and	CCONJ	O	O	2077
CSF	PROPN	O	O	2077
concentrations	NOUN	O	O	2077
and	CCONJ	O	O	2077
correlated	VERB	O	O	2077
significantly	ADV	O	O	2077
with	ADP	O	O	2077
the	PRON	O	O	2077
former	ADJ	O	O	2077
.	PUNCT	O	O	2077
It	PRON	O	O	2078
is	AUX	O	O	2078
concluded	VERB	O	O	2078
that	SCONJ	O	O	2078
advanced	ADJ	O	O	2078
pregnancy	NOUN	O	O	2078
has	VERB	O	O	2078
a	PRON	O	O	2078
negligible	ADJ	O	O	2078
effect	VERB	O	O	2078
on	ADP	O	O	2078
the	PRON	O	O	2078
neurotoxic	ADJ	O	Disease	2078
response	NOUN	O	O	2078
to	PART	O	O	2078
theophylline	ADV	O	Chemical	2078
in	ADP	O	O	2078
rats	NOUN	O	O	2078
.	PUNCT	O	O	2078
Hyperkalemia	NOUN	O	O	2081
induced	VERB	O	O	2081
by	ADP	O	O	2081
indomethacin	VERB	O	Chemical	2081
and	CCONJ	O	O	2081
naproxen	PROPN	O	Chemical	2081
and	CCONJ	O	O	2081
reversed	VERB	O	O	2081
by	ADP	O	O	2081
fludrocortisone	PROPN	O	O	2081
.	PUNCT	O	O	2081
We	PRON	O	O	2082
have	VERB	O	O	2082
described	VERB	O	O	2082
a	PRON	O	O	2082
patient	NOUN	O	O	2082
with	ADP	O	O	2082
severe	ADJ	O	O	2082
rheumatoid arthritis	NOUN	O	Disease	2082
and	CCONJ	O	O	2082
a	PRON	O	O	2082
history	NOUN	O	O	2082
of	ADP	O	O	2082
mefenamic acid	NOUN	O	Chemical	2082
nephropathy	NOUN	O	Disease	2082
in	ADP	O	O	2082
whom	PRON	O	O	2082
hyperkalemia	NOUN	O	O	2082
and	CCONJ	O	O	2082
inappropriate	ADJ	O	O	2082
hypoaldosteronism	NOUN	O	O	2082
were	AUX	O	O	2082
caused	VERB	O	O	2082
by	ADP	O	O	2082
both	PRON	O	O	2082
indomethacin	VERB	O	Chemical	2082
and	CCONJ	O	O	2082
naproxen	PROPN	O	Chemical	2082
,	PUNCT	O	O	2082
without	ADP	O	O	2082
major	ADJ	O	O	2082
decline	VERB	O	O	2082
in	ADP	O	O	2082
renal	ADJ	O	O	2082
function	NOUN	O	O	2082
.	PUNCT	O	O	2082
It	PRON	O	O	2083
is	AUX	O	O	2083
likely	ADV	O	O	2083
that	SCONJ	O	O	2083
preexisting	VERB	O	O	2083
renal disease	NOUN	O	Disease	2083
predisposed	ADJ	O	O	2083
this	PRON	O	O	2083
patient	NOUN	O	O	2083
to	PART	O	O	2083
type	NOUN	O	O	2083
IV	NUM	O	O	2083
renal	ADJ	O	O	2083
tubular	ADJ	O	O	2083
acidosis	NOUN	O	Disease	2083
with	ADP	O	O	2083
prostaglandin	NOUN	O	Chemical	2083
synthetase	PROPN	O	O	2083
inhibitors	NOUN	O	O	2083
.	PUNCT	O	O	2083
Because	SCONJ	O	O	2084
he	PRON	O	O	2084
was	AUX	O	O	2084
unable	ADJ	O	O	2084
to	PART	O	O	2084
discontinue	VERB	O	O	2084
nonsteroidal	ADJ	O	O	2084
anti	ADJ	O	O	2084
-	PUNCT	O	O	2084
inflammatory	ADJ	O	O	2084
drug	NOUN	O	O	2084
therapy	NOUN	O	O	2084
,	PUNCT	O	O	2084
fludrocortisone	PROPN	O	O	2084
was	AUX	O	O	2084
added	VERB	O	O	2084
,	PUNCT	O	O	2084
correcting	VERB	O	O	2084
the	PRON	O	O	2084
hyperkalemia	NOUN	O	O	2084
and	CCONJ	O	O	2084
allowing	VERB	O	O	2084
indomethacin	VERB	O	Chemical	2084
therapy	NOUN	O	O	2084
to	PART	O	O	2084
be	AUX	O	O	2084
continued	VERB	O	O	2084
safely	ADV	O	O	2084
.	PUNCT	O	O	2084
Hypotension	NOUN	O	Disease	2087
as	ADP	O	O	2087
a	PRON	O	O	2087
manifestation	NOUN	O	O	2087
of	ADP	O	O	2087
cardiotoxicity	NOUN	O	Disease	2087
in	ADP	O	O	2087
three	NUM	O	O	2087
patients	NOUN	O	O	2087
receiving	VERB	O	O	2087
cisplatin	NOUN	O	Chemical	2087
and	CCONJ	O	O	2087
5-fluorouracil	NOUN	O	Chemical	2087
.	PUNCT	O	O	2087
Cardiac	ADJ	O	O	2088
symptoms	NOUN	O	O	2088
,	PUNCT	O	O	2088
including	VERB	O	O	2088
hypotension	NOUN	O	Disease	2088
,	PUNCT	O	O	2088
developed	VERB	O	O	2088
in	ADP	O	O	2088
three	NUM	O	O	2088
patients	NOUN	O	O	2088
with	ADP	O	O	2088
advanced	ADJ	O	O	2088
colorectal	ADJ	O	O	2088
carcinoma	NOUN	O	Disease	2088
while	SCONJ	O	O	2088
being	AUX	O	O	2088
treated	VERB	O	O	2088
with	ADP	O	O	2088
cisplatin	NOUN	O	Chemical	2088
(	PUNCT	O	O	2088
CDDP	PROPN	O	Chemical	2088
)	PUNCT	O	O	2088
and	CCONJ	O	O	2088
5-fluorouracil	NOUN	O	Chemical	2088
(	PUNCT	O	O	2088
5-FU	NOUN	O	Chemical	2088
)	PUNCT	O	O	2088
.	PUNCT	O	O	2088
In	ADP	O	O	2089
two	NUM	O	O	2089
patients	NOUN	O	O	2089
,	PUNCT	O	O	2089
hypotension	NOUN	O	Disease	2089
was	AUX	O	O	2089
associated	VERB	O	O	2089
with	ADP	O	O	2089
severe	ADJ	O	O	2089
left ventricular dysfunction	NOUN	O	Disease	2089
.	PUNCT	O	O	2089
The	PRON	O	O	2090
presentation	NOUN	O	O	2090
and	CCONJ	O	O	2090
cardiac	ADJ	O	O	2090
evaluation	NOUN	O	O	2090
(	PUNCT	O	O	2090
hemodynamic	ADJ	O	O	2090
,	PUNCT	O	O	2090
echocardiographic	NOUN	O	O	2090
,	PUNCT	O	O	2090
and	CCONJ	O	O	2090
scintigraphic	NOUN	O	O	2090
)	PUNCT	O	O	2090
of	ADP	O	O	2090
these	PRON	O	O	2090
patients	NOUN	O	O	2090
suggest	VERB	O	O	2090
new	ADJ	O	O	2090
manifestations	NOUN	O	O	2090
of	ADP	O	O	2090
5-FU	NOUN	O	Chemical	2090
cardiotoxicity	NOUN	O	Disease	2090
that	SCONJ	O	O	2090
may	AUX	O	O	2090
be	AUX	O	O	2090
influenced	VERB	O	O	2090
by	ADP	O	O	2090
CDDP	PROPN	O	Chemical	2090
.	PUNCT	O	O	2090
Fatal	ADJ	O	O	2093
aplastic anemia	NOUN	O	Disease	2093
in	ADP	O	O	2093
a	PRON	O	O	2093
patient	NOUN	O	O	2093
treated	VERB	O	O	2093
with	ADP	O	O	2093
carbamazepine	NOUN	O	Chemical	2093
.	PUNCT	O	O	2093
A	PRON	O	O	2094
case	NOUN	O	O	2094
of	ADP	O	O	2094
fatal	ADJ	O	O	2094
aplastic anemia	NOUN	O	Disease	2094
due	ADJ	O	O	2094
to	PART	O	O	2094
carbamazepine	NOUN	O	Chemical	2094
treatment	NOUN	O	O	2094
in	ADP	O	O	2094
an	PRON	O	O	2094
epileptic	ADJ	O	Disease	2094
woman	NOUN	O	O	2094
is	AUX	O	O	2094
reported	VERB	O	O	2094
.	PUNCT	O	O	2094
Despite	SCONJ	O	O	2095
concerns	NOUN	O	O	2095
of	ADP	O	O	2095
fatal	ADJ	O	O	2095
bone	NOUN	O	O	2095
marrow toxicity	NOUN	O	Disease	2095
due	ADJ	O	O	2095
to	PART	O	O	2095
carbamazepine	NOUN	O	Chemical	2095
,	PUNCT	O	O	2095
this	PRON	O	O	2095
is	AUX	O	O	2095
only	ADV	O	O	2095
the	PRON	O	O	2095
fourth	ADV	O	O	2095
documented	VERB	O	O	2095
and	CCONJ	O	O	2095
published	VERB	O	O	2095
report	VERB	O	O	2095
.	PUNCT	O	O	2095
Carbamazepine	NOUN	O	Chemical	2096
is	AUX	O	O	2096
a	PRON	O	O	2096
safe	ADJ	O	O	2096
drug	NOUN	O	O	2096
,	PUNCT	O	O	2096
but	CCONJ	O	O	2096
physicians	NOUN	O	O	2096
and	CCONJ	O	O	2096
patients	NOUN	O	O	2096
should	AUX	O	O	2096
be	AUX	O	O	2096
aware	ADJ	O	O	2096
of	ADP	O	O	2096
the	PRON	O	O	2096
exceedingly	ADV	O	O	2096
rare	ADJ	O	O	2096
but	CCONJ	O	O	2096
potentially	ADV	O	O	2096
fatal	ADJ	O	O	2096
side	NOUN	O	O	2096
effects	NOUN	O	O	2096
,	PUNCT	O	O	2096
better	ADV	O	O	2096
prevented	VERB	O	O	2096
by	ADP	O	O	2096
clinical	ADJ	O	O	2096
than	ADP	O	O	2096
by	ADP	O	O	2096
laboratory	NOUN	O	O	2096
monitoring	NOUN	O	O	2096
.	PUNCT	O	O	2096
Participation	NOUN	O	O	2099
of	ADP	O	O	2099
a	PRON	O	O	2099
bulbospinal	ADJ	O	O	2099
serotonergic	ADJ	O	O	2099
pathway	NOUN	O	O	2099
in	ADP	O	O	2099
the	PRON	O	O	2099
rat	NOUN	O	O	2099
brain	NOUN	O	O	2099
in	ADP	O	O	2099
clonidine	NOUN	O	Chemical	2099
-	PUNCT	O	O	2099
induced	VERB	O	O	2099
hypotension	NOUN	O	Disease	2099
and	CCONJ	O	O	2099
bradycardia	NOUN	O	Disease	2099
.	PUNCT	O	O	2099
The	PRON	O	O	2100
effects	NOUN	O	O	2100
of	ADP	O	O	2100
microinjection	NOUN	O	O	2100
of	ADP	O	O	2100
clonidine	NOUN	O	Chemical	2100
(	PUNCT	O	O	2100
1	X	O	O	2100
-	PUNCT	O	O	2100
10	NUM	O	O	2100
micrograms	NOUN	O	O	2100
in	ADP	O	O	2100
1	X	O	O	2100
microliter	ADJ	O	O	2100
)	PUNCT	O	O	2100
into	ADP	O	O	2100
a	PRON	O	O	2100
region	NOUN	O	O	2100
adjacent	ADJ	O	O	2100
to	PART	O	O	2100
the	PRON	O	O	2100
ventrolateral	ADJ	O	O	2100
surface	NOUN	O	O	2100
of	ADP	O	O	2100
the	PRON	O	O	2100
medulla	NOUN	O	O	2100
oblongata	VERB	O	O	2100
on	ADP	O	O	2100
cardiovascular	ADJ	O	O	2100
function	NOUN	O	O	2100
were	AUX	O	O	2100
assessed	VERB	O	O	2100
in	ADP	O	O	2100
urethane	NOUN	O	Chemical	2100
-	PUNCT	O	O	2100
anesthetized	VERB	O	O	2100
rats	NOUN	O	O	2100
.	PUNCT	O	O	2100
Intramedullary	PROPN	O	O	2101
administration	NOUN	O	O	2101
of	ADP	O	O	2101
clonidine	NOUN	O	Chemical	2101
,	PUNCT	O	O	2101
but	CCONJ	O	O	2101
not	PART	O	O	2101
saline	NOUN	O	O	2101
vehicle	NOUN	O	O	2101
,	PUNCT	O	O	2101
caused	VERB	O	O	2101
a	PRON	O	O	2101
dose	NOUN	O	O	2101
-	PUNCT	O	O	2101
dependent	ADJ	O	O	2101
decrease	VERB	O	O	2101
in	ADP	O	O	2101
both	PRON	O	O	2101
the	PRON	O	O	2101
mean	VERB	O	O	2101
arterial	ADJ	O	O	2101
pressure	NOUN	O	O	2101
and	CCONJ	O	O	2101
the	PRON	O	O	2101
heart	NOUN	O	O	2101
rate	NOUN	O	O	2101
.	PUNCT	O	O	2101
The	PRON	O	O	2102
clonidine	NOUN	O	Chemical	2102
-	PUNCT	O	O	2102
induced	VERB	O	O	2102
hypotension	NOUN	O	Disease	2102
was	AUX	O	O	2102
antagonized	VERB	O	O	2102
by	ADP	O	O	2102
prior	ADV	O	O	2102
spinal	NOUN	O	O	2102
transection	NOUN	O	O	2102
,	PUNCT	O	O	2102
but	CCONJ	O	O	2102
not	PART	O	O	2102
bilateral	ADJ	O	O	2102
vagotomy	NOUN	O	O	2102
.	PUNCT	O	O	2102
On	ADP	O	O	2103
the	PRON	O	O	2103
other	ADJ	O	O	2103
hand	NOUN	O	O	2103
,	PUNCT	O	O	2103
the	PRON	O	O	2103
clonidine	NOUN	O	Chemical	2103
-	PUNCT	O	O	2103
induced	VERB	O	O	2103
bradycardia	NOUN	O	Disease	2103
was	AUX	O	O	2103
antagonized	VERB	O	O	2103
by	ADP	O	O	2103
prior	ADV	O	O	2103
bilateral	ADJ	O	O	2103
vagotomy	NOUN	O	O	2103
,	PUNCT	O	O	2103
but	CCONJ	O	O	2103
not	PART	O	O	2103
spinal	NOUN	O	O	2103
transection	NOUN	O	O	2103
.	PUNCT	O	O	2103
Furthermore	ADV	O	O	2104
,	PUNCT	O	O	2104
selective	ADJ	O	O	2104
destruction	NOUN	O	O	2104
of	ADP	O	O	2104
the	PRON	O	O	2104
spinal	NOUN	O	O	2104
5-HT	NOUN	O	Chemical	2104
nerves	NOUN	O	O	2104
,	PUNCT	O	O	2104
produced	VERB	O	O	2104
by	ADP	O	O	2104
bilateral	ADJ	O	O	2104
spinal	NOUN	O	O	2104
injection	NOUN	O	O	2104
of	ADP	O	O	2104
5,7-dihydroxytryptamine	NOUN	O	Chemical	2104
,	PUNCT	O	O	2104
reduced	VERB	O	O	2104
the	PRON	O	O	2104
magnitude	NOUN	O	O	2104
of	ADP	O	O	2104
the	PRON	O	O	2104
vasodepressor	NOUN	O	O	2104
or	CCONJ	O	O	2104
the	PRON	O	O	2104
bradycardiac	PROPN	O	O	2104
responses	NOUN	O	O	2104
to	PART	O	O	2104
clonidine	NOUN	O	Chemical	2104
microinjected	VERB	O	O	2104
into	ADP	O	O	2104
the	PRON	O	O	2104
area	NOUN	O	O	2104
near	ADP	O	O	2104
the	PRON	O	O	2104
ventrolateral	ADJ	O	O	2104
surface	NOUN	O	O	2104
of	ADP	O	O	2104
the	PRON	O	O	2104
medulla	NOUN	O	O	2104
oblongata	VERB	O	O	2104
in	ADP	O	O	2104
rats	NOUN	O	O	2104
.	PUNCT	O	O	2104
The	PRON	O	O	2105
data	NOUN	O	O	2105
indicate	VERB	O	O	2105
that	SCONJ	O	O	2105
a	PRON	O	O	2105
bulbospinal	ADJ	O	O	2105
serotonergic	ADJ	O	O	2105
pathway	NOUN	O	O	2105
is	AUX	O	O	2105
involved	VERB	O	O	2105
in	ADP	O	O	2105
development	NOUN	O	O	2105
of	ADP	O	O	2105
clonidine	NOUN	O	Chemical	2105
-	PUNCT	O	O	2105
induced	VERB	O	O	2105
hypotension	NOUN	O	Disease	2105
and	CCONJ	O	O	2105
bradycardia	NOUN	O	Disease	2105
.	PUNCT	O	O	2105
The	PRON	O	O	2106
induced	VERB	O	O	2106
hypotension	NOUN	O	Disease	2106
is	AUX	O	O	2106
brought	VERB	O	O	2106
about	ADP	O	O	2106
by	ADP	O	O	2106
a	PRON	O	O	2106
decrease	VERB	O	O	2106
in	ADP	O	O	2106
sympathetic	ADJ	O	O	2106
efferent	VERB	O	O	2106
activity	NOUN	O	O	2106
,	PUNCT	O	O	2106
whereas	SCONJ	O	O	2106
the	PRON	O	O	2106
induced	VERB	O	O	2106
bradycardia	NOUN	O	Disease	2106
was	AUX	O	O	2106
due	ADJ	O	O	2106
to	PART	O	O	2106
an	PRON	O	O	2106
increase	VERB	O	O	2106
in	ADP	O	O	2106
vagal	ADJ	O	O	2106
efferent	VERB	O	O	2106
activity	NOUN	O	O	2106
.	PUNCT	O	O	2106
Hypertension	NOUN	O	Disease	2109
in	ADP	O	O	2109
neuroblastoma	NOUN	O	Disease	2109
induced	VERB	O	O	2109
by	ADP	O	O	2109
imipramine	X	O	O	2109
.	PUNCT	O	O	2109
Hypertension	NOUN	O	Disease	2110
is	AUX	O	O	2110
a	PRON	O	O	2110
well	ADV	O	O	2110
-	PUNCT	O	O	2110
known	VERB	O	O	2110
finding	VERB	O	O	2110
in	ADP	O	O	2110
some	PRON	O	O	2110
patients	NOUN	O	O	2110
with	ADP	O	O	2110
neuroblastoma	NOUN	O	Disease	2110
.	PUNCT	O	O	2110
However	ADV	O	O	2111
,	PUNCT	O	O	2111
it	PRON	O	O	2111
has	VERB	O	O	2111
not	PART	O	O	2111
previously	ADV	O	O	2111
been	AUX	O	O	2111
described	VERB	O	O	2111
in	ADP	O	O	2111
association	PROPN	O	O	2111
with	ADP	O	O	2111
the	PRON	O	O	2111
use	VERB	O	O	2111
of	ADP	O	O	2111
Imipramine	PROPN	O	O	2111
.	PUNCT	O	O	2111
We	PRON	O	O	2112
report	VERB	O	O	2112
the	PRON	O	O	2112
occurrence	NOUN	O	O	2112
of	ADP	O	O	2112
severe	ADJ	O	O	2112
hypertension	NOUN	O	Disease	2112
(	PUNCT	O	O	2112
blood	NOUN	O	O	2112
pressure	NOUN	O	O	2112
190/160	PRON	O	O	2112
)	PUNCT	O	O	2112
in	ADP	O	O	2112
a	PRON	O	O	2112
4-year	NOUN	O	O	2112
-	PUNCT	O	O	2112
old	ADJ	O	O	2112
girl	NOUN	O	O	2112
with	ADP	O	O	2112
neuroblastoma	NOUN	O	Disease	2112
who	PRON	O	O	2112
was	AUX	O	O	2112
given	VERB	O	O	2112
Imipramine	PROPN	O	O	2112
to	PART	O	O	2112
control	VERB	O	O	2112
a	PRON	O	O	2112
behavior	NOUN	O	O	2112
disorder	NOUN	O	O	2112
.	PUNCT	O	O	2112
It	PRON	O	O	2113
was	AUX	O	O	2113
determined	VERB	O	O	2113
later	ADV	O	O	2113
that	SCONJ	O	O	2113
this	PRON	O	O	2113
patient	NOUN	O	O	2113
's	AUX	O	O	2113
tumor	NOUN	O	Disease	2113
was	AUX	O	O	2113
recurring	VERB	O	O	2113
at	ADP	O	O	2113
the	PRON	O	O	2113
time	NOUN	O	O	2113
of	ADP	O	O	2113
her	PRON	O	O	2113
hypertensive	ADJ	O	Disease	2113
episode	PROPN	O	O	2113
.	PUNCT	O	O	2113
Since	SCONJ	O	O	2114
she	PRON	O	O	2114
had	VERB	O	O	2114
no	PRON	O	O	2114
blood	NOUN	O	O	2114
pressure	NOUN	O	O	2114
elevation	NOUN	O	O	2114
at	ADP	O	O	2114
initial	ADJ	O	O	2114
diagnosis	NOUN	O	O	2114
and	CCONJ	O	O	2114
none	NOUN	O	O	2114
following	VERB	O	O	2114
discontinuation	NOUN	O	O	2114
of	ADP	O	O	2114
the	PRON	O	O	2114
Imipramine	PROPN	O	O	2114
(	PUNCT	O	O	2114
when	SCONJ	O	O	2114
she	PRON	O	O	2114
was	AUX	O	O	2114
in	ADP	O	O	2114
florid	ADJ	O	O	2114
relapse	VERB	O	O	2114
)	PUNCT	O	O	2114
,	PUNCT	O	O	2114
we	PRON	O	O	2114
believe	VERB	O	O	2114
that	SCONJ	O	O	2114
this	PRON	O	O	2114
drug	NOUN	O	O	2114
rather	ADV	O	O	2114
than	ADP	O	O	2114
her	PRON	O	O	2114
underlying	VERB	O	O	2114
disease	PROPN	O	O	2114
alone	ADV	O	O	2114
caused	VERB	O	O	2114
her	PRON	O	O	2114
hypertension	NOUN	O	Disease	2114
.	PUNCT	O	O	2114
The	PRON	O	O	2115
mechanism	NOUN	O	O	2115
for	ADP	O	O	2115
this	PRON	O	O	2115
reaction	NOUN	O	O	2115
is	AUX	O	O	2115
believed	VERB	O	O	2115
to	PART	O	O	2115
be	AUX	O	O	2115
increased	VERB	O	O	2115
levels	NOUN	O	O	2115
of	ADP	O	O	2115
vasoactive	ADJ	O	O	2115
catecholamines	NOUN	O	Chemical	2115
due	ADJ	O	O	2115
to	PART	O	O	2115
interference	NOUN	O	O	2115
of	ADP	O	O	2115
their	PRON	O	O	2115
physiologic	ADJ	O	O	2115
inactivation	NOUN	O	O	2115
by	ADP	O	O	2115
Imipramine	PROPN	O	O	2115
.	PUNCT	O	O	2115
From	ADP	O	O	2116
this	PRON	O	O	2116
experience	NOUN	O	O	2116
,	PUNCT	O	O	2116
we	PRON	O	O	2116
urge	VERB	O	O	2116
extreme	ADJ	O	O	2116
caution	NOUN	O	O	2116
in	ADP	O	O	2116
the	PRON	O	O	2116
use	VERB	O	O	2116
of	ADP	O	O	2116
tricyclic	ADJ	O	O	2116
antidepressants	NOUN	O	O	2116
in	ADP	O	O	2116
children	NOUN	O	O	2116
with	ADP	O	O	2116
active	ADJ	O	O	2116
neuroblastoma	NOUN	O	Disease	2116
.	PUNCT	O	O	2116
Rechallenge	NOUN	O	O	2119
of	ADP	O	O	2119
patients	NOUN	O	O	2119
who	PRON	O	O	2119
developed	VERB	O	O	2119
oral	ADJ	O	O	2119
candidiasis	NOUN	O	O	2119
or	CCONJ	O	O	2119
hoarseness	NOUN	O	O	2119
with	ADP	O	O	2119
beclomethasone	PROPN	O	O	2119
dipropionate	NOUN	O	O	2119
.	PUNCT	O	O	2119
Of	ADV	O	O	2120
158	NUM	O	O	2120
asthmatic	ADJ	O	O	2120
patients	NOUN	O	O	2120
who	PRON	O	O	2120
were	AUX	O	O	2120
placed	VERB	O	O	2120
on	ADP	O	O	2120
inhaled	VERB	O	O	2120
beclomethasone	PROPN	O	O	2120
,	PUNCT	O	O	2120
15	NUM	O	O	2120
(	PUNCT	O	O	2120
9.5%	NOUN	O	O	2120
)	PUNCT	O	O	2120
developed	VERB	O	O	2120
either	ADV	O	O	2120
hoarseness	NOUN	O	O	2120
(	PUNCT	O	O	2120
8)	NUM	O	O	2120
,	PUNCT	O	O	2120
oral	ADJ	O	O	2120
thrush	NOUN	O	O	2120
(	PUNCT	O	O	2120
6	NUM	O	O	2120
)	PUNCT	O	O	2120
,	PUNCT	O	O	2120
or	CCONJ	O	O	2120
both	PRON	O	O	2120
(	PUNCT	O	O	2120
1	X	O	O	2120
)	PUNCT	O	O	2120
.	PUNCT	O	O	2120
When	SCONJ	O	O	2121
their	PRON	O	O	2121
adverse	ADJ	O	O	2121
reactions	NOUN	O	O	2121
subsided	VERB	O	O	2121
,	PUNCT	O	O	2121
seven	NUM	O	O	2121
of	ADP	O	O	2121
these	PRON	O	O	2121
15	NUM	O	O	2121
patients	NOUN	O	O	2121
were	AUX	O	O	2121
rechallenged	VERB	O	O	2121
with	ADP	O	O	2121
inhaled	VERB	O	O	2121
beclomethasone	PROPN	O	O	2121
.	PUNCT	O	O	2121
These	PRON	O	O	2122
included	VERB	O	O	2122
five	NUM	O	O	2122
cases	NOUN	O	O	2122
who	PRON	O	O	2122
developed	VERB	O	O	2122
hoarseness	NOUN	O	O	2122
and	CCONJ	O	O	2122
three	NUM	O	O	2122
who	PRON	O	O	2122
developed	VERB	O	O	2122
Candidiasis	NOUN	O	O	2122
.	PUNCT	O	O	2122
Oral	NOUN	O	O	2123
thrush	NOUN	O	O	2123
did	VERB	O	O	2123
not	PART	O	O	2123
recur	VERB	O	O	2123
,	PUNCT	O	O	2123
but	CCONJ	O	O	2123
60%	NOUN	O	O	2123
(	PUNCT	O	O	2123
3/5	NUM	O	O	2123
)	PUNCT	O	O	2123
of	ADP	O	O	2123
patients	NOUN	O	O	2123
with	ADP	O	O	2123
hoarseness	NOUN	O	O	2123
had	VERB	O	O	2123
recurrence	NOUN	O	O	2123
.	PUNCT	O	O	2123
We	PRON	O	O	2124
conclude	VERB	O	O	2124
that	SCONJ	O	O	2124
patients	NOUN	O	O	2124
may	AUX	O	O	2124
be	AUX	O	O	2124
restarted	VERB	O	O	2124
on	ADP	O	O	2124
inhaled	VERB	O	O	2124
beclomethasone	PROPN	O	O	2124
when	SCONJ	O	O	2124
clinically	ADV	O	O	2124
indicated	VERB	O	O	2124
;	PUNCT	O	O	2124
however	ADV	O	O	2124
,	PUNCT	O	O	2124
because	SCONJ	O	O	2124
of	ADP	O	O	2124
the	PRON	O	O	2124
high	ADJ	O	O	2124
recurrence	NOUN	O	O	2124
rate	NOUN	O	O	2124
,	PUNCT	O	O	2124
patients	NOUN	O	O	2124
who	PRON	O	O	2124
develop	VERB	O	O	2124
hoarseness	NOUN	O	O	2124
should	AUX	O	O	2124
not	PART	O	O	2124
be	AUX	O	O	2124
re	ADP	O	O	2124
-	PUNCT	O	O	2124
challenged	VERB	O	O	2124
.	PUNCT	O	O	2124
Concomitant	ADJ	O	O	2125
use	VERB	O	O	2125
of	ADP	O	O	2125
oral	ADJ	O	O	2125
prednisone	NOUN	O	Chemical	2125
and	CCONJ	O	O	2125
topical	ADJ	O	O	2125
beclomethasone	PROPN	O	O	2125
may	AUX	O	O	2125
increase	VERB	O	O	2125
the	PRON	O	O	2125
risk	NOUN	O	O	2125
of	ADP	O	O	2125
developing	VERB	O	O	2125
hoarseness	NOUN	O	O	2125
or	CCONJ	O	O	2125
candidiasis	NOUN	O	O	2125
.	PUNCT	O	O	2125
Cyclophosphamide	PROPN	O	Chemical	2128
cardiotoxicity	NOUN	O	Disease	2128
:	PUNCT	O	O	2128
an	PRON	O	O	2128
analysis	NOUN	O	O	2128
of	ADP	O	O	2128
dosing	VERB	O	O	2128
as	ADP	O	O	2128
a	PRON	O	O	2128
risk	NOUN	O	O	2128
factor	NOUN	O	O	2128
.	PUNCT	O	O	2128
Patients	NOUN	O	O	2129
who	PRON	O	O	2129
undergo	VERB	O	O	2129
bone	NOUN	O	O	2129
marrow	PROPN	O	O	2129
transplantation	NOUN	O	O	2129
are	AUX	O	O	2129
generally	ADV	O	O	2129
immunosuppressed	ADJ	O	O	2129
with	ADP	O	O	2129
a	PRON	O	O	2129
dose	NOUN	O	O	2129
of	ADP	O	O	2129
cyclophosphamide	VERB	O	Chemical	2129
(	PUNCT	O	O	2129
CYA	PROPN	O	O	2129
)	PUNCT	O	O	2129
which	PRON	O	O	2129
is	AUX	O	O	2129
usually	ADV	O	O	2129
calculated	VERB	O	O	2129
based	VERB	O	O	2129
on	ADP	O	O	2129
the	PRON	O	O	2129
patient	NOUN	O	O	2129
's	AUX	O	O	2129
weight	NOUN	O	O	2129
.	PUNCT	O	O	2129
At	ADP	O	O	2130
these	PRON	O	O	2130
high	ADJ	O	O	2130
doses	NOUN	O	O	2130
of	ADP	O	O	2130
CYA	PROPN	O	O	2130
,	PUNCT	O	O	2130
serious	ADJ	O	O	2130
cardiotoxicity	NOUN	O	Disease	2130
may	AUX	O	O	2130
occur	VERB	O	O	2130
,	PUNCT	O	O	2130
but	CCONJ	O	O	2130
definitive	ADJ	O	O	2130
risk	NOUN	O	O	2130
factors	NOUN	O	O	2130
for	ADP	O	O	2130
the	PRON	O	O	2130
development	NOUN	O	O	2130
of	ADP	O	O	2130
such	ADJ	O	O	2130
cardiotoxicity	NOUN	O	Disease	2130
have	VERB	O	O	2130
not	PART	O	O	2130
been	AUX	O	O	2130
described	VERB	O	O	2130
.	PUNCT	O	O	2130
Since	SCONJ	O	O	2131
chemotherapeutic	NOUN	O	O	2131
agent	NOUN	O	O	2131
toxicity	NOUN	O	Disease	2131
generally	ADV	O	O	2131
correlates	VERB	O	O	2131
with	ADP	O	O	2131
dose	NOUN	O	O	2131
per	ADP	O	O	2131
body	NOUN	O	O	2131
surface	NOUN	O	O	2131
area	NOUN	O	O	2131
,	PUNCT	O	O	2131
we	PRON	O	O	2131
retrospectively	ADV	O	O	2131
calculated	VERB	O	O	2131
the	PRON	O	O	2131
dose	NOUN	O	O	2131
of	ADP	O	O	2131
CYA	PROPN	O	O	2131
in	ADP	O	O	2131
patients	NOUN	O	O	2131
transplanted	VERB	O	O	2131
at	ADP	O	O	2131
our	PRON	O	O	2131
institution	NOUN	O	O	2131
to	PART	O	O	2131
determine	VERB	O	O	2131
whether	SCONJ	O	O	2131
the	PRON	O	O	2131
incidence	NOUN	O	O	2131
of	ADP	O	O	2131
CYA	PROPN	O	O	2131
cardiotoxicity	NOUN	O	Disease	2131
correlated	VERB	O	O	2131
with	ADP	O	O	2131
the	PRON	O	O	2131
dose	NOUN	O	O	2131
per	ADP	O	O	2131
body	NOUN	O	O	2131
surface	NOUN	O	O	2131
area	NOUN	O	O	2131
.	PUNCT	O	O	2131
Eighty	NUM	O	O	2132
patients	NOUN	O	O	2132
who	PRON	O	O	2132
were	AUX	O	O	2132
to	PART	O	O	2132
receive	VERB	O	O	2132
CYA	PROPN	O	O	2132
50	NUM	O	O	2132
mg	VERB	O	O	2132
/	PUNCT	O	O	2132
kg	VERB	O	O	2132
/	PUNCT	O	O	2132
d	X	O	O	2132
for	ADP	O	O	2132
four	NUM	O	O	2132
days	NOUN	O	O	2132
as	ADP	O	O	2132
preparation	NOUN	O	O	2132
for	ADP	O	O	2132
marrow	PROPN	O	O	2132
grafting	VERB	O	O	2132
underwent	VERB	O	O	2132
a	PRON	O	O	2132
total	ADJ	O	O	2132
of	ADP	O	O	2132
84	NUM	O	O	2132
transplants	NOUN	O	O	2132
for	ADP	O	O	2132
aplastic anemia	NOUN	O	Disease	2132
,	PUNCT	O	O	2132
Wiskott	PROPN	O	O	2132
-	PUNCT	O	O	2132
Aldrich	PROPN	O	O	2132
syndrome	NOUN	O	O	2132
,	PUNCT	O	O	2132
or	CCONJ	O	O	2132
severe	ADJ	O	O	2132
combined	VERB	O	O	2132
immunodeficiency	NOUN	O	Disease	2132
syndrome	NOUN	O	O	2132
.	PUNCT	O	O	2132
Fourteen	NUM	O	O	2133
of	ADP	O	O	2133
84	NUM	O	O	2133
(	PUNCT	O	O	2133
17%	NOUN	O	O	2133
)	PUNCT	O	O	2133
patients	NOUN	O	O	2133
had	VERB	O	O	2133
symptoms	NOUN	O	O	2133
and	CCONJ	O	O	2133
signs	NOUN	O	O	2133
consistent	ADJ	O	O	2133
with	ADP	O	O	2133
CYA	PROPN	O	O	2133
cardiotoxicity	NOUN	O	Disease	2133
within	ADP	O	O	2133
ten	NUM	O	O	2133
days	NOUN	O	O	2133
of	ADP	O	O	2133
receiving	VERB	O	O	2133
1	X	O	O	2133
to	PART	O	O	2133
4	NUM	O	O	2133
doses	NOUN	O	O	2133
of	ADP	O	O	2133
CYA	PROPN	O	O	2133
.	PUNCT	O	O	2133
Six	NUM	O	O	2134
of	ADP	O	O	2134
the	PRON	O	O	2134
14	NUM	O	O	2134
patients	NOUN	O	O	2134
died	VERB	O	O	2134
with	ADP	O	O	2134
congestive	ADJ	O	O	2134
heart failure	NOUN	O	Disease	2134
.	PUNCT	O	O	2134
The	PRON	O	O	2135
dose	NOUN	O	O	2135
of	ADP	O	O	2135
CYA	PROPN	O	O	2135
per	ADP	O	O	2135
body	NOUN	O	O	2135
surface	NOUN	O	O	2135
area	NOUN	O	O	2135
was	AUX	O	O	2135
calculated	VERB	O	O	2135
for	ADP	O	O	2135
all	PRON	O	O	2135
patients	NOUN	O	O	2135
and	CCONJ	O	O	2135
the	PRON	O	O	2135
patients	NOUN	O	O	2135
were	AUX	O	O	2135
divided	VERB	O	O	2135
into	ADP	O	O	2135
two	NUM	O	O	2135
groups	NOUN	O	O	2135
based	VERB	O	O	2135
on	ADP	O	O	2135
daily	ADV	O	O	2135
CYA	PROPN	O	O	2135
dose	NOUN	O	O	2135
:	PUNCT	O	O	2135
Group	PROPN	O	O	2135
1	X	O	O	2135
,	PUNCT	O	O	2135
CYA	PROPN	O	O	2135
less	ADV	O	O	2135
than	ADP	O	O	2135
or	CCONJ	O	O	2135
equal	ADJ	O	O	2135
to	PART	O	O	2135
1.55	NUM	O	O	2135
g	X	O	O	2135
/	PUNCT	O	O	2135
m2/d	NOUN	O	O	2135
;	PUNCT	O	O	2135
Group	PROPN	O	O	2135
2	X	O	O	2135
,	PUNCT	O	O	2135
CYA	PROPN	O	O	2135
greater	ADJ	O	O	2135
than	ADP	O	O	2135
1.55	NUM	O	O	2135
Cardiotoxicity	NOUN	O	Disease	2136
that	SCONJ	O	O	2136
was	AUX	O	O	2136
thought	VERB	O	O	2136
to	PART	O	O	2136
be	AUX	O	O	2136
related	ADJ	O	O	2136
to	PART	O	O	2136
CYA	PROPN	O	O	2136
occurred	VERB	O	O	2136
in	ADP	O	O	2136
1/32	NUM	O	O	2136
(	PUNCT	O	O	2136
3%	NOUN	O	O	2136
)	PUNCT	O	O	2136
of	ADP	O	O	2136
patients	NOUN	O	O	2136
in	ADP	O	O	2136
Group	PROPN	O	O	2136
1	X	O	O	2136
and	CCONJ	O	O	2136
in	ADP	O	O	2136
13/52	NUM	O	O	2136
(	PUNCT	O	O	2136
25%	NOUN	O	O	2136
)	PUNCT	O	O	2136
patients	NOUN	O	O	2136
in	ADP	O	O	2136
Group	PROPN	O	O	2136
2	X	O	O	2136
(	PUNCT	O	O	2136
P	NOUN	O	Chemical	2136
less	ADV	O	O	2136
than	ADP	O	O	2136
0.025	NUM	O	O	2136
)	PUNCT	O	O	2136
.	PUNCT	O	O	2136
Congestive	NOUN	O	O	2137
heart failure	NOUN	O	Disease	2137
caused	VERB	O	O	2137
or	CCONJ	O	O	2137
contributed	VERB	O	O	2137
to	PART	O	O	2137
death	NOUN	O	O	2137
in	ADP	O	O	2137
0/32	NUM	O	O	2137
patients	NOUN	O	O	2137
in	ADP	O	O	2137
Group	PROPN	O	O	2137
1	X	O	O	2137
v	NOUN	O	O	2137
6/52	NUM	O	O	2137
(	PUNCT	O	O	2137
12%	NOUN	O	O	2137
)	PUNCT	O	O	2137
of	ADP	O	O	2137
patients	NOUN	O	O	2137
in	ADP	O	O	2137
Group	PROPN	O	O	2137
2	X	O	O	2137
(	PUNCT	O	O	2137
P	NOUN	O	Chemical	2137
less	ADV	O	O	2137
than	ADP	O	O	2137
0.25	NUM	O	O	2137
)	PUNCT	O	O	2137
.	PUNCT	O	O	2137
We	PRON	O	O	2138
conclude	VERB	O	O	2138
that	SCONJ	O	O	2138
the	PRON	O	O	2138
CYA	PROPN	O	O	2138
cardiotoxicity	NOUN	O	Disease	2138
correlates	VERB	O	O	2138
with	ADP	O	O	2138
CYA	PROPN	O	O	2138
dosage	NOUN	O	O	2138
as	ADP	O	O	2138
calculated	VERB	O	O	2138
by	ADP	O	O	2138
body	NOUN	O	O	2138
surface	NOUN	O	O	2138
area	NOUN	O	O	2138
,	PUNCT	O	O	2138
and	CCONJ	O	O	2138
that	SCONJ	O	O	2138
patients	NOUN	O	O	2138
with	ADP	O	O	2138
aplastic anemia	NOUN	O	Disease	2138
and	CCONJ	O	O	2138
immunodeficiencies	NOUN	O	O	2138
can	AUX	O	O	2138
be	AUX	O	O	2138
effectively	ADV	O	O	2138
prepared	VERB	O	O	2138
for	ADP	O	O	2138
bone	NOUN	O	O	2138
marrow	PROPN	O	O	2138
grafting	VERB	O	O	2138
at	ADP	O	O	2138
a	PRON	O	O	2138
CYA	PROPN	O	O	2138
dose	NOUN	O	O	2138
of	ADP	O	O	2138
1.55	NUM	O	O	2138
g	X	O	O	2138
/	PUNCT	O	O	2138
m2/d	NOUN	O	O	2138
for	ADP	O	O	2138
four	NUM	O	O	2138
days	NOUN	O	O	2138
with	ADP	O	O	2138
a	PRON	O	O	2138
lower	ADJ	O	O	2138
incidence	NOUN	O	O	2138
of	ADP	O	O	2138
cardiotoxicity	NOUN	O	Disease	2138
than	ADP	O	O	2138
patients	NOUN	O	O	2138
whose	DET	O	O	2138
CYA	PROPN	O	O	2138
dosage	NOUN	O	O	2138
is	AUX	O	O	2138
calculated	VERB	O	O	2138
based	VERB	O	O	2138
on	ADP	O	O	2138
weight	NOUN	O	O	2138
.	PUNCT	O	O	2138
This	PRON	O	O	2139
study	VERB	O	O	2139
reaffirms	VERB	O	O	2139
the	PRON	O	O	2139
principle	NOUN	O	O	2139
that	SCONJ	O	O	2139
drug	NOUN	O	O	2139
toxicity	NOUN	O	Disease	2139
correlates	VERB	O	O	2139
with	ADP	O	O	2139
dose	NOUN	O	O	2139
per	ADP	O	O	2139
body	NOUN	O	O	2139
surface	NOUN	O	O	2139
area	NOUN	O	O	2139
.	PUNCT	O	O	2139
Studies	NOUN	O	O	2142
of	ADP	O	O	2142
risk	NOUN	O	O	2142
factors	NOUN	O	O	2142
for	ADP	O	O	2142
aminoglycoside	ADV	O	Chemical	2142
nephrotoxicity	NOUN	O	Disease	2142
.	PUNCT	O	O	2142
The	PRON	O	O	2143
epidemiology	NOUN	O	O	2143
of	ADP	O	O	2143
aminoglycoside	ADV	O	Chemical	2143
-	PUNCT	O	O	2143
induced	VERB	O	O	2143
nephrotoxicity	NOUN	O	Disease	2143
is	AUX	O	O	2143
not	PART	O	O	2143
fully	ADV	O	O	2143
understood	VERB	O	O	2143
.	PUNCT	O	O	2143
Experimental	ADJ	O	O	2144
studies	NOUN	O	O	2144
in	ADP	O	O	2144
healthy	ADJ	O	O	2144
human	PROPN	O	O	2144
volunteers	NOUN	O	O	2144
indicate	VERB	O	O	2144
aminoglycosides	NOUN	O	Chemical	2144
cause	VERB	O	O	2144
proximal	ADJ	O	O	2144
tubular	ADJ	O	O	2144
damage	NOUN	O	O	2144
in	ADP	O	O	2144
most	ADV	O	O	2144
patients	NOUN	O	O	2144
,	PUNCT	O	O	2144
but	CCONJ	O	O	2144
rarely	ADV	O	O	2144
,	PUNCT	O	O	2144
if	SCONJ	O	O	2144
ever	ADV	O	O	2144
,	PUNCT	O	O	2144
cause	VERB	O	O	2144
glomerular	ADJ	O	O	2144
or	CCONJ	O	O	2144
tubular	ADJ	O	O	2144
dysfunction	NOUN	O	O	2144
.	PUNCT	O	O	2144
Clinical	NOUN	O	O	2145
trials	NOUN	O	O	2145
of	ADP	O	O	2145
aminoglycosides	NOUN	O	Chemical	2145
in	ADP	O	O	2145
seriously	ADV	O	O	2145
ill	PROPN	O	O	2145
patients	NOUN	O	O	2145
indicate	VERB	O	O	2145
that	SCONJ	O	O	2145
the	PRON	O	O	2145
relative	ADJ	O	O	2145
risk	NOUN	O	O	2145
for	ADP	O	O	2145
developing	VERB	O	O	2145
acute	ADJ	O	O	2145
renal failure	NOUN	O	Disease	2145
during	ADP	O	O	2145
therapy	NOUN	O	O	2145
ranges	VERB	O	O	2145
from	ADP	O	O	2145
8	NUM	O	O	2145
to	PART	O	O	2145
10	NUM	O	O	2145
and	CCONJ	O	O	2145
that	SCONJ	O	O	2145
the	PRON	O	O	2145
attributable	ADJ	O	O	2145
risk	NOUN	O	O	2145
is	AUX	O	O	2145
70%	NOUN	O	O	2145
to	PART	O	O	2145
80%	NOUN	O	O	2145
.	PUNCT	O	O	2145
Further	ADV	O	O	2146
analysis	NOUN	O	O	2146
of	ADP	O	O	2146
these	PRON	O	O	2146
data	NOUN	O	O	2146
suggests	VERB	O	O	2146
that	SCONJ	O	O	2146
the	PRON	O	O	2146
duration	NOUN	O	O	2146
of	ADP	O	O	2146
therapy	NOUN	O	O	2146
,	PUNCT	O	O	2146
plasma	NOUN	O	O	2146
aminoglycoside	ADV	O	Chemical	2146
levels	NOUN	O	O	2146
,	PUNCT	O	O	2146
liver disease	NOUN	O	Disease	2146
,	PUNCT	O	O	2146
advanced	ADJ	O	O	2146
age	NOUN	O	O	2146
,	PUNCT	O	O	2146
high	ADJ	O	O	2146
initial	ADJ	O	O	2146
estimated	VERB	O	O	2146
creatinine	PROPN	O	Chemical	2146
clearance	NOUN	O	O	2146
and	CCONJ	O	O	2146
,	PUNCT	O	O	2146
possibly	ADV	O	O	2146
,	PUNCT	O	O	2146
female	ADJ	O	O	2146
gender	NOUN	O	O	2146
all	PRON	O	O	2146
increase	VERB	O	O	2146
the	PRON	O	O	2146
risk	NOUN	O	O	2146
for	ADP	O	O	2146
nephrotoxicity	NOUN	O	Disease	2146
.	PUNCT	O	O	2146
Other	ADJ	O	O	2147
causes	VERB	O	O	2147
of	ADP	O	O	2147
acute	ADJ	O	O	2147
renal failure	NOUN	O	Disease	2147
,	PUNCT	O	O	2147
such	ADJ	O	O	2147
as	ADP	O	O	2147
shock	NOUN	O	O	2147
,	PUNCT	O	O	2147
appear	VERB	O	O	2147
to	PART	O	O	2147
have	VERB	O	O	2147
an	PRON	O	O	2147
additive	NOUN	O	O	2147
effect	VERB	O	O	2147
.	PUNCT	O	O	2147
These	PRON	O	O	2148
models	NOUN	O	O	2148
may	AUX	O	O	2148
also	ADV	O	O	2148
be	AUX	O	O	2148
useful	ADJ	O	O	2148
in	ADP	O	O	2148
developing	VERB	O	O	2148
insights	NOUN	O	O	2148
into	ADP	O	O	2148
the	PRON	O	O	2148
pathophysiology	NOUN	O	O	2148
of	ADP	O	O	2148
aminoglycoside	ADV	O	Chemical	2148
-	PUNCT	O	O	2148
induced	VERB	O	O	2148
nephrotoxicity	NOUN	O	Disease	2148
.	PUNCT	O	O	2148
Flurothyl	NOUN	O	O	2151
seizure	NOUN	O	Disease	2151
thresholds	NOUN	O	O	2151
in	ADP	O	O	2151
mice	NOUN	O	O	2151
treated	VERB	O	O	2151
neonatally	ADV	O	O	2151
with	ADP	O	O	2151
a	PRON	O	O	2151
single	ADJ	O	O	2151
injection	NOUN	O	O	2151
of	ADP	O	O	2151
monosodium	NOUN	O	O	2151
glutamate	NOUN	O	Chemical	2151
(	PUNCT	O	O	2151
MSG	PROPN	O	O	2151
)	PUNCT	O	O	2151
:	PUNCT	O	O	2151
evaluation	NOUN	O	O	2151
of	ADP	O	O	2151
experimental	ADJ	O	O	2151
parameters	NOUN	O	O	2151
in	ADP	O	O	2151
flurothyl	PROPN	O	Chemical	2151
seizure	NOUN	O	Disease	2151
testing	NOUN	O	O	2151
.	PUNCT	O	O	2151
Monosodium	NOUN	O	O	2152
glutamate	NOUN	O	Chemical	2152
(	PUNCT	O	O	2152
MSG	PROPN	O	O	2152
)	PUNCT	O	O	2152
administration	NOUN	O	O	2152
to	PART	O	O	2152
neonatal	NOUN	O	O	2152
rodents	NOUN	O	O	2152
produces	VERB	O	O	2152
convulsions	NOUN	O	Disease	2152
and	CCONJ	O	O	2152
results	VERB	O	O	2152
in	ADP	O	O	2152
numerous	ADJ	O	O	2152
biochemical	ADJ	O	O	2152
and	CCONJ	O	O	2152
behavioral	ADJ	O	O	2152
deficits	NOUN	O	O	2152
.	PUNCT	O	O	2152
These	PRON	O	O	2153
studies	NOUN	O	O	2153
were	AUX	O	O	2153
undertaken	VERB	O	O	2153
to	PART	O	O	2153
determine	VERB	O	O	2153
if	SCONJ	O	O	2153
neonatal	NOUN	O	O	2153
administration	NOUN	O	O	2153
of	ADP	O	O	2153
MSG	PROPN	O	O	2153
produced	VERB	O	O	2153
permanent	ADJ	O	O	2153
alterations	NOUN	O	O	2153
in	ADP	O	O	2153
seizure	NOUN	O	Disease	2153
susceptibility	NOUN	O	O	2153
,	PUNCT	O	O	2153
since	SCONJ	O	O	2153
previous	ADJ	O	O	2153
investigations	NOUN	O	O	2153
were	AUX	O	O	2153
inconclusive	ADJ	O	O	2153
.	PUNCT	O	O	2153
A	PRON	O	O	2154
flurothyl	PROPN	O	Chemical	2154
ether	X	O	O	2154
seizure	NOUN	O	Disease	2154
screening	VERB	O	O	2154
technique	NOUN	O	O	2154
was	AUX	O	O	2154
used	VERB	O	O	2154
to	PART	O	O	2154
evaluate	VERB	O	O	2154
seizure	NOUN	O	Disease	2154
susceptibility	NOUN	O	O	2154
in	ADP	O	O	2154
adult	NOUN	O	O	2154
mice	NOUN	O	O	2154
that	SCONJ	O	O	2154
received	VERB	O	O	2154
neonatal	NOUN	O	O	2154
injections	NOUN	O	O	2154
of	ADP	O	O	2154
MSG	PROPN	O	O	2154
(	PUNCT	O	O	2154
4	NUM	O	O	2154
mg	VERB	O	O	2154
/	PUNCT	O	O	2154
g	X	O	O	2154
and	CCONJ	O	O	2154
1	X	O	O	2154
mg	VERB	O	O	2154
/	PUNCT	O	O	2154
g	X	O	O	2154
)	PUNCT	O	O	2154
.	PUNCT	O	O	2154
MSG	PROPN	O	O	2155
treatment	NOUN	O	O	2155
resulted	VERB	O	O	2155
in	ADP	O	O	2155
significant	ADJ	O	O	2155
reductions	NOUN	O	O	2155
in	ADP	O	O	2155
whole	NOUN	O	O	2155
brain	NOUN	O	O	2155
weight	NOUN	O	O	2155
but	CCONJ	O	O	2155
did	VERB	O	O	2155
not	PART	O	O	2155
alter	VERB	O	O	2155
seizure	NOUN	O	Disease	2155
threshold	NOUN	O	O	2155
.	PUNCT	O	O	2155
A	PRON	O	O	2156
naloxone	NOUN	O	Chemical	2156
(	PUNCT	O	O	2156
5	NUM	O	O	2156
mg	VERB	O	O	2156
/	PUNCT	O	O	2156
kg	VERB	O	O	2156
)	PUNCT	O	O	2156
challenge	NOUN	O	O	2156
was	AUX	O	O	2156
also	ADV	O	O	2156
ineffective	ADJ	O	O	2156
in	ADP	O	O	2156
altering	VERB	O	O	2156
the	PRON	O	O	2156
seizure	NOUN	O	Disease	2156
thresholds	NOUN	O	O	2156
of	ADP	O	O	2156
either	ADV	O	O	2156
control	VERB	O	O	2156
of	ADP	O	O	2156
MSG	PROPN	O	O	2156
-	PUNCT	O	O	2156
treated	VERB	O	O	2156
mice	NOUN	O	O	2156
.	PUNCT	O	O	2156
Flurothyl	NOUN	O	O	2157
ether	X	O	O	2157
produced	VERB	O	O	2157
hypothermia	VERB	O	Disease	2157
which	PRON	O	O	2157
was	AUX	O	O	2157
correlated	VERB	O	O	2157
with	ADP	O	O	2157
the	PRON	O	O	2157
duration	NOUN	O	O	2157
of	ADP	O	O	2157
flurothyl	PROPN	O	Chemical	2157
exposure	NOUN	O	O	2157
;	PUNCT	O	O	2157
however	ADV	O	O	2157
,	PUNCT	O	O	2157
the	PRON	O	O	2157
relationship	NOUN	O	O	2157
of	ADP	O	O	2157
hypothermia	VERB	O	Disease	2157
to	PART	O	O	2157
seizure	NOUN	O	Disease	2157
induction	NOUN	O	O	2157
was	AUX	O	O	2157
unclear	ADJ	O	O	2157
.	PUNCT	O	O	2157
Flurothyl	NOUN	O	O	2158
seizure	NOUN	O	Disease	2158
testing	NOUN	O	O	2158
proved	VERB	O	O	2158
to	PART	O	O	2158
be	AUX	O	O	2158
a	PRON	O	O	2158
rapid	ADJ	O	O	2158
and	CCONJ	O	O	2158
reliable	ADJ	O	O	2158
technique	NOUN	O	O	2158
with	ADP	O	O	2158
which	PRON	O	O	2158
to	PART	O	O	2158
evaluate	VERB	O	O	2158
seizure	NOUN	O	Disease	2158
susceptibility	NOUN	O	O	2158
.	PUNCT	O	O	2158
Susceptibility	NOUN	O	O	2161
to	PART	O	O	2161
seizures	NOUN	O	Disease	2161
produced	VERB	O	O	2161
by	ADP	O	O	2161
pilocarpine	NOUN	O	Chemical	2161
in	ADP	O	O	2161
rats	NOUN	O	O	2161
after	ADP	O	O	2161
microinjection	NOUN	O	O	2161
of	ADP	O	O	2161
isoniazid	NOUN	O	Chemical	2161
or	CCONJ	O	O	2161
gamma	PROPN	O	O	2161
-	PUNCT	O	O	2161
vinyl	NOUN	O	O	2161
-	PUNCT	O	O	2161
GABA	PROPN	O	Chemical	2161
into	ADP	O	O	2161
the	PRON	O	O	2161
substantia	X	O	O	2161
nigra	NOUN	O	O	2161
.	PUNCT	O	O	2161
Pilocarpine	NOUN	O	Chemical	2162
,	PUNCT	O	O	2162
given	VERB	O	O	2162
intraperitoneally	ADV	O	O	2162
to	PART	O	O	2162
rats	NOUN	O	O	2162
,	PUNCT	O	O	2162
reproduces	VERB	O	O	2162
the	PRON	O	O	2162
neuropathological	PROPN	O	O	2162
sequelae	ADJ	O	O	2162
of	ADP	O	O	2162
temporal lobe epilepsy	NOUN	O	Disease	2162
and	CCONJ	O	O	2162
provides	VERB	O	O	2162
a	PRON	O	O	2162
relevant	ADJ	O	O	2162
animal	NOUN	O	O	2162
model	NOUN	O	O	2162
for	ADP	O	O	2162
studying	VERB	O	O	2162
mechanisms	NOUN	O	O	2162
of	ADP	O	O	2162
buildup	NOUN	O	O	2162
of	ADP	O	O	2162
convulsive	ADJ	O	Disease	2162
activity	NOUN	O	O	2162
and	CCONJ	O	O	2162
pathways	NOUN	O	O	2162
operative	NOUN	O	O	2162
in	ADP	O	O	2162
the	PRON	O	O	2162
generalization	NOUN	O	O	2162
and	CCONJ	O	O	2162
propagation	NOUN	O	O	2162
of	ADP	O	O	2162
seizures	NOUN	O	Disease	2162
within	ADP	O	O	2162
the	PRON	O	O	2162
forebrain	NOUN	O	O	2162
.	PUNCT	O	O	2162
In	ADP	O	O	2163
the	PRON	O	O	2163
present	NOUN	O	O	2163
study	VERB	O	O	2163
,	PUNCT	O	O	2163
the	PRON	O	O	2163
effects	NOUN	O	O	2163
of	ADP	O	O	2163
manipulating	VERB	O	O	2163
the	PRON	O	O	2163
activity	NOUN	O	O	2163
of	ADP	O	O	2163
the	PRON	O	O	2163
gamma	PROPN	O	O	2163
-	PUNCT	O	O	2163
aminobutyric	PROPN	O	O	2163
acid	PROPN	O	O	2163
(	PUNCT	O	O	2163
GABA)-mediated	VERB	O	O	2163
synaptic	ADJ	O	O	2163
inhibition	NOUN	O	O	2163
within	ADP	O	O	2163
the	PRON	O	O	2163
substantia	X	O	O	2163
nigra	NOUN	O	O	2163
on	ADP	O	O	2163
seizures	NOUN	O	Disease	2163
produced	VERB	O	O	2163
by	ADP	O	O	2163
pilocarpine	NOUN	O	Chemical	2163
in	ADP	O	O	2163
rats	NOUN	O	O	2163
,	PUNCT	O	O	2163
were	AUX	O	O	2163
investigated	VERB	O	O	2163
.	PUNCT	O	O	2163
In	ADP	O	O	2164
animals	NOUN	O	O	2164
pretreated	VERB	O	O	2164
with	ADP	O	O	2164
microinjections	NOUN	O	O	2164
of	ADP	O	O	2164
isoniazid	NOUN	O	Chemical	2164
,	PUNCT	O	O	2164
150	NUM	O	O	2164
micrograms	NOUN	O	O	2164
,	PUNCT	O	O	2164
an	PRON	O	O	2164
inhibitor	NOUN	O	O	2164
of	ADP	O	O	2164
activity	NOUN	O	O	2164
of	ADP	O	O	2164
the	PRON	O	O	2164
GABA	PROPN	O	Chemical	2164
-	PUNCT	O	O	2164
synthesizing	VERB	O	O	2164
enzyme	NOUN	O	O	2164
,	PUNCT	O	O	2164
L	NOUN	O	O	2164
-	PUNCT	O	O	2164
glutamic acid	NOUN	O	Chemical	2164
decarboxylase	PROPN	O	O	2164
,	PUNCT	O	O	2164
into	ADP	O	O	2164
the	PRON	O	O	2164
substantia	X	O	O	2164
nigra	NOUN	O	O	2164
pars	NOUN	O	O	2164
reticulata	NOUN	O	O	2164
(	PUNCT	O	O	2164
SNR	NOUN	O	O	2164
)	PUNCT	O	O	2164
,	PUNCT	O	O	2164
bilaterally	ADV	O	O	2164
,	PUNCT	O	O	2164
non	ADJ	O	O	2164
-	PUNCT	O	O	2164
convulsant	ADJ	O	O	2164
doses	NOUN	O	O	2164
of	ADP	O	O	2164
pilocarpine	NOUN	O	Chemical	2164
,	PUNCT	O	O	2164
100	NUM	O	O	2164
and	CCONJ	O	O	2164
200	NUM	O	O	2164
mg	VERB	O	O	2164
/	PUNCT	O	O	2164
kg	VERB	O	O	2164
,	PUNCT	O	O	2164
resulted	VERB	O	O	2164
in	ADP	O	O	2164
severe	ADJ	O	O	2164
motor	NOUN	O	O	2164
limbic	PROPN	O	O	2164
seizures	NOUN	O	Disease	2164
and	CCONJ	O	O	2164
status epilepticus	VERB	O	Disease	2164
.	PUNCT	O	O	2164
Electroencephalographic	PROPN	O	O	2165
and	CCONJ	O	O	2165
behavioral	ADJ	O	O	2165
monitoring	NOUN	O	O	2165
revealed	VERB	O	O	2165
a	PRON	O	O	2165
profound	ADJ	O	O	2165
reduction	NOUN	O	O	2165
of	ADP	O	O	2165
the	PRON	O	O	2165
threshold	NOUN	O	O	2165
for	ADP	O	O	2165
pilocarpine	NOUN	O	Chemical	2165
-	PUNCT	O	O	2165
induced	VERB	O	O	2165
convulsions	NOUN	O	Disease	2165
.	PUNCT	O	O	2165
Morphological	ADJ	O	O	2166
analysis	NOUN	O	O	2166
of	ADP	O	O	2166
frontal	ADJ	O	O	2166
forebrain	NOUN	O	O	2166
sections	NOUN	O	O	2166
with	ADP	O	O	2166
light	ADJ	O	O	2166
microscopy	NOUN	O	O	2166
revealed	VERB	O	O	2166
seizure	NOUN	O	Disease	2166
-	PUNCT	O	O	2166
related	ADJ	O	O	2166
damage	NOUN	O	O	2166
to	PART	O	O	2166
the	PRON	O	O	2166
hippocampal	NOUN	O	O	2166
formation	NOUN	O	O	2166
,	PUNCT	O	O	2166
thalamus	NOUN	O	O	2166
,	PUNCT	O	O	2166
amygdala	NOUN	O	O	2166
,	PUNCT	O	O	2166
olfactory	NOUN	O	O	2166
cortex	VERB	O	O	2166
,	PUNCT	O	O	2166
substantia	X	O	O	2166
nigra	NOUN	O	O	2166
and	CCONJ	O	O	2166
neocortex	NOUN	O	O	2166
,	PUNCT	O	O	2166
which	PRON	O	O	2166
is	AUX	O	O	2166
typically	ADV	O	O	2166
observed	VERB	O	O	2166
with	ADP	O	O	2166
pilocarpine	NOUN	O	Chemical	2166
in	ADP	O	O	2166
doses	NOUN	O	O	2166
exceeding	VERB	O	O	2166
350	NUM	O	O	2166
mg	VERB	O	O	2166
/	PUNCT	O	O	2166
kg	VERB	O	O	2166
.	PUNCT	O	O	2166
Bilateral	ADJ	O	O	2167
intrastriatal	PROPN	O	O	2167
injections	NOUN	O	O	2167
of	ADP	O	O	2167
isoniazid	NOUN	O	Chemical	2167
did	VERB	O	O	2167
not	PART	O	O	2167
augment	VERB	O	O	2167
seizures	NOUN	O	Disease	2167
produced	VERB	O	O	2167
by	ADP	O	O	2167
pilocarpine	NOUN	O	Chemical	2167
,	PUNCT	O	O	2167
200	NUM	O	O	2167
mg	VERB	O	O	2167
/	PUNCT	O	O	2167
kg	VERB	O	O	2167
.	PUNCT	O	O	2167
Application	NOUN	O	O	2168
of	ADP	O	O	2168
an	PRON	O	O	2168
irreversible	ADJ	O	O	2168
inhibitor	NOUN	O	O	2168
of	ADP	O	O	2168
GABA	PROPN	O	Chemical	2168
transaminase	X	O	O	2168
,	PUNCT	O	O	2168
gamma	PROPN	O	O	2168
-	PUNCT	O	O	2168
vinyl	NOUN	O	O	2168
-	PUNCT	O	O	2168
GABA	PROPN	O	Chemical	2168
(	PUNCT	O	O	2168
D	NOUN	O	O	2168
,	PUNCT	O	O	2168
L-4-amino	NOUN	O	O	2168
-	PUNCT	O	O	2168
hex-5-enoic	NOUN	O	O	2168
acid	PROPN	O	O	2168
)	PUNCT	O	O	2168
,	PUNCT	O	O	2168
5	NUM	O	O	2168
micrograms	NOUN	O	O	2168
,	PUNCT	O	O	2168
into	ADP	O	O	2168
the	PRON	O	O	2168
SNR	NOUN	O	O	2168
,	PUNCT	O	O	2168
bilaterally	ADV	O	O	2168
,	PUNCT	O	O	2168
suppressed	VERB	O	O	2168
the	PRON	O	O	2168
appearance	NOUN	O	O	2168
of	ADP	O	O	2168
electrographic	PROPN	O	O	2168
and	CCONJ	O	O	2168
behavioral	ADJ	O	O	2168
seizures	NOUN	O	Disease	2168
produced	VERB	O	O	2168
by	ADP	O	O	2168
pilocarpine	NOUN	O	Chemical	2168
,	PUNCT	O	O	2168
380	NUM	O	O	2168
mg	VERB	O	O	2168
/	PUNCT	O	O	2168
kg	VERB	O	O	2168
.	PUNCT	O	O	2168
This	PRON	O	O	2169
treatment	NOUN	O	O	2169
was	AUX	O	O	2169
also	ADV	O	O	2169
sufficient	ADJ	O	O	2169
to	PART	O	O	2169
protect	VERB	O	O	2169
animals	NOUN	O	O	2169
from	ADP	O	O	2169
the	PRON	O	O	2169
occurrence	NOUN	O	O	2169
of	ADP	O	O	2169
brain damage	NOUN	O	Disease	2169
.	PUNCT	O	O	2169
Microinjections	NOUN	O	O	2170
of	ADP	O	O	2170
gamma	PROPN	O	O	2170
-	PUNCT	O	O	2170
vinyl	NOUN	O	O	2170
-	PUNCT	O	O	2170
GABA	PROPN	O	Chemical	2170
,	PUNCT	O	O	2170
5	NUM	O	O	2170
micrograms	NOUN	O	O	2170
,	PUNCT	O	O	2170
into	ADP	O	O	2170
the	PRON	O	O	2170
dorsal	PROPN	O	O	2170
striatum	NOUN	O	O	2170
,	PUNCT	O	O	2170
bilaterally	ADV	O	O	2170
,	PUNCT	O	O	2170
failed	VERB	O	O	2170
to	PART	O	O	2170
prevent	VERB	O	O	2170
the	PRON	O	O	2170
development	NOUN	O	O	2170
of	ADP	O	O	2170
convulsions	NOUN	O	Disease	2170
produced	VERB	O	O	2170
by	ADP	O	O	2170
pilocarpine	NOUN	O	Chemical	2170
,	PUNCT	O	O	2170
380	NUM	O	O	2170
mg	VERB	O	O	2170
/	PUNCT	O	O	2170
kg	VERB	O	O	2170
.	PUNCT	O	O	2170
The	PRON	O	O	2171
results	VERB	O	O	2171
demonstrate	VERB	O	O	2171
that	SCONJ	O	O	2171
the	PRON	O	O	2171
threshold	NOUN	O	O	2171
for	ADP	O	O	2171
pilocarpine	NOUN	O	Chemical	2171
-	PUNCT	O	O	2171
induced	VERB	O	O	2171
seizures	NOUN	O	Disease	2171
in	ADP	O	O	2171
rats	NOUN	O	O	2171
is	AUX	O	O	2171
subjected	VERB	O	O	2171
to	PART	O	O	2171
the	PRON	O	O	2171
regulation	NOUN	O	O	2171
of	ADP	O	O	2171
the	PRON	O	O	2171
GABA	PROPN	O	Chemical	2171
-	PUNCT	O	O	2171
mediated	VERB	O	O	2171
synaptic	ADJ	O	O	2171
inhibition	NOUN	O	O	2171
within	ADP	O	O	2171
the	PRON	O	O	2171
substantia	X	O	O	2171
nigra	NOUN	O	O	2171
.	PUNCT	O	O	2171
Non	NOUN	O	O	2174
-	PUNCT	O	O	2174
invasive	ADJ	O	O	2174
detection	NOUN	O	O	2174
of	ADP	O	O	2174
coronary artery disease	NOUN	O	Disease	2174
by	ADP	O	O	2174
body	NOUN	O	O	2174
surface	NOUN	O	O	2174
electrocardiographic	NOUN	O	O	2174
mapping	NOUN	O	O	2174
after	ADP	O	O	2174
dipyridamole	NOUN	O	Chemical	2174
infusion	NOUN	O	O	2174
.	PUNCT	O	O	2174
Electrocardiographic	NOUN	O	O	2175
changes	VERB	O	O	2175
after	ADP	O	O	2175
dipyridamole	NOUN	O	Chemical	2175
infusion	NOUN	O	O	2175
(	PUNCT	O	O	2175
0.568	NUM	O	O	2175
mg	VERB	O	O	2175
/	PUNCT	O	O	2175
kg/4	PROPN	O	O	2175
min	NOUN	O	O	2175
)	PUNCT	O	O	2175
were	AUX	O	O	2175
studied	VERB	O	O	2175
in	ADP	O	O	2175
41	NUM	O	O	2175
patients	NOUN	O	O	2175
with	ADP	O	O	2175
coronary artery disease	NOUN	O	Disease	2175
and	CCONJ	O	O	2175
compared	VERB	O	O	2175
with	ADP	O	O	2175
those	PRON	O	O	2175
after	ADP	O	O	2175
submaximal	ADJ	O	O	2175
treadmill	NOUN	O	O	2175
exercise	VERB	O	O	2175
by	ADP	O	O	2175
use	VERB	O	O	2175
of	ADP	O	O	2175
the	PRON	O	O	2175
body	NOUN	O	O	2175
surface	NOUN	O	O	2175
mapping	NOUN	O	O	2175
technique	NOUN	O	O	2175
.	PUNCT	O	O	2175
Patients	NOUN	O	O	2176
were	AUX	O	O	2176
divided	VERB	O	O	2176
into	ADP	O	O	2176
three	NUM	O	O	2176
groups	NOUN	O	O	2176
;	PUNCT	O	O	2176
19	NUM	O	O	2176
patients	NOUN	O	O	2176
without	ADP	O	O	2176
myocardial infarction	NOUN	O	Disease	2176
(	PUNCT	O	O	2176
non	ADJ	O	O	2176
-	PUNCT	O	O	2176
MI	PROPN	O	Disease	2176
group	NOUN	O	O	2176
)	PUNCT	O	O	2176
,	PUNCT	O	O	2176
14	NUM	O	O	2176
with	ADP	O	O	2176
anterior	PROPN	O	O	2176
infarction	NOUN	O	O	2176
(	PUNCT	O	O	2176
ANT	PROPN	O	O	2176
-	PUNCT	O	O	2176
MI	PROPN	O	Disease	2176
)	PUNCT	O	O	2176
and	CCONJ	O	O	2176
eight	NUM	O	O	2176
with	ADP	O	O	2176
inferior	ADJ	O	O	2176
infarction	NOUN	O	O	2176
(	PUNCT	O	O	2176
INF	PROPN	O	O	2176
-	PUNCT	O	O	2176
MI	PROPN	O	Disease	2176
)	PUNCT	O	O	2176
.	PUNCT	O	O	2176
After	ADP	O	O	2177
dipyridamole	NOUN	O	Chemical	2177
,	PUNCT	O	O	2177
ischemic	VERB	O	Disease	2177
ST	PROPN	O	O	2177
-	PUNCT	O	O	2177
segment	NOUN	O	O	2177
depression	PROPN	O	Disease	2177
(	PUNCT	O	O	2177
0.05	NUM	O	O	2177
mV	PROPN	O	O	2177
or	CCONJ	O	O	2177
more	ADJ	O	O	2177
)	PUNCT	O	O	2177
was	AUX	O	O	2177
observed	VERB	O	O	2177
in	ADP	O	O	2177
84%	NOUN	O	O	2177
of	ADP	O	O	2177
the	PRON	O	O	2177
non	ADJ	O	O	2177
-	PUNCT	O	O	2177
MI	PROPN	O	Disease	2177
group	NOUN	O	O	2177
,	PUNCT	O	O	2177
29%	NOUN	O	O	2177
of	ADP	O	O	2177
the	PRON	O	O	2177
ANT	PROPN	O	O	2177
-	PUNCT	O	O	2177
MI	PROPN	O	Disease	2177
group	NOUN	O	O	2177
,	PUNCT	O	O	2177
63%	NOUN	O	O	2177
of	ADP	O	O	2177
the	PRON	O	O	2177
INF	PROPN	O	O	2177
-	PUNCT	O	O	2177
MI	PROPN	O	Disease	2177
group	NOUN	O	O	2177
and	CCONJ	O	O	2177
61%	NOUN	O	O	2177
of	ADP	O	O	2177
the	PRON	O	O	2177
total	ADJ	O	O	2177
population	NOUN	O	O	2177
.	PUNCT	O	O	2177
Exercise	NOUN	O	O	2178
-	PUNCT	O	O	2178
induced	VERB	O	O	2178
ST	PROPN	O	O	2178
depression	PROPN	O	Disease	2178
was	AUX	O	O	2178
observed	VERB	O	O	2178
in	ADP	O	O	2178
84%	NOUN	O	O	2178
of	ADP	O	O	2178
the	PRON	O	O	2178
non	ADJ	O	O	2178
-	PUNCT	O	O	2178
MI	PROPN	O	Disease	2178
group	NOUN	O	O	2178
,	PUNCT	O	O	2178
43%	NOUN	O	O	2178
of	ADP	O	O	2178
the	PRON	O	O	2178
ANT	PROPN	O	O	2178
-	PUNCT	O	O	2178
MI	PROPN	O	Disease	2178
group	NOUN	O	O	2178
,	PUNCT	O	O	2178
38%	NOUN	O	O	2178
of	ADP	O	O	2178
the	PRON	O	O	2178
INF	PROPN	O	O	2178
-	PUNCT	O	O	2178
MI	PROPN	O	Disease	2178
group	NOUN	O	O	2178
and	CCONJ	O	O	2178
61%	NOUN	O	O	2178
of	ADP	O	O	2178
the	PRON	O	O	2178
total	ADJ	O	O	2178
.	PUNCT	O	O	2178
For	ADP	O	O	2179
individual	ADJ	O	O	2179
patients	NOUN	O	O	2179
,	PUNCT	O	O	2179
there	ADV	O	O	2179
were	AUX	O	O	2179
no	PRON	O	O	2179
obvious	ADJ	O	O	2179
differences	NOUN	O	O	2179
between	ADP	O	O	2179
the	PRON	O	O	2179
body	NOUN	O	O	2179
surface	NOUN	O	O	2179
distribution	NOUN	O	O	2179
of	ADP	O	O	2179
ST	PROPN	O	O	2179
depression	PROPN	O	Disease	2179
in	ADP	O	O	2179
both	PRON	O	O	2179
tests	VERB	O	O	2179
.	PUNCT	O	O	2179
The	PRON	O	O	2180
increase	VERB	O	O	2180
in	ADP	O	O	2180
pressure	NOUN	O	O	2180
rate	NOUN	O	O	2180
product	NOUN	O	O	2180
after	ADP	O	O	2180
dipyridamole	NOUN	O	Chemical	2180
was	AUX	O	O	2180
significantly	ADV	O	O	2180
less	ADV	O	O	2180
than	ADP	O	O	2180
that	SCONJ	O	O	2180
during	ADP	O	O	2180
the	PRON	O	O	2180
treadmill	NOUN	O	O	2180
exercise	VERB	O	O	2180
.	PUNCT	O	O	2180
The	PRON	O	O	2181
data	NOUN	O	O	2181
suggest	VERB	O	O	2181
that	SCONJ	O	O	2181
the	PRON	O	O	2181
dipyridamole	NOUN	O	Chemical	2181
-	PUNCT	O	O	2181
induced	VERB	O	O	2181
myocardial ischemia	NOUN	O	Disease	2181
is	AUX	O	O	2181
caused	VERB	O	O	2181
by	ADP	O	O	2181
the	PRON	O	O	2181
inhomogenous	ADJ	O	O	2181
distribution	NOUN	O	O	2181
of	ADP	O	O	2181
myocardial	ADJ	O	O	2181
blood	NOUN	O	O	2181
flow	NOUN	O	O	2181
.	PUNCT	O	O	2181
We	PRON	O	O	2182
conclude	VERB	O	O	2182
that	SCONJ	O	O	2182
the	PRON	O	O	2182
dipyridamole	NOUN	O	Chemical	2182
ECG	PROPN	O	O	2182
test	NOUN	O	O	2182
is	AUX	O	O	2182
as	ADP	O	O	2182
useful	ADJ	O	O	2182
as	ADP	O	O	2182
the	PRON	O	O	2182
exercise	VERB	O	O	2182
ECG	PROPN	O	O	2182
test	NOUN	O	O	2182
for	ADP	O	O	2182
the	PRON	O	O	2182
assessment	NOUN	O	O	2182
of	ADP	O	O	2182
coronary artery disease	NOUN	O	Disease	2182
.	PUNCT	O	O	2182
Bradycardia	PROPN	O	Disease	2185
after	ADP	O	O	2185
high	ADJ	O	O	2185
-	PUNCT	O	O	2185
dose	NOUN	O	O	2185
intravenous	ADJ	O	O	2185
methylprednisolone	NOUN	O	Chemical	2185
therapy	NOUN	O	O	2185
.	PUNCT	O	O	2185
In	ADP	O	O	2186
5	NUM	O	O	2186
consecutive	ADJ	O	O	2186
patients	NOUN	O	O	2186
with	ADP	O	O	2186
rheumatoid arthritis	NOUN	O	Disease	2186
who	PRON	O	O	2186
received	VERB	O	O	2186
intravenous	ADJ	O	O	2186
high	ADJ	O	O	2186
-	PUNCT	O	O	2186
dose	NOUN	O	O	2186
methylprednisolone	NOUN	O	Chemical	2186
(	PUNCT	O	O	2186
MP	PROPN	O	Chemical	2186
)	PUNCT	O	O	2186
therapy	NOUN	O	O	2186
(	PUNCT	O	O	2186
1	X	O	O	2186
g	X	O	O	2186
daily	ADV	O	O	2186
for	ADP	O	O	2186
2	X	O	O	2186
or	CCONJ	O	O	2186
3	X	O	O	2186
consecutive	ADJ	O	O	2186
days	NOUN	O	O	2186
)	PUNCT	O	O	2186
,	PUNCT	O	O	2186
a	PRON	O	O	2186
decline	VERB	O	O	2186
in	ADP	O	O	2186
pulse	NOUN	O	O	2186
rate	NOUN	O	O	2186
was	AUX	O	O	2186
observed	VERB	O	O	2186
,	PUNCT	O	O	2186
most	ADV	O	O	2186
pronounced	VERB	O	O	2186
on	ADP	O	O	2186
day	NOUN	O	O	2186
4	NUM	O	O	2186
.	PUNCT	O	O	2186
In	ADP	O	O	2187
one	NUM	O	O	2187
of	ADP	O	O	2187
the	PRON	O	O	2187
5	NUM	O	O	2187
patients	NOUN	O	O	2187
the	PRON	O	O	2187
bradycardia	NOUN	O	Disease	2187
was	AUX	O	O	2187
associated	VERB	O	O	2187
with	ADP	O	O	2187
complaints	NOUN	O	O	2187
of	ADP	O	O	2187
substernal	ADJ	O	O	2187
pressure	NOUN	O	O	2187
.	PUNCT	O	O	2187
Electrocardiographic	NOUN	O	O	2188
registrations	NOUN	O	O	2188
showed	VERB	O	O	2188
sinus	NOUN	O	O	2188
bradycardia	NOUN	O	Disease	2188
in	ADP	O	O	2188
all	PRON	O	O	2188
cases	NOUN	O	O	2188
.	PUNCT	O	O	2188
Careful	ADJ	O	O	2189
observation	NOUN	O	O	2189
of	ADP	O	O	2189
patients	NOUN	O	O	2189
receiving	VERB	O	O	2189
high	ADJ	O	O	2189
-	PUNCT	O	O	2189
dose	NOUN	O	O	2189
MP	PROPN	O	Chemical	2189
is	AUX	O	O	2189
recommended	VERB	O	O	2189
.	PUNCT	O	O	2189
High	ADJ	O	O	2190
-	PUNCT	O	O	2190
dose	NOUN	O	O	2190
MP	PROPN	O	Chemical	2190
may	AUX	O	O	2190
be	AUX	O	O	2190
contraindicated	VERB	O	O	2190
in	ADP	O	O	2190
patients	NOUN	O	O	2190
with	ADP	O	O	2190
known	VERB	O	O	2190
heart disease	NOUN	O	Disease	2190
.	PUNCT	O	O	2190
Two	NUM	O	O	2193
cases	NOUN	O	O	2193
of	ADP	O	O	2193
downbeat	ADJ	O	O	2193
nystagmus	VERB	O	Disease	2193
and	CCONJ	O	O	2193
oscillopsia	PROPN	O	O	2193
associated	VERB	O	O	2193
with	ADP	O	O	2193
carbamazepine	NOUN	O	Chemical	2193
.	PUNCT	O	O	2193
Downbeat	ADJ	O	O	2194
nystagmus	VERB	O	Disease	2194
is	AUX	O	O	2194
often	ADV	O	O	2194
associated	VERB	O	O	2194
with	ADP	O	O	2194
structural	ADJ	O	O	2194
lesions	NOUN	O	O	2194
at	ADP	O	O	2194
the	PRON	O	O	2194
craniocervical	VERB	O	O	2194
junction	NOUN	O	O	2194
,	PUNCT	O	O	2194
but	CCONJ	O	O	2194
has	VERB	O	O	2194
occasionally	ADV	O	O	2194
been	AUX	O	O	2194
reported	VERB	O	O	2194
as	ADP	O	O	2194
a	PRON	O	O	2194
manifestation	NOUN	O	O	2194
of	ADP	O	O	2194
metabolic	ADJ	O	O	2194
imbalance	NOUN	O	O	2194
or	CCONJ	O	O	2194
drug	NOUN	O	O	2194
intoxication	NOUN	O	O	2194
.	PUNCT	O	O	2194
We	PRON	O	O	2195
recorded	VERB	O	O	2195
the	PRON	O	O	2195
eye	NOUN	O	O	2195
movements	NOUN	O	O	2195
of	ADP	O	O	2195
two	NUM	O	O	2195
patients	NOUN	O	O	2195
with	ADP	O	O	2195
reversible	ADJ	O	O	2195
downbeat	ADJ	O	O	2195
nystagmus	VERB	O	Disease	2195
related	ADJ	O	O	2195
to	PART	O	O	2195
carbamazepine	NOUN	O	Chemical	2195
therapy	NOUN	O	O	2195
.	PUNCT	O	O	2195
The	PRON	O	O	2196
nystagmus	VERB	O	Disease	2196
of	ADP	O	O	2196
both	PRON	O	O	2196
patients	NOUN	O	O	2196
resolved	VERB	O	O	2196
after	ADP	O	O	2196
reduction	NOUN	O	O	2196
of	ADP	O	O	2196
the	PRON	O	O	2196
serum	NOUN	O	O	2196
carbamazepine	NOUN	O	Chemical	2196
levels	NOUN	O	O	2196
.	PUNCT	O	O	2196
In	ADP	O	O	2197
patients	NOUN	O	O	2197
with	ADP	O	O	2197
downbeat	ADJ	O	O	2197
nystagmus	VERB	O	Disease	2197
who	PRON	O	O	2197
are	AUX	O	O	2197
taking	VERB	O	O	2197
anticonvulsant	ADJ	O	O	2197
medications	NOUN	O	O	2197
,	PUNCT	O	O	2197
consideration	NOUN	O	O	2197
should	AUX	O	O	2197
be	AUX	O	O	2197
given	VERB	O	O	2197
to	PART	O	O	2197
reduction	NOUN	O	O	2197
in	ADP	O	O	2197
dose	NOUN	O	O	2197
before	ADP	O	O	2197
further	ADV	O	O	2197
investigation	NOUN	O	O	2197
is	AUX	O	O	2197
undertaken	VERB	O	O	2197
.	PUNCT	O	O	2197
Improvement	NOUN	O	O	2200
by	ADP	O	O	2200
denopamine	NOUN	O	O	2200
(	PUNCT	O	O	2200
TA-064	PRON	O	O	2200
)	PUNCT	O	O	2200
of	ADP	O	O	2200
pentobarbital	NOUN	O	Chemical	2200
-	PUNCT	O	O	2200
induced	VERB	O	O	2200
cardiac failure	NOUN	O	Disease	2200
in	ADP	O	O	2200
the	PRON	O	O	2200
dog	NOUN	O	O	2200
heart	NOUN	O	O	2200
-	PUNCT	O	O	2200
lung	NOUN	O	O	2200
preparation	NOUN	O	O	2200
.	PUNCT	O	O	2200
The	PRON	O	O	2201
efficacy	NOUN	O	O	2201
of	ADP	O	O	2201
denopamine	NOUN	O	O	2201
,	PUNCT	O	O	2201
an	PRON	O	O	2201
orally	ADV	O	O	2201
active	ADJ	O	O	2201
beta	NOUN	O	O	2201
1-adrenoceptor	NOUN	O	O	2201
agonist	NOUN	O	O	2201
,	PUNCT	O	O	2201
in	ADP	O	O	2201
improving	VERB	O	O	2201
cardiac failure	NOUN	O	Disease	2201
was	AUX	O	O	2201
assessed	VERB	O	O	2201
in	ADP	O	O	2201
dog	NOUN	O	O	2201
heart	NOUN	O	O	2201
-	PUNCT	O	O	2201
lung	NOUN	O	O	2201
preparations	NOUN	O	O	2201
.	PUNCT	O	O	2201
Cardiac	ADJ	O	O	2202
functions	VERB	O	O	2202
depressed	ADJ	O	O	2202
by	ADP	O	O	2202
pentobarbital	NOUN	O	Chemical	2202
(	PUNCT	O	O	2202
118	NUM	O	O	2202
+	ADP	O	O	2202
/-	PUNCT	O	O	2202
SD	NOUN	O	O	2203
)	PUNCT	O	O	2203
such	ADJ	O	O	2203
that	SCONJ	O	O	2203
cardiac	ADJ	O	O	2203
output	NOUN	O	O	2203
and	CCONJ	O	O	2203
maximum	ADV	O	O	2203
rate	NOUN	O	O	2203
of	ADP	O	O	2203
rise	VERB	O	O	2203
of	ADP	O	O	2203
left	VERB	O	O	2203
ventricular	ADJ	O	O	2203
pressure	NOUN	O	O	2203
(	PUNCT	O	O	2203
LV	PROPN	O	Disease	2203
dP	X	O	O	2203
/	PUNCT	O	O	2203
dt	PROPN	O	O	2203
max	PROPN	O	O	2203
)	PUNCT	O	O	2203
had	VERB	O	O	2203
been	AUX	O	O	2203
reduced	VERB	O	O	2203
by	ADP	O	O	2203
about	ADP	O	O	2203
35%	NOUN	O	O	2203
and	CCONJ	O	O	2203
26%	NOUN	O	O	2203
of	ADP	O	O	2203
the	PRON	O	O	2203
respective	ADJ	O	O	2203
controls	VERB	O	O	2203
were	AUX	O	O	2203
improved	VERB	O	O	2203
by	ADP	O	O	2203
denopamine	NOUN	O	O	2203
(	PUNCT	O	O	2203
10	NUM	O	O	2203
-	PUNCT	O	O	2203
300	NUM	O	O	2203
micrograms	NOUN	O	O	2203
)	PUNCT	O	O	2203
in	ADP	O	O	2203
a	PRON	O	O	2203
dose	NOUN	O	O	2203
-	PUNCT	O	O	2203
dependent	ADJ	O	O	2203
manner	VERB	O	O	2203
.	PUNCT	O	O	2203
With	ADP	O	O	2204
100	NUM	O	O	2204
micrograms	NOUN	O	O	2204
denopamine	NOUN	O	O	2204
,	PUNCT	O	O	2204
almost	ADV	O	O	2204
complete	VERB	O	O	2204
restoration	NOUN	O	O	2204
of	ADP	O	O	2204
cardiac	ADJ	O	O	2204
performance	NOUN	O	O	2204
was	AUX	O	O	2204
attained	VERB	O	O	2204
,	PUNCT	O	O	2204
associated	VERB	O	O	2204
with	ADP	O	O	2204
a	PRON	O	O	2204
slight	ADJ	O	O	2204
increase	VERB	O	O	2204
in	ADP	O	O	2204
heart	NOUN	O	O	2204
rate	NOUN	O	O	2204
.	PUNCT	O	O	2204
No	PRON	O	O	2205
arrhythmias	VERB	O	Disease	2205
were	AUX	O	O	2205
induced	VERB	O	O	2205
by	ADP	O	O	2205
these	PRON	O	O	2205
doses	NOUN	O	O	2205
of	ADP	O	O	2205
denopamine	NOUN	O	O	2205
.	PUNCT	O	O	2205
The	PRON	O	O	2206
results	VERB	O	O	2206
warrant	NOUN	O	O	2206
clinical	ADJ	O	O	2206
trials	NOUN	O	O	2206
of	ADP	O	O	2206
denopamine	NOUN	O	O	2206
in	ADP	O	O	2206
the	PRON	O	O	2206
treatment	NOUN	O	O	2206
of	ADP	O	O	2206
cardiac failure	NOUN	O	Disease	2206
.	PUNCT	O	O	2206
Clonazepam	NOUN	O	O	2209
monotherapy	X	O	O	2209
for	ADP	O	O	2209
epilepsy	NOUN	O	Disease	2209
in	ADP	O	O	2209
childhood	NOUN	O	O	2209
.	PUNCT	O	O	2209
Sixty	NUM	O	O	2210
patients	NOUN	O	O	2210
(	PUNCT	O	O	2210
age	NOUN	O	O	2210
-	PUNCT	O	O	2210
range	VERB	O	O	2210
one	NUM	O	O	2210
month	NOUN	O	O	2210
to	PART	O	O	2210
14	NUM	O	O	2210
years	NOUN	O	O	2210
)	PUNCT	O	O	2210
with	ADP	O	O	2210
other	ADJ	O	O	2210
types	NOUN	O	O	2210
of	ADP	O	O	2210
epilepsy	NOUN	O	Disease	2210
than	ADP	O	O	2210
infantile	ADJ	O	O	2210
spasms	NOUN	O	O	2210
were	AUX	O	O	2210
treated	VERB	O	O	2210
with	ADP	O	O	2210
clonazepam	NOUN	O	Chemical	2210
.	PUNCT	O	O	2210
Disappearance	NOUN	O	O	2211
of	ADP	O	O	2211
seizures	NOUN	O	Disease	2211
and	CCONJ	O	O	2211
normalization	NOUN	O	O	2211
of	ADP	O	O	2211
abnormal	ADJ	O	O	2211
EEG	NOUN	O	O	2211
with	ADP	O	O	2211
disappearance	NOUN	O	O	2211
of	ADP	O	O	2211
seizures	NOUN	O	Disease	2211
were	AUX	O	O	2211
recognized	VERB	O	O	2211
in	ADP	O	O	2211
77%	NOUN	O	O	2211
and	CCONJ	O	O	2211
50%	NOUN	O	O	2211
,	PUNCT	O	O	2211
respectively	ADV	O	O	2211
.	PUNCT	O	O	2211
Seizures	NOUN	O	Disease	2212
disappeared	VERB	O	O	2212
in	ADP	O	O	2212
71%	NOUN	O	O	2212
of	ADP	O	O	2212
the	PRON	O	O	2212
patients	NOUN	O	O	2212
with	ADP	O	O	2212
generalized	VERB	O	O	2212
seizures	NOUN	O	Disease	2212
and	CCONJ	O	O	2212
89%	NOUN	O	O	2212
of	ADP	O	O	2212
partial	ADJ	O	O	2212
seizures	NOUN	O	Disease	2212
.	PUNCT	O	O	2212
The	PRON	O	O	2213
incidence	NOUN	O	O	2213
of	ADP	O	O	2213
side	NOUN	O	O	2213
effects	NOUN	O	O	2213
such	ADJ	O	O	2213
as	ADP	O	O	2213
drowsiness	NOUN	O	Disease	2213
and	CCONJ	O	O	2213
ataxia	NOUN	O	Disease	2213
was	AUX	O	O	2213
only	ADV	O	O	2213
5%	NOUN	O	O	2213
.	PUNCT	O	O	2213
Postmarketing	NOUN	O	O	2216
study	VERB	O	O	2216
of	ADP	O	O	2216
timolol	PROPN	O	Chemical	2216
-	PUNCT	O	O	2216
hydrochlorothiazide	ADV	O	Chemical	2216
antihypertensive	ADV	O	O	2216
therapy	NOUN	O	O	2216
.	PUNCT	O	O	2216
A	PRON	O	O	2217
postmarketing	VERB	O	O	2217
surveillance	NOUN	O	O	2217
study	VERB	O	O	2217
was	AUX	O	O	2217
conducted	VERB	O	O	2217
to	PART	O	O	2217
determine	VERB	O	O	2217
the	PRON	O	O	2217
safety	NOUN	O	O	2217
and	CCONJ	O	O	2217
efficacy	NOUN	O	O	2217
of	ADP	O	O	2217
a	PRON	O	O	2217
fixed	VERB	O	O	2217
-	PUNCT	O	O	2217
ratio	NOUN	O	O	2217
combination	NOUN	O	O	2217
containing	VERB	O	O	2217
10	NUM	O	O	2217
mg	VERB	O	O	2217
of	ADP	O	O	2217
timolol	PROPN	O	Chemical	2217
maleate	NOUN	O	O	2217
and	CCONJ	O	O	2217
25	NUM	O	O	2217
mg	VERB	O	O	2217
of	ADP	O	O	2217
hydrochlorothiazide	ADV	O	Chemical	2217
,	PUNCT	O	O	2217
administered	VERB	O	O	2217
twice	ADV	O	O	2217
daily	ADV	O	O	2217
for	ADP	O	O	2217
one	NUM	O	O	2217
month	NOUN	O	O	2217
to	PART	O	O	2217
hypertensive	ADJ	O	Disease	2217
patients	NOUN	O	O	2217
.	PUNCT	O	O	2217
Mean	VERB	O	O	2218
systolic	ADV	O	O	2218
blood	NOUN	O	O	2218
pressure	NOUN	O	O	2218
decreased	VERB	O	O	2218
25	NUM	O	O	2218
mmHg	PROPN	O	O	2218
and	CCONJ	O	O	2218
mean	VERB	O	O	2218
diastolic	ADV	O	O	2218
blood	NOUN	O	O	2218
pressure	NOUN	O	O	2218
declined	VERB	O	O	2218
15	NUM	O	O	2218
mmHg	PROPN	O	O	2218
after	ADP	O	O	2218
one	NUM	O	O	2218
month	NOUN	O	O	2218
of	ADP	O	O	2218
timolol	PROPN	O	Chemical	2218
-	PUNCT	O	O	2218
hydrochlorothiazide	ADV	O	Chemical	2218
therapy	NOUN	O	O	2218
(	PUNCT	O	O	2218
P	NOUN	O	Chemical	2218
less	ADV	O	O	2218
than	ADP	O	O	2218
0.01	NUM	O	O	2218
,	PUNCT	O	O	2218
both	PRON	O	O	2218
comparisons	NOUN	O	O	2218
)	PUNCT	O	O	2218
.	PUNCT	O	O	2218
The	PRON	O	O	2219
antihypertensive	ADV	O	O	2219
effect	VERB	O	O	2219
of	ADP	O	O	2219
the	PRON	O	O	2219
drug	NOUN	O	O	2219
was	AUX	O	O	2219
greater	ADJ	O	O	2219
in	ADP	O	O	2219
patients	NOUN	O	O	2219
with	ADP	O	O	2219
more	ADJ	O	O	2219
severe	ADJ	O	O	2219
hypertension	NOUN	O	Disease	2219
.	PUNCT	O	O	2219
Overall	ADV	O	O	2220
,	PUNCT	O	O	2220
1,453	NUM	O	O	2220
patients	NOUN	O	O	2220
experienced	ADJ	O	O	2220
a	PRON	O	O	2220
total	ADJ	O	O	2220
of	ADP	O	O	2220
2,658	NUM	O	O	2220
adverse	ADJ	O	O	2220
events	NOUN	O	O	2220
,	PUNCT	O	O	2220
the	PRON	O	O	2220
most	ADV	O	O	2220
common	ADJ	O	O	2220
being	AUX	O	O	2220
fatigue	NOUN	O	Disease	2220
,	PUNCT	O	O	2220
dizziness	NOUN	O	Disease	2220
,	PUNCT	O	O	2220
and	CCONJ	O	O	2220
weakness	NOUN	O	Disease	2220
.	PUNCT	O	O	2220
Salicylate	NOUN	O	O	2223
nephropathy	NOUN	O	Disease	2223
in	ADP	O	O	2223
the	PRON	O	O	2223
Gunn	PROPN	O	O	2223
rat	NOUN	O	O	2223
:	PUNCT	O	O	2223
potential	ADJ	O	O	2223
role	NOUN	O	O	2223
of	ADP	O	O	2223
prostaglandins	NOUN	O	Chemical	2223
.	PUNCT	O	O	2223
We	PRON	O	O	2224
examined	VERB	O	O	2224
the	PRON	O	O	2224
potential	ADJ	O	O	2224
role	NOUN	O	O	2224
of	ADP	O	O	2224
prostaglandins	NOUN	O	Chemical	2224
in	ADP	O	O	2224
the	PRON	O	O	2224
development	NOUN	O	O	2224
of	ADP	O	O	2224
analgesic	PROPN	O	O	2224
nephropathy	NOUN	O	Disease	2224
in	ADP	O	O	2224
the	PRON	O	O	2224
Gunn	PROPN	O	O	2224
strain	VERB	O	O	2224
of	ADP	O	O	2224
rat	NOUN	O	O	2224
.	PUNCT	O	O	2224
The	PRON	O	O	2225
homozygous	ADJ	O	O	2225
Gunn	PROPN	O	O	2225
rats	NOUN	O	O	2225
have	VERB	O	O	2225
unconjugated	ADJ	O	O	2225
hyperbilirubinemia	PROPN	O	Disease	2225
due	ADJ	O	O	2225
to	PART	O	O	2225
the	PRON	O	O	2225
absence	NOUN	O	O	2225
of	ADP	O	O	2225
glucuronyl	NOUN	O	O	2225
transferase	PROPN	O	O	2225
,	PUNCT	O	O	2225
leading	VERB	O	O	2225
to	PART	O	O	2225
marked	VERB	O	O	2225
bilirubin	ADJ	O	Chemical	2225
deposition	NOUN	O	O	2225
in	ADP	O	O	2225
renal	ADJ	O	O	2225
medulla	NOUN	O	O	2225
and	CCONJ	O	O	2225
papilla	NOUN	O	O	2225
.	PUNCT	O	O	2225
These	PRON	O	O	2226
rats	NOUN	O	O	2226
are	AUX	O	O	2226
also	ADV	O	O	2226
highly	ADV	O	O	2226
susceptible	ADJ	O	O	2226
to	PART	O	O	2226
develop	VERB	O	O	2226
papillary	ADJ	O	O	2226
necrosis	NOUN	O	Disease	2226
with	ADP	O	O	2226
analgesic	PROPN	O	O	2226
administration	NOUN	O	O	2226
.	PUNCT	O	O	2226
Four	NUM	O	O	2227
groups	NOUN	O	O	2227
of	ADP	O	O	2227
rats	NOUN	O	O	2227
(	PUNCT	O	O	2227
n	CCONJ	O	O	2227
=	PUNCT	O	O	2227
7	NUM	O	O	2227
)	PUNCT	O	O	2227
were	AUX	O	O	2227
studied	VERB	O	O	2227
:	PUNCT	O	O	2227
jj	X	O	O	2227
and	CCONJ	O	O	2227
jJ	INTJ	O	O	2227
rats	NOUN	O	O	2227
treated	VERB	O	O	2227
either	ADV	O	O	2227
with	ADP	O	O	2227
aspirin	NOUN	O	Chemical	2227
300	NUM	O	O	2227
mg	VERB	O	O	2227
/	PUNCT	O	O	2227
kg	VERB	O	O	2227
every	PRON	O	O	2227
other	ADJ	O	O	2227
day	NOUN	O	O	2227
or	CCONJ	O	O	2227
sham	NOUN	O	O	2227
-	PUNCT	O	O	2227
treated	VERB	O	O	2227
.	PUNCT	O	O	2227
After	ADP	O	O	2228
one	NUM	O	O	2228
week	NOUN	O	O	2228
,	PUNCT	O	O	2228
slices	NOUN	O	O	2228
of	ADP	O	O	2228
cortex	VERB	O	O	2228
,	PUNCT	O	O	2228
outer	NOUN	O	O	2228
and	CCONJ	O	O	2228
inner	ADJ	O	O	2228
medulla	NOUN	O	O	2228
from	ADP	O	O	2228
one	NUM	O	O	2228
kidney	NOUN	O	O	2228
were	AUX	O	O	2228
incubated	VERB	O	O	2228
in	ADP	O	O	2228
buffer	NOUN	O	O	2228
and	CCONJ	O	O	2228
prostaglandin	NOUN	O	Chemical	2228
synthesis	NOUN	O	O	2228
was	AUX	O	O	2228
determined	VERB	O	O	2228
by	ADP	O	O	2228
radioimmunoassay	PROPN	O	O	2228
.	PUNCT	O	O	2228
A	PRON	O	O	2229
marked	VERB	O	O	2229
corticomedullary	NOUN	O	O	2229
gradient	NOUN	O	O	2229
of	ADP	O	O	2229
prostaglandin	NOUN	O	Chemical	2229
synthesis	NOUN	O	O	2229
was	AUX	O	O	2229
observed	VERB	O	O	2229
in	ADP	O	O	2229
all	PRON	O	O	2229
groups	NOUN	O	O	2229
.	PUNCT	O	O	2229
PGE2	NOUN	O	Chemical	2230
synthesis	NOUN	O	O	2230
was	AUX	O	O	2230
significantly	ADV	O	O	2230
higher	ADJ	O	O	2230
in	ADP	O	O	2230
outer	NOUN	O	O	2230
medulla	NOUN	O	O	2230
,	PUNCT	O	O	2230
but	CCONJ	O	O	2230
not	PART	O	O	2230
cortex	VERB	O	O	2230
or	CCONJ	O	O	2230
inner	ADJ	O	O	2230
medulla	NOUN	O	O	2230
,	PUNCT	O	O	2230
of	ADP	O	O	2230
jj	X	O	O	2230
(	PUNCT	O	O	2230
38	NUM	O	O	2230
+	ADP	O	O	2230
/-	PUNCT	O	O	2230
Aspirin	NOUN	O	Chemical	2231
treatment	NOUN	O	O	2231
reduced	VERB	O	O	2231
PGE2	NOUN	O	Chemical	2231
synthesis	NOUN	O	O	2231
in	ADP	O	O	2231
all	PRON	O	O	2231
regions	NOUN	O	O	2231
,	PUNCT	O	O	2231
but	CCONJ	O	O	2231
outer	NOUN	O	O	2231
medullary	ADJ	O	O	2231
PGE2	NOUN	O	Chemical	2231
remained	VERB	O	O	2231
higher	ADJ	O	O	2231
in	ADP	O	O	2231
jj	X	O	O	2231
(	PUNCT	O	O	2231
18	NUM	O	O	2231
+	ADP	O	O	2231
/-	PUNCT	O	O	2231
PGF2	PROPN	O	O	2232
alpha	PROPN	O	O	2232
was	AUX	O	O	2232
also	ADV	O	O	2232
significantly	ADV	O	O	2232
higher	ADJ	O	O	2232
in	ADP	O	O	2232
the	PRON	O	O	2232
outer	NOUN	O	O	2232
medulla	NOUN	O	O	2232
of	ADP	O	O	2232
jj	X	O	O	2232
rats	NOUN	O	O	2232
with	ADP	O	O	2232
and	CCONJ	O	O	2232
without	ADP	O	O	2232
aspirin	NOUN	O	Chemical	2232
administration	NOUN	O	O	2232
(	PUNCT	O	O	2232
p	NOUN	O	O	2232
less	ADV	O	O	2232
than	ADP	O	O	2232
0.05	NUM	O	O	2232
)	PUNCT	O	O	2232
.	PUNCT	O	O	2232
The	PRON	O	O	2233
changes	VERB	O	O	2233
in	ADP	O	O	2233
renal	ADJ	O	O	2233
prostaglandin	NOUN	O	Chemical	2233
synthesis	NOUN	O	O	2233
were	AUX	O	O	2233
accompanied	VERB	O	O	2233
by	ADP	O	O	2233
evidence	NOUN	O	O	2233
of	ADP	O	O	2233
renal damage	NOUN	O	Disease	2233
in	ADP	O	O	2233
aspirin	NOUN	O	Chemical	2233
-	PUNCT	O	O	2233
treated	VERB	O	O	2233
jj	X	O	O	2233
but	CCONJ	O	O	2233
not	PART	O	O	2233
jJ	INTJ	O	O	2233
rats	NOUN	O	O	2233
as	ADP	O	O	2233
evidenced	VERB	O	O	2233
by	ADP	O	O	2233
:	PUNCT	O	O	2233
increased	VERB	O	O	2233
incidence	NOUN	O	O	2233
and	CCONJ	O	O	2233
severity	NOUN	O	O	2233
of	ADP	O	O	2233
hematuria	PROPN	O	Disease	2233
(	PUNCT	O	O	2233
p	NOUN	O	O	2233
less	ADV	O	O	2233
than	ADP	O	O	2233
0.01	NUM	O	O	2233
)	PUNCT	O	O	2233
;	PUNCT	O	O	2233
increased	VERB	O	O	2233
serum	NOUN	O	O	2233
creatinine	PROPN	O	Chemical	2233
(	PUNCT	O	O	2233
p	NOUN	O	O	2233
less	ADV	O	O	2233
than	ADP	O	O	2233
0.05	NUM	O	O	2233
)	PUNCT	O	O	2233
;	PUNCT	O	O	2233
and	CCONJ	O	O	2233
increase	VERB	O	O	2233
in	ADP	O	O	2233
outer	NOUN	O	O	2233
medullary	ADJ	O	O	2233
histopathologic	VERB	O	O	2233
lesions	NOUN	O	O	2233
(	PUNCT	O	O	2233
p	NOUN	O	O	2233
less	ADV	O	O	2233
than	ADP	O	O	2233
0.005	NUM	O	O	2233
compared	VERB	O	O	2233
to	PART	O	O	2233
either	ADV	O	O	2233
sham	NOUN	O	O	2233
-	PUNCT	O	O	2233
treated	VERB	O	O	2233
jj	X	O	O	2233
or	CCONJ	O	O	2233
aspirin	NOUN	O	Chemical	2233
-	PUNCT	O	O	2233
treated	VERB	O	O	2233
jJ	INTJ	O	O	2233
)	PUNCT	O	O	2233
.	PUNCT	O	O	2233
These	PRON	O	O	2234
results	VERB	O	O	2234
suggest	VERB	O	O	2234
that	SCONJ	O	O	2234
enhanced	VERB	O	O	2234
prostaglandin	NOUN	O	Chemical	2234
synthesis	NOUN	O	O	2234
contributes	VERB	O	O	2234
to	PART	O	O	2234
maintenance	NOUN	O	O	2234
of	ADP	O	O	2234
renal	ADJ	O	O	2234
function	NOUN	O	O	2234
and	CCONJ	O	O	2234
morphological	ADJ	O	O	2234
integrity	NOUN	O	O	2234
,	PUNCT	O	O	2234
and	CCONJ	O	O	2234
that	SCONJ	O	O	2234
inhibition	NOUN	O	O	2234
of	ADP	O	O	2234
prostaglandin	NOUN	O	Chemical	2234
synthesis	NOUN	O	O	2234
may	AUX	O	O	2234
lead	VERB	O	Chemical	2234
to	PART	O	O	2234
pathological	ADJ	O	O	2234
renal	ADJ	O	O	2234
medullary	ADJ	O	O	2234
lesions	NOUN	O	O	2234
and	CCONJ	O	O	2234
deterioration	NOUN	O	O	2234
of	ADP	O	O	2234
renal	ADJ	O	O	2234
function	NOUN	O	O	2234
.	PUNCT	O	O	2234
Prophylactic	ADJ	O	O	2237
lidocaine	NOUN	O	Chemical	2237
in	ADP	O	O	2237
the	PRON	O	O	2237
early	ADV	O	O	2237
phase	NOUN	O	O	2237
of	ADP	O	O	2237
suspected	VERB	O	O	2237
myocardial infarction	NOUN	O	Disease	2237
.	PUNCT	O	O	2237
Four	NUM	O	O	2238
hundred	NUM	O	O	2238
two	NUM	O	O	2238
patients	NOUN	O	O	2238
with	ADP	O	O	2238
suspected	VERB	O	O	2238
myocardial infarction	NOUN	O	Disease	2238
seen	VERB	O	O	2238
within	ADP	O	O	2238
6	NUM	O	O	2238
hours	NOUN	O	O	2238
of	ADP	O	O	2238
the	PRON	O	O	2238
onset	VERB	O	O	2238
of	ADP	O	O	2238
symptoms	NOUN	O	O	2238
entered	VERB	O	O	2238
a	PRON	O	O	2238
double	ADJ	O	O	2238
-	PUNCT	O	O	2238
blind	ADJ	O	Disease	2238
randomized	VERB	O	O	2238
trial	NOUN	O	O	2238
of	ADP	O	O	2238
lidocaine	NOUN	O	Chemical	2238
vs	ADP	O	O	2238
placebo	NOUN	O	O	2238
.	PUNCT	O	O	2238
During	ADP	O	O	2239
the	PRON	O	O	2239
1	X	O	O	2239
hour	NOUN	O	O	2239
after	ADP	O	O	2239
administration	NOUN	O	O	2239
of	ADP	O	O	2239
the	PRON	O	O	2239
drug	NOUN	O	O	2239
the	PRON	O	O	2239
incidence	NOUN	O	O	2239
of	ADP	O	O	2239
ventricular fibrillation	NOUN	O	Disease	2239
or	CCONJ	O	O	2239
sustained	VERB	O	O	2239
ventricular tachycardia	NOUN	O	Disease	2239
among	ADP	O	O	2239
the	PRON	O	O	2239
204	NUM	O	O	2239
patients	NOUN	O	O	2239
with	ADP	O	O	2239
acute	ADJ	O	O	2239
myocardial infarction	NOUN	O	Disease	2239
was	AUX	O	O	2239
low	ADJ	O	O	2239
,	PUNCT	O	O	2239
1.5%	NOUN	O	O	2239
.	PUNCT	O	O	2239
Lidocaine	PROPN	O	O	2240
,	PUNCT	O	O	2240
given	VERB	O	O	2240
in	ADP	O	O	2240
a	PRON	O	O	2240
300	NUM	O	O	2240
mg	VERB	O	O	2240
dose	NOUN	O	O	2240
intramuscularly	ADV	O	O	2240
followed	VERB	O	O	2240
by	ADP	O	O	2240
100	NUM	O	O	2240
mg	VERB	O	O	2240
intravenously	ADV	O	O	2240
,	PUNCT	O	O	2240
did	VERB	O	O	2240
not	PART	O	O	2240
prevent	VERB	O	O	2240
sustained	VERB	O	O	2240
ventricular tachycardia	NOUN	O	Disease	2240
,	PUNCT	O	O	2240
although	SCONJ	O	O	2240
there	ADV	O	O	2240
was	AUX	O	O	2240
a	PRON	O	O	2240
significant	ADJ	O	O	2240
reduction	NOUN	O	O	2240
in	ADP	O	O	2240
the	PRON	O	O	2240
number	NOUN	O	O	2240
of	ADP	O	O	2240
patients	NOUN	O	O	2240
with	ADP	O	O	2240
warning	VERB	O	O	2240
arrhythmias	VERB	O	Disease	2240
between	ADP	O	O	2240
15	NUM	O	O	2240
and	CCONJ	O	O	2240
45	NUM	O	O	2240
minutes	NOUN	O	O	2240
after	ADP	O	O	2240
the	PRON	O	O	2240
administration	NOUN	O	O	2240
of	ADP	O	O	2240
lidocaine	NOUN	O	Chemical	2240
(	PUNCT	O	O	2240
p	NOUN	O	O	2240
less	ADV	O	O	2240
than	ADP	O	O	2240
0.05	NUM	O	O	2240
)	PUNCT	O	O	2240
.	PUNCT	O	O	2240
The	PRON	O	O	2241
average	ADJ	O	O	2241
plasma	NOUN	O	O	2241
lidocaine	NOUN	O	Chemical	2241
level	VERB	O	O	2241
10	NUM	O	O	2241
minutes	NOUN	O	O	2241
after	ADP	O	O	2241
administration	NOUN	O	O	2241
for	ADP	O	O	2241
patients	NOUN	O	O	2241
without	ADP	O	O	2241
a	PRON	O	O	2241
myocardial infarction	NOUN	O	Disease	2241
was	AUX	O	O	2241
significantly	ADV	O	O	2241
higher	ADJ	O	O	2241
than	ADP	O	O	2241
that	SCONJ	O	O	2241
for	ADP	O	O	2241
patients	NOUN	O	O	2241
with	ADP	O	O	2241
an	PRON	O	O	2241
acute	ADJ	O	O	2241
infarction	NOUN	O	O	2241
.	PUNCT	O	O	2241
The	PRON	O	O	2242
mean	VERB	O	O	2242
plasma	NOUN	O	O	2242
lidocaine	NOUN	O	Chemical	2242
level	VERB	O	O	2242
of	ADP	O	O	2242
patients	NOUN	O	O	2242
on	ADP	O	O	2242
beta	NOUN	O	O	2242
-	PUNCT	O	O	2242
blocking	VERB	O	O	2242
agents	NOUN	O	O	2242
was	AUX	O	O	2242
no	PRON	O	O	2242
different	ADJ	O	O	2242
from	ADP	O	O	2242
that	SCONJ	O	O	2242
in	ADP	O	O	2242
patients	NOUN	O	O	2242
not	PART	O	O	2242
on	ADP	O	O	2242
beta	NOUN	O	O	2242
blocking	VERB	O	O	2242
agents	NOUN	O	O	2242
.	PUNCT	O	O	2242
During	ADP	O	O	2243
the	PRON	O	O	2243
1-hour	NOUN	O	O	2243
study	VERB	O	O	2243
period	NOUN	O	O	2243
,	PUNCT	O	O	2243
the	PRON	O	O	2243
incidence	NOUN	O	O	2243
of	ADP	O	O	2243
central	ADJ	O	O	2243
nervous	ADJ	O	O	2243
system	NOUN	O	O	2243
side	NOUN	O	O	2243
effects	NOUN	O	O	2243
was	AUX	O	O	2243
significantly	ADV	O	O	2243
greater	ADJ	O	O	2243
in	ADP	O	O	2243
the	PRON	O	O	2243
lidocaine	NOUN	O	Chemical	2243
group	NOUN	O	O	2243
,	PUNCT	O	O	2243
hypotension	NOUN	O	Disease	2243
occurred	VERB	O	O	2243
in	ADP	O	O	2243
11	NUM	O	O	2243
patients	NOUN	O	O	2243
,	PUNCT	O	O	2243
nine	NUM	O	O	2243
of	ADP	O	O	2243
whom	PRON	O	O	2243
had	VERB	O	O	2243
received	VERB	O	O	2243
lidocaine	NOUN	O	Chemical	2243
,	PUNCT	O	O	2243
and	CCONJ	O	O	2243
four	NUM	O	O	2243
patients	NOUN	O	O	2243
died	VERB	O	O	2243
from	ADP	O	O	2243
asystole	NOUN	O	Disease	2243
,	PUNCT	O	O	2243
three	NUM	O	O	2243
of	ADP	O	O	2243
whom	PRON	O	O	2243
had	VERB	O	O	2243
had	VERB	O	O	2243
lidocaine	NOUN	O	Chemical	2243
.	PUNCT	O	O	2243
We	PRON	O	O	2244
can	AUX	O	O	2244
not	PART	O	O	2244
advocate	NOUN	O	O	2244
the	PRON	O	O	2244
administration	NOUN	O	O	2244
of	ADP	O	O	2244
lidocaine	NOUN	O	Chemical	2244
prophylactically	ADV	O	O	2244
in	ADP	O	O	2244
the	PRON	O	O	2244
early	ADV	O	O	2244
hours	NOUN	O	O	2244
of	ADP	O	O	2244
suspected	VERB	O	O	2244
myocardial infarction	NOUN	O	Disease	2244
.	PUNCT	O	O	2244
Evidence	NOUN	O	O	2247
for	ADP	O	O	2247
a	PRON	O	O	2247
cholinergic	ADJ	O	O	2247
role	NOUN	O	O	2247
in	ADP	O	O	2247
haloperidol	NOUN	O	Chemical	2247
-	PUNCT	O	O	2247
induced	VERB	O	O	2247
catalepsy	VERB	O	Disease	2247
.	PUNCT	O	O	2247
Experiments	NOUN	O	O	2248
in	ADP	O	O	2248
mice	NOUN	O	O	2248
tested	VERB	O	O	2248
previous	ADJ	O	O	2248
evidence	NOUN	O	O	2248
that	SCONJ	O	O	2248
activation	NOUN	O	O	2248
of	ADP	O	O	2248
cholinergic	ADJ	O	O	2248
systems	NOUN	O	O	2248
promotes	VERB	O	O	2248
catalepsy	VERB	O	Disease	2248
and	CCONJ	O	O	2248
that	SCONJ	O	O	2248
cholinergic	ADJ	O	O	2248
mechanisms	NOUN	O	O	2248
need	VERB	O	O	2248
to	PART	O	O	2248
be	AUX	O	O	2248
intact	ADJ	O	O	2248
for	ADP	O	O	2248
full	ADJ	O	O	2248
expression	NOUN	O	O	2248
of	ADP	O	O	2248
neuroleptic	NOUN	O	O	2248
-	PUNCT	O	O	2248
induced	VERB	O	O	2248
catalepsy	VERB	O	Disease	2248
.	PUNCT	O	O	2248
Large	ADJ	O	O	2249
doses	NOUN	O	O	2249
of	ADP	O	O	2249
the	PRON	O	O	2249
cholinomimetic	ADJ	O	O	2249
,	PUNCT	O	O	2249
pilocarpine	NOUN	O	Chemical	2249
,	PUNCT	O	O	2249
could	AUX	O	O	2249
induce	VERB	O	O	2249
catalepsy	VERB	O	Disease	2249
when	SCONJ	O	O	2249
peripheral	ADJ	O	O	2249
cholinergic	ADJ	O	O	2249
receptors	NOUN	O	O	2249
were	AUX	O	O	2249
blocked	VERB	O	O	2249
.	PUNCT	O	O	2249
Low	ADJ	O	O	2250
doses	NOUN	O	O	2250
of	ADP	O	O	2250
pilocarpine	NOUN	O	Chemical	2250
caused	VERB	O	O	2250
a	PRON	O	O	2250
pronounced	VERB	O	O	2250
enhancement	NOUN	O	O	2250
of	ADP	O	O	2250
the	PRON	O	O	2250
catalepsy	VERB	O	Disease	2250
that	SCONJ	O	O	2250
was	AUX	O	O	2250
induced	VERB	O	O	2250
by	ADP	O	O	2250
the	PRON	O	O	2250
dopaminergic	ADJ	O	O	2250
blocker	NOUN	O	O	2250
,	PUNCT	O	O	2250
haloperidol	NOUN	O	Chemical	2250
.	PUNCT	O	O	2250
A	PRON	O	O	2251
muscarinic	PROPN	O	O	2251
receptor	NOUN	O	O	2251
blocker	NOUN	O	O	2251
,	PUNCT	O	O	2251
atropine	NOUN	O	Chemical	2251
,	PUNCT	O	O	2251
disrupted	VERB	O	O	2251
haloperidol	NOUN	O	Chemical	2251
-	PUNCT	O	O	2251
induced	VERB	O	O	2251
catalepsy	VERB	O	Disease	2251
.	PUNCT	O	O	2251
Intracranial	ADJ	O	O	2252
injection	NOUN	O	O	2252
of	ADP	O	O	2252
an	PRON	O	O	2252
acetylcholine	NOUN	O	Chemical	2252
-	PUNCT	O	O	2252
synthesis	NOUN	O	O	2252
inhibitor	NOUN	O	O	2252
,	PUNCT	O	O	2252
hemicholinium	NOUN	O	O	2252
,	PUNCT	O	O	2252
prevented	VERB	O	O	2252
the	PRON	O	O	2252
catalepsy	VERB	O	Disease	2252
that	SCONJ	O	O	2252
is	AUX	O	O	2252
usually	ADV	O	O	2252
induced	VERB	O	O	2252
by	ADP	O	O	2252
haloperidol	NOUN	O	Chemical	2252
.	PUNCT	O	O	2252
These	PRON	O	O	2253
findings	NOUN	O	O	2253
suggest	VERB	O	O	2253
the	PRON	O	O	2253
hypothesis	NOUN	O	O	2253
that	SCONJ	O	O	2253
the	PRON	O	O	2253
catalepsy	VERB	O	Disease	2253
that	SCONJ	O	O	2253
is	AUX	O	O	2253
produced	VERB	O	O	2253
by	ADP	O	O	2253
neuroleptics	NOUN	O	O	2253
such	ADJ	O	O	2253
as	ADP	O	O	2253
haloperidol	NOUN	O	Chemical	2253
is	AUX	O	O	2253
actually	ADV	O	O	2253
mediated	VERB	O	O	2253
by	ADP	O	O	2253
intrinsic	ADJ	O	O	2253
central	ADJ	O	O	2253
cholinergic	ADJ	O	O	2253
systems	NOUN	O	O	2253
.	PUNCT	O	O	2253
Alternatively	ADV	O	O	2254
,	PUNCT	O	O	2254
activation	NOUN	O	O	2254
of	ADP	O	O	2254
central	ADJ	O	O	2254
cholinergic	ADJ	O	O	2254
systems	NOUN	O	O	2254
could	AUX	O	O	2254
promote	VERB	O	O	2254
catalepsy	VERB	O	Disease	2254
by	ADP	O	O	2254
suppression	NOUN	O	O	2254
of	ADP	O	O	2254
dopaminergic	ADJ	O	O	2254
systems	NOUN	O	O	2254
.	PUNCT	O	O	2254
Cardiovascular dysfunction	NOUN	O	O	2257
and	CCONJ	O	O	2257
hypersensitivity	NOUN	O	Disease	2257
to	PART	O	O	2257
sodium	NOUN	O	Chemical	2257
pentobarbital	NOUN	O	Chemical	2257
induced	VERB	O	O	2257
by	ADP	O	O	2257
chronic	ADJ	O	O	2257
barium	PROPN	O	O	2257
chloride	NOUN	O	Chemical	2257
ingestion	NOUN	O	O	2257
.	PUNCT	O	O	2257
Barium	NOUN	O	O	2258
-	PUNCT	O	O	2258
supplemented	VERB	O	O	2258
Long	ADV	O	O	2258
-	PUNCT	O	O	2258
Evans	PROPN	O	O	2258
hooded	ADJ	O	O	2258
rats	NOUN	O	O	2258
were	AUX	O	O	2258
characterized	VERB	O	O	2258
by	ADP	O	O	2258
a	PRON	O	O	2258
persistent	ADJ	O	O	2258
hypertension	NOUN	O	Disease	2258
that	SCONJ	O	O	2258
was	AUX	O	O	2258
evident	ADJ	O	O	2258
after	ADP	O	O	2258
1	X	O	O	2258
month	NOUN	O	O	2258
of	ADP	O	O	2258
barium	PROPN	O	O	2258
(	PUNCT	O	O	2258
100	NUM	O	O	2258
micrograms	NOUN	O	O	2258
/	PUNCT	O	O	2258
ml	ADP	O	O	2258
mineral	NOUN	O	O	2258
fortified	VERB	O	O	2258
water	PROPN	O	O	2258
)	PUNCT	O	O	2258
treatment	NOUN	O	O	2258
.	PUNCT	O	O	2258
myocardial	ADJ	O	O	2259
excitability	NOUN	O	O	2259
,	PUNCT	O	O	2259
contractility	NOUN	O	O	2259
,	PUNCT	O	O	2259
and	CCONJ	O	O	2259
metabolic	ADJ	O	O	2259
characteristics	NOUN	O	O	2259
at	ADP	O	O	2259
16	NUM	O	O	2259
months	NOUN	O	O	2259
revealed	VERB	O	O	2259
other	ADJ	O	O	2259
significant	ADJ	O	O	2259
barium	PROPN	O	O	2259
-	PUNCT	O	O	2259
induced	VERB	O	O	2259
disturbances	NOUN	O	O	2259
within	ADP	O	O	2259
the	PRON	O	O	2259
cardiovascular	ADJ	O	O	2259
system	NOUN	O	O	2259
.	PUNCT	O	O	2259
The	PRON	O	O	2260
most	ADV	O	O	2260
distinctive	ADJ	O	O	2260
aspect	NOUN	O	O	2260
of	ADP	O	O	2260
the	PRON	O	O	2260
barium	PROPN	O	O	2260
effect	VERB	O	O	2260
was	AUX	O	O	2260
a	PRON	O	O	2260
demonstrated	VERB	O	O	2260
hypersensitivity	NOUN	O	Disease	2260
of	ADP	O	O	2260
the	PRON	O	O	2260
cardiovascular	ADJ	O	O	2260
system	NOUN	O	O	2260
to	PART	O	O	2260
sodium	NOUN	O	Chemical	2260
pentobarbital	NOUN	O	Chemical	2260
.	PUNCT	O	O	2260
Under	ADP	O	O	2261
barbiturate	NOUN	O	Chemical	2261
anesthesia	NOUN	O	O	2261
,	PUNCT	O	O	2261
virtually	ADV	O	O	2261
all	PRON	O	O	2261
of	ADP	O	O	2261
the	PRON	O	O	2261
myocardial	ADJ	O	O	2261
contractile	ADJ	O	O	2261
indices	NOUN	O	O	2261
were	AUX	O	O	2261
depressed	ADJ	O	O	2261
significantly	ADV	O	O	2261
in	ADP	O	O	2261
barium	PROPN	O	O	2261
-	PUNCT	O	O	2261
exposed	VERB	O	O	2261
rats	NOUN	O	O	2261
relative	ADJ	O	O	2261
to	PART	O	O	2261
the	PRON	O	O	2261
corresponding	VERB	O	O	2261
control	VERB	O	O	2261
-	PUNCT	O	O	2261
fed	VERB	O	O	2261
rats	NOUN	O	O	2261
.	PUNCT	O	O	2261
The	PRON	O	O	2262
lack	VERB	O	O	2262
of	ADP	O	O	2262
a	PRON	O	O	2262
similar	ADJ	O	O	2262
response	NOUN	O	O	2262
to	PART	O	O	2262
ketamine	VERB	O	Chemical	2262
and	CCONJ	O	O	2262
xylazine	NOUN	O	O	2262
anesthesia	NOUN	O	O	2262
revealed	VERB	O	O	2262
that	SCONJ	O	O	2262
the	PRON	O	O	2262
cardiovascular	ADJ	O	O	2262
actions	NOUN	O	O	2262
of	ADP	O	O	2262
sodium	NOUN	O	Chemical	2262
pentobarbital	NOUN	O	Chemical	2262
in	ADP	O	O	2262
barium	PROPN	O	O	2262
-	PUNCT	O	O	2262
treated	VERB	O	O	2262
rats	NOUN	O	O	2262
were	AUX	O	O	2262
linked	VERB	O	O	2262
specifically	ADV	O	O	2262
to	PART	O	O	2262
this	PRON	O	O	2262
anesthetic	NOUN	O	O	2262
,	PUNCT	O	O	2262
and	CCONJ	O	O	2262
were	AUX	O	O	2262
not	PART	O	O	2262
representative	NOUN	O	O	2262
of	ADP	O	O	2262
a	PRON	O	O	2262
generalized	VERB	O	O	2262
anesthetic	NOUN	O	O	2262
response	NOUN	O	O	2262
.	PUNCT	O	O	2262
Other	ADJ	O	O	2263
myocardial	ADJ	O	O	2263
pathophysiologic	ADJ	O	O	2263
and	CCONJ	O	O	2263
metabolic	ADJ	O	O	2263
changes	VERB	O	O	2263
induced	VERB	O	O	2263
by	ADP	O	O	2263
barium	PROPN	O	O	2263
were	AUX	O	O	2263
manifest	VERB	O	O	2263
,	PUNCT	O	O	2263
irrespective	ADV	O	O	2263
of	ADP	O	O	2263
the	PRON	O	O	2263
anesthetic	NOUN	O	O	2263
employed	VERB	O	O	2263
.	PUNCT	O	O	2263
The	PRON	O	O	2264
contractile	ADJ	O	O	2264
element	NOUN	O	O	2264
shortening	NOUN	O	O	2264
velocity	NOUN	O	O	2264
of	ADP	O	O	2264
the	PRON	O	O	2264
cardiac	ADJ	O	O	2264
muscle	NOUN	O	O	2264
fibers	NOUN	O	O	2264
was	AUX	O	O	2264
significantly	ADV	O	O	2264
slower	ADJ	O	O	2264
in	ADP	O	O	2264
both	PRON	O	O	2264
groups	NOUN	O	O	2264
of	ADP	O	O	2264
barium	PROPN	O	O	2264
-	PUNCT	O	O	2264
treated	VERB	O	O	2264
rats	NOUN	O	O	2264
relative	ADJ	O	O	2264
to	PART	O	O	2264
the	PRON	O	O	2264
control	VERB	O	O	2264
groups	NOUN	O	O	2264
,	PUNCT	O	O	2264
irrespective	ADV	O	O	2264
of	ADP	O	O	2264
the	PRON	O	O	2264
anesthetic	NOUN	O	O	2264
regimen	NOUN	O	O	2264
.	PUNCT	O	O	2264
Similarly	ADV	O	O	2265
,	PUNCT	O	O	2265
significant	ADJ	O	O	2265
disturbances	NOUN	O	O	2265
in	ADP	O	O	2265
myocardial	ADJ	O	O	2265
energy	PROPN	O	O	2265
metabolism	NOUN	O	O	2265
were	AUX	O	O	2265
detected	VERB	O	O	2265
in	ADP	O	O	2265
the	PRON	O	O	2265
barium	PROPN	O	O	2265
-	PUNCT	O	O	2265
exposed	VERB	O	O	2265
rats	NOUN	O	O	2265
which	PRON	O	O	2265
were	AUX	O	O	2265
consistent	ADJ	O	O	2265
with	ADP	O	O	2265
the	PRON	O	O	2265
reduced	VERB	O	O	2265
contractile	ADJ	O	O	2265
element	NOUN	O	O	2265
shortening	NOUN	O	O	2265
velocity	NOUN	O	O	2265
.	PUNCT	O	O	2265
In	ADP	O	O	2266
addition	NOUN	O	O	2266
,	PUNCT	O	O	2266
the	PRON	O	O	2266
excitability	NOUN	O	O	2266
of	ADP	O	O	2266
the	PRON	O	O	2266
cardiac	ADJ	O	O	2266
conduction	NOUN	O	O	2266
system	NOUN	O	O	2266
was	AUX	O	O	2266
depressed	ADJ	O	O	2266
preferentially	ADV	O	O	2266
in	ADP	O	O	2266
the	PRON	O	O	2266
atrioventricular	ADJ	O	O	2266
nodal	ADJ	O	O	2266
region	NOUN	O	O	2266
of	ADP	O	O	2266
hearts	NOUN	O	O	2266
from	ADP	O	O	2266
barium	PROPN	O	O	2266
-	PUNCT	O	O	2266
exposed	VERB	O	O	2266
rats	NOUN	O	O	2266
.	PUNCT	O	O	2266
Overall	ADV	O	O	2267
,	PUNCT	O	O	2267
the	PRON	O	O	2267
altered	VERB	O	O	2267
cardiac	ADJ	O	O	2267
contractility	NOUN	O	O	2267
and	CCONJ	O	O	2267
excitability	NOUN	O	O	2267
characteristics	NOUN	O	O	2267
,	PUNCT	O	O	2267
the	PRON	O	O	2267
myocardial	ADJ	O	O	2267
metabolic	ADJ	O	O	2267
disturbances	NOUN	O	O	2267
,	PUNCT	O	O	2267
and	CCONJ	O	O	2267
the	PRON	O	O	2267
hypersensitivity	NOUN	O	Disease	2267
of	ADP	O	O	2267
the	PRON	O	O	2267
cardiovascular	ADJ	O	O	2267
system	NOUN	O	O	2267
to	PART	O	O	2267
sodium	NOUN	O	Chemical	2267
pentobarbital	NOUN	O	Chemical	2267
suggest	VERB	O	O	2267
the	PRON	O	O	2267
existence	NOUN	O	O	2267
of	ADP	O	O	2267
a	PRON	O	O	2267
heretofore	ADV	O	O	2267
undescribed	ADJ	O	O	2267
cardiomyopathic	PROPN	O	O	2267
disorder	NOUN	O	O	2267
induced	VERB	O	O	2267
by	ADP	O	O	2267
chronic	ADJ	O	O	2267
barium	PROPN	O	O	2267
exposure	NOUN	O	O	2267
.	PUNCT	O	O	2267
These	PRON	O	O	2268
experimental	ADJ	O	O	2268
findings	NOUN	O	O	2268
represent	VERB	O	O	2268
the	PRON	O	O	2268
first	ADV	O	O	2268
indication	NOUN	O	O	2268
that	SCONJ	O	O	2268
life	NOUN	O	O	2268
-	PUNCT	O	O	2268
long	ADV	O	O	2268
barium	PROPN	O	O	2268
ingestion	NOUN	O	O	2268
may	AUX	O	O	2268
have	VERB	O	O	2268
significant	ADJ	O	O	2268
adverse	ADJ	O	O	2268
effects	NOUN	O	O	2268
on	ADP	O	O	2268
the	PRON	O	O	2268
mammalian	ADJ	O	O	2268
cardiovascular	ADJ	O	O	2268
system	NOUN	O	O	2268
.	PUNCT	O	O	2268
Propranolol	NOUN	O	Chemical	2271
antagonism	NOUN	O	O	2271
of	ADP	O	O	2271
phenylpropanolamine	PROPN	O	Chemical	2271
-	PUNCT	O	O	2271
induced	VERB	O	O	2271
hypertension	NOUN	O	Disease	2271
.	PUNCT	O	O	2271
Phenylpropanolamine	NOUN	O	Chemical	2272
(	PUNCT	O	O	2272
PPA	PROPN	O	Chemical	2272
)	PUNCT	O	O	2272
overdose	NOUN	O	Disease	2272
can	AUX	O	O	2272
cause	VERB	O	O	2272
severe	ADJ	O	O	2272
hypertension	NOUN	O	Disease	2272
,	PUNCT	O	O	2272
intracerebral hemorrhage	NOUN	O	Disease	2272
,	PUNCT	O	O	2272
and	CCONJ	O	O	2272
death	NOUN	O	O	2272
.	PUNCT	O	O	2272
We	PRON	O	O	2273
studied	VERB	O	O	2273
the	PRON	O	O	2273
efficacy	NOUN	O	O	2273
and	CCONJ	O	O	2273
safety	NOUN	O	O	2273
of	ADP	O	O	2273
propranolol	NOUN	O	Chemical	2273
in	ADP	O	O	2273
the	PRON	O	O	2273
treatment	NOUN	O	O	2273
of	ADP	O	O	2273
PPA	PROPN	O	Chemical	2273
-	PUNCT	O	O	2273
induced	VERB	O	O	2273
hypertension	NOUN	O	Disease	2273
.	PUNCT	O	O	2273
Subjects	NOUN	O	O	2274
received	VERB	O	O	2274
propranolol	NOUN	O	Chemical	2274
either	ADV	O	O	2274
by	ADP	O	O	2274
mouth	PROPN	O	O	2274
for	ADP	O	O	2274
48	NUM	O	O	2274
hours	NOUN	O	O	2274
before	ADP	O	O	2274
PPA	PROPN	O	Chemical	2274
or	CCONJ	O	O	2274
as	ADP	O	O	2274
a	PRON	O	O	2274
rapid	ADJ	O	O	2274
intravenous	ADJ	O	O	2274
infusion	NOUN	O	O	2274
after	ADP	O	O	2274
PPA	PROPN	O	Chemical	2274
.	PUNCT	O	O	2274
PPA	PROPN	O	Chemical	2275
,	PUNCT	O	O	2275
75	NUM	O	O	2275
mg	VERB	O	O	2275
alone	ADV	O	O	2275
,	PUNCT	O	O	2275
increased	VERB	O	O	2275
blood	NOUN	O	O	2275
pressure	NOUN	O	O	2275
(	PUNCT	O	O	2275
31	NUM	O	O	2275
+	ADP	O	O	2275
/-	PUNCT	O	O	2275
5	NUM	O	O	2276
mm	INTJ	O	O	2276
Hg	PROPN	O	O	2276
diastolic	ADV	O	O	2276
)	PUNCT	O	O	2276
,	PUNCT	O	O	2276
and	CCONJ	O	O	2276
propranolol	NOUN	O	Chemical	2276
pretreatment	NOUN	O	O	2276
antagonized	VERB	O	O	2276
this	PRON	O	O	2276
increase	VERB	O	O	2276
(	PUNCT	O	O	2276
12	NUM	O	O	2276
+	ADP	O	O	2276
/-	PUNCT	O	O	2276
Intravenous	PROPN	O	O	2277
propranolol	NOUN	O	Chemical	2277
after	ADP	O	O	2277
PPA	PROPN	O	Chemical	2277
also	ADV	O	O	2277
decreased	VERB	O	O	2277
blood	NOUN	O	O	2277
pressure	NOUN	O	O	2277
.	PUNCT	O	O	2277
Left	VERB	O	O	2278
ventricular	ADJ	O	O	2278
function	NOUN	O	O	2278
(	PUNCT	O	O	2278
assessed	VERB	O	O	2278
by	ADP	O	O	2278
echocardiography	NOUN	O	O	2278
)	PUNCT	O	O	2278
showed	VERB	O	O	2278
that	SCONJ	O	O	2278
PPA	PROPN	O	Chemical	2278
increased	VERB	O	O	2278
the	PRON	O	O	2278
stroke	VERB	O	Disease	2278
volume	PROPN	O	O	2278
30%	NOUN	O	O	2278
(	PUNCT	O	O	2278
from	ADP	O	O	2278
62.5	NUM	O	O	2278
+	ADP	O	O	2278
/-	PUNCT	O	O	2278
Intravenous	PROPN	O	O	2279
propranolol	NOUN	O	Chemical	2279
reversed	VERB	O	O	2279
these	PRON	O	O	2279
effects	NOUN	O	O	2279
.	PUNCT	O	O	2279
Systemic	ADJ	O	O	2280
vascular	ADJ	O	O	2280
resistance	NOUN	O	O	2280
was	AUX	O	O	2280
increased	VERB	O	O	2280
by	ADP	O	O	2280
PPA	PROPN	O	Chemical	2280
28%	NOUN	O	O	2280
(	PUNCT	O	O	2280
from	ADP	O	O	2280
1710	NUM	O	O	2280
+	ADP	O	O	2280
/-	PUNCT	O	O	2280
sec	PROPN	O	O	2281
/	PUNCT	O	O	2281
cm5	NOUN	O	O	2281
)	PUNCT	O	O	2281
and	CCONJ	O	O	2281
was	AUX	O	O	2281
further	ADV	O	O	2281
increased	VERB	O	O	2281
by	ADP	O	O	2281
propranolol	NOUN	O	Chemical	2281
22%	NOUN	O	O	2281
(	PUNCT	O	O	2281
to	PART	O	O	2281
2660	NUM	O	O	2281
+	ADP	O	O	2281
/-	PUNCT	O	O	2281
We	PRON	O	O	2282
conclude	VERB	O	O	2282
that	SCONJ	O	O	2282
PPA	PROPN	O	Chemical	2282
increases	VERB	O	O	2282
blood	NOUN	O	O	2282
pressure	NOUN	O	O	2282
by	ADP	O	O	2282
increasing	VERB	O	O	2282
systemic	ADJ	O	O	2282
vascular	ADJ	O	O	2282
resistance	NOUN	O	O	2282
and	CCONJ	O	O	2282
cardiac	ADJ	O	O	2282
output	NOUN	O	O	2282
,	PUNCT	O	O	2282
and	CCONJ	O	O	2282
that	SCONJ	O	O	2282
propranolol	NOUN	O	Chemical	2282
antagonizes	VERB	O	O	2282
this	PRON	O	O	2282
increase	VERB	O	O	2282
by	ADP	O	O	2282
reversing	VERB	O	O	2282
the	PRON	O	O	2282
effect	VERB	O	O	2282
of	ADP	O	O	2282
PPA	PROPN	O	Chemical	2282
on	ADP	O	O	2282
cardiac	ADJ	O	O	2282
output	NOUN	O	O	2282
.	PUNCT	O	O	2282
That	PRON	O	O	2283
propranolol	NOUN	O	Chemical	2283
antagonizes	VERB	O	O	2283
the	PRON	O	O	2283
pressor	ADJ	O	O	2283
effect	VERB	O	O	2283
of	ADP	O	O	2283
PPA	PROPN	O	Chemical	2283
is	AUX	O	O	2283
in	ADP	O	O	2283
contrast	NOUN	O	O	2283
to	PART	O	O	2283
the	PRON	O	O	2283
interaction	NOUN	O	O	2283
in	ADP	O	O	2283
which	PRON	O	O	2283
propranolol	NOUN	O	Chemical	2283
enhances	VERB	O	O	2283
the	PRON	O	O	2283
pressor	ADJ	O	O	2283
effect	VERB	O	O	2283
of	ADP	O	O	2283
norepinephrine	NOUN	O	Chemical	2283
.	PUNCT	O	O	2283
This	PRON	O	O	2284
is	AUX	O	O	2284
probably	ADV	O	O	2284
because	SCONJ	O	O	2284
PPA	PROPN	O	Chemical	2284
has	VERB	O	O	2284
less	ADV	O	O	2284
beta	NOUN	O	O	2284
2	X	O	O	2284
activity	NOUN	O	O	2284
than	ADP	O	O	2284
does	VERB	O	O	2284
norepinephrine	NOUN	O	Chemical	2284
.	PUNCT	O	O	2284
Mesangial	PROPN	O	O	2287
function	NOUN	O	O	2287
and	CCONJ	O	O	2287
glomerular	ADJ	O	O	2287
sclerosis	NOUN	O	O	2287
in	ADP	O	O	2287
rats	NOUN	O	O	2287
with	ADP	O	O	2287
aminonucleoside	NOUN	O	Chemical	2287
nephrosis	NOUN	O	Disease	2287
.	PUNCT	O	O	2287
The	PRON	O	O	2288
possible	ADJ	O	O	2288
relationship	NOUN	O	O	2288
between	ADP	O	O	2288
mesangial	ADJ	O	O	2288
dysfunction	NOUN	O	O	2288
and	CCONJ	O	O	2288
development	NOUN	O	O	2288
of	ADP	O	O	2288
glomerular	ADJ	O	O	2288
sclerosis	NOUN	O	O	2288
was	AUX	O	O	2288
studied	VERB	O	O	2288
in	ADP	O	O	2288
the	PRON	O	O	2288
puromycin aminonucleoside	NOUN	O	Chemical	2288
(	PUNCT	O	O	2288
PAN	PROPN	O	Chemical	2288
)	PUNCT	O	O	2288
model	NOUN	O	O	2288
.	PUNCT	O	O	2288
Five	NUM	O	O	2289
male	NOUN	O	O	2289
Wistar	PROPN	O	O	2289
rats	NOUN	O	O	2289
received	VERB	O	O	2289
repeated	VERB	O	O	2289
subcutaneous	ADJ	O	O	2289
PAN	PROPN	O	Chemical	2289
injections	NOUN	O	O	2289
;	PUNCT	O	O	2289
five	NUM	O	O	2289
controls	VERB	O	O	2289
received	VERB	O	O	2289
saline	NOUN	O	O	2289
only	ADV	O	O	2289
.	PUNCT	O	O	2289
After	ADP	O	O	2290
4	NUM	O	O	2290
weeks	NOUN	O	O	2290
the	PRON	O	O	2290
PAN	PROPN	O	Chemical	2290
rats	NOUN	O	O	2290
were	AUX	O	O	2290
severely	ADV	O	O	2290
proteinuric	ADJ	O	O	2290
(	PUNCT	O	O	2290
190	NUM	O	O	2290
+	ADP	O	O	2290
/-	PUNCT	O	O	2290
80	NUM	O	O	2291
mg/24	NOUN	O	O	2291
hr	NOUN	O	O	2291
)	PUNCT	O	O	2291
,	PUNCT	O	O	2291
and	CCONJ	O	O	2291
all	PRON	O	O	2291
rats	NOUN	O	O	2291
were	AUX	O	O	2291
given	VERB	O	O	2291
colloidal	NOUN	O	O	2291
carbon	NOUN	O	O	2291
(	PUNCT	O	O	2291
CC	NOUN	O	Chemical	2291
)	PUNCT	O	O	2291
intravenously	ADV	O	O	2291
.	PUNCT	O	O	2291
At	ADP	O	O	2292
5	NUM	O	O	2292
months	NOUN	O	O	2292
glomerular	ADJ	O	O	2292
sclerosis	NOUN	O	O	2292
was	AUX	O	O	2292
found	VERB	O	O	2292
in	ADP	O	O	2292
7.6	NUM	O	O	2292
+	ADP	O	O	2292
/-	PUNCT	O	O	2292
3.4%	NOUN	O	O	2293
of	ADP	O	O	2293
the	PRON	O	O	2293
glomeruli	VERB	O	O	2293
of	ADP	O	O	2293
PAN	PROPN	O	Chemical	2293
rats	NOUN	O	O	2293
;	PUNCT	O	O	2293
glomeruli	VERB	O	O	2293
of	ADP	O	O	2293
the	PRON	O	O	2293
controls	VERB	O	O	2293
were	AUX	O	O	2293
normal	ADJ	O	O	2293
.	PUNCT	O	O	2293
Glomeruli	PROPN	O	O	2294
of	ADP	O	O	2294
PAN	PROPN	O	Chemical	2294
rats	NOUN	O	O	2294
contained	VERB	O	O	2294
significantly	ADV	O	O	2294
more	ADJ	O	O	2294
CC	NOUN	O	Chemical	2294
than	ADP	O	O	2294
glomeruli	VERB	O	O	2294
of	ADP	O	O	2294
controls	VERB	O	O	2294
.	PUNCT	O	O	2294
Glomeruli	PROPN	O	O	2295
with	ADP	O	O	2295
sclerosis	NOUN	O	O	2295
contained	VERB	O	O	2295
significantly	ADV	O	O	2295
more	ADJ	O	O	2295
CC	NOUN	O	Chemical	2295
than	ADP	O	O	2295
non	ADJ	O	O	2295
-	PUNCT	O	O	2295
sclerotic	ADJ	O	O	2295
glomeruli	VERB	O	O	2295
in	ADP	O	O	2295
the	PRON	O	O	2295
same	ADJ	O	O	2295
kidneys	NOUN	O	O	2295
.	PUNCT	O	O	2295
Since	SCONJ	O	O	2296
mesangial	ADJ	O	O	2296
CC	NOUN	O	Chemical	2296
clearance	NOUN	O	O	2296
from	ADP	O	O	2296
the	PRON	O	O	2296
mesangium	NOUN	O	O	2296
did	VERB	O	O	2296
not	PART	O	O	2296
change	VERB	O	O	2296
during	ADP	O	O	2296
chronic	ADJ	O	O	2296
PAN	PROPN	O	Chemical	2296
treatment	NOUN	O	O	2296
,	PUNCT	O	O	2296
we	PRON	O	O	2296
conclude	VERB	O	O	2296
that	SCONJ	O	O	2296
this	PRON	O	O	2296
preferential	ADJ	O	O	2296
CC	NOUN	O	Chemical	2296
localization	NOUN	O	O	2296
within	ADP	O	O	2296
the	PRON	O	O	2296
lesions	NOUN	O	O	2296
is	AUX	O	O	2296
caused	VERB	O	O	2296
by	ADP	O	O	2296
an	PRON	O	O	2296
increased	VERB	O	O	2296
CC	NOUN	O	Chemical	2296
uptake	NOUN	O	O	2296
shortly	ADV	O	O	2296
after	ADP	O	O	2296
injection	NOUN	O	O	2296
in	ADP	O	O	2296
apparent	ADJ	O	O	2296
vulnerable	ADJ	O	O	2296
areas	NOUN	O	O	2296
where	SCONJ	O	O	2296
sclerosis	NOUN	O	O	2296
will	AUX	O	O	2296
develop	VERB	O	O	2296
subsequently	ADV	O	O	2296
.	PUNCT	O	O	2296
Cluster	NOUN	O	O	2297
analysis	NOUN	O	O	2297
showed	VERB	O	O	2297
a	PRON	O	O	2297
random	ADJ	O	O	2297
distribution	NOUN	O	O	2297
of	ADP	O	O	2297
lesions	NOUN	O	O	2297
in	ADP	O	O	2297
the	PRON	O	O	2297
PAN	PROPN	O	Chemical	2297
glomeruli	VERB	O	O	2297
in	ADP	O	O	2297
concordance	NOUN	O	O	2297
with	ADP	O	O	2297
the	PRON	O	O	2297
random	ADJ	O	O	2297
localization	NOUN	O	O	2297
of	ADP	O	O	2297
mesangial	ADJ	O	O	2297
areas	NOUN	O	O	2297
with	ADP	O	O	2297
dysfunction	NOUN	O	O	2297
in	ADP	O	O	2297
this	PRON	O	O	2297
model	NOUN	O	O	2297
.	PUNCT	O	O	2297
Similar	ADJ	O	O	2298
to	PART	O	O	2298
the	PRON	O	O	2298
remnant	ADJ	O	O	2298
kidney	NOUN	O	O	2298
model	NOUN	O	O	2298
in	ADP	O	O	2298
PAN	PROPN	O	Chemical	2298
nephrosis	NOUN	O	Disease	2298
the	PRON	O	O	2298
development	NOUN	O	O	2298
of	ADP	O	O	2298
glomerular	ADJ	O	O	2298
sclerosis	NOUN	O	O	2298
may	AUX	O	O	2298
be	AUX	O	O	2298
related	ADJ	O	O	2298
to	PART	O	O	2298
""""	PUNCT	O	O	2298
mesangial	ADJ	O	O	2298
overloading	VERB	O	O	2298
.	PUNCT	O	O	2298
""""	PUNCT	O	O	2298
Relationship	NOUN	O	O	2301
between	ADP	O	O	2301
nicotine	NOUN	O	Chemical	2301
-	PUNCT	O	O	2301
induced	VERB	O	O	2301
seizures	NOUN	O	Disease	2301
and	CCONJ	O	O	2301
hippocampal	NOUN	O	O	2301
nicotinic	ADJ	O	O	2301
receptors	NOUN	O	O	2301
.	PUNCT	O	O	2301
Using	VERB	O	O	2302
mice	NOUN	O	O	2302
derived	VERB	O	O	2302
from	ADP	O	O	2302
a	PRON	O	O	2302
classical	ADJ	O	O	2302
F2	NOUN	O	O	2302
and	CCONJ	O	O	2302
backcross	NOUN	O	O	2302
genetic	ADJ	O	O	2302
design	NOUN	O	O	2302
,	PUNCT	O	O	2302
a	PRON	O	O	2302
relationship	NOUN	O	O	2302
between	ADP	O	O	2302
nicotine	NOUN	O	Chemical	2302
-	PUNCT	O	O	2302
induced	VERB	O	O	2302
seizures	NOUN	O	Disease	2302
and	CCONJ	O	O	2302
alpha	PROPN	O	O	2302
-	PUNCT	O	O	2302
bungarotoxin	PROPN	O	O	2302
nicotinic	ADJ	O	O	2302
receptor	NOUN	O	O	2302
concentration	NOUN	O	O	2302
was	AUX	O	O	2302
found	VERB	O	O	2302
.	PUNCT	O	O	2302
Mice	NOUN	O	O	2303
sensitive	ADJ	O	O	2303
to	PART	O	O	2303
the	PRON	O	O	2303
convulsant	ADJ	O	O	2303
effects	NOUN	O	O	2303
of	ADP	O	O	2303
nicotine	NOUN	O	Chemical	2303
had	VERB	O	O	2303
greater	ADJ	O	O	2303
alpha	PROPN	O	O	2303
-	PUNCT	O	O	2303
bungarotoxin	PROPN	O	O	2303
binding	VERB	O	O	2303
in	ADP	O	O	2303
the	PRON	O	O	2303
hippocampus	NOUN	O	O	2303
than	ADP	O	O	2303
seizure	NOUN	O	Disease	2303
insensitive	ADJ	O	O	2303
mice	NOUN	O	O	2303
.	PUNCT	O	O	2303
The	PRON	O	O	2304
binding	VERB	O	O	2304
sites	NOUN	O	O	2304
from	ADP	O	O	2304
seizure	NOUN	O	Disease	2304
sensitive	ADJ	O	O	2304
and	CCONJ	O	O	2304
resistant	ADJ	O	O	2304
mice	NOUN	O	O	2304
were	AUX	O	O	2304
equally	ADV	O	O	2304
affected	VERB	O	O	2304
by	ADP	O	O	2304
treatment	NOUN	O	O	2304
with	ADP	O	O	2304
dithiothreitol	PROPN	O	O	2304
,	PUNCT	O	O	2304
trypsin	VERB	O	O	2304
or	CCONJ	O	O	2304
heat	NOUN	O	O	2304
.	PUNCT	O	O	2304
Thus	ADV	O	O	2305
it	PRON	O	O	2305
appears	VERB	O	O	2305
that	SCONJ	O	O	2305
the	PRON	O	O	2305
difference	NOUN	O	O	2305
between	ADP	O	O	2305
seizure	NOUN	O	Disease	2305
sensitive	ADJ	O	O	2305
and	CCONJ	O	O	2305
insensitive	ADJ	O	O	2305
animals	NOUN	O	O	2305
may	AUX	O	O	2305
be	AUX	O	O	2305
due	ADJ	O	O	2305
to	PART	O	O	2305
a	PRON	O	O	2305
difference	NOUN	O	O	2305
in	ADP	O	O	2305
hippocampal	NOUN	O	O	2305
nicotinic	ADJ	O	O	2305
receptor	NOUN	O	O	2305
concentration	NOUN	O	O	2305
as	ADP	O	O	2305
measured	VERB	O	O	2305
with	ADP	O	O	2305
alpha	PROPN	O	O	2305
-	PUNCT	O	O	2305
bungarotoxin	PROPN	O	O	2305
binding	VERB	O	O	2305
.	PUNCT	O	O	2305
The	PRON	O	O	2308
role	NOUN	O	O	2308
of	ADP	O	O	2308
p	NOUN	O	O	2308
-	PUNCT	O	O	2308
aminophenol	NOUN	O	O	2308
in	ADP	O	O	2308
acetaminophen	PROPN	O	Chemical	2308
-	PUNCT	O	O	2308
induced	VERB	O	O	2308
nephrotoxicity	NOUN	O	Disease	2308
:	PUNCT	O	O	2308
effect	VERB	O	O	2308
of	ADP	O	O	2308
bis(p	PROPN	O	O	2308
-	PUNCT	O	O	2308
nitrophenyl	NOUN	O	O	2308
)	PUNCT	O	O	2308
phosphate	NOUN	O	Chemical	2308
on	ADP	O	O	2308
acetaminophen	PROPN	O	Chemical	2308
and	CCONJ	O	O	2308
p	NOUN	O	O	2308
-	PUNCT	O	O	2308
aminophenol	NOUN	O	O	2308
nephrotoxicity	NOUN	O	Disease	2308
and	CCONJ	O	O	2308
metabolism	NOUN	O	O	2308
in	ADP	O	O	2308
Fischer	PROPN	O	O	2308
344	NUM	O	O	2308
rats	NOUN	O	O	2308
.	PUNCT	O	O	2308
Acetaminophen	PROPN	O	O	2309
(	PUNCT	O	O	2309
APAP	PROPN	O	O	2309
)	PUNCT	O	O	2309
produces	VERB	O	O	2309
proximal	ADJ	O	O	2309
tubular necrosis	NOUN	O	Disease	2309
in	ADP	O	O	2309
Fischer	PROPN	O	O	2309
344	NUM	O	O	2309
(	PUNCT	O	O	2309
F344	PROPN	O	O	2309
)	PUNCT	O	O	2309
rats	NOUN	O	O	2309
.	PUNCT	O	O	2309
Recently	ADV	O	O	2310
,	PUNCT	O	O	2310
p	NOUN	O	O	2310
-	PUNCT	O	O	2310
aminophenol	NOUN	O	O	2310
(	PUNCT	O	O	2310
PAP	NOUN	O	O	2310
)	PUNCT	O	O	2310
,	PUNCT	O	O	2310
a	PRON	O	O	2310
known	VERB	O	O	2310
potent	ADJ	O	O	2310
nephrotoxicant	ADJ	O	O	2310
,	PUNCT	O	O	2310
was	AUX	O	O	2310
identified	VERB	O	O	2310
as	ADP	O	O	2310
a	PRON	O	O	2310
metabolite	NOUN	O	O	2310
of	ADP	O	O	2310
APAP	PROPN	O	O	2310
in	ADP	O	O	2310
F344	PROPN	O	O	2310
rats	NOUN	O	O	2310
.	PUNCT	O	O	2310
The	PRON	O	O	2311
purpose	NOUN	O	O	2311
of	ADP	O	O	2311
this	PRON	O	O	2311
study	VERB	O	O	2311
was	AUX	O	O	2311
to	PART	O	O	2311
determine	VERB	O	O	2311
if	SCONJ	O	O	2311
PAP	NOUN	O	O	2311
formation	NOUN	O	O	2311
is	AUX	O	O	2311
a	PRON	O	O	2311
requisite	ADJ	O	O	2311
step	VERB	O	O	2311
in	ADP	O	O	2311
APAP	PROPN	O	O	2311
-	PUNCT	O	O	2311
induced	VERB	O	O	2311
nephrotoxicity	NOUN	O	Disease	2311
.	PUNCT	O	O	2311
Therefore	ADV	O	O	2312
,	PUNCT	O	O	2312
the	PRON	O	O	2312
effect	VERB	O	O	2312
of	ADP	O	O	2312
bis(p	PROPN	O	O	2312
-	PUNCT	O	O	2312
nitrophenyl	NOUN	O	O	2312
)	PUNCT	O	O	2312
phosphate	NOUN	O	Chemical	2312
(	PUNCT	O	O	2312
BNPP	PROPN	O	O	2312
)	PUNCT	O	O	2312
,	PUNCT	O	O	2312
an	PRON	O	O	2312
acylamidase	PROPN	O	O	2312
inhibitor	NOUN	O	O	2312
,	PUNCT	O	O	2312
on	ADP	O	O	2312
APAP	PROPN	O	O	2312
and	CCONJ	O	O	2312
PAP	NOUN	O	O	2312
nephrotoxicity	NOUN	O	Disease	2312
and	CCONJ	O	O	2312
metabolism	NOUN	O	O	2312
was	AUX	O	O	2312
determined	VERB	O	O	2312
.	PUNCT	O	O	2312
BNPP	PROPN	O	O	2313
(	PUNCT	O	O	2313
1	X	O	O	2313
to	PART	O	O	2313
8	NUM	O	O	2313
mM	ADJ	O	O	2313
)	PUNCT	O	O	2313
reduced	VERB	O	O	2313
APAP	PROPN	O	O	2313
deacetylation	NOUN	O	O	2313
and	CCONJ	O	O	2313
covalent	ADJ	O	O	2313
binding	VERB	O	O	2313
in	ADP	O	O	2313
F344	PROPN	O	O	2313
renal	ADJ	O	O	2313
cortical	ADJ	O	O	2313
homogenates	VERB	O	O	2313
in	ADP	O	O	2313
a	PRON	O	O	2313
concentration	NOUN	O	O	2313
-	PUNCT	O	O	2313
dependent	ADJ	O	O	2313
manner	VERB	O	O	2313
.	PUNCT	O	O	2313
Pretreatment	NOUN	O	O	2314
of	ADP	O	O	2314
animals	NOUN	O	O	2314
with	ADP	O	O	2314
BNPP	PROPN	O	O	2314
prior	ADV	O	O	2314
to	PART	O	O	2314
APAP	PROPN	O	O	2314
or	CCONJ	O	O	2314
PAP	NOUN	O	O	2314
administration	NOUN	O	O	2314
resulted	VERB	O	O	2314
in	ADP	O	O	2314
marked	VERB	O	O	2314
reduction	NOUN	O	O	2314
of	ADP	O	O	2314
APAP	PROPN	O	O	2314
(	PUNCT	O	O	2314
900	NUM	O	O	2314
mg	VERB	O	O	2314
/	PUNCT	O	O	2314
kg	VERB	O	O	2314
)	PUNCT	O	O	2314
nephrotoxicity	NOUN	O	Disease	2315
but	CCONJ	O	O	2315
not	PART	O	O	2315
PAP	NOUN	O	O	2315
nephrotoxicity	NOUN	O	Disease	2315
.	PUNCT	O	O	2315
This	PRON	O	O	2316
result	VERB	O	O	2316
was	AUX	O	O	2316
not	PART	O	O	2316
due	ADJ	O	O	2316
to	PART	O	O	2316
altered	VERB	O	O	2316
disposition	NOUN	O	O	2316
of	ADP	O	O	2316
either	ADV	O	O	2316
APAP	PROPN	O	O	2316
or	CCONJ	O	O	2316
acetylated	VERB	O	O	2316
metabolites	VERB	O	O	2316
in	ADP	O	O	2316
plasma	NOUN	O	O	2316
or	CCONJ	O	O	2316
renal	ADJ	O	O	2316
cortical	ADJ	O	O	2316
and	CCONJ	O	O	2316
hepatic	ADJ	O	O	2316
tissue	NOUN	O	O	2316
.	PUNCT	O	O	2316
Rather	ADV	O	O	2317
,	PUNCT	O	O	2317
BNPP	PROPN	O	O	2317
pretreatment	NOUN	O	O	2317
reduced	VERB	O	O	2317
the	PRON	O	O	2317
fraction	NOUN	O	O	2317
of	ADP	O	O	2317
APAP	PROPN	O	O	2317
excreted	VERB	O	O	2317
as	ADP	O	O	2317
PAP	NOUN	O	O	2317
by	ADP	O	O	2317
64	NUM	O	O	2317
and	CCONJ	O	O	2317
75%	NOUN	O	O	2317
after	ADP	O	O	2317
APAP	PROPN	O	O	2317
doses	NOUN	O	O	2317
of	ADP	O	O	2317
750	NUM	O	O	2317
and	CCONJ	O	O	2317
900	NUM	O	O	2317
mg	VERB	O	O	2317
/	PUNCT	O	O	2317
kg	VERB	O	O	2317
.	PUNCT	O	O	2317
BNPP	PROPN	O	O	2318
did	VERB	O	O	2318
not	PART	O	O	2318
alter	VERB	O	O	2318
the	PRON	O	O	2318
excretion	NOUN	O	O	2318
of	ADP	O	O	2318
APAP	PROPN	O	O	2318
or	CCONJ	O	O	2318
any	PRON	O	O	2318
of	ADP	O	O	2318
its	PRON	O	O	2318
non	ADJ	O	O	2318
-	PUNCT	O	O	2318
deacetylated	VERB	O	O	2318
metabolites	VERB	O	O	2318
nor	CCONJ	O	O	2318
did	VERB	O	O	2318
BNPP	PROPN	O	O	2318
alter	VERB	O	O	2318
excretion	NOUN	O	O	2318
of	ADP	O	O	2318
PAP	NOUN	O	O	2318
or	CCONJ	O	O	2318
its	PRON	O	O	2318
metabolites	VERB	O	O	2318
after	ADP	O	O	2318
PAP	NOUN	O	O	2318
doses	NOUN	O	O	2318
of	ADP	O	O	2318
150	NUM	O	O	2318
and	CCONJ	O	O	2318
300	NUM	O	O	2318
mg	VERB	O	O	2318
/	PUNCT	O	O	2318
kg	VERB	O	O	2318
.	PUNCT	O	O	2318
Therefore	ADV	O	O	2319
,	PUNCT	O	O	2319
the	PRON	O	O	2319
BNPP	PROPN	O	O	2319
-	PUNCT	O	O	2319
induced	VERB	O	O	2319
reduction	NOUN	O	O	2319
in	ADP	O	O	2319
APAP	PROPN	O	O	2319
-	PUNCT	O	O	2319
induced	VERB	O	O	2319
nephrotoxicity	NOUN	O	Disease	2319
appears	VERB	O	O	2319
to	PART	O	O	2319
be	AUX	O	O	2319
due	ADJ	O	O	2319
to	PART	O	O	2319
inhibition	NOUN	O	O	2319
of	ADP	O	O	2319
APAP	PROPN	O	O	2319
deacetylation	NOUN	O	O	2319
.	PUNCT	O	O	2319
It	PRON	O	O	2320
is	AUX	O	O	2320
concluded	VERB	O	O	2320
that	SCONJ	O	O	2320
PAP	NOUN	O	O	2320
formation	NOUN	O	O	2320
,	PUNCT	O	O	2320
in	ADP	O	O	2320
vivo	VERB	O	O	2320
,	PUNCT	O	O	2320
accounts	VERB	O	O	2320
,	PUNCT	O	O	2320
at	ADP	O	O	2320
least	ADJ	O	O	2320
in	ADP	O	O	2320
part	NOUN	O	O	2320
,	PUNCT	O	O	2320
for	ADP	O	O	2320
APAP	PROPN	O	O	2320
-	PUNCT	O	O	2320
induced	VERB	O	O	2320
renal	ADJ	O	O	2320
tubular necrosis	NOUN	O	Disease	2320
.	PUNCT	O	O	2320
Morphine	NOUN	O	Chemical	2323
-	PUNCT	O	O	2323
induced	VERB	O	O	2323
seizures	NOUN	O	Disease	2323
in	ADP	O	O	2323
newborn	ADJ	O	O	2323
infants	NOUN	O	O	2323
.	PUNCT	O	O	2323
Two	NUM	O	O	2324
neonates	NOUN	O	O	2324
suffered	VERB	O	O	2324
from	ADP	O	O	2324
generalized	VERB	O	O	2324
seizures	NOUN	O	Disease	2324
during	ADP	O	O	2324
the	PRON	O	O	2324
course	NOUN	O	O	2324
of	ADP	O	O	2324
intravenous	ADJ	O	O	2324
morphine	NOUN	O	Chemical	2324
sulfate	NOUN	O	O	2324
for	ADP	O	O	2324
post	VERB	O	O	2324
-	PUNCT	O	O	2324
operative	NOUN	O	O	2324
analgesia	NOUN	O	Disease	2324
.	PUNCT	O	O	2324
They	PRON	O	O	2325
received	VERB	O	O	2325
morphine	NOUN	O	Chemical	2325
in	ADP	O	O	2325
doses	NOUN	O	O	2325
of	ADP	O	O	2325
32	NUM	O	O	2325
micrograms	NOUN	O	O	2325
/	PUNCT	O	O	2325
kg	VERB	O	O	2325
/	PUNCT	O	O	2325
hr	NOUN	O	O	2325
and	CCONJ	O	O	2325
40	NUM	O	O	2325
micrograms	NOUN	O	O	2325
/	PUNCT	O	O	2325
kg	VERB	O	O	2325
/	PUNCT	O	O	2325
hr	NOUN	O	O	2325
larger	ADJ	O	O	2325
than	ADP	O	O	2325
a	PRON	O	O	2325
group	NOUN	O	O	2325
of	ADP	O	O	2325
10	NUM	O	O	2325
neonates	NOUN	O	O	2325
who	PRON	O	O	2325
received	VERB	O	O	2325
6	NUM	O	O	2325
-	PUNCT	O	O	2325
24	NUM	O	O	2325
micrograms	NOUN	O	O	2325
/	PUNCT	O	O	2325
kg	VERB	O	O	2325
/	PUNCT	O	O	2326
hr	NOUN	O	O	2326
and	CCONJ	O	O	2326
had	VERB	O	O	2326
no	PRON	O	O	2326
seizures	NOUN	O	Disease	2326
.	PUNCT	O	O	2326
Plasma	NOUN	O	O	2327
concentrations	NOUN	O	O	2327
of	ADP	O	O	2327
morphine	NOUN	O	Chemical	2327
in	ADP	O	O	2327
these	PRON	O	O	2327
neonates	NOUN	O	O	2327
was	AUX	O	O	2327
excessive	ADJ	O	O	2327
(	PUNCT	O	O	2327
60	NUM	O	O	2327
and	CCONJ	O	O	2327
90	NUM	O	O	2327
mg	VERB	O	O	2327
/	PUNCT	O	O	2327
ml	ADP	O	O	2327
)	PUNCT	O	O	2327
.	PUNCT	O	O	2327
Other	ADJ	O	O	2328
known	VERB	O	O	2328
reasons	NOUN	O	O	2328
for	ADP	O	O	2328
seizures	NOUN	O	Disease	2328
were	AUX	O	O	2328
ruled	VERB	O	O	2328
out	ADP	O	O	2328
and	CCONJ	O	O	2328
the	PRON	O	O	2328
convulsions	NOUN	O	Disease	2328
stopped	VERB	O	O	2328
a	PRON	O	O	2328
few	ADJ	O	O	2328
hours	NOUN	O	O	2328
after	ADP	O	O	2328
cessation	NOUN	O	O	2328
of	ADP	O	O	2328
morphine	NOUN	O	Chemical	2328
and	CCONJ	O	O	2328
did	VERB	O	O	2328
not	PART	O	O	2328
reoccur	VERB	O	O	2328
in	ADP	O	O	2328
the	PRON	O	O	2328
subsequent	ADJ	O	O	2328
8	NUM	O	O	2328
months	NOUN	O	O	2328
.	PUNCT	O	O	2328
It	PRON	O	O	2329
is	AUX	O	O	2329
suggested	VERB	O	O	2329
that	SCONJ	O	O	2329
post	VERB	O	O	2329
-	PUNCT	O	O	2329
operative	NOUN	O	O	2329
intravenous	ADJ	O	O	2329
morphine	NOUN	O	Chemical	2329
should	AUX	O	O	2329
not	PART	O	O	2329
exceed	VERB	O	O	2329
20	NUM	O	O	2329
micrograms	NOUN	O	O	2329
/	PUNCT	O	O	2329
kg	VERB	O	O	2329
/	PUNCT	O	O	2329
ml	ADP	O	O	2329
in	ADP	O	O	2329
neonates	NOUN	O	O	2329
.	PUNCT	O	O	2329
Effect	VERB	O	O	2332
of	ADP	O	O	2332
vincristine	NOUN	O	Chemical	2332
sulfate	NOUN	O	O	2332
on	ADP	O	O	2332
Pseudomonas	NOUN	O	O	2332
infections	NOUN	O	Disease	2332
in	ADP	O	O	2332
monkeys	NOUN	O	O	2332
.	PUNCT	O	O	2332
Leukocytosis	NOUN	O	O	2333
was	AUX	O	O	2333
observed	VERB	O	O	2333
in	ADP	O	O	2333
all	PRON	O	O	2333
monkeys	NOUN	O	O	2333
.	PUNCT	O	O	2333
Intravenous	PROPN	O	O	2334
or	CCONJ	O	O	2334
intratracheal	PROPN	O	O	2334
inoculation	NOUN	O	O	2334
of	ADP	O	O	2334
2.0	NUM	O	O	2334
to	PART	O	O	2334
2.5	NUM	O	O	2334
mg	VERB	O	O	2334
of	ADP	O	O	2334
vincristine	NOUN	O	Chemical	2334
sulfate	NOUN	O	O	2334
was	AUX	O	O	2334
followed	VERB	O	O	2334
by	ADP	O	O	2334
leukopenia	PROPN	O	Disease	2334
in	ADP	O	O	2334
4	NUM	O	O	2334
to	PART	O	O	2334
5	NUM	O	O	2334
days	NOUN	O	O	2334
.	PUNCT	O	O	2334
Pseudomonas	NOUN	O	O	2335
organisms	NOUN	O	O	2335
in	ADP	O	O	2335
monkeys	NOUN	O	O	2335
given	VERB	O	O	2335
vincristine	NOUN	O	Chemical	2335
sulfate	NOUN	O	O	2335
4	NUM	O	O	2335
days	NOUN	O	O	2335
previously	ADV	O	O	2335
resulted	VERB	O	O	2335
in	ADP	O	O	2335
fatal	ADJ	O	O	2335
infection	NOUN	O	Disease	2335
in	ADP	O	O	2335
11	NUM	O	O	2335
of	ADP	O	O	2335
14	NUM	O	O	2335
monkeys	NOUN	O	O	2335
,	PUNCT	O	O	2335
whereas	SCONJ	O	O	2335
none	NOUN	O	O	2335
of	ADP	O	O	2335
four	NUM	O	O	2335
receiving	VERB	O	O	2335
Pseudomonas	NOUN	O	O	2335
alone	ADV	O	O	2335
died	VERB	O	O	2335
.	PUNCT	O	O	2335
These	PRON	O	O	2336
studies	NOUN	O	O	2336
suggest	VERB	O	O	2336
that	SCONJ	O	O	2336
an	PRON	O	O	2336
antimetabolite	ADJ	O	O	2336
-	PUNCT	O	O	2336
induced	VERB	O	O	2336
leukopenia	PROPN	O	Disease	2336
predisposes	VERB	O	O	2336
to	PART	O	O	2336
severe	ADJ	O	O	2336
Pseudomonas	NOUN	O	O	2336
sepsis	NOUN	O	Disease	2336
and	CCONJ	O	O	2336
that	SCONJ	O	O	2336
such	ADJ	O	O	2336
monkeys	NOUN	O	O	2336
may	AUX	O	O	2336
serve	VERB	O	O	2336
as	ADP	O	O	2336
a	PRON	O	O	2336
biological	ADJ	O	O	2336
model	NOUN	O	O	2336
for	ADP	O	O	2336
study	VERB	O	O	2336
of	ADP	O	O	2336
comparative	ADJ	O	O	2336
efficacy	NOUN	O	O	2336
of	ADP	O	O	2336
antimicrobial	ADJ	O	O	2336
agents	NOUN	O	O	2336
.	PUNCT	O	O	2336
Central	ADJ	O	O	2339
excitatory	ADJ	O	O	2339
actions	NOUN	O	O	2339
of	ADP	O	O	2339
flurazepam	NOUN	O	O	2339
.	PUNCT	O	O	2339
Toxic	ADJ	O	O	2340
actions	NOUN	O	O	2340
of	ADP	O	O	2340
flurazepam	NOUN	O	O	2340
(	PUNCT	O	O	2340
FZP	PROPN	O	O	2340
)	PUNCT	O	O	2340
were	AUX	O	O	2340
studied	VERB	O	O	2340
in	ADP	O	O	2340
cats	NOUN	O	O	2340
,	PUNCT	O	O	2340
mice	NOUN	O	O	2340
and	CCONJ	O	O	2340
rats	NOUN	O	O	2340
.	PUNCT	O	O	2340
High	ADJ	O	O	2341
doses	NOUN	O	O	2341
caused	VERB	O	O	2341
an	PRON	O	O	2341
apparent	ADJ	O	O	2341
central	ADJ	O	O	2341
excitation	NOUN	O	O	2341
,	PUNCT	O	O	2341
most	ADV	O	O	2341
clearly	ADV	O	O	2341
seen	VERB	O	O	2341
as	ADP	O	O	2341
clonic	ADJ	O	O	2341
convulsions	NOUN	O	Disease	2341
,	PUNCT	O	O	2341
superimposed	VERB	O	O	2341
on	ADP	O	O	2341
general	ADJ	O	O	2341
depression	PROPN	O	Disease	2341
.	PUNCT	O	O	2341
Following	VERB	O	O	2342
a	PRON	O	O	2342
lethal	ADJ	O	O	2342
dose	NOUN	O	O	2342
,	PUNCT	O	O	2342
death	NOUN	O	O	2342
was	AUX	O	O	2342
always	ADV	O	O	2342
associated	VERB	O	O	2342
with	ADP	O	O	2342
convulsions	NOUN	O	Disease	2342
.	PUNCT	O	O	2342
Comparing	VERB	O	O	2343
the	PRON	O	O	2343
relative	ADJ	O	O	2343
sensitivity	NOUN	O	O	2343
to	PART	O	O	2343
central	ADJ	O	O	2343
depression	PROPN	O	Disease	2343
and	CCONJ	O	O	2343
excitation	NOUN	O	O	2343
revealed	VERB	O	O	2343
that	SCONJ	O	O	2343
rats	NOUN	O	O	2343
were	AUX	O	O	2343
least	ADJ	O	O	2343
likely	ADV	O	O	2343
to	PART	O	O	2343
have	VERB	O	O	2343
convulsions	NOUN	O	Disease	2343
at	ADP	O	O	2343
doses	NOUN	O	O	2343
that	SCONJ	O	O	2343
did	VERB	O	O	2343
not	PART	O	O	2343
first	ADV	O	O	2343
cause	VERB	O	O	2343
loss	NOUN	O	O	2343
of	ADP	O	O	2343
consciousness	NOUN	O	O	2343
,	PUNCT	O	O	2343
while	SCONJ	O	O	2343
cats	NOUN	O	O	2343
most	ADV	O	O	2343
clearly	ADV	O	O	2343
showed	VERB	O	O	2343
marked	VERB	O	O	2343
central	ADJ	O	O	2343
excitatory	ADJ	O	O	2343
actions	NOUN	O	O	2343
.	PUNCT	O	O	2343
Signs	NOUN	O	O	2344
of	ADP	O	O	2344
FZP	PROPN	O	O	2344
toxocity	NOUN	O	O	2344
in	ADP	O	O	2344
cats	NOUN	O	O	2344
included	VERB	O	O	2344
excessive	ADJ	O	O	2344
salivation	NOUN	O	Disease	2344
,	PUNCT	O	O	2344
extreme	ADJ	O	O	2344
apprehensive	ADJ	O	O	2344
behavior	NOUN	O	O	2344
,	PUNCT	O	O	2344
retching	VERB	O	O	2344
,	PUNCT	O	O	2344
muscle	NOUN	O	O	2344
tremors	NOUN	O	Disease	2344
and	CCONJ	O	O	2344
convulsions	NOUN	O	Disease	2344
.	PUNCT	O	O	2344
An	PRON	O	O	2345
interaction	NOUN	O	O	2345
between	ADP	O	O	2345
FZP	PROPN	O	O	2345
and	CCONJ	O	O	2345
pentylenetetrazol	NOUN	O	O	2345
(	PUNCT	O	O	2345
PTZ	PROPN	O	Chemical	2345
)	PUNCT	O	O	2345
was	AUX	O	O	2345
shown	VERB	O	O	2345
by	ADP	O	O	2345
pretreating	VERB	O	O	2345
mice	NOUN	O	O	2345
with	ADP	O	O	2345
FZP	PROPN	O	O	2345
before	ADP	O	O	2345
PTZ	PROPN	O	Chemical	2345
challenge	NOUN	O	O	2345
.	PUNCT	O	O	2345
As	ADP	O	O	2346
a	PRON	O	O	2346
function	NOUN	O	O	2346
of	ADP	O	O	2346
dose	NOUN	O	O	2346
,	PUNCT	O	O	2346
FZP	PROPN	O	O	2346
first	ADV	O	O	2346
protected	VERB	O	O	2346
against	ADP	O	O	2346
convulsions	NOUN	O	Disease	2346
and	CCONJ	O	O	2346
death	NOUN	O	O	2346
.	PUNCT	O	O	2346
At	ADP	O	O	2347
higher	ADJ	O	O	2347
doses	NOUN	O	O	2347
,	PUNCT	O	O	2347
however	ADV	O	O	2347
,	PUNCT	O	O	2347
convulsions	NOUN	O	Disease	2347
again	ADV	O	O	2347
emerged	VERB	O	O	2347
.	PUNCT	O	O	2347
These	PRON	O	O	2348
doses	NOUN	O	O	2348
of	ADP	O	O	2348
FZP	PROPN	O	O	2348
were	AUX	O	O	2348
lower	ADJ	O	O	2348
than	ADP	O	O	2348
those	PRON	O	O	2348
that	SCONJ	O	O	2348
would	AUX	O	O	2348
alone	ADV	O	O	2348
cause	VERB	O	O	2348
convulsions	NOUN	O	Disease	2348
.	PUNCT	O	O	2348
These	PRON	O	O	2349
results	VERB	O	O	2349
may	AUX	O	O	2349
be	AUX	O	O	2349
relevant	ADJ	O	O	2349
to	PART	O	O	2349
the	PRON	O	O	2349
use	VERB	O	O	2349
of	ADP	O	O	2349
FZP	PROPN	O	O	2349
in	ADP	O	O	2349
clinical	ADJ	O	O	2349
situations	NOUN	O	O	2349
in	ADP	O	O	2349
which	PRON	O	O	2349
there	ADV	O	O	2349
is	AUX	O	O	2349
increased	VERB	O	O	2349
neural	NOUN	O	O	2349
excitability	NOUN	O	O	2349
,	PUNCT	O	O	2349
such	ADJ	O	O	2349
as	ADP	O	O	2349
epilepsy	NOUN	O	Disease	2349
or	CCONJ	O	O	2349
sedative	NOUN	O	O	2349
-	PUNCT	O	O	2349
hypnotic	ADJ	O	O	2349
drug	NOUN	O	O	2349
withdrawal	NOUN	O	O	2349
.	PUNCT	O	O	2349
We	PRON	O	O	2352
compared	VERB	O	O	2352
the	PRON	O	O	2352
effects	NOUN	O	O	2352
of	ADP	O	O	2352
single	ADJ	O	O	2352
doses	NOUN	O	O	2352
of	ADP	O	O	2352
50	NUM	O	O	2352
mg	VERB	O	O	2352
atenolol	PROPN	O	Chemical	2352
(	PUNCT	O	O	2352
cardioselective	PROPN	O	O	2352
)	PUNCT	O	O	2352
,	PUNCT	O	O	2352
40	NUM	O	O	2352
mg	VERB	O	O	2352
propranolol	NOUN	O	Chemical	2352
(	PUNCT	O	O	2352
nonselective	ADJ	O	O	2352
)	PUNCT	O	O	2352
,	PUNCT	O	O	2352
and	CCONJ	O	O	2352
placebo	NOUN	O	O	2352
on	ADP	O	O	2352
both	PRON	O	O	2352
exercise-	VERB	O	O	2352
and	CCONJ	O	O	2352
isoproterenol	NOUN	O	Chemical	2352
-	PUNCT	O	O	2352
induced	VERB	O	O	2352
tachycardia	PROPN	O	Disease	2352
in	ADP	O	O	2352
two	NUM	O	O	2352
experiments	NOUN	O	O	2352
involving	VERB	O	O	2352
nine	NUM	O	O	2352
normal	ADJ	O	O	2352
subjects	NOUN	O	O	2352
.	PUNCT	O	O	2352
7	NUM	O	O	2353
bpm	VERB	O	O	2353
after	ADP	O	O	2353
atenolol	PROPN	O	Chemical	2353
and	CCONJ	O	O	2353
138	NUM	O	O	2353
+	ADP	O	O	2353
/-	PUNCT	O	O	2353
6	NUM	O	O	2354
bpm	VERB	O	O	2354
after	ADP	O	O	2354
propranolol	NOUN	O	Chemical	2354
,	PUNCT	O	O	2354
The	PRON	O	O	2355
effects	NOUN	O	O	2355
on	ADP	O	O	2355
isoproterenol	NOUN	O	Chemical	2355
tachycardia	PROPN	O	Disease	2355
were	AUX	O	O	2355
determined	VERB	O	O	2355
before	ADP	O	O	2355
and	CCONJ	O	O	2355
after	ADP	O	O	2355
atropine	NOUN	O	Chemical	2355
(	PUNCT	O	O	2355
0.04	NUM	O	O	2355
mg	VERB	O	O	2355
/	PUNCT	O	O	2355
kg	VERB	O	O	2355
IV	NUM	O	O	2355
)	PUNCT	O	O	2355
.	PUNCT	O	O	2355
Isoproterenol	NOUN	O	Chemical	2356
sensitivity	NOUN	O	O	2356
was	AUX	O	O	2356
determined	VERB	O	O	2356
as	ADP	O	O	2356
the	PRON	O	O	2356
intravenous	ADJ	O	O	2356
dose	NOUN	O	O	2356
that	SCONJ	O	O	2356
increased	VERB	O	O	2356
heart	NOUN	O	O	2356
rate	NOUN	O	O	2356
by	ADP	O	O	2356
25	NUM	O	O	2356
bpm	VERB	O	O	2356
(	PUNCT	O	O	2356
CD25	PROPN	O	O	2356
)	PUNCT	O	O	2356
and	CCONJ	O	O	2356
this	PRON	O	O	2356
was	AUX	O	O	2356
increased	VERB	O	O	2356
from	ADP	O	O	2356
1.8	NUM	O	O	2356
+	ADP	O	O	2356
/-	PUNCT	O	O	2356
8.3	NUM	O	O	2357
micrograms	NOUN	O	O	2357
after	ADP	O	O	2357
propranolol	NOUN	O	Chemical	2357
and	CCONJ	O	O	2357
8.3	NUM	O	O	2357
+	ADP	O	O	2357
/-	PUNCT	O	O	2357
1.7	NUM	O	O	2358
micrograms	NOUN	O	O	2358
after	ADP	O	O	2358
atenolol	PROPN	O	Chemical	2358
.	PUNCT	O	O	2358
After	ADP	O	O	2359
atropine	NOUN	O	Chemical	2359
the	PRON	O	O	2359
CD25	PROPN	O	O	2359
was	AUX	O	O	2359
unchanged	ADJ	O	O	2359
after	ADP	O	O	2359
placebo	NOUN	O	O	2359
(	PUNCT	O	O	2359
2.3	NUM	O	O	2359
+	ADP	O	O	2359
/-	PUNCT	O	O	2359
0.3	NUM	O	O	2360
micrograms	NOUN	O	O	2360
)	PUNCT	O	O	2360
and	CCONJ	O	O	2360
atenolol	PROPN	O	Chemical	2360
(	PUNCT	O	O	2360
7.7	NUM	O	O	2360
+	ADP	O	O	2360
/-	PUNCT	O	O	2360
1.3	NUM	O	O	2361
micrograms	NOUN	O	O	2361
)	PUNCT	O	O	2361
;	PUNCT	O	O	2361
it	PRON	O	O	2361
was	AUX	O	O	2361
reduced	VERB	O	O	2361
after	ADP	O	O	2361
propranolol	NOUN	O	Chemical	2361
(	PUNCT	O	O	2361
24.8	NUM	O	O	2361
+	ADP	O	O	2361
/-	PUNCT	O	O	2361
5.0	NUM	O	O	2362
micrograms	NOUN	O	O	2362
)	PUNCT	O	O	2362
,	PUNCT	O	O	2362
but	CCONJ	O	O	2362
remained	VERB	O	O	2362
different	ADJ	O	O	2362
from	ADP	O	O	2362
atenolol	PROPN	O	Chemical	2362
.	PUNCT	O	O	2362
This	PRON	O	O	2363
change	VERB	O	O	2363
with	ADP	O	O	2363
propranolol	NOUN	O	Chemical	2363
sensitivity	NOUN	O	O	2363
was	AUX	O	O	2363
calculated	VERB	O	O	2363
as	ADP	O	O	2363
the	PRON	O	O	2363
apparent	ADJ	O	O	2363
Ka	PROPN	O	O	2363
,	PUNCT	O	O	2363
this	PRON	O	O	2363
was	AUX	O	O	2363
unchanged	ADJ	O	O	2363
by	ADP	O	O	2363
atropine	NOUN	O	Chemical	2363
(	PUNCT	O	O	2363
11.7	NUM	O	O	2363
+	ADP	O	O	2363
/-	PUNCT	O	O	2363
These	PRON	O	O	2364
data	NOUN	O	O	2364
are	AUX	O	O	2364
consistent	ADJ	O	O	2364
with	ADP	O	O	2364
the	PRON	O	O	2364
hypothesis	NOUN	O	O	2364
that	SCONJ	O	O	2364
exercise	VERB	O	O	2364
-	PUNCT	O	O	2364
induced	VERB	O	O	2364
tachycardia	PROPN	O	Disease	2364
results	VERB	O	O	2364
largely	ADV	O	O	2364
from	ADP	O	O	2364
beta	NOUN	O	O	2364
1-receptor	NOUN	O	O	2364
activation	NOUN	O	O	2364
that	SCONJ	O	O	2364
is	AUX	O	O	2364
blocked	VERB	O	O	2364
by	ADP	O	O	2364
both	PRON	O	O	2364
cardioselective	PROPN	O	O	2364
and	CCONJ	O	O	2364
nonselective	ADJ	O	O	2364
drugs	NOUN	O	O	2364
,	PUNCT	O	O	2364
whereas	SCONJ	O	O	2364
isoproterenol	NOUN	O	Chemical	2364
activates	VERB	O	O	2364
both	PRON	O	O	2364
beta	NOUN	O	O	2364
1-	X	O	O	2364
and	CCONJ	O	O	2364
beta	NOUN	O	O	2364
2-receptors	NOUN	O	O	2364
so	ADV	O	O	2364
that	SCONJ	O	O	2364
after	ADP	O	O	2364
cardioselective	PROPN	O	O	2364
blockade	VERB	O	O	2364
there	ADV	O	O	2364
remains	VERB	O	O	2364
a	PRON	O	O	2364
beta	NOUN	O	O	2364
2-component	NOUN	O	O	2364
that	SCONJ	O	O	2364
can	AUX	O	O	2364
be	AUX	O	O	2364
blocked	VERB	O	O	2364
with	ADP	O	O	2364
a	PRON	O	O	2364
nonselective	ADJ	O	O	2364
drug	NOUN	O	O	2364
.	PUNCT	O	O	2364
Hormones	NOUN	O	O	2367
and	CCONJ	O	O	2367
risk	NOUN	O	O	2367
of	ADP	O	O	2367
breast cancer	NOUN	O	Disease	2367
.	PUNCT	O	O	2367
It	PRON	O	O	2368
was	AUX	O	O	2368
hypothesized	VERB	O	O	2368
that	SCONJ	O	O	2368
progestins	NOUN	O	O	2368
could	AUX	O	O	2368
equilibrate	VERB	O	O	2368
the	PRON	O	O	2368
effects	NOUN	O	O	2368
of	ADP	O	O	2368
the	PRON	O	O	2368
estrogenic	ADJ	O	O	2368
stimulation	NOUN	O	O	2368
on	ADP	O	O	2368
the	PRON	O	O	2368
mammary	ADJ	O	O	2368
and	CCONJ	O	O	2368
endometrial	ADJ	O	O	2368
target	NOUN	O	O	2368
tissues	NOUN	O	O	2368
of	ADP	O	O	2368
women	NOUN	O	O	2368
on	ADP	O	O	2368
hormonal	ADJ	O	O	2368
replacement	NOUN	O	O	2368
therapy	NOUN	O	O	2368
.	PUNCT	O	O	2368
The	PRON	O	O	2369
treatment	NOUN	O	O	2369
schedule	NOUN	O	O	2369
consisted	VERB	O	O	2369
of	ADP	O	O	2369
conjugated	VERB	O	O	2369
estrogens	NOUN	O	Chemical	2369
(	PUNCT	O	O	2369
Premarin	NOUN	O	O	2369
)	PUNCT	O	O	2369
1.25	NUM	O	O	2369
mg	VERB	O	O	2369
/	PUNCT	O	O	2370
day	NOUN	O	O	2370
for	ADP	O	O	2370
21	NUM	O	O	2370
days	NOUN	O	O	2370
and	CCONJ	O	O	2370
Medroxyprogesterone	NOUN	O	O	2370
acetate	NOUN	O	O	2370
10	NUM	O	O	2370
mg	VERB	O	O	2370
/	PUNCT	O	O	2370
day	NOUN	O	O	2370
for	ADP	O	O	2370
10	NUM	O	O	2370
days	NOUN	O	O	2370
in	ADP	O	O	2370
each	PRON	O	O	2370
month	NOUN	O	O	2370
.	PUNCT	O	O	2370
Mastodynia	PROPN	O	O	2371
was	AUX	O	O	2371
reported	VERB	O	O	2371
by	ADP	O	O	2371
21	NUM	O	O	2371
patients	NOUN	O	O	2371
,	PUNCT	O	O	2371
and	CCONJ	O	O	2371
physical	ADJ	O	O	2371
examination	NOUN	O	O	2371
revealed	VERB	O	O	2371
a	PRON	O	O	2371
light	ADJ	O	O	2371
increase	VERB	O	O	2371
in	ADP	O	O	2371
breast	NOUN	O	O	2371
firmness	NOUN	O	O	2371
in	ADP	O	O	2371
12	NUM	O	O	2371
women	NOUN	O	O	2371
and	CCONJ	O	O	2371
a	PRON	O	O	2371
moderate	ADJ	O	O	2371
increase	VERB	O	O	2371
in	ADP	O	O	2371
breast	NOUN	O	O	2371
nodularity	NOUN	O	O	2371
in	ADP	O	O	2371
2	X	O	O	2371
women	NOUN	O	O	2371
.	PUNCT	O	O	2371
Themography	NOUN	O	O	2372
confirmed	VERB	O	O	2372
the	PRON	O	O	2372
existence	NOUN	O	O	2372
of	ADP	O	O	2372
an	PRON	O	O	2372
excessive	ADJ	O	O	2372
breast	NOUN	O	O	2372
stimulation	NOUN	O	O	2372
in	ADP	O	O	2372
1	X	O	O	2372
women	NOUN	O	O	2372
who	PRON	O	O	2372
complained	VERB	O	O	2372
of	ADP	O	O	2372
moderate	ADJ	O	O	2372
mastodynia	NOUN	O	O	2372
and	CCONJ	O	O	2372
in	ADP	O	O	2372
5	NUM	O	O	2372
of	ADP	O	O	2372
the	PRON	O	O	2372
7	NUM	O	O	2372
women	NOUN	O	O	2372
who	PRON	O	O	2372
complained	VERB	O	O	2372
of	ADP	O	O	2372
severe	ADJ	O	O	2372
mastodynia	NOUN	O	O	2372
.	PUNCT	O	O	2372
Normalization	NOUN	O	O	2373
was	AUX	O	O	2373
obtained	VERB	O	O	2373
by	ADP	O	O	2373
halving	VERB	O	O	2373
the	PRON	O	O	2373
estrogen	PROPN	O	Chemical	2373
dose	NOUN	O	O	2373
.	PUNCT	O	O	2373
Early	ADJ	O	O	2376
infections	NOUN	O	Disease	2376
in	ADP	O	O	2376
kidney	NOUN	O	O	2376
,	PUNCT	O	O	2376
heart	NOUN	O	O	2376
,	PUNCT	O	O	2376
and	CCONJ	O	O	2376
liver	NOUN	O	O	2376
transplant	NOUN	O	O	2376
recipients	NOUN	O	O	2376
on	ADP	O	O	2376
cyclosporine	NOUN	O	Chemical	2376
.	PUNCT	O	O	2376
Eighty	NUM	O	O	2377
-	PUNCT	O	O	2377
one	NUM	O	O	2377
renal	ADJ	O	O	2377
,	PUNCT	O	O	2377
seventeen	NUM	O	O	2377
heart	NOUN	O	O	2377
,	PUNCT	O	O	2377
and	CCONJ	O	O	2377
twenty	NUM	O	O	2377
-	PUNCT	O	O	2377
four	NUM	O	O	2377
liver	NOUN	O	O	2377
transplant	NOUN	O	O	2377
patients	NOUN	O	O	2377
were	AUX	O	O	2377
followed	VERB	O	O	2377
for	ADP	O	O	2377
infection	NOUN	O	Disease	2377
.	PUNCT	O	O	2377
Seventeen	NUM	O	O	2378
renal	ADJ	O	O	2378
patients	NOUN	O	O	2378
received	VERB	O	O	2378
azathioprine	ADV	O	Chemical	2378
(	PUNCT	O	O	2378
Aza	NOUN	O	O	2378
)	PUNCT	O	O	2378
and	CCONJ	O	O	2378
prednisone	NOUN	O	Chemical	2378
as	ADP	O	O	2378
part	NOUN	O	O	2378
of	ADP	O	O	2378
a	PRON	O	O	2378
randomized	VERB	O	O	2378
trial	NOUN	O	O	2378
of	ADP	O	O	2378
immunosuppression	NOUN	O	O	2378
with	ADP	O	O	2378
21	NUM	O	O	2378
cyclosporine	NOUN	O	Chemical	2378
-	PUNCT	O	O	2378
and	CCONJ	O	O	2378
-	PUNCT	O	O	2378
prednisone	NOUN	O	Chemical	2378
-	PUNCT	O	O	2378
treated	VERB	O	O	2378
renal	ADJ	O	O	2378
transplant	NOUN	O	O	2378
patients	NOUN	O	O	2378
.	PUNCT	O	O	2378
All	PRON	O	O	2379
others	NOUN	O	O	2379
received	VERB	O	O	2379
cyclosporine	NOUN	O	Chemical	2379
and	CCONJ	O	O	2379
prednisone	NOUN	O	Chemical	2379
.	PUNCT	O	O	2379
The	PRON	O	O	2380
randomized	VERB	O	O	2380
Aza	NOUN	O	O	2380
patients	NOUN	O	O	2380
had	VERB	O	O	2380
more	ADJ	O	O	2380
overall	ADV	O	O	2380
infections	NOUN	O	Disease	2380
(	PUNCT	O	O	2380
P	NOUN	O	Chemical	2380
less	ADV	O	O	2380
than	ADP	O	O	2380
0.05	NUM	O	O	2380
)	PUNCT	O	O	2380
and	CCONJ	O	O	2380
more	ADJ	O	O	2380
nonviral	ADJ	O	O	2380
infections	NOUN	O	Disease	2380
(	PUNCT	O	O	2380
P	NOUN	O	Chemical	2380
less	ADV	O	O	2380
than	ADP	O	O	2380
0.02	NUM	O	O	2380
)	PUNCT	O	O	2380
than	ADP	O	O	2380
the	PRON	O	O	2380
randomized	VERB	O	O	2380
cyclosporine	NOUN	O	Chemical	2380
patients	NOUN	O	O	2380
.	PUNCT	O	O	2380
Heart	NOUN	O	O	2381
and	CCONJ	O	O	2381
liver	NOUN	O	O	2381
patients	NOUN	O	O	2381
had	VERB	O	O	2381
more	ADJ	O	O	2381
infections	NOUN	O	Disease	2381
than	ADP	O	O	2381
cyclosporine	NOUN	O	Chemical	2381
renal	ADJ	O	O	2381
patients	NOUN	O	O	2381
but	CCONJ	O	O	2381
fewer	ADJ	O	O	2381
infections	NOUN	O	Disease	2381
than	ADP	O	O	2381
the	PRON	O	O	2381
Aza	NOUN	O	O	2381
renal	ADJ	O	O	2381
patients	NOUN	O	O	2381
.	PUNCT	O	O	2381
There	ADV	O	O	2382
were	AUX	O	O	2382
no	PRON	O	O	2382
infectious	ADJ	O	O	2382
deaths	NOUN	O	O	2382
in	ADP	O	O	2382
renal	ADJ	O	O	2382
transplant	NOUN	O	O	2382
patients	NOUN	O	O	2382
on	ADP	O	O	2382
cyclosporine	NOUN	O	Chemical	2382
or	CCONJ	O	O	2382
Aza	NOUN	O	O	2382
,	PUNCT	O	O	2382
but	CCONJ	O	O	2382
infection	NOUN	O	Disease	2382
played	VERB	O	O	2382
a	PRON	O	O	2382
major	ADJ	O	O	2382
role	NOUN	O	O	2382
in	ADP	O	O	2382
3	X	O	O	2382
out	ADP	O	O	2382
of	ADP	O	O	2382
6	NUM	O	O	2382
cardiac	ADJ	O	O	2382
transplant	NOUN	O	O	2382
deaths	NOUN	O	O	2382
and	CCONJ	O	O	2382
in	ADP	O	O	2382
8	NUM	O	O	2382
out	ADP	O	O	2382
of	ADP	O	O	2382
9	NUM	O	O	2382
liver	NOUN	O	O	2382
transplant	NOUN	O	O	2382
deaths	NOUN	O	O	2382
.	PUNCT	O	O	2382
Renal	NOUN	O	O	2383
patients	NOUN	O	O	2383
on	ADP	O	O	2383
cyclosporine	NOUN	O	Chemical	2383
had	VERB	O	O	2383
the	PRON	O	O	2383
fewest	ADJ	O	O	2383
bacteremias	PROPN	O	O	2383
.	PUNCT	O	O	2383
Analysis	NOUN	O	O	2384
of	ADP	O	O	2384
site	NOUN	O	O	2384
of	ADP	O	O	2384
infection	NOUN	O	Disease	2384
showed	VERB	O	O	2384
a	PRON	O	O	2384
preponderance	NOUN	O	O	2384
of	ADP	O	O	2384
abdominal	ADJ	O	O	2384
infections	NOUN	O	Disease	2384
in	ADP	O	O	2384
liver	NOUN	O	O	2384
patients	NOUN	O	O	2384
,	PUNCT	O	O	2384
intrathoracic	ADJ	O	O	2384
infections	NOUN	O	Disease	2384
in	ADP	O	O	2384
heart	NOUN	O	O	2384
patients	NOUN	O	O	2384
,	PUNCT	O	O	2384
and	CCONJ	O	O	2384
urinary	ADJ	O	O	2384
tract	NOUN	O	O	2384
infections	NOUN	O	Disease	2384
in	ADP	O	O	2384
renal	ADJ	O	O	2384
patients	NOUN	O	O	2384
.	PUNCT	O	O	2384
Pulmonary	NOUN	O	O	2385
infections	NOUN	O	Disease	2385
were	AUX	O	O	2385
less	ADV	O	O	2385
common	ADJ	O	O	2385
in	ADP	O	O	2385
cyclosporine	NOUN	O	Chemical	2385
-	PUNCT	O	O	2385
treated	VERB	O	O	2385
renal	ADJ	O	O	2385
patients	NOUN	O	O	2385
than	ADP	O	O	2385
in	ADP	O	O	2385
Aza	NOUN	O	O	2385
-	PUNCT	O	O	2385
treated	VERB	O	O	2385
patients	NOUN	O	O	2385
(	PUNCT	O	O	2385
P	NOUN	O	Chemical	2385
less	ADV	O	O	2385
than	ADP	O	O	2385
0.05	NUM	O	O	2385
)	PUNCT	O	O	2385
.	PUNCT	O	O	2385
Aza	NOUN	O	O	2386
patients	NOUN	O	O	2386
had	VERB	O	O	2386
significantly	ADV	O	O	2386
more	ADJ	O	O	2386
staphylococcal	ADJ	O	O	2386
infections	NOUN	O	Disease	2386
than	ADP	O	O	2386
all	PRON	O	O	2386
other	ADJ	O	O	2386
transplant	NOUN	O	O	2386
groups	NOUN	O	O	2386
(	PUNCT	O	O	2386
P	NOUN	O	Chemical	2386
less	ADV	O	O	2386
than	ADP	O	O	2386
0.005	NUM	O	O	2386
)	PUNCT	O	O	2386
,	PUNCT	O	O	2386
and	CCONJ	O	O	2386
systemic	ADJ	O	O	2386
fungal infections	NOUN	O	O	2386
occurred	VERB	O	O	2386
only	ADV	O	O	2386
in	ADP	O	O	2386
the	PRON	O	O	2386
liver	NOUN	O	O	2386
transplant	NOUN	O	O	2386
group	NOUN	O	O	2386
.	PUNCT	O	O	2386
Cytomegalovirus	PROPN	O	O	2387
(	PUNCT	O	O	2387
CMV	PROPN	O	O	2387
)	PUNCT	O	O	2387
shedding	VERB	O	O	2387
or	CCONJ	O	O	2387
serological	ADJ	O	O	2387
rises	VERB	O	O	2387
in	ADP	O	O	2387
antibody	NOUN	O	O	2387
titer	NOUN	O	O	2387
,	PUNCT	O	O	2387
or	CCONJ	O	O	2387
both	PRON	O	O	2387
occurred	VERB	O	O	2387
in	ADP	O	O	2387
78%	NOUN	O	O	2387
of	ADP	O	O	2387
cyclosporine	NOUN	O	Chemical	2387
patients	NOUN	O	O	2387
and	CCONJ	O	O	2387
76%	NOUN	O	O	2387
of	ADP	O	O	2387
Aza	NOUN	O	O	2387
patients	NOUN	O	O	2387
.	PUNCT	O	O	2387
Of	ADV	O	O	2388
the	PRON	O	O	2388
cyclosporine	NOUN	O	Chemical	2388
patients	NOUN	O	O	2388
,	PUNCT	O	O	2388
15%	NOUN	O	O	2388
had	VERB	O	O	2388
symptoms	NOUN	O	O	2388
related	ADJ	O	O	2388
to	PART	O	O	2388
CMV	PROPN	O	O	2388
infection	NOUN	O	Disease	2388
.	PUNCT	O	O	2388
Serological	ADJ	O	O	2389
evidence	NOUN	O	O	2389
for	ADP	O	O	2389
Epstein	PROPN	O	O	2389
Barr	PROPN	O	O	2389
Virus	PROPN	O	O	2389
infection	NOUN	O	Disease	2389
was	AUX	O	O	2389
found	VERB	O	O	2389
in	ADP	O	O	2389
20%	NOUN	O	O	2389
of	ADP	O	O	2389
65	NUM	O	O	2389
cyclosporine	NOUN	O	Chemical	2389
patients	NOUN	O	O	2389
studied	VERB	O	O	2389
.	PUNCT	O	O	2389
Three	NUM	O	O	2390
had	VERB	O	O	2390
associated	VERB	O	O	2390
symptoms	NOUN	O	O	2390
,	PUNCT	O	O	2390
and	CCONJ	O	O	2390
one	NUM	O	O	2390
developed	VERB	O	O	2390
a	PRON	O	O	2390
lymphoma	PROPN	O	Disease	2390
.	PUNCT	O	O	2390
Structure	NOUN	O	O	2393
-	PUNCT	O	O	2393
activity	NOUN	O	O	2393
and	CCONJ	O	O	2393
dose	NOUN	O	O	2393
-	PUNCT	O	O	2393
effect	VERB	O	O	2393
relationships	NOUN	O	O	2393
of	ADP	O	O	2393
the	PRON	O	O	2393
antagonism	NOUN	O	O	2393
of	ADP	O	O	2393
picrotoxin	PROPN	O	Chemical	2393
-	PUNCT	O	O	2393
induced	VERB	O	O	2393
seizures	NOUN	O	Disease	2393
by	ADP	O	O	2393
cholecystokinin	NOUN	O	O	2393
,	PUNCT	O	O	2393
fragments	NOUN	O	O	2393
and	CCONJ	O	O	2393
analogues	NOUN	O	O	2393
of	ADP	O	O	2393
cholecystokinin	NOUN	O	O	2393
in	ADP	O	O	2393
mice	NOUN	O	O	2393
.	PUNCT	O	O	2393
Intraperitoneal	NOUN	O	O	2394
administration	NOUN	O	O	2394
of	ADP	O	O	2394
cholecystokinin	NOUN	O	O	2394
octapeptide	NOUN	O	O	2394
sulphate	NOUN	O	O	2394
ester	PROPN	O	O	2394
(	PUNCT	O	O	2394
CCK-8-SE	PROPN	O	O	2394
)	PUNCT	O	O	2394
and	CCONJ	O	O	2394
nonsulphated	VERB	O	O	2394
cholecystokinin	NOUN	O	O	2394
octapeptide	NOUN	O	O	2394
(	PUNCT	O	O	2394
CCK-8-NS	PROPN	O	O	2394
)	PUNCT	O	O	2394
enhanced	VERB	O	O	2394
the	PRON	O	O	2394
latency	VERB	O	O	2394
of	ADP	O	O	2394
seizures	NOUN	O	Disease	2394
induced	VERB	O	O	2394
by	ADP	O	O	2394
picrotoxin	PROPN	O	Chemical	2394
in	ADP	O	O	2394
mice	NOUN	O	O	2394
.	PUNCT	O	O	2394
The	PRON	O	O	2395
analogues	NOUN	O	O	2395
CCK-8-SE	PROPN	O	O	2395
and	CCONJ	O	O	2395
CCK-8-NS	PROPN	O	O	2395
(	PUNCT	O	O	2395
dose	NOUN	O	O	2395
range	VERB	O	O	2395
0.2	NUM	O	O	2395
-	PUNCT	O	O	2395
6.4	NUM	O	O	2395
mumol	PROPN	O	O	2395
/	PUNCT	O	O	2395
kg	VERB	O	O	2395
)	PUNCT	O	O	2395
and	CCONJ	O	O	2395
caerulein	ADP	O	O	2395
dose	NOUN	O	O	2395
range	VERB	O	O	2395
0.1	NUM	O	O	2395
-	PUNCT	O	O	2395
0.8	NUM	O	O	2395
mumol	PROPN	O	O	2395
/	PUNCT	O	O	2395
kg	VERB	O	O	2395
)	PUNCT	O	O	2395
showed	VERB	O	O	2395
bell	PROPN	O	O	2395
-	PUNCT	O	O	2395
shaped	VERB	O	O	2395
dose	NOUN	O	O	2395
-	PUNCT	O	O	2395
effect	VERB	O	O	2395
curves	NOUN	O	O	2395
,	PUNCT	O	O	2395
with	ADP	O	O	2395
the	PRON	O	O	2395
greatest	ADJ	O	O	2395
maximum	ADV	O	O	2395
inhibition	NOUN	O	O	2395
for	ADP	O	O	2395
CCK-8-NS	PROPN	O	O	2395
.	PUNCT	O	O	2395
The	PRON	O	O	2396
peptide	NOUN	O	O	2396
CCK-5	PROPN	O	O	2396
-	PUNCT	O	O	2396
8	NUM	O	O	2396
had	VERB	O	O	2396
weak	ADJ	O	O	2396
anticonvulsant	ADJ	O	O	2396
activity	NOUN	O	O	2396
in	ADP	O	O	2396
comparison	NOUN	O	O	2396
to	PART	O	O	2396
the	PRON	O	O	2396
octapeptides	NOUN	O	O	2396
,	PUNCT	O	O	2396
3.2	NUM	O	O	2396
mumol	PROPN	O	O	2396
/	PUNCT	O	O	2396
kg	VERB	O	O	2396
and	CCONJ	O	O	2396
larger	ADJ	O	O	2396
doses	NOUN	O	O	2396
of	ADP	O	O	2396
the	PRON	O	O	2396
reference	NOUN	O	O	2396
drug	NOUN	O	O	2396
,	PUNCT	O	O	2396
diazepam	NOUN	O	Chemical	2396
,	PUNCT	O	O	2396
totally	ADV	O	O	2396
prevented	VERB	O	O	2396
picrotoxin	PROPN	O	Chemical	2396
-	PUNCT	O	O	2396
induced	VERB	O	O	2396
seizures	NOUN	O	Disease	2396
and	CCONJ	O	O	2396
mortality	NOUN	O	O	2396
.	PUNCT	O	O	2396
The	PRON	O	O	2397
maximum	ADV	O	O	2397
effect	VERB	O	O	2397
of	ADP	O	O	2397
the	PRON	O	O	2397
peptides	NOUN	O	O	2397
tested	VERB	O	O	2397
was	AUX	O	O	2397
less	ADV	O	O	2397
than	ADP	O	O	2397
that	SCONJ	O	O	2397
of	ADP	O	O	2397
diazepam	NOUN	O	Chemical	2397
.	PUNCT	O	O	2397
Experiments	NOUN	O	O	2398
with	ADP	O	O	2398
analogues	NOUN	O	O	2398
and	CCONJ	O	O	2398
derivatives	NOUN	O	O	2398
of	ADP	O	O	2398
CCK-5	PROPN	O	O	2398
-	PUNCT	O	O	2398
8	NUM	O	O	2398
demonstrated	VERB	O	O	2398
that	SCONJ	O	O	2398
the	PRON	O	O	2398
effectiveness	NOUN	O	O	2398
of	ADP	O	O	2398
the	PRON	O	O	2398
beta	NOUN	O	O	2398
-	PUNCT	O	O	2398
alanyl	ADV	O	O	2398
derivatives	NOUN	O	O	2398
of	ADP	O	O	2398
CCK-5	PROPN	O	O	2398
-	PUNCT	O	O	2398
8	NUM	O	O	2398
were	AUX	O	O	2398
enhanced	VERB	O	O	2398
and	CCONJ	O	O	2398
that	SCONJ	O	O	2398
they	PRON	O	O	2398
were	AUX	O	O	2398
equipotent	ADJ	O	O	2398
with	ADP	O	O	2398
CCK-8-SE	PROPN	O	O	2398
.	PUNCT	O	O	2398
Of	ADV	O	O	2399
the	PRON	O	O	2399
CCK-2	PROPN	O	O	2399
-	PUNCT	O	O	2399
8	NUM	O	O	2399
analogues	NOUN	O	O	2399
,	PUNCT	O	O	2399
Ser(SO3H)7-Ac	PROPN	O	O	2399
-	PUNCT	O	O	2399
CCK-2	PROPN	O	O	2399
-	PUNCT	O	O	2399
8-SE	NOUN	O	O	2399
and	CCONJ	O	O	2399
Thr(SO3H)7-Ac	PROPN	O	O	2399
-	PUNCT	O	O	2399
CCK-2	PROPN	O	O	2399
-	PUNCT	O	O	2399
8-SE	NOUN	O	O	2399
and	CCONJ	O	O	2399
Hyp(SO3H)-Ac	PROPN	O	O	2399
-	PUNCT	O	O	2399
CCK-2	PROPN	O	O	2399
-	PUNCT	O	O	2399
8-SE	NOUN	O	O	2399
were	AUX	O	O	2399
slightly	ADV	O	O	2399
more	ADJ	O	O	2399
active	ADJ	O	O	2399
than	ADP	O	O	2399
CCK-8-SE	PROPN	O	O	2399
.	PUNCT	O	O	2399
Vasopressin	NOUN	O	Chemical	2402
as	ADP	O	O	2402
a	PRON	O	O	2402
possible	ADJ	O	O	2402
contributor	NOUN	O	O	2402
to	PART	O	O	2402
hypertension	NOUN	O	Disease	2402
.	PUNCT	O	O	2402
The	PRON	O	O	2403
role	NOUN	O	O	2403
of	ADP	O	O	2403
vasopressin	NOUN	O	Chemical	2403
as	ADP	O	O	2403
a	PRON	O	O	2403
pressor	ADJ	O	O	2403
agent	NOUN	O	O	2403
to	PART	O	O	2403
the	PRON	O	O	2403
hypertensive	ADJ	O	Disease	2403
process	NOUN	O	O	2403
was	AUX	O	O	2403
examined	VERB	O	O	2403
.	PUNCT	O	O	2403
Vasopressin	NOUN	O	Chemical	2404
plays	VERB	O	O	2404
a	PRON	O	O	2404
major	ADJ	O	O	2404
role	NOUN	O	O	2404
in	ADP	O	O	2404
the	PRON	O	O	2404
pathogenesis	NOUN	O	O	2404
of	ADP	O	O	2404
DOCA	PROPN	O	O	2404
-	PUNCT	O	O	2404
salt	NOUN	O	O	2404
hypertension	NOUN	O	Disease	2404
,	PUNCT	O	O	2404
since	SCONJ	O	O	2404
the	PRON	O	O	2404
elevation	NOUN	O	O	2404
of	ADP	O	O	2404
blood	NOUN	O	O	2404
pressure	NOUN	O	O	2404
was	AUX	O	O	2404
not	PART	O	O	2404
substantial	ADJ	O	O	2404
in	ADP	O	O	2404
the	PRON	O	O	2404
rats	NOUN	O	O	2404
with	ADP	O	O	2404
lithium	NOUN	O	Chemical	2404
-	PUNCT	O	O	2404
treated	VERB	O	O	2404
diabetes insipidus	NOUN	O	Disease	2404
after	ADP	O	O	2404
DOCA	PROPN	O	O	2404
-	PUNCT	O	O	2404
salt	NOUN	O	O	2404
treatment	NOUN	O	O	2404
.	PUNCT	O	O	2404
Administration	NOUN	O	O	2405
of	ADP	O	O	2405
DDAVP	PROPN	O	O	2405
which	PRON	O	O	2405
has	VERB	O	O	2405
antidiuretic	ADJ	O	O	2405
action	NOUN	O	O	2405
but	CCONJ	O	O	2405
minimal	ADJ	O	O	2405
vasopressor	NOUN	O	O	2405
effect	VERB	O	O	2405
failed	VERB	O	O	2405
to	PART	O	O	2405
increase	VERB	O	O	2405
blood	NOUN	O	O	2405
pressure	NOUN	O	O	2405
to	PART	O	O	2405
the	PRON	O	O	2405
levels	NOUN	O	O	2405
observed	VERB	O	O	2405
after	ADP	O	O	2405
administration	NOUN	O	O	2405
of	ADP	O	O	2405
AVP	NOUN	O	O	2405
.	PUNCT	O	O	2405
Furthermore	ADV	O	O	2406
,	PUNCT	O	O	2406
the	PRON	O	O	2406
pressor	ADJ	O	O	2406
action	NOUN	O	O	2406
of	ADP	O	O	2406
vasopressin	NOUN	O	Chemical	2406
appears	VERB	O	O	2406
to	PART	O	O	2406
be	AUX	O	O	2406
important	ADJ	O	O	2406
in	ADP	O	O	2406
the	PRON	O	O	2406
development	NOUN	O	O	2406
of	ADP	O	O	2406
this	PRON	O	O	2406
model	NOUN	O	O	2406
of	ADP	O	O	2406
hypertension	NOUN	O	Disease	2406
,	PUNCT	O	O	2406
since	SCONJ	O	O	2406
the	PRON	O	O	2406
enhanced	VERB	O	O	2406
pressor	ADJ	O	O	2406
responsiveness	NOUN	O	O	2406
to	PART	O	O	2406
the	PRON	O	O	2406
hormone	NOUN	O	O	2406
was	AUX	O	O	2406
observed	VERB	O	O	2406
in	ADP	O	O	2406
the	PRON	O	O	2406
initial	ADJ	O	O	2406
stage	NOUN	O	O	2406
of	ADP	O	O	2406
hypertension	NOUN	O	Disease	2406
.	PUNCT	O	O	2406
Increased	VERB	O	O	2407
secretion	NOUN	O	O	2407
of	ADP	O	O	2407
vasopressin	NOUN	O	Chemical	2407
from	ADP	O	O	2407
neurohypophysis	VERB	O	O	2407
also	ADV	O	O	2407
promotes	VERB	O	O	2407
the	PRON	O	O	2407
function	NOUN	O	O	2407
of	ADP	O	O	2407
the	PRON	O	O	2407
hormone	NOUN	O	O	2407
as	ADP	O	O	2407
a	PRON	O	O	2407
pathogenetic	NOUN	O	O	2407
factor	NOUN	O	O	2407
in	ADP	O	O	2407
hypertension	NOUN	O	Disease	2407
.	PUNCT	O	O	2407
An	PRON	O	O	2408
unproportional	ADJ	O	O	2408
release	NOUN	O	O	2408
of	ADP	O	O	2408
vasopressin	NOUN	O	Chemical	2408
compared	VERB	O	O	2408
to	PART	O	O	2408
plasma	NOUN	O	O	2408
osmolality	NOUN	O	O	2408
may	AUX	O	O	2408
be	AUX	O	O	2408
induced	VERB	O	O	2408
by	ADP	O	O	2408
the	PRON	O	O	2408
absence	NOUN	O	O	2408
of	ADP	O	O	2408
an	PRON	O	O	2408
adjusting	VERB	O	O	2408
control	VERB	O	O	2408
of	ADP	O	O	2408
angiotensin II	PROPN	O	Chemical	2408
forming	VERB	O	O	2408
and	CCONJ	O	O	2408
receptor	NOUN	O	O	2408
binding	VERB	O	O	2408
capacity	NOUN	O	O	2408
for	ADP	O	O	2408
sodium	NOUN	O	Chemical	2408
balance	NOUN	O	O	2408
in	ADP	O	O	2408
the	PRON	O	O	2408
brain	NOUN	O	O	2408
.	PUNCT	O	O	2408
However	ADV	O	O	2409
,	PUNCT	O	O	2409
the	PRON	O	O	2409
role	NOUN	O	O	2409
of	ADP	O	O	2409
vasopressin	NOUN	O	Chemical	2409
remains	VERB	O	O	2409
to	PART	O	O	2409
be	AUX	O	O	2409
determined	VERB	O	O	2409
in	ADP	O	O	2409
human	PROPN	O	O	2409
essential	ADJ	O	O	2409
hypertension	NOUN	O	Disease	2409
.	PUNCT	O	O	2409
Toxic	ADJ	O	O	2412
hepatitis	NOUN	O	Disease	2412
induced	VERB	O	O	2412
by	ADP	O	O	2412
disulfiram	PROPN	O	Chemical	2412
in	ADP	O	O	2412
a	PRON	O	O	2412
non	ADJ	O	O	2412
-	PUNCT	O	O	2412
alcoholic	ADJ	O	O	2412
.	PUNCT	O	O	2412
A	PRON	O	O	2413
reversible	ADJ	O	O	2413
toxic	ADJ	O	O	2413
liver damage	NOUN	O	Disease	2413
was	AUX	O	O	2413
observed	VERB	O	O	2413
in	ADP	O	O	2413
a	PRON	O	O	2413
non	ADJ	O	O	2413
-	PUNCT	O	O	2413
alcoholic	ADJ	O	O	2413
woman	NOUN	O	O	2413
treated	VERB	O	O	2413
with	ADP	O	O	2413
disulfiram	PROPN	O	Chemical	2413
.	PUNCT	O	O	2413
Atrial	PROPN	O	O	2416
thrombosis	NOUN	O	Disease	2416
involving	VERB	O	O	2416
the	PRON	O	O	2416
heart	NOUN	O	O	2416
of	ADP	O	O	2416
F-344	NOUN	O	O	2416
rats	NOUN	O	O	2416
ingesting	VERB	O	O	2416
quinacrine	NOUN	O	O	2416
hydrochloride	NOUN	O	O	2416
.	PUNCT	O	O	2416
Quinacrine	NOUN	O	O	2417
hydrochloride	NOUN	O	O	2417
is	AUX	O	O	2417
toxic	ADJ	O	O	2417
for	ADP	O	O	2417
the	PRON	O	O	2417
heart	NOUN	O	O	2417
of	ADP	O	O	2417
F-344	NOUN	O	O	2417
rats	NOUN	O	O	2417
.	PUNCT	O	O	2417
Rats	NOUN	O	O	2418
treated	VERB	O	O	2418
with	ADP	O	O	2418
500	NUM	O	O	2418
ppm	ADP	O	O	2418
quinacrine	NOUN	O	O	2418
hydrochloride	NOUN	O	O	2418
in	ADP	O	O	2418
the	PRON	O	O	2418
diet	PROPN	O	O	2418
all	PRON	O	O	2418
developed	VERB	O	O	2418
a	PRON	O	O	2418
high	ADJ	O	O	2418
incidence	NOUN	O	O	2418
of	ADP	O	O	2418
left	VERB	O	O	2418
atrial	ADJ	O	O	2418
thrombosis	NOUN	O	Disease	2418
.	PUNCT	O	O	2418
The	PRON	O	O	2419
lesion	NOUN	O	O	2419
was	AUX	O	O	2419
associated	VERB	O	O	2419
with	ADP	O	O	2419
cardiac hypertrophy	NOUN	O	Disease	2419
and	CCONJ	O	O	2419
dilatation	NOUN	O	O	2419
and	CCONJ	O	O	2419
focal	ADJ	O	O	2419
myocardial	ADJ	O	O	2419
degeneration	NOUN	O	O	2419
.	PUNCT	O	O	2419
Rats	NOUN	O	O	2420
died	VERB	O	O	2420
from	ADP	O	O	2420
cardiac hypertrophy	NOUN	O	Disease	2420
with	ADP	O	O	2420
severe	ADJ	O	O	2420
acute	ADJ	O	O	2420
and	CCONJ	O	O	2420
chronic	ADJ	O	O	2420
congestion	NOUN	O	O	2420
of	ADP	O	O	2420
the	PRON	O	O	2420
lungs	VERB	O	O	2420
,	PUNCT	O	O	2420
liver	NOUN	O	O	2420
,	PUNCT	O	O	2420
and	CCONJ	O	O	2420
other	ADJ	O	O	2420
organs	NOUN	O	O	2420
.	PUNCT	O	O	2420
Seventy	NUM	O	O	2421
percent	NOUN	O	O	2421
of	ADP	O	O	2421
rats	NOUN	O	O	2421
given	VERB	O	O	2421
250	NUM	O	O	2421
ppm	ADP	O	O	2421
quinacrine	NOUN	O	O	2421
hydrochloride	NOUN	O	O	2421
and	CCONJ	O	O	2421
1,000	NUM	O	O	2421
ppm	ADP	O	O	2421
sodium	NOUN	O	Chemical	2421
nitrite	PROPN	O	Chemical	2421
simultaneously	ADV	O	O	2421
in	ADP	O	O	2421
the	PRON	O	O	2421
diet	PROPN	O	O	2421
had	VERB	O	O	2421
thrombosis	NOUN	O	Disease	2421
of	ADP	O	O	2421
the	PRON	O	O	2421
atria	ADV	O	O	2421
of	ADP	O	O	2421
the	PRON	O	O	2421
heart	NOUN	O	O	2421
,	PUNCT	O	O	2421
while	SCONJ	O	O	2421
untreated	ADJ	O	O	2421
control	VERB	O	O	2421
rats	NOUN	O	O	2421
in	ADP	O	O	2421
this	PRON	O	O	2421
laboratory	NOUN	O	O	2421
did	VERB	O	O	2421
not	PART	O	O	2421
have	VERB	O	O	2421
atrial	ADJ	O	O	2421
thrombosis	NOUN	O	Disease	2421
.	PUNCT	O	O	2421
Sodium	NOUN	O	Chemical	2422
nitrite	PROPN	O	Chemical	2422
in	ADP	O	O	2422
combination	NOUN	O	O	2422
with	ADP	O	O	2422
quinacrine	NOUN	O	O	2422
hydrochloride	NOUN	O	O	2422
appeared	VERB	O	O	2422
to	PART	O	O	2422
have	VERB	O	O	2422
no	PRON	O	O	2422
additional	ADJ	O	O	2422
effect	VERB	O	O	2422
.	PUNCT	O	O	2422
Alternating	VERB	O	O	2425
sinus	NOUN	O	O	2425
rhythm	VERB	O	O	2425
and	CCONJ	O	O	2425
intermittent	ADJ	O	O	2425
sinoatrial	NOUN	O	O	2425
block	NOUN	O	O	2425
induced	VERB	O	O	2425
by	ADP	O	O	2425
propranolol	NOUN	O	Chemical	2425
.	PUNCT	O	O	2425
Alternating	VERB	O	O	2426
sinus	NOUN	O	O	2426
rhythm	VERB	O	O	2426
and	CCONJ	O	O	2426
intermittent	ADJ	O	O	2426
sinoatrial	NOUN	O	O	2426
(	PUNCT	O	O	2426
S	NOUN	O	O	2426
-	PUNCT	O	O	2426
A	PRON	O	O	2426
)	PUNCT	O	O	2426
block	NOUN	O	O	2426
was	AUX	O	O	2426
observed	VERB	O	O	2426
in	ADP	O	O	2426
a	PRON	O	O	2426
57-year	NOUN	O	O	2426
-	PUNCT	O	O	2426
old	ADJ	O	O	2426
woman	NOUN	O	O	2426
,	PUNCT	O	O	2426
under	ADP	O	O	2426
treatment	NOUN	O	O	2426
for	ADP	O	O	2426
angina	NOUN	O	Disease	2426
with	ADP	O	O	2426
80	NUM	O	O	2426
mg	VERB	O	O	2426
propranolol	NOUN	O	Chemical	2426
daily	ADV	O	O	2426
.	PUNCT	O	O	2426
Following	VERB	O	O	2427
these	PRON	O	O	2427
basic	ADJ	O	O	2427
sinus	NOUN	O	O	2427
cycles	NOUN	O	O	2427
,	PUNCT	O	O	2427
alternating	VERB	O	O	2427
rhythm	VERB	O	O	2427
started	VERB	O	O	2427
with	ADP	O	O	2427
the	PRON	O	O	2427
longer	ADV	O	O	2427
P	NOUN	O	Chemical	2427
-	PUNCT	O	O	2427
P	NOUN	O	Chemical	2427
interval	NOUN	O	O	2427
.	PUNCT	O	O	2427
In	ADP	O	O	2428
one	NUM	O	O	2428
recording	NOUN	O	O	2428
a	PRON	O	O	2428
short	ADJ	O	O	2428
period	NOUN	O	O	2428
of	ADP	O	O	2428
regular	ADJ	O	O	2428
sinus	NOUN	O	O	2428
rhythm	VERB	O	O	2428
with	ADP	O	O	2428
intermittent	ADJ	O	O	2428
2/1	NUM	O	O	2428
S	NOUN	O	O	2428
-	PUNCT	O	O	2428
A	PRON	O	O	2428
block	NOUN	O	O	2428
was	AUX	O	O	2428
observed	VERB	O	O	2428
.	PUNCT	O	O	2428
Atropine	NOUN	O	Chemical	2429
1	X	O	O	2429
mg	VERB	O	O	2429
given	VERB	O	O	2429
intravenously	ADV	O	O	2429
resulted	VERB	O	O	2429
in	ADP	O	O	2429
shortening	NOUN	O	O	2429
of	ADP	O	O	2429
all	PRON	O	O	2429
P	NOUN	O	Chemical	2429
-	PUNCT	O	O	2429
P	NOUN	O	Chemical	2429
intervals	NOUN	O	O	2429
without	ADP	O	O	2429
changing	VERB	O	O	2429
the	PRON	O	O	2429
rhythm	VERB	O	O	2429
.	PUNCT	O	O	2429
The	PRON	O	O	2430
abnormal	ADJ	O	O	2430
rhythm	VERB	O	O	2430
disappeared	VERB	O	O	2430
with	ADP	O	O	2430
the	PRON	O	O	2430
withdrawal	NOUN	O	O	2430
of	ADP	O	O	2430
propranolol	NOUN	O	Chemical	2430
and	CCONJ	O	O	2430
when	SCONJ	O	O	2430
the	PRON	O	O	2430
drug	NOUN	O	O	2430
was	AUX	O	O	2430
restarted	VERB	O	O	2430
a	PRON	O	O	2430
2/1	NUM	O	O	2430
S	NOUN	O	O	2430
-	PUNCT	O	O	2430
A	PRON	O	O	2430
block	NOUN	O	O	2430
was	AUX	O	O	2430
seen	VERB	O	O	2430
.	PUNCT	O	O	2430
This	PRON	O	O	2431
was	AUX	O	O	2431
accepted	VERB	O	O	2431
as	ADP	O	O	2431
evidence	NOUN	O	O	2431
for	ADP	O	O	2431
propranolol	NOUN	O	Chemical	2431
being	AUX	O	O	2431
the	PRON	O	O	2431
cause	VERB	O	O	2431
of	ADP	O	O	2431
this	PRON	O	O	2431
conduction	NOUN	O	O	2431
disorder	NOUN	O	O	2431
.	PUNCT	O	O	2431
Antitumor	PROPN	O	O	2434
effect	VERB	O	O	2434
,	PUNCT	O	O	2434
cardiotoxicity	NOUN	O	Disease	2434
,	PUNCT	O	O	2434
and	CCONJ	O	O	2434
nephrotoxicity	NOUN	O	Disease	2434
of	ADP	O	O	2434
doxorubicin	VERB	O	Chemical	2434
in	ADP	O	O	2434
the	PRON	O	O	2434
IgM	PROPN	O	O	2434
solid	ADJ	O	O	2434
immunocytoma	NOUN	O	O	2434
-	PUNCT	O	O	2434
bearing	VERB	O	O	2434
LOU	PROPN	O	O	2434
/	PUNCT	O	O	2434
M	NOUN	O	Chemical	2434
/	PUNCT	O	O	2434
WSL	PROPN	O	O	2434
rat	NOUN	O	O	2434
.	PUNCT	O	O	2434
Antitumor	PROPN	O	O	2435
activity	NOUN	O	O	2435
,	PUNCT	O	O	2435
cardiotoxicity	NOUN	O	Disease	2435
,	PUNCT	O	O	2435
and	CCONJ	O	O	2435
nephrotoxicity	NOUN	O	Disease	2435
induced	VERB	O	O	2435
by	ADP	O	O	2435
doxorubicin	VERB	O	Chemical	2435
were	AUX	O	O	2435
studied	VERB	O	O	2435
in	ADP	O	O	2435
LOU	PROPN	O	O	2435
/	PUNCT	O	O	2435
M	NOUN	O	Chemical	2435
/	PUNCT	O	O	2435
WSL	PROPN	O	O	2435
inbred	ADJ	O	O	2435
rats	NOUN	O	O	2435
each	PRON	O	O	2435
bearing	VERB	O	O	2435
a	PRON	O	O	2435
transplantable	ADJ	O	O	2435
solid	ADJ	O	O	2435
IgM	PROPN	O	O	2435
immunocytoma	NOUN	O	O	2435
.	PUNCT	O	O	2435
Animals	NOUN	O	O	2436
with	ADP	O	O	2436
a	PRON	O	O	2436
tumor	NOUN	O	Disease	2436
(	PUNCT	O	O	2436
diameter	NOUN	O	O	2436
,	PUNCT	O	O	2436
15.8	NUM	O	O	2436
+	ADP	O	O	2436
/-	PUNCT	O	O	2436
3.3	NUM	O	O	2437
mm	INTJ	O	O	2437
)	PUNCT	O	O	2437
were	AUX	O	O	2437
treated	VERB	O	O	2437
with	ADP	O	O	2437
iv	X	O	O	2437
injections	NOUN	O	O	2437
of	ADP	O	O	2437
doxorubicin	VERB	O	Chemical	2437
on	ADP	O	O	2437
5	NUM	O	O	2437
consecutive	ADJ	O	O	2437
days	NOUN	O	O	2437
,	PUNCT	O	O	2437
followed	VERB	O	O	2437
by	ADP	O	O	2437
1	X	O	O	2437
weekly	ADV	O	O	2437
injection	NOUN	O	O	2437
for	ADP	O	O	2437
7	NUM	O	O	2437
weeks	NOUN	O	O	2437
(	PUNCT	O	O	2437
dose	NOUN	O	O	2437
range	VERB	O	O	2437
,	PUNCT	O	O	2437
0.015	NUM	O	O	2437
-	PUNCT	O	O	2437
4.0	NUM	O	O	2437
Tumor	NOUN	O	O	2438
regression	NOUN	O	O	2438
was	AUX	O	O	2438
observed	VERB	O	O	2438
with	ADP	O	O	2438
0.5	NUM	O	O	2438
mg	VERB	O	O	2438
doxorubicin	VERB	O	Chemical	2438
/	PUNCT	O	O	2438
kg	VERB	O	O	2438
.	PUNCT	O	O	2438
Complete	ADJ	O	O	2439
disappearance	NOUN	O	O	2439
of	ADP	O	O	2439
the	PRON	O	O	2439
tumor	NOUN	O	Disease	2439
was	AUX	O	O	2439
induced	VERB	O	O	2439
with	ADP	O	O	2439
1.0	NUM	O	O	2439
mg	VERB	O	O	2439
doxorubicin	VERB	O	Chemical	2439
/	PUNCT	O	O	2439
kg	VERB	O	O	2439
.	PUNCT	O	O	2439
Histologic	NOUN	O	O	2440
evidence	NOUN	O	O	2440
of	ADP	O	O	2440
cardiotoxicity	NOUN	O	Disease	2440
scored	VERB	O	O	2440
as	ADP	O	O	2440
grade	NOUN	O	O	2440
III	NUM	O	O	2440
was	AUX	O	O	2440
only	ADV	O	O	2440
observed	VERB	O	O	2440
at	ADP	O	O	2440
a	PRON	O	O	2440
dose	NOUN	O	O	2440
of	ADP	O	O	2440
1.0	NUM	O	O	2440
mg	VERB	O	O	2440
doxorubicin	VERB	O	Chemical	2440
/	PUNCT	O	O	2440
kg	VERB	O	O	2440
.	PUNCT	O	O	2440
Light	NOUN	O	O	2441
microscopic	ADJ	O	O	2441
evidence	NOUN	O	O	2441
of	ADP	O	O	2441
renal damage	NOUN	O	Disease	2441
was	AUX	O	O	2441
seen	VERB	O	O	2441
above	ADP	O	O	2441
a	PRON	O	O	2441
dose	NOUN	O	O	2441
of	ADP	O	O	2441
0.5	NUM	O	O	2441
mg	VERB	O	O	2441
doxorubicin	VERB	O	Chemical	2441
/	PUNCT	O	O	2441
kg	VERB	O	O	2441
,	PUNCT	O	O	2441
which	PRON	O	O	2441
resulted	VERB	O	O	2441
in	ADP	O	O	2441
albuminuria	PROPN	O	Disease	2441
and	CCONJ	O	O	2441
very	ADV	O	O	2441
low	ADJ	O	O	2441
serum	NOUN	O	O	2441
albumin	PROPN	O	O	2441
levels	NOUN	O	O	2441
.	PUNCT	O	O	2441
In	ADP	O	O	2442
the	PRON	O	O	2442
group	NOUN	O	O	2442
that	SCONJ	O	O	2442
received	VERB	O	O	2442
1.0	NUM	O	O	2442
mg	VERB	O	O	2442
doxorubicin	VERB	O	Chemical	2442
/	PUNCT	O	O	2442
kg	VERB	O	O	2442
,	PUNCT	O	O	2442
the	PRON	O	O	2442
serum	NOUN	O	O	2442
albumin	PROPN	O	O	2442
level	VERB	O	O	2442
decreased	VERB	O	O	2442
from	ADP	O	O	2442
33.6	NUM	O	O	2442
+	ADP	O	O	2442
/-	PUNCT	O	O	2442
Ascites	NOUN	O	O	2443
and	CCONJ	O	O	2443
hydrothorax	ADJ	O	O	2443
were	AUX	O	O	2443
observed	VERB	O	O	2443
simultaneously	ADV	O	O	2443
.	PUNCT	O	O	2443
The	PRON	O	O	2444
same	ADJ	O	O	2444
experiments	NOUN	O	O	2444
were	AUX	O	O	2444
performed	VERB	O	O	2444
with	ADP	O	O	2444
non	ADJ	O	O	2444
-	PUNCT	O	O	2444
tumor	NOUN	O	Disease	2444
-	PUNCT	O	O	2444
bearing	VERB	O	O	2444
rats	NOUN	O	O	2444
,	PUNCT	O	O	2444
in	ADP	O	O	2444
which	PRON	O	O	2444
no	PRON	O	O	2444
major	ADJ	O	O	2444
differences	NOUN	O	O	2444
were	AUX	O	O	2444
observed	VERB	O	O	2444
.	PUNCT	O	O	2444
In	ADP	O	O	2445
conclusion	NOUN	O	O	2445
,	PUNCT	O	O	2445
antitumor	PROPN	O	O	2445
activity	NOUN	O	O	2445
,	PUNCT	O	O	2445
cardiotoxicity	NOUN	O	Disease	2445
,	PUNCT	O	O	2445
and	CCONJ	O	O	2445
nephrotoxicity	NOUN	O	Disease	2445
were	AUX	O	O	2445
studied	VERB	O	O	2445
simultaneously	ADV	O	O	2445
in	ADP	O	O	2445
the	PRON	O	O	2445
same	ADJ	O	O	2445
LOU	PROPN	O	O	2445
/	PUNCT	O	O	2445
M	NOUN	O	Chemical	2445
/	PUNCT	O	O	2445
WSL	PROPN	O	O	2445
rat	NOUN	O	O	2445
.	PUNCT	O	O	2445
Albuminuria	PROPN	O	O	2446
due	ADJ	O	O	2446
to	PART	O	O	2446
renal damage	NOUN	O	Disease	2446
led	VERB	O	O	2446
to	PART	O	O	2446
extremely	ADV	O	O	2446
low	ADJ	O	O	2446
serum	NOUN	O	O	2446
albumin	PROPN	O	O	2446
levels	NOUN	O	O	2446
,	PUNCT	O	O	2446
so	ADV	O	O	2446
ascites	NOUN	O	Disease	2446
and	CCONJ	O	O	2446
hydrothorax	ADJ	O	O	2446
were	AUX	O	O	2446
not	PART	O	O	2446
necessarily	ADV	O	O	2446
a	PRON	O	O	2446
consequence	NOUN	O	O	2446
of	ADP	O	O	2446
the	PRON	O	O	2446
observed	VERB	O	O	2446
cardiomyopathy	ADJ	O	Disease	2446
.	PUNCT	O	O	2446
Intraoperative	PROPN	O	O	2449
bradycardia	NOUN	O	Disease	2449
and	CCONJ	O	O	2449
hypotension	NOUN	O	Disease	2449
associated	VERB	O	O	2449
with	ADP	O	O	2449
timolol	PROPN	O	Chemical	2449
and	CCONJ	O	O	2449
pilocarpine	NOUN	O	Chemical	2449
eye	NOUN	O	O	2449
drops	VERB	O	O	2449
.	PUNCT	O	O	2449
A	PRON	O	O	2450
69-yr	NOUN	O	O	2450
-	PUNCT	O	O	2450
old	ADJ	O	O	2450
man	NOUN	O	O	2450
,	PUNCT	O	O	2450
who	PRON	O	O	2450
was	AUX	O	O	2450
concurrently	ADV	O	O	2450
being	AUX	O	O	2450
treated	VERB	O	O	2450
with	ADP	O	O	2450
pilocarpine	NOUN	O	Chemical	2450
nitrate	NOUN	O	Chemical	2450
and	CCONJ	O	O	2450
timolol	PROPN	O	Chemical	2450
maleate	NOUN	O	O	2450
eye	NOUN	O	O	2450
drops	VERB	O	O	2450
,	PUNCT	O	O	2450
developed	VERB	O	O	2450
a	PRON	O	O	2450
bradycardia	NOUN	O	Disease	2450
and	CCONJ	O	O	2450
became	VERB	O	O	2450
hypotensive	ADJ	O	Disease	2450
during	ADP	O	O	2450
halothane	VERB	O	Chemical	2450
anaesthesia	NOUN	O	O	2450
.	PUNCT	O	O	2450
Both	PRON	O	O	2451
timolol	PROPN	O	Chemical	2451
and	CCONJ	O	O	2451
pilocarpine	NOUN	O	Chemical	2451
were	AUX	O	O	2451
subsequently	ADV	O	O	2451
identified	VERB	O	O	2451
in	ADP	O	O	2451
a	PRON	O	O	2451
24-h	NOUN	O	O	2451
collection	NOUN	O	O	2451
of	ADP	O	O	2451
urine	NOUN	O	O	2451
.	PUNCT	O	O	2451
Timolol	PROPN	O	Chemical	2452
(	PUNCT	O	O	2452
but	CCONJ	O	O	2452
not	PART	O	O	2452
pilocarpine	NOUN	O	Chemical	2452
)	PUNCT	O	O	2452
was	AUX	O	O	2452
detected	VERB	O	O	2452
in	ADP	O	O	2452
a	PRON	O	O	2452
sample	NOUN	O	O	2452
of	ADP	O	O	2452
plasma	NOUN	O	O	2452
removed	VERB	O	O	2452
during	ADP	O	O	2452
surgery	NOUN	O	O	2452
;	PUNCT	O	O	2452
the	PRON	O	O	2452
plasma	NOUN	O	O	2452
concentration	NOUN	O	O	2452
of	ADP	O	O	2452
timolol	PROPN	O	Chemical	2452
(	PUNCT	O	O	2452
2.6	NUM	O	O	2452
ng	PROPN	O	O	2452
ml-1	PUNCT	O	O	2452
)	PUNCT	O	O	2452
was	AUX	O	O	2452
consistent	ADJ	O	O	2452
with	ADP	O	O	2452
partial	ADJ	O	O	2452
beta	NOUN	O	O	2452
-	PUNCT	O	O	2452
adrenoceptor	NOUN	O	O	2452
blockade	VERB	O	O	2452
.	PUNCT	O	O	2452
It	PRON	O	O	2453
is	AUX	O	O	2453
postulated	VERB	O	O	2453
that	SCONJ	O	O	2453
this	PRON	O	O	2453
action	NOUN	O	O	2453
may	AUX	O	O	2453
have	VERB	O	O	2453
been	AUX	O	O	2453
enhanced	VERB	O	O	2453
during	ADP	O	O	2453
halothane	VERB	O	Chemical	2453
anaesthesia	NOUN	O	O	2453
with	ADP	O	O	2453
resultant	NOUN	O	O	2453
bradycardia	NOUN	O	Disease	2453
and	CCONJ	O	O	2453
hypotension	NOUN	O	Disease	2453
.	PUNCT	O	O	2453
Pilocarpine	NOUN	O	Chemical	2454
may	AUX	O	O	2454
have	VERB	O	O	2454
had	VERB	O	O	2454
a	PRON	O	O	2454
contributory	ADJ	O	O	2454
effect	VERB	O	O	2454
.	PUNCT	O	O	2454
Succinylcholine	NOUN	O	Chemical	2457
apnoea	NOUN	O	Disease	2457
:	PUNCT	O	O	2457
attempted	VERB	O	O	2457
reversal	NOUN	O	O	2457
with	ADP	O	O	2457
anticholinesterases	PROPN	O	O	2457
.	PUNCT	O	O	2457
Anticholinesterases	NOUN	O	O	2458
were	AUX	O	O	2458
administered	VERB	O	O	2458
in	ADP	O	O	2458
an	PRON	O	O	2458
attempt	VERB	O	O	2458
to	PART	O	O	2458
antagonize	VERB	O	O	2458
prolonged	VERB	O	O	2458
neuromuscular blockade	NOUN	O	Disease	2458
following	VERB	O	O	2458
the	PRON	O	O	2458
administration	NOUN	O	O	2458
of	ADP	O	O	2458
succinylcholine	NOUN	O	Chemical	2458
in	ADP	O	O	2458
a	PRON	O	O	2458
patient	NOUN	O	O	2458
later	ADV	O	O	2458
found	VERB	O	O	2458
to	PART	O	O	2458
be	AUX	O	O	2458
homozygous	ADJ	O	O	2458
for	ADP	O	O	2458
atypical	ADJ	O	O	2458
plasma	NOUN	O	O	2458
cholinesterase	NOUN	O	O	2458
.	PUNCT	O	O	2458
Edrophonium	NOUN	O	O	2459
10	NUM	O	O	2459
mg	VERB	O	O	2459
,	PUNCT	O	O	2459
given	VERB	O	O	2459
74	NUM	O	O	2459
min	NOUN	O	O	2459
after	ADP	O	O	2459
succinylcholine	NOUN	O	Chemical	2459
,	PUNCT	O	O	2459
when	SCONJ	O	O	2459
train	VERB	O	O	2459
-	PUNCT	O	O	2459
of	ADP	O	O	2459
-	PUNCT	O	O	2459
four	NUM	O	O	2459
stimulation	NOUN	O	O	2459
was	AUX	O	O	2459
characteristic	ADJ	O	O	2459
of	ADP	O	O	2459
phase	NOUN	O	O	2459
II	NUM	O	O	2459
block	NOUN	O	O	2459
,	PUNCT	O	O	2459
produced	VERB	O	O	2459
partial	ADJ	O	O	2459
antagonism	NOUN	O	O	2459
which	PRON	O	O	2459
was	AUX	O	O	2459
not	PART	O	O	2459
sustained	VERB	O	O	2459
.	PUNCT	O	O	2459
Repeated	VERB	O	O	2460
doses	NOUN	O	O	2460
of	ADP	O	O	2460
edrophonium	NOUN	O	Chemical	2460
to	PART	O	O	2460
70	NUM	O	O	2460
mg	VERB	O	O	2460
and	CCONJ	O	O	2460
neostigmine	NOUN	O	O	2460
to	PART	O	O	2460
2.5	NUM	O	O	2460
mg	VERB	O	O	2460
did	VERB	O	O	2460
not	PART	O	O	2460
antagonize	VERB	O	O	2460
or	CCONJ	O	O	2460
augment	VERB	O	O	2460
the	PRON	O	O	2460
block	NOUN	O	O	2460
.	PUNCT	O	O	2460
Spontaneous	ADJ	O	O	2461
respiration	NOUN	O	O	2461
recommenced	VERB	O	O	2461
200	NUM	O	O	2461
min	NOUN	O	O	2461
after	ADP	O	O	2461
succinylcholine	NOUN	O	Chemical	2461
administration	NOUN	O	O	2461
.	PUNCT	O	O	2461
It	PRON	O	O	2462
is	AUX	O	O	2462
concluded	VERB	O	O	2462
that	SCONJ	O	O	2462
anticholinesterases	PROPN	O	O	2462
are	AUX	O	O	2462
only	ADV	O	O	2462
partially	ADV	O	O	2462
effective	ADJ	O	O	2462
in	ADP	O	O	2462
restoring	VERB	O	O	2462
neuromuscular	ADJ	O	O	2462
function	NOUN	O	O	2462
in	ADP	O	O	2462
succinylcholine	NOUN	O	Chemical	2462
apnoea	NOUN	O	Disease	2462
despite	SCONJ	O	O	2462
muscle	NOUN	O	O	2462
twitch	VERB	O	O	2462
activity	NOUN	O	O	2462
typical	ADJ	O	O	2462
of	ADP	O	O	2462
phase	NOUN	O	O	2462
II	NUM	O	O	2462
block	NOUN	O	O	2462
.	PUNCT	O	O	2462
Effect	VERB	O	O	2465
of	ADP	O	O	2465
doxorubicin	VERB	O	Chemical	2465
on	ADP	O	O	2465
[	X	O	O	2465
omega	PROPN	O	O	2465
-	PUNCT	O	O	2465
I-131]heptadecanoic	PROPN	O	O	2465
acid	PROPN	O	O	2465
myocardial	ADJ	O	O	2465
scintigraphy	VERB	O	O	2465
and	CCONJ	O	O	2465
echocardiography	NOUN	O	O	2465
in	ADP	O	O	2465
dogs	NOUN	O	O	2465
.	PUNCT	O	O	2465
The	PRON	O	O	2466
effects	NOUN	O	O	2466
of	ADP	O	O	2466
serial	ADJ	O	O	2466
treatment	NOUN	O	O	2466
with	ADP	O	O	2466
doxorubicin	VERB	O	Chemical	2466
on	ADP	O	O	2466
dynamic	ADJ	O	O	2466
myocardial	ADJ	O	O	2466
scintigraphy	VERB	O	O	2466
with	ADP	O	O	2466
[	X	O	O	2466
omega	PROPN	O	O	2466
-	PUNCT	O	O	2466
I-131]heptadecanoic	PROPN	O	O	2466
acid	PROPN	O	O	2466
(	PUNCT	O	O	2466
I-131	PROPN	O	O	2466
HA	NOUN	O	O	2466
)	PUNCT	O	O	2466
,	PUNCT	O	O	2466
and	CCONJ	O	O	2466
on	ADP	O	O	2466
global	ADJ	O	O	2466
left	VERB	O	O	2466
-	PUNCT	O	O	2466
ventricular	ADJ	O	O	2466
function	NOUN	O	O	2466
determined	VERB	O	O	2466
echocardiographically	ADV	O	O	2466
,	PUNCT	O	O	2466
were	AUX	O	O	2466
studied	VERB	O	O	2466
in	ADP	O	O	2466
a	PRON	O	O	2466
group	NOUN	O	O	2466
of	ADP	O	O	2466
nine	NUM	O	O	2466
mongrel	ADJ	O	O	2466
dogs	NOUN	O	O	2466
.	PUNCT	O	O	2466
Total	ADJ	O	O	2467
extractable	ADJ	O	O	2467
myocardial	ADJ	O	O	2467
lipid	NOUN	O	O	2467
was	AUX	O	O	2467
compared	VERB	O	O	2467
postmortem	PROPN	O	O	2467
between	ADP	O	O	2467
a	PRON	O	O	2467
group	NOUN	O	O	2467
of	ADP	O	O	2467
control	VERB	O	O	2467
dogs	NOUN	O	O	2467
and	CCONJ	O	O	2467
doxorubicin	VERB	O	Chemical	2467
-	PUNCT	O	O	2467
treated	VERB	O	O	2467
dogs	NOUN	O	O	2467
.	PUNCT	O	O	2467
A	PRON	O	O	2468
significant	ADJ	O	O	2468
and	CCONJ	O	O	2468
then	ADV	O	O	2468
progressive	ADJ	O	O	2468
fall	VERB	O	O	2468
in	ADP	O	O	2468
global	ADJ	O	O	2468
LV	PROPN	O	Disease	2468
function	NOUN	O	O	2468
was	AUX	O	O	2468
observed	VERB	O	O	2468
at	ADP	O	O	2468
a	PRON	O	O	2468
cumulative	ADJ	O	O	2468
doxorubicin	VERB	O	Chemical	2468
dose	NOUN	O	O	2468
of	ADP	O	O	2468
4	NUM	O	O	2468
mg	VERB	O	O	2468
/	PUNCT	O	O	2468
kg	VERB	O	O	2468
.	PUNCT	O	O	2468
A	PRON	O	O	2469
significant	ADJ	O	O	2469
increase	VERB	O	O	2469
in	ADP	O	O	2469
the	PRON	O	O	2469
myocardial	ADJ	O	O	2469
t1/2	NUM	O	O	2469
of	ADP	O	O	2469
the	PRON	O	O	2469
I-131	PROPN	O	O	2469
HA	NOUN	O	O	2469
was	AUX	O	O	2469
observed	VERB	O	O	2469
only	ADV	O	O	2469
at	ADP	O	O	2469
a	PRON	O	O	2469
higher	ADJ	O	O	2469
cumulative	ADJ	O	O	2469
dose	NOUN	O	O	2469
,	PUNCT	O	O	2469
10	NUM	O	O	2469
mg	VERB	O	O	2469
/	PUNCT	O	O	2469
kg	VERB	O	O	2469
.	PUNCT	O	O	2469
No	PRON	O	O	2470
significant	ADJ	O	O	2470
alteration	NOUN	O	O	2470
in	ADP	O	O	2470
total	ADJ	O	O	2470
extractable	ADJ	O	O	2470
myocardial	ADJ	O	O	2470
lipids	NOUN	O	O	2470
was	AUX	O	O	2470
observed	VERB	O	O	2470
between	ADP	O	O	2470
control	VERB	O	O	2470
dogs	NOUN	O	O	2470
and	CCONJ	O	O	2470
those	PRON	O	O	2470
treated	VERB	O	O	2470
with	ADP	O	O	2470
doxorubicin	VERB	O	Chemical	2470
.	PUNCT	O	O	2470
Our	PRON	O	O	2471
findings	NOUN	O	O	2471
suggest	VERB	O	O	2471
that	SCONJ	O	O	2471
the	PRON	O	O	2471
changes	VERB	O	O	2471
leading	VERB	O	O	2471
to	PART	O	O	2471
an	PRON	O	O	2471
alteration	NOUN	O	O	2471
of	ADP	O	O	2471
myocardial	ADJ	O	O	2471
dynamic	ADJ	O	O	2471
imaging	VERB	O	O	2471
with	ADP	O	O	2471
I-131	PROPN	O	O	2471
HA	NOUN	O	O	2471
are	AUX	O	O	2471
not	PART	O	O	2471
the	PRON	O	O	2471
initiating	VERB	O	O	2471
factor	NOUN	O	O	2471
in	ADP	O	O	2471
doxorubicin	VERB	O	Chemical	2471
cardiotoxicity	NOUN	O	Disease	2471
.	PUNCT	O	O	2471
Hemodynamics	NOUN	O	O	2474
and	CCONJ	O	O	2474
myocardial	ADJ	O	O	2474
metabolism	NOUN	O	O	2474
under	ADP	O	O	2474
deliberate	VERB	O	O	2474
hypotension	NOUN	O	Disease	2474
.	PUNCT	O	O	2474
Coronary	ADJ	O	O	2475
blood	NOUN	O	O	2475
flow	NOUN	O	O	2475
,	PUNCT	O	O	2475
cardiac	ADJ	O	O	2475
work	NOUN	O	O	2475
and	CCONJ	O	O	2475
metabolism	NOUN	O	O	2475
were	AUX	O	O	2475
studied	VERB	O	O	2475
in	ADP	O	O	2475
dogs	NOUN	O	O	2475
under	ADP	O	O	2475
sodium	NOUN	O	Chemical	2475
nitroprusside	ADV	O	Chemical	2475
(	PUNCT	O	O	2475
SNP	PROPN	O	O	2475
)	PUNCT	O	O	2475
and	CCONJ	O	O	2475
trimetaphan	NOUN	O	O	2475
(	PUNCT	O	O	2475
TMP	PROPN	O	O	2475
)	PUNCT	O	O	2475
deliberate	VERB	O	O	2475
hypotension	NOUN	O	Disease	2475
(	PUNCT	O	O	2475
20%	NOUN	O	O	2475
and	CCONJ	O	O	2475
Regarding	VERB	O	O	2476
the	PRON	O	O	2476
effects	NOUN	O	O	2476
of	ADP	O	O	2476
drug	NOUN	O	O	2476
-	PUNCT	O	O	2476
induced	VERB	O	O	2476
hypotension	NOUN	O	Disease	2476
on	ADP	O	O	2476
coronary	ADJ	O	O	2476
blood	NOUN	O	O	2476
flow	NOUN	O	O	2476
,	PUNCT	O	O	2476
aortic	ADJ	O	O	2476
and	CCONJ	O	O	2476
coronary	ADJ	O	O	2476
sinus	NOUN	O	O	2476
metabolic	ADJ	O	O	2476
data	NOUN	O	O	2476
(	PUNCT	O	O	2476
pH	NOUN	O	O	2476
,	PUNCT	O	O	2476
pO2	PROPN	O	O	2476
,	PUNCT	O	O	2476
pCO2	X	O	O	2476
)	PUNCT	O	O	2476
we	PRON	O	O	2476
could	AUX	O	O	2476
confirm	VERB	O	O	2476
that	SCONJ	O	O	2476
nitroprusside	ADV	O	Chemical	2476
hypotension	NOUN	O	Disease	2476
could	AUX	O	O	2476
be	AUX	O	O	2476
safely	ADV	O	O	2476
used	VERB	O	O	2476
to	PART	O	O	2476
30%	NOUN	O	O	2476
mean	VERB	O	O	2476
blood	NOUN	O	O	2476
pressure	NOUN	O	O	2476
decrease	VERB	O	O	2476
from	ADP	O	O	2476
control	VERB	O	O	2476
,	PUNCT	O	O	2476
trimetaphan	NOUN	O	O	2476
hypotension	NOUN	O	Disease	2476
to	PART	O	O	2476
20%	NOUN	O	O	2476
mean	VERB	O	O	2476
blood	NOUN	O	O	2476
pressure	NOUN	O	O	2476
decrease	VERB	O	O	2476
.	PUNCT	O	O	2476
Cardiac	ADJ	O	O	2477
work	NOUN	O	O	2477
was	AUX	O	O	2477
significantly	ADV	O	O	2477
reduced	VERB	O	O	2477
during	ADP	O	O	2477
SNP	PROPN	O	O	2477
hypotension	NOUN	O	Disease	2477
.	PUNCT	O	O	2477
Myocardial	PROPN	O	O	2478
O2	PROPN	O	O	2478
consumption	NOUN	O	O	2478
and	CCONJ	O	O	2478
O2	PROPN	O	O	2478
availability	NOUN	O	O	2478
were	AUX	O	O	2478
directly	ADV	O	O	2478
dependent	ADJ	O	O	2478
on	ADP	O	O	2478
the	PRON	O	O	2478
coronary	ADJ	O	O	2478
perfusion	NOUN	O	O	2478
.	PUNCT	O	O	2478
Evidence	NOUN	O	O	2481
for	ADP	O	O	2481
a	PRON	O	O	2481
selective	ADJ	O	O	2481
brain	NOUN	O	O	2481
noradrenergic	ADJ	O	O	2481
involvement	NOUN	O	O	2481
in	ADP	O	O	2481
the	PRON	O	O	2481
locomotor	PROPN	O	O	2481
stimulant	NOUN	O	O	2481
effects	NOUN	O	O	2481
of	ADP	O	O	2481
amphetamine	NOUN	O	Chemical	2481
in	ADP	O	O	2481
the	PRON	O	O	2481
rat	NOUN	O	O	2481
.	PUNCT	O	O	2481
Male	NOUN	O	O	2482
rats	NOUN	O	O	2482
received	VERB	O	O	2482
the	PRON	O	O	2482
noradrenaline	NOUN	O	Chemical	2482
neurotoxin	NOUN	O	O	2482
DSP4	PROPN	O	O	2482
(	PUNCT	O	O	2482
50	NUM	O	O	2482
mg	VERB	O	O	2482
/	PUNCT	O	O	2482
kg	VERB	O	O	2482
)	PUNCT	O	O	2482
7	NUM	O	O	2482
days	NOUN	O	O	2482
prior	ADV	O	O	2482
to	PART	O	O	2482
injection	NOUN	O	O	2482
of	ADP	O	O	2482
D	NOUN	O	O	2482
-	PUNCT	O	O	2482
amphetamine	NOUN	O	Chemical	2482
(	PUNCT	O	O	2482
10	NUM	O	O	2482
or	CCONJ	O	O	2482
40	NUM	O	O	2482
mumol	PROPN	O	O	2482
/	PUNCT	O	O	2482
kg	VERB	O	O	2482
i.p	NOUN	O	O	2482
.	PUNCT	O	O	2482
)	PUNCT	O	O	2482
.	PUNCT	O	O	2482
The	PRON	O	O	2483
hyperactivity	NOUN	O	Disease	2483
induced	VERB	O	O	2483
by	ADP	O	O	2483
D	NOUN	O	O	2483
-	PUNCT	O	O	2483
amphetamine	NOUN	O	Chemical	2483
(	PUNCT	O	O	2483
10	NUM	O	O	2483
mumol	PROPN	O	O	2483
/	PUNCT	O	O	2483
kg	VERB	O	O	2483
)	PUNCT	O	O	2483
was	AUX	O	O	2483
significantly	ADV	O	O	2483
reduced	VERB	O	O	2483
by	ADP	O	O	2483
DSP4	PROPN	O	O	2483
pretreatment	NOUN	O	O	2483
.	PUNCT	O	O	2483
However	ADV	O	O	2484
,	PUNCT	O	O	2484
the	PRON	O	O	2484
increased	VERB	O	O	2484
rearings	VERB	O	O	2484
and	CCONJ	O	O	2484
the	PRON	O	O	2484
amphetamine	NOUN	O	Chemical	2484
-	PUNCT	O	O	2484
induced	VERB	O	O	2484
stereotypies	NOUN	O	Disease	2484
were	AUX	O	O	2484
not	PART	O	O	2484
blocked	VERB	O	O	2484
by	ADP	O	O	2484
pretreatment	NOUN	O	O	2484
with	ADP	O	O	2484
DSP4	PROPN	O	O	2484
.	PUNCT	O	O	2484
The	PRON	O	O	2485
reduction	NOUN	O	O	2485
of	ADP	O	O	2485
amphetamine	NOUN	O	Chemical	2485
hyperactivity	NOUN	O	Disease	2485
induced	VERB	O	O	2485
by	ADP	O	O	2485
DSP4	PROPN	O	O	2485
was	AUX	O	O	2485
blocked	VERB	O	O	2485
by	ADP	O	O	2485
pretreatment	NOUN	O	O	2485
with	ADP	O	O	2485
the	PRON	O	O	2485
noradrenaline	NOUN	O	Chemical	2485
-	PUNCT	O	O	2485
uptake	NOUN	O	O	2485
blocking	VERB	O	O	2485
agent	NOUN	O	O	2485
,	PUNCT	O	O	2485
desipramine	NOUN	O	Chemical	2485
,	PUNCT	O	O	2485
which	PRON	O	O	2485
prevents	VERB	O	O	2485
the	PRON	O	O	2485
neurotoxic	ADJ	O	Disease	2485
action	NOUN	O	O	2485
of	ADP	O	O	2485
DSP4	PROPN	O	O	2485
.	PUNCT	O	O	2485
The	PRON	O	O	2486
present	NOUN	O	O	2486
results	VERB	O	O	2486
suggest	VERB	O	O	2486
a	PRON	O	O	2486
selective	ADJ	O	O	2486
involvement	NOUN	O	O	2486
of	ADP	O	O	2486
central	ADJ	O	O	2486
noradrenergic	ADJ	O	O	2486
neurones	NOUN	O	O	2486
in	ADP	O	O	2486
the	PRON	O	O	2486
locomotor	PROPN	O	O	2486
stimulant	NOUN	O	O	2486
effect	VERB	O	O	2486
of	ADP	O	O	2486
amphetamine	NOUN	O	Chemical	2486
in	ADP	O	O	2486
the	PRON	O	O	2486
rat	NOUN	O	O	2486
.	PUNCT	O	O	2486
Accelerated	VERB	O	O	2489
junctional	ADJ	O	O	2489
rhythms	NOUN	O	O	2489
during	ADP	O	O	2489
oral	ADJ	O	O	2489
verapamil	PROPN	O	Chemical	2489
therapy	NOUN	O	O	2489
.	PUNCT	O	O	2489
This	PRON	O	O	2490
study	VERB	O	O	2490
examined	VERB	O	O	2490
the	PRON	O	O	2490
frequency	NOUN	O	O	2490
of	ADP	O	O	2490
atrioventricular	ADJ	O	O	2490
(	PUNCT	O	O	2490
AV	NOUN	O	O	2490
)	PUNCT	O	O	2490
dissociation	NOUN	O	O	2490
and	CCONJ	O	O	2490
accelerated	VERB	O	O	2490
junctional	ADJ	O	O	2490
rhythms	NOUN	O	O	2490
in	ADP	O	O	2490
59	NUM	O	O	2490
patients	NOUN	O	O	2490
receiving	VERB	O	O	2490
oral	ADJ	O	O	2490
verapamil	PROPN	O	Chemical	2490
.	PUNCT	O	O	2490
Accelerated	VERB	O	O	2491
junctional	ADJ	O	O	2491
rhythms	NOUN	O	O	2491
and	CCONJ	O	O	2491
AV	NOUN	O	O	2491
dissociation	NOUN	O	O	2491
were	AUX	O	O	2491
frequent	ADJ	O	O	2491
in	ADP	O	O	2491
patients	NOUN	O	O	2491
with	ADP	O	O	2491
supraventricular tachyarrhythmias	NOUN	O	O	2491
,	PUNCT	O	O	2491
particularly	ADV	O	O	2491
AV	NOUN	O	O	2491
nodal	ADJ	O	O	2491
reentry	NOUN	O	O	2491
.	PUNCT	O	O	2491
Verapamil	PROPN	O	Chemical	2492
administration	NOUN	O	O	2492
to	PART	O	O	2492
these	PRON	O	O	2492
patients	NOUN	O	O	2492
led	VERB	O	O	2492
to	PART	O	O	2492
an	PRON	O	O	2492
asymptomatic	ADJ	O	O	2492
increase	VERB	O	O	2492
in	ADP	O	O	2492
activity	NOUN	O	O	2492
of	ADP	O	O	2492
these	PRON	O	O	2492
junctional	ADJ	O	O	2492
pacemakers	NOUN	O	O	2492
.	PUNCT	O	O	2492
In	ADP	O	O	2493
patients	NOUN	O	O	2493
with	ADP	O	O	2493
various	ADJ	O	O	2493
chest pain	NOUN	O	Disease	2493
syndromes	NOUN	O	O	2493
,	PUNCT	O	O	2493
verapamil	PROPN	O	Chemical	2493
neither	ADV	O	O	2493
increased	VERB	O	O	2493
the	PRON	O	O	2493
frequency	NOUN	O	O	2493
of	ADP	O	O	2493
junctional	ADJ	O	O	2493
rhythms	NOUN	O	O	2493
nor	CCONJ	O	O	2493
suppressed	VERB	O	O	2493
their	PRON	O	O	2493
role	NOUN	O	O	2493
as	ADP	O	O	2493
escape	VERB	O	O	2493
rhythms	NOUN	O	O	2493
under	ADP	O	O	2493
physiologically	ADV	O	O	2493
appropriate	ADJ	O	O	2493
circumstances	NOUN	O	O	2493
.	PUNCT	O	O	2493
Treatment	NOUN	O	O	2496
of	ADP	O	O	2496
ovarian cancer	NOUN	O	Disease	2496
with	ADP	O	O	2496
a	PRON	O	O	2496
combination	NOUN	O	O	2496
of	ADP	O	O	2496
cis	PROPN	O	O	2496
-	PUNCT	O	O	2496
platinum	NOUN	O	Chemical	2496
,	PUNCT	O	O	2496
adriamycin	PROPN	O	Chemical	2496
,	PUNCT	O	O	2496
cyclophosphamide	VERB	O	Chemical	2496
and	CCONJ	O	O	2496
hexamethylmelamine	NOUN	O	O	2496
.	PUNCT	O	O	2496
During	ADP	O	O	2497
the	PRON	O	O	2497
last	VERB	O	O	2497
2	X	O	O	2497
1/2	NUM	O	O	2497
years	NOUN	O	O	2497
,	PUNCT	O	O	2497
38	NUM	O	O	2497
patients	NOUN	O	O	2497
with	ADP	O	O	2497
ovarian cancer	NOUN	O	Disease	2497
were	AUX	O	O	2497
treated	VERB	O	O	2497
with	ADP	O	O	2497
a	PRON	O	O	2497
combination	NOUN	O	O	2497
of	ADP	O	O	2497
cisplatinum	VERB	O	O	2497
(	PUNCT	O	O	2497
CPDD	PROPN	O	O	2497
)	PUNCT	O	O	2497
,	PUNCT	O	O	2497
50	NUM	O	O	2497
mg	VERB	O	O	2497
/	PUNCT	O	O	2497
m2	PROPN	O	O	2497
,	PUNCT	O	O	2497
adriamycin	PROPN	O	Chemical	2497
,	PUNCT	O	O	2497
30	NUM	O	O	2497
mg	VERB	O	O	2497
/	PUNCT	O	O	2497
m2	PROPN	O	O	2497
,	PUNCT	O	O	2497
cyclophosphamide	VERB	O	Chemical	2497
,	PUNCT	O	O	2497
300	NUM	O	O	2497
mg	VERB	O	O	2497
/	PUNCT	O	O	2497
m2	PROPN	O	O	2497
,	PUNCT	O	O	2497
on	ADP	O	O	2497
day	NOUN	O	O	2497
1	X	O	O	2497
;	PUNCT	O	O	2497
and	CCONJ	O	O	2497
hexamethylmelamine	NOUN	O	O	2497
(	PUNCT	O	O	2497
HMM	PROPN	O	O	2497
)	PUNCT	O	O	2497
,	PUNCT	O	O	2497
6	NUM	O	O	2497
mg	VERB	O	O	2497
/	PUNCT	O	O	2497
kg	VERB	O	O	2497
daily	ADV	O	O	2497
,	PUNCT	O	O	2497
for	ADP	O	O	2497
14	NUM	O	O	2497
days	NOUN	O	O	2497
.	PUNCT	O	O	2497
14	NUM	O	O	2498
of	ADP	O	O	2498
the	PRON	O	O	2498
38	NUM	O	O	2498
patients	NOUN	O	O	2498
were	AUX	O	O	2498
previously	ADV	O	O	2498
treated	VERB	O	O	2498
with	ADP	O	O	2498
chemotherapy	NOUN	O	O	2498
,	PUNCT	O	O	2498
1	X	O	O	2498
with	ADP	O	O	2498
radiation	NOUN	O	O	2498
,	PUNCT	O	O	2498
6	NUM	O	O	2498
with	ADP	O	O	2498
both	PRON	O	O	2498
chemotherapy	NOUN	O	O	2498
and	CCONJ	O	O	2498
radiation	NOUN	O	O	2498
,	PUNCT	O	O	2498
and	CCONJ	O	O	2498
17	NUM	O	O	2498
did	VERB	O	O	2498
not	PART	O	O	2498
have	VERB	O	O	2498
any	PRON	O	O	2498
treatment	NOUN	O	O	2498
before	ADP	O	O	2498
CPDD	PROPN	O	O	2498
combination	NOUN	O	O	2498
.	PUNCT	O	O	2498
Hematologic	PROPN	O	O	2499
toxicity	NOUN	O	Disease	2499
was	AUX	O	O	2499
moderate	ADJ	O	O	2499
and	CCONJ	O	O	2499
with	ADP	O	O	2499
reversible	ADJ	O	O	2499
anemia	NOUN	O	Disease	2499
developing	VERB	O	O	2499
in	ADP	O	O	2499
71%	NOUN	O	O	2499
of	ADP	O	O	2499
patients	NOUN	O	O	2499
.	PUNCT	O	O	2499
Gastrointestinal	ADJ	O	O	2500
side	NOUN	O	O	2500
effects	NOUN	O	O	2500
from	ADP	O	O	2500
CPDD	PROPN	O	O	2500
were	AUX	O	O	2500
universal	ADJ	O	O	2500
.	PUNCT	O	O	2500
HMM	PROPN	O	O	2501
gastrointestinal toxicity	NOUN	O	Disease	2501
necessitated	VERB	O	O	2501
discontinuation	NOUN	O	O	2501
of	ADP	O	O	2501
the	PRON	O	O	2501
drug	NOUN	O	O	2501
in	ADP	O	O	2501
5	NUM	O	O	2501
patients	NOUN	O	O	2501
.	PUNCT	O	O	2501
Severe	ADJ	O	O	2502
nephrotoxicity	NOUN	O	Disease	2502
was	AUX	O	O	2502
observed	VERB	O	O	2502
in	ADP	O	O	2502
2	X	O	O	2502
patients	NOUN	O	O	2502
but	CCONJ	O	O	2502
was	AUX	O	O	2502
reversible	ADJ	O	O	2502
.	PUNCT	O	O	2502
Nontraumatic	ADJ	O	O	2505
dissecting	VERB	O	O	2505
aneurysm	PROPN	O	O	2505
of	ADP	O	O	2505
the	PRON	O	O	2505
basilar	ADJ	O	O	2505
artery	NOUN	O	O	2505
.	PUNCT	O	O	2505
A	PRON	O	O	2506
case	NOUN	O	O	2506
of	ADP	O	O	2506
nontraumatic	ADJ	O	O	2506
dissecting	VERB	O	O	2506
aneurysm	PROPN	O	O	2506
of	ADP	O	O	2506
the	PRON	O	O	2506
basilar	ADJ	O	O	2506
artery	NOUN	O	O	2506
in	ADP	O	O	2506
association	PROPN	O	O	2506
with	ADP	O	O	2506
hypertension	NOUN	O	Disease	2506
,	PUNCT	O	O	2506
smoke	VERB	O	O	2506
,	PUNCT	O	O	2506
and	CCONJ	O	O	2506
oral contraceptives	NOUN	O	Chemical	2506
is	AUX	O	O	2506
reported	VERB	O	O	2506
in	ADP	O	O	2506
a	PRON	O	O	2506
young	ADJ	O	O	2506
female	ADJ	O	O	2506
patient	NOUN	O	O	2506
with	ADP	O	O	2506
a	PRON	O	O	2506
locked	ADJ	O	O	2506
-	PUNCT	O	O	2506
in	ADP	O	O	2506
syndrome	NOUN	O	O	2506
.	PUNCT	O	O	2506
Propylthiouracil	NOUN	O	O	2509
-	PUNCT	O	O	2509
induced	VERB	O	O	2509
hepatic damage	NOUN	O	Disease	2509
.	PUNCT	O	O	2509
Two	NUM	O	O	2510
cases	NOUN	O	O	2510
of	ADP	O	O	2510
propylthiouracil	NOUN	O	Chemical	2510
-	PUNCT	O	O	2510
induced	VERB	O	O	2510
liver damage	NOUN	O	Disease	2510
have	VERB	O	O	2510
been	AUX	O	O	2510
observed	VERB	O	O	2510
.	PUNCT	O	O	2510
The	PRON	O	O	2511
first	ADV	O	O	2511
case	NOUN	O	O	2511
is	AUX	O	O	2511
of	ADP	O	O	2511
an	PRON	O	O	2511
acute	ADJ	O	O	2511
type	NOUN	O	O	2511
of	ADP	O	O	2511
damage	NOUN	O	O	2511
,	PUNCT	O	O	2511
proven	VERB	O	O	2511
by	ADP	O	O	2511
rechallenge	VERB	O	O	2511
;	PUNCT	O	O	2511
the	PRON	O	O	2511
second	ADV	O	O	2511
presents	VERB	O	O	2511
a	PRON	O	O	2511
clinical	ADJ	O	O	2511
and	CCONJ	O	O	2511
histologic	ADJ	O	O	2511
picture	NOUN	O	O	2511
resembling	VERB	O	O	2511
chronic	ADJ	O	O	2511
active	ADJ	O	O	2511
hepatitis	NOUN	O	Disease	2511
,	PUNCT	O	O	2511
with	ADP	O	O	2511
spontaneous	ADJ	O	O	2511
remission	NOUN	O	O	2511
.	PUNCT	O	O	2511
Studies	NOUN	O	O	2514
on	ADP	O	O	2514
the	PRON	O	O	2514
bradycardia	NOUN	O	Disease	2514
induced	VERB	O	O	2514
by	ADP	O	O	2514
bepridil	PROPN	O	O	2514
.	PUNCT	O	O	2514
Bepridil	PROPN	O	O	2515
,	PUNCT	O	O	2515
a	PRON	O	O	2515
novel	NOUN	O	O	2515
active	ADJ	O	O	2515
compound	NOUN	O	O	2515
for	ADP	O	O	2515
prophylactic	ADJ	O	O	2515
treatment	NOUN	O	O	2515
of	ADP	O	O	2515
anginal	PROPN	O	Disease	2515
attacks	NOUN	O	O	2515
,	PUNCT	O	O	2515
induced	VERB	O	O	2515
persistent	ADJ	O	O	2515
bradycardia	NOUN	O	Disease	2515
and	CCONJ	O	O	2515
a	PRON	O	O	2515
non	ADJ	O	O	2515
-	PUNCT	O	O	2515
specific	ADJ	O	O	2515
anti	ADJ	O	O	2515
-	PUNCT	O	O	2515
tachycardial	PROPN	O	O	2515
effect	VERB	O	O	2515
,	PUNCT	O	O	2515
the	PRON	O	O	2515
mechanisms	NOUN	O	O	2515
of	ADP	O	O	2515
which	PRON	O	O	2515
were	AUX	O	O	2515
investigated	VERB	O	O	2515
in	ADP	O	O	2515
vitro	X	O	O	2515
and	CCONJ	O	O	2515
in	ADP	O	O	2515
vivo	VERB	O	O	2515
.	PUNCT	O	O	2515
In	ADP	O	O	2516
vitro	X	O	O	2516
perfusion	NOUN	O	O	2516
of	ADP	O	O	2516
bepridil	PROPN	O	O	2516
in	ADP	O	O	2516
the	PRON	O	O	2516
life	NOUN	O	O	2516
-	PUNCT	O	O	2516
support	NOUN	O	O	2516
medium	ADJ	O	O	2516
for	ADP	O	O	2516
isolated	VERB	O	O	2516
sino	ADJ	O	O	2516
-	PUNCT	O	O	2516
atrial	ADJ	O	O	2516
tissue	NOUN	O	O	2516
from	ADP	O	O	2516
rabbit	NOUN	O	O	2516
heart	NOUN	O	O	2516
,	PUNCT	O	O	2516
caused	VERB	O	O	2516
a	PRON	O	O	2516
reduction	NOUN	O	O	2516
in	ADP	O	O	2516
action	NOUN	O	O	2516
potential	ADJ	O	O	2516
(	PUNCT	O	O	2516
AP	PROPN	O	O	2516
)	PUNCT	O	O	2516
spike	PROPN	O	O	2516
frequency	NOUN	O	O	2516
(	PUNCT	O	O	2516
recorded	VERB	O	O	2516
by	ADP	O	O	2516
KCl	PROPN	O	Chemical	2516
microelectrodes	NOUN	O	O	2516
)	PUNCT	O	O	2516
starting	VERB	O	O	2516
at	ADP	O	O	2516
doses	NOUN	O	O	2516
of	ADP	O	O	2516
5	NUM	O	O	2516
X	NOUN	O	O	2516
10(-6	NUM	O	O	2516
)	PUNCT	O	O	2516
M.	PROPN	O	O	2516
Bepridil	PROPN	O	O	2517
at	ADP	O	O	2517
a	PRON	O	O	2517
dose	NOUN	O	O	2517
of	ADP	O	O	2517
5	NUM	O	O	2517
X	NOUN	O	O	2517
10(-6	NUM	O	O	2517
)	PUNCT	O	O	2517
In	ADP	O	O	2518
vivo	VERB	O	O	2518
injection	NOUN	O	O	2518
of	ADP	O	O	2518
bepridil	PROPN	O	O	2518
at	ADP	O	O	2518
a	PRON	O	O	2518
dose	NOUN	O	O	2518
of	ADP	O	O	2518
5	NUM	O	O	2518
mg	VERB	O	O	2518
/	PUNCT	O	O	2518
kg	VERB	O	O	2518
(	PUNCT	O	O	2518
i.v	NOUN	O	O	2518
.	PUNCT	O	O	2518
)	PUNCT	O	O	2518
It	PRON	O	O	2519
is	AUX	O	O	2519
concluded	VERB	O	O	2519
that	SCONJ	O	O	2519
bepridil	PROPN	O	O	2519
reduces	VERB	O	O	2519
heart	NOUN	O	O	2519
rate	NOUN	O	O	2519
by	ADP	O	O	2519
acting	VERB	O	O	2519
directly	ADV	O	O	2519
on	ADP	O	O	2519
the	PRON	O	O	2519
sinus	NOUN	O	O	2519
node	NOUN	O	O	2519
.	PUNCT	O	O	2519
This	PRON	O	O	2520
effect	VERB	O	O	2520
,	PUNCT	O	O	2520
which	PRON	O	O	2520
results	VERB	O	O	2520
in	ADP	O	O	2520
a	PRON	O	O	2520
flattening	VERB	O	O	2520
of	ADP	O	O	2520
the	PRON	O	O	2520
phase	NOUN	O	O	2520
0	NUM	O	O	2520
and	CCONJ	O	O	2520
phase	NOUN	O	O	2520
4	NUM	O	O	2520
slope	NOUN	O	O	2520
,	PUNCT	O	O	2520
together	ADV	O	O	2520
with	ADP	O	O	2520
a	PRON	O	O	2520
longer	ADV	O	O	2520
AP	PROPN	O	O	2520
duration	NOUN	O	O	2520
,	PUNCT	O	O	2520
may	AUX	O	O	2520
be	AUX	O	O	2520
due	ADJ	O	O	2520
to	PART	O	O	2520
an	PRON	O	O	2520
increase	VERB	O	O	2520
in	ADP	O	O	2520
the	PRON	O	O	2520
time	NOUN	O	O	2520
constants	NOUN	O	O	2520
of	ADP	O	O	2520
slow	VERB	O	O	2520
inward	ADV	O	O	2520
ionic	NOUN	O	O	2520
currents	NOUN	O	O	2520
(	PUNCT	O	O	2520
already	ADV	O	O	2520
demonstrated	VERB	O	O	2520
elsewhere	ADV	O	O	2520
)	PUNCT	O	O	2520
,	PUNCT	O	O	2520
but	CCONJ	O	O	2520
also	ADV	O	O	2520
to	PART	O	O	2520
an	PRON	O	O	2520
increased	VERB	O	O	2520
time	NOUN	O	O	2520
constant	ADJ	O	O	2520
for	ADP	O	O	2520
deactivation	NOUN	O	O	2520
of	ADP	O	O	2520
the	PRON	O	O	2520
outward	ADV	O	O	2520
potassium	NOUN	O	Chemical	2520
current	ADJ	O	O	2520
(	PUNCT	O	O	2520
Ip	NOUN	O	O	2520
)	PUNCT	O	O	2520
.	PUNCT	O	O	2520
Hepatitis	NOUN	O	O	2523
and	CCONJ	O	O	2523
renal	ADJ	O	O	2523
tubular	ADJ	O	O	2523
acidosis	NOUN	O	Disease	2523
after	ADP	O	O	2523
anesthesia	NOUN	O	O	2523
with	ADP	O	O	2523
methoxyflurane	NOUN	O	O	2523
.	PUNCT	O	O	2523
A	PRON	O	O	2524
69-year	NOUN	O	O	2524
-	PUNCT	O	O	2524
old	ADJ	O	O	2524
man	NOUN	O	O	2524
operated	VERB	O	O	2524
for	ADP	O	O	2524
acute	ADJ	O	O	2524
cholecystitis	NOUN	O	O	2524
under	ADP	O	O	2524
methoxyflurane	NOUN	O	O	2524
anesthesia	NOUN	O	O	2524
developed	VERB	O	O	2524
postoperatively	PROPN	O	O	2524
a	PRON	O	O	2524
hepatic	ADJ	O	O	2524
insufficiency	NOUN	O	O	2524
syndrome	NOUN	O	O	2524
and	CCONJ	O	O	2524
renal	ADJ	O	O	2524
tubular	ADJ	O	O	2524
acidosis	NOUN	O	Disease	2524
.	PUNCT	O	O	2524
Massive	ADJ	O	O	2525
bleeding	VERB	O	Disease	2525
appeared	VERB	O	O	2525
during	ADP	O	O	2525
surgery	NOUN	O	O	2525
which	PRON	O	O	2525
lasted	VERB	O	O	2525
for	ADP	O	O	2525
six	NUM	O	O	2525
hours	NOUN	O	O	2525
.	PUNCT	O	O	2525
Pituitary	NOUN	O	O	2528
response	NOUN	O	O	2528
to	PART	O	O	2528
luteinizing	VERB	O	O	2528
hormone	NOUN	O	O	2528
-	PUNCT	O	O	2528
releasing	VERB	O	O	2528
hormone	NOUN	O	O	2528
during	ADP	O	O	2528
haloperidol	NOUN	O	Chemical	2528
-	PUNCT	O	O	2528
induced	VERB	O	O	2528
hyperprolactinemia	NOUN	O	Disease	2528
.	PUNCT	O	O	2528
The	PRON	O	O	2529
effects	NOUN	O	O	2529
of	ADP	O	O	2529
a	PRON	O	O	2529
6-hour	NOUN	O	O	2529
infusion	NOUN	O	O	2529
with	ADP	O	O	2529
haloperidol	NOUN	O	Chemical	2529
on	ADP	O	O	2529
serum	NOUN	O	O	2529
prolactin	PROPN	O	O	2529
and	CCONJ	O	O	2529
luteinizing	VERB	O	O	2529
hormone	NOUN	O	O	2529
(	PUNCT	O	O	2529
LH	PROPN	O	O	2529
)	PUNCT	O	O	2529
Control	NOUN	O	O	2530
patients	NOUN	O	O	2530
received	VERB	O	O	2530
infusions	NOUN	O	O	2530
of	ADP	O	O	2530
0.9%	NOUN	O	O	2530
NaCl	NOUN	O	O	2530
solution	NOUN	O	O	2530
.	PUNCT	O	O	2530
During	ADP	O	O	2531
the	PRON	O	O	2531
course	NOUN	O	O	2531
of	ADP	O	O	2531
haloperidol	NOUN	O	Chemical	2531
infusions	NOUN	O	O	2531
,	PUNCT	O	O	2531
significant	ADJ	O	O	2531
hyperprolactinemia	NOUN	O	Disease	2531
was	AUX	O	O	2531
found	VERB	O	O	2531
,	PUNCT	O	O	2531
together	ADV	O	O	2531
with	ADP	O	O	2531
an	PRON	O	O	2531
abolished	VERB	O	O	2531
pituitary	NOUN	O	O	2531
response	NOUN	O	O	2531
to	PART	O	O	2531
LH	PROPN	O	O	2531
-	PUNCT	O	O	2531
RH	PROPN	O	O	2531
,	PUNCT	O	O	2531
as	ADP	O	O	2531
compared	VERB	O	O	2531
with	ADP	O	O	2531
responses	NOUN	O	O	2531
of	ADP	O	O	2531
control	VERB	O	O	2531
subjects	NOUN	O	O	2531
.	PUNCT	O	O	2531
Antirifampicin	PROPN	O	O	2534
antibodies	NOUN	O	O	2534
in	ADP	O	O	2534
acute	ADJ	O	O	2534
rifampicin	VERB	O	Chemical	2534
-	PUNCT	O	O	2534
associated	VERB	O	O	2534
renal failure	NOUN	O	Disease	2534
.	PUNCT	O	O	2534
5	NUM	O	O	2535
patients	NOUN	O	O	2535
with	ADP	O	O	2535
acute	ADJ	O	O	2535
renal failure	NOUN	O	Disease	2535
(	PUNCT	O	O	2535
3	X	O	O	2535
with	ADP	O	O	2535
thrombopenia	NOUN	O	O	2535
and	CCONJ	O	O	2535
hemolysis	NOUN	O	Disease	2535
)	PUNCT	O	O	2535
induced	VERB	O	O	2535
by	ADP	O	O	2535
the	PRON	O	O	2535
reintroduction	NOUN	O	O	2535
of	ADP	O	O	2535
rifampicin	VERB	O	Chemical	2535
are	AUX	O	O	2535
described	VERB	O	O	2535
.	PUNCT	O	O	2535
Antibodies	NOUN	O	O	2536
suggested	VERB	O	O	2536
to	PART	O	O	2536
be	AUX	O	O	2536
of	ADP	O	O	2536
the	PRON	O	O	2536
IgM	PROPN	O	O	2536
class	NOUN	O	O	2536
were	AUX	O	O	2536
detected	VERB	O	O	2536
in	ADP	O	O	2536
all	PRON	O	O	2536
3	X	O	O	2536
patients	NOUN	O	O	2536
with	ADP	O	O	2536
hematological disorders	NOUN	O	Disease	2536
.	PUNCT	O	O	2536
The	PRON	O	O	2537
pattern	NOUN	O	O	2537
of	ADP	O	O	2537
non	ADJ	O	O	2537
-	PUNCT	O	O	2537
specific	ADJ	O	O	2537
acute	ADJ	O	O	2537
tubular necrosis	NOUN	O	Disease	2537
found	VERB	O	O	2537
in	ADP	O	O	2537
the	PRON	O	O	2537
2	X	O	O	2537
biopsied	VERB	O	O	2537
patients	NOUN	O	O	2537
,	PUNCT	O	O	2537
indistinguishable	ADJ	O	O	2537
from	ADP	O	O	2537
that	SCONJ	O	O	2537
of	ADP	O	O	2537
ischemic	VERB	O	Disease	2537
origin	NOUN	O	O	2537
,	PUNCT	O	O	2537
raised	VERB	O	O	2537
the	PRON	O	O	2537
possibility	NOUN	O	O	2537
of	ADP	O	O	2537
a	PRON	O	O	2537
vascular	ADJ	O	O	2537
-	PUNCT	O	O	2537
mediated	VERB	O	O	2537
damage	NOUN	O	O	2537
.	PUNCT	O	O	2537
Cardiovascular	NOUN	O	O	2540
effects	NOUN	O	O	2540
of	ADP	O	O	2540
hypotension	NOUN	O	Disease	2540
induced	VERB	O	O	2540
by	ADP	O	O	2540
adenosine	PROPN	O	Chemical	2540
triphosphate	NOUN	O	O	2540
and	CCONJ	O	O	2540
sodium	NOUN	O	Chemical	2540
nitroprusside	ADV	O	Chemical	2540
on	ADP	O	O	2540
dogs	NOUN	O	O	2540
with	ADP	O	O	2540
denervated	VERB	O	O	2540
hearts	NOUN	O	O	2540
.	PUNCT	O	O	2540
Adenosine	NOUN	O	Chemical	2541
triphosphate	NOUN	O	O	2541
(	PUNCT	O	O	2541
ATP	PROPN	O	Chemical	2541
)	PUNCT	O	O	2541
and	CCONJ	O	O	2541
sodium	NOUN	O	Chemical	2541
nitroprusside	ADV	O	Chemical	2541
(	PUNCT	O	O	2541
SNP	PROPN	O	O	2541
)	PUNCT	O	O	2541
are	AUX	O	O	2541
administered	VERB	O	O	2541
to	PART	O	O	2541
patients	NOUN	O	O	2541
to	PART	O	O	2541
induce	VERB	O	O	2541
and	CCONJ	O	O	2541
control	VERB	O	O	2541
hypotension	NOUN	O	Disease	2541
during	ADP	O	O	2541
anesthesia	NOUN	O	O	2541
.	PUNCT	O	O	2541
SNP	PROPN	O	O	2542
is	AUX	O	O	2542
authorized	VERB	O	O	2542
for	ADP	O	O	2542
clinical	ADJ	O	O	2542
use	VERB	O	O	2542
in	ADP	O	O	2542
USA	PROPN	O	O	2542
and	CCONJ	O	O	2542
UK	PROPN	O	O	2542
,	PUNCT	O	O	2542
and	CCONJ	O	O	2542
ATP	PROPN	O	Chemical	2542
is	AUX	O	O	2542
clinically	ADV	O	O	2542
used	VERB	O	O	2542
in	ADP	O	O	2542
other	ADJ	O	O	2542
countries	NOUN	O	O	2542
such	ADJ	O	O	2542
as	ADP	O	O	2542
Japan	PROPN	O	O	2542
.	PUNCT	O	O	2542
ATP	PROPN	O	Chemical	2543
(	PUNCT	O	O	2543
10	NUM	O	O	2543
dogs	NOUN	O	O	2543
)	PUNCT	O	O	2543
or	CCONJ	O	O	2543
SNP	PROPN	O	O	2543
(	PUNCT	O	O	2543
10	NUM	O	O	2543
dogs	NOUN	O	O	2543
)	PUNCT	O	O	2543
was	AUX	O	O	2543
administered	VERB	O	O	2543
to	PART	O	O	2543
reduce	VERB	O	O	2543
mean	VERB	O	O	2543
arterial	ADJ	O	O	2543
pressure	NOUN	O	O	2543
by	ADP	O	O	2543
30%	NOUN	O	O	2543
to	PART	O	O	2543
70%	NOUN	O	O	2543
of	ADP	O	O	2543
control	VERB	O	O	2543
.	PUNCT	O	O	2543
Before	ADP	O	O	2544
,	PUNCT	O	O	2544
during	ADP	O	O	2544
and	CCONJ	O	O	2544
after	ADP	O	O	2544
induced	VERB	O	O	2544
hypotension	NOUN	O	Disease	2544
,	PUNCT	O	O	2544
we	PRON	O	O	2544
measured	VERB	O	O	2544
major	ADJ	O	O	2544
cardiovascular	ADJ	O	O	2544
parameters	NOUN	O	O	2544
.	PUNCT	O	O	2544
Hypotension	NOUN	O	Disease	2545
induced	VERB	O	O	2545
by	ADP	O	O	2545
ATP	PROPN	O	Chemical	2545
was	AUX	O	O	2545
accompanied	VERB	O	O	2545
by	ADP	O	O	2545
significant	ADJ	O	O	2545
decreases	VERB	O	O	2545
in	ADP	O	O	2545
mean	VERB	O	O	2545
pulmonary	ADJ	O	O	2545
arterial	ADJ	O	O	2545
pressure	NOUN	O	O	2545
(	PUNCT	O	O	2545
p	NOUN	O	O	2545
less	ADV	O	O	2545
than	ADP	O	O	2545
0.001	NUM	O	O	2545
)	PUNCT	O	O	2545
,	PUNCT	O	O	2545
central	ADJ	O	O	2545
venous	ADJ	O	O	2545
pressure	NOUN	O	O	2545
(	PUNCT	O	O	2545
p	NOUN	O	O	2545
less	ADV	O	O	2545
than	ADP	O	O	2545
0.001	NUM	O	O	2545
)	PUNCT	O	O	2545
,	PUNCT	O	O	2545
left	VERB	O	O	2545
ventricular	ADJ	O	O	2545
end	VERB	O	O	2545
-	PUNCT	O	O	2545
diastolic	ADV	O	O	2545
pressure	NOUN	O	O	2545
(	PUNCT	O	O	2545
p	NOUN	O	O	2545
less	ADV	O	O	2545
than	ADP	O	O	2545
0.001	NUM	O	O	2545
)	PUNCT	O	O	2545
,	PUNCT	O	O	2545
total	ADJ	O	O	2545
peripheral	ADJ	O	O	2545
resistance	NOUN	O	O	2545
(	PUNCT	O	O	2545
p	NOUN	O	O	2545
less	ADV	O	O	2545
than	ADP	O	O	2545
0.001	NUM	O	O	2545
)	PUNCT	O	O	2545
,	PUNCT	O	O	2545
rate	NOUN	O	O	2545
pressure	NOUN	O	O	2545
product	NOUN	O	O	2545
(	PUNCT	O	O	2545
p	NOUN	O	O	2545
less	ADV	O	O	2545
than	ADP	O	O	2545
0.001	NUM	O	O	2545
)	PUNCT	O	O	2545
,	PUNCT	O	O	2545
total	ADJ	O	O	2545
body	NOUN	O	O	2545
oxygen	NOUN	O	Chemical	2545
consumption	NOUN	O	O	2545
(	PUNCT	O	O	2545
p	NOUN	O	O	2545
less	ADV	O	O	2545
than	ADP	O	O	2545
0.05	NUM	O	O	2545
)	PUNCT	O	O	2545
,	PUNCT	O	O	2545
and	CCONJ	O	O	2545
heart	NOUN	O	O	2545
rate	NOUN	O	O	2545
(	PUNCT	O	O	2545
p	NOUN	O	O	2545
less	ADV	O	O	2545
than	ADP	O	O	2545
0.001	NUM	O	O	2545
)	PUNCT	O	O	2545
;	PUNCT	O	O	2545
all	PRON	O	O	2545
these	PRON	O	O	2545
variables	NOUN	O	O	2545
returned	VERB	O	O	2545
normal	ADJ	O	O	2545
within	ADP	O	O	2545
30	NUM	O	O	2545
min	NOUN	O	O	2545
after	ADP	O	O	2545
ATP	PROPN	O	Chemical	2545
was	AUX	O	O	2545
stopped	VERB	O	O	2545
.	PUNCT	O	O	2545
During	ADP	O	O	2546
hypotension	NOUN	O	Disease	2546
produced	VERB	O	O	2546
by	ADP	O	O	2546
SNP	PROPN	O	O	2546
similar	ADJ	O	O	2546
decreases	VERB	O	O	2546
were	AUX	O	O	2546
observed	VERB	O	O	2546
in	ADP	O	O	2546
mean	VERB	O	O	2546
pulmonary	ADJ	O	O	2546
arterial	ADJ	O	O	2546
pressure	NOUN	O	O	2546
(	PUNCT	O	O	2546
p	NOUN	O	O	2546
less	ADV	O	O	2546
than	ADP	O	O	2546
0.01	NUM	O	O	2546
)	PUNCT	O	O	2546
,	PUNCT	O	O	2546
central	ADJ	O	O	2546
venous	ADJ	O	O	2546
pressure	NOUN	O	O	2546
(	PUNCT	O	O	2546
p	NOUN	O	O	2546
less	ADV	O	O	2546
than	ADP	O	O	2546
0.001	NUM	O	O	2546
)	PUNCT	O	O	2546
,	PUNCT	O	O	2546
left	VERB	O	O	2546
ventricular	ADJ	O	O	2546
end	VERB	O	O	2546
-	PUNCT	O	O	2546
diastolic	ADV	O	O	2546
pressure	NOUN	O	O	2546
(	PUNCT	O	O	2546
p	NOUN	O	O	2546
less	ADV	O	O	2546
than	ADP	O	O	2546
0.01	NUM	O	O	2546
)	PUNCT	O	O	2546
,	PUNCT	O	O	2546
total	ADJ	O	O	2546
peripheral	ADJ	O	O	2546
resistance	NOUN	O	O	2546
(	PUNCT	O	O	2546
p	NOUN	O	O	2546
less	ADV	O	O	2546
than	ADP	O	O	2546
0.001	NUM	O	O	2546
)	PUNCT	O	O	2546
,	PUNCT	O	O	2546
rate	NOUN	O	O	2546
pressure	NOUN	O	O	2546
product	NOUN	O	O	2546
(	PUNCT	O	O	2546
p	NOUN	O	O	2546
less	ADV	O	O	2546
than	ADP	O	O	2546
0.001	NUM	O	O	2546
)	PUNCT	O	O	2546
,	PUNCT	O	O	2546
and	CCONJ	O	O	2546
oxygen	NOUN	O	Chemical	2546
content	NOUN	O	O	2546
difference	NOUN	O	O	2546
between	ADP	O	O	2546
arterial	ADJ	O	O	2546
and	CCONJ	O	O	2546
mixed	VERB	O	O	2546
venous	ADJ	O	O	2546
blood	NOUN	O	O	2546
(	PUNCT	O	O	2546
p	NOUN	O	O	2546
less	ADV	O	O	2546
than	ADP	O	O	2546
0.05	NUM	O	O	2546
)	PUNCT	O	O	2546
,	PUNCT	O	O	2546
while	SCONJ	O	O	2546
heart	NOUN	O	O	2546
rate	NOUN	O	O	2546
(	PUNCT	O	O	2546
p	NOUN	O	O	2546
less	ADV	O	O	2546
than	ADP	O	O	2546
0.001	NUM	O	O	2546
)	PUNCT	O	O	2546
and	CCONJ	O	O	2546
cardiac	ADJ	O	O	2546
output	NOUN	O	O	2546
(	PUNCT	O	O	2546
p	NOUN	O	O	2546
less	ADV	O	O	2546
than	ADP	O	O	2546
0.05	NUM	O	O	2546
)	PUNCT	O	O	2546
were	AUX	O	O	2546
increased	VERB	O	O	2546
.	PUNCT	O	O	2546
Recoveries	NOUN	O	O	2547
of	ADP	O	O	2547
heart	NOUN	O	O	2547
rate	NOUN	O	O	2547
and	CCONJ	O	O	2547
left	VERB	O	O	2547
ventricular	ADJ	O	O	2547
end	VERB	O	O	2547
-	PUNCT	O	O	2547
diastolic	ADV	O	O	2547
pressure	NOUN	O	O	2547
were	AUX	O	O	2547
not	PART	O	O	2547
shown	VERB	O	O	2547
within	ADP	O	O	2547
60	NUM	O	O	2547
min	NOUN	O	O	2547
after	ADP	O	O	2547
SNP	PROPN	O	O	2547
had	VERB	O	O	2547
been	AUX	O	O	2547
stopped	VERB	O	O	2547
.	PUNCT	O	O	2547
Both	PRON	O	O	2548
ATP	PROPN	O	Chemical	2548
and	CCONJ	O	O	2548
SNP	PROPN	O	O	2548
should	AUX	O	O	2548
act	VERB	O	O	2548
on	ADP	O	O	2548
the	PRON	O	O	2548
pacemaker	NOUN	O	O	2548
tissue	NOUN	O	O	2548
of	ADP	O	O	2548
the	PRON	O	O	2548
heart	NOUN	O	O	2548
.	PUNCT	O	O	2548
Comparative	ADJ	O	O	2551
study	VERB	O	O	2551
:	PUNCT	O	O	2551
Endografine	NOUN	O	O	2551
(	PUNCT	O	O	2551
diatrizoate	ADJ	O	Chemical	2551
)	PUNCT	O	O	2551
,	PUNCT	O	O	2551
Vasurix	PROPN	O	O	2551
polyvidone	ADJ	O	O	2551
(	PUNCT	O	O	2551
acetrizoate	NOUN	O	O	2551
)	PUNCT	O	O	2551
,	PUNCT	O	O	2551
Dimer	NOUN	O	O	2551
-	PUNCT	O	O	2551
X	NOUN	O	O	2551
(	PUNCT	O	O	2551
iocarmate	ADJ	O	O	2551
)	PUNCT	O	O	2551
and	CCONJ	O	O	2551
Hexabrix	PROPN	O	O	2551
(	PUNCT	O	O	2551
ioxaglate	ADJ	O	O	2551
)	PUNCT	O	O	2551
in	ADP	O	O	2551
hysterosalpingography	NOUN	O	O	2551
.	PUNCT	O	O	2551
Side	NOUN	O	O	2552
effects	NOUN	O	O	2552
of	ADP	O	O	2552
hysterosalpingography	NOUN	O	O	2552
with	ADP	O	O	2552
Dimer	NOUN	O	O	2552
-	PUNCT	O	O	2552
X	NOUN	O	O	2552
,	PUNCT	O	O	2552
Hexabrix	PROPN	O	O	2552
,	PUNCT	O	O	2552
Vasurix	PROPN	O	O	2552
polyvidone	ADJ	O	O	2552
and	CCONJ	O	O	2552
Endografine	NOUN	O	O	2552
in	ADP	O	O	2552
142	NUM	O	O	2552
consecutive	ADJ	O	O	2552
patients	NOUN	O	O	2552
,	PUNCT	O	O	2552
receiving	VERB	O	O	2552
one	NUM	O	O	2552
of	ADP	O	O	2552
the	PRON	O	O	2552
four	NUM	O	O	2552
tested	VERB	O	O	2552
media	NOUN	O	O	2552
were	AUX	O	O	2552
evaluated	VERB	O	O	2552
from	ADP	O	O	2552
replies	VERB	O	O	2552
to	PART	O	O	2552
postal	NOUN	O	O	2552
questionnaires	NOUN	O	O	2552
.	PUNCT	O	O	2552
The	PRON	O	O	2553
Dimer	NOUN	O	O	2553
-	PUNCT	O	O	2553
X	NOUN	O	O	2553
group	NOUN	O	O	2553
had	VERB	O	O	2553
a	PRON	O	O	2553
higher	ADJ	O	O	2553
incidence	NOUN	O	O	2553
of	ADP	O	O	2553
nausea	NOUN	O	Disease	2553
and	CCONJ	O	O	2553
dizziness	NOUN	O	Disease	2553
.	PUNCT	O	O	2553
The	PRON	O	O	2554
Endografine	NOUN	O	O	2554
group	NOUN	O	O	2554
had	VERB	O	O	2554
a	PRON	O	O	2554
higher	ADJ	O	O	2554
incidence	NOUN	O	O	2554
of	ADP	O	O	2554
abdominal pain	NOUN	O	Disease	2554
.	PUNCT	O	O	2554
Hexabrix	PROPN	O	O	2555
and	CCONJ	O	O	2555
Vasurix	PROPN	O	O	2555
polyvidone	ADJ	O	O	2555
are	AUX	O	O	2555
considered	VERB	O	O	2555
the	PRON	O	O	2555
best	ADV	O	O	2555
contrast media	NOUN	O	Chemical	2555
for	ADP	O	O	2555
hysterosalpingography	NOUN	O	O	2555
and	CCONJ	O	O	2555
perhaps	ADV	O	O	2555
because	SCONJ	O	O	2555
of	ADP	O	O	2555
its	PRON	O	O	2555
low	ADJ	O	O	2555
toxicity	NOUN	O	Disease	2555
Hexabrix	PROPN	O	O	2555
should	AUX	O	O	2555
be	AUX	O	O	2555
preferred	VERB	O	O	2555
.	PUNCT	O	O	2555
Post	NOUN	O	O	2558
-	PUNCT	O	O	2558
suxamethonium	NOUN	O	O	2558
pains	NOUN	O	O	2558
in	ADP	O	O	2558
Nigerian	PROPN	O	O	2558
surgical	ADJ	O	O	2558
patients	NOUN	O	O	2558
.	PUNCT	O	O	2558
Contrary	ADV	O	O	2559
to	PART	O	O	2559
an	PRON	O	O	2559
earlier	ADV	O	O	2559
report	VERB	O	O	2559
by	ADP	O	O	2559
Coxon	PROPN	O	O	2559
,	PUNCT	O	O	2559
scoline	VERB	O	O	2559
pain	NOUN	O	Disease	2559
occurs	VERB	O	O	2559
in	ADP	O	O	2559
African	ADJ	O	O	2559
negroes	NOUN	O	O	2559
.	PUNCT	O	O	2559
About	ADP	O	O	2560
62%	NOUN	O	O	2560
of	ADP	O	O	2560
the	PRON	O	O	2560
out	ADP	O	O	2560
-	PUNCT	O	O	2560
patients	NOUN	O	O	2560
developed	VERB	O	O	2560
scoline	VERB	O	O	2560
pain	NOUN	O	Disease	2560
as	ADP	O	O	2560
compared	VERB	O	O	2560
with	ADP	O	O	2560
about	ADP	O	O	2560
26%	NOUN	O	O	2560
among	ADP	O	O	2560
the	PRON	O	O	2560
in	ADP	O	O	2560
-	PUNCT	O	O	2560
patients	NOUN	O	O	2560
.	PUNCT	O	O	2560
The	PRON	O	O	2561
abolition	PROPN	O	O	2561
of	ADP	O	O	2561
muscle fasciculations	NOUN	O	O	2561
(	PUNCT	O	O	2561
by	ADP	O	O	2561
0.075mg	NUM	O	O	2561
/	PUNCT	O	O	2561
kg	VERB	O	O	2561
dose	NOUN	O	O	2561
of	ADP	O	O	2561
Fazadinium	NOUN	O	O	2561
)	PUNCT	O	O	2561
did	VERB	O	O	2561
not	PART	O	O	2561
influence	NOUN	O	O	2561
the	PRON	O	O	2561
occurrence	NOUN	O	O	2561
of	ADP	O	O	2561
scoline	VERB	O	O	2561
pain	NOUN	O	Disease	2561
.	PUNCT	O	O	2561
Neither	PRON	O	O	2562
the	PRON	O	O	2562
type	NOUN	O	O	2562
of	ADP	O	O	2562
induction	NOUN	O	O	2562
agent	NOUN	O	O	2562
(	PUNCT	O	O	2562
Althesin	PROPN	O	O	2562
or	CCONJ	O	O	2562
Thiopentone	NOUN	O	O	2562
)	PUNCT	O	O	2562
nor	CCONJ	O	O	2562
the	PRON	O	O	2562
salt	NOUN	O	O	2562
preparation	NOUN	O	O	2562
of	ADP	O	O	2562
suxamethonium	NOUN	O	O	2562
used	VERB	O	O	2562
(	PUNCT	O	O	2562
chloride	NOUN	O	Chemical	2562
or	CCONJ	O	O	2562
bromide	NOUN	O	O	2562
)	PUNCT	O	O	2562
,	PUNCT	O	O	2562
affected	VERB	O	O	2562
the	PRON	O	O	2562
incidence	NOUN	O	O	2562
of	ADP	O	O	2562
scoline	VERB	O	O	2562
pain	NOUN	O	Disease	2562
.	PUNCT	O	O	2562
Medial	ADJ	O	O	2565
changes	VERB	O	O	2565
in	ADP	O	O	2565
arterial	ADJ	O	O	2565
spasm	NOUN	O	Disease	2565
induced	VERB	O	O	2565
by	ADP	O	O	2565
L	NOUN	O	O	2565
-	PUNCT	O	O	2565
norepinephrine	NOUN	O	Chemical	2565
.	PUNCT	O	O	2565
In	ADP	O	O	2566
the	PRON	O	O	2566
media	NOUN	O	O	2566
of	ADP	O	O	2566
the	PRON	O	O	2566
saphenous	ADJ	O	O	2566
artery	NOUN	O	O	2566
and	CCONJ	O	O	2566
its	PRON	O	O	2566
distal	NOUN	O	O	2566
branch	NOUN	O	O	2566
,	PUNCT	O	O	2566
vasoconstriction	NOUN	O	O	2566
induced	VERB	O	O	2566
by	ADP	O	O	2566
L	NOUN	O	O	2566
-	PUNCT	O	O	2566
norepinephrine	NOUN	O	Chemical	2566
produced	VERB	O	O	2566
many	ADJ	O	O	2566
cell	NOUN	O	O	2566
-	PUNCT	O	O	2566
to	PART	O	O	2566
-	PUNCT	O	O	2566
cell	NOUN	O	O	2566
hernias	NOUN	O	O	2566
within	ADP	O	O	2566
15	NUM	O	O	2566
minutes	NOUN	O	O	2566
.	PUNCT	O	O	2566
The	PRON	O	O	2567
experimental	ADJ	O	O	2567
data	NOUN	O	O	2567
are	AUX	O	O	2567
discussed	VERB	O	O	2567
in	ADP	O	O	2567
relation	NOUN	O	O	2567
to	PART	O	O	2567
medial	ADJ	O	O	2567
changes	VERB	O	O	2567
observed	VERB	O	O	2567
in	ADP	O	O	2567
other	ADJ	O	O	2567
instances	NOUN	O	O	2567
of	ADP	O	O	2567
arterial	ADJ	O	O	2567
spasm	NOUN	O	Disease	2567
.	PUNCT	O	O	2567
Abnormalities	NOUN	O	O	2570
of	ADP	O	O	2570
the	PRON	O	O	2570
pupil	NOUN	O	O	2570
and	CCONJ	O	O	2570
visual	ADJ	O	O	2570
-	PUNCT	O	O	2570
evoked	VERB	O	O	2570
potential	ADJ	O	O	2570
in	ADP	O	O	2570
quinine	NOUN	O	Chemical	2570
amblyopia	NOUN	O	O	2570
.	PUNCT	O	O	2570
Total	ADJ	O	O	2571
blindness	NOUN	O	Disease	2571
with	ADP	O	O	2571
a	PRON	O	O	2571
transient	ADJ	O	O	2571
tonic	PROPN	O	O	2571
pupillary	ADJ	O	O	2571
response	NOUN	O	O	2571
,	PUNCT	O	O	2571
denervation	NOUN	O	O	2571
supersensitivity	NOUN	O	O	2571
,	PUNCT	O	O	2571
and	CCONJ	O	O	2571
abnormal	ADJ	O	O	2571
visual	ADJ	O	O	2571
-	PUNCT	O	O	2571
evoked	VERB	O	O	2571
potentials	NOUN	O	O	2571
developed	VERB	O	O	2571
in	ADP	O	O	2571
a	PRON	O	O	2571
54-year	NOUN	O	O	2571
-	PUNCT	O	O	2571
old	ADJ	O	O	2571
man	NOUN	O	O	2571
after	ADP	O	O	2571
the	PRON	O	O	2571
use	VERB	O	O	2571
of	ADP	O	O	2571
quinine	NOUN	O	Chemical	2571
sulfate	NOUN	O	O	2571
for	ADP	O	O	2571
leg	NOUN	O	O	2571
cramps	NOUN	O	O	2571
.	PUNCT	O	O	2571
A	PRON	O	O	2572
transient	ADJ	O	O	2572
tonic	PROPN	O	O	2572
pupillary	ADJ	O	O	2572
response	NOUN	O	O	2572
,	PUNCT	O	O	2572
denervation	NOUN	O	O	2572
supersensitivity	NOUN	O	O	2572
,	PUNCT	O	O	2572
and	CCONJ	O	O	2572
abnormal	ADJ	O	O	2572
visual	ADJ	O	O	2572
-	PUNCT	O	O	2572
evoked	VERB	O	O	2572
potentials	NOUN	O	O	2572
in	ADP	O	O	2572
quinine	NOUN	O	Chemical	2572
toxicity	NOUN	O	Disease	2572
,	PUNCT	O	O	2572
to	PART	O	O	2572
our	PRON	O	O	2572
knowledge	NOUN	O	O	2572
,	PUNCT	O	O	2572
have	VERB	O	O	2572
not	PART	O	O	2572
been	AUX	O	O	2572
previously	ADV	O	O	2572
reported	VERB	O	O	2572
.	PUNCT	O	O	2572
Suxamethonium	NOUN	O	O	2575
-	PUNCT	O	O	2575
induced	VERB	O	O	2575
jaw	INTJ	O	O	2575
stiffness	VERB	O	O	2575
and	CCONJ	O	O	2575
myalgia	NOUN	O	Disease	2575
associated	VERB	O	O	2575
with	ADP	O	O	2575
atypical	ADJ	O	O	2575
cholinesterase	NOUN	O	O	2575
:	PUNCT	O	O	2575
case	NOUN	O	O	2575
report	VERB	O	O	2575
.	PUNCT	O	O	2575
An	PRON	O	O	2576
11-year	NOUN	O	O	2576
-	PUNCT	O	O	2576
old	ADJ	O	O	2576
boy	NOUN	O	O	2576
was	AUX	O	O	2576
given	VERB	O	O	2576
halothane	VERB	O	Chemical	2576
,	PUNCT	O	O	2576
nitrous oxide	NOUN	O	Chemical	2576
and	CCONJ	O	O	2576
oxygen	NOUN	O	Chemical	2576
,	PUNCT	O	O	2576
pancuronium	VERB	O	O	2576
0.4	NUM	O	O	2576
mg	VERB	O	O	2576
and	CCONJ	O	O	2576
suxamethonium	NOUN	O	O	2576
100	NUM	O	O	2576
mg	VERB	O	O	2576
for	ADP	O	O	2576
induction	NOUN	O	O	2576
of	ADP	O	O	2576
anaesthesia	NOUN	O	O	2576
.	PUNCT	O	O	2576
In	ADP	O	O	2577
response	NOUN	O	O	2577
to	PART	O	O	2577
this	PRON	O	O	2577
a	PRON	O	O	2577
marked	VERB	O	O	2577
jaw	INTJ	O	O	2577
stiffness	VERB	O	O	2577
occurred	VERB	O	O	2577
which	PRON	O	O	2577
lasted	VERB	O	O	2577
for	ADP	O	O	2577
two	NUM	O	O	2577
minutes	NOUN	O	O	2577
and	CCONJ	O	O	2577
the	PRON	O	O	2577
anaesthesia	NOUN	O	O	2577
were	AUX	O	O	2577
terminated	VERB	O	O	2577
.	PUNCT	O	O	2577
Four	NUM	O	O	2578
hours	NOUN	O	O	2578
of	ADP	O	O	2578
apnoea	NOUN	O	Disease	2578
ensued	VERB	O	O	2578
and	CCONJ	O	O	2578
he	PRON	O	O	2578
suffered	VERB	O	O	2578
generalized	VERB	O	O	2578
severe	ADJ	O	O	2578
myalgia	NOUN	O	Disease	2578
lasting	VERB	O	O	2578
for	ADP	O	O	2578
one	NUM	O	O	2578
week	NOUN	O	O	2578
.	PUNCT	O	O	2578
He	PRON	O	O	2579
was	AUX	O	O	2579
found	VERB	O	O	2579
to	PART	O	O	2579
have	VERB	O	O	2579
atypical	ADJ	O	O	2579
plasma	NOUN	O	O	2579
cholinesterase	NOUN	O	O	2579
with	ADP	O	O	2579
a	PRON	O	O	2579
dibucaine	PROPN	O	O	2579
number	NOUN	O	O	2579
of	ADP	O	O	2579
12	NUM	O	O	2579
,	PUNCT	O	O	2579
indicating	VERB	O	O	2579
homozygocity	NOUN	O	O	2579
.	PUNCT	O	O	2579
The	PRON	O	O	2580
case	NOUN	O	O	2580
shows	VERB	O	O	2580
that	SCONJ	O	O	2580
prolonged	VERB	O	O	2580
jaw	INTJ	O	O	2580
rigidity	NOUN	O	Disease	2580
and	CCONJ	O	O	2580
myalgia	NOUN	O	Disease	2580
may	AUX	O	O	2580
occur	VERB	O	O	2580
after	ADP	O	O	2580
suxamethonium	NOUN	O	O	2580
in	ADP	O	O	2580
patients	NOUN	O	O	2580
with	ADP	O	O	2580
atypical	ADJ	O	O	2580
cholinesterase	NOUN	O	O	2580
despite	SCONJ	O	O	2580
pretreatment	NOUN	O	O	2580
with	ADP	O	O	2580
pancuronium	VERB	O	O	2580
.	PUNCT	O	O	2580
Indomethacin	PROPN	O	Chemical	2583
-	PUNCT	O	O	2583
induced	VERB	O	O	2583
hyperkalemia	NOUN	O	O	2583
in	ADP	O	O	2583
three	NUM	O	O	2583
patients	NOUN	O	O	2583
with	ADP	O	O	2583
gouty	PROPN	O	O	2583
arthritis	NOUN	O	Disease	2583
.	PUNCT	O	O	2583
We	PRON	O	O	2584
describe	VERB	O	O	2584
three	NUM	O	O	2584
patients	NOUN	O	O	2584
in	ADP	O	O	2584
whom	PRON	O	O	2584
severe	ADJ	O	O	2584
,	PUNCT	O	O	2584
life	NOUN	O	O	2584
-	PUNCT	O	O	2584
threatening	VERB	O	O	2584
hyperkalemia	NOUN	O	O	2584
and	CCONJ	O	O	2584
renal insufficiency	NOUN	O	Disease	2584
developed	VERB	O	O	2584
after	ADP	O	O	2584
treatment	NOUN	O	O	2584
of	ADP	O	O	2584
acute	ADJ	O	O	2584
gouty	PROPN	O	O	2584
arthritis	NOUN	O	Disease	2584
with	ADP	O	O	2584
indomethacin	VERB	O	Chemical	2584
.	PUNCT	O	O	2584
This	PRON	O	O	2585
complication	NOUN	O	O	2585
may	AUX	O	O	2585
result	VERB	O	O	2585
from	ADP	O	O	2585
an	PRON	O	O	2585
inhibition	NOUN	O	O	2585
of	ADP	O	O	2585
prostaglandin	NOUN	O	Chemical	2585
synthesis	NOUN	O	O	2585
and	CCONJ	O	O	2585
consequent	NOUN	O	O	2585
hyporeninemic	ADJ	O	O	2585
hypoaidosteronism	NOUN	O	O	2585
.	PUNCT	O	O	2585
Careful	ADJ	O	O	2586
attention	NOUN	O	O	2586
to	PART	O	O	2586
renal	ADJ	O	O	2586
function	NOUN	O	O	2586
and	CCONJ	O	O	2586
potassium	NOUN	O	Chemical	2586
balance	NOUN	O	O	2586
in	ADP	O	O	2586
patients	NOUN	O	O	2586
receiving	VERB	O	O	2586
indomethacin	VERB	O	Chemical	2586
or	CCONJ	O	O	2586
other	ADJ	O	O	2586
nonsteroidal	ADJ	O	O	2586
anti	ADJ	O	O	2586
-	PUNCT	O	O	2586
inflammatory	ADJ	O	O	2586
agents	NOUN	O	O	2586
,	PUNCT	O	O	2586
particularly	ADV	O	O	2586
in	ADP	O	O	2586
those	PRON	O	O	2586
patients	NOUN	O	O	2586
with	ADP	O	O	2586
diabetes mellitus	ADJ	O	Disease	2586
or	CCONJ	O	O	2586
preexisting	VERB	O	O	2586
renal disease	NOUN	O	Disease	2586
,	PUNCT	O	O	2586
will	AUX	O	O	2586
help	VERB	O	O	2586
prevent	VERB	O	O	2586
this	PRON	O	O	2586
potentially	ADV	O	O	2586
serious	ADJ	O	O	2586
complication	NOUN	O	O	2586
.	PUNCT	O	O	2586
Etomidate	NOUN	O	O	2589
:	PUNCT	O	O	2589
a	PRON	O	O	2589
foreshortened	VERB	O	O	2589
clinical	ADJ	O	O	2589
trial	NOUN	O	O	2589
.	PUNCT	O	O	2589
A	PRON	O	O	2590
clinical	ADJ	O	O	2590
evaluation	NOUN	O	O	2590
of	ADP	O	O	2590
etomidate	VERB	O	Chemical	2590
for	ADP	O	O	2590
outpatient	NOUN	O	O	2590
cystoscopy	VERB	O	O	2590
was	AUX	O	O	2590
embarked	VERB	O	O	2590
upon	SCONJ	O	O	2590
.	PUNCT	O	O	2590
Unpremedicated	PROPN	O	O	2591
patients	NOUN	O	O	2591
were	AUX	O	O	2591
given	VERB	O	O	2591
fentanyl	ADJ	O	Chemical	2591
1	X	O	O	2591
microgram	PROPN	O	O	2591
/	PUNCT	O	O	2591
kg	VERB	O	O	2591
followed	VERB	O	O	2591
by	ADP	O	O	2591
etomidate	VERB	O	Chemical	2591
0.3	NUM	O	O	2591
mg	VERB	O	O	2591
/	PUNCT	O	O	2591
kg	VERB	O	O	2591
.	PUNCT	O	O	2591
Anaesthesia	NOUN	O	O	2592
was	AUX	O	O	2592
maintained	VERB	O	O	2592
with	ADP	O	O	2592
intermittent	ADJ	O	O	2592
etomidate	VERB	O	Chemical	2592
in	ADP	O	O	2592
2	X	O	O	2592
-	PUNCT	O	O	2592
4	NUM	O	O	2592
mg	VERB	O	O	2592
doses	NOUN	O	O	2592
.	PUNCT	O	O	2592
Venous	ADJ	O	O	2593
pain	NOUN	O	Disease	2593
occurred	VERB	O	O	2593
in	ADP	O	O	2593
68%	NOUN	O	O	2593
of	ADP	O	O	2593
patients	NOUN	O	O	2593
and	CCONJ	O	O	2593
50%	NOUN	O	O	2593
had	VERB	O	O	2593
redness	NOUN	O	O	2593
,	PUNCT	O	O	2593
pain	NOUN	O	Disease	2593
or	CCONJ	O	O	2593
swelling	VERB	O	Disease	2593
related	ADJ	O	O	2593
to	PART	O	O	2593
the	PRON	O	O	2593
injection	NOUN	O	O	2593
site	NOUN	O	O	2593
,	PUNCT	O	O	2593
in	ADP	O	O	2593
some	PRON	O	O	2593
cases	NOUN	O	O	2593
lasting	VERB	O	O	2593
up	ADP	O	O	2593
to	PART	O	O	2593
three	NUM	O	O	2593
weeks	NOUN	O	O	2593
after	ADP	O	O	2593
anaesthesia	NOUN	O	O	2593
.	PUNCT	O	O	2593
Skeletal	ADJ	O	O	2594
movements	NOUN	O	O	2594
occurred	VERB	O	O	2594
in	ADP	O	O	2594
50%	NOUN	O	O	2594
of	ADP	O	O	2594
patients	NOUN	O	O	2594
;	PUNCT	O	O	2594
30%	NOUN	O	O	2594
experienced	ADJ	O	O	2594
respiratory	NOUN	O	O	2594
upset	ADJ	O	O	2594
,	PUNCT	O	O	2594
one	NUM	O	O	2594
sufficiently	ADV	O	O	2594
severe	ADJ	O	O	2594
to	PART	O	O	2594
necessitate	ADJ	O	O	2594
abandoning	VERB	O	O	2594
the	PRON	O	O	2594
technique	NOUN	O	O	2594
.	PUNCT	O	O	2594
Nausea	NOUN	O	Disease	2595
and	CCONJ	O	O	2595
vomiting	VERB	O	Disease	2595
occurred	VERB	O	O	2595
in	ADP	O	O	2595
40%	NOUN	O	O	2595
and	CCONJ	O	O	2595
25%	NOUN	O	O	2595
had	VERB	O	O	2595
disturbing	ADJ	O	O	2595
emergence	NOUN	O	O	2595
psychoses	NOUN	O	Disease	2595
.	PUNCT	O	O	2595
Levodopa	NOUN	O	Chemical	2598
-	PUNCT	O	O	2598
induced	VERB	O	O	2598
dyskinesias	PROPN	O	Disease	2598
are	AUX	O	O	2598
improved	VERB	O	O	2598
by	ADP	O	O	2598
fluoxetine	NOUN	O	Chemical	2598
.	PUNCT	O	O	2598
We	PRON	O	O	2599
evaluated	VERB	O	O	2599
the	PRON	O	O	2599
severity	NOUN	O	O	2599
of	ADP	O	O	2599
motor	NOUN	O	O	2599
disability	NOUN	O	O	2599
and	CCONJ	O	O	2599
dyskinesias	PROPN	O	Disease	2599
in	ADP	O	O	2599
seven	NUM	O	O	2599
levodopa	NOUN	O	Chemical	2599
-	PUNCT	O	O	2599
responsive	ADJ	O	O	2599
patients	NOUN	O	O	2599
with	ADP	O	O	2599
Parkinson	NOUN	O	O	2599
's	AUX	O	O	2599
disease	PROPN	O	O	2599
after	ADP	O	O	2599
an	PRON	O	O	2599
acute	ADJ	O	O	2599
challenge	NOUN	O	O	2599
with	ADP	O	O	2599
the	PRON	O	O	2599
mixed	VERB	O	O	2599
dopamine	NOUN	O	Chemical	2599
agonist	NOUN	O	O	2599
,	PUNCT	O	O	2599
apomorphine	PROPN	O	Chemical	2599
,	PUNCT	O	O	2599
before	ADP	O	O	2599
and	CCONJ	O	O	2599
after	ADP	O	O	2599
the	PRON	O	O	2599
administration	NOUN	O	O	2599
of	ADP	O	O	2599
fluoxetine	NOUN	O	Chemical	2599
(	PUNCT	O	O	2599
20	NUM	O	O	2599
mg	VERB	O	O	2599
twice	ADV	O	O	2599
per	ADP	O	O	2599
day	NOUN	O	O	2599
)	PUNCT	O	O	2599
for	ADP	O	O	2599
11	NUM	O	O	2599
+	ADP	O	O	2599
/-	PUNCT	O	O	2599
After	ADP	O	O	2600
fluoxetine	NOUN	O	Chemical	2600
treatment	NOUN	O	O	2600
,	PUNCT	O	O	2600
there	ADV	O	O	2600
was	AUX	O	O	2600
a	PRON	O	O	2600
significant	ADJ	O	O	2600
47%	NOUN	O	O	2600
improvement	NOUN	O	O	2600
(	PUNCT	O	O	2600
p	NOUN	O	O	2600
<	X	O	O	2600
0.05	NUM	O	O	2600
)	PUNCT	O	O	2600
of	ADP	O	O	2600
apomorphine	PROPN	O	Chemical	2600
-	PUNCT	O	O	2600
induced	VERB	O	O	2600
dyskinesias	PROPN	O	Disease	2600
without	ADP	O	O	2600
modification	NOUN	O	O	2600
of	ADP	O	O	2600
parkinsonian	PROPN	O	Disease	2600
motor	NOUN	O	O	2600
disability	NOUN	O	O	2600
.	PUNCT	O	O	2600
The	PRON	O	O	2601
dyskinesias	PROPN	O	Disease	2601
were	AUX	O	O	2601
reduced	VERB	O	O	2601
predominantly	ADV	O	O	2601
in	ADP	O	O	2601
the	PRON	O	O	2601
lower	ADJ	O	O	2601
limbs	NOUN	O	O	2601
during	ADP	O	O	2601
the	PRON	O	O	2601
onset	VERB	O	O	2601
and	CCONJ	O	O	2601
disappearance	NOUN	O	O	2601
of	ADP	O	O	2601
dystonic	ADJ	O	Disease	2601
dyskinesias	PROPN	O	Disease	2601
(	PUNCT	O	O	2601
onset-	NOUN	O	O	2601
and	CCONJ	O	O	2601
end	VERB	O	O	2601
-	PUNCT	O	O	2601
of	ADP	O	O	2601
-	PUNCT	O	O	2601
dose	NOUN	O	O	2601
dyskinesias	PROPN	O	Disease	2601
)	PUNCT	O	O	2601
and	CCONJ	O	O	2601
in	ADP	O	O	2601
the	PRON	O	O	2601
upper	ADJ	O	O	2601
limbs	NOUN	O	O	2601
during	ADP	O	O	2601
choreic	PROPN	O	O	2601
mid	PROPN	O	O	2601
-	PUNCT	O	O	2601
dose	NOUN	O	O	2601
dyskinesias	PROPN	O	Disease	2601
.	PUNCT	O	O	2601
The	PRON	O	O	2602
results	VERB	O	O	2602
suggest	VERB	O	O	2602
that	SCONJ	O	O	2602
increased	VERB	O	O	2602
brain	NOUN	O	O	2602
serotoninergic	ADJ	O	O	2602
transmission	NOUN	O	O	2602
with	ADP	O	O	2602
fluoxetine	NOUN	O	Chemical	2602
may	AUX	O	O	2602
reduce	VERB	O	O	2602
levodopa-	PROPN	O	O	2602
or	CCONJ	O	O	2602
dopamine	NOUN	O	Chemical	2602
agonist	NOUN	O	O	2602
-	PUNCT	O	O	2602
induced	VERB	O	O	2602
dyskinesias	PROPN	O	Disease	2602
without	ADP	O	O	2602
aggravating	ADJ	O	O	2602
parkinsonian	PROPN	O	Disease	2602
motor	NOUN	O	O	2602
disability	NOUN	O	O	2602
.	PUNCT	O	O	2602
A	PRON	O	O	2605
large	ADJ	O	O	2605
population	NOUN	O	O	2605
-	PUNCT	O	O	2605
based	VERB	O	O	2605
follow	VERB	O	O	2605
-	PUNCT	O	O	2605
up	ADP	O	O	2605
study	VERB	O	O	2605
of	ADP	O	O	2605
trimethoprim	PROPN	O	O	2605
-	PUNCT	O	O	2605
sulfamethoxazole	NOUN	O	O	2605
,	PUNCT	O	O	2605
trimethoprim	PROPN	O	O	2605
,	PUNCT	O	O	2605
and	CCONJ	O	O	2605
cephalexin	PROPN	O	O	2605
for	ADP	O	O	2605
uncommon	ADJ	O	O	2605
serious	ADJ	O	O	2605
drug	NOUN	O	O	2605
toxicity	NOUN	O	Disease	2605
.	PUNCT	O	O	2605
We	PRON	O	O	2606
conducted	VERB	O	O	2606
a	PRON	O	O	2606
population	NOUN	O	O	2606
-	PUNCT	O	O	2606
based	VERB	O	O	2606
45-day	NOUN	O	O	2606
follow	VERB	O	O	2606
-	PUNCT	O	O	2606
up	ADP	O	O	2606
study	VERB	O	O	2606
of	ADP	O	O	2606
232,390	NUM	O	O	2606
people	NOUN	O	O	2606
who	PRON	O	O	2606
were	AUX	O	O	2606
prescribed	VERB	O	O	2606
trimethoprim	PROPN	O	O	2606
-	PUNCT	O	O	2606
sulfamethoxazole	NOUN	O	O	2606
(	PUNCT	O	O	2606
TMP	PROPN	O	O	2606
-	PUNCT	O	O	2606
SMZ	NOUN	O	O	2606
)	PUNCT	O	O	2606
,	PUNCT	O	O	2606
266,951	NUM	O	O	2606
prescribed	VERB	O	O	2606
trimethoprim	PROPN	O	O	2606
alone	ADV	O	O	2606
,	PUNCT	O	O	2606
and	CCONJ	O	O	2606
196,397	NUM	O	O	2606
prescribed	VERB	O	O	2606
cephalexin	PROPN	O	O	2606
,	PUNCT	O	O	2606
to	PART	O	O	2606
estimate	VERB	O	O	2606
the	PRON	O	O	2606
risk	NOUN	O	O	2606
of	ADP	O	O	2606
serious	ADJ	O	O	2606
liver	NOUN	O	O	2606
,	PUNCT	O	O	2606
blood	NOUN	O	O	2606
,	PUNCT	O	O	2606
skin	NOUN	O	O	2606
,	PUNCT	O	O	2606
and	CCONJ	O	O	2606
renal disorders	NOUN	O	Disease	2606
resulting	VERB	O	O	2606
in	ADP	O	O	2606
referral	NOUN	O	O	2606
or	CCONJ	O	O	2606
hospitalization	NOUN	O	O	2606
associated	VERB	O	O	2606
with	ADP	O	O	2606
these	PRON	O	O	2606
drugs	NOUN	O	O	2606
.	PUNCT	O	O	2606
The	PRON	O	O	2607
risk	NOUN	O	O	2607
of	ADP	O	O	2607
clinically	ADV	O	O	2607
important	ADJ	O	O	2607
idiopathic	ADJ	O	O	2607
liver disease	NOUN	O	Disease	2607
was	AUX	O	O	2607
similar	ADJ	O	O	2607
for	ADP	O	O	2607
persons	NOUN	O	O	2607
prescribed	VERB	O	O	2607
TMP	PROPN	O	O	2607
-	PUNCT	O	O	2607
SMZ	NOUN	O	O	2607
(	PUNCT	O	O	2607
5.2/100,000	NUM	O	O	2607
)	PUNCT	O	O	2607
and	CCONJ	O	O	2607
those	PRON	O	O	2607
prescribed	VERB	O	O	2607
trimethoprim	PROPN	O	O	2607
alone	ADV	O	O	2607
(	PUNCT	O	O	2607
3.8/100,000	NUM	O	O	2607
)	PUNCT	O	O	2607
.	PUNCT	O	O	2607
The	PRON	O	O	2608
risk	NOUN	O	O	2608
for	ADP	O	O	2608
those	PRON	O	O	2608
prescribed	VERB	O	O	2608
cephalexin	PROPN	O	O	2608
was	AUX	O	O	2608
somewhat	ADV	O	O	2608
lower	ADJ	O	O	2608
(	PUNCT	O	O	2608
2.0/100,000	NUM	O	O	2608
)	PUNCT	O	O	2608
.	PUNCT	O	O	2608
Only	ADV	O	O	2609
five	NUM	O	O	2609
patients	NOUN	O	O	2609
experienced	ADJ	O	O	2609
blood	NOUN	O	O	2609
disorders	NOUN	O	O	2609
,	PUNCT	O	O	2609
one	NUM	O	O	2609
of	ADP	O	O	2609
whom	PRON	O	O	2609
was	AUX	O	O	2609
exposed	VERB	O	O	2609
to	PART	O	O	2609
TMP	PROPN	O	O	2609
-	PUNCT	O	O	2609
SMZ	NOUN	O	O	2609
;	PUNCT	O	O	2609
of	ADP	O	O	2609
seven	NUM	O	O	2609
with	ADP	O	O	2609
erythema	NOUN	O	O	2609
multiforme	NOUN	O	O	2609
and	CCONJ	O	O	2609
Stevens	PROPN	O	O	2609
-	PUNCT	O	O	2609
Johnson	PROPN	O	O	2609
syndrome	NOUN	O	O	2609
,	PUNCT	O	O	2609
four	NUM	O	O	2609
were	AUX	O	O	2609
exposed	VERB	O	O	2609
to	PART	O	O	2609
TMP	PROPN	O	O	2609
-	PUNCT	O	O	2609
SMZ	NOUN	O	O	2609
.	PUNCT	O	O	2609
The	PRON	O	O	2610
one	NUM	O	O	2610
case	NOUN	O	O	2610
of	ADP	O	O	2610
toxic	ADJ	O	O	2610
epidermal	ADJ	O	O	2610
necrolysis	VERB	O	O	2610
occurred	VERB	O	O	2610
in	ADP	O	O	2610
a	PRON	O	O	2610
patient	NOUN	O	O	2610
who	PRON	O	O	2610
took	VERB	O	O	2610
cephalexin	PROPN	O	O	2610
.	PUNCT	O	O	2610
Finally	ADV	O	O	2611
,	PUNCT	O	O	2611
only	ADV	O	O	2611
five	NUM	O	O	2611
cases	NOUN	O	O	2611
of	ADP	O	O	2611
acute	ADJ	O	O	2611
parenchymal	ADJ	O	O	2611
renal disease	NOUN	O	Disease	2611
occurred	VERB	O	O	2611
,	PUNCT	O	O	2611
none	NOUN	O	O	2611
likely	ADV	O	O	2611
to	PART	O	O	2611
be	AUX	O	O	2611
caused	VERB	O	O	2611
by	ADP	O	O	2611
a	PRON	O	O	2611
study	VERB	O	O	2611
drug	NOUN	O	O	2611
.	PUNCT	O	O	2611
Clinical	NOUN	O	O	2614
safety	NOUN	O	O	2614
of	ADP	O	O	2614
lidocaine	NOUN	O	Chemical	2614
in	ADP	O	O	2614
patients	NOUN	O	O	2614
with	ADP	O	O	2614
cocaine	NOUN	O	Chemical	2614
-	PUNCT	O	O	2614
associated	VERB	O	O	2614
myocardial infarction	NOUN	O	Disease	2614
.	PUNCT	O	O	2614
STUDY	NOUN	O	O	2615
OBJECTIVE	VERB	O	O	2615
:	PUNCT	O	O	2615
To	PART	O	O	2615
evaluate	VERB	O	O	2615
the	PRON	O	O	2615
safety	NOUN	O	O	2615
of	ADP	O	O	2615
lidocaine	NOUN	O	Chemical	2615
in	ADP	O	O	2615
the	PRON	O	O	2615
setting	VERB	O	O	2615
of	ADP	O	O	2615
cocaine	NOUN	O	Chemical	2615
-	PUNCT	O	O	2615
induced	VERB	O	O	2615
myocardial infarction	NOUN	O	Disease	2615
(	PUNCT	O	O	2615
MI	PROPN	O	Disease	2615
)	PUNCT	O	O	2615
.	PUNCT	O	O	2615
Patients	NOUN	O	O	2616
with	ADP	O	O	2616
cocaine	NOUN	O	Chemical	2616
-	PUNCT	O	O	2616
associated	VERB	O	O	2616
MI	PROPN	O	Disease	2616
who	PRON	O	O	2616
received	VERB	O	O	2616
lidocaine	NOUN	O	Chemical	2616
in	ADP	O	O	2616
the	PRON	O	O	2616
emergency	NOUN	O	O	2616
department	NOUN	O	O	2616
.	PUNCT	O	O	2616
Of	ADV	O	O	2617
29	NUM	O	O	2617
patients	NOUN	O	O	2617
who	PRON	O	O	2617
received	VERB	O	O	2617
lidocaine	NOUN	O	Chemical	2617
in	ADP	O	O	2617
the	PRON	O	O	2617
setting	VERB	O	O	2617
of	ADP	O	O	2617
cocaine	NOUN	O	Chemical	2617
-	PUNCT	O	O	2617
associated	VERB	O	O	2617
MI	PROPN	O	Disease	2617
,	PUNCT	O	O	2617
no	PRON	O	O	2617
patient	NOUN	O	O	2617
died	VERB	O	O	2617
;	PUNCT	O	O	2617
exhibited	VERB	O	O	2617
bradydysrhythmias	NOUN	O	O	2617
,	PUNCT	O	O	2617
ventricular tachycardia	NOUN	O	Disease	2617
,	PUNCT	O	O	2617
or	CCONJ	O	O	2617
ventricular fibrillation	NOUN	O	Disease	2617
;	PUNCT	O	O	2617
or	CCONJ	O	O	2617
experienced	ADJ	O	O	2617
seizures	NOUN	O	Disease	2617
after	ADP	O	O	2617
administration	NOUN	O	O	2617
of	ADP	O	O	2617
lidocaine	NOUN	O	Chemical	2617
(	PUNCT	O	O	2617
95%	NOUN	O	O	2617
confidence	NOUN	O	O	2617
interval	NOUN	O	O	2617
,	PUNCT	O	O	2617
0%	NOUN	O	O	2617
to	PART	O	O	2617
11%	NOUN	O	O	2617
)	PUNCT	O	O	2617
.	PUNCT	O	O	2617
CONCLUSION	PROPN	O	O	2618
:	PUNCT	O	O	2618
Despite	SCONJ	O	O	2618
theoretical	ADJ	O	O	2618
concerns	NOUN	O	O	2618
that	SCONJ	O	O	2618
lidocaine	NOUN	O	Chemical	2618
may	AUX	O	O	2618
enhance	VERB	O	O	2618
cocaine	NOUN	O	Chemical	2618
toxicity	NOUN	O	Disease	2618
,	PUNCT	O	O	2618
the	PRON	O	O	2618
use	VERB	O	O	2618
of	ADP	O	O	2618
lidocaine	NOUN	O	Chemical	2618
in	ADP	O	O	2618
patients	NOUN	O	O	2618
with	ADP	O	O	2618
cocaine	NOUN	O	Chemical	2618
-	PUNCT	O	O	2618
associated	VERB	O	O	2618
MI	PROPN	O	Disease	2618
was	AUX	O	O	2618
not	PART	O	O	2618
associated	VERB	O	O	2618
with	ADP	O	O	2618
significant	ADJ	O	O	2618
cardiovascular	ADJ	O	O	2618
or	CCONJ	O	O	2618
central nervous system toxicity	NOUN	O	Disease	2618
.	PUNCT	O	O	2618
Paclitaxel	PROPN	O	Chemical	2621
3-hour	NOUN	O	O	2621
infusion	NOUN	O	O	2621
given	VERB	O	O	2621
alone	ADV	O	O	2621
and	CCONJ	O	O	2621
combined	VERB	O	O	2621
with	ADP	O	O	2621
carboplatin	PROPN	O	Chemical	2621
:	PUNCT	O	O	2621
preliminary	ADJ	O	O	2621
results	VERB	O	O	2621
of	ADP	O	O	2621
dose	NOUN	O	O	2621
-	PUNCT	O	O	2621
escalation	NOUN	O	O	2621
trials	NOUN	O	O	2621
.	PUNCT	O	O	2621
Paclitaxel	PROPN	O	Chemical	2622
(	PUNCT	O	O	2622
Taxol	PROPN	O	Chemical	2622
;	PUNCT	O	O	2622
Bristol	PROPN	O	O	2622
-	PUNCT	O	O	2622
Myers	PROPN	O	O	2622
Squibb	PROPN	O	O	2622
Company	NOUN	O	O	2622
,	PUNCT	O	O	2622
Princeton	PROPN	O	O	2622
,	PUNCT	O	O	2622
NJ	PROPN	O	O	2622
)	PUNCT	O	O	2622
by	ADP	O	O	2622
3-hour	NOUN	O	O	2622
infusion	NOUN	O	O	2622
was	AUX	O	O	2622
combined	VERB	O	O	2622
with	ADP	O	O	2622
carboplatin	PROPN	O	Chemical	2622
in	ADP	O	O	2622
a	PRON	O	O	2622
phase	NOUN	O	O	2622
I	PRON	O	O	2622
/	PUNCT	O	O	2622
II	NUM	O	O	2622
study	VERB	O	O	2622
directed	VERB	O	O	2622
to	PART	O	O	2622
patients	NOUN	O	O	2622
with	ADP	O	O	2622
non	ADJ	O	O	2622
-	PUNCT	O	O	2622
small	ADJ	O	O	2622
cell	NOUN	O	O	2622
lung cancer	NOUN	O	Disease	2622
.	PUNCT	O	O	2622
Carboplatin	NOUN	O	Chemical	2623
was	AUX	O	O	2623
given	VERB	O	O	2623
at	ADP	O	O	2623
a	PRON	O	O	2623
fixed	VERB	O	O	2623
target	NOUN	O	O	2623
area	NOUN	O	O	2623
under	ADP	O	O	2623
the	PRON	O	O	2623
concentration	NOUN	O	O	2623
-	PUNCT	O	O	2623
time	NOUN	O	O	2623
curve	NOUN	O	O	2623
of	ADP	O	O	2623
6.0	NUM	O	O	2623
by	ADP	O	O	2623
the	PRON	O	O	2623
Calvert	NOUN	O	O	2623
formula	NOUN	O	O	2623
,	PUNCT	O	O	2623
whereas	SCONJ	O	O	2623
paclitaxel	NOUN	O	Chemical	2623
was	AUX	O	O	2623
escalated	VERB	O	O	2623
in	ADP	O	O	2623
patient	NOUN	O	O	2623
cohorts	NOUN	O	O	2623
from	ADP	O	O	2623
150	NUM	O	O	2623
mg	VERB	O	O	2623
/	PUNCT	O	O	2623
m2	PROPN	O	O	2623
(	PUNCT	O	O	2623
dose	NOUN	O	O	2623
level	VERB	O	O	2623
I	PRON	O	O	2623
)	PUNCT	O	O	2623
to	PART	O	O	2623
175	NUM	O	O	2623
,	PUNCT	O	O	2623
200	NUM	O	O	2623
,	PUNCT	O	O	2623
225	NUM	O	O	2623
,	PUNCT	O	O	2623
and	CCONJ	O	O	2623
250	NUM	O	O	2623
mg	VERB	O	O	2623
/	PUNCT	O	O	2623
m2	PROPN	O	O	2623
.	PUNCT	O	O	2623
The	PRON	O	O	2624
225	NUM	O	O	2624
mg	VERB	O	O	2624
/	PUNCT	O	O	2624
m2	PROPN	O	O	2624
level	VERB	O	O	2624
was	AUX	O	O	2624
expanded	VERB	O	O	2624
for	ADP	O	O	2624
the	PRON	O	O	2624
phase	NOUN	O	O	2624
II	NUM	O	O	2624
study	VERB	O	O	2624
since	SCONJ	O	O	2624
the	PRON	O	O	2624
highest	ADJ	O	O	2624
level	VERB	O	O	2624
achieved	VERB	O	O	2624
(	PUNCT	O	O	2624
250	NUM	O	O	2624
mg	VERB	O	O	2624
/	PUNCT	O	O	2624
m2	PROPN	O	O	2624
)	PUNCT	O	O	2624
required	VERB	O	O	2624
modification	NOUN	O	O	2624
because	SCONJ	O	O	2624
of	ADP	O	O	2624
nonhematologic	ADJ	O	O	2624
toxicities	NOUN	O	Disease	2624
(	PUNCT	O	O	2624
arthralgia	ADV	O	Disease	2624
and	CCONJ	O	O	2624
sensory	ADJ	O	O	2624
neuropathy	NOUN	O	Disease	2624
)	PUNCT	O	O	2624
.	PUNCT	O	O	2624
Toxicities	NOUN	O	Disease	2625
were	AUX	O	O	2625
compared	VERB	O	O	2625
with	ADP	O	O	2625
a	PRON	O	O	2625
cohort	NOUN	O	O	2625
of	ADP	O	O	2625
patients	NOUN	O	O	2625
in	ADP	O	O	2625
a	PRON	O	O	2625
phase	NOUN	O	O	2625
I	PRON	O	O	2625
trial	NOUN	O	O	2625
of	ADP	O	O	2625
paclitaxel	NOUN	O	Chemical	2625
alone	ADV	O	O	2625
at	ADP	O	O	2625
identical	ADJ	O	O	2625
dose	NOUN	O	O	2625
levels	NOUN	O	O	2625
.	PUNCT	O	O	2625
Carboplatin	NOUN	O	Chemical	2626
did	VERB	O	O	2626
not	PART	O	O	2626
appear	VERB	O	O	2626
to	PART	O	O	2626
add	VERB	O	O	2626
to	PART	O	O	2626
the	PRON	O	O	2626
hematologic	ADJ	O	O	2626
toxicities	NOUN	O	Disease	2626
observed	VERB	O	O	2626
,	PUNCT	O	O	2626
and	CCONJ	O	O	2626
the	PRON	O	O	2627
paclitaxel	NOUN	O	Chemical	2627
/	PUNCT	O	O	2627
carboplatin	PROPN	O	Chemical	2627
combination	NOUN	O	O	2627
could	AUX	O	O	2627
be	AUX	O	O	2627
dosed	VERB	O	O	2627
every	PRON	O	O	2627
3	X	O	O	2627
weeks	NOUN	O	O	2627
.	PUNCT	O	O	2627
The	PRON	O	O	2630
dose	NOUN	O	O	2630
-	PUNCT	O	O	2630
dependent	ADJ	O	O	2630
effect	VERB	O	O	2630
of	ADP	O	O	2630
misoprostol	PROPN	O	Chemical	2630
on	ADP	O	O	2630
indomethacin	VERB	O	Chemical	2630
-	PUNCT	O	O	2630
induced	VERB	O	O	2630
renal dysfunction	NOUN	O	Disease	2630
in	ADP	O	O	2630
well	ADV	O	O	2630
compensated	VERB	O	O	2630
cirrhosis	NOUN	O	Disease	2630
.	PUNCT	O	O	2630
Misoprostol	PROPN	O	O	2631
(	PUNCT	O	O	2631
200	NUM	O	O	2631
micrograms	NOUN	O	O	2631
)	PUNCT	O	O	2631
has	VERB	O	O	2631
been	AUX	O	O	2631
shown	VERB	O	O	2631
to	PART	O	O	2631
acutely	ADV	O	O	2631
counteract	VERB	O	O	2631
the	PRON	O	O	2631
indomethacin	VERB	O	Chemical	2631
-	PUNCT	O	O	2631
induced	VERB	O	O	2631
renal dysfunction	NOUN	O	Disease	2631
in	ADP	O	O	2631
well	ADV	O	O	2631
compensated	VERB	O	O	2631
cirrhotic	ADJ	O	O	2631
patients	NOUN	O	O	2631
.	PUNCT	O	O	2631
The	PRON	O	O	2632
aim	VERB	O	O	2632
of	ADP	O	O	2632
this	PRON	O	O	2632
study	VERB	O	O	2632
was	AUX	O	O	2632
to	PART	O	O	2632
determine	VERB	O	O	2632
if	SCONJ	O	O	2632
the	PRON	O	O	2632
prophylactic	ADJ	O	O	2632
value	NOUN	O	O	2632
of	ADP	O	O	2632
misoprostol	PROPN	O	Chemical	2632
was	AUX	O	O	2632
dose	NOUN	O	O	2632
-	PUNCT	O	O	2632
dependent	ADJ	O	O	2632
.	PUNCT	O	O	2632
Parameters	NOUN	O	O	2633
of	ADP	O	O	2633
renal	ADJ	O	O	2633
hemodynamics	NOUN	O	O	2633
and	CCONJ	O	O	2633
tubular	ADJ	O	O	2633
sodium	NOUN	O	Chemical	2633
and	CCONJ	O	O	2633
water	PROPN	O	O	2633
handling	VERB	O	O	2633
were	AUX	O	O	2633
assessed	VERB	O	O	2633
by	ADP	O	O	2633
clearance	NOUN	O	O	2633
techniques	NOUN	O	O	2633
in	ADP	O	O	2633
26	NUM	O	O	2633
well	ADV	O	O	2633
compensated	VERB	O	O	2633
cirrhotic	ADJ	O	O	2633
patients	NOUN	O	O	2633
before	ADP	O	O	2633
and	CCONJ	O	O	2633
after	ADP	O	O	2633
an	PRON	O	O	2633
oral	ADJ	O	O	2633
combination	NOUN	O	O	2633
of	ADP	O	O	2633
50	NUM	O	O	2633
mg	VERB	O	O	2633
of	ADP	O	O	2633
indomethacin	VERB	O	Chemical	2633
and	CCONJ	O	O	2633
various	ADJ	O	O	2633
doses	NOUN	O	O	2633
of	ADP	O	O	2633
misoprostol	PROPN	O	Chemical	2633
.	PUNCT	O	O	2633
The	PRON	O	O	2634
200-micrograms	NOUN	O	O	2634
dose	NOUN	O	O	2634
was	AUX	O	O	2634
able	ADJ	O	O	2634
to	PART	O	O	2634
totally	ADV	O	O	2634
abolish	VERB	O	O	2634
the	PRON	O	O	2634
deleterious	ADJ	O	O	2634
renal	ADJ	O	O	2634
effects	NOUN	O	O	2634
of	ADP	O	O	2634
indomethacin	VERB	O	Chemical	2634
,	PUNCT	O	O	2634
whereas	SCONJ	O	O	2634
the	PRON	O	O	2634
800-micrograms	NOUN	O	O	2634
dose	NOUN	O	O	2634
resulted	VERB	O	O	2634
in	ADP	O	O	2634
significant	ADJ	O	O	2634
worsening	VERB	O	O	2634
of	ADP	O	O	2634
renal	ADJ	O	O	2634
hemodynamics	NOUN	O	O	2634
and	CCONJ	O	O	2634
sodium	NOUN	O	Chemical	2634
retention	NOUN	O	O	2634
.	PUNCT	O	O	2634
These	PRON	O	O	2635
results	VERB	O	O	2635
suggest	VERB	O	O	2635
that	SCONJ	O	O	2635
the	PRON	O	O	2635
renal	ADJ	O	O	2635
protective	ADJ	O	O	2635
effects	NOUN	O	O	2635
of	ADP	O	O	2635
misoprostol	PROPN	O	Chemical	2635
is	AUX	O	O	2635
dose	NOUN	O	O	2635
-	PUNCT	O	O	2635
dependent	ADJ	O	O	2635
.	PUNCT	O	O	2635
However	ADV	O	O	2636
,	PUNCT	O	O	2636
until	ADP	O	O	2636
this	PRON	O	O	2636
apparent	ADJ	O	O	2636
ability	NOUN	O	O	2636
of	ADP	O	O	2636
200	NUM	O	O	2636
micrograms	NOUN	O	O	2636
of	ADP	O	O	2636
misoprostol	PROPN	O	Chemical	2636
to	PART	O	O	2636
prevent	VERB	O	O	2636
the	PRON	O	O	2636
adverse	ADJ	O	O	2636
effects	NOUN	O	O	2636
of	ADP	O	O	2636
indomethacin	VERB	O	Chemical	2636
on	ADP	O	O	2636
renal	ADJ	O	O	2636
function	NOUN	O	O	2636
is	AUX	O	O	2636
confirmed	VERB	O	O	2636
with	ADP	O	O	2636
chronic	ADJ	O	O	2636
frequent	ADJ	O	O	2636
dosing	VERB	O	O	2636
,	PUNCT	O	O	2636
it	PRON	O	O	2636
would	AUX	O	O	2636
be	AUX	O	O	2636
prudent	ADJ	O	O	2636
to	PART	O	O	2636
avoid	VERB	O	O	2636
nonsteroidal	ADJ	O	O	2636
anti	ADJ	O	O	2636
-	PUNCT	O	O	2636
inflammatory	ADJ	O	O	2636
therapy	NOUN	O	O	2636
in	ADP	O	O	2636
patients	NOUN	O	O	2636
with	ADP	O	O	2636
cirrhosis	NOUN	O	Disease	2636
.	PUNCT	O	O	2636
Increased	VERB	O	O	2639
frequency	NOUN	O	O	2639
and	CCONJ	O	O	2639
severity	NOUN	O	O	2639
of	ADP	O	O	2639
angio	PROPN	O	O	2639
-	PUNCT	O	O	2639
oedema	NOUN	O	Disease	2639
related	ADJ	O	O	2639
to	PART	O	O	2639
long	ADV	O	O	2639
-	PUNCT	O	O	2639
term	NOUN	O	O	2639
therapy	NOUN	O	O	2639
with	ADP	O	O	2639
angiotensin	NOUN	O	Chemical	2639
-	PUNCT	O	O	2639
converting	VERB	O	O	2639
enzyme	NOUN	O	O	2639
inhibitor	NOUN	O	O	2639
in	ADP	O	O	2639
two	NUM	O	O	2639
patients	NOUN	O	O	2639
.	PUNCT	O	O	2639
Adverse	ADJ	O	O	2640
reactions	NOUN	O	O	2640
to	PART	O	O	2640
drugs	NOUN	O	O	2640
are	AUX	O	O	2640
well	ADV	O	O	2640
recognized	VERB	O	O	2640
as	ADP	O	O	2640
a	PRON	O	O	2640
cause	VERB	O	O	2640
of	ADP	O	O	2640
acute	ADJ	O	O	2640
or	CCONJ	O	O	2640
chronic	ADJ	O	O	2640
urticaria	PROPN	O	Disease	2640
,	PUNCT	O	O	2640
and	CCONJ	O	O	2640
angio	PROPN	O	O	2640
-	PUNCT	O	O	2640
oedema	NOUN	O	Disease	2640
.	PUNCT	O	O	2640
Angiotensin	NOUN	O	O	2641
-	PUNCT	O	O	2641
converting	VERB	O	O	2641
enzyme	NOUN	O	O	2641
(	PUNCT	O	O	2641
ACE	PROPN	O	O	2641
)	PUNCT	O	O	2641
inhibitors	NOUN	O	O	2641
,	PUNCT	O	O	2641
used	VERB	O	O	2641
to	PART	O	O	2641
treat	VERB	O	O	2641
hypertension	NOUN	O	Disease	2641
and	CCONJ	O	O	2641
congestive	ADJ	O	O	2641
heart failure	NOUN	O	Disease	2641
,	PUNCT	O	O	2641
were	AUX	O	O	2641
introduced	VERB	O	O	2641
in	ADP	O	O	2641
Europe	PROPN	O	O	2641
in	ADP	O	O	2641
the	PRON	O	O	2641
middle	ADJ	O	O	2641
of	ADP	O	O	2641
the	PRON	O	O	2641
eighties	NOUN	O	O	2641
,	PUNCT	O	O	2641
and	CCONJ	O	O	2641
the	PRON	O	O	2641
use	VERB	O	O	2641
of	ADP	O	O	2641
these	PRON	O	O	2641
drugs	NOUN	O	O	2641
has	VERB	O	O	2641
increased	VERB	O	O	2641
progressively	ADV	O	O	2641
.	PUNCT	O	O	2641
Soon	ADV	O	O	2642
after	ADP	O	O	2642
the	PRON	O	O	2642
introduction	NOUN	O	O	2642
of	ADP	O	O	2642
ACE	PROPN	O	O	2642
inhibitors	NOUN	O	O	2642
,	PUNCT	O	O	2642
acute	ADJ	O	O	2642
bouts	NOUN	O	O	2642
of	ADP	O	O	2642
angio	PROPN	O	O	2642
-	PUNCT	O	O	2642
oedema	NOUN	O	Disease	2642
were	AUX	O	O	2642
reported	VERB	O	O	2642
in	ADP	O	O	2642
association	PROPN	O	O	2642
with	ADP	O	O	2642
the	PRON	O	O	2642
use	VERB	O	O	2642
of	ADP	O	O	2642
these	PRON	O	O	2642
drugs	NOUN	O	O	2642
.	PUNCT	O	O	2642
We	PRON	O	O	2643
wish	VERB	O	O	2643
to	PART	O	O	2643
draw	VERB	O	O	2643
attention	NOUN	O	O	2643
to	PART	O	O	2643
the	PRON	O	O	2643
possibility	NOUN	O	O	2643
of	ADP	O	O	2643
adverse	ADJ	O	O	2643
reactions	NOUN	O	O	2643
to	PART	O	O	2643
ACE	PROPN	O	O	2643
inhibitors	NOUN	O	O	2643
after	ADP	O	O	2643
long	ADV	O	O	2643
-	PUNCT	O	O	2643
term	NOUN	O	O	2643
use	VERB	O	O	2643
and	CCONJ	O	O	2643
in	ADP	O	O	2643
patients	NOUN	O	O	2643
with	ADP	O	O	2643
pre	VERB	O	O	2643
-	PUNCT	O	O	2643
existing	VERB	O	O	2643
angio	PROPN	O	O	2643
-	PUNCT	O	O	2643
oedema	NOUN	O	Disease	2643
.	PUNCT	O	O	2643
Myoclonus	NOUN	O	Disease	2646
associated	VERB	O	O	2646
with	ADP	O	O	2646
lorazepam	PROPN	O	Chemical	2646
therapy	NOUN	O	O	2646
in	ADP	O	O	2646
very	ADV	O	O	2646
-	PUNCT	O	O	2646
low	ADJ	O	O	2646
-	PUNCT	O	O	2646
birth	NOUN	O	O	2646
-	PUNCT	O	O	2646
weight	NOUN	O	O	2646
infants	NOUN	O	O	2646
.	PUNCT	O	O	2646
Lorazepam	NOUN	O	O	2647
is	AUX	O	O	2647
being	AUX	O	O	2647
used	VERB	O	O	2647
with	ADP	O	O	2647
increasing	VERB	O	O	2647
frequency	NOUN	O	O	2647
as	ADP	O	O	2647
a	PRON	O	O	2647
sedative	NOUN	O	O	2647
in	ADP	O	O	2647
the	PRON	O	O	2647
newborn	ADJ	O	O	2647
and	CCONJ	O	O	2647
the	PRON	O	O	2647
young	ADJ	O	O	2647
infant	NOUN	O	O	2647
.	PUNCT	O	O	2647
Concern	NOUN	O	O	2648
has	VERB	O	O	2648
been	AUX	O	O	2648
raised	VERB	O	O	2648
with	ADP	O	O	2648
regard	NOUN	O	O	2648
to	PART	O	O	2648
the	PRON	O	O	2648
safety	NOUN	O	O	2648
of	ADP	O	O	2648
lorazepam	PROPN	O	Chemical	2648
in	ADP	O	O	2648
this	PRON	O	O	2648
age	NOUN	O	O	2648
group	NOUN	O	O	2648
,	PUNCT	O	O	2648
especially	ADV	O	O	2648
in	ADP	O	O	2648
very	ADV	O	O	2648
-	PUNCT	O	O	2648
low	ADJ	O	O	2648
-	PUNCT	O	O	2648
birth	NOUN	O	O	2648
-	PUNCT	O	O	2648
weight	NOUN	O	O	2648
(	PUNCT	O	O	2648
VLBW	NOUN	O	O	2648
;	PUNCT	O	O	2648
<	X	O	O	2648
1,500	NUM	O	O	2648
g	X	O	O	2648
)	PUNCT	O	O	2648
infants	NOUN	O	O	2648
.	PUNCT	O	O	2648
Three	NUM	O	O	2649
young	ADJ	O	O	2649
infants	NOUN	O	O	2649
,	PUNCT	O	O	2649
all	PRON	O	O	2649
of	ADP	O	O	2649
birth	NOUN	O	O	2649
weight	NOUN	O	O	2649
<	X	O	O	2649
1,500	NUM	O	O	2649
g	X	O	O	2649
,	PUNCT	O	O	2649
experienced	ADJ	O	O	2649
myoclonus	NOUN	O	Disease	2649
following	VERB	O	O	2649
the	PRON	O	O	2649
intravenous	ADJ	O	O	2649
administration	NOUN	O	O	2649
of	ADP	O	O	2649
lorazepam	PROPN	O	Chemical	2649
.	PUNCT	O	O	2649
The	PRON	O	O	2650
potential	ADJ	O	O	2650
neurotoxic	ADJ	O	Disease	2650
effects	NOUN	O	O	2650
of	ADP	O	O	2650
the	PRON	O	O	2650
drug	NOUN	O	O	2650
(	PUNCT	O	O	2650
and	CCONJ	O	O	2650
its	PRON	O	O	2650
vehicle	NOUN	O	O	2650
)	PUNCT	O	O	2650
in	ADP	O	O	2650
this	PRON	O	O	2650
population	NOUN	O	O	2650
are	AUX	O	O	2650
discussed	VERB	O	O	2650
.	PUNCT	O	O	2650
Injectable	ADJ	O	O	2651
lorazepam	PROPN	O	Chemical	2651
should	AUX	O	O	2651
be	AUX	O	O	2651
used	VERB	O	O	2651
with	ADP	O	O	2651
caution	NOUN	O	O	2651
in	ADP	O	O	2651
VLBW	NOUN	O	O	2651
infants	NOUN	O	O	2651
.	PUNCT	O	O	2651
right	ADV	O	O	2654
ventricular	ADJ	O	O	2654
pacing	NOUN	O	O	2654
during	ADP	O	O	2654
cardiopulmonary	VERB	O	O	2654
resuscitation	NOUN	O	O	2654
of	ADP	O	O	2654
pediatric	ADJ	O	O	2654
patients	NOUN	O	O	2654
with	ADP	O	O	2654
acute	ADJ	O	O	2654
cardiomyopathy	ADJ	O	Disease	2654
.	PUNCT	O	O	2654
We	PRON	O	O	2655
describe	VERB	O	O	2655
the	PRON	O	O	2655
cardiopulmonary	VERB	O	O	2655
resuscitation	NOUN	O	O	2655
efforts	NOUN	O	O	2655
on	ADP	O	O	2655
five	NUM	O	O	2655
patients	NOUN	O	O	2655
who	PRON	O	O	2655
presented	VERB	O	O	2655
in	ADP	O	O	2655
acute	ADJ	O	O	2655
circulatory	ADJ	O	O	2655
failure	NOUN	O	O	2655
from	ADP	O	O	2655
myocardial	ADJ	O	O	2655
dysfunction	NOUN	O	O	2655
.	PUNCT	O	O	2655
Three	NUM	O	O	2656
patients	NOUN	O	O	2656
had	VERB	O	O	2656
acute	ADJ	O	O	2656
viral	ADJ	O	O	2656
myocarditis	ADV	O	Disease	2656
,	PUNCT	O	O	2656
one	NUM	O	O	2656
had	VERB	O	O	2656
a	PRON	O	O	2656
carbamazepine	NOUN	O	Chemical	2656
-	PUNCT	O	O	2656
induced	VERB	O	O	2656
acute	ADJ	O	O	2656
eosinophilic myocarditis	ADV	O	Disease	2656
,	PUNCT	O	O	2656
and	CCONJ	O	O	2656
one	NUM	O	O	2656
had	VERB	O	O	2656
cardiac	ADJ	O	O	2656
hemosiderosis	VERB	O	Disease	2656
resulting	VERB	O	O	2656
in	ADP	O	O	2656
acute	ADJ	O	O	2656
cardiogenic shock	NOUN	O	Disease	2656
.	PUNCT	O	O	2656
An	PRON	O	O	2657
introducer	NOUN	O	O	2657
sheath	NOUN	O	O	2657
,	PUNCT	O	O	2657
a	PRON	O	O	2657
pacemaker	NOUN	O	O	2657
,	PUNCT	O	O	2657
and	CCONJ	O	O	2657
sterile	ADJ	O	O	2657
pacing	NOUN	O	O	2657
wires	NOUN	O	O	2657
were	AUX	O	O	2657
made	VERB	O	O	2657
readily	ADV	O	O	2657
available	ADJ	O	O	2657
for	ADP	O	O	2657
the	PRON	O	O	2657
patients	NOUN	O	O	2657
,	PUNCT	O	O	2657
should	AUX	O	O	2657
the	PRON	O	O	2657
need	VERB	O	O	2657
arise	VERB	O	O	2657
to	PART	O	O	2657
terminate	VERB	O	O	2657
resistant	ADJ	O	O	2657
cardiac	ADJ	O	O	2657
dysrhythmias	VERB	O	Disease	2657
.	PUNCT	O	O	2657
All	PRON	O	O	2658
patients	NOUN	O	O	2658
developed	VERB	O	O	2658
cardiocirculatory	NOUN	O	O	2658
arrest	VERB	O	O	2658
associated	VERB	O	O	2658
with	ADP	O	O	2658
extreme	ADJ	O	O	2658
hypotension	NOUN	O	Disease	2658
and	CCONJ	O	O	2658
dysrhythmias	VERB	O	Disease	2658
within	ADP	O	O	2658
the	PRON	O	O	2658
first	ADV	O	O	2658
48	NUM	O	O	2658
hours	NOUN	O	O	2658
of	ADP	O	O	2658
their	PRON	O	O	2658
admission	NOUN	O	O	2658
to	PART	O	O	2658
the	PRON	O	O	2658
pediatric	ADJ	O	O	2658
intensive	ADJ	O	O	2658
care	VERB	O	O	2658
unit	NOUN	O	O	2658
(	PUNCT	O	O	2658
PICU	NOUN	O	O	2658
)	PUNCT	O	O	2658
.	PUNCT	O	O	2658
These	PRON	O	O	2659
patients	NOUN	O	O	2659
had	VERB	O	O	2659
a	PRON	O	O	2659
second	ADV	O	O	2659
event	NOUN	O	O	2659
of	ADP	O	O	2659
cardiac arrest	NOUN	O	Disease	2659
,	PUNCT	O	O	2659
resulting	VERB	O	O	2659
in	ADP	O	O	2659
death	NOUN	O	O	2659
,	PUNCT	O	O	2659
within	ADP	O	O	2659
10	NUM	O	O	2659
to	PART	O	O	2659
60	NUM	O	O	2659
minutes	NOUN	O	O	2659
.	PUNCT	O	O	2659
We	PRON	O	O	2660
conclude	VERB	O	O	2660
that	SCONJ	O	O	2660
cardiac	ADJ	O	O	2660
pacing	NOUN	O	O	2660
during	ADP	O	O	2660
resuscitative	PROPN	O	O	2660
efforts	NOUN	O	O	2660
in	ADP	O	O	2660
pediatric	ADJ	O	O	2660
patients	NOUN	O	O	2660
suffering	VERB	O	O	2660
from	ADP	O	O	2660
acute	ADJ	O	O	2660
myocardial	ADJ	O	O	2660
dysfunction	NOUN	O	O	2660
may	AUX	O	O	2660
not	PART	O	O	2660
have	VERB	O	O	2660
long	ADV	O	O	2660
-	PUNCT	O	O	2660
term	NOUN	O	O	2660
value	NOUN	O	O	2660
in	ADP	O	O	2660
and	CCONJ	O	O	2660
of	ADP	O	O	2660
itself	PRON	O	O	2660
;	PUNCT	O	O	2660
however	ADV	O	O	2660
,	PUNCT	O	O	2660
if	SCONJ	O	O	2660
temporary	ADJ	O	O	2660
hemodynamic	ADJ	O	O	2660
stability	PROPN	O	O	2660
is	AUX	O	O	2660
achieved	VERB	O	O	2660
by	ADP	O	O	2660
this	PRON	O	O	2660
procedure	NOUN	O	O	2660
,	PUNCT	O	O	2660
it	PRON	O	O	2660
may	AUX	O	O	2660
provide	VERB	O	O	2660
additional	ADJ	O	O	2660
time	NOUN	O	O	2660
needed	VERB	O	O	2660
to	PART	O	O	2660
institute	PROPN	O	O	2660
other	ADJ	O	O	2660
therapeutic	ADJ	O	O	2660
modalities	NOUN	O	O	2660
.	PUNCT	O	O	2660
Efficacy	NOUN	O	O	2663
and	CCONJ	O	O	2663
safety	NOUN	O	O	2663
of	ADP	O	O	2663
granisetron	NOUN	O	O	2663
,	PUNCT	O	O	2663
a	PRON	O	O	2663
selective	ADJ	O	O	2663
5-hydroxytryptamine-3	NUM	O	O	2663
receptor	NOUN	O	O	2663
antagonist	NOUN	O	O	2663
,	PUNCT	O	O	2663
in	ADP	O	O	2663
the	PRON	O	O	2663
prevention	NOUN	O	O	2663
of	ADP	O	O	2663
nausea	NOUN	O	Disease	2663
and	CCONJ	O	O	2663
vomiting	VERB	O	Disease	2663
induced	VERB	O	O	2663
by	ADP	O	O	2663
high	ADJ	O	O	2663
-	PUNCT	O	O	2663
dose	NOUN	O	O	2663
cisplatin	NOUN	O	Chemical	2663
.	PUNCT	O	O	2663
PURPOSE	NOUN	O	O	2664
:	PUNCT	O	O	2664
To	PART	O	O	2664
assess	VERB	O	O	2664
the	PRON	O	O	2664
antiemetic	ADJ	O	O	2664
effects	NOUN	O	O	2664
and	CCONJ	O	O	2664
safety	NOUN	O	O	2664
profile	NOUN	O	O	2664
of	ADP	O	O	2664
four	NUM	O	O	2664
different	ADJ	O	O	2664
doses	NOUN	O	O	2664
of	ADP	O	O	2664
granisetron	NOUN	O	O	2664
(	PUNCT	O	O	2664
Kytril	PROPN	O	O	2664
;	PUNCT	O	O	2664
SmithKline	PROPN	O	O	2664
Beecham	PROPN	O	O	2664
Pharmaceuticals	NOUN	O	O	2664
,	PUNCT	O	O	2664
Philadelphia	PROPN	O	O	2664
,	PUNCT	O	O	2664
PA	PROPN	O	Disease	2664
)	PUNCT	O	O	2664
when	SCONJ	O	O	2664
administered	VERB	O	O	2664
as	ADP	O	O	2664
a	PRON	O	O	2664
single	ADJ	O	O	2664
intravenous	ADJ	O	O	2664
(	PUNCT	O	O	2664
IV	NUM	O	O	2664
)	PUNCT	O	O	2664
dose	NOUN	O	O	2664
for	ADP	O	O	2664
prophylaxis	NOUN	O	O	2664
of	ADP	O	O	2664
cisplatin	NOUN	O	Chemical	2664
-	PUNCT	O	O	2664
induced	VERB	O	O	2664
nausea	NOUN	O	Disease	2664
and	CCONJ	O	O	2664
vomiting	VERB	O	Disease	2664
.	PUNCT	O	O	2664
One	NUM	O	O	2665
hundred	NUM	O	O	2665
eighty	NUM	O	O	2665
-	PUNCT	O	O	2665
four	NUM	O	O	2665
chemotherapy	NOUN	O	O	2665
-	PUNCT	O	O	2665
naive	ADJ	O	O	2665
patients	NOUN	O	O	2665
receiving	VERB	O	O	2665
high	ADJ	O	O	2665
-	PUNCT	O	O	2665
dose	NOUN	O	O	2665
cisplatin	NOUN	O	Chemical	2665
(	PUNCT	O	O	2665
81	NUM	O	O	2665
to	PART	O	O	2665
120	NUM	O	O	2665
mg	VERB	O	O	2665
/	PUNCT	O	O	2665
m2	PROPN	O	O	2665
)	PUNCT	O	O	2665
were	AUX	O	O	2665
randomized	VERB	O	O	2665
to	PART	O	O	2665
receive	VERB	O	O	2665
one	NUM	O	O	2665
of	ADP	O	O	2665
four	NUM	O	O	2665
granisetron	NOUN	O	O	2665
doses	NOUN	O	O	2665
(	PUNCT	O	O	2665
5	NUM	O	O	2665
,	PUNCT	O	O	2665
10	NUM	O	O	2665
,	PUNCT	O	O	2665
20	NUM	O	O	2665
,	PUNCT	O	O	2665
or	CCONJ	O	O	2665
40	NUM	O	O	2665
micrograms	NOUN	O	O	2665
/	PUNCT	O	O	2665
kg	VERB	O	O	2665
)	PUNCT	O	O	2665
administered	VERB	O	O	2665
before	ADP	O	O	2665
chemotherapy	NOUN	O	O	2665
.	PUNCT	O	O	2665
Patients	NOUN	O	O	2666
were	AUX	O	O	2666
observed	VERB	O	O	2666
on	ADP	O	O	2666
an	PRON	O	O	2666
inpatient	ADJ	O	O	2666
basis	NOUN	O	O	2666
for	ADP	O	O	2666
18	NUM	O	O	2666
to	PART	O	O	2666
24	NUM	O	O	2666
hours	NOUN	O	O	2666
,	PUNCT	O	O	2666
and	CCONJ	O	O	2666
vital	ADJ	O	O	2666
signs	NOUN	O	O	2666
,	PUNCT	O	O	2666
nausea	NOUN	O	Disease	2666
,	PUNCT	O	O	2666
vomiting	VERB	O	Disease	2666
,	PUNCT	O	O	2666
retching	VERB	O	O	2666
,	PUNCT	O	O	2666
and	CCONJ	O	O	2666
appetite	PROPN	O	O	2666
were	AUX	O	O	2666
assessed	VERB	O	O	2666
.	PUNCT	O	O	2666
After	ADP	O	O	2667
granisetron	NOUN	O	O	2667
doses	NOUN	O	O	2667
of	ADP	O	O	2667
5	NUM	O	O	2667
,	PUNCT	O	O	2667
10	NUM	O	O	2667
,	PUNCT	O	O	2667
20	NUM	O	O	2667
,	PUNCT	O	O	2667
and	CCONJ	O	O	2667
40	NUM	O	O	2667
micrograms	NOUN	O	O	2667
/	PUNCT	O	O	2667
kg	VERB	O	O	2667
,	PUNCT	O	O	2667
a	PRON	O	O	2667
major	ADJ	O	O	2667
response	NOUN	O	O	2667
(	PUNCT	O	O	2667
<	X	O	O	2667
or	CCONJ	O	O	2667
=	PUNCT	O	O	2667
two	NUM	O	O	2667
vomiting	VERB	O	Disease	2667
or	CCONJ	O	O	2667
retching	VERB	O	O	2667
episodes	NOUN	O	O	2667
,	PUNCT	O	O	2667
and	CCONJ	O	O	2667
no	PRON	O	O	2667
antiemetic	ADJ	O	O	2667
rescue	NOUN	O	O	2667
)	PUNCT	O	O	2667
was	AUX	O	O	2667
recorded	VERB	O	O	2667
in	ADP	O	O	2667
23%	NOUN	O	O	2667
,	PUNCT	O	O	2667
57%	NOUN	O	O	2667
,	PUNCT	O	O	2667
58%	NOUN	O	O	2667
,	PUNCT	O	O	2667
and	CCONJ	O	O	2667
60%	NOUN	O	O	2667
of	ADP	O	O	2667
patients	NOUN	O	O	2667
,	PUNCT	O	O	2667
respectively	ADV	O	O	2667
,	PUNCT	O	O	2667
and	CCONJ	O	O	2667
a	PRON	O	O	2667
complete	VERB	O	O	2667
response	NOUN	O	O	2667
(	PUNCT	O	O	2667
no	PRON	O	O	2667
vomiting	VERB	O	Disease	2667
or	CCONJ	O	O	2667
retching	VERB	O	O	2667
,	PUNCT	O	O	2667
and	CCONJ	O	O	2667
no	PRON	O	O	2667
antiemetic	ADJ	O	O	2667
rescue	NOUN	O	O	2667
)	PUNCT	O	O	2667
in	ADP	O	O	2667
18%	NOUN	O	O	2667
,	PUNCT	O	O	2667
41%	NOUN	O	O	2667
,	PUNCT	O	O	2667
40%	NOUN	O	O	2667
,	PUNCT	O	O	2667
and	CCONJ	O	O	2667
47%	NOUN	O	O	2667
of	ADP	O	O	2667
patients	NOUN	O	O	2667
,	PUNCT	O	O	2667
respectively	ADV	O	O	2667
.	PUNCT	O	O	2667
There	ADV	O	O	2668
was	AUX	O	O	2668
a	PRON	O	O	2668
statistically	ADV	O	O	2668
longer	ADV	O	O	2668
time	NOUN	O	O	2668
to	PART	O	O	2668
first	ADV	O	O	2668
episode	PROPN	O	O	2668
of	ADP	O	O	2668
nausea	NOUN	O	Disease	2668
(	PUNCT	O	O	2668
P	NOUN	O	Chemical	2668
=	PUNCT	O	O	2668
.0015	PUNCT	O	O	2668
)	PUNCT	O	O	2668
and	CCONJ	O	O	2668
vomiting	VERB	O	Disease	2668
(	PUNCT	O	O	2668
P	NOUN	O	Chemical	2668
=	PUNCT	O	O	2668
.0001	PUNCT	O	O	2668
)	PUNCT	O	O	2668
,	PUNCT	O	O	2668
and	CCONJ	O	O	2668
fewer	ADJ	O	O	2668
patients	NOUN	O	O	2668
were	AUX	O	O	2668
administered	VERB	O	O	2668
additional	ADJ	O	O	2668
antiemetic	ADJ	O	O	2668
medication	NOUN	O	O	2668
in	ADP	O	O	2668
the	PRON	O	O	2668
10-micrograms	NOUN	O	O	2668
/	PUNCT	O	O	2668
kg	VERB	O	O	2668
dosing	VERB	O	O	2668
groups	NOUN	O	O	2668
than	ADP	O	O	2668
in	ADP	O	O	2668
the	PRON	O	O	2668
5-micrograms	NOUN	O	O	2668
/	PUNCT	O	O	2668
kg	VERB	O	O	2668
dosing	VERB	O	O	2668
group	NOUN	O	O	2668
.	PUNCT	O	O	2668
As	ADP	O	O	2669
granisetron	NOUN	O	O	2669
dose	NOUN	O	O	2669
increased	VERB	O	O	2669
,	PUNCT	O	O	2669
appetite	PROPN	O	O	2669
return	VERB	O	O	2669
increased	VERB	O	O	2669
(	PUNCT	O	O	2669
P	NOUN	O	Chemical	2669
=	PUNCT	O	O	2669
.040	NUM	O	O	2669
)	PUNCT	O	O	2669
.	PUNCT	O	O	2669
Headache	NOUN	O	Disease	2670
was	AUX	O	O	2670
the	PRON	O	O	2670
most	ADV	O	O	2670
frequently	ADV	O	O	2670
reported	VERB	O	O	2670
adverse	ADJ	O	O	2670
event	NOUN	O	O	2670
(	PUNCT	O	O	2670
20%	NOUN	O	O	2670
)	PUNCT	O	O	2670
.	PUNCT	O	O	2670
A	PRON	O	O	2671
single	ADJ	O	O	2671
10-	X	O	O	2671
,	PUNCT	O	O	2671
20-	NUM	O	O	2671
,	PUNCT	O	O	2671
or	CCONJ	O	O	2671
40-micrograms	NOUN	O	O	2671
/	PUNCT	O	O	2671
kg	VERB	O	O	2671
dose	NOUN	O	O	2671
of	ADP	O	O	2671
granisetron	NOUN	O	O	2671
was	AUX	O	O	2671
effective	ADJ	O	O	2671
in	ADP	O	O	2671
controlling	VERB	O	O	2671
vomiting	VERB	O	Disease	2671
in	ADP	O	O	2671
57%	NOUN	O	O	2671
to	PART	O	O	2671
60%	NOUN	O	O	2671
of	ADP	O	O	2671
patients	NOUN	O	O	2671
who	PRON	O	O	2671
received	VERB	O	O	2671
cisplatin	NOUN	O	Chemical	2671
at	ADP	O	O	2671
doses	NOUN	O	O	2671
greater	ADJ	O	O	2671
than	ADP	O	O	2671
81	NUM	O	O	2671
mg	VERB	O	O	2671
/	PUNCT	O	O	2671
m2	PROPN	O	O	2671
and	CCONJ	O	O	2671
totally	ADV	O	O	2671
prevented	VERB	O	O	2671
vomiting	VERB	O	Disease	2671
in	ADP	O	O	2671
40%	NOUN	O	O	2671
to	PART	O	O	2671
47%	NOUN	O	O	2671
of	ADP	O	O	2671
patients	NOUN	O	O	2671
.	PUNCT	O	O	2671
Granisetron	NOUN	O	O	2672
was	AUX	O	O	2672
well	ADV	O	O	2672
tolerated	VERB	O	O	2672
at	ADP	O	O	2672
all	PRON	O	O	2672
doses	NOUN	O	O	2672
.	PUNCT	O	O	2672
Adverse	ADJ	O	O	2675
interaction	NOUN	O	O	2675
between	ADP	O	O	2675
clonidine	NOUN	O	Chemical	2675
and	CCONJ	O	O	2675
verapamil	PROPN	O	Chemical	2675
.	PUNCT	O	O	2675
OBJECTIVE	VERB	O	O	2676
:	PUNCT	O	O	2676
To	PART	O	O	2676
report	VERB	O	O	2676
two	NUM	O	O	2676
cases	NOUN	O	O	2676
of	ADP	O	O	2676
a	PRON	O	O	2676
possible	ADJ	O	O	2676
adverse	ADJ	O	O	2676
interaction	NOUN	O	O	2676
between	ADP	O	O	2676
clonidine	NOUN	O	Chemical	2676
and	CCONJ	O	O	2676
verapamil	PROPN	O	Chemical	2676
resulting	VERB	O	O	2676
in	ADP	O	O	2676
atrioventricular	ADJ	O	O	2676
(	PUNCT	O	O	2676
AV	NOUN	O	O	2676
)	PUNCT	O	O	2676
block	NOUN	O	O	2676
in	ADP	O	O	2676
both	PRON	O	O	2676
patients	NOUN	O	O	2676
and	CCONJ	O	O	2676
severe	ADJ	O	O	2676
hypotension	NOUN	O	Disease	2676
in	ADP	O	O	2676
one	NUM	O	O	2676
patient	NOUN	O	O	2676
.	PUNCT	O	O	2676
A	PRON	O	O	2677
54-year	NOUN	O	O	2677
-	PUNCT	O	O	2677
old	ADJ	O	O	2677
woman	NOUN	O	O	2677
with	ADP	O	O	2677
hyperaldosteronism	NOUN	O	O	2677
was	AUX	O	O	2677
treated	VERB	O	O	2677
with	ADP	O	O	2677
verapamil	PROPN	O	Chemical	2677
480	NUM	O	O	2677
mg	VERB	O	O	2677
/	PUNCT	O	O	2677
d	X	O	O	2677
and	CCONJ	O	O	2677
spironolactone	NOUN	O	Chemical	2677
100	NUM	O	O	2677
mg	VERB	O	O	2677
/	PUNCT	O	O	2677
d	X	O	O	2677
.	PUNCT	O	O	2677
After	ADP	O	O	2678
the	PRON	O	O	2678
addition	NOUN	O	O	2678
of	ADP	O	O	2678
a	PRON	O	O	2678
minimal	ADJ	O	O	2678
dose	NOUN	O	O	2678
of	ADP	O	O	2678
clonidine	NOUN	O	Chemical	2678
(	PUNCT	O	O	2678
0.15	NUM	O	O	2678
mg	VERB	O	O	2678
bid	VERB	O	O	2678
)	PUNCT	O	O	2678
,	PUNCT	O	O	2678
she	PRON	O	O	2678
developed	VERB	O	O	2678
complete	VERB	O	O	2678
AV	NOUN	O	O	2678
block	NOUN	O	O	2678
and	CCONJ	O	O	2678
severe	ADJ	O	O	2678
hypotension	NOUN	O	Disease	2678
,	PUNCT	O	O	2678
which	PRON	O	O	2678
resolved	VERB	O	O	2678
upon	SCONJ	O	O	2678
cessation	NOUN	O	O	2678
of	ADP	O	O	2678
all	PRON	O	O	2678
medications	NOUN	O	O	2678
.	PUNCT	O	O	2678
A	PRON	O	O	2679
65-year	NOUN	O	O	2679
-	PUNCT	O	O	2679
old	ADJ	O	O	2679
woman	NOUN	O	O	2679
was	AUX	O	O	2679
treated	VERB	O	O	2679
with	ADP	O	O	2679
extended	VERB	O	O	2679
-	PUNCT	O	O	2679
release	NOUN	O	O	2679
verapamil	PROPN	O	Chemical	2679
240	NUM	O	O	2679
mg	VERB	O	O	2679
/	PUNCT	O	O	2679
d	X	O	O	2679
.	PUNCT	O	O	2679
After	ADP	O	O	2680
the	PRON	O	O	2680
addition	NOUN	O	O	2680
of	ADP	O	O	2680
clonidine	NOUN	O	Chemical	2680
0.15	NUM	O	O	2680
mg	VERB	O	O	2680
bid	VERB	O	O	2680
she	PRON	O	O	2680
developed	VERB	O	O	2680
complete	VERB	O	O	2680
AV	NOUN	O	O	2680
block	NOUN	O	O	2680
,	PUNCT	O	O	2680
which	PRON	O	O	2680
resolved	VERB	O	O	2680
after	ADP	O	O	2680
all	PRON	O	O	2680
therapy	NOUN	O	O	2680
was	AUX	O	O	2680
stopped	VERB	O	O	2680
.	PUNCT	O	O	2680
DISCUSSION	NOUN	O	O	2681
:	PUNCT	O	O	2681
An	PRON	O	O	2681
adverse	ADJ	O	O	2681
interaction	NOUN	O	O	2681
between	ADP	O	O	2681
clonidine	NOUN	O	Chemical	2681
and	CCONJ	O	O	2681
verapamil	PROPN	O	Chemical	2681
has	VERB	O	O	2681
not	PART	O	O	2681
been	AUX	O	O	2681
reported	VERB	O	O	2681
previously	ADV	O	O	2681
.	PUNCT	O	O	2681
Caution	NOUN	O	O	2682
is	AUX	O	O	2682
recommended	VERB	O	O	2682
in	ADP	O	O	2682
combining	VERB	O	O	2682
clonidine	NOUN	O	Chemical	2682
and	CCONJ	O	O	2682
verapamil	PROPN	O	Chemical	2682
therapy	NOUN	O	O	2682
,	PUNCT	O	O	2682
even	ADV	O	O	2682
in	ADP	O	O	2682
patients	NOUN	O	O	2682
who	PRON	O	O	2682
do	VERB	O	O	2682
not	PART	O	O	2682
have	VERB	O	O	2682
sinus	NOUN	O	O	2682
or	CCONJ	O	O	2682
AV	NOUN	O	O	2682
node	NOUN	O	O	2682
dysfunction	NOUN	O	O	2682
.	PUNCT	O	O	2682
Pharmacological	ADJ	O	O	2685
studies	NOUN	O	O	2685
on	ADP	O	O	2685
a	PRON	O	O	2685
new	ADJ	O	O	2685
dihydrothienopyridine	NOUN	O	O	2685
calcium	NOUN	O	Chemical	2685
antagonist	NOUN	O	O	2685
,	PUNCT	O	O	2685
S-312-d	NOUN	O	O	2685
.	PUNCT	O	O	2685
S-312	PROPN	O	O	2686
,	PUNCT	O	O	2686
S-312-d	NOUN	O	O	2686
,	PUNCT	O	O	2686
but	CCONJ	O	O	2686
not	PART	O	O	2686
S-312-l	NOUN	O	O	2686
,	PUNCT	O	O	2686
L	NOUN	O	O	2686
-	PUNCT	O	O	2686
type	NOUN	O	O	2686
calcium	NOUN	O	Chemical	2686
channel	PROPN	O	O	2686
antagonists	NOUN	O	O	2686
,	PUNCT	O	O	2686
showed	VERB	O	O	2686
anticonvulsant	ADJ	O	O	2686
effects	NOUN	O	O	2686
on	ADP	O	O	2686
the	PRON	O	O	2686
audiogenic	ADJ	O	O	2686
tonic	PROPN	O	O	2686
convulsions	NOUN	O	Disease	2686
in	ADP	O	O	2686
DBA/2	PROPN	O	O	2686
mice	NOUN	O	O	2686
;	PUNCT	O	O	2686
and	CCONJ	O	O	2686
their	PRON	O	O	2686
ED50	PROPN	O	O	2686
values	NOUN	O	O	2686
were	AUX	O	O	2686
18.4	NUM	O	O	2686
(	PUNCT	O	O	2686
12.8	NUM	O	O	2686
-	PUNCT	O	O	2686
27.1	NUM	O	O	2686
)	PUNCT	O	O	2686
mg	VERB	O	O	2686
/	PUNCT	O	O	2686
kg	VERB	O	O	2686
,	PUNCT	O	O	2686
p.o	PROPN	O	O	2686
.	PUNCT	O	O	2686
and	CCONJ	O	O	2687
15.0	NUM	O	O	2687
(	PUNCT	O	O	2687
10.2	NUM	O	O	2687
-	PUNCT	O	O	2687
23.7	NUM	O	O	2687
)	PUNCT	O	O	2687
mg	VERB	O	O	2687
/	PUNCT	O	O	2687
kg	VERB	O	O	2687
,	PUNCT	O	O	2687
p.o	PROPN	O	O	2687
.	PUNCT	O	O	2687
,	PUNCT	O	O	2687
respectively	ADV	O	O	2687
,	PUNCT	O	O	2687
while	SCONJ	O	O	2687
that	SCONJ	O	O	2687
of	ADP	O	O	2687
flunarizine	VERB	O	O	2687
was	AUX	O	O	2687
34.0	NUM	O	O	2687
(	PUNCT	O	O	2687
26.0	NUM	O	O	2687
-	PUNCT	O	O	2687
44.8	NUM	O	O	2687
Although	SCONJ	O	O	2688
moderate	ADJ	O	O	2688
anticonvulsant	ADJ	O	O	2688
effects	NOUN	O	O	2688
of	ADP	O	O	2688
S-312-d	NOUN	O	O	2688
in	ADP	O	O	2688
higher	ADJ	O	O	2688
doses	NOUN	O	O	2688
were	AUX	O	O	2688
observed	VERB	O	O	2688
against	ADP	O	O	2688
the	PRON	O	O	2688
clonic	ADJ	O	O	2688
convulsions	NOUN	O	Disease	2688
induced	VERB	O	O	2688
by	ADP	O	O	2688
pentylenetetrazole	NOUN	O	Chemical	2688
(	PUNCT	O	O	2688
85	NUM	O	O	2688
mg	VERB	O	O	2688
/	PUNCT	O	O	2688
kg	VERB	O	O	2688
,	PUNCT	O	O	2688
s.c	PROPN	O	O	2688
.	PUNCT	O	O	2688
)	PUNCT	O	O	2688
or	CCONJ	O	O	2688
bemegride	ADV	O	O	2688
(	PUNCT	O	O	2688
40	NUM	O	O	2688
mg	VERB	O	O	2688
/	PUNCT	O	O	2688
kg	VERB	O	O	2688
,	PUNCT	O	O	2688
s.c	PROPN	O	O	2688
.	PUNCT	O	O	2688
)	PUNCT	O	O	2688
,	PUNCT	O	O	2688
no	PRON	O	O	2688
effects	NOUN	O	O	2688
were	AUX	O	O	2688
observed	VERB	O	O	2688
in	ADP	O	O	2688
convulsions	NOUN	O	Disease	2688
induced	VERB	O	O	2688
by	ADP	O	O	2688
N	NUM	O	O	2688
-	PUNCT	O	O	2688
methyl	NOUN	O	O	2688
-	PUNCT	O	O	2688
D	NOUN	O	O	2688
-	PUNCT	O	O	2688
aspartate	NOUN	O	Chemical	2688
,	PUNCT	O	O	2688
picrotoxin	PROPN	O	Chemical	2688
,	PUNCT	O	O	2688
or	CCONJ	O	O	2688
electroshock	NOUN	O	O	2688
in	ADP	O	O	2688
Slc	PROPN	O	O	2688
:	PUNCT	O	O	2688
ddY	NUM	O	O	2688
mice	NOUN	O	O	2688
.	PUNCT	O	O	2688
S-312-d	NOUN	O	O	2689
may	AUX	O	O	2689
be	AUX	O	O	2689
useful	ADJ	O	O	2689
in	ADP	O	O	2689
the	PRON	O	O	2689
therapy	NOUN	O	O	2689
of	ADP	O	O	2689
certain	ADJ	O	O	2689
types	NOUN	O	O	2689
of	ADP	O	O	2689
human	PROPN	O	O	2689
epilepsy	NOUN	O	Disease	2689
.	PUNCT	O	O	2689
Transmural	PROPN	O	O	2692
myocardial infarction	NOUN	O	Disease	2692
with	ADP	O	O	2692
sumatriptan	PROPN	O	O	2692
.	PUNCT	O	O	2692
For	ADP	O	O	2693
sumatriptan	PROPN	O	O	2693
,	PUNCT	O	O	2693
tightness	NOUN	O	O	2693
in	ADP	O	O	2693
the	PRON	O	O	2693
chest	NOUN	O	O	2693
caused	VERB	O	O	2693
by	ADP	O	O	2693
an	PRON	O	O	2693
unknown	ADJ	O	O	2693
mechanism	NOUN	O	O	2693
has	VERB	O	O	2693
been	AUX	O	O	2693
reported	VERB	O	O	2693
in	ADP	O	O	2693
3	X	O	O	2693
-	PUNCT	O	O	2693
5%	NOUN	O	O	2693
of	ADP	O	O	2693
users	NOUN	O	O	2693
.	PUNCT	O	O	2693
We	PRON	O	O	2694
describe	VERB	O	O	2694
a	PRON	O	O	2694
47-year	NOUN	O	O	2694
-	PUNCT	O	O	2694
old	ADJ	O	O	2694
woman	NOUN	O	O	2694
with	ADP	O	O	2694
an	PRON	O	O	2694
acute	ADJ	O	O	2694
myocardial infarction	NOUN	O	Disease	2694
after	ADP	O	O	2694
administration	NOUN	O	O	2694
of	ADP	O	O	2694
sumatriptan	PROPN	O	O	2694
6	NUM	O	O	2694
mg	VERB	O	O	2694
subcutaneously	ADV	O	O	2694
for	ADP	O	O	2694
cluster headache	NOUN	O	Disease	2694
.	PUNCT	O	O	2694
The	PRON	O	O	2695
patient	NOUN	O	O	2695
had	VERB	O	O	2695
no	PRON	O	O	2695
history	NOUN	O	O	2695
of	ADP	O	O	2695
underlying	VERB	O	O	2695
ischaemic	ADJ	O	O	2695
heart disease	NOUN	O	Disease	2695
or	CCONJ	O	O	2695
Prinzmetal	PROPN	O	O	2695
's	AUX	O	O	2695
angina	NOUN	O	Disease	2695
.	PUNCT	O	O	2695
Flumazenil	PROPN	O	Chemical	2698
induces	VERB	O	O	2698
seizures	NOUN	O	Disease	2698
and	CCONJ	O	O	2698
death	NOUN	O	O	2698
in	ADP	O	O	2698
mixed	VERB	O	O	2698
cocaine	NOUN	O	Chemical	2698
-	PUNCT	O	O	2698
diazepam	NOUN	O	Chemical	2698
intoxications	NOUN	O	O	2698
.	PUNCT	O	O	2698
Administration	NOUN	O	O	2699
of	ADP	O	O	2699
the	PRON	O	O	2699
benzodiazepine	PROPN	O	Chemical	2699
antagonist	NOUN	O	O	2699
flumazenil	NOUN	O	Chemical	2699
may	AUX	O	O	2699
unmask	VERB	O	O	2699
seizures	NOUN	O	Disease	2699
in	ADP	O	O	2699
mixed	VERB	O	O	2699
cocaine	NOUN	O	Chemical	2699
-	PUNCT	O	O	2699
benzodiazepine	PROPN	O	Chemical	2699
intoxication	NOUN	O	O	2699
.	PUNCT	O	O	2699
Male	NOUN	O	O	2700
Sprague	PROPN	O	O	2700
-	PUNCT	O	O	2700
Dawley	NOUN	O	O	2700
rats	NOUN	O	O	2700
received	VERB	O	O	2700
100	NUM	O	O	2700
mg	VERB	O	O	2700
/	PUNCT	O	O	2700
kg	VERB	O	O	2700
cocaine	NOUN	O	Chemical	2700
IP	PROPN	O	O	2700
alone	ADV	O	O	2700
,	PUNCT	O	O	2700
5	NUM	O	O	2700
mg	VERB	O	O	2700
/	PUNCT	O	O	2700
kg	VERB	O	O	2700
diazepam	NOUN	O	Chemical	2700
alone	ADV	O	O	2700
,	PUNCT	O	O	2700
or	CCONJ	O	O	2700
a	PRON	O	O	2700
combination	NOUN	O	O	2700
of	ADP	O	O	2700
diazepam	NOUN	O	Chemical	2700
and	CCONJ	O	O	2700
cocaine	NOUN	O	Chemical	2700
.	PUNCT	O	O	2700
Three	NUM	O	O	2701
minutes	NOUN	O	O	2701
later	ADV	O	O	2701
,	PUNCT	O	O	2701
groups	NOUN	O	O	2701
were	AUX	O	O	2701
challenged	VERB	O	O	2701
with	ADP	O	O	2701
vehicle	NOUN	O	O	2701
or	CCONJ	O	O	2701
flumazenil	NOUN	O	Chemical	2701
5	NUM	O	O	2701
or	CCONJ	O	O	2701
10	NUM	O	O	2701
mg	VERB	O	O	2701
/	PUNCT	O	O	2701
kg	VERB	O	O	2701
IP	PROPN	O	O	2701
.	PUNCT	O	O	2701
Animal	NOUN	O	O	2702
behavior	NOUN	O	O	2702
,	PUNCT	O	O	2702
seizures	NOUN	O	Disease	2702
(	PUNCT	O	O	2702
time	NOUN	O	O	2702
to	PART	O	O	2702
and	CCONJ	O	O	2702
incidence	NOUN	O	O	2702
)	PUNCT	O	O	2702
,	PUNCT	O	O	2702
death	NOUN	O	O	2702
(	PUNCT	O	O	2702
time	NOUN	O	O	2702
to	PART	O	O	2702
and	CCONJ	O	O	2702
incidence	NOUN	O	O	2702
)	PUNCT	O	O	2702
,	PUNCT	O	O	2702
and	CCONJ	O	O	2702
cortical	ADJ	O	O	2702
EEG	NOUN	O	O	2702
tracings	NOUN	O	O	2702
were	AUX	O	O	2702
recorded	VERB	O	O	2702
.	PUNCT	O	O	2702
Administration	NOUN	O	O	2703
of	ADP	O	O	2703
flumazenil	NOUN	O	Chemical	2703
to	PART	O	O	2703
animals	NOUN	O	O	2703
after	ADP	O	O	2703
they	PRON	O	O	2703
had	VERB	O	O	2703
received	VERB	O	O	2703
a	PRON	O	O	2703
combination	NOUN	O	O	2703
dose	NOUN	O	O	2703
of	ADP	O	O	2703
cocaine	NOUN	O	Chemical	2703
and	CCONJ	O	O	2703
diazepam	NOUN	O	Chemical	2703
.	PUNCT	O	O	2703
In	ADP	O	O	2704
group	NOUN	O	O	2704
1	X	O	O	2704
,	PUNCT	O	O	2704
animals	NOUN	O	O	2704
received	VERB	O	O	2704
cocaine	NOUN	O	Chemical	2704
followed	VERB	O	O	2704
by	ADP	O	O	2704
vehicle	NOUN	O	O	2704
.	PUNCT	O	O	2704
This	PRON	O	O	2705
resulted	VERB	O	O	2705
in	ADP	O	O	2705
100%	NOUN	O	O	2705
developing	VERB	O	O	2705
seizures	NOUN	O	Disease	2705
and	CCONJ	O	O	2705
death	NOUN	O	O	2705
.	PUNCT	O	O	2705
Group	PROPN	O	O	2706
2	X	O	O	2706
received	VERB	O	O	2706
diazepam	NOUN	O	Chemical	2706
alone	ADV	O	O	2706
followed	VERB	O	O	2706
by	ADP	O	O	2706
vehicle	NOUN	O	O	2706
.	PUNCT	O	O	2706
Group	PROPN	O	O	2707
3	X	O	O	2707
received	VERB	O	O	2707
diazepam	NOUN	O	Chemical	2707
followed	VERB	O	O	2707
by	ADP	O	O	2707
5	NUM	O	O	2707
mg	VERB	O	O	2707
/	PUNCT	O	O	2707
kg	VERB	O	O	2707
flumazenil	NOUN	O	Chemical	2707
.	PUNCT	O	O	2707
Animals	NOUN	O	O	2708
became	VERB	O	O	2708
somnolent	ADJ	O	O	2708
after	ADP	O	O	2708
diazepam	NOUN	O	Chemical	2708
and	CCONJ	O	O	2708
then	ADV	O	O	2708
active	ADJ	O	O	2708
after	ADP	O	O	2708
flumazenil	NOUN	O	Chemical	2708
administration	NOUN	O	O	2708
.	PUNCT	O	O	2708
In	ADP	O	O	2709
group	NOUN	O	O	2709
4	NUM	O	O	2709
,	PUNCT	O	O	2709
a	PRON	O	O	2709
combination	NOUN	O	O	2709
of	ADP	O	O	2709
cocaine	NOUN	O	Chemical	2709
and	CCONJ	O	O	2709
diazepam	NOUN	O	Chemical	2709
was	AUX	O	O	2709
administered	VERB	O	O	2709
simultaneously	ADV	O	O	2709
.	PUNCT	O	O	2709
This	PRON	O	O	2710
resulted	VERB	O	O	2710
in	ADP	O	O	2710
no	PRON	O	O	2710
overt	ADJ	O	O	2710
or	CCONJ	O	O	2710
EEG	NOUN	O	O	2710
-	PUNCT	O	O	2710
detectable	ADJ	O	O	2710
seizures	NOUN	O	Disease	2710
and	CCONJ	O	O	2710
a	PRON	O	O	2710
50%	NOUN	O	O	2710
incidence	NOUN	O	O	2710
of	ADP	O	O	2710
death	NOUN	O	O	2710
.	PUNCT	O	O	2710
Group	PROPN	O	O	2711
5	NUM	O	O	2711
received	VERB	O	O	2711
a	PRON	O	O	2711
similar	ADJ	O	O	2711
combination	NOUN	O	O	2711
of	ADP	O	O	2711
cocaine	NOUN	O	Chemical	2711
and	CCONJ	O	O	2711
diazepam	NOUN	O	Chemical	2711
,	PUNCT	O	O	2711
followed	VERB	O	O	2711
later	ADV	O	O	2711
by	ADP	O	O	2711
5	NUM	O	O	2711
mg	VERB	O	O	2711
/	PUNCT	O	O	2711
kg	VERB	O	O	2711
flumazenil	NOUN	O	Chemical	2711
.	PUNCT	O	O	2711
This	PRON	O	O	2712
resulted	VERB	O	O	2712
in	ADP	O	O	2712
an	PRON	O	O	2712
increased	VERB	O	O	2712
incidence	NOUN	O	O	2712
of	ADP	O	O	2712
seizures	NOUN	O	Disease	2712
,	PUNCT	O	O	2712
90%	NOUN	O	O	2712
(	PUNCT	O	O	2712
P	NOUN	O	Chemical	2712
<	X	O	O	2712
.01	NUM	O	O	2712
)	PUNCT	O	O	2712
,	PUNCT	O	O	2712
and	CCONJ	O	O	2712
death	NOUN	O	O	2712
,	PUNCT	O	O	2712
100%	NOUN	O	O	2712
Group	PROPN	O	O	2713
6	NUM	O	O	2713
received	VERB	O	O	2713
cocaine	NOUN	O	Chemical	2713
and	CCONJ	O	O	2713
diazepam	NOUN	O	Chemical	2713
followed	VERB	O	O	2713
by	ADP	O	O	2713
10	NUM	O	O	2713
mg	VERB	O	O	2713
/	PUNCT	O	O	2714
kg	VERB	O	O	2714
flumazenil	NOUN	O	Chemical	2714
.	PUNCT	O	O	2714
This	PRON	O	O	2715
also	ADV	O	O	2715
resulted	VERB	O	O	2715
in	ADP	O	O	2715
an	PRON	O	O	2715
increased	VERB	O	O	2715
incidence	NOUN	O	O	2715
of	ADP	O	O	2715
seizures	NOUN	O	Disease	2715
,	PUNCT	O	O	2715
90%	NOUN	O	O	2715
CONCLUSION	PROPN	O	O	2716
:	PUNCT	O	O	2716
Flumazenil	PROPN	O	Chemical	2716
can	AUX	O	O	2716
unmask	VERB	O	O	2716
seizures	NOUN	O	Disease	2716
and	CCONJ	O	O	2716
increase	VERB	O	O	2716
the	PRON	O	O	2716
incidence	NOUN	O	O	2716
of	ADP	O	O	2716
death	NOUN	O	O	2716
in	ADP	O	O	2716
a	PRON	O	O	2716
model	NOUN	O	O	2716
of	ADP	O	O	2716
combined	VERB	O	O	2716
cocaine	NOUN	O	Chemical	2716
-	PUNCT	O	O	2716
diazepam	NOUN	O	Chemical	2716
intoxications	NOUN	O	O	2716
.	PUNCT	O	O	2716
Mechanisms	NOUN	O	O	2719
for	ADP	O	O	2719
protective	ADJ	O	O	2719
effects	NOUN	O	O	2719
of	ADP	O	O	2719
free	ADJ	O	O	2719
radical	ADJ	O	O	2719
scavengers	NOUN	O	O	2719
on	ADP	O	O	2719
gentamicin	VERB	O	Chemical	2719
-	PUNCT	O	O	2719
mediated	VERB	O	O	2719
nephropathy	NOUN	O	Disease	2719
in	ADP	O	O	2719
rats	NOUN	O	O	2719
.	PUNCT	O	O	2719
Studies	NOUN	O	O	2720
were	AUX	O	O	2720
performed	VERB	O	O	2720
to	PART	O	O	2720
examine	VERB	O	O	2720
the	PRON	O	O	2720
mechanisms	NOUN	O	O	2720
for	ADP	O	O	2720
the	PRON	O	O	2720
protective	ADJ	O	O	2720
effects	NOUN	O	O	2720
of	ADP	O	O	2720
free	ADJ	O	O	2720
radical	ADJ	O	O	2720
scavengers	NOUN	O	O	2720
on	ADP	O	O	2720
gentamicin	VERB	O	Chemical	2720
(	PUNCT	O	O	2720
GM)-mediated	VERB	O	O	2720
nephropathy	NOUN	O	Disease	2720
.	PUNCT	O	O	2720
Administration	NOUN	O	O	2721
of	ADP	O	O	2721
GM	PROPN	O	O	2721
at	ADP	O	O	2721
40	NUM	O	O	2721
mg	VERB	O	O	2721
/	PUNCT	O	O	2721
kg	VERB	O	O	2721
sc	PROPN	O	O	2721
for	ADP	O	O	2721
13	NUM	O	O	2721
days	NOUN	O	O	2721
to	PART	O	O	2721
rats	NOUN	O	O	2721
induced	VERB	O	O	2721
a	PRON	O	O	2721
significant	ADJ	O	O	2721
reduction	NOUN	O	O	2721
in	ADP	O	O	2721
renal	ADJ	O	O	2721
blood	NOUN	O	O	2721
flow	NOUN	O	O	2721
(	PUNCT	O	O	2721
RBF	PROPN	O	O	2721
)	PUNCT	O	O	2721
and	CCONJ	O	O	2721
inulin	PROPN	O	O	2721
clearance	NOUN	O	O	2721
(	PUNCT	O	O	2721
CIn	PROPN	O	O	2721
)	PUNCT	O	O	2721
as	ADP	O	O	2721
well	ADV	O	O	2721
as	ADP	O	O	2721
marked	VERB	O	O	2721
tubular	ADJ	O	O	2721
damage	NOUN	O	O	2721
.	PUNCT	O	O	2721
A	PRON	O	O	2722
significant	ADJ	O	O	2722
reduction	NOUN	O	O	2722
in	ADP	O	O	2722
urinary	ADJ	O	O	2722
guanosine	NOUN	O	Chemical	2722
3',5'-cyclic	NUM	O	O	2722
monophosphate	PROPN	O	O	2722
(	PUNCT	O	O	2722
cGMP	PROPN	O	O	2722
)	PUNCT	O	O	2722
excretion	NOUN	O	O	2722
and	CCONJ	O	O	2722
a	PRON	O	O	2722
significant	ADJ	O	O	2722
increase	VERB	O	O	2722
in	ADP	O	O	2722
renal	ADJ	O	O	2722
cortical	ADJ	O	O	2722
renin	PROPN	O	O	2722
and	CCONJ	O	O	2722
endothelin-1	NUM	O	O	2722
contents	NOUN	O	O	2722
were	AUX	O	O	2722
also	ADV	O	O	2722
observed	VERB	O	O	2722
in	ADP	O	O	2722
GM	PROPN	O	O	2722
-	PUNCT	O	O	2722
mediated	VERB	O	O	2722
nephropathy	NOUN	O	Disease	2722
.	PUNCT	O	O	2722
Superoxide	NOUN	O	Chemical	2723
dismutase	ADP	O	O	2723
(	PUNCT	O	O	2723
SOD	PROPN	O	O	2723
)	PUNCT	O	O	2723
or	CCONJ	O	O	2723
dimethylthiourea	NOUN	O	O	2723
(	PUNCT	O	O	2723
DMTU	PROPN	O	O	2723
)	PUNCT	O	O	2723
significantly	ADV	O	O	2723
lessened	VERB	O	O	2723
the	PRON	O	O	2723
GM	PROPN	O	O	2723
-	PUNCT	O	O	2723
induced	VERB	O	O	2723
decrement	NOUN	O	O	2723
in	ADP	O	O	2723
CIn	PROPN	O	O	2723
.	PUNCT	O	O	2723
The	PRON	O	O	2724
SOD	PROPN	O	O	2724
-	PUNCT	O	O	2724
induced	VERB	O	O	2724
increase	VERB	O	O	2724
in	ADP	O	O	2724
glomerular	ADJ	O	O	2724
filtration	NOUN	O	O	2724
rate	NOUN	O	O	2724
was	AUX	O	O	2724
associated	VERB	O	O	2724
with	ADP	O	O	2724
a	PRON	O	O	2724
marked	VERB	O	O	2724
improvement	NOUN	O	O	2724
in	ADP	O	O	2724
RBF	PROPN	O	O	2724
,	PUNCT	O	O	2724
an	PRON	O	O	2724
increase	VERB	O	O	2724
in	ADP	O	O	2724
urinary	ADJ	O	O	2724
cGMP	PROPN	O	O	2724
excretion	NOUN	O	O	2724
,	PUNCT	O	O	2724
and	CCONJ	O	O	2724
a	PRON	O	O	2724
decrease	VERB	O	O	2724
in	ADP	O	O	2724
renal	ADJ	O	O	2724
renin	PROPN	O	O	2724
and	CCONJ	O	O	2724
endothelin-1	NUM	O	O	2724
content	NOUN	O	O	2724
.	PUNCT	O	O	2724
SOD	PROPN	O	O	2725
did	VERB	O	O	2725
not	PART	O	O	2725
attenuate	VERB	O	O	2725
the	PRON	O	O	2725
tubular	ADJ	O	O	2725
damage	NOUN	O	O	2725
.	PUNCT	O	O	2725
In	ADP	O	O	2726
contrast	NOUN	O	O	2726
,	PUNCT	O	O	2726
DMTU	PROPN	O	O	2726
significantly	ADV	O	O	2726
reduced	VERB	O	O	2726
the	PRON	O	O	2726
tubular	ADJ	O	O	2726
damage	NOUN	O	O	2726
and	CCONJ	O	O	2726
lipid	NOUN	O	O	2726
peroxidation	NOUN	O	O	2726
,	PUNCT	O	O	2726
but	CCONJ	O	O	2726
it	PRON	O	O	2726
did	VERB	O	O	2726
not	PART	O	O	2726
affect	VERB	O	O	2726
renal	ADJ	O	O	2726
hemodynamics	NOUN	O	O	2726
and	CCONJ	O	O	2726
vasoactive	ADJ	O	O	2726
substances	NOUN	O	O	2726
.	PUNCT	O	O	2726
Neither	PRON	O	O	2727
SOD	PROPN	O	O	2727
nor	CCONJ	O	O	2727
DMTU	PROPN	O	O	2727
affected	VERB	O	O	2727
the	PRON	O	O	2727
renal	ADJ	O	O	2727
cortical	ADJ	O	O	2727
GM	PROPN	O	O	2727
content	NOUN	O	O	2727
in	ADP	O	O	2727
GM	PROPN	O	O	2727
-	PUNCT	O	O	2727
treated	VERB	O	O	2727
rats	NOUN	O	O	2727
.	PUNCT	O	O	2727
These	PRON	O	O	2728
results	VERB	O	O	2728
suggest	VERB	O	O	2728
that	SCONJ	O	O	2728
1	X	O	O	2728
)	PUNCT	O	O	2728
both	PRON	O	O	2728
SOD	PROPN	O	O	2728
and	CCONJ	O	O	2728
DMTU	PROPN	O	O	2728
have	VERB	O	O	2728
protective	ADJ	O	O	2728
effects	NOUN	O	O	2728
on	ADP	O	O	2728
GM	PROPN	O	O	2728
-	PUNCT	O	O	2728
mediated	VERB	O	O	2728
nephropathy	NOUN	O	Disease	2728
,	PUNCT	O	O	2728
2	X	O	O	2728
)	PUNCT	O	O	2728
the	PRON	O	O	2728
mechanisms	NOUN	O	O	2728
for	ADP	O	O	2728
the	PRON	O	O	2728
protective	ADJ	O	O	2728
effects	NOUN	O	O	2728
differ	VERB	O	O	2728
for	ADP	O	O	2728
SOD	PROPN	O	O	2728
and	CCONJ	O	O	2728
DMTU	PROPN	O	O	2728
,	PUNCT	O	O	2728
and	CCONJ	O	O	2728
3	X	O	O	2728
)	PUNCT	O	O	2728
superoxide	NOUN	O	Chemical	2728
anions	NOUN	O	O	2728
play	VERB	O	O	2728
a	PRON	O	O	2728
critical	ADJ	O	O	2728
role	NOUN	O	O	2728
in	ADP	O	O	2728
GM	PROPN	O	O	2728
-	PUNCT	O	O	2728
induced	VERB	O	O	2728
renal	ADJ	O	O	2728
vasoconstriction	NOUN	O	O	2728
.	PUNCT	O	O	2728
Assessment	NOUN	O	O	2731
of	ADP	O	O	2731
cardiomyocyte	NOUN	O	O	2731
DNA	NOUN	O	O	2731
synthesis	NOUN	O	O	2731
during	ADP	O	O	2731
hypertrophy	VERB	O	Disease	2731
in	ADP	O	O	2731
adult	NOUN	O	O	2731
mice	NOUN	O	O	2731
.	PUNCT	O	O	2731
The	PRON	O	O	2732
ability	NOUN	O	O	2732
of	ADP	O	O	2732
cardiomyocytes	NOUN	O	O	2732
to	PART	O	O	2732
synthesize	VERB	O	O	2732
DNA	NOUN	O	O	2732
in	ADP	O	O	2732
response	NOUN	O	O	2732
to	PART	O	O	2732
experimentally	ADV	O	O	2732
induced	VERB	O	O	2732
cardiac hypertrophy	NOUN	O	Disease	2732
was	AUX	O	O	2732
assessed	VERB	O	O	2732
in	ADP	O	O	2732
adult	NOUN	O	O	2732
mice	NOUN	O	O	2732
.	PUNCT	O	O	2732
Isoproterenol	NOUN	O	Chemical	2733
delivered	VERB	O	O	2733
by	ADP	O	O	2733
osmotic	NOUN	O	O	2733
minipump	NOUN	O	O	2733
implantation	NOUN	O	O	2733
in	ADP	O	O	2733
adult	NOUN	O	O	2733
C3Heb	NUM	O	O	2733
/	PUNCT	O	O	2733
FeJ	NOUN	O	O	2733
mice	NOUN	O	O	2733
resulted	VERB	O	O	2733
in	ADP	O	O	2733
a	PRON	O	O	2733
46%	NOUN	O	O	2733
increase	VERB	O	O	2733
in	ADP	O	O	2733
heart	NOUN	O	O	2733
weight	NOUN	O	O	2733
and	CCONJ	O	O	2733
a	PRON	O	O	2733
19.3%	NOUN	O	O	2733
increase	VERB	O	O	2733
in	ADP	O	O	2733
cardiomyocyte	NOUN	O	O	2733
area	NOUN	O	O	2733
.	PUNCT	O	O	2733
No	PRON	O	O	2734
DNA	NOUN	O	O	2734
synthesis	NOUN	O	O	2734
,	PUNCT	O	O	2734
as	ADP	O	O	2734
assessed	VERB	O	O	2734
by	ADP	O	O	2734
autoradiographic	ADV	O	O	2734
analysis	NOUN	O	O	2734
of	ADP	O	O	2734
isolated	VERB	O	O	2734
cardiomyocytes	NOUN	O	O	2734
,	PUNCT	O	O	2734
was	AUX	O	O	2734
observed	VERB	O	O	2734
in	ADP	O	O	2734
control	VERB	O	O	2734
or	CCONJ	O	O	2734
hypertrophic	NOUN	O	Disease	2734
hearts	NOUN	O	O	2734
.	PUNCT	O	O	2734
To	PART	O	O	2735
determine	VERB	O	O	2735
whether	SCONJ	O	O	2735
the	PRON	O	O	2735
capacity	NOUN	O	O	2735
for	ADP	O	O	2735
reactive	ADJ	O	O	2735
DNA	NOUN	O	O	2735
synthesis	NOUN	O	O	2735
was	AUX	O	O	2735
also	ADV	O	O	2735
subject	ADJ	O	O	2735
to	PART	O	O	2735
genetic	ADJ	O	O	2735
regulation	NOUN	O	O	2735
,	PUNCT	O	O	2735
cardiac hypertrophy	NOUN	O	Disease	2735
was	AUX	O	O	2735
induced	VERB	O	O	2735
in	ADP	O	O	2735
the	PRON	O	O	2735
strains	VERB	O	O	2735
of	ADP	O	O	2735
mice	NOUN	O	O	2735
comprising	VERB	O	O	2735
the	PRON	O	O	2735
extremes	NOUN	O	O	2735
of	ADP	O	O	2735
the	PRON	O	O	2735
nuclear	ADJ	O	O	2735
number	NOUN	O	O	2735
survey	PROPN	O	O	2735
.	PUNCT	O	O	2735
These	PRON	O	O	2736
data	NOUN	O	O	2736
indicate	VERB	O	O	2736
that	SCONJ	O	O	2736
adult	NOUN	O	O	2736
mouse	PROPN	O	O	2736
atrial	ADJ	O	O	2736
and	CCONJ	O	O	2736
ventricular	ADJ	O	O	2736
cardiomyocytes	NOUN	O	O	2736
do	VERB	O	O	2736
not	PART	O	O	2736
synthesize	VERB	O	O	2736
DNA	NOUN	O	O	2736
in	ADP	O	O	2736
response	NOUN	O	O	2736
to	PART	O	O	2736
isoproterenol	NOUN	O	Chemical	2736
-	PUNCT	O	O	2736
induced	VERB	O	O	2736
cardiac hypertrophy	NOUN	O	Disease	2736
.	PUNCT	O	O	2736
Central	ADJ	O	O	2739
cardiovascular	ADJ	O	O	2739
effects	NOUN	O	O	2739
of	ADP	O	O	2739
AVP	NOUN	O	O	2739
and	CCONJ	O	O	2739
ANP	NOUN	O	O	2739
in	ADP	O	O	2739
normotensive	PROPN	O	O	2739
and	CCONJ	O	O	2739
spontaneously	ADV	O	O	2739
hypertensive	ADJ	O	Disease	2739
rats	NOUN	O	O	2739
.	PUNCT	O	O	2739
The	PRON	O	O	2740
purpose	NOUN	O	O	2740
of	ADP	O	O	2740
the	PRON	O	O	2740
present	NOUN	O	O	2740
study	VERB	O	O	2740
was	AUX	O	O	2740
to	PART	O	O	2740
compare	VERB	O	O	2740
influence	NOUN	O	O	2740
of	ADP	O	O	2740
central	ADJ	O	O	2740
arginine	PROPN	O	O	2740
vasopressin	NOUN	O	Chemical	2740
(	PUNCT	O	O	2740
AVP	NOUN	O	O	2740
)	PUNCT	O	O	2740
and	CCONJ	O	O	2740
of	ADP	O	O	2740
atrial	ADJ	O	O	2740
natriuretic	ADJ	O	O	2740
peptide	NOUN	O	O	2740
(	PUNCT	O	O	2740
ANP	NOUN	O	O	2740
)	PUNCT	O	O	2740
on	ADP	O	O	2740
control	VERB	O	O	2740
of	ADP	O	O	2740
arterial	ADJ	O	O	2740
blood	NOUN	O	O	2740
pressure	NOUN	O	O	2740
(	PUNCT	O	O	2740
MAP	PROPN	O	O	2740
)	PUNCT	O	O	2740
and	CCONJ	O	O	2740
heart	NOUN	O	O	2740
rate	NOUN	O	O	2740
(	PUNCT	O	O	2740
HR	NOUN	O	O	2740
)	PUNCT	O	O	2740
in	ADP	O	O	2740
normotensive	PROPN	O	O	2740
(	PUNCT	O	O	2740
WKY	PROPN	O	O	2740
)	PUNCT	O	O	2740
and	CCONJ	O	O	2740
spontaneously	ADV	O	O	2740
hypertensive	ADJ	O	Disease	2740
(	PUNCT	O	O	2740
SHR	PROPN	O	O	2740
)	PUNCT	O	O	2740
rats	NOUN	O	O	2740
.	PUNCT	O	O	2740
injections	NOUN	O	O	2741
of	ADP	O	O	2741
either	ADV	O	O	2741
vehicle	NOUN	O	O	2741
or	CCONJ	O	O	2741
1	X	O	O	2741
,	PUNCT	O	O	2741
10	NUM	O	O	2741
and	CCONJ	O	O	2741
50	NUM	O	O	2741
ng	PROPN	O	O	2741
of	ADP	O	O	2741
AVP	NOUN	O	O	2741
and	CCONJ	O	O	2741
25	NUM	O	O	2741
,	PUNCT	O	O	2741
125	NUM	O	O	2741
and	CCONJ	O	O	2741
500	NUM	O	O	2741
ng	PROPN	O	O	2741
of	ADP	O	O	2741
ANP	NOUN	O	O	2741
.	PUNCT	O	O	2741
Sensitivity	NOUN	O	O	2742
of	ADP	O	O	2742
cardiac	ADJ	O	O	2742
component	NOUN	O	O	2742
of	ADP	O	O	2742
baroreflex	NOUN	O	O	2742
(	PUNCT	O	O	2742
CCB	NOUN	O	O	2742
)	PUNCT	O	O	2742
,	PUNCT	O	O	2742
expressed	VERB	O	O	2742
as	ADP	O	O	2742
a	PRON	O	O	2742
slope	NOUN	O	O	2742
of	ADP	O	O	2742
the	PRON	O	O	2742
regression	NOUN	O	O	2742
line	NOUN	O	O	2742
was	AUX	O	O	2742
determined	VERB	O	O	2742
from	ADP	O	O	2742
relationships	NOUN	O	O	2742
between	ADP	O	O	2742
systolic	ADV	O	O	2742
arterial	ADJ	O	O	2742
pressure	NOUN	O	O	2742
(	PUNCT	O	O	2742
SAP	PROPN	O	O	2742
)	PUNCT	O	O	2742
and	CCONJ	O	O	2742
HR	NOUN	O	O	2742
period	NOUN	O	O	2742
(	PUNCT	O	O	2742
HRp	PROPN	O	O	2742
)	PUNCT	O	O	2742
during	ADP	O	O	2742
phenylephrine	NOUN	O	Chemical	2742
(	PUNCT	O	O	2742
Phe)-induced	VERB	O	O	2742
hypertension	NOUN	O	Disease	2742
and	CCONJ	O	O	2742
sodium	NOUN	O	Chemical	2742
nitroprusside	ADV	O	Chemical	2742
(	PUNCT	O	O	2742
SN)-induced	VERB	O	O	2742
hypotension	NOUN	O	Disease	2742
.	PUNCT	O	O	2742
CCB	NOUN	O	O	2743
was	AUX	O	O	2743
measured	VERB	O	O	2743
before	ADP	O	O	2743
and	CCONJ	O	O	2743
after	ADP	O	O	2743
administration	NOUN	O	O	2743
of	ADP	O	O	2743
either	ADV	O	O	2743
vehicle	NOUN	O	O	2743
,	PUNCT	O	O	2743
AVP	NOUN	O	O	2743
,	PUNCT	O	O	2743
ANP	NOUN	O	O	2743
,	PUNCT	O	O	2743
or	CCONJ	O	O	2743
both	PRON	O	O	2743
peptides	NOUN	O	O	2743
together	ADV	O	O	2743
.	PUNCT	O	O	2743
Increases	VERB	O	O	2744
of	ADP	O	O	2744
MAP	PROPN	O	O	2744
occurred	VERB	O	O	2744
after	ADP	O	O	2744
LV	PROPN	O	Disease	2744
administration	NOUN	O	O	2744
of	ADP	O	O	2744
1	X	O	O	2744
,	PUNCT	O	O	2744
10	NUM	O	O	2744
and	CCONJ	O	O	2744
50	NUM	O	O	2744
ng	PROPN	O	O	2744
of	ADP	O	O	2744
AVP	NOUN	O	O	2744
in	ADP	O	O	2744
WKY	PROPN	O	O	2744
and	CCONJ	O	O	2744
of	ADP	O	O	2744
10	NUM	O	O	2744
and	CCONJ	O	O	2744
50	NUM	O	O	2744
ng	PROPN	O	O	2744
in	ADP	O	O	2744
SHR	PROPN	O	O	2744
.	PUNCT	O	O	2744
ANP	NOUN	O	O	2745
did	VERB	O	O	2745
not	PART	O	O	2745
cause	VERB	O	O	2745
significant	ADJ	O	O	2745
changes	VERB	O	O	2745
in	ADP	O	O	2745
MAP	PROPN	O	O	2745
in	ADP	O	O	2745
both	PRON	O	O	2745
strains	VERB	O	O	2745
as	ADP	O	O	2745
compared	VERB	O	O	2745
to	PART	O	O	2745
vehicle	NOUN	O	O	2745
,	PUNCT	O	O	2745
but	CCONJ	O	O	2745
it	PRON	O	O	2745
abolished	VERB	O	O	2745
AVP	NOUN	O	O	2745
-	PUNCT	O	O	2745
induced	VERB	O	O	2745
MAP	PROPN	O	O	2745
increase	VERB	O	O	2745
in	ADP	O	O	2745
WKY	PROPN	O	O	2745
and	CCONJ	O	O	2745
SHR	PROPN	O	O	2745
.	PUNCT	O	O	2745
CCB	NOUN	O	O	2746
was	AUX	O	O	2746
reduced	VERB	O	O	2746
in	ADP	O	O	2746
WKY	PROPN	O	O	2746
and	CCONJ	O	O	2746
SHR	PROPN	O	O	2746
after	ADP	O	O	2746
LV	PROPN	O	Disease	2746
administration	NOUN	O	O	2746
of	ADP	O	O	2746
AVP	NOUN	O	O	2746
during	ADP	O	O	2746
SN	NOUN	O	O	2746
-	PUNCT	O	O	2746
induced	VERB	O	O	2746
hypotension	NOUN	O	Disease	2746
.	PUNCT	O	O	2746
In	ADP	O	O	2747
SHR	PROPN	O	O	2747
but	CCONJ	O	O	2747
not	PART	O	O	2747
in	ADP	O	O	2747
WKY	PROPN	O	O	2747
administration	NOUN	O	O	2747
of	ADP	O	O	2747
ANP	NOUN	O	O	2747
,	PUNCT	O	O	2747
AVP	NOUN	O	O	2747
and	CCONJ	O	O	2747
ANP	NOUN	O	O	2747
+	ADP	O	O	2747
AVP	NOUN	O	O	2747
decreased	VERB	O	O	2747
CCB	NOUN	O	O	2747
during	ADP	O	O	2747
Phe	PROPN	O	O	2747
-	PUNCT	O	O	2747
induced	VERB	O	O	2747
MAP	PROPN	O	O	2747
elevation	NOUN	O	O	2747
.	PUNCT	O	O	2747
The	PRON	O	O	2748
results	VERB	O	O	2748
indicate	VERB	O	O	2748
that	SCONJ	O	O	2748
centrally	ADV	O	O	2748
applied	VERB	O	O	2748
AVP	NOUN	O	O	2748
and	CCONJ	O	O	2748
ANP	NOUN	O	O	2748
exert	VERB	O	O	2748
differential	ADJ	O	O	2748
effects	NOUN	O	O	2748
on	ADP	O	O	2748
blood	NOUN	O	O	2748
pressure	NOUN	O	O	2748
and	CCONJ	O	O	2748
baroreflex	NOUN	O	O	2748
control	VERB	O	O	2748
of	ADP	O	O	2748
heart	NOUN	O	O	2748
rate	NOUN	O	O	2748
in	ADP	O	O	2748
WKY	PROPN	O	O	2748
and	CCONJ	O	O	2748
SHR	PROPN	O	O	2748
and	CCONJ	O	O	2748
suggest	VERB	O	O	2748
interaction	NOUN	O	O	2748
of	ADP	O	O	2748
these	PRON	O	O	2748
two	NUM	O	O	2748
peptides	NOUN	O	O	2748
in	ADP	O	O	2748
blood	NOUN	O	O	2748
pressure	NOUN	O	O	2748
regulation	NOUN	O	O	2748
at	ADP	O	O	2748
the	PRON	O	O	2748
level	VERB	O	O	2748
of	ADP	O	O	2748
central	ADJ	O	O	2748
nervous	ADJ	O	O	2748
system	NOUN	O	O	2748
.	PUNCT	O	O	2748
Cutaneous	ADJ	O	O	2751
exposure	NOUN	O	O	2751
to	PART	O	O	2751
warfarin	VERB	O	Chemical	2751
-	PUNCT	O	O	2751
like	INTJ	O	O	2751
anticoagulant	ADJ	O	O	2751
causing	VERB	O	O	2751
an	PRON	O	O	2751
intracerebral hemorrhage	NOUN	O	Disease	2751
:	PUNCT	O	O	2751
a	PRON	O	O	2751
case	NOUN	O	O	2751
report	VERB	O	O	2751
.	PUNCT	O	O	2751
A	PRON	O	O	2752
case	NOUN	O	O	2752
of	ADP	O	O	2752
intercerebral	NOUN	O	O	2752
hematoma	NOUN	O	Disease	2752
due	ADJ	O	O	2752
to	PART	O	O	2752
warfarin	VERB	O	Chemical	2752
-	PUNCT	O	O	2752
induced	VERB	O	O	2752
coagulopathy	VERB	O	Disease	2752
is	AUX	O	O	2752
presented	VERB	O	O	2752
.	PUNCT	O	O	2752
The	PRON	O	O	2753
39-year	NOUN	O	O	2753
-	PUNCT	O	O	2753
old	ADJ	O	O	2753
woman	NOUN	O	O	2753
had	VERB	O	O	2753
spread	VERB	O	O	2753
a	PRON	O	O	2753
warfarin	VERB	O	Chemical	2753
-	PUNCT	O	O	2753
type	NOUN	O	O	2753
rat	NOUN	O	O	2753
poison	NOUN	O	O	2753
around	ADV	O	O	2753
her	PRON	O	O	2753
house	PROPN	O	O	2753
weekly	ADV	O	O	2753
using	VERB	O	O	2753
her	PRON	O	O	2753
bare	PROPN	O	O	2753
hands	NOUN	O	O	2753
,	PUNCT	O	O	2753
with	ADP	O	O	2753
no	PRON	O	O	2753
washing	NOUN	O	O	2753
post	VERB	O	O	2753
application	NOUN	O	O	2753
.	PUNCT	O	O	2753
Percutaneous	PROPN	O	O	2754
absorption	NOUN	O	O	2754
of	ADP	O	O	2754
warfarin	VERB	O	Chemical	2754
causing	VERB	O	O	2754
coagulopathy	VERB	O	Disease	2754
,	PUNCT	O	O	2754
reported	VERB	O	O	2754
three	NUM	O	O	2754
times	NOUN	O	O	2754
in	ADP	O	O	2754
the	PRON	O	O	2754
past	ADP	O	O	2754
,	PUNCT	O	O	2754
is	AUX	O	O	2754
a	PRON	O	O	2754
significant	ADJ	O	O	2754
risk	NOUN	O	O	2754
if	SCONJ	O	O	2754
protective	ADJ	O	O	2754
measures	NOUN	O	O	2754
,	PUNCT	O	O	2754
such	ADJ	O	O	2754
as	ADP	O	O	2754
gloves	NOUN	O	O	2754
,	PUNCT	O	O	2754
are	AUX	O	O	2754
not	PART	O	O	2754
used	VERB	O	O	2754
.	PUNCT	O	O	2754
An	PRON	O	O	2755
adverse	ADJ	O	O	2755
drug	NOUN	O	O	2755
interaction	NOUN	O	O	2755
with	ADP	O	O	2755
piroxicam	VERB	O	O	2755
,	PUNCT	O	O	2755
which	PRON	O	O	2755
she	PRON	O	O	2755
took	VERB	O	O	2755
occasionally	ADV	O	O	2755
,	PUNCT	O	O	2755
may	AUX	O	O	2755
have	VERB	O	O	2755
exacerbated	VERB	O	O	2755
the	PRON	O	O	2755
coagulopathy	VERB	O	Disease	2755
.	PUNCT	O	O	2755
Pediatric	ADJ	O	O	2758
heart	NOUN	O	O	2758
transplantation	NOUN	O	O	2758
without	ADP	O	O	2758
chronic	ADJ	O	O	2758
maintenance	NOUN	O	O	2758
steroids	NOUN	O	Chemical	2758
.	PUNCT	O	O	2758
Indications	NOUN	O	O	2759
for	ADP	O	O	2759
transplantation	NOUN	O	O	2759
were	AUX	O	O	2759
idiopathic	ADJ	O	O	2759
cardiomyopathy	ADJ	O	Disease	2759
(	PUNCT	O	O	2759
52%	NOUN	O	O	2759
)	PUNCT	O	O	2759
,	PUNCT	O	O	2759
congenital	NOUN	O	O	2759
heart disease	NOUN	O	Disease	2759
(	PUNCT	O	O	2759
35%	NOUN	O	O	2759
)	PUNCT	O	O	2759
with	ADP	O	O	2759
and	CCONJ	O	O	2759
without	ADP	O	O	2759
prior	ADV	O	O	2759
repair	PROPN	O	O	2759
(	PUNCT	O	O	2759
71%	NOUN	O	O	2759
and	CCONJ	O	O	2759
29%	NOUN	O	O	2759
,	PUNCT	O	O	2759
respectively	ADV	O	O	2759
)	PUNCT	O	O	2759
,	PUNCT	O	O	2759
hypertrophic cardiomyopathy	NOUN	O	Disease	2759
(	PUNCT	O	O	2759
5%	NOUN	O	O	2759
)	PUNCT	O	O	2759
,	PUNCT	O	O	2759
valvular	ADJ	O	O	2759
heart disease	NOUN	O	Disease	2759
(	PUNCT	O	O	2759
3%	NOUN	O	O	2759
)	PUNCT	O	O	2759
,	PUNCT	O	O	2759
and	CCONJ	O	O	2759
doxorubicin	VERB	O	Chemical	2759
cardiomyopathy	ADJ	O	Disease	2759
(	PUNCT	O	O	2759
5%	NOUN	O	O	2759
)	PUNCT	O	O	2759
.	PUNCT	O	O	2759
Patients	NOUN	O	O	2760
were	AUX	O	O	2760
managed	VERB	O	O	2760
with	ADP	O	O	2760
cyclosporine	NOUN	O	Chemical	2760
and	CCONJ	O	O	2760
azathioprine	ADV	O	Chemical	2760
.	PUNCT	O	O	2760
Steroids	NOUN	O	Chemical	2761
were	AUX	O	O	2761
given	VERB	O	O	2761
to	PART	O	O	2761
39%	NOUN	O	O	2761
of	ADP	O	O	2761
patients	NOUN	O	O	2761
for	ADP	O	O	2761
refractory	ADJ	O	O	2761
rejection	NOUN	O	O	2761
,	PUNCT	O	O	2761
but	CCONJ	O	O	2761
weaning	VERB	O	O	2761
was	AUX	O	O	2761
always	ADV	O	O	2761
attempted	VERB	O	O	2761
and	CCONJ	O	O	2761
generally	ADV	O	O	2761
successful	ADJ	O	O	2761
(	PUNCT	O	O	2761
64%	NOUN	O	O	2761
)	PUNCT	O	O	2761
.	PUNCT	O	O	2761
Five	NUM	O	O	2762
patients	NOUN	O	O	2762
(	PUNCT	O	O	2762
14%	NOUN	O	O	2762
)	PUNCT	O	O	2762
received	VERB	O	O	2762
maintenance	NOUN	O	O	2762
steroids	NOUN	O	Chemical	2762
.	PUNCT	O	O	2762
There	ADV	O	O	2763
have	VERB	O	O	2763
been	AUX	O	O	2763
no	PRON	O	O	2763
deaths	NOUN	O	O	2763
related	ADJ	O	O	2763
to	PART	O	O	2763
rejection	NOUN	O	O	2763
or	CCONJ	O	O	2763
infection	NOUN	O	Disease	2763
.	PUNCT	O	O	2763
Freedom	NOUN	O	O	2764
from	ADP	O	O	2764
serious	ADJ	O	O	2764
infections	NOUN	O	Disease	2764
was	AUX	O	O	2764
83%	NOUN	O	O	2764
at	ADP	O	O	2764
1	X	O	O	2764
month	NOUN	O	O	2764
and	CCONJ	O	O	2764
65%	NOUN	O	O	2764
at	ADP	O	O	2764
1	X	O	O	2764
year	NOUN	O	O	2764
.	PUNCT	O	O	2764
Cytomegalovirus	PROPN	O	O	2765
infections	NOUN	O	Disease	2765
were	AUX	O	O	2765
treated	VERB	O	O	2765
successfully	ADV	O	O	2765
with	ADP	O	O	2765
ganciclovir	NOUN	O	O	2765
in	ADP	O	O	2765
11	NUM	O	O	2765
patients	NOUN	O	O	2765
.	PUNCT	O	O	2765
Twenty	NUM	O	O	2766
-	PUNCT	O	O	2766
one	NUM	O	O	2766
patients	NOUN	O	O	2766
(	PUNCT	O	O	2766
60%	NOUN	O	O	2766
)	PUNCT	O	O	2766
have	VERB	O	O	2766
undergone	VERB	O	O	2766
annual	ADJ	O	O	2766
catheterizations	NOUN	O	O	2766
and	CCONJ	O	O	2766
no	PRON	O	O	2766
sign	VERB	O	O	2766
of	ADP	O	O	2766
graft	NOUN	O	O	2766
atherosclerosis	NOUN	O	Disease	2766
has	VERB	O	O	2766
been	AUX	O	O	2766
observed	VERB	O	O	2766
.	PUNCT	O	O	2766
Seizures	NOUN	O	Disease	2767
occurred	VERB	O	O	2767
in	ADP	O	O	2767
five	NUM	O	O	2767
patients	NOUN	O	O	2767
(	PUNCT	O	O	2767
14%	NOUN	O	O	2767
)	PUNCT	O	O	2767
and	CCONJ	O	O	2767
hypertension	NOUN	O	Disease	2767
was	AUX	O	O	2767
treated	VERB	O	O	2767
in	ADP	O	O	2767
10	NUM	O	O	2767
patients	NOUN	O	O	2767
(	PUNCT	O	O	2767
28%	NOUN	O	O	2767
)	PUNCT	O	O	2767
.	PUNCT	O	O	2767
No	PRON	O	O	2768
patient	NOUN	O	O	2768
was	AUX	O	O	2768
disabled	ADJ	O	O	2768
and	CCONJ	O	O	2768
no	PRON	O	O	2768
lymphoproliferative	VERB	O	O	2768
disorder	NOUN	O	O	2768
was	AUX	O	O	2768
observed.(ABSTRACT	PROPN	O	O	2768
TRUNCATED	ADJ	O	O	2768
AT	ADP	O	O	2768
250	NUM	O	O	2768
WORDS	NOUN	O	O	2768
)	PUNCT	O	O	2768
Delirium	NOUN	O	O	2771
during	ADP	O	O	2771
fluoxetine	NOUN	O	Chemical	2771
treatment	NOUN	O	O	2771
.	PUNCT	O	O	2771
Only	ADV	O	O	2772
a	PRON	O	O	2772
few	ADJ	O	O	2772
reports	VERB	O	O	2772
exist	VERB	O	O	2772
,	PUNCT	O	O	2772
however	ADV	O	O	2772
,	PUNCT	O	O	2772
on	ADP	O	O	2772
the	PRON	O	O	2772
relationship	NOUN	O	O	2772
between	ADP	O	O	2772
the	PRON	O	O	2772
serum	NOUN	O	O	2772
concentrations	NOUN	O	O	2772
of	ADP	O	O	2772
selective	ADJ	O	O	2772
serotonin	PROPN	O	Chemical	2772
reuptake	PROPN	O	O	2772
inhibitors	NOUN	O	O	2772
(	PUNCT	O	O	2772
SSRIs	NOUN	O	O	2772
)	PUNCT	O	O	2772
and	CCONJ	O	O	2772
their	PRON	O	O	2772
toxic	ADJ	O	O	2772
effects	NOUN	O	O	2772
.	PUNCT	O	O	2772
In	ADP	O	O	2773
some	PRON	O	O	2773
cases	NOUN	O	O	2773
,	PUNCT	O	O	2773
a	PRON	O	O	2773
high	ADJ	O	O	2773
serum	NOUN	O	O	2773
concentration	NOUN	O	O	2773
of	ADP	O	O	2773
citalopram	PROPN	O	Chemical	2773
(	PUNCT	O	O	2773
>	PUNCT	O	O	2773
600	NUM	O	O	2773
nmol	PROPN	O	O	2773
/	PUNCT	O	O	2773
L	NOUN	O	O	2773
)	PUNCT	O	O	2773
in	ADP	O	O	2773
elderly	ADJ	O	O	2773
patients	NOUN	O	O	2773
has	VERB	O	O	2773
been	AUX	O	O	2773
associated	VERB	O	O	2773
with	ADP	O	O	2773
increased	VERB	O	O	2773
somnolence	NOUN	O	Disease	2773
and	CCONJ	O	O	2773
movement	NOUN	O	O	2773
difficulties	NOUN	O	O	2773
.	PUNCT	O	O	2773
Widespread	ADJ	O	O	2774
cognitive	ADJ	O	O	2774
disorders	NOUN	O	O	2774
,	PUNCT	O	O	2774
such	ADJ	O	O	2774
as	ADP	O	O	2774
delirium	NOUN	O	Disease	2774
,	PUNCT	O	O	2774
have	VERB	O	O	2774
not	PART	O	O	2774
been	AUX	O	O	2774
previously	ADV	O	O	2774
linked	VERB	O	O	2774
with	ADP	O	O	2774
high	ADJ	O	O	2774
blood	NOUN	O	O	2774
levels	NOUN	O	O	2774
of	ADP	O	O	2774
SSRIs	NOUN	O	O	2774
.	PUNCT	O	O	2774
In	ADP	O	O	2775
this	PRON	O	O	2775
report	VERB	O	O	2775
,	PUNCT	O	O	2775
we	PRON	O	O	2775
describe	VERB	O	O	2775
a	PRON	O	O	2775
patient	NOUN	O	O	2775
with	ADP	O	O	2775
acute	ADJ	O	O	2775
hyperkinetic	ADJ	O	Disease	2775
delirium	NOUN	O	Disease	2775
connected	VERB	O	O	2775
with	ADP	O	O	2775
a	PRON	O	O	2775
high	ADJ	O	O	2775
serum	NOUN	O	O	2775
total	ADJ	O	O	2775
fluoxetine	NOUN	O	Chemical	2775
(	PUNCT	O	O	2775
fluoxetine	NOUN	O	Chemical	2775
plus	CCONJ	O	O	2775
desmethylfluoxetine	NOUN	O	O	2775
)	PUNCT	O	O	2775
concentration	NOUN	O	O	2775
.	PUNCT	O	O	2775
Pulmonary	NOUN	O	O	2778
edema	NOUN	O	Disease	2778
and	CCONJ	O	O	2778
shock	NOUN	O	O	2778
after	ADP	O	O	2778
high	ADJ	O	O	2778
-	PUNCT	O	O	2778
dose	NOUN	O	O	2778
aracytine	VERB	O	O	2778
-	PUNCT	O	O	2778
C	NOUN	O	O	2778
for	ADP	O	O	2778
lymphoma	PROPN	O	Disease	2778
;	PUNCT	O	O	2778
possible	ADJ	O	O	2778
role	NOUN	O	O	2778
of	ADP	O	O	2778
TNF	PROPN	O	O	2778
-	PUNCT	O	O	2778
alpha	PROPN	O	O	2778
and	CCONJ	O	O	2778
PAF	PROPN	O	O	2778
.	PUNCT	O	O	2778
Four	NUM	O	O	2779
out	ADP	O	O	2779
of	ADP	O	O	2779
23	NUM	O	O	2779
consecutive	ADJ	O	O	2779
patients	NOUN	O	O	2779
treated	VERB	O	O	2779
with	ADP	O	O	2779
high	ADJ	O	O	2779
-	PUNCT	O	O	2779
dose	NOUN	O	O	2779
Ara	PROPN	O	O	2779
-	PUNCT	O	O	2779
C	NOUN	O	O	2779
for	ADP	O	O	2779
lymphomas	NOUN	O	O	2779
in	ADP	O	O	2779
our	PRON	O	O	2779
institution	NOUN	O	O	2779
developed	VERB	O	O	2779
a	PRON	O	O	2779
strikingly	ADV	O	O	2779
similar	ADJ	O	O	2779
syndrome	NOUN	O	O	2779
during	ADP	O	O	2779
the	PRON	O	O	2779
perfusion	NOUN	O	O	2779
.	PUNCT	O	O	2779
It	PRON	O	O	2780
was	AUX	O	O	2780
characterized	VERB	O	O	2780
by	ADP	O	O	2780
the	PRON	O	O	2780
onset	VERB	O	O	2780
of	ADP	O	O	2780
fever	NOUN	O	Disease	2780
,	PUNCT	O	O	2780
diarrhea	PROPN	O	Disease	2780
,	PUNCT	O	O	2780
shock	NOUN	O	O	2780
,	PUNCT	O	O	2780
pulmonary edema	NOUN	O	Disease	2780
,	PUNCT	O	O	2780
acute	ADJ	O	O	2780
renal failure	NOUN	O	Disease	2780
,	PUNCT	O	O	2780
metabolic acidosis	NOUN	O	Disease	2780
,	PUNCT	O	O	2780
weight	NOUN	O	O	2780
gain	VERB	O	O	2780
and	CCONJ	O	O	2780
leukocytosis	NOUN	O	O	2780
.	PUNCT	O	O	2780
Thorough	ADJ	O	O	2781
bacteriological	ADJ	O	O	2781
screening	VERB	O	O	2781
failed	VERB	O	O	2781
to	PART	O	O	2781
provide	VERB	O	O	2781
evidence	NOUN	O	O	2781
of	ADP	O	O	2781
infection	NOUN	O	Disease	2781
.	PUNCT	O	O	2781
Sequential	ADJ	O	O	2782
biological	ADJ	O	O	2782
assays	NOUN	O	O	2782
of	ADP	O	O	2782
IL-1	NUM	O	O	2782
,	PUNCT	O	O	2782
IL-2	X	O	O	2782
,	PUNCT	O	O	2782
TNF	PROPN	O	O	2782
and	CCONJ	O	O	2782
PAF	PROPN	O	O	2782
were	AUX	O	O	2782
performed	VERB	O	O	2782
during	ADP	O	O	2782
Ara	PROPN	O	O	2782
-	PUNCT	O	O	2782
C	NOUN	O	O	2782
infusion	NOUN	O	O	2782
to	PART	O	O	2782
ten	NUM	O	O	2782
patients	NOUN	O	O	2782
,	PUNCT	O	O	2782
including	VERB	O	O	2782
the	PRON	O	O	2782
four	NUM	O	O	2782
who	PRON	O	O	2782
developed	VERB	O	O	2782
the	PRON	O	O	2782
syndrome	NOUN	O	O	2782
.	PUNCT	O	O	2782
As	ADP	O	O	2783
TNF	PROPN	O	O	2783
and	CCONJ	O	O	2783
PAF	PROPN	O	O	2783
are	AUX	O	O	2783
thought	VERB	O	O	2783
to	PART	O	O	2783
be	AUX	O	O	2783
involved	VERB	O	O	2783
in	ADP	O	O	2783
the	PRON	O	O	2783
development	NOUN	O	O	2783
of	ADP	O	O	2783
septic	ADJ	O	O	2783
shock	NOUN	O	O	2783
and	CCONJ	O	O	2783
adult	NOUN	O	O	2783
respiratory	NOUN	O	O	2783
distress	NOUN	O	O	2783
syndrome	NOUN	O	O	2783
,	PUNCT	O	O	2783
we	PRON	O	O	2783
hypothesize	VERB	O	O	2783
that	SCONJ	O	O	2783
high	ADJ	O	O	2783
-	PUNCT	O	O	2783
dose	NOUN	O	O	2783
Ara	PROPN	O	O	2783
-	PUNCT	O	O	2783
C	NOUN	O	O	2783
may	AUX	O	O	2783
be	AUX	O	O	2783
associated	VERB	O	O	2783
with	ADP	O	O	2783
cytokine	NOUN	O	O	2783
release	NOUN	O	O	2783
.	PUNCT	O	O	2783
Protective	NOUN	O	O	2786
effect	VERB	O	O	2786
of	ADP	O	O	2786
clentiazem	PROPN	O	O	2786
against	ADP	O	O	2786
epinephrine	NOUN	O	Chemical	2786
-	PUNCT	O	O	2786
induced	VERB	O	O	2786
cardiac	ADJ	O	O	2786
injury	NOUN	O	O	2786
in	ADP	O	O	2786
rats	NOUN	O	O	2786
.	PUNCT	O	O	2786
We	PRON	O	O	2787
investigated	VERB	O	O	2787
the	PRON	O	O	2787
effects	NOUN	O	O	2787
of	ADP	O	O	2787
clentiazem	PROPN	O	O	2787
,	PUNCT	O	O	2787
a	PRON	O	O	2787
1,5-benzothiazepine	NOUN	O	O	2787
calcium	NOUN	O	Chemical	2787
antagonist	NOUN	O	O	2787
,	PUNCT	O	O	2787
on	ADP	O	O	2787
epinephrine	NOUN	O	Chemical	2787
-	PUNCT	O	O	2787
induced	VERB	O	O	2787
cardiomyopathy	ADJ	O	Disease	2787
in	ADP	O	O	2787
rats	NOUN	O	O	2787
.	PUNCT	O	O	2787
With	ADP	O	O	2788
2-week	NOUN	O	O	2788
chronic	ADJ	O	O	2788
epinephrine	NOUN	O	Chemical	2788
infusion	NOUN	O	O	2788
,	PUNCT	O	O	2788
16	NUM	O	O	2788
of	ADP	O	O	2788
30	NUM	O	O	2788
rats	NOUN	O	O	2788
died	VERB	O	O	2788
within	ADP	O	O	2788
4	NUM	O	O	2788
days	NOUN	O	O	2788
,	PUNCT	O	O	2788
and	CCONJ	O	O	2788
severe	ADJ	O	O	2788
ischemic	VERB	O	Disease	2788
lesions	NOUN	O	O	2788
and	CCONJ	O	O	2788
fibrosis	NOUN	O	Disease	2788
of	ADP	O	O	2788
the	PRON	O	O	2788
left	VERB	O	O	2788
ventricles	VERB	O	O	2788
were	AUX	O	O	2788
observed	VERB	O	O	2788
.	PUNCT	O	O	2788
In	ADP	O	O	2789
epinephrine	NOUN	O	Chemical	2789
-	PUNCT	O	O	2789
treated	VERB	O	O	2789
rats	NOUN	O	O	2789
,	PUNCT	O	O	2789
left	VERB	O	O	2789
atrial	ADJ	O	O	2789
and	CCONJ	O	O	2789
left	VERB	O	O	2789
ventricular	ADJ	O	O	2789
papillary	ADJ	O	O	2789
muscle	NOUN	O	O	2789
contractile	ADJ	O	O	2789
responses	NOUN	O	O	2789
to	PART	O	O	2789
isoproterenol	NOUN	O	Chemical	2789
were	AUX	O	O	2789
reduced	VERB	O	O	2789
,	PUNCT	O	O	2789
but	CCONJ	O	O	2789
responses	NOUN	O	O	2789
to	PART	O	O	2789
calcium	NOUN	O	Chemical	2789
were	AUX	O	O	2789
normal	ADJ	O	O	2789
or	CCONJ	O	O	2789
enhanced	VERB	O	O	2789
compared	VERB	O	O	2789
to	PART	O	O	2789
controls	VERB	O	O	2789
.	PUNCT	O	O	2789
Treatment	NOUN	O	O	2790
with	ADP	O	O	2790
clentiazem	PROPN	O	O	2790
prevented	VERB	O	O	2790
epinephrine	NOUN	O	Chemical	2790
-	PUNCT	O	O	2790
induced	VERB	O	O	2790
death	NOUN	O	O	2790
(	PUNCT	O	O	2790
P	NOUN	O	Chemical	2790
<	X	O	O	2790
.05	NUM	O	O	2791
)	PUNCT	O	O	2791
,	PUNCT	O	O	2791
and	CCONJ	O	O	2791
attenuated	VERB	O	O	2791
the	PRON	O	O	2791
ventricular	ADJ	O	O	2791
ischemic	VERB	O	Disease	2791
lesions	NOUN	O	O	2791
and	CCONJ	O	O	2791
fibrosis	NOUN	O	Disease	2791
,	PUNCT	O	O	2791
in	ADP	O	O	2791
a	PRON	O	O	2791
dose	NOUN	O	O	2791
-	PUNCT	O	O	2791
dependent	ADJ	O	O	2791
manner	VERB	O	O	2791
.	PUNCT	O	O	2791
Left	VERB	O	O	2791
atrial	ADJ	O	O	2791
and	CCONJ	O	O	2791
left	VERB	O	O	2791
ventricular	ADJ	O	O	2791
papillary	ADJ	O	O	2791
muscle	NOUN	O	O	2791
contractile	ADJ	O	O	2791
responses	NOUN	O	O	2791
to	PART	O	O	2791
isoproterenol	NOUN	O	Chemical	2791
were	AUX	O	O	2791
reduced	VERB	O	O	2791
compared	VERB	O	O	2791
to	PART	O	O	2791
controls	VERB	O	O	2791
in	ADP	O	O	2791
groups	NOUN	O	O	2791
treated	VERB	O	O	2791
with	ADP	O	O	2791
clentiazem	PROPN	O	O	2791
alone	ADV	O	O	2791
,	PUNCT	O	O	2791
but	CCONJ	O	O	2791
combined	VERB	O	O	2791
with	ADP	O	O	2791
epinephrine	NOUN	O	Chemical	2791
,	PUNCT	O	O	2791
clentiazem	PROPN	O	O	2791
restored	VERB	O	O	2791
left	VERB	O	O	2791
atrial	ADJ	O	O	2791
responses	NOUN	O	O	2791
and	CCONJ	O	O	2791
enhanced	VERB	O	O	2791
left	VERB	O	O	2791
ventricular	ADJ	O	O	2791
papillary	ADJ	O	O	2791
responses	NOUN	O	O	2791
to	PART	O	O	2791
isoproterenol	NOUN	O	Chemical	2791
.	PUNCT	O	O	2791
On	ADP	O	O	2792
the	PRON	O	O	2792
other	ADJ	O	O	2792
hand	NOUN	O	O	2792
clentiazem	PROPN	O	O	2792
did	VERB	O	O	2792
not	PART	O	O	2792
prevent	VERB	O	O	2792
epinephrine	NOUN	O	Chemical	2792
-	PUNCT	O	O	2792
induced	VERB	O	O	2792
down	ADP	O	O	2792
-	PUNCT	O	O	2792
regulation	NOUN	O	O	2792
of	ADP	O	O	2792
alpha	PROPN	O	O	2792
and	CCONJ	O	O	2792
beta	NOUN	O	O	2792
adrenoceptors	VERB	O	O	2792
.	PUNCT	O	O	2792
Interestingly	ADV	O	O	2793
,	PUNCT	O	O	2793
clentiazem	PROPN	O	O	2793
,	PUNCT	O	O	2793
infused	VERB	O	O	2793
alone	ADV	O	O	2793
,	PUNCT	O	O	2793
resulted	VERB	O	O	2793
in	ADP	O	O	2793
decreased	VERB	O	O	2793
adrenergic	NOUN	O	O	2793
receptor	NOUN	O	O	2793
densities	NOUN	O	O	2793
in	ADP	O	O	2793
the	PRON	O	O	2793
left	VERB	O	O	2793
ventricle	NOUN	O	O	2793
.	PUNCT	O	O	2793
Clentiazem	PROPN	O	O	2794
also	ADV	O	O	2794
did	VERB	O	O	2794
not	PART	O	O	2794
prevent	VERB	O	O	2794
the	PRON	O	O	2794
enhanced	VERB	O	O	2794
responses	NOUN	O	O	2794
to	PART	O	O	2794
calcium	NOUN	O	Chemical	2794
seen	VERB	O	O	2794
in	ADP	O	O	2794
the	PRON	O	O	2794
epinephrine	NOUN	O	Chemical	2794
-	PUNCT	O	O	2794
treated	VERB	O	O	2794
animals	NOUN	O	O	2794
,	PUNCT	O	O	2794
although	SCONJ	O	O	2794
the	PRON	O	O	2794
high	ADJ	O	O	2794
dose	NOUN	O	O	2794
of	ADP	O	O	2794
clentiazem	PROPN	O	O	2794
partially	ADV	O	O	2794
attenuated	VERB	O	O	2794
the	PRON	O	O	2794
maximal	ADJ	O	O	2794
response	NOUN	O	O	2794
to	PART	O	O	2794
calcium	NOUN	O	Chemical	2794
compared	VERB	O	O	2794
to	PART	O	O	2794
epinephrine	NOUN	O	Chemical	2794
-	PUNCT	O	O	2794
treated	VERB	O	O	2794
animals	NOUN	O	O	2794
.	PUNCT	O	O	2794
In	ADP	O	O	2795
conclusion	NOUN	O	O	2795
,	PUNCT	O	O	2795
clentiazem	PROPN	O	O	2795
attenuated	VERB	O	O	2795
epinephrine	NOUN	O	Chemical	2795
-	PUNCT	O	O	2795
induced	VERB	O	O	2795
cardiac	ADJ	O	O	2795
injury	NOUN	O	O	2795
,	PUNCT	O	O	2795
possibly	ADV	O	O	2795
through	ADP	O	O	2795
its	PRON	O	O	2795
effect	VERB	O	O	2795
on	ADP	O	O	2795
the	PRON	O	O	2795
adrenergic	NOUN	O	O	2795
pathway	NOUN	O	O	2795
.	PUNCT	O	O	2795
Cocaine	NOUN	O	Chemical	2798
induced	VERB	O	O	2798
myocardial ischemia	NOUN	O	Disease	2798
.	PUNCT	O	O	2798
We	PRON	O	O	2799
report	VERB	O	O	2799
a	PRON	O	O	2799
case	NOUN	O	O	2799
of	ADP	O	O	2799
myocardial ischemia	NOUN	O	Disease	2799
induced	VERB	O	O	2799
by	ADP	O	O	2799
cocaine	NOUN	O	Chemical	2799
.	PUNCT	O	O	2799
The	PRON	O	O	2800
ischemia	NOUN	O	Disease	2800
probably	ADV	O	O	2800
induced	VERB	O	O	2800
by	ADP	O	O	2800
coronary artery spasm	NOUN	O	Disease	2800
was	AUX	O	O	2800
reversed	VERB	O	O	2800
by	ADP	O	O	2800
nitroglycerin	PROPN	O	Chemical	2800
and	CCONJ	O	O	2800
calcium	NOUN	O	Chemical	2800
blocking	VERB	O	O	2800
agents	NOUN	O	O	2800
.	PUNCT	O	O	2800
Doxorubicin	PROPN	O	Chemical	2803
-	PUNCT	O	O	2803
induced	VERB	O	O	2803
cardiotoxicity	NOUN	O	Disease	2803
monitored	VERB	O	O	2803
by	ADP	O	O	2803
ECG	PROPN	O	O	2803
in	ADP	O	O	2803
freely	ADV	O	O	2803
moving	VERB	O	O	2803
mice	NOUN	O	O	2803
.	PUNCT	O	O	2803
In	ADP	O	O	2804
laboratory	NOUN	O	O	2804
animals	NOUN	O	O	2804
,	PUNCT	O	O	2804
histology	NOUN	O	O	2804
is	AUX	O	O	2804
most	ADV	O	O	2804
commonly	ADV	O	O	2804
used	VERB	O	O	2804
to	PART	O	O	2804
study	VERB	O	O	2804
doxorubicin	VERB	O	Chemical	2804
-	PUNCT	O	O	2804
induced	VERB	O	O	2804
cardiotoxicity	NOUN	O	Disease	2804
.	PUNCT	O	O	2804
With	ADP	O	O	2805
this	PRON	O	O	2805
model	NOUN	O	O	2805
we	PRON	O	O	2805
investigated	VERB	O	O	2805
the	PRON	O	O	2805
effect	VERB	O	O	2805
of	ADP	O	O	2805
chronic	ADJ	O	O	2805
doxorubicin	VERB	O	Chemical	2805
administration	NOUN	O	O	2805
on	ADP	O	O	2805
the	PRON	O	O	2805
ECG	PROPN	O	O	2805
of	ADP	O	O	2805
freely	ADV	O	O	2805
moving	VERB	O	O	2805
BALB	PROPN	O	O	2805
/	PUNCT	O	O	2805
c	X	O	O	2805
mice	NOUN	O	O	2805
and	CCONJ	O	O	2805
the	PRON	O	O	2805
efficacy	NOUN	O	O	2805
of	ADP	O	O	2805
ICRF-187	PUNCT	O	Chemical	2805
as	ADP	O	O	2805
a	PRON	O	O	2805
protective	ADJ	O	O	2805
agent	NOUN	O	O	2805
.	PUNCT	O	O	2805
11.8	NUM	O	O	2806
ms	PROPN	O	O	2806
in	ADP	O	O	2806
week	NOUN	O	O	2806
10	NUM	O	O	2806
(	PUNCT	O	O	2806
7	NUM	O	O	2806
weekly	ADV	O	O	2806
doses	NOUN	O	O	2806
of	ADP	O	O	2806
4	NUM	O	O	2806
mg	VERB	O	O	2806
/	PUNCT	O	O	2806
kg	VERB	O	O	2806
doxorubicin	VERB	O	Chemical	2806
given	VERB	O	O	2806
i.v	NOUN	O	O	2806
.	PUNCT	O	O	2806
After	ADP	O	O	2807
sacrifice	VERB	O	O	2807
the	PRON	O	O	2807
hearts	NOUN	O	O	2807
of	ADP	O	O	2807
doxorubicin	VERB	O	Chemical	2807
-	PUNCT	O	O	2807
treated	VERB	O	O	2807
animals	NOUN	O	O	2807
were	AUX	O	O	2807
enlarged	VERB	O	O	2807
and	CCONJ	O	O	2807
the	PRON	O	O	2807
atria	ADV	O	O	2807
were	AUX	O	O	2807
hypertrophic	NOUN	O	Disease	2807
.	PUNCT	O	O	2807
As	ADP	O	O	2808
this	PRON	O	O	2808
schedule	NOUN	O	O	2808
exerted	VERB	O	O	2808
more	ADJ	O	O	2808
toxicity	NOUN	O	Disease	2808
than	ADP	O	O	2808
needed	VERB	O	O	2808
to	PART	O	O	2808
investigate	VERB	O	O	2808
protective	ADJ	O	O	2808
agents	NOUN	O	O	2808
,	PUNCT	O	O	2808
the	PRON	O	O	2808
protection	NOUN	O	O	2808
of	ADP	O	O	2808
ICRF-187	PUNCT	O	Chemical	2808
was	AUX	O	O	2808
determined	VERB	O	O	2808
using	VERB	O	O	2808
a	PRON	O	O	2808
dose	NOUN	O	O	2808
schedule	NOUN	O	O	2808
with	ADP	O	O	2808
lower	ADJ	O	O	2808
general	ADJ	O	O	2808
toxicity	NOUN	O	Disease	2808
(	PUNCT	O	O	2808
6	NUM	O	O	2808
weekly	ADV	O	O	2808
doses	NOUN	O	O	2808
of	ADP	O	O	2808
4	NUM	O	O	2808
mg	VERB	O	O	2808
/	PUNCT	O	O	2808
kg	VERB	O	O	2808
doxorubicin	VERB	O	Chemical	2808
given	VERB	O	O	2808
i.v	NOUN	O	O	2808
.	PUNCT	O	O	2808
On	ADP	O	O	2809
this	PRON	O	O	2809
schedule	NOUN	O	O	2809
,	PUNCT	O	O	2809
the	PRON	O	O	2809
animals	NOUN	O	O	2809
'	PUNCT	O	O	2809
hearts	NOUN	O	O	2809
appeared	VERB	O	O	2809
normal	ADJ	O	O	2809
after	ADP	O	O	2809
sacrifice	VERB	O	O	2809
and	CCONJ	O	O	2809
ICRF-187	PUNCT	O	Chemical	2809
(	PUNCT	O	O	2809
50	NUM	O	O	2809
mg	VERB	O	O	2809
/	PUNCT	O	O	2809
kg	VERB	O	O	2809
given	VERB	O	O	2809
i.p	NOUN	O	O	2809
.	PUNCT	O	O	2809
1	X	O	O	2810
h	X	O	O	2810
before	ADP	O	O	2810
doxorubicin	VERB	O	Chemical	2810
)	PUNCT	O	O	2810
provided	VERB	O	O	2810
almost	ADV	O	O	2810
full	ADJ	O	O	2810
protection	NOUN	O	O	2810
.	PUNCT	O	O	2810
The	PRON	O	O	2811
results	VERB	O	O	2811
indicate	VERB	O	O	2811
that	SCONJ	O	O	2811
this	PRON	O	O	2811
new	ADJ	O	O	2811
model	NOUN	O	O	2811
is	AUX	O	O	2811
very	ADV	O	O	2811
sensitive	ADJ	O	O	2811
and	CCONJ	O	O	2811
enables	VERB	O	O	2811
monitoring	NOUN	O	O	2811
of	ADP	O	O	2811
the	PRON	O	O	2811
development	NOUN	O	O	2811
of	ADP	O	O	2811
cardiotoxicity	NOUN	O	Disease	2811
with	ADP	O	O	2811
time	NOUN	O	O	2811
.	PUNCT	O	O	2811
These	PRON	O	O	2812
findings	NOUN	O	O	2812
result	VERB	O	O	2812
in	ADP	O	O	2812
a	PRON	O	O	2812
model	NOUN	O	O	2812
that	SCONJ	O	O	2812
allows	VERB	O	O	2812
the	PRON	O	O	2812
testing	NOUN	O	O	2812
of	ADP	O	O	2812
protectors	NOUN	O	O	2812
against	ADP	O	O	2812
doxorubicin	VERB	O	Chemical	2812
-	PUNCT	O	O	2812
induced	VERB	O	O	2812
cardiotoxicity	NOUN	O	Disease	2812
as	ADP	O	O	2812
demonstrated	VERB	O	O	2812
by	ADP	O	O	2812
the	PRON	O	O	2812
protection	NOUN	O	O	2812
provided	VERB	O	O	2812
by	ADP	O	O	2812
ICRF-187	PUNCT	O	Chemical	2812
.	PUNCT	O	O	2812
Epinephrine	NOUN	O	Chemical	2815
dysrhythmogenicity	NOUN	O	O	2815
is	AUX	O	O	2815
not	PART	O	O	2815
enhanced	VERB	O	O	2815
by	ADP	O	O	2815
subtoxic	PROPN	O	O	2815
bupivacaine	NOUN	O	Chemical	2815
in	ADP	O	O	2815
dogs	NOUN	O	O	2815
.	PUNCT	O	O	2815
Since	SCONJ	O	O	2816
bupivacaine	NOUN	O	Chemical	2816
and	CCONJ	O	O	2816
epinephrine	NOUN	O	Chemical	2816
may	AUX	O	O	2816
both	PRON	O	O	2816
precipitate	VERB	O	O	2816
dysrhythmias	VERB	O	Disease	2816
,	PUNCT	O	O	2816
circulating	VERB	O	O	2816
bupivacaine	NOUN	O	Chemical	2816
during	ADP	O	O	2816
regional	ADJ	O	O	2816
anesthesia	NOUN	O	O	2816
could	AUX	O	O	2816
potentiate	VERB	O	O	2816
dysrhythmogenic	ADJ	O	O	2816
effects	NOUN	O	O	2816
of	ADP	O	O	2816
epinephrine	NOUN	O	Chemical	2816
.	PUNCT	O	O	2816
We	PRON	O	O	2817
therefore	ADV	O	O	2817
examined	VERB	O	O	2817
whether	SCONJ	O	O	2817
bupivacaine	NOUN	O	Chemical	2817
alters	VERB	O	O	2817
the	PRON	O	O	2817
dysrhythmogenicity	NOUN	O	O	2817
of	ADP	O	O	2817
subsequent	ADJ	O	O	2817
administration	NOUN	O	O	2817
of	ADP	O	O	2817
epinephrine	NOUN	O	Chemical	2817
in	ADP	O	O	2817
conscious	ADJ	O	O	2817
,	PUNCT	O	O	2817
healthy	ADJ	O	O	2817
dogs	NOUN	O	O	2817
and	CCONJ	O	O	2817
in	ADP	O	O	2817
anesthetized	VERB	O	O	2817
dogs	NOUN	O	O	2817
with	ADP	O	O	2817
myocardial infarction	NOUN	O	Disease	2817
.	PUNCT	O	O	2817
Forty	NUM	O	O	2818
-	PUNCT	O	O	2818
one	NUM	O	O	2818
conscious	ADJ	O	O	2818
dogs	NOUN	O	O	2818
received	VERB	O	O	2818
10	NUM	O	O	2818
micrograms.kg-1.min-1	VERB	O	O	2818
epinephrine	NOUN	O	Chemical	2818
.	PUNCT	O	O	2818
Seventeen	NUM	O	O	2819
animals	NOUN	O	O	2819
responded	VERB	O	O	2819
with	ADP	O	O	2819
ventricular tachycardia	NOUN	O	Disease	2819
(	PUNCT	O	O	2819
VT	PROPN	O	Disease	2819
)	PUNCT	O	O	2819
within	ADP	O	O	2819
3	X	O	O	2819
min	NOUN	O	O	2819
.	PUNCT	O	O	2819
After	ADP	O	O	2820
3	X	O	O	2820
h	X	O	O	2820
,	PUNCT	O	O	2820
these	PRON	O	O	2820
responders	NOUN	O	O	2820
randomly	ADV	O	O	2820
received	VERB	O	O	2820
1	X	O	O	2820
or	CCONJ	O	O	2820
2	X	O	O	2820
mg	VERB	O	O	2820
/	PUNCT	O	O	2820
kg	VERB	O	O	2820
bupivacaine	NOUN	O	Chemical	2820
or	CCONJ	O	O	2820
saline	NOUN	O	O	2820
over	ADP	O	O	2820
5	NUM	O	O	2820
min	NOUN	O	O	2820
,	PUNCT	O	O	2820
followed	VERB	O	O	2820
by	ADP	O	O	2820
10	NUM	O	O	2820
micrograms.kg-1.min-1	VERB	O	O	2820
epinephrine	NOUN	O	Chemical	2820
.	PUNCT	O	O	2820
In	ADP	O	O	2821
the	PRON	O	O	2821
bupivacaine	NOUN	O	Chemical	2821
groups	NOUN	O	O	2821
,	PUNCT	O	O	2821
epinephrine	NOUN	O	Chemical	2821
caused	VERB	O	O	2821
fewer	ADJ	O	O	2821
prodysrhythmic	ADJ	O	O	2821
effects	NOUN	O	O	2821
than	ADP	O	O	2821
without	ADP	O	O	2821
bupivacaine	NOUN	O	Chemical	2821
.	PUNCT	O	O	2821
VT	PROPN	O	Disease	2822
appeared	VERB	O	O	2822
in	ADP	O	O	2822
fewer	ADJ	O	O	2822
dogs	NOUN	O	O	2822
and	CCONJ	O	O	2822
at	ADP	O	O	2822
a	PRON	O	O	2822
later	ADV	O	O	2822
time	NOUN	O	O	2822
,	PUNCT	O	O	2822
and	CCONJ	O	O	2822
there	ADV	O	O	2822
were	AUX	O	O	2822
more	ADJ	O	O	2822
sinoatrial	NOUN	O	O	2822
beats	NOUN	O	O	2822
and	CCONJ	O	O	2822
less	ADV	O	O	2822
ectopies	VERB	O	O	2822
.	PUNCT	O	O	2822
Epinephrine	NOUN	O	Chemical	2823
shortened	VERB	O	O	2823
QT	NOUN	O	O	2823
less	ADV	O	O	2823
after	ADP	O	O	2823
bupivacaine	NOUN	O	Chemical	2823
than	ADP	O	O	2823
in	ADP	O	O	2823
control	VERB	O	O	2823
animals	NOUN	O	O	2823
.	PUNCT	O	O	2823
One	NUM	O	O	2824
day	NOUN	O	O	2824
after	ADP	O	O	2824
experimental	ADJ	O	O	2824
myocardial infarction	NOUN	O	Disease	2824
,	PUNCT	O	O	2824
six	NUM	O	O	2824
additional	ADJ	O	O	2824
halothane	VERB	O	Chemical	2824
-	PUNCT	O	O	2824
anesthetized	VERB	O	O	2824
dogs	NOUN	O	O	2824
received	VERB	O	O	2824
4	NUM	O	O	2824
micrograms.kg-1.min-1	VERB	O	O	2824
epinephrine	NOUN	O	Chemical	2824
until	ADP	O	O	2824
VT	PROPN	O	Disease	2824
appeared	VERB	O	O	2824
.	PUNCT	O	O	2824
After	ADP	O	O	2825
45	NUM	O	O	2825
min	NOUN	O	O	2825
,	PUNCT	O	O	2825
1	X	O	O	2825
mg	VERB	O	O	2825
/	PUNCT	O	O	2825
kg	VERB	O	O	2825
bupivacaine	NOUN	O	Chemical	2825
was	AUX	O	O	2825
injected	VERB	O	O	2825
over	ADP	O	O	2825
5	NUM	O	O	2825
min	NOUN	O	O	2825
,	PUNCT	O	O	2825
again	ADV	O	O	2825
followed	VERB	O	O	2825
by	ADP	O	O	2825
4	NUM	O	O	2825
micrograms.kg-1.min-1	VERB	O	O	2825
epinephrine	NOUN	O	Chemical	2825
.	PUNCT	O	O	2825
In	ADP	O	O	2826
these	PRON	O	O	2826
dogs	NOUN	O	O	2826
,	PUNCT	O	O	2826
the	PRON	O	O	2826
prodysrhythmic	ADJ	O	O	2826
response	NOUN	O	O	2826
to	PART	O	O	2826
epinephrine	NOUN	O	Chemical	2826
was	AUX	O	O	2826
also	ADV	O	O	2826
mitigated	VERB	O	O	2826
by	ADP	O	O	2826
preceding	VERB	O	O	2826
bupivacaine	NOUN	O	Chemical	2826
.	PUNCT	O	O	2826
Bupivacaine	NOUN	O	Chemical	2827
antagonizes	VERB	O	O	2827
epinephrine	NOUN	O	Chemical	2827
dysrhythmogenicity	NOUN	O	O	2827
in	ADP	O	O	2827
conscious	ADJ	O	O	2827
dogs	NOUN	O	O	2827
susceptible	ADJ	O	O	2827
to	PART	O	O	2827
VT	PROPN	O	Disease	2827
and	CCONJ	O	O	2827
in	ADP	O	O	2827
anesthetized	VERB	O	O	2827
dogs	NOUN	O	O	2827
with	ADP	O	O	2827
spontaneous	ADJ	O	O	2827
postinfarct	NOUN	O	O	2827
dysrhythmias	VERB	O	Disease	2827
.	PUNCT	O	O	2827
There	ADV	O	O	2828
is	AUX	O	O	2828
no	PRON	O	O	2828
evidence	NOUN	O	O	2828
that	SCONJ	O	O	2828
systemic	ADJ	O	O	2828
subtoxic	PROPN	O	O	2828
bupivacaine	NOUN	O	Chemical	2828
administration	NOUN	O	O	2828
enhances	VERB	O	O	2828
the	PRON	O	O	2828
dysrhythmogenicity	NOUN	O	O	2828
of	ADP	O	O	2828
subsequent	ADJ	O	O	2828
epinephrine	NOUN	O	Chemical	2828
.	PUNCT	O	O	2828
Milk	NOUN	O	O	2831
-	PUNCT	O	O	2831
alkali	ADJ	O	O	2831
syndrome	NOUN	O	O	2831
induced	VERB	O	O	2831
by	ADP	O	O	2831
1,25(OH)2D	NUM	O	O	2831
in	ADP	O	O	2831
a	PRON	O	O	2831
patient	NOUN	O	O	2831
with	ADP	O	O	2831
hypoparathyroidism	NOUN	O	O	2831
.	PUNCT	O	O	2831
Milk	NOUN	O	O	2832
-	PUNCT	O	O	2832
alkali	ADJ	O	O	2832
syndrome	NOUN	O	O	2832
was	AUX	O	O	2832
first	ADV	O	O	2832
described	VERB	O	O	2832
70	NUM	O	O	2832
years	NOUN	O	O	2832
ago	ADV	O	O	2832
in	ADP	O	O	2832
the	PRON	O	O	2832
context	NOUN	O	O	2832
of	ADP	O	O	2832
the	PRON	O	O	2832
treatment	NOUN	O	O	2832
of	ADP	O	O	2832
peptic	ADJ	O	O	2832
ulcer	NOUN	O	O	2832
disease	PROPN	O	O	2832
with	ADP	O	O	2832
large	ADJ	O	O	2832
amounts	VERB	O	O	2832
of	ADP	O	O	2832
calcium	NOUN	O	Chemical	2832
and	CCONJ	O	O	2832
alkali	ADJ	O	O	2832
.	PUNCT	O	O	2832
Although	SCONJ	O	O	2833
with	ADP	O	O	2833
current	ADJ	O	O	2833
ulcer	NOUN	O	O	2833
therapy	NOUN	O	O	2833
(	PUNCT	O	O	2833
H-2	NOUN	O	O	2833
blockers	NOUN	O	O	2833
,	PUNCT	O	O	2833
omeprazole	NOUN	O	O	2833
,	PUNCT	O	O	2833
and	CCONJ	O	O	2833
sucralfate	NOUN	O	O	2833
)	PUNCT	O	O	2833
,	PUNCT	O	O	2833
the	PRON	O	O	2833
frequency	NOUN	O	O	2833
of	ADP	O	O	2833
milk	NOUN	O	O	2833
-	PUNCT	O	O	2833
alkali	ADJ	O	O	2833
syndrome	NOUN	O	O	2833
has	VERB	O	O	2833
decreased	VERB	O	O	2833
significantly	ADV	O	O	2833
,	PUNCT	O	O	2833
the	PRON	O	O	2833
classic	ADJ	O	O	2833
triad	PROPN	O	O	2833
of	ADP	O	O	2833
hypercalcemia	NOUN	O	Disease	2833
,	PUNCT	O	O	2833
alkalosis	NOUN	O	O	2833
,	PUNCT	O	O	2833
and	CCONJ	O	O	2833
renal impairment	NOUN	O	Disease	2833
remains	VERB	O	O	2833
the	PRON	O	O	2833
hallmark	NOUN	O	O	2833
of	ADP	O	O	2833
the	PRON	O	O	2833
syndrome	NOUN	O	O	2833
.	PUNCT	O	O	2833
Milk	NOUN	O	O	2834
-	PUNCT	O	O	2834
alkali	ADJ	O	O	2834
syndrome	NOUN	O	O	2834
can	AUX	O	O	2834
present	NOUN	O	O	2834
serious	ADJ	O	O	2834
and	CCONJ	O	O	2834
occasionally	ADV	O	O	2834
life	NOUN	O	O	2834
-	PUNCT	O	O	2834
threatening	VERB	O	O	2834
illness	VERB	O	O	2834
unless	SCONJ	O	O	2834
diagnosed	VERB	O	O	2834
and	CCONJ	O	O	2834
treated	VERB	O	O	2834
appropriately	ADV	O	O	2834
.	PUNCT	O	O	2834
This	PRON	O	O	2835
article	NOUN	O	O	2835
presents	VERB	O	O	2835
a	PRON	O	O	2835
patient	NOUN	O	O	2835
with	ADP	O	O	2835
hypoparathyroidism	NOUN	O	O	2835
who	PRON	O	O	2835
was	AUX	O	O	2835
treated	VERB	O	O	2835
with	ADP	O	O	2835
calcium carbonate	NOUN	O	Chemical	2835
and	CCONJ	O	O	2835
calcitriol	PROPN	O	O	2835
resulting	VERB	O	O	2835
in	ADP	O	O	2835
two	NUM	O	O	2835
admissions	NOUN	O	O	2835
to	PART	O	O	2835
the	PRON	O	O	2835
hospital	PROPN	O	O	2835
for	ADP	O	O	2835
milk	NOUN	O	O	2835
-	PUNCT	O	O	2835
alkali	ADJ	O	O	2835
syndrome	NOUN	O	O	2835
.	PUNCT	O	O	2835
The	PRON	O	O	2836
patient	NOUN	O	O	2836
was	AUX	O	O	2836
successfully	ADV	O	O	2836
treated	VERB	O	O	2836
with	ADP	O	O	2836
intravenous	ADJ	O	O	2836
pamidronate	PROPN	O	Chemical	2836
on	ADP	O	O	2836
his	PRON	O	O	2836
first	ADV	O	O	2836
admission	NOUN	O	O	2836
and	CCONJ	O	O	2836
with	ADP	O	O	2836
hydrocortisone	NOUN	O	Chemical	2836
on	ADP	O	O	2836
the	PRON	O	O	2836
second	ADV	O	O	2836
.	PUNCT	O	O	2836
This	PRON	O	O	2837
illustrates	VERB	O	O	2837
intravenous	ADJ	O	O	2837
pamidronate	PROPN	O	Chemical	2837
as	ADP	O	O	2837
a	PRON	O	O	2837
valuable	ADJ	O	O	2837
therapeutic	ADJ	O	O	2837
tool	NOUN	O	O	2837
when	SCONJ	O	O	2837
milk	NOUN	O	O	2837
-	PUNCT	O	O	2837
alkali	ADJ	O	O	2837
syndrome	NOUN	O	O	2837
presents	VERB	O	O	2837
as	ADP	O	O	2837
hypercalcemic	ADV	O	O	2837
emergency	NOUN	O	O	2837
.	PUNCT	O	O	2837
Encephalopathy	NOUN	O	O	2840
during	ADP	O	O	2840
amitriptyline	PROPN	O	Chemical	2840
therapy	NOUN	O	O	2840
:	PUNCT	O	O	2840
are	AUX	O	O	2840
neuroleptic malignant syndrome	NOUN	O	Disease	2840
and	CCONJ	O	O	2840
serotonin syndrome	NOUN	O	Disease	2840
spectrum	NOUN	O	O	2840
disorders	NOUN	O	O	2840
?	PUNCT	O	O	2840
This	PRON	O	O	2841
report	VERB	O	O	2841
describes	VERB	O	O	2841
a	PRON	O	O	2841
case	NOUN	O	O	2841
of	ADP	O	O	2841
encephalopathy	NOUN	O	Disease	2841
developed	VERB	O	O	2841
in	ADP	O	O	2841
the	PRON	O	O	2841
course	NOUN	O	O	2841
of	ADP	O	O	2841
amitriptyline	PROPN	O	Chemical	2841
therapy	NOUN	O	O	2841
,	PUNCT	O	O	2841
during	ADP	O	O	2841
a	PRON	O	O	2841
remission	NOUN	O	O	2841
of	ADP	O	O	2841
unipolar	ADJ	O	O	2841
depression	PROPN	O	Disease	2841
.	PUNCT	O	O	2841
This	PRON	O	O	2842
patient	NOUN	O	O	2842
could	AUX	O	O	2842
have	VERB	O	O	2842
been	AUX	O	O	2842
diagnosed	VERB	O	O	2842
as	ADP	O	O	2842
having	VERB	O	O	2842
either	ADV	O	O	2842
neuroleptic malignant syndrome	NOUN	O	Disease	2842
(	PUNCT	O	O	2842
NMS	PROPN	O	Disease	2842
)	PUNCT	O	O	2842
or	CCONJ	O	O	2842
serotonin syndrome	NOUN	O	Disease	2842
(	PUNCT	O	O	2842
SS	NOUN	O	O	2842
)	PUNCT	O	O	2842
.	PUNCT	O	O	2842
The	PRON	O	O	2843
major	ADJ	O	O	2843
determinant	NOUN	O	O	2843
of	ADP	O	O	2843
the	PRON	O	O	2843
symptoms	NOUN	O	O	2843
may	AUX	O	O	2843
have	VERB	O	O	2843
been	AUX	O	O	2843
dopamine	NOUN	O	Chemical	2843
/	PUNCT	O	O	2843
serotonin	PROPN	O	Chemical	2843
imbalance	NOUN	O	O	2843
in	ADP	O	O	2843
the	PRON	O	O	2843
central	ADJ	O	O	2843
nervous	ADJ	O	O	2843
system	NOUN	O	O	2843
.	PUNCT	O	O	2843
The	PRON	O	O	2844
NMS	PROPN	O	Disease	2844
-	PUNCT	O	O	2844
like	INTJ	O	O	2844
encephalopathy	NOUN	O	Disease	2844
that	SCONJ	O	O	2844
develops	VERB	O	O	2844
in	ADP	O	O	2844
association	PROPN	O	O	2844
with	ADP	O	O	2844
the	PRON	O	O	2844
use	VERB	O	O	2844
of	ADP	O	O	2844
antidepressants	NOUN	O	O	2844
indicates	VERB	O	O	2844
that	SCONJ	O	O	2844
NMS	PROPN	O	Disease	2844
and	CCONJ	O	O	2844
SS	NOUN	O	O	2844
are	AUX	O	O	2844
spectrum	NOUN	O	O	2844
disorders	NOUN	O	O	2844
induced	VERB	O	O	2844
by	ADP	O	O	2844
drugs	NOUN	O	O	2844
with	ADP	O	O	2844
both	PRON	O	O	2844
antidopaminergic	ADV	O	O	2844
and	CCONJ	O	O	2844
serotonergic	ADJ	O	O	2844
effects	NOUN	O	O	2844
.	PUNCT	O	O	2844
Genetic	ADJ	O	O	2847
separation	NOUN	O	O	2847
of	ADP	O	O	2847
tumor	NOUN	O	Disease	2847
growth	NOUN	O	O	2847
and	CCONJ	O	O	2847
hemorrhagic	ADJ	O	Disease	2847
phenotypes	NOUN	O	O	2847
in	ADP	O	O	2847
an	PRON	O	O	2847
estrogen	PROPN	O	Chemical	2847
-	PUNCT	O	O	2847
induced	VERB	O	O	2847
tumor	NOUN	O	Disease	2847
.	PUNCT	O	O	2847
Chronic	NOUN	O	O	2848
administration	NOUN	O	O	2848
of	ADP	O	O	2848
estrogen	PROPN	O	Chemical	2848
to	PART	O	O	2848
the	PRON	O	O	2848
Fischer	PROPN	O	O	2848
344	NUM	O	O	2848
(	PUNCT	O	O	2848
F344	PROPN	O	O	2848
)	PUNCT	O	O	2848
rat	NOUN	O	O	2848
induces	VERB	O	O	2848
growth	NOUN	O	O	2848
of	ADP	O	O	2848
large	ADJ	O	O	2848
,	PUNCT	O	O	2848
hemorrhagic	ADJ	O	Disease	2848
pituitary tumors	NOUN	O	Disease	2848
.	PUNCT	O	O	2848
Ten	NUM	O	O	2849
weeks	NOUN	O	O	2849
of	ADP	O	O	2849
diethylstilbestrol	NOUN	O	O	2849
(	PUNCT	O	O	2849
DES	PROPN	O	O	2849
)	PUNCT	O	O	2849
treatment	NOUN	O	O	2849
caused	VERB	O	O	2849
female	ADJ	O	O	2849
F344	PROPN	O	O	2849
rat	NOUN	O	O	2849
pituitaries	NOUN	O	O	2849
to	PART	O	O	2849
grow	VERB	O	O	2849
to	PART	O	O	2849
an	PRON	O	O	2849
average	ADJ	O	O	2849
of	ADP	O	O	2849
109.2	NUM	O	O	2849
+	ADP	O	O	2849
/-	PUNCT	O	O	2849
1.4	NUM	O	O	2850
mg	VERB	O	O	2850
for	ADP	O	O	2850
untreated	ADJ	O	O	2850
rats	NOUN	O	O	2850
,	PUNCT	O	O	2850
and	CCONJ	O	O	2850
to	PART	O	O	2850
become	VERB	O	O	2850
highly	ADV	O	O	2850
hemorrhagic	ADJ	O	Disease	2850
.	PUNCT	O	O	2850
The	PRON	O	O	2851
same	ADJ	O	O	2851
DES	PROPN	O	O	2851
treatment	NOUN	O	O	2851
produced	VERB	O	O	2851
no	PRON	O	O	2851
significant	ADJ	O	O	2851
growth	NOUN	O	O	2851
(	PUNCT	O	O	2851
8.9	NUM	O	O	2851
+	ADP	O	O	2851
/-	PUNCT	O	O	2851
An	PRON	O	O	2852
F1	NOUN	O	O	2852
hybrid	NOUN	O	O	2852
of	ADP	O	O	2852
F344	PROPN	O	O	2852
and	CCONJ	O	O	2852
BN	PROPN	O	O	2852
exhibited	VERB	O	O	2852
significant	ADJ	O	O	2852
pituitary	NOUN	O	O	2852
growth	NOUN	O	O	2852
after	ADP	O	O	2852
10	NUM	O	O	2852
weeks	NOUN	O	O	2852
of	ADP	O	O	2852
DES	PROPN	O	O	2852
treatment	NOUN	O	O	2852
with	ADP	O	O	2852
an	PRON	O	O	2852
average	ADJ	O	O	2852
mass	PROPN	O	O	2852
of	ADP	O	O	2852
26.3	NUM	O	O	2852
+	ADP	O	O	2852
/-	PUNCT	O	O	2852
Surprisingly	ADV	O	O	2853
,	PUNCT	O	O	2853
the	PRON	O	O	2853
F1	NOUN	O	O	2853
hybrid	NOUN	O	O	2853
tumors	NOUN	O	Disease	2853
were	AUX	O	O	2853
not	PART	O	O	2853
hemorrhagic	ADJ	O	Disease	2853
and	CCONJ	O	O	2853
had	VERB	O	O	2853
hemoglobin	NOUN	O	O	2853
content	NOUN	O	O	2853
and	CCONJ	O	O	2853
outward	ADV	O	O	2853
appearance	NOUN	O	O	2853
identical	ADJ	O	O	2853
to	PART	O	O	2853
that	SCONJ	O	O	2853
of	ADP	O	O	2853
BN	PROPN	O	O	2853
.	PUNCT	O	O	2853
However	ADV	O	O	2854
,	PUNCT	O	O	2854
while	SCONJ	O	O	2854
DES	PROPN	O	O	2854
-	PUNCT	O	O	2854
induced	VERB	O	O	2854
pituitary	NOUN	O	O	2854
growth	NOUN	O	O	2854
exhibited	VERB	O	O	2854
quantitative	ADJ	O	O	2854
,	PUNCT	O	O	2854
additive	NOUN	O	O	2854
inheritance	NOUN	O	O	2854
,	PUNCT	O	O	2854
the	PRON	O	O	2854
hemorrhagic	ADJ	O	Disease	2854
phenotype	NOUN	O	O	2854
exhibited	VERB	O	O	2854
recessive	ADJ	O	O	2854
,	PUNCT	O	O	2854
epistatic	ADJ	O	O	2854
inheritance	NOUN	O	O	2854
.	PUNCT	O	O	2854
Only	ADV	O	O	2855
5	NUM	O	O	2855
of	ADP	O	O	2855
the	PRON	O	O	2855
160	NUM	O	O	2855
F2	NOUN	O	O	2855
pituitaries	NOUN	O	O	2855
exhibited	VERB	O	O	2855
the	PRON	O	O	2855
hemorrhagic	ADJ	O	Disease	2855
phenotype	NOUN	O	O	2855
;	PUNCT	O	O	2855
36	NUM	O	O	2855
of	ADP	O	O	2855
the	PRON	O	O	2855
160	NUM	O	O	2855
F2	NOUN	O	O	2855
pituitaries	NOUN	O	O	2855
were	AUX	O	O	2855
in	ADP	O	O	2855
the	PRON	O	O	2855
F344	PROPN	O	O	2855
range	VERB	O	O	2855
of	ADP	O	O	2855
mass	PROPN	O	O	2855
,	PUNCT	O	O	2855
but	CCONJ	O	O	2855
31	NUM	O	O	2855
of	ADP	O	O	2855
these	PRON	O	O	2855
were	AUX	O	O	2855
not	PART	O	O	2855
hemorrhagic	ADJ	O	Disease	2855
,	PUNCT	O	O	2855
indicating	VERB	O	O	2855
that	SCONJ	O	O	2855
the	PRON	O	O	2855
hemorrhagic	ADJ	O	Disease	2855
phenotype	NOUN	O	O	2855
is	AUX	O	O	2855
not	PART	O	O	2855
merely	ADV	O	O	2855
a	PRON	O	O	2855
consequence	NOUN	O	O	2855
of	ADP	O	O	2855
extensive	ADJ	O	O	2855
growth	NOUN	O	O	2855
.	PUNCT	O	O	2855
The	PRON	O	O	2856
hemorrhagic	ADJ	O	Disease	2856
F2	NOUN	O	O	2856
pituitaries	NOUN	O	O	2856
were	AUX	O	O	2856
all	PRON	O	O	2856
among	ADP	O	O	2856
the	PRON	O	O	2856
most	ADV	O	O	2856
massive	ADJ	O	O	2856
,	PUNCT	O	O	2856
indicating	VERB	O	O	2856
that	SCONJ	O	O	2856
some	PRON	O	O	2856
of	ADP	O	O	2856
the	PRON	O	O	2856
genes	NOUN	O	O	2856
regulate	VERB	O	O	2856
both	PRON	O	O	2856
phenotypes	NOUN	O	O	2856
.	PUNCT	O	O	2856
Increased	VERB	O	O	2859
expression	NOUN	O	O	2859
of	ADP	O	O	2859
neuronal	ADJ	O	O	2859
nitric oxide	NOUN	O	Chemical	2859
synthase	NOUN	O	O	2859
in	ADP	O	O	2859
bladder	NOUN	O	O	2859
afferent	NOUN	O	O	2859
pathways	NOUN	O	O	2859
following	VERB	O	O	2859
chronic	ADJ	O	O	2859
bladder irritation	NOUN	O	Disease	2859
.	PUNCT	O	O	2859
Immunocytochemical	PROPN	O	O	2860
techniques	NOUN	O	O	2860
were	AUX	O	O	2860
used	VERB	O	O	2860
to	PART	O	O	2860
examine	VERB	O	O	2860
alterations	NOUN	O	O	2860
in	ADP	O	O	2860
the	PRON	O	O	2860
expression	NOUN	O	O	2860
of	ADP	O	O	2860
neuronal	ADJ	O	O	2860
nitric oxide	NOUN	O	Chemical	2860
synthase	NOUN	O	O	2860
(	PUNCT	O	O	2860
NOS	PROPN	O	O	2860
)	PUNCT	O	O	2860
in	ADP	O	O	2860
bladder	NOUN	O	O	2860
pathways	NOUN	O	O	2860
following	VERB	O	O	2860
acute	ADJ	O	O	2860
and	CCONJ	O	O	2860
chronic	ADJ	O	O	2860
irritation	NOUN	O	O	2860
of	ADP	O	O	2860
the	PRON	O	O	2860
urinary	ADJ	O	O	2860
tract	NOUN	O	O	2860
of	ADP	O	O	2860
the	PRON	O	O	2860
rat	NOUN	O	O	2860
.	PUNCT	O	O	2860
Chemical	NOUN	O	O	2861
cystitis	NOUN	O	Disease	2861
was	AUX	O	O	2861
induced	VERB	O	O	2861
by	ADP	O	O	2861
cyclophosphamide	VERB	O	Chemical	2861
(	PUNCT	O	O	2861
CYP	PROPN	O	Chemical	2861
)	PUNCT	O	O	2861
which	PRON	O	O	2861
is	AUX	O	O	2861
metabolized	VERB	O	O	2861
to	PART	O	O	2861
acrolein	PROPN	O	Chemical	2861
,	PUNCT	O	O	2861
an	PRON	O	O	2861
irritant	NOUN	O	O	2861
eliminated	VERB	O	O	2861
in	ADP	O	O	2861
the	PRON	O	O	2861
urine	NOUN	O	O	2861
.	PUNCT	O	O	2861
Injection	NOUN	O	O	2862
of	ADP	O	O	2862
CYP	PROPN	O	Chemical	2862
(	PUNCT	O	O	2862
n	CCONJ	O	O	2862
=	PUNCT	O	O	2862
10	NUM	O	O	2862
,	PUNCT	O	O	2862
75	NUM	O	O	2862
mg	VERB	O	O	2862
/	PUNCT	O	O	2862
kg	VERB	O	O	2862
,	PUNCT	O	O	2862
i.p	NOUN	O	O	2862
.	PUNCT	O	O	2862
)	PUNCT	O	O	2862
Fos	PROPN	O	O	2863
-	PUNCT	O	O	2863
IR	PROPN	O	O	2863
in	ADP	O	O	2863
the	PRON	O	O	2863
spinal	NOUN	O	O	2863
cord	NOUN	O	O	2863
was	AUX	O	O	2863
not	PART	O	O	2863
changed	VERB	O	O	2863
in	ADP	O	O	2863
rats	NOUN	O	O	2863
receiving	VERB	O	O	2863
chronic	ADJ	O	O	2863
CYP	PROPN	O	Chemical	2863
treatment	NOUN	O	O	2863
(	PUNCT	O	O	2863
In	ADP	O	O	2864
control	VERB	O	O	2864
animals	NOUN	O	O	2864
and	CCONJ	O	O	2864
in	ADP	O	O	2864
animals	NOUN	O	O	2864
treated	VERB	O	O	2864
acutely	ADV	O	O	2864
with	ADP	O	O	2864
CYP	PROPN	O	Chemical	2864
,	PUNCT	O	O	2864
only	ADV	O	O	2864
small	ADJ	O	O	2864
numbers	NOUN	O	O	2864
of	ADP	O	O	2864
NOS	PROPN	O	O	2864
-	PUNCT	O	O	2864
IR	PROPN	O	O	2864
cells	NOUN	O	O	2864
(	PUNCT	O	O	2864
0.5	NUM	O	O	2864
-	PUNCT	O	O	2864
0.7	NUM	O	O	2864
cell	NOUN	O	O	2864
profiles	NOUN	O	O	2864
/	PUNCT	O	O	2864
sections	NOUN	O	O	2864
)	PUNCT	O	O	2864
were	AUX	O	O	2864
detected	VERB	O	O	2864
in	ADP	O	O	2864
the	PRON	O	O	2864
L6-S1	PROPN	O	O	2864
dorsal	PROPN	O	O	2864
root	NOUN	O	O	2864
ganglia	NOUN	O	O	2864
(	PUNCT	O	O	2864
DRG	PROPN	O	O	2864
)	PUNCT	O	O	2864
.	PUNCT	O	O	2864
Chronic	NOUN	O	O	2865
CYP	PROPN	O	Chemical	2865
administration	NOUN	O	O	2865
significantly	ADV	O	O	2865
(	PUNCT	O	O	2865
P	NOUN	O	Chemical	2865
<	X	O	O	2865
or	CCONJ	O	O	2865
=	PUNCT	O	O	2865
.002	NUM	O	O	2865
)	PUNCT	O	O	2865
increased	VERB	O	O	2865
bladder	NOUN	O	O	2865
weight	NOUN	O	O	2865
by	ADP	O	O	2865
60%	NOUN	O	O	2865
and	CCONJ	O	O	2865
increased	VERB	O	O	2865
(	PUNCT	O	O	2865
7-	X	O	O	2865
to	PART	O	O	2865
11-fold	ADV	O	O	2865
)	PUNCT	O	O	2865
the	PRON	O	O	2865
numbers	NOUN	O	O	2865
of	ADP	O	O	2865
NOS	PROPN	O	O	2865
-	PUNCT	O	O	2865
immunoreactive	ADP	O	O	2865
(	PUNCT	O	O	2865
IR	PROPN	O	O	2865
)	PUNCT	O	O	2865
afferent	NOUN	O	O	2865
neurons	NOUN	O	O	2865
in	ADP	O	O	2865
the	PRON	O	O	2865
L6-S1	PROPN	O	O	2865
DRG	PROPN	O	O	2865
.	PUNCT	O	O	2865
Bladder	NOUN	O	O	2866
afferent	NOUN	O	O	2866
cells	NOUN	O	O	2866
in	ADP	O	O	2866
the	PRON	O	O	2866
L6-S1	PROPN	O	O	2866
DRG	PROPN	O	O	2866
labeled	VERB	O	O	2866
by	ADP	O	O	2866
Fluorogold	PROPN	O	O	2866
(	PUNCT	O	O	2866
40	NUM	O	O	2866
microliters	NOUN	O	O	2866
)	PUNCT	O	O	2866
injected	VERB	O	O	2866
into	ADP	O	O	2866
the	PRON	O	O	2866
bladder	NOUN	O	O	2866
wall	PROPN	O	O	2866
did	VERB	O	O	2866
not	PART	O	O	2866
exhibit	VERB	O	O	2866
NOS	PROPN	O	O	2866
-	PUNCT	O	O	2866
IR	PROPN	O	O	2866
in	ADP	O	O	2866
control	VERB	O	O	2866
animals	NOUN	O	O	2866
;	PUNCT	O	O	2866
however	ADV	O	O	2866
,	PUNCT	O	O	2866
following	VERB	O	O	2866
chronic	ADJ	O	O	2866
CYP	PROPN	O	Chemical	2866
administration	NOUN	O	O	2866
,	PUNCT	O	O	2866
a	PRON	O	O	2866
significant	ADJ	O	O	2866
percentage	NOUN	O	O	2866
of	ADP	O	O	2866
bladder	NOUN	O	O	2866
afferent	NOUN	O	O	2866
neurons	NOUN	O	O	2866
were	AUX	O	O	2866
NOS	PROPN	O	O	2866
-	PUNCT	O	O	2866
IR	PROPN	O	O	2866
:	PUNCT	O	O	2866
Effects	NOUN	O	O	2869
of	ADP	O	O	2869
a	PRON	O	O	2869
new	ADJ	O	O	2869
calcium	NOUN	O	Chemical	2869
antagonist	NOUN	O	O	2869
,	PUNCT	O	O	2869
CD-832	PRON	O	O	2869
,	PUNCT	O	O	2869
on	ADP	O	O	2869
isoproterenol	NOUN	O	Chemical	2869
-	PUNCT	O	O	2869
induced	VERB	O	O	2869
myocardial ischemia	NOUN	O	Disease	2869
in	ADP	O	O	2869
dogs	NOUN	O	O	2869
with	ADP	O	O	2869
partial	ADJ	O	O	2869
coronary stenosis	NOUN	O	Disease	2869
.	PUNCT	O	O	2869
Effects	NOUN	O	O	2870
of	ADP	O	O	2870
CD-832	PRON	O	O	2870
on	ADP	O	O	2870
isoproterenol	NOUN	O	Chemical	2870
(	PUNCT	O	O	2870
ISO)-induced	VERB	O	O	2870
myocardial ischemia	NOUN	O	Disease	2870
were	AUX	O	O	2870
studied	VERB	O	O	2870
in	ADP	O	O	2870
dogs	NOUN	O	O	2870
with	ADP	O	O	2870
partial	ADJ	O	O	2870
coronary stenosis	NOUN	O	Disease	2870
of	ADP	O	O	2870
the	PRON	O	O	2870
left	VERB	O	O	2870
circumflex	NOUN	O	O	2870
coronary	ADJ	O	O	2870
artery	NOUN	O	O	2870
and	CCONJ	O	O	2870
findings	NOUN	O	O	2870
were	AUX	O	O	2870
compared	VERB	O	O	2870
with	ADP	O	O	2870
those	PRON	O	O	2870
for	ADP	O	O	2870
nifedipine	PROPN	O	Chemical	2870
or	CCONJ	O	O	2870
diltiazem	VERB	O	Chemical	2870
.	PUNCT	O	O	2870
In	ADP	O	O	2871
the	PRON	O	O	2871
presence	NOUN	O	O	2871
of	ADP	O	O	2871
coronary artery stenosis	NOUN	O	Disease	2871
,	PUNCT	O	O	2871
3-min	NOUN	O	O	2871
periods	NOUN	O	O	2871
of	ADP	O	O	2871
intracoronary	NOUN	O	O	2871
ISO	PROPN	O	Chemical	2871
infusion	NOUN	O	O	2871
(	PUNCT	O	O	2871
10	NUM	O	O	2871
ng	PROPN	O	O	2871
/	PUNCT	O	O	2871
kg	VERB	O	O	2871
/	PUNCT	O	O	2871
min	NOUN	O	O	2871
)	PUNCT	O	O	2871
increased	VERB	O	O	2871
heart	NOUN	O	O	2871
rate	NOUN	O	O	2871
and	CCONJ	O	O	2871
maximal	ADJ	O	O	2871
rate	NOUN	O	O	2871
of	ADP	O	O	2871
left	VERB	O	O	2871
ventricular	ADJ	O	O	2871
pressure	NOUN	O	O	2871
rise	VERB	O	O	2871
,	PUNCT	O	O	2871
which	PRON	O	O	2871
resulted	VERB	O	O	2871
in	ADP	O	O	2871
a	PRON	O	O	2871
decrease	VERB	O	O	2871
in	ADP	O	O	2871
percentage	NOUN	O	O	2871
segmental	ADJ	O	O	2871
shortening	NOUN	O	O	2871
and	CCONJ	O	O	2871
ST	PROPN	O	O	2871
-	PUNCT	O	O	2871
segment	NOUN	O	O	2871
elevation	NOUN	O	O	2871
of	ADP	O	O	2871
the	PRON	O	O	2871
epicardial	ADJ	O	O	2871
electrocardiogram	PROPN	O	O	2871
.	PUNCT	O	O	2871
After	ADP	O	O	2872
the	PRON	O	O	2872
control	VERB	O	O	2872
ISO	PROPN	O	Chemical	2872
infusion	NOUN	O	O	2872
with	ADP	O	O	2872
stenosis	NOUN	O	O	2872
was	AUX	O	O	2872
performed	VERB	O	O	2872
,	PUNCT	O	O	2872
equihypotensive	PROPN	O	O	2872
doses	NOUN	O	O	2872
of	ADP	O	O	2872
CD-832	PRON	O	O	2872
(	PUNCT	O	O	2872
3	X	O	O	2872
and	CCONJ	O	O	2872
10	NUM	O	O	2872
micrograms	NOUN	O	O	2872
/	PUNCT	O	O	2872
kg	VERB	O	O	2872
/	PUNCT	O	O	2872
min	NOUN	O	O	2872
,	PUNCT	O	O	2872
n	CCONJ	O	O	2872
=	PUNCT	O	O	2872
7	NUM	O	O	2872
)	PUNCT	O	O	2872
,	PUNCT	O	O	2872
nifedipine	PROPN	O	Chemical	2872
(	PUNCT	O	O	2873
1	X	O	O	2873
and	CCONJ	O	O	2873
3	X	O	O	2873
micrograms	NOUN	O	O	2873
/	PUNCT	O	O	2873
kg	VERB	O	O	2873
/	PUNCT	O	O	2873
min	NOUN	O	O	2873
,	PUNCT	O	O	2873
n	CCONJ	O	O	2873
=	PUNCT	O	O	2873
9	NUM	O	O	2873
)	PUNCT	O	O	2873
or	CCONJ	O	O	2873
diltiazem	VERB	O	Chemical	2873
(	PUNCT	O	O	2873
10	NUM	O	O	2873
and	CCONJ	O	O	2873
30	NUM	O	O	2874
micrograms	NOUN	O	O	2874
/	PUNCT	O	O	2874
kg	VERB	O	O	2874
/	PUNCT	O	O	2874
min	NOUN	O	O	2874
,	PUNCT	O	O	2874
n	CCONJ	O	O	2874
=	PUNCT	O	O	2874
7	NUM	O	O	2874
)	PUNCT	O	O	2874
were	AUX	O	O	2874
infused	VERB	O	O	2874
5	NUM	O	O	2874
min	NOUN	O	O	2874
before	ADP	O	O	2874
and	CCONJ	O	O	2874
during	ADP	O	O	2874
the	PRON	O	O	2874
second	ADV	O	O	2874
and	CCONJ	O	O	2874
third	ADV	O	O	2874
ISO	PROPN	O	Chemical	2874
infusion	NOUN	O	O	2874
.	PUNCT	O	O	2874
Both	PRON	O	O	2875
CD-832	PRON	O	O	2875
and	CCONJ	O	O	2875
diltiazem	VERB	O	Chemical	2875
,	PUNCT	O	O	2875
but	CCONJ	O	O	2875
not	PART	O	O	2875
nifedipine	PROPN	O	Chemical	2875
,	PUNCT	O	O	2875
significantly	ADV	O	O	2875
reduced	VERB	O	O	2875
the	PRON	O	O	2875
increase	VERB	O	O	2875
in	ADP	O	O	2875
heart	NOUN	O	O	2875
rate	NOUN	O	O	2875
induced	VERB	O	O	2875
by	ADP	O	O	2875
ISO	PROPN	O	Chemical	2875
infusion	NOUN	O	O	2875
.	PUNCT	O	O	2875
In	ADP	O	O	2876
contrast	NOUN	O	O	2876
to	PART	O	O	2876
nifedipine	PROPN	O	Chemical	2876
,	PUNCT	O	O	2876
CD-832	PRON	O	O	2876
(	PUNCT	O	O	2876
10	NUM	O	O	2876
micrograms	NOUN	O	O	2876
/	PUNCT	O	O	2876
<	X	O	O	2877
.01	NUM	O	O	2877
)	PUNCT	O	O	2877
at	ADP	O	O	2877
3	X	O	O	2877
min	NOUN	O	O	2877
after	ADP	O	O	2877
ISO	PROPN	O	Chemical	2877
infusion	NOUN	O	O	2877
with	ADP	O	O	2877
stenosis	NOUN	O	O	2877
.	PUNCT	O	O	2877
Diltiazem	PROPN	O	Chemical	2878
(	PUNCT	O	O	2878
30	NUM	O	O	2878
micrograms	NOUN	O	O	2878
/	PUNCT	O	O	2878
kg	VERB	O	O	2878
/	PUNCT	O	O	2878
min	NOUN	O	O	2878
)	PUNCT	O	O	2878
also	ADV	O	O	2878
prevented	VERB	O	O	2878
the	PRON	O	O	2878
decrease	VERB	O	O	2878
in	ADP	O	O	2878
percentage	NOUN	O	O	2878
segmental	ADJ	O	O	2878
shortening	NOUN	O	O	2878
from	ADP	O	O	2878
34	NUM	O	O	2878
+	ADP	O	O	2878
/-	PUNCT	O	O	2878
.01	NUM	O	O	2879
)	PUNCT	O	O	2879
at	ADP	O	O	2879
3	X	O	O	2879
min	NOUN	O	O	2879
after	ADP	O	O	2879
ISO	PROPN	O	Chemical	2879
infusion	NOUN	O	O	2879
with	ADP	O	O	2879
stenosis	NOUN	O	O	2879
.	PUNCT	O	O	2879
These	PRON	O	O	2880
data	NOUN	O	O	2880
show	VERB	O	O	2880
that	SCONJ	O	O	2880
CD-832	PRON	O	O	2880
improves	VERB	O	O	2880
myocardial ischemia	NOUN	O	Disease	2880
during	ADP	O	O	2880
ISO	PROPN	O	Chemical	2880
infusion	NOUN	O	O	2880
with	ADP	O	O	2880
stenosis	NOUN	O	O	2880
and	CCONJ	O	O	2880
suggest	VERB	O	O	2880
that	SCONJ	O	O	2880
the	PRON	O	O	2880
negative	ADJ	O	O	2880
chronotropic	NOUN	O	O	2880
property	NOUN	O	O	2880
of	ADP	O	O	2880
CD-832	PRON	O	O	2880
plays	VERB	O	O	2880
a	PRON	O	O	2880
major	ADJ	O	O	2880
role	NOUN	O	O	2880
in	ADP	O	O	2880
the	PRON	O	O	2880
beneficial	ADJ	O	O	2880
effects	NOUN	O	O	2880
of	ADP	O	O	2880
CD-832	PRON	O	O	2880
.	PUNCT	O	O	2880
The	PRON	O	O	2883
effect	VERB	O	O	2883
of	ADP	O	O	2883
recombinant	ADJ	O	O	2883
human	PROPN	O	O	2883
insulin	NOUN	O	O	2883
-	PUNCT	O	O	2883
like	INTJ	O	O	2883
growth	NOUN	O	O	2883
factor	NOUN	O	O	2883
-	PUNCT	O	O	2883
I	PRON	O	O	2883
on	ADP	O	O	2883
chronic	ADJ	O	O	2883
puromycin aminonucleoside	NOUN	O	Chemical	2883
nephropathy	NOUN	O	Disease	2883
in	ADP	O	O	2883
rats	NOUN	O	O	2883
.	PUNCT	O	O	2883
We	PRON	O	O	2884
recently	ADV	O	O	2884
demonstrated	VERB	O	O	2884
that	SCONJ	O	O	2884
recombinant	ADJ	O	O	2884
hGH	PROPN	O	O	2884
exacerbates	VERB	O	O	2884
renal	ADJ	O	O	2884
functional	ADJ	O	O	2884
and	CCONJ	O	O	2884
structural	ADJ	O	O	2884
injury	NOUN	O	O	2884
in	ADP	O	O	2884
chronic	ADJ	O	O	2884
puromycin aminonucleoside	NOUN	O	Chemical	2884
(	PUNCT	O	O	2884
PAN	PROPN	O	Chemical	2884
)	PUNCT	O	O	2884
nephropathy	NOUN	O	Disease	2885
,	PUNCT	O	O	2885
an	PRON	O	O	2885
experimental	ADJ	O	O	2885
model	NOUN	O	O	2885
of	ADP	O	O	2885
glomerular disease	NOUN	O	Disease	2885
.	PUNCT	O	O	2885
IGF	PROPN	O	O	2886
-	PUNCT	O	O	2886
I	PRON	O	O	2886
is	AUX	O	O	2886
a	PRON	O	O	2886
safer	ADJ	O	O	2886
alternative	ADV	O	O	2886
for	ADP	O	O	2886
the	PRON	O	O	2886
treatment	NOUN	O	O	2886
of	ADP	O	O	2886
growth	NOUN	O	O	2886
failure	NOUN	O	O	2886
in	ADP	O	O	2886
rats	NOUN	O	O	2886
with	ADP	O	O	2886
chronic	ADJ	O	O	2886
PAN	PROPN	O	Chemical	2886
nephropathy	NOUN	O	Disease	2886
.	PUNCT	O	O	2886
The	PRON	O	O	2887
glomerulopathy	ADJ	O	O	2887
was	AUX	O	O	2887
induced	VERB	O	O	2887
by	ADP	O	O	2887
seven	NUM	O	O	2887
serial	ADJ	O	O	2887
injections	NOUN	O	O	2887
of	ADP	O	O	2887
PAN	PROPN	O	Chemical	2887
over	ADP	O	O	2887
12	NUM	O	O	2887
wk	X	O	O	2887
.	PUNCT	O	O	2887
rhIGF	PUNCT	O	O	2888
-	PUNCT	O	O	2888
I	PRON	O	O	2888
improved	VERB	O	O	2888
weight	NOUN	O	O	2888
gain	VERB	O	O	2888
by	ADP	O	O	2888
14%	NOUN	O	O	2888
(	PUNCT	O	O	2888
p	NOUN	O	O	2888
<	X	O	O	2888
0.05	NUM	O	O	2888
)	PUNCT	O	O	2888
,	PUNCT	O	O	2888
without	ADP	O	O	2888
altering	VERB	O	O	2888
hematocrit	PROPN	O	O	2888
or	CCONJ	O	O	2888
blood	NOUN	O	O	2888
pressure	NOUN	O	O	2888
in	ADP	O	O	2888
rats	NOUN	O	O	2888
with	ADP	O	O	2888
renal disease	NOUN	O	Disease	2888
.	PUNCT	O	O	2888
I	PRON	O	O	2889
treatment	NOUN	O	O	2889
in	ADP	O	O	2889
rats	NOUN	O	O	2889
with	ADP	O	O	2889
chronic	ADJ	O	O	2889
PAN	PROPN	O	Chemical	2889
nephropathy	NOUN	O	Disease	2889
.	PUNCT	O	O	2889
0.06	NUM	O	O	2890
mL	PROPN	O	O	2890
/	PUNCT	O	O	2890
min/100	PRON	O	O	2890
g	X	O	O	2890
of	ADP	O	O	2890
body	NOUN	O	O	2890
weight	NOUN	O	O	2890
in	ADP	O	O	2890
untreated	ADJ	O	O	2890
PAN	PROPN	O	Chemical	2890
nephropathy	NOUN	O	Disease	2890
animals	NOUN	O	O	2890
,	PUNCT	O	O	2890
p	NOUN	O	O	2890
The	PRON	O	O	2891
improvement	NOUN	O	O	2891
in	ADP	O	O	2891
GFR	NOUN	O	O	2891
was	AUX	O	O	2891
not	PART	O	O	2891
associated	VERB	O	O	2891
with	ADP	O	O	2891
enhanced	VERB	O	O	2891
glomerular	ADJ	O	O	2891
hypertrophy	VERB	O	Disease	2891
or	CCONJ	O	O	2891
increased	VERB	O	O	2891
segmental	ADJ	O	O	2891
glomerulosclerosis	PROPN	O	O	2891
,	PUNCT	O	O	2891
tubulointerstitial injury	NOUN	O	Disease	2891
,	PUNCT	O	O	2891
or	CCONJ	O	O	2891
renal	ADJ	O	O	2891
cortical	ADJ	O	O	2891
malondialdehyde	PROPN	O	Chemical	2891
content	NOUN	O	O	2891
.	PUNCT	O	O	2891
In	ADP	O	O	2892
rats	NOUN	O	O	2892
with	ADP	O	O	2892
PAN	PROPN	O	Chemical	2892
nephropathy	NOUN	O	Disease	2892
,	PUNCT	O	O	2892
administration	NOUN	O	O	2892
of	ADP	O	O	2892
rhIGF	PUNCT	O	O	2892
-	PUNCT	O	O	2892
I	PRON	O	O	2892
increased	VERB	O	O	2892
IGF	PROPN	O	O	2892
-	PUNCT	O	O	2892
I	PRON	O	O	2892
and	CCONJ	O	O	2892
GH	PROPN	O	O	2892
receptor	NOUN	O	O	2892
gene	NOUN	O	O	2892
expression	NOUN	O	O	2892
,	PUNCT	O	O	2892
without	ADP	O	O	2892
altering	VERB	O	O	2892
the	PRON	O	O	2892
steady	ADJ	O	O	2892
state	NOUN	O	O	2892
level	VERB	O	O	2892
of	ADP	O	O	2892
IGF	PROPN	O	O	2892
-	PUNCT	O	O	2892
I	PRON	O	O	2892
receptor	NOUN	O	O	2892
mRNA	PROPN	O	O	2892
.	PUNCT	O	O	2892
In	ADP	O	O	2893
normal	ADJ	O	O	2893
rats	NOUN	O	O	2893
with	ADP	O	O	2893
intact	ADJ	O	O	2893
kidneys	NOUN	O	O	2893
,	PUNCT	O	O	2893
rhIGF	PUNCT	O	O	2893
-	PUNCT	O	O	2893
I	PRON	O	O	2893
administration	NOUN	O	O	2893
(	PUNCT	O	O	2893
n	CCONJ	O	O	2893
=	PUNCT	O	O	2893
4	NUM	O	O	2893
)	PUNCT	O	O	2893
did	VERB	O	O	2893
not	PART	O	O	2893
alter	VERB	O	O	2893
weight	NOUN	O	O	2893
gain	VERB	O	O	2893
,	PUNCT	O	O	2893
blood	NOUN	O	O	2893
pressure	NOUN	O	O	2893
,	PUNCT	O	O	2893
proteinuria	X	O	Disease	2893
,	PUNCT	O	O	2893
GFR	NOUN	O	O	2893
,	PUNCT	O	O	2893
glomerular	ADJ	O	O	2893
planar	ADJ	O	O	2893
area	NOUN	O	O	2893
,	PUNCT	O	O	2893
renal	ADJ	O	O	2893
cortical	ADJ	O	O	2893
malondialdehyde	PROPN	O	Chemical	2893
content	NOUN	O	O	2893
,	PUNCT	O	O	2893
or	CCONJ	O	O	2893
glomerular	ADJ	O	O	2893
or	CCONJ	O	O	2893
tubulointerstitial	ADJ	O	O	2893
damage	NOUN	O	O	2893
,	PUNCT	O	O	2893
compared	VERB	O	O	2893
with	ADP	O	O	2893
untreated	ADJ	O	O	2893
animals	NOUN	O	O	2893
(	PUNCT	O	O	2893
n	CCONJ	O	O	2893
=	PUNCT	O	O	2893
4	NUM	O	O	2893
)	PUNCT	O	O	2893
.	PUNCT	O	O	2893
We	PRON	O	O	2894
conclude	VERB	O	O	2894
that	SCONJ	O	O	2894
:	PUNCT	O	O	2894
1	X	O	O	2894
)	PUNCT	O	O	2894
administration	NOUN	O	O	2894
of	ADP	O	O	2894
rhIGF	PUNCT	O	O	2894
-	PUNCT	O	O	2894
I	PRON	O	O	2894
improves	VERB	O	O	2894
growth	NOUN	O	O	2894
and	CCONJ	O	O	2894
GFR	NOUN	O	O	2894
in	ADP	O	O	2894
rats	NOUN	O	O	2894
with	ADP	O	O	2894
chronic	ADJ	O	O	2894
PAN	PROPN	O	Chemical	2894
nephropathy	NOUN	O	Disease	2894
and	CCONJ	O	O	2894
2	X	O	O	2894
)	PUNCT	O	O	2894
unlike	ADP	O	O	2894
rhGH	ADJ	O	O	2894
,	PUNCT	O	O	2894
long	ADV	O	O	2894
-	PUNCT	O	O	2894
term	NOUN	O	O	2894
use	VERB	O	O	2894
of	ADP	O	O	2894
rhIGF	PUNCT	O	O	2894
-	PUNCT	O	O	2894
I	PRON	O	O	2894
does	VERB	O	O	2894
not	PART	O	O	2894
worsen	VERB	O	O	2894
renal	ADJ	O	O	2894
functional	ADJ	O	O	2894
and	CCONJ	O	O	2894
structural	ADJ	O	O	2894
injury	NOUN	O	O	2894
in	ADP	O	O	2894
this	PRON	O	O	2894
disease	PROPN	O	O	2894
model	NOUN	O	O	2894
.	PUNCT	O	O	2894
Nefiracetam	NOUN	O	O	2897
(	PUNCT	O	O	2897
DM-9384	PROPN	O	O	2897
)	PUNCT	O	O	2897
reverses	VERB	O	O	2897
apomorphine	PROPN	O	Chemical	2897
-	PUNCT	O	O	2897
induced	VERB	O	O	2897
amnesia	NOUN	O	Disease	2897
of	ADP	O	O	2897
a	PRON	O	O	2897
passive	ADJ	O	O	2897
avoidance	NOUN	O	O	2897
response	NOUN	O	O	2897
:	PUNCT	O	O	2897
Nefiracetam	NOUN	O	O	2898
is	AUX	O	O	2898
a	PRON	O	O	2898
novel	NOUN	O	O	2898
pyrrolidone	NOUN	O	O	2898
derivative	ADJ	O	O	2898
which	PRON	O	O	2898
attenuates	VERB	O	O	2898
scopolamine	NOUN	O	Chemical	2898
-	PUNCT	O	O	2898
induced	VERB	O	O	2898
learning	VERB	O	O	2898
and	CCONJ	O	O	2898
post	VERB	O	O	2898
-	PUNCT	O	O	2898
training	NOUN	O	O	2898
consolidation	NOUN	O	O	2898
deficits	NOUN	O	O	2898
.	PUNCT	O	O	2898
Given	VERB	O	O	2899
that	SCONJ	O	O	2899
apomorphine	PROPN	O	Chemical	2899
inhibits	VERB	O	O	2899
passive	ADJ	O	O	2899
avoidance	NOUN	O	O	2899
retention	NOUN	O	O	2899
when	SCONJ	O	O	2899
given	VERB	O	O	2899
during	ADP	O	O	2899
training	NOUN	O	O	2899
or	CCONJ	O	O	2899
in	ADP	O	O	2899
a	PRON	O	O	2899
defined	VERB	O	O	2899
10	NUM	O	O	2899
-	PUNCT	O	O	2899
12h	NUM	O	O	2899
post	VERB	O	O	2899
-	PUNCT	O	O	2899
training	NOUN	O	O	2899
period	NOUN	O	O	2899
,	PUNCT	O	O	2899
we	PRON	O	O	2899
evaluated	VERB	O	O	2899
the	PRON	O	O	2899
ability	NOUN	O	O	2899
of	ADP	O	O	2899
nefiracetam	VERB	O	O	2899
to	PART	O	O	2899
attenuate	VERB	O	O	2899
amnesia	NOUN	O	Disease	2899
induced	VERB	O	O	2899
by	ADP	O	O	2899
dopaminergic	ADJ	O	O	2899
agonism	NOUN	O	O	2899
.	PUNCT	O	O	2899
A	PRON	O	O	2900
step	VERB	O	O	2900
-	PUNCT	O	O	2900
down	ADP	O	O	2900
passive	ADJ	O	O	2900
avoidance	NOUN	O	O	2900
paradigm	NOUN	O	O	2900
was	AUX	O	O	2900
employed	VERB	O	O	2900
and	CCONJ	O	O	2900
nefiracetam	VERB	O	O	2900
(	PUNCT	O	O	2900
3	X	O	O	2900
mg	VERB	O	O	2900
/	PUNCT	O	O	2900
kg	VERB	O	O	2900
)	PUNCT	O	O	2900
and	CCONJ	O	O	2900
apomorphine	PROPN	O	Chemical	2900
(	PUNCT	O	O	2900
0.5	NUM	O	O	2900
mg	VERB	O	O	2900
/	PUNCT	O	O	2900
kg	VERB	O	O	2900
)	PUNCT	O	O	2900
were	AUX	O	O	2900
given	VERB	O	O	2900
alone	ADV	O	O	2900
or	CCONJ	O	O	2900
in	ADP	O	O	2900
combination	NOUN	O	O	2900
during	ADP	O	O	2900
training	NOUN	O	O	2900
and	CCONJ	O	O	2900
at	ADP	O	O	2900
the	PRON	O	O	2900
10	NUM	O	O	2900
-	PUNCT	O	O	2900
12h	NUM	O	O	2900
post	VERB	O	O	2900
-	PUNCT	O	O	2900
training	NOUN	O	O	2900
period	NOUN	O	O	2900
of	ADP	O	O	2900
consolidation	NOUN	O	O	2900
.	PUNCT	O	O	2900
Co	PROPN	O	O	2901
-	PUNCT	O	O	2901
administration	NOUN	O	O	2901
of	ADP	O	O	2901
nefiracetam	VERB	O	O	2901
and	CCONJ	O	O	2901
apomorphine	PROPN	O	Chemical	2901
during	ADP	O	O	2901
training	NOUN	O	O	2901
or	CCONJ	O	O	2901
10h	NUM	O	O	2901
thereafter	ADV	O	O	2901
produced	VERB	O	O	2901
no	PRON	O	O	2901
significant	ADJ	O	O	2901
anti	ADJ	O	O	2901
-	PUNCT	O	O	2901
amnesic	ADJ	O	Disease	2901
effect	VERB	O	O	2901
.	PUNCT	O	O	2901
However	ADV	O	O	2902
,	PUNCT	O	O	2902
administration	NOUN	O	O	2902
of	ADP	O	O	2902
nefiracetam	VERB	O	O	2902
during	ADP	O	O	2902
training	NOUN	O	O	2902
completely	ADV	O	O	2902
reversed	VERB	O	O	2902
the	PRON	O	O	2902
amnesia	NOUN	O	Disease	2902
induced	VERB	O	O	2902
by	ADP	O	O	2902
apomorphine	PROPN	O	Chemical	2902
at	ADP	O	O	2902
the	PRON	O	O	2902
10h	NUM	O	O	2902
post	VERB	O	O	2902
-	PUNCT	O	O	2902
training	NOUN	O	O	2902
time	NOUN	O	O	2902
and	CCONJ	O	O	2902
the	PRON	O	O	2902
converse	VERB	O	O	2902
was	AUX	O	O	2902
also	ADV	O	O	2902
true	ADJ	O	O	2902
.	PUNCT	O	O	2902
These	PRON	O	O	2903
effects	NOUN	O	O	2903
were	AUX	O	O	2903
not	PART	O	O	2903
mediated	VERB	O	O	2903
by	ADP	O	O	2903
a	PRON	O	O	2903
dopaminergic	ADJ	O	O	2903
mechanism	NOUN	O	O	2903
as	ADP	O	O	2903
nefiracetam	VERB	O	O	2903
,	PUNCT	O	O	2903
at	ADP	O	O	2903
millimolar	ADJ	O	O	2903
concentrations	NOUN	O	O	2903
,	PUNCT	O	O	2903
failed	VERB	O	O	2903
to	PART	O	O	2903
displace	VERB	O	O	2903
either	ADV	O	O	2903
[	X	O	O	2903
3H]SCH 23390	NUM	O	O	2903
or	CCONJ	O	O	2903
[	X	O	O	2903
3H]spiperone	NUM	O	O	2903
binding	VERB	O	O	2903
from	ADP	O	O	2903
D1	PROPN	O	O	2903
or	CCONJ	O	O	2903
D2	NOUN	O	O	2903
dopamine	NOUN	O	Chemical	2903
receptor	NOUN	O	O	2903
subtypes	NOUN	O	O	2903
,	PUNCT	O	O	2903
respectively	ADV	O	O	2903
.	PUNCT	O	O	2903
It	PRON	O	O	2904
is	AUX	O	O	2904
suggested	VERB	O	O	2904
that	SCONJ	O	O	2904
nefiracetam	VERB	O	O	2904
augments	VERB	O	O	2904
molecular	ADJ	O	O	2904
processes	NOUN	O	O	2904
in	ADP	O	O	2904
the	PRON	O	O	2904
early	ADV	O	O	2904
stages	NOUN	O	O	2904
of	ADP	O	O	2904
events	NOUN	O	O	2904
which	PRON	O	O	2904
ultimately	ADV	O	O	2904
lead	VERB	O	Chemical	2904
to	PART	O	O	2904
consolidation	NOUN	O	O	2904
of	ADP	O	O	2904
memory	NOUN	O	O	2904
.	PUNCT	O	O	2904
Human	NOUN	O	O	2907
corticotropin	NOUN	O	O	2907
-	PUNCT	O	O	2907
releasing	VERB	O	O	2907
hormone	NOUN	O	O	2907
and	CCONJ	O	O	2907
thyrotropin	ADP	O	O	2907
-	PUNCT	O	O	2907
releasing	VERB	O	O	2907
hormone	NOUN	O	O	2907
modulate	VERB	O	O	2907
the	PRON	O	O	2907
hypercapnic	VERB	O	O	2907
ventilatory	ADJ	O	O	2907
response	NOUN	O	O	2907
in	ADP	O	O	2907
humans	NOUN	O	O	2907
.	PUNCT	O	O	2907
Human	NOUN	O	O	2908
corticotropin	NOUN	O	O	2908
-	PUNCT	O	O	2908
releasing	VERB	O	O	2908
hormone	NOUN	O	O	2908
(	PUNCT	O	O	2908
hCRH	NUM	O	O	2908
)	PUNCT	O	O	2908
and	CCONJ	O	O	2908
thyrotropin	ADP	O	O	2908
-	PUNCT	O	O	2908
releasing	VERB	O	O	2908
hormone	NOUN	O	O	2908
(	PUNCT	O	O	2908
TRH	PROPN	O	O	2908
)	PUNCT	O	O	2908
are	AUX	O	O	2908
known	VERB	O	O	2908
to	PART	O	O	2908
stimulate	VERB	O	O	2908
ventilation	NOUN	O	O	2908
after	ADP	O	O	2908
i.v	NOUN	O	O	2908
.	PUNCT	O	O	2908
Two	NUM	O	O	2909
subsequent	ADJ	O	O	2909
CO2-rebreathing	NOUN	O	O	2909
tests	VERB	O	O	2909
were	AUX	O	O	2909
performed	VERB	O	O	2909
in	ADP	O	O	2909
healthy	ADJ	O	O	2909
young	ADJ	O	O	2909
volunteers	NOUN	O	O	2909
.	PUNCT	O	O	2909
During	ADP	O	O	2910
the	PRON	O	O	2910
first	ADV	O	O	2910
test	NOUN	O	O	2910
0.9%	NOUN	O	O	2910
NaCl	NOUN	O	O	2910
was	AUX	O	O	2910
given	VERB	O	O	2910
i.v	NOUN	O	O	2910
.	PUNCT	O	O	2910
Nine	NUM	O	O	2911
subjects	NOUN	O	O	2911
received	VERB	O	O	2911
0.9%	NOUN	O	O	2911
NaCl	NOUN	O	O	2911
i.v	NOUN	O	O	2911
.	PUNCT	O	O	2911
The	PRON	O	O	2912
CO2-response	NOUN	O	O	2912
curves	NOUN	O	O	2912
for	ADP	O	O	2912
the	PRON	O	O	2912
two	NUM	O	O	2912
tests	VERB	O	O	2912
were	AUX	O	O	2912
compared	VERB	O	O	2912
within	ADP	O	O	2912
the	PRON	O	O	2912
same	ADJ	O	O	2912
subject	ADJ	O	O	2912
.	PUNCT	O	O	2912
In	ADP	O	O	2913
the	PRON	O	O	2913
hCRH	NUM	O	O	2913
group	NOUN	O	O	2913
a	PRON	O	O	2913
marked	VERB	O	O	2913
parallel	ADJ	O	O	2913
shift	NOUN	O	O	2913
of	ADP	O	O	2913
the	PRON	O	O	2913
CO2-response	NOUN	O	O	2913
curve	NOUN	O	O	2913
to	PART	O	O	2913
the	PRON	O	O	2913
left	VERB	O	O	2913
was	AUX	O	O	2913
observed	VERB	O	O	2913
after	ADP	O	O	2913
hCRH	NUM	O	O	2913
(	PUNCT	O	O	2913
P	NOUN	O	Chemical	2913
<	X	O	O	2913
0.01	NUM	O	O	2913
)	PUNCT	O	O	2913
.	PUNCT	O	O	2913
hCRH	NUM	O	O	2914
and	CCONJ	O	O	2914
TRH	PROPN	O	O	2914
caused	VERB	O	O	2914
a	PRON	O	O	2914
reduction	NOUN	O	O	2914
in	ADP	O	O	2914
the	PRON	O	O	2914
CO2	PROPN	O	Chemical	2914
threshold	NOUN	O	O	2914
.	PUNCT	O	O	2914
The	PRON	O	O	2915
CO2-response	NOUN	O	O	2915
curves	NOUN	O	O	2915
in	ADP	O	O	2915
the	PRON	O	O	2915
control	VERB	O	O	2915
group	NOUN	O	O	2915
were	AUX	O	O	2915
nearly	ADV	O	O	2915
identical	ADJ	O	O	2915
.	PUNCT	O	O	2915
The	PRON	O	O	2916
results	VERB	O	O	2916
indicate	VERB	O	O	2916
an	PRON	O	O	2916
additive	NOUN	O	O	2916
effect	VERB	O	O	2916
of	ADP	O	O	2916
both	PRON	O	O	2916
releasing	VERB	O	O	2916
hormones	NOUN	O	O	2916
on	ADP	O	O	2916
the	PRON	O	O	2916
hypercapnic	VERB	O	O	2916
ventilatory	ADJ	O	O	2916
response	NOUN	O	O	2916
in	ADP	O	O	2916
humans	NOUN	O	O	2916
,	PUNCT	O	O	2916
presumably	ADV	O	O	2916
independent	ADJ	O	O	2916
of	ADP	O	O	2916
central	ADJ	O	O	2916
chemosensitivity	NOUN	O	O	2916
.	PUNCT	O	O	2916
Lamivudine	NOUN	O	O	2919
is	AUX	O	O	2919
effective	ADJ	O	O	2919
in	ADP	O	O	2919
suppressing	VERB	O	O	2919
hepatitis B	PROPN	O	Disease	2919
virus	NOUN	O	O	2919
DNA	NOUN	O	O	2919
in	ADP	O	O	2919
Chinese	PROPN	O	O	2919
hepatitis B surface antigen	NOUN	O	Chemical	2919
carriers	NOUN	O	O	2919
:	PUNCT	O	O	2919
a	PRON	O	O	2919
placebo	NOUN	O	O	2919
-	PUNCT	O	O	2919
controlled	VERB	O	O	2919
trial	NOUN	O	O	2919
.	PUNCT	O	O	2919
Lamivudine	NOUN	O	O	2920
is	AUX	O	O	2920
a	PRON	O	O	2920
novel	NOUN	O	O	2920
2',3'-dideoxy	NUM	O	O	2920
cytosine	NOUN	O	O	2920
analogue	NOUN	O	O	2920
that	SCONJ	O	O	2920
has	VERB	O	O	2920
potent	ADJ	O	O	2920
inhibitory	ADJ	O	O	2920
effects	NOUN	O	O	2920
on	ADP	O	O	2920
hepatitis B	PROPN	O	Disease	2920
virus	NOUN	O	O	2920
replication	NOUN	O	O	2920
in	ADP	O	O	2920
vitro	X	O	O	2920
and	CCONJ	O	O	2920
in	ADP	O	O	2920
vivo	VERB	O	O	2920
.	PUNCT	O	O	2920
We	PRON	O	O	2921
performed	VERB	O	O	2921
a	PRON	O	O	2921
single	ADJ	O	O	2921
-	PUNCT	O	O	2921
blind	ADJ	O	Disease	2921
,	PUNCT	O	O	2921
placebo	NOUN	O	O	2921
-	PUNCT	O	O	2921
controlled	VERB	O	O	2921
study	VERB	O	O	2921
to	PART	O	O	2921
assess	VERB	O	O	2921
its	PRON	O	O	2921
effectiveness	NOUN	O	O	2921
and	CCONJ	O	O	2921
safety	NOUN	O	O	2921
in	ADP	O	O	2921
Chinese	PROPN	O	O	2921
hepatitis B surface antigen	NOUN	O	Chemical	2921
(	PUNCT	O	O	2921
HBsAg	PROPN	O	Chemical	2921
)	PUNCT	O	O	2921
carriers	NOUN	O	O	2921
.	PUNCT	O	O	2921
Forty	NUM	O	O	2922
-	PUNCT	O	O	2922
two	NUM	O	O	2922
Chinese	PROPN	O	O	2922
HBsAg	PROPN	O	Chemical	2922
carriers	NOUN	O	O	2922
were	AUX	O	O	2922
randomized	VERB	O	O	2922
to	PART	O	O	2922
receive	VERB	O	O	2922
placebo	NOUN	O	O	2922
(	PUNCT	O	O	2922
6	NUM	O	O	2922
patients	NOUN	O	O	2922
)	PUNCT	O	O	2922
or	CCONJ	O	O	2922
lamivudine	NOUN	O	Chemical	2922
orally	ADV	O	O	2922
in	ADP	O	O	2922
dosages	NOUN	O	O	2922
of	ADP	O	O	2922
25	NUM	O	O	2922
mg	VERB	O	O	2922
,	PUNCT	O	O	2922
100	NUM	O	O	2922
mg	VERB	O	O	2922
,	PUNCT	O	O	2922
or	CCONJ	O	O	2922
300	NUM	O	O	2922
mg	VERB	O	O	2922
daily	ADV	O	O	2922
(	PUNCT	O	O	2922
12	NUM	O	O	2922
patients	NOUN	O	O	2922
for	ADP	O	O	2922
each	PRON	O	O	2922
dosage	NOUN	O	O	2922
)	PUNCT	O	O	2922
.	PUNCT	O	O	2922
All	PRON	O	O	2923
36	NUM	O	O	2923
patients	NOUN	O	O	2923
receiving	VERB	O	O	2923
lamivudine	NOUN	O	Chemical	2923
had	VERB	O	O	2923
a	PRON	O	O	2923
decrease	VERB	O	O	2923
in	ADP	O	O	2923
hepatitis B	PROPN	O	Disease	2923
virus	NOUN	O	O	2923
(	PUNCT	O	O	2923
HBV	NOUN	O	O	2923
)	PUNCT	O	O	2923
DNA	NOUN	O	O	2923
values	NOUN	O	O	2923
of	ADP	O	O	2923
>	PUNCT	O	O	2923
90%	NOUN	O	O	2923
(	PUNCT	O	O	2923
P	NOUN	O	Chemical	2923
<	X	O	O	2923
.001	NUM	O	O	2923
compared	VERB	O	O	2923
with	ADP	O	O	2923
placebo	NOUN	O	O	2923
)	PUNCT	O	O	2923
.	PUNCT	O	O	2923
Although	SCONJ	O	O	2924
25	NUM	O	O	2924
mg	VERB	O	O	2924
of	ADP	O	O	2924
lamivudine	NOUN	O	Chemical	2924
was	AUX	O	O	2924
slightly	ADV	O	O	2924
less	ADV	O	O	2924
effective	ADJ	O	O	2924
than	ADP	O	O	2924
100	NUM	O	O	2924
mg	VERB	O	O	2924
(	PUNCT	O	O	2924
P	NOUN	O	Chemical	2924
=	PUNCT	O	O	2924
.011	NUM	O	O	2924
)	PUNCT	O	O	2924
and	CCONJ	O	O	2924
300	NUM	O	O	2924
mg	VERB	O	O	2924
(	PUNCT	O	O	2924
P	NOUN	O	Chemical	2924
=	PUNCT	O	O	2924
.005	NUM	O	O	2924
)	PUNCT	O	O	2924
,	PUNCT	O	O	2924
it	PRON	O	O	2924
still	ADV	O	O	2924
induced	VERB	O	O	2924
94%	NOUN	O	O	2924
suppression	NOUN	O	O	2924
of	ADP	O	O	2924
HBV	NOUN	O	O	2924
DNA	NOUN	O	O	2924
after	ADP	O	O	2924
the	PRON	O	O	2924
fourth	ADV	O	O	2924
week	NOUN	O	O	2924
of	ADP	O	O	2924
therapy	NOUN	O	O	2924
.	PUNCT	O	O	2924
There	ADV	O	O	2925
was	AUX	O	O	2925
no	PRON	O	O	2925
change	VERB	O	O	2925
in	ADP	O	O	2925
the	PRON	O	O	2925
hepatitis B	PROPN	O	Disease	2925
e	X	O	O	2925
antigen	PROPN	O	O	2925
status	NOUN	O	O	2925
or	CCONJ	O	O	2925
in	ADP	O	O	2925
aminotransferase	PROPN	O	O	2925
levels	NOUN	O	O	2925
.	PUNCT	O	O	2925
In	ADP	O	O	2926
conclusion	NOUN	O	O	2926
,	PUNCT	O	O	2926
a	PRON	O	O	2926
4-week	NOUN	O	O	2926
course	NOUN	O	O	2926
of	ADP	O	O	2926
lamivudine	NOUN	O	Chemical	2926
was	AUX	O	O	2926
safe	ADJ	O	O	2926
and	CCONJ	O	O	2926
effective	ADJ	O	O	2926
in	ADP	O	O	2926
suppression	NOUN	O	O	2926
of	ADP	O	O	2926
HBV	NOUN	O	O	2926
DNA	NOUN	O	O	2926
in	ADP	O	O	2926
Chinese	PROPN	O	O	2926
HBsAg	PROPN	O	Chemical	2926
carriers	NOUN	O	O	2926
.	PUNCT	O	O	2926
Studies	NOUN	O	O	2927
with	ADP	O	O	2927
long	ADV	O	O	2927
-	PUNCT	O	O	2927
term	NOUN	O	O	2927
lamivudine	NOUN	O	Chemical	2927
administration	NOUN	O	O	2927
should	AUX	O	O	2927
be	AUX	O	O	2927
performed	VERB	O	O	2927
to	PART	O	O	2927
determine	VERB	O	O	2927
if	SCONJ	O	O	2927
prolonged	VERB	O	O	2927
suppression	NOUN	O	O	2927
of	ADP	O	O	2927
HBV	NOUN	O	O	2927
DNA	NOUN	O	O	2927
can	AUX	O	O	2927
be	AUX	O	O	2927
achieved	VERB	O	O	2927
.	PUNCT	O	O	2927
Population	NOUN	O	O	2930
-	PUNCT	O	O	2930
based	VERB	O	O	2930
study	VERB	O	O	2930
of	ADP	O	O	2930
risk	NOUN	O	O	2930
of	ADP	O	O	2930
venous thromboembolism	NOUN	O	Disease	2930
associated	VERB	O	O	2930
with	ADP	O	O	2930
various	ADJ	O	O	2930
oral contraceptives	NOUN	O	Chemical	2930
.	PUNCT	O	O	2930
BACKGROUND	NOUN	O	O	2931
:	PUNCT	O	O	2931
Four	NUM	O	O	2931
studies	NOUN	O	O	2931
published	VERB	O	O	2931
since	SCONJ	O	O	2931
December	PROPN	O	O	2931
,	PUNCT	O	O	2931
1995	NUM	O	O	2931
,	PUNCT	O	O	2931
reported	VERB	O	O	2931
that	SCONJ	O	O	2931
the	PRON	O	O	2931
incidence	NOUN	O	O	2931
of	ADP	O	O	2931
venous thromboembolism	NOUN	O	Disease	2931
(	PUNCT	O	O	2931
VTE	PROPN	O	Disease	2931
)	PUNCT	O	O	2931
was	AUX	O	O	2931
higher	ADJ	O	O	2931
in	ADP	O	O	2931
women	NOUN	O	O	2931
who	PRON	O	O	2931
used	VERB	O	O	2931
oral contraceptives	NOUN	O	Chemical	2931
(	PUNCT	O	O	2931
OCs	NOUN	O	O	2931
)	PUNCT	O	O	2931
containing	VERB	O	O	2931
the	PRON	O	O	2931
third	ADV	O	O	2931
-	PUNCT	O	O	2931
generation	NOUN	O	O	2931
progestagens	NOUN	O	O	2931
gestodene	PROPN	O	O	2931
or	CCONJ	O	O	2931
desogestrel	VERB	O	O	2931
than	ADP	O	O	2931
in	ADP	O	O	2931
users	NOUN	O	O	2931
of	ADP	O	O	2931
OCs	NOUN	O	O	2931
containing	VERB	O	O	2931
second	ADV	O	O	2931
-	PUNCT	O	O	2931
generation	NOUN	O	O	2931
progestagens	NOUN	O	O	2931
.	PUNCT	O	O	2931
The	PRON	O	O	2932
aim	VERB	O	O	2932
of	ADP	O	O	2932
our	PRON	O	O	2932
study	VERB	O	O	2932
was	AUX	O	O	2932
to	PART	O	O	2932
re	ADP	O	O	2932
-	PUNCT	O	O	2932
examine	VERB	O	O	2932
the	PRON	O	O	2932
association	PROPN	O	O	2932
between	ADP	O	O	2932
risk	NOUN	O	O	2932
of	ADP	O	O	2932
VTE	PROPN	O	Disease	2932
and	CCONJ	O	O	2932
OC	PROPN	O	O	2932
use	VERB	O	O	2932
with	ADP	O	O	2932
a	PRON	O	O	2932
different	ADJ	O	O	2932
study	VERB	O	O	2932
design	NOUN	O	O	2932
and	CCONJ	O	O	2932
analysis	NOUN	O	O	2932
to	PART	O	O	2932
avoid	VERB	O	O	2932
some	PRON	O	O	2932
of	ADP	O	O	2932
the	PRON	O	O	2932
bias	VERB	O	O	2932
and	CCONJ	O	O	2932
confounding	VERB	O	O	2932
of	ADP	O	O	2932
the	PRON	O	O	2932
earlier	ADV	O	O	2932
studies	NOUN	O	O	2932
.	PUNCT	O	O	2932
All	PRON	O	O	2933
women	NOUN	O	O	2933
who	PRON	O	O	2933
had	VERB	O	O	2933
a	PRON	O	O	2933
recorded	VERB	O	O	2933
diagnosis	NOUN	O	O	2933
of	ADP	O	O	2933
deep	ADJ	O	O	2933
-	PUNCT	O	O	2933
vein thrombosis	NOUN	O	Disease	2933
,	PUNCT	O	O	2933
venous thrombosis	NOUN	O	Disease	2933
not	PART	O	O	2933
otherwise	ADV	O	O	2933
specified	VERB	O	O	2933
,	PUNCT	O	O	2933
or	CCONJ	O	O	2933
pulmonary	ADJ	O	O	2933
embolus	NOUN	O	O	2933
during	ADP	O	O	2933
the	PRON	O	O	2933
study	VERB	O	O	2933
period	NOUN	O	O	2933
,	PUNCT	O	O	2933
and	CCONJ	O	O	2933
who	PRON	O	O	2933
had	VERB	O	O	2933
been	AUX	O	O	2933
treated	VERB	O	O	2933
with	ADP	O	O	2933
an	PRON	O	O	2933
anticoagulant	ADJ	O	O	2933
were	AUX	O	O	2933
identified	VERB	O	O	2933
as	ADP	O	O	2933
potential	ADJ	O	O	2933
cases	NOUN	O	O	2933
of	ADP	O	O	2933
VTE	PROPN	O	Disease	2933
.	PUNCT	O	O	2933
We	PRON	O	O	2934
did	VERB	O	O	2934
a	PRON	O	O	2934
cohort	NOUN	O	O	2934
analysis	NOUN	O	O	2934
to	PART	O	O	2934
estimate	VERB	O	O	2934
and	CCONJ	O	O	2934
compare	VERB	O	O	2934
incidence	NOUN	O	O	2934
of	ADP	O	O	2934
VTE	PROPN	O	Disease	2934
in	ADP	O	O	2934
users	NOUN	O	O	2934
of	ADP	O	O	2934
the	PRON	O	O	2934
main	ADJ	O	O	2934
OC	PROPN	O	O	2934
preparations	NOUN	O	O	2934
,	PUNCT	O	O	2934
and	CCONJ	O	O	2934
a	PRON	O	O	2934
nested	VERB	O	O	2934
case	NOUN	O	O	2934
-	PUNCT	O	O	2934
control	VERB	O	O	2934
study	VERB	O	O	2934
to	PART	O	O	2934
calculate	VERB	O	O	2934
the	PRON	O	O	2934
odds	NOUN	O	O	2934
ratios	VERB	O	O	2934
of	ADP	O	O	2934
VTE	PROPN	O	Disease	2934
associated	VERB	O	O	2934
with	ADP	O	O	2934
use	VERB	O	O	2934
of	ADP	O	O	2934
different	ADJ	O	O	2934
types	NOUN	O	O	2934
of	ADP	O	O	2934
OC	PROPN	O	O	2934
,	PUNCT	O	O	2934
after	ADP	O	O	2934
adjustment	NOUN	O	O	2934
for	ADP	O	O	2934
potential	ADJ	O	O	2934
confounding	VERB	O	O	2934
factors	NOUN	O	O	2934
.	PUNCT	O	O	2934
In	ADP	O	O	2935
the	PRON	O	O	2935
case	NOUN	O	O	2935
-	PUNCT	O	O	2935
control	VERB	O	O	2935
study	VERB	O	O	2935
,	PUNCT	O	O	2935
we	PRON	O	O	2935
matched	VERB	O	O	2935
cases	NOUN	O	O	2935
to	PART	O	O	2935
controls	VERB	O	O	2935
by	ADP	O	O	2935
exact	VERB	O	O	2935
year	NOUN	O	O	2935
of	ADP	O	O	2935
birth	NOUN	O	O	2935
,	PUNCT	O	O	2935
practice	VERB	O	O	2935
,	PUNCT	O	O	2935
and	CCONJ	O	O	2935
current	ADJ	O	O	2935
use	VERB	O	O	2935
of	ADP	O	O	2935
OCs	NOUN	O	O	2935
.	PUNCT	O	O	2935
We	PRON	O	O	2936
used	VERB	O	O	2936
a	PRON	O	O	2936
multiple	ADJ	O	O	2936
logistic	ADJ	O	O	2936
regression	NOUN	O	O	2936
model	NOUN	O	O	2936
that	SCONJ	O	O	2936
included	VERB	O	O	2936
body	NOUN	O	O	2936
-	PUNCT	O	O	2936
mass	PROPN	O	O	2936
index	NOUN	O	O	2936
,	PUNCT	O	O	2936
number	NOUN	O	O	2936
of	ADP	O	O	2936
cycles	NOUN	O	O	2936
,	PUNCT	O	O	2936
change	VERB	O	O	2936
in	ADP	O	O	2936
type	NOUN	O	O	2936
of	ADP	O	O	2936
OC	PROPN	O	O	2936
prescribed	VERB	O	O	2936
within	ADP	O	O	2936
3	X	O	O	2936
months	NOUN	O	O	2936
of	ADP	O	O	2936
the	PRON	O	O	2936
event	NOUN	O	O	2936
,	PUNCT	O	O	2936
previous	ADJ	O	O	2936
pregnancy	NOUN	O	O	2936
,	PUNCT	O	O	2936
and	CCONJ	O	O	2936
concurrent	ADJ	O	O	2936
disease	PROPN	O	O	2936
.	PUNCT	O	O	2936
FINDINGS	PROPN	O	O	2937
:	PUNCT	O	O	2937
85	NUM	O	O	2937
women	NOUN	O	O	2937
met	VERB	O	O	2937
the	PRON	O	O	2937
inclusion	NOUN	O	O	2937
criteria	NOUN	O	O	2937
for	ADP	O	O	2937
VTE	PROPN	O	Disease	2937
,	PUNCT	O	O	2937
two	NUM	O	O	2937
of	ADP	O	O	2937
whom	PRON	O	O	2937
were	AUX	O	O	2937
users	NOUN	O	O	2937
of	ADP	O	O	2937
progestagen	PROPN	O	O	2937
-	PUNCT	O	O	2937
only	ADV	O	O	2937
OCs	NOUN	O	O	2937
.	PUNCT	O	O	2937
Of	ADV	O	O	2938
the	PRON	O	O	2938
83	NUM	O	O	2938
cases	NOUN	O	O	2938
of	ADP	O	O	2938
VTE	PROPN	O	Disease	2938
associated	VERB	O	O	2938
with	ADP	O	O	2938
use	VERB	O	O	2938
of	ADP	O	O	2938
combined	VERB	O	O	2938
OCs	NOUN	O	O	2938
,	PUNCT	O	O	2938
43	NUM	O	O	2938
were	AUX	O	O	2938
recorded	VERB	O	O	2938
as	ADP	O	O	2938
deep	ADJ	O	O	2938
-	PUNCT	O	O	2938
vein thrombosis	NOUN	O	Disease	2938
,	PUNCT	O	O	2938
35	NUM	O	O	2938
as	ADP	O	O	2938
pulmonary	ADJ	O	O	2938
thrombosis	NOUN	O	Disease	2938
,	PUNCT	O	O	2938
and	CCONJ	O	O	2938
five	NUM	O	O	2938
as	ADP	O	O	2938
venous thrombosis	NOUN	O	Disease	2938
not	PART	O	O	2938
otherwise	ADV	O	O	2938
specified	VERB	O	O	2938
.	PUNCT	O	O	2938
The	PRON	O	O	2939
crude	ADJ	O	O	2939
rate	NOUN	O	O	2939
of	ADP	O	O	2939
VTE	PROPN	O	Disease	2939
per	ADP	O	O	2939
10,000	NUM	O	O	2939
woman	NOUN	O	O	2939
-	PUNCT	O	O	2939
years	NOUN	O	O	2939
was	AUX	O	O	2939
4.10	NUM	O	O	2939
in	ADP	O	O	2939
current	ADJ	O	O	2939
users	NOUN	O	O	2939
of	ADP	O	O	2939
any	PRON	O	O	2939
OC	PROPN	O	O	2939
,	PUNCT	O	O	2939
3.10	NUM	O	O	2939
in	ADP	O	O	2939
users	NOUN	O	O	2939
of	ADP	O	O	2939
second	ADV	O	O	2939
-	PUNCT	O	O	2939
generation	NOUN	O	O	2939
OCs	NOUN	O	O	2939
,	PUNCT	O	O	2939
and	CCONJ	O	O	2939
4.96	NUM	O	O	2939
in	ADP	O	O	2939
users	NOUN	O	O	2939
of	ADP	O	O	2939
third	ADV	O	O	2939
-	PUNCT	O	O	2939
generation	NOUN	O	O	2939
preparations	NOUN	O	O	2939
.	PUNCT	O	O	2939
After	ADP	O	O	2940
adjustment	NOUN	O	O	2940
for	ADP	O	O	2940
age	NOUN	O	O	2940
,	PUNCT	O	O	2940
the	PRON	O	O	2940
rate	NOUN	O	O	2940
ratio	NOUN	O	O	2940
of	ADP	O	O	2940
VTE	PROPN	O	Disease	2940
in	ADP	O	O	2940
users	NOUN	O	O	2940
of	ADP	O	O	2940
third	ADV	O	O	2940
-	PUNCT	O	O	2940
generation	NOUN	O	O	2940
relative	ADJ	O	O	2940
to	PART	O	O	2940
second	ADV	O	O	2940
-	PUNCT	O	O	2940
generation	NOUN	O	O	2940
OCs	NOUN	O	O	2940
was	AUX	O	O	2940
1.68	NUM	O	O	2940
(	PUNCT	O	O	2940
95%	NOUN	O	O	2940
CI	NOUN	O	O	2940
1.04	NUM	O	O	2940
-	PUNCT	O	O	2940
2.75	NUM	O	O	2940
)	PUNCT	O	O	2940
.	PUNCT	O	O	2940
Logistic	ADJ	O	O	2941
regression	NOUN	O	O	2941
showed	VERB	O	O	2941
no	PRON	O	O	2941
significant	ADJ	O	O	2941
difference	NOUN	O	O	2941
in	ADP	O	O	2941
the	PRON	O	O	2941
risk	NOUN	O	O	2941
of	ADP	O	O	2941
VTE	PROPN	O	Disease	2941
between	ADP	O	O	2941
users	NOUN	O	O	2941
of	ADP	O	O	2941
third	ADV	O	O	2941
-	PUNCT	O	O	2941
generation	NOUN	O	O	2941
and	CCONJ	O	O	2941
second	ADV	O	O	2941
-	PUNCT	O	O	2941
generation	NOUN	O	O	2941
OCs	NOUN	O	O	2941
.	PUNCT	O	O	2941
Among	ADP	O	O	2942
users	NOUN	O	O	2942
of	ADP	O	O	2942
third	ADV	O	O	2942
-	PUNCT	O	O	2942
generation	NOUN	O	O	2942
progestagens	NOUN	O	O	2942
,	PUNCT	O	O	2942
the	PRON	O	O	2942
risk	NOUN	O	O	2942
of	ADP	O	O	2942
VTE	PROPN	O	Disease	2942
was	AUX	O	O	2942
higher	ADJ	O	O	2942
in	ADP	O	O	2942
users	NOUN	O	O	2942
of	ADP	O	O	2942
desogestrel	VERB	O	O	2942
with	ADP	O	O	2942
20	NUM	O	O	2942
g	X	O	O	2942
ethinyloestradiol	VERB	O	O	2942
than	ADP	O	O	2942
in	ADP	O	O	2942
users	NOUN	O	O	2942
of	ADP	O	O	2942
gestodene	PROPN	O	O	2942
or	CCONJ	O	O	2942
desogestrel	VERB	O	O	2942
with	ADP	O	O	2942
30	NUM	O	O	2942
g	X	O	O	2942
ethinyloestradiol	VERB	O	O	2942
.	PUNCT	O	O	2942
With	ADP	O	O	2943
all	PRON	O	O	2943
second	ADV	O	O	2943
-	PUNCT	O	O	2943
generation	NOUN	O	O	2943
OCs	NOUN	O	O	2943
as	ADP	O	O	2943
the	PRON	O	O	2943
reference	NOUN	O	O	2943
,	PUNCT	O	O	2943
the	PRON	O	O	2943
odds	NOUN	O	O	2943
ratios	VERB	O	O	2943
for	ADP	O	O	2943
VTE	PROPN	O	Disease	2943
were	AUX	O	O	2943
3.49	NUM	O	O	2943
(	PUNCT	O	O	2943
1.21	NUM	O	O	2943
-	PUNCT	O	O	2943
10.12	NUM	O	O	2943
)	PUNCT	O	O	2943
for	ADP	O	O	2943
desogestrel	VERB	O	O	2943
plus	CCONJ	O	O	2943
20	NUM	O	O	2943
g	X	O	O	2943
ethinyloestradiol	VERB	O	O	2943
and	CCONJ	O	O	2943
1.18	NUM	O	O	2943
(	PUNCT	O	O	2943
0.66	NUM	O	O	2943
-	PUNCT	O	O	2943
2.17	NUM	O	O	2943
)	PUNCT	O	O	2943
for	ADP	O	O	2943
the	PRON	O	O	2943
other	ADJ	O	O	2943
third	ADV	O	O	2943
-	PUNCT	O	O	2943
generation	NOUN	O	O	2943
progestagens	NOUN	O	O	2943
.	PUNCT	O	O	2943
The	PRON	O	O	2944
previously	ADV	O	O	2944
reported	VERB	O	O	2944
increase	VERB	O	O	2944
in	ADP	O	O	2944
odds	NOUN	O	O	2944
ratio	NOUN	O	O	2944
associated	VERB	O	O	2944
with	ADP	O	O	2944
third	ADV	O	O	2944
-	PUNCT	O	O	2944
generation	NOUN	O	O	2944
OCs	NOUN	O	O	2944
when	SCONJ	O	O	2944
compared	VERB	O	O	2944
with	ADP	O	O	2944
second	ADV	O	O	2944
-	PUNCT	O	O	2944
generation	NOUN	O	O	2944
products	NOUN	O	O	2944
is	AUX	O	O	2944
likely	ADV	O	O	2944
to	PART	O	O	2944
have	VERB	O	O	2944
been	AUX	O	O	2944
the	PRON	O	O	2944
result	VERB	O	O	2944
of	ADP	O	O	2944
residual	ADJ	O	O	2944
confounding	VERB	O	O	2944
by	ADP	O	O	2944
age	NOUN	O	O	2944
.	PUNCT	O	O	2944
The	PRON	O	O	2945
increased	VERB	O	O	2945
odds	NOUN	O	O	2945
ratio	NOUN	O	O	2945
associated	VERB	O	O	2945
with	ADP	O	O	2945
products	NOUN	O	O	2945
containing	VERB	O	O	2945
20	NUM	O	O	2945
micrograms	NOUN	O	O	2945
ethinyloestradiol	VERB	O	O	2945
and	CCONJ	O	O	2945
desogestrel	VERB	O	O	2945
compared	VERB	O	O	2945
with	ADP	O	O	2945
the	PRON	O	O	2945
30	NUM	O	O	2945
micrograms	NOUN	O	O	2945
product	NOUN	O	O	2945
is	AUX	O	O	2945
biologically	ADV	O	O	2945
implausible	ADJ	O	O	2945
,	PUNCT	O	O	2945
and	CCONJ	O	O	2945
is	AUX	O	O	2945
likely	ADV	O	O	2945
to	PART	O	O	2945
be	AUX	O	O	2945
the	PRON	O	O	2945
result	VERB	O	O	2945
of	ADP	O	O	2945
preferential	ADJ	O	O	2945
prescribing	VERB	O	O	2945
and	CCONJ	O	O	2945
,	PUNCT	O	O	2945
thus	ADV	O	O	2945
,	PUNCT	O	O	2945
confounding	VERB	O	O	2945
.	PUNCT	O	O	2945
MK-801	PROPN	O	Chemical	2948
augments	VERB	O	O	2948
pilocarpine	NOUN	O	Chemical	2948
-	PUNCT	O	O	2948
induced	VERB	O	O	2948
electrographic	PROPN	O	O	2948
seizure	NOUN	O	Disease	2948
but	CCONJ	O	O	2948
protects	VERB	O	O	2948
against	ADP	O	O	2948
brain damage	NOUN	O	Disease	2948
in	ADP	O	O	2948
rats	NOUN	O	O	2948
The	PRON	O	O	2949
authors	NOUN	O	O	2949
examined	VERB	O	O	2949
the	PRON	O	O	2949
anticonvulsant	ADJ	O	O	2949
effects	NOUN	O	O	2949
of	ADP	O	O	2949
MK-801	PROPN	O	Chemical	2949
on	ADP	O	O	2949
the	PRON	O	O	2949
pilocarpine	NOUN	O	Chemical	2949
-	PUNCT	O	O	2949
induced	VERB	O	O	2949
seizure	NOUN	O	Disease	2949
model	NOUN	O	O	2949
.	PUNCT	O	O	2949
Intraperitoneal	NOUN	O	O	2950
injection	NOUN	O	O	2950
of	ADP	O	O	2950
pilocarpine	NOUN	O	Chemical	2950
(	PUNCT	O	O	2950
400	NUM	O	O	2950
mg	VERB	O	O	2950
/	PUNCT	O	O	2950
kg	VERB	O	O	2950
)	PUNCT	O	O	2950
induced	VERB	O	O	2950
tonic	PROPN	O	O	2950
and	CCONJ	O	O	2950
clonic	ADJ	O	O	2950
seizure	NOUN	O	Disease	2950
.	PUNCT	O	O	2950
Scopolamine	NOUN	O	Chemical	2951
(	PUNCT	O	O	2951
10	NUM	O	O	2951
mg	VERB	O	O	2951
/	PUNCT	O	O	2951
kg	VERB	O	O	2951
)	PUNCT	O	O	2951
and	CCONJ	O	O	2951
pentobarbital	NOUN	O	Chemical	2951
(	PUNCT	O	O	2951
5	NUM	O	O	2951
mg	VERB	O	O	2951
/	PUNCT	O	O	2951
kg	VERB	O	O	2951
)	PUNCT	O	O	2951
prevented	VERB	O	O	2951
development	NOUN	O	O	2951
of	ADP	O	O	2951
pilocarpine	NOUN	O	Chemical	2951
-	PUNCT	O	O	2951
induced	VERB	O	O	2951
behavioral	ADJ	O	O	2951
seizure	NOUN	O	Disease	2951
but	CCONJ	O	O	2951
MK-801	PROPN	O	Chemical	2951
(	PUNCT	O	O	2951
0.5	NUM	O	O	2951
mg	VERB	O	O	2951
/	PUNCT	O	O	2951
kg	VERB	O	O	2951
)	PUNCT	O	O	2951
did	VERB	O	O	2951
not	PART	O	O	2951
.	PUNCT	O	O	2951
An	PRON	O	O	2952
electrical	ADJ	O	O	2952
seizure	NOUN	O	Disease	2952
measured	VERB	O	O	2952
with	ADP	O	O	2952
hippocampal	NOUN	O	O	2952
EEG	NOUN	O	O	2952
appeared	VERB	O	O	2952
in	ADP	O	O	2952
the	PRON	O	O	2952
pilocarpine	NOUN	O	Chemical	2952
-	PUNCT	O	O	2952
treated	VERB	O	O	2952
group	NOUN	O	O	2952
.	PUNCT	O	O	2952
Scopolamine	NOUN	O	Chemical	2953
and	CCONJ	O	O	2953
pentobarbital	NOUN	O	Chemical	2953
blocked	VERB	O	O	2953
the	PRON	O	O	2953
pilocarpine	NOUN	O	Chemical	2953
-	PUNCT	O	O	2953
induced	VERB	O	O	2953
electrographic	PROPN	O	O	2953
seizure	NOUN	O	Disease	2953
,	PUNCT	O	O	2953
MK-801	PROPN	O	Chemical	2953
treatment	NOUN	O	O	2953
augmented	VERB	O	O	2953
the	PRON	O	O	2953
electrographic	PROPN	O	O	2953
seizure	NOUN	O	Disease	2953
induced	VERB	O	O	2953
by	ADP	O	O	2953
pilocarpine	NOUN	O	Chemical	2953
.	PUNCT	O	O	2953
Brain	NOUN	O	O	2954
damage	NOUN	O	O	2954
was	AUX	O	O	2954
assessed	VERB	O	O	2954
by	ADP	O	O	2954
examining	VERB	O	O	2954
the	PRON	O	O	2954
hippocampus	NOUN	O	O	2954
microscopically	ADV	O	O	2954
.	PUNCT	O	O	2954
Pilocarpine	NOUN	O	Chemical	2955
produced	VERB	O	O	2955
neuronal	ADJ	O	O	2955
death	NOUN	O	O	2955
in	ADP	O	O	2955
the	PRON	O	O	2955
hippocampus	NOUN	O	O	2955
,	PUNCT	O	O	2955
which	PRON	O	O	2955
showed	VERB	O	O	2955
pyknotic	ADJ	O	O	2955
changes	VERB	O	O	2955
.	PUNCT	O	O	2955
Pentobarbital	PROPN	O	O	2956
,	PUNCT	O	O	2956
scopolamine	NOUN	O	Chemical	2956
and	CCONJ	O	O	2956
MK-801	PROPN	O	Chemical	2956
protected	VERB	O	O	2956
the	PRON	O	O	2956
brain damage	NOUN	O	Disease	2956
by	ADP	O	O	2956
pilocarpine	NOUN	O	Chemical	2956
,	PUNCT	O	O	2956
though	SCONJ	O	O	2956
in	ADP	O	O	2956
the	PRON	O	O	2956
MK-801-treated	VERB	O	O	2956
group	NOUN	O	O	2956
,	PUNCT	O	O	2956
the	PRON	O	O	2956
pyramidal	ADJ	O	O	2956
cells	NOUN	O	O	2956
of	ADP	O	O	2956
hippocampus	NOUN	O	O	2956
appeared	VERB	O	O	2956
darker	ADJ	O	O	2956
than	ADP	O	O	2956
normal	ADJ	O	O	2956
.	PUNCT	O	O	2956
These	PRON	O	O	2957
results	VERB	O	O	2957
indicate	VERB	O	O	2957
that	SCONJ	O	O	2957
status epilepticus	VERB	O	Disease	2957
induced	VERB	O	O	2957
by	ADP	O	O	2957
pilocarpine	NOUN	O	Chemical	2957
is	AUX	O	O	2957
initiated	VERB	O	O	2957
by	ADP	O	O	2957
cholinergic	ADJ	O	O	2957
overstimulation	NOUN	O	O	2957
and	CCONJ	O	O	2957
propagated	VERB	O	O	2957
by	ADP	O	O	2957
glutamatergic	ADJ	O	O	2957
transmission	NOUN	O	O	2957
,	PUNCT	O	O	2957
the	PRON	O	O	2957
elevation	NOUN	O	O	2957
of	ADP	O	O	2957
which	PRON	O	O	2957
may	AUX	O	O	2957
cause	VERB	O	O	2957
brain damage	NOUN	O	Disease	2957
through	ADP	O	O	2957
an	PRON	O	O	2957
excitatory	ADJ	O	O	2957
NMDA	PROPN	O	Chemical	2957
receptor	NOUN	O	O	2957
-	PUNCT	O	O	2957
mediated	VERB	O	O	2957
mechanism	NOUN	O	O	2957
.	PUNCT	O	O	2957
Paclitaxel	PROPN	O	Chemical	2960
,	PUNCT	O	O	2960
5-fluorouracil	NOUN	O	Chemical	2960
,	PUNCT	O	O	2960
and	CCONJ	O	O	2960
folinic	PROPN	O	O	2960
acid	PROPN	O	O	2960
in	ADP	O	O	2960
metastatic	ADJ	O	O	2960
breast cancer	NOUN	O	Disease	2960
:	PUNCT	O	O	2960
5-Fluorouracil	NOUN	O	O	2961
plus	CCONJ	O	O	2961
folinic	PROPN	O	O	2961
acid	PROPN	O	O	2961
and	CCONJ	O	O	2961
paclitaxel	NOUN	O	Chemical	2961
(	PUNCT	O	O	2962
Taxol	PROPN	O	Chemical	2962
;	PUNCT	O	O	2962
Bristol	PROPN	O	O	2962
-	PUNCT	O	O	2962
Myers	PROPN	O	O	2962
Squibb	PROPN	O	O	2962
Company	NOUN	O	O	2962
,	PUNCT	O	O	2962
Princeton	PROPN	O	O	2962
,	PUNCT	O	O	2962
NJ	PROPN	O	O	2962
)	PUNCT	O	O	2962
are	AUX	O	O	2962
effective	ADJ	O	O	2962
salvage	NOUN	O	O	2962
therapies	NOUN	O	O	2962
for	ADP	O	O	2962
metastatic	ADJ	O	O	2962
breast cancer	NOUN	O	Disease	2962
patients	NOUN	O	O	2962
.	PUNCT	O	O	2962
Paclitaxel	PROPN	O	Chemical	2963
and	CCONJ	O	O	2963
5-fluorouracil	NOUN	O	Chemical	2963
have	VERB	O	O	2963
additive	NOUN	O	O	2963
cytotoxicity	NOUN	O	Disease	2963
in	ADP	O	O	2963
MCF-7	PROPN	O	O	2963
cell	NOUN	O	O	2963
lines	NOUN	O	O	2963
.	PUNCT	O	O	2963
We	PRON	O	O	2964
performed	VERB	O	O	2964
a	PRON	O	O	2964
phase	NOUN	O	O	2964
II	NUM	O	O	2964
trial	NOUN	O	O	2964
of	ADP	O	O	2964
paclitaxel	NOUN	O	Chemical	2964
175	NUM	O	O	2964
mg	VERB	O	O	2964
/	PUNCT	O	O	2964
m2	PROPN	O	O	2964
over	ADP	O	O	2964
3	X	O	O	2964
hours	NOUN	O	O	2964
on	ADP	O	O	2964
day	NOUN	O	O	2964
I	PRON	O	O	2964
followed	VERB	O	O	2964
by	ADP	O	O	2964
folinic	PROPN	O	O	2964
acid	PROPN	O	O	2964
300	NUM	O	O	2964
mg	VERB	O	O	2964
over	ADP	O	O	2964
1	X	O	O	2964
hour	NOUN	O	O	2964
before	ADP	O	O	2964
5-fluorouracil	NOUN	O	Chemical	2964
350	NUM	O	O	2964
mg	VERB	O	O	2964
/	PUNCT	O	O	2964
m2	PROPN	O	O	2964
on	ADP	O	O	2964
days	NOUN	O	O	2964
1	X	O	O	2964
to	PART	O	O	2964
3	X	O	O	2964
every	PRON	O	O	2964
28	NUM	O	O	2964
days	NOUN	O	O	2964
(	PUNCT	O	O	2964
TFL	PROPN	O	O	2964
)	PUNCT	O	O	2964
in	ADP	O	O	2964
women	NOUN	O	O	2964
with	ADP	O	O	2964
metastatic	ADJ	O	O	2964
breast cancer	NOUN	O	Disease	2964
.	PUNCT	O	O	2964
Analysis	NOUN	O	O	2965
is	AUX	O	O	2965
reported	VERB	O	O	2965
on	ADP	O	O	2965
37	NUM	O	O	2965
patients	NOUN	O	O	2965
with	ADP	O	O	2965
a	PRON	O	O	2965
minimum	ADJ	O	O	2965
of	ADP	O	O	2965
6	NUM	O	O	2965
months	NOUN	O	O	2965
follow	VERB	O	O	2965
-	PUNCT	O	O	2965
up	ADP	O	O	2965
who	PRON	O	O	2965
received	VERB	O	O	2965
a	PRON	O	O	2965
total	ADJ	O	O	2965
of	ADP	O	O	2965
192	NUM	O	O	2965
cycles	NOUN	O	O	2965
of	ADP	O	O	2965
TFL	PROPN	O	O	2965
:	PUNCT	O	O	2965
nine	NUM	O	O	2965
cycles	NOUN	O	O	2965
(	PUNCT	O	O	2965
5%	NOUN	O	O	2965
)	PUNCT	O	O	2965
were	AUX	O	O	2965
associated	VERB	O	O	2965
with	ADP	O	O	2965
grade	NOUN	O	O	2965
3/4	NUM	O	O	2965
neutropenia	ADJ	O	Disease	2965
requiring	VERB	O	O	2965
hospitalization	NOUN	O	O	2965
;	PUNCT	O	O	2965
seven	NUM	O	O	2965
(	PUNCT	O	O	2965
4%	NOUN	O	O	2965
)	PUNCT	O	O	2965
cycles	NOUN	O	O	2965
in	ADP	O	O	2965
two	NUM	O	O	2965
patients	NOUN	O	O	2965
required	VERB	O	O	2965
granulocyte	NOUN	O	O	2965
colony	NOUN	O	O	2965
-	PUNCT	O	O	2965
stimulating	VERB	O	O	2965
factor	NOUN	O	O	2965
due	ADJ	O	O	2965
to	PART	O	O	2965
neutropenia	ADJ	O	Disease	2965
;	PUNCT	O	O	2965
no	PRON	O	O	2965
patient	NOUN	O	O	2965
required	VERB	O	O	2965
platelet	NOUN	O	O	2965
transfusions	NOUN	O	O	2965
.	PUNCT	O	O	2965
Grade	NOUN	O	O	2966
3/4	NUM	O	O	2966
nonhematologic	ADJ	O	O	2966
toxicities	NOUN	O	Disease	2966
were	AUX	O	O	2966
uncommon	ADJ	O	O	2966
.	PUNCT	O	O	2966
Of	ADV	O	O	2967
the	PRON	O	O	2967
19	NUM	O	O	2967
evaluable	ADJ	O	O	2967
patients	NOUN	O	O	2967
with	ADP	O	O	2967
prior	ADV	O	O	2967
doxorubicin	VERB	O	Chemical	2967
exposure	NOUN	O	O	2967
,	PUNCT	O	O	2967
11	NUM	O	O	2967
(	PUNCT	O	O	2967
58%	NOUN	O	O	2967
)	PUNCT	O	O	2967
responded	VERB	O	O	2967
compared	VERB	O	O	2967
with	ADP	O	O	2967
nine	NUM	O	O	2967
of	ADP	O	O	2967
15	NUM	O	O	2967
(	PUNCT	O	O	2967
60%	NOUN	O	O	2967
)	PUNCT	O	O	2967
without	ADP	O	O	2967
prior	ADV	O	O	2967
doxorubicin	VERB	O	Chemical	2967
.	PUNCT	O	O	2967
Plasma	NOUN	O	O	2968
paclitaxel	NOUN	O	Chemical	2968
concentrations	NOUN	O	O	2968
were	AUX	O	O	2968
measured	VERB	O	O	2968
at	ADP	O	O	2968
the	PRON	O	O	2968
completion	NOUN	O	O	2968
of	ADP	O	O	2968
paclitaxel	NOUN	O	Chemical	2968
infusion	NOUN	O	O	2968
and	CCONJ	O	O	2968
at	ADP	O	O	2968
24	NUM	O	O	2968
hours	NOUN	O	O	2968
in	ADP	O	O	2968
19	NUM	O	O	2968
patients	NOUN	O	O	2968
.	PUNCT	O	O	2968
TFL	PROPN	O	O	2969
is	AUX	O	O	2969
an	PRON	O	O	2969
active	ADJ	O	O	2969
,	PUNCT	O	O	2969
well	ADV	O	O	2969
-	PUNCT	O	O	2969
tolerated	VERB	O	O	2969
regimen	NOUN	O	O	2969
in	ADP	O	O	2969
metastatic	ADJ	O	O	2969
breast cancer	NOUN	O	Disease	2969
.	PUNCT	O	O	2969
Efficacy	NOUN	O	O	2972
and	CCONJ	O	O	2972
proarrhythmia	NOUN	O	O	2972
with	ADP	O	O	2972
the	PRON	O	O	2972
use	VERB	O	O	2972
of	ADP	O	O	2972
d	X	O	O	2972
,	PUNCT	O	O	2972
l	X	O	O	2972
-	PUNCT	O	O	2972
sotalol	VERB	O	O	2972
for	ADP	O	O	2972
sustained	VERB	O	O	2972
ventricular tachyarrhythmias	NOUN	O	Disease	2972
.	PUNCT	O	O	2972
This	PRON	O	O	2973
study	VERB	O	O	2973
prospectively	ADV	O	O	2973
evaluated	VERB	O	O	2973
the	PRON	O	O	2973
clinical	ADJ	O	O	2973
efficacy	NOUN	O	O	2973
,	PUNCT	O	O	2973
the	PRON	O	O	2973
incidence	NOUN	O	O	2973
of	ADP	O	O	2973
torsades de pointes	NOUN	O	Disease	2973
,	PUNCT	O	O	2973
and	CCONJ	O	O	2973
the	PRON	O	O	2973
presumable	ADJ	O	O	2973
risk	NOUN	O	O	2973
factors	NOUN	O	O	2973
for	ADP	O	O	2973
torsades de pointes	NOUN	O	Disease	2973
in	ADP	O	O	2973
patients	NOUN	O	O	2973
treated	VERB	O	O	2973
with	ADP	O	O	2973
d	X	O	O	2973
,	PUNCT	O	O	2973
l	X	O	O	2973
-	PUNCT	O	O	2973
sotalol	VERB	O	O	2973
for	ADP	O	O	2973
sustained	VERB	O	O	2973
ventricular tachyarrhythmias	NOUN	O	Disease	2973
.	PUNCT	O	O	2973
Eighty	NUM	O	O	2974
-	PUNCT	O	O	2974
one	NUM	O	O	2974
consecutive	ADJ	O	O	2974
patients	NOUN	O	O	2974
(	PUNCT	O	O	2974
54	NUM	O	O	2974
with	ADP	O	O	2974
coronary artery disease	NOUN	O	Disease	2974
,	PUNCT	O	O	2974
and	CCONJ	O	O	2974
20	NUM	O	O	2974
with	ADP	O	O	2974
dilated	ADJ	O	O	2974
cardiomyopathy	ADJ	O	Disease	2974
)	PUNCT	O	O	2974
with	ADP	O	O	2974
inducible	VERB	O	O	2974
sustained	VERB	O	O	2974
ventricular tachycardia	NOUN	O	Disease	2974
or	CCONJ	O	O	2974
ventricular fibrillation	NOUN	O	Disease	2974
received	VERB	O	O	2974
oral	ADJ	O	O	2974
d	X	O	O	2974
,	PUNCT	O	O	2974
l	X	O	O	2974
-	PUNCT	O	O	2974
sotalol	VERB	O	O	2974
to	PART	O	O	2974
prevent	VERB	O	O	2974
induction	NOUN	O	O	2974
of	ADP	O	O	2974
the	PRON	O	O	2974
ventricular	ADJ	O	O	2974
tachyarrhythmia	ADV	O	O	2974
.	PUNCT	O	O	2974
During	ADP	O	O	2975
oral	ADJ	O	O	2975
loading	NOUN	O	O	2975
with	ADP	O	O	2975
d	X	O	O	2975
,	PUNCT	O	O	2975
l	X	O	O	2975
-	PUNCT	O	O	2975
sotalol	VERB	O	O	2975
,	PUNCT	O	O	2975
continuous	ADJ	O	O	2975
electrocardiographic	NOUN	O	O	2975
(	PUNCT	O	O	2975
ECG	PROPN	O	O	2975
)	PUNCT	O	O	2975
monitoring	NOUN	O	O	2975
was	AUX	O	O	2975
performed	VERB	O	O	2975
.	PUNCT	O	O	2975
Those	PRON	O	O	2976
patients	NOUN	O	O	2976
in	ADP	O	O	2976
whom	PRON	O	O	2976
d	X	O	O	2976
,	PUNCT	O	O	2976
l	X	O	O	2976
-	PUNCT	O	O	2976
sotalol	VERB	O	O	2976
prevented	VERB	O	O	2976
induction	NOUN	O	O	2976
of	ADP	O	O	2976
ventricular tachycardia	NOUN	O	Disease	2976
or	CCONJ	O	O	2976
ventricular fibrillation	NOUN	O	Disease	2976
were	AUX	O	O	2976
discharged	VERB	O	O	2976
with	ADP	O	O	2976
the	PRON	O	O	2976
drug	NOUN	O	O	2976
and	CCONJ	O	O	2976
followed	VERB	O	O	2976
up	ADP	O	O	2976
on	ADP	O	O	2976
an	PRON	O	O	2976
outpatient	NOUN	O	O	2976
basis	NOUN	O	O	2976
for	ADP	O	O	2976
21	NUM	O	O	2976
+	ADP	O	O	2976
/-	PUNCT	O	O	2976
Induction	NOUN	O	O	2977
of	ADP	O	O	2977
the	PRON	O	O	2977
ventricular	ADJ	O	O	2977
tachyarrhythmia	ADV	O	O	2977
was	AUX	O	O	2977
prevented	VERB	O	O	2977
by	ADP	O	O	2977
oral	ADJ	O	O	2977
d	X	O	O	2977
,	PUNCT	O	O	2977
l	X	O	O	2977
-	PUNCT	O	O	2977
sotalol	VERB	O	O	2977
in	ADP	O	O	2977
35	NUM	O	O	2977
(	PUNCT	O	O	2977
43%	NOUN	O	O	2977
)	PUNCT	O	O	2977
patients	NOUN	O	O	2977
;	PUNCT	O	O	2977
the	PRON	O	O	2977
ventricular	ADJ	O	O	2977
tachyarrhythmia	ADV	O	O	2977
remained	VERB	O	O	2977
inducible	VERB	O	O	2977
in	ADP	O	O	2977
40	NUM	O	O	2977
(	PUNCT	O	O	2977
49%	NOUN	O	O	2977
)	PUNCT	O	O	2977
patients	NOUN	O	O	2977
;	PUNCT	O	O	2977
and	CCONJ	O	O	2977
two	NUM	O	O	2977
(	PUNCT	O	O	2977
2.5%	NOUN	O	O	2977
)	PUNCT	O	O	2977
patients	NOUN	O	O	2978
did	VERB	O	O	2978
not	PART	O	O	2978
tolerate	VERB	O	O	2978
even	ADV	O	O	2978
40	NUM	O	O	2978
mg	VERB	O	O	2978
of	ADP	O	O	2978
d	X	O	O	2978
,	PUNCT	O	O	2978
l	X	O	O	2978
-	PUNCT	O	O	2978
sotalol	VERB	O	O	2978
once	ADV	O	O	2978
daily	ADV	O	O	2978
.	PUNCT	O	O	2978
Four	NUM	O	O	2979
(	PUNCT	O	O	2979
5%	NOUN	O	O	2979
)	PUNCT	O	O	2979
patients	NOUN	O	O	2979
had	VERB	O	O	2979
from	ADP	O	O	2979
torsades de pointes	NOUN	O	Disease	2979
during	ADP	O	O	2979
the	PRON	O	O	2979
initial	ADJ	O	O	2979
oral	ADJ	O	O	2979
treatment	NOUN	O	O	2979
with	ADP	O	O	2979
d	X	O	O	2979
,	PUNCT	O	O	2979
l	X	O	O	2979
-	PUNCT	O	O	2979
sotalol	VERB	O	O	2979
.	PUNCT	O	O	2979
Neither	PRON	O	O	2980
ECG	PROPN	O	O	2980
[	X	O	O	2980
sinus	NOUN	O	O	2980
-	PUNCT	O	O	2980
cycle	PROPN	O	O	2980
length	NOUN	O	O	2980
(	PUNCT	O	O	2980
SCL	PROPN	O	O	2980
)	PUNCT	O	O	2980
,	PUNCT	O	O	2980
QT	NOUN	O	O	2980
or	CCONJ	O	O	2980
QTc	VERB	O	O	2980
interval	NOUN	O	O	2980
,	PUNCT	O	O	2980
or	CCONJ	O	O	2980
U	NOUN	O	O	2980
wave	NOUN	O	O	2980
]	PUNCT	O	O	2980
nor	CCONJ	O	O	2980
clinical	ADJ	O	O	2980
parameters	NOUN	O	O	2980
identified	VERB	O	O	2980
patients	NOUN	O	O	2980
at	ADP	O	O	2980
risk	NOUN	O	O	2980
for	ADP	O	O	2980
torsades de pointes	NOUN	O	Disease	2980
.	PUNCT	O	O	2980
However	ADV	O	O	2981
,	PUNCT	O	O	2981
the	PRON	O	O	2981
oral	ADJ	O	O	2981
dose	NOUN	O	O	2981
of	ADP	O	O	2981
d	X	O	O	2981
,	PUNCT	O	O	2981
l	X	O	O	2981
-	PUNCT	O	O	2981
sotalol	VERB	O	O	2981
was	AUX	O	O	2981
significantly	ADV	O	O	2981
lower	ADJ	O	O	2981
in	ADP	O	O	2981
patients	NOUN	O	O	2981
with	ADP	O	O	2981
torsades de pointes	NOUN	O	Disease	2981
(	PUNCT	O	O	2981
200	NUM	O	O	2981
+	ADP	O	O	2981
/-	PUNCT	O	O	2981
Risk	NOUN	O	O	2982
factors	NOUN	O	O	2982
associated	VERB	O	O	2982
with	ADP	O	O	2982
the	PRON	O	O	2982
development	NOUN	O	O	2982
of	ADP	O	O	2982
torsades de pointes	NOUN	O	Disease	2982
were	AUX	O	O	2982
the	PRON	O	O	2982
appearance	NOUN	O	O	2982
of	ADP	O	O	2982
an	PRON	O	O	2982
U	NOUN	O	O	2982
wave	NOUN	O	O	2982
(	PUNCT	O	O	2982
p	NOUN	O	O	2982
=	PUNCT	O	O	2982
0.049	NUM	O	O	2982
)	PUNCT	O	O	2982
,	PUNCT	O	O	2982
female	ADJ	O	O	2982
gender	NOUN	O	O	2982
(	PUNCT	O	O	2982
p	NOUN	O	O	2982
=	PUNCT	O	O	2982
0.015	NUM	O	O	2982
)	PUNCT	O	O	2982
,	PUNCT	O	O	2982
and	CCONJ	O	O	2982
significant	ADJ	O	O	2982
dose	NOUN	O	O	2982
-	PUNCT	O	O	2982
corrected	VERB	O	O	2982
changes	VERB	O	O	2982
of	ADP	O	O	2982
SCL	PROPN	O	O	2982
,	PUNCT	O	O	2982
QT	NOUN	O	O	2982
interval	NOUN	O	O	2982
,	PUNCT	O	O	2982
and	CCONJ	O	O	2982
QTc	VERB	O	O	2982
interval	NOUN	O	O	2982
(	PUNCT	O	O	2982
During	ADP	O	O	2983
follow	VERB	O	O	2983
-	PUNCT	O	O	2983
up	ADP	O	O	2983
,	PUNCT	O	O	2983
seven	NUM	O	O	2983
(	PUNCT	O	O	2983
20%	NOUN	O	O	2983
)	PUNCT	O	O	2983
patients	NOUN	O	O	2983
had	VERB	O	O	2983
a	PRON	O	O	2983
nonfatal	ADJ	O	O	2983
ventricular tachycardia	NOUN	O	Disease	2983
recurrence	NOUN	O	O	2983
,	PUNCT	O	O	2983
and	CCONJ	O	O	2983
two	NUM	O	O	2983
(	PUNCT	O	O	2983
6%	NOUN	O	O	2983
)	PUNCT	O	O	2983
One	NUM	O	O	2984
female	ADJ	O	O	2984
patient	NOUN	O	O	2984
with	ADP	O	O	2984
stable	ADJ	O	O	2984
cardiac disease	NOUN	O	Disease	2984
had	VERB	O	O	2984
recurrent	ADJ	O	O	2984
torsades de pointes	NOUN	O	Disease	2984
after	ADP	O	O	2984
2	X	O	O	2984
years	NOUN	O	O	2984
of	ADP	O	O	2984
successful	ADJ	O	O	2984
treatment	NOUN	O	O	2984
with	ADP	O	O	2984
d	X	O	O	2984
,	PUNCT	O	O	2984
l	X	O	O	2984
-	PUNCT	O	O	2984
sotalol	VERB	O	O	2984
.	PUNCT	O	O	2984
Torsades	NOUN	O	O	2985
de	VERB	O	O	2985
pointes	VERB	O	O	2985
occurred	VERB	O	O	2985
early	ADV	O	O	2985
during	ADP	O	O	2985
treatment	NOUN	O	O	2985
even	ADV	O	O	2985
with	ADP	O	O	2985
low	ADJ	O	O	2985
doses	NOUN	O	O	2985
of	ADP	O	O	2985
oral	ADJ	O	O	2985
d	X	O	O	2985
,	PUNCT	O	O	2985
l	X	O	O	2985
-	PUNCT	O	O	2985
sotalol	VERB	O	O	2985
.	PUNCT	O	O	2985
Pronounced	VERB	O	O	2986
changes	VERB	O	O	2986
in	ADP	O	O	2986
the	PRON	O	O	2986
surface	NOUN	O	O	2986
ECG	PROPN	O	O	2986
(	PUNCT	O	O	2986
cycle	PROPN	O	O	2986
length	NOUN	O	O	2986
,	PUNCT	O	O	2986
QT	NOUN	O	O	2986
,	PUNCT	O	O	2986
and	CCONJ	O	O	2986
QTc	VERB	O	O	2986
)	PUNCT	O	O	2986
in	ADP	O	O	2986
relation	NOUN	O	O	2986
to	PART	O	O	2986
the	PRON	O	O	2986
dose	NOUN	O	O	2986
of	ADP	O	O	2986
oral	ADJ	O	O	2986
d	X	O	O	2986
,	PUNCT	O	O	2986
l	X	O	O	2986
-	PUNCT	O	O	2986
sotalol	VERB	O	O	2986
might	AUX	O	O	2986
identify	VERB	O	O	2986
a	PRON	O	O	2986
subgroup	PROPN	O	O	2986
of	ADP	O	O	2986
patients	NOUN	O	O	2986
with	ADP	O	O	2986
an	PRON	O	O	2986
increased	VERB	O	O	2986
risk	NOUN	O	O	2986
for	ADP	O	O	2986
torsades de pointes	NOUN	O	Disease	2986
.	PUNCT	O	O	2986
Other	ADJ	O	O	2987
ECG	PROPN	O	O	2987
parameters	NOUN	O	O	2987
before	ADP	O	O	2987
the	PRON	O	O	2987
application	NOUN	O	O	2987
of	ADP	O	O	2987
d	X	O	O	2987
,	PUNCT	O	O	2987
l	X	O	O	2987
-	PUNCT	O	O	2987
sotalol	VERB	O	O	2987
did	VERB	O	O	2987
not	PART	O	O	2987
identify	VERB	O	O	2987
patients	NOUN	O	O	2987
at	ADP	O	O	2987
increased	VERB	O	O	2987
risk	NOUN	O	O	2987
for	ADP	O	O	2987
torsades de pointes	NOUN	O	Disease	2987
.	PUNCT	O	O	2987
Recurrence	NOUN	O	O	2988
rates	NOUN	O	O	2988
of	ADP	O	O	2988
ventricular tachyarrhythmias	NOUN	O	Disease	2988
are	AUX	O	O	2988
high	ADJ	O	O	2988
despite	SCONJ	O	O	2988
complete	VERB	O	O	2988
suppression	NOUN	O	O	2988
of	ADP	O	O	2988
the	PRON	O	O	2988
arrhythmia	NOUN	O	Disease	2988
during	ADP	O	O	2988
programmed	VERB	O	O	2988
stimulation	NOUN	O	O	2988
.	PUNCT	O	O	2988
Therefore	ADV	O	O	2989
programmed	VERB	O	O	2989
electrical	ADJ	O	O	2989
stimulation	NOUN	O	O	2989
in	ADP	O	O	2989
the	PRON	O	O	2989
case	NOUN	O	O	2989
of	ADP	O	O	2989
d	X	O	O	2989
,	PUNCT	O	O	2989
l	X	O	O	2989
-	PUNCT	O	O	2989
sotalol	VERB	O	O	2989
seems	VERB	O	O	2989
to	PART	O	O	2989
be	AUX	O	O	2989
of	ADP	O	O	2989
limited	VERB	O	O	2989
prognostic	ADJ	O	O	2989
value	NOUN	O	O	2989
.	PUNCT	O	O	2989
Chronic	NOUN	O	O	2992
hyperprolactinemia	NOUN	O	Disease	2992
and	CCONJ	O	O	2992
changes	VERB	O	O	2992
in	ADP	O	O	2992
dopamine	NOUN	O	Chemical	2992
neurons	NOUN	O	O	2992
.	PUNCT	O	O	2992
The	PRON	O	O	2993
purpose	NOUN	O	O	2993
of	ADP	O	O	2993
this	PRON	O	O	2993
study	VERB	O	O	2993
was	AUX	O	O	2993
to	PART	O	O	2993
induce	VERB	O	O	2993
hyperprolactinemia	NOUN	O	Disease	2993
in	ADP	O	O	2993
rats	NOUN	O	O	2993
for	ADP	O	O	2993
extended	VERB	O	O	2993
periods	NOUN	O	O	2993
of	ADP	O	O	2993
time	NOUN	O	O	2993
and	CCONJ	O	O	2993
examine	VERB	O	O	2993
its	PRON	O	O	2993
effects	NOUN	O	O	2993
on	ADP	O	O	2993
dopaminergic	ADJ	O	O	2993
systems	NOUN	O	O	2993
in	ADP	O	O	2993
the	PRON	O	O	2993
brain	NOUN	O	O	2993
.	PUNCT	O	O	2993
Hyperprolactinemia	PROPN	O	Disease	2994
was	AUX	O	O	2994
induced	VERB	O	O	2994
by	ADP	O	O	2994
treatment	NOUN	O	O	2994
with	ADP	O	O	2994
haloperidol	NOUN	O	Chemical	2994
,	PUNCT	O	O	2994
a	PRON	O	O	2994
dopamine	NOUN	O	Chemical	2994
receptor	NOUN	O	O	2994
antagonist	NOUN	O	O	2994
,	PUNCT	O	O	2994
and	CCONJ	O	O	2994
Palkovits	PROPN	O	O	2994
'	PUNCT	O	O	2994
microdissection	NOUN	O	O	2994
technique	NOUN	O	O	2994
in	ADP	O	O	2994
combination	NOUN	O	O	2994
with	ADP	O	O	2994
high	ADJ	O	O	2994
-	PUNCT	O	O	2994
performance	NOUN	O	O	2994
liquid	ADJ	O	O	2994
chromatography	NOUN	O	O	2994
was	AUX	O	O	2994
used	VERB	O	O	2994
to	PART	O	O	2994
measure	VERB	O	O	2994
neurotransmitter	NOUN	O	O	2994
concentrations	NOUN	O	O	2994
in	ADP	O	O	2994
several	ADJ	O	O	2994
areas	NOUN	O	O	2994
of	ADP	O	O	2994
the	PRON	O	O	2994
brain	NOUN	O	O	2994
.	PUNCT	O	O	2994
After	ADP	O	O	2995
6	NUM	O	O	2995
months	NOUN	O	O	2995
of	ADP	O	O	2995
hyperprolactinemia	NOUN	O	Disease	2995
,	PUNCT	O	O	2995
dopamine	NOUN	O	Chemical	2995
(	PUNCT	O	O	2995
DA	NOUN	O	Chemical	2995
)	PUNCT	O	O	2995
concentrations	NOUN	O	O	2995
in	ADP	O	O	2995
the	PRON	O	O	2995
median	ADJ	O	O	2995
eminence	NOUN	O	O	2995
(	PUNCT	O	O	2995
ME	PRON	O	O	2995
)	PUNCT	O	O	2995
increased	VERB	O	O	2995
by	ADP	O	O	2995
84%	NOUN	O	O	2995
over	ADP	O	O	2995
the	PRON	O	O	2995
control	VERB	O	O	2995
group	NOUN	O	O	2995
.	PUNCT	O	O	2995
Nine	NUM	O	O	2996
months	NOUN	O	O	2996
of	ADP	O	O	2996
hyperprolactinemia	NOUN	O	Disease	2996
produced	VERB	O	O	2996
a	PRON	O	O	2996
50%	NOUN	O	O	2996
increase	VERB	O	O	2996
in	ADP	O	O	2996
DA	NOUN	O	Chemical	2996
concentrations	NOUN	O	O	2996
in	ADP	O	O	2996
the	PRON	O	O	2996
ME	PRON	O	O	2996
over	ADP	O	O	2996
the	PRON	O	O	2996
control	VERB	O	O	2996
group	NOUN	O	O	2996
.	PUNCT	O	O	2996
However	ADV	O	O	2997
,	PUNCT	O	O	2997
DA	NOUN	O	Chemical	2997
response	NOUN	O	O	2997
was	AUX	O	O	2997
lost	VERB	O	O	2997
if	SCONJ	O	O	2997
a	PRON	O	O	2997
9-month	NOUN	O	O	2997
long	ADV	O	O	2997
haloperidol	NOUN	O	Chemical	2997
-	PUNCT	O	O	2997
induced	VERB	O	O	2997
hyperprolactinemia	NOUN	O	Disease	2997
was	AUX	O	O	2997
followed	VERB	O	O	2997
by	ADP	O	O	2997
a	PRON	O	O	2997
1	X	O	O	2997
1/2	NUM	O	O	2997
month	NOUN	O	O	2997
-	PUNCT	O	O	2997
long	ADV	O	O	2997
extremely	ADV	O	O	2997
high	ADJ	O	O	2997
increase	VERB	O	O	2997
in	ADP	O	O	2997
serum	NOUN	O	O	2997
PRL	NOUN	O	Chemical	2997
levels	NOUN	O	O	2997
produced	VERB	O	O	2997
by	ADP	O	O	2997
implantation	NOUN	O	O	2997
of	ADP	O	O	2997
MMQ	NOUN	O	O	2997
cells	NOUN	O	O	2997
under	ADP	O	O	2997
the	PRON	O	O	2997
kidney	NOUN	O	O	2997
capsule	NOUN	O	O	2997
.	PUNCT	O	O	2997
There	ADV	O	O	2998
was	AUX	O	O	2998
no	PRON	O	O	2998
change	VERB	O	O	2998
in	ADP	O	O	2998
the	PRON	O	O	2998
levels	NOUN	O	O	2998
of	ADP	O	O	2998
DA	NOUN	O	Chemical	2998
,	PUNCT	O	O	2998
norepinephrine	NOUN	O	Chemical	2998
(	PUNCT	O	O	2998
NE	PROPN	O	Chemical	2998
)	PUNCT	O	O	2998
,	PUNCT	O	O	2998
serotonin	PROPN	O	Chemical	2998
(	PUNCT	O	O	2998
5-HT	NOUN	O	Chemical	2998
)	PUNCT	O	O	2998
,	PUNCT	O	O	2998
or	CCONJ	O	O	2998
their	PRON	O	O	2998
metabolites	VERB	O	O	2998
in	ADP	O	O	2998
the	PRON	O	O	2998
arcuate	ADJ	O	O	2998
nucleus	PROPN	O	O	2998
(	PUNCT	O	O	2998
AN	PRON	O	O	2998
)	PUNCT	O	O	2998
,	PUNCT	O	O	2998
medial	ADJ	O	O	2998
preoptic	ADJ	O	O	2998
area	NOUN	O	O	2998
(	PUNCT	O	O	2998
MPA	PROPN	O	O	2998
)	PUNCT	O	O	2998
,	PUNCT	O	O	2998
caudate	ADJ	O	O	2998
putamen	NOUN	O	O	2998
(	PUNCT	O	O	2998
CP	PROPN	O	Chemical	2998
)	PUNCT	O	O	2998
,	PUNCT	O	O	2998
substantia	X	O	O	2998
nigra	NOUN	O	O	2998
(	PUNCT	O	O	2998
SN	NOUN	O	O	2998
)	PUNCT	O	O	2998
,	PUNCT	O	O	2998
and	CCONJ	O	O	2998
zona	PROPN	O	O	2998
incerta	X	O	O	2998
(	PUNCT	O	O	2998
ZI	NOUN	O	O	2998
)	PUNCT	O	O	2998
,	PUNCT	O	O	2998
except	SCONJ	O	O	2998
for	ADP	O	O	2998
a	PRON	O	O	2998
decrease	VERB	O	O	2998
in	ADP	O	O	2998
5-hydroxyindoleacetic acid	NOUN	O	Chemical	2998
(	PUNCT	O	O	2998
5-HIAA	PROPN	O	Chemical	2998
)	PUNCT	O	O	2998
in	ADP	O	O	2998
the	PRON	O	O	2998
AN	PRON	O	O	2998
after	ADP	O	O	2998
6-months	NOUN	O	O	2998
of	ADP	O	O	2998
hyperprolactinemia	NOUN	O	Disease	2998
and	CCONJ	O	O	2998
an	PRON	O	O	2998
increase	VERB	O	O	2998
in	ADP	O	O	2998
DA	NOUN	O	Chemical	2998
concentrations	NOUN	O	O	2998
in	ADP	O	O	2998
the	PRON	O	O	2998
AN	PRON	O	O	2998
after	ADP	O	O	2998
9-months	NOUN	O	O	2998
of	ADP	O	O	2998
hyperprolactinemia	NOUN	O	Disease	2998
.	PUNCT	O	O	2998
These	PRON	O	O	2999
results	VERB	O	O	2999
demonstrate	VERB	O	O	2999
that	SCONJ	O	O	2999
hyperprolactinemia	NOUN	O	Disease	2999
specifically	ADV	O	O	2999
affects	VERB	O	O	2999
TIDA	ADJ	O	O	2999
neurons	NOUN	O	O	2999
and	CCONJ	O	O	2999
these	PRON	O	O	2999
effects	NOUN	O	O	2999
vary	VERB	O	O	2999
,	PUNCT	O	O	2999
depending	VERB	O	O	2999
on	ADP	O	O	2999
the	PRON	O	O	2999
duration	NOUN	O	O	2999
and	CCONJ	O	O	2999
intensity	NOUN	O	O	2999
of	ADP	O	O	2999
hyperprolactinemia	NOUN	O	Disease	2999
.	PUNCT	O	O	2999
The	PRON	O	O	3000
age	NOUN	O	O	3000
-	PUNCT	O	O	3000
related	ADJ	O	O	3000
decrease	VERB	O	O	3000
in	ADP	O	O	3000
hypothalamic	ADJ	O	O	3000
dopamine	NOUN	O	Chemical	3000
function	NOUN	O	O	3000
may	AUX	O	O	3000
be	AUX	O	O	3000
associated	VERB	O	O	3000
with	ADP	O	O	3000
increases	VERB	O	O	3000
in	ADP	O	O	3000
PRL	NOUN	O	Chemical	3000
secretion	NOUN	O	O	3000
.	PUNCT	O	O	3000
Treatment	NOUN	O	O	3003
-	PUNCT	O	O	3003
related	ADJ	O	O	3003
disseminated	VERB	O	O	3003
necrotizing	VERB	O	Disease	3003
leukoencephalopathy	ADJ	O	Disease	3003
with	ADP	O	O	3003
characteristic	ADJ	O	O	3003
contrast	NOUN	O	O	3003
enhancement	NOUN	O	O	3003
of	ADP	O	O	3003
the	PRON	O	O	3003
white	ADJ	O	O	3003
matter	VERB	O	O	3003
.	PUNCT	O	O	3003
This	PRON	O	O	3004
report	VERB	O	O	3004
describes	VERB	O	O	3004
unique	ADJ	O	O	3004
contrast	NOUN	O	O	3004
enhancement	NOUN	O	O	3004
of	ADP	O	O	3004
the	PRON	O	O	3004
white	ADJ	O	O	3004
matter	VERB	O	O	3004
on	ADP	O	O	3004
T1-weighted	VERB	O	O	3004
magnetic	ADJ	O	O	3004
resonance	NOUN	O	O	3004
images	NOUN	O	O	3004
of	ADP	O	O	3004
two	NUM	O	O	3004
patients	NOUN	O	O	3004
with	ADP	O	O	3004
disseminated	VERB	O	O	3004
necrotizing	VERB	O	Disease	3004
leukoencephalopathy	ADJ	O	Disease	3004
,	PUNCT	O	O	3004
which	PRON	O	O	3004
developed	VERB	O	O	3004
from	ADP	O	O	3004
acute	ADJ	O	O	3004
lymphoblastic	NOUN	O	O	3004
leukemia	NOUN	O	Disease	3004
treated	VERB	O	O	3004
with	ADP	O	O	3004
high	ADJ	O	O	3004
-	PUNCT	O	O	3004
dose	NOUN	O	O	3004
methotrexate	CCONJ	O	Chemical	3004
.	PUNCT	O	O	3004
Necropsy	PROPN	O	O	3005
of	ADP	O	O	3005
the	PRON	O	O	3005
first	ADV	O	O	3005
case	NOUN	O	O	3005
revealed	VERB	O	O	3005
loss	NOUN	O	O	3005
of	ADP	O	O	3005
myelination	NOUN	O	O	3005
and	CCONJ	O	O	3005
necrosis	NOUN	O	Disease	3005
of	ADP	O	O	3005
the	PRON	O	O	3005
white	ADJ	O	O	3005
matter	VERB	O	O	3005
.	PUNCT	O	O	3005
Possible	ADJ	O	O	3006
mechanisms	NOUN	O	O	3006
causing	VERB	O	O	3006
such	ADJ	O	O	3006
a	PRON	O	O	3006
leukoencephalopathy	ADJ	O	Disease	3006
are	AUX	O	O	3006
discussed	VERB	O	O	3006
.	PUNCT	O	O	3006
Thrombotic	ADJ	O	Disease	3009
complications	NOUN	O	O	3009
in	ADP	O	O	3009
acute promyelocytic leukemia	NOUN	O	Disease	3009
during	ADP	O	O	3009
all	PRON	O	O	3009
-	PUNCT	O	O	3009
trans	PROPN	O	O	3009
-	PUNCT	O	O	3009
retinoic	NOUN	O	O	3009
acid	PROPN	O	O	3009
therapy	NOUN	O	O	3009
.	PUNCT	O	O	3009
A	PRON	O	O	3010
case	NOUN	O	O	3010
of	ADP	O	O	3010
acute	ADJ	O	O	3010
renal failure	NOUN	O	Disease	3010
,	PUNCT	O	O	3010
due	ADJ	O	O	3010
to	PART	O	O	3010
occlusion	NOUN	O	O	3010
of	ADP	O	O	3010
renal	ADJ	O	O	3010
vessels	NOUN	O	O	3010
in	ADP	O	O	3010
a	PRON	O	O	3010
patient	NOUN	O	O	3010
with	ADP	O	O	3010
acute promyelocytic leukemia	NOUN	O	Disease	3010
(	PUNCT	O	O	3010
APL	PROPN	O	Disease	3010
)	PUNCT	O	O	3010
treated	VERB	O	O	3010
with	ADP	O	O	3010
all	PRON	O	O	3010
-	PUNCT	O	O	3010
trans	PROPN	O	O	3010
-	PUNCT	O	O	3010
retinoic	NOUN	O	O	3010
acid	PROPN	O	O	3010
(	PUNCT	O	O	3010
ATRA	NOUN	O	Chemical	3010
)	PUNCT	O	O	3010
and	CCONJ	O	O	3010
tranexamic acid	PROPN	O	Chemical	3010
has	VERB	O	O	3010
been	AUX	O	O	3010
described	VERB	O	O	3010
recently	ADV	O	O	3010
.	PUNCT	O	O	3010
We	PRON	O	O	3011
report	VERB	O	O	3011
a	PRON	O	O	3011
case	NOUN	O	O	3011
of	ADP	O	O	3011
acute	ADJ	O	O	3011
renal failure	NOUN	O	Disease	3011
in	ADP	O	O	3011
an	PRON	O	O	3011
APL	PROPN	O	Disease	3011
patient	NOUN	O	O	3011
treated	VERB	O	O	3011
with	ADP	O	O	3011
ATRA	NOUN	O	Chemical	3011
alone	ADV	O	O	3011
.	PUNCT	O	O	3011
This	PRON	O	O	3012
case	NOUN	O	O	3012
further	ADV	O	O	3012
supports	VERB	O	O	3012
the	PRON	O	O	3012
concern	NOUN	O	O	3012
about	ADP	O	O	3012
thromboembolic complications	NOUN	O	Disease	3012
associated	VERB	O	O	3012
with	ADP	O	O	3012
ATRA	NOUN	O	Chemical	3012
therapy	NOUN	O	O	3012
in	ADP	O	O	3012
APL	PROPN	O	Disease	3012
patients	NOUN	O	O	3012
.	PUNCT	O	O	3012
The	PRON	O	O	3013
patients	NOUN	O	O	3013
,	PUNCT	O	O	3013
a	PRON	O	O	3013
43-year	NOUN	O	O	3013
-	PUNCT	O	O	3013
old	ADJ	O	O	3013
man	NOUN	O	O	3013
,	PUNCT	O	O	3013
presented	VERB	O	O	3013
all	PRON	O	O	3013
the	PRON	O	O	3013
signs	NOUN	O	O	3013
and	CCONJ	O	O	3013
symptoms	NOUN	O	O	3013
of	ADP	O	O	3013
APL	PROPN	O	Disease	3013
and	CCONJ	O	O	3013
was	AUX	O	O	3013
included	VERB	O	O	3013
in	ADP	O	O	3013
a	PRON	O	O	3013
treatment	NOUN	O	O	3013
protocol	PROPN	O	O	3013
with	ADP	O	O	3013
ATRA	NOUN	O	Chemical	3013
.	PUNCT	O	O	3013
After	ADP	O	O	3014
10	NUM	O	O	3014
days	NOUN	O	O	3014
of	ADP	O	O	3014
treatment	NOUN	O	O	3014
,	PUNCT	O	O	3014
he	PRON	O	O	3014
developed	VERB	O	O	3014
acute	ADJ	O	O	3014
renal failure	NOUN	O	Disease	3014
that	SCONJ	O	O	3014
was	AUX	O	O	3014
completely	ADV	O	O	3014
reversible	ADJ	O	O	3014
after	ADP	O	O	3014
complete	VERB	O	O	3014
remission	NOUN	O	O	3014
of	ADP	O	O	3014
APL	PROPN	O	Disease	3014
was	AUX	O	O	3014
achieved	VERB	O	O	3014
and	CCONJ	O	O	3014
therapy	NOUN	O	O	3014
discontinued	VERB	O	O	3014
.	PUNCT	O	O	3014
We	PRON	O	O	3015
conclude	VERB	O	O	3015
that	SCONJ	O	O	3015
ATRA	NOUN	O	Chemical	3015
is	AUX	O	O	3015
a	PRON	O	O	3015
valid	ADJ	O	O	3015
therapeutic	ADJ	O	O	3015
choice	NOUN	O	O	3015
for	ADP	O	O	3015
patients	NOUN	O	O	3015
with	ADP	O	O	3015
APL	PROPN	O	Disease	3015
,	PUNCT	O	O	3015
although	SCONJ	O	O	3015
the	PRON	O	O	3015
procoagulant	NOUN	O	O	3015
tendency	NOUN	O	O	3015
is	AUX	O	O	3015
not	PART	O	O	3015
completely	ADV	O	O	3015
corrected	VERB	O	O	3015
.	PUNCT	O	O	3015
Thrombotic	ADJ	O	Disease	3016
events	NOUN	O	O	3016
,	PUNCT	O	O	3016
however	ADV	O	O	3016
,	PUNCT	O	O	3016
could	AUX	O	O	3016
be	AUX	O	O	3016
avoided	VERB	O	O	3016
by	ADP	O	O	3016
using	VERB	O	O	3016
low	ADJ	O	O	3016
-	PUNCT	O	O	3016
dose	NOUN	O	O	3016
heparin	NOUN	O	Chemical	3016
.	PUNCT	O	O	3016
Pupillary	PROPN	O	O	3019
changes	VERB	O	O	3019
associated	VERB	O	O	3019
with	ADP	O	O	3019
the	PRON	O	O	3019
development	NOUN	O	O	3019
of	ADP	O	O	3019
stimulant	NOUN	O	O	3019
-	PUNCT	O	O	3019
induced	VERB	O	O	3019
mania	NOUN	O	O	3019
:	PUNCT	O	O	3019
a	PRON	O	O	3019
case	NOUN	O	O	3019
report	VERB	O	O	3019
.	PUNCT	O	O	3019
A	PRON	O	O	3020
30-year	NOUN	O	O	3020
-	PUNCT	O	O	3020
old	ADJ	O	O	3020
cocaine	NOUN	O	Chemical	3020
-	PUNCT	O	O	3020
dependent	ADJ	O	O	3020
man	NOUN	O	O	3020
who	PRON	O	O	3020
was	AUX	O	O	3020
a	PRON	O	O	3020
subject	ADJ	O	O	3020
in	ADP	O	O	3020
a	PRON	O	O	3020
study	VERB	O	O	3020
evaluating	VERB	O	O	3020
the	PRON	O	O	3020
anticraving	VERB	O	O	3020
efficacy	NOUN	O	O	3020
of	ADP	O	O	3020
the	PRON	O	O	3020
stimulant	NOUN	O	O	3020
medication	NOUN	O	O	3020
diethylpropion	NOUN	O	O	3020
(	PUNCT	O	O	3020
DEP	PROPN	O	O	3020
)	PUNCT	O	O	3020
became	VERB	O	O	3020
manic	ADJ	O	O	3020
during	ADP	O	O	3020
his	PRON	O	O	3020
second	ADV	O	O	3020
week	NOUN	O	O	3020
on	ADP	O	O	3020
the	PRON	O	O	3020
study	VERB	O	O	3020
drug	NOUN	O	O	3020
.	PUNCT	O	O	3020
Pupillometric	PROPN	O	O	3021
changes	VERB	O	O	3021
while	SCONJ	O	O	3021
on	ADP	O	O	3021
DEP	PROPN	O	O	3021
,	PUNCT	O	O	3021
especially	ADV	O	O	3021
changes	VERB	O	O	3021
in	ADP	O	O	3021
the	PRON	O	O	3021
total	ADJ	O	O	3021
power	NOUN	O	O	3021
of	ADP	O	O	3021
pupillary oscillation	NOUN	O	Disease	3021
,	PUNCT	O	O	3021
were	AUX	O	O	3021
dramatically	ADV	O	O	3021
different	ADJ	O	O	3021
than	ADP	O	O	3021
those	PRON	O	O	3021
observed	VERB	O	O	3021
in	ADP	O	O	3021
the	PRON	O	O	3021
eight	NUM	O	O	3021
other	ADJ	O	O	3021
study	VERB	O	O	3021
subjects	NOUN	O	O	3021
who	PRON	O	O	3021
did	VERB	O	O	3021
not	PART	O	O	3021
become	VERB	O	O	3021
manic	ADJ	O	O	3021
.	PUNCT	O	O	3021
The	PRON	O	O	3022
large	ADJ	O	O	3022
changes	VERB	O	O	3022
in	ADP	O	O	3022
total	ADJ	O	O	3022
power	NOUN	O	O	3022
of	ADP	O	O	3022
pupillary oscillation	NOUN	O	Disease	3022
occurred	VERB	O	O	3022
a	PRON	O	O	3022
few	ADJ	O	O	3022
days	NOUN	O	O	3022
before	ADP	O	O	3022
the	PRON	O	O	3022
patient	NOUN	O	O	3022
became	VERB	O	O	3022
fully	ADV	O	O	3022
manic	ADJ	O	O	3022
.	PUNCT	O	O	3022
Such	ADJ	O	O	3023
medication	NOUN	O	O	3023
-	PUNCT	O	O	3023
associated	VERB	O	O	3023
changes	VERB	O	O	3023
in	ADP	O	O	3023
the	PRON	O	O	3023
total	ADJ	O	O	3023
power	NOUN	O	O	3023
of	ADP	O	O	3023
pupillary oscillation	NOUN	O	Disease	3023
might	AUX	O	O	3023
be	AUX	O	O	3023
of	ADP	O	O	3023
utility	NOUN	O	O	3023
in	ADP	O	O	3023
identifying	VERB	O	O	3023
persons	NOUN	O	O	3023
at	ADP	O	O	3023
risk	NOUN	O	O	3023
for	ADP	O	O	3023
manic	ADJ	O	O	3023
-	PUNCT	O	O	3023
like	INTJ	O	O	3023
adverse	ADJ	O	O	3023
effects	NOUN	O	O	3023
during	ADP	O	O	3023
the	PRON	O	O	3023
medical	ADJ	O	O	3023
use	VERB	O	O	3023
of	ADP	O	O	3023
psychomotor	NOUN	O	O	3023
stimulants	NOUN	O	O	3023
or	CCONJ	O	O	3023
sympathomimetic	ADJ	O	O	3023
agents	NOUN	O	O	3023
.	PUNCT	O	O	3023
OBJECTIVE	VERB	O	O	3026
:	PUNCT	O	O	3026
We	PRON	O	O	3026
wanted	VERB	O	O	3026
to	PART	O	O	3026
test	NOUN	O	O	3026
whether	SCONJ	O	O	3026
assessment	NOUN	O	O	3026
of	ADP	O	O	3026
both	PRON	O	O	3026
a	PRON	O	O	3026
central	ADJ	O	O	3026
pain	NOUN	O	Disease	3026
-	PUNCT	O	O	3026
related	ADJ	O	O	3026
signal	VERB	O	O	3026
(	PUNCT	O	O	3026
chemo	NOUN	O	O	3026
-	PUNCT	O	O	3026
somatosensory	NOUN	O	O	3026
evoked	VERB	O	O	3026
potential	ADJ	O	O	3026
,	PUNCT	O	O	3026
CSSEP	NOUN	O	O	3026
)	PUNCT	O	O	3026
and	CCONJ	O	O	3026
a	PRON	O	O	3026
concomitantly	ADV	O	O	3026
recorded	VERB	O	O	3026
peripheral	ADJ	O	O	3026
signal	VERB	O	O	3026
(	PUNCT	O	O	3026
negative	ADJ	O	O	3026
mucosal	ADJ	O	O	3026
potential	ADJ	O	O	3026
,	PUNCT	O	O	3026
NMP	PROPN	O	O	3026
)	PUNCT	O	O	3026
allows	VERB	O	O	3026
for	ADP	O	O	3026
separation	NOUN	O	O	3026
of	ADP	O	O	3026
central	ADJ	O	O	3026
and	CCONJ	O	O	3026
peripheral	ADJ	O	O	3026
effects	NOUN	O	O	3026
of	ADP	O	O	3026
NSAIDs	NOUN	O	Chemical	3026
.	PUNCT	O	O	3026
For	ADP	O	O	3027
this	PRON	O	O	3027
purpose	NOUN	O	O	3027
,	PUNCT	O	O	3027
experimental	ADJ	O	O	3027
conditions	NOUN	O	O	3027
were	AUX	O	O	3027
created	VERB	O	O	3027
in	ADP	O	O	3027
which	PRON	O	O	3027
NSAIDs	NOUN	O	Chemical	3027
had	VERB	O	O	3027
previously	ADV	O	O	3027
been	AUX	O	O	3027
observed	VERB	O	O	3027
to	PART	O	O	3027
produce	VERB	O	O	3027
effects	NOUN	O	O	3027
on	ADP	O	O	3027
phasic	ADJ	O	O	3027
and	CCONJ	O	O	3027
tonic	PROPN	O	O	3027
pain	NOUN	O	Disease	3027
by	ADP	O	O	3027
either	ADV	O	O	3027
central	ADJ	O	O	3027
or	CCONJ	O	O	3027
peripheral	ADJ	O	O	3027
mechanisms	NOUN	O	O	3027
.	PUNCT	O	O	3027
According	VERB	O	O	3028
to	PART	O	O	3028
a	PRON	O	O	3028
double	ADJ	O	O	3028
-	PUNCT	O	O	3028
blind	ADJ	O	Disease	3028
,	PUNCT	O	O	3028
randomised	VERB	O	O	3028
,	PUNCT	O	O	3028
controlled	VERB	O	O	3028
,	PUNCT	O	O	3028
threefold	VERB	O	O	3028
cross	VERB	O	O	3028
-	PUNCT	O	O	3028
over	ADP	O	O	3028
design	NOUN	O	O	3028
,	PUNCT	O	O	3028
18	NUM	O	O	3028
healthy	ADJ	O	O	3028
subjects	NOUN	O	O	3028
(	PUNCT	O	O	3028
11	NUM	O	O	3028
males	NOUN	O	O	3028
,	PUNCT	O	O	3028
7	NUM	O	O	3028
females	NOUN	O	O	3028
;	PUNCT	O	O	3028
mean	VERB	O	O	3028
age	NOUN	O	O	3028
26	NUM	O	O	3028
years	NOUN	O	O	3028
)	PUNCT	O	O	3028
received	VERB	O	O	3028
either	ADV	O	O	3028
placebo	NOUN	O	O	3028
,	PUNCT	O	O	3028
400	NUM	O	O	3028
mg	VERB	O	O	3028
ibuprofen	PROPN	O	Chemical	3028
,	PUNCT	O	O	3028
or	CCONJ	O	O	3028
800	NUM	O	O	3028
mg	VERB	O	O	3028
ibuprofen	PROPN	O	Chemical	3028
.	PUNCT	O	O	3028
Phasic	PROPN	O	O	3029
pain	NOUN	O	Disease	3029
was	AUX	O	O	3029
applied	VERB	O	O	3029
by	ADP	O	O	3029
means	VERB	O	O	3029
of	ADP	O	O	3029
short	ADJ	O	O	3029
pulses	NOUN	O	O	3029
of	ADP	O	O	3029
CO2	PROPN	O	Chemical	3029
to	PART	O	O	3029
the	PRON	O	O	3029
nasal	ADJ	O	O	3029
mucosa	PROPN	O	O	3029
(	PUNCT	O	O	3029
stimulus	NOUN	O	O	3029
duration	NOUN	O	O	3029
500	NUM	O	O	3029
ms	PROPN	O	O	3029
,	PUNCT	O	O	3029
interval	NOUN	O	O	3029
approximately	ADV	O	O	3029
60	NUM	O	O	3029
s	X	O	O	3029
)	PUNCT	O	O	3029
,	PUNCT	O	O	3029
and	CCONJ	O	O	3029
tonic	PROPN	O	O	3029
pain	NOUN	O	Disease	3029
was	AUX	O	O	3029
induced	VERB	O	O	3029
in	ADP	O	O	3029
the	PRON	O	O	3029
nasal	ADJ	O	O	3029
cavity	NOUN	O	O	3029
by	ADP	O	O	3029
means	VERB	O	O	3029
of	ADP	O	O	3029
dry	VERB	O	O	3029
air	NOUN	O	O	3029
of	ADP	O	O	3029
controlled	VERB	O	O	3029
temperature	NOUN	O	O	3029
,	PUNCT	O	O	3029
humidity	NOUN	O	O	3029
and	CCONJ	O	O	3029
flow	NOUN	O	O	3029
rate	NOUN	O	O	3029
(	PUNCT	O	O	3029
22	NUM	O	O	3029
degrees	NOUN	O	O	3029
C	NOUN	O	O	3029
,	PUNCT	O	O	3029
0%	NOUN	O	O	3029
relative	ADJ	O	O	3029
humidity	NOUN	O	O	3029
,	PUNCT	O	O	3029
145	NUM	O	O	3029
ml.s-1	X	O	O	3029
)	PUNCT	O	O	3029
.	PUNCT	O	O	3029
Both	PRON	O	O	3030
CSSEPs	NOUN	O	O	3030
as	ADP	O	O	3030
central	ADJ	O	O	3030
and	CCONJ	O	O	3030
NMPs	NOUN	O	O	3030
as	ADP	O	O	3030
peripheral	ADJ	O	O	3030
correlates	VERB	O	O	3030
of	ADP	O	O	3030
pain	NOUN	O	Disease	3030
were	AUX	O	O	3030
obtained	VERB	O	O	3030
in	ADP	O	O	3030
response	NOUN	O	O	3030
to	PART	O	O	3030
the	PRON	O	O	3030
CO2	PROPN	O	Chemical	3030
stimuli	NOUN	O	O	3030
.	PUNCT	O	O	3030
Additionally	ADV	O	O	3031
,	PUNCT	O	O	3031
the	PRON	O	O	3031
subjects	NOUN	O	O	3031
rated	VERB	O	O	3031
the	PRON	O	O	3031
intensity	NOUN	O	O	3031
of	ADP	O	O	3031
both	PRON	O	O	3031
phasic	ADJ	O	O	3031
and	CCONJ	O	O	3031
tonic	PROPN	O	O	3031
pain	NOUN	O	Disease	3031
by	ADP	O	O	3031
means	VERB	O	O	3031
of	ADP	O	O	3031
visual	ADJ	O	O	3031
analogue	NOUN	O	O	3031
scales	NOUN	O	O	3031
.	PUNCT	O	O	3031
As	ADP	O	O	3032
described	VERB	O	O	3032
earlier	ADV	O	O	3032
,	PUNCT	O	O	3032
administration	NOUN	O	O	3032
of	ADP	O	O	3032
ibuprofen	PROPN	O	Chemical	3032
was	AUX	O	O	3032
followed	VERB	O	O	3032
by	ADP	O	O	3032
a	PRON	O	O	3032
decrease	VERB	O	O	3032
in	ADP	O	O	3032
tonic	PROPN	O	O	3032
pain	NOUN	O	Disease	3032
but	CCONJ	O	O	3032
-	PUNCT	O	O	3032
relative	ADJ	O	O	3032
to	PART	O	O	3032
placebo	NOUN	O	O	3032
-	PUNCT	O	O	3032
an	PRON	O	O	3032
increase	VERB	O	O	3032
in	ADP	O	O	3032
correlates	VERB	O	O	3032
of	ADP	O	O	3032
phasic	ADJ	O	O	3032
pain	NOUN	O	Disease	3032
,	PUNCT	O	O	3032
indicating	VERB	O	O	3032
a	PRON	O	O	3032
specific	ADJ	O	O	3032
effect	VERB	O	O	3032
of	ADP	O	O	3032
ibuprofen	PROPN	O	Chemical	3032
on	ADP	O	O	3032
the	PRON	O	O	3032
interaction	NOUN	O	O	3032
between	ADP	O	O	3032
the	PRON	O	O	3032
pain	NOUN	O	Disease	3032
stimuli	NOUN	O	O	3032
under	ADP	O	O	3032
these	PRON	O	O	3032
special	ADJ	O	O	3032
experimental	ADJ	O	O	3032
conditions	NOUN	O	O	3032
.	PUNCT	O	O	3032
The	PRON	O	O	3033
major	ADJ	O	O	3033
advantage	NOUN	O	O	3033
of	ADP	O	O	3033
this	PRON	O	O	3033
pain	NOUN	O	Disease	3033
model	NOUN	O	O	3033
is	AUX	O	O	3033
the	PRON	O	O	3033
possibility	NOUN	O	O	3033
of	ADP	O	O	3033
obtaining	VERB	O	O	3033
peripheral	ADJ	O	O	3033
pain	NOUN	O	Disease	3033
-	PUNCT	O	O	3033
related	ADJ	O	O	3033
activity	NOUN	O	O	3033
directly	ADV	O	O	3033
using	VERB	O	O	3033
a	PRON	O	O	3033
non	ADJ	O	O	3033
-	PUNCT	O	O	3033
invasive	ADJ	O	O	3033
technique	NOUN	O	O	3033
in	ADP	O	O	3033
humans	NOUN	O	O	3033
.	PUNCT	O	O	3033
Acute	PROPN	O	O	3036
severe	ADJ	O	O	3036
depression	PROPN	O	Disease	3036
following	VERB	O	O	3036
peri	PROPN	O	O	3036
-	PUNCT	O	O	3036
operative	NOUN	O	O	3036
ondansetron	X	O	O	3036
.	PUNCT	O	O	3036
A	PRON	O	O	3037
41-year	NOUN	O	O	3037
-	PUNCT	O	O	3037
old	ADJ	O	O	3037
woman	NOUN	O	O	3037
with	ADP	O	O	3037
a	PRON	O	O	3037
strong	ADJ	O	O	3037
history	NOUN	O	O	3037
of	ADP	O	O	3037
postoperative	ADJ	O	O	3037
nausea	NOUN	O	Disease	3037
and	CCONJ	O	O	3037
vomiting	VERB	O	Disease	3037
presented	VERB	O	O	3037
for	ADP	O	O	3037
abdominal	ADJ	O	O	3037
hysterectomy	NOUN	O	O	3037
3	X	O	O	3037
months	NOUN	O	O	3037
after	ADP	O	O	3037
a	PRON	O	O	3037
previous	ADJ	O	O	3037
anaesthetic	NOUN	O	O	3037
where	SCONJ	O	O	3037
ondansetron	X	O	O	3037
prophylaxis	NOUN	O	O	3037
had	VERB	O	O	3037
been	AUX	O	O	3037
used	VERB	O	O	3037
.	PUNCT	O	O	3037
She	PRON	O	O	3038
had	VERB	O	O	3038
developed	VERB	O	O	3038
a	PRON	O	O	3038
severe	ADJ	O	O	3038
acute	ADJ	O	O	3038
major	ADJ	O	O	3038
depression	PROPN	O	Disease	3038
disorder	NOUN	O	O	3038
almost	ADV	O	O	3038
immediately	ADV	O	O	3038
thereafter	ADV	O	O	3038
,	PUNCT	O	O	3038
possibly	ADV	O	O	3038
related	ADJ	O	O	3038
to	PART	O	O	3038
the	PRON	O	O	3038
use	VERB	O	O	3038
of	ADP	O	O	3038
a	PRON	O	O	3038
serotonin	PROPN	O	Chemical	3038
antagonist	NOUN	O	O	3038
.	PUNCT	O	O	3038
Nine	NUM	O	O	3039
years	NOUN	O	O	3039
before	ADP	O	O	3039
she	PRON	O	O	3039
had	VERB	O	O	3039
experienced	ADJ	O	O	3039
a	PRON	O	O	3039
self	VERB	O	O	3039
-	PUNCT	O	O	3039
limited	VERB	O	O	3039
puerperal	ADJ	O	O	3039
depressive	ADJ	O	Disease	3039
episode	PROPN	O	O	3039
.	PUNCT	O	O	3039
Anaesthesia	NOUN	O	O	3040
with	ADP	O	O	3040
a	PRON	O	O	3040
propofol	VERB	O	Chemical	3040
infusion	NOUN	O	O	3040
and	CCONJ	O	O	3040
avoidance	NOUN	O	O	3040
of	ADP	O	O	3040
serotonin	PROPN	O	Chemical	3040
antagonists	NOUN	O	O	3040
provided	VERB	O	O	3040
a	PRON	O	O	3040
nausea	NOUN	O	Disease	3040
-	PUNCT	O	O	3040
free	ADJ	O	O	3040
postoperative	ADJ	O	O	3040
course	NOUN	O	O	3040
without	ADP	O	O	3040
exacerbation	NOUN	O	O	3040
of	ADP	O	O	3040
the	PRON	O	O	3040
depression	PROPN	O	Disease	3040
disorder	NOUN	O	O	3040
.	PUNCT	O	O	3040
Hypertensive	NOUN	O	O	3043
response	NOUN	O	O	3043
during	ADP	O	O	3043
dobutamine	NOUN	O	Chemical	3043
stress	NOUN	O	O	3043
echocardiography	NOUN	O	O	3043
.	PUNCT	O	O	3043
Among	ADP	O	O	3044
3,129	NUM	O	O	3044
dobutamine	NOUN	O	Chemical	3044
stress	NOUN	O	O	3044
echocardiographic	NOUN	O	O	3044
studies	NOUN	O	O	3044
,	PUNCT	O	O	3044
a	PRON	O	O	3044
hypertensive	ADJ	O	Disease	3044
response	NOUN	O	O	3044
,	PUNCT	O	O	3044
defined	VERB	O	O	3044
as	ADP	O	O	3044
systolic	ADV	O	O	3044
blood	NOUN	O	O	3044
pressure	NOUN	O	O	3044
(	PUNCT	O	O	3044
BP	PROPN	O	O	3044
)	PUNCT	O	O	3044
>	PUNCT	O	O	3044
or	CCONJ	O	O	3044
=	PUNCT	O	O	3044
220	NUM	O	O	3044
mm	INTJ	O	O	3044
Hg	PROPN	O	O	3044
and/or	CCONJ	O	O	3044
diastolic	ADV	O	O	3044
BP	PROPN	O	O	3044
>	PUNCT	O	O	3044
or	CCONJ	O	O	3044
=	PUNCT	O	O	3044
110	NUM	O	O	3044
mm	INTJ	O	O	3044
Hg	PROPN	O	O	3044
,	PUNCT	O	O	3044
occurred	VERB	O	O	3044
in	ADP	O	O	3044
30	NUM	O	O	3044
patients	NOUN	O	O	3044
(	PUNCT	O	O	3044
1%	NOUN	O	O	3044
)	PUNCT	O	O	3044
.	PUNCT	O	O	3044
Patients	NOUN	O	O	3045
with	ADP	O	O	3045
this	PRON	O	O	3045
response	NOUN	O	O	3045
more	ADJ	O	O	3045
often	ADV	O	O	3045
had	VERB	O	O	3045
a	PRON	O	O	3045
history	NOUN	O	O	3045
of	ADP	O	O	3045
hypertension	NOUN	O	Disease	3045
and	CCONJ	O	O	3045
had	VERB	O	O	3045
higher	ADJ	O	O	3045
resting	VERB	O	O	3045
systolic	ADV	O	O	3045
and	CCONJ	O	O	3045
diastolic	ADV	O	O	3045
BP	PROPN	O	O	3046
before	ADP	O	O	3046
dobutamine	NOUN	O	Chemical	3046
infusion	NOUN	O	O	3046
.	PUNCT	O	O	3046
Continuously	ADV	O	O	3049
nebulized	VERB	O	O	3049
albuterol	NOUN	O	O	3049
in	ADP	O	O	3049
severe	ADJ	O	O	3049
exacerbations	NOUN	O	O	3049
of	ADP	O	O	3049
asthma	PROPN	O	Disease	3049
in	ADP	O	O	3049
adults	NOUN	O	O	3049
:	PUNCT	O	O	3049
a	PRON	O	O	3049
case	NOUN	O	O	3049
-	PUNCT	O	O	3049
controlled	VERB	O	O	3049
study	VERB	O	O	3049
.	PUNCT	O	O	3049
A	PRON	O	O	3050
retrospective	ADJ	O	O	3050
,	PUNCT	O	O	3050
case	NOUN	O	O	3050
-	PUNCT	O	O	3050
controlled	VERB	O	O	3050
analysis	NOUN	O	O	3050
comparing	VERB	O	O	3050
patients	NOUN	O	O	3050
admitted	VERB	O	O	3050
to	PART	O	O	3050
a	PRON	O	O	3050
medical	ADJ	O	O	3050
intensive	ADJ	O	O	3050
care	VERB	O	O	3050
unit	NOUN	O	O	3050
with	ADP	O	O	3050
severe	ADJ	O	O	3050
exacerbations	NOUN	O	O	3050
of	ADP	O	O	3050
asthma	PROPN	O	Disease	3050
who	PRON	O	O	3050
received	VERB	O	O	3050
continuously	ADV	O	O	3050
nebulized	VERB	O	O	3050
albuterol	NOUN	O	O	3050
(	PUNCT	O	O	3050
CNA	PROPN	O	O	3050
)	PUNCT	O	O	3050
versus	ADP	O	O	3050
intermittent	ADJ	O	O	3050
albuterol	NOUN	O	O	3050
(	PUNCT	O	O	3050
INA	PROPN	O	O	3050
)	PUNCT	O	O	3050
treatments	NOUN	O	O	3050
is	AUX	O	O	3050
reported	VERB	O	O	3050
.	PUNCT	O	O	3050
Forty	NUM	O	O	3051
matched	VERB	O	O	3051
pairs	NOUN	O	O	3051
of	ADP	O	O	3051
patients	NOUN	O	O	3051
with	ADP	O	O	3051
asthma	PROPN	O	Disease	3051
are	AUX	O	O	3051
compared	VERB	O	O	3051
.	PUNCT	O	O	3051
The	PRON	O	O	3052
incidence	NOUN	O	O	3052
of	ADP	O	O	3052
cardiac	ADJ	O	O	3052
dysrhythmias	VERB	O	Disease	3052
was	AUX	O	O	3052
similar	ADJ	O	O	3052
between	ADP	O	O	3052
groups	NOUN	O	O	3052
.	PUNCT	O	O	3052
Symptomatic	ADJ	O	O	3053
hypokalemia	PROPN	O	Disease	3053
did	VERB	O	O	3053
not	PART	O	O	3053
occur	VERB	O	O	3053
.	PUNCT	O	O	3053
Hyperosmolar	PROPN	O	O	3056
nonketotic	ADJ	O	O	3056
coma	NOUN	O	Disease	3056
precipitated	VERB	O	O	3056
by	ADP	O	O	3056
lithium	NOUN	O	Chemical	3056
-	PUNCT	O	O	3056
induced	VERB	O	O	3056
nephrogenic	PROPN	O	O	3056
diabetes insipidus	NOUN	O	Disease	3056
.	PUNCT	O	O	3056
A	PRON	O	O	3057
45-year	NOUN	O	O	3057
-	PUNCT	O	O	3057
old	ADJ	O	O	3057
man	NOUN	O	O	3057
,	PUNCT	O	O	3057
with	ADP	O	O	3057
a	PRON	O	O	3057
10-year	NOUN	O	O	3057
history	NOUN	O	O	3057
of	ADP	O	O	3057
manic	ADJ	O	O	3057
depression	PROPN	O	Disease	3057
treated	VERB	O	O	3057
with	ADP	O	O	3057
lithium	NOUN	O	Chemical	3057
,	PUNCT	O	O	3057
was	AUX	O	O	3057
admitted	VERB	O	O	3057
with	ADP	O	O	3057
hyperosmolar	VERB	O	O	3057
,	PUNCT	O	O	3057
nonketotic	ADJ	O	O	3057
coma	NOUN	O	Disease	3057
.	PUNCT	O	O	3057
He	PRON	O	O	3058
gave	VERB	O	O	3058
a	PRON	O	O	3058
five	NUM	O	O	3058
-	PUNCT	O	O	3058
year	NOUN	O	O	3058
history	NOUN	O	O	3058
of	ADP	O	O	3058
polyuria	PROPN	O	Disease	3058
and	CCONJ	O	O	3058
polydipsia	PROPN	O	Disease	3058
,	PUNCT	O	O	3058
during	ADP	O	O	3058
which	PRON	O	O	3058
time	NOUN	O	O	3058
urinalysis	NOUN	O	O	3058
had	VERB	O	O	3058
been	AUX	O	O	3058
negative	ADJ	O	O	3058
for	ADP	O	O	3058
glucose	NOUN	O	Chemical	3058
.	PUNCT	O	O	3058
After	ADP	O	O	3059
recovery	NOUN	O	O	3059
from	ADP	O	O	3059
hyperglycaemia	NOUN	O	O	3059
,	PUNCT	O	O	3059
he	PRON	O	O	3059
remained	VERB	O	O	3059
polyuric	ADJ	O	Disease	3059
despite	SCONJ	O	O	3059
normal	ADJ	O	O	3059
blood	NOUN	O	O	3059
glucose	NOUN	O	Chemical	3059
concentrations	NOUN	O	O	3059
;	PUNCT	O	O	3059
water	PROPN	O	O	3059
deprivation	NOUN	O	O	3059
testing	NOUN	O	O	3059
indicated	VERB	O	O	3059
nephrogenic	PROPN	O	O	3059
diabetes insipidus	NOUN	O	Disease	3059
,	PUNCT	O	O	3059
likely	ADV	O	O	3059
to	PART	O	O	3059
be	AUX	O	O	3059
lithium	NOUN	O	Chemical	3059
-	PUNCT	O	O	3059
induced	VERB	O	O	3059
.	PUNCT	O	O	3059
We	PRON	O	O	3060
hypothesize	VERB	O	O	3060
that	SCONJ	O	O	3060
when	SCONJ	O	O	3060
this	PRON	O	O	3060
man	NOUN	O	O	3060
developed	VERB	O	O	3060
type	NOUN	O	O	3060
2	X	O	O	3060
diabetes	NOUN	O	Disease	3060
,	PUNCT	O	O	3060
chronic	ADJ	O	O	3060
polyuria	PROPN	O	Disease	3060
due	ADJ	O	O	3060
to	PART	O	O	3060
nephrogenic	PROPN	O	O	3060
diabetes insipidus	NOUN	O	Disease	3060
was	AUX	O	O	3060
sufficient	ADJ	O	O	3060
to	PART	O	O	3060
precipitate	VERB	O	O	3060
hyperosmolar	VERB	O	O	3060
dehydration	NOUN	O	Disease	3060
.	PUNCT	O	O	3060
Effects	NOUN	O	O	3063
of	ADP	O	O	3063
the	PRON	O	O	3063
intracoronary	NOUN	O	O	3063
infusion	NOUN	O	O	3063
of	ADP	O	O	3063
cocaine	NOUN	O	Chemical	3063
on	ADP	O	O	3063
left	VERB	O	O	3063
ventricular	ADJ	O	O	3063
systolic	ADV	O	O	3063
and	CCONJ	O	O	3063
diastolic	ADV	O	O	3063
function	NOUN	O	O	3063
in	ADP	O	O	3063
humans	NOUN	O	O	3063
.	PUNCT	O	O	3063
In	ADP	O	O	3064
dogs	NOUN	O	O	3064
,	PUNCT	O	O	3064
a	PRON	O	O	3064
large	ADJ	O	O	3064
amount	NOUN	O	O	3064
of	ADP	O	O	3064
intravenous	ADJ	O	O	3064
cocaine	NOUN	O	Chemical	3064
causes	VERB	O	O	3064
a	PRON	O	O	3064
profound	ADJ	O	O	3064
deterioration	NOUN	O	O	3064
of	ADP	O	O	3064
left	VERB	O	O	3064
ventricular	ADJ	O	O	3064
(	PUNCT	O	O	3064
LV	PROPN	O	Disease	3064
)	PUNCT	O	O	3064
systolic	ADV	O	O	3064
function	NOUN	O	O	3064
and	CCONJ	O	O	3064
an	PRON	O	O	3064
increase	VERB	O	O	3064
in	ADP	O	O	3064
LV	PROPN	O	Disease	3064
end	VERB	O	O	3064
-	PUNCT	O	O	3064
diastolic	ADV	O	O	3064
pressure	NOUN	O	O	3064
.	PUNCT	O	O	3064
This	PRON	O	O	3065
study	VERB	O	O	3065
was	AUX	O	O	3065
done	VERB	O	O	3065
to	PART	O	O	3065
assess	VERB	O	O	3065
the	PRON	O	O	3065
influence	NOUN	O	O	3065
of	ADP	O	O	3065
a	PRON	O	O	3065
high	ADJ	O	O	3065
intracoronary	NOUN	O	O	3065
cocaine	NOUN	O	Chemical	3065
concentration	NOUN	O	O	3065
on	ADP	O	O	3065
LV	PROPN	O	Disease	3065
systolic	ADV	O	O	3065
and	CCONJ	O	O	3065
diastolic	ADV	O	O	3065
function	NOUN	O	O	3065
in	ADP	O	O	3065
humans	NOUN	O	O	3065
.	PUNCT	O	O	3065
METHODS	NOUN	O	O	3066
AND	CCONJ	O	O	3066
RESULTS	VERB	O	O	3066
:	PUNCT	O	O	3066
In	ADP	O	O	3066
20	NUM	O	O	3066
patients	NOUN	O	O	3066
(	PUNCT	O	O	3066
14	NUM	O	O	3066
men	NOUN	O	O	3066
and	CCONJ	O	O	3066
6	NUM	O	O	3066
women	NOUN	O	O	3066
aged	ADJ	O	O	3066
39	NUM	O	O	3066
to	PART	O	O	3066
72	NUM	O	O	3066
years	NOUN	O	O	3066
)	PUNCT	O	O	3066
referred	VERB	O	O	3066
for	ADP	O	O	3066
cardiac	ADJ	O	O	3066
catheterization	NOUN	O	O	3066
for	ADP	O	O	3066
the	PRON	O	O	3066
evaluation	NOUN	O	O	3066
of	ADP	O	O	3066
chest pain	NOUN	O	Disease	3066
,	PUNCT	O	O	3066
we	PRON	O	O	3066
measured	VERB	O	O	3066
heart	NOUN	O	O	3066
rate	NOUN	O	O	3066
,	PUNCT	O	O	3066
systemic	ADJ	O	O	3066
arterial	ADJ	O	O	3066
pressure	NOUN	O	O	3066
,	PUNCT	O	O	3066
LV	PROPN	O	Disease	3066
pressure	NOUN	O	O	3066
and	CCONJ	O	O	3066
its	PRON	O	O	3066
first	ADV	O	O	3066
derivative	ADJ	O	O	3066
(	PUNCT	O	O	3066
dP	X	O	O	3066
/	PUNCT	O	O	3066
dt	PROPN	O	O	3066
)	PUNCT	O	O	3066
,	PUNCT	O	O	3066
and	CCONJ	O	O	3066
LV	PROPN	O	Disease	3066
volumes	NOUN	O	O	3066
and	CCONJ	O	O	3066
ejection	NOUN	O	O	3066
fraction	NOUN	O	O	3066
before	ADP	O	O	3066
and	CCONJ	O	O	3066
during	ADP	O	O	3066
the	PRON	O	O	3066
final	ADJ	O	O	3066
2	X	O	O	3066
to	PART	O	O	3066
3	X	O	O	3066
minutes	NOUN	O	O	3066
of	ADP	O	O	3066
a	PRON	O	O	3066
15-minute	NOUN	O	O	3066
intracoronary	NOUN	O	O	3066
infusion	NOUN	O	O	3066
of	ADP	O	O	3066
saline	NOUN	O	O	3066
(	PUNCT	O	O	3066
n=10	VERB	O	O	3066
,	PUNCT	O	O	3066
control	VERB	O	O	3066
subjects	NOUN	O	O	3066
)	PUNCT	O	O	3066
or	CCONJ	O	O	3066
cocaine	NOUN	O	Chemical	3066
hydrochloride	NOUN	O	O	3066
1	X	O	O	3066
mg	VERB	O	O	3066
/	PUNCT	O	O	3066
min	NOUN	O	O	3066
(	PUNCT	O	O	3066
n=10	VERB	O	O	3066
)	PUNCT	O	O	3066
.	PUNCT	O	O	3066
With	ADP	O	O	3067
cocaine	NOUN	O	Chemical	3067
,	PUNCT	O	O	3067
the	PRON	O	O	3067
drug	NOUN	O	O	3067
concentration	NOUN	O	O	3067
in	ADP	O	O	3067
blood	NOUN	O	O	3067
obtained	VERB	O	O	3067
from	ADP	O	O	3067
the	PRON	O	O	3067
coronary	ADJ	O	O	3067
sinus	NOUN	O	O	3067
was	AUX	O	O	3067
3.0+/-0.4	NUM	O	O	3067
(	PUNCT	O	O	3067
mean+/-SD	VERB	O	O	3067
)	PUNCT	O	O	3067
/	PUNCT	O	O	3068
L	NOUN	O	O	3068
,	PUNCT	O	O	3068
similar	ADJ	O	O	3068
in	ADP	O	O	3068
magnitude	NOUN	O	O	3068
to	PART	O	O	3068
the	PRON	O	O	3068
blood	NOUN	O	O	3068
cocaine	NOUN	O	Chemical	3068
concentration	NOUN	O	O	3068
reported	VERB	O	O	3068
in	ADP	O	O	3068
abusers	NOUN	O	O	3068
dying	VERB	O	O	3068
of	ADP	O	O	3068
cocaine	NOUN	O	Chemical	3068
intoxication	NOUN	O	O	3068
.	PUNCT	O	O	3068
Cocaine	NOUN	O	Chemical	3069
induced	VERB	O	O	3069
no	PRON	O	O	3069
significant	ADJ	O	O	3069
change	VERB	O	O	3069
in	ADP	O	O	3069
heart	NOUN	O	O	3069
rate	NOUN	O	O	3069
,	PUNCT	O	O	3069
LV	PROPN	O	Disease	3069
dP	X	O	O	3069
/	PUNCT	O	O	3069
dt	PROPN	O	O	3069
(	PUNCT	O	O	3069
positive	ADJ	O	O	3069
or	CCONJ	O	O	3069
negative	ADJ	O	O	3069
)	PUNCT	O	O	3069
,	PUNCT	O	O	3069
or	CCONJ	O	O	3069
LV	PROPN	O	Disease	3069
end	VERB	O	O	3069
-	PUNCT	O	O	3069
diastolic	ADV	O	O	3069
volume	PROPN	O	O	3069
,	PUNCT	O	O	3069
but	CCONJ	O	O	3069
it	PRON	O	O	3069
caused	VERB	O	O	3069
an	PRON	O	O	3069
increase	VERB	O	O	3069
in	ADP	O	O	3069
systolic	ADV	O	O	3069
and	CCONJ	O	O	3069
mean	VERB	O	O	3069
arterial	ADJ	O	O	3069
pressures	NOUN	O	O	3069
,	PUNCT	O	O	3069
LV	PROPN	O	Disease	3069
end	VERB	O	O	3069
-	PUNCT	O	O	3069
diastolic	ADV	O	O	3069
pressure	NOUN	O	O	3069
,	PUNCT	O	O	3069
and	CCONJ	O	O	3069
LV	PROPN	O	Disease	3069
end	VERB	O	O	3069
-	PUNCT	O	O	3069
systolic	ADV	O	O	3069
volume	PROPN	O	O	3069
,	PUNCT	O	O	3069
as	ADP	O	O	3069
well	ADV	O	O	3069
as	ADP	O	O	3069
a	PRON	O	O	3069
decrease	VERB	O	O	3069
in	ADP	O	O	3069
LV	PROPN	O	Disease	3069
ejection	NOUN	O	O	3069
fraction	NOUN	O	O	3069
.	PUNCT	O	O	3069
In	ADP	O	O	3070
humans	NOUN	O	O	3070
,	PUNCT	O	O	3070
the	PRON	O	O	3070
intracoronary	NOUN	O	O	3070
infusion	NOUN	O	O	3070
of	ADP	O	O	3070
cocaine	NOUN	O	Chemical	3070
sufficient	ADJ	O	O	3070
in	ADP	O	O	3070
amount	NOUN	O	O	3070
to	PART	O	O	3070
achieve	VERB	O	O	3070
a	PRON	O	O	3070
high	ADJ	O	O	3070
drug	NOUN	O	O	3070
concentration	NOUN	O	O	3070
in	ADP	O	O	3070
coronary	ADJ	O	O	3070
sinus	NOUN	O	O	3070
blood	NOUN	O	O	3070
causes	VERB	O	O	3070
a	PRON	O	O	3070
deterioration	NOUN	O	O	3070
of	ADP	O	O	3070
LV	PROPN	O	Disease	3070
systolic	ADV	O	O	3070
and	CCONJ	O	O	3070
diastolic	ADV	O	O	3070
performance	NOUN	O	O	3070
.	PUNCT	O	O	3070
Heparin	PROPN	O	Chemical	3073
-	PUNCT	O	O	3073
induced	VERB	O	O	3073
thrombocytopenia	PROPN	O	Disease	3073
,	PUNCT	O	O	3073
paradoxical	ADJ	O	O	3073
thromboembolism	NOUN	O	Disease	3073
,	PUNCT	O	O	3073
and	CCONJ	O	O	3073
other	ADJ	O	O	3073
side	NOUN	O	O	3073
effects	NOUN	O	O	3073
of	ADP	O	O	3073
heparin	NOUN	O	Chemical	3073
therapy	NOUN	O	O	3073
.	PUNCT	O	O	3073
Although	SCONJ	O	O	3074
several	ADJ	O	O	3074
new	ADJ	O	O	3074
anticoagulant	ADJ	O	O	3074
drugs	NOUN	O	O	3074
are	AUX	O	O	3074
in	ADP	O	O	3074
development	NOUN	O	O	3074
,	PUNCT	O	O	3074
heparin	NOUN	O	Chemical	3074
remains	VERB	O	O	3074
the	PRON	O	O	3074
drug	NOUN	O	O	3074
of	ADP	O	O	3074
choice	NOUN	O	O	3074
for	ADP	O	O	3074
most	ADV	O	O	3074
anticoagulation	NOUN	O	O	3074
needs	VERB	O	O	3074
.	PUNCT	O	O	3074
The	PRON	O	O	3075
clinical	ADJ	O	O	3075
effects	NOUN	O	O	3075
of	ADP	O	O	3075
heparin	NOUN	O	Chemical	3075
are	AUX	O	O	3075
meritorious	ADJ	O	O	3075
,	PUNCT	O	O	3075
but	CCONJ	O	O	3075
side	NOUN	O	O	3075
effects	NOUN	O	O	3075
do	VERB	O	O	3075
exist	VERB	O	O	3075
.	PUNCT	O	O	3075
Important	ADJ	O	O	3076
untoward	ADJ	O	O	3076
effects	NOUN	O	O	3076
of	ADP	O	O	3076
heparin	NOUN	O	Chemical	3076
therapy	NOUN	O	O	3076
including	VERB	O	O	3076
heparin	NOUN	O	Chemical	3076
-	PUNCT	O	O	3076
induced	VERB	O	O	3076
thrombocytopenia	PROPN	O	Disease	3076
,	PUNCT	O	O	3076
heparin	NOUN	O	Chemical	3076
-	PUNCT	O	O	3076
associated	VERB	O	O	3076
osteoporosis	NOUN	O	Disease	3076
,	PUNCT	O	O	3076
eosinophilia	PROPN	O	Disease	3076
,	PUNCT	O	O	3076
skin	NOUN	O	O	3076
reactions	NOUN	O	O	3076
,	PUNCT	O	O	3076
allergic	ADJ	O	O	3076
reactions	NOUN	O	O	3076
other	ADJ	O	O	3076
than	ADP	O	O	3076
thrombocytopenia	PROPN	O	Disease	3076
and	CCONJ	O	O	3076
alopecia	NOUN	O	O	3076
will	AUX	O	O	3076
be	AUX	O	O	3076
discussed	VERB	O	O	3076
in	ADP	O	O	3076
this	PRON	O	O	3076
article	NOUN	O	O	3076
.	PUNCT	O	O	3076
Nonopaque	PROPN	O	O	3079
crystal	PROPN	O	O	3079
deposition	NOUN	O	O	3079
causing	VERB	O	O	3079
ureteric	ADJ	O	O	3079
obstruction	NOUN	O	O	3079
in	ADP	O	O	3079
patients	NOUN	O	O	3079
with	ADP	O	O	3079
HIV	PROPN	O	O	3079
undergoing	VERB	O	O	3079
indinavir	NOUN	O	O	3079
therapy	NOUN	O	O	3079
.	PUNCT	O	O	3079
We	PRON	O	O	3080
describe	VERB	O	O	3080
the	PRON	O	O	3080
unique	ADJ	O	O	3080
CT	PROPN	O	O	3080
features	VERB	O	O	3080
of	ADP	O	O	3080
ureteric	ADJ	O	O	3080
calculi	NOUN	O	O	3080
in	ADP	O	O	3080
six	NUM	O	O	3080
HIV	PROPN	O	O	3080
-	PUNCT	O	O	3080
infected	VERB	O	O	3080
patients	NOUN	O	O	3080
receiving	VERB	O	O	3080
indinavir	NOUN	O	O	3080
,	PUNCT	O	O	3080
the	PRON	O	O	3080
most	ADV	O	O	3080
commonly	ADV	O	O	3080
used	VERB	O	O	3080
HIV	PROPN	O	O	3080
protease	NOUN	O	O	3080
inhibitor	NOUN	O	O	3080
,	PUNCT	O	O	3080
which	PRON	O	O	3080
is	AUX	O	O	3080
associated	VERB	O	O	3080
with	ADP	O	O	3080
an	PRON	O	O	3080
increased	VERB	O	O	3080
incidence	NOUN	O	O	3080
of	ADP	O	O	3080
urolithiasis	NOUN	O	O	3080
.	PUNCT	O	O	3080
CONCLUSION	PROPN	O	O	3081
:	PUNCT	O	O	3081
Ureteric	PROPN	O	O	3081
obstruction	NOUN	O	O	3081
caused	VERB	O	O	3081
by	ADP	O	O	3081
precipitated	VERB	O	O	3081
indinavir	NOUN	O	O	3081
crystals	NOUN	O	O	3081
may	AUX	O	O	3081
be	AUX	O	O	3081
difficult	ADJ	O	O	3081
to	PART	O	O	3081
diagnose	VERB	O	O	3081
with	ADP	O	O	3081
unenhanced	ADJ	O	O	3081
CT	PROPN	O	O	3081
.	PUNCT	O	O	3081
contrast	NOUN	O	O	3082
material	ADJ	O	O	3082
to	PART	O	O	3082
enable	VERB	O	O	3082
diagnosis	NOUN	O	O	3082
of	ADP	O	O	3082
ureteric	ADJ	O	O	3082
stones	NOUN	O	O	3082
or	CCONJ	O	O	3082
obstruction	NOUN	O	O	3082
in	ADP	O	O	3082
patients	NOUN	O	O	3082
with	ADP	O	O	3082
HIV	PROPN	O	O	3082
infection	NOUN	O	Disease	3082
who	PRON	O	O	3082
receive	VERB	O	O	3082
indinavir	NOUN	O	O	3082
therapy	NOUN	O	O	3082
.	PUNCT	O	O	3082
Ischemic	PROPN	O	O	3085
colitis	NOUN	O	O	3085
and	CCONJ	O	O	3085
sumatriptan	PROPN	O	O	3085
use	VERB	O	O	3085
.	PUNCT	O	O	3085
Sumatriptan	PROPN	O	O	3086
succinate	NOUN	O	O	3086
,	PUNCT	O	O	3086
a	PRON	O	O	3086
serotonin-1	NUM	O	O	3086
(	PUNCT	O	O	3086
5-hydroxytryptamine-1	NUM	O	O	3086
)	PUNCT	O	O	3086
receptor	NOUN	O	O	3086
agonist	NOUN	O	O	3086
,	PUNCT	O	O	3086
is	AUX	O	O	3086
an	PRON	O	O	3086
antimigraine	NOUN	O	O	3086
drug	NOUN	O	O	3086
that	SCONJ	O	O	3086
is	AUX	O	O	3086
reported	VERB	O	O	3086
to	PART	O	O	3086
act	VERB	O	O	3086
by	ADP	O	O	3086
selectively	ADV	O	O	3086
constricting	VERB	O	O	3086
intracranial	ADJ	O	O	3086
arteries	NOUN	O	O	3086
.	PUNCT	O	O	3086
Cases	NOUN	O	O	3087
have	VERB	O	O	3087
been	AUX	O	O	3087
published	VERB	O	O	3087
of	ADP	O	O	3087
coronary vasospasm	NOUN	O	Disease	3087
,	PUNCT	O	O	3087
myocardial ischemia	NOUN	O	Disease	3087
,	PUNCT	O	O	3087
and	CCONJ	O	O	3087
myocardial infarction	NOUN	O	Disease	3087
occurring	VERB	O	O	3087
after	ADP	O	O	3087
sumatriptan	PROPN	O	O	3087
use	VERB	O	O	3087
.	PUNCT	O	O	3087
We	PRON	O	O	3088
report	VERB	O	O	3088
on	ADP	O	O	3088
the	PRON	O	O	3088
development	NOUN	O	O	3088
of	ADP	O	O	3088
8	NUM	O	O	3088
serious	ADJ	O	O	3088
cases	NOUN	O	O	3088
of	ADP	O	O	3088
ischemic	VERB	O	Disease	3088
colitis	NOUN	O	O	3088
in	ADP	O	O	3088
patients	NOUN	O	O	3088
with	ADP	O	O	3088
migraine	NOUN	O	Disease	3088
treated	VERB	O	O	3088
with	ADP	O	O	3088
sumatriptan	PROPN	O	O	3088
.	PUNCT	O	O	3088
51	NUM	O	O	3091
patients	NOUN	O	O	3091
with	ADP	O	O	3091
medically	ADV	O	O	3091
refractory	ADJ	O	O	3091
Parkinson	NOUN	O	O	3091
's	AUX	O	O	3091
disease	PROPN	O	O	3091
underwent	VERB	O	O	3091
stereotactic	NOUN	O	O	3091
posteromedial	ADJ	O	O	3091
pallidotomy	NOUN	O	O	3091
between	ADP	O	O	3091
August	PROPN	O	O	3091
1993	NUM	O	O	3091
and	CCONJ	O	O	3091
February	PROPN	O	O	3091
1997	NUM	O	O	3091
for	ADP	O	O	3091
treatment	NOUN	O	O	3091
of	ADP	O	O	3091
bradykinesia	NOUN	O	Disease	3091
,	PUNCT	O	O	3091
rigidity	NOUN	O	Disease	3091
,	PUNCT	O	O	3091
and	CCONJ	O	O	3091
L	NOUN	O	O	3091
-	PUNCT	O	O	3091
DOPA	PROPN	O	O	3091
-	PUNCT	O	O	3091
induced	VERB	O	O	3091
dyskinesias	PROPN	O	Disease	3091
.	PUNCT	O	O	3091
Clinical	NOUN	O	O	3092
assessment	NOUN	O	O	3092
as	ADP	O	O	3092
well	ADV	O	O	3092
as	ADP	O	O	3092
blinded	VERB	O	O	3092
ratings	NOUN	O	O	3092
of	ADP	O	O	3092
Unified	VERB	O	O	3092
Parkinson	NOUN	O	O	3092
's	AUX	O	O	3092
Disease	NOUN	O	O	3092
Rating	NOUN	O	O	3092
Scale	NOUN	O	O	3092
(	PUNCT	O	O	3092
UPDRS	PROPN	O	O	3092
)	PUNCT	O	O	3092
85	NUM	O	O	3093
percent	NOUN	O	O	3093
of	ADP	O	O	3093
patients	NOUN	O	O	3093
with	ADP	O	O	3093
dyskinesias	PROPN	O	Disease	3093
were	AUX	O	O	3093
relieved	VERB	O	O	3093
of	ADP	O	O	3093
symptoms	NOUN	O	O	3093
,	PUNCT	O	O	3093
regardless	ADV	O	O	3093
of	ADP	O	O	3093
whether	SCONJ	O	O	3093
the	PRON	O	O	3093
pallidotomies	NOUN	O	O	3093
were	AUX	O	O	3093
performed	VERB	O	O	3093
with	ADP	O	O	3093
the	PRON	O	O	3093
Gamma	PROPN	O	O	3093
Knife	NOUN	O	O	3093
or	CCONJ	O	O	3093
radiofrequency	NOUN	O	O	3093
methods	NOUN	O	O	3093
.	PUNCT	O	O	3093
About	ADP	O	O	3094
2/3	NUM	O	O	3094
of	ADP	O	O	3094
the	PRON	O	O	3094
patients	NOUN	O	O	3094
in	ADP	O	O	3094
both	PRON	O	O	3094
Gamma	PROPN	O	O	3094
Knife	NOUN	O	O	3094
and	CCONJ	O	O	3094
radiofrequency	NOUN	O	O	3094
groups	NOUN	O	O	3094
showed	VERB	O	O	3094
improvements	NOUN	O	O	3094
in	ADP	O	O	3094
bradykinesia	NOUN	O	Disease	3094
and	CCONJ	O	O	3094
rigidity	NOUN	O	Disease	3094
,	PUNCT	O	O	3094
although	SCONJ	O	O	3094
when	SCONJ	O	O	3094
considered	VERB	O	O	3094
as	ADP	O	O	3094
a	PRON	O	O	3094
group	NOUN	O	O	3094
neither	ADV	O	O	3094
the	PRON	O	O	3094
Gamma	PROPN	O	O	3094
Knife	NOUN	O	O	3094
nor	CCONJ	O	O	3094
the	PRON	O	O	3094
radiofrequency	NOUN	O	O	3094
group	NOUN	O	O	3094
showed	VERB	O	O	3094
statistically	ADV	O	O	3094
significant	ADJ	O	O	3094
improvements	NOUN	O	O	3094
in	ADP	O	O	3094
UPDRS	PROPN	O	O	3094
scores	NOUN	O	O	3094
.	PUNCT	O	O	3094
One	NUM	O	O	3095
patient	NOUN	O	O	3095
in	ADP	O	O	3095
the	PRON	O	O	3095
Gamma	PROPN	O	O	3095
Knife	NOUN	O	O	3095
group	NOUN	O	O	3095
(	PUNCT	O	O	3095
3.4%	NOUN	O	O	3095
)	PUNCT	O	O	3095
developed	VERB	O	O	3095
a	PRON	O	O	3095
homonymous hemianopsia	NOUN	O	Disease	3095
9	NUM	O	O	3095
months	NOUN	O	O	3095
following	VERB	O	O	3095
treatment	NOUN	O	O	3095
and	CCONJ	O	O	3095
5	NUM	O	O	3095
patients	NOUN	O	O	3095
(	PUNCT	O	O	3095
27.7%	NOUN	O	O	3095
)	PUNCT	O	O	3095
in	ADP	O	O	3095
the	PRON	O	O	3095
radiofrequency	NOUN	O	O	3095
group	NOUN	O	O	3095
became	VERB	O	O	3095
transiently	ADV	O	O	3095
confused	ADJ	O	O	3095
postoperatively	PROPN	O	O	3095
.	PUNCT	O	O	3095
Gamma	PROPN	O	O	3096
Knife	NOUN	O	O	3096
pallidotomy	NOUN	O	O	3096
is	AUX	O	O	3096
as	ADP	O	O	3096
effective	ADJ	O	O	3096
as	ADP	O	O	3096
radiofrequency	NOUN	O	O	3096
pallidotomy	NOUN	O	O	3096
in	ADP	O	O	3096
controlling	VERB	O	O	3096
certain	ADJ	O	O	3096
of	ADP	O	O	3096
the	PRON	O	O	3096
symptoms	NOUN	O	O	3096
of	ADP	O	O	3096
Parkinson	NOUN	O	O	3096
's	AUX	O	O	3096
disease	PROPN	O	O	3096
.	PUNCT	O	O	3096
It	PRON	O	O	3097
may	AUX	O	O	3097
be	AUX	O	O	3097
the	PRON	O	O	3097
only	ADV	O	O	3097
practical	ADJ	O	O	3097
technique	NOUN	O	O	3097
available	ADJ	O	O	3097
in	ADP	O	O	3097
certain	ADJ	O	O	3097
patients	NOUN	O	O	3097
,	PUNCT	O	O	3097
such	ADJ	O	O	3097
as	ADP	O	O	3097
those	PRON	O	O	3097
who	PRON	O	O	3097
take	VERB	O	O	3097
anticoagulants	NOUN	O	O	3097
,	PUNCT	O	O	3097
have	VERB	O	O	3097
bleeding	VERB	O	Disease	3097
diatheses	NOUN	O	O	3097
or	CCONJ	O	O	3097
serious	ADJ	O	O	3097
systemic	ADJ	O	O	3097
medical	ADJ	O	O	3097
illnesses	NOUN	O	O	3097
.	PUNCT	O	O	3097
Neuroleptic malignant syndrome	NOUN	O	Disease	3100
and	CCONJ	O	O	3100
methylphenidate	VERB	O	Chemical	3100
.	PUNCT	O	O	3100
A	PRON	O	O	3101
1-year	NOUN	O	O	3101
-	PUNCT	O	O	3101
old	ADJ	O	O	3101
female	ADJ	O	O	3101
presented	VERB	O	O	3101
with	ADP	O	O	3101
neuroleptic malignant syndrome	NOUN	O	Disease	3101
probably	ADV	O	O	3101
caused	VERB	O	O	3101
by	ADP	O	O	3101
methylphenidate	VERB	O	Chemical	3101
.	PUNCT	O	O	3101
She	PRON	O	O	3102
had	VERB	O	O	3102
defects	NOUN	O	O	3102
in	ADP	O	O	3102
the	PRON	O	O	3102
supratentorial	PROPN	O	O	3102
brain	NOUN	O	O	3102
including	VERB	O	O	3102
the	PRON	O	O	3102
basal	PROPN	O	O	3102
ganglia	NOUN	O	O	3102
and	CCONJ	O	O	3102
the	PRON	O	O	3102
striatum	NOUN	O	O	3102
(	PUNCT	O	O	3102
multicystic	ADJ	O	O	3102
encephalomalacia	VERB	O	O	3102
)	PUNCT	O	O	3102
due	ADJ	O	O	3102
to	PART	O	O	3102
severe	ADJ	O	O	3102
perinatal	ADJ	O	O	3102
hypoxic	ADJ	O	Disease	3102
-	PUNCT	O	O	3102
ischemic	VERB	O	Disease	3102
encephalopathy	NOUN	O	Disease	3102
,	PUNCT	O	O	3102
which	PRON	O	O	3102
was	AUX	O	O	3102
considered	VERB	O	O	3102
to	PART	O	O	3102
be	AUX	O	O	3102
a	PRON	O	O	3102
possible	ADJ	O	O	3102
predisposing	VERB	O	O	3102
factor	NOUN	O	O	3102
causing	VERB	O	O	3102
neuroleptic malignant syndrome	NOUN	O	Disease	3102
.	PUNCT	O	O	3102
However	ADV	O	O	3103
,	PUNCT	O	O	3103
methylphenidate	VERB	O	Chemical	3103
is	AUX	O	O	3103
a	PRON	O	O	3103
dopamine	NOUN	O	Chemical	3103
agonist	NOUN	O	O	3103
via	ADP	O	O	3103
the	PRON	O	O	3103
inhibition	NOUN	O	O	3103
of	ADP	O	O	3103
uptake	NOUN	O	O	3103
of	ADP	O	O	3103
dopamine	NOUN	O	Chemical	3103
,	PUNCT	O	O	3103
and	CCONJ	O	O	3103
therefore	ADV	O	O	3103
dopaminergic	ADJ	O	O	3103
systems	NOUN	O	O	3103
in	ADP	O	O	3103
the	PRON	O	O	3103
brainstem	NOUN	O	O	3103
(	PUNCT	O	O	3103
mainly	ADV	O	O	3103
the	PRON	O	O	3103
midbrain	NOUN	O	O	3103
)	PUNCT	O	O	3103
and	CCONJ	O	O	3103
the	PRON	O	O	3103
spinal	NOUN	O	O	3103
cord	NOUN	O	O	3103
were	AUX	O	O	3103
unlikely	ADJ	O	O	3103
to	PART	O	O	3103
participate	VERB	O	O	3103
in	ADP	O	O	3103
the	PRON	O	O	3103
onset	VERB	O	O	3103
of	ADP	O	O	3103
this	PRON	O	O	3103
syndrome	NOUN	O	O	3103
.	PUNCT	O	O	3103
A	PRON	O	O	3104
relative	ADJ	O	O	3104
gamma	PROPN	O	O	3104
-	PUNCT	O	O	3104
aminobutyric	PROPN	O	O	3104
acid	PROPN	O	O	3104
-	PUNCT	O	O	3104
ergic	NOUN	O	O	3104
deficiency	NOUN	O	O	3104
might	AUX	O	O	3104
occur	VERB	O	O	3104
because	SCONJ	O	O	3104
diazepam	NOUN	O	Chemical	3104
,	PUNCT	O	O	3104
a	PRON	O	O	3104
gamma	PROPN	O	O	3104
-	PUNCT	O	O	3104
aminobutyric	PROPN	O	O	3104
acid	PROPN	O	O	3104
-	PUNCT	O	O	3104
mimetic	NOUN	O	O	3104
agent	NOUN	O	O	3104
,	PUNCT	O	O	3104
was	AUX	O	O	3104
strikingly	ADV	O	O	3104
effective	ADJ	O	O	3104
.	PUNCT	O	O	3104
This	PRON	O	O	3105
is	AUX	O	O	3105
the	PRON	O	O	3105
first	ADV	O	O	3105
reported	VERB	O	O	3105
patient	NOUN	O	O	3105
with	ADP	O	O	3105
neuroleptic malignant syndrome	NOUN	O	Disease	3105
probably	ADV	O	O	3105
caused	VERB	O	O	3105
by	ADP	O	O	3105
methylphenidate	VERB	O	Chemical	3105
.	PUNCT	O	O	3105
Differential	ADJ	O	O	3108
effects	NOUN	O	O	3108
of	ADP	O	O	3108
17alpha	NUM	O	O	3108
-	PUNCT	O	O	3108
ethinylestradiol	NOUN	O	Chemical	3108
on	ADP	O	O	3108
the	PRON	O	O	3108
neutral	ADJ	O	O	3108
and	CCONJ	O	O	3108
acidic	ADJ	O	O	3108
pathways	NOUN	O	O	3108
of	ADP	O	O	3108
bile	NOUN	O	O	3108
salt	NOUN	O	O	3108
synthesis	NOUN	O	O	3108
in	ADP	O	O	3108
the	PRON	O	O	3108
rat	NOUN	O	O	3108
.	PUNCT	O	O	3108
Effects	NOUN	O	O	3109
of	ADP	O	O	3109
17alpha	NUM	O	O	3109
-	PUNCT	O	O	3109
ethinylestradiol	NOUN	O	Chemical	3109
(	PUNCT	O	O	3109
EE	NOUN	O	Chemical	3109
)	PUNCT	O	O	3109
on	ADP	O	O	3109
the	PRON	O	O	3109
neutral	ADJ	O	O	3109
and	CCONJ	O	O	3109
acidic	ADJ	O	O	3109
biosynthetic	ADJ	O	O	3109
pathways	NOUN	O	O	3109
of	ADP	O	O	3109
bile	NOUN	O	O	3109
salt	NOUN	O	O	3109
(	PUNCT	O	O	3109
BS	PROPN	O	O	3109
)	PUNCT	O	O	3109
synthesis	NOUN	O	O	3109
were	AUX	O	O	3109
evaluated	VERB	O	O	3109
in	ADP	O	O	3109
rats	NOUN	O	O	3109
with	ADP	O	O	3109
an	PRON	O	O	3109
intact	ADJ	O	O	3109
enterohepatic	VERB	O	O	3109
circulation	NOUN	O	O	3109
and	CCONJ	O	O	3109
in	ADP	O	O	3109
rats	NOUN	O	O	3109
with	ADP	O	O	3109
long	ADV	O	O	3109
-	PUNCT	O	O	3109
term	NOUN	O	O	3109
bile	NOUN	O	O	3109
diversion	NOUN	O	O	3109
to	PART	O	O	3109
induce	VERB	O	O	3109
BS	PROPN	O	O	3109
synthesis	NOUN	O	O	3109
.	PUNCT	O	O	3109
For	ADP	O	O	3110
this	PRON	O	O	3110
purpose	NOUN	O	O	3110
,	PUNCT	O	O	3110
bile	NOUN	O	O	3110
salt	NOUN	O	O	3110
pool	NOUN	O	O	3110
composition	NOUN	O	O	3110
,	PUNCT	O	O	3110
synthesis	NOUN	O	O	3110
of	ADP	O	O	3110
individual	ADJ	O	O	3110
BS	PROPN	O	O	3110
in	ADP	O	O	3110
vivo	VERB	O	O	3110
,	PUNCT	O	O	3110
hepatic	ADJ	O	O	3110
activities	NOUN	O	O	3110
,	PUNCT	O	O	3110
and	CCONJ	O	O	3110
expression	NOUN	O	O	3110
levels	NOUN	O	O	3110
of	ADP	O	O	3110
cholesterol	NOUN	O	Chemical	3110
7alpha	NUM	O	O	3110
-	PUNCT	O	O	3110
hydroxylase	NOUN	O	O	3110
(	PUNCT	O	O	3110
CYP7A	NOUN	O	O	3110
)	PUNCT	O	O	3110
,	PUNCT	O	O	3110
and	CCONJ	O	O	3110
sterol	NOUN	O	O	3110
27-hydroxylase	NOUN	O	O	3110
(	PUNCT	O	O	3110
CYP27	NOUN	O	O	3110
)	PUNCT	O	O	3110
,	PUNCT	O	O	3110
as	ADP	O	O	3110
well	ADV	O	O	3110
as	ADP	O	O	3110
of	ADP	O	O	3110
other	ADJ	O	O	3110
enzymes	NOUN	O	O	3110
involved	VERB	O	O	3110
in	ADP	O	O	3110
BS	PROPN	O	O	3110
synthesis	NOUN	O	O	3110
,	PUNCT	O	O	3110
were	AUX	O	O	3110
analyzed	VERB	O	O	3110
in	ADP	O	O	3110
rats	NOUN	O	O	3110
treated	VERB	O	O	3110
with	ADP	O	O	3110
EE	NOUN	O	Chemical	3110
(	PUNCT	O	O	3110
5	NUM	O	O	3110
mg	VERB	O	O	3110
/	PUNCT	O	O	3110
kg	VERB	O	O	3110
,	PUNCT	O	O	3110
3	X	O	O	3110
days	NOUN	O	O	3110
)	PUNCT	O	O	3110
or	CCONJ	O	O	3110
its	PRON	O	O	3110
vehicle	NOUN	O	O	3110
.	PUNCT	O	O	3110
BS	PROPN	O	O	3111
pool	NOUN	O	O	3111
size	NOUN	O	O	3111
was	AUX	O	O	3111
decreased	VERB	O	O	3111
by	ADP	O	O	3111
27%	NOUN	O	O	3111
but	CCONJ	O	O	3111
total	ADJ	O	O	3111
BS	PROPN	O	O	3111
synthesis	NOUN	O	O	3111
was	AUX	O	O	3111
not	PART	O	O	3111
affected	VERB	O	O	3111
by	ADP	O	O	3111
EE	NOUN	O	Chemical	3111
in	ADP	O	O	3111
intact	ADJ	O	O	3111
rats	NOUN	O	O	3111
.	PUNCT	O	O	3111
Synthesis	NOUN	O	O	3112
of	ADP	O	O	3112
cholate	PROPN	O	O	3112
was	AUX	O	O	3112
reduced	VERB	O	O	3112
by	ADP	O	O	3112
68%	NOUN	O	O	3112
in	ADP	O	O	3112
EE	NOUN	O	Chemical	3112
-	PUNCT	O	O	3112
treated	VERB	O	O	3112
rats	NOUN	O	O	3112
,	PUNCT	O	O	3112
while	SCONJ	O	O	3112
that	SCONJ	O	O	3112
of	ADP	O	O	3112
chenodeoxycholate	PROPN	O	O	3112
was	AUX	O	O	3112
increased	VERB	O	O	3112
by	ADP	O	O	3112
60%	NOUN	O	O	3112
.	PUNCT	O	O	3112
The	PRON	O	O	3113
recently	ADV	O	O	3113
identified	VERB	O	O	3113
Delta22-isomer	NOUN	O	O	3113
of	ADP	O	O	3113
beta	NOUN	O	O	3113
-	PUNCT	O	O	3113
muricholate	ADV	O	O	3113
contributed	VERB	O	O	3113
for	ADP	O	O	3113
5.4%	NOUN	O	O	3113
and	CCONJ	O	O	3113
18.3	NUM	O	O	3113
%	INTJ	O	O	3113
(	PUNCT	O	O	3113
P	NOUN	O	Chemical	3113
<	X	O	O	3113
0.01	NUM	O	O	3113
)	PUNCT	O	O	3113
to	PART	O	O	3113
the	PRON	O	O	3113
pool	NOUN	O	O	3113
in	ADP	O	O	3113
control	VERB	O	O	3113
and	CCONJ	O	O	3113
EE	NOUN	O	Chemical	3113
-	PUNCT	O	O	3113
treated	VERB	O	O	3113
rats	NOUN	O	O	3113
,	PUNCT	O	O	3113
respectively	ADV	O	O	3113
,	PUNCT	O	O	3113
but	CCONJ	O	O	3113
could	AUX	O	O	3113
not	PART	O	O	3113
be	AUX	O	O	3113
detected	VERB	O	O	3113
in	ADP	O	O	3113
bile	NOUN	O	O	3113
after	ADP	O	O	3113
exhaustion	NOUN	O	O	3113
of	ADP	O	O	3113
the	PRON	O	O	3113
pool	NOUN	O	O	3113
.	PUNCT	O	O	3113
A	PRON	O	O	3114
clear	ADJ	O	O	3114
reduction	NOUN	O	O	3114
of	ADP	O	O	3114
BS	PROPN	O	O	3114
synthesis	NOUN	O	O	3114
was	AUX	O	O	3114
found	VERB	O	O	3114
in	ADP	O	O	3114
bile	NOUN	O	O	3114
-	PUNCT	O	O	3114
diverted	VERB	O	O	3114
rats	NOUN	O	O	3114
treated	VERB	O	O	3114
with	ADP	O	O	3114
EE	NOUN	O	Chemical	3114
,	PUNCT	O	O	3114
yet	ADV	O	O	3114
biliary	ADJ	O	O	3114
BS	PROPN	O	O	3114
composition	NOUN	O	O	3114
was	AUX	O	O	3114
only	ADV	O	O	3114
minimally	ADV	O	O	3114
affected	VERB	O	O	3114
.	PUNCT	O	O	3114
Activity	NOUN	O	O	3115
of	ADP	O	O	3115
CYP7A	NOUN	O	O	3115
was	AUX	O	O	3115
decreased	VERB	O	O	3115
by	ADP	O	O	3115
EE	NOUN	O	Chemical	3115
in	ADP	O	O	3115
both	PRON	O	O	3115
intact	ADJ	O	O	3115
and	CCONJ	O	O	3115
bile	NOUN	O	O	3115
-	PUNCT	O	O	3115
diverted	VERB	O	O	3115
rats	NOUN	O	O	3115
,	PUNCT	O	O	3115
whereas	SCONJ	O	O	3115
the	PRON	O	O	3115
activity	NOUN	O	O	3115
of	ADP	O	O	3115
the	PRON	O	O	3115
CYP27	NOUN	O	O	3115
was	AUX	O	O	3115
not	PART	O	O	3115
affected	VERB	O	O	3115
.	PUNCT	O	O	3115
Hepatic	ADJ	O	O	3116
mRNA	PROPN	O	O	3116
levels	NOUN	O	O	3116
of	ADP	O	O	3116
CYP7A	NOUN	O	O	3116
were	AUX	O	O	3116
significantly	ADV	O	O	3116
reduced	VERB	O	O	3116
by	ADP	O	O	3116
EE	NOUN	O	Chemical	3116
in	ADP	O	O	3116
bile	NOUN	O	O	3116
-	PUNCT	O	O	3116
diverted	VERB	O	O	3116
rats	NOUN	O	O	3116
only	ADV	O	O	3116
;	PUNCT	O	O	3116
CYP27	NOUN	O	O	3116
mRNA	PROPN	O	O	3116
levels	NOUN	O	O	3116
were	AUX	O	O	3116
not	PART	O	O	3116
affected	VERB	O	O	3116
by	ADP	O	O	3116
EE	NOUN	O	Chemical	3116
.	PUNCT	O	O	3116
In	ADP	O	O	3117
addition	NOUN	O	O	3117
,	PUNCT	O	O	3117
mRNA	PROPN	O	O	3117
levels	NOUN	O	O	3117
of	ADP	O	O	3117
sterol	NOUN	O	O	3117
12alpha	NUM	O	O	3117
-	PUNCT	O	O	3117
hydroxylase	NOUN	O	O	3117
and	CCONJ	O	O	3117
lithocholate	NOUN	O	O	3117
6beta	NUM	O	O	3118
-	PUNCT	O	O	3118
hydroxylase	NOUN	O	O	3118
were	AUX	O	O	3118
increased	VERB	O	O	3118
by	ADP	O	O	3118
bile	NOUN	O	O	3118
diversion	NOUN	O	O	3118
and	CCONJ	O	O	3118
suppressed	VERB	O	O	3118
by	ADP	O	O	3118
EE	NOUN	O	Chemical	3118
.	PUNCT	O	O	3118
This	PRON	O	O	3119
study	VERB	O	O	3119
shows	VERB	O	O	3119
that	SCONJ	O	O	3119
17alpha	NUM	O	O	3119
-	PUNCT	O	O	3119
ethinylestradiol	NOUN	O	Chemical	3119
(	PUNCT	O	O	3119
EE)-induced	VERB	O	O	3119
intrahepatic	ADJ	O	O	3119
cholestasis	NOUN	O	Disease	3119
in	ADP	O	O	3119
rats	NOUN	O	O	3119
is	AUX	O	O	3119
associated	VERB	O	O	3119
with	ADP	O	O	3119
selective	ADJ	O	O	3119
inhibition	NOUN	O	O	3119
of	ADP	O	O	3119
the	PRON	O	O	3119
neutral	ADJ	O	O	3119
pathway	NOUN	O	O	3119
of	ADP	O	O	3119
bile	NOUN	O	O	3119
salt	NOUN	O	O	3119
(	PUNCT	O	O	3119
BS	PROPN	O	O	3119
)	PUNCT	O	O	3119
synthesis	NOUN	O	O	3119
.	PUNCT	O	O	3119
Simultaneous	ADJ	O	O	3120
impairment	NOUN	O	O	3120
of	ADP	O	O	3120
other	ADJ	O	O	3120
enzymes	NOUN	O	O	3120
in	ADP	O	O	3120
the	PRON	O	O	3120
BS	PROPN	O	O	3120
biosynthetic	ADJ	O	O	3120
pathways	NOUN	O	O	3120
may	AUX	O	O	3120
contribute	VERB	O	O	3120
to	PART	O	O	3120
overall	ADV	O	O	3120
effects	NOUN	O	O	3120
of	ADP	O	O	3120
EE	NOUN	O	Chemical	3120
on	ADP	O	O	3120
BS	PROPN	O	O	3120
synthesis	NOUN	O	O	3120
.	PUNCT	O	O	3120
Glibenclamide	ADP	O	O	3123
-	PUNCT	O	O	3123
sensitive	ADJ	O	O	3123
hypotension	NOUN	O	Disease	3123
produced	VERB	O	O	3123
by	ADP	O	O	3123
helodermin	NOUN	O	O	3123
assessed	VERB	O	O	3123
in	ADP	O	O	3123
the	PRON	O	O	3123
rat	NOUN	O	O	3123
.	PUNCT	O	O	3123
The	PRON	O	O	3124
effects	NOUN	O	O	3124
of	ADP	O	O	3124
helodermin	NOUN	O	O	3124
,	PUNCT	O	O	3124
a	PRON	O	O	3124
basic	ADJ	O	O	3124
35-amino acid	NOUN	O	O	3124
peptide	NOUN	O	O	3124
isolated	VERB	O	O	3124
from	ADP	O	O	3124
the	PRON	O	O	3124
venom	NOUN	O	O	3124
of	ADP	O	O	3124
a	PRON	O	O	3124
lizard	NOUN	O	O	3124
salivary	PROPN	O	O	3124
gland	NOUN	O	O	3124
,	PUNCT	O	O	3124
on	ADP	O	O	3124
arterial	ADJ	O	O	3124
blood	NOUN	O	O	3124
pressure	NOUN	O	O	3124
and	CCONJ	O	O	3124
heart	NOUN	O	O	3124
rate	NOUN	O	O	3124
were	AUX	O	O	3124
examined	VERB	O	O	3124
in	ADP	O	O	3124
the	PRON	O	O	3124
rat	NOUN	O	O	3124
,	PUNCT	O	O	3124
focusing	VERB	O	O	3124
on	ADP	O	O	3124
the	PRON	O	O	3124
possibility	NOUN	O	O	3124
that	SCONJ	O	O	3124
activation	NOUN	O	O	3124
of	ADP	O	O	3124
ATP	PROPN	O	Chemical	3124
sensitive	ADJ	O	O	3124
K+	NOUN	O	O	3124
(	PUNCT	O	O	3124
K(ATP	ADP	O	O	3124
)	PUNCT	O	O	3124
)	PUNCT	O	O	3124
channels	NOUN	O	O	3124
is	AUX	O	O	3124
involved	VERB	O	O	3124
in	ADP	O	O	3124
the	PRON	O	O	3124
responses	NOUN	O	O	3124
.	PUNCT	O	O	3124
Helodermin	PROPN	O	O	3125
produced	VERB	O	O	3125
hypotension	NOUN	O	Disease	3125
in	ADP	O	O	3125
a	PRON	O	O	3125
dose	NOUN	O	O	3125
-	PUNCT	O	O	3125
dependent	ADJ	O	O	3125
manner	VERB	O	O	3125
with	ADP	O	O	3125
approximately	ADV	O	O	3125
similar	ADJ	O	O	3125
potency	NOUN	O	O	3125
and	CCONJ	O	O	3125
duration	NOUN	O	O	3125
to	PART	O	O	3125
VIP	VERB	O	O	3125
.	PUNCT	O	O	3125
Hypotension	NOUN	O	Disease	3126
induced	VERB	O	O	3126
by	ADP	O	O	3126
both	PRON	O	O	3126
peptides	NOUN	O	O	3126
was	AUX	O	O	3126
significantly	ADV	O	O	3126
attenuated	VERB	O	O	3126
by	ADP	O	O	3126
glibenclamide	ADP	O	O	3126
,	PUNCT	O	O	3126
which	PRON	O	O	3126
abolished	VERB	O	O	3126
a	PRON	O	O	3126
levcromakalim	NOUN	O	O	3126
-	PUNCT	O	O	3126
produced	VERB	O	O	3126
decrease	VERB	O	O	3126
in	ADP	O	O	3126
arterial	ADJ	O	O	3126
blood	NOUN	O	O	3126
pressure	NOUN	O	O	3126
.	PUNCT	O	O	3126
Oxyhemoglobin	PROPN	O	O	3127
did	VERB	O	O	3127
not	PART	O	O	3127
affect	VERB	O	O	3127
helodermin	NOUN	O	O	3127
-	PUNCT	O	O	3127
induced	VERB	O	O	3127
hypotension	NOUN	O	Disease	3127
,	PUNCT	O	O	3127
whereas	SCONJ	O	O	3127
it	PRON	O	O	3127
shortened	VERB	O	O	3127
the	PRON	O	O	3127
duration	NOUN	O	O	3127
of	ADP	O	O	3127
acetylcholine	NOUN	O	Chemical	3127
(	PUNCT	O	O	3127
ACh)-produced	VERB	O	O	3127
hypotension	NOUN	O	Disease	3127
.	PUNCT	O	O	3127
These	PRON	O	O	3128
findings	NOUN	O	O	3128
suggest	VERB	O	O	3128
that	SCONJ	O	O	3128
helodermin	NOUN	O	O	3128
-	PUNCT	O	O	3128
produced	VERB	O	O	3128
hypotension	NOUN	O	Disease	3128
is	AUX	O	O	3128
partly	ADV	O	O	3128
attributable	ADJ	O	O	3128
to	PART	O	O	3128
the	PRON	O	O	3128
activation	NOUN	O	O	3128
of	ADP	O	O	3128
glibenclamide	ADP	O	O	3128
-	PUNCT	O	O	3128
sensitive	ADJ	O	O	3128
K+	NOUN	O	O	3128
channels	NOUN	O	O	3128
(	PUNCT	O	O	3128
K(ATP	ADP	O	O	3128
)	PUNCT	O	O	3128
channels	NOUN	O	O	3128
)	PUNCT	O	O	3128
,	PUNCT	O	O	3128
which	PRON	O	O	3128
presumably	ADV	O	O	3128
exist	VERB	O	O	3128
on	ADP	O	O	3128
arterial	ADJ	O	O	3128
smooth	VERB	O	O	3128
muscle	NOUN	O	O	3128
cells	NOUN	O	O	3128
.	PUNCT	O	O	3128
EDRF	NOUN	O	O	3129
(	PUNCT	O	O	3129
endothelium	NOUN	O	O	3129
-	PUNCT	O	O	3129
derived	VERB	O	O	3129
relaxing	VERB	O	O	3129
factor)/nitric oxide	NOUN	O	O	3129
does	VERB	O	O	3129
not	PART	O	O	3129
seem	VERB	O	O	3129
to	PART	O	O	3129
play	VERB	O	O	3129
an	PRON	O	O	3129
important	ADJ	O	O	3129
role	NOUN	O	O	3129
in	ADP	O	O	3129
the	PRON	O	O	3129
peptide	NOUN	O	O	3129
-	PUNCT	O	O	3129
produced	VERB	O	O	3129
hypotension	NOUN	O	Disease	3129
.	PUNCT	O	O	3129
Long	ADV	O	O	3132
-	PUNCT	O	O	3132
term	NOUN	O	O	3132
efficacy	NOUN	O	O	3132
and	CCONJ	O	O	3132
adverse	ADJ	O	O	3132
event	NOUN	O	O	3132
of	ADP	O	O	3132
nifedipine	PROPN	O	Chemical	3132
sustained	VERB	O	O	3132
-	PUNCT	O	O	3132
release	NOUN	O	O	3132
tablets	NOUN	O	O	3132
for	ADP	O	O	3132
cyclosporin A	PRON	O	Chemical	3132
-	PUNCT	O	O	3132
induced	VERB	O	O	3132
hypertension	NOUN	O	Disease	3132
in	ADP	O	O	3132
patients	NOUN	O	O	3132
with	ADP	O	O	3132
psoriasis	NOUN	O	Disease	3132
.	PUNCT	O	O	3132
Thirteen	NUM	O	O	3133
psoriatic	NOUN	O	O	3133
patients	NOUN	O	O	3133
with	ADP	O	O	3133
hypertension	NOUN	O	Disease	3133
during	ADP	O	O	3133
the	PRON	O	O	3133
course	NOUN	O	O	3133
of	ADP	O	O	3133
cyclosporin A	PRON	O	Chemical	3133
therapy	NOUN	O	O	3133
were	AUX	O	O	3133
treated	VERB	O	O	3133
for	ADP	O	O	3133
25	NUM	O	O	3133
months	NOUN	O	O	3133
with	ADP	O	O	3133
a	PRON	O	O	3133
calcium	NOUN	O	Chemical	3133
channel	PROPN	O	O	3133
blocker	NOUN	O	O	3133
,	PUNCT	O	O	3133
sustained	VERB	O	O	3133
-	PUNCT	O	O	3133
release	NOUN	O	O	3133
nifedipine	PROPN	O	Chemical	3133
,	PUNCT	O	O	3133
to	PART	O	O	3133
study	VERB	O	O	3133
the	PRON	O	O	3133
clinical	ADJ	O	O	3133
antihypertensive	ADV	O	O	3133
effects	NOUN	O	O	3133
and	CCONJ	O	O	3133
adverse	ADJ	O	O	3133
events	NOUN	O	O	3133
during	ADP	O	O	3133
treatment	NOUN	O	O	3133
with	ADP	O	O	3133
both	PRON	O	O	3133
drugs	NOUN	O	O	3133
.	PUNCT	O	O	3133
Seven	NUM	O	O	3134
of	ADP	O	O	3134
the	PRON	O	O	3134
13	NUM	O	O	3134
patients	NOUN	O	O	3134
had	VERB	O	O	3134
exhibited	VERB	O	O	3134
a	PRON	O	O	3134
subclinical	ADJ	O	O	3134
hypertensive	ADJ	O	Disease	3134
state	NOUN	O	O	3134
before	ADP	O	O	3134
cyclosporin A	PRON	O	Chemical	3134
therapy	NOUN	O	O	3134
.	PUNCT	O	O	3134
Both	PRON	O	O	3135
systolic	ADV	O	O	3135
and	CCONJ	O	O	3135
diastolic	ADV	O	O	3135
blood	NOUN	O	O	3135
pressures	NOUN	O	O	3135
of	ADP	O	O	3135
these	PRON	O	O	3135
13	NUM	O	O	3135
patients	NOUN	O	O	3135
were	AUX	O	O	3135
decreased	VERB	O	O	3135
significantly	ADV	O	O	3135
after	ADP	O	O	3135
4	NUM	O	O	3135
weeks	NOUN	O	O	3135
of	ADP	O	O	3135
nifedipine	PROPN	O	Chemical	3135
therapy	NOUN	O	O	3135
,	PUNCT	O	O	3135
and	CCONJ	O	O	3135
blood	NOUN	O	O	3135
pressure	NOUN	O	O	3135
was	AUX	O	O	3135
maintained	VERB	O	O	3135
within	ADP	O	O	3135
the	PRON	O	O	3135
normal	ADJ	O	O	3135
range	VERB	O	O	3135
thereafter	ADV	O	O	3135
for	ADP	O	O	3135
25	NUM	O	O	3135
months	NOUN	O	O	3135
.	PUNCT	O	O	3135
The	PRON	O	O	3136
adverse	ADJ	O	O	3136
events	NOUN	O	O	3136
during	ADP	O	O	3136
combined	VERB	O	O	3136
therapy	NOUN	O	O	3136
with	ADP	O	O	3136
cyclosporin A	PRON	O	Chemical	3136
and	CCONJ	O	O	3136
nifedipine	PROPN	O	Chemical	3136
included	VERB	O	O	3136
an	PRON	O	O	3136
increase	VERB	O	O	3136
in	ADP	O	O	3136
blood	NOUN	O	O	3136
urea nitrogen	NOUN	O	Chemical	3136
levels	NOUN	O	O	3136
in	ADP	O	O	3136
9	NUM	O	O	3136
of	ADP	O	O	3136
the	PRON	O	O	3136
13	NUM	O	O	3136
patients	NOUN	O	O	3136
and	CCONJ	O	O	3136
development	NOUN	O	O	3136
of	ADP	O	O	3136
gingival	PROPN	O	O	3136
hyperplasia	NOUN	O	Disease	3136
in	ADP	O	O	3136
2	X	O	O	3136
of	ADP	O	O	3136
the	PRON	O	O	3136
13	NUM	O	O	3136
patients	NOUN	O	O	3136
.	PUNCT	O	O	3136
Our	PRON	O	O	3137
findings	NOUN	O	O	3137
indicate	VERB	O	O	3137
that	SCONJ	O	O	3137
sustained	VERB	O	O	3137
-	PUNCT	O	O	3137
release	NOUN	O	O	3137
nifedipine	PROPN	O	Chemical	3137
is	AUX	O	O	3137
useful	ADJ	O	O	3137
for	ADP	O	O	3137
hypertensive	ADJ	O	Disease	3137
psoriatic	NOUN	O	O	3137
patients	NOUN	O	O	3137
under	ADP	O	O	3137
long	ADV	O	O	3137
-	PUNCT	O	O	3137
term	NOUN	O	O	3137
treatment	NOUN	O	O	3137
with	ADP	O	O	3137
cyclosporin A	PRON	O	Chemical	3137
,	PUNCT	O	O	3137
but	CCONJ	O	O	3137
that	SCONJ	O	O	3137
these	PRON	O	O	3137
patients	NOUN	O	O	3137
should	AUX	O	O	3137
be	AUX	O	O	3137
monitored	VERB	O	O	3137
for	ADP	O	O	3137
gingival	PROPN	O	O	3137
hyperplasia	NOUN	O	Disease	3137
.	PUNCT	O	O	3137
Torsade de pointes	VERB	O	Disease	3140
ventricular tachycardia	NOUN	O	Disease	3140
during	ADP	O	O	3140
low	ADJ	O	O	3140
dose	NOUN	O	O	3140
intermittent	ADJ	O	O	3140
dobutamine	NOUN	O	Chemical	3140
treatment	NOUN	O	O	3140
in	ADP	O	O	3140
a	PRON	O	O	3140
patient	NOUN	O	O	3140
with	ADP	O	O	3140
dilated	ADJ	O	O	3140
cardiomyopathy	ADJ	O	Disease	3140
and	CCONJ	O	O	3140
congestive	ADJ	O	O	3140
heart failure	NOUN	O	Disease	3140
.	PUNCT	O	O	3140
The	PRON	O	O	3141
authors	NOUN	O	O	3141
describe	VERB	O	O	3141
the	PRON	O	O	3141
case	NOUN	O	O	3141
of	ADP	O	O	3141
a	PRON	O	O	3141
56-year	NOUN	O	O	3141
-	PUNCT	O	O	3141
old	ADJ	O	O	3141
woman	NOUN	O	O	3141
with	ADP	O	O	3141
chronic	ADJ	O	O	3141
,	PUNCT	O	O	3141
severe	ADJ	O	O	3141
heart failure	NOUN	O	Disease	3141
secondary	ADJ	O	O	3141
to	PART	O	O	3141
dilated	ADJ	O	O	3141
cardiomyopathy	ADJ	O	Disease	3141
and	CCONJ	O	O	3141
absence	NOUN	O	O	3141
of	ADP	O	O	3141
significant	ADJ	O	O	3141
ventricular arrhythmias	NOUN	O	Disease	3141
who	PRON	O	O	3141
developed	VERB	O	O	3141
QT prolongation	NOUN	O	Disease	3141
and	CCONJ	O	O	3141
torsade de pointes	NOUN	O	Disease	3141
ventricular tachycardia	NOUN	O	Disease	3141
during	ADP	O	O	3141
one	NUM	O	O	3141
cycle	PROPN	O	O	3141
of	ADP	O	O	3141
intermittent	ADJ	O	O	3141
low	ADJ	O	O	3141
dose	NOUN	O	O	3141
(	PUNCT	O	O	3141
2.5	NUM	O	O	3141
mcg	PROPN	O	O	3141
/	PUNCT	O	O	3141
kg	VERB	O	O	3141
per	ADP	O	O	3141
min	NOUN	O	O	3141
)	PUNCT	O	O	3141
dobutamine	NOUN	O	Chemical	3142
.	PUNCT	O	O	3142
This	PRON	O	O	3143
report	VERB	O	O	3143
of	ADP	O	O	3143
torsade de pointes	NOUN	O	Disease	3143
ventricular tachycardia	NOUN	O	Disease	3143
during	ADP	O	O	3143
intermittent	ADJ	O	O	3143
dobutamine	NOUN	O	Chemical	3143
supports	VERB	O	O	3143
the	PRON	O	O	3143
hypothesis	NOUN	O	O	3143
that	SCONJ	O	O	3143
unpredictable	ADJ	O	O	3143
fatal	ADJ	O	O	3143
arrhythmias	VERB	O	Disease	3143
may	AUX	O	O	3143
occur	VERB	O	O	3143
even	ADV	O	O	3143
with	ADP	O	O	3143
low	ADJ	O	O	3143
doses	NOUN	O	O	3143
and	CCONJ	O	O	3143
in	ADP	O	O	3143
patients	NOUN	O	O	3143
with	ADP	O	O	3143
no	PRON	O	O	3143
history	NOUN	O	O	3143
of	ADP	O	O	3143
significant	ADJ	O	O	3143
rhythm	VERB	O	O	3143
disturbances	NOUN	O	O	3143
.	PUNCT	O	O	3143
The	PRON	O	O	3144
mechanisms	NOUN	O	O	3144
of	ADP	O	O	3144
proarrhythmic	ADJ	O	O	3144
effects	NOUN	O	O	3144
of	ADP	O	O	3144
Dubutamine	PROPN	O	O	3144
are	AUX	O	O	3144
discussed	VERB	O	O	3144
.	PUNCT	O	O	3144
Positive	PROPN	O	O	3147
skin	NOUN	O	O	3147
tests	VERB	O	O	3147
in	ADP	O	O	3147
late	ADV	O	O	3147
reactions	NOUN	O	O	3147
to	PART	O	O	3147
radiographic	ADJ	O	O	3147
contrast media	NOUN	O	Chemical	3147
.	PUNCT	O	O	3147
In	ADP	O	O	3148
the	PRON	O	O	3148
last	VERB	O	O	3148
few	ADJ	O	O	3148
years	NOUN	O	O	3148
delayed	VERB	O	O	3148
reactions	NOUN	O	O	3148
several	ADJ	O	O	3148
hours	NOUN	O	O	3148
after	ADP	O	O	3148
the	PRON	O	O	3148
injection	NOUN	O	O	3148
of	ADP	O	O	3148
radiographic	ADJ	O	O	3148
and	CCONJ	O	O	3148
contrast	NOUN	O	O	3148
materials	NOUN	O	O	3148
(	PUNCT	O	O	3148
PRC	PROPN	O	O	3148
)	PUNCT	O	O	3148
have	VERB	O	O	3148
been	AUX	O	O	3148
described	VERB	O	O	3148
with	ADP	O	O	3148
increasing	VERB	O	O	3148
frequency	NOUN	O	O	3148
.	PUNCT	O	O	3148
The	PRON	O	O	3149
authors	NOUN	O	O	3149
report	VERB	O	O	3149
two	NUM	O	O	3149
observations	NOUN	O	O	3149
on	ADP	O	O	3149
patients	NOUN	O	O	3149
with	ADP	O	O	3149
delayed	VERB	O	O	3149
reactions	NOUN	O	O	3149
in	ADP	O	O	3149
whom	PRON	O	O	3149
intradermoreactions	NOUN	O	O	3149
(	PUNCT	O	O	3149
IDR	PROPN	O	O	3149
)	PUNCT	O	O	3149
and	CCONJ	O	O	3149
patch	VERB	O	O	3149
tests	VERB	O	O	3149
to	PART	O	O	3149
a	PRON	O	O	3149
series	PROPN	O	O	3149
of	ADP	O	O	3149
ionic	NOUN	O	O	3149
and	CCONJ	O	O	3149
non	ADJ	O	O	3149
ionic	NOUN	O	O	3149
PRC	PROPN	O	O	3149
were	AUX	O	O	3149
studied	VERB	O	O	3149
.	PUNCT	O	O	3149
After	ADP	O	O	3150
angiography	NOUN	O	O	3150
by	ADP	O	O	3150
the	PRON	O	O	3150
venous	ADJ	O	O	3150
route	VERB	O	O	3150
in	ADP	O	O	3150
patient	NOUN	O	O	3150
n	CCONJ	O	O	3150
degree	PROPN	O	O	3150
1	X	O	O	3150
a	PRON	O	O	3150
biphasic	ADJ	O	O	3150
reaction	NOUN	O	O	3150
with	ADP	O	O	3150
an	PRON	O	O	3150
immediate	ADJ	O	O	3150
reaction	NOUN	O	O	3150
(	PUNCT	O	O	3150
dyspnea	ADJ	O	O	3150
,	PUNCT	O	O	3150
loss	NOUN	O	O	3150
of	ADP	O	O	3150
consciousness	NOUN	O	O	3150
)	PUNCT	O	O	3150
and	CCONJ	O	O	3150
delayed	VERB	O	O	3150
macro	NOUN	O	O	3150
-	PUNCT	O	O	3150
papular	ADJ	O	O	3150
rash	ADJ	O	Disease	3150
appeared	VERB	O	O	3150
,	PUNCT	O	O	3150
whilst	SCONJ	O	O	3150
patient	NOUN	O	O	3150
n	CCONJ	O	O	3150
degree	PROPN	O	O	3150
2	X	O	O	3150
developed	VERB	O	O	3150
a	PRON	O	O	3150
generalised	VERB	O	O	3150
sensation	NOUN	O	O	3150
of	ADP	O	O	3150
heat	NOUN	O	O	3150
,	PUNCT	O	O	3150
persistent	ADJ	O	O	3150
pain	NOUN	O	Disease	3150
at	ADP	O	O	3150
the	PRON	O	O	3150
site	NOUN	O	O	3150
of	ADP	O	O	3150
injection	NOUN	O	O	3150
immediately	ADV	O	O	3150
and	CCONJ	O	O	3150
a	PRON	O	O	3150
generalised	VERB	O	O	3150
macro	NOUN	O	O	3150
-	PUNCT	O	O	3150
papular	ADJ	O	O	3150
reaction	NOUN	O	O	3150
after	ADP	O	O	3150
24	NUM	O	O	3150
hours	NOUN	O	O	3150
.	PUNCT	O	O	3150
The	PRON	O	O	3151
skin	NOUN	O	O	3151
tests	VERB	O	O	3151
revealed	VERB	O	O	3151
positive	ADJ	O	O	3151
delayed	VERB	O	O	3151
reactions	NOUN	O	O	3151
of	ADP	O	O	3151
24	NUM	O	O	3151
hours	NOUN	O	O	3151
and	CCONJ	O	O	3151
48	NUM	O	O	3151
hours	NOUN	O	O	3151
by	ADP	O	O	3151
IDR	PROPN	O	O	3151
and	CCONJ	O	O	3151
patch	VERB	O	O	3151
tests	VERB	O	O	3151
to	PART	O	O	3151
only	ADV	O	O	3151
some	PRON	O	O	3151
PRC	PROPN	O	O	3151
with	ADP	O	O	3151
common	ADJ	O	O	3151
chains	NOUN	O	O	3151
in	ADP	O	O	3151
their	PRON	O	O	3151
structures	NOUN	O	O	3151
.	PUNCT	O	O	3151
The	PRON	O	O	3152
positive	ADJ	O	O	3152
skin	NOUN	O	O	3152
tests	VERB	O	O	3152
are	AUX	O	O	3152
in	ADP	O	O	3152
favour	VERB	O	O	3152
of	ADP	O	O	3152
immunological	ADJ	O	O	3152
reactions	NOUN	O	O	3152
and	CCONJ	O	O	3152
may	AUX	O	O	3152
help	VERB	O	O	3152
in	ADP	O	O	3152
diagnosis	NOUN	O	O	3152
of	ADP	O	O	3152
allergy	PROPN	O	O	3152
in	ADP	O	O	3152
the	PRON	O	O	3152
patients	NOUN	O	O	3152
.	PUNCT	O	O	3152
Risk	NOUN	O	O	3155
of	ADP	O	O	3155
transient	ADJ	O	O	3155
hyperammonemic	VERB	O	O	3155
encephalopathy	NOUN	O	Disease	3155
in	ADP	O	O	3155
cancer	NOUN	O	Disease	3155
patients	NOUN	O	O	3155
who	PRON	O	O	3155
received	VERB	O	O	3155
continuous	ADJ	O	O	3155
infusion	NOUN	O	O	3155
of	ADP	O	O	3155
5-fluorouracil	NOUN	O	Chemical	3155
with	ADP	O	O	3155
the	PRON	O	O	3155
complication	NOUN	O	O	3155
of	ADP	O	O	3155
dehydration	NOUN	O	Disease	3155
and	CCONJ	O	O	3155
infection	NOUN	O	Disease	3155
.	PUNCT	O	O	3155
From	ADP	O	O	3156
1986	NUM	O	O	3156
to	PART	O	O	3156
1998	NUM	O	O	3156
,	PUNCT	O	O	3156
29	NUM	O	O	3156
cancer	NOUN	O	Disease	3156
patients	NOUN	O	O	3156
who	PRON	O	O	3156
had	VERB	O	O	3156
32	NUM	O	O	3156
episodes	NOUN	O	O	3156
of	ADP	O	O	3156
transient	ADJ	O	O	3156
hyperammonemic	VERB	O	O	3156
encephalopathy	NOUN	O	Disease	3156
related	ADJ	O	O	3156
to	PART	O	O	3156
continuous	ADJ	O	O	3156
infusion	NOUN	O	O	3156
of	ADP	O	O	3156
5-fluorouracil	NOUN	O	Chemical	3156
(	PUNCT	O	O	3156
5-FU	NOUN	O	Chemical	3156
)	PUNCT	O	O	3156
were	AUX	O	O	3156
identified	VERB	O	O	3156
.	PUNCT	O	O	3156
None	NOUN	O	O	3157
of	ADP	O	O	3157
the	PRON	O	O	3157
patients	NOUN	O	O	3157
had	VERB	O	O	3157
decompensated	VERB	O	O	3157
liver disease	NOUN	O	Disease	3157
.	PUNCT	O	O	3157
Onset	NOUN	O	O	3158
of	ADP	O	O	3158
hyperammonemic	VERB	O	O	3158
encephalopathy	NOUN	O	Disease	3158
varied	ADJ	O	O	3158
from	ADP	O	O	3158
0.5	NUM	O	O	3158
to	PART	O	O	3158
5	NUM	O	O	3158
days	NOUN	O	O	3158
(	PUNCT	O	O	3158
mean	VERB	O	O	3158
:	PUNCT	O	O	3158
2.6	NUM	O	O	3158
+	ADP	O	O	3158
/-	PUNCT	O	O	3158
Plasma	NOUN	O	O	3159
ammonium	NOUN	O	O	3159
level	VERB	O	O	3159
ranged	VERB	O	O	3159
from	ADP	O	O	3159
248	NUM	O	O	3159
to	PART	O	O	3159
2387	NUM	O	O	3159
microg%	NUM	O	O	3159
(	PUNCT	O	O	3159
mean	VERB	O	O	3159
:	PUNCT	O	O	3159
626	NUM	O	O	3159
+	ADP	O	O	3159
/-	PUNCT	O	O	3159
Among	ADP	O	O	3160
the	PRON	O	O	3160
32	NUM	O	O	3160
episodes	NOUN	O	O	3160
,	PUNCT	O	O	3160
26	NUM	O	O	3160
(	PUNCT	O	O	3160
81%	NOUN	O	O	3160
)	PUNCT	O	O	3160
had	VERB	O	O	3160
various	ADJ	O	O	3160
degrees	NOUN	O	O	3160
of	ADP	O	O	3160
azotemia	NOUN	O	O	3160
,	PUNCT	O	O	3160
18	NUM	O	O	3160
(	PUNCT	O	O	3160
56%	NOUN	O	O	3160
)	PUNCT	O	O	3160
occurred	VERB	O	O	3160
during	ADP	O	O	3160
bacterial infections	NOUN	O	Disease	3160
and	CCONJ	O	O	3160
14	NUM	O	O	3160
(	PUNCT	O	O	3160
44%	NOUN	O	O	3160
)	PUNCT	O	O	3160
without	ADP	O	O	3160
infection	NOUN	O	Disease	3160
occurred	VERB	O	O	3160
during	ADP	O	O	3160
periods	NOUN	O	O	3160
of	ADP	O	O	3160
dehydration	NOUN	O	Disease	3160
.	PUNCT	O	O	3160
Higher	ADV	O	O	3161
plasma	NOUN	O	O	3161
ammonium	NOUN	O	O	3161
levels	NOUN	O	O	3161
and	CCONJ	O	O	3161
more	ADJ	O	O	3161
rapid	ADJ	O	O	3161
onset	VERB	O	O	3161
of	ADP	O	O	3161
hyperammonemia	PROPN	O	Disease	3161
were	AUX	O	O	3161
seen	VERB	O	O	3161
in	ADP	O	O	3161
18	NUM	O	O	3161
patients	NOUN	O	O	3161
with	ADP	O	O	3161
bacterial infections	NOUN	O	Disease	3161
(	PUNCT	O	O	3161
p=0.003	PUNCT	O	O	3161
and	CCONJ	O	O	3161
0.0006	NUM	O	O	3161
,	PUNCT	O	O	3161
respectively	ADV	O	O	3161
)	PUNCT	O	O	3161
and	CCONJ	O	O	3161
in	ADP	O	O	3161
nine	NUM	O	O	3161
patients	NOUN	O	O	3161
receiving	VERB	O	O	3161
high	ADJ	O	O	3161
daily	ADV	O	O	3161
doses	NOUN	O	O	3161
(	PUNCT	O	O	3161
2600	NUM	O	O	3161
or	CCONJ	O	O	3161
1800	NUM	O	O	3161
mg	VERB	O	O	3161
/	PUNCT	O	O	3161
m2	PROPN	O	O	3161
)	PUNCT	O	O	3161
of	ADP	O	O	3161
5-FU	NOUN	O	Chemical	3161
(	PUNCT	O	O	3161
p=0.0001	NOUN	O	O	3161
and	CCONJ	O	O	3161
In	ADP	O	O	3162
25	NUM	O	O	3162
out	ADP	O	O	3162
of	ADP	O	O	3162
32	NUM	O	O	3162
episodes	NOUN	O	O	3162
(	PUNCT	O	O	3162
78%	NOUN	O	O	3162
)	PUNCT	O	O	3162
,	PUNCT	O	O	3162
plasma	NOUN	O	O	3162
ammonium	NOUN	O	O	3162
levels	NOUN	O	O	3162
and	CCONJ	O	O	3162
mental	ADJ	O	O	3162
status	NOUN	O	O	3162
returned	VERB	O	O	3162
to	PART	O	O	3162
normal	ADJ	O	O	3162
within	ADP	O	O	3162
2	X	O	O	3162
days	NOUN	O	O	3162
after	ADP	O	O	3162
adequate	ADJ	O	O	3162
management	NOUN	O	O	3162
.	PUNCT	O	O	3162
In	ADP	O	O	3163
conclusion	NOUN	O	O	3163
,	PUNCT	O	O	3163
hyperammonemic	VERB	O	O	3163
encephalopathy	NOUN	O	Disease	3163
can	AUX	O	O	3163
occur	VERB	O	O	3163
in	ADP	O	O	3163
patients	NOUN	O	O	3163
receiving	VERB	O	O	3163
continuous	ADJ	O	O	3163
infusion	NOUN	O	O	3163
of	ADP	O	O	3163
5-FU	NOUN	O	Chemical	3163
.	PUNCT	O	O	3163
Azotemia	PROPN	O	O	3164
,	PUNCT	O	O	3164
body	NOUN	O	O	3164
fluid	NOUN	O	O	3164
insufficiency	NOUN	O	O	3164
and	CCONJ	O	O	3164
bacterial infections	NOUN	O	Disease	3164
were	AUX	O	O	3164
frequently	ADV	O	O	3164
found	VERB	O	O	3164
in	ADP	O	O	3164
these	PRON	O	O	3164
patients	NOUN	O	O	3164
.	PUNCT	O	O	3164
It	PRON	O	O	3165
is	AUX	O	O	3165
therefore	ADV	O	O	3165
important	ADJ	O	O	3165
to	PART	O	O	3165
recognize	VERB	O	O	3165
this	PRON	O	O	3165
condition	NOUN	O	O	3165
in	ADP	O	O	3165
patients	NOUN	O	O	3165
receiving	VERB	O	O	3165
continuous	ADJ	O	O	3165
infusion	NOUN	O	O	3165
of	ADP	O	O	3165
5-FU	NOUN	O	Chemical	3165
.	PUNCT	O	O	3165
The	PRON	O	O	3168
effects	NOUN	O	O	3168
of	ADP	O	O	3168
quinine	NOUN	O	Chemical	3168
and	CCONJ	O	O	3168
4-aminopyridine	NOUN	O	Chemical	3168
on	ADP	O	O	3168
conditioned	VERB	O	O	3168
place	NOUN	O	O	3168
preference	NOUN	O	O	3168
and	CCONJ	O	O	3168
changes	VERB	O	O	3168
in	ADP	O	O	3168
motor	NOUN	O	O	3168
activity	NOUN	O	O	3168
induced	VERB	O	O	3168
by	ADP	O	O	3168
morphine	NOUN	O	Chemical	3168
in	ADP	O	O	3168
rats	NOUN	O	O	3168
The	PRON	O	O	3169
effects	NOUN	O	O	3169
of	ADP	O	O	3169
two	NUM	O	O	3169
unselective	PROPN	O	O	3169
potassium	NOUN	O	Chemical	3169
(	PUNCT	O	O	3169
K(+)-	PROPN	O	O	3169
)	PUNCT	O	O	3169
channel	PROPN	O	O	3169
blockers	NOUN	O	O	3169
,	PUNCT	O	O	3169
quinine	NOUN	O	Chemical	3169
(	PUNCT	O	O	3169
12.5	NUM	O	O	3169
,	PUNCT	O	O	3169
25	NUM	O	O	3169
and	CCONJ	O	O	3169
50	NUM	O	O	3169
mg	VERB	O	O	3169
/	PUNCT	O	O	3169
kg	VERB	O	O	3169
)	PUNCT	O	O	3169
and	CCONJ	O	O	3169
4-aminopyridine	NOUN	O	Chemical	3169
(	PUNCT	O	O	3169
1	X	O	O	3169
and	CCONJ	O	O	3169
2	X	O	O	3169
mg	VERB	O	O	3169
/	PUNCT	O	O	3169
kg	VERB	O	O	3169
)	PUNCT	O	O	3169
,	PUNCT	O	O	3169
on	ADP	O	O	3169
conditioned	VERB	O	O	3169
place	NOUN	O	O	3169
preference	NOUN	O	O	3169
and	CCONJ	O	O	3169
biphasic	ADJ	O	O	3169
changes	VERB	O	O	3169
in	ADP	O	O	3169
motor	NOUN	O	O	3169
activity	NOUN	O	O	3169
induced	VERB	O	O	3169
by	ADP	O	O	3169
morphine	NOUN	O	Chemical	3169
(	PUNCT	O	O	3169
10	NUM	O	O	3169
mg	VERB	O	O	3169
/	PUNCT	O	O	3169
kg	VERB	O	O	3169
)	PUNCT	O	O	3169
were	AUX	O	O	3169
tested	VERB	O	O	3169
in	ADP	O	O	3169
Wistar	PROPN	O	O	3169
rats	NOUN	O	O	3169
.	PUNCT	O	O	3169
Quinine	NOUN	O	Chemical	3170
is	AUX	O	O	3170
known	VERB	O	O	3170
to	PART	O	O	3170
block	NOUN	O	O	3170
voltage-	ADJ	O	O	3170
,	PUNCT	O	O	3170
calcium-	ADV	O	O	3170
and	CCONJ	O	O	3170
ATP	PROPN	O	Chemical	3170
-	PUNCT	O	O	3170
sensitive	ADJ	O	O	3170
K(+)-channels	NOUN	O	O	3170
while	SCONJ	O	O	3170
4-aminopyridine	NOUN	O	Chemical	3170
is	AUX	O	O	3170
known	VERB	O	O	3170
to	PART	O	O	3170
block	NOUN	O	O	3170
voltage	NOUN	O	O	3170
-	PUNCT	O	O	3170
sensitive	ADJ	O	O	3170
K(+)-channels	NOUN	O	O	3170
.	PUNCT	O	O	3170
In	ADP	O	O	3171
the	PRON	O	O	3171
counterbalanced	VERB	O	O	3171
method	NOUN	O	O	3171
,	PUNCT	O	O	3171
quinine	NOUN	O	Chemical	3171
attenuated	VERB	O	O	3171
morphine	NOUN	O	Chemical	3171
-	PUNCT	O	O	3171
induced	VERB	O	O	3171
place	NOUN	O	O	3171
preference	NOUN	O	O	3171
,	PUNCT	O	O	3171
whereas	SCONJ	O	O	3171
4-aminopyridine	NOUN	O	Chemical	3171
was	AUX	O	O	3171
ineffective	ADJ	O	O	3171
.	PUNCT	O	O	3171
In	ADP	O	O	3172
the	PRON	O	O	3172
motor	NOUN	O	O	3172
activity	NOUN	O	O	3172
test	NOUN	O	O	3172
measured	VERB	O	O	3172
with	ADP	O	O	3172
an	PRON	O	O	3172
Animex	PROPN	O	O	3172
-	PUNCT	O	O	3172
activity	NOUN	O	O	3172
meter	NOUN	O	O	3172
neither	ADV	O	O	3172
of	ADP	O	O	3172
the	PRON	O	O	3172
K(+)-channel	PROPN	O	O	3172
blockers	NOUN	O	O	3172
affected	VERB	O	O	3172
morphine	NOUN	O	Chemical	3172
-	PUNCT	O	O	3172
induced	VERB	O	O	3172
hypoactivity	NOUN	O	O	3172
,	PUNCT	O	O	3172
but	CCONJ	O	O	3172
both	PRON	O	O	3172
K(+)-channel	PROPN	O	O	3172
blockers	NOUN	O	O	3172
prevented	VERB	O	O	3172
morphine	NOUN	O	Chemical	3172
-	PUNCT	O	O	3172
induced	VERB	O	O	3172
secondary	ADJ	O	O	3172
hyperactivity	NOUN	O	Disease	3172
.	PUNCT	O	O	3172
These	PRON	O	O	3173
results	VERB	O	O	3173
suggest	VERB	O	O	3173
the	PRON	O	O	3173
involvement	NOUN	O	O	3173
of	ADP	O	O	3173
quinine	NOUN	O	Chemical	3173
-	PUNCT	O	O	3173
sensitive	ADJ	O	O	3173
but	CCONJ	O	O	3173
not	PART	O	O	3173
4-aminopyridine	NOUN	O	Chemical	3173
-	PUNCT	O	O	3173
sensitive	ADJ	O	O	3173
K(+)-channels	NOUN	O	O	3173
in	ADP	O	O	3173
morphine	NOUN	O	Chemical	3173
reward	NOUN	O	O	3173
.	PUNCT	O	O	3173
It	PRON	O	O	3174
is	AUX	O	O	3174
also	ADV	O	O	3174
suggested	VERB	O	O	3174
that	SCONJ	O	O	3174
the	PRON	O	O	3174
blockade	VERB	O	O	3174
of	ADP	O	O	3174
K(+)-channels	NOUN	O	O	3174
sensitive	ADJ	O	O	3174
to	PART	O	O	3174
these	PRON	O	O	3174
blockers	NOUN	O	O	3174
is	AUX	O	O	3174
not	PART	O	O	3174
sufficient	ADJ	O	O	3174
to	PART	O	O	3174
prevent	VERB	O	O	3174
morphine	NOUN	O	Chemical	3174
-	PUNCT	O	O	3174
induced	VERB	O	O	3174
hypoactivity	NOUN	O	O	3174
whereas	SCONJ	O	O	3174
morphine	NOUN	O	Chemical	3174
-	PUNCT	O	O	3174
induced	VERB	O	O	3174
hyperactivity	NOUN	O	Disease	3174
seems	VERB	O	O	3174
to	PART	O	O	3174
be	AUX	O	O	3174
connected	VERB	O	O	3174
to	PART	O	O	3174
both	PRON	O	O	3174
quinine-	NOUN	O	O	3174
and	CCONJ	O	O	3174
4-aminopyridine	NOUN	O	Chemical	3174
-	PUNCT	O	O	3174
sensitive	ADJ	O	O	3174
K(+)-channels	NOUN	O	O	3174
.	PUNCT	O	O	3174
Nociceptin	PROPN	O	O	3177
/	PUNCT	O	O	3177
orphanin	NOUN	O	O	3177
FQ	PROPN	O	O	3177
and	CCONJ	O	O	3177
nocistatin	NOUN	O	O	3177
on	ADP	O	O	3177
learning	VERB	O	O	3177
and	CCONJ	O	O	3177
memory impairment	NOUN	O	Disease	3177
induced	VERB	O	O	3177
by	ADP	O	O	3177
scopolamine	NOUN	O	Chemical	3177
in	ADP	O	O	3177
mice	NOUN	O	O	3177
Nociceptin	PROPN	O	O	3178
,	PUNCT	O	O	3178
also	ADV	O	O	3178
known	VERB	O	O	3178
as	ADP	O	O	3178
orphanin	NOUN	O	O	3178
FQ	PROPN	O	O	3178
,	PUNCT	O	O	3178
is	AUX	O	O	3178
an	PRON	O	O	3178
endogenous	ADJ	O	O	3178
ligand	NOUN	O	O	3178
for	ADP	O	O	3178
the	PRON	O	O	3178
orphan	NOUN	O	O	3178
opioid	NOUN	O	O	3178
receptor	NOUN	O	O	3178
-	PUNCT	O	O	3178
like	INTJ	O	O	3178
receptor	NOUN	O	O	3178
1	X	O	O	3178
(	PUNCT	O	O	3178
ORL1	PROPN	O	O	3178
)	PUNCT	O	O	3178
and	CCONJ	O	O	3178
involves	VERB	O	O	3178
in	ADP	O	O	3178
various	ADJ	O	O	3178
functions	VERB	O	O	3178
in	ADP	O	O	3178
the	PRON	O	O	3178
central	ADJ	O	O	3178
nervous	ADJ	O	O	3178
system	NOUN	O	O	3178
(	PUNCT	O	O	3178
CNS	PROPN	O	O	3178
)	PUNCT	O	O	3178
.	PUNCT	O	O	3178
On	ADP	O	O	3179
the	PRON	O	O	3179
other	ADJ	O	O	3179
hand	NOUN	O	O	3179
,	PUNCT	O	O	3179
nocistatin	NOUN	O	O	3179
is	AUX	O	O	3179
recently	ADV	O	O	3179
isolated	VERB	O	O	3179
from	ADP	O	O	3179
the	PRON	O	O	3179
same	ADJ	O	O	3179
precursor	NOUN	O	O	3179
as	ADP	O	O	3179
nociceptin	X	O	O	3179
and	CCONJ	O	O	3179
blocks	NOUN	O	O	3179
nociceptin	X	O	O	3179
-	PUNCT	O	O	3179
induced	VERB	O	O	3179
allodynia	NOUN	O	Disease	3179
and	CCONJ	O	O	3179
hyperalgesia	NOUN	O	Disease	3179
.	PUNCT	O	O	3179
The	PRON	O	O	3180
present	NOUN	O	O	3180
study	VERB	O	O	3180
was	AUX	O	O	3180
designed	VERB	O	O	3180
to	PART	O	O	3180
investigate	VERB	O	O	3180
whether	SCONJ	O	O	3180
nociceptin	X	O	O	3180
/	PUNCT	O	O	3180
orphanin	NOUN	O	O	3180
FQ	PROPN	O	O	3180
and	CCONJ	O	O	3180
nocistatin	NOUN	O	O	3180
could	AUX	O	O	3180
modulate	VERB	O	O	3180
impairment	NOUN	O	O	3180
of	ADP	O	O	3180
learning	VERB	O	O	3180
and	CCONJ	O	O	3180
memory	NOUN	O	O	3180
induced	VERB	O	O	3180
by	ADP	O	O	3180
scopolamine	NOUN	O	Chemical	3180
,	PUNCT	O	O	3180
a	PRON	O	O	3180
muscarinic	PROPN	O	O	3180
cholinergic	ADJ	O	O	3180
receptor	NOUN	O	O	3180
antagonist	NOUN	O	O	3180
,	PUNCT	O	O	3180
using	VERB	O	O	3180
spontaneous	ADJ	O	O	3180
alternation	NOUN	O	O	3180
of	ADP	O	O	3180
Y	NOUN	O	O	3180
-	PUNCT	O	O	3180
maze	NOUN	O	O	3180
and	CCONJ	O	O	3180
step	VERB	O	O	3180
-	PUNCT	O	O	3180
down	ADP	O	O	3180
type	NOUN	O	O	3180
passive	ADJ	O	O	3180
avoidance	NOUN	O	O	3180
tasks	NOUN	O	O	3180
in	ADP	O	O	3180
mice	NOUN	O	O	3180
.	PUNCT	O	O	3180
While	SCONJ	O	O	3181
nocistatin	NOUN	O	O	3181
(	PUNCT	O	O	3181
0.5	NUM	O	O	3181
-	PUNCT	O	O	3181
5.0	NUM	O	O	3181
nmol	PROPN	O	O	3181
mouse-1	NUM	O	O	3181
,	PUNCT	O	O	3181
i.c.v	NOUN	O	O	3181
.	PUNCT	O	O	3181
)	PUNCT	O	O	3181
administered	VERB	O	O	3182
30	NUM	O	O	3182
min	NOUN	O	O	3182
before	ADP	O	O	3182
spontaneous	ADJ	O	O	3182
alternation	NOUN	O	O	3182
performance	NOUN	O	O	3182
or	CCONJ	O	O	3182
the	PRON	O	O	3182
training	NOUN	O	O	3182
session	NOUN	O	O	3182
of	ADP	O	O	3182
the	PRON	O	O	3182
passive	ADJ	O	O	3182
avoidance	NOUN	O	O	3182
task	NOUN	O	O	3182
,	PUNCT	O	O	3182
had	VERB	O	O	3182
no	PRON	O	O	3182
effect	VERB	O	O	3182
on	ADP	O	O	3182
spontaneous	ADJ	O	O	3182
alternation	NOUN	O	O	3182
or	CCONJ	O	O	3182
passive	ADJ	O	O	3182
avoidance	NOUN	O	O	3182
behaviours	NOUN	O	O	3182
,	PUNCT	O	O	3182
a	PRON	O	O	3182
lower	ADJ	O	O	3182
per	ADP	O	O	3182
cent	NOUN	O	O	3182
alternation	NOUN	O	O	3182
and	CCONJ	O	O	3182
shorter	ADJ	O	O	3182
median	ADJ	O	O	3182
step	VERB	O	O	3182
-	PUNCT	O	O	3182
down	ADP	O	O	3182
latency	VERB	O	O	3182
in	ADP	O	O	3182
the	PRON	O	O	3182
retention	NOUN	O	O	3182
test	NOUN	O	O	3182
were	AUX	O	O	3182
obtained	VERB	O	O	3182
in	ADP	O	O	3182
nociceptin	X	O	O	3182
(	PUNCT	O	O	3182
1.5	NUM	O	O	3182
and/or	CCONJ	O	O	3182
5.0	NUM	O	O	3182
nmol	PROPN	O	O	3182
mouse-1	NUM	O	O	3182
,	PUNCT	O	O	3182
Administration	NOUN	O	O	3183
of	ADP	O	O	3183
nocistatin	NOUN	O	O	3183
(	PUNCT	O	O	3183
1.5	NUM	O	O	3183
and/or	CCONJ	O	O	3183
5.0	NUM	O	O	3183
nmol	PROPN	O	O	3183
mouse-1	NUM	O	O	3183
,	PUNCT	O	O	3183
i.c.v	NOUN	O	O	3183
.	PUNCT	O	O	3183
)	PUNCT	O	O	3183
30	NUM	O	O	3183
min	NOUN	O	O	3183
before	ADP	O	O	3183
spontaneous	ADJ	O	O	3183
alternation	NOUN	O	O	3183
performance	NOUN	O	O	3183
or	CCONJ	O	O	3183
the	PRON	O	O	3183
training	NOUN	O	O	3183
session	NOUN	O	O	3183
of	ADP	O	O	3183
the	PRON	O	O	3183
passive	ADJ	O	O	3183
avoidance	NOUN	O	O	3183
task	NOUN	O	O	3183
,	PUNCT	O	O	3183
attenuated	VERB	O	O	3183
the	PRON	O	O	3183
scopolamine	NOUN	O	Chemical	3183
-	PUNCT	O	O	3183
induced	VERB	O	O	3183
impairment	NOUN	O	O	3183
of	ADP	O	O	3183
spontaneous	ADJ	O	O	3183
alternation	NOUN	O	O	3183
and	CCONJ	O	O	3183
passive	ADJ	O	O	3183
avoidance	NOUN	O	O	3183
behaviours	NOUN	O	O	3183
.	PUNCT	O	O	3183
These	PRON	O	O	3184
results	VERB	O	O	3184
indicated	VERB	O	O	3184
that	SCONJ	O	O	3184
nocistatin	NOUN	O	O	3184
,	PUNCT	O	O	3184
a	PRON	O	O	3184
new	ADJ	O	O	3184
biologically	ADV	O	O	3184
active	ADJ	O	O	3184
peptide	NOUN	O	O	3184
,	PUNCT	O	O	3184
ameliorates	VERB	O	O	3184
impairments	VERB	O	O	3184
of	ADP	O	O	3184
spontaneous	ADJ	O	O	3184
alternation	NOUN	O	O	3184
and	CCONJ	O	O	3184
passive	ADJ	O	O	3184
avoidance	NOUN	O	O	3184
induced	VERB	O	O	3184
by	ADP	O	O	3184
scopolamine	NOUN	O	Chemical	3184
,	PUNCT	O	O	3184
and	CCONJ	O	O	3184
suggested	VERB	O	O	3184
that	SCONJ	O	O	3184
these	PRON	O	O	3184
peptides	NOUN	O	O	3184
play	VERB	O	O	3184
opposite	ADV	O	O	3184
roles	NOUN	O	O	3184
in	ADP	O	O	3184
learning	VERB	O	O	3184
and	CCONJ	O	O	3184
memory	NOUN	O	O	3184
.	PUNCT	O	O	3184
Meloxicam	NOUN	O	O	3187
-	PUNCT	O	O	3187
induced	VERB	O	O	3187
liver toxicity	NOUN	O	Disease	3187
.	PUNCT	O	O	3187
We	PRON	O	O	3188
report	VERB	O	O	3188
the	PRON	O	O	3188
case	NOUN	O	O	3188
of	ADP	O	O	3188
a	PRON	O	O	3188
female	ADJ	O	O	3188
patient	NOUN	O	O	3188
with	ADP	O	O	3188
rheumatoid arthritis	NOUN	O	Disease	3188
who	PRON	O	O	3188
developed	VERB	O	O	3188
acute	ADJ	O	O	3188
cytolytic	ADJ	O	O	3188
hepatitis	NOUN	O	Disease	3188
due	ADJ	O	O	3188
to	PART	O	O	3188
meloxicam	PROPN	O	O	3188
.	PUNCT	O	O	3188
Recently	ADV	O	O	3189
introduced	VERB	O	O	3189
in	ADP	O	O	3189
Belgium	PROPN	O	O	3189
,	PUNCT	O	O	3189
meloxicam	PROPN	O	O	3189
is	AUX	O	O	3189
the	PRON	O	O	3189
first	ADV	O	O	3189
nonsteroidal	ADJ	O	O	3189
antiinflammatory	ADJ	O	O	3189
drug	NOUN	O	O	3189
with	ADP	O	O	3189
selective	ADJ	O	O	3189
action	NOUN	O	O	3189
on	ADP	O	O	3189
the	PRON	O	O	3189
inducible	VERB	O	O	3189
form	NOUN	O	O	3189
of	ADP	O	O	3189
cyclooxygenase	PROPN	O	O	3189
2	X	O	O	3189
.	PUNCT	O	O	3189
The	PRON	O	O	3190
acute	ADJ	O	O	3190
cytolytic	ADJ	O	O	3190
hepatitis	NOUN	O	Disease	3190
occurred	VERB	O	O	3190
rapidly	ADV	O	O	3190
after	ADP	O	O	3190
meloxicam	PROPN	O	O	3190
administration	NOUN	O	O	3190
and	CCONJ	O	O	3190
was	AUX	O	O	3190
associated	VERB	O	O	3190
with	ADP	O	O	3190
the	PRON	O	O	3190
development	NOUN	O	O	3190
of	ADP	O	O	3190
antinuclear	ADJ	O	O	3190
antibodies	NOUN	O	O	3190
suggesting	VERB	O	O	3190
a	PRON	O	O	3190
hypersensitivity	NOUN	O	Disease	3190
mechanism	NOUN	O	O	3190
.	PUNCT	O	O	3190
This	PRON	O	O	3191
first	ADV	O	O	3191
case	NOUN	O	O	3191
of	ADP	O	O	3191
meloxicam	PROPN	O	O	3191
related	ADJ	O	O	3191
liver toxicity	NOUN	O	Disease	3191
demonstrates	VERB	O	O	3191
the	PRON	O	O	3191
potential	ADJ	O	O	3191
of	ADP	O	O	3191
this	PRON	O	O	3191
drug	NOUN	O	O	3191
to	PART	O	O	3191
induce	VERB	O	O	3191
hepatic damage	NOUN	O	Disease	3191
.	PUNCT	O	O	3191
Induction	NOUN	O	O	3194
of	ADP	O	O	3194
apoptosis	NOUN	O	O	3194
by	ADP	O	O	3194
remoxipride	ADV	O	O	3194
metabolites	VERB	O	O	3194
in	ADP	O	O	3194
HL60	NOUN	O	O	3194
and	CCONJ	O	O	3194
CD34+/CD19-	ADP	O	O	3194
human	PROPN	O	O	3194
bone	NOUN	O	O	3194
marrow	PROPN	O	O	3194
progenitor	NOUN	O	O	3194
cells	NOUN	O	O	3194
:	PUNCT	O	O	3194
potential	ADJ	O	O	3194
relevance	NOUN	O	O	3194
to	PART	O	O	3194
remoxipride	ADV	O	O	3194
-	PUNCT	O	O	3194
induced	VERB	O	O	3194
aplastic anemia	NOUN	O	Disease	3194
.	PUNCT	O	O	3194
The	PRON	O	O	3195
antipsychotic	ADJ	O	O	3195
agent	NOUN	O	O	3195
,	PUNCT	O	O	3195
remoxipride	ADV	O	O	3195
[	X	O	O	3195
(	PUNCT	O	O	3195
S)-(-)-3-bromo	NOUN	O	O	3195
-	PUNCT	O	O	3195
N-[(1-ethyl-2-pyrrolidinyl)methyl]-2,6-dimethoxybenz	NOUN	O	O	3195
amide	PROPN	O	O	3195
]	PUNCT	O	O	3195
has	VERB	O	O	3195
been	AUX	O	O	3195
associated	VERB	O	O	3195
with	ADP	O	O	3195
acquired	VERB	O	O	3195
aplastic anemia	NOUN	O	Disease	3195
.	PUNCT	O	O	3195
We	PRON	O	O	3196
have	VERB	O	O	3196
examined	VERB	O	O	3196
the	PRON	O	O	3196
ability	NOUN	O	O	3196
of	ADP	O	O	3196
remoxipride	ADV	O	O	3196
,	PUNCT	O	O	3196
three	NUM	O	O	3196
pyrrolidine	NOUN	O	O	3196
ring	NOUN	O	O	3196
metabolites	VERB	O	O	3196
and	CCONJ	O	O	3196
five	NUM	O	O	3196
aromatic	ADJ	O	O	3196
ring	NOUN	O	O	3196
metabolites	VERB	O	O	3196
of	ADP	O	O	3196
the	PRON	O	O	3196
parent	NOUN	O	O	3196
compound	NOUN	O	O	3196
to	PART	O	O	3196
induce	VERB	O	O	3196
apoptosis	NOUN	O	O	3196
in	ADP	O	O	3196
HL60	NOUN	O	O	3196
cells	NOUN	O	O	3196
and	CCONJ	O	O	3196
human	PROPN	O	O	3196
bone	NOUN	O	O	3196
marrow	PROPN	O	O	3196
progenitor	NOUN	O	O	3196
(	PUNCT	O	O	3196
HBMP	PROPN	O	O	3196
)	PUNCT	O	O	3196
cells	NOUN	O	O	3196
.	PUNCT	O	O	3196
Apoptosis	NOUN	O	O	3197
was	AUX	O	O	3197
assessed	VERB	O	O	3197
by	ADP	O	O	3197
fluorescence	NOUN	O	O	3197
microscopy	NOUN	O	O	3197
in	ADP	O	O	3197
Hoechst	PROPN	O	O	3197
33342-	NUM	O	O	3197
and	CCONJ	O	O	3197
propidium	NOUN	O	O	3197
iodide	NOUN	O	O	3197
stained	VERB	O	O	3197
cell	NOUN	O	O	3197
samples	NOUN	O	O	3197
.	PUNCT	O	O	3197
The	PRON	O	O	3198
catechol	NOUN	O	O	3198
and	CCONJ	O	O	3198
hydroquinone	NOUN	O	O	3198
metabolites	VERB	O	O	3198
,	PUNCT	O	O	3198
NCQ436	NUM	O	O	3198
and	CCONJ	O	O	3198
NCQ344	NOUN	O	O	3198
,	PUNCT	O	O	3198
induced	VERB	O	O	3198
apoptosis	NOUN	O	O	3198
in	ADP	O	O	3198
HL60	NOUN	O	O	3198
and	CCONJ	O	O	3198
HBMP	PROPN	O	O	3198
cells	NOUN	O	O	3198
in	ADP	O	O	3198
a	PRON	O	O	3198
time-	PUNCT	O	O	3198
and	CCONJ	O	O	3198
concentration	NOUN	O	O	3198
dependent	ADJ	O	O	3198
manner	VERB	O	O	3198
,	PUNCT	O	O	3198
while	SCONJ	O	O	3198
the	PRON	O	O	3198
phenols	NOUN	O	O	3198
,	PUNCT	O	O	3198
NCR181	NOUN	O	O	3198
,	PUNCT	O	O	3198
FLA873	PROPN	O	O	3198
,	PUNCT	O	O	3198
and	CCONJ	O	O	3198
FLA797	NOUN	O	O	3198
,	PUNCT	O	O	3198
and	CCONJ	O	O	3198
the	PRON	O	O	3198
derivatives	NOUN	O	O	3198
formed	VERB	O	O	3198
by	ADP	O	O	3198
oxidation	ADV	O	O	3198
of	ADP	O	O	3198
the	PRON	O	O	3198
pyrrolidine	NOUN	O	O	3198
ring	NOUN	O	O	3198
,	PUNCT	O	O	3198
FLA838	VERB	O	O	3198
,	PUNCT	O	O	3198
NCM001	NOUN	O	O	3198
,	PUNCT	O	O	3198
and	CCONJ	O	O	3198
NCL118	PROPN	O	O	3198
,	PUNCT	O	O	3198
had	VERB	O	O	3198
no	PRON	O	O	3198
effect	VERB	O	O	3198
.	PUNCT	O	O	3198
No	PRON	O	O	3199
necrosis	NOUN	O	Disease	3199
was	AUX	O	O	3199
observed	VERB	O	O	3199
in	ADP	O	O	3199
cells	NOUN	O	O	3199
treated	VERB	O	O	3199
with	ADP	O	O	3199
NCQ436	NUM	O	O	3199
but	CCONJ	O	O	3199
NCQ344	NOUN	O	O	3199
had	VERB	O	O	3199
a	PRON	O	O	3199
biphasic	ADJ	O	O	3199
effect	VERB	O	O	3199
in	ADP	O	O	3199
both	PRON	O	O	3199
cell	NOUN	O	O	3199
types	NOUN	O	O	3199
,	PUNCT	O	O	3199
inducing	VERB	O	O	3199
apoptosis	NOUN	O	O	3199
at	ADP	O	O	3199
lower	ADJ	O	O	3199
concentrations	NOUN	O	O	3199
and	CCONJ	O	O	3199
necrosis	NOUN	O	Disease	3199
at	ADP	O	O	3199
higher	ADJ	O	O	3199
concentrations	NOUN	O	O	3199
.	PUNCT	O	O	3199
These	PRON	O	O	3200
data	NOUN	O	O	3200
show	VERB	O	O	3200
that	SCONJ	O	O	3200
the	PRON	O	O	3200
catechol	NOUN	O	O	3200
and	CCONJ	O	O	3200
hydroquinone	NOUN	O	O	3200
metabolites	VERB	O	O	3200
of	ADP	O	O	3200
remoxipride	ADV	O	O	3200
have	VERB	O	O	3200
direct	ADJ	O	O	3200
toxic	ADJ	O	O	3200
effects	NOUN	O	O	3200
in	ADP	O	O	3200
HL60	NOUN	O	O	3200
and	CCONJ	O	O	3200
HBMP	PROPN	O	O	3200
cells	NOUN	O	O	3200
,	PUNCT	O	O	3200
leading	VERB	O	O	3200
to	PART	O	O	3200
apoptosis	NOUN	O	O	3200
,	PUNCT	O	O	3200
while	SCONJ	O	O	3200
the	PRON	O	O	3200
phenol	NOUN	O	O	3200
metabolites	VERB	O	O	3200
were	AUX	O	O	3200
inactive	ADJ	O	O	3200
.	PUNCT	O	O	3200
Similarly	ADV	O	O	3201
,	PUNCT	O	O	3201
benzene	PROPN	O	O	3201
-	PUNCT	O	O	3201
derived	VERB	O	O	3201
catechol	NOUN	O	O	3201
and	CCONJ	O	O	3201
hydroquinone	NOUN	O	O	3201
,	PUNCT	O	O	3201
but	CCONJ	O	O	3201
not	PART	O	O	3201
phenol	NOUN	O	O	3201
,	PUNCT	O	O	3201
induce	VERB	O	O	3201
apoptosis	NOUN	O	O	3201
in	ADP	O	O	3201
HBMP	PROPN	O	O	3201
cells	NOUN	O	O	3201
We	PRON	O	O	3202
propose	VERB	O	O	3202
that	SCONJ	O	O	3202
remoxipride	ADV	O	O	3202
and	CCONJ	O	O	3202
benzene	PROPN	O	O	3202
may	AUX	O	O	3202
induce	VERB	O	O	3202
aplastic anemia	NOUN	O	Disease	3202
via	ADP	O	O	3202
production	NOUN	O	O	3202
of	ADP	O	O	3202
similar	ADJ	O	O	3202
reactive	ADJ	O	O	3202
metabolites	VERB	O	O	3202
and	CCONJ	O	O	3202
that	SCONJ	O	O	3202
the	PRON	O	O	3202
ability	NOUN	O	O	3202
of	ADP	O	O	3202
NCQ436	NUM	O	O	3202
and	CCONJ	O	O	3202
NCQ344	NOUN	O	O	3202
to	PART	O	O	3202
induce	VERB	O	O	3202
apoptosis	NOUN	O	O	3202
in	ADP	O	O	3202
HBMP	PROPN	O	O	3202
cells	NOUN	O	O	3202
may	AUX	O	O	3202
contribute	VERB	O	O	3202
to	PART	O	O	3202
the	PRON	O	O	3202
mechanism	NOUN	O	O	3202
underlying	VERB	O	O	3202
acquired	VERB	O	O	3202
aplastic anemia	NOUN	O	Disease	3202
that	SCONJ	O	O	3202
has	VERB	O	O	3202
been	AUX	O	O	3202
associated	VERB	O	O	3202
with	ADP	O	O	3202
remoxipride	ADV	O	O	3202
.	PUNCT	O	O	3202
Synthesis	NOUN	O	O	3205
and	CCONJ	O	O	3205
preliminary	ADJ	O	O	3205
pharmacological	ADJ	O	O	3205
investigations	NOUN	O	O	3205
of	ADP	O	O	3205
1-(1,2-dihydro-2-acenaphthylenyl)piperazine	NOUN	O	O	3205
derivatives	NOUN	O	O	3205
as	ADP	O	O	3205
potential	ADJ	O	O	3205
atypical	ADJ	O	O	3205
antipsychotic	ADJ	O	O	3205
agents	NOUN	O	O	3205
in	ADP	O	O	3205
mice	NOUN	O	O	3205
.	PUNCT	O	O	3205
The	PRON	O	O	3206
synthesis	NOUN	O	O	3206
and	CCONJ	O	O	3206
preliminary	ADJ	O	O	3206
pharmacological	ADJ	O	O	3206
evaluation	NOUN	O	O	3206
of	ADP	O	O	3206
a	PRON	O	O	3206
series	PROPN	O	O	3206
of	ADP	O	O	3206
potential	ADJ	O	O	3206
atypical	ADJ	O	O	3206
antipsychotic	ADJ	O	O	3206
agents	NOUN	O	O	3206
based	VERB	O	O	3206
on	ADP	O	O	3206
the	PRON	O	O	3206
structure	NOUN	O	O	3206
of	ADP	O	O	3206
1-(1,2-dihydro-2-acenaphthylenyl)piperazine	NOUN	O	O	3206
(	PUNCT	O	O	3206
7	NUM	O	O	3206
)	PUNCT	O	O	3206
is	AUX	O	O	3206
described	VERB	O	O	3206
.	PUNCT	O	O	3206
Compound	NOUN	O	O	3207
7e	PROPN	O	O	3207
,	PUNCT	O	O	3207
5-{2-[4-(1,2-dihydro-2-acenaphthylenyl)piperazinyl]ethyl}-2,3-dihy	NOUN	O	O	3207
dro-1H-	NUM	O	O	3207
indol-2-one	NUM	O	O	3207
,	PUNCT	O	O	3207
from	ADP	O	O	3207
this	PRON	O	O	3207
series	PROPN	O	O	3207
showed	VERB	O	O	3207
significant	ADJ	O	O	3207
affinities	VERB	O	O	3207
at	ADP	O	O	3207
the	PRON	O	O	3207
5-HT1A	NOUN	O	O	3207
and	CCONJ	O	O	3207
5-HT2A	NOUN	O	O	3207
receptors	NOUN	O	O	3207
and	CCONJ	O	O	3207
moderate	ADJ	O	O	3207
affinity	NOUN	O	O	3207
at	ADP	O	O	3207
the	PRON	O	O	3207
D2	NOUN	O	O	3207
receptor	NOUN	O	O	3207
.	PUNCT	O	O	3207
7e	PROPN	O	O	3208
exhibits	VERB	O	O	3208
a	PRON	O	O	3208
high	ADJ	O	O	3208
reversal	NOUN	O	O	3208
of	ADP	O	O	3208
catalepsy	VERB	O	Disease	3208
induced	VERB	O	O	3208
by	ADP	O	O	3208
haloperidol	NOUN	O	Chemical	3208
indicating	VERB	O	O	3208
its	PRON	O	O	3208
atypical	ADJ	O	O	3208
antipsychotic	ADJ	O	O	3208
nature	NOUN	O	O	3208
.	PUNCT	O	O	3208
Sub	NOUN	O	O	3211
-	PUNCT	O	O	3211
chronic	ADJ	O	O	3211
inhibition	NOUN	O	O	3211
of	ADP	O	O	3211
nitric	NOUN	O	O	3211
-	PUNCT	O	O	3211
oxide	NOUN	O	O	3211
synthesis	NOUN	O	O	3211
modifies	VERB	O	O	3211
haloperidol	NOUN	O	Chemical	3211
-	PUNCT	O	O	3211
induced	VERB	O	O	3211
catalepsy	VERB	O	Disease	3211
and	CCONJ	O	O	3211
the	PRON	O	O	3211
number	NOUN	O	O	3211
of	ADP	O	O	3211
NADPH	PROPN	O	O	3211
-	PUNCT	O	O	3211
diaphorase	NOUN	O	O	3211
neurons	NOUN	O	O	3211
in	ADP	O	O	3211
mice	NOUN	O	O	3211
.	PUNCT	O	O	3211
NG	PROPN	O	O	3212
-	PUNCT	O	O	3212
nitro	NOUN	O	O	3212
-	PUNCT	O	O	3212
L	NOUN	O	O	3212
-	PUNCT	O	O	3212
arginine	PROPN	O	O	3212
(	PUNCT	O	O	3212
L	NOUN	O	O	3212
-	PUNCT	O	O	3212
NOARG	ADJ	O	O	3212
)	PUNCT	O	O	3212
,	PUNCT	O	O	3212
an	PRON	O	O	3212
inhibitor	NOUN	O	O	3212
of	ADP	O	O	3212
nitric	NOUN	O	O	3212
-	PUNCT	O	O	3212
oxide	NOUN	O	O	3212
synthase	NOUN	O	O	3212
(	PUNCT	O	O	3212
NOS	PROPN	O	O	3212
)	PUNCT	O	O	3212
,	PUNCT	O	O	3212
induces	VERB	O	O	3212
catalepsy	VERB	O	Disease	3212
in	ADP	O	O	3212
mice	NOUN	O	O	3212
.	PUNCT	O	O	3212
This	PRON	O	O	3213
effect	VERB	O	O	3213
undergoes	VERB	O	O	3213
rapid	ADJ	O	O	3213
tolerance	NOUN	O	O	3213
,	PUNCT	O	O	3213
showing	VERB	O	O	3213
a	PRON	O	O	3213
significant	ADJ	O	O	3213
decrease	VERB	O	O	3213
after	ADP	O	O	3213
2	X	O	O	3213
days	NOUN	O	O	3213
of	ADP	O	O	3213
sub	ADJ	O	O	3213
-	PUNCT	O	O	3213
chronic	ADJ	O	O	3213
L	NOUN	O	O	3213
-	PUNCT	O	O	3213
NOARG	ADJ	O	O	3213
treatment	NOUN	O	O	3213
.	PUNCT	O	O	3213
Nitric oxide	NOUN	O	Chemical	3214
(	PUNCT	O	O	3214
NO	PRON	O	Chemical	3214
)	PUNCT	O	O	3214
has	VERB	O	O	3214
been	AUX	O	O	3214
shown	VERB	O	O	3214
to	PART	O	O	3214
influence	NOUN	O	O	3214
dopaminergic	ADJ	O	O	3214
neurotransmission	NOUN	O	O	3214
in	ADP	O	O	3214
the	PRON	O	O	3214
striatum	NOUN	O	O	3214
.	PUNCT	O	O	3214
Neuroleptic	NOUN	O	O	3215
drugs	NOUN	O	O	3215
such	ADJ	O	O	3215
as	ADP	O	O	3215
haloperidol	NOUN	O	Chemical	3215
,	PUNCT	O	O	3215
which	PRON	O	O	3215
block	NOUN	O	O	3215
dopamine	NOUN	O	Chemical	3215
receptors	NOUN	O	O	3215
,	PUNCT	O	O	3215
also	ADV	O	O	3215
cause	VERB	O	O	3215
catalepsy	VERB	O	Disease	3215
in	ADP	O	O	3215
rodents	NOUN	O	O	3215
.	PUNCT	O	O	3215
To	PART	O	O	3216
investigate	VERB	O	O	3216
the	PRON	O	O	3216
effects	NOUN	O	O	3216
of	ADP	O	O	3216
subchronic	VERB	O	O	3216
L	NOUN	O	O	3216
-	PUNCT	O	O	3216
NOARG	ADJ	O	O	3216
treatment	NOUN	O	O	3216
in	ADP	O	O	3216
haloperidol	NOUN	O	Chemical	3216
-	PUNCT	O	O	3216
induced	VERB	O	O	3216
catalepsy	VERB	O	Disease	3216
and	CCONJ	O	O	3216
the	PRON	O	O	3216
number	NOUN	O	O	3216
of	ADP	O	O	3216
NOS	PROPN	O	O	3216
neurons	NOUN	O	O	3216
in	ADP	O	O	3216
areas	NOUN	O	O	3216
related	ADJ	O	O	3216
to	PART	O	O	3216
motor	NOUN	O	O	3216
control	VERB	O	O	3216
.	PUNCT	O	O	3216
Male	NOUN	O	O	3217
albino	PROPN	O	O	3217
Swiss	PROPN	O	O	3217
mice	NOUN	O	O	3217
were	AUX	O	O	3217
treated	VERB	O	O	3217
sub	ADJ	O	O	3217
-	PUNCT	O	O	3217
chronically	ADV	O	O	3217
(	PUNCT	O	O	3217
twice	ADV	O	O	3217
a	PRON	O	O	3217
day	NOUN	O	O	3217
for	ADP	O	O	3217
4	NUM	O	O	3217
days	NOUN	O	O	3217
)	PUNCT	O	O	3217
with	ADP	O	O	3217
L	NOUN	O	O	3217
-	PUNCT	O	O	3217
NOARG	ADJ	O	O	3217
(	PUNCT	O	O	3217
40	NUM	O	O	3217
mg	VERB	O	O	3217
/	PUNCT	O	O	3217
kg	VERB	O	O	3217
i.p	NOUN	O	O	3217
.	PUNCT	O	O	3217
)	PUNCT	O	O	3217
or	CCONJ	O	O	3218
haloperidol	NOUN	O	Chemical	3218
(	PUNCT	O	O	3218
1	X	O	O	3218
mg	VERB	O	O	3218
/	PUNCT	O	O	3218
kg	VERB	O	O	3218
i.p	NOUN	O	O	3218
.	PUNCT	O	O	3218
)	PUNCT	O	O	3218
.	PUNCT	O	O	3218
Catalepsy	NOUN	O	Disease	3219
was	AUX	O	O	3219
evaluated	VERB	O	O	3219
at	ADP	O	O	3219
the	PRON	O	O	3219
beginning	VERB	O	O	3219
and	CCONJ	O	O	3219
the	PRON	O	O	3219
end	VERB	O	O	3219
of	ADP	O	O	3219
the	PRON	O	O	3219
treatments	NOUN	O	O	3219
.	PUNCT	O	O	3219
Reduced	VERB	O	O	3220
nicotinamide	PROPN	O	O	3220
adenine	ADJ	O	O	3220
dinucleotide	PROPN	O	O	3220
phosphate	NOUN	O	Chemical	3220
-	PUNCT	O	O	3220
diaphorase	NOUN	O	O	3220
(	PUNCT	O	O	3220
NADPH	PROPN	O	O	3220
-	PUNCT	O	O	3220
d	X	O	O	3220
)	PUNCT	O	O	3220
L	NOUN	O	O	3221
-	PUNCT	O	O	3221
NOARG	ADJ	O	O	3221
sub	ADJ	O	O	3221
-	PUNCT	O	O	3221
chronic	ADJ	O	O	3221
administration	NOUN	O	O	3221
produced	VERB	O	O	3221
tolerance	NOUN	O	O	3221
of	ADP	O	O	3221
L	NOUN	O	O	3221
-	PUNCT	O	O	3221
NOARG	ADJ	O	O	3221
and	CCONJ	O	O	3221
of	ADP	O	O	3221
haloperidol	NOUN	O	Chemical	3221
-	PUNCT	O	O	3221
induced	VERB	O	O	3221
catalepsy	VERB	O	Disease	3221
.	PUNCT	O	O	3221
It	PRON	O	O	3222
also	ADV	O	O	3222
induced	VERB	O	O	3222
an	PRON	O	O	3222
increase	VERB	O	O	3222
in	ADP	O	O	3222
the	PRON	O	O	3222
number	NOUN	O	O	3222
of	ADP	O	O	3222
NADPH	PROPN	O	O	3222
-	PUNCT	O	O	3222
d	X	O	O	3222
-	PUNCT	O	O	3222
positive	ADJ	O	O	3222
cells	NOUN	O	O	3222
in	ADP	O	O	3222
the	PRON	O	O	3222
dorsal	PROPN	O	O	3222
part	NOUN	O	O	3222
of	ADP	O	O	3222
the	PRON	O	O	3222
caudate	ADJ	O	O	3222
and	CCONJ	O	O	3222
accumbens	NOUN	O	O	3222
nuclei	NOUN	O	O	3222
compared	VERB	O	O	3222
with	ADP	O	O	3222
haloperidol	NOUN	O	Chemical	3222
and	CCONJ	O	O	3222
in	ADP	O	O	3222
the	PRON	O	O	3222
pedunculopontine	NOUN	O	O	3222
tegmental	NOUN	O	O	3222
nucleus	PROPN	O	O	3222
compared	VERB	O	O	3222
with	ADP	O	O	3222
saline	NOUN	O	O	3222
.	PUNCT	O	O	3222
In	ADP	O	O	3223
contrast	NOUN	O	O	3223
,	PUNCT	O	O	3223
there	ADV	O	O	3223
was	AUX	O	O	3223
a	PRON	O	O	3223
decrease	VERB	O	O	3223
in	ADP	O	O	3223
NADPH	PROPN	O	O	3223
-	PUNCT	O	O	3223
d	X	O	O	3223
neuron	PROPN	O	O	3223
number	NOUN	O	O	3223
in	ADP	O	O	3223
the	PRON	O	O	3223
substantia	X	O	O	3223
nigra	NOUN	O	O	3223
,	PUNCT	O	O	3223
pars	NOUN	O	O	3223
compacta	NOUN	O	O	3223
in	ADP	O	O	3223
both	PRON	O	O	3223
haloperidol	NOUN	O	Chemical	3223
-	PUNCT	O	O	3223
treated	VERB	O	O	3223
and	CCONJ	O	O	3223
L	NOUN	O	O	3223
-	PUNCT	O	O	3223
NOARG	ADJ	O	O	3223
-	PUNCT	O	O	3223
treated	VERB	O	O	3223
animals	NOUN	O	O	3223
.	PUNCT	O	O	3223
CONCLUSIONS	NOUN	O	O	3224
:	PUNCT	O	O	3224
The	PRON	O	O	3224
results	VERB	O	O	3224
give	VERB	O	O	3224
further	ADV	O	O	3224
support	NOUN	O	O	3224
to	PART	O	O	3224
the	PRON	O	O	3224
hypothesis	NOUN	O	O	3224
that	SCONJ	O	O	3224
NO	PRON	O	Chemical	3224
plays	VERB	O	O	3224
a	PRON	O	O	3224
role	NOUN	O	O	3224
in	ADP	O	O	3224
motor	NOUN	O	O	3224
behavior	NOUN	O	O	3224
control	VERB	O	O	3224
and	CCONJ	O	O	3224
suggest	VERB	O	O	3224
that	SCONJ	O	O	3224
it	PRON	O	O	3224
may	AUX	O	O	3224
take	VERB	O	O	3224
part	NOUN	O	O	3224
in	ADP	O	O	3224
the	PRON	O	O	3224
synaptic	ADJ	O	O	3224
changes	VERB	O	O	3224
produced	VERB	O	O	3224
by	ADP	O	O	3224
antipsychotic	ADJ	O	O	3224
treatment	NOUN	O	O	3224
.	PUNCT	O	O	3224
Prolonged	VERB	O	O	3227
left ventricular dysfunction	NOUN	O	Disease	3227
occurs	VERB	O	O	3227
in	ADP	O	O	3227
patients	NOUN	O	O	3227
with	ADP	O	O	3227
coronary artery disease	NOUN	O	Disease	3227
after	ADP	O	O	3227
both	PRON	O	O	3227
dobutamine	NOUN	O	Chemical	3227
and	CCONJ	O	O	3227
exercise	VERB	O	O	3227
induced	VERB	O	O	3227
myocardial ischaemia	NOUN	O	Disease	3227
.	PUNCT	O	O	3227
OBJECTIVE	VERB	O	O	3228
:	PUNCT	O	O	3228
To	PART	O	O	3228
determine	VERB	O	O	3228
whether	SCONJ	O	O	3228
pharmacological	ADJ	O	O	3228
stress	NOUN	O	O	3228
leads	VERB	O	O	3228
to	PART	O	O	3228
prolonged	VERB	O	O	3228
but	CCONJ	O	O	3228
reversible	ADJ	O	O	3228
left ventricular dysfunction	NOUN	O	Disease	3228
in	ADP	O	O	3228
patients	NOUN	O	O	3228
with	ADP	O	O	3228
coronary artery disease	NOUN	O	Disease	3228
,	PUNCT	O	O	3228
similar	ADJ	O	O	3228
to	PART	O	O	3228
that	SCONJ	O	O	3228
seen	VERB	O	O	3228
after	ADP	O	O	3228
exercise	VERB	O	O	3228
.	PUNCT	O	O	3228
A	PRON	O	O	3229
randomised	VERB	O	O	3229
crossover	NOUN	O	O	3229
study	VERB	O	O	3229
of	ADP	O	O	3229
recovery	NOUN	O	O	3229
time	NOUN	O	O	3229
of	ADP	O	O	3229
systolic	ADV	O	O	3229
and	CCONJ	O	O	3229
diastolic	ADV	O	O	3229
left	VERB	O	O	3229
ventricular	ADJ	O	O	3229
function	NOUN	O	O	3229
after	ADP	O	O	3229
exercise	VERB	O	O	3229
and	CCONJ	O	O	3229
dobutamine	NOUN	O	Chemical	3229
induced	VERB	O	O	3229
ischaemia	NOUN	O	O	3229
.	PUNCT	O	O	3229
SUBJECTS	NOUN	O	O	3230
:	PUNCT	O	O	3230
10	NUM	O	O	3230
patients	NOUN	O	O	3230
with	ADP	O	O	3230
stable angina	NOUN	O	Disease	3230
,	PUNCT	O	O	3230
angiographically	ADV	O	O	3230
proven	VERB	O	O	3230
coronary artery disease	NOUN	O	Disease	3230
,	PUNCT	O	O	3230
and	CCONJ	O	O	3230
normal	ADJ	O	O	3230
left	VERB	O	O	3230
ventricular	ADJ	O	O	3230
function	NOUN	O	O	3230
.	PUNCT	O	O	3230
INTERVENTIONS	NOUN	O	O	3231
:	PUNCT	O	O	3231
Treadmill	NOUN	O	O	3231
exercise	VERB	O	O	3231
and	CCONJ	O	O	3231
dobutamine	NOUN	O	Chemical	3231
stress	NOUN	O	O	3231
were	AUX	O	O	3231
performed	VERB	O	O	3231
on	ADP	O	O	3231
different	ADJ	O	O	3231
days	NOUN	O	O	3231
.	PUNCT	O	O	3231
There	ADV	O	O	3232
was	AUX	O	O	3232
no	PRON	O	O	3232
difference	NOUN	O	O	3232
in	ADP	O	O	3232
the	PRON	O	O	3232
maximum	ADV	O	O	3232
double	ADJ	O	O	3232
product	NOUN	O	O	3232
(	PUNCT	O	O	3232
p	NOUN	O	O	3232
=	PUNCT	O	O	3232
0.53	NUM	O	O	3232
)	PUNCT	O	O	3232
or	CCONJ	O	O	3232
ST	PROPN	O	O	3232
depression	PROPN	O	Disease	3232
(	PUNCT	O	O	3232
p	NOUN	O	O	3232
=	PUNCT	O	O	3232
0.63	NUM	O	O	3232
)	PUNCT	O	O	3232
with	ADP	O	O	3232
either	ADV	O	O	3232
form	NOUN	O	O	3232
of	ADP	O	O	3232
stress	NOUN	O	O	3232
.	PUNCT	O	O	3232
After	ADP	O	O	3233
exercise	VERB	O	O	3233
,	PUNCT	O	O	3233
ejection	NOUN	O	O	3233
fraction	NOUN	O	O	3233
was	AUX	O	O	3233
reduced	VERB	O	O	3233
at	ADP	O	O	3233
15	NUM	O	O	3233
and	CCONJ	O	O	3233
30	NUM	O	O	3233
minutes	NOUN	O	O	3233
compared	VERB	O	O	3233
with	ADP	O	O	3233
baseline	VERB	O	O	3233
(	PUNCT	O	O	3233
mean	VERB	O	O	3233
(	PUNCT	O	O	3233
SEM	INTJ	O	O	3233
)	PUNCT	O	O	3233
,	PUNCT	O	O	3233
-5.6	ADV	O	O	3233
(	PUNCT	O	O	3233
1.5)%	NUM	O	O	3233
,	PUNCT	O	O	3233
p	NOUN	O	O	3233
<	X	O	O	3233
0.05	NUM	O	O	3233
;	PUNCT	O	O	3233
and	CCONJ	O	O	3233
-6.1	NOUN	O	O	3233
(	PUNCT	O	O	3233
2.2)%	NUM	O	O	3233
,	PUNCT	O	O	3233
p	NOUN	O	O	3233
<	X	O	O	3233
0	NUM	O	O	3233
.	PUNCT	O	O	3233
01	NUM	O	O	3233
)	PUNCT	O	O	3233
,	PUNCT	O	O	3233
and	CCONJ	O	O	3233
at	ADP	O	O	3233
30	NUM	O	O	3233
and	CCONJ	O	O	3233
45	NUM	O	O	3233
minutes	NOUN	O	O	3233
after	ADP	O	O	3233
dobutamine	NOUN	O	Chemical	3233
(	PUNCT	O	O	3233
-10.8	PUNCT	O	O	3233
(	PUNCT	O	O	3233
1.8)%	PUNCT	O	O	3233
and	CCONJ	O	O	3233
-5	INTJ	O	O	3233
.	PUNCT	O	O	3233
Regional	ADJ	O	O	3234
analysis	NOUN	O	O	3234
showed	VERB	O	O	3234
a	PRON	O	O	3234
reduction	NOUN	O	O	3234
in	ADP	O	O	3234
the	PRON	O	O	3234
worst	ADJ	O	O	3234
affected	VERB	O	O	3234
segment	NOUN	O	O	3234
15	NUM	O	O	3234
and	CCONJ	O	O	3234
30	NUM	O	O	3234
minutes	NOUN	O	O	3234
after	ADP	O	O	3234
exercise	VERB	O	O	3234
(	PUNCT	O	O	3234
-27.9	VERB	O	O	3234
(	PUNCT	O	O	3234
7.2)%	NUM	O	O	3234
and	CCONJ	O	O	3234
-28.6	ADP	O	O	3234
(	PUNCT	O	O	3234
5.7)%	PROPN	O	O	3234
,	PUNCT	O	O	3234
both	PRON	O	O	3234
p	NOUN	O	O	3234
<	X	O	O	3234
0.01	NUM	O	O	3234
)	PUNCT	O	O	3234
,	PUNCT	O	O	3234
and	CCONJ	O	O	3234
at	ADP	O	O	3234
30	NUM	O	O	3234
minutes	NOUN	O	O	3234
after	ADP	O	O	3234
dobutamine	NOUN	O	Chemical	3234
In	ADP	O	O	3235
patients	NOUN	O	O	3235
with	ADP	O	O	3235
coronary artery disease	NOUN	O	Disease	3235
,	PUNCT	O	O	3235
dobutamine	NOUN	O	Chemical	3235
induced	VERB	O	O	3235
ischaemia	NOUN	O	O	3235
results	VERB	O	O	3235
in	ADP	O	O	3235
prolonged	VERB	O	O	3235
reversible	ADJ	O	O	3235
left ventricular dysfunction	NOUN	O	Disease	3235
,	PUNCT	O	O	3235
presumed	VERB	O	O	3235
to	PART	O	O	3235
be	AUX	O	O	3235
myocardial	ADJ	O	O	3235
stunning	ADJ	O	O	3235
,	PUNCT	O	O	3235
similar	ADJ	O	O	3235
to	PART	O	O	3235
that	SCONJ	O	O	3235
seen	VERB	O	O	3235
after	ADP	O	O	3235
exercise	VERB	O	O	3235
.	PUNCT	O	O	3235
Dobutamine	NOUN	O	Chemical	3236
induced	VERB	O	O	3236
ischaemia	NOUN	O	O	3236
could	AUX	O	O	3236
therefore	ADV	O	O	3236
be	AUX	O	O	3236
used	VERB	O	O	3236
to	PART	O	O	3236
study	VERB	O	O	3236
the	PRON	O	O	3236
pathophysiology	NOUN	O	O	3236
of	ADP	O	O	3236
this	PRON	O	O	3236
phenomenon	NOUN	O	O	3236
further	ADV	O	O	3236
in	ADP	O	O	3236
patients	NOUN	O	O	3236
with	ADP	O	O	3236
coronary artery disease	NOUN	O	Disease	3236
.	PUNCT	O	O	3236
Anorexigens	NOUN	O	O	3239
and	CCONJ	O	O	3239
pulmonary hypertension	NOUN	O	Disease	3239
in	ADP	O	O	3239
the	PRON	O	O	3239
United	PROPN	O	O	3239
States	NOUN	O	O	3239
:	PUNCT	O	O	3239
results	VERB	O	O	3239
from	ADP	O	O	3239
the	PRON	O	O	3239
surveillance	NOUN	O	O	3239
of	ADP	O	O	3239
North	NOUN	O	O	3239
American	ADJ	O	O	3239
pulmonary hypertension	NOUN	O	Disease	3239
.	PUNCT	O	O	3239
BACKGROUND	NOUN	O	O	3240
:	PUNCT	O	O	3240
The	PRON	O	O	3240
use	VERB	O	O	3240
of	ADP	O	O	3240
appetite	PROPN	O	O	3240
suppressants	NOUN	O	O	3240
in	ADP	O	O	3240
Europe	PROPN	O	O	3240
has	VERB	O	O	3240
been	AUX	O	O	3240
associated	VERB	O	O	3240
with	ADP	O	O	3240
the	PRON	O	O	3240
development	NOUN	O	O	3240
of	ADP	O	O	3240
primary	NOUN	O	O	3240
pulmonary hypertension	NOUN	O	Disease	3240
(	PUNCT	O	O	3240
PPH	PROPN	O	O	3240
)	PUNCT	O	O	3240
.	PUNCT	O	O	3240
Recently	ADV	O	O	3241
,	PUNCT	O	O	3241
fenfluramine	NOUN	O	Chemical	3241
appetite	PROPN	O	O	3241
suppressants	NOUN	O	O	3241
became	VERB	O	O	3241
widely	ADV	O	O	3241
used	VERB	O	O	3241
in	ADP	O	O	3241
the	PRON	O	O	3241
United	PROPN	O	O	3241
States	NOUN	O	O	3241
but	CCONJ	O	O	3241
were	AUX	O	O	3241
withdrawn	VERB	O	O	3241
in	ADP	O	O	3241
September	PROPN	O	O	3241
1997	NUM	O	O	3241
because	SCONJ	O	O	3241
of	ADP	O	O	3241
concerns	NOUN	O	O	3241
over	ADP	O	O	3241
adverse	ADJ	O	O	3241
effects	NOUN	O	O	3241
.	PUNCT	O	O	3241
:	PUNCT	O	O	3242
We	PRON	O	O	3242
conducted	VERB	O	O	3242
a	PRON	O	O	3242
prospective	ADJ	O	O	3242
surveillance	NOUN	O	O	3242
study	VERB	O	O	3242
on	ADP	O	O	3242
patients	NOUN	O	O	3242
diagnosed	VERB	O	O	3242
with	ADP	O	O	3242
pulmonary hypertension	NOUN	O	Disease	3242
at	ADP	O	O	3242
12	NUM	O	O	3242
large	ADJ	O	O	3242
referral	NOUN	O	O	3242
centers	NOUN	O	O	3242
in	ADP	O	O	3242
North	NOUN	O	O	3242
America	PROPN	O	O	3242
.	PUNCT	O	O	3242
Data	NOUN	O	O	3243
collected	VERB	O	O	3243
on	ADP	O	O	3243
patients	NOUN	O	O	3243
seen	VERB	O	O	3243
from	ADP	O	O	3243
September	PROPN	O	O	3243
1	X	O	O	3243
,	PUNCT	O	O	3243
1996	NUM	O	O	3243
,	PUNCT	O	O	3243
to	PART	O	O	3243
December	PROPN	O	O	3243
31	NUM	O	O	3243
,	PUNCT	O	O	3243
1997	NUM	O	O	3243
,	PUNCT	O	O	3243
included	VERB	O	O	3243
the	PRON	O	O	3243
cause	VERB	O	O	3243
of	ADP	O	O	3243
the	PRON	O	O	3243
pulmonary hypertension	NOUN	O	Disease	3243
and	CCONJ	O	O	3243
its	PRON	O	O	3243
severity	NOUN	O	O	3243
.	PUNCT	O	O	3243
Patients	NOUN	O	O	3244
with	ADP	O	O	3244
no	PRON	O	O	3244
identifiable	ADJ	O	O	3244
cause	VERB	O	O	3244
of	ADP	O	O	3244
pulmonary hypertension	NOUN	O	Disease	3244
were	AUX	O	O	3244
classed	VERB	O	O	3244
as	ADP	O	O	3244
PPH	PROPN	O	O	3244
.	PUNCT	O	O	3244
A	PRON	O	O	3245
history	NOUN	O	O	3245
of	ADP	O	O	3245
drug	NOUN	O	O	3245
exposure	NOUN	O	O	3245
also	ADV	O	O	3245
was	AUX	O	O	3245
taken	VERB	O	O	3245
with	ADP	O	O	3245
special	ADJ	O	O	3245
attention	NOUN	O	O	3245
on	ADP	O	O	3245
the	PRON	O	O	3245
use	VERB	O	O	3245
of	ADP	O	O	3245
antidepressants	NOUN	O	O	3245
,	PUNCT	O	O	3245
anorexigens	NOUN	O	O	3245
,	PUNCT	O	O	3245
and	CCONJ	O	O	3245
amphetamines	NOUN	O	Chemical	3245
.	PUNCT	O	O	3245
Five	NUM	O	O	3246
hundred	NUM	O	O	3246
seventy	NUM	O	O	3246
-	PUNCT	O	O	3246
nine	NUM	O	O	3246
patients	NOUN	O	O	3246
were	AUX	O	O	3246
studied	VERB	O	O	3246
,	PUNCT	O	O	3246
205	NUM	O	O	3246
with	ADP	O	O	3246
PPH	PROPN	O	O	3246
and	CCONJ	O	O	3246
374	NUM	O	O	3246
with	ADP	O	O	3246
pulmonary hypertension	NOUN	O	Disease	3246
from	ADP	O	O	3246
other	ADJ	O	O	3246
causes	VERB	O	O	3246
(	PUNCT	O	O	3246
secondary	ADJ	O	O	3246
pulmonary hypertension	NOUN	O	Disease	3246
[	X	O	O	3246
SPH	NOUN	O	O	3246
]	PUNCT	O	O	3246
)	PUNCT	O	O	3246
.	PUNCT	O	O	3246
However	ADV	O	O	3247
,	PUNCT	O	O	3247
of	ADP	O	O	3247
the	PRON	O	O	3247
medications	NOUN	O	O	3247
surveyed	VERB	O	O	3247
,	PUNCT	O	O	3247
only	ADV	O	O	3247
the	PRON	O	O	3247
fenfluramines	NOUN	O	O	3247
had	VERB	O	O	3247
a	PRON	O	O	3247
significant	ADJ	O	O	3247
preferential	ADJ	O	O	3247
association	PROPN	O	O	3247
with	ADP	O	O	3247
PPH	PROPN	O	O	3247
as	ADP	O	O	3247
compared	VERB	O	O	3247
with	ADP	O	O	3247
SPH	NOUN	O	O	3247
(	PUNCT	O	O	3247
adjusted	VERB	O	O	3247
odds	NOUN	O	O	3247
ratio	NOUN	O	O	3247
for	ADP	O	O	3247
use	VERB	O	O	3247
>	PUNCT	O	O	3247
6	NUM	O	O	3247
months	NOUN	O	O	3247
,	PUNCT	O	O	3247
7.5	NUM	O	O	3247
;	PUNCT	O	O	3247
95%	NOUN	O	O	3247
confidence	NOUN	O	O	3247
interval	NOUN	O	O	3247
,	PUNCT	O	O	3247
1.7	NUM	O	O	3247
to	PART	O	O	3247
32.4	NUM	O	O	3247
)	PUNCT	O	O	3247
.	PUNCT	O	O	3247
The	PRON	O	O	3248
magnitude	NOUN	O	O	3248
of	ADP	O	O	3248
the	PRON	O	O	3248
association	PROPN	O	O	3248
with	ADP	O	O	3248
PPH	PROPN	O	O	3248
,	PUNCT	O	O	3248
the	PRON	O	O	3248
increase	VERB	O	O	3248
of	ADP	O	O	3248
association	PROPN	O	O	3248
with	ADP	O	O	3248
increasing	VERB	O	O	3248
duration	NOUN	O	O	3248
of	ADP	O	O	3248
use	VERB	O	O	3248
,	PUNCT	O	O	3248
and	CCONJ	O	O	3248
the	PRON	O	O	3248
specificity	NOUN	O	O	3248
for	ADP	O	O	3248
fenfluramines	NOUN	O	O	3248
are	AUX	O	O	3248
consistent	ADJ	O	O	3248
with	ADP	O	O	3248
previous	ADJ	O	O	3248
studies	NOUN	O	O	3248
indicating	VERB	O	O	3248
that	SCONJ	O	O	3248
fenfluramines	NOUN	O	O	3248
are	AUX	O	O	3248
causally	ADV	O	O	3248
related	ADJ	O	O	3248
to	PART	O	O	3248
PPH	PROPN	O	O	3248
.	PUNCT	O	O	3248
The	PRON	O	O	3249
high	ADJ	O	O	3249
prevalence	NOUN	O	O	3249
of	ADP	O	O	3249
anorexigen	PROPN	O	O	3249
use	VERB	O	O	3249
in	ADP	O	O	3249
patients	NOUN	O	O	3249
with	ADP	O	O	3249
SPH	NOUN	O	O	3249
also	ADV	O	O	3249
raises	VERB	O	O	3249
the	PRON	O	O	3249
possibility	NOUN	O	O	3249
that	SCONJ	O	O	3249
these	PRON	O	O	3249
drugs	NOUN	O	O	3249
precipitate	VERB	O	O	3249
pulmonary hypertension	NOUN	O	Disease	3249
in	ADP	O	O	3249
patients	NOUN	O	O	3249
with	ADP	O	O	3249
underlying	VERB	O	O	3249
conditions	NOUN	O	O	3249
associated	VERB	O	O	3249
with	ADP	O	O	3249
SPH	NOUN	O	O	3249
.	PUNCT	O	O	3249
Clinical	NOUN	O	O	3252
aspects	NOUN	O	O	3252
of	ADP	O	O	3252
heparin	NOUN	O	Chemical	3252
-	PUNCT	O	O	3252
induced	VERB	O	O	3252
thrombocytopenia	PROPN	O	Disease	3252
and	CCONJ	O	O	3252
thrombosis	NOUN	O	Disease	3252
and	CCONJ	O	O	3252
other	ADJ	O	O	3252
side	NOUN	O	O	3252
effects	NOUN	O	O	3252
of	ADP	O	O	3252
heparin	NOUN	O	Chemical	3252
therapy	NOUN	O	O	3252
.	PUNCT	O	O	3252
Heparin	PROPN	O	Chemical	3253
,	PUNCT	O	O	3253
first	ADV	O	O	3253
used	VERB	O	O	3253
to	PART	O	O	3253
prevent	VERB	O	O	3253
the	PRON	O	O	3253
clotting	VERB	O	O	3253
of	ADP	O	O	3253
blood	NOUN	O	O	3253
in	ADP	O	O	3253
vitro	X	O	O	3253
,	PUNCT	O	O	3253
has	VERB	O	O	3253
been	AUX	O	O	3253
clinically	ADV	O	O	3253
used	VERB	O	O	3253
to	PART	O	O	3253
treat	VERB	O	O	3253
thrombosis	NOUN	O	Disease	3253
for	ADP	O	O	3253
more	ADJ	O	O	3253
than	ADP	O	O	3253
50	NUM	O	O	3253
years	NOUN	O	O	3253
.	PUNCT	O	O	3253
Although	SCONJ	O	O	3254
several	ADJ	O	O	3254
new	ADJ	O	O	3254
anticoagulant	ADJ	O	O	3254
drugs	NOUN	O	O	3254
are	AUX	O	O	3254
in	ADP	O	O	3254
development	NOUN	O	O	3254
,	PUNCT	O	O	3254
heparin	NOUN	O	Chemical	3254
remains	VERB	O	O	3254
the	PRON	O	O	3254
anticoagulant	ADJ	O	O	3254
of	ADP	O	O	3254
choice	NOUN	O	O	3254
to	PART	O	O	3254
treat	VERB	O	O	3254
acute	ADJ	O	O	3254
thrombotic	ADJ	O	Disease	3254
episodes	NOUN	O	O	3254
.	PUNCT	O	O	3254
The	PRON	O	O	3255
clinical	ADJ	O	O	3255
effects	NOUN	O	O	3255
of	ADP	O	O	3255
heparin	NOUN	O	Chemical	3255
are	AUX	O	O	3255
meritorious	ADJ	O	O	3255
,	PUNCT	O	O	3255
but	CCONJ	O	O	3255
side	NOUN	O	O	3255
effects	NOUN	O	O	3255
do	VERB	O	O	3255
exist	VERB	O	O	3255
.	PUNCT	O	O	3255
Bleeding	VERB	O	O	3256
is	AUX	O	O	3256
the	PRON	O	O	3256
primary	NOUN	O	O	3256
untoward	ADJ	O	O	3256
effect	VERB	O	O	3256
of	ADP	O	O	3256
heparin	NOUN	O	Chemical	3256
.	PUNCT	O	O	3256
Major	ADJ	O	O	3257
bleeding	VERB	O	Disease	3257
is	AUX	O	O	3257
of	ADP	O	O	3257
primary	NOUN	O	O	3257
concern	NOUN	O	O	3257
in	ADP	O	O	3257
patients	NOUN	O	O	3257
receiving	VERB	O	O	3257
heparin	NOUN	O	Chemical	3257
therapy	NOUN	O	O	3257
.	PUNCT	O	O	3257
However	ADV	O	O	3258
,	PUNCT	O	O	3258
additional	ADJ	O	O	3258
important	ADJ	O	O	3258
untoward	ADJ	O	O	3258
effects	NOUN	O	O	3258
of	ADP	O	O	3258
heparin	NOUN	O	Chemical	3258
therapy	NOUN	O	O	3258
include	VERB	O	O	3258
heparin	NOUN	O	Chemical	3258
-	PUNCT	O	O	3258
induced	VERB	O	O	3258
thrombocytopenia	PROPN	O	Disease	3258
,	PUNCT	O	O	3258
heparin	NOUN	O	Chemical	3258
-	PUNCT	O	O	3258
associated	VERB	O	O	3258
osteoporosis	NOUN	O	Disease	3258
,	PUNCT	O	O	3258
eosinophilia	PROPN	O	Disease	3258
,	PUNCT	O	O	3258
skin	NOUN	O	O	3258
reactions	NOUN	O	O	3258
,	PUNCT	O	O	3258
allergic	ADJ	O	O	3258
reactions	NOUN	O	O	3258
other	ADJ	O	O	3258
than	ADP	O	O	3258
thrombocytopenia	PROPN	O	Disease	3258
,	PUNCT	O	O	3258
alopecia	NOUN	O	O	3258
,	PUNCT	O	O	3258
transaminasemia	NOUN	O	O	3258
,	PUNCT	O	O	3258
hyperkalemia	NOUN	O	O	3258
,	PUNCT	O	O	3258
hypoaldosteronism	NOUN	O	O	3258
,	PUNCT	O	O	3258
and	CCONJ	O	O	3258
priapism	ADV	O	O	3258
.	PUNCT	O	O	3258
These	PRON	O	O	3259
side	NOUN	O	O	3259
effects	NOUN	O	O	3259
are	AUX	O	O	3259
relatively	ADV	O	O	3259
rare	ADJ	O	O	3259
in	ADP	O	O	3259
a	PRON	O	O	3259
given	VERB	O	O	3259
individual	ADJ	O	O	3259
,	PUNCT	O	O	3259
but	CCONJ	O	O	3259
given	VERB	O	O	3259
the	PRON	O	O	3259
extremely	ADV	O	O	3259
widespread	ADJ	O	O	3259
use	VERB	O	O	3259
of	ADP	O	O	3259
heparin	NOUN	O	Chemical	3259
,	PUNCT	O	O	3259
some	PRON	O	O	3259
are	AUX	O	O	3259
quite	ADV	O	O	3259
common	ADJ	O	O	3259
,	PUNCT	O	O	3259
particularly	ADV	O	O	3259
HITT	PROPN	O	O	3259
and	CCONJ	O	O	3259
osteoporosis	NOUN	O	Disease	3259
.	PUNCT	O	O	3259
Although	SCONJ	O	O	3260
reasonable	ADJ	O	O	3260
incidences	NOUN	O	O	3260
of	ADP	O	O	3260
many	ADJ	O	O	3260
of	ADP	O	O	3260
these	PRON	O	O	3260
side	NOUN	O	O	3260
effects	NOUN	O	O	3260
can	AUX	O	O	3260
be	AUX	O	O	3260
""""	PUNCT	O	O	3260
softly	ADV	O	O	3260
""""	PUNCT	O	O	3260
deduced	VERB	O	O	3260
from	ADP	O	O	3260
current	ADJ	O	O	3260
reports	VERB	O	O	3260
dealing	VERB	O	O	3260
with	ADP	O	O	3260
unfractionated	VERB	O	O	3260
heparin	NOUN	O	Chemical	3260
,	PUNCT	O	O	3260
at	ADP	O	O	3260
present	NOUN	O	O	3260
the	PRON	O	O	3260
incidences	NOUN	O	O	3260
of	ADP	O	O	3260
these	PRON	O	O	3260
side	NOUN	O	O	3260
effects	NOUN	O	O	3260
with	ADP	O	O	3260
newer	ADJ	O	O	3260
low	ADJ	O	O	3260
molecular	ADJ	O	O	3260
weight	NOUN	O	O	3260
heparins	NOUN	O	O	3260
appear	VERB	O	O	3260
to	PART	O	O	3260
be	AUX	O	O	3260
much	ADJ	O	O	3260
less	ADV	O	O	3260
common	ADJ	O	O	3260
.	PUNCT	O	O	3260
A	PRON	O	O	3263
case	NOUN	O	O	3263
of	ADP	O	O	3263
bilateral	ADJ	O	O	3263
optic neuropathy	NOUN	O	Disease	3263
in	ADP	O	O	3263
a	PRON	O	O	3263
patient	NOUN	O	O	3263
on	ADP	O	O	3263
tacrolimus	NOUN	O	Chemical	3263
(	PUNCT	O	O	3263
FK506	NOUN	O	Chemical	3263
)	PUNCT	O	O	3263
therapy	NOUN	O	O	3263
after	ADP	O	O	3263
liver	NOUN	O	O	3263
transplantation	NOUN	O	O	3263
.	PUNCT	O	O	3263
PURPOSE	NOUN	O	O	3264
:	PUNCT	O	O	3264
To	PART	O	O	3264
report	VERB	O	O	3264
a	PRON	O	O	3264
case	NOUN	O	O	3264
of	ADP	O	O	3264
bilateral	ADJ	O	O	3264
optic neuropathy	NOUN	O	Disease	3264
in	ADP	O	O	3264
a	PRON	O	O	3264
patient	NOUN	O	O	3264
receiving	VERB	O	O	3264
tacrolimus	NOUN	O	Chemical	3264
(	PUNCT	O	O	3264
FK	PROPN	O	O	3264
506	NUM	O	O	3264
,	PUNCT	O	O	3264
Prograf	PROPN	O	O	3264
;	PUNCT	O	O	3264
Fujisawa	PROPN	O	O	3264
USA	PROPN	O	O	3264
,	PUNCT	O	O	3264
Inc	PROPN	O	O	3264
,	PUNCT	O	O	3264
Deerfield	PROPN	O	O	3264
,	PUNCT	O	O	3264
Illinois	PROPN	O	O	3264
)	PUNCT	O	O	3264
for	ADP	O	O	3264
immunosuppression	NOUN	O	O	3264
after	ADP	O	O	3264
orthotropic	ADJ	O	O	3264
liver	NOUN	O	O	3264
transplantation	NOUN	O	O	3264
.	PUNCT	O	O	3264
In	ADP	O	O	3265
a	PRON	O	O	3265
58-year	NOUN	O	O	3265
-	PUNCT	O	O	3265
old	ADJ	O	O	3265
man	NOUN	O	O	3265
receiving	VERB	O	O	3265
tacrolimus	NOUN	O	Chemical	3265
after	ADP	O	O	3265
orthotropic	ADJ	O	O	3265
liver	NOUN	O	O	3265
transplantation	NOUN	O	O	3265
,	PUNCT	O	O	3265
serial	ADJ	O	O	3265
neuro	PROPN	O	O	3265
-	PUNCT	O	O	3265
ophthalmologic	ADV	O	O	3265
examinations	NOUN	O	O	3265
and	CCONJ	O	O	3265
laboratory	NOUN	O	O	3265
studies	NOUN	O	O	3265
were	AUX	O	O	3265
performed	VERB	O	O	3265
.	PUNCT	O	O	3265
The	PRON	O	O	3266
patient	NOUN	O	O	3266
had	VERB	O	O	3266
episodic	ADJ	O	O	3266
deterioration of vision	NOUN	O	Disease	3266
in	ADP	O	O	3266
both	PRON	O	O	3266
eyes	NOUN	O	O	3266
,	PUNCT	O	O	3266
with	ADP	O	O	3266
clinical	ADJ	O	O	3266
features	VERB	O	O	3266
resembling	VERB	O	O	3266
ischemic	VERB	O	Disease	3266
optic neuropathies	NOUN	O	Disease	3266
.	PUNCT	O	O	3266
Deterioration	NOUN	O	O	3267
of	ADP	O	O	3267
vision	PROPN	O	O	3267
occurred	VERB	O	O	3267
despite	SCONJ	O	O	3267
discontinuation	NOUN	O	O	3267
of	ADP	O	O	3267
the	PRON	O	O	3267
tacrolimus	NOUN	O	Chemical	3267
.	PUNCT	O	O	3267
Tacrolimus	PROPN	O	Chemical	3268
and	CCONJ	O	O	3268
other	ADJ	O	O	3268
immunosuppressive	ADJ	O	O	3268
agents	NOUN	O	O	3268
may	AUX	O	O	3268
be	AUX	O	O	3268
associated	VERB	O	O	3268
with	ADP	O	O	3268
optic	NOUN	O	O	3268
nerve	NOUN	O	O	3268
toxicity	NOUN	O	Disease	3268
.	PUNCT	O	O	3268
Hypercalcemia	NOUN	O	O	3271
,	PUNCT	O	O	3271
arrhythmia	NOUN	O	Disease	3271
,	PUNCT	O	O	3271
and	CCONJ	O	O	3271
mood	NOUN	O	O	3271
stabilizers	NOUN	O	O	3271
.	PUNCT	O	O	3271
Recent	ADJ	O	O	3272
findings	NOUN	O	O	3272
in	ADP	O	O	3272
a	PRON	O	O	3272
bipolar	ADJ	O	O	3272
patient	NOUN	O	O	3272
receiving	VERB	O	O	3272
maintenance	NOUN	O	O	3272
lithium	NOUN	O	Chemical	3272
therapy	NOUN	O	O	3272
who	PRON	O	O	3272
developed	VERB	O	O	3272
hypercalcemia	NOUN	O	Disease	3272
and	CCONJ	O	O	3272
severe	ADJ	O	O	3272
bradyarrhythmia	NOUN	O	O	3272
prompted	VERB	O	O	3272
the	PRON	O	O	3272
authors	NOUN	O	O	3272
to	PART	O	O	3272
conduct	VERB	O	O	3272
a	PRON	O	O	3272
retrospective	ADJ	O	O	3272
study	VERB	O	O	3272
of	ADP	O	O	3272
bipolar	ADJ	O	O	3272
patients	NOUN	O	O	3272
with	ADP	O	O	3272
lithium	NOUN	O	Chemical	3272
-	PUNCT	O	O	3272
associated	VERB	O	O	3272
hypercalcemia	NOUN	O	Disease	3272
.	PUNCT	O	O	3272
A	PRON	O	O	3273
printout	NOUN	O	O	3273
of	ADP	O	O	3273
all	PRON	O	O	3273
cases	NOUN	O	O	3273
of	ADP	O	O	3273
hypercalcemia	NOUN	O	Disease	3273
that	SCONJ	O	O	3273
presented	VERB	O	O	3273
during	ADP	O	O	3273
a	PRON	O	O	3273
1-year	NOUN	O	O	3273
period	NOUN	O	O	3273
was	AUX	O	O	3273
generated	VERB	O	O	3273
.	PUNCT	O	O	3273
After	ADP	O	O	3274
eliminating	VERB	O	O	3274
spurious	ADJ	O	O	3274
hypercalcemias	PROPN	O	O	3274
or	CCONJ	O	O	3274
those	PRON	O	O	3274
associated	VERB	O	O	3274
with	ADP	O	O	3274
intravenous	ADJ	O	O	3274
fluids	NOUN	O	O	3274
,	PUNCT	O	O	3274
the	PRON	O	O	3274
authors	NOUN	O	O	3274
identified	VERB	O	O	3274
18	NUM	O	O	3274
non	ADJ	O	O	3274
-	PUNCT	O	O	3274
lithium	NOUN	O	Chemical	3274
-	PUNCT	O	O	3274
treated	VERB	O	O	3274
patients	NOUN	O	O	3274
with	ADP	O	O	3274
hypercalcemias	PROPN	O	O	3274
related	ADJ	O	O	3274
to	PART	O	O	3274
malignancies	NOUN	O	O	3274
and	CCONJ	O	O	3274
other	ADJ	O	O	3274
medical	ADJ	O	O	3274
conditions	NOUN	O	O	3274
(	PUNCT	O	O	3274
group	NOUN	O	O	3274
A	PRON	O	O	3274
)	PUNCT	O	O	3274
and	CCONJ	O	O	3274
12	NUM	O	O	3274
patients	NOUN	O	O	3274
with	ADP	O	O	3274
lithium	NOUN	O	Chemical	3274
-	PUNCT	O	O	3274
associated	VERB	O	O	3274
hypercalcemia	NOUN	O	Disease	3274
(	PUNCT	O	O	3274
group	NOUN	O	O	3274
B	NOUN	O	O	3274
)	PUNCT	O	O	3274
.	PUNCT	O	O	3274
Thus	ADV	O	O	3275
,	PUNCT	O	O	3275
two	NUM	O	O	3275
control	VERB	O	O	3275
groups	NOUN	O	O	3275
were	AUX	O	O	3275
generated	VERB	O	O	3275
:	PUNCT	O	O	3275
group	NOUN	O	O	3275
C1	PROPN	O	O	3275
,	PUNCT	O	O	3275
which	PRON	O	O	3275
included	VERB	O	O	3275
age-	ADJ	O	O	3275
and	CCONJ	O	O	3275
sex	NOUN	O	O	3275
-	PUNCT	O	O	3275
comparable	ADJ	O	O	3275
lithium	NOUN	O	Chemical	3275
-	PUNCT	O	O	3275
treated	VERB	O	O	3275
bipolar	ADJ	O	O	3275
normocalcemic	PROPN	O	O	3275
patients	NOUN	O	O	3275
,	PUNCT	O	O	3275
and	CCONJ	O	O	3275
group	NOUN	O	O	3275
C2	PROPN	O	O	3275
,	PUNCT	O	O	3275
which	PRON	O	O	3275
included	VERB	O	O	3275
bipolar	ADJ	O	O	3275
normocalcemic	PROPN	O	O	3275
patients	NOUN	O	O	3275
treated	VERB	O	O	3275
with	ADP	O	O	3275
anticonvulsant	ADJ	O	O	3275
mood	NOUN	O	O	3275
stabilizers	NOUN	O	O	3275
.	PUNCT	O	O	3275
Patients	NOUN	O	O	3276
with	ADP	O	O	3276
hypercalcemia	NOUN	O	Disease	3276
resulting	VERB	O	O	3276
from	ADP	O	O	3276
medical	ADJ	O	O	3276
diseases	NOUN	O	O	3276
and	CCONJ	O	O	3276
bipolar	ADJ	O	O	3276
patients	NOUN	O	O	3276
with	ADP	O	O	3276
lithium	NOUN	O	Chemical	3276
-	PUNCT	O	O	3276
associated	VERB	O	O	3276
hypercalcemia	NOUN	O	Disease	3276
had	VERB	O	O	3276
significantly	ADV	O	O	3276
higher	ADJ	O	O	3276
frequencies	NOUN	O	O	3276
of	ADP	O	O	3276
conduction	NOUN	O	O	3276
defects	NOUN	O	O	3276
.	PUNCT	O	O	3276
Attenuation	NOUN	O	O	3279
of	ADP	O	O	3279
nephrotoxicity	NOUN	O	Disease	3279
by	ADP	O	O	3279
a	PRON	O	O	3279
novel	NOUN	O	O	3279
lipid	NOUN	O	O	3279
nanosphere	PROPN	O	O	3279
(	PUNCT	O	O	3279
NS-718	NOUN	O	O	3279
)	PUNCT	O	O	3279
incorporating	VERB	O	O	3279
amphotericin B.	PROPN	O	O	3279
NS-718	NOUN	O	O	3279
,	PUNCT	O	O	3279
a	PRON	O	O	3279
lipid	NOUN	O	O	3279
nanosphere	PROPN	O	O	3279
incorporating	VERB	O	O	3279
amphotericin B	NOUN	O	Chemical	3279
,	PUNCT	O	O	3279
is	AUX	O	O	3279
effective	ADJ	O	O	3279
against	ADP	O	O	3279
pathogenic	ADJ	O	O	3279
fungi	NOUN	O	O	3279
and	CCONJ	O	O	3279
has	VERB	O	O	3279
low	ADJ	O	O	3279
toxicity	NOUN	O	Disease	3279
.	PUNCT	O	O	3279
We	PRON	O	O	3280
compared	VERB	O	O	3280
the	PRON	O	O	3280
toxicity	NOUN	O	Disease	3280
of	ADP	O	O	3280
NS-718	NOUN	O	O	3280
with	ADP	O	O	3280
that	SCONJ	O	O	3280
of	ADP	O	O	3280
Fungizone	NOUN	O	O	3280
(	PUNCT	O	O	3280
amphotericin B	NOUN	O	Chemical	3280
-	PUNCT	O	O	3280
sodium deoxycholate	VERB	O	Chemical	3280
;	PUNCT	O	O	3280
D	NOUN	O	O	3280
-	PUNCT	O	O	3280
AmB	PROPN	O	Chemical	3280
)	PUNCT	O	O	3280
in	ADP	O	O	3280
vitro	X	O	O	3280
using	VERB	O	O	3280
renal	ADJ	O	O	3280
cell	NOUN	O	O	3280
cultures	NOUN	O	O	3280
and	CCONJ	O	O	3280
in	ADP	O	O	3280
vivo	VERB	O	O	3280
by	ADP	O	O	3280
biochemical	ADJ	O	O	3280
analysis	NOUN	O	O	3280
,	PUNCT	O	O	3280
histopathological	ADJ	O	O	3280
study	VERB	O	O	3280
of	ADP	O	O	3280
the	PRON	O	O	3280
kidney	NOUN	O	O	3280
and	CCONJ	O	O	3280
pharmacokinetic	VERB	O	O	3280
study	VERB	O	O	3280
of	ADP	O	O	3280
amphotericin B	NOUN	O	Chemical	3280
following	VERB	O	O	3280
intravenous	ADJ	O	O	3280
infusion	NOUN	O	O	3280
of	ADP	O	O	3280
the	PRON	O	O	3280
formulation	NOUN	O	O	3280
in	ADP	O	O	3280
rats	NOUN	O	O	3280
.	PUNCT	O	O	3280
Incubation	NOUN	O	O	3281
with	ADP	O	O	3281
NS-718	NOUN	O	O	3281
resulted	VERB	O	O	3281
in	ADP	O	O	3281
significantly	ADV	O	O	3281
less	ADV	O	O	3281
damage	NOUN	O	O	3281
of	ADP	O	O	3281
cultured	ADJ	O	O	3281
human	PROPN	O	O	3281
renal	ADJ	O	O	3281
proximal	ADJ	O	O	3281
tubular	ADJ	O	O	3281
epithelial	ADJ	O	O	3281
cells	NOUN	O	O	3281
compared	VERB	O	O	3281
with	ADP	O	O	3281
D	NOUN	O	O	3281
-	PUNCT	O	O	3281
AmB.	NOUN	O	O	3281
Serum	NOUN	O	O	3281
blood	NOUN	O	O	3281
urea	PROPN	O	Chemical	3281
and	CCONJ	O	O	3281
creatinine	PROPN	O	Chemical	3281
concentrations	NOUN	O	O	3281
increased	VERB	O	O	3281
significantly	ADV	O	O	3281
in	ADP	O	O	3281
rats	NOUN	O	O	3281
given	VERB	O	O	3281
an	PRON	O	O	3281
iv	X	O	O	3281
infusion	NOUN	O	O	3281
of	ADP	O	O	3281
D	NOUN	O	O	3281
-	PUNCT	O	O	3281
AmB	PROPN	O	Chemical	3281
3	X	O	O	3281
mg	VERB	O	O	3281
/	PUNCT	O	O	3281
kg	VERB	O	O	3281
but	CCONJ	O	O	3281
not	PART	O	O	3281
in	ADP	O	O	3281
those	PRON	O	O	3281
given	VERB	O	O	3281
the	PRON	O	O	3281
same	ADJ	O	O	3281
dose	NOUN	O	O	3281
of	ADP	O	O	3281
NS-718	NOUN	O	O	3281
.	PUNCT	O	O	3281
Histopathological	PROPN	O	O	3282
examination	NOUN	O	O	3282
of	ADP	O	O	3282
the	PRON	O	O	3282
kidney	NOUN	O	O	3282
showed	VERB	O	O	3282
tubular necrosis	NOUN	O	Disease	3282
in	ADP	O	O	3282
D	NOUN	O	O	3282
-	PUNCT	O	O	3282
AmB	PROPN	O	Chemical	3282
-	PUNCT	O	O	3282
treated	VERB	O	O	3282
rats	NOUN	O	O	3282
but	CCONJ	O	O	3282
no	PRON	O	O	3282
change	VERB	O	O	3282
in	ADP	O	O	3282
NS-718-treated	VERB	O	O	3282
rats	NOUN	O	O	3282
.	PUNCT	O	O	3282
Amphotericin B	PROPN	O	Chemical	3283
concentrations	NOUN	O	O	3283
in	ADP	O	O	3283
the	PRON	O	O	3283
kidney	NOUN	O	O	3283
in	ADP	O	O	3283
NS-718-treated	VERB	O	O	3283
rats	NOUN	O	O	3283
were	AUX	O	O	3283
higher	ADJ	O	O	3283
than	ADP	O	O	3283
those	PRON	O	O	3283
in	ADP	O	O	3283
D	NOUN	O	O	3283
-	PUNCT	O	O	3283
AmB	PROPN	O	Chemical	3283
-	PUNCT	O	O	3283
treated	VERB	O	O	3283
rats	NOUN	O	O	3283
.	PUNCT	O	O	3283
Our	PRON	O	O	3284
in	ADP	O	O	3284
vitro	X	O	O	3284
and	CCONJ	O	O	3284
in	ADP	O	O	3284
vivo	VERB	O	O	3284
results	VERB	O	O	3284
suggest	VERB	O	O	3284
that	SCONJ	O	O	3284
incorporation	NOUN	O	O	3284
of	ADP	O	O	3284
amphotericin B	NOUN	O	Chemical	3284
into	ADP	O	O	3284
lipid	NOUN	O	O	3284
nanospheres	NOUN	O	O	3284
of	ADP	O	O	3284
NS-718	NOUN	O	O	3284
attenuates	VERB	O	O	3284
the	PRON	O	O	3284
nephrotoxicity	NOUN	O	Disease	3284
of	ADP	O	O	3284
amphotericin B.	PROPN	O	O	3284
Patterns	NOUN	O	O	3287
of	ADP	O	O	3287
sulfadiazine	NOUN	O	O	3287
acute	ADJ	O	O	3287
nephrotoxicity	NOUN	O	Disease	3287
.	PUNCT	O	O	3287
Sulfadiazine	NOUN	O	O	3288
acute	ADJ	O	O	3288
nephrotoxicity	NOUN	O	Disease	3288
is	AUX	O	O	3288
reviving	VERB	O	O	3288
specially	ADV	O	O	3288
because	SCONJ	O	O	3288
of	ADP	O	O	3288
its	PRON	O	O	3288
use	VERB	O	O	3288
in	ADP	O	O	3288
toxoplasmosis	NOUN	O	O	3288
in	ADP	O	O	3288
HIV	PROPN	O	O	3288
-	PUNCT	O	O	3288
positive	ADJ	O	O	3288
patients	NOUN	O	O	3288
.	PUNCT	O	O	3288
Under	ADP	O	O	3289
treatment	NOUN	O	O	3289
with	ADP	O	O	3289
sulfadiazine	NOUN	O	O	3289
they	PRON	O	O	3289
developed	VERB	O	O	3289
oliguria	PROPN	O	O	3289
,	PUNCT	O	O	3289
abdominal pain	NOUN	O	Disease	3289
,	PUNCT	O	O	3289
renal failure	NOUN	O	Disease	3289
and	CCONJ	O	O	3289
showed	VERB	O	O	3289
multiple	ADJ	O	O	3289
radiolucent	ADJ	O	O	3289
renal	ADJ	O	O	3289
calculi	NOUN	O	O	3289
in	ADP	O	O	3289
echography	NOUN	O	O	3289
.	PUNCT	O	O	3289
A	PRON	O	O	3290
nephrostomy	NOUN	O	O	3290
tube	NOUN	O	O	3290
had	VERB	O	O	3290
to	PART	O	O	3290
be	AUX	O	O	3290
placed	VERB	O	O	3290
in	ADP	O	O	3290
one	NUM	O	O	3290
of	ADP	O	O	3290
the	PRON	O	O	3290
patients	NOUN	O	O	3290
for	ADP	O	O	3290
ureteral	ADJ	O	O	3290
lithiasis	NOUN	O	O	3290
in	ADP	O	O	3290
a	PRON	O	O	3290
single	ADJ	O	O	3290
functional	ADJ	O	O	3290
kidney	NOUN	O	O	3290
.	PUNCT	O	O	3290
Treatment	NOUN	O	O	3291
with	ADP	O	O	3291
sulfadiazine	NOUN	O	O	3291
requires	VERB	O	O	3291
exquisite	ADJ	O	O	3291
control	VERB	O	O	3291
of	ADP	O	O	3291
renal	ADJ	O	O	3291
function	NOUN	O	O	3291
,	PUNCT	O	O	3291
an	PRON	O	O	3291
increase	VERB	O	O	3291
in	ADP	O	O	3291
water	PROPN	O	O	3291
ingestion	NOUN	O	O	3291
and	CCONJ	O	O	3291
possibly	ADV	O	O	3291
the	PRON	O	O	3291
alcalinization	NOUN	O	O	3291
of	ADP	O	O	3291
the	PRON	O	O	3291
urine	NOUN	O	O	3291
.	PUNCT	O	O	3291
Downbeat	ADJ	O	O	3294
nystagmus	VERB	O	Disease	3294
associated	VERB	O	O	3294
with	ADP	O	O	3294
intravenous	ADJ	O	O	3294
patient	NOUN	O	O	3294
-	PUNCT	O	O	3294
controlled	VERB	O	O	3294
administration	NOUN	O	O	3294
of	ADP	O	O	3294
morphine	NOUN	O	Chemical	3294
.	PUNCT	O	O	3294
This	PRON	O	O	3295
case	NOUN	O	O	3295
documents	NOUN	O	O	3295
a	PRON	O	O	3295
patient	NOUN	O	O	3295
who	PRON	O	O	3295
developed	VERB	O	O	3295
dizziness	NOUN	O	Disease	3295
with	ADP	O	O	3295
downbeating	NOUN	O	O	3295
nystagmus	VERB	O	Disease	3295
while	SCONJ	O	O	3295
receiving	VERB	O	O	3295
a	PRON	O	O	3295
relatively	ADV	O	O	3295
large	ADJ	O	O	3295
dose	NOUN	O	O	3295
of	ADP	O	O	3295
IV	NUM	O	O	3295
patient	NOUN	O	O	3295
-	PUNCT	O	O	3295
controlled	VERB	O	O	3295
analgesia	NOUN	O	Disease	3295
morphine	NOUN	O	Chemical	3295
.	PUNCT	O	O	3295
Although	SCONJ	O	O	3296
there	ADV	O	O	3296
have	VERB	O	O	3296
been	AUX	O	O	3296
case	NOUN	O	O	3296
reports	VERB	O	O	3296
of	ADP	O	O	3296
epidural	ADV	O	O	3296
morphine	NOUN	O	Chemical	3296
with	ADP	O	O	3296
these	PRON	O	O	3296
symptoms	NOUN	O	O	3296
and	CCONJ	O	O	3296
signs	NOUN	O	O	3296
,	PUNCT	O	O	3296
this	PRON	O	O	3296
has	VERB	O	O	3296
not	PART	O	O	3296
been	AUX	O	O	3296
previously	ADV	O	O	3296
documented	VERB	O	O	3296
with	ADP	O	O	3296
IV	NUM	O	O	3296
or	CCONJ	O	O	3296
patient	NOUN	O	O	3296
-	PUNCT	O	O	3296
controlled	VERB	O	O	3296
analgesia	NOUN	O	Disease	3296
morphine	NOUN	O	Chemical	3296
.	PUNCT	O	O	3296
Hemodynamic	PROPN	O	O	3299
and	CCONJ	O	O	3299
antiadrenergic	NOUN	O	O	3299
effects	NOUN	O	O	3299
of	ADP	O	O	3299
dronedarone	PROPN	O	O	3299
and	CCONJ	O	O	3299
amiodarone	NOUN	O	Chemical	3299
in	ADP	O	O	3299
animals	NOUN	O	O	3299
with	ADP	O	O	3299
a	PRON	O	O	3299
healed	VERB	O	O	3299
myocardial infarction	NOUN	O	Disease	3299
.	PUNCT	O	O	3299
The	PRON	O	O	3300
hemodynamic	ADJ	O	O	3300
and	CCONJ	O	O	3300
antiadrenergic	NOUN	O	O	3300
effects	NOUN	O	O	3300
of	ADP	O	O	3300
dronedarone	PROPN	O	O	3300
,	PUNCT	O	O	3300
a	PRON	O	O	3300
noniodinated	VERB	O	O	3300
compound	NOUN	O	O	3300
structurally	ADV	O	O	3300
related	ADJ	O	O	3300
to	PART	O	O	3300
amiodarone	NOUN	O	Chemical	3300
,	PUNCT	O	O	3300
were	AUX	O	O	3300
compared	VERB	O	O	3300
with	ADP	O	O	3300
those	PRON	O	O	3300
of	ADP	O	O	3300
amiodarone	NOUN	O	Chemical	3300
after	ADP	O	O	3300
prolonged	VERB	O	O	3300
oral	ADJ	O	O	3300
administration	NOUN	O	O	3300
,	PUNCT	O	O	3300
both	PRON	O	O	3300
at	ADP	O	O	3300
rest	VERB	O	O	3300
and	CCONJ	O	O	3300
during	ADP	O	O	3300
sympathetic	ADJ	O	O	3300
stimulation	NOUN	O	O	3300
in	ADP	O	O	3300
conscious	ADJ	O	O	3300
dogs	NOUN	O	O	3300
with	ADP	O	O	3300
a	PRON	O	O	3300
healed	VERB	O	O	3300
myocardial infarction	NOUN	O	Disease	3300
.	PUNCT	O	O	3300
All	PRON	O	O	3301
dogs	NOUN	O	O	3301
(	PUNCT	O	O	3301
n	CCONJ	O	O	3301
=	PUNCT	O	O	3301
6	NUM	O	O	3301
)	PUNCT	O	O	3301
randomly	ADV	O	O	3301
received	VERB	O	O	3301
orally	ADV	O	O	3301
dronedarone	PROPN	O	O	3301
(	PUNCT	O	O	3301
10	NUM	O	O	3301
and	CCONJ	O	O	3301
30	NUM	O	O	3301
mg	VERB	O	O	3301
/	PUNCT	O	O	3301
kg	VERB	O	O	3301
)	PUNCT	O	O	3301
,	PUNCT	O	O	3301
amiodarone	NOUN	O	Chemical	3301
(	PUNCT	O	O	3301
10	NUM	O	O	3301
and	CCONJ	O	O	3301
30	NUM	O	O	3301
mg	VERB	O	O	3301
/	PUNCT	O	O	3301
kg	VERB	O	O	3301
)	PUNCT	O	O	3301
,	PUNCT	O	O	3301
and	CCONJ	O	O	3301
placebo	NOUN	O	O	3301
twice	ADV	O	O	3301
daily	ADV	O	O	3301
for	ADP	O	O	3301
7	NUM	O	O	3301
days	NOUN	O	O	3301
,	PUNCT	O	O	3301
with	ADP	O	O	3301
a	PRON	O	O	3301
3-week	NOUN	O	O	3301
washout	NOUN	O	O	3301
between	ADP	O	O	3301
consecutive	ADJ	O	O	3301
treatments	NOUN	O	O	3301
.	PUNCT	O	O	3301
Heart	NOUN	O	O	3302
rate	NOUN	O	O	3302
(	PUNCT	O	O	3302
HR	NOUN	O	O	3302
)	PUNCT	O	O	3302
,	PUNCT	O	O	3302
mean	VERB	O	O	3302
arterial	ADJ	O	O	3302
pressure	NOUN	O	O	3302
(	PUNCT	O	O	3302
MBP	PROPN	O	O	3302
)	PUNCT	O	O	3302
,	PUNCT	O	O	3302
positive	ADJ	O	O	3302
rate	NOUN	O	O	3302
of	ADP	O	O	3302
increase	VERB	O	O	3302
of	ADP	O	O	3302
left	VERB	O	O	3302
ventricular	ADJ	O	O	3302
pressure	NOUN	O	O	3302
(	PUNCT	O	O	3302
+	ADP	O	O	3302
LVdP	NOUN	O	O	3302
/	PUNCT	O	O	3302
dt	PROPN	O	O	3302
)	PUNCT	O	O	3302
,	PUNCT	O	O	3302
echocardiographically	ADV	O	O	3302
assessed	VERB	O	O	3302
left	VERB	O	O	3302
ventricular	ADJ	O	O	3302
ejection	NOUN	O	O	3302
fraction	NOUN	O	O	3302
(	PUNCT	O	O	3302
LVEF	PROPN	O	O	3302
)	PUNCT	O	O	3302
,	PUNCT	O	O	3302
and	CCONJ	O	O	3302
fractional	ADJ	O	O	3302
shortening	NOUN	O	O	3302
(	PUNCT	O	O	3302
FS	NOUN	O	O	3302
)	PUNCT	O	O	3302
,	PUNCT	O	O	3302
as	ADP	O	O	3302
well	ADV	O	O	3302
as	ADP	O	O	3302
chronotropic	NOUN	O	O	3302
response	NOUN	O	O	3302
to	PART	O	O	3302
isoproterenol	NOUN	O	Chemical	3302
and	CCONJ	O	O	3302
exercise	VERB	O	O	3302
-	PUNCT	O	O	3302
induced	VERB	O	O	3302
sympathetic	ADJ	O	O	3302
stimulation	NOUN	O	O	3302
were	AUX	O	O	3302
evaluated	VERB	O	O	3302
under	ADP	O	O	3302
baseline	VERB	O	O	3302
and	CCONJ	O	O	3302
posttreatment	NOUN	O	O	3302
conditions	NOUN	O	O	3302
.	PUNCT	O	O	3302
Resting	VERB	O	O	3303
values	NOUN	O	O	3303
of	ADP	O	O	3303
LVEF	PROPN	O	O	3303
,	PUNCT	O	O	3303
FS	NOUN	O	O	3303
,	PUNCT	O	O	3303
+	ADP	O	O	3303
LVdP	NOUN	O	O	3303
/	PUNCT	O	O	3303
dt	PROPN	O	O	3303
,	PUNCT	O	O	3303
and	CCONJ	O	O	3303
MBP	PROPN	O	O	3303
remained	VERB	O	O	3303
unchanged	ADJ	O	O	3303
whatever	PRON	O	O	3303
the	PRON	O	O	3303
drug	NOUN	O	O	3303
and	CCONJ	O	O	3303
the	PRON	O	O	3303
dosing	VERB	O	O	3303
regimen	NOUN	O	O	3303
,	PUNCT	O	O	3303
whereas	SCONJ	O	O	3303
resting	VERB	O	O	3303
HR	NOUN	O	O	3303
was	AUX	O	O	3303
significantly	ADV	O	O	3303
and	CCONJ	O	O	3303
dose	NOUN	O	O	3303
-	PUNCT	O	O	3303
dependently	ADV	O	O	3303
lowered	VERB	O	O	3303
after	ADP	O	O	3303
dronedarone	PROPN	O	O	3303
and	CCONJ	O	O	3303
to	PART	O	O	3303
a	PRON	O	O	3303
lesser	ADJ	O	O	3303
extent	NOUN	O	O	3303
after	ADP	O	O	3303
amiodarone	NOUN	O	Chemical	3303
.	PUNCT	O	O	3303
Both	PRON	O	O	3304
dronedarone	PROPN	O	O	3304
and	CCONJ	O	O	3304
amiodarone	NOUN	O	Chemical	3304
significantly	ADV	O	O	3304
reduced	VERB	O	O	3304
the	PRON	O	O	3304
exercise	VERB	O	O	3304
-	PUNCT	O	O	3304
induced	VERB	O	O	3304
tachycardia	PROPN	O	Disease	3304
and	CCONJ	O	O	3304
,	PUNCT	O	O	3304
at	ADP	O	O	3304
the	PRON	O	O	3304
highest	ADJ	O	O	3304
dose	NOUN	O	O	3304
,	PUNCT	O	O	3304
decreased	VERB	O	O	3304
the	PRON	O	O	3304
isoproterenol	NOUN	O	Chemical	3304
-	PUNCT	O	O	3304
induced	VERB	O	O	3304
tachycardia	PROPN	O	Disease	3304
.	PUNCT	O	O	3304
Thus	ADV	O	O	3305
,	PUNCT	O	O	3305
dronedarone	PROPN	O	O	3305
and	CCONJ	O	O	3305
amiodarone	NOUN	O	Chemical	3305
displayed	VERB	O	O	3305
a	PRON	O	O	3305
similar	ADJ	O	O	3305
level	VERB	O	O	3305
of	ADP	O	O	3305
antiadrenergic	NOUN	O	O	3305
effect	VERB	O	O	3305
and	CCONJ	O	O	3305
did	VERB	O	O	3305
not	PART	O	O	3305
impair	VERB	O	O	3305
the	PRON	O	O	3305
resting	VERB	O	O	3305
left	VERB	O	O	3305
ventricular	ADJ	O	O	3305
function	NOUN	O	O	3305
.	PUNCT	O	O	3305
Consequently	ADV	O	O	3306
,	PUNCT	O	O	3306
dronedarone	PROPN	O	O	3306
might	AUX	O	O	3306
be	AUX	O	O	3306
particularly	ADV	O	O	3306
suitable	ADJ	O	O	3306
for	ADP	O	O	3306
the	PRON	O	O	3306
treatment	NOUN	O	O	3306
and	CCONJ	O	O	3306
prevention	NOUN	O	O	3306
of	ADP	O	O	3306
various	ADJ	O	O	3306
clinical	ADJ	O	O	3306
arrhythmias	VERB	O	Disease	3306
,	PUNCT	O	O	3306
without	ADP	O	O	3306
compromising	VERB	O	O	3306
the	PRON	O	O	3306
left	VERB	O	O	3306
ventricular	ADJ	O	O	3306
function	NOUN	O	O	3306
.	PUNCT	O	O	3306
Phase	NOUN	O	O	3309
2	X	O	O	3309
trial	NOUN	O	O	3309
of	ADP	O	O	3309
liposomal	NOUN	O	O	3309
doxorubicin	VERB	O	Chemical	3309
(	PUNCT	O	O	3309
40	NUM	O	O	3309
mg	VERB	O	O	3309
/	PUNCT	O	O	3309
m(2	NUM	O	O	3309
)	PUNCT	O	O	3309
)	PUNCT	O	O	3309
in	ADP	O	O	3309
platinum	NOUN	O	Chemical	3309
/	PUNCT	O	O	3309
paclitaxel	NOUN	O	Chemical	3309
-	PUNCT	O	O	3309
refractory	ADJ	O	O	3309
ovarian	NOUN	O	O	3309
and	CCONJ	O	O	3309
fallopian	ADJ	O	O	3309
tube	NOUN	O	O	3309
cancers	NOUN	O	Disease	3309
and	CCONJ	O	O	3309
primary	NOUN	O	O	3309
carcinoma	NOUN	O	Disease	3309
of	ADP	O	O	3309
the	PRON	O	O	3309
peritoneum	NOUN	O	O	3309
.	PUNCT	O	O	3309
Several	ADJ	O	O	3310
studies	NOUN	O	O	3310
have	VERB	O	O	3310
demonstrated	VERB	O	O	3310
liposomal	NOUN	O	O	3310
doxorubicin	VERB	O	Chemical	3310
(	PUNCT	O	O	3310
Doxil	NOUN	O	O	3310
)	PUNCT	O	O	3310
to	PART	O	O	3310
be	AUX	O	O	3310
an	PRON	O	O	3310
active	ADJ	O	O	3310
antineoplastic	ADJ	O	O	3310
agent	NOUN	O	O	3310
in	ADP	O	O	3310
platinum	NOUN	O	Chemical	3310
-	PUNCT	O	O	3310
resistant	ADJ	O	O	3310
ovarian cancer	NOUN	O	Disease	3310
,	PUNCT	O	O	3310
with	ADP	O	O	3310
dose	NOUN	O	O	3310
limiting	VERB	O	O	3310
toxicity	NOUN	O	Disease	3310
of	ADP	O	O	3310
the	PRON	O	O	3310
standard	PROPN	O	O	3310
dosing	VERB	O	O	3310
regimen	NOUN	O	O	3310
(	PUNCT	O	O	3310
50	NUM	O	O	3310
mg	VERB	O	O	3310
/	PUNCT	O	O	3310
m(2	NUM	O	O	3310
)	PUNCT	O	O	3310
q	X	O	O	3311
4	NUM	O	O	3311
weeks	NOUN	O	O	3311
)	PUNCT	O	O	3311
being	AUX	O	O	3311
severe	ADJ	O	O	3311
erythrodysesthesia	ADV	O	O	3311
(	PUNCT	O	O	3311
""""	PUNCT	O	O	3311
hand	NOUN	O	O	3311
-	PUNCT	O	O	3311
foot	NOUN	O	O	3311
syndrome	NOUN	O	O	3311
""""	PUNCT	O	O	3311
)	PUNCT	O	O	3311
and	CCONJ	O	O	3311
stomatitis	PROPN	O	O	3311
.	PUNCT	O	O	3311
We	PRON	O	O	3312
wished	VERB	O	O	3312
to	PART	O	O	3312
develop	VERB	O	O	3312
a	PRON	O	O	3312
more	ADJ	O	O	3312
tolerable	ADJ	O	O	3312
liposomal	NOUN	O	O	3312
doxorubicin	VERB	O	Chemical	3312
treatment	NOUN	O	O	3312
regimen	NOUN	O	O	3312
and	CCONJ	O	O	3312
document	NOUN	O	O	3312
its	PRON	O	O	3312
level	VERB	O	O	3312
of	ADP	O	O	3312
activity	NOUN	O	O	3312
in	ADP	O	O	3312
a	PRON	O	O	3312
well	ADV	O	O	3312
-	PUNCT	O	O	3312
defined	VERB	O	O	3312
patient	NOUN	O	O	3312
population	NOUN	O	O	3312
with	ADP	O	O	3312
platinum	NOUN	O	Chemical	3312
/	PUNCT	O	O	3312
paclitaxel	NOUN	O	Chemical	3312
-	PUNCT	O	O	3312
refractory	ADJ	O	O	3312
disease	PROPN	O	O	3312
.	PUNCT	O	O	3312
Patients	NOUN	O	O	3313
with	ADP	O	O	3313
ovarian	NOUN	O	O	3313
or	CCONJ	O	O	3313
fallopian	ADJ	O	O	3313
tube	NOUN	O	O	3313
cancers	NOUN	O	Disease	3313
or	CCONJ	O	O	3313
primary	NOUN	O	O	3313
peritoneal	ADJ	O	O	3313
carcinoma	NOUN	O	Disease	3313
with	ADP	O	O	3313
platinum	NOUN	O	Chemical	3313
/	PUNCT	O	O	3313
paclitaxel	NOUN	O	Chemical	3313
-	PUNCT	O	O	3313
refractory	ADJ	O	O	3313
disease	PROPN	O	O	3313
(	PUNCT	O	O	3313
stable	ADJ	O	O	3313
or	CCONJ	O	O	3313
progressive	ADJ	O	O	3313
disease	PROPN	O	O	3313
following	VERB	O	O	3313
treatment	NOUN	O	O	3313
with	ADP	O	O	3313
these	PRON	O	O	3313
agents	NOUN	O	O	3313
or	CCONJ	O	O	3313
previous	ADJ	O	O	3313
objective	VERB	O	O	3313
response	NOUN	O	O	3313
<3	X	O	O	3313
months	NOUN	O	O	3313
in	ADP	O	O	3313
duration	NOUN	O	O	3313
)	PUNCT	O	O	3313
were	AUX	O	O	3313
treated	VERB	O	O	3313
with	ADP	O	O	3313
liposomal	NOUN	O	O	3313
doxorubicin	VERB	O	Chemical	3313
at	ADP	O	O	3313
a	PRON	O	O	3313
dose	NOUN	O	O	3313
of	ADP	O	O	3313
40	NUM	O	O	3313
mg	VERB	O	O	3313
/	PUNCT	O	O	3313
m(2	NUM	O	O	3313
)	PUNCT	O	O	3313
q	X	O	O	3313
4	NUM	O	O	3313
weeks	NOUN	O	O	3313
.	PUNCT	O	O	3313
Six	NUM	O	O	3314
(	PUNCT	O	O	3314
12%	NOUN	O	O	3314
)	PUNCT	O	O	3314
and	CCONJ	O	O	3314
4	NUM	O	O	3314
(	PUNCT	O	O	3314
8%	NOUN	O	O	3314
)	PUNCT	O	O	3314
patients	NOUN	O	O	3314
experienced	ADJ	O	O	3314
grade	NOUN	O	O	3314
2	X	O	O	3314
hand	NOUN	O	O	3314
-	PUNCT	O	O	3314
foot	NOUN	O	O	3314
syndrome	NOUN	O	O	3314
and	CCONJ	O	O	3314
stomatitis	PROPN	O	O	3314
,	PUNCT	O	O	3314
respectively	ADV	O	O	3314
(	PUNCT	O	O	3314
no	PRON	O	O	3314
episodes	NOUN	O	O	3314
of	ADP	O	O	3314
grade	NOUN	O	O	3314
3	X	O	O	3314
)	PUNCT	O	O	3314
.	PUNCT	O	O	3314
One	NUM	O	O	3315
patient	NOUN	O	O	3315
developed	VERB	O	O	3315
grade	NOUN	O	O	3315
3	X	O	O	3315
diarrhea	PROPN	O	Disease	3315
requiring	VERB	O	O	3315
hospitalization	NOUN	O	O	3315
for	ADP	O	O	3315
hydration	NOUN	O	O	3315
.	PUNCT	O	O	3315
The	PRON	O	O	3316
median	ADJ	O	O	3316
number	NOUN	O	O	3316
of	ADP	O	O	3316
courses	NOUN	O	O	3316
of	ADP	O	O	3316
liposomal	NOUN	O	O	3316
doxorubicin	VERB	O	Chemical	3316
administered	VERB	O	O	3316
on	ADP	O	O	3316
this	PRON	O	O	3316
protocol	PROPN	O	O	3316
was	AUX	O	O	3316
2	X	O	O	3316
(	PUNCT	O	O	3316
range	VERB	O	O	3316
:	PUNCT	O	O	3316
1	X	O	O	3316
-	PUNCT	O	O	3316
12	NUM	O	O	3316
)	PUNCT	O	O	3316
.	PUNCT	O	O	3316
This	PRON	O	O	3317
modified	VERB	O	O	3317
liposomal	NOUN	O	O	3317
doxorubicin	VERB	O	Chemical	3317
regimen	NOUN	O	O	3317
results	VERB	O	O	3317
in	ADP	O	O	3317
less	ADV	O	O	3317
toxicity	NOUN	O	Disease	3317
(	PUNCT	O	O	3317
stomatitis	PROPN	O	O	3317
,	PUNCT	O	O	3317
hand	NOUN	O	O	3317
-	PUNCT	O	O	3317
foot	NOUN	O	O	3317
syndrome	NOUN	O	O	3317
)	PUNCT	O	O	3317
than	ADP	O	O	3317
the	PRON	O	O	3317
standard	PROPN	O	O	3317
FDA	PROPN	O	O	3317
-	PUNCT	O	O	3317
approved	VERB	O	O	3317
dose	NOUN	O	O	3317
schedule	NOUN	O	O	3317
.	PUNCT	O	O	3317
Definite	ADJ	O	O	3318
,	PUNCT	O	O	3318
although	SCONJ	O	O	3318
limited	VERB	O	O	3318
,	PUNCT	O	O	3318
antineoplastic	ADJ	O	O	3318
activity	NOUN	O	O	3318
is	AUX	O	O	3318
observed	VERB	O	O	3318
in	ADP	O	O	3318
patients	NOUN	O	O	3318
with	ADP	O	O	3318
well	ADV	O	O	3318
-	PUNCT	O	O	3318
defined	VERB	O	O	3318
platinum-	ADJ	O	O	3318
and	CCONJ	O	O	3318
paclitaxel	NOUN	O	Chemical	3318
-	PUNCT	O	O	3318
refractory	ADJ	O	O	3318
ovarian cancer	NOUN	O	Disease	3318
.	PUNCT	O	O	3318
Efficacy	NOUN	O	O	3321
of	ADP	O	O	3321
olanzapine	NOUN	O	Chemical	3321
in	ADP	O	O	3321
acute	ADJ	O	O	3321
bipolar mania	NOUN	O	Disease	3321
:	PUNCT	O	O	3321
a	PRON	O	O	3321
double	ADJ	O	O	3321
-	PUNCT	O	O	3321
blind	ADJ	O	Disease	3321
,	PUNCT	O	O	3321
placebo	NOUN	O	O	3321
-	PUNCT	O	O	3321
controlled	VERB	O	O	3321
study	VERB	O	O	3321
.	PUNCT	O	O	3321
The	PRON	O	O	3322
Olanzipine	NOUN	O	O	3322
HGGW	NOUN	O	O	3322
Study	NOUN	O	O	3322
Group	PROPN	O	O	3322
.	PUNCT	O	O	3322
We	PRON	O	O	3323
compared	VERB	O	O	3323
the	PRON	O	O	3323
efficacy	NOUN	O	O	3323
and	CCONJ	O	O	3323
safety	NOUN	O	O	3323
of	ADP	O	O	3323
olanzapine	NOUN	O	Chemical	3323
vs	ADP	O	O	3323
placebo	NOUN	O	O	3323
for	ADP	O	O	3323
the	PRON	O	O	3323
treatment	NOUN	O	O	3323
of	ADP	O	O	3323
acute	ADJ	O	O	3323
bipolar mania	NOUN	O	Disease	3323
.	PUNCT	O	O	3323
A	PRON	O	O	3324
total	ADJ	O	O	3324
of	ADP	O	O	3324
115	NUM	O	O	3324
patients	NOUN	O	O	3324
with	ADP	O	O	3324
a	PRON	O	O	3324
DSM	PROPN	O	O	3324
-	PUNCT	O	O	3324
IV	NUM	O	O	3324
diagnosis	NOUN	O	O	3324
of	ADP	O	O	3324
bipolar disorder	NOUN	O	Disease	3324
,	PUNCT	O	O	3324
manic	ADJ	O	O	3324
or	CCONJ	O	O	3324
mixed	VERB	O	O	3324
,	PUNCT	O	O	3324
were	AUX	O	O	3324
randomized	VERB	O	O	3324
to	PART	O	O	3324
olanzapine	NOUN	O	Chemical	3324
,	PUNCT	O	O	3324
5	NUM	O	O	3324
to	PART	O	O	3324
20	NUM	O	O	3324
mg	VERB	O	O	3324
/	PUNCT	O	O	3324
d	X	O	O	3324
(	PUNCT	O	O	3324
n	CCONJ	O	O	3324
=	PUNCT	O	O	3324
55	NUM	O	O	3324
)	PUNCT	O	O	3324
,	PUNCT	O	O	3324
or	CCONJ	O	O	3324
placebo	NOUN	O	O	3324
(	PUNCT	O	O	3324
n	CCONJ	O	O	3324
=	PUNCT	O	O	3324
60	NUM	O	O	3324
)	PUNCT	O	O	3324
.	PUNCT	O	O	3324
The	PRON	O	O	3325
primary	NOUN	O	O	3325
efficacy	NOUN	O	O	3325
measure	VERB	O	O	3325
was	AUX	O	O	3325
the	PRON	O	O	3325
Young	ADJ	O	O	3325
-	PUNCT	O	O	3325
Mania	NOUN	O	O	3325
Rating	NOUN	O	O	3325
Scale	NOUN	O	O	3325
(	PUNCT	O	O	3325
Y	NOUN	O	O	3325
-	PUNCT	O	O	3325
MRS	PROPN	O	O	3325
)	PUNCT	O	O	3325
total	ADJ	O	O	3325
score	VERB	O	O	3325
.	PUNCT	O	O	3325
Safety	NOUN	O	O	3326
was	AUX	O	O	3326
assessed	VERB	O	O	3326
using	VERB	O	O	3326
adverse	ADJ	O	O	3326
events	NOUN	O	O	3326
,	PUNCT	O	O	3326
Extrapyramidal	NOUN	O	O	3326
Symptom	NOUN	O	O	3326
(	PUNCT	O	O	3326
EPS	PROPN	O	Disease	3326
)	PUNCT	O	O	3326
rating	NOUN	O	O	3326
scales	NOUN	O	O	3326
,	PUNCT	O	O	3326
laboratory	NOUN	O	O	3326
values	NOUN	O	O	3326
,	PUNCT	O	O	3326
electrocardiograms	VERB	O	O	3326
,	PUNCT	O	O	3326
vital	ADJ	O	O	3326
signs	NOUN	O	O	3326
,	PUNCT	O	O	3326
and	CCONJ	O	O	3326
weight	NOUN	O	O	3326
change	VERB	O	O	3326
.	PUNCT	O	O	3326
Olanzapine	NOUN	O	O	3327
-	PUNCT	O	O	3327
treated	VERB	O	O	3327
patients	NOUN	O	O	3327
demonstrated	VERB	O	O	3327
a	PRON	O	O	3327
statistically	ADV	O	O	3327
significant	ADJ	O	O	3327
greater	ADJ	O	O	3327
mean	VERB	O	O	3327
(	PUNCT	O	O	3327
+	ADP	O	O	3327
/-	PUNCT	O	O	3327
Olanzapine	NOUN	O	O	3328
-	PUNCT	O	O	3328
treated	VERB	O	O	3328
patients	NOUN	O	O	3328
demonstrated	VERB	O	O	3328
a	PRON	O	O	3328
higher	ADJ	O	O	3328
rate	NOUN	O	O	3328
of	ADP	O	O	3328
response	NOUN	O	O	3328
(	PUNCT	O	O	3328
65%	NOUN	O	O	3328
vs	ADP	O	O	3328
43%	NOUN	O	O	3328
,	PUNCT	O	O	3328
respectively	ADV	O	O	3328
;	PUNCT	O	O	3328
P	NOUN	O	Chemical	3328
=	PUNCT	O	O	3328
.02	NUM	O	O	3328
)	PUNCT	O	O	3328
and	CCONJ	O	O	3328
euthymia	VERB	O	O	3328
(	PUNCT	O	O	3328
There	ADV	O	O	3329
were	AUX	O	O	3329
no	PRON	O	O	3329
statistically	ADV	O	O	3329
significant	ADJ	O	O	3329
differences	NOUN	O	O	3329
in	ADP	O	O	3329
EPSs	NOUN	O	O	3329
between	ADP	O	O	3329
groups	NOUN	O	O	3329
.	PUNCT	O	O	3329
However	ADV	O	O	3330
,	PUNCT	O	O	3330
olanzapine	NOUN	O	Chemical	3330
-	PUNCT	O	O	3330
treated	VERB	O	O	3330
patients	NOUN	O	O	3330
had	VERB	O	O	3330
a	PRON	O	O	3330
statistically	ADV	O	O	3330
significant	ADJ	O	O	3330
greater	ADJ	O	O	3330
mean	VERB	O	O	3330
(	PUNCT	O	O	3330
+	ADP	O	O	3330
/-	PUNCT	O	O	3330
SD	NOUN	O	O	3331
)	PUNCT	O	O	3331
weight	NOUN	O	O	3331
gain	VERB	O	O	3331
than	ADP	O	O	3331
placebo	NOUN	O	O	3331
-	PUNCT	O	O	3331
treated	VERB	O	O	3331
patients	NOUN	O	O	3331
(	PUNCT	O	O	3331
2.1	NUM	O	O	3331
+	ADP	O	O	3331
/-	PUNCT	O	O	3331
2.3	NUM	O	O	3332
kg	VERB	O	O	3332
,	PUNCT	O	O	3332
respectively	ADV	O	O	3332
)	PUNCT	O	O	3332
and	CCONJ	O	O	3332
also	ADV	O	O	3332
experienced	ADJ	O	O	3332
more	ADJ	O	O	3332
treatment	NOUN	O	O	3332
-	PUNCT	O	O	3332
emergent	ADJ	O	O	3332
somnolence	NOUN	O	Disease	3332
(	PUNCT	O	O	3332
21	NUM	O	O	3332
patients	NOUN	O	O	3332
[	X	O	O	3332
38.2%	NOUN	O	O	3332
]	PUNCT	O	O	3332
vs	ADP	O	O	3332
5	NUM	O	O	3332
[	X	O	O	3332
8.3%	NOUN	O	O	3332
]	PUNCT	O	O	3332
,	PUNCT	O	O	3332
respectively	ADV	O	O	3332
)	PUNCT	O	O	3332
.	PUNCT	O	O	3332
CONCLUSION	PROPN	O	O	3333
:	PUNCT	O	O	3333
Olanzapine	NOUN	O	O	3333
demonstrated	VERB	O	O	3333
greater	ADJ	O	O	3333
efficacy	NOUN	O	O	3333
than	ADP	O	O	3333
placebo	NOUN	O	O	3333
in	ADP	O	O	3333
the	PRON	O	O	3333
treatment	NOUN	O	O	3333
of	ADP	O	O	3333
acute	ADJ	O	O	3333
bipolar mania	NOUN	O	Disease	3333
and	CCONJ	O	O	3333
was	AUX	O	O	3333
generally	ADV	O	O	3333
well	ADV	O	O	3333
tolerated	VERB	O	O	3333
.	PUNCT	O	O	3333
The	PRON	O	O	3336
effect	VERB	O	O	3336
of	ADP	O	O	3336
pupil	NOUN	O	O	3336
dilation	NOUN	O	O	3336
with	ADP	O	O	3336
tropicamide	NOUN	O	Chemical	3336
on	ADP	O	O	3336
vision	PROPN	O	O	3336
and	CCONJ	O	O	3336
driving	VERB	O	O	3336
simulator	PROPN	O	O	3336
performance	NOUN	O	O	3336
.	PUNCT	O	O	3336
To	PART	O	O	3337
assess	VERB	O	O	3337
the	PRON	O	O	3337
effect	VERB	O	O	3337
of	ADP	O	O	3337
pupil	NOUN	O	O	3337
dilation	NOUN	O	O	3337
on	ADP	O	O	3337
vision	PROPN	O	O	3337
and	CCONJ	O	O	3337
driving	VERB	O	O	3337
ability	NOUN	O	O	3337
.	PUNCT	O	O	3337
METHODS	NOUN	O	O	3338
:	PUNCT	O	O	3338
A	PRON	O	O	3338
series	PROPN	O	O	3338
of	ADP	O	O	3338
tests	VERB	O	O	3338
on	ADP	O	O	3338
various	ADJ	O	O	3338
parameters	NOUN	O	O	3338
of	ADP	O	O	3338
visual	ADJ	O	O	3338
function	NOUN	O	O	3338
and	CCONJ	O	O	3338
driving	VERB	O	O	3338
simulator	PROPN	O	O	3338
performance	NOUN	O	O	3338
were	AUX	O	O	3338
performed	VERB	O	O	3338
on	ADP	O	O	3338
12	NUM	O	O	3338
healthy	ADJ	O	O	3338
drivers	NOUN	O	O	3338
,	PUNCT	O	O	3338
before	ADP	O	O	3338
and	CCONJ	O	O	3338
after	ADP	O	O	3338
pupil	NOUN	O	O	3338
dilation	NOUN	O	O	3338
using	VERB	O	O	3338
guttae	NOUN	O	O	3338
tropicamide	NOUN	O	Chemical	3338
1%	NOUN	O	O	3338
.	PUNCT	O	O	3338
RESULTS	VERB	O	O	3339
:	PUNCT	O	O	3339
Pupillary	PROPN	O	O	3339
dilation	NOUN	O	O	3339
resulted	VERB	O	O	3339
in	ADP	O	O	3339
a	PRON	O	O	3339
statistically	ADV	O	O	3339
significant	ADJ	O	O	3339
deterioration	NOUN	O	O	3339
in	ADP	O	O	3339
CT	PROPN	O	O	3339
and	CCONJ	O	O	3339
HCVA	PROPN	O	O	3339
only	ADV	O	O	3339
.	PUNCT	O	O	3339
Pupillary	PROPN	O	O	3340
dilation	NOUN	O	O	3340
may	AUX	O	O	3340
lead	VERB	O	Chemical	3340
to	PART	O	O	3340
a	PRON	O	O	3340
decrease	VERB	O	O	3340
in	ADP	O	O	3340
vision	PROPN	O	O	3340
and	CCONJ	O	O	3340
daylight	NOUN	O	O	3340
driving	VERB	O	O	3340
performance	NOUN	O	O	3340
in	ADP	O	O	3340
young	ADJ	O	O	3340
people	NOUN	O	O	3340
.	PUNCT	O	O	3340
A	PRON	O	O	3343
case	NOUN	O	O	3343
of	ADP	O	O	3343
isotretinoin	PROPN	O	O	3343
embryopathy	PROPN	O	O	3343
with	ADP	O	O	3343
bilateral	ADJ	O	O	3343
anotia	VERB	O	O	3343
and	CCONJ	O	O	3343
Taussig	PROPN	O	O	3343
-	PUNCT	O	O	3343
Bing	NOUN	O	O	3343
malformation	NOUN	O	O	3343
.	PUNCT	O	O	3343
We	PRON	O	O	3344
report	VERB	O	O	3344
a	PRON	O	O	3344
newborn	ADJ	O	O	3344
infant	NOUN	O	O	3344
with	ADP	O	O	3344
multiple	ADJ	O	O	3344
congenital	NOUN	O	O	3344
anomalies	NOUN	O	O	3344
(	PUNCT	O	O	3344
anotia	VERB	O	O	3344
and	CCONJ	O	O	3344
Taussig	PROPN	O	O	3344
-	PUNCT	O	O	3344
Bing	NOUN	O	O	3344
malformation	NOUN	O	O	3344
)	PUNCT	O	O	3344
due	ADJ	O	O	3344
to	PART	O	O	3344
exposure	NOUN	O	O	3344
to	PART	O	O	3344
isotretinoin	PROPN	O	O	3344
within	ADP	O	O	3344
the	PRON	O	O	3344
first	ADV	O	O	3344
trimester	VERB	O	O	3344
.	PUNCT	O	O	3344
In	ADP	O	O	3345
this	PRON	O	O	3345
paper	PROPN	O	O	3345
we	PRON	O	O	3345
aim	VERB	O	O	3345
to	PART	O	O	3345
draw	VERB	O	O	3345
to	PART	O	O	3345
the	PRON	O	O	3345
fact	NOUN	O	O	3345
that	SCONJ	O	O	3345
caution	NOUN	O	O	3345
is	AUX	O	O	3345
needed	VERB	O	O	3345
when	SCONJ	O	O	3345
prescribing	VERB	O	O	3345
vitamin	NOUN	O	O	3345
A	PRON	O	O	3345
-	PUNCT	O	O	3345
containing	VERB	O	O	3345
drugs	NOUN	O	O	3345
to	PART	O	O	3345
women	NOUN	O	O	3345
of	ADP	O	O	3345
childbearing	VERB	O	O	3345
years	NOUN	O	O	3345
.	PUNCT	O	O	3345
Effect	VERB	O	O	3348
of	ADP	O	O	3348
methoxamine	NOUN	O	Chemical	3348
on	ADP	O	O	3348
maximum	ADV	O	O	3348
urethral	NOUN	O	O	3348
pressure	NOUN	O	O	3348
in	ADP	O	O	3348
women	NOUN	O	O	3348
with	ADP	O	O	3348
genuine	ADJ	O	O	3348
stress	NOUN	O	O	3348
incontinence	NOUN	O	O	3348
:	PUNCT	O	O	3348
a	PRON	O	O	3348
placebo	NOUN	O	O	3348
-	PUNCT	O	O	3348
controlled	VERB	O	O	3348
,	PUNCT	O	O	3348
double	ADJ	O	O	3348
-	PUNCT	O	O	3348
blind	ADJ	O	Disease	3348
crossover	NOUN	O	O	3348
study	VERB	O	O	3348
.	PUNCT	O	O	3348
The	PRON	O	O	3349
aim	VERB	O	O	3349
of	ADP	O	O	3349
the	PRON	O	O	3349
study	VERB	O	O	3349
was	AUX	O	O	3349
to	PART	O	O	3349
evaluate	VERB	O	O	3349
the	PRON	O	O	3349
potential	ADJ	O	O	3349
role	NOUN	O	O	3349
for	ADP	O	O	3349
a	PRON	O	O	3349
selective	ADJ	O	O	3349
alpha1-adrenoceptor	NOUN	O	O	3349
agonist	NOUN	O	O	3349
in	ADP	O	O	3349
the	PRON	O	O	3349
treatment	NOUN	O	O	3349
of	ADP	O	O	3349
urinary	ADJ	O	O	3349
stress	NOUN	O	O	3349
incontinence	NOUN	O	O	3349
.	PUNCT	O	O	3349
Half	ADV	O	O	3350
log	VERB	O	O	3350
incremental	ADJ	O	O	3350
doses	NOUN	O	O	3350
of	ADP	O	O	3350
intravenous	ADJ	O	O	3350
methoxamine	NOUN	O	Chemical	3350
or	CCONJ	O	O	3350
placebo	NOUN	O	O	3350
(	PUNCT	O	O	3350
saline	NOUN	O	O	3350
)	PUNCT	O	O	3350
were	AUX	O	O	3350
administered	VERB	O	O	3350
to	PART	O	O	3350
a	PRON	O	O	3350
group	NOUN	O	O	3350
of	ADP	O	O	3350
women	NOUN	O	O	3350
with	ADP	O	O	3350
genuine	ADJ	O	O	3350
stress	NOUN	O	O	3350
incontinence	NOUN	O	O	3350
while	SCONJ	O	O	3350
measuring	VERB	O	O	3350
maximum	ADV	O	O	3350
urethral	NOUN	O	O	3350
pressure	NOUN	O	O	3350
(	PUNCT	O	O	3350
MUP	PROPN	O	O	3350
)	PUNCT	O	O	3350
,	PUNCT	O	O	3350
blood	NOUN	O	O	3350
pressure	NOUN	O	O	3350
,	PUNCT	O	O	3350
heart	NOUN	O	O	3350
rate	NOUN	O	O	3350
,	PUNCT	O	O	3350
and	CCONJ	O	O	3350
symptomatic	ADJ	O	O	3350
side	NOUN	O	O	3350
effects	NOUN	O	O	3350
.	PUNCT	O	O	3350
Methoxamine	NOUN	O	O	3351
evoked	VERB	O	O	3351
non	ADJ	O	O	3351
-	PUNCT	O	O	3351
significant	ADJ	O	O	3351
increases	VERB	O	O	3351
in	ADP	O	O	3351
MUP	PROPN	O	O	3351
and	CCONJ	O	O	3351
diastolic	ADV	O	O	3351
blood	NOUN	O	O	3351
pressure	NOUN	O	O	3351
but	CCONJ	O	O	3351
caused	VERB	O	O	3351
a	PRON	O	O	3351
significant	ADJ	O	O	3351
rise	VERB	O	O	3351
in	ADP	O	O	3351
systolic	ADV	O	O	3351
blood	NOUN	O	O	3351
pressure	NOUN	O	O	3351
and	CCONJ	O	O	3351
significant	ADJ	O	O	3351
fall	VERB	O	O	3351
in	ADP	O	O	3351
heart	NOUN	O	O	3351
rate	NOUN	O	O	3351
at	ADP	O	O	3351
maximum	ADV	O	O	3351
dosage	NOUN	O	O	3351
.	PUNCT	O	O	3351
Systemic	ADJ	O	O	3352
side	NOUN	O	O	3352
effects	NOUN	O	O	3352
including	VERB	O	O	3352
piloerection	NOUN	O	O	3352
,	PUNCT	O	O	3352
headache	PROPN	O	Disease	3352
,	PUNCT	O	O	3352
and	CCONJ	O	O	3352
cold	ADJ	O	O	3352
extremities	NOUN	O	O	3352
were	AUX	O	O	3352
experienced	ADJ	O	O	3352
in	ADP	O	O	3352
all	PRON	O	O	3352
subjects	NOUN	O	O	3352
.	PUNCT	O	O	3352
The	PRON	O	O	3353
results	VERB	O	O	3353
indicate	VERB	O	O	3353
that	SCONJ	O	O	3353
the	PRON	O	O	3353
clinical	ADJ	O	O	3353
usefulness	NOUN	O	O	3353
of	ADP	O	O	3353
direct	ADJ	O	O	3353
,	PUNCT	O	O	3353
peripherally	ADV	O	O	3353
acting	VERB	O	O	3353
sub	ADJ	O	O	3353
-	PUNCT	O	O	3353
type	NOUN	O	O	3353
-	PUNCT	O	O	3353
selective	ADJ	O	O	3353
alpha1-adrenoceptor	NOUN	O	O	3353
agonists	NOUN	O	O	3353
in	ADP	O	O	3353
the	PRON	O	O	3353
medical	ADJ	O	O	3353
treatment	NOUN	O	O	3353
of	ADP	O	O	3353
stress	NOUN	O	O	3353
incontinence	NOUN	O	O	3353
may	AUX	O	O	3353
be	AUX	O	O	3353
limited	VERB	O	O	3353
by	ADP	O	O	3353
associated	VERB	O	O	3353
piloerection	NOUN	O	O	3353
and	CCONJ	O	O	3353
cardiovascular	ADJ	O	O	3353
side	NOUN	O	O	3353
effects	NOUN	O	O	3353
.	PUNCT	O	O	3353
Toleration	NOUN	O	O	3356
of	ADP	O	O	3356
high	ADJ	O	O	3356
doses	NOUN	O	O	3356
of	ADP	O	O	3356
angiotensin	NOUN	O	Chemical	3356
-	PUNCT	O	O	3356
converting	VERB	O	O	3356
enzyme	NOUN	O	O	3356
inhibitors	NOUN	O	O	3356
in	ADP	O	O	3356
patients	NOUN	O	O	3356
with	ADP	O	O	3356
chronic	ADJ	O	O	3356
heart failure	NOUN	O	Disease	3356
:	PUNCT	O	O	3356
results	VERB	O	O	3356
from	ADP	O	O	3356
the	PRON	O	O	3356
ATLAS	PROPN	O	O	3356
trial	NOUN	O	O	3356
.	PUNCT	O	O	3356
The	PRON	O	O	3357
Assessment	NOUN	O	O	3357
of	ADP	O	O	3357
Treatment	NOUN	O	O	3357
with	ADP	O	O	3357
Lisinopril	PROPN	O	O	3357
and	CCONJ	O	O	3357
Survival	NOUN	O	O	3357
.	PUNCT	O	O	3357
BACKGROUND	NOUN	O	O	3358
:	PUNCT	O	O	3358
Treatment	NOUN	O	O	3358
with	ADP	O	O	3358
angiotensin	NOUN	O	Chemical	3358
-	PUNCT	O	O	3358
converting	VERB	O	O	3358
enzyme	NOUN	O	O	3358
(	PUNCT	O	O	3358
ACE	PROPN	O	O	3358
)	PUNCT	O	O	3358
inhibitors	NOUN	O	O	3358
reduces	VERB	O	O	3358
mortality	NOUN	O	O	3358
and	CCONJ	O	O	3358
morbidity	NOUN	O	O	3358
in	ADP	O	O	3358
patients	NOUN	O	O	3358
with	ADP	O	O	3358
chronic	ADJ	O	O	3358
heart failure	NOUN	O	Disease	3358
(	PUNCT	O	O	3358
CHF	PROPN	O	Disease	3358
)	PUNCT	O	O	3358
,	PUNCT	O	O	3358
but	CCONJ	O	O	3358
most	ADV	O	O	3358
affected	VERB	O	O	3358
patients	NOUN	O	O	3358
are	AUX	O	O	3358
not	PART	O	O	3358
receiving	VERB	O	O	3358
these	PRON	O	O	3358
agents	NOUN	O	O	3358
or	CCONJ	O	O	3358
are	AUX	O	O	3358
being	AUX	O	O	3358
treated	VERB	O	O	3358
with	ADP	O	O	3358
doses	NOUN	O	O	3358
lower	ADJ	O	O	3358
than	ADP	O	O	3358
those	PRON	O	O	3358
found	VERB	O	O	3358
to	PART	O	O	3358
be	AUX	O	O	3358
efficacious	ADJ	O	O	3358
in	ADP	O	O	3358
trials	NOUN	O	O	3358
,	PUNCT	O	O	3358
primarily	ADV	O	O	3358
because	SCONJ	O	O	3358
of	ADP	O	O	3358
concerns	NOUN	O	O	3358
about	ADP	O	O	3358
the	PRON	O	O	3358
safety	NOUN	O	O	3358
and	CCONJ	O	O	3358
tolerability	NOUN	O	O	3358
of	ADP	O	O	3358
these	PRON	O	O	3358
agents	NOUN	O	O	3358
,	PUNCT	O	O	3358
especially	ADV	O	O	3358
at	ADP	O	O	3358
the	PRON	O	O	3358
recommended	VERB	O	O	3358
doses	NOUN	O	O	3358
.	PUNCT	O	O	3358
The	PRON	O	O	3359
present	NOUN	O	O	3359
study	VERB	O	O	3359
examines	VERB	O	O	3359
the	PRON	O	O	3359
safety	NOUN	O	O	3359
and	CCONJ	O	O	3359
tolerability	NOUN	O	O	3359
of	ADP	O	O	3359
high-	NOUN	O	O	3359
compared	VERB	O	O	3359
with	ADP	O	O	3359
low	ADJ	O	O	3359
-	PUNCT	O	O	3359
dose	NOUN	O	O	3359
lisinopril	PROPN	O	O	3359
in	ADP	O	O	3359
CHF	PROPN	O	Disease	3359
.	PUNCT	O	O	3359
The	PRON	O	O	3360
Assessment	NOUN	O	O	3360
of	ADP	O	O	3360
Lisinopril	PROPN	O	O	3360
and	CCONJ	O	O	3360
Survival	NOUN	O	O	3360
study	VERB	O	O	3360
was	AUX	O	O	3360
a	PRON	O	O	3360
multicenter	ADJ	O	O	3360
,	PUNCT	O	O	3360
randomized	VERB	O	O	3360
,	PUNCT	O	O	3360
double	ADJ	O	O	3360
-	PUNCT	O	O	3360
blind	ADJ	O	Disease	3360
trial	NOUN	O	O	3360
in	ADP	O	O	3360
which	PRON	O	O	3360
patients	NOUN	O	O	3360
with	ADP	O	O	3360
or	CCONJ	O	O	3360
without	ADP	O	O	3360
previous	ADJ	O	O	3360
ACE	PROPN	O	O	3360
inhibitor	NOUN	O	O	3360
treatment	NOUN	O	O	3360
were	AUX	O	O	3360
stabilized	VERB	O	O	3360
receiving	VERB	O	O	3360
medium	ADJ	O	O	3360
-	PUNCT	O	O	3360
dose	NOUN	O	O	3360
lisinopril	PROPN	O	O	3360
(	PUNCT	O	O	3360
12.5	NUM	O	O	3360
or	CCONJ	O	O	3360
15.0	NUM	O	O	3360
mg	VERB	O	O	3360
once	ADV	O	O	3360
daily	ADV	O	O	3360
[	X	O	O	3360
OD	NOUN	O	O	3360
]	PUNCT	O	O	3360
)	PUNCT	O	O	3360
for	ADP	O	O	3360
2	X	O	O	3360
to	PART	O	O	3360
4	NUM	O	O	3360
weeks	NOUN	O	O	3360
and	CCONJ	O	O	3360
then	ADV	O	O	3360
randomized	VERB	O	O	3360
to	PART	O	O	3360
high-	NOUN	O	O	3360
(	PUNCT	O	O	3360
35.0	NUM	O	O	3360
or	CCONJ	O	O	3360
32.5	NUM	O	O	3360
mg	VERB	O	O	3360
OD	NOUN	O	O	3360
)	PUNCT	O	O	3360
or	CCONJ	O	O	3360
low	ADJ	O	O	3360
-	PUNCT	O	O	3360
dose	NOUN	O	O	3360
(	PUNCT	O	O	3360
5.0	NUM	O	O	3360
or	CCONJ	O	O	3360
2.5	NUM	O	O	3360
mg	VERB	O	O	3360
OD	NOUN	O	O	3360
)	PUNCT	O	O	3360
groups	NOUN	O	O	3360
.	PUNCT	O	O	3360
Patients	NOUN	O	O	3361
with	ADP	O	O	3361
New	ADJ	O	O	3361
York	PROPN	O	O	3361
Heart	NOUN	O	O	3361
Association	PROPN	O	O	3361
classes	NOUN	O	O	3361
II	NUM	O	O	3361
to	PART	O	O	3361
IV	NUM	O	O	3361
CHF	PROPN	O	Disease	3361
and	CCONJ	O	O	3361
left	VERB	O	O	3361
ventricular	ADJ	O	O	3361
ejection	NOUN	O	O	3361
fractions	NOUN	O	O	3361
of	ADP	O	O	3361
no	PRON	O	O	3361
greater	ADJ	O	O	3361
than	ADP	O	O	3361
0.30	NUM	O	O	3361
(	PUNCT	O	O	3361
n	CCONJ	O	O	3361
=	PUNCT	O	O	3361
3164	NUM	O	O	3361
)	PUNCT	O	O	3361
were	AUX	O	O	3361
randomized	VERB	O	O	3361
and	CCONJ	O	O	3361
followed	VERB	O	O	3361
up	ADP	O	O	3361
for	ADP	O	O	3361
a	PRON	O	O	3361
median	ADJ	O	O	3361
of	ADP	O	O	3361
46	NUM	O	O	3361
months	NOUN	O	O	3361
.	PUNCT	O	O	3361
We	PRON	O	O	3362
examined	VERB	O	O	3362
the	PRON	O	O	3362
occurrence	NOUN	O	O	3362
of	ADP	O	O	3362
adverse	ADJ	O	O	3362
events	NOUN	O	O	3362
and	CCONJ	O	O	3362
the	PRON	O	O	3362
need	VERB	O	O	3362
for	ADP	O	O	3362
discontinuation	NOUN	O	O	3362
and	CCONJ	O	O	3362
dose	NOUN	O	O	3362
reduction	NOUN	O	O	3362
during	ADP	O	O	3362
treatment	NOUN	O	O	3362
,	PUNCT	O	O	3362
with	ADP	O	O	3362
a	PRON	O	O	3362
focus	NOUN	O	O	3362
on	ADP	O	O	3362
hypotension	NOUN	O	Disease	3362
and	CCONJ	O	O	3362
renal dysfunction	NOUN	O	Disease	3362
.	PUNCT	O	O	3362
Of	ADV	O	O	3363
405	NUM	O	O	3363
patients	NOUN	O	O	3363
not	PART	O	O	3363
previously	ADV	O	O	3363
receiving	VERB	O	O	3363
an	PRON	O	O	3363
ACE	PROPN	O	O	3363
inhibitor	NOUN	O	O	3363
,	PUNCT	O	O	3363
doses	NOUN	O	O	3363
in	ADP	O	O	3363
only	ADV	O	O	3363
4.2%	NOUN	O	O	3363
could	AUX	O	O	3363
not	PART	O	O	3363
be	AUX	O	O	3363
titrated	VERB	O	O	3363
to	PART	O	O	3363
the	PRON	O	O	3363
medium	ADJ	O	O	3363
doses	NOUN	O	O	3363
required	VERB	O	O	3363
for	ADP	O	O	3363
randomization	NOUN	O	O	3363
because	SCONJ	O	O	3363
of	ADP	O	O	3363
symptoms	NOUN	O	O	3363
possibly	ADV	O	O	3363
related	ADJ	O	O	3363
to	PART	O	O	3363
hypotension	NOUN	O	Disease	3363
(	PUNCT	O	O	3363
2.0%	NOUN	O	O	3363
)	PUNCT	O	O	3363
or	CCONJ	O	O	3363
because	SCONJ	O	O	3363
of	ADP	O	O	3363
renal dysfunction	NOUN	O	Disease	3363
or	CCONJ	O	O	3363
hyperkalemia	NOUN	O	O	3363
(	PUNCT	O	O	3363
2.3%	NOUN	O	O	3363
)	PUNCT	O	O	3363
.	PUNCT	O	O	3363
Subgroups	NOUN	O	O	3364
presumed	VERB	O	O	3364
to	PART	O	O	3364
be	AUX	O	O	3364
at	ADP	O	O	3364
higher	ADJ	O	O	3364
risk	NOUN	O	O	3364
for	ADP	O	O	3364
ACE	PROPN	O	O	3364
inhibitor	NOUN	O	O	3364
intolerance	NOUN	O	O	3364
(	PUNCT	O	O	3364
blood	NOUN	O	O	3364
pressure	NOUN	O	O	3364
,	PUNCT	O	O	3364
<	X	O	O	3364
creatinine	PROPN	O	Chemical	3365
,	PUNCT	O	O	3365
>	PUNCT	O	O	3365
or	CCONJ	O	O	3365
=	PUNCT	O	O	3365
132.6	NUM	O	O	3365
micromol	NOUN	O	O	3365
/	PUNCT	O	O	3365
L	NOUN	O	O	3365
[	X	O	O	3365
>	PUNCT	O	O	3365
or	CCONJ	O	O	3365
=	PUNCT	O	O	3365
1.5	NUM	O	O	3365
mg	VERB	O	O	3365
/	PUNCT	O	O	3365
dL	VERB	O	O	3365
]	PUNCT	O	O	3365
;	PUNCT	O	O	3365
age	NOUN	O	O	3365
,	PUNCT	O	O	3365
>	PUNCT	O	O	3365
or	CCONJ	O	O	3365
=	PUNCT	O	O	3365
70	NUM	O	O	3365
years	NOUN	O	O	3365
;	PUNCT	O	O	3365
and	CCONJ	O	O	3365
patients	NOUN	O	O	3365
with	ADP	O	O	3365
diabetes	NOUN	O	Disease	3365
)	PUNCT	O	O	3365
generally	ADV	O	O	3365
tolerated	VERB	O	O	3365
the	PRON	O	O	3365
high	ADJ	O	O	3365
-	PUNCT	O	O	3365
dose	NOUN	O	O	3365
strategy	NOUN	O	O	3365
.	PUNCT	O	O	3365
These	PRON	O	O	3366
findings	NOUN	O	O	3366
demonstrate	VERB	O	O	3366
that	SCONJ	O	O	3366
ACE	PROPN	O	O	3366
inhibitor	NOUN	O	O	3366
therapy	NOUN	O	O	3366
in	ADP	O	O	3366
most	ADV	O	O	3366
patients	NOUN	O	O	3366
with	ADP	O	O	3366
CHF	PROPN	O	Disease	3366
can	AUX	O	O	3366
be	AUX	O	O	3366
successfully	ADV	O	O	3366
titrated	VERB	O	O	3366
to	PART	O	O	3366
and	CCONJ	O	O	3366
maintained	VERB	O	O	3366
at	ADP	O	O	3366
high	ADJ	O	O	3366
doses	NOUN	O	O	3366
,	PUNCT	O	O	3366
and	CCONJ	O	O	3366
that	SCONJ	O	O	3366
more	ADJ	O	O	3366
aggressive	ADJ	O	O	3366
use	VERB	O	O	3366
of	ADP	O	O	3366
these	PRON	O	O	3366
agents	NOUN	O	O	3366
is	AUX	O	O	3366
warranted	VERB	O	O	3366
.	PUNCT	O	O	3366
Cocaine	NOUN	O	Chemical	3369
,	PUNCT	O	O	3369
ethanol	NOUN	O	Chemical	3369
,	PUNCT	O	O	3369
and	CCONJ	O	O	3369
cocaethylene	VERB	O	O	3369
cardiotoxity	NOUN	O	O	3369
in	ADP	O	O	3369
an	PRON	O	O	3369
animal	NOUN	O	O	3369
model	NOUN	O	O	3369
of	ADP	O	O	3369
cocaine	NOUN	O	Chemical	3369
and	CCONJ	O	O	3369
ethanol	NOUN	O	Chemical	3369
abuse	VERB	O	O	3369
.	PUNCT	O	O	3369
Simultaneous	ADJ	O	O	3370
abuse	VERB	O	O	3370
of	ADP	O	O	3370
cocaine	NOUN	O	Chemical	3370
and	CCONJ	O	O	3370
ethanol	NOUN	O	Chemical	3370
affects	VERB	O	O	3370
12	NUM	O	O	3370
million	NUM	O	O	3370
Americans	PROPN	O	O	3370
annually	ADV	O	O	3370
.	PUNCT	O	O	3370
Their	PRON	O	O	3371
combined	VERB	O	O	3371
cardiac toxicity	NOUN	O	Disease	3371
may	AUX	O	O	3371
be	AUX	O	O	3371
due	ADJ	O	O	3371
to	PART	O	O	3371
independent	ADJ	O	O	3371
effects	NOUN	O	O	3371
of	ADP	O	O	3371
each	PRON	O	O	3371
drug	NOUN	O	O	3371
;	PUNCT	O	O	3371
however	ADV	O	O	3371
,	PUNCT	O	O	3371
they	PRON	O	O	3371
may	AUX	O	O	3371
also	ADV	O	O	3371
be	AUX	O	O	3371
due	ADJ	O	O	3371
to	PART	O	O	3371
cocaethylene	VERB	O	O	3371
(	PUNCT	O	O	3371
CE	PROPN	O	O	3371
)	PUNCT	O	O	3371
,	PUNCT	O	O	3371
a	PRON	O	O	3371
cocaine	NOUN	O	Chemical	3371
metabolite	NOUN	O	O	3371
formed	VERB	O	O	3371
only	ADV	O	O	3371
in	ADP	O	O	3371
the	PRON	O	O	3371
presence	NOUN	O	O	3371
of	ADP	O	O	3371
ethanol	NOUN	O	Chemical	3371
.	PUNCT	O	O	3371
The	PRON	O	O	3372
purpose	NOUN	O	O	3372
of	ADP	O	O	3372
this	PRON	O	O	3372
study	VERB	O	O	3372
was	AUX	O	O	3372
to	PART	O	O	3372
delineate	VERB	O	O	3372
the	PRON	O	O	3372
role	NOUN	O	O	3372
of	ADP	O	O	3372
CE	PROPN	O	O	3372
in	ADP	O	O	3372
the	PRON	O	O	3372
combined	VERB	O	O	3372
cardiotoxicity	NOUN	O	Disease	3372
of	ADP	O	O	3372
cocaine	NOUN	O	Chemical	3372
and	CCONJ	O	O	3372
ethanol	NOUN	O	Chemical	3372
in	ADP	O	O	3372
a	PRON	O	O	3372
model	NOUN	O	O	3372
simulating	VERB	O	O	3372
their	PRON	O	O	3372
abuse	VERB	O	O	3372
.	PUNCT	O	O	3372
Twenty	NUM	O	O	3373
-	PUNCT	O	O	3373
three	NUM	O	O	3373
dogs	NOUN	O	O	3373
were	AUX	O	O	3373
randomized	VERB	O	O	3373
to	PART	O	O	3373
receive	VERB	O	O	3373
either	ADV	O	O	3373
1	X	O	O	3373
)	PUNCT	O	O	3373
three	NUM	O	O	3373
intravenous	ADJ	O	O	3373
(	PUNCT	O	O	3373
IV	NUM	O	O	3373
)	PUNCT	O	O	3373
boluses	NOUN	O	O	3373
of	ADP	O	O	3373
cocaine	NOUN	O	Chemical	3373
7.5	NUM	O	O	3373
mg	VERB	O	O	3373
/	PUNCT	O	O	3373
kg	VERB	O	O	3373
with	ADP	O	O	3373
ethanol	NOUN	O	Chemical	3373
(	PUNCT	O	O	3373
1	X	O	O	3373
g	X	O	O	3373
/	PUNCT	O	O	3373
kg	VERB	O	O	3373
)	PUNCT	O	O	3373
as	ADP	O	O	3373
an	PRON	O	O	3373
IV	NUM	O	O	3373
infusion	NOUN	O	O	3373
(	PUNCT	O	O	3373
C+E	NUM	O	O	3373
,	PUNCT	O	O	3373
n	CCONJ	O	O	3374
=	PUNCT	O	O	3374
8)	NUM	O	O	3374
,	PUNCT	O	O	3374
2	X	O	O	3374
)	PUNCT	O	O	3374
three	NUM	O	O	3374
cocaine	NOUN	O	Chemical	3374
boluses	NOUN	O	O	3374
only	ADV	O	O	3374
(	PUNCT	O	O	3374
C	NOUN	O	O	3374
,	PUNCT	O	O	3374
n	CCONJ	O	O	3374
=	PUNCT	O	O	3374
6	NUM	O	O	3374
)	PUNCT	O	O	3374
,	PUNCT	O	O	3374
3	X	O	O	3374
)	PUNCT	O	O	3374
ethanol	NOUN	O	Chemical	3374
infusion	NOUN	O	O	3374
only	ADV	O	O	3374
(	PUNCT	O	O	3374
E	NOUN	O	Chemical	3374
,	PUNCT	O	O	3374
n	CCONJ	O	O	3374
=	PUNCT	O	O	3374
5	NUM	O	O	3374
)	PUNCT	O	O	3374
,	PUNCT	O	O	3374
or	CCONJ	O	O	3374
4	NUM	O	O	3374
)	PUNCT	O	O	3374
placebo	NOUN	O	O	3374
boluses	NOUN	O	O	3374
and	CCONJ	O	O	3374
infusion	NOUN	O	O	3374
(	PUNCT	O	O	3374
n	CCONJ	O	O	3374
=	PUNCT	O	O	3374
4	NUM	O	O	3374
)	PUNCT	O	O	3374
.	PUNCT	O	O	3374
Two	NUM	O	O	3375
of	ADP	O	O	3375
eight	NUM	O	O	3375
dogs	NOUN	O	O	3375
in	ADP	O	O	3375
the	PRON	O	O	3375
C+E	NUM	O	O	3375
group	NOUN	O	O	3375
experienced	ADJ	O	O	3375
cardiovascular	ADJ	O	O	3375
collapse	VERB	O	O	3375
.	PUNCT	O	O	3375
The	PRON	O	O	3376
most	ADV	O	O	3376
dramatic	ADJ	O	O	3376
hemodynamic	ADJ	O	O	3376
changes	VERB	O	O	3376
occurred	VERB	O	O	3376
after	ADP	O	O	3376
each	PRON	O	O	3376
cocaine	NOUN	O	Chemical	3376
bolus	NOUN	O	O	3376
in	ADP	O	O	3376
the	PRON	O	O	3376
C+E	NUM	O	O	3376
and	CCONJ	O	O	3376
C	NOUN	O	O	3376
only	ADV	O	O	3376
groups	NOUN	O	O	3376
;	PUNCT	O	O	3376
however	ADV	O	O	3376
,	PUNCT	O	O	3376
persistent	ADJ	O	O	3376
hemodynamic	ADJ	O	O	3376
changes	VERB	O	O	3376
occurred	VERB	O	O	3376
in	ADP	O	O	3376
the	PRON	O	O	3376
C+E	NUM	O	O	3376
group	NOUN	O	O	3376
.	PUNCT	O	O	3376
Peak	NOUN	O	O	3377
CE	PROPN	O	O	3377
levels	NOUN	O	O	3377
were	AUX	O	O	3377
associated	VERB	O	O	3377
with	ADP	O	O	3377
a	PRON	O	O	3377
45%	NOUN	O	O	3377
(	PUNCT	O	O	3377
SD	NOUN	O	O	3377
+	ADP	O	O	3377
/-	PUNCT	O	O	3377
22%	NOUN	O	O	3378
to	PART	O	O	3378
69%	NOUN	O	O	3378
)	PUNCT	O	O	3378
decrease	VERB	O	O	3378
in	ADP	O	O	3378
cardiac	ADJ	O	O	3378
output	NOUN	O	O	3378
(	PUNCT	O	O	3378
p	NOUN	O	O	3378
<	X	O	O	3378
0.05	NUM	O	O	3378
)	PUNCT	O	O	3378
,	PUNCT	O	O	3378
a	PRON	O	O	3378
56%	NOUN	O	O	3378
(	PUNCT	O	O	3378
SD	NOUN	O	O	3378
+	ADP	O	O	3378
/-	PUNCT	O	O	3378
Ventricular	PROPN	O	O	3379
arrhythmias	VERB	O	Disease	3379
were	AUX	O	O	3379
primarily	ADV	O	O	3379
observed	VERB	O	O	3379
in	ADP	O	O	3379
the	PRON	O	O	3379
C+E	NUM	O	O	3379
group	NOUN	O	O	3379
,	PUNCT	O	O	3379
in	ADP	O	O	3379
which	PRON	O	O	3379
four	NUM	O	O	3379
of	ADP	O	O	3379
eight	NUM	O	O	3379
dogs	NOUN	O	O	3379
experienced	ADJ	O	O	3379
ventricular tachycardia	NOUN	O	Disease	3379
.	PUNCT	O	O	3379
Cocaine	NOUN	O	Chemical	3380
and	CCONJ	O	O	3380
ethanol	NOUN	O	Chemical	3380
in	ADP	O	O	3380
combination	NOUN	O	O	3380
were	AUX	O	O	3380
more	ADJ	O	O	3380
toxic	ADJ	O	O	3380
than	ADP	O	O	3380
either	ADV	O	O	3380
substance	NOUN	O	O	3380
alone	ADV	O	O	3380
.	PUNCT	O	O	3380
Co	PROPN	O	O	3381
-	PUNCT	O	O	3381
administration	NOUN	O	O	3381
resulted	VERB	O	O	3381
in	ADP	O	O	3381
prolonged	VERB	O	O	3381
cardiac toxicity	NOUN	O	Disease	3381
and	CCONJ	O	O	3381
was	AUX	O	O	3381
dysrhythmogenic	ADJ	O	O	3381
.	PUNCT	O	O	3381
Peak	NOUN	O	O	3382
serum	NOUN	O	O	3382
cocaethylene	VERB	O	O	3382
concentrations	NOUN	O	O	3382
were	AUX	O	O	3382
associated	VERB	O	O	3382
with	ADP	O	O	3382
prolonged	VERB	O	O	3382
myocardial	ADJ	O	O	3382
depression	PROPN	O	Disease	3382
.	PUNCT	O	O	3382
Worsening	VERB	O	O	3385
of	ADP	O	O	3385
Parkinsonism	NOUN	O	Disease	3385
after	ADP	O	O	3385
the	PRON	O	O	3385
use	VERB	O	O	3385
of	ADP	O	O	3385
veralipride	NOUN	O	O	3385
for	ADP	O	O	3385
treatment	NOUN	O	O	3385
of	ADP	O	O	3385
menopause	NOUN	O	O	3385
:	PUNCT	O	O	3385
case	NOUN	O	O	3385
report	VERB	O	O	3385
.	PUNCT	O	O	3385
We	PRON	O	O	3386
describe	VERB	O	O	3386
a	PRON	O	O	3386
female	ADJ	O	O	3386
patient	NOUN	O	O	3386
with	ADP	O	O	3386
stable	ADJ	O	O	3386
Parkinson	NOUN	O	O	3386
's	AUX	O	O	3386
disease	PROPN	O	O	3386
who	PRON	O	O	3386
has	VERB	O	O	3386
shown	VERB	O	O	3386
a	PRON	O	O	3386
marked	VERB	O	O	3386
worsening	VERB	O	O	3386
of	ADP	O	O	3386
her	PRON	O	O	3386
motor	NOUN	O	O	3386
functions	VERB	O	O	3386
following	VERB	O	O	3386
therapy	NOUN	O	O	3386
of	ADP	O	O	3386
menopause	NOUN	O	O	3386
related	ADJ	O	O	3386
symptoms	NOUN	O	O	3386
with	ADP	O	O	3386
veralipride	NOUN	O	O	3386
,	PUNCT	O	O	3386
as	ADP	O	O	3386
well	ADV	O	O	3386
as	ADP	O	O	3386
the	PRON	O	O	3386
improvement	NOUN	O	O	3386
of	ADP	O	O	3386
her	PRON	O	O	3386
symptoms	NOUN	O	O	3386
back	ADV	O	O	3386
to	PART	O	O	3386
baseline	VERB	O	O	3386
after	ADP	O	O	3386
discontinuation	NOUN	O	O	3386
of	ADP	O	O	3386
the	PRON	O	O	3386
drug	NOUN	O	O	3386
.	PUNCT	O	O	3386
We	PRON	O	O	3387
emphasize	VERB	O	O	3387
the	PRON	O	O	3387
anti	ADJ	O	O	3387
-	PUNCT	O	O	3387
dopaminergic	ADJ	O	O	3387
effect	VERB	O	O	3387
of	ADP	O	O	3387
veralipride	NOUN	O	O	3387
.	PUNCT	O	O	3387
Viracept	PROPN	O	O	3390
and	CCONJ	O	O	3390
irregular	ADJ	O	O	3390
heartbeat	NOUN	O	O	3390
warning	VERB	O	O	3390
.	PUNCT	O	O	3390
A	PRON	O	O	3391
group	NOUN	O	O	3391
of	ADP	O	O	3391
doctors	NOUN	O	O	3391
in	ADP	O	O	3391
Boston	PROPN	O	O	3391
warn	VERB	O	O	3391
that	SCONJ	O	O	3391
the	PRON	O	O	3391
protease	NOUN	O	O	3391
inhibitor	NOUN	O	O	3391
Viracept	PROPN	O	O	3391
may	AUX	O	O	3391
cause	VERB	O	O	3391
an	PRON	O	O	3391
irregular	ADJ	O	O	3391
heart	NOUN	O	O	3391
beat	VERB	O	O	3391
,	PUNCT	O	O	3391
known	VERB	O	O	3391
as	ADP	O	O	3391
bradycardia	NOUN	O	Disease	3391
,	PUNCT	O	O	3391
in	ADP	O	O	3391
people	NOUN	O	O	3391
with	ADP	O	O	3391
HIV	PROPN	O	O	3391
.	PUNCT	O	O	3391
Bradycardia	PROPN	O	Disease	3392
occurred	VERB	O	O	3392
in	ADP	O	O	3392
a	PRON	O	O	3392
45-year	NOUN	O	O	3392
-	PUNCT	O	O	3392
old	ADJ	O	O	3392
male	NOUN	O	O	3392
patient	NOUN	O	O	3392
who	PRON	O	O	3392
was	AUX	O	O	3392
Viracept	PROPN	O	O	3392
in	ADP	O	O	3392
combination	NOUN	O	O	3392
with	ADP	O	O	3392
other	ADJ	O	O	3392
anti	ADJ	O	O	3392
-	PUNCT	O	O	3392
HIV	PROPN	O	O	3392
drugs	NOUN	O	O	3392
.	PUNCT	O	O	3392
Frequency	NOUN	O	O	3395
of	ADP	O	O	3395
appearance	NOUN	O	O	3395
of	ADP	O	O	3395
myeloperoxidase	PROPN	O	O	3395
-	PUNCT	O	O	3395
antineutrophil	PROPN	O	O	3395
cytoplasmic	ADJ	O	O	3395
antibody	NOUN	O	O	3395
(	PUNCT	O	O	3395
MPO	PROPN	O	O	3395
-	PUNCT	O	O	3395
ANCA	PROPN	O	O	3395
)	PUNCT	O	O	3395
in	ADP	O	O	3395
Graves	NOUN	O	O	3395
'	PUNCT	O	O	3395
disease	PROPN	O	O	3395
patients	NOUN	O	O	3395
treated	VERB	O	O	3395
with	ADP	O	O	3395
propylthiouracil	NOUN	O	Chemical	3395
and	CCONJ	O	O	3395
the	PRON	O	O	3395
relationship	NOUN	O	O	3395
between	ADP	O	O	3395
MPO	PROPN	O	O	3395
-	PUNCT	O	O	3395
ANCA	PROPN	O	O	3395
and	CCONJ	O	O	3395
clinical	ADJ	O	O	3395
manifestations	NOUN	O	O	3395
.	PUNCT	O	O	3395
OBJECTIVE	VERB	O	O	3396
:	PUNCT	O	O	3396
Myeloperoxidase	PROPN	O	O	3396
antineutrophil	PROPN	O	O	3396
cytoplasmic	ADJ	O	O	3396
antibody	NOUN	O	O	3396
(	PUNCT	O	O	3396
MPO	PROPN	O	O	3396
-	PUNCT	O	O	3396
ANCA)-positive	ADJ	O	O	3396
vasculitis	NOUN	O	Disease	3396
has	VERB	O	O	3396
been	AUX	O	O	3396
reported	VERB	O	O	3396
in	ADP	O	O	3396
patients	NOUN	O	O	3396
with	ADP	O	O	3396
Graves	NOUN	O	O	3396
'	PUNCT	O	O	3396
disease	PROPN	O	O	3396
who	PRON	O	O	3396
were	AUX	O	O	3396
treated	VERB	O	O	3396
with	ADP	O	O	3396
propylthiouracil	NOUN	O	Chemical	3396
(	PUNCT	O	O	3396
PTU	PROPN	O	Chemical	3396
)	PUNCT	O	O	3396
.	PUNCT	O	O	3396
The	PRON	O	O	3397
appearance	NOUN	O	O	3397
of	ADP	O	O	3397
MPO	PROPN	O	O	3397
-	PUNCT	O	O	3397
ANCA	PROPN	O	O	3397
in	ADP	O	O	3397
these	PRON	O	O	3397
cases	NOUN	O	O	3397
was	AUX	O	O	3397
suspected	VERB	O	O	3397
of	ADP	O	O	3397
being	AUX	O	O	3397
related	ADJ	O	O	3397
to	PART	O	O	3397
PTU	PROPN	O	Chemical	3397
because	SCONJ	O	O	3397
the	PRON	O	O	3397
titres	NOUN	O	O	3397
of	ADP	O	O	3397
MPO	PROPN	O	O	3397
-	PUNCT	O	O	3397
ANCA	PROPN	O	O	3397
decreased	VERB	O	O	3397
when	SCONJ	O	O	3397
PTU	PROPN	O	Chemical	3397
was	AUX	O	O	3397
stopped	VERB	O	O	3397
.	PUNCT	O	O	3397
Nevertheless	ADV	O	O	3398
,	PUNCT	O	O	3398
there	ADV	O	O	3398
have	VERB	O	O	3398
been	AUX	O	O	3398
no	PRON	O	O	3398
studies	NOUN	O	O	3398
on	ADP	O	O	3398
the	PRON	O	O	3398
temporal	ADJ	O	O	3398
relationship	NOUN	O	O	3398
between	ADP	O	O	3398
the	PRON	O	O	3398
appearance	NOUN	O	O	3398
of	ADP	O	O	3398
MPO	PROPN	O	O	3398
-	PUNCT	O	O	3398
ANCA	PROPN	O	O	3398
and	CCONJ	O	O	3398
vasculitis	NOUN	O	Disease	3398
during	ADP	O	O	3398
PTU	PROPN	O	Chemical	3398
therapy	NOUN	O	O	3398
,	PUNCT	O	O	3398
or	CCONJ	O	O	3398
on	ADP	O	O	3398
the	PRON	O	O	3398
incidence	NOUN	O	O	3398
of	ADP	O	O	3398
MPO	PROPN	O	O	3398
-	PUNCT	O	O	3398
ANCA	PROPN	O	O	3398
in	ADP	O	O	3398
untreated	ADJ	O	O	3398
Graves	NOUN	O	O	3398
'	PUNCT	O	O	3398
disease	PROPN	O	O	3398
patients	NOUN	O	O	3398
.	PUNCT	O	O	3398
Therefore	ADV	O	O	3399
,	PUNCT	O	O	3399
we	PRON	O	O	3399
sought	VERB	O	O	3399
to	PART	O	O	3399
address	NOUN	O	O	3399
these	PRON	O	O	3399
parameters	NOUN	O	O	3399
in	ADP	O	O	3399
patients	NOUN	O	O	3399
with	ADP	O	O	3399
Graves	NOUN	O	O	3399
'	PUNCT	O	O	3399
disease	PROPN	O	O	3399
.	PUNCT	O	O	3399
We	PRON	O	O	3400
investigated	VERB	O	O	3400
102	NUM	O	O	3400
untreated	ADJ	O	O	3400
patients	NOUN	O	O	3400
with	ADP	O	O	3400
hyperthyroidism	NOUN	O	Disease	3400
due	ADJ	O	O	3400
to	PART	O	O	3400
Graves	NOUN	O	O	3400
'	PUNCT	O	O	3400
disease	PROPN	O	O	3400
for	ADP	O	O	3400
the	PRON	O	O	3400
presence	NOUN	O	O	3400
of	ADP	O	O	3400
MPO	PROPN	O	O	3400
-	PUNCT	O	O	3400
ANCA	PROPN	O	O	3400
,	PUNCT	O	O	3400
and	CCONJ	O	O	3400
for	ADP	O	O	3400
the	PRON	O	O	3400
development	NOUN	O	O	3400
vasculitis	NOUN	O	Disease	3400
after	ADP	O	O	3400
starting	VERB	O	O	3400
PTU	PROPN	O	Chemical	3400
therapy	NOUN	O	O	3400
.	PUNCT	O	O	3400
Twenty	NUM	O	O	3401
-	PUNCT	O	O	3401
nine	NUM	O	O	3401
of	ADP	O	O	3401
them	PRON	O	O	3401
were	AUX	O	O	3401
later	ADV	O	O	3401
excluded	VERB	O	O	3401
because	SCONJ	O	O	3401
of	ADP	O	O	3401
adverse	ADJ	O	O	3401
effects	NOUN	O	O	3401
of	ADP	O	O	3401
PTU	PROPN	O	Chemical	3401
or	CCONJ	O	O	3401
because	SCONJ	O	O	3401
the	PRON	O	O	3401
observation	NOUN	O	O	3401
period	NOUN	O	O	3401
was	AUX	O	O	3401
less	ADV	O	O	3401
than	ADP	O	O	3401
3	X	O	O	3401
months	NOUN	O	O	3401
.	PUNCT	O	O	3401
Before	ADP	O	O	3402
treatment	NOUN	O	O	3402
,	PUNCT	O	O	3402
the	PRON	O	O	3402
MPO	PROPN	O	O	3402
-	PUNCT	O	O	3402
ANCA	PROPN	O	O	3402
titres	NOUN	O	O	3402
of	ADP	O	O	3402
all	PRON	O	O	3402
102	NUM	O	O	3402
untreated	ADJ	O	O	3402
Graves	NOUN	O	O	3402
'	PUNCT	O	O	3402
disease	PROPN	O	O	3402
patients	NOUN	O	O	3402
were	AUX	O	O	3402
within	ADP	O	O	3402
the	PRON	O	O	3402
reference	NOUN	O	O	3402
range	VERB	O	O	3402
(	PUNCT	O	O	3402
below	ADP	O	O	3402
10	NUM	O	O	3402
U	NOUN	O	O	3402
/	PUNCT	O	O	3402
ml	ADP	O	O	3402
)	PUNCT	O	O	3402
.	PUNCT	O	O	3402
Three	NUM	O	O	3403
(	PUNCT	O	O	3403
4.1%	NOUN	O	O	3403
)	PUNCT	O	O	3403
of	ADP	O	O	3403
the	PRON	O	O	3403
73	NUM	O	O	3403
patients	NOUN	O	O	3403
were	AUX	O	O	3403
positive	ADJ	O	O	3403
for	ADP	O	O	3403
MPO	PROPN	O	O	3403
-	PUNCT	O	O	3403
ANCA	PROPN	O	O	3403
at	ADP	O	O	3403
13	NUM	O	O	3403
,	PUNCT	O	O	3403
16	NUM	O	O	3403
and	CCONJ	O	O	3403
17	NUM	O	O	3403
months	NOUN	O	O	3403
,	PUNCT	O	O	3403
respectively	ADV	O	O	3403
,	PUNCT	O	O	3403
after	ADP	O	O	3403
the	PRON	O	O	3403
start	VERB	O	O	3403
of	ADP	O	O	3403
PTU	PROPN	O	Chemical	3403
therapy	NOUN	O	O	3403
.	PUNCT	O	O	3403
In	ADP	O	O	3404
two	NUM	O	O	3404
of	ADP	O	O	3404
them	PRON	O	O	3404
,	PUNCT	O	O	3404
the	PRON	O	O	3404
MPO	PROPN	O	O	3404
-	PUNCT	O	O	3404
ANCA	PROPN	O	O	3404
titres	NOUN	O	O	3404
transiently	ADV	O	O	3404
increased	VERB	O	O	3404
to	PART	O	O	3404
12.8	NUM	O	O	3404
and	CCONJ	O	O	3404
15.0	NUM	O	O	3404
U	NOUN	O	O	3404
/	PUNCT	O	O	3404
ml	ADP	O	O	3404
,	PUNCT	O	O	3404
respectively	ADV	O	O	3404
,	PUNCT	O	O	3404
despite	SCONJ	O	O	3404
continued	VERB	O	O	3404
PTU	PROPN	O	Chemical	3404
therapy	NOUN	O	O	3404
,	PUNCT	O	O	3404
but	CCONJ	O	O	3404
no	PRON	O	O	3404
vasculitic	ADJ	O	O	3404
disorders	NOUN	O	O	3404
developed	VERB	O	O	3404
.	PUNCT	O	O	3404
In	ADP	O	O	3405
the	PRON	O	O	3405
third	ADV	O	O	3405
patient	NOUN	O	O	3405
,	PUNCT	O	O	3405
the	PRON	O	O	3405
MPO	PROPN	O	O	3405
-	PUNCT	O	O	3405
ANCA	PROPN	O	O	3405
titre	PROPN	O	O	3405
increased	VERB	O	O	3405
to	PART	O	O	3405
204	NUM	O	O	3405
U	NOUN	O	O	3405
/	PUNCT	O	O	3405
ml	ADP	O	O	3405
and	CCONJ	O	O	3405
she	PRON	O	O	3405
developed	VERB	O	O	3405
a	PRON	O	O	3405
higher	ADJ	O	O	3405
fever	NOUN	O	Disease	3405
,	PUNCT	O	O	3405
oral	ADJ	O	O	3405
ulcers	NOUN	O	O	3405
and	CCONJ	O	O	3405
polyarthralgia	NOUN	O	O	3405
,	PUNCT	O	O	3405
but	CCONJ	O	O	3405
the	PRON	O	O	3405
symptoms	NOUN	O	O	3405
resolved	VERB	O	O	3405
2	X	O	O	3405
weeks	NOUN	O	O	3405
after	ADP	O	O	3405
stopping	VERB	O	O	3405
PTU	PROPN	O	Chemical	3405
therapy	NOUN	O	O	3405
,	PUNCT	O	O	3405
and	CCONJ	O	O	3405
the	PRON	O	O	3405
MPO	PROPN	O	O	3405
-	PUNCT	O	O	3405
ANCA	PROPN	O	O	3405
titre	PROPN	O	O	3405
decreased	VERB	O	O	3405
to	PART	O	O	3405
20.7	NUM	O	O	3405
U	NOUN	O	O	3406
/	PUNCT	O	O	3406
ml	ADP	O	O	3406
by	ADP	O	O	3406
4	NUM	O	O	3406
months	NOUN	O	O	3406
after	ADP	O	O	3406
discontinuing	VERB	O	O	3406
PTU	PROPN	O	Chemical	3406
.	PUNCT	O	O	3406
PTU	PROPN	O	Chemical	3407
therapy	NOUN	O	O	3407
may	AUX	O	O	3407
be	AUX	O	O	3407
related	ADJ	O	O	3407
to	PART	O	O	3407
the	PRON	O	O	3407
appearance	NOUN	O	O	3407
of	ADP	O	O	3407
MPO	PROPN	O	O	3407
-	PUNCT	O	O	3407
ANCA	PROPN	O	O	3407
,	PUNCT	O	O	3407
but	CCONJ	O	O	3407
MPO	PROPN	O	O	3407
-	PUNCT	O	O	3407
ANCA	PROPN	O	O	3407
does	VERB	O	O	3407
not	PART	O	O	3407
appear	VERB	O	O	3407
to	PART	O	O	3407
be	AUX	O	O	3407
closely	ADV	O	O	3407
related	ADJ	O	O	3407
to	PART	O	O	3407
vasculitis	NOUN	O	Disease	3407
.	PUNCT	O	O	3407
Prevalence	NOUN	O	O	3410
of	ADP	O	O	3410
heart disease	NOUN	O	Disease	3410
in	ADP	O	O	3410
asymptomatic	ADJ	O	O	3410
chronic	ADJ	O	O	3410
cocaine	NOUN	O	Chemical	3410
users	NOUN	O	O	3410
.	PUNCT	O	O	3410
To	PART	O	O	3411
determine	VERB	O	O	3411
the	PRON	O	O	3411
prevalence	NOUN	O	O	3411
of	ADP	O	O	3411
heart disease	NOUN	O	Disease	3411
in	ADP	O	O	3411
outpatient	NOUN	O	O	3411
young	ADJ	O	O	3411
asymptomatic	ADJ	O	O	3411
chronic	ADJ	O	O	3411
cocaine	NOUN	O	Chemical	3411
users	NOUN	O	O	3411
,	PUNCT	O	O	3411
35	NUM	O	O	3411
cocaine	NOUN	O	Chemical	3411
users	NOUN	O	O	3411
and	CCONJ	O	O	3411
32	NUM	O	O	3411
age	NOUN	O	O	3411
-	PUNCT	O	O	3411
matched	VERB	O	O	3411
controls	VERB	O	O	3411
underwent	VERB	O	O	3411
resting	VERB	O	O	3411
and	CCONJ	O	O	3411
exercise	VERB	O	O	3411
electrocardiography	NOUN	O	O	3411
(	PUNCT	O	O	3411
ECG	PROPN	O	O	3411
)	PUNCT	O	O	3411
and	CCONJ	O	O	3411
Doppler	PROPN	O	O	3411
echocardiography	NOUN	O	O	3411
.	PUNCT	O	O	3411
Findings	NOUN	O	O	3412
consistent	ADJ	O	O	3412
with	ADP	O	O	3412
coronary artery disease	NOUN	O	Disease	3412
were	AUX	O	O	3412
detected	VERB	O	O	3412
in	ADP	O	O	3412
12	NUM	O	O	3412
(	PUNCT	O	O	3412
34%	NOUN	O	O	3412
)	PUNCT	O	O	3412
patients	NOUN	O	O	3412
and	CCONJ	O	O	3412
3	X	O	O	3412
(	PUNCT	O	O	3412
9%	NOUN	O	O	3412
)	PUNCT	O	O	3412
controls	VERB	O	O	3412
(	PUNCT	O	O	3412
p	NOUN	O	O	3412
=	PUNCT	O	O	3412
0.01	NUM	O	O	3412
)	PUNCT	O	O	3412
.	PUNCT	O	O	3412
Finally	ADV	O	O	3413
,	PUNCT	O	O	3413
resting	VERB	O	O	3413
and	CCONJ	O	O	3413
peak	PROPN	O	O	3413
exercise	VERB	O	O	3413
abnormal	ADJ	O	O	3413
left	VERB	O	O	3413
ventricular	ADJ	O	O	3413
filling	VERB	O	O	3413
was	AUX	O	O	3413
detected	VERB	O	O	3413
in	ADP	O	O	3413
38	NUM	O	O	3413
and	CCONJ	O	O	3413
35%	NOUN	O	O	3413
of	ADP	O	O	3413
patients	NOUN	O	O	3413
as	ADP	O	O	3413
compared	VERB	O	O	3413
to	PART	O	O	3413
19	NUM	O	O	3413
and	CCONJ	O	O	3413
9%	NOUN	O	O	3413
of	ADP	O	O	3413
controls	VERB	O	O	3413
,	PUNCT	O	O	3413
respectively	ADV	O	O	3413
(	PUNCT	O	O	3413
p	NOUN	O	O	3413
=	PUNCT	O	O	3413
0.11	NUM	O	O	3413
and	CCONJ	O	O	3413
0.02	NUM	O	O	3413
,	PUNCT	O	O	3413
respectively	ADV	O	O	3413
)	PUNCT	O	O	3413
.	PUNCT	O	O	3413
We	PRON	O	O	3414
conclude	VERB	O	O	3414
that	SCONJ	O	O	3414
coronary	ADJ	O	O	3414
artery	NOUN	O	O	3414
or	CCONJ	O	O	3414
myocardial disease	NOUN	O	Disease	3414
is	AUX	O	O	3414
common	ADJ	O	O	3414
(	PUNCT	O	O	3414
38%	NOUN	O	O	3414
)	PUNCT	O	O	3414
in	ADP	O	O	3414
young	ADJ	O	O	3414
asymptomatic	ADJ	O	O	3414
chronic	ADJ	O	O	3414
cocaine	NOUN	O	Chemical	3414
users	NOUN	O	O	3414
.	PUNCT	O	O	3414
Cardioprotective	PROPN	O	O	3417
effects	NOUN	O	O	3417
of	ADP	O	O	3417
Picrorrhiza	PROPN	O	O	3417
kurroa	NOUN	O	O	3417
against	ADP	O	O	3417
isoproterenol	NOUN	O	Chemical	3417
-	PUNCT	O	O	3417
induced	VERB	O	O	3417
myocardial	ADJ	O	O	3417
stress	NOUN	O	O	3417
in	ADP	O	O	3417
rats	NOUN	O	O	3417
.	PUNCT	O	O	3417
The	PRON	O	O	3418
cardioprotective	ADJ	O	O	3418
effect	VERB	O	O	3418
of	ADP	O	O	3418
the	PRON	O	O	3418
ethanol	NOUN	O	Chemical	3418
extract	VERB	O	O	3418
of	ADP	O	O	3418
Picrorrhiza	PROPN	O	O	3418
kurroa	NOUN	O	O	3418
rhizomes	NOUN	O	O	3418
and	CCONJ	O	O	3418
roots	NOUN	O	O	3418
(	PUNCT	O	O	3418
PK	NOUN	O	O	3418
)	PUNCT	O	O	3418
on	ADP	O	O	3418
isoproterenol	NOUN	O	Chemical	3418
-	PUNCT	O	O	3418
induced	VERB	O	O	3418
myocardial infarction	NOUN	O	Disease	3418
in	ADP	O	O	3418
rats	NOUN	O	O	3418
with	ADP	O	O	3418
respect	VERB	O	O	3418
to	PART	O	O	3418
lipid	NOUN	O	O	3418
metabolism	NOUN	O	O	3418
in	ADP	O	O	3418
serum	NOUN	O	O	3418
and	CCONJ	O	O	3418
heart	NOUN	O	O	3418
tissue	NOUN	O	O	3418
has	VERB	O	O	3418
been	AUX	O	O	3418
investigated	VERB	O	O	3418
.	PUNCT	O	O	3418
day(-1	VERB	O	O	3419
)	PUNCT	O	O	3419
for	ADP	O	O	3419
15	NUM	O	O	3419
days	NOUN	O	O	3419
)	PUNCT	O	O	3419
significantly	ADV	O	O	3419
prevented	VERB	O	O	3419
the	PRON	O	O	3419
isoproterenol	NOUN	O	Chemical	3419
-	PUNCT	O	O	3419
induced	VERB	O	O	3419
myocardial infarction	NOUN	O	Disease	3419
and	CCONJ	O	O	3419
maintained	VERB	O	O	3419
the	PRON	O	O	3419
rats	NOUN	O	O	3419
at	ADP	O	O	3419
near	ADP	O	O	3419
normal	ADJ	O	O	3419
status	NOUN	O	O	3419
.	PUNCT	O	O	3419
Phase	NOUN	O	O	3422
2	X	O	O	3422
early	ADV	O	O	3422
afterdepolarization	NOUN	O	O	3422
as	ADP	O	O	3422
a	PRON	O	O	3422
trigger	NOUN	O	O	3422
of	ADP	O	O	3422
polymorphic	ADJ	O	O	3422
ventricular tachycardia	NOUN	O	Disease	3422
in	ADP	O	O	3422
acquired	VERB	O	O	3422
long	ADV	O	O	3422
-	PUNCT	O	O	3422
QT	NOUN	O	O	3422
syndrome	NOUN	O	O	3422
:	PUNCT	O	O	3422
direct	ADJ	O	O	3422
evidence	NOUN	O	O	3422
from	ADP	O	O	3422
intracellular	ADJ	O	O	3422
recordings	NOUN	O	O	3422
in	ADP	O	O	3422
the	PRON	O	O	3422
intact	ADJ	O	O	3422
left	VERB	O	O	3422
ventricular	ADJ	O	O	3422
wall	PROPN	O	O	3422
.	PUNCT	O	O	3422
This	PRON	O	O	3423
study	VERB	O	O	3423
examined	VERB	O	O	3423
the	PRON	O	O	3423
role	NOUN	O	O	3423
of	ADP	O	O	3423
phase	NOUN	O	O	3423
2	X	O	O	3423
early	ADV	O	O	3423
afterdepolarization	NOUN	O	O	3423
(	PUNCT	O	O	3423
EAD	PROPN	O	O	3423
)	PUNCT	O	O	3423
in	ADP	O	O	3423
producing	VERB	O	O	3423
a	PRON	O	O	3423
trigger	NOUN	O	O	3423
to	PART	O	O	3423
initiate	VERB	O	O	3423
torsade de pointes	NOUN	O	Disease	3423
(	PUNCT	O	O	3423
TdP	NOUN	O	Disease	3423
)	PUNCT	O	O	3423
with	ADP	O	O	3423
QT prolongation	NOUN	O	Disease	3423
induced	VERB	O	O	3423
by	ADP	O	O	3423
dl	X	O	O	3423
-	PUNCT	O	O	3423
sotalol	VERB	O	O	3423
and	CCONJ	O	O	3423
azimilide	ADJ	O	O	3423
.	PUNCT	O	O	3423
The	PRON	O	O	3424
contribution	NOUN	O	O	3424
of	ADP	O	O	3424
transmural	ADJ	O	O	3424
dispersion	NOUN	O	O	3424
of	ADP	O	O	3424
repolarization	NOUN	O	O	3424
(	PUNCT	O	O	3424
TDR	PROPN	O	O	3424
)	PUNCT	O	O	3424
to	PART	O	O	3424
transmural	ADJ	O	O	3424
propagation	NOUN	O	O	3424
of	ADP	O	O	3424
EAD	PROPN	O	O	3424
and	CCONJ	O	O	3424
the	PRON	O	O	3424
maintenance	NOUN	O	O	3424
of	ADP	O	O	3424
TdP	NOUN	O	Disease	3424
was	AUX	O	O	3424
also	ADV	O	O	3424
evaluated	VERB	O	O	3424
.	PUNCT	O	O	3424
-	PUNCT	O	O	3425
Sotalol	NOUN	O	O	3425
preferentially	ADV	O	O	3425
prolonged	VERB	O	O	3425
action	NOUN	O	O	3425
potential	ADJ	O	O	3425
duration	NOUN	O	O	3425
(	PUNCT	O	O	3425
APD	PROPN	O	O	3425
)	PUNCT	O	O	3425
in	ADP	O	O	3425
M	NOUN	O	Chemical	3425
cells	NOUN	O	O	3425
dose	NOUN	O	O	3425
-	PUNCT	O	O	3425
dependently	ADV	O	O	3425
(	PUNCT	O	O	3425
1	X	O	O	3425
to	PART	O	O	3425
100	NUM	O	O	3425
micromol	NOUN	O	O	3425
/	PUNCT	O	O	3425
L	NOUN	O	O	3425
)	PUNCT	O	O	3425
,	PUNCT	O	O	3425
leading	VERB	O	O	3425
to	PART	O	O	3425
QT prolongation	NOUN	O	Disease	3425
and	CCONJ	O	O	3425
an	PRON	O	O	3425
increase	VERB	O	O	3425
in	ADP	O	O	3425
TDR	PROPN	O	O	3425
.	PUNCT	O	O	3425
Azimilide	PROPN	O	O	3426
,	PUNCT	O	O	3426
however	ADV	O	O	3426
,	PUNCT	O	O	3426
significantly	ADV	O	O	3426
prolonged	VERB	O	O	3426
APD	PROPN	O	O	3426
and	CCONJ	O	O	3426
QT	NOUN	O	O	3426
interval	NOUN	O	O	3426
at	ADP	O	O	3426
concentrations	NOUN	O	O	3426
from	ADP	O	O	3426
0.1	NUM	O	O	3426
to	PART	O	O	3426
10	NUM	O	O	3426
Unlike	ADP	O	O	3427
dl	X	O	O	3427
-	PUNCT	O	O	3427
sotalol	VERB	O	O	3427
,	PUNCT	O	O	3427
azimilide	ADJ	O	O	3427
(	PUNCT	O	O	3427
>	PUNCT	O	O	3427
3	X	O	O	3427
micromol	NOUN	O	O	3427
/	PUNCT	O	O	3427
L	NOUN	O	O	3427
)	PUNCT	O	O	3427
increased	VERB	O	O	3427
epicardial	ADJ	O	O	3427
APD	PROPN	O	O	3427
markedly	ADV	O	O	3427
,	PUNCT	O	O	3427
causing	VERB	O	O	3427
a	PRON	O	O	3427
diminished	VERB	O	O	3427
TDR	PROPN	O	O	3427
.	PUNCT	O	O	3427
Although	SCONJ	O	O	3428
both	PRON	O	O	3428
dl	X	O	O	3428
-	PUNCT	O	O	3428
sotalol	VERB	O	O	3428
and	CCONJ	O	O	3428
azimilide	ADJ	O	O	3428
rarely	ADV	O	O	3428
induced	VERB	O	O	3428
EADs	NOUN	O	O	3428
in	ADP	O	O	3428
canine	NOUN	O	O	3428
left	VERB	O	O	3428
ventricles	VERB	O	O	3428
,	PUNCT	O	O	3428
they	PRON	O	O	3428
produced	VERB	O	O	3428
frequent	ADJ	O	O	3428
EADs	NOUN	O	O	3428
in	ADP	O	O	3428
rabbits	NOUN	O	O	3428
,	PUNCT	O	O	3428
in	ADP	O	O	3428
which	PRON	O	O	3428
more	ADJ	O	O	3428
pronounced	VERB	O	O	3428
QT prolongation	NOUN	O	Disease	3428
was	AUX	O	O	3428
seen	VERB	O	O	3428
.	PUNCT	O	O	3428
An	PRON	O	O	3429
increase	VERB	O	O	3429
in	ADP	O	O	3429
TDR	PROPN	O	O	3429
by	ADP	O	O	3429
dl	X	O	O	3429
-	PUNCT	O	O	3429
sotalol	VERB	O	O	3429
facilitated	VERB	O	O	3429
transmural	ADJ	O	O	3429
propagation	NOUN	O	O	3429
of	ADP	O	O	3429
EADs	NOUN	O	O	3429
that	SCONJ	O	O	3429
initiated	VERB	O	O	3429
multiple	ADJ	O	O	3429
episodes	NOUN	O	O	3429
of	ADP	O	O	3429
spontaneous	ADJ	O	O	3429
TdP	NOUN	O	Disease	3429
in	ADP	O	O	3429
3	X	O	O	3429
of	ADP	O	O	3429
6	NUM	O	O	3429
rabbit	NOUN	O	O	3429
left	VERB	O	O	3429
ventricles	VERB	O	O	3429
.	PUNCT	O	O	3429
Of	ADV	O	O	3430
note	VERB	O	O	3430
,	PUNCT	O	O	3430
although	SCONJ	O	O	3430
azimilide	ADJ	O	O	3430
(	PUNCT	O	O	3430
3	X	O	O	3430
to	PART	O	O	3430
10	NUM	O	O	3430
micromol	NOUN	O	O	3430
/	PUNCT	O	O	3430
L	NOUN	O	O	3430
)	PUNCT	O	O	3430
increased	VERB	O	O	3430
APD	PROPN	O	O	3430
more	ADJ	O	O	3430
than	ADP	O	O	3430
dl	X	O	O	3430
-	PUNCT	O	O	3430
sotalol	VERB	O	O	3430
,	PUNCT	O	O	3430
its	PRON	O	O	3430
EADs	NOUN	O	O	3430
often	ADV	O	O	3430
failed	VERB	O	O	3430
to	PART	O	O	3430
propagate	VERB	O	O	3430
transmurally	ADV	O	O	3430
,	PUNCT	O	O	3430
probably	ADV	O	O	3430
because	SCONJ	O	O	3430
of	ADP	O	O	3430
a	PRON	O	O	3430
diminished	VERB	O	O	3430
TDR	PROPN	O	O	3430
.	PUNCT	O	O	3430
This	PRON	O	O	3431
study	VERB	O	O	3431
provides	VERB	O	O	3431
the	PRON	O	O	3431
first	ADV	O	O	3431
direct	ADJ	O	O	3431
evidence	NOUN	O	O	3431
from	ADP	O	O	3431
intracellular	ADJ	O	O	3431
action	NOUN	O	O	3431
potential	ADJ	O	O	3431
recordings	NOUN	O	O	3431
that	SCONJ	O	O	3431
phase	NOUN	O	O	3431
2	X	O	O	3431
EAD	PROPN	O	O	3431
can	AUX	O	O	3431
be	AUX	O	O	3431
generated	VERB	O	O	3431
from	ADP	O	O	3431
intact	ADJ	O	O	3431
ventricular	ADJ	O	O	3431
wall	PROPN	O	O	3431
and	CCONJ	O	O	3431
produce	VERB	O	O	3431
a	PRON	O	O	3431
trigger	NOUN	O	O	3431
to	PART	O	O	3431
initiate	VERB	O	O	3431
the	PRON	O	O	3431
onset	VERB	O	O	3431
of	ADP	O	O	3431
TdP	NOUN	O	Disease	3431
under	ADP	O	O	3431
QT prolongation	NOUN	O	Disease	3431
.	PUNCT	O	O	3431
Prenatal	NOUN	O	O	3434
cocaine	NOUN	O	Chemical	3434
exposure	NOUN	O	O	3434
and	CCONJ	O	O	3434
cranial	ADJ	O	O	3434
sonographic	NOUN	O	O	3434
findings	NOUN	O	O	3434
in	ADP	O	O	3434
preterm	NOUN	O	O	3434
infants	NOUN	O	O	3434
.	PUNCT	O	O	3434
Prenatal	NOUN	O	O	3435
cocaine	NOUN	O	Chemical	3435
exposure	NOUN	O	O	3435
has	VERB	O	O	3435
been	AUX	O	O	3435
linked	VERB	O	O	3435
with	ADP	O	O	3435
subependymal	NOUN	O	O	3435
hemorrhage	NOUN	O	Disease	3435
and	CCONJ	O	O	3435
the	PRON	O	O	3435
formation	NOUN	O	O	3435
of	ADP	O	O	3435
cysts	NOUN	O	O	3435
that	SCONJ	O	O	3435
are	AUX	O	O	3435
detectable	ADJ	O	O	3435
on	ADP	O	O	3435
cranial	ADJ	O	O	3435
sonography	NOUN	O	O	3435
in	ADP	O	O	3435
neonates	NOUN	O	O	3435
born	VERB	O	O	3435
at	ADP	O	O	3435
term	NOUN	O	O	3435
.	PUNCT	O	O	3435
We	PRON	O	O	3436
sought	VERB	O	O	3436
to	PART	O	O	3436
determine	VERB	O	O	3436
if	SCONJ	O	O	3436
prenatal	ADJ	O	O	3436
cocaine	NOUN	O	Chemical	3436
exposure	NOUN	O	O	3436
increases	VERB	O	O	3436
the	PRON	O	O	3436
incidence	NOUN	O	O	3436
of	ADP	O	O	3436
subependymal	NOUN	O	O	3436
cysts	NOUN	O	O	3436
in	ADP	O	O	3436
preterm	NOUN	O	O	3436
infants	NOUN	O	O	3436
.	PUNCT	O	O	3436
METHODS	NOUN	O	O	3437
:	PUNCT	O	O	3437
We	PRON	O	O	3437
retrospectively	ADV	O	O	3437
reviewed	VERB	O	O	3437
the	PRON	O	O	3437
medical	ADJ	O	O	3437
records	NOUN	O	O	3437
and	CCONJ	O	O	3437
cranial	ADJ	O	O	3437
sonograms	NOUN	O	O	3437
obtained	VERB	O	O	3437
during	ADP	O	O	3437
a	PRON	O	O	3437
1-year	NOUN	O	O	3437
period	NOUN	O	O	3437
on	ADP	O	O	3437
122	NUM	O	O	3437
premature	ADJ	O	O	3437
(	PUNCT	O	O	3437
<	X	O	O	3437
36	NUM	O	O	3437
weeks	NOUN	O	O	3437
of	ADP	O	O	3437
gestation	NOUN	O	O	3437
)	PUNCT	O	O	3437
infants	NOUN	O	O	3437
.	PUNCT	O	O	3437
Infants	NOUN	O	O	3438
were	AUX	O	O	3438
categorized	VERB	O	O	3438
into	ADP	O	O	3438
1	X	O	O	3438
of	ADP	O	O	3438
2	X	O	O	3438
groups	NOUN	O	O	3438
:	PUNCT	O	O	3438
those	PRON	O	O	3438
exposed	VERB	O	O	3438
to	PART	O	O	3438
cocaine	NOUN	O	Chemical	3438
and	CCONJ	O	O	3438
those	PRON	O	O	3438
not	PART	O	O	3438
exposed	VERB	O	O	3438
to	PART	O	O	3438
cocaine	NOUN	O	Chemical	3438
.	PUNCT	O	O	3438
Infants	NOUN	O	O	3439
were	AUX	O	O	3439
assigned	VERB	O	O	3439
to	PART	O	O	3439
the	PRON	O	O	3439
cocaine	NOUN	O	Chemical	3439
-	PUNCT	O	O	3439
exposed	VERB	O	O	3439
group	NOUN	O	O	3439
if	SCONJ	O	O	3439
there	ADV	O	O	3439
was	AUX	O	O	3439
a	PRON	O	O	3439
maternal	ADJ	O	O	3439
history	NOUN	O	O	3439
of	ADP	O	O	3439
cocaine abuse	NOUN	O	Disease	3439
during	ADP	O	O	3439
pregnancy	NOUN	O	O	3439
or	CCONJ	O	O	3439
if	SCONJ	O	O	3439
maternal	ADJ	O	O	3439
or	CCONJ	O	O	3439
neonatal	NOUN	O	O	3439
urine	NOUN	O	O	3439
toxicology	NOUN	O	O	3439
results	VERB	O	O	3439
were	AUX	O	O	3439
positive	ADJ	O	O	3439
at	ADP	O	O	3439
the	PRON	O	O	3439
time	NOUN	O	O	3439
of	ADP	O	O	3439
delivery	NOUN	O	O	3439
.	PUNCT	O	O	3439
The	PRON	O	O	3440
incidence	NOUN	O	O	3440
of	ADP	O	O	3440
subependymal	NOUN	O	O	3440
cysts	NOUN	O	O	3440
in	ADP	O	O	3440
the	PRON	O	O	3440
117	NUM	O	O	3440
remaining	VERB	O	O	3440
infants	NOUN	O	O	3440
was	AUX	O	O	3440
14%	NOUN	O	O	3440
(	PUNCT	O	O	3440
16	NUM	O	O	3440
of	ADP	O	O	3440
117	NUM	O	O	3440
)	PUNCT	O	O	3440
.	PUNCT	O	O	3440
The	PRON	O	O	3441
incidence	NOUN	O	O	3441
of	ADP	O	O	3441
subependymal	NOUN	O	O	3441
cysts	NOUN	O	O	3441
in	ADP	O	O	3441
infants	NOUN	O	O	3441
exposed	VERB	O	O	3441
to	PART	O	O	3441
cocaine	NOUN	O	Chemical	3441
prenatally	ADV	O	O	3441
was	AUX	O	O	3441
44%	NOUN	O	O	3441
(	PUNCT	O	O	3441
8	NUM	O	O	3441
of	ADP	O	O	3441
18	NUM	O	O	3441
)	PUNCT	O	O	3441
compared	VERB	O	O	3441
with	ADP	O	O	3441
8%	NOUN	O	O	3441
(	PUNCT	O	O	3441
8	NUM	O	O	3441
of	ADP	O	O	3441
99	NUM	O	O	3441
)	PUNCT	O	O	3441
in	ADP	O	O	3441
the	PRON	O	O	3441
unexposed	ADJ	O	O	3441
group	NOUN	O	O	3441
(	PUNCT	O	O	3441
p	NOUN	O	O	3441
We	PRON	O	O	3442
found	VERB	O	O	3442
an	PRON	O	O	3442
increased	VERB	O	O	3442
incidence	NOUN	O	O	3442
of	ADP	O	O	3442
subependymal	NOUN	O	O	3442
cyst	NOUN	O	O	3442
formation	NOUN	O	O	3442
in	ADP	O	O	3442
preterm	NOUN	O	O	3442
infants	NOUN	O	O	3442
who	PRON	O	O	3442
were	AUX	O	O	3442
exposed	VERB	O	O	3442
to	PART	O	O	3442
cocaine	NOUN	O	Chemical	3442
prenatally	ADV	O	O	3442
.	PUNCT	O	O	3442
Thalidomide	NOUN	O	O	3445
neuropathy	NOUN	O	Disease	3445
in	ADP	O	O	3445
patients	NOUN	O	O	3445
treated	VERB	O	O	3445
for	ADP	O	O	3445
metastatic	ADJ	O	O	3445
prostate cancer	NOUN	O	Disease	3445
.	PUNCT	O	O	3445
We	PRON	O	O	3446
prospectively	ADV	O	O	3446
evaluated	VERB	O	O	3446
thalidomide	NOUN	O	Chemical	3446
-	PUNCT	O	O	3446
induced	VERB	O	O	3446
neuropathy	NOUN	O	Disease	3446
using	VERB	O	O	3446
electrodiagnostic	NOUN	O	O	3446
studies	NOUN	O	O	3446
.	PUNCT	O	O	3446
Sixty	NUM	O	O	3447
-	PUNCT	O	O	3447
seven	NUM	O	O	3447
men	NOUN	O	O	3447
with	ADP	O	O	3447
metastatic	ADJ	O	O	3447
androgen	PROPN	O	Chemical	3447
-	PUNCT	O	O	3447
independent	ADJ	O	O	3447
prostate cancer	NOUN	O	Disease	3447
in	ADP	O	O	3447
an	PRON	O	O	3447
open	VERB	O	O	3447
-	PUNCT	O	O	3447
label	PROPN	O	O	3447
trial	NOUN	O	O	3447
of	ADP	O	O	3447
oral	ADJ	O	O	3447
thalidomide	NOUN	O	Chemical	3447
underwent	VERB	O	O	3447
neurologic	ADJ	O	O	3447
examinations	NOUN	O	O	3447
and	CCONJ	O	O	3447
nerve	NOUN	O	O	3447
conduction	NOUN	O	O	3447
studies	NOUN	O	O	3447
(	PUNCT	O	O	3447
NCS	PROPN	O	O	3447
)	PUNCT	O	O	3447
prior	ADV	O	O	3447
to	PART	O	O	3447
and	CCONJ	O	O	3447
at	ADP	O	O	3447
3-month	NOUN	O	O	3447
intervals	NOUN	O	O	3447
during	ADP	O	O	3447
treatment	NOUN	O	O	3447
.	PUNCT	O	O	3447
Thalidomide	NOUN	O	O	3448
was	AUX	O	O	3448
discontinued	VERB	O	O	3448
in	ADP	O	O	3448
55	NUM	O	O	3448
patients	NOUN	O	O	3448
for	ADP	O	O	3448
lack	VERB	O	O	3448
of	ADP	O	O	3448
therapeutic	ADJ	O	O	3448
response	NOUN	O	O	3448
.	PUNCT	O	O	3448
Of	ADV	O	O	3449
67	NUM	O	O	3449
patients	NOUN	O	O	3449
initially	ADV	O	O	3449
enrolled	VERB	O	O	3449
,	PUNCT	O	O	3449
24	NUM	O	O	3449
remained	VERB	O	O	3449
on	ADP	O	O	3449
thalidomide	NOUN	O	Chemical	3449
for	ADP	O	O	3449
3	X	O	O	3449
months	NOUN	O	O	3449
,	PUNCT	O	O	3449
8	NUM	O	O	3449
remained	VERB	O	O	3449
at	ADP	O	O	3449
6	NUM	O	O	3449
months	NOUN	O	O	3449
,	PUNCT	O	O	3449
and	CCONJ	O	O	3449
3	X	O	O	3449
remained	VERB	O	O	3449
at	ADP	O	O	3449
9	NUM	O	O	3449
months	NOUN	O	O	3449
.	PUNCT	O	O	3449
Six	NUM	O	O	3450
patients	NOUN	O	O	3450
developed	VERB	O	O	3450
neuropathy	NOUN	O	Disease	3450
.	PUNCT	O	O	3450
Neuropathy	PROPN	O	O	3451
may	AUX	O	O	3451
thus	ADV	O	O	3451
be	AUX	O	O	3451
a	PRON	O	O	3451
common	ADJ	O	O	3451
complication	NOUN	O	O	3451
of	ADP	O	O	3451
thalidomide	NOUN	O	Chemical	3451
in	ADP	O	O	3451
older	ADJ	O	O	3451
patients	NOUN	O	O	3451
.	PUNCT	O	O	3451
The	PRON	O	O	3452
SNAP	VERB	O	O	3452
index	NOUN	O	O	3452
can	AUX	O	O	3452
be	AUX	O	O	3452
used	VERB	O	O	3452
to	PART	O	O	3452
monitor	VERB	O	O	3452
peripheral neuropathy	NOUN	O	Disease	3452
,	PUNCT	O	O	3452
but	CCONJ	O	O	3452
not	PART	O	O	3452
for	ADP	O	O	3452
early	ADV	O	O	3452
detection	NOUN	O	O	3452
.	PUNCT	O	O	3452
Overexpression	NOUN	O	O	3455
of	ADP	O	O	3455
copper	NOUN	O	O	3455
/	PUNCT	O	O	3455
zinc	PROPN	O	Chemical	3455
-	PUNCT	O	O	3455
superoxide	NOUN	O	Chemical	3455
dismutase	ADP	O	O	3455
protects	VERB	O	O	3455
from	ADP	O	O	3455
kanamycin	VERB	O	Chemical	3455
-	PUNCT	O	O	3455
induced	VERB	O	O	3455
hearing loss	NOUN	O	Disease	3455
.	PUNCT	O	O	3455
The	PRON	O	O	3456
participation	NOUN	O	O	3456
of	ADP	O	O	3456
reactive	ADJ	O	O	3456
oxygen	NOUN	O	Chemical	3456
species	NOUN	O	O	3456
in	ADP	O	O	3456
aminoglycoside	ADV	O	Chemical	3456
-	PUNCT	O	O	3456
induced	VERB	O	O	3456
ototoxicity	NOUN	O	Disease	3456
has	VERB	O	O	3456
been	AUX	O	O	3456
deduced	VERB	O	O	3456
from	ADP	O	O	3456
observations	NOUN	O	O	3456
that	SCONJ	O	O	3456
aminoglycoside	ADV	O	Chemical	3456
-	PUNCT	O	O	3456
iron	NOUN	O	Chemical	3456
complexes	NOUN	O	O	3456
catalyze	VERB	O	O	3456
the	PRON	O	O	3456
formation	NOUN	O	O	3456
of	ADP	O	O	3456
superoxide	NOUN	O	Chemical	3456
radicals	NOUN	O	O	3456
in	ADP	O	O	3456
vitro	X	O	O	3456
and	CCONJ	O	O	3456
that	SCONJ	O	O	3456
antioxidants	NOUN	O	O	3456
attenuate	VERB	O	O	3456
ototoxicity	NOUN	O	Disease	3456
in	ADP	O	O	3456
vivo	VERB	O	O	3456
.	PUNCT	O	O	3456
We	PRON	O	O	3457
therefore	ADV	O	O	3457
hypothesized	VERB	O	O	3457
that	SCONJ	O	O	3457
overexpression	NOUN	O	O	3457
of	ADP	O	O	3457
Cu	NOUN	O	O	3457
/	PUNCT	O	O	3457
Zn	PROPN	O	O	3457
-	PUNCT	O	O	3457
superoxide	NOUN	O	Chemical	3457
dismutase	ADP	O	O	3457
(	PUNCT	O	O	3457
h	X	O	O	3457
-	PUNCT	O	O	3457
SOD1	PROPN	O	O	3457
)	PUNCT	O	O	3457
should	AUX	O	O	3457
protect	VERB	O	O	3457
transgenic	NOUN	O	O	3457
mice	NOUN	O	O	3457
from	ADP	O	O	3457
ototoxicity	NOUN	O	Disease	3457
.	PUNCT	O	O	3457
Transgenic	NOUN	O	O	3458
and	CCONJ	O	O	3458
nontransgenic	ADJ	O	O	3458
littermates	NOUN	O	O	3458
received	VERB	O	O	3458
kanamycin	VERB	O	Chemical	3458
(	PUNCT	O	O	3458
400	NUM	O	O	3458
mg	VERB	O	O	3458
/	PUNCT	O	O	3458
kg	VERB	O	O	3458
body	NOUN	O	O	3458
weight	NOUN	O	O	3458
/	PUNCT	O	O	3458
day	NOUN	O	O	3458
)	PUNCT	O	O	3458
for	ADP	O	O	3458
10	NUM	O	O	3458
days	NOUN	O	O	3458
beginning	VERB	O	O	3458
on	ADP	O	O	3458
day	NOUN	O	O	3458
10	NUM	O	O	3458
after	ADP	O	O	3458
birth	NOUN	O	O	3458
.	PUNCT	O	O	3458
In	ADP	O	O	3459
nontransgenic	ADJ	O	O	3459
animals	NOUN	O	O	3459
,	PUNCT	O	O	3459
the	PRON	O	O	3459
threshold	NOUN	O	O	3459
in	ADP	O	O	3459
the	PRON	O	O	3459
kanamycin	VERB	O	Chemical	3459
-	PUNCT	O	O	3459
treated	VERB	O	O	3459
group	NOUN	O	O	3459
was	AUX	O	O	3459
45	NUM	O	O	3459
-	PUNCT	O	O	3459
50	NUM	O	O	3459
dB	NOUN	O	O	3459
higher	ADJ	O	O	3459
than	ADP	O	O	3459
in	ADP	O	O	3459
saline	NOUN	O	O	3459
-	PUNCT	O	O	3459
injected	VERB	O	O	3459
controls	VERB	O	O	3459
.	PUNCT	O	O	3459
In	ADP	O	O	3460
the	PRON	O	O	3460
transgenic	NOUN	O	O	3460
group	NOUN	O	O	3460
,	PUNCT	O	O	3460
kanamycin	VERB	O	Chemical	3460
increased	VERB	O	O	3460
the	PRON	O	O	3460
threshold	NOUN	O	O	3460
by	ADP	O	O	3460
only	ADV	O	O	3460
15	NUM	O	O	3460
dB	NOUN	O	O	3460
over	ADP	O	O	3460
the	PRON	O	O	3460
respective	ADJ	O	O	3460
controls	VERB	O	O	3460
.	PUNCT	O	O	3460
The	PRON	O	O	3461
protection	NOUN	O	O	3461
by	ADP	O	O	3461
overexpression	NOUN	O	O	3461
of	ADP	O	O	3461
superoxide	NOUN	O	Chemical	3461
dismutase	ADP	O	O	3461
supports	VERB	O	O	3461
the	PRON	O	O	3461
hypothesis	NOUN	O	O	3461
that	SCONJ	O	O	3461
oxidant	ADJ	O	O	3461
stress	NOUN	O	O	3461
plays	VERB	O	O	3461
a	PRON	O	O	3461
significant	ADJ	O	O	3461
role	NOUN	O	O	3461
in	ADP	O	O	3461
aminoglycoside	ADV	O	Chemical	3461
-	PUNCT	O	O	3461
induced	VERB	O	O	3461
ototoxicity	NOUN	O	Disease	3461
.	PUNCT	O	O	3461
Prednisone	NOUN	O	O	3464
induces	VERB	O	O	3464
anxiety	NOUN	O	Disease	3464
and	CCONJ	O	O	3464
glial	ADJ	O	O	3464
cerebral	ADJ	O	O	3464
changes	VERB	O	O	3464
in	ADP	O	O	3464
rats	NOUN	O	O	3464
.	PUNCT	O	O	3464
OBJECTIVE	VERB	O	O	3465
:	PUNCT	O	O	3465
To	PART	O	O	3465
assess	VERB	O	O	3465
whether	SCONJ	O	O	3465
prednisone	NOUN	O	Chemical	3465
(	PUNCT	O	O	3465
PDN	PROPN	O	O	3465
)	PUNCT	O	O	3465
produces	VERB	O	O	3465
anxiety	NOUN	O	Disease	3465
and/or	CCONJ	O	O	3465
cerebral	ADJ	O	O	3465
glial	ADJ	O	O	3465
changes	VERB	O	O	3465
in	ADP	O	O	3465
rats	NOUN	O	O	3465
.	PUNCT	O	O	3465
The	PRON	O	O	3466
moderate	ADJ	O	O	3466
-	PUNCT	O	O	3466
dose	NOUN	O	O	3466
group	NOUN	O	O	3466
received	VERB	O	O	3466
5	NUM	O	O	3466
mg	VERB	O	O	3466
/	PUNCT	O	O	3466
kg	VERB	O	O	3466
/	PUNCT	O	O	3466
day	NOUN	O	O	3466
PDN	PROPN	O	O	3466
released	VERB	O	O	3466
from	ADP	O	O	3466
a	PRON	O	O	3466
subcutaneous	ADJ	O	O	3466
implant	NOUN	O	O	3466
.	PUNCT	O	O	3466
In	ADP	O	O	3467
the	PRON	O	O	3467
high	ADJ	O	O	3467
-	PUNCT	O	O	3467
dose	NOUN	O	O	3467
group	NOUN	O	O	3467
,	PUNCT	O	O	3467
implants	NOUN	O	O	3467
containing	VERB	O	O	3467
PDN	PROPN	O	O	3467
equivalent	ADJ	O	O	3467
to	PART	O	O	3467
60	NUM	O	O	3467
mg	VERB	O	O	3467
/	PUNCT	O	O	3467
kg	VERB	O	O	3467
/	PUNCT	O	O	3467
day	NOUN	O	O	3467
were	AUX	O	O	3467
applied	VERB	O	O	3467
.	PUNCT	O	O	3467
In	ADP	O	O	3468
the	PRON	O	O	3468
control	VERB	O	O	3468
group	NOUN	O	O	3468
implants	NOUN	O	O	3468
contained	VERB	O	O	3468
no	PRON	O	O	3468
PDN	PROPN	O	O	3468
.	PUNCT	O	O	3468
Anxiety	NOUN	O	O	3469
was	AUX	O	O	3469
assessed	VERB	O	O	3469
using	VERB	O	O	3469
an	PRON	O	O	3469
open	VERB	O	O	3469
field	NOUN	O	O	3469
and	CCONJ	O	O	3469
elevated	ADJ	O	O	3469
plus	CCONJ	O	O	3469
-	PUNCT	O	O	3469
maze	NOUN	O	O	3469
devices	NOUN	O	O	3469
.	PUNCT	O	O	3469
Anxiety	NOUN	O	O	3470
was	AUX	O	O	3470
documented	VERB	O	O	3470
in	ADP	O	O	3470
both	PRON	O	O	3470
groups	NOUN	O	O	3470
of	ADP	O	O	3470
PDN	PROPN	O	O	3470
treated	VERB	O	O	3470
rats	NOUN	O	O	3470
compared	VERB	O	O	3470
with	ADP	O	O	3470
controls	VERB	O	O	3470
.	PUNCT	O	O	3470
The	PRON	O	O	3471
magnitude	NOUN	O	O	3471
of	ADP	O	O	3471
transformation	NOUN	O	O	3471
of	ADP	O	O	3471
the	PRON	O	O	3471
microglia	PROPN	O	O	3471
assessed	VERB	O	O	3471
by	ADP	O	O	3471
the	PRON	O	O	3471
number	NOUN	O	O	3471
of	ADP	O	O	3471
intersections	NOUN	O	O	3471
was	AUX	O	O	3471
significantly	ADV	O	O	3471
higher	ADJ	O	O	3471
in	ADP	O	O	3471
the	PRON	O	O	3471
PDN	PROPN	O	O	3471
groups	NOUN	O	O	3471
than	ADP	O	O	3471
in	ADP	O	O	3471
controls	VERB	O	O	3471
in	ADP	O	O	3471
the	PRON	O	O	3471
prefrontal	ADJ	O	O	3471
cortex	VERB	O	O	3471
(	PUNCT	O	O	3471
moderate	ADJ	O	O	3471
-	PUNCT	O	O	3471
dose	NOUN	O	O	3471
,	PUNCT	O	O	3471
24.1	NUM	O	O	3471
;	PUNCT	O	O	3471
high	ADJ	O	O	3471
-	PUNCT	O	O	3471
dose	NOUN	O	O	3471
,	PUNCT	O	O	3471
23.6	NUM	O	O	3471
;	PUNCT	O	O	3471
controls	VERB	O	O	3471
18.7	NUM	O	O	3471
;	PUNCT	O	O	3471
The	PRON	O	O	3472
number	NOUN	O	O	3472
of	ADP	O	O	3472
stained	VERB	O	O	3472
microglia	PROPN	O	O	3472
cells	NOUN	O	O	3472
was	AUX	O	O	3472
significantly	ADV	O	O	3472
higher	ADJ	O	O	3472
in	ADP	O	O	3472
the	PRON	O	O	3472
PDN	PROPN	O	O	3472
treated	VERB	O	O	3472
groups	NOUN	O	O	3472
in	ADP	O	O	3472
the	PRON	O	O	3472
prefrontal	ADJ	O	O	3472
cortex	VERB	O	O	3472
than	ADP	O	O	3472
in	ADP	O	O	3472
controls	VERB	O	O	3472
(	PUNCT	O	O	3472
moderate	ADJ	O	O	3472
-	PUNCT	O	O	3472
dose	NOUN	O	O	3472
,	PUNCT	O	O	3472
29.1	NUM	O	O	3472
;	PUNCT	O	O	3472
high	ADJ	O	O	3472
-	PUNCT	O	O	3472
dose	NOUN	O	O	3472
,	PUNCT	O	O	3472
28.4	NUM	O	O	3472
;	PUNCT	O	O	3472
control	VERB	O	O	3472
,	PUNCT	O	O	3472
17.7	NUM	O	O	3472
cells	NOUN	O	O	3472
per	ADP	O	O	3472
field	NOUN	O	O	3472
;	PUNCT	O	O	3472
p	NOUN	O	O	3472
<	X	O	O	3472
0.01	NUM	O	O	3472
)	PUNCT	O	O	3472
.	PUNCT	O	O	3472
CONCLUSION	PROPN	O	O	3473
:	PUNCT	O	O	3473
Subacute	VERB	O	O	3473
exposure	NOUN	O	O	3473
to	PART	O	O	3473
PDN	PROPN	O	O	3473
induced	VERB	O	O	3473
anxiety	NOUN	O	Disease	3473
and	CCONJ	O	O	3473
reactivity	NOUN	O	O	3473
of	ADP	O	O	3473
microglia	PROPN	O	O	3473
.	PUNCT	O	O	3473
The	PRON	O	O	3474
relevance	NOUN	O	O	3474
of	ADP	O	O	3474
these	PRON	O	O	3474
features	VERB	O	O	3474
for	ADP	O	O	3474
patients	NOUN	O	O	3474
using	VERB	O	O	3474
PDN	PROPN	O	O	3474
remains	VERB	O	O	3474
to	PART	O	O	3474
be	AUX	O	O	3474
elucidated	VERB	O	O	3474
.	PUNCT	O	O	3474
Phase	NOUN	O	O	3477
II	NUM	O	O	3477
study	VERB	O	O	3477
of	ADP	O	O	3477
carboplatin	PROPN	O	Chemical	3477
and	CCONJ	O	O	3477
liposomal	NOUN	O	O	3477
doxorubicin	VERB	O	Chemical	3478
in	ADP	O	O	3478
patients	NOUN	O	O	3478
with	ADP	O	O	3478
recurrent	ADJ	O	O	3478
squamous	ADJ	O	O	3478
cell	NOUN	O	O	3478
carcinoma	NOUN	O	Disease	3478
of	ADP	O	O	3478
the	PRON	O	O	3478
cervix	NOUN	O	O	3478
.	PUNCT	O	O	3478
The	PRON	O	O	3479
activity	NOUN	O	O	3479
of	ADP	O	O	3479
the	PRON	O	O	3479
combination	NOUN	O	O	3479
of	ADP	O	O	3479
carboplatin	PROPN	O	Chemical	3479
and	CCONJ	O	O	3479
liposomal	NOUN	O	O	3479
doxorubicin	VERB	O	Chemical	3479
was	AUX	O	O	3479
tested	VERB	O	O	3479
in	ADP	O	O	3479
a	PRON	O	O	3479
Phase	NOUN	O	O	3479
II	NUM	O	O	3479
study	VERB	O	O	3479
of	ADP	O	O	3479
patients	NOUN	O	O	3479
with	ADP	O	O	3479
recurrent	ADJ	O	O	3479
cervical	ADJ	O	O	3479
carcinoma	NOUN	O	Disease	3479
.	PUNCT	O	O	3479
METHODS	NOUN	O	O	3480
:	PUNCT	O	O	3480
The	PRON	O	O	3480
combination	NOUN	O	O	3480
of	ADP	O	O	3480
carboplatin	PROPN	O	Chemical	3480
(	PUNCT	O	O	3480
area	NOUN	O	O	3480
under	ADP	O	O	3480
the	PRON	O	O	3480
concentration	NOUN	O	O	3480
curve	NOUN	O	O	3480
[	X	O	O	3480
AUC	NOUN	O	O	3480
]	PUNCT	O	O	3480
,	PUNCT	O	O	3480
5	NUM	O	O	3480
)	PUNCT	O	O	3480
and	CCONJ	O	O	3480
liposomal	NOUN	O	O	3480
doxorubicin	VERB	O	Chemical	3480
(	PUNCT	O	O	3480
Doxil	NOUN	O	O	3480
;	PUNCT	O	O	3480
starting	VERB	O	O	3480
dose	NOUN	O	O	3480
,	PUNCT	O	O	3480
40	NUM	O	O	3480
mg	VERB	O	O	3480
/	PUNCT	O	O	3480
m(2	NUM	O	O	3480
)	PUNCT	O	O	3480
)	PUNCT	O	O	3480
was	AUX	O	O	3480
administered	VERB	O	O	3480
intravenously	ADV	O	O	3480
every	PRON	O	O	3480
28	NUM	O	O	3480
days	NOUN	O	O	3480
to	PART	O	O	3480
37	NUM	O	O	3480
patients	NOUN	O	O	3480
with	ADP	O	O	3480
recurrent	ADJ	O	O	3480
squamous	ADJ	O	O	3480
cell	NOUN	O	O	3480
cervical	ADJ	O	O	3480
carcinoma	NOUN	O	Disease	3480
to	PART	O	O	3480
determine	VERB	O	O	3480
antitumor	PROPN	O	O	3480
activity	NOUN	O	O	3480
and	CCONJ	O	O	3480
toxicity	NOUN	O	Disease	3480
profile	NOUN	O	O	3480
.	PUNCT	O	O	3480
Twenty	NUM	O	O	3481
-	PUNCT	O	O	3481
nine	NUM	O	O	3481
patients	NOUN	O	O	3481
were	AUX	O	O	3481
assessable	ADJ	O	O	3481
for	ADP	O	O	3481
response	NOUN	O	O	3481
,	PUNCT	O	O	3481
and	CCONJ	O	O	3481
35	NUM	O	O	3481
patients	NOUN	O	O	3481
were	AUX	O	O	3481
assessable	ADJ	O	O	3481
for	ADP	O	O	3481
toxicity	NOUN	O	Disease	3481
.	PUNCT	O	O	3481
The	PRON	O	O	3482
main	ADJ	O	O	3482
toxic	ADJ	O	O	3482
effect	VERB	O	O	3482
was	AUX	O	O	3482
myelosuppression	NOUN	O	Disease	3482
,	PUNCT	O	O	3482
with	ADP	O	O	3482
Grade	NOUN	O	O	3482
3	X	O	O	3482
and	CCONJ	O	O	3482
4	NUM	O	O	3482
neutropenia	ADJ	O	Disease	3482
in	ADP	O	O	3482
16	NUM	O	O	3482
patients	NOUN	O	O	3482
,	PUNCT	O	O	3482
anemia	NOUN	O	Disease	3482
in	ADP	O	O	3482
12	NUM	O	O	3482
patients	NOUN	O	O	3482
,	PUNCT	O	O	3482
thrombocytopenia	PROPN	O	Disease	3482
in	ADP	O	O	3482
11	NUM	O	O	3482
patients	NOUN	O	O	3482
,	PUNCT	O	O	3482
and	CCONJ	O	O	3482
neutropenic	ADJ	O	Disease	3482
fever	NOUN	O	Disease	3482
in	ADP	O	O	3482
3	X	O	O	3482
patients	NOUN	O	O	3482
.	PUNCT	O	O	3482
Four	NUM	O	O	3483
patients	NOUN	O	O	3483
had	VERB	O	O	3483
five	NUM	O	O	3483
infusion	NOUN	O	O	3483
-	PUNCT	O	O	3483
related	ADJ	O	O	3483
reactions	NOUN	O	O	3483
during	ADP	O	O	3483
the	PRON	O	O	3483
infusion	NOUN	O	O	3483
of	ADP	O	O	3483
liposomal	NOUN	O	O	3483
doxorubicin	VERB	O	Chemical	3483
,	PUNCT	O	O	3483
leading	VERB	O	O	3483
to	PART	O	O	3483
treatment	NOUN	O	O	3483
discontinuation	NOUN	O	O	3483
in	ADP	O	O	3483
three	NUM	O	O	3483
patients	NOUN	O	O	3483
.	PUNCT	O	O	3483
Grade	NOUN	O	O	3484
>	PUNCT	O	O	3484
or	CCONJ	O	O	3484
=	PUNCT	O	O	3484
2	X	O	O	3484
nonhematologic toxicity	NOUN	O	O	3484
included	VERB	O	O	3484
nausea	NOUN	O	Disease	3484
in	ADP	O	O	3484
17	NUM	O	O	3484
patients	NOUN	O	O	3484
,	PUNCT	O	O	3484
emesis	VERB	O	Disease	3484
in	ADP	O	O	3484
14	NUM	O	O	3484
patients	NOUN	O	O	3484
,	PUNCT	O	O	3484
fatigue	NOUN	O	Disease	3484
in	ADP	O	O	3484
9	NUM	O	O	3484
patients	NOUN	O	O	3484
,	PUNCT	O	O	3484
mucositis	NOUN	O	Disease	3484
and/or	CCONJ	O	O	3484
stomatitis	PROPN	O	O	3484
in	ADP	O	O	3484
8	NUM	O	O	3484
patients	NOUN	O	O	3484
,	PUNCT	O	O	3484
constipation	NOUN	O	Disease	3484
in	ADP	O	O	3484
6	NUM	O	O	3484
patients	NOUN	O	O	3484
,	PUNCT	O	O	3484
weight loss	NOUN	O	Disease	3484
in	ADP	O	O	3484
5	NUM	O	O	3484
patients	NOUN	O	O	3484
,	PUNCT	O	O	3484
hand	NOUN	O	O	3484
-	PUNCT	O	O	3484
foot	NOUN	O	O	3484
syndrome	NOUN	O	O	3484
in	ADP	O	O	3484
2	X	O	O	3484
patients	NOUN	O	O	3484
,	PUNCT	O	O	3484
and	CCONJ	O	O	3484
skin	NOUN	O	O	3484
reactions	NOUN	O	O	3484
in	ADP	O	O	3484
3	X	O	O	3484
patients	NOUN	O	O	3484
.	PUNCT	O	O	3484
The	PRON	O	O	3485
combination	NOUN	O	O	3485
of	ADP	O	O	3485
carboplatin	PROPN	O	Chemical	3485
and	CCONJ	O	O	3485
liposomal	NOUN	O	O	3485
doxorubicin	VERB	O	Chemical	3486
has	VERB	O	O	3486
modest	ADJ	O	O	3486
activity	NOUN	O	O	3486
in	ADP	O	O	3486
patients	NOUN	O	O	3486
with	ADP	O	O	3486
recurrent	ADJ	O	O	3486
cervical	ADJ	O	O	3486
carcinoma	NOUN	O	Disease	3486
.	PUNCT	O	O	3486
Antimicrobial	ADJ	O	O	3489
-	PUNCT	O	O	3489
induced	VERB	O	O	3489
mania	NOUN	O	O	3489
(	PUNCT	O	O	3489
antibiomania	PROPN	O	O	3489
)	PUNCT	O	O	3489
:	PUNCT	O	O	3489
a	PRON	O	O	3489
review	VERB	O	O	3489
of	ADP	O	O	3489
spontaneous	ADJ	O	O	3489
reports	VERB	O	O	3489
.	PUNCT	O	O	3489
The	PRON	O	O	3490
authors	NOUN	O	O	3490
reviewed	VERB	O	O	3490
reported	VERB	O	O	3490
cases	NOUN	O	O	3490
of	ADP	O	O	3490
antibiotic	ADJ	O	O	3490
-	PUNCT	O	O	3490
induced	VERB	O	O	3490
manic	ADJ	O	O	3490
episodes	NOUN	O	O	3490
by	ADP	O	O	3490
means	VERB	O	O	3490
of	ADP	O	O	3490
a	PRON	O	O	3490
MEDLINE	NOUN	O	O	3490
and	CCONJ	O	O	3490
PsychLit	PROPN	O	O	3490
search	NOUN	O	O	3490
for	ADP	O	O	3490
reports	VERB	O	O	3490
of	ADP	O	O	3490
antibiotic	ADJ	O	O	3490
-	PUNCT	O	O	3490
induced	VERB	O	O	3490
mania	NOUN	O	O	3490
.	PUNCT	O	O	3490
Twenty	NUM	O	O	3491
-	PUNCT	O	O	3491
one	NUM	O	O	3491
reports	VERB	O	O	3491
of	ADP	O	O	3491
antimicrobial	ADJ	O	O	3491
-	PUNCT	O	O	3491
induced	VERB	O	O	3491
mania	NOUN	O	O	3491
were	AUX	O	O	3491
found	VERB	O	O	3491
in	ADP	O	O	3491
the	PRON	O	O	3491
literature	NOUN	O	O	3491
.	PUNCT	O	O	3491
There	ADV	O	O	3492
were	AUX	O	O	3492
6	NUM	O	O	3492
cases	NOUN	O	O	3492
implicating	VERB	O	O	3492
clarithromycin	PROPN	O	Chemical	3492
,	PUNCT	O	O	3492
13	NUM	O	O	3492
implicating	VERB	O	O	3492
isoniazid	NOUN	O	Chemical	3492
,	PUNCT	O	O	3492
and	CCONJ	O	O	3492
1	X	O	O	3492
case	NOUN	O	O	3492
each	PRON	O	O	3492
implicating	VERB	O	O	3492
erythromycin	PROPN	O	Chemical	3492
and	CCONJ	O	O	3492
amoxicillin	PROPN	O	O	3492
.	PUNCT	O	O	3492
Of	ADV	O	O	3493
these	PRON	O	O	3493
,	PUNCT	O	O	3493
clarithromycin	PROPN	O	Chemical	3493
was	AUX	O	O	3493
implicated	VERB	O	O	3493
in	ADP	O	O	3493
23	NUM	O	O	3493
(	PUNCT	O	O	3493
27.6%	NOUN	O	O	3493
)	PUNCT	O	O	3493
cases	NOUN	O	O	3493
,	PUNCT	O	O	3493
ciprofloxacin	VERB	O	Chemical	3493
in	ADP	O	O	3493
12	NUM	O	O	3493
(	PUNCT	O	O	3493
14.4%	NOUN	O	O	3493
)	PUNCT	O	O	3493
cases	NOUN	O	O	3493
,	PUNCT	O	O	3493
and	CCONJ	O	O	3493
ofloxacin	PROPN	O	O	3493
in	ADP	O	O	3493
10	NUM	O	O	3493
(	PUNCT	O	O	3493
12%	NOUN	O	O	3493
)	PUNCT	O	O	3493
cases	NOUN	O	O	3493
.	PUNCT	O	O	3493
Cotrimoxazole	NOUN	O	O	3494
,	PUNCT	O	O	3494
metronidazole	VERB	O	O	3494
,	PUNCT	O	O	3494
and	CCONJ	O	O	3494
erythromycin	PROPN	O	Chemical	3494
were	AUX	O	O	3494
involved	VERB	O	O	3494
in	ADP	O	O	3494
15	NUM	O	O	3494
reported	VERB	O	O	3494
manic	ADJ	O	O	3494
episodes	NOUN	O	O	3494
.	PUNCT	O	O	3494
Cases	NOUN	O	O	3495
reported	VERB	O	O	3495
by	ADP	O	O	3495
the	PRON	O	O	3495
FDA	PROPN	O	O	3495
showed	VERB	O	O	3495
clarithromycin	PROPN	O	Chemical	3495
and	CCONJ	O	O	3495
ciprofloxacin	VERB	O	Chemical	3495
to	PART	O	O	3495
be	AUX	O	O	3495
the	PRON	O	O	3495
most	ADV	O	O	3495
frequently	ADV	O	O	3495
associated	VERB	O	O	3495
with	ADP	O	O	3495
the	PRON	O	O	3495
development	NOUN	O	O	3495
of	ADP	O	O	3495
mania	NOUN	O	O	3495
.	PUNCT	O	O	3495
Patients	NOUN	O	O	3496
have	VERB	O	O	3496
an	PRON	O	O	3496
increased	VERB	O	O	3496
risk	NOUN	O	O	3496
of	ADP	O	O	3496
developing	VERB	O	O	3496
mania	NOUN	O	O	3496
while	SCONJ	O	O	3496
being	AUX	O	O	3496
treated	VERB	O	O	3496
with	ADP	O	O	3496
antimicrobials	NOUN	O	O	3496
.	PUNCT	O	O	3496
Further	ADV	O	O	3497
research	NOUN	O	O	3497
clearly	ADV	O	O	3497
is	AUX	O	O	3497
required	VERB	O	O	3497
to	PART	O	O	3497
determine	VERB	O	O	3497
the	PRON	O	O	3497
incidence	NOUN	O	O	3497
of	ADP	O	O	3497
antimicrobial	ADJ	O	O	3497
-	PUNCT	O	O	3497
induced	VERB	O	O	3497
mania	NOUN	O	O	3497
,	PUNCT	O	O	3497
the	PRON	O	O	3497
relative	ADJ	O	O	3497
risk	NOUN	O	O	3497
factors	NOUN	O	O	3497
of	ADP	O	O	3497
developing	VERB	O	O	3497
an	PRON	O	O	3497
antimicrobial	ADJ	O	O	3497
-	PUNCT	O	O	3497
induced	VERB	O	O	3497
manic	ADJ	O	O	3497
episode	PROPN	O	O	3497
among	ADP	O	O	3497
various	ADJ	O	O	3497
demographic	ADJ	O	O	3497
populations	NOUN	O	O	3497
,	PUNCT	O	O	3497
and	CCONJ	O	O	3497
the	PRON	O	O	3497
incidence	NOUN	O	O	3497
of	ADP	O	O	3497
patients	NOUN	O	O	3497
who	PRON	O	O	3497
continue	VERB	O	O	3497
to	PART	O	O	3497
have	VERB	O	O	3497
persistent	ADJ	O	O	3497
affective disorders	NOUN	O	Disease	3497
once	ADV	O	O	3497
the	PRON	O	O	3497
initial	ADJ	O	O	3497
episode	PROPN	O	O	3497
,	PUNCT	O	O	3497
which	PRON	O	O	3497
occurs	VERB	O	O	3497
while	SCONJ	O	O	3497
the	PRON	O	O	3497
patient	NOUN	O	O	3497
is	AUX	O	O	3497
taking	VERB	O	O	3497
antibiotics	VERB	O	O	3497
,	PUNCT	O	O	3497
subsides	VERB	O	O	3497
.	PUNCT	O	O	3497
The	PRON	O	O	3498
authors	NOUN	O	O	3498
elected	VERB	O	O	3498
to	PART	O	O	3498
name	NOUN	O	O	3498
this	PRON	O	O	3498
syndrome	NOUN	O	O	3498
""""	PUNCT	O	O	3498
antibiomania	PROPN	O	O	3498
.	PUNCT	O	O	3498
""""	PUNCT	O	O	3498
Levodopa	NOUN	O	Chemical	3501
-	PUNCT	O	O	3501
induced	VERB	O	O	3501
ocular	ADJ	O	O	3501
dyskinesias	PROPN	O	Disease	3501
in	ADP	O	O	3501
Parkinson	NOUN	O	O	3501
's	AUX	O	O	3501
disease	PROPN	O	O	3501
.	PUNCT	O	O	3501
Levodopa	NOUN	O	Chemical	3502
-	PUNCT	O	O	3502
induced	VERB	O	O	3502
ocular	ADJ	O	O	3502
dyskinesias	PROPN	O	Disease	3502
are	AUX	O	O	3502
very	ADV	O	O	3502
uncommon	ADJ	O	O	3502
.	PUNCT	O	O	3502
Usually	ADV	O	O	3503
they	PRON	O	O	3503
occur	VERB	O	O	3503
simultaneously	ADV	O	O	3503
with	ADP	O	O	3503
limb	NOUN	O	O	3503
peak	PROPN	O	O	3503
-	PUNCT	O	O	3503
dose	NOUN	O	O	3503
choreatic	NOUN	O	O	3503
dyskinesias	PROPN	O	Disease	3503
.	PUNCT	O	O	3503
We	PRON	O	O	3504
report	VERB	O	O	3504
on	ADP	O	O	3504
a	PRON	O	O	3504
patient	NOUN	O	O	3504
with	ADP	O	O	3504
leftward	ADV	O	O	3504
and	CCONJ	O	O	3504
upward	ADV	O	O	3504
deviations	NOUN	O	O	3504
of	ADP	O	O	3504
gaze	VERB	O	O	3504
during	ADP	O	O	3504
the	PRON	O	O	3504
peak	PROPN	O	O	3504
effect	VERB	O	O	3504
of	ADP	O	O	3504
levodopa	NOUN	O	Chemical	3504
,	PUNCT	O	O	3504
and	CCONJ	O	O	3504
hypothesize	VERB	O	O	3504
that	SCONJ	O	O	3504
a	PRON	O	O	3504
severe	ADJ	O	O	3504
dopaminergic	ADJ	O	O	3504
denervation	NOUN	O	O	3504
in	ADP	O	O	3504
the	PRON	O	O	3504
caudate	ADJ	O	O	3504
nucleus	PROPN	O	O	3504
is	AUX	O	O	3504
needed	VERB	O	O	3504
for	ADP	O	O	3504
the	PRON	O	O	3504
appearance	NOUN	O	O	3504
of	ADP	O	O	3504
these	PRON	O	O	3504
levodopa	NOUN	O	Chemical	3504
-	PUNCT	O	O	3504
induce	VERB	O	O	3504
ocular	ADJ	O	O	3504
dyskinesias	PROPN	O	Disease	3504
.	PUNCT	O	O	3504
A	PRON	O	O	3507
comparison	NOUN	O	O	3507
of	ADP	O	O	3507
glyceryl trinitrate	PROPN	O	Chemical	3507
with	ADP	O	O	3507
diclofenac	PROPN	O	Chemical	3507
for	ADP	O	O	3507
the	PRON	O	O	3507
treatment	NOUN	O	O	3507
of	ADP	O	O	3507
primary	NOUN	O	O	3507
dysmenorrhea	PROPN	O	O	3507
:	PUNCT	O	O	3507
an	PRON	O	O	3507
open	VERB	O	O	3507
,	PUNCT	O	O	3507
randomized	VERB	O	O	3507
,	PUNCT	O	O	3507
cross	VERB	O	O	3507
-	PUNCT	O	O	3507
over	ADP	O	O	3507
trial	NOUN	O	O	3507
.	PUNCT	O	O	3507
Primary	NOUN	O	O	3508
dysmenorrhea	PROPN	O	O	3508
is	AUX	O	O	3508
a	PRON	O	O	3508
syndrome	NOUN	O	O	3508
characterized	VERB	O	O	3508
by	ADP	O	O	3508
painful	ADJ	O	Disease	3508
uterine	ADJ	O	O	3508
contractility	NOUN	O	O	3508
caused	VERB	O	O	3508
by	ADP	O	O	3508
a	PRON	O	O	3508
hypersecretion	PROPN	O	O	3508
of	ADP	O	O	3508
endometrial	ADJ	O	O	3508
prostaglandins	NOUN	O	Chemical	3508
;	PUNCT	O	O	3508
non	ADJ	O	O	3508
-	PUNCT	O	O	3508
steroidal	ADJ	O	O	3508
anti	ADJ	O	O	3508
-	PUNCT	O	O	3508
inflammatory	ADJ	O	O	3508
drugs	NOUN	O	O	3508
are	AUX	O	O	3508
the	PRON	O	O	3508
first	ADV	O	O	3508
choice	NOUN	O	O	3508
for	ADP	O	O	3508
its	PRON	O	O	3508
treatment	NOUN	O	O	3508
.	PUNCT	O	O	3508
However	ADV	O	O	3509
,	PUNCT	O	O	3509
in	ADP	O	O	3509
vivo	VERB	O	O	3509
and	CCONJ	O	O	3509
in	ADP	O	O	3509
vitro	X	O	O	3509
studies	NOUN	O	O	3509
have	VERB	O	O	3509
demonstrated	VERB	O	O	3509
that	SCONJ	O	O	3509
myometrial	ADJ	O	O	3509
cells	NOUN	O	O	3509
are	AUX	O	O	3509
also	ADV	O	O	3509
targets	VERB	O	O	3509
of	ADP	O	O	3509
the	PRON	O	O	3509
relaxant	NOUN	O	O	3509
effects	NOUN	O	O	3509
of	ADP	O	O	3509
nitric oxide	NOUN	O	Chemical	3509
(	PUNCT	O	O	3509
NO	PRON	O	Chemical	3509
)	PUNCT	O	O	3509
.	PUNCT	O	O	3509
The	PRON	O	O	3510
aim	VERB	O	O	3510
of	ADP	O	O	3510
the	PRON	O	O	3510
present	NOUN	O	O	3510
study	VERB	O	O	3510
was	AUX	O	O	3510
to	PART	O	O	3510
determine	VERB	O	O	3510
the	PRON	O	O	3510
efficacy	NOUN	O	O	3510
of	ADP	O	O	3510
glyceryl trinitrate	PROPN	O	Chemical	3510
(	PUNCT	O	O	3510
GTN	NOUN	O	Chemical	3510
)	PUNCT	O	O	3510
,	PUNCT	O	O	3510
an	PRON	O	O	3510
NO	PRON	O	Chemical	3510
donor	NOUN	O	O	3510
,	PUNCT	O	O	3510
in	ADP	O	O	3510
the	PRON	O	O	3510
resolution	NOUN	O	O	3510
of	ADP	O	O	3510
primary	NOUN	O	O	3510
dysmenorrhea	PROPN	O	O	3510
in	ADP	O	O	3510
comparison	NOUN	O	O	3510
with	ADP	O	O	3510
diclofenac	PROPN	O	Chemical	3510
(	PUNCT	O	O	3510
DCF	PROPN	O	O	3510
)	PUNCT	O	O	3510
.	PUNCT	O	O	3510
A	PRON	O	O	3511
total	ADJ	O	O	3511
of	ADP	O	O	3511
24	NUM	O	O	3511
patients	NOUN	O	O	3511
with	ADP	O	O	3511
the	PRON	O	O	3511
diagnosis	NOUN	O	O	3511
of	ADP	O	O	3511
severe	ADJ	O	O	3511
primary	NOUN	O	O	3511
dysmenorrhea	PROPN	O	O	3511
were	AUX	O	O	3511
studied	VERB	O	O	3511
during	ADP	O	O	3511
two	NUM	O	O	3511
consecutive	ADJ	O	O	3511
menstrual	ADJ	O	O	3511
cycles	NOUN	O	O	3511
.	PUNCT	O	O	3511
cross	VERB	O	O	3512
-	PUNCT	O	O	3512
over	ADP	O	O	3512
,	PUNCT	O	O	3512
controlled	VERB	O	O	3512
design	NOUN	O	O	3512
,	PUNCT	O	O	3512
patients	NOUN	O	O	3512
were	AUX	O	O	3512
randomized	VERB	O	O	3512
to	PART	O	O	3512
receive	VERB	O	O	3512
either	ADV	O	O	3512
DCF	PROPN	O	O	3512
per	ADP	O	O	3512
os	INTJ	O	O	3512
or	CCONJ	O	O	3512
GTN	NOUN	O	Chemical	3512
patches	NOUN	O	O	3512
the	PRON	O	O	3512
first	ADV	O	O	3512
days	NOUN	O	O	3512
of	ADP	O	O	3512
menses	NOUN	O	O	3512
,	PUNCT	O	O	3512
when	SCONJ	O	O	3512
menstrual	ADJ	O	O	3512
cramps	NOUN	O	O	3512
became	VERB	O	O	3512
unendurable	ADJ	O	O	3512
.	PUNCT	O	O	3512
Patients	NOUN	O	O	3513
received	VERB	O	O	3513
up	ADP	O	O	3513
to	PART	O	O	3513
3	X	O	O	3513
doses	NOUN	O	O	3513
/	PUNCT	O	O	3513
day	NOUN	O	O	3513
of	ADP	O	O	3513
50	NUM	O	O	3513
mg	VERB	O	O	3513
DCF	PROPN	O	O	3513
or	CCONJ	O	O	3513
2.5	NUM	O	O	3513
mg/24	NOUN	O	O	3513
h	X	O	O	3514
transdermal	NOUN	O	O	3514
GTN	NOUN	O	Chemical	3514
for	ADP	O	O	3514
the	PRON	O	O	3514
first	ADV	O	O	3514
3	X	O	O	3514
days	NOUN	O	O	3514
of	ADP	O	O	3514
the	PRON	O	O	3514
cycle	PROPN	O	O	3514
,	PUNCT	O	O	3514
according	VERB	O	O	3514
to	PART	O	O	3514
their	PRON	O	O	3514
needs	VERB	O	O	3514
.	PUNCT	O	O	3514
The	PRON	O	O	3515
difference	NOUN	O	O	3515
in	ADP	O	O	3515
pain	NOUN	O	Disease	3515
intensity	NOUN	O	O	3515
score	VERB	O	O	3515
(	PUNCT	O	O	3515
DPI	PROPN	O	O	3515
)	PUNCT	O	O	3515
was	AUX	O	O	3515
the	PRON	O	O	3515
main	ADJ	O	O	3515
outcome	NOUN	O	O	3515
variable	NOUN	O	O	3515
.	PUNCT	O	O	3515
Both	PRON	O	O	3516
treatments	NOUN	O	O	3516
significantly	ADV	O	O	3516
reduced	VERB	O	O	3516
DPI	PROPN	O	O	3516
by	ADP	O	O	3516
the	PRON	O	O	3516
30th	PROPN	O	O	3516
minute	VERB	O	O	3516
(	PUNCT	O	O	3516
GTN	NOUN	O	Chemical	3516
,	PUNCT	O	O	3516
-12.8	NOUN	O	O	3516
DCF	PROPN	O	O	3517
,	PUNCT	O	O	3517
-18.9	PUNCT	O	O	3517
However	ADV	O	O	3518
,	PUNCT	O	O	3518
DCF	PROPN	O	O	3518
continued	VERB	O	O	3518
to	PART	O	O	3518
be	AUX	O	O	3518
effective	ADJ	O	O	3518
in	ADP	O	O	3518
reducing	VERB	O	O	3518
pelvic	VERB	O	O	3518
pain	NOUN	O	Disease	3518
for	ADP	O	O	3518
two	NUM	O	O	3518
hours	NOUN	O	O	3518
,	PUNCT	O	O	3518
whereas	SCONJ	O	O	3518
GTN	NOUN	O	Chemical	3518
scores	NOUN	O	O	3518
remained	VERB	O	O	3518
more	ADJ	O	O	3518
or	CCONJ	O	O	3518
less	ADV	O	O	3518
stable	ADJ	O	O	3518
after	ADP	O	O	3518
30	NUM	O	O	3518
min	NOUN	O	O	3518
and	CCONJ	O	O	3518
significantly	ADV	O	O	3518
higher	ADJ	O	O	3518
than	ADP	O	O	3518
those	PRON	O	O	3518
for	ADP	O	O	3518
DFC	PROPN	O	O	3518
(	PUNCT	O	O	3518
after	ADP	O	O	3518
one	NUM	O	O	3518
hour	NOUN	O	O	3518
:	PUNCT	O	O	3518
GTN	NOUN	O	Chemical	3519
,	PUNCT	O	O	3519
-12.8	NOUN	O	O	3519
16.6	NUM	O	O	3520
and	CCONJ	O	O	3520
after	ADP	O	O	3520
two	NUM	O	O	3520
hours	NOUN	O	O	3520
:	PUNCT	O	O	3520
GTN	NOUN	O	Chemical	3520
,	PUNCT	O	O	3520
-23.7	NUM	O	O	3520
Low	ADJ	O	O	3521
back	ADV	O	O	3521
pain	NOUN	O	Disease	3521
was	AUX	O	O	3521
also	ADV	O	O	3521
relieved	VERB	O	O	3521
by	ADP	O	O	3521
both	PRON	O	O	3521
drugs	NOUN	O	O	3521
.	PUNCT	O	O	3521
Headache	NOUN	O	Disease	3522
was	AUX	O	O	3522
significantly	ADV	O	O	3522
increased	VERB	O	O	3522
by	ADP	O	O	3522
GTN	NOUN	O	Chemical	3522
but	CCONJ	O	O	3522
not	PART	O	O	3522
by	ADP	O	O	3522
DCF	PROPN	O	O	3522
.	PUNCT	O	O	3522
Eight	NUM	O	O	3523
patients	NOUN	O	O	3523
stopped	VERB	O	O	3523
using	VERB	O	O	3523
GTN	NOUN	O	Chemical	3523
because	SCONJ	O	O	3523
headache	PROPN	O	Disease	3523
--	PUNCT	O	O	3523
attributed	VERB	O	O	3523
to	PART	O	O	3523
its	PRON	O	O	3523
use	VERB	O	O	3523
--	PUNCT	O	O	3523
became	VERB	O	O	3523
intolerable	ADJ	O	O	3523
.	PUNCT	O	O	3523
These	PRON	O	O	3524
findings	NOUN	O	O	3524
indicate	VERB	O	O	3524
that	SCONJ	O	O	3524
GTN	NOUN	O	Chemical	3524
has	VERB	O	O	3524
a	PRON	O	O	3524
reduced	VERB	O	O	3524
efficacy	NOUN	O	O	3524
and	CCONJ	O	O	3524
tolerability	NOUN	O	O	3524
by	ADP	O	O	3524
comparison	NOUN	O	O	3524
with	ADP	O	O	3524
DCF	PROPN	O	O	3524
in	ADP	O	O	3524
the	PRON	O	O	3524
treatment	NOUN	O	O	3524
of	ADP	O	O	3524
primary	NOUN	O	O	3524
dysmenorrhea	PROPN	O	O	3524
.	PUNCT	O	O	3524
Temocapril	PROPN	O	O	3527
,	PUNCT	O	O	3527
a	PRON	O	O	3527
long	ADV	O	O	3527
-	PUNCT	O	O	3527
acting	VERB	O	O	3527
non	ADJ	O	O	3527
-	PUNCT	O	O	3527
SH	PROPN	O	O	3527
group	NOUN	O	O	3527
angiotensin	NOUN	O	Chemical	3527
converting	VERB	O	O	3527
enzyme	NOUN	O	O	3527
inhibitor	NOUN	O	O	3527
,	PUNCT	O	O	3527
modulates	VERB	O	O	3527
glomerular	ADJ	O	O	3527
injury	NOUN	O	O	3527
in	ADP	O	O	3527
chronic	ADJ	O	O	3527
puromycin aminonucleoside	NOUN	O	Chemical	3527
nephrosis	NOUN	O	Disease	3527
.	PUNCT	O	O	3527
The	PRON	O	O	3528
purpose	NOUN	O	O	3528
of	ADP	O	O	3528
the	PRON	O	O	3528
present	NOUN	O	O	3528
study	VERB	O	O	3528
was	AUX	O	O	3528
to	PART	O	O	3528
determine	VERB	O	O	3528
whether	SCONJ	O	O	3528
chronic	ADJ	O	O	3528
administration	NOUN	O	O	3528
of	ADP	O	O	3528
temocapril	PROPN	O	O	3528
,	PUNCT	O	O	3528
a	PRON	O	O	3528
long	ADV	O	O	3528
-	PUNCT	O	O	3528
acting	VERB	O	O	3528
non	ADJ	O	O	3528
-	PUNCT	O	O	3528
SH	PROPN	O	O	3528
group	NOUN	O	O	3528
angiotensin	NOUN	O	Chemical	3528
converting	VERB	O	O	3528
enzyme	NOUN	O	O	3528
(	PUNCT	O	O	3528
ACE	PROPN	O	O	3528
)	PUNCT	O	O	3528
inhibitor	NOUN	O	O	3528
,	PUNCT	O	O	3528
reduced	VERB	O	O	3528
proteinuria	X	O	Disease	3528
,	PUNCT	O	O	3528
inhibited	VERB	O	O	3528
glomerular	ADJ	O	O	3528
hypertrophy	VERB	O	Disease	3528
and	CCONJ	O	O	3528
prevented	VERB	O	O	3528
glomerulosclerosis	PROPN	O	O	3528
in	ADP	O	O	3528
chronic	ADJ	O	O	3528
puromycin aminonucleoside	NOUN	O	Chemical	3528
(	PUNCT	O	O	3528
PAN	PROPN	O	Chemical	3528
)	PUNCT	O	O	3528
-	PUNCT	O	O	3528
induced	VERB	O	O	3528
nephrotic	NOUN	O	Disease	3528
rats	NOUN	O	O	3528
.	PUNCT	O	O	3528
Nephrosis	NOUN	O	O	3529
was	AUX	O	O	3529
induced	VERB	O	O	3529
by	ADP	O	O	3529
injection	NOUN	O	O	3529
of	ADP	O	O	3529
PAN	PROPN	O	Chemical	3529
(	PUNCT	O	O	3529
15mg/100	NUM	O	O	3529
g	X	O	O	3529
body	NOUN	O	O	3529
weight	NOUN	O	O	3529
)	PUNCT	O	O	3529
in	ADP	O	O	3529
male	NOUN	O	O	3529
Sprague	PROPN	O	O	3529
-	PUNCT	O	O	3529
Dawley	NOUN	O	O	3529
(	PUNCT	O	O	3529
SD	NOUN	O	O	3529
)	PUNCT	O	O	3529
rats	NOUN	O	O	3529
.	PUNCT	O	O	3529
Four	NUM	O	O	3530
groups	NOUN	O	O	3530
were	AUX	O	O	3530
used	VERB	O	O	3530
,	PUNCT	O	O	3530
i	PRON	O	O	3530
)	PUNCT	O	O	3530
the	PRON	O	O	3530
PAN	PROPN	O	Chemical	3530
group	NOUN	O	O	3530
(	PUNCT	O	O	3530
14	NUM	O	O	3530
)	PUNCT	O	O	3530
,	PUNCT	O	O	3530
ii	PROPN	O	O	3530
)	PUNCT	O	O	3530
PAN	PROPN	O	Chemical	3531
/	PUNCT	O	O	3531
temocapril	PROPN	O	O	3531
(	PUNCT	O	O	3531
13	NUM	O	O	3531
)	PUNCT	O	O	3531
,	PUNCT	O	O	3531
iii	X	O	O	3531
)	PUNCT	O	O	3531
temocapril	PROPN	O	O	3531
(	PUNCT	O	O	3531
14	NUM	O	O	3531
)	PUNCT	O	O	3531
and	CCONJ	O	O	3531
iv	X	O	O	3531
)	PUNCT	O	O	3531
untreated	ADJ	O	O	3531
controls	VERB	O	O	3531
(	PUNCT	O	O	3531
15	NUM	O	O	3531
)	PUNCT	O	O	3531
.	PUNCT	O	O	3531
Temocapril	PROPN	O	O	3532
(	PUNCT	O	O	3532
8	NUM	O	O	3532
mg	VERB	O	O	3532
/	PUNCT	O	O	3532
kg	VERB	O	O	3532
/	PUNCT	O	O	3532
day	NOUN	O	O	3532
)	PUNCT	O	O	3532
was	AUX	O	O	3532
administered	VERB	O	O	3532
to	PART	O	O	3532
the	PRON	O	O	3532
rats	NOUN	O	O	3532
which	PRON	O	O	3532
were	AUX	O	O	3532
killed	VERB	O	O	3532
at	ADP	O	O	3532
weeks	NOUN	O	O	3532
4	NUM	O	O	3532
,	PUNCT	O	O	3532
14	NUM	O	O	3532
or	CCONJ	O	O	3532
20	NUM	O	O	3532
.	PUNCT	O	O	3532
Systolic	PROPN	O	O	3533
BP	PROPN	O	O	3533
in	ADP	O	O	3533
the	PRON	O	O	3533
PAN	PROPN	O	Chemical	3533
group	NOUN	O	O	3533
was	AUX	O	O	3533
significantly	ADV	O	O	3533
high	ADJ	O	O	3533
at	ADP	O	O	3533
4	NUM	O	O	3533
,	PUNCT	O	O	3533
14	NUM	O	O	3533
and	CCONJ	O	O	3533
20	NUM	O	O	3533
weeks	NOUN	O	O	3533
,	PUNCT	O	O	3533
but	CCONJ	O	O	3533
was	AUX	O	O	3533
normal	ADJ	O	O	3533
in	ADP	O	O	3533
the	PRON	O	O	3533
PAN	PROPN	O	Chemical	3533
/	PUNCT	O	O	3533
temocapril	PROPN	O	O	3533
group	NOUN	O	O	3533
.	PUNCT	O	O	3533
Urinary	NOUN	O	O	3534
protein excretion	NOUN	O	Disease	3534
in	ADP	O	O	3534
the	PRON	O	O	3534
PAN	PROPN	O	Chemical	3534
group	NOUN	O	O	3534
increased	VERB	O	O	3534
significantly	ADV	O	O	3534
,	PUNCT	O	O	3534
peaking	VERB	O	O	3534
at	ADP	O	O	3534
8	NUM	O	O	3534
days	NOUN	O	O	3534
,	PUNCT	O	O	3534
then	ADV	O	O	3534
decreased	VERB	O	O	3534
at	ADP	O	O	3534
4	NUM	O	O	3534
weeks	NOUN	O	O	3534
,	PUNCT	O	O	3534
but	CCONJ	O	O	3534
rose	VERB	O	O	3534
again	ADV	O	O	3534
significantly	ADV	O	O	3534
at	ADP	O	O	3534
14	NUM	O	O	3534
and	CCONJ	O	O	3534
20	NUM	O	O	3534
weeks	NOUN	O	O	3534
.	PUNCT	O	O	3534
Temocapril	PROPN	O	O	3535
did	VERB	O	O	3535
not	PART	O	O	3535
attenuate	VERB	O	O	3535
proteinuria	X	O	Disease	3535
at	ADP	O	O	3535
8	NUM	O	O	3535
days	NOUN	O	O	3535
,	PUNCT	O	O	3535
but	CCONJ	O	O	3535
it	PRON	O	O	3535
did	VERB	O	O	3535
markedly	ADV	O	O	3535
lower	ADJ	O	O	3535
it	PRON	O	O	3535
from	ADP	O	O	3535
weeks	NOUN	O	O	3535
4	NUM	O	O	3535
to	PART	O	O	3535
20	NUM	O	O	3535
.	PUNCT	O	O	3535
The	PRON	O	O	3536
glomerulosclerosis	PROPN	O	O	3536
index	NOUN	O	O	3536
(	PUNCT	O	O	3536
GSI	PROPN	O	O	3536
)	PUNCT	O	O	3536
was	AUX	O	O	3536
6.21	NUM	O	O	3536
%	INTJ	O	O	3536
at	ADP	O	O	3536
4	NUM	O	O	3536
weeks	NOUN	O	O	3536
and	CCONJ	O	O	3536
respectively	ADV	O	O	3536
25.35	NUM	O	O	3536
%	INTJ	O	O	3536
and	CCONJ	O	O	3536
30.49	NUM	O	O	3536
%	INTJ	O	O	3536
at	ADP	O	O	3536
14	NUM	O	O	3536
and	CCONJ	O	O	3536
20	NUM	O	O	3536
weeks	NOUN	O	O	3536
in	ADP	O	O	3536
the	PRON	O	O	3536
PAN	PROPN	O	Chemical	3536
group	NOUN	O	O	3536
.	PUNCT	O	O	3536
The	PRON	O	O	3537
ratio	NOUN	O	O	3537
of	ADP	O	O	3537
glomerular	ADJ	O	O	3537
tuft	NOUN	O	O	3537
area	NOUN	O	O	3537
to	PART	O	O	3537
the	PRON	O	O	3537
area	NOUN	O	O	3537
of	ADP	O	O	3537
Bowman	PROPN	O	O	3537
's	AUX	O	O	3537
capsules	NOUN	O	O	3537
(	PUNCT	O	O	3537
GT	NOUN	O	O	3537
/	PUNCT	O	O	3537
BC	PROPN	O	O	3537
)	PUNCT	O	O	3537
in	ADP	O	O	3537
the	PRON	O	O	3537
PAN	PROPN	O	Chemical	3537
group	NOUN	O	O	3537
was	AUX	O	O	3537
significantly	ADV	O	O	3537
increased	VERB	O	O	3537
,	PUNCT	O	O	3537
but	CCONJ	O	O	3537
it	PRON	O	O	3537
was	AUX	O	O	3537
significantly	ADV	O	O	3537
lower	ADJ	O	O	3537
in	ADP	O	O	3537
the	PRON	O	O	3537
PAN	PROPN	O	Chemical	3537
/	PUNCT	O	O	3537
temocapril	PROPN	O	O	3537
group	NOUN	O	O	3537
.	PUNCT	O	O	3537
It	PRON	O	O	3538
appears	VERB	O	O	3538
that	SCONJ	O	O	3538
temocapril	PROPN	O	O	3538
was	AUX	O	O	3538
effective	ADJ	O	O	3538
in	ADP	O	O	3538
retarding	VERB	O	O	3538
renal	ADJ	O	O	3538
progression	NOUN	O	O	3538
and	CCONJ	O	O	3538
protected	VERB	O	O	3538
renal	ADJ	O	O	3538
function	NOUN	O	O	3538
in	ADP	O	O	3538
PAN	PROPN	O	Chemical	3538
neprotic	PROPN	O	O	3538
rats	NOUN	O	O	3538
.	PUNCT	O	O	3538
Pulmonary	NOUN	O	O	3541
hypertension	NOUN	O	Disease	3541
after	ADP	O	O	3541
ibuprofen	PROPN	O	Chemical	3541
prophylaxis	NOUN	O	O	3541
in	ADP	O	O	3541
very	ADV	O	O	3541
preterm	NOUN	O	O	3541
infants	NOUN	O	O	3541
.	PUNCT	O	O	3541
We	PRON	O	O	3542
report	VERB	O	O	3542
three	NUM	O	O	3542
cases	NOUN	O	O	3542
of	ADP	O	O	3542
severe	ADJ	O	O	3542
hypoxaemia	ADV	O	O	3542
after	ADP	O	O	3542
ibuprofen	PROPN	O	Chemical	3542
administration	NOUN	O	O	3542
during	ADP	O	O	3542
a	PRON	O	O	3542
randomised	VERB	O	O	3542
controlled	VERB	O	O	3542
trial	NOUN	O	O	3542
of	ADP	O	O	3542
prophylactic	ADJ	O	O	3542
treatment	NOUN	O	O	3542
of	ADP	O	O	3542
patent	NOUN	O	O	3542
ductus	NOUN	O	O	3542
arteriosus	NOUN	O	O	3542
with	ADP	O	O	3542
ibuprofen	PROPN	O	Chemical	3542
in	ADP	O	O	3542
premature	ADJ	O	O	3542
infants	NOUN	O	O	3542
born	VERB	O	O	3542
at	ADP	O	O	3542
less	ADV	O	O	3542
than	ADP	O	O	3542
28	NUM	O	O	3542
weeks	NOUN	O	O	3542
of	ADP	O	O	3542
gestation	NOUN	O	O	3542
.	PUNCT	O	O	3542
Hypoxaemia	PROPN	O	O	3543
resolved	VERB	O	O	3543
quickly	ADV	O	O	3543
on	ADP	O	O	3543
inhaled	VERB	O	O	3543
nitric oxide	NOUN	O	Chemical	3543
therapy	NOUN	O	O	3543
.	PUNCT	O	O	3543
We	PRON	O	O	3544
suggest	VERB	O	O	3544
that	SCONJ	O	O	3544
investigators	NOUN	O	O	3544
involved	VERB	O	O	3544
in	ADP	O	O	3544
similar	ADJ	O	O	3544
trials	NOUN	O	O	3544
pay	VERB	O	O	3544
close	ADV	O	O	3544
attention	NOUN	O	O	3544
to	PART	O	O	3544
pulmonary	ADJ	O	O	3544
pressure	NOUN	O	O	3544
if	SCONJ	O	O	3544
hypoxaemia	ADV	O	O	3544
occurs	VERB	O	O	3544
after	ADP	O	O	3544
prophylactic	ADJ	O	O	3544
administration	NOUN	O	O	3544
of	ADP	O	O	3544
ibuprofen	PROPN	O	Chemical	3544
.	PUNCT	O	O	3544
Hyponatremia	NOUN	O	O	3547
and	CCONJ	O	O	3547
syndrome	NOUN	O	O	3547
of	ADP	O	O	3547
inappropriate	ADJ	O	O	3547
anti	ADJ	O	O	3547
-	PUNCT	O	O	3547
diuretic	ADJ	O	Chemical	3547
hormone	NOUN	O	O	3547
reported	VERB	O	O	3547
with	ADP	O	O	3547
the	PRON	O	O	3547
use	VERB	O	O	3547
of	ADP	O	O	3547
Vincristine	NOUN	O	O	3547
:	PUNCT	O	O	3547
an	PRON	O	O	3547
over	ADP	O	O	3547
-	PUNCT	O	O	3547
representation	NOUN	O	O	3547
of	ADP	O	O	3547
Asians	PROPN	O	O	3547
?	PUNCT	O	O	3547
This	PRON	O	O	3548
retrospective	ADJ	O	O	3548
study	VERB	O	O	3548
used	VERB	O	O	3548
a	PRON	O	O	3548
pharmaceutical	NOUN	O	O	3548
company	NOUN	O	O	3548
's	AUX	O	O	3548
global	ADJ	O	O	3548
safety	NOUN	O	O	3548
database	NOUN	O	O	3548
to	PART	O	O	3548
determine	VERB	O	O	3548
the	PRON	O	O	3548
reporting	VERB	O	O	3548
rate	NOUN	O	O	3548
of	ADP	O	O	3548
hyponatremia	NOUN	O	O	3548
and/or	CCONJ	O	O	3548
syndrome	NOUN	O	O	3548
of	ADP	O	O	3548
inappropriate	ADJ	O	O	3548
secretion	NOUN	O	O	3548
of	ADP	O	O	3548
anti	ADJ	O	O	3548
-	PUNCT	O	O	3548
diuretic	ADJ	O	Chemical	3548
hormone	NOUN	O	O	3548
(	PUNCT	O	O	3548
SIADH	PROPN	O	Disease	3548
)	PUNCT	O	O	3548
among	ADP	O	O	3548
vincristine	NOUN	O	Chemical	3548
-	PUNCT	O	O	3548
treated	VERB	O	O	3548
patients	NOUN	O	O	3548
and	CCONJ	O	O	3548
to	PART	O	O	3548
explore	VERB	O	O	3548
the	PRON	O	O	3548
possibility	NOUN	O	O	3548
of	ADP	O	O	3548
at	ADP	O	O	3548
-	PUNCT	O	O	3548
risk	NOUN	O	O	3548
population	NOUN	O	O	3548
subgroups	NOUN	O	O	3548
.	PUNCT	O	O	3548
METHOD	NOUN	O	O	3549
:	PUNCT	O	O	3549
We	PRON	O	O	3549
searched	VERB	O	O	3549
the	PRON	O	O	3549
Eli	PROPN	O	O	3549
Lilly	NOUN	O	O	3549
and	CCONJ	O	O	3549
Company	NOUN	O	O	3549
's	AUX	O	O	3549
computerized	VERB	O	O	3549
adverse	ADJ	O	O	3549
event	NOUN	O	O	3549
database	NOUN	O	O	3549
for	ADP	O	O	3549
all	PRON	O	O	3549
reported	VERB	O	O	3549
cases	NOUN	O	O	3549
of	ADP	O	O	3549
hyponatremia	NOUN	O	O	3549
and/or	CCONJ	O	O	3549
SIADH	PROPN	O	Disease	3549
as	ADP	O	O	3549
of	ADP	O	O	3549
1	X	O	O	3549
November	PROPN	O	O	3549
1999	NUM	O	O	3549
that	SCONJ	O	O	3549
had	VERB	O	O	3549
been	AUX	O	O	3549
reported	VERB	O	O	3549
during	ADP	O	O	3549
the	PRON	O	O	3549
use	VERB	O	O	3549
of	ADP	O	O	3549
vincristine	NOUN	O	Chemical	3549
.	PUNCT	O	O	3549
A	PRON	O	O	3550
total	ADJ	O	O	3550
of	ADP	O	O	3550
76	NUM	O	O	3550
cases	NOUN	O	O	3550
of	ADP	O	O	3550
hyponatremia	NOUN	O	O	3550
and/or	CCONJ	O	O	3550
SIADH	PROPN	O	Disease	3550
associated	VERB	O	O	3550
with	ADP	O	O	3550
vincristine	NOUN	O	Chemical	3550
use	VERB	O	O	3550
were	AUX	O	O	3550
identified	VERB	O	O	3550
.	PUNCT	O	O	3550
Approximately	ADV	O	O	3551
75%	NOUN	O	O	3551
of	ADP	O	O	3551
the	PRON	O	O	3551
patients	NOUN	O	O	3551
were	AUX	O	O	3551
receiving	VERB	O	O	3551
treatment	NOUN	O	O	3551
for	ADP	O	O	3551
leukemia	NOUN	O	Disease	3551
or	CCONJ	O	O	3551
lymphoma	PROPN	O	Disease	3551
.	PUNCT	O	O	3551
CONCLUSION	PROPN	O	O	3552
:	PUNCT	O	O	3552
Our	PRON	O	O	3552
data	NOUN	O	O	3552
suggest	VERB	O	O	3552
that	SCONJ	O	O	3552
Asian	ADJ	O	O	3552
patients	NOUN	O	O	3552
may	AUX	O	O	3552
be	AUX	O	O	3552
at	ADP	O	O	3552
increased	VERB	O	O	3552
risk	NOUN	O	O	3552
of	ADP	O	O	3552
hyponatremia	NOUN	O	O	3552
and/or	CCONJ	O	O	3552
SIADH	PROPN	O	Disease	3552
associated	VERB	O	O	3552
with	ADP	O	O	3552
vincristine	NOUN	O	Chemical	3552
use	VERB	O	O	3552
.	PUNCT	O	O	3552
Although	SCONJ	O	O	3553
the	PRON	O	O	3553
overall	ADV	O	O	3553
reported	VERB	O	O	3553
rate	NOUN	O	O	3553
of	ADP	O	O	3553
SIADH	PROPN	O	Disease	3553
associated	VERB	O	O	3553
with	ADP	O	O	3553
vincristine	NOUN	O	Chemical	3553
is	AUX	O	O	3553
very	ADV	O	O	3553
low	ADJ	O	O	3553
,	PUNCT	O	O	3553
physicians	NOUN	O	O	3553
caring	VERB	O	O	3553
for	ADP	O	O	3553
Asian	ADJ	O	O	3553
oncology	NOUN	O	O	3553
patients	NOUN	O	O	3553
should	AUX	O	O	3553
be	AUX	O	O	3553
aware	ADJ	O	O	3553
of	ADP	O	O	3553
this	PRON	O	O	3553
potential	ADJ	O	O	3553
serious	ADJ	O	O	3553
but	CCONJ	O	O	3553
reversible	ADJ	O	O	3553
adverse	ADJ	O	O	3553
event	NOUN	O	O	3553
.	PUNCT	O	O	3553
Delayed	VERB	O	O	3556
toxicity	NOUN	O	Disease	3556
of	ADP	O	O	3556
cyclophosphamide	VERB	O	Chemical	3556
on	ADP	O	O	3556
the	PRON	O	O	3556
bladder	NOUN	O	O	3556
of	ADP	O	O	3556
DBA/2	PROPN	O	O	3556
and	CCONJ	O	O	3556
C57BL/6	NOUN	O	O	3556
female	ADJ	O	O	3556
mouse	PROPN	O	O	3556
.	PUNCT	O	O	3556
The	PRON	O	O	3557
present	NOUN	O	O	3557
study	VERB	O	O	3557
describes	VERB	O	O	3557
the	PRON	O	O	3557
delayed	VERB	O	O	3557
development	NOUN	O	O	3557
of	ADP	O	O	3557
a	PRON	O	O	3557
severe	ADJ	O	O	3557
bladder	NOUN	O	O	3557
pathology	NOUN	O	O	3557
in	ADP	O	O	3557
a	PRON	O	O	3557
susceptible	ADJ	O	O	3557
strain	VERB	O	O	3557
of	ADP	O	O	3557
mice	NOUN	O	O	3557
(	PUNCT	O	O	3557
DBA/2	PROPN	O	O	3557
)	PUNCT	O	O	3557
but	CCONJ	O	O	3557
not	PART	O	O	3557
in	ADP	O	O	3557
a	PRON	O	O	3557
resistant	ADJ	O	O	3557
strain	VERB	O	O	3557
(	PUNCT	O	O	3557
C57BL/6	NOUN	O	O	3557
)	PUNCT	O	O	3557
when	SCONJ	O	O	3557
both	PRON	O	O	3557
were	AUX	O	O	3557
treated	VERB	O	O	3557
with	ADP	O	O	3557
a	PRON	O	O	3557
single	ADJ	O	O	3557
300	NUM	O	O	3557
mg	VERB	O	O	3557
/	PUNCT	O	O	3557
kg	VERB	O	O	3557
dose	NOUN	O	O	3557
of	ADP	O	O	3557
cyclophosphamide	VERB	O	Chemical	3557
(	PUNCT	O	O	3557
CY	PROPN	O	O	3557
)	PUNCT	O	O	3557
.	PUNCT	O	O	3557
Inbred	PROPN	O	O	3558
DBA/2	PROPN	O	O	3558
and	CCONJ	O	O	3558
C57BL/6	NOUN	O	O	3558
female	ADJ	O	O	3558
mice	NOUN	O	O	3558
were	AUX	O	O	3558
injected	VERB	O	O	3558
with	ADP	O	O	3558
CY	PROPN	O	O	3558
,	PUNCT	O	O	3558
and	CCONJ	O	O	3558
the	PRON	O	O	3558
effect	VERB	O	O	3558
of	ADP	O	O	3558
the	PRON	O	O	3558
drug	NOUN	O	O	3558
on	ADP	O	O	3558
the	PRON	O	O	3558
bladder	NOUN	O	O	3558
was	AUX	O	O	3558
assessed	VERB	O	O	3558
during	ADP	O	O	3558
100	NUM	O	O	3558
days	NOUN	O	O	3558
by	ADP	O	O	3558
light	ADJ	O	O	3558
microscopy	NOUN	O	O	3558
using	VERB	O	O	3558
different	ADJ	O	O	3558
staining	VERB	O	O	3558
procedures	NOUN	O	O	3558
,	PUNCT	O	O	3558
and	CCONJ	O	O	3558
after	ADP	O	O	3558
30	NUM	O	O	3558
days	NOUN	O	O	3558
by	ADP	O	O	3558
conventional	ADJ	O	O	3558
electron	NOUN	O	O	3558
microscopy	NOUN	O	O	3558
.	PUNCT	O	O	3558
Early	ADJ	O	O	3559
CY	PROPN	O	O	3559
toxicity	NOUN	O	Disease	3559
caused	VERB	O	O	3559
a	PRON	O	O	3559
typical	ADJ	O	O	3559
haemorrhagic	ADJ	O	Disease	3559
cystitis	NOUN	O	Disease	3559
in	ADP	O	O	3559
both	PRON	O	O	3559
strains	VERB	O	O	3559
that	SCONJ	O	O	3559
was	AUX	O	O	3559
completely	ADV	O	O	3559
repaired	VERB	O	O	3559
in	ADP	O	O	3559
about	ADP	O	O	3559
7	NUM	O	O	3559
-	PUNCT	O	O	3559
10	NUM	O	O	3559
days	NOUN	O	O	3559
.	PUNCT	O	O	3559
After	ADP	O	O	3560
30	NUM	O	O	3560
days	NOUN	O	O	3560
of	ADP	O	O	3560
CY	PROPN	O	O	3560
injection	NOUN	O	O	3560
ulcerous	ADJ	O	O	3560
and	CCONJ	O	O	3560
non	ADJ	O	O	3560
-	PUNCT	O	O	3560
ulcerous	ADJ	O	O	3560
forms	NOUN	O	O	3560
of	ADP	O	O	3560
chronic	ADJ	O	O	3560
cystitis	NOUN	O	Disease	3560
appeared	VERB	O	O	3560
in	ADP	O	O	3560
86%	NOUN	O	O	3560
of	ADP	O	O	3560
DBA/2	PROPN	O	O	3560
mice	NOUN	O	O	3560
but	CCONJ	O	O	3560
only	ADV	O	O	3560
in	ADP	O	O	3560
4%	NOUN	O	O	3560
of	ADP	O	O	3560
C57BL/6	NOUN	O	O	3560
mice	NOUN	O	O	3560
.	PUNCT	O	O	3560
Delayed	VERB	O	O	3561
cystitis	NOUN	O	Disease	3561
was	AUX	O	O	3561
characterized	VERB	O	O	3561
by	ADP	O	O	3561
infiltration	NOUN	O	O	3561
and	CCONJ	O	O	3561
transepithelial	NOUN	O	O	3561
passage	NOUN	O	O	3561
into	ADP	O	O	3561
the	PRON	O	O	3561
lumen	NOUN	O	O	3561
of	ADP	O	O	3561
inflammatory	ADJ	O	O	3561
cells	NOUN	O	O	3561
and	CCONJ	O	O	3561
by	ADP	O	O	3561
frequent	ADJ	O	O	3561
exfoliation	NOUN	O	O	3561
of	ADP	O	O	3561
the	PRON	O	O	3561
urothelium	NOUN	O	O	3561
.	PUNCT	O	O	3561
Delayed	VERB	O	O	3562
cystitis	NOUN	O	Disease	3562
still	ADV	O	O	3562
persisted	VERB	O	O	3562
in	ADP	O	O	3562
DBA/2	PROPN	O	O	3562
mice	NOUN	O	O	3562
100	NUM	O	O	3562
days	NOUN	O	O	3562
after	ADP	O	O	3562
treatment	NOUN	O	O	3562
.	PUNCT	O	O	3562
These	PRON	O	O	3563
results	VERB	O	O	3563
indicate	VERB	O	O	3563
that	SCONJ	O	O	3563
delayed	VERB	O	O	3563
toxicity	NOUN	O	Disease	3563
of	ADP	O	O	3563
CY	PROPN	O	O	3563
in	ADP	O	O	3563
female	ADJ	O	O	3563
DBA/2	PROPN	O	O	3563
mice	NOUN	O	O	3563
causes	VERB	O	O	3563
a	PRON	O	O	3563
bladder	NOUN	O	O	3563
pathology	NOUN	O	O	3563
that	SCONJ	O	O	3563
is	AUX	O	O	3563
not	PART	O	O	3563
observed	VERB	O	O	3563
in	ADP	O	O	3563
C57BL/6	NOUN	O	O	3563
mice	NOUN	O	O	3563
.	PUNCT	O	O	3563
This	PRON	O	O	3564
pathology	NOUN	O	O	3564
resembles	VERB	O	O	3564
interstitial	ADJ	O	O	3564
cystitis	NOUN	O	Disease	3564
in	ADP	O	O	3564
humans	NOUN	O	O	3564
and	CCONJ	O	O	3564
could	AUX	O	O	3564
perhaps	ADV	O	O	3564
be	AUX	O	O	3564
used	VERB	O	O	3564
as	ADP	O	O	3564
an	PRON	O	O	3564
animal	NOUN	O	O	3564
model	NOUN	O	O	3564
for	ADP	O	O	3564
studies	NOUN	O	O	3564
on	ADP	O	O	3564
the	PRON	O	O	3564
disease	PROPN	O	O	3564
.	PUNCT	O	O	3564
High	ADJ	O	O	3567
-	PUNCT	O	O	3567
dose	NOUN	O	O	3567
5-fluorouracil	NOUN	O	Chemical	3567
/	PUNCT	O	O	3567
folinic	PROPN	O	O	3567
acid	PROPN	O	O	3567
in	ADP	O	O	3567
combination	NOUN	O	O	3567
with	ADP	O	O	3567
three	NUM	O	O	3567
-	PUNCT	O	O	3567
weekly	ADV	O	O	3567
mitomycin C	PROPN	O	Chemical	3567
in	ADP	O	O	3567
the	PRON	O	O	3567
treatment	NOUN	O	O	3567
of	ADP	O	O	3567
advanced	ADJ	O	O	3567
gastric	ADJ	O	O	3567
cancer	NOUN	O	Disease	3567
.	PUNCT	O	O	3567
BACKGROUND	NOUN	O	O	3568
:	PUNCT	O	O	3568
The	PRON	O	O	3568
24-hour	NOUN	O	O	3568
continuous	ADJ	O	O	3568
infusion	NOUN	O	O	3568
of	ADP	O	O	3568
5-fluorouracil	NOUN	O	Chemical	3568
(	PUNCT	O	O	3568
5-FU	NOUN	O	Chemical	3568
)	PUNCT	O	O	3568
and	CCONJ	O	O	3568
folinic	PROPN	O	O	3568
acid	PROPN	O	O	3568
(	PUNCT	O	O	3568
FA	NOUN	O	Chemical	3568
)	PUNCT	O	O	3568
as	ADP	O	O	3568
part	NOUN	O	O	3568
of	ADP	O	O	3568
several	ADJ	O	O	3568
new	ADJ	O	O	3568
multidrug	NOUN	O	O	3568
chemotherapy	NOUN	O	O	3568
regimens	NOUN	O	O	3568
in	ADP	O	O	3568
advanced	ADJ	O	O	3568
gastric	ADJ	O	O	3568
cancer	NOUN	O	Disease	3568
(	PUNCT	O	O	3568
AGC	PROPN	O	O	3568
)	PUNCT	O	O	3568
has	VERB	O	O	3568
shown	VERB	O	O	3568
to	PART	O	O	3568
be	AUX	O	O	3568
effective	ADJ	O	O	3568
,	PUNCT	O	O	3568
with	ADP	O	O	3568
low	ADJ	O	O	3568
toxicity	NOUN	O	Disease	3568
.	PUNCT	O	O	3568
In	ADP	O	O	3569
a	PRON	O	O	3569
previous	ADJ	O	O	3569
phase	NOUN	O	O	3569
II	NUM	O	O	3569
study	VERB	O	O	3569
with	ADP	O	O	3569
3-weekly	NOUN	O	O	3569
bolus	NOUN	O	O	3569
5-FU	NOUN	O	Chemical	3569
,	PUNCT	O	O	3569
FA	NOUN	O	Chemical	3569
and	CCONJ	O	O	3569
mitomycin C	PROPN	O	Chemical	3569
(	PUNCT	O	O	3569
MMC	PROPN	O	Chemical	3569
)	PUNCT	O	O	3569
we	PRON	O	O	3569
found	VERB	O	O	3569
a	PRON	O	O	3569
low	ADJ	O	O	3569
toxicity	NOUN	O	Disease	3569
rate	NOUN	O	O	3569
and	CCONJ	O	O	3569
response	NOUN	O	O	3569
rates	NOUN	O	O	3569
comparable	ADJ	O	O	3569
to	PART	O	O	3569
those	PRON	O	O	3569
of	ADP	O	O	3569
regimens	NOUN	O	O	3569
such	ADJ	O	O	3569
as	ADP	O	O	3569
ELF	NOUN	O	O	3569
,	PUNCT	O	O	3569
FAM	PROPN	O	O	3569
or	CCONJ	O	O	3569
FAMTX	NOUN	O	O	3569
,	PUNCT	O	O	3569
and	CCONJ	O	O	3569
a	PRON	O	O	3569
promising	VERB	O	O	3569
median	ADJ	O	O	3569
overall	ADV	O	O	3569
survival	NOUN	O	O	3569
.	PUNCT	O	O	3569
In	ADP	O	O	3570
order	NOUN	O	O	3570
to	PART	O	O	3570
improve	VERB	O	O	3570
this	PRON	O	O	3570
MMC	PROPN	O	Chemical	3570
-	PUNCT	O	O	3570
dependent	ADJ	O	O	3570
schedule	NOUN	O	O	3570
we	PRON	O	O	3570
initiated	VERB	O	O	3570
a	PRON	O	O	3570
phase	NOUN	O	O	3570
II	NUM	O	O	3570
study	VERB	O	O	3570
with	ADP	O	O	3570
high	ADJ	O	O	3570
-	PUNCT	O	O	3570
dose	NOUN	O	O	3570
5-FU	NOUN	O	Chemical	3570
/	PUNCT	O	O	3570
FA	NOUN	O	Chemical	3570
and	CCONJ	O	O	3570
3-weekly	NOUN	O	O	3570
bolus	NOUN	O	O	3570
MMC	PROPN	O	Chemical	3570
.	PUNCT	O	O	3570
From	ADP	O	O	3571
February	PROPN	O	O	3571
,	PUNCT	O	O	3571
1998	NUM	O	O	3571
to	PART	O	O	3571
September	PROPN	O	O	3571
,	PUNCT	O	O	3571
2000	NUM	O	O	3571
we	PRON	O	O	3571
recruited	VERB	O	O	3571
33	NUM	O	O	3571
patients	NOUN	O	O	3571
with	ADP	O	O	3571
AGC	PROPN	O	O	3571
to	PART	O	O	3571
receive	VERB	O	O	3571
weekly	ADV	O	O	3571
24-hour	NOUN	O	O	3571
5-FU	NOUN	O	Chemical	3571
2,600	NUM	O	O	3571
mg	VERB	O	O	3571
/	PUNCT	O	O	3571
m(2	NUM	O	O	3571
)	PUNCT	O	O	3571
preceded	VERB	O	O	3571
by	ADP	O	O	3571
2-hour	NOUN	O	O	3571
FA	NOUN	O	Chemical	3571
500	NUM	O	O	3571
mg	VERB	O	O	3571
/	PUNCT	O	O	3571
m(2	NUM	O	O	3571
)	PUNCT	O	O	3571
for	ADP	O	O	3571
6	NUM	O	O	3571
weeks	NOUN	O	O	3571
,	PUNCT	O	O	3571
followed	VERB	O	O	3571
by	ADP	O	O	3571
a	PRON	O	O	3571
2-week	NOUN	O	O	3571
rest	VERB	O	O	3571
period	NOUN	O	O	3571
.	PUNCT	O	O	3571
MMC	PROPN	O	Chemical	3572
10	NUM	O	O	3572
mg	VERB	O	O	3572
/	PUNCT	O	O	3572
m(2	NUM	O	O	3572
)	PUNCT	O	O	3572
was	AUX	O	O	3572
added	VERB	O	O	3572
in	ADP	O	O	3572
3-weekly	NOUN	O	O	3572
intervals	NOUN	O	O	3572
.	PUNCT	O	O	3572
18	NUM	O	O	3573
patients	NOUN	O	O	3573
had	VERB	O	O	3573
a	PRON	O	O	3573
primary	NOUN	O	O	3573
AGC	PROPN	O	O	3573
,	PUNCT	O	O	3573
and	CCONJ	O	O	3573
15	NUM	O	O	3573
showed	VERB	O	O	3573
a	PRON	O	O	3573
relapsed	VERB	O	O	3573
AGC	PROPN	O	O	3573
.	PUNCT	O	O	3573
The	PRON	O	O	3574
worst	ADJ	O	O	3574
toxicities	NOUN	O	Disease	3574
(	PUNCT	O	O	3574
%	INTJ	O	O	3574
)	PUNCT	O	O	3574
observed	VERB	O	O	3574
were	AUX	O	O	3574
(	PUNCT	O	O	3574
CTC	PROPN	O	O	3574
-	PUNCT	O	O	3574
NCI	PROPN	O	O	3574
1/2/3	NUM	O	O	3574
)	PUNCT	O	O	3574
:	PUNCT	O	O	3574
leukopenia	PROPN	O	Disease	3575
45.5/18.2/6.1	NOUN	O	O	3575
,	PUNCT	O	O	3575
thrombocytopenia	PROPN	O	Disease	3575
33.3/9.1/6.1	NUM	O	O	3575
,	PUNCT	O	O	3575
vomitus	NOUN	O	O	3575
24.2/9.1/0	NUM	O	O	3575
,	PUNCT	O	O	3575
diarrhea	PROPN	O	Disease	3575
36.4/6.1/3.0	NUM	O	O	3575
,	PUNCT	O	O	3575
stomatitis	PROPN	O	O	3575
18.2/9.1/0	VERB	O	O	3575
,	PUNCT	O	O	3575
hand	NOUN	O	O	3575
-	PUNCT	O	O	3575
foot	NOUN	O	O	3575
syndrome	NOUN	O	O	3575
12.1/0/0	NUM	O	O	3575
.	PUNCT	O	O	3575
Two	NUM	O	O	3576
patients	NOUN	O	O	3576
developed	VERB	O	O	3576
hemolytic	ADJ	O	O	3576
-	PUNCT	O	O	3576
uremic	ADJ	O	O	3576
syndrome	NOUN	O	O	3576
(	PUNCT	O	O	3576
HUS	PROPN	O	Disease	3576
)	PUNCT	O	O	3576
.	PUNCT	O	O	3576
High	ADJ	O	O	3577
-	PUNCT	O	O	3577
dose	NOUN	O	O	3577
5-FU	NOUN	O	Chemical	3577
/	PUNCT	O	O	3577
FA	NOUN	O	Chemical	3577
/	PUNCT	O	O	3577
MMC	PROPN	O	Chemical	3577
is	AUX	O	O	3577
an	PRON	O	O	3577
effective	ADJ	O	O	3577
and	CCONJ	O	O	3577
well	ADV	O	O	3577
-	PUNCT	O	O	3577
tolerated	VERB	O	O	3577
outpatient	NOUN	O	O	3577
regimen	NOUN	O	O	3577
for	ADP	O	O	3577
AGC	PROPN	O	O	3577
(	PUNCT	O	O	3577
objective	VERB	O	O	3577
response	NOUN	O	O	3577
rate	NOUN	O	O	3577
54.6%	NOUN	O	O	3577
)	PUNCT	O	O	3577
.	PUNCT	O	O	3577
It	PRON	O	O	3578
may	AUX	O	O	3578
serve	VERB	O	O	3578
as	ADP	O	O	3578
an	PRON	O	O	3578
alternative	ADV	O	O	3578
to	PART	O	O	3578
cisplatin	NOUN	O	Chemical	3578
-	PUNCT	O	O	3578
containing	VERB	O	O	3578
regimens	NOUN	O	O	3578
;	PUNCT	O	O	3578
however	ADV	O	O	3578
,	PUNCT	O	O	3578
it	PRON	O	O	3578
has	VERB	O	O	3578
to	PART	O	O	3578
be	AUX	O	O	3578
considered	VERB	O	O	3578
that	SCONJ	O	O	3578
possibly	ADV	O	O	3578
HUS	PROPN	O	Disease	3578
may	AUX	O	O	3578
occur	VERB	O	O	3578
.	PUNCT	O	O	3578
Persistent	ADJ	O	O	3581
sterile	ADJ	O	O	3581
leukocyturia	PROPN	O	O	3581
is	AUX	O	O	3581
associated	VERB	O	O	3581
with	ADP	O	O	3581
impaired renal function	NOUN	O	Disease	3581
in	ADP	O	O	3581
human	PROPN	O	O	3581
immunodeficiency	NOUN	O	Disease	3581
virus	NOUN	O	O	3581
type	NOUN	O	O	3581
1-infected	VERB	O	O	3581
children	NOUN	O	O	3581
treated	VERB	O	O	3581
with	ADP	O	O	3581
indinavir	NOUN	O	O	3581
.	PUNCT	O	O	3581
BACKGROUND	NOUN	O	O	3582
:	PUNCT	O	O	3582
Prolonged	VERB	O	O	3582
administration	NOUN	O	O	3582
of	ADP	O	O	3582
indinavir	NOUN	O	O	3582
is	AUX	O	O	3582
associated	VERB	O	O	3582
with	ADP	O	O	3582
the	PRON	O	O	3582
occurrence	NOUN	O	O	3582
of	ADP	O	O	3582
a	PRON	O	O	3582
variety	NOUN	O	O	3582
of	ADP	O	O	3582
renal	ADJ	O	O	3582
complications	NOUN	O	O	3582
in	ADP	O	O	3582
adults	NOUN	O	O	3582
.	PUNCT	O	O	3582
A	PRON	O	O	3583
prospective	ADJ	O	O	3583
study	VERB	O	O	3583
to	PART	O	O	3583
monitor	VERB	O	O	3583
indinavir	NOUN	O	O	3583
-	PUNCT	O	O	3583
related	ADJ	O	O	3583
nephrotoxicity	NOUN	O	Disease	3583
in	ADP	O	O	3583
a	PRON	O	O	3583
cohort	NOUN	O	O	3583
of	ADP	O	O	3583
30	NUM	O	O	3583
human	PROPN	O	O	3583
immunodeficiency	NOUN	O	Disease	3583
virus	NOUN	O	O	3583
type	NOUN	O	O	3583
1-infected	VERB	O	O	3583
children	NOUN	O	O	3583
treated	VERB	O	O	3583
with	ADP	O	O	3583
indinavir	NOUN	O	O	3583
.	PUNCT	O	O	3583
METHODS	NOUN	O	O	3584
:	PUNCT	O	O	3584
Urinary	NOUN	O	O	3584
pH	NOUN	O	O	3584
,	PUNCT	O	O	3584
albumin	PROPN	O	O	3584
,	PUNCT	O	O	3584
creatinine	PROPN	O	Chemical	3584
,	PUNCT	O	O	3584
the	PRON	O	O	3584
presence	NOUN	O	O	3584
of	ADP	O	O	3584
erythrocytes	VERB	O	O	3584
,	PUNCT	O	O	3584
leukocytes	VERB	O	O	3584
,	PUNCT	O	O	3584
bacteria	NOUN	O	O	3584
and	CCONJ	O	O	3584
crystals	NOUN	O	O	3584
,	PUNCT	O	O	3584
and	CCONJ	O	O	3584
culture	NOUN	O	O	3584
were	AUX	O	O	3584
analyzed	VERB	O	O	3584
every	PRON	O	O	3584
3	X	O	O	3584
months	NOUN	O	O	3584
for	ADP	O	O	3584
96	NUM	O	O	3584
weeks	NOUN	O	O	3584
.	PUNCT	O	O	3584
Serum	NOUN	O	O	3585
creatinine	PROPN	O	Chemical	3585
levels	NOUN	O	O	3585
were	AUX	O	O	3585
routinely	ADV	O	O	3585
determined	VERB	O	O	3585
at	ADP	O	O	3585
the	PRON	O	O	3585
same	ADJ	O	O	3585
time	NOUN	O	O	3585
points	VERB	O	O	3585
.	PUNCT	O	O	3585
Steady	ADJ	O	O	3586
-	PUNCT	O	O	3586
state	NOUN	O	O	3586
pharmacokinetics	NOUN	O	O	3586
of	ADP	O	O	3586
indinavir	NOUN	O	O	3586
were	AUX	O	O	3586
done	VERB	O	O	3586
at	ADP	O	O	3586
week	NOUN	O	O	3586
4	NUM	O	O	3586
after	ADP	O	O	3586
the	PRON	O	O	3586
initiation	NOUN	O	O	3586
of	ADP	O	O	3586
indinavir	NOUN	O	O	3586
.	PUNCT	O	O	3586
The	PRON	O	O	3587
cumulative	ADJ	O	O	3587
incidence	NOUN	O	O	3587
of	ADP	O	O	3587
persistent	ADJ	O	O	3587
sterile	ADJ	O	O	3587
leukocyturia	PROPN	O	O	3587
(	PUNCT	O	O	3587
>	PUNCT	O	O	3587
or	CCONJ	O	O	3587
=	PUNCT	O	O	3587
75	NUM	O	O	3587
cells/	NUM	O	O	3587
micro	NOUN	O	O	3587
L	NOUN	O	O	3587
in	ADP	O	O	3587
at	ADP	O	O	3587
least	ADJ	O	O	3587
2	X	O	O	3587
consecutive	ADJ	O	O	3587
visits	VERB	O	O	3587
)	PUNCT	O	O	3587
after	ADP	O	O	3587
96	NUM	O	O	3587
weeks	NOUN	O	O	3587
was	AUX	O	O	3587
53%	NOUN	O	O	3587
.	PUNCT	O	O	3587
Persistent	ADJ	O	O	3588
sterile	ADJ	O	O	3588
leukocyturia	PROPN	O	O	3588
was	AUX	O	O	3588
frequently	ADV	O	O	3588
associated	VERB	O	O	3588
with	ADP	O	O	3588
a	PRON	O	O	3588
mild	ADJ	O	O	3588
increase	VERB	O	O	3588
in	ADP	O	O	3588
the	PRON	O	O	3588
urine	NOUN	O	O	3588
albumin	PROPN	O	O	3588
/	PUNCT	O	O	3588
creatinine	PROPN	O	Chemical	3588
ratio	NOUN	O	O	3588
and	CCONJ	O	O	3588
by	ADP	O	O	3588
microscopic	ADJ	O	O	3588
hematuria	PROPN	O	Disease	3588
.	PUNCT	O	O	3588
The	PRON	O	O	3589
cumulative	ADJ	O	O	3589
incidence	NOUN	O	O	3589
of	ADP	O	O	3589
serum	NOUN	O	O	3589
creatinine	PROPN	O	Chemical	3589
levels	NOUN	O	O	3589
>	PUNCT	O	O	3589
50%	NOUN	O	O	3589
above	ADP	O	O	3589
normal	ADJ	O	O	3589
was	AUX	O	O	3589
33%	NOUN	O	O	3589
after	ADP	O	O	3589
96	NUM	O	O	3589
weeks	NOUN	O	O	3589
.	PUNCT	O	O	3589
Children	NOUN	O	O	3590
with	ADP	O	O	3590
persistent	ADJ	O	O	3590
sterile	ADJ	O	O	3590
leukocyturia	PROPN	O	O	3590
more	ADJ	O	O	3590
frequently	ADV	O	O	3590
had	VERB	O	O	3590
serum	NOUN	O	O	3590
creatinine	PROPN	O	Chemical	3590
levels	NOUN	O	O	3590
of	ADP	O	O	3590
50%	NOUN	O	O	3590
above	ADP	O	O	3590
normal	ADJ	O	O	3590
than	ADP	O	O	3590
those	PRON	O	O	3590
children	NOUN	O	O	3590
without	ADP	O	O	3590
persistent	ADJ	O	O	3590
sterile	ADJ	O	O	3590
leukocyturia	PROPN	O	O	3590
.	PUNCT	O	O	3590
In	ADP	O	O	3591
children	NOUN	O	O	3591
younger	ADJ	O	O	3591
than	ADP	O	O	3591
5.6	NUM	O	O	3591
years	NOUN	O	O	3591
,	PUNCT	O	O	3591
persistent	ADJ	O	O	3591
sterile	ADJ	O	O	3591
leukocyturia	PROPN	O	O	3591
was	AUX	O	O	3591
significantly	ADV	O	O	3591
more	ADJ	O	O	3591
frequent	ADJ	O	O	3591
than	ADP	O	O	3591
in	ADP	O	O	3591
older	ADJ	O	O	3591
children	NOUN	O	O	3591
.	PUNCT	O	O	3591
A	PRON	O	O	3592
higher	ADJ	O	O	3592
cumulative	ADJ	O	O	3592
incidence	NOUN	O	O	3592
of	ADP	O	O	3592
persistent	ADJ	O	O	3592
leukocyturia	PROPN	O	O	3592
was	AUX	O	O	3592
found	VERB	O	O	3592
in	ADP	O	O	3592
children	NOUN	O	O	3592
with	ADP	O	O	3592
an	PRON	O	O	3592
area	NOUN	O	O	3592
under	ADP	O	O	3592
the	PRON	O	O	3592
curve	NOUN	O	O	3592
>	PUNCT	O	O	3592
19	NUM	O	O	3592
mg	VERB	O	O	3592
/	PUNCT	O	O	3592
L	NOUN	O	O	3592
x	X	O	O	3592
h	X	O	O	3592
or	CCONJ	O	O	3592
a	PRON	O	O	3592
peak	PROPN	O	O	3592
serum	NOUN	O	O	3592
level	VERB	O	O	3592
of	ADP	O	O	3592
indinavir	NOUN	O	O	3592
>	PUNCT	O	O	3592
12	NUM	O	O	3592
mg	VERB	O	O	3592
In	ADP	O	O	3593
4	NUM	O	O	3593
children	NOUN	O	O	3593
,	PUNCT	O	O	3593
indinavir	NOUN	O	O	3593
was	AUX	O	O	3593
discontinued	VERB	O	O	3593
because	SCONJ	O	O	3593
of	ADP	O	O	3593
nephrotoxicity	NOUN	O	Disease	3593
.	PUNCT	O	O	3593
Subsequently	PROPN	O	O	3594
,	PUNCT	O	O	3594
the	PRON	O	O	3594
serum	NOUN	O	O	3594
creatinine	PROPN	O	Chemical	3594
levels	NOUN	O	O	3594
decreased	VERB	O	O	3594
,	PUNCT	O	O	3594
the	PRON	O	O	3594
urine	NOUN	O	O	3594
albumin	PROPN	O	O	3594
/	PUNCT	O	O	3594
creatinine	PROPN	O	Chemical	3594
ratios	VERB	O	O	3594
returned	VERB	O	O	3594
to	PART	O	O	3594
zero	NUM	O	O	3594
,	PUNCT	O	O	3594
and	CCONJ	O	O	3594
the	PRON	O	O	3594
leukocyturia	PROPN	O	O	3594
disappeared	VERB	O	O	3594
within	ADP	O	O	3594
3	X	O	O	3594
months	NOUN	O	O	3594
.	PUNCT	O	O	3594
Children	NOUN	O	O	3595
treated	VERB	O	O	3595
with	ADP	O	O	3595
indinavir	NOUN	O	O	3595
have	VERB	O	O	3595
a	PRON	O	O	3595
high	ADJ	O	O	3595
cumulative	ADJ	O	O	3595
incidence	NOUN	O	O	3595
of	ADP	O	O	3595
persistent	ADJ	O	O	3595
sterile	ADJ	O	O	3595
leukocyturia	PROPN	O	O	3595
.	PUNCT	O	O	3595
Children	NOUN	O	O	3596
with	ADP	O	O	3596
persistent	ADJ	O	O	3596
sterile	ADJ	O	O	3596
leukocyturia	PROPN	O	O	3596
more	ADJ	O	O	3596
frequently	ADV	O	O	3596
had	VERB	O	O	3596
an	PRON	O	O	3596
increase	VERB	O	O	3596
in	ADP	O	O	3596
serum	NOUN	O	O	3596
creatinine	PROPN	O	Chemical	3596
levels	NOUN	O	O	3596
of	ADP	O	O	3596
>	PUNCT	O	O	3596
50%	NOUN	O	O	3596
above	ADP	O	O	3596
normal	ADJ	O	O	3596
.	PUNCT	O	O	3596
The	PRON	O	O	3597
impairment	NOUN	O	O	3597
of	ADP	O	O	3597
the	PRON	O	O	3597
renal	ADJ	O	O	3597
function	NOUN	O	O	3597
in	ADP	O	O	3597
these	PRON	O	O	3597
children	NOUN	O	O	3597
occurred	VERB	O	O	3597
in	ADP	O	O	3597
the	PRON	O	O	3597
absence	NOUN	O	O	3597
of	ADP	O	O	3597
clinical	ADJ	O	O	3597
symptoms	NOUN	O	O	3597
of	ADP	O	O	3597
nephrolithiasis	NOUN	O	Disease	3597
.	PUNCT	O	O	3597
Indinavir	NOUN	O	O	3598
-	PUNCT	O	O	3598
associated	VERB	O	O	3598
nephrotoxicity	NOUN	O	Disease	3598
must	AUX	O	O	3598
be	AUX	O	O	3598
monitored	VERB	O	O	3598
closely	ADV	O	O	3598
,	PUNCT	O	O	3598
especially	ADV	O	O	3598
in	ADP	O	O	3598
children	NOUN	O	O	3598
with	ADP	O	O	3598
risk	NOUN	O	O	3598
factors	NOUN	O	O	3598
such	ADJ	O	O	3598
as	ADP	O	O	3598
persistent	ADJ	O	O	3598
sterile	ADJ	O	O	3598
leukocyturia	PROPN	O	O	3598
,	PUNCT	O	O	3598
age	NOUN	O	O	3598
<	X	O	O	3599
5.6	NUM	O	O	3599
years	NOUN	O	O	3599
,	PUNCT	O	O	3599
an	PRON	O	O	3599
area	NOUN	O	O	3599
under	ADP	O	O	3599
the	PRON	O	O	3599
curve	NOUN	O	O	3599
of	ADP	O	O	3599
indinavir	NOUN	O	O	3599
>	PUNCT	O	O	3599
19	NUM	O	O	3599
mg	VERB	O	O	3599
/	PUNCT	O	O	3599
L	NOUN	O	O	3599
x	X	O	O	3599
h	X	O	O	3599
,	PUNCT	O	O	3599
and	CCONJ	O	O	3599
a	PRON	O	O	3599
C(max	NUM	O	O	3599
)	PUNCT	O	O	3599
Utility	NOUN	O	O	3602
of	ADP	O	O	3602
troponin	PROPN	O	O	3602
I	PRON	O	O	3602
in	ADP	O	O	3602
patients	NOUN	O	O	3602
with	ADP	O	O	3602
cocaine	NOUN	O	Chemical	3602
-	PUNCT	O	O	3602
associated	VERB	O	O	3602
chest pain	NOUN	O	Disease	3602
.	PUNCT	O	O	3602
Baseline	PROPN	O	O	3603
electrocardiogram	PROPN	O	O	3603
abnormalities	NOUN	O	O	3603
and	CCONJ	O	O	3603
market	NOUN	O	O	3603
elevations	NOUN	O	O	3603
not	PART	O	O	3603
associated	VERB	O	O	3603
with	ADP	O	O	3603
myocardial	ADJ	O	O	3603
necrosis	NOUN	O	Disease	3603
make	VERB	O	O	3603
accurate	ADJ	O	O	3603
diagnosis	NOUN	O	O	3603
of	ADP	O	O	3603
myocardial infarction	NOUN	O	Disease	3603
(	PUNCT	O	O	3603
MI	PROPN	O	Disease	3603
)	PUNCT	O	O	3603
difficult	ADJ	O	O	3603
in	ADP	O	O	3603
patients	NOUN	O	O	3603
with	ADP	O	O	3603
cocaine	NOUN	O	Chemical	3603
-	PUNCT	O	O	3603
associated	VERB	O	O	3603
chest pain	NOUN	O	Disease	3603
.	PUNCT	O	O	3603
OBJECTIVE	VERB	O	O	3604
:	PUNCT	O	O	3604
To	PART	O	O	3604
assess	VERB	O	O	3604
outcomes	NOUN	O	O	3604
based	VERB	O	O	3604
on	ADP	O	O	3604
troponin	PROPN	O	O	3604
positivity	NOUN	O	O	3604
in	ADP	O	O	3604
patients	NOUN	O	O	3604
with	ADP	O	O	3604
cocaine	NOUN	O	Chemical	3604
chest pain	NOUN	O	Disease	3604
admitted	VERB	O	O	3604
for	ADP	O	O	3604
exclusion	NOUN	O	O	3604
of	ADP	O	O	3604
MI	PROPN	O	Disease	3604
.	PUNCT	O	O	3604
Outcomes	NOUN	O	O	3605
were	AUX	O	O	3605
examined	VERB	O	O	3605
in	ADP	O	O	3605
patients	NOUN	O	O	3605
admitted	VERB	O	O	3605
for	ADP	O	O	3605
possible	ADJ	O	O	3605
MI	PROPN	O	Disease	3605
after	ADP	O	O	3605
cocaine	NOUN	O	Chemical	3605
use	VERB	O	O	3605
.	PUNCT	O	O	3605
All	PRON	O	O	3606
patients	NOUN	O	O	3606
underwent	VERB	O	O	3606
a	PRON	O	O	3606
rapid	ADJ	O	O	3606
rule	NOUN	O	O	3606
-	PUNCT	O	O	3606
in	ADP	O	O	3606
protocol	PROPN	O	O	3606
that	SCONJ	O	O	3606
included	VERB	O	O	3606
serial	ADJ	O	O	3606
sampling	NOUN	O	O	3606
of	ADP	O	O	3606
creatine	PROPN	O	Chemical	3606
kinase	VERB	O	O	3606
(	PUNCT	O	O	3606
CK	PROPN	O	O	3606
)	PUNCT	O	O	3606
,	PUNCT	O	O	3606
CK	PROPN	O	O	3606
-	PUNCT	O	O	3606
MB	NOUN	O	O	3606
,	PUNCT	O	O	3606
and	CCONJ	O	O	3606
cardiac	ADJ	O	O	3606
troponin	PROPN	O	O	3606
I	PRON	O	O	3606
(	PUNCT	O	O	3606
cTnI	VERB	O	O	3606
)	PUNCT	O	O	3606
over	ADP	O	O	3606
eight	NUM	O	O	3606
hours	NOUN	O	O	3606
.	PUNCT	O	O	3606
Outcomes	NOUN	O	O	3607
included	VERB	O	O	3607
CK	PROPN	O	O	3607
-	PUNCT	O	O	3607
MB	NOUN	O	O	3607
MI	PROPN	O	Disease	3607
(	PUNCT	O	O	3607
CK	PROPN	O	O	3607
-	PUNCT	O	O	3607
MB	NOUN	O	O	3607
>	PUNCT	O	O	3608
or=	PROPN	O	O	3608
4	NUM	O	O	3608
,	PUNCT	O	O	3608
cardiac	ADJ	O	O	3608
death	NOUN	O	O	3608
,	PUNCT	O	O	3608
and	CCONJ	O	O	3608
significant	ADJ	O	O	3608
coronary disease	NOUN	O	Disease	3608
(	PUNCT	O	O	3608
>	PUNCT	O	O	3608
or=50%	NOUN	O	O	3608
)	PUNCT	O	O	3608
.	PUNCT	O	O	3608
Of	ADV	O	O	3609
the	PRON	O	O	3609
246	NUM	O	O	3609
admitted	VERB	O	O	3609
patients	NOUN	O	O	3609
,	PUNCT	O	O	3609
34	NUM	O	O	3609
(	PUNCT	O	O	3609
14%	NOUN	O	O	3609
)	PUNCT	O	O	3609
met	VERB	O	O	3609
CK	PROPN	O	O	3609
-	PUNCT	O	O	3609
MB	NOUN	O	O	3609
criteria	NOUN	O	O	3609
for	ADP	O	O	3609
MI	PROPN	O	Disease	3609
and	CCONJ	O	O	3609
38	NUM	O	O	3609
(	PUNCT	O	O	3609
16%	NOUN	O	O	3609
)	PUNCT	O	O	3609
Three	NUM	O	O	3610
of	ADP	O	O	3610
the	PRON	O	O	3610
four	NUM	O	O	3610
patients	NOUN	O	O	3610
without	ADP	O	O	3610
significant	ADJ	O	O	3610
disease	PROPN	O	O	3610
who	PRON	O	O	3610
had	VERB	O	O	3610
cTnI	VERB	O	O	3610
elevations	NOUN	O	O	3610
met	VERB	O	O	3610
CK	PROPN	O	O	3610
-	PUNCT	O	O	3610
MB	NOUN	O	O	3610
criteria	NOUN	O	O	3610
for	ADP	O	O	3610
MI	PROPN	O	Disease	3610
,	PUNCT	O	O	3610
and	CCONJ	O	O	3610
the	PRON	O	O	3610
other	ADJ	O	O	3610
had	VERB	O	O	3610
a	PRON	O	O	3610
peak	PROPN	O	O	3610
CK	PROPN	O	O	3610
-	PUNCT	O	O	3610
MB	NOUN	O	O	3610
level	VERB	O	O	3610
of	ADP	O	O	3610
13	NUM	O	O	3610
ng	PROPN	O	O	3610
/	PUNCT	O	O	3610
mL.	PROPN	O	O	3610
Sensitivities	NOUN	O	O	3610
,	PUNCT	O	O	3610
specificities	NOUN	O	O	3610
,	PUNCT	O	O	3610
and	CCONJ	O	O	3610
positive	ADJ	O	O	3610
and	CCONJ	O	O	3610
negative	ADJ	O	O	3610
likelihood	NOUN	O	O	3610
ratios	VERB	O	O	3610
for	ADP	O	O	3610
predicting	VERB	O	O	3610
cardiac	ADJ	O	O	3610
death	NOUN	O	O	3610
or	CCONJ	O	O	3610
significant	ADJ	O	O	3610
disease	PROPN	O	O	3610
were	AUX	O	O	3610
high	ADJ	O	O	3610
for	ADP	O	O	3610
both	PRON	O	O	3610
CK	PROPN	O	O	3610
-	PUNCT	O	O	3610
MB	NOUN	O	O	3610
MI	PROPN	O	Disease	3610
and	CCONJ	O	O	3610
cTnI	VERB	O	O	3610
and	CCONJ	O	O	3610
were	AUX	O	O	3610
not	PART	O	O	3610
significantly	ADV	O	O	3610
different	ADJ	O	O	3610
.	PUNCT	O	O	3610
CONCLUSIONS	NOUN	O	O	3611
:	PUNCT	O	O	3611
Most	ADV	O	O	3611
patients	NOUN	O	O	3611
with	ADP	O	O	3611
cTnI	VERB	O	O	3611
elevations	NOUN	O	O	3611
meet	VERB	O	O	3611
CK	PROPN	O	O	3611
-	PUNCT	O	O	3611
MB	NOUN	O	O	3611
criteria	NOUN	O	O	3611
for	ADP	O	O	3611
MI	PROPN	O	Disease	3611
,	PUNCT	O	O	3611
as	ADP	O	O	3611
well	ADV	O	O	3611
as	ADP	O	O	3611
have	VERB	O	O	3611
a	PRON	O	O	3611
high	ADJ	O	O	3611
incidence	NOUN	O	O	3611
of	ADP	O	O	3611
underlying	VERB	O	O	3611
significant	ADJ	O	O	3611
disease	PROPN	O	O	3611
.	PUNCT	O	O	3611
Troponin	PROPN	O	O	3612
appears	VERB	O	O	3612
to	PART	O	O	3612
have	VERB	O	O	3612
an	PRON	O	O	3612
equivalent	ADJ	O	O	3612
diagnostic	ADJ	O	O	3612
accuracy	NOUN	O	O	3612
compared	VERB	O	O	3612
with	ADP	O	O	3612
CK	PROPN	O	O	3612
-	PUNCT	O	O	3612
MB	NOUN	O	O	3612
for	ADP	O	O	3612
diagnosing	VERB	O	O	3612
necrosis	NOUN	O	Disease	3612
in	ADP	O	O	3612
patients	NOUN	O	O	3612
with	ADP	O	O	3612
cocaine	NOUN	O	Chemical	3612
-	PUNCT	O	O	3612
associated	VERB	O	O	3612
chest pain	NOUN	O	Disease	3612
and	CCONJ	O	O	3612
suspected	VERB	O	O	3612
MI	PROPN	O	Disease	3612
.	PUNCT	O	O	3612
Acute	PROPN	O	O	3615
interstitial nephritis	NOUN	O	Disease	3615
due	ADJ	O	O	3615
to	PART	O	O	3615
nicergoline	NOUN	O	O	3615
(	PUNCT	O	O	3615
Sermion	PROPN	O	O	3615
)	PUNCT	O	O	3615
.	PUNCT	O	O	3615
We	PRON	O	O	3616
report	VERB	O	O	3616
a	PRON	O	O	3616
case	NOUN	O	O	3616
of	ADP	O	O	3616
acute	ADJ	O	O	3616
interstitial nephritis	NOUN	O	Disease	3616
(	PUNCT	O	O	3616
AIN	PROPN	O	O	3616
)	PUNCT	O	O	3616
due	ADJ	O	O	3616
to	PART	O	O	3616
nicergoline	NOUN	O	O	3616
(	PUNCT	O	O	3616
Sermion	PROPN	O	O	3616
)	PUNCT	O	O	3616
.	PUNCT	O	O	3616
A	PRON	O	O	3617
50-year	NOUN	O	O	3617
-	PUNCT	O	O	3617
old	ADJ	O	O	3617
patient	NOUN	O	O	3617
admitted	VERB	O	O	3617
to	PART	O	O	3617
our	PRON	O	O	3617
hospital	PROPN	O	O	3617
for	ADP	O	O	3617
fever	NOUN	O	Disease	3617
and	CCONJ	O	O	3617
acute	ADJ	O	O	3617
renal failure	NOUN	O	Disease	3617
.	PUNCT	O	O	3617
Before	ADP	O	O	3618
admission	NOUN	O	O	3618
,	PUNCT	O	O	3618
he	PRON	O	O	3618
had	VERB	O	O	3618
been	AUX	O	O	3618
taking	VERB	O	O	3618
nicergoline	NOUN	O	O	3618
and	CCONJ	O	O	3618
bendazac	PROPN	O	O	3618
lysine	PROPN	O	O	3618
due	ADJ	O	O	3618
to	PART	O	O	3618
retinal	ADJ	O	O	3618
vein	NOUN	O	O	3618
occlusion	NOUN	O	O	3618
at	ADP	O	O	3618
ophthalmologic	ADV	O	O	3618
department	NOUN	O	O	3618
.	PUNCT	O	O	3618
Thereafter	ADV	O	O	3619
,	PUNCT	O	O	3619
he	PRON	O	O	3619
experienced	ADJ	O	O	3619
intermittent	ADJ	O	O	3619
fever	NOUN	O	Disease	3619
and	CCONJ	O	O	3619
skin rash	ADJ	O	Disease	3619
.	PUNCT	O	O	3619
On	ADP	O	O	3620
admission	NOUN	O	O	3620
,	PUNCT	O	O	3620
clinical	ADJ	O	O	3620
symptoms	NOUN	O	O	3620
(	PUNCT	O	O	3620
i.e.	X	O	O	3620
arthralgia	ADV	O	Disease	3620
and	CCONJ	O	O	3620
fever	NOUN	O	Disease	3620
)	PUNCT	O	O	3620
and	CCONJ	O	O	3620
laboratory	NOUN	O	O	3620
findings	NOUN	O	O	3620
(	PUNCT	O	O	3620
i.e.	X	O	O	3620
eosinophilia	PROPN	O	Disease	3620
and	CCONJ	O	O	3620
renal failure	NOUN	O	Disease	3620
)	PUNCT	O	O	3620
suggested	VERB	O	O	3620
AIN	PROPN	O	O	3620
,	PUNCT	O	O	3620
and	CCONJ	O	O	3620
which	PRON	O	O	3620
was	AUX	O	O	3620
confirmed	VERB	O	O	3620
by	ADP	O	O	3620
pathologic	ADJ	O	O	3620
findings	NOUN	O	O	3620
on	ADP	O	O	3620
renal	ADJ	O	O	3620
biopsy	PROPN	O	O	3620
.	PUNCT	O	O	3620
A	PRON	O	O	3621
lymphocyte	NOUN	O	O	3621
transformation	NOUN	O	O	3621
test	NOUN	O	O	3621
demonstrated	VERB	O	O	3621
a	PRON	O	O	3621
positive	ADJ	O	O	3621
result	VERB	O	O	3621
against	ADP	O	O	3621
nicergoline	NOUN	O	O	3621
.	PUNCT	O	O	3621
Treatment	NOUN	O	O	3622
was	AUX	O	O	3622
consisted	VERB	O	O	3622
of	ADP	O	O	3622
withdrawal	NOUN	O	O	3622
of	ADP	O	O	3622
nicergoline	NOUN	O	O	3622
and	CCONJ	O	O	3622
intravenous	ADJ	O	O	3622
methylprednisolone	NOUN	O	Chemical	3622
,	PUNCT	O	O	3622
and	CCONJ	O	O	3622
his	PRON	O	O	3622
renal	ADJ	O	O	3622
function	NOUN	O	O	3622
was	AUX	O	O	3622
completely	ADV	O	O	3622
recovered	VERB	O	O	3622
.	PUNCT	O	O	3622
To	PART	O	O	3623
our	PRON	O	O	3623
knowledge	NOUN	O	O	3623
,	PUNCT	O	O	3623
this	PRON	O	O	3623
is	AUX	O	O	3623
the	PRON	O	O	3623
first	ADV	O	O	3623
report	VERB	O	O	3623
of	ADP	O	O	3623
nicergoline	NOUN	O	O	3623
-	PUNCT	O	O	3623
associated	VERB	O	O	3623
AIN	PROPN	O	O	3623
.	PUNCT	O	O	3623
Neuroleptic malignant syndrome	NOUN	O	Disease	3626
complicated	VERB	O	O	3626
by	ADP	O	O	3626
massive	ADJ	O	O	3626
intestinal	ADJ	O	Disease	3626
bleeding	VERB	O	Disease	3626
in	ADP	O	O	3626
a	PRON	O	O	3626
patient	NOUN	O	O	3626
with	ADP	O	O	3626
chronic	ADJ	O	O	3626
renal failure	NOUN	O	Disease	3626
.	PUNCT	O	O	3626
A	PRON	O	O	3627
patient	NOUN	O	O	3627
with	ADP	O	O	3627
chronic	ADJ	O	O	3627
renal failure	NOUN	O	Disease	3627
(	PUNCT	O	O	3627
CRF	PROPN	O	O	3627
)	PUNCT	O	O	3627
developed	VERB	O	O	3627
neuroleptic malignant syndrome	NOUN	O	Disease	3627
(	PUNCT	O	O	3627
NMS	PROPN	O	Disease	3627
)	PUNCT	O	O	3627
after	ADP	O	O	3627
administration	NOUN	O	O	3627
of	ADP	O	O	3627
risperidone	VERB	O	Chemical	3627
and	CCONJ	O	O	3627
levomepromazine	NOUN	O	Chemical	3627
.	PUNCT	O	O	3627
In	ADP	O	O	3628
addition	NOUN	O	O	3628
to	PART	O	O	3628
the	PRON	O	O	3628
typical	ADJ	O	O	3628
symptoms	NOUN	O	O	3628
of	ADP	O	O	3628
NMS	PROPN	O	Disease	3628
,	PUNCT	O	O	3628
massive	ADJ	O	O	3628
intestinal	ADJ	O	Disease	3628
bleeding	VERB	O	Disease	3628
was	AUX	O	O	3628
observed	VERB	O	O	3628
during	ADP	O	O	3628
the	PRON	O	O	3628
episode	PROPN	O	O	3628
.	PUNCT	O	O	3628
This	PRON	O	O	3629
report	VERB	O	O	3629
suggests	VERB	O	O	3629
that	SCONJ	O	O	3629
NMS	PROPN	O	Disease	3629
in	ADP	O	O	3629
a	PRON	O	O	3629
patient	NOUN	O	O	3629
with	ADP	O	O	3629
CRF	PROPN	O	O	3629
may	AUX	O	O	3629
be	AUX	O	O	3629
complicated	VERB	O	O	3629
by	ADP	O	O	3629
intestinal	ADJ	O	Disease	3629
bleeding	VERB	O	Disease	3629
and	CCONJ	O	O	3629
needs	VERB	O	O	3629
special	ADJ	O	O	3629
caution	NOUN	O	O	3629
for	ADP	O	O	3629
this	PRON	O	O	3629
complication	NOUN	O	O	3629
.	PUNCT	O	O	3629
Adrenaline	NOUN	O	O	3632
-	PUNCT	O	O	3632
induced	VERB	O	O	3632
hypertension	NOUN	O	Disease	3632
was	AUX	O	O	3632
used	VERB	O	O	3632
to	PART	O	O	3632
destroy	VERB	O	O	3632
the	PRON	O	O	3632
BBB	PROPN	O	O	3632
,	PUNCT	O	O	3632
which	PRON	O	O	3632
was	AUX	O	O	3632
evaluated	VERB	O	O	3632
using	VERB	O	O	3632
triphenyltetrazolium	NOUN	O	O	3632
(	PUNCT	O	O	3632
TTC	PROPN	O	Chemical	3632
)	PUNCT	O	O	3632
staining	VERB	O	O	3632
of	ADP	O	O	3632
the	PRON	O	O	3632
brain	NOUN	O	O	3632
slices	NOUN	O	O	3632
just	ADV	O	O	3632
after	ADP	O	O	3632
giving	VERB	O	O	3632
adrenaline	NOUN	O	Chemical	3632
for	ADP	O	O	3632
30	NUM	O	O	3632
s.	PROPN	O	O	3632
In	ADP	O	O	3633
normal	ADJ	O	O	3633
rats	NOUN	O	O	3633
,	PUNCT	O	O	3633
the	PRON	O	O	3633
whole	NOUN	O	O	3633
brain	NOUN	O	O	3633
sections	NOUN	O	O	3633
exhibited	VERB	O	O	3633
complete	VERB	O	O	3633
staining	VERB	O	O	3633
with	ADP	O	O	3633
TTC	PROPN	O	Chemical	3633
.	PUNCT	O	O	3633
After	ADP	O	O	3634
adrenaline	NOUN	O	Chemical	3634
infusion	NOUN	O	O	3634
for	ADP	O	O	3634
30	NUM	O	O	3634
s	X	O	O	3634
,	PUNCT	O	O	3634
there	ADV	O	O	3634
were	AUX	O	O	3634
large	ADJ	O	O	3634
unstained	ADJ	O	O	3634
areas	NOUN	O	O	3634
in	ADP	O	O	3634
the	PRON	O	O	3634
left	VERB	O	O	3634
brain	NOUN	O	O	3634
in	ADP	O	O	3634
right	ADV	O	O	3634
-	PUNCT	O	O	3634
pawed	VERB	O	O	3634
animals	NOUN	O	O	3634
,	PUNCT	O	O	3634
and	CCONJ	O	O	3634
vice	NOUN	O	O	3634
versa	VERB	O	O	3634
in	ADP	O	O	3634
left	VERB	O	O	3634
-	PUNCT	O	O	3634
pawed	VERB	O	O	3634
animals	NOUN	O	O	3634
.	PUNCT	O	O	3634
Similar	ADJ	O	O	3635
results	VERB	O	O	3635
were	AUX	O	O	3635
obtained	VERB	O	O	3635
in	ADP	O	O	3635
seizure	NOUN	O	Disease	3635
-	PUNCT	O	O	3635
induced	VERB	O	O	3635
breakdown	NOUN	O	O	3635
of	ADP	O	O	3635
BBB	PROPN	O	O	3635
.	PUNCT	O	O	3635
Carvedilol	PROPN	O	O	3638
protects	VERB	O	O	3638
against	ADP	O	O	3638
doxorubicin	VERB	O	Chemical	3638
-	PUNCT	O	O	3638
induced	VERB	O	O	3638
mitochondrial	ADJ	O	O	3638
cardiomyopathy	ADJ	O	Disease	3638
.	PUNCT	O	O	3638
Several	ADJ	O	O	3639
cytopathic	ADJ	O	O	3639
mechanisms	NOUN	O	O	3639
have	VERB	O	O	3639
been	AUX	O	O	3639
suggested	VERB	O	O	3639
to	PART	O	O	3639
mediate	VERB	O	O	3639
the	PRON	O	O	3639
dose	NOUN	O	O	3639
-	PUNCT	O	O	3639
limiting	VERB	O	O	3639
cumulative	ADJ	O	O	3639
and	CCONJ	O	O	3639
irreversible	ADJ	O	O	3639
cardiomyopathy	ADJ	O	Disease	3639
caused	VERB	O	O	3639
by	ADP	O	O	3639
doxorubicin	VERB	O	Chemical	3639
.	PUNCT	O	O	3639
Recent	ADJ	O	O	3640
evidence	NOUN	O	O	3640
indicates	VERB	O	O	3640
that	SCONJ	O	O	3640
oxidative	NOUN	O	O	3640
stress	NOUN	O	O	3640
and	CCONJ	O	O	3640
mitochondrial	ADJ	O	O	3640
dysfunction	NOUN	O	O	3640
are	AUX	O	O	3640
key	NOUN	O	O	3640
factors	NOUN	O	O	3640
in	ADP	O	O	3640
the	PRON	O	O	3640
pathogenic	ADJ	O	O	3640
process	NOUN	O	O	3640
.	PUNCT	O	O	3640
The	PRON	O	O	3641
objective	VERB	O	O	3641
of	ADP	O	O	3641
this	PRON	O	O	3641
investigation	NOUN	O	O	3641
was	AUX	O	O	3641
to	PART	O	O	3641
test	NOUN	O	O	3641
the	PRON	O	O	3641
hypothesis	NOUN	O	O	3641
that	SCONJ	O	O	3641
carvedilol	VERB	O	O	3641
,	PUNCT	O	O	3641
a	PRON	O	O	3641
nonselective	ADJ	O	O	3641
beta	NOUN	O	O	3641
-	PUNCT	O	O	3641
adrenergic	NOUN	O	O	3641
receptor	NOUN	O	O	3641
antagonist	NOUN	O	O	3641
with	ADP	O	O	3641
potent	ADJ	O	O	3641
antioxidant	ADJ	O	O	3641
properties	NOUN	O	O	3641
,	PUNCT	O	O	3641
protects	VERB	O	O	3641
against	ADP	O	O	3641
the	PRON	O	O	3641
cardiac	ADJ	O	O	3641
and	CCONJ	O	O	3641
hepatic	ADJ	O	O	3641
mitochondrial	ADJ	O	O	3641
bioenergetic	NOUN	O	O	3641
dysfunction	NOUN	O	O	3641
associated	VERB	O	O	3641
with	ADP	O	O	3641
subchronic	VERB	O	O	3641
doxorubicin	VERB	O	Chemical	3641
toxicity	NOUN	O	Disease	3641
.	PUNCT	O	O	3641
Heart	NOUN	O	O	3642
and	CCONJ	O	O	3642
liver	NOUN	O	O	3642
mitochondria	PROPN	O	O	3642
were	AUX	O	O	3642
isolated	VERB	O	O	3642
from	ADP	O	O	3642
rats	NOUN	O	O	3642
treated	VERB	O	O	3642
for	ADP	O	O	3642
7	NUM	O	O	3642
weeks	NOUN	O	O	3642
with	ADP	O	O	3642
doxorubicin	VERB	O	Chemical	3642
(	PUNCT	O	O	3642
2	X	O	O	3642
mg	VERB	O	O	3642
/	PUNCT	O	O	3642
kg	VERB	O	O	3642
sc	PROPN	O	O	3642
/	PUNCT	O	O	3642
week	NOUN	O	O	3642
)	PUNCT	O	O	3642
,	PUNCT	O	O	3642
carvedilol	VERB	O	O	3642
(	PUNCT	O	O	3642
1	X	O	O	3642
mg	VERB	O	O	3642
/	PUNCT	O	O	3642
kg	VERB	O	O	3642
ip	X	O	O	3642
/	PUNCT	O	O	3642
week	NOUN	O	O	3642
)	PUNCT	O	O	3642
,	PUNCT	O	O	3642
or	CCONJ	O	O	3642
the	PRON	O	O	3642
combination	NOUN	O	O	3642
of	ADP	O	O	3642
the	PRON	O	O	3642
two	NUM	O	O	3642
drugs	NOUN	O	O	3642
.	PUNCT	O	O	3642
Heart	NOUN	O	O	3643
mitochondria	PROPN	O	O	3643
isolated	VERB	O	O	3643
from	ADP	O	O	3643
doxorubicin	VERB	O	Chemical	3643
-	PUNCT	O	O	3643
treated	VERB	O	O	3643
rats	NOUN	O	O	3643
exhibited	VERB	O	O	3643
depressed	ADJ	O	O	3643
rates	NOUN	O	O	3643
for	ADP	O	O	3643
state	NOUN	O	O	3643
3	X	O	O	3643
respiration	NOUN	O	O	3643
(	PUNCT	O	O	3643
336	NUM	O	O	3643
+	ADP	O	O	3643
/-	PUNCT	O	O	3643
Mitochondrial	NOUN	O	O	3644
calcium	NOUN	O	Chemical	3644
-	PUNCT	O	O	3644
loading	NOUN	O	O	3644
capacity	NOUN	O	O	3644
and	CCONJ	O	O	3644
the	PRON	O	O	3644
activity	NOUN	O	O	3644
of	ADP	O	O	3644
NADH	PROPN	O	O	3644
-	PUNCT	O	O	3644
dehydrogenase	NOUN	O	O	3644
were	AUX	O	O	3644
also	ADV	O	O	3644
suppressed	VERB	O	O	3644
in	ADP	O	O	3644
cardiac	ADJ	O	O	3644
mitochondria	PROPN	O	O	3644
from	ADP	O	O	3644
doxorubicin	VERB	O	Chemical	3644
-	PUNCT	O	O	3644
treated	VERB	O	O	3644
rats	NOUN	O	O	3644
.	PUNCT	O	O	3644
Doxorubicin	PROPN	O	Chemical	3645
treatment	NOUN	O	O	3645
also	ADV	O	O	3645
caused	VERB	O	O	3645
a	PRON	O	O	3645
decrease	VERB	O	O	3645
in	ADP	O	O	3645
RCR	PROPN	O	O	3645
for	ADP	O	O	3645
liver	NOUN	O	O	3645
mitochondria	PROPN	O	O	3645
(	PUNCT	O	O	3645
3.9	NUM	O	O	3645
+	ADP	O	O	3645
/-	PUNCT	O	O	3645
Coadministration	NOUN	O	O	3646
of	ADP	O	O	3646
carvedilol	VERB	O	O	3646
decreased	VERB	O	O	3646
the	PRON	O	O	3646
extent	NOUN	O	O	3646
of	ADP	O	O	3646
cellular	NOUN	O	O	3646
vacuolization	NOUN	O	O	3646
in	ADP	O	O	3646
cardiac	ADJ	O	O	3646
myocytes	NOUN	O	O	3646
and	CCONJ	O	O	3646
prevented	VERB	O	O	3646
the	PRON	O	O	3646
inhibitory	ADJ	O	O	3646
effect	VERB	O	O	3646
of	ADP	O	O	3646
doxorubicin	VERB	O	Chemical	3646
on	ADP	O	O	3646
mitochondrial	ADJ	O	O	3646
respiration	NOUN	O	O	3646
in	ADP	O	O	3646
both	PRON	O	O	3646
heart	NOUN	O	O	3646
and	CCONJ	O	O	3646
liver	NOUN	O	O	3646
.	PUNCT	O	O	3646
Carvedilol	PROPN	O	O	3647
also	ADV	O	O	3647
prevented	VERB	O	O	3647
the	PRON	O	O	3647
decrease	VERB	O	O	3647
in	ADP	O	O	3647
mitochondrial	ADJ	O	O	3647
Ca(2	PROPN	O	O	3647
+	ADP	O	O	3647
)	PUNCT	O	O	3647
loading	NOUN	O	O	3647
capacity	NOUN	O	O	3647
and	CCONJ	O	O	3647
the	PRON	O	O	3647
inhibition	NOUN	O	O	3647
of	ADP	O	O	3647
the	PRON	O	O	3647
respiratory	NOUN	O	O	3647
complexes	NOUN	O	O	3647
of	ADP	O	O	3647
heart	NOUN	O	O	3647
mitochondria	PROPN	O	O	3647
caused	VERB	O	O	3647
by	ADP	O	O	3647
doxorubicin	VERB	O	Chemical	3647
.	PUNCT	O	O	3647
Carvedilol	PROPN	O	O	3648
by	ADP	O	O	3648
itself	PRON	O	O	3648
did	VERB	O	O	3648
not	PART	O	O	3648
affect	VERB	O	O	3648
any	PRON	O	O	3648
of	ADP	O	O	3648
the	PRON	O	O	3648
parameters	NOUN	O	O	3648
measured	VERB	O	O	3648
for	ADP	O	O	3648
heart	NOUN	O	O	3648
or	CCONJ	O	O	3648
liver	NOUN	O	O	3648
mitochondria	PROPN	O	O	3648
.	PUNCT	O	O	3648
It	PRON	O	O	3649
is	AUX	O	O	3649
concluded	VERB	O	O	3649
that	SCONJ	O	O	3649
this	PRON	O	O	3649
protection	NOUN	O	O	3649
by	ADP	O	O	3649
carvedilol	VERB	O	O	3649
against	ADP	O	O	3649
both	PRON	O	O	3649
the	PRON	O	O	3649
structural	ADJ	O	O	3649
and	CCONJ	O	O	3649
functional	ADJ	O	O	3649
cardiac	ADJ	O	O	3649
tissue	NOUN	O	O	3649
damage	NOUN	O	O	3649
may	AUX	O	O	3649
afford	VERB	O	O	3649
significant	ADJ	O	O	3649
clinical	ADJ	O	O	3649
advantage	NOUN	O	O	3649
in	ADP	O	O	3649
minimizing	VERB	O	O	3649
the	PRON	O	O	3649
dose	NOUN	O	O	3649
-	PUNCT	O	O	3649
limiting	VERB	O	O	3649
mitochondrial	ADJ	O	O	3649
dysfunction	NOUN	O	O	3649
and	CCONJ	O	O	3649
cardiomyopathy	ADJ	O	Disease	3649
that	SCONJ	O	O	3649
accompanies	VERB	O	O	3649
long	ADV	O	O	3649
-	PUNCT	O	O	3649
term	NOUN	O	O	3649
doxorubicin	VERB	O	Chemical	3649
therapy	NOUN	O	O	3649
in	ADP	O	O	3649
cancer	NOUN	O	Disease	3649
patients	NOUN	O	O	3649
.	PUNCT	O	O	3649
Cocaine	NOUN	O	Chemical	3652
-	PUNCT	O	O	3652
induced	VERB	O	O	3652
hyperactivity	NOUN	O	Disease	3652
is	AUX	O	O	3652
more	ADJ	O	O	3652
influenced	VERB	O	O	3652
by	ADP	O	O	3652
adenosine	PROPN	O	Chemical	3652
receptor	NOUN	O	O	3652
agonists	NOUN	O	O	3652
than	ADP	O	O	3652
amphetamine	NOUN	O	Chemical	3652
-	PUNCT	O	O	3652
induced	VERB	O	O	3652
hyperactivity	NOUN	O	Disease	3652
.	PUNCT	O	O	3652
The	PRON	O	O	3653
influence	NOUN	O	O	3653
of	ADP	O	O	3653
adenosine	PROPN	O	Chemical	3653
receptor	NOUN	O	O	3653
agonists	NOUN	O	O	3653
and	CCONJ	O	O	3653
antagonists	NOUN	O	O	3653
on	ADP	O	O	3653
cocaine	NOUN	O	Chemical	3653
-	PUNCT	O	O	3653
and	CCONJ	O	O	3653
amphetamine	NOUN	O	Chemical	3653
-	PUNCT	O	O	3653
induced	VERB	O	O	3653
hyperactivity	NOUN	O	Disease	3653
was	AUX	O	O	3653
examined	VERB	O	O	3653
in	ADP	O	O	3653
mice	NOUN	O	O	3653
.	PUNCT	O	O	3653
All	PRON	O	O	3654
adenosine	PROPN	O	Chemical	3654
receptor	NOUN	O	O	3654
agonists	NOUN	O	O	3654
significantly	ADV	O	O	3654
decreased	VERB	O	O	3654
the	PRON	O	O	3654
locomotor	PROPN	O	O	3654
activity	NOUN	O	O	3654
in	ADP	O	O	3654
mice	NOUN	O	O	3654
,	PUNCT	O	O	3654
and	CCONJ	O	O	3654
the	PRON	O	O	3654
effects	NOUN	O	O	3654
were	AUX	O	O	3654
dose	NOUN	O	O	3654
-	PUNCT	O	O	3654
dependent	ADJ	O	O	3654
.	PUNCT	O	O	3654
It	PRON	O	O	3655
seems	VERB	O	O	3655
that	SCONJ	O	O	3655
adenosine	PROPN	O	Chemical	3655
A1	PROPN	O	O	3655
and	CCONJ	O	O	3655
A2	PROPN	O	O	3655
receptors	NOUN	O	O	3655
might	AUX	O	O	3655
be	AUX	O	O	3655
involved	VERB	O	O	3655
in	ADP	O	O	3655
this	PRON	O	O	3655
reaction	NOUN	O	O	3655
.	PUNCT	O	O	3655
Moreover	ADV	O	O	3656
,	PUNCT	O	O	3656
all	PRON	O	O	3656
adenosine	PROPN	O	Chemical	3656
receptor	NOUN	O	O	3656
agonists	NOUN	O	O	3656
:	PUNCT	O	O	3656
2-p-(2-carboxyethyl)phenethylamino-5'-N	NOUN	O	O	3656
-	PUNCT	O	O	3656
ethylcarboxamidoadenosine	PROPN	O	O	3656
(	PUNCT	O	O	3656
CGS 21680	NUM	O	Chemical	3656
)	PUNCT	O	O	3656
,	PUNCT	O	O	3656
A2A	PROPN	O	O	3657
receptor	NOUN	O	O	3657
agonist	NOUN	O	O	3657
,	PUNCT	O	O	3657
N6-cyclopentyladenosine	ADJ	O	O	3657
(	PUNCT	O	O	3657
CPA	NOUN	O	Chemical	3657
)	PUNCT	O	O	3657
,	PUNCT	O	O	3657
A1	PROPN	O	O	3657
receptor	NOUN	O	O	3657
agonist	NOUN	O	O	3657
,	PUNCT	O	O	3657
and	CCONJ	O	O	3657
5'-N	NUM	O	O	3657
-	PUNCT	O	O	3657
ethylcarboxamidoadenosine	PROPN	O	O	3657
(	PUNCT	O	O	3657
NECA	PROPN	O	O	3657
)	PUNCT	O	O	3657
,	PUNCT	O	O	3657
A2/A1	PROPN	O	O	3657
receptor	NOUN	O	O	3657
agonist	NOUN	O	O	3657
significantly	ADV	O	O	3657
and	CCONJ	O	O	3657
dose	NOUN	O	O	3657
-	PUNCT	O	O	3657
dependently	ADV	O	O	3657
decreased	VERB	O	O	3657
cocaine	NOUN	O	Chemical	3657
-	PUNCT	O	O	3657
induced	VERB	O	O	3657
locomotor	PROPN	O	O	3657
activity	NOUN	O	O	3657
.	PUNCT	O	O	3657
CPA	NOUN	O	Chemical	3658
reduced	VERB	O	O	3658
cocaine	NOUN	O	Chemical	3658
action	NOUN	O	O	3658
at	ADP	O	O	3658
the	PRON	O	O	3658
doses	NOUN	O	O	3658
which	PRON	O	O	3658
,	PUNCT	O	O	3658
given	VERB	O	O	3658
alone	ADV	O	O	3658
,	PUNCT	O	O	3658
did	VERB	O	O	3658
not	PART	O	O	3658
influence	NOUN	O	O	3658
motility	NOUN	O	O	3658
,	PUNCT	O	O	3658
while	SCONJ	O	O	3658
CGS 21680	NUM	O	Chemical	3658
and	CCONJ	O	O	3658
NECA	PROPN	O	O	3658
decreased	VERB	O	O	3658
the	PRON	O	O	3658
action	NOUN	O	O	3658
of	ADP	O	O	3658
cocaine	NOUN	O	Chemical	3658
at	ADP	O	O	3658
the	PRON	O	O	3658
doses	NOUN	O	O	3658
which	PRON	O	O	3658
,	PUNCT	O	O	3658
given	VERB	O	O	3658
alone	ADV	O	O	3658
,	PUNCT	O	O	3658
decreased	VERB	O	O	3658
locomotor	PROPN	O	O	3658
activity	NOUN	O	O	3658
in	ADP	O	O	3658
animals	NOUN	O	O	3658
.	PUNCT	O	O	3658
These	PRON	O	O	3659
results	VERB	O	O	3659
suggest	VERB	O	O	3659
the	PRON	O	O	3659
involvement	NOUN	O	O	3659
of	ADP	O	O	3659
both	PRON	O	O	3659
adenosine	PROPN	O	Chemical	3659
receptors	NOUN	O	O	3659
in	ADP	O	O	3659
the	PRON	O	O	3659
action	NOUN	O	O	3659
of	ADP	O	O	3659
cocaine	NOUN	O	Chemical	3659
although	SCONJ	O	O	3659
agonists	NOUN	O	O	3659
of	ADP	O	O	3659
A1	PROPN	O	O	3659
receptors	NOUN	O	O	3659
seem	VERB	O	O	3659
to	PART	O	O	3659
have	VERB	O	O	3659
stronger	ADJ	O	O	3659
influence	NOUN	O	O	3659
on	ADP	O	O	3659
it	PRON	O	O	3659
.	PUNCT	O	O	3659
The	PRON	O	O	3660
selective	ADJ	O	O	3660
blockade	VERB	O	O	3660
of	ADP	O	O	3660
A2	PROPN	O	O	3660
adenosine	PROPN	O	Chemical	3660
receptor	NOUN	O	O	3660
by	ADP	O	O	3660
DMPX	NOUN	O	O	3660
(	PUNCT	O	O	3660
3,7-dimethyl-1-propargylxanthine	ADJ	O	O	3660
)	PUNCT	O	O	3660
significantly	ADV	O	O	3660
enhanced	VERB	O	O	3660
cocaine	NOUN	O	Chemical	3660
-	PUNCT	O	O	3660
induced	VERB	O	O	3660
locomotor	PROPN	O	O	3660
activity	NOUN	O	O	3660
of	ADP	O	O	3660
animals	NOUN	O	O	3660
.	PUNCT	O	O	3660
Caffeine	NOUN	O	Chemical	3661
had	VERB	O	O	3661
similar	ADJ	O	O	3661
action	NOUN	O	O	3661
but	CCONJ	O	O	3661
the	PRON	O	O	3661
effect	VERB	O	O	3661
was	AUX	O	O	3661
not	PART	O	O	3661
significant	ADJ	O	O	3661
.	PUNCT	O	O	3661
CPT	PROPN	O	O	3662
(	PUNCT	O	O	3662
8-cyclopentyltheophylline)--A1	NOUN	O	O	3662
receptor	NOUN	O	O	3662
antagonist	NOUN	O	O	3662
,	PUNCT	O	O	3662
did	VERB	O	O	3662
not	PART	O	O	3662
show	VERB	O	O	3662
any	PRON	O	O	3662
influence	NOUN	O	O	3662
in	ADP	O	O	3662
this	PRON	O	O	3662
test	NOUN	O	O	3662
.	PUNCT	O	O	3662
Similarly	ADV	O	O	3663
,	PUNCT	O	O	3663
all	PRON	O	O	3663
adenosine	PROPN	O	Chemical	3663
receptor	NOUN	O	O	3663
agonists	NOUN	O	O	3663
decreased	VERB	O	O	3663
amphetamine	NOUN	O	Chemical	3663
-	PUNCT	O	O	3663
induced	VERB	O	O	3663
hyperactivity	NOUN	O	Disease	3663
,	PUNCT	O	O	3663
but	CCONJ	O	O	3663
at	ADP	O	O	3663
the	PRON	O	O	3663
higher	ADJ	O	O	3663
doses	NOUN	O	O	3663
than	ADP	O	O	3663
those	PRON	O	O	3663
which	PRON	O	O	3663
were	AUX	O	O	3663
active	ADJ	O	O	3663
in	ADP	O	O	3663
cocaine	NOUN	O	Chemical	3663
-	PUNCT	O	O	3663
induced	VERB	O	O	3663
hyperactivity	NOUN	O	Disease	3663
.	PUNCT	O	O	3663
The	PRON	O	O	3664
selective	ADJ	O	O	3664
blockade	VERB	O	O	3664
of	ADP	O	O	3664
A2	PROPN	O	O	3664
adenosine	PROPN	O	Chemical	3664
receptors	NOUN	O	O	3664
(	PUNCT	O	O	3664
DMPX	NOUN	O	O	3664
)	PUNCT	O	O	3664
and	CCONJ	O	O	3664
non	ADJ	O	O	3664
-	PUNCT	O	O	3664
selective	ADJ	O	O	3664
blockade	VERB	O	O	3664
of	ADP	O	O	3664
adenosine	PROPN	O	Chemical	3664
receptors	NOUN	O	O	3664
(	PUNCT	O	O	3664
caffeine	NOUN	O	Chemical	3664
)	PUNCT	O	O	3664
significantly	ADV	O	O	3664
increased	VERB	O	O	3664
the	PRON	O	O	3664
action	NOUN	O	O	3664
of	ADP	O	O	3664
amphetamine	NOUN	O	Chemical	3664
in	ADP	O	O	3664
the	PRON	O	O	3664
locomotor	PROPN	O	O	3664
activity	NOUN	O	O	3664
test	NOUN	O	O	3664
.	PUNCT	O	O	3664
Our	PRON	O	O	3665
results	VERB	O	O	3665
have	VERB	O	O	3665
shown	VERB	O	O	3665
that	SCONJ	O	O	3665
all	PRON	O	O	3665
adenosine	PROPN	O	Chemical	3665
receptor	NOUN	O	O	3665
agonists	NOUN	O	O	3665
(	PUNCT	O	O	3665
A1	PROPN	O	O	3665
and	CCONJ	O	O	3665
A2	PROPN	O	O	3665
)	PUNCT	O	O	3665
reduce	VERB	O	O	3665
cocaine-	NOUN	O	O	3665
and	CCONJ	O	O	3665
amphetamine	NOUN	O	Chemical	3665
-	PUNCT	O	O	3665
induced	VERB	O	O	3665
locomotor	PROPN	O	O	3665
activity	NOUN	O	O	3665
and	CCONJ	O	O	3665
indicate	VERB	O	O	3665
that	SCONJ	O	O	3665
cocaine	NOUN	O	Chemical	3665
-	PUNCT	O	O	3665
induced	VERB	O	O	3665
hyperactivity	NOUN	O	Disease	3665
is	AUX	O	O	3665
more	ADJ	O	O	3665
influenced	VERB	O	O	3665
by	ADP	O	O	3665
adenosine	PROPN	O	Chemical	3665
receptor	NOUN	O	O	3665
agonists	NOUN	O	O	3665
(	PUNCT	O	O	3665
particularly	ADV	O	O	3665
A1	PROPN	O	O	3665
receptors	NOUN	O	O	3665
)	PUNCT	O	O	3665
than	ADP	O	O	3665
amphetamine	NOUN	O	Chemical	3665
-	PUNCT	O	O	3665
induced	VERB	O	O	3665
hyperactivity	NOUN	O	Disease	3665
.	PUNCT	O	O	3665
Amiodarone	NOUN	O	Chemical	3668
and	CCONJ	O	O	3668
the	PRON	O	O	3668
risk	NOUN	O	O	3668
of	ADP	O	O	3668
bradyarrhythmia	NOUN	O	O	3668
requiring	VERB	O	O	3668
permanent	ADJ	O	O	3668
pacemaker	NOUN	O	O	3668
in	ADP	O	O	3668
elderly	ADJ	O	O	3668
patients	NOUN	O	O	3668
with	ADP	O	O	3668
atrial fibrillation	NOUN	O	Disease	3668
and	CCONJ	O	O	3668
prior	ADV	O	O	3668
myocardial infarction	NOUN	O	Disease	3668
.	PUNCT	O	O	3668
OBJECTIVES	NOUN	O	O	3669
:	PUNCT	O	O	3669
The	PRON	O	O	3669
aim	VERB	O	O	3669
of	ADP	O	O	3669
this	PRON	O	O	3669
study	VERB	O	O	3669
was	AUX	O	O	3669
to	PART	O	O	3669
determine	VERB	O	O	3669
whether	SCONJ	O	O	3669
the	PRON	O	O	3669
use	VERB	O	O	3669
of	ADP	O	O	3669
amiodarone	NOUN	O	Chemical	3669
in	ADP	O	O	3669
patients	NOUN	O	O	3669
with	ADP	O	O	3669
atrial fibrillation	NOUN	O	Disease	3669
(	PUNCT	O	O	3669
AF	PROPN	O	Disease	3669
)	PUNCT	O	O	3669
increases	VERB	O	O	3669
the	PRON	O	O	3669
risk	NOUN	O	O	3669
of	ADP	O	O	3669
bradyarrhythmia	NOUN	O	O	3669
requiring	VERB	O	O	3669
a	PRON	O	O	3669
permanent	ADJ	O	O	3669
pacemaker	NOUN	O	O	3669
.	PUNCT	O	O	3669
Reports	NOUN	O	O	3670
of	ADP	O	O	3670
severe	ADJ	O	O	3670
bradyarrhythmia	NOUN	O	O	3670
during	ADP	O	O	3670
amiodarone	NOUN	O	Chemical	3670
therapy	NOUN	O	O	3670
are	AUX	O	O	3670
infrequent	ADJ	O	O	3670
and	CCONJ	O	O	3670
limited	VERB	O	O	3670
to	PART	O	O	3670
studies	NOUN	O	O	3670
assessing	VERB	O	O	3670
the	PRON	O	O	3670
therapy	NOUN	O	O	3670
's	AUX	O	O	3670
use	VERB	O	O	3670
in	ADP	O	O	3670
the	PRON	O	O	3670
management	NOUN	O	O	3670
of	ADP	O	O	3670
patients	NOUN	O	O	3670
with	ADP	O	O	3670
ventricular arrhythmias	NOUN	O	Disease	3670
.	PUNCT	O	O	3670
METHODS	NOUN	O	O	3671
:	PUNCT	O	O	3671
A	PRON	O	O	3671
study	VERB	O	O	3671
cohort	NOUN	O	O	3671
of	ADP	O	O	3671
8,770	NUM	O	O	3671
patients	NOUN	O	O	3671
age	NOUN	O	O	3671
>	PUNCT	O	O	3671
or	CCONJ	O	O	3671
=	PUNCT	O	O	3671
65	NUM	O	O	3671
years	NOUN	O	O	3671
with	ADP	O	O	3671
a	PRON	O	O	3671
new	ADJ	O	O	3671
diagnosis	NOUN	O	O	3671
of	ADP	O	O	3671
AF	PROPN	O	Disease	3671
was	AUX	O	O	3671
identified	VERB	O	O	3671
from	ADP	O	O	3671
a	PRON	O	O	3671
provincewide	NOUN	O	O	3671
database	NOUN	O	O	3671
of	ADP	O	O	3671
Quebec	PROPN	O	O	3671
residents	NOUN	O	O	3671
with	ADP	O	O	3671
a	PRON	O	O	3671
myocardial infarction	NOUN	O	Disease	3671
(	PUNCT	O	O	3671
MI	PROPN	O	Disease	3671
)	PUNCT	O	O	3671
between	ADP	O	O	3671
1991	NUM	O	O	3671
and	CCONJ	O	O	3671
1999	NUM	O	O	3671
.	PUNCT	O	O	3671
Using	VERB	O	O	3672
a	PRON	O	O	3672
nested	VERB	O	O	3672
case	NOUN	O	O	3672
-	PUNCT	O	O	3672
control	VERB	O	O	3672
design	NOUN	O	O	3672
,	PUNCT	O	O	3672
477	NUM	O	O	3672
cases	NOUN	O	O	3672
of	ADP	O	O	3672
bradyarrhythmia	NOUN	O	O	3672
requiring	VERB	O	O	3672
a	PRON	O	O	3672
permanent	ADJ	O	O	3672
pacemaker	NOUN	O	O	3672
were	AUX	O	O	3672
matched	VERB	O	O	3672
(	PUNCT	O	O	3672
1:4	NUM	O	O	3672
)	PUNCT	O	O	3672
to	PART	O	O	3672
1,908	NUM	O	O	3672
controls	VERB	O	O	3672
.	PUNCT	O	O	3672
Multivariable	ADJ	O	O	3673
logistic	ADJ	O	O	3673
regression	NOUN	O	O	3673
was	AUX	O	O	3673
used	VERB	O	O	3673
to	PART	O	O	3673
estimate	VERB	O	O	3673
the	PRON	O	O	3673
odds	NOUN	O	O	3673
ratio	NOUN	O	O	3673
(	PUNCT	O	O	3673
OR	CCONJ	O	O	3673
)	PUNCT	O	O	3673
of	ADP	O	O	3673
pacemaker	NOUN	O	O	3673
insertion	NOUN	O	O	3673
associated	VERB	O	O	3673
with	ADP	O	O	3673
amiodarone	NOUN	O	Chemical	3673
use	VERB	O	O	3673
,	PUNCT	O	O	3673
controlling	VERB	O	O	3673
for	ADP	O	O	3673
baseline	VERB	O	O	3673
risk	NOUN	O	O	3673
factors	NOUN	O	O	3673
and	CCONJ	O	O	3673
exposure	NOUN	O	O	3673
to	PART	O	O	3673
sotalol	VERB	O	O	3673
,	PUNCT	O	O	3673
Class	NOUN	O	O	3674
I	PRON	O	O	3674
antiarrhythmic	PROPN	O	O	3674
agents	NOUN	O	O	3674
,	PUNCT	O	O	3674
beta	NOUN	O	O	3674
-	PUNCT	O	O	3674
blockers	NOUN	O	O	3674
,	PUNCT	O	O	3674
calcium	NOUN	O	Chemical	3674
channel	PROPN	O	O	3674
blockers	NOUN	O	O	3674
,	PUNCT	O	O	3674
and	CCONJ	O	O	3674
digoxin	PROPN	O	Chemical	3674
.	PUNCT	O	O	3674
RESULTS	VERB	O	O	3675
:	PUNCT	O	O	3675
amiodarone	NOUN	O	Chemical	3675
use	VERB	O	O	3675
was	AUX	O	O	3675
associated	VERB	O	O	3675
with	ADP	O	O	3675
an	PRON	O	O	3675
increased	VERB	O	O	3675
risk	NOUN	O	O	3675
of	ADP	O	O	3675
pacemaker	NOUN	O	O	3675
insertion	NOUN	O	O	3675
(	PUNCT	O	O	3675
OR	CCONJ	O	O	3675
:	PUNCT	O	O	3675
2.14	NUM	O	O	3675
,	PUNCT	O	O	3675
95%	NOUN	O	O	3675
confidence	NOUN	O	O	3675
interval	NOUN	O	O	3675
[	X	O	O	3675
CI	NOUN	O	O	3675
]	PUNCT	O	O	3675
:	PUNCT	O	O	3675
1.30	NUM	O	O	3675
to	PART	O	O	3675
3.54	NUM	O	O	3675
)	PUNCT	O	O	3675
.	PUNCT	O	O	3675
Digoxin	NOUN	O	O	3676
was	AUX	O	O	3676
the	PRON	O	O	3676
only	ADV	O	O	3676
other	ADJ	O	O	3676
medication	NOUN	O	O	3676
associated	VERB	O	O	3676
with	ADP	O	O	3676
an	PRON	O	O	3676
increased	VERB	O	O	3676
risk	NOUN	O	O	3676
of	ADP	O	O	3676
pacemaker	NOUN	O	O	3676
insertion	NOUN	O	O	3676
(	PUNCT	O	O	3676
OR	CCONJ	O	O	3676
:	PUNCT	O	O	3676
1.78	NUM	O	O	3676
,	PUNCT	O	O	3676
95%	NOUN	O	O	3676
CI	NOUN	O	O	3676
:	PUNCT	O	O	3676
1.37	NUM	O	O	3676
to	PART	O	O	3676
2.31	NUM	O	O	3676
)	PUNCT	O	O	3676
.	PUNCT	O	O	3676
This	PRON	O	O	3677
study	VERB	O	O	3677
suggests	VERB	O	O	3677
that	SCONJ	O	O	3677
the	PRON	O	O	3677
use	VERB	O	O	3677
of	ADP	O	O	3677
amiodarone	NOUN	O	Chemical	3677
in	ADP	O	O	3677
elderly	ADJ	O	O	3677
patients	NOUN	O	O	3677
with	ADP	O	O	3677
AF	PROPN	O	Disease	3677
and	CCONJ	O	O	3677
a	PRON	O	O	3677
previous	ADJ	O	O	3677
MI	PROPN	O	Disease	3677
increases	VERB	O	O	3677
the	PRON	O	O	3677
risk	NOUN	O	O	3677
of	ADP	O	O	3677
bradyarrhythmia	NOUN	O	O	3677
requiring	VERB	O	O	3677
a	PRON	O	O	3677
permanent	ADJ	O	O	3677
pacemaker	NOUN	O	O	3677
.	PUNCT	O	O	3677
The	PRON	O	O	3678
finding	VERB	O	O	3678
of	ADP	O	O	3678
an	PRON	O	O	3678
augmented	VERB	O	O	3678
risk	NOUN	O	O	3678
of	ADP	O	O	3678
pacemaker	NOUN	O	O	3678
insertion	NOUN	O	O	3678
in	ADP	O	O	3678
elderly	ADJ	O	O	3678
women	NOUN	O	O	3678
receiving	VERB	O	O	3678
amiodarone	NOUN	O	Chemical	3678
requires	VERB	O	O	3678
further	ADV	O	O	3678
investigation	NOUN	O	O	3678
.	PUNCT	O	O	3678
Indomethacin	PROPN	O	Chemical	3681
-	PUNCT	O	O	3681
induced	VERB	O	O	3681
morphologic	ADJ	O	O	3681
changes	VERB	O	O	3681
in	ADP	O	O	3681
the	PRON	O	O	3681
rat	NOUN	O	O	3681
urinary	ADJ	O	O	3681
bladder	NOUN	O	O	3681
epithelium	NOUN	O	O	3681
.	PUNCT	O	O	3681
OBJECTIVES	NOUN	O	O	3682
:	PUNCT	O	O	3682
To	PART	O	O	3682
evaluate	VERB	O	O	3682
the	PRON	O	O	3682
morphologic	ADJ	O	O	3682
changes	VERB	O	O	3682
in	ADP	O	O	3682
rat	NOUN	O	O	3682
urothelium	NOUN	O	O	3682
induced	VERB	O	O	3682
by	ADP	O	O	3682
indomethacin	VERB	O	Chemical	3682
.	PUNCT	O	O	3682
Nonsteroidal	ADJ	O	O	3683
anti	ADJ	O	O	3683
-	PUNCT	O	O	3683
inflammatory	ADJ	O	O	3683
drug	NOUN	O	O	3683
-	PUNCT	O	O	3683
induced	VERB	O	O	3683
cystitis	NOUN	O	Disease	3683
is	AUX	O	O	3683
a	PRON	O	O	3683
poorly	ADV	O	O	3683
recognized	VERB	O	O	3683
and	CCONJ	O	O	3683
under	ADP	O	O	3683
-	PUNCT	O	O	3683
reported	VERB	O	O	3683
condition	NOUN	O	O	3683
.	PUNCT	O	O	3683
In	ADP	O	O	3684
addition	NOUN	O	O	3684
to	PART	O	O	3684
tiaprofenic	NOUN	O	O	3684
acid	PROPN	O	O	3684
,	PUNCT	O	O	3684
indomethacin	VERB	O	Chemical	3684
has	VERB	O	O	3684
been	AUX	O	O	3684
reported	VERB	O	O	3684
to	PART	O	O	3684
be	AUX	O	O	3684
associated	VERB	O	O	3684
with	ADP	O	O	3684
this	PRON	O	O	3684
condition	NOUN	O	O	3684
.	PUNCT	O	O	3684
Three	NUM	O	O	3685
groups	NOUN	O	O	3685
were	AUX	O	O	3685
established	VERB	O	O	3685
:	PUNCT	O	O	3685
a	PRON	O	O	3685
control	VERB	O	O	3685
group	NOUN	O	O	3685
(	PUNCT	O	O	3685
n	CCONJ	O	O	3685
=	PUNCT	O	O	3685
10	NUM	O	O	3685
)	PUNCT	O	O	3685
,	PUNCT	O	O	3685
a	PRON	O	O	3685
high	ADJ	O	O	3685
-	PUNCT	O	O	3685
dose	NOUN	O	O	3685
group	NOUN	O	O	3685
(	PUNCT	O	O	3685
n	CCONJ	O	O	3685
=	PUNCT	O	O	3685
10	NUM	O	O	3685
)	PUNCT	O	O	3685
,	PUNCT	O	O	3685
treated	VERB	O	O	3685
with	ADP	O	O	3685
one	NUM	O	O	3685
intraperitoneal	ADJ	O	O	3685
injection	NOUN	O	O	3685
of	ADP	O	O	3685
indomethacin	VERB	O	Chemical	3685
20	NUM	O	O	3685
mg	VERB	O	O	3685
/	PUNCT	O	O	3685
kg	VERB	O	O	3685
,	PUNCT	O	O	3685
and	CCONJ	O	O	3685
a	PRON	O	O	3685
therapeutic	ADJ	O	O	3685
dose	NOUN	O	O	3685
group	NOUN	O	O	3685
(	PUNCT	O	O	3685
n	CCONJ	O	O	3685
=	PUNCT	O	O	3685
10	NUM	O	O	3685
)	PUNCT	O	O	3685
in	ADP	O	O	3685
which	PRON	O	O	3685
oral	ADJ	O	O	3685
indomethacin	VERB	O	Chemical	3685
was	AUX	O	O	3685
administered	VERB	O	O	3685
3.25	NUM	O	O	3685
mg	VERB	O	O	3685
/	PUNCT	O	O	3685
kg	VERB	O	O	3685
body	NOUN	O	O	3685
weight	NOUN	O	O	3685
daily	ADV	O	O	3685
for	ADP	O	O	3685
3	X	O	O	3685
weeks	NOUN	O	O	3685
.	PUNCT	O	O	3685
When	SCONJ	O	O	3686
compared	VERB	O	O	3686
with	ADP	O	O	3686
the	PRON	O	O	3686
control	VERB	O	O	3686
group	NOUN	O	O	3686
,	PUNCT	O	O	3686
both	PRON	O	O	3686
indomethacin	VERB	O	Chemical	3686
groups	NOUN	O	O	3686
revealed	VERB	O	O	3686
statistically	ADV	O	O	3686
increased	VERB	O	O	3686
numbers	NOUN	O	O	3686
of	ADP	O	O	3686
mast	NOUN	O	O	3686
cells	NOUN	O	O	3686
in	ADP	O	O	3686
the	PRON	O	O	3686
mucosa	PROPN	O	O	3686
(	PUNCT	O	O	3686
P	NOUN	O	Chemical	3686
<	X	O	O	3686
0.0001	NUM	O	O	3686
)	PUNCT	O	O	3686
and	CCONJ	O	O	3686
penetration	NOUN	O	O	3686
of	ADP	O	O	3686
lanthanum	NOUN	O	O	3686
nitrate	NOUN	O	Chemical	3686
through	ADP	O	O	3686
intercellular	ADJ	O	O	3686
areas	NOUN	O	O	3686
of	ADP	O	O	3686
the	PRON	O	O	3686
epithelium	NOUN	O	O	3686
.	PUNCT	O	O	3686
Indomethacin	PROPN	O	Chemical	3687
resulted	VERB	O	O	3687
in	ADP	O	O	3687
histopathologic	VERB	O	O	3687
findings	NOUN	O	O	3687
typical	ADJ	O	O	3687
of	ADP	O	O	3687
interstitial	ADJ	O	O	3687
cystitis	NOUN	O	Disease	3687
,	PUNCT	O	O	3687
such	ADJ	O	O	3687
as	ADP	O	O	3687
leaky	ADJ	O	O	3687
bladder	NOUN	O	O	3687
epithelium	NOUN	O	O	3687
and	CCONJ	O	O	3687
mucosal	ADJ	O	O	3687
mastocytosis	VERB	O	O	3687
.	PUNCT	O	O	3687
The	PRON	O	O	3688
true	ADJ	O	O	3688
incidence	NOUN	O	O	3688
of	ADP	O	O	3688
nonsteroidal	ADJ	O	O	3688
anti	ADJ	O	O	3688
-	PUNCT	O	O	3688
inflammatory	ADJ	O	O	3688
drug	NOUN	O	O	3688
-	PUNCT	O	O	3688
induced	VERB	O	O	3688
cystitis	NOUN	O	Disease	3688
in	ADP	O	O	3688
humans	NOUN	O	O	3688
must	AUX	O	O	3688
be	AUX	O	O	3688
clarified	VERB	O	O	3688
by	ADP	O	O	3688
prospective	ADJ	O	O	3688
clinical	ADJ	O	O	3688
trials	NOUN	O	O	3688
.	PUNCT	O	O	3688
An	PRON	O	O	3691
open	VERB	O	O	3691
-	PUNCT	O	O	3691
label	PROPN	O	O	3691
phase	NOUN	O	O	3691
II	NUM	O	O	3691
study	VERB	O	O	3691
of	ADP	O	O	3691
low	ADJ	O	O	3691
-	PUNCT	O	O	3691
dose	NOUN	O	O	3691
thalidomide	NOUN	O	Chemical	3691
in	ADP	O	O	3691
androgen	PROPN	O	Chemical	3691
-	PUNCT	O	O	3691
independent	ADJ	O	O	3691
prostate cancer	NOUN	O	Disease	3691
.	PUNCT	O	O	3691
The	PRON	O	O	3692
antiangiogenic	ADJ	O	O	3692
effects	NOUN	O	O	3692
of	ADP	O	O	3692
thalidomide	NOUN	O	Chemical	3692
have	VERB	O	O	3692
been	AUX	O	O	3692
assessed	VERB	O	O	3692
in	ADP	O	O	3692
clinical	ADJ	O	O	3692
trials	NOUN	O	O	3692
in	ADP	O	O	3692
patients	NOUN	O	O	3692
with	ADP	O	O	3692
various	ADJ	O	O	3692
solid	ADJ	O	O	3692
and	CCONJ	O	O	3692
haematological	NOUN	O	O	3692
malignancies	NOUN	O	O	3692
.	PUNCT	O	O	3692
Thalidomide	NOUN	O	O	3693
blocks	NOUN	O	O	3693
the	PRON	O	O	3693
activity	NOUN	O	O	3693
of	ADP	O	O	3693
angiogenic	ADJ	O	O	3693
agents	NOUN	O	O	3693
including	VERB	O	O	3693
bFGF	NOUN	O	O	3693
,	PUNCT	O	O	3693
VEGF	PROPN	O	O	3693
and	CCONJ	O	O	3693
IL-6	NUM	O	O	3693
.	PUNCT	O	O	3693
We	PRON	O	O	3694
undertook	VERB	O	O	3694
an	PRON	O	O	3694
open	VERB	O	O	3694
-	PUNCT	O	O	3694
label	PROPN	O	O	3694
study	VERB	O	O	3694
using	VERB	O	O	3694
thalidomide	NOUN	O	Chemical	3694
100	NUM	O	O	3694
mg	VERB	O	O	3694
once	ADV	O	O	3694
daily	ADV	O	O	3694
for	ADP	O	O	3694
up	ADP	O	O	3694
to	PART	O	O	3694
6	NUM	O	O	3694
months	NOUN	O	O	3694
in	ADP	O	O	3694
20	NUM	O	O	3694
men	NOUN	O	O	3694
with	ADP	O	O	3694
androgen	PROPN	O	Chemical	3694
-	PUNCT	O	O	3694
independent	ADJ	O	O	3694
prostate cancer	NOUN	O	Disease	3694
.	PUNCT	O	O	3694
Patients	NOUN	O	O	3695
underwent	VERB	O	O	3695
regular	ADJ	O	O	3695
measurement	NOUN	O	O	3695
of	ADP	O	O	3695
prostate	NOUN	O	O	3695
-	PUNCT	O	O	3695
specific	ADJ	O	O	3695
antigen	PROPN	O	O	3695
(	PUNCT	O	O	3695
PSA	PROPN	O	O	3695
)	PUNCT	O	O	3695
,	PUNCT	O	O	3695
urea	PROPN	O	Chemical	3695
and	CCONJ	O	O	3695
electrolytes	NOUN	O	O	3695
,	PUNCT	O	O	3695
serum	NOUN	O	O	3695
bFGF	NOUN	O	O	3695
and	CCONJ	O	O	3695
VEGF	PROPN	O	O	3695
.	PUNCT	O	O	3695
Adverse	ADJ	O	O	3696
effects	NOUN	O	O	3696
included	VERB	O	O	3696
constipation	NOUN	O	Disease	3696
,	PUNCT	O	O	3696
morning	NOUN	O	O	3696
drowsiness	NOUN	O	Disease	3696
,	PUNCT	O	O	3696
dizziness	NOUN	O	Disease	3696
and	CCONJ	O	O	3696
rash	ADJ	O	Disease	3696
,	PUNCT	O	O	3696
and	CCONJ	O	O	3696
resulted	VERB	O	O	3696
in	ADP	O	O	3696
withdrawal	NOUN	O	O	3696
from	ADP	O	O	3696
the	PRON	O	O	3696
study	VERB	O	O	3696
by	ADP	O	O	3696
three	NUM	O	O	3696
men	NOUN	O	O	3696
.	PUNCT	O	O	3696
Evidence	NOUN	O	O	3697
of	ADP	O	O	3697
peripheral	ADJ	O	O	3697
sensory	ADJ	O	O	3697
neuropathy	NOUN	O	Disease	3697
was	AUX	O	O	3697
found	VERB	O	O	3697
in	ADP	O	O	3697
nine	NUM	O	O	3697
of	ADP	O	O	3697
13	NUM	O	O	3697
men	NOUN	O	O	3697
before	ADP	O	O	3697
treatment	NOUN	O	O	3697
.	PUNCT	O	O	3697
In	ADP	O	O	3698
the	PRON	O	O	3698
seven	NUM	O	O	3698
men	NOUN	O	O	3698
who	PRON	O	O	3698
completed	VERB	O	O	3698
six	NUM	O	O	3698
months	NOUN	O	O	3698
on	ADP	O	O	3698
thalidomide	NOUN	O	Chemical	3698
,	PUNCT	O	O	3698
subclinical	ADJ	O	O	3698
evidence	NOUN	O	O	3698
of	ADP	O	O	3698
peripheral neuropathy	NOUN	O	Disease	3698
was	AUX	O	O	3698
found	VERB	O	O	3698
in	ADP	O	O	3698
four	NUM	O	O	3698
before	ADP	O	O	3698
treatment	NOUN	O	O	3698
,	PUNCT	O	O	3698
but	CCONJ	O	O	3698
in	ADP	O	O	3698
all	PRON	O	O	3698
seven	NUM	O	O	3698
at	ADP	O	O	3698
repeat	VERB	O	O	3698
testing	NOUN	O	O	3698
.	PUNCT	O	O	3698
The	PRON	O	O	3699
findings	NOUN	O	O	3699
indicate	VERB	O	O	3699
that	SCONJ	O	O	3699
thalidomide	NOUN	O	Chemical	3699
may	AUX	O	O	3699
be	AUX	O	O	3699
an	PRON	O	O	3699
option	NOUN	O	O	3699
for	ADP	O	O	3699
patients	NOUN	O	O	3699
who	PRON	O	O	3699
have	VERB	O	O	3699
failed	VERB	O	O	3699
other	ADJ	O	O	3699
forms	NOUN	O	O	3699
of	ADP	O	O	3699
therapy	NOUN	O	O	3699
,	PUNCT	O	O	3699
provided	VERB	O	O	3699
close	ADV	O	O	3699
follow	VERB	O	O	3699
-	PUNCT	O	O	3699
up	ADP	O	O	3699
is	AUX	O	O	3699
maintained	VERB	O	O	3699
for	ADP	O	O	3699
development	NOUN	O	O	3699
of	ADP	O	O	3699
peripheral neuropathy	NOUN	O	Disease	3699
.	PUNCT	O	O	3699
Central	ADJ	O	O	3702
nervous	ADJ	O	O	3702
system	NOUN	O	O	3702
toxicity	NOUN	O	Disease	3702
following	VERB	O	O	3702
the	PRON	O	O	3702
administration	NOUN	O	O	3702
of	ADP	O	O	3702
levobupivacaine	PROPN	O	Chemical	3702
for	ADP	O	O	3702
lumbar	NOUN	O	O	3702
plexus	NOUN	O	O	3702
block	NOUN	O	O	3702
:	PUNCT	O	O	3702
Central	ADJ	O	O	3703
nervous	ADJ	O	O	3703
system	NOUN	O	O	3703
and	CCONJ	O	O	3703
cardiac toxicity	NOUN	O	Disease	3703
following	VERB	O	O	3703
the	PRON	O	O	3703
administration	NOUN	O	O	3703
of	ADP	O	O	3703
local	ADJ	O	O	3703
anesthetics	NOUN	O	O	3703
is	AUX	O	O	3703
a	PRON	O	O	3703
recognized	VERB	O	O	3703
complication	NOUN	O	O	3703
of	ADP	O	O	3703
regional	ADJ	O	O	3703
anesthesia	NOUN	O	O	3703
.	PUNCT	O	O	3703
Levobupivacaine	NOUN	O	O	3704
,	PUNCT	O	O	3704
the	PRON	O	O	3704
pure	ADJ	O	O	3704
S(-	PROPN	O	O	3704
)	PUNCT	O	O	3704
enantiomer	NOUN	O	O	3705
of	ADP	O	O	3705
bupivacaine	NOUN	O	Chemical	3705
,	PUNCT	O	O	3705
was	AUX	O	O	3705
developed	VERB	O	O	3705
to	PART	O	O	3705
improve	VERB	O	O	3705
the	PRON	O	O	3705
cardiac	ADJ	O	O	3705
safety	NOUN	O	O	3705
profile	NOUN	O	O	3705
of	ADP	O	O	3705
bupivacaine	NOUN	O	Chemical	3705
.	PUNCT	O	O	3705
We	PRON	O	O	3706
describe	VERB	O	O	3706
2	X	O	O	3706
cases	NOUN	O	O	3706
of	ADP	O	O	3706
grand mal seizures	NOUN	O	Disease	3706
following	VERB	O	O	3706
accidental	ADJ	O	O	3706
intravascular	ADJ	O	O	3706
injection	NOUN	O	O	3706
of	ADP	O	O	3706
levobupivacaine	PROPN	O	Chemical	3706
.	PUNCT	O	O	3706
Immediately	ADV	O	O	3707
after	ADP	O	O	3707
the	PRON	O	O	3707
administration	NOUN	O	O	3707
of	ADP	O	O	3707
levobupivacaine	PROPN	O	Chemical	3707
0.5%	NOUN	O	O	3707
with	ADP	O	O	3707
epinephrine	NOUN	O	Chemical	3707
2.5	NUM	O	O	3707
microgram	PROPN	O	O	3707
/	PUNCT	O	O	3707
mL	PROPN	O	O	3707
,	PUNCT	O	O	3707
the	PRON	O	O	3707
patients	NOUN	O	O	3707
developed	VERB	O	O	3707
grand mal seizures	NOUN	O	Disease	3707
,	PUNCT	O	O	3707
despite	SCONJ	O	O	3707
negative	ADJ	O	O	3707
aspiration	NOUN	O	O	3707
for	ADP	O	O	3707
blood	NOUN	O	O	3707
and	CCONJ	O	O	3707
no	PRON	O	O	3707
clinical	ADJ	O	O	3707
signs	NOUN	O	O	3707
of	ADP	O	O	3707
intravenous	ADJ	O	O	3707
epinephrine	NOUN	O	Chemical	3707
administration	NOUN	O	O	3707
.	PUNCT	O	O	3707
The	PRON	O	O	3708
seizures	NOUN	O	Disease	3708
were	AUX	O	O	3708
successfully	ADV	O	O	3708
treated	VERB	O	O	3708
with	ADP	O	O	3708
sodium	NOUN	O	Chemical	3708
thiopental	NOUN	O	Chemical	3708
in	ADP	O	O	3708
addition	NOUN	O	O	3708
to	PART	O	O	3708
succinylcholine	NOUN	O	Chemical	3708
in	ADP	O	O	3708
1	X	O	O	3708
patient	NOUN	O	O	3708
.	PUNCT	O	O	3708
Neither	PRON	O	O	3709
patient	NOUN	O	O	3709
developed	VERB	O	O	3709
signs	NOUN	O	O	3709
of	ADP	O	O	3709
cardiovascular toxicity	NOUN	O	Disease	3709
.	PUNCT	O	O	3709
Both	PRON	O	O	3710
patients	NOUN	O	O	3710
were	AUX	O	O	3710
treated	VERB	O	O	3710
preoperatively	ADV	O	O	3710
with	ADP	O	O	3710
beta	NOUN	O	O	3710
-	PUNCT	O	O	3710
adrenergic	NOUN	O	O	3710
antagonist	NOUN	O	O	3710
medications	NOUN	O	O	3710
,	PUNCT	O	O	3710
which	PRON	O	O	3710
may	AUX	O	O	3710
have	VERB	O	O	3710
masked	VERB	O	O	3710
the	PRON	O	O	3710
cardiovascular	ADJ	O	O	3710
signs	NOUN	O	O	3710
of	ADP	O	O	3710
the	PRON	O	O	3710
unintentional	ADJ	O	O	3710
intravascular	ADJ	O	O	3710
administration	NOUN	O	O	3710
of	ADP	O	O	3710
levobupivacaine	PROPN	O	Chemical	3710
with	ADP	O	O	3710
epinephrine	NOUN	O	Chemical	3710
.	PUNCT	O	O	3710
Although	SCONJ	O	O	3711
levobupivacaine	PROPN	O	Chemical	3711
may	AUX	O	O	3711
have	VERB	O	O	3711
a	PRON	O	O	3711
safer	ADJ	O	O	3711
cardiac toxicity	NOUN	O	Disease	3711
profile	NOUN	O	O	3711
than	ADP	O	O	3711
racemic	ADJ	O	O	3711
bupivacaine	NOUN	O	Chemical	3711
,	PUNCT	O	O	3711
if	SCONJ	O	O	3711
adequate	ADJ	O	O	3711
amounts	VERB	O	O	3711
of	ADP	O	O	3711
levobupivacaine	PROPN	O	Chemical	3711
reach	VERB	O	O	3711
the	PRON	O	O	3711
circulation	NOUN	O	O	3711
,	PUNCT	O	O	3711
it	PRON	O	O	3711
will	AUX	O	O	3711
result	VERB	O	O	3711
in	ADP	O	O	3711
convulsions	NOUN	O	Disease	3711
.	PUNCT	O	O	3711
Plasma	NOUN	O	O	3712
concentrations	NOUN	O	O	3712
sufficient	ADJ	O	O	3712
to	PART	O	O	3712
result	VERB	O	O	3712
in	ADP	O	O	3712
central nervous system toxicity	NOUN	O	Disease	3712
did	VERB	O	O	3712
not	PART	O	O	3712
produce	VERB	O	O	3712
manifestations	NOUN	O	O	3712
of	ADP	O	O	3712
cardiac toxicity	NOUN	O	Disease	3712
in	ADP	O	O	3712
these	PRON	O	O	3712
2	X	O	O	3712
patients	NOUN	O	O	3712
.	PUNCT	O	O	3712
Anaesthetic	NOUN	O	O	3715
complications	NOUN	O	O	3715
associated	VERB	O	O	3715
with	ADP	O	O	3715
myotonia	NOUN	O	O	3715
congenita	NOUN	O	O	3715
:	PUNCT	O	O	3715
case	NOUN	O	O	3715
study	VERB	O	O	3715
and	CCONJ	O	O	3715
comparison	NOUN	O	O	3715
with	ADP	O	O	3715
other	ADJ	O	O	3715
myotonic	PROPN	O	O	3715
disorders	NOUN	O	O	3715
.	PUNCT	O	O	3715
Myotonia	NOUN	O	O	3716
congenita	NOUN	O	O	3716
(	PUNCT	O	O	3716
MC	PROPN	O	Chemical	3716
)	PUNCT	O	O	3716
is	AUX	O	O	3716
caused	VERB	O	O	3716
by	ADP	O	O	3716
a	PRON	O	O	3716
defect	NOUN	O	O	3716
in	ADP	O	O	3716
the	PRON	O	O	3716
skeletal	ADJ	O	O	3716
muscle	NOUN	O	O	3716
chloride	NOUN	O	Chemical	3716
channel	PROPN	O	O	3716
function	NOUN	O	O	3716
,	PUNCT	O	O	3716
which	PRON	O	O	3716
may	AUX	O	O	3716
cause	VERB	O	O	3716
sustained	VERB	O	O	3716
membrane	NOUN	O	O	3716
depolarisation	NOUN	O	O	3716
.	PUNCT	O	O	3716
We	PRON	O	O	3717
describe	VERB	O	O	3717
a	PRON	O	O	3717
previously	ADV	O	O	3717
healthy	ADJ	O	O	3717
32-year	NOUN	O	O	3717
-	PUNCT	O	O	3717
old	ADJ	O	O	3717
woman	NOUN	O	O	3717
who	PRON	O	O	3717
developed	VERB	O	O	3717
a	PRON	O	O	3717
life	NOUN	O	O	3717
-	PUNCT	O	O	3717
threatening	VERB	O	O	3717
muscle	NOUN	O	O	3717
spasm	NOUN	O	Disease	3717
and	CCONJ	O	O	3717
secondary	ADJ	O	O	3717
ventilation	NOUN	O	O	3717
difficulties	NOUN	O	O	3717
following	VERB	O	O	3717
a	PRON	O	O	3717
preoperative	ADJ	O	O	3717
injection	NOUN	O	O	3717
of	ADP	O	O	3717
suxamethonium	NOUN	O	O	3717
.	PUNCT	O	O	3717
The	PRON	O	O	3718
muscle spasms	VERB	O	Disease	3718
disappeared	VERB	O	O	3718
spontaneously	ADV	O	O	3718
and	CCONJ	O	O	3718
the	PRON	O	O	3718
surgery	NOUN	O	O	3718
proceeded	VERB	O	O	3718
without	ADP	O	O	3718
further	ADV	O	O	3718
problems	NOUN	O	O	3718
.	PUNCT	O	O	3718
When	SCONJ	O	O	3719
subsequently	ADV	O	O	3719
questioned	VERB	O	O	3719
,	PUNCT	O	O	3719
she	PRON	O	O	3719
reported	VERB	O	O	3719
minor	ADJ	O	O	3719
symptoms	NOUN	O	O	3719
suggesting	VERB	O	O	3719
a	PRON	O	O	3719
myotonic	PROPN	O	O	3719
condition	NOUN	O	O	3719
.	PUNCT	O	O	3719
Myotonia	NOUN	O	O	3720
was	AUX	O	O	3720
found	VERB	O	O	3720
on	ADP	O	O	3720
clinical	ADJ	O	O	3720
examination	NOUN	O	O	3720
and	CCONJ	O	O	3720
EMG	PROPN	O	O	3720
.	PUNCT	O	O	3720
The	PRON	O	O	3721
diagnosis	NOUN	O	O	3721
MC	PROPN	O	Chemical	3721
was	AUX	O	O	3721
confirmed	VERB	O	O	3721
genetically	ADV	O	O	3721
.	PUNCT	O	O	3721
We	PRON	O	O	3722
give	VERB	O	O	3722
a	PRON	O	O	3722
brief	PROPN	O	O	3722
overview	NOUN	O	O	3722
of	ADP	O	O	3722
ion	PROPN	O	O	3722
channel	PROPN	O	O	3722
disorders	NOUN	O	O	3722
including	VERB	O	O	3722
malignant hyperthermia	NOUN	O	Disease	3722
and	CCONJ	O	O	3722
their	PRON	O	O	3722
anaesthetic	NOUN	O	O	3722
considerations	NOUN	O	O	3722
.	PUNCT	O	O	3722
Respiratory	NOUN	O	O	3725
pattern	NOUN	O	O	3725
in	ADP	O	O	3725
a	PRON	O	O	3725
rat	NOUN	O	O	3725
model	NOUN	O	O	3725
of	ADP	O	O	3725
epilepsy	NOUN	O	Disease	3725
.	PUNCT	O	O	3725
Apnea	PROPN	O	O	3726
is	AUX	O	O	3726
known	VERB	O	O	3726
to	PART	O	O	3726
occur	VERB	O	O	3726
during	ADP	O	O	3726
seizures	NOUN	O	Disease	3726
,	PUNCT	O	O	3726
but	CCONJ	O	O	3726
systematic	ADJ	O	O	3726
studies	NOUN	O	O	3726
of	ADP	O	O	3726
ictal	ADJ	O	O	3726
respiratory	NOUN	O	O	3726
changes	VERB	O	O	3726
in	ADP	O	O	3726
adults	NOUN	O	O	3726
are	AUX	O	O	3726
few	ADJ	O	O	3726
.	PUNCT	O	O	3726
Here	ADV	O	O	3727
we	PRON	O	O	3727
sought	VERB	O	O	3727
to	PART	O	O	3727
generate	VERB	O	O	3727
information	NOUN	O	O	3727
with	ADP	O	O	3727
regard	NOUN	O	O	3727
to	PART	O	O	3727
the	PRON	O	O	3727
interictal	NOUN	O	O	3727
period	NOUN	O	O	3727
in	ADP	O	O	3727
animals	NOUN	O	O	3727
with	ADP	O	O	3727
pilocarpine	NOUN	O	Chemical	3727
-	PUNCT	O	O	3727
induced	VERB	O	O	3727
epilepsy	NOUN	O	Disease	3727
.	PUNCT	O	O	3727
METHODS	NOUN	O	O	3728
:	PUNCT	O	O	3728
Twelve	NUM	O	O	3728
rats	NOUN	O	O	3728
(	PUNCT	O	O	3728
six	NUM	O	O	3728
chronically	ADV	O	O	3728
epileptic	ADJ	O	Disease	3728
animals	NOUN	O	O	3728
and	CCONJ	O	O	3728
six	NUM	O	O	3728
controls	VERB	O	O	3728
)	PUNCT	O	O	3728
were	AUX	O	O	3728
anesthetized	VERB	O	O	3728
,	PUNCT	O	O	3728
given	VERB	O	O	3728
tracheotomies	NOUN	O	O	3728
,	PUNCT	O	O	3728
and	CCONJ	O	O	3728
subjected	VERB	O	O	3728
to	PART	O	O	3728
hyperventilation	NOUN	O	O	3728
or	CCONJ	O	O	3728
hypoventilation	NOUN	O	Disease	3728
conditions	NOUN	O	O	3728
.	PUNCT	O	O	3728
The	PRON	O	O	3729
hyperventilation	NOUN	O	O	3729
maneuver	VERB	O	O	3729
caused	VERB	O	O	3729
a	PRON	O	O	3729
decrease	VERB	O	O	3729
in	ADP	O	O	3729
spontaneous	ADJ	O	O	3729
ventilation	NOUN	O	O	3729
in	ADP	O	O	3729
pilocarpine	NOUN	O	Chemical	3729
-	PUNCT	O	O	3729
treated	VERB	O	O	3729
and	CCONJ	O	O	3729
control	VERB	O	O	3729
rats	NOUN	O	O	3729
.	PUNCT	O	O	3729
Although	SCONJ	O	O	3730
VE	NOUN	O	O	3730
had	VERB	O	O	3730
a	PRON	O	O	3730
similar	ADJ	O	O	3730
decrease	VERB	O	O	3730
in	ADP	O	O	3730
both	PRON	O	O	3730
groups	NOUN	O	O	3730
,	PUNCT	O	O	3730
in	ADP	O	O	3730
the	PRON	O	O	3730
epileptic	ADJ	O	Disease	3730
group	NOUN	O	O	3730
,	PUNCT	O	O	3730
the	PRON	O	O	3730
decrease	VERB	O	O	3730
in	ADP	O	O	3730
VE	NOUN	O	O	3730
was	AUX	O	O	3730
due	ADJ	O	O	3730
to	PART	O	O	3730
a	PRON	O	O	3730
significant	ADJ	O	O	3730
(	PUNCT	O	O	3730
p	NOUN	O	O	3730
<	X	O	O	3730
0.05	NUM	O	O	3730
)	PUNCT	O	O	3730
increase	VERB	O	O	3730
in	ADP	O	O	3730
TE	PROPN	O	O	3730
peak	PROPN	O	O	3730
in	ADP	O	O	3730
relation	NOUN	O	O	3730
to	PART	O	O	3730
that	SCONJ	O	O	3730
of	ADP	O	O	3730
the	PRON	O	O	3730
control	VERB	O	O	3730
animals	NOUN	O	O	3730
.	PUNCT	O	O	3730
In	ADP	O	O	3731
the	PRON	O	O	3731
epileptic	ADJ	O	Disease	3731
group	NOUN	O	O	3731
,	PUNCT	O	O	3731
the	PRON	O	O	3731
increase	VERB	O	O	3731
in	ADP	O	O	3731
VE	NOUN	O	O	3731
was	AUX	O	O	3731
mediated	VERB	O	O	3731
by	ADP	O	O	3731
a	PRON	O	O	3731
significant	ADJ	O	O	3731
(	PUNCT	O	O	3731
p	NOUN	O	O	3731
<	X	O	O	3731
0.05	NUM	O	O	3731
)	PUNCT	O	O	3731
decrease	VERB	O	O	3731
in	ADP	O	O	3731
TE	PROPN	O	O	3731
peak	PROPN	O	O	3731
compared	VERB	O	O	3731
with	ADP	O	O	3731
the	PRON	O	O	3731
control	VERB	O	O	3731
group	NOUN	O	O	3731
.	PUNCT	O	O	3731
CONCLUSIONS	NOUN	O	O	3732
:	PUNCT	O	O	3732
The	PRON	O	O	3732
data	NOUN	O	O	3732
indicate	VERB	O	O	3732
that	SCONJ	O	O	3732
pilocarpine	NOUN	O	Chemical	3732
-	PUNCT	O	O	3732
treated	VERB	O	O	3732
animals	NOUN	O	O	3732
have	VERB	O	O	3732
an	PRON	O	O	3732
altered	VERB	O	O	3732
ability	NOUN	O	O	3732
to	PART	O	O	3732
react	VERB	O	O	3732
to	PART	O	O	3732
(	PUNCT	O	O	3732
or	CCONJ	O	O	3732
compensate	VERB	O	O	3732
for	ADP	O	O	3732
)	PUNCT	O	O	3732
blood	NOUN	O	O	3732
gas	NOUN	O	O	3732
changes	VERB	O	O	3732
with	ADP	O	O	3732
changes	VERB	O	O	3732
in	ADP	O	O	3732
ventilation	NOUN	O	O	3732
and	CCONJ	O	O	3732
suggest	VERB	O	O	3732
that	SCONJ	O	O	3732
it	PRON	O	O	3732
is	AUX	O	O	3732
centrally	ADV	O	O	3732
determined	VERB	O	O	3732
.	PUNCT	O	O	3732
We	PRON	O	O	3733
speculate	VERB	O	O	3733
on	ADP	O	O	3733
the	PRON	O	O	3733
possible	ADJ	O	O	3733
relation	NOUN	O	O	3733
of	ADP	O	O	3733
the	PRON	O	O	3733
current	ADJ	O	O	3733
findings	NOUN	O	O	3733
on	ADP	O	O	3733
treating	VERB	O	O	3733
different	ADJ	O	O	3733
epilepsy	NOUN	O	Disease	3733
-	PUNCT	O	O	3733
associated	VERB	O	O	3733
conditions	NOUN	O	O	3733
.	PUNCT	O	O	3733
Increased	VERB	O	O	3736
serum	NOUN	O	O	3736
soluble	ADJ	O	O	3736
Fas	PROPN	O	O	3736
in	ADP	O	O	3736
patients	NOUN	O	O	3736
with	ADP	O	O	3736
acute liver failure	NOUN	O	Disease	3736
due	ADJ	O	O	3736
to	PART	O	O	3736
paracetamol	PROPN	O	Chemical	3736
overdose	NOUN	O	Disease	3736
.	PUNCT	O	O	3736
Experimental	ADJ	O	O	3737
studies	NOUN	O	O	3737
have	VERB	O	O	3737
suggested	VERB	O	O	3737
that	SCONJ	O	O	3737
apoptosis	NOUN	O	O	3737
via	ADP	O	O	3737
the	PRON	O	O	3737
Fas	PROPN	O	O	3737
/	PUNCT	O	O	3737
Fas	PROPN	O	O	3737
Ligand	NOUN	O	O	3737
signaling	VERB	O	O	3737
system	NOUN	O	O	3737
may	AUX	O	O	3737
play	VERB	O	O	3737
an	PRON	O	O	3737
important	ADJ	O	O	3737
role	NOUN	O	O	3737
in	ADP	O	O	3737
the	PRON	O	O	3737
development	NOUN	O	O	3737
of	ADP	O	O	3737
acute liver failure	NOUN	O	Disease	3737
.	PUNCT	O	O	3737
The	PRON	O	O	3738
aim	VERB	O	O	3738
of	ADP	O	O	3738
the	PRON	O	O	3738
study	VERB	O	O	3738
was	AUX	O	O	3738
to	PART	O	O	3738
investigate	VERB	O	O	3738
the	PRON	O	O	3738
soluble	ADJ	O	O	3738
form	NOUN	O	O	3738
of	ADP	O	O	3738
Fas	PROPN	O	O	3738
in	ADP	O	O	3738
patients	NOUN	O	O	3738
with	ADP	O	O	3738
acute liver failure	NOUN	O	Disease	3738
.	PUNCT	O	O	3738
METHODOLOGY	NOUN	O	O	3739
:	PUNCT	O	O	3739
Serum	NOUN	O	O	3739
levels	NOUN	O	O	3739
of	ADP	O	O	3739
sFas	PROPN	O	O	3739
(	PUNCT	O	O	3739
soluble	ADJ	O	O	3739
Fas	PROPN	O	O	3739
)	PUNCT	O	O	3739
were	AUX	O	O	3739
measured	VERB	O	O	3739
by	ADP	O	O	3739
ELISA	PROPN	O	O	3739
in	ADP	O	O	3739
24	NUM	O	O	3739
patients	NOUN	O	O	3739
with	ADP	O	O	3739
acute liver failure	NOUN	O	Disease	3739
and	CCONJ	O	O	3739
10	NUM	O	O	3739
normal	ADJ	O	O	3739
control	VERB	O	O	3739
subjects	NOUN	O	O	3739
.	PUNCT	O	O	3739
Serum	NOUN	O	O	3740
levels	NOUN	O	O	3740
of	ADP	O	O	3740
tumor	NOUN	O	Disease	3740
necrosis	NOUN	O	Disease	3740
factor	NOUN	O	O	3740
-	PUNCT	O	O	3740
alpha	PROPN	O	O	3740
and	CCONJ	O	O	3740
interferon	PROPN	O	Chemical	3740
-	PUNCT	O	O	3740
gamma	PROPN	O	O	3740
were	AUX	O	O	3740
also	ADV	O	O	3740
determined	VERB	O	O	3740
by	ADP	O	O	3740
ELISA	PROPN	O	O	3740
.	PUNCT	O	O	3740
Serum	NOUN	O	O	3741
sFas	PROPN	O	O	3741
was	AUX	O	O	3741
significantly	ADV	O	O	3741
increased	VERB	O	O	3741
in	ADP	O	O	3741
patients	NOUN	O	O	3741
with	ADP	O	O	3741
acute liver failure	NOUN	O	Disease	3741
(	PUNCT	O	O	3741
median	ADJ	O	O	3741
,	PUNCT	O	O	3741
26.8	NUM	O	O	3741
U	NOUN	O	O	3741
/	PUNCT	O	O	3741
mL	PROPN	O	O	3741
;	PUNCT	O	O	3741
range	VERB	O	O	3741
,	PUNCT	O	O	3741
6.9	NUM	O	O	3741
-	PUNCT	O	O	3741
52.7	NUM	O	O	3741
U	NOUN	O	O	3741
/	PUNCT	O	O	3741
mL	PROPN	O	O	3741
)	PUNCT	O	O	3741
compared	VERB	O	O	3741
to	PART	O	O	3741
the	PRON	O	O	3741
normal	ADJ	O	O	3741
controls	VERB	O	O	3741
(	PUNCT	O	O	3741
median	ADJ	O	O	3741
,	PUNCT	O	O	3741
8.6	NUM	O	O	3741
U	NOUN	O	O	3741
/	PUNCT	O	O	3741
mL	PROPN	O	O	3741
;	PUNCT	O	O	3741
range	VERB	O	O	3741
,	PUNCT	O	O	3741
6.5	NUM	O	O	3741
-	PUNCT	O	O	3741
12.0	NUM	O	O	3741
U	NOUN	O	O	3741
/	PUNCT	O	O	3741
mL	PROPN	O	O	3741
,	PUNCT	O	O	3741
P	NOUN	O	Chemical	3741
<	X	O	O	3741
0.0001	NUM	O	O	3741
)	PUNCT	O	O	3741
.	PUNCT	O	O	3741
Levels	NOUN	O	O	3742
were	AUX	O	O	3742
significantly	ADV	O	O	3742
greater	ADJ	O	O	3742
in	ADP	O	O	3742
patients	NOUN	O	O	3742
with	ADP	O	O	3742
acute liver failure	NOUN	O	Disease	3742
due	ADJ	O	O	3742
to	PART	O	O	3742
paracetamol	PROPN	O	Chemical	3742
overdose	NOUN	O	Disease	3742
(	PUNCT	O	O	3742
median	ADJ	O	O	3742
,	PUNCT	O	O	3742
28.7	NUM	O	O	3742
U	NOUN	O	O	3742
/	PUNCT	O	O	3742
mL	PROPN	O	O	3742
;	PUNCT	O	O	3742
range	VERB	O	O	3742
,	PUNCT	O	O	3742
12.8	NUM	O	O	3742
-	PUNCT	O	O	3742
52.7	NUM	O	O	3742
U	NOUN	O	O	3742
/	PUNCT	O	O	3742
mL	PROPN	O	O	3742
,	PUNCT	O	O	3742
n	CCONJ	O	O	3742
=	PUNCT	O	O	3742
17	NUM	O	O	3742
)	PUNCT	O	O	3742
than	ADP	O	O	3742
those	PRON	O	O	3742
due	ADJ	O	O	3742
to	PART	O	O	3742
non	ADJ	O	O	3742
-	PUNCT	O	O	3742
A	PRON	O	O	3742
to	PART	O	O	3742
E	NOUN	O	Chemical	3742
hepatitis	NOUN	O	Disease	3742
(	PUNCT	O	O	3742
median	ADJ	O	O	3742
,	PUNCT	O	O	3742
12.5	NUM	O	O	3742
U	NOUN	O	O	3742
/	PUNCT	O	O	3742
mL	PROPN	O	O	3742
;	PUNCT	O	O	3742
range	VERB	O	O	3742
,	PUNCT	O	O	3742
6.9	NUM	O	O	3742
-	PUNCT	O	O	3742
46.0	NUM	O	O	3742
U	NOUN	O	O	3742
/	PUNCT	O	O	3742
mL	PROPN	O	O	3742
,	PUNCT	O	O	3742
A	PRON	O	O	3743
significant	ADJ	O	O	3743
correlation	NOUN	O	O	3743
was	AUX	O	O	3743
observed	VERB	O	O	3743
between	ADP	O	O	3743
serum	NOUN	O	O	3743
sFas	PROPN	O	O	3743
levels	NOUN	O	O	3743
and	CCONJ	O	O	3743
aspartate	NOUN	O	Chemical	3743
aminotransferase	PROPN	O	O	3743
(	PUNCT	O	O	3743
r	X	O	O	3743
=	PUNCT	O	O	3743
0.613	NUM	O	O	3743
,	PUNCT	O	O	3743
P	NOUN	O	Chemical	3743
<	X	O	O	3743
0.01	NUM	O	O	3743
)	PUNCT	O	O	3743
.	PUNCT	O	O	3743
The	PRON	O	O	3744
increased	VERB	O	O	3744
concentration	NOUN	O	O	3744
of	ADP	O	O	3744
sFas	PROPN	O	O	3744
in	ADP	O	O	3744
serum	NOUN	O	O	3744
of	ADP	O	O	3744
patients	NOUN	O	O	3744
with	ADP	O	O	3744
acute liver failure	NOUN	O	Disease	3744
may	AUX	O	O	3744
reflect	VERB	O	O	3744
activation	NOUN	O	O	3744
of	ADP	O	O	3744
Fas	PROPN	O	O	3744
-	PUNCT	O	O	3744
mediated	VERB	O	O	3744
apoptosis	NOUN	O	O	3744
in	ADP	O	O	3744
the	PRON	O	O	3744
liver	NOUN	O	O	3744
and	CCONJ	O	O	3744
this	PRON	O	O	3744
together	ADV	O	O	3744
with	ADP	O	O	3744
increased	VERB	O	O	3744
tumor	NOUN	O	Disease	3744
necrosis	NOUN	O	Disease	3744
factor	NOUN	O	O	3744
-	PUNCT	O	O	3744
alpha	PROPN	O	O	3744
may	AUX	O	O	3744
be	AUX	O	O	3744
an	PRON	O	O	3744
important	ADJ	O	O	3744
factor	NOUN	O	O	3744
in	ADP	O	O	3744
liver	NOUN	O	O	3744
cell	NOUN	O	O	3744
loss	NOUN	O	O	3744
.	PUNCT	O	O	3744
Bilateral	ADJ	O	O	3747
subthalamic	ADJ	O	O	3747
nucleus	PROPN	O	O	3747
stimulation	NOUN	O	O	3747
for	ADP	O	O	3747
Parkinson	NOUN	O	O	3747
's	AUX	O	O	3747
disease	PROPN	O	O	3747
.	PUNCT	O	O	3747
High	ADJ	O	O	3748
frequency	NOUN	O	O	3748
stimulation	NOUN	O	O	3748
of	ADP	O	O	3748
the	PRON	O	O	3748
subthalamic	ADJ	O	O	3748
nucleus	PROPN	O	O	3748
(	PUNCT	O	O	3748
STN	PROPN	O	O	3748
)	PUNCT	O	O	3748
is	AUX	O	O	3748
known	VERB	O	O	3748
to	PART	O	O	3748
ameliorate	VERB	O	O	3748
the	PRON	O	O	3748
signs	NOUN	O	O	3748
and	CCONJ	O	O	3748
symptoms	NOUN	O	O	3748
of	ADP	O	O	3748
advanced	ADJ	O	O	3748
Parkinson	NOUN	O	O	3748
's	AUX	O	O	3748
disease	PROPN	O	O	3748
.	PUNCT	O	O	3748
METHOD	NOUN	O	O	3749
:	PUNCT	O	O	3749
Twenty	NUM	O	O	3749
-	PUNCT	O	O	3749
three	NUM	O	O	3749
patients	NOUN	O	O	3749
suffering	VERB	O	O	3749
from	ADP	O	O	3749
severe	ADJ	O	O	3749
Parkinson	NOUN	O	O	3749
's	AUX	O	O	3749
disease	PROPN	O	O	3749
(	PUNCT	O	O	3750
Stages	NOUN	O	O	3750
III	NUM	O	O	3750
-	PUNCT	O	O	3750
V	NOUN	O	O	3750
on	ADP	O	O	3750
Hoehn	PROPN	O	O	3750
and	CCONJ	O	O	3750
Yahr	NOUN	O	O	3750
scale	NOUN	O	O	3750
)	PUNCT	O	O	3750
and	CCONJ	O	O	3750
,	PUNCT	O	O	3750
particularly	ADV	O	O	3750
bradykinesia	NOUN	O	Disease	3750
,	PUNCT	O	O	3750
rigidity	NOUN	O	Disease	3750
,	PUNCT	O	O	3750
and	CCONJ	O	O	3750
levodopa	NOUN	O	Chemical	3750
-	PUNCT	O	O	3750
induced	VERB	O	O	3750
dyskinesias	PROPN	O	Disease	3750
underwent	VERB	O	O	3750
bilateral	ADJ	O	O	3750
implantation	NOUN	O	O	3750
of	ADP	O	O	3750
electrodes	NOUN	O	O	3750
in	ADP	O	O	3750
the	PRON	O	O	3750
STN	PROPN	O	O	3750
.	PUNCT	O	O	3750
Preoperative	PROPN	O	O	3751
and	CCONJ	O	O	3751
postoperative	ADJ	O	O	3751
assessments	NOUN	O	O	3751
of	ADP	O	O	3751
these	PRON	O	O	3751
patients	NOUN	O	O	3751
at	ADP	O	O	3751
1	X	O	O	3751
,	PUNCT	O	O	3751
3	X	O	O	3751
,	PUNCT	O	O	3751
6	NUM	O	O	3751
and	CCONJ	O	O	3751
12	NUM	O	O	3751
months	NOUN	O	O	3751
follow	VERB	O	O	3751
-	PUNCT	O	O	3751
up	ADP	O	O	3751
,	PUNCT	O	O	3751
in	ADP	O	O	3751
""""	PUNCT	O	O	3751
on	ADP	O	O	3751
""""	PUNCT	O	O	3751
and	CCONJ	O	O	3751
""""	PUNCT	O	O	3751
off	ADP	O	O	3751
""""	PUNCT	O	O	3751
drug	NOUN	O	O	3751
conditions	NOUN	O	O	3751
,	PUNCT	O	O	3751
was	AUX	O	O	3751
carried	VERB	O	O	3751
out	ADP	O	O	3751
using	VERB	O	O	3751
Unified	VERB	O	O	3751
Parkinson	NOUN	O	O	3751
's	AUX	O	O	3751
Disease	NOUN	O	O	3751
Rating	NOUN	O	O	3751
Scale	NOUN	O	O	3751
,	PUNCT	O	O	3751
Hoehn	PROPN	O	O	3751
and	CCONJ	O	O	3751
Yahr	NOUN	O	O	3751
staging	NOUN	O	O	3751
,	PUNCT	O	O	3751
England	PROPN	O	O	3751
activities	NOUN	O	O	3751
of	ADP	O	O	3751
daily	ADV	O	O	3751
living	VERB	O	O	3751
score	VERB	O	O	3751
and	CCONJ	O	O	3751
video	NOUN	O	O	3751
recordings	NOUN	O	O	3751
.	PUNCT	O	O	3751
(	PUNCT	O	O	3752
Unified	VERB	O	O	3752
Parkinson	NOUN	O	O	3752
's	AUX	O	O	3752
Disease	NOUN	O	O	3752
Rating	NOUN	O	O	3752
Scale	NOUN	O	O	3752
parts	NOUN	O	O	3752
II	NUM	O	O	3752
and	CCONJ	O	O	3752
III	NUM	O	O	3752
)	PUNCT	O	O	3752
off	ADP	O	O	3752
medication	NOUN	O	O	3752
improved	VERB	O	O	3752
by	ADP	O	O	3752
62%	NOUN	O	O	3752
and	CCONJ	O	O	3752
61%	NOUN	O	O	3752
respectively	ADV	O	O	3752
(	PUNCT	O	O	3752
p<0.0005	VERB	O	O	3752
)	PUNCT	O	O	3752
.	PUNCT	O	O	3752
The	PRON	O	O	3753
subscores	NOUN	O	O	3753
for	ADP	O	O	3753
the	PRON	O	O	3753
akinesia	NOUN	O	Disease	3753
,	PUNCT	O	O	3753
rigidity	NOUN	O	Disease	3753
,	PUNCT	O	O	3753
tremor	NOUN	O	Disease	3753
and	CCONJ	O	O	3753
gait	VERB	O	O	3753
also	ADV	O	O	3753
improved	VERB	O	O	3753
.	PUNCT	O	O	3753
The	PRON	O	O	3754
average	ADJ	O	O	3754
levodopa	NOUN	O	Chemical	3754
dose	NOUN	O	O	3754
decreased	VERB	O	O	3754
from	ADP	O	O	3754
813	NUM	O	O	3754
mg	VERB	O	O	3754
to	PART	O	O	3754
359	NUM	O	O	3754
mg	VERB	O	O	3754
.	PUNCT	O	O	3754
Bilateral	ADJ	O	O	3755
subthalamic	ADJ	O	O	3755
nucleus	PROPN	O	O	3755
stimulation	NOUN	O	O	3755
is	AUX	O	O	3755
an	PRON	O	O	3755
effective	ADJ	O	O	3755
treatment	NOUN	O	O	3755
for	ADP	O	O	3755
advanced	ADJ	O	O	3755
Parkinson	NOUN	O	O	3755
's	AUX	O	O	3755
disease	PROPN	O	O	3755
.	PUNCT	O	O	3755
It	PRON	O	O	3756
reduces	VERB	O	O	3756
the	PRON	O	O	3756
severity	NOUN	O	O	3756
of	ADP	O	O	3756
""""	PUNCT	O	O	3756
off	ADP	O	O	3756
""""	PUNCT	O	O	3756
phase	NOUN	O	O	3756
symptoms	NOUN	O	O	3756
,	PUNCT	O	O	3756
improves	VERB	O	O	3756
the	PRON	O	O	3756
axial	ADJ	O	O	3756
symptoms	NOUN	O	O	3756
and	CCONJ	O	O	3756
reduces	VERB	O	O	3756
levodopa	NOUN	O	Chemical	3756
requirements	NOUN	O	O	3756
.	PUNCT	O	O	3756
The	PRON	O	O	3757
reduction	NOUN	O	O	3757
in	ADP	O	O	3757
the	PRON	O	O	3757
levodopa	NOUN	O	Chemical	3757
dose	NOUN	O	O	3757
is	AUX	O	O	3757
useful	ADJ	O	O	3757
in	ADP	O	O	3757
controlling	VERB	O	O	3757
drug	NOUN	O	O	3757
-	PUNCT	O	O	3757
induced	VERB	O	O	3757
dyskinesias	PROPN	O	Disease	3757
.	PUNCT	O	O	3757
Ocular	ADJ	O	O	3760
motility	NOUN	O	O	3760
changes	VERB	O	O	3760
after	ADP	O	O	3760
subtenon	PROPN	O	O	3760
carboplatin	PROPN	O	Chemical	3760
chemotherapy	NOUN	O	O	3760
for	ADP	O	O	3760
retinoblastoma	NOUN	O	O	3760
.	PUNCT	O	O	3760
Focal	ADJ	O	O	3761
subtenon	PROPN	O	O	3761
carboplatin	PROPN	O	Chemical	3761
injections	NOUN	O	O	3761
have	VERB	O	O	3761
recently	ADV	O	O	3761
been	AUX	O	O	3761
used	VERB	O	O	3761
as	ADP	O	O	3761
a	PRON	O	O	3761
presumably	ADV	O	O	3761
toxicity	NOUN	O	Disease	3761
-	PUNCT	O	O	3761
free	ADJ	O	O	3761
adjunct	NOUN	O	O	3761
to	PART	O	O	3761
systemic	ADJ	O	O	3761
chemotherapy	NOUN	O	O	3761
for	ADP	O	O	3761
intraocular	ADJ	O	O	3761
retinoblastoma	NOUN	O	O	3761
.	PUNCT	O	O	3761
OBJECTIVE	VERB	O	O	3762
:	PUNCT	O	O	3762
To	PART	O	O	3762
report	VERB	O	O	3762
our	PRON	O	O	3762
clinical	ADJ	O	O	3762
experience	NOUN	O	O	3762
with	ADP	O	O	3762
abnormal	ADJ	O	O	3762
ocular	ADJ	O	O	3762
motility	NOUN	O	O	3762
in	ADP	O	O	3762
patients	NOUN	O	O	3762
treated	VERB	O	O	3762
with	ADP	O	O	3762
subtenon	PROPN	O	O	3762
carboplatin	PROPN	O	Chemical	3762
chemotherapy	NOUN	O	O	3762
.	PUNCT	O	O	3762
:	PUNCT	O	O	3763
We	PRON	O	O	3763
noted	VERB	O	O	3763
abnormal	ADJ	O	O	3763
ocular	ADJ	O	O	3763
motility	NOUN	O	O	3763
in	ADP	O	O	3763
10	NUM	O	O	3763
consecutive	ADJ	O	O	3763
patients	NOUN	O	O	3763
with	ADP	O	O	3763
retinoblastoma	NOUN	O	O	3763
who	PRON	O	O	3763
had	VERB	O	O	3763
received	VERB	O	O	3763
subtenon	PROPN	O	O	3763
carboplatin	PROPN	O	Chemical	3763
.	PUNCT	O	O	3763
During	ADP	O	O	3764
ocular	ADJ	O	O	3764
manipulation	NOUN	O	O	3764
under	ADP	O	O	3764
general	ADJ	O	O	3764
anesthesia	NOUN	O	O	3764
,	PUNCT	O	O	3764
we	PRON	O	O	3764
assessed	VERB	O	O	3764
their	PRON	O	O	3764
eyes	NOUN	O	O	3764
by	ADP	O	O	3764
forced	VERB	O	O	3764
duction	NOUN	O	O	3764
testing	NOUN	O	O	3764
,	PUNCT	O	O	3764
comparing	VERB	O	O	3764
ocular	ADJ	O	O	3764
motility	NOUN	O	O	3764
after	ADP	O	O	3764
tumor	NOUN	O	Disease	3764
control	VERB	O	O	3764
with	ADP	O	O	3764
ocular	ADJ	O	O	3764
motility	NOUN	O	O	3764
at	ADP	O	O	3764
diagnosis	NOUN	O	O	3764
.	PUNCT	O	O	3764
Limitation	NOUN	O	O	3765
of	ADP	O	O	3765
ocular	ADJ	O	O	3765
motility	NOUN	O	O	3765
was	AUX	O	O	3765
detected	VERB	O	O	3765
in	ADP	O	O	3765
all	PRON	O	O	3765
12	NUM	O	O	3765
eyes	NOUN	O	O	3765
of	ADP	O	O	3765
10	NUM	O	O	3765
patients	NOUN	O	O	3765
treated	VERB	O	O	3765
for	ADP	O	O	3765
intraocular	ADJ	O	O	3765
retinoblastoma	NOUN	O	O	3765
with	ADP	O	O	3765
1	X	O	O	3765
to	PART	O	O	3765
6	NUM	O	O	3765
injections	NOUN	O	O	3765
of	ADP	O	O	3765
subtenon	PROPN	O	O	3765
carboplatin	PROPN	O	Chemical	3765
as	ADP	O	O	3765
part	NOUN	O	O	3765
of	ADP	O	O	3765
multimodality	NOUN	O	O	3765
therapy	NOUN	O	O	3765
.	PUNCT	O	O	3765
Histopathological	PROPN	O	O	3766
examination	NOUN	O	O	3766
revealed	VERB	O	O	3766
many	ADJ	O	O	3766
lipophages	VERB	O	O	3766
in	ADP	O	O	3766
the	PRON	O	O	3766
periorbital	ADJ	O	O	3766
fat	ADJ	O	Chemical	3766
surrounding	VERB	O	O	3766
the	PRON	O	O	3766
optic	NOUN	O	O	3766
nerve	NOUN	O	O	3766
in	ADP	O	O	3766
1	X	O	O	3766
eye	NOUN	O	O	3766
,	PUNCT	O	O	3766
indicative	ADJ	O	O	3766
of	ADP	O	O	3766
phagocytosis	NOUN	O	O	3766
of	ADP	O	O	3766
previously	ADV	O	O	3766
existing	VERB	O	O	3766
fat	ADJ	O	Chemical	3766
cells	NOUN	O	O	3766
and	CCONJ	O	O	3766
suggesting	VERB	O	O	3766
prior	ADV	O	O	3766
fat	ADJ	O	Chemical	3766
necrosis	NOUN	O	Disease	3766
.	PUNCT	O	O	3766
The	PRON	O	O	3767
enucleations	NOUN	O	O	3767
were	AUX	O	O	3767
technically	ADV	O	O	3767
difficult	ADJ	O	O	3767
and	CCONJ	O	O	3767
hazardous	ADJ	O	O	3767
for	ADP	O	O	3767
globe	NOUN	O	O	3767
rupture	NOUN	O	Disease	3767
because	SCONJ	O	O	3767
of	ADP	O	O	3767
extensive	ADJ	O	O	3767
orbital	ADJ	O	O	3767
soft	ADJ	O	O	3767
tissue	NOUN	O	O	3767
adhesions	NOUN	O	O	3767
.	PUNCT	O	O	3767
Subtenon	PROPN	O	O	3768
carboplatin	PROPN	O	Chemical	3768
chemotherapy	NOUN	O	O	3768
is	AUX	O	O	3768
associated	VERB	O	O	3768
with	ADP	O	O	3768
significant	ADJ	O	O	3768
fibrosis	NOUN	O	Disease	3768
of	ADP	O	O	3768
orbital	ADJ	O	O	3768
soft	ADJ	O	O	3768
tissues	NOUN	O	O	3768
,	PUNCT	O	O	3768
leading	VERB	O	O	3768
to	PART	O	O	3768
mechanical	ADJ	O	O	3768
restriction	NOUN	O	O	3768
of	ADP	O	O	3768
eye	NOUN	O	O	3768
movements	NOUN	O	O	3768
and	CCONJ	O	O	3768
making	VERB	O	O	3768
subsequent	ADJ	O	O	3768
enucleation	NOUN	O	O	3768
difficult	ADJ	O	O	3768
.	PUNCT	O	O	3768
Subtenon	PROPN	O	O	3769
carboplatin	PROPN	O	Chemical	3769
is	AUX	O	O	3769
not	PART	O	O	3769
free	ADJ	O	O	3769
of	ADP	O	O	3769
toxicity	NOUN	O	Disease	3769
,	PUNCT	O	O	3769
and	CCONJ	O	O	3769
its	PRON	O	O	3769
use	VERB	O	O	3769
is	AUX	O	O	3769
best	ADV	O	O	3769
restricted	VERB	O	O	3769
to	PART	O	O	3769
specific	ADJ	O	O	3769
indications	NOUN	O	O	3769
.	PUNCT	O	O	3769
Ethambutol	PROPN	O	Chemical	3772
and	CCONJ	O	O	3772
optic neuropathy	NOUN	O	Disease	3772
.	PUNCT	O	O	3772
PURPOSE	NOUN	O	O	3773
:	PUNCT	O	O	3773
To	PART	O	O	3773
demonstrate	VERB	O	O	3773
the	PRON	O	O	3773
association	PROPN	O	O	3773
between	ADP	O	O	3773
ethambutol	PROPN	O	Chemical	3773
and	CCONJ	O	O	3773
optic neuropathy	NOUN	O	Disease	3773
.	PUNCT	O	O	3773
METHOD	NOUN	O	O	3774
:	PUNCT	O	O	3774
Thirteen	NUM	O	O	3774
patients	NOUN	O	O	3774
who	PRON	O	O	3774
developed	VERB	O	O	3774
optic neuropathy	NOUN	O	Disease	3774
after	ADP	O	O	3774
being	AUX	O	O	3774
treated	VERB	O	O	3774
with	ADP	O	O	3774
ethambutol	PROPN	O	Chemical	3774
for	ADP	O	O	3774
tuberculosis	NOUN	O	Disease	3774
of	ADP	O	O	3774
the	PRON	O	O	3774
lung	NOUN	O	O	3774
or	CCONJ	O	O	3774
lymph	NOUN	O	O	3774
node	NOUN	O	O	3774
at	ADP	O	O	3774
Siriraj	NOUN	O	O	3774
Hospital	NOUN	O	O	3774
between	ADP	O	O	3774
1997	NUM	O	O	3774
and	CCONJ	O	O	3774
2001	NUM	O	O	3774
were	AUX	O	O	3774
retrospectively	ADV	O	O	3774
reviewed	VERB	O	O	3774
.	PUNCT	O	O	3774
RESULTS	VERB	O	O	3775
:	PUNCT	O	O	3775
All	PRON	O	O	3775
patients	NOUN	O	O	3775
had	VERB	O	O	3775
optic neuropathy	NOUN	O	Disease	3775
between	ADP	O	O	3775
1	X	O	O	3775
to	PART	O	O	3775
6	NUM	O	O	3775
months	NOUN	O	O	3775
(	PUNCT	O	O	3775
mean	VERB	O	O	3775
=	PUNCT	O	O	3775
2.9	NUM	O	O	3775
months	NOUN	O	O	3775
)	PUNCT	O	O	3775
after	ADP	O	O	3775
starting	VERB	O	O	3775
ethambutol	PROPN	O	Chemical	3775
therapy	NOUN	O	O	3775
at	ADP	O	O	3775
a	PRON	O	O	3775
dosage	NOUN	O	O	3775
ranging	VERB	O	O	3775
from	ADP	O	O	3775
13	NUM	O	O	3775
to	PART	O	O	3775
20	NUM	O	O	3775
mg	VERB	O	O	3775
/	PUNCT	O	O	3775
kg	VERB	O	O	3775
/	PUNCT	O	O	3775
day	NOUN	O	O	3775
(	PUNCT	O	O	3775
mean	VERB	O	O	3775
=	PUNCT	O	O	3775
17	NUM	O	O	3775
mg	VERB	O	O	3775
/	PUNCT	O	O	3775
kg	VERB	O	O	3775
/	PUNCT	O	O	3775
day	NOUN	O	O	3775
)	PUNCT	O	O	3775
.	PUNCT	O	O	3775
Of	ADV	O	O	3776
6	NUM	O	O	3776
patients	NOUN	O	O	3776
with	ADP	O	O	3776
irreversible	ADJ	O	O	3776
visual	ADJ	O	O	3776
impairment	NOUN	O	O	3776
,	PUNCT	O	O	3776
4	NUM	O	O	3776
patients	NOUN	O	O	3776
had	VERB	O	O	3776
diabetes mellitus	ADJ	O	Disease	3776
,	PUNCT	O	O	3776
glaucoma	NOUN	O	Disease	3776
and	CCONJ	O	O	3776
a	PRON	O	O	3776
history	NOUN	O	O	3776
of	ADP	O	O	3776
heavy	ADJ	O	O	3776
smoking	VERB	O	O	3776
.	PUNCT	O	O	3776
CONCLUSION	PROPN	O	O	3777
:	PUNCT	O	O	3777
Early	ADJ	O	O	3777
recognition	NOUN	O	O	3777
of	ADP	O	O	3777
optic neuropathy	NOUN	O	Disease	3777
should	AUX	O	O	3777
be	AUX	O	O	3777
considered	VERB	O	O	3777
in	ADP	O	O	3777
patients	NOUN	O	O	3777
with	ADP	O	O	3777
ethambutol	PROPN	O	Chemical	3777
therapy	NOUN	O	O	3777
.	PUNCT	O	O	3777
A	PRON	O	O	3778
low	ADJ	O	O	3778
dose	NOUN	O	O	3778
and	CCONJ	O	O	3778
prompt	PROPN	O	O	3778
discontinuation	NOUN	O	O	3778
of	ADP	O	O	3778
the	PRON	O	O	3778
drug	NOUN	O	O	3778
is	AUX	O	O	3778
recommended	VERB	O	O	3778
particularly	ADV	O	O	3778
in	ADP	O	O	3778
individuals	NOUN	O	O	3778
with	ADP	O	O	3778
diabetes mellitus	ADJ	O	Disease	3778
,	PUNCT	O	O	3778
glaucoma	NOUN	O	Disease	3778
or	CCONJ	O	O	3778
who	PRON	O	O	3778
are	AUX	O	O	3778
heavy	ADJ	O	O	3778
smokers	NOUN	O	O	3778
.	PUNCT	O	O	3778
Treatment	NOUN	O	O	3781
of	ADP	O	O	3781
compensatory	ADJ	O	O	3781
gustatory	NOUN	O	O	3781
hyperhidrosis	PROPN	O	O	3781
with	ADP	O	O	3781
topical	ADJ	O	O	3781
glycopyrrolate	VERB	O	Chemical	3781
.	PUNCT	O	O	3781
Gustatory	NOUN	O	O	3782
hyperhidrosis	PROPN	O	O	3782
is	AUX	O	O	3782
facial	ADJ	O	O	3782
sweating	VERB	O	O	3782
usually	ADV	O	O	3782
associated	VERB	O	O	3782
with	ADP	O	O	3782
the	PRON	O	O	3782
eating	VERB	O	O	3782
of	ADP	O	O	3782
hot	ADJ	O	O	3782
spicy	ADJ	O	O	3782
food	NOUN	O	O	3782
or	CCONJ	O	O	3782
even	ADV	O	O	3782
smelling	VERB	O	O	3782
this	PRON	O	O	3782
food	NOUN	O	O	3782
.	PUNCT	O	O	3782
Current	ADJ	O	O	3783
options	NOUN	O	O	3783
of	ADP	O	O	3783
treatment	NOUN	O	O	3783
include	VERB	O	O	3783
oral	ADJ	O	O	3783
anticholinergic	ADJ	O	O	3783
drugs	NOUN	O	O	3783
,	PUNCT	O	O	3783
the	PRON	O	O	3783
topical	ADJ	O	O	3783
application	NOUN	O	O	3783
of	ADP	O	O	3783
anticholinergics	NOUN	O	O	3783
or	CCONJ	O	O	3783
aluminum	NOUN	O	Chemical	3783
chloride	NOUN	O	Chemical	3783
,	PUNCT	O	O	3783
and	CCONJ	O	O	3783
the	PRON	O	O	3783
injection	NOUN	O	O	3783
of	ADP	O	O	3783
botulinum	NOUN	O	O	3783
toxin	NOUN	O	O	3783
.	PUNCT	O	O	3783
Thirteen	NUM	O	O	3784
patients	NOUN	O	O	3784
have	VERB	O	O	3784
been	AUX	O	O	3784
treated	VERB	O	O	3784
to	PART	O	O	3784
date	PROPN	O	O	3784
with	ADP	O	O	3784
1.5%	NOUN	O	O	3784
or	CCONJ	O	O	3784
2%	NOUN	O	O	3784
topical	ADJ	O	O	3784
glycopyrrolate	VERB	O	Chemical	3784
.	PUNCT	O	O	3784
All	PRON	O	O	3785
patients	NOUN	O	O	3785
had	VERB	O	O	3785
gustatory	NOUN	O	O	3785
hyperhidrosis	PROPN	O	O	3785
,	PUNCT	O	O	3785
which	PRON	O	O	3785
interfered	VERB	O	O	3785
with	ADP	O	O	3785
their	PRON	O	O	3785
social	ADJ	O	O	3785
activities	NOUN	O	O	3785
,	PUNCT	O	O	3785
after	ADP	O	O	3785
transthroacic	PROPN	O	O	3785
endoscopic	ADJ	O	O	3785
sympathectomy	NOUN	O	O	3785
,	PUNCT	O	O	3785
and	CCONJ	O	O	3785
which	PRON	O	O	3785
was	AUX	O	O	3785
associated	VERB	O	O	3785
with	ADP	O	O	3785
compensatory	ADJ	O	O	3785
focal	ADJ	O	O	3785
hyperhidrosis	PROPN	O	O	3785
.	PUNCT	O	O	3785
After	ADP	O	O	3786
applying	VERB	O	O	3786
topical	ADJ	O	O	3786
glycopyrrolate	VERB	O	Chemical	3786
,	PUNCT	O	O	3786
the	PRON	O	O	3786
subjective	ADJ	O	O	3786
effect	VERB	O	O	3786
was	AUX	O	O	3786
excellent	ADJ	O	O	3786
(	PUNCT	O	O	3786
no	PRON	O	O	3786
sweating	VERB	O	O	3786
after	ADP	O	O	3786
eating	VERB	O	O	3786
hot	ADJ	O	O	3786
spicy	ADJ	O	O	3786
food	NOUN	O	O	3786
)	PUNCT	O	O	3786
in	ADP	O	O	3786
10	NUM	O	O	3786
patients	NOUN	O	O	3786
(	PUNCT	O	O	3786
77%	NOUN	O	O	3786
)	PUNCT	O	O	3786
,	PUNCT	O	O	3786
and	CCONJ	O	O	3786
fair	ADJ	O	O	3786
(	PUNCT	O	O	3786
clearly	ADV	O	O	3786
reduced	VERB	O	O	3786
sweating	VERB	O	O	3786
)	PUNCT	O	O	3786
in	ADP	O	O	3786
3	X	O	O	3786
patients	NOUN	O	O	3786
(	PUNCT	O	O	3786
23%	NOUN	O	O	3786
)	PUNCT	O	O	3786
.	PUNCT	O	O	3786
Adverse	ADJ	O	O	3787
effects	NOUN	O	O	3787
included	VERB	O	O	3787
a	PRON	O	O	3787
mildly	ADV	O	O	3787
dry mouth	NOUN	O	Disease	3787
and	CCONJ	O	O	3787
a	PRON	O	O	3787
sore	ADJ	O	O	3787
throat	NOUN	O	O	3787
in	ADP	O	O	3787
2	X	O	O	3787
patients	NOUN	O	O	3787
(	PUNCT	O	O	3787
2%	NOUN	O	O	3787
glycopyrrolate	VERB	O	Chemical	3787
)	PUNCT	O	O	3787
,	PUNCT	O	O	3787
a	PRON	O	O	3787
light	ADJ	O	O	3787
headache	PROPN	O	Disease	3787
in	ADP	O	O	3787
1	X	O	O	3787
patient	NOUN	O	O	3787
(	PUNCT	O	O	3787
1.5%	NOUN	O	O	3787
glycopyrrolate	VERB	O	Chemical	3787
)	PUNCT	O	O	3787
.	PUNCT	O	O	3787
The	PRON	O	O	3788
topical	ADJ	O	O	3788
application	NOUN	O	O	3788
of	ADP	O	O	3788
a	PRON	O	O	3788
glycopyrrolate	VERB	O	Chemical	3788
pad	NOUN	O	O	3788
appeared	VERB	O	O	3788
to	PART	O	O	3788
be	AUX	O	O	3788
safe	ADJ	O	O	3788
,	PUNCT	O	O	3788
efficacious	ADJ	O	O	3788
,	PUNCT	O	O	3788
well	ADV	O	O	3788
tolerated	VERB	O	O	3788
,	PUNCT	O	O	3788
and	CCONJ	O	O	3788
a	PRON	O	O	3788
convenient	ADJ	O	O	3788
method	NOUN	O	O	3788
of	ADP	O	O	3788
treatment	NOUN	O	O	3788
for	ADP	O	O	3788
moderate	ADJ	O	O	3788
to	PART	O	O	3788
severe	ADJ	O	O	3788
symptoms	NOUN	O	O	3788
of	ADP	O	O	3788
gustatory	NOUN	O	O	3788
hyperhidrosis	PROPN	O	O	3788
in	ADP	O	O	3788
post	VERB	O	O	3788
transthoracic	PROPN	O	O	3788
endoscopic	ADJ	O	O	3788
sympathectomy	NOUN	O	O	3788
or	CCONJ	O	O	3788
sympathicotomy	VERB	O	O	3788
patients	NOUN	O	O	3788
,	PUNCT	O	O	3788
with	ADP	O	O	3788
few	ADJ	O	O	3788
side	NOUN	O	O	3788
effects	NOUN	O	O	3788
.	PUNCT	O	O	3788
Pharmacological	ADJ	O	O	3791
characteristics	NOUN	O	O	3791
and	CCONJ	O	O	3791
side	NOUN	O	O	3791
effects	NOUN	O	O	3791
of	ADP	O	O	3791
a	PRON	O	O	3791
new	ADJ	O	O	3791
galenic	VERB	O	O	3791
formulation	NOUN	O	O	3791
of	ADP	O	O	3791
propofol	VERB	O	Chemical	3791
without	ADP	O	O	3791
soyabean	PROPN	O	O	3791
oil	NOUN	O	O	3791
.	PUNCT	O	O	3791
We	PRON	O	O	3792
compared	VERB	O	O	3792
the	PRON	O	O	3792
pharmacokinetics	NOUN	O	O	3792
,	PUNCT	O	O	3792
pharmacodynamics	NOUN	O	O	3792
and	CCONJ	O	O	3792
safety	NOUN	O	O	3792
profile	NOUN	O	O	3792
of	ADP	O	O	3792
a	PRON	O	O	3792
new	ADJ	O	O	3792
galenic	VERB	O	O	3792
formulation	NOUN	O	O	3792
of	ADP	O	O	3792
propofol	VERB	O	Chemical	3792
(	PUNCT	O	O	3792
AM149	PROPN	O	O	3792
1%	NOUN	O	O	3792
)	PUNCT	O	O	3792
,	PUNCT	O	O	3792
which	PRON	O	O	3792
does	VERB	O	O	3792
not	PART	O	O	3792
contain	VERB	O	O	3792
soyabean	PROPN	O	O	3792
oil	NOUN	O	O	3792
,	PUNCT	O	O	3792
with	ADP	O	O	3792
a	PRON	O	O	3792
standard	PROPN	O	O	3792
formulation	NOUN	O	O	3792
of	ADP	O	O	3792
propofol	VERB	O	Chemical	3792
(	PUNCT	O	O	3792
Disoprivan	PROPN	O	O	3792
1%	NOUN	O	O	3792
)	PUNCT	O	O	3792
.	PUNCT	O	O	3792
In	ADP	O	O	3793
a	PRON	O	O	3793
randomised	VERB	O	O	3793
,	PUNCT	O	O	3793
double	ADJ	O	O	3793
-	PUNCT	O	O	3793
blind	ADJ	O	Disease	3793
,	PUNCT	O	O	3793
cross	VERB	O	O	3793
-	PUNCT	O	O	3793
over	ADP	O	O	3793
study	VERB	O	O	3793
,	PUNCT	O	O	3793
30	NUM	O	O	3793
healthy	ADJ	O	O	3793
volunteers	NOUN	O	O	3793
received	VERB	O	O	3793
a	PRON	O	O	3793
single	ADJ	O	O	3793
intravenous	ADJ	O	O	3793
bolus	NOUN	O	O	3793
injection	NOUN	O	O	3793
of	ADP	O	O	3793
2.5	NUM	O	O	3793
mg.kg-1	NOUN	O	O	3793
propofol	VERB	O	Chemical	3793
.	PUNCT	O	O	3793
Plasma	NOUN	O	O	3794
propofol	VERB	O	Chemical	3794
levels	NOUN	O	O	3794
were	AUX	O	O	3794
measured	VERB	O	O	3794
for	ADP	O	O	3794
48	NUM	O	O	3794
h	X	O	O	3794
following	VERB	O	O	3794
drug	NOUN	O	O	3794
administration	NOUN	O	O	3794
and	CCONJ	O	O	3794
evaluated	VERB	O	O	3794
according	VERB	O	O	3794
to	PART	O	O	3794
a	PRON	O	O	3794
three	NUM	O	O	3794
-	PUNCT	O	O	3794
compartment	NOUN	O	O	3794
model	NOUN	O	O	3794
.	PUNCT	O	O	3794
The	PRON	O	O	3795
pharmacodynamic	ADJ	O	O	3795
parameters	NOUN	O	O	3795
assessed	VERB	O	O	3795
included	VERB	O	O	3795
induction	NOUN	O	O	3795
and	CCONJ	O	O	3795
emergence	NOUN	O	O	3795
times	NOUN	O	O	3795
,	PUNCT	O	O	3795
respiratory	NOUN	O	O	3795
and	CCONJ	O	O	3795
cardiovascular	ADJ	O	O	3795
effects	NOUN	O	O	3795
,	PUNCT	O	O	3795
and	CCONJ	O	O	3795
pain	NOUN	O	Disease	3795
on	ADP	O	O	3795
injection	NOUN	O	O	3795
.	PUNCT	O	O	3795
Owing	VERB	O	O	3796
to	PART	O	O	3796
a	PRON	O	O	3796
high	ADJ	O	O	3796
incidence	NOUN	O	O	3796
of	ADP	O	O	3796
thrombophlebitis	NOUN	O	Disease	3796
,	PUNCT	O	O	3796
the	PRON	O	O	3796
study	VERB	O	O	3796
was	AUX	O	O	3796
terminated	VERB	O	O	3796
prematurely	ADV	O	O	3796
and	CCONJ	O	O	3796
only	ADV	O	O	3796
the	PRON	O	O	3796
data	NOUN	O	O	3796
of	ADP	O	O	3796
the	PRON	O	O	3796
two	NUM	O	O	3796
parallel	ADJ	O	O	3796
treatment	NOUN	O	O	3796
groups	NOUN	O	O	3796
(	PUNCT	O	O	3796
15	NUM	O	O	3796
patients	NOUN	O	O	3796
in	ADP	O	O	3796
each	PRON	O	O	3796
group	NOUN	O	O	3796
)	PUNCT	O	O	3796
were	AUX	O	O	3796
analysed	VERB	O	O	3796
.	PUNCT	O	O	3796
Pain	NOUN	O	Disease	3797
on	ADP	O	O	3797
injection	NOUN	O	O	3797
(	PUNCT	O	O	3797
80	NUM	O	O	3797
vs.	CCONJ	O	O	3797
20%	NOUN	O	O	3797
,	PUNCT	O	O	3797
p	NOUN	O	O	3797
<	X	O	O	3797
0.01	NUM	O	O	3797
)	PUNCT	O	O	3797
and	CCONJ	O	O	3797
thrombophlebitis	NOUN	O	Disease	3797
(	PUNCT	O	O	3797
93.3	NUM	O	O	3797
vs.	CCONJ	O	O	3797
6.6%	NOUN	O	O	3797
,	PUNCT	O	O	3797
p	NOUN	O	O	3797
<	X	O	O	3798
0.001	NUM	O	O	3798
)	PUNCT	O	O	3798
occurred	VERB	O	O	3798
more	ADJ	O	O	3798
frequently	ADV	O	O	3798
with	ADP	O	O	3798
AM149	PROPN	O	O	3798
than	ADP	O	O	3798
with	ADP	O	O	3798
Disoprivan	PROPN	O	O	3798
.	PUNCT	O	O	3798
Although	SCONJ	O	O	3799
both	PRON	O	O	3799
formulations	NOUN	O	O	3799
had	VERB	O	O	3799
similar	ADJ	O	O	3799
pharmacokinetic	VERB	O	O	3799
and	CCONJ	O	O	3799
pharmacodynamic	ADJ	O	O	3799
profiles	NOUN	O	O	3799
the	PRON	O	O	3799
new	ADJ	O	O	3799
formulation	NOUN	O	O	3799
is	AUX	O	O	3799
not	PART	O	O	3799
suitable	ADJ	O	O	3799
for	ADP	O	O	3799
clinical	ADJ	O	O	3799
use	VERB	O	O	3799
due	ADJ	O	O	3799
to	PART	O	O	3799
the	PRON	O	O	3799
high	ADJ	O	O	3799
incidence	NOUN	O	O	3799
of	ADP	O	O	3799
thrombophlebitis	NOUN	O	Disease	3799
produced	VERB	O	O	3799
.	PUNCT	O	O	3799
Vinorelbine	NOUN	O	O	3802
-	PUNCT	O	O	3802
related	ADJ	O	O	3802
cardiac	ADJ	O	O	3802
events	NOUN	O	O	3802
:	PUNCT	O	O	3802
a	PRON	O	O	3802
meta	PROPN	O	O	3802
-	PUNCT	O	O	3802
analysis	NOUN	O	O	3802
of	ADP	O	O	3802
randomized	VERB	O	O	3802
clinical	ADJ	O	O	3802
trials	NOUN	O	O	3802
.	PUNCT	O	O	3802
Several	ADJ	O	O	3803
cases	NOUN	O	O	3803
of	ADP	O	O	3803
cardiac	ADJ	O	O	3803
adverse	ADJ	O	O	3803
reactions	NOUN	O	O	3803
related	ADJ	O	O	3803
to	PART	O	O	3803
vinorelbine	VERB	O	O	3803
(	PUNCT	O	O	3803
VNR	PROPN	O	O	3803
)	PUNCT	O	O	3803
have	VERB	O	O	3803
been	AUX	O	O	3803
reported	VERB	O	O	3803
in	ADP	O	O	3803
the	PRON	O	O	3803
literature	NOUN	O	O	3803
.	PUNCT	O	O	3803
In	ADP	O	O	3804
order	NOUN	O	O	3804
to	PART	O	O	3804
quantify	VERB	O	O	3804
the	PRON	O	O	3804
incidence	NOUN	O	O	3804
of	ADP	O	O	3804
these	PRON	O	O	3804
cardiac	ADJ	O	O	3804
events	NOUN	O	O	3804
,	PUNCT	O	O	3804
we	PRON	O	O	3804
performed	VERB	O	O	3804
a	PRON	O	O	3804
meta	PROPN	O	O	3804
-	PUNCT	O	O	3804
analysis	NOUN	O	O	3804
of	ADP	O	O	3804
clinical	ADJ	O	O	3804
trials	NOUN	O	O	3804
comparing	VERB	O	O	3804
VNR	PROPN	O	O	3804
with	ADP	O	O	3804
other	ADJ	O	O	3804
chemotherapeutic	NOUN	O	O	3804
agents	NOUN	O	O	3804
in	ADP	O	O	3804
the	PRON	O	O	3804
treatment	NOUN	O	O	3804
of	ADP	O	O	3804
various	ADJ	O	O	3804
malignancies	NOUN	O	O	3804
.	PUNCT	O	O	3804
Randomized	VERB	O	O	3805
clinical	ADJ	O	O	3805
trials	NOUN	O	O	3805
comparing	VERB	O	O	3805
VNR	PROPN	O	O	3805
with	ADP	O	O	3805
other	ADJ	O	O	3805
drugs	NOUN	O	O	3805
in	ADP	O	O	3805
the	PRON	O	O	3805
treatment	NOUN	O	O	3805
of	ADP	O	O	3805
cancer	NOUN	O	Disease	3805
were	AUX	O	O	3805
searched	VERB	O	O	3805
in	ADP	O	O	3805
Medline	NOUN	O	O	3805
,	PUNCT	O	O	3805
Embase	NOUN	O	O	3805
,	PUNCT	O	O	3805
Evidence	NOUN	O	O	3805
-	PUNCT	O	O	3805
based	VERB	O	O	3805
Medicine	NOUN	O	O	3805
Reviews	NOUN	O	O	3805
databases	NOUN	O	O	3805
and	CCONJ	O	O	3805
the	PRON	O	O	3805
Cochrane	PROPN	O	O	3805
library	PROPN	O	O	3805
from	ADP	O	O	3805
1987	NUM	O	O	3805
to	PART	O	O	3805
2002	NUM	O	O	3805
.	PUNCT	O	O	3805
We	PRON	O	O	3806
found	VERB	O	O	3806
19	NUM	O	O	3806
trials	NOUN	O	O	3806
,	PUNCT	O	O	3806
involving	VERB	O	O	3806
2441	NUM	O	O	3806
patients	NOUN	O	O	3806
treated	VERB	O	O	3806
by	ADP	O	O	3806
VNR	PROPN	O	O	3806
and	CCONJ	O	O	3806
2050	NUM	O	O	3806
control	VERB	O	O	3806
patients	NOUN	O	O	3806
.	PUNCT	O	O	3806
The	PRON	O	O	3807
incidence	NOUN	O	O	3807
of	ADP	O	O	3807
cardiac	ADJ	O	O	3807
events	NOUN	O	O	3807
with	ADP	O	O	3807
VNR	PROPN	O	O	3807
was	AUX	O	O	3807
1.19%	NOUN	O	O	3807
[	X	O	O	3807
95%	NOUN	O	O	3807
confidence	NOUN	O	O	3807
interval	NOUN	O	O	3807
(	PUNCT	O	O	3807
CI	NOUN	O	O	3807
)	PUNCT	O	O	3807
(	PUNCT	O	O	3807
0.75	NUM	O	O	3807
;	PUNCT	O	O	3807
1.67	NUM	O	O	3807
)	PUNCT	O	O	3807
]	PUNCT	O	O	3807
.	PUNCT	O	O	3807
There	ADV	O	O	3808
was	AUX	O	O	3808
no	PRON	O	O	3808
difference	NOUN	O	O	3808
in	ADP	O	O	3808
the	PRON	O	O	3808
risk	NOUN	O	O	3808
of	ADP	O	O	3808
cardiac	ADJ	O	O	3808
events	NOUN	O	O	3808
between	ADP	O	O	3808
VNR	PROPN	O	O	3808
and	CCONJ	O	O	3808
other	ADJ	O	O	3808
drugs	NOUN	O	O	3808
[	X	O	O	3808
odds	NOUN	O	O	3808
ratio	NOUN	O	O	3808
:	PUNCT	O	O	3808
0.92	NUM	O	O	3808
,	PUNCT	O	O	3808
95%	NOUN	O	O	3808
CI	NOUN	O	O	3808
(	PUNCT	O	O	3808
0.54	NUM	O	O	3808
;	PUNCT	O	O	3808
1.55	NUM	O	O	3808
)	PUNCT	O	O	3808
]	PUNCT	O	O	3808
.	PUNCT	O	O	3808
The	PRON	O	O	3809
risk	NOUN	O	O	3809
of	ADP	O	O	3809
VNR	PROPN	O	O	3809
cardiac	ADJ	O	O	3809
events	NOUN	O	O	3809
was	AUX	O	O	3809
similar	ADJ	O	O	3809
to	PART	O	O	3809
vindesine	PROPN	O	O	3809
(	PUNCT	O	O	3809
VDS	NOUN	O	O	3809
)	PUNCT	O	O	3809
and	CCONJ	O	O	3809
other	ADJ	O	O	3809
cardiotoxic	ADJ	O	Disease	3809
drugs	NOUN	O	O	3809
[	X	O	O	3809
fluorouracil	NOUN	O	Chemical	3809
,	PUNCT	O	O	3809
anthracyclines	NOUN	O	Chemical	3809
,	PUNCT	O	O	3809
gemcitabine	NOUN	O	O	3809
(	PUNCT	O	O	3809
GEM	NOUN	O	O	3809
)	PUNCT	O	O	3809
em	PRON	O	O	3809
leader	NOUN	O	O	3809
]	PUNCT	O	O	3809
.	PUNCT	O	O	3809
Even	ADV	O	O	3810
if	SCONJ	O	O	3810
it	PRON	O	O	3810
did	VERB	O	O	3810
not	PART	O	O	3810
reach	VERB	O	O	3810
statistical	ADJ	O	O	3810
significance	NOUN	O	O	3810
because	SCONJ	O	O	3810
of	ADP	O	O	3810
a	PRON	O	O	3810
few	ADJ	O	O	3810
number	NOUN	O	O	3810
of	ADP	O	O	3810
cases	NOUN	O	O	3810
,	PUNCT	O	O	3810
the	PRON	O	O	3810
risk	NOUN	O	O	3810
was	AUX	O	O	3810
lower	ADJ	O	O	3810
in	ADP	O	O	3810
trials	NOUN	O	O	3810
excluding	VERB	O	O	3810
patients	NOUN	O	O	3810
with	ADP	O	O	3810
cardiac	ADJ	O	O	3810
history	NOUN	O	O	3810
,	PUNCT	O	O	3810
and	CCONJ	O	O	3810
seemed	VERB	O	O	3810
to	PART	O	O	3810
be	AUX	O	O	3810
higher	ADJ	O	O	3810
in	ADP	O	O	3810
trials	NOUN	O	O	3810
including	VERB	O	O	3810
patients	NOUN	O	O	3810
with	ADP	O	O	3810
pre	VERB	O	O	3810
-	PUNCT	O	O	3810
existing	VERB	O	O	3810
cardiac diseases	NOUN	O	O	3810
.	PUNCT	O	O	3810
Vinorelbine	NOUN	O	O	3811
-	PUNCT	O	O	3811
related	ADJ	O	O	3811
cardiac	ADJ	O	O	3811
events	NOUN	O	O	3811
concern	NOUN	O	O	3811
about	ADP	O	O	3811
1%	NOUN	O	O	3811
of	ADP	O	O	3811
treated	VERB	O	O	3811
patients	NOUN	O	O	3811
in	ADP	O	O	3811
clinical	ADJ	O	O	3811
trials	NOUN	O	O	3811
.	PUNCT	O	O	3811
However	ADV	O	O	3812
,	PUNCT	O	O	3812
the	PRON	O	O	3812
risk	NOUN	O	O	3812
associated	VERB	O	O	3812
with	ADP	O	O	3812
VNR	PROPN	O	O	3812
seems	VERB	O	O	3812
to	PART	O	O	3812
be	AUX	O	O	3812
similar	ADJ	O	O	3812
to	PART	O	O	3812
that	SCONJ	O	O	3812
of	ADP	O	O	3812
other	ADJ	O	O	3812
chemotherapeutic	NOUN	O	O	3812
agents	NOUN	O	O	3812
in	ADP	O	O	3812
the	PRON	O	O	3812
same	ADJ	O	O	3812
indications	NOUN	O	O	3812
.	PUNCT	O	O	3812
MRI	PROPN	O	O	3815
findings	NOUN	O	O	3815
of	ADP	O	O	3815
hypoxic	ADJ	O	Disease	3815
cortical	ADJ	O	O	3815
laminar	ADJ	O	O	3815
necrosis	NOUN	O	Disease	3815
in	ADP	O	O	3815
a	PRON	O	O	3815
child	NOUN	O	O	3815
with	ADP	O	O	3815
hemolytic anemia	NOUN	O	Disease	3815
crisis	NOUN	O	O	3815
.	PUNCT	O	O	3815
We	PRON	O	O	3816
present	NOUN	O	O	3816
magnetic	ADJ	O	O	3816
resonance	NOUN	O	O	3816
imaging	VERB	O	O	3816
findings	NOUN	O	O	3816
of	ADP	O	O	3816
a	PRON	O	O	3816
5-year	NOUN	O	O	3816
-	PUNCT	O	O	3816
old	ADJ	O	O	3816
girl	NOUN	O	O	3816
who	PRON	O	O	3816
had	VERB	O	O	3816
a	PRON	O	O	3816
rapidly	ADV	O	O	3816
installing	VERB	O	O	3816
hemolytic anemia	NOUN	O	Disease	3816
crisis	NOUN	O	O	3816
induced	VERB	O	O	3816
by	ADP	O	O	3816
trimethoprim	PROPN	O	O	3816
-	PUNCT	O	O	3816
sulfomethoxazole	PROPN	O	O	3816
,	PUNCT	O	O	3816
resulting	VERB	O	O	3816
in	ADP	O	O	3816
cerebral	ADJ	O	O	3816
anoxia	NOUN	O	O	3816
leading	VERB	O	O	3816
to	PART	O	O	3816
permanent	ADJ	O	O	3816
damage	NOUN	O	O	3816
.	PUNCT	O	O	3816
Magnetic	ADJ	O	O	3817
Resonance	NOUN	O	O	3817
imaging	VERB	O	O	3817
revealed	VERB	O	O	3817
cortical	ADJ	O	O	3817
laminar	ADJ	O	O	3817
necrosis	NOUN	O	Disease	3817
in	ADP	O	O	3817
arterial	ADJ	O	O	3817
border	NOUN	O	O	3817
zones	NOUN	O	O	3817
in	ADP	O	O	3817
both	PRON	O	O	3817
cerebral	ADJ	O	O	3817
hemispheres	NOUN	O	O	3817
,	PUNCT	O	O	3817
ischemic	VERB	O	Disease	3817
changes	VERB	O	O	3817
in	ADP	O	O	3817
subcortical	ADJ	O	O	3817
white	ADJ	O	O	3817
matter	VERB	O	O	3817
of	ADP	O	O	3817
left	VERB	O	O	3817
cerebral	ADJ	O	O	3817
hemisphere	ADV	O	O	3817
,	PUNCT	O	O	3817
and	CCONJ	O	O	3817
in	ADP	O	O	3817
the	PRON	O	O	3817
left	VERB	O	O	3817
putamen	NOUN	O	O	3817
.	PUNCT	O	O	3817
Although	SCONJ	O	O	3818
cortical	ADJ	O	O	3818
laminar	ADJ	O	O	3818
necrosis	NOUN	O	Disease	3818
is	AUX	O	O	3818
a	PRON	O	O	3818
classic	ADJ	O	O	3818
entity	NOUN	O	O	3818
in	ADP	O	O	3818
adulthood	NOUN	O	O	3818
related	ADJ	O	O	3818
to	PART	O	O	3818
conditions	NOUN	O	O	3818
of	ADP	O	O	3818
energy	PROPN	O	O	3818
depletions	NOUN	O	O	3818
,	PUNCT	O	O	3818
there	ADV	O	O	3818
are	AUX	O	O	3818
few	ADJ	O	O	3818
reports	VERB	O	O	3818
available	ADJ	O	O	3818
in	ADP	O	O	3818
children	NOUN	O	O	3818
.	PUNCT	O	O	3818
The	PRON	O	O	3821
natural	ADJ	O	O	3821
history	NOUN	O	O	3821
of	ADP	O	O	3821
Vigabatrin	PROPN	O	O	3821
associated	VERB	O	O	3821
visual	ADJ	O	O	3821
field	NOUN	O	O	3821
defects	NOUN	O	O	3821
in	ADP	O	O	3821
patients	NOUN	O	O	3821
electing	VERB	O	O	3821
to	PART	O	O	3821
continue	VERB	O	O	3821
their	PRON	O	O	3821
medication	NOUN	O	O	3821
.	PUNCT	O	O	3821
PURPOSE	NOUN	O	O	3822
:	PUNCT	O	O	3822
To	PART	O	O	3822
determine	VERB	O	O	3822
the	PRON	O	O	3822
natural	ADJ	O	O	3822
history	NOUN	O	O	3822
of	ADP	O	O	3822
visual	ADJ	O	O	3822
field	NOUN	O	O	3822
defects	NOUN	O	O	3822
in	ADP	O	O	3822
a	PRON	O	O	3822
group	NOUN	O	O	3822
of	ADP	O	O	3822
patients	NOUN	O	O	3822
known	VERB	O	O	3822
to	PART	O	O	3822
have	VERB	O	O	3822
Vigabatrin	PROPN	O	O	3822
-	PUNCT	O	O	3822
associated	VERB	O	O	3822
changes	VERB	O	O	3822
who	PRON	O	O	3822
elected	VERB	O	O	3822
to	PART	O	O	3822
continue	VERB	O	O	3822
the	PRON	O	O	3822
medication	NOUN	O	O	3822
because	SCONJ	O	O	3822
of	ADP	O	O	3822
good	ADJ	O	O	3822
seizure	NOUN	O	Disease	3822
control	VERB	O	O	3822
.	PUNCT	O	O	3822
All	PRON	O	O	3823
patients	NOUN	O	O	3823
taking	VERB	O	O	3823
Vigabatrin	PROPN	O	O	3823
alone	ADV	O	O	3823
or	CCONJ	O	O	3823
in	ADP	O	O	3823
combination	NOUN	O	O	3823
with	ADP	O	O	3823
other	ADJ	O	O	3823
antiepileptic	ADJ	O	O	3823
drugs	NOUN	O	O	3823
for	ADP	O	O	3823
at	ADP	O	O	3823
least	ADJ	O	O	3823
5	NUM	O	O	3823
years	NOUN	O	O	3823
(	PUNCT	O	O	3823
range	VERB	O	O	3823
5	NUM	O	O	3823
-	PUNCT	O	O	3823
12	NUM	O	O	3823
years	NOUN	O	O	3823
)	PUNCT	O	O	3823
were	AUX	O	O	3823
entered	VERB	O	O	3823
into	ADP	O	O	3823
a	PRON	O	O	3823
visual	ADJ	O	O	3823
surveillance	NOUN	O	O	3823
programme	NOUN	O	O	3823
.	PUNCT	O	O	3823
Following	VERB	O	O	3824
already	ADV	O	O	3824
published	VERB	O	O	3824
methodology	NOUN	O	O	3824
(	PUNCT	O	O	3824
Eye	NOUN	O	O	3824
2002	NUM	O	O	3824
;	PUNCT	O	O	3824
16;567	NUM	O	O	3824
-	PUNCT	O	O	3824
571	NUM	O	O	3824
)	PUNCT	O	O	3824
monocular	ADJ	O	O	3824
mean	VERB	O	O	3824
radial	ADJ	O	O	3824
degrees	NOUN	O	O	3824
(	PUNCT	O	O	3824
MRDs	NOUN	O	O	3824
)	PUNCT	O	O	3824
to	PART	O	O	3824
the	PRON	O	O	3824
I/4e	X	O	O	3824
isopter	VERB	O	O	3824
on	ADP	O	O	3824
Goldmann	PROPN	O	O	3824
perimetry	NOUN	O	O	3824
was	AUX	O	O	3824
calculated	VERB	O	O	3824
for	ADP	O	O	3824
the	PRON	O	O	3824
right	ADV	O	O	3824
eye	NOUN	O	O	3824
at	ADP	O	O	3824
the	PRON	O	O	3824
time	NOUN	O	O	3824
of	ADP	O	O	3824
discovery	NOUN	O	O	3824
of	ADP	O	O	3824
a	PRON	O	O	3824
visual	ADJ	O	O	3824
field	NOUN	O	O	3824
defect	NOUN	O	O	3824
and	CCONJ	O	O	3824
again	ADV	O	O	3824
after	ADP	O	O	3824
not	PART	O	O	3824
less	ADV	O	O	3824
than	ADP	O	O	3824
18	NUM	O	O	3824
months	NOUN	O	O	3824
follow	VERB	O	O	3824
-	PUNCT	O	O	3824
up	ADP	O	O	3824
.	PUNCT	O	O	3824
Only	ADV	O	O	3825
one	NUM	O	O	3825
patient	NOUN	O	O	3825
demonstrated	VERB	O	O	3825
a	PRON	O	O	3825
deterioration	NOUN	O	O	3825
in	ADP	O	O	3825
visual	ADJ	O	O	3825
field	NOUN	O	O	3825
during	ADP	O	O	3825
the	PRON	O	O	3825
study	VERB	O	O	3825
period	NOUN	O	O	3825
and	CCONJ	O	O	3825
discontinued	VERB	O	O	3825
treatment	NOUN	O	O	3825
.	PUNCT	O	O	3825
Established	VERB	O	O	3826
visual	ADJ	O	O	3826
field	NOUN	O	O	3826
defects	NOUN	O	O	3826
presumed	VERB	O	O	3826
to	PART	O	O	3826
be	AUX	O	O	3826
due	ADJ	O	O	3826
to	PART	O	O	3826
Vigabatrin	PROPN	O	O	3826
therapy	NOUN	O	O	3826
did	VERB	O	O	3826
not	PART	O	O	3826
usually	ADV	O	O	3826
progress	VERB	O	O	3826
in	ADP	O	O	3826
spite	NOUN	O	O	3826
of	ADP	O	O	3826
continuing	VERB	O	O	3826
use	VERB	O	O	3826
of	ADP	O	O	3826
the	PRON	O	O	3826
medication	NOUN	O	O	3826
.	PUNCT	O	O	3826
These	PRON	O	O	3827
data	NOUN	O	O	3827
give	VERB	O	O	3827
support	NOUN	O	O	3827
to	PART	O	O	3827
the	PRON	O	O	3827
hypothesis	NOUN	O	O	3827
that	SCONJ	O	O	3827
the	PRON	O	O	3827
pathogenesis	NOUN	O	O	3827
of	ADP	O	O	3827
Vigabatrin	PROPN	O	O	3827
-	PUNCT	O	O	3827
associated	VERB	O	O	3827
visual	ADJ	O	O	3827
field	NOUN	O	O	3827
defects	NOUN	O	O	3827
may	AUX	O	O	3827
be	AUX	O	O	3827
an	PRON	O	O	3827
idiosyncratic	ADJ	O	O	3827
adverse	ADJ	O	O	3827
drug	NOUN	O	O	3827
reaction	NOUN	O	O	3827
rather	ADV	O	O	3827
than	ADP	O	O	3827
dose	NOUN	O	O	3827
-	PUNCT	O	O	3827
dependent	ADJ	O	O	3827
toxicity	NOUN	O	Disease	3827
.	PUNCT	O	O	3827
Induction	NOUN	O	O	3830
of	ADP	O	O	3830
rosaceiform	NOUN	O	O	3830
dermatitis	NOUN	O	Disease	3830
during	ADP	O	O	3830
treatment	NOUN	O	O	3830
of	ADP	O	O	3830
facial	ADJ	O	O	3830
inflammatory	ADJ	O	O	3830
dermatoses	VERB	O	O	3830
with	ADP	O	O	3830
tacrolimus	NOUN	O	Chemical	3830
ointment	NOUN	O	O	3830
.	PUNCT	O	O	3830
Tacrolimus	PROPN	O	Chemical	3831
ointment	NOUN	O	O	3831
is	AUX	O	O	3831
increasingly	ADV	O	O	3831
used	VERB	O	O	3831
for	ADP	O	O	3831
anti	ADJ	O	O	3831
-	PUNCT	O	O	3831
inflammatory	ADJ	O	O	3831
treatment	NOUN	O	O	3831
of	ADP	O	O	3831
sensitive	ADJ	O	O	3831
areas	NOUN	O	O	3831
such	ADJ	O	O	3831
as	ADP	O	O	3831
the	PRON	O	O	3831
face	NOUN	O	O	3831
,	PUNCT	O	O	3831
and	CCONJ	O	O	3831
recent	ADJ	O	O	3831
observations	NOUN	O	O	3831
indicate	VERB	O	O	3831
that	SCONJ	O	O	3831
the	PRON	O	O	3831
treatment	NOUN	O	O	3831
is	AUX	O	O	3831
effective	ADJ	O	O	3831
in	ADP	O	O	3831
steroid	NOUN	O	Chemical	3831
-	PUNCT	O	O	3831
aggravated	VERB	O	O	3831
rosacea	PROPN	O	Disease	3831
and	CCONJ	O	O	3831
perioral	ADJ	O	O	3831
dermatitis	NOUN	O	Disease	3831
.	PUNCT	O	O	3831
We	PRON	O	O	3832
report	VERB	O	O	3832
on	ADP	O	O	3832
rosaceiform	NOUN	O	O	3832
dermatitis	NOUN	O	Disease	3832
as	ADP	O	O	3832
a	PRON	O	O	3832
complication	NOUN	O	O	3832
of	ADP	O	O	3832
treatment	NOUN	O	O	3832
with	ADP	O	O	3832
tacrolimus	NOUN	O	Chemical	3832
ointment	NOUN	O	O	3832
.	PUNCT	O	O	3832
Six	NUM	O	O	3833
adult	NOUN	O	O	3833
patients	NOUN	O	O	3833
with	ADP	O	O	3833
inflammatory	ADJ	O	O	3833
facial	ADJ	O	O	3833
dermatoses	VERB	O	O	3833
were	AUX	O	O	3833
treated	VERB	O	O	3833
with	ADP	O	O	3833
tacrolimus	NOUN	O	Chemical	3833
ointment	NOUN	O	O	3833
because	SCONJ	O	O	3833
of	ADP	O	O	3833
the	PRON	O	O	3833
ineffectiveness	VERB	O	O	3833
of	ADP	O	O	3833
standard	PROPN	O	O	3833
treatments	NOUN	O	O	3833
.	PUNCT	O	O	3833
Within	ADP	O	O	3834
2	X	O	O	3834
to	PART	O	O	3834
3	X	O	O	3834
weeks	NOUN	O	O	3834
of	ADP	O	O	3834
initially	ADV	O	O	3834
effective	ADJ	O	O	3834
and	CCONJ	O	O	3834
well	ADV	O	O	3834
-	PUNCT	O	O	3834
tolerated	VERB	O	O	3834
treatment	NOUN	O	O	3834
,	PUNCT	O	O	3834
3	X	O	O	3834
patients	NOUN	O	O	3834
with	ADP	O	O	3834
a	PRON	O	O	3834
history	NOUN	O	O	3834
of	ADP	O	O	3834
rosacea	PROPN	O	Disease	3834
and	CCONJ	O	O	3834
1	X	O	O	3834
with	ADP	O	O	3834
a	PRON	O	O	3834
history	NOUN	O	O	3834
of	ADP	O	O	3834
acne	NOUN	O	O	3834
experienced	ADJ	O	O	3834
sudden	ADJ	O	O	3834
worsening	VERB	O	O	3834
with	ADP	O	O	3834
pustular	ADJ	O	O	3834
rosaceiform	NOUN	O	O	3834
lesions	NOUN	O	O	3834
.	PUNCT	O	O	3834
In	ADP	O	O	3835
1	X	O	O	3835
patient	NOUN	O	O	3835
with	ADP	O	O	3835
eyelid	VERB	O	O	3835
eczema	NOUN	O	O	3835
,	PUNCT	O	O	3835
rosaceiform	NOUN	O	O	3835
periocular	ADJ	O	O	3835
dermatitis	NOUN	O	Disease	3835
gradually	ADV	O	O	3835
appeared	VERB	O	O	3835
after	ADP	O	O	3835
3	X	O	O	3835
weeks	NOUN	O	O	3835
of	ADP	O	O	3835
treatment	NOUN	O	O	3835
.	PUNCT	O	O	3835
In	ADP	O	O	3836
1	X	O	O	3836
patient	NOUN	O	O	3836
with	ADP	O	O	3836
atopic	NOUN	O	O	3836
dermatitis	NOUN	O	Disease	3836
,	PUNCT	O	O	3836
telangiectatic	ADJ	O	O	3836
and	CCONJ	O	O	3836
papular	ADJ	O	O	3836
rosacea	PROPN	O	Disease	3836
insidiously	ADV	O	O	3836
appeared	VERB	O	O	3836
after	ADP	O	O	3836
5	NUM	O	O	3836
months	NOUN	O	O	3836
of	ADP	O	O	3836
treatment	NOUN	O	O	3836
.	PUNCT	O	O	3836
Our	PRON	O	O	3837
observations	NOUN	O	O	3837
suggest	VERB	O	O	3837
that	SCONJ	O	O	3837
the	PRON	O	O	3837
spectrum	NOUN	O	O	3837
of	ADP	O	O	3837
rosaceiform	NOUN	O	O	3837
dermatitis	NOUN	O	Disease	3837
as	ADP	O	O	3837
a	PRON	O	O	3837
complication	NOUN	O	O	3837
of	ADP	O	O	3837
treatment	NOUN	O	O	3837
with	ADP	O	O	3837
tacrolimus	NOUN	O	Chemical	3837
ointment	NOUN	O	O	3837
is	AUX	O	O	3837
heterogeneous	ADJ	O	O	3837
.	PUNCT	O	O	3837
A	PRON	O	O	3838
variety	NOUN	O	O	3838
of	ADP	O	O	3838
factors	NOUN	O	O	3838
,	PUNCT	O	O	3838
such	ADJ	O	O	3838
as	ADP	O	O	3838
vasoactive	ADJ	O	O	3838
properties	NOUN	O	O	3838
of	ADP	O	O	3838
tacrolimus	NOUN	O	Chemical	3838
,	PUNCT	O	O	3838
proliferation	NOUN	O	O	3838
of	ADP	O	O	3838
Demodex	PROPN	O	O	3838
due	ADJ	O	O	3838
to	PART	O	O	3838
local	ADJ	O	O	3838
immunosuppression	NOUN	O	O	3838
,	PUNCT	O	O	3838
and	CCONJ	O	O	3838
the	PRON	O	O	3838
occlusive	ADJ	O	O	3838
properties	NOUN	O	O	3838
of	ADP	O	O	3838
the	PRON	O	O	3838
ointment	NOUN	O	O	3838
,	PUNCT	O	O	3838
may	AUX	O	O	3838
be	AUX	O	O	3838
involved	VERB	O	O	3838
in	ADP	O	O	3838
the	PRON	O	O	3838
observed	VERB	O	O	3838
phenomena	VERB	O	O	3838
.	PUNCT	O	O	3838
Structural	ADJ	O	O	3841
abnormalities	NOUN	O	O	3841
in	ADP	O	O	3841
the	PRON	O	O	3841
brains	NOUN	O	O	3841
of	ADP	O	O	3841
human	PROPN	O	O	3841
subjects	NOUN	O	O	3841
who	PRON	O	O	3841
use	VERB	O	O	3841
methamphetamine	NOUN	O	Chemical	3841
.	PUNCT	O	O	3841
We	PRON	O	O	3842
visualize	VERB	O	O	3842
,	PUNCT	O	O	3842
for	ADP	O	O	3842
the	PRON	O	O	3842
first	ADV	O	O	3842
time	NOUN	O	O	3842
,	PUNCT	O	O	3842
the	PRON	O	O	3842
profile	NOUN	O	O	3842
of	ADP	O	O	3842
structural	ADJ	O	O	3842
deficits	NOUN	O	O	3842
in	ADP	O	O	3842
the	PRON	O	O	3842
human	PROPN	O	O	3842
brain	NOUN	O	O	3842
associated	VERB	O	O	3842
with	ADP	O	O	3842
chronic	ADJ	O	O	3842
methamphetamine	NOUN	O	Chemical	3842
(	PUNCT	O	O	3842
MA	PROPN	O	Chemical	3842
)	PUNCT	O	O	3842
abuse	VERB	O	O	3842
.	PUNCT	O	O	3842
Studies	NOUN	O	O	3843
of	ADP	O	O	3843
human	PROPN	O	O	3843
subjects	NOUN	O	O	3843
who	PRON	O	O	3843
have	VERB	O	O	3843
used	VERB	O	O	3843
MA	PROPN	O	Chemical	3843
chronically	ADV	O	O	3843
have	VERB	O	O	3843
revealed	VERB	O	O	3843
deficits	NOUN	O	O	3843
in	ADP	O	O	3843
dopaminergic	ADJ	O	O	3843
and	CCONJ	O	O	3843
serotonergic	ADJ	O	O	3843
systems	NOUN	O	O	3843
and	CCONJ	O	O	3843
cerebral	ADJ	O	O	3843
metabolic	ADJ	O	O	3843
abnormalities	NOUN	O	O	3843
.	PUNCT	O	O	3843
Using	VERB	O	O	3844
magnetic	ADJ	O	O	3844
resonance	NOUN	O	O	3844
imaging	VERB	O	O	3844
(	PUNCT	O	O	3844
MRI	PROPN	O	O	3844
)	PUNCT	O	O	3844
and	CCONJ	O	O	3844
new	ADJ	O	O	3844
computational	ADJ	O	O	3844
brain	NOUN	O	O	3844
-	PUNCT	O	O	3844
mapping	NOUN	O	O	3844
techniques	NOUN	O	O	3844
,	PUNCT	O	O	3844
we	PRON	O	O	3844
determined	VERB	O	O	3844
the	PRON	O	O	3844
pattern	NOUN	O	O	3844
of	ADP	O	O	3844
structural	ADJ	O	O	3844
brain	NOUN	O	O	3844
alterations	NOUN	O	O	3844
associated	VERB	O	O	3844
with	ADP	O	O	3844
chronic	ADJ	O	O	3844
MA	PROPN	O	Chemical	3844
abuse	VERB	O	O	3844
in	ADP	O	O	3844
human	PROPN	O	O	3844
subjects	NOUN	O	O	3844
and	CCONJ	O	O	3844
related	ADJ	O	O	3844
these	PRON	O	O	3844
deficits	NOUN	O	O	3844
to	PART	O	O	3844
cognitive impairment	NOUN	O	Disease	3844
.	PUNCT	O	O	3844
We	PRON	O	O	3845
used	VERB	O	O	3845
high	ADJ	O	O	3845
-	PUNCT	O	O	3845
resolution	NOUN	O	O	3845
MRI	PROPN	O	O	3845
and	CCONJ	O	O	3845
surface	NOUN	O	O	3845
-	PUNCT	O	O	3845
based	VERB	O	O	3845
computational	ADJ	O	O	3845
image	NOUN	O	O	3845
analyses	NOUN	O	O	3845
to	PART	O	O	3845
map	NOUN	O	O	3845
regional	ADJ	O	O	3845
abnormalities	NOUN	O	O	3845
in	ADP	O	O	3845
the	PRON	O	O	3845
cortex	VERB	O	O	3845
,	PUNCT	O	O	3845
hippocampus	NOUN	O	O	3845
,	PUNCT	O	O	3845
white	ADJ	O	O	3845
matter	VERB	O	O	3845
,	PUNCT	O	O	3845
and	CCONJ	O	O	3845
ventricles	VERB	O	O	3845
in	ADP	O	O	3845
22	NUM	O	O	3845
human	PROPN	O	O	3845
subjects	NOUN	O	O	3845
who	PRON	O	O	3845
used	VERB	O	O	3845
MA	PROPN	O	Chemical	3845
and	CCONJ	O	O	3845
21	NUM	O	O	3845
age	NOUN	O	O	3845
-	PUNCT	O	O	3845
matched	VERB	O	O	3845
,	PUNCT	O	O	3845
healthy	ADJ	O	O	3845
controls	VERB	O	O	3845
.	PUNCT	O	O	3845
Cortical	ADJ	O	O	3846
maps	NOUN	O	O	3846
revealed	VERB	O	O	3846
severe	ADJ	O	O	3846
gray	PROPN	O	O	3846
-	PUNCT	O	O	3846
matter	VERB	O	O	3846
deficits	NOUN	O	O	3846
in	ADP	O	O	3846
the	PRON	O	O	3846
cingulate	NOUN	O	O	3846
,	PUNCT	O	O	3846
limbic	PROPN	O	O	3846
,	PUNCT	O	O	3846
and	CCONJ	O	O	3846
paralimbic	PROPN	O	O	3846
cortices	NOUN	O	O	3846
of	ADP	O	O	3846
MA	PROPN	O	Chemical	3846
abusers	NOUN	O	O	3846
(	PUNCT	O	O	3846
averaging	VERB	O	O	3846
11.3%	NOUN	O	O	3846
below	ADP	O	O	3846
control	VERB	O	O	3846
;	PUNCT	O	O	3846
On	ADP	O	O	3847
average	ADJ	O	O	3847
,	PUNCT	O	O	3847
MA	PROPN	O	Chemical	3847
abusers	NOUN	O	O	3847
had	VERB	O	O	3847
7.8%	NOUN	O	O	3847
smaller	ADJ	O	O	3847
hippocampal	NOUN	O	O	3847
volumes	NOUN	O	O	3847
than	ADP	O	O	3847
control	VERB	O	O	3847
subjects	NOUN	O	O	3847
(	PUNCT	O	O	3847
p	NOUN	O	O	3847
<	X	O	O	3847
0.01	NUM	O	O	3847
;	PUNCT	O	O	3847
left	VERB	O	O	3847
,	PUNCT	O	O	3847
p	NOUN	O	O	3847
=	PUNCT	O	O	3847
0.01	NUM	O	O	3847
;	PUNCT	O	O	3847
right	ADV	O	O	3847
,	PUNCT	O	O	3847
p	NOUN	O	O	3847
<	X	O	O	3847
0.05	NUM	O	O	3847
)	PUNCT	O	O	3847
and	CCONJ	O	O	3847
significant	ADJ	O	O	3847
white	ADJ	O	O	3847
-	PUNCT	O	O	3847
matter	VERB	O	O	3847
hypertrophy	VERB	O	Disease	3847
(	PUNCT	O	O	3847
7.0%	NOUN	O	O	3847
;	PUNCT	O	O	3847
MRI	PROPN	O	O	3848
-	PUNCT	O	O	3848
based	VERB	O	O	3848
maps	NOUN	O	O	3848
suggest	VERB	O	O	3848
that	SCONJ	O	O	3848
chronic	ADJ	O	O	3848
methamphetamine abuse	NOUN	O	O	3848
causes	VERB	O	O	3848
a	PRON	O	O	3848
selective	ADJ	O	O	3848
pattern	NOUN	O	O	3848
of	ADP	O	O	3848
cerebral	ADJ	O	O	3848
deterioration	NOUN	O	O	3848
that	SCONJ	O	O	3848
contributes	VERB	O	O	3848
to	PART	O	O	3848
impaired memory	NOUN	O	Disease	3848
performance	NOUN	O	O	3848
.	PUNCT	O	O	3848
MA	PROPN	O	Chemical	3849
may	AUX	O	O	3849
selectively	ADV	O	O	3849
damage	NOUN	O	O	3849
the	PRON	O	O	3849
medial	ADJ	O	O	3849
temporal	ADJ	O	O	3849
lobe	NOUN	O	O	3849
and	CCONJ	O	O	3849
,	PUNCT	O	O	3849
consistent	ADJ	O	O	3849
with	ADP	O	O	3849
metabolic	ADJ	O	O	3849
studies	NOUN	O	O	3849
,	PUNCT	O	O	3849
the	PRON	O	O	3849
cingulate	NOUN	O	O	3849
-	PUNCT	O	O	3849
limbic	PROPN	O	O	3849
cortex	VERB	O	O	3849
,	PUNCT	O	O	3849
inducing	VERB	O	O	3849
neuroadaptation	NOUN	O	O	3849
,	PUNCT	O	O	3849
neuropil	PROPN	O	O	3849
reduction	NOUN	O	O	3849
,	PUNCT	O	O	3849
or	CCONJ	O	O	3849
cell	NOUN	O	O	3849
death	NOUN	O	O	3849
.	PUNCT	O	O	3849
Prominent	ADJ	O	O	3850
white	ADJ	O	O	3850
-	PUNCT	O	O	3850
matter	VERB	O	O	3850
hypertrophy	VERB	O	Disease	3850
may	AUX	O	O	3850
result	VERB	O	O	3850
from	ADP	O	O	3850
altered	VERB	O	O	3850
myelination	NOUN	O	O	3850
and	CCONJ	O	O	3850
adaptive	ADJ	O	O	3850
glial	ADJ	O	O	3850
changes	VERB	O	O	3850
,	PUNCT	O	O	3850
including	VERB	O	O	3850
gliosis	NOUN	O	O	3850
secondary	ADJ	O	O	3850
to	PART	O	O	3850
neuronal damage	NOUN	O	Disease	3850
.	PUNCT	O	O	3850
These	PRON	O	O	3851
brain	NOUN	O	O	3851
substrates	NOUN	O	O	3851
may	AUX	O	O	3851
help	VERB	O	O	3851
account	VERB	O	O	3851
for	ADP	O	O	3851
the	PRON	O	O	3851
symptoms	NOUN	O	O	3851
of	ADP	O	O	3851
MA	PROPN	O	Chemical	3851
abuse	VERB	O	O	3851
,	PUNCT	O	O	3851
providing	VERB	O	O	3851
therapeutic	ADJ	O	O	3851
targets	VERB	O	O	3851
for	ADP	O	O	3851
drug	NOUN	O	O	3851
-	PUNCT	O	O	3851
induced	VERB	O	O	3851
brain	NOUN	O	O	3851
injury	NOUN	O	O	3851
.	PUNCT	O	O	3851
Disruption	NOUN	O	O	3854
of	ADP	O	O	3854
hepatic	ADJ	O	O	3854
lipid	NOUN	O	O	3854
homeostasis	NOUN	O	O	3854
in	ADP	O	O	3854
mice	NOUN	O	O	3854
after	ADP	O	O	3854
amiodarone	NOUN	O	Chemical	3854
treatment	NOUN	O	O	3854
is	AUX	O	O	3854
associated	VERB	O	O	3854
with	ADP	O	O	3854
peroxisome	PROPN	O	O	3854
proliferator	NOUN	O	O	3854
-	PUNCT	O	O	3854
activated	VERB	O	O	3854
receptor	NOUN	O	O	3854
-	PUNCT	O	O	3854
alpha	PROPN	O	O	3854
target	NOUN	O	O	3854
gene	NOUN	O	O	3854
activation	NOUN	O	O	3854
.	PUNCT	O	O	3854
Amiodarone	NOUN	O	Chemical	3855
,	PUNCT	O	O	3855
an	PRON	O	O	3855
efficacious	ADJ	O	O	3855
and	CCONJ	O	O	3855
widely	ADV	O	O	3855
used	VERB	O	O	3855
antiarrhythmic	PROPN	O	O	3855
agent	NOUN	O	O	3855
,	PUNCT	O	O	3855
has	VERB	O	O	3855
been	AUX	O	O	3855
reported	VERB	O	O	3855
to	PART	O	O	3855
cause	VERB	O	O	3855
hepatotoxicity	NOUN	O	Disease	3855
in	ADP	O	O	3855
some	PRON	O	O	3855
patients	NOUN	O	O	3855
.	PUNCT	O	O	3855
To	PART	O	O	3856
gain	VERB	O	O	3856
insight	NOUN	O	O	3856
into	ADP	O	O	3856
the	PRON	O	O	3856
mechanism	NOUN	O	O	3856
of	ADP	O	O	3856
this	PRON	O	O	3856
unwanted	ADJ	O	O	3856
effect	VERB	O	O	3856
,	PUNCT	O	O	3856
mice	NOUN	O	O	3856
were	AUX	O	O	3856
administered	VERB	O	O	3856
various	ADJ	O	O	3856
doses	NOUN	O	O	3856
of	ADP	O	O	3856
amiodarone	NOUN	O	Chemical	3856
and	CCONJ	O	O	3856
examined	VERB	O	O	3856
for	ADP	O	O	3856
changes	VERB	O	O	3856
in	ADP	O	O	3856
hepatic	ADJ	O	O	3856
histology	NOUN	O	O	3856
and	CCONJ	O	O	3856
gene	NOUN	O	O	3856
regulation	NOUN	O	O	3856
.	PUNCT	O	O	3856
Amiodarone	NOUN	O	Chemical	3857
induced	VERB	O	O	3857
hepatomegaly	NOUN	O	Disease	3857
,	PUNCT	O	O	3857
hepatocyte	NOUN	O	O	3857
microvesicular	ADJ	O	O	3857
lipid	NOUN	O	O	3857
accumulation	NOUN	O	O	3857
,	PUNCT	O	O	3857
and	CCONJ	O	O	3857
a	PRON	O	O	3857
significant	ADJ	O	O	3857
decrease	VERB	O	O	3857
in	ADP	O	O	3857
serum	NOUN	O	O	3857
triglycerides	NOUN	O	Chemical	3857
and	CCONJ	O	O	3857
glucose	NOUN	O	Chemical	3857
.	PUNCT	O	O	3857
Northern	ADJ	O	O	3858
blot	NOUN	O	O	3858
analysis	NOUN	O	O	3858
of	ADP	O	O	3858
hepatic	ADJ	O	O	3858
RNA	PROPN	O	O	3858
revealed	VERB	O	O	3858
a	PRON	O	O	3858
dose	NOUN	O	O	3858
-	PUNCT	O	O	3858
dependent	ADJ	O	O	3858
increase	VERB	O	O	3858
in	ADP	O	O	3858
the	PRON	O	O	3858
expression	NOUN	O	O	3858
of	ADP	O	O	3858
a	PRON	O	O	3858
number	NOUN	O	O	3858
of	ADP	O	O	3858
genes	NOUN	O	O	3858
critical	ADJ	O	O	3858
for	ADP	O	O	3858
fatty	ADJ	O	O	3858
acid	PROPN	O	O	3858
oxidation	ADV	O	O	3858
,	PUNCT	O	O	3858
lipoprotein	NOUN	O	O	3858
assembly	PROPN	O	O	3858
,	PUNCT	O	O	3858
and	CCONJ	O	O	3858
lipid	NOUN	O	O	3858
transport	NOUN	O	O	3858
.	PUNCT	O	O	3858
The	PRON	O	O	3859
absence	NOUN	O	O	3859
of	ADP	O	O	3859
induction	NOUN	O	O	3859
of	ADP	O	O	3859
these	PRON	O	O	3859
genes	NOUN	O	O	3859
as	ADP	O	O	3859
well	ADV	O	O	3859
as	ADP	O	O	3859
hepatomegaly	NOUN	O	Disease	3859
in	ADP	O	O	3859
PPARalpha	PROPN	O	O	3859
knockout	NOUN	O	O	3859
[	X	O	O	3859
PPARalpha-/-	PROPN	O	O	3859
]	PUNCT	O	O	3859
mice	NOUN	O	O	3859
indicated	VERB	O	O	3859
that	SCONJ	O	O	3859
the	PRON	O	O	3859
effects	NOUN	O	O	3859
of	ADP	O	O	3859
amiodarone	NOUN	O	Chemical	3859
were	AUX	O	O	3859
dependent	ADJ	O	O	3859
upon	SCONJ	O	O	3859
the	PRON	O	O	3859
presence	NOUN	O	O	3859
of	ADP	O	O	3859
a	PRON	O	O	3859
functional	ADJ	O	O	3859
PPARalpha	PROPN	O	O	3859
gene	NOUN	O	O	3859
.	PUNCT	O	O	3859
Compared	VERB	O	O	3860
to	PART	O	O	3860
wild	ADJ	O	O	3860
-	PUNCT	O	O	3860
type	NOUN	O	O	3860
mice	NOUN	O	O	3860
,	PUNCT	O	O	3860
treatment	NOUN	O	O	3860
of	ADP	O	O	3860
PPARalpha-/-	PROPN	O	O	3860
mice	NOUN	O	O	3860
with	ADP	O	O	3860
amiodarone	NOUN	O	Chemical	3860
resulted	VERB	O	O	3860
in	ADP	O	O	3860
an	PRON	O	O	3860
increased	VERB	O	O	3860
rate	NOUN	O	O	3860
and	CCONJ	O	O	3860
extent	NOUN	O	O	3860
of	ADP	O	O	3860
total	ADJ	O	O	3860
body	NOUN	O	O	3860
weight loss	NOUN	O	Disease	3860
.	PUNCT	O	O	3860
The	PRON	O	O	3861
inability	NOUN	O	O	3861
of	ADP	O	O	3861
amiodarone	NOUN	O	Chemical	3861
to	PART	O	O	3861
directly	ADV	O	O	3861
activate	VERB	O	O	3861
either	ADV	O	O	3861
human	PROPN	O	O	3861
or	CCONJ	O	O	3861
mouse	PROPN	O	O	3861
PPARalpha	PROPN	O	O	3861
transiently	ADV	O	O	3861
expressed	VERB	O	O	3861
in	ADP	O	O	3861
human	PROPN	O	O	3861
HepG2	PROPN	O	O	3861
hepatoma	VERB	O	Disease	3861
cells	NOUN	O	O	3861
indicates	VERB	O	O	3861
that	SCONJ	O	O	3861
the	PRON	O	O	3861
effects	NOUN	O	O	3861
of	ADP	O	O	3861
amiodarone	NOUN	O	Chemical	3861
on	ADP	O	O	3861
the	PRON	O	O	3861
function	NOUN	O	O	3861
of	ADP	O	O	3861
this	PRON	O	O	3861
receptor	NOUN	O	O	3861
were	AUX	O	O	3861
indirect	ADJ	O	O	3861
.	PUNCT	O	O	3861
Based	VERB	O	O	3862
upon	SCONJ	O	O	3862
these	PRON	O	O	3862
results	VERB	O	O	3862
,	PUNCT	O	O	3862
we	PRON	O	O	3862
conclude	VERB	O	O	3862
that	SCONJ	O	O	3862
amiodarone	NOUN	O	Chemical	3862
disrupts	VERB	O	O	3862
hepatic	ADJ	O	O	3862
lipid	NOUN	O	O	3862
homeostasis	NOUN	O	O	3862
and	CCONJ	O	O	3862
that	SCONJ	O	O	3862
the	PRON	O	O	3862
increased	VERB	O	O	3862
expression	NOUN	O	O	3862
of	ADP	O	O	3862
PPARalpha	PROPN	O	O	3862
target	NOUN	O	O	3862
genes	NOUN	O	O	3862
is	AUX	O	O	3862
secondary	ADJ	O	O	3862
to	PART	O	O	3862
this	PRON	O	O	3862
toxic	ADJ	O	O	3862
effect	VERB	O	O	3862
.	PUNCT	O	O	3862
These	PRON	O	O	3863
results	VERB	O	O	3863
provide	VERB	O	O	3863
important	ADJ	O	O	3863
new	ADJ	O	O	3863
mechanistic	ADJ	O	O	3863
information	NOUN	O	O	3863
regarding	VERB	O	O	3863
the	PRON	O	O	3863
hepatotoxic	ADJ	O	Disease	3863
effects	NOUN	O	O	3863
of	ADP	O	O	3863
amiodarone	NOUN	O	Chemical	3863
and	CCONJ	O	O	3863
indicate	VERB	O	O	3863
that	SCONJ	O	O	3863
PPARalpha	PROPN	O	O	3863
protects	VERB	O	O	3863
against	ADP	O	O	3863
amiodarone	NOUN	O	Chemical	3863
-	PUNCT	O	O	3863
induced	VERB	O	O	3863
hepatotoxicity	NOUN	O	Disease	3863
.	PUNCT	O	O	3863
Safety	NOUN	O	O	3866
and	CCONJ	O	O	3866
compliance	NOUN	O	O	3866
with	ADP	O	O	3866
once	ADV	O	O	3866
-	PUNCT	O	O	3866
daily	ADV	O	O	3866
niacin	PROPN	O	O	3866
extended	VERB	O	O	3866
-	PUNCT	O	O	3866
release	NOUN	O	O	3866
/	PUNCT	O	O	3866
lovastatin	NOUN	O	Chemical	3866
as	ADP	O	O	3866
initial	ADJ	O	O	3866
therapy	NOUN	O	O	3866
in	ADP	O	O	3866
the	PRON	O	O	3866
Impact	NOUN	O	O	3866
of	ADP	O	O	3866
Medical	NOUN	O	O	3866
Subspecialty	NOUN	O	O	3866
on	ADP	O	O	3866
Patient	NOUN	O	O	3866
Compliance	NOUN	O	O	3866
to	PART	O	O	3866
Treatment	NOUN	O	O	3866
(	PUNCT	O	O	3866
IMPACT	NOUN	O	O	3866
)	PUNCT	O	O	3866
study	VERB	O	O	3866
.	PUNCT	O	O	3866
Niacin	PROPN	O	O	3867
extended	VERB	O	O	3867
-	PUNCT	O	O	3867
release	NOUN	O	O	3867
/	PUNCT	O	O	3867
lovastatin	NOUN	O	Chemical	3867
is	AUX	O	O	3867
a	PRON	O	O	3867
new	ADJ	O	O	3867
combination	NOUN	O	O	3867
product	NOUN	O	O	3867
approved	VERB	O	O	3867
for	ADP	O	O	3867
treatment	NOUN	O	O	3867
of	ADP	O	O	3867
primary	NOUN	O	O	3867
hypercholesterolemia	NOUN	O	Disease	3867
and	CCONJ	O	O	3867
mixed	VERB	O	O	3867
dyslipidemia	NOUN	O	O	3867
.	PUNCT	O	O	3867
This	PRON	O	O	3868
open	VERB	O	O	3868
-	PUNCT	O	O	3868
labeled	VERB	O	O	3868
,	PUNCT	O	O	3868
multicenter	ADJ	O	O	3868
study	VERB	O	O	3868
evaluated	VERB	O	O	3868
the	PRON	O	O	3868
safety	NOUN	O	O	3868
of	ADP	O	O	3868
bedtime	NOUN	O	O	3868
niacin	PROPN	O	O	3868
extended	VERB	O	O	3868
-	PUNCT	O	O	3868
release	NOUN	O	O	3868
/	PUNCT	O	O	3868
lovastatin	NOUN	O	Chemical	3868
when	SCONJ	O	O	3868
dosed	VERB	O	O	3868
as	ADP	O	O	3868
initial	ADJ	O	O	3868
therapy	NOUN	O	O	3868
and	CCONJ	O	O	3868
patient	NOUN	O	O	3868
compliance	NOUN	O	O	3868
to	PART	O	O	3868
treatment	NOUN	O	O	3868
in	ADP	O	O	3868
various	ADJ	O	O	3868
clinical	ADJ	O	O	3868
practice	VERB	O	O	3868
settings	NOUN	O	O	3868
.	PUNCT	O	O	3868
A	PRON	O	O	3869
total	ADJ	O	O	3869
of	ADP	O	O	3869
4,499	NUM	O	O	3869
patients	NOUN	O	O	3869
with	ADP	O	O	3869
dyslipidemia	NOUN	O	O	3869
requiring	VERB	O	O	3869
drug	NOUN	O	O	3869
intervention	NOUN	O	O	3869
was	AUX	O	O	3869
enrolled	VERB	O	O	3869
at	ADP	O	O	3869
1,081	NUM	O	O	3869
sites	NOUN	O	O	3869
.	PUNCT	O	O	3869
Patients	NOUN	O	O	3870
were	AUX	O	O	3870
treated	VERB	O	O	3870
with	ADP	O	O	3870
1	X	O	O	3870
tablet	PROPN	O	O	3870
(	PUNCT	O	O	3870
500	NUM	O	O	3870
mg	VERB	O	O	3870
of	ADP	O	O	3870
niacin	PROPN	O	O	3870
extended	VERB	O	O	3870
-	PUNCT	O	O	3870
release/20	PROPN	O	O	3870
mg	VERB	O	O	3870
of	ADP	O	O	3870
lovastatin	NOUN	O	Chemical	3870
)	PUNCT	O	O	3870
once	ADV	O	O	3870
nightly	ADV	O	O	3870
for	ADP	O	O	3870
4	NUM	O	O	3870
weeks	NOUN	O	O	3870
and	CCONJ	O	O	3870
then	ADV	O	O	3870
2	X	O	O	3870
tablets	NOUN	O	O	3870
for	ADP	O	O	3870
8	NUM	O	O	3870
weeks	NOUN	O	O	3870
.	PUNCT	O	O	3870
Patients	NOUN	O	O	3871
also	ADV	O	O	3871
received	VERB	O	O	3871
dietary	ADJ	O	O	3871
counseling	NOUN	O	O	3871
,	PUNCT	O	O	3871
educational	ADJ	O	O	3871
materials	NOUN	O	O	3871
,	PUNCT	O	O	3871
and	CCONJ	O	O	3871
reminders	NOUN	O	O	3871
to	PART	O	O	3871
call	VERB	O	O	3871
a	PRON	O	O	3871
toll	NOUN	O	O	3871
-	PUNCT	O	O	3871
free	ADJ	O	O	3871
number	NOUN	O	O	3871
that	SCONJ	O	O	3871
provided	VERB	O	O	3871
further	ADV	O	O	3871
education	NOUN	O	O	3871
about	ADP	O	O	3871
dyslipidemia	NOUN	O	O	3871
and	CCONJ	O	O	3871
niacin	PROPN	O	O	3871
extended	VERB	O	O	3871
-	PUNCT	O	O	3871
release	NOUN	O	O	3871
/	PUNCT	O	O	3871
lovastatin	NOUN	O	Chemical	3871
.	PUNCT	O	O	3871
Primary	NOUN	O	O	3872
end	VERB	O	O	3872
points	VERB	O	O	3872
were	AUX	O	O	3872
study	VERB	O	O	3872
compliance	NOUN	O	O	3872
,	PUNCT	O	O	3872
increases	VERB	O	O	3872
in	ADP	O	O	3872
liver	NOUN	O	O	3872
transaminases	NOUN	O	O	3872
to	PART	O	O	3872
>	PUNCT	O	O	3872
3	X	O	O	3872
times	NOUN	O	O	3872
the	PRON	O	O	3872
upper	ADJ	O	O	3872
limit	NOUN	O	O	3872
of	ADP	O	O	3872
normal	ADJ	O	O	3872
,	PUNCT	O	O	3872
and	CCONJ	O	O	3872
clinical	ADJ	O	O	3872
myopathy	PROPN	O	Disease	3872
.	PUNCT	O	O	3872
Compliance	NOUN	O	O	3873
to	PART	O	O	3873
niacin	PROPN	O	O	3873
extended	VERB	O	O	3873
-	PUNCT	O	O	3873
release	NOUN	O	O	3873
/	PUNCT	O	O	3873
lovastatin	NOUN	O	Chemical	3873
was	AUX	O	O	3873
77%	NOUN	O	O	3873
,	PUNCT	O	O	3873
with	ADP	O	O	3873
3,245	NUM	O	O	3873
patients	NOUN	O	O	3873
completing	VERB	O	O	3873
the	PRON	O	O	3873
study	VERB	O	O	3873
.	PUNCT	O	O	3873
Flushing	VERB	O	O	3874
was	AUX	O	O	3874
the	PRON	O	O	3874
most	ADV	O	O	3874
common	ADJ	O	O	3874
adverse	ADJ	O	O	3874
event	NOUN	O	O	3874
,	PUNCT	O	O	3874
reported	VERB	O	O	3874
by	ADP	O	O	3874
18%	NOUN	O	O	3874
of	ADP	O	O	3874
patients	NOUN	O	O	3874
and	CCONJ	O	O	3874
leading	VERB	O	O	3874
to	PART	O	O	3874
discontinuation	NOUN	O	O	3874
by	ADP	O	O	3874
6%	NOUN	O	O	3874
.	PUNCT	O	O	3874
Incidence	NOUN	O	O	3875
of	ADP	O	O	3875
increased	VERB	O	O	3875
aspartate	NOUN	O	Chemical	3875
aminotransferase	PROPN	O	O	3875
and/or	CCONJ	O	O	3875
alanine	NOUN	O	Chemical	3875
aminotransferase	PROPN	O	O	3875
>	PUNCT	O	O	3875
3	X	O	O	3875
times	NOUN	O	O	3875
the	PRON	O	O	3875
upper	ADJ	O	O	3875
limit	NOUN	O	O	3875
of	ADP	O	O	3875
normal	ADJ	O	O	3875
was	AUX	O	O	3875
<	X	O	O	3875
0.3%	NOUN	O	O	3875
.	PUNCT	O	O	3875
An	PRON	O	O	3876
increase	VERB	O	O	3876
of	ADP	O	O	3876
creatine	PROPN	O	Chemical	3876
phosphokinase	NOUN	O	O	3876
to	PART	O	O	3876
>	PUNCT	O	O	3876
5	NUM	O	O	3876
times	NOUN	O	O	3876
the	PRON	O	O	3876
upper	ADJ	O	O	3876
limit	NOUN	O	O	3876
of	ADP	O	O	3876
normal	ADJ	O	O	3876
occurred	VERB	O	O	3876
in	ADP	O	O	3876
0.24%	NOUN	O	O	3876
of	ADP	O	O	3876
patients	NOUN	O	O	3876
,	PUNCT	O	O	3876
and	CCONJ	O	O	3876
no	PRON	O	O	3876
cases	NOUN	O	O	3876
of	ADP	O	O	3876
drug	NOUN	O	O	3876
-	PUNCT	O	O	3876
induced	VERB	O	O	3876
myopathy	PROPN	O	Disease	3876
were	AUX	O	O	3876
observed	VERB	O	O	3876
.	PUNCT	O	O	3876
Niacin	PROPN	O	O	3877
extended	VERB	O	O	3877
-	PUNCT	O	O	3877
release	NOUN	O	O	3877
/	PUNCT	O	O	3877
lovastatin	NOUN	O	Chemical	3877
1,000/40	NUM	O	O	3877
mg	VERB	O	O	3877
,	PUNCT	O	O	3877
dosed	VERB	O	O	3877
as	ADP	O	O	3877
initial	ADJ	O	O	3877
therapy	NOUN	O	O	3877
,	PUNCT	O	O	3877
was	AUX	O	O	3877
associated	VERB	O	O	3877
with	ADP	O	O	3877
good	ADJ	O	O	3877
compliance	NOUN	O	O	3877
and	CCONJ	O	O	3877
safety	NOUN	O	O	3877
and	CCONJ	O	O	3877
had	VERB	O	O	3877
very	ADV	O	O	3877
low	ADJ	O	O	3877
incidences	NOUN	O	O	3877
of	ADP	O	O	3877
increased	VERB	O	O	3877
liver	NOUN	O	O	3877
and	CCONJ	O	O	3877
muscle	NOUN	O	O	3877
enzymes	NOUN	O	O	3877
.	PUNCT	O	O	3877
Protective	NOUN	O	O	3880
effect	VERB	O	O	3880
of	ADP	O	O	3880
Terminalia	PROPN	O	O	3880
chebula	VERB	O	O	3880
against	ADP	O	O	3880
experimental	ADJ	O	O	3880
myocardial injury	NOUN	O	Disease	3880
induced	VERB	O	O	3880
by	ADP	O	O	3880
isoproterenol	NOUN	O	Chemical	3880
.	PUNCT	O	O	3880
Cardioprotective	PROPN	O	O	3881
effect	VERB	O	O	3881
of	ADP	O	O	3881
ethanolic	NOUN	O	O	3881
extract	VERB	O	O	3881
of	ADP	O	O	3881
Terminalia	PROPN	O	O	3881
chebula	VERB	O	O	3881
fruits	NOUN	O	O	3881
(	PUNCT	O	O	3881
500	NUM	O	O	3881
mg	VERB	O	O	3881
/	PUNCT	O	O	3881
kg	VERB	O	O	3881
body	NOUN	O	O	3881
wt	NOUN	O	O	3881
)	PUNCT	O	O	3881
was	AUX	O	O	3881
examined	VERB	O	O	3881
in	ADP	O	O	3881
isoproterenol	NOUN	O	Chemical	3881
(	PUNCT	O	O	3881
200	NUM	O	O	3881
mg	VERB	O	O	3881
/	PUNCT	O	O	3881
kg	VERB	O	O	3881
body	NOUN	O	O	3881
wt	NOUN	O	O	3882
)	PUNCT	O	O	3882
induced	VERB	O	O	3882
myocardial damage	NOUN	O	Disease	3882
in	ADP	O	O	3882
rats	NOUN	O	O	3882
.	PUNCT	O	O	3882
In	ADP	O	O	3883
isoproterenol	NOUN	O	Chemical	3883
administered	VERB	O	O	3883
rats	NOUN	O	O	3883
,	PUNCT	O	O	3883
the	PRON	O	O	3883
level	VERB	O	O	3883
of	ADP	O	O	3883
lipid	NOUN	O	O	3883
peroxides	NOUN	O	O	3883
increased	VERB	O	O	3883
significantly	ADV	O	O	3883
in	ADP	O	O	3883
the	PRON	O	O	3883
serum	NOUN	O	O	3883
and	CCONJ	O	O	3883
heart	NOUN	O	O	3883
.	PUNCT	O	O	3883
Histopathological	PROPN	O	O	3884
examination	NOUN	O	O	3884
was	AUX	O	O	3884
carried	VERB	O	O	3884
out	ADP	O	O	3884
to	PART	O	O	3884
confirm	VERB	O	O	3884
the	PRON	O	O	3884
myocardial	ADJ	O	O	3884
necrosis	NOUN	O	Disease	3884
.	PUNCT	O	O	3884
T.	NOUN	O	O	3885
chebula	VERB	O	O	3885
extract	VERB	O	O	3885
pretreatment	NOUN	O	O	3885
was	AUX	O	O	3885
found	VERB	O	O	3885
to	PART	O	O	3885
ameliorate	VERB	O	O	3885
the	PRON	O	O	3885
effect	VERB	O	O	3885
of	ADP	O	O	3885
isoproterenol	NOUN	O	Chemical	3885
on	ADP	O	O	3885
lipid	NOUN	O	O	3885
peroxide	NOUN	O	O	3885
formation	NOUN	O	O	3885
and	CCONJ	O	O	3885
retained	VERB	O	O	3885
the	PRON	O	O	3885
activities	NOUN	O	O	3885
of	ADP	O	O	3885
the	PRON	O	O	3885
diagnostic	ADJ	O	O	3885
marker	NOUN	O	O	3885
enzymes	NOUN	O	O	3885
.	PUNCT	O	O	3885
A	PRON	O	O	3888
case	NOUN	O	O	3888
of	ADP	O	O	3888
postoperative	ADJ	O	O	3888
anxiety	NOUN	O	Disease	3888
due	ADJ	O	O	3888
to	PART	O	O	3888
low	ADJ	O	O	3888
dose	NOUN	O	O	3888
droperidol	NOUN	O	Chemical	3888
used	VERB	O	O	3888
with	ADP	O	O	3888
patient	NOUN	O	O	3888
-	PUNCT	O	O	3888
controlled	VERB	O	O	3888
analgesia	NOUN	O	Disease	3888
.	PUNCT	O	O	3888
Postoperatively	PROPN	O	O	3889
,	PUNCT	O	O	3889
she	PRON	O	O	3889
was	AUX	O	O	3889
given	VERB	O	O	3889
a	PRON	O	O	3889
patient	NOUN	O	O	3889
-	PUNCT	O	O	3889
controlled	VERB	O	O	3889
analgesia	NOUN	O	Disease	3889
device	NOUN	O	O	3889
delivering	VERB	O	O	3889
boluses	NOUN	O	O	3889
of	ADP	O	O	3889
diamorphine	NOUN	O	O	3889
0.5	NUM	O	O	3889
mg	VERB	O	O	3889
and	CCONJ	O	O	3889
droperidol	NOUN	O	Chemical	3889
0.025	NUM	O	O	3889
mg	VERB	O	O	3889
.	PUNCT	O	O	3889
The	PRON	O	O	3890
diagnosis	NOUN	O	O	3890
of	ADP	O	O	3890
droperidol	NOUN	O	Chemical	3890
-	PUNCT	O	O	3890
induced	VERB	O	O	3890
psychological	ADJ	O	O	3890
disturbance	NOUN	O	O	3890
was	AUX	O	O	3890
not	PART	O	O	3890
made	VERB	O	O	3890
straight	ADJ	O	O	3890
away	ADV	O	O	3890
although	SCONJ	O	O	3890
on	ADP	O	O	3890
subsequent	ADJ	O	O	3890
close	ADV	O	O	3890
questioning	VERB	O	O	3890
the	PRON	O	O	3890
patient	NOUN	O	O	3890
gave	VERB	O	O	3890
a	PRON	O	O	3890
very	ADV	O	O	3890
clear	ADJ	O	O	3890
history	NOUN	O	O	3890
.	PUNCT	O	O	3890
After	ADP	O	O	3891
she	PRON	O	O	3891
had	VERB	O	O	3891
received	VERB	O	O	3891
a	PRON	O	O	3891
total	ADJ	O	O	3891
of	ADP	O	O	3891
only	ADV	O	O	3891
0.9	NUM	O	O	3891
mg	VERB	O	O	3891
droperidol	NOUN	O	Chemical	3891
,	PUNCT	O	O	3891
a	PRON	O	O	3891
syringe	NOUN	O	O	3891
containing	VERB	O	O	3891
diamorphine	NOUN	O	O	3891
only	ADV	O	O	3891
was	AUX	O	O	3891
substituted	VERB	O	O	3891
and	CCONJ	O	O	3891
her	PRON	O	O	3891
unease	NOUN	O	O	3891
resolved	VERB	O	O	3891
completely	ADV	O	O	3891
.	PUNCT	O	O	3891
Accurate	ADJ	O	O	3894
patient	NOUN	O	O	3894
history	NOUN	O	O	3894
contributes	VERB	O	O	3894
to	PART	O	O	3894
differentiating	VERB	O	O	3894
diabetes insipidus	NOUN	O	Disease	3894
:	PUNCT	O	O	3894
a	PRON	O	O	3894
case	NOUN	O	O	3894
study	VERB	O	O	3894
.	PUNCT	O	O	3894
The	PRON	O	O	3895
case	NOUN	O	O	3895
discussed	VERB	O	O	3895
herein	VERB	O	O	3895
initially	ADV	O	O	3895
appeared	VERB	O	O	3895
to	PART	O	O	3895
be	AUX	O	O	3895
neurogenic	ADJ	O	O	3895
diabetes insipidus	NOUN	O	Disease	3895
(	PUNCT	O	O	3895
DI	PROPN	O	O	3895
)	PUNCT	O	O	3895
secondary	ADJ	O	O	3895
to	PART	O	O	3895
a	PRON	O	O	3895
traumatic	ADJ	O	O	3895
brain	NOUN	O	O	3895
injury	NOUN	O	O	3895
.	PUNCT	O	O	3895
The	PRON	O	O	3896
nursing	NOUN	O	O	3896
staff	NOUN	O	O	3896
,	PUNCT	O	O	3896
by	ADP	O	O	3896
reviewing	VERB	O	O	3896
the	PRON	O	O	3896
patient	NOUN	O	O	3896
's	AUX	O	O	3896
health	NOUN	O	O	3896
history	NOUN	O	O	3896
with	ADP	O	O	3896
his	PRON	O	O	3896
family	NOUN	O	O	3896
,	PUNCT	O	O	3896
discovered	VERB	O	O	3896
a	PRON	O	O	3896
history	NOUN	O	O	3896
of	ADP	O	O	3896
polydipsia	PROPN	O	Disease	3896
and	CCONJ	O	O	3896
long	ADV	O	O	3896
-	PUNCT	O	O	3896
standing	VERB	O	O	3896
lithium	NOUN	O	Chemical	3896
use	VERB	O	O	3896
.	PUNCT	O	O	3896
Lithium	NOUN	O	Chemical	3897
is	AUX	O	O	3897
implicated	VERB	O	O	3897
in	ADP	O	O	3897
drug	NOUN	O	O	3897
-	PUNCT	O	O	3897
induced	VERB	O	O	3897
nephrogenic	PROPN	O	O	3897
DI	PROPN	O	O	3897
,	PUNCT	O	O	3897
and	CCONJ	O	O	3897
because	SCONJ	O	O	3897
the	PRON	O	O	3897
patient	NOUN	O	O	3897
had	VERB	O	O	3897
not	PART	O	O	3897
received	VERB	O	O	3897
lithium	NOUN	O	Chemical	3897
since	SCONJ	O	O	3897
being	AUX	O	O	3897
admitted	VERB	O	O	3897
to	PART	O	O	3897
the	PRON	O	O	3897
hospital	PROPN	O	O	3897
,	PUNCT	O	O	3897
his	PRON	O	O	3897
treatment	NOUN	O	O	3897
changed	VERB	O	O	3897
to	PART	O	O	3897
focus	NOUN	O	O	3897
on	ADP	O	O	3897
nephrogenic	PROPN	O	O	3897
DI	PROPN	O	O	3897
.	PUNCT	O	O	3897
By	ADP	O	O	3898
combining	VERB	O	O	3898
information	NOUN	O	O	3898
from	ADP	O	O	3898
the	PRON	O	O	3898
patient	NOUN	O	O	3898
history	NOUN	O	O	3898
,	PUNCT	O	O	3898
the	PRON	O	O	3898
physical	ADJ	O	O	3898
examination	NOUN	O	O	3898
,	PUNCT	O	O	3898
and	CCONJ	O	O	3898
radiologic	ADJ	O	O	3898
and	CCONJ	O	O	3898
laboratory	NOUN	O	O	3898
studies	NOUN	O	O	3898
,	PUNCT	O	O	3898
the	PRON	O	O	3898
critical	ADJ	O	O	3898
care	VERB	O	O	3898
team	NOUN	O	O	3898
demonstrated	VERB	O	O	3898
that	SCONJ	O	O	3898
the	PRON	O	O	3898
patient	NOUN	O	O	3898
had	VERB	O	O	3898
been	AUX	O	O	3898
self	VERB	O	O	3898
-	PUNCT	O	O	3898
treating	VERB	O	O	3898
his	PRON	O	O	3898
lithium	NOUN	O	Chemical	3898
-	PUNCT	O	O	3898
induced	VERB	O	O	3898
nephrogenic	PROPN	O	O	3898
DI	PROPN	O	O	3898
and	CCONJ	O	O	3898
developed	VERB	O	O	3898
neurogenic	ADJ	O	O	3898
DI	PROPN	O	O	3898
secondary	ADJ	O	O	3898
to	PART	O	O	3898
brain	NOUN	O	O	3898
trauma	NOUN	O	O	3898
.	PUNCT	O	O	3898
Thus	ADV	O	O	3899
successful	ADJ	O	O	3899
treatment	NOUN	O	O	3899
required	VERB	O	O	3899
that	SCONJ	O	O	3899
nephrogenic	PROPN	O	O	3899
and	CCONJ	O	O	3899
neurogenic	ADJ	O	O	3899
DI	PROPN	O	O	3899
be	AUX	O	O	3899
treated	VERB	O	O	3899
concomitantly	ADV	O	O	3899
.	PUNCT	O	O	3899
Factors	NOUN	O	O	3902
contributing	VERB	O	O	3902
to	PART	O	O	3902
ribavirin	NOUN	O	Chemical	3902
-	PUNCT	O	O	3902
induced	VERB	O	O	3902
anemia	NOUN	O	Disease	3902
.	PUNCT	O	O	3902
Interferon	PROPN	O	O	3903
and	CCONJ	O	O	3903
ribavirin	NOUN	O	Chemical	3903
combination	NOUN	O	O	3903
therapy	NOUN	O	O	3903
for	ADP	O	O	3903
chronic hepatitis C	NOUN	O	Disease	3903
produces	VERB	O	O	3903
hemolytic anemia	NOUN	O	Disease	3903
.	PUNCT	O	O	3903
This	PRON	O	O	3904
study	VERB	O	O	3904
was	AUX	O	O	3904
conducted	VERB	O	O	3904
to	PART	O	O	3904
identify	VERB	O	O	3904
the	PRON	O	O	3904
factors	NOUN	O	O	3904
contributing	VERB	O	O	3904
to	PART	O	O	3904
ribavirin	NOUN	O	Chemical	3904
-	PUNCT	O	O	3904
induced	VERB	O	O	3904
anemia	NOUN	O	Disease	3904
.	PUNCT	O	O	3904
METHODS	NOUN	O	O	3905
:	PUNCT	O	O	3905
Eighty	NUM	O	O	3905
-	PUNCT	O	O	3905
eight	NUM	O	O	3905
patients	NOUN	O	O	3905
with	ADP	O	O	3905
chronic hepatitis C	NOUN	O	Disease	3905
who	PRON	O	O	3905
received	VERB	O	O	3905
interferon	PROPN	O	Chemical	3905
-	PUNCT	O	O	3905
alpha-2b	ADV	O	O	3905
at	ADP	O	O	3905
a	PRON	O	O	3905
dose	NOUN	O	O	3905
of	ADP	O	O	3905
6	NUM	O	O	3905
MU	NOUN	O	O	3905
administered	VERB	O	O	3905
intramuscularly	ADV	O	O	3905
for	ADP	O	O	3905
24	NUM	O	O	3905
weeks	NOUN	O	O	3905
in	ADP	O	O	3905
combination	NOUN	O	O	3905
with	ADP	O	O	3905
ribavirin	NOUN	O	Chemical	3905
administered	VERB	O	O	3905
orally	ADV	O	O	3905
at	ADP	O	O	3905
a	PRON	O	O	3905
dose	NOUN	O	O	3905
of	ADP	O	O	3905
600	NUM	O	O	3905
mg	VERB	O	O	3905
or	CCONJ	O	O	3905
800	NUM	O	O	3905
mg	VERB	O	O	3905
participated	VERB	O	O	3905
in	ADP	O	O	3905
the	PRON	O	O	3905
study	VERB	O	O	3905
.	PUNCT	O	O	3905
A	PRON	O	O	3906
hemoglobin	NOUN	O	O	3906
concentration	NOUN	O	O	3906
of	ADP	O	O	3906
<	X	O	O	3906
10	NUM	O	O	3906
g	X	O	O	3906
/	PUNCT	O	O	3906
dL	VERB	O	O	3906
was	AUX	O	O	3906
defined	VERB	O	O	3906
as	ADP	O	O	3906
ribavirin	NOUN	O	Chemical	3906
-	PUNCT	O	O	3906
induced	VERB	O	O	3906
anemia	NOUN	O	Disease	3906
.	PUNCT	O	O	3906
Ribavirin	NOUN	O	Chemical	3907
-	PUNCT	O	O	3907
induced	VERB	O	O	3907
anemia	NOUN	O	Disease	3907
occurred	VERB	O	O	3907
in	ADP	O	O	3907
18	NUM	O	O	3907
(	PUNCT	O	O	3907
20.5%	NOUN	O	O	3907
)	PUNCT	O	O	3907
patients	NOUN	O	O	3907
during	ADP	O	O	3907
treatment	NOUN	O	O	3907
.	PUNCT	O	O	3907
A	PRON	O	O	3908
2	X	O	O	3908
g	X	O	O	3908
/	PUNCT	O	O	3908
dL	VERB	O	O	3908
decrease	VERB	O	O	3908
in	ADP	O	O	3908
hemoglobin	NOUN	O	O	3908
concentrations	NOUN	O	O	3908
in	ADP	O	O	3908
patients	NOUN	O	O	3908
with	ADP	O	O	3908
anemia	NOUN	O	Disease	3908
was	AUX	O	O	3908
observed	VERB	O	O	3908
at	ADP	O	O	3908
week	NOUN	O	O	3908
2	X	O	O	3908
after	ADP	O	O	3908
the	PRON	O	O	3908
start	VERB	O	O	3908
of	ADP	O	O	3908
treatment	NOUN	O	O	3908
.	PUNCT	O	O	3908
A	PRON	O	O	3909
significant	ADJ	O	O	3909
relationship	NOUN	O	O	3909
was	AUX	O	O	3909
observed	VERB	O	O	3909
between	ADP	O	O	3909
the	PRON	O	O	3909
rate	NOUN	O	O	3909
of	ADP	O	O	3909
reduction	NOUN	O	O	3909
of	ADP	O	O	3909
hemoglobin	NOUN	O	O	3909
concentrations	NOUN	O	O	3909
at	ADP	O	O	3909
week	NOUN	O	O	3909
2	X	O	O	3909
and	CCONJ	O	O	3909
the	PRON	O	O	3909
severity	NOUN	O	O	3909
of	ADP	O	O	3909
anemia	NOUN	O	Disease	3909
(	PUNCT	O	O	3909
P	NOUN	O	Chemical	3909
<	X	O	O	3909
0.01	NUM	O	O	3909
)	PUNCT	O	O	3909
.	PUNCT	O	O	3909
Such	ADJ	O	O	3910
factors	NOUN	O	O	3910
as	ADP	O	O	3910
sex	NOUN	O	O	3910
(	PUNCT	O	O	3910
female	ADJ	O	O	3910
)	PUNCT	O	O	3910
,	PUNCT	O	O	3910
age	NOUN	O	O	3910
(	PUNCT	O	O	3910
>	PUNCT	O	O	3910
or	CCONJ	O	O	3910
=	PUNCT	O	O	3910
60	NUM	O	O	3910
years	NOUN	O	O	3910
old	ADJ	O	O	3910
)	PUNCT	O	O	3910
,	PUNCT	O	O	3910
and	CCONJ	O	O	3910
the	PRON	O	O	3910
ribavirin	NOUN	O	Chemical	3910
dose	NOUN	O	O	3910
by	ADP	O	O	3910
body	NOUN	O	O	3910
weight	NOUN	O	O	3910
(	PUNCT	O	O	3910
12	NUM	O	O	3910
mg	VERB	O	O	3910
/	PUNCT	O	O	3910
kg	VERB	O	O	3910
or	CCONJ	O	O	3910
more	ADJ	O	O	3910
)	PUNCT	O	O	3910
were	AUX	O	O	3910
significant	ADJ	O	O	3910
by	ADP	O	O	3910
univariate	ADJ	O	O	3910
analysis	NOUN	O	O	3910
.	PUNCT	O	O	3910
Careful	ADJ	O	O	3911
administration	NOUN	O	O	3911
is	AUX	O	O	3911
necessary	ADJ	O	O	3911
in	ADP	O	O	3911
patients	NOUN	O	O	3911
>	PUNCT	O	O	3911
or	CCONJ	O	O	3911
=	PUNCT	O	O	3911
60	NUM	O	O	3911
years	NOUN	O	O	3911
old	ADJ	O	O	3911
,	PUNCT	O	O	3911
in	ADP	O	O	3911
female	ADJ	O	O	3911
patients	NOUN	O	O	3911
,	PUNCT	O	O	3911
and	CCONJ	O	O	3911
in	ADP	O	O	3911
patients	NOUN	O	O	3911
receiving	VERB	O	O	3911
a	PRON	O	O	3911
ribavirin	NOUN	O	Chemical	3911
dose	NOUN	O	O	3911
of	ADP	O	O	3911
12	NUM	O	O	3911
mg	VERB	O	O	3911
/	PUNCT	O	O	3911
kg	VERB	O	O	3911
or	CCONJ	O	O	3911
more	ADJ	O	O	3911
.	PUNCT	O	O	3911
Oxidative	NOUN	O	O	3914
damage	NOUN	O	O	3914
precedes	VERB	O	O	3914
nitrative	NOUN	O	O	3914
damage	NOUN	O	O	3914
in	ADP	O	O	3914
adriamycin	PROPN	O	Chemical	3914
-	PUNCT	O	O	3914
induced	VERB	O	O	3914
cardiac	ADJ	O	O	3914
mitochondrial injury	NOUN	O	Disease	3914
.	PUNCT	O	O	3914
The	PRON	O	O	3915
purpose	NOUN	O	O	3915
of	ADP	O	O	3915
the	PRON	O	O	3915
present	NOUN	O	O	3915
study	VERB	O	O	3915
was	AUX	O	O	3915
to	PART	O	O	3915
determine	VERB	O	O	3915
if	SCONJ	O	O	3915
elevated	ADJ	O	O	3915
reactive	ADJ	O	O	3915
oxygen	NOUN	O	Chemical	3915
(	PUNCT	O	O	3915
ROS)/nitrogen	NOUN	O	O	3915
species	NOUN	O	O	3915
(	PUNCT	O	O	3915
RNS	NOUN	O	O	3915
)	PUNCT	O	O	3915
reported	VERB	O	O	3915
to	PART	O	O	3915
be	AUX	O	O	3915
present	NOUN	O	O	3915
in	ADP	O	O	3915
adriamycin	PROPN	O	Chemical	3915
(	PUNCT	O	O	3915
ADR)-induced	ADJ	O	O	3915
cardiotoxicity	NOUN	O	Disease	3915
actually	ADV	O	O	3915
resulted	VERB	O	O	3915
in	ADP	O	O	3915
cardiomyocyte	NOUN	O	O	3915
B6C3	PROPN	O	O	3916
mice	NOUN	O	O	3916
were	AUX	O	O	3916
treated	VERB	O	O	3916
with	ADP	O	O	3916
a	PRON	O	O	3916
single	ADJ	O	O	3916
dose	NOUN	O	O	3916
of	ADP	O	O	3916
20	NUM	O	O	3916
mg	VERB	O	O	3916
/	PUNCT	O	O	3916
kg	VERB	O	O	3916
ADR	PROPN	O	Chemical	3916
.	PUNCT	O	O	3916
Ultrastructural	NOUN	O	O	3917
damage	NOUN	O	O	3917
and	CCONJ	O	O	3917
levels	NOUN	O	O	3917
of	ADP	O	O	3917
4-hydroxy-2-nonenal	ADJ	O	O	3917
(	PUNCT	O	O	3917
4HNE)-protein	NUM	O	O	3917
adducts	VERB	O	O	3917
and	CCONJ	O	O	3917
3-nitrotyrosine	NOUN	O	O	3917
(	PUNCT	O	O	3917
3NT	NUM	O	O	3917
)	PUNCT	O	O	3917
were	AUX	O	O	3917
analyzed	VERB	O	O	3917
.	PUNCT	O	O	3917
Analysis	NOUN	O	O	3918
of	ADP	O	O	3918
4HNE	PROPN	O	O	3918
protein	NOUN	O	O	3918
adducts	VERB	O	O	3918
by	ADP	O	O	3918
immunogold	VERB	O	O	3918
electron	NOUN	O	O	3918
microscopy	NOUN	O	O	3918
showed	VERB	O	O	3918
appearance	NOUN	O	O	3918
of	ADP	O	O	3918
4HNE	PROPN	O	O	3918
protein	NOUN	O	O	3918
adducts	VERB	O	O	3918
in	ADP	O	O	3918
mitochondria	PROPN	O	O	3918
as	ADP	O	O	3918
early	ADV	O	O	3918
as	ADP	O	O	3918
3	X	O	O	3918
hours	NOUN	O	O	3918
,	PUNCT	O	O	3918
with	ADP	O	O	3918
a	PRON	O	O	3918
peak	PROPN	O	O	3918
at	ADP	O	O	3918
6	NUM	O	O	3918
hours	NOUN	O	O	3918
and	CCONJ	O	O	3918
subsequent	ADJ	O	O	3918
decline	VERB	O	O	3918
at	ADP	O	O	3918
24	NUM	O	O	3918
hours	NOUN	O	O	3918
.	PUNCT	O	O	3918
3NT	NUM	O	O	3919
levels	NOUN	O	O	3919
were	AUX	O	O	3919
significantly	ADV	O	O	3919
increased	VERB	O	O	3919
in	ADP	O	O	3919
all	PRON	O	O	3919
subcellular	ADJ	O	O	3919
compartments	NOUN	O	O	3919
at	ADP	O	O	3919
6	NUM	O	O	3919
hours	NOUN	O	O	3919
and	CCONJ	O	O	3919
subsequently	ADV	O	O	3919
declined	VERB	O	O	3919
at	ADP	O	O	3919
24	NUM	O	O	3919
hours	NOUN	O	O	3919
.	PUNCT	O	O	3919
Our	PRON	O	O	3920
data	NOUN	O	O	3920
showed	VERB	O	O	3920
ADR	PROPN	O	Chemical	3920
induced	VERB	O	O	3920
4HNE	PROPN	O	O	3920
-	PUNCT	O	O	3920
protein	NOUN	O	O	3920
adducts	VERB	O	O	3920
in	ADP	O	O	3920
mitochondria	PROPN	O	O	3920
at	ADP	O	O	3920
the	PRON	O	O	3920
same	ADJ	O	O	3920
time	NOUN	O	O	3920
point	VERB	O	O	3920
as	ADP	O	O	3920
when	SCONJ	O	O	3920
mitochondrial injury	NOUN	O	Disease	3920
initially	ADV	O	O	3920
appeared	VERB	O	O	3920
.	PUNCT	O	O	3920
These	PRON	O	O	3921
results	VERB	O	O	3921
document	NOUN	O	O	3921
for	ADP	O	O	3921
the	PRON	O	O	3921
first	ADV	O	O	3921
time	NOUN	O	O	3921
in	ADP	O	O	3921
vivo	VERB	O	O	3921
that	SCONJ	O	O	3921
mitochondrial	ADJ	O	O	3921
oxidative	NOUN	O	O	3921
damage	NOUN	O	O	3921
precedes	VERB	O	O	3921
nitrative	NOUN	O	O	3921
damage	NOUN	O	O	3921
.	PUNCT	O	O	3921
The	PRON	O	O	3922
progressive	ADJ	O	O	3922
nature	NOUN	O	O	3922
of	ADP	O	O	3922
mitochondrial injury	NOUN	O	Disease	3922
suggests	VERB	O	O	3922
that	SCONJ	O	O	3922
mitochondria	PROPN	O	O	3922
,	PUNCT	O	O	3922
not	PART	O	O	3922
other	ADJ	O	O	3922
subcellular	ADJ	O	O	3922
organelles	NOUN	O	O	3922
,	PUNCT	O	O	3922
are	AUX	O	O	3922
the	PRON	O	O	3922
major	ADJ	O	O	3922
site	NOUN	O	O	3922
of	ADP	O	O	3922
intracellular	ADJ	O	O	3922
injury	NOUN	O	O	3922
.	PUNCT	O	O	3922
Sotalol	NOUN	O	O	3925
-	PUNCT	O	O	3925
induced	VERB	O	O	3925
coronary spasm	NOUN	O	Disease	3925
in	ADP	O	O	3925
a	PRON	O	O	3925
patient	NOUN	O	O	3925
with	ADP	O	O	3925
dilated	ADJ	O	O	3925
cardiomyopathy	ADJ	O	Disease	3925
associated	VERB	O	O	3925
with	ADP	O	O	3925
sustained	VERB	O	O	3925
ventricular tachycardia	NOUN	O	Disease	3925
.	PUNCT	O	O	3925
A	PRON	O	O	3926
54-year	NOUN	O	O	3926
-	PUNCT	O	O	3926
old	ADJ	O	O	3926
man	NOUN	O	O	3926
with	ADP	O	O	3926
severe	ADJ	O	O	3926
left ventricular dysfunction	NOUN	O	Disease	3926
due	ADJ	O	O	3926
to	PART	O	O	3926
dilated	ADJ	O	O	3926
cardiomyopathy	ADJ	O	Disease	3926
was	AUX	O	O	3926
referred	VERB	O	O	3926
to	PART	O	O	3926
our	PRON	O	O	3926
hospital	PROPN	O	O	3926
for	ADP	O	O	3926
symptomatic	ADJ	O	O	3926
incessant	ADJ	O	O	3926
sustained	VERB	O	O	3926
ventricular tachycardia	NOUN	O	Disease	3926
(	PUNCT	O	O	3926
VT	PROPN	O	Disease	3926
)	PUNCT	O	O	3926
.	PUNCT	O	O	3926
After	ADP	O	O	3927
the	PRON	O	O	3927
administration	NOUN	O	O	3927
of	ADP	O	O	3927
nifekalant	VERB	O	O	3927
hydrochloride	NOUN	O	O	3927
,	PUNCT	O	O	3927
sustained	VERB	O	O	3927
VT	PROPN	O	Disease	3927
was	AUX	O	O	3927
terminated	VERB	O	O	3927
.	PUNCT	O	O	3927
An	PRON	O	O	3928
alternate	ADJ	O	O	3928
class	NOUN	O	O	3928
III	NUM	O	O	3928
agent	NOUN	O	O	3928
,	PUNCT	O	O	3928
sotalol	VERB	O	O	3928
,	PUNCT	O	O	3928
was	AUX	O	O	3928
also	ADV	O	O	3928
effective	ADJ	O	O	3928
for	ADP	O	O	3928
the	PRON	O	O	3928
prevention	NOUN	O	O	3928
of	ADP	O	O	3928
VT	PROPN	O	Disease	3928
.	PUNCT	O	O	3928
However	ADV	O	O	3929
,	PUNCT	O	O	3929
one	NUM	O	O	3929
month	NOUN	O	O	3929
after	ADP	O	O	3929
switching	VERB	O	O	3929
over	ADP	O	O	3929
nifekalant	VERB	O	O	3929
to	PART	O	O	3929
sotalol	VERB	O	O	3929
,	PUNCT	O	O	3929
a	PRON	O	O	3929
short	ADJ	O	O	3929
duration	NOUN	O	O	3929
of	ADP	O	O	3929
ST	PROPN	O	O	3929
elevation	NOUN	O	O	3929
was	AUX	O	O	3929
documented	VERB	O	O	3929
in	ADP	O	O	3929
ECG	PROPN	O	O	3929
monitoring	NOUN	O	O	3929
at	ADP	O	O	3929
almost	ADV	O	O	3929
the	PRON	O	O	3929
same	ADJ	O	O	3929
time	NOUN	O	O	3929
for	ADP	O	O	3929
three	NUM	O	O	3929
consecutive	ADJ	O	O	3929
days	NOUN	O	O	3929
.	PUNCT	O	O	3929
ST	PROPN	O	O	3930
elevation	NOUN	O	O	3930
with	ADP	O	O	3930
chest	NOUN	O	O	3930
discomfort	VERB	O	O	3930
disappeared	VERB	O	O	3930
since	SCONJ	O	O	3930
he	PRON	O	O	3930
began	VERB	O	O	3930
taking	VERB	O	O	3930
long	ADV	O	O	3930
-	PUNCT	O	O	3930
acting	VERB	O	O	3930
diltiazem	VERB	O	Chemical	3930
.	PUNCT	O	O	3930
Coronary	ADJ	O	O	3931
vasospasm	NOUN	O	Disease	3931
may	AUX	O	O	3931
be	AUX	O	O	3931
induced	VERB	O	O	3931
by	ADP	O	O	3931
the	PRON	O	O	3931
non	ADJ	O	O	3931
-	PUNCT	O	O	3931
selective	ADJ	O	O	3931
beta	NOUN	O	O	3931
-	PUNCT	O	O	3931
blocking	VERB	O	O	3931
properties	NOUN	O	O	3931
of	ADP	O	O	3931
sotalol	VERB	O	O	3931
.	PUNCT	O	O	3931
Effects	NOUN	O	O	3934
of	ADP	O	O	3934
the	PRON	O	O	3934
antidepressant	NOUN	O	O	3934
trazodone	NOUN	O	Chemical	3934
,	PUNCT	O	O	3934
a	PRON	O	O	3934
5-HT	NOUN	O	Chemical	3934
2A/2C	NUM	O	O	3934
receptor	NOUN	O	O	3934
antagonist	NOUN	O	O	3934
,	PUNCT	O	O	3934
on	ADP	O	O	3934
dopamine	NOUN	O	Chemical	3934
-	PUNCT	O	O	3934
dependent	ADJ	O	O	3934
behaviors	NOUN	O	O	3934
in	ADP	O	O	3934
rats	NOUN	O	O	3934
.	PUNCT	O	O	3934
RATIONALE	PROPN	O	O	3935
:	PUNCT	O	O	3935
5-Hydroxytryptamine	PROPN	O	O	3935
,	PUNCT	O	O	3935
via	ADP	O	O	3935
stimulation	NOUN	O	O	3935
of	ADP	O	O	3935
5-HT	NOUN	O	Chemical	3935
2C	PROPN	O	O	3935
receptors	NOUN	O	O	3935
,	PUNCT	O	O	3935
exerts	VERB	O	O	3935
a	PRON	O	O	3935
tonic	PROPN	O	O	3935
inhibitory	ADJ	O	O	3935
influence	NOUN	O	O	3935
on	ADP	O	O	3935
dopaminergic	ADJ	O	O	3935
neurotransmission	NOUN	O	O	3935
,	PUNCT	O	O	3935
whereas	SCONJ	O	O	3935
activation	NOUN	O	O	3935
of	ADP	O	O	3935
5-HT	NOUN	O	Chemical	3935
2A	X	O	O	3935
receptors	NOUN	O	O	3935
enhances	VERB	O	O	3935
stimulated	VERB	O	O	3935
DAergic	NUM	O	O	3935
neurotransmission	NOUN	O	O	3935
.	PUNCT	O	O	3935
The	PRON	O	O	3936
antidepressant	NOUN	O	O	3936
trazodone	NOUN	O	Chemical	3936
is	AUX	O	O	3936
a	PRON	O	O	3936
5-HT	NOUN	O	Chemical	3936
2A/2C	NUM	O	O	3936
receptor	NOUN	O	O	3936
antagonist	NOUN	O	O	3936
.	PUNCT	O	O	3936
OBJECTIVES	NOUN	O	O	3937
:	PUNCT	O	O	3937
To	PART	O	O	3937
evaluate	VERB	O	O	3937
the	PRON	O	O	3937
effect	VERB	O	O	3937
of	ADP	O	O	3937
trazodone	NOUN	O	Chemical	3937
treatment	NOUN	O	O	3937
on	ADP	O	O	3937
behaviors	NOUN	O	O	3937
dependent	ADJ	O	O	3937
on	ADP	O	O	3937
the	PRON	O	O	3937
functional	ADJ	O	O	3937
status	NOUN	O	O	3937
of	ADP	O	O	3937
the	PRON	O	O	3937
nigrostriatal	NOUN	O	O	3937
DAergic	NUM	O	O	3937
system	NOUN	O	O	3937
.	PUNCT	O	O	3937
The	PRON	O	O	3938
effect	VERB	O	O	3938
of	ADP	O	O	3938
pretreatment	NOUN	O	O	3938
with	ADP	O	O	3938
trazodone	NOUN	O	Chemical	3938
on	ADP	O	O	3938
dexamphetamine-	CCONJ	O	O	3938
and	CCONJ	O	O	3938
apomorphine	PROPN	O	Chemical	3938
-	PUNCT	O	O	3938
induced	VERB	O	O	3938
oral	ADJ	O	O	3938
stereotypies	NOUN	O	Disease	3938
,	PUNCT	O	O	3938
on	ADP	O	O	3938
catalepsy	VERB	O	Disease	3938
induced	VERB	O	O	3938
by	ADP	O	O	3938
haloperidol	NOUN	O	Chemical	3938
and	CCONJ	O	O	3938
apomorphine	PROPN	O	Chemical	3938
(	PUNCT	O	O	3938
0.05	NUM	O	O	3938
mg	VERB	O	O	3938
/	PUNCT	O	O	3938
kg	VERB	O	O	3938
,	PUNCT	O	O	3938
i.p	NOUN	O	O	3938
.	PUNCT	O	O	3938
)	PUNCT	O	O	3938
,	PUNCT	O	O	3938
on	ADP	O	O	3938
ergometrine	VERB	O	O	3938
-	PUNCT	O	O	3938
induced	VERB	O	O	3938
wet	ADJ	O	O	3938
dog	NOUN	O	O	3938
shake	VERB	O	O	3938
(	PUNCT	O	O	3938
WDS	PROPN	O	O	3938
)	PUNCT	O	O	3938
behavior	NOUN	O	O	3938
and	CCONJ	O	O	3938
fluoxetine	NOUN	O	Chemical	3938
-	PUNCT	O	O	3938
induced	VERB	O	O	3938
penile	NOUN	O	O	3938
erections	NOUN	O	O	3938
was	AUX	O	O	3938
studied	VERB	O	O	3938
in	ADP	O	O	3938
rats	NOUN	O	O	3938
.	PUNCT	O	O	3938
We	PRON	O	O	3939
also	ADV	O	O	3939
investigated	VERB	O	O	3939
whether	SCONJ	O	O	3939
trazodone	NOUN	O	Chemical	3939
induces	VERB	O	O	3939
catalepsy	VERB	O	Disease	3939
in	ADP	O	O	3939
rats	NOUN	O	O	3939
.	PUNCT	O	O	3939
Trazodone	NOUN	O	O	3940
at	ADP	O	O	3940
2.5	NUM	O	O	3940
-	PUNCT	O	O	3940
20	NUM	O	O	3940
mg	VERB	O	O	3940
did	VERB	O	O	3941
not	PART	O	O	3941
induce	VERB	O	O	3941
catalepsy	VERB	O	Disease	3941
,	PUNCT	O	O	3941
and	CCONJ	O	O	3941
did	VERB	O	O	3941
not	PART	O	O	3941
antagonize	VERB	O	O	3941
apomorphine	PROPN	O	Chemical	3941
(	PUNCT	O	O	3941
1.5	NUM	O	O	3941
and	CCONJ	O	O	3941
3	X	O	O	3941
mg	VERB	O	O	3941
/	PUNCT	O	O	3941
kg	VERB	O	O	3941
)	PUNCT	O	O	3941
stereotypy	PROPN	O	O	3942
and	CCONJ	O	O	3942
apomorphine	PROPN	O	Chemical	3942
(	PUNCT	O	O	3942
0.05	NUM	O	O	3942
mg	VERB	O	O	3942
/	PUNCT	O	O	3943
kg)-induced	VERB	O	O	3943
catalepsy	VERB	O	Disease	3943
.	PUNCT	O	O	3943
trazodone	NOUN	O	Chemical	3944
enhanced	VERB	O	O	3944
dexamphetamine	NOUN	O	O	3944
stereotypy	PROPN	O	O	3944
,	PUNCT	O	O	3944
and	CCONJ	O	O	3944
antagonized	VERB	O	O	3944
haloperidol	NOUN	O	Chemical	3944
catalepsy	VERB	O	Disease	3944
,	PUNCT	O	O	3944
ergometrine	VERB	O	O	3944
-	PUNCT	O	O	3944
induced	VERB	O	O	3944
WDS	PROPN	O	O	3944
behavior	NOUN	O	O	3944
and	CCONJ	O	O	3944
fluoxetine	NOUN	O	Chemical	3944
-	PUNCT	O	O	3944
induced	VERB	O	O	3944
penile	NOUN	O	O	3944
erections	NOUN	O	O	3944
.	PUNCT	O	O	3944
Trazodone	NOUN	O	O	3945
at	ADP	O	O	3945
30	NUM	O	O	3945
,	PUNCT	O	O	3945
40	NUM	O	O	3945
and	CCONJ	O	O	3945
50	NUM	O	O	3945
mg	VERB	O	O	3945
induced	VERB	O	O	3946
catalepsy	VERB	O	Disease	3946
and	CCONJ	O	O	3946
antagonized	VERB	O	O	3946
apomorphine	PROPN	O	Chemical	3946
and	CCONJ	O	O	3946
dexamphetamine	NOUN	O	O	3946
stereotypies	NOUN	O	Disease	3946
.	PUNCT	O	O	3946
Our	PRON	O	O	3947
results	VERB	O	O	3947
indicate	VERB	O	O	3947
that	SCONJ	O	O	3947
trazodone	NOUN	O	Chemical	3947
at	ADP	O	O	3947
2.5	NUM	O	O	3947
-	PUNCT	O	O	3947
20	NUM	O	O	3947
mg	VERB	O	O	3947
/	PUNCT	O	O	3947
kg	VERB	O	O	3947
does	VERB	O	O	3947
not	PART	O	O	3947
block	NOUN	O	O	3947
pre-	ADV	O	O	3947
and	CCONJ	O	O	3947
postsynaptic	ADJ	O	O	3947
striatal	ADJ	O	O	3947
D2	NOUN	O	O	3947
DA	NOUN	O	Chemical	3947
receptors	NOUN	O	O	3947
,	PUNCT	O	O	3947
while	SCONJ	O	O	3947
at	ADP	O	O	3947
30	NUM	O	O	3947
,	PUNCT	O	O	3947
40	NUM	O	O	3947
and	CCONJ	O	O	3947
50	NUM	O	O	3947
mg	VERB	O	O	3947
/	PUNCT	O	O	3947
kg	VERB	O	O	3947
it	PRON	O	O	3947
blocks	NOUN	O	O	3947
postsynaptic	ADJ	O	O	3947
striatal	ADJ	O	O	3947
D2	NOUN	O	O	3947
DA	NOUN	O	Chemical	3947
receptors	NOUN	O	O	3947
.	PUNCT	O	O	3947
Furthermore	ADV	O	O	3948
,	PUNCT	O	O	3948
at	ADP	O	O	3948
5	NUM	O	O	3948
,	PUNCT	O	O	3948
10	NUM	O	O	3948
and	CCONJ	O	O	3948
20	NUM	O	O	3948
mg	VERB	O	O	3948
/	PUNCT	O	O	3948
kg	VERB	O	O	3948
,	PUNCT	O	O	3948
trazodone	NOUN	O	Chemical	3948
blocks	NOUN	O	O	3948
5-HT	NOUN	O	Chemical	3948
2A	X	O	O	3948
and	CCONJ	O	O	3948
5-HT	NOUN	O	Chemical	3948
2C	PROPN	O	O	3948
receptors	NOUN	O	O	3948
.	PUNCT	O	O	3948
We	PRON	O	O	3949
suggest	VERB	O	O	3949
that	SCONJ	O	O	3949
trazodone	NOUN	O	Chemical	3949
(	PUNCT	O	O	3949
5	NUM	O	O	3949
,	PUNCT	O	O	3949
10	NUM	O	O	3949
and	CCONJ	O	O	3949
20	NUM	O	O	3949
mg	VERB	O	O	3949
/	PUNCT	O	O	3949
kg	VERB	O	O	3949
)	PUNCT	O	O	3949
,	PUNCT	O	O	3949
by	ADP	O	O	3949
blocking	VERB	O	O	3949
the	PRON	O	O	3949
5-HT	NOUN	O	Chemical	3949
2C	PROPN	O	O	3949
receptors	NOUN	O	O	3949
,	PUNCT	O	O	3949
releases	VERB	O	O	3949
the	PRON	O	O	3949
nigrostriatal	NOUN	O	O	3949
DAergic	NUM	O	O	3949
neurons	NOUN	O	O	3949
from	ADP	O	O	3949
tonic	PROPN	O	O	3949
inhibition	NOUN	O	O	3949
caused	VERB	O	O	3949
by	ADP	O	O	3949
5-HT	NOUN	O	Chemical	3949
,	PUNCT	O	O	3949
and	CCONJ	O	O	3949
thereby	ADV	O	O	3949
potentiates	VERB	O	O	3949
dexamphetamine	NOUN	O	O	3949
stereotypy	PROPN	O	O	3949
and	CCONJ	O	O	3949
antagonizes	VERB	O	O	3949
haloperidol	NOUN	O	Chemical	3949
catalepsy	VERB	O	Disease	3949
.	PUNCT	O	O	3949
Swallowing	VERB	O	O	3952
abnormalities	NOUN	O	O	3952
and	CCONJ	O	O	3952
dyskinesia	NOUN	O	Disease	3952
in	ADP	O	O	3952
Parkinson	NOUN	O	O	3952
's	AUX	O	O	3952
disease	PROPN	O	O	3952
.	PUNCT	O	O	3952
Gastrointestinal	ADJ	O	O	3953
abnormalities	NOUN	O	O	3953
in	ADP	O	O	3953
Parkinson	NOUN	O	O	3953
's	AUX	O	O	3953
disease	PROPN	O	O	3953
(	PUNCT	O	O	3953
PD	PROPN	O	Disease	3953
)	PUNCT	O	O	3953
have	VERB	O	O	3953
been	AUX	O	O	3953
known	VERB	O	O	3953
for	ADP	O	O	3953
almost	ADV	O	O	3953
two	NUM	O	O	3953
centuries	NOUN	O	O	3953
,	PUNCT	O	O	3953
but	CCONJ	O	O	3953
many	ADJ	O	O	3953
aspects	NOUN	O	O	3953
concerning	VERB	O	O	3953
their	PRON	O	O	3953
pathophysiology	NOUN	O	O	3953
have	VERB	O	O	3953
not	PART	O	O	3953
been	AUX	O	O	3953
completely	ADV	O	O	3953
clarified	VERB	O	O	3953
.	PUNCT	O	O	3953
The	PRON	O	O	3954
aim	VERB	O	O	3954
of	ADP	O	O	3954
this	PRON	O	O	3954
study	VERB	O	O	3954
was	AUX	O	O	3954
to	PART	O	O	3954
characterize	VERB	O	O	3954
the	PRON	O	O	3954
oropharyngeal	ADJ	O	O	3954
dynamics	NOUN	O	O	3954
in	ADP	O	O	3954
PD	PROPN	O	Disease	3954
patients	NOUN	O	O	3954
with	ADP	O	O	3954
and	CCONJ	O	O	3954
without	ADP	O	O	3954
levodopa	NOUN	O	Chemical	3954
-	PUNCT	O	O	3954
induced	VERB	O	O	3954
dyskinesia	NOUN	O	Disease	3954
.	PUNCT	O	O	3954
Fifteen	NUM	O	O	3955
dyskinetic	VERB	O	Disease	3955
,	PUNCT	O	O	3955
12	NUM	O	O	3955
nondyskinetic	NOUN	O	O	3955
patients	NOUN	O	O	3955
,	PUNCT	O	O	3955
and	CCONJ	O	O	3955
a	PRON	O	O	3955
control	VERB	O	O	3955
group	NOUN	O	O	3955
were	AUX	O	O	3955
included	VERB	O	O	3955
.	PUNCT	O	O	3955
Patients	NOUN	O	O	3956
were	AUX	O	O	3956
asked	VERB	O	O	3956
about	ADP	O	O	3956
dysphagia	NOUN	O	O	3956
and	CCONJ	O	O	3956
evaluated	VERB	O	O	3956
with	ADP	O	O	3956
the	PRON	O	O	3956
Unified	VERB	O	O	3956
Parkinson	NOUN	O	O	3956
's	AUX	O	O	3956
Disease	NOUN	O	O	3956
Rating	NOUN	O	O	3956
Scale	NOUN	O	O	3956
Parts	NOUN	O	O	3956
II	NUM	O	O	3956
and	CCONJ	O	O	3956
III	NUM	O	O	3956
and	CCONJ	O	O	3956
the	PRON	O	O	3956
Hoehn	PROPN	O	O	3956
and	CCONJ	O	O	3956
Yahr	NOUN	O	O	3956
scale	NOUN	O	O	3956
.	PUNCT	O	O	3956
Deglutition	NOUN	O	O	3957
was	AUX	O	O	3957
assessed	VERB	O	O	3957
using	VERB	O	O	3957
modified	VERB	O	O	3957
barium	PROPN	O	O	3957
swallow	VERB	O	O	3957
with	ADP	O	O	3957
videofluoroscopy	PROPN	O	O	3957
.	PUNCT	O	O	3957
Nondyskinetic	NOUN	O	O	3958
patients	NOUN	O	O	3958
,	PUNCT	O	O	3958
but	CCONJ	O	O	3958
not	PART	O	O	3958
the	PRON	O	O	3958
dyskinetic	VERB	O	Disease	3958
ones	NOUN	O	O	3958
,	PUNCT	O	O	3958
showed	VERB	O	O	3958
less	ADV	O	O	3958
oropharyngeal	ADJ	O	O	3958
swallowing	VERB	O	O	3958
efficiency	NOUN	O	O	3958
(	PUNCT	O	O	3958
OPSE	NOUN	O	O	3958
)	PUNCT	O	O	3958
for	ADP	O	O	3958
liquid	ADJ	O	O	3958
food	NOUN	O	O	3958
than	ADP	O	O	3958
controls	VERB	O	O	3958
(	PUNCT	O	O	3958
Dunnett	PROPN	O	O	3958
,	PUNCT	O	O	3958
P	NOUN	O	Chemical	3958
=	PUNCT	O	O	3958
0.02	NUM	O	O	3958
)	PUNCT	O	O	3958
.	PUNCT	O	O	3958
Dyskinetic	NOUN	O	O	3959
patients	NOUN	O	O	3959
tended	VERB	O	O	3959
to	PART	O	O	3959
have	VERB	O	O	3959
a	PRON	O	O	3959
greater	ADJ	O	O	3959
OPSE	NOUN	O	O	3959
than	ADP	O	O	3959
nondyskinetic	NOUN	O	O	3959
(	PUNCT	O	O	3959
Dunnett	PROPN	O	O	3959
,	PUNCT	O	O	3959
P	NOUN	O	Chemical	3959
=	PUNCT	O	O	3959
0.06	NUM	O	O	3959
)	PUNCT	O	O	3959
.	PUNCT	O	O	3959
Patients	NOUN	O	O	3960
who	PRON	O	O	3960
were	AUX	O	O	3960
using	VERB	O	O	3960
a	PRON	O	O	3960
higher	ADJ	O	O	3960
dose	NOUN	O	O	3960
of	ADP	O	O	3960
levodopa	NOUN	O	Chemical	3960
had	VERB	O	O	3960
a	PRON	O	O	3960
greater	ADJ	O	O	3960
OPSE	NOUN	O	O	3960
and	CCONJ	O	O	3960
a	PRON	O	O	3960
trend	NOUN	O	O	3960
toward	ADP	O	O	3960
a	PRON	O	O	3960
smaller	ADJ	O	O	3960
oral	ADJ	O	O	3960
transit	NOUN	O	O	3960
time	NOUN	O	O	3960
(	PUNCT	O	O	3960
Pearson	PROPN	O	O	3960
's	AUX	O	O	3960
correlation	NOUN	O	O	3960
,	PUNCT	O	O	3960
P	NOUN	O	Chemical	3960
=	PUNCT	O	O	3960
0.01	NUM	O	O	3960
and	CCONJ	O	O	3960
0.08	NUM	O	O	3960
,	PUNCT	O	O	3960
respectively	ADV	O	O	3960
)	PUNCT	O	O	3960
.	PUNCT	O	O	3960
Neither	PRON	O	O	3961
the	PRON	O	O	3961
report	VERB	O	O	3961
of	ADP	O	O	3961
dysphagia	NOUN	O	O	3961
nor	CCONJ	O	O	3961
any	PRON	O	O	3961
of	ADP	O	O	3961
the	PRON	O	O	3961
PD	PROPN	O	Disease	3961
severity	NOUN	O	O	3961
parameters	NOUN	O	O	3961
correlated	VERB	O	O	3961
to	PART	O	O	3961
the	PRON	O	O	3961
videofluoroscopic	NOUN	O	O	3961
variables	NOUN	O	O	3961
.	PUNCT	O	O	3961
In	ADP	O	O	3962
the	PRON	O	O	3962
current	ADJ	O	O	3962
study	VERB	O	O	3962
,	PUNCT	O	O	3962
dyskinetic	VERB	O	Disease	3962
patients	NOUN	O	O	3962
performed	VERB	O	O	3962
better	ADV	O	O	3962
in	ADP	O	O	3962
swallowing	VERB	O	O	3962
function	NOUN	O	O	3962
,	PUNCT	O	O	3962
which	PRON	O	O	3962
could	AUX	O	O	3962
be	AUX	O	O	3962
explained	VERB	O	O	3962
on	ADP	O	O	3962
the	PRON	O	O	3962
basis	NOUN	O	O	3962
of	ADP	O	O	3962
a	PRON	O	O	3962
greater	ADJ	O	O	3962
levodopa	NOUN	O	Chemical	3962
dose	NOUN	O	O	3962
.	PUNCT	O	O	3962
Our	PRON	O	O	3963
results	VERB	O	O	3963
suggest	VERB	O	O	3963
a	PRON	O	O	3963
role	NOUN	O	O	3963
for	ADP	O	O	3963
levodopa	NOUN	O	Chemical	3963
in	ADP	O	O	3963
the	PRON	O	O	3963
oral	ADJ	O	O	3963
phase	NOUN	O	O	3963
of	ADP	O	O	3963
deglutition	NOUN	O	O	3963
and	CCONJ	O	O	3963
confirm	VERB	O	O	3963
that	SCONJ	O	O	3963
dysphagia	NOUN	O	O	3963
is	AUX	O	O	3963
not	PART	O	O	3963
a	PRON	O	O	3963
good	ADJ	O	O	3963
predictor	NOUN	O	O	3963
of	ADP	O	O	3963
deglutition	NOUN	O	O	3963
alterations	NOUN	O	O	3963
in	ADP	O	O	3963
PD	PROPN	O	Disease	3963
.	PUNCT	O	O	3963
Inhibition	NOUN	O	O	3966
of	ADP	O	O	3966
nuclear	ADJ	O	O	3966
factor	NOUN	O	O	3966
-	PUNCT	O	O	3966
kappaB	NOUN	O	O	3966
activation	NOUN	O	O	3966
attenuates	VERB	O	O	3966
tubulointerstitial nephritis	NOUN	O	O	3966
induced	VERB	O	O	3966
by	ADP	O	O	3966
gentamicin	VERB	O	Chemical	3966
.	PUNCT	O	O	3966
:	PUNCT	O	O	3967
Animals	NOUN	O	O	3967
treated	VERB	O	O	3967
with	ADP	O	O	3967
gentamicin	VERB	O	Chemical	3967
can	AUX	O	O	3967
show	VERB	O	O	3967
residual	ADJ	O	O	3967
areas	NOUN	O	O	3967
of	ADP	O	O	3967
interstitial	ADJ	O	O	3967
fibrosis	NOUN	O	Disease	3967
in	ADP	O	O	3967
the	PRON	O	O	3967
renal	ADJ	O	O	3967
cortex	VERB	O	O	3967
.	PUNCT	O	O	3967
kinases	NOUN	O	O	3968
and	CCONJ	O	O	3968
macrophages	VERB	O	O	3968
in	ADP	O	O	3968
the	PRON	O	O	3968
renal	ADJ	O	O	3968
cortex	VERB	O	O	3968
and	CCONJ	O	O	3968
structural	ADJ	O	O	3968
and	CCONJ	O	O	3968
functional	ADJ	O	O	3968
renal	ADJ	O	O	3968
changes	VERB	O	O	3968
of	ADP	O	O	3968
rats	NOUN	O	O	3968
treated	VERB	O	O	3968
with	ADP	O	O	3968
gentamicin	VERB	O	Chemical	3968
or	CCONJ	O	O	3968
gentamicin	VERB	O	Chemical	3968
+	ADP	O	O	3968
pyrrolidine	NOUN	O	O	3968
dithiocarbamate	NOUN	O	O	3968
(	PUNCT	O	O	3968
PDTC	NOUN	O	O	3968
)	PUNCT	O	O	3968
,	PUNCT	O	O	3968
an	PRON	O	O	3968
NF	PROPN	O	O	3968
-	PUNCT	O	O	3968
kappaB	NOUN	O	O	3968
inhibitor	NOUN	O	O	3968
.	PUNCT	O	O	3968
METHODS	NOUN	O	O	3969
:	PUNCT	O	O	3969
38	NUM	O	O	3969
female	ADJ	O	O	3969
Wistar	PROPN	O	O	3969
rats	NOUN	O	O	3969
were	AUX	O	O	3969
injected	VERB	O	O	3969
with	ADP	O	O	3969
gentamicin	VERB	O	Chemical	3969
,	PUNCT	O	O	3969
40	NUM	O	O	3969
mg	VERB	O	O	3969
/	PUNCT	O	O	3969
kg	VERB	O	O	3969
,	PUNCT	O	O	3969
twice	ADV	O	O	3969
a	PRON	O	O	3969
day	NOUN	O	O	3969
for	ADP	O	O	3969
9	NUM	O	O	3969
days	NOUN	O	O	3969
,	PUNCT	O	O	3969
38	NUM	O	O	3969
with	ADP	O	O	3969
gentamicin	VERB	O	Chemical	3969
+	ADP	O	O	3969
PDTC	NOUN	O	O	3969
,	PUNCT	O	O	3969
and	CCONJ	O	O	3969
28	NUM	O	O	3969
with	ADP	O	O	3969
0.15	NUM	O	O	3969
M	NOUN	O	Chemical	3969
NaCl	NOUN	O	O	3969
solution	NOUN	O	O	3969
.	PUNCT	O	O	3969
Gentamicin	PROPN	O	Chemical	3970
-	PUNCT	O	O	3970
treated	VERB	O	O	3970
rats	NOUN	O	O	3970
presented	VERB	O	O	3970
a	PRON	O	O	3970
transitory	ADJ	O	O	3970
increase	VERB	O	O	3970
in	ADP	O	O	3970
plasma	NOUN	O	O	3970
creatinine	PROPN	O	Chemical	3970
levels	NOUN	O	O	3970
.	PUNCT	O	O	3970
Increased	VERB	O	O	3971
ED-1	NOUN	O	O	3971
,	PUNCT	O	O	3971
MAP	PROPN	O	O	3971
kinases	NOUN	O	O	3971
and	CCONJ	O	O	3971
NF	PROPN	O	O	3971
-	PUNCT	O	O	3971
kappaB	NOUN	O	O	3971
staining	VERB	O	O	3971
were	AUX	O	O	3971
also	ADV	O	O	3971
observed	VERB	O	O	3971
in	ADP	O	O	3971
the	PRON	O	O	3971
renal	ADJ	O	O	3971
cortex	VERB	O	O	3971
from	ADP	O	O	3971
all	PRON	O	O	3971
gentamicin	VERB	O	Chemical	3971
-	PUNCT	O	O	3971
treated	VERB	O	O	3971
rats	NOUN	O	O	3971
compared	VERB	O	O	3971
to	PART	O	O	3971
control	VERB	O	O	3971
(	PUNCT	O	O	3971
p	NOUN	O	O	3971
<	X	O	O	3971
0.05	NUM	O	O	3971
)	PUNCT	O	O	3971
.	PUNCT	O	O	3971
The	PRON	O	O	3972
animals	NOUN	O	O	3972
killed	VERB	O	O	3972
on	ADP	O	O	3972
day	NOUN	O	O	3972
30	NUM	O	O	3972
also	ADV	O	O	3972
presented	VERB	O	O	3972
fibrosis	NOUN	O	Disease	3972
in	ADP	O	O	3972
the	PRON	O	O	3972
renal	ADJ	O	O	3972
cortex	VERB	O	O	3972
despite	SCONJ	O	O	3972
the	PRON	O	O	3972
recovery	NOUN	O	O	3972
of	ADP	O	O	3972
renal	ADJ	O	O	3972
function	NOUN	O	O	3972
.	PUNCT	O	O	3972
Treatment	NOUN	O	O	3973
with	ADP	O	O	3973
PDTC	NOUN	O	O	3973
reduced	VERB	O	O	3973
the	PRON	O	O	3973
functional	ADJ	O	O	3973
and	CCONJ	O	O	3973
structural	ADJ	O	O	3973
changes	VERB	O	O	3973
induced	VERB	O	O	3973
by	ADP	O	O	3973
gentamicin	VERB	O	Chemical	3973
.	PUNCT	O	O	3973
These	PRON	O	O	3974
data	NOUN	O	O	3974
show	VERB	O	O	3974
that	SCONJ	O	O	3974
inhibition	NOUN	O	O	3974
of	ADP	O	O	3974
NF	PROPN	O	O	3974
-	PUNCT	O	O	3974
kappaB	NOUN	O	O	3974
activation	NOUN	O	O	3974
attenuates	VERB	O	O	3974
tubulointerstitial nephritis	NOUN	O	O	3974
induced	VERB	O	O	3974
by	ADP	O	O	3974
gentamicin	VERB	O	Chemical	3974
.	PUNCT	O	O	3974
Glucose	NOUN	O	O	3977
metabolism	NOUN	O	O	3977
in	ADP	O	O	3977
patients	NOUN	O	O	3977
with	ADP	O	O	3977
schizophrenia	PROPN	O	Disease	3977
treated	VERB	O	O	3977
with	ADP	O	O	3977
atypical	ADJ	O	O	3977
antipsychotic	ADJ	O	O	3977
agents	NOUN	O	O	3977
:	PUNCT	O	O	3977
a	PRON	O	O	3977
frequently	ADV	O	O	3977
sampled	VERB	O	O	3977
intravenous	ADJ	O	O	3977
glucose	NOUN	O	Chemical	3977
tolerance	NOUN	O	O	3977
test	NOUN	O	O	3977
and	CCONJ	O	O	3977
minimal	ADJ	O	O	3977
model	NOUN	O	O	3977
analysis	NOUN	O	O	3977
.	PUNCT	O	O	3977
While	SCONJ	O	O	3978
the	PRON	O	O	3978
incidence	NOUN	O	O	3978
of	ADP	O	O	3978
new	ADJ	O	O	3978
-	PUNCT	O	O	3978
onset	VERB	O	O	3978
diabetes mellitus	ADJ	O	Disease	3978
may	AUX	O	O	3978
be	AUX	O	O	3978
increasing	VERB	O	O	3978
in	ADP	O	O	3978
patients	NOUN	O	O	3978
with	ADP	O	O	3978
schizophrenia	PROPN	O	Disease	3978
treated	VERB	O	O	3978
with	ADP	O	O	3978
certain	ADJ	O	O	3978
atypical	ADJ	O	O	3978
antipsychotic	ADJ	O	O	3978
agents	NOUN	O	O	3978
,	PUNCT	O	O	3978
it	PRON	O	O	3978
remains	VERB	O	O	3978
unclear	ADJ	O	O	3978
whether	SCONJ	O	O	3978
atypical	ADJ	O	O	3978
agents	NOUN	O	O	3978
are	AUX	O	O	3978
directly	ADV	O	O	3978
affecting	VERB	O	O	3978
glucose	NOUN	O	Chemical	3978
metabolism	NOUN	O	O	3978
or	CCONJ	O	O	3978
simply	ADV	O	O	3978
increasing	VERB	O	O	3978
known	VERB	O	O	3978
risk	NOUN	O	O	3978
factors	NOUN	O	O	3978
for	ADP	O	O	3978
diabetes	NOUN	O	Disease	3978
.	PUNCT	O	O	3978
OBJECTIVE	VERB	O	O	3979
:	PUNCT	O	O	3979
To	PART	O	O	3979
study	VERB	O	O	3979
the	PRON	O	O	3979
2	X	O	O	3979
drugs	NOUN	O	O	3979
most	ADV	O	O	3979
clearly	ADV	O	O	3979
implicated	VERB	O	O	3979
(	PUNCT	O	O	3979
clozapine	PROPN	O	Chemical	3979
and	CCONJ	O	O	3979
olanzapine	NOUN	O	Chemical	3979
)	PUNCT	O	O	3979
and	CCONJ	O	O	3979
risperidone	VERB	O	Chemical	3979
using	VERB	O	O	3979
a	PRON	O	O	3979
frequently	ADV	O	O	3979
sampled	VERB	O	O	3979
intravenous	ADJ	O	O	3979
glucose	NOUN	O	Chemical	3979
tolerance	NOUN	O	O	3979
test	NOUN	O	O	3979
.	PUNCT	O	O	3979
A	PRON	O	O	3980
cross	VERB	O	O	3980
-	PUNCT	O	O	3980
sectional	ADJ	O	O	3980
design	NOUN	O	O	3980
in	ADP	O	O	3980
stable	ADJ	O	O	3980
,	PUNCT	O	O	3980
treated	VERB	O	O	3980
patients	NOUN	O	O	3980
with	ADP	O	O	3980
schizophrenia	PROPN	O	Disease	3980
evaluated	VERB	O	O	3980
using	VERB	O	O	3980
a	PRON	O	O	3980
frequently	ADV	O	O	3980
sampled	VERB	O	O	3980
intravenous	ADJ	O	O	3980
glucose	NOUN	O	Chemical	3980
tolerance	NOUN	O	O	3980
test	NOUN	O	O	3980
and	CCONJ	O	O	3980
the	PRON	O	O	3980
Bergman	PROPN	O	O	3980
minimal	ADJ	O	O	3980
model	NOUN	O	O	3980
analysis	NOUN	O	O	3980
.	PUNCT	O	O	3980
Patients	NOUN	O	O	3981
Fifty	NUM	O	O	3981
subjects	NOUN	O	O	3981
signed	VERB	O	O	3981
informed	VERB	O	O	3981
consent	NOUN	O	O	3981
and	CCONJ	O	O	3981
41	NUM	O	O	3981
underwent	VERB	O	O	3981
the	PRON	O	O	3981
frequently	ADV	O	O	3981
sampled	VERB	O	O	3981
intravenous	ADJ	O	O	3981
glucose	NOUN	O	Chemical	3981
tolerance	NOUN	O	O	3981
test	NOUN	O	O	3981
.	PUNCT	O	O	3981
Thirty	NUM	O	O	3982
-	PUNCT	O	O	3982
six	NUM	O	O	3982
nonobese	ADV	O	O	3982
subjects	NOUN	O	O	3982
with	ADP	O	O	3982
schizophrenia	PROPN	O	Disease	3982
or	CCONJ	O	O	3982
schizoaffective	VERB	O	O	3982
disorder	NOUN	O	O	3982
,	PUNCT	O	O	3982
matched	VERB	O	O	3982
by	ADP	O	O	3982
body	NOUN	O	O	3982
mass	PROPN	O	O	3982
index	NOUN	O	O	3982
and	CCONJ	O	O	3982
treated	VERB	O	O	3982
with	ADP	O	O	3982
either	ADV	O	O	3982
clozapine	PROPN	O	Chemical	3982
,	PUNCT	O	O	3982
olanzapine	NOUN	O	Chemical	3982
,	PUNCT	O	O	3982
or	CCONJ	O	O	3982
risperidone	VERB	O	Chemical	3982
,	PUNCT	O	O	3982
were	AUX	O	O	3982
included	VERB	O	O	3982
in	ADP	O	O	3982
the	PRON	O	O	3982
analysis	NOUN	O	O	3982
.	PUNCT	O	O	3982
Fasting	VERB	O	O	3983
plasma	NOUN	O	O	3983
glucose	NOUN	O	Chemical	3983
and	CCONJ	O	O	3983
fasting	VERB	O	O	3983
serum	NOUN	O	O	3983
insulin	NOUN	O	O	3983
levels	NOUN	O	O	3983
,	PUNCT	O	O	3983
insulin	NOUN	O	O	3983
sensitivity	NOUN	O	O	3983
index	NOUN	O	O	3983
,	PUNCT	O	O	3983
homeostasis	NOUN	O	O	3983
model	NOUN	O	O	3983
assessment	NOUN	O	O	3983
of	ADP	O	O	3983
insulin	NOUN	O	O	3983
resistance	NOUN	O	O	3983
,	PUNCT	O	O	3983
and	CCONJ	O	O	3983
glucose	NOUN	O	Chemical	3983
effectiveness	NOUN	O	O	3983
.	PUNCT	O	O	3983
28.9	NUM	O	O	3984
months	NOUN	O	O	3984
(	PUNCT	O	O	3984
clozapine	PROPN	O	Chemical	3984
)	PUNCT	O	O	3984
,	PUNCT	O	O	3984
29.5	NUM	O	O	3984
+	ADP	O	O	3984
/-	PUNCT	O	O	3984
17.5	NUM	O	O	3985
months	NOUN	O	O	3985
(	PUNCT	O	O	3985
olanzapine	NOUN	O	Chemical	3985
)	PUNCT	O	O	3985
,	PUNCT	O	O	3985
and	CCONJ	O	O	3985
40.9	NUM	O	O	3985
+	ADP	O	O	3985
/-	PUNCT	O	O	3985
33.7	NUM	O	O	3986
(	PUNCT	O	O	3986
risperidone	VERB	O	Chemical	3986
)	PUNCT	O	O	3986
.	PUNCT	O	O	3986
Fasting	VERB	O	O	3987
serum	NOUN	O	O	3987
insulin	NOUN	O	O	3987
concentrations	NOUN	O	O	3987
differed	VERB	O	O	3987
among	ADP	O	O	3987
groups	NOUN	O	O	3987
(	PUNCT	O	O	3987
F(33	NUM	O	O	3987
)	PUNCT	O	O	3987
=	PUNCT	O	O	3987
3.35	NUM	O	O	3987
;	PUNCT	O	O	3987
P	NOUN	O	Chemical	3987
=	PUNCT	O	O	3987
.047	NUM	O	O	3987
)	PUNCT	O	O	3987
(	PUNCT	O	O	3987
clozapine	PROPN	O	Chemical	3987
>	PUNCT	O	O	3987
olanzapine	NOUN	O	Chemical	3987
>	PUNCT	O	O	3987
risperidone	VERB	O	Chemical	3987
)	PUNCT	O	O	3987
with	ADP	O	O	3987
significant	ADJ	O	O	3987
differences	NOUN	O	O	3987
between	ADP	O	O	3987
clozapine	PROPN	O	Chemical	3987
and	CCONJ	O	O	3987
risperidone	VERB	O	Chemical	3987
(	PUNCT	O	O	3987
t(33	PROPN	O	O	3987
)	PUNCT	O	O	3987
=	PUNCT	O	O	3987
2.32	NUM	O	O	3987
;	PUNCT	O	O	3987
P	NOUN	O	Chemical	3987
=	PUNCT	O	O	3987
.03	NUM	O	O	3987
)	PUNCT	O	O	3987
and	CCONJ	O	O	3987
olanzapine	NOUN	O	Chemical	3987
and	CCONJ	O	O	3987
risperidone	VERB	O	Chemical	3987
(	PUNCT	O	O	3987
t(33	PROPN	O	O	3987
)	PUNCT	O	O	3987
=	PUNCT	O	O	3987
2.15	NUM	O	O	3987
;	PUNCT	O	O	3987
P	NOUN	O	Chemical	3987
=	PUNCT	O	O	3987
.04	NUM	O	O	3987
)	PUNCT	O	O	3987
.	PUNCT	O	O	3987
There	ADV	O	O	3988
was	AUX	O	O	3988
a	PRON	O	O	3988
significant	ADJ	O	O	3988
difference	NOUN	O	O	3988
in	ADP	O	O	3988
insulin	NOUN	O	O	3988
sensitivity	NOUN	O	O	3988
index	NOUN	O	O	3988
among	ADP	O	O	3988
groups	NOUN	O	O	3988
(	PUNCT	O	O	3988
F(33	NUM	O	O	3988
)	PUNCT	O	O	3988
=	PUNCT	O	O	3988
10.66	NUM	O	O	3988
;	PUNCT	O	O	3988
P<.001	NOUN	O	O	3988
)	PUNCT	O	O	3988
(	PUNCT	O	O	3988
clozapine	PROPN	O	Chemical	3988
<	X	O	O	3988
olanzapine	NOUN	O	Chemical	3988
<	X	O	O	3988
risperidone	VERB	O	Chemical	3988
)	PUNCT	O	O	3988
,	PUNCT	O	O	3988
with	ADP	O	O	3988
subjects	NOUN	O	O	3988
who	PRON	O	O	3988
received	VERB	O	O	3988
clozapine	PROPN	O	Chemical	3988
and	CCONJ	O	O	3988
olanzapine	NOUN	O	Chemical	3988
exhibiting	VERB	O	O	3988
significant	ADJ	O	O	3988
insulin	NOUN	O	O	3988
resistance	NOUN	O	O	3988
compared	VERB	O	O	3988
with	ADP	O	O	3988
subjects	NOUN	O	O	3988
who	PRON	O	O	3988
were	AUX	O	O	3988
treated	VERB	O	O	3988
with	ADP	O	O	3988
risperidone	VERB	O	Chemical	3988
(	PUNCT	O	O	3988
clozapine	PROPN	O	Chemical	3988
vs	ADP	O	O	3988
risperidone	VERB	O	Chemical	3988
,	PUNCT	O	O	3988
t(33	PROPN	O	O	3988
)	PUNCT	O	O	3988
=	PUNCT	O	O	3988
-4.29	NUM	O	O	3988
;	PUNCT	O	O	3988
P<.001	NOUN	O	O	3988
;	PUNCT	O	O	3988
olanzapine	NOUN	O	Chemical	3988
vs	ADP	O	O	3988
risperidone	VERB	O	Chemical	3988
,	PUNCT	O	O	3988
t(33	PROPN	O	O	3988
)	PUNCT	O	O	3988
=	PUNCT	O	O	3988
-3.62	NUM	O	O	3988
;	PUNCT	O	O	3988
P	NOUN	O	Chemical	3988
=	PUNCT	O	O	3988
.001	NUM	O	O	3988
[	X	O	O	3988
P<.001	NOUN	O	O	3988
]	PUNCT	O	O	3988
)	PUNCT	O	O	3988
.	PUNCT	O	O	3988
The	PRON	O	O	3989
homeostasis	NOUN	O	O	3989
model	NOUN	O	O	3989
assessment	NOUN	O	O	3989
of	ADP	O	O	3989
insulin	NOUN	O	O	3989
resistance	NOUN	O	O	3989
also	ADV	O	O	3989
differed	VERB	O	O	3989
significantly	ADV	O	O	3989
among	ADP	O	O	3989
groups	NOUN	O	O	3989
(	PUNCT	O	O	3989
F(33	NUM	O	O	3989
)	PUNCT	O	O	3989
=	PUNCT	O	O	3989
4.92	NUM	O	O	3989
;	PUNCT	O	O	3989
P	NOUN	O	Chemical	3989
=	PUNCT	O	O	3989
.01	NUM	O	O	3989
)	PUNCT	O	O	3989
(	PUNCT	O	O	3989
clozapine	PROPN	O	Chemical	3989
>	PUNCT	O	O	3989
olanzapine	NOUN	O	Chemical	3989
>	PUNCT	O	O	3989
risperidone	VERB	O	Chemical	3989
)	PUNCT	O	O	3989
(	PUNCT	O	O	3989
clozapine	PROPN	O	Chemical	3989
vs	ADP	O	O	3989
risperidone	VERB	O	Chemical	3989
,	PUNCT	O	O	3989
t(33	PROPN	O	O	3989
)	PUNCT	O	O	3989
=	PUNCT	O	O	3989
2.94	NUM	O	O	3989
;	PUNCT	O	O	3989
P	NOUN	O	Chemical	3989
=	PUNCT	O	O	3989
.006	NUM	O	O	3989
;	PUNCT	O	O	3989
olanzapine	NOUN	O	Chemical	3989
vs	ADP	O	O	3989
risperidone	VERB	O	Chemical	3989
,	PUNCT	O	O	3989
t(33	PROPN	O	O	3989
)	PUNCT	O	O	3989
=	PUNCT	O	O	3989
2.42	NUM	O	O	3989
;	PUNCT	O	O	3989
P	NOUN	O	Chemical	3989
=	PUNCT	O	O	3989
.02	NUM	O	O	3989
)	PUNCT	O	O	3989
.	PUNCT	O	O	3989
There	ADV	O	O	3990
was	AUX	O	O	3990
a	PRON	O	O	3990
significant	ADJ	O	O	3990
difference	NOUN	O	O	3990
among	ADP	O	O	3990
groups	NOUN	O	O	3990
in	ADP	O	O	3990
glucose	NOUN	O	Chemical	3990
effectiveness	NOUN	O	O	3990
(	PUNCT	O	O	3990
F(30	PROPN	O	O	3990
)	PUNCT	O	O	3990
=	PUNCT	O	O	3990
4.18	NUM	O	O	3990
;	PUNCT	O	O	3990
P	NOUN	O	Chemical	3991
=	PUNCT	O	O	3991
.02	NUM	O	O	3991
)	PUNCT	O	O	3991
(	PUNCT	O	O	3991
clozapine	PROPN	O	Chemical	3991
<	X	O	O	3991
olanzapine	NOUN	O	Chemical	3991
<	X	O	O	3991
risperidone	VERB	O	Chemical	3991
)	PUNCT	O	O	3991
with	ADP	O	O	3991
significant	ADJ	O	O	3991
differences	NOUN	O	O	3991
between	ADP	O	O	3991
clozapine	PROPN	O	Chemical	3991
and	CCONJ	O	O	3991
risperidone	VERB	O	Chemical	3991
(	PUNCT	O	O	3991
t(30	PUNCT	O	O	3991
)	PUNCT	O	O	3991
=	PUNCT	O	O	3991
-2.59	NUM	O	O	3991
;	PUNCT	O	O	3991
P	NOUN	O	Chemical	3991
=	PUNCT	O	O	3991
.02	NUM	O	O	3991
)	PUNCT	O	O	3991
and	CCONJ	O	O	3991
olanzapine	NOUN	O	Chemical	3991
and	CCONJ	O	O	3991
risperidone	VERB	O	Chemical	3991
(	PUNCT	O	O	3991
t(30	PUNCT	O	O	3991
)	PUNCT	O	O	3991
=	PUNCT	O	O	3991
-2.34	NUM	O	O	3991
,	PUNCT	O	O	3991
P	NOUN	O	Chemical	3991
=	PUNCT	O	O	3991
.03	NUM	O	O	3991
)	PUNCT	O	O	3991
.	PUNCT	O	O	3991
Both	PRON	O	O	3992
nonobese	ADV	O	O	3992
clozapine-	NOUN	O	O	3992
and	CCONJ	O	O	3992
olanzapine	NOUN	O	Chemical	3993
-	PUNCT	O	O	3993
treated	VERB	O	O	3993
groups	NOUN	O	O	3993
displayed	VERB	O	O	3993
significant	ADJ	O	O	3993
insulin	NOUN	O	O	3993
resistance	NOUN	O	O	3993
and	CCONJ	O	O	3993
impairment	NOUN	O	O	3993
of	ADP	O	O	3993
glucose	NOUN	O	Chemical	3993
effectiveness	NOUN	O	O	3993
compared	VERB	O	O	3993
with	ADP	O	O	3993
risperidone	VERB	O	Chemical	3993
-	PUNCT	O	O	3993
treated	VERB	O	O	3993
subjects	NOUN	O	O	3993
.	PUNCT	O	O	3993
Patients	NOUN	O	O	3994
taking	VERB	O	O	3994
clozapine	PROPN	O	Chemical	3994
and	CCONJ	O	O	3994
olanzapine	NOUN	O	Chemical	3994
must	AUX	O	O	3994
be	AUX	O	O	3994
examined	VERB	O	O	3994
for	ADP	O	O	3994
insulin	NOUN	O	O	3994
resistance	NOUN	O	O	3994
and	CCONJ	O	O	3994
its	PRON	O	O	3994
consequences	NOUN	O	O	3994
.	PUNCT	O	O	3994
Focal	ADJ	O	O	3997
cerebral ischemia	NOUN	O	Disease	3997
in	ADP	O	O	3997
rats	NOUN	O	O	3997
:	PUNCT	O	O	3997
effect	VERB	O	O	3997
of	ADP	O	O	3997
phenylephrine	NOUN	O	Chemical	3997
-	PUNCT	O	O	3997
induced	VERB	O	O	3997
hypertension	NOUN	O	Disease	3997
during	ADP	O	O	3997
reperfusion	NOUN	O	O	3997
.	PUNCT	O	O	3997
After	ADP	O	O	3998
180	NUM	O	O	3998
min	NOUN	O	O	3998
of	ADP	O	O	3998
temporary	ADJ	O	O	3998
middle	ADJ	O	O	3998
cerebral artery occlusion	NOUN	O	Disease	3998
in	ADP	O	O	3998
spontaneously	ADV	O	O	3998
hypertensive	ADJ	O	Disease	3998
rats	NOUN	O	O	3998
,	PUNCT	O	O	3998
the	PRON	O	O	3998
effect	VERB	O	O	3998
of	ADP	O	O	3998
phenylephrine	NOUN	O	Chemical	3998
-	PUNCT	O	O	3998
induced	VERB	O	O	3998
hypertension	NOUN	O	Disease	3998
on	ADP	O	O	3998
ischemic brain injury	NOUN	O	Disease	3998
and	CCONJ	O	O	3998
blood	NOUN	O	O	3998
-	PUNCT	O	O	3998
brain	NOUN	O	O	3998
barrier	NOUN	O	O	3998
permeability	NOUN	O	O	3998
was	AUX	O	O	3998
determined	VERB	O	O	3998
.	PUNCT	O	O	3998
Blood	NOUN	O	O	3999
pressure	NOUN	O	O	3999
was	AUX	O	O	3999
manipulated	VERB	O	O	3999
by	ADP	O	O	3999
one	NUM	O	O	3999
of	ADP	O	O	3999
the	PRON	O	O	3999
following	VERB	O	O	3999
schedules	NOUN	O	O	3999
during	ADP	O	O	3999
120	NUM	O	O	3999
min	NOUN	O	O	3999
of	ADP	O	O	3999
reperfusion	NOUN	O	O	3999
:	PUNCT	O	O	3999
Control	NOUN	O	O	3999
,	PUNCT	O	O	3999
normotensive	PROPN	O	O	3999
reperfusion	NOUN	O	O	3999
;	PUNCT	O	O	3999
90/hypertension	NOUN	O	O	3999
(	PUNCT	O	O	3999
90/HTN	NOUN	O	O	3999
)	PUNCT	O	O	3999
,	PUNCT	O	O	3999
blood	NOUN	O	O	3999
pressure	NOUN	O	O	3999
was	AUX	O	O	3999
increased	VERB	O	O	3999
by	ADP	O	O	3999
35	NUM	O	O	3999
mm	INTJ	O	O	3999
Hg	PROPN	O	O	3999
during	ADP	O	O	3999
the	PRON	O	O	3999
initial	ADJ	O	O	3999
90	NUM	O	O	3999
min	NOUN	O	O	3999
of	ADP	O	O	3999
reperfusion	NOUN	O	O	3999
only	ADV	O	O	3999
;	PUNCT	O	O	3999
15/hypertension	NOUN	O	O	3999
(	PUNCT	O	O	3999
15/HTN	NOUN	O	O	3999
)	PUNCT	O	O	3999
,	PUNCT	O	O	3999
normotensive	PROPN	O	O	3999
reperfusion	NOUN	O	O	3999
for	ADP	O	O	3999
30	NUM	O	O	3999
min	NOUN	O	O	3999
followed	VERB	O	O	3999
by	ADP	O	O	3999
15	NUM	O	O	3999
min	NOUN	O	O	3999
of	ADP	O	O	3999
hypertension	NOUN	O	Disease	3999
and	CCONJ	O	O	3999
75	NUM	O	O	3999
min	NOUN	O	O	3999
of	ADP	O	O	3999
normotension	NOUN	O	O	3999
.	PUNCT	O	O	3999
Part	NOUN	O	O	4000
A	PRON	O	O	4000
,	PUNCT	O	O	4000
for	ADP	O	O	4000
eight	NUM	O	O	4000
rats	NOUN	O	O	4000
in	ADP	O	O	4000
each	PRON	O	O	4000
group	NOUN	O	O	4000
brain	NOUN	O	O	4000
injury	NOUN	O	O	4000
was	AUX	O	O	4000
evaluated	VERB	O	O	4000
by	ADP	O	O	4000
staining	VERB	O	O	4000
tissue	NOUN	O	O	4000
using	VERB	O	O	4000
2,3,5-triphenyltetrazolium	NOUN	O	Chemical	4000
chloride	NOUN	O	Chemical	4000
and	CCONJ	O	O	4000
edema	NOUN	O	Disease	4000
was	AUX	O	O	4000
evaluated	VERB	O	O	4000
by	ADP	O	O	4000
microgravimetry	NOUN	O	O	4000
.	PUNCT	O	O	4000
Brain	NOUN	O	O	4001
injury	NOUN	O	O	4001
(	PUNCT	O	O	4001
percentage	NOUN	O	O	4001
of	ADP	O	O	4001
the	PRON	O	O	4001
ischemic	VERB	O	Disease	4001
hemisphere	ADV	O	O	4001
)	PUNCT	O	O	4001
was	AUX	O	O	4001
less	ADV	O	O	4001
in	ADP	O	O	4001
the	PRON	O	O	4001
15/HTN	NOUN	O	O	4001
group	NOUN	O	O	4001
(	PUNCT	O	O	4001
16	NUM	O	O	4001
+	ADP	O	O	4001
/-	PUNCT	O	O	4001
SD	NOUN	O	O	4002
)	PUNCT	O	O	4002
versus	ADP	O	O	4002
the	PRON	O	O	4002
90/HTN	NOUN	O	O	4002
group	NOUN	O	O	4002
(	PUNCT	O	O	4002
30	NUM	O	O	4002
+	ADP	O	O	4002
/-	PUNCT	O	O	4002
Specific	ADJ	O	O	4003
gravity	NOUN	O	O	4003
was	AUX	O	O	4003
greater	ADJ	O	O	4003
in	ADP	O	O	4003
the	PRON	O	O	4003
15/HTN	NOUN	O	O	4003
group	NOUN	O	O	4003
(	PUNCT	O	O	4003
1.043	NUM	O	O	4003
+	ADP	O	O	4003
/-	PUNCT	O	O	4003
0.002	NUM	O	O	4004
)	PUNCT	O	O	4004
versus	ADP	O	O	4004
the	PRON	O	O	4004
90/HTN	NOUN	O	O	4004
(	PUNCT	O	O	4004
1.036	NUM	O	O	4004
+	ADP	O	O	4004
/-	PUNCT	O	O	4004
0.003	NUM	O	O	4004
)	PUNCT	O	O	4004
and	CCONJ	O	O	4004
control	VERB	O	O	4004
(	PUNCT	O	O	4004
1.037	NUM	O	O	4004
+	ADP	O	O	4004
/-	PUNCT	O	O	4004
Evans	PROPN	O	O	4005
Blue	ADJ	O	O	4005
(	PUNCT	O	O	4005
mug	NOUN	O	O	4005
g-1	PROPN	O	O	4005
of	ADP	O	O	4005
brain	NOUN	O	O	4005
tissue	NOUN	O	O	4005
)	PUNCT	O	O	4005
was	AUX	O	O	4005
greater	ADJ	O	O	4005
in	ADP	O	O	4005
the	PRON	O	O	4005
90/HTN	NOUN	O	O	4005
group	NOUN	O	O	4005
(	PUNCT	O	O	4005
24.4	NUM	O	O	4005
+	ADP	O	O	4005
/-	PUNCT	O	O	4005
4.1	NUM	O	O	4006
)	PUNCT	O	O	4006
,	PUNCT	O	O	4006
which	PRON	O	O	4006
was	AUX	O	O	4006
in	ADP	O	O	4006
turn	VERB	O	O	4006
greater	ADJ	O	O	4006
than	ADP	O	O	4006
the	PRON	O	O	4006
15/HTN	NOUN	O	O	4006
group	NOUN	O	O	4006
(	PUNCT	O	O	4006
7.3	NUM	O	O	4006
+	ADP	O	O	4006
/-	PUNCT	O	O	4006
This	PRON	O	O	4007
study	VERB	O	O	4007
supports	VERB	O	O	4007
a	PRON	O	O	4007
hypothesis	NOUN	O	O	4007
that	SCONJ	O	O	4007
during	ADP	O	O	4007
reperfusion	NOUN	O	O	4007
,	PUNCT	O	O	4007
a	PRON	O	O	4007
short	ADJ	O	O	4007
interval	NOUN	O	O	4007
of	ADP	O	O	4007
hypertension	NOUN	O	Disease	4007
decreases	VERB	O	O	4007
brain	NOUN	O	O	4007
injury	NOUN	O	O	4007
and	CCONJ	O	O	4007
edema	NOUN	O	Disease	4007
;	PUNCT	O	O	4007
and	CCONJ	O	O	4007
that	SCONJ	O	O	4007
sustained	VERB	O	O	4007
hypertension	NOUN	O	Disease	4007
increases	VERB	O	O	4007
the	PRON	O	O	4007
risk	NOUN	O	O	4007
of	ADP	O	O	4007
vasogenic	PROPN	O	O	4007
edema	NOUN	O	Disease	4007
.	PUNCT	O	O	4007
People	NOUN	O	O	4010
aged	ADJ	O	O	4010
over	ADP	O	O	4010
75	NUM	O	O	4010
in	ADP	O	O	4010
atrial fibrillation	NOUN	O	Disease	4010
on	ADP	O	O	4010
warfarin	VERB	O	Chemical	4010
:	PUNCT	O	O	4010
the	PRON	O	O	4010
rate	NOUN	O	O	4010
of	ADP	O	O	4010
major	ADJ	O	O	4010
hemorrhage	NOUN	O	Disease	4010
and	CCONJ	O	O	4010
stroke	VERB	O	Disease	4010
in	ADP	O	O	4010
more	ADJ	O	O	4010
than	ADP	O	O	4010
500	NUM	O	O	4010
patient	NOUN	O	O	4010
-	PUNCT	O	O	4010
years	NOUN	O	O	4010
of	ADP	O	O	4010
follow	VERB	O	O	4010
-	PUNCT	O	O	4010
up	ADP	O	O	4010
.	PUNCT	O	O	4010
OBJECTIVES	NOUN	O	O	4011
:	PUNCT	O	O	4011
To	PART	O	O	4011
determine	VERB	O	O	4011
the	PRON	O	O	4011
incidence	NOUN	O	O	4011
of	ADP	O	O	4011
major	ADJ	O	O	4011
hemorrhage	NOUN	O	Disease	4011
and	CCONJ	O	O	4011
stroke	VERB	O	Disease	4011
in	ADP	O	O	4011
people	NOUN	O	O	4011
aged	ADJ	O	O	4011
76	NUM	O	O	4011
and	CCONJ	O	O	4011
older	ADJ	O	O	4011
with	ADP	O	O	4011
atrial fibrillation	NOUN	O	Disease	4011
on	ADP	O	O	4011
adjusted	VERB	O	O	4011
-	PUNCT	O	O	4011
dose	NOUN	O	O	4011
warfarin	VERB	O	Chemical	4011
who	PRON	O	O	4011
had	VERB	O	O	4011
been	AUX	O	O	4011
recently	ADV	O	O	4011
been	AUX	O	O	4011
admitted	VERB	O	O	4011
to	PART	O	O	4011
hospital	PROPN	O	O	4011
.	PUNCT	O	O	4011
Two	NUM	O	O	4012
hundred	NUM	O	O	4012
thirty	NUM	O	O	4012
-	PUNCT	O	O	4012
five	NUM	O	O	4012
patients	NOUN	O	O	4012
aged	ADJ	O	O	4012
76	NUM	O	O	4012
and	CCONJ	O	O	4012
older	ADJ	O	O	4012
admitted	VERB	O	O	4012
to	PART	O	O	4012
a	PRON	O	O	4012
major	ADJ	O	O	4012
healthcare	PROPN	O	O	4012
network	NOUN	O	O	4012
between	ADP	O	O	4012
July	PROPN	O	O	4012
1	X	O	O	4012
,	PUNCT	O	O	4012
2001	NUM	O	O	4012
,	PUNCT	O	O	4012
and	CCONJ	O	O	4012
June	PROPN	O	O	4012
30	NUM	O	O	4012
,	PUNCT	O	O	4012
2002	NUM	O	O	4012
,	PUNCT	O	O	4012
with	ADP	O	O	4012
atrial fibrillation	NOUN	O	Disease	4012
on	ADP	O	O	4012
warfarin	VERB	O	Chemical	4012
were	AUX	O	O	4012
enrolled	VERB	O	O	4012
.	PUNCT	O	O	4012
Information	NOUN	O	O	4013
regarding	VERB	O	O	4013
major	ADJ	O	O	4013
bleeding	VERB	O	Disease	4013
episodes	NOUN	O	O	4013
,	PUNCT	O	O	4013
strokes	NOUN	O	Disease	4013
,	PUNCT	O	O	4013
and	CCONJ	O	O	4013
warfarin	VERB	O	Chemical	4013
use	VERB	O	O	4013
was	AUX	O	O	4013
obtained	VERB	O	O	4013
from	ADP	O	O	4013
patients	NOUN	O	O	4013
,	PUNCT	O	O	4013
relatives	NOUN	O	O	4013
,	PUNCT	O	O	4013
primary	NOUN	O	O	4013
physicians	NOUN	O	O	4013
,	PUNCT	O	O	4013
and	CCONJ	O	O	4013
medical	ADJ	O	O	4013
records	NOUN	O	O	4013
.	PUNCT	O	O	4013
Total	ADJ	O	O	4014
follow	VERB	O	O	4014
-	PUNCT	O	O	4014
up	ADP	O	O	4014
on	ADP	O	O	4014
warfarin	VERB	O	Chemical	4014
was	AUX	O	O	4014
530	NUM	O	O	4014
years	NOUN	O	O	4014
(	PUNCT	O	O	4014
mean	VERB	O	O	4014
28	NUM	O	O	4014
months	NOUN	O	O	4014
)	PUNCT	O	O	4014
.	PUNCT	O	O	4014
There	ADV	O	O	4015
were	AUX	O	O	4015
53	NUM	O	O	4015
major	ADJ	O	O	4015
hemorrhages	VERB	O	O	4015
,	PUNCT	O	O	4015
for	ADP	O	O	4015
an	PRON	O	O	4015
annual	ADJ	O	O	4015
rate	NOUN	O	O	4015
of	ADP	O	O	4015
10.0%	NOUN	O	O	4015
,	PUNCT	O	O	4015
including	VERB	O	O	4015
24	NUM	O	O	4015
(	PUNCT	O	O	4015
45.3%	NOUN	O	O	4015
)	PUNCT	O	O	4015
life	NOUN	O	O	4015
-	PUNCT	O	O	4015
threatening	VERB	O	O	4015
and	CCONJ	O	O	4015
five	NUM	O	O	4015
(	PUNCT	O	O	4015
9.4%	NOUN	O	O	4015
)	PUNCT	O	O	4015
fatal	ADJ	O	O	4015
bleeds	VERB	O	O	4015
.	PUNCT	O	O	4015
The	PRON	O	O	4016
annual	ADJ	O	O	4016
stroke	VERB	O	Disease	4016
rate	NOUN	O	O	4016
after	ADP	O	O	4016
initiation	NOUN	O	O	4016
of	ADP	O	O	4016
warfarin	VERB	O	Chemical	4016
was	AUX	O	O	4016
2.6%	NOUN	O	O	4016
.	PUNCT	O	O	4016
The	PRON	O	O	4017
rate	NOUN	O	O	4017
of	ADP	O	O	4017
major	ADJ	O	O	4017
hemorrhage	NOUN	O	Disease	4017
was	AUX	O	O	4017
high	ADJ	O	O	4017
in	ADP	O	O	4017
this	PRON	O	O	4017
old	ADJ	O	O	4017
,	PUNCT	O	O	4017
frail	ADJ	O	O	4017
group	NOUN	O	O	4017
,	PUNCT	O	O	4017
but	CCONJ	O	O	4017
excluding	VERB	O	O	4017
fatalities	NOUN	O	O	4017
,	PUNCT	O	O	4017
resulted	VERB	O	O	4017
in	ADP	O	O	4017
no	PRON	O	O	4017
long	ADV	O	O	4017
-	PUNCT	O	O	4017
term	NOUN	O	O	4017
sequelae	ADJ	O	O	4017
,	PUNCT	O	O	4017
and	CCONJ	O	O	4017
the	PRON	O	O	4017
stroke	VERB	O	Disease	4017
rate	NOUN	O	O	4017
on	ADP	O	O	4017
warfarin	VERB	O	Chemical	4017
was	AUX	O	O	4017
low	ADJ	O	O	4017
,	PUNCT	O	O	4017
demonstrating	VERB	O	O	4017
how	SCONJ	O	O	4017
effective	ADJ	O	O	4017
warfarin	VERB	O	Chemical	4017
treatment	NOUN	O	O	4017
is	AUX	O	O	4017
.	PUNCT	O	O	4017
Safety	NOUN	O	O	4020
of	ADP	O	O	4020
celecoxib	PROPN	O	O	4020
in	ADP	O	O	4020
patients	NOUN	O	O	4020
with	ADP	O	O	4020
adverse	ADJ	O	O	4020
skin	NOUN	O	O	4020
reactions	NOUN	O	O	4020
to	PART	O	O	4020
acetaminophen	PROPN	O	Chemical	4020
(	PUNCT	O	O	4020
paracetamol	PROPN	O	Chemical	4020
)	PUNCT	O	O	4020
and	CCONJ	O	O	4020
nimesulide	ADP	O	Chemical	4020
associated	VERB	O	O	4020
or	CCONJ	O	O	4020
not	PART	O	O	4020
with	ADP	O	O	4020
common	ADJ	O	O	4020
non	ADJ	O	O	4020
-	PUNCT	O	O	4020
steroidal	ADJ	O	O	4020
anti	ADJ	O	O	4020
-	PUNCT	O	O	4020
inflammatory	ADJ	O	O	4020
drugs	NOUN	O	O	4020
.	PUNCT	O	O	4020
BACKGROUND	NOUN	O	O	4021
:	PUNCT	O	O	4021
Acetaminophen	PROPN	O	O	4021
(	PUNCT	O	O	4021
paracetamol	PROPN	O	Chemical	4021
--	PUNCT	O	O	4021
P	NOUN	O	Chemical	4021
)	PUNCT	O	O	4021
and	CCONJ	O	O	4021
Nimesulide	NOUN	O	O	4021
(	PUNCT	O	O	4021
N	NUM	O	O	4021
)	PUNCT	O	O	4021
are	AUX	O	O	4021
widely	ADV	O	O	4021
used	VERB	O	O	4021
analgesic	PROPN	O	O	4021
-	PUNCT	O	O	4021
antipyretic	ADJ	O	O	4021
/	PUNCT	O	O	4021
anti	ADJ	O	O	4021
-	PUNCT	O	O	4021
inflammatory	ADJ	O	O	4021
drugs	NOUN	O	O	4021
.	PUNCT	O	O	4021
The	PRON	O	O	4022
rate	NOUN	O	O	4022
of	ADP	O	O	4022
adverse	ADJ	O	O	4022
hypersensitivity	NOUN	O	Disease	4022
reactions	NOUN	O	O	4022
to	PART	O	O	4022
these	PRON	O	O	4022
agents	NOUN	O	O	4022
is	AUX	O	O	4022
generally	ADV	O	O	4022
low	ADJ	O	O	4022
.	PUNCT	O	O	4022
Celecoxib	PROPN	O	O	4023
(	PUNCT	O	O	4023
CE	PROPN	O	O	4023
)	PUNCT	O	O	4023
is	AUX	O	O	4023
a	PRON	O	O	4023
novel	NOUN	O	O	4023
drug	NOUN	O	O	4023
,	PUNCT	O	O	4023
with	ADP	O	O	4023
high	ADJ	O	O	4023
selectivity	NOUN	O	O	4023
and	CCONJ	O	O	4023
affinity	NOUN	O	O	4023
for	ADP	O	O	4023
COX-2	ADJ	O	O	4023
enzyme	NOUN	O	O	4023
.	PUNCT	O	O	4023
We	PRON	O	O	4024
evaluated	VERB	O	O	4024
the	PRON	O	O	4024
tolerability	NOUN	O	O	4024
of	ADP	O	O	4024
CE	PROPN	O	O	4024
in	ADP	O	O	4024
a	PRON	O	O	4024
group	NOUN	O	O	4024
of	ADP	O	O	4024
patients	NOUN	O	O	4024
with	ADP	O	O	4024
documented	VERB	O	O	4024
history	NOUN	O	O	4024
of	ADP	O	O	4024
adverse	ADJ	O	O	4024
cutaneous	ADJ	O	O	4024
reactions	NOUN	O	O	4024
to	PART	O	O	4024
P	NOUN	O	Chemical	4024
and	CCONJ	O	O	4024
N	NUM	O	O	4024
associated	VERB	O	O	4024
or	CCONJ	O	O	4024
not	PART	O	O	4024
to	PART	O	O	4024
classic	ADJ	O	O	4024
NSAIDs	NOUN	O	Chemical	4024
.	PUNCT	O	O	4024
:	PUNCT	O	O	4025
We	PRON	O	O	4025
studied	VERB	O	O	4025
9	NUM	O	O	4025
patients	NOUN	O	O	4025
with	ADP	O	O	4025
hypersensitivity	NOUN	O	Disease	4025
to	PART	O	O	4025
P	NOUN	O	Chemical	4025
and	CCONJ	O	O	4025
N	NUM	O	O	4025
with	ADP	O	O	4025
or	CCONJ	O	O	4025
without	ADP	O	O	4025
associated	VERB	O	O	4025
reactions	NOUN	O	O	4025
to	PART	O	O	4025
classic	ADJ	O	O	4025
NSAIDs	NOUN	O	Chemical	4025
.	PUNCT	O	O	4025
The	PRON	O	O	4026
diagnosis	NOUN	O	O	4026
of	ADP	O	O	4026
P	NOUN	O	Chemical	4026
and	CCONJ	O	O	4026
N	NUM	O	O	4026
-	PUNCT	O	O	4026
induced	VERB	O	O	4026
skin	NOUN	O	O	4026
reactions	NOUN	O	O	4026
was	AUX	O	O	4026
based	VERB	O	O	4026
in	ADP	O	O	4026
vivo	VERB	O	O	4026
challenge	NOUN	O	O	4026
.	PUNCT	O	O	4026
After	ADP	O	O	4027
three	NUM	O	O	4027
days	NOUN	O	O	4027
,	PUNCT	O	O	4027
a	PRON	O	O	4027
cumulative	ADJ	O	O	4027
dosage	NOUN	O	O	4027
of	ADP	O	O	4027
200	NUM	O	O	4027
mg	VERB	O	O	4027
of	ADP	O	O	4027
CE	PROPN	O	O	4027
in	ADP	O	O	4027
refracted	VERB	O	O	4027
doses	NOUN	O	O	4027
were	AUX	O	O	4027
given	VERB	O	O	4027
.	PUNCT	O	O	4027
The	PRON	O	O	4028
challenge	NOUN	O	O	4028
was	AUX	O	O	4028
considered	VERB	O	O	4028
positive	ADJ	O	O	4028
if	SCONJ	O	O	4028
one	NUM	O	O	4028
or	CCONJ	O	O	4028
more	ADJ	O	O	4028
of	ADP	O	O	4028
the	PRON	O	O	4028
following	VERB	O	O	4028
appeared	VERB	O	O	4028
:	PUNCT	O	O	4028
erythema	NOUN	O	O	4028
,	PUNCT	O	O	4028
rush	NOUN	O	O	4028
or	CCONJ	O	O	4028
urticaria	PROPN	O	Disease	4028
-	PUNCT	O	O	4028
angioedema	NOUN	O	Disease	4028
.	PUNCT	O	O	4028
No	PRON	O	O	4029
reaction	NOUN	O	O	4029
was	AUX	O	O	4029
observed	VERB	O	O	4029
with	ADP	O	O	4029
placebo	NOUN	O	O	4029
and	CCONJ	O	O	4029
eight	NUM	O	O	4029
patients	NOUN	O	O	4029
(	PUNCT	O	O	4029
88.8%	NOUN	O	O	4029
)	PUNCT	O	O	4029
tolerated	VERB	O	O	4029
CE	PROPN	O	O	4029
.	PUNCT	O	O	4029
Only	ADV	O	O	4030
one	NUM	O	O	4030
patient	NOUN	O	O	4030
developed	VERB	O	O	4030
a	PRON	O	O	4030
moderate	ADJ	O	O	4030
angioedema	NOUN	O	Disease	4030
of	ADP	O	O	4030
the	PRON	O	O	4030
lips	NOUN	O	O	4030
.	PUNCT	O	O	4030
CONCLUSION	PROPN	O	O	4031
:	PUNCT	O	O	4031
Only	ADV	O	O	4031
one	NUM	O	O	4031
hypersensitivity	NOUN	O	Disease	4031
reaction	NOUN	O	O	4031
to	PART	O	O	4031
CE	PROPN	O	O	4031
was	AUX	O	O	4031
documented	VERB	O	O	4031
among	ADP	O	O	4031
9	NUM	O	O	4031
P	NOUN	O	Chemical	4031
and	CCONJ	O	O	4031
N	NUM	O	O	4031
-	PUNCT	O	O	4031
highly	ADV	O	O	4031
NSAIDs	NOUN	O	Chemical	4031
intolerant	ADJ	O	O	4031
patients	NOUN	O	O	4031
.	PUNCT	O	O	4031
Thus	ADV	O	O	4032
,	PUNCT	O	O	4032
we	PRON	O	O	4032
conclude	VERB	O	O	4032
that	SCONJ	O	O	4032
CE	PROPN	O	O	4032
is	AUX	O	O	4032
a	PRON	O	O	4032
reasonably	ADV	O	O	4032
safe	ADJ	O	O	4032
alternative	ADV	O	O	4032
to	PART	O	O	4032
be	AUX	O	O	4032
used	VERB	O	O	4032
in	ADP	O	O	4032
subjects	NOUN	O	O	4032
who	PRON	O	O	4032
do	VERB	O	O	4032
not	PART	O	O	4032
tolerate	VERB	O	O	4032
P	NOUN	O	Chemical	4032
and	CCONJ	O	O	4032
N.	NOUN	O	O	4032
Case	NOUN	O	O	4035
-	PUNCT	O	O	4035
control	VERB	O	O	4035
study	VERB	O	O	4035
of	ADP	O	O	4035
regular	ADJ	O	O	4035
analgesic	PROPN	O	O	4035
and	CCONJ	O	O	4035
nonsteroidal	ADJ	O	O	4035
anti	ADJ	O	O	4035
-	PUNCT	O	O	4035
inflammatory	ADJ	O	O	4035
use	VERB	O	O	4035
and	CCONJ	O	O	4035
end	VERB	O	O	4035
-	PUNCT	O	O	4035
stage	NOUN	O	O	4035
renal disease	NOUN	O	Disease	4035
.	PUNCT	O	O	4035
Studies	NOUN	O	O	4036
on	ADP	O	O	4036
the	PRON	O	O	4036
association	PROPN	O	O	4036
between	ADP	O	O	4036
the	PRON	O	O	4036
long	ADV	O	O	4036
-	PUNCT	O	O	4036
term	NOUN	O	O	4036
use	VERB	O	O	4036
of	ADP	O	O	4036
aspirin	NOUN	O	Chemical	4036
and	CCONJ	O	O	4036
other	ADJ	O	O	4036
analgesic	PROPN	O	O	4036
and	CCONJ	O	O	4036
nonsteroidal	ADJ	O	O	4036
anti	ADJ	O	O	4036
-	PUNCT	O	O	4036
inflammatory	ADJ	O	O	4036
drugs	NOUN	O	O	4036
(	PUNCT	O	O	4036
NSAIDs	NOUN	O	Chemical	4036
)	PUNCT	O	O	4036
and	CCONJ	O	O	4036
end	VERB	O	O	4036
-	PUNCT	O	O	4036
stage	NOUN	O	O	4036
renal disease	NOUN	O	Disease	4036
(	PUNCT	O	O	4036
ESRD	PROPN	O	Disease	4036
)	PUNCT	O	O	4036
have	VERB	O	O	4036
given	VERB	O	O	4036
conflicting	VERB	O	O	4036
results	VERB	O	O	4036
.	PUNCT	O	O	4036
In	ADP	O	O	4037
order	NOUN	O	O	4037
to	PART	O	O	4037
examine	VERB	O	O	4037
this	PRON	O	O	4037
association	PROPN	O	O	4037
,	PUNCT	O	O	4037
a	PRON	O	O	4037
case	NOUN	O	O	4037
-	PUNCT	O	O	4037
control	VERB	O	O	4037
study	VERB	O	O	4037
with	ADP	O	O	4037
incident	NOUN	O	O	4037
cases	NOUN	O	O	4037
of	ADP	O	O	4037
ESRD	PROPN	O	Disease	4037
was	AUX	O	O	4037
carried	VERB	O	O	4037
out	ADP	O	O	4037
.	PUNCT	O	O	4037
METHODS	NOUN	O	O	4038
:	PUNCT	O	O	4038
The	PRON	O	O	4038
cases	NOUN	O	O	4038
were	AUX	O	O	4038
all	PRON	O	O	4038
patients	NOUN	O	O	4038
entering	VERB	O	O	4038
the	PRON	O	O	4038
local	ADJ	O	O	4038
dialysis	NOUN	O	O	4038
program	PROPN	O	O	4038
because	SCONJ	O	O	4038
of	ADP	O	O	4038
ESRD	PROPN	O	Disease	4038
in	ADP	O	O	4038
the	PRON	O	O	4038
study	VERB	O	O	4038
area	NOUN	O	O	4038
between	ADP	O	O	4038
June	PROPN	O	O	4038
1	X	O	O	4038
,	PUNCT	O	O	4038
1995	NUM	O	O	4038
and	CCONJ	O	O	4038
November	PROPN	O	O	4038
30	NUM	O	O	4038
,	PUNCT	O	O	4038
1997	NUM	O	O	4038
.	PUNCT	O	O	4038
They	PRON	O	O	4039
were	AUX	O	O	4039
classified	VERB	O	O	4039
according	VERB	O	O	4039
to	PART	O	O	4039
the	PRON	O	O	4039
underlying	VERB	O	O	4039
disease	PROPN	O	O	4039
,	PUNCT	O	O	4039
which	PRON	O	O	4039
had	VERB	O	O	4039
presumably	ADV	O	O	4039
led	VERB	O	O	4039
them	PRON	O	O	4039
to	PART	O	O	4039
ESRD	PROPN	O	Disease	4039
.	PUNCT	O	O	4039
For	ADP	O	O	4040
specific	ADJ	O	O	4040
groups	NOUN	O	O	4040
of	ADP	O	O	4040
drugs	NOUN	O	O	4040
,	PUNCT	O	O	4040
the	PRON	O	O	4040
risks	NOUN	O	O	4040
were	AUX	O	O	4040
1.56	NUM	O	O	4040
(	PUNCT	O	O	4040
1.05	NUM	O	O	4040
-	PUNCT	O	O	4040
2.30	NUM	O	O	4040
)	PUNCT	O	O	4040
for	ADP	O	O	4040
aspirin	NOUN	O	Chemical	4040
,	PUNCT	O	O	4040
1.03	NUM	O	O	4040
(	PUNCT	O	O	4040
0.60	NUM	O	O	4040
-	PUNCT	O	O	4040
1.76	NUM	O	O	4040
)	PUNCT	O	O	4040
for	ADP	O	O	4041
pyrazolones	NOUN	O	O	4041
,	PUNCT	O	O	4041
0.80	NUM	O	O	4041
(	PUNCT	O	O	4041
0.39	NUM	O	O	4041
-	PUNCT	O	O	4041
1.63	NUM	O	O	4041
)	PUNCT	O	O	4041
for	ADP	O	O	4041
paracetamol	PROPN	O	Chemical	4041
,	PUNCT	O	O	4041
and	CCONJ	O	O	4041
0.94	NUM	O	O	4041
(	PUNCT	O	O	4041
0.57	NUM	O	O	4041
-	PUNCT	O	O	4041
1.56	NUM	O	O	4041
)	PUNCT	O	O	4041
for	ADP	O	O	4041
nonaspirin	NOUN	O	O	4041
NSAIDs	NOUN	O	Chemical	4041
.	PUNCT	O	O	4041
The	PRON	O	O	4042
risk	NOUN	O	O	4042
of	ADP	O	O	4042
ESRD	PROPN	O	Disease	4042
associated	VERB	O	O	4042
with	ADP	O	O	4042
aspirin	NOUN	O	Chemical	4042
was	AUX	O	O	4042
related	ADJ	O	O	4042
to	PART	O	O	4042
the	PRON	O	O	4042
cumulated	VERB	O	O	4042
dose	NOUN	O	O	4042
and	CCONJ	O	O	4042
duration	NOUN	O	O	4042
of	ADP	O	O	4042
use	VERB	O	O	4042
,	PUNCT	O	O	4042
and	CCONJ	O	O	4042
it	PRON	O	O	4042
was	AUX	O	O	4042
particularly	ADV	O	O	4042
high	ADJ	O	O	4042
among	ADP	O	O	4042
the	PRON	O	O	4042
subset	VERB	O	O	4042
of	ADP	O	O	4042
patients	NOUN	O	O	4042
with	ADP	O	O	4042
vascular	ADJ	O	O	4042
nephropathy	NOUN	O	Disease	4042
as	ADP	O	O	4042
underlying	VERB	O	O	4042
disease	PROPN	O	O	4042
[	X	O	O	4042
2.35	NUM	O	O	4042
(	PUNCT	O	O	4042
1.17	NUM	O	O	4042
-	PUNCT	O	O	4042
4.72	NUM	O	O	4042
)	PUNCT	O	O	4042
]	PUNCT	O	O	4042
.	PUNCT	O	O	4042
CONCLUSION	PROPN	O	O	4043
:	PUNCT	O	O	4043
Our	PRON	O	O	4043
data	NOUN	O	O	4043
indicate	VERB	O	O	4043
that	SCONJ	O	O	4043
long	ADV	O	O	4043
-	PUNCT	O	O	4043
term	NOUN	O	O	4043
use	VERB	O	O	4043
of	ADP	O	O	4043
nonaspirin	NOUN	O	O	4043
analgesic	PROPN	O	O	4043
drugs	NOUN	O	O	4043
and	CCONJ	O	O	4043
NSAIDs	NOUN	O	Chemical	4043
is	AUX	O	O	4043
not	PART	O	O	4043
associated	VERB	O	O	4043
with	ADP	O	O	4043
an	PRON	O	O	4043
increased	VERB	O	O	4043
risk	NOUN	O	O	4043
of	ADP	O	O	4043
ESRD	PROPN	O	Disease	4043
.	PUNCT	O	O	4043
However	ADV	O	O	4044
,	PUNCT	O	O	4044
the	PRON	O	O	4044
chronic	ADJ	O	O	4044
use	VERB	O	O	4044
of	ADP	O	O	4044
aspirin	NOUN	O	Chemical	4044
may	AUX	O	O	4044
increase	VERB	O	O	4044
the	PRON	O	O	4044
risk	NOUN	O	O	4044
of	ADP	O	O	4044
ESRD	PROPN	O	Disease	4044
.	PUNCT	O	O	4044
Two	NUM	O	O	4047
cases	NOUN	O	O	4047
of	ADP	O	O	4047
amisulpride	ADV	O	Chemical	4047
overdose	NOUN	O	Disease	4047
:	PUNCT	O	O	4047
a	PRON	O	O	4047
cause	VERB	O	O	4047
for	ADP	O	O	4047
prolonged	VERB	O	O	4047
QT	NOUN	O	O	4047
syndrome	NOUN	O	O	4047
.	PUNCT	O	O	4047
Two	NUM	O	O	4048
cases	NOUN	O	O	4048
of	ADP	O	O	4048
deliberate	VERB	O	O	4048
self	VERB	O	O	4048
-	PUNCT	O	O	4048
poisoning	VERB	O	O	4048
with	ADP	O	O	4048
5	NUM	O	O	4048
g	X	O	O	4048
and	CCONJ	O	O	4048
3.6	NUM	O	O	4048
g	X	O	O	4048
of	ADP	O	O	4048
amisulpride	ADV	O	Chemical	4048
,	PUNCT	O	O	4048
respectively	ADV	O	O	4048
,	PUNCT	O	O	4048
are	AUX	O	O	4048
reported	VERB	O	O	4048
.	PUNCT	O	O	4048
In	ADP	O	O	4049
both	PRON	O	O	4049
cases	NOUN	O	O	4049
,	PUNCT	O	O	4049
QT prolongation	NOUN	O	Disease	4049
and	CCONJ	O	O	4049
hypocalcaemia	NOUN	O	O	4049
were	AUX	O	O	4049
noted	VERB	O	O	4049
.	PUNCT	O	O	4049
The	PRON	O	O	4050
QT prolongation	NOUN	O	Disease	4050
appeared	VERB	O	O	4050
to	PART	O	O	4050
respond	VERB	O	O	4050
to	PART	O	O	4050
administration	NOUN	O	O	4050
of	ADP	O	O	4050
i.v	NOUN	O	O	4050
.	PUNCT	O	O	4050
calcium	NOUN	O	Chemical	4051
gluconate	VERB	O	O	4051
.	PUNCT	O	O	4051
Growth	NOUN	O	O	4054
-	PUNCT	O	O	4054
associated	VERB	O	O	4054
protein	NOUN	O	O	4054
43	NUM	O	O	4054
expression	NOUN	O	O	4054
in	ADP	O	O	4054
hippocampal	NOUN	O	O	4054
molecular	ADJ	O	O	4054
layer	NOUN	O	O	4054
of	ADP	O	O	4054
chronic	ADJ	O	O	4054
epileptic	ADJ	O	Disease	4054
rats	NOUN	O	O	4054
treated	VERB	O	O	4054
with	ADP	O	O	4054
cycloheximide	NOUN	O	Chemical	4054
.	PUNCT	O	O	4054
GAP43	PROPN	O	O	4055
has	VERB	O	O	4055
been	AUX	O	O	4055
thought	VERB	O	O	4055
to	PART	O	O	4055
be	AUX	O	O	4055
linked	VERB	O	O	4055
with	ADP	O	O	4055
mossy	NOUN	O	O	4055
fiber	PROPN	O	O	4055
sprouting	VERB	O	O	4055
(	PUNCT	O	O	4055
MFS	PROPN	O	O	4055
)	PUNCT	O	O	4055
in	ADP	O	O	4055
various	ADJ	O	O	4055
experimental	ADJ	O	O	4055
models	NOUN	O	O	4055
of	ADP	O	O	4055
epilepsy	NOUN	O	Disease	4055
.	PUNCT	O	O	4055
To	PART	O	O	4056
investigate	VERB	O	O	4056
how	SCONJ	O	O	4056
GAP43	PROPN	O	O	4056
expression	NOUN	O	O	4056
(	PUNCT	O	O	4056
GAP43-ir	NOUN	O	O	4056
)	PUNCT	O	O	4056
correlates	VERB	O	O	4056
with	ADP	O	O	4056
MFS	PROPN	O	O	4056
,	PUNCT	O	O	4056
we	PRON	O	O	4056
assessed	VERB	O	O	4056
the	PRON	O	O	4056
intensity	NOUN	O	O	4056
(	PUNCT	O	O	4056
densitometry	NOUN	O	O	4056
)	PUNCT	O	O	4056
and	CCONJ	O	O	4056
extension	NOUN	O	O	4056
(	PUNCT	O	O	4056
width	VERB	O	O	4056
)	PUNCT	O	O	4056
of	ADP	O	O	4056
GAP43-ir	NOUN	O	O	4056
in	ADP	O	O	4056
the	PRON	O	O	4056
inner	ADJ	O	O	4056
molecular	ADJ	O	O	4056
layer	NOUN	O	O	4056
of	ADP	O	O	4056
the	PRON	O	O	4056
dentate	ADJ	O	O	4056
gyrus	PROPN	O	O	4056
(	PUNCT	O	O	4056
IML	PROPN	O	O	4056
)	PUNCT	O	O	4056
of	ADP	O	O	4056
rats	NOUN	O	O	4056
subject	ADJ	O	O	4056
to	PART	O	O	4056
status epilepticus	VERB	O	Disease	4056
induced	VERB	O	O	4056
by	ADP	O	O	4056
pilocarpine	NOUN	O	Chemical	4056
(	PUNCT	O	O	4056
Pilo	PROPN	O	O	4056
)	PUNCT	O	O	4056
,	PUNCT	O	O	4056
previously	ADV	O	O	4056
injected	VERB	O	O	4056
or	CCONJ	O	O	4056
not	PART	O	O	4056
with	ADP	O	O	4056
cycloheximide	NOUN	O	Chemical	4056
(	PUNCT	O	O	4056
CHX	PROPN	O	O	4056
)	PUNCT	O	O	4056
,	PUNCT	O	O	4056
which	PRON	O	O	4056
has	VERB	O	O	4056
been	AUX	O	O	4056
shown	VERB	O	O	4056
to	PART	O	O	4056
inhibit	VERB	O	O	4056
MFS	PROPN	O	O	4056
.	PUNCT	O	O	4056
CHX	PROPN	O	O	4057
was	AUX	O	O	4057
injected	VERB	O	O	4057
before	ADP	O	O	4057
the	PRON	O	O	4057
Pilo	PROPN	O	O	4057
injection	NOUN	O	O	4057
in	ADP	O	O	4057
adult	NOUN	O	O	4057
Wistar	PROPN	O	O	4057
rats	NOUN	O	O	4057
.	PUNCT	O	O	4057
The	PRON	O	O	4058
Pilo	PROPN	O	O	4058
group	NOUN	O	O	4058
was	AUX	O	O	4058
injected	VERB	O	O	4058
with	ADP	O	O	4058
the	PRON	O	O	4058
same	ADJ	O	O	4058
drugs	NOUN	O	O	4058
,	PUNCT	O	O	4058
except	SCONJ	O	O	4058
for	ADP	O	O	4058
CHX	PROPN	O	O	4058
.	PUNCT	O	O	4058
RESULTS	VERB	O	O	4059
:	PUNCT	O	O	4059
Densitometry	NOUN	O	O	4059
showed	VERB	O	O	4059
no	PRON	O	O	4059
significant	ADJ	O	O	4059
difference	NOUN	O	O	4059
regarding	VERB	O	O	4059
GAP43-ir	NOUN	O	O	4059
in	ADP	O	O	4059
the	PRON	O	O	4059
IML	PROPN	O	O	4059
between	ADP	O	O	4059
Pilo	PROPN	O	O	4059
,	PUNCT	O	O	4059
CHX+Pilo	ADP	O	O	4059
,	PUNCT	O	O	4059
and	CCONJ	O	O	4059
control	VERB	O	O	4059
groups	NOUN	O	O	4059
.	PUNCT	O	O	4059
However	ADV	O	O	4060
,	PUNCT	O	O	4060
the	PRON	O	O	4060
results	VERB	O	O	4060
of	ADP	O	O	4060
the	PRON	O	O	4060
width	VERB	O	O	4060
of	ADP	O	O	4060
the	PRON	O	O	4060
GAP43-ir	NOUN	O	O	4060
band	NOUN	O	O	4060
in	ADP	O	O	4060
the	PRON	O	O	4060
IML	PROPN	O	O	4060
showed	VERB	O	O	4060
that	SCONJ	O	O	4060
CHX+Pilo	ADP	O	O	4060
and	CCONJ	O	O	4060
control	VERB	O	O	4060
animals	NOUN	O	O	4060
had	VERB	O	O	4060
a	PRON	O	O	4060
significantly	ADV	O	O	4060
larger	ADJ	O	O	4060
band	NOUN	O	O	4060
(	PUNCT	O	O	4060
p	NOUN	O	O	4060
=	PUNCT	O	O	4060
0.03	NUM	O	O	4060
)	PUNCT	O	O	4060
as	ADP	O	O	4060
compared	VERB	O	O	4060
with	ADP	O	O	4060
that	SCONJ	O	O	4060
in	ADP	O	O	4060
the	PRON	O	O	4060
Pilo	PROPN	O	O	4060
group	NOUN	O	O	4060
.	PUNCT	O	O	4060
Our	PRON	O	O	4061
current	ADJ	O	O	4061
finding	VERB	O	O	4061
that	SCONJ	O	O	4061
animals	NOUN	O	O	4061
in	ADP	O	O	4061
the	PRON	O	O	4061
CHX+Pilo	ADP	O	O	4061
group	NOUN	O	O	4061
have	VERB	O	O	4061
a	PRON	O	O	4061
GAP43-ir	NOUN	O	O	4061
band	NOUN	O	O	4061
in	ADP	O	O	4061
the	PRON	O	O	4061
IML	PROPN	O	O	4061
,	PUNCT	O	O	4061
similar	ADJ	O	O	4061
to	PART	O	O	4061
that	SCONJ	O	O	4061
of	ADP	O	O	4061
controls	VERB	O	O	4061
,	PUNCT	O	O	4061
reinforces	VERB	O	O	4061
prior	ADV	O	O	4061
data	NOUN	O	O	4061
on	ADP	O	O	4061
the	PRON	O	O	4061
blockade	VERB	O	O	4061
of	ADP	O	O	4061
MFS	PROPN	O	O	4061
in	ADP	O	O	4061
these	PRON	O	O	4061
animals	NOUN	O	O	4061
.	PUNCT	O	O	4061
The	PRON	O	O	4062
change	VERB	O	O	4062
in	ADP	O	O	4062
GAP43-ir	NOUN	O	O	4062
present	NOUN	O	O	4062
in	ADP	O	O	4062
Pilo	PROPN	O	O	4062
-	PUNCT	O	O	4062
treated	VERB	O	O	4062
animals	NOUN	O	O	4062
was	AUX	O	O	4062
a	PRON	O	O	4062
thinning	VERB	O	O	4062
of	ADP	O	O	4062
the	PRON	O	O	4062
band	NOUN	O	O	4062
to	PART	O	O	4062
a	PRON	O	O	4062
very	ADV	O	O	4062
narrow	ADJ	O	O	4062
layer	NOUN	O	O	4062
just	ADV	O	O	4062
above	ADP	O	O	4062
the	PRON	O	O	4062
granule	NOUN	O	O	4062
cell	NOUN	O	O	4062
layer	NOUN	O	O	4062
that	SCONJ	O	O	4062
is	AUX	O	O	4062
likely	ADV	O	O	4062
to	PART	O	O	4062
be	AUX	O	O	4062
associated	VERB	O	O	4062
with	ADP	O	O	4062
the	PRON	O	O	4062
loss	NOUN	O	O	4062
of	ADP	O	O	4062
hilar	ADJ	O	O	4062
cell	NOUN	O	O	4062
projections	NOUN	O	O	4062
that	SCONJ	O	O	4062
express	VERB	O	O	4062
GAP-43	NUM	O	O	4062
.	PUNCT	O	O	4062
Nicotine	NOUN	O	Chemical	4065
antagonizes	VERB	O	O	4065
caffeine-	ADJ	O	O	4066
but	CCONJ	O	O	4066
not	PART	O	O	4066
pentylenetetrazole	NOUN	O	Chemical	4066
-	PUNCT	O	O	4066
induced	VERB	O	O	4066
anxiogenic	ADJ	O	O	4066
effect	VERB	O	O	4066
in	ADP	O	O	4066
mice	NOUN	O	O	4066
.	PUNCT	O	O	4066
Nicotine	NOUN	O	Chemical	4067
and	CCONJ	O	O	4067
caffeine	NOUN	O	Chemical	4067
are	AUX	O	O	4067
widely	ADV	O	O	4067
consumed	VERB	O	O	4067
licit	ADJ	O	O	4067
psychoactive	ADJ	O	O	4067
drugs	NOUN	O	O	4067
worldwide	ADV	O	O	4067
.	PUNCT	O	O	4067
Although	SCONJ	O	O	4068
some	PRON	O	O	4068
studies	NOUN	O	O	4068
in	ADP	O	O	4068
experimental	ADJ	O	O	4068
animals	NOUN	O	O	4068
indicate	VERB	O	O	4068
clear	ADJ	O	O	4068
pharmacological	ADJ	O	O	4068
interactions	NOUN	O	O	4068
between	ADP	O	O	4068
them	PRON	O	O	4068
,	PUNCT	O	O	4068
no	PRON	O	O	4068
studies	NOUN	O	O	4068
have	VERB	O	O	4068
shown	VERB	O	O	4068
a	PRON	O	O	4068
specific	ADJ	O	O	4068
interaction	NOUN	O	O	4068
on	ADP	O	O	4068
anxiety	NOUN	O	Disease	4068
responses	NOUN	O	O	4068
.	PUNCT	O	O	4068
The	PRON	O	O	4069
present	NOUN	O	O	4069
study	VERB	O	O	4069
investigates	VERB	O	O	4069
the	PRON	O	O	4069
effects	NOUN	O	O	4069
of	ADP	O	O	4069
nicotine	NOUN	O	Chemical	4069
on	ADP	O	O	4069
anxiety	NOUN	O	Disease	4069
induced	VERB	O	O	4069
by	ADP	O	O	4069
caffeine	NOUN	O	Chemical	4069
and	CCONJ	O	O	4069
another	PRON	O	O	4069
anxiogenic	ADJ	O	O	4069
drug	NOUN	O	O	4069
,	PUNCT	O	O	4069
pentylenetetrazole	NOUN	O	Chemical	4069
,	PUNCT	O	O	4069
in	ADP	O	O	4069
mice	NOUN	O	O	4069
.	PUNCT	O	O	4069
test	NOUN	O	O	4070
was	AUX	O	O	4070
used	VERB	O	O	4070
to	PART	O	O	4070
evaluate	VERB	O	O	4070
the	PRON	O	O	4070
effects	NOUN	O	O	4070
of	ADP	O	O	4070
drugs	NOUN	O	O	4070
on	ADP	O	O	4070
anxiety	NOUN	O	Disease	4070
.	PUNCT	O	O	4070
Adult	NOUN	O	O	4071
male	NOUN	O	O	4071
Swiss	PROPN	O	O	4071
Webster	PROPN	O	O	4071
mice	NOUN	O	O	4071
(	PUNCT	O	O	4071
25	NUM	O	O	4071
-	PUNCT	O	O	4071
32	NUM	O	O	4071
g	X	O	O	4071
)	PUNCT	O	O	4071
were	AUX	O	O	4071
given	VERB	O	O	4071
nicotine	NOUN	O	Chemical	4071
(	PUNCT	O	O	4071
0.05	NUM	O	O	4071
-	PUNCT	O	O	4071
0.25	NUM	O	O	4071
mg	VERB	O	O	4071
/	PUNCT	O	O	4071
kg	VERB	O	O	4071
s.c	PROPN	O	O	4071
.	PUNCT	O	O	4071
)	PUNCT	O	O	4071
or	CCONJ	O	O	4071
saline	NOUN	O	O	4071
10	NUM	O	O	4071
min	NOUN	O	O	4071
before	ADP	O	O	4071
caffeine	NOUN	O	Chemical	4071
(	PUNCT	O	O	4071
70	NUM	O	O	4071
mg	VERB	O	O	4071
/	PUNCT	O	O	4071
kg	VERB	O	O	4071
i.p	NOUN	O	O	4071
.	PUNCT	O	O	4071
)	PUNCT	O	O	4071
or	CCONJ	O	O	4071
pentylenetetrazole	NOUN	O	Chemical	4071
(	PUNCT	O	O	4071
15	NUM	O	O	4071
and	CCONJ	O	O	4071
30	NUM	O	O	4071
mg	VERB	O	O	4071
Nicotine	NOUN	O	Chemical	4072
(	PUNCT	O	O	4072
0.05	NUM	O	O	4072
-	PUNCT	O	O	4072
0.25	NUM	O	O	4072
mg	VERB	O	O	4072
/	PUNCT	O	O	4072
kg	VERB	O	O	4072
)	PUNCT	O	O	4072
itself	PRON	O	O	4072
did	VERB	O	O	4072
not	PART	O	O	4072
produce	VERB	O	O	4072
any	PRON	O	O	4072
significant	ADJ	O	O	4072
effect	VERB	O	O	4072
in	ADP	O	O	4072
the	PRON	O	O	4072
EPM	PROPN	O	O	4072
test	NOUN	O	O	4072
,	PUNCT	O	O	4072
whereas	SCONJ	O	O	4072
caffeine	NOUN	O	Chemical	4072
(	PUNCT	O	O	4072
70	NUM	O	O	4072
mg	VERB	O	O	4072
/	PUNCT	O	O	4072
kg	VERB	O	O	4072
)	PUNCT	O	O	4072
and	CCONJ	O	O	4072
pentylenetetrazole	NOUN	O	Chemical	4072
(	PUNCT	O	O	4072
30	NUM	O	O	4072
mg	VERB	O	O	4072
/	PUNCT	O	O	4072
kg	VERB	O	O	4072
)	PUNCT	O	O	4072
produced	VERB	O	O	4072
an	PRON	O	O	4072
anxiogenic	ADJ	O	O	4072
effect	VERB	O	O	4072
,	PUNCT	O	O	4072
apparent	ADJ	O	O	4072
with	ADP	O	O	4072
decreases	VERB	O	O	4072
in	ADP	O	O	4072
open	VERB	O	O	4072
-	PUNCT	O	O	4072
arm	VERB	O	O	4072
time	NOUN	O	O	4072
and	CCONJ	O	O	4072
entry	NOUN	O	O	4072
.	PUNCT	O	O	4072
Nicotine	NOUN	O	Chemical	4073
(	PUNCT	O	O	4073
0.25	NUM	O	O	4073
mg	VERB	O	O	4073
/	PUNCT	O	O	4073
kg	VERB	O	O	4073
)	PUNCT	O	O	4073
pretreatment	NOUN	O	O	4073
blocked	VERB	O	O	4073
the	PRON	O	O	4073
caffeine-	ADJ	O	O	4073
but	CCONJ	O	O	4073
not	PART	O	O	4073
pentylenetetrazole	NOUN	O	Chemical	4073
-	PUNCT	O	O	4073
induced	VERB	O	O	4073
anxiety	NOUN	O	Disease	4073
.	PUNCT	O	O	4073
Our	PRON	O	O	4074
results	VERB	O	O	4074
suggest	VERB	O	O	4074
that	SCONJ	O	O	4074
the	PRON	O	O	4074
antagonistic	ADJ	O	O	4074
effect	VERB	O	O	4074
of	ADP	O	O	4074
nicotine	NOUN	O	Chemical	4074
on	ADP	O	O	4074
caffeine	NOUN	O	Chemical	4074
-	PUNCT	O	O	4074
induced	VERB	O	O	4074
anxiety	NOUN	O	Disease	4074
is	AUX	O	O	4074
specific	ADJ	O	O	4074
to	PART	O	O	4074
caffeine	NOUN	O	Chemical	4074
,	PUNCT	O	O	4074
instead	ADV	O	O	4074
of	ADP	O	O	4074
a	PRON	O	O	4074
non	ADJ	O	O	4074
-	PUNCT	O	O	4074
specific	ADJ	O	O	4074
anxiolytic	ADJ	O	O	4074
effect	VERB	O	O	4074
.	PUNCT	O	O	4074
Thus	ADV	O	O	4075
,	PUNCT	O	O	4075
it	PRON	O	O	4075
may	AUX	O	O	4075
extend	VERB	O	O	4075
the	PRON	O	O	4075
current	ADJ	O	O	4075
findings	NOUN	O	O	4075
on	ADP	O	O	4075
the	PRON	O	O	4075
interaction	NOUN	O	O	4075
between	ADP	O	O	4075
nicotine	NOUN	O	Chemical	4075
and	CCONJ	O	O	4075
caffeine	NOUN	O	Chemical	4075
.	PUNCT	O	O	4075
Hormone	NOUN	O	O	4078
therapy	NOUN	O	O	4078
(	PUNCT	O	O	4078
HT	PROPN	O	O	4078
)	PUNCT	O	O	4078
is	AUX	O	O	4078
widely	ADV	O	O	4078
used	VERB	O	O	4078
for	ADP	O	O	4078
controlling	VERB	O	O	4078
menopausal	PROPN	O	O	4078
symptoms	NOUN	O	O	4078
.	PUNCT	O	O	4078
It	PRON	O	O	4079
has	VERB	O	O	4079
also	ADV	O	O	4079
been	AUX	O	O	4079
used	VERB	O	O	4079
for	ADP	O	O	4079
the	PRON	O	O	4079
management	NOUN	O	O	4079
and	CCONJ	O	O	4079
prevention	NOUN	O	O	4079
of	ADP	O	O	4079
cardiovascular disease	NOUN	O	Disease	4079
,	PUNCT	O	O	4079
osteoporosis	NOUN	O	Disease	4079
and	CCONJ	O	O	4079
dementia	NOUN	O	Disease	4079
in	ADP	O	O	4079
older	ADJ	O	O	4079
women	NOUN	O	O	4079
but	CCONJ	O	O	4079
the	PRON	O	O	4079
evidence	NOUN	O	O	4079
supporting	VERB	O	O	4079
its	PRON	O	O	4079
use	VERB	O	O	4079
for	ADP	O	O	4079
these	PRON	O	O	4079
indications	NOUN	O	O	4079
is	AUX	O	O	4079
largely	ADV	O	O	4079
observational	ADJ	O	O	4079
.	PUNCT	O	O	4079
To	PART	O	O	4080
assess	VERB	O	O	4080
the	PRON	O	O	4080
effect	VERB	O	O	4080
of	ADP	O	O	4080
long	ADV	O	O	4080
-	PUNCT	O	O	4080
term	NOUN	O	O	4080
HT	PROPN	O	O	4080
on	ADP	O	O	4080
mortality	NOUN	O	O	4080
,	PUNCT	O	O	4080
heart disease	NOUN	O	Disease	4080
,	PUNCT	O	O	4080
venous thromboembolism	NOUN	O	Disease	4080
,	PUNCT	O	O	4080
stroke	VERB	O	Disease	4080
,	PUNCT	O	O	4080
transient	ADJ	O	O	4080
ischaemic	ADJ	O	O	4080
attacks	NOUN	O	O	4080
,	PUNCT	O	O	4080
breast cancer	NOUN	O	Disease	4080
,	PUNCT	O	O	4080
colorectal cancer	NOUN	O	Disease	4080
,	PUNCT	O	O	4080
ovarian cancer	NOUN	O	Disease	4080
,	PUNCT	O	O	4080
endometrial cancer	NOUN	O	Disease	4080
,	PUNCT	O	O	4080
gallbladder disease	NOUN	O	Disease	4080
,	PUNCT	O	O	4080
cognitive	ADJ	O	O	4080
function	NOUN	O	O	4080
,	PUNCT	O	O	4080
dementia	NOUN	O	Disease	4080
,	PUNCT	O	O	4080
fractures	NOUN	O	Disease	4080
and	CCONJ	O	O	4080
quality	NOUN	O	O	4080
of	ADP	O	O	4080
life	NOUN	O	O	4080
.	PUNCT	O	O	4080
SELECTION	PROPN	O	O	4081
CRITERIA	NOUN	O	O	4081
:	PUNCT	O	O	4081
Randomised	VERB	O	O	4081
double	ADJ	O	O	4081
-	PUNCT	O	O	4081
blind	ADJ	O	Disease	4081
trials	NOUN	O	O	4081
of	ADP	O	O	4081
HT	PROPN	O	O	4081
(	PUNCT	O	O	4081
oestrogens	PROPN	O	Chemical	4081
with	ADP	O	O	4081
or	CCONJ	O	O	4081
without	ADP	O	O	4081
progestogens	NOUN	O	Chemical	4081
)	PUNCT	O	O	4081
versus	ADP	O	O	4081
placebo	NOUN	O	O	4081
,	PUNCT	O	O	4081
taken	VERB	O	O	4081
for	ADP	O	O	4081
at	ADP	O	O	4081
least	ADJ	O	O	4081
one	NUM	O	O	4081
year	NOUN	O	O	4081
by	ADP	O	O	4081
perimenopausal	ADJ	O	O	4081
or	CCONJ	O	O	4081
postmenopausal	NOUN	O	O	4081
women	NOUN	O	O	4081
.	PUNCT	O	O	4081
In	ADP	O	O	4082
relatively	ADV	O	O	4082
healthy	ADJ	O	O	4082
women	NOUN	O	O	4082
,	PUNCT	O	O	4082
combined	VERB	O	O	4082
continuous	ADJ	O	O	4082
HT	PROPN	O	O	4082
significantly	ADV	O	O	4082
increased	VERB	O	O	4082
the	PRON	O	O	4082
risk	NOUN	O	O	4082
of	ADP	O	O	4082
venous thromboembolism	NOUN	O	Disease	4082
or	CCONJ	O	O	4082
coronary	ADJ	O	O	4082
event	NOUN	O	O	4082
(	PUNCT	O	O	4082
after	ADP	O	O	4082
one	NUM	O	O	4082
year	NOUN	O	O	4082
's	AUX	O	O	4082
use	VERB	O	O	4082
)	PUNCT	O	O	4082
,	PUNCT	O	O	4082
stroke	VERB	O	Disease	4082
(	PUNCT	O	O	4082
after	ADP	O	O	4082
3	X	O	O	4082
years	NOUN	O	O	4082
)	PUNCT	O	O	4082
,	PUNCT	O	O	4082
breast cancer	NOUN	O	Disease	4082
(	PUNCT	O	O	4082
after	ADP	O	O	4082
5	NUM	O	O	4082
years	NOUN	O	O	4082
)	PUNCT	O	O	4082
and	CCONJ	O	O	4082
gallbladder disease	NOUN	O	Disease	4082
.	PUNCT	O	O	4082
Long	ADV	O	O	4083
-	PUNCT	O	O	4083
term	NOUN	O	O	4083
oestrogen	PROPN	O	Chemical	4083
-	PUNCT	O	O	4083
only	ADV	O	O	4083
HT	PROPN	O	O	4083
also	ADV	O	O	4083
significantly	ADV	O	O	4083
increased	VERB	O	O	4083
the	PRON	O	O	4083
risk	NOUN	O	O	4083
of	ADP	O	O	4083
stroke	VERB	O	Disease	4083
and	CCONJ	O	O	4083
gallbladder disease	NOUN	O	Disease	4083
.	PUNCT	O	O	4083
Overall	ADV	O	O	4084
,	PUNCT	O	O	4084
the	PRON	O	O	4084
only	ADV	O	O	4084
statistically	ADV	O	O	4084
significant	ADJ	O	O	4084
benefits	NOUN	O	O	4084
of	ADP	O	O	4084
HT	PROPN	O	O	4084
were	AUX	O	O	4084
a	PRON	O	O	4084
decreased	VERB	O	O	4084
incidence	NOUN	O	O	4084
of	ADP	O	O	4084
fractures	NOUN	O	Disease	4084
and	CCONJ	O	O	4084
colon cancer	NOUN	O	Disease	4084
with	ADP	O	O	4084
long	ADV	O	O	4084
-	PUNCT	O	O	4084
term	NOUN	O	O	4084
use	VERB	O	O	4084
.	PUNCT	O	O	4084
Among	ADP	O	O	4085
relatively	ADV	O	O	4085
healthy	ADJ	O	O	4085
women	NOUN	O	O	4085
over	ADP	O	O	4085
65	NUM	O	O	4085
years	NOUN	O	O	4085
taking	VERB	O	O	4085
continuous	ADJ	O	O	4085
combined	VERB	O	O	4085
HT	PROPN	O	O	4085
,	PUNCT	O	O	4085
there	ADV	O	O	4085
was	AUX	O	O	4085
a	PRON	O	O	4085
statistically	ADV	O	O	4085
significant	ADJ	O	O	4085
increase	VERB	O	O	4085
in	ADP	O	O	4085
the	PRON	O	O	4085
incidence	NOUN	O	O	4085
of	ADP	O	O	4085
dementia	NOUN	O	Disease	4085
.	PUNCT	O	O	4085
Among	ADP	O	O	4086
women	NOUN	O	O	4086
with	ADP	O	O	4086
cardiovascular disease	NOUN	O	Disease	4086
,	PUNCT	O	O	4086
long	ADV	O	O	4086
-	PUNCT	O	O	4086
term	NOUN	O	O	4086
use	VERB	O	O	4086
of	ADP	O	O	4086
combined	VERB	O	O	4086
continuous	ADJ	O	O	4086
HT	PROPN	O	O	4086
significantly	ADV	O	O	4086
increased	VERB	O	O	4086
the	PRON	O	O	4086
risk	NOUN	O	O	4086
of	ADP	O	O	4086
venous thromboembolism	NOUN	O	Disease	4086
.	PUNCT	O	O	4086
However	ADV	O	O	4087
,	PUNCT	O	O	4087
one	NUM	O	O	4087
trial	NOUN	O	O	4087
analysed	VERB	O	O	4087
subgroups	NOUN	O	O	4087
of	ADP	O	O	4087
2839	NUM	O	O	4087
relatively	ADV	O	O	4087
healthy	ADJ	O	O	4087
50	NUM	O	O	4087
to	PART	O	O	4087
59	NUM	O	O	4087
year	NOUN	O	O	4087
-	PUNCT	O	O	4087
old	ADJ	O	O	4087
women	NOUN	O	O	4087
taking	VERB	O	O	4087
combined	VERB	O	O	4087
continuous	ADJ	O	O	4087
HT	PROPN	O	O	4087
and	CCONJ	O	O	4087
1637	NUM	O	O	4087
taking	VERB	O	O	4087
oestrogen	PROPN	O	Chemical	4087
-	PUNCT	O	O	4087
only	ADV	O	O	4087
HT	PROPN	O	O	4087
,	PUNCT	O	O	4087
versus	ADP	O	O	4087
similar	ADJ	O	O	4087
-	PUNCT	O	O	4087
sized	ADJ	O	O	4087
placebo	NOUN	O	O	4087
groups	NOUN	O	O	4087
.	PUNCT	O	O	4087
The	PRON	O	O	4088
only	ADV	O	O	4088
significantly	ADV	O	O	4088
increased	VERB	O	O	4088
risk	NOUN	O	O	4088
reported	VERB	O	O	4088
was	AUX	O	O	4088
for	ADP	O	O	4088
venous thromboembolism	NOUN	O	Disease	4088
in	ADP	O	O	4088
women	NOUN	O	O	4088
taking	VERB	O	O	4088
combined	VERB	O	O	4088
continuous	ADJ	O	O	4088
HT	PROPN	O	O	4088
;	PUNCT	O	O	4088
their	PRON	O	O	4088
absolute	ADJ	O	O	4088
risk	NOUN	O	O	4088
remained	VERB	O	O	4088
very	ADV	O	O	4088
low	ADJ	O	O	4088
.	PUNCT	O	O	4088
HT	PROPN	O	O	4089
is	AUX	O	O	4089
not	PART	O	O	4089
indicated	VERB	O	O	4089
for	ADP	O	O	4089
the	PRON	O	O	4089
routine	ADJ	O	O	4089
management	NOUN	O	O	4089
of	ADP	O	O	4089
chronic	ADJ	O	O	4089
disease	PROPN	O	O	4089
.	PUNCT	O	O	4089
Drug	NOUN	O	O	4092
-	PUNCT	O	O	4092
induced	VERB	O	O	4092
liver injury	NOUN	O	Disease	4092
:	PUNCT	O	O	4092
an	PRON	O	O	4092
analysis	NOUN	O	O	4092
of	ADP	O	O	4092
461	NUM	O	O	4092
incidences	NOUN	O	O	4092
submitted	VERB	O	O	4092
to	PART	O	O	4092
the	PRON	O	O	4092
Spanish	ADJ	O	O	4092
registry	NOUN	O	O	4092
over	ADP	O	O	4092
a	PRON	O	O	4092
10-year	NOUN	O	O	4092
period	NOUN	O	O	4092
.	PUNCT	O	O	4092
Progress	NOUN	O	O	4093
in	ADP	O	O	4093
the	PRON	O	O	4093
understanding	NOUN	O	O	4093
of	ADP	O	O	4093
susceptibility	NOUN	O	O	4093
factors	NOUN	O	O	4093
to	PART	O	O	4093
drug	NOUN	O	O	4093
-	PUNCT	O	O	4093
induced	VERB	O	O	4093
liver injury	NOUN	O	Disease	4093
(	PUNCT	O	O	4093
DILI	PROPN	O	O	4093
)	PUNCT	O	O	4093
and	CCONJ	O	O	4093
outcome	NOUN	O	O	4093
predictability	NOUN	O	O	4093
are	AUX	O	O	4093
hampered	VERB	O	O	4093
by	ADP	O	O	4093
the	PRON	O	O	4093
lack	VERB	O	O	4093
of	ADP	O	O	4093
systematic	ADJ	O	O	4093
programs	NOUN	O	O	4093
to	PART	O	O	4093
detect	VERB	O	O	4093
bona	X	O	O	4093
fide	ADJ	O	O	4093
cases	NOUN	O	O	4093
.	PUNCT	O	O	4093
A	PRON	O	O	4094
cooperative	ADJ	O	O	4094
network	NOUN	O	O	4094
was	AUX	O	O	4094
created	VERB	O	O	4094
in	ADP	O	O	4094
1994	NUM	O	O	4094
in	ADP	O	O	4094
Spain	PROPN	O	O	4094
to	PART	O	O	4094
identify	VERB	O	O	4094
all	PRON	O	O	4094
suspicions	NOUN	O	O	4094
of	ADP	O	O	4094
DILI	PROPN	O	O	4094
following	VERB	O	O	4094
a	PRON	O	O	4094
prospective	ADJ	O	O	4094
structured	VERB	O	O	4094
report	VERB	O	O	4094
form	NOUN	O	O	4094
.	PUNCT	O	O	4094
The	PRON	O	O	4095
liver damage	NOUN	O	Disease	4095
was	AUX	O	O	4095
characterized	VERB	O	O	4095
according	VERB	O	O	4095
to	PART	O	O	4095
hepatocellular	NOUN	O	O	4095
,	PUNCT	O	O	4095
cholestatic	ADJ	O	Disease	4095
,	PUNCT	O	O	4095
and	CCONJ	O	O	4095
mixed	VERB	O	O	4095
laboratory	NOUN	O	O	4095
criteria	NOUN	O	O	4095
and	CCONJ	O	O	4095
to	PART	O	O	4095
histologic	ADJ	O	O	4095
criteria	NOUN	O	O	4095
when	SCONJ	O	O	4095
available	ADJ	O	O	4095
.	PUNCT	O	O	4095
Since	SCONJ	O	O	4096
April	PROPN	O	O	4096
1994	NUM	O	O	4096
to	PART	O	O	4096
August	PROPN	O	O	4096
2004	NUM	O	O	4096
,	PUNCT	O	O	4096
461	NUM	O	O	4096
out	ADP	O	O	4096
of	ADP	O	O	4096
570	NUM	O	O	4096
submitted	VERB	O	O	4096
cases	NOUN	O	O	4096
,	PUNCT	O	O	4096
involving	VERB	O	O	4096
505	NUM	O	O	4096
drugs	NOUN	O	O	4096
,	PUNCT	O	O	4096
were	AUX	O	O	4096
deemed	VERB	O	O	4096
to	PART	O	O	4096
be	AUX	O	O	4096
related	ADJ	O	O	4096
to	PART	O	O	4096
DILI	PROPN	O	O	4096
.	PUNCT	O	O	4096
The	PRON	O	O	4097
antiinfective	PROPN	O	O	4097
group	NOUN	O	O	4097
of	ADP	O	O	4097
drugs	NOUN	O	O	4097
was	AUX	O	O	4097
the	PRON	O	O	4097
more	ADJ	O	O	4097
frequently	ADV	O	O	4097
incriminated	VERB	O	O	4097
,	PUNCT	O	O	4097
amoxicillin	PROPN	O	O	4097
-	PUNCT	O	O	4097
clavulanate	VERB	O	O	4097
accounting	VERB	O	O	4097
for	ADP	O	O	4097
the	PRON	O	O	4097
12.8%	NOUN	O	O	4097
of	ADP	O	O	4097
the	PRON	O	O	4097
whole	NOUN	O	O	4097
series	PROPN	O	O	4097
.	PUNCT	O	O	4097
Indeed	ADV	O	O	4098
,	PUNCT	O	O	4098
the	PRON	O	O	4098
incidence	NOUN	O	O	4098
of	ADP	O	O	4098
liver	NOUN	O	O	4098
transplantation	NOUN	O	O	4098
and	CCONJ	O	O	4098
death	NOUN	O	O	4098
in	ADP	O	O	4098
this	PRON	O	O	4098
group	NOUN	O	O	4098
was	AUX	O	O	4098
11.7%	NOUN	O	O	4098
if	SCONJ	O	O	4098
patients	NOUN	O	O	4098
had	VERB	O	O	4098
jaundice	NOUN	O	Disease	4098
at	ADP	O	O	4098
presentation	NOUN	O	O	4098
,	PUNCT	O	O	4098
whereas	SCONJ	O	O	4098
the	PRON	O	O	4098
corresponding	VERB	O	O	4098
figure	NOUN	O	O	4098
was	AUX	O	O	4098
3.8%	NOUN	O	O	4098
in	ADP	O	O	4098
nonjaundiced	VERB	O	O	4098
patients	NOUN	O	O	4098
(	PUNCT	O	O	4098
P	NOUN	O	Chemical	4098
<	X	O	O	4098
.04	NUM	O	O	4098
)	PUNCT	O	O	4098
.	PUNCT	O	O	4098
Factors	NOUN	O	O	4099
associated	VERB	O	O	4099
with	ADP	O	O	4099
the	PRON	O	O	4099
development	NOUN	O	O	4099
of	ADP	O	O	4099
fulminant	ADJ	O	O	4099
hepatic failure	NOUN	O	Disease	4099
were	AUX	O	O	4099
female	ADJ	O	O	4099
sex	NOUN	O	O	4099
(	PUNCT	O	O	4099
OR	CCONJ	O	O	4099
=	PUNCT	O	O	4099
25	NUM	O	O	4099
;	PUNCT	O	O	4099
95%	NOUN	O	O	4099
CI	NOUN	O	O	4099
:	PUNCT	O	O	4099
4.1	NUM	O	O	4099
-	PUNCT	O	O	4099
151	NUM	O	O	4099
;	PUNCT	O	O	4099
P	NOUN	O	Chemical	4099
95%	NOUN	O	O	4100
CI	NOUN	O	O	4100
:	PUNCT	O	O	4100
1.6	NUM	O	O	4100
-	PUNCT	O	O	4100
37	NUM	O	O	4100
;	PUNCT	O	O	4100
P	NOUN	O	Chemical	4100
<	X	O	O	4100
.009	NUM	O	O	4100
)	PUNCT	O	O	4100
,	PUNCT	O	O	4100
and	CCONJ	O	O	4100
higher	ADJ	O	O	4100
baseline	VERB	O	O	4100
plasma	NOUN	O	O	4100
bilirubin	ADJ	O	Chemical	4100
value	NOUN	O	O	4100
(	PUNCT	O	O	4100
OR	CCONJ	O	O	4100
=	PUNCT	O	O	4100
1.15	NUM	O	O	4100
;	PUNCT	O	O	4100
95%	NOUN	O	O	4100
CI	NOUN	O	O	4100
:	PUNCT	O	O	4100
1.09	NUM	O	O	4100
-	PUNCT	O	O	4100
1.22	NUM	O	O	4100
;	PUNCT	O	O	4100
P	NOUN	O	Chemical	4100
Patients	NOUN	O	O	4101
with	ADP	O	O	4101
drug	NOUN	O	O	4101
-	PUNCT	O	O	4101
induced	VERB	O	O	4101
hepatocellular	NOUN	O	O	4101
jaundice	NOUN	O	Disease	4101
have	VERB	O	O	4101
11.7%	NOUN	O	O	4101
chance	NOUN	O	O	4101
of	ADP	O	O	4101
progressing	VERB	O	O	4101
to	PART	O	O	4101
death	NOUN	O	O	4101
or	CCONJ	O	O	4101
transplantation	NOUN	O	O	4101
.	PUNCT	O	O	4101
Amoxicillin	PROPN	O	O	4102
-	PUNCT	O	O	4102
clavulanate	VERB	O	O	4102
stands	VERB	O	O	4102
out	ADP	O	O	4102
as	ADP	O	O	4102
the	PRON	O	O	4102
most	ADV	O	O	4102
common	ADJ	O	O	4102
drug	NOUN	O	O	4102
related	ADJ	O	O	4102
to	PART	O	O	4102
DILI	PROPN	O	O	4102
.	PUNCT	O	O	4102
Morphological	ADJ	O	O	4105
evaluation	NOUN	O	O	4105
of	ADP	O	O	4105
the	PRON	O	O	4105
effect	VERB	O	O	4105
of	ADP	O	O	4105
d	X	O	O	4105
-	PUNCT	O	O	4105
ribose	NOUN	O	O	4105
on	ADP	O	O	4105
adriamycin	PROPN	O	Chemical	4105
-	PUNCT	O	O	4105
evoked	VERB	O	O	4105
cardiotoxicity	NOUN	O	Disease	4105
in	ADP	O	O	4105
rats	NOUN	O	O	4105
.	PUNCT	O	O	4105
The	PRON	O	O	4106
influence	NOUN	O	O	4106
of	ADP	O	O	4106
d	X	O	O	4106
-	PUNCT	O	O	4106
ribose	NOUN	O	O	4106
on	ADP	O	O	4106
adriamycin	PROPN	O	Chemical	4106
-	PUNCT	O	O	4106
induced	VERB	O	O	4106
myocardiopathy	ADJ	O	O	4106
in	ADP	O	O	4106
rats	NOUN	O	O	4106
was	AUX	O	O	4106
studied	VERB	O	O	4106
.	PUNCT	O	O	4106
Adriamycin	PROPN	O	Chemical	4107
in	ADP	O	O	4107
the	PRON	O	O	4107
cumulative	ADJ	O	O	4107
dose	NOUN	O	O	4107
of	ADP	O	O	4107
25	NUM	O	O	4107
mg	VERB	O	O	4107
/	PUNCT	O	O	4107
kg	VERB	O	O	4107
evoked	VERB	O	O	4107
fully	ADV	O	O	4107
developed	VERB	O	O	4107
cardiac toxicity	NOUN	O	Disease	4107
.	PUNCT	O	O	4107
D	NOUN	O	O	4108
-	PUNCT	O	O	4108
ribose	NOUN	O	O	4108
in	ADP	O	O	4108
the	PRON	O	O	4108
multiple	ADJ	O	O	4108
doses	NOUN	O	O	4108
of	ADP	O	O	4108
200	NUM	O	O	4108
mg	VERB	O	O	4108
/	PUNCT	O	O	4108
kg	VERB	O	O	4108
did	VERB	O	O	4108
not	PART	O	O	4108
influence	NOUN	O	O	4108
ADR	PROPN	O	Chemical	4108
cardiotoxicity	NOUN	O	Disease	4108
.	PUNCT	O	O	4108
In	ADP	O	O	4111
vivo	VERB	O	O	4111
evidences	NOUN	O	O	4111
suggesting	VERB	O	O	4111
the	PRON	O	O	4111
role	NOUN	O	O	4111
of	ADP	O	O	4111
oxidative	NOUN	O	O	4111
stress	NOUN	O	O	4111
in	ADP	O	O	4111
pathogenesis	NOUN	O	O	4111
of	ADP	O	O	4111
vancomycin	VERB	O	Chemical	4111
-	PUNCT	O	O	4111
induced	VERB	O	O	4111
nephrotoxicity	NOUN	O	Disease	4111
:	PUNCT	O	O	4111
protection	NOUN	O	O	4111
by	ADP	O	O	4111
erdosteine	NOUN	O	O	4111
.	PUNCT	O	O	4111
The	PRON	O	O	4112
aims	VERB	O	O	4112
of	ADP	O	O	4112
this	PRON	O	O	4112
study	VERB	O	O	4112
were	AUX	O	O	4112
to	PART	O	O	4112
examine	VERB	O	O	4112
vancomycin	VERB	O	Chemical	4112
(	PUNCT	O	O	4112
VCM)-induced	NUM	O	O	4112
oxidative	NOUN	O	O	4112
stress	NOUN	O	O	4112
that	SCONJ	O	O	4112
promotes	VERB	O	O	4112
production	NOUN	O	O	4112
of	ADP	O	O	4112
reactive	ADJ	O	O	4112
oxygen	NOUN	O	Chemical	4112
species	NOUN	O	O	4112
(	PUNCT	O	O	4112
ROS	PROPN	O	O	4112
)	PUNCT	O	O	4112
and	CCONJ	O	O	4112
to	PART	O	O	4112
investigate	VERB	O	O	4112
the	PRON	O	O	4112
role	NOUN	O	O	4112
of	ADP	O	O	4112
erdosteine	NOUN	O	O	4112
,	PUNCT	O	O	4112
an	PRON	O	O	4112
expectorant	ADJ	O	O	4112
agent	NOUN	O	O	4112
,	PUNCT	O	O	4112
which	PRON	O	O	4112
has	VERB	O	O	4112
also	ADV	O	O	4112
antioxidant	ADJ	O	O	4112
properties	NOUN	O	O	4112
,	PUNCT	O	O	4112
on	ADP	O	O	4112
kidney	NOUN	O	O	4112
tissue	NOUN	O	O	4112
against	ADP	O	O	4112
the	PRON	O	O	4112
possible	ADJ	O	O	4112
VCM	PROPN	O	O	4112
-	PUNCT	O	O	4112
induced	VERB	O	O	4112
renal impairment	NOUN	O	Disease	4112
in	ADP	O	O	4112
rats	NOUN	O	O	4112
.	PUNCT	O	O	4112
Rats	NOUN	O	O	4113
were	AUX	O	O	4113
divided	VERB	O	O	4113
into	ADP	O	O	4113
three	NUM	O	O	4113
groups	NOUN	O	O	4113
:	PUNCT	O	O	4113
sham	NOUN	O	O	4113
,	PUNCT	O	O	4113
VCM	PROPN	O	O	4113
and	CCONJ	O	O	4113
VCM	PROPN	O	O	4113
plus	CCONJ	O	O	4113
erdosteine	NOUN	O	O	4113
.	PUNCT	O	O	4113
VCM	PROPN	O	O	4114
was	AUX	O	O	4114
administrated	VERB	O	O	4114
intraperitoneally	ADV	O	O	4114
(	PUNCT	O	O	4114
i.p	NOUN	O	O	4114
.	PUNCT	O	O	4114
)	PUNCT	O	O	4114
Erdosteine	NOUN	O	O	4115
was	AUX	O	O	4115
administered	VERB	O	O	4115
orally	ADV	O	O	4115
.	PUNCT	O	O	4115
VCM	PROPN	O	O	4116
administration	NOUN	O	O	4116
to	PART	O	O	4116
control	VERB	O	O	4116
rats	NOUN	O	O	4116
significantly	ADV	O	O	4116
increased	VERB	O	O	4116
renal	ADJ	O	O	4116
malondialdehyde	PROPN	O	Chemical	4116
(	PUNCT	O	O	4116
MDA	PROPN	O	Chemical	4116
)	PUNCT	O	O	4116
and	CCONJ	O	O	4116
urinary	ADJ	O	O	4116
(	PUNCT	O	O	4117
NAG	PROPN	O	O	4117
,	PUNCT	O	O	4117
a	PRON	O	O	4117
marker	NOUN	O	O	4117
of	ADP	O	O	4117
renal	ADJ	O	O	4117
tubular	ADJ	O	O	4117
injury	NOUN	O	O	4117
)	PUNCT	O	O	4117
excretion	NOUN	O	O	4117
but	CCONJ	O	O	4117
decreased	VERB	O	O	4117
superoxide	NOUN	O	Chemical	4117
dismutase	ADP	O	O	4117
(	PUNCT	O	O	4117
SOD	PROPN	O	O	4117
)	PUNCT	O	O	4117
and	CCONJ	O	O	4117
catalase	VERB	O	O	4117
(	PUNCT	O	O	4117
CAT	NOUN	O	O	4117
)	PUNCT	O	O	4117
activities	NOUN	O	O	4117
.	PUNCT	O	O	4117
Erdosteine	NOUN	O	O	4118
administration	NOUN	O	O	4118
with	ADP	O	O	4118
VCM	PROPN	O	O	4118
injections	NOUN	O	O	4118
caused	VERB	O	O	4118
significantly	ADV	O	O	4118
decreased	VERB	O	O	4118
renal	ADJ	O	O	4118
MDA	PROPN	O	Chemical	4118
and	CCONJ	O	O	4118
urinary	ADJ	O	O	4118
NAG	PROPN	O	O	4118
excretion	NOUN	O	O	4118
,	PUNCT	O	O	4118
and	CCONJ	O	O	4118
increased	VERB	O	O	4118
SOD	PROPN	O	O	4118
activity	NOUN	O	O	4118
,	PUNCT	O	O	4118
but	CCONJ	O	O	4118
not	PART	O	O	4118
CAT	NOUN	O	O	4118
activity	NOUN	O	O	4118
in	ADP	O	O	4118
renal	ADJ	O	O	4118
tissue	NOUN	O	O	4118
when	SCONJ	O	O	4118
compared	VERB	O	O	4118
with	ADP	O	O	4118
VCM	PROPN	O	O	4118
alone	ADV	O	O	4118
.	PUNCT	O	O	4118
Erdosteine	NOUN	O	O	4119
showed	VERB	O	O	4119
histopathological	ADJ	O	O	4119
protection	NOUN	O	O	4119
against	ADP	O	O	4119
VCM	PROPN	O	O	4119
-	PUNCT	O	O	4119
induced	VERB	O	O	4119
nephrotoxicity	NOUN	O	Disease	4119
.	PUNCT	O	O	4119
There	ADV	O	O	4120
were	AUX	O	O	4120
a	PRON	O	O	4120
significant	ADJ	O	O	4120
dilatation	NOUN	O	O	4120
of	ADP	O	O	4120
tubular	ADJ	O	O	4120
lumens	NOUN	O	O	4120
,	PUNCT	O	O	4120
extensive	ADJ	O	O	4120
epithelial	ADJ	O	O	4120
cell	NOUN	O	O	4120
vacuolization	NOUN	O	O	4120
,	PUNCT	O	O	4120
atrophy	NOUN	O	Disease	4120
,	PUNCT	O	O	4120
desquamation	NOUN	O	O	4120
,	PUNCT	O	O	4120
and	CCONJ	O	O	4120
necrosis	NOUN	O	Disease	4120
in	ADP	O	O	4120
VCM	PROPN	O	O	4120
-	PUNCT	O	O	4120
treated	VERB	O	O	4120
rats	NOUN	O	O	4120
more	ADJ	O	O	4120
than	ADP	O	O	4120
those	PRON	O	O	4120
of	ADP	O	O	4120
the	PRON	O	O	4120
control	VERB	O	O	4120
and	CCONJ	O	O	4120
the	PRON	O	O	4120
erdosteine	NOUN	O	O	4120
groups	NOUN	O	O	4120
.	PUNCT	O	O	4120
Erdosteine	NOUN	O	O	4121
caused	VERB	O	O	4121
a	PRON	O	O	4121
marked	VERB	O	O	4121
reduction	NOUN	O	O	4121
in	ADP	O	O	4121
the	PRON	O	O	4121
extent	NOUN	O	O	4121
of	ADP	O	O	4121
tubular	ADJ	O	O	4121
damage	NOUN	O	O	4121
.	PUNCT	O	O	4121
It	PRON	O	O	4122
is	AUX	O	O	4122
concluded	VERB	O	O	4122
that	SCONJ	O	O	4122
oxidative	NOUN	O	O	4122
tubular	ADJ	O	O	4122
damage	NOUN	O	O	4122
plays	VERB	O	O	4122
an	PRON	O	O	4122
important	ADJ	O	O	4122
role	NOUN	O	O	4122
in	ADP	O	O	4122
the	PRON	O	O	4122
VCM	PROPN	O	O	4122
-	PUNCT	O	O	4122
induced	VERB	O	O	4122
nephrotoxicity	NOUN	O	Disease	4122
and	CCONJ	O	O	4122
the	PRON	O	O	4122
modulation	NOUN	O	O	4122
of	ADP	O	O	4122
oxidative	NOUN	O	O	4122
stress	NOUN	O	O	4122
with	ADP	O	O	4122
erdosteine	NOUN	O	O	4122
reduces	VERB	O	O	4122
the	PRON	O	O	4122
VCM	PROPN	O	O	4122
-	PUNCT	O	O	4122
induced	VERB	O	O	4122
kidney	NOUN	O	O	4122
damage	NOUN	O	O	4122
both	PRON	O	O	4122
at	ADP	O	O	4122
the	PRON	O	O	4122
biochemical	ADJ	O	O	4122
and	CCONJ	O	O	4122
histological	ADJ	O	O	4122
levels	NOUN	O	O	4122
.	PUNCT	O	O	4122
Does	VERB	O	O	4125
domperidone	PROPN	O	O	4125
potentiate	VERB	O	O	4125
mirtazapine	NOUN	O	O	4125
-	PUNCT	O	O	4125
associated	VERB	O	O	4125
restless	ADJ	O	O	4125
legs	NOUN	O	O	4125
syndrome	NOUN	O	O	4125
?	PUNCT	O	O	4125
There	ADV	O	O	4126
is	AUX	O	O	4126
now	ADV	O	O	4126
evidence	NOUN	O	O	4126
to	PART	O	O	4126
suggest	VERB	O	O	4126
a	PRON	O	O	4126
central	ADJ	O	O	4126
role	NOUN	O	O	4126
for	ADP	O	O	4126
the	PRON	O	O	4126
dopaminergic	ADJ	O	O	4126
system	NOUN	O	O	4126
in	ADP	O	O	4126
restless	ADJ	O	O	4126
legs	NOUN	O	O	4126
syndrome	NOUN	O	O	4126
(	PUNCT	O	O	4126
RLS	PROPN	O	O	4126
)	PUNCT	O	O	4126
.	PUNCT	O	O	4126
For	ADP	O	O	4127
example	NOUN	O	O	4127
,	PUNCT	O	O	4127
the	PRON	O	O	4127
symptoms	NOUN	O	O	4127
of	ADP	O	O	4127
RLS	PROPN	O	O	4127
can	AUX	O	O	4127
be	AUX	O	O	4127
dramatically	ADV	O	O	4127
improved	VERB	O	O	4127
by	ADP	O	O	4127
levodopa	NOUN	O	Chemical	4127
and	CCONJ	O	O	4127
dopamine	NOUN	O	Chemical	4127
agonists	NOUN	O	O	4127
,	PUNCT	O	O	4127
whereas	SCONJ	O	O	4127
central	ADJ	O	O	4127
dopamine	NOUN	O	Chemical	4127
D2	NOUN	O	O	4127
receptor	NOUN	O	O	4127
antagonists	NOUN	O	O	4127
can	AUX	O	O	4127
induce	VERB	O	O	4127
or	CCONJ	O	O	4127
aggravate	VERB	O	O	4127
RLS	PROPN	O	O	4127
symptoms	NOUN	O	O	4127
.	PUNCT	O	O	4127
To	PART	O	O	4128
our	PRON	O	O	4128
knowledge	NOUN	O	O	4128
,	PUNCT	O	O	4128
there	ADV	O	O	4128
is	AUX	O	O	4128
no	PRON	O	O	4128
previous	ADJ	O	O	4128
report	VERB	O	O	4128
regarding	VERB	O	O	4128
whether	SCONJ	O	O	4128
domperidone	PROPN	O	O	4128
,	PUNCT	O	O	4128
a	PRON	O	O	4128
peripheral	ADJ	O	O	4128
dopamine	NOUN	O	Chemical	4128
D2	NOUN	O	O	4128
receptor	NOUN	O	O	4128
antagonist	NOUN	O	O	4128
,	PUNCT	O	O	4128
can	AUX	O	O	4128
also	ADV	O	O	4128
induce	VERB	O	O	4128
or	CCONJ	O	O	4128
aggravate	VERB	O	O	4128
symptoms	NOUN	O	O	4128
of	ADP	O	O	4128
RLS	PROPN	O	O	4128
.	PUNCT	O	O	4128
Mirtazapine	NOUN	O	O	4129
,	PUNCT	O	O	4129
the	PRON	O	O	4129
first	ADV	O	O	4129
noradrenergic	ADJ	O	O	4129
and	CCONJ	O	O	4129
specific	ADJ	O	O	4129
serotonergic	ADJ	O	O	4129
antidepressant	NOUN	O	O	4129
(	PUNCT	O	O	4129
NaSSA	PROPN	O	O	4129
)	PUNCT	O	O	4129
,	PUNCT	O	O	4129
has	VERB	O	O	4129
been	AUX	O	O	4129
associated	VERB	O	O	4129
with	ADP	O	O	4129
RLS	PROPN	O	O	4129
in	ADP	O	O	4129
several	ADJ	O	O	4129
recent	ADJ	O	O	4129
publications	NOUN	O	O	4129
.	PUNCT	O	O	4129
The	PRON	O	O	4130
authors	NOUN	O	O	4130
report	VERB	O	O	4130
here	ADV	O	O	4130
a	PRON	O	O	4130
depressed	ADJ	O	O	4130
patient	NOUN	O	O	4130
comorbid	NOUN	O	O	4130
with	ADP	O	O	4130
postprandial	ADJ	O	O	4130
dyspepsia	NOUN	O	O	4130
who	PRON	O	O	4130
developed	VERB	O	O	4130
RLS	PROPN	O	O	4130
after	ADP	O	O	4130
mirtazapine	NOUN	O	O	4130
had	VERB	O	O	4130
been	AUX	O	O	4130
added	VERB	O	O	4130
to	PART	O	O	4130
his	PRON	O	O	4130
domperidone	PROPN	O	O	4130
therapy	NOUN	O	O	4130
.	PUNCT	O	O	4130
Our	PRON	O	O	4131
patient	NOUN	O	O	4131
started	VERB	O	O	4131
to	PART	O	O	4131
have	VERB	O	O	4131
symptoms	NOUN	O	O	4131
of	ADP	O	O	4131
RLS	PROPN	O	O	4131
only	ADV	O	O	4131
after	ADP	O	O	4131
he	PRON	O	O	4131
had	VERB	O	O	4131
been	AUX	O	O	4131
treated	VERB	O	O	4131
with	ADP	O	O	4131
mirtazapine	NOUN	O	O	4131
,	PUNCT	O	O	4131
and	CCONJ	O	O	4131
his	PRON	O	O	4131
RLS	PROPN	O	O	4131
symptoms	NOUN	O	O	4131
resolved	VERB	O	O	4131
completely	ADV	O	O	4131
upon	SCONJ	O	O	4131
discontinuation	NOUN	O	O	4131
of	ADP	O	O	4131
his	PRON	O	O	4131
mirtazapine	NOUN	O	O	4131
.	PUNCT	O	O	4131
Such	ADJ	O	O	4132
a	PRON	O	O	4132
temporal	ADJ	O	O	4132
relationship	NOUN	O	O	4132
between	ADP	O	O	4132
the	PRON	O	O	4132
use	VERB	O	O	4132
of	ADP	O	O	4132
mirtazapine	NOUN	O	O	4132
and	CCONJ	O	O	4132
the	PRON	O	O	4132
symptoms	NOUN	O	O	4132
of	ADP	O	O	4132
RLS	PROPN	O	O	4132
in	ADP	O	O	4132
our	PRON	O	O	4132
patient	NOUN	O	O	4132
did	VERB	O	O	4132
not	PART	O	O	4132
support	NOUN	O	O	4132
a	PRON	O	O	4132
potentiating	VERB	O	O	4132
effect	VERB	O	O	4132
of	ADP	O	O	4132
domperione	NOUN	O	O	4132
on	ADP	O	O	4132
mirtazapine	NOUN	O	O	4132
-	PUNCT	O	O	4132
associated	VERB	O	O	4132
RLS	PROPN	O	O	4132
.	PUNCT	O	O	4132
However	ADV	O	O	4133
,	PUNCT	O	O	4133
physicians	NOUN	O	O	4133
should	AUX	O	O	4133
be	AUX	O	O	4133
aware	ADJ	O	O	4133
of	ADP	O	O	4133
the	PRON	O	O	4133
possibility	NOUN	O	O	4133
that	SCONJ	O	O	4133
mirtazapine	NOUN	O	O	4133
can	AUX	O	O	4133
be	AUX	O	O	4133
associated	VERB	O	O	4133
with	ADP	O	O	4133
RLS	PROPN	O	O	4133
in	ADP	O	O	4133
some	PRON	O	O	4133
individuals	NOUN	O	O	4133
,	PUNCT	O	O	4133
especially	ADV	O	O	4133
those	PRON	O	O	4133
receiving	VERB	O	O	4133
concomitant	ADJ	O	O	4133
dopamine	NOUN	O	Chemical	4133
D2	NOUN	O	O	4133
receptor	NOUN	O	O	4133
antagonists	NOUN	O	O	4133
.	PUNCT	O	O	4133
Antiandrogenic	PROPN	O	O	4136
therapy	NOUN	O	O	4136
can	AUX	O	O	4136
cause	VERB	O	O	4136
coronary	ADJ	O	O	4136
arterial	ADJ	O	O	4136
disease	PROPN	O	O	4136
.	PUNCT	O	O	4136
AIM	VERB	O	O	4137
:	PUNCT	O	O	4137
To	PART	O	O	4137
study	VERB	O	O	4137
the	PRON	O	O	4137
change	VERB	O	O	4137
of	ADP	O	O	4137
lipid	NOUN	O	O	4137
metabolism	NOUN	O	O	4137
by	ADP	O	O	4137
antiandrogen	PROPN	O	O	4137
therapy	NOUN	O	O	4137
in	ADP	O	O	4137
patients	NOUN	O	O	4137
with	ADP	O	O	4137
prostate cancer	NOUN	O	Disease	4137
.	PUNCT	O	O	4137
We	PRON	O	O	4138
studied	VERB	O	O	4138
with	ADP	O	O	4138
a	PRON	O	O	4138
2.5	NUM	O	O	4138
years	NOUN	O	O	4138
follow	VERB	O	O	4138
-	PUNCT	O	O	4138
up	ADP	O	O	4138
the	PRON	O	O	4138
changes	VERB	O	O	4138
in	ADP	O	O	4138
plasma	NOUN	O	O	4138
cholesterols	NOUN	O	O	4138
(	PUNCT	O	O	4138
C	NOUN	O	O	4138
)	PUNCT	O	O	4138
,	PUNCT	O	O	4138
triglycerides	NOUN	O	Chemical	4138
(	PUNCT	O	O	4138
TG	PROPN	O	O	4138
)	PUNCT	O	O	4138
,	PUNCT	O	O	4138
lipoproteins	NOUN	O	O	4138
(	PUNCT	O	O	4138
LP	NOUN	O	O	4138
)	PUNCT	O	O	4138
,	PUNCT	O	O	4138
and	CCONJ	O	O	4138
apolipoproteins	NOUN	O	O	4138
(	PUNCT	O	O	4138
Apo	PROPN	O	O	4138
)	PUNCT	O	O	4138
fi	NOUN	O	O	4139
les	VERB	O	O	4139
in	ADP	O	O	4139
24	NUM	O	O	4139
patients	NOUN	O	O	4139
of	ADP	O	O	4139
mean	VERB	O	O	4139
age	NOUN	O	O	4139
60	NUM	O	O	4139
years	NOUN	O	O	4139
with	ADP	O	O	4139
low	ADJ	O	O	4139
risk	NOUN	O	O	4139
prostate cancer	NOUN	O	Disease	4139
(	PUNCT	O	O	4139
stage	NOUN	O	O	4139
:	PUNCT	O	O	4139
T1cN0M0	NOUN	O	O	4139
,	PUNCT	O	O	4139
Gleason	PROPN	O	O	4139
score	VERB	O	O	4139
:	PUNCT	O	O	4139
2	X	O	O	4139
-	PUNCT	O	O	4139
5	NUM	O	O	4139
)	PUNCT	O	O	4139
during	ADP	O	O	4139
treatment	NOUN	O	O	4139
with	ADP	O	O	4139
cyproterone acetate	NOUN	O	Chemical	4139
(	PUNCT	O	O	4139
CPA	NOUN	O	Chemical	4139
)	PUNCT	O	O	4139
without	ADP	O	O	4139
surgical	ADJ	O	O	4139
management	NOUN	O	O	4139
or	CCONJ	O	O	4139
radiation	NOUN	O	O	4139
therapy	NOUN	O	O	4139
.	PUNCT	O	O	4139
Significant	ADJ	O	O	4140
decreases	VERB	O	O	4140
of	ADP	O	O	4140
HDL	PROPN	O	O	4140
-	PUNCT	O	O	4140
C	NOUN	O	O	4140
,	PUNCT	O	O	4140
Apo	PROPN	O	O	4140
A	PRON	O	O	4140
-	PUNCT	O	O	4140
I	PRON	O	O	4140
and	CCONJ	O	O	4140
Apo	PROPN	O	O	4140
A	PRON	O	O	4140
-	PUNCT	O	O	4140
II	NUM	O	O	4140
and	CCONJ	O	O	4140
an	PRON	O	O	4140
increase	VERB	O	O	4140
of	ADP	O	O	4140
triglyceride	PROPN	O	O	4140
levels	NOUN	O	O	4140
in	ADP	O	O	4140
VLDL	NOUN	O	O	4140
were	AUX	O	O	4140
induced	VERB	O	O	4140
by	ADP	O	O	4140
CPA	NOUN	O	Chemical	4140
.	PUNCT	O	O	4140
After	ADP	O	O	4141
a	PRON	O	O	4141
period	NOUN	O	O	4141
of	ADP	O	O	4141
2.5	NUM	O	O	4141
years	NOUN	O	O	4141
on	ADP	O	O	4141
CPA	NOUN	O	Chemical	4141
treatment	NOUN	O	O	4141
,	PUNCT	O	O	4141
four	NUM	O	O	4141
patients	NOUN	O	O	4141
out	ADP	O	O	4141
of	ADP	O	O	4141
twenty	NUM	O	O	4141
-	PUNCT	O	O	4141
four	NUM	O	O	4141
were	AUX	O	O	4141
found	VERB	O	O	4141
to	PART	O	O	4141
be	AUX	O	O	4141
affected	VERB	O	O	4141
by	ADP	O	O	4141
coronary	ADJ	O	O	4141
heart disease	NOUN	O	Disease	4141
.	PUNCT	O	O	4141
Ischaemic	PROPN	O	O	4142
coronary	ADJ	O	O	4142
arteriosclerosis	NOUN	O	O	4142
with	ADP	O	O	4142
an	PRON	O	O	4142
incidence	NOUN	O	O	4142
rate	NOUN	O	O	4142
of	ADP	O	O	4142
16.6%	NOUN	O	O	4142
as	ADP	O	O	4142
caused	VERB	O	O	4142
by	ADP	O	O	4142
prolonged	VERB	O	O	4142
CPA	NOUN	O	Chemical	4142
therapy	NOUN	O	O	4142
is	AUX	O	O	4142
mediated	VERB	O	O	4142
through	ADP	O	O	4142
changes	VERB	O	O	4142
in	ADP	O	O	4142
HDL	PROPN	O	O	4142
cholesterol	NOUN	O	Chemical	4142
,	PUNCT	O	O	4142
Apo	PROPN	O	O	4142
A	PRON	O	O	4142
-	PUNCT	O	O	4142
I	PRON	O	O	4142
and	CCONJ	O	O	4142
Apo	PROPN	O	O	4142
pro	ADJ	O	O	4143
fi	NOUN	O	O	4143
les	VERB	O	O	4143
,	PUNCT	O	O	4143
other	ADJ	O	O	4143
than	ADP	O	O	4143
the	PRON	O	O	4143
well	ADV	O	O	4143
-	PUNCT	O	O	4143
known	VERB	O	O	4143
hyperglyceridemic	PROPN	O	O	4143
effect	VERB	O	O	4143
caused	VERB	O	O	4143
by	ADP	O	O	4143
estrogen	PROPN	O	Chemical	4143
.	PUNCT	O	O	4143
5-Fluorouracil	NOUN	O	O	4146
cardiotoxicity	NOUN	O	Disease	4146
induced	VERB	O	O	4146
by	ADP	O	O	4146
alpha	PROPN	O	O	4146
-	PUNCT	O	O	4146
fluoro	ADJ	O	O	4146
-	PUNCT	O	O	4146
beta	NOUN	O	O	4146
-	PUNCT	O	O	4146
alanine	NOUN	O	Chemical	4146
.	PUNCT	O	O	4146
Cardiotoxicity	NOUN	O	Disease	4147
is	AUX	O	O	4147
a	PRON	O	O	4147
rare	ADJ	O	O	4147
complication	NOUN	O	O	4147
occurring	VERB	O	O	4147
during	ADP	O	O	4147
5-fluorouracil	NOUN	O	Chemical	4147
(	PUNCT	O	O	4147
5-FU	NOUN	O	Chemical	4147
)	PUNCT	O	O	4147
treatment	NOUN	O	O	4147
for	ADP	O	O	4147
malignancies	NOUN	O	O	4147
.	PUNCT	O	O	4147
We	PRON	O	O	4148
herein	VERB	O	O	4148
report	VERB	O	O	4148
the	PRON	O	O	4148
case	NOUN	O	O	4148
of	ADP	O	O	4148
a	PRON	O	O	4148
70-year	NOUN	O	O	4148
-	PUNCT	O	O	4148
old	ADJ	O	O	4148
man	NOUN	O	O	4148
with	ADP	O	O	4148
5-FU	NOUN	O	Chemical	4148
-	PUNCT	O	O	4148
induced	VERB	O	O	4148
cardiotoxicity	NOUN	O	Disease	4148
,	PUNCT	O	O	4148
in	ADP	O	O	4148
whom	PRON	O	O	4148
a	PRON	O	O	4148
high	ADJ	O	O	4148
serum	NOUN	O	O	4148
level	VERB	O	O	4148
of	ADP	O	O	4148
alpha	PROPN	O	O	4148
-	PUNCT	O	O	4148
fluoro	ADJ	O	O	4148
-	PUNCT	O	O	4148
beta	NOUN	O	O	4148
-	PUNCT	O	O	4148
alanine	NOUN	O	Chemical	4148
(	PUNCT	O	O	4148
FBAL	PROPN	O	O	4148
)	PUNCT	O	O	4148
was	AUX	O	O	4148
observed	VERB	O	O	4148
.	PUNCT	O	O	4148
The	PRON	O	O	4149
patient	NOUN	O	O	4149
,	PUNCT	O	O	4149
who	PRON	O	O	4149
had	VERB	O	O	4149
unresectable	ADJ	O	O	4149
colon cancer	NOUN	O	Disease	4149
metastases	NOUN	O	Disease	4149
to	PART	O	O	4149
the	PRON	O	O	4149
liver	NOUN	O	O	4149
and	CCONJ	O	O	4149
lung	NOUN	O	O	4149
,	PUNCT	O	O	4149
was	AUX	O	O	4149
referred	VERB	O	O	4149
to	PART	O	O	4149
us	PRON	O	O	4149
for	ADP	O	O	4149
chemotherapy	NOUN	O	O	4149
from	ADP	O	O	4149
an	PRON	O	O	4149
affiliated	VERB	O	O	4149
hospital	PROPN	O	O	4149
;	PUNCT	O	O	4149
he	PRON	O	O	4149
had	VERB	O	O	4149
no	PRON	O	O	4149
cardiac	ADJ	O	O	4149
history	NOUN	O	O	4149
.	PUNCT	O	O	4149
After	ADP	O	O	4150
admission	NOUN	O	O	4150
,	PUNCT	O	O	4150
the	PRON	O	O	4150
patient	NOUN	O	O	4150
received	VERB	O	O	4150
a	PRON	O	O	4150
continuous	ADJ	O	O	4150
intravenous	ADJ	O	O	4150
infusion	NOUN	O	O	4150
of	ADP	O	O	4150
5-FU	NOUN	O	Chemical	4150
(	PUNCT	O	O	4150
1000	NUM	O	O	4150
mg	VERB	O	O	4150
/	PUNCT	O	O	4150
day	NOUN	O	O	4150
)	PUNCT	O	O	4150
,	PUNCT	O	O	4150
during	ADP	O	O	4150
which	PRON	O	O	4150
precordial	ADJ	O	O	4150
pain	NOUN	O	Disease	4150
with	ADP	O	O	4150
right bundle branch block	NOUN	O	Disease	4150
occurred	VERB	O	O	4150
concomitantly	ADV	O	O	4150
with	ADP	O	O	4150
a	PRON	O	O	4150
high	ADJ	O	O	4150
serum	NOUN	O	O	4150
FBAL	PROPN	O	O	4150
concentration	NOUN	O	O	4150
of	ADP	O	O	4150
1955	NUM	O	O	4150
ng	PROPN	O	O	4150
/	PUNCT	O	O	4150
ml	ADP	O	O	4150
.	PUNCT	O	O	4150
Both	PRON	O	O	4151
the	PRON	O	O	4151
precordial	ADJ	O	O	4151
pain	NOUN	O	Disease	4151
and	CCONJ	O	O	4151
the	PRON	O	O	4151
electrocardiographic	NOUN	O	O	4151
changes	VERB	O	O	4151
disappeared	VERB	O	O	4151
spontaneously	ADV	O	O	4151
after	ADP	O	O	4151
the	PRON	O	O	4151
discontinuation	NOUN	O	O	4151
of	ADP	O	O	4151
5-FU	NOUN	O	Chemical	4151
.	PUNCT	O	O	4151
As	ADP	O	O	4152
the	PRON	O	O	4152
precordial	ADJ	O	O	4152
pain	NOUN	O	Disease	4152
in	ADP	O	O	4152
this	PRON	O	O	4152
patient	NOUN	O	O	4152
was	AUX	O	O	4152
considered	VERB	O	O	4152
to	PART	O	O	4152
have	VERB	O	O	4152
been	AUX	O	O	4152
due	ADJ	O	O	4152
to	PART	O	O	4152
5-FU	NOUN	O	Chemical	4152
-	PUNCT	O	O	4152
induced	VERB	O	O	4152
cardiotoxicity	NOUN	O	Disease	4152
,	PUNCT	O	O	4152
the	PRON	O	O	4152
administration	NOUN	O	O	4152
of	ADP	O	O	4152
5-FU	NOUN	O	Chemical	4152
was	AUX	O	O	4152
abandoned	VERB	O	O	4152
.	PUNCT	O	O	4152
Instead	ADV	O	O	4153
,	PUNCT	O	O	4153
oral	ADJ	O	O	4153
administration	NOUN	O	O	4153
of	ADP	O	O	4153
S-1	NOUN	O	O	4153
(	PUNCT	O	O	4153
a	PRON	O	O	4153
derivative	ADJ	O	O	4153
of	ADP	O	O	4153
5-FU	NOUN	O	Chemical	4153
)	PUNCT	O	O	4153
,	PUNCT	O	O	4153
at	ADP	O	O	4153
200	NUM	O	O	4153
mg	VERB	O	O	4153
/	PUNCT	O	O	4153
day	NOUN	O	O	4153
twice	ADV	O	O	4153
a	PRON	O	O	4153
week	NOUN	O	O	4153
,	PUNCT	O	O	4153
was	AUX	O	O	4153
instituted	VERB	O	O	4153
,	PUNCT	O	O	4153
because	SCONJ	O	O	4153
S-1	NOUN	O	O	4153
has	VERB	O	O	4153
a	PRON	O	O	4153
strong	ADJ	O	O	4153
inhibitory	ADJ	O	O	4153
effect	VERB	O	O	4153
on	ADP	O	O	4153
dihydropyrimidine	NOUN	O	O	4153
dehydrogenase	NOUN	O	O	4153
,	PUNCT	O	O	4153
which	PRON	O	O	4153
catalyzes	VERB	O	O	4153
the	PRON	O	O	4153
degradative	PROPN	O	O	4153
of	ADP	O	O	4153
5-FU	NOUN	O	Chemical	4153
into	ADP	O	O	4153
FBAL	PROPN	O	O	4153
.	PUNCT	O	O	4153
The	PRON	O	O	4154
serum	NOUN	O	O	4154
FBAL	PROPN	O	O	4154
concentration	NOUN	O	O	4154
subsequently	ADV	O	O	4154
decreased	VERB	O	O	4154
to	PART	O	O	4154
352	NUM	O	O	4154
ng	PROPN	O	O	4154
/	PUNCT	O	O	4154
ml	ADP	O	O	4154
,	PUNCT	O	O	4154
the	PRON	O	O	4154
same	ADJ	O	O	4154
as	ADP	O	O	4154
the	PRON	O	O	4154
value	NOUN	O	O	4154
measured	VERB	O	O	4154
on	ADP	O	O	4154
the	PRON	O	O	4154
first	ADV	O	O	4154
day	NOUN	O	O	4154
of	ADP	O	O	4154
S-1	NOUN	O	O	4154
administration	NOUN	O	O	4154
.	PUNCT	O	O	4154
Thereafter	ADV	O	O	4155
,	PUNCT	O	O	4155
no	PRON	O	O	4155
cardiac	ADJ	O	O	4155
symptoms	NOUN	O	O	4155
were	AUX	O	O	4155
observed	VERB	O	O	4155
.	PUNCT	O	O	4155
The	PRON	O	O	4156
experience	NOUN	O	O	4156
of	ADP	O	O	4156
this	PRON	O	O	4156
case	NOUN	O	O	4156
,	PUNCT	O	O	4156
together	ADV	O	O	4156
with	ADP	O	O	4156
a	PRON	O	O	4156
review	VERB	O	O	4156
of	ADP	O	O	4156
the	PRON	O	O	4156
literature	NOUN	O	O	4156
,	PUNCT	O	O	4156
suggests	VERB	O	O	4156
that	SCONJ	O	O	4156
FBAL	PROPN	O	O	4156
is	AUX	O	O	4156
related	ADJ	O	O	4156
to	PART	O	O	4156
5-FU	NOUN	O	Chemical	4156
-	PUNCT	O	O	4156
induced	VERB	O	O	4156
cardiotoxicity	NOUN	O	Disease	4156
.	PUNCT	O	O	4156
S-1	NOUN	O	O	4157
may	AUX	O	O	4157
be	AUX	O	O	4157
administered	VERB	O	O	4157
safely	ADV	O	O	4157
to	PART	O	O	4157
patients	NOUN	O	O	4157
with	ADP	O	O	4157
5-FU	NOUN	O	Chemical	4157
-	PUNCT	O	O	4157
induced	VERB	O	O	4157
cardiotoxicity	NOUN	O	Disease	4157
.	PUNCT	O	O	4157
The	PRON	O	O	4160
influence	NOUN	O	O	4160
of	ADP	O	O	4160
the	PRON	O	O	4160
time	NOUN	O	O	4160
interval	NOUN	O	O	4160
between	ADP	O	O	4160
monoHER	NUM	O	O	4160
and	CCONJ	O	O	4160
doxorubicin	VERB	O	Chemical	4160
administration	NOUN	O	O	4160
on	ADP	O	O	4160
the	PRON	O	O	4160
protection	NOUN	O	O	4160
against	ADP	O	O	4160
doxorubicin	VERB	O	Chemical	4160
-	PUNCT	O	O	4160
induced	VERB	O	O	4160
cardiotoxicity	NOUN	O	Disease	4160
in	ADP	O	O	4160
mice	NOUN	O	O	4160
.	PUNCT	O	O	4160
Despite	SCONJ	O	O	4161
its	PRON	O	O	4161
well	ADV	O	O	4161
-	PUNCT	O	O	4161
known	VERB	O	O	4161
cardiotoxicity	NOUN	O	Disease	4161
,	PUNCT	O	O	4161
the	PRON	O	O	4161
anthracyclin	PROPN	O	O	4161
doxorubicin	VERB	O	Chemical	4161
(	PUNCT	O	O	4161
DOX	PROPN	O	Chemical	4161
)	PUNCT	O	O	4161
continues	VERB	O	O	4161
to	PART	O	O	4161
be	AUX	O	O	4161
an	PRON	O	O	4161
effective	ADJ	O	O	4161
and	CCONJ	O	O	4161
widely	ADV	O	O	4161
used	VERB	O	O	4161
chemotherapeutic	NOUN	O	O	4161
agent	NOUN	O	O	4161
.	PUNCT	O	O	4161
DOX	PROPN	O	Chemical	4162
-	PUNCT	O	O	4162
induced	VERB	O	O	4162
cardiac damage	NOUN	O	Disease	4162
presumably	ADV	O	O	4162
results	VERB	O	O	4162
from	ADP	O	O	4162
the	PRON	O	O	4162
formation	NOUN	O	O	4162
of	ADP	O	O	4162
free	ADJ	O	O	4162
radicals	NOUN	O	O	4162
by	ADP	O	O	4162
DOX	PROPN	O	Chemical	4162
.	PUNCT	O	O	4162
Reactive	ADJ	O	O	4163
oxygen	NOUN	O	Chemical	4163
species	NOUN	O	O	4163
particularly	ADV	O	O	4163
affect	VERB	O	O	4163
the	PRON	O	O	4163
cardiac	ADJ	O	O	4163
myocytes	NOUN	O	O	4163
because	SCONJ	O	O	4163
these	PRON	O	O	4163
cells	NOUN	O	O	4163
seem	VERB	O	O	4163
to	PART	O	O	4163
have	VERB	O	O	4163
a	PRON	O	O	4163
relatively	ADV	O	O	4163
poor	ADJ	O	O	4163
antioxidant	ADJ	O	O	4163
defense	NOUN	O	O	4163
system	NOUN	O	O	4163
.	PUNCT	O	O	4163
The	PRON	O	O	4164
semisynthetic	ADJ	O	O	4164
flavonoid	NOUN	O	O	4164
monohydroxyethylrutoside	NOUN	O	O	4164
(	PUNCT	O	O	4164
monoHER	NUM	O	O	4164
)	PUNCT	O	O	4164
showed	VERB	O	O	4164
cardioprotection	NOUN	O	O	4164
against	ADP	O	O	4164
DOX	PROPN	O	Chemical	4164
-	PUNCT	O	O	4164
induced	VERB	O	O	4164
cardiotoxicity	NOUN	O	Disease	4164
through	ADP	O	O	4164
its	PRON	O	O	4164
radical	ADJ	O	O	4164
scavenging	VERB	O	O	4164
and	CCONJ	O	O	4164
iron	NOUN	O	Chemical	4164
chelating	VERB	O	O	4164
properties	NOUN	O	O	4164
.	PUNCT	O	O	4164
Because	SCONJ	O	O	4165
of	ADP	O	O	4165
the	PRON	O	O	4165
relatively	ADV	O	O	4165
short	ADJ	O	O	4165
final	ADJ	O	O	4165
half	NOUN	O	O	4165
-	PUNCT	O	O	4165
life	NOUN	O	O	4165
of	ADP	O	O	4165
monoHER	NUM	O	O	4165
(	PUNCT	O	O	4165
about	ADP	O	O	4165
30	NUM	O	O	4165
min	NOUN	O	O	4165
)	PUNCT	O	O	4165
,	PUNCT	O	O	4165
it	PRON	O	O	4165
is	AUX	O	O	4165
expected	VERB	O	O	4165
that	SCONJ	O	O	4165
the	PRON	O	O	4165
time	NOUN	O	O	4165
interval	NOUN	O	O	4165
between	ADP	O	O	4165
monoHER	NUM	O	O	4165
and	CCONJ	O	O	4165
DOX	PROPN	O	Chemical	4165
might	AUX	O	O	4165
be	AUX	O	O	4165
of	ADP	O	O	4165
influence	NOUN	O	O	4165
on	ADP	O	O	4165
the	PRON	O	O	4165
cardioprotective	ADJ	O	O	4165
effect	VERB	O	O	4165
of	ADP	O	O	4165
monoHER	NUM	O	O	4165
.	PUNCT	O	O	4165
Six	NUM	O	O	4166
groups	NOUN	O	O	4166
of	ADP	O	O	4166
6	NUM	O	O	4166
BALB	PROPN	O	O	4166
/	PUNCT	O	O	4166
c	X	O	O	4166
mice	NOUN	O	O	4166
were	AUX	O	O	4166
treated	VERB	O	O	4166
with	ADP	O	O	4166
saline	NOUN	O	O	4166
,	PUNCT	O	O	4166
DOX	PROPN	O	Chemical	4166
alone	ADV	O	O	4166
or	CCONJ	O	O	4166
DOX	PROPN	O	Chemical	4166
(	PUNCT	O	O	4166
4	NUM	O	O	4166
mg	VERB	O	O	4166
/	PUNCT	O	O	4166
kg	VERB	O	O	4166
i.v	NOUN	O	O	4166
.	PUNCT	O	O	4166
)	PUNCT	O	O	4166
preceded	VERB	O	O	4167
by	ADP	O	O	4167
monoHER	NUM	O	O	4167
(	PUNCT	O	O	4167
500	NUM	O	O	4167
mg	VERB	O	O	4167
/	PUNCT	O	O	4167
kg	VERB	O	O	4167
i.p	NOUN	O	O	4167
.	PUNCT	O	O	4167
)	PUNCT	O	O	4167
with	ADP	O	O	4167
an	PRON	O	O	4167
interval	NOUN	O	O	4167
of	ADP	O	O	4167
10	NUM	O	O	4167
,	PUNCT	O	O	4167
30	NUM	O	O	4167
,	PUNCT	O	O	4167
60	NUM	O	O	4167
or	CCONJ	O	O	4167
120	NUM	O	O	4167
min	NOUN	O	O	4167
.	PUNCT	O	O	4167
Their	PRON	O	O	4168
cardiac	ADJ	O	O	4168
tissues	NOUN	O	O	4168
were	AUX	O	O	4168
processed	VERB	O	O	4168
for	ADP	O	O	4168
light	ADJ	O	O	4168
microscopy	NOUN	O	O	4168
,	PUNCT	O	O	4168
after	ADP	O	O	4168
which	PRON	O	O	4168
cardiomyocyte	NOUN	O	O	4168
damage	NOUN	O	O	4168
was	AUX	O	O	4168
evaluated	VERB	O	O	4168
according	VERB	O	O	4168
to	PART	O	O	4168
Billingham	PROPN	O	O	4168
(	PUNCT	O	O	4168
in	ADP	O	O	4168
Cancer	NOUN	O	O	4168
Treat	VERB	O	O	4168
Rep	PROPN	O	O	4168
62(6):865	NUM	O	O	4168
-	PUNCT	O	O	4168
872	NUM	O	O	4168
,	PUNCT	O	O	4168
1978	NUM	O	O	4168
)	PUNCT	O	O	4168
.	PUNCT	O	O	4168
Microscopic	ADJ	O	O	4169
evaluation	NOUN	O	O	4169
revealed	VERB	O	O	4169
that	SCONJ	O	O	4169
treatment	NOUN	O	O	4169
with	ADP	O	O	4169
DOX	PROPN	O	Chemical	4169
alone	ADV	O	O	4169
induced	VERB	O	O	4169
significant	ADJ	O	O	4169
cardiac damage	NOUN	O	Disease	4169
in	ADP	O	O	4169
comparison	NOUN	O	O	4169
to	PART	O	O	4169
the	PRON	O	O	4169
saline	NOUN	O	O	4169
control	VERB	O	O	4169
group	NOUN	O	O	4169
(	PUNCT	O	O	4169
P<0.001	ADJ	O	O	4169
)	PUNCT	O	O	4169
.	PUNCT	O	O	4169
The	PRON	O	O	4170
number	NOUN	O	O	4170
of	ADP	O	O	4170
damaged	VERB	O	O	4170
cardiomyocytes	NOUN	O	O	4170
was	AUX	O	O	4170
9.6-fold	ADV	O	O	4170
(	PUNCT	O	O	4170
95%	NOUN	O	O	4170
CI	NOUN	O	O	4170
4.4	NUM	O	O	4170
-	PUNCT	O	O	4170
21.0	NUM	O	O	4170
)	PUNCT	O	O	4170
higher	ADJ	O	O	4170
in	ADP	O	O	4170
mice	NOUN	O	O	4170
treated	VERB	O	O	4170
with	ADP	O	O	4170
DOX	PROPN	O	Chemical	4170
alone	ADV	O	O	4170
than	ADP	O	O	4170
that	SCONJ	O	O	4170
in	ADP	O	O	4170
animals	NOUN	O	O	4170
of	ADP	O	O	4170
the	PRON	O	O	4170
control	VERB	O	O	4170
group	NOUN	O	O	4170
.	PUNCT	O	O	4170
The	PRON	O	O	4171
ratio	NOUN	O	O	4171
of	ADP	O	O	4171
aberrant	ADJ	O	O	4171
cardiomyocytes	NOUN	O	O	4171
in	ADP	O	O	4171
mice	NOUN	O	O	4171
treated	VERB	O	O	4171
with	ADP	O	O	4171
DOX	PROPN	O	Chemical	4171
preceded	VERB	O	O	4171
by	ADP	O	O	4171
monoHER	NUM	O	O	4171
and	CCONJ	O	O	4171
those	PRON	O	O	4171
in	ADP	O	O	4171
mice	NOUN	O	O	4171
treated	VERB	O	O	4171
with	ADP	O	O	4171
saline	NOUN	O	O	4171
ranged	VERB	O	O	4171
from	ADP	O	O	4171
1.6	NUM	O	O	4171
to	PART	O	O	4171
2.8	NUM	O	O	4171
(	PUNCT	O	O	4171
mean	VERB	O	O	4171
2.2	NUM	O	O	4171
,	PUNCT	O	O	4171
95%	NOUN	O	O	4171
CI	NOUN	O	O	4171
1.2	NUM	O	O	4171
-	PUNCT	O	O	4171
4.1	NUM	O	O	4171
,	PUNCT	O	O	4171
P=0.019	VERB	O	O	4171
)	PUNCT	O	O	4171
.	PUNCT	O	O	4171
The	PRON	O	O	4172
mean	VERB	O	O	4172
protective	ADJ	O	O	4172
effect	VERB	O	O	4172
by	ADP	O	O	4172
adding	VERB	O	O	4172
monoHER	NUM	O	O	4172
before	ADP	O	O	4172
DOX	PROPN	O	Chemical	4172
led	VERB	O	O	4172
to	PART	O	O	4172
a	PRON	O	O	4172
significant	ADJ	O	O	4172
4.4-fold	ADV	O	O	4172
reduction	NOUN	O	O	4172
(	PUNCT	O	O	4172
P<0.001	ADJ	O	O	4172
,	PUNCT	O	O	4172
95%	NOUN	O	O	4172
CI	NOUN	O	O	4172
2.3	NUM	O	O	4172
-	PUNCT	O	O	4172
8.2	NUM	O	O	4172
)	PUNCT	O	O	4172
of	ADP	O	O	4172
abnormal	ADJ	O	O	4172
cardiomyocytes	NOUN	O	O	4172
.	PUNCT	O	O	4172
This	PRON	O	O	4173
protective	ADJ	O	O	4173
effect	VERB	O	O	4173
did	VERB	O	O	4173
not	PART	O	O	4173
depend	VERB	O	O	4173
on	ADP	O	O	4173
the	PRON	O	O	4173
time	NOUN	O	O	4173
interval	NOUN	O	O	4173
between	ADP	O	O	4173
monoHER	NUM	O	O	4173
and	CCONJ	O	O	4173
DOX	PROPN	O	Chemical	4173
administration	NOUN	O	O	4173
(	PUNCT	O	O	4173
P=0.345	NOUN	O	O	4173
)	PUNCT	O	O	4173
.	PUNCT	O	O	4173
CONCLUSION	PROPN	O	O	4174
:	PUNCT	O	O	4174
The	PRON	O	O	4174
results	VERB	O	O	4174
indicate	VERB	O	O	4174
that	SCONJ	O	O	4174
in	ADP	O	O	4174
an	PRON	O	O	4174
outpatient	NOUN	O	O	4174
clinical	ADJ	O	O	4174
setting	VERB	O	O	4174
monoHER	NUM	O	O	4174
may	AUX	O	O	4174
be	AUX	O	O	4174
administered	VERB	O	O	4174
shortly	ADV	O	O	4174
before	ADP	O	O	4174
DOX	PROPN	O	Chemical	4174
.	PUNCT	O	O	4174
Clinical	NOUN	O	O	4177
evaluation	NOUN	O	O	4177
of	ADP	O	O	4177
adverse	ADJ	O	O	4177
effects	NOUN	O	O	4177
during	ADP	O	O	4177
bepridil	PROPN	O	O	4177
administration	NOUN	O	O	4177
for	ADP	O	O	4177
atrial fibrillation	NOUN	O	Disease	4177
and	CCONJ	O	O	4177
flutter	VERB	O	O	4177
.	PUNCT	O	O	4177
Bepridil	PROPN	O	O	4178
hydrochloride	NOUN	O	O	4178
(	PUNCT	O	O	4178
Bpd	PROPN	O	O	4178
)	PUNCT	O	O	4178
has	VERB	O	O	4178
attracted	VERB	O	O	4178
attention	NOUN	O	O	4178
as	ADP	O	O	4178
an	PRON	O	O	4178
effective	ADJ	O	O	4178
drug	NOUN	O	O	4178
for	ADP	O	O	4178
atrial fibrillation	NOUN	O	Disease	4178
(	PUNCT	O	O	4178
AF	PROPN	O	Disease	4178
)	PUNCT	O	O	4178
and	CCONJ	O	O	4178
atrial flutter	NOUN	O	Disease	4178
(	PUNCT	O	O	4178
AFL	PROPN	O	O	4178
)	PUNCT	O	O	4178
.	PUNCT	O	O	4178
However	ADV	O	O	4179
,	PUNCT	O	O	4179
serious	ADJ	O	O	4179
adverse	ADJ	O	O	4179
effects	NOUN	O	O	4179
,	PUNCT	O	O	4179
including	VERB	O	O	4179
torsade de pointes	NOUN	O	Disease	4179
(	PUNCT	O	O	4179
Tdp	NOUN	O	O	4179
)	PUNCT	O	O	4179
,	PUNCT	O	O	4179
have	VERB	O	O	4179
been	AUX	O	O	4179
reported	VERB	O	O	4179
.	PUNCT	O	O	4179
Adverse	ADJ	O	O	4180
effects	NOUN	O	O	4180
of	ADP	O	O	4180
Bpd	PROPN	O	O	4180
requiring	VERB	O	O	4180
discontinuation	NOUN	O	O	4180
of	ADP	O	O	4180
treatment	NOUN	O	O	4180
were	AUX	O	O	4180
evaluated	VERB	O	O	4180
.	PUNCT	O	O	4180
Bpd	PROPN	O	O	4181
was	AUX	O	O	4181
administered	VERB	O	O	4181
to	PART	O	O	4181
459	NUM	O	O	4181
patients	NOUN	O	O	4181
(	PUNCT	O	O	4181
361	NUM	O	O	4181
males	NOUN	O	O	4181
,	PUNCT	O	O	4181
63+/-12	NUM	O	O	4181
years	NOUN	O	O	4181
old	ADJ	O	O	4181
)	PUNCT	O	O	4181
comprising	VERB	O	O	4181
378	NUM	O	O	4181
AF	PROPN	O	Disease	4181
and	CCONJ	O	O	4181
81	NUM	O	O	4181
AFL	PROPN	O	O	4181
cases	NOUN	O	O	4181
.	PUNCT	O	O	4181
There	ADV	O	O	4182
was	AUX	O	O	4182
marked	VERB	O	O	4182
QT prolongation	NOUN	O	Disease	4182
greater	ADJ	O	O	4182
than	ADP	O	O	4182
0.55	NUM	O	O	4182
s	X	O	O	4182
in	ADP	O	O	4182
13	NUM	O	O	4182
patients	NOUN	O	O	4182
,	PUNCT	O	O	4182
bradycardia	NOUN	O	Disease	4182
less	ADV	O	O	4182
than	ADP	O	O	4182
40	NUM	O	O	4182
beats	NOUN	O	O	4182
/	PUNCT	O	O	4182
min	NOUN	O	O	4183
in	ADP	O	O	4183
6	NUM	O	O	4183
patients	NOUN	O	O	4183
,	PUNCT	O	O	4183
dizziness	NOUN	O	Disease	4183
and	CCONJ	O	O	4183
general	ADJ	O	O	4183
fatigue	NOUN	O	Disease	4183
in	ADP	O	O	4183
1	X	O	O	4183
patient	NOUN	O	O	4183
each	PRON	O	O	4183
.	PUNCT	O	O	4183
In	ADP	O	O	4184
4	NUM	O	O	4184
of	ADP	O	O	4184
13	NUM	O	O	4184
patients	NOUN	O	O	4184
with	ADP	O	O	4184
QT prolongation	NOUN	O	Disease	4184
,	PUNCT	O	O	4184
Tdp	NOUN	O	O	4184
occurred	VERB	O	O	4184
.	PUNCT	O	O	4184
The	PRON	O	O	4185
major	ADJ	O	O	4185
triggering	VERB	O	O	4185
factors	NOUN	O	O	4185
of	ADP	O	O	4185
Tdp	NOUN	O	O	4185
were	AUX	O	O	4185
hypokalemia	PROPN	O	Disease	4185
and	CCONJ	O	O	4185
sudden	ADJ	O	O	4185
decrease	VERB	O	O	4185
in	ADP	O	O	4185
heart	NOUN	O	O	4185
rate	NOUN	O	O	4185
.	PUNCT	O	O	4185
There	ADV	O	O	4186
were	AUX	O	O	4186
no	PRON	O	O	4186
differences	NOUN	O	O	4186
in	ADP	O	O	4186
the	PRON	O	O	4186
clinical	ADJ	O	O	4186
backgrounds	NOUN	O	O	4186
of	ADP	O	O	4186
the	PRON	O	O	4186
patients	NOUN	O	O	4186
with	ADP	O	O	4186
and	CCONJ	O	O	4186
without	ADP	O	O	4186
Tdp	NOUN	O	O	4186
other	ADJ	O	O	4186
than	ADP	O	O	4186
LAD	PROPN	O	O	4186
and	CCONJ	O	O	4186
age	NOUN	O	O	4186
,	PUNCT	O	O	4186
which	PRON	O	O	4186
were	AUX	O	O	4186
larger	ADJ	O	O	4186
and	CCONJ	O	O	4186
older	ADJ	O	O	4186
in	ADP	O	O	4186
the	PRON	O	O	4186
patients	NOUN	O	O	4186
with	ADP	O	O	4186
Tdp	NOUN	O	O	4186
.	PUNCT	O	O	4186
CONCLUSION	PROPN	O	O	4187
:	PUNCT	O	O	4187
Careful	ADJ	O	O	4187
observation	NOUN	O	O	4187
of	ADP	O	O	4187
serum	NOUN	O	O	4187
potassium	NOUN	O	Chemical	4187
concentration	NOUN	O	O	4187
and	CCONJ	O	O	4187
the	PRON	O	O	4187
ECG	PROPN	O	O	4187
should	AUX	O	O	4187
always	ADV	O	O	4187
be	AUX	O	O	4187
done	VERB	O	O	4187
during	ADP	O	O	4187
Bpd	PROPN	O	O	4187
administration	NOUN	O	O	4187
,	PUNCT	O	O	4187
particularly	ADV	O	O	4187
in	ADP	O	O	4187
elderly	ADJ	O	O	4187
patients	NOUN	O	O	4187
.	PUNCT	O	O	4187
Enhanced	VERB	O	O	4190
isoproterenol	NOUN	O	Chemical	4190
-	PUNCT	O	O	4190
induced	VERB	O	O	4190
cardiac hypertrophy	NOUN	O	Disease	4190
in	ADP	O	O	4190
transgenic	NOUN	O	O	4190
rats	NOUN	O	O	4190
with	ADP	O	O	4190
low	ADJ	O	O	4190
brain	NOUN	O	O	4190
angiotensinogen	PROPN	O	O	4190
.	PUNCT	O	O	4190
We	PRON	O	O	4191
have	VERB	O	O	4191
previously	ADV	O	O	4191
shown	VERB	O	O	4191
that	SCONJ	O	O	4191
a	PRON	O	O	4191
permanent	ADJ	O	O	4191
deficiency	NOUN	O	O	4191
in	ADP	O	O	4191
the	PRON	O	O	4191
brain	NOUN	O	O	4191
renin	PROPN	O	O	4191
-	PUNCT	O	O	4191
angiotensin	NOUN	O	Chemical	4191
system	NOUN	O	O	4191
(	PUNCT	O	O	4191
RAS	PROPN	O	O	4191
)	PUNCT	O	O	4191
may	AUX	O	O	4191
increase	VERB	O	O	4191
the	PRON	O	O	4191
sensitivity	NOUN	O	O	4191
of	ADP	O	O	4191
the	PRON	O	O	4191
baroreflex	NOUN	O	O	4191
control	VERB	O	O	4191
of	ADP	O	O	4191
heart	NOUN	O	O	4191
rate	NOUN	O	O	4191
.	PUNCT	O	O	4191
agonist	NOUN	O	O	4192
isoproterenol	NOUN	O	Chemical	4192
(	PUNCT	O	O	4192
Iso	PROPN	O	O	4192
)	PUNCT	O	O	4192
.	PUNCT	O	O	4192
In	ADP	O	O	4193
isolated	VERB	O	O	4193
hearts	NOUN	O	O	4193
,	PUNCT	O	O	4193
Iso	PROPN	O	O	4193
induced	VERB	O	O	4193
a	PRON	O	O	4193
significantly	ADV	O	O	4193
greater	ADJ	O	O	4193
increase	VERB	O	O	4193
in	ADP	O	O	4193
left	VERB	O	O	4193
ventricular	ADJ	O	O	4193
(	PUNCT	O	O	4193
LV	PROPN	O	Disease	4193
)	PUNCT	O	O	4193
pressure	NOUN	O	O	4193
and	CCONJ	O	O	4193
maximal	ADJ	O	O	4193
contraction	NOUN	O	O	4193
(	PUNCT	O	O	4193
+	ADP	O	O	4193
dP	X	O	O	4193
/	PUNCT	O	O	4193
dt(max	PROPN	O	O	4193
)	PUNCT	O	O	4193
)	PUNCT	O	O	4193
in	ADP	O	O	4193
the	PRON	O	O	4193
TGR	PROPN	O	O	4193
than	ADP	O	O	4193
in	ADP	O	O	4193
the	PRON	O	O	4193
Sprague	PROPN	O	O	4193
-	PUNCT	O	O	4193
Dawley	NOUN	O	O	4193
(	PUNCT	O	O	4193
SD	NOUN	O	O	4193
)	PUNCT	O	O	4193
rats	NOUN	O	O	4193
.	PUNCT	O	O	4193
LV	PROPN	O	Disease	4194
hypertrophy	VERB	O	Disease	4194
induced	VERB	O	O	4194
by	ADP	O	O	4194
Iso	PROPN	O	O	4194
treatment	NOUN	O	O	4194
was	AUX	O	O	4194
significantly	ADV	O	O	4194
higher	ADJ	O	O	4194
in	ADP	O	O	4194
TGR	PROPN	O	O	4194
than	ADP	O	O	4194
in	ADP	O	O	4194
SD	NOUN	O	O	4194
rats	NOUN	O	O	4194
(	PUNCT	O	O	4194
in	ADP	O	O	4194
g	X	O	O	4194
LV	PROPN	O	Disease	4194
wt/100	NUM	O	O	4194
The	PRON	O	O	4195
greater	ADJ	O	O	4195
LV	PROPN	O	Disease	4195
hypertrophy	VERB	O	Disease	4195
in	ADP	O	O	4195
TGR	PROPN	O	O	4195
rats	NOUN	O	O	4195
was	AUX	O	O	4195
associated	VERB	O	O	4195
with	ADP	O	O	4195
more	ADJ	O	O	4195
pronounced	VERB	O	O	4195
downregulation	NOUN	O	O	4195
of	ADP	O	O	4195
beta	NOUN	O	O	4195
-	PUNCT	O	O	4195
AR	PROPN	O	O	4195
and	CCONJ	O	O	4195
upregulation	NOUN	O	O	4195
of	ADP	O	O	4195
LV	PROPN	O	Disease	4195
beta	NOUN	O	O	4195
-	PUNCT	O	O	4195
AR	PROPN	O	O	4195
kinase-1	VERB	O	O	4195
mRNA	PROPN	O	O	4195
levels	NOUN	O	O	4195
compared	VERB	O	O	4195
with	ADP	O	O	4195
those	PRON	O	O	4195
in	ADP	O	O	4195
SD	NOUN	O	O	4195
rats	NOUN	O	O	4195
.	PUNCT	O	O	4195
The	PRON	O	O	4196
decrease	VERB	O	O	4196
in	ADP	O	O	4196
the	PRON	O	O	4196
heart	NOUN	O	O	4196
rate	NOUN	O	O	4196
(	PUNCT	O	O	4196
HR	NOUN	O	O	4196
)	PUNCT	O	O	4196
induced	VERB	O	O	4196
by	ADP	O	O	4196
the	PRON	O	O	4196
beta	NOUN	O	O	4196
-	PUNCT	O	O	4196
AR	PROPN	O	O	4196
antagonist	NOUN	O	O	4196
metoprolol	NOUN	O	Chemical	4196
in	ADP	O	O	4196
conscious	ADJ	O	O	4196
rats	NOUN	O	O	4196
was	AUX	O	O	4196
significantly	ADV	O	O	4196
attenuated	VERB	O	O	4196
in	ADP	O	O	4196
TGR	PROPN	O	O	4196
compared	VERB	O	O	4196
with	ADP	O	O	4196
SD	NOUN	O	O	4196
rats	NOUN	O	O	4196
(	PUNCT	O	O	4196
-9.9	ADJ	O	O	4196
1.5%	NOUN	O	O	4197
)	PUNCT	O	O	4197
,	PUNCT	O	O	4197
whereas	SCONJ	O	O	4197
the	PRON	O	O	4197
effect	VERB	O	O	4197
of	ADP	O	O	4197
parasympathetic	ADJ	O	O	4197
blockade	VERB	O	O	4197
by	ADP	O	O	4197
atropine	NOUN	O	Chemical	4197
on	ADP	O	O	4197
HR	NOUN	O	O	4197
was	AUX	O	O	4197
similar	ADJ	O	O	4197
in	ADP	O	O	4197
both	PRON	O	O	4197
strains	VERB	O	O	4197
.	PUNCT	O	O	4197
These	PRON	O	O	4198
results	VERB	O	O	4198
indicate	VERB	O	O	4198
that	SCONJ	O	O	4198
TGR	PROPN	O	O	4198
are	AUX	O	O	4198
more	ADJ	O	O	4198
sensitive	ADJ	O	O	4198
to	PART	O	O	4198
beta	NOUN	O	O	4198
-	PUNCT	O	O	4198
AR	PROPN	O	O	4198
agonist	NOUN	O	O	4198
-	PUNCT	O	O	4198
induced	VERB	O	O	4198
cardiac	ADJ	O	O	4198
inotropic	NOUN	O	O	4198
response	NOUN	O	O	4198
and	CCONJ	O	O	4198
hypertrophy	VERB	O	Disease	4198
,	PUNCT	O	O	4198
possibly	ADV	O	O	4198
due	ADJ	O	O	4198
to	PART	O	O	4198
chronically	ADV	O	O	4198
low	ADJ	O	O	4198
sympathetic	ADJ	O	O	4198
outflow	NOUN	O	O	4198
directed	VERB	O	O	4198
to	PART	O	O	4198
the	PRON	O	O	4198
heart	NOUN	O	O	4198
.	PUNCT	O	O	4198
Drug	NOUN	O	O	4201
-	PUNCT	O	O	4201
induced	VERB	O	O	4201
long QT syndrome	NOUN	O	Disease	4201
in	ADP	O	O	4201
injection	NOUN	O	O	4201
drug	NOUN	O	O	4201
users	NOUN	O	O	4201
receiving	VERB	O	O	4201
methadone	NOUN	O	Chemical	4201
:	PUNCT	O	O	4201
high	ADJ	O	O	4201
frequency	NOUN	O	O	4201
in	ADP	O	O	4201
hospitalized	VERB	O	O	4201
patients	NOUN	O	O	4201
and	CCONJ	O	O	4201
risk	NOUN	O	O	4201
factors	NOUN	O	O	4201
.	PUNCT	O	O	4201
Drug	NOUN	O	O	4202
-	PUNCT	O	O	4202
induced	VERB	O	O	4202
long QT syndrome	NOUN	O	Disease	4202
is	AUX	O	O	4202
a	PRON	O	O	4202
serious	ADJ	O	O	4202
adverse	ADJ	O	O	4202
drug	NOUN	O	O	4202
reaction	NOUN	O	O	4202
.	PUNCT	O	O	4202
Methadone	NOUN	O	Chemical	4203
prolongs	VERB	O	O	4203
the	PRON	O	O	4203
QT	NOUN	O	O	4203
interval	NOUN	O	O	4203
in	ADP	O	O	4203
vitro	X	O	O	4203
in	ADP	O	O	4203
a	PRON	O	O	4203
dose	NOUN	O	O	4203
-	PUNCT	O	O	4203
dependent	ADJ	O	O	4203
manner	VERB	O	O	4203
.	PUNCT	O	O	4203
In	ADP	O	O	4204
the	PRON	O	O	4204
inpatient	ADJ	O	O	4204
setting	VERB	O	O	4204
,	PUNCT	O	O	4204
the	PRON	O	O	4204
frequency	NOUN	O	O	4204
of	ADP	O	O	4204
QT	NOUN	O	O	4204
interval	NOUN	O	O	4204
prolongation	NOUN	O	O	4204
with	ADP	O	O	4204
methadone	NOUN	O	Chemical	4204
treatment	NOUN	O	O	4204
,	PUNCT	O	O	4204
its	PRON	O	O	4204
dose	NOUN	O	O	4204
dependence	NOUN	O	O	4204
,	PUNCT	O	O	4204
and	CCONJ	O	O	4204
the	PRON	O	O	4204
importance	NOUN	O	O	4204
of	ADP	O	O	4204
cofactors	NOUN	O	O	4204
such	ADJ	O	O	4204
as	ADP	O	O	4204
drug	NOUN	O	O	4204
-	PUNCT	O	O	4204
drug	NOUN	O	O	4204
interactions	NOUN	O	O	4204
remain	VERB	O	O	4204
unknown	ADJ	O	O	4204
.	PUNCT	O	O	4204
:	PUNCT	O	O	4205
We	PRON	O	O	4205
performed	VERB	O	O	4205
a	PRON	O	O	4205
systematic	ADJ	O	O	4205
,	PUNCT	O	O	4205
retrospective	ADJ	O	O	4205
study	VERB	O	O	4205
comparing	VERB	O	O	4205
active	ADJ	O	O	4205
or	CCONJ	O	O	4205
former	ADJ	O	O	4205
intravenous	ADJ	O	O	4205
drug	NOUN	O	O	4205
users	NOUN	O	O	4205
receiving	VERB	O	O	4205
methadone	NOUN	O	Chemical	4205
and	CCONJ	O	O	4205
those	PRON	O	O	4205
not	PART	O	O	4205
receiving	VERB	O	O	4205
methadone	NOUN	O	Chemical	4205
among	ADP	O	O	4205
all	PRON	O	O	4205
patients	NOUN	O	O	4205
hospitalized	VERB	O	O	4205
over	ADP	O	O	4205
a	PRON	O	O	4205
5-year	NOUN	O	O	4205
period	NOUN	O	O	4205
in	ADP	O	O	4205
a	PRON	O	O	4205
tertiary	ADJ	O	O	4205
care	VERB	O	O	4205
hospital	PROPN	O	O	4205
.	PUNCT	O	O	4205
A	PRON	O	O	4206
total	ADJ	O	O	4206
of	ADP	O	O	4206
167	NUM	O	O	4206
patients	NOUN	O	O	4206
receiving	VERB	O	O	4206
methadone	NOUN	O	Chemical	4206
fulfilled	VERB	O	O	4206
the	PRON	O	O	4206
inclusion	NOUN	O	O	4206
criteria	NOUN	O	O	4206
and	CCONJ	O	O	4206
were	AUX	O	O	4206
compared	VERB	O	O	4206
with	ADP	O	O	4206
a	PRON	O	O	4206
control	VERB	O	O	4206
group	NOUN	O	O	4206
of	ADP	O	O	4206
80	NUM	O	O	4206
injection	NOUN	O	O	4206
drug	NOUN	O	O	4206
users	NOUN	O	O	4206
not	PART	O	O	4206
receiving	VERB	O	O	4206
methadone	NOUN	O	Chemical	4206
.	PUNCT	O	O	4206
In	ADP	O	O	4207
addition	NOUN	O	O	4207
to	PART	O	O	4207
methadone	NOUN	O	Chemical	4207
dose	NOUN	O	O	4207
,	PUNCT	O	O	4207
15	NUM	O	O	4207
demographic	ADJ	O	O	4207
,	PUNCT	O	O	4207
biological	ADJ	O	O	4207
,	PUNCT	O	O	4207
and	CCONJ	O	O	4207
pharmacological	ADJ	O	O	4207
variables	NOUN	O	O	4207
were	AUX	O	O	4207
considered	VERB	O	O	4207
as	ADP	O	O	4207
potential	ADJ	O	O	4207
risk	NOUN	O	O	4207
factors	NOUN	O	O	4207
for	ADP	O	O	4207
QT prolongation	NOUN	O	Disease	4207
.	PUNCT	O	O	4207
Among	ADP	O	O	4208
167	NUM	O	O	4208
methadone	NOUN	O	Chemical	4208
maintenance	NOUN	O	O	4208
patients	NOUN	O	O	4208
,	PUNCT	O	O	4208
the	PRON	O	O	4208
prevalence	NOUN	O	O	4208
of	ADP	O	O	4208
QTc	VERB	O	O	4208
prolongation	NOUN	O	O	4208
to	PART	O	O	4208
0.50	NUM	O	O	4208
second((1/2	NUM	O	O	4208
)	PUNCT	O	O	4208
)	PUNCT	O	O	4208
or	CCONJ	O	O	4208
longer	ADV	O	O	4208
was	AUX	O	O	4208
16.2%	NOUN	O	O	4208
compared	VERB	O	O	4208
with	ADP	O	O	4208
0%	NOUN	O	O	4208
in	ADP	O	O	4208
80	NUM	O	O	4208
control	VERB	O	O	4208
subjects	NOUN	O	O	4208
.	PUNCT	O	O	4208
Six	NUM	O	O	4209
patients	NOUN	O	O	4209
(	PUNCT	O	O	4209
3.6%	NOUN	O	O	4209
)	PUNCT	O	O	4209
in	ADP	O	O	4209
the	PRON	O	O	4209
methadone	NOUN	O	Chemical	4209
group	NOUN	O	O	4209
presented	VERB	O	O	4209
torsades de pointes	NOUN	O	Disease	4209
.	PUNCT	O	O	4209
QTc	VERB	O	O	4210
length	NOUN	O	O	4210
was	AUX	O	O	4210
weakly	ADV	O	O	4210
but	CCONJ	O	O	4210
significantly	ADV	O	O	4210
associated	VERB	O	O	4210
with	ADP	O	O	4210
methadone	NOUN	O	Chemical	4210
daily	ADV	O	O	4210
dose	NOUN	O	O	4210
(	PUNCT	O	O	4210
Spearman	NOUN	O	O	4210
rank	NOUN	O	O	4210
correlation	NOUN	O	O	4210
coefficient	NOUN	O	O	4210
,	PUNCT	O	O	4210
0.20	NUM	O	O	4210
;	PUNCT	O	O	4210
P<.01	PROPN	O	O	4210
)	PUNCT	O	O	4210
.	PUNCT	O	O	4210
Multivariate	NOUN	O	O	4211
regression	NOUN	O	O	4211
analysis	NOUN	O	O	4211
allowed	VERB	O	O	4211
attribution	VERB	O	O	4211
of	ADP	O	O	4211
31.8%	NOUN	O	O	4211
of	ADP	O	O	4211
QTc	VERB	O	O	4211
variability	NOUN	O	O	4211
to	PART	O	O	4211
methadone	NOUN	O	Chemical	4211
dose	NOUN	O	O	4211
,	PUNCT	O	O	4211
cytochrome	ADP	O	O	4211
P-450	ADV	O	O	4212
3A4	X	O	O	4212
drug	NOUN	O	O	4212
-	PUNCT	O	O	4212
drug	NOUN	O	O	4212
interactions	NOUN	O	O	4212
,	PUNCT	O	O	4212
hypokalemia	PROPN	O	Disease	4212
,	PUNCT	O	O	4212
and	CCONJ	O	O	4212
altered	VERB	O	O	4212
liver	NOUN	O	O	4212
function	NOUN	O	O	4212
.	PUNCT	O	O	4212
QT	NOUN	O	O	4213
interval	NOUN	O	O	4213
prolongation	NOUN	O	O	4213
in	ADP	O	O	4213
methadone	NOUN	O	Chemical	4213
maintenance	NOUN	O	O	4213
patients	NOUN	O	O	4213
hospitalized	VERB	O	O	4213
in	ADP	O	O	4213
a	PRON	O	O	4213
tertiary	ADJ	O	O	4213
care	VERB	O	O	4213
center	PROPN	O	O	4213
is	AUX	O	O	4213
a	PRON	O	O	4213
frequent	ADJ	O	O	4213
finding	VERB	O	O	4213
.	PUNCT	O	O	4213
Methadone	NOUN	O	Chemical	4214
dose	NOUN	O	O	4214
,	PUNCT	O	O	4214
presence	NOUN	O	O	4214
of	ADP	O	O	4214
cytochrome	ADP	O	O	4214
P-450	ADV	O	O	4214
3A4	X	O	O	4214
inhibitors	NOUN	O	O	4214
,	PUNCT	O	O	4214
potassium	NOUN	O	Chemical	4214
level	VERB	O	O	4214
,	PUNCT	O	O	4214
and	CCONJ	O	O	4214
liver	NOUN	O	O	4214
function	NOUN	O	O	4214
contribute	VERB	O	O	4214
to	PART	O	O	4214
QT prolongation	NOUN	O	Disease	4214
.	PUNCT	O	O	4214
Long	ADV	O	O	4215
QT	NOUN	O	O	4215
syndrome	NOUN	O	O	4215
can	AUX	O	O	4215
occur	VERB	O	O	4215
with	ADP	O	O	4215
low	ADJ	O	O	4215
doses	NOUN	O	O	4215
of	ADP	O	O	4215
methadone	NOUN	O	Chemical	4215
.	PUNCT	O	O	4215
Mechanisms	NOUN	O	O	4218
of	ADP	O	O	4218
hypertension	NOUN	O	Disease	4218
induced	VERB	O	O	4218
by	ADP	O	O	4218
nitric oxide	NOUN	O	Chemical	4218
(	PUNCT	O	O	4218
NO	PRON	O	Chemical	4218
)	PUNCT	O	O	4218
deficiency	NOUN	O	O	4218
:	PUNCT	O	O	4218
focus	NOUN	O	O	4218
on	ADP	O	O	4218
venous	ADJ	O	O	4218
function	NOUN	O	O	4218
.	PUNCT	O	O	4218
Loss	NOUN	O	O	4219
of	ADP	O	O	4219
endothelial	NOUN	O	O	4219
cell	NOUN	O	O	4219
-	PUNCT	O	O	4219
derived	VERB	O	O	4219
nitric oxide	NOUN	O	Chemical	4219
(	PUNCT	O	O	4219
NO	PRON	O	Chemical	4219
)	PUNCT	O	O	4219
in	ADP	O	O	4219
hypertension	NOUN	O	Disease	4219
is	AUX	O	O	4219
a	PRON	O	O	4219
hallmark	NOUN	O	O	4219
of	ADP	O	O	4219
arterial	ADJ	O	O	4219
dysfunction	NOUN	O	O	4219
.	PUNCT	O	O	4219
Experimental	ADJ	O	O	4220
hypertension	NOUN	O	Disease	4220
created	VERB	O	O	4220
by	ADP	O	O	4220
the	PRON	O	O	4220
removal	NOUN	O	O	4220
of	ADP	O	O	4220
NO	PRON	O	Chemical	4220
,	PUNCT	O	O	4220
however	ADV	O	O	4220
,	PUNCT	O	O	4220
involves	VERB	O	O	4220
mechanisms	NOUN	O	O	4220
in	ADP	O	O	4220
addition	NOUN	O	O	4220
to	PART	O	O	4220
decreased	VERB	O	O	4220
arterial	ADJ	O	O	4220
vasodilator	NOUN	O	O	4220
activity	NOUN	O	O	4220
.	PUNCT	O	O	4220
We	PRON	O	O	4221
hypothesized	VERB	O	O	4221
that	SCONJ	O	O	4221
increased	VERB	O	O	4221
venous	ADJ	O	O	4221
smooth	VERB	O	O	4221
muscle	NOUN	O	O	4221
(	PUNCT	O	O	4221
venomotor	NOUN	O	O	4221
)	PUNCT	O	O	4221
tone	NOUN	O	O	4221
plays	VERB	O	O	4221
a	PRON	O	O	4221
role	NOUN	O	O	4221
in	ADP	O	O	4221
Nomega	NOUN	O	O	4221
-	PUNCT	O	O	4221
nitro	NOUN	O	O	4221
-	PUNCT	O	O	4221
L	NOUN	O	O	4221
-	PUNCT	O	O	4221
arginine	PROPN	O	O	4221
(	PUNCT	O	O	4221
LNNA	PROPN	O	O	4221
)	PUNCT	O	O	4221
hypertension	NOUN	O	Disease	4221
through	ADP	O	O	4221
these	PRON	O	O	4221
mechanisms	NOUN	O	O	4221
.	PUNCT	O	O	4221
Rats	NOUN	O	O	4222
were	AUX	O	O	4222
treated	VERB	O	O	4222
with	ADP	O	O	4222
the	PRON	O	O	4222
NO	PRON	O	Chemical	4222
synthase	NOUN	O	O	4222
inhibitor	NOUN	O	O	4222
LNNA	PROPN	O	O	4222
(	PUNCT	O	O	4222
0.5	NUM	O	O	4222
g	X	O	O	4222
/	PUNCT	O	O	4222
L	NOUN	O	O	4222
in	ADP	O	O	4222
drinking	VERB	O	O	4222
water	PROPN	O	O	4222
)	PUNCT	O	O	4222
for	ADP	O	O	4222
2	X	O	O	4222
weeks	NOUN	O	O	4222
.	PUNCT	O	O	4222
5	NUM	O	O	4223
mm	INTJ	O	O	4223
Hg	PROPN	O	O	4223
in	ADP	O	O	4223
LNNA	PROPN	O	O	4223
rats	NOUN	O	O	4223
(	PUNCT	O	O	4223
P<0.05	NOUN	O	O	4223
)	PUNCT	O	O	4223
.	PUNCT	O	O	4223
Maximal	PROPN	O	O	4224
contraction	NOUN	O	O	4224
to	PART	O	O	4224
norepinephrine	NOUN	O	Chemical	4224
was	AUX	O	O	4224
modestly	ADV	O	O	4224
reduced	VERB	O	O	4224
in	ADP	O	O	4224
arteries	NOUN	O	O	4224
from	ADP	O	O	4224
LNNA	PROPN	O	O	4224
compared	VERB	O	O	4224
with	ADP	O	O	4224
control	VERB	O	O	4224
rats	NOUN	O	O	4224
whereas	SCONJ	O	O	4224
the	PRON	O	O	4224
maximum	ADV	O	O	4224
contraction	NOUN	O	O	4224
to	PART	O	O	4224
ET-1	ADV	O	O	4224
was	AUX	O	O	4224
significantly	ADV	O	O	4224
reduced	VERB	O	O	4224
(	PUNCT	O	O	4224
54%	NOUN	O	O	4224
control	VERB	O	O	4224
)	PUNCT	O	O	4224
.	PUNCT	O	O	4224
Maximum	ADJ	O	O	4225
contraction	NOUN	O	O	4225
of	ADP	O	O	4225
vena	PROPN	O	O	4225
cava	NOUN	O	O	4225
to	PART	O	O	4225
norepinephrine	NOUN	O	Chemical	4225
(	PUNCT	O	O	4225
37%	NOUN	O	O	4225
control	VERB	O	O	4225
)	PUNCT	O	O	4225
also	ADV	O	O	4225
was	AUX	O	O	4225
reduced	VERB	O	O	4225
but	CCONJ	O	O	4225
no	PRON	O	O	4225
change	VERB	O	O	4225
in	ADP	O	O	4225
response	NOUN	O	O	4225
to	PART	O	O	4225
ET-1	ADV	O	O	4225
was	AUX	O	O	4225
observed	VERB	O	O	4225
.	PUNCT	O	O	4225
Mean	VERB	O	O	4226
circulatory	ADJ	O	O	4226
filling	VERB	O	O	4226
pressure	NOUN	O	O	4226
,	PUNCT	O	O	4226
an	PRON	O	O	4226
in	ADP	O	O	4226
vivo	VERB	O	O	4226
measure	VERB	O	O	4226
of	ADP	O	O	4226
venomotor	NOUN	O	O	4226
tone	NOUN	O	O	4226
,	PUNCT	O	O	4226
was	AUX	O	O	4226
not	PART	O	O	4226
elevated	ADJ	O	O	4226
in	ADP	O	O	4226
LNNA	PROPN	O	O	4226
hypertension	NOUN	O	Disease	4226
at	ADP	O	O	4226
1	X	O	O	4226
or	CCONJ	O	O	4226
2	X	O	O	4226
weeks	NOUN	O	O	4226
after	ADP	O	O	4226
LNNA	PROPN	O	O	4226
.	PUNCT	O	O	4226
The	PRON	O	O	4227
superoxide	NOUN	O	Chemical	4227
scavenger	NOUN	O	O	4227
tempol	PROPN	O	O	4227
(	PUNCT	O	O	4227
30	NUM	O	O	4227
,	PUNCT	O	O	4227
100	NUM	O	O	4227
,	PUNCT	O	O	4227
and	CCONJ	O	O	4227
300	NUM	O	O	4227
micromol	NOUN	O	O	4227
kg(-1	NOUN	O	O	4227
)	PUNCT	O	O	4227
,	PUNCT	O	O	4227
IV	NUM	O	O	4227
)	PUNCT	O	O	4227
did	VERB	O	O	4227
not	PART	O	O	4227
change	VERB	O	O	4227
arterial	ADJ	O	O	4227
pressure	NOUN	O	O	4227
in	ADP	O	O	4227
control	VERB	O	O	4227
rats	NOUN	O	O	4227
but	CCONJ	O	O	4227
caused	VERB	O	O	4227
a	PRON	O	O	4227
dose	NOUN	O	O	4227
-	PUNCT	O	O	4227
dependent	ADJ	O	O	4227
decrease	VERB	O	O	4227
in	ADP	O	O	4227
LNNA	PROPN	O	O	4227
rats	NOUN	O	O	4227
(	PUNCT	O	O	4227
-18	NUM	O	O	4227
+	ADP	O	O	4227
/-	PUNCT	O	O	4227
Similarly	ADV	O	O	4228
,	PUNCT	O	O	4228
ganglionic	ADJ	O	O	4228
blockade	VERB	O	O	4228
with	ADP	O	O	4228
hexamethonium	ADJ	O	Chemical	4228
caused	VERB	O	O	4228
a	PRON	O	O	4228
significantly	ADV	O	O	4228
greater	ADJ	O	O	4228
fall	VERB	O	O	4228
in	ADP	O	O	4228
LNNA	PROPN	O	O	4228
hypertensive	ADJ	O	Disease	4228
rats	NOUN	O	O	4228
(	PUNCT	O	O	4228
76	NUM	O	O	4228
+	ADP	O	O	4228
/-	PUNCT	O	O	4228
Carotid	PROPN	O	O	4229
arteries	NOUN	O	O	4229
,	PUNCT	O	O	4229
vena	PROPN	O	O	4229
cava	NOUN	O	O	4229
,	PUNCT	O	O	4229
and	CCONJ	O	O	4229
sympathetic	ADJ	O	O	4229
ganglia	NOUN	O	O	4229
from	ADP	O	O	4229
LNNA	PROPN	O	O	4229
rats	NOUN	O	O	4229
had	VERB	O	O	4229
higher	ADJ	O	O	4229
basal	PROPN	O	O	4229
levels	NOUN	O	O	4229
of	ADP	O	O	4229
superoxide	NOUN	O	Chemical	4229
compared	VERB	O	O	4229
with	ADP	O	O	4229
those	PRON	O	O	4229
from	ADP	O	O	4229
control	VERB	O	O	4229
rats	NOUN	O	O	4229
.	PUNCT	O	O	4229
These	PRON	O	O	4230
data	NOUN	O	O	4230
suggest	VERB	O	O	4230
that	SCONJ	O	O	4230
while	SCONJ	O	O	4230
NO	PRON	O	Chemical	4230
deficiency	NOUN	O	O	4230
increases	VERB	O	O	4230
oxidative	NOUN	O	O	4230
stress	NOUN	O	O	4230
and	CCONJ	O	O	4230
sympathetic	ADJ	O	O	4230
activity	NOUN	O	O	4230
in	ADP	O	O	4230
both	PRON	O	O	4230
arterial	ADJ	O	O	4230
and	CCONJ	O	O	4230
venous	ADJ	O	O	4230
vessels	NOUN	O	O	4230
,	PUNCT	O	O	4230
the	PRON	O	O	4230
impact	NOUN	O	O	4230
on	ADP	O	O	4230
veins	NOUN	O	O	4230
does	VERB	O	O	4230
not	PART	O	O	4230
make	VERB	O	O	4230
a	PRON	O	O	4230
major	ADJ	O	O	4230
contribution	NOUN	O	O	4230
to	PART	O	O	4230
this	PRON	O	O	4230
form	NOUN	O	O	4230
of	ADP	O	O	4230
hypertension	NOUN	O	Disease	4230
.	PUNCT	O	O	4230
Association	PROPN	O	O	4233
of	ADP	O	O	4233
DRD2	PROPN	O	O	4233
polymorphisms	NOUN	O	O	4233
and	CCONJ	O	O	4233
chlorpromazine	NOUN	O	Chemical	4233
-	PUNCT	O	O	4233
induced	VERB	O	O	4233
extrapyramidal syndrome	NOUN	O	Disease	4233
in	ADP	O	O	4233
Chinese	PROPN	O	O	4233
schizophrenic	ADJ	O	Disease	4233
patients	NOUN	O	O	4233
.	PUNCT	O	O	4233
Extrapyramidal	NOUN	O	O	4234
syndrome	NOUN	O	O	4234
(	PUNCT	O	O	4234
EPS	PROPN	O	Disease	4234
)	PUNCT	O	O	4234
is	AUX	O	O	4234
most	ADV	O	O	4234
commonly	ADV	O	O	4234
affected	VERB	O	O	4234
by	ADP	O	O	4234
typical	ADJ	O	O	4234
antipsychotic	ADJ	O	O	4234
drugs	NOUN	O	O	4234
that	SCONJ	O	O	4234
have	VERB	O	O	4234
a	PRON	O	O	4234
high	ADJ	O	O	4234
affinity	NOUN	O	O	4234
with	ADP	O	O	4234
the	PRON	O	O	4234
D2	NOUN	O	O	4234
receptor	NOUN	O	O	4234
.	PUNCT	O	O	4234
Recently	ADV	O	O	4235
,	PUNCT	O	O	4235
many	ADJ	O	O	4235
research	NOUN	O	O	4235
groups	NOUN	O	O	4235
have	VERB	O	O	4235
reported	VERB	O	O	4235
on	ADP	O	O	4235
the	PRON	O	O	4235
positive	ADJ	O	O	4235
relationship	NOUN	O	O	4235
between	ADP	O	O	4235
the	PRON	O	O	4235
genetic	ADJ	O	O	4235
variations	NOUN	O	O	4235
in	ADP	O	O	4235
the	PRON	O	O	4235
DRD2	PROPN	O	O	4235
gene	NOUN	O	O	4235
and	CCONJ	O	O	4235
the	PRON	O	O	4235
therapeutic	ADJ	O	O	4235
response	NOUN	O	O	4235
in	ADP	O	O	4235
schizophrenia	PROPN	O	Disease	4235
patients	NOUN	O	O	4235
as	ADP	O	O	4235
a	PRON	O	O	4235
result	VERB	O	O	4235
of	ADP	O	O	4235
the	PRON	O	O	4235
role	NOUN	O	O	4235
of	ADP	O	O	4235
variations	NOUN	O	O	4235
in	ADP	O	O	4235
the	PRON	O	O	4235
receptor	NOUN	O	O	4235
in	ADP	O	O	4235
modulating	VERB	O	O	4235
receptor	NOUN	O	O	4235
expression	NOUN	O	O	4235
.	PUNCT	O	O	4235
In	ADP	O	O	4236
this	PRON	O	O	4236
study	VERB	O	O	4236
,	PUNCT	O	O	4236
we	PRON	O	O	4236
evaluate	VERB	O	O	4236
the	PRON	O	O	4236
role	NOUN	O	O	4236
DRD2	PROPN	O	O	4236
plays	VERB	O	O	4236
in	ADP	O	O	4236
chlorpromazine	NOUN	O	Chemical	4236
-	PUNCT	O	O	4236
induced	VERB	O	O	4236
EPS	PROPN	O	Disease	4236
in	ADP	O	O	4236
schizophrenic	ADJ	O	Disease	4236
patients	NOUN	O	O	4236
.	PUNCT	O	O	4236
:	PUNCT	O	O	4237
We	PRON	O	O	4237
identified	VERB	O	O	4237
seven	NUM	O	O	4237
SNP(single	NOUN	O	O	4237
nucleotide	NOUN	O	O	4237
polymorphism	NOUN	O	O	4237
)	PUNCT	O	O	4237
(	PUNCT	O	O	4237
-141Cins	NOUN	O	O	4237
>	PUNCT	O	O	4237
del	PROPN	O	O	4237
,	PUNCT	O	O	4237
TaqIB	VERB	O	O	4237
,	PUNCT	O	O	4237
TaqID	NOUN	O	O	4237
,	PUNCT	O	O	4237
Ser311Cys	VERB	O	O	4237
,	PUNCT	O	O	4237
rs6275	NOUN	O	O	4237
,	PUNCT	O	O	4237
rs6277	NOUN	O	O	4237
and	CCONJ	O	O	4237
TaqIA	PROPN	O	O	4237
)	PUNCT	O	O	4237
in	ADP	O	O	4237
the	PRON	O	O	4237
DRD2	PROPN	O	O	4237
gene	NOUN	O	O	4237
in	ADP	O	O	4237
146	NUM	O	O	4237
schizophrenic	ADJ	O	Disease	4237
inpatients	NOUN	O	O	4237
(	PUNCT	O	O	4237
59	NUM	O	O	4237
with	ADP	O	O	4237
EPS	PROPN	O	Disease	4237
and	CCONJ	O	O	4237
87	NUM	O	O	4237
without	ADP	O	O	4237
EPS	PROPN	O	Disease	4237
according	VERB	O	O	4237
to	PART	O	O	4237
the	PRON	O	O	4237
Simpson	PROPN	O	O	4237
-	PUNCT	O	O	4237
Angus	PROPN	O	O	4237
Scale	NOUN	O	O	4237
)	PUNCT	O	O	4237
treated	VERB	O	O	4237
with	ADP	O	O	4237
chlorpromazine	NOUN	O	Chemical	4237
after	ADP	O	O	4237
8	NUM	O	O	4237
weeks	NOUN	O	O	4237
.	PUNCT	O	O	4237
CONCLUSION	PROPN	O	O	4238
:	PUNCT	O	O	4238
Our	PRON	O	O	4238
results	VERB	O	O	4238
did	VERB	O	O	4238
not	PART	O	O	4238
lend	VERB	O	O	4238
strong	ADJ	O	O	4238
support	NOUN	O	O	4238
to	PART	O	O	4238
the	PRON	O	O	4238
view	VERB	O	O	4238
that	SCONJ	O	O	4238
the	PRON	O	O	4238
genetic	ADJ	O	O	4238
variation	NOUN	O	O	4238
of	ADP	O	O	4238
the	PRON	O	O	4238
DRD2	PROPN	O	O	4238
gene	NOUN	O	O	4238
plays	VERB	O	O	4238
a	PRON	O	O	4238
major	ADJ	O	O	4238
role	NOUN	O	O	4238
in	ADP	O	O	4238
the	PRON	O	O	4238
individually	ADV	O	O	4238
variable	NOUN	O	O	4238
adverse	ADJ	O	O	4238
effect	VERB	O	O	4238
induced	VERB	O	O	4238
by	ADP	O	O	4238
chlorpromazine	NOUN	O	Chemical	4238
,	PUNCT	O	O	4238
at	ADP	O	O	4238
least	ADJ	O	O	4238
in	ADP	O	O	4238
Chinese	PROPN	O	O	4238
patients	NOUN	O	O	4238
with	ADP	O	O	4238
schizophrenia	PROPN	O	Disease	4238
.	PUNCT	O	O	4238
Our	PRON	O	O	4239
results	VERB	O	O	4239
confirmed	VERB	O	O	4239
a	PRON	O	O	4239
previous	ADJ	O	O	4239
study	VERB	O	O	4239
on	ADP	O	O	4239
the	PRON	O	O	4239
relationship	NOUN	O	O	4239
between	ADP	O	O	4239
DRD2	PROPN	O	O	4239
and	CCONJ	O	O	4239
EPS	PROPN	O	Disease	4239
in	ADP	O	O	4239
Caucasians	PROPN	O	O	4239
.	PUNCT	O	O	4239
Physical	NOUN	O	O	4242
training	NOUN	O	O	4242
decreases	VERB	O	O	4242
susceptibility	NOUN	O	O	4242
to	PART	O	O	4242
subsequent	ADJ	O	O	4242
pilocarpine	NOUN	O	Chemical	4242
-	PUNCT	O	O	4242
induced	VERB	O	O	4242
seizures	NOUN	O	Disease	4242
in	ADP	O	O	4242
the	PRON	O	O	4242
rat	NOUN	O	O	4242
.	PUNCT	O	O	4242
Regular	ADJ	O	O	4243
motor	NOUN	O	O	4243
activity	NOUN	O	O	4243
has	VERB	O	O	4243
many	ADJ	O	O	4243
benefits	NOUN	O	O	4243
for	ADP	O	O	4243
mental	ADJ	O	O	4243
and	CCONJ	O	O	4243
physical	ADJ	O	O	4243
condition	NOUN	O	O	4243
but	CCONJ	O	O	4243
its	PRON	O	O	4243
implications	NOUN	O	O	4243
for	ADP	O	O	4243
epilepsy	NOUN	O	Disease	4243
are	AUX	O	O	4243
still	ADV	O	O	4243
controversial	ADJ	O	O	4243
.	PUNCT	O	O	4243
In	ADP	O	O	4244
order	NOUN	O	O	4244
to	PART	O	O	4244
elucidate	VERB	O	O	4244
this	PRON	O	O	4244
problem	NOUN	O	O	4244
,	PUNCT	O	O	4244
we	PRON	O	O	4244
have	VERB	O	O	4244
studied	VERB	O	O	4244
the	PRON	O	O	4244
effect	VERB	O	O	4244
of	ADP	O	O	4244
long	ADV	O	O	4244
-	PUNCT	O	O	4244
term	NOUN	O	O	4244
physical	ADJ	O	O	4244
activity	NOUN	O	O	4244
on	ADP	O	O	4244
susceptibility	NOUN	O	O	4244
to	PART	O	O	4244
subsequent	ADJ	O	O	4244
seizures	NOUN	O	Disease	4244
.	PUNCT	O	O	4244
Thereafter	ADV	O	O	4245
,	PUNCT	O	O	4245
seizures	NOUN	O	Disease	4245
were	AUX	O	O	4245
induced	VERB	O	O	4245
by	ADP	O	O	4245
pilocarpine	NOUN	O	Chemical	4245
injections	NOUN	O	O	4245
in	ADP	O	O	4245
trained	VERB	O	O	4245
and	CCONJ	O	O	4245
non	ADJ	O	O	4245
-	PUNCT	O	O	4245
trained	VERB	O	O	4245
control	VERB	O	O	4245
groups	NOUN	O	O	4245
.	PUNCT	O	O	4245
During	ADP	O	O	4246
the	PRON	O	O	4246
acute	ADJ	O	O	4246
period	NOUN	O	O	4246
of	ADP	O	O	4246
status epilepticus	VERB	O	Disease	4246
,	PUNCT	O	O	4246
we	PRON	O	O	4246
measured	VERB	O	O	4246
:	PUNCT	O	O	4246
(	PUNCT	O	O	4246
1	X	O	O	4246
)	PUNCT	O	O	4246
the	PRON	O	O	4246
latency	VERB	O	O	4246
of	ADP	O	O	4246
the	PRON	O	O	4246
first	ADV	O	O	4246
motor	NOUN	O	O	4246
sign	VERB	O	O	4246
,	PUNCT	O	O	4246
(	PUNCT	O	O	4246
2	X	O	O	4246
)	PUNCT	O	O	4246
the	PRON	O	O	4246
intensity	NOUN	O	O	4246
of	ADP	O	O	4246
seizures	NOUN	O	Disease	4246
,	PUNCT	O	O	4246
(	PUNCT	O	O	4246
3	X	O	O	4246
)	PUNCT	O	O	4246
the	PRON	O	O	4246
time	NOUN	O	O	4246
when	SCONJ	O	O	4246
it	PRON	O	O	4246
occurred	VERB	O	O	4246
within	ADP	O	O	4246
the	PRON	O	O	4246
6-h	NOUN	O	O	4246
observation	NOUN	O	O	4246
period	NOUN	O	O	4246
,	PUNCT	O	O	4246
and	CCONJ	O	O	4246
(	PUNCT	O	O	4246
4	NUM	O	O	4246
)	PUNCT	O	O	4246
the	PRON	O	O	4246
time	NOUN	O	O	4246
when	SCONJ	O	O	4246
the	PRON	O	O	4246
acute	ADJ	O	O	4246
period	NOUN	O	O	4246
ended	VERB	O	O	4246
.	PUNCT	O	O	4246
All	PRON	O	O	4247
these	PRON	O	O	4247
behavioral	ADJ	O	O	4247
parameters	NOUN	O	O	4247
showed	VERB	O	O	4247
statistically	ADV	O	O	4247
significant	ADJ	O	O	4247
changes	VERB	O	O	4247
suggesting	VERB	O	O	4247
that	SCONJ	O	O	4247
regular	ADJ	O	O	4247
physical	ADJ	O	O	4247
exercises	NOUN	O	O	4247
decrease	VERB	O	O	4247
susceptibility	NOUN	O	O	4247
to	PART	O	O	4247
subsequently	ADV	O	O	4247
induced	VERB	O	O	4247
seizures	NOUN	O	Disease	4247
and	CCONJ	O	O	4247
ameliorate	VERB	O	O	4247
the	PRON	O	O	4247
course	NOUN	O	O	4247
of	ADP	O	O	4247
experimentally	ADV	O	O	4247
induced	VERB	O	O	4247
status epilepticus	VERB	O	Disease	4247
.	PUNCT	O	O	4247
Tonic	NOUN	O	O	4250
dopaminergic	ADJ	O	O	4250
stimulation	NOUN	O	O	4250
impairs	VERB	O	O	4250
associative	ADJ	O	O	4250
learning	VERB	O	O	4250
in	ADP	O	O	4250
healthy	ADJ	O	O	4250
subjects	NOUN	O	O	4250
.	PUNCT	O	O	4250
Endogenous	ADJ	O	O	4251
dopamine	NOUN	O	Chemical	4251
plays	VERB	O	O	4251
a	PRON	O	O	4251
central	ADJ	O	O	4251
role	NOUN	O	O	4251
in	ADP	O	O	4251
salience	NOUN	O	O	4251
coding	VERB	O	O	4251
during	ADP	O	O	4251
associative	ADJ	O	O	4251
learning	VERB	O	O	4251
.	PUNCT	O	O	4251
Administration	NOUN	O	O	4252
of	ADP	O	O	4252
the	PRON	O	O	4252
dopamine	NOUN	O	Chemical	4252
precursor	NOUN	O	O	4252
levodopa	NOUN	O	Chemical	4252
enhances	VERB	O	O	4252
learning	VERB	O	O	4252
in	ADP	O	O	4252
healthy	ADJ	O	O	4252
subjects	NOUN	O	O	4252
and	CCONJ	O	O	4252
stroke	VERB	O	Disease	4252
patients	NOUN	O	O	4252
.	PUNCT	O	O	4252
Because	SCONJ	O	O	4253
levodopa	NOUN	O	Chemical	4253
increases	VERB	O	O	4253
both	PRON	O	O	4253
phasic	ADJ	O	O	4253
and	CCONJ	O	O	4253
tonic	PROPN	O	O	4253
dopaminergic	ADJ	O	O	4253
neurotransmission	NOUN	O	O	4253
,	PUNCT	O	O	4253
the	PRON	O	O	4253
critical	ADJ	O	O	4253
mechanism	NOUN	O	O	4253
mediating	VERB	O	O	4253
the	PRON	O	O	4253
enhancement	NOUN	O	O	4253
of	ADP	O	O	4253
learning	VERB	O	O	4253
is	AUX	O	O	4253
unresolved	ADJ	O	O	4253
.	PUNCT	O	O	4253
Subjects	NOUN	O	O	4254
received	VERB	O	O	4254
the	PRON	O	O	4254
tonically	ADV	O	O	4254
stimulating	VERB	O	O	4254
dopamine	NOUN	O	Chemical	4254
-	PUNCT	O	O	4254
receptor	NOUN	O	O	4254
agonist	NOUN	O	O	4254
pergolide	NOUN	O	O	4254
(	PUNCT	O	O	4254
0.1	NUM	O	O	4254
mg	VERB	O	O	4254
)	PUNCT	O	O	4254
vs	ADP	O	O	4254
placebo	NOUN	O	O	4254
120	NUM	O	O	4254
min	NOUN	O	O	4254
before	ADP	O	O	4254
training	NOUN	O	O	4254
on	ADP	O	O	4254
each	PRON	O	O	4254
training	NOUN	O	O	4254
day	NOUN	O	O	4254
.	PUNCT	O	O	4254
The	PRON	O	O	4255
dopamine	NOUN	O	Chemical	4255
agonist	NOUN	O	O	4255
significantly	ADV	O	O	4255
impaired	VERB	O	O	4255
novel	NOUN	O	O	4255
word	NOUN	O	O	4255
learning	VERB	O	O	4255
compared	VERB	O	O	4255
to	PART	O	O	4255
placebo	NOUN	O	O	4255
.	PUNCT	O	O	4255
Subjects	NOUN	O	O	4256
treated	VERB	O	O	4256
with	ADP	O	O	4256
pergolide	NOUN	O	O	4256
also	ADV	O	O	4256
showed	VERB	O	O	4256
restricted	VERB	O	O	4256
emotional	ADJ	O	O	4256
responses	NOUN	O	O	4256
compared	VERB	O	O	4256
to	PART	O	O	4256
the	PRON	O	O	4256
PLACEBO	PROPN	O	O	4256
group	NOUN	O	O	4256
.	PUNCT	O	O	4256
The	PRON	O	O	4257
extent	NOUN	O	O	4257
of	ADP	O	O	4257
'	PUNCT	O	O	4257
flattened	VERB	O	O	4257
'	PUNCT	O	O	4257
affect	VERB	O	O	4257
with	ADP	O	O	4257
pergolide	NOUN	O	O	4257
was	AUX	O	O	4257
related	ADJ	O	O	4257
to	PART	O	O	4257
the	PRON	O	O	4257
degree	PROPN	O	O	4257
of	ADP	O	O	4257
learning	VERB	O	O	4257
inhibition	NOUN	O	O	4257
.	PUNCT	O	O	4257
These	PRON	O	O	4258
findings	NOUN	O	O	4258
suggest	VERB	O	O	4258
that	SCONJ	O	O	4258
tonic	PROPN	O	O	4258
occupation	NOUN	O	O	4258
of	ADP	O	O	4258
dopamine	NOUN	O	Chemical	4258
receptors	NOUN	O	O	4258
impairs	VERB	O	O	4258
learning	VERB	O	O	4258
by	ADP	O	O	4258
competition	NOUN	O	O	4258
with	ADP	O	O	4258
phasic	ADJ	O	O	4258
dopamine	NOUN	O	Chemical	4258
signals	VERB	O	O	4258
.	PUNCT	O	O	4258
Thus	ADV	O	O	4259
,	PUNCT	O	O	4259
phasic	ADJ	O	O	4259
signaling	VERB	O	O	4259
seems	VERB	O	O	4259
to	PART	O	O	4259
be	AUX	O	O	4259
the	PRON	O	O	4259
critical	ADJ	O	O	4259
mechanism	NOUN	O	O	4259
by	ADP	O	O	4259
which	PRON	O	O	4259
dopamine	NOUN	O	Chemical	4259
enhances	VERB	O	O	4259
associative	ADJ	O	O	4259
learning	VERB	O	O	4259
in	ADP	O	O	4259
healthy	ADJ	O	O	4259
subjects	NOUN	O	O	4259
and	CCONJ	O	O	4259
stroke	VERB	O	Disease	4259
patients	NOUN	O	O	4259
.	PUNCT	O	O	4259
Minocycline	NOUN	O	O	4262
-	PUNCT	O	O	4262
induced	VERB	O	O	4262
vasculitis	NOUN	O	Disease	4262
fulfilling	VERB	O	O	4262
the	PRON	O	O	4262
criteria	NOUN	O	O	4262
of	ADP	O	O	4262
polyarteritis	NOUN	O	O	4262
nodosa	NOUN	O	O	4262
.	PUNCT	O	O	4262
A	PRON	O	O	4263
47-year	NOUN	O	O	4263
-	PUNCT	O	O	4263
old	ADJ	O	O	4263
man	NOUN	O	O	4263
who	PRON	O	O	4263
had	VERB	O	O	4263
been	AUX	O	O	4263
taking	VERB	O	O	4263
minocycline	NOUN	O	O	4263
for	ADP	O	O	4263
palmoplantar	PROPN	O	O	4263
pustulosis	NOUN	O	O	4263
developed	VERB	O	O	4263
fever	NOUN	O	Disease	4263
,	PUNCT	O	O	4263
myalgias	PROPN	O	O	4263
,	PUNCT	O	O	4263
polyneuropathy	ADJ	O	Disease	4263
,	PUNCT	O	O	4263
and	CCONJ	O	O	4263
testicular	ADJ	O	O	4263
pain	NOUN	O	Disease	4263
,	PUNCT	O	O	4263
with	ADP	O	O	4263
elevated	ADJ	O	O	4263
C	NOUN	O	O	4263
-	PUNCT	O	O	4263
reactive	ADJ	O	O	4263
protein	NOUN	O	O	4263
(	PUNCT	O	O	4263
CRP	PROPN	O	O	4263
)	PUNCT	O	O	4263
.	PUNCT	O	O	4263
These	PRON	O	O	4264
manifestations	NOUN	O	O	4264
met	VERB	O	O	4264
the	PRON	O	O	4264
American	ADJ	O	O	4264
College	NOUN	O	O	4264
of	ADP	O	O	4264
Rheumatology	NOUN	O	O	4264
1990	NUM	O	O	4264
criteria	NOUN	O	O	4264
for	ADP	O	O	4264
the	PRON	O	O	4264
classification	NOUN	O	O	4264
of	ADP	O	O	4264
polyarteritis	NOUN	O	O	4264
nodosa	NOUN	O	O	4264
.	PUNCT	O	O	4264
Stopping	VERB	O	O	4265
minocycline	NOUN	O	O	4265
led	VERB	O	O	4265
to	PART	O	O	4265
amelioration	NOUN	O	O	4265
of	ADP	O	O	4265
symptoms	NOUN	O	O	4265
and	CCONJ	O	O	4265
normalization	NOUN	O	O	4265
of	ADP	O	O	4265
CRP	PROPN	O	O	4265
level	VERB	O	O	4265
.	PUNCT	O	O	4265
To	PART	O	O	4266
our	PRON	O	O	4266
knowledge	NOUN	O	O	4266
,	PUNCT	O	O	4266
this	PRON	O	O	4266
is	AUX	O	O	4266
the	PRON	O	O	4266
second	ADV	O	O	4266
case	NOUN	O	O	4266
of	ADP	O	O	4266
minocycline	NOUN	O	O	4266
-	PUNCT	O	O	4266
induced	VERB	O	O	4266
vasculitis	NOUN	O	Disease	4266
satisfying	VERB	O	O	4266
the	PRON	O	O	4266
criteria	NOUN	O	O	4266
.	PUNCT	O	O	4266
Differential	ADJ	O	O	4267
diagnosis	NOUN	O	O	4267
for	ADP	O	O	4267
drug	NOUN	O	O	4267
-	PUNCT	O	O	4267
induced	VERB	O	O	4267
disease	PROPN	O	O	4267
is	AUX	O	O	4267
invaluable	ADJ	O	O	4267
even	ADV	O	O	4267
for	ADP	O	O	4267
patients	NOUN	O	O	4267
with	ADP	O	O	4267
classical	ADJ	O	O	4267
polyarteritis	NOUN	O	O	4267
nodosa	NOUN	O	O	4267
.	PUNCT	O	O	4267
Intramuscular	NOUN	O	O	4270
hepatitis B	PROPN	O	Disease	4270
immune	NOUN	O	O	4270
globulin	NOUN	O	O	4270
combined	VERB	O	O	4270
with	ADP	O	O	4270
lamivudine	NOUN	O	Chemical	4270
in	ADP	O	O	4270
prevention	NOUN	O	O	4270
of	ADP	O	O	4270
hepatitis B	PROPN	O	Disease	4270
recurrence	NOUN	O	O	4270
after	ADP	O	O	4270
liver	NOUN	O	O	4270
transplantation	NOUN	O	O	4270
.	PUNCT	O	O	4270
BACKGROUND	NOUN	O	O	4271
:	PUNCT	O	O	4271
Combined	VERB	O	O	4271
hepatitis B	PROPN	O	Disease	4271
immune	NOUN	O	O	4271
globulin	NOUN	O	O	4271
(	PUNCT	O	O	4271
HBIg	NOUN	O	O	4271
)	PUNCT	O	O	4271
and	CCONJ	O	O	4271
lamivudine	NOUN	O	Chemical	4271
in	ADP	O	O	4271
prophylaxis	NOUN	O	O	4271
of	ADP	O	O	4271
the	PRON	O	O	4271
recurrence	NOUN	O	O	4271
of	ADP	O	O	4271
hepatitis B	PROPN	O	Disease	4271
after	ADP	O	O	4271
liver	NOUN	O	O	4271
transplantation	NOUN	O	O	4271
has	VERB	O	O	4271
significantly	ADV	O	O	4271
improved	VERB	O	O	4271
the	PRON	O	O	4271
survival	NOUN	O	O	4271
of	ADP	O	O	4271
HBsAg	PROPN	O	Chemical	4271
positive	ADJ	O	O	4271
patients	NOUN	O	O	4271
.	PUNCT	O	O	4271
This	PRON	O	O	4272
study	VERB	O	O	4272
was	AUX	O	O	4272
undertaken	VERB	O	O	4272
to	PART	O	O	4272
evaluate	VERB	O	O	4272
the	PRON	O	O	4272
outcomes	NOUN	O	O	4272
of	ADP	O	O	4272
liver	NOUN	O	O	4272
transplantation	NOUN	O	O	4272
for	ADP	O	O	4272
patients	NOUN	O	O	4272
with	ADP	O	O	4272
hepatitis B	PROPN	O	Disease	4272
virus	NOUN	O	O	4272
(	PUNCT	O	O	4272
HBV	NOUN	O	O	4272
)	PUNCT	O	O	4272
.	PUNCT	O	O	4272
A	PRON	O	O	4273
retrospective	ADJ	O	O	4273
chart	NOUN	O	O	4273
analysis	NOUN	O	O	4273
and	CCONJ	O	O	4273
a	PRON	O	O	4273
review	VERB	O	O	4273
of	ADP	O	O	4273
the	PRON	O	O	4273
organ	NOUN	O	O	4273
transplant	NOUN	O	O	4273
database	NOUN	O	O	4273
identified	VERB	O	O	4273
51	NUM	O	O	4273
patients	NOUN	O	O	4273
(	PUNCT	O	O	4273
43	NUM	O	O	4273
men	NOUN	O	O	4273
and	CCONJ	O	O	4273
8	NUM	O	O	4273
women	NOUN	O	O	4273
)	PUNCT	O	O	4273
transplanted	VERB	O	O	4273
for	ADP	O	O	4273
benign	ADJ	O	O	4273
HBV	NOUN	O	O	4273
-	PUNCT	O	O	4273
related	ADJ	O	O	4273
cirrhotic	ADJ	O	O	4273
diseases	NOUN	O	O	4273
between	ADP	O	O	4273
June	PROPN	O	O	4273
2002	NUM	O	O	4273
and	CCONJ	O	O	4273
December	PROPN	O	O	4273
2004	NUM	O	O	4273
who	PRON	O	O	4273
had	VERB	O	O	4273
survived	VERB	O	O	4273
more	ADJ	O	O	4273
than	ADP	O	O	4273
3	X	O	O	4273
months	NOUN	O	O	4273
.	PUNCT	O	O	4273
A	PRON	O	O	4274
daily	ADV	O	O	4274
oral	ADJ	O	O	4274
dose	NOUN	O	O	4274
of	ADP	O	O	4274
100	NUM	O	O	4274
mg	VERB	O	O	4274
lamivudine	NOUN	O	Chemical	4274
for	ADP	O	O	4274
2	X	O	O	4274
weeks	NOUN	O	O	4274
before	ADP	O	O	4274
transplantation	NOUN	O	O	4274
for	ADP	O	O	4274
10	NUM	O	O	4274
patients	NOUN	O	O	4274
enabled	VERB	O	O	4274
57.1%	NOUN	O	O	4274
(	PUNCT	O	O	4274
4/7	NUM	O	O	4274
)	PUNCT	O	O	4274
and	CCONJ	O	O	4274
62.5%	NOUN	O	O	4274
(	PUNCT	O	O	4274
5/8	NUM	O	O	4274
)	PUNCT	O	O	4274
of	ADP	O	O	4274
HBV	NOUN	O	O	4274
-	PUNCT	O	O	4274
DNA	NOUN	O	O	4274
and	CCONJ	O	O	4274
HBeAg	PROPN	O	Chemical	4274
positive	ADJ	O	O	4274
patients	NOUN	O	O	4274
respectively	ADV	O	O	4274
to	PART	O	O	4274
convert	VERB	O	O	4274
to	PART	O	O	4274
be	AUX	O	O	4274
negative	ADJ	O	O	4274
.	PUNCT	O	O	4274
Lamivudine	NOUN	O	O	4275
combined	VERB	O	O	4275
with	ADP	O	O	4275
intramuscular	ADJ	O	O	4275
HBIg	NOUN	O	O	4275
can	AUX	O	O	4275
effectively	ADV	O	O	4275
prevent	VERB	O	O	4275
allograft	NOUN	O	O	4275
from	ADP	O	O	4275
the	PRON	O	O	4275
recurrence	NOUN	O	O	4275
of	ADP	O	O	4275
HBV	NOUN	O	O	4275
after	ADP	O	O	4275
liver	NOUN	O	O	4275
transplantation	NOUN	O	O	4275
.	PUNCT	O	O	4275
Anticonvulsant	NOUN	O	O	4278
effect	VERB	O	O	4278
of	ADP	O	O	4278
eslicarbazepine	VERB	O	O	4278
acetate	NOUN	O	O	4278
(	PUNCT	O	O	4278
BIA	NOUN	O	O	4278
2	X	O	O	4278
-	PUNCT	O	O	4278
093	NUM	O	O	4278
)	PUNCT	O	O	4278
on	ADP	O	O	4278
seizures	NOUN	O	Disease	4278
induced	VERB	O	O	4278
by	ADP	O	O	4278
microperfusion	NOUN	O	O	4278
of	ADP	O	O	4278
picrotoxin	PROPN	O	Chemical	4278
in	ADP	O	O	4278
the	PRON	O	O	4278
hippocampus	NOUN	O	O	4278
of	ADP	O	O	4278
freely	ADV	O	O	4278
moving	VERB	O	O	4278
rats	NOUN	O	O	4278
.	PUNCT	O	O	4278
Eslicarbazepine	NOUN	O	O	4279
acetate	NOUN	O	O	4279
(	PUNCT	O	O	4279
BIA	NOUN	O	O	4279
2	X	O	O	4279
-	PUNCT	O	O	4279
093	NUM	O	O	4279
,	PUNCT	O	O	4279
S-(-)-10-acetoxy-10,11-dihydro-5H	VERB	O	O	4279
-	PUNCT	O	O	4279
dibenzo	NOUN	O	O	4279
/	PUNCT	O	O	4279
b	X	O	O	4279
,	PUNCT	O	O	4279
f	X	O	O	4279
/	PUNCT	O	O	4279
azepine-5-carboxamide	NOUN	O	O	4279
)	PUNCT	O	O	4279
is	AUX	O	O	4279
a	PRON	O	O	4279
novel	NOUN	O	O	4279
antiepileptic	ADJ	O	O	4279
drug	NOUN	O	O	4279
,	PUNCT	O	O	4279
now	ADV	O	O	4279
in	ADP	O	O	4279
Phase	NOUN	O	O	4279
III	NUM	O	O	4279
clinical	ADJ	O	O	4279
trials	NOUN	O	O	4279
,	PUNCT	O	O	4279
designed	VERB	O	O	4279
with	ADP	O	O	4279
the	PRON	O	O	4279
aim	VERB	O	O	4279
of	ADP	O	O	4279
improving	VERB	O	O	4279
efficacy	NOUN	O	O	4279
and	CCONJ	O	O	4279
safety	NOUN	O	O	4279
in	ADP	O	O	4279
comparison	NOUN	O	O	4279
with	ADP	O	O	4279
the	PRON	O	O	4279
structurally	ADV	O	O	4279
related	ADJ	O	O	4279
drugs	NOUN	O	O	4279
carbamazepine	NOUN	O	Chemical	4279
(	PUNCT	O	O	4279
CBZ	PROPN	O	Chemical	4279
)	PUNCT	O	O	4279
and	CCONJ	O	O	4279
oxcarbazepine	NOUN	O	O	4279
(	PUNCT	O	O	4279
OXC	ADV	O	O	4279
)	PUNCT	O	O	4279
.	PUNCT	O	O	4279
We	PRON	O	O	4280
have	VERB	O	O	4280
studied	VERB	O	O	4280
the	PRON	O	O	4280
effects	NOUN	O	O	4280
of	ADP	O	O	4280
oral	ADJ	O	O	4280
treatment	NOUN	O	O	4280
with	ADP	O	O	4280
eslicarbazepine	VERB	O	O	4280
acetate	NOUN	O	O	4280
on	ADP	O	O	4280
a	PRON	O	O	4280
whole	NOUN	O	O	4280
-	PUNCT	O	O	4280
animal	NOUN	O	O	4280
model	NOUN	O	O	4280
in	ADP	O	O	4280
which	PRON	O	O	4280
partial	ADJ	O	O	4280
seizures	NOUN	O	Disease	4280
can	AUX	O	O	4280
be	AUX	O	O	4280
elicited	VERB	O	O	4280
repeatedly	ADV	O	O	4280
on	ADP	O	O	4280
different	ADJ	O	O	4280
days	NOUN	O	O	4280
without	ADP	O	O	4280
changes	VERB	O	O	4280
in	ADP	O	O	4280
threshold	NOUN	O	O	4280
or	CCONJ	O	O	4280
seizure	NOUN	O	Disease	4280
patterns	NOUN	O	O	4280
.	PUNCT	O	O	4280
In	ADP	O	O	4281
the	PRON	O	O	4281
animals	NOUN	O	O	4281
treated	VERB	O	O	4281
with	ADP	O	O	4281
threshold	NOUN	O	O	4281
doses	NOUN	O	O	4281
of	ADP	O	O	4281
picrotoxin	PROPN	O	Chemical	4281
,	PUNCT	O	O	4281
the	PRON	O	O	4281
average	ADJ	O	O	4281
number	NOUN	O	O	4281
of	ADP	O	O	4281
seizures	NOUN	O	Disease	4281
was	AUX	O	O	4281
2.3+/-1.2	NUM	O	O	4281
,	PUNCT	O	O	4281
and	CCONJ	O	O	4281
average	ADJ	O	O	4281
seizure	NOUN	O	Disease	4281
duration	NOUN	O	O	4281
was	AUX	O	O	4281
39.5+/-8.4s	NUM	O	O	4281
.	PUNCT	O	O	4281
Pre	ADJ	O	O	4282
-	PUNCT	O	O	4282
treatment	NOUN	O	O	4282
with	ADP	O	O	4282
a	PRON	O	O	4282
dose	NOUN	O	O	4282
of	ADP	O	O	4282
30	NUM	O	O	4282
mg	VERB	O	O	4282
/	PUNCT	O	O	4282
kg	VERB	O	O	4282
2h	NUM	O	O	4282
before	ADP	O	O	4282
picrotoxin	PROPN	O	Chemical	4282
microperfusion	NOUN	O	O	4282
prevented	VERB	O	O	4282
seizures	NOUN	O	Disease	4282
in	ADP	O	O	4282
the	PRON	O	O	4282
75%	NOUN	O	O	4282
of	ADP	O	O	4282
the	PRON	O	O	4282
rats	NOUN	O	O	4282
.	PUNCT	O	O	4282
Lower	ADJ	O	O	4283
doses	NOUN	O	O	4283
(	PUNCT	O	O	4283
3	X	O	O	4283
and	CCONJ	O	O	4283
10mg	NOUN	O	O	4283
/	PUNCT	O	O	4283
kg	VERB	O	O	4283
)	PUNCT	O	O	4283
did	VERB	O	O	4283
not	PART	O	O	4283
suppress	VERB	O	O	4283
seizures	NOUN	O	Disease	4283
,	PUNCT	O	O	4283
however	ADV	O	O	4283
,	PUNCT	O	O	4283
after	ADP	O	O	4283
administration	NOUN	O	O	4283
of	ADP	O	O	4283
10mg	NOUN	O	O	4283
/	PUNCT	O	O	4283
kg	VERB	O	O	4284
,	PUNCT	O	O	4284
significant	ADJ	O	O	4284
reductions	NOUN	O	O	4284
in	ADP	O	O	4284
seizures	NOUN	O	Disease	4284
duration	NOUN	O	O	4284
(	PUNCT	O	O	4284
24.3+/-6.8s	NUM	O	O	4284
)	PUNCT	O	O	4284
and	CCONJ	O	O	4284
seizure	NOUN	O	Disease	4284
number	NOUN	O	O	4284
(	PUNCT	O	O	4284
1.6+/-0.34	NUM	O	O	4284
)	PUNCT	O	O	4284
were	AUX	O	O	4284
found	VERB	O	O	4284
.	PUNCT	O	O	4284
No	PRON	O	O	4285
adverse	ADJ	O	O	4285
effects	NOUN	O	O	4285
of	ADP	O	O	4285
eslicarbazepine	VERB	O	O	4285
acetate	NOUN	O	O	4285
were	AUX	O	O	4285
observed	VERB	O	O	4285
in	ADP	O	O	4285
the	PRON	O	O	4285
behavioral	ADJ	O	O	4285
/	PUNCT	O	O	4285
EEG	NOUN	O	O	4285
patterns	NOUN	O	O	4285
studied	VERB	O	O	4285
,	PUNCT	O	O	4285
including	VERB	O	O	4285
sleep	VERB	O	O	4285
/	PUNCT	O	O	4285
wakefulness	NOUN	O	O	4285
cycle	PROPN	O	O	4285
,	PUNCT	O	O	4285
at	ADP	O	O	4285
the	PRON	O	O	4285
doses	NOUN	O	O	4285
studied	VERB	O	O	4285
.	PUNCT	O	O	4285
Acute	PROPN	O	O	4288
renal failure	NOUN	O	Disease	4288
associated	VERB	O	O	4288
with	ADP	O	O	4288
prolonged	VERB	O	O	4288
intake	PROPN	O	O	4288
of	ADP	O	O	4288
slimming	VERB	O	O	4288
pills	NOUN	O	O	4288
containing	VERB	O	O	4288
anthraquinones	NOUN	O	O	4288
.	PUNCT	O	O	4288
Chinese	PROPN	O	O	4289
herbal	ADJ	O	O	4289
medicine	NOUN	O	O	4289
preparations	NOUN	O	O	4289
are	AUX	O	O	4289
widely	ADV	O	O	4289
available	ADJ	O	O	4289
and	CCONJ	O	O	4289
often	ADV	O	O	4289
regarded	VERB	O	O	4289
by	ADP	O	O	4289
the	PRON	O	O	4289
public	ADJ	O	O	4289
as	ADP	O	O	4289
natural	ADJ	O	O	4289
and	CCONJ	O	O	4289
safe	ADJ	O	O	4289
remedies	NOUN	O	O	4289
for	ADP	O	O	4289
a	PRON	O	O	4289
variety	NOUN	O	O	4289
of	ADP	O	O	4289
medical	ADJ	O	O	4289
conditions	NOUN	O	O	4289
.	PUNCT	O	O	4289
Nephropathy	PROPN	O	Disease	4290
caused	VERB	O	O	4290
by	ADP	O	O	4290
Chinese	PROPN	O	O	4290
herbs	NOUN	O	O	4290
has	VERB	O	O	4290
previously	ADV	O	O	4290
been	AUX	O	O	4290
reported	VERB	O	O	4290
,	PUNCT	O	O	4290
usually	ADV	O	O	4290
involving	VERB	O	O	4290
the	PRON	O	O	4290
use	VERB	O	O	4290
of	ADP	O	O	4290
aristolochic	NOUN	O	O	4290
acids	NOUN	O	O	4290
.	PUNCT	O	O	4290
We	PRON	O	O	4291
report	VERB	O	O	4291
a	PRON	O	O	4291
23-year	NOUN	O	O	4291
-	PUNCT	O	O	4291
old	ADJ	O	O	4291
woman	NOUN	O	O	4291
who	PRON	O	O	4291
developed	VERB	O	O	4291
acute	ADJ	O	O	4291
renal failure	NOUN	O	Disease	4291
following	VERB	O	O	4291
prolonged	VERB	O	O	4291
use	VERB	O	O	4291
of	ADP	O	O	4291
a	PRON	O	O	4291
proprietary	ADJ	O	O	4291
Chinese	PROPN	O	O	4291
herbal	ADJ	O	O	4291
slimming	VERB	O	O	4291
pill	NOUN	O	O	4291
that	SCONJ	O	O	4291
contained	VERB	O	O	4291
anthraquinone	NOUN	O	O	4291
derivatives	NOUN	O	O	4291
,	PUNCT	O	O	4291
extracted	VERB	O	O	4291
from	ADP	O	O	4291
Rhizoma	ADJ	O	O	4291
Rhei	PROPN	O	O	4291
(	PUNCT	O	O	4291
rhubarb	PROPN	O	O	4291
)	PUNCT	O	O	4291
.	PUNCT	O	O	4291
The	PRON	O	O	4292
renal injury	NOUN	O	Disease	4292
was	AUX	O	O	4292
probably	ADV	O	O	4292
aggravated	VERB	O	O	4292
by	ADP	O	O	4292
the	PRON	O	O	4292
concomitant	ADJ	O	O	4292
intake	PROPN	O	O	4292
of	ADP	O	O	4292
a	PRON	O	O	4292
non	ADJ	O	O	4292
-	PUNCT	O	O	4292
steroidal	ADJ	O	O	4292
anti	ADJ	O	O	4292
-	PUNCT	O	O	4292
inflammatory	ADJ	O	O	4292
drug	NOUN	O	O	4292
,	PUNCT	O	O	4292
diclofenac	PROPN	O	Chemical	4292
.	PUNCT	O	O	4292
Renal	NOUN	O	O	4293
pathology	NOUN	O	O	4293
was	AUX	O	O	4293
that	SCONJ	O	O	4293
of	ADP	O	O	4293
hypocellular	ADJ	O	O	4293
interstitial	ADJ	O	O	4293
fibrosis	NOUN	O	Disease	4293
.	PUNCT	O	O	4293
Spontaneous	ADJ	O	O	4294
renal	ADJ	O	O	4294
recovery	NOUN	O	O	4294
occurred	VERB	O	O	4294
upon	SCONJ	O	O	4294
cessation	NOUN	O	O	4294
of	ADP	O	O	4294
the	PRON	O	O	4294
slimming	VERB	O	O	4294
pills	NOUN	O	O	4294
,	PUNCT	O	O	4294
but	CCONJ	O	O	4294
mild	ADJ	O	O	4294
interstitial	ADJ	O	O	4294
fibrosis	NOUN	O	Disease	4294
and	CCONJ	O	O	4294
tubular	ADJ	O	O	4294
atrophy	NOUN	O	Disease	4294
was	AUX	O	O	4294
still	ADV	O	O	4294
evident	ADJ	O	O	4294
histologically	ADV	O	O	4294
4	NUM	O	O	4294
months	NOUN	O	O	4294
later	ADV	O	O	4294
.	PUNCT	O	O	4294
Although	SCONJ	O	O	4295
a	PRON	O	O	4295
causal	NOUN	O	O	4295
relationship	NOUN	O	O	4295
between	ADP	O	O	4295
the	PRON	O	O	4295
use	VERB	O	O	4295
of	ADP	O	O	4295
an	PRON	O	O	4295
anthraquinone	NOUN	O	O	4295
-	PUNCT	O	O	4295
containing	VERB	O	O	4295
herbal	ADJ	O	O	4295
agent	NOUN	O	O	4295
and	CCONJ	O	O	4295
renal injury	NOUN	O	Disease	4295
remains	VERB	O	O	4295
to	PART	O	O	4295
be	AUX	O	O	4295
proven	VERB	O	O	4295
,	PUNCT	O	O	4295
phytotherapy	NOUN	O	O	4295
-	PUNCT	O	O	4295
associated	VERB	O	O	4295
interstitial	ADJ	O	O	4295
nephropathy	NOUN	O	Disease	4295
should	AUX	O	O	4295
be	AUX	O	O	4295
considered	VERB	O	O	4295
in	ADP	O	O	4295
patients	NOUN	O	O	4295
who	PRON	O	O	4295
present	NOUN	O	O	4295
with	ADP	O	O	4295
unexplained	ADJ	O	O	4295
renal failure	NOUN	O	Disease	4295
.	PUNCT	O	O	4295
Chloroacetaldehyde	PROPN	O	O	4298
as	ADP	O	O	4298
a	PRON	O	O	4298
sulfhydryl	PROPN	O	O	4298
reagent	NOUN	O	O	4298
:	PUNCT	O	O	4298
the	PRON	O	O	4298
role	NOUN	O	O	4298
of	ADP	O	O	4298
critical	ADJ	O	O	4298
thiol	NOUN	O	Chemical	4298
groups	NOUN	O	O	4298
in	ADP	O	O	4298
ifosfamide	ADP	O	Chemical	4298
nephropathy	NOUN	O	Disease	4298
.	PUNCT	O	O	4298
Chloroacetaldehyde	PROPN	O	O	4299
(	PUNCT	O	O	4299
CAA	PROPN	O	O	4299
)	PUNCT	O	O	4299
is	AUX	O	O	4299
a	PRON	O	O	4299
metabolite	NOUN	O	O	4299
of	ADP	O	O	4299
the	PRON	O	O	4299
alkylating	VERB	O	O	4299
agent	NOUN	O	O	4299
ifosfamide	ADP	O	Chemical	4299
(	PUNCT	O	O	4299
IFO	PROPN	O	O	4299
)	PUNCT	O	O	4299
and	CCONJ	O	O	4299
putatively	ADV	O	O	4299
responsible	ADJ	O	O	4299
for	ADP	O	O	4299
renal damage	NOUN	O	Disease	4299
following	VERB	O	O	4299
anti	ADJ	O	O	4299
-	PUNCT	O	O	4299
tumor	NOUN	O	Disease	4299
therapy	NOUN	O	O	4299
with	ADP	O	O	4299
IFO	PROPN	O	O	4299
.	PUNCT	O	O	4299
Depletion	NOUN	O	O	4300
of	ADP	O	O	4300
sulfhydryl	PROPN	O	O	4300
(	PUNCT	O	O	4300
SH	PROPN	O	O	4300
)	PUNCT	O	O	4300
In	ADP	O	O	4301
this	PRON	O	O	4301
work	NOUN	O	O	4301
the	PRON	O	O	4301
effect	VERB	O	O	4301
of	ADP	O	O	4301
CAA	PROPN	O	O	4301
on	ADP	O	O	4301
human	PROPN	O	O	4301
proximal	ADJ	O	O	4301
tubule	NOUN	O	O	4301
cells	NOUN	O	O	4301
in	ADP	O	O	4301
primary	NOUN	O	O	4301
culture	NOUN	O	O	4301
(	PUNCT	O	O	4301
hRPTEC	NOUN	O	O	4301
)	PUNCT	O	O	4301
was	AUX	O	O	4301
investigated	VERB	O	O	4301
.	PUNCT	O	O	4301
Toxicity	NOUN	O	Disease	4302
of	ADP	O	O	4302
CAA	PROPN	O	O	4302
was	AUX	O	O	4302
determined	VERB	O	O	4302
by	ADP	O	O	4302
protein	NOUN	O	O	4302
content	NOUN	O	O	4302
,	PUNCT	O	O	4302
cell	NOUN	O	O	4302
number	NOUN	O	O	4302
,	PUNCT	O	O	4302
LDH	PROPN	O	O	4302
release	NOUN	O	O	4302
,	PUNCT	O	O	4302
trypan	VERB	O	O	4302
blue	ADJ	O	O	4302
exclusion	NOUN	O	O	4302
assay	NOUN	O	O	4302
and	CCONJ	O	O	4302
caspase-3	NUM	O	O	4302
activity	NOUN	O	O	4302
.	PUNCT	O	O	4302
Free	ADJ	O	O	4303
thiols	NOUN	O	O	4303
were	AUX	O	O	4303
measured	VERB	O	O	4303
by	ADP	O	O	4303
the	PRON	O	O	4303
method	NOUN	O	O	4303
of	ADP	O	O	4303
Ellman	PROPN	O	O	4303
.	PUNCT	O	O	4303
CAA	PROPN	O	O	4304
reduced	VERB	O	O	4304
hRPTEC	NOUN	O	O	4304
cell	NOUN	O	O	4304
number	NOUN	O	O	4304
and	CCONJ	O	O	4304
protein	NOUN	O	O	4304
,	PUNCT	O	O	4304
induced	VERB	O	O	4304
a	PRON	O	O	4304
loss	NOUN	O	O	4304
in	ADP	O	O	4304
free	ADJ	O	O	4304
intracellular	ADJ	O	O	4304
thiols	NOUN	O	O	4304
and	CCONJ	O	O	4304
an	PRON	O	O	4304
increase	VERB	O	O	4304
in	ADP	O	O	4304
necrosis	NOUN	O	Disease	4304
markers	NOUN	O	O	4304
.	PUNCT	O	O	4304
CAA	PROPN	O	O	4305
but	CCONJ	O	O	4305
not	PART	O	O	4305
acrolein	PROPN	O	Chemical	4305
inhibited	VERB	O	O	4305
the	PRON	O	O	4305
cysteine	NOUN	O	O	4305
B.	PROPN	O	O	4306
Caspase	NOUN	O	O	4306
activation	NOUN	O	O	4306
by	ADP	O	O	4306
cisplatin	NOUN	O	Chemical	4306
was	AUX	O	O	4306
inhibited	VERB	O	O	4306
by	ADP	O	O	4306
CAA	PROPN	O	O	4306
.	PUNCT	O	O	4306
In	ADP	O	O	4307
cells	NOUN	O	O	4307
stained	VERB	O	O	4307
with	ADP	O	O	4307
fluorescent	NOUN	O	O	4307
dyes	NOUN	O	O	4307
targeting	VERB	O	O	4307
lysosomes	VERB	O	O	4307
,	PUNCT	O	O	4307
CAA	PROPN	O	O	4307
induced	VERB	O	O	4307
an	PRON	O	O	4307
increase	VERB	O	O	4307
in	ADP	O	O	4307
lysosomal	NOUN	O	O	4307
size	NOUN	O	O	4307
and	CCONJ	O	O	4307
lysosomal	NOUN	O	O	4307
leakage	NOUN	O	O	4307
.	PUNCT	O	O	4307
The	PRON	O	O	4308
effects	NOUN	O	O	4308
of	ADP	O	O	4308
CAA	PROPN	O	O	4308
on	ADP	O	O	4308
cysteine	NOUN	O	O	4308
protease	NOUN	O	O	4308
activities	NOUN	O	O	4308
and	CCONJ	O	O	4308
thiols	NOUN	O	O	4308
could	AUX	O	O	4308
be	AUX	O	O	4308
reproduced	VERB	O	O	4308
in	ADP	O	O	4308
cell	NOUN	O	O	4308
lysate	NOUN	O	O	4308
.	PUNCT	O	O	4308
Acidification	NOUN	O	O	4309
,	PUNCT	O	O	4309
which	PRON	O	O	4309
slowed	VERB	O	O	4309
the	PRON	O	O	4309
reaction	NOUN	O	O	4309
of	ADP	O	O	4309
CAA	PROPN	O	O	4309
with	ADP	O	O	4309
thiol	NOUN	O	Chemical	4309
donors	NOUN	O	O	4309
,	PUNCT	O	O	4309
could	AUX	O	O	4309
also	ADV	O	O	4309
attenuate	VERB	O	O	4309
effects	NOUN	O	O	4309
of	ADP	O	O	4309
CAA	PROPN	O	O	4309
on	ADP	O	O	4309
necrosis	NOUN	O	Disease	4309
markers	NOUN	O	O	4309
,	PUNCT	O	O	4309
thiol	NOUN	O	Chemical	4309
depletion	NOUN	O	O	4309
and	CCONJ	O	O	4309
cysteine	NOUN	O	O	4309
protease	NOUN	O	O	4309
inhibition	NOUN	O	O	4309
in	ADP	O	O	4309
living	VERB	O	O	4309
cells	NOUN	O	O	4309
.	PUNCT	O	O	4309
Thus	ADV	O	O	4310
,	PUNCT	O	O	4310
CAA	PROPN	O	O	4310
directly	ADV	O	O	4310
reacts	VERB	O	O	4310
with	ADP	O	O	4310
cellular	NOUN	O	O	4310
protein	NOUN	O	O	4310
and	CCONJ	O	O	4310
non	ADJ	O	O	4310
-	PUNCT	O	O	4310
protein	NOUN	O	O	4310
thiols	NOUN	O	O	4310
,	PUNCT	O	O	4310
mediating	VERB	O	O	4310
its	PRON	O	O	4310
toxicity	NOUN	O	Disease	4310
on	ADP	O	O	4310
hRPTEC	NOUN	O	O	4310
.	PUNCT	O	O	4310
Therefore	ADV	O	O	4311
,	PUNCT	O	O	4311
urinary	ADJ	O	O	4311
acidification	NOUN	O	O	4311
could	AUX	O	O	4311
be	AUX	O	O	4311
an	PRON	O	O	4311
option	NOUN	O	O	4311
to	PART	O	O	4311
prevent	VERB	O	O	4311
IFO	PROPN	O	O	4311
nephropathy	NOUN	O	Disease	4311
in	ADP	O	O	4311
patients	NOUN	O	O	4311
.	PUNCT	O	O	4311
Stereological	PROPN	O	O	4314
methods	NOUN	O	O	4314
reveal	VERB	O	O	4314
the	PRON	O	O	4314
robust	ADJ	O	O	4314
size	NOUN	O	O	4314
and	CCONJ	O	O	4314
stability	PROPN	O	O	4314
of	ADP	O	O	4314
ectopic	ADJ	O	O	4314
hilar	ADJ	O	O	4314
granule	NOUN	O	O	4314
cells	NOUN	O	O	4314
after	ADP	O	O	4314
pilocarpine	NOUN	O	Chemical	4314
-	PUNCT	O	O	4314
induced	VERB	O	O	4314
status epilepticus	VERB	O	Disease	4314
in	ADP	O	O	4314
the	PRON	O	O	4314
adult	NOUN	O	O	4314
rat	NOUN	O	O	4314
.	PUNCT	O	O	4314
Following	VERB	O	O	4315
status epilepticus	VERB	O	Disease	4315
in	ADP	O	O	4315
the	PRON	O	O	4315
rat	NOUN	O	O	4315
,	PUNCT	O	O	4315
dentate	ADJ	O	O	4315
granule	NOUN	O	O	4315
cell	NOUN	O	O	4315
neurogenesis	VERB	O	O	4315
increases	VERB	O	O	4315
greatly	ADV	O	O	4315
,	PUNCT	O	O	4315
and	CCONJ	O	O	4315
many	ADJ	O	O	4315
of	ADP	O	O	4315
the	PRON	O	O	4315
new	ADJ	O	O	4315
neurons	NOUN	O	O	4315
appear	VERB	O	O	4315
to	PART	O	O	4315
develop	VERB	O	O	4315
ectopically	ADV	O	O	4315
,	PUNCT	O	O	4315
in	ADP	O	O	4315
the	PRON	O	O	4315
hilar	ADJ	O	O	4315
region	NOUN	O	O	4315
of	ADP	O	O	4315
the	PRON	O	O	4315
hippocampal	NOUN	O	O	4315
formation	NOUN	O	O	4315
.	PUNCT	O	O	4315
It	PRON	O	O	4316
has	VERB	O	O	4316
been	AUX	O	O	4316
suggested	VERB	O	O	4316
that	SCONJ	O	O	4316
the	PRON	O	O	4316
ectopic	ADJ	O	O	4316
hilar	ADJ	O	O	4316
granule	NOUN	O	O	4316
cells	NOUN	O	O	4316
could	AUX	O	O	4316
contribute	VERB	O	O	4316
to	PART	O	O	4316
the	PRON	O	O	4316
spontaneous	ADJ	O	O	4316
seizures	NOUN	O	Disease	4316
that	SCONJ	O	O	4316
ultimately	ADV	O	O	4316
develop	VERB	O	O	4316
after	ADP	O	O	4316
status epilepticus	VERB	O	Disease	4316
.	PUNCT	O	O	4316
To	PART	O	O	4317
quantify	VERB	O	O	4317
this	PRON	O	O	4317
population	NOUN	O	O	4317
,	PUNCT	O	O	4317
the	PRON	O	O	4317
total	ADJ	O	O	4317
number	NOUN	O	O	4317
of	ADP	O	O	4317
ectopic	ADJ	O	O	4317
hilar	ADJ	O	O	4317
granule	NOUN	O	O	4317
cells	NOUN	O	O	4317
was	AUX	O	O	4317
estimated	VERB	O	O	4317
using	VERB	O	O	4317
unbiased	ADJ	O	O	4317
stereology	NOUN	O	O	4317
at	ADP	O	O	4317
different	ADJ	O	O	4317
times	NOUN	O	O	4317
after	ADP	O	O	4317
pilocarpine	NOUN	O	Chemical	4317
-	PUNCT	O	O	4317
induced	VERB	O	O	4317
status epilepticus	VERB	O	Disease	4317
.	PUNCT	O	O	4317
The	PRON	O	O	4318
results	VERB	O	O	4318
indicate	VERB	O	O	4318
that	SCONJ	O	O	4318
the	PRON	O	O	4318
size	NOUN	O	O	4318
of	ADP	O	O	4318
the	PRON	O	O	4318
hilar	ADJ	O	O	4318
ectopic	ADJ	O	O	4318
granule	NOUN	O	O	4318
cell	NOUN	O	O	4318
population	NOUN	O	O	4318
after	ADP	O	O	4318
status epilepticus	VERB	O	Disease	4318
is	AUX	O	O	4318
substantial	ADJ	O	O	4318
,	PUNCT	O	O	4318
and	CCONJ	O	O	4318
stable	ADJ	O	O	4318
over	ADP	O	O	4318
time	NOUN	O	O	4318
.	PUNCT	O	O	4318
Interestingly	ADV	O	O	4319
,	PUNCT	O	O	4319
the	PRON	O	O	4319
size	NOUN	O	O	4319
of	ADP	O	O	4319
the	PRON	O	O	4319
population	NOUN	O	O	4319
appears	VERB	O	O	4319
to	PART	O	O	4319
be	AUX	O	O	4319
correlated	VERB	O	O	4319
with	ADP	O	O	4319
the	PRON	O	O	4319
frequency	NOUN	O	O	4319
of	ADP	O	O	4319
behavioral	ADJ	O	O	4319
seizures	NOUN	O	Disease	4319
,	PUNCT	O	O	4319
because	SCONJ	O	O	4319
animals	NOUN	O	O	4319
with	ADP	O	O	4319
more	ADJ	O	O	4319
ectopic	ADJ	O	O	4319
granule	NOUN	O	O	4319
cells	NOUN	O	O	4319
in	ADP	O	O	4319
the	PRON	O	O	4319
hilus	PROPN	O	O	4319
have	VERB	O	O	4319
more	ADJ	O	O	4319
frequent	ADJ	O	O	4319
behavioral	ADJ	O	O	4319
seizures	NOUN	O	Disease	4319
.	PUNCT	O	O	4319
The	PRON	O	O	4320
results	VERB	O	O	4320
provide	VERB	O	O	4320
new	ADJ	O	O	4320
insight	NOUN	O	O	4320
into	ADP	O	O	4320
the	PRON	O	O	4320
potential	ADJ	O	O	4320
role	NOUN	O	O	4320
of	ADP	O	O	4320
ectopic	ADJ	O	O	4320
hilar	ADJ	O	O	4320
granule	NOUN	O	O	4320
cells	NOUN	O	O	4320
in	ADP	O	O	4320
the	PRON	O	O	4320
pilocarpine	NOUN	O	Chemical	4320
model	NOUN	O	O	4320
of	ADP	O	O	4320
temporal lobe epilepsy	NOUN	O	Disease	4320
.	PUNCT	O	O	4320
A	PRON	O	O	4323
prospective	ADJ	O	O	4323
,	PUNCT	O	O	4323
open	VERB	O	O	4323
-	PUNCT	O	O	4323
label	PROPN	O	O	4323
trial	NOUN	O	O	4323
of	ADP	O	O	4323
galantamine	NOUN	O	O	4323
in	ADP	O	O	4323
autistic	ADJ	O	O	4323
disorder	NOUN	O	O	4323
.	PUNCT	O	O	4323
Post	NOUN	O	O	4324
-	PUNCT	O	O	4324
mortem	PROPN	O	O	4324
studies	NOUN	O	O	4324
have	VERB	O	O	4324
reported	VERB	O	O	4324
abnormalities	NOUN	O	O	4324
of	ADP	O	O	4324
the	PRON	O	O	4324
cholinergic	ADJ	O	O	4324
system	NOUN	O	O	4324
in	ADP	O	O	4324
autism	NOUN	O	O	4324
.	PUNCT	O	O	4324
The	PRON	O	O	4325
purpose	NOUN	O	O	4325
of	ADP	O	O	4325
this	PRON	O	O	4325
study	VERB	O	O	4325
was	AUX	O	O	4325
to	PART	O	O	4325
assess	VERB	O	O	4325
the	PRON	O	O	4325
use	VERB	O	O	4325
of	ADP	O	O	4325
galantamine	NOUN	O	O	4325
,	PUNCT	O	O	4325
an	PRON	O	O	4325
acetylcholinesterase	NOUN	O	O	4325
inhibitor	NOUN	O	O	4325
and	CCONJ	O	O	4325
nicotinic	ADJ	O	O	4325
receptor	NOUN	O	O	4325
modulator	PROPN	O	O	4325
,	PUNCT	O	O	4325
in	ADP	O	O	4325
the	PRON	O	O	4325
treatment	NOUN	O	O	4325
of	ADP	O	O	4325
interfering	VERB	O	O	4325
behaviors	NOUN	O	O	4325
in	ADP	O	O	4325
children	NOUN	O	O	4325
with	ADP	O	O	4325
autism	NOUN	O	O	4325
.	PUNCT	O	O	4325
Thirteen	NUM	O	O	4326
medication	NOUN	O	O	4326
-	PUNCT	O	O	4326
free	ADJ	O	O	4326
children	NOUN	O	O	4326
with	ADP	O	O	4326
autism	NOUN	O	O	4326
(	PUNCT	O	O	4326
mean	VERB	O	O	4326
age	NOUN	O	O	4326
,	PUNCT	O	O	4326
8.8	NUM	O	O	4326
+	ADP	O	O	4326
/-	PUNCT	O	O	4326
3.5	NUM	O	O	4327
years	NOUN	O	O	4327
)	PUNCT	O	O	4327
participated	VERB	O	O	4327
in	ADP	O	O	4327
a	PRON	O	O	4327
12-week	NOUN	O	O	4327
,	PUNCT	O	O	4327
open	VERB	O	O	4327
-	PUNCT	O	O	4327
label	PROPN	O	O	4327
trial	NOUN	O	O	4327
of	ADP	O	O	4327
galantamine	NOUN	O	O	4327
.	PUNCT	O	O	4327
Patients	NOUN	O	O	4328
showed	VERB	O	O	4328
a	PRON	O	O	4328
significant	ADJ	O	O	4328
reduction	NOUN	O	O	4328
in	ADP	O	O	4328
parent	NOUN	O	O	4328
-	PUNCT	O	O	4328
rated	VERB	O	O	4328
irritability	NOUN	O	Disease	4328
and	CCONJ	O	O	4328
social	ADJ	O	O	4328
withdrawal	NOUN	O	O	4328
on	ADP	O	O	4328
the	PRON	O	O	4328
ABC	PROPN	O	O	4328
as	ADP	O	O	4328
well	ADV	O	O	4328
as	ADP	O	O	4328
significant	ADJ	O	O	4328
improvements	NOUN	O	O	4328
in	ADP	O	O	4328
emotional	ADJ	O	O	4328
lability	NOUN	O	O	4328
and	CCONJ	O	O	4328
inattention	NOUN	O	O	4328
on	ADP	O	O	4328
the	PRON	O	O	4328
Conners	PROPN	O	O	4328
'	PUNCT	O	O	4328
Parent	NOUN	O	O	4328
Rating	NOUN	O	O	4328
Scale	NOUN	O	O	4328
--	PUNCT	O	O	4328
Revised	VERB	O	O	4328
.	PUNCT	O	O	4328
Overall	ADV	O	O	4329
,	PUNCT	O	O	4329
galantamine	NOUN	O	O	4329
was	AUX	O	O	4329
well	ADV	O	O	4329
-	PUNCT	O	O	4329
tolerated	VERB	O	O	4329
,	PUNCT	O	O	4329
with	ADP	O	O	4329
no	PRON	O	O	4329
significant	ADJ	O	O	4329
adverse	ADJ	O	O	4329
effects	NOUN	O	O	4329
apart	ADV	O	O	4329
from	ADP	O	O	4329
headaches	NOUN	O	Disease	4329
in	ADP	O	O	4329
one	NUM	O	O	4329
patient	NOUN	O	O	4329
.	PUNCT	O	O	4329
In	ADP	O	O	4330
this	PRON	O	O	4330
open	VERB	O	O	4330
trial	NOUN	O	O	4330
,	PUNCT	O	O	4330
galantamine	NOUN	O	O	4330
was	AUX	O	O	4330
well	ADV	O	O	4330
-	PUNCT	O	O	4330
tolerated	VERB	O	O	4330
and	CCONJ	O	O	4330
appeared	VERB	O	O	4330
to	PART	O	O	4330
be	AUX	O	O	4330
beneficial	ADJ	O	O	4330
for	ADP	O	O	4330
the	PRON	O	O	4330
treatment	NOUN	O	O	4330
of	ADP	O	O	4330
interfering	VERB	O	O	4330
behaviors	NOUN	O	O	4330
in	ADP	O	O	4330
children	NOUN	O	O	4330
with	ADP	O	O	4330
autism	NOUN	O	O	4330
,	PUNCT	O	O	4330
particularly	ADV	O	O	4330
aggression	NOUN	O	Disease	4330
,	PUNCT	O	O	4330
behavioral	ADJ	O	O	4330
dyscontrol	VERB	O	O	4330
,	PUNCT	O	O	4330
and	CCONJ	O	O	4330
inattention	NOUN	O	O	4330
.	PUNCT	O	O	4330
Randomized	VERB	O	O	4333
comparison	NOUN	O	O	4333
of	ADP	O	O	4333
olanzapine	NOUN	O	Chemical	4333
versus	ADP	O	O	4333
risperidone	VERB	O	Chemical	4333
for	ADP	O	O	4333
the	PRON	O	O	4333
treatment	NOUN	O	O	4333
of	ADP	O	O	4333
first	ADV	O	O	4333
-	PUNCT	O	O	4333
episode	PROPN	O	O	4333
schizophrenia	PROPN	O	Disease	4333
:	PUNCT	O	O	4333
4-month	NOUN	O	O	4333
outcomes	NOUN	O	O	4333
.	PUNCT	O	O	4333
OBJECTIVE	VERB	O	O	4334
:	PUNCT	O	O	4334
The	PRON	O	O	4334
authors	NOUN	O	O	4334
compared	VERB	O	O	4334
4-month	NOUN	O	O	4334
treatment	NOUN	O	O	4334
outcomes	NOUN	O	O	4334
for	ADP	O	O	4334
olanzapine	NOUN	O	Chemical	4334
versus	ADP	O	O	4334
risperidone	VERB	O	Chemical	4334
in	ADP	O	O	4334
patients	NOUN	O	O	4334
with	ADP	O	O	4334
first	ADV	O	O	4334
-	PUNCT	O	O	4334
episode	PROPN	O	O	4334
schizophrenia	PROPN	O	Disease	4334
spectrum	NOUN	O	O	4334
disorders	NOUN	O	O	4334
.	PUNCT	O	O	4334
One	NUM	O	O	4335
hundred	NUM	O	O	4335
twelve	NUM	O	O	4335
subjects	NOUN	O	O	4335
(	PUNCT	O	O	4335
70%	NOUN	O	O	4335
male	NOUN	O	O	4335
;	PUNCT	O	O	4335
mean	VERB	O	O	4335
age=23.3	PROPN	O	O	4335
years	NOUN	O	O	4335
[	X	O	O	4335
SD	NOUN	O	O	4335
=	PUNCT	O	O	4335
5.1	NUM	O	O	4335
]	PUNCT	O	O	4335
)	PUNCT	O	O	4335
with	ADP	O	O	4335
first	ADV	O	O	4335
-	PUNCT	O	O	4335
episode	PROPN	O	O	4335
schizophrenia	PROPN	O	Disease	4335
(	PUNCT	O	O	4335
75%	NOUN	O	O	4335
)	PUNCT	O	O	4335
,	PUNCT	O	O	4335
schizophreniform	X	O	O	4335
disorder	NOUN	O	O	4335
(	PUNCT	O	O	4335
17%	NOUN	O	O	4335
)	PUNCT	O	O	4335
,	PUNCT	O	O	4335
or	CCONJ	O	O	4335
schizoaffective	VERB	O	O	4335
disorder	NOUN	O	O	4335
(	PUNCT	O	O	4335
8%	NOUN	O	O	4335
)	PUNCT	O	O	4335
were	AUX	O	O	4335
randomly	ADV	O	O	4335
assigned	VERB	O	O	4335
to	PART	O	O	4335
treatment	NOUN	O	O	4335
with	ADP	O	O	4335
olanzapine	NOUN	O	Chemical	4335
(	PUNCT	O	O	4335
2.5	NUM	O	O	4335
-	PUNCT	O	O	4335
20	NUM	O	O	4335
mg	VERB	O	O	4335
/	PUNCT	O	O	4335
day	NOUN	O	O	4335
)	PUNCT	O	O	4335
or	CCONJ	O	O	4335
risperidone	VERB	O	Chemical	4335
(	PUNCT	O	O	4335
1	X	O	O	4335
-	PUNCT	O	O	4335
6	NUM	O	O	4335
mg	VERB	O	O	4335
/	PUNCT	O	O	4335
day	NOUN	O	O	4335
)	PUNCT	O	O	4335
.	PUNCT	O	O	4335
Response	NOUN	O	O	4336
rates	NOUN	O	O	4336
did	VERB	O	O	4336
not	PART	O	O	4336
significantly	ADV	O	O	4336
differ	VERB	O	O	4336
between	ADP	O	O	4336
olanzapine	NOUN	O	Chemical	4336
(	PUNCT	O	O	4336
43.7%	NOUN	O	O	4336
,	PUNCT	O	O	4336
95%	NOUN	O	O	4336
CI=28.8%-58.6%	NOUN	O	O	4336
)	PUNCT	O	O	4336
and	CCONJ	O	O	4336
risperidone	VERB	O	Chemical	4336
(	PUNCT	O	O	4336
54.3%	NOUN	O	O	4336
,	PUNCT	O	O	4336
95%	NOUN	O	O	4336
CI=39.9%-68.7%	NOUN	O	O	4336
)	PUNCT	O	O	4336
.	PUNCT	O	O	4336
Among	ADP	O	O	4337
those	PRON	O	O	4337
responding	VERB	O	O	4337
to	PART	O	O	4337
treatment	NOUN	O	O	4337
,	PUNCT	O	O	4337
more	ADJ	O	O	4337
subjects	NOUN	O	O	4337
in	ADP	O	O	4337
the	PRON	O	O	4337
olanzapine	NOUN	O	Chemical	4337
group	NOUN	O	O	4337
(	PUNCT	O	O	4337
40.9%	NOUN	O	O	4337
,	PUNCT	O	O	4337
95%	NOUN	O	O	4337
CI=16.8%-65.0%	NOUN	O	O	4337
)	PUNCT	O	O	4337
than	ADP	O	O	4337
in	ADP	O	O	4337
the	PRON	O	O	4337
risperidone	VERB	O	Chemical	4337
group	NOUN	O	O	4337
(	PUNCT	O	O	4337
18.9%	NOUN	O	O	4337
,	PUNCT	O	O	4337
95%	NOUN	O	O	4337
CI=0%-39.2%	NOUN	O	O	4337
)	PUNCT	O	O	4337
had	VERB	O	O	4337
subsequent	ADJ	O	O	4337
ratings	NOUN	O	O	4337
not	PART	O	O	4337
meeting	NOUN	O	O	4337
response	NOUN	O	O	4337
criteria	NOUN	O	O	4337
.	PUNCT	O	O	4337
Negative	ADJ	O	O	4338
symptom	NOUN	O	O	4338
outcomes	NOUN	O	O	4338
and	CCONJ	O	O	4338
measures	NOUN	O	O	4338
of	ADP	O	O	4338
parkinsonism	NOUN	O	Disease	4338
and	CCONJ	O	O	4338
akathisia	PROPN	O	Disease	4338
did	VERB	O	O	4338
not	PART	O	O	4338
differ	VERB	O	O	4338
between	ADP	O	O	4338
medications	NOUN	O	O	4338
.	PUNCT	O	O	4338
Extrapyramidal	NOUN	O	O	4339
symptom	NOUN	O	O	4339
severity	NOUN	O	O	4339
scores	NOUN	O	O	4339
were	AUX	O	O	4339
1.4	NUM	O	O	4339
(	PUNCT	O	O	4339
95%	NOUN	O	O	4339
CI=1.2	NOUN	O	O	4339
-	PUNCT	O	O	4339
1.6	NUM	O	O	4339
)	PUNCT	O	O	4339
with	ADP	O	O	4339
risperidone	VERB	O	Chemical	4339
and	CCONJ	O	O	4339
1.2	NUM	O	O	4339
(	PUNCT	O	O	4339
95%	NOUN	O	O	4339
CI=1.0	PROPN	O	O	4339
-	PUNCT	O	O	4339
1.4	NUM	O	O	4339
)	PUNCT	O	O	4339
with	ADP	O	O	4339
olanzapine	NOUN	O	Chemical	4339
.	PUNCT	O	O	4339
Significantly	ADV	O	O	4340
more	ADJ	O	O	4340
weight	NOUN	O	O	4340
gain	VERB	O	O	4340
occurred	VERB	O	O	4340
with	ADP	O	O	4340
olanzapine	NOUN	O	Chemical	4340
than	ADP	O	O	4340
with	ADP	O	O	4340
risperidone	VERB	O	Chemical	4340
:	PUNCT	O	O	4340
the	PRON	O	O	4340
increase	VERB	O	O	4340
in	ADP	O	O	4340
weight	NOUN	O	O	4340
at	ADP	O	O	4340
4	NUM	O	O	4340
months	NOUN	O	O	4340
relative	ADJ	O	O	4340
to	PART	O	O	4340
baseline	VERB	O	O	4340
weight	NOUN	O	O	4340
was	AUX	O	O	4340
17.3%	NOUN	O	O	4340
(	PUNCT	O	O	4340
95%	NOUN	O	O	4340
CI=14.2%-20.5%	NOUN	O	O	4340
)	PUNCT	O	O	4340
with	ADP	O	O	4340
olanzapine	NOUN	O	Chemical	4340
and	CCONJ	O	O	4340
11.3%	NOUN	O	O	4340
(	PUNCT	O	O	4340
95%	NOUN	O	O	4340
CI=8.4%-14.3%	NOUN	O	O	4340
)	PUNCT	O	O	4340
with	ADP	O	O	4340
risperidone	VERB	O	Chemical	4340
.	PUNCT	O	O	4340
Body	NOUN	O	O	4341
mass	PROPN	O	O	4341
index	NOUN	O	O	4341
at	ADP	O	O	4341
baseline	VERB	O	O	4341
and	CCONJ	O	O	4341
at	ADP	O	O	4341
4	NUM	O	O	4341
months	NOUN	O	O	4341
was	AUX	O	O	4341
24.3	NUM	O	O	4341
(	PUNCT	O	O	4341
95%	NOUN	O	O	4341
CI=22.8	NUM	O	O	4341
-	PUNCT	O	O	4341
25.7	NUM	O	O	4341
)	PUNCT	O	O	4341
versus	ADP	O	O	4341
28.2	NUM	O	O	4341
(	PUNCT	O	O	4341
95%	NOUN	O	O	4341
CI=26.7	NUM	O	O	4341
-	PUNCT	O	O	4341
29.7	NUM	O	O	4341
)	PUNCT	O	O	4341
with	ADP	O	O	4341
olanzapine	NOUN	O	Chemical	4341
and	CCONJ	O	O	4341
23.9	NUM	O	O	4341
(	PUNCT	O	O	4341
95%	NOUN	O	O	4341
CI=22.5	NUM	O	O	4341
-	PUNCT	O	O	4341
25.3	NUM	O	O	4341
)	PUNCT	O	O	4341
versus	ADP	O	O	4341
26.7	NUM	O	O	4341
(	PUNCT	O	O	4341
95%	NOUN	O	O	4341
CI=25.2	NUM	O	O	4341
-	PUNCT	O	O	4341
28.2	NUM	O	O	4341
)	PUNCT	O	O	4341
with	ADP	O	O	4341
risperidone	VERB	O	Chemical	4341
.	PUNCT	O	O	4341
CONCLUSIONS	NOUN	O	O	4342
:	PUNCT	O	O	4342
Clinical	NOUN	O	O	4342
outcomes	NOUN	O	O	4342
with	ADP	O	O	4342
risperidone	VERB	O	Chemical	4342
were	AUX	O	O	4342
equal	ADJ	O	O	4342
to	PART	O	O	4342
those	PRON	O	O	4342
with	ADP	O	O	4342
olanzapine	NOUN	O	Chemical	4342
,	PUNCT	O	O	4342
and	CCONJ	O	O	4342
response	NOUN	O	O	4342
may	AUX	O	O	4342
be	AUX	O	O	4342
more	ADJ	O	O	4342
stable	ADJ	O	O	4342
.	PUNCT	O	O	4342
Olanzapine	NOUN	O	O	4343
may	AUX	O	O	4343
have	VERB	O	O	4343
an	PRON	O	O	4343
advantage	NOUN	O	O	4343
for	ADP	O	O	4343
motor	NOUN	O	O	4343
side	NOUN	O	O	4343
effects	NOUN	O	O	4343
.	PUNCT	O	O	4343
Both	PRON	O	O	4344
medications	NOUN	O	O	4344
caused	VERB	O	O	4344
substantial	ADJ	O	O	4344
rapid	ADJ	O	O	4344
weight	NOUN	O	O	4344
gain	VERB	O	O	4344
,	PUNCT	O	O	4344
but	CCONJ	O	O	4344
weight	NOUN	O	O	4344
gain	VERB	O	O	4344
was	AUX	O	O	4344
greater	ADJ	O	O	4344
with	ADP	O	O	4344
olanzapine	NOUN	O	Chemical	4344
.	PUNCT	O	O	4344
Early	ADJ	O	O	4347
paracentral	ADJ	O	O	4347
visual field loss	NOUN	O	Disease	4347
in	ADP	O	O	4347
patients	NOUN	O	O	4347
taking	VERB	O	O	4347
hydroxychloroquine	NOUN	O	Chemical	4347
.	PUNCT	O	O	4347
OBJECTIVE	VERB	O	O	4348
:	PUNCT	O	O	4348
To	PART	O	O	4348
review	VERB	O	O	4348
the	PRON	O	O	4348
natural	ADJ	O	O	4348
history	NOUN	O	O	4348
and	CCONJ	O	O	4348
ocular	ADJ	O	O	4348
and	CCONJ	O	O	4348
systemic	ADJ	O	O	4348
adverse	ADJ	O	O	4348
effects	NOUN	O	O	4348
of	ADP	O	O	4348
patients	NOUN	O	O	4348
taking	VERB	O	O	4348
hydroxychloroquine	NOUN	O	Chemical	4348
sulfate	NOUN	O	O	4348
who	PRON	O	O	4348
attended	VERB	O	O	4348
an	PRON	O	O	4348
ophthalmic	ADJ	O	O	4348
screening	VERB	O	O	4348
program	PROPN	O	O	4348
.	PUNCT	O	O	4348
RESULTS	VERB	O	O	4349
:	PUNCT	O	O	4349
Records	NOUN	O	O	4349
of	ADP	O	O	4349
262	NUM	O	O	4349
patients	NOUN	O	O	4349
who	PRON	O	O	4349
were	AUX	O	O	4349
taking	VERB	O	O	4349
hydroxychloroquine	NOUN	O	Chemical	4349
and	CCONJ	O	O	4349
screened	VERB	O	O	4349
in	ADP	O	O	4349
the	PRON	O	O	4349
Department	NOUN	O	O	4349
of	ADP	O	O	4349
Ophthalmology	NOUN	O	O	4349
were	AUX	O	O	4349
reviewed	VERB	O	O	4349
.	PUNCT	O	O	4349
Thirty	NUM	O	O	4350
-	PUNCT	O	O	4350
five	NUM	O	O	4350
patients	NOUN	O	O	4350
(	PUNCT	O	O	4350
13.4%	NOUN	O	O	4350
)	PUNCT	O	O	4350
had	VERB	O	O	4350
visual	ADJ	O	O	4350
field	NOUN	O	O	4350
abnormalities	NOUN	O	O	4350
,	PUNCT	O	O	4350
which	PRON	O	O	4350
were	AUX	O	O	4350
attributed	VERB	O	O	4350
to	PART	O	O	4350
hydroxychloroquine	NOUN	O	Chemical	4350
treatment	NOUN	O	O	4350
in	ADP	O	O	4350
4	NUM	O	O	4350
patients	NOUN	O	O	4350
(	PUNCT	O	O	4350
1.5%	NOUN	O	O	4350
)	PUNCT	O	O	4350
.	PUNCT	O	O	4350
The	PRON	O	O	4351
current	ADJ	O	O	4351
study	VERB	O	O	4351
used	VERB	O	O	4351
a	PRON	O	O	4351
protocol	PROPN	O	O	4351
of	ADP	O	O	4351
visual	ADJ	O	O	4351
acuity	NOUN	O	O	4351
and	CCONJ	O	O	4351
color	NOUN	O	O	4351
vision	PROPN	O	O	4351
assessment	NOUN	O	O	4351
,	PUNCT	O	O	4351
funduscopy	NOUN	O	O	4351
,	PUNCT	O	O	4351
and	CCONJ	O	O	4351
Humphrey	PROPN	O	O	4351
10	NUM	O	O	4351
-	PUNCT	O	O	4351
2	X	O	O	4351
visual	ADJ	O	O	4351
field	NOUN	O	O	4351
testing	NOUN	O	O	4351
and	CCONJ	O	O	4351
shows	VERB	O	O	4351
that	SCONJ	O	O	4351
visual	ADJ	O	O	4351
field	NOUN	O	O	4351
defects	NOUN	O	O	4351
appeared	VERB	O	O	4351
before	ADP	O	O	4351
any	PRON	O	O	4351
corresponding	VERB	O	O	4351
changes	VERB	O	O	4351
in	ADP	O	O	4351
any	PRON	O	O	4351
other	ADJ	O	O	4351
tested	VERB	O	O	4351
clinical	ADJ	O	O	4351
parameters	NOUN	O	O	4351
;	PUNCT	O	O	4351
the	PRON	O	O	4351
defects	NOUN	O	O	4351
were	AUX	O	O	4351
reproducible	ADJ	O	O	4351
and	CCONJ	O	O	4351
the	PRON	O	O	4351
test	NOUN	O	O	4351
parameters	NOUN	O	O	4351
were	AUX	O	O	4351
reliable	ADJ	O	O	4351
.	PUNCT	O	O	4351
Patients	NOUN	O	O	4352
taking	VERB	O	O	4352
hydroxychloroquine	NOUN	O	Chemical	4352
can	AUX	O	O	4352
demonstrate	VERB	O	O	4352
a	PRON	O	O	4352
toxic	ADJ	O	O	4352
reaction	NOUN	O	O	4352
in	ADP	O	O	4352
the	PRON	O	O	4352
retina	PROPN	O	O	4352
despite	SCONJ	O	O	4352
the	PRON	O	O	4352
absence	NOUN	O	O	4352
of	ADP	O	O	4352
known	VERB	O	O	4352
risk	NOUN	O	O	4352
factors	NOUN	O	O	4352
.	PUNCT	O	O	4352
Peri	PROPN	O	O	4355
-	PUNCT	O	O	4355
operative	NOUN	O	O	4355
atrioventricular block	NOUN	O	Disease	4355
as	ADP	O	O	4355
a	PRON	O	O	4355
result	VERB	O	O	4355
of	ADP	O	O	4355
chemotherapy	NOUN	O	O	4355
with	ADP	O	O	4355
epirubicin	VERB	O	O	4355
and	CCONJ	O	O	4355
paclitaxel	NOUN	O	Chemical	4355
.	PUNCT	O	O	4355
A	PRON	O	O	4356
47-year	NOUN	O	O	4356
-	PUNCT	O	O	4356
old	ADJ	O	O	4356
woman	NOUN	O	O	4356
presented	VERB	O	O	4356
for	ADP	O	O	4356
mastectomy	NOUN	O	O	4356
and	CCONJ	O	O	4356
immediate	ADJ	O	O	4356
latissimus	NOUN	O	O	4356
dorsi	NOUN	O	O	4356
flap	NOUN	O	O	4356
reconstruction	NOUN	O	O	4356
having	VERB	O	O	4356
been	AUX	O	O	4356
diagnosed	VERB	O	O	4356
with	ADP	O	O	4356
carcinoma	NOUN	O	Disease	4356
of	ADP	O	O	4356
the	PRON	O	O	4356
breast	NOUN	O	O	4356
6	NUM	O	O	4356
months	NOUN	O	O	4356
previously	ADV	O	O	4356
.	PUNCT	O	O	4356
In	ADP	O	O	4357
the	PRON	O	O	4357
preceding	VERB	O	O	4357
months	NOUN	O	O	4357
she	PRON	O	O	4357
had	VERB	O	O	4357
received	VERB	O	O	4357
neo	NOUN	O	O	4357
-	PUNCT	O	O	4357
adjuvant	NOUN	O	O	4357
chemotherapy	NOUN	O	O	4357
with	ADP	O	O	4357
epirubicin	VERB	O	O	4357
,	PUNCT	O	O	4357
paclitaxel	NOUN	O	Chemical	4357
(	PUNCT	O	O	4357
Taxol	PROPN	O	Chemical	4357
)	PUNCT	O	O	4357
and	CCONJ	O	O	4357
cyclophosphamide	VERB	O	Chemical	4357
.	PUNCT	O	O	4357
She	PRON	O	O	4358
was	AUX	O	O	4358
found	VERB	O	O	4358
to	PART	O	O	4358
be	AUX	O	O	4358
bradycardic	NOUN	O	O	4358
at	ADP	O	O	4358
pre	VERB	O	O	4358
-	PUNCT	O	O	4358
operative	NOUN	O	O	4358
assessment	NOUN	O	O	4358
but	CCONJ	O	O	4358
had	VERB	O	O	4358
no	PRON	O	O	4358
cardiac	ADJ	O	O	4358
symptoms	NOUN	O	O	4358
.	PUNCT	O	O	4358
Second	ADJ	O	O	4359
degree	PROPN	O	O	4359
Mobitz	PROPN	O	O	4359
type	NOUN	O	O	4359
II	NUM	O	O	4359
atrioventricular block	NOUN	O	Disease	4359
was	AUX	O	O	4359
diagnosed	VERB	O	O	4359
on	ADP	O	O	4359
electrocardiogram	PROPN	O	O	4359
,	PUNCT	O	O	4359
and	CCONJ	O	O	4359
temporary	ADJ	O	O	4359
transvenous	VERB	O	O	4359
ventricular	ADJ	O	O	4359
pacing	NOUN	O	O	4359
instituted	VERB	O	O	4359
in	ADP	O	O	4359
the	PRON	O	O	4359
peri	PROPN	O	O	4359
-	PUNCT	O	O	4359
operative	NOUN	O	O	4359
period	NOUN	O	O	4359
.	PUNCT	O	O	4359
We	PRON	O	O	4360
discuss	VERB	O	O	4360
how	SCONJ	O	O	4360
evidence	NOUN	O	O	4360
-	PUNCT	O	O	4360
based	VERB	O	O	4360
guidelines	NOUN	O	O	4360
would	AUX	O	O	4360
not	PART	O	O	4360
have	VERB	O	O	4360
been	AUX	O	O	4360
helpful	ADJ	O	O	4360
in	ADP	O	O	4360
this	PRON	O	O	4360
case	NOUN	O	O	4360
,	PUNCT	O	O	4360
and	CCONJ	O	O	4360
how	SCONJ	O	O	4360
chemotherapy	NOUN	O	O	4360
can	AUX	O	O	4360
exhibit	VERB	O	O	4360
substantial	ADJ	O	O	4360
cardiotoxicity	NOUN	O	Disease	4360
that	SCONJ	O	O	4360
may	AUX	O	O	4360
develop	VERB	O	O	4360
over	ADP	O	O	4360
many	ADJ	O	O	4360
years	NOUN	O	O	4360
.	PUNCT	O	O	4360
Risks	NOUN	O	O	4363
and	CCONJ	O	O	4363
benefits	NOUN	O	O	4363
of	ADP	O	O	4363
COX-2	ADJ	O	O	4363
inhibitors	NOUN	O	O	4363
vs	ADP	O	O	4363
non	ADJ	O	O	4363
-	PUNCT	O	O	4363
selective	ADJ	O	O	4363
NSAIDs	NOUN	O	Chemical	4363
:	PUNCT	O	O	4363
does	VERB	O	O	4363
their	PRON	O	O	4363
cardiovascular	ADJ	O	O	4363
risk	NOUN	O	O	4363
exceed	VERB	O	O	4363
their	PRON	O	O	4363
gastrointestinal	ADJ	O	O	4363
benefit	VERB	O	O	4363
?	PUNCT	O	O	4363
The	PRON	O	O	4364
risk	NOUN	O	O	4364
of	ADP	O	O	4364
acute	ADJ	O	O	4364
myocardial infarction	NOUN	O	Disease	4364
(	PUNCT	O	O	4364
AMI	PROPN	O	O	4364
)	PUNCT	O	O	4364
with	ADP	O	O	4364
COX-2	ADJ	O	O	4364
inhibitors	NOUN	O	O	4364
may	AUX	O	O	4364
offset	VERB	O	O	4364
their	PRON	O	O	4364
gastrointestinal	ADJ	O	O	4364
(	PUNCT	O	O	4364
GI	PROPN	O	O	4364
)	PUNCT	O	O	4364
benefit	VERB	O	O	4364
compared	VERB	O	O	4364
with	ADP	O	O	4364
non	ADJ	O	O	4364
-	PUNCT	O	O	4364
selective	ADJ	O	O	4364
(	PUNCT	O	O	4364
NS	PROPN	O	Disease	4364
)	PUNCT	O	O	4364
non	ADJ	O	O	4365
-	PUNCT	O	O	4365
steroidal	ADJ	O	O	4365
anti	ADJ	O	O	4365
-	PUNCT	O	O	4365
inflammatory	ADJ	O	O	4365
drugs	NOUN	O	O	4365
(	PUNCT	O	O	4365
NSAIDs	NOUN	O	Chemical	4365
)	PUNCT	O	O	4365
.	PUNCT	O	O	4365
We	PRON	O	O	4366
aimed	VERB	O	O	4366
to	PART	O	O	4366
compare	VERB	O	O	4366
the	PRON	O	O	4366
risks	NOUN	O	O	4366
of	ADP	O	O	4366
hospitalization	NOUN	O	O	4366
for	ADP	O	O	4366
AMI	PROPN	O	O	4366
and	CCONJ	O	O	4366
GI	PROPN	O	O	4366
bleeding	VERB	O	Disease	4366
among	ADP	O	O	4366
elderly	ADJ	O	O	4366
patients	NOUN	O	O	4366
using	VERB	O	O	4366
COX-2	ADJ	O	O	4366
inhibitors	NOUN	O	O	4366
,	PUNCT	O	O	4366
NS	PROPN	O	Disease	4366
-	PUNCT	O	O	4366
NSAIDs	NOUN	O	Chemical	4366
and	CCONJ	O	O	4366
acetaminophen	PROPN	O	Chemical	4366
.	PUNCT	O	O	4366
METHODS	NOUN	O	O	4367
:	PUNCT	O	O	4367
We	PRON	O	O	4367
conducted	VERB	O	O	4367
a	PRON	O	O	4367
retrospective	ADJ	O	O	4367
cohort	NOUN	O	O	4367
study	VERB	O	O	4367
using	VERB	O	O	4367
administrative	PROPN	O	O	4367
data	NOUN	O	O	4367
of	ADP	O	O	4367
patients	NOUN	O	O	4367
>	PUNCT	O	O	4367
or	CCONJ	O	O	4367
=	PUNCT	O	O	4367
65	NUM	O	O	4367
years	NOUN	O	O	4367
of	ADP	O	O	4367
age	NOUN	O	O	4367
who	PRON	O	O	4367
filled	VERB	O	O	4367
a	PRON	O	O	4367
prescription	NOUN	O	O	4367
for	ADP	O	O	4367
NSAID	PROPN	O	Chemical	4367
or	CCONJ	O	O	4367
acetaminophen	PROPN	O	Chemical	4367
during	ADP	O	O	4367
1999	NUM	O	O	4367
-	PUNCT	O	O	4367
2002	NUM	O	O	4367
.	PUNCT	O	O	4367
Person	NOUN	O	O	4368
-	PUNCT	O	O	4368
years	NOUN	O	O	4368
of	ADP	O	O	4368
exposure	NOUN	O	O	4368
among	ADP	O	O	4368
non	ADJ	O	O	4368
-	PUNCT	O	O	4368
users	NOUN	O	O	4368
of	ADP	O	O	4368
aspirin	NOUN	O	Chemical	4368
were	AUX	O	O	4368
:	PUNCT	O	O	4368
75,761	NUM	O	O	4368
to	PART	O	O	4368
acetaminophen	PROPN	O	Chemical	4368
,	PUNCT	O	O	4368
42,671	NUM	O	O	4368
to	PART	O	O	4368
rofecoxib	PROPN	O	O	4368
65,860	NUM	O	O	4368
to	PART	O	O	4368
celecoxib	PROPN	O	O	4368
,	PUNCT	O	O	4368
and	CCONJ	O	O	4368
37,495	NUM	O	O	4368
to	PART	O	O	4368
NS	PROPN	O	Disease	4368
-	PUNCT	O	O	4368
NSAIDs	NOUN	O	Chemical	4368
.	PUNCT	O	O	4368
Among	ADP	O	O	4369
users	NOUN	O	O	4369
of	ADP	O	O	4369
aspirin	NOUN	O	Chemical	4369
,	PUNCT	O	O	4369
they	PRON	O	O	4369
were	AUX	O	O	4369
:	PUNCT	O	O	4369
14,671	NUM	O	O	4369
to	PART	O	O	4369
rofecoxib	PROPN	O	O	4369
,	PUNCT	O	O	4369
22,875	NUM	O	O	4369
to	PART	O	O	4369
celecoxib	PROPN	O	O	4369
,	PUNCT	O	O	4369
9,832	NUM	O	O	4369
to	PART	O	O	4369
NS	PROPN	O	Disease	4369
-	PUNCT	O	O	4369
NSAIDs	NOUN	O	Chemical	4369
and	CCONJ	O	O	4369
38,048	NUM	O	O	4369
to	PART	O	O	4369
acetaminophen	PROPN	O	Chemical	4369
.	PUNCT	O	O	4369
Among	ADP	O	O	4370
non	ADJ	O	O	4370
-	PUNCT	O	O	4370
users	NOUN	O	O	4370
of	ADP	O	O	4370
aspirin	NOUN	O	Chemical	4370
,	PUNCT	O	O	4370
the	PRON	O	O	4370
adjusted	VERB	O	O	4370
hazard	NOUN	O	O	4370
ratios	VERB	O	O	4370
(	PUNCT	O	O	4370
95%	NOUN	O	O	4370
confidence	NOUN	O	O	4370
interval	NOUN	O	O	4370
)	PUNCT	O	O	4370
of	ADP	O	O	4370
hospitalization	NOUN	O	O	4370
for	ADP	O	O	4370
AMI	PROPN	O	O	4370
/	PUNCT	O	O	4370
GI	PROPN	O	O	4370
vs	ADP	O	O	4370
the	PRON	O	O	4370
acetaminophen	PROPN	O	Chemical	4370
(	PUNCT	O	O	4370
with	ADP	O	O	4370
no	PRON	O	O	4370
aspirin	NOUN	O	Chemical	4370
)	PUNCT	O	O	4370
group	NOUN	O	O	4371
were	AUX	O	O	4371
:	PUNCT	O	O	4371
rofecoxib	PROPN	O	O	4371
1.27	NUM	O	O	4371
(	PUNCT	O	O	4371
1.13	NUM	O	O	4371
,	PUNCT	O	O	4371
1.42	NUM	O	O	4371
)	PUNCT	O	O	4371
,	PUNCT	O	O	4371
celecoxib	PROPN	O	O	4371
0.93	NUM	O	O	4371
(	PUNCT	O	O	4371
0.83	NUM	O	O	4371
,	PUNCT	O	O	4371
1.03	NUM	O	O	4371
)	PUNCT	O	O	4371
,	PUNCT	O	O	4371
naproxen	PROPN	O	Chemical	4371
1.59	NUM	O	O	4371
(	PUNCT	O	O	4371
1.31	NUM	O	O	4371
,	PUNCT	O	O	4371
1.93	NUM	O	O	4371
)	PUNCT	O	O	4371
,	PUNCT	O	O	4371
diclofenac	PROPN	O	Chemical	4371
1.17	NUM	O	O	4371
(	PUNCT	O	O	4371
0.99	NUM	O	O	4371
,	PUNCT	O	O	4371
1.38	NUM	O	O	4371
)	PUNCT	O	O	4371
and	CCONJ	O	O	4371
ibuprofen	PROPN	O	Chemical	4371
1.05	NUM	O	O	4371
(	PUNCT	O	O	4371
0.74	NUM	O	O	4371
,	PUNCT	O	O	4371
1.51	NUM	O	O	4371
)	PUNCT	O	O	4371
.	PUNCT	O	O	4371
Among	ADP	O	O	4372
users	NOUN	O	O	4372
of	ADP	O	O	4372
aspirin	NOUN	O	Chemical	4372
,	PUNCT	O	O	4372
they	PRON	O	O	4372
were	AUX	O	O	4372
:	PUNCT	O	O	4372
rofecoxib	PROPN	O	O	4372
1.73	NUM	O	O	4372
(	PUNCT	O	O	4372
1.52	NUM	O	O	4372
,	PUNCT	O	O	4372
1.98	NUM	O	O	4372
)	PUNCT	O	O	4372
,	PUNCT	O	O	4372
celecoxib	PROPN	O	O	4372
1.34	NUM	O	O	4372
(	PUNCT	O	O	4372
1.19	NUM	O	O	4372
,	PUNCT	O	O	4372
1.52	NUM	O	O	4372
)	PUNCT	O	O	4372
,	PUNCT	O	O	4372
ibuprofen	PROPN	O	Chemical	4372
1.51	NUM	O	O	4372
(	PUNCT	O	O	4372
0.95	NUM	O	O	4372
,	PUNCT	O	O	4372
2.41	NUM	O	O	4372
)	PUNCT	O	O	4372
,	PUNCT	O	O	4372
diclofenac	PROPN	O	Chemical	4372
1.69	NUM	O	O	4372
(	PUNCT	O	O	4372
1.35	NUM	O	O	4372
,	PUNCT	O	O	4372
2.10	NUM	O	O	4372
)	PUNCT	O	O	4372
,	PUNCT	O	O	4372
naproxen	PROPN	O	Chemical	4372
1.35	NUM	O	O	4372
(	PUNCT	O	O	4372
0.97	NUM	O	O	4372
,	PUNCT	O	O	4372
1.88	NUM	O	O	4372
)	PUNCT	O	O	4372
and	CCONJ	O	O	4372
acetaminophen	PROPN	O	Chemical	4372
1.29	NUM	O	O	4372
(	PUNCT	O	O	4372
1.17	NUM	O	O	4372
,	PUNCT	O	O	4372
1.42	NUM	O	O	4372
)	PUNCT	O	O	4372
.	PUNCT	O	O	4372
Among	ADP	O	O	4373
non	ADJ	O	O	4373
-	PUNCT	O	O	4373
users	NOUN	O	O	4373
of	ADP	O	O	4373
aspirin	NOUN	O	Chemical	4373
,	PUNCT	O	O	4373
naproxen	PROPN	O	Chemical	4373
seemed	VERB	O	O	4373
to	PART	O	O	4373
carry	VERB	O	O	4373
the	PRON	O	O	4373
highest	ADJ	O	O	4373
risk	NOUN	O	O	4373
for	ADP	O	O	4373
AMI	PROPN	O	O	4373
/	PUNCT	O	O	4373
GI	PROPN	O	O	4373
bleeding	VERB	O	Disease	4373
.	PUNCT	O	O	4373
The	PRON	O	O	4374
AMI	PROPN	O	O	4374
/	PUNCT	O	O	4374
GI toxicity	NOUN	O	Disease	4374
of	ADP	O	O	4374
celecoxib	PROPN	O	O	4374
was	AUX	O	O	4374
similar	ADJ	O	O	4374
to	PART	O	O	4374
that	SCONJ	O	O	4374
of	ADP	O	O	4374
acetaminophen	PROPN	O	Chemical	4374
and	CCONJ	O	O	4374
seemed	VERB	O	O	4374
to	PART	O	O	4374
be	AUX	O	O	4374
better	ADV	O	O	4374
than	ADP	O	O	4374
those	PRON	O	O	4374
of	ADP	O	O	4374
rofecoxib	PROPN	O	O	4374
and	CCONJ	O	O	4374
NS	PROPN	O	Disease	4374
-	PUNCT	O	O	4374
NSAIDs	NOUN	O	Chemical	4374
.	PUNCT	O	O	4374
Among	ADP	O	O	4375
users	NOUN	O	O	4375
of	ADP	O	O	4375
aspirin	NOUN	O	Chemical	4375
,	PUNCT	O	O	4375
both	PRON	O	O	4375
celecoxib	PROPN	O	O	4375
and	CCONJ	O	O	4375
naproxen	PROPN	O	Chemical	4375
seemed	VERB	O	O	4375
to	PART	O	O	4375
be	AUX	O	O	4375
the	PRON	O	O	4375
least	ADJ	O	O	4375
toxic	ADJ	O	O	4375
.	PUNCT	O	O	4375
Quinine	NOUN	O	Chemical	4378
-	PUNCT	O	O	4378
induced	VERB	O	O	4378
arrhythmia	NOUN	O	Disease	4378
in	ADP	O	O	4378
a	PRON	O	O	4378
patient	NOUN	O	O	4378
with	ADP	O	O	4378
severe	ADJ	O	O	4378
malaria	NOUN	O	O	4378
.	PUNCT	O	O	4378
It	PRON	O	O	4379
was	AUX	O	O	4379
reported	VERB	O	O	4379
that	SCONJ	O	O	4379
there	ADV	O	O	4379
was	AUX	O	O	4379
a	PRON	O	O	4379
case	NOUN	O	O	4379
of	ADP	O	O	4379
severe	ADJ	O	O	4379
malaria	NOUN	O	O	4379
patient	NOUN	O	O	4379
with	ADP	O	O	4379
jaundice	NOUN	O	Disease	4379
who	PRON	O	O	4379
presented	VERB	O	O	4379
with	ADP	O	O	4379
arrhythmia	NOUN	O	Disease	4379
(	PUNCT	O	O	4379
premature	ADJ	O	O	4379
ventricular	ADJ	O	O	4379
contraction	NOUN	O	O	4379
)	PUNCT	O	O	4379
while	SCONJ	O	O	4379
getting	VERB	O	O	4379
quinine	NOUN	O	Chemical	4379
infusion	NOUN	O	O	4379
was	AUX	O	O	4379
reported	VERB	O	O	4379
.	PUNCT	O	O	4379
A	PRON	O	O	4380
man	NOUN	O	O	4380
,	PUNCT	O	O	4380
25	NUM	O	O	4380
years	NOUN	O	O	4380
old	ADJ	O	O	4380
,	PUNCT	O	O	4380
was	AUX	O	O	4380
admitted	VERB	O	O	4380
to	PART	O	O	4380
hospital	PROPN	O	O	4380
with	ADP	O	O	4380
high	ADJ	O	O	4380
fever	NOUN	O	Disease	4380
,	PUNCT	O	O	4380
chill	VERB	O	O	4380
,	PUNCT	O	O	4380
vomiting	VERB	O	Disease	4380
,	PUNCT	O	O	4380
jaundice	NOUN	O	Disease	4380
.	PUNCT	O	O	4380
On	ADP	O	O	4381
admission	NOUN	O	O	4381
,	PUNCT	O	O	4381
laboratory	NOUN	O	O	4381
examination	NOUN	O	O	4381
showed	VERB	O	O	4381
Plasmodium	NOUN	O	O	4381
falciparum	NOUN	O	O	4381
(	PUNCT	O	O	4381
+	ADP	O	O	4381
+	ADP	O	O	4381
+	ADP	O	O	4381
+	ADP	O	O	4381
)	PUNCT	O	O	4381
,	PUNCT	O	O	4381
total	ADJ	O	O	4381
bilirubin	ADJ	O	Chemical	4381
8.25	NUM	O	O	4381
mg	VERB	O	O	4381
/	PUNCT	O	O	4381
dL	VERB	O	O	4381
,	PUNCT	O	O	4381
conjugated	VERB	O	O	4381
bilirubin	ADJ	O	Chemical	4382
4.36	NUM	O	O	4382
mg	VERB	O	O	4382
/	PUNCT	O	O	4382
dL	VERB	O	O	4382
,	PUNCT	O	O	4382
unconjugated	ADJ	O	O	4382
bilirubin	ADJ	O	Chemical	4382
3.89	NUM	O	O	4382
mg	VERB	O	O	4382
/	PUNCT	O	O	4382
dL	VERB	O	O	4382
,	PUNCT	O	O	4382
potassium	NOUN	O	Chemical	4382
3.52	NUM	O	O	4383
meq	NOUN	O	O	4383
/	PUNCT	O	O	4383
L	NOUN	O	O	4383
Patient	NOUN	O	O	4383
was	AUX	O	O	4383
diagnosed	VERB	O	O	4383
as	ADP	O	O	4383
severe	ADJ	O	O	4383
malaria	NOUN	O	O	4383
with	ADP	O	O	4383
jaundice	NOUN	O	Disease	4383
and	CCONJ	O	O	4383
got	VERB	O	O	4383
quinine	NOUN	O	Chemical	4383
infusion	NOUN	O	O	4383
in	ADP	O	O	4383
dextrose	ADJ	O	Chemical	4383
5%	NOUN	O	O	4383
500	NUM	O	O	4383
mg/8	NOUN	O	O	4383
hour	NOUN	O	O	4383
.	PUNCT	O	O	4383
On	ADP	O	O	4384
the	PRON	O	O	4384
second	ADV	O	O	4384
day	NOUN	O	O	4384
the	PRON	O	O	4384
patient	NOUN	O	O	4384
had	VERB	O	O	4384
vomitus	NOUN	O	O	4384
,	PUNCT	O	O	4384
diarrhea	PROPN	O	Disease	4384
,	PUNCT	O	O	4384
tinnitus	PROPN	O	O	4384
,	PUNCT	O	O	4384
loss	NOUN	O	O	4384
of	ADP	O	O	4384
hearing	NOUN	O	O	4384
.	PUNCT	O	O	4384
After	ADP	O	O	4385
30	NUM	O	O	4385
hours	NOUN	O	O	4385
of	ADP	O	O	4385
quinine	NOUN	O	Chemical	4385
infusion	NOUN	O	O	4385
the	PRON	O	O	4385
patient	NOUN	O	O	4385
felt	VERB	O	O	4385
palpitation	NOUN	O	O	4385
and	CCONJ	O	O	4385
electrocardiography	NOUN	O	O	4385
(	PUNCT	O	O	4385
ECG	PROPN	O	O	4385
)	PUNCT	O	O	4385
recording	NOUN	O	O	4385
showed	VERB	O	O	4385
premature	ADJ	O	O	4385
ventricular	ADJ	O	O	4385
contraction	NOUN	O	O	4385
(	PUNCT	O	O	4385
PVC	NOUN	O	O	4385
)	PUNCT	O	O	4385
>	PUNCT	O	O	4386
5	NUM	O	O	4386
x	X	O	O	4386
/	PUNCT	O	O	4386
minute	VERB	O	O	4386
,	PUNCT	O	O	4386
trigemini	NOUN	O	O	4386
,	PUNCT	O	O	4386
constant	ADJ	O	O	4386
type	NOUN	O	O	4386
--	PUNCT	O	O	4386
sinoatrial	NOUN	O	O	4386
block	NOUN	O	O	4386
,	PUNCT	O	O	4386
positive	ADJ	O	O	4386
U	NOUN	O	O	4386
wave	NOUN	O	O	4386
.	PUNCT	O	O	4386
He	PRON	O	O	4387
was	AUX	O	O	4387
treated	VERB	O	O	4387
with	ADP	O	O	4387
lidocaine	NOUN	O	Chemical	4387
50	NUM	O	O	4387
mg	VERB	O	O	4387
intravenously	ADV	O	O	4387
followed	VERB	O	O	4387
by	ADP	O	O	4387
infusion	NOUN	O	O	4387
1500	NUM	O	O	4387
mg	VERB	O	O	4387
in	ADP	O	O	4387
dextrose	ADJ	O	Chemical	4387
5%/24	NUM	O	O	4387
hour	NOUN	O	O	4387
and	CCONJ	O	O	4387
potassium	NOUN	O	Chemical	4387
aspartate	NOUN	O	Chemical	4387
tablet	PROPN	O	O	4387
.	PUNCT	O	O	4387
Quinine	NOUN	O	Chemical	4388
infusion	NOUN	O	O	4388
was	AUX	O	O	4388
discontinued	VERB	O	O	4388
and	CCONJ	O	O	4388
changed	VERB	O	O	4388
with	ADP	O	O	4388
sulfate	NOUN	O	O	4388
quinine	NOUN	O	Chemical	4388
tablets	NOUN	O	O	4388
.	PUNCT	O	O	4388
Three	NUM	O	O	4389
hours	NOUN	O	O	4389
later	ADV	O	O	4389
the	PRON	O	O	4389
patient	NOUN	O	O	4389
felt	VERB	O	O	4389
better	ADV	O	O	4389
,	PUNCT	O	O	4389
the	PRON	O	O	4389
frequency	NOUN	O	O	4389
of	ADP	O	O	4389
PVC	NOUN	O	O	4389
reduced	VERB	O	O	4389
to	PART	O	O	4389
4	NUM	O	O	4389
-	PUNCT	O	O	4389
5	NUM	O	O	4389
x	X	O	O	4389
/	PUNCT	O	O	4389
minute	VERB	O	O	4389
and	CCONJ	O	O	4389
on	ADP	O	O	4389
the	PRON	O	O	4389
third	ADV	O	O	4389
day	NOUN	O	O	4389
ECG	PROPN	O	O	4389
was	AUX	O	O	4389
normal	ADJ	O	O	4389
,	PUNCT	O	O	4389
potassium	NOUN	O	Chemical	4389
level	VERB	O	O	4389
was	AUX	O	O	4389
3.34	NUM	O	O	4389
meq	NOUN	O	O	4389
/	PUNCT	O	O	4389
L.	PROPN	O	O	4389
Quinine	NOUN	O	Chemical	4390
,	PUNCT	O	O	4390
like	INTJ	O	O	4390
quinidine	PROPN	O	Chemical	4390
,	PUNCT	O	O	4390
is	AUX	O	O	4390
a	PRON	O	O	4390
chincona	PROPN	O	O	4390
alkaloid	NOUN	O	O	4390
that	SCONJ	O	O	4390
has	VERB	O	O	4390
anti	ADJ	O	O	4390
-	PUNCT	O	O	4390
arrhythmic	ADJ	O	Disease	4390
property	NOUN	O	O	4390
,	PUNCT	O	O	4390
although	SCONJ	O	O	4390
it	PRON	O	O	4390
also	ADV	O	O	4390
pro	ADJ	O	O	4390
-	PUNCT	O	O	4390
arrhythmic	ADJ	O	Disease	4390
that	SCONJ	O	O	4390
can	AUX	O	O	4390
cause	VERB	O	O	4390
various	ADJ	O	O	4390
arrhythmias	VERB	O	Disease	4390
,	PUNCT	O	O	4390
including	VERB	O	O	4390
severe	ADJ	O	O	4390
arrhythmia	NOUN	O	Disease	4390
such	ADJ	O	O	4390
as	ADP	O	O	4390
multiple	ADJ	O	O	4390
PVC	NOUN	O	O	4390
.	PUNCT	O	O	4390
Administration	NOUN	O	O	4391
of	ADP	O	O	4391
parenteral	ADJ	O	O	4391
quinine	NOUN	O	Chemical	4391
must	AUX	O	O	4391
be	AUX	O	O	4391
done	VERB	O	O	4391
carefully	ADV	O	O	4391
and	CCONJ	O	O	4391
with	ADP	O	O	4391
good	ADJ	O	O	4391
observation	NOUN	O	O	4391
because	SCONJ	O	O	4391
of	ADP	O	O	4391
its	PRON	O	O	4391
pro	ADJ	O	O	4391
-	PUNCT	O	O	4391
arrhythmic	ADJ	O	Disease	4391
effect	VERB	O	O	4391
,	PUNCT	O	O	4391
especially	ADV	O	O	4391
in	ADP	O	O	4391
older	ADJ	O	O	4391
patients	NOUN	O	O	4391
who	PRON	O	O	4391
have	VERB	O	O	4391
heart diseases	NOUN	O	O	4391
or	CCONJ	O	O	4391
patients	NOUN	O	O	4391
with	ADP	O	O	4391
electrolyte	NOUN	O	O	4391
disorder	NOUN	O	O	4391
(	PUNCT	O	O	4391
hypokalemia	PROPN	O	Disease	4391
)	PUNCT	O	O	4391
which	PRON	O	O	4391
frequently	ADV	O	O	4391
occurs	VERB	O	O	4391
due	ADJ	O	O	4391
to	PART	O	O	4391
vomiting	VERB	O	Disease	4391
and	CCONJ	O	O	4391
or	CCONJ	O	O	4391
diarrhea	PROPN	O	Disease	4391
in	ADP	O	O	4391
malaria	NOUN	O	O	4391
cases	NOUN	O	O	4391
.	PUNCT	O	O	4391
Penicillamine	NOUN	O	Chemical	4394
-	PUNCT	O	O	4394
related	ADJ	O	O	4394
lichenoid	PROPN	O	O	4394
dermatitis	NOUN	O	Disease	4394
and	CCONJ	O	O	4394
utility	NOUN	O	O	4394
of	ADP	O	O	4394
zinc	PROPN	O	Chemical	4394
acetate	NOUN	O	O	4394
in	ADP	O	O	4394
a	PRON	O	O	4394
Wilson	PROPN	O	O	4394
disease	PROPN	O	O	4394
patient	NOUN	O	O	4394
with	ADP	O	O	4394
hepatic	ADJ	O	O	4394
presentation	NOUN	O	O	4394
,	PUNCT	O	O	4394
anxiety	NOUN	O	Disease	4394
and	CCONJ	O	O	4394
SPECT	PROPN	O	O	4394
abnormalities	NOUN	O	O	4394
.	PUNCT	O	O	4394
Wilson	PROPN	O	O	4395
's	AUX	O	O	4395
disease	PROPN	O	O	4395
is	AUX	O	O	4395
an	PRON	O	O	4395
autosomal	ADJ	O	O	4395
recessive	ADJ	O	O	4395
disorder	NOUN	O	O	4395
of	ADP	O	O	4395
hepatic	ADJ	O	O	4395
copper	NOUN	O	O	4395
metabolism	NOUN	O	O	4395
with	ADP	O	O	4395
consequent	NOUN	O	O	4395
copper	NOUN	O	O	4395
accumulation	NOUN	O	O	4395
and	CCONJ	O	O	4395
toxicity	NOUN	O	Disease	4395
in	ADP	O	O	4395
many	ADJ	O	O	4395
tissues	NOUN	O	O	4395
and	CCONJ	O	O	4395
consequent	NOUN	O	O	4395
hepatic	ADJ	O	O	4395
,	PUNCT	O	O	4395
neurologic	ADJ	O	O	4395
and	CCONJ	O	O	4395
psychiatric disorders	NOUN	O	Disease	4395
.	PUNCT	O	O	4395
We	PRON	O	O	4396
report	VERB	O	O	4396
a	PRON	O	O	4396
case	NOUN	O	O	4396
of	ADP	O	O	4396
Wilson	PROPN	O	O	4396
's	AUX	O	O	4396
disease	PROPN	O	O	4396
with	ADP	O	O	4396
chronic	ADJ	O	O	4396
liver disease	NOUN	O	Disease	4396
;	PUNCT	O	O	4396
moreover	ADV	O	O	4396
,	PUNCT	O	O	4396
in	ADP	O	O	4396
our	PRON	O	O	4396
patient	NOUN	O	O	4396
,	PUNCT	O	O	4396
presenting	VERB	O	O	4396
also	ADV	O	O	4396
with	ADP	O	O	4396
high	ADJ	O	O	4396
levels	NOUN	O	O	4396
of	ADP	O	O	4396
state	NOUN	O	O	4396
anxiety	NOUN	O	Disease	4396
without	ADP	O	O	4396
depression	PROPN	O	Disease	4396
,	PUNCT	O	O	4396
99mTc	NUM	O	O	4396
-	PUNCT	O	O	4396
ECD	PROPN	O	O	4396
-	PUNCT	O	O	4396
SPECT	PROPN	O	O	4396
showed	VERB	O	O	4396
cortical	ADJ	O	O	4396
hypoperfusion	NOUN	O	O	4396
in	ADP	O	O	4396
frontal	ADJ	O	O	4396
lobes	NOUN	O	O	4396
,	PUNCT	O	O	4396
more	ADJ	O	O	4396
marked	VERB	O	O	4396
on	ADP	O	O	4396
the	PRON	O	O	4396
left	VERB	O	O	4396
frontal	ADJ	O	O	4396
lobe	NOUN	O	O	4396
.	PUNCT	O	O	4396
During	ADP	O	O	4397
the	PRON	O	O	4397
follow	VERB	O	O	4397
-	PUNCT	O	O	4397
up	ADP	O	O	4397
of	ADP	O	O	4397
our	PRON	O	O	4397
patient	NOUN	O	O	4397
,	PUNCT	O	O	4397
penicillamine	NOUN	O	Chemical	4397
was	AUX	O	O	4397
interrupted	VERB	O	O	4397
after	ADP	O	O	4397
the	PRON	O	O	4397
appearance	NOUN	O	O	4397
of	ADP	O	O	4397
a	PRON	O	O	4397
lichenoid	PROPN	O	O	4397
dermatitis	NOUN	O	Disease	4397
,	PUNCT	O	O	4397
and	CCONJ	O	O	4397
zinc	PROPN	O	Chemical	4397
acetate	NOUN	O	O	4397
permitted	VERB	O	O	4397
to	PART	O	O	4397
continue	VERB	O	O	4397
the	PRON	O	O	4397
successful	ADJ	O	O	4397
treatment	NOUN	O	O	4397
of	ADP	O	O	4397
the	PRON	O	O	4397
patient	NOUN	O	O	4397
without	ADP	O	O	4397
side	NOUN	O	O	4397
-	PUNCT	O	O	4397
effects	NOUN	O	O	4397
.	PUNCT	O	O	4397
In	ADP	O	O	4398
our	PRON	O	O	4398
case	NOUN	O	O	4398
the	PRON	O	O	4398
therapy	NOUN	O	O	4398
with	ADP	O	O	4398
zinc	PROPN	O	Chemical	4398
acetate	NOUN	O	O	4398
represented	VERB	O	O	4398
an	PRON	O	O	4398
effective	ADJ	O	O	4398
treatment	NOUN	O	O	4398
for	ADP	O	O	4398
a	PRON	O	O	4398
Wilson	PROPN	O	O	4398
's	AUX	O	O	4398
disease	PROPN	O	O	4398
patient	NOUN	O	O	4398
in	ADP	O	O	4398
which	PRON	O	O	4398
penicillamine	NOUN	O	Chemical	4398
-	PUNCT	O	O	4398
related	ADJ	O	O	4398
side	NOUN	O	O	4398
effects	NOUN	O	O	4398
appeared	VERB	O	O	4398
.	PUNCT	O	O	4398
The	PRON	O	O	4399
safety	NOUN	O	O	4399
of	ADP	O	O	4399
the	PRON	O	O	4399
zinc	PROPN	O	Chemical	4399
acetate	NOUN	O	O	4399
allowed	VERB	O	O	4399
us	PRON	O	O	4399
to	PART	O	O	4399
avoid	VERB	O	O	4399
other	ADJ	O	O	4399
potentially	ADV	O	O	4399
toxic	ADJ	O	O	4399
chelating	VERB	O	O	4399
drugs	NOUN	O	O	4399
;	PUNCT	O	O	4399
this	PRON	O	O	4399
observation	NOUN	O	O	4399
is	AUX	O	O	4399
in	ADP	O	O	4399
line	NOUN	O	O	4399
with	ADP	O	O	4399
the	PRON	O	O	4399
growing	VERB	O	O	4399
evidence	NOUN	O	O	4399
on	ADP	O	O	4399
the	PRON	O	O	4399
efficacy	NOUN	O	O	4399
of	ADP	O	O	4399
the	PRON	O	O	4399
drug	NOUN	O	O	4399
in	ADP	O	O	4399
the	PRON	O	O	4399
treatment	NOUN	O	O	4399
of	ADP	O	O	4399
Wilson	PROPN	O	O	4399
's	AUX	O	O	4399
disease	PROPN	O	O	4399
.	PUNCT	O	O	4399
Since	SCONJ	O	O	4400
most	ADV	O	O	4400
of	ADP	O	O	4400
Wilson	PROPN	O	O	4400
's	AUX	O	O	4400
disease	PROPN	O	O	4400
penicillamine	NOUN	O	Chemical	4400
-	PUNCT	O	O	4400
treated	VERB	O	O	4400
patients	NOUN	O	O	4400
do	VERB	O	O	4400
not	PART	O	O	4400
seem	VERB	O	O	4400
to	PART	O	O	4400
develop	VERB	O	O	4400
this	PRON	O	O	4400
skin lesion	NOUN	O	Disease	4400
,	PUNCT	O	O	4400
it	PRON	O	O	4400
could	AUX	O	O	4400
be	AUX	O	O	4400
conceivable	ADJ	O	O	4400
that	SCONJ	O	O	4400
a	PRON	O	O	4400
specific	ADJ	O	O	4400
genetic	ADJ	O	O	4400
factor	NOUN	O	O	4400
is	AUX	O	O	4400
involved	VERB	O	O	4400
in	ADP	O	O	4400
drug	NOUN	O	O	4400
response	NOUN	O	O	4400
.	PUNCT	O	O	4400
Further	ADV	O	O	4401
studies	NOUN	O	O	4401
are	AUX	O	O	4401
needed	VERB	O	O	4401
for	ADP	O	O	4401
a	PRON	O	O	4401
better	ADV	O	O	4401
clarification	NOUN	O	O	4401
of	ADP	O	O	4401
Wilson	PROPN	O	O	4401
's	AUX	O	O	4401
disease	PROPN	O	O	4401
therapy	NOUN	O	O	4401
,	PUNCT	O	O	4401
and	CCONJ	O	O	4401
in	ADP	O	O	4401
particular	ADJ	O	O	4401
to	PART	O	O	4401
differentiate	VERB	O	O	4401
specific	ADJ	O	O	4401
therapies	NOUN	O	O	4401
for	ADP	O	O	4401
different	ADJ	O	O	4401
Wilson	PROPN	O	O	4401
's	AUX	O	O	4401
disease	PROPN	O	O	4401
phenotypes	NOUN	O	O	4401
.	PUNCT	O	O	4401
A	PRON	O	O	4404
dramatic	ADJ	O	O	4404
drop	VERB	O	O	4404
in	ADP	O	O	4404
blood	NOUN	O	O	4404
pressure	NOUN	O	O	4404
following	VERB	O	O	4404
prehospital	PROPN	O	O	4404
GTN	NOUN	O	Chemical	4404
administration	NOUN	O	O	4404
.	PUNCT	O	O	4404
A	PRON	O	O	4405
male	NOUN	O	O	4405
in	ADP	O	O	4405
his	PRON	O	O	4405
sixties	NOUN	O	O	4405
with	ADP	O	O	4405
no	PRON	O	O	4405
history	NOUN	O	O	4405
of	ADP	O	O	4405
cardiac	ADJ	O	O	4405
chest pain	NOUN	O	Disease	4405
awoke	VERB	O	O	4405
with	ADP	O	O	4405
chest pain	NOUN	O	Disease	4405
following	VERB	O	O	4405
an	PRON	O	O	4405
afternoon	NOUN	O	O	4405
sleep	VERB	O	O	4405
.	PUNCT	O	O	4405
The	PRON	O	O	4406
patient	NOUN	O	O	4406
's	AUX	O	O	4406
observations	NOUN	O	O	4406
were	AUX	O	O	4406
within	ADP	O	O	4406
normal	ADJ	O	O	4406
limits	NOUN	O	O	4406
,	PUNCT	O	O	4406
he	PRON	O	O	4406
was	AUX	O	O	4406
administered	VERB	O	O	4406
oxygen	NOUN	O	Chemical	4406
via	ADP	O	O	4406
a	PRON	O	O	4406
face	NOUN	O	O	4406
mask	VERB	O	O	4406
and	CCONJ	O	O	4406
glyceryl trinitrate	PROPN	O	Chemical	4406
(	PUNCT	O	O	4406
GTN	NOUN	O	Chemical	4406
)	PUNCT	O	O	4406
.	PUNCT	O	O	4406
Several	ADJ	O	O	4407
minutes	NOUN	O	O	4407
after	ADP	O	O	4407
the	PRON	O	O	4407
GTN	NOUN	O	Chemical	4407
the	PRON	O	O	4407
patient	NOUN	O	O	4407
experienced	ADJ	O	O	4407
a	PRON	O	O	4407
sudden	ADJ	O	O	4407
drop	VERB	O	O	4407
in	ADP	O	O	4407
blood	NOUN	O	O	4407
pressure	NOUN	O	O	4407
and	CCONJ	O	O	4407
heart	NOUN	O	O	4407
rate	NOUN	O	O	4407
,	PUNCT	O	O	4407
this	PRON	O	O	4407
was	AUX	O	O	4407
rectified	VERB	O	O	4407
by	ADP	O	O	4407
atropine	NOUN	O	Chemical	4407
sulphate	NOUN	O	O	4407
and	CCONJ	O	O	4407
a	PRON	O	O	4407
fluid	NOUN	O	O	4407
challenge	NOUN	O	O	4407
.	PUNCT	O	O	4407
Prehospital	PROPN	O	O	4408
care	VERB	O	O	4408
providers	NOUN	O	O	4408
who	PRON	O	O	4408
are	AUX	O	O	4408
managing	VERB	O	O	4408
any	PRON	O	O	4408
patient	NOUN	O	O	4408
with	ADP	O	O	4408
a	PRON	O	O	4408
syncopal	ADJ	O	O	4408
episode	PROPN	O	O	4408
that	SCONJ	O	O	4408
fails	VERB	O	O	4408
to	PART	O	O	4408
recover	VERB	O	O	4408
within	ADP	O	O	4408
a	PRON	O	O	4408
reasonable	ADJ	O	O	4408
time	NOUN	O	O	4408
frame	PROPN	O	O	4408
should	AUX	O	O	4408
consider	VERB	O	O	4408
the	PRON	O	O	4408
Bezold	PROPN	O	O	4408
-	PUNCT	O	O	4408
Jarisch	PROPN	O	O	4408
reflex	NOUN	O	O	4408
as	ADP	O	O	4408
the	PRON	O	O	4408
cause	VERB	O	O	4408
and	CCONJ	O	O	4408
manage	VERB	O	O	4408
the	PRON	O	O	4408
patient	NOUN	O	O	4408
accordingly	ADV	O	O	4408
.	PUNCT	O	O	4408
Acute	PROPN	O	O	4411
encephalopathy	NOUN	O	Disease	4411
and	CCONJ	O	O	4411
cerebral	ADJ	O	O	4411
vasospasm	NOUN	O	Disease	4411
after	ADP	O	O	4411
multiagent	ADJ	O	O	4411
chemotherapy	NOUN	O	O	4411
including	VERB	O	O	4411
PEG	NOUN	O	O	4411
-	PUNCT	O	O	4411
asparaginase	PROPN	O	O	4411
and	CCONJ	O	O	4411
intrathecal	ADJ	O	O	4411
cytarabine	NOUN	O	O	4411
for	ADP	O	O	4411
the	PRON	O	O	4411
treatment	NOUN	O	O	4411
of	ADP	O	O	4411
acute	ADJ	O	O	4411
lymphoblastic	NOUN	O	O	4411
leukemia	NOUN	O	Disease	4411
.	PUNCT	O	O	4411
A	PRON	O	O	4412
7-year	NOUN	O	O	4412
-	PUNCT	O	O	4412
old	ADJ	O	O	4412
girl	NOUN	O	O	4412
with	ADP	O	O	4412
an	PRON	O	O	4412
unusual	ADJ	O	O	4412
reaction	NOUN	O	O	4412
to	PART	O	O	4412
induction	NOUN	O	O	4412
chemotherapy	NOUN	O	O	4412
for	ADP	O	O	4412
precursor	NOUN	O	O	4412
B	NOUN	O	O	4412
-	PUNCT	O	O	4412
cell	NOUN	O	O	4412
acute	ADJ	O	O	4412
lymphoblastic	NOUN	O	O	4412
leukemia	NOUN	O	Disease	4412
(	PUNCT	O	O	4412
ALL	PRON	O	O	4412
)	PUNCT	O	O	4412
is	AUX	O	O	4412
described	VERB	O	O	4412
.	PUNCT	O	O	4412
The	PRON	O	O	4413
patient	NOUN	O	O	4413
developed	VERB	O	O	4413
acute	ADJ	O	O	4413
encephalopathy	NOUN	O	Disease	4413
evidenced	VERB	O	O	4413
by	ADP	O	O	4413
behavioral	ADJ	O	O	4413
changes	VERB	O	O	4413
,	PUNCT	O	O	4413
aphasia	NOUN	O	O	4413
,	PUNCT	O	O	4413
incontinence	NOUN	O	O	4413
,	PUNCT	O	O	4413
visual hallucinations	NOUN	O	Disease	4413
,	PUNCT	O	O	4413
and	CCONJ	O	O	4413
right	ADV	O	O	4413
-	PUNCT	O	O	4413
sided	VERB	O	O	4413
weakness	NOUN	O	Disease	4413
with	ADP	O	O	4413
diffuse	VERB	O	O	4413
cerebral	ADJ	O	O	4413
vasospasm	NOUN	O	Disease	4413
on	ADP	O	O	4413
magnetic	ADJ	O	O	4413
resonance	NOUN	O	O	4413
angiography	NOUN	O	O	4413
after	ADP	O	O	4413
the	PRON	O	O	4413
administration	NOUN	O	O	4413
of	ADP	O	O	4413
intrathecal	ADJ	O	O	4413
cytarabine	NOUN	O	O	4413
.	PUNCT	O	O	4413
Vincristine	NOUN	O	O	4414
,	PUNCT	O	O	4414
dexamethasone	NOUN	O	Chemical	4414
,	PUNCT	O	O	4414
and	CCONJ	O	O	4414
polyethylene	NOUN	O	O	4414
glycol	NOUN	O	O	4414
-	PUNCT	O	O	4414
asparaginase	PROPN	O	O	4414
were	AUX	O	O	4414
also	ADV	O	O	4414
administered	VERB	O	O	4414
before	ADP	O	O	4414
the	PRON	O	O	4414
episode	PROPN	O	O	4414
as	ADP	O	O	4414
part	NOUN	O	O	4414
of	ADP	O	O	4414
induction	NOUN	O	O	4414
therapy	NOUN	O	O	4414
.	PUNCT	O	O	4414
Comparison	NOUN	O	O	4417
of	ADP	O	O	4417
valsartan	PROPN	O	Chemical	4417
/	PUNCT	O	O	4417
hydrochlorothiazide	ADV	O	Chemical	4417
combination	NOUN	O	O	4417
therapy	NOUN	O	O	4417
at	ADP	O	O	4417
doses	NOUN	O	O	4417
up	ADP	O	O	4417
to	PART	O	O	4417
320/25	PROPN	O	O	4417
mg	VERB	O	O	4417
versus	ADP	O	O	4417
monotherapy	X	O	O	4417
:	PUNCT	O	O	4417
a	PRON	O	O	4417
double	ADJ	O	O	4417
-	PUNCT	O	O	4417
blind	ADJ	O	Disease	4417
,	PUNCT	O	O	4417
placebo	NOUN	O	O	4417
-	PUNCT	O	O	4417
controlled	VERB	O	O	4417
study	VERB	O	O	4417
followed	VERB	O	O	4417
by	ADP	O	O	4417
long	ADV	O	O	4417
-	PUNCT	O	O	4417
term	NOUN	O	O	4417
combination	NOUN	O	O	4417
therapy	NOUN	O	O	4417
in	ADP	O	O	4417
hypertensive	ADJ	O	Disease	4417
adults	NOUN	O	O	4417
.	PUNCT	O	O	4417
One	NUM	O	O	4418
third	ADV	O	O	4418
of	ADP	O	O	4418
patients	NOUN	O	O	4418
treated	VERB	O	O	4418
for	ADP	O	O	4418
hypertension	NOUN	O	Disease	4418
attain	VERB	O	O	4418
adequate	ADJ	O	O	4418
blood	NOUN	O	O	4418
pressure	NOUN	O	O	4418
(	PUNCT	O	O	4418
BP	PROPN	O	O	4418
)	PUNCT	O	O	4418
control	VERB	O	O	4418
,	PUNCT	O	O	4418
and	CCONJ	O	O	4418
multidrug	NOUN	O	O	4418
regimens	NOUN	O	O	4418
are	AUX	O	O	4418
often	ADV	O	O	4418
required	VERB	O	O	4418
.	PUNCT	O	O	4418
Given	VERB	O	O	4419
the	PRON	O	O	4419
lifelong	ADJ	O	O	4419
nature	NOUN	O	O	4419
of	ADP	O	O	4419
hypertension	NOUN	O	Disease	4419
,	PUNCT	O	O	4419
there	ADV	O	O	4419
is	AUX	O	O	4419
a	PRON	O	O	4419
need	VERB	O	O	4419
to	PART	O	O	4419
evaluate	VERB	O	O	4419
the	PRON	O	O	4419
long	ADV	O	O	4419
-	PUNCT	O	O	4419
term	NOUN	O	O	4419
efficacy	NOUN	O	O	4419
and	CCONJ	O	O	4419
tolerability	NOUN	O	O	4419
of	ADP	O	O	4419
higher	ADJ	O	O	4419
doses	NOUN	O	O	4419
of	ADP	O	O	4419
combination	NOUN	O	O	4419
anti	ADJ	O	O	4419
-	PUNCT	O	O	4419
hypertensive	ADJ	O	Disease	4419
therapies	NOUN	O	O	4419
.	PUNCT	O	O	4419
This	PRON	O	O	4420
study	VERB	O	O	4420
investigated	VERB	O	O	4420
the	PRON	O	O	4420
efficacy	NOUN	O	O	4420
and	CCONJ	O	O	4420
tolerability	NOUN	O	O	4420
of	ADP	O	O	4420
valsartan	PROPN	O	Chemical	4420
(	PUNCT	O	O	4420
VAL	PROPN	O	O	4420
)	PUNCT	O	O	4420
or	CCONJ	O	O	4420
hydrochlorothiazide	ADV	O	Chemical	4420
(	PUNCT	O	O	4420
HCTZ)-monotherapy	NOUN	O	O	4420
and	CCONJ	O	O	4420
higher	ADJ	O	O	4420
-	PUNCT	O	O	4420
dose	NOUN	O	O	4420
combinations	NOUN	O	O	4420
in	ADP	O	O	4420
patients	NOUN	O	O	4420
with	ADP	O	O	4420
essential	ADJ	O	O	4420
hypertension	NOUN	O	Disease	4420
.	PUNCT	O	O	4420
Patients	NOUN	O	O	4421
with	ADP	O	O	4421
essential	ADJ	O	O	4421
hypertension	NOUN	O	Disease	4421
(	PUNCT	O	O	4421
mean	VERB	O	O	4421
sitting	VERB	O	O	4421
diastolic	ADV	O	O	4421
BP	PROPN	O	O	4421
[	X	O	O	4421
MSDBP	NOUN	O	O	4421
]	PUNCT	O	O	4421
,	PUNCT	O	O	4421
>	PUNCT	O	O	4421
or	CCONJ	O	O	4421
=	PUNCT	O	O	4421
95	NUM	O	O	4421
mm	INTJ	O	O	4421
Hg	PROPN	O	O	4421
and	CCONJ	O	O	4421
<	X	O	O	4421
110	NUM	O	O	4421
mm	INTJ	O	O	4421
Hg	PROPN	O	O	4421
)	PUNCT	O	O	4421
were	AUX	O	O	4421
randomized	VERB	O	O	4421
to	PART	O	O	4421
1	X	O	O	4421
of	ADP	O	O	4421
8	NUM	O	O	4421
treatment	NOUN	O	O	4421
groups	NOUN	O	O	4421
:	PUNCT	O	O	4421
VAL	PROPN	O	O	4421
160	NUM	O	O	4421
or	CCONJ	O	O	4421
320	NUM	O	O	4421
mg	VERB	O	O	4421
;	PUNCT	O	O	4421
HCTZ	NOUN	O	Chemical	4421
12.5	NUM	O	O	4421
or	CCONJ	O	O	4421
25	NUM	O	O	4421
mg	VERB	O	O	4421
;	PUNCT	O	O	4421
VAL	PROPN	O	O	4421
/	PUNCT	O	O	4421
HCTZ	NOUN	O	Chemical	4421
160/12.5	NUM	O	O	4421
,	PUNCT	O	O	4421
320/12.5	NUM	O	O	4421
,	PUNCT	O	O	4421
or	CCONJ	O	O	4421
320/25	PROPN	O	O	4421
mg	VERB	O	O	4421
;	PUNCT	O	O	4421
or	CCONJ	O	O	4421
placebo	NOUN	O	O	4421
.	PUNCT	O	O	4421
VAL	PROPN	O	O	4422
/	PUNCT	O	O	4422
HCTZ	NOUN	O	Chemical	4422
320/12.5	NUM	O	O	4422
and	CCONJ	O	O	4422
320/25	PROPN	O	O	4422
mg	VERB	O	O	4422
were	AUX	O	O	4422
further	ADV	O	O	4422
investigated	VERB	O	O	4422
in	ADP	O	O	4422
a	PRON	O	O	4422
54-week	NOUN	O	O	4422
,	PUNCT	O	O	4422
open	VERB	O	O	4422
-	PUNCT	O	O	4422
label	PROPN	O	O	4422
extension	NOUN	O	O	4422
.	PUNCT	O	O	4422
All	PRON	O	O	4423
active	ADJ	O	O	4423
treatments	NOUN	O	O	4423
were	AUX	O	O	4423
associated	VERB	O	O	4423
with	ADP	O	O	4423
significantly	ADV	O	O	4423
reduced	VERB	O	O	4423
MSSBP	NOUN	O	O	4423
and	CCONJ	O	O	4423
MSDBP	NOUN	O	O	4423
during	ADP	O	O	4423
the	PRON	O	O	4423
core	NOUN	O	O	4423
8-week	NOUN	O	O	4423
study	VERB	O	O	4423
,	PUNCT	O	O	4423
with	ADP	O	O	4423
each	PRON	O	O	4423
monotherapy	X	O	O	4423
significantly	ADV	O	O	4423
contributing	VERB	O	O	4423
to	PART	O	O	4423
the	PRON	O	O	4423
overall	ADV	O	O	4423
effect	VERB	O	O	4423
of	ADP	O	O	4423
combination	NOUN	O	O	4423
therapy	NOUN	O	O	4423
(	PUNCT	O	O	4423
VAL	PROPN	O	O	4423
and	CCONJ	O	O	4423
HCTZ	NOUN	O	Chemical	4423
,	PUNCT	O	O	4423
P	NOUN	O	Chemical	4423
The	PRON	O	O	4424
mean	VERB	O	O	4424
reduction	NOUN	O	O	4424
in	ADP	O	O	4424
MSSBP	NOUN	O	O	4424
/	PUNCT	O	O	4424
MSDBP	NOUN	O	O	4424
with	ADP	O	O	4424
VAL	PROPN	O	O	4424
/	PUNCT	O	O	4424
HCTZ	NOUN	O	Chemical	4424
320/25	PROPN	O	O	4424
mg	VERB	O	O	4424
was	AUX	O	O	4424
24.7/16.6	NUM	O	O	4424
mm	INTJ	O	O	4424
Hg	PROPN	O	O	4424
,	PUNCT	O	O	4424
compared	VERB	O	O	4424
with	ADP	O	O	4424
5.9/7.0	NUM	O	O	4424
mm	INTJ	O	O	4424
Hg	PROPN	O	O	4424
with	ADP	O	O	4424
placebo	NOUN	O	O	4424
.	PUNCT	O	O	4424
The	PRON	O	O	4425
reduction	NOUN	O	O	4425
in	ADP	O	O	4425
MSSBP	NOUN	O	O	4425
was	AUX	O	O	4425
significantly	ADV	O	O	4425
greater	ADJ	O	O	4425
with	ADP	O	O	4425
VAL	PROPN	O	O	4425
/	PUNCT	O	O	4425
HCTZ	NOUN	O	Chemical	4425
320/25	PROPN	O	O	4425
mg	VERB	O	O	4425
compared	VERB	O	O	4425
with	ADP	O	O	4425
VAL	PROPN	O	O	4425
/	PUNCT	O	O	4425
HCTZ	NOUN	O	Chemical	4425
160/12.5	NUM	O	O	4425
mg	VERB	O	O	4425
(	PUNCT	O	O	4425
P	NOUN	O	Chemical	4425
<	X	O	O	4425
0.002	NUM	O	O	4425
)	PUNCT	O	O	4425
.	PUNCT	O	O	4425
The	PRON	O	O	4426
incidence	NOUN	O	O	4426
of	ADP	O	O	4426
hypokalemia	PROPN	O	Disease	4426
was	AUX	O	O	4426
lower	ADJ	O	O	4426
with	ADP	O	O	4426
VAL	PROPN	O	O	4426
/	PUNCT	O	O	4426
HCTZ	NOUN	O	Chemical	4426
combinations	NOUN	O	O	4426
(	PUNCT	O	O	4426
1.8%-6.1%	NOUN	O	O	4426
)	PUNCT	O	O	4426
than	ADP	O	O	4426
with	ADP	O	O	4426
HCTZ	NOUN	O	Chemical	4426
monotherapies	NOUN	O	O	4426
(	PUNCT	O	O	4426
7.1%-13.3%	NOUN	O	O	4426
)	PUNCT	O	O	4426
.	PUNCT	O	O	4426
The	PRON	O	O	4427
efficacy	NOUN	O	O	4427
and	CCONJ	O	O	4427
tolerability	NOUN	O	O	4427
of	ADP	O	O	4427
VAL	PROPN	O	O	4427
/	PUNCT	O	O	4427
HCTZ	NOUN	O	Chemical	4427
combinations	NOUN	O	O	4427
were	AUX	O	O	4427
maintained	VERB	O	O	4427
during	ADP	O	O	4427
the	PRON	O	O	4427
extension	NOUN	O	O	4427
(	PUNCT	O	O	4427
797	NUM	O	O	4427
patients	NOUN	O	O	4427
)	PUNCT	O	O	4427
.	PUNCT	O	O	4427
In	ADP	O	O	4428
this	PRON	O	O	4428
study	VERB	O	O	4428
population	NOUN	O	O	4428
,	PUNCT	O	O	4428
combination	NOUN	O	O	4428
therapies	NOUN	O	O	4428
with	ADP	O	O	4428
VAL	PROPN	O	O	4428
/	PUNCT	O	O	4428
HCTZ	NOUN	O	Chemical	4428
were	AUX	O	O	4428
associated	VERB	O	O	4428
with	ADP	O	O	4428
significantly	ADV	O	O	4428
greater	ADJ	O	O	4428
BP	PROPN	O	O	4428
reductions	NOUN	O	O	4428
compared	VERB	O	O	4428
with	ADP	O	O	4428
either	ADV	O	O	4428
monotherapy	X	O	O	4428
,	PUNCT	O	O	4428
were	AUX	O	O	4428
well	ADV	O	O	4428
tolerated	VERB	O	O	4428
,	PUNCT	O	O	4428
and	CCONJ	O	O	4428
were	AUX	O	O	4428
associated	VERB	O	O	4428
with	ADP	O	O	4428
less	ADV	O	O	4428
hypokalemia	PROPN	O	Disease	4428
than	ADP	O	O	4428
HCTZ	NOUN	O	Chemical	4428
alone	ADV	O	O	4428
.	PUNCT	O	O	4428
Succimer	NOUN	O	O	4431
chelation	NOUN	O	O	4431
improves	VERB	O	O	4431
learning	VERB	O	O	4431
,	PUNCT	O	O	4431
attention	NOUN	O	O	4431
,	PUNCT	O	O	4431
and	CCONJ	O	O	4431
arousal	NOUN	O	O	4431
regulation	NOUN	O	O	4431
in	ADP	O	O	4431
lead	VERB	O	Chemical	4431
-	PUNCT	O	O	4431
exposed	VERB	O	O	4431
rats	NOUN	O	O	4431
but	CCONJ	O	O	4431
produces	VERB	O	O	4431
lasting	VERB	O	O	4431
cognitive impairment	NOUN	O	Disease	4431
in	ADP	O	O	4431
the	PRON	O	O	4431
absence	NOUN	O	O	4431
of	ADP	O	O	4431
lead	VERB	O	Chemical	4431
exposure	NOUN	O	O	4431
.	PUNCT	O	O	4431
BACKGROUND	NOUN	O	O	4432
:	PUNCT	O	O	4432
There	ADV	O	O	4432
is	AUX	O	O	4432
growing	VERB	O	O	4432
pressure	NOUN	O	O	4432
for	ADP	O	O	4432
clinicians	NOUN	O	O	4432
to	PART	O	O	4432
prescribe	VERB	O	O	4432
chelation	NOUN	O	O	4432
therapy	NOUN	O	O	4432
at	ADP	O	O	4432
only	ADV	O	O	4432
slightly	ADV	O	O	4432
elevated	ADJ	O	O	4432
blood	NOUN	O	O	4432
lead	VERB	O	Chemical	4432
levels	NOUN	O	O	4432
.	PUNCT	O	O	4432
However	ADV	O	O	4433
,	PUNCT	O	O	4433
very	ADV	O	O	4433
few	ADJ	O	O	4433
studies	NOUN	O	O	4433
have	VERB	O	O	4433
evaluated	VERB	O	O	4433
whether	SCONJ	O	O	4433
chelation	NOUN	O	O	4433
improves	VERB	O	O	4433
cognitive	ADJ	O	O	4433
outcomes	NOUN	O	O	4433
in	ADP	O	O	4433
Pb	PROPN	O	O	4433
-	PUNCT	O	O	4433
exposed	VERB	O	O	4433
children	NOUN	O	O	4433
,	PUNCT	O	O	4433
or	CCONJ	O	O	4433
whether	SCONJ	O	O	4433
these	PRON	O	O	4433
agents	NOUN	O	O	4433
have	VERB	O	O	4433
adverse	ADJ	O	O	4433
effects	NOUN	O	O	4433
that	SCONJ	O	O	4433
may	AUX	O	O	4433
affect	VERB	O	O	4433
brain	NOUN	O	O	4433
development	NOUN	O	O	4433
in	ADP	O	O	4433
the	PRON	O	O	4433
absence	NOUN	O	O	4433
of	ADP	O	O	4433
Pb	PROPN	O	O	4433
exposure	NOUN	O	O	4433
.	PUNCT	O	O	4433
The	PRON	O	O	4434
present	NOUN	O	O	4434
study	VERB	O	O	4434
was	AUX	O	O	4434
designed	VERB	O	O	4434
to	PART	O	O	4434
answer	VERB	O	O	4434
these	PRON	O	O	4434
questions	NOUN	O	O	4434
,	PUNCT	O	O	4434
using	VERB	O	O	4434
a	PRON	O	O	4434
rodent	NOUN	O	O	4434
model	NOUN	O	O	4434
of	ADP	O	O	4434
early	ADV	O	O	4434
childhood	NOUN	O	O	4434
Pb	PROPN	O	O	4434
exposure	NOUN	O	O	4434
and	CCONJ	O	O	4434
treatment	NOUN	O	O	4434
with	ADP	O	O	4434
succimer	PROPN	O	O	4434
,	PUNCT	O	O	4434
a	PRON	O	O	4434
widely	ADV	O	O	4434
used	VERB	O	O	4434
chelating	VERB	O	O	4434
agent	NOUN	O	O	4434
for	ADP	O	O	4434
the	PRON	O	O	4434
treatment	NOUN	O	O	4434
of	ADP	O	O	4434
Pb	PROPN	O	O	4434
poisoning	VERB	O	O	4434
.	PUNCT	O	O	4434
Pb	PROPN	O	O	4435
exposure	NOUN	O	O	4435
produced	VERB	O	O	4435
lasting	VERB	O	O	4435
impairments	VERB	O	O	4435
in	ADP	O	O	4435
learning	VERB	O	O	4435
,	PUNCT	O	O	4435
attention	NOUN	O	O	4435
,	PUNCT	O	O	4435
inhibitory	ADJ	O	O	4435
control	VERB	O	O	4435
,	PUNCT	O	O	4435
and	CCONJ	O	O	4435
arousal	NOUN	O	O	4435
regulation	NOUN	O	O	4435
,	PUNCT	O	O	4435
paralleling	VERB	O	O	4435
the	PRON	O	O	4435
areas	NOUN	O	O	4435
of	ADP	O	O	4435
dysfunction	NOUN	O	O	4435
seen	VERB	O	O	4435
in	ADP	O	O	4435
Pb	PROPN	O	O	4435
-	PUNCT	O	O	4435
exposed	VERB	O	O	4435
children	NOUN	O	O	4435
.	PUNCT	O	O	4435
Succimer	NOUN	O	O	4436
treatment	NOUN	O	O	4436
of	ADP	O	O	4436
the	PRON	O	O	4436
Pb	PROPN	O	O	4436
-	PUNCT	O	O	4436
exposed	VERB	O	O	4436
rats	NOUN	O	O	4436
significantly	ADV	O	O	4436
improved	VERB	O	O	4436
learning	VERB	O	O	4436
,	PUNCT	O	O	4436
attention	NOUN	O	O	4436
,	PUNCT	O	O	4436
and	CCONJ	O	O	4436
arousal	NOUN	O	O	4436
regulation	NOUN	O	O	4436
,	PUNCT	O	O	4436
although	SCONJ	O	O	4436
the	PRON	O	O	4436
efficacy	NOUN	O	O	4436
of	ADP	O	O	4436
the	PRON	O	O	4436
treatment	NOUN	O	O	4436
varied	ADJ	O	O	4436
as	ADP	O	O	4436
a	PRON	O	O	4436
function	NOUN	O	O	4436
of	ADP	O	O	4436
the	PRON	O	O	4436
Pb	PROPN	O	O	4436
exposure	NOUN	O	O	4436
level	VERB	O	O	4436
and	CCONJ	O	O	4436
the	PRON	O	O	4436
specific	ADJ	O	O	4436
functional	ADJ	O	O	4436
deficit	NOUN	O	O	4436
.	PUNCT	O	O	4436
In	ADP	O	O	4437
contrast	NOUN	O	O	4437
,	PUNCT	O	O	4437
succimer	PROPN	O	O	4437
treatment	NOUN	O	O	4437
of	ADP	O	O	4437
rats	NOUN	O	O	4437
not	PART	O	O	4437
previously	ADV	O	O	4437
exposed	VERB	O	O	4437
to	PART	O	O	4437
Pb	PROPN	O	O	4437
produced	VERB	O	O	4437
lasting	VERB	O	O	4437
and	CCONJ	O	O	4437
pervasive	ADJ	O	O	4437
cognitive	ADJ	O	O	4437
and	CCONJ	O	O	4437
affective	ADJ	O	O	4437
dysfunction	NOUN	O	O	4437
comparable	ADJ	O	O	4437
in	ADP	O	O	4437
magnitude	NOUN	O	O	4437
to	PART	O	O	4437
that	SCONJ	O	O	4437
produced	VERB	O	O	4437
by	ADP	O	O	4437
the	PRON	O	O	4437
higher	ADJ	O	O	4437
Pb	PROPN	O	O	4437
exposure	NOUN	O	O	4437
regimen	NOUN	O	O	4437
.	PUNCT	O	O	4437
These	PRON	O	O	4438
are	AUX	O	O	4438
the	PRON	O	O	4438
first	ADV	O	O	4438
data	NOUN	O	O	4438
,	PUNCT	O	O	4438
to	PART	O	O	4438
our	PRON	O	O	4438
knowledge	NOUN	O	O	4438
,	PUNCT	O	O	4438
to	PART	O	O	4438
show	VERB	O	O	4438
that	SCONJ	O	O	4438
treatment	NOUN	O	O	4438
with	ADP	O	O	4438
any	PRON	O	O	4438
chelating	VERB	O	O	4438
agent	NOUN	O	O	4438
can	AUX	O	O	4438
alleviate	VERB	O	O	4438
cognitive deficits	NOUN	O	Disease	4438
due	ADJ	O	O	4438
to	PART	O	O	4438
Pb	PROPN	O	O	4438
exposure	NOUN	O	O	4438
.	PUNCT	O	O	4438
These	PRON	O	O	4439
findings	NOUN	O	O	4439
suggest	VERB	O	O	4439
that	SCONJ	O	O	4439
it	PRON	O	O	4439
may	AUX	O	O	4439
be	AUX	O	O	4439
possible	ADJ	O	O	4439
to	PART	O	O	4439
identify	VERB	O	O	4439
a	PRON	O	O	4439
succimer	PROPN	O	O	4439
treatment	NOUN	O	O	4439
protocol	PROPN	O	O	4439
that	SCONJ	O	O	4439
improves	VERB	O	O	4439
cognitive	ADJ	O	O	4439
outcomes	NOUN	O	O	4439
in	ADP	O	O	4439
Pb	PROPN	O	O	4439
-	PUNCT	O	O	4439
exposed	VERB	O	O	4439
children	NOUN	O	O	4439
.	PUNCT	O	O	4439
However	ADV	O	O	4440
,	PUNCT	O	O	4440
they	PRON	O	O	4440
also	ADV	O	O	4440
suggest	VERB	O	O	4440
that	SCONJ	O	O	4440
succimer	PROPN	O	O	4440
treatment	NOUN	O	O	4440
should	AUX	O	O	4440
be	AUX	O	O	4440
strongly	ADV	O	O	4440
discouraged	VERB	O	O	4440
for	ADP	O	O	4440
children	NOUN	O	O	4440
who	PRON	O	O	4440
do	VERB	O	O	4440
not	PART	O	O	4440
have	VERB	O	O	4440
elevated	ADJ	O	O	4440
tissue	NOUN	O	O	4440
levels	NOUN	O	O	4440
of	ADP	O	O	4440
Pb	PROPN	O	O	4440
or	CCONJ	O	O	4440
other	ADJ	O	O	4440
heavy	ADJ	O	O	4440
metals	NOUN	O	O	4440
.	PUNCT	O	O	4440
Caffeine	NOUN	O	Chemical	4443
challenge	NOUN	O	O	4443
test	NOUN	O	O	4443
in	ADP	O	O	4443
panic	VERB	O	O	4443
disorder	NOUN	O	O	4443
and	CCONJ	O	O	4443
depression	PROPN	O	Disease	4443
with	ADP	O	O	4443
panic	VERB	O	O	4443
attacks	NOUN	O	O	4443
.	PUNCT	O	O	4443
Our	PRON	O	O	4444
aim	VERB	O	O	4444
was	AUX	O	O	4444
to	PART	O	O	4444
observe	VERB	O	O	4444
if	SCONJ	O	O	4444
patients	NOUN	O	O	4444
with	ADP	O	O	4444
panic	VERB	O	O	4444
disorder	NOUN	O	O	4444
(	PUNCT	O	O	4444
PD	PROPN	O	Disease	4444
)	PUNCT	O	O	4444
and	CCONJ	O	O	4444
patients	NOUN	O	O	4444
with	ADP	O	O	4444
major	ADJ	O	O	4444
depression	PROPN	O	Disease	4444
with	ADP	O	O	4444
panic	VERB	O	O	4444
attacks	NOUN	O	O	4444
(	PUNCT	O	O	4444
MDP	PROPN	O	O	4444
)	PUNCT	O	O	4444
(	PUNCT	O	O	4444
Diagnostic	ADJ	O	O	4444
and	CCONJ	O	O	4444
Statistical	ADJ	O	O	4444
Manual	NOUN	O	O	4444
of	ADP	O	O	4444
Mental Disorders	PROPN	O	Disease	4444
,	PUNCT	O	O	4444
Fourth	ADJ	O	O	4444
Edition	PROPN	O	O	4444
criteria	NOUN	O	O	4444
)	PUNCT	O	O	4444
respond	VERB	O	O	4444
in	ADP	O	O	4444
a	PRON	O	O	4444
similar	ADJ	O	O	4444
way	NOUN	O	O	4444
to	PART	O	O	4444
the	PRON	O	O	4444
induction	NOUN	O	O	4444
of	ADP	O	O	4444
panic	VERB	O	O	4444
attacks	NOUN	O	O	4444
by	ADP	O	O	4444
an	PRON	O	O	4444
oral	ADJ	O	O	4444
caffeine	NOUN	O	Chemical	4444
challenge	NOUN	O	O	4444
test	NOUN	O	O	4444
.	PUNCT	O	O	4444
We	PRON	O	O	4445
randomly	ADV	O	O	4445
selected	VERB	O	O	4445
29	NUM	O	O	4445
patients	NOUN	O	O	4445
with	ADP	O	O	4445
PD	PROPN	O	Disease	4445
,	PUNCT	O	O	4445
27	NUM	O	O	4445
with	ADP	O	O	4445
MDP	PROPN	O	O	4445
,	PUNCT	O	O	4445
25	NUM	O	O	4445
with	ADP	O	O	4445
major	ADJ	O	O	4445
depression	PROPN	O	Disease	4445
without	ADP	O	O	4445
panic	VERB	O	O	4445
attacks	NOUN	O	O	4445
(	PUNCT	O	O	4445
MD	PROPN	O	Disease	4445
)	PUNCT	O	O	4445
,	PUNCT	O	O	4445
and	CCONJ	O	O	4445
28	NUM	O	O	4445
healthy	ADJ	O	O	4445
volunteers	NOUN	O	O	4445
.	PUNCT	O	O	4445
In	ADP	O	O	4446
a	PRON	O	O	4446
randomized	VERB	O	O	4446
double	ADJ	O	O	4446
-	PUNCT	O	O	4446
blind	ADJ	O	Disease	4446
experiment	NOUN	O	O	4446
performed	VERB	O	O	4446
in	ADP	O	O	4446
2	X	O	O	4446
occasions	NOUN	O	O	4446
7	NUM	O	O	4446
days	NOUN	O	O	4446
apart	ADV	O	O	4446
,	PUNCT	O	O	4446
480	NUM	O	O	4446
mg	VERB	O	O	4446
caffeine	NOUN	O	Chemical	4446
and	CCONJ	O	O	4446
a	PRON	O	O	4446
caffeine	NOUN	O	Chemical	4446
-	PUNCT	O	O	4446
free	ADJ	O	O	4446
(	PUNCT	O	O	4446
placebo	NOUN	O	O	4446
)	PUNCT	O	O	4446
solution	NOUN	O	O	4446
were	AUX	O	O	4446
administered	VERB	O	O	4446
in	ADP	O	O	4446
a	PRON	O	O	4446
coffee	NOUN	O	O	4446
form	NOUN	O	O	4446
and	CCONJ	O	O	4446
anxiety	NOUN	O	Disease	4446
scales	NOUN	O	O	4446
were	AUX	O	O	4446
applied	VERB	O	O	4446
before	ADP	O	O	4446
and	CCONJ	O	O	4446
after	ADP	O	O	4446
each	PRON	O	O	4446
test	NOUN	O	O	4446
.	PUNCT	O	O	4446
A	PRON	O	O	4447
total	ADJ	O	O	4447
of	ADP	O	O	4447
58.6%	NOUN	O	O	4447
(	PUNCT	O	O	4447
n	CCONJ	O	O	4447
=	PUNCT	O	O	4447
17	NUM	O	O	4447
)	PUNCT	O	O	4447
of	ADP	O	O	4447
patients	NOUN	O	O	4447
with	ADP	O	O	4447
PD	PROPN	O	Disease	4447
,	PUNCT	O	O	4447
44.4%	NOUN	O	O	4447
(	PUNCT	O	O	4447
n	CCONJ	O	O	4447
=	PUNCT	O	O	4447
12	NUM	O	O	4447
)	PUNCT	O	O	4447
of	ADP	O	O	4447
patients	NOUN	O	O	4447
with	ADP	O	O	4447
MDP	PROPN	O	O	4447
,	PUNCT	O	O	4447
12.0%	NOUN	O	O	4447
(	PUNCT	O	O	4448
n	CCONJ	O	O	4448
=	PUNCT	O	O	4448
3	X	O	O	4448
)	PUNCT	O	O	4448
of	ADP	O	O	4448
patients	NOUN	O	O	4448
with	ADP	O	O	4448
MD	PROPN	O	Disease	4448
,	PUNCT	O	O	4448
and	CCONJ	O	O	4448
7.1%	NOUN	O	O	4448
(	PUNCT	O	O	4448
n=	PUNCT	O	O	4448
2	X	O	O	4448
)	PUNCT	O	O	4448
of	ADP	O	O	4448
control	VERB	O	O	4448
subjects	NOUN	O	O	4448
had	VERB	O	O	4448
a	PRON	O	O	4448
panic	VERB	O	O	4448
attack	VERB	O	O	4448
after	ADP	O	O	4448
the	PRON	O	O	4448
480-mg	NOUN	O	O	4448
caffeine	NOUN	O	Chemical	4448
challenge	NOUN	O	O	4448
test	NOUN	O	O	4448
(	PUNCT	O	O	4448
chi(2)(3	NOUN	O	O	4448
)	PUNCT	O	O	4448
=	PUNCT	O	O	4448
16.22	NUM	O	O	4448
,	PUNCT	O	O	4448
P	NOUN	O	Chemical	4448
=	PUNCT	O	O	4448
.001	NUM	O	O	4448
)	PUNCT	O	O	4448
.	PUNCT	O	O	4448
The	PRON	O	O	4449
patients	NOUN	O	O	4449
with	ADP	O	O	4449
PD	PROPN	O	Disease	4449
and	CCONJ	O	O	4449
MDP	PROPN	O	O	4449
were	AUX	O	O	4449
more	ADJ	O	O	4449
sensitive	ADJ	O	O	4449
to	PART	O	O	4449
caffeine	NOUN	O	Chemical	4449
than	ADP	O	O	4449
were	AUX	O	O	4449
patients	NOUN	O	O	4449
with	ADP	O	O	4449
MD	PROPN	O	Disease	4449
and	CCONJ	O	O	4449
healthy	ADJ	O	O	4449
volunteers	NOUN	O	O	4449
.	PUNCT	O	O	4449
No	PRON	O	O	4450
panic	VERB	O	O	4450
attack	VERB	O	O	4450
was	AUX	O	O	4450
observed	VERB	O	O	4450
after	ADP	O	O	4450
the	PRON	O	O	4450
caffeine	NOUN	O	Chemical	4450
-	PUNCT	O	O	4450
free	ADJ	O	O	4450
solution	NOUN	O	O	4450
intake	PROPN	O	O	4450
.	PUNCT	O	O	4450
The	PRON	O	O	4451
patients	NOUN	O	O	4451
with	ADP	O	O	4451
MD	PROPN	O	Disease	4451
had	VERB	O	O	4451
a	PRON	O	O	4451
lower	ADJ	O	O	4451
heart	NOUN	O	O	4451
rate	NOUN	O	O	4451
response	NOUN	O	O	4451
to	PART	O	O	4451
the	PRON	O	O	4451
test	NOUN	O	O	4451
than	ADP	O	O	4451
all	PRON	O	O	4451
the	PRON	O	O	4451
other	ADJ	O	O	4451
groups	NOUN	O	O	4451
(	PUNCT	O	O	4451
2-way	NOUN	O	O	4451
analysis	NOUN	O	O	4451
of	ADP	O	O	4451
variance	NOUN	O	O	4451
,	PUNCT	O	O	4451
group	NOUN	O	O	4451
by	ADP	O	O	4451
time	NOUN	O	O	4451
interaction	NOUN	O	O	4451
with	ADP	O	O	4451
Greenhouse	NOUN	O	O	4451
-	PUNCT	O	O	4451
Geisser	PROPN	O	O	4451
correction	PROPN	O	O	4451
:	PUNCT	O	O	4451
F(3,762	PROPN	O	O	4451
)	PUNCT	O	O	4451
=	PUNCT	O	O	4451
2.85	NUM	O	O	4451
,	PUNCT	O	O	4451
P	NOUN	O	Chemical	4451
=	PUNCT	O	O	4451
.026	NUM	O	O	4451
)	PUNCT	O	O	4451
.	PUNCT	O	O	4451
Our	PRON	O	O	4452
data	NOUN	O	O	4452
suggest	VERB	O	O	4452
that	SCONJ	O	O	4452
there	ADV	O	O	4452
is	AUX	O	O	4452
an	PRON	O	O	4452
association	PROPN	O	O	4452
between	ADP	O	O	4452
panic	VERB	O	O	4452
attacks	NOUN	O	O	4452
,	PUNCT	O	O	4452
no	PRON	O	O	4452
matter	VERB	O	O	4452
if	SCONJ	O	O	4452
associated	VERB	O	O	4452
with	ADP	O	O	4452
PD	PROPN	O	Disease	4452
or	CCONJ	O	O	4452
MDP	PROPN	O	O	4452
,	PUNCT	O	O	4452
and	CCONJ	O	O	4452
hyperreactivity	NOUN	O	O	4452
to	PART	O	O	4452
an	PRON	O	O	4452
oral	ADJ	O	O	4452
caffeine	NOUN	O	Chemical	4452
challenge	NOUN	O	O	4452
test	NOUN	O	O	4452
.	PUNCT	O	O	4452
Mitral	NOUN	O	O	4455
annuloplasty	NOUN	O	O	4455
as	ADP	O	O	4455
a	PRON	O	O	4455
ventricular	ADJ	O	O	4455
restoration	NOUN	O	O	4455
method	NOUN	O	O	4455
for	ADP	O	O	4455
the	PRON	O	O	4455
failing	VERB	O	O	4455
left	VERB	O	O	4455
ventricle	NOUN	O	O	4455
:	PUNCT	O	O	4455
a	PRON	O	O	4455
pilot	NOUN	O	O	4455
study	VERB	O	O	4455
.	PUNCT	O	O	4455
Undersized	ADJ	O	O	4456
mitral	ADJ	O	O	4456
annuloplasty	NOUN	O	O	4456
(	PUNCT	O	O	4456
MAP	PROPN	O	O	4456
)	PUNCT	O	O	4456
is	AUX	O	O	4456
effective	ADJ	O	O	4456
in	ADP	O	O	4456
patients	NOUN	O	O	4456
with	ADP	O	O	4456
dilated	ADJ	O	O	4456
cardiomyopathy	ADJ	O	Disease	4456
and	CCONJ	O	O	4456
functional	ADJ	O	O	4456
mitral regurgitation	NOUN	O	Disease	4456
(	PUNCT	O	O	4456
MR	PROPN	O	O	4456
)	PUNCT	O	O	4456
since	SCONJ	O	O	4456
,	PUNCT	O	O	4456
as	ADP	O	O	4456
well	ADV	O	O	4456
as	ADP	O	O	4456
addressing	VERB	O	O	4456
the	PRON	O	O	4456
MR	PROPN	O	O	4456
,	PUNCT	O	O	4456
the	PRON	O	O	4456
MAP	PROPN	O	O	4456
may	AUX	O	O	4456
also	ADV	O	O	4456
reshape	VERB	O	O	4456
the	PRON	O	O	4456
dilated	ADJ	O	O	4456
left	VERB	O	O	4456
ventricular	ADJ	O	O	4456
(	PUNCT	O	O	4456
LV	PROPN	O	Disease	4456
)	PUNCT	O	O	4456
base	PROPN	O	O	4456
.	PUNCT	O	O	4456
However	ADV	O	O	4457
,	PUNCT	O	O	4457
the	PRON	O	O	4457
direct	ADJ	O	O	4457
benefits	NOUN	O	O	4457
of	ADP	O	O	4457
this	PRON	O	O	4457
possible	ADJ	O	O	4457
reshaping	VERB	O	O	4457
on	ADP	O	O	4457
LV	PROPN	O	Disease	4457
function	NOUN	O	O	4457
in	ADP	O	O	4457
the	PRON	O	O	4457
absence	NOUN	O	O	4457
of	ADP	O	O	4457
underlying	VERB	O	O	4457
MR	PROPN	O	O	4457
remain	VERB	O	O	4457
incompletely	ADV	O	O	4457
understood	VERB	O	O	4457
.	PUNCT	O	O	4457
The	PRON	O	O	4458
study	VERB	O	O	4458
aim	VERB	O	O	4458
was	AUX	O	O	4458
to	PART	O	O	4458
identify	VERB	O	O	4458
these	PRON	O	O	4458
benefits	NOUN	O	O	4458
in	ADP	O	O	4458
a	PRON	O	O	4458
canine	NOUN	O	O	4458
model	NOUN	O	O	4458
of	ADP	O	O	4458
acute	ADJ	O	O	4458
heart failure	NOUN	O	Disease	4458
.	PUNCT	O	O	4458
Acute	PROPN	O	O	4459
heart failure	NOUN	O	Disease	4459
was	AUX	O	O	4459
induced	VERB	O	O	4459
by	ADP	O	O	4459
propranolol	NOUN	O	Chemical	4459
and	CCONJ	O	O	4459
volume	PROPN	O	O	4459
loading	NOUN	O	O	4459
after	ADP	O	O	4459
weaning	VERB	O	O	4459
from	ADP	O	O	4459
cardiopulmonary	VERB	O	O	4459
bypass	NOUN	O	O	4459
;	PUNCT	O	O	4459
an	PRON	O	O	4459
absence	NOUN	O	O	4459
of	ADP	O	O	4459
MR	PROPN	O	O	4459
was	AUX	O	O	4459
confirmed	VERB	O	O	4459
by	ADP	O	O	4459
echocardiography	NOUN	O	O	4459
.	PUNCT	O	O	4459
Data	NOUN	O	O	4460
were	AUX	O	O	4460
acquired	VERB	O	O	4460
at	ADP	O	O	4460
baseline	VERB	O	O	4460
,	PUNCT	O	O	4460
after	ADP	O	O	4460
induction	NOUN	O	O	4460
of	ADP	O	O	4460
acute	ADJ	O	O	4460
heart failure	NOUN	O	Disease	4460
,	PUNCT	O	O	4460
and	CCONJ	O	O	4460
after	ADP	O	O	4460
MAP	PROPN	O	O	4460
.	PUNCT	O	O	4460
:	PUNCT	O	O	4461
The	PRON	O	O	4461
data	NOUN	O	O	4461
acquired	VERB	O	O	4461
suggest	VERB	O	O	4461
that	SCONJ	O	O	4461
isolated	VERB	O	O	4461
MAP	PROPN	O	O	4461
may	AUX	O	O	4461
have	VERB	O	O	4461
certain	ADJ	O	O	4461
benefits	NOUN	O	O	4461
on	ADP	O	O	4461
LV	PROPN	O	Disease	4461
dimension	NOUN	O	O	4461
/	PUNCT	O	O	4461
function	NOUN	O	O	4461
in	ADP	O	O	4461
acute	ADJ	O	O	4461
heart failure	NOUN	O	Disease	4461
,	PUNCT	O	O	4461
even	ADV	O	O	4461
in	ADP	O	O	4461
the	PRON	O	O	4461
absence	NOUN	O	O	4461
of	ADP	O	O	4461
MR	PROPN	O	O	4461
.	PUNCT	O	O	4461
However	ADV	O	O	4462
,	PUNCT	O	O	4462
further	ADV	O	O	4462
investigations	NOUN	O	O	4462
are	AUX	O	O	4462
warranted	VERB	O	O	4462
in	ADP	O	O	4462
a	PRON	O	O	4462
model	NOUN	O	O	4462
of	ADP	O	O	4462
chronic	ADJ	O	O	4462
heart failure	NOUN	O	Disease	4462
.	PUNCT	O	O	4462
Piperacillin	PROPN	O	O	4465
/	PUNCT	O	O	4465
tazobactam	NOUN	O	O	4465
-	PUNCT	O	O	4465
induced	VERB	O	O	4465
seizure	NOUN	O	Disease	4465
rapidly	ADV	O	O	4465
reversed	VERB	O	O	4465
by	ADP	O	O	4465
high	ADJ	O	O	4465
flux	PROPN	O	O	4465
hemodialysis	NOUN	O	O	4465
in	ADP	O	O	4465
a	PRON	O	O	4465
patient	NOUN	O	O	4465
on	ADP	O	O	4465
peritoneal	ADJ	O	O	4465
dialysis	NOUN	O	O	4465
.	PUNCT	O	O	4465
Despite	SCONJ	O	O	4466
popular	ADJ	O	O	4466
use	VERB	O	O	4466
of	ADP	O	O	4466
piperacillin	PROPN	O	Chemical	4466
,	PUNCT	O	O	4466
the	PRON	O	O	4466
dire	X	O	O	4466
neurotoxicity	NOUN	O	Disease	4466
associated	VERB	O	O	4466
with	ADP	O	O	4466
piperacillin	PROPN	O	Chemical	4466
still	ADV	O	O	4466
goes	VERB	O	O	4466
unrecognized	ADJ	O	O	4466
,	PUNCT	O	O	4466
leading	VERB	O	O	4466
to	PART	O	O	4466
a	PRON	O	O	4466
delay	NOUN	O	O	4466
in	ADP	O	O	4466
appropriate	ADJ	O	O	4466
management	NOUN	O	O	4466
.	PUNCT	O	O	4466
We	PRON	O	O	4467
report	VERB	O	O	4467
a	PRON	O	O	4467
57-year	NOUN	O	O	4467
-	PUNCT	O	O	4467
old	ADJ	O	O	4467
woman	NOUN	O	O	4467
with	ADP	O	O	4467
end	VERB	O	O	4467
-	PUNCT	O	O	4467
stage	NOUN	O	O	4467
renal disease	NOUN	O	Disease	4467
receiving	VERB	O	O	4467
continuous	ADJ	O	O	4467
ambulatory	ADJ	O	O	4467
peritoneal	ADJ	O	O	4467
dialysis	NOUN	O	O	4467
(	PUNCT	O	O	4467
CAPD	NOUN	O	O	4467
)	PUNCT	O	O	4467
,	PUNCT	O	O	4467
who	PRON	O	O	4467
developed	VERB	O	O	4467
slurred	VERB	O	O	4467
speech	NOUN	O	O	4467
,	PUNCT	O	O	4467
tremor	NOUN	O	Disease	4467
,	PUNCT	O	O	4467
bizarre	ADJ	O	O	4467
behavior	NOUN	O	O	4467
,	PUNCT	O	O	4467
progressive	ADJ	O	O	4467
mental	ADJ	O	O	4467
confusion	NOUN	O	Disease	4467
,	PUNCT	O	O	4467
and	CCONJ	O	O	4467
2	X	O	O	4467
episodes	NOUN	O	O	4467
of	ADP	O	O	4467
generalized	VERB	O	O	4467
tonic	PROPN	O	O	4467
-	PUNCT	O	O	4467
clonic	ADJ	O	O	4467
seizure	NOUN	O	Disease	4467
(	PUNCT	O	O	4467
GTCS	PROPN	O	O	4467
)	PUNCT	O	O	4467
after	ADP	O	O	4467
5	NUM	O	O	4467
doses	NOUN	O	O	4467
of	ADP	O	O	4467
piperacillin	PROPN	O	Chemical	4467
/	PUNCT	O	O	4467
tazobactam	NOUN	O	O	4467
(	PUNCT	O	O	4467
2	X	O	O	4467
g/250	VERB	O	O	4467
mg	VERB	O	O	4467
)	PUNCT	O	O	4467
were	AUX	O	O	4467
given	VERB	O	O	4467
for	ADP	O	O	4467
bronchiectasis	NOUN	O	O	4467
with	ADP	O	O	4467
secondary	ADJ	O	O	4467
infection	NOUN	O	Disease	4467
.	PUNCT	O	O	4467
The	PRON	O	O	4468
laboratory	NOUN	O	O	4468
data	NOUN	O	O	4468
revealed	VERB	O	O	4468
normal	ADJ	O	O	4468
plasma	NOUN	O	O	4468
electrolyte	NOUN	O	O	4468
and	CCONJ	O	O	4468
ammonia	NOUN	O	Chemical	4468
levels	NOUN	O	O	4468
but	CCONJ	O	O	4468
leukocytosis	NOUN	O	O	4468
.	PUNCT	O	O	4468
Neurologic	ADJ	O	O	4469
examinations	NOUN	O	O	4469
showed	VERB	O	O	4469
dysarthria	NOUN	O	O	4469
and	CCONJ	O	O	4469
bilateral	ADJ	O	O	4469
Babinski	PROPN	O	O	4469
sign	VERB	O	O	4469
.	PUNCT	O	O	4469
Despite	SCONJ	O	O	4470
the	PRON	O	O	4470
use	VERB	O	O	4470
of	ADP	O	O	4470
antiepileptic	ADJ	O	O	4470
agents	NOUN	O	O	4470
,	PUNCT	O	O	4470
another	PRON	O	O	4470
GTCS	PROPN	O	O	4470
episode	PROPN	O	O	4470
recurred	VERB	O	O	4470
after	ADP	O	O	4470
the	PRON	O	O	4470
sixth	ADV	O	O	4470
dose	NOUN	O	O	4470
of	ADP	O	O	4470
piperacillin	PROPN	O	Chemical	4470
/	PUNCT	O	O	4470
tazobactam	NOUN	O	O	4470
.	PUNCT	O	O	4470
Brain	NOUN	O	O	4471
magnetic	ADJ	O	O	4471
resonance	NOUN	O	O	4471
imaging	VERB	O	O	4471
did	VERB	O	O	4471
not	PART	O	O	4471
demonstrate	VERB	O	O	4471
acute	ADJ	O	O	4471
infarction	NOUN	O	O	4471
and	CCONJ	O	O	4471
organic	ADJ	O	O	4471
brain	NOUN	O	O	4471
lesions	NOUN	O	O	4471
.	PUNCT	O	O	4471
Piperacillin	PROPN	O	O	4472
-	PUNCT	O	O	4472
induced	VERB	O	O	4472
encephalopathy	NOUN	O	Disease	4472
should	AUX	O	O	4472
be	AUX	O	O	4472
considered	VERB	O	O	4472
in	ADP	O	O	4472
any	PRON	O	O	4472
uremic	ADJ	O	O	4472
patients	NOUN	O	O	4472
with	ADP	O	O	4472
unexplained	ADJ	O	O	4472
neurological	ADJ	O	O	4472
manifestations	NOUN	O	O	4472
.	PUNCT	O	O	4472
CAPD	NOUN	O	O	4473
is	AUX	O	O	4473
inefficient	ADJ	O	O	4473
in	ADP	O	O	4473
removing	VERB	O	O	4473
piperacillin	PROPN	O	Chemical	4473
,	PUNCT	O	O	4473
whereas	SCONJ	O	O	4473
hemodialysis	NOUN	O	O	4473
can	AUX	O	O	4473
rapidly	ADV	O	O	4473
terminate	VERB	O	O	4473
the	PRON	O	O	4473
piperacillin	PROPN	O	Chemical	4473
-	PUNCT	O	O	4473
induced	VERB	O	O	4473
encephalopathy	NOUN	O	Disease	4473
.	PUNCT	O	O	4473
Frequency	NOUN	O	O	4476
of	ADP	O	O	4476
transient	ADJ	O	O	4476
ipsilateral	ADJ	O	O	4476
vocal	ADJ	O	O	4476
cord	NOUN	O	O	4476
paralysis	NOUN	O	Disease	4476
in	ADP	O	O	4476
patients	NOUN	O	O	4476
undergoing	VERB	O	O	4476
carotid	NOUN	O	O	4476
endarterectomy	ADJ	O	O	4476
under	ADP	O	O	4476
local	ADJ	O	O	4476
anesthesia	NOUN	O	O	4476
.	PUNCT	O	O	4476
Temporary	ADJ	O	O	4477
ipsilateral	ADJ	O	O	4477
vocal	ADJ	O	O	4477
nerve	NOUN	O	O	4477
palsies	NOUN	O	O	4477
due	ADJ	O	O	4477
to	PART	O	O	4477
local	ADJ	O	O	4477
anesthetics	NOUN	O	O	4477
have	VERB	O	O	4477
been	AUX	O	O	4477
described	VERB	O	O	4477
,	PUNCT	O	O	4477
however	ADV	O	O	4477
.	PUNCT	O	O	4477
Such	ADJ	O	O	4478
complications	NOUN	O	O	4478
are	AUX	O	O	4478
most	ADV	O	O	4478
important	ADJ	O	O	4478
in	ADP	O	O	4478
situations	NOUN	O	O	4478
where	SCONJ	O	O	4478
there	ADV	O	O	4478
is	AUX	O	O	4478
a	PRON	O	O	4478
pre	VERB	O	O	4478
-	PUNCT	O	O	4478
existing	VERB	O	O	4478
contralateral	ADJ	O	O	4478
paralysis	NOUN	O	Disease	4478
.	PUNCT	O	O	4478
Anesthesia	NOUN	O	O	4479
was	AUX	O	O	4479
performed	VERB	O	O	4479
by	ADP	O	O	4479
injecting	VERB	O	O	4479
20	NUM	O	O	4479
to	PART	O	O	4479
40	NUM	O	O	4479
mL	PROPN	O	O	4479
of	ADP	O	O	4479
a	PRON	O	O	4479
mixture	NOUN	O	O	4479
of	ADP	O	O	4479
long	ADV	O	O	4479
-	PUNCT	O	O	4479
acting	VERB	O	O	4479
(	PUNCT	O	O	4479
ropivacaine	NOUN	O	Chemical	4479
)	PUNCT	O	O	4479
and	CCONJ	O	O	4479
short	ADJ	O	O	4479
-	PUNCT	O	O	4479
acting	VERB	O	O	4479
(	PUNCT	O	O	4479
prilocaine	NOUN	O	O	4479
)	PUNCT	O	O	4479
anesthetic	NOUN	O	O	4479
.	PUNCT	O	O	4479
Twelve	NUM	O	O	4480
patients	NOUN	O	O	4480
(	PUNCT	O	O	4480
43%	NOUN	O	O	4480
)	PUNCT	O	O	4480
were	AUX	O	O	4480
found	VERB	O	O	4480
to	PART	O	O	4480
have	VERB	O	O	4480
intraoperative	ADJ	O	O	4480
ipsilateral	ADJ	O	O	4480
vocal	ADJ	O	O	4480
cord	NOUN	O	O	4480
paralysis	NOUN	O	Disease	4480
.	PUNCT	O	O	4480
There	ADV	O	O	4481
were	AUX	O	O	4481
no	PRON	O	O	4481
significant	ADJ	O	O	4481
differences	NOUN	O	O	4481
in	ADP	O	O	4481
operating	VERB	O	O	4481
time	NOUN	O	O	4481
or	CCONJ	O	O	4481
volume	PROPN	O	O	4481
or	CCONJ	O	O	4481
frequency	NOUN	O	O	4481
of	ADP	O	O	4481
anesthetic	NOUN	O	O	4481
administration	NOUN	O	O	4481
in	ADP	O	O	4481
patients	NOUN	O	O	4481
with	ADP	O	O	4481
temporary	ADJ	O	O	4481
vocal	ADJ	O	O	4481
cord	NOUN	O	O	4481
paralysis	NOUN	O	Disease	4481
compared	VERB	O	O	4481
with	ADP	O	O	4481
those	PRON	O	O	4481
without	ADP	O	O	4481
.	PUNCT	O	O	4481
CONCLUSION	PROPN	O	O	4482
:	PUNCT	O	O	4482
Local	ADJ	O	O	4482
anesthesia	NOUN	O	O	4482
led	VERB	O	O	4482
to	PART	O	O	4482
temporary	ADJ	O	O	4482
ipsilateral	ADJ	O	O	4482
vocal	ADJ	O	O	4482
cord	NOUN	O	O	4482
paralysis	NOUN	O	Disease	4482
in	ADP	O	O	4482
almost	ADV	O	O	4482
half	NOUN	O	O	4482
of	ADP	O	O	4482
these	PRON	O	O	4482
patients	NOUN	O	O	4482
.	PUNCT	O	O	4482
Because	SCONJ	O	O	4483
pre	VERB	O	O	4483
-	PUNCT	O	O	4483
existing	VERB	O	O	4483
paralysis	NOUN	O	Disease	4483
is	AUX	O	O	4483
of	ADP	O	O	4483
a	PRON	O	O	4483
relevant	ADJ	O	O	4483
frequency	NOUN	O	O	4483
(	PUNCT	O	O	4483
up	ADP	O	O	4483
to	PART	O	O	4483
3%	NOUN	O	O	4483
)	PUNCT	O	O	4483
,	PUNCT	O	O	4483
a	PRON	O	O	4483
preoperative	ADJ	O	O	4483
evaluation	NOUN	O	O	4483
of	ADP	O	O	4483
vocal	ADJ	O	O	4483
cord	NOUN	O	O	4483
function	NOUN	O	O	4483
before	ADP	O	O	4483
carotid	NOUN	O	O	4483
endarterectomy	ADJ	O	O	4483
under	ADP	O	O	4483
local	ADJ	O	O	4483
anesthesia	NOUN	O	O	4483
is	AUX	O	O	4483
recommended	VERB	O	O	4483
to	PART	O	O	4483
avoid	VERB	O	O	4483
intraoperative	ADJ	O	O	4483
bilateral	ADJ	O	O	4483
paralysis	NOUN	O	Disease	4483
.	PUNCT	O	O	4483
In	ADP	O	O	4484
patients	NOUN	O	O	4484
with	ADP	O	O	4484
preoperative	ADJ	O	O	4484
contralateral	ADJ	O	O	4484
vocal	ADJ	O	O	4484
cord	NOUN	O	O	4484
paralysis	NOUN	O	Disease	4484
,	PUNCT	O	O	4484
surgery	NOUN	O	O	4484
under	ADP	O	O	4484
general	ADJ	O	O	4484
anesthesia	NOUN	O	O	4484
should	AUX	O	O	4484
be	AUX	O	O	4484
considered	VERB	O	O	4484
.	PUNCT	O	O	4484
Neuroprotective	NOUN	O	O	4487
effects	NOUN	O	O	4487
of	ADP	O	O	4487
melatonin	PROPN	O	Chemical	4487
upon	SCONJ	O	O	4487
the	PRON	O	O	4487
offspring	VERB	O	O	4487
cerebellar	ADJ	O	O	4487
cortex	VERB	O	O	4487
in	ADP	O	O	4487
the	PRON	O	O	4487
rat	NOUN	O	O	4487
model	NOUN	O	O	4487
of	ADP	O	O	4487
BCNU	PROPN	O	O	4487
-	PUNCT	O	O	4487
induced	VERB	O	O	4487
cortical	ADJ	O	O	4487
dysplasia	NOUN	O	O	4487
.	PUNCT	O	O	4487
Cortical	ADJ	O	O	4488
dysplasia	NOUN	O	O	4488
is	AUX	O	O	4488
a	PRON	O	O	4488
malformation	NOUN	O	O	4488
characterized	VERB	O	O	4488
by	ADP	O	O	4488
defects	NOUN	O	O	4488
in	ADP	O	O	4488
proliferation	NOUN	O	O	4488
,	PUNCT	O	O	4488
migration	NOUN	O	O	4488
and	CCONJ	O	O	4488
maturation	NOUN	O	O	4488
.	PUNCT	O	O	4488
This	PRON	O	O	4489
study	VERB	O	O	4489
was	AUX	O	O	4489
designed	VERB	O	O	4489
to	PART	O	O	4489
evaluate	VERB	O	O	4489
the	PRON	O	O	4489
alterations	NOUN	O	O	4489
in	ADP	O	O	4489
offspring	VERB	O	O	4489
rat	NOUN	O	O	4489
cerebellum	NOUN	O	O	4489
induced	VERB	O	O	4489
by	ADP	O	O	4489
maternal	ADJ	O	O	4489
exposure	NOUN	O	O	4489
to	PART	O	O	4489
carmustine-[1,3-bis	ADJ	O	O	4489
(	PUNCT	O	O	4489
2-chloroethyl)-1-nitrosoure	NOUN	O	O	4489
]	PUNCT	O	O	4489
(	PUNCT	O	O	4489
BCNU	PROPN	O	O	4489
)	PUNCT	O	O	4489
and	CCONJ	O	O	4489
to	PART	O	O	4489
investigate	VERB	O	O	4489
the	PRON	O	O	4489
effects	NOUN	O	O	4489
of	ADP	O	O	4489
exogenous	ADJ	O	O	4489
melatonin	PROPN	O	Chemical	4489
upon	SCONJ	O	O	4489
cerebellar	ADJ	O	O	4489
BCNU	PROPN	O	O	4489
-	PUNCT	O	O	4489
induced	VERB	O	O	4489
cortical	ADJ	O	O	4489
dysplasia	NOUN	O	O	4489
,	PUNCT	O	O	4489
using	VERB	O	O	4489
histological	ADJ	O	O	4489
and	CCONJ	O	O	4489
biochemical	ADJ	O	O	4489
analyses	NOUN	O	O	4489
.	PUNCT	O	O	4489
Pregnant	ADJ	O	O	4490
Wistar	PROPN	O	O	4490
rats	NOUN	O	O	4490
were	AUX	O	O	4490
assigned	VERB	O	O	4490
to	PART	O	O	4490
five	NUM	O	O	4490
groups	NOUN	O	O	4490
:	PUNCT	O	O	4490
intact	ADJ	O	O	4490
-	PUNCT	O	O	4490
control	VERB	O	O	4490
,	PUNCT	O	O	4490
saline	NOUN	O	O	4490
-	PUNCT	O	O	4490
control	VERB	O	O	4490
,	PUNCT	O	O	4490
melatonin	PROPN	O	Chemical	4490
-	PUNCT	O	O	4490
treated	VERB	O	O	4490
,	PUNCT	O	O	4490
BCNU	PROPN	O	O	4490
-	PUNCT	O	O	4490
exposed	VERB	O	O	4490
and	CCONJ	O	O	4490
BCNU	PROPN	O	O	4490
-	PUNCT	O	O	4490
exposed	VERB	O	O	4490
plus	CCONJ	O	O	4490
melatonin	PROPN	O	Chemical	4490
.	PUNCT	O	O	4490
Rats	NOUN	O	O	4491
were	AUX	O	O	4491
exposed	VERB	O	O	4491
to	PART	O	O	4491
BCNU	PROPN	O	O	4491
on	ADP	O	O	4491
embryonic	ADJ	O	O	4491
day	NOUN	O	O	4491
15	NUM	O	O	4491
and	CCONJ	O	O	4491
melatonin	PROPN	O	Chemical	4491
was	AUX	O	O	4491
given	VERB	O	O	4491
until	ADP	O	O	4491
delivery	NOUN	O	O	4491
.	PUNCT	O	O	4491
Immuno	PROPN	O	O	4492
/	PUNCT	O	O	4492
histochemistry	NOUN	O	O	4492
and	CCONJ	O	O	4492
electron	NOUN	O	O	4492
microscopy	NOUN	O	O	4492
were	AUX	O	O	4492
carried	VERB	O	O	4492
out	ADP	O	O	4492
on	ADP	O	O	4492
the	PRON	O	O	4492
offspring	VERB	O	O	4492
cerebellum	NOUN	O	O	4492
,	PUNCT	O	O	4492
and	CCONJ	O	O	4492
levels	NOUN	O	O	4492
of	ADP	O	O	4492
malondialdehyde	PROPN	O	Chemical	4492
and	CCONJ	O	O	4492
superoxide	NOUN	O	Chemical	4492
dismutase	ADP	O	O	4492
were	AUX	O	O	4492
determined	VERB	O	O	4492
.	PUNCT	O	O	4492
Histopathologically	PROPN	O	O	4493
,	PUNCT	O	O	4493
typical	ADJ	O	O	4493
findings	NOUN	O	O	4493
were	AUX	O	O	4493
observed	VERB	O	O	4493
in	ADP	O	O	4493
the	PRON	O	O	4493
cerebella	NOUN	O	O	4493
from	ADP	O	O	4493
the	PRON	O	O	4493
control	VERB	O	O	4493
groups	NOUN	O	O	4493
,	PUNCT	O	O	4493
but	CCONJ	O	O	4493
the	PRON	O	O	4493
findings	NOUN	O	O	4493
consistent	ADJ	O	O	4493
with	ADP	O	O	4493
early	ADV	O	O	4493
embryonic	ADJ	O	O	4493
development	NOUN	O	O	4493
were	AUX	O	O	4493
noted	VERB	O	O	4493
in	ADP	O	O	4493
BCNU	PROPN	O	O	4493
-	PUNCT	O	O	4493
exposed	VERB	O	O	4493
cortical	ADJ	O	O	4493
dysplasia	NOUN	O	O	4493
group	NOUN	O	O	4493
.	PUNCT	O	O	4493
There	ADV	O	O	4494
was	AUX	O	O	4494
a	PRON	O	O	4494
marked	VERB	O	O	4494
increase	VERB	O	O	4494
in	ADP	O	O	4494
the	PRON	O	O	4494
number	NOUN	O	O	4494
of	ADP	O	O	4494
TUNEL	NOUN	O	O	4494
positive	ADJ	O	O	4494
cells	NOUN	O	O	4494
and	CCONJ	O	O	4494
nestin	NOUN	O	O	4494
positive	ADJ	O	O	4494
cells	NOUN	O	O	4494
in	ADP	O	O	4494
BCNU	PROPN	O	O	4494
-	PUNCT	O	O	4494
exposed	VERB	O	O	4494
group	NOUN	O	O	4494
,	PUNCT	O	O	4494
but	CCONJ	O	O	4494
a	PRON	O	O	4494
decreased	VERB	O	O	4494
immunoreactivity	NOUN	O	O	4494
to	PART	O	O	4494
glial	ADJ	O	O	4494
fibrillary	NOUN	O	O	4494
acidic	ADJ	O	O	4494
protein	NOUN	O	O	4494
,	PUNCT	O	O	4494
synaptophysin	NOUN	O	O	4494
and	CCONJ	O	O	4494
transforming	VERB	O	O	4494
growth	NOUN	O	O	4494
factor	NOUN	O	O	4494
beta1	NOUN	O	O	4494
was	AUX	O	O	4494
observed	VERB	O	O	4494
,	PUNCT	O	O	4494
indicating	VERB	O	O	4494
a	PRON	O	O	4494
delayed	VERB	O	O	4494
maturation	NOUN	O	O	4494
,	PUNCT	O	O	4494
and	CCONJ	O	O	4494
melatonin	PROPN	O	Chemical	4494
significantly	ADV	O	O	4494
reversed	VERB	O	O	4494
these	PRON	O	O	4494
changes	VERB	O	O	4494
.	PUNCT	O	O	4494
Malondialdehyde	PROPN	O	O	4495
level	VERB	O	O	4495
in	ADP	O	O	4495
BCNU	PROPN	O	O	4495
-	PUNCT	O	O	4495
exposed	VERB	O	O	4495
group	NOUN	O	O	4495
was	AUX	O	O	4495
higher	ADJ	O	O	4495
than	ADP	O	O	4495
those	PRON	O	O	4495
in	ADP	O	O	4495
control	VERB	O	O	4495
groups	NOUN	O	O	4495
and	CCONJ	O	O	4495
melatonin	PROPN	O	Chemical	4495
decreased	VERB	O	O	4495
malondialdehyde	PROPN	O	Chemical	4495
levels	NOUN	O	O	4495
in	ADP	O	O	4495
BCNU	PROPN	O	O	4495
group	NOUN	O	O	4495
(	PUNCT	O	O	4495
P<0.01	ADV	O	O	4495
)	PUNCT	O	O	4495
,	PUNCT	O	O	4495
while	SCONJ	O	O	4495
there	ADV	O	O	4495
were	AUX	O	O	4495
no	PRON	O	O	4495
significant	ADJ	O	O	4495
differences	NOUN	O	O	4495
in	ADP	O	O	4495
the	PRON	O	O	4495
superoxide	NOUN	O	Chemical	4495
dismutase	ADP	O	O	4495
levels	NOUN	O	O	4495
between	ADP	O	O	4495
these	PRON	O	O	4495
groups	NOUN	O	O	4495
.	PUNCT	O	O	4495
These	PRON	O	O	4496
data	NOUN	O	O	4496
suggest	VERB	O	O	4496
that	SCONJ	O	O	4496
exposure	NOUN	O	O	4496
of	ADP	O	O	4496
animals	NOUN	O	O	4496
to	PART	O	O	4496
BCNU	PROPN	O	O	4496
during	ADP	O	O	4496
pregnancy	NOUN	O	O	4496
leads	VERB	O	O	4496
to	PART	O	O	4496
delayed	VERB	O	O	4496
maturation	NOUN	O	O	4496
of	ADP	O	O	4496
offspring	VERB	O	O	4496
cerebellum	NOUN	O	O	4496
and	CCONJ	O	O	4496
melatonin	PROPN	O	Chemical	4496
protects	VERB	O	O	4496
the	PRON	O	O	4496
cerebellum	NOUN	O	O	4496
against	ADP	O	O	4496
the	PRON	O	O	4496
effects	NOUN	O	O	4496
of	ADP	O	O	4496
BCNU	PROPN	O	O	4496
.	PUNCT	O	O	4496
Myo	PROPN	O	O	4499
-	PUNCT	O	O	4499
inositol-1-phosphate	NOUN	O	O	4499
(	PUNCT	O	O	4499
MIP	PROPN	O	O	4499
)	PUNCT	O	O	4499
Lithium	NOUN	O	Chemical	4500
and	CCONJ	O	O	4500
valproate	VERB	O	Chemical	4500
are	AUX	O	O	4500
the	PRON	O	O	4500
prototypic	NOUN	O	O	4500
mood	NOUN	O	O	4500
stabilizers	NOUN	O	O	4500
and	CCONJ	O	O	4500
have	VERB	O	O	4500
diverse	ADJ	O	O	4500
structures	NOUN	O	O	4500
and	CCONJ	O	O	4500
targets	VERB	O	O	4500
.	PUNCT	O	O	4500
Both	PRON	O	O	4501
drugs	NOUN	O	O	4501
influence	NOUN	O	O	4501
inositol	PROPN	O	O	4501
metabolism	NOUN	O	O	4501
.	PUNCT	O	O	4501
Lithium	NOUN	O	Chemical	4502
inhibits	VERB	O	O	4502
IMPase	VERB	O	O	4502
and	CCONJ	O	O	4502
valproate	VERB	O	Chemical	4502
inhibits	VERB	O	O	4502
MIP	PROPN	O	O	4502
synthase	NOUN	O	O	4502
.	PUNCT	O	O	4502
This	PRON	O	O	4503
study	VERB	O	O	4503
shows	VERB	O	O	4503
that	SCONJ	O	O	4503
MIP	PROPN	O	O	4503
synthase	NOUN	O	O	4503
inhibition	NOUN	O	O	4503
does	VERB	O	O	4503
not	PART	O	O	4503
replicate	VERB	O	O	4503
or	CCONJ	O	O	4503
augment	VERB	O	O	4503
the	PRON	O	O	4503
effects	NOUN	O	O	4503
of	ADP	O	O	4503
lithium	NOUN	O	Chemical	4503
in	ADP	O	O	4503
the	PRON	O	O	4503
inositol	PROPN	O	O	4503
sensitive	ADJ	O	O	4503
pilocarpine	NOUN	O	Chemical	4503
-	PUNCT	O	O	4503
induced	VERB	O	O	4503
seizures	NOUN	O	Disease	4503
model	NOUN	O	O	4503
.	PUNCT	O	O	4503
This	PRON	O	O	4504
lack	VERB	O	O	4504
of	ADP	O	O	4504
effects	NOUN	O	O	4504
may	AUX	O	O	4504
stem	VERB	O	O	4504
from	ADP	O	O	4504
the	PRON	O	O	4504
low	ADJ	O	O	4504
contribution	NOUN	O	O	4504
of	ADP	O	O	4504
de	VERB	O	O	4504
-	PUNCT	O	O	4504
novo	PROPN	O	O	4504
synthesis	NOUN	O	O	4504
to	PART	O	O	4504
cellular	NOUN	O	O	4504
inositol	PROPN	O	O	4504
supply	NOUN	O	O	4504
or	CCONJ	O	O	4504
to	PART	O	O	4504
the	PRON	O	O	4504
inhibition	NOUN	O	O	4504
of	ADP	O	O	4504
the	PRON	O	O	4504
de	VERB	O	O	4504
-	PUNCT	O	O	4504
novo	PROPN	O	O	4504
synthesis	NOUN	O	O	4504
by	ADP	O	O	4504
lithium	NOUN	O	Chemical	4504
itself	PRON	O	O	4504
.	PUNCT	O	O	4504
Non	NOUN	O	O	4507
-	PUNCT	O	O	4507
steroidal	ADJ	O	O	4507
anti	ADJ	O	O	4507
-	PUNCT	O	O	4507
inflammatory	ADJ	O	O	4507
drugs	NOUN	O	O	4507
-	PUNCT	O	O	4507
associated	VERB	O	O	4507
acute	ADJ	O	O	4507
interstitial nephritis	NOUN	O	Disease	4507
with	ADP	O	O	4507
granular	ADJ	O	O	4507
tubular	ADJ	O	O	4507
basement	NOUN	O	O	4507
membrane	NOUN	O	O	4507
deposits	NOUN	O	O	4507
.	PUNCT	O	O	4507
Acute	PROPN	O	O	4508
tubulo	NOUN	O	O	4508
-	PUNCT	O	O	4508
interstitial nephritis	NOUN	O	Disease	4508
(	PUNCT	O	O	4508
ATIN	PROPN	O	O	4508
)	PUNCT	O	O	4508
is	AUX	O	O	4508
an	PRON	O	O	4508
important	ADJ	O	O	4508
cause	VERB	O	O	4508
of	ADP	O	O	4508
acute	ADJ	O	O	4508
renal failure	NOUN	O	Disease	4508
resulting	VERB	O	O	4508
from	ADP	O	O	4508
a	PRON	O	O	4508
variety	NOUN	O	O	4508
of	ADP	O	O	4508
insults	NOUN	O	O	4508
,	PUNCT	O	O	4508
including	VERB	O	O	4508
immune	NOUN	O	O	4508
complex	ADJ	O	O	4508
-	PUNCT	O	O	4508
mediated	VERB	O	O	4508
tubulo	NOUN	O	O	4508
-	PUNCT	O	O	4508
interstitial	ADJ	O	O	4508
injury	NOUN	O	O	4508
,	PUNCT	O	O	4508
but	CCONJ	O	O	4508
drugs	NOUN	O	O	4508
such	ADJ	O	O	4508
as	ADP	O	O	4508
non	ADJ	O	O	4508
-	PUNCT	O	O	4508
steroidal	ADJ	O	O	4508
anti	ADJ	O	O	4508
-	PUNCT	O	O	4508
inflammatory	ADJ	O	O	4508
drugs	NOUN	O	O	4508
(	PUNCT	O	O	4508
NSAIDs	NOUN	O	Chemical	4508
)	PUNCT	O	O	4508
are	AUX	O	O	4508
a	PRON	O	O	4508
far	ADV	O	O	4508
more	ADJ	O	O	4508
frequent	ADJ	O	O	4508
cause	VERB	O	O	4508
.	PUNCT	O	O	4508
Overall	ADV	O	O	4509
,	PUNCT	O	O	4509
as	ADP	O	O	4509
an	PRON	O	O	4509
entity	NOUN	O	O	4509
,	PUNCT	O	O	4509
ATIN	PROPN	O	O	4509
remains	VERB	O	O	4509
under	ADP	O	O	4509
-	PUNCT	O	O	4509
diagnosed	VERB	O	O	4509
,	PUNCT	O	O	4509
as	ADP	O	O	4509
symptoms	NOUN	O	O	4509
resolve	VERB	O	O	4509
spontaneously	ADV	O	O	4509
if	SCONJ	O	O	4509
the	PRON	O	O	4509
medication	NOUN	O	O	4509
is	AUX	O	O	4509
stopped	VERB	O	O	4509
.	PUNCT	O	O	4509
We	PRON	O	O	4510
report	VERB	O	O	4510
on	ADP	O	O	4510
a	PRON	O	O	4510
14-year	NOUN	O	O	4510
-	PUNCT	O	O	4510
old	ADJ	O	O	4510
boy	NOUN	O	O	4510
who	PRON	O	O	4510
developed	VERB	O	O	4510
acute	ADJ	O	O	4510
renal failure	NOUN	O	Disease	4510
2	X	O	O	4510
weeks	NOUN	O	O	4510
after	ADP	O	O	4510
aortic	ADJ	O	O	4510
valve	PROPN	O	O	4510
surgery	NOUN	O	O	4510
.	PUNCT	O	O	4510
He	PRON	O	O	4511
was	AUX	O	O	4511
put	VERB	O	O	4511
on	ADP	O	O	4511
aspirin	NOUN	O	Chemical	4511
following	VERB	O	O	4511
surgery	NOUN	O	O	4511
and	CCONJ	O	O	4511
took	VERB	O	O	4511
ibuprofen	PROPN	O	Chemical	4511
for	ADP	O	O	4511
fever	NOUN	O	Disease	4511
for	ADP	O	O	4511
nearly	ADV	O	O	4511
a	PRON	O	O	4511
week	NOUN	O	O	4511
prior	ADV	O	O	4511
to	PART	O	O	4511
presentation	NOUN	O	O	4511
.	PUNCT	O	O	4511
He	PRON	O	O	4512
then	ADV	O	O	4512
presented	VERB	O	O	4512
to	PART	O	O	4512
the	PRON	O	O	4512
emergency	NOUN	O	O	4512
department	NOUN	O	O	4512
feeling	VERB	O	O	4512
quite	ADV	O	O	4512
ill	PROPN	O	O	4512
and	CCONJ	O	O	4512
was	AUX	O	O	4512
found	VERB	O	O	4512
to	PART	O	O	4512
have	VERB	O	O	4512
a	PRON	O	O	4512
blood	NOUN	O	O	4512
urea nitrogen	NOUN	O	Chemical	4512
(	PUNCT	O	O	4512
BUN	PROPN	O	Chemical	4512
)	PUNCT	O	O	4512
concentration	NOUN	O	O	4512
of	ADP	O	O	4512
of	ADP	O	O	4512
147	NUM	O	O	4512
mg	VERB	O	O	4512
/	PUNCT	O	O	4512
dl	X	O	O	4512
,	PUNCT	O	O	4512
creatinine	PROPN	O	Chemical	4512
of	ADP	O	O	4512
15.3	NUM	O	O	4512
mg	VERB	O	O	4512
/	PUNCT	O	O	4512
dl	X	O	O	4512
and	CCONJ	O	O	4512
serum	NOUN	O	O	4512
potassium	NOUN	O	Chemical	4512
of	ADP	O	O	4512
8.7	NUM	O	O	4512
mEq	VERB	O	O	4512
/	PUNCT	O	O	4512
l	X	O	O	4512
.	PUNCT	O	O	4512
A	PRON	O	O	4513
kidney	NOUN	O	O	4513
biopsy	PROPN	O	O	4513
showed	VERB	O	O	4513
inflammatory	ADJ	O	O	4513
infiltrate	VERB	O	O	4513
consistent	ADJ	O	O	4513
with	ADP	O	O	4513
ATIN	PROPN	O	O	4513
.	PUNCT	O	O	4513
He	PRON	O	O	4514
needed	VERB	O	O	4514
dialysis	NOUN	O	O	4514
for	ADP	O	O	4514
2	X	O	O	4514
weeks	NOUN	O	O	4514
and	CCONJ	O	O	4514
was	AUX	O	O	4514
treated	VERB	O	O	4514
successfully	ADV	O	O	4514
with	ADP	O	O	4514
steroids	NOUN	O	Chemical	4514
for	ADP	O	O	4514
6	NUM	O	O	4514
months	NOUN	O	O	4514
.	PUNCT	O	O	4514
His	PRON	O	O	4515
renal	ADJ	O	O	4515
recovery	NOUN	O	O	4515
and	CCONJ	O	O	4515
disappearance	NOUN	O	O	4515
of	ADP	O	O	4515
proteinuria	X	O	Disease	4515
took	VERB	O	O	4515
a	PRON	O	O	4515
year	NOUN	O	O	4515
.	PUNCT	O	O	4515
In	ADP	O	O	4516
conclusion	NOUN	O	O	4516
,	PUNCT	O	O	4516
this	PRON	O	O	4516
is	AUX	O	O	4516
a	PRON	O	O	4516
first	ADV	O	O	4516
report	VERB	O	O	4516
of	ADP	O	O	4516
NSAIDs	NOUN	O	Chemical	4516
-	PUNCT	O	O	4516
associated	VERB	O	O	4516
ATIN	PROPN	O	O	4516
,	PUNCT	O	O	4516
showing	VERB	O	O	4516
deposits	NOUN	O	O	4516
of	ADP	O	O	4516
granular	ADJ	O	O	4516
immune	NOUN	O	O	4516
complex	ADJ	O	O	4516
present	NOUN	O	O	4516
only	ADV	O	O	4516
in	ADP	O	O	4516
the	PRON	O	O	4516
TBM	PROPN	O	O	4516
and	CCONJ	O	O	4516
not	PART	O	O	4516
in	ADP	O	O	4516
the	PRON	O	O	4516
glomeruli	VERB	O	O	4516
.	PUNCT	O	O	4516
Rifampicin	PROPN	O	O	4519
-	PUNCT	O	O	4519
associated	VERB	O	O	4519
segmental necrotizing glomerulonephritis	NOUN	O	Disease	4519
in	ADP	O	O	4519
staphylococcal	ADJ	O	O	4519
endocarditis	NOUN	O	O	4519
.	PUNCT	O	O	4519
necrotising	VERB	O	O	4520
glomerulonephritis	NOUN	O	Disease	4520
has	VERB	O	O	4520
been	AUX	O	O	4520
reported	VERB	O	O	4520
as	ADP	O	O	4520
complication	NOUN	O	O	4520
of	ADP	O	O	4520
rifampicin	VERB	O	Chemical	4520
therapy	NOUN	O	O	4520
in	ADP	O	O	4520
patients	NOUN	O	O	4520
receiving	VERB	O	O	4520
treatment	NOUN	O	O	4520
for	ADP	O	O	4520
tuberculosis	NOUN	O	Disease	4520
.	PUNCT	O	O	4520
Changing	VERB	O	O	4521
epidemiology	NOUN	O	O	4521
of	ADP	O	O	4521
infections	NOUN	O	Disease	4521
such	ADJ	O	O	4521
as	ADP	O	O	4521
infective	ADJ	O	O	4521
endocarditis	NOUN	O	O	4521
(	PUNCT	O	O	4521
IE	PROPN	O	O	4521
)	PUNCT	O	O	4521
has	VERB	O	O	4521
led	VERB	O	O	4521
to	PART	O	O	4521
an	PRON	O	O	4521
increase	VERB	O	O	4521
in	ADP	O	O	4521
the	PRON	O	O	4521
use	VERB	O	O	4521
of	ADP	O	O	4521
rifampicin	VERB	O	Chemical	4521
for	ADP	O	O	4521
Staphylococcal	ADJ	O	O	4521
infections	NOUN	O	Disease	4521
.	PUNCT	O	O	4521
We	PRON	O	O	4522
describe	VERB	O	O	4522
a	PRON	O	O	4522
case	NOUN	O	O	4522
of	ADP	O	O	4522
a	PRON	O	O	4522
patient	NOUN	O	O	4522
with	ADP	O	O	4522
Staphylococcal	ADJ	O	O	4522
IE	PROPN	O	O	4522
who	PRON	O	O	4522
developed	VERB	O	O	4522
acute	ADJ	O	O	4522
renal failure	NOUN	O	Disease	4522
secondary	ADJ	O	O	4522
to	PART	O	O	4522
a	PRON	O	O	4522
segmental	ADJ	O	O	4522
necrotising	VERB	O	O	4522
glomerulonephritis	NOUN	O	Disease	4522
while	SCONJ	O	O	4522
being	AUX	O	O	4522
treated	VERB	O	O	4522
with	ADP	O	O	4522
rifampicin	VERB	O	Chemical	4522
,	PUNCT	O	O	4522
and	CCONJ	O	O	4522
review	VERB	O	O	4522
the	PRON	O	O	4522
literature	NOUN	O	O	4522
regarding	VERB	O	O	4522
this	PRON	O	O	4522
complication	NOUN	O	O	4522
of	ADP	O	O	4522
rifampicin	VERB	O	Chemical	4522
therapy	NOUN	O	O	4522
.	PUNCT	O	O	4522
Rate	NOUN	O	O	4525
of	ADP	O	O	4525
YMDD	NOUN	O	O	4525
motif	NOUN	O	O	4525
mutants	NOUN	O	O	4525
in	ADP	O	O	4525
lamivudine	NOUN	O	Chemical	4525
-	PUNCT	O	O	4525
untreated	ADJ	O	O	4525
Iranian	ADJ	O	O	4525
patients	NOUN	O	O	4525
with	ADP	O	O	4525
chronic	ADJ	O	O	4525
hepatitis B	PROPN	O	Disease	4525
virus	NOUN	O	O	4525
infection	NOUN	O	Disease	4525
.	PUNCT	O	O	4525
Lamivudine	NOUN	O	O	4526
is	AUX	O	O	4526
used	VERB	O	O	4526
for	ADP	O	O	4526
the	PRON	O	O	4526
treatment	NOUN	O	O	4526
of	ADP	O	O	4526
chronic	ADJ	O	O	4526
hepatitis B	PROPN	O	Disease	4526
patients	NOUN	O	O	4526
.	PUNCT	O	O	4526
Recent	ADJ	O	O	4527
studies	NOUN	O	O	4527
show	VERB	O	O	4527
that	SCONJ	O	O	4527
the	PRON	O	O	4527
YMDD	NOUN	O	O	4527
motif	NOUN	O	O	4527
mutants	NOUN	O	O	4527
(	PUNCT	O	O	4527
resistant	ADJ	O	O	4527
hepatitis B	PROPN	O	Disease	4527
virus	NOUN	O	O	4527
)	PUNCT	O	O	4527
occur	VERB	O	O	4527
as	ADP	O	O	4527
natural	ADJ	O	O	4527
genome	NOUN	O	O	4527
variability	NOUN	O	O	4527
in	ADP	O	O	4527
lamivudine	NOUN	O	Chemical	4527
-	PUNCT	O	O	4527
untreated	ADJ	O	O	4527
chronic	ADJ	O	O	4527
hepatitis B	PROPN	O	Disease	4527
patients	NOUN	O	O	4527
.	PUNCT	O	O	4527
In	ADP	O	O	4528
this	PRON	O	O	4528
study	VERB	O	O	4528
we	PRON	O	O	4528
aimed	VERB	O	O	4528
to	PART	O	O	4528
determine	VERB	O	O	4528
the	PRON	O	O	4528
rate	NOUN	O	O	4528
of	ADP	O	O	4528
YMDD	NOUN	O	O	4528
motif	NOUN	O	O	4528
mutants	NOUN	O	O	4528
in	ADP	O	O	4528
lamivudine	NOUN	O	Chemical	4528
-	PUNCT	O	O	4528
untreated	ADJ	O	O	4528
chronic	ADJ	O	O	4528
hepatitis B	PROPN	O	Disease	4528
patients	NOUN	O	O	4528
in	ADP	O	O	4528
Iran	PROPN	O	O	4528
.	PUNCT	O	O	4528
A	PRON	O	O	4529
total	ADJ	O	O	4529
of	ADP	O	O	4529
77	NUM	O	O	4529
chronic	ADJ	O	O	4529
hepatitis B	PROPN	O	Disease	4529
patients	NOUN	O	O	4529
who	PRON	O	O	4529
had	VERB	O	O	4529
not	PART	O	O	4529
been	AUX	O	O	4529
treated	VERB	O	O	4529
with	ADP	O	O	4529
lamivudine	NOUN	O	Chemical	4529
were	AUX	O	O	4529
included	VERB	O	O	4529
in	ADP	O	O	4529
the	PRON	O	O	4529
study	VERB	O	O	4529
.	PUNCT	O	O	4529
All	PRON	O	O	4530
patients	NOUN	O	O	4530
were	AUX	O	O	4530
also	ADV	O	O	4530
tested	VERB	O	O	4530
for	ADP	O	O	4530
liver	NOUN	O	O	4530
enzymes	NOUN	O	O	4530
,	PUNCT	O	O	4530
anti	ADJ	O	O	4530
-	PUNCT	O	O	4530
HCV	PROPN	O	O	4530
,	PUNCT	O	O	4530
HBeAg	PROPN	O	Chemical	4530
,	PUNCT	O	O	4530
and	CCONJ	O	O	4530
anti	ADJ	O	O	4530
-	PUNCT	O	O	4530
HBe	PROPN	O	O	4530
.	PUNCT	O	O	4530
HBeAg	PROPN	O	Chemical	4531
was	AUX	O	O	4531
positive	ADJ	O	O	4531
in	ADP	O	O	4531
40%	NOUN	O	O	4531
and	CCONJ	O	O	4531
anti	ADJ	O	O	4531
-	PUNCT	O	O	4531
HBe	PROPN	O	O	4531
in	ADP	O	O	4531
60%	NOUN	O	O	4531
of	ADP	O	O	4531
the	PRON	O	O	4531
patients	NOUN	O	O	4531
.	PUNCT	O	O	4531
YMDD	NOUN	O	O	4532
motif	NOUN	O	O	4532
mutants	NOUN	O	O	4532
were	AUX	O	O	4532
not	PART	O	O	4532
detected	VERB	O	O	4532
in	ADP	O	O	4532
any	PRON	O	O	4532
of	ADP	O	O	4532
the	PRON	O	O	4532
patients	NOUN	O	O	4532
despite	SCONJ	O	O	4532
the	PRON	O	O	4532
liver	NOUN	O	O	4532
enzyme	NOUN	O	O	4532
levels	NOUN	O	O	4532
and	CCONJ	O	O	4532
the	PRON	O	O	4532
presence	NOUN	O	O	4532
of	ADP	O	O	4532
HBeAg	PROPN	O	Chemical	4532
or	CCONJ	O	O	4532
anti	ADJ	O	O	4532
-	PUNCT	O	O	4532
HBe	PROPN	O	O	4532
.	PUNCT	O	O	4532
CONCLUSION	PROPN	O	O	4533
:	PUNCT	O	O	4533
Although	SCONJ	O	O	4533
the	PRON	O	O	4533
natural	ADJ	O	O	4533
occurrence	NOUN	O	O	4533
of	ADP	O	O	4533
YMDD	NOUN	O	O	4533
motif	NOUN	O	O	4533
mutants	NOUN	O	O	4533
in	ADP	O	O	4533
lamivudine	NOUN	O	Chemical	4533
-	PUNCT	O	O	4533
untreated	ADJ	O	O	4533
patients	NOUN	O	O	4533
with	ADP	O	O	4533
chronic	ADJ	O	O	4533
hepatitis B	PROPN	O	Disease	4533
has	VERB	O	O	4533
been	AUX	O	O	4533
reported	VERB	O	O	4533
,	PUNCT	O	O	4533
these	PRON	O	O	4533
mutants	NOUN	O	O	4533
were	AUX	O	O	4533
not	PART	O	O	4533
detected	VERB	O	O	4533
in	ADP	O	O	4533
Iranian	ADJ	O	O	4533
lamivudine	NOUN	O	Chemical	4533
-	PUNCT	O	O	4533
untreated	ADJ	O	O	4533
chronic	ADJ	O	O	4533
hepatitis B	PROPN	O	Disease	4533
patients	NOUN	O	O	4533
.	PUNCT	O	O	4533
Branch	NOUN	O	O	4536
retinal	ADJ	O	O	4536
vein	NOUN	O	O	4536
occlusion	NOUN	O	O	4536
and	CCONJ	O	O	4536
fluoxetine	NOUN	O	Chemical	4536
.	PUNCT	O	O	4536
A	PRON	O	O	4537
case	NOUN	O	O	4537
of	ADP	O	O	4537
branch	NOUN	O	O	4537
retinal	ADJ	O	O	4537
vein	NOUN	O	O	4537
occlusion	NOUN	O	O	4537
associated	VERB	O	O	4537
with	ADP	O	O	4537
fluoxetine	NOUN	O	Chemical	4537
-	PUNCT	O	O	4537
induced	VERB	O	O	4537
secondary	ADJ	O	O	4537
hypertension	NOUN	O	Disease	4537
is	AUX	O	O	4537
described	VERB	O	O	4537
.	PUNCT	O	O	4537
Although	SCONJ	O	O	4538
an	PRON	O	O	4538
infrequent	ADJ	O	O	4538
complication	NOUN	O	O	4538
of	ADP	O	O	4538
selective	ADJ	O	O	4538
serotonin	PROPN	O	Chemical	4538
reuptake	PROPN	O	O	4538
inhibitor	NOUN	O	O	4538
therapy	NOUN	O	O	4538
,	PUNCT	O	O	4538
it	PRON	O	O	4538
is	AUX	O	O	4538
important	ADJ	O	O	4538
that	SCONJ	O	O	4538
ophthalmologists	NOUN	O	O	4538
are	AUX	O	O	4538
aware	ADJ	O	O	4538
that	SCONJ	O	O	4538
these	PRON	O	O	4538
agents	NOUN	O	O	4538
can	AUX	O	O	4538
cause	VERB	O	O	4538
hypertension	NOUN	O	Disease	4538
because	SCONJ	O	O	4538
this	PRON	O	O	4538
class	NOUN	O	O	4538
of	ADP	O	O	4538
drugs	NOUN	O	O	4538
is	AUX	O	O	4538
widely	ADV	O	O	4538
prescribed	VERB	O	O	4538
.	PUNCT	O	O	4538
The	PRON	O	O	4541
differential	ADJ	O	O	4541
effects	NOUN	O	O	4541
of	ADP	O	O	4541
bupivacaine	NOUN	O	Chemical	4541
and	CCONJ	O	O	4541
lidocaine	NOUN	O	Chemical	4541
on	ADP	O	O	4541
prostaglandin E2	NOUN	O	Chemical	4541
release	NOUN	O	O	4541
,	PUNCT	O	O	4541
cyclooxygenase	PROPN	O	O	4541
gene	NOUN	O	O	4541
expression	NOUN	O	O	4541
and	CCONJ	O	O	4541
pain	NOUN	O	Disease	4541
in	ADP	O	O	4541
a	PRON	O	O	4541
clinical	ADJ	O	O	4541
pain	NOUN	O	Disease	4541
model	NOUN	O	O	4541
.	PUNCT	O	O	4541
In	ADP	O	O	4542
addition	NOUN	O	O	4542
to	PART	O	O	4542
blocking	VERB	O	O	4542
nociceptive	ADJ	O	O	4542
input	NOUN	O	O	4542
from	ADP	O	O	4542
surgical	ADJ	O	O	4542
sites	NOUN	O	O	4542
,	PUNCT	O	O	4542
long	ADV	O	O	4542
-	PUNCT	O	O	4542
acting	VERB	O	O	4542
local	ADJ	O	O	4542
anesthetics	NOUN	O	O	4542
might	AUX	O	O	4542
directly	ADV	O	O	4542
modulate	VERB	O	O	4542
inflammation	NOUN	O	Disease	4542
.	PUNCT	O	O	4542
In	ADP	O	O	4543
the	PRON	O	O	4543
present	NOUN	O	O	4543
study	VERB	O	O	4543
,	PUNCT	O	O	4543
we	PRON	O	O	4543
describe	VERB	O	O	4543
the	PRON	O	O	4543
proinflammatory	ADJ	O	O	4543
effects	NOUN	O	O	4543
of	ADP	O	O	4543
bupivacaine	NOUN	O	Chemical	4543
on	ADP	O	O	4543
local	ADJ	O	O	4543
prostaglandin E2	NOUN	O	Chemical	4543
(	PUNCT	O	O	4543
PGE2	NOUN	O	Chemical	4543
)	PUNCT	O	O	4543
production	NOUN	O	O	4543
and	CCONJ	O	O	4543
cyclooxygenase	PROPN	O	O	4543
(	PUNCT	O	O	4543
COX	PROPN	O	O	4543
)	PUNCT	O	O	4543
gene	NOUN	O	O	4543
expression	NOUN	O	O	4543
that	SCONJ	O	O	4543
increases	VERB	O	O	4543
postoperative	ADJ	O	O	4543
pain	NOUN	O	Disease	4543
in	ADP	O	O	4543
human	PROPN	O	O	4543
subjects	NOUN	O	O	4543
.	PUNCT	O	O	4543
METHODS	NOUN	O	O	4544
:	PUNCT	O	O	4544
Subjects	NOUN	O	O	4544
(	PUNCT	O	O	4544
n	CCONJ	O	O	4544
=	PUNCT	O	O	4544
114	NUM	O	O	4544
)	PUNCT	O	O	4544
undergoing	VERB	O	O	4544
extraction	NOUN	O	O	4544
of	ADP	O	O	4544
impacted	VERB	O	O	4544
third	ADV	O	O	4544
molars	NOUN	O	O	4544
received	VERB	O	O	4544
either	ADV	O	O	4544
2%	NOUN	O	O	4544
lidocaine	NOUN	O	Chemical	4544
or	CCONJ	O	O	4544
0.5%	NOUN	O	O	4544
bupivacaine	NOUN	O	Chemical	4544
before	ADP	O	O	4544
surgery	NOUN	O	O	4544
and	CCONJ	O	O	4544
either	ADV	O	O	4544
rofecoxib	PROPN	O	O	4544
50	NUM	O	O	4544
mg	VERB	O	O	4544
or	CCONJ	O	O	4544
placebo	NOUN	O	O	4544
orally	ADV	O	O	4544
90	NUM	O	O	4544
min	NOUN	O	O	4544
before	ADP	O	O	4544
surgery	NOUN	O	O	4544
and	CCONJ	O	O	4544
for	ADP	O	O	4544
the	PRON	O	O	4544
following	VERB	O	O	4544
48	NUM	O	O	4544
h.	PROPN	O	O	4544
Oral	NOUN	O	O	4544
mucosal	ADJ	O	O	4544
biopsies	NOUN	O	O	4544
were	AUX	O	O	4544
taken	VERB	O	O	4544
before	ADP	O	O	4544
surgery	NOUN	O	O	4544
and	CCONJ	O	O	4544
48	NUM	O	O	4544
h	X	O	O	4544
after	ADP	O	O	4544
surgery	NOUN	O	O	4544
.	PUNCT	O	O	4544
After	ADP	O	O	4545
extraction	NOUN	O	O	4545
,	PUNCT	O	O	4545
a	PRON	O	O	4545
microdialysis	NOUN	O	O	4545
probe	NOUN	O	O	4545
was	AUX	O	O	4545
placed	VERB	O	O	4545
at	ADP	O	O	4545
the	PRON	O	O	4545
surgical	ADJ	O	O	4545
site	NOUN	O	O	4545
for	ADP	O	O	4545
PGE2	NOUN	O	Chemical	4545
and	CCONJ	O	O	4545
thromboxane	NOUN	O	O	4545
B2	NOUN	O	O	4545
(	PUNCT	O	O	4545
TXB2	PROPN	O	O	4545
)	PUNCT	O	O	4545
measurements	NOUN	O	O	4545
.	PUNCT	O	O	4545
The	PRON	O	O	4546
bupivacaine	NOUN	O	Chemical	4546
/	PUNCT	O	O	4546
rofecoxib	PROPN	O	O	4546
group	NOUN	O	O	4546
reported	VERB	O	O	4546
significantly	ADV	O	O	4546
less	ADV	O	O	4546
pain	NOUN	O	Disease	4546
,	PUNCT	O	O	4546
as	ADP	O	O	4546
assessed	VERB	O	O	4546
by	ADP	O	O	4546
a	PRON	O	O	4546
visual	ADJ	O	O	4546
analog	NOUN	O	O	4546
scale	NOUN	O	O	4546
,	PUNCT	O	O	4546
compared	VERB	O	O	4546
with	ADP	O	O	4546
the	PRON	O	O	4546
other	ADJ	O	O	4546
three	NUM	O	O	4546
treatment	NOUN	O	O	4546
groups	NOUN	O	O	4546
over	ADP	O	O	4546
the	PRON	O	O	4546
first	ADV	O	O	4546
4	NUM	O	O	4546
h.	PROPN	O	O	4546
However	ADV	O	O	4547
,	PUNCT	O	O	4547
the	PRON	O	O	4547
bupivacaine	NOUN	O	Chemical	4547
/	PUNCT	O	O	4547
placebo	NOUN	O	O	4547
group	NOUN	O	O	4547
reported	VERB	O	O	4547
significantly	ADV	O	O	4547
more	ADJ	O	O	4547
pain	NOUN	O	Disease	4547
at	ADP	O	O	4547
24	NUM	O	O	4547
h	X	O	O	4547
and	CCONJ	O	O	4547
PGE2	NOUN	O	Chemical	4547
levels	NOUN	O	O	4547
during	ADP	O	O	4547
the	PRON	O	O	4547
first	ADV	O	O	4547
4	NUM	O	O	4547
h	X	O	O	4547
were	AUX	O	O	4547
significantly	ADV	O	O	4547
higher	ADJ	O	O	4547
than	ADP	O	O	4547
the	PRON	O	O	4547
other	ADJ	O	O	4547
three	NUM	O	O	4547
treatment	NOUN	O	O	4547
groups	NOUN	O	O	4547
.	PUNCT	O	O	4547
Moreover	ADV	O	O	4548
,	PUNCT	O	O	4548
bupivacaine	NOUN	O	Chemical	4548
significantly	ADV	O	O	4548
increased	VERB	O	O	4548
COX-2	ADJ	O	O	4548
gene	NOUN	O	O	4548
expression	NOUN	O	O	4548
at	ADP	O	O	4548
48	NUM	O	O	4548
h	X	O	O	4548
as	ADP	O	O	4548
compared	VERB	O	O	4548
with	ADP	O	O	4548
the	PRON	O	O	4548
lidocaine	NOUN	O	Chemical	4548
/	PUNCT	O	O	4548
placebo	NOUN	O	O	4548
group	NOUN	O	O	4548
.	PUNCT	O	O	4548
Thromboxane	NOUN	O	O	4549
levels	NOUN	O	O	4549
were	AUX	O	O	4549
not	PART	O	O	4549
significantly	ADV	O	O	4549
affected	VERB	O	O	4549
by	ADP	O	O	4549
any	PRON	O	O	4549
of	ADP	O	O	4549
the	PRON	O	O	4549
treatments	NOUN	O	O	4549
,	PUNCT	O	O	4549
indicating	VERB	O	O	4549
that	SCONJ	O	O	4549
the	PRON	O	O	4549
effects	NOUN	O	O	4549
seen	VERB	O	O	4549
were	AUX	O	O	4549
attributable	ADJ	O	O	4549
to	PART	O	O	4549
inhibition	NOUN	O	O	4549
of	ADP	O	O	4549
COX-2	ADJ	O	O	4549
,	PUNCT	O	O	4549
but	CCONJ	O	O	4549
not	PART	O	O	4549
COX-1	NUM	O	O	4549
.	PUNCT	O	O	4549
These	PRON	O	O	4550
results	VERB	O	O	4550
suggest	VERB	O	O	4550
that	SCONJ	O	O	4550
bupivacaine	NOUN	O	Chemical	4550
stimulates	VERB	O	O	4550
COX-2	ADJ	O	O	4550
gene	NOUN	O	O	4550
expression	NOUN	O	O	4550
after	ADP	O	O	4550
tissue	NOUN	O	O	4550
injury	NOUN	O	O	4550
,	PUNCT	O	O	4550
which	PRON	O	O	4550
is	AUX	O	O	4550
associated	VERB	O	O	4550
with	ADP	O	O	4550
higher	ADJ	O	O	4550
PGE2	NOUN	O	Chemical	4550
production	NOUN	O	O	4550
and	CCONJ	O	O	4550
pain	NOUN	O	Disease	4550
after	ADP	O	O	4550
the	PRON	O	O	4550
local	ADJ	O	O	4550
anesthetic	NOUN	O	O	4550
effect	VERB	O	O	4550
dissipates	VERB	O	O	4550
.	PUNCT	O	O	4550
p75NTR	PROPN	O	O	4553
expression	NOUN	O	O	4553
in	ADP	O	O	4553
rat	NOUN	O	O	4553
urinary	ADJ	O	O	4553
bladder	NOUN	O	O	4553
sensory	ADJ	O	O	4553
neurons	NOUN	O	O	4553
and	CCONJ	O	O	4553
spinal	NOUN	O	O	4553
cord	NOUN	O	O	4553
with	ADP	O	O	4553
cyclophosphamide	VERB	O	Chemical	4553
-	PUNCT	O	O	4553
induced	VERB	O	O	4553
cystitis	NOUN	O	Disease	4553
.	PUNCT	O	O	4553
Previous	ADJ	O	O	4554
studies	NOUN	O	O	4554
have	VERB	O	O	4554
examined	VERB	O	O	4554
the	PRON	O	O	4554
expression	NOUN	O	O	4554
and	CCONJ	O	O	4554
regulation	NOUN	O	O	4554
of	ADP	O	O	4554
tyrosine	NOUN	O	Chemical	4554
kinase	VERB	O	O	4554
receptors	NOUN	O	O	4554
(	PUNCT	O	O	4554
Trks	NOUN	O	O	4554
)	PUNCT	O	O	4554
in	ADP	O	O	4554
micturition	NOUN	O	O	4554
reflexes	NOUN	O	O	4554
with	ADP	O	O	4554
urinary	ADJ	O	O	4554
bladder inflammation	NOUN	O	Disease	4554
.	PUNCT	O	O	4554
The	PRON	O	O	4555
present	NOUN	O	O	4555
studies	NOUN	O	O	4555
examine	VERB	O	O	4555
the	PRON	O	O	4555
expression	NOUN	O	O	4555
and	CCONJ	O	O	4555
regulation	NOUN	O	O	4555
of	ADP	O	O	4555
another	PRON	O	O	4555
receptor	NOUN	O	O	4555
known	VERB	O	O	4555
to	PART	O	O	4555
bind	VERB	O	O	4555
NGF	PROPN	O	O	4555
,	PUNCT	O	O	4555
p75(NTR	PROPN	O	O	4555
)	PUNCT	O	O	4555
,	PUNCT	O	O	4555
after	ADP	O	O	4555
various	ADJ	O	O	4555
durations	NOUN	O	O	4555
of	ADP	O	O	4555
bladder inflammation	NOUN	O	Disease	4555
induced	VERB	O	O	4555
by	ADP	O	O	4555
cyclophosphamide	VERB	O	Chemical	4555
(	PUNCT	O	O	4555
CYP	PROPN	O	Chemical	4555
)	PUNCT	O	O	4555
.	PUNCT	O	O	4555
CYP	PROPN	O	Chemical	4556
-	PUNCT	O	O	4556
induced	VERB	O	O	4556
cystitis	NOUN	O	Disease	4556
increased	VERB	O	O	4556
(	PUNCT	O	O	4556
P	NOUN	O	Chemical	4556
<	X	O	O	4556
or	CCONJ	O	O	4556
=	PUNCT	O	O	4556
0.001	NUM	O	O	4556
)	PUNCT	O	O	4556
The	PRON	O	O	4557
number	NOUN	O	O	4557
of	ADP	O	O	4557
p75(NTR)-immunoreactive	NUM	O	O	4557
(	PUNCT	O	O	4557
-IR	INTJ	O	O	4557
)	PUNCT	O	O	4557
cells	NOUN	O	O	4557
in	ADP	O	O	4557
the	PRON	O	O	4557
lumbosacral	PROPN	O	O	4557
dorsal	PROPN	O	O	4557
root	NOUN	O	O	4557
ganglia	NOUN	O	O	4557
(	PUNCT	O	O	4557
DRG	PROPN	O	O	4557
)	PUNCT	O	O	4557
also	ADV	O	O	4557
increased	VERB	O	O	4557
(	PUNCT	O	O	4557
P	NOUN	O	Chemical	4557
<	X	O	O	4557
or	CCONJ	O	O	4557
=	PUNCT	O	O	4557
0.05	NUM	O	O	4557
)	PUNCT	O	O	4557
with	ADP	O	O	4557
CYP	PROPN	O	Chemical	4557
-	PUNCT	O	O	4557
induced	VERB	O	O	4557
cystitis	NOUN	O	Disease	4557
(	PUNCT	O	O	4557
acute	ADJ	O	O	4557
,	PUNCT	O	O	4557
intermediate	PROPN	O	O	4557
,	PUNCT	O	O	4557
and	CCONJ	O	O	4557
chronic	ADJ	O	O	4557
)	PUNCT	O	O	4557
.	PUNCT	O	O	4557
Quantitative	ADJ	O	O	4558
,	PUNCT	O	O	4558
real	ADV	O	O	4558
-	PUNCT	O	O	4558
time	NOUN	O	O	4558
polymerase	NOUN	O	O	4558
chain	NOUN	O	O	4558
reaction	NOUN	O	O	4558
also	ADV	O	O	4558
demonstrated	VERB	O	O	4558
significant	ADJ	O	O	4558
increases	VERB	O	O	4558
(	PUNCT	O	O	4558
P	NOUN	O	Chemical	4558
<	X	O	O	4558
or	CCONJ	O	O	4558
=	PUNCT	O	O	4558
0.01	NUM	O	O	4558
)	PUNCT	O	O	4558
in	ADP	O	O	4558
p75(NTR	PROPN	O	O	4558
)	PUNCT	O	O	4558
mRNA	PROPN	O	O	4558
in	ADP	O	O	4558
DRG	PROPN	O	O	4558
with	ADP	O	O	4558
intermediate	PROPN	O	O	4558
and	CCONJ	O	O	4558
chronic	ADJ	O	O	4558
CYP	PROPN	O	Chemical	4558
-	PUNCT	O	O	4558
induced	VERB	O	O	4558
cystitis	NOUN	O	Disease	4558
.	PUNCT	O	O	4558
In	ADP	O	O	4559
bladder	NOUN	O	O	4559
afferent	NOUN	O	O	4559
cells	NOUN	O	O	4559
in	ADP	O	O	4559
DRG	PROPN	O	O	4559
,	PUNCT	O	O	4559
p75(NTR)-IR	NOUN	O	O	4559
was	AUX	O	O	4559
also	ADV	O	O	4559
increased	VERB	O	O	4559
(	PUNCT	O	O	4559
P	NOUN	O	Chemical	4559
<	X	O	O	4559
or	CCONJ	O	O	4559
=	PUNCT	O	O	4559
0.01	NUM	O	O	4559
)	PUNCT	O	O	4559
with	ADP	O	O	4559
cystitis	NOUN	O	Disease	4559
.	PUNCT	O	O	4559
These	PRON	O	O	4560
studies	NOUN	O	O	4560
demonstrate	VERB	O	O	4560
that	SCONJ	O	O	4560
p75(NTR	PROPN	O	O	4560
)	PUNCT	O	O	4560
expression	NOUN	O	O	4560
in	ADP	O	O	4560
micturition	NOUN	O	O	4560
reflexes	NOUN	O	O	4560
is	AUX	O	O	4560
present	NOUN	O	O	4560
constitutively	ADV	O	O	4560
and	CCONJ	O	O	4560
modified	VERB	O	O	4560
by	ADP	O	O	4560
bladder inflammation	NOUN	O	Disease	4560
.	PUNCT	O	O	4560
Azathioprine	ADV	O	Chemical	4563
-	PUNCT	O	O	4563
induced	VERB	O	O	4563
suicidal	ADJ	O	O	4563
erythrocyte	PROPN	O	O	4563
death	NOUN	O	O	4563
.	PUNCT	O	O	4563
Azathioprine	ADV	O	Chemical	4564
is	AUX	O	O	4564
widely	ADV	O	O	4564
used	VERB	O	O	4564
as	ADP	O	O	4564
an	PRON	O	O	4564
immunosuppressive	ADJ	O	O	4564
drug	NOUN	O	O	4564
.	PUNCT	O	O	4564
The	PRON	O	O	4565
side	NOUN	O	O	4565
effects	NOUN	O	O	4565
of	ADP	O	O	4565
azathioprine	ADV	O	Chemical	4565
include	VERB	O	O	4565
anemia	NOUN	O	Disease	4565
,	PUNCT	O	O	4565
which	PRON	O	O	4565
has	VERB	O	O	4565
been	AUX	O	O	4565
attributed	VERB	O	O	4565
to	PART	O	O	4565
bone	NOUN	O	O	4565
marrow suppression	NOUN	O	Disease	4565
.	PUNCT	O	O	4565
Alternatively	ADV	O	O	4566
,	PUNCT	O	O	4566
anemia	NOUN	O	Disease	4566
could	AUX	O	O	4566
result	VERB	O	O	4566
from	ADP	O	O	4566
accelerated	VERB	O	O	4566
suicidal	ADJ	O	O	4566
erythrocyte	PROPN	O	O	4566
death	NOUN	O	O	4566
or	CCONJ	O	O	4566
eryptosis	NOUN	O	O	4566
,	PUNCT	O	O	4566
which	PRON	O	O	4566
is	AUX	O	O	4566
characterized	VERB	O	O	4566
by	ADP	O	O	4566
exposure	NOUN	O	O	4566
of	ADP	O	O	4566
phosphatidylserine	NOUN	O	O	4566
(	PUNCT	O	O	4566
PS	PROPN	O	O	4566
)	PUNCT	O	O	4566
at	ADP	O	O	4566
the	PRON	O	O	4566
erythrocyte	PROPN	O	O	4566
surface	NOUN	O	O	4566
and	CCONJ	O	O	4566
by	ADP	O	O	4566
cell	NOUN	O	O	4566
shrinkage	VERB	O	O	4566
.	PUNCT	O	O	4566
METHODS	NOUN	O	O	4567
:	PUNCT	O	O	4567
The	PRON	O	O	4567
present	NOUN	O	O	4567
experiments	NOUN	O	O	4567
explored	VERB	O	O	4567
whether	SCONJ	O	O	4567
azathioprine	ADV	O	Chemical	4567
influences	NOUN	O	O	4567
eryptosis	NOUN	O	O	4567
.	PUNCT	O	O	4567
According	VERB	O	O	4568
to	PART	O	O	4568
annexin	PROPN	O	O	4568
V	NOUN	O	O	4568
binding	VERB	O	O	4568
,	PUNCT	O	O	4568
erythrocytes	VERB	O	O	4568
from	ADP	O	O	4568
patients	NOUN	O	O	4568
indeed	ADV	O	O	4568
showed	VERB	O	O	4568
a	PRON	O	O	4568
significant	ADJ	O	O	4568
increase	VERB	O	O	4568
of	ADP	O	O	4568
PS	PROPN	O	O	4568
exposure	NOUN	O	O	4568
within	ADP	O	O	4568
1	X	O	O	4568
week	NOUN	O	O	4568
of	ADP	O	O	4568
treatment	NOUN	O	O	4568
with	ADP	O	O	4568
azathioprine	ADV	O	Chemical	4568
.	PUNCT	O	O	4568
In	ADP	O	O	4569
a	PRON	O	O	4569
second	ADV	O	O	4569
series	PROPN	O	O	4569
,	PUNCT	O	O	4569
cytosolic	ADJ	O	O	4569
Ca2	VERB	O	O	4569
+	ADP	O	O	4569
activity	NOUN	O	O	4569
(	PUNCT	O	O	4569
Fluo3	PROPN	O	O	4569
fluorescence	NOUN	O	O	4569
)	PUNCT	O	O	4569
,	PUNCT	O	O	4569
cell	NOUN	O	O	4569
volume	PROPN	O	O	4569
(	PUNCT	O	O	4569
forward	ADV	O	O	4569
scatter	VERB	O	O	4569
)	PUNCT	O	O	4569
,	PUNCT	O	O	4569
and	CCONJ	O	O	4569
PS	PROPN	O	O	4569
-	PUNCT	O	O	4569
exposure	NOUN	O	O	4569
(	PUNCT	O	O	4569
annexin	PROPN	O	O	4569
V	NOUN	O	O	4569
binding	VERB	O	O	4569
)	PUNCT	O	O	4569
were	AUX	O	O	4569
determined	VERB	O	O	4569
by	ADP	O	O	4569
FACS	PROPN	O	O	4569
analysis	NOUN	O	O	4569
in	ADP	O	O	4569
erythrocytes	VERB	O	O	4569
from	ADP	O	O	4569
healthy	ADJ	O	O	4569
volunteers	NOUN	O	O	4569
.	PUNCT	O	O	4569
Exposure	NOUN	O	O	4570
to	PART	O	O	4570
azathioprine	ADV	O	Chemical	4570
(	PUNCT	O	O	4570
>	PUNCT	O	O	4570
or	CCONJ	O	O	4570
=	PUNCT	O	O	4570
2	X	O	O	4570
microg	PROPN	O	O	4570
/	PUNCT	O	O	4570
mL	PROPN	O	O	4570
)	PUNCT	O	O	4570
for	ADP	O	O	4570
48	NUM	O	O	4570
hours	NOUN	O	O	4570
increased	VERB	O	O	4570
cytosolic	ADJ	O	O	4570
Ca2	VERB	O	O	4570
+	ADP	O	O	4570
activity	NOUN	O	O	4570
and	CCONJ	O	O	4570
annexin	PROPN	O	O	4570
V	NOUN	O	O	4570
binding	VERB	O	O	4570
and	CCONJ	O	O	4570
decreased	VERB	O	O	4570
forward	ADV	O	O	4570
scatter	VERB	O	O	4570
.	PUNCT	O	O	4570
The	PRON	O	O	4571
effect	VERB	O	O	4571
of	ADP	O	O	4571
azathioprine	ADV	O	Chemical	4571
on	ADP	O	O	4571
both	PRON	O	O	4571
annexin	PROPN	O	O	4571
V	NOUN	O	O	4571
binding	VERB	O	O	4571
and	CCONJ	O	O	4571
forward	ADV	O	O	4571
scatter	VERB	O	O	4571
was	AUX	O	O	4571
significantly	ADV	O	O	4571
blunted	VERB	O	O	4571
in	ADP	O	O	4571
the	PRON	O	O	4571
nominal	ADJ	O	O	4571
absence	NOUN	O	O	4571
of	ADP	O	O	4571
extracellular	ADJ	O	O	4571
Ca2	VERB	O	O	4571
+	ADP	O	O	4571
.	PUNCT	O	O	4571
Azathioprine	ADV	O	Chemical	4572
triggers	VERB	O	O	4572
suicidal	ADJ	O	O	4572
erythrocyte	PROPN	O	O	4572
death	NOUN	O	O	4572
,	PUNCT	O	O	4572
an	PRON	O	O	4572
effect	VERB	O	O	4572
presumably	ADV	O	O	4572
contributing	VERB	O	O	4572
to	PART	O	O	4572
azathioprine	ADV	O	Chemical	4572
-	PUNCT	O	O	4572
induced	VERB	O	O	4572
anemia	NOUN	O	Disease	4572
.	PUNCT	O	O	4572
BACKGROUND	NOUN	O	O	4575
:	PUNCT	O	O	4575
Spinal	NOUN	O	O	4575
anaesthesia	NOUN	O	O	4575
is	AUX	O	O	4575
widely	ADV	O	O	4575
employed	VERB	O	O	4575
in	ADP	O	O	4575
clinical	ADJ	O	O	4575
practice	VERB	O	O	4575
but	CCONJ	O	O	4575
has	VERB	O	O	4575
the	PRON	O	O	4575
main	ADJ	O	O	4575
drawback	NOUN	O	O	4575
of	ADP	O	O	4575
post	VERB	O	O	4575
-	PUNCT	O	O	4575
spinal	NOUN	O	O	4575
block	NOUN	O	O	4575
hypotension	NOUN	O	Disease	4575
.	PUNCT	O	O	4575
In	ADP	O	O	4576
the	PRON	O	O	4576
lateral	PROPN	O	O	4576
position	NOUN	O	O	4576
with	ADP	O	O	4576
operative	NOUN	O	O	4576
side	NOUN	O	O	4576
down	ADP	O	O	4576
,	PUNCT	O	O	4576
patients	NOUN	O	O	4576
recived	VERB	O	O	4576
10	NUM	O	O	4576
mg	VERB	O	O	4576
(	PUNCT	O	O	4576
2mls	NUM	O	O	4576
)	PUNCT	O	O	4576
of	ADP	O	O	4576
0.5%	NOUN	O	O	4576
hyperbaric	PROPN	O	O	4576
bupivacaine	NOUN	O	Chemical	4576
through	ADP	O	O	4576
a	PRON	O	O	4576
25-gauge	NOUN	O	O	4576
spinal	NOUN	O	O	4576
needle	NOUN	O	O	4576
.	PUNCT	O	O	4576
Blood	NOUN	O	O	4577
pressure	NOUN	O	O	4577
,	PUNCT	O	O	4577
heart	NOUN	O	O	4577
rate	NOUN	O	O	4577
,	PUNCT	O	O	4577
respiratory	NOUN	O	O	4577
rate	NOUN	O	O	4577
and	CCONJ	O	O	4577
oxygen	NOUN	O	Chemical	4577
saturation	NOUN	O	O	4577
were	AUX	O	O	4577
monitored	VERB	O	O	4577
over	ADP	O	O	4577
1	X	O	O	4577
hour	NOUN	O	O	4577
.	PUNCT	O	O	4577
RESULTS	VERB	O	O	4578
:	PUNCT	O	O	4578
Three	NUM	O	O	4578
patients	NOUN	O	O	4578
(	PUNCT	O	O	4578
8.1%	NOUN	O	O	4578
)	PUNCT	O	O	4578
in	ADP	O	O	4578
the	PRON	O	O	4578
unilateral	ADJ	O	O	4578
group	NOUN	O	O	4578
and	CCONJ	O	O	4578
5	NUM	O	O	4578
(	PUNCT	O	O	4578
13.5%	NOUN	O	O	4578
)	PUNCT	O	O	4578
in	ADP	O	O	4578
the	PRON	O	O	4578
conventional	ADJ	O	O	4578
group	NOUN	O	O	4578
developed	VERB	O	O	4578
hypotension	NOUN	O	Disease	4578
,	PUNCT	O	O	4578
P=	VERB	O	O	4578
0.71	NUM	O	O	4578
.	PUNCT	O	O	4578
Four	NUM	O	O	4579
(	PUNCT	O	O	4579
10.8%	NOUN	O	O	4579
)	PUNCT	O	O	4579
patients	NOUN	O	O	4579
in	ADP	O	O	4579
the	PRON	O	O	4579
conventional	ADJ	O	O	4579
group	NOUN	O	O	4579
and	CCONJ	O	O	4579
1	X	O	O	4579
(	PUNCT	O	O	4579
2.7%	NOUN	O	O	4579
)	PUNCT	O	O	4579
in	ADP	O	O	4579
the	PRON	O	O	4579
unilateral	ADJ	O	O	4579
group	NOUN	O	O	4579
,	PUNCT	O	O	4579
P=	VERB	O	O	4579
0.17	NUM	O	O	4579
required	VERB	O	O	4579
epinephrine	NOUN	O	Chemical	4579
infusion	NOUN	O	O	4579
to	PART	O	O	4579
treat	VERB	O	O	4579
hypotension	NOUN	O	Disease	4579
.	PUNCT	O	O	4579
The	PRON	O	O	4580
mean	VERB	O	O	4580
respiratory	NOUN	O	O	4580
rate	NOUN	O	O	4580
and	CCONJ	O	O	4580
oxygen	NOUN	O	Chemical	4580
saturations	NOUN	O	O	4580
in	ADP	O	O	4580
the	PRON	O	O	4580
two	NUM	O	O	4580
groups	NOUN	O	O	4580
were	AUX	O	O	4580
similar	ADJ	O	O	4580
.	PUNCT	O	O	4580
Also	ADV	O	O	4581
,	PUNCT	O	O	4581
the	PRON	O	O	4581
type	NOUN	O	O	4581
of	ADP	O	O	4581
spinal	NOUN	O	O	4581
block	NOUN	O	O	4581
instituted	VERB	O	O	4581
affected	VERB	O	O	4581
neither	ADV	O	O	4581
the	PRON	O	O	4581
respiratory	NOUN	O	O	4581
rate	NOUN	O	O	4581
nor	CCONJ	O	O	4581
the	PRON	O	O	4581
arterial	ADJ	O	O	4581
oxygen	NOUN	O	Chemical	4581
saturation	NOUN	O	O	4581
.	PUNCT	O	O	4581
Spectrum	NOUN	O	O	4584
of	ADP	O	O	4584
adverse	ADJ	O	O	4584
events	NOUN	O	O	4584
after	ADP	O	O	4584
generic	ADJ	O	O	4584
HAART	PROPN	O	O	4584
in	ADP	O	O	4584
southern	ADJ	O	O	4584
Indian	PROPN	O	O	4584
HIV	PROPN	O	O	4584
-	PUNCT	O	O	4584
infected	VERB	O	O	4584
patients	NOUN	O	O	4584
.	PUNCT	O	O	4584
To	PART	O	O	4585
determine	VERB	O	O	4585
the	PRON	O	O	4585
incidence	NOUN	O	O	4585
of	ADP	O	O	4585
clinically	ADV	O	O	4585
significant	ADJ	O	O	4585
adverse	ADJ	O	O	4585
events	NOUN	O	O	4585
after	ADP	O	O	4585
long	ADV	O	O	4585
-	PUNCT	O	O	4585
term	NOUN	O	O	4585
,	PUNCT	O	O	4585
fixed	VERB	O	O	4585
-	PUNCT	O	O	4585
dose	NOUN	O	O	4585
,	PUNCT	O	O	4585
generic	ADJ	O	O	4585
highly	ADV	O	O	4585
active	ADJ	O	O	4585
antiretroviral	ADJ	O	O	4585
therapy	NOUN	O	O	4585
(	PUNCT	O	O	4585
HAART	PROPN	O	O	4585
)	PUNCT	O	O	4585
use	VERB	O	O	4585
among	ADP	O	O	4585
HIV	PROPN	O	O	4585
-	PUNCT	O	O	4585
infected	VERB	O	O	4585
individuals	NOUN	O	O	4585
in	ADP	O	O	4585
South	NOUN	O	O	4585
India	PROPN	O	O	4585
,	PUNCT	O	O	4585
we	PRON	O	O	4585
examined	VERB	O	O	4585
the	PRON	O	O	4585
experiences	NOUN	O	O	4585
of	ADP	O	O	4585
3154	NUM	O	O	4585
HIV	PROPN	O	O	4585
-	PUNCT	O	O	4585
infected	VERB	O	O	4585
individuals	NOUN	O	O	4585
who	PRON	O	O	4585
received	VERB	O	O	4585
a	PRON	O	O	4585
minimum	ADJ	O	O	4585
of	ADP	O	O	4585
3	X	O	O	4585
months	NOUN	O	O	4585
of	ADP	O	O	4585
generic	ADJ	O	O	4585
HAART	PROPN	O	O	4585
between	ADP	O	O	4585
February	PROPN	O	O	4585
1996	NUM	O	O	4585
and	CCONJ	O	O	4585
December	PROPN	O	O	4585
2006	NUM	O	O	4585
at	ADP	O	O	4585
a	PRON	O	O	4585
tertiary	ADJ	O	O	4585
HIV	PROPN	O	O	4585
care	VERB	O	O	4585
referral	NOUN	O	O	4585
center	PROPN	O	O	4585
in	ADP	O	O	4585
South	NOUN	O	O	4585
India	PROPN	O	O	4585
.	PUNCT	O	O	4585
The	PRON	O	O	4586
most	ADV	O	O	4586
common	ADJ	O	O	4586
regimens	NOUN	O	O	4586
were	AUX	O	O	4586
3TC	NUM	O	O	4586
+	ADP	O	O	4586
d4	PROPN	O	O	4586
T	NOUN	O	Chemical	4586
+	ADP	O	O	4586
nevirapine	ADJ	O	O	4586
(	PUNCT	O	O	4586
NVP	PROPN	O	O	4586
)	PUNCT	O	O	4586
(	PUNCT	O	O	4586
54.8%	NOUN	O	O	4586
)	PUNCT	O	O	4586
,	PUNCT	O	O	4586
zidovudine	NOUN	O	Chemical	4586
(	PUNCT	O	O	4586
AZT	PROPN	O	Chemical	4586
)	PUNCT	O	O	4586
+	ADP	O	O	4587
3TC	NUM	O	O	4587
+	ADP	O	O	4587
NVP	PROPN	O	O	4587
(	PUNCT	O	O	4587
14.5%	NOUN	O	O	4587
)	PUNCT	O	O	4587
,	PUNCT	O	O	4587
3TC	NUM	O	O	4587
+	ADP	O	O	4587
d4	PROPN	O	O	4588
T	NOUN	O	Chemical	4588
+	ADP	O	O	4588
efavirenz	PROPN	O	O	4588
(	PUNCT	O	O	4588
EFV	PROPN	O	O	4588
)	PUNCT	O	O	4588
(	PUNCT	O	O	4588
20.1%	NOUN	O	O	4588
)	PUNCT	O	O	4588
,	PUNCT	O	O	4588
and	CCONJ	O	O	4588
AZT	PROPN	O	Chemical	4588
+	ADP	O	O	4588
3TC	NUM	O	O	4588
+	ADP	O	O	4588
EFV	PROPN	O	O	4588
(	PUNCT	O	O	4588
5.4%	NOUN	O	O	4588
)	PUNCT	O	O	4588
.	PUNCT	O	O	4588
The	PRON	O	O	4589
most	ADV	O	O	4589
common	ADJ	O	O	4589
adverse	ADJ	O	O	4589
events	NOUN	O	O	4589
and	CCONJ	O	O	4589
median	ADJ	O	O	4589
CD4	PROPN	O	O	4589
at	ADP	O	O	4589
time	NOUN	O	O	4589
of	ADP	O	O	4589
event	NOUN	O	O	4589
were	AUX	O	O	4589
rash	ADJ	O	Disease	4589
(	PUNCT	O	O	4589
15.2%	NOUN	O	O	4589
;	PUNCT	O	O	4589
CD4	PROPN	O	O	4589
,	PUNCT	O	O	4589
285	NUM	O	O	4589
cells	NOUN	O	O	4589
/	PUNCT	O	O	4589
microL	CCONJ	O	O	4589
)	PUNCT	O	O	4589
and	CCONJ	O	O	4589
peripheral neuropathy	NOUN	O	Disease	4589
(	PUNCT	O	O	4589
9.0%	NOUN	O	O	4589
and	CCONJ	O	O	4589
348	NUM	O	O	4589
cells	NOUN	O	O	4589
/	PUNCT	O	O	4589
microL	CCONJ	O	O	4589
)	PUNCT	O	O	4589
.	PUNCT	O	O	4589
Clinically	ADV	O	O	4590
significant	ADJ	O	O	4590
anemia	NOUN	O	Disease	4590
(	PUNCT	O	O	4590
hemoglobin	NOUN	O	O	4590
<	X	O	O	4591
7	NUM	O	O	4591
g	X	O	O	4591
/	PUNCT	O	O	4591
dL	VERB	O	O	4591
)	PUNCT	O	O	4591
was	AUX	O	O	4591
observed	VERB	O	O	4591
in	ADP	O	O	4591
5.4%	NOUN	O	O	4591
of	ADP	O	O	4591
patients	NOUN	O	O	4591
(	PUNCT	O	O	4591
CD4	PROPN	O	O	4591
,	PUNCT	O	O	4591
165	NUM	O	O	4591
cells	NOUN	O	O	4591
/	PUNCT	O	O	4591
microL	CCONJ	O	O	4591
)	PUNCT	O	O	4591
and	CCONJ	O	O	4591
hepatitis	NOUN	O	Disease	4591
(	PUNCT	O	O	4591
clinical	ADJ	O	O	4591
jaundice	NOUN	O	Disease	4591
with	ADP	O	O	4591
alanine	NOUN	O	Chemical	4591
aminotransferase	PROPN	O	O	4591
>	PUNCT	O	O	4591
5	NUM	O	O	4591
times	NOUN	O	O	4591
upper	ADJ	O	O	4591
limits	NOUN	O	O	4591
of	ADP	O	O	4591
normal	ADJ	O	O	4591
)	PUNCT	O	O	4591
in	ADP	O	O	4591
3.5%	NOUN	O	O	4591
of	ADP	O	O	4591
patients	NOUN	O	O	4591
(	PUNCT	O	O	4591
CD4	PROPN	O	O	4591
,	PUNCT	O	O	4591
260	NUM	O	O	4591
cells	NOUN	O	O	4591
/	PUNCT	O	O	4591
microL	CCONJ	O	O	4591
)	PUNCT	O	O	4591
.	PUNCT	O	O	4591
Women	NOUN	O	O	4592
were	AUX	O	O	4592
significantly	ADV	O	O	4592
more	ADJ	O	O	4592
likely	ADV	O	O	4592
to	PART	O	O	4592
experience	NOUN	O	O	4592
lactic acidosis	NOUN	O	Disease	4592
,	PUNCT	O	O	4592
while	SCONJ	O	O	4592
men	NOUN	O	O	4592
were	AUX	O	O	4592
significantly	ADV	O	O	4592
more	ADJ	O	O	4592
likely	ADV	O	O	4592
to	PART	O	O	4592
experience	NOUN	O	O	4592
immune	NOUN	O	O	4592
reconstitution	NOUN	O	O	4592
syndrome	NOUN	O	O	4592
(	PUNCT	O	O	4592
p	NOUN	O	O	4592
<	X	O	O	4592
0.05	NUM	O	O	4592
)	PUNCT	O	O	4592
.	PUNCT	O	O	4592
Among	ADP	O	O	4593
the	PRON	O	O	4593
patients	NOUN	O	O	4593
with	ADP	O	O	4593
1	X	O	O	4593
year	NOUN	O	O	4593
of	ADP	O	O	4593
follow	VERB	O	O	4593
-	PUNCT	O	O	4593
up	ADP	O	O	4593
,	PUNCT	O	O	4593
NVP	PROPN	O	O	4593
therapy	NOUN	O	O	4593
was	AUX	O	O	4593
significantly	ADV	O	O	4593
associated	VERB	O	O	4593
with	ADP	O	O	4593
developing	VERB	O	O	4593
rash	ADJ	O	Disease	4593
and	CCONJ	O	O	4593
d4	PROPN	O	O	4593
T	NOUN	O	Chemical	4593
therapy	NOUN	O	O	4593
with	ADP	O	O	4593
developing	VERB	O	O	4593
peripheral neuropathy	NOUN	O	Disease	4593
(	PUNCT	O	O	4593
p	NOUN	O	O	4593
<	X	O	O	4593
0.05	NUM	O	O	4593
)	PUNCT	O	O	4593
.	PUNCT	O	O	4593
Anemia	NOUN	O	Disease	4594
and	CCONJ	O	O	4594
hepatitis	NOUN	O	Disease	4594
often	ADV	O	O	4594
occur	VERB	O	O	4594
within	ADP	O	O	4594
12	NUM	O	O	4594
weeks	NOUN	O	O	4594
of	ADP	O	O	4594
initiating	VERB	O	O	4594
generic	ADJ	O	O	4594
HAART	PROPN	O	O	4594
.	PUNCT	O	O	4594
Frequent	ADJ	O	O	4595
and	CCONJ	O	O	4595
early	ADV	O	O	4595
monitoring	NOUN	O	O	4595
for	ADP	O	O	4595
these	PRON	O	O	4595
toxicities	NOUN	O	Disease	4595
is	AUX	O	O	4595
warranted	VERB	O	O	4595
in	ADP	O	O	4595
developing	VERB	O	O	4595
countries	NOUN	O	O	4595
where	SCONJ	O	O	4595
generic	ADJ	O	O	4595
HAART	PROPN	O	O	4595
is	AUX	O	O	4595
increasingly	ADV	O	O	4595
available	ADJ	O	O	4595
.	PUNCT	O	O	4595
Thalidomide	NOUN	O	O	4598
and	CCONJ	O	O	4598
sensory	ADJ	O	O	4598
neurotoxicity	NOUN	O	Disease	4598
:	PUNCT	O	O	4598
a	PRON	O	O	4598
neurophysiological	ADJ	O	O	4598
study	VERB	O	O	4598
.	PUNCT	O	O	4598
Recent	ADJ	O	O	4599
studies	NOUN	O	O	4599
confirmed	VERB	O	O	4599
a	PRON	O	O	4599
high	ADJ	O	O	4599
incidence	NOUN	O	O	4599
of	ADP	O	O	4599
sensory	ADJ	O	O	4599
axonal	ADJ	O	O	4599
neuropathy	NOUN	O	Disease	4599
in	ADP	O	O	4599
patients	NOUN	O	O	4599
treated	VERB	O	O	4599
with	ADP	O	O	4599
different	ADJ	O	O	4599
doses	NOUN	O	O	4599
of	ADP	O	O	4599
thalidomide	NOUN	O	Chemical	4599
.	PUNCT	O	O	4599
The	PRON	O	O	4600
study	VERB	O	O	4600
's	AUX	O	O	4600
aims	VERB	O	O	4600
were	AUX	O	O	4600
to	PART	O	O	4600
measure	VERB	O	O	4600
variations	NOUN	O	O	4600
in	ADP	O	O	4600
sural	ADJ	O	O	4600
nerve	NOUN	O	O	4600
sensory	ADJ	O	O	4600
action	NOUN	O	O	4600
potential	ADJ	O	O	4600
(	PUNCT	O	O	4600
SAP	PROPN	O	O	4600
)	PUNCT	O	O	4600
amplitude	VERB	O	O	4600
in	ADP	O	O	4600
patients	NOUN	O	O	4600
with	ADP	O	O	4600
refractory	ADJ	O	O	4600
cutaneous	ADJ	O	O	4600
lupus	PROPN	O	Disease	4600
erythematosus	NOUN	O	O	4600
(	PUNCT	O	O	4600
CLE	PROPN	O	O	4600
)	PUNCT	O	O	4600
treated	VERB	O	O	4600
with	ADP	O	O	4600
thalidomide	NOUN	O	Chemical	4600
and	CCONJ	O	O	4600
use	VERB	O	O	4600
these	PRON	O	O	4600
findings	NOUN	O	O	4600
to	PART	O	O	4600
identify	VERB	O	O	4600
the	PRON	O	O	4600
neurotoxic	ADJ	O	Disease	4600
potential	ADJ	O	O	4600
of	ADP	O	O	4600
thalidomide	NOUN	O	Chemical	4600
and	CCONJ	O	O	4600
the	PRON	O	O	4600
recovery	NOUN	O	O	4600
capacity	NOUN	O	O	4600
of	ADP	O	O	4600
sensory	ADJ	O	O	4600
fibres	NOUN	O	O	4600
after	ADP	O	O	4600
discontinuation	NOUN	O	O	4600
of	ADP	O	O	4600
treatment	NOUN	O	O	4600
.	PUNCT	O	O	4600
Clinical	NOUN	O	O	4601
and	CCONJ	O	O	4601
electrophysiological	ADJ	O	O	4601
data	NOUN	O	O	4601
in	ADP	O	O	4601
12	NUM	O	O	4601
female	ADJ	O	O	4601
patients	NOUN	O	O	4601
with	ADP	O	O	4601
CLE	PROPN	O	O	4601
during	ADP	O	O	4601
treatment	NOUN	O	O	4601
with	ADP	O	O	4601
thalidomide	NOUN	O	Chemical	4601
and	CCONJ	O	O	4601
up	ADP	O	O	4601
to	PART	O	O	4601
47	NUM	O	O	4601
months	NOUN	O	O	4601
after	ADP	O	O	4601
discontinuation	NOUN	O	O	4601
of	ADP	O	O	4601
treatment	NOUN	O	O	4601
were	AUX	O	O	4601
analysed	VERB	O	O	4601
.	PUNCT	O	O	4601
Five	NUM	O	O	4602
patients	NOUN	O	O	4602
complained	VERB	O	O	4602
of	ADP	O	O	4602
paresthesias	PROPN	O	O	4602
and	CCONJ	O	O	4602
leg	NOUN	O	O	4602
cramps	NOUN	O	O	4602
.	PUNCT	O	O	4602
After	ADP	O	O	4603
thalidomide	NOUN	O	Chemical	4603
treatment	NOUN	O	O	4603
,	PUNCT	O	O	4603
sural	ADJ	O	O	4603
SAP	PROPN	O	O	4603
amplitude	VERB	O	O	4603
recovered	VERB	O	O	4603
in	ADP	O	O	4603
3	X	O	O	4603
patients	NOUN	O	O	4603
.	PUNCT	O	O	4603
At	ADP	O	O	4604
detection	NOUN	O	O	4604
of	ADP	O	O	4604
reduction	NOUN	O	O	4604
in	ADP	O	O	4604
sural	ADJ	O	O	4604
nerve	NOUN	O	O	4604
SAP	PROPN	O	O	4604
amplitude	VERB	O	O	4604
,	PUNCT	O	O	4604
the	PRON	O	O	4604
median	ADJ	O	O	4604
thalidomide	NOUN	O	Chemical	4604
cumulative	ADJ	O	O	4604
dose	NOUN	O	O	4604
was	AUX	O	O	4604
21.4	NUM	O	O	4604
g.	PROPN	O	O	4604
The	PRON	O	O	4604
threshold	NOUN	O	O	4604
neurotoxic	ADJ	O	Disease	4604
dosage	NOUN	O	O	4604
is	AUX	O	O	4604
lower	ADJ	O	O	4604
than	ADP	O	O	4604
previously	ADV	O	O	4604
reported	VERB	O	O	4604
.	PUNCT	O	O	4604
This	PRON	O	O	4605
electrophysiological	ADJ	O	O	4605
parameter	NOUN	O	O	4605
provides	VERB	O	O	4605
information	NOUN	O	O	4605
about	ADP	O	O	4605
subclinical	ADJ	O	O	4605
neurotoxic	ADJ	O	Disease	4605
potential	ADJ	O	O	4605
of	ADP	O	O	4605
thalidomide	NOUN	O	Chemical	4605
but	CCONJ	O	O	4605
is	AUX	O	O	4605
not	PART	O	O	4605
helpful	ADJ	O	O	4605
in	ADP	O	O	4605
predicting	VERB	O	O	4605
the	PRON	O	O	4605
appearance	NOUN	O	O	4605
of	ADP	O	O	4605
sensory	ADJ	O	O	4605
symptoms	NOUN	O	O	4605
.	PUNCT	O	O	4605
Amiodarone	NOUN	O	Chemical	4608
-	PUNCT	O	O	4608
related	ADJ	O	O	4608
pulmonary	ADJ	O	O	4608
mass	PROPN	O	O	4608
and	CCONJ	O	O	4608
unique	ADJ	O	O	4608
membranous glomerulonephritis	NOUN	O	Disease	4608
in	ADP	O	O	4608
a	PRON	O	O	4608
patient	NOUN	O	O	4608
with	ADP	O	O	4608
valvular	ADJ	O	O	4608
heart disease	NOUN	O	Disease	4608
:	PUNCT	O	O	4608
Diagnostic	ADJ	O	O	4608
pitfall	NOUN	O	O	4608
and	CCONJ	O	O	4608
new	ADJ	O	O	4608
findings	NOUN	O	O	4608
.	PUNCT	O	O	4608
Amiodarone	NOUN	O	Chemical	4609
is	AUX	O	O	4609
an	PRON	O	O	4609
anti	ADJ	O	O	4609
-	PUNCT	O	O	4609
arrhythmic	ADJ	O	Disease	4609
drug	NOUN	O	O	4609
for	ADP	O	O	4609
life	NOUN	O	O	4609
-	PUNCT	O	O	4609
threatening	VERB	O	O	4609
tachycardia	PROPN	O	Disease	4609
,	PUNCT	O	O	4609
but	CCONJ	O	O	4609
various	ADJ	O	O	4609
adverse	ADJ	O	O	4609
effects	NOUN	O	O	4609
have	VERB	O	O	4609
been	AUX	O	O	4609
reported	VERB	O	O	4609
.	PUNCT	O	O	4609
Reported	VERB	O	O	4610
herein	VERB	O	O	4610
is	AUX	O	O	4610
an	PRON	O	O	4610
autopsy	ADJ	O	O	4610
case	NOUN	O	O	4610
of	ADP	O	O	4610
valvular	ADJ	O	O	4610
heart disease	NOUN	O	Disease	4610
,	PUNCT	O	O	4610
in	ADP	O	O	4610
a	PRON	O	O	4610
patient	NOUN	O	O	4610
who	PRON	O	O	4610
developed	VERB	O	O	4610
a	PRON	O	O	4610
lung	NOUN	O	O	4610
mass	PROPN	O	O	4610
(	PUNCT	O	O	4610
1.5	NUM	O	O	4610
cm	NOUN	O	O	4610
in	ADP	O	O	4610
diameter	NOUN	O	O	4610
)	PUNCT	O	O	4610
and	CCONJ	O	O	4610
proteinuria	X	O	Disease	4610
(	PUNCT	O	O	4610
2.76	NUM	O	O	4610
g	X	O	O	4610
/	PUNCT	O	O	4610
day	NOUN	O	O	4610
)	PUNCT	O	O	4610
after	ADP	O	O	4610
treatment	NOUN	O	O	4610
with	ADP	O	O	4610
amiodarone	NOUN	O	Chemical	4610
for	ADP	O	O	4610
a	PRON	O	O	4610
long	ADV	O	O	4610
time	NOUN	O	O	4610
.	PUNCT	O	O	4610
The	PRON	O	O	4611
lung	NOUN	O	O	4611
mass	PROPN	O	O	4611
was	AUX	O	O	4611
highly	ADV	O	O	4611
suspected	VERB	O	O	4611
to	PART	O	O	4611
be	AUX	O	O	4611
lung cancer	NOUN	O	Disease	4611
on	ADP	O	O	4611
CT	PROPN	O	O	4611
and	CCONJ	O	O	4611
positron	NOUN	O	O	4611
emission	NOUN	O	O	4611
tomography	NOUN	O	O	4611
,	PUNCT	O	O	4611
but	CCONJ	O	O	4611
histologically	ADV	O	O	4611
the	PRON	O	O	4611
lesion	NOUN	O	O	4611
was	AUX	O	O	4611
composed	VERB	O	O	4611
of	ADP	O	O	4611
lymphoplasmacytic	NOUN	O	O	4611
infiltrates	VERB	O	O	4611
in	ADP	O	O	4611
alveolar	ADJ	O	O	4611
walls	NOUN	O	O	4611
and	CCONJ	O	O	4611
intra	ADJ	O	O	4611
-	PUNCT	O	O	4611
alveolar	ADJ	O	O	4611
accumulation	NOUN	O	O	4611
of	ADP	O	O	4611
foamy	NOUN	O	O	4611
macrophages	VERB	O	O	4611
containing	VERB	O	O	4611
characteristic	ADJ	O	O	4611
myelinoid	PROPN	O	O	4611
bodies	NOUN	O	O	4611
,	PUNCT	O	O	4611
indicating	VERB	O	O	4611
that	SCONJ	O	O	4611
it	PRON	O	O	4611
was	AUX	O	O	4611
an	PRON	O	O	4611
amiodarone	NOUN	O	Chemical	4611
-	PUNCT	O	O	4611
related	ADJ	O	O	4611
lesion	NOUN	O	O	4611
.	PUNCT	O	O	4611
In	ADP	O	O	4612
addition	NOUN	O	O	4612
,	PUNCT	O	O	4612
the	PRON	O	O	4612
lung	NOUN	O	O	4612
tissue	NOUN	O	O	4612
had	VERB	O	O	4612
unevenly	ADV	O	O	4612
distributed	VERB	O	O	4612
hemosiderin	PROPN	O	O	4612
deposition	NOUN	O	O	4612
,	PUNCT	O	O	4612
and	CCONJ	O	O	4612
abnormally	ADV	O	O	4612
tortuous	ADJ	O	O	4612
capillaries	VERB	O	O	4612
were	AUX	O	O	4612
seen	VERB	O	O	4612
in	ADP	O	O	4612
the	PRON	O	O	4612
mass	PROPN	O	O	4612
and	CCONJ	O	O	4612
in	ADP	O	O	4612
heavily	ADV	O	O	4612
hemosiderotic	ADJ	O	O	4612
lung	NOUN	O	O	4612
portions	NOUN	O	O	4612
outside	ADV	O	O	4612
the	PRON	O	O	4612
mass	PROPN	O	O	4612
.	PUNCT	O	O	4612
Autoimmune	PROPN	O	O	4613
diseases	NOUN	O	O	4613
,	PUNCT	O	O	4613
viral hepatitis	NOUN	O	Disease	4613
,	PUNCT	O	O	4613
malignant	ADJ	O	O	4613
neoplasms	NOUN	O	O	4613
or	CCONJ	O	O	4613
other	ADJ	O	O	4613
diseases	NOUN	O	O	4613
with	ADP	O	O	4613
a	PRON	O	O	4613
known	VERB	O	O	4613
relationship	NOUN	O	O	4613
to	PART	O	O	4613
membranous glomerulonephritis	NOUN	O	Disease	4613
were	AUX	O	O	4613
not	PART	O	O	4613
found	VERB	O	O	4613
.	PUNCT	O	O	4613
The	PRON	O	O	4614
present	NOUN	O	O	4614
case	NOUN	O	O	4614
highlights	VERB	O	O	4614
the	PRON	O	O	4614
possibility	NOUN	O	O	4614
that	SCONJ	O	O	4614
differential	ADJ	O	O	4614
diagnosis	NOUN	O	O	4614
between	ADP	O	O	4614
an	PRON	O	O	4614
amiodarone	NOUN	O	Chemical	4614
-	PUNCT	O	O	4614
related	ADJ	O	O	4614
pulmonary	ADJ	O	O	4614
lesion	NOUN	O	O	4614
and	CCONJ	O	O	4614
a	PRON	O	O	4614
neoplasm	NOUN	O	O	4614
can	AUX	O	O	4614
be	AUX	O	O	4614
very	ADV	O	O	4614
difficult	ADJ	O	O	4614
radiologically	ADV	O	O	4614
,	PUNCT	O	O	4614
and	CCONJ	O	O	4614
suggests	VERB	O	O	4614
that	SCONJ	O	O	4614
membranous glomerulonephritis	NOUN	O	Disease	4614
might	AUX	O	O	4614
be	AUX	O	O	4614
another	PRON	O	O	4614
possible	ADJ	O	O	4614
complication	NOUN	O	O	4614
of	ADP	O	O	4614
amiodarone	NOUN	O	Chemical	4614
treatment	NOUN	O	O	4614
.	PUNCT	O	O	4614
Risk	NOUN	O	O	4617
of	ADP	O	O	4617
coronary artery disease	NOUN	O	Disease	4617
associated	VERB	O	O	4617
with	ADP	O	O	4617
initial	ADJ	O	O	4617
sulphonylurea	PROPN	O	O	4617
treatment	NOUN	O	O	4617
of	ADP	O	O	4617
patients	NOUN	O	O	4617
with	ADP	O	O	4617
type	NOUN	O	O	4617
2	X	O	O	4617
diabetes	NOUN	O	Disease	4617
:	PUNCT	O	O	4617
a	PRON	O	O	4617
matched	VERB	O	O	4617
case	NOUN	O	O	4617
-	PUNCT	O	O	4617
control	VERB	O	O	4617
study	VERB	O	O	4617
.	PUNCT	O	O	4617
This	PRON	O	O	4618
study	VERB	O	O	4618
sought	VERB	O	O	4618
to	PART	O	O	4618
assess	VERB	O	O	4618
the	PRON	O	O	4618
risk	NOUN	O	O	4618
of	ADP	O	O	4618
developing	VERB	O	O	4618
coronary artery disease	NOUN	O	Disease	4618
(	PUNCT	O	O	4618
CAD	NOUN	O	O	4618
)	PUNCT	O	O	4618
associated	VERB	O	O	4618
with	ADP	O	O	4618
initial	ADJ	O	O	4618
treatment	NOUN	O	O	4618
of	ADP	O	O	4618
type	NOUN	O	O	4618
2	X	O	O	4618
diabetes	NOUN	O	Disease	4618
with	ADP	O	O	4618
different	ADJ	O	O	4618
sulphonylureas	PROPN	O	O	4618
.	PUNCT	O	O	4618
METHODS	NOUN	O	O	4619
:	PUNCT	O	O	4619
In	ADP	O	O	4619
type	NOUN	O	O	4619
2	X	O	O	4619
diabetic	ADJ	O	Disease	4619
patients	NOUN	O	O	4619
,	PUNCT	O	O	4619
cases	NOUN	O	O	4619
who	PRON	O	O	4619
developed	VERB	O	O	4619
CAD	NOUN	O	O	4619
were	AUX	O	O	4619
compared	VERB	O	O	4619
retrospectively	ADV	O	O	4619
with	ADP	O	O	4619
controls	VERB	O	O	4619
that	SCONJ	O	O	4619
did	VERB	O	O	4619
not	PART	O	O	4619
.	PUNCT	O	O	4619
The	PRON	O	O	4620
20-year	NOUN	O	O	4620
risk	NOUN	O	O	4620
of	ADP	O	O	4620
CAD	NOUN	O	O	4620
at	ADP	O	O	4620
diagnosis	NOUN	O	O	4620
of	ADP	O	O	4620
diabetes	NOUN	O	Disease	4620
,	PUNCT	O	O	4620
using	VERB	O	O	4620
the	PRON	O	O	4620
UKPDS	PROPN	O	O	4620
risk	NOUN	O	O	4620
engine	NOUN	O	O	4620
,	PUNCT	O	O	4620
was	AUX	O	O	4620
used	VERB	O	O	4620
to	PART	O	O	4620
match	VERB	O	O	4620
cases	NOUN	O	O	4620
with	ADP	O	O	4620
controls	VERB	O	O	4620
.	PUNCT	O	O	4620
The	PRON	O	O	4621
76	NUM	O	O	4621
cases	NOUN	O	O	4621
of	ADP	O	O	4621
CAD	NOUN	O	O	4621
were	AUX	O	O	4621
compared	VERB	O	O	4621
with	ADP	O	O	4621
152	NUM	O	O	4621
controls	VERB	O	O	4621
.	PUNCT	O	O	4621
The	PRON	O	O	4622
hazard	NOUN	O	O	4622
of	ADP	O	O	4622
developing	VERB	O	O	4622
CAD	NOUN	O	O	4622
(	PUNCT	O	O	4622
95%	NOUN	O	O	4622
CI	NOUN	O	O	4622
)	PUNCT	O	O	4622
associated	VERB	O	O	4622
with	ADP	O	O	4622
initial	ADJ	O	O	4622
treatment	NOUN	O	O	4622
increased	VERB	O	O	4622
by	ADP	O	O	4622
2.4-fold	ADV	O	O	4622
(	PUNCT	O	O	4622
1.3	NUM	O	O	4622
-	PUNCT	O	O	4622
4.3	NUM	O	O	4622
,	PUNCT	O	O	4622
P=0.004	NUM	O	O	4622
)	PUNCT	O	O	4622
with	ADP	O	O	4622
glibenclamide	ADP	O	O	4622
;	PUNCT	O	O	4622
2-fold	VERB	O	O	4622
(	PUNCT	O	O	4622
0.9	NUM	O	O	4622
-	PUNCT	O	O	4622
4.6	NUM	O	O	4622
,	PUNCT	O	O	4622
P=0.099	NUM	O	O	4622
)	PUNCT	O	O	4622
with	ADP	O	O	4622
glipizide	NOUN	O	O	4622
;	PUNCT	O	O	4622
2.9-fold	ADV	O	O	4622
(	PUNCT	O	O	4622
1.6	NUM	O	O	4622
-	PUNCT	O	O	4622
5.1	NUM	O	O	4622
,	PUNCT	O	O	4622
P=0.000	NUM	O	O	4622
)	PUNCT	O	O	4622
with	ADP	O	O	4622
either	ADV	O	O	4622
,	PUNCT	O	O	4622
and	CCONJ	O	O	4622
was	AUX	O	O	4622
unchanged	ADJ	O	O	4622
with	ADP	O	O	4622
metformin	PROPN	O	Chemical	4622
.	PUNCT	O	O	4622
The	PRON	O	O	4623
hazard	NOUN	O	O	4623
decreased	VERB	O	O	4623
0.3-fold	ADV	O	O	4623
(	PUNCT	O	O	4623
0.7	NUM	O	O	4623
-	PUNCT	O	O	4623
1.7	NUM	O	O	4623
,	PUNCT	O	O	4623
P=0.385	NUM	O	O	4623
)	PUNCT	O	O	4623
with	ADP	O	O	4623
glimepiride	PROPN	O	O	4623
,	PUNCT	O	O	4623
0.4-fold	ADV	O	O	4623
(	PUNCT	O	O	4623
0.7	NUM	O	O	4623
-	PUNCT	O	O	4623
1.3	NUM	O	O	4623
,	PUNCT	O	O	4623
P=0.192	VERB	O	O	4623
)	PUNCT	O	O	4623
with	ADP	O	O	4623
gliclazide	NOUN	O	O	4623
,	PUNCT	O	O	4623
and	CCONJ	O	O	4623
0.4-fold	ADV	O	O	4623
(	PUNCT	O	O	4623
0.7	NUM	O	O	4623
-	PUNCT	O	O	4623
1.1	NUM	O	O	4623
,	PUNCT	O	O	4623
P=0.09	PROPN	O	O	4623
)	PUNCT	O	O	4623
with	ADP	O	O	4623
either	ADV	O	O	4623
.	PUNCT	O	O	4623
CONCLUSIONS	NOUN	O	O	4624
:	PUNCT	O	O	4624
Initiating	VERB	O	O	4624
treatment	NOUN	O	O	4624
of	ADP	O	O	4624
type	NOUN	O	O	4624
2	X	O	O	4624
diabetes	NOUN	O	Disease	4624
with	ADP	O	O	4624
glibenclamide	ADP	O	O	4624
or	CCONJ	O	O	4624
glipizide	NOUN	O	O	4624
is	AUX	O	O	4624
associated	VERB	O	O	4624
with	ADP	O	O	4624
increased	VERB	O	O	4624
risk	NOUN	O	O	4624
of	ADP	O	O	4624
CAD	NOUN	O	O	4624
in	ADP	O	O	4624
comparison	NOUN	O	O	4624
to	PART	O	O	4624
gliclazide	NOUN	O	O	4624
or	CCONJ	O	O	4624
glimepiride	PROPN	O	O	4624
.	PUNCT	O	O	4624
If	SCONJ	O	O	4625
confirmed	VERB	O	O	4625
,	PUNCT	O	O	4625
this	PRON	O	O	4625
may	AUX	O	O	4625
be	AUX	O	O	4625
important	ADJ	O	O	4625
because	SCONJ	O	O	4625
most	ADV	O	O	4625
Indian	PROPN	O	O	4625
patients	NOUN	O	O	4625
receive	VERB	O	O	4625
the	PRON	O	O	4625
cheaper	ADJ	O	O	4625
older	ADJ	O	O	4625
sulphonylureas	PROPN	O	O	4625
,	PUNCT	O	O	4625
and	CCONJ	O	O	4625
present	NOUN	O	O	4625
guidelines	NOUN	O	O	4625
do	VERB	O	O	4625
not	PART	O	O	4625
distinguish	VERB	O	O	4625
between	ADP	O	O	4625
individual	ADJ	O	O	4625
agents	NOUN	O	O	4625
.	PUNCT	O	O	4625
Reduced	VERB	O	O	4628
progression	NOUN	O	O	4628
of	ADP	O	O	4628
adriamycin	PROPN	O	Chemical	4628
nephropathy	NOUN	O	Disease	4628
in	ADP	O	O	4628
spontaneously	ADV	O	O	4628
hypertensive	ADJ	O	Disease	4628
rats	NOUN	O	O	4628
treated	VERB	O	O	4628
by	ADP	O	O	4628
losartan	NOUN	O	O	4628
.	PUNCT	O	O	4628
The	PRON	O	O	4629
aim	VERB	O	O	4629
of	ADP	O	O	4629
the	PRON	O	O	4629
study	VERB	O	O	4629
was	AUX	O	O	4629
to	PART	O	O	4629
investigate	VERB	O	O	4629
the	PRON	O	O	4629
antihypertensive	ADV	O	O	4629
effects	NOUN	O	O	4629
of	ADP	O	O	4629
angiotensin II	PROPN	O	Chemical	4629
type-1	NOUN	O	O	4629
receptor	NOUN	O	O	4629
blocker	NOUN	O	O	4629
,	PUNCT	O	O	4629
losartan	NOUN	O	O	4629
,	PUNCT	O	O	4629
and	CCONJ	O	O	4629
its	PRON	O	O	4629
potential	ADJ	O	O	4629
in	ADP	O	O	4629
slowing	VERB	O	O	4629
down	ADP	O	O	4629
renal disease	NOUN	O	Disease	4629
progression	NOUN	O	O	4629
in	ADP	O	O	4629
spontaneously	ADV	O	O	4629
hypertensive	ADJ	O	Disease	4629
rats	NOUN	O	O	4629
(	PUNCT	O	O	4629
SHR	PROPN	O	O	4629
)	PUNCT	O	O	4629
with	ADP	O	O	4629
adriamycin	PROPN	O	Chemical	4629
(	PUNCT	O	O	4629
ADR	PROPN	O	Chemical	4629
)	PUNCT	O	O	4629
nephropathy	NOUN	O	Disease	4630
.	PUNCT	O	O	4630
Groups	NOUN	O	O	4631
ADR(6	NOUN	O	O	4631
)	PUNCT	O	O	4631
,	PUNCT	O	O	4631
ADR+LOS(6	PRON	O	O	4631
)	PUNCT	O	O	4631
and	CCONJ	O	O	4631
ADR(12	ADV	O	O	4631
)	PUNCT	O	O	4631
,	PUNCT	O	O	4631
and	CCONJ	O	O	4631
ADR+LOS(12	NOUN	O	O	4631
)	PUNCT	O	O	4631
received	VERB	O	O	4631
ADR	PROPN	O	Chemical	4631
(	PUNCT	O	O	4631
2	X	O	O	4631
mg	VERB	O	O	4631
/	PUNCT	O	O	4631
kg	VERB	O	O	4631
/	PUNCT	O	O	4631
b.w	PROPN	O	O	4631
.	PUNCT	O	O	4631
Group	PROPN	O	O	4632
ADR+LOS(6	PRON	O	O	4632
)	PUNCT	O	O	4632
received	VERB	O	O	4632
losartan	NOUN	O	O	4632
(	PUNCT	O	O	4633
10	NUM	O	O	4633
mg	VERB	O	O	4633
/	PUNCT	O	O	4633
kg	VERB	O	O	4633
/	PUNCT	O	O	4633
b.w./day	NOUN	O	O	4633
by	ADP	O	O	4633
gavages	VERB	O	O	4633
)	PUNCT	O	O	4633
for	ADP	O	O	4633
6	NUM	O	O	4633
weeks	NOUN	O	O	4633
and	CCONJ	O	O	4633
group	NOUN	O	O	4633
ADR+LOS(12	NOUN	O	O	4633
)	PUNCT	O	O	4633
for	ADP	O	O	4633
12	NUM	O	O	4633
weeks	NOUN	O	O	4633
after	ADP	O	O	4633
second	ADV	O	O	4633
injection	NOUN	O	O	4633
of	ADP	O	O	4633
ADR	PROPN	O	Chemical	4633
.	PUNCT	O	O	4633
Short	ADJ	O	O	4634
-	PUNCT	O	O	4634
term	NOUN	O	O	4634
losartan	NOUN	O	O	4634
treatment	NOUN	O	O	4634
,	PUNCT	O	O	4634
besides	ADV	O	O	4634
antihypertensive	ADV	O	O	4634
effect	VERB	O	O	4634
,	PUNCT	O	O	4634
improved	VERB	O	O	4634
glomerular	ADJ	O	O	4634
filtration	NOUN	O	O	4634
rate	NOUN	O	O	4634
and	CCONJ	O	O	4634
ameliorated	VERB	O	O	4634
glomerulosclerosis	PROPN	O	O	4634
resulting	VERB	O	O	4634
in	ADP	O	O	4634
decreased	VERB	O	O	4634
proteinuria	X	O	Disease	4634
.	PUNCT	O	O	4634
Prolonged	VERB	O	O	4635
treatment	NOUN	O	O	4635
with	ADP	O	O	4635
losartan	NOUN	O	O	4635
showed	VERB	O	O	4635
further	ADV	O	O	4635
reduction	NOUN	O	O	4635
of	ADP	O	O	4635
glomerulosclerosis	PROPN	O	O	4635
associated	VERB	O	O	4635
with	ADP	O	O	4635
reduced	VERB	O	O	4635
progression	NOUN	O	O	4635
of	ADP	O	O	4635
tubular	ADJ	O	O	4635
atrophy	NOUN	O	Disease	4635
and	CCONJ	O	O	4635
interstitial	ADJ	O	O	4635
fibrosis	NOUN	O	Disease	4635
,	PUNCT	O	O	4635
thus	ADV	O	O	4635
preventing	VERB	O	O	4635
heavy	ADJ	O	O	4635
proteinuria	X	O	Disease	4635
and	CCONJ	O	O	4635
chronic	ADJ	O	O	4635
renal failure	NOUN	O	Disease	4635
.	PUNCT	O	O	4635
Losartan	PROPN	O	O	4636
reduced	VERB	O	O	4636
uraemia	NOUN	O	O	4636
and	CCONJ	O	O	4636
increased	VERB	O	O	4636
urea	PROPN	O	Chemical	4636
clearance	NOUN	O	O	4636
in	ADP	O	O	4636
advanced	ADJ	O	O	4636
ADR	PROPN	O	Chemical	4636
nephropathy	NOUN	O	Disease	4636
in	ADP	O	O	4636
SHR	PROPN	O	O	4636
.	PUNCT	O	O	4636
Histological	NOUN	O	O	4637
examination	NOUN	O	O	4637
showed	VERB	O	O	4637
that	SCONJ	O	O	4637
losartan	NOUN	O	O	4637
could	AUX	O	O	4637
prevent	VERB	O	O	4637
tubular	ADJ	O	O	4637
atrophy	NOUN	O	Disease	4637
,	PUNCT	O	O	4637
interstitial	ADJ	O	O	4637
infiltration	NOUN	O	O	4637
and	CCONJ	O	O	4637
fibrosis	NOUN	O	Disease	4637
in	ADP	O	O	4637
ADR	PROPN	O	Chemical	4637
nephropathy	NOUN	O	Disease	4637
.	PUNCT	O	O	4637
CONCLUSION	PROPN	O	O	4638
:	PUNCT	O	O	4638
Losartan	PROPN	O	O	4638
reduces	VERB	O	O	4638
the	PRON	O	O	4638
rate	NOUN	O	O	4638
of	ADP	O	O	4638
progression	NOUN	O	O	4638
of	ADP	O	O	4638
ADR	PROPN	O	Chemical	4638
-	PUNCT	O	O	4638
induced	VERB	O	O	4638
focal	ADJ	O	O	4638
segmental	ADJ	O	O	4638
glomerulosclerosis	PROPN	O	O	4638
to	PART	O	O	4638
end	VERB	O	O	4638
-	PUNCT	O	O	4638
stage	NOUN	O	O	4638
renal disease	NOUN	O	Disease	4638
in	ADP	O	O	4638
SHR	PROPN	O	O	4638
.	PUNCT	O	O	4638
The	PRON	O	O	4641
risks	NOUN	O	O	4641
of	ADP	O	O	4641
aprotinin	PROPN	O	O	4641
and	CCONJ	O	O	4641
tranexamic acid	PROPN	O	Chemical	4641
in	ADP	O	O	4641
cardiac	ADJ	O	O	4641
surgery	NOUN	O	O	4641
:	PUNCT	O	O	4641
a	PRON	O	O	4641
one	NUM	O	O	4641
-	PUNCT	O	O	4641
year	NOUN	O	O	4641
follow	VERB	O	O	4641
-	PUNCT	O	O	4641
up	ADP	O	O	4641
of	ADP	O	O	4641
1188	NUM	O	O	4641
consecutive	ADJ	O	O	4641
patients	NOUN	O	O	4641
.	PUNCT	O	O	4641
BACKGROUND	NOUN	O	O	4642
:	PUNCT	O	O	4642
Our	PRON	O	O	4642
aim	VERB	O	O	4642
was	AUX	O	O	4642
to	PART	O	O	4642
investigate	VERB	O	O	4642
postoperative	ADJ	O	O	4642
complications	NOUN	O	O	4642
and	CCONJ	O	O	4642
mortality	NOUN	O	O	4642
after	ADP	O	O	4642
administration	NOUN	O	O	4642
of	ADP	O	O	4642
aprotinin	PROPN	O	O	4642
compared	VERB	O	O	4642
to	PART	O	O	4642
tranexamic acid	PROPN	O	Chemical	4642
in	ADP	O	O	4642
an	PRON	O	O	4642
unselected	ADJ	O	O	4642
,	PUNCT	O	O	4642
consecutive	ADJ	O	O	4642
cohort	NOUN	O	O	4642
.	PUNCT	O	O	4642
During	ADP	O	O	4643
the	PRON	O	O	4643
first	ADV	O	O	4643
5	NUM	O	O	4643
mo	PROPN	O	O	4643
,	PUNCT	O	O	4643
596	NUM	O	O	4643
patients	NOUN	O	O	4643
received	VERB	O	O	4643
aprotinin	PROPN	O	O	4643
(	PUNCT	O	O	4643
Group	PROPN	O	O	4643
A	PRON	O	O	4643
)	PUNCT	O	O	4643
;	PUNCT	O	O	4643
in	ADP	O	O	4643
the	PRON	O	O	4643
next	ADV	O	O	4643
5	NUM	O	O	4643
mo	PROPN	O	O	4643
,	PUNCT	O	O	4643
592	NUM	O	O	4643
patients	NOUN	O	O	4643
were	AUX	O	O	4643
treated	VERB	O	O	4643
with	ADP	O	O	4643
tranexamic acid	PROPN	O	Chemical	4643
(	PUNCT	O	O	4643
Group	PROPN	O	O	4643
T	NOUN	O	Chemical	4643
)	PUNCT	O	O	4643
.	PUNCT	O	O	4643
Postoperatively	PROPN	O	O	4644
,	PUNCT	O	O	4644
a	PRON	O	O	4644
significantly	ADV	O	O	4644
higher	ADJ	O	O	4644
incidence	NOUN	O	O	4644
of	ADP	O	O	4644
seizures	NOUN	O	Disease	4644
was	AUX	O	O	4644
found	VERB	O	O	4644
in	ADP	O	O	4644
Group	PROPN	O	O	4644
T	NOUN	O	Chemical	4644
(	PUNCT	O	O	4644
4.6%	NOUN	O	O	4644
vs	ADP	O	O	4644
1.2%	NOUN	O	O	4644
,	PUNCT	O	O	4644
P	NOUN	O	Chemical	4644
Persistent	ADJ	O	O	4645
atrial fibrillation	NOUN	O	Disease	4645
(	PUNCT	O	O	4645
7.9%	NOUN	O	O	4645
vs	ADP	O	O	4645
2.3%	NOUN	O	O	4645
,	PUNCT	O	O	4645
P	NOUN	O	Chemical	4645
=	PUNCT	O	O	4645
0.020	NUM	O	O	4645
)	PUNCT	O	O	4645
and	CCONJ	O	O	4645
renal failure	NOUN	O	Disease	4645
(	PUNCT	O	O	4645
9.7%	NOUN	O	O	4645
vs	ADP	O	O	4645
1.7%	NOUN	O	O	4645
,	PUNCT	O	O	4645
P	NOUN	O	Chemical	4645
=	PUNCT	O	O	4645
0.002	NUM	O	O	4645
)	PUNCT	O	O	4645
were	AUX	O	O	4645
also	ADV	O	O	4645
more	ADJ	O	O	4645
common	ADJ	O	O	4645
in	ADP	O	O	4645
Group	PROPN	O	O	4645
T	NOUN	O	Chemical	4645
,	PUNCT	O	O	4645
in	ADP	O	O	4645
the	PRON	O	O	4645
primary	NOUN	O	O	4645
valve	PROPN	O	O	4645
surgery	NOUN	O	O	4645
subgroup	PROPN	O	O	4645
.	PUNCT	O	O	4645
On	ADP	O	O	4646
the	PRON	O	O	4646
contrary	ADV	O	O	4646
,	PUNCT	O	O	4646
among	ADP	O	O	4646
primary	NOUN	O	O	4646
coronary	ADJ	O	O	4646
artery	NOUN	O	O	4646
bypass	NOUN	O	O	4646
surgery	NOUN	O	O	4646
patients	NOUN	O	O	4646
,	PUNCT	O	O	4646
there	ADV	O	O	4646
were	AUX	O	O	4646
more	ADJ	O	O	4646
acute	ADJ	O	O	4646
myocardial infarctions	NOUN	O	O	4646
and	CCONJ	O	O	4646
renal dysfunction	NOUN	O	Disease	4646
in	ADP	O	O	4646
Group	PROPN	O	O	4646
A	PRON	O	O	4646
(	PUNCT	O	O	4646
5.8%	NOUN	O	O	4646
vs	ADP	O	O	4646
2.0%	NOUN	O	O	4646
,	PUNCT	O	O	4646
P	NOUN	O	Chemical	4646
=	PUNCT	O	O	4646
0.027	NUM	O	O	4646
;	PUNCT	O	O	4646
22.5%	NOUN	O	O	4646
vs	ADP	O	O	4646
15.2%	NOUN	O	O	4646
,	PUNCT	O	O	4646
P	NOUN	O	Chemical	4646
=	PUNCT	O	O	4646
0.036	NUM	O	O	4646
,	PUNCT	O	O	4646
respectively	ADV	O	O	4646
)	PUNCT	O	O	4646
.	PUNCT	O	O	4646
Administration	NOUN	O	O	4647
of	ADP	O	O	4647
aprotinin	PROPN	O	O	4647
should	AUX	O	O	4647
be	AUX	O	O	4647
avoided	VERB	O	O	4647
in	ADP	O	O	4647
coronary	ADJ	O	O	4647
artery	NOUN	O	O	4647
bypass	NOUN	O	O	4647
graft	NOUN	O	O	4647
and	CCONJ	O	O	4647
high	ADJ	O	O	4647
risk	NOUN	O	O	4647
patients	NOUN	O	O	4647
,	PUNCT	O	O	4647
whereas	SCONJ	O	O	4647
administration	NOUN	O	O	4647
of	ADP	O	O	4647
tranexamic acid	PROPN	O	Chemical	4647
is	AUX	O	O	4647
not	PART	O	O	4647
recommended	VERB	O	O	4647
in	ADP	O	O	4647
valve	PROPN	O	O	4647
surgery	NOUN	O	O	4647
.	PUNCT	O	O	4647
The	PRON	O	O	4650
biological	ADJ	O	O	4650
properties	NOUN	O	O	4650
of	ADP	O	O	4650
the	PRON	O	O	4650
optical	PROPN	O	O	4650
isomers	NOUN	O	O	4650
of	ADP	O	O	4650
propranolol	NOUN	O	Chemical	4650
and	CCONJ	O	O	4650
their	PRON	O	O	4650
effects	NOUN	O	O	4650
on	ADP	O	O	4650
cardiac arrhythmias	VERB	O	Disease	4650
.	PUNCT	O	O	4650
1	X	O	O	4650
.	PUNCT	O	O	4650
The	PRON	O	O	4651
optical	PROPN	O	O	4651
isomers	NOUN	O	O	4651
of	ADP	O	O	4651
propranolol	NOUN	O	Chemical	4651
have	VERB	O	O	4651
been	AUX	O	O	4651
compared	VERB	O	O	4651
for	ADP	O	O	4651
their	PRON	O	O	4651
beta	NOUN	O	O	4651
-	PUNCT	O	O	4651
blocking	VERB	O	O	4651
and	CCONJ	O	O	4651
antiarrhythmic	PROPN	O	O	4651
activities.2	NOUN	O	O	4651
.	PUNCT	O	O	4651
In	ADP	O	O	4652
blocking	VERB	O	O	4652
the	PRON	O	O	4652
positive	ADJ	O	O	4652
inotropic	NOUN	O	O	4652
and	CCONJ	O	O	4652
chronotropic	NOUN	O	O	4652
responses	NOUN	O	O	4652
to	PART	O	O	4652
isoprenaline	PROPN	O	O	4652
,	PUNCT	O	O	4652
(	PUNCT	O	O	4652
+	ADP	O	O	4652
)	PUNCT	O	O	4652
-propranolol	X	O	O	4653
had	VERB	O	O	4653
less	ADV	O	O	4653
than	ADP	O	O	4653
one	NUM	O	O	4653
hundredth	ADJ	O	O	4653
the	PRON	O	O	4653
potency	NOUN	O	O	4653
of	ADP	O	O	4653
(	PUNCT	O	O	4653
-)-propranolol	INTJ	O	O	4653
.	PUNCT	O	O	4653
At	ADP	O	O	4654
dose	NOUN	O	O	4654
levels	NOUN	O	O	4654
of	ADP	O	O	4654
(	PUNCT	O	O	4654
+	ADP	O	O	4654
)	PUNCT	O	O	4654
-propranolol	X	O	O	4654
which	PRON	O	O	4654
attenuated	VERB	O	O	4654
the	PRON	O	O	4654
responses	NOUN	O	O	4654
to	PART	O	O	4654
isoprenaline	PROPN	O	O	4654
,	PUNCT	O	O	4654
there	ADV	O	O	4654
was	AUX	O	O	4654
a	PRON	O	O	4654
significant	ADJ	O	O	4654
prolongation	NOUN	O	O	4654
of	ADP	O	O	4654
the	PRON	O	O	4654
PR	NOUN	O	O	4654
interval	NOUN	O	O	4654
of	ADP	O	O	4654
the	PRON	O	O	4654
electrocardiogram.3	NOUN	O	O	4654
.	PUNCT	O	O	4654
The	PRON	O	O	4655
metabolic	ADJ	O	O	4655
responses	NOUN	O	O	4655
to	PART	O	O	4655
isoprenaline	PROPN	O	O	4655
in	ADP	O	O	4655
dogs	NOUN	O	O	4655
(	PUNCT	O	O	4655
an	PRON	O	O	4655
increase	VERB	O	O	4655
in	ADP	O	O	4655
circulating	VERB	O	O	4655
glucose	NOUN	O	Chemical	4655
,	PUNCT	O	O	4655
lactate	NOUN	O	Chemical	4655
and	CCONJ	O	O	4655
free	ADJ	O	O	4655
fatty acids	NOUN	O	Chemical	4655
)	PUNCT	O	O	4655
were	AUX	O	O	4655
all	PRON	O	O	4655
blocked	VERB	O	O	4655
by	ADP	O	O	4655
(	PUNCT	O	O	4655
-)-propranolol	INTJ	O	O	4655
.	PUNCT	O	O	4655
-Propranolol	INTJ	O	O	4656
had	VERB	O	O	4656
no	PRON	O	O	4656
effect	VERB	O	O	4656
on	ADP	O	O	4656
fatty	ADJ	O	O	4656
acid	PROPN	O	O	4656
mobilization	NOUN	O	O	4656
but	CCONJ	O	O	4656
significantly	ADV	O	O	4656
reduced	VERB	O	O	4656
the	PRON	O	O	4656
increments	NOUN	O	O	4656
in	ADP	O	O	4656
both	PRON	O	O	4656
lactate	NOUN	O	Chemical	4656
and	CCONJ	O	O	4656
glucose.4	VERB	O	O	4656
.	PUNCT	O	O	4656
Both	PRON	O	O	4657
isomers	NOUN	O	O	4657
of	ADP	O	O	4657
propranolol	NOUN	O	Chemical	4657
possessed	VERB	O	O	4657
similar	ADJ	O	O	4657
depressant	NOUN	O	O	4657
potency	NOUN	O	O	4657
on	ADP	O	O	4657
isolated	VERB	O	O	4657
atrial	ADJ	O	O	4657
muscle	NOUN	O	O	4657
taken	VERB	O	O	4657
from	ADP	O	O	4657
guinea	NOUN	O	O	4657
-	PUNCT	O	O	4657
pigs.5	ADJ	O	O	4657
.	PUNCT	O	O	4657
The	PRON	O	O	4658
isomers	NOUN	O	O	4658
of	ADP	O	O	4658
propranolol	NOUN	O	Chemical	4658
exhibited	VERB	O	O	4658
similar	ADJ	O	O	4658
local	ADJ	O	O	4658
anaesthetic	NOUN	O	O	4658
potencies	NOUN	O	O	4658
on	ADP	O	O	4658
an	PRON	O	O	4658
isolated	VERB	O	O	4658
frog	NOUN	O	O	4658
nerve	NOUN	O	O	4658
preparation	NOUN	O	O	4658
at	ADP	O	O	4658
a	PRON	O	O	4658
level	VERB	O	O	4658
approximately	ADV	O	O	4658
three	NUM	O	O	4658
times	NOUN	O	O	4658
that	SCONJ	O	O	4658
of	ADP	O	O	4658
procaine	NOUN	O	O	4658
.	PUNCT	O	O	4658
Both	PRON	O	O	4659
isomers	NOUN	O	O	4659
of	ADP	O	O	4659
propranolol	NOUN	O	Chemical	4659
were	AUX	O	O	4659
capable	ADJ	O	O	4659
of	ADP	O	O	4659
preventing	VERB	O	O	4659
adrenaline	NOUN	O	Chemical	4659
-	PUNCT	O	O	4659
induced	VERB	O	O	4659
cardiac arrhythmias	VERB	O	Disease	4659
in	ADP	O	O	4659
cats	NOUN	O	O	4659
anaesthetized	VERB	O	O	4659
with	ADP	O	O	4659
halothane	VERB	O	Chemical	4659
,	PUNCT	O	O	4659
but	CCONJ	O	O	4659
the	PRON	O	O	4659
mean	VERB	O	O	4659
dose	NOUN	O	O	4659
of	ADP	O	O	4659
(	PUNCT	O	O	4659
-)-propranolol	INTJ	O	O	4659
was	AUX	O	O	4659
0.09+/-0.02	NUM	O	O	4659
mg	VERB	O	O	4659
/	PUNCT	O	O	4659
kg	VERB	O	O	4659
whereas	SCONJ	O	O	4659
that	SCONJ	O	O	4659
of	ADP	O	O	4659
(	PUNCT	O	O	4659
+	ADP	O	O	4659
)	PUNCT	O	O	4659
-propranolol	X	O	O	4659
was	AUX	O	O	4659
4.2+/-1.2	NUM	O	O	4659
mg	VERB	O	O	4659
/	PUNCT	O	O	4659
kg	VERB	O	O	4659
.	PUNCT	O	O	4659
-propranolol	X	O	O	4660
there	ADV	O	O	4660
was	AUX	O	O	4660
a	PRON	O	O	4660
significant	ADJ	O	O	4660
prolongation	NOUN	O	O	4660
of	ADP	O	O	4660
the	PRON	O	O	4660
PR	NOUN	O	O	4660
interval	NOUN	O	O	4660
of	ADP	O	O	4660
the	PRON	O	O	4660
electrocardiogram	PROPN	O	O	4660
.	PUNCT	O	O	4660
Blockade	NOUN	O	O	4661
of	ADP	O	O	4661
arrhythmias	VERB	O	Disease	4661
with	ADP	O	O	4661
both	PRON	O	O	4661
isomers	NOUN	O	O	4661
was	AUX	O	O	4661
surmountable	ADJ	O	O	4661
by	ADP	O	O	4661
increasing	VERB	O	O	4661
the	PRON	O	O	4661
dose	NOUN	O	O	4661
of	ADP	O	O	4661
adrenaline.7	ADV	O	O	4661
.	PUNCT	O	O	4661
Both	PRON	O	O	4662
isomers	NOUN	O	O	4662
of	ADP	O	O	4662
propranolol	NOUN	O	Chemical	4662
were	AUX	O	O	4662
also	ADV	O	O	4662
capable	ADJ	O	O	4662
of	ADP	O	O	4662
reversing	VERB	O	O	4662
ventricular tachycardia	NOUN	O	Disease	4662
caused	VERB	O	O	4662
by	ADP	O	O	4662
ouabain	PROPN	O	Chemical	4662
in	ADP	O	O	4662
anaesthetized	VERB	O	O	4662
cats	NOUN	O	O	4662
and	CCONJ	O	O	4662
dogs	NOUN	O	O	4662
.	PUNCT	O	O	4662
The	PRON	O	O	4663
dose	NOUN	O	O	4663
of	ADP	O	O	4663
(	PUNCT	O	O	4663
-)-propranolol	INTJ	O	O	4663
was	AUX	O	O	4663
significantly	ADV	O	O	4663
smaller	ADJ	O	O	4663
than	ADP	O	O	4663
that	SCONJ	O	O	4663
of	ADP	O	O	4663
(	PUNCT	O	O	4663
+	ADP	O	O	4663
)	PUNCT	O	O	4663
-propranolol	X	O	O	4663
in	ADP	O	O	4663
both	PRON	O	O	4663
species	NOUN	O	O	4663
but	CCONJ	O	O	4663
much	ADJ	O	O	4663
higher	ADJ	O	O	4663
than	ADP	O	O	4663
that	SCONJ	O	O	4663
required	VERB	O	O	4663
to	PART	O	O	4663
produce	VERB	O	O	4663
evidence	NOUN	O	O	4663
of	ADP	O	O	4663
beta	NOUN	O	O	4663
-	PUNCT	O	O	4663
blockade.8	NOUN	O	O	4663
.	PUNCT	O	O	4663
Topotecan	ADJ	O	O	4666
in	ADP	O	O	4666
combination	NOUN	O	O	4666
with	ADP	O	O	4666
radiotherapy	NOUN	O	O	4666
in	ADP	O	O	4666
unresectable	ADJ	O	O	4666
glioblastoma	NOUN	O	Disease	4666
:	PUNCT	O	O	4666
a	PRON	O	O	4666
phase	NOUN	O	O	4666
2	X	O	O	4666
study	VERB	O	O	4666
.	PUNCT	O	O	4666
Improving	VERB	O	O	4667
glioblastoma	NOUN	O	Disease	4667
multiforme	NOUN	O	O	4667
(	PUNCT	O	O	4667
GBM	PROPN	O	O	4667
)	PUNCT	O	O	4667
treatment	NOUN	O	O	4667
with	ADP	O	O	4667
radio	NOUN	O	O	4667
-	PUNCT	O	O	4667
chemotherapy	NOUN	O	O	4667
remains	VERB	O	O	4667
a	PRON	O	O	4667
challenge	NOUN	O	O	4667
.	PUNCT	O	O	4667
Topotecan	ADJ	O	O	4668
is	AUX	O	O	4668
an	PRON	O	O	4668
attractive	ADJ	O	O	4668
option	NOUN	O	O	4668
as	ADP	O	O	4668
it	PRON	O	O	4668
exhibits	VERB	O	O	4668
growth	NOUN	O	O	4668
inhibition	NOUN	O	O	4668
of	ADP	O	O	4668
human	PROPN	O	O	4668
glioma	NOUN	O	Disease	4668
as	ADP	O	O	4668
well	ADV	O	O	4668
as	ADP	O	O	4668
brain	NOUN	O	O	4668
penetration	NOUN	O	O	4668
.	PUNCT	O	O	4668
The	PRON	O	O	4669
present	NOUN	O	O	4669
study	VERB	O	O	4669
assessed	VERB	O	O	4669
the	PRON	O	O	4669
combination	NOUN	O	O	4669
of	ADP	O	O	4669
radiotherapy	NOUN	O	O	4669
(	PUNCT	O	O	4669
60	NUM	O	O	4669
Gy/30	NOUN	O	O	4669
fractions/40	ADP	O	O	4669
days	NOUN	O	O	4669
)	PUNCT	O	O	4669
and	CCONJ	O	O	4669
topotecan	NOUN	O	O	4669
(	PUNCT	O	O	4669
0.9	NUM	O	O	4669
mg	VERB	O	O	4669
/	PUNCT	O	O	4669
m(2)/day	NOUN	O	O	4669
on	ADP	O	O	4669
days	NOUN	O	O	4669
1	X	O	O	4669
-	PUNCT	O	O	4669
5	NUM	O	O	4669
on	ADP	O	O	4669
weeks	NOUN	O	O	4669
1	X	O	O	4669
,	PUNCT	O	O	4669
3	X	O	O	4669
and	CCONJ	O	O	4669
5	NUM	O	O	4669
)	PUNCT	O	O	4669
in	ADP	O	O	4669
50	NUM	O	O	4669
adults	NOUN	O	O	4669
with	ADP	O	O	4669
histologically	ADV	O	O	4669
proven	VERB	O	O	4669
and	CCONJ	O	O	4669
untreated	ADJ	O	O	4669
GBM	PROPN	O	O	4669
.	PUNCT	O	O	4669
The	PRON	O	O	4670
incidence	NOUN	O	O	4670
of	ADP	O	O	4670
non	ADJ	O	O	4670
-	PUNCT	O	O	4670
hematological toxicities	NOUN	O	Disease	4670
was	AUX	O	O	4670
low	ADJ	O	O	4670
and	CCONJ	O	O	4670
grade	NOUN	O	O	4670
3	X	O	O	4670
-	PUNCT	O	O	4670
4	NUM	O	O	4670
hematological toxicities	NOUN	O	Disease	4670
were	AUX	O	O	4670
reported	VERB	O	O	4670
in	ADP	O	O	4670
20	NUM	O	O	4670
patients	NOUN	O	O	4670
(	PUNCT	O	O	4670
mainly	ADV	O	O	4670
lymphopenia	NOUN	O	O	4670
and	CCONJ	O	O	4670
neutropenia	ADJ	O	Disease	4670
)	PUNCT	O	O	4670
.	PUNCT	O	O	4670
Topotecan	ADJ	O	O	4671
in	ADP	O	O	4671
combination	NOUN	O	O	4671
with	ADP	O	O	4671
radiotherapy	NOUN	O	O	4671
was	AUX	O	O	4671
well	ADV	O	O	4671
tolerated	VERB	O	O	4671
.	PUNCT	O	O	4671
However	ADV	O	O	4672
,	PUNCT	O	O	4672
while	SCONJ	O	O	4672
response	NOUN	O	O	4672
and	CCONJ	O	O	4672
stabilization	NOUN	O	O	4672
concerned	VERB	O	O	4672
one	NUM	O	O	4672
-	PUNCT	O	O	4672
third	ADV	O	O	4672
of	ADP	O	O	4672
the	PRON	O	O	4672
patients	NOUN	O	O	4672
,	PUNCT	O	O	4672
the	PRON	O	O	4672
study	VERB	O	O	4672
did	VERB	O	O	4672
not	PART	O	O	4672
show	VERB	O	O	4672
increased	VERB	O	O	4672
benefits	NOUN	O	O	4672
in	ADP	O	O	4672
terms	NOUN	O	O	4672
of	ADP	O	O	4672
survival	NOUN	O	O	4672
in	ADP	O	O	4672
patients	NOUN	O	O	4672
with	ADP	O	O	4672
unresectable	ADJ	O	O	4672
GBM	PROPN	O	O	4672
.	PUNCT	O	O	4672
Long	ADV	O	O	4675
-	PUNCT	O	O	4675
term	NOUN	O	O	4675
lithium	NOUN	O	Chemical	4675
therapy	NOUN	O	O	4675
leading	VERB	O	O	4675
to	PART	O	O	4675
hyperparathyroidism	NOUN	O	O	4675
:	PUNCT	O	O	4675
a	PRON	O	O	4675
case	NOUN	O	O	4675
report	VERB	O	O	4675
.	PUNCT	O	O	4675
This	PRON	O	O	4676
paper	PROPN	O	O	4676
reviews	NOUN	O	O	4676
the	PRON	O	O	4676
effect	VERB	O	O	4676
of	ADP	O	O	4676
chronic	ADJ	O	O	4676
lithium	NOUN	O	Chemical	4676
therapy	NOUN	O	O	4676
on	ADP	O	O	4676
serum	NOUN	O	O	4676
calcium	NOUN	O	Chemical	4676
level	VERB	O	O	4676
and	CCONJ	O	O	4676
parathyroid	ADJ	O	O	4676
glands	NOUN	O	O	4676
,	PUNCT	O	O	4676
its	PRON	O	O	4676
pathogenesis	NOUN	O	O	4676
,	PUNCT	O	O	4676
and	CCONJ	O	O	4676
treatment	NOUN	O	O	4676
options	NOUN	O	O	4676
.	PUNCT	O	O	4676
We	PRON	O	O	4677
examined	VERB	O	O	4677
the	PRON	O	O	4677
case	NOUN	O	O	4677
of	ADP	O	O	4677
a	PRON	O	O	4677
lithium	NOUN	O	Chemical	4677
-	PUNCT	O	O	4677
treated	VERB	O	O	4677
patient	NOUN	O	O	4677
who	PRON	O	O	4677
had	VERB	O	O	4677
recurrent	ADJ	O	O	4677
hypercalcemia	NOUN	O	Disease	4677
to	PART	O	O	4677
better	ADV	O	O	4677
understand	VERB	O	O	4677
the	PRON	O	O	4677
disease	PROPN	O	O	4677
process	NOUN	O	O	4677
.	PUNCT	O	O	4677
CONCLUSION	PROPN	O	O	4678
:	PUNCT	O	O	4678
Primary	NOUN	O	O	4678
hyperparathyroidism	NOUN	O	O	4678
is	AUX	O	O	4678
a	PRON	O	O	4678
rare	ADJ	O	O	4678
but	CCONJ	O	O	4678
potentially	ADV	O	O	4678
life	NOUN	O	O	4678
-	PUNCT	O	O	4678
threatening	VERB	O	O	4678
side	NOUN	O	O	4678
effect	VERB	O	O	4678
of	ADP	O	O	4678
long	ADV	O	O	4678
-	PUNCT	O	O	4678
term	NOUN	O	O	4678
lithium	NOUN	O	Chemical	4678
therapy	NOUN	O	O	4678
.	PUNCT	O	O	4678
PRACTICAL	ADJ	O	O	4679
IMPLICATIONS	NOUN	O	O	4679
:	PUNCT	O	O	4679
As	ADP	O	O	4679
much	ADJ	O	O	4679
as	ADP	O	O	4679
15%	NOUN	O	O	4679
of	ADP	O	O	4679
lithium	NOUN	O	Chemical	4679
-	PUNCT	O	O	4679
treated	VERB	O	O	4679
patients	NOUN	O	O	4679
become	VERB	O	O	4679
hypercalcemic	ADV	O	O	4679
.	PUNCT	O	O	4679
By	ADP	O	O	4680
routinely	ADV	O	O	4680
monitoring	NOUN	O	O	4680
serum	NOUN	O	O	4680
calcium	NOUN	O	Chemical	4680
levels	NOUN	O	O	4680
,	PUNCT	O	O	4680
healthcare	PROPN	O	O	4680
providers	NOUN	O	O	4680
can	AUX	O	O	4680
improve	VERB	O	O	4680
the	PRON	O	O	4680
quality	NOUN	O	O	4680
of	ADP	O	O	4680
life	NOUN	O	O	4680
of	ADP	O	O	4680
this	PRON	O	O	4680
patient	NOUN	O	O	4680
group	NOUN	O	O	4680
.	PUNCT	O	O	4680
The	PRON	O	O	4683
purpose	NOUN	O	O	4683
of	ADP	O	O	4683
this	PRON	O	O	4683
study	VERB	O	O	4683
was	AUX	O	O	4683
to	PART	O	O	4683
compare	VERB	O	O	4683
surgical	ADJ	O	O	4683
conditions	NOUN	O	O	4683
,	PUNCT	O	O	4683
including	VERB	O	O	4683
the	PRON	O	O	4683
amount	NOUN	O	O	4683
of	ADP	O	O	4683
intraoperative	ADJ	O	O	4683
bleeding	VERB	O	Disease	4683
as	ADP	O	O	4683
well	ADV	O	O	4683
as	ADP	O	O	4683
intraoperative	ADJ	O	O	4683
blood	NOUN	O	O	4683
pressure	NOUN	O	O	4683
,	PUNCT	O	O	4683
during	ADP	O	O	4683
functional	ADJ	O	O	4683
endoscopic	ADJ	O	O	4683
sinus	NOUN	O	O	4683
surgery	NOUN	O	O	4683
(	PUNCT	O	O	4683
FESS	PROPN	O	O	4683
)	PUNCT	O	O	4683
using	VERB	O	O	4683
flexible	ADJ	O	O	4683
reinforced	VERB	O	O	4683
laryngeal	NOUN	O	O	4683
mask	VERB	O	O	4683
airway	NOUN	O	O	4683
(	PUNCT	O	O	4683
FRLMA	PROPN	O	O	4683
)	PUNCT	O	O	4683
versus	ADP	O	O	4683
endotracheal	VERB	O	O	4683
tube	NOUN	O	O	4683
(	PUNCT	O	O	4683
ETT	PROPN	O	O	4683
)	PUNCT	O	O	4683
in	ADP	O	O	4683
maintaining	VERB	O	O	4683
controlled	VERB	O	O	4683
hypotension	NOUN	O	Disease	4683
anesthesia	NOUN	O	O	4683
induced	VERB	O	O	4683
by	ADP	O	O	4683
propofol	VERB	O	Chemical	4683
-	PUNCT	O	O	4683
remifentanil	NOUN	O	Chemical	4683
total	ADJ	O	O	4683
i.v	NOUN	O	O	4683
.	PUNCT	O	O	4683
METHODS	NOUN	O	O	4684
:	PUNCT	O	O	4684
Sixty	NUM	O	O	4684
normotensive	PROPN	O	O	4684
American	ADJ	O	O	4684
Society	NOUN	O	O	4684
of	ADP	O	O	4684
Anesthesiologists	NOUN	O	O	4684
I	PRON	O	O	4684
-	PUNCT	O	O	4684
II	NUM	O	O	4684
adult	NOUN	O	O	4684
patients	NOUN	O	O	4684
undergoing	VERB	O	O	4684
FESS	PROPN	O	O	4684
under	ADP	O	O	4684
controlled	VERB	O	O	4684
hypotension	NOUN	O	Disease	4684
anesthesia	NOUN	O	O	4684
caused	VERB	O	O	4684
by	ADP	O	O	4684
propofol	VERB	O	Chemical	4684
-	PUNCT	O	O	4684
remifentanil	NOUN	O	Chemical	4684
-	PUNCT	O	O	4684
TIVA	NOUN	O	O	4684
were	AUX	O	O	4684
randomly	ADV	O	O	4684
assigned	VERB	O	O	4684
into	ADP	O	O	4684
two	NUM	O	O	4684
groups	NOUN	O	O	4684
:	PUNCT	O	O	4684
group	NOUN	O	O	4684
I	PRON	O	O	4684
,	PUNCT	O	O	4684
FRLMA	PROPN	O	O	4684
;	PUNCT	O	O	4684
group	NOUN	O	O	4684
II	NUM	O	O	4684
,	PUNCT	O	O	4684
ETT	PROPN	O	O	4684
.	PUNCT	O	O	4684
Hemorrhage	NOUN	O	O	4685
was	AUX	O	O	4685
measured	VERB	O	O	4685
and	CCONJ	O	O	4685
the	PRON	O	O	4685
visibility	NOUN	O	O	4685
of	ADP	O	O	4685
the	PRON	O	O	4685
operative	NOUN	O	O	4685
field	NOUN	O	O	4685
was	AUX	O	O	4685
evaluated	VERB	O	O	4685
according	VERB	O	O	4685
to	PART	O	O	4685
a	PRON	O	O	4685
six	NUM	O	O	4685
-	PUNCT	O	O	4685
point	VERB	O	O	4685
scale	NOUN	O	O	4685
.	PUNCT	O	O	4685
Controlled	VERB	O	O	4686
hypotension	NOUN	O	Disease	4686
was	AUX	O	O	4686
achieved	VERB	O	O	4686
within	ADP	O	O	4686
a	PRON	O	O	4686
shorter	ADJ	O	O	4686
period	NOUN	O	O	4686
using	VERB	O	O	4686
laryngeal	NOUN	O	O	4686
mask	VERB	O	O	4686
using	VERB	O	O	4686
lower	ADJ	O	O	4686
rates	NOUN	O	O	4686
of	ADP	O	O	4686
remifentanil	NOUN	O	Chemical	4686
infusion	NOUN	O	O	4686
and	CCONJ	O	O	4686
lower	ADJ	O	O	4686
total	ADJ	O	O	4686
dose	NOUN	O	O	4686
of	ADP	O	O	4686
remifentanil	NOUN	O	Chemical	4686
.	PUNCT	O	O	4686
In	ADP	O	O	4687
summary	NOUN	O	O	4687
,	PUNCT	O	O	4687
our	PRON	O	O	4687
results	VERB	O	O	4687
indicate	VERB	O	O	4687
that	SCONJ	O	O	4687
airway	NOUN	O	O	4687
management	NOUN	O	O	4687
using	VERB	O	O	4687
FRLMA	PROPN	O	O	4687
during	ADP	O	O	4687
controlled	VERB	O	O	4687
hypotension	NOUN	O	Disease	4687
anesthesia	NOUN	O	O	4687
provided	VERB	O	O	4687
better	ADV	O	O	4687
surgical	ADJ	O	O	4687
conditions	NOUN	O	O	4687
in	ADP	O	O	4687
terms	NOUN	O	O	4687
of	ADP	O	O	4687
quality	NOUN	O	O	4687
of	ADP	O	O	4687
operative	NOUN	O	O	4687
field	NOUN	O	O	4687
and	CCONJ	O	O	4687
blood loss	NOUN	O	Disease	4687
and	CCONJ	O	O	4687
allowed	VERB	O	O	4687
for	ADP	O	O	4687
convenient	ADJ	O	O	4687
induced	VERB	O	O	4687
hypotension	NOUN	O	Disease	4687
with	ADP	O	O	4687
low	ADJ	O	O	4687
doses	NOUN	O	O	4687
of	ADP	O	O	4687
remifentanil	NOUN	O	Chemical	4687
during	ADP	O	O	4687
TIVA	NOUN	O	O	4687
in	ADP	O	O	4687
patients	NOUN	O	O	4687
undergoing	VERB	O	O	4687
FESS	PROPN	O	O	4687
.	PUNCT	O	O	4687
Nonalcoholic	ADJ	O	O	4690
fatty	ADJ	O	O	4690
liver disease	NOUN	O	Disease	4690
during	ADP	O	O	4690
valproate	VERB	O	Chemical	4690
therapy	NOUN	O	O	4690
.	PUNCT	O	O	4690
Valproic acid	NOUN	O	Chemical	4691
(	PUNCT	O	O	4691
VPA	PROPN	O	Chemical	4691
)	PUNCT	O	O	4691
is	AUX	O	O	4691
effective	ADJ	O	O	4691
for	ADP	O	O	4691
the	PRON	O	O	4691
treatment	NOUN	O	O	4691
of	ADP	O	O	4691
many	ADJ	O	O	4691
types	NOUN	O	O	4691
of	ADP	O	O	4691
epilepsy	NOUN	O	Disease	4691
,	PUNCT	O	O	4691
but	CCONJ	O	O	4691
its	PRON	O	O	4691
use	VERB	O	O	4691
can	AUX	O	O	4691
be	AUX	O	O	4691
associated	VERB	O	O	4691
with	ADP	O	O	4691
an	PRON	O	O	4691
increase	VERB	O	O	4691
in	ADP	O	O	4691
body	NOUN	O	O	4691
weight	NOUN	O	O	4691
.	PUNCT	O	O	4691
We	PRON	O	O	4692
report	VERB	O	O	4692
a	PRON	O	O	4692
case	NOUN	O	O	4692
of	ADP	O	O	4692
nonalcoholic	ADJ	O	O	4692
fatty	ADJ	O	O	4692
liver disease	NOUN	O	Disease	4692
(	PUNCT	O	O	4692
NAFLD	PROPN	O	O	4692
)	PUNCT	O	O	4692
arising	VERB	O	O	4692
in	ADP	O	O	4692
a	PRON	O	O	4692
child	NOUN	O	O	4692
who	PRON	O	O	4692
developed	VERB	O	O	4692
obesity	NOUN	O	Disease	4692
during	ADP	O	O	4692
VPA	PROPN	O	Chemical	4692
treatment	NOUN	O	O	4692
.	PUNCT	O	O	4692
Laboratory	NOUN	O	O	4693
data	NOUN	O	O	4693
revealed	VERB	O	O	4693
hyperinsulinemia	NOUN	O	O	4693
with	ADP	O	O	4693
insulin	NOUN	O	O	4693
resistance	NOUN	O	O	4693
.	PUNCT	O	O	4693
After	ADP	O	O	4694
the	PRON	O	O	4694
withdrawal	NOUN	O	O	4694
of	ADP	O	O	4694
VPA	PROPN	O	Chemical	4694
therapy	NOUN	O	O	4694
,	PUNCT	O	O	4694
our	PRON	O	O	4694
patient	NOUN	O	O	4694
showed	VERB	O	O	4694
a	PRON	O	O	4694
significant	ADJ	O	O	4694
weight loss	NOUN	O	Disease	4694
,	PUNCT	O	O	4694
a	PRON	O	O	4694
decrease	VERB	O	O	4694
of	ADP	O	O	4694
body	NOUN	O	O	4694
mass	PROPN	O	O	4694
index	NOUN	O	O	4694
,	PUNCT	O	O	4694
and	CCONJ	O	O	4694
normalization	NOUN	O	O	4694
of	ADP	O	O	4694
metabolic	ADJ	O	O	4694
and	CCONJ	O	O	4694
endocrine	NOUN	O	O	4694
parameters	NOUN	O	O	4694
;	PUNCT	O	O	4694
moreover	ADV	O	O	4694
,	PUNCT	O	O	4694
ultrasound	VERB	O	O	4694
measurements	NOUN	O	O	4694
showed	VERB	O	O	4694
a	PRON	O	O	4694
complete	VERB	O	O	4694
normalization	NOUN	O	O	4694
.	PUNCT	O	O	4694
The	PRON	O	O	4695
present	NOUN	O	O	4695
case	NOUN	O	O	4695
suggests	VERB	O	O	4695
that	SCONJ	O	O	4695
obesity	NOUN	O	Disease	4695
,	PUNCT	O	O	4695
hyperinsulinemia	NOUN	O	O	4695
,	PUNCT	O	O	4695
insulin	NOUN	O	O	4695
resistance	NOUN	O	O	4695
,	PUNCT	O	O	4695
and	CCONJ	O	O	4695
long	ADV	O	O	4695
-	PUNCT	O	O	4695
term	NOUN	O	O	4695
treatment	NOUN	O	O	4695
with	ADP	O	O	4695
VPA	PROPN	O	Chemical	4695
may	AUX	O	O	4695
be	AUX	O	O	4695
all	PRON	O	O	4695
associated	VERB	O	O	4695
with	ADP	O	O	4695
the	PRON	O	O	4695
development	NOUN	O	O	4695
of	ADP	O	O	4695
NAFLD	PROPN	O	O	4695
;	PUNCT	O	O	4695
this	PRON	O	O	4695
side	NOUN	O	O	4695
effect	VERB	O	O	4695
is	AUX	O	O	4695
reversible	ADJ	O	O	4695
after	ADP	O	O	4695
VPA	PROPN	O	Chemical	4695
withdrawal	NOUN	O	O	4695
.	PUNCT	O	O	4695
Carbimazole	NOUN	O	O	4698
induced	VERB	O	O	4698
ANCA	PROPN	O	O	4698
positive	ADJ	O	O	4698
vasculitis	NOUN	O	Disease	4698
.	PUNCT	O	O	4698
Anti	ADJ	O	O	4699
-	PUNCT	O	O	4699
thyroid	NOUN	O	O	4699
drugs	NOUN	O	O	4699
,	PUNCT	O	O	4699
like	INTJ	O	O	4699
carbimazole	PROPN	O	Chemical	4699
and	CCONJ	O	O	4699
propylthiouracil	NOUN	O	Chemical	4699
(	PUNCT	O	O	4699
PTU	PROPN	O	Chemical	4699
)	PUNCT	O	O	4699
are	AUX	O	O	4699
commonly	ADV	O	O	4699
prescribed	VERB	O	O	4699
for	ADP	O	O	4699
the	PRON	O	O	4699
treatment	NOUN	O	O	4699
of	ADP	O	O	4699
hyperthyroidism	NOUN	O	Disease	4699
.	PUNCT	O	O	4699
One	NUM	O	O	4700
should	AUX	O	O	4700
be	AUX	O	O	4700
aware	ADJ	O	O	4700
of	ADP	O	O	4700
the	PRON	O	O	4700
side	NOUN	O	O	4700
effects	NOUN	O	O	4700
of	ADP	O	O	4700
antithyroid	ADJ	O	O	4700
medications	NOUN	O	O	4700
.	PUNCT	O	O	4700
Antineutrophil	PROPN	O	O	4701
cytoplasmic	ADJ	O	O	4701
antibody	NOUN	O	O	4701
(	PUNCT	O	O	4701
ANCA)--associated	VERB	O	O	4701
vasculitis	NOUN	O	Disease	4701
is	AUX	O	O	4701
a	PRON	O	O	4701
potentially	ADV	O	O	4701
life	NOUN	O	O	4701
-	PUNCT	O	O	4701
threatening	VERB	O	O	4701
adverse	ADJ	O	O	4701
effect	VERB	O	O	4701
of	ADP	O	O	4701
antithyroidmedications	NOUN	O	O	4701
.	PUNCT	O	O	4701
We	PRON	O	O	4702
report	VERB	O	O	4702
a	PRON	O	O	4702
patient	NOUN	O	O	4702
with	ADP	O	O	4702
Graves	NOUN	O	O	4702
'	PUNCT	O	O	4702
disease	PROPN	O	O	4702
who	PRON	O	O	4702
developed	VERB	O	O	4702
ANCA	PROPN	O	O	4702
positive	ADJ	O	O	4702
carbimazole	PROPN	O	Chemical	4702
induced	VERB	O	O	4702
vasculitis	NOUN	O	Disease	4702
.	PUNCT	O	O	4702
The	PRON	O	O	4703
episode	PROPN	O	O	4703
was	AUX	O	O	4703
characterized	VERB	O	O	4703
by	ADP	O	O	4703
a	PRON	O	O	4703
vasculitic	ADJ	O	O	4703
skin rash	ADJ	O	Disease	4703
associated	VERB	O	O	4703
with	ADP	O	O	4703
large	ADJ	O	O	4703
joint	ADJ	O	O	4703
arthritis	NOUN	O	Disease	4703
,	PUNCT	O	O	4703
pyrexia	PROPN	O	O	4703
and	CCONJ	O	O	4703
parotiditis	NOUN	O	O	4703
but	CCONJ	O	O	4703
no	PRON	O	O	4703
renal	ADJ	O	O	4703
or	CCONJ	O	O	4703
pulmonary	ADJ	O	O	4703
involvement	NOUN	O	O	4703
.	PUNCT	O	O	4703
He	PRON	O	O	4704
was	AUX	O	O	4704
referred	VERB	O	O	4704
to	PART	O	O	4704
us	PRON	O	O	4704
for	ADP	O	O	4704
neurological	ADJ	O	O	4704
evaluation	NOUN	O	O	4704
because	SCONJ	O	O	4704
he	PRON	O	O	4704
had	VERB	O	O	4704
difficulty	NOUN	O	O	4704
in	ADP	O	O	4704
getting	VERB	O	O	4704
up	ADP	O	O	4704
from	ADP	O	O	4704
squatting	VERB	O	O	4704
position	NOUN	O	O	4704
and	CCONJ	O	O	4704
was	AUX	O	O	4704
suspected	VERB	O	O	4704
to	PART	O	O	4704
have	VERB	O	O	4704
myositis	PROPN	O	Disease	4704
.	PUNCT	O	O	4704
Carbimazole	NOUN	O	O	4705
and	CCONJ	O	O	4705
methimazole	VERB	O	Chemical	4705
have	VERB	O	O	4705
a	PRON	O	O	4705
lower	ADJ	O	O	4705
incidence	NOUN	O	O	4705
of	ADP	O	O	4705
reported	VERB	O	O	4705
ANCA	PROPN	O	O	4705
positive	ADJ	O	O	4705
side	NOUN	O	O	4705
effects	NOUN	O	O	4705
than	ADP	O	O	4705
PUT	VERB	O	O	4705
.	PUNCT	O	O	4705
To	PART	O	O	4706
the	PRON	O	O	4706
best	ADV	O	O	4706
of	ADP	O	O	4706
our	PRON	O	O	4706
knowledge	NOUN	O	O	4706
this	PRON	O	O	4706
is	AUX	O	O	4706
the	PRON	O	O	4706
first	ADV	O	O	4706
ANCA	PROPN	O	O	4706
positive	ADJ	O	O	4706
carbimazole	PROPN	O	Chemical	4706
induced	VERB	O	O	4706
vasculitis	NOUN	O	Disease	4706
case	NOUN	O	O	4706
reported	VERB	O	O	4706
from	ADP	O	O	4706
India	PROPN	O	O	4706
.	PUNCT	O	O	4706
Aspirin	NOUN	O	Chemical	4709
for	ADP	O	O	4709
the	PRON	O	O	4709
primary	NOUN	O	O	4709
prevention	NOUN	O	O	4709
of	ADP	O	O	4709
cardiovascular events	NOUN	O	O	4709
:	PUNCT	O	O	4709
an	PRON	O	O	4709
update	VERB	O	O	4709
of	ADP	O	O	4709
the	PRON	O	O	4709
evidence	NOUN	O	O	4709
for	ADP	O	O	4709
the	PRON	O	O	4709
U.S.	PROPN	O	O	4709
Preventive	PROPN	O	O	4709
Services	NOUN	O	O	4709
Task	NOUN	O	O	4709
Force	NOUN	O	O	4709
.	PUNCT	O	O	4709
Coronary	ADJ	O	O	4710
heart disease	NOUN	O	Disease	4710
and	CCONJ	O	O	4710
cerebrovascular	ADJ	O	O	4710
disease	PROPN	O	O	4710
are	AUX	O	O	4710
leading	VERB	O	O	4710
causes	VERB	O	O	4710
of	ADP	O	O	4710
death	NOUN	O	O	4710
in	ADP	O	O	4710
the	PRON	O	O	4710
United	PROPN	O	O	4710
States	NOUN	O	O	4710
.	PUNCT	O	O	4710
In	ADP	O	O	4711
2002	NUM	O	O	4711
,	PUNCT	O	O	4711
the	PRON	O	O	4711
U.S.	PROPN	O	O	4711
Preventive	PROPN	O	O	4711
Services	NOUN	O	O	4711
Task	NOUN	O	O	4711
Force	NOUN	O	O	4711
(	PUNCT	O	O	4711
USPSTF	PROPN	O	O	4711
)	PUNCT	O	O	4711
strongly	ADV	O	O	4711
recommended	VERB	O	O	4711
that	SCONJ	O	O	4711
clinicians	NOUN	O	O	4711
discuss	VERB	O	O	4711
aspirin	NOUN	O	Chemical	4711
with	ADP	O	O	4711
adults	NOUN	O	O	4711
who	PRON	O	O	4711
are	AUX	O	O	4711
at	ADP	O	O	4711
increased	VERB	O	O	4711
risk	NOUN	O	O	4711
for	ADP	O	O	4711
coronary	ADJ	O	O	4711
heart disease	NOUN	O	Disease	4711
.	PUNCT	O	O	4711
PURPOSE	NOUN	O	O	4712
:	PUNCT	O	O	4712
To	PART	O	O	4712
determine	VERB	O	O	4712
the	PRON	O	O	4712
benefits	NOUN	O	O	4712
and	CCONJ	O	O	4712
harms	VERB	O	O	4712
of	ADP	O	O	4712
taking	VERB	O	O	4712
aspirin	NOUN	O	Chemical	4712
for	ADP	O	O	4712
the	PRON	O	O	4712
primary	NOUN	O	O	4712
prevention	NOUN	O	O	4712
of	ADP	O	O	4712
myocardial infarctions	NOUN	O	O	4712
,	PUNCT	O	O	4712
strokes	NOUN	O	Disease	4712
,	PUNCT	O	O	4712
and	CCONJ	O	O	4712
death	NOUN	O	O	4712
.	PUNCT	O	O	4712
STUDY	NOUN	O	O	4713
SELECTION	PROPN	O	O	4713
:	PUNCT	O	O	4713
English	PROPN	O	O	4713
-	PUNCT	O	O	4713
language	NOUN	O	O	4713
randomized	VERB	O	O	4713
,	PUNCT	O	O	4713
controlled	VERB	O	O	4713
trials	NOUN	O	O	4713
(	PUNCT	O	O	4713
RCTs	NOUN	O	O	4713
)	PUNCT	O	O	4713
;	PUNCT	O	O	4713
case	NOUN	O	O	4713
-	PUNCT	O	O	4713
control	VERB	O	O	4713
studies	NOUN	O	O	4713
;	PUNCT	O	O	4713
meta	PROPN	O	O	4713
-	PUNCT	O	O	4713
analyses	NOUN	O	O	4713
;	PUNCT	O	O	4713
and	CCONJ	O	O	4713
systematic	ADJ	O	O	4713
reviews	NOUN	O	O	4713
of	ADP	O	O	4713
aspirin	NOUN	O	Chemical	4713
versus	ADP	O	O	4713
control	VERB	O	O	4713
for	ADP	O	O	4713
the	PRON	O	O	4713
primary	NOUN	O	O	4713
prevention	NOUN	O	O	4713
of	ADP	O	O	4713
cardiovascular disease	NOUN	O	Disease	4713
(	PUNCT	O	O	4713
CVD	PROPN	O	O	4713
)	PUNCT	O	O	4713
were	AUX	O	O	4713
selected	VERB	O	O	4713
to	PART	O	O	4713
answer	VERB	O	O	4713
the	PRON	O	O	4713
following	VERB	O	O	4713
questions	NOUN	O	O	4713
:	PUNCT	O	O	4713
Does	VERB	O	O	4713
aspirin	NOUN	O	Chemical	4713
decrease	VERB	O	O	4713
coronary	ADJ	O	O	4713
heart	NOUN	O	O	4713
events	NOUN	O	O	4713
,	PUNCT	O	O	4713
strokes	NOUN	O	Disease	4713
,	PUNCT	O	O	4713
death	NOUN	O	O	4713
from	ADP	O	O	4713
coronary	ADJ	O	O	4713
heart	NOUN	O	O	4713
events	NOUN	O	O	4713
or	CCONJ	O	O	4713
stroke	VERB	O	Disease	4713
,	PUNCT	O	O	4713
or	CCONJ	O	O	4713
all	PRON	O	O	4713
-	PUNCT	O	O	4713
cause	VERB	O	O	4713
mortality	NOUN	O	O	4713
in	ADP	O	O	4713
adults	NOUN	O	O	4713
without	ADP	O	O	4713
known	VERB	O	O	4713
CVD	PROPN	O	O	4714
?	PUNCT	O	O	4714
Does	VERB	O	O	4715
aspirin	NOUN	O	Chemical	4715
increase	VERB	O	O	4715
gastrointestinal	ADJ	O	O	4715
bleeding	VERB	O	Disease	4715
or	CCONJ	O	O	4715
hemorrhagic strokes	NOUN	O	Disease	4715
?	PUNCT	O	O	4715
DATA	NOUN	O	O	4716
SYNTHESIS	PROPN	O	O	4716
:	PUNCT	O	O	4716
New	ADJ	O	O	4716
evidence	NOUN	O	O	4716
from	ADP	O	O	4716
1	X	O	O	4716
good	ADJ	O	O	4716
-	PUNCT	O	O	4716
quality	NOUN	O	O	4716
RCT	PROPN	O	O	4716
,	PUNCT	O	O	4716
1	X	O	O	4716
good	ADJ	O	O	4716
-	PUNCT	O	O	4716
quality	NOUN	O	O	4716
meta	PROPN	O	O	4716
-	PUNCT	O	O	4716
analysis	NOUN	O	O	4716
,	PUNCT	O	O	4716
and	CCONJ	O	O	4716
2	X	O	O	4716
fair	ADJ	O	O	4716
-	PUNCT	O	O	4716
quality	NOUN	O	O	4716
subanalyses	NOUN	O	O	4716
of	ADP	O	O	4716
RCTs	NOUN	O	O	4716
demonstrates	VERB	O	O	4716
that	SCONJ	O	O	4716
aspirin	NOUN	O	Chemical	4716
use	VERB	O	O	4716
reduces	VERB	O	O	4716
the	PRON	O	O	4716
number	NOUN	O	O	4716
of	ADP	O	O	4716
CVD	PROPN	O	O	4716
events	NOUN	O	O	4716
in	ADP	O	O	4716
patients	NOUN	O	O	4716
without	ADP	O	O	4716
known	VERB	O	O	4716
CVD	PROPN	O	O	4716
.	PUNCT	O	O	4716
Men	NOUN	O	O	4717
in	ADP	O	O	4717
these	PRON	O	O	4717
studies	NOUN	O	O	4717
experienced	ADJ	O	O	4717
fewer	ADJ	O	O	4717
myocardial infarctions	NOUN	O	O	4717
and	CCONJ	O	O	4717
women	NOUN	O	O	4717
experienced	ADJ	O	O	4717
fewer	ADJ	O	O	4717
ischemic	VERB	O	Disease	4717
strokes	NOUN	O	Disease	4717
.	PUNCT	O	O	4717
Aspirin	NOUN	O	Chemical	4718
does	VERB	O	O	4718
not	PART	O	O	4718
seem	VERB	O	O	4718
to	PART	O	O	4718
affect	VERB	O	O	4718
CVD	PROPN	O	O	4718
mortality	NOUN	O	O	4718
or	CCONJ	O	O	4718
all	PRON	O	O	4718
-	PUNCT	O	O	4718
cause	VERB	O	O	4718
mortality	NOUN	O	O	4718
in	ADP	O	O	4718
either	ADV	O	O	4718
men	NOUN	O	O	4718
or	CCONJ	O	O	4718
women	NOUN	O	O	4718
.	PUNCT	O	O	4718
The	PRON	O	O	4719
use	VERB	O	O	4719
of	ADP	O	O	4719
aspirin	NOUN	O	Chemical	4719
for	ADP	O	O	4719
primary	NOUN	O	O	4719
prevention	NOUN	O	O	4719
increases	VERB	O	O	4719
the	PRON	O	O	4719
risk	NOUN	O	O	4719
for	ADP	O	O	4719
major	ADJ	O	O	4719
bleeding	VERB	O	Disease	4719
events	NOUN	O	O	4719
,	PUNCT	O	O	4719
primarily	ADV	O	O	4719
gastrointestinal	ADJ	O	O	4719
bleeding	VERB	O	Disease	4719
events	NOUN	O	O	4719
,	PUNCT	O	O	4719
in	ADP	O	O	4719
both	PRON	O	O	4719
men	NOUN	O	O	4719
and	CCONJ	O	O	4719
women	NOUN	O	O	4719
.	PUNCT	O	O	4719
Men	NOUN	O	O	4720
have	VERB	O	O	4720
an	PRON	O	O	4720
increased	VERB	O	O	4720
risk	NOUN	O	O	4720
for	ADP	O	O	4720
hemorrhagic strokes	NOUN	O	Disease	4720
with	ADP	O	O	4720
aspirin	NOUN	O	Chemical	4720
use	VERB	O	O	4720
.	PUNCT	O	O	4720
A	PRON	O	O	4721
new	ADJ	O	O	4721
RCT	PROPN	O	O	4721
and	CCONJ	O	O	4721
meta	PROPN	O	O	4721
-	PUNCT	O	O	4721
analysis	NOUN	O	O	4721
suggest	VERB	O	O	4721
that	SCONJ	O	O	4721
the	PRON	O	O	4721
risk	NOUN	O	O	4721
for	ADP	O	O	4721
hemorrhagic strokes	NOUN	O	Disease	4721
in	ADP	O	O	4721
women	NOUN	O	O	4721
is	AUX	O	O	4721
not	PART	O	O	4721
statistically	ADV	O	O	4721
significantly	ADV	O	O	4721
increased	VERB	O	O	4721
.	PUNCT	O	O	4721
New	ADJ	O	O	4722
evidence	NOUN	O	O	4722
on	ADP	O	O	4722
aspirin	NOUN	O	Chemical	4722
for	ADP	O	O	4722
the	PRON	O	O	4722
primary	NOUN	O	O	4722
prevention	NOUN	O	O	4722
of	ADP	O	O	4722
CVD	PROPN	O	O	4722
is	AUX	O	O	4722
limited	VERB	O	O	4722
.	PUNCT	O	O	4722
The	PRON	O	O	4723
dose	NOUN	O	O	4723
of	ADP	O	O	4723
aspirin	NOUN	O	Chemical	4723
used	VERB	O	O	4723
in	ADP	O	O	4723
the	PRON	O	O	4723
RCTs	NOUN	O	O	4723
varied	ADJ	O	O	4723
,	PUNCT	O	O	4723
which	PRON	O	O	4723
prevented	VERB	O	O	4723
the	PRON	O	O	4723
estimation	NOUN	O	O	4723
of	ADP	O	O	4723
the	PRON	O	O	4723
most	ADV	O	O	4723
appropriate	ADJ	O	O	4723
dose	NOUN	O	O	4723
for	ADP	O	O	4723
primary	NOUN	O	O	4723
prevention	NOUN	O	O	4723
.	PUNCT	O	O	4723
Aspirin	NOUN	O	Chemical	4724
reduces	VERB	O	O	4724
the	PRON	O	O	4724
risk	NOUN	O	O	4724
for	ADP	O	O	4724
myocardial infarction	NOUN	O	Disease	4724
in	ADP	O	O	4724
men	NOUN	O	O	4724
and	CCONJ	O	O	4724
strokes	NOUN	O	Disease	4724
in	ADP	O	O	4724
women	NOUN	O	O	4724
.	PUNCT	O	O	4724
Aspirin	NOUN	O	Chemical	4725
use	VERB	O	O	4725
increases	VERB	O	O	4725
the	PRON	O	O	4725
risk	NOUN	O	O	4725
for	ADP	O	O	4725
serious	ADJ	O	O	4725
bleeding	VERB	O	Disease	4725
events	NOUN	O	O	4725
.	PUNCT	O	O	4725
Reducing	VERB	O	O	4728
harm	NOUN	O	O	4728
associated	VERB	O	O	4728
with	ADP	O	O	4728
anticoagulation	NOUN	O	O	4728
:	PUNCT	O	O	4728
practical	ADJ	O	O	4728
considerations	NOUN	O	O	4728
of	ADP	O	O	4728
argatroban	NOUN	O	O	4728
therapy	NOUN	O	O	4728
in	ADP	O	O	4728
heparin	NOUN	O	Chemical	4728
-	PUNCT	O	O	4728
induced	VERB	O	O	4728
thrombocytopenia	PROPN	O	Disease	4728
.	PUNCT	O	O	4728
Argatroban	NOUN	O	O	4729
is	AUX	O	O	4729
a	PRON	O	O	4729
hepatically	ADV	O	O	4729
metabolized	VERB	O	O	4729
,	PUNCT	O	O	4729
direct	ADJ	O	O	4729
thrombin	PROPN	O	O	4729
inhibitor	NOUN	O	O	4729
used	VERB	O	O	4729
for	ADP	O	O	4729
prophylaxis	NOUN	O	O	4729
or	CCONJ	O	O	4729
treatment	NOUN	O	O	4729
of	ADP	O	O	4729
thrombosis	NOUN	O	Disease	4729
in	ADP	O	O	4729
heparin	NOUN	O	Chemical	4729
-	PUNCT	O	O	4729
induced	VERB	O	O	4729
thrombocytopenia	PROPN	O	Disease	4729
(	PUNCT	O	O	4729
HIT	VERB	O	Disease	4729
)	PUNCT	O	O	4729
and	CCONJ	O	O	4729
for	ADP	O	O	4729
patients	NOUN	O	O	4729
with	ADP	O	O	4729
or	CCONJ	O	O	4729
at	ADP	O	O	4729
risk	NOUN	O	O	4729
of	ADP	O	O	4729
HIT	VERB	O	Disease	4729
undergoing	VERB	O	O	4729
percutaneous	ADJ	O	O	4729
coronary	ADJ	O	O	4729
intervention	NOUN	O	O	4729
(	PUNCT	O	O	4729
PCI	NOUN	O	O	4729
)	PUNCT	O	O	4729
.	PUNCT	O	O	4729
The	PRON	O	O	4730
objective	VERB	O	O	4730
of	ADP	O	O	4730
this	PRON	O	O	4730
review	VERB	O	O	4730
is	AUX	O	O	4730
to	PART	O	O	4730
summarize	VERB	O	O	4730
practical	ADJ	O	O	4730
considerations	NOUN	O	O	4730
of	ADP	O	O	4730
argatroban	NOUN	O	O	4730
therapy	NOUN	O	O	4730
in	ADP	O	O	4730
HIT	VERB	O	Disease	4730
.	PUNCT	O	O	4730
The	PRON	O	O	4731
US	PROPN	O	O	4731
FDA	PROPN	O	O	4731
-	PUNCT	O	O	4731
recommended	VERB	O	O	4731
argatroban	NOUN	O	O	4731
dose	NOUN	O	O	4731
in	ADP	O	O	4731
HIT	VERB	O	Disease	4731
is	AUX	O	O	4731
2	X	O	O	4731
microg	PROPN	O	O	4731
/	PUNCT	O	O	4731
kg	VERB	O	O	4731
/	PUNCT	O	O	4731
min	NOUN	O	O	4731
(	PUNCT	O	O	4731
reduced	VERB	O	O	4731
in	ADP	O	O	4731
patients	NOUN	O	O	4731
with	ADP	O	O	4731
hepatic	ADJ	O	O	4731
impairment	NOUN	O	O	4731
and	CCONJ	O	O	4731
in	ADP	O	O	4731
paediatric	ADJ	O	O	4731
patients	NOUN	O	O	4731
)	PUNCT	O	O	4731
,	PUNCT	O	O	4731
adjusted	VERB	O	O	4731
to	PART	O	O	4731
achieve	VERB	O	O	4731
activated	VERB	O	O	4731
partial	ADJ	O	O	4731
thromboplastin	VERB	O	O	4731
times	NOUN	O	O	4731
(	PUNCT	O	O	4731
aPTTs	NUM	O	O	4731
)	PUNCT	O	O	4731
1.5	NUM	O	O	4731
-	PUNCT	O	O	4731
3	X	O	O	4731
times	NOUN	O	O	4731
baseline	VERB	O	O	4731
(	PUNCT	O	O	4731
not	PART	O	O	4731
>	PUNCT	O	O	4731
100	NUM	O	O	4731
seconds	NOUN	O	O	4731
)	PUNCT	O	O	4731
.	PUNCT	O	O	4731
Contemporary	ADJ	O	O	4732
experiences	NOUN	O	O	4732
indicate	VERB	O	O	4732
that	SCONJ	O	O	4732
reduced	VERB	O	O	4732
doses	NOUN	O	O	4732
are	AUX	O	O	4732
also	ADV	O	O	4732
needed	VERB	O	O	4732
in	ADP	O	O	4732
patients	NOUN	O	O	4732
with	ADP	O	O	4732
conditions	NOUN	O	O	4732
associated	VERB	O	O	4732
with	ADP	O	O	4732
hepatic	ADJ	O	O	4732
hypoperfusion	NOUN	O	O	4732
,	PUNCT	O	O	4732
e.g.	ADV	O	O	4732
heart failure	NOUN	O	Disease	4732
,	PUNCT	O	O	4732
yet	ADV	O	O	4732
are	AUX	O	O	4732
unnecessary	ADJ	O	O	4732
for	ADP	O	O	4732
renal dysfunction	NOUN	O	Disease	4732
,	PUNCT	O	O	4732
adult	NOUN	O	O	4732
age	NOUN	O	O	4732
,	PUNCT	O	O	4732
sex	NOUN	O	O	4732
,	PUNCT	O	O	4732
race	NOUN	O	O	4732
/	PUNCT	O	O	4732
ethnicity	NOUN	O	O	4732
or	CCONJ	O	O	4732
obesity	NOUN	O	Disease	4732
.	PUNCT	O	O	4732
Argatroban	NOUN	O	O	4733
0.5	NUM	O	O	4733
-	PUNCT	O	O	4733
1.2	NUM	O	O	4733
For	ADP	O	O	4734
PCI	NOUN	O	O	4734
,	PUNCT	O	O	4734
argatroban	NOUN	O	O	4734
has	VERB	O	O	4734
not	PART	O	O	4734
been	AUX	O	O	4734
investigated	VERB	O	O	4734
in	ADP	O	O	4734
hepatically	ADV	O	O	4734
impaired	VERB	O	O	4734
patients	NOUN	O	O	4734
;	PUNCT	O	O	4734
dose	NOUN	O	O	4734
adjustment	NOUN	O	O	4734
is	AUX	O	O	4734
unnecessary	ADJ	O	O	4734
for	ADP	O	O	4734
adult	NOUN	O	O	4734
age	NOUN	O	O	4734
,	PUNCT	O	O	4734
sex	NOUN	O	O	4734
,	PUNCT	O	O	4734
race	NOUN	O	O	4734
/	PUNCT	O	O	4734
ethnicity	NOUN	O	O	4734
or	CCONJ	O	O	4734
obesity	NOUN	O	Disease	4734
,	PUNCT	O	O	4734
and	CCONJ	O	O	4734
lesser	ADJ	O	O	4734
doses	NOUN	O	O	4734
may	AUX	O	O	4734
be	AUX	O	O	4734
adequate	ADJ	O	O	4734
with	ADP	O	O	4734
concurrent	ADJ	O	O	4734
glycoprotein	NOUN	O	O	4734
IIb	PROPN	O	O	4734
/	PUNCT	O	O	4734
IIIa	NOUN	O	O	4734
inhibition	NOUN	O	O	4734
.	PUNCT	O	O	4734
Argatroban	NOUN	O	O	4735
prolongs	VERB	O	O	4735
the	PRON	O	O	4735
International	PROPN	O	O	4735
Normalized	VERB	O	O	4735
Ratio	NOUN	O	O	4735
,	PUNCT	O	O	4735
and	CCONJ	O	O	4735
published	VERB	O	O	4735
approaches	VERB	O	O	4735
for	ADP	O	O	4735
monitoring	NOUN	O	O	4735
the	PRON	O	O	4735
argatroban	NOUN	O	O	4735
-	PUNCT	O	O	4735
to	PART	O	O	4735
-	PUNCT	O	O	4735
warfarin	VERB	O	Chemical	4735
transition	NOUN	O	O	4735
should	AUX	O	O	4735
be	AUX	O	O	4735
followed	VERB	O	O	4735
.	PUNCT	O	O	4735
Major	ADJ	O	O	4736
bleeding	VERB	O	Disease	4736
with	ADP	O	O	4736
argatroban	NOUN	O	O	4736
is	AUX	O	O	4736
0	NUM	O	O	4736
-	PUNCT	O	O	4736
10%	NOUN	O	O	4736
in	ADP	O	O	4736
the	PRON	O	O	4736
non	ADJ	O	O	4736
-	PUNCT	O	O	4736
interventional	ADJ	O	O	4736
setting	VERB	O	O	4736
and	CCONJ	O	O	4736
0	NUM	O	O	4736
-	PUNCT	O	O	4736
5.8%	NOUN	O	O	4736
periprocedurally	NOUN	O	O	4736
.	PUNCT	O	O	4736
Argatroban	NOUN	O	O	4737
has	VERB	O	O	4737
no	PRON	O	O	4737
specific	ADJ	O	O	4737
antidote	VERB	O	O	4737
,	PUNCT	O	O	4737
and	CCONJ	O	O	4737
if	SCONJ	O	O	4737
excessive	ADJ	O	O	4737
anticoagulation	NOUN	O	O	4737
occurs	VERB	O	O	4737
,	PUNCT	O	O	4737
argatroban	NOUN	O	O	4737
infusion	NOUN	O	O	4737
should	AUX	O	O	4737
be	AUX	O	O	4737
stopped	VERB	O	O	4737
or	CCONJ	O	O	4737
reduced	VERB	O	O	4737
.	PUNCT	O	O	4737
Improved	VERB	O	O	4738
familiarity	NOUN	O	O	4738
of	ADP	O	O	4738
healthcare	PROPN	O	O	4738
professionals	NOUN	O	O	4738
with	ADP	O	O	4738
argatroban	NOUN	O	O	4738
therapy	NOUN	O	O	4738
in	ADP	O	O	4738
HIT	VERB	O	Disease	4738
,	PUNCT	O	O	4738
including	VERB	O	O	4738
in	ADP	O	O	4738
special	ADJ	O	O	4738
populations	NOUN	O	O	4738
and	CCONJ	O	O	4738
during	ADP	O	O	4738
PCI	NOUN	O	O	4738
,	PUNCT	O	O	4738
may	AUX	O	O	4738
facilitate	VERB	O	O	4738
reduction	NOUN	O	O	4738
of	ADP	O	O	4738
harm	NOUN	O	O	4738
associated	VERB	O	O	4738
with	ADP	O	O	4738
HIT	VERB	O	Disease	4738
(	PUNCT	O	O	4738
e.g.	ADV	O	O	4738
fewer	ADJ	O	O	4738
thromboses	NOUN	O	O	4738
)	PUNCT	O	O	4738
or	CCONJ	O	O	4738
its	PRON	O	O	4738
treatment	NOUN	O	O	4738
(	PUNCT	O	O	4738
e.g.	ADV	O	O	4738
fewer	ADJ	O	O	4738
argatroban	NOUN	O	O	4738
medication	NOUN	O	O	4738
errors	NOUN	O	O	4738
)	PUNCT	O	O	4738
.	PUNCT	O	O	4738
Rhabdomyolysis	NOUN	O	O	4741
and	CCONJ	O	O	4741
brain ischemic	VERB	O	Disease	4741
stroke	VERB	O	Disease	4741
in	ADP	O	O	4741
a	PRON	O	O	4741
heroin	NOUN	O	Chemical	4741
-	PUNCT	O	O	4741
dependent	ADJ	O	O	4741
male	NOUN	O	O	4741
under	ADP	O	O	4741
methadone	NOUN	O	Chemical	4741
maintenance	NOUN	O	O	4741
therapy	NOUN	O	O	4741
.	PUNCT	O	O	4741
OBJECTIVE	VERB	O	O	4742
:	PUNCT	O	O	4742
There	ADV	O	O	4742
are	AUX	O	O	4742
several	ADJ	O	O	4742
complications	NOUN	O	O	4742
associated	VERB	O	O	4742
with	ADP	O	O	4742
heroin	NOUN	O	Chemical	4742
abuse	VERB	O	O	4742
,	PUNCT	O	O	4742
some	PRON	O	O	4742
of	ADP	O	O	4742
which	PRON	O	O	4742
are	AUX	O	O	4742
life	NOUN	O	O	4742
-	PUNCT	O	O	4742
threatening	VERB	O	O	4742
.	PUNCT	O	O	4742
Methadone	NOUN	O	Chemical	4743
may	AUX	O	O	4743
aggravate	VERB	O	O	4743
this	PRON	O	O	4743
problem	NOUN	O	O	4743
.	PUNCT	O	O	4743
A	PRON	O	O	4744
33-year	NOUN	O	O	4744
-	PUNCT	O	O	4744
old	ADJ	O	O	4744
man	NOUN	O	O	4744
presented	VERB	O	O	4744
with	ADP	O	O	4744
rhabdomyolysis	NOUN	O	Disease	4744
and	CCONJ	O	O	4744
cerebral	ADJ	O	O	4744
ischemic	VERB	O	Disease	4744
stroke	VERB	O	Disease	4744
after	ADP	O	O	4744
intravenous	ADJ	O	O	4744
heroin	NOUN	O	Chemical	4744
.	PUNCT	O	O	4744
He	PRON	O	O	4745
had	VERB	O	O	4745
used	VERB	O	O	4745
heroin	NOUN	O	Chemical	4745
since	SCONJ	O	O	4745
age	NOUN	O	O	4745
20	NUM	O	O	4745
,	PUNCT	O	O	4745
and	CCONJ	O	O	4745
had	VERB	O	O	4745
used	VERB	O	O	4745
150	NUM	O	O	4745
mg	VERB	O	O	4745
methadone	NOUN	O	Chemical	4745
daily	ADV	O	O	4745
for	ADP	O	O	4745
6	NUM	O	O	4745
months	NOUN	O	O	4745
.	PUNCT	O	O	4745
He	PRON	O	O	4746
was	AUX	O	O	4746
found	VERB	O	O	4746
unconsciousness	NOUN	O	O	4746
at	ADP	O	O	4746
home	NOUN	O	O	4746
and	CCONJ	O	O	4746
was	AUX	O	O	4746
sent	VERB	O	O	4746
to	PART	O	O	4746
our	PRON	O	O	4746
hospital	PROPN	O	O	4746
.	PUNCT	O	O	4746
In	ADP	O	O	4747
the	PRON	O	O	4747
ICU	PROPN	O	O	4747
,	PUNCT	O	O	4747
we	PRON	O	O	4747
found	VERB	O	O	4747
rhabdomyolysis	NOUN	O	Disease	4747
,	PUNCT	O	O	4747
acute	ADJ	O	O	4747
renal failure	NOUN	O	Disease	4747
and	CCONJ	O	O	4747
acute	ADJ	O	O	4747
respiratory failure	NOUN	O	Disease	4747
.	PUNCT	O	O	4747
After	ADP	O	O	4748
transfer	NOUN	O	O	4748
to	PART	O	O	4748
an	PRON	O	O	4748
internal	ADJ	O	O	4748
ward	PROPN	O	O	4748
,	PUNCT	O	O	4748
we	PRON	O	O	4748
noted	VERB	O	O	4748
aphasia	NOUN	O	O	4748
and	CCONJ	O	O	4748
weakness	NOUN	O	Disease	4748
of	ADP	O	O	4748
his	PRON	O	O	4748
left	VERB	O	O	4748
limbs	NOUN	O	O	4748
.	PUNCT	O	O	4748
After	ADP	O	O	4749
MRI	PROPN	O	O	4749
,	PUNCT	O	O	4749
we	PRON	O	O	4749
found	VERB	O	O	4749
cerebral	ADJ	O	O	4749
ischemic	VERB	O	Disease	4749
infarction	NOUN	O	O	4749
.	PUNCT	O	O	4749
Those	PRON	O	O	4750
using	VERB	O	O	4750
methadone	NOUN	O	Chemical	4750
and	CCONJ	O	O	4750
heroin	NOUN	O	Chemical	4750
simultaneously	ADV	O	O	4750
may	AUX	O	O	4750
increase	VERB	O	O	4750
risk	NOUN	O	O	4750
of	ADP	O	O	4750
rhabdomyolysis	NOUN	O	Disease	4750
and	CCONJ	O	O	4750
ischemic	VERB	O	Disease	4750
stroke	VERB	O	Disease	4750
.	PUNCT	O	O	4750
Patients	NOUN	O	O	4751
under	ADP	O	O	4751
methadone	NOUN	O	Chemical	4751
maintenance	NOUN	O	O	4751
therapy	NOUN	O	O	4751
should	AUX	O	O	4751
be	AUX	O	O	4751
warned	VERB	O	O	4751
regarding	VERB	O	O	4751
these	PRON	O	O	4751
serious	ADJ	O	O	4751
adverse	ADJ	O	O	4751
events	NOUN	O	O	4751
.	PUNCT	O	O	4751
Hypotheses	NOUN	O	O	4752
of	ADP	O	O	4752
heroin	NOUN	O	Chemical	4752
-	PUNCT	O	O	4752
related	ADJ	O	O	4752
rhabdomyolysis	NOUN	O	Disease	4752
and	CCONJ	O	O	4752
stroke	VERB	O	Disease	4752
in	ADP	O	O	4752
heroin	NOUN	O	Chemical	4752
abusers	NOUN	O	O	4752
are	AUX	O	O	4752
discussed	VERB	O	O	4752
.	PUNCT	O	O	4752
Increased	VERB	O	O	4755
vulnerability	NOUN	O	O	4755
to	PART	O	O	4755
6-hydroxydopamine	NOUN	O	Chemical	4755
lesion	NOUN	O	O	4755
and	CCONJ	O	O	4755
reduced	VERB	O	O	4755
development	NOUN	O	O	4755
of	ADP	O	O	4755
dyskinesias	PROPN	O	Disease	4755
in	ADP	O	O	4755
mice	NOUN	O	O	4755
lacking	VERB	O	O	4755
CB1	PROPN	O	O	4755
cannabinoid	NOUN	O	O	4755
receptors	NOUN	O	O	4755
.	PUNCT	O	O	4755
Motor	NOUN	O	O	4756
impairment	NOUN	O	O	4756
,	PUNCT	O	O	4756
dopamine	NOUN	O	Chemical	4756
(	PUNCT	O	O	4756
DA	NOUN	O	Chemical	4756
)	PUNCT	O	O	4756
neuronal	ADJ	O	O	4756
activity	NOUN	O	O	4756
and	CCONJ	O	O	4756
proenkephalin	PROPN	O	O	4756
(	PUNCT	O	O	4756
PENK	PROPN	O	O	4756
)	PUNCT	O	O	4756
gene	NOUN	O	O	4756
expression	NOUN	O	O	4756
in	ADP	O	O	4756
the	PRON	O	O	4756
caudate	ADJ	O	O	4756
-	PUNCT	O	O	4756
putamen	NOUN	O	O	4756
(	PUNCT	O	O	4756
CPu	NOUN	O	O	4756
)	PUNCT	O	O	4756
were	AUX	O	O	4756
measured	VERB	O	O	4756
in	ADP	O	O	4756
6-OHDA	NOUN	O	Chemical	4756
-	PUNCT	O	O	4756
lesioned	VERB	O	O	4756
and	CCONJ	O	O	4756
treated	VERB	O	O	4756
(	PUNCT	O	O	4756
L	NOUN	O	O	4756
-	PUNCT	O	O	4756
DOPA+benserazide	ADJ	O	O	4756
)	PUNCT	O	O	4756
A	PRON	O	O	4757
lesion	NOUN	O	O	4757
induced	VERB	O	O	4757
by	ADP	O	O	4757
6-OHDA	NOUN	O	Chemical	4757
produced	VERB	O	O	4757
more	ADJ	O	O	4757
severe	ADJ	O	O	4757
motor	NOUN	O	O	4757
deterioration	NOUN	O	O	4757
in	ADP	O	O	4757
CB1	PROPN	O	O	4757
KO	PROPN	O	O	4757
mice	NOUN	O	O	4757
accompanied	VERB	O	O	4757
by	ADP	O	O	4757
more	ADJ	O	O	4757
loss	NOUN	O	O	4757
of	ADP	O	O	4757
DA	NOUN	O	Chemical	4757
neurons	NOUN	O	O	4757
and	CCONJ	O	O	4757
increased	VERB	O	O	4757
PENK	PROPN	O	O	4757
gene	NOUN	O	O	4757
expression	NOUN	O	O	4757
in	ADP	O	O	4757
the	PRON	O	O	4757
CPu	NOUN	O	O	4757
.	PUNCT	O	O	4757
CB1	PROPN	O	O	4758
KO	PROPN	O	O	4758
mice	NOUN	O	O	4758
exhibited	VERB	O	O	4758
higher	ADJ	O	O	4758
MDA	PROPN	O	Chemical	4758
levels	NOUN	O	O	4758
and	CCONJ	O	O	4758
iNOS	PROPN	O	O	4758
protein	NOUN	O	O	4758
expression	NOUN	O	O	4758
in	ADP	O	O	4758
the	PRON	O	O	4758
CPu	NOUN	O	O	4758
and	CCONJ	O	O	4758
Cg	PROPN	O	O	4758
compared	VERB	O	O	4758
to	PART	O	O	4758
WT	NOUN	O	O	4758
mice	NOUN	O	O	4758
.	PUNCT	O	O	4758
Treatment	NOUN	O	O	4759
with	ADP	O	O	4759
L	NOUN	O	O	4759
-	PUNCT	O	O	4759
DOPA+benserazide	ADJ	O	O	4759
(	PUNCT	O	O	4759
12	NUM	O	O	4759
weeks	NOUN	O	O	4759
)	PUNCT	O	O	4759
resulted	VERB	O	O	4759
in	ADP	O	O	4759
less	ADV	O	O	4759
severe	ADJ	O	O	4759
dyskinesias	PROPN	O	Disease	4759
in	ADP	O	O	4759
CB1	PROPN	O	O	4759
KO	PROPN	O	O	4759
than	ADP	O	O	4759
in	ADP	O	O	4759
WT	NOUN	O	O	4759
mice	NOUN	O	O	4759
.	PUNCT	O	O	4759
The	PRON	O	O	4760
results	VERB	O	O	4760
revealed	VERB	O	O	4760
that	SCONJ	O	O	4760
the	PRON	O	O	4760
lack	VERB	O	O	4760
of	ADP	O	O	4760
cannabinoid	NOUN	O	O	4760
CB1	PROPN	O	O	4760
receptors	NOUN	O	O	4760
increased	VERB	O	O	4760
the	PRON	O	O	4760
severity	NOUN	O	O	4760
of	ADP	O	O	4760
motor	NOUN	O	O	4760
impairment	NOUN	O	O	4760
and	CCONJ	O	O	4760
DA	NOUN	O	Chemical	4760
lesion	NOUN	O	O	4760
,	PUNCT	O	O	4760
and	CCONJ	O	O	4760
reduced	VERB	O	O	4760
L	NOUN	O	O	4760
-	PUNCT	O	O	4760
DOPA	PROPN	O	O	4760
-	PUNCT	O	O	4760
induced	VERB	O	O	4760
dyskinesias	PROPN	O	Disease	4760
.	PUNCT	O	O	4760
These	PRON	O	O	4761
results	VERB	O	O	4761
suggest	VERB	O	O	4761
that	SCONJ	O	O	4761
activation	NOUN	O	O	4761
of	ADP	O	O	4761
CB1	PROPN	O	O	4761
receptors	NOUN	O	O	4761
offers	VERB	O	O	4761
neuroprotection	NOUN	O	O	4761
against	ADP	O	O	4761
dopaminergic	ADJ	O	O	4761
lesion	NOUN	O	O	4761
and	CCONJ	O	O	4761
the	PRON	O	O	4761
development	NOUN	O	O	4761
of	ADP	O	O	4761
L	NOUN	O	O	4761
-	PUNCT	O	O	4761
DOPA	PROPN	O	O	4761
-	PUNCT	O	O	4761
induced	VERB	O	O	4761
dyskinesias	PROPN	O	Disease	4761
.	PUNCT	O	O	4761
Animal	NOUN	O	O	4764
model	NOUN	O	O	4764
of	ADP	O	O	4764
mania	NOUN	O	O	4764
induced	VERB	O	O	4764
by	ADP	O	O	4764
ouabain	PROPN	O	Chemical	4764
:	PUNCT	O	O	4764
Evidence	NOUN	O	O	4764
of	ADP	O	O	4764
oxidative	NOUN	O	O	4764
stress	NOUN	O	O	4764
in	ADP	O	O	4764
submitochondrial	NOUN	O	O	4764
particles	NOUN	O	O	4764
of	ADP	O	O	4764
the	PRON	O	O	4764
rat	NOUN	O	O	4764
brain	NOUN	O	O	4764
.	PUNCT	O	O	4764
The	PRON	O	O	4765
intracerebroventricular	PROPN	O	O	4765
(	PUNCT	O	O	4765
ICV	PROPN	O	O	4765
)	PUNCT	O	O	4765
administration	NOUN	O	O	4765
of	ADP	O	O	4765
ouabain	PROPN	O	Chemical	4765
(	PUNCT	O	O	4765
a	PRON	O	O	4765
Na(+)/K(+)-ATPase	VERB	O	O	4765
inhibitor	NOUN	O	O	4765
)	PUNCT	O	O	4765
in	ADP	O	O	4765
rats	NOUN	O	O	4765
has	VERB	O	O	4765
been	AUX	O	O	4765
suggested	VERB	O	O	4765
to	PART	O	O	4765
mimic	VERB	O	O	4765
some	PRON	O	O	4765
symptoms	NOUN	O	O	4765
of	ADP	O	O	4765
human	PROPN	O	O	4765
bipolar mania	NOUN	O	Disease	4765
.	PUNCT	O	O	4765
Clinical	NOUN	O	O	4766
studies	NOUN	O	O	4766
have	VERB	O	O	4766
shown	VERB	O	O	4766
that	SCONJ	O	O	4766
bipolar disorder	NOUN	O	Disease	4766
may	AUX	O	O	4766
be	AUX	O	O	4766
related	ADJ	O	O	4766
to	PART	O	O	4766
mitochondrial	ADJ	O	O	4766
dysfunction	NOUN	O	O	4766
.	PUNCT	O	O	4766
Herein	ADV	O	O	4767
,	PUNCT	O	O	4767
we	PRON	O	O	4767
investigated	VERB	O	O	4767
the	PRON	O	O	4767
behavioral	ADJ	O	O	4767
and	CCONJ	O	O	4767
biochemical	ADJ	O	O	4767
effects	NOUN	O	O	4767
induced	VERB	O	O	4767
by	ADP	O	O	4767
the	PRON	O	O	4767
ICV	PROPN	O	O	4767
administration	NOUN	O	O	4767
of	ADP	O	O	4767
ouabain	PROPN	O	Chemical	4767
in	ADP	O	O	4767
rats	NOUN	O	O	4767
.	PUNCT	O	O	4767
To	PART	O	O	4768
achieve	VERB	O	O	4768
this	PRON	O	O	4768
aim	VERB	O	O	4768
,	PUNCT	O	O	4768
the	PRON	O	O	4768
effects	NOUN	O	O	4768
of	ADP	O	O	4768
ouabain	PROPN	O	Chemical	4768
injection	NOUN	O	O	4768
immediately	ADV	O	O	4768
after	ADP	O	O	4768
and	CCONJ	O	O	4768
7	NUM	O	O	4768
days	NOUN	O	O	4768
following	VERB	O	O	4768
a	PRON	O	O	4768
single	ADJ	O	O	4768
ICV	PROPN	O	O	4768
administration	NOUN	O	O	4768
(	PUNCT	O	O	4768
at	ADP	O	O	4768
concentrations	NOUN	O	O	4768
of	ADP	O	O	4768
10(-2	NOUN	O	O	4768
)	PUNCT	O	O	4768
and	CCONJ	O	O	4768
10(-3)M	X	O	O	4768
)	PUNCT	O	O	4768
on	ADP	O	O	4768
locomotion	NOUN	O	O	4768
was	AUX	O	O	4768
measured	VERB	O	O	4768
using	VERB	O	O	4768
the	PRON	O	O	4768
open	VERB	O	O	4768
-	PUNCT	O	O	4768
field	NOUN	O	O	4768
test	NOUN	O	O	4768
.	PUNCT	O	O	4768
Additionally	ADV	O	O	4769
,	PUNCT	O	O	4769
thiobarbituric acid reactive substances	NOUN	O	Chemical	4769
(	PUNCT	O	O	4769
TBARSs	NOUN	O	O	4769
)	PUNCT	O	O	4769
and	CCONJ	O	O	4769
superoxide	NOUN	O	Chemical	4770
production	NOUN	O	O	4770
were	AUX	O	O	4770
measured	VERB	O	O	4770
in	ADP	O	O	4770
submitochondrial	NOUN	O	O	4770
particles	NOUN	O	O	4770
of	ADP	O	O	4770
the	PRON	O	O	4770
prefrontal	ADJ	O	O	4770
cortex	VERB	O	O	4770
,	PUNCT	O	O	4770
hippocampus	NOUN	O	O	4770
,	PUNCT	O	O	4770
striatum	NOUN	O	O	4770
and	CCONJ	O	O	4770
amygdala	NOUN	O	O	4770
.	PUNCT	O	O	4770
Our	PRON	O	O	4771
findings	NOUN	O	O	4771
demonstrated	VERB	O	O	4771
that	SCONJ	O	O	4771
ouabain	PROPN	O	Chemical	4771
at	ADP	O	O	4771
10(-2	NOUN	O	O	4771
)	PUNCT	O	O	4771
and	CCONJ	O	O	4771
10(-3)M	X	O	O	4771
induced	VERB	O	O	4771
hyperlocomotion	NOUN	O	Disease	4771
in	ADP	O	O	4771
rats	NOUN	O	O	4771
,	PUNCT	O	O	4771
and	CCONJ	O	O	4771
this	PRON	O	O	4771
response	NOUN	O	O	4771
remained	VERB	O	O	4771
up	ADP	O	O	4771
to	PART	O	O	4771
7	NUM	O	O	4771
days	NOUN	O	O	4771
following	VERB	O	O	4771
a	PRON	O	O	4771
single	ADJ	O	O	4771
ICV	PROPN	O	O	4771
injection	NOUN	O	O	4771
.	PUNCT	O	O	4771
In	ADP	O	O	4772
addition	NOUN	O	O	4772
,	PUNCT	O	O	4772
we	PRON	O	O	4772
observed	VERB	O	O	4772
that	SCONJ	O	O	4772
the	PRON	O	O	4772
persistent	ADJ	O	O	4772
increase	VERB	O	O	4772
in	ADP	O	O	4772
the	PRON	O	O	4772
rat	NOUN	O	O	4772
spontaneous	ADJ	O	O	4772
locomotion	NOUN	O	O	4772
is	AUX	O	O	4772
associated	VERB	O	O	4772
with	ADP	O	O	4772
increased	VERB	O	O	4772
TBARS	NOUN	O	O	4772
levels	NOUN	O	O	4772
and	CCONJ	O	O	4772
superoxide	NOUN	O	Chemical	4772
generation	NOUN	O	O	4772
in	ADP	O	O	4772
submitochondrial	NOUN	O	O	4772
particles	NOUN	O	O	4772
in	ADP	O	O	4772
the	PRON	O	O	4772
prefrontal	ADJ	O	O	4772
cortex	VERB	O	O	4772
,	PUNCT	O	O	4772
striatum	NOUN	O	O	4772
and	CCONJ	O	O	4772
amygdala	NOUN	O	O	4772
.	PUNCT	O	O	4772
In	ADP	O	O	4773
conclusion	NOUN	O	O	4773
,	PUNCT	O	O	4773
ouabain	PROPN	O	Chemical	4773
-	PUNCT	O	O	4773
induced	VERB	O	O	4773
mania	NOUN	O	O	4773
-	PUNCT	O	O	4773
like	INTJ	O	O	4773
behavior	NOUN	O	O	4773
may	AUX	O	O	4773
provide	VERB	O	O	4773
a	PRON	O	O	4773
useful	ADJ	O	O	4773
animal	NOUN	O	O	4773
model	NOUN	O	O	4773
to	PART	O	O	4773
test	NOUN	O	O	4773
the	PRON	O	O	4773
hypothesis	NOUN	O	O	4773
of	ADP	O	O	4773
the	PRON	O	O	4773
involvement	NOUN	O	O	4773
of	ADP	O	O	4773
oxidative	NOUN	O	O	4773
stress	NOUN	O	O	4773
in	ADP	O	O	4773
bipolar disorder	NOUN	O	Disease	4773
.	PUNCT	O	O	4773
Intraoperative	PROPN	O	O	4776
dialysis	NOUN	O	O	4776
during	ADP	O	O	4776
liver	NOUN	O	O	4776
transplantation	NOUN	O	O	4776
with	ADP	O	O	4776
citrate	PROPN	O	Chemical	4776
dialysate	VERB	O	O	4776
.	PUNCT	O	O	4776
Liver	NOUN	O	O	4777
transplantation	NOUN	O	O	4777
for	ADP	O	O	4777
acutely	ADV	O	O	4777
ill	PROPN	O	O	4777
patients	NOUN	O	O	4777
with	ADP	O	O	4777
fulminant	ADJ	O	O	4777
liver failure	NOUN	O	Disease	4777
carries	VERB	O	O	4777
high	ADJ	O	O	4777
intraoperative	ADJ	O	O	4777
and	CCONJ	O	O	4777
immediate	ADJ	O	O	4777
postoperative	ADJ	O	O	4777
risks	NOUN	O	O	4777
.	PUNCT	O	O	4777
These	PRON	O	O	4778
are	AUX	O	O	4778
increased	VERB	O	O	4778
with	ADP	O	O	4778
the	PRON	O	O	4778
presence	NOUN	O	O	4778
of	ADP	O	O	4778
concomitant	ADJ	O	O	4778
acute	ADJ	O	O	4778
kidney	NOUN	O	O	4778
injury	NOUN	O	O	4778
(	PUNCT	O	O	4778
AKI	PROPN	O	O	4778
)	PUNCT	O	O	4778
and	CCONJ	O	O	4778
intraoperative	ADJ	O	O	4778
dialysis	NOUN	O	O	4778
is	AUX	O	O	4778
sometimes	ADV	O	O	4778
required	VERB	O	O	4778
to	PART	O	O	4778
allow	VERB	O	O	4778
the	PRON	O	O	4778
transplant	NOUN	O	O	4778
to	PART	O	O	4778
proceed	VERB	O	O	4778
.	PUNCT	O	O	4778
The	PRON	O	O	4779
derangements	NOUN	O	O	4779
in	ADP	O	O	4779
the	PRON	O	O	4779
procoagulant	NOUN	O	O	4779
and	CCONJ	O	O	4779
anticoagulant	ADJ	O	O	4779
pathways	NOUN	O	O	4779
during	ADP	O	O	4779
fulminant	ADJ	O	O	4779
liver failure	NOUN	O	Disease	4779
can	AUX	O	O	4779
lead	VERB	O	Chemical	4779
to	PART	O	O	4779
difficulties	NOUN	O	O	4779
with	ADP	O	O	4779
anticoagulation	NOUN	O	O	4779
during	ADP	O	O	4779
dialysis	NOUN	O	O	4779
,	PUNCT	O	O	4779
especially	ADV	O	O	4779
when	SCONJ	O	O	4779
continued	VERB	O	O	4779
in	ADP	O	O	4779
the	PRON	O	O	4779
operating	VERB	O	O	4779
room	NOUN	O	O	4779
.	PUNCT	O	O	4779
Systemic	ADJ	O	O	4780
anticoagulation	NOUN	O	O	4780
is	AUX	O	O	4780
unsafe	ADJ	O	O	4780
and	CCONJ	O	O	4780
regional	ADJ	O	O	4780
citrate	PROPN	O	Chemical	4780
anticoagulation	NOUN	O	O	4780
in	ADP	O	O	4780
the	PRON	O	O	4780
absence	NOUN	O	O	4780
of	ADP	O	O	4780
a	PRON	O	O	4780
functional	ADJ	O	O	4780
liver	NOUN	O	O	4780
carries	VERB	O	O	4780
the	PRON	O	O	4780
risk	NOUN	O	O	4780
of	ADP	O	O	4780
citrate	PROPN	O	Chemical	4780
toxicity	NOUN	O	Disease	4780
.	PUNCT	O	O	4780
Citrate	NOUN	O	O	4781
dialysate	VERB	O	O	4781
,	PUNCT	O	O	4781
a	PRON	O	O	4781
new	ADJ	O	O	4781
dialysate	VERB	O	O	4781
with	ADP	O	O	4781
citric	PROPN	O	O	4781
acid	PROPN	O	O	4781
can	AUX	O	O	4781
be	AUX	O	O	4781
used	VERB	O	O	4781
for	ADP	O	O	4781
anticoagulation	NOUN	O	O	4781
in	ADP	O	O	4781
patients	NOUN	O	O	4781
who	PRON	O	O	4781
can	AUX	O	O	4781
not	PART	O	O	4781
tolerate	VERB	O	O	4781
heparin	NOUN	O	Chemical	4781
or	CCONJ	O	O	4781
regional	ADJ	O	O	4781
citrate	PROPN	O	Chemical	4781
.	PUNCT	O	O	4781
We	PRON	O	O	4782
report	VERB	O	O	4782
a	PRON	O	O	4782
case	NOUN	O	O	4782
of	ADP	O	O	4782
a	PRON	O	O	4782
40-year	NOUN	O	O	4782
-	PUNCT	O	O	4782
old	ADJ	O	O	4782
female	ADJ	O	O	4782
with	ADP	O	O	4782
acetaminophen	PROPN	O	Chemical	4782
-	PUNCT	O	O	4782
induced	VERB	O	O	4782
fulminant	ADJ	O	O	4782
liver failure	NOUN	O	Disease	4782
with	ADP	O	O	4782
associated	VERB	O	O	4782
AKI	PROPN	O	O	4782
who	PRON	O	O	4782
underwent	VERB	O	O	4782
intraoperative	ADJ	O	O	4782
dialytic	VERB	O	O	4782
support	NOUN	O	O	4782
during	ADP	O	O	4782
liver	NOUN	O	O	4782
transplantation	NOUN	O	O	4782
anticoagulated	VERB	O	O	4782
with	ADP	O	O	4782
citrate	PROPN	O	Chemical	4782
dialysate	VERB	O	O	4782
during	ADP	O	O	4782
the	PRON	O	O	4782
entire	ADJ	O	O	4782
procedure	NOUN	O	O	4782
.	PUNCT	O	O	4782
The	PRON	O	O	4783
patient	NOUN	O	O	4783
tolerated	VERB	O	O	4783
the	PRON	O	O	4783
procedure	NOUN	O	O	4783
well	ADV	O	O	4783
without	ADP	O	O	4783
any	PRON	O	O	4783
signs	NOUN	O	O	4783
of	ADP	O	O	4783
citrate	PROPN	O	Chemical	4783
toxicity	NOUN	O	Disease	4783
and	CCONJ	O	O	4783
maintained	VERB	O	O	4783
adequate	ADJ	O	O	4783
anticoagulation	NOUN	O	O	4783
for	ADP	O	O	4783
patency	NOUN	O	O	4783
of	ADP	O	O	4783
the	PRON	O	O	4783
dialysis	NOUN	O	O	4783
circuit	PROPN	O	O	4783
.	PUNCT	O	O	4783
Citrate	NOUN	O	O	4784
dialysate	VERB	O	O	4784
is	AUX	O	O	4784
a	PRON	O	O	4784
safe	ADJ	O	O	4784
alternative	ADV	O	O	4784
for	ADP	O	O	4784
intradialytic	VERB	O	O	4784
support	NOUN	O	O	4784
of	ADP	O	O	4784
liver	NOUN	O	O	4784
transplantation	NOUN	O	O	4784
in	ADP	O	O	4784
fulminant	ADJ	O	O	4784
liver failure	NOUN	O	Disease	4784
.	PUNCT	O	O	4784
Delirium	NOUN	O	O	4787
in	ADP	O	O	4787
a	PRON	O	O	4787
patient	NOUN	O	O	4787
with	ADP	O	O	4787
toxic	ADJ	O	O	4787
flecainide	PROPN	O	O	4787
plasma	NOUN	O	O	4787
concentrations	NOUN	O	O	4787
:	PUNCT	O	O	4787
the	PRON	O	O	4787
role	NOUN	O	O	4787
of	ADP	O	O	4787
a	PRON	O	O	4787
pharmacokinetic	VERB	O	O	4787
drug	NOUN	O	O	4787
interaction	NOUN	O	O	4787
with	ADP	O	O	4787
paroxetine	NOUN	O	Chemical	4787
.	PUNCT	O	O	4787
OBJECTIVE	VERB	O	O	4788
:	PUNCT	O	O	4788
To	PART	O	O	4788
describe	VERB	O	O	4788
a	PRON	O	O	4788
case	NOUN	O	O	4788
of	ADP	O	O	4788
flecainide	PROPN	O	O	4788
-	PUNCT	O	O	4788
induced	VERB	O	O	4788
delirium	NOUN	O	Disease	4788
associated	VERB	O	O	4788
with	ADP	O	O	4788
a	PRON	O	O	4788
pharmacokinetic	VERB	O	O	4788
drug	NOUN	O	O	4788
interaction	NOUN	O	O	4788
with	ADP	O	O	4788
paroxetine	NOUN	O	Chemical	4788
.	PUNCT	O	O	4788
A	PRON	O	O	4789
69-year	NOUN	O	O	4789
-	PUNCT	O	O	4789
old	ADJ	O	O	4789
white	ADJ	O	O	4789
female	ADJ	O	O	4789
presented	VERB	O	O	4789
to	PART	O	O	4789
the	PRON	O	O	4789
emergency	NOUN	O	O	4789
department	NOUN	O	O	4789
with	ADP	O	O	4789
a	PRON	O	O	4789
history	NOUN	O	O	4789
of	ADP	O	O	4789
confusion	NOUN	O	Disease	4789
and	CCONJ	O	O	4789
paranoia	NOUN	O	Disease	4789
over	ADP	O	O	4789
the	PRON	O	O	4789
past	ADP	O	O	4789
several	ADJ	O	O	4789
days	NOUN	O	O	4789
.	PUNCT	O	O	4789
On	ADP	O	O	4790
admission	NOUN	O	O	4790
the	PRON	O	O	4790
patient	NOUN	O	O	4790
was	AUX	O	O	4790
taking	VERB	O	O	4790
carvedilol	VERB	O	O	4790
12	NUM	O	O	4790
mg	VERB	O	O	4790
twice	ADV	O	O	4790
daily	ADV	O	O	4790
,	PUNCT	O	O	4790
warfarin	VERB	O	Chemical	4790
2	X	O	O	4790
mg	VERB	O	O	4790
/	PUNCT	O	O	4790
day	NOUN	O	O	4790
,	PUNCT	O	O	4790
folic acid	NOUN	O	Chemical	4790
1	X	O	O	4790
mg	VERB	O	O	4790
/	PUNCT	O	O	4790
day	NOUN	O	O	4790
,	PUNCT	O	O	4790
levothyroxine	VERB	O	O	4790
100	NUM	O	O	4790
microg	PROPN	O	O	4790
/	PUNCT	O	O	4791
day	NOUN	O	O	4791
,	PUNCT	O	O	4791
pantoprazole	NOUN	O	O	4791
40	NUM	O	O	4791
mg	VERB	O	O	4791
/	PUNCT	O	O	4791
day	NOUN	O	O	4791
,	PUNCT	O	O	4791
paroxetine	NOUN	O	Chemical	4791
40	NUM	O	O	4791
mg	VERB	O	O	4791
/	PUNCT	O	O	4791
day	NOUN	O	O	4791
,	PUNCT	O	O	4791
and	CCONJ	O	O	4791
flecainide	PROPN	O	O	4791
100	NUM	O	O	4791
mg	VERB	O	O	4791
twice	ADV	O	O	4791
daily	ADV	O	O	4791
.	PUNCT	O	O	4791
Flecainide	PROPN	O	O	4792
had	VERB	O	O	4792
been	AUX	O	O	4792
started	VERB	O	O	4792
2	X	O	O	4792
weeks	NOUN	O	O	4792
prior	ADV	O	O	4792
for	ADP	O	O	4792
atrial fibrillation	NOUN	O	Disease	4792
.	PUNCT	O	O	4792
Laboratory	NOUN	O	O	4793
test	NOUN	O	O	4793
findings	NOUN	O	O	4793
on	ADP	O	O	4793
admission	NOUN	O	O	4793
were	AUX	O	O	4793
notable	ADJ	O	O	4793
only	ADV	O	O	4793
for	ADP	O	O	4793
a	PRON	O	O	4793
flecainide	PROPN	O	O	4793
plasma	NOUN	O	O	4793
concentration	NOUN	O	O	4793
of	ADP	O	O	4793
1360	NUM	O	O	4793
microg	PROPN	O	O	4793
/	PUNCT	O	O	4793
L	NOUN	O	O	4793
(	PUNCT	O	O	4793
reference	NOUN	O	O	4793
range	VERB	O	O	4793
200	NUM	O	O	4793
-	PUNCT	O	O	4793
1000	NUM	O	O	4793
)	PUNCT	O	O	4793
.	PUNCT	O	O	4793
A	PRON	O	O	4794
metabolic	ADJ	O	O	4794
drug	NOUN	O	O	4794
interaction	NOUN	O	O	4794
between	ADP	O	O	4794
flecainide	PROPN	O	O	4794
and	CCONJ	O	O	4794
paroxetine	NOUN	O	Chemical	4794
,	PUNCT	O	O	4794
which	PRON	O	O	4794
the	PRON	O	O	4794
patient	NOUN	O	O	4794
had	VERB	O	O	4794
been	AUX	O	O	4794
taking	VERB	O	O	4794
for	ADP	O	O	4794
more	ADJ	O	O	4794
than	ADP	O	O	4794
5	NUM	O	O	4794
years	NOUN	O	O	4794
,	PUNCT	O	O	4794
was	AUX	O	O	4794
considered	VERB	O	O	4794
.	PUNCT	O	O	4794
Paroxetine	NOUN	O	O	4795
was	AUX	O	O	4795
discontinued	VERB	O	O	4795
and	CCONJ	O	O	4795
the	PRON	O	O	4795
dose	NOUN	O	O	4795
of	ADP	O	O	4795
flecainide	PROPN	O	O	4795
was	AUX	O	O	4795
reduced	VERB	O	O	4795
to	PART	O	O	4795
50	NUM	O	O	4795
mg	VERB	O	O	4795
twice	ADV	O	O	4795
daily	ADV	O	O	4795
.	PUNCT	O	O	4795
Her	PRON	O	O	4796
delirium	NOUN	O	Disease	4796
resolved	VERB	O	O	4796
3	X	O	O	4796
days	NOUN	O	O	4796
later	ADV	O	O	4796
.	PUNCT	O	O	4796
DISCUSSION	NOUN	O	O	4797
:	PUNCT	O	O	4797
Flecainide	PROPN	O	O	4797
and	CCONJ	O	O	4797
pharmacologically	ADV	O	O	4798
similar	ADJ	O	O	4798
agents	NOUN	O	O	4798
that	SCONJ	O	O	4798
interact	VERB	O	O	4798
with	ADP	O	O	4798
sodium	NOUN	O	Chemical	4798
channels	NOUN	O	O	4798
may	AUX	O	O	4798
cause	VERB	O	O	4798
delirium	NOUN	O	Disease	4798
in	ADP	O	O	4798
susceptible	ADJ	O	O	4798
patients	NOUN	O	O	4798
.	PUNCT	O	O	4798
A	PRON	O	O	4799
MEDLINE	NOUN	O	O	4799
search	NOUN	O	O	4799
(	PUNCT	O	O	4799
1966-January	PROPN	O	O	4799
2009	NUM	O	O	4799
)	PUNCT	O	O	4799
revealed	VERB	O	O	4799
one	NUM	O	O	4799
in	ADP	O	O	4799
vivo	VERB	O	O	4799
pharmacokinetic	VERB	O	O	4799
study	VERB	O	O	4799
on	ADP	O	O	4799
the	PRON	O	O	4799
interaction	NOUN	O	O	4799
between	ADP	O	O	4799
flecainide	PROPN	O	O	4799
,	PUNCT	O	O	4799
a	PRON	O	O	4799
CYP2D6	VERB	O	O	4799
substrate	NOUN	O	O	4799
,	PUNCT	O	O	4799
and	CCONJ	O	O	4799
paroxetine	NOUN	O	Chemical	4799
,	PUNCT	O	O	4799
a	PRON	O	O	4799
CYP2D6	VERB	O	O	4799
inhibitor	NOUN	O	O	4799
,	PUNCT	O	O	4799
as	ADP	O	O	4799
well	ADV	O	O	4799
as	ADP	O	O	4799
3	X	O	O	4799
case	NOUN	O	O	4799
reports	VERB	O	O	4799
of	ADP	O	O	4799
flecainide	PROPN	O	O	4799
-	PUNCT	O	O	4799
induced	VERB	O	O	4799
delirium	NOUN	O	Disease	4799
.	PUNCT	O	O	4799
According	VERB	O	O	4800
to	PART	O	O	4800
the	PRON	O	O	4800
Naranjo	PROPN	O	O	4800
probability	NOUN	O	O	4800
scale	NOUN	O	O	4800
,	PUNCT	O	O	4800
flecainide	PROPN	O	O	4800
was	AUX	O	O	4800
the	PRON	O	O	4800
probable	ADJ	O	O	4800
cause	VERB	O	O	4800
of	ADP	O	O	4800
the	PRON	O	O	4800
patient	NOUN	O	O	4800
's	AUX	O	O	4800
delirium	NOUN	O	Disease	4800
;	PUNCT	O	O	4800
the	PRON	O	O	4800
Horn	PROPN	O	O	4800
Drug	NOUN	O	O	4800
Interaction	NOUN	O	O	4800
Probability	NOUN	O	O	4800
Scale	NOUN	O	O	4800
indicates	VERB	O	O	4800
a	PRON	O	O	4800
possible	ADJ	O	O	4800
pharmacokinetic	VERB	O	O	4800
drug	NOUN	O	O	4800
interaction	NOUN	O	O	4800
between	ADP	O	O	4800
flecainide	PROPN	O	O	4800
and	CCONJ	O	O	4800
paroxetine	NOUN	O	Chemical	4800
.	PUNCT	O	O	4800
Supratherapeutic	NOUN	O	O	4801
flecainide	PROPN	O	O	4801
plasma	NOUN	O	O	4801
concentrations	NOUN	O	O	4801
may	AUX	O	O	4801
cause	VERB	O	O	4801
delirium	NOUN	O	Disease	4801
.	PUNCT	O	O	4801
Because	SCONJ	O	O	4802
toxicity	NOUN	O	Disease	4802
may	AUX	O	O	4802
occur	VERB	O	O	4802
when	SCONJ	O	O	4802
flecainide	PROPN	O	O	4802
is	AUX	O	O	4802
prescribed	VERB	O	O	4802
with	ADP	O	O	4802
paroxetine	NOUN	O	Chemical	4802
and	CCONJ	O	O	4802
other	ADJ	O	O	4802
potent	ADJ	O	O	4802
CYP2D6	VERB	O	O	4802
inhibitors	NOUN	O	O	4802
,	PUNCT	O	O	4802
flecainide	PROPN	O	O	4802
plasma	NOUN	O	O	4802
concentrations	NOUN	O	O	4802
should	AUX	O	O	4802
be	AUX	O	O	4802
monitored	VERB	O	O	4802
closely	ADV	O	O	4802
with	ADP	O	O	4802
commencement	NOUN	O	O	4802
of	ADP	O	O	4802
CYP2D6	VERB	O	O	4802
inhibitors	NOUN	O	O	4802
.	PUNCT	O	O	4802
Efficacy	NOUN	O	O	4805
of	ADP	O	O	4805
everolimus	ADJ	O	Chemical	4805
(	PUNCT	O	O	4805
RAD001	NOUN	O	O	4805
)	PUNCT	O	O	4805
in	ADP	O	O	4805
patients	NOUN	O	O	4805
with	ADP	O	O	4805
advanced	ADJ	O	O	4805
NSCLC	PROPN	O	Disease	4805
previously	ADV	O	O	4805
treated	VERB	O	O	4805
with	ADP	O	O	4805
chemotherapy	NOUN	O	O	4805
alone	ADV	O	O	4805
or	CCONJ	O	O	4805
with	ADP	O	O	4805
chemotherapy	NOUN	O	O	4805
and	CCONJ	O	O	4805
EGFR	PROPN	O	O	4805
inhibitors	NOUN	O	O	4805
.	PUNCT	O	O	4805
BACKGROUND	NOUN	O	O	4806
:	PUNCT	O	O	4806
Treatment	NOUN	O	O	4806
options	NOUN	O	O	4806
are	AUX	O	O	4806
scarce	ADJ	O	O	4806
in	ADP	O	O	4806
pretreated	VERB	O	O	4806
advanced	ADJ	O	O	4806
non	ADJ	O	O	4806
-	PUNCT	O	O	4806
small	ADJ	O	O	4806
-	PUNCT	O	O	4806
cell	NOUN	O	O	4806
lung cancer	NOUN	O	Disease	4806
(	PUNCT	O	O	4806
NSCLC	PROPN	O	Disease	4806
)	PUNCT	O	O	4806
patients	NOUN	O	O	4806
.	PUNCT	O	O	4806
RAD001	NOUN	O	O	4807
,	PUNCT	O	O	4807
an	PRON	O	O	4807
oral	ADJ	O	O	4807
inhibitor	NOUN	O	O	4807
of	ADP	O	O	4807
the	PRON	O	O	4807
mammalian	ADJ	O	O	4807
target	NOUN	O	O	4807
of	ADP	O	O	4807
rapamycin	NOUN	O	Chemical	4807
(	PUNCT	O	O	4807
mTOR	PROPN	O	O	4807
)	PUNCT	O	O	4807
,	PUNCT	O	O	4807
has	VERB	O	O	4807
shown	VERB	O	O	4807
phase	NOUN	O	O	4807
I	PRON	O	O	4807
efficacy	NOUN	O	O	4807
in	ADP	O	O	4807
NSCLC	PROPN	O	Disease	4807
.	PUNCT	O	O	4807
METHODS	NOUN	O	O	4808
:	PUNCT	O	O	4808
Stage	NOUN	O	O	4808
IIIb	PROPN	O	O	4808
or	CCONJ	O	O	4808
IV	NUM	O	O	4808
NSCLC	PROPN	O	Disease	4808
patients	NOUN	O	O	4808
,	PUNCT	O	O	4808
with	ADP	O	O	4808
two	NUM	O	O	4808
or	CCONJ	O	O	4808
fewer	ADJ	O	O	4808
prior	ADV	O	O	4808
chemotherapy	NOUN	O	O	4808
regimens	NOUN	O	O	4808
,	PUNCT	O	O	4808
one	NUM	O	O	4808
platinum	NOUN	O	Chemical	4808
based	VERB	O	O	4808
(	PUNCT	O	O	4808
stratum	NOUN	O	O	4808
1	X	O	O	4808
)	PUNCT	O	O	4808
or	CCONJ	O	O	4808
both	PRON	O	O	4808
chemotherapy	NOUN	O	O	4808
and	CCONJ	O	O	4808
epidermal	ADJ	O	O	4808
growth	NOUN	O	O	4808
factor	NOUN	O	O	4808
receptor	NOUN	O	O	4808
tyrosine	NOUN	O	Chemical	4808
kinase	VERB	O	O	4808
inhibitors	NOUN	O	O	4808
(	PUNCT	O	O	4808
stratum	NOUN	O	O	4808
2	X	O	O	4808
)	PUNCT	O	O	4808
,	PUNCT	O	O	4808
received	VERB	O	O	4808
RAD001	NOUN	O	O	4808
10	NUM	O	O	4808
mg	VERB	O	O	4808
/	PUNCT	O	O	4808
day	NOUN	O	O	4808
until	ADP	O	O	4808
progression	NOUN	O	O	4808
or	CCONJ	O	O	4808
unacceptable	ADJ	O	O	4808
toxicity	NOUN	O	Disease	4808
.	PUNCT	O	O	4808
Analyses	NOUN	O	O	4809
of	ADP	O	O	4809
markers	NOUN	O	O	4809
associated	VERB	O	O	4809
with	ADP	O	O	4809
the	PRON	O	O	4809
mTOR	PROPN	O	O	4809
pathway	NOUN	O	O	4809
were	AUX	O	O	4809
carried	VERB	O	O	4809
out	ADP	O	O	4809
on	ADP	O	O	4809
archival	PROPN	O	O	4809
tumor	NOUN	O	Disease	4809
from	ADP	O	O	4809
a	PRON	O	O	4809
subgroup	PROPN	O	O	4809
using	VERB	O	O	4809
immunohistochemistry	NOUN	O	O	4809
(	PUNCT	O	O	4809
IHC	PROPN	O	O	4809
)	PUNCT	O	O	4809
and	CCONJ	O	O	4809
direct	ADJ	O	O	4809
mutation	NOUN	O	O	4809
sequencing	VERB	O	O	4809
.	PUNCT	O	O	4809
Common	ADJ	O	O	4810
>	PUNCT	O	O	4810
or	CCONJ	O	O	4810
=	PUNCT	O	O	4810
grade	NOUN	O	O	4810
3	X	O	O	4810
events	NOUN	O	O	4810
were	AUX	O	O	4810
fatigue	NOUN	O	Disease	4810
,	PUNCT	O	O	4810
dyspnea	ADJ	O	O	4810
,	PUNCT	O	O	4810
stomatitis	PROPN	O	O	4810
,	PUNCT	O	O	4810
anemia	NOUN	O	Disease	4810
,	PUNCT	O	O	4810
and	CCONJ	O	O	4810
thrombocytopenia	PROPN	O	Disease	4810
.	PUNCT	O	O	4810
Pneumonitis	NOUN	O	O	4811
,	PUNCT	O	O	4811
probably	ADV	O	O	4811
or	CCONJ	O	O	4811
possibly	ADV	O	O	4811
related	ADJ	O	O	4811
,	PUNCT	O	O	4811
mainly	ADV	O	O	4811
grade	NOUN	O	O	4811
1/2	NUM	O	O	4811
,	PUNCT	O	O	4811
occurred	VERB	O	O	4811
in	ADP	O	O	4811
25%	NOUN	O	O	4811
.	PUNCT	O	O	4811
RAD001	NOUN	O	O	4812
10	NUM	O	O	4812
mg	VERB	O	O	4812
/	PUNCT	O	O	4812
day	NOUN	O	O	4812
was	AUX	O	O	4812
well	ADV	O	O	4812
tolerated	VERB	O	O	4812
,	PUNCT	O	O	4812
showing	VERB	O	O	4812
modest	ADJ	O	O	4812
clinical	ADJ	O	O	4812
activity	NOUN	O	O	4812
in	ADP	O	O	4812
pretreated	VERB	O	O	4812
NSCLC	PROPN	O	Disease	4812
.	PUNCT	O	O	4812
Evaluation	NOUN	O	O	4813
of	ADP	O	O	4813
RAD001	NOUN	O	O	4813
plus	CCONJ	O	O	4813
standard	PROPN	O	O	4813
therapy	NOUN	O	O	4813
for	ADP	O	O	4813
metastatic	ADJ	O	O	4813
NSCLC	PROPN	O	Disease	4814
continues	VERB	O	O	4814
.	PUNCT	O	O	4814
Posttransplant	PROPN	O	O	4817
anemia	NOUN	O	Disease	4817
:	PUNCT	O	O	4817
the	PRON	O	O	4817
role	NOUN	O	O	4817
of	ADP	O	O	4817
sirolimus	NOUN	O	Chemical	4817
.	PUNCT	O	O	4817
Posttransplant	PROPN	O	O	4818
anemia	NOUN	O	Disease	4818
is	AUX	O	O	4818
a	PRON	O	O	4818
common	ADJ	O	O	4818
problem	NOUN	O	O	4818
that	SCONJ	O	O	4818
may	AUX	O	O	4818
hinder	VERB	O	O	4818
patients	NOUN	O	O	4818
'	PUNCT	O	O	4818
quality	NOUN	O	O	4818
of	ADP	O	O	4818
life	NOUN	O	O	4818
.	PUNCT	O	O	4818
A	PRON	O	O	4819
variety	NOUN	O	O	4819
of	ADP	O	O	4819
factors	NOUN	O	O	4819
have	VERB	O	O	4819
been	AUX	O	O	4819
identified	VERB	O	O	4819
that	SCONJ	O	O	4819
increase	VERB	O	O	4819
the	PRON	O	O	4819
risk	NOUN	O	O	4819
of	ADP	O	O	4819
posttransplant	PROPN	O	O	4819
anemia	NOUN	O	Disease	4819
,	PUNCT	O	O	4819
of	ADP	O	O	4819
which	PRON	O	O	4819
the	PRON	O	O	4819
level	VERB	O	O	4819
of	ADP	O	O	4819
renal	ADJ	O	O	4819
function	NOUN	O	O	4819
is	AUX	O	O	4819
most	ADV	O	O	4819
important	ADJ	O	O	4819
.	PUNCT	O	O	4819
Sirolimus	NOUN	O	Chemical	4820
,	PUNCT	O	O	4820
a	PRON	O	O	4820
mammalian	ADJ	O	O	4820
target	NOUN	O	O	4820
of	ADP	O	O	4820
rapamycin	NOUN	O	Chemical	4820
inhibitor	NOUN	O	O	4820
,	PUNCT	O	O	4820
has	VERB	O	O	4820
been	AUX	O	O	4820
implicated	VERB	O	O	4820
as	ADP	O	O	4820
playing	VERB	O	O	4820
a	PRON	O	O	4820
special	ADJ	O	O	4820
role	NOUN	O	O	4820
in	ADP	O	O	4820
posttransplant	PROPN	O	O	4820
anemia	NOUN	O	Disease	4820
.	PUNCT	O	O	4820
This	PRON	O	O	4821
review	VERB	O	O	4821
considers	VERB	O	O	4821
anemia	NOUN	O	Disease	4821
associated	VERB	O	O	4821
with	ADP	O	O	4821
sirolimus	NOUN	O	Chemical	4821
,	PUNCT	O	O	4821
including	VERB	O	O	4821
its	PRON	O	O	4821
presentation	NOUN	O	O	4821
,	PUNCT	O	O	4821
mechanisms	NOUN	O	O	4821
,	PUNCT	O	O	4821
and	CCONJ	O	O	4821
management	NOUN	O	O	4821
.	PUNCT	O	O	4821
Coronary	ADJ	O	O	4824
computerized	VERB	O	O	4824
tomography	NOUN	O	O	4824
angiography	NOUN	O	O	4824
for	ADP	O	O	4824
rapid	ADJ	O	O	4824
discharge	VERB	O	O	4824
of	ADP	O	O	4824
low	ADJ	O	O	4824
-	PUNCT	O	O	4824
risk	NOUN	O	O	4824
patients	NOUN	O	O	4824
with	ADP	O	O	4824
cocaine	NOUN	O	Chemical	4824
-	PUNCT	O	O	4824
associated	VERB	O	O	4824
chest pain	NOUN	O	Disease	4824
.	PUNCT	O	O	4824
Most	ADV	O	O	4825
patients	NOUN	O	O	4825
presenting	VERB	O	O	4825
to	PART	O	O	4825
emergency	NOUN	O	O	4825
departments	NOUN	O	O	4825
(	PUNCT	O	O	4825
EDs	NOUN	O	O	4825
)	PUNCT	O	O	4825
with	ADP	O	O	4825
cocaine	NOUN	O	Chemical	4825
-	PUNCT	O	O	4825
associated	VERB	O	O	4825
chest pain	NOUN	O	Disease	4825
are	AUX	O	O	4825
admitted	VERB	O	O	4825
for	ADP	O	O	4825
at	ADP	O	O	4825
least	ADJ	O	O	4825
12	NUM	O	O	4825
hours	NOUN	O	O	4825
and	CCONJ	O	O	4825
receive	VERB	O	O	4825
a	PRON	O	O	4825
""""	PUNCT	O	O	4825
rule	NOUN	O	O	4825
out	ADP	O	O	4825
acute	ADJ	O	O	4825
coronary	ADJ	O	O	4825
syndrome	NOUN	O	O	4825
""""	PUNCT	O	O	4825
protocol	PROPN	O	O	4825
,	PUNCT	O	O	4825
often	ADV	O	O	4825
with	ADP	O	O	4825
noninvasive	ADJ	O	O	4825
testing	NOUN	O	O	4825
prior	ADV	O	O	4825
to	PART	O	O	4825
discharge	VERB	O	O	4825
.	PUNCT	O	O	4825
In	ADP	O	O	4826
patients	NOUN	O	O	4826
without	ADP	O	O	4826
cocaine	NOUN	O	Chemical	4826
use	VERB	O	O	4826
,	PUNCT	O	O	4826
coronary	ADJ	O	O	4826
computerized	VERB	O	O	4826
tomography	NOUN	O	O	4826
angiography	NOUN	O	O	4826
(	PUNCT	O	O	4826
CTA	NOUN	O	O	4826
)	PUNCT	O	O	4826
has	VERB	O	O	4826
been	AUX	O	O	4826
shown	VERB	O	O	4826
to	PART	O	O	4826
be	AUX	O	O	4826
useful	ADJ	O	O	4826
for	ADP	O	O	4826
identifying	VERB	O	O	4826
a	PRON	O	O	4826
group	NOUN	O	O	4826
of	ADP	O	O	4826
patients	NOUN	O	O	4826
at	ADP	O	O	4826
low	ADJ	O	O	4826
risk	NOUN	O	O	4826
for	ADP	O	O	4826
cardiac	ADJ	O	O	4826
events	NOUN	O	O	4826
who	PRON	O	O	4826
can	AUX	O	O	4826
be	AUX	O	O	4826
safely	ADV	O	O	4826
discharged	VERB	O	O	4826
.	PUNCT	O	O	4826
It	PRON	O	O	4827
is	AUX	O	O	4827
unclear	ADJ	O	O	4827
whether	SCONJ	O	O	4827
a	PRON	O	O	4827
coronary	ADJ	O	O	4827
CTA	NOUN	O	O	4827
strategy	NOUN	O	O	4827
would	AUX	O	O	4827
be	AUX	O	O	4827
efficacious	ADJ	O	O	4827
in	ADP	O	O	4827
cocaine	NOUN	O	Chemical	4827
-	PUNCT	O	O	4827
associated	VERB	O	O	4827
chest pain	NOUN	O	Disease	4827
,	PUNCT	O	O	4827
as	ADP	O	O	4827
coronary vasospasm	NOUN	O	Disease	4827
may	AUX	O	O	4827
account	VERB	O	O	4827
for	ADP	O	O	4827
some	PRON	O	O	4827
of	ADP	O	O	4827
the	PRON	O	O	4827
ischemia	NOUN	O	Disease	4827
.	PUNCT	O	O	4827
We	PRON	O	O	4828
studied	VERB	O	O	4828
whether	SCONJ	O	O	4828
a	PRON	O	O	4828
negative	ADJ	O	O	4828
coronary	ADJ	O	O	4828
CTA	NOUN	O	O	4828
in	ADP	O	O	4828
patients	NOUN	O	O	4828
with	ADP	O	O	4828
cocaine	NOUN	O	Chemical	4828
-	PUNCT	O	O	4828
associated	VERB	O	O	4828
chest pain	NOUN	O	Disease	4828
could	AUX	O	O	4828
identify	VERB	O	O	4828
a	PRON	O	O	4828
subset	VERB	O	O	4828
safe	ADJ	O	O	4828
for	ADP	O	O	4828
discharge	VERB	O	O	4828
.	PUNCT	O	O	4828
:	PUNCT	O	O	4829
We	PRON	O	O	4829
prospectively	ADV	O	O	4829
evaluated	VERB	O	O	4829
the	PRON	O	O	4829
safety	NOUN	O	O	4829
of	ADP	O	O	4829
coronary	ADJ	O	O	4829
CTA	NOUN	O	O	4829
for	ADP	O	O	4829
low	ADJ	O	O	4829
-	PUNCT	O	O	4829
risk	NOUN	O	O	4829
patients	NOUN	O	O	4829
who	PRON	O	O	4829
presented	VERB	O	O	4829
to	PART	O	O	4829
the	PRON	O	O	4829
ED	PROPN	O	O	4829
with	ADP	O	O	4829
cocaineassociated	VERB	O	O	4829
chest pain	NOUN	O	Disease	4829
(	PUNCT	O	O	4829
self	VERB	O	O	4829
-	PUNCT	O	O	4829
reported	VERB	O	O	4829
or	CCONJ	O	O	4829
positive	ADJ	O	O	4829
urine	NOUN	O	O	4829
test	NOUN	O	O	4829
)	PUNCT	O	O	4829
.	PUNCT	O	O	4829
Patients	NOUN	O	O	4830
with	ADP	O	O	4830
negative	ADJ	O	O	4830
coronary	ADJ	O	O	4830
CTA	NOUN	O	O	4830
(	PUNCT	O	O	4830
maximal	ADJ	O	O	4830
stenosis	NOUN	O	O	4830
less	ADV	O	O	4830
than	ADP	O	O	4830
50%	NOUN	O	O	4830
)	PUNCT	O	O	4830
were	AUX	O	O	4830
discharged	VERB	O	O	4830
.	PUNCT	O	O	4830
The	PRON	O	O	4831
main	ADJ	O	O	4831
outcome	NOUN	O	O	4831
was	AUX	O	O	4831
30-day	NOUN	O	O	4831
cardiovascular	ADJ	O	O	4831
death	NOUN	O	O	4831
or	CCONJ	O	O	4831
myocardial infarction	NOUN	O	Disease	4831
.	PUNCT	O	O	4831
A	PRON	O	O	4832
total	ADJ	O	O	4832
of	ADP	O	O	4832
59	NUM	O	O	4832
patients	NOUN	O	O	4832
with	ADP	O	O	4832
cocaine	NOUN	O	Chemical	4832
-	PUNCT	O	O	4832
associated	VERB	O	O	4832
chest pain	NOUN	O	Disease	4832
were	AUX	O	O	4832
evaluated	VERB	O	O	4832
.	PUNCT	O	O	4832
Six	NUM	O	O	4833
patients	NOUN	O	O	4833
had	VERB	O	O	4833
coronary stenosis	NOUN	O	Disease	4833
>	PUNCT	O	O	4833
During	ADP	O	O	4834
the	PRON	O	O	4834
30-day	NOUN	O	O	4834
follow	VERB	O	O	4834
-	PUNCT	O	O	4834
up	ADP	O	O	4834
period	NOUN	O	O	4834
,	PUNCT	O	O	4834
no	PRON	O	O	4834
patients	NOUN	O	O	4834
died	VERB	O	O	4834
of	ADP	O	O	4834
a	PRON	O	O	4834
cardiovascular	ADJ	O	O	4834
event	NOUN	O	O	4834
(	PUNCT	O	O	4834
0%	NOUN	O	O	4834
;	PUNCT	O	O	4834
95%	NOUN	O	O	4834
CI	NOUN	O	O	4834
,	PUNCT	O	O	4834
0	NUM	O	O	4834
-	PUNCT	O	O	4834
6.1%	NOUN	O	O	4834
)	PUNCT	O	O	4834
and	CCONJ	O	O	4834
no	PRON	O	O	4834
patient	NOUN	O	O	4834
sustained	VERB	O	O	4834
a	PRON	O	O	4834
nonfatal	ADJ	O	O	4834
myocardial infarction	NOUN	O	Disease	4834
(	PUNCT	O	O	4834
0%	NOUN	O	O	4834
;	PUNCT	O	O	4834
95%	NOUN	O	O	4834
CI	NOUN	O	O	4834
,	PUNCT	O	O	4834
0	NUM	O	O	4834
-	PUNCT	O	O	4834
6.1%	NOUN	O	O	4834
)	PUNCT	O	O	4834
.	PUNCT	O	O	4834
Although	SCONJ	O	O	4835
cocaine	NOUN	O	Chemical	4835
-	PUNCT	O	O	4835
associated	VERB	O	O	4835
myocardial ischemia	NOUN	O	Disease	4835
can	AUX	O	O	4835
result	VERB	O	O	4835
from	ADP	O	O	4835
coronary	ADJ	O	O	4835
vasoconstriction	NOUN	O	O	4835
,	PUNCT	O	O	4835
patients	NOUN	O	O	4835
with	ADP	O	O	4835
cocaine	NOUN	O	Chemical	4835
associated	VERB	O	O	4835
chest pain	NOUN	O	Disease	4835
,	PUNCT	O	O	4835
a	PRON	O	O	4835
non	ADJ	O	O	4835
-	PUNCT	O	O	4835
ischemic	VERB	O	Disease	4835
ECG	PROPN	O	O	4835
,	PUNCT	O	O	4835
and	CCONJ	O	O	4835
a	PRON	O	O	4835
TIMI	PROPN	O	O	4835
risk	NOUN	O	O	4835
score	VERB	O	O	4835
Late	ADV	O	O	4838
fulminant	ADJ	O	O	4838
posterior	ADJ	O	O	4838
reversible	ADJ	O	O	4838
encephalopathy	NOUN	O	Disease	4838
syndrome	NOUN	O	O	4838
after	ADP	O	O	4838
liver	NOUN	O	O	4838
transplant	NOUN	O	O	4838
.	PUNCT	O	O	4838
Posterior	PROPN	O	O	4839
leukoencephalopathy	ADJ	O	Disease	4839
due	ADJ	O	O	4839
to	PART	O	O	4839
calcineurin	NOUN	O	O	4839
-	PUNCT	O	O	4839
inhibitor	NOUN	O	O	4839
-	PUNCT	O	O	4839
related	ADJ	O	O	4839
neurotoxicity	NOUN	O	Disease	4839
is	AUX	O	O	4839
a	PRON	O	O	4839
rare	ADJ	O	O	4839
but	CCONJ	O	O	4839
severe	ADJ	O	O	4839
complication	NOUN	O	O	4839
that	SCONJ	O	O	4839
results	VERB	O	O	4839
from	ADP	O	O	4839
treatment	NOUN	O	O	4839
with	ADP	O	O	4839
immunosuppressive	ADJ	O	O	4839
agents	NOUN	O	O	4839
(	PUNCT	O	O	4839
primarily	ADV	O	O	4839
those	PRON	O	O	4839
administered	VERB	O	O	4839
after	ADP	O	O	4839
a	PRON	O	O	4839
liver	NOUN	O	O	4839
or	CCONJ	O	O	4839
kidney	NOUN	O	O	4839
transplant	NOUN	O	O	4839
)	PUNCT	O	O	4839
.	PUNCT	O	O	4839
:	PUNCT	O	O	4840
We	PRON	O	O	4840
report	VERB	O	O	4840
the	PRON	O	O	4840
case	NOUN	O	O	4840
of	ADP	O	O	4840
a	PRON	O	O	4840
46-year	NOUN	O	O	4840
-	PUNCT	O	O	4840
old	ADJ	O	O	4840
woman	NOUN	O	O	4840
who	PRON	O	O	4840
received	VERB	O	O	4840
a	PRON	O	O	4840
liver	NOUN	O	O	4840
transplant	NOUN	O	O	4840
in	ADP	O	O	4840
our	PRON	O	O	4840
center	PROPN	O	O	4840
as	ADP	O	O	4840
treatment	NOUN	O	O	4840
for	ADP	O	O	4840
alcoholic	ADJ	O	O	4840
cirrhosis	NOUN	O	Disease	4840
and	CCONJ	O	O	4840
in	ADP	O	O	4840
whom	PRON	O	O	4840
either	ADV	O	O	4840
a	PRON	O	O	4840
fulminant	ADJ	O	O	4840
course	NOUN	O	O	4840
of	ADP	O	O	4840
posterior	ADJ	O	O	4840
leukoencephalopathy	ADJ	O	Disease	4840
or	CCONJ	O	O	4840
posterior	ADJ	O	O	4840
reversible	ADJ	O	O	4840
encephalopathy	NOUN	O	Disease	4840
syndrome	NOUN	O	O	4840
developed	VERB	O	O	4840
110	NUM	O	O	4840
days	NOUN	O	O	4840
after	ADP	O	O	4840
transplant	NOUN	O	O	4840
.	PUNCT	O	O	4840
Switching	VERB	O	O	4841
the	PRON	O	O	4841
immunosuppressive	ADJ	O	O	4841
regimen	NOUN	O	O	4841
from	ADP	O	O	4841
tacrolimus	NOUN	O	Chemical	4841
to	PART	O	O	4841
cyclosporine	NOUN	O	Chemical	4841
did	VERB	O	O	4841
not	PART	O	O	4841
improve	VERB	O	O	4841
the	PRON	O	O	4841
clinical	ADJ	O	O	4841
situation	NOUN	O	O	4841
.	PUNCT	O	O	4841
Posterior	PROPN	O	O	4842
reversible	ADJ	O	O	4842
encephalopathy	NOUN	O	Disease	4842
syndrome	NOUN	O	O	4842
after	ADP	O	O	4842
liver	NOUN	O	O	4842
transplant	NOUN	O	O	4842
is	AUX	O	O	4842
rare	ADJ	O	O	4842
.	PUNCT	O	O	4842
Prolonged	VERB	O	O	4845
hypothermia	VERB	O	Disease	4845
as	ADP	O	O	4845
a	PRON	O	O	4845
bridge	PROPN	O	O	4845
to	PART	O	O	4845
recovery	NOUN	O	O	4845
for	ADP	O	O	4845
cerebral edema	NOUN	O	Disease	4845
and	CCONJ	O	O	4845
intracranial	ADJ	O	O	4845
hypertension	NOUN	O	Disease	4845
associated	VERB	O	O	4845
with	ADP	O	O	4845
fulminant	ADJ	O	O	4845
hepatic failure	NOUN	O	Disease	4845
.	PUNCT	O	O	4845
BACKGROUND	NOUN	O	O	4846
:	PUNCT	O	O	4846
To	PART	O	O	4846
review	VERB	O	O	4846
evidence	NOUN	O	O	4846
-	PUNCT	O	O	4846
based	VERB	O	O	4846
treatment	NOUN	O	O	4846
options	NOUN	O	O	4846
in	ADP	O	O	4846
patients	NOUN	O	O	4846
with	ADP	O	O	4846
cerebral edema	NOUN	O	Disease	4846
complicating	VERB	O	O	4846
fulminant	ADJ	O	O	4846
hepatic failure	NOUN	O	Disease	4846
(	PUNCT	O	O	4846
FHF	VERB	O	O	4846
)	PUNCT	O	O	4846
and	CCONJ	O	O	4846
discuss	VERB	O	O	4846
the	PRON	O	O	4846
potential	ADJ	O	O	4846
applications	NOUN	O	O	4846
of	ADP	O	O	4846
hypothermia	VERB	O	Disease	4846
.	PUNCT	O	O	4846
METHOD	NOUN	O	O	4847
:	PUNCT	O	O	4847
Case	NOUN	O	O	4847
-	PUNCT	O	O	4847
based	VERB	O	O	4847
observations	NOUN	O	O	4847
from	ADP	O	O	4847
a	PRON	O	O	4847
medical	ADJ	O	O	4847
intensive	ADJ	O	O	4847
care	VERB	O	O	4847
unit	NOUN	O	O	4847
(	PUNCT	O	O	4847
MICU	PROPN	O	O	4847
)	PUNCT	O	O	4847
in	ADP	O	O	4847
a	PRON	O	O	4847
tertiary	ADJ	O	O	4847
care	VERB	O	O	4847
facility	NOUN	O	O	4847
in	ADP	O	O	4847
a	PRON	O	O	4847
27-year	NOUN	O	O	4847
-	PUNCT	O	O	4847
old	ADJ	O	O	4847
female	ADJ	O	O	4847
with	ADP	O	O	4847
FHF	VERB	O	O	4847
from	ADP	O	O	4847
acetaminophen	PROPN	O	Chemical	4847
and	CCONJ	O	O	4847
resultant	NOUN	O	O	4847
cerebral edema	NOUN	O	Disease	4847
.	PUNCT	O	O	4847
Our	PRON	O	O	4848
patient	NOUN	O	O	4848
was	AUX	O	O	4848
admitted	VERB	O	O	4848
to	PART	O	O	4848
the	PRON	O	O	4848
MICU	PROPN	O	O	4848
after	ADP	O	O	4848
being	AUX	O	O	4848
found	VERB	O	O	4848
unresponsive	ADJ	O	O	4848
with	ADP	O	O	4848
presumed	VERB	O	O	4848
toxicity	NOUN	O	Disease	4848
from	ADP	O	O	4848
acetaminophen	PROPN	O	Chemical	4848
which	PRON	O	O	4848
was	AUX	O	O	4848
ingested	VERB	O	O	4848
over	ADP	O	O	4848
a	PRON	O	O	4848
2-day	NOUN	O	O	4848
period	NOUN	O	O	4848
.	PUNCT	O	O	4848
Initial	ADJ	O	O	4849
evaluation	NOUN	O	O	4849
confirmed	VERB	O	O	4849
FHF	VERB	O	O	4849
from	ADP	O	O	4849
acetaminophen	PROPN	O	Chemical	4849
and	CCONJ	O	O	4849
cerebral edema	NOUN	O	Disease	4849
.	PUNCT	O	O	4849
The	PRON	O	O	4850
patient	NOUN	O	O	4850
was	AUX	O	O	4850
treated	VERB	O	O	4850
with	ADP	O	O	4850
hyperosmolar	VERB	O	O	4850
therapy	NOUN	O	O	4850
,	PUNCT	O	O	4850
hyperventilation	NOUN	O	O	4850
,	PUNCT	O	O	4850
sedation	NOUN	O	O	4850
,	PUNCT	O	O	4850
and	CCONJ	O	O	4850
chemical	PROPN	O	O	4850
paralysis	NOUN	O	Disease	4850
.	PUNCT	O	O	4850
We	PRON	O	O	4851
then	ADV	O	O	4851
initiated	VERB	O	O	4851
therapeutic	ADJ	O	O	4851
hypothermia	VERB	O	Disease	4851
which	PRON	O	O	4851
was	AUX	O	O	4851
continued	VERB	O	O	4851
for	ADP	O	O	4851
5	NUM	O	O	4851
days	NOUN	O	O	4851
.	PUNCT	O	O	4851
At	ADP	O	O	4852
re	ADP	O	O	4852
-	PUNCT	O	O	4852
warming	VERB	O	O	4852
,	PUNCT	O	O	4852
patient	NOUN	O	O	4852
had	VERB	O	O	4852
resolution	NOUN	O	O	4852
of	ADP	O	O	4852
her	PRON	O	O	4852
cerebral edema	NOUN	O	Disease	4852
and	CCONJ	O	O	4852
intracranial	ADJ	O	O	4852
hypertension	NOUN	O	Disease	4852
.	PUNCT	O	O	4852
In	ADP	O	O	4853
patients	NOUN	O	O	4853
with	ADP	O	O	4853
FHF	VERB	O	O	4853
and	CCONJ	O	O	4853
cerebral edema	NOUN	O	Disease	4853
from	ADP	O	O	4853
acetaminophen	PROPN	O	Chemical	4853
overdose	NOUN	O	Disease	4853
,	PUNCT	O	O	4853
prolonged	VERB	O	O	4853
therapeutic	ADJ	O	O	4853
hypothermia	VERB	O	Disease	4853
could	AUX	O	O	4853
potentially	ADV	O	O	4853
be	AUX	O	O	4853
used	VERB	O	O	4853
as	ADP	O	O	4853
a	PRON	O	O	4853
life	NOUN	O	O	4853
saving	VERB	O	O	4853
therapy	NOUN	O	O	4853
and	CCONJ	O	O	4853
a	PRON	O	O	4853
bridge	PROPN	O	O	4853
to	PART	O	O	4853
hepatic	ADJ	O	O	4853
and	CCONJ	O	O	4853
neurological	ADJ	O	O	4853
recovery	NOUN	O	O	4853
.	PUNCT	O	O	4853
A	PRON	O	O	4854
clinical	ADJ	O	O	4854
trial	NOUN	O	O	4854
of	ADP	O	O	4854
hypothermia	VERB	O	Disease	4854
in	ADP	O	O	4854
patients	NOUN	O	O	4854
with	ADP	O	O	4854
this	PRON	O	O	4854
condition	NOUN	O	O	4854
is	AUX	O	O	4854
warranted	VERB	O	O	4854
.	PUNCT	O	O	4854
Binasal	PROPN	O	O	4857
visual	ADJ	O	O	4857
field	NOUN	O	O	4857
defects	NOUN	O	O	4857
are	AUX	O	O	4857
not	PART	O	O	4857
specific	ADJ	O	O	4857
to	PART	O	O	4857
vigabatrin	PROPN	O	Chemical	4857
.	PUNCT	O	O	4857
This	PRON	O	O	4858
study	VERB	O	O	4858
investigated	VERB	O	O	4858
the	PRON	O	O	4858
visual	ADJ	O	O	4858
defects	NOUN	O	O	4858
associated	VERB	O	O	4858
with	ADP	O	O	4858
the	PRON	O	O	4858
antiepileptic	ADJ	O	O	4858
drug	NOUN	O	O	4858
vigabatrin	PROPN	O	Chemical	4858
(	PUNCT	O	O	4858
VGB	VERB	O	O	4858
)	PUNCT	O	O	4858
.	PUNCT	O	O	4858
Two	NUM	O	O	4859
hundred	NUM	O	O	4859
four	NUM	O	O	4859
people	NOUN	O	O	4859
with	ADP	O	O	4859
epilepsy	NOUN	O	Disease	4859
were	AUX	O	O	4859
grouped	VERB	O	O	4859
on	ADP	O	O	4859
the	PRON	O	O	4859
basis	NOUN	O	O	4859
of	ADP	O	O	4859
antiepileptic	ADJ	O	O	4859
drug	NOUN	O	O	4859
therapy	NOUN	O	O	4859
(	PUNCT	O	O	4859
current	ADJ	O	O	4859
,	PUNCT	O	O	4859
previous	ADJ	O	O	4859
,	PUNCT	O	O	4859
or	CCONJ	O	O	4859
no	PRON	O	O	4859
exposure	NOUN	O	O	4859
to	PART	O	O	4859
VGB	VERB	O	O	4859
)	PUNCT	O	O	4859
.	PUNCT	O	O	4859
Groups	NOUN	O	O	4860
were	AUX	O	O	4860
matched	VERB	O	O	4860
with	ADP	O	O	4860
respect	VERB	O	O	4860
to	PART	O	O	4860
age	NOUN	O	O	4860
,	PUNCT	O	O	4860
gender	NOUN	O	O	4860
,	PUNCT	O	O	4860
and	CCONJ	O	O	4860
seizure	NOUN	O	Disease	4860
frequency	NOUN	O	O	4860
.	PUNCT	O	O	4860
Bilateral	ADJ	O	O	4861
visual field constriction	NOUN	O	Disease	4861
was	AUX	O	O	4861
observed	VERB	O	O	4861
in	ADP	O	O	4861
59%	NOUN	O	O	4861
of	ADP	O	O	4861
patients	NOUN	O	O	4861
currently	ADV	O	O	4861
taking	VERB	O	O	4861
VGB	VERB	O	O	4861
,	PUNCT	O	O	4861
43%	NOUN	O	O	4861
of	ADP	O	O	4861
patients	NOUN	O	O	4861
who	PRON	O	O	4861
previously	ADV	O	O	4861
took	VERB	O	O	4861
VGB	VERB	O	O	4861
,	PUNCT	O	O	4861
and	CCONJ	O	O	4861
24%	NOUN	O	O	4861
of	ADP	O	O	4861
patients	NOUN	O	O	4861
with	ADP	O	O	4861
no	PRON	O	O	4861
exposure	NOUN	O	O	4861
to	PART	O	O	4861
VGB	VERB	O	O	4861
.	PUNCT	O	O	4861
Assessment	NOUN	O	O	4862
of	ADP	O	O	4862
retinal	ADJ	O	O	4862
function	NOUN	O	O	4862
revealed	VERB	O	O	4862
abnormal	ADJ	O	O	4862
responses	NOUN	O	O	4862
in	ADP	O	O	4862
48%	NOUN	O	O	4862
of	ADP	O	O	4862
current	ADJ	O	O	4862
VGB	VERB	O	O	4862
users	NOUN	O	O	4862
and	CCONJ	O	O	4862
22%	NOUN	O	O	4862
of	ADP	O	O	4862
prior	ADV	O	O	4862
VGB	VERB	O	O	4862
users	NOUN	O	O	4862
,	PUNCT	O	O	4862
but	CCONJ	O	O	4862
in	ADP	O	O	4862
none	NOUN	O	O	4862
of	ADP	O	O	4862
the	PRON	O	O	4862
patients	NOUN	O	O	4862
without	ADP	O	O	4862
previous	ADJ	O	O	4862
exposure	NOUN	O	O	4862
to	PART	O	O	4862
VGB	VERB	O	O	4862
.	PUNCT	O	O	4862
Bilateral	ADJ	O	O	4863
visual	ADJ	O	O	4863
field	NOUN	O	O	4863
abnormalities	NOUN	O	O	4863
are	AUX	O	O	4863
common	ADJ	O	O	4863
in	ADP	O	O	4863
the	PRON	O	O	4863
treated	VERB	O	O	4863
epilepsy	NOUN	O	Disease	4863
population	NOUN	O	O	4863
,	PUNCT	O	O	4863
irrespective	ADV	O	O	4863
of	ADP	O	O	4863
drug	NOUN	O	O	4863
history	NOUN	O	O	4863
.	PUNCT	O	O	4863
Assessment	NOUN	O	O	4864
by	ADP	O	O	4864
conventional	ADJ	O	O	4864
static	ADJ	O	O	4864
perimetry	NOUN	O	O	4864
may	AUX	O	O	4864
neither	ADV	O	O	4864
be	AUX	O	O	4864
sufficiently	ADV	O	O	4864
sensitive	ADJ	O	O	4864
nor	CCONJ	O	O	4864
specific	ADJ	O	O	4864
to	PART	O	O	4864
reliably	ADV	O	O	4864
identify	VERB	O	O	4864
retinal	ADJ	O	O	4864
toxicity	NOUN	O	Disease	4864
associated	VERB	O	O	4864
with	ADP	O	O	4864
VGB	VERB	O	O	4864
.	PUNCT	O	O	4864
Smoking	VERB	O	O	4867
of	ADP	O	O	4867
crack cocaine	NOUN	O	Chemical	4867
as	ADP	O	O	4867
a	PRON	O	O	4867
risk	NOUN	O	O	4867
factor	NOUN	O	O	4867
for	ADP	O	O	4867
HIV	PROPN	O	O	4867
infection	NOUN	O	Disease	4867
among	ADP	O	O	4867
people	NOUN	O	O	4867
who	PRON	O	O	4867
use	VERB	O	O	4867
injection	NOUN	O	O	4867
drugs	NOUN	O	O	4867
.	PUNCT	O	O	4867
Little	ADJ	O	O	4868
is	AUX	O	O	4868
known	VERB	O	O	4868
about	ADP	O	O	4868
the	PRON	O	O	4868
possible	ADJ	O	O	4868
role	NOUN	O	O	4868
that	SCONJ	O	O	4868
smoking	VERB	O	O	4868
crack cocaine	NOUN	O	Chemical	4868
has	VERB	O	O	4868
on	ADP	O	O	4868
the	PRON	O	O	4868
incidence	NOUN	O	O	4868
of	ADP	O	O	4868
HIV	PROPN	O	O	4868
infection	NOUN	O	Disease	4868
.	PUNCT	O	O	4868
Given	VERB	O	O	4869
the	PRON	O	O	4869
increasing	VERB	O	O	4869
use	VERB	O	O	4869
of	ADP	O	O	4869
crack cocaine	NOUN	O	Chemical	4869
,	PUNCT	O	O	4869
we	PRON	O	O	4869
sought	VERB	O	O	4869
to	PART	O	O	4869
examine	VERB	O	O	4869
whether	SCONJ	O	O	4869
use	VERB	O	O	4869
of	ADP	O	O	4869
this	PRON	O	O	4869
illicit	ADJ	O	O	4869
drug	NOUN	O	O	4869
has	VERB	O	O	4869
become	VERB	O	O	4869
a	PRON	O	O	4869
risk	NOUN	O	O	4869
factor	NOUN	O	O	4869
for	ADP	O	O	4869
HIV	PROPN	O	O	4869
infection	NOUN	O	Disease	4869
.	PUNCT	O	O	4869
To	PART	O	O	4870
determine	VERB	O	O	4870
whether	SCONJ	O	O	4870
the	PRON	O	O	4870
risk	NOUN	O	O	4870
of	ADP	O	O	4870
HIV	PROPN	O	O	4870
seroconversion	NOUN	O	O	4870
among	ADP	O	O	4870
daily	ADV	O	O	4870
smokers	NOUN	O	O	4870
of	ADP	O	O	4870
crack cocaine	NOUN	O	Chemical	4870
changed	VERB	O	O	4870
over	ADP	O	O	4870
time	NOUN	O	O	4870
,	PUNCT	O	O	4870
we	PRON	O	O	4870
used	VERB	O	O	4870
Cox	PROPN	O	O	4870
proportional	ADJ	O	O	4870
hazards	NOUN	O	O	4870
regression	NOUN	O	O	4870
and	CCONJ	O	O	4870
divided	VERB	O	O	4870
the	PRON	O	O	4870
study	VERB	O	O	4870
into	ADP	O	O	4870
3	X	O	O	4870
periods	NOUN	O	O	4870
:	PUNCT	O	O	4870
May	AUX	O	O	4870
1	X	O	O	4870
,	PUNCT	O	O	4870
1996-Nov	PROPN	O	O	4870
.	PUNCT	O	O	4870
30	NUM	O	O	4870
,	PUNCT	O	O	4870
1999	NUM	O	O	4870
(	PUNCT	O	O	4870
period	NOUN	O	O	4870
1	X	O	O	4870
)	PUNCT	O	O	4870
,	PUNCT	O	O	4870
Dec.	PROPN	O	O	4870
1	X	O	O	4870
,	PUNCT	O	O	4870
1999-Nov	PROPN	O	O	4870
.	PUNCT	O	O	4870
30	NUM	O	O	4870
,	PUNCT	O	O	4870
2002	NUM	O	O	4870
(	PUNCT	O	O	4870
period	NOUN	O	O	4870
2	X	O	O	4870
)	PUNCT	O	O	4870
,	PUNCT	O	O	4870
and	CCONJ	O	O	4870
Dec.	PROPN	O	O	4870
1	X	O	O	4870
,	PUNCT	O	O	4870
2002-Dec	PROPN	O	O	4870
.	PUNCT	O	O	4870
30	NUM	O	O	4870
,	PUNCT	O	O	4870
2005	NUM	O	O	4870
(	PUNCT	O	O	4870
period	NOUN	O	O	4870
3	X	O	O	4870
)	PUNCT	O	O	4870
.	PUNCT	O	O	4870
Of	ADV	O	O	4871
these	PRON	O	O	4871
,	PUNCT	O	O	4871
137	NUM	O	O	4871
acquired	VERB	O	O	4871
HIV	PROPN	O	O	4871
infection	NOUN	O	Disease	4871
during	ADP	O	O	4871
follow	VERB	O	O	4871
-	PUNCT	O	O	4871
up	ADP	O	O	4871
.	PUNCT	O	O	4871
The	PRON	O	O	4872
mean	VERB	O	O	4872
proportion	NOUN	O	O	4872
of	ADP	O	O	4872
participants	NOUN	O	O	4872
who	PRON	O	O	4872
reported	VERB	O	O	4872
daily	ADV	O	O	4872
smoking	VERB	O	O	4872
of	ADP	O	O	4872
crack cocaine	NOUN	O	Chemical	4872
increased	VERB	O	O	4872
from	ADP	O	O	4872
11.6%	NOUN	O	O	4872
in	ADP	O	O	4872
period	NOUN	O	O	4872
1	X	O	O	4872
to	PART	O	O	4872
39.7%	NOUN	O	O	4872
in	ADP	O	O	4872
period	NOUN	O	O	4872
3	X	O	O	4872
.	PUNCT	O	O	4872
After	ADP	O	O	4873
adjusting	VERB	O	O	4873
for	ADP	O	O	4873
potential	ADJ	O	O	4873
confounders	NOUN	O	O	4873
,	PUNCT	O	O	4873
we	PRON	O	O	4873
found	VERB	O	O	4873
that	SCONJ	O	O	4873
the	PRON	O	O	4873
risk	NOUN	O	O	4873
of	ADP	O	O	4873
HIV	PROPN	O	O	4873
seroconversion	NOUN	O	O	4873
among	ADP	O	O	4873
participants	NOUN	O	O	4873
who	PRON	O	O	4873
were	AUX	O	O	4873
daily	ADV	O	O	4873
smokers	NOUN	O	O	4873
of	ADP	O	O	4873
crack cocaine	NOUN	O	Chemical	4873
increased	VERB	O	O	4873
over	ADP	O	O	4873
time	NOUN	O	O	4873
(	PUNCT	O	O	4873
period	NOUN	O	O	4873
1	X	O	O	4873
:	PUNCT	O	O	4873
hazard	NOUN	O	O	4873
ratio	NOUN	O	O	4873
[	X	O	O	4873
HR	NOUN	O	O	4873
]	PUNCT	O	O	4873
1.03	NUM	O	O	4873
,	PUNCT	O	O	4873
95%	NOUN	O	O	4873
confidence	NOUN	O	O	4873
interval	NOUN	O	O	4873
[	X	O	O	4873
CI	NOUN	O	O	4873
]	PUNCT	O	O	4873
0.57	NUM	O	O	4873
-	PUNCT	O	O	4873
1.85	NUM	O	O	4873
;	PUNCT	O	O	4873
period	NOUN	O	O	4873
2	X	O	O	4873
:	PUNCT	O	O	4873
HR	NOUN	O	O	4873
1.68	NUM	O	O	4873
,	PUNCT	O	O	4873
95%	NOUN	O	O	4873
INTERPRETATION	NOUN	O	O	4874
:	PUNCT	O	O	4874
Smoking	VERB	O	O	4874
of	ADP	O	O	4874
crack cocaine	NOUN	O	Chemical	4874
was	AUX	O	O	4874
found	VERB	O	O	4874
to	PART	O	O	4874
be	AUX	O	O	4874
an	PRON	O	O	4874
independent	ADJ	O	O	4874
risk	NOUN	O	O	4874
factor	NOUN	O	O	4874
for	ADP	O	O	4874
HIV	PROPN	O	O	4874
seroconversion	NOUN	O	O	4874
among	ADP	O	O	4874
people	NOUN	O	O	4874
who	PRON	O	O	4874
were	AUX	O	O	4874
injection	NOUN	O	O	4874
drug	NOUN	O	O	4874
users	NOUN	O	O	4874
.	PUNCT	O	O	4874
This	PRON	O	O	4875
finding	VERB	O	O	4875
points	VERB	O	O	4875
to	PART	O	O	4875
the	PRON	O	O	4875
urgent	ADJ	O	O	4875
need	VERB	O	O	4875
for	ADP	O	O	4875
evidence	NOUN	O	O	4875
-	PUNCT	O	O	4875
based	VERB	O	O	4875
public	ADJ	O	O	4875
health	NOUN	O	O	4875
initiatives	NOUN	O	O	4875
targeted	VERB	O	O	4875
at	ADP	O	O	4875
people	NOUN	O	O	4875
who	PRON	O	O	4875
smoke	VERB	O	O	4875
crack cocaine	NOUN	O	Chemical	4875
.	PUNCT	O	O	4875
Fluoxetine	NOUN	O	Chemical	4878
improves	VERB	O	O	4878
the	PRON	O	O	4878
memory	NOUN	O	O	4878
deficits	NOUN	O	O	4878
caused	VERB	O	O	4878
by	ADP	O	O	4878
the	PRON	O	O	4878
chemotherapy	NOUN	O	O	4878
agent	NOUN	O	O	4878
5-fluorouracil	NOUN	O	Chemical	4878
.	PUNCT	O	O	4878
Cancer	NOUN	O	O	4879
patients	NOUN	O	O	4879
who	PRON	O	O	4879
have	VERB	O	O	4879
been	AUX	O	O	4879
treated	VERB	O	O	4879
with	ADP	O	O	4879
systemic	ADJ	O	O	4879
adjuvant	NOUN	O	O	4879
chemotherapy	NOUN	O	O	4879
have	VERB	O	O	4879
described	VERB	O	O	4879
experiencing	VERB	O	O	4879
deteriorations	NOUN	O	O	4879
in	ADP	O	O	4879
cognition	NOUN	O	O	4879
.	PUNCT	O	O	4879
A	PRON	O	O	4880
widely	ADV	O	O	4880
used	VERB	O	O	4880
chemotherapeutic	NOUN	O	O	4880
agent	NOUN	O	O	4880
,	PUNCT	O	O	4880
5-fluorouracil	NOUN	O	Chemical	4880
(	PUNCT	O	O	4880
5-FU	NOUN	O	Chemical	4880
)	PUNCT	O	O	4880
,	PUNCT	O	O	4880
readily	ADV	O	O	4880
crosses	NOUN	O	O	4880
the	PRON	O	O	4880
blood	NOUN	O	O	4880
-	PUNCT	O	O	4880
brain	NOUN	O	O	4880
barrier	NOUN	O	O	4880
and	CCONJ	O	O	4880
so	ADV	O	O	4880
could	AUX	O	O	4880
have	VERB	O	O	4880
a	PRON	O	O	4880
direct	ADJ	O	O	4880
effect	VERB	O	O	4880
on	ADP	O	O	4880
brain	NOUN	O	O	4880
function	NOUN	O	O	4880
.	PUNCT	O	O	4880
In	ADP	O	O	4881
contrast	NOUN	O	O	4881
reports	VERB	O	O	4881
indicate	VERB	O	O	4881
that	SCONJ	O	O	4881
hippocampal	NOUN	O	O	4881
dependent	ADJ	O	O	4881
neurogenesis	VERB	O	O	4881
and	CCONJ	O	O	4881
cognition	NOUN	O	O	4881
are	AUX	O	O	4881
enhanced	VERB	O	O	4881
by	ADP	O	O	4881
the	PRON	O	O	4881
SSRI	NOUN	O	O	4881
antidepressant	NOUN	O	O	4881
Fluoxetine	NOUN	O	Chemical	4881
.	PUNCT	O	O	4881
In	ADP	O	O	4882
this	PRON	O	O	4882
investigation	NOUN	O	O	4882
the	PRON	O	O	4882
behavioural	ADJ	O	O	4882
effects	NOUN	O	O	4882
of	ADP	O	O	4882
chronic	ADJ	O	O	4882
(	PUNCT	O	O	4882
two	NUM	O	O	4882
week	NOUN	O	O	4882
)	PUNCT	O	O	4882
treatment	NOUN	O	O	4882
with	ADP	O	O	4882
5-FU	NOUN	O	Chemical	4882
and	CCONJ	O	O	4882
(	PUNCT	O	O	4882
three	NUM	O	O	4882
weeks	NOUN	O	O	4882
)	PUNCT	O	O	4882
with	ADP	O	O	4882
Fluoxetine	NOUN	O	Chemical	4882
either	ADV	O	O	4882
separately	ADV	O	O	4882
or	CCONJ	O	O	4882
in	ADP	O	O	4882
combination	NOUN	O	O	4882
with	ADP	O	O	4882
5-FU	NOUN	O	Chemical	4882
were	AUX	O	O	4882
tested	VERB	O	O	4882
on	ADP	O	O	4882
adult	NOUN	O	O	4882
Lister	PROPN	O	O	4882
hooded	ADJ	O	O	4882
rats	NOUN	O	O	4882
.	PUNCT	O	O	4882
Behavioural	NOUN	O	O	4883
effects	NOUN	O	O	4883
were	AUX	O	O	4883
tested	VERB	O	O	4883
using	VERB	O	O	4883
a	PRON	O	O	4883
context	NOUN	O	O	4883
dependent	ADJ	O	O	4883
conditioned	VERB	O	O	4883
emotional	ADJ	O	O	4883
response	NOUN	O	O	4883
test	NOUN	O	O	4883
(	PUNCT	O	O	4883
CER	PROPN	O	O	4883
)	PUNCT	O	O	4883
which	PRON	O	O	4883
showed	VERB	O	O	4883
that	SCONJ	O	O	4883
animals	NOUN	O	O	4883
treated	VERB	O	O	4883
with	ADP	O	O	4883
5-FU	NOUN	O	Chemical	4883
had	VERB	O	O	4883
a	PRON	O	O	4883
significant	ADJ	O	O	4883
reduction	NOUN	O	O	4883
in	ADP	O	O	4883
freezing	VERB	O	O	4883
time	NOUN	O	O	4883
compared	VERB	O	O	4883
to	PART	O	O	4883
controls	VERB	O	O	4883
.	PUNCT	O	O	4883
Animals	NOUN	O	O	4884
treated	VERB	O	O	4884
only	ADV	O	O	4884
with	ADP	O	O	4884
5-FU	NOUN	O	Chemical	4884
showed	VERB	O	O	4884
significant	ADJ	O	O	4884
deficits	NOUN	O	O	4884
in	ADP	O	O	4884
their	PRON	O	O	4884
ability	NOUN	O	O	4884
to	PART	O	O	4884
carry	VERB	O	O	4884
out	ADP	O	O	4884
the	PRON	O	O	4884
OLR	PROPN	O	O	4884
task	NOUN	O	O	4884
but	CCONJ	O	O	4884
co	NOUN	O	O	4884
administration	NOUN	O	O	4884
of	ADP	O	O	4884
Fluoxetine	NOUN	O	Chemical	4884
improved	VERB	O	O	4884
their	PRON	O	O	4884
performance	NOUN	O	O	4884
.	PUNCT	O	O	4884
5-FU	NOUN	O	Chemical	4885
chemotherapy	NOUN	O	O	4885
caused	VERB	O	O	4885
a	PRON	O	O	4885
significant	ADJ	O	O	4885
reduction	NOUN	O	O	4885
in	ADP	O	O	4885
the	PRON	O	O	4885
number	NOUN	O	O	4885
of	ADP	O	O	4885
proliferating	VERB	O	O	4885
cells	NOUN	O	O	4885
in	ADP	O	O	4885
the	PRON	O	O	4885
sub	ADJ	O	O	4885
granular	ADJ	O	O	4885
zone	PROPN	O	O	4885
of	ADP	O	O	4885
the	PRON	O	O	4885
dentate	ADJ	O	O	4885
gyrus	PROPN	O	O	4885
compared	VERB	O	O	4885
to	PART	O	O	4885
controls	VERB	O	O	4885
.	PUNCT	O	O	4885
This	PRON	O	O	4886
reduction	NOUN	O	O	4886
was	AUX	O	O	4886
eliminated	VERB	O	O	4886
when	SCONJ	O	O	4886
Fluoxetine	NOUN	O	Chemical	4886
was	AUX	O	O	4886
co	NOUN	O	O	4886
administered	VERB	O	O	4886
with	ADP	O	O	4886
5-FU	NOUN	O	Chemical	4886
.	PUNCT	O	O	4886
Fluoxetine	NOUN	O	Chemical	4887
on	ADP	O	O	4887
its	PRON	O	O	4887
own	ADJ	O	O	4887
had	VERB	O	O	4887
no	PRON	O	O	4887
effect	VERB	O	O	4887
on	ADP	O	O	4887
proliferating	VERB	O	O	4887
cell	NOUN	O	O	4887
number	NOUN	O	O	4887
or	CCONJ	O	O	4887
behaviour	NOUN	O	O	4887
.	PUNCT	O	O	4887
These	PRON	O	O	4888
findings	NOUN	O	O	4888
suggest	VERB	O	O	4888
that	SCONJ	O	O	4888
5-FU	NOUN	O	Chemical	4888
can	AUX	O	O	4888
negatively	ADV	O	O	4888
affect	VERB	O	O	4888
both	PRON	O	O	4888
cell	NOUN	O	O	4888
proliferation	NOUN	O	O	4888
and	CCONJ	O	O	4888
hippocampal	NOUN	O	O	4888
dependent	ADJ	O	O	4888
working	VERB	O	O	4888
memory	NOUN	O	O	4888
and	CCONJ	O	O	4888
that	SCONJ	O	O	4888
these	PRON	O	O	4888
deficits	NOUN	O	O	4888
can	AUX	O	O	4888
be	AUX	O	O	4888
reversed	VERB	O	O	4888
by	ADP	O	O	4888
the	PRON	O	O	4888
simultaneous	ADJ	O	O	4888
administration	NOUN	O	O	4888
of	ADP	O	O	4888
the	PRON	O	O	4888
antidepressant	NOUN	O	O	4888
Fluoxetine	NOUN	O	Chemical	4888
.	PUNCT	O	O	4888
Liver	NOUN	O	O	4891
-	PUNCT	O	O	4891
specific	ADJ	O	O	4891
ablation	NOUN	O	O	4891
of	ADP	O	O	4891
integrin	NOUN	O	O	4891
-	PUNCT	O	O	4891
linked	VERB	O	O	4891
kinase	VERB	O	O	4891
in	ADP	O	O	4891
mice	NOUN	O	O	4891
results	VERB	O	O	4891
in	ADP	O	O	4891
enhanced	VERB	O	O	4891
and	CCONJ	O	O	4891
prolonged	VERB	O	O	4891
cell	NOUN	O	O	4891
proliferation	NOUN	O	O	4891
and	CCONJ	O	O	4891
hepatomegaly	NOUN	O	Disease	4891
after	ADP	O	O	4891
phenobarbital	NOUN	O	Chemical	4891
administration	NOUN	O	O	4891
.	PUNCT	O	O	4891
This	PRON	O	O	4892
study	VERB	O	O	4892
investigates	VERB	O	O	4892
the	PRON	O	O	4892
role	NOUN	O	O	4892
of	ADP	O	O	4892
ILK	X	O	O	4892
in	ADP	O	O	4892
liver	NOUN	O	O	4892
enlargement	NOUN	O	O	4892
induced	VERB	O	O	4892
by	ADP	O	O	4892
phenobarbital	NOUN	O	Chemical	4892
(	PUNCT	O	O	4892
PB	PROPN	O	Chemical	4892
)	PUNCT	O	O	4892
.	PUNCT	O	O	4892
liver-/-	NOUN	O	O	4893
mice	NOUN	O	O	4893
were	AUX	O	O	4893
given	VERB	O	O	4893
PB	PROPN	O	Chemical	4893
(	PUNCT	O	O	4893
0.1%	NOUN	O	O	4893
in	ADP	O	O	4893
drinking	VERB	O	O	4893
water	PROPN	O	O	4893
)	PUNCT	O	O	4893
for	ADP	O	O	4893
10	NUM	O	O	4893
days	NOUN	O	O	4893
.	PUNCT	O	O	4893
Livers	NOUN	O	O	4894
were	AUX	O	O	4894
harvested	VERB	O	O	4894
on	ADP	O	O	4894
2	X	O	O	4894
,	PUNCT	O	O	4894
5	NUM	O	O	4894
,	PUNCT	O	O	4894
and	CCONJ	O	O	4894
10	NUM	O	O	4894
days	NOUN	O	O	4894
during	ADP	O	O	4894
PB	PROPN	O	Chemical	4894
administration	NOUN	O	O	4894
.	PUNCT	O	O	4894
There	ADV	O	O	4895
were	AUX	O	O	4895
slightly	ADV	O	O	4895
increased	VERB	O	O	4895
proliferating	VERB	O	O	4895
cell	NOUN	O	O	4895
nuclear	ADJ	O	O	4895
antigen	PROPN	O	O	4895
-	PUNCT	O	O	4895
positive	ADJ	O	O	4895
cells	NOUN	O	O	4895
in	ADP	O	O	4895
the	PRON	O	O	4895
ILK	X	O	O	4895
/	PUNCT	O	O	4895
liver-/-	NOUN	O	O	4895
animals	NOUN	O	O	4895
at	ADP	O	O	4895
day	NOUN	O	O	4895
2	X	O	O	4895
as	ADP	O	O	4895
compared	VERB	O	O	4895
to	PART	O	O	4895
WT	NOUN	O	O	4895
after	ADP	O	O	4895
PB	PROPN	O	Chemical	4895
administration	NOUN	O	O	4895
.	PUNCT	O	O	4895
/	PUNCT	O	O	4896
liver-/-	NOUN	O	O	4896
mice	NOUN	O	O	4896
also	ADV	O	O	4896
showed	VERB	O	O	4896
increased	VERB	O	O	4896
expression	NOUN	O	O	4896
of	ADP	O	O	4896
key	NOUN	O	O	4896
genes	NOUN	O	O	4896
involved	VERB	O	O	4896
in	ADP	O	O	4896
hepatocyte	NOUN	O	O	4896
proliferation	NOUN	O	O	4896
at	ADP	O	O	4896
different	ADJ	O	O	4896
time	NOUN	O	O	4896
points	VERB	O	O	4896
during	ADP	O	O	4896
PB	PROPN	O	Chemical	4896
administration	NOUN	O	O	4896
.	PUNCT	O	O	4896
Lack	NOUN	O	O	4897
of	ADP	O	O	4897
ILK	X	O	O	4897
in	ADP	O	O	4897
the	PRON	O	O	4897
hepatocytes	VERB	O	O	4897
imparts	VERB	O	O	4897
prolonged	VERB	O	O	4897
proliferative	ADJ	O	O	4897
response	NOUN	O	O	4897
not	PART	O	O	4897
only	ADV	O	O	4897
to	PART	O	O	4897
stimuli	NOUN	O	O	4897
related	ADJ	O	O	4897
to	PART	O	O	4897
liver	NOUN	O	O	4897
regeneration	NOUN	O	O	4897
but	CCONJ	O	O	4897
also	ADV	O	O	4897
to	PART	O	O	4897
xenobiotic	PROPN	O	O	4897
chemical	PROPN	O	O	4897
mitogens	NOUN	O	O	4897
,	PUNCT	O	O	4897
such	ADJ	O	O	4897
as	ADP	O	O	4897
PB	PROPN	O	Chemical	4897
.	PUNCT	O	O	4897
Decreased	VERB	O	O	4900
Expression	NOUN	O	O	4900
of	ADP	O	O	4900
Na	INTJ	O	Chemical	4900
/	PUNCT	O	O	4900
K	PROPN	O	Chemical	4900
-	PUNCT	O	O	4900
ATPase	X	O	O	4900
,	PUNCT	O	O	4900
NHE3	PROPN	O	O	4900
,	PUNCT	O	O	4900
NBC1	NOUN	O	O	4900
,	PUNCT	O	O	4900
AQP1	PROPN	O	O	4900
and	CCONJ	O	O	4900
OAT	PROPN	O	O	4900
in	ADP	O	O	4900
Gentamicin	PROPN	O	Chemical	4900
-	PUNCT	O	O	4900
induced	VERB	O	O	4900
Nephropathy	PROPN	O	Disease	4900
.	PUNCT	O	O	4900
The	PRON	O	O	4901
present	NOUN	O	O	4901
study	VERB	O	O	4901
was	AUX	O	O	4901
aimed	VERB	O	O	4901
to	PART	O	O	4901
determine	VERB	O	O	4901
whether	SCONJ	O	O	4901
there	ADV	O	O	4901
is	AUX	O	O	4901
an	PRON	O	O	4901
altered	VERB	O	O	4901
regulation	NOUN	O	O	4901
of	ADP	O	O	4901
tubular	ADJ	O	O	4901
transporters	NOUN	O	O	4901
in	ADP	O	O	4901
gentamicin	VERB	O	Chemical	4901
-	PUNCT	O	O	4901
induced	VERB	O	O	4901
nephropathy	NOUN	O	Disease	4901
.	PUNCT	O	O	4901
Sprague	PROPN	O	O	4902
-	PUNCT	O	O	4902
Dawley	NOUN	O	O	4902
male	NOUN	O	O	4902
rats	NOUN	O	O	4902
(	PUNCT	O	O	4902
200~250	NOUN	O	O	4902
g	X	O	O	4902
)	PUNCT	O	O	4902
were	AUX	O	O	4902
subcutaneously	ADV	O	O	4902
injected	VERB	O	O	4902
with	ADP	O	O	4902
gentamicin	VERB	O	Chemical	4902
(	PUNCT	O	O	4902
100	NUM	O	O	4902
mg	VERB	O	O	4902
/	PUNCT	O	O	4902
kg	VERB	O	O	4902
per	ADP	O	O	4902
day	NOUN	O	O	4902
)	PUNCT	O	O	4902
for	ADP	O	O	4902
7	NUM	O	O	4902
days	NOUN	O	O	4902
,	PUNCT	O	O	4902
and	CCONJ	O	O	4902
the	PRON	O	O	4902
expression	NOUN	O	O	4902
of	ADP	O	O	4902
tubular	ADJ	O	O	4902
transporters	NOUN	O	O	4902
was	AUX	O	O	4902
determined	VERB	O	O	4902
by	ADP	O	O	4902
immunoblotting	VERB	O	O	4902
and	CCONJ	O	O	4902
immunohistochemistry	NOUN	O	O	4902
.	PUNCT	O	O	4902
Gentamicin	PROPN	O	Chemical	4903
-	PUNCT	O	O	4903
treated	VERB	O	O	4903
rats	NOUN	O	O	4903
exhibited	VERB	O	O	4903
significantly	ADV	O	O	4903
decreased	VERB	O	O	4903
creatinine	PROPN	O	Chemical	4903
clearance	NOUN	O	O	4903
along	ADV	O	O	4903
with	ADP	O	O	4903
increased	VERB	O	O	4903
plasma	NOUN	O	O	4903
creatinine	PROPN	O	Chemical	4903
levels	NOUN	O	O	4903
.	PUNCT	O	O	4903
Accordingly	ADV	O	O	4904
,	PUNCT	O	O	4904
the	PRON	O	O	4904
fractional	ADJ	O	O	4904
excretion	NOUN	O	O	4904
of	ADP	O	O	4904
sodium	NOUN	O	Chemical	4904
increased	VERB	O	O	4904
.	PUNCT	O	O	4904
Immunoblotting	VERB	O	O	4905
and	CCONJ	O	O	4905
immunohistochemistry	NOUN	O	O	4905
revealed	VERB	O	O	4905
decreased	VERB	O	O	4905
expression	NOUN	O	O	4905
of	ADP	O	O	4905
Na(+)/K(+)-ATPase	VERB	O	O	4905
,	PUNCT	O	O	4905
NHE3	PROPN	O	O	4905
,	PUNCT	O	O	4905
NBC1	NOUN	O	O	4905
,	PUNCT	O	O	4905
and	CCONJ	O	O	4905
AQP1	PROPN	O	O	4905
in	ADP	O	O	4905
the	PRON	O	O	4905
kidney	NOUN	O	O	4905
of	ADP	O	O	4905
gentamicin	VERB	O	Chemical	4905
-	PUNCT	O	O	4905
treated	VERB	O	O	4905
rats	NOUN	O	O	4905
.	PUNCT	O	O	4905
Gentamicin	PROPN	O	Chemical	4906
-	PUNCT	O	O	4906
induced	VERB	O	O	4906
nephropathy	NOUN	O	Disease	4906
may	AUX	O	O	4906
at	ADP	O	O	4906
least	ADJ	O	O	4906
in	ADP	O	O	4906
part	NOUN	O	O	4906
be	AUX	O	O	4906
causally	ADV	O	O	4906
related	ADJ	O	O	4906
with	ADP	O	O	4906
a	PRON	O	O	4906
decreased	VERB	O	O	4906
expression	NOUN	O	O	4906
of	ADP	O	O	4906
Na(+)/K(+)-ATPase	VERB	O	O	4906
,	PUNCT	O	O	4906
NHE3	PROPN	O	O	4906
,	PUNCT	O	O	4906
NBC1	NOUN	O	O	4906
,	PUNCT	O	O	4906
AQP1	PROPN	O	O	4906
and	CCONJ	O	O	4906
OAT	PROPN	O	O	4906
.	PUNCT	O	O	4906
Longitudinal	PROPN	O	O	4909
association	PROPN	O	O	4909
of	ADP	O	O	4909
alcohol	NOUN	O	Chemical	4909
use	VERB	O	O	4909
with	ADP	O	O	4909
HIV disease	NOUN	O	Disease	4909
progression	NOUN	O	O	4909
and	CCONJ	O	O	4909
psychological	ADJ	O	O	4909
health	NOUN	O	O	4909
of	ADP	O	O	4909
women	NOUN	O	O	4909
with	ADP	O	O	4909
HIV	PROPN	O	O	4909
.	PUNCT	O	O	4909
We	PRON	O	O	4910
evaluated	VERB	O	O	4910
the	PRON	O	O	4910
association	PROPN	O	O	4910
of	ADP	O	O	4910
alcohol	NOUN	O	Chemical	4910
consumption	NOUN	O	O	4910
and	CCONJ	O	O	4910
depression	PROPN	O	Disease	4910
,	PUNCT	O	O	4910
and	CCONJ	O	O	4910
their	PRON	O	O	4910
effects	NOUN	O	O	4910
on	ADP	O	O	4910
HIV disease	NOUN	O	Disease	4910
progression	NOUN	O	O	4910
among	ADP	O	O	4910
women	NOUN	O	O	4910
with	ADP	O	O	4910
HIV	PROPN	O	O	4910
.	PUNCT	O	O	4910
The	PRON	O	O	4911
participants	NOUN	O	O	4911
had	VERB	O	O	4911
physical	ADJ	O	O	4911
examination	NOUN	O	O	4911
,	PUNCT	O	O	4911
medical	ADJ	O	O	4911
record	NOUN	O	O	4911
extraction	NOUN	O	O	4911
,	PUNCT	O	O	4911
and	CCONJ	O	O	4911
venipuncture	NOUN	O	O	4911
,	PUNCT	O	O	4911
CD4+T	NUM	O	O	4911
-	PUNCT	O	O	4911
cell	NOUN	O	O	4911
counts	VERB	O	O	4911
determination	NOUN	O	O	4911
,	PUNCT	O	O	4911
measurement	NOUN	O	O	4911
of	ADP	O	O	4911
depression	PROPN	O	Disease	4911
symptoms	NOUN	O	O	4911
(	PUNCT	O	O	4911
using	VERB	O	O	4911
the	PRON	O	O	4911
self	VERB	O	O	4911
-	PUNCT	O	O	4911
report	VERB	O	O	4911
Center	NOUN	O	O	4911
for	ADP	O	O	4911
Epidemiological	ADJ	O	O	4911
Studies	NOUN	O	O	4911
-	PUNCT	O	O	4911
Depression	NOUN	O	O	4911
Scale	NOUN	O	O	4911
)	PUNCT	O	O	4911
,	PUNCT	O	O	4911
and	CCONJ	O	O	4911
alcohol	NOUN	O	Chemical	4911
use	VERB	O	O	4911
assessment	NOUN	O	O	4911
at	ADP	O	O	4911
enrollment	NOUN	O	O	4911
,	PUNCT	O	O	4911
and	CCONJ	O	O	4911
semiannually	ADV	O	O	4911
until	ADP	O	O	4911
March	PROPN	O	O	4911
2000	NUM	O	O	4911
.	PUNCT	O	O	4911
There	ADV	O	O	4912
was	AUX	O	O	4912
no	PRON	O	O	4912
significant	ADJ	O	O	4912
association	PROPN	O	O	4912
between	ADP	O	O	4912
level	VERB	O	O	4912
of	ADP	O	O	4912
alcohol	NOUN	O	Chemical	4912
use	VERB	O	O	4912
and	CCONJ	O	O	4912
CD4	PROPN	O	O	4912
+	ADP	O	O	4912
T	NOUN	O	Chemical	4912
-	PUNCT	O	O	4912
cell	NOUN	O	O	4912
counts	VERB	O	O	4912
.	PUNCT	O	O	4912
When	SCONJ	O	O	4913
participants	NOUN	O	O	4913
were	AUX	O	O	4913
stratified	ADJ	O	O	4913
by	ADP	O	O	4913
antiretroviral	ADJ	O	O	4913
therapy	NOUN	O	O	4913
(	PUNCT	O	O	4913
ART	NOUN	O	O	4913
)	PUNCT	O	O	4913
use	VERB	O	O	4913
,	PUNCT	O	O	4913
the	PRON	O	O	4913
association	PROPN	O	O	4913
between	ADP	O	O	4913
alcohol	NOUN	O	Chemical	4913
and	CCONJ	O	O	4913
CD4	PROPN	O	O	4913
+	ADP	O	O	4913
T	NOUN	O	Chemical	4913
-	PUNCT	O	O	4913
cell	NOUN	O	O	4913
did	VERB	O	O	4913
not	PART	O	O	4913
reach	VERB	O	O	4913
statistical	ADJ	O	O	4913
significance	NOUN	O	O	4913
.	PUNCT	O	O	4913
The	PRON	O	O	4914
association	PROPN	O	O	4914
between	ADP	O	O	4914
alcohol	NOUN	O	Chemical	4914
consumption	NOUN	O	O	4914
and	CCONJ	O	O	4914
depression	PROPN	O	Disease	4914
was	AUX	O	O	4914
significant	ADJ	O	O	4914
(	PUNCT	O	O	4914
p<0.001	ADJ	O	O	4914
)	PUNCT	O	O	4914
.	PUNCT	O	O	4914
Depression	NOUN	O	O	4915
had	VERB	O	O	4915
a	PRON	O	O	4915
significant	ADJ	O	O	4915
negative	ADJ	O	O	4915
effect	VERB	O	O	4915
on	ADP	O	O	4915
CD4	PROPN	O	O	4915
+	ADP	O	O	4915
T	NOUN	O	Chemical	4915
-	PUNCT	O	O	4915
cell	NOUN	O	O	4915
counts	VERB	O	O	4915
over	ADP	O	O	4915
time	NOUN	O	O	4915
regardless	ADV	O	O	4915
of	ADP	O	O	4915
ART	NOUN	O	O	4915
use	VERB	O	O	4915
.	PUNCT	O	O	4915
Our	PRON	O	O	4916
findings	NOUN	O	O	4916
suggest	VERB	O	O	4916
that	SCONJ	O	O	4916
alcohol	NOUN	O	Chemical	4916
consumption	NOUN	O	O	4916
has	VERB	O	O	4916
a	PRON	O	O	4916
direct	ADJ	O	O	4916
association	PROPN	O	O	4916
with	ADP	O	O	4916
depression	PROPN	O	Disease	4916
.	PUNCT	O	O	4916
Moreover	ADV	O	O	4917
,	PUNCT	O	O	4917
depression	PROPN	O	Disease	4917
is	AUX	O	O	4917
associated	VERB	O	O	4917
with	ADP	O	O	4917
HIV disease	NOUN	O	Disease	4917
progression	NOUN	O	O	4917
.	PUNCT	O	O	4917
Our	PRON	O	O	4918
findings	NOUN	O	O	4918
have	VERB	O	O	4918
implications	NOUN	O	O	4918
for	ADP	O	O	4918
the	PRON	O	O	4918
provision	NOUN	O	O	4918
of	ADP	O	O	4918
alcohol	NOUN	O	Chemical	4918
use	VERB	O	O	4918
interventions	NOUN	O	O	4918
and	CCONJ	O	O	4918
psychological	ADJ	O	O	4918
resources	NOUN	O	O	4918
to	PART	O	O	4918
improve	VERB	O	O	4918
the	PRON	O	O	4918
health	NOUN	O	O	4918
of	ADP	O	O	4918
women	NOUN	O	O	4918
with	ADP	O	O	4918
HIV	PROPN	O	O	4918
.	PUNCT	O	O	4918
Chemokine	PROPN	O	O	4921
CCL2	NOUN	O	O	4921
and	CCONJ	O	O	4921
its	PRON	O	O	4921
receptor	NOUN	O	O	4921
CCR2	PROPN	O	O	4921
are	AUX	O	O	4921
increased	VERB	O	O	4921
in	ADP	O	O	4921
the	PRON	O	O	4921
hippocampus	NOUN	O	O	4921
following	VERB	O	O	4921
pilocarpine	NOUN	O	Chemical	4921
-	PUNCT	O	O	4921
induced	VERB	O	O	4921
status epilepticus	VERB	O	Disease	4921
.	PUNCT	O	O	4921
Neuroinflammation	NOUN	O	O	4922
occurs	VERB	O	O	4922
after	ADP	O	O	4922
seizures	NOUN	O	Disease	4922
and	CCONJ	O	O	4922
is	AUX	O	O	4922
implicated	VERB	O	O	4922
in	ADP	O	O	4922
epileptogenesis	NOUN	O	O	4922
.	PUNCT	O	O	4922
CCR2	PROPN	O	O	4923
is	AUX	O	O	4923
a	PRON	O	O	4923
chemokine	NOUN	O	O	4923
receptor	NOUN	O	O	4923
for	ADP	O	O	4923
CCL2	NOUN	O	O	4923
and	CCONJ	O	O	4923
their	PRON	O	O	4923
interaction	NOUN	O	O	4923
mediates	VERB	O	O	4923
monocyte	PROPN	O	O	4923
infiltration	NOUN	O	O	4923
in	ADP	O	O	4923
the	PRON	O	O	4923
neuroinflammatory	NOUN	O	O	4923
cascade	NOUN	O	O	4923
triggered	VERB	O	O	4923
in	ADP	O	O	4923
different	ADJ	O	O	4923
brain	NOUN	O	O	4923
pathologies	NOUN	O	O	4923
.	PUNCT	O	O	4923
In	ADP	O	O	4924
this	PRON	O	O	4924
work	NOUN	O	O	4924
CCR2	PROPN	O	O	4924
and	CCONJ	O	O	4924
CCL2	NOUN	O	O	4924
expression	NOUN	O	O	4924
were	AUX	O	O	4924
examined	VERB	O	O	4924
following	VERB	O	O	4924
status epilepticus	VERB	O	Disease	4924
(	PUNCT	O	O	4924
SE	PROPN	O	O	4924
)	PUNCT	O	O	4924
induced	VERB	O	O	4924
by	ADP	O	O	4924
pilocarpine	NOUN	O	Chemical	4924
injection	NOUN	O	O	4924
.	PUNCT	O	O	4924
METHODS	NOUN	O	O	4925
:	PUNCT	O	O	4925
SE	PROPN	O	O	4925
was	AUX	O	O	4925
induced	VERB	O	O	4925
by	ADP	O	O	4925
pilocarpine	NOUN	O	Chemical	4925
injection	NOUN	O	O	4925
.	PUNCT	O	O	4925
Control	NOUN	O	O	4926
rats	NOUN	O	O	4926
were	AUX	O	O	4926
injected	VERB	O	O	4926
with	ADP	O	O	4926
saline	NOUN	O	O	4926
instead	ADV	O	O	4926
of	ADP	O	O	4926
pilocarpine	NOUN	O	Chemical	4926
.	PUNCT	O	O	4926
Five	NUM	O	O	4927
days	NOUN	O	O	4927
after	ADP	O	O	4927
SE	PROPN	O	O	4927
,	PUNCT	O	O	4927
CCR2	PROPN	O	O	4927
staining	VERB	O	O	4927
in	ADP	O	O	4927
neurons	NOUN	O	O	4927
and	CCONJ	O	O	4927
glial	ADJ	O	O	4927
cells	NOUN	O	O	4927
was	AUX	O	O	4927
examined	VERB	O	O	4927
using	VERB	O	O	4927
imunohistochemical	PROPN	O	O	4927
analyses	NOUN	O	O	4927
.	PUNCT	O	O	4927
Increased	VERB	O	O	4928
CCR2	PROPN	O	O	4928
was	AUX	O	O	4928
observed	VERB	O	O	4928
in	ADP	O	O	4928
the	PRON	O	O	4928
hippocampus	NOUN	O	O	4928
after	ADP	O	O	4928
SE	PROPN	O	O	4928
.	PUNCT	O	O	4928
Seizures	NOUN	O	Disease	4929
also	ADV	O	O	4929
resulted	VERB	O	O	4929
in	ADP	O	O	4929
alterations	NOUN	O	O	4929
to	PART	O	O	4929
the	PRON	O	O	4929
cell	NOUN	O	O	4929
types	NOUN	O	O	4929
expressing	VERB	O	O	4929
CCR2	PROPN	O	O	4929
.	PUNCT	O	O	4929
Increased	VERB	O	O	4930
numbers	NOUN	O	O	4930
of	ADP	O	O	4930
neurons	NOUN	O	O	4930
that	SCONJ	O	O	4930
expressed	VERB	O	O	4930
CCR2	PROPN	O	O	4930
was	AUX	O	O	4930
observed	VERB	O	O	4930
following	VERB	O	O	4930
SE	PROPN	O	O	4930
.	PUNCT	O	O	4930
Microglial	PROPN	O	O	4931
cells	NOUN	O	O	4931
were	AUX	O	O	4931
more	ADJ	O	O	4931
closely	ADV	O	O	4931
apposed	VERB	O	O	4931
to	PART	O	O	4931
the	PRON	O	O	4931
CCR2-labeled	VERB	O	O	4931
cells	NOUN	O	O	4931
in	ADP	O	O	4931
SE	PROPN	O	O	4931
rats	NOUN	O	O	4931
.	PUNCT	O	O	4931
In	ADP	O	O	4932
addition	NOUN	O	O	4932
,	PUNCT	O	O	4932
rats	NOUN	O	O	4932
that	SCONJ	O	O	4932
experienced	ADJ	O	O	4932
SE	PROPN	O	O	4932
exhibited	VERB	O	O	4932
CCR2-labeling	NOUN	O	O	4932
in	ADP	O	O	4932
populations	NOUN	O	O	4932
of	ADP	O	O	4932
hypertrophied	ADJ	O	O	4932
astrocytes	VERB	O	O	4932
,	PUNCT	O	O	4932
especially	ADV	O	O	4932
in	ADP	O	O	4932
CA1	PROPN	O	O	4932
and	CCONJ	O	O	4932
dentate	ADJ	O	O	4932
gyrus	PROPN	O	O	4932
.	PUNCT	O	O	4932
Examination	NOUN	O	O	4933
of	ADP	O	O	4933
CCL2	NOUN	O	O	4933
expression	NOUN	O	O	4933
showed	VERB	O	O	4933
that	SCONJ	O	O	4933
it	PRON	O	O	4933
was	AUX	O	O	4933
elevated	ADJ	O	O	4933
in	ADP	O	O	4933
the	PRON	O	O	4933
hippocampus	NOUN	O	O	4933
following	VERB	O	O	4933
SE	PROPN	O	O	4933
.	PUNCT	O	O	4933
CONCLUSION	PROPN	O	O	4934
:	PUNCT	O	O	4934
The	PRON	O	O	4934
data	NOUN	O	O	4934
show	VERB	O	O	4934
that	SCONJ	O	O	4934
CCR2	PROPN	O	O	4934
and	CCONJ	O	O	4934
CCL2	NOUN	O	O	4934
are	AUX	O	O	4934
up	ADP	O	O	4934
-	PUNCT	O	O	4934
regulated	VERB	O	O	4934
in	ADP	O	O	4934
the	PRON	O	O	4934
hippocampus	NOUN	O	O	4934
after	ADP	O	O	4934
pilocarpine	NOUN	O	Chemical	4934
-	PUNCT	O	O	4934
induced	VERB	O	O	4934
SE	PROPN	O	O	4934
.	PUNCT	O	O	4934
Seizures	NOUN	O	Disease	4935
also	ADV	O	O	4935
result	VERB	O	O	4935
in	ADP	O	O	4935
changes	VERB	O	O	4935
to	PART	O	O	4935
CCR2	PROPN	O	O	4935
receptor	NOUN	O	O	4935
expression	NOUN	O	O	4935
in	ADP	O	O	4935
neurons	NOUN	O	O	4935
and	CCONJ	O	O	4935
astrocytes	VERB	O	O	4935
.	PUNCT	O	O	4935
These	PRON	O	O	4936
changes	VERB	O	O	4936
might	AUX	O	O	4936
be	AUX	O	O	4936
involved	VERB	O	O	4936
in	ADP	O	O	4936
detrimental	ADJ	O	O	4936
neuroplasticity	NOUN	O	O	4936
and	CCONJ	O	O	4936
neuroinflammatory	NOUN	O	O	4936
changes	VERB	O	O	4936
that	SCONJ	O	O	4936
occur	VERB	O	O	4936
following	VERB	O	O	4936
seizures	NOUN	O	Disease	4936
.	PUNCT	O	O	4936
Metallothionein	PROPN	O	O	4939
induction	NOUN	O	O	4939
reduces	VERB	O	O	4939
caspase-3	NUM	O	O	4939
activity	NOUN	O	O	4939
and	CCONJ	O	O	4939
TNFalpha	NOUN	O	O	4939
levels	NOUN	O	O	4939
with	ADP	O	O	4939
preservation	NOUN	O	O	4939
of	ADP	O	O	4939
cognitive	ADJ	O	O	4939
function	NOUN	O	O	4939
and	CCONJ	O	O	4939
intact	ADJ	O	O	4939
hippocampal	NOUN	O	O	4939
neurons	NOUN	O	O	4939
in	ADP	O	O	4939
carmustine	NOUN	O	O	4939
-	PUNCT	O	O	4939
treated	VERB	O	O	4939
rats	NOUN	O	O	4939
.	PUNCT	O	O	4939
On	ADP	O	O	4940
the	PRON	O	O	4940
other	ADJ	O	O	4940
hand	NOUN	O	O	4940
,	PUNCT	O	O	4940
induction	NOUN	O	O	4940
of	ADP	O	O	4940
metallothionein	ADJ	O	O	4940
(	PUNCT	O	O	4940
MT	PROPN	O	O	4940
)	PUNCT	O	O	4940
by	ADP	O	O	4940
ZnSO(4	NOUN	O	O	4940
)	PUNCT	O	O	4940
and	CCONJ	O	O	4940
its	PRON	O	O	4940
role	NOUN	O	O	4940
in	ADP	O	O	4940
neuroprotection	NOUN	O	O	4940
has	VERB	O	O	4940
been	AUX	O	O	4940
documented	VERB	O	O	4940
.	PUNCT	O	O	4940
The	PRON	O	O	4941
present	NOUN	O	O	4941
study	VERB	O	O	4941
aimed	VERB	O	O	4941
to	PART	O	O	4941
explore	VERB	O	O	4941
the	PRON	O	O	4941
effect	VERB	O	O	4941
of	ADP	O	O	4941
MT	PROPN	O	O	4941
induction	NOUN	O	O	4941
on	ADP	O	O	4941
carmustine	NOUN	O	O	4941
(	PUNCT	O	O	4941
BCNU)-induced	VERB	O	O	4941
hippocampal	NOUN	O	O	4941
cognitive dysfunction	NOUN	O	Disease	4941
in	ADP	O	O	4941
rats	NOUN	O	O	4941
.	PUNCT	O	O	4941
A	PRON	O	O	4942
total	ADJ	O	O	4942
of	ADP	O	O	4942
60	NUM	O	O	4942
male	NOUN	O	O	4942
Wistar	PROPN	O	O	4942
albino	PROPN	O	O	4942
rats	NOUN	O	O	4942
were	AUX	O	O	4942
randomly	ADV	O	O	4942
divided	VERB	O	O	4942
into	ADP	O	O	4942
four	NUM	O	O	4942
groups	NOUN	O	O	4942
(	PUNCT	O	O	4942
15/group	NOUN	O	O	4942
)	PUNCT	O	O	4942
:	PUNCT	O	O	4942
The	PRON	O	O	4942
control	VERB	O	O	4942
group	NOUN	O	O	4942
injected	VERB	O	O	4942
with	ADP	O	O	4942
single	ADJ	O	O	4942
doses	NOUN	O	O	4942
of	ADP	O	O	4942
normal	ADJ	O	O	4942
saline	NOUN	O	O	4942
(	PUNCT	O	O	4942
i.c.v	NOUN	O	O	4942
)	PUNCT	O	O	4942
followed	VERB	O	O	4942
24	NUM	O	O	4942
h	X	O	O	4942
later	ADV	O	O	4942
by	ADP	O	O	4942
BCNU	PROPN	O	O	4942
solvent	NOUN	O	O	4942
(	PUNCT	O	O	4942
i.v	NOUN	O	O	4942
)	PUNCT	O	O	4942
.	PUNCT	O	O	4942
The	PRON	O	O	4943
second	ADV	O	O	4943
group	NOUN	O	O	4943
administered	VERB	O	O	4943
ZnSO(4	NOUN	O	O	4943
)	PUNCT	O	O	4943
(	PUNCT	O	O	4943
0.1	NUM	O	O	4943
micromol/10	ADV	O	O	4943
microl	NOUN	O	O	4943
normal	ADJ	O	O	4943
saline	NOUN	O	O	4943
,	PUNCT	O	O	4943
i.c.v	NOUN	O	O	4943
,	PUNCT	O	O	4943
once	ADV	O	O	4943
)	PUNCT	O	O	4943
then	ADV	O	O	4944
BCNU	PROPN	O	O	4944
solvent	NOUN	O	O	4944
(	PUNCT	O	O	4944
i.v	NOUN	O	O	4944
)	PUNCT	O	O	4944
after	ADP	O	O	4944
24	NUM	O	O	4944
h.	PROPN	O	O	4944
Third	ADJ	O	O	4944
group	NOUN	O	O	4944
received	VERB	O	O	4944
BCNU	PROPN	O	O	4944
(	PUNCT	O	O	4944
20	NUM	O	O	4944
mg	VERB	O	O	4944
/	PUNCT	O	O	4944
kg	VERB	O	O	4944
,	PUNCT	O	O	4944
i.v	NOUN	O	O	4944
,	PUNCT	O	O	4944
once	ADV	O	O	4944
)	PUNCT	O	O	4944
Fourth	ADJ	O	O	4945
group	NOUN	O	O	4945
received	VERB	O	O	4945
a	PRON	O	O	4945
single	ADJ	O	O	4945
dose	NOUN	O	O	4945
of	ADP	O	O	4945
ZnSO(4	NOUN	O	O	4945
)	PUNCT	O	O	4945
(	PUNCT	O	O	4945
0.1	NUM	O	O	4945
micromol/10	ADV	O	O	4945
microl	NOUN	O	O	4945
normal	ADJ	O	O	4945
saline	NOUN	O	O	4945
,	PUNCT	O	O	4945
i.c.v	NOUN	O	O	4945
)	PUNCT	O	O	4945
then	ADV	O	O	4945
BCNU	PROPN	O	O	4945
(	PUNCT	O	O	4945
20	NUM	O	O	4945
mg	VERB	O	O	4945
/	PUNCT	O	O	4945
kg	VERB	O	O	4945
,	PUNCT	O	O	4945
i.v	NOUN	O	O	4945
,	PUNCT	O	O	4945
once	ADV	O	O	4945
)	PUNCT	O	O	4945
after	ADP	O	O	4945
24	NUM	O	O	4945
h.	PROPN	O	O	4945
The	PRON	O	O	4945
obtained	VERB	O	O	4945
data	NOUN	O	O	4945
revealed	VERB	O	O	4945
that	SCONJ	O	O	4945
BCNU	PROPN	O	O	4945
administration	NOUN	O	O	4945
resulted	VERB	O	O	4945
in	ADP	O	O	4945
deterioration	NOUN	O	O	4945
of	ADP	O	O	4945
learning	VERB	O	O	4945
and	CCONJ	O	O	4945
short	ADJ	O	O	4945
-	PUNCT	O	O	4945
term	NOUN	O	O	4945
memory	NOUN	O	O	4945
(	PUNCT	O	O	4945
STM	PROPN	O	O	4945
)	PUNCT	O	O	4945
,	PUNCT	O	O	4945
as	ADP	O	O	4945
measured	VERB	O	O	4945
by	ADP	O	O	4945
using	VERB	O	O	4945
radial	ADJ	O	O	4945
arm	VERB	O	O	4945
water	PROPN	O	O	4945
maze	NOUN	O	O	4945
,	PUNCT	O	O	4945
accompanied	VERB	O	O	4945
with	ADP	O	O	4945
decreased	VERB	O	O	4945
hippocampal	NOUN	O	O	4945
glutathione	NOUN	O	Chemical	4945
reductase	NOUN	O	O	4945
(	PUNCT	O	O	4945
GR	PROPN	O	O	4945
)	PUNCT	O	O	4945
activity	NOUN	O	O	4945
and	CCONJ	O	O	4945
reduced glutathione	NOUN	O	Chemical	4945
(	PUNCT	O	O	4945
GSH	PROPN	O	O	4945
)	PUNCT	O	O	4945
content	NOUN	O	O	4945
.	PUNCT	O	O	4945
Also	ADV	O	O	4946
,	PUNCT	O	O	4946
BCNU	PROPN	O	O	4946
administration	NOUN	O	O	4946
increased	VERB	O	O	4946
serum	NOUN	O	O	4946
tumor	NOUN	O	Disease	4946
necrosis	NOUN	O	Disease	4946
factor	NOUN	O	O	4946
-	PUNCT	O	O	4946
alpha	PROPN	O	O	4946
(	PUNCT	O	O	4946
TNFalpha	NOUN	O	O	4946
)	PUNCT	O	O	4946
,	PUNCT	O	O	4946
hippocampal	NOUN	O	O	4946
MT	PROPN	O	O	4946
and	CCONJ	O	O	4946
malondialdehyde	PROPN	O	Chemical	4946
(	PUNCT	O	O	4946
MDA	PROPN	O	Chemical	4946
)	PUNCT	O	O	4946
contents	NOUN	O	O	4946
as	ADP	O	O	4946
well	ADV	O	O	4946
as	ADP	O	O	4946
caspase-3	NUM	O	O	4946
activity	NOUN	O	O	4946
in	ADP	O	O	4946
addition	NOUN	O	O	4946
to	PART	O	O	4946
histological	ADJ	O	O	4946
alterations	NOUN	O	O	4946
.	PUNCT	O	O	4946
ZnSO(4	NOUN	O	O	4947
)	PUNCT	O	O	4947
pretreatment	NOUN	O	O	4947
counteracted	VERB	O	O	4947
BCNU	PROPN	O	O	4947
-	PUNCT	O	O	4947
induced	VERB	O	O	4947
inhibition	NOUN	O	O	4947
of	ADP	O	O	4947
GR	PROPN	O	O	4947
and	CCONJ	O	O	4947
depletion	NOUN	O	O	4947
of	ADP	O	O	4947
GSH	PROPN	O	O	4947
and	CCONJ	O	O	4947
resulted	VERB	O	O	4947
in	ADP	O	O	4947
significant	ADJ	O	O	4947
reduction	NOUN	O	O	4947
in	ADP	O	O	4947
the	PRON	O	O	4947
levels	NOUN	O	O	4947
of	ADP	O	O	4947
MDA	PROPN	O	Chemical	4947
and	CCONJ	O	O	4947
TNFalpha	NOUN	O	O	4947
as	ADP	O	O	4947
well	ADV	O	O	4947
as	ADP	O	O	4947
the	PRON	O	O	4947
activity	NOUN	O	O	4947
of	ADP	O	O	4947
caspase-3	NUM	O	O	4947
.	PUNCT	O	O	4947
The	PRON	O	O	4948
histological	ADJ	O	O	4948
features	VERB	O	O	4948
were	AUX	O	O	4948
improved	VERB	O	O	4948
in	ADP	O	O	4948
hippocampus	NOUN	O	O	4948
of	ADP	O	O	4948
rats	NOUN	O	O	4948
treated	VERB	O	O	4948
with	ADP	O	O	4948
ZnSO(4	NOUN	O	O	4948
)	PUNCT	O	O	4948
+	ADP	O	O	4949
BCNU	PROPN	O	O	4949
compared	VERB	O	O	4949
to	PART	O	O	4949
only	ADV	O	O	4949
BCNU	PROPN	O	O	4949
-	PUNCT	O	O	4949
treated	VERB	O	O	4949
animals	NOUN	O	O	4949
.	PUNCT	O	O	4949
In	ADP	O	O	4950
conclusion	NOUN	O	O	4950
,	PUNCT	O	O	4950
MT	PROPN	O	O	4950
induction	NOUN	O	O	4950
halts	VERB	O	O	4950
BCNU	PROPN	O	O	4950
-	PUNCT	O	O	4950
induced	VERB	O	O	4950
hippocampal	NOUN	O	O	4950
toxicity	NOUN	O	Disease	4950
as	ADP	O	O	4950
it	PRON	O	O	4950
prevented	VERB	O	O	4950
GR	PROPN	O	O	4950
inhibition	NOUN	O	O	4950
and	CCONJ	O	O	4950
GSH	PROPN	O	O	4950
depletion	NOUN	O	O	4950
and	CCONJ	O	O	4950
counteracted	VERB	O	O	4950
the	PRON	O	O	4950
increased	VERB	O	O	4950
levels	NOUN	O	O	4950
of	ADP	O	O	4950
TNFalpha	NOUN	O	O	4950
,	PUNCT	O	O	4950
MDA	PROPN	O	Chemical	4950
and	CCONJ	O	O	4950
caspase-3	NUM	O	O	4950
activity	NOUN	O	O	4950
with	ADP	O	O	4950
subsequent	ADJ	O	O	4950
preservation	NOUN	O	O	4950
of	ADP	O	O	4950
cognition	NOUN	O	O	4950
.	PUNCT	O	O	4950
Fatal	ADJ	O	O	4953
carbamazepine	NOUN	O	Chemical	4953
induced	VERB	O	O	4953
fulminant	ADJ	O	O	4953
eosinophilic	ADJ	O	Disease	4953
(	PUNCT	O	O	4953
hypersensitivity	NOUN	O	Disease	4953
)	PUNCT	O	O	4953
myocarditis	ADV	O	Disease	4954
:	PUNCT	O	O	4954
emphasis	NOUN	O	O	4954
on	ADP	O	O	4954
anatomical	ADJ	O	O	4954
and	CCONJ	O	O	4954
histological	ADJ	O	O	4954
characteristics	NOUN	O	O	4954
,	PUNCT	O	O	4954
mechanisms	NOUN	O	O	4954
and	CCONJ	O	O	4954
genetics	NOUN	O	O	4954
of	ADP	O	O	4954
drug	NOUN	O	O	4954
hypersensitivity	NOUN	O	Disease	4954
and	CCONJ	O	O	4954
differential	ADJ	O	O	4954
diagnosis	NOUN	O	O	4954
.	PUNCT	O	O	4954
The	PRON	O	O	4955
most	ADV	O	O	4955
severe	ADJ	O	O	4955
adverse	ADJ	O	O	4955
reactions	NOUN	O	O	4955
to	PART	O	O	4955
carbamazepine	NOUN	O	Chemical	4955
have	VERB	O	O	4955
been	AUX	O	O	4955
observed	VERB	O	O	4955
in	ADP	O	O	4955
the	PRON	O	O	4955
haemopoietic	ADJ	O	O	4955
system	NOUN	O	O	4955
,	PUNCT	O	O	4955
the	PRON	O	O	4955
liver	NOUN	O	O	4955
and	CCONJ	O	O	4955
the	PRON	O	O	4955
cardiovascular	ADJ	O	O	4955
system	NOUN	O	O	4955
.	PUNCT	O	O	4955
A	PRON	O	O	4956
frequently	ADV	O	O	4956
fatal	ADJ	O	O	4956
,	PUNCT	O	O	4956
although	SCONJ	O	O	4956
exceptionally	ADV	O	O	4956
rare	ADJ	O	O	4956
side	NOUN	O	O	4956
effect	VERB	O	O	4956
of	ADP	O	O	4956
carbamazepine	NOUN	O	Chemical	4956
is	AUX	O	O	4956
necrotizing	VERB	O	Disease	4956
eosinophilic	ADJ	O	Disease	4956
(	PUNCT	O	O	4956
hypersensitivity	NOUN	O	Disease	4956
)	PUNCT	O	O	4956
myocarditis	ADV	O	Disease	4957
.	PUNCT	O	O	4957
We	PRON	O	O	4958
report	VERB	O	O	4958
a	PRON	O	O	4958
case	NOUN	O	O	4958
of	ADP	O	O	4958
hypersensitivity	NOUN	O	Disease	4958
myocarditis	ADV	O	Disease	4958
secondary	ADJ	O	O	4958
to	PART	O	O	4958
administration	NOUN	O	O	4958
of	ADP	O	O	4958
carbamazepine	NOUN	O	Chemical	4958
.	PUNCT	O	O	4958
Acute	PROPN	O	O	4959
hypersensitivity	NOUN	O	Disease	4959
myocarditis	ADV	O	Disease	4959
was	AUX	O	O	4959
not	PART	O	O	4959
suspected	VERB	O	O	4959
clinically	ADV	O	O	4959
,	PUNCT	O	O	4959
and	CCONJ	O	O	4959
the	PRON	O	O	4959
diagnosis	NOUN	O	O	4959
was	AUX	O	O	4959
made	VERB	O	O	4959
post	VERB	O	O	4959
-	PUNCT	O	O	4959
mortem	PROPN	O	O	4959
.	PUNCT	O	O	4959
Clinically	ADV	O	O	4960
,	PUNCT	O	O	4960
death	NOUN	O	O	4960
was	AUX	O	O	4960
due	ADJ	O	O	4960
to	PART	O	O	4960
cardiogenic shock	NOUN	O	Disease	4960
.	PUNCT	O	O	4960
To	PART	O	O	4961
best	ADV	O	O	4961
of	ADP	O	O	4961
our	PRON	O	O	4961
knowledge	NOUN	O	O	4961
this	PRON	O	O	4961
is	AUX	O	O	4961
the	PRON	O	O	4961
second	ADV	O	O	4961
case	NOUN	O	O	4961
of	ADP	O	O	4961
fatal	ADJ	O	O	4961
carbamazepine	NOUN	O	Chemical	4961
induced	VERB	O	O	4961
myocarditis	ADV	O	Disease	4961
reported	VERB	O	O	4961
in	ADP	O	O	4961
English	PROPN	O	O	4961
literature	NOUN	O	O	4961
.	PUNCT	O	O	4961
Neuropsychiatric	ADJ	O	O	4964
behaviors	NOUN	O	O	4964
in	ADP	O	O	4964
the	PRON	O	O	4964
MPTP	PROPN	O	Chemical	4964
marmoset	NOUN	O	O	4964
model	NOUN	O	O	4964
of	ADP	O	O	4964
Parkinson	NOUN	O	O	4964
's	AUX	O	O	4964
disease	PROPN	O	O	4964
.	PUNCT	O	O	4964
Neuropsychiatric	ADJ	O	O	4965
symptoms	NOUN	O	O	4965
are	AUX	O	O	4965
increasingly	ADV	O	O	4965
recognised	VERB	O	O	4965
as	ADP	O	O	4965
a	PRON	O	O	4965
significant	ADJ	O	O	4965
problem	NOUN	O	O	4965
in	ADP	O	O	4965
patients	NOUN	O	O	4965
with	ADP	O	O	4965
Parkinson	NOUN	O	O	4965
's	AUX	O	O	4965
disease	PROPN	O	O	4965
(	PUNCT	O	O	4965
PD	PROPN	O	Disease	4965
)	PUNCT	O	O	4965
.	PUNCT	O	O	4965
These	PRON	O	O	4966
symptoms	NOUN	O	O	4966
may	AUX	O	O	4966
be	AUX	O	O	4966
due	ADJ	O	O	4966
to	PART	O	O	4966
'	PUNCT	O	O	4966
sensitisation	NOUN	O	O	4966
'	PUNCT	O	O	4966
following	VERB	O	O	4966
repeated	VERB	O	O	4966
levodopa	NOUN	O	Chemical	4966
treatment	NOUN	O	O	4966
or	CCONJ	O	O	4966
a	PRON	O	O	4966
direct	ADJ	O	O	4966
effect	VERB	O	O	4966
of	ADP	O	O	4966
dopamine	NOUN	O	Chemical	4966
on	ADP	O	O	4966
the	PRON	O	O	4966
disease	PROPN	O	O	4966
state	NOUN	O	O	4966
.	PUNCT	O	O	4966
The	PRON	O	O	4967
levodopa	NOUN	O	Chemical	4967
-	PUNCT	O	O	4967
treated	VERB	O	O	4967
MPTP	PROPN	O	Chemical	4967
-	PUNCT	O	O	4967
lesioned	VERB	O	O	4967
marmoset	NOUN	O	O	4967
was	AUX	O	O	4967
used	VERB	O	O	4967
as	ADP	O	O	4967
a	PRON	O	O	4967
model	NOUN	O	O	4967
of	ADP	O	O	4967
neuropsychiatric	ADJ	O	O	4967
symptoms	NOUN	O	O	4967
in	ADP	O	O	4967
PD	PROPN	O	Disease	4967
patients	NOUN	O	O	4967
.	PUNCT	O	O	4967
Here	ADV	O	O	4968
we	PRON	O	O	4968
compare	VERB	O	O	4968
the	PRON	O	O	4968
time	NOUN	O	O	4968
course	NOUN	O	O	4968
of	ADP	O	O	4968
levodopa	NOUN	O	Chemical	4968
-	PUNCT	O	O	4968
induced	VERB	O	O	4968
motor	NOUN	O	O	4968
fluctuations	NOUN	O	O	4968
and	CCONJ	O	O	4968
neuropsychiatric	ADJ	O	O	4968
-	PUNCT	O	O	4968
like	INTJ	O	O	4968
behaviors	NOUN	O	O	4968
to	PART	O	O	4968
determine	VERB	O	O	4968
the	PRON	O	O	4968
relationship	NOUN	O	O	4968
between	ADP	O	O	4968
duration	NOUN	O	O	4968
of	ADP	O	O	4968
treatment	NOUN	O	O	4968
and	CCONJ	O	O	4968
onset	VERB	O	O	4968
of	ADP	O	O	4968
symptoms	NOUN	O	O	4968
.	PUNCT	O	O	4968
Marmosets	NOUN	O	O	4969
were	AUX	O	O	4969
administered	VERB	O	O	4969
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	ADJ	O	Chemical	4969
(	PUNCT	O	O	4969
2.0	NUM	O	O	4969
mg	VERB	O	O	4969
/	PUNCT	O	O	4969
kg	VERB	O	O	4969
s.c	PROPN	O	O	4969
.	PUNCT	O	O	4969
)	PUNCT	O	O	4969
for	ADP	O	O	4970
five	NUM	O	O	4970
days	NOUN	O	O	4970
,	PUNCT	O	O	4970
resulting	VERB	O	O	4970
in	ADP	O	O	4970
stable	ADJ	O	O	4970
parkinsonism	NOUN	O	Disease	4970
.	PUNCT	O	O	4970
Levodopa	NOUN	O	Chemical	4971
(	PUNCT	O	O	4971
15	NUM	O	O	4971
mg	VERB	O	O	4971
/	PUNCT	O	O	4971
kg	VERB	O	O	4971
and	CCONJ	O	O	4971
benserazide	VERB	O	Chemical	4971
,	PUNCT	O	O	4971
3.75	NUM	O	O	4971
mg	VERB	O	O	4971
/	PUNCT	O	O	4971
kg	VERB	O	O	4971
)	PUNCT	O	O	4971
Animals	NOUN	O	O	4972
were	AUX	O	O	4972
evaluated	VERB	O	O	4972
for	ADP	O	O	4972
parkinsonian	PROPN	O	Disease	4972
disability	NOUN	O	O	4972
,	PUNCT	O	O	4972
dyskinesia	NOUN	O	Disease	4972
and	CCONJ	O	O	4972
on	ADP	O	O	4972
-	PUNCT	O	O	4972
time	NOUN	O	O	4972
(	PUNCT	O	O	4972
motor	NOUN	O	O	4972
fluctuations	NOUN	O	O	4972
)	PUNCT	O	O	4972
and	CCONJ	O	O	4972
neuropsychiatric	ADJ	O	O	4972
-	PUNCT	O	O	4972
like	INTJ	O	O	4972
behaviors	NOUN	O	O	4972
on	ADP	O	O	4972
Day	NOUN	O	O	4972
0	NUM	O	O	4972
(	PUNCT	O	O	4972
prior	ADV	O	O	4972
to	PART	O	O	4972
levodopa	NOUN	O	Chemical	4972
)	PUNCT	O	O	4972
and	CCONJ	O	O	4972
on	ADP	O	O	4972
Days	NOUN	O	O	4972
1	X	O	O	4972
,	PUNCT	O	O	4972
7	NUM	O	O	4972
,	PUNCT	O	O	4972
13	NUM	O	O	4972
,	PUNCT	O	O	4972
27	NUM	O	O	4972
and	CCONJ	O	O	4972
30	NUM	O	O	4972
of	ADP	O	O	4972
treatment	NOUN	O	O	4972
using	VERB	O	O	4972
post	VERB	O	O	4972
hoc	PROPN	O	O	4972
DVD	NOUN	O	O	4972
analysis	NOUN	O	O	4972
by	ADP	O	O	4972
a	PRON	O	O	4972
trained	VERB	O	O	4972
rater	PROPN	O	O	4972
,	PUNCT	O	O	4972
blind	ADJ	O	Disease	4972
to	PART	O	O	4972
the	PRON	O	O	4972
treatment	NOUN	O	O	4972
day	NOUN	O	O	4972
.	PUNCT	O	O	4972
The	PRON	O	O	4973
neuropsychiatric	ADJ	O	O	4973
-	PUNCT	O	O	4973
like	INTJ	O	O	4973
behavior	NOUN	O	O	4973
rating	NOUN	O	O	4973
scale	NOUN	O	O	4973
demonstrated	VERB	O	O	4973
high	ADJ	O	O	4973
interrater	NOUN	O	O	4973
reliability	NOUN	O	O	4973
between	ADP	O	O	4973
three	NUM	O	O	4973
trained	VERB	O	O	4973
raters	NOUN	O	O	4973
of	ADP	O	O	4973
differing	VERB	O	O	4973
professional	ADJ	O	O	4973
backgrounds	NOUN	O	O	4973
.	PUNCT	O	O	4973
As	ADP	O	O	4974
anticipated	VERB	O	O	4974
,	PUNCT	O	O	4974
animals	NOUN	O	O	4974
exhibited	VERB	O	O	4974
a	PRON	O	O	4974
progressive	ADJ	O	O	4974
increase	VERB	O	O	4974
in	ADP	O	O	4974
levodopa	NOUN	O	Chemical	4974
-	PUNCT	O	O	4974
induced	VERB	O	O	4974
motor	NOUN	O	O	4974
fluctuations	NOUN	O	O	4974
,	PUNCT	O	O	4974
dyskinesia	NOUN	O	Disease	4974
and	CCONJ	O	O	4974
wearing	VERB	O	O	4974
-	PUNCT	O	O	4974
off	ADP	O	O	4974
,	PUNCT	O	O	4974
that	SCONJ	O	O	4974
correlated	VERB	O	O	4974
with	ADP	O	O	4974
the	PRON	O	O	4974
duration	NOUN	O	O	4974
of	ADP	O	O	4974
levodopa	NOUN	O	Chemical	4974
therapy	NOUN	O	O	4974
.	PUNCT	O	O	4974
In	ADP	O	O	4975
contrast	NOUN	O	O	4975
,	PUNCT	O	O	4975
levodopa	NOUN	O	Chemical	4975
-	PUNCT	O	O	4975
induced	VERB	O	O	4975
neuropsychiatric	ADJ	O	O	4975
-	PUNCT	O	O	4975
like	INTJ	O	O	4975
behaviors	NOUN	O	O	4975
were	AUX	O	O	4975
present	NOUN	O	O	4975
on	ADP	O	O	4975
Day	NOUN	O	O	4975
1	X	O	O	4975
of	ADP	O	O	4975
levodopa	NOUN	O	Chemical	4975
treatment	NOUN	O	O	4975
and	CCONJ	O	O	4975
their	PRON	O	O	4975
severity	NOUN	O	O	4975
did	VERB	O	O	4975
not	PART	O	O	4975
correlate	VERB	O	O	4975
with	ADP	O	O	4975
duration	NOUN	O	O	4975
of	ADP	O	O	4975
treatment	NOUN	O	O	4975
.	PUNCT	O	O	4975
The	PRON	O	O	4976
data	NOUN	O	O	4976
suggest	VERB	O	O	4976
that	SCONJ	O	O	4976
neuropsychiatric disorders	NOUN	O	O	4976
in	ADP	O	O	4976
PD	PROPN	O	Disease	4976
are	AUX	O	O	4976
more	ADJ	O	O	4976
likely	ADV	O	O	4976
an	PRON	O	O	4976
interaction	NOUN	O	O	4976
between	ADP	O	O	4976
levodopa	NOUN	O	Chemical	4976
and	CCONJ	O	O	4976
the	PRON	O	O	4976
disease	PROPN	O	O	4976
state	NOUN	O	O	4976
than	ADP	O	O	4976
a	PRON	O	O	4976
consequence	NOUN	O	O	4976
of	ADP	O	O	4976
sensitisation	NOUN	O	O	4976
to	PART	O	O	4976
repeated	VERB	O	O	4976
dopaminergic	ADJ	O	O	4976
therapy	NOUN	O	O	4976
.	PUNCT	O	O	4976
Contrast	NOUN	O	O	4979
medium	ADJ	O	O	4979
nephrotoxicity	NOUN	O	Disease	4979
after	ADP	O	O	4979
renal	ADJ	O	O	4979
artery	NOUN	O	O	4979
and	CCONJ	O	O	4979
coronary	ADJ	O	O	4979
angioplasty	ADJ	O	O	4979
.	PUNCT	O	O	4979
Renal	NOUN	O	O	4980
dysfunction	NOUN	O	O	4980
induced	VERB	O	O	4980
by	ADP	O	O	4980
iodinated	VERB	O	O	4980
contrast	NOUN	O	O	4980
medium	ADJ	O	O	4980
(	PUNCT	O	O	4980
CM	PROPN	O	Disease	4980
)	PUNCT	O	O	4980
administration	NOUN	O	O	4980
can	AUX	O	O	4980
minimize	VERB	O	O	4980
the	PRON	O	O	4980
benefit	VERB	O	O	4980
of	ADP	O	O	4980
the	PRON	O	O	4980
interventional	ADJ	O	O	4980
procedure	NOUN	O	O	4980
in	ADP	O	O	4980
patients	NOUN	O	O	4980
undergoing	VERB	O	O	4980
renal	ADJ	O	O	4980
angioplasty	ADJ	O	O	4980
(	PUNCT	O	O	4980
PTRA	NOUN	O	O	4980
)	PUNCT	O	O	4980
.	PUNCT	O	O	4980
To	PART	O	O	4981
compare	VERB	O	O	4981
the	PRON	O	O	4981
susceptibility	NOUN	O	O	4981
to	PART	O	O	4981
nephrotoxic	NOUN	O	Disease	4981
effect	VERB	O	O	4981
of	ADP	O	O	4981
CM	PROPN	O	Disease	4981
in	ADP	O	O	4981
patients	NOUN	O	O	4981
undergoing	VERB	O	O	4981
PTRA	NOUN	O	O	4981
with	ADP	O	O	4981
that	SCONJ	O	O	4981
of	ADP	O	O	4981
patients	NOUN	O	O	4981
submitted	VERB	O	O	4981
to	PART	O	O	4981
percutaneous	ADJ	O	O	4981
coronary	ADJ	O	O	4981
intervention	NOUN	O	O	4981
(	PUNCT	O	O	4981
PCI	NOUN	O	O	4981
)	PUNCT	O	O	4981
.	PUNCT	O	O	4981
A	PRON	O	O	4982
total	ADJ	O	O	4982
of	ADP	O	O	4982
33	NUM	O	O	4982
patients	NOUN	O	O	4982
successfully	ADV	O	O	4982
treated	VERB	O	O	4982
with	ADP	O	O	4982
PTRA	NOUN	O	O	4982
(	PUNCT	O	O	4982
PTRA	NOUN	O	O	4982
group	NOUN	O	O	4982
,	PUNCT	O	O	4982
mean	VERB	O	O	4982
age	NOUN	O	O	4982
70+/-12	NUM	O	O	4982
years	NOUN	O	O	4982
,	PUNCT	O	O	4982
23	NUM	O	O	4982
female	ADJ	O	O	4982
,	PUNCT	O	O	4982
basal	PROPN	O	O	4982
creatinine	PROPN	O	Chemical	4982
1.46+/-0.79	NUM	O	O	4982
,	PUNCT	O	O	4982
range	VERB	O	O	4982
0.7	NUM	O	O	4982
-	PUNCT	O	O	4982
4.9	NUM	O	O	4982
mg	VERB	O	O	4982
/	PUNCT	O	O	4982
dl	X	O	O	4982
)	PUNCT	O	O	4982
were	AUX	O	O	4982
compared	VERB	O	O	4982
with	ADP	O	O	4982
33	NUM	O	O	4982
patients	NOUN	O	O	4982
undergoing	VERB	O	O	4982
successful	ADJ	O	O	4982
PCI	NOUN	O	O	4982
(	PUNCT	O	O	4982
PCI	NOUN	O	O	4982
group	NOUN	O	O	4982
)	PUNCT	O	O	4982
,	PUNCT	O	O	4982
matched	VERB	O	O	4982
for	ADP	O	O	4982
basal	PROPN	O	O	4982
creatinine	PROPN	O	Chemical	4982
(	PUNCT	O	O	4982
1.44+/-0.6	NUM	O	O	4982
,	PUNCT	O	O	4982
range	VERB	O	O	4982
0.7	NUM	O	O	4982
-	PUNCT	O	O	4982
3.4	NUM	O	O	4982
mg	VERB	O	O	4982
/	PUNCT	O	O	4982
dl	X	O	O	4982
)	PUNCT	O	O	4982
,	PUNCT	O	O	4982
gender	NOUN	O	O	4982
,	PUNCT	O	O	4982
and	CCONJ	O	O	4982
age	NOUN	O	O	4982
.	PUNCT	O	O	4982
serum	NOUN	O	O	4983
creatinine	PROPN	O	Chemical	4983
was	AUX	O	O	4983
measured	VERB	O	O	4983
.	PUNCT	O	O	4983
RESULTS	VERB	O	O	4984
:	PUNCT	O	O	4984
Postprocedural	PROPN	O	O	4984
creatinine	PROPN	O	Chemical	4984
level	VERB	O	O	4984
decreased	VERB	O	O	4984
nonsignificantly	ADV	O	O	4984
in	ADP	O	O	4984
the	PRON	O	O	4984
PTRA	NOUN	O	O	4984
group	NOUN	O	O	4984
(	PUNCT	O	O	4984
1.46+/-0.8	NUM	O	O	4984
vs.	CCONJ	O	O	4984
1.34+/-0.5	NUM	O	O	4984
mg	VERB	O	O	4984
/	PUNCT	O	O	4984
dl	X	O	O	4984
,	PUNCT	O	O	4984
Changes	NOUN	O	O	4985
in	ADP	O	O	4985
serum	NOUN	O	O	4985
creatinine	PROPN	O	Chemical	4985
after	ADP	O	O	4985
intervention	NOUN	O	O	4985
(	PUNCT	O	O	4985
after	ADP	O	O	4985
-	PUNCT	O	O	4985
before	ADP	O	O	4985
)	PUNCT	O	O	4985
were	AUX	O	O	4985
significantly	ADV	O	O	4985
different	ADJ	O	O	4985
between	ADP	O	O	4985
the	PRON	O	O	4985
PTRA	NOUN	O	O	4985
and	CCONJ	O	O	4985
PCI	NOUN	O	O	4985
groups	NOUN	O	O	4985
(	PUNCT	O	O	4985
-0.12+/-0.5	NUM	O	O	4985
vs.	CCONJ	O	O	4985
0.13+/-0.3	NUM	O	O	4985
,	PUNCT	O	O	4985
P=0.014	ADV	O	O	4985
)	PUNCT	O	O	4985
.	PUNCT	O	O	4985
This	PRON	O	O	4986
difference	NOUN	O	O	4986
was	AUX	O	O	4986
not	PART	O	O	4986
related	ADJ	O	O	4986
to	PART	O	O	4986
either	ADV	O	O	4986
a	PRON	O	O	4986
different	ADJ	O	O	4986
clinical	ADJ	O	O	4986
risk	NOUN	O	O	4986
profile	NOUN	O	O	4986
or	CCONJ	O	O	4986
to	PART	O	O	4986
the	PRON	O	O	4986
volume	PROPN	O	O	4986
of	ADP	O	O	4986
CM	PROPN	O	Disease	4986
administered	VERB	O	O	4986
.	PUNCT	O	O	4986
CONCLUSION	PROPN	O	O	4987
:	PUNCT	O	O	4987
In	ADP	O	O	4987
this	PRON	O	O	4987
preliminary	ADJ	O	O	4987
study	VERB	O	O	4987
patients	NOUN	O	O	4987
submitted	VERB	O	O	4987
to	PART	O	O	4987
PTRA	NOUN	O	O	4987
showed	VERB	O	O	4987
a	PRON	O	O	4987
lower	ADJ	O	O	4987
susceptibility	NOUN	O	O	4987
to	PART	O	O	4987
renal damage	NOUN	O	Disease	4987
induced	VERB	O	O	4987
by	ADP	O	O	4987
CM	PROPN	O	Disease	4987
administration	NOUN	O	O	4987
than	ADP	O	O	4987
PCI	NOUN	O	O	4987
patients	NOUN	O	O	4987
.	PUNCT	O	O	4987
The	PRON	O	O	4988
effectiveness	NOUN	O	O	4988
of	ADP	O	O	4988
PTRA	NOUN	O	O	4988
on	ADP	O	O	4988
renal	ADJ	O	O	4988
function	NOUN	O	O	4988
seems	VERB	O	O	4988
to	PART	O	O	4988
be	AUX	O	O	4988
barely	ADV	O	O	4988
influenced	VERB	O	O	4988
by	ADP	O	O	4988
CM	PROPN	O	Disease	4988
toxicity	NOUN	O	Disease	4988
.	PUNCT	O	O	4988
Medical	NOUN	O	O	4991
and	CCONJ	O	O	4991
psychiatric	ADJ	O	Disease	4991
outcomes	NOUN	O	O	4991
for	ADP	O	O	4991
patients	NOUN	O	O	4991
transplanted	VERB	O	O	4991
for	ADP	O	O	4991
acetaminophen	PROPN	O	Chemical	4991
-	PUNCT	O	O	4991
induced	VERB	O	O	4991
acute liver failure	NOUN	O	Disease	4991
:	PUNCT	O	O	4991
a	PRON	O	O	4991
case	NOUN	O	O	4991
-	PUNCT	O	O	4991
control	VERB	O	O	4991
study	VERB	O	O	4991
.	PUNCT	O	O	4991
Acetaminophen	PROPN	O	O	4992
-	PUNCT	O	O	4992
induced	VERB	O	O	4992
hepatotoxicity	NOUN	O	Disease	4992
is	AUX	O	O	4992
the	PRON	O	O	4992
most	ADV	O	O	4992
common	ADJ	O	O	4992
cause	VERB	O	O	4992
of	ADP	O	O	4992
acute liver failure	NOUN	O	Disease	4992
(	PUNCT	O	O	4992
ALF	PROPN	O	Disease	4992
)	PUNCT	O	O	4992
in	ADP	O	O	4992
the	PRON	O	O	4992
UK	PROPN	O	O	4992
.	PUNCT	O	O	4992
:	PUNCT	O	O	4993
We	PRON	O	O	4993
compared	VERB	O	O	4993
the	PRON	O	O	4993
severity	NOUN	O	O	4993
of	ADP	O	O	4993
pretransplant	ADJ	O	O	4993
illness	VERB	O	O	4993
,	PUNCT	O	O	4993
psychiatric	ADJ	O	Disease	4993
co	NOUN	O	O	4993
-	PUNCT	O	O	4993
morbidity	NOUN	O	O	4993
,	PUNCT	O	O	4993
medical	ADJ	O	O	4993
and	CCONJ	O	O	4993
psychosocial	ADJ	O	O	4993
outcomes	NOUN	O	O	4993
of	ADP	O	O	4993
all	PRON	O	O	4993
patients	NOUN	O	O	4993
who	PRON	O	O	4993
had	VERB	O	O	4993
undergone	VERB	O	O	4993
liver	NOUN	O	O	4993
transplantation	NOUN	O	O	4993
(	PUNCT	O	O	4993
LT	PROPN	O	O	4993
)	PUNCT	O	O	4993
emergently	ADV	O	O	4993
between	ADP	O	O	4993
1999	NUM	O	O	4993
-	PUNCT	O	O	4993
2004	NUM	O	O	4993
for	ADP	O	O	4993
acetaminophen	PROPN	O	Chemical	4993
-	PUNCT	O	O	4993
induced	VERB	O	O	4993
ALF	PROPN	O	Disease	4993
(	PUNCT	O	O	4993
n=36	PROPN	O	O	4993
)	PUNCT	O	O	4993
with	ADP	O	O	4993
age-	ADJ	O	O	4993
and	CCONJ	O	O	4993
sex	NOUN	O	O	4993
-	PUNCT	O	O	4993
matched	VERB	O	O	4993
patients	NOUN	O	O	4993
undergoing	VERB	O	O	4993
emergent	ADJ	O	O	4993
LT	PROPN	O	O	4993
for	ADP	O	O	4993
non	ADJ	O	O	4993
-	PUNCT	O	O	4993
acetaminophen	PROPN	O	Chemical	4993
-	PUNCT	O	O	4993
induced	VERB	O	O	4993
ALF	PROPN	O	Disease	4993
(	PUNCT	O	O	4993
n=35	NOUN	O	O	4993
)	PUNCT	O	O	4993
and	CCONJ	O	O	4993
elective	PROPN	O	O	4993
LT	PROPN	O	O	4993
for	ADP	O	O	4993
chronic	ADJ	O	O	4993
liver disease	NOUN	O	Disease	4993
(	PUNCT	O	O	4993
CLD	VERB	O	O	4993
,	PUNCT	O	O	4993
n=34	VERB	O	O	4993
)	PUNCT	O	O	4993
.	PUNCT	O	O	4993
Acetaminophen	PROPN	O	O	4994
-	PUNCT	O	O	4994
induced	VERB	O	O	4994
ALF	PROPN	O	Disease	4994
patients	NOUN	O	O	4994
undergoing	VERB	O	O	4994
LT	PROPN	O	O	4994
had	VERB	O	O	4994
a	PRON	O	O	4994
greater	ADJ	O	O	4994
severity	NOUN	O	O	4994
of	ADP	O	O	4994
pre	VERB	O	O	4994
-	PUNCT	O	O	4994
LT	PROPN	O	O	4994
illness	VERB	O	O	4994
reflected	VERB	O	O	4994
by	ADP	O	O	4994
higher	ADJ	O	O	4994
Acute	PROPN	O	O	4994
Physiology	NOUN	O	O	4994
and	CCONJ	O	O	4994
Chronic	NOUN	O	O	4994
Health	NOUN	O	O	4994
Evaluation	NOUN	O	O	4994
II	NUM	O	O	4994
Twenty	NUM	O	O	4995
(	PUNCT	O	O	4995
56%	NOUN	O	O	4995
)	PUNCT	O	O	4995
acetaminophen	PROPN	O	Chemical	4995
-	PUNCT	O	O	4995
induced	VERB	O	O	4995
ALF	PROPN	O	Disease	4995
patients	NOUN	O	O	4995
had	VERB	O	O	4995
a	PRON	O	O	4995
formal	ADJ	O	O	4995
psychiatric	ADJ	O	Disease	4995
diagnosis	NOUN	O	O	4995
before	ADP	O	O	4995
LT	PROPN	O	O	4995
(	PUNCT	O	O	4995
non	ADJ	O	O	4995
-	PUNCT	O	O	4995
acetaminophen	PROPN	O	Chemical	4995
-	PUNCT	O	O	4995
induced	VERB	O	O	4995
ALF=0/35	ADV	O	O	4995
,	PUNCT	O	O	4995
CLD=2/34	NUM	O	O	4995
;	PUNCT	O	O	4995
P<0.01	ADV	O	O	4995
for	ADP	O	O	4995
all	PRON	O	O	4995
)	PUNCT	O	O	4995
and	CCONJ	O	O	4995
nine	NUM	O	O	4995
(	PUNCT	O	O	4995
25%	NOUN	O	O	4995
)	PUNCT	O	O	4995
had	VERB	O	O	4995
a	PRON	O	O	4995
previous	ADJ	O	O	4995
suicide	NOUN	O	O	4995
attempt	VERB	O	O	4995
.	PUNCT	O	O	4995
During	ADP	O	O	4996
follow	VERB	O	O	4996
-	PUNCT	O	O	4996
up	ADP	O	O	4996
(	PUNCT	O	O	4996
median	ADJ	O	O	4996
5	NUM	O	O	4996
years	NOUN	O	O	4996
)	PUNCT	O	O	4996
,	PUNCT	O	O	4996
there	ADV	O	O	4996
were	AUX	O	O	4996
no	PRON	O	O	4996
significant	ADJ	O	O	4996
differences	NOUN	O	O	4996
in	ADP	O	O	4996
rejection	NOUN	O	O	4996
(	PUNCT	O	O	4996
acute	ADJ	O	O	4996
and	CCONJ	O	O	4996
chronic	ADJ	O	O	4996
)	PUNCT	O	O	4996
,	PUNCT	O	O	4996
graft	NOUN	O	O	4996
failure	NOUN	O	O	4996
or	CCONJ	O	O	4996
survival	NOUN	O	O	4996
between	ADP	O	O	4996
the	PRON	O	O	4996
groups	NOUN	O	O	4996
(	PUNCT	O	O	4996
acetaminophen	PROPN	O	Chemical	4996
-	PUNCT	O	O	4996
induced	VERB	O	O	4996
ALF	PROPN	O	Disease	4996
1	X	O	O	4996
year	NOUN	O	O	4996
87%	NOUN	O	O	4996
,	PUNCT	O	O	4996
5	NUM	O	O	4996
years	NOUN	O	O	4996
75%	NOUN	O	O	4996
;	PUNCT	O	O	4996
non	ADJ	O	O	4996
-	PUNCT	O	O	4996
acetaminophen	PROPN	O	Chemical	4996
-	PUNCT	O	O	4996
induced	VERB	O	O	4996
ALF	PROPN	O	Disease	4996
88%	NOUN	O	O	4996
,	PUNCT	O	O	4996
78%	NOUN	O	O	4996
;	PUNCT	O	O	4996
CLD	VERB	O	O	4996
93%	NOUN	O	O	4996
,	PUNCT	O	O	4996
82%	NOUN	O	O	4996
:	PUNCT	O	O	4996
P>0.6	NOUN	O	O	4996
log	VERB	O	O	4996
rank	NOUN	O	O	4996
)	PUNCT	O	O	4996
.	PUNCT	O	O	4996
Two	NUM	O	O	4997
acetaminophen	PROPN	O	Chemical	4997
-	PUNCT	O	O	4997
induced	VERB	O	O	4997
ALF	PROPN	O	Disease	4997
patients	NOUN	O	O	4997
reattempted	VERB	O	O	4997
suicide	NOUN	O	O	4997
post	VERB	O	O	4997
-	PUNCT	O	O	4997
LT	PROPN	O	O	4997
(	PUNCT	O	O	4997
one	NUM	O	O	4997
died	VERB	O	O	4997
8	NUM	O	O	4997
years	NOUN	O	O	4997
post	VERB	O	O	4997
-	PUNCT	O	O	4997
LT	PROPN	O	O	4997
)	PUNCT	O	O	4997
.	PUNCT	O	O	4997
Despite	SCONJ	O	O	4998
a	PRON	O	O	4998
high	ADJ	O	O	4998
prevalence	NOUN	O	O	4998
of	ADP	O	O	4998
psychiatric	ADJ	O	Disease	4998
disturbance	NOUN	O	O	4998
,	PUNCT	O	O	4998
outcomes	NOUN	O	O	4998
for	ADP	O	O	4998
patients	NOUN	O	O	4998
transplanted	VERB	O	O	4998
emergently	ADV	O	O	4998
for	ADP	O	O	4998
acetaminophen	PROPN	O	Chemical	4998
-	PUNCT	O	O	4998
induced	VERB	O	O	4998
ALF	PROPN	O	Disease	4998
were	AUX	O	O	4998
comparable	ADJ	O	O	4998
to	PART	O	O	4998
those	PRON	O	O	4998
transplanted	VERB	O	O	4998
for	ADP	O	O	4998
non	ADJ	O	O	4998
-	PUNCT	O	O	4998
acetaminophen	PROPN	O	Chemical	4998
-	PUNCT	O	O	4998
induced	VERB	O	O	4998
ALF	PROPN	O	Disease	4998
and	CCONJ	O	O	4998
electively	ADV	O	O	4998
for	ADP	O	O	4998
CLD	VERB	O	O	4998
.	PUNCT	O	O	4998
Studies	NOUN	O	O	5001
of	ADP	O	O	5001
synergy	PROPN	O	O	5001
between	ADP	O	O	5001
morphine	NOUN	O	Chemical	5001
and	CCONJ	O	O	5001
a	PRON	O	O	5001
novel	NOUN	O	O	5001
sodium	NOUN	O	Chemical	5001
channel	PROPN	O	O	5001
blocker	NOUN	O	O	5001
,	PUNCT	O	O	5001
CNSB002	NOUN	O	O	5001
,	PUNCT	O	O	5001
in	ADP	O	O	5001
rat	NOUN	O	O	5001
models	NOUN	O	O	5001
of	ADP	O	O	5001
inflammatory	ADJ	O	O	5001
and	CCONJ	O	O	5001
neuropathic pain	NOUN	O	Disease	5001
.	PUNCT	O	O	5001
This	PRON	O	O	5002
study	VERB	O	O	5002
determined	VERB	O	O	5002
the	PRON	O	O	5002
antihyperalgesic	NOUN	O	O	5002
effect	VERB	O	O	5002
of	ADP	O	O	5002
CNSB002	NOUN	O	O	5002
,	PUNCT	O	O	5002
a	PRON	O	O	5002
sodium	NOUN	O	Chemical	5002
channel	PROPN	O	O	5002
blocker	NOUN	O	O	5002
with	ADP	O	O	5002
antioxidant	ADJ	O	O	5002
properties	NOUN	O	O	5002
given	VERB	O	O	5002
alone	ADV	O	O	5002
and	CCONJ	O	O	5002
in	ADP	O	O	5002
combinations	NOUN	O	O	5002
with	ADP	O	O	5002
morphine	NOUN	O	Chemical	5002
in	ADP	O	O	5002
rat	NOUN	O	O	5002
models	NOUN	O	O	5002
of	ADP	O	O	5002
inflammatory	ADJ	O	O	5002
and	CCONJ	O	O	5002
neuropathic pain	NOUN	O	Disease	5002
.	PUNCT	O	O	5002
Dose	NOUN	O	O	5003
response	NOUN	O	O	5003
curves	NOUN	O	O	5003
for	ADP	O	O	5003
nonsedating	VERB	O	O	5003
doses	NOUN	O	O	5003
of	ADP	O	O	5003
morphine	NOUN	O	Chemical	5003
and	CCONJ	O	O	5003
CNSB002	NOUN	O	O	5003
given	VERB	O	O	5003
intraperitoneally	ADV	O	O	5003
alone	ADV	O	O	5003
and	CCONJ	O	O	5003
together	ADV	O	O	5003
in	ADP	O	O	5003
combinations	NOUN	O	O	5003
were	AUX	O	O	5003
constructed	VERB	O	O	5003
for	ADP	O	O	5003
antihyperalgesic	NOUN	O	O	5003
effect	VERB	O	O	5003
using	VERB	O	O	5003
paw	PROPN	O	O	5003
withdrawal	NOUN	O	O	5003
from	ADP	O	O	5003
noxious	ADJ	O	O	5003
heat	NOUN	O	O	5003
in	ADP	O	O	5003
two	NUM	O	O	5003
rat	NOUN	O	O	5003
pain	NOUN	O	Disease	5003
models	NOUN	O	O	5003
:	PUNCT	O	O	5003
carrageenan	NOUN	O	Chemical	5003
-	PUNCT	O	O	5003
induced	VERB	O	O	5003
paw	PROPN	O	O	5003
inflammation	NOUN	O	Disease	5003
and	CCONJ	O	O	5003
streptozotocin	PROPN	O	Chemical	5003
(	PUNCT	O	O	5003
STZ)-induced	VERB	O	O	5003
diabetic	ADJ	O	Disease	5003
neuropathy	NOUN	O	Disease	5003
.	PUNCT	O	O	5003
The	PRON	O	O	5004
maximum	ADV	O	O	5004
nonsedating	VERB	O	O	5004
doses	NOUN	O	O	5004
were	AUX	O	O	5004
:	PUNCT	O	O	5004
morphine	NOUN	O	Chemical	5004
,	PUNCT	O	O	5004
3.2	NUM	O	O	5004
mg	VERB	O	O	5004
/	PUNCT	O	O	5004
kg	VERB	O	O	5004
;	PUNCT	O	O	5004
CNSB002	NOUN	O	O	5004
10.0	NUM	O	O	5004
mg	VERB	O	O	5004
/	PUNCT	O	O	5004
kg	VERB	O	O	5004
;	PUNCT	O	O	5004
5.0	NUM	O	O	5004
mg	VERB	O	O	5004
/	PUNCT	O	O	5004
kg	VERB	O	O	5004
CNSB002	NOUN	O	O	5004
with	ADP	O	O	5004
morphine	NOUN	O	Chemical	5004
3.2	NUM	O	O	5004
mg	VERB	O	O	5004
/	PUNCT	O	O	5004
kg	VERB	O	O	5004
in	ADP	O	O	5004
combination	NOUN	O	O	5004
.	PUNCT	O	O	5004
The	PRON	O	O	5005
doses	NOUN	O	O	5005
calculated	VERB	O	O	5005
to	PART	O	O	5005
cause	VERB	O	O	5005
50%	NOUN	O	O	5005
reversal	NOUN	O	O	5005
of	ADP	O	O	5005
hyperalgesia	NOUN	O	Disease	5005
(	PUNCT	O	O	5005
ED50	PROPN	O	O	5005
)	PUNCT	O	O	5005
were	AUX	O	O	5005
7.54	NUM	O	O	5005
(	PUNCT	O	O	5005
1.81	NUM	O	O	5005
)	PUNCT	O	O	5005
and	CCONJ	O	O	5005
4.83	NUM	O	O	5005
(	PUNCT	O	O	5005
1.54	NUM	O	O	5005
)	PUNCT	O	O	5005
in	ADP	O	O	5005
the	PRON	O	O	5005
carrageenan	NOUN	O	Chemical	5005
model	NOUN	O	O	5005
and	CCONJ	O	O	5005
44.18	NUM	O	O	5005
(	PUNCT	O	O	5005
1.37	NUM	O	O	5005
)	PUNCT	O	O	5005
and	CCONJ	O	O	5005
9.14	NUM	O	O	5005
(	PUNCT	O	O	5005
1.24	NUM	O	O	5005
)	PUNCT	O	O	5005
in	ADP	O	O	5005
the	PRON	O	O	5005
STZ	PROPN	O	Chemical	5005
-	PUNCT	O	O	5005
induced	VERB	O	O	5005
neuropathy	NOUN	O	Disease	5005
model	NOUN	O	O	5005
for	ADP	O	O	5005
CNSB002	NOUN	O	O	5005
and	CCONJ	O	O	5005
morphine	NOUN	O	Chemical	5005
,	PUNCT	O	O	5005
respectively	ADV	O	O	5005
(	PUNCT	O	O	5005
mg	VERB	O	O	5005
/	PUNCT	O	O	5005
kg	VERB	O	O	5005
;	PUNCT	O	O	5005
mean	VERB	O	O	5005
,	PUNCT	O	O	5005
SEM	INTJ	O	O	5005
)	PUNCT	O	O	5005
.	PUNCT	O	O	5005
The	PRON	O	O	5006
ED50	PROPN	O	O	5006
values	NOUN	O	O	5006
for	ADP	O	O	5006
morphine	NOUN	O	Chemical	5006
when	SCONJ	O	O	5006
given	VERB	O	O	5006
in	ADP	O	O	5006
combination	NOUN	O	O	5006
with	ADP	O	O	5006
CNSB002	NOUN	O	O	5006
(	PUNCT	O	O	5006
5	NUM	O	O	5006
mg	VERB	O	O	5006
/	PUNCT	O	O	5006
kg	VERB	O	O	5006
)	PUNCT	O	O	5006
were	AUX	O	O	5006
less	ADV	O	O	5006
than	ADP	O	O	5006
the	PRON	O	O	5006
maximum	ADV	O	O	5006
nonsedating	VERB	O	O	5006
dose	NOUN	O	O	5006
:	PUNCT	O	O	5006
0.56	NUM	O	O	5006
(	PUNCT	O	O	5006
1.55	NUM	O	O	5006
)	PUNCT	O	O	5006
in	ADP	O	O	5006
the	PRON	O	O	5006
carrageenan	NOUN	O	Chemical	5006
model	NOUN	O	O	5006
and	CCONJ	O	O	5006
1.37	NUM	O	O	5006
(	PUNCT	O	O	5006
1.23	NUM	O	O	5006
)	PUNCT	O	O	5006
in	ADP	O	O	5006
the	PRON	O	O	5006
neuropathy	NOUN	O	Disease	5006
model	NOUN	O	O	5006
(	PUNCT	O	O	5006
mg	VERB	O	O	5006
/	PUNCT	O	O	5006
kg	VERB	O	O	5006
;	PUNCT	O	O	5006
mean	VERB	O	O	5006
,	PUNCT	O	O	5006
SEM	INTJ	O	O	5006
)	PUNCT	O	O	5006
.	PUNCT	O	O	5006
The	PRON	O	O	5007
antinociception	NOUN	O	O	5007
after	ADP	O	O	5007
morphine	NOUN	O	Chemical	5007
(	PUNCT	O	O	5007
3.2	NUM	O	O	5007
mg	VERB	O	O	5007
/	PUNCT	O	O	5007
kg	VERB	O	O	5007
)	PUNCT	O	O	5007
was	AUX	O	O	5007
increased	VERB	O	O	5007
by	ADP	O	O	5007
co	NOUN	O	O	5007
-	PUNCT	O	O	5007
administration	NOUN	O	O	5007
with	ADP	O	O	5007
CNSB002	NOUN	O	O	5007
from	ADP	O	O	5007
28.0	NUM	O	O	5007
and	CCONJ	O	O	5007
31.7%	NOUN	O	O	5007
to	PART	O	O	5007
114.6	NUM	O	O	5007
and	CCONJ	O	O	5007
56.9%	NOUN	O	O	5007
reversal	NOUN	O	O	5007
of	ADP	O	O	5007
hyperalgesia	NOUN	O	Disease	5007
in	ADP	O	O	5007
the	PRON	O	O	5007
inflammatory	ADJ	O	O	5007
and	CCONJ	O	O	5007
neuropathic	ADJ	O	O	5007
models	NOUN	O	O	5007
,	PUNCT	O	O	5007
respectively	ADV	O	O	5007
(	PUNCT	O	O	5007
P	NOUN	O	Chemical	5007
<	X	O	O	5007
0.01	NUM	O	O	5007
;	PUNCT	O	O	5007
one	NUM	O	O	5007
-	PUNCT	O	O	5007
way	NOUN	O	O	5007
analysis	NOUN	O	O	5007
of	ADP	O	O	5007
variance	NOUN	O	O	5007
-	PUNCT	O	O	5007
significantly	ADV	O	O	5007
greater	ADJ	O	O	5007
than	ADP	O	O	5007
either	ADV	O	O	5007
drug	NOUN	O	O	5007
given	VERB	O	O	5007
alone	ADV	O	O	5007
)	PUNCT	O	O	5007
.	PUNCT	O	O	5007
The	PRON	O	O	5008
maximum	ADV	O	O	5008
antihyperalgesic	NOUN	O	O	5008
effect	VERB	O	O	5008
achievable	ADJ	O	O	5008
with	ADP	O	O	5008
nonsedating	VERB	O	O	5008
doses	NOUN	O	O	5008
of	ADP	O	O	5008
morphine	NOUN	O	Chemical	5008
may	AUX	O	O	5008
be	AUX	O	O	5008
increased	VERB	O	O	5008
significantly	ADV	O	O	5008
when	SCONJ	O	O	5008
the	PRON	O	O	5008
drug	NOUN	O	O	5008
is	AUX	O	O	5008
used	VERB	O	O	5008
in	ADP	O	O	5008
combination	NOUN	O	O	5008
with	ADP	O	O	5008
CNSB002	NOUN	O	O	5008
.	PUNCT	O	O	5008
Heparin	PROPN	O	Chemical	5011
-	PUNCT	O	O	5011
induced	VERB	O	O	5011
thrombocytopenia	PROPN	O	Disease	5011
:	PUNCT	O	O	5011
a	PRON	O	O	5011
practical	ADJ	O	O	5011
review	VERB	O	O	5011
.	PUNCT	O	O	5011
Heparin	PROPN	O	Chemical	5012
-	PUNCT	O	O	5012
induced	VERB	O	O	5012
thrombocytopenia	PROPN	O	Disease	5012
(	PUNCT	O	O	5012
HIT	VERB	O	Disease	5012
)	PUNCT	O	O	5012
remains	VERB	O	O	5012
under	ADP	O	O	5012
-	PUNCT	O	O	5012
recognized	VERB	O	O	5012
despite	SCONJ	O	O	5012
its	PRON	O	O	5012
potentially	ADV	O	O	5012
devastating	ADJ	O	O	5012
outcomes	NOUN	O	O	5012
.	PUNCT	O	O	5012
It	PRON	O	O	5013
begins	VERB	O	O	5013
when	SCONJ	O	O	5013
heparin	NOUN	O	Chemical	5013
exposure	NOUN	O	O	5013
stimulates	VERB	O	O	5013
the	PRON	O	O	5013
formation	NOUN	O	O	5013
of	ADP	O	O	5013
heparin	NOUN	O	Chemical	5013
-	PUNCT	O	O	5013
platelet	NOUN	O	O	5013
factor	NOUN	O	O	5013
4	NUM	O	O	5013
antibodies	NOUN	O	O	5013
,	PUNCT	O	O	5013
which	PRON	O	O	5013
in	ADP	O	O	5013
turn	VERB	O	O	5013
triggers	VERB	O	O	5013
the	PRON	O	O	5013
release	NOUN	O	O	5013
of	ADP	O	O	5013
procoagulant	NOUN	O	O	5013
platelet	NOUN	O	O	5013
particles	NOUN	O	O	5013
.	PUNCT	O	O	5013
Thrombosis	NOUN	O	Disease	5014
and	CCONJ	O	O	5014
thrombocytopenia	PROPN	O	Disease	5014
that	SCONJ	O	O	5014
follow	VERB	O	O	5014
comprise	VERB	O	O	5014
the	PRON	O	O	5014
2	X	O	O	5014
hallmark	NOUN	O	O	5014
traits	NOUN	O	O	5014
of	ADP	O	O	5014
HIT	VERB	O	Disease	5014
,	PUNCT	O	O	5014
with	ADP	O	O	5014
the	PRON	O	O	5014
former	ADJ	O	O	5014
largely	ADV	O	O	5014
responsible	ADJ	O	O	5014
for	ADP	O	O	5014
significant	ADJ	O	O	5014
vascular	ADJ	O	O	5014
complications	NOUN	O	O	5014
.	PUNCT	O	O	5014
The	PRON	O	O	5015
prevalence	NOUN	O	O	5015
of	ADP	O	O	5015
HIT	VERB	O	Disease	5015
varies	VERB	O	O	5015
among	ADP	O	O	5015
several	ADJ	O	O	5015
subgroups	NOUN	O	O	5015
,	PUNCT	O	O	5015
with	ADP	O	O	5015
greater	ADJ	O	O	5015
incidence	NOUN	O	O	5015
in	ADP	O	O	5015
surgical	ADJ	O	O	5015
as	ADP	O	O	5015
compared	VERB	O	O	5015
with	ADP	O	O	5015
medical	ADJ	O	O	5015
populations	NOUN	O	O	5015
.	PUNCT	O	O	5015
HIT	VERB	O	Disease	5016
must	AUX	O	O	5016
be	AUX	O	O	5016
acknowledged	VERB	O	O	5016
for	ADP	O	O	5016
its	PRON	O	O	5016
intense	ADJ	O	O	5016
predilection	NOUN	O	O	5016
for	ADP	O	O	5016
thrombosis	NOUN	O	Disease	5016
and	CCONJ	O	O	5016
suspected	VERB	O	O	5016
whenever	SCONJ	O	O	5016
thrombosis	NOUN	O	Disease	5016
occurs	VERB	O	O	5016
after	ADP	O	O	5016
heparin	NOUN	O	Chemical	5016
exposure	NOUN	O	O	5016
.	PUNCT	O	O	5016
The	PRON	O	O	5017
treatment	NOUN	O	O	5017
of	ADP	O	O	5017
HIT	VERB	O	Disease	5017
mandates	NOUN	O	O	5017
an	PRON	O	O	5017
immediate	ADJ	O	O	5017
cessation	NOUN	O	O	5017
of	ADP	O	O	5017
all	PRON	O	O	5017
heparin	NOUN	O	Chemical	5017
exposure	NOUN	O	O	5017
and	CCONJ	O	O	5017
the	PRON	O	O	5017
institution	NOUN	O	O	5017
of	ADP	O	O	5017
an	PRON	O	O	5017
antithrombotic	ADJ	O	O	5017
therapy	NOUN	O	O	5017
,	PUNCT	O	O	5017
most	ADV	O	O	5017
commonly	ADV	O	O	5017
using	VERB	O	O	5017
a	PRON	O	O	5017
direct	ADJ	O	O	5017
thrombin	PROPN	O	O	5017
inhibitor	NOUN	O	O	5017
.	PUNCT	O	O	5017
Current	ADJ	O	O	5018
""""	PUNCT	O	O	5018
diagnostic	ADJ	O	O	5018
""""	PUNCT	O	O	5018
tests	VERB	O	O	5018
,	PUNCT	O	O	5018
which	PRON	O	O	5018
primarily	ADV	O	O	5018
include	VERB	O	O	5018
functional	ADJ	O	O	5018
and	CCONJ	O	O	5018
antigenic	ADJ	O	O	5018
assays	NOUN	O	O	5018
,	PUNCT	O	O	5018
have	VERB	O	O	5018
more	ADJ	O	O	5018
of	ADP	O	O	5018
a	PRON	O	O	5018
confirmatory	NOUN	O	O	5018
than	ADP	O	O	5018
diagnostic	ADJ	O	O	5018
role	NOUN	O	O	5018
in	ADP	O	O	5018
the	PRON	O	O	5018
management	NOUN	O	O	5018
of	ADP	O	O	5018
HIT	VERB	O	Disease	5018
.	PUNCT	O	O	5018
Special	ADJ	O	O	5019
attention	NOUN	O	O	5019
must	AUX	O	O	5019
be	AUX	O	O	5019
paid	VERB	O	O	5019
to	PART	O	O	5019
cardiac	ADJ	O	O	5019
patients	NOUN	O	O	5019
who	PRON	O	O	5019
are	AUX	O	O	5019
often	ADV	O	O	5019
exposed	VERB	O	O	5019
to	PART	O	O	5019
heparin	NOUN	O	Chemical	5019
multiple	ADJ	O	O	5019
times	NOUN	O	O	5019
during	ADP	O	O	5019
their	PRON	O	O	5019
course	NOUN	O	O	5019
of	ADP	O	O	5019
treatment	NOUN	O	O	5019
.	PUNCT	O	O	5019
Direct	ADJ	O	O	5020
thrombin	PROPN	O	O	5020
inhibitors	NOUN	O	O	5020
are	AUX	O	O	5020
appropriate	ADJ	O	O	5020
,	PUNCT	O	O	5020
evidence	NOUN	O	O	5020
-	PUNCT	O	O	5020
based	VERB	O	O	5020
alternatives	NOUN	O	O	5020
to	PART	O	O	5020
heparin	NOUN	O	Chemical	5020
in	ADP	O	O	5020
patients	NOUN	O	O	5020
with	ADP	O	O	5020
a	PRON	O	O	5020
history	NOUN	O	O	5020
of	ADP	O	O	5020
HIT	VERB	O	Disease	5020
,	PUNCT	O	O	5020
who	PRON	O	O	5020
need	VERB	O	O	5020
to	PART	O	O	5020
undergo	VERB	O	O	5020
percutaneous	ADJ	O	O	5020
coronary	ADJ	O	O	5020
intervention	NOUN	O	O	5020
.	PUNCT	O	O	5020
As	ADP	O	O	5021
heparin	NOUN	O	Chemical	5021
remains	VERB	O	O	5021
one	NUM	O	O	5021
of	ADP	O	O	5021
the	PRON	O	O	5021
most	ADV	O	O	5021
frequently	ADV	O	O	5021
used	VERB	O	O	5021
medications	NOUN	O	O	5021
today	NOUN	O	O	5021
with	ADP	O	O	5021
potential	ADJ	O	O	5021
for	ADP	O	O	5021
HIT	VERB	O	Disease	5021
with	ADP	O	O	5021
every	PRON	O	O	5021
heparin	NOUN	O	Chemical	5021
exposure	NOUN	O	O	5021
,	PUNCT	O	O	5021
a	PRON	O	O	5021
close	ADV	O	O	5021
vigilance	NOUN	O	O	5021
of	ADP	O	O	5021
platelet	NOUN	O	O	5021
counts	VERB	O	O	5021
must	AUX	O	O	5021
be	AUX	O	O	5021
practiced	VERB	O	O	5021
whenever	SCONJ	O	O	5021
heparin	NOUN	O	Chemical	5021
is	AUX	O	O	5021
initiated	VERB	O	O	5021
.	PUNCT	O	O	5021
Abductor	PROPN	O	O	5024
paralysis	NOUN	O	Disease	5024
after	ADP	O	O	5024
botox	PROPN	O	O	5024
injection	NOUN	O	O	5024
for	ADP	O	O	5024
adductor	PROPN	O	O	5024
spasmodic	ADJ	O	O	5024
dysphonia	PROPN	O	O	5024
.	PUNCT	O	O	5024
Botulinum	NOUN	O	O	5025
toxin	NOUN	O	O	5025
(	PUNCT	O	O	5025
Botox	PROPN	O	O	5025
)	PUNCT	O	O	5026
injections	NOUN	O	O	5026
into	ADP	O	O	5026
the	PRON	O	O	5026
thyroarytenoid	PROPN	O	O	5026
muscles	NOUN	O	O	5026
are	AUX	O	O	5026
the	PRON	O	O	5026
current	ADJ	O	O	5026
standard	PROPN	O	O	5026
of	ADP	O	O	5026
care	VERB	O	O	5026
for	ADP	O	O	5026
adductor	PROPN	O	O	5026
spasmodic	ADJ	O	O	5026
dysphonia	PROPN	O	O	5026
(	PUNCT	O	O	5026
ADSD	NOUN	O	O	5026
)	PUNCT	O	O	5026
.	PUNCT	O	O	5026
Reported	VERB	O	O	5027
adverse	ADJ	O	O	5027
effects	NOUN	O	O	5027
include	VERB	O	O	5027
a	PRON	O	O	5027
period	NOUN	O	O	5027
of	ADP	O	O	5027
breathiness	VERB	O	O	5027
,	PUNCT	O	O	5027
throat	NOUN	O	O	5027
pain	NOUN	O	Disease	5027
,	PUNCT	O	O	5027
and	CCONJ	O	O	5027
difficulty	NOUN	O	O	5027
with	ADP	O	O	5027
swallowing	VERB	O	O	5027
liquids	NOUN	O	O	5027
.	PUNCT	O	O	5027
Here	ADV	O	O	5028
we	PRON	O	O	5028
report	VERB	O	O	5028
multiple	ADJ	O	O	5028
cases	NOUN	O	O	5028
of	ADP	O	O	5028
bilateral	ADJ	O	O	5028
abductor	PROPN	O	O	5028
paralysis	NOUN	O	Disease	5028
following	VERB	O	O	5028
Botox	PROPN	O	O	5028
injections	NOUN	O	O	5028
for	ADP	O	O	5028
ADSD	NOUN	O	O	5028
,	PUNCT	O	O	5028
a	PRON	O	O	5028
complication	NOUN	O	O	5028
previously	ADV	O	O	5028
unreported	ADJ	O	O	5028
.	PUNCT	O	O	5028
Patients	NOUN	O	O	5029
that	SCONJ	O	O	5029
received	VERB	O	O	5029
Botox	PROPN	O	O	5029
injections	NOUN	O	O	5029
for	ADP	O	O	5029
spasmodic	ADJ	O	O	5029
dysphonia	PROPN	O	O	5029
between	ADP	O	O	5029
January	PROPN	O	O	5029
2000	NUM	O	O	5029
and	CCONJ	O	O	5029
October	PROPN	O	O	5029
2009	NUM	O	O	5029
were	AUX	O	O	5029
evaluated	VERB	O	O	5029
.	PUNCT	O	O	5029
Patients	NOUN	O	O	5030
with	ADP	O	O	5030
ADSD	NOUN	O	O	5030
were	AUX	O	O	5030
identified	VERB	O	O	5030
.	PUNCT	O	O	5030
For	ADP	O	O	5031
patients	NOUN	O	O	5031
with	ADP	O	O	5031
bilateral	ADJ	O	O	5031
abductor	PROPN	O	O	5031
paralysis	NOUN	O	Disease	5031
,	PUNCT	O	O	5031
age	NOUN	O	O	5031
,	PUNCT	O	O	5031
sex	NOUN	O	O	5031
,	PUNCT	O	O	5031
paralytic	ADJ	O	O	5031
Botox	PROPN	O	O	5031
dose	NOUN	O	O	5031
,	PUNCT	O	O	5031
prior	ADV	O	O	5031
Botox	PROPN	O	O	5031
dose	NOUN	O	O	5031
,	PUNCT	O	O	5031
and	CCONJ	O	O	5031
course	NOUN	O	O	5031
following	VERB	O	O	5031
paralysis	NOUN	O	Disease	5031
were	AUX	O	O	5031
noted	VERB	O	O	5031
.	PUNCT	O	O	5031
From	ADP	O	O	5032
a	PRON	O	O	5032
database	NOUN	O	O	5032
of	ADP	O	O	5032
452	NUM	O	O	5032
patients	NOUN	O	O	5032
receiving	VERB	O	O	5032
Botox	PROPN	O	O	5032
,	PUNCT	O	O	5032
352	NUM	O	O	5032
patients	NOUN	O	O	5032
had	VERB	O	O	5032
been	AUX	O	O	5032
diagnosed	VERB	O	O	5032
with	ADP	O	O	5032
ADSD	NOUN	O	O	5032
.	PUNCT	O	O	5032
Of	ADV	O	O	5033
these	PRON	O	O	5033
352	NUM	O	O	5033
patients	NOUN	O	O	5033
,	PUNCT	O	O	5033
eight	NUM	O	O	5033
patients	NOUN	O	O	5033
suffered	VERB	O	O	5033
bilateral	ADJ	O	O	5033
abductor	PROPN	O	O	5033
paralysis	NOUN	O	Disease	5033
,	PUNCT	O	O	5033
and	CCONJ	O	O	5033
two	NUM	O	O	5033
suffered	VERB	O	O	5033
this	PRON	O	O	5033
complication	NOUN	O	O	5033
twice	ADV	O	O	5033
.	PUNCT	O	O	5033
Most	ADV	O	O	5034
patients	NOUN	O	O	5034
had	VERB	O	O	5034
received	VERB	O	O	5034
treatments	NOUN	O	O	5034
prior	ADV	O	O	5034
to	PART	O	O	5034
abductor	PROPN	O	O	5034
paralysis	NOUN	O	Disease	5034
and	CCONJ	O	O	5034
continued	VERB	O	O	5034
receiving	VERB	O	O	5034
after	ADP	O	O	5034
paralysis	NOUN	O	Disease	5034
.	PUNCT	O	O	5034
The	PRON	O	O	5035
incidence	NOUN	O	O	5035
of	ADP	O	O	5035
abductor	PROPN	O	O	5035
paralysis	NOUN	O	Disease	5035
after	ADP	O	O	5035
Botox	PROPN	O	O	5035
injection	NOUN	O	O	5035
for	ADP	O	O	5035
ADSD	NOUN	O	O	5035
was	AUX	O	O	5035
0.34%	NOUN	O	O	5035
.	PUNCT	O	O	5035
Bilateral	ADJ	O	O	5036
abductor	PROPN	O	O	5036
paralysis	NOUN	O	Disease	5036
is	AUX	O	O	5036
a	PRON	O	O	5036
rare	ADJ	O	O	5036
complication	NOUN	O	O	5036
of	ADP	O	O	5036
Botox	PROPN	O	O	5036
injections	NOUN	O	O	5036
for	ADP	O	O	5036
ADSD	NOUN	O	O	5036
,	PUNCT	O	O	5036
causing	VERB	O	O	5036
difficulty	NOUN	O	O	5036
with	ADP	O	O	5036
breathing	VERB	O	O	5036
upon	SCONJ	O	O	5036
exertion	NOUN	O	O	5036
.	PUNCT	O	O	5036
The	PRON	O	O	5037
likely	ADV	O	O	5037
mechanism	NOUN	O	O	5037
of	ADP	O	O	5037
paralysis	NOUN	O	Disease	5037
is	AUX	O	O	5037
diffusion	NOUN	O	O	5037
of	ADP	O	O	5037
Botox	PROPN	O	O	5037
around	ADV	O	O	5037
the	PRON	O	O	5037
muscular	ADJ	O	O	5037
process	NOUN	O	O	5037
of	ADP	O	O	5037
the	PRON	O	O	5037
arytenoid	VERB	O	O	5037
to	PART	O	O	5037
the	PRON	O	O	5037
posterior	ADJ	O	O	5037
cricoarytenoid	NOUN	O	O	5037
muscles	NOUN	O	O	5037
.	PUNCT	O	O	5037
The	PRON	O	O	5038
paralysis	NOUN	O	Disease	5038
is	AUX	O	O	5038
temporary	ADJ	O	O	5038
,	PUNCT	O	O	5038
and	CCONJ	O	O	5038
watchful	ADJ	O	O	5038
waiting	VERB	O	O	5038
with	ADP	O	O	5038
restriction	NOUN	O	O	5038
of	ADP	O	O	5038
activity	NOUN	O	O	5038
is	AUX	O	O	5038
the	PRON	O	O	5038
recommended	VERB	O	O	5038
management	NOUN	O	O	5038
.	PUNCT	O	O	5038
Mitochondrial	NOUN	O	O	5041
impairment	NOUN	O	O	5041
contributes	VERB	O	O	5041
to	PART	O	O	5041
cocaine	NOUN	O	Chemical	5041
-	PUNCT	O	O	5041
induced	VERB	O	O	5041
cardiac dysfunction	NOUN	O	Disease	5041
:	PUNCT	O	O	5041
Prevention	NOUN	O	O	5041
by	ADP	O	O	5041
the	PRON	O	O	5041
targeted	VERB	O	O	5041
antioxidant	ADJ	O	O	5041
MitoQ.	PROPN	O	O	5041
The	PRON	O	O	5042
goal	NOUN	O	O	5042
of	ADP	O	O	5042
this	PRON	O	O	5042
study	VERB	O	O	5042
was	AUX	O	O	5042
to	PART	O	O	5042
assess	VERB	O	O	5042
mitochondrial	ADJ	O	O	5042
function	NOUN	O	O	5042
and	CCONJ	O	O	5042
ROS	PROPN	O	O	5042
production	NOUN	O	O	5042
in	ADP	O	O	5042
an	PRON	O	O	5042
experimental	ADJ	O	O	5042
model	NOUN	O	O	5042
of	ADP	O	O	5042
cocaine	NOUN	O	Chemical	5042
-	PUNCT	O	O	5042
induced	VERB	O	O	5042
cardiac dysfunction	NOUN	O	Disease	5042
.	PUNCT	O	O	5042
We	PRON	O	O	5043
hypothesized	VERB	O	O	5043
that	SCONJ	O	O	5043
cocaine abuse	NOUN	O	Disease	5043
may	AUX	O	O	5043
lead	VERB	O	Chemical	5043
to	PART	O	O	5043
altered	VERB	O	O	5043
mitochondrial	ADJ	O	O	5043
function	NOUN	O	O	5043
that	SCONJ	O	O	5043
in	ADP	O	O	5043
turn	VERB	O	O	5043
may	AUX	O	O	5043
cause	VERB	O	O	5043
left ventricular dysfunction	NOUN	O	Disease	5043
.	PUNCT	O	O	5043
Seven	NUM	O	O	5044
days	NOUN	O	O	5044
of	ADP	O	O	5044
cocaine	NOUN	O	Chemical	5044
administration	NOUN	O	O	5044
to	PART	O	O	5044
rats	NOUN	O	O	5044
led	VERB	O	O	5044
to	PART	O	O	5044
an	PRON	O	O	5044
increased	VERB	O	O	5044
oxygen	NOUN	O	Chemical	5044
consumption	NOUN	O	O	5044
detected	VERB	O	O	5044
in	ADP	O	O	5044
cardiac	ADJ	O	O	5044
fibers	NOUN	O	O	5044
,	PUNCT	O	O	5044
specifically	ADV	O	O	5044
through	ADP	O	O	5044
complex	ADJ	O	O	5044
I	PRON	O	O	5044
and	CCONJ	O	O	5044
complex	ADJ	O	O	5044
III	NUM	O	O	5044
.	PUNCT	O	O	5044
In	ADP	O	O	5045
parallel	ADJ	O	O	5045
there	ADV	O	O	5045
was	AUX	O	O	5045
a	PRON	O	O	5045
decrease	VERB	O	O	5045
in	ADP	O	O	5045
ATP	PROPN	O	Chemical	5045
synthesis	NOUN	O	O	5045
,	PUNCT	O	O	5045
whereas	SCONJ	O	O	5045
no	PRON	O	O	5045
difference	NOUN	O	O	5045
was	AUX	O	O	5045
observed	VERB	O	O	5045
in	ADP	O	O	5045
subsarcolemmal	NOUN	O	O	5045
mitochondria	PROPN	O	O	5045
.	PUNCT	O	O	5045
This	PRON	O	O	5046
uncoupling	VERB	O	O	5046
effect	VERB	O	O	5046
on	ADP	O	O	5046
oxidative	NOUN	O	O	5046
phosphorylation	NOUN	O	O	5046
was	AUX	O	O	5046
not	PART	O	O	5046
detectable	ADJ	O	O	5046
after	ADP	O	O	5046
short	ADJ	O	O	5046
-	PUNCT	O	O	5046
term	NOUN	O	O	5046
exposure	NOUN	O	O	5046
to	PART	O	O	5046
cocaine	NOUN	O	Chemical	5046
,	PUNCT	O	O	5046
suggesting	VERB	O	O	5046
that	SCONJ	O	O	5046
these	PRON	O	O	5046
mitochondrial	ADJ	O	O	5046
abnormalities	NOUN	O	O	5046
were	AUX	O	O	5046
a	PRON	O	O	5046
late	ADV	O	O	5046
rather	ADV	O	O	5046
than	ADP	O	O	5046
a	PRON	O	O	5046
primary	NOUN	O	O	5046
event	NOUN	O	O	5046
in	ADP	O	O	5046
the	PRON	O	O	5046
pathological	ADJ	O	O	5046
response	NOUN	O	O	5046
to	PART	O	O	5046
cocaine	NOUN	O	Chemical	5046
.	PUNCT	O	O	5046
MitoQ	VERB	O	O	5047
,	PUNCT	O	O	5047
a	PRON	O	O	5047
mitochondrial	ADJ	O	O	5047
-	PUNCT	O	O	5047
targeted	VERB	O	O	5047
antioxidant	ADJ	O	O	5047
,	PUNCT	O	O	5047
was	AUX	O	O	5047
shown	VERB	O	O	5047
to	PART	O	O	5047
completely	ADV	O	O	5047
prevent	VERB	O	O	5047
these	PRON	O	O	5047
mitochondrial	ADJ	O	O	5047
abnormalities	NOUN	O	O	5047
as	ADP	O	O	5047
well	ADV	O	O	5047
as	ADP	O	O	5047
cardiac dysfunction	NOUN	O	Disease	5047
characterized	VERB	O	O	5047
here	ADV	O	O	5047
by	ADP	O	O	5047
a	PRON	O	O	5047
diastolic	ADV	O	O	5047
dysfunction	NOUN	O	O	5047
studied	VERB	O	O	5047
with	ADP	O	O	5047
a	PRON	O	O	5047
conductance	NOUN	O	O	5047
catheter	VERB	O	O	5047
to	PART	O	O	5047
obtain	VERB	O	O	5047
pressure	NOUN	O	O	5047
-	PUNCT	O	O	5047
volume	PROPN	O	O	5047
data	NOUN	O	O	5047
.	PUNCT	O	O	5047
Taken	VERB	O	O	5048
together	ADV	O	O	5048
,	PUNCT	O	O	5048
these	PRON	O	O	5048
results	VERB	O	O	5048
extend	VERB	O	O	5048
previous	ADJ	O	O	5048
studies	NOUN	O	O	5048
and	CCONJ	O	O	5048
demonstrate	VERB	O	O	5048
that	SCONJ	O	O	5048
cocaine	NOUN	O	Chemical	5048
-	PUNCT	O	O	5048
induced	VERB	O	O	5048
cardiac dysfunction	NOUN	O	Disease	5048
may	AUX	O	O	5048
be	AUX	O	O	5048
due	ADJ	O	O	5048
to	PART	O	O	5048
a	PRON	O	O	5048
mitochondrial	ADJ	O	O	5048
defect	NOUN	O	O	5048
.	PUNCT	O	O	5048
Trimethoprim	NUM	O	O	5051
-	PUNCT	O	O	5051
induced	VERB	O	O	5051
immune	NOUN	O	O	5051
hemolytic anemia	NOUN	O	Disease	5051
in	ADP	O	O	5051
a	PRON	O	O	5051
pediatric	ADJ	O	O	5051
oncology	NOUN	O	O	5051
patient	NOUN	O	O	5051
presenting	VERB	O	O	5051
as	ADP	O	O	5051
an	PRON	O	O	5051
acute	ADJ	O	O	5051
hemolytic	ADJ	O	O	5051
transfusion	NOUN	O	O	5051
reaction	NOUN	O	O	5051
.	PUNCT	O	O	5051
A	PRON	O	O	5052
10-year	NOUN	O	O	5052
-	PUNCT	O	O	5052
old	ADJ	O	O	5052
male	NOUN	O	O	5052
with	ADP	O	O	5052
acute	ADJ	O	O	5052
leukemia	NOUN	O	Disease	5052
presented	VERB	O	O	5052
with	ADP	O	O	5052
post	VERB	O	O	5052
-	PUNCT	O	O	5052
chemotherapy	NOUN	O	O	5052
anemia	NOUN	O	Disease	5052
.	PUNCT	O	O	5052
During	ADP	O	O	5053
red	ADJ	O	O	5053
cell	NOUN	O	O	5053
transfusion	NOUN	O	O	5053
,	PUNCT	O	O	5053
he	PRON	O	O	5053
developed	VERB	O	O	5053
hemoglobinuria	PROPN	O	O	5053
.	PUNCT	O	O	5053
Drug	NOUN	O	O	5054
-	PUNCT	O	O	5054
induced	VERB	O	O	5054
immune	NOUN	O	O	5054
hemolytic anemia	NOUN	O	Disease	5054
was	AUX	O	O	5054
suspected	VERB	O	O	5054
because	SCONJ	O	O	5054
of	ADP	O	O	5054
positive	ADJ	O	O	5054
direct	ADJ	O	O	5054
antiglobulin	PROPN	O	O	5054
test	NOUN	O	O	5054
,	PUNCT	O	O	5054
negative	ADJ	O	O	5054
eluate	ADJ	O	O	5054
,	PUNCT	O	O	5054
and	CCONJ	O	O	5054
microspherocytes	VERB	O	O	5054
on	ADP	O	O	5054
smear	VERB	O	O	5054
pre-	ADV	O	O	5054
and	CCONJ	O	O	5054
post	VERB	O	O	5054
-	PUNCT	O	O	5054
transfusion	NOUN	O	O	5054
.	PUNCT	O	O	5054
Drug	NOUN	O	O	5055
studies	NOUN	O	O	5055
using	VERB	O	O	5055
the	PRON	O	O	5055
indirect	ADJ	O	O	5055
antiglobulin	PROPN	O	O	5055
test	NOUN	O	O	5055
were	AUX	O	O	5055
strongly	ADV	O	O	5055
positive	ADJ	O	O	5055
with	ADP	O	O	5055
trimethoprim	PROPN	O	O	5055
and	CCONJ	O	O	5055
trimethoprim	PROPN	O	O	5055
-	PUNCT	O	O	5055
sulfamethoxazole	NOUN	O	O	5055
but	CCONJ	O	O	5055
negative	ADJ	O	O	5055
with	ADP	O	O	5055
sulfamethoxazole	NOUN	O	O	5055
.	PUNCT	O	O	5055
Other	ADJ	O	O	5056
causes	VERB	O	O	5056
of	ADP	O	O	5056
anemia	NOUN	O	Disease	5056
should	AUX	O	O	5056
be	AUX	O	O	5056
considered	VERB	O	O	5056
in	ADP	O	O	5056
patients	NOUN	O	O	5056
with	ADP	O	O	5056
worse	ADJ	O	O	5056
-	PUNCT	O	O	5056
than	ADP	O	O	5056
-	PUNCT	O	O	5056
expected	VERB	O	O	5056
anemia	NOUN	O	Disease	5056
after	ADP	O	O	5056
chemotherapy	NOUN	O	O	5056
.	PUNCT	O	O	5056
Furthermore	ADV	O	O	5057
,	PUNCT	O	O	5057
hemolysis	NOUN	O	Disease	5057
during	ADP	O	O	5057
transfusion	NOUN	O	O	5057
is	AUX	O	O	5057
not	PART	O	O	5057
always	ADV	O	O	5057
a	PRON	O	O	5057
transfusion	NOUN	O	O	5057
reaction	NOUN	O	O	5057
.	PUNCT	O	O	5057
Blockade	NOUN	O	O	5060
of	ADP	O	O	5060
endothelial	NOUN	O	O	5060
-	PUNCT	O	O	5060
mesenchymal	NOUN	O	O	5060
transition	NOUN	O	O	5060
by	ADP	O	O	5060
a	PRON	O	O	5060
Smad3	NOUN	O	O	5060
inhibitor	NOUN	O	O	5060
delays	VERB	O	O	5060
the	PRON	O	O	5060
early	ADV	O	O	5060
development	NOUN	O	O	5060
of	ADP	O	O	5060
streptozotocin	PROPN	O	Chemical	5060
-	PUNCT	O	O	5060
induced	VERB	O	O	5060
diabetic nephropathy	NOUN	O	Disease	5060
.	PUNCT	O	O	5060
OBJECTIVE	VERB	O	O	5061
:	PUNCT	O	O	5061
A	PRON	O	O	5061
multicenter	ADJ	O	O	5061
,	PUNCT	O	O	5061
controlled	VERB	O	O	5061
trial	NOUN	O	O	5061
showed	VERB	O	O	5061
that	SCONJ	O	O	5061
early	ADV	O	O	5061
blockade	VERB	O	O	5061
of	ADP	O	O	5061
the	PRON	O	O	5061
renin	PROPN	O	O	5061
-	PUNCT	O	O	5061
angiotensin	NOUN	O	Chemical	5061
system	NOUN	O	O	5061
in	ADP	O	O	5061
patients	NOUN	O	O	5061
with	ADP	O	O	5061
type	NOUN	O	O	5061
1	X	O	O	5061
diabetes	NOUN	O	Disease	5061
and	CCONJ	O	O	5061
normoalbuminuria	PROPN	O	O	5061
did	VERB	O	O	5061
not	PART	O	O	5061
retard	NOUN	O	O	5061
the	PRON	O	O	5061
progression	NOUN	O	O	5061
of	ADP	O	O	5061
nephropathy	NOUN	O	Disease	5061
,	PUNCT	O	O	5061
suggesting	VERB	O	O	5061
that	SCONJ	O	O	5061
other	ADJ	O	O	5061
mechanism(s	NOUN	O	O	5061
)	PUNCT	O	O	5061
are	AUX	O	O	5061
involved	VERB	O	O	5061
in	ADP	O	O	5061
the	PRON	O	O	5061
pathogenesis	NOUN	O	O	5061
of	ADP	O	O	5061
early	ADV	O	O	5061
diabetic nephropathy	NOUN	O	Disease	5061
(	PUNCT	O	O	5061
diabetic nephropathy	NOUN	O	Disease	5061
)	PUNCT	O	O	5061
.	PUNCT	O	O	5061
We	PRON	O	O	5062
have	VERB	O	O	5062
previously	ADV	O	O	5062
demonstrated	VERB	O	O	5062
that	SCONJ	O	O	5062
endothelial	NOUN	O	O	5062
-	PUNCT	O	O	5062
mesenchymal	NOUN	O	O	5062
-	PUNCT	O	O	5062
transition	NOUN	O	O	5062
(	PUNCT	O	O	5062
EndoMT	NOUN	O	O	5062
)	PUNCT	O	O	5062
contributes	VERB	O	O	5062
to	PART	O	O	5062
the	PRON	O	O	5062
early	ADV	O	O	5062
development	NOUN	O	O	5062
of	ADP	O	O	5062
renal	ADJ	O	O	5062
interstitial	ADJ	O	O	5062
fibrosis	NOUN	O	Disease	5062
independently	ADV	O	O	5062
of	ADP	O	O	5062
microalbuminuria	PROPN	O	O	5062
in	ADP	O	O	5062
mice	NOUN	O	O	5062
with	ADP	O	O	5062
streptozotocin	PROPN	O	Chemical	5062
(	PUNCT	O	O	5062
STZ)-induced	VERB	O	O	5062
diabetes	NOUN	O	Disease	5062
.	PUNCT	O	O	5062
In	ADP	O	O	5063
the	PRON	O	O	5063
present	NOUN	O	O	5063
study	VERB	O	O	5063
,	PUNCT	O	O	5063
we	PRON	O	O	5063
hypothesized	VERB	O	O	5063
that	SCONJ	O	O	5063
blocking	VERB	O	O	5063
EndoMT	NOUN	O	O	5063
reduces	VERB	O	O	5063
the	PRON	O	O	5063
early	ADV	O	O	5063
development	NOUN	O	O	5063
of	ADP	O	O	5063
diabetic nephropathy	NOUN	O	Disease	5063
.	PUNCT	O	O	5063
Blocking	VERB	O	O	5064
studies	NOUN	O	O	5064
using	VERB	O	O	5064
receptor	NOUN	O	O	5064
for	ADP	O	O	5064
AGE	NOUN	O	O	5064
siRNA	PROPN	O	O	5064
and	CCONJ	O	O	5064
a	PRON	O	O	5064
specific	ADJ	O	O	5064
inhibitor	NOUN	O	O	5064
of	ADP	O	O	5064
Smad3	NOUN	O	O	5064
(	PUNCT	O	O	5064
SIS3	PROPN	O	O	5064
)	PUNCT	O	O	5064
were	AUX	O	O	5064
performed	VERB	O	O	5064
in	ADP	O	O	5064
MMECs	NOUN	O	O	5064
and	CCONJ	O	O	5064
in	ADP	O	O	5064
STZ	PROPN	O	Chemical	5064
-	PUNCT	O	O	5064
induced	VERB	O	O	5064
diabetic nephropathy	NOUN	O	Disease	5064
in	ADP	O	O	5064
Tie2-Cre;Loxp	NUM	O	O	5064
-	PUNCT	O	O	5064
EGFP	NOUN	O	O	5064
mice	NOUN	O	O	5064
.	PUNCT	O	O	5064
/	PUNCT	O	O	5065
Western	ADJ	O	O	5065
blotting	VERB	O	O	5065
showed	VERB	O	O	5065
that	SCONJ	O	O	5065
Smad3	NOUN	O	O	5065
was	AUX	O	O	5065
activated	VERB	O	O	5065
by	ADP	O	O	5065
AGEs	NOUN	O	O	5065
but	CCONJ	O	O	5065
was	AUX	O	O	5065
inhibited	VERB	O	O	5065
by	ADP	O	O	5065
SIS3	PROPN	O	O	5065
in	ADP	O	O	5065
MMECs	NOUN	O	O	5065
and	CCONJ	O	O	5065
in	ADP	O	O	5065
STZ	PROPN	O	Chemical	5065
-	PUNCT	O	O	5065
induced	VERB	O	O	5065
diabetic nephropathy	NOUN	O	Disease	5065
.	PUNCT	O	O	5065
Confocal	PROPN	O	O	5066
microscopy	NOUN	O	O	5066
and	CCONJ	O	O	5066
real	ADV	O	O	5066
-	PUNCT	O	O	5066
time	NOUN	O	O	5066
PCR	PROPN	O	O	5066
further	ADV	O	O	5066
demonstrated	VERB	O	O	5066
that	SCONJ	O	O	5066
SIS3	PROPN	O	O	5066
abrogated	VERB	O	O	5066
EndoMT	NOUN	O	O	5066
,	PUNCT	O	O	5066
reduced	VERB	O	O	5066
renal	ADJ	O	O	5066
fibrosis	NOUN	O	Disease	5066
,	PUNCT	O	O	5066
and	CCONJ	O	O	5066
retarded	ADJ	O	O	5066
progression	NOUN	O	O	5066
of	ADP	O	O	5066
nephropathy	NOUN	O	Disease	5066
.	PUNCT	O	O	5066
EndoMT	NOUN	O	O	5067
is	AUX	O	O	5067
a	PRON	O	O	5067
novel	NOUN	O	O	5067
pathway	NOUN	O	O	5067
leading	VERB	O	O	5067
to	PART	O	O	5067
early	ADV	O	O	5067
development	NOUN	O	O	5067
of	ADP	O	O	5067
diabetic nephropathy	NOUN	O	Disease	5067
.	PUNCT	O	O	5067
Blockade	NOUN	O	O	5068
of	ADP	O	O	5068
EndoMT	NOUN	O	O	5068
by	ADP	O	O	5068
SIS3	PROPN	O	O	5068
may	AUX	O	O	5068
provide	VERB	O	O	5068
a	PRON	O	O	5068
new	ADJ	O	O	5068
strategy	NOUN	O	O	5068
to	PART	O	O	5068
retard	NOUN	O	O	5068
the	PRON	O	O	5068
progression	NOUN	O	O	5068
of	ADP	O	O	5068
diabetic nephropathy	NOUN	O	Disease	5068
and	CCONJ	O	O	5068
other	ADJ	O	O	5068
diabetes	NOUN	O	Disease	5068
complications	NOUN	O	O	5068
.	PUNCT	O	O	5068
Cytostatic	ADJ	O	O	5071
and	CCONJ	O	O	5071
anti	ADJ	O	O	5071
-	PUNCT	O	O	5071
angiogenic	ADJ	O	O	5071
effects	NOUN	O	O	5071
of	ADP	O	O	5071
temsirolimus	VERB	O	O	5071
in	ADP	O	O	5071
refractory	ADJ	O	O	5071
mantle	NOUN	O	O	5071
cell	NOUN	O	O	5071
lymphoma	PROPN	O	Disease	5071
.	PUNCT	O	O	5071
Mantle	NOUN	O	O	5072
cell	NOUN	O	O	5072
lymphoma	PROPN	O	Disease	5072
(	PUNCT	O	O	5072
MCL	NOUN	O	O	5072
)	PUNCT	O	O	5072
is	AUX	O	O	5072
a	PRON	O	O	5072
rare	ADJ	O	O	5072
and	CCONJ	O	O	5072
aggressive	ADJ	O	O	5072
type	NOUN	O	O	5072
of	ADP	O	O	5072
B	NOUN	O	O	5072
-	PUNCT	O	O	5072
cell	NOUN	O	O	5072
non	ADJ	O	O	5072
-	PUNCT	O	O	5072
Hodgkin	PROPN	O	O	5072
's	AUX	O	O	5072
lymphoma	PROPN	O	Disease	5072
.	PUNCT	O	O	5072
However	ADV	O	O	5073
,	PUNCT	O	O	5073
a	PRON	O	O	5073
38%	NOUN	O	O	5073
remission	NOUN	O	O	5073
rate	NOUN	O	O	5073
has	VERB	O	O	5073
been	AUX	O	O	5073
recently	ADV	O	O	5073
reported	VERB	O	O	5073
in	ADP	O	O	5073
refractory	ADJ	O	O	5073
MCL	NOUN	O	O	5073
treated	VERB	O	O	5073
with	ADP	O	O	5073
temsirolimus	VERB	O	O	5073
,	PUNCT	O	O	5073
a	PRON	O	O	5073
mTOR	PROPN	O	O	5073
inhibitor	NOUN	O	O	5073
.	PUNCT	O	O	5073
Here	ADV	O	O	5074
we	PRON	O	O	5074
had	VERB	O	O	5074
the	PRON	O	O	5074
opportunity	NOUN	O	O	5074
to	PART	O	O	5074
study	VERB	O	O	5074
a	PRON	O	O	5074
case	NOUN	O	O	5074
of	ADP	O	O	5074
refractory	ADJ	O	O	5074
MCL	NOUN	O	O	5074
who	PRON	O	O	5074
had	VERB	O	O	5074
tumor	NOUN	O	Disease	5074
regression	NOUN	O	O	5074
two	NUM	O	O	5074
months	NOUN	O	O	5074
after	ADP	O	O	5074
temsirolimus	VERB	O	O	5074
treatment	NOUN	O	O	5074
,	PUNCT	O	O	5074
and	CCONJ	O	O	5074
a	PRON	O	O	5074
progression	NOUN	O	O	5074
-	PUNCT	O	O	5074
free	ADJ	O	O	5074
survival	NOUN	O	O	5074
of	ADP	O	O	5074
10	NUM	O	O	5074
months	NOUN	O	O	5074
.	PUNCT	O	O	5074
In	ADP	O	O	5075
this	PRON	O	O	5075
case	NOUN	O	O	5075
,	PUNCT	O	O	5075
lymph	NOUN	O	O	5075
node	NOUN	O	O	5075
biopsies	NOUN	O	O	5075
were	AUX	O	O	5075
performed	VERB	O	O	5075
before	ADP	O	O	5075
and	CCONJ	O	O	5075
six	NUM	O	O	5075
months	NOUN	O	O	5075
after	ADP	O	O	5075
temsirolimus	VERB	O	O	5075
therapy	NOUN	O	O	5075
.	PUNCT	O	O	5075
Comparison	NOUN	O	O	5076
of	ADP	O	O	5076
the	PRON	O	O	5076
two	NUM	O	O	5076
biopsies	NOUN	O	O	5076
showed	VERB	O	O	5076
that	SCONJ	O	O	5076
temsirolimus	VERB	O	O	5076
inhibited	VERB	O	O	5076
tumor	NOUN	O	Disease	5076
cell	NOUN	O	O	5076
proliferation	NOUN	O	O	5076
through	ADP	O	O	5076
cell	NOUN	O	O	5076
cycle	PROPN	O	O	5076
arrest	VERB	O	O	5076
,	PUNCT	O	O	5076
but	CCONJ	O	O	5076
did	VERB	O	O	5076
not	PART	O	O	5076
induce	VERB	O	O	5076
any	PRON	O	O	5076
change	VERB	O	O	5076
in	ADP	O	O	5076
the	PRON	O	O	5076
number	NOUN	O	O	5076
of	ADP	O	O	5076
apoptotic	ADJ	O	O	5076
tumor	NOUN	O	Disease	5076
cells	NOUN	O	O	5076
.	PUNCT	O	O	5076
Apart	ADV	O	O	5077
from	ADP	O	O	5077
this	PRON	O	O	5077
cytostatic	ADJ	O	O	5077
effect	VERB	O	O	5077
,	PUNCT	O	O	5077
temsirolimus	VERB	O	O	5077
had	VERB	O	O	5077
an	PRON	O	O	5077
antiangiogenic	ADJ	O	O	5077
effect	VERB	O	O	5077
with	ADP	O	O	5077
decrease	VERB	O	O	5077
of	ADP	O	O	5077
tumor	NOUN	O	Disease	5077
microvessel	NOUN	O	O	5077
density	NOUN	O	O	5077
and	CCONJ	O	O	5077
of	ADP	O	O	5077
VEGF	PROPN	O	O	5077
expression	NOUN	O	O	5077
.	PUNCT	O	O	5077
Moreover	ADV	O	O	5078
,	PUNCT	O	O	5078
numerous	ADJ	O	O	5078
patchy	ADJ	O	O	5078
,	PUNCT	O	O	5078
well	ADV	O	O	5078
-	PUNCT	O	O	5078
limited	VERB	O	O	5078
fibrotic	ADJ	O	O	5078
areas	NOUN	O	O	5078
,	PUNCT	O	O	5078
compatible	ADJ	O	O	5078
with	ADP	O	O	5078
post	VERB	O	O	5078
-	PUNCT	O	O	5078
necrotic	ADJ	O	O	5078
tissue	NOUN	O	O	5078
repair	PROPN	O	O	5078
,	PUNCT	O	O	5078
were	AUX	O	O	5078
found	VERB	O	O	5078
after	ADP	O	O	5078
6-month	NOUN	O	O	5078
temsirolimus	VERB	O	O	5078
therapy	NOUN	O	O	5078
.	PUNCT	O	O	5078
Thus	ADV	O	O	5079
,	PUNCT	O	O	5079
temsirolimus	VERB	O	O	5079
reduced	VERB	O	O	5079
tumor	NOUN	O	Disease	5079
burden	VERB	O	O	5079
through	ADP	O	O	5079
associated	VERB	O	O	5079
cytostatic	ADJ	O	O	5079
and	CCONJ	O	O	5079
anti	ADJ	O	O	5079
-	PUNCT	O	O	5079
angiogenic	ADJ	O	O	5079
effects	NOUN	O	O	5079
.	PUNCT	O	O	5079
This	PRON	O	O	5080
dual	ADJ	O	O	5080
effect	VERB	O	O	5080
of	ADP	O	O	5080
temsirolimus	VERB	O	O	5080
on	ADP	O	O	5080
tumor	NOUN	O	Disease	5080
tissue	NOUN	O	O	5080
could	AUX	O	O	5080
contribute	VERB	O	O	5080
to	PART	O	O	5080
its	PRON	O	O	5080
recently	ADV	O	O	5080
reported	VERB	O	O	5080
efficiency	NOUN	O	O	5080
in	ADP	O	O	5080
refractory	ADJ	O	O	5080
MCL	NOUN	O	O	5080
resistant	ADJ	O	O	5080
to	PART	O	O	5080
conventional	ADJ	O	O	5080
chemotherapy	NOUN	O	O	5080
.	PUNCT	O	O	5080
Syncope	NOUN	O	Disease	5083
caused	VERB	O	O	5083
by	ADP	O	O	5083
hyperkalemia	NOUN	O	O	5083
during	ADP	O	O	5083
use	VERB	O	O	5083
of	ADP	O	O	5083
a	PRON	O	O	5083
combined	VERB	O	O	5083
therapy	NOUN	O	O	5083
with	ADP	O	O	5083
the	PRON	O	O	5083
angiotensin	NOUN	O	Chemical	5083
-	PUNCT	O	O	5083
converting	VERB	O	O	5083
enzyme	NOUN	O	O	5083
inhibitor	NOUN	O	O	5083
and	CCONJ	O	O	5083
spironolactone	NOUN	O	Chemical	5083
.	PUNCT	O	O	5083
A	PRON	O	O	5084
76	NUM	O	O	5084
year	NOUN	O	O	5084
-	PUNCT	O	O	5084
old	ADJ	O	O	5084
woman	NOUN	O	O	5084
with	ADP	O	O	5084
a	PRON	O	O	5084
history	NOUN	O	O	5084
of	ADP	O	O	5084
coronary	ADJ	O	O	5084
artery	NOUN	O	O	5084
bypass	NOUN	O	O	5084
grafting	VERB	O	O	5084
and	CCONJ	O	O	5084
prior	ADV	O	O	5084
myocardial infarction	NOUN	O	Disease	5084
was	AUX	O	O	5084
transferred	VERB	O	O	5084
to	PART	O	O	5084
the	PRON	O	O	5084
emergency	NOUN	O	O	5084
room	NOUN	O	O	5084
with	ADP	O	O	5084
loss	NOUN	O	O	5084
of	ADP	O	O	5084
consciousness	NOUN	O	O	5084
due	ADJ	O	O	5084
to	PART	O	O	5084
marked	VERB	O	O	5084
bradycardia	NOUN	O	Disease	5084
caused	VERB	O	O	5084
by	ADP	O	O	5084
hyperkalemia	NOUN	O	O	5084
.	PUNCT	O	O	5084
The	PRON	O	O	5085
concentration	NOUN	O	O	5085
of	ADP	O	O	5085
serum	NOUN	O	O	5085
potassium	NOUN	O	Chemical	5085
was	AUX	O	O	5085
high	ADJ	O	O	5085
,	PUNCT	O	O	5085
and	CCONJ	O	O	5085
normal	ADJ	O	O	5085
sinus	NOUN	O	O	5085
rhythm	VERB	O	O	5085
was	AUX	O	O	5085
restored	VERB	O	O	5085
after	ADP	O	O	5085
correction	PROPN	O	O	5085
of	ADP	O	O	5085
the	PRON	O	O	5085
serum	NOUN	O	O	5085
potassium	NOUN	O	Chemical	5085
level	VERB	O	O	5085
.	PUNCT	O	O	5085
The	PRON	O	O	5086
cause	VERB	O	O	5086
of	ADP	O	O	5086
hyperkalemia	NOUN	O	O	5086
was	AUX	O	O	5086
considered	VERB	O	O	5086
to	PART	O	O	5086
be	AUX	O	O	5086
several	ADJ	O	O	5086
doses	NOUN	O	O	5086
of	ADP	O	O	5086
spiranolactone	NOUN	O	O	5086
,	PUNCT	O	O	5086
an	PRON	O	O	5086
aldosterone	NOUN	O	Chemical	5086
antagonist	NOUN	O	O	5086
,	PUNCT	O	O	5086
in	ADP	O	O	5086
addition	NOUN	O	O	5086
to	PART	O	O	5086
the	PRON	O	O	5086
long	ADV	O	O	5086
-	PUNCT	O	O	5086
term	NOUN	O	O	5086
intake	PROPN	O	O	5086
of	ADP	O	O	5086
ramipril	PROPN	O	O	5086
,	PUNCT	O	O	5086
an	PRON	O	O	5086
ACE	PROPN	O	O	5086
inhibitor	NOUN	O	O	5086
.	PUNCT	O	O	5086
Clinicians	NOUN	O	O	5087
should	AUX	O	O	5087
be	AUX	O	O	5087
alert	ADJ	O	O	5087
to	PART	O	O	5087
the	PRON	O	O	5087
possibility	NOUN	O	O	5087
of	ADP	O	O	5087
hyperkalemia	NOUN	O	O	5087
,	PUNCT	O	O	5087
especially	ADV	O	O	5087
in	ADP	O	O	5087
elderly	ADJ	O	O	5087
patients	NOUN	O	O	5087
using	VERB	O	O	5087
ACE	PROPN	O	O	5087
/	PUNCT	O	O	5087
ARB	PROPN	O	O	5087
in	ADP	O	O	5087
combination	NOUN	O	O	5087
with	ADP	O	O	5087
potassium	NOUN	O	Chemical	5087
sparing	VERB	O	O	5087
agents	NOUN	O	O	5087
and	CCONJ	O	O	5087
who	PRON	O	O	5087
have	VERB	O	O	5087
mild	ADJ	O	O	5087
renal	ADJ	O	O	5087
disturbance	NOUN	O	O	5087
.	PUNCT	O	O	5087
Diffuse	VERB	O	O	5090
skeletal	ADJ	O	O	5090
pain	NOUN	O	Disease	5090
after	ADP	O	O	5090
administration	NOUN	O	O	5090
of	ADP	O	O	5090
alendronate	NOUN	O	O	5090
.	PUNCT	O	O	5090
Osteoporosis	NOUN	O	O	5091
is	AUX	O	O	5091
caused	VERB	O	O	5091
by	ADP	O	O	5091
bone	NOUN	O	O	5091
resorption	NOUN	O	O	5091
in	ADP	O	O	5091
excess	ADJ	O	O	5091
of	ADP	O	O	5091
bone	NOUN	O	O	5091
formation	NOUN	O	O	5091
,	PUNCT	O	O	5091
and	CCONJ	O	O	5091
bisphosphonates	VERB	O	O	5091
,	PUNCT	O	O	5091
are	AUX	O	O	5091
used	VERB	O	O	5091
to	PART	O	O	5091
inhibit	VERB	O	O	5091
bone	NOUN	O	O	5091
resorption	NOUN	O	O	5091
.	PUNCT	O	O	5091
Alendronate	NOUN	O	O	5092
,	PUNCT	O	O	5092
a	PRON	O	O	5092
biphosphonate	VERB	O	O	5092
,	PUNCT	O	O	5092
is	AUX	O	O	5092
effective	ADJ	O	O	5092
for	ADP	O	O	5092
both	PRON	O	O	5092
the	PRON	O	O	5092
treatment	NOUN	O	O	5092
and	CCONJ	O	O	5092
prevention	NOUN	O	O	5092
of	ADP	O	O	5092
osteoporosis	NOUN	O	Disease	5092
in	ADP	O	O	5092
postmenopausal	NOUN	O	O	5092
women	NOUN	O	O	5092
.	PUNCT	O	O	5092
Musculoskeletal	ADJ	O	O	5093
pain	NOUN	O	Disease	5093
may	AUX	O	O	5093
be	AUX	O	O	5093
an	PRON	O	O	5093
important	ADJ	O	O	5093
side	NOUN	O	O	5093
effect	VERB	O	O	5093
in	ADP	O	O	5093
these	PRON	O	O	5093
patients	NOUN	O	O	5093
.	PUNCT	O	O	5093
We	PRON	O	O	5094
presented	VERB	O	O	5094
a	PRON	O	O	5094
patient	NOUN	O	O	5094
admitted	VERB	O	O	5094
to	PART	O	O	5094
our	PRON	O	O	5094
out	ADP	O	O	5094
-	PUNCT	O	O	5094
patient	NOUN	O	O	5094
clinic	NOUN	O	O	5094
with	ADP	O	O	5094
diffuse	VERB	O	O	5094
skeletal	ADJ	O	O	5094
pain	NOUN	O	Disease	5094
after	ADP	O	O	5094
three	NUM	O	O	5094
consecutive	ADJ	O	O	5094
administration	NOUN	O	O	5094
of	ADP	O	O	5094
alendronate	NOUN	O	O	5094
.	PUNCT	O	O	5094
We	PRON	O	O	5095
conclude	VERB	O	O	5095
that	SCONJ	O	O	5095
patients	NOUN	O	O	5095
with	ADP	O	O	5095
osteoporosis	NOUN	O	Disease	5095
can	AUX	O	O	5095
report	VERB	O	O	5095
pain	NOUN	O	Disease	5095
,	PUNCT	O	O	5095
and	CCONJ	O	O	5095
bisphosphonate	NOUN	O	O	5095
-	PUNCT	O	O	5095
related	ADJ	O	O	5095
pain	NOUN	O	Disease	5095
should	AUX	O	O	5095
also	ADV	O	O	5095
be	AUX	O	O	5095
considered	VERB	O	O	5095
before	ADP	O	O	5095
ascribing	VERB	O	O	5095
this	PRON	O	O	5095
complaint	NOUN	O	O	5095
to	PART	O	O	5095
osteoporosis	NOUN	O	Disease	5095
.	PUNCT	O	O	5095
Cerebrospinal	NOUN	O	O	5098
fluid	NOUN	O	O	5098
penetration	NOUN	O	O	5098
of	ADP	O	O	5098
high	ADJ	O	O	5098
-	PUNCT	O	O	5098
dose	NOUN	O	O	5098
daptomycin	PROPN	O	O	5098
in	ADP	O	O	5098
suspected	VERB	O	O	5098
Staphylococcus	PROPN	O	O	5098
aureus	PROPN	O	O	5098
meningitis	PROPN	O	O	5098
.	PUNCT	O	O	5098
OBJECTIVE	VERB	O	O	5099
:	PUNCT	O	O	5099
To	PART	O	O	5099
report	VERB	O	O	5099
a	PRON	O	O	5099
case	NOUN	O	O	5099
of	ADP	O	O	5099
methicillin	VERB	O	O	5099
-	PUNCT	O	O	5099
sensitive	ADJ	O	O	5099
Staphylococcus	PROPN	O	O	5099
aureus	PROPN	O	O	5099
(	PUNCT	O	O	5099
MSSA	PROPN	O	O	5099
)	PUNCT	O	O	5099
bacteremia	NOUN	O	Disease	5099
with	ADP	O	O	5099
suspected	VERB	O	O	5099
MSSA	PROPN	O	O	5099
meningitis	PROPN	O	O	5099
treated	VERB	O	O	5099
with	ADP	O	O	5099
high	ADJ	O	O	5099
-	PUNCT	O	O	5099
dose	NOUN	O	O	5099
daptomycin	PROPN	O	O	5099
assessed	VERB	O	O	5099
with	ADP	O	O	5099
concurrent	ADJ	O	O	5099
serum	NOUN	O	O	5099
and	CCONJ	O	O	5099
cerebrospinal	ADJ	O	O	5099
fluid	NOUN	O	O	5099
(	PUNCT	O	O	5099
CSF	PROPN	O	O	5099
)	PUNCT	O	O	5099
concentrations	NOUN	O	O	5099
.	PUNCT	O	O	5099
A	PRON	O	O	5100
54-year	NOUN	O	O	5100
-	PUNCT	O	O	5100
old	ADJ	O	O	5100
male	NOUN	O	O	5100
presented	VERB	O	O	5100
to	PART	O	O	5100
the	PRON	O	O	5100
emergency	NOUN	O	O	5100
department	NOUN	O	O	5100
with	ADP	O	O	5100
generalized	VERB	O	O	5100
weakness	NOUN	O	Disease	5100
and	CCONJ	O	O	5100
presumed	VERB	O	O	5100
health	NOUN	O	O	5100
-	PUNCT	O	O	5100
care	VERB	O	O	5100
-	PUNCT	O	O	5100
associated	VERB	O	O	5100
pneumonia	NOUN	O	Disease	5100
shown	VERB	O	O	5100
on	ADP	O	O	5100
chest	NOUN	O	O	5100
radiograph	NOUN	O	O	5100
.	PUNCT	O	O	5100
Treatment	NOUN	O	O	5101
was	AUX	O	O	5101
empirically	ADV	O	O	5101
initiated	VERB	O	O	5101
with	ADP	O	O	5101
vancomycin	VERB	O	Chemical	5101
,	PUNCT	O	O	5101
levofloxacin	PROPN	O	Chemical	5101
,	PUNCT	O	O	5101
and	CCONJ	O	O	5101
piperacillin	PROPN	O	Chemical	5101
/	PUNCT	O	O	5101
tazobactam	NOUN	O	O	5101
.	PUNCT	O	O	5101
Blood	NOUN	O	O	5102
cultures	NOUN	O	O	5102
revealed	VERB	O	O	5102
S.	PROPN	O	O	5102
aureus	PROPN	O	O	5102
susceptible	ADJ	O	O	5102
to	PART	O	O	5102
oxacillin	PROPN	O	Chemical	5102
.	PUNCT	O	O	5102
Empiric	NOUN	O	O	5103
antibiotic	ADJ	O	O	5103
treatment	NOUN	O	O	5103
was	AUX	O	O	5103
narrowed	VERB	O	O	5103
to	PART	O	O	5103
nafcillin	PROPN	O	O	5103
on	ADP	O	O	5103
day	NOUN	O	O	5103
4	NUM	O	O	5103
.	PUNCT	O	O	5103
On	ADP	O	O	5104
day	NOUN	O	O	5104
8	NUM	O	O	5104
,	PUNCT	O	O	5104
the	PRON	O	O	5104
patient	NOUN	O	O	5104
developed	VERB	O	O	5104
acute	ADJ	O	O	5104
renal failure	NOUN	O	Disease	5104
(	PUNCT	O	O	5104
serum	NOUN	O	O	5104
creatinine	PROPN	O	Chemical	5104
1.9	NUM	O	O	5104
mg	VERB	O	O	5104
/	PUNCT	O	O	5104
dL	VERB	O	O	5104
,	PUNCT	O	O	5104
increased	VERB	O	O	5104
from	ADP	O	O	5104
1.2	NUM	O	O	5104
mg	VERB	O	O	5104
/	PUNCT	O	O	5104
dL	VERB	O	O	5104
the	PRON	O	O	5104
previous	ADJ	O	O	5104
day	NOUN	O	O	5104
and	CCONJ	O	O	5104
0.8	NUM	O	O	5104
mg	VERB	O	O	5104
/	PUNCT	O	O	5104
dL	VERB	O	O	5104
on	ADP	O	O	5104
admission	NOUN	O	O	5104
)	PUNCT	O	O	5104
.	PUNCT	O	O	5104
The	PRON	O	O	5105
patient	NOUN	O	O	5105
's	AUX	O	O	5105
Glasgow	PROPN	O	O	5105
Coma	NOUN	O	O	5105
Score	NOUN	O	O	5105
was	AUX	O	O	5105
3	X	O	O	5105
,	PUNCT	O	O	5105
with	ADP	O	O	5105
normal	ADJ	O	O	5105
findings	NOUN	O	O	5105
shown	VERB	O	O	5105
on	ADP	O	O	5105
computed	VERB	O	O	5105
tomography	NOUN	O	O	5105
scan	VERB	O	O	5105
of	ADP	O	O	5105
the	PRON	O	O	5105
head	NOUN	O	O	5105
72	NUM	O	O	5105
hours	NOUN	O	O	5105
following	VERB	O	O	5105
an	PRON	O	O	5105
episode	PROPN	O	O	5105
of	ADP	O	O	5105
cardiac arrest	NOUN	O	Disease	5105
on	ADP	O	O	5105
day	NOUN	O	O	5105
10	NUM	O	O	5105
.	PUNCT	O	O	5105
The	PRON	O	O	5106
patient	NOUN	O	O	5106
experienced	ADJ	O	O	5106
relapsing	VERB	O	O	5106
MSSA	PROPN	O	O	5106
bacteremia	NOUN	O	Disease	5106
on	ADP	O	O	5106
day	NOUN	O	O	5106
9	NUM	O	O	5106
,	PUNCT	O	O	5106
increasing	VERB	O	O	5106
the	PRON	O	O	5106
suspicion	NOUN	O	O	5106
for	ADP	O	O	5106
a	PRON	O	O	5106
central	ADJ	O	O	5106
nervous	ADJ	O	O	5106
system	NOUN	O	O	5106
(	PUNCT	O	O	5106
CNS	PROPN	O	O	5106
)	PUNCT	O	O	5106
infection	NOUN	O	Disease	5106
.	PUNCT	O	O	5106
Nafcillin	PROPN	O	O	5107
was	AUX	O	O	5107
discontinued	VERB	O	O	5107
and	CCONJ	O	O	5107
daptomycin	PROPN	O	O	5107
9	NUM	O	O	5107
mg	VERB	O	O	5107
/	PUNCT	O	O	5107
kg	VERB	O	O	5107
daily	ADV	O	O	5107
was	AUX	O	O	5107
initiated	VERB	O	O	5107
for	ADP	O	O	5107
suspected	VERB	O	O	5107
meningitis	PROPN	O	O	5107
and	CCONJ	O	O	5107
was	AUX	O	O	5107
continued	VERB	O	O	5107
until	ADP	O	O	5107
the	PRON	O	O	5107
patient	NOUN	O	O	5107
's	AUX	O	O	5107
death	NOUN	O	O	5107
on	ADP	O	O	5107
day	NOUN	O	O	5107
16	NUM	O	O	5107
.	PUNCT	O	O	5107
Daptomycin	PROPN	O	O	5108
serum	NOUN	O	O	5108
and	CCONJ	O	O	5108
CSF	PROPN	O	O	5108
trough	NOUN	O	O	5108
concentrations	NOUN	O	O	5108
were	AUX	O	O	5108
11.21	NUM	O	O	5108
ug	NOUN	O	O	5108
/	PUNCT	O	O	5108
mL	PROPN	O	O	5108
and	CCONJ	O	O	5108
0.52	NUM	O	O	5108
Creatine	PROPN	O	O	5109
kinase	VERB	O	O	5109
levels	NOUN	O	O	5109
were	AUX	O	O	5109
normal	ADJ	O	O	5109
prior	ADV	O	O	5109
to	PART	O	O	5109
daptomycin	PROPN	O	O	5109
therapy	NOUN	O	O	5109
and	CCONJ	O	O	5109
were	AUX	O	O	5109
not	PART	O	O	5109
reassessed	VERB	O	O	5109
.	PUNCT	O	O	5109
Daptomycin	PROPN	O	O	5110
was	AUX	O	O	5110
initiated	VERB	O	O	5110
in	ADP	O	O	5110
our	PRON	O	O	5110
patient	NOUN	O	O	5110
secondary	ADJ	O	O	5110
to	PART	O	O	5110
possible	ADJ	O	O	5110
nafcillin	PROPN	O	O	5110
-	PUNCT	O	O	5110
induced	VERB	O	O	5110
acute	ADJ	O	O	5110
interstitial nephritis	NOUN	O	Disease	5110
and	CCONJ	O	O	5110
relapsing	VERB	O	O	5110
bacteremia	NOUN	O	Disease	5110
.	PUNCT	O	O	5110
High	ADJ	O	O	5111
-	PUNCT	O	O	5111
dose	NOUN	O	O	5111
daptomycin	PROPN	O	O	5111
may	AUX	O	O	5111
be	AUX	O	O	5111
an	PRON	O	O	5111
alternative	ADV	O	O	5111
option	NOUN	O	O	5111
for	ADP	O	O	5111
MSSA	PROPN	O	O	5111
bacteremia	NOUN	O	Disease	5111
with	ADP	O	O	5111
or	CCONJ	O	O	5111
without	ADP	O	O	5111
a	PRON	O	O	5111
CNS	PROPN	O	O	5111
source	NOUN	O	O	5111
in	ADP	O	O	5111
patients	NOUN	O	O	5111
who	PRON	O	O	5111
have	VERB	O	O	5111
failed	VERB	O	O	5111
or	CCONJ	O	O	5111
can	AUX	O	O	5111
not	PART	O	O	5111
tolerate	VERB	O	O	5111
standard	PROPN	O	O	5111
therapy	NOUN	O	O	5111
.	PUNCT	O	O	5111
Further	ADV	O	O	5112
clinical	ADJ	O	O	5112
evaluation	NOUN	O	O	5112
in	ADP	O	O	5112
patients	NOUN	O	O	5112
with	ADP	O	O	5112
confirmed	VERB	O	O	5112
meningitis	PROPN	O	O	5112
is	AUX	O	O	5112
warranted	VERB	O	O	5112
.	PUNCT	O	O	5112
The	PRON	O	O	5115
role	NOUN	O	O	5115
of	ADP	O	O	5115
nitric oxide	NOUN	O	Chemical	5115
in	ADP	O	O	5115
convulsions	NOUN	O	Disease	5115
induced	VERB	O	O	5115
by	ADP	O	O	5115
lindane	NOUN	O	Chemical	5115
in	ADP	O	O	5115
rats	NOUN	O	O	5115
.	PUNCT	O	O	5115
Lindane	NOUN	O	O	5116
is	AUX	O	O	5116
an	PRON	O	O	5116
organochloride	NOUN	O	O	5116
pesticide	NOUN	O	O	5116
and	CCONJ	O	O	5116
scabicide	NOUN	O	O	5116
.	PUNCT	O	O	5116
It	PRON	O	O	5117
evokes	VERB	O	O	5117
convulsions	NOUN	O	Disease	5117
mainly	ADV	O	O	5117
trough	NOUN	O	O	5117
the	PRON	O	O	5117
blockage	NOUN	O	O	5117
of	ADP	O	O	5117
GABA(A	X	O	O	5117
)	PUNCT	O	O	5117
receptors	NOUN	O	O	5117
.	PUNCT	O	O	5117
Nitric oxide	NOUN	O	Chemical	5118
(	PUNCT	O	O	5118
NO	PRON	O	Chemical	5118
)	PUNCT	O	O	5118
,	PUNCT	O	O	5118
gaseous	ADJ	O	O	5118
neurotransmitter	NOUN	O	O	5118
,	PUNCT	O	O	5118
has	VERB	O	O	5118
contradictor	NOUN	O	O	5118
role	NOUN	O	O	5118
in	ADP	O	O	5118
epileptogenesis	NOUN	O	O	5118
due	ADJ	O	O	5118
to	PART	O	O	5118
opposite	ADV	O	O	5118
effects	NOUN	O	O	5118
of	ADP	O	O	5118
L	NOUN	O	O	5118
-	PUNCT	O	O	5118
arginine	PROPN	O	O	5118
,	PUNCT	O	O	5118
precursor	NOUN	O	O	5118
of	ADP	O	O	5118
NO	PRON	O	Chemical	5118
syntheses	NOUN	O	O	5118
(	PUNCT	O	O	5118
NOS	PROPN	O	O	5118
)	PUNCT	O	O	5118
,	PUNCT	O	O	5118
and	CCONJ	O	O	5118
L	NOUN	O	O	5118
-	PUNCT	O	O	5118
NAME	NOUN	O	O	5118
(	PUNCT	O	O	5118
NOS	PROPN	O	O	5118
inhibitor	NOUN	O	O	5118
)	PUNCT	O	O	5118
observed	VERB	O	O	5118
in	ADP	O	O	5118
different	ADJ	O	O	5118
epilepsy	NOUN	O	Disease	5118
models	NOUN	O	O	5118
.	PUNCT	O	O	5118
The	PRON	O	O	5119
aim	VERB	O	O	5119
of	ADP	O	O	5119
the	PRON	O	O	5119
current	ADJ	O	O	5119
study	VERB	O	O	5119
was	AUX	O	O	5119
to	PART	O	O	5119
determine	VERB	O	O	5119
the	PRON	O	O	5119
effects	NOUN	O	O	5119
of	ADP	O	O	5119
NO	PRON	O	Chemical	5119
on	ADP	O	O	5119
the	PRON	O	O	5119
behavioral	ADJ	O	O	5119
and	CCONJ	O	O	5119
EEG	NOUN	O	O	5119
characteristics	NOUN	O	O	5119
of	ADP	O	O	5119
lindane	NOUN	O	Chemical	5119
-	PUNCT	O	O	5119
induced	VERB	O	O	5119
epilepsy	NOUN	O	Disease	5119
in	ADP	O	O	5119
male	NOUN	O	O	5119
Wistar	PROPN	O	O	5119
albino	PROPN	O	O	5119
rats	NOUN	O	O	5119
.	PUNCT	O	O	5119
The	PRON	O	O	5120
administration	NOUN	O	O	5120
of	ADP	O	O	5120
L	NOUN	O	O	5120
-	PUNCT	O	O	5120
arginine	PROPN	O	O	5120
(	PUNCT	O	O	5120
600	NUM	O	O	5120
,	PUNCT	O	O	5120
800	NUM	O	O	5120
and	CCONJ	O	O	5120
1000	NUM	O	O	5120
mg	VERB	O	O	5120
/	PUNCT	O	O	5120
in	ADP	O	O	5121
dose	NOUN	O	O	5121
-	PUNCT	O	O	5121
dependent	ADJ	O	O	5121
manner	VERB	O	O	5121
significantly	ADV	O	O	5121
increased	VERB	O	O	5121
convulsion	NOUN	O	Disease	5121
incidence	NOUN	O	O	5121
and	CCONJ	O	O	5121
severity	NOUN	O	O	5121
and	CCONJ	O	O	5121
shortened	VERB	O	O	5121
latency	VERB	O	O	5121
time	NOUN	O	O	5121
to	PART	O	O	5121
first	ADV	O	O	5121
convulsion	NOUN	O	Disease	5121
elicited	VERB	O	O	5121
by	ADP	O	O	5121
lower	ADJ	O	O	5121
lindane	NOUN	O	Chemical	5121
dose	NOUN	O	O	5121
(	PUNCT	O	O	5121
4	NUM	O	O	5121
mg	VERB	O	O	5121
/	PUNCT	O	O	5121
kg	VERB	O	O	5121
,	PUNCT	O	O	5121
i.p	NOUN	O	O	5121
.	PUNCT	O	O	5121
)	PUNCT	O	O	5121
.	PUNCT	O	O	5121
On	ADP	O	O	5122
the	PRON	O	O	5122
contrary	ADV	O	O	5122
,	PUNCT	O	O	5122
pretreatment	NOUN	O	O	5122
with	ADP	O	O	5122
L	NOUN	O	O	5122
-	PUNCT	O	O	5122
NAME	NOUN	O	O	5122
(	PUNCT	O	O	5122
500	NUM	O	O	5122
,	PUNCT	O	O	5122
700	NUM	O	O	5122
and	CCONJ	O	O	5122
900	NUM	O	O	5122
mg	VERB	O	O	5122
/	PUNCT	O	O	5122
kg	VERB	O	O	5122
,	PUNCT	O	O	5122
i.p	NOUN	O	O	5122
.	PUNCT	O	O	5122
)	PUNCT	O	O	5122
decreased	VERB	O	O	5123
convulsion	NOUN	O	Disease	5123
incidence	NOUN	O	O	5123
and	CCONJ	O	O	5123
severity	NOUN	O	O	5123
and	CCONJ	O	O	5123
prolonged	VERB	O	O	5123
latency	VERB	O	O	5123
time	NOUN	O	O	5123
to	PART	O	O	5123
convulsion	NOUN	O	Disease	5123
following	VERB	O	O	5123
injection	NOUN	O	O	5123
with	ADP	O	O	5123
a	PRON	O	O	5123
convulsive	ADJ	O	Disease	5123
dose	NOUN	O	O	5123
of	ADP	O	O	5123
lindane	NOUN	O	Chemical	5123
(	PUNCT	O	O	5123
8	NUM	O	O	5123
mg	VERB	O	O	5123
/	PUNCT	O	O	5123
kg	VERB	O	O	5123
,	PUNCT	O	O	5123
i.p	NOUN	O	O	5123
.	PUNCT	O	O	5123
)	PUNCT	O	O	5123
.	PUNCT	O	O	5123
EEG	NOUN	O	O	5124
analyses	NOUN	O	O	5124
showed	VERB	O	O	5124
increase	VERB	O	O	5124
of	ADP	O	O	5124
number	NOUN	O	O	5124
and	CCONJ	O	O	5124
duration	NOUN	O	O	5124
of	ADP	O	O	5124
ictal	ADJ	O	O	5124
periods	NOUN	O	O	5124
in	ADP	O	O	5124
EEG	NOUN	O	O	5124
of	ADP	O	O	5124
rats	NOUN	O	O	5124
receiving	VERB	O	O	5124
l	X	O	O	5124
-	PUNCT	O	O	5124
arginine	PROPN	O	O	5124
prior	ADV	O	O	5124
to	PART	O	O	5124
lindane	NOUN	O	Chemical	5124
and	CCONJ	O	O	5124
decrease	VERB	O	O	5124
of	ADP	O	O	5124
this	PRON	O	O	5124
number	NOUN	O	O	5124
in	ADP	O	O	5124
rats	NOUN	O	O	5124
pretreated	VERB	O	O	5124
with	ADP	O	O	5124
L	NOUN	O	O	5124
-	PUNCT	O	O	5124
NAME	NOUN	O	O	5124
.	PUNCT	O	O	5124
These	PRON	O	O	5125
results	VERB	O	O	5125
support	NOUN	O	O	5125
the	PRON	O	O	5125
conclusion	NOUN	O	O	5125
that	SCONJ	O	O	5125
NO	PRON	O	Chemical	5125
plays	VERB	O	O	5125
a	PRON	O	O	5125
role	NOUN	O	O	5125
of	ADP	O	O	5125
endogenous	ADJ	O	O	5125
convulsant	ADJ	O	O	5125
in	ADP	O	O	5125
rat	NOUN	O	O	5125
model	NOUN	O	O	5125
of	ADP	O	O	5125
lindane	NOUN	O	Chemical	5125
seizures	NOUN	O	Disease	5125
.	PUNCT	O	O	5125
Long	ADV	O	O	5128
-	PUNCT	O	O	5128
term	NOUN	O	O	5128
oral	ADJ	O	O	5128
galactose	PROPN	O	O	5128
treatment	NOUN	O	O	5128
prevents	VERB	O	O	5128
cognitive deficits	NOUN	O	Disease	5128
in	ADP	O	O	5128
male	NOUN	O	O	5128
Wistar	PROPN	O	O	5128
rats	NOUN	O	O	5128
treated	VERB	O	O	5128
intracerebroventricularly	ADV	O	O	5128
with	ADP	O	O	5128
streptozotocin	PROPN	O	Chemical	5128
.	PUNCT	O	O	5128
Basic	PROPN	O	O	5129
and	CCONJ	O	O	5129
clinical	ADJ	O	O	5129
research	NOUN	O	O	5129
has	VERB	O	O	5129
demonstrated	VERB	O	O	5129
that	SCONJ	O	O	5129
dementia	NOUN	O	Disease	5129
of	ADP	O	O	5129
sporadic	ADJ	O	O	5129
Alzheimer	NOUN	O	Disease	5129
's	AUX	O	O	5129
disease	PROPN	O	O	5129
(	PUNCT	O	O	5129
sAD	NOUN	O	O	5129
)	PUNCT	O	O	5129
type	NOUN	O	O	5129
is	AUX	O	O	5129
associated	VERB	O	O	5129
with	ADP	O	O	5129
dysfunction	NOUN	O	O	5129
of	ADP	O	O	5129
the	PRON	O	O	5129
insulin	NOUN	O	O	5129
-	PUNCT	O	O	5129
receptor	NOUN	O	O	5129
(	PUNCT	O	O	5129
IR	PROPN	O	O	5129
)	PUNCT	O	O	5129
system	NOUN	O	O	5129
followed	VERB	O	O	5129
by	ADP	O	O	5129
decreased	VERB	O	O	5129
glucose	NOUN	O	Chemical	5129
transport	NOUN	O	O	5129
via	ADP	O	O	5129
glucose	NOUN	O	Chemical	5129
transporter	NOUN	O	O	5129
GLUT4	PROPN	O	O	5129
and	CCONJ	O	O	5129
decreased	VERB	O	O	5129
glucose	NOUN	O	Chemical	5129
metabolism	NOUN	O	O	5129
in	ADP	O	O	5129
brain	NOUN	O	O	5129
cells	NOUN	O	O	5129
.	PUNCT	O	O	5129
An	PRON	O	O	5130
alternative	ADV	O	O	5130
source	NOUN	O	O	5130
of	ADP	O	O	5130
energy	PROPN	O	O	5130
is	AUX	O	O	5130
d	X	O	O	5130
-	PUNCT	O	O	5130
galactose	PROPN	O	O	5130
(	PUNCT	O	O	5130
the	PRON	O	O	5130
C-4-epimer	NOUN	O	O	5130
of	ADP	O	O	5130
d	X	O	O	5130
-	PUNCT	O	O	5130
glucose	NOUN	O	Chemical	5130
)	PUNCT	O	O	5130
which	PRON	O	O	5130
is	AUX	O	O	5130
transported	VERB	O	O	5130
into	ADP	O	O	5130
the	PRON	O	O	5130
brain	NOUN	O	O	5130
by	ADP	O	O	5130
insulin	NOUN	O	O	5130
-	PUNCT	O	O	5130
independent	ADJ	O	O	5130
GLUT3	PROPN	O	O	5130
transporter	NOUN	O	O	5130
where	SCONJ	O	O	5130
it	PRON	O	O	5130
might	AUX	O	O	5130
be	AUX	O	O	5130
metabolized	VERB	O	O	5130
to	PART	O	O	5130
glucose	NOUN	O	Chemical	5130
via	ADP	O	O	5130
the	PRON	O	O	5130
Leloir	NOUN	O	O	5130
pathway	NOUN	O	O	5130
.	PUNCT	O	O	5130
Exclusively	ADV	O	O	5131
parenteral	ADJ	O	O	5131
daily	ADV	O	O	5131
injections	NOUN	O	O	5131
of	ADP	O	O	5131
galactose	PROPN	O	O	5131
induce	VERB	O	O	5131
memory	NOUN	O	O	5131
deterioration	NOUN	O	O	5131
in	ADP	O	O	5131
rodents	NOUN	O	O	5131
and	CCONJ	O	O	5131
are	AUX	O	O	5131
used	VERB	O	O	5131
to	PART	O	O	5131
generate	VERB	O	O	5131
animal	NOUN	O	O	5131
aging	VERB	O	O	5131
model	NOUN	O	O	5131
,	PUNCT	O	O	5131
but	CCONJ	O	O	5131
the	PRON	O	O	5131
effects	NOUN	O	O	5131
of	ADP	O	O	5131
oral	ADJ	O	O	5131
galactose	PROPN	O	O	5131
treatment	NOUN	O	O	5131
on	ADP	O	O	5131
cognitive	ADJ	O	O	5131
functions	VERB	O	O	5131
have	VERB	O	O	5131
never	ADV	O	O	5131
been	AUX	O	O	5131
tested	VERB	O	O	5131
.	PUNCT	O	O	5131
We	PRON	O	O	5132
have	VERB	O	O	5132
investigated	VERB	O	O	5132
the	PRON	O	O	5132
effects	NOUN	O	O	5132
of	ADP	O	O	5132
continuous	ADJ	O	O	5132
daily	ADV	O	O	5132
oral	ADJ	O	O	5132
galactose	PROPN	O	O	5132
(	PUNCT	O	O	5132
200	NUM	O	O	5132
mg	VERB	O	O	5132
/	PUNCT	O	O	5132
kg	VERB	O	O	5132
/	PUNCT	O	O	5132
day	NOUN	O	O	5132
)	PUNCT	O	O	5132
treatment	NOUN	O	O	5132
on	ADP	O	O	5132
cognitive deficits	NOUN	O	Disease	5132
in	ADP	O	O	5132
streptozotocin	PROPN	O	Chemical	5132
-	PUNCT	O	O	5132
induced	VERB	O	O	5132
(	PUNCT	O	O	5132
STZ	PROPN	O	Chemical	5132
-	PUNCT	O	O	5132
icv	VERB	O	O	5132
)	PUNCT	O	O	5132
rat	NOUN	O	O	5132
model	NOUN	O	O	5132
of	ADP	O	O	5132
sAD	NOUN	O	O	5132
,	PUNCT	O	O	5132
tested	VERB	O	O	5132
by	ADP	O	O	5132
Morris	PROPN	O	O	5132
Water	NOUN	O	O	5132
Maze	NOUN	O	O	5132
and	CCONJ	O	O	5132
Passive	ADJ	O	O	5132
Avoidance	NOUN	O	O	5132
test	NOUN	O	O	5132
,	PUNCT	O	O	5132
respectively	ADV	O	O	5132
.	PUNCT	O	O	5132
One	NUM	O	O	5133
month	NOUN	O	O	5133
of	ADP	O	O	5133
oral	ADJ	O	O	5133
galactose	PROPN	O	O	5133
treatment	NOUN	O	O	5133
initiated	VERB	O	O	5133
immediately	ADV	O	O	5133
after	ADP	O	O	5133
the	PRON	O	O	5133
STZ	PROPN	O	Chemical	5133
-	PUNCT	O	O	5133
icv	VERB	O	O	5133
administration	NOUN	O	O	5133
,	PUNCT	O	O	5133
successfully	ADV	O	O	5133
prevented	VERB	O	O	5133
development	NOUN	O	O	5133
of	ADP	O	O	5133
the	PRON	O	O	5133
STZ	PROPN	O	Chemical	5133
-	PUNCT	O	O	5133
icv	VERB	O	O	5133
-	PUNCT	O	O	5133
induced	VERB	O	O	5133
cognitive deficits	NOUN	O	Disease	5133
.	PUNCT	O	O	5133
Beneficial	PROPN	O	O	5134
effect	VERB	O	O	5134
of	ADP	O	O	5134
oral	ADJ	O	O	5134
galactose	PROPN	O	O	5134
was	AUX	O	O	5134
independent	ADJ	O	O	5134
of	ADP	O	O	5134
the	PRON	O	O	5134
rat	NOUN	O	O	5134
age	NOUN	O	O	5134
and	CCONJ	O	O	5134
of	ADP	O	O	5134
the	PRON	O	O	5134
galactose	PROPN	O	O	5134
dose	NOUN	O	O	5134
ranging	VERB	O	O	5134
from	ADP	O	O	5134
100	NUM	O	O	5134
to	PART	O	O	5134
300	NUM	O	O	5134
mg	VERB	O	O	5134
Additionally	ADV	O	O	5135
,	PUNCT	O	O	5135
oral	ADJ	O	O	5135
galactose	PROPN	O	O	5135
administration	NOUN	O	O	5135
led	VERB	O	O	5135
to	PART	O	O	5135
the	PRON	O	O	5135
appearance	NOUN	O	O	5135
of	ADP	O	O	5135
galactose	PROPN	O	O	5135
in	ADP	O	O	5135
the	PRON	O	O	5135
blood	NOUN	O	O	5135
.	PUNCT	O	O	5135
The	PRON	O	O	5136
increase	VERB	O	O	5136
of	ADP	O	O	5136
galactose	PROPN	O	O	5136
concentration	NOUN	O	O	5136
in	ADP	O	O	5136
the	PRON	O	O	5136
cerebrospinal	ADJ	O	O	5136
fluid	NOUN	O	O	5136
was	AUX	O	O	5136
several	ADJ	O	O	5136
times	NOUN	O	O	5136
lower	ADJ	O	O	5136
after	ADP	O	O	5136
oral	ADJ	O	O	5136
than	ADP	O	O	5136
after	ADP	O	O	5136
parenteral	ADJ	O	O	5136
administration	NOUN	O	O	5136
of	ADP	O	O	5136
the	PRON	O	O	5136
same	ADJ	O	O	5136
galactose	PROPN	O	O	5136
dose	NOUN	O	O	5136
.	PUNCT	O	O	5136
Oral	NOUN	O	O	5137
galactose	PROPN	O	O	5137
exposure	NOUN	O	O	5137
might	AUX	O	O	5137
have	VERB	O	O	5137
beneficial	ADJ	O	O	5137
effects	NOUN	O	O	5137
on	ADP	O	O	5137
learning	VERB	O	O	5137
and	CCONJ	O	O	5137
memory	NOUN	O	O	5137
ability	NOUN	O	O	5137
and	CCONJ	O	O	5137
could	AUX	O	O	5137
be	AUX	O	O	5137
worth	ADJ	O	O	5137
investigating	VERB	O	O	5137
for	ADP	O	O	5137
improvement	NOUN	O	O	5137
of	ADP	O	O	5137
cognitive deficits	NOUN	O	Disease	5137
associated	VERB	O	O	5137
with	ADP	O	O	5137
glucose	NOUN	O	Chemical	5137
hypometabolism	NOUN	O	O	5137
in	ADP	O	O	5137
AD	NOUN	O	Disease	5137
.	PUNCT	O	O	5137
